Some~78
patients~11457
converted~29
from~6586
ventricular~1194
fibrillation~60
to~24640
organized~21
rhythms~2
by~9234
defibrillation-trained~1
ambulance~5
technicians~6
(EMT-Ds)~1
will~366
refibrillate~2
before~880
hospital~296
arrival.~7
The~11934
authors~339
analyzed~260
271~7
cases~1324
of~65103
managed~80
EMT-Ds~1
working~45
without~1162
paramedic~7
back-up.~1
Of~534
111~20
initially~151
rhythms,~3
19~250
(17%)~17
refibrillated,~1
11~507
(58%)~10
whom~404
were~14856
reconverted~1
perfusing~6
including~419
nine~379
(82%)~8
who~2010
had~4886
spontaneous~216
pulses~28
prior~311
refibrillation.~1
Among~154
admission~107
rates~559
lower~944
for~11055
refibrillated~1
than~6991
did~1434
not~4696
(53%~2
versus~295
76%,~2
P~501
=~2072
NS),~10
although~359
discharge~68
virtually~51
identical~134
(37%~1
and~43632
35%,~5
respectively).~76
Scene-to-hospital~1
transport~214
times~386
predictively~2
associated~1499
with~20646
either~866
the~62239
frequency~455
refibrillation~4
or~7715
patient~1718
outcome.~65
Defibrillation-trained~1
EMTs~2
can~1373
effectively~72
manage~21
additional~293
shocks~12
are~4098
at~5488
a~20235
significant~1779
disadvantage~5
when~1417
back-up~2
is~8453
available.~37
There~988
controversy~15
regarding~99
appropriate~208
utilization~69
health~260
care~402
resources~13
in~38023
management~395
tricyclic~20
antidepressant~20
overdosage.~2
Antidepressant~2
overdose~21
presenting~129
emergency~210
department~55
(ED)~2
routinely~40
admitted~141
intensive~85
units,~10
but~2956
only~1630
small~618
proportion~160
develop~158
cardiac~805
arrhythmias~86
other~1651
complications~399
requiring~111
such~812
an~4962
environment.~17
reviewed~235
findings~863
165~14
ED~19
overdose.~4
They~150
found~1670
that~9275
major~632
manifestations~85
toxicity~114
on~5283
evaluation~355
(altered~1
mental~88
status,~60
seizures,~26
arrhythmias,~17
conduction~154
defects)~1
commonly~154
complicated~87
course.~30
Patients~416
isolated~412
sinus~184
tachycardia~189
QTc~31
prolongation~50
no~2366
complications.~121
No~549
experienced~143
serious~155
toxic~110
event~52
evidence~662
continued~134
during~2968
These~1701
data~1001
support~323
concept~76
proper~51
identify~176
large~481
body~498
trivial~4
ingestions~2
may~2668
require~139
observation.~20
As~227
use~1024
helicopters~1
air~131
critically~37
ill~66
increases,~8
availability~48
monitoring~218
devices~24
physiological~85
parameters~198
flight~13
becomes~24
important.~23
It~826
has~1841
long~215
been~2173
known~288
arterial~642
PO2~28
(PaO2)~8
decreases~127
unsupplemented,~1
non-pressurized~1
flight.~3
In~4016
this~3632
study,~242
examined~610
transconjunctival~2
oxygen~463
(cjO2)~1
monitor~54
assessing~71
adequacy~29
oxygenation~39
helicopter~9
four~932
healthy~349
volunteers.~39
Arterial~36
PaO2~35
as~5173
measured~980
conventional~167
blood~2092
gas~154
analysis~669
was~16657
compared~1631
cjO2~4
ground~18
level,~58
5,000~6
feet,~8
10,000~11
feet~22
altitude.~5
Mean~179
dropped~35
significantly~2037
93.5~2
81.5~2
58.5~1
mm~519
Hg,~73
respectively~54
(P~910
less~3713
0.001,~20
variance~46
repeated~122
measures).~2
also~1601
decreased~951
63.8~1
52.0~1
34.8~3
Within~51
individual~234
subjects,~135
accurate~139
predictor~65
multiple~435
regression~180
analysis).~3
relationship~437
between~2450
linear~148
coefficient~45
1.147.~1
conclude~467
O2~158
be~5562
useful~412
hemodynamically~16
stable~158
patients.~1103
results~1776
study~1827
supplemental~22
all~1896
subjected~89
transport.~26
A~2676
prospective~170
clinical~1710
trial~107
conducted~159
estimate~92
rise~177
serum~1357
glucose~251
level~719
after~4072
intravenous~339
bolus~104
50~375
ml~184
50%~227
dextrose~14
solution~126
(D-50)~1
setting.~27
Fifty~31
one~1871
subjects~916
altered~173
levels~1636
consciousness~19
studied.~198
these,~38
23~215
diabetics,~2
28~223
diabetic.~1
change~621
total~1116
group~1810
ranged~241
low~826
37~155
mg/dl~35
high~1141
370~4
mg/dl,~10
mean~1315
166~8
+/-~4345
77~45
mg/dl.~12
diabetic~251
non-diabetic~9
groups~791
177~13
80~127
154~11
75~96
suggest~956
cannot~123
quantitatively~39
predicted~166
single~505
D-50.~1
An~373
unusual~148
case~788
misdirected~2
nasogastric~9
tube~100
described.~226
elderly~196
woman~142
brought~17
following~716
intentional~4
drug~495
Initially~3
unrecognized~32
errant~1
placement~91
large-bore~3
resulted~448
tension~97
pneumothorax,~6
pneumonia,~9
subsequent~330
death.~95
Pertinent~3
medical~493
literature~195
reviewed,~32
considerations~27
discussed,~22
suggestions~19
offered.~4
massive~76
degloving~1
injury~487
trunk,~4
open~139
pelvic~120
fracture,~27
evisceration~4
abdominal~284
contents~51
blunt~71
trauma~184
presented.~216
most~1176
aspect~32
transfusion~76
173~6
units~107
packed~17
cells~1586
176~7
fresh~46
frozen~28
plasma~1043
first~907
thirty~15
hours.~133
ultimately~25
recovered~121
returned~136
work.~15
course~287
pregnant~108
term~103
acutely~41
exposed~162
carbon~70
monoxide~12
review~262
fetal-maternal~1
carboxyhemoglobin~2
relationships~71
differences~624
fetal~366
oxyhemoglobin~6
physiology~20
used~1356
explain~105
recommendation~11
women~739
poisoning~17
should~876
receive~76
100%~94
therapy~813
up~361
five~772
longer~160
otherwise~70
necessary.~39
role~527
hyperbaric~25
considered.~48
child,~13
administration~475
fluids~35
medications~29
via~167
intraosseous~16
route~61
often~383
proves~4
life-saving.~1
describe~157
child~123
status~197
epilepticus~5
phenytoin~39
administered~346
route,~6
seizure~50
resolution~92
therapeutic~237
achieved.~31
Intraosseous~3
reserved~15
rare~214
vascular~585
access~66
impossible.~7
Boerhaave's~5
syndrome~536
represents~106
diagnostic~355
dilemma~8
physician.~17
prognosis~122
truly~2
life-threatening~46
darkened~1
any~583
delay.~12
Unfortunately,~11
classic~55
expected~120
symptoms~567
signs~227
frequently~289
absent~64
presentation,~37
circumstance~5
leads~84
frequent~209
misdiagnosis.~1
Two~440
"atypical"~7
presentations~11
discussed.~295
clear~108
always~130
suspected~132
sudden~84
chest,~6
abdominal,~3
back~76
pain~466
emesis.~3
However,~740
emphasis~44
placed~173
fact~60
entity~51
occur~298
chest~254
radiograph~25
helpful~75
aid.~5
Undoubtedly,~1
maintenance~107
degree~354
suspicion~30
physician~156
lead~142
consistently~99
earlier~98
diagnosis,~77
aggressive~89
intervention~88
result~455
considerable~78
reduction~532
both~2090
morbidity~187
mortality.~66
~4395
infusions~55
widely~83
pediatric~147
1930s~1
1940s.~1
Recent~62
reports~163
have~2904
re-introduced~1
confirmed~234
its~852
safety~90
ready~6
accessability~1
fluid~406
administration.~80
these~2741
addressed~24
difficulties~47
encountered~71
insertion~68
needle.~9
Spinal~11
needles,~4
standard~328
metal~24
(IV)~12
bone~667
marrow~191
biopsy~366
needles~17
suggested~337
infusion.~62
tested~274
ease~22
cadaver~13
leg.~8
site~349
needle~101
evaluated~495
study.~168
13-gauge~3
Kormed/Jamshidi~1
disposable~13
marrow/aspiration~1
easiest~2
insert~5
plug~7
tissue~637
insertion.~14
area~442
proximal~306
medial~109
malleolus~4
provide~325
stable,~12
relatively~256
flat,~3
easily~87
penetrable~1
location~93
placement.~13
This~2016
method~530
successfully~185
utilized~60
ten~235
adult~320
safe,~36
rapid~280
gain~63
venous~359
circulation.~35
By~172
utilizing~38
techniques,~48
usable~2
line~100
established~147
even~339
dehydrated~7
man~180
injected~152
turpentine~1
intravenously~80
attempt~85
kill~3
himself~1
reported.~202
developed~845
immediate~149
pulmonary~1033
edema~102
hypoxia,~12
followed~549
later~189
cellulitis~11
injection.~68
Although~523
death~251
date~22
attributed~93
form~248
chemical~78
abuse,~17
extensive~209
local~328
reactions,~14
involvement,~37
central~405
nervous~171
system~554
depression,~34
febrile~42
reactions~160
anticipated,~4
hospital.~35
observed~903
myonecrosis~3
around~89
injection,~31
especially~212
12-24~5
hours~531
later.~64
users~39
illicit~3
drugs~250
endangered~1
unpredictable~8
concentrations~883
unexpected~28
adulterants~1
present.~63
Cocaine~4
adulterated~1
admixed~10
numerous~49
substances,~7
among~623
them~160
anesthetics,~4
amphetamine,~3
phencyclidine,~1
strychnine.~1
We~2289
report~543
three~1571
thallium~58
nasal~139
insufflation~11
substance~75
believed~60
cocaine.~8
injection~279
ethchlorvynol~3
uncommon~79
cause~473
noncardiac~16
edema.~26
ethchlorvynol-induced~1
fell~120
asleep~3
injecting~15
liquid~151
Placydil~1
capsules~17
(ethchlorvynol)~1
awoke~1
several~342
severe~615
dyspnea.~5
gases~19
demonstrated~675
marked~293
hypoxia.~22
Chest~17
radiographs~77
revealed~574
bilateral~199
diffuse~122
alveolar~137
densities.~2
patients'~76
radiographic~121
resolved~81
days~731
supportive~17
care.~53
Changes~69
lung~615
caused~528
direct~313
effect~1253
lung.~35
suffering~41
baclofen~9
treated~1103
atropine~55
Three~345
ingestion~74
least~442
300~64
mg~406
dose,~30
became~150
comatose~6
subsequently~147
bradycardic,~1
hypotensive,~1
hypothermic.~1
prompt~47
increase~1296
heart~764
rate~1560
pressure~1297
1~1249
sulfate.~10
Atropine~8
appears~358
treating~71
bradycardia~21
hypotension.~19
caustic~10
involving~141
Compound~2
W,~5
over~812
counter~6
wart~1
remover~1
Chemical~3
burns~51
tongue,~6
pharynx~6
larynx~34
developed.~48
active~349
ingredient~3
preparation:~1
salicylic~5
acid~677
flexible~54
collodion~2
vehicle~60
produces~82
through~623
keratolytic~1
action,~14
which~2425
enhanced~180
presence~832
collodion.~1
Our~279
ethylene~13
oxide~35
retention~57
sterilization~12
increased~2131
cuprammonium~3
cellulose~22
plate~31
dialyzers~10
containing~233
potting~3
compound.~6
contrast,~284
compound~51
characterized~211
disappearance~38
retained~58
sterilization.~8
Whether~23
incidence~635
SARD~1
do~231
contain~69
material~129
matter~58
experimentation.~1
Calcium~24
carbonate~14
effective~471
aluminum~78
hydroxide~9
binding~537
dietary~206
phosphorus~41
hemodialysis~102
long-term~325
medication~52
acceptable~55
view~97
today's~6
options.~4
Based~84
our~530
preliminary~57
studies~971
we~1114
argon~31
laser~202
welding~2
4-8~1
internal~243
diameter~190
veins,~14
arteries,~28
arteriovenous~64
fistulas~38
potential~465
advantages~65
suture~31
techniques.~67
benefits~54
repairs~5
include~169
improved~322
mechanical~195
properties,~16
absence~366
foreign~35
response~1093
related~652
sutures.~5
Laser~15
sterile,~3
nontactile~1
possibly~96
time~1148
conserving,~1
wounds~73
heal~11
rapidly~157
aneurysms~74
excess~99
proliferation.~20
System~16
7~393
pump/actuator/engine~1
combination~285
biologic~45
compatibility~6
physiologic~125
effectiveness~85
responsiveness~86
TVAS~1
vivo~253
studies.~120
recent~198
75-day~1
implant~50
supports~63
feasibility~30
extended~71
reliability~45
components.~21
Postoperative~59
necessary~162
because~529
nonhermetic~1
design~64
7.~8
ability~270
pump~62
l/min~15
120~93
beats/min,~11
synchronize~1
beat~19
144~17
against~304
pressures~165
more~2213
150~71
mmHg~54
while~659
maintaining~44
hematologic~17
biochemical~129
values~645
within~878
range~359
sets~31
very~314
optimistic~1
stage~286
8~494
hardware.~1
shown~359
Figure~1
14.~12
hardware~5
thermal~52
salt~66
package~2
capable~78
providing~74
completely~157
untethered~1
circulatory~45
nominal~2
8-h~3
period.~253
Recharge~1
accomplished~52
transcutaneous~24
transformer~1
h.~55
Thermal~5
problems~204
become~138
minimal,~10
average~388
energy~245
input~19
15.8~4
W~22
(peak~3
24.9~5
W).~2
human~960
preclinical~11
testing~226
start~44
1988.~1
roller~9
screw~15
electric~7
VAD~2
easier~17
manufacture~5
25%~81
lighter~3
previously~533
described~358
drum~4
cam~1
model.~74
device~92
requires~109
12~789
15~632
6~683
minimal~165
hemolysis.~6
motor~228
drive~18
functioned~5
periods~140
93~31
measurable~27
wear.~2
compliance~72
chamber~75
volume~576
varies~23
100~354
cc~12
function~717
does~333
so~197
variations~78
below~176
mmHg.~14
Compliance~5
loss~407
2~1289
5~798
cc/day~1
explained~94
SPU.~1
subcutaneous~79
sampling~38
port~4
provides~189
sealed~6
system.~133
order~234
perform~49
quantitative~119
vitro~359
removal~215
Al~18
combined~236
DFO~10
HD,~5
HPLC~11
measuring~128
leaky~3
membrane~401
permeability~75
middle~122
molecular~155
substances~36
infusion~435
rises~19
(regarded~1
indicating~184
elution~12
accumulated~26
Al)~1
undergoing~248
HD.~6
Plasma~136
those~1551
pain.~77
Examination~32
clearances~25
content~343
passed~27
HD~20
membranes~106
micrograms/l,~3
well~780
one.~42
1:1~12
complex~259
aqueous~40
confirmed,~3
formation~263
Al-rich~1
complexes~75
suggested.~26
concluded~270
Al-DFO~1
formed~62
removed~143
across~108
membrane.~51
under~450
diaphragm~62
CAPD~21
low,~26
causes~219
directly~189
attributable~40
techniques~263
lower.~8
Bowel~2
perforation~52
generally~152
larger~171
collection~38
diaphragm.~12
With~236
111In-labeled~13
platelets~144
125I-labeled~23
bovine~103
fibrinogen,~9
regional~224
mapping~30
platelet~283
fibrinogen~59
deposition~68
leaflets~13
sewing~5
rings~16
obtained.~51
Ten~126
Holstein~1
calves~5
received~567
25-mm~1
mitral~257
valves~55
(ISLM)~1
killed~48
1,~140
14,~17
30~613
implantation.~12
Twenty-four~38
killed,~5
350~9
450~8
microCi~4
200~113
250~426
intravenously.~7
components~144
valves,~11
i.e.,~42
rings,~2
separated.~1
Each~118
leaflet~29
cut~23
into~1030
sections:~1
free~439
edge,~1
zone,~11
flexion~48
attachment~34
zone.~14
From~152
radioactivity~35
blood,~52
zones,~6
count,~20
density~230
adherent~25
platelets,~25
fibrinogen-fibrin,~1
fibrinogen/platelet~1
calculated.~29
deposited~17
postimplantation.~1
number~648
molecules~54
per~1252
fivefold~8
20-fold~8
higher~1014
receptor~415
concentration~674
suggesting~256
heterogeneity~35
fibrinogen-fibrin~1
thrombus~42
valve.~26
demonstrates~77
20~669
microns~32
porous,~1
Replamineform~1
silicone~47
rubber~31
prostheses~30
remain~74
isocompliant~1
adjacent~98
segments~90
months~842
finding~183
contrasts~6
currently~76
available~233
prostheses,~3
autologous~62
vein,~16
minimally~29
compliant.~1
construction~19
implantation~52
improve~146
success~106
reconstruction~104
eliminating~19
failures~37
intimal~52
hyperplasia.~23
To~699
summarize~6
results:~3
Bilirubin~3
hemoperfusion~12
performed~1040
premature~94
infant.~20
adverse~132
effects~1116
state~199
bilirubin~51
90~124
min--13~1
mg--indicates~1
existence~57
extravascular~22
pool.~7
Hemoperfusion~2
newborn~76
babies,~4
reducing~93
need~246
exchange~98
bank~10
blood.~45
new~501
hydroxyl~11
carboxyl~4
original~79
fibers~105
masked~8
cationic~21
synthetic~62
polymers.~2
tests~269
affect~189
activation~172
complement~99
little,~3
it~1158
retains~4
dialysis~136
efficiency,~5
good~277
tolerance~92
steam~1
autoclave~1
sterilization,~3
economical~4
production~295
cost~89
characteristics~233
thus~193
optimum~16
qualities~4
needed~115
pharmacokinetics~52
atracurium~32
studied~1105
infants~441
children~779
anaesthetized~17
isoflurane~59
nitrous~34
oxygen.~16
distribution~299
(area)~2
(139~4
v.~18
152~11
kg-1),~3
clearance~288
(5.1~7
5.3~16
kg-1~98
min-1),~3
T1/2~8
alpha~281
(2.1~7
2.0~63
min),~6
beta~238
(19.1~2
20.3~4
min)~33
normal~2162
hepatic~374
renal~915
moderately~47
impaired~131
transplantation.~8
(176~1
139~14
kg-1)~20
(9.1~1
5.1~17
min-1)~14
excretory~15
function.~161
m-2~3
min-1~71
(153~1
133)~1
tended~105
greater~1160
shorter~81
(1.0~20
13.6~4
19.1)~1
function;~4
however,~478
trends~34
reach~52
statistical~92
significance.~28
laudanosine~7
ng~28
ml-1~26
liver~563
disease~1591
15-45~2
min~339
0.5~154
kg-1.~5
surgery~523
assessed~377
dysfunction~134
biliary~161
atresia.~7
initial~522
dose~597
0.6~85
provided~208
excellent~128
intubating~1
conditions~231
Subsequent~21
neuromuscular~60
blockade~115
monitored~124
peripheral~399
nerve~440
stimulator~17
incremental~38
doses~354
given~479
reappearance~4
twitch.~2
Neuromuscular~3
allowed~108
return~95
end~247
careful~54
timing~35
increments~32
antagonize~6
two~2281
4~767
years~980
January~54
1981~35
December~40
1984,~52
186~14
1362~1
halothane~60
anaesthetics.~2
Twenty-five~38
10~1009
year.~56
postoperative~474
jaundice.~3
Sixty-nine~6
anaesthetics~8
149~8
occasions~22
serial~97
estimations~10
enzyme~227
Minor~7
increases~362
AST~4
ALT~1
recorded~221
10.6%~1
4.7%~6
entries,~1
respectively.~403
GGT~3
SAP~6
2.7%~7
entries.~1
anaesthetic~34
likely~338
further~456
changes.~68
histamine~149
releasing~8
equivalent~97
vecuronium~19
0.12~28
halothane.~11
Blood~98
samples~286
obtained~796
before,~39
blocker.~7
twitch~23
0.15~28
Hz~32
evaluated.~80
None~96
receiving~309
concentration.~73
atracurium,~7
markedly,~5
apparent~174
manifestations.~6
Recovery~17
(to~17
95%~74
height)~3
faster~42
0.02).~49
14~414
intubated,~2
spontaneously~109
breathing~100
weight~454
(bw)~1
ranging~113
8.3~18
25.6~2
kg,~9
influence~255
midazolam~5
0.1~110
i.m.~4
(group~139
M0.1,~1
n~133
7)~32
0.2~115
M0.2,~1
premedication,~2
sedation,~4
ventilation,~31
ventilatory~64
dioxide~52
hormonal~40
stress~200
connection~32
minor~128
surgical~736
procedures~257
anaesthesia.~19
catecholamines,~5
ACTH~56
cortisol~81
immediately~142
induction,~9
undisturbed~6
anaesthesia,~11
procedure.~116
Sedation~3
better~283
catecholamine~57
anaesthesia~52
midazolam.~1
During~372
recovery~253
there~945
hormone~278
concentrations.~76
recovery,~24
hormones~59
surgery,~133
VE~8
respiratory~364
somewhat~37
M0.2~1
E'~1
CO2~47
similar.~32
dependent~137
depression~233
found.~93
clinically,~11
considered~356
adequate~185
groups.~349
alcuronium~8
evoked~178
electromyographic~41
responses~464
adductor~18
pollicis~12
investigated~321
ulnar~20
stimulated~183
trains~3
supramaximal~10
ms~43
duration~383
intervals~137
s.~12
using~1056
strain~88
gauge~21
force~88
transducer~13
action~229
(ECAP)~2
simultaneously~72
Medelec~1
MS91~1
electromyography~11
Depression~19
responses,~28
similar~931
onset~304
antagonism~31
blockade.~18
alcuronium,~2
depressed~97
extent~255
ECAP.~2
difference~535
neostigmine.~2
similar,~26
fade~6
group.~288
ratio.~26
Electromyographic~6
train-of-four~12
ratios~127
measurements~347
drug-specific~1
pronounced~51
neostigmine~24
0.07~15
edrophonium~19
0.8~59
antagonists~69
profound~37
induced~510
59~69
ablation~54
end-point~4
ratio~415
70%.~6
point~101
(duration~4
TOF70)~1
66.7~4
control~1380
(no~17
antagonist),~1
43.5~1
59.8~1
edrophonium.~2
TOF70~5
0.01)~174
differ~163
29~165
durations~14
66.4,~1
44.1~3
54.9~1
control,~50
groups,~144
0.01),~79
control.~64
0.01).~199
show~288
antagonized~24
agents,~29
if~464
reversal~52
required~524
circumstances,~12
would~334
drug.~47
Antagonism~1
atracurium-induced~1
tetanic~9
(50~42
Hz)~10
(2~64
muscle~700
22~211
anticholinesterase~4
acted~8
(six~25
each~859
anticholinesterase)~1
attempted~65
95-98%~1
response,~70
0.75~16
i.v.~49
statistically~238
different~900
group;~11
2.5~101
0.001).~256
edrophonium,~2
0.05).~280
When~372
commencement~2
block~154
sustained,~5
whereas~557
persistent~137
phase~282
shortened.~2
(n~524
5)~29
0.3~80
i.v.,~6
until~162
peak~440
height~72
contraction~132
reached~82
approximately~320
value.(ABSTRACT~1
TRUNCATED~406
AT~413
WORDS)~406
studied,~40
enflurane~26
tubocurarine-induced~2
kg-1,~9
tubocurarine~12
calculated~201
percent~663
twitch,~2
determined~572
second,~22
third~205
fourth~56
twitches~3
train-of-four.~1
pattern~311
blocking~52
agents~210
T2,~2
T3~138
T4~80
reappearing~1
93%,~5
89%~21
86%~22
residual~184
blockade,~16
reported~735
Lee~1
(1975)~4
that,~106
count~57
give~54
incorrect~14
vecuronium,~1
comparing~92
visually~22
responses.~38
Responses~14
stimuli~69
nerves~68
transducer,~2
movements~66
contralateral~121
thumb.~3
For~292
enflurane,~11
reappeared~6
84~52
(+/-~117
10)%,~1
76~27
11)%,~1
70~133
12)%~1
patients,~875
narcotic-barbiturate~1
technique,~68
81~48
8)%,~1
68~56
9)%,~1
11)%.~1
long-acting~4
drug,~37
galanthamine,~1
eight~493
After~446
decrease~537
galanthamine~4
biexponential~2
curve.~9
543~3
47~57
128~22
6.42~1
2.15~2
min,~64
then~346
declined~69
slowly~39
264~7
min.~74
Total~83
amounted~11
5.37~1
0.87~2
1.36~3
0.10~14
cumulative~91
urinary~356
excretion~223
0~101
48~216
h~350
28.0~6
5.4%~3
dose.~44
24~622
0.1%~10
glucuronide~7
sulphate~11
conjugation~11
galanthamine.~1
flow~1088
chlormethiazole~4
extraction~103
lungs,~26
liver,~72
kidneys~49
gut~33
awake~46
unrestrained~7
sheep~67
(controls)~5
same~622
animals~490
1.5%~22
whilst~11
thoracic~113
subarachnoid~67
amethocaine.~1
control-drug~1
studies,~110
infused~97
sub-sedative~1
produced~563
changes~1125
haemodynamics~5
kinetics~52
iodohippurate~1
(renal~2
flows).~1
Chlormethiazole~1
eliminated~39
predominantly~94
(mean~401
clearance,~12
respectively,~197
0.90~9
1.3~50
litre~4
lungs~89
(0.15;~1
min-1).~5
Renal~45
negligible~15
(greater~102
Because~198
derived~172
Under~47
general~244
reductions~74
output,~41
54%,~6
63%~16
43%~15
control);~1
reduced,~23
82%~18
56%~13
abolished.~9
clearances.~2
Double-lumen~1
endobronchial~11
tubes~27
"blindly"~1
thoracotomy.~12
Clinical~133
criteria~170
satisfactory~65
positioning~11
cases;~19
fibreoptic~5
bronchoscopy~20
malposition~5
48%.~2
Bronchoscopic~1
included~401
inability~35
bronchial~113
cuff,~4
narrowing~33
lumen~47
cuff~32
herniation~28
carina.~1
hazards~20
Active~7
forms~146
vitamin~209
D3,~3
alpha-hydroxyvitamin~3
D3~42
alpha,25-dihydroxyvitamin~3
open-design~1
40~278
psoriasis~27
vulgaris~11
ways:~4
17~344
orally~44
1.0~88
micrograms/day~5
months,~119
microgram/day~2
applied~182
topically~17
microgram/g~5
base~86
weeks.~116
Improvement~7
13~423
(76%)~13
Group~311
period~621
treatment~1649
SD)~67
2.7~33
3~1032
treatment,~166
16~400
(84%)~8
3.3~31
1.2~61
side-effects~4
trials.~14
respond~73
metabolites~90
abnormalities~372
D~142
metabolism~174
skin~481
involved~285
pathogenesis~112
disease.~704
psoriatic~27
topical~54
alpha,24-dihydroxycholecalciferol,~1
analogue~32
D3.~4
lesions~685
cleared~20
1-4~7
weeks,~70
some~578
relapses~13
occurred~829
shortly~31
cessation~46
treatment.~357
side-effects.~1
alpha,~15
24(OH)2D3~1
merits~12
investigation~136
potentially~131
psoriasis.~12
Twelve~86
(34%)~6
thirty-five~3
infection~428
palms~3
soles~2
Hendersonula~1
toruloidea~3
Scytalidium~1
hyalinum~3
circulating~124
antibodies~351
organisms~53
immunoelectrophoresis~9
immunodiffusion,~2
9%~40
uninfected~11
controls.~261
every~135
instance~15
cross-reactivity~14
positive~652
sera~119
heterologous~9
non-dermatophyte~2
antigen.~37
Using~166
crossed~17
intermediate~86
gel~90
cytoplasmic~49
extracts~70
H.~14
S.~66
showed~1324
34~129
41~103
precipitin~2
peaks~19
shared~23
organisms.~13
cross-reactions~2
hyperimmune~2
animal~129
antisera~14
raised~80
Trichophyton~16
rubrum,~1
interdigitale,~1
Aspergillus~8
fumigatus~3
Candida~21
albicans.~1
Exoantigens~1
prepared~105
non-dermatophytes~1
species.~40
antigenic~24
structure,~18
lends~6
they~540
closely~109
related.~14
antigenically~7
distinct~139
pathogenic~20
fungi~5
infect~7
skin,~35
their~1469
cultural~14
identification~90
recognition~84
specimens.~47
indomethacin~42
UVB~14
UVC~3
erythema~38
objectively~9
reflectance~3
instrument.~8
irradiation,~17
UVR~1
(ultraviolet~1
radiation)~2
dose-dependent~88
suppression~96
wavelengths~7
36~150
irradiation~79
base-treated~2
sites~278
equally~66
erythematous.~2
Suppression~10
application~177
delayed~193
showing~72
prostaglandin~54
synthesis~194
remains~150
throughout~152
time,~111
achieved~257
eventual~21
equal~374
due~719
tachyphylaxis~10
inadequate~48
dosage.~10
Construction~2
dose-response~57
curves~119
indomethacin-responsive~1
indomethacin-unresponsive~1
shows~94
erythemal~1
radiation~221
mediators~16
wavelengths.~6
behavioural~9
habit~4
reversal,~1
hydrocortisone~11
cream,~2
cream~16
alone~264
atopic~30
dermatitis.~14
assigned~74
randomly~101
regular~67
ointment~8
scratching~3
Both~304
improved,~17
habit-reversal~1
more.~18
strong~96
correlation~476
improvement~280
status.~54
Percutaneous~33
absorption~172
18~414
(aged~16
weeks~427
1/2~54
years)~103
seborrhoeic~1
dermatitis,~6
1%~69
cream.~5
Endogenous~10
secretion~282
suppressed~81
dexamethasone.~7
test~581
children.~107
six,~9
percutaneous~132
detected.~36
highest~181
basis~250
test.~64
short~179
children,~84
98~29
2669~1
nmol/l.~2
evaluate~224
previous~349
glucocorticoids.~3
Suppressed~1
adrenocortical~30
post-application~1
levels.~166
disorder~184
older~213
mild~218
moderate~168
succeeded~3
reproducing~1
eczematous~3
lesion~244
apparently~92
dermatitis~42
continuous~176
ferritin-labelled~1
mite~7
entry~65
antigen~229
biopsies~116
Fe-staining.~1
Scratched~1
urticarial~3
reaction~159
typical~116
type~575
I~415
allergy~30
changed~100
IV~123
allergy.~11
histologically.~13
secondary~295
syphilis~7
facial~109
resembled~33
Sweet's~2
clinically~274
serological~20
syndrome.~174
present~918
11-month-old~5
baby~20
burn~85
healed~35
normally~68
month,~13
successive~25
crops~1
blisters~3
scar.~6
his~121
condition.~44
Clinical,~5
immunological,~1
histological~93
ultrastructural~41
diagnosis~780
microtrauma.~1
Electron~29
microscopy~119
sub-epidermal~1
nature~115
underlying~151
fibrin~34
deposits.~12
Retrospective~8
82~34
pregnancies~61
ulcerative~82
colitis~71
Crohn's~96
general,~39
neither~109
pregnancy~242
birth-weights~1
babies~35
born~56
inflammatory~196
bowel~157
marginally~14
matched~114
age~1051
parity,~6
haemoglobin~18
pregnancy,~51
mode~56
delivery~183
and/or~277
proteinuria.~10
relapse,~7
obstetric~28
management.~55
interferon-alpha~2
specific~592
two-site~2
immunoradiometric~2
assay~152
variety~153
tissues~156
collected~137
pregnancy.~78
Maternal~27
non-pregnant~7
adults~131
contained~161
little~220
interferon-alpha.~1
Fetal~21
organs,~10
placenta,~6
membranes,~25
amniotic~31
decidua~7
roughly~17
amounts~136
1.1~57
u/ml~1
(or~45
g~180
tissue).~4
demonstrate~242
fetus~53
surroundings~4
permeated~2
interferon.~3
play~121
regulation~105
maternal-fetal~2
graft~136
relation.~2
phagocytic~13
activity~1140
mononuclear~66
phagocytes~9
Staphylococcus~45
epidermis~39
relation~187
gestational~81
age.~146
distributed~48
trimesters.~1
variables~217
investigated:~4
phagocytosis~21
bacteria~61
monocyte~38
phagocytosis.~5
progressed~35
gradual~27
monocytes~48
macrophages~100
six~686
phagocyte.~1
Random-dot~1
stereograms~1
producing~78
fusional~2
vergence~8
amplitudes~29
monocular~8
contours.~2
artefact~1
contours~4
target~78
borders~8
instrument~46
comparable~181
second~416
fusion~53
targets~15
amblyoscope.~1
diplopia~5
monocularly~1
recognisable~2
amplitudes.~4
capsular~32
bag~15
fixation~159
Sinsky-Kratz~1
posterior~280
intraocular~61
lens~62
presented,~24
various~382
methods~276
position~163
lenses~20
outlined.~16
forceps~25
rationale~18
adoption~6
illustrated,~1
step-by-step~2
fashion.~32
Their~64
anterior~468
mentioned.~8
brief~64
summary~8
author's~8
experience~216
Labrador~1
keratopathy~3
(LK)~1
acquired~134
corneal~75
degeneration~53
thought~117
chronic~800
exposure~321
solar~13
irradiation.~26
Reports~6
far~54
progressive~195
stationary~16
detailed~70
recommended~142
therapy.~328
LK~3
extracapsular~18
cataract~37
extraction.~14
Seventeen~37
black~79
(26~18
eyes)~13
mature~46
cataracts~8
underwent~537
severity~254
photographically~2
pre-~35
postoperatively.~43
follow-up~483
fifteen~23
months.~247
eyes~179
(92%)~17
LK.~2
ultraviolet~24
light~211
aphakic~13
photophobia~1
could~749
factors~543
led~140
assess~240
prevalence~208
sports~25
eye~122
injuries~238
register~4
kept~46
October~15
1982~53
March~17
1984.~48
Squash,~1
association~316
football,~2
badminton,~1
tennis~2
main~124
offenders.~3
severest~3
golf~1
ball,~3
fractured~7
zygoma.~2
retinal~183
dialysis,~10
dislocation~48
Spectacles~1
broken~10
contact~106
Glass~1
fragments~64
operative~251
case,~69
penetrating~41
injuries.~59
value~420
protection,~5
worn~4
emphasised.~2
Beading~1
vein~239
draining~16
choroidal~32
melanoma~73
reported,~24
endothelial~168
proliferation~101
beading~2
borne~9
factor(s)~6
traversing~4
capillary~115
non-perfusion~2
beaded~4
part~290
process.~64
illumination~5
slit-lamp~5
biomicroscopy~3
segment,~13
Vogt,~1
eye.~24
ocular~81
fundus~30
difficult.~20
particular,~26
photography~6
parts~38
demands~13
technical~69
arrangements~4
appearances~11
recorded.~46
suggestion~16
protective~59
gear~1
pose~9
threat~6
crystalline~15
retina~28
epidemiological~15
view.~9
accentuate~4
pre-existing~14
high-risk~61
hazard~16
significance~131
low-risk~15
hazards.~2
Five~190
insulin~91
few~175
cotton-wool~3
spots~8
'soft~1
exudates'~1
totally~49
fewer~82
microaneurysms.~1
observations~151
early~802
retinopathy.~9
Significant~77
biological~64
glycosylated~14
thrombin~34
generation,~4
slight~55
coagulation~50
possible~443
Bilateral~16
optic~67
atrophy~59
who,~12
long-standing~15
leaves~8
Catha~1
edulis,~1
chewed~2
quantities~25
usual.~2
Since~169
plant~14
native~38
source~96
mildly~27
stimulant~8
narcotic,~2
idiosyncratic~7
unusually~12
histopathological~18
distinctly~8
inherited~31
juvenile~35
dystrophies~1
indicate~530
defect~140
mitochondrial~42
cytopathy~1
involves~59
pigment~46
epithelium,~15
Laurence-Moon-Biedl~1
photoreceptor~3
primarily~147
affected.~24
murine~80
IgG2a~1
monoclonal~184
antibody~355
6-19~2
binds~33
wide~128
nonhematopoietic~1
marrow-derived~1
stromal~42
bind~39
cells.~357
rabbit~126
Fibroblast~3
colonies~32
incubation~73
complement.~6
growth~411
composition~89
granulocytic~6
erythroid~30
unaffected.~16
Specific~31
mediated~139
cytotoxicity~30
passaged~7
fibroblasts~69
(more~27
99.6%~1
treatment).~2
Similar~72
umbilical~32
cord~271
addition,~264
abolished~68
initiation~80
Dexter~2
culture~194
stroma.~9
Incubation~17
cell~1381
suspensions~12
allow~82
stroma-free~2
cultures.~20
Sl/Sld~10
mice~235
defective~24
hemopoietic~12
microenvironment.~1
assumed,~2
based~266
upon~161
primary~702
abnormality~110
simply~25
lack~138
inductive~4
cultures~167
characterize~51
microenvironmental~1
mice.~55
mouse~109
10%~120
multipotent~2
unipotent~1
progenitor~18
normal,~67
congenic~2
+/+~6
If~105
mixed~109
establishing~26
cultures,~17
added~130
inhibition~270
hemopoiesis.~2
pre-established,~1
confluent~15
layer~65
inhibited~247
hemopoiesis~2
nearly~107
70%,~6
dishes~2
irradiated~44
inhibitory~134
abrogated~3
stroma~14
addition~275
Similarly,~44
unirradiated,~1
9~305
Gy~10
factor-dependent~1
FDC-P1~1
line.~20
Thus,~348
microenvironment~3
actively~26
inhibits~48
vitro,~33
partially~108
Epinephrine~8
aggregation~73
interacting~5
2-adrenergic~26
receptors~224
surface.~26
Platelet~22
glycoprotein~52
IIb-IIIa~11
complex.~30
identifiable~24
surface~375
resting~111
expressed~127
activation.~17
current~228
designed~174
examine~126
occupancy~11
epinephrine~99
expression~177
platelets.~20
induce~91
conditions:~12
acute~873
stimulation~433
(less~99
prolonged~249
latter~145
"desensitization"~1
response.~103
Expression~9
125I-fibrinogen~1
125I-PAC-1~1
(PAC-1),~1
activated.~6
PAC-1~2
2-receptor~1
extracellular~93
Ca~38
(KCa~1
mumol/L).~7
itself,~11
mmol/L~25
Mg~10
unable~44
induction~172
epinephrine.~11
requirement~44
about~413
orders~6
magnitude.~3
Prolonged~18
unstirred~9
70%~94
stirred.~1
Despite~133
desensitized~5
bound~97
normally,~5
expression.~22
desensitization~27
affected~327
pretreatment~98
aspirin,~11
prevented~101
chelated~5
EDTA~6
once~53
occupied~14
epinephrine,~19
initiating~13
supporting~28
fibrinogen.~2
Furthermore.~1
Ca-dependent~2
maximal~305
Lymphocytes~5
Wiskott-Aldrich~3
Syndrome~10
(WAS)~3
scanning~113
electron~158
(SEM).~4
Most~163
lymphocytes~105
individuals~206
covered~27
slender~3
microvillus~4
projections,~2
WAS~8
devoid~22
microvilli.~3
lymphocyte~87
morphology~58
scoring~23
quantify~23
microvilli:~1
Grade~30
classified~102
75%~63
microvilli~4
decrements~8
grade~144
score~77
3.62~1
.22.~1
substantially~68
(2.89~1
.27,~1
.001).~46
qualitatively~19
abnormal,~5
short,~5
blunted~19
morphological~43
diagnose~27
"at-risk"~1
patient.~166
immunodeficiency~52
identified~414
aid~53
diagnosis.~120
ultimate~15
destruction~41
red~193
(RBCs)~3
oxidative~31
damage~183
Heinz~7
understood.~10
correlated~446
RBC~25
protein~802
oxidant~8
alterations~138
deformability~26
whole~142
membranes.~31
RBCs~15
phenylhydrazine~2
mg/dL~46
degrees~371
C~294
hour~114
bodies,~16
bodies~54
coating~20
inner~54
phenylhydrazine.~1
Sodium~19
dodecyl~30
sulfate-polyacrylamide~16
electrophoresis~41
quantity~35
hemoglobin~131
ghost~5
RBCs.~3
Electrophoresis~2
dithiothreitol~2
indicated~324
disulfide~6
bridges~7
abundant~29
proteins~183
bond~5
spectrin,~2
ankyrin,~1
band~40
3,~79
appearance~149
260,000-dalton~1
observed.~115
mg/dL,~6
filtration~83
2.6-,~1
4.5-,~2
6.8-microns~1
pores~2
filter~31
aspiration~90
technique~555
altered.~9
phenylhydrazine,~1
entire~119
coated~21
filterability~2
drastically~4
reduced.~30
discrete~34
focal~120
rigidification~1
global~61
cellular~193
cover~13
endoface.~1
hematology,~1
composition,~9
globin~7
gene~180
young~215
Turkish~1
boy~21
zero-thalassemia~3
homozygosity~2
relatives.~4
Evidence~27
presented~406
chromosome~69
determinant~59
carries~11
gamma-globin~6
quadruplication,~1
perhaps~43
-G~1
gamma-G~2
gamma-A~1
gamma-gene~1
arrangement.~2
genes~71
G~33
gamma~67
chains~28
95~61
ratio,~38
99%~15
patient's~172
type.~30
condition~155
thalassemia~4
intermedia.~1
HbF~14
beta-thalassemia~6
heterozygotes~8
varied~137
4.2%~3
percentages~28
averaged~81
87%~22
95%;~1
haplotype~10
chromosome.~5
All~674
carried~155
alpha-globin~10
genes;~1
BglII~1
polymorphism~10
psi~1
gene.~24
sialic~19
concent~1
retinoic~7
(RA)-resistant~1
6-thioguanine~1
(6TG)-resistant~1
HL-60~15
tenfold~12
dimethylsulfoxide~3
(DMSO)-resistant~1
twofold~18
parental,~1
wild-type~11
(wt)~1
Neuraminidase-inaccessible,~1
ie~1
cell-associated~5
neuraminidase~7
four-~3
twelvefold~1
differentiation-inducer-resistant~1
sublines~5
parent~19
Neuraminidase~1
glycoproteins~17
(SMGs)~1
wt~55
two-dimensional~74
electrophoretic~13
having~248
features~340
common~525
RA-~1
6TG-resistant~1
alter~125
sensitivity~330
differentiation~78
RA,~4
hypoxanthine~12
(purine~1
base),~1
DMSO.~1
peripheral,~3
neuraminidase-accessible~1
acids~124
important~545
determinants~54
mobility~31
SMGs~1
differentiation-resistance~1
mechanism.~35
Further~75
determine~691
hyposialylation~1
cryptic,~1
neuraminidase-inaccessible~1
functional~332
defensins,~2
cysteine-rich~3
peptides~52
granules~44
granulocytes,~5
tumor~793
targets.~4
HNP-1,~1
HNP-2,~1
HNP-3,~1
lysed~3
chromium~3
release~366
dye~37
exclusion~10
assays.~16
Defensin-mediated~1
lysis~21
concentration-dependent,~1
serum,~31
temperature-sensitive~4
events.~25
Lysis~2
detected~366
plateau~26
teratocarcinoma~2
HNP~1
1-3~7
oncogenicity~1
vivo.~53
Nonmalignant~1
susceptible~70
defensin-mediated~1
lysis.~5
Four~210
granulocyte~30
defensins~3
exerted~21
(NP-1,~1
NP-2)~1
(NP-3a,~1
NP-3b)~1
cytotoxic~46
activity,~123
defensin~1
NP-5~1
cytotoxic.~1
incubated~106
hydrogen~43
peroxide,~4
synergistic~12
released~98
granulocytes~28
stimuli,~15
contribute~109
independent~206
reactive~61
intermediates.~1
peptic~25
ulcer~102
(PUD)~1
rheumatoid~121
arthritis~116
(RA)~14
population.~97
Unusual~3
susceptibility~64
PUD~7
therapy,~155
compare~79
RA~47
others~89
predisposition~21
PUD,~1
hospitalized~54
(65~6
55~98
osteoarthritis)~1
questionnaire~62
history,~42
history~406
relevant~56
variables.~29
sex~142
distribution,~18
smoking,~26
alcohol~155
consumption~153
anti-inflammatory~19
patterns.~30
osteoarthritis~32
(OA)~6
(RA~1
15%,~9
OA~22
18%).~1
suggests~326
factor~338
(probably~4
drugs)~3
responsible.~5
feel~21
documented~172
probably~228
Available~4
ever~9
occurs~172
manifestation~60
RA.~7
Rates~14
superoxide~52
(SA)~4
generation~67
ex~20
corticosteroid~29
SA~8
pre-incubating~1
prednisolone~27
output~168
IgG-treated~1
zymosan~5
(ITZ)~1
fluoride~19
ion~56
(F),~3
serum-treated~2
(STZ)~2
steroid~99
ITZ,~1
STZ~1
F~44
stimuli.~19
yields,~1
size~299
cytochemistry~3
shift~76
traffic.~2
Methotrexate~3
(MTX)~3
refractory~88
efficacy~191
uncertain.~12
retrospective~135
MTX~16
comparison~172
purine~14
analogues,~3
azathioprine~6
6-mercaptopurine~1
made~406
life-table~10
analysis.~70
Eighty-four~4
took~39
median~210
7.5~19
mg/week~1
mg/day~14
(median).~1
19.3%~1
ceased~3
toxicity,~15
29.3%~1
analogues.~3
Toxicity~9
enough~50
warrant~18
stopping~16
At~412
61.5%~1
defined~201
25.6%~2
analogues~9
(p~1208
improving~30
low-dose~54
regimen~71
superior~148
Cells~25
mutations~21
hypoxanthine-guanine~1
phosphoribosyl~2
transferase~6
(HPRT)~1
locus~31
resistance~334
thioguanine.~1
HPRT~2
mutants~7
connective~46
diseases~135
drugs.~56
cyclophosphamide~29
abnormal~414
drug-induced~24
mutations.~1
chlorambucil~3
controls--either~1
or,~14
likely,~1
sufficiently~22
sensitive~201
detect~105
them.~28
possibilities~9
intractable~27
antilymphocyte~1
globulin~21
(ALG),~1
agent,~39
usually~279
azathioprine,~1
0.05)~240
early-morning~1
stiffness,~7
grip~6
strength~97
nodules~39
vasculitis~23
visit.~6
benefit~106
sustained~229
despite~212
fall~134
ESR~14
maintained~196
carpal~29
tunnel~32
syndromes~34
value,~19
individually~17
combinations.~7
physical~280
sign~51
condition,~25
electrodiagnosis~3
tests.~51
monoarthropathy~1
Hodgkin's~46
disease,~361
invasion~67
synovium,~1
juxta-articular~1
bone.~35
Episodic~2
cystic~98
fibrosis.~31
21-year-old~5
fibrosis~97
suffered~82
episodic~5
vasculitic~2
lesions.~133
Aetiology~1
discussed~92
reference~86
immune~175
inhibitors~64
stone~73
(zinc,~1
magnesium,~17
citrates~1
glycosaminoglycans~2
(GAG)~1
controls~285
recurrent~272
calcium~496
formers~2
fixed~69
diet~277
restricted~71
calcium,~59
oxalates~1
purines.~1
Zn,~5
GAG.~2
citrate~32
feature~62
pH~181
above~220
6.~9
Citrate~2
(per~5
litre)~1
h)~28
33%~46
determinations.~11
overall~256
0.56,~2
figure~11
agreement~64
data.~50
Fistula~2
deep~141
complication~185
xanthogranulomatous~2
pyelonephritis~11
(XPN)~1
British~13
literature.~73
clinicopathological~4
nephrodiaphragmatic~1
complicating~26
XPN,~1
nephrocolic~1
fistula,~16
fistula~79
childhood~45
XPN.~1
clinical,~47
radiological~44
pathological~72
XPN~1
reviewed.~191
nephrectomy,~8
together~88
excision~116
sinuses~7
fistulae,~3
choice.~13
manifest~20
solitary~33
metastatic~192
metastases~207
silent~36
discovered~32
autopsy.~22
Review~31
autopsy~78
19%~26
died~337
carcinoma~455
parallels~6
series.~43
solid~58
raise~25
metastases,~27
computed~220
tomography~199
mass~284
relative~358
homogeneity~11
enhancement.~7
More~59
CT~305
scan~85
staging~54
cancer~511
render~10
kidney~130
ante~1
mortem~2
Over~73
1-year~14
period,~164
rigid~50
ureteroscopy~9
retrieve~2
ureteric~14
calculi~24
details,~4
failure~423
78%~30
replace~17
blind~33
stones.~11
Eleven~62
vesicoureteric~6
reflux~107
neuropathic~7
bladder~213
endoscopic~144
pyrolised~1
polytetrafluoroethylene~14
(Polytef)~1
paste.~2
Thirteen~61
ureters~6
amount~231
Polytef~5
paste~6
0.9~55
0.45~11
ml).~9
complications,~47
except~151
ureter~22
where~209
distension~11
collecting~24
slightly~141
pre-operative~11
urogram.~1
serotonin~51
(5-hydroxytryptamine)~1
detrusor~24
pig~65
detrusor,~2
trigone,~4
neck~192
urethral~74
smooth~155
explored~23
series~260
experiments.~20
Serotonin~4
reversible~60
detrusor.~2
reverse~39
triggered~33
muscle--a~1
relaxation.~9
maximum~234
amplitude~128
relaxation~87
85~59
15%~70
electrical~144
stimulation.~61
unaltered~13
ganglia,~2
alpha-~19
beta-adrenergic~66
receptors,~31
cholinergic~63
synthesis.~38
ketanserin,~4
methysergide~6
cyproheptadine~4
partly~46
serotonin.~3
differed~89
potency~46
strips~26
origin.~46
ineffective~30
serotonin-S2-receptors~1
predominating~3
muscle.~50
neurotransmitter~23
tract~218
muscle,~54
importance~175
micturition~7
pathophysiology~32
unknown.~48
graphic~3
representation~6
cycle~161
pressure-volume~18
plot~12
women,~92
incontinent~6
voiding~27
prediction~53
outcome~211
sphincter~81
incompetence~12
colposuspension~3
instability~37
filling.~7
Where~10
competent,~1
urge~14
incontinence~29
filling~135
cystometry~3
drugs,~46
voiding.~2
Urethral~5
characterised~11
pressure.~131
haematuria~4
seen~579
1976~22
1977.~4
symptom~67
definite~49
up.~10
urological~14
symptoms,~68
none~145
malignancy~76
genito-urinary~1
tract.~23
Possible~37
bleeding~110
hundred~189
seventy-seven~1
advanced~172
prostatic~81
orchiectomy~11
oestrogen.~1
2-year~25
favourable~12
oestrogen~12
group,~232
particularly~210
emphasised~3
poorly~69
differentiated~68
tumour~69
evaluations~29
cardiovascular~169
side~220
fracture~190
penis~17
surgically~80
1968~12
Long-term~27
17.~4
post-operative~6
stated~18
achieving~29
painless~19
erections;~1
penile~45
curvature~18
sexual~79
activities.~28
strongly~133
recommend~67
encouraging~16
results.~109
Spastic~1
instructed~8
make~84
accurate,~5
ankle~46
dorsiflexion~14
plantarflexion~1
distances~13
target.~4
Ankle~2
electromyograms~6
(EMGs)~1
tibialis~21
(TA)~3
soleus~13
(SOL)~2
muscles~132
spastic~17
tested,~26
velocity-dependent~1
antagonist~84
impeded~3
movement~100
limb~145
unintentionally~1
reversed~74
direction.~4
propose~31
reflex~97
origin~119
since~208
tightly~10
synchronized,~1
amplitude,~16
movement,~8
velocity~197
dependent.~10
One~469
reflex-induced~1
clonus~2
plantarflexion.~1
overshot~1
stretched~8
clonus.~2
hyperactive~6
stretch~20
reflexes~25
deficits.~11
Skilled~1
forelimb~6
rats~765
unilateral~114
sensorimotor~12
cortex,~31
caudate-putamen,~2
dopaminergic~24
nigrostriatal~5
bundle,~2
task~22
reaching~25
food.~7
Limb~3
preference~14
efficiency~64
evaluated,~9
use,~35
spontaneous,~6
methamphetamine-induced~2
rotation~73
bias,~6
preoperatively~46
nonpreferred~1
limb,~8
bracelet,~1
movements,~5
attached~59
forearm~50
preferred~36
forelimb.~2
Whereas~29
cortical~172
forepaw~1
cortex~87
influenced~93
preference.~3
Furthermore,~119
medium-sized~8
surprising~10
forced~47
bracelet.~1
Large~22
Impairments~1
caudate-putamen~1
dopamine~103
depletions~1
blocked~87
depletion~61
ipsilateral~86
limb.~11
Correlational~1
weak~41
similarity~27
deficits~60
basal~232
ganglia~17
skilled~8
depends~56
neural~92
organization~27
systems.~45
investigates~11
hypothesis~203
consequence~39
Parkinson's~69
disturbed~13
caudate~14
outflow~77
cognitive~66
functions~54
integrity~29
prefrontal~2
focus~46
caudatofugal~1
signals.~2
extra-striatal~1
midbrain~6
reduce~147
extrinsic~18
supply~70
region,~20
double~71
risk.~39
Forty~30
nondemented~9
parkinsonian~12
drawn~41
pool~36
consecutive~299
according~165
age,~279
education,~19
IQ,~3
sex.~16
rated~35
neurological~141
indices~68
Neuropsychological~5
assessment~201
intelligence,~2
psychomotor~9
skills,~6
memory,~3
visuospatial~10
executive~5
functions.~11
decline~106
Moreover,~93
memory~36
abilities~14
intact.~12
cluster~9
emerged,~1
interpreted~40
reflecting~34
impairment~113
generate~23
efficient~40
strategies~37
relying~3
self-directed~2
task-specific~1
planning.~6
frontal~47
lobe~64
distinguished~52
lateralized~4
right~572
left~1042
body.~22
Deficits~2
strategic~4
planning~43
attributes~4
IQ~18
performance~203
tasks.~5
Results~153
investigations~48
perspective~9
cerebral~425
ganglia.~8
crucial~26
planning,~6
validity~44
model~400
predicting~77
consequences~45
nucleus~65
supported.~1
investigate~132
axonal~33
disturbances~38
Doxorubicin,~1
antineoplastic~9
interferes~10
DNA,~20
selective~163
sensory~93
dorsal~71
root~49
(4~41
mg/kg)~63
male~342
Wistar~27
rats,~105
slow~81
component~137
(SCa)~1
retarded,~2
being~341
17%~28
(0.85~2
0.06~25
mm/day~2
vs~329
1.03~4
controls).~12
fast~41
anterograde~11
retrograde~76
(aFC~1
rFC)~1
unchanged~110
mg/kg,~33
aFC~1
27%~27
(3.2~3
0.9%~10
4.4~21
1.1%~10
neuronopathy~2
doxorubicin~24
66~69
histologically~84
myopathy~11
birth~158
years,~254
61%.~2
Nineteen~35
similarly~47
clinically:~1
external~163
ophthalmoplegia~3
weakness~45
limbs~44
exertion~6
(55%);~2
(18%);~1
features,~36
ataxia,~8
dementia,~12
deafness,~1
involuntary~5
exclusively~46
arising~53
CNS~32
(27%).~3
overlap~19
pigmentary~14
retinopathy,~12
36%~38
three.~17
twenty~23
(all~30
3)~40
severely~77
disabled~16
42~107
still~171
able~105
metabolism,~19
33~133
cases,~204
deficiencies~24
chain~66
localized~110
(18~17
patients)~100
III~174
(9).~1
picture~29
emerged~17
defects.~23
three-dimensional~19
horn~24
C8~6
segment~152
spinal~337
recognized~138
lateral~217
zones~31
neuron~13
groupings,~2
recognize~27
subgroups~25
neurons~94
groupings~4
resembling~15
anatomical~47
columns~5
investigators.~7
observation~108
invalidate~1
pools.~6
cords~14
identified,~22
consistent~248
sectional~9
imply~20
varying~82
pools~14
neurons.~22
aged~194
discrimination~29
interhemispheric~8
transfer~124
tactile~7
information~296
tactuomotor~1
learning~36
callosotomy.~1
Comparison~40
preoperative~264
capacities~12
younger~145
considerably~47
interruption~16
callosal~5
transmission~98
speech~23
participation~37
commissure~2
largely~64
excluded~48
compensatory~31
mechanisms.~26
plausible~7
explanation~48
preservation~53
integration~19
reliance~5
pathways.~13
hand,~59
come~9
depend~32
extensively~30
pathways~53
corpus~30
callosum~7
reaches~7
maturity.~3
Previous~68
subpopulations~13
sclerosis~83
(MS)~9
periodic~35
OKT8~2
(T8+)~1
longitudinal~47
twice~117
monthly~13
participant~8
out~276
phases~43
lasting~43
fluctuations~26
T8+~6
MS~36
subpopulation~13
spouses~6
siblings,~4
unrelated~56
occurring~193
10/13~1
5/9~2
families;~2
temporal~129
remainder.~2
Taking~3
significant,~33
12/13~1
7/9~1
spouses,~2
6/13~2
siblings~34
4/13~1
(chi~23
12.5;~1
stage.~26
indirect~71
environmental~59
determining~84
certain~151
immunological~19
illustrate~29
family~345
specificity~150
research~135
experiment~42
fundamental~23
aspects~69
spatial~41
ability,~5
namely~24
right-left~2
manipulation~29
concepts~25
perspectives.~2
Measures~5
accuracy~133
taken.~5
task.~13
Neither~66
literature,~24
nor~180
idea~9
generalized~70
deficit~58
inhalation~88
dual~21
tracer~35
radioactive~41
isotope~19
(Rowland~1
et~35
al.,~11
1986),~1
small-~3
tracers.~1
oedema~23
smoke~21
resuscitation~73
[corrected].~2
post-injury.~1
appear~239
tracers~3
transit~54
compartment.~17
water~256
gravimetric~3
analyses~83
lungs.~22
Thus~67
detectable~100
post-injury,~1
towards~17
challenged~26
periods.~30
Fluid~7
exacerbates~2
therefore~148
modifications~38
injury.~144
succinate~3
substrate,~5
mitochondria~24
burned~31
Sprague-Dawley~41
full~99
thickness~109
covering~11
cent~371
15,~31
30,~42
45~149
60~268
burn,~2
post-burn.~1
sham~28
succinic~8
dehydrogenase~62
activities~142
cytochromes~1
b~4
c~10
+~165
burning.~3
metabolic~200
usefulness~79
scar~25
flaps~57
repair~152
Burn~4
contractures~19
repaired~19
scarred~5
axial~55
flaps,~8
musculocutaneous~13
fasciocutaneous~6
contention~12
strictly~10
limited.~14
example~28
ear~81
shown.~6
cell-mediated~20
humoral~30
undertaken~84
post-burn~5
see~36
bacterial~94
consequently~12
healing~106
multidisciplinary~12
approach~265
counselling~1
parents~57
parental~16
anxiety,~9
medical,~9
psychological~44
social~95
discussions.~1
industrial~16
Royal~5
Brisbane~1
Hospital~107
years.~347
182~9
survey--173~1
males~118
(95~15
cent)~70
females~86
(5~72
cent).~22
31.5~2
18.5~6
admissions~24
unit~94
past~96
old.~19
31~129
Two-thirds~3
cent.~40
While~97
scalds~2
commonest~16
(19.4~4
cent),~10
flame~6
clothing~2
ignited~1
burns.~12
Face~1
hands~30
involved.~27
Burns~3
regions~121
mainly~92
Eye~10
comprised~45
5.5~31
sample~148
chemicals,~3
explosions~1
flash.~1
Twenty-six~28
(14~26
Only~202
died.~36
Progress~3
carelessness~2
error~71
take~32
toll.~1
epidemiology~13
analysed.~7
September~21
August~14
1983~48
27~190
Unit~10
Copenhagen.~1
majority~162
domestic~16
fire~6
predominant~53
cause.~18
vulnerable~8
areas~248
arms~14
legs,~5
predisposing~26
accidents,~5
prevention~85
stressed.~12
preceding~40
1985,~59
140~40
lightning~2
44~91
thunderbolts.~1
bodies.~16
victims~40
consisting~69
rupture~89
clothes~1
superficial~115
dermal~49
along~118
head~261
occurrence~177
flashovers.~1
remaining~229
flash~8
effect.~68
noteworthy~7
survived,~10
survived.~18
indicates~121
flashover~4
body,~13
probability~86
survival~633
experimentally,~1
imposing~2
artificial~59
voltage~38
impulses~8
developing~108
flashovers~1
survived~95
drop~41
point,~9
waveform~16
exhibited~148
sharp~17
peak.~8
microseconds,~2
cone~15
shape.~3
appreciably~4
diminishes~11
dissipation~3
survival.~82
Pillars~1
calcification~24
rarely~104
skin.~48
interesting~15
rows~4
grafted~9
partial~226
shin.~1
heterotropic~1
ossification~10
vesico-enteric~1
resection~278
intestine~60
dome~13
drainage~118
intervening~5
abscess.~14
search~33
reveals~36
high-voltage~2
motion~166
hand~79
obvious~39
adapted~23
games~9
interest~48
aroused~2
incentive~1
his/her~1
programme.~4
players,~1
intellectual~18
levels,~122
ranges~28
motion:~2
fingers,~2
wrist,~2
elbow~34
shoulder.~6
former~61
patient,~128
now~157
retired,~1
copied~1
occupational~31
therapist,~2
Israeli~5
manufacture.~2
autoclaved~1
much~210
outlet~14
distraction~14
signifies.~1
electromagnetic~19
spectrum~84
consists~44
radiant~17
Man~5
constantly~7
portion~98
spectrum,~3
ultraviolet,~4
visible~44
infrared~12
regions.~19
non-ionizing~2
energy.~9
possess~16
endogenous~82
mechanisms~211
minimize~29
exposure,~41
radiation.~23
cornea,~3
range.~48
Part~16
two-part~2
article~84
examines~29
structures~79
damage;~4
II,~85
published~61
next~42
issue~12
Journal,~1
focuses~15
protection.~12
variable~115
suction~27
irrigation,~2
vitrectomy.~3
regulated~31
operator's~2
finger-tip.~1
Supramaximal~1
rectus~25
correct~82
horizontal~30
deviations~17
seven~452
sixth~16
palsy~28
palsy,~6
cases.~251
disadvantages~17
Nerve~5
fibre~27
bundle~29
visual~291
field~133
defects~113
hallmark~5
pathology~66
retina.~13
series,~30
intracranial~135
acuity~65
spared~10
eyes.~19
opposite~34
offer~62
clue~6
localization~69
lesion.~57
56-year-old~3
10-year~20
torsional~7
oscillopsia.~1
intermittent~75
first,~16
practically~4
uninterrupted~2
last~144
She~30
diagnosed~268
oblique~35
myokymia~1
Adequate~8
trials~85
oral~325
carbamazepine,~2
unsuccessful~18
suppressing~13
her~76
symptoms.~116
year~292
she~37
tenectomy~1
inferior~131
recession.~1
eventually~52
operation~255
cure~31
annoying~1
down-gaze.~1
signet-ring~4
lymphoma~83
orbit.~4
variant~62
non-Hodgkin's~28
contains~38
vacuolated~11
eosinophilic~23
inclusions~17
squeeze~1
cell.~22
stained~34
positively~56
PAS,~1
immunoglobulin~66
M~157
(IgM)~1
heavy~72
kappa~15
chain.~4
granular~24
electron-dense~4
trapped~8
distended~7
loops~10
rough~15
endoplasmic~20
reticulum.~4
Twenty-two~31
elsewhere~12
Between~56
1979~44
June~32
allergic~90
interstitial~83
nephritis~22
nephrology~2
service~43
temporally~8
drug:~1
nonsteroidal~18
agent~146
(NSAID)~1
(in~49
patients),~69
cimetidine~49
three),~1
antibiotics~50
two)~1
allopurinol~17
one).~2
insidious~5
seven.~7
fever,~40
rash,~2
hematuria,~11
pyuria~2
eosinophiluria,~1
proteinuria~43
cells,~221
lymphocytes,~10
eosinophils.~4
hemodialysis;~1
steroids~44
well.~37
Steroid~14
NSAID-induced~2
35~188
days,~104
deterioration~49
Acute~62
uptake~299
gallium~14
67,~1
discontinuation~38
implicated~42
characteristic~157
nephritis,~2
eosinophils~28
sometimes~52
IgE~86
hypersensitivity~58
reaction.~24
ambiguity~1
suicidal~6
motivations~1
detail,~5
attention~80
changeability~1
motivations.~1
taken~187
paraquat,~1
highly~228
lethal~44
herbicide,~3
questioned~14
motivation~3
25~342
claimed~10
wished~8
die~12
admission,~24
surviving~40
live~33
died,~26
interview~32
themselves.~9
emphasize~28
thoroughly~3
situation~34
risks.~4
intentions~6
Off-road~1
vehicles~2
attained~31
growing~43
popularity,~1
expanding~16
markets~3
increasing~301
injury,~95
people.~9
1984-85,~1
148~13
Children's~26
Eastern~6
Ontario,~4
Ottawa,~1
off-road~1
accidents.~9
Soft-tissue~2
21~319
179~5
fractures~201
133~20
mechanism~308
losing~3
tumbling~1
machine.~2
struck~1
own~43
vehicles,~2
39~102
collided~1
objects~4
cars,~1
trees~2
costs~38
accidents~29
concerns~24
legislation~9
protect~20
consumers,~1
young.~3
prognostic~161
242~8
preleukemic~2
myelodysplastic~7
(MDS)~3
myeloproliferative~4
disorders~133
(MPD),~1
karyotypic~6
clone~14
death,~39
progression~99
leukemia~66
hematopoietic~17
dysfunction.~44
Conversely,~28
hemic~1
alteration~64
(involving~2
translocation),~1
reduced~662
abnormality.~19
markedly~202
shortened~26
monosomy~2
conclusions~23
concerning~65
grave~3
preleukemia~1
reflect~104
clones~27
cytogenetic~9
Prior~23
knowledge~79
evaluating~84
attempts~55
find~42
difficult~145
disorders.~66
Ninety-six~5
disseminated~39
malignant~313
thrice~3
weekly~51
intramuscular~34
injections~113
leukocyte~55
recombinant~27
interferon~34
(rIFN-alpha~2
A,~62
Roferon-A,~1
Hoffmann~3
La~2
Roche)~1
X~714
10(6)~28
U/m2~4
immunorestorative~1
agent.~37
chemotherapy,~31
complete~400
(3~47
soft~108
metastasis)~2
exceptionally~7
durable~6
(months)~1
29+~1
(soft~3
tissue;~7
lesion),~1
31+~1
tissue),~2
35+~1
lesions).~3
parameters.~29
noted~264
previously,~11
melanoma,~10
achieve~78
objective~107
rIFN-alpha~1
A.~21
morphologic~93
89~41
yolk~4
sac~13
(YS)~1
embryonal~9
(EC)~5
(29~17
teratomas)~1
submitted~33
Rare~1
Tumor~30
Registry~6
Southwest~1
Oncology~14
(1971-1979)~1
Pediatric~13
(1980-1984)~1
1971~11
1984~67
5-year~73
regardless~88
site,~29
"pure"~3
tumors~360
teratomatous~6
components,~20
YS~1
EC~13
sacrococcygeal~4
neonatal~128
poor~215
"benign"~3
teratomas~5
resected~48
coccygectomy~1
recur~9
YS,~1
testicular~82
EC,~2
mediastinal~76
females.~24
Methylglyoxal~1
bis~3
(guanylhydrazone)~1
(MGBG)~1
inhibitor~93
polyamine~5
accumulation~132
S~57
G2~7
cycle.~37
entered~42
Phase~14
II~364
MGBG.~1
MGBG,~1
500~49
mg/M2,~1
Dose~5
treatments.~19
chemotherapy~165
recurrence.~44
evaluable~25
toxicities~8
nausea,~13
vomiting,~20
diarrhea,~14
stomatitis.~2
Myelosuppression~3
patients;~80
700~6
mg/M2~1
tolerated.~5
MGBG~2
22%~40
(range,~62
6%-41%).~1
heavily~20
pretreated~37
effects,~40
numbers~111
warranted.~14
July~35
1973~17
1979,~9
1171~1
breast~210
doxorubicin-containing~3
chemotherapy.~43
195~8
osseous~12
only.~42
Upon~16
48%~23
osteolytic~1
metastases;~5
13%~33
osteoblastic~9
38%~28
osteoporosis~18
destruction.~8
involvement~236
spine~116
(62%),~1
lumbosacral~11
(72%),~1
pelvis~28
(79%).~2
Objective~5
59%~10
7%,~4
52%.~4
1-118~1
months).~57
lapse~2
1-109~1
32~153
responded~93
discontinued~26
remission~73
completion~37
57%;~2
spine,~11
compression~119
fractures,~31
ribs.~2
incidences~16
hypercalcemia~35
10%,~6
dysgerminoma~5
ovary~14
etoposide,~3
bleomycin,~5
cisplatin~34
University~76
Texas~14
M.D.~2
Anderson~6
Institute~25
Houston.~1
remission.~17
Patient~33
recurrence~198
para-aortic~7
lymph~241
nodes~104
salpingo-oophorectomy~2
alone.~106
cycles~79
Stage~81
lymphangiogram~1
nodes.~30
remissions~12
second-look~4
laparotomy.~15
Chemotherapy~8
alternative~144
radiotherapy~82
selected~223
conclusion~40
might~238
expand~10
indications~66
Forty-three~18
79~43
germ~25
52-83).~1
69%,~3
32%~34
Limited~10
histopathologically~6
proven~53
postchemotherapy~2
necrosis~131
resectability~4
posttreatment~15
teratoma~8
favorable~71
20%~109
30%~84
salvaged~7
Posttreatment~3
whenever~23
possible,~25
reactivation~8
Raynaud-like~1
phenomena~18
gastrointestinal~125
sequel~5
(10%-15%)~1
modern~24
multimodality~3
(fertility-related~1
here).~1
lifestyle~4
seems~124
unaffected~60
1561~1
registered~19
Intergroup~3
Rhabdomyosarcoma~3
Study~31
(IRS)~1
May~16
1983,~34
78~50
(5%)~14
(1-20~3
age)~15
male/female~4
grouping,~1
rates.~46
Infants~21
undifferentiated~23
sarcoma,~10
18%~39
7%~43
0.005).~53
cancers~80
botryoid~1
pathology,~8
4%~44
newly~76
proposed~106
IRS~1
cytopathologic~2
classification,~5
pathologic~164
types~280
bladder-prostate-vagina~1
24%~36
prescribed~29
differences,~17
curve~89
contrast~269
Wilms'~3
neuroblastoma,~1
year)~3
factor,~24
rhabdomyosarcoma.~1
(TNM~1
IIB-IVB)~1
mycosis~14
fungoides~10
program~165
bleomycin~17
methotrexate~52
weekly,~3
nitrogen~62
mustard~6
daily~220
(BAM-M).~1
Seven~111
105+~2
duration.~14
Median~27
16.5+~1
splenomegaly~6
splenectomy.~13
unmaintained~2
disease-free~40
survivals~9
36+,~1
100+,~1
BAM-M~1
splenectomy~32
further.~8
seemingly~7
Waldeyer's~5
ring~37
(WR-NHL),~1
lymphangiography~2
(LAG)~1
gallium-67~1
scans~146
(Ga-67~1
scans)~2
done.~13
Before~32
procedures,~45
I,~76
II.~33
LAG~3
done~158
Ga-67~3
32,~8
both.~42
(16%)~9
upstaged~2
scans.~22
(3%)~13
findings,~65
region.~31
rate,~163
WR-NHL.~1
Cell-mediated~1
submucous~1
(OSMF)~1
oral-leukoplakia,~1
high-affinity~5
rosette-forming~2
(HARFC)~1
OSMF~3
cancer,~72
(TRFC)~1
remained~338
unaltered.~12
Levels~21
IgA,~16
IgD,~2
elevated~391
cancer.~107
Immunologic~6
derangements~10
OSMF.~1
enumeration~2
HARFC~1
estimation~24
intermediary~6
transformation~45
cell,~15
serve~41
markers~63
detection~225
Virus-associated~1
hemophagocytic~4
recently~120
benign,~7
histiocytic~10
Rappaport's~1
hystiocytosis.~1
Other~90
etiologic~22
bacteria,~4
identified.~53
tuberculous~15
sepsis~48
Benign~5
striking~51
hemophagocytosis~2
disseminated,~2
multisystemic~1
systemic~414
anergic~3
422~3
Mayo~10
Clinic~17
1907~2
bone,~25
multifocal~16
lymphoma,~23
nodal~53
both)~6
last-mentioned~1
separated~66
nonosseous~1
indicator~65
5-~5
were,~18
58%~21
53%~24
12.5%~7
42%~23
35%~48
Features~9
histologic~231
(according~1
Working~7
Formulation~3
Kiel~1
system),~2
T-cell~51
cleaved~15
both).~6
adequately~32
address~22
fact,~22
Head~7
meningeal~24
carcinomatosis.~1
invasiveness~1
rather~201
distant~58
metastasis.~19
preclude~16
close~104
proximity~12
cranial~65
meninges.~1
Six~147
cerebrospinal~68
fluid.~30
specimen~51
lumbar~105
punctures~2
negative.~34
presentation~117
involvement.~43
VI~4
V~23
frequent.~8
Headache~2
seizures~78
two.~26
meningismus.~1
plan~29
Ommaya~2
Reservoir~1
intraventricular~27
methotrexate.~3
whose~185
undergo~66
Meningeal~1
carcinomatosis~1
prevalent~25
extension~76
hematogenous~6
spread.~9
testosterone~105
(STL)~1
female~249
gastric~416
58~60
benign~170
STL~4
(446~1
ng/dl)~9
(532~1
132~17
Even~34
(440~2
117~24
(31.6~1
16.0~5
(46.3~1
15.3~4
gastrectomy~15
0.005)~41
(0.025~1
obviously~5
Therefore,~129
Serum~147
(TSA)~1
lipid-associated~2
(LASA)~1
carbohydrate~80
aberrations~11
TSA,~1
LASA,~1
(TP),~1
TSA/TP~4
171~6
differing~15
102~27
nonmalignant~15
(pathologic~1
controls),~3
individuals.~47
Data~94
TSA~2
(78.1~2
19.2~6
12.4~6
3.8~22
mg/g,~1
respectively)~43
(76.0~1
11.6~12
mg/g)~1
(67.3~1
7.1~13
9.0~11
mg/g),~1
TP~9
(6.4~1
g/dl)~4
(6.6~4
(7.5~9
g/dl).~1
LASA~1
values.~99
involved,~16
severe.~11
detecting~88
malignancies.~11
marker~95
prove~37
approaches.~4
Chondrosarcoma~1
Clinically~9
confused~10
sclerosis,~15
glomus~4
jugulare~3
tumors,~53
meningioma,~1
chordomas.~1
palsies~6
anatomic~136
locations~25
tumors.~85
eleven~28
Histologically~5
exhibit~48
myxoid~6
features.~20
must~256
chordoma~2
chondroid~1
chordoma.~1
unacceptable~8
neurologic~175
sequelae.~29
Proton~2
beam~18
short-term~67
avoiding~17
effects.~91
clinicopathologic~21
remarkable~24
subependymal~2
periventricular~11
spread~65
brain~349
neuron-specific~7
enolase-positive,~1
anaplastic~13
carcinoma.~109
Involvement~7
choroid~15
plexus~42
leptomeninges~1
absent.~13
Intraparenchymatous~1
nodular~41
nonspecific~55
orthostatic~17
hypotension,~14
infiltration~33
floor~23
ventricles.~7
examination,~63
normal.~116
contrast-enhanced~9
scanning.~14
Multivariate~22
unselected~13
population~238
253~5
neuroblastoma~15
Denmark~2
1943~1
1980~44
stage,~32
Calendar~1
factors.~65
multimodal~6
significantly.~37
theory~27
neuroblastomas~2
congenital;~2
therefore,~83
reflects~38
tumor.~69
theory,~6
measure~164
micrometastases~2
Additional~31
eradicated~6
disappeared~42
implications~70
policy~24
theory.~5
males,~26
uncle~2
nephew~1
families~79
members~106
included.~9
familial~64
hereditary~40
contributing~32
factor.~38
(including~41
own)~1
sufficient~98
given,~9
(60%)~19
risk~879
Traditional~5
pleural~77
effusions~14
includes~54
thoracentesis~1
instillation~22
irritants~5
pleurodesis.~1
lengthy~5
hospitalization,~18
discomfort,~6
appreciable~16
rate.~101
drawbacks,~1
shunting~22
peritoneal~128
cavity~59
effusions.~5
undergone~88
thoracenteses~1
failed~214
sclerosis.~18
shunt~77
valved~6
catheters,~13
manual~39
abdominal/pleural~1
gradient.~10
Operative~24
anesthesia~120
complication.~41
benefit,~3
moribund~4
compress~2
effectively.~3
diminished~84
stabilized~19
effusion;~1
palliated,~1
effusion~29
required.~28
Peritoneal~11
dissemination~16
pleuroperitoneal~1
valid~24
palliate~1
morbidity.~31
Advantages~9
tubing~8
possibility~151
hospitalization~34
outpatient~86
Shunting~1
applicable~27
requisite~1
pumping~10
suitable~75
Many~67
mesothelioma~10
dyspnea~21
Cardiac~52
symptomatology~8
differentiate~47
pleuropulmonary~1
define~99
mesothelioma,~3
electrocardiographic~76
(EKG)~2
echocardiographic~99
64~77
biopsy-proven~8
19/64~1
(30%)~21
review.~11
EKG~5
(89%).~2
half~185
arrhythmia,~6
(42%),~4
atrial~284
contractions~101
(13%),~4
(3%),~5
flutter~7
(1%).~7
(37%)~14
abnormality,~10
branch~58
hemiblock~2
(8.5%),~1
incomplete~61
(13%).~2
Echocardiography~7
pericardial~59
effusions,~4
thickening,~9
sonolucent~1
space.~32
autopsies,~1
(74%),~4
pericardium~7
quarter~3
myocardium.~21
that:~28
great~70
echocardiogram~4
differentiating~23
mesothelioma.~1
Simultaneous~19
cytometry,~6
cytologic,~1
cystoscopic~3
examinations~100
3-month~14
minimum~97
intravesical~12
bacillus~11
Calmette-Guerin~10
(BCG)~3
Flow~14
cytometry~16
(FCM)~4
cytology~34
concordant~11
57~72
103~21
examinations;~3
FCM~11
38~127
instances,~18
(92.1%).~1
instances~44
negative,~16
(31.3%).~1
suspicious~13
46~84
determinations~54
discordant~14
subdivided~18
pathologically~18
recurrences~48
(25~27
instances)~1
(21~22
instances).~1
recurrences,~8
(72.0%),~1
(12.0%),~2
negative~313
(16.0%),~1
(36.0%),~1
(52.0%).~1
BCG-induced~1
elevation~137
hyperdiploid~2
population,~44
epithelial~179
regeneration~28
recurrence,~22
hyperploidy~1
(15)~2
(4)~5
FCM,~2
aneuploid~22
populations.~27
least,~7
harboring~4
occult~49
Conventional~9
nonrecurrent~3
(4.8%),~1
(33.3%),~2
(61.9%).~1
biopsy,~24
false-negative~20
19.7%;~1
40.9%.~1
cytology,~5
false-positive~25
stemlines~1
populations~60
irrigation~23
specimens~273
BCG~7
carcinoma,~54
cytology.~3
greatest~77
difficulty~45
present,~46
inflammation.~23
here~70
stringent~6
represent~128
accuracy.~9
Potential~6
improvements~29
immunologic~42
markers,~12
hold~8
hope~10
FCM.~3
transitional~46
carcinomas~101
(TCCs)~1
studying~33
radical~110
cystectomy~10
2000~9
rad~20
week~144
bladders~10
TCC~2
23%~25
nonirradiated~8
TCCs~1
papillary~65
irradiated,~3
79%~12
lacked~17
cystectomy,~3
invasive~101
noticed.~2
Flat~2
situ~91
(CIS)~3
nuclear~140
pleomorphism~2
60%~81
TCCs,~1
biopsy.~37
squamous~90
neoplastic~39
only,~16
affecting~70
nonneoplastic~3
urothelium.~2
once-obscure~1
ventricle~96
becoming~18
evident.~9
ventricle,~17
once-considered-passive~1
conduit~16
proved~139
essential~158
output.~33
coronary~921
artery~836
circulation~97
after-load~2
ventricle.~30
congestive~78
failure,~79
relates~13
capacity,~27
not,~25
ejection~160
fraction~235
guide~34
aortic~488
valvular~37
evident,~5
precise~50
interplay~3
yet~88
explained.~3
hypertension,~88
elevate~4
pressures.~24
devoted~4
compromise~28
myocardial~582
infarction.~80
Little~23
disproportionate~11
therefrom.~1
Recognition~15
problem~129
paramount~5
importance,~7
measures~148
implemented.~3
deal~16
learned~13
failing~8
Much~10
reserve,~5
defining~10
factors,~80
quantitating~7
optimally~5
perioperative~54
Recognizing~3
preoperative,~1
enlightened~1
disposition~31
team.~7
Awareness~9
conduct~12
mortality~455
failure.~118
imposition~1
imperfection.~1
Appropriate~5
effort~64
toward~129
minimizing~23
insult~8
decreasing~70
impetus~4
continuing~25
dictates~1
appropriately~23
treat~59
preventable~9
problem.~46
prohibits~2
separation~44
cardiopulmonary~79
bypass,~18
employed,~6
correction~103
hypoxia~60
acidosis,~8
loading,~9
inotropic~40
Infusion~18
vasodilators--particularly~1
nitroprusside--should~1
elevated.~14
unsatisfactory,~3
intra-aortic~2
balloon~169
counterpulsation~4
employed.~13
right-atrial-to-pulmonary-artery~1
bypass~150
Bio-Medicus~1
centrifugal~3
centers~30
Pierce-Donachy~1
pneumatic~17
assist-pump~1
congenital~202
cannulae~8
technically~26
feasible,~8
high-frequency~15
high-volume~2
ventilation~154
quite~34
promising.~4
Utilization~5
creation~16
septal~97
lifesaving,~1
RV~57
LV~134
coexist.~2
Experimental~20
resistance.~44
thereby~63
transpulmonary~13
hydrostatic~15
contribution~53
Treatment~117
aimed~23
restoring~8
persists~17
simple~182
problem,~20
commenced.~1
inotropes,~1
adjustments~14
assist~28
RHBP~2
powerful~23
device,~10
perfusion~183
encouraging--most~1
allowing~42
weaned~20
assist.~1
constant~173
attention.~12
PABC~2
device.~20
extremely~95
depressed--cardiac~1
normal--PABC~1
Current~21
gold~19
clearly~119
Doppler~167
echocardiography~113
quantitate~23
intracardiac~29
velocities~32
stroke~161
volumes~67
fetuses~36
gestation.~34
spectra~9
aortic,~7
pulmonary,~6
tricuspid,~5
digitized~11
obtain~64
(m/sec)~1
integrals.~2
Aortic~11
diameters~37
valve~342
images~156
cross-sectional~56
assuming~7
circular~22
orifice.~7
Ventricular~22
product~79
vessel~96
integral~19
vessel.~7
linearly~29
(r~307
.82,~2
r~74
.84),~1
exceeded~61
diameter.~32
age:~6
exponentially~7
0.7~54
7.6~9
.87)~1
5.2~22
.91).~1
outputs.~6
44%~18
volumes.~8
.96)~1
28%.(ABSTRACT~1
androgens~11
(testosterone,~1
androstenedione,~10
dehydroepiandrosterone~28
sulfate~99
[DHEA-S]),~1
estrogen~126
(estradiol)~1
progestin~9
(progesterone)~1
lipoprotein~89
cholesterol~244
(very~1
low-density~34
[VLDL],~1
[LDL],~1
high-density~23
[HDL])~1
apolipoproteins~2
(apo~1
A-I~7
apo~12
B)~10
white~153
251)~1
258)~1
adolescent~39
boys,~11
ages~87
Bogalusa~1
Heart~58
Study.~5
Black~12
boys~48
estradiol,~23
HDL~22
cholesterol,~32
A-I,~1
androstenedione~9
VLDL~19
adiposity.~2
Age~25
DHEA-S~7
estradiol~109
races.~4
(positively),~1
(negatively),~2
(negatively).~1
Overall,~51
inversely~51
progesterone~120
races~5
adjusting~14
Partial~20
correlations~81
lipoproteins~41
adjusted~40
adiposity~3
associations~20
race.~8
inverse~28
relations~25
group.(ABSTRACT~4
best~189
114~23
medically~21
angiograms~27
apart.~7
stenoses~39
visualized~34
projections~11
Vessel~3
edges~7
catheter~230
calibration~19
automated~26
computer~52
algorithm~19
yielding~19
"absolute~1
dimensions"~1
diameters)~1
(percent~8
stenosis~228
atheroma~2
area)~5
"normal~1
reference"~1
variation~101
atheroma.~1
t~24
(6.7~4
14.1%~2
decrease),~1
whether~436
measurement~164
deviation~26
subset~39
estimated~178
470~4
interventional~13
(207~1
reduction)~1
confidence~78
90%~97
power.~10
Atrial~7
pacing~127
angina~128
rest~160
70%)~1
morning~40
(10~83
A.M.~23
P.M.),~2
afternoon~9
night~26
(12~34
midnight~4
A.M.)~1
circadian~20
ischemic~307
threshold.~3
night.~4
ST~114
shift)~2
reproducible~35
results,~54
thresholds~30
(125~2
138~15
SEM;~1
p~578
.005).~18
elevation,~8
(68%).~3
nocturnal~24
threshold,~10
facilitate~53
development~434
transmural~39
ischemia~249
pacing.~13
spasm~31
reproduced~9
maneuvers~15
pharmacologic~53
agents.~46
known,~18
what~49
agonist-receptor~2
interactions~51
supersensitivity~4
vasospastic~5
diverse~17
vasoconstrictive~5
provoke~4
spasm.~16
Ergonovine,~1
hyperventilation,~6
handgrip,~2
cold~100
pressor,~1
exercise-tests,~1
administered.~14
Spasm~1
provoked~28
ergonovine~11
96%~18
hyperventilation~27
47%,~2
exercise~481
46%,~4
pressor~65
handgrip~13
11%~41
provocative~14
arteries~218
nonsignificant~13
individual,~3
39%.~4
Tests~7
reproducibility~20
paralleled~20
sensitivity.~18
angina,~19
interaction~114
plays~59
genesis~17
(VT)~21
("arrhythmic~1
events")~1
prospectively~95
Signal-averaged~2
electrocardiograms~18
(ECGs)~1
serially~24
hr~144
Holter~31
determined.~65
Sixty-five~15
1)~55
signal-averaged~20
ECGs~10
(voltage~1
msec~44
filtered~15
QRS~78
microV~5
msec),~4
92~48
2),~13
(excluded~1
normalization~22
overall.~8
(median~21
11),~3
suddenly~19
again~67
symptomatic~170
VT.~12
65~96
arrhythmic~13
(1%)~4
ECG~80
events~89
92%~34
62%.~3
(11.0~1
32.0~1
21.9~2
microV;~1
.001)~42
events,~14
(121~2
105~34
msec;~6
logistic~42
ectopy~4
discharge.~28
identifying~52
Dynamic~8
terminal~66
endomyocardial~12
radioligand~8
(-)[125I]iodocyanopindolol~1
(ICYP).~1
ICYP~2
crude,~1
high-yield~1
preparation~86
(specificity~5
90%),~1
affinity~102
(KD~2
pM),~1
saturable~10
stereospecific~4
(-)~3
(+)~8
isomer~2
isoproterenol.~8
Subjects~29
mild-moderate~2
biventricular~9
respective~53
38.2%~2
57.7%~1
averaged,~2
dissociation~50
constant.~12
subgroup~43
(LVEF)~1
(LVEF~2
0.50~14
0.40)~3
0.20)~1
graded~52
sequential~68
dobutamine~20
gluconate.~1
Those~44
dP/dt~12
work~151
index~315
intact~171
failure-associated~1
down-regulation~8
begins~13
dysfunction,~29
beta-receptor~8
pharmacologically~16
beta-agonist-mediated~1
contractile~90
Therapy~20
dilated~73
limited~235
concern~27
compromised.~5
fractions~72
lowest~63
vasodilator~36
diuretic~23
wedge~47
(PCWs)~1
Hg~198
baseline).~1
Stroke~11
baseline.~16
g-m/m2.~1
PCWs,~1
PCW~1
upright~18
tolerated~39
supine~85
PCW.~1
Normal~39
established.~32
afterload-corrected~1
end-systolic~45
(ratio~5
[ESS/ESVI])~1
regurgitation~46
replacement.~36
Therefore~16
ESS/ESVI~3
hemodynamic~187
predictors~57
regurgitation,~16
stenosis,~30
stenosis.~66
Twenty-seven~20
S)~2
NYHA~12
class~102
fraction.~26
IV,~22
subnormal~21
deemed~10
unsatisfactory~15
U).~1
pressure,~185
end-diastolic~50
index,~35
(ESVI),~1
wall~327
U,~4
U.~10
stepwise~28
discriminant~10
multivariate~43
analysis,~56
ESVI~2
(who~3
biased~5
study)~3
excluded,~8
predictive~149
variable.~17
indicators~32
Combined~15
perimembranous~1
muscular~63
noninvasive~80
methods,~29
necessitating~10
angiography~124
Detection~10
color~25
imaging~340
Doppler.~3
four-chamber~4
angiography.~34
Fifty-one~11
(age~23
5.6~15
Eighteen~48
defects,~19
septum~33
served~59
two-dimensional/Doppler~3
false~48
positives.~1
72%~20
(100%~7
Color~6
(two~43
weighing~24
kg~48
flow).~2
missed~29
Low-level~1
63~55
(VT).~3
old~111
infarction~239
antiarrhythmic~58
VT,~16
isopotential~1
maps~17
time-averaged~1
high-pass)~1
dipolar,~2
extrema~3
distant,~2
precordial~15
back,~3
prolonged.~13
posterobasal~1
VT~137
posteroapical~1
sites.~62
Generally,~3
modified~162
surgery.~255
Late~19
potentials~105
orthogonal~14
distributions~19
delay~76
Sources~2
near~86
torso~1
produce~208
extrema,~1
deeper~18
sources~37
extrema.~1
Body~19
idiopathic~139
QT~24
(LQTS)~1
integrals~3
QRST~3
ST-T~6
displayed~58
isointegral~1
(ISOI)~1
maps.~2
ISOI~4
thorax~9
multipeak~1
LQTS~5
map~15
represented~40
weighted~6
sum~21
(eigenvectors)~1
nondipolar~4
content.~43
eigenvectors~2
beyond~60
third)~2
Specifically,~8
abnormally~34
(nine~19
4%),~2
true~86
4%).~5
syncopal~7
episodes.~20
infrequent~28
atypical~69
prominent~48
electronegative~1
repolarization~9
heart.~32
sympathetic~118
pathogenetic~13
LQTS.~1
Multipeak~1
disparities~2
account~107
arrhythmias.~24
Guiding~2
endocardial~20
necessitates~5
arrhythmogenic~14
site.~55
mathematical~17
cineradiographic~1
compute~3
points:~1
ostia~6
apex.~5
enable~19
surgeon~58
sites,~28
wire~34
skeleton~13
(one~54
patient)~15
representing~47
site(s)~2
points~43
constructed.~9
inserted~52
Side~10
branches~33
intraoperative~98
simultaneous~92
Sixteen~47
morphologically~26
monomorphic~27
tachycardias~7
mapped~10
mapping.~2
distance~57
cm~158
tachycardia.~35
positions~33
reliable~102
guiding~12
inducible~50
mapping,~4
additive~20
value.~41
convenient~16
procainamide~19
(7.5,~1
22.5,~1
conduction,~6
unimorphic~5
rate-dependent~2
conduction.~6
corresponding~150
SD),~9
1.6,~4
12.6~4
2.2,~7
16.3~1
3.2~34
mg/liter.~1
mg/kg~151
increment~15
22.5~5
potentiated~16
procainamide,~10
7.5,~4
procainamide.~6
nonsustained~30
procainamide;~1
conclusion,~56
electropharmacologic~1
worthwhile~5
concentration,~53
avoid~66
lower,~16
Coronary~38
angioplasty~87
53~69
unstable~40
reoccurred~1
Single-vessel~1
64%~20
multivessel~19
36%.~5
80%~90
Forty-five~10
treatment;~13
exertion.~7
Angioplasty~4
(average~33
infarction).~2
(47/53).~1
(29/35,~1
83%)~2
(18/18,~1
100%)~7
.06).~3
deaths~156
failures,~6
procedure~371
procedure-related~3
8%~49
(4/53).~1
26%~28
(14/53)~2
repeat~58
angioplasty,~19
late~269
deaths.~28
(6/53~1
patients).(ABSTRACT~1
dissection~84
occlusion~246
leading~87
transluminal~36
(PTCA)~5
unpredictable.~3
angiographic~90
pre-PTCA~1
I)~31
random~65
(stratified~1
descending~95
arteries)~4
1151~1
II).~18
Stenosis~2
"complicated"~1
present:~1
irregular~19
borders,~2
intraluminal~37
lucency,~2
bifurcation.~3
Baseline~18
characteristics,~20
inflation~24
pressures,~19
catheters~87
used,~34
properties~138
(severity,~1
length,~23
eccentricity,~1
calcification)~1
Irregular~2
PTCA~18
.05),~24
lucency~2
pts~1
bifurcation~12
(NS).~6
Complicated~1
occlusion.~52
selection~75
PTCA.~2
thrombolysis~7
enzymatic~43
infarct~75
size,~67
function,~86
subsets~23
randomized~97
trial.~14
Early~73
thrombolytic~29
intracoronary~37
streptokinase~30
(152~1
preceded~57
(117~3
(264~1
patients).~63
533~3
indicative~33
eighty-eight~3
eligible~17
245~8
allocated~21
243~3
212~8
Patency~4
infarct-related~8
181~5
(85%).~4
Enzymatic~2
alpha-hydroxybutyrate~1
release,~30
smaller~126
760~3
1170~2
U/liter~1
.0001).~7
Left~36
radionuclide~89
month~124
(6%~3
14%~48
.006).~2
limitation,~2
fraction,~18
Killip~2
admission.~21
Thrombolysis~2
mV~21
On~202
beneficial~71
Myocardial~25
generated~82
arrest~66
manipulate~2
intrathoracic~18
Augmentation~1
high-pressure~16
dogs~305
flows~40
brain,~27
endotracheal~45
intubation~49
devices.~12
pneumatically~1
cycled~2
vest~7
(vest~1
[CPR]).~1
achievable~5
arrest.~28
Peak~55
380~6
Microsphere-determined~1
108~19
ml/min/100~4
(100~49
16%~31
prearrest~2
flow)~4
51~89
(165~3
39%~26
prearrest).~1
Severe~36
dogs.~79
280~12
hemodynamics~39
Vest~1
CPR~29
(300~11
newtons)~2
(430~1
sternal~15
force.~5
fibrillation,~10
26~199
Defibrillation~4
performed.(ABSTRACT~2
Radiographic~15
material,~13
alters~12
measured.~65
Newer~4
nonionic~7
hemodynamic,~4
inotropic,~1
rheologic~2
ionic~16
media~69
flow.~84
instrumented~30
probes~38
subendocardial~17
ultrasonic~15
crystals.~6
Intracoronary~5
iohexol~7
mg/ml~10
iodine)~1
establish~67
ml/sec;~1
ml/sec.~1
31%~33
.01)~31
77%~15
ml/sec~1
69%~26
magnitude~145
nadir~18
Decrements~1
fractional~61
shortening~51
beats~32
29%.~5
volume.~21
slower~37
rates,~39
contrast-induced~2
modulating~13
factor.(ABSTRACT~1
reperfusion~80
free-radical~2
scavenger~7
dismutase~19
(h-SOD)~2
prevent~140
it,~13
open-chest~21
circumflex~40
occlusion,~39
moment~12
h-SOD~5
(400,000~1
IU~18
atrium~43
300,000~3
iv~35
hr)~7
saline.~17
region~147
(by~28
postmortem~34
angiography)~1
gross~94
pathology).~1
investigators~24
blinded~15
code~7
Hemodynamic~13
collateral~59
Infarct~10
8)~29
22.4~2
3.1%~6
52.2~2
7.1%~2
13.3~7
0.8%~10
33.6~5
2.1%~4
h-SOD-treated~3
.05).~63
Infarcts~3
smaller,~5
distinctive~33
"patchiness,"~1
protection~57
distributions.~3
flows.~4
myocardium~59
separate~135
damage,~26
presumably~40
linked~51
radicals~17
reflow.~1
hearts~75
ischemia,~48
scavenging~3
reflow~4
novel~38
promising~14
paramagnetic~4
gadolinium~4
diethylenetriamine~1
pentaacetic~1
(Gd-DTPA)~1
magnetic~200
resonance~204
reperfusion.~26
(LAD).~2
LAD~12
occluded~43
II)~28
Gd-DTPA~4
(0.34~1
mM/kg)~1
ligation,~5
excised~53
imaged~9
spin~7
echo~27
inversion~17
pulse~149
sequences~67
0.35~20
Tesla~3
imager.~1
Reperfused~1
reperfused~17
nonreperfused~1
Gd-DTPA.~1
enhancement~66
images.~36
Studies~54
gated~18
Contrast-enhanced~1
allows~86
statement~3
physicians~181
replaces~1
American~78
Association's~2
Diet~12
Disease,~2
1978.~2
guidelines~46
optimal~105
preventive~17
Emphasis~7
saturated~18
fat~200
fat.~13
Complex~4
carbohydrates~5
replacement~155
calories~19
Polyunsaturated~1
monounsaturated~2
fats~3
sources.~9
Cholesterol~7
sodium~325
caloric~30
intake,~23
upper~308
limit~55
each.~19
means~215
preventing~65
advised.~1
Maintenance~3
ideal~34
calorie~11
emphasized.~21
prehospital~19
setting~54
poor.~8
compromises~2
embarrassment,~1
bradyarrhythmias~3
asystole.~2
Emergency~30
services~54
(EMS)~3
systems~85
injured~53
child.~14
survey~100
training~171
programs~89
EMT~2
education~91
emergencies~7
inadequate.~8
Forty-one~14
surveyed~29
training.~26
EMS~8
providers~15
equipped~12
Los~13
Angeles~10
facilities:~1
Departments~1
Approved~1
Pediatrics~3
Critical~9
Care~12
Centers.~1
voluntary~39
85%~40
hospitals~55
guidelines.~8
state,~26
training,~28
equipping~1
personnel,~6
life~164
course,~26
trained~67
out-of-hospital~14
communities~11
sizes.~7
special~78
consideration~50
communities,~3
chiefly~2
calls.~1
Communities~1
considering~21
implementing~4
defibrillation~21
technician~1
(EMT-D)~1
and,~176
inadequate,~4
implementation~14
program,~23
permanent,~4
formal~20
skill~14
protocols~25
many~310
successful~251
conversion,~2
defibrillator~2
Finally,~51
community~99
instituting~2
EMT-D~5
maintain~82
documents~19
survival-to-discharge~1
program.~46
statewide~4
preferable~16
programs.~28
arrest,~12
lay~12
rescuers~2
motivated~2
get~7
overcome~15
fear~14
needed.~18
Adults~4
learn~15
didactic~5
understanding~82
skills~36
repetition~16
reinforcement.~3
Due~15
commit~2
CPR,~5
simplification~3
Teaching~2
two-rescuer~1
adults,~27
individuals,~29
one-rescuer~1
CPR.~9
Infant~6
taught~15
Methods~10
reinforcement~12
routine~160
basis.~22
Whenever~4
courses~39
reinforcement,~1
maximizing~2
learning.~2
Advanced~8
(ACLS)~3
professionals.~5
ACLS~8
instruction~7
needs~48
logistically~1
enhance~68
retention.~14
Good,~2
validated~18
rotated.~1
Better~4
look~11
cost-benefit~4
Several~72
drowning~6
near-drowned~1
victims.~13
Regardless~15
cause,~10
begin~14
soon~43
closed-chest~12
massage~7
question~45
seawater,~1
intrapulmonary~17
occur,~11
ensure~29
Near~3
multisystem~8
emphasized,~1
definitive~55
tailored~10
needs.~13
decades,~4
United~111
States~55
greatly~77
improved.~15
Organization~10
Seattle~1
40%~90
outside-the-hospital~1
saved~5
basic~90
responders~24
paramedics.~2
care,~42
meet~26
capabilities.~1
critical~98
resuscitate~3
occurred:~2
starting~24
rescue~8
indicated,~8
support,~19
component.~17
earliest~20
benefit.~10
advent~13
automatic~15
semiautomatic~2
defibrillators,~1
defibrillate~1
people~55
paramedics,~2
approached~23
caution~26
properly~20
trained.~2
(CPR)~2
vital~67
organ~70
questioned,~1
coughing~4
compressing~4
heart,~33
cough~27
pure~57
"thoracic~1
pump"~1
mechanism,~16
passive~63
vasculature~12
aorta,~15
brachiocephalic~2
bed~51
protected~23
closure~98
inlet~5
valves.~14
Right~15
veins~56
applications~36
modalities~30
exploiting~1
recordings:~1
inflation,~4
binder.~2
fibrillation.~16
Preliminary~26
primate~17
successful.~21
Considerable~7
expended~5
laboratories~12
resuscitation.~22
briefly~29
summarizes~6
massage.~6
canine~99
preparations~79
implanted~67
transducers~6
measurements.~39
compressions~4
velocity,~17
force,~7
120/min~2
seemed~42
optimize~8
termed~31
high-impulse~1
High-impulse~1
setting,~15
man.~29
experience,~24
Association~45
Management~24
airway~264
obstruction~202
continues~29
disagreement~8
doubt~9
uniformly~33
accepted~37
representative~25
event.~21
models~67
analyzed,~9
variables,~31
kinetic~25
inertial~4
aerodynamic~1
forces~35
controversy.~1
Human~53
volunteers,~9
anesthetized~85
paralyzed~11
cadavers~12
used.~97
subdiaphragmatic~3
choice,~5
firm~8
blows~1
hanging~4
downward~5
relieve~16
obstruction.~68
conflicting~14
views~28
reconciled~3
consensus~14
effected.~1
Artificial~4
cornerstone~3
support-cardiopulmonary~1
(BLS-CPR).~1
corroborate~5
1950s~3
1960s,~1
standards~16
ventilation.~26
unprotected~5
airway.~10
Present~5
BLS-CPR~1
breaths.~2
predispose~27
victim~15
insufflation.~1
Alternative~2
inspiratory~109
Additionally,~28
how~80
apply~11
cricoid~12
bicarbonate~63
refibrillation,~1
(1~108
meq/kg)~1
placebo~139
pentobarbital-anesthetized~4
placebo.~29
defibrillated,~1
bicarbonate-treated~1
electromechanical~3
NS).~23
Spontaneous~20
Successful~17
Pco2,~1
.003).~3
gradient~117
diastolic~220
resuscitated,~3
dying~22
.02).~9
final~90
resuscitation,~8
administration,~44
gradients~30
.01).~43
Microsphere~1
aortic-right~1
.86)~1
0.43~10
0.03~31
ml/min/g~2
survivors~74
0.22~13
0.01~51
nonsurvivors~12
.01).(ABSTRACT~1
authorized~1
(EMTs)~1
defibrillatory~1
(EMT-D).~1
controlled~131
answered~7
questions.~6
urban,~1
suburban,~2
rural~12
backup.~1
errors~41
commission~1
omission~2
acceptably~8
incidence.~3
Issues~3
defibrillators~1
Medical~88
supervision~10
quality~124
core,~3
confirmation~27
principle~19
defibrillation.~1
Wider~1
(CT)~86
laryngectomy.~3
larynx,~6
whole-mount~1
sections~89
laryngeal~56
specimens,~27
plane,~3
scan.~24
plane~30
accurately.~7
T-staging~1
choice~88
i.e.~11
smoking~130
tobacco~32
adversely~21
non-smokers.~5
cogent~1
subject~96
home.~16
aim~41
relate~25
children's~10
sore~10
throats~3
habits~15
parents.~7
asked~35
sex,~86
birthweight,~2
postnatal~23
feeding~59
school~77
day~354
nursery~5
throats,~2
tonsillectomy~7
household,~1
family,~11
dwelling~2
occupation~5
father.~3
Analysis~92
maternal~194
smoking.~16
Reduction~20
cigarette~60
he~60
suffers.~1
bacteriological~3
swimmers~13
non-swimmers~3
grommets~2
secretory~73
otitis~28
media.~19
otorrhoea~1
pathogens~13
(7.9%)~2
(8.0%).~2
Subdividing~1
'wetters'~1
'strictly~1
dry'~1
pathogens.~5
swim~7
continue~44
postoperatively~65
infections.~58
colour~6
crystal~11
film~27
cm-2.~1
corresponded~24
nostril~9
quiet~17
breathing.~10
breathe~6
regularly~25
examined.~83
nostril.~1
non-invasive~12
examining~32
vocal~41
epithelia~13
incorporating~10
video~11
time-lapse~2
microscopy.~53
Different~12
photographed~3
taking~76
'stills'~1
television~8
play-back.~1
Outgrowths~1
explants~11
monolayers.~2
Mitoses~1
mid-way~1
explant~3
edge~16
outgrowth.~3
oscillating~1
blebs~1
detached~4
themselves~28
monolayer~26
appearance.~14
chemokinetic~2
chemotactic~67
attraction~4
mitotic~27
T-suppressor~1
valuable~58
tool~58
T-lymphocytes~4
LAK~1
DNA~281
yield~52
information.~21
Static~4
cytofluorometry~1
smears~18
microlaryngoscopy~1
107~21
(96~4
stem~49
lines~84
diploid~27
3;~5
dysplasia~59
polyploid.~1
proliferative~76
(percentage~1
nuclei~47
peak)~1
hyperplasia~63
dysplasia,~18
4.0%~4
6.8%~4
carcinomas.~27
Hypertetraploid~1
(HT~1
cells)~16
dysplasia.~22
HT~15
cells;~21
Nine~104
T1~43
&~9
T2~42
carcinomas;~1
Fourteen~62
especially,~1
demonstration~42
importance.(ABSTRACT~1
modification~54
Patterson's~1
antro-ethmoidectomy~1
simpler~10
transantral~1
decompression~37
nose~25
bleeds~6
varicose~11
vessels~147
transection~22
followed-up~4
operation,~77
vessels.~46
began~47
operated~96
sides.~3
(55%)~15
spite~41
Mucosal~6
crusting~1
Transection~1
bleeds.~1
classical~37
autonomic~76
innervation~27
mucosa~111
states~46
postganglionic~6
neurones~41
lie~6
cervical~319
ganglion~19
parasympathetic~14
pterygopalatine~2
ganglion.~3
fine~36
structure~100
cat~20
Jabonero,~1
Champy~1
Maillet~1
Koelle-Friedenwald.~1
microganglia~4
turbinate~4
glands.~13
anticholinesterase.~1
deduce~1
pathway~94
turbinate.~1
cats~35
neostigmine,~3
turbinectomy~2
Vidian~2
neurectomy.~1
Resection~11
hypersecretion~4
noticeable~3
neurectomy~6
addition.~5
crystals~27
casts~15
urine~223
triamterene~4
experimental~243
animals.~110
Twenty~74
Casts~2
2-11~2
diuretic.~1
Cast~1
acidic~41
alkalinization~3
potassium~160
citrate.~1
Animal~6
crystallization~1
cast~23
medullary~26
ducts~18
rat~362
kidney.~24
nephrotoxicity~19
triamterene,~1
non-steroidal~1
Records~7
ultrasound~37
Forty-nine~6
yielded~85
(89.1%).~1
Transient~16
hematuria~29
sole~33
(10.9%).~1
safely~56
intraperitoneal~33
heparin~87
(5000~3
U)~1
CAPD.~5
linearily~1
1.78~4
U/ml~11
1.13~2
4-hour~7
dwell~4
time.~107
antithrombin~28
III-concentration~2
0.56~5
1.87%~1
III-portion~1
0.62%~1
0.79%~1
dialysate.~7
fibrinopeptide~18
A-concentration,~1
37.1~1
11.8~6
ng/ml~56
(normal~16
range:~3
ng/ml)~17
153.4~1
16.8~5
dialysate~24
5000~8
U~25
A-concentration~1
2.6~37
experiments~122
intraperitoneally~15
inhibit~94
acceleration~23
heparin.~5
87-year-old~1
nephrotic~43
ketoprofen,~1
osteoarthritis.~7
laboratory~175
nephropathy.~5
Kidney~6
membranous~39
glomerulonephritis.~16
Evolution~1
withdrawal~38
NSAID~1
glomerulonephritis~32
Lesions~13
pedicles~4
challenge.~31
osteoid~20
osteoma~1
pedicle~10
vertebra~6
17-year-old~5
girl.~5
dura~12
medially~8
vertebral~89
anterolaterally~1
transpillar~1
approach.~31
transosseus~1
preserved~38
facet~27
joints~41
elements~68
obviated~7
interbody~4
fusion.~12
Twenty-three~28
scoliosis~34
extremity~69
proprioceptive~9
deformity,~10
degrees.~25
scoliotics~1
16.1~2
20.8~4
Controls~9
deformity~47
procedures.~86
scoliotic~10
asymmetry~15
threshold~96
joint~184
reproduce~6
angles~14
positioned~26
0.025).~11
Slight~3
reproduction~6
0.013);~1
Performance~7
designated~31
bad~8
groups;~17
scoliotics'~1
inferiorly~1
angle~51
imply,~1
localize,~1
Inyo~3
nail~22
intramedullary~23
distal~321
fibula.~4
tapered~5
V-shaped~2
malleable~4
stainless~10
steel,~1
fixation.~16
Torsional~2
resisted~4
triflanged~1
introduced~44
closed,~4
image~72
intensifier.~2
evaluated:~3
Internal~9
Fixation~7
(ASIF)~2
technique.~104
Eighty-five~8
good,~5
I.~27
fractures.~40
Stress~10
intraoperative.~1
Surgery~28
supination~6
Type~57
injuries,~43
demands.~3
Anatomic~12
weight-bearing~7
result.~38
malunions~1
nail.~2
football~6
players~12
ligament~64
(MCL)~4
knee~150
conservative~62
rehabilitation~28
progressing~5
immobilization~25
orthotic~3
brace,~4
strengthening~2
agility~1
exercise.~81
days.~171
athletes~37
competitive~40
confirm~72
nonoperative~11
MCL~11
roentgen~3
stereophotogrammetric~2
(RSA),~1
tibial~97
tibia~46
knees,~3
cemented~10
Kinematic~1
prosthesis~55
gonarthrosis.~1
Migration~1
1.9~22
two-year~17
Displacement,~1
forces,~7
Measurable~1
migration~43
displacement~60
rule~24
exception~34
arthroplasty~29
(TKA).~1
Accordingly,~30
absolute~73
TKA.~1
quadriceps~20
patellar~18
tendons~10
Excellent~11
tendons.~5
disclosed~36
incongruences~1
patella~18
femoral~142
groove~4
tangential~3
cranial-caudal~1
tendon~45
ruptures~9
ruptures.~2
patellofemoral~9
incongruity~3
two-thirds~20
asymptomatic,~12
movement.~8
Nevertheless,~14
exact~27
adaptation~23
periarticular~5
patello-femoral~2
articulation.~2
Reinforcement~2
cerclage~5
consequent~24
rupture.~22
end-to-end~12
sutures~16
sufficient.~3
reconstructing~2
cruciate~34
(ACL)~4
place~49
ends~18
drill~6
channels~56
correctly,~5
ACL~14
isometric~36
position.~35
standardized~55
substitute.~1
frame~11
adjustable~4
tube.~15
Drilling~1
anteromedial~3
tibia,~10
upwards,~1
space~91
femur~17
straight~10
line,~15
drilled~4
precision~24
guided~17
drilling~6
free-hand~2
place.~10
alta~4
trait.~8
spurt,~1
orthoroentgenograms~1
(growth~1
films)~1
retrospectively~71
0.85)~5
level.~72
Girls~2
boys.~7
condition;~4
overgrowth~11
spurt~3
complaints,~10
interpretation~33
Lachman~5
(passive~1
translation~16
flexion).~1
posteromedially~1
tibia.~8
leg~80
examination~289
examiner,~1
rotation.~6
Reaching~1
create~14
inadvertent~7
(internal~3
translation)~1
inaccurate~9
comparisons~29
legs.~9
reliably~38
295~4
infantry~3
recruits~3
41%~19
Routine~18
scintigraphic~15
abnormalities.~59
46%.~4
periostitis.~1
compartment~58
Physical~9
scintigraphically~3
tibias.~1
swelling~29
one-third~22
fracture.~25
Ninety-eight~8
arthrotomy~2
meniscectomy~2
intraarticular~18
methylprednisolone~6
(40~28
mg)~40
double-blind~38
twelve~22
operation.~140
accelerated~29
respect~116
subjectively~6
motion,~18
advantage~66
rehabilitation.~6
Computed~49
torsion~27
medial-type~1
osteoarthritic~8
knees~31
adults.~52
rotation,~13
11.3~11
degrees,~22
23.5~2
torsion.~4
metaphysis.~3
shaft~33
sliding~6
hip~110
trochanteric~2
antegrade~18
Ender~3
nailing~8
nails~10
bicortical~2
plating~11
screws.~2
internally~3
Sliding~1
performed.~110
Antegrade~2
avoids~9
Decreased~7
loss,~50
difficulty,~4
mobilization~32
multiple-injured~1
Femoral~3
reduction,~18
circlerage~1
stability,~4
alignment~13
comminution~4
crutch~6
ambulation.~5
advantageous~8
in-depth~3
radiographic,~8
62-year-old~5
reabsorption~29
(THA).~2
THA~2
revised~6
Thirty~54
millimeters~3
calcar~7
resorption~42
radiographically.~5
bending~16
implant,~4
wear~16
acetabular~19
cup~7
noted.~41
cement~24
invading~13
Intracellular~15
polymethylene~1
debris~11
mass.~38
fragmented~7
methylmethacrylate~4
bone-cement~5
interface~12
remodelling~6
interposed~10
recruitment~12
polyethylene~19
process~164
perpetuated~1
fragmentation~9
cement,~3
interface,~2
extreme~32
general.~3
osteochondritis~5
dissecans~5
talar~3
closed~93
ostoechondral~1
fragment~47
percutaneously~9
osteotomizing~1
malleolus.~1
so-called~22
hips~14
normality~2
demonstrable~36
joint.~26
pistol~1
deformity.~14
slipped~3
capital~6
epiphysis~11
(recognized~2
time),~3
Legg-Perthes'~1
epiphyseal~7
spondyloepiphyseal~1
intraacetabular~1
labrum,~1
as,~4
conjunction~51
readily,~1
hemochromatosis,~2
ochronosis,~1
pyrophosphate~4
monarticular~2
arthritis,~15
exist~41
does,~1
extraordinarily~3
rare.~38
calcaneal~9
dislocation,~4
runs~6
forward~23
behind~10
sustentaculum~1
tali,~1
hindfoot.~1
calcaneus~7
splits~4
posterolateral~15
fragment.~4
Rupture~5
move~16
laterally~5
subjacent~2
Closed~3
Open~14
essential.~11
sufficient,~3
incision~45
19-year-old~7
man,~16
overuse~3
nondominant~8
radioulnar~2
synostosis.~1
persistence~28
synostosis,~1
Isolated~15
healing.~25
beneficial.~2
excessive~77
causing~84
subperiosteal~5
hemorrhage~142
stimulate~76
exuberant~2
callus~10
formation.~47
Fractures~12
shaft,~1
undisplaced,~1
immobilized~11
overuse.~1
disc~91
inject~2
fluoroscopic~7
mixture~34
anesthetic~66
steroid.~5
osteophytes~5
joints.~17
Otherwise,~3
(15~40
20;~2
75%)~2
months;~23
33%)~2
Repeat~12
injections,~5
done,~4
temporary~61
relief~82
five;~2
20%).~1
patients:~20
screening~189
sciatica;~1
tenderness~9
joints;~2
radiologic~51
degenerative~46
Facet~3
Light~13
matrix~37
degradation~54
chymopapain-treated~2
untreated~124
disc.~10
viable~37
patches~16
disc,~2
illustrated~12
well-circumscribed~1
protrusion~4
canal,~16
aggravate~6
entrapment,~2
low-grade~18
recess~3
protrusion.~2
aggravation~3
considerations.~5
arch~43
osteopetrosis.~1
cast.~5
osteopetrotic~1
resists~1
parallel~69
layer,~7
fragile~15
layer.~11
Tibia~1
divided~131
groups:~53
fixation;~1
III,~50
(53%)~13
union,~2
malunion,~4
nonunion.~1
union~24
6.5~23
sores~3
emboli.~9
(9%),~6
wound~185
uneventfully,~2
thrombosis~76
tibias~1
nonunions,~1
Nonoperative~3
union.~4
fixation,~15
excluding~21
orthopedic~11
justifiable~3
uncomplicated~39
Maquet~4
2-2.5~2
tubercle~2
osteoarthrosis~3
Fifty-three~14
procedure;~3
relieved~31
pain,~112
realigned~1
tracking~11
condyles~1
Fish-mouthing~1
drain~10
Ferguson's~2
Maquet's~1
1.25-cm~1
transverse~54
incision;~3
converting~24
arthrosis~4
Achilles~7
rare,~33
English~19
44-year-old~5
woman,~13
Affected~8
persons~140
fifth~29
seventh~11
decades~12
life.~58
concomitant~96
trauma.~49
goals~18
preventative,~1
bracing~7
tendon.~5
Localized~2
mineralization~16
fibroblastic~5
mineralized~3
clusters~19
giant~67
spaces~28
Investigations~4
osteogenic~1
direction,~3
polygonal~1
shapes,~1
well-banded~1
collagen~153
tissue.~100
Differentiation~4
due,~8
part,~34
confined~49
Growth~13
living~58
fluorescence~38
microscope.~10
probe~48
microanalysis~1
mineral~66
hydroxyapatite.~2
Initiating~1
vesicular~14
lipid,~6
products~85
degeneration.~14
Once~18
initiated,~4
appeared~244
collagenous~9
structures,~15
skeletal-type~1
dystrophic~9
mineralization.~2
Published~4
histomorphometric~3
derive~9
thicknesses~5
trabecular~41
plates~18
completed~84
(the~56
multicellular~4
carrying~23
remodelling,~1
BMU,~1
structural~111
BSU).~1
stochastic~3
set~60
predictions~14
BMU~4
"thicknesses"~1
pseudorandom~1
generator.~1
day,~43
surfaces~37
quiescent~5
assumed~39
1:900~1
chance~33
Resorption~3
(active,~1
days;~16
phase,~30
days)~36
(94~3
balance~81
depth~47
36.8~2
9.2~8
micron.~3
Fenestration~1
(thickness~1
0)~3
permanent~87
trabecula.~1
unrealistically~1
thin~36
trabeculae~6
lost.~2
corrected~65
tendency~52
thicken,~1
loading.~11
lost~76
unchanged.~55
About~14
one-half~24
fenestrations~2
deeper-than-average~1
cavities~6
trabeculae,~3
remainder~31
coincident~11
surfaces.~12
osteoblast~10
lifespan~1
36.7%~2
83.1~1
micron,~8
compatible~51
Courpron's~1
Simulating~1
formation;~3
doubling~16
BMUs~1
transiently~21
recovery.~50
span~17
osteoporosis,~4
plus~150
supplements~24
parathyroid~86
peptide~103
hPTH~1
1-34.~1
girl~34
multicentric~8
originating~24
sphenoid~14
sella~11
turcica~5
radius.~6
Curettage~2
packing~4
processed~13
osteomyelitis~16
drainage.~23
radial~81
autogenous~14
iliac~40
recurrences.~16
segmental~71
resulting~195
bony~39
bridged~3
wrist~15
Osteoarthrosis~1
imbalance,~1
"joint~1
failure"~1
"heart~1
failure,"~1
role.~16
cartilage~54
phenomena.~7
steep~5
stiffness~26
subchondral~10
Progression~5
stiffened~3
situations,~9
stresses~16
articular~35
stiffening~5
congruent~4
musculoskeletal~16
dynamic~67
attenuation~37
overlying~21
bed.~8
osteoarthrosis,~1
conditions.~76
Stiffening~1
conformation,~2
deformation~12
load.~13
origin,~27
infiltrates~16
synovium~6
immunofluorescent~10
immune-reactant~1
(knees,~1
hips,~4
joints)~1
processes~68
arthritis.~33
Further,~28
polyarthropathy~1
propensity~12
disorder.~69
Wide~4
synovial~46
changes,~54
asymptomatology~1
causative~28
degradation.~4
exists~42
whereby~8
explored.~11
Tamoxifen,~2
antagonist,~41
erosive~6
meniscectomy-induced~1
rabbits.~38
worsened~12
it.~30
tamoxifen~15
proteoglycan,~2
prostaglandin,~2
proteoglycanase~1
hormone-sensitive~2
future.~8
inflammation~64
salicylates~9
antiinflammatory~6
(NSAIDs).~1
synovitis~11
contributes~24
breakdown~26
NSAIDs~5
natural~112
humans~73
known.~32
NSAIDs,~1
salicylates,~1
suppress~25
proteoglycan~11
vitro.~80
cartilage.~6
salicylate~16
degenerating~2
vivo,~32
aggravating~2
itself.~18
damaged~28
today~4
molar~31
viewed~16
teachers~6
medication.~19
neurodevelopmental~4
educational~35
testing.~42
questionnaires~23
interviews.~1
Children~33
unless~33
impulsive,~2
inattentive,~2
overactive~1
behavior~123
environments~2
(home,~1
school,~8
clinic).~1
Fifty-two~18
(80%)~16
Follow-up~57
percent,~60
doing~15
nonpharmacologic~2
interventions.~11
Initial~35
race,~31
SES,~1
resource~3
help~78
distinguish~38
4.88,~1
0.05),~94
weren't~1
academically~2
6.30,~1
9.01,~1
psychosocial~49
reveal~50
outside~45
problems.~44
Repetitive~4
obscure~7
adolescents.~9
4.1-year~1
Equally~2
reassuring~2
reassurance~3
Information~17
ethyl~2
intoxication~24
scarce.~1
chart~28
reviews~28
ethanol~109
Alberta~1
Hospital,~20
Foothills~2
Provincial~2
Calgary~2
General~28
Holy~1
Cross~3
1969~8
hypoglycemia~25
convulsion.~3
elimination~101
6.2~16
mM/L/hr~1
(28.4~1
mg/dl/hr),~1
hypokalemia,~6
acidosis.~8
Mobile~1
Intensive~6
(MICU)~1
Jerusalem~1
625~2
emergencies,~2
5%~115
MICU~1
205~3
(33%).~6
(175~1
28%).~2
71~46
(11.4%)~3
Resuscitation~7
37,~3
survivors.~11
Almost~23
asystole,~1
antecedent~10
Compared~61
limited,~2
priority~6
emergencies.~1
Foreign~6
emphysema~9
atelectasis~12
x-ray.~2
tracheal~52
x-rays~13
read~10
suggestive~81
aspiration.~14
tracheobronchial~20
purpose~138
exogenous~70
normotensive~114
hypertensive~225
subjects.~254
Eight~111
volunteer~13
Inulin~1
para-aminohippuric~3
(PAH)~3
clearances,~2
natriuresis,~4
dosing~34
micrograms/min/kg)~1
subjects:~2
31.8%~1
3.7%~5
vs.~261
16.2%~2
1.2%~8
inulin~8
83.3%~1
10.5%~4
41.1%~2
3.4%~6
PAH~2
331%~1
216%~1
natriuresis~4
hyperresponsiveness~7
hypertension.~112
argument~4
favoring~6
Dopamine~10
phenotyped~3
isoniazid~8
acetylator~2
amrinone~12
minutes.~73
specified~14
24-hour~87
dosing.~9
method.~70
fitted~13
nonlinear~17
regression.~6
first-order~5
t1/2~14
acetylators~4
hours,~82
steady~53
state.~48
Clearance~10
acetylators,~4
16.6~5
L/hr,~2
37.2~4
L/hr~2
AUC~5
4.96~1
micrograms~113
ml-1,~3
2.20~2
Concentrations~21
N-acetyl~9
metabolite~61
N-acetylamrinone~1
expected,~20
anxiolytics~1
crossover~41
students.~16
(tracking,~1
attention,~6
Maddox~2
wing,~1
etc.)~2
subjective~58
(visual~1
scales~29
questionnaires)~1
doses.~26
Diazepam~3
(0.15~6
0.30~12
relatedly~1
rendered~22
drowsy,~1
calm,~1
mentally~11
slow,~3
clumsy.~1
Buspirone~1
inactive~23
diazepam~22
(0.30~3
subjectively.~1
combinations,~6
buspirone~11
wing~1
letter~2
cancellation~2
counteract~4
acquisition.~3
Subjectively~1
diazepam-induced~1
sedation.~3
Increased~40
calmness~2
buspirone.~1
combining~20
decrement~15
performance.~30
diazepam-buspirone~1
SQ~7
28,668~5
analog~21
thromboxane~65
A2.~1
Fifty-six~9
1200~8
mg.~16
manner.~46
shape~53
concentration-time~7
enterohepatic~4
recirculation.~2
A2~19
(estimated~2
Schild~7
analysis)~5
nmol/L.~1
Approximately~34
94%~17
template~3
Dose-ranging~1
antithrombotic~9
expensive.~2
reason,~8
therapeutically~8
aspirin.~12
Pinacidil~1
investigational~8
antihypertensive~54
metabolized~14
pinacidil~3
N-oxide.~1
pinacidil's~3
subject's~19
debrisoquin~6
phenotype,~4
cirrhosis~74
volunteers~93
metabolizers~5
debrisoquin,~1
metabolizer~1
phenotype.~13
N-oxide~3
subjects'~8
Cirrhosis~4
(20.7~1
1.4~57
42.1~1
L/hr;~1
0.0005)~4
3.9~30
6.1~14
Less~16
add~16
pharmacology~3
ritodrine~18
peripartum~6
fails~12
labor~63
inhibited.~5
parturients~5
studied;~6
mothers~77
infants.~63
delivery.~39
(free~3
conjugated)~1
electrochemical~6
detection.~7
plasma,~28
minutes~319
equilibrium~41
Seventy-six~9
excreted~31
mother~47
conjugate.~3
Ninety~20
neonate~15
Intravenous~47
cimetidine,~10
400~75
mg,~38
ranitidine,~3
randomized,~27
Aspirates~3
juice~30
dosing,~2
pH,~32
titratable~1
acidity,~1
volume,~49
baseline~221
71/2~1
subject.~23
magnitudes~5
regimens.~18
interventions~26
sharply~16
substantially.~4
inhalation,~4
puffs,~2
pressurized~3
aerosol~35
(160~2
epinephrine/puff).~1
SE)~35
1.50~4
0.61)~2
4.22~1
1.93)~1
nmol/L~6
minute~84
finger~25
tremor~17
0.81~7
mmol/L.~2
occasion~10
1/1000~1
micrograms)~17
subcutaneously~21
2.43~2
0.47)~1
minutes,~45
2.05~1
0.41)~1
Reductions~6
(LV)~32
sympatholytic~1
inhibitors,~19
channel~96
blocker~23
nitrendipine~19
12-month~15
monotherapy~11
propranolol~90
Nitrendipine~5
lowered~47
148/97~1
136/83~1
Supine~2
155/103~1
134/86~1
but,~17
again,~7
significant.~62
lowering~22
Close,~1
collaboration~3
obstetrician,~1
psychiatrist,~1
nurses~16
disciplines~3
psychosis~4
"either/or"~1
specialists~4
disciplines.~3
schizophrenia.~2
Knowledge~11
side-effect~5
classes~37
antipsychotic~3
clinician~20
arrive~5
rational~17
high-potency~1
neuroleptic.~1
principles~46
psychopharmacology~1
followed:~1
Consider~1
benefits;~1
prerequisite;~1
diagnosis;~10
select~21
psychotropic~7
class,~7
effective;~3
choose~11
stop~7
drug;~3
possible;~2
element~24
comprehensive~43
strategy.~5
consideration,~4
e.g.,~17
psychotherapy,~2
vocational~6
rehabilitation;~2
consultation~28
subspecialists~3
sought~34
readily~48
indicated.~28
Clinicians~9
aware~30
cardinal~4
anxiety~29
geriatric~21
psychotherapeutic,~1
behavioral,~4
diminish~16
Intraoral~1
patch~63
nickel.~1
Maxillary~2
acrylic~4
pieces~5
66%~15
nickel~23
h,~49
readings~16
removal.~29
Few~14
detected,~14
mucosal~120
lichenoid~1
reactions.~25
Biopsies~5
non-specific~11
Dermatitis~1
2-chloromethyl-4-phenyl-6-chloroquinazoline-3-oxide,~1
chlorodiazepoxide,~1
workers~45
pharmaceutical~5
plant.~3
quinazoline~3
0.05%.~1
face~40
hands.~5
sensitized~32
washing~9
workers,~7
m~10
building.~1
Allergic~2
machine~11
operatives~1
cutting~13
oil~46
epoxy~6
stabilizer.~1
Positive~17
men~373
Skin~26
quantification~11
erythematous~6
allergens~13
Reflectance~1
numerical~11
severity.~17
allergen~35
formulations~11
Rubber~3
glove~4
intolerance~8
dermatological~1
occur.~31
gloves,~3
discomfort~33
itch~2
gloves~5
wearing~19
scratch~5
chemicals~8
powders.~2
RAST-tests~1
extract~38
tree~19
(Hevea~1
brasiliensis).~1
6/15~1
urticaria~8
latex~13
demonstrated.~31
resin~12
manufacturing~7
plant,~1
228~3
work-related~3
eruptions;~1
tested.~45
consisted~133
process,~36
battery~20
sensitizers.~1
sensitization~18
epichlorohydrin~2
resins~1
6.1%.~3
(3.5%)~3
(MW~3
385)~1
observed,~30
980).~1
Sensitization~2
Bisphenol~1
seen.~38
micro-computer~1
analyse~3
501~2
attending~30
clinic.~12
71%~26
tests;~3
12%~40
dermatitis;~3
irritant~18
eczema.~2
Grevillea~8
'Robyn~4
Gordon'~4
Australian~4
hybrid~8
planted~1
Australia~2
exported~1
Western~21
countries.~15
Recently,~19
explosion~1
cross~40
Toxicodendron~1
Toxicodendron,~1
pentadecylcatechol,~1
5-pentadecylresorcinol,~1
banksii~1
tridecylresorcinol~2
robusta.~2
Patch~8
implicating~4
sensitizing~6
alkyl~3
resorcinols~1
likelihood~45
extends~13
plants~6
genus,~1
markets,~1
increasingly~41
common.~28
catering~2
staff~48
cleaners~8
questionnaire,~9
employed~75
Hand~3
caterers~1
cleaners.~1
majority,~1
wet~31
occupations.~1
Cleaners~1
jewellery~2
nickel,~5
invariably~24
predict~114
atopic,~1
encountered.~18
carry~23
occupations~3
1970~25
records~126
unequivocal~10
distribution.~23
preponderance~10
(61%),~2
10-20~8
40-50~2
females,~22
males.~27
sensitivities~14
6th~2
decade~26
sexes.~11
Nickel~2
(92%),~2
dichromate~5
predominated~10
(64%).~1
5(2.5%)~1
atopics,~1
hypochlorite,~1
bleaching~2
product.~9
testing,~49
hypochlorite~2
1.0%~8
useful.~7
regard~65
unidentified~7
Irritant~1
lauryl~3
(SLS)~3
macroscopically~3
microscopically~12
guinea~86
pigs.~15
2%~71
SLS~5
solutions~52
gave~80
naked~1
assessment,~16
epidermal~83
solution.~37
(lymphocytic)~1
nature.~12
organic~66
solvents~3
ranked~8
internally.~1
Trichlorethylene~1
solvent,~2
ranking~2
SLS.~3
chlorinated~2
hydrocarbons~3
aromatic~8
alcohols~1
acetone~2
White~16
spirit~1
trichlorethylene.~1
Thinners~1
irritant,~1
4-day~9
potential,~12
Glyphosate,~1
irritation,~5
photoirritation~1
photoallergic~2
346~3
herbicide~1
dishwashing~1
detergent~5
cleaner.~1
photoirritation,~1
glyphosate~1
coumarins~4
perfumery,~2
cosmetics~2
ointments,~1
capacity.~20
compounds,~10
4-methyl-esculetin,~1
serves~15
sunscreen~5
sensitizer.~2
dihydroxycoumarin~1
sensitizer~2
enzymically~1
oxidized~7
orthoquinone~1
chloracne~1
lumber~1
pressure-treated~1
pentachlorophenol~1
(PCP).~1
presumed~33
arose~17
polychlorinated~2
compounds~53
(dioxins~1
furans)~1
contaminate~1
PCP.~1
isotretinoin.~1
cobalt~11
brands~4
Asian~15
8.1~9
14.2~10
micrograms/g~16
14.9~6
28.5~3
micrograms/g,~5
metals~10
insoluble~11
salts;~1
water-soluble~4
cements~3
0.39~10
0.65~10
0-1.2~1
(4/272)~1
prefabrication~2
factory~5
chromate~5
cement.~4
worker~7
secondarily~5
existing~24
1.8%~5
(5/272)~1
sensitivity:~1
watches,~1
asymptomatic~157
soluble~33
salts~19
sensitize~4
impact~106
permeation~7
ions~13
permeating~3
barrier~43
lag~21
bioavailable,~1
chloride~66
sulphate.~2
eyelid~22
11.~8
transfusions~26
septic~52
distress~63
(ARDS).~3
ARDS~23
C3a~8
(250~10
(0%)~7
7;~2
C3a,~2
600~28
ng/ml;~4
ARDS,~4
55%)~5
21;~1
540~4
19%).~2
Placement~3
unheated~3
miniaturized~2
electrode~49
palpebral~3
conjunctiva~12
permits~35
tension.~9
conjunctival~32
(PcjO2)~1
cardiorespiratory~15
protocol~84
hemorrhage.~52
Anesthetized~4
bled~19
retransfused~2
shed~18
PcjO2~3
prehemorrhage~2
reinfused.~3
normalize.~1
0.76~8
0.05~74
(SEM)~14
0.02~33
0.003~3
hemorrhage,~42
complete.~4
Conjunctival~3
Oxygen~18
(VO2),~5
production,~22
quotient,~1
expenditure~40
(RME),~1
52~68
cerebrovascular~49
RME~1
norepinephrine~147
excretion;~3
187%~1
uninjured~9
person~24
size.~51
VO2~56
excretion.~24
facts~4
RME.~1
hypermetabolic~4
caring~11
malnutrition~12
immunity.~4
ICU~17
(74%)~6
(87%)~5
Pneumocystis~4
carinii~3
cytomegalovirus~25
pneumonia.~17
(63%)~10
Respiratory~14
Overall~39
(77%);~2
(91%)~11
(38%)~22
lived~17
usual~59
prerequisite~8
intubated~9
removed.~15
researchers~10
tubes.~14
joules~4
tension-time~5
breathed~16
sized~4
27.5-cm~1
tidal~28
ml.~12
frequency,~22
L/min.~4
decreased,~26
increased.~63
magnified~2
ventilations~1
6-~5
7-mm~1
tubes,~4
fatigue~20
exceeded.~1
43~88
(noncardiac)~1
Dobutamine,~1
beginning~68
(2.5~15
micrograms/kg~46
(CI),~2
(DO2),~1
resistances;~1
gases,~10
changed.~11
CI.~1
terminally~6
hypovolemic~9
fluids,~4
DO2~1
perfusion,~15
appreciated.~6
thermodilution~17
transthoracic~11
impedance~25
methods.~57
electrodes,~7
resistivity~1
(rho)~2
substituted~11
Kubicek's~1
empiric~5
formula~25
calculating~9
impedance.~1
electrodes~34
rho-value~1
ohm~1
0.17~19
2.4~40
L/min).~5
Ventilation~8
end-expiratory~2
bias~16
estimate,~1
(SD~21
L/min,~3
1.5~81
(zero-wave),~1
length~217
electrodes.~9
BP,~9
pulses,~5
hypotensive~39
reportedly~4
newborns~17
administering~21
high-dose~69
retrospectively.~12
increased;~2
dopamine.~10
high-dosage~2
sick~15
Consequently,~27
necessary,~10
stability~54
(PtcCO2)~1
Thirty-two~19
neonates~48
alternately~2
enrolled~22
(results~2
PtcO2~8
PtcCO2~3
management)~1
available).~2
mandatory~17
(IMV)~1
settings~13
transport,~12
arrived~7
PCO2~20
arrival~10
hospital,~13
acidosis~52
hypercarbia~1
IMV~4
needing~9
percentage~184
spent~26
(35~15
torr)~1
Continuous~13
offers~53
opportunity~32
risks~62
transporting~3
neonate.~8
fibronectin~19
infectious~79
purpura.~2
Fibronectin~6
purpura~12
sepsis,~14
shock~80
nonshock~1
ecchymotic~1
necrotic~15
petechial~4
purpura;~1
cutaneous~166
sequelae,~5
deficiency~206
applicability~8
hemofiltration~11
(CAVH)~1
catastrophic~6
illnesses.~11
CAVH~4
hemodialysis.~31
employed;~1
anuric~2
infant,~5
continuously~49
fluid,~22
electrolyte,~5
acid-base~20
balance,~10
parenteral~40
nutrition.~4
anticoagulation,~3
establishment~15
access,~5
hemofilter~5
suction-assistance,~1
employ~7
prototype~11
attain~7
ultrafiltration~22
objectives~18
purposes;~1
smallest~10
infants,~45
assessed.~32
epiglottitis~8
uncommon.~12
Bacteroides~14
melanogenicus~1
supraglottic~8
pathogen~9
causitive~1
epiglottitis.~3
Pulmonary~74
situations.~17
contribute.~2
Laryngospasm~1
laryngospasm~1
adolescents~30
obstruction,~43
four,~12
"laryngospasm"~1
forme~1
fruste~1
sleep~182
apnea~46
nasopharyngeal~23
abnormalities,~51
anesthesia.~62
resolves~4
monitoring.~25
2,209~1
why~23
Techniques~3
vigorously~3
supervised.~1
Central~11
cared~3
protocols.~6
Overt~2
phlebitis~2
(353/1,024)~1
centrally~20
(18/713),~1
though~79
2.9~30
Pneumothorax~1
713~3
catheterization,~10
hemothorax~3
pneumothoraces~6
thoracostomy~7
1,496~1
peripherally~9
phlebectomy~1
suppurative~11
thrombophlebitis.~1
Supervision~1
keep~7
catheterization~70
Peripheral~14
catheter.~30
medroxyprogesterone~6
acetate,~5
stimulant,~1
episodes~160
disordered~14
nonhypercapnic~2
obstructive~85
apnea.~6
Nocturnal~5
polysomnography~3
acetate~76
(60~15
mg/day)~10
apneic~3
(31.3~1
5.7~14
[+/-~3
SE]),~1
(26.8~2
6.6),~1
(23.6~2
7.0)~1
5.6),~1
(21.4~2
5.8),~1
(23.1~1
6.3)~1
Medroxyprogesterone~2
breathing,~13
desaturation~8
hypercapnia~13
state;~2
amyloidosis~17
center.~16
amyloid~40
plaques~38
atelectasis,~3
two,~24
pseudotumor~7
masses~24
incidental~24
bronchoscopic~9
finding.~13
parenchymal~40
amyloidosis,~5
static.~2
Fifteen~78
amyloidosis.~7
failure;~5
post-mortem~5
finding;~2
senile~11
autopsy;~1
three,~18
malignancy.~32
embarrassment~2
diffusion~24
irrespective~29
etiology~68
anxiolytic,~2
alprazolam,~2
relieving~6
dyspnea,~7
placebo-controlled~18
alprazolam~5
(0.5~38
bid)~1
week,~20
week.~21
Assessment~17
outset,~2
finally~8
were:~45
bicycle~25
ergometer,~3
walk.~3
Subjective~6
sensations~13
guarded~2
exercise,~58
feelings~13
walk~5
perception~35
Mechanical~6
flow,~64
hepatic-extraction~1
pharmacokinetic~33
lidocaine,~6
well-known~9
nonrestrictive~1
gasometric~2
weaning~17
washout~32
protocol:~1
lidocaine~49
(1.5~12
intravenously),~1
1.7~39
mg/min~5
minutes).~10
3.22~1
0.37~5
mg/L~12
2.40~1
Steady-state~1
2.10~1
0.20~10
1.64~2
0.16~14
604.2~1
87.0~1
ml/min~45
775.0~1
112.1~1
Elimination~5
half-life~64
245.2~1
50.6~1
160.0~1
40.6~1
Distribution~3
188.6~1
50.2~2
L~30
183.0~1
50.8~1
(not~16
significant).~17
dosage~78
adjustment~44
hepatic-extracted~1
investigated.~50
revascularization~31
mammary~50
grafts~100
recipient~21
grafts,~11
way~60
access.~6
Upper~11
expiratory~91
flow-volume~8
capacity~221
(mid-vital~1
ratio);~1
established,~17
variability~106
exists.~8
mid-vital~5
accounted~102
curves,~7
nonsmokers~13
(30~48
women)~15
0.72~9
0.19~16
0.77~8
0.18~12
women.~110
limits~53
0.79~5
0.70~12
0.84~10
Maximum~16
129~11
H2O~18
91~22
Normalizing~1
variation,~5
wide,~4
standardizing~2
suddenly.~2
rhythm~48
normally.~6
system,~62
phenomena,~1
outgrowth~10
Measurement~28
angiotensin-converting~9
(ACE)~8
sarcoidosis.~15
ACE-inhibitor~2
affects~50
ACE~26
mere~2
eight-fold~1
dilution~23
1:8~2
dilutions~8
eliminate~39
inhibitor.~9
MW~9
50,000~8
daltons,~3
reversibility~10
Dialysis~2
inhibitor-containing~1
saline~123
irreversible,~2
distinction~22
alinearity~1
units/ml.~1
Dual~1
systems,~20
anomalously~2
Valsalva,~2
53-year-old~8
exercise-induced~28
ST-depression~1
anteroseptal~2
(V2-4).~1
hitherto~13
undescribed~5
anomaly~34
Recurrent~25
embolism~36
extremities~29
pelvis,~4
vena~68
cava~33
(IVC).~1
IVC~20
ameliorate~6
duplication~7
IVC.~2
anomalies~48
interrupting~5
57-year-old~4
leiomyosarcoma~8
uterus~23
intrapleural~2
tetracycline.~2
appreciated~7
theophylline~115
exhibits~11
intersubject~5
variation.~8
Within-subject~1
exacerbations~11
cor~6
pulmonale~1
Apparent~2
describes~116
morbidly~5
obese~78
kg)~18
two-month~2
Frequent~5
8.2~8
27.3~3
micrograms/ml.~17
explanations~13
starvation.~3
Daily~10
1600~3
mg/d.~3
within-subject~2
substantial,~1
flank~14
suprofen~2
urea~58
creatinine~99
cefamandole~6
day.~45
Serum,~2
adipose~21
tissue,~38
drainage,~18
chromatography~66
0.001)~181
(297~1
ml/min)~12
intraoperatively~16
(254~1
ml/min).~4
Volume~4
10.3~9
2.3)~1
L,~6
18.3~5
3.9)~5
1.67~1
0.63)~1
h-1.~1
Tissue~21
3.5~45
micrograms/ml~45
interval~171
Intraoperative~20
q6h~1
molindone~3
weight.~37
Monthly~3
weights~43
neuroleptic~14
dosages~22
psychiatric~90
molindone,~1
neuroleptics,~2
challenge~79
opinion~19
antipsychotics.~1
national~41
dermatologists~7
pharmacists~22
pharmacist~3
elicit~23
professional~43
interrelations.~1
dermatologists'~1
complaint~12
pharmacists'~5
unwillingness~1
prescriptions.~2
communication~35
professions~2
matters~1
inventory~3
prescription~15
refill~1
substitution~25
pharmacists,~2
preparedness~2
disorders,~29
limiting~25
complaints.~14
Ewes~1
systemically~12
periovulatory~5
antihistamines~5
diphenhydramine~4
(H1-receptor~1
antagonist)~2
and(or)~1
(H2-receptor~1
antagonist).~1
treatments~58
ovulation.~6
luteum~7
(CL)~3
progesterone.~8
Administration~56
pituitary~142
LH.~5
Injection~9
antrum~13
preovulatory~17
follicle~18
aberrant~10
luteal~78
Intrafollicular~1
CL.~1
Antihistamines~1
thecal~2
antral~36
influx~46
transudate~1
follicular~77
Function~3
matured~2
CL~12
compromised~18
antihistamines.~1
Actions~1
ovine~9
ovulation,~1
ensuing~5
hyperemic~13
follicles~37
enhances~23
consequence,~7
avascular~18
granulosal~1
LH~89
luteinization~4
decidualization~1
uterine~125
immunoglobulins~23
(Igs),~1
IgG,~23
(SC)~4
decidual~5
(DCR)~2
hormonally~7
primed~9
ovariectomized~17
rats.~196
progesterone-treated~1
mg/day,~4
horn,~6
horn.~4
conditions,~74
IgG~183
10-fold~20
DCR~4
IgA~73
SC~17
progesterone-induced~1
estradiol.~10
(0.2~8
microgram)~8
lumen.~11
5-fold~15
SC,~4
endocrine~48
accumulation.~10
blastocysts.~3
PRL~108
modulates~9
sweat.~5
Full~2
immunoincompetent,~1
nude,~1
congenitally~12
athymic~5
heals~1
survives~2
Mice~13
sweat~41
glands~66
analytical~13
Presumably~1
reconstructive~21
49~72
pilocarpine~13
iontophoresis~5
12.9~6
6.7~15
meq/liter,~1
bearing~39
anti-human~6
(hPRL).~1
anti-PRL.~1
61.9~2
8.25~2
meq/liter.~1
rabbits~124
hPRL~1
diluted~12
anti-hPRL.~1
GH~142
BWTG3~1
x~5
hepatocyte~15
somatic~27
hybrids,~2
unique~106
chromosomes,~6
genomic~24
Southern~22
blotting.~3
Radiolabeled~1
complementary~35
DNAs~5
(cDNAs)~1
encoding~17
probes.~7
assignments,~2
evolutionarily~3
dispersed~17
chromosomes~20
(ERs)~1
endometrial~88
cynomolgus~7
macaques~5
artificially~9
menstruation~7
repair.~33
Silastic~19
implants~36
filled~28
(E2)~16
(P)~19
spayed~1
E2~62
P.~28
withdrew~3
(but~15
E2)~3
uteri~15
0,~25
0.5,~17
2,~118
4,~55
5,~48
7,~17
Uterine~11
assayed~59
biochemically~12
ER~24
content,~46
histology~41
immunocytochemistry~7
antiestrophilins.~1
endometrium~18
[1330~1
201~10
9)~13
fmol/mg~20
DNA].~1
evident~80
3-4~12
2762~1
190~11
6)~23
DNA;~3
0.001].~2
0.5-7~1
0.88).~2
staining~97
glandular~36
epithelium~73
Beginning~5
withdrawal,~6
intensity~136
myometrial~16
5-7~6
zones.~4
luteal-follicular~1
transition~31
almost~147
fibroblasts.~10
D-dependent~2
calcium-binding~5
(9~24
K~41
CaBP)~1
1,25-dihydroxycholecalciferol~11
[1,25(OH)2D3]~2
duodenum~32
[32P]complementary~1
CaBP~16
RNA~81
transcription~23
(actinomycin~1
D,~23
alpha-amanitin)~1
(cycloheximide).~1
messenger~37
(mRNA)~10
dot-blot~2
hybridization~38
RIA.~16
80-95%~1
[35S]methionine~12
[3H]uridine~1
incorporation~53
RNA,~5
D-deficient~4
1,25(OH)2D3~13
(650~1
pmol/100~5
BW)~6
mRNA~92
actinomycin~11
micrograms/100~8
hormone-induced~4
duodenal~132
mRNA,~4
doubled~21
alpha-Amanitin~1
cycloheximide~7
1,25(OH)2D3-induced~1
posttranscriptional~1
steps.~4
duodenum.~9
beta-estradiol~16
(17~19
(D2)~1
secretion.~68
Anterior~10
pituitaries~9
medium~166
199,~1
(DA)~8
purified~130
quantified~31
[3H]spiperone;~1
Addition~31
10(-10)~14
10(-6)~47
reversibly~14
DA~49
0.001),~79
dose-related~31
10(-8)~31
E2.~6
(Kd~3
0.11~19
nM~33
E2).~1
estrogen-induced~2
DA-binding~1
spiperone~4
steroid,~2
30-min~12
[3H]17~1
E2,~6
labeled~103
D2~7
ligand~18
modify~27
already~38
7-min~1
mimicked~12
alpha-stereoisomer,~1
progesterone,~14
testosterone.~9
stimulatory~24
DA.~3
D2.~1
latency~96
discards~3
Surgically~3
cryptorchid~4
testes~19
spermatogonia~4
cultured~170
(Bu)2cAMP~8
(retinol).~1
retinol~22
spermatogonia.~3
retinol,~2
place;~1
disintegration~1
seminiferous~5
tubules~16
instead.~2
0.001-0.4~1
mM,~7
Likewise,~13
occurred.~76
decreased.~41
puromycin,~2
cycloheximide,~4
retinol-(Bu)2cAMP-induced~1
cAMP~52
trigger~15
promoting~11
macromolecules~12
Vasoactive~5
intestinal~270
(VIP)~5
inducer~6
release.~46
immunocytochemical~13
VIP~38
hypothalamus~14
lactating~11
transcription.~9
uses~31
transcribed~3
exons~6
devised~16
method,~47
2000-base~2
coding~22
hypothalamus.~5
VIP-related~2
PHM/I~1
(peptide~1
histidine~8
methionine~18
amide~3
isoleucine~1
amide).~1
VIP-encoding~3
cortex.~25
2-fold~19
hypothalamic~15
lactation.~15
maturation.~7
Taken~8
together,~11
neuroendocrine~11
hormone.~23
thyroid~226
iodide~21
activity.~171
Preincubation~14
slices~20
microM)~32
thyroid-medium~1
radioiodide~1
respects,~3
higher,~14
radiolabeled~42
(125I)~1
(131I)~2
eluted~20
Sephadex~7
G-25~2
columns.~1
Fractions~1
125I~14
131I~5
(125I/131I)~1
iodoproteins~1
void~13
125I/131I~3
fractions.~13
Thereafter,~6
lysozyme~10
(Mr~6
14,300)~1
6,000),~1
mol~52
8,000~14
10,000.~2
peak,~7
B,~65
column~30
MIT~6
Mr~28
2,000.~1
Ascending~2
paper~89
solvent~11
B~252
comigrated~6
MIT.~2
autoregulation~15
iodination~5
approximate~11
reason~36
labeling~44
iodide-induced~4
(iodide~1
autoregulation)~1
slices.~4
Thyroid~11
60-120~1
iodide,~3
synthesis,~20
washed~15
mM~82
methimazole~1
remove~34
iodide.~1
Iodide~1
90-min~5
incubations.~1
preexposure~7
autoregulation.~8
puromycin~3
microgram/ml~10
emetine.~1
Cycloheximide~3
TSH-stimulated~8
Two-dimensional~20
electrophoresis-isoelectric~1
focusing~12
employing~17
dual-isotope~1
iodoprotein~1
cycloheximide-treated~1
8-~3
10-kilodalton~1
gland.~19
650~4
pmol~20
1,25-dihydroxyvitamin~34
[1,25-(OH)2D3]~3
chicks~12
adenylate~66
cyclase~66
basolateral~21
accompanied~127
calmodulin~33
exogenously~8
(up~14
micrograms/ml)~13
(from~80
10(-7)-10(-5)~1
M)~47
trifluoperazine,~4
W7,~1
W13~1
alkaline~70
phosphatase~67
sequentially~21
tip~47
villus,~1
midregion~1
(a~50
brush~24
border~29
enzyme)~1
tip.~4
Adenylate~5
1,25-(OH)2D3,~3
midvillus.~1
1,25-(OH)2D3~19
villus~9
Male~23
(31.2~1
ng)/day~1
Alzet~1
osmotic~45
minipumps~2
s.c.~12
Animals~32
(11.2~1
10.2~10
136%~1
(187~3
pg/ml),~4
25-hydroxyvitamin~12
ng/ml).~11
metaphysis~5
(15%~5
6.5%),~1
(4.2%~1
0.1%),~1
(31%~2
19/mm~1
21%~24
14/mm,~1
respectively),~18
osteoclast~7
(11%~5
2/mm~1
6/mm,~1
vertebra.~6
Increases~7
fat-free~10
tetracycline~19
45Ca~6
bones~31
vertebrae~9
1,25-(OH)2D3-infused~1
mass,~29
(15-120~1
glucocorticoid-mediated~1
envisioned~1
thymic~16
lymphocytes.~17
1500~21
gels~17
influences~33
mRNAs,~4
pIs~1
glucocorticoids~7
thymus~15
codes~5
glucocortin,~1
inductions~4
1N~1
15-30~4
dexamethasone~33
mRNAs~8
poorly.~2
underlie~14
hormones,~7
testosterone,~19
T3,~13
deoxycorticosterone~11
messages.~2
1N,~1
M,~23
classification~78
glucocorticoid~36
agonist.~6
inductions,~2
1N.~1
specifically~64
induces~50
glucocortin.~1
ovaries~8
steroidogenesis~20
granulosa~11
VIP-messenger~1
ovaries,~1
peptide.~7
VIP-gene~1
expression,~10
ovaries.~7
(peptide-histidine-methionine).~1
VIP-mRNA~1
12-fold-higher~1
organs.~18
beta-Estradiol~2
neurohormones~1
LHRH,~2
TRH,~1
dopamine,~7
coupling~15
pinpoint~7
modulation~26
phospholipid~29
methylation.~2
(ovx)~1
ovx~1
E2-treated~1
Methylated~1
phospholipids~22
TLC.~2
Incorporation~3
[3H]methyl~2
S-adenosyl-L-methyl~1
[3H]methionine;~1
Mg2+~4
manner~59
S-adenosyl-L-homocysteine,~1
methyltransferase~4
critical.~4
Formation~2
phosphatidyl-monoethanolamine,~1
phosphatidyl-dimethylethanolamine,~1
phosphatidylcholine~14
progressively~61
(Vmax)~6
substrate~43
methylating~2
enzyme.~10
Vmax~25
alpha-estradiol,~2
stereoisomer~1
ineffective,~2
pointing~3
interaction.~9
differential~122
centrifugation~13
(L)~3
microsomal~35
(N)~7
(M)~7
sucrose~33
centrifugation,~6
methylated~2
preferentially~23
reticulum~18
granules.~13
subcellular~9
fractions;~1
enzymes~61
markers.~7
methylation~2
mediobasal~2
E2-induced~2
fusion,~8
hybridomas~6
secreting~15
antiovine~1
placental~24
lactogen~1
(oPL)~1
secrete~17
(Ig)G~1
subclass,~1
IgM~96
antibodies.~38
Ascites~2
solid-phase~6
RIAs~2
subclass~10
antibodies,~44
ineffective.~6
RIAs,~1
[125I]iodo-oPL~1
unlabeled~19
oPL,~2
(oPRL),~1
(oGH),~1
extract.~8
[125I]~4
iodo-oPL~1
receptors(s)~1
receptor(s)~6
gland~109
inhibiting~34
oPL~11
gland,~21
liver.~39
weakly~16
[125I]iodo-oPRL~1
[125I]iodo-oGH~1
radioreceptor~4
(RRA)~1
(RRA-PRL)~1
(RRA-GH)~1
parallelism~1
standard.~6
sequence(s):~1
responsible~173
receptor(s).~3
located~100
another.~15
Alternatively,~8
receptor(s)-binding~1
sequence(s)~1
conformational~9
thymocyte~4
participates~9
T3.~5
regulating~24
guanyl~3
nucleotide-dependent~3
freshly~18
ng/100~3
80%.~12
storage~54
stored~47
preparations,~8
dialyzed.~2
antagonists,~14
calmidazolium,~1
concentration-dependent~22
calmodulin.~5
stored,~1
antagonists.~15
dialyzed~7
restored~50
thymocytes~3
mediates~15
produces.~1
Such~82
mediation~9
explains~9
calcium-dependent~4
Bone~39
ovarian~106
ovariohysterectomy~5
beagle~13
static~51
crest~20
sham-operated~40
Cessation~3
ovariohysterectomy.~2
phosphorus,~17
Cancellous~1
osteoblasts~9
osteoblast,~1
is,~60
bone-forming~1
Parameters~4
Osteoblastic~1
insufficiency~71
androgen~36
GH-secretory~4
patterns~207
androgen-resistant~1
(testicular~1
feminized)~1
littermates.~4
intraatrial~4
(0800-1600~1
h).~17
littermates~8
bursts~18
2.5-3~1
trough~18
undetectable~28
45-90~1
hour.~14
littermates,~2
GH-trough~1
profiles~64
testicular-feminized~1
masculine~2
antiestrogens~2
(AEs)~1
(E)~6
turnover~52
(MBH)~1
insight~21
DA-PRL-E/AE~1
interrelationships.~1
21-day-old~1
E~78
MBH~6
time-~5
microgram/day),~1
1300~3
pg/mg~3
.~3
AEs~4
tamoxifen,~4
monohydroxytamoxifen,~2
CI628,~2
LY117018~2
uterotropic~1
E.~18
LY117018,~1
competed~7
affinities~13
190%,~2
185%,~1
6.7%,~1
1.4%,~1
100%;~3
receptors.~47
2-fold,~2
E-induced~1
successfully.~7
bromocriptine,~2
AE~9
(approximately~37
2-fold)~1
Hence,~15
actions~44
independently~64
MBH.~1
behave~14
agonists/antagonists~1
terms~95
turnover.~6
MCR,~2
(rt1/2)~1
half-lives~17
(r)~5
TSH,~5
TSH~104
crude~19
hypothyroid~22
sera,~15
secreted~56
euthyroid~30
rTSH~2
precipitation~13
MCR~13
(0.53~2
(0.52~1
0.03),~7
(0.32~1
0.03)~13
(0.33~2
(8.4~3
ml)~33
(11.4~1
0.7)~3
(10.9~1
0.8).~1
reflected~73
rt1/2~3
(12.6~2
0.5)~5
(5.7~4
0.4)~2
pituitaries.~3
(8.5~2
0.9)~1
rTSH.~1
(bTSH)~2
deglycosylated~5
bTSH~11
(dg-bTSH)~2
compared.~40
dg-bTSH~7
(0.71~3
(0.59~4
0.02),~23
(3.8~3
(4.7~5
0.2).~1
Uptake~7
[125I]rTSH~1
times,~24
54%~23
180~43
rat,~21
differs~31
vary~44
derived;~1
2)~57
deglycosylation~4
speculate~6
structure;~1
clearance.~18
Diencephalic~1
mesencephalic~2
biphasic~29
golden~3
hamsters~22
estrogen.~10
Double~4
barreled~1
unilaterally~7
bilaterally~24
preoptic~4
area,~43
hypothalamus,~6
ventromedial~1
(VMH),~1
gray,~1
interpeduncular~2
nucleus.~11
Testing~8
paradigm;~1
facilitation~13
commenced~2
priming.~1
P-filled~1
VMH~5
facilitated~18
lordosis~6
promoted~13
receptivity.~3
Lordosis~1
20-36%~1
area.~74
gray~21
facilitating~10
behavior.~30
pretest,~2
behavioral~73
4-5~2
pretest~3
inhibition,~6
receptive~19
attacked~2
nonreceptive~1
scores~112
receptivity~6
experiments,~35
investigating~16
copulation~2
mediating~25
VMH,~1
importantly,~8
hamster~22
diencephalon,~2
[125I]T3~11
skeletal~139
incubating~7
[125I]T3.~1
asymptotically;~1
0.238~1
0.021%~1
1/5~1
C.~104
uptake,~25
subtracting~4
microM~58
Washout~1
radioactivity,~4
released,~2
intracellular~142
L-T3,~1
D-T3~2
L-T4~4
uptake;~2
nM,~8
microM,~18
oligomycin~1
antimycin~1
3%~53
Monodansylcadaverine~1
bacitracin,~2
receptor-mediated~11
endocytosis,~2
67~49
62~57
2%,~4
saturable,~7
stereospecific,~1
energy-dependent~2
responsible,~3
endocytosis~8
Angiotensin~9
(AII)~5
lactotroph~3
stimulates~25
estrogens~17
exert~24
regulatory~41
secretion,~43
AII~34
E2-containing~1
PRA~3
[125I]AII~1
membrane-rich~2
6%~53
affinity.~4
estrous~12
(0.01-1~1
nM).~5
culture,~20
substantial~100
nM)~17
TRH~6
AII-stimulated~1
pituitary,~8
postreceptor~4
AII.~2
52K~6
quantitated~22
pulse-chase~5
secreted,~1
successively~5
48K~2
34K~1
protein.~51
stable.~9
processing~42
lysosomotropic~2
leupeptin,~2
vesicles,~9
lysosomes~9
endosomes.~1
Estradiol~17
immunoreactive~35
4-fold.~1
Its~41
medium,~19
constitutive~7
[3H]mannose~1
endoglycosydase~1
H~46
altered,~3
modulate~29
glycosylation~7
step.~2
Antiestrogens~2
proteins.~35
precursor~40
34K.~1
precursor.~3
Physiological~3
Ca2+-ATPase~3
reticulocyte~21
preincubation~9
ghosts~4
10(-11)~9
female-source~3
male-type~1
(inhibition~1
activity).~3
male-source~2
female-type~1
(stimulation~2
steroid-sensitive~1
hormone-dependent~2
structure-activity~2
analogs~16
steroids.~18
beta-Androstanes~1
assays~54
alpha-androstanes~1
active.~8
beta-androstanes,~1
C3-~1
C17-position.~1
Nongonadal~1
active,~9
Assayed~1
estrone~18
3-hydroxy-1,3,5-(10)7-estratraen-17-one~1
(equilin)~1
beta-estradiol,~1
estriol~5
aldosterone~28
76%~19
71%,~3
gonadal~13
steroid-cytoplasmic~1
interactions,~3
steroid-thyroid~1
messengers~1
Ca++~49
proopiomelanocortin~5
(POMC)~3
cloned~19
cAMP-related~2
POMC~13
(IL)~2
serum-free~9
medium.~31
8-Bromo-cAMP~1
mM),~8
8-bromo-cGMP~1
IL~8
cyclase-activating~1
forskolin~23
cholera~12
toxin~31
phosphodiesterase~10
RO~1
20-1724~1
microM).~7
beta-endorphin~17
biosynthesis.~8
Incubating~1
D600~2
microM),~9
verapamil~61
dihydropyridine~10
nifedipine~57
(0.1~21
BAYK~2
8644~9
activates~9
channel,~6
forskolin,~6
forskolin-increased~1
regulate~16
POMC.~1
teleost~2
fish,~4
tilapia~2
(Oreochromis~1
mossambicus),~1
calcium.~19
source(s)~1
action(s)~1
Also~14
undefined~5
regulators~6
investigation,~10
K+~62
incubations~5
depolarizing~8
(56~8
mM)~26
18-20~1
incubation.~9
perifusion~3
incubation,~5
elicited~47
D600,~1
blocker,~7
10(-5)~40
K+-induced~2
CoCl2,~1
blocks~22
calcium-mediated~1
influx,~6
hyposmotic~1
dependent,~5
voltage-regulated~1
plasmalemma~1
Daylength~1
(photoperiod)~1
reproductive~31
juveniles~4
photoperiodic~2
daylength~2
prenatal~55
perceived~27
profoundly~12
development.~37
Djungarian~3
hamster,~6
pineal~24
hormone,~25
melatonin,~2
daylength.~1
pinealectomy~1
photoperiod~2
pups,~4
communicates~1
fetus.~16
melatonin~23
pinealectomized~1
dams~6
gestation~57
weights.~5
1,25(OH)2D3,~4
steady-state~42
pre-proparathyroid~1
(pre-proPTH)~1
occurs.~14
PTH~33
10-15%~1
(10(-11)M)~1
fully~63
reversible.~5
hemolytic~28
plaque~32
casein~14
bioassay~9
PRL.~1
formed.~6
exquisite~2
(156~1
fg~1
slide)~1
biopotency~1
"plaque~1
bioassay"~1
PRL,~3
bio-~1
immuno-potencies~1
secretors~1
estimates.~4
Given~13
variants~33
efficacies,~1
another~145
form(s)~1
released.~3
Rat~7
insulin-like~10
factor-II~1
(IGF-II)~1
step~39
chromatographic~22
agarose-IGF-II~1
4.~12
Determined~1
IGF-II~17
RIA~21
receptor,~21
purification~15
2000-fold~1
28%~27
preparations.~27
sulfate-electrophoresis~2
autoradiography~8
radioiodinated~3
affinity-labeled~1
250K.~1
Scatchard~14
solubilized~11
10(10)~2
liter/mol~1
Potent~1
rabbits,~13
1:170,000~1
precipitating~17
IGF-II-prelabeled~1
1:50,000.~1
reacted~39
kidney,~34
lung,~41
spleen.~9
mannose~2
(Man)~1
oligosaccharide~4
beta-subunits~6
heterodimers~2
alpha-subunits.~2
Mouse~5
thyrotropic~2
mice,~29
D-[2-3H]Man,~1
homogenized,~3
buffer~29
dissociate~3
heterodimers.~1
Highly~5
enriched~17
beta-subunits,~2
heterodimers,~1
anti-TSH~1
alpha-subunits~2
anti-LH~1
alpha-serum.~1
High~39
endoglycosidase~2
chromatography.~34
oligosaccharides~5
residues~33
subunits.~5
types,~11
accumulate~13
Man-trimming~1
Man9GlcNAc~3
Man8GlcNAc~2
proceeded~6
alpha-subunits,~1
beta-subunit~4
type;~8
equaled~8
physiologically~14
regulated.~6
Hypothyroid~2
calf~28
slowed~7
alpha-subunit~2
beta-subunits.~1
CG~5
(hCG)~10
LH/hCG~2
hCG~84
stages~89
pseudopregnancy~2
Pseudopregnancy~1
mating~3
sterile~22
microspheres~23
autopsy,~14
corpora~10
lutea~5
extirpated~1
stereomicroscope.~1
These,~1
ovary,~6
counted~6
Progesterone~11
tissues.~45
pseudopregnancy.~2
intraarterial~17
IU)~2
(saline)~2
6,~45
pseudopregnancy,~3
redistribution~33
NIH-LH-B9,~1
hCG.~7
ip~3
conscious~37
45%~30
4-fold~6
ovary.~6
exposure.~43
nonresponsive.~1
coincides~3
vasoactive~36
substances.~8
increase,~12
rendering~3
unlikely~38
somatomedins~3
[insulin-like~1
(IGF-I~1
IGF-II)]~1
L6~4
myoblasts.~2
IGF-I~47
potent~103
stimulators~3
amino~133
proliferation,~6
differentiation;~1
measurements,~28
potencies~4
insulin.~8
DNA-produced~2
IGF-I,~3
(Thr59)IGF-I~1
(N-Met)IGF-I,~1
IGF~12
molecules.~12
350K~1
molecule~37
dissociated~14
sulfhydryl~4
reduction),~1
220K~1
reduction).~2
coupled~49
(compared~3
IGF-II)~1
Leydig~14
Constitutive~1
constitutively~4
R2C~9
trophic~8
hormone-responsive~1
MA-10~6
Unlike~29
synthesize~15
cAMP-protein~1
kinase~90
pathway.~22
toxin,~5
cAMP-dependent~4
processes.~27
steroidogenic~4
lactate~109
formation,~32
dependence~39
biosynthesis~17
parallelled~1
Cycloheximide,~1
bioassay,~2
extramitochondrial~2
cycloheximide-sensitive~2
functionally~25
pregnenolone~5
cAMP-independent~2
activated~110
corticosteroids~20
unclear.~28
postbinding~3
peroxide~12
acts~28
3T3-L1~2
peroxide-induced~1
type,~34
insulin,~8
lipids~48
transporters,~1
lipids,~20
dexamethasone-induced~1
somatomedin-C/insulin-like~2
(Sm-C/IGF-I)~2
Sertoli~16
sexually~20
immature~29
25,000,~1
immunoblot~4
polyacrylamide~19
electrophoresis.~14
Isoelectric~2
isoelectric~23
neutrality.~1
cross-reacted~3
Sm-C/IGF-I,~1
acetic~5
acid.~28
C18~3
Sm-C/IGF-I~9
wt.~3
species~107
neutral~33
form,~15
9.8.~1
pI~5
GH-dependent~2
serum.~46
peptide,~12
unlike~27
behaved~7
BALB/c-3T3~1
[125I]Sm-C/IGF-I~1
summary,~18
Sm-C/IGF-I.~1
Proliferin~1
(PLF)~1
member~12
PRL-GH~1
proliferating~10
placenta.~7
Suspensions~1
PLF~3
immunoprecipitation.~2
Here~30
heterogeneous~22
preprotein~1
signal~127
Placental~3
immunologically~13
distinguishable~9
lactogens.~1
outer~51
(zona~2
fasciculata/glomerulosa)~1
reticularis)~1
adrenal~127
pig.~6
zone~78
(LDL)~10
explore~20
3-hydroxy-3-methylglutaryl~3
coenzyme~10
(HMG-CoA)~1
reductase,~4
rate-limiting~3
report.~19
HMG-CoA~7
reductase~28
230~10
mevalonate~1
formed/min~1
protein).~3
4-~15
LDL~44
administered,~8
50%,~16
happens~1
Why~2
clear,~10
phosphorylation/dephosphorylation~2
phosphatase,~9
pharmacological~25
prodynorphin-derived~5
opioid~43
peptides,~5
dynorphin~9
alpha-neo-endorphin,~2
magnocellular/posterior~1
rat.~34
prodynorphin~2
mammalian~33
representatives~2
mammals:~1
(order~3
Rodentia),~1
Artiodactyla),~1
rhesus~13
monkey~15
Primates).~1
species-specific~3
conversion~33
A-(1-17)~2
A-(1-8).~1
rodents,~2
pigs,~3
1:2~4
2.5:1,~1
monkey,~4
10:1~1
14:1,~1
A-(1-8)~1
porcine~50
pituitary.~4
Species-specific~2
alpha-neo-endorphin~1
B-(1-13).~1
opioids~10
leu-enkephalin~1
Developmental~8
lactotrope~2
(ICC).~1
Pituitary~3
sexes~23
monodispersed~1
trypsin.~4
Freshly~2
Cunningham~1
chambers~18
plaque-forming~6
formed,~1
glass~10
slides~11
ICC.~1
gradually~67
proestrus~5
37%~24
Sexual~4
thereafter.~24
1,100~3
15,600~1
6,700~1
age;~15
5,500~2
3,200~2
estrogen-dependent.~1
ICC~6
assay,~30
forming~21
plaques.~7
47%~21
immunostained~1
difference,~10
puberty~14
ions,~4
cyclic~75
nucleotides,~4
catecholamines~40
pregnant,~3
cyclic,~1
nonpregnant~28
gilts.~5
flushings~2
(UTF)~1
(ENDOM)~1
gilts~6
10,~51
12,~20
3).~15
Protein,~1
Na+,~6
UTF~9
Ca2+~65
biphasically,~2
12.~7
Endometrial~5
cGMP~3
(NE)~4
NE~22
(DA),~4
peaked~25
metabolite,~9
3,4-dihydroxyphenylglycol,~1
ENDOM~3
2.4-fold~2
Effects~18
60,~18
360~14
post-E~1
post-saline-ethanol~1
(C)~11
9).~6
Potassium,~1
Plasmin~2
postinjection~2
E,~10
Ca2+,~3
Na+~26
E-treated~2
secretions~26
(except~7
plasmin~8
inhibitor)~2
E-stimulated~1
vesicle~13
exocytosis.(ABSTRACT~1
GH4C1~2
half-maximally~1
(EC50)~2
EC50~8
production.~44
estrogens:~1
estriol,~7
estrone,~5
metabolism-resistant~1
ethynyl~1
moxestrol.~1
agonists~43
[3H]estradiol~5
estrogen-responsive~1
cDNA~30
library~7
chosen~33
growth.~39
mRNA.~9
(Sc)~2
[3H]inulin~2
polarized~6
transferrin~13
(Trf)~1
androgen-binding~2
(ABP)~3
two-compartment~3
chamber.~10
Sc~4
14-~2
18-day-old~1
media:~1
Modified~7
Eagle's~1
Medium-Ham's~1
F-12~1
(DFM),~1
DFM~4
hydrocortisone,~1
vitamins~11
(6F),~1
6F~4
(7F),~1
7F~2
FSH~8
(8F),~1
(6F2S),~1
(6F5S).~1
3-5~9
18-~5
14-day~4
animals,~62
DFM.~1
Morphological~2
tight~21
junctions~18
neighbouring~3
de~29
novo~17
Secretion~1
Trf~6
steadily~17
declined.~5
media,~9
Medium~3
inconsistently~4
8F~3
6F.~1
Supplementation~2
ABP,~1
depending~40
composition;~1
differentially~7
polarity~3
ABP~16
compartments~18
(OC/IC)~1
6F,~1
7F,~1
8F.~1
serum-containing~1
OC/IC~2
5.0~27
13.~7
Trf,~1
supplementation~62
6.0~25
grown~36
permeable~12
monolayers~31
macromolecules,~2
junctions.~4
Purified~5
relaxin~30
(3000~3
U/mg)~1
im~6
(RLX-IM;~1
mg;~4
os~7
(RLX-OS;~1
273~5
parturition~8
occurs)~1
(E1),~1
beta-E2)~1
beef~11
heifers.~1
PBS~1
ml,~31
im;~1
gel-PBS~1
(gel;~1
os;~1
os.~1
relaxin-treated~1
(im)~1
heifer~2
calved~1
thus,~20
Relaxin-treated~1
heifers~4
relaxin,~1
precipitous~3
E1~10
beta-E2.~1
4.95,~1
1.5,~7
0.24~11
RLX-IM,~3
RLX-OS,~3
23-31~1
1-2.5~1
returning~12
5-12~1
Relaxin~5
73%,~4
E1,~3
beta-E2~3
treatments,~7
abrupt~19
2-2.5,~1
2-3.5~1
-5.43,~1
-3.05,~1
-0.92~1
rebounded~1
61%~11
62%~18
RLX-IM~1
RLX-OS.~1
407.3,~1
306.5,~1
71.5~2
pg/ml~43
82.2,~1
35.8,~1
7.8~14
controls,~97
luteolytic~2
cattle~5
separating~7
neuronal~71
glial~18
nuclei,~7
Glial~1
homogenization~2
cerebellum,~7
discontinuous~13
2.2~31
sucrose.~4
purposes~24
comparison,~13
Microscopic~14
purity~3
extranuclear~1
contamination.~3
saturation~68
(Bmax)~1
(Kd)~5
least-squares~9
C,~70
Bmax~7
1203~1
118~16
6),~24
196~6
7).~10
contamination,~4
DNA.~14
299~3
6).~14
Kd~19
0.38~6
0.04~36
0.34~8
0.33~13
neuronal,~1
glial,~1
competition~16
(T3~1
rT3)~1
myelination~4
Anestrous~1
gonadotropin~64
surges,~1
experiment,~14
anestrous~3
transferred~35
cyclicity.~1
Morning~2
Females~5
autopsied~7
vaginal~73
estrus~4
estrus.~2
display~28
surges~7
uteri,~1
se~18
anestrus,~1
anestrus.~2
Phenobarbital~1
gonadotropins~7
promotes~16
maturation~15
cascade~7
First,~18
resume,~1
cease.~2
Then,~5
decline,~5
ovulatory~10
surge~6
triggered.~1
deficient~45
naturally,~1
moiety~8
undertaken,~1
question.~7
anhydrous~1
fluoride.~2
Amino~8
originally~19
judged~43
assays,~11
affinity,~5
half-maximal~8
[125I]bTSH~1
Nonetheless,~5
stimulating~36
cyclase-stimulating~2
weakly,~1
abolition~12
40-fold~2
dg-bTSH.~1
FRTL5~1
thyroid,~4
growth,~30
[3H]thymidine~9
accord~1
assay.~37
recognition,~6
intermolecular~1
disulfide-linked~3
multimers~2
(as~32
monomers/oligomer).~1
glutathione~65
(GSH)~2
monomeric~19
intragranular~2
osmolality~24
oligomers~4
key~34
granule~23
Hormone~6
hyperosmotic~3
raffinose~5
43.5%~1
70-100%~1
Augmented~1
GSH~7
raffinose,~1
17.9%~2
(PRL)~4
75.6%~1
(GH)~6
IC50~5
0.62~5
M;~5
shifted~19
GSH.~1
Raffinose~1
7.8.~3
Interference~2
gradient,~5
maneuver~16
disruption~48
0.5%~28
deoxycholate~3
inhibition.~13
Molecular~5
sizing~2
Superose-6~1
(Pharmacia)~1
monomers~5
pelletable~1
GSH-stimulated~1
thiol:disulfide~1
equilibria~1
osmolality.~7
exocytosis~6
osmotically~2
thiols~1
granule:plasma~1
tibiae.~2
fed~244
supplemented~36
fractured,~1
nonfractured~1
healing,~13
[3H]vitamin~1
callus,~1
epiphysis,~2
diaphysis,~1
duodenum,~9
Histological~21
calluses~2
bones,~6
dihydroxylated~2
[3H]24,25-dihydroxyvitamin~1
coincide~4
cartilaginous~8
chicks,~1
[3H]1,25-dihydroxyvitamin~2
coinciding~4
repair,~10
requirements~66
lines,~16
MDA-MB-157~2
BT20.~1
express~31
isoenzyme~22
3-fold~13
72-h~3
10(-7)~30
[1,25-(OH)2D3],~2
(HC),~1
hormones.~15
BT20~3
phenotypic~19
breast,~6
ectopically~1
placenta~15
embryonic~36
isoenzyme.~2
HC,~1
nanograms~3
protein,~64
cycloheximide.~3
1,25-(OH)2D3-binding~1
isomer.~1
HC~4
lines.~20
epididymal~8
euthyroid,~2
hypothyroid,~5
hyperthyroid~11
(lipogenic)~1
diet.~67
Radioautographs~1
translational~5
computer-assisted~13
videodensitometry~3
statistics.~3
responsive~26
spot~5
lipogenic~2
diet,~34
decreasing.~3
fashion~44
carbohydrate-generated~1
thyroid-hormone~1
alterations,~5
duplicated~7
analyzed.~46
brown~8
(BAT)~4
pulse-labeling~1
Maximal~26
Nuclear~13
locally~34
T4.~5
multiplied,~1
T3/mg~1
71%.~3
Fifty-five~17
locally,~3
BAT~10
hence,~7
5000/cell)~1
contributions~21
data,~63
5'-deiodinase~6
oxytocin~27
(OT)~5
OT-producing~2
drinking~57
NaCl~29
OT~44
Northern~13
blot~27
microdissected~3
supraoptic~4
(SON)~1
paraventricular~2
(PVN).~1
vasopressin~77
(VP)~4
VP~20
neurointermediate~4
SON,~2
PVN,~2
commissural~4
similarly,~3
1.5-fold~2
magnocellular~2
stimulus,~6
SON~1
PVN.~2
electrolyte~31
balance.~16
macropinocytosis~1
colloid~31
droplets.~2
elicits~6
macropinocytotic~3
TSH-responsive~2
T4,~7
acid-Schiff-stained~1
3-microns~1
thyroids~1
droplet~3
recruitment,~1
droplet-containing~3
mU~4
rats:~3
TSH)~3
67%~28
TSH).~1
pinocytotic~1
thyrocyte~1
extra-~1
intrathyroidal~3
factors:~6
example,~25
iodine-deficient~1
90%.~5
Obviously,~1
distinguished:~4
droplets~3
Recruitment~2
thyrocytes~1
stimulus~66
Norepinephrine~9
tyrosine~19
hydroxylase~17
brains~20
moderate-seizure~2
severe-seizure~2
genetically~20
epilepsy-prone~1
(GEPRs)~1
nonepileptic~2
(GEPR-3)~1
(GEPR-9)~1
widespread~50
Abnormalities~16
midbrain.~1
susceptibility,~3
severity,~14
GEPR~1
noradrenergic~17
hypothalamus/thalamus.~1
telencephalon,~1
midbrain,~3
pons-medulla.~1
Seizure~2
cerebellum.~4
progeny~7
coisogenic~1
C57BL/6J~2
homozygous~23
tottering~2
(tg/tg)~2
wildtype~1
(+/+)~2
allele~9
paternal~11
anticonvulsant~21
malformations.~7
Pregnancy~5
outcomes~29
one,~40
both,~29
epileptic~28
genotype~7
phenytoin-treated~1
aggravated~7
seizures.~23
polytherapy~1
inappropriate~28
(for~11
epilepsy)~1
astatic-myoclonic~1
phenomenon~75
apt~3
epilepsy~38
spike-wave~1
discharges~8
EEG,~4
Lennox-Gastaut~1
interictal~2
epileptiform~8
(IEDs)~1
prolactin~43
(CPS)~3
subclinical~23
ictal~4
all-night~2
polygraphic~3
recording~68
imaging.~35
IEDs~2
non-REM~6
REM~38
sampled~15
intervals,~15
0.005),~14
environment~24
mechanisms,~16
modest~31
discharges.~1
599~2
southern~11
province~4
Finland~3
date,~15
(2.0%).~3
age-adjusted~15
(67%)~12
epilepsy),~1
attacks~58
19.3~2
surveillance~21
1985.~47
comorbidity~1
epilepsy.~20
specialist~5
medicine.~21
practitioners~11
mailed~11
Dutch~7
neurologists~11
practitioners.~2
opinion.~1
real~27
retrieved~8
registers~2
Demographic,~3
psychosocial,~3
sampled.~3
Specialists~1
tend~25
want~4
role;~2
desire~10
change.~45
change,~21
future~72
supervised~9
practitioner~6
demographic~33
large.~5
Epilepsy~1
Differences~32
attitude~21
direct,~5
experiences~26
topic~3
indirect,~1
nonbehavioral~1
experiences.~3
epilepsy,~10
practice,~19
posttest~4
controlling~47
students~112
teacher-training~1
colleges.~1
attitudes,~4
way.~9
Treatments~1
effective.~15
Direct~20
restrain~2
Rochester-Olmsted~1
County~11
Linkage~2
Project~4
fertility~19
Population~3
age-specific~3
Rochester~3
residents~96
1935-1974~1
births~28
Minnesota~12
Department~20
Health~54
Statistics~7
Vital~6
U.S.~32
persons.~20
Individuals~10
(simple~2
complex)~3
disadvantaged,~1
not.~66
disadvantaged~1
male-female~2
(after~7
1965).~1
ever-married~1
person-years~2
differences.~19
academic~37
achievement~13
122~19
making~45
progress~41
Academic~2
arithmetic,~3
spelling,~1
reading,~1
comprehension,~1
word~4
recognition.~6
strongest~22
correlates~43
onset,~18
lifetime~14
(absence~1
tonic-clonic).~1
vulnerability~8
neuropsychological~18
education.~18
nationwide~10
VA~8
Cooperative~9
622~2
well-defined~11
Seventy-four~9
centers.~9
scored~25
measures.~23
(Finger~1
Tapping,~1
Pegboard,~1
Naming),~1
cognitive-attention~1
(Digit~1
Symbol,~1
Discriminative~1
Reaction~5
Time,~1
Word~1
Fluency),~1
subtests~2
Profile~3
Mood~3
Status~5
(tension,~1
vigor,~1
confusion).~1
profile~57
unmedicated~1
Unilateral~8
pitched~1
tinnitus~13
45-year-old~7
woman.~15
Electrographic~2
originated~18
midtemporal~1
tinnitus.~7
gyrus~11
supramarginal~1
gyrus.~5
illustrates~41
(PF)~4
(with~22
tubal~49
patency)~1
laparoscopy,~4
lavage,~4
hysteroscopy.~1
PF~14
aspirated~14
cul-de-sac~3
irrigation.~3
(19%)~15
(11%)~17
endometriosis~35
0.6)~1
Refluxed~1
PF,~4
(42%)~10
0.03).~20
endometriosis.~10
mutually~3
exclusive,~2
other,~11
pathophysiologic~23
endometriotic~9
(PGF)~1
mediator~21
endometriosis,~9
PGF~8
mild,~26
moderate,~10
severe,~21
implants,~7
criteria,~33
reddish;~1
brown;~1
powder-burn~2
black.~3
Petechial~1
turn~20
Powder-burn~1
PGF,~1
implant.~9
afford~5
assistance~12
subtle~26
intrauterine~46
ectopic~80
microsurgery.~2
microsurgical~19
salpingostomies~1
hysterosalpingogram~2
formulate~3
58.3%~2
36.6%~2
9.5%~3
0%~21
IV.~17
adhesions,~6
38.8%~1
adhesion,~2
32.0%~1
26.6%~2
5.5%~8
adhesions.~5
microsurgery~2
fertilization.~5
couples~12
unexplained~38
infertility~40
luteinizing~17
(LH)~7
phase.~35
abrupted~1
surge.~4
luteinized~1
unruptured~8
diagnosed,~5
examination.~65
repetitive.~1
contraceptives~19
estrogen/progestogen~1
(monophasic~1
nonalkylated~3
estrogen/norethindrone,~1
monophasic~7
ethinyl~12
(EE2)/norethindrone,~1
progestogen~4
norethindrone,~3
triphasic~7
EE2/levonorgestrel)~1
insulin-dependent~25
6-month~15
fasting~89
glucose,~30
requirements,~13
glycated~1
hemoglobin,~7
fatty~156
acids,~23
concentrations,~43
cholesterol/total~1
estrogen/norethindrone~2
EE2/levonorgestrel~2
formulations,~3
EE2/norethindrone~1
triglyceride~40
unfavorable~15
Norethindrone-only~1
formulations.~1
Thirty-four~17
infertile~20
alternated~2
intracervical~1
insemination~16
(ICI)~1
ejaculate~3
homologous~37
semen~24
(mean,~53
cycles/patient)~1
(IUI)~1
sperm~54
3.4~24
cycles/patient).~1
postcoital~4
demonstrating~53
motile~8
high-powered~1
(HPF).~1
conceived~9
IUI~5
(30.0%);~1
ICI~5
0.06,~4
Mantel-Haenszel~2
chi-square~5
test).~12
6/72~1
(8.3%),~1
0/66~1
(0.0%)~1
cycle,~22
0.04,~9
Fisher's~5
HPF.~1
(7.1%),~2
(14.3%),~1
1/42~1
(2.4%),~1
2/42~1
(4.8%)~2
HPF)~1
HPF).~1
1128~2
sterilized~8
juxtaposed~1
telephone~31
interviews~24
regret~1
268~3
histories~29
examined,~24
screened,~3
selectively,~3
regret.~2
unwanted~7
conception~15
wastage~2
nonreturn~1
Institutional~1
return.~2
Variables~4
postponed~3
fertilization-embryo~1
(IVF-ET)~1
culminated~2
oocyte~9
pickup.~1
disparity~6
chorionic~67
undetected~9
Another~25
cohort~54
defined.~25
IVF-ET~1
subunit~10
singleton~12
fertilization~32
(IVF)~7
56~89
embryo~39
(ET).~1
conceptions.~1
151~9
IVF~10
embryos~44
embryo.~7
8,~31
20,~33
ET.~1
declines~9
first-trimester~2
abortion~36
pregnancies.~19
ET~5
implantations~4
utero~12
contributory~11
IVF.~3
suitability~2
(IVF).~1
Two-cell~1
blastocysts~2
72~96
Whittingham's~1
T6~4
Significantly~16
hatched~2
weeks'~41
Expanded~2
2-cell~2
supplements,~7
aging,~10
coatings.~1
Ham's~2
F-10~2
(GIBCO,~1
Grand~2
Island,~3
NY)~3
supported~35
albumin~139
(BSA),~5
(FCS),~2
blastulation~1
(medium~1
alone,~69
89.4%;~1
BSA,~7
86.4%;~1
FCS,~3
90%;~1
MS,~12
74.7%).~1
Unsupplemented~2
daltons~5
peaks,~1
high-performance~26
(HPLC)~4
(SDS-PAGE),~1
protein(s)~1
storing~1
425~5
(blastulation~1
rates:~2
fresh,~4
84%;~1
77.7%).~1
talc-coated~1
(TC)~2
"talc-free,"~1
starch-coated~1
embryotoxic~1
touched~2
lengths~25
uncoated~4
(UL)~1
untouched~2
Quality~9
handling~20
reemphasized,~1
supplementation,~8
contamination~12
talc-free,~1
reevaluated.~1
granulosa-luteal~2
adenosine~147
3',5'-monophosphate~2
(cAMP)~7
hyperstimulated~2
fertilized~6
laparoscopy~16
gonadotropins.~2
desensitization.~4
preincubated~3
hCG,~8
bring~5
Time-course~2
hCG-stimulated~1
improves~20
cells'~3
principle,~2
azoospermia~4
explanations:~1
duct~107
parenchyma.~8
loop~30
caudally~1
two-layer~2
side-to-end~1
anastomosis~64
vas~10
deferens.~5
anastomosis,~16
primarily.~2
cross-over~9
reoperation,~10
side.~28
empty,~1
epididymis~4
oligozoospermia~2
offered~18
supplementary~14
epididymovasostomy.~2
evaluation,~23
(85%)~11
sperms~1
fathered~3
normospermia~1
antisperm~5
prognosis.~58
single-loop~1
patent~71
anastomoses~10
interfere~30
reoperation.~7
Solid-phase~1
immunoassays,~1
placental-type~1
phosphatases,~1
seminal~17
fertile~12
men.~54
placental-like~1
(PLAP-like~2
AP),~1
plasma.~33
donor.~4
Seminal~1
AP)~1
ejaculate.~1
roles~20
motility~61
creatine~69
phosphate~101
donors.~16
Semen~2
migrated~13
mmol~22
28)~4
mumol~16
Verapamil,~1
10).~7
(four~27
frames~5
drops)~1
calcium-creatine~1
increased,~40
0.001~25
Sperm~2
Verapamil~10
phosphate.~5
rapidly;~1
loading~44
Magnesium~2
velocity.~8
fertilizing~1
gamete~3
intrafallopian~3
Endometriosis~3
implanting~2
mesenteries~1
diathermy,~1
danazol,~3
indomethacin.~5
untreated.~4
mesenteries.~1
Reproductive~2
implants.~10
restoration~34
Microsurgery~1
danazol~7
Adhesions~1
diathermy~4
indomethacin,~6
cysts~69
injection:~1
antiprostaglandin~1
subfascial~1
dextran~20
intraabdominal~16
Hyskon.~1
Seroma~1
dehiscence~6
ruled~25
out.~22
nonleaking~2
fascial~12
TBT~3
reestablishment~7
patency~68
transcervical~4
dilatation~91
recanalization~16
proximally~2
fallopian~18
infertility.~10
gravid~1
CS~14
(95.5%),~1
SIN~1
(32.6%).~1
ampulla~8
isthmus~9
TPs.~1
Accurate~8
virilization.~1
virilization~1
hyperandrogenism~2
studies:~5
computerized~81
(CT);~2
catheterization;~2
131I-iodomethyl-norcholesterol~1
(NP-59)~1
scintigraphy.~13
accuracies~1
diagnoses~78
virilized~1
endocrinologic~4
suppression/stimulation~1
deficiencies;~1
spurious~4
data;~1
NP-59~1
scintigraphy,~9
depicting~2
hypersecretion,~2
virilizing~1
syndromes.~16
ovulated~4
clomiphene~12
conceive,~2
expressible~1
galactorrhea~2
5.68~1
error)~5
30.20~1
0.46~6
(Group~68
A)~16
bromocriptine~14
(1.25~1
bedtime~3
cycle;~2
pyridoxine~6
continuously;~1
C)~37
65%~23
(Lee-Desu~1
statistic~3
4.66,~2
Women~31
2.3~39
conceive~2
pyridoxine.~1
galactorrheic~1
conceive.~2
Expressible~1
bedtime.~1
progestins~2
estrogen-primed,~2
postmenopausal~51
biochemistry~5
(MPA),~3
norgestrel,~1
dydrogesterone,~2
premenopausal,~1
endometria~1
measured,~16
Potencies,~1
norgestrel~2
(D/L~1
4),~6
MPA~4
0.1,~5
dydrogesterone~1
0.02,~10
0.002.~2
norethindrone~4
mg/day.~4
agree~7
(delay~1
premenopausal~20
women).~7
Plasminogen~3
cycles.~22
ovulation~23
postovulatory~2
0.57~6
0.36~9
0.01,~18
plasminogen~18
extrusion.~2
(and~15
controls)~6
autoimmune~56
fertility.~3
"progestin~1
protein"~1
(PEP)~3
sample.~22
PEP~8
21),~4
cycling~20
19).~4
salient~6
heretofore~7
(mol~8
70,000)~1
(18/20)~2
(0/35).~1
Eighty-two~4
symmetric~7
cornual~1
blockage~4
hysterosalpingography~8
Serial~33
164~13
portions~19
44%.~2
influencing~26
revealed:~2
maximized~2
length;~1
intramural~11
portion;~1
inflammation;~2
inclusion~26
wall;~2
1974~26
321~2
conservatively~13
laparoscopic~20
laparotomy~46
trophoblastic~22
desiring~3
(64.4%)~1
(22%).~6
(45.8%)~1
attempting~7
(29.2%)~1
history.~21
85.5%~1
I),~9
16.1%~2
28.6%~2
damage.~50
spermatozoa,~1
14%;~1
30%;~2
45%;~2
46%~25
60%.~7
ninety~5
104~29
oocytes~28
obtained,~23
fertilized,~5
resulted;~1
81%~20
324~2
(ET)~2
22%;~1
309~5
rate;~3
91%~17
69~50
12%.~8
Probability~4
14%,~6
14%.~1
ejaculation,~2
occasional~27
reasonable~25
motility,~5
hormone-timed,~1
urine.~13
sperm,~1
timing,~2
cost-effective~12
ejaculation.~3
cumulus-fimbria~1
(PF).~1
oviductal~7
fimbria~2
nonendometriosis~2
199~9
(control),~2
oocyte-cumulus~1
5-minute~2
fimbrial~6
capability~17
ovum~6
capture~10
(ovum~1
capturability~1
[OCDT]~1
)~1
23.3~4
(standard~10
mean),~1
51.7~1
2.9,~2
61.3~1
OCDT~1
cell-free~7
ultrafiltrated~1
100,000~34
(26.0~2
2.8~23
26.1~3
PF.~1
Cannulation~1
fimbriated~1
(GIFT)~2
minilaparotomy.~1
GIFT~4
stirrable,~1
diameter,~18
sturdy~1
manipulation.~11
Cook~2
Ob/Gyne,~1
Division~4
Inc.,~5
Indiana,~1
easy~31
(37%).~3
inhibin~2
OCCC,~2
egg~15
cleavage.~2
putative~32
signal,~5
discovered.~4
Inhibin~1
OCCC~1
cleavage~20
oocytes.~5
eggs.~2
empty~25
High-volume~1
urography~7
Subtle~1
15.9%~2
urologic~18
hydroureter~1
ureteral~72
IVP.~1
1-blocker~2
beta-stimulator~2
idiopathically~1
Bunazosin~1
(alpha~10
1-blocker,~1
procaterol~4
(beta-stimulator,~1
micrograms/day)~2
(80%).~3
relaxations~14
myoid~1
stenotic~17
tubules,~4
discontinuously,~1
tubular~88
histochemical~15
premalignant~10
dimethylhydrazine~2
colonic~123
carcinogenesis.~7
Biweekly~1
colonoscopic~9
colon~146
wk~62
dimethylhydrazine-treated~4
Biopsy~17
splenic~60
flexure,~1
rectum,~4
acid-Schiff~2
mucins,~2
high-iron~4
diamine~1
alcian~4
blue~43
sialylated~1
sulfated~14
fluoresceinated~2
peanut~5
agglutinin,~6
Ulex~8
europeus~7
agglutinin.~2
mucosa.~28
positivity~15
13-16~1
wk.~26
agglutinin~11
93%~13
rectum~40
flexure)~1
blockers~54
chemically~27
F344~1
verapamil,~10
diltiazem,~7
ethanol-~1
indomethacin-induced~2
histopathologic~64
evaluation.~45
stomach,~30
lesions,~74
ethanol-induced~7
speculated~7
therapies~14
ulcers~50
humans.~50
Yersinia~12
enterocolitica~4
feces~14
facility~18
media;~1
isolates~75
laboratory.~16
isolates,~8
serotypes~3
enterocolitica.~2
fredriksenii~1
Clostridium~7
difficile.~1
Diarrhea~4
(64%)~10
common,~14
fever~82
(9%)~8
bloody~6
stools~15
(8%)~16
unusual.~7
Use~35
(24%)~17
opiates~5
(28%)~12
ileum~34
radiographically~11
barium~27
Fiberoptic~4
endoscopy~35
pseudomembranous~2
difficile~7
cytotoxin~3
colitis.~25
New~107
geographic~21
contributed~39
isolation~35
organism.~6
sporadically,~1
serotypes,~2
broader~9
formerly~8
gastroesophageal~42
Barrett's~28
esophagus~75
reevaluate~3
Endoscopy~6
97~30
(12.4%)~3
esophagus.~18
radiology~15
esophagus,~14
esophagitis,~8
esophageal~216
daytime~18
heartburn~2
esophagitis~18
complicates~5
believed.~6
exocrine~21
pancreatic~177
absorb~2
lipase~21
Nonpancreatic~2
lipolytic~17
aspirates~26
alcoholism~33
alcoholics~40
(controls).~3
Samples~11
postprandial~41
nonpancreatic~6
aspirates.~3
Lipolytic~2
Pancreatic~4
Treitz~1
opposed~33
(lingual~1
lipase)~1
digestion~18
abuse.~28
Impairment~5
microcirculation~23
report,~25
capillaries~19
intragastric~26
ethanol.~15
disrupted~6
luminal~59
256~12
Capillary~7
Pretreatment~36
cysteamine,~5
mg/100~12
g,~24
F2~18
beta,~7
extended.~1
afforded~12
1-min~4
stomach~56
sparing~14
muscularis~13
mucosa,~24
reduces~47
abolish~6
capillaries.~6
hiatus~5
hernia~22
(HH)~1
(GER),~2
recordings~54
populations:~4
GER~16
HH,~2
HH~10
Acid~7
cm.~30
manometrically~1
(LES)~3
15-ml.~2
N~50
HCl~12
LES.~4
mu~21
Ci~5
99mTc-sulfur~2
colloid.~1
LES~13
non-HH~3
swallow~19
response)~4
swallows~6
response).~4
Radionuclide~10
isotope-labeled~1
accompanying~38
Swallow-induced~1
observations,~10
refluxes~1
LES,~3
HH.~1
enzymic~3
hydrolysates~4
jejunal~42
perfused~83
(OH1~1
OH2)~1
dipeptides~1
tripeptides,~1
(OH3)~1
tripeptide~5
pentapeptides~2
chromatographically.~1
Nitrogen~8
mixture,~2
OH3,~1
mixtures,~3
OH1~2
OH2,~1
absorbed~42
OH3~1
OH2.~1
mixtures~17
residues,~4
hydrolysis~30
tetrapeptides~2
simulate~13
contents.~7
subclasses~3
pepsinogen~11
alpha-PG~3
beta-PG~2
reactivity~82
recognizes~11
epitope~21
isozymogens.~1
purify~3
beta-isozymogens~1
genetic~110
PG~6
alpha-epitope~1
pepsin~3
isozymogens~1
(Pg~2
Pg~1
alpha)~3
isozymogen~1
beta)~5
net~66
charge~21
beta-subclasses~1
substitutions~3
encoded~12
genes:~1
PGA3,~1
PGA4,~1
PGA5.~1
fecal~60
bile~245
diarrhea~33
purposes:~1
stool~58
(induced~3
absorbable~9
solutions);~1
malabsorption~25
correlate~116
ileal~40
Schilling~9
test;~6
(cholestyramine)~1
radiolabel~4
(t1/2~3
236~6
taurocholic~1
cholestyramine~16
acid),~3
absorptive~13
diarrhea.~17
Cisapride~4
prokinetic~3
acetylcholine~41
myenteric~12
gut.~4
cisapride~7
emptying~88
solids~6
indigestible~4
(gastroparesis).~1
nausea~18
400-kcal~1
meal~66
radiopaque~13
metoclopramide~22
cisapride,~3
metoclopramide.~6
acute,~14
accelerates~4
gastroparesis.~4
cholecystokinin~29
(CCK)~6
(gallbladder~1
fundus)~1
neurally~4
(small~1
intestine).~1
CCK~33
fundus,~3
gallbladder,~7
tetrodotoxin~12
Cholecystokinin~4
locations.~9
C-terminal~14
octapeptide~7
doses,~24
proglumide,~1
constants.~3
gallbladder~62
185~12
muscle;~4
constants~26
proglumide~5
437~1
80-300~1
(D50's~1
19-21~1
(inhibitory~1
constants,~4
[corrected]).~1
(i.e.,~56
location)~2
locations).~1
Colonoscopy~2
"weight"~1
357~3
606~2
colonoscopies,~1
colitis,~32
indeterminate~6
mo.~11
final,~1
definite,~1
endoscopy-independent~1
Accuracy~4
colonoscopy~9
89%,~4
diagnoses.~8
Errors~2
(9%).~4
anal~29
cobblestoning~1
erosions~5
microulcers~1
granularity~1
selecting~17
"endoscopic~1
score"~1
"likelihood~1
ratios."~1
Hepatitis~9
virus~244
deoxyribonucleic~27
(DNA)~8
antigens~99
(HBsAg~1
HBcAg)~1
HBsAg-positive~3
diseases.~44
Free~11
integrated~35
viral~103
83~41
(79%)~6
HBsAg~37
HBcAg~6
immunohistologically~1
96~53
(37%),~8
HBcAg,~1
(2%)~15
23)~4
22)~5
directed~79
DNAs.~1
alcoholic~54
cirrhosis.~20
dehydroepiandrosterone,~5
dihydrotestosterone,~5
17-hydroxyprogesterone~9
Systemic~35
Sex~10
depended~16
extractions~7
indocyanine~6
green~11
0.74-0.92,~1
0.05;~9
0.17,~3
globulin.~4
globulin,~6
impairment.~21
20%-50%~1
Production~4
Liver~28
(178~3
transjugular)~1
217~6
noncirrhotics~1
cirrhotics,~2
yr.~21
Cirrhotic~1
categorized~18
"hepatitis"~9
inflammation,~15
necrosis,~28
Mallory~3
mortality,~28
yr~65
(7.1%~1
4.0%)~1
7%),~4
(26.5%~1
4.5%,~2
(47%~3
5%,~17
Importantly,~4
1-yr~1
(most~4
liver)~2
(6.9%~1
3.3%)~1
(24%~3
6%).~3
[combined~1
index:~1
"hepatitis":~6
4.9~24
0.7,~9
0.01;~8
Disse:~1
2.1~46
0.4,~5
3.7~34
0.3,~9
area:~2
682~1
micron~34
841~1
0.01].~2
transjugular~1
Collagen~5
Disse~1
noncirrhotic~4
fibrous~56
septa,~1
se,~5
"hepatitis."~1
relapse~61
retreatment,~1
hepatitis~211
antigen-negative~1
0.4~106
yr)~16
Selection~6
206~11
(36%)~12
relapsed~18
retreated.~1
illness~129
(8~31
mo,~10
frequencies~43
relapsed.~5
relapsed,~3
(21%)~19
retreatment.~1
Remission~3
(50%).~4
Major~25
retreatment~3
(59%~2
29%,~7
enter~10
remission,~6
Relapse~4
prognosis,~18
gastritis~18
duodenitis~1
endoscopically~14
Chronic~36
Pure~5
sarcomas~19
exceedingly~6
sarcoma~60
adolescent.~1
resected,~2
esophagectomy.~4
alive~64
mo~28
polypoid~5
esophagectomy,~2
autoradiographic~7
[3H]dihydrotestosterone~1
baboons~10
pancreas,~15
intestines~8
baboons.~1
silver~28
grains~4
Androgen~3
tunica~11
intestines.~1
Estrogen~12
gut,~4
islet~5
Protein~8
autosomal~44
dominant~46
Heterozygotes~1
thromboembolism,~8
mesenteric~53
30-yr-old~1
deficiency.~49
mother,~12
brother,~2
niece.~1
brother~4
thrombotic~15
Transit~1
simplified~21
ingested~32
radiography.~6
Mouth-to-anus~1
transits~5
radiographs.~12
estimates~68
film,~5
single-film~1
previous,~1
inconvenient,~1
approach,~19
73.~1
35.0~2
SE);~1
colon,~36
11.4~7
rectosigmoid.~2
Men~5
0.06)~4
0.07)~3
fiber.~3
simple,~40
usage,~5
vasoconstrictor~26
eicosanoids.~1
prostaglandins~11
thromboxanes,~1
complex-mediated~2
hypersensitivity-mediated~1
Organ~3
cyclooxygenase~12
synthetase~18
Colonic~5
Thromboxane~4
dazoxiben~1
Prostaglandin~4
ibuprofen~16
vasodilatory~11
10-day-old~1
suckling~13
reovirus~6
adheres~2
selectively~35
penetrates~3
appear,~1
reovirus,~1
endocytosed~3
7.4%.~2
Reovirus~1
adherence~50
2-6-day-old~1
reovirus.~1
Adherence~3
M-cell~2
Peyer's~4
5-day-old~1
ages.~7
Membranous~1
endocytose~1
apical~38
cytoplasm.~6
nonselective~8
profiles,~9
profiles.~5
myoelectric~20
sickness~7
vection~2
illusory~1
self-motion.~1
fasted~24
seated~18
inside~20
drum,~1
signals~27
self-motion~1
conflict~12
vestibular~20
mismatched~3
input).~1
electrogastrogram~1
15-min.~1
periods:~5
baseline,~24
stopped.~7
Respiration,~1
volunteered~6
continuation~9
3-cycles/min.~1
sickness.~6
cycles/min.~3
4-9~1
Running~5
spectral~24
correspondence~4
tachygastria~1
Any~9
impending~11
illness.~42
Falls~3
dizziness.~4
MI,~3
stroke,~16
GI~1
falls.~3
tract,~24
respiratory,~1
infection.~133
Avoid~1
open-ended~1
questions,~1
"What~1
happened?"~1
tripped--possibly~1
fall.~6
questions~46
("Did~1
you~4
walking?"~1
"Did~1
dizzy?")~1
adjunct~40
plain~24
x-ray~39
osteoporotic~5
radioiodine~6
scan,~10
biopsies,~12
myelography~23
painful~41
controversial.~33
anesthesia,~34
immobility,~1
laminectomy~13
biomechanics~4
spine.~17
hearing~57
and--to~1
extent--irreversible~1
deprivation.~5
screen~23
pure-tone~1
Battery-operated,~1
in-office,~1
limited-frequency~1
audiometers~1
$350.~1
Gastrointestinal~7
anorexia~23
nervosa~8
oesophageal~25
meeting~13
(Feighner~1
al;~1
DSM~1
III).~7
suffer~10
achalasia~1
instead~26
nervosa,~3
gastro-oesophageal~4
hypertonicity,~1
non-propulsive~2
repetitive~19
prevailed~2
oesophagus~10
six.~6
dysmotility~3
responding~26
manometry,~7
semisolid~10
Emptying~4
(half~1
97-330~1
median:~3
147~13
21-119~2
domperidone~12
Half~18
domperidone.~2
Conclusions:~2
mistaken~3
nervosa;~1
underlies~1
symptoms;~4
Symptomatic~8
irritable~16
gastroenterological~1
Symptoms~19
reflux,~7
dysphagia,~10
globus~7
sensation~20
commoner~3
clinic~47
Ambulatory~10
macroscopic~15
oesophagitis~2
Lower~18
peristalsis~2
Oesophageal~1
predisposed~11
paired~39
campylobacter~3
like~43
(33%)~17
61~56
(73%)~15
prospectively,~5
(83%)~10
biopsies.~20
mostly~32
metaplasia,~2
Statistically~6
gastric,~5
ulcer,~11
ulcer.~17
ACTH,~9
(10-1000~2
ranitidine.~4
Cortisol,~1
corticosterone,~3
outputs~13
Cimetidine~11
ranitidine~21
320~6
1000~40
ACTH-stimulated~4
corticosterone~7
(1000~4
micrograms/ml),~7
beta-hydroxylation~1
Vagal~2
absorption.~15
Gastric~22
triple~16
Sham~2
1.29~1
7.73~1
mmol/h~1
Jejunal~1
41.0~2
26.8~5
ml/30cm/h~1
2.60~1
0.74~6
mmol/30cm/h~2
0.05,~18
2.68~3
vagal~43
coeliac~9
IgM.~6
Frazer's~1
gluten~18
alpha-gliadin~1
insignificant.~2
fructose~33
breath~52
Fructose~3
lactulose~2
standards.~4
ppm~25
hydrogen)~1
50,~16
37.5,~1
25,~11
eight,~6
seven,~7
five,~10
fructose.~6
+25~1
+12.5~1
challenges~17
g.~12
higher.~10
Glucose~9
elucidation~5
relevance~25
Faecal~3
metronidazole~15
hydroxymetronidazole~2
Bactericidal~2
faecal~9
metronidazole,~3
Metronidazole~2
diarrhoea~10
faeces~4
intracolonic~1
antibiotic~92
amines~5
(1-18~1
months)~38
gastroenteritis~11
desorption~2
spectrometry~11
lactone~2
fluorescamine~1
derivatives~13
separation.~3
p-Tyramine,~2
2-phenylethylamine,~1
diamines,~1
putrescine~6
cadaverine~1
acyl~14
constituents,~3
characterised.~1
amine~11
dansyl~1
comparative~30
(diarrhoea)~1
amine,~4
0.02)~42
p-tyramine~1
tyramine~5
cow's~11
milk.~16
Seventy~19
(39~10
adenomas~54
adenoma~43
cholecystectomy~27
adenomas.~8
gathered~8
records.~13
cholecystectomy.~6
separately,~8
(odds~25
infinity~3
1.7,~6
(44.4%)~1
sided~4
(13%)~20
referred~68
cholangiopancreatography~14
endoscopist,~1
duodenoscopic~1
periampullary~2
tumour.~9
neoplastic,~1
non-neoplastic~6
(pseudotumours).~1
neoplasms~74
appearances.~5
cholangiopancreatograms~1
gall~10
stones~57
pseudotumour.~1
Endoscopic~20
correctly~55
ampullary~5
pseudotumour~1
Whipple's~14
procedure,~57
sphincterotomy~10
44.7%.~1
pseudotumours~1
follow~48
(range~90
12-41~1
months),~18
causes.~22
cholangiography~11
(ERC)~1
papillotomy~4
(EPT)~1
Billroth-II~2
operations~100
described,~31
(since~1
1980)~1
134~19
endoscopists~4
success,~8
ordinary~10
systematically~15
aspect,~2
areas,~17
outlined~6
yellowish~2
network~20
(resembling~2
mosaic),~1
stomach.~21
portal~157
hypertension~279
cirrhosis,~20
94~29
varices~15
aspect.~2
non~4
cirrhotic~13
end-to-side~4
portacaval~15
shunts.~6
submucosal~20
congestion~4
highlighting~1
areae~1
gastricae~1
mosaic~2
sensible~3
whatever~11
splanchnic~27
(A,~1
(modified~4
Pugh's~1
classification).~1
so,~9
Wedged~2
latter.~7
Azygos~1
0.477~1
0.242~1
(0.642~1
0.224~1
1.061~1
0.476~1
l/min,~1
haemodynamics.~1
azygos~8
haemodynamic~18
acting~28
Congo~7
methylene~8
areas.~51
Duodenal~7
gastrin~85
ulcers,~18
placebo,~19
Japan~8
prevents~22
Eosinophilic~1
submucosa~5
serosa.~1
iron~133
anaemia~9
owing~11
emphasises~1
gastroenteritis.~1
postcholecystectomy~3
stricture~18
conservatively,~5
pathophysiological~15
sequelae~30
circumstances~17
attendant~11
risks,~3
demonstrated,~10
chronically~60
(4.84%~1
0.81%).~1
temperatures~34
means,~3
itself~43
activating~8
interleukin~4
1.~18
note~14
temperature~154
septicaemia~2
develops~21
explanation.~5
(CAVU)~1
constitute~25
CAVU~4
decompensated~4
Laennec's~2
stabilize~11
mobilize~2
traditional~54
session~16
uremic~44
calcemia,~1
PTH-MM.~1
25-OH~4
calcemia~1
removing~21
phosphate,~15
temporarily~14
author~22
detoxification~6
hemoperfusion,~4
ambulatory~110
dialysis.~24
poisoning,~3
fulminant~20
aluminium~6
iron,~14
assists.~1
enzymes,~9
multienzymes,~1
immunosorbents,~1
adsorbent~3
microencapsulated~3
adsorbent,~1
ultrathin~4
equilibration~7
metabolites.~8
charcoal~27
hemoperfusion.~3
absorbents,~1
immunosorbents~1
emboli~17
depleting~3
application.~16
approaches~46
centre.~4
adsorbents~2
polymers~15
haemosorbents~1
intended~20
exemplified~6
Procedures~5
haemoperfusion~2
on-line~5
sorbent~10
(plasma~11
perfusion).~1
extracorporeal~34
circuits~5
hepatectomy.~1
Authors'~1
programmes~3
applied.~16
Programme~4
(34~16
substituting~9
each)~2
each,~11
B.~23
Programmes~1
hematochemical,~1
nutritional~62
instrumental~15
hemodialysis-hemoperfusion~1
hemodialyzer~1
70-gram~1
Indications~20
pericarditis,~1
neuropathy,~17
clotting~28
hemodialyzers~1
frequency.~20
hematological~10
maintained.~9
cost-effective.~6
filmadsorber~1
description~19
steps~22
Exact~1
difficult,~17
insufficient~30
fit~44
curves.~18
mathematics~2
turned~13
exponential~15
developed,~14
isotherms~2
adsorption,~1
proportional~33
column.~8
in-vitro~3
intraparticle~1
transfer,~7
powder~3
adsorbents.~1
tools~11
optimization~4
geometry.~1
enables~18
Amberlite~1
XAD-4~1
sedative-hypnotics,~1
analgesics~9
intoxication.~9
dramatic~39
coma~18
Thrombocytopenia~1
pre-perfusion~1
2.5%~11
albumin.~16
Albumin~5
recently,~11
N-acetylprocainamide~17
Macroporous~1
polystyrene~5
polyvinylpyridine~1
beads~10
quaternary~7
ammonium~25
tertiary~14
tailor-made~1
adsorption~15
unconjugated~19
bilirubin.~2
synthesized~36
macroporous~2
pore~4
160~29
possible.~33
crosslinking~4
4%-40%~1
adsorbed~11
mg/g~1
mg/g.~1
Resins~1
Adsorption~3
jaundiced~4
dog~40
duct-inferior~1
silicon~2
0.25~40
(SD)~41
mg%~3
mg%.~1
gm~45
macroreticular~1
NK-110~2
vein.~16
ml/min.~12
7.4~23
0.61~4
(SD),~5
conjugated~22
6.97~1
0.63~3
4.2~18
(SD).~4
blood-compatible~1
properties.~18
Suspension~1
hepatocytes~57
alginate~1
galactosamine~3
galactosamine,~3
pairs.~5
pair~30
microcapsules~2
hepatocytes.~10
Basic~8
hydrophobic~14
denatured~6
sorbents~2
bonded~3
polyvinylalcohol~1
residue~12
covalent~4
bond.~3
reticulo-endothelial~2
supplement~14
(RES)~2
Clinically,~10
angiitis~2
Raynaud's~18
lupus~53
erythematosus~22
remarkably~17
ARES~3
Virtually~6
(constant~1
point),~1
IgM,~17
dimer,~1
C3,~5
C4,~6
elute~2
hypercholesterolemia,~7
Liposorber~3
LA-40~1
commercially~16
selectivity~16
adsorbs~3
specially~22
plasmapheretic~1
hypercholesterolemia.~2
column,~2
apolipoprotein-B,~1
selectivity,~1
loss.~43
apheresis~2
paper,~8
macromolecule~3
therapeutics.~1
Limitations~1
exchange,~14
exist.~9
Membrane~6
practical~42
alternative.~2
Solute~1
operating~67
membrane/module~1
design.~20
solute~11
Operation~8
(cryofiltration)~1
suited~13
aggregative~1
solutes,~1
solutes~9
temperature.~15
safe~134
perform,~5
versatile~5
sorption~1
applications.~11
plasmapheresis~13
(DFPP)~1
viscosity-increasing~1
realize~5
filters,~4
fractionation~8
installed~3
Selective~12
property~16
filters.~2
conservation~9
supplementation.~13
authors'~23
Fluosol~8
recruitment.~3
Capillaries~1
recruited~4
bear~8
gravity.~2
upper,~2
middle,~3
passage~30
fluorescent~23
dogs,~57
12.3~5
s~35
3.1~22
midlung,~1
1.6~40
speed~27
establishes~9
vertical~34
networks~4
recruited,~1
sparsely~1
beds~4
combine~10
reserve.~11
sleep.~25
airflow~21
respiration.~5
(P0.1)~2
unstimulated~10
rebreathing-induced~1
wakefulness~13
non-rapid-eye-movement~4
(NREM)~5
rapid-eye-movement~3
(REM)~10
females)~10
snorers~3
NREM~11
nonsnorers.~1
Unstimulated~3
P0.1,~3
largest~41
increase.~18
hypercapnic~14
P0.1~5
waking~9
sleep,~13
multifactorial~17
drive.~4
Respiration~1
(REMS)~1
ordering~6
unrestrained,~2
naturally~24
sleeping~14
electroencephalogram,~1
electrooculogram,~1
electromyogram,~2
diaphragmatic~59
electromyogram~10
(EMG)~11
moving~15
(MAdi).~1
reference,~3
MAdi~2
"tonic"~1
REMS,~2
fairly~22
"Control"~1
(PEMG),~1
(TI),~1
postinspiratory~1
slope~66
(PEMG/TI)~1
overlaying~1
traces~7
tonic~21
REMS~4
composite~24
tracing.~2
Next,~8
EMG~51
breaths~10
slow-wave~8
(SWS)~2
(both~21
phasic)~1
composite.~1
tabulated~1
phasic~28
slopes~14
SWS~2
(excitation)~1
(inhibition)~2
"typical"~6
REMS.~1
TI~8
EMG,~4
PEMG.(ABSTRACT~1
Adipocytes~1
(SHR)~13
isoproterenol~44
dibutyryl~7
3',5'-cyclic~11
monophosphate~27
Wistar-Kyoto~20
adipocytes~7
SHR.~10
Decreases~8
isoproterenol-stimulated~5
Basal~23
agonist-induced~2
lipolysis~7
SHR~49
60-min~7
run~14
sedentary~25
5'-guanylyl~1
imidophosphate.~1
existed~19
dihydroalprenolol~2
agonist~52
beta-Adrenergic~3
[3H]dihydroalprenolol~2
guanine~17
nucleotide~24
level.(ABSTRACT~2
loaded~15
resistive~21
(resistance~1
cmH2O~31
l-1~13
s)~10
2-3~6
power~91
(iEMG)~1
dividing~10
(iEMG1,~1
iEMG2,~1
iEMG3).~1
iEMG~7
transdiaphragmatic~10
(Pdi)~2
started~25
total-breath~2
iEMG3,~1
inspiration.~4
iEMG3.~1
IFR~1
loads~21
Pdi~7
breath.~5
effort.~5
nonadrenergic~12
nerves.~23
(EFS),~1
VIP,~3
(Iso)~1
airways~59
(PHM),~1
coexists~1
nerves,~15
sequence~82
(VIP1-10~1
VIP16-28)~1
thoracotomy~34
bath.~2
bronchi~10
EFS~1
tetrodotoxin,~3
bronchioles~4
PHM,~2
Iso~3
bronchi,~5
PHM~2
50-fold~2
Iso.~1
Iso,~1
relaxed~15
PHM.~1
relaxant~4
bronchodilators~7
neurotransmitters~6
airways.~11
Newborn~2
hypoxic~60
(10%~7
N2)~3
(BW)~2
nose-tail~1
(H)~6
air.~15
Hematocrit~3
rose~73
51%.~1
manometric~25
rats;~9
BW.~3
plethysmograph,~5
(whether~2
air)~3
normoxic~18
values,~54
transient~168
dry~57
weight-to-BW~1
Lung~21
BW~26
O2-carrying~1
demands,~1
availability,~3
structure-function~2
eventually,~3
organ.~3
adrenocorticotropin~1
(ACTH)~5
high-intensity~7
bout~4
ergometer~14
120%~3
uptake.~23
rest,~21
bout,~1
postexercise.~4
pmol/l~4
0.40~11
mumol/l~8
0.52~4
ACTH-induced~2
caliber~10
phrenic~32
afferents.~3
chloralose-anesthetized,~1
airflow,~3
electrically~20
nerve.~34
70,~8
140,~3
Stimulation~14
fibers,~12
reflexly~3
I-IV~1
bronchodilation~5
phentolamine~11
atropine.~10
afferents~5
withdrawing~1
tone~53
overnight~23
food~130
restriction,~5
during,~23
(LBPP)~1
(LBNP)~1
-10~4
-20~5
-30~5
LBPP~5
LBNP~4
plastic~46
box~2
encasing~4
xiphoid~4
down,~1
(CVP)~3
mmHg,~17
13.4~8
LBNP.~1
arginine~25
(AVP)~10
CVP~3
Torr~6
115~28
beats/min~33
osmolality,~3
sodium,~22
experiment.~16
Hemoglobin~5
LBNP,~1
hematocrit~49
LBNP.(ABSTRACT~1
anemia~56
retransfusion~3
erythrocytes~62
Anemia~4
venesections.~1
8-11~1
wk).~3
Exercise~26
venesection~1
(C),~3
anemic~5
(A),~1
(R).~1
146~8
g/l~8
110~35
145~12
R.~2
4.55~1
0.6,~3
3.74~2
4.45~1
R,~5
rather,~6
accentuated~4
retransfusion.~1
adaptive~15
submaximal~30
(cycling~1
150-175~1
W)~2
(mainly~5
rate)~7
Furthermore~1
confirmed.~6
Workman-Armstrong~1
equation~31
walking~23
reexpressed~1
terminology,~1
walking.~4
Employing~3
analyze~34
VO2/step~1
elaboration~4
three-compartment~6
walking's~1
powers~3
actual~57
Doubt~1
"comfortable~1
walking"~1
definable~2
terms.~1
comfortable~4
curvilinearity~1
ground-speed~1
freely~10
muscarinic~50
complexity~13
airways,~6
characterization~24
unfeasible.~1
homogenates~24
disaggregated~2
trachea~25
[1-3H]quinuclidinyl~1
benzilate~7
([3H]QNB)~1
Receptors~3
carbachol~21
(10(-4)~6
86~30
SE,~7
20).~5
[dissociation~1
(KD)~4
nM]~1
propranolol.~16
[3H]QNB~1
pM)~1
fmol/10(6)~1
35,000~3
Estimated~5
micromolar~4
nanomolar~2
Histamine,~2
alpha-adrenergic,~1
binding.~38
density.~13
lobes~18
statically~2
inflated~13
perfusate~41
permeability-surface~7
injectates~1
injectate~1
125I-albumin~5
51Cr-erythrocytes~1
tracers;~1
[14C]urea~3
tracer.~6
"erythrocyte~1
trapping"~1
calculation~28
albumin-erythrocyte~1
calculation.~1
Ethane~2
(25-100~2
(3-40~1
(HFV)~5
equilibrated~2
ethane,~1
ethane~4
washout.~5
uniform~26
nonuniform~4
three-phase~2
corresponds~10
washout,~2
lasted~34
diverged.~1
ratios,~11
paths~3
path~7
opening.~6
Inspiratory~3
airway:~1
supralaryngeal~1
airway,~5
oropharynx,~2
nasopharynx.~4
segments:~2
lungs-larynx-retroepiglottal~1
(esophageal-supralaryngeal~1
pressure),~4
hypopharynx~3
(supralaryngeal-oropharynx~1
transpalatal~3
(oropharynx-nasopharynx~1
pressure).~4
hypopharyngeal~9
existed.~2
palate.~3
subject,~9
predictable~25
wakefulness.~4
uvulopalatopharyngoplasty~3
apneas~4
hydration~9
intravascular~55
immersion~14
hematocrit,~11
renin~19
(PRA),~1
(PA),~2
(PVP)~1
24-h~27
dehydration;~1
rehydration.~3
23-46~1
standing~38
45-min~1
immersion,~5
dehydrated,~2
rehydration~5
water.~23
Immersion~1
isotonic~12
expansion~33
PA~47
immersions~1
rehydrated~1
immersion.~4
tonicity~1
PVP~5
occlusive~47
sleep-induced~3
compromise,~2
monitoring,~12
(VT),~3
pneumotachograph,~1
tight-fitting~1
mask,~4
(Rp).~1
I/II~1
subjects;~14
resistance,~35
waxing~1
waning~2
phases.~12
Resistive~2
periodicity.~2
Rp~6
1/VT,~1
hypopneas.~2
diminution~11
predisposes~6
collapse.~3
apnea,~11
(TI~1
TE)~2
(EMGdi)~2
curvilinear~5
EMGdi~7
0.87,~2
0.89,~4
0.94,~5
fluctuates~2
changing~54
afferent~48
mechanoreceptors.~1
trachea.~10
modulations~1
prolongs~4
contractions.~24
capsaicin~12
pretreatment,~5
serotonin-precontracted~1
deepithelialized~1
concentration-response~9
hyporeactivity~1
relaxing~5
hypothesized,~2
P-ergic~1
innervation.~4
Muscarinic~3
antigen-induced~5
4-Aminopyridine~1
epithelium-dependent~1
potentiations~1
serotonin,~6
cascade.~3
Epithelial-dependent~1
contracting~6
catheterized~7
glycogen~21
g/kg)~2
gavage~3
(FF~1
rats)~9
restriction~63
(FR~1
rats).~3
[3-3H]-~1
[U-14C]glucose~1
treadmill~56
running.~2
(Ra)~2
disappearance,~1
work-loads~1
Ra~2
FF~2
FR~3
Breakdown~1
[14C]glucose~2
label~10
14C~7
disagreed~3
3H,~1
futile~3
glucose.~8
postexercise~16
14C/3H~3
exercising~7
feedforward~1
incorporated~23
trioses.~1
breakdown.~4
determination~85
glycogenolysis~2
doubtful~6
inhaled~40
histamine,~18
(IgE)~1
inbred~10
immunized~30
ragweed~14
grass~7
nonimmunized~3
colony.~1
Airway~8
(ED200).~1
(e.g.,~28
antigen)~5
ragweed-sensitized~4
(reflected~2
nonimmunologic~3
(histamine~3
ED200:~1
0.73,~2
0.75,~2
Antigen~5
ED200~1
0.74;~1
inversely.~2
breath-hold~2
divers~8
Tsushima~1
Japan.~8
divers,~1
rectal~115
(Tre)~2
(Tsk)~2
(VO2)~11
diving~7
summer~13
(27~12
water)~4
winter~14
water).~3
insulation~4
estimated.~5
summer,~4
clad~1
suits~2
(protected)~1
swimming~11
trunks~2
(unprotected),~1
winter,~3
wore~9
suits.~1
Tre~9
36.4~3
1-h~5
work,~12
36.9~1
winter.~4
Tsk~3
32.9~1
Average~23
190%~3
1,070~1
780~1
110%~2
330~1
690~2
(tissue~3
suit)~1
0.065~1
0.006~2
kcal-1~2
h-1~9
0.135~1
0.019~2
winter.(ABSTRACT~1
estimating~16
variability.~9
drawbacks:~1
closed-loop~3
utilized;~2
intercept~10
estimated;~1
fail~20
circumstances.~9
proposes~1
new,~15
corrupted~1
stimulus-response~5
structure.~18
[directed~1
squares~5
(DLS)]~1
reduced-major-axis~1
(RMA)~1
Kermack~1
Haldane~1
(Biometrics~1
37:~1
30-41,~1
1950)~1
normalized~40
equal.~4
DLS~2
estimators~2
scale~62
invariant,~1
unbiased~2
assume~12
variance.~9
modifications,~1
If,~2
uncertain,~9
RMA~1
optimal,~4
asymptotic~1
ovalbumin-sensitized~1
(TSM)~1
shorten~6
bronchoconstriction.~7
shortening.~3
lever~5
quick~9
releases~2
TSM~2
0.5-s~1
lightly~2
preloaded~4
10-s~2
contraction.~21
contraction,~16
[0.35~2
0.033/s~1
(SE)]~1
bridges.~2
operative,~2
probable~35
bronchoconstriction~24
early,~9
muscles.~21
tendonous~2
proportionally~6
effected~11
location.~10
Estimates~9
Trunk-only~1
bath~14
rewarming~15
whole-body~14
hypothermia.~5
made.~40
Authorities~1
favor~19
trunk-only~3
proposal~6
assumption~15
core~33
afterdrop~1
minimized~13
vasodilation~22
immersed~6
hypothermic~17
twice,~6
hypothermia,~7
afterdrop,~1
rewarming.~2
genioglossus~2
(GG)~1
micrognathia~1
tongue~19
maintenance.~3
GG~8
GG-EMG~6
occasion,~5
recorded;~1
unassociated~2
embarrassment.~1
sigh~1
breaths,~3
mechanoreceptor~3
chemoreceptor~4
modulation.~1
trials,~14
excursions).~1
pharyngeal~27
trial,~16
(upper~3
closing~6
pressure)~3
closure,~7
micrognathic~1
inert~16
ambient~16
joints,~11
undertaken.~21
tagged~3
13N~6
accelerator.~1
rebreathed~2
circuit~15
40-~1
100-min~1
room~73
positron~2
detectors.~2
decay~17
(half-life~1
9.96~1
Various~22
Fat~7
AMP~21
(cyclic~3
AMP-PDE)~1
homogenate,~3
P5,~1
P48,~1
S48~2
AMP-PDE~4
(pmol~2
mg-1)~1
homogenate~13
P48~2
AMP.~3
Cyclic~4
plots~8
Lineweaver-Burk~1
Michaelis~5
(Km)~4
nonlinear,~1
form.~16
Km~23
P5~2
particulate~16
Phosphodiesterase~1
methylxanthines~5
equipment~33
free-diving~1
Weddell~1
seals~4
Leptonychotes~1
weddelli~1
withdrawn~15
submersible,~1
peristaltic~19
single-~5
multiple-sample~1
sampler~2
dive.~3
dedicated~3
microcomputer~6
combinations~37
ascending~38
depth,~4
selectable~2
intervals.~18
transmitted~31
computer,~2
retrieved,~2
seal~7
surfaced~1
breathe.~1
ponies~1
(Tar)~1
stress,~20
interested~6
whether,~2
extent,~10
Tar-Tre~2
corrections.~1
(Ta)~3
Tar~7
(37.1~1
Elevating~2
Ta~8
10-18~1
2-days~1
(2-days)~1
elevating~4
inspired~22
1.8~41
mph~7
grade,~16
0.01).(ABSTRACT~3
equations~18
convective~4
(WCV)~1
evaporative~3
insensible~3
(WEV)~1
heat~59
exchanges.~4
sea-level~2
barometric~3
(SLA)~1
hypo-~2
hyperbaria~1
(HA)~3
(HAA)~1
atmospheres.~2
SLA:~1
(TI)~2
vapor~9
(PIH2O);~1
HA:~1
TI,~2
PIH2O,~2
(PB);~1
HAA:~1
IT,~3
PB,~3
volumetric~2
(rho~3
mix),~1
(cp~1
mix)~1
mixture.~5
liter~3
(WCV/V~1
WEV/V)~1
J~16
dm-3~1
BTPS.~1
(V)~6
(W).~1
25-60%~1
nonpulmonary~4
cannulated~7
cannula.~3
preparation,~18
accurate.~4
overestimated~14
lymph.~2
preparation.~18
describing~15
nondepolarizing~4
naive~11
d-tubocurarine~4
90%)~4
infusions.~8
Edrophonium~1
hypothetical~14
"effect"~1
model;~2
squared~1
46,~4
45,~2
87,~1
Also,~39
model,~52
subanesthetic~4
N2O~16
(0.25~6
atm)~4
N2~27
11.33~1
warm~30
cool~5
cooler~4
falling~15
hypothermia~29
thermoregulation~3
thermoregulation,~1
opposing~6
drains~7
(SVP)~1
SVP~8
considers~5
promote~22
infusion,~45
positive-pressure~1
therapies.~8
(PAP),~3
(LAP),~1
unanesthetized~8
sheep.~12
Occlusion~4
balloons~17
caval~17
occluder~3
inflated.~2
Three-hour~1
LAP~3
wet-to-dry~2
microvascular~45
(pentobarbital~1
elastances~3
to,~12
50.1,~1
32.3,~1
17.7~7
l-1.~1
pressure-vs.-flow~1
determined;~2
intrinsic~79
4.1~31
s),~9
others:~1
pressure-flow~14
upward~18
concavity,~1
convexity.~1
elastance~5
64.0~1
5.4~14
losses~33
force-length~1
force-velocity~2
distortion~18
configuration.~2
postulated~30
"rate-of-living~1
theory"~2
raising~8
longevity~11
6-mo-old~1
SPF~2
Long-Evans~5
accustomed~1
(23~16
C).~7
h/day,~1
days/wk.~1
intake~156
cold-exposed~3
rats'~3
968~1
141~13
923~1
159~9
neoplasia,~11
sarcomas;~1
necropsied~2
malignancies~38
57%~17
longevity.~4
nicotine~54
vagi,~1
(Rc)~1
(Rp)~1
micrograms/kg.~3
Rc~4
vagi~6
propranolol,~16
vagotomy,~5
micrograms/kg,~9
suppressive~12
vagi.~3
depressed.~4
Combinations~4
chlorpheniramine~1
phenoxybenzamine~4
nicotine.~4
Additionally~3
hexamethonium.~1
sweating,~3
cycle-ergometer~1
(60%~3
consumption)~2
beta-blockade~12
(BB,~1
propranolol).~1
(esophageal~1
temperature,~23
Tes),~1
(Tsk),~2
(Tch),~1
(msw)~1
sweating~5
msw~1
Tes~4
sweating.~3
msw-Tes~2
1.80~2
1.30~3
cm-2~1
C-1~2
BB.~3
(36.8~1
BB~7
32.8~1
32.2~2
Tch~1
BB,~1
equation,~3
18%,~7
arterioles~35
supplying~12
regionally~2
arteriolar~34
morphology.~11
Conscious~1
unbled~1
40-45~4
Regional~33
[14C]iodoantipyrine~2
fluorescein~39
isothiocyanate-dextran~1
morphometric~27
indexes.~3
microvasculature~5
stain.~7
g-1,~1
redistribution.~3
capillaries/mm2,~1
perfused.~2
unperfused~2
reserve~46
so.~12
pons.~4
51%~9
arterioles,~9
mobilized~4
reserves~4
hippocampus~13
(78%),~4
(67%),~2
medulla~13
(73%).(ABSTRACT~1
elasticity~8
(PWC)~1
men,~62
16-18~2
carotid~267
pulse-wave~2
(c)~3
rest.~10
slope,~4
S(c)~2
reactivity.~8
(HR)~11
load~67
ergometer;~2
S(PWC)~1
HR~50
170~18
(PWC170).~1
PWC170~3
4.6~18
W/kg,~1
6.8~19
m/s.~2
-0.76),~1
0.68)~1
0.74).~1
S(PWC);~1
elasticity,~1
adaptations~5
leaving~15
isolated,~13
ventilated~47
cyclicly.~1
balanced~25
erythrocyte~78
distensible~2
vessels,~27
fluctuation~5
(Vc).~1
0.084~1
0.47~6
(SE)~15
1-16%~1
Vc.~1
fluctuation.~1
respiration~19
cycles/min~2
one-sixth~1
Vc~1
respiration,~5
Plantaris~1
hypertrophy~89
gastrocnemius~16
nontumor-~1
GH3~3
tumor-bearing~5
8-10).~1
(10(6))~1
150-g~2
Wistar-Furth~2
initiate~19
gained~23
wt/day~3
nontumor-bearing~2
nontumor~5
plantaris~6
45.6~1
44.0%~1
unoperated~11
(right~4
side)~1
heavier~11
additive,~2
hormone-secreting~1
work-induced~1
hypertrophy.~19
rib~29
cage~23
strapping~8
volumes,~10
(Raw),~1
(Rrs)~1
reactance~2
(Xrs).~1
Rib~2
cage,~1
(respectively,~1
-36~1
-34%),~1
(TLC)~5
(-31~1
-27%),~1
(FRC)~5
(-28~2
-28%),~1
(-40~1
-48%)~1
conductance~43
(+24~1
+30%)~1
TLC~9
(+47~1
+42%).~1
(RV)~16
(-12%)~1
Abdominal~12
Rrs,~1
frequencies;~1
Rrs~5
induced.~8
pattern,~23
FRC.~3
Xrs~3
frequencies,~1
strapping;~1
resonant~4
frequencies.~6
Partitioning~1
mechanics.~2
vagotomy~36
edema,~30
compliance,~20
atelectasis.~3
18-fold~2
leak~34
washes~5
prelabeled~1
wash~2
sizes~25
different.~27
tensions~16
19.6~5
9.4~11
dyn/cm~1
surfactant,~1
surfactant~26
lipid~127
kilogram~19
compliances~1
Vagotomy~1
African~12
Caucasian~14
ascertained~9
sedentary,~2
participated~38
racial~10
Muscle~22
fiber~72
proportions~32
(I,~2
IIa,~1
IIb),~2
vastus~10
lateralis.~2
Caucasians~8
(8%,~1
IIa~3
(6.7%,~1
Africans.~1
IIb~7
Enzymes~2
catalyzing~1
phosphagenic~2
[creatine~1
(CK)]~1
glycolytic~9
[hexokinase~1
(HK),~1
phosphofructokinase~4
(PFK),~1
(LDH)]~1
(about~12
30-40%)~1
[malate~1
(MDH),~1
oxoglutarate~3
(OGDH),~1
3-hydroxyacyl-CoA~1
(HADH)].~1
PFK/OGDH~1
Africans~2
are,~10
endowed~5
sport~7
Adenosine~12
discomfort.~3
exclude~39
(70-80~1
Resting~15
(VE)~3
isocapnic~5
hyperoxic~4
[mean~8
increase:~2
l/min;~1
0.02],~1
end-tidal~18
(PETCO2)~1
fall:~1
-3.9~1
Torr),~1
beats/min)~13
(control:~1
-0.68~2
l~11
%SaO2-1,~1
%SaO2~1
saturation;~1
adenosine:~1
-2.40~1
%SaO2-1;~1
PETCO2~10
38.3~3
chemoreception.~1
Contrary~10
hindlimb~4
(J.~8
Appl.~9
Physiol.~13
58:~1
2054-61,~1
1985).~5
digitalis~4
digoxin~69
contractility~22
V)~1
2-s~1
stimulations~3
10-100~2
Swan-Ganz~5
(Qdi)~2
timed~12
collections~12
effluent.~2
sartorius~1
concomitantly~9
Pdi.~1
90,~7
plasmatic~2
(1.8~4
ng/ml),~3
Qdi~6
digoxin,~7
B.(ABSTRACT~2
surgery:~6
(VC),~1
(FRC),~3
Diaphragmatic~7
(delta~23
Pga)~1
Pdi).~1
Finally~3
delta~94
(Pdi~1
stim).~1
Pga/delta~1
0.480~1
0.040~1
-0.097~1
0.152~1
VC~20
3,900~1
630~2
2,060~1
520~5
FRC~27
stim~2
periphery~15
(chest~2
peritoneum),~1
(hGH)~4
(VO2max),~4
7/group),~1
21-30~1
yr,~10
runners~23
(MR),~1
(FR),~1
(MC),~2
(FC)~1
hGH~24
endurance~21
(CRE).~1
(Glc),~1
Glc~1
(increases)~1
(decreases)~1
runners.~8
FRs~1
FCs~2
MRs~2
MCs,~1
(vs.~7
MCs)~1
MCs~7
(runners~1
32-36%~1
sex-related~2
(sex,~2
11-19%~1
hGH,~2
exercise.(ABSTRACT~2
inflow~24
(VO)~2
jump~2
(Pv)~1
(Pa)~2
Pv.~1
Pa(t)~1
Pv(t)~1
converge~2
concave~6
VO~2
dilution.~4
Cst)~1
Cdyn).~1
Cdyn~9
(AO)~1
isovolumic,~1
Pa~4
Pv~2
instant~2
AO.~1
compartmental~6
constructed~33
walls~25
viscoelastic.~1
convergence~6
concavity~1
isovolumic~10
AO,~1
According~15
Cst~2
viscosity~22
Model~5
ways~21
viscoelasticity~1
lobar~10
Hypoxic~1
vasoconstriction~38
viscosity.~7
plethysmography,~4
costal~7
crural~7
diaphragm,~10
sonomicrometry,~1
supine,~3
deflation,~1
lengthened~8
inflation-deflation~2
phrenicotomy.~1
inflation.~5
inspiration~29
phrenicotomy~1
lengthened,~2
phrenicotomy)~1
phrenicotomy).~1
situ,~3
simultaneously.~12
4.5~35
(Pla)~1
atmospheric~4
Pla~1
50-min~1
midway~3
perfusion.~18
ml/h,~6
lymph-to-plasma~7
oncotic~5
(pi~1
L/pi~3
P)~3
0.48.~1
pi~4
135~30
lowered.~2
gain,~10
space,~15
drained~8
lymphatics.~2
high-frequency,~1
anesthetized,~11
paralyzed,~6
propranolol-treated~4
Gas~4
(Vco2)~2
45-s~1
HFV~8
(control~13
1),~18
transected~11
15-s~1
3.6~24
s,~9
Vco2~4
stopped,~1
prestimulation~2
oscillation~6
HFV-mediated~2
simulated~38
transport.(ABSTRACT~1
Bed-rest~1
deconditioning~4
impairing~4
variability,~7
broadband~1
interbeat~3
spectrum.~4
autonomically~1
modulated~16
aerobically~1
conditioned~28
35-49~1
pre-bed~3
7-10~4
Spectra~1
Fourier~11
sets.~4
Spectral~7
computing~4
root-mean-square~1
(rms)~1
encompassing~6
2nd~3
64th~1
harmonics~2
beats:~1
rms~2
(NS,~2
6);~4
"unmasks"~1
athletic~12
evidenced~23
bed-rest~1
perturbations~9
dynamics.~4
macromolecular~8
Prontosil-dextran~1
(PD)~7
carbonic~3
anhydrase~3
(CA)~4
Krebs-Ringer~6
(KRB)~1
inhibitor,~8
PD~20
100,000),~1
5,000),~1
low-molecular-weight~5
(Prontosil~1
acetazolamide).~1
effluent~15
stop-flow~2
apparatus.~7
expired~20
KRB~1
prebubbled~1
CO2-~2
O2-~8
N2.~3
PD's~1
postcapillary~2
disequilibria~1
pH)~1
perfusate.~10
acetazolamide~5
Prontosil~1
Vco2.~1
CA,~6
accessible~12
HCO3-~8
-H+~1
(possibly~2
intracellular)~1
CA~20
alveolar-capillary~4
(perhaps~1
diffusion),~1
equilibration.~1
Slowly~1
adapting~6
hypothesized~24
vagally~5
volume-related~2
(TE)~4
TE~17
summation~2
(PSR)~2
elastic~30
single-breath~4
PSR's~1
(TE).~2
VE.~1
VE-TE~1
loads.~10
plotted~9
trajectory,~2
PSR~5
spikes~1
expiration~16
load-dependent~1
postures~4
(VC)~4
arms:~1
up,~4
bar,~2
down~35
gripping~1
bars.~1
flex~2
extend~21
trunk:~1
sit-up~2
standing.~3
extremes~5
efforts:~1
posture~20
spirometer.~2
Control~45
unstressed~6
rebreathing.~1
small,~28
arms,~3
extreme.~2
VC,~9
trunk~32
action.~17
hematocrits~9
nonimmersed~3
arm~87
sat~4
hung~1
vertically~6
(28~17
(38~12
cold-warm~1
(immersion~1
process)~2
immersion).~1
antecubital~6
fossae.~2
(Hct~3
diff)~1
forearm's~2
dry)~1
wet).~1
Hct~6
diff~2
zero~25
3-way~1
variance).~2
large-vessel~2
immersing~1
pleural,~1
(Pga,~1
Ppl,~2
Pdi,~2
EMGdi.~1
essentially~48
Pga~2
0.98,~6
tracings~10
paradoxical~16
length-tension~1
characteristics.~26
apneas,~1
(RLD)~1
ignored~4
nose,~12
Weber's~1
law~15
predicts~16
R50~4
presentations)~2
background~43
(R0)~1
R50/R0~1
Weber~2
fraction)~5
load,~8
wondered~2
RLD.~1
R0~3
(RN),~1
decongested~1
(3.0~4
8.0~10
mouth,~7
mouth~38
s).~3
decongestant~1
RN~1
[4.3~1
0.05]~1
(1.7~7
(1.4~5
(0.28~2
0.03,~9
0.02).(ABSTRACT~3
repayment~1
Mongrel~1
Torr.~4
adrenergic~98
influences.~3
alpha-adrenergic~14
vasoconstriction.~10
Whole-body~1
(9%~3
N2),~1
partitioned~8
nonmuscle~2
delivery,~26
deficit.~18
leukotrienes~4
C4~20
(LTC4)~3
D4~6
(LTD4)~3
coefficient,~2
conductivity~2
water,~27
(PVR)~5
isolated-perfused~1
LTC4~11
LTD4~18
Ringer-perfused~4
blood-perfused~7
(Ppa)~4
(Pcap)~1
occlusions.~3
(Rv)~1
blood-perused~1
LTC4.~1
PVR~9
B2~20
(TxB2)~1
LTC4-stimulated~1
meclofenamate~5
M).~17
Ppa~8
Pcap~1
lungs;~3
stabilizing~11
Rv~2
Ra.~1
LTD4-stimulated~1
TxB2~12
LTC4,~1
Ppa,~2
Pcap,~1
PVR,~2
response.(ABSTRACT~3
(VO2max)~4
defend~2
VO2max~17
Propranolol~8
high-altitude~3
(4,300~1
m)~1
ascent~2
(80~17
daily)~7
(lactose).~1
altitude,~3
NS)~11
altitude~12
discontinued.~9
(80%~3
VO2max)~2
4,300~3
saturation,~3
Rather,~7
heartbeat.~1
contrary~8
hypothesis,~16
impair~14
erythrocythemia~2
intense~49
running~32
(U)~1
(450~4
ml/U)~1
2-7~5
5.04~2
5.24~1
(R2)~1
5.38~1
(R3).~1
28.2~2
29.8~3
R2,~2
33.1~4
R3.~2
Corresponding~5
unchanged,~18
R2~7
R3~1
bouts~4
erythrocythemia.~2
reinfusion~9
hematology~3
aerobic~53
surpassed~1
Measurements~49
(pHm)~2
phosphagen~5
meter,~3
phosphocreatine~12
ATP~85
degraded~8
Attempts~9
arresting~1
unsuccessful.~4
pHm~10
accomplish~5
this,~24
phosphagens~1
hydrolysis.~3
samples,~22
acidification~11
0.008~4
0.033~1
units.~11
substantiates~4
samples.~36
Airflow~2
passages~3
air-pollutant-induced~1
baboon~5
(13.9~1
wt)~3
thermistor~4
visualization,~3
cinephotographic~1
acrylic,~1
hollow~8
made,~11
record~31
wind~2
propel~2
passing~9
cast,~2
cinephotography~2
Reynolds~2
turbulence~1
vortex-like~1
(25.3~1
exercised~25
[low~1
(L)],~1
[moderate~1
(M)],~1
%VO2max~1
[high~1
(H)]~2
Sweat~4
(UB),~1
(LB),~2
midchest~1
(S),~1
thigh~14
(T)~12
washdown~1
(W)~2
(N).~1
(several~1
significantly,~24
Regression~16
(mg/h)~1
follows--L:~1
0.727~1
(S)~7
-~37
1.366(UB)~1
1.181(T)~1
65.470~1
29.5,~1
R~30
0.90;~4
M:~1
0.598(MC)~1
0.649(UB)~1
0.244(LB)~1
43.238~1
30.4,~1
0.99;~3
H:~1
0.274(S)~1
0.560(T)~1
0.223(MC)~1
131.104~1
4.3,~2
Intensities:~1
0.497(MC)~1
0.483(T)~1
0.112(LB)~1
69.554~1
31.5,~2
0.96.~1
98.3~1
SE).~2
Interinvestigator~1
0.511)~1
investigator~11
(93.3~1
103.2~2
3.5%)~2
Repeated~10
intrainvestigator~2
coefficients~52
(0.385~1
0.820).~1
Together,~6
high;~3
inter-~5
vary.(ABSTRACT~1
explaining~8
windkessel~1
criterion~29
consumption.~17
resemble~17
correct.~5
satisfies~1
minimization.~1
forty~14
core-decompression~1
thirty-one~6
four-year~9
ascertain~29
Stage-1~1
Stage-2~1
eighteen~9
collapse~15
criteria.~29
Computerized~10
tomographic~92
testing;~4
isotopic~4
bone-scanning~1
Functional~27
Ficat~1
reports.~13
metacarpophalangeal~6
thumb~20
Stener~4
lesion)~1
1972~17
1977,~10
1977~32
Considering~12
operatively,~1
sixteen~6
lesion,~35
rolled~1
lying~6
beneath~17
aponeurosis.~2
1976,~3
flexion.~8
thumbs~3
surgically,~3
1977;~2
reattachment~8
cent.(ABSTRACT~1
thirty-three~5
Harrington~15
rod~13
below-the-shoulder~1
twenty-four~15
seventy-two~7
follow-up,~64
resumed~12
limitations.~5
legs~33
nineteen~5
anterior-compartment~1
syndrome,~109
fasciotomy.~5
legs)~3
peroneal~46
nerve:~2
fasciectomy~2
fasciotomy~13
compression,~10
anomalous.~1
twenty-five~7
unlimited~3
(twenty-eight~2
twenty-eight~3
198~9
multiple-trauma~1
referral~31
center~67
three-year~19
9.1~12
(eighteen~2
intracompartmental~2
saline-injection~1
four-compartment~1
bone;~1
comminuted,~1
grade-III~1
pedestrian.~1
trauma,~40
neurapraxia~3
quadriplegia.~2
burning~18
numbness,~2
tingling,~2
sensation,~5
paralysis.~14
thirty-six~5
forty-eight~3
Except~15
paresthesia,~1
full,~3
pain-free~3
roentgenograms~20
dislocations~19
roentgenographic~24
developmental~60
seventeen~13
intervertebral~17
us.~2
roentgenogram~8
thirty-two~10
forty-nine~5
0.80~7
available,~22
1.00~11
0.0001)~27
503~2
schools~30
participating~17
National~44
Collegiate~1
Athletic~2
(NCAA)~1
season~13
cord.~23
instability,~8
anteroposterior~14
canal.~19
postulate~8
canal~63
can,~6
hyperextension~5
hyperflexion,~2
compressed,~1
transitory~5
manifestations.(ABSTRACT~1
quadriplegia~4
incurred~13
playing~5
narrow~20
opinion,~2
myelogram~5
quadriplegia,~3
extremities,~6
advised~10
discontinue~6
sports.~2
1966~6
suspension~27
Shriners~1
Institute,~5
Galveston,~2
Texas,~2
626~1
extremities.~17
Skeletal~7
863~1
(76.5~1
skin-grafting~2
265~5
(23.5~2
burn-acquired~1
deformities.~4
fifty~16
(4.4~7
suspension,~2
forty-five~6
(4.0~6
infections~170
pins~10
antibiotics,~17
Gaucher~7
crisis,~1
osteomyelitis.~6
Massachusetts~14
crisis~15
fracture-healing~1
nutrients.~7
isolate~13
fracture-healing,~1
minimum-soft-tissue~1
pinning~5
femur,~4
created.~3
produced.~6
Immediately~14
diet-treatment~1
subgroups.~6
Subgroup~5
diet;~3
protein-free~8
mineral-free~1
lacking~21
D.~22
protein-supplemented~1
composed~60
mineral-supplemented~1
osteomalacia.~6
torsion-testing~1
failure.(ABSTRACT~1
ingrowth~12
porous~10
coverage~23
remodeling~9
cementless~1
arthroplasty.~15
titanium-alloy~1
titanium~5
stem:~1
sintered~3
fiber-metal,~1
beads,~1
flame-spray~1
coating.~4
circumferentially~2
flame-sprayed~1
stem.~7
Ingrowth~2
secure~4
stems~3
(25.2~2
fiber-metal~2
(16.6~1
(23.3~2
(37.3~1
proximal-to-distal~1
circumferential~24
three-part~6
humerus~4
tension-band~2
wiring~4
AO~2
buttress~5
plate.~10
strength,~14
shoulder~57
fifty-four~3
shoulders~16
126~7
abduction,~1
humeral~16
revision~24
hemiarthroplasty.~1
healthy,~14
humerus.~2
wiring.~3
1980,~25
senior~7
us~55
(C.S.R.)~1
101~28
replacements~9
eighty-five~2
fifty-five~1
Survivorship~3
calculate~18
follow-up.~64
durability~2
loosening~14
else~1
revisions~6
aseptic~5
necessitated~14
revision,~2
Life-table~3
calculations~10
survivorship~3
87.6~1
replacement,~9
coxarthrosis,~1
durably~1
middle-aged~27
sixty-four~2
try~9
accurately~66
risk,~29
milliliters~4
proposed.~19
Atlanto-axial~1
rotatory~2
atlanto-axial~11
Rotatory~1
atlas~3
(Type~6
instability.~13
rotated~4
odontoid~3
radiographs,~9
computerised~4
tomography.~7
halter~1
traction~35
axis~45
Non-operative~1
Minerva~3
traumatic~56
good;~4
hyperpathia,~1
Lhermitte's~1
perianal~15
sensation.~5
highlighted~4
charting~1
neuroanatomical~1
assumptions~8
tried~6
vibratory~6
girls~31
age-matched~65
vibration~8
Curve~1
0.172)~1
0.126).~1
right-~1
left-sided~12
aberration~3
aetiology~9
scoliosis.~9
Magnetic~31
(MRI)~17
MRI~77
chemonucleolysis~4
chymopapain.~2
single-level~1
discs~25
discography~7
pulposus~7
culminating~5
chemonucleolysis.~2
Chymopapain~3
analogous~21
varied;~1
Transitory~1
end-plate~5
discitis.~2
width~15
girls,~6
dimensions~30
Computerised~1
prolapse~29
equivocal~12
radiculograms.~1
10.~10
diagnosing~35
facilities~22
scarce~2
Great~6
Britain)~1
non-contributory~3
radiculography.~1
brachial~30
axillary~52
outlet.~2
Investigation~8
aims~7
cords,~2
particular~108
obtaining~37
intradural~6
(pre-ganglionic)~1
exploration~44
plexus.~7
accuracy,~6
C5~23
C6~4
allogeneic~8
intra-articular~18
ligament.~13
Depending~4
extra-articular~3
sporting~3
recommended.~17
malunion~2
direction~30
angulation~13
acceptability~5
angular~14
avoidance~19
radius,~3
interosseous~5
gap~33
shafts~2
radius~15
ulna.~2
capitellum~3
Baumann~4
angle).~1
angle.~3
supracondylar~4
follow-up;~2
Pain~19
paraesthesia~1
hypo-aesthesia~1
urgent~8
delayed,~7
engineering~2
1074~1
car~5
2520~1
occupants.~1
details~27
crash~5
cars.~1
all,~18
occupants~6
1.7%~5
front~20
rear~3
seat~13
body;~1
Associated~14
belts~3
(delta-V)~1
(42~16
km/h)~1
delta-V~1
mph.~2
weeks)~21
paralytic~10
triceps~14
surae~4
leg,~7
elongation~10
division~12
tendo~2
equinus~4
(13~19
limbs)~2
hemitransplantation~1
calcaneus.~1
limbs,~10
nine.~4
fault~1
transplanted~16
two-stage~9
radiography~28
(RSA)~1
cranially~1
distally.~3
initiated~33
polymerisation~1
cement;~2
metallic~10
sink.~1
Standard~18
loosening,~1
RSA~1
bulky~5
dressing~6
Robert~1
Jones~6
bandage)~1
orthopaedic~10
surgeons.~9
helped~14
bleeding,~20
haemarthroses.~1
15-year-old~9
desmoid~2
buttock;~1
hindquarter~3
amputation~52
expectant~3
justified~20
non-malignant~1
Proximal~7
osteotomy~18
osteotomies~4
4.8~18
painful,~7
50.5%~1
severely;~1
45.7%~1
15.2%~1
restrict~6
progress,~2
valgus~18
relief.~13
St~3
Georg~1
modular~2
73~52
replaced;~1
hinge~2
arthrodesis.~2
unicompartmental~3
localised~5
generalised~13
prefer~4
semiconstrained~1
condylar~5
prosthesis.~18
rachitic~2
deformities~20
alpha-OHD3)~1
symptomatic,~8
alpha-OHD3~1
nation-wide~1
Sweden~3
1975.~5
4505~1
arthroplasties~8
3495~1
actuarial~37
hinged~1
prostheses.~5
Two-and~1
two-~11
Knee~4
osteocutaneous~2
fibular~7
revascularised~1
anastomoses,~3
one-stage~14
flap~105
vascularised~1
makes~42
designing~7
flap,~9
tourniquet.~2
119~16
Perthes'~8
widening~9
14.2%.~2
synovitis.~6
premise~4
aetiological~8
connection.~6
mobilisation~2
incisions,~3
midline~21
parapatellar~4
lies~11
perpendicular~7
flexion;~1
liable~3
mobilisation.~1
pain;~4
technetium~9
findings.~73
compartment(s)~1
unsuccessful;~1
success.~14
epithelioid~11
enchondroma~1
chrome-cobalt~1
Instability~1
leg-length~1
discrepancy.~1
radiologically~5
arthroscopically.~2
arthroscopy~5
functionless~1
meniscus~6
retropatellar~1
subluxation~22
leg-lengthening~1
orientated~3
substratum~6
axons~32
synapses.~1
basement~52
striated~10
sciatic~20
electrophysiology.~1
coaxially~3
aligned~5
fascicles~4
Grafts~3
myotubes~6
axon~8
penetration~36
degenerated~7
fibres,~3
recolonisation~1
stump~15
Ball-and-socket~2
coalition~4
tarsal~12
digital~42
rays~5
aplasia~4
hypoplasia~17
Arthrography~1
configuration~30
ball-and-socket~3
compensation~10
eversion~3
coalition.~2
congenital,~2
intracavitary~6
Kobe~1
cough,~10
palpitation~2
syncope.~2
Definite~3
echo-~1
cineangiocardiography.~3
myxomas,~4
leiomyoma~5
myxosarcoma.~1
instances),~1
(3).~3
crystalloid~13
cardioplegia.~2
Tumors~11
en~12
bloc~9
annuloplasty~7
commissurotomy.~1
myxoma~11
postoperatively:~1
chordal~5
Re-excision~1
myxosarcoma~1
Eighty-one~8
(90%)~19
period;~6
excessively;~1
re-explored.~1
haemoglobins~1
8.5~15
G/dl~3
stay.~8
transfused~30
Post-operative~3
894~1
Loss~9
481~1
510~4
transfused.~1
Haemoglobin~2
Discharge~3
10.5~10
G/dl.~2
pancreatitis~69
fourth.~1
transfusion.~13
Haemoglobins~1
untransfused~1
supraventricular~13
serous~14
discharges;~1
infected.~3
dehiscences.~1
expense~8
avoidable~3
saving~4
exceptional~5
echinococcosis~3
metastasis~47
parasitosis~1
parasitic~6
clots~10
veins.~24
Myxomas~1
atrium.~8
subaortic~15
prolapsing~1
"annulus"~1
Bjork-Shiley~9
reoperation~55
offending~6
trimmed~2
tucked~1
regurgitation.~15
Prolapse~3
unravelled~1
knots~1
Everting~1
skirt~1
270~9
Service.~2
dislocations.~8
suspicion,~3
thorough~26
flowmeter~6
broad~35
indication~46
exploration,~3
fasciotomies,~1
shunts~26
(usually~7
plates),~1
stabilization~42
preserved,~3
(89%)~9
salvage~61
92.6%.~1
Surgical~59
DVT~9
thrombectomy~20
Fogarty~4
catheter,~18
satisfactory,~4
opinions~4
postphlebitic~1
thrombi~49
DVT,~4
femoro-femoral~2
EPTFE~1
reinforced~4
grafts)~1
8-18~1
sixty-one~3
popliteal~26
thrombosed~11
ischaemic~16
claudication.~1
ulceration~22
claudication~9
pulses.~4
Thrombosis~7
femoro-tibial~2
graft.~10
revascularization.~13
occluded.~6
obliterative~2
atheromatous~8
aneurysmal~17
thrombosis,~17
reconstructions~9
glutaraldehyde-tanned~1
(H.U.V.)~1
out:~2
femoropopliteal,~1
aortopopliteal~2
Dacron~12
proximally),~1
femorotibial,~1
axillofemoral,~1
femorofemoral,~1
iliofemoral~7
bypass.~19
Autogenous~2
saphenous~34
(89.7%).~1
42.8%~1
35.1%~1
H.U.V.~4
by-passes~3
52.4%~1
41.9%~2
femoropopliteal~7
by-passes.~1
femorotibial~3
axillofemoral~5
Perioperative~7
5.1%,~1
17.2%.~1
8-year~3
grafts.~13
aneurysms.~18
Forty-four~13
aneurysm.~24
Forty-six~14
electively.~2
23.7%~1
7.8%.~1
s-creatinine.~1
Impaired~10
electively~9
52%~17
acutely.~3
32.4%~1
8.7%~2
aminoglycosides,~3
clamping~6
aorta~95
hypotension~91
aneurysm~113
hypovolaemia.~1
periaortic~2
haematoma~4
(acute)~1
elective~71
well-controlled~4
triad~12
pulsatile~53
palpable.~1
confusing~4
rapid,~16
leaking~2
AAA~6
documented,~6
rarely.~5
identifies~14
ruptured~33
"months"~1
operation--a~1
"contained~1
chronic"~1
ongoing~21
aneurysmorrhaphy~1
directing~2
decisive~5
information,~12
management;~1
workup~9
Blunt~3
youth~5
quadrant~11
abdomen,~8
dramatic.~4
conduits.~3
discrepant~1
deprived~4
extremity.~7
Disseminated~5
coagulopathy~5
(DIC)~7
thromboexclusion~1
dissecting~8
extra-anatomic~3
grafting~22
coagulopathy.~4
Low-dose~4
fresh-frozen~7
adopted~13
DIC,~2
thromboexclusion.~1
bronchitis~16
dyspnoea~5
parasternal~10
murmur~6
execution~2
cirsoid~1
supplied~27
arteries.~62
Diagnostic~26
fistulous~5
impossible~11
obstructing~21
substernal~3
goiter~11
Cardiopulmonary~2
aging~54
age-related~25
health,~15
30-92~1
osteopenia.~2
(25OHD)~1
advancing~30
-0.47;~1
24,25-dihydroxyvitamin~5
[24,25-(OH)2D]~1
-0.41;~1
1,25-(OH)2D~2
-0.07;~1
-0.24;~1
0.38;~1
(creatinine~1
clearance)~4
-0.71;~1
(single~2
photon~11
absorptiometry)~1
slight,~5
-0.72;~1
0.0001).~36
25OHD~1
24,25-(OH)2D~2
0.47;~2
0.51;~2
0.46;~2
Multiple~49
metabolism.~42
somatomedin-binding~1
(SMBP)~1
44)~3
nondiabetic~24
14)~13
diabetes~199
diabetes.~28
SMBP~4
trimester~22
percentile~14
-0.51).~1
2-~13
(IGF-I)~4
0.49)~2
percentiles~4
SMBP,~1
0.57),~1
SE~27
23%.~4
weight,~72
mothers.~13
fetal-placental~1
homeostasis~7
alpha-reductase~3
infancy~16
pseudohermaphrodites~1
Dominican~3
Republic.~1
dihydrotestosterone~4
etiocholanolone~1
androsterone~1
tetrahydrocortisol~1
(THF)~1
alpha-tetrahydrocortisol~1
alpha-THF)~1
chromatography/mass~2
spectrometry,~1
THF/5~2
alpha-THF~2
infancy.~7
carrier~20
homozygotes.~1
kindred~9
counseling,~2
rearing.~1
(Mabs)~1
37-amino~1
polypeptide~46
carboxyl-terminus~1
(CTP)~1
epitopes~15
CTP~2
alpha-subunit-reactive~1
Mab.~3
monoclonal-immunoradiometric~1
ng/ml.~14
hCG-like~1
229~10
donors;~1
4.6%~2
0.23~9
0.05-0.20~1
fertilization;~1
hCG-producing~1
anti-peptide~1
anti-hCG~1
Mabs~1
26-yr-old~1
hirsutism,~8
scalp~40
baldness~5
("geheimratsecken"),~1
menstrual~52
irregularities.~1
Cushing's~21
Cortisol~3
transcortin~1
excretion,~20
diurnal~11
cortisol,~15
GH,~7
insulin-induced~6
hypoglycemia.~6
father~5
brothers~9
(at~24
hair~81
cyclicity,~1
(insulin~1
test,~51
rhythm)~1
set-point.~1
dominantly~1
(partial)~1
insensitivity,~1
afflicted~4
propositus.~2
distinguishing~23
tumorous~1
PRL-secreting~7
viability~24
dispersion~10
dispase~1
75%.~2
(500~8
SEM).~4
dopamine-mediated~1
Cultured~10
transsphenoidal~6
estradiol-induced~4
insensitivity~5
prolactinoma~4
bromocriptine.~2
(agonists),~1
tamoxifen.~2
propionate~5
propionate-19,19,19-d3.~1
propionate-19,19,19-d3,~1
testosterone-19,19,19-d3,~1
chromatography-mass~4
spectrometry.~7
Testosterone~7
propionate-19,19,19-d3~2
2-4~8
testosterone-19,19,19-d3~1
little.~2
ketoconazole~20
600-800~1
3-13~1
17-ketosteroid,~1
tetrahydro-11-deoxycortisol~2
periodically~7
CRH~2
Rapid~21
patient;~5
17-ketosteroid~2
Urinary~34
suppressibility~1
Ketoconazole~2
hypercortisolism~3
beta-hydroxylase~2
17,20-lyase,~1
unknown~62
way,~4
Galanin~1
immunoreactivity~24
RIA,~6
non-C-~1
galanin,~1
adrenals~6
pheochromocytomas~7
pheochromocytomas.~5
galanin-like~1
galanin.~1
non-C-terminally~1
was,~20
galanin~5
localize~18
immunocytochemistry.~4
SEM)~38
pmol/g~1
5).~12
pmol/g;~1
16).~6
Gel~7
pheochromocytoma~13
pmol/liter).~1
immunocytochemistry,~1
scattered~12
chromaffin~4
adrenals.~2
Twenty-nine~31
hyperparathyroidism~20
ultrasound,~3
sonographically~2
aspiration,~9
aspirate~7
immunostaining~3
PTH.~1
enlarged~24
retrosternally~1
ultrasound.~6
multinodular~11
localization.~3
osteodystrophy,~1
preoperatively.~13
Cytology~1
diagnostic,~6
cytological~6
Immunostaining~1
PTH,~4
Ultrasound~4
hyperparathyroidism.~11
Fine~3
confirmation,~2
FFA~37
meq/liter;~1
occasionally~47
seriously~19
ill.~3
oleic~15
pooled~11
content)~4
meq/liter~1
5:1,~1
nonthyroid~2
Affi-Gel~1
readdition~1
following:~26
serum;~3
supraphysiological~2
vitro)~1
FFA-binding~1
(apparently~2
5:1),~1
interact~22
proteins,~24
hormone-binding~22
concentration;~4
binders)~1
FFA.~1
illness,~45
unit.~28
mEq/liter~4
2.39~2
0.29~15
g/dl~6
1.53~3
0.41.~1
exceed~18
5:1~1
occurs,~3
(bioavailable)~1
T~139
(FT)~2
albumin-bound~7
T.~33
bioavailable~5
precipitate~14
(SHBG)-bound~1
supernatant~10
non-SHBG-bound~5
(non-SHBG-T)~1
(65-83~1
old)~11
(22-39~1
old).~2
T,~13
FT,~1
non-SHBG-T~3
impotent~7
27-37~1
old,~20
48-64~2
66-69~1
old),~1
FT~3
monocyte-derived~3
metabolize~5
[3H]25-hydroxyvitamin~1
(25OHD3).~1
lipopolysaccharide~8
(LPS)~4
[3H]25OHD3~1
polar~6
pmol/10(6)~2
cells).~5
Untreated~5
metabolite.~3
biologically~16
[1,25-(OH)2D3].~1
(1)~23
(2)~21
chick~12
authentic~5
1,25-(OH)2D3.~3
(3)~16
macrophage~45
chicks)~1
LPS-stimulated~3
1,25-(OH)2D3-like~2
fashion;~1
typically~27
100-200~3
LPS/10(6)~1
Polymyxin~1
LPS~8
25OHD3~2
macrophages.~17
modulate,~1
1,25-(OH)2D3-responsive~1
ipodate~5
infant~100
hyperthyroidism~22
Graves'~42
(day~7
micrograms/dl~6
590~8
ng/dl,~2
ipodate,~1
40%,~7
209-278~1
ng/dl~8
39-day~1
respectively;~16
thereafter~17
19-22~1
micrograms/dl.~2
hyperiodothyroninemia~1
abated.~1
rT3~11
468-672~1
1400~4
Thyroid-stimulating~1
thyroid-stimulating~11
Antithyroglobulin~2
antimicrosomal~5
titers~61
thereafter;~1
titer~37
growth-blocking~2
(IgG)~7
myxedema,~2
goitrous~11
Hashimoto's~10
thyroiditis,~5
TSH-induced~5
FRTL-5.~2
[3H]Thymidine~1
mU/ml~6
myxedema~7
thyroiditis.~3
phorbol-12-myristate-13-acetate.~1
IgGs~2
myxedema.~2
Primary~24
lipoprotein-depleted~2
lipoprotein-supplemented~1
principal~40
(hLDL)~1
nonsulfoconjugated~1
steroids,~7
dehydroepiandrosterone.~1
beta-hydroxyandrostenedione~2
cortisol.~3
hLDL,~1
cholesterologenesis~2
rate-determining~4
biosynthesis,~4
Immunoblot~1
97K~1
Interestingly,~13
Pulsatile~2
(CC;~1
midluteal~6
CC~24
alternate~18
15-min~4
LH,~6
(E2),~1
SEM)/8~1
0.6/8~1
(13.6~2
mIU/ml)~1
mIU/ml;~1
13.5~6
CC.~2
Luteal~3
CC-treated~2
GnRH~10
episodes,~17
cycles,~5
permissive~6
luteolysis~1
human.~3
4-week~4
abused~13
abstinent~6
(FAS),~1
healthy.~3
FAS~2
low.~36
16-24th~2
FAS.~1
fluctuated~1
widely,~2
abuse~74
accompanied,~1
secondarily,~1
Half-hourly~1
Sleep~6
denied~9
0700~1
awakening~3
accommodation~2
7100~1
(D3)~1
nights~1
2300-0700~1
missed.~5
modulatory~5
deprivation~13
D1-2~6
(1100-3500,~1
3500-5900~1
resumption~5
nightly~4
(5900-8300)~1
basally~3
synchronization~4
basal,~6
deprived,~2
longer,~7
maxima~6
cosine~2
acrophases~1
resumed.~3
cosinor~2
sleep-resumed~1
ellipses~1
later,~40
1700-2300~1
rising~24
Prompt~8
reversion~1
arisen~4
generating~10
oscillator.~1
noninsulin-dependent~3
mellitus~49
(NIDDM),~2
nonobese~5
5-h~2
clamp~18
microU/ml~4
(0-150~1
(150-300~1
min).~20
two-way~4
NIDDM,~1
NIDDM~7
insulin-stimulated~3
-0.67;~1
resistant~59
comparable.~8
Yearly~2
remissions,~1
recognizable~9
transphenoidal~1
resection,~34
radiotherapy.~21
mineralocorticoid~4
surreptitious~1
hypercorticism~1
carcinoma-associated~2
hypercalcemia.~12
pg/ml)~9
pg/ml,~23
normocalcemic~6
Eighty-seven~8
30)~8
hypercalcemic~7
pg/ml).~9
39)~7
hypercalcemia,~5
Insulin~4
mediate~27
insulin-resistant~1
states.~12
hyperandrogenism,~3
acanthosis~3
nigricans~1
hyperinsulinemic-euglycemic~1
U/kg~10
mU/kg~1
12-16~1
1832~1
292~3
achieved;~3
clamped~5
116~22
receptor.~29
Dehydroepiandrosterone~2
(DHEA-S)~1
nigricans.~2
rhythmicity,~1
hyperinsulinemia~1
12-~1
16-h~2
indeed,~2
hypernatremia~5
concentrating~5
hyperosmolality~1
ultralow~2
hypodipsia,~1
osmoreceptor~2
puberty,~4
hypotonic~10
diuresis~15
Vasopressin~3
0.4-12~1
fmol/kg~2
vasopressin,~9
1-desamino-8-D-arginine~1
(DDAVP)~2
reporting,~1
thirst.~1
DDAVP~2
vasopressin.~7
private~16
self-stimulation~1
orgasm~2
13).~5
indwelling~23
catheters.~17
pressed~1
finish~1
orgasm/ejaculation.~1
arousal~10
blood-pulse~1
photoplethysmograph~1
electromyograph~2
connected~17
polygraph~1
room.~11
pelvic/pubic~1
orgasm/ejaculation~1
orgasm.~2
characterizing~14
(MAbs)~1
recognizing~13
(dPTCs),~1
MAb~15
(4F2)~1
avidly~4
4F2~5
adenomatous~29
dPTCs~2
[53.8~1
7.9%~3
SEM)]~1
(Ca)-stimulated~1
mM).~9
Typically,~3
1:10(4)~1
1:10(5).~1
Cell~19
trypan~4
90-95%)~1
immunofluorescence.~1
Parallel~6
Ca-sensitive~1
Quin-2~1
4F2-treated~1
cytosolic~29
(Cai)~1
188%~1
Ca;~1
Cai~1
Ca.~1
Mab~5
P3~11
63,~2
dPTCs,~2
LC7-2,~1
Cai.~1
Immunoprecipitation~7
145,~2
85,~4
nonreducing~2
kilodaltons~2
mercaptoethanol.~1
Mab-4F2~1
vitro;~1
Cai;~1
heterodimeric~1
(approximately)~1
85K~1
45K;~1
4)~27
Ca-sensing~1
signal-transducing~1
undertook~14
20-min~6
18-33~2
yr),~5
yr).~4
(IGHC),~1
denoted~2
duration,~33
(FGHP).~1
IGHC~3
0.025)~16
0.003).~13
FGHP~4
0.006,~1
0.0001,~2
0.53;~2
0.59;~1
0.0002).~6
correcting~10
0.43;~1
0.006)~1
somatomedin-C.~1
Somatomedin-C~1
interrelated~1
amplifying~1
clarify~35
angiotensin~99
mesangial~24
contracted~14
depolarized~7
AVP.~1
depolarization~21
ionophore~8
A23187~4
depolarization.~7
(Vr)~1
AVP~40
-29~2
-25~2
Not~10
Vr~2
AII-induced~7
ionophore-induced~1
Cl-~13
Ca++-free~4
EGTA.~1
-activated~1
[Ca++]i~1
organellae.~1
Fibroblasts~5
pedigree~7
osteogenesis~4
imperfecta~2
(OI)~1
pro~9
2(I)~5
chains.~9
normal;~8
deletion~30
helical~7
domain.~6
mutation~18
posttranslational~3
amino-terminal~4
1(I)~1
chains,~6
lowers~6
melting~2
incorporate~5
mutant~38
chain,~10
delays~15
culture.~46
linkage~8
families,~9
OI~4
phenotype~33
heterozygosity~2
collagen.~16
normotensives~2
hypertensives~6
characterized.~14
96.7~2
122.2~1
mmHg)~10
age-matched,~1
Chinese~18
nitroprusside,~6
(propranolol).~1
Hypertensives~1
(2,295~1
1713~1
dyn-s/cm5),~2
(145.7~1
93.9~1
(1,579~1
1174~1
mW),~1
reflections~2
backward~6
wave~88
0.54~9
0.44),~1
crossing~4
(4.15~1
2.97~3
Hz).~3
vasodilatation.~1
exacerbated~6
Beta~5
reflections.~3
(increased~2
reflections,~1
compliance)~2
vasomotor~8
unmasked~3
vesicles~57
Isotopic~1
gluconate~6
nmol/mg~9
disulfonic~2
stilbenes.~2
Imposition~1
interior-positive~1
Kinetic~8
bicarbonate-dependent~2
10.4~4
mM.~14
electrogenic~5
(negatively~1
charged)~1
sodium/bicarbonate~1
cotransporter~1
electrogenicity~1
implies~19
stoichiometry~5
ion.~4
sickle~51
xerocytic~1
depleted~25
cations~13
previously.~20
permeabilities~2
potassium,~19
deoxygenated.~2
ouabain-insensitive~1
fluxes~6
equivalent,~3
cation~22
ouabain,~4
4,4'-diisothiocyanostilbene-2,2'-disulfonate,~1
deoxygenation.~1
oxygenated~11
xerocytes~2
ouabain.~5
"passive"~1
deoxygenated~3
leaks~11
cation.~1
ontogenic~1
switch~12
ones,~3
progenitors~11
midswitch~2
skewed~5
beta-globin~10
programs,~13
Gaussian~1
141-153~1
d~37
(midswitch).~1
Mononuclear~4
methyl~35
erythropoietin,~1
BFU-E-derived~1
[3H]leucine.~1
Globin~1
fluorography.~2
skewed,~1
progenitors,~2
non-Gaussian~1
switching~5
ontogeny.~2
radioimmunoassay~45
insulinlike~2
(IGF)~2
(BP)~14
53-kD,~1
acid-stable~2
BP~71
subunit,~2
125~19
kD.~4
cross-reactivity,~1
IGF-II,~2
Circulating~5
threefold~20
puberty.~11
65,~8
6.12~2
1.43~2
micrograms/ml,~11
Strong~4
hormone-dependence~1
seen;~1
2.2-fold~1
acromegaly~2
50-80%~2
Poorly~1
third-term~1
(LPL)~4
(HTGL)~1
postheparin~2
(PHP).~1
LPL~15
PHP~6
triglyceride-rich~2
just~47
cholesterol.~6
chylomicrons,~2
HTGL~1
preheparin~1
position,~26
lipoproteins,~6
PHP.~1
milk~85
eluting~1
LDL.~6
NaCl)~4
ultracentrifugation~4
solutions,~11
lipoproteins.~5
immunoaffinity~2
apolipoprotein~13
(apo)~3
lipolysis,~1
remnants~6
chylomicrons~6
Hypocalcemic~1
(D)-depleted~1
25(OH)D3~5
hypocalcemic~4
Constant~3
administrations~8
[14C]D3~1
regimens~71
uncovered~6
supplementation;~1
D3-25~2
hydroxylase.~1
1,25(OH)2D3.~2
25(OH)[3H]D3~1
D-depleted~1
accelerating~4
convoluted~8
tubule~30
(PCT)~2
length.~19
nephron~7
glomerular~130
(SNGFR)~1
28.7~4
nl/min~4
hydropenia~1
41.5~1
euvolemia,~1
bicarbonate,~5
chloride,~5
(1st~1
mm)~23
PCT~12
proportionally:~1
354~4
peq/mm~4
5.9~14
nl/mm~2
585~3
10.1~7
further,~7
SNGFR~1
went~10
51.2~2
50.7~2
natriuretic~7
glucagon~47
Anion~1
dependence.~4
alkalosis,~3
PCT.~3
high-capacity,~1
flow-responsive~1
anion-~1
water-reabsorptive~1
alkalemia.~1
intakes.~4
(FFM)~2
densitometry~5
expenditures~7
(24EE)~1
(24EE~1
[kcal/d]~1
597~2
26.5~5
FFM);~1
24EE~2
(coefficient~2
2.4%);~1
FFM,~1
interperson~1
expenditure.~1
"fidgeting,"~1
100-800~1
kcal/d~1
constituents~10
cotton~18
byssinosis~3
injuring~3
dust,~2
bract,~2
field-dried~3
bract~5
A549~1
pneumocytes.~1
Injury~10
pneumocyte~2
detachment,~11
Extracts~3
dust~22
dose-~4
time-dependent~12
detachment~43
damaging.~1
polyvinylpolypyrrolidone~1
tannins~2
5,7,3',4'-tetrahydroxy-flavan~1
3,4-diol~1
(THF),~1
tannin~1
Field-dried~1
THF~3
Endotoxin~5
desquamation,~2
endotoxin~17
Instillation~1
constriction,~3
polyvinylpolypyrrolidone-treated~1
alveolar,~1
tracheal,~1
C5a~30
des~15
Arg~3
anionic~14
(cochemotaxin)~1
cochemotaxin~3
attaches~2
polymorphonuclear~33
leukocytes.~6
enhancing~24
Arg,~2
C5a,~6
N-formyl-methionyl-leucyl-phenylalanine.~3
Arg.~1
Sialic~1
Arg-cochemotaxin~1
complexes,~11
electrophoresis,~12
sieve~4
gels,~3
ultracentrifugation.~3
Small~17
(0.1-0.5~2
amylase~38
octapeptide,~1
acini.~5
Deoxycholate~4
cholate,~2
chenodeoxycholate,~2
ursodeoxycholate,~1
taurocholate~18
secretagogue-induced~3
diacylglycerol~6
phospholipase~12
C-mediated~2
phosphatidylinositol~11
phosphatidylinositol-4-monophosphate.~1
phosphatidylinositol-4,5-bisphosphate~1
mobilization.~5
C-activating~1
12-O-tetradecanoylphorbol-13-acetate~2
ionomycin.~2
secretagogue~4
HCO3~10
Cl~13
self-exchange~3
tubule.~6
peritubular~7
[Cl]~2
(Km,~2
4-11~1
Cl-HCO3~3
carrier-mediated.~2
Addition/removal~1
diffusive~3
transepithelial~9
HCO3/CO2~2
conductive~3
exchanger.~3
anion~22
electroneutral~2
exchanger~9
conductance),~1
mycelial~3
yeast~9
transitions~3
Downs~2
Histoplasma~4
capsulatum~6
(low~7
virulence)~1
G184A~2
G222B,~1
virulent~9
strains~101
pathogenicity~4
G222B~1
strain.~5
Downs.~1
uncoupling~7
phosphorylation.~5
strains.~14
Considered~1
accounting~10
virulence~4
phosphorylation~14
inexorably~1
storage.~5
spectrin-actin~4
(50%)~21
4.1.~2
Actual~2
spectrin-actin-protein~1
(R~5
0.9932)~1
spectrin~30
dithiothreitol.~2
weaken~2
prolonging~3
shelf~1
Platelet-activating~1
(PAF-acether),~1
neutrophil~89
chemotaxis,~4
eosinophil~19
locomotion~3
(chemotaxis~1
chemokinesis).~1
(25-95%~1
purity)~1
donors~47
hypereosinophilia.~1
PAF-acether~6
directional~4
eosinophils,~8
fashion,~11
lyso-PAF~2
PAF-acether,~1
locomotory~1
leukotriene~19
B4~4
(LTB4),~1
valyl-~1
alanyl-eosinophil~1
anaphylaxis~11
(ECF-A)~1
negligible.~7
(optimum~2
LTB4~5
chemotaxis~13
chemokinesis~3
qualitative~28
chemoattractants,~2
LTB4.~1
eosinophilotactic~1
infiltration.~11
B-100~1
(apoB-100)~1
leukocytes~42
apoB-100~9
translated~4
livers~24
abetalipoproteinemic~4
5',~1
3'~6
abetalipoproteinemia~2
insertions~5
deletions.~1
Polyadenylated~1
sixfold~2
ApoB-100~1
immunohistochemical~19
up-regulation~1
Thrombospondin~3
fibronectin,~8
von~14
Willebrand~3
adhesive~13
GPIIb-IIIa.~1
Thrombasthenic~1
GPIIb-IIIa~7
thrombospondin~5
Radioiodinated~1
thrombin-stimulated~5
thrombasthenic~4
thrombospondin,~1
divalent~10
ion-dependent~6
-independent~1
ligands~7
interacts~5
Mucus~1
colorectal~97
respects~3
normally:~1
O-acetyl~3
substituents~3
acid,~57
mucin.~3
bordering~3
"Normal"~1
diverticular~2
Sections~5
Schiff~1
(mPAS)~1
(selectively~1
stains~18
group)~17
Reactions~2
weak,~4
intense.~2
Phenylhydrazine~1
interposition~10
mPAS~1
effect,~29
acid:fucose.~1
unsuspected~16
goblet~15
sialomucin~6
apparent.~15
neurone~4
enolase~6
(NSE)~3
S100~16
melanomas~16
melanocytic~5
NSE~5
melanoma.~21
naevi~1
0.011).~1
Intensity~3
melanomas.~3
intradermal~16
tumours~35
naevi.~1
NSE.~1
behaviour~21
eccrine~8
poroma~2
metastasised,~1
strict~17
nodule~17
polyclonal~29
stroma,~4
centre~10
nodule.~10
paraproteinaemia.~1
granulation~5
know,~3
called~34
granuloma~10
thyroid.~4
Separate~5
keratocyst,~1
dentigerous~1
cyst,~11
radicular~8
cyst~63
antiserum~16
antigen,~32
X,~3
keratin,~1
keratocyst~1
fluids.~3
bands~24
sulphate-polyacrylamide~1
(SDS-PAGE)~2
disulphide~2
bonds.~1
keratocysts;~1
Pyomyositis~2
tropics.~3
tropics~2
temperate~1
climates~1
aureus.~9
mind~9
fatal~71
panel~24
anaerobic~47
organisms,~6
Bifidobacterium~1
bifidum,~1
Coprococcus~2
comes~7
(ME46),~1
(Sp4),~1
Eubacterium~1
limosum~1
titres~5
Antigenic~2
unexplained.~2
Nomifensine,~1
Britain,~2
popular~11
north~4
west~2
England.~2
Haemolytic~5
recognised~9
North~24
West~8
Transfusion~2
Centre,~1
0.006%.~1
nomifensine~3
market~6
January,~8
1986.~11
intralesional~6
U/ml)~6
warts~8
dilute~9
recalcitrant~7
warts.~4
Warts~1
U/ml,~3
3-week~5
persisted~70
recurred~30
months'~13
seventy-nine~1
sixty-two~1
(78%)~6
cured~25
injections.~15
Responding~2
hemorrhagic~64
eschar~2
responded,~2
cured.~9
U/ml.~1
Bleomycin~2
permit~48
Cryosurgery~3
modality~34
presents~44
cryosurgery~5
dermatologist's~1
office.~2
Understanding~3
cryobiologic~1
prerequisite.~2
Aspects~3
equipment,~8
contraindications~6
technics~3
depth-dose~1
cosmetic~24
favorably~24
modalities.~12
others.~18
Microsporum~4
nanum~2
dermatophyte~3
ringworm~1
M.~46
here.~10
tinea~12
faciei~1
cruris.~1
clotrimazole~2
miconazole~8
griseofulvin.~1
hog~1
farmers~2
Occupational~2
Chancroid,~1
disappearing~2
States,~17
reintroduced~1
country~7
immigrants~5
Caribbean,~1
Mexico,~6
Southeast~8
Asia.~1
Point~1
epidemics~4
resulted,~2
prostitution.~2
4-month~6
Massachusetts,~3
thirty-seven~4
Boston~11
records,~9
anthralin~8
stain~31
polyester/35%~1
cotton,~2
polyester,~1
shower~6
curtain,~1
tile~2
crevice,~1
ceramic~5
technic~7
10-minute~6
soak~1
full-strength~1
chlorine~3
bleach~2
(Good~1
Measure~1
Clorox)~1
rinse~6
drying.~2
fabrics.~1
curtains,~1
tiles,~1
tiles~1
fingernails~1
(type~17
pityriasis~6
rubra~3
pilaris~3
fingernail~1
twenty-seven~5
Distal~7
yellow-brown~3
discoloration,~1
subungual~6
hyperkeratosis,~3
splinter~1
hemorrhages~12
psoriasis,~5
onycholysis~1
(particularly~6
marginal),~1
salmon~2
patches,~1
pits,~2
indentations~1
Histology~4
erythroderma~5
Sezary~8
matrix.~10
(trachyonychia)~1
ninety-seven~2
photochemotherapy~3
(PUVA)-treated~1
418~3
reevaluated~6
PUVA.~5
63.1~1
carcinogens~3
arsenic~8
ionizing~9
PUVA~12
II;~5
unexposed~6
(UVA)~2
UVA~23
carcinogenesis,~1
substantiate~7
PUVA-treated~1
confirms~29
nonmelanoma~2
vitiligo~5
depigmentation~3
vitiligo.~2
Vitiligo~1
A-sepharose~1
immunoprecipitation~7
Antibodies~9
involved),~2
thirteen~15
fourteen~10
(93%)~9
involved).~1
2.9%~6
2.03,~1
5.6%~4
2.92,~1
8.0%~3
3.03~1
SD,~12
bowenoid~5
papulosis~8
Bowen's~7
genital~33
argon,~2
Nd:YAG,~1
laser.~10
coagulating~1
macular~40
papular~5
pigmented~26
Nd:YAG~12
lasers~11
leukoplakia-like~1
verrucous~3
Medium-depth~1
peeling~1
trichloroacetic~7
phenolic~1
cauterant~1
Combining~5
regeneration.~11
actinic~8
degeneration,~11
acne~7
scarring,~6
rhytids,~1
Lymphoscintigraphy~2
Technetium~1
antimony~4
sulfur~18
(TASC)~1
lymphatic~33
node~143
dissection.~20
TASC~1
visualization~39
tiers~1
pustular~6
development,~19
pilonidal~2
rhomboid~1
treated.~23
intention,~1
Earlier~9
ulceration,~10
prerequisites~4
BCC.~1
large-caliber~1
BCCs~1
parotid~35
penetrate~12
rich~14
microscopic~90
warranted~9
Drug~26
1975~37
lipid-influencing~1
8,341~1
electrocardiogram-documented~1
dextrothyroxine~1
clofibrate~1
Niacin~1
nonfatal~21
termination~18
niacin,~6
Mortality~21
niacin~3
(52.0~1
58.2%;~1
0.0004).~1
reinfarction~3
cholesterol-lowering~3
infarction,~56
excluded.~36
aneurysm:~1
25):~1
artery;~4
27):~1
23):~1
4):~1
artery.~101
Single~10
(aneurysm)~2
Groups~37
aneurysm)~2
2(4)~1
12.8;~1
0.012).~2
Collateral~4
(0.9~6
2.4,~2
embolic~20
inherent~26
Multivessel~1
uncommonly~2
nitrates~4
magnification~6
aspirin~51
intracoronary)~1
isosorbide~13
dinitrate~5
1A)~2
1B)~1
dinitrate,~3
Relative~8
19.5~4
assessed:~4
24.7~4
NS~11
postaspirin~2
1B).~1
6-ketoprostaglandin-F1~1
1B~1
prostacyclin~8
dilation~58
double-blind,~28
restenosis~20
angioplasty.~23
forty-one~4
nifedipine,~8
(123~1
(118~1
4.3~24
restudy~3
angiogram~6
(81%)~14
29.5%~3
36.7~3
pill~7
complied~3
regimen.~20
29%~26
inducibility~9
programmed~44
extrastimuli~17
paced~15
lengths.~4
arrhythmia~55
(sustained~2
fibrillation)~3
investigation.~21
Sustained~8
207~10
(five~30
monomorphic,~1
polymorphic),~1
kinase,~5
stenosed~13
(47~12
10%)~4
(Holter)~2
(223~2
259~8
ms;~8
+/-5~1
arrhythmia.(ABSTRACT~1
constraint~5
size;~3
cardiomegaly)~1
collapsible~1
balloon.~8
opened.~4
grossly~32
Excluding~6
outlying~1
0.689).~1
6.4~9
g-m/m2~1
pericardiotomy~1
pressure;~4
constraint.~1
exerts~18
notable~10
exceptions,~7
exceeds~6
ventricles~28
geometry~7
cavity.~18
dramatically~31
deranged~4
end-systole~4
diastole,~3
(129~6
ms,~25
transmitral~9
diastole~15
9%,~7
short-axis~13
(32~12
11%)~5
(78~5
flattened~6
(normalized~2
0.19)~2
end-diastole~3
0.68~7
0.19,~2
0.005).(ABSTRACT~1
quantitative,~4
cinevideodensitometric~1
arteriography~29
Projected~1
arteriograms~7
512~6
pixel~3
background-corrected~1
videodensitometric~6
segments.~22
worsening~18
transplant~12
arteriogram~5
systolic~207
29.3~4
(90%~6
interval,~38
45%)~3
56%).~2
(F~12
5.81,~1
4.37,~1
atherosclerosis~30
arteriogram.~3
progression.~15
insufficiency,~13
regurgitant~14
aortography~4
pulsed~35
insufficiency.~24
deceleration~7
tracing~6
(1.6~4
m/s2),~1
(2.7~6
m/s2)~2
aortography.~2
Deceleration~1
m/s2~1
half-time~7
grades~15
exhibiting~8
shortest~13
half-times.~1
echocardiography.~33
End-diastolic~4
0.28)~1
catheter-measured~1
equilibrate~3
diastole.~5
scintigraphy~45
Pulsed~6
anulus.~4
wave,~4
end-diastole,~1
(early,~1
total).~1
anulus~16
Scintigraphic~2
end-systole,~1
0.84)~1
systole~20
0.85),~1
0.83),~2
0.94)~1
Normalized~2
volume.(ABSTRACT~2
Electrocardiographic~3
nadolol~14
ligation~54
dog.~8
20)~8
triplets~6
exceeding~27
270/min.~1
(421~1
seconds~45
tachycardia,~27
(375~1
beats/min).~3
(378~1
Nadolol~2
19)~11
(241~3
328~3
beats/min;~3
hour;~3
0.004)~1
(0%;~1
(88%;~1
365~1
(rapid~2
triplets)~1
altering~27
substrate.~9
mongrel~24
13)~14
hypokalemia~17
17).~5
sulfonate~2
g/kg~6
weight)~16
colon.~24
deviation)~11
3.81~1
0.21~13
2.92~1
mEq/liter;~1
electrolytes.~1
micrograms/kg)~17
10%.~8
7.7%~2
Mitochondrial~1
10%.(ABSTRACT~1
tear~13
heparinized~5
Scanning~12
denudation~2
Visible~1
mural~19
study;~8
indium-111-labeled~4
116.4~1
10(6)/cm2~3
(4%).~6
thrombus,~3
7.0~9
0.0008).~1
pigs~40
scanned~8
camera,~2
scintigram.~2
deposition,~7
scintigram~7
>~1
platelets/cm2~1
Hematoporphyrin~2
derivative,~8
photosensitive~2
humans,~24
atherosclerotic~38
hematoporphyrin~13
derivative~31
light,~9
porphyrin~1
plaque,~5
plaque-free~1
fluorescence.~3
plaques,~8
injury)~3
Zealand~16
fluoresced~1
Fluorescence~3
photochemical~1
atherosclerosis.~15
Single,~1
truncated~3
delivered~80
vectors~1
interventricular~13
(catheter~1
epicardial~38
ventricle)~3
(22.6~2
26.4~2
J,~2
(1,004~1
1,094~2
V,~9
terminate~8
defibrillate.~2
patch,~1
extrathoracic~8
(7.7,~2
8.7~14
(424,~1
436~2
424~2
shocks.~3
Infarcted~2
noninfarcted~3
coarctation~59
infancy,~3
subclavian~47
anastomosis.~20
Sixty-three~7
1960~13
1.54~3
0.93~12
2.70~2
anatomy~48
hypoplasia.~5
2.55~2
0.51~7
8.2),~1
7.97~1
3.61~2
21).~6
Indication~2
Reoperation~5
0.0356~1
reoperations~16
patient-year,~2
0.0342~1
patient-year~1
0.94).~3
individual's~8
measures,~15
16.3%~2
15.7%~4
resection.(ABSTRACT~1
anomalous~30
infracardiac~1
nine,~4
supracardiac~1
five.~8
nonphasic,~2
phasic,~1
nonlaminar~1
intervention.~22
septa~1
septation~4
atrioventricular~86
(AV)~26
defect,~15
AV~112
cardiomyopathy~46
ostium~3
secundum~3
defect.~25
(24.8~1
9.9%~2
7.9%,~1
occupying~6
48.2~2
7.0%~3
(versus~1
57.9~2
4.1%~2
(39.4~2
5.0%~3
7.0%,~1
primum~2
greater.~3
expanded~25
capabilities~13
utero.~4
hydropic~2
Complete~29
hydrops~6
fetalis~2
lead,~3
necropsy.~7
utero,~3
(Canadian~1
IV).~4
laser-heated~1
capped~2
energy,~6
seconds.~10
burning,~2
spasm,~9
embolization~35
debris.~9
performing~51
myocardium,~15
(dP/dt)~2
myocyte~10
subendocardium.~1
enlargement~30
myocytes~8
number.~7
hypertrophied~10
Cellular~11
Abnormal~19
performance,~15
precede~8
(determined~8
echocardiography)~1
ventriculography)~1
blocker)~3
hydrochlorothiazide,~1
(156/103~1
12/7~2
137/89~1
10/6~1
Hg).~12
(270~2
193~12
0.01);~6
(2.03~1
2.30~1
counts/s~1
[EDC/s],~1
(137~1
g),~6
2.01~3
EDC/s.~1
67)~2
exertional~7
angina.~15
apart,~8
sublingual~11
Nifedipine~11
99~17
(33~16
W),~1
(68~2
hypoventilation,~2
tension,~7
(31~12
0.001).(ABSTRACT~4
cardiology~2
imaging,~20
angiocardiography~6
utility~35
(I~1
important;~3
indicated).~1
Selected~5
references~4
provided.~8
ragweed-sensitive~1
glycol-modified~3
regimens,~7
rhinoconjunctivitis~1
schedule~29
ragweed-specific~2
Immediate~13
rush~2
regimen;~1
H1~18
(diphenhydramine~2
hydrochloride)~1
H2~30
(cimetidine)~1
histamine.~15
occasions.~7
noses~2
hydrochloride,~15
unprovoked~9
Doxepin~2
antidepressant,~2
Efficacy~3
scores,~8
antihistamine~4
histamine-~2
codeine-induced~2
wheal~5
Doxepin-treated~2
lesser~52
angioedema~8
placebo-treated~8
0.13~17
tablets~10
1.48~3
tablets,~1
Lethargy~2
use.~47
Dry~1
constipation~10
doxepin~2
urticaria.~1
immunity~25
cat-scratch~4
(CSD)~2
granulomatous~26
histopathology~16
CSD~7
unresponsive~15
nonviable~4
CSD.~1
lymphangiectasia~1
7-year~7
Lymphedema~1
noticed~15
Thoracentesis~1
yellow,~1
milky~2
predicted.~4
Strict~2
low-fat~4
high-protein~6
lymphopenia~3
mitogens~4
Dietary~18
hypogammaglobulinemia,~4
circulation,~14
difference.~12
9-month~3
compromise.~6
Stability~4
right-sided~19
pleurodesis,~1
pleurodesis~1
IgD~3
European~12
biparental~1
0.025~4
0.005,~6
nonallergic~5
1.20~4
IU/ml)~2
fourfold~18
smoked~13
Paternal~1
influence,~1
subgroup,~4
0.04).~9
smoke.~1
life,~22
"low-risk"~2
sensitization,~2
synergy~6
matter.~7
Pregnant~6
encouraged~9
trimethoprim-sulfamethoxazole~5
(TMS)~1
wheezing~15
30-year-old~6
Pneumocytis~1
Pentamidine~1
myositis,~4
deterioration,~4
TMS~2
attempted.~6
fevers,~2
arthralgia,~3
completed.~8
situations~22
urgently~3
basophil~14
flank.~1
infiltrate~18
basophils~8
neutrophils~87
monocytes.~5
Ocular~4
priming~4
immunization~18
elicitation~3
flare~5
Very~11
flares.~1
(basophils,~1
neutrophils),~1
onto~12
diseases,~30
vernal~3
conjunctivitis~4
lens-associated~1
conjunctivitis.~3
hypothesize~9
transformed~20
mast~99
(MCs)~1
MC~5
glycerin~1
diluent~1
4).~16
formalin,~1
acetate.~5
Alcian~5
blue,~4
49.7%~3
("typical"~2
MCs:~2
2916~1
581/mm3;~1
formalin~4
1955~6
537/mm3).~1
diluent,~1
late-phase~3
(LPR),~1
induration~2
LPR~4
diluent.~1
0.85;~1
markedly.~4
participate~26
LPR.~1
OADs~1
social,~13
ethical,~2
moral~4
issues~30
economic~19
dilemmas.~1
endeavors,~1
appreciation~4
researcher~1
defend,~1
deny~2
argues~4
extrapolates~1
scientific~22
findings--a~1
research.~21
issues,~5
confusion~6
distrust~1
OAD~1
enormous~4
parties.~1
Task~8
recommendations~42
consider~34
nonmedical~2
nonscientific~1
industry~8
welcomed~1
asthma~100
international~6
scope.~1
well-designed,~1
large-scale,~1
epidemiologic~41
precisely~25
worldwide~2
created~48
countries,~11
reasons~49
hyperreactivity~8
Paradoxically,~3
advances~16
increasing.~6
urban~21
indoor~4
outdoor~1
pollution,~1
crowding,~1
Still~3
unknowns~2
urban-rural~1
residences~2
countries~24
helminth~1
hyper~1
IgE-stimulating~1
occupationally~3
worksites~1
industrialization~1
emergence~12
allergies~3
documentation~24
observations.~4
bronchiolitis;~1
triggering~7
asthmatic~56
occurrence,~8
years;~29
sinusitis~19
infection.(ABSTRACT~1
652~1
western~13
red-cedar~4
sawmill,~1
allergens,~3
responsiveness,~5
plicatic~4
RAST.~1
Dust~1
personal~38
employment.~4
RAST,~2
hyperresponsiveness.~3
Elevation~9
RAST~8
(46%)~9
elevation.~6
workers.~11
Bronchial~6
dust-exposure~1
employment~13
acid-specific~1
causal~15
Allergy~2
potato~13
uncommon,~12
pollen.~2
antigens.~28
11-year-old~2
girl,~5
breast-fed~14
anaphylactic~8
Subsequently,~14
urticaria,~8
angioedema,~6
potatoes,~4
cooking~7
potatoes~1
allergenic~7
pulp,~3
peel,~1
pollen~20
prepared.~2
Polyacrylamide~1
isoelectrofocusing~1
IgE-mediated~6
reactivity,~2
pulp~6
electroblotting~1
14,000~3
40,000~1
daltons.~8
C1-inhibitor~7
Rocket~1
C4d~1
plasmas~1
elevated)~1
attenuated~49
androgens.~1
C2,~4
C1~15
measured;~1
deficiency,~20
Histamine~8
(CU)~2
CU.~1
48/80~3
CU~1
numbers.~3
Drinking~2
wine~6
bronchospasm~5
asthma.~25
reaction,~12
wine-induced~2
received,~10
(SO2)~1
SO2~16
challenge,~16
385~5
reached.~3
challenges.~1
labels~4
spirometry,~4
FEV1~34
(PC20)~2
ascorbic~15
gm)~7
orally,~8
4.3.1~1
two-treatment~1
spirometry~3
performed,~40
PC20~16
reassessed.~3
FVC~22
bronchodilator~13
inhalations~3
metered-dose~4
aerosol).~1
slow.~1
4.65~1
1.09~6
8.31)~1
nmol/L,~3
Inhaled~1
dependently~2
absorbed.~4
2.72~1
(0.75~3
5.67)~1
7.19~1
(2.10~1
13.83)~1
inhalation.~7
Inhalation~4
self-administration~2
insect~9
(Hymenoptera)~1
stings.~1
Apart~8
advantageous,~2
58-year-old~2
sawdust~2
(tenfold~1
FEV1)~2
cedar~1
exposing~8
PC20,~1
reexposed~1
FEV1,~12
recover.~3
persist~16
stratified~24
puncture~30
(ST~2
+)~2
Lolium~1
perenne~1
(rye~1
grass)-pollen~1
(LPE)~1
16%.~4
84%~12
LPE~3
[Ab~1
+])~1
Ab~12
Lol~18
(Rye~2
allergy-enriched~2
361~2
LPE.~1
LPE,~2
responder~6
nonresponder~1
responders.~3
interrelationships~4
ST,~2
IgE,~3
allergen,~7
log-log~1
Ab.~1
commonality~1
Abs~1
allergen.~3
Log-log~1
points,~3
(98%),~2
(91%),~2
(83%),~2
Ia-restricted~1
Prepregnancy~1
healthy-sized~5
low-income~7
underweight,~2
overweight,~2
obese.~3
(MIC)~5
projects~4
Cleveland~7
Minneapolis.~1
Subsamples~1
sample,~14
prepregnancy~4
384~2
pairs~38
subsample~4
Minneapolis~1
Prenatal~2
gains~11
(newborns~1
3,000~8
4,500~1
MIC~8
lb~4
interviewed~29
Food~21
Stamps,~1
WIC~4
coupons,~1
cash~1
meals~21
public~35
Stamp~1
allotments~1
recall~12
recalls~2
food-buying~1
depleted.~3
bought~1
month.~17
nutrient~26
intakes~40
Recommended~4
Allowances,~1
diets~93
thiamin,~6
riboflavin,~5
B-12,~1
inadequately~4
B-6,~5
zinc,~11
pantothenic~6
beginning,~2
nutrition~54
intermittent,~2
continuous.~1
extended-care~1
facilities,~6
306~4
employees~24
life-style.~1
respondents~19
female,~5
married,~3
35.~3
checks,~1
seldom~14
infections,~27
leisure~6
activities,~17
felt~29
jobs.~1
smokers~77
average,~15
smoked.~2
Perception~2
overweight~8
skipped~2
Consumption~4
fried~2
foods~39
sweets~1
consumed~42
products.~12
employee~7
coffee~10
colas.~1
participants~42
alcohol.~16
away~35
home~60
exercise;~4
regularly.~3
fitness~15
sessions.~6
Occurrence~5
university~23
residence~8
hall~1
foodservice~6
entree~3
categories.~13
entrees~3
single-item,~1
combination,~10
roast.~1
2-week~5
span.~3
3,891~1
297~2
59.2%~1
23.3%~1
17.5%~2
delays.~1
single-item~1
roast~1
entrees,~3
prepreparation~1
entrees.~2
serving~8
0.9,~4
3.5.~2
1.4,~5
serving.~2
item~9
0.8.~3
Roast~1
minute,~2
0.6.~1
February~13
Institutes~4
sponsored~3
Consensus~2
Development~9
Conference~1
Implications~13
Obesity.~1
experts~5
tables~6
(BMI)~2
obesity~24
dietitian,~1
arise~27
select.~1
BMI~5
contradictions~1
1959~5
Metropolitan~6
Life~17
Insurance~4
height-weight~2
table.~2
California~13
dietitians~10
ethnic~15
Cultural~1
dietetics~4
curriculums.~2
Dietitians~3
Demographic~4
requested,~2
colleges~3
universities~4
offering~7
ADA~2
Plan~3
sent~14
goals,~2
methodology~14
enrollment~6
courses.~6
dietitian~2
(no.~8
184;~1
51%)~2
.05)~43
correct)~1
college~20
16;~3
93%)~1
universities,~3
Course~1
answers~6
questionnaire.~8
"ethnic~1
habits"~2
"disease~2
Competency~1
Oklahoma's~1
Dietetic~3
Support~7
Personnel~1
Training~6
Program~15
assure~12
graduates.~2
tests'~3
assured~1
elaborate~5
committee~8
validation~13
split-halves~1
criterion-related~1
non-parametric~1
workers'~2
employers'~1
on-the-job~1
ratings.~5
indexes~26
0.88~7
0.97,~8
consistency.~3
0.78,~3
destabilizing~1
postural~24
response:~4
Postural~3
Test~18
(PST).~1
Suitable~2
evaluates~7
appropriateness~9
Experience~19
elderly.~19
Systematic~4
multidimensional~4
Inventory~16
(FAI)~1
measurement,~4
needs,~6
purposes.~14
FAI~4
structured~18
rating~24
compares~25
descriptive~10
phrases.~2
areas:~2
resources,~8
(ADL).~1
ratings~41
interdisciplinary~4
team~24
(weighted~2
kappas~1
.583~1
.780)~1
ADL~4
.85)~1
rater~1
definition~28
ADL.~1
personnel~32
questions:~3
Can~1
Dementia~11
Alzheimer's~68
(DAT)~4
treated?~1
Does~2
status?~1
Do~2
coexisting~7
DAT~14
nondepressed~4
patients?~3
131~6
(31%)~16
met~20
DMS-III~1
affective~29
antidepressant),~1
mood,~2
vegetative~7
signs,~12
(ADLs)~1
record.~3
(measured~9
Folstein~2
Mini-Mental~2
State)~1
one-quarter~2
mood~21
ADLs~1
demented.~2
wheelchair~12
nursing~36
homes,~2
cognitively~2
walked,~2
wheelchair.~1
residents,~8
endurance,~2
vision~45
falling,~1
resident's~1
decision~50
mobility.~8
focused~23
resident~28
limitations~24
environment,~10
self-initiated~1
sense~29
well-being.~5
staff.~11
raises~21
understand~25
declining~17
1080~1
care/coronary~1
Autopsy~11
(70%),~1
(52%),~3
disturbance~28
(48%),~1
(45%),~2
(41%).~1
bore~6
prognoses~5
house~17
officers,~1
suddenness~1
marital~23
intensively~4
strikingly~11
demanding~5
honest~1
re-appraisal~1
restore~11
research,~15
dementia~65
attended~15
five-year~32
situation,~11
co-existent~2
worker,~1
neuropsychiatrist,~1
participation,~2
stay,~6
disposition.~2
observation,~8
ancillary~9
services,~9
specialty~24
clinics,~3
physicians.~23
assisted~11
social-nursing-recreational~1
Neuropsychiatric~1
management,~19
attendance~10
devised,~1
integrated,~2
supervised,~2
cooperation~16
physicians,~15
thyrotoxicosis~7
cardiac,~5
gastrointestinal,~2
neuromuscular,~1
neuropsychiatric~7
amenable~14
pursued.~2
admittedly~1
making,~1
suspecting,~1
elderly,~15
signs.~14
community-wide~2
hyperthyroidism.~3
Community-wide~1
falls~25
break-even~1
detector~5
(FT3I),~1
falsely~9
extrathyroidal~2
T4-to-T3~1
conversion.~2
ultrasensitive~1
statements~7
considerably.~6
hyper-~2
hypothyroidism.~11
discussions,~1
Alcoholic~5
annual~39
capita~2
hyaline~13
hepatitis,~20
non-A,~2
non-B~4
alcoholics.~11
Behcet's~5
(oral,~1
genital,~2
lesions)~3
manifestations,~8
episode~47
ileitis,~2
nonspecific;~1
Esophageal~7
Seventy-five~14
80-90~2
endoscopies.~1
emergencies)~1
endoscopies~1
sigmoidoscopies).~1
short-lived~3
complications;~2
vomiting~30
bleeding.~25
pyloric~8
esophagitis.~10
Bleeding~8
(8)~3
polyps~50
(7)~2
often.~1
same.~7
diverticula,~1
hernia,~4
radiologically.~3
radiologically,~3
endoscopy.~7
dumping~3
food,~7
nutrients~23
Baragwanath~1
Johannesburg,~1
appendicitis~14
10-19-year-old~1
bias.~8
Parasitic~1
ova~5
appendix~12
(3.6%).~1
Fecaliths,~1
diseased~19
appendices,~3
(50%-75%).~1
1,000~18
annually,~2
appendectomies~5
prevail~2
blacks,~8
fiber,~12
(nor~1
noninfective~2
diseases).~2
Inflammatory~4
(IBD)~1
background.~4
IBD.~1
Antiviral~1
IBD~3
weak-positive~1
(50%~9
CPE~4
1:10~1
serum).~1
antiviral~16
amnion~2
Wish~1
Intestine-407~1
sensitive.~6
jaundice~13
South~13
diagnostic.~7
Choledocholithiasis~1
gallstones~17
hepatitis.~11
hepatitis--five~1
hepatitis-B~1
positive.~22
cirrhosis).~2
postoperatively,~25
chemistries~2
worsen~6
anesthesia-related~1
tolerate~15
America,~6
Asia~4
industrialized~3
nations~2
twentieth~2
century.~1
amebic~6
abscess~64
emphasizes~26
versatility~3
roentgenologic~1
serologic~25
transendoscopic~1
incision.~10
discuss~35
variety.~2
hypertrophic~30
osteoarthropathy~4
enteritis,~1
association.~11
artifactual~3
Hypertrophic~2
enteritis~7
18-year-old~8
He~34
sulfasalazine~3
prednisone,~9
pericarditis~20
(IBD).~1
looking~6
celiac~18
sprue~1
sulindac.~1
promptly~15
re-administration.~1
drug-related~7
list~15
"flat"~1
Hibiclens~1
cleanser~1
enema.~2
invaluable.~1
soapsuds~1
chemical-containing~1
enemas;~1
soap~2
damaging~8
enemas~10
Cowden~3
(multiple~2
harmartoma~1
syndrome)~8
mucocutaneous~7
polyposis~11
case.~42
seven-year~5
Congenital~8
(Caroli's~1
disease)~12
cholangitis.~4
Caroli's~4
antemortem.~1
35-year-old~5
subphrenic~3
tree;~1
undetected.~4
Episodes~6
pyrexia,~1
carefully~47
attributing~2
Budd-Chiari-like~1
compressed~8
cava.~10
"sinus~1
histiocytosis~2
lymphadenopathy."~1
forty-six~4
strictures,~4
sinuses,~5
"fissures."~1
coincidence~6
strictures~28
stricture.~9
"Fissures,"~1
blind-ending~2
tracts~13
coat,~4
types.~28
fibromuscular~7
sinus.~9
bases~6
"acute~1
fissure."~1
fissures~4
steatosis,~3
cholinesterase~12
nonalcoholic~9
cutoff~7
limit,~5
overlaps~2
low-caloric~1
steatosis.~2
Prazosin,~3
1-adrenoceptor,~1
encephalomyelitis~4
(EAE)~1
Lewis~7
1-receptor.~1
leakage~35
(CNS)~8
[125I]albumin,~1
quantitation~21
passively~9
prazosin~34
suppresses~13
[125I]albumin~1
additionally~5
EAE.~1
validate~8
EAE,~2
1-adrenoceptor.~1
similarities~26
immunodeficiencies~3
CBA/N~2
X-chromosome-linked~1
inheritance,~2
antigens,~14
imbalance~16
subpopulations.~5
polysaccharides~3
predominantly,~1
exclusively,~2
subclass--IgG2~1
IgG3~5
mouse.~4
IgG2~6
seem~48
IgG2.~3
Quite~1
contrary,~6
subclasses,~1
Pertussigen~2
Bordetella~1
pertussis~11
delayed-type~4
(DTH)~3
pertussigen~3
antigen-specific~9
macrophage-activating~1
lymphokine(s);~1
lymphokine(s)~2
procoagulant~11
(mPCA),~1
activator~19
(PA)~12
Lymphoid~1
keyhole~3
limpet~3
hemocyanin,~1
ovalbumin,~2
gamma-globulin.~1
supernatants~18
monocyte-like~3
WEHI-265~2
mPCA~2
immunization,~5
enhanced;~1
specific.~10
IgG4~12
P1~3
Dermatophagoides~3
pteronyssinus~3
extracts,~6
cross-link~4
Previously,~4
IgG1~15
Sepharose-bound~1
preferential~13
Fab~13
solid-phase-bound~1
cross-linking~5
fluid-phase~5
incapability~1
bridge~12
phenomenon,~13
IgG1.~2
IgG1-~1
IgG4-containing~2
sucrose-density~1
gradients.~4
radioimmunoprecipitation~2
glycol~15
efficiently.~3
low-affinity~7
response;~2
probably,~2
underestimated~14
antibody-bound~2
Monoclonal~8
(mAb)~3
toxin-1~2
(TSST-1)~1
TSST-1,~1
mitogenicity~4
TSST-1~4
independently.~3
ascitic~8
mAb~13
isotypes.~2
IgG1,~2
IgM;~1
Immunoglobulin~6
hybridoma-generated~1
TSST-1-induced~1
immunosuppression.~4
IgG1)~1
toxin-induced~1
suppression.~7
neutralizing~8
cyanogen~5
bromide~14
(CNBr)-generated~1
aforementioned~3
mitogenic~19
dalton~4
CNBr~2
Infection~19
protozoan~3
parasite~17
Leishmania~21
host~56
membrane,~17
event:~1
(L-LPS)~1
(gp63).~1
L-LPS~3
operates.~1
(LRC-L119)~1
lacks~9
infective~26
gerbil~3
Kenya~2
phenotypically~3
L.~41
LRC-L119~3
analyzing~13
genome~5
major.~2
promastigotes~17
phagocytosed~7
major,~4
hr.~28
(V121)~1
confers~6
survive~11
Erythema~2
nodosum~1
leprosum~1
(ENL)~1
reactional~1
lepromatous~2
leprosy~3
suppressor~45
numbers,~4
reasoned~1
cyclosporine~23
(CsA),~1
ENL~1
CsA~13
leprae-triggered~1
ENL,~1
CsA.~1
ENL.~1
PFC~7
L-glutamic~2
acid60-L-alanine30-L-tyrosine10~1
(GAT)~1
acid50-L-tyrosine50~1
(GT).~1
I-J+.~1
GAT-TsF1~2
MHC-restricted~2
GAT-TsF2~2
obligatory,~1
idiotype-specific~2
spleen~41
(TsF1/TsF2)-induced~1
fused~8
AKR~1
thymoma,~1
BW5147,~1
GAT-specific~3
GAT~1
co-polymer,~1
GT;~1
idiotypes~9
Sepharose~7
hybridomas.~2
reactivities~5
anti-GAT~1
overlapping~6
identical.~6
activity;~6
bears~3
I-J~1
determinant,~2
possesses~11
idiotype-binding~2
molecule.~13
MHC-~1
Igh-linked~1
genes,~9
transcomplementation~1
F1~23
MHC-congenic~1
Igh-congenic~1
Mishell-Dutton~1
nonidentical~2
anti-idiotypic~7
NK-1.1(-)~6
anti-NK-1.1~1
adulthood.~5
Spleen~3
NK-1.1+~1
null~6
(Thy-1-~1
B220-)~1
NK~33
YAC~1
IFN-alpha~3
IFN-beta.~1
(BM)~1
precursors~27
cells:~3
BM~9
rIL~1
Qa-5,~1
Thy-1,~1
AsGm-1,~1
NK-1.1~1
NK-1.1-;~1
reconstituted~12
NK-depleted~1
recipients.~5
Lymphokine-activated~1
killer~14
spleens~5
NK-1.1-~1
ontogeny~2
lectin-induced~2
(NKC)~1
students,~13
outbreak~21
influenza~17
A/Philippines/2/82(H3N2)~1
febrile,~1
noninfluenzal~2
outbreak.~5
CD4:CD8~1
phytohemagglutinin~2
concanavalin~6
NKC~4
pokeweed~4
mitogen~12
leukocytosis~9
lymphopenia.~1
Lymphocyte~8
noninfluenza~1
incapable~5
CD3~1
CD2~1
reflective~3
Influenza-infected~1
neutropenia~12
influenza-infected~1
infected~107
(anti-Id)~1
thyroglobulin~8
(anti-hTg)~1
idiotype~9
Sera~15
thyroiditis~14
(HT),~1
(GD),~1
(RA),~5
(SLE)~5
anti-Id~6
anti-hTg~5
(McAb)~1
ELISA~28
Microtitration~1
McAb,~1
hTg~2
molecule,~4
sera.~10
peroxidase~21
IgG.~13
HT,~1
GD,~1
Tg-anti-Tg~1
SDS-PAGE,~2
McAb~3
1:243~1
1:2187.~1
hTg,~1
3403,~1
A-3,~1
F(ab')2~8
isolation.~3
3403~1
fragment,~6
Fc~15
react~18
antinuclear~7
cross-reactive~7
Sm~9
MRL-lpr/lpr~2
anti-DNA~3
anti-Sm~1
monoclonals~2
affinity-purified~3
(RIgG)~1
(HIgG).~1
cross-reactivities~1
antibody,~20
immunoabsorption~2
polyspecific~2
C11~3
(anti-DNA,~1
anti-Sm)~1
Sepharose-DNA~1
Sepharose-RIgG~1
RIgG~4
Sepharose-bovine~1
monomolecular~1
cross-reacting~10
C11;~1
64%,~2
33%.~4
Aggregated~1
HIgG,~1
Sm,~1
RIgG,~1
Ig.~2
autoantibodies~29
emerge~7
syngeneic~6
(HepSS-1)~1
methylcholanthrene-induced~1
fibrosarcoma,~1
Meth-A.~1
HepSS-1~13
human,~8
chicken.~1
iodinated~3
Meth-A~4
HepSS-1,~1
4B~3
sandwich-type~1
species,~21
heparan~13
glycosaminoglycan~7
(HS-GAG).~1
heparitinase~2
heparinase,~1
chondroitinase~2
ABC~1
hyaluronidase,~2
Second,~11
HS-GAG~5
GAG~1
(hyaluronic~1
heparin,~8
chondroitin,~1
chondroitin~5
4-sulfate,~1
6-sulfate,~1
dermatan~2
sulfate,~27
keratan~1
sulfate)~3
Third,~3
whale~1
omega-heparin,~1
O-sulfated~1
N-acetylated~1
glucosamine.~1
NIH~4
3T3~11
confluency~2
G1,~1
Kirsten-ras~1
oncogene~11
SV-40~2
density-dependent~2
epitopes.~3
Kirsten~2
non-permissive~1
temperatures.~7
elucidate~14
transformation.~6
Bombesin~2
neuroepithelial~2
oat~4
Monocytes-macrophages~1
share~25
macrophage-specific~1
bombesin-like~1
neuropeptides~6
bombesin,~3
neuropeptide~9
Adherent~1
bombesin.~1
radioimmunoassay,~7
immunohistochemistry,~3
monospecific~1
Schistosoma~3
mansoni,~1
200,000~5
schistosomulum~2
cercariae~2
miracidia~2
schistosomula~2
haematobium~1
bovis.~1
20,000~6
antigen;~1
cross-react~4
eggs~9
anti-Mr~3
isotype~6
complement-dependent~3
mAb.~1
vaccinated~7
cercariae.~1
Complementary~2
polypeptides~12
chromosomal~25
localizations~4
polymorphic~16
arrays~1
Following~82
panels~9
hybrids~6
C5-associated~2
H-associated~2
3.~17
inheritance~26
fragment-length~1
polymorphisms~10
Sas-1~1
Hc.~1
three-point~2
crosses,~1
turn,~7
cM~1
Sd~1
2.~39
loci~6
Cfh~1
C5,~2
genes.~10
binding,~12
C3b/C4b~1
(CR1)~1
detergent-insoluble~2
cytoskeleton~5
cross-linked~9
anti-CR1,~1
dimeric~6
C3b,~2
anti-CR1~2
goat~4
anti-mouse~1
F(ab')2.~1
CR1~7
monovalent~2
cytoskeleton.~2
MHC~22
Class~36
associated.~5
filamentous~4
actin~34
(F-actin)~1
extracted~39
Low~35
Salt-detergent~3
buffer,~5
FITC-phalloidin,~1
cytoskeletons~2
polymerized~2
F-actin,~1
F-actin.~1
neutrophils.~10
depolymerization~2
F-actin~12
DNAse~1
cytoskeletal-associated~2
CR1.~1
immunoadsorbed~1
CR1,~2
125I-actin.~2
CR3,~1
neutrophils,~13
indirectly~23
actin.~2
I-region~1
recombinants~8
(Is/Ik)~1
I-region-specific~1
strains,~16
B10.ASR1,~1
B10.ASR11,~1
B10.ASR12;~1
B10.S(9R)~1
B10.HTT~1
earlier.~8
reciprocal~11
orientation~31
too~44
kb~7
intron,~2
exon,~2
exon.~1
alleles~14
identical,~6
exons.~1
exon~7
S1~4
nuclease~2
intron~2
upstream~7
crossover.~1
k~12
haplotypes~14
1-beta~2
I-E~2
conserved~7
I-E-restricted~1
intron.~1
nonresponse~2
Cryptomeria~1
japonica~1
(Japanese~1
cedar)~1
(CPAg),~1
HLA-linked~3
(1).~6
anti-CPAg~1
isotype-specific~1
manner,~7
antigen-driven~1
clarified~5
HLA-DR~17
CPAg-driven~1
I-A~1
(Ir-genes),~1
anti-HLA-DR~1
monocyte-depleted~1
(PBL)~4
CPAg~5
HLA-DR.~1
PBL~5
nonresponders~8
Leu-2+3-~2
depleted,~2
Leu-2-3+~2
CPAg,~1
CPAg-specific~3
nonresponsiveness~1
(Is-CPAg).~1
Mapping~1
Is-CPAg~1
HLA-DQ~3
subregion~1
Natural~4
(NKCC)~1
dissemination.~3
stress;~2
impairs~13
NKCC.~3
postsurgical~11
NKCC~3
hind~20
amputation,~8
recover~16
Anesthetic~2
marrow,~5
Mixing~1
cell-to-cell~3
contact,~5
pyrimidinone~1
2-amino-5-bromo-6-phenyl-4-pyrimidinol.~1
prospect~5
NK-specific~1
immunotherapy~10
surface-active~3
haptenated~3
liposomes~15
surfactants~4
copolymers~1
hydrophilic~5
polyoxyethylene~1
(POE)~1
polyoxypropylene~1
(POP)~1
m.w.,~1
POE,~1
POP~3
POE.~1
tripeptide-enlarged~1
dinitrophenyl~1
phosphatidylethanolamine,~2
liposomal~1
hemagglutination~8
(PFC)~1
extents.~1
Block~2
flanking~4
POE~2
center,~13
adjuvant~60
adjuvants~3
(25R1)~1
liposome~7
surfactants,~2
polymer~13
immunogenicity.~1
Optimal~11
route.~11
Conclusively,~1
liposomes.~3
Nucleated~1
resist~5
attack~27
cytolytic~8
endocytic~1
exocytic~1
predominates,~1
vesiculation~1
sec~20
Ultrastructural~10
ring-like~2
"classical"~3
C9~6
sulfate-resistant,~1
m.w.~2
inaccessible~1
C9-specific~1
degraded,~1
internalization~5
proteolysis~3
Neutrophils~6
C3dg~8
CR2~1
(CR4).~1
immunofluorescence~19
Monocytes,~1
C3dg,~1
Binding~24
glutaraldehyde-cross-linked~1
1940~1
8),~15
660~7
3930~1
bound.~6
Activation~10
CR4~2
125I-C3dg~1
competitively~5
iC3b,~1
C3b.~1
elutriated~2
platelet-monocyte~1
complexes.~11
confer~3
C3dg-coated~1
particles.~4
leukocyte-derived~1
lipoxin~1
(LXA;~1
5S,-6R,15S-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic~1
acid)~8
(NK)~6
LXA~6
isomers~2
Dose-response~6
cytotoxicity.~4
6S-LXA,~1
6S-OH~1
configuration,~5
LXA.~1
6S-11-trans-LXA~2
11-trans-LXA~1
esters~19
6S-LXA~1
acids.~22
displays~6
clear-cut~8
stereochemistry.~2
conjugates.~7
polarization~8
Golgi~11
apparatus,~3
moves~4
ester~27
LXA,~1
apparati~1
oriented.~1
polarization.~1
NK-target~1
conjugate~15
Together~4
LXA-induced~1
act~52
disrupting~4
"signals"~1
Golgi.~2
Sequential~10
braziliensis~8
(VD5/25)~1
forms.~8
anti-L.~1
antiserum,~1
epitopes,~4
VD5/25,~1
promastigotes.~1
lysates~6
surface-iodinated~1
65,000~2
Mr,~3
unreduced~4
(GP65).~1
chagasi~2
promastigotes,~3
parasites~18
mexicana~10
VD5/25.~1
appears,~3
GP65~1
promastigote~1
leishmania~1
macrophage.~1
C3~13
microorganisms~13
antigen-antibody~2
covalently~7
C3b~9
C3-activating~1
"complement~1
activation"~1
histocompatibility~11
complex,~27
1q32.~1
dermatophytes~1
dermatophytosis,~2
spores~8
mycelia~1
mentagrophytes~9
inoculation~15
dead~20
mycelia.~3
pustules~3
inoculated~20
C'~3
(PMN)~6
chemoattractant,~2
Spores~1
mycelia,~1
activate~18
C'.~1
dermatophytic~1
dermatophyte.~1
dermatophyte's~1
chemoattracting~1
PMNs~6
fungus-laden~1
stratum~32
corneum.~5
X-linked~20
Tabby~1
mimics~9
sex-linked~2
anhidrotic~1
(hypohidrotic)~1
ectodermal~6
(Christ-Siemens-Touraine~1
CST)~1
anhidrosis,~1
CST,~1
Tabby.~1
perspire~1
volar~12
plantar~28
paws,~1
hemizygous~3
Ta/Y~1
anhidrosis~1
glands,~12
sufferers~3
CST.~3
melanocytes~10
hampered~10
fastidious~1
melanocyte,~1
cultivate.~1
melanocyte~6
(MGF),~1
mitogens.~1
foreskin-derived~1
melanocytes.~5
MGF~2
30-fold~2
Cholera~1
another,~7
escape~15
modulation;~1
conferring~1
Improved~10
insights~7
keratinocytes~15
membrane-associated~4
thioredoxin~4
spin-labeled~1
saturating~4
found:~5
Cultures~8
thioprotein~1
parachloromecuribenzoate~1
dinitrochlorobenzene).~1
Stratified~2
Product~4
NADP+~1
inactivated~6
vitiliginous~1
UV-generated~1
reductase.~1
Sebaceous~1
wax~10
acylceramides~2
Fatty~3
(FAME)~1
esterified~10
linoleate~7
(18:2~2
9,12),~1
sebaleate~2
5,8),~1
sapienate~1
(16:1~1
sebum~10
sustainable~1
(WESR)~1
forehead~5
esters/(cholesterol~1
esters)~1
[WE/(CH~1
CE)]~1
lipid.~4
FAME~2
sebaleate,~1
WE/(CH~2
CE)~1
WESR.~1
CE).~1
acylceramides,~1
replaced~39
sapienate,~1
sebum.~1
sebaceous~7
lipids.~8
Colloidal~1
staphylococcal~13
(SpA)~1
high-resolution~15
visualize~10
colloidal~10
SpA,~2
gelatin~9
glutaraldehyde-fixed,~1
plastic-embedded~1
rabbit,~9
mouse,~6
keratohyaline~5
epidermis,~6
phosphorus-rich~1
(PR)~6
sulphur-rich~1
(SR)~3
PR~25
particles,~7
SR~12
unlabeled.~2
cornified~7
lucidum).~1
protein-conjugated~1
clear.~11
charged~11
particles~43
electrostatic~3
Frozen~2
cryosections,~1
thick,~2
layers.~9
dried,~1
chloroform-methanol~1
chromatographed~1
silica~8
spraying~3
sulfuric~1
charring,~2
densitometer.~1
layers,~6
extending~34
surface,~17
ceramides~2
Glucosylceramide~1
acylglucosylceramide~1
granulosum~1
corneum~17
abruptly~10
theories~10
adhesion~23
Cow~1
snout~1
digested~8
0.25%~3
trypsin~17
Percoll~5
centrifugation.~7
fluidity~14
5-doxyl~1
stearic~1
(5-DSA)~1
parameter(s)~1
decreased:~1
0.632;~1
0.645;~1
horny~2
0.680.~1
plasma-spreading~1
glycoprotein,~9
epibolin~5
kD~15
serum-spreading~1
vitronectin),~1
component,~17
coepibolin,~1
spreading~20
spreading,~1
coepibolin~5
epibolin.~1
entirely~38
purified,~2
associates~1
others;~1
certainly~5
(BSA)~3
ovalbumin~2
phorbol~20
ester,~3
12-tetra-decanoyl-1-phorbol-13-acetate~1
(TPA)~2
TPA~12
BSA~11
ovalbumin.~3
Coepibolin~1
associate~6
tumor-promoting~1
phorbol-12,13-didecanoate,~1
non-tumor-promoting~1
isomer,~1
phorbol-4~1
alpha-phorbol-12,13-didecanoate,~1
proteinaceous~2
plasma-derived~1
cofactor~6
spreading.~1
acetone/ether~3
5-20~5
enduring~3
days),~9
chapped~1
scaly~2
water-holding~4
sebaceous-rich~1
(SL)~3
10-min~9
(SCL)~1
lipid-depleted~1
SCL~3
squalane~1
alpha-monomethyl~1
heptadecyl~1
glyceryl~2
ether~8
(GE)~2
conductance,~4
scaling~6
nontreatment~1
GE/squalane~3
base,~8
SL~5
scaling.~1
chromatographically~1
Out~7
fractions:~1
glycolipids,~1
ceramide,~2
ceramide~1
base.~5
glycolipids~1
all.~9
strengthen~3
intercellular~19
corneum,~2
intact,~5
viable,~2
Follicles~1
freed~2
surrounding~64
shearing,~1
loosely~2
fitting~10
scissors,~1
gentle~7
sheared~1
dermis~23
capsule~35
encircles~1
hair.~3
isolation,~8
retain~11
autoradiography.~4
plucked~2
affords~6
follicles,~2
resort~2
appendages~4
dermis.~15
middle-wave~1
(UVB)~1
UVB-irradiated~1
BALB/c~14
degranulator~1
ears~37
min-7~1
sunlamp~1
(10-100~2
mJ/cm2).~1
compound-evoked~1
(ESR)~4
degranulation~15
mJ/cm2)~2
postirradiation,~1
mJ/cm2.~1
5-hydroxytryptamine~6
UV~11
counts~79
(200-500~2
tremendous~4
cell/vasoactive~1
degranulator.~1
Vascular~19
Merkel~12
debate,~2
immigrated~1
dermal,~2
nerve-associated~1
fetuses,~4
epithelium-type~3
cytokeratins~1
17-week-old~1
fetus,~6
(epidermal~1
dermal)~1
compartment,~6
14-week-old~1
3.9%~5
dermal-epidermal~3
junction.~11
Thirteen-week-old~1
Twelve-week-old~1
section~77
7-~2
9-week~1
embryos,~1
recognized.~14
stages,~6
cytokeratin~4
polypeptides.~4
speak~1
crest-derived~1
passage.~4
arise,~2
8-12,~1
cytokeratins.~1
detach~1
migrate~4
scleroderma~11
aminopropeptides~4
(Fab~1
assay).~1
organs~43
aminopropeptides.~2
antibody-based~1
aminopropeptide.~1
visceral~26
leishmaniasis~4
endemic~13
Brazil,~2
perspectives~3
leishmaniasis.~4
segregated~4
20),~2
kala-azar~2
serology~6
15).~9
disease;~27
(25%)~13
(75%)~21
hepatomegaly,~3
splenomegaly,~5
fever.~8
Malaise~1
Giemsa-stained~1
kala-azar.~3
muramyl~3
dipeptide~1
(MDP),~2
streptococcal~15
peptidoglycan,~1
rheumatic~29
(ARF).~3
enzyme-linked~28
immunosorbent~31
multivalent~1
MDP~4
54~72
ARF~12
poststreptococcal~4
MDP,~1
hemolysis~29
rubella~19
virus-specific~2
characteristically~8
6,723~1
99.0%.~1
97.3%,~1
serodiagnosis~1
(increase~1
IgM)~1
91.2%.~1
convalescence~2
(70-310~1
symptoms).~3
Soft~9
70-100~1
virus,~20
serodiagnostic~1
principle.~4
Igm~1
iontophoresis,~1
20-~3
60-fold.~1
orolabial~1
herpes~36
study:~5
vidarabine~1
(ara-AMP),~1
acyclovir~17
(ACV),~1
NaCl.~2
Ara-AMP-treated~1
ACV~1
Ara-AMP~1
shedding~8
crust~1
trend~43
ara-AMP~1
institution~55
(2.4%)~3
seroconverted~3
539~1
person-years.~1
B;~5
disability~26
$7,772.~1
seroconverters~2
alanine~35
aminotransferase,~7
converters~1
alone;~6
client~5
contact.~6
Difficulty~2
nonoccupational~1
institutional~4
seroconversions~2
acquired.~3
vaccine~39
client-care~1
personnel.~10
(EQ)~1
(EDR)~1
"ideal"~3
11.9~6
"normally"~1
100.~1
normalizing~2
1539~1
232~5
EDR~2
embryo-quality~1
eventuate~1
EQ~2
(2-4)~1
above-average~2
(EDR~1
129).~1
Poor-quality~1
underrepresented~1
inferences~5
2.73~2
cycle),~1
substantiated~5
freezing,~3
day-to-day~5
bacteriologic~10
(ARF)~4
(AGN)~1
southeast~1
district~6
Santiago,~1
Chile,~1
1978,~4
1982.~18
AGN~4
postpharyngeal~1
postpyodermal~1
neighborhoods~1
socioeconomic~30
streptococci~9
household~13
contacts~9
contacts.~3
throat~7
colonization~14
geometric~24
anti-streptolysin~1
O~14
noninfected~5
Streptococci~1
M-type~1
rheumatogenic~1
(representing~4
never~55
AGN,~1
milieus~1
emerge.~1
exploration.~10
portasystemic~3
hyperkinetic~2
microsphere~12
shunts,~4
Portal~7
tributary~2
shunts;~1
se.~4
Spontaneously~1
(WKY)~9
Previously~7
(1,25[OH]2D3)~1
inappropriately~9
ionized~22
hypocalcemia~16
WKY~21
(51.5~1
82.3~1
14.1~6
0.06).~4
U/hr~2
hours)~23
504~4
1016~1
211~6
mumol/hr/100~1
thyroparathyroidectomized~2
121~25
557~1
(83~7
hypophosphatemia~3
nitrogen/urine~1
(UUN/UCr)~1
"spot"~1
UUN~2
nitrogen,~8
Strategies~4
inexpensively~1
quinidine-induced~2
thrombocytopenia~31
quinidine~45
epinephrine-induced~5
aggregation,~11
hemostatic~12
2-adrenoceptor~5
tritiated~13
yohimbine~10
2-adrenoceptors~3
KD~5
aggregation.~6
arachidonate~1
combination.~8
phagocytes.~2
Cigarette~3
(AM).~1
AM~13
43.0~2
7.7~13
12.8~5
nmol/1~1
nonsmokers,~5
smokers'~3
internalization,~1
iron-saturated~1
nonsmokers.~4
smoking-related~4
fate~11
internalized~6
iron.~9
Iron~10
cytoplasmic,~1
ferritin-associated,~1
smokers,~7
11.0%~2
59Fe~3
36.0%~1
2.3%~5
tauroursodeoxycholate~1
(TU)~1
(Tm)~1
sulfobromophthalein~4
(BSP)~2
BSP~8
TU~7
mumol/min/100~4
Tm~5
equimolar~11
(TC).~1
(1.2~7
(0.6~6
gm).~1
gm),~1
TC~1
Tm,~1
TC.~2
storage)~1
BSP.~1
Baumgartner~4
apparatus~25
subendothelium~4
microvesicles~4
SKNMC~2
(human~4
neuroblastoma)~1
aggregate~7
diphosphate~6
(ADP)-dependent~1
U87MG~3
glioblastoma)~1
thrombin-dependent~1
inducing~22
thrombogenesis~2
undigested~3
alpha-chymotrypsin-digested~1
subendothelium.~3
Thrombus~3
sevenfold~4
microvesicles.~1
thromboembolic~31
(CAM/CCR)~1
controversial~11
invoked~1
explanations.~2
character~8
pancreatitis.~33
mg/24~10
Proteinuria~3
9/9~1
10/10~2
hr,~25
8/9~1
10.9~6
Twenty-one~29
CAM/CCR~1
pattern.~34
permeability.~9
2/4~1
concentrated~13
enters~7
pancreatitis,~11
which,~23
filtration,~6
malfunction~6
hyperbilirubinemia~6
phototherapy.~4
hyperbilirubinemia.~2
closer~10
333~1
teaching~50
practice~143
comparison:~1
Family~31
Practice~8
Center.~14
mix,~2
charges,~1
consultants~4
cost-efficient~1
unit,~9
exceptions~2
introduction~34
expenses~2
College~16
Physicians~30
Canada~6
office~20
candidates~29
certification~7
certificant~1
college.~1
outline~6
residents'~3
interviewing~10
prepare~7
practice.~41
nanogram~2
picogram~1
cocaine~58
equivalents~2
perspiration~1
stains,~1
bloodstains,~1
radioimmunoassay.~13
chromatographic/mass~1
spectrometric~2
(GC/MS)~2
9-tetrahydrocannabinol,~2
11-hydroxy-delta~1
11-nor-delta~2
9-tetrahydrocannabinol-9-carboxylic~2
homicide~15
drivers~18
Bexar~1
1985~34
cannabinoids.~2
130~31
homicides~5
victims,~4
(34%),~2
drivers,~5
(28%),~6
motorcycle~3
drivers.~2
Ethyl~1
55%~25
Drugs~3
cannabinoids~4
nondistorted,~1
phosphoglucomutase-1~5
subtyping~2
bloodstains.~1
0.2-mm-thick~1
interelectrode~1
wick~1
(w/v)~1
N-(2-hydroxyethyl)~1
piperazine-N-3-propanesulfonic~1
(EPPS)~1
ampholytes~1
(4%~2
w/v).~1
laboratory-prepared~1
bloodstains~3
typed~4
typing~13
casework~1
FBI~1
Laboratory.~1
discriminating~15
subtyped,~1
calls~10
(65.6~1
36.2%)~1
dried~5
(16.4~1
13.1%)~1
vitreous~52
freezing~13
autolysis~2
Noradrenaline~1
(NA)~3
(44.2~1
ng/mL).~2
Autolysis~1
33.5~1
ng/mL,~4
ng/mL.~5
autolysis.~4
Adrenaline~2
(A)~2
(3.9~7
ng/mL)~1
NA~5
19.4~5
6.9~17
109~25
57.3~1
ng/mL),~4
twentyfold~1
213.2~1
168.7~1
eightfold~4
tenfold.~1
Concerning~2
noradrenaline~18
vitreous,~3
interpreting~6
notch/acetabular~1
consistency~14
comprising~17
notch~4
discriminator~2
tissues,~30
craniometric~1
Vienna,~1
Austria.~1
skull,~5
prominence~4
ossa~1
nasalia,~1
40%.~6
nutrition,~7
mimicry,~1
forth,~1
depths~3
extent.~15
thinner~8
ones.~9
adjust~6
disharmonies~1
profile.~5
toxicology~4
examiner~11
autopsies~9
Pima~2
County,~6
Arizona,~4
toxicologic~2
deaths,~12
accident~24
fatalities,~2
homicides,~1
suicides.~1
thin-layer~4
chromatography,~9
swabs,~1
benzoylecgonine~1
Marked~8
cocaine/metabolite~1
legal~23
spouse~8
Domestic~1
violence~5
accept~5
violent~18
normative.~1
characterizes~5
battered~3
encounter,~2
patterns,~8
explores~6
dynamics~21
abusive~1
relationship,~6
discusses~20
compel~1
relationships.~8
addresses~3
"battered~1
syndrome"~5
defense~17
spousal~5
homicide.~2
neglected~6
husband.~2
harm~4
parents,~5
doctor-parent~1
relationship.~9
Overdiagnosing~1
harmful~10
security~1
forensic~12
psychiatrist~2
files~5
203~7
facility.~9
Nearly~11
pretrial~2
defendants~1
proceeding~3
malingering~1
prison.~1
glyoxalase~1
esterase~13
phosphoglucomutase~3
bloodstain~1
Bloodstains~1
Trace~3
reassembled.~1
places~9
skeletons~2
magnesium/zinc~1
zinc/sodium,~1
magnesium/sodium,~1
chromium/sodium~1
reassemble~1
belonging~7
Mid-facial~1
orthodontic~1
Statistical~16
dental~23
reconstructions.~2
Sudden~3
Death~8
(SIDS)~1
dicyclomine~5
ng/mL~11
infantile~14
colic,~3
coma.~3
200-ng/mL~1
SIDS~2
categorization~4
SIDS.~1
punishment~1
lying,~1
foster~6
five-year-old~3
poured~1
pepper~4
throat.~1
dyspneic,~2
apneic,~1
pepper.~2
Mechanisms~6
asphyxia~10
volatile~9
oils~2
Histopathologic~14
bites~11
gunshot~18
entrance~12
presternal~2
stab~18
screwdriver.~1
traumatizing,~1
perforating~7
agencies~6
bullet's~1
crushing~4
power,~5
morphine~64
ingestion,~6
Morphine~6
rotenone~3
three-and-a-half-year-old~1
partitioning~9
cleanup~1
exposures~30
insecticide~3
organophosphorous~1
chlordane~2
heptachlor.~1
neuropathy.~25
toxicity.~33
casual~4
Presented~6
deliberate~2
(V).~1
Blood,~2
urine,~19
(GC-NPD).~1
Identification~3
norverapamil~1
(NV)~1
presumptive~10
o-demethylnorverapamil~1
(DNV)~1
subcapsular~7
hematoma~36
thrombophlebitis~6
Vietnam~8
War~5
prisoners~1
war~1
(POWs),~1
332~3
Air~3
Force~7
flyers~1
maltreatment,~1
confinement,~1
boredom~1
coping~17
styles~4
USAF~1
POWs~1
successful/unsuccessful~1
stance~8
captivity~1
prisoner~1
repatriation.~1
Findings~17
style~3
postrepatriation~1
Postrepatriation~1
MMPI~17
personality~42
intake.~35
therapist~9
integration,~1
unintegrated~1
emotional~31
integrated.~1
Psychodynamic~1
psychotherapy~5
hypnosis~1
proceed~10
acceptance~15
integration.~2
hindered~1
repression~2
denial,~1
secrecy,~1
crises.~1
countertransferences~1
anger,~4
exasperation,~1
exhaustion.~3
tedious~2
consuming,~2
eminently~1
persevere.~1
high-functioning~1
competence,~5
neurotic~1
psychoanalysis.~1
misdiagnosed~10
Dissociation~2
thoughts,~2
feelings,~3
stream~6
memory.~2
Dissociative~1
Experiences~2
Scale~44
(DES)~2
items~36
interviews,~7
consultations~13
dissociation.~2
Pilot~3
refine~2
wording~1
format~8
scale.~12
28-item~1
self-report~12
slashes~1
100-mm~1
continuum~5
(age,~5
occupation,~4
education)~1
DES~2
score.~7
alcoholism,~14
agoraphobia,~1
phobic-anxious~1
posttraumatic~27
disorder,~45
schizophrenia,~3
Reliability~2
test-retest~6
split-half~1
reliability.~5
Item-scale~1
construct~6
validity.~5
Kruskal-Wallis~2
post~23
hoc~1
scale's~1
criterion-referenced~1
validity.(ABSTRACT~1
(types~3
(HbA1)~2
Seventy-one~5
criteria-defined~1
illness;~3
.02)~7
10.8%)~1
psychiatrically~4
9.6%).~1
.0001~1
HbA1~4
.25)~1
poorer~18
Interview~7
Schedule~7
(DIS),~1
underdiagnosis~2
mellitus.~15
(total~15
296,~1
discounted,~1
6.7%~2
increase)~4
significant;~3
DIS~6
illnesses~15
Parts~3
Kingdom~5
incidence,~15
world.~8
ascertainment~4
standardised,~1
declined,~4
ascertainment.~2
England~13
(63/10(5)),~1
Ireland~3
(76-79/10(5)),~1
Wales~2
(c.~1
113/10(5)),~1
North-East~1
Scotland~6
(155/10(5))~1
Orkneys~1
(258/10(5))~1
HLA-DR2~4
(21-50%).~1
However~10
Scotland,~2
Kingdom,~1
concurrence~3
conversely~2
Orkney~1
Islands,~1
hypothesis.~8
Eighty~19
neuritis~6
(32%)~18
Actuarial~17
neuritis.~4
21-40~1
HLA-B7~1
HLA-DR4~1
Cerebral~27
cysticercosis~4
infestation~7
infestation,~1
paying~4
hydrocephalus~18
long-standing,~6
responds~9
praziquantel~8
hydrocephalus,~5
supratentorial~13
cysts,~9
granulomata~1
aggressive,~5
subacute~27
gait~28
disturbances,~11
palsies,~3
hemisphere~27
syndromes,~9
meningitis~23
stroke.~20
stabilised~3
carbamazepine~13
viloxazine~4
carbamazepine-10,11-epoxide~2
(16%).~1
intoxication,~3
regressed~9
viloxazine.~1
10,11-epoxide~1
197%~1
137%~1
antidepressants~6
carbamazepine.~1
epoxide~1
Fast~2
analysed~33
requested~9
draw~5
tablet~13
triangles~1
burst~26
figures~31
trace~18
pauses~5
vertices~1
ballistic~1
trajectories.~1
VEPs~4
Parkinsonism~1
Parkinsonian~8
VEP~15
square~14
grating).~1
Parkinsonism).~1
differently~13
latency,~4
stimulus.~13
haloperidol~12
perisylvian~2
cortico-subcortical~1
thalamic~5
linguistically~1
semantically~1
loose~13
writing.~2
prompting~5
semiautomatically.~1
hypergraphia~1
Passive~7
displacements~5
torque~20
Stiffness~3
Nm/radian~1
"normal"~12
("neutral"~1
angle)~1
"tone"~1
rigidity~12
spasticity.~2
reproducibly~7
"tone",~1
motor.~2
(previously~2
reported)~1
(92~9
degrees)~5
normals~16
(107~2
degrees),~2
stiffer~1
place,~5
flexed~2
stiffness.~2
antirigidity~1
followed.~10
Fluctuations~2
psychic~1
"mobile"~1
"immobile"~1
"end-of-dose~1
deterioration".~1
mobile~17
immobile~3
fair~17
behaviour.~4
Temporary~4
immobility~1
activation,~17
pinch~3
dorsum~4
Charcot~1
arthropathy.~1
Vibration~2
thresholds,~3
potentials,~15
flexor~17
digitorum~8
brevis,~1
Pinch~1
insensitive~12
Subacute~2
folate~35
Disturbance~1
B12~16
Methyl~1
tetrahydrofolate~2
folic~6
transported~24
CNS.~3
theoretically~9
advantageous.~3
haematological,~2
calibrate~3
spectrometer~2
premixed~1
vapors~6
cylinders,~1
mixer~1
resistances~10
tubings~1
diluting~1
noting~2
Empiric~1
viscosity,~2
air,~10
oxide,~7
dioxide,~3
anesthetics~15
resistor.~1
solenoid~1
multiplexed~1
rooms.~2
Oxygen,~1
halothane,~17
vaporized~4
50-ml~3
vaporizers.~1
calibrations~1
2%.~5
oximetry~11
catheterization.~21
0.95)~2
y~9
0.91x~1
8.1.~1
0.93x~1
6.0)~1
cyanotic~14
saturation.~3
cathode~4
polarographic~4
electrode,~5
drift~12
heated~11
drift,~1
Transcutaneous~2
sensors~5
calibrated~10
157~15
(room~1
rechecked~1
sensor~14
208~9
463.6~1
administered:~1
isoflurane,~8
oxide-narcotic,~1
local/regional.~1
recalibration~2
Hg.~39
Room~1
enflurane.~4
manufacturer's~4
specifications.~1
(AIS)~1
anesthesiologist~6
anesthesiologist-computer~1
user~8
AIS~5
touch-sensitive,~1
screen.~2
touching~4
virtual~3
keys~1
window~6
automatically~6
temperatures,~5
manually~6
ventilator~8
settings.~21
ray~4
pages.~1
distributor~1
page~1
gives~27
page.~1
one-page~1
multicolor~1
plotter~1
interfering~9
imitated~1
anesthesiologist's~1
responsibility~11
anesthetic.~4
avulsion~7
oscillometry~1
prone~36
Epidermal~4
shearing~3
avoided~32
wrapping~2
gauze~1
cuffed~1
arm.~10
monitors~11
multitude~2
today.~4
Monitoring~10
problems,~34
hard~14
monitors,~1
negligible,~1
misuse~4
difficulties,~3
abandon~1
modality.~8
Regular~5
electroencephalogram~4
clinicians~21
familiar~13
interpret~10
disaster~12
(such~15
hypoxia)~1
high.~9
dollars~5
malpractice~5
award~1
buy~1
monitors.~4
art~3
mid-1980s~1
capnography~1
oxygenation.~9
negligible-risk~1
feasible.~4
design,~12
formats~1
MDS~6
331~3
43%.~2
(51%),~2
leukemia.~12
Chromosomal~1
analyzable~2
metaphases~2
(79%;~1
group).~12
metachronous~15
therapy-related~1
(43%~1
v~36
18%),~1
karyotypes~4
(18%~3
50%).~4
Chromosome~5
alkylating~2
procarbazine,~1
nitrosoureas~1
(72%~3
83%),~1
cyclophosphamide-based~1
(29%),~6
chemotherapies~1
(14%),~6
(29%).~2
Survival~29
weeks);~3
category,~2
evolution~42
antileukemia~1
(CR).~2
(MDS~1
leukemia)~1
blasts~2
(IBC).~1
(RT)~7
(170~1
1975,~8
(control,~3
RT~24
(45~10
boost)~1
chemotherapy:~3
Adriamycin~19
(Adria~5
Laboratories,~11
Columbus,~7
Ohio),~1
vincristine,~9
(AVM)~3
cyclical~5
schedule;~1
cyclophosphamide,~17
5-fluorouracil~21
(5-FU)~5
(VCF).~1
1982,~21
Adriamycin,~4
methotrexate,~16
5-FU~9
(AVCMF)~1
VCF~6
Hormonal~4
Disease-free~1
.005~3
.00001~2
.01~5
B).~11
74%~24
.17~1
.001~5
aggressiveness,~3
course)~1
important,~13
IBC.~1
1978~29
1981,~15
463~3
operable~6
Ludwig~1
Breast~7
Cancer~30
(Ludwig~1
III)~12
chemoendocrine~3
5-fluorouracil,~4
(CMFp~1
T)~4
prednisone~33
year,~31
mastectomy~26
(observation).~1
(DFS)~3
CMFp~3
.0001),~4
(OS)~2
.16;~1
.07).~1
life-oriented~1
endpoint~2
(TWiST).~1
discount~1
postmastectomy~2
TWiST~2
Adjuvant~5
emerging~7
OS~2
(120~8
mg/m2~19
etoposide~7
non-small-cell~4
(NSCLC).~1
standard-dose~1
arm;~1
myelosuppression)~1
cisplatin.~6
progression,~6
five-day~7
(CDDP)~1
hypertonic~14
saline,~16
myelosuppression~7
neurotoxicity~7
(NSCLC),~1
delivering~16
(200~14
mg/m2)~5
schedule.~10
pilot~28
mg/m2.~8
schedule,~4
neuropathy~60
(6%).~4
(eight~15
platinum~6
Accumulation~4
ultrafiltrate~12
encouraging,~4
CDDP~1
NSCLC~1
neurotoxicity,~2
multicenter~9
(A~4
[Adria~1
OH]).~1
(22~18
67),~2
(CRs).~1
death;~3
violations.~3
Toxicity,~1
nonprotocol~5
adherence,~4
5-FU,~3
mitomycin~2
(FAM).~1
Forty-two~13
intransit~2
mechlorethamine~2
(nitrogen~2
mustard).~1
12)~12
years).~67
follows:~43
(CR)~9
none;~1
CR~20
19.~1
16,~11
21,~8
33,~4
Relapse-free~1
(RLN)~2
RLN-negative~1
RLN-positive~1
perfusions~3
satellitosis~1
chemotherapeutic~16
prompted~21
cloning~12
Slopes~3
steepest~1
small-cell~10
flat.~1
Suggestions~4
melphalan~10
neck,~14
cancer;~10
mitoxantrone~1
Prospective~11
Hexamethylene~1
bisacetamide~1
(HMBA,~1
NSC~1
95580)~1
polar-planar~1
leukemic~12
nonleukemic~1
HMBA~6
g/m2/d.~1
Dose-limiting~2
hyperchloremic~1
acidemia/acidosis,~1
manifested~48
agitation~4
delirium,~3
Moderate~7
myelosuppression,~2
mucositis,~1
elimination.~2
6-acetoamidohexanoic~1
74%)~1
g/m2/d,~1
mmol/L,~5
approaching~10
effectiveness,~3
differentiation,~9
renal-cell~1
radiation,~12
methyl-methacrylate~1
Preoperative~30
hypervascular~6
comparable,~6
(64%~5
44%).~2
benefitted~2
neurologically~21
(70%)~17
(45%).~2
(before~4
feasible~23
outcome,~14
integrate~4
context~20
tasks,~3
(LPC),~2
P300,~1
scalp-recorded~3
attentional~9
LPC~9
monkeys.~18
auditory~68
(AEP)~1
concussion~1
percussion~8
percussion)~1
steel~17
screws~5
AEP~2
recording)~1
skull.~2
paradigm~6
LPC.~1
Pupillary~2
tones.~1
discriminable~2
tones~1
tail~10
(tone-shock).~1
tone-shock~1
presentations,~3
inferred~9
pupillary~20
dilation.~4
alerting~1
enhanced,~3
tone-shock.~1
concussion.~1
reflexes,~9
coordination,~3
orienting~1
disrupt~2
higher-order~1
Tethered~2
cord,~20
tethered~6
incontinence.~15
elongated~11
anchored~3
thick~24
filum~2
terminale~2
structures.~26
extensibility~2
lumbar,~3
sacral,~2
coccygeal~2
overstretching.~1
elongate~1
dentate~15
ligaments.~3
correspond~12
traction.~4
tethering.~1
mid-basilar~3
neck.~21
Balloon~15
detachable~5
occlude~4
alert.~1
pontine~10
cerebellar~27
challenging~6
chondroma~1
76-year-old~7
Chondromas~1
schwannoma~9
cauda~8
equina~7
discrepancy~23
myelography,~2
equina.~1
cavernous~16
angioma~2
28-year-old~2
low-back~10
headache~17
Lumbar~5
vascularity.~2
Metrizamide~4
Laminectomy~2
L1-3~1
25-year-old~5
pachymeningitis~2
hypertrophica~1
radiculopathy.~3
Decompressive~1
improvement.~33
neurosurgical~9
sphenoidal~1
utilizes~7
cavity,~8
2-mm~5
blunt-tipped~1
suction/cutting~1
(nucleotome)~1
vitrectomy~17
instrumentation~16
ophthalmic~33
guidance.~5
nucleotome~1
instrumentation,~4
landmarks~4
herniated~16
L3-4~2
L4-5~5
level)~2
failed.~10
fragments.~13
contraindicated~8
extruded~3
herniations~2
L5-S1~5
pending~3
161~12
saccular~11
21.3~3
mm,~28
institution.~14
rupture,~7
715~4
obliterated~6
(3.8%~1
cases).~20
obliterated,~1
rebleeding~4
0.14%~1
on.~6
87~23
premonitory~2
leak.~4
44.4~1
cases),~37
communicating~8
pericallosal~2
ipsilateral,~1
hemicranial,~1
hemifacial,~1
periorbital~7
saw~6
physician,~6
leak,~7
53%.~4
misdiagnosis~3
on,~4
puncture,~2
unrecognized,~3
unreliable~7
event,~6
unclippable~3
balloons,~2
65;~2
artery,~54
supraclinoid~4
basilar~19
aneurysms,~9
circle~9
Willis~2
xenon~7
heparinization~3
desired~14
instantaneously~1
deflation~5
embolic;~1
deflation.~1
balloon,~4
events;~4
(1.5%~1
morbidity).~1
Extracranial-intracranial~2
proof~4
thrombosis.~25
trapping~6
trapping.~3
convenient,~4
indolent~6
melanin-producing,~1
encapsulated,~1
benign-appearing~3
trigeminal~25
9-year-old~4
boy.~7
subtotally~3
melanocytomas.~2
craniopagus~4
twins~24
joined~3
temporoparietal~4
craniopagus.~1
scalp,~4
dura.~2
three-step~3
sheets.~2
expanders~1
closure.~13
dural~6
Cerebrospinal~6
lumboperitoneal~1
ventriculoperitoneal~6
twin~23
developmentally~4
connections~13
twins.~10
therapeutic,~2
medulloblastoma~1
60%,~7
recurrence-free~8
Seventy-two~10
differentiation.~13
34%~13
under.~1
(72%)~14
resection.~49
Chang~1
fossa~19
mater~7
804~1
cheap,~2
plentiful~2
everyday~7
Annual~6
inspection~12
sterility~2
immunogenicity~4
18-year~3
craniotomy~12
inconclusive~2
gender~25
exercise-redistribution~2
201Tl~4
bilinear~1
interpolative~1
subtraction~17
proportionately~9
Faster~1
ascribed~13
sex-specific~4
infection,~96
sensitivity,~24
312~4
sixty-nine~3
antibiotics;~1
143~8
antibiotics.~27
88.7%~1
therapy;~13
92.1%~1
Scintigraphy~3
metaiodobenzylguanidine~2
MEN~4
adrenomedullary~3
mentioned~11
pathologies.~5
[99mTc]RBC~1
63-yr-old~1
intrahepatic~21
"reversed"~1
extrahepatic~27
(these~3
mesentery~3
bowel).~1
angiosarcomas.~1
angiosarcomas~1
hemangiomas.~2
Indium-111-labeled~2
44-yr-old~1
Four-~1
twenty-four-hour~1
abdomen~26
photopenia~2
rim~17
medially.~1
rim.~2
Exploratory~1
necrotizing~20
Wegener's~3
granulomatosis~3
iodinate~1
vial,~1
1,3,4,6-tetrachloro-3a,~1
6a-diphenyl~1
glycouril~1
(iodogen),~1
Iodination~1
AG1-X8~1
resin,~2
vial.~1
incorporated,~1
OC125~1
mCi/mg.~1
Immunoreactivities~1
radioiodination~1
vial~2
takes~17
medicine~71
product,~9
apyrogenic,~1
radiotherapeutic~1
(PDFR)~1
(EF)~8
techniques--gated~1
(RNA)~1
(NCP)--were~1
ventriculography~20
(CAD).~7
PDFR~6
Good~14
NCP~5
0.83,~3
ventriculography.~6
Ejection~6
0.96~4
EF~19
0.79)~1
0.64),~1
RNA.~7
CAD~49
EDV/sec~1
s.d.],~1
0.0001),~14
ventriculography,~4
NCP,~1
CAD.~15
homocystinuria,~2
VII~3
beta-Thromboglobulin,~1
beta-thromboglobulin~4
clotting,~1
homocystinuria.~1
transsulfuration~1
homocystinuria~1
liver-dependent~1
bronchopulmonary~17
(BPD)~3
age-~20
size-matched~1
BPD~12
(FRC;~1
ml/kg)~4
conception,~2
concave,~1
limitation.~5
size-corrected~1
rehospitalization~2
second)~4
centimeters)~1
(2.25~2
4.52),~1
(SaO2~2
negatively~24
FRC,~6
SaO2~26
BPD.~2
growth;~3
helps~14
preterm~67
neonates,~11
determined:~1
committed~11
granulocyte-macrophage~4
(CFU-GM).~1
limitation~23
CFU-GM~17
(7%~2
thymidine~16
suicide,~3
32%),~1
(55%,~1
75%,~8
need,~3
exhaustion~2
nonheated~1
oximeter~18
(SaO2).~1
(tcPO2)~2
co-oximeter.~2
PO2,~5
PCO2,~4
0.86,~2
Y~6
29.64~1
0.68X)~1
0.91,~8
6.29~1
0.96X)~1
tcPO2~8
-14.5~1
11.1~8
4.3%~7
95%.~3
instruments~31
child's~21
self-competence~2
encopresis.~1
interview.~9
encopresis~2
Locus~4
other;~2
encopresis,~2
gender,~20
identifing~1
acellular~9
Japan:~1
hemagglutinin~3
(F-HA)~1
(PT)-F-HA~1
lot~9
manufacturers~4
(lots~1
F-HA~1
PT-F-HA~1
type).~3
lots~1
(temperature~3
2.6%~5
1.9%~5
2.4%~7
3.3%~8
anti-PT~2
vaccines~11
convalescent~10
anti-F-HA~2
convalescing~1
Lot~2
antibody.~21
Northwest~1
Screening~7
(NWRSP)~1
hypopituitary~3
hypothyroidism~19
thyroxine~22
(T4)-supplemental~1
(TSH)~5
strategy,~2
NWRSP~1
screened~25
850,431~1
192~9
(1:4429)~1
(1:106,304).~1
begun~21
hypopituitarism,~3
hypoglycemia,~3
jaundice,~6
microgenitalia,~1
insipidus,~2
midface~1
hypoplasia,~6
cleft~19
lip~15
palate,~10
vision.~12
hypopituitarism~3
retrospect)~1
Oregon,~1
center;~2
1:29,000.~1
T4-supplemental~1
strategy~28
LAV/HTLV~4
tests,~45
isoagglutinins,~2
post-vaccination~1
Candida.~1
GP110,~1
P18,~1
P25~1
opportunistic~19
peculiar~11
Mycoplasma~12
hominis~11
Ureaplasma~6
urealyticum~11
Proved~1
bacteremia.~14
191~8
CSF~92
Mycoplasma,~1
voided~1
suprapubic~10
Genital~3
mycoplasmas~1
childhood.~12
shaking.~1
impairment,~13
hemorrhages,~4
subdural~29
hematomas~16
Skull~2
intraparenchymal~6
another;~1
MRI.~8
Subarachnoid~3
shaking,~1
document~47
milder~7
pseudoobstruction~6
entity,~14
gynecologic~21
colonoscopy,~6
intervention,~13
simplex~17
acyclovir.~4
Oral~20
contraceptives,~2
institutions~17
conception.~3
1,084~1
1,174~1
(22.2%).~1
endometritis~4
polyps),~1
disturbing~7
Pelvimetry~1
scanner~3
projection~12
(Scout~1
View)~1
slice~3
pelvis.~8
yields~11
magnification.~1
assessed,~4
hyperextension.~2
pelvimetry.~1
quick,~5
cost,~7
pelvimetry~2
colposcope~1
vulvar~17
vulvodynia~1
vestibule,~1
cactus,~1
camel~1
humps~1
stony~1
colonial~1
pavement~1
vagina,~1
looked~6
folds.~2
papillomavirus~35
Reid's~1
capsid~8
Past~4
partners~8
herpesvirus~3
vulvodynia,~1
colposcopic~10
vulva~6
vagina~17
psychosomatic~6
pruritus~8
vulvae~1
conscientious~2
time-consuming,~2
transparent~4
drape~4
grid~2
Seventy-seven~5
carbon-coated-dextran~1
punch~6
episiotomy~3
labor.~23
drawn,~2
Heparin-induced~1
thromboembolism~10
anticoagulants,~3
coumarin~3
derivatives.~3
poses~7
mucous~16
heparin-induced~2
Replacing~2
brand~4
DIC~6
anticoagulation~40
contraindicated,~2
dean's~1
letters,~3
letters~6
students'~15
undergraduate~21
deans~1
residency~46
Deans~1
student~12
affairs~1
124~12
write.~1
edit~2
evaluations,~6
letter-writing~2
statements,~2
attitudes~38
writers~3
science~15
evaluations.~5
student's~4
rank.~2
narrative~1
Negative~3
writers.~1
descriptions~16
categories~43
explanatory~3
writing~2
credible~1
letters.~1
Board~9
Examiners~4
(NBME)~1
policies~12
pass~15
NBME~1
curriculum~23
officially~1
medicine,~15
relied~4
inpatient~31
instruction,~2
teacher,~2
Psychologists~1
residencies.~1
emphasized~23
psychophysiological~2
pharmacotherapy,~1
awareness,~1
residencies~4
specialties~6
13,~16
.0001)~7
instruction.~2
teach~15
peers.~6
Residents~4
postgraduate~6
period:~3
self-ratings~2
residents.~10
helpful,~2
teaching,~4
teaching.~1
Students'~1
scanty~2
validly.~1
profit~2
introductory~3
endure~1
(CPE)~1
described:~2
mainstream~1
objectives,~2
experiences,~5
assessment;~3
occurs;~2
problem-based~1
strengths~5
drawbacks~6
29.9~3
Gunshot~1
(91.7%)~1
(47.2%).~1
(76.4%).~1
(23.6%)~1
arteriographic~5
(1.4%)~4
unnecessary~29
intermediates~9
freeze-clamp~1
0.25,~2
1.0,~9
3.0,~2
4.0-5.0~1
Fed~1
glucose-6-phosphate~2
(G6P)~1
G6P~2
catabolites~1
gluconeogenic~4
Phosphoenolpyruvate~1
(PEP),~1
high-energy~9
intermediate,~5
animal,~2
restored,~2
fasting.~3
states,~7
Contrariwise,~1
protocol.~29
seatbelt~7
law,~3
nation,~2
York~43
State~14
passengers~6
pre-legislation~3
(Phase~3
5-month~1
post-legislation~2
compulsory~1
civil~6
fines~1
$50~1
violators,~1
position).~1
highway~1
City~14
counties~2
63%,~2
seek~11
Ninety-four~5
tracheostomy~20
cricothyroidotomy~1
Chevalier~1
Jackson.~1
seconds,~8
Autopsies~2
followup,~3
more,~13
detailed.~9
head,~12
medium-term~1
followup.~3
38-year-old~5
rarity~9
inverted~5
periosteum.~1
sulcus.~3
16-year-old~12
hemopneumothorax~1
chest.~9
complained~14
confirmatory~8
foramen~9
Bochdalek.~1
X-ray~32
gas-filled~3
viscus~2
hit~3
bullet~7
herniation.~3
hemophiliac~1
self-inflicted~3
tomography,~20
technetium-99m~4
(Tc-99m~1
RBC)~1
intra-abdominal~36
ultrasound;~2
31-year-old~4
reduction.~22
male,~11
lifting~3
object,~1
biceps~9
brachii~2
musculature,~4
surprisingly~8
flexion,~10
albeit~8
torn~3
sutured~6
preferable,~2
hazardous~7
reinsertion~1
tendon,~6
time-distance~1
triage~3
on-scene~6
(LOC)~1
verbal~27
stimulation;~1
(RR)~2
30;~3
90;~1
120.~1
crew~2
assessment.~10
Entrapment~1
fatalities~17
vehicular~5
logistics~2
Severity~7
Score~3
29.1)~1
Unresponsiveness~1
criterion,~3
85%.~5
Time-distance~1
235~5
(19~17
arrival,~2
room,~5
room),~1
accordance~8
evolving~19
Definitive~6
(59.7%),~1
(16.3%),~1
(24%).~8
(Injury~1
Scores),~1
permitted~29
Comparative~4
reflection~21
bodily~3
managed.~6
enabled~23
management:~1
stability;~1
findings;~6
splenorrhaphy~2
preferred,~3
precluded~10
repairs,~3
abandoned~6
intraoperatively.~6
non-steroid-treated~1
(Glasgow~1
Coma~9
Scores,~1
4-9).~1
nonprotein~5
Urine~9
0.04)~9
brain-injured~5
catabolic~15
argue~8
catabolism~8
issue,~1
538~2
214~9
(40%),~3
auto-pedestrian~1
(17%),~10
crush~5
(5%),~6
assault~3
skiing~8
Ninety-two~4
postinjury~6
38),~2
14),~2
perineal~16
PASG~11
(71%)~16
tamponade~24
lavage~64
External~8
(95%).~1
Pelvic~2
Sixty-eight~12
(54%)~13
sepsis.(ABSTRACT~1
forty-four~6
Asplenic~2
28.6~2
followup~13
8,810~1
12-144~1
intra-operative~4
Fulminant~1
pneumococcal~5
27-year-old~5
Septicemia~1
pneumonia~40
prosthetic~35
encapsulated~6
(30%),~7
(18.5%~1
5.9%~3
(7%)~13
(30-80%).~1
salvage,~3
procedure.(ABSTRACT~2
multidiscipline~1
epidemiologists,~1
toxicologists,~1
chemists.~2
laboratory's~1
instruments,~1
knowledge,~44
illustrations.~3
chemist~2
toxicants~2
prioritizing~1
toxic-specific~1
incident-reported~1
inorganic~22
toxicants.~1
scheme~7
prioritized~1
limitations,~4
Glycolic~1
(EG)~1
accumulates~12
EG.~2
glycolic~3
tool.~7
EG~1
Louisiana~2
Poison~2
poisoned~1
ml/kg~16
bromide,~6
bromide.~1
bioavailability~13
75-118%~1
6%.~8
I.V.~1
0.10).~3
caffeine~43
intoxicated~7
street~5
ephedrine,~4
phenylpropanolamine,~1
caffeine,~4
theobromine.~1
theobromine,~2
theophylline,~11
1,7-dimethylxanthine.~1
Sequentially~1
nonlinear.~1
27.6~4
micrograms/ml/hr~1
284.6~1
ke~2
0.097~1
hr-1~4
Theophylline~7
0.069~2
10.0~15
Extensive~16
DEET~3
episodically~1
bedclothes.~1
Local~28
self-medication,~1
repellant,~1
1-2~13
light-bulb~1
box.~1
incoherence~1
session.~11
Aggressiveness~1
psychotic~9
ideation~3
hyperactivity,~2
pressured~1
speech,~3
tangentiality,~1
ideas,~4
grandiose~1
delusions.~2
haloperidol.~1
mania.~5
Street~1
1163~1
stimulants~2
614~2
alleged~6
19.2%,~1
substitutes~5
22.5%,~1
473~1
amphetamine~2
27.1%,~1
23.0%~1
49.9%~1
methamphetamine~2
32.9%~1
validity,~4
substitutes,~1
63.2%~1
methamphetamine.~1
74~45
Caffeine,~1
procaine~13
substitutes.~1
held~28
homeopathic~1
medicines~2
ingredients,~1
Latin~8
purchased~3
mail~6
Values~14
four.~8
Arsenic~1
sales~4
warning~8
dangers~6
ingestion.~9
warnings~2
labels.~1
Ex~1
nephrectomy~18
reconstruction.~18
malformation,~8
autotransplantation~4
kidneys),~2
(11~32
kidneys).~1
believe~84
renovascular~13
184~5
injury;~4
ligation.~10
Injured~1
cava,~7
iliac,~1
femoral,~2
popliteal,~1
veins;~1
ligated~15
phleborrhaphy.~1
Adjunctive~1
mitigate~1
Sixty~20
complaints~39
(CCA).~1
Hollenhorst~3
remediable;~1
endarterectomy~28
(CEA).~2
photography:~1
patients--in~1
amaurosis~4
fugax~4
CEA.~4
homonymous~5
hemianopsia,~2
occlusions,~1
retinopathies)~1
Amaurosis~1
blindness~20
uncertain~17
amenabe~1
Anticoagulation~4
limb-threatening~5
resolving~10
sepsis.~19
Phlebography~1
5:2.~1
anticoagulants~7
groin.~2
afebrile~4
begun.~5
unnecessary.~6
Residual~17
femorodistal~2
155~12
overlooked~11
(17.4%),~1
(6.4%).~1
graft,~6
(4.2%),~1
deleterious~22
limits.~13
ischemia.~64
(TIAs)~3
(National~2
Deaths)~1
(16.5%)~1
deficits,~7
strokes~6
TIAs,~3
TIAs~5
endarterectomy.~8
operations,~12
prophylactic~57
arteriography.~8
(5.5~5
(4%)~17
occurred--an~1
TIA~13
stops~1
Diagnosis~14
indium-labeled~1
phlebograms.~1
Venous~10
Greenfield~1
embolism.~16
albicans,~1
amphotericin~16
cure.~11
Tuberculous~1
aortitis~1
tuberculosis.~10
adenopathy.~4
Isoniazid~3
rifampin~5
started,~3
stopped~17
sweats,~1
effusion,~7
tender~2
Infrarenal~3
ethambutol~7
streptomycin.~3
embolus.~6
infragenicular~1
clamps~3
patency.~3
calcific~18
salvage.~10
(AIDS)~24
San~13
Francisco~2
charges~11
AIDS~72
$9024,~1
$7026~1
$23,425,~1
$27,571.~1
AIDS,~10
cyclosporine,~3
mg/kg/d,~1
vehicle.~4
recipients~26
treatment:~2
clearing~11
moderately,~2
minimally;~1
vehicle-treated~7
Vehicle-treated~1
impressive~5
cyclosporine.~3
(95%)~8
Mitotic~3
efficacy-side~1
determined,~10
advance~13
mercury~8
vapors.~2
hematuria.~10
2,3-dimercaptopropane-1-sulfonate,~1
(IND~1
19,276).~1
mercury,~5
11.2~7
Clearing~1
2,3-dimercaptopropane-1-sulfonate~1
Cambodian~1
refugees~4
hydrochloride.~5
Psychiatric~5
extraordinary~3
stresses.~6
Indochinese~5
Therapeutic~13
Trial~5
Mild~9
Hypertension,~4
purported~5
invalidating~1
million~21
prescriptions~2
Disease~20
Index.~4
penicillins~4
aminopenicillins~1
doubled.~6
Cephalosporins~1
Nationwide~3
Centers~6
Control,~1
Atlanta,~1
1986,~13
922~1
(5.5%)~1
16,748~1
Ninety-five~8
belonged~3
AIDS;~3
"no~8
risk"~2
workers)~1
belong~3
88~29
heterosexual~2
unobtainable~1
reclassified.~1
AIDS.~16
worksite~2
promotion~9
utilization.~10
Johnson~4
(N~86
5192~1
3259)~1
Live~3
Life,~1
screens,~1
life-style~3
healthier~1
life-styles,~1
2955)~1
covariance~9
costs,~12
admissions,~6
costs.~9
$43~1
$42~1
$76~1
non-Live~1
admissions.~4
sucrose,~4
isocaloric~8
isoenergic)~1
provided,~5
fructose,~1
starch.~8
one-~6
two-hour~2
starch~15
glycemic~14
pansinusitis~1
orbital~63
fungus~8
Curvularia~1
(Cochliobolus)~1
lunata.~1
Key~3
mucoid~5
exudate~5
fungal~32
hyphae,~1
eosinophilia,~5
precipitins~3
lunata,~1
Curvularia-specific~1
lunata~1
exaggerated~17
pansinusitis.~2
hyphae~2
alert~9
Sinus~4
imipramine~6
first-pass~10
angiography,~14
intolerable~2
Nortriptyline~2
hydrochloride~33
imipramine.~1
nortriptyline~4
emerges~2
15,438~1
inpatients~23
Collaborative~2
Surveillance~1
22,227~1
358~3
347~2
2.2%.~2
Rashes~1
products,~13
mucolytics.~1
Amoxicillin~1
(51.4~2
exposed),~1
(33.8/1000),~1
ampicillin~29
(33.2/1000)~1
Drug-specific~1
51.4~1
exanthems,~1
ventilators~2
utilized.~8
ventilator.~4
unweaned~1
ventilation:~2
days).~27
nonsurgical~13
conservative.~2
graduates~16
(FMGs)~1
Medicine's~1
(ABIM)~1
certifying~2
US~21
graduates,~4
citizen~2
FMGs~4
alien~2
FMGs,~1
ABIM~4
Educational~4
Commission~8
Graduates~3
educated~12
citizens~10
Asia,~1
sizable~1
minority~9
Europe.~5
Scores~3
directors'~1
FMGs.~1
director.~1
career~5
weigh~1
decisions.~5
Increasingly,~1
professionals;~1
autonomy~4
institutions,~2
government,~2
third-party~5
payers;~1
technological~4
changes;~3
economics~2
analyzes~5
emphasizing~6
physician's~20
career:~1
lymphoproliferative~10
ie,~17
lymphocytic~24
porphobilinogen~7
deaminase~27
(PBGD)~1
neoplasms,~11
87%,~3
lymphoma.~23
PBGD~2
anemia,~22
constitutional~4
lymphadenopathy~27
100%,~12
reinitiate~1
retreat~1
Oregon~1
farm,~1
Campylobacter~7
jejuni~3
total,~7
(88%)~9
raw~15
milk,~9
ill,~5
Acutely~2
jejuni-specific~2
immunoglobulins,~3
rise.~3
acute-phase~2
jejuni.~1
School~8
Houston~3
rejected~4
school.~11
Admissions~2
Committee,~1
contrasting~7
Committee~8
attrition~3
meaningful~8
applicants.~1
222~8
Ninety-seven~4
porphyria~8
range,~40
underscores~4
confirming~21
porphyria.~2
latent~10
carriers~24
permitting~15
precautions~6
porphyric~3
attacks.~16
rhabdomyolysis,~1
vacuolar~4
myopathy,~4
carnitine~22
palmitoyltransferase~2
palmitoyl-coenzyme~1
palmitoylcarnitine~1
oxidation~29
interacted~5
palmitoyltransferase-A~1
rhabdomyolysis~5
precipitated~16
preferences~5
attire~2
etiquette,~1
Francisco.~2
shoes,~3
jeans,~1
neckties,~1
dresses~1
skirts.~1
wanted~9
name,~2
name.~1
concurrent~48
physicians'~13
officers~3
preferred.~2
(60%),~5
(20%),~7
clamping.~4
insult.~4
88%~24
lived,~2
Shifting~1
postischemic~15
(Al)~2
deferoxamine~11
(DFO)~1
aluminum-induced~3
histomorphometry~1
chemistries.~1
mg/rat~2
i.p.,~1
weeks):~1
DFO,~1
(75~12
sacrificed~25
Al.~2
front,~1
osteoid.~2
however~4
(PST)~1
ammonia~35
glutamine~26
(substrate~1
production)~1
PST,~1
PST.~1
Luminal~1
(Jgln)~1
(0.05~4
Jgln~4
flux~36
flux.~2
flux,~2
resorption.~7
(Vmax~1
20.9~5
mm-1,~1
km~3
(HCO3)~3
6.8,~4
(12%)~16
(10%)~14
Peritubular~2
nonperfused~1
PST~1
[14C]-glutamine~1
solution,~19
unity~3
(3.83~1
0.34,~2
(11.37~1
1.13)~1
min.(ABSTRACT~1
triphosphate~33
(ATP),~3
(Pi)~1
31phosphorus~5
(31P~2
NMR)~3
depletion,~6
Pi~10
accumulation,~5
concurrently.~3
Metabolic~13
post-hypotensive~2
(ATN):~1
(GFR),~5
polyuria~3
oliguria,~1
potassium.~4
pre-renal~2
incipient~4
ATN.~2
split~6
hydronephrotic~5
observe~11
arcuate~3
interlobular~3
arterioles.~6
Efferent~1
glomeruli~11
preglomerular~5
Higher~10
10(-4)~29
10(-3)~16
efferent~20
haloperidol,~3
dilate~11
postglomerular~3
constrictions~3
dilator~17
welling~1
points)~2
M),~11
constrictor~10
(CAPD)~7
non-mineralized~2
(osteoid)~1
seam~3
width,~5
time-spaced~1
(tetracycline)~1
(that~6
mineralization).~1
histomorphology~1
aluminum.~2
mineralizing~1
skeleton.~4
Unknown~1
solute(s)~1
purity.~1
Rigorous~1
identity~11
ligands.~4
Purification~5
of:~2
3.0~37
polystyrene-divinylbenzene~1
(XAD-2);~1
methanol~5
drying~4
formic~5
acid;~1
SP-Sephadex~2
cations,~4
pigments;~1
QAE-Sephadex,~1
gradient;~1
C-8~1
C-18~1
reversed-phase~3
spectroscopy~26
spectroscopy,~4
ligand,~2
hippurate,~1
beta-(m-hydroxyphenyl)-hydracrylate~1
p-hydroxyphenylacetate~1
inhibitors.~5
Non-excretor~1
excrete~6
head-out~5
hormonal,~1
ascites,~3
mEq/liter,~1
(12.9~2
35.9~1
Glomerular~7
(inulin~1
ml/min/1.73~3
m2,~4
para-aminohippurate~3
ml/min,~23
(8.6~2
ng/ml/hr,~1
(82~6
(1155~1
183~6
603~2
immersion.(ABSTRACT~1
uric~46
nephrolithiasis~3
stones)~1
5.33~1
2.78~1
mEq/day,~1
mEq/day).~2
(5.30~1
0.31~6
(6.19~1
6.46)~1
undissociated~1
204~7
(64~6
225~8
852~1
998~1
oxalate~14
1.68~2
stones/year~2
chi~9
square).~1
94.4%~1
99.2%.~1
Detailed~14
alkali~11
persistently~11
(typically~1
5.5)~2
normouricosuria,~1
hyperuricemia.~4
passed,~2
composition.~10
citrate,~4
mEq/day),~1
radiolucent~7
(uric~2
calculus~10
"calcified"~1
patients.(ABSTRACT~8
(MW)~1
cut-off~2
fabricated~3
polysulfone~3
dialyzer~7
(F60,~1
Fresenius,~1
FRG)~1
glomerulus.~1
device's~1
60,000~7
(beta~6
2-microglobulin,~1
myoglobin,~1
RBP,~1
1-microglobulin,~1
1-glycoprotein,~1
1-antitrypsin,~2
prealbumin,~1
nephelometry~1
radioimmune~7
assay;~2
sieving~13
eliminations~1
proteinuria,~17
tubulo-interstitial~2
nephrosis.~1
adriamycin~8
(ADR)~1
nephrosis~1
ADR-induced~1
glomerulopathy~3
breaking~4
(TBM),~1
glomerulosclerosis~3
(FSG)~1
necessarily~21
Tubulo-interstitial~1
Kyoto~1
(WKy)~1
(1,25D3).~1
everted~4
sacs~3
1,25D3~4
12-week-old~1
SHR,~7
Inability~1
unexcluded~1
possibility.~5
vigorously,~1
WKy~2
3),~8
four-week-old~1
(41.4~1
31.1~1
mg/day;~2
61.6~2
48.1%),~1
1,25D3.~1
(42.9~1
60.1~1
53.7%).~1
(33.0~1
39.1~3
mg/day),~3
mg/day).~3
deprivation,~6
35-week-old~1
(70.9~1
53.0%).(ABSTRACT~1
(i.v.)~4
intracarotid~6
(IC)~8
hemodynamics,~12
antidiuretic~12
(ADH)~1
hydropenic~3
12.7~7
ng/kg/min~4
(MAP,~1
(GFR,~1
(CPAH,~1
maximally~21
(Uosm,~1
mOsm/kg~3
H2O,~7
ADH~4
IC~12
5.8~18
ng/kg/min)~4
hemodynamics;~1
undetectable.~1
ng/kg/min),~1
MAP~20
(86~10
GFR~29
(81.3~3
68.6~1
CPAH~1
(291~1
223~5
modestly.~1
Uosm~1
(1429~1
1114~1
(1.66~1
1.88~2
Usom~1
(1787~1
1664~1
altered.(ABSTRACT~1
nephrectomized~12
Rats~27
chow~16
cohorts~6
chow.~4
prevalences~5
sclerotic~9
eating~27
ablation.~5
sclerosed~1
retarded~16
mass.(ABSTRACT~1
Healthy~7
ingesta~3
outermost~1
(rich~1
tubules)~1
inside-out~1
ouabain-insensitive,~1
Na-pump~2
ouabain-sensitive,~1
Na,K-pump~1
Na-pump's~1
Na,K-pump.~1
"extrarenal~1
adaptation"~1
(HK)~1
withdrawn,~3
HK~4
Correction~7
extrarenal~3
adaptation.~5
conclude:~4
potassium-adapted~1
paradoxically~2
controls;~9
constriction~41
(RVC)~1
Munich-Wistar~3
RVC~3
transcapillary~3
hydraulic~11
hrs~2
saralasin,~1
indices,~6
kidney),~1
RVC.~2
[125I]dextrans~1
(molecular~2
radii~2
18-60~2
(CDEX/CIN)~1
CDEX/CIN~2
dextrans~3
44A),~1
42A).~1
Saralasin~1
dextrans.~1
heteroporous~1
non-selective~4
pores.~2
microcirculatory~6
largely,~1
entirely,~1
size-selectivity~1
(CCT)~4
(DRTA)~1
furosemide~17
orally)~1
H+~5
Na~12
segment.~13
amiloride,~2
transtubular~4
(lumen-negative)~1
CCT~9
reabsorption.~5
DRTA,~1
acidemia,~3
hyperkalemic~4
variety,~3
RTA,~2
5.5,~3
generated,~2
denotes~1
proton~18
CCT.~2
regards~6
voltage.(ABSTRACT~1
Synthetic~6
polycations~1
neutralize~3
polyanions~1
(GPA),~1
(GCW).~1
platelet-derived~6
(HuPlt~1
CP),~1
permeability,~5
GCW~6
HuPlt~10
CP~19
thrombin,~3
platelet-activating~5
(PAF),~1
phagocytable~1
CP,~1
(pI)~1
10.5.~1
deposits~48
(SLE),~5
polyanion,~1
molarity~1
SLE.~5
staining,~7
sialoglycoproteins.~1
restores~4
neutralization~4
GPA.~1
PAF~26
staining.~8
polycationic~1
non-selected~1
(CRFh)~1
free,~5
sulfo-~2
glucuroconjugated~1
(NE),~5
(EPI).~1
CRFh,~2
EPI~3
scrutiny~4
sub-groups~1
plasma-free~1
exist;~1
Suspecting~1
glucuro-conjugated~5
DA,~3
sulfo-conjugated~3
CA;~2
CRFh~1
meaning,~1
any,~8
moment.~2
tyrosine,~3
CA.~5
amines.(ABSTRACT~1
radioimmunoassays~6
7-S~1
domain~16
laminin~15
proteolytic~4
collagenase,~1
pepsin.~1
hydroxyproline~9
concentration)~4
decrease.~8
diabetics~35
peroxidase-antiperoxidase~2
mesangium~3
Bowmans~1
capsules,~3
thicker~9
stainings.~1
hypersensitivity.~2
Markedly~2
6400~2
mg/dl)~4
kappa-casein~1
predominating.~2
hemagglutinating~2
(1:40,960).~1
Cross-reacting~1
beef,~2
pork~1
flounder~1
focally~6
CIC~1
16,000~1
32-fold~1
amelioration~11
nephritis.~5
consume~6
statural~1
catch-up~3
hypersensitive~2
disturbance,~10
stunting,~1
Neutron~1
(NAA)~1
Cs,~2
Cu,~4
Fe,~5
Mn~8
non-essential~1
Br~2
subnormal.~2
Cr~6
(20~48
level).~1
Co~1
Rb~1
Se~8
Zn~23
Effect~4
(0~7
800~14
sodium-dependent~2
L-(14C)alanine~1
D-(14C)glucose~1
lambda~15
(lambda-1~1
lambda-2)~1
urines~4
myeloma.~5
pmole/mg~6
lambda-1~2
136~24
lambda-2~2
194~6
(I50)~1
kappa,~1
68,~2
120,~4
beta-lactoglobulin~4
myeloma~23
Bence~2
(NSN)~1
(OSN)~1
horse~4
apoferritin~1
(HAF),~1
NSN~5
OSN~5
anti-HAF,~2
HAF~2
reactants~2
deposits;~1
crescentic~4
glomerulonephritis,~10
tubulointerstitial~8
reactants;~1
crescent~1
glomeruli.~7
C5a)~1
component(s)~2
(CHO)~1
CHO-energy~1
(initial~2
weight:~2
g)~27
"ad~2
lib"~2
(L~2
CHO-restricted~1
(starch~1
glucose)~1
creatinine,~18
CHO~3
(R1~2
(R2~15
(L1~1
g).~9
identically~6
R1~5
L1~4
(79%,~2
81%,~3
53%)~3
27%,~5
83%~18
L1,~2
Diffuse~5
R1,~1
preserve~25
parenchyma,~2
"simple"~1
"complex"~2
beneficial,~2
investigations.~10
(MA)~1
osteomalacia~8
Alterations~14
(TPTX)~2
MA~1
(TPTX-A),~1
non-acidotic~1
TPTX~5
(TPTX-C)~1
MA,~1
mid-shaft,~1
TPTX-A,~4
7.24~1
0.10,~3
TPTX-C,~2
7.39~1
7.43~2
89.8~1
TPTX-C~3
150.2~1
25.9~1
micrograms/mg/creatinine~1
0.01.~3
0.6%~9
4.0~35
1.6%~7
1.1%.~2
15.5~4
0.05.~6
TPTX-A~1
observed.(ABSTRACT~4
Quantitative~19
stainable~13
Histomorphometry~2
resorption,~4
osteoid-bone~1
atomic~8
spectrophotometry.~3
(81~1
9.6~11
low-turnover~1
adynamic~1
predominant-hyperparathyroid~1
lamellar~16
woven~3
osteoclastic~8
doubly~5
labelled~9
seams,~1
apposition~6
Stainable~2
(COP)~1
41.1~1
g/liter,~2
COP~2
Hg)~32
65.0~2
overhydration,~2
hydration,~4
occasionally,~6
dehydration.~3
113~11
(ECFV).~1
ECFV~4
300%~5
200%~5
normohydration,~1
Apparently,~1
hypoproteinemia~1
normoproteinemic.~1
hypoproteinemia,~1
tissue-fluid~1
nondialyzed,~2
wasting~5
intakes,~4
needs;~3
alternatively,~4
inappropriate.~2
Energy~9
calorimetry~6
nondialyzed~1
sitting,~2
bicycle,~1
meal.~7
(kcal/min/1.73~1
m2)~6
0.94~6
0.91~8
0.20,~4
0.97~3
0.10.~2
sitting~24
correlated.~8
bicycling,~1
Absorption~5
complicate~9
Utilizing~3
meal,~8
made:~4
A.)~1
deficiency)~2
(186~2
30).~4
B.)~1
1,25(OH)2-D3,~1
272~5
C.)~1
antacids~4
D.)~1
Aluminum~5
modestly~6
1,25(OH)2-D3~1
carbonate.~3
(NSAIDs)~1
(RPF),~1
prostanoid~3
(zero~7
(CRI)~2
ketoprofen~3
(K)~3
(I)~4
(K:~3
0.001;~4
I:~6
0.032;~1
RPF~5
0.002;~1
0.016);~1
PGE2~10
0.60~7
0.08~22
ng/min,~2
0.042).~1
Fractional~9
(CH2O/CIn)~1
excretions~8
significantly.(ABSTRACT~1
IAP~4
ferritin~27
resectable~10
n(+)~1
n(-),~1
noncurative~3
curative~29
Ferritin~4
III.~14
OK-432~1
59-year-old,~1
dark-complexioned~1
infiltrating~16
scalp.~5
Widespread~6
myelophthisic~2
anemia.~15
large,~22
metastases.~45
ear.~8
bringing~2
routes~8
Interferon-beta~3
(Human~1
Interferon)~1
advanced,~9
hormone-refractory~2
prostate~80
Prostate~4
(NPCP~1
Protocol~3
2100).~1
Chills~1
(62.5%),~1
NPCP~1
6.3~11
lymphomas,~6
200,000.~1
symptoms--less~1
months--and~1
dominated~8
laparotomized~1
operations.~32
cytostatic~3
Cases~11
lymphomas~19
high-grade~28
(70+~1
mucopolysaccharide~7
migratory~6
mucopolysaccharides~4
adenocarcinoma~62
(GBA)~2
GBA~14
(ECOG)~4
EST-2273~2
pH.~17
50%)~9
unanimous~1
88.9%.~1
ECOG~2
recommends~5
stratification~7
dysphagia.~7
Excision~4
curative.~4
36-year-old~3
Saudi~5
penectomy~2
corporeal~3
metastasis,~10
myocutaneous~25
gracilis~2
intercourse.~3
leukopenia,~4
oropharyngeal~6
soreness.~1
Superficial~5
(5/15).~1
Sixty-one~5
(11/18)~1
monilia~2
albicans~2
(9/18)~1
monilial~2
moniliasis.~1
succumbed;~1
longer.~14
succumbed~3
candidiasis.~2
fatal,~2
Kaposi's~21
Center~40
Shreveport~1
extended-field~1
summarized.~4
ninth~3
parenchyma~24
Polypoid~2
Vater~9
fiberoptic~37
nonspecific.~4
Life-threatening~2
transformations~4
unreported)~1
villous~24
neoplasm~28
toto~1
T1N0,~1
T2N0,~1
shrinkage~4
beam,~3
T3N0,~1
T1-3N1,~1
deeply~7
afterloading~2
nidus)~1
cm3.~2
(reference)~2
7,500~1
rads~7
time-dose-fractionation~1
[TDF]~2
131-140),~2
(TDF~3
8,500~1
150).~2
preliminary.~1
branches.~3
intercostal~13
snares.~1
clamping,~1
opened~15
longitudinally~6
incised,~1
opening~29
distally~6
coarctation.~7
ductus~35
divided.~3
pulled~3
preserving~8
4.24~2
(mean:~10
14.8~8
kg).~8
Recatheterization~1
coarctation,~3
isthmic~2
dipyridamole~36
California,~8
(ages~10
45)~6
36.5~4
deaths:~2
endocarditis~46
parent,~2
referring~7
(3.9%)~1
perioperatively~8
spontaneously.~12
(5.9%)~2
complications:~1
nosebleeds~3
warfarin~16
anticoagulation:~1
preference,~2
perivalvular~3
dipyridamole)~1
Hemorrhagic~3
atriopulmonary~9
anastomotic~33
(Fontan-Kreutzer),~1
Fontan~20
167~5
(65%)~12
connection,~4
distortion,~3
(62%).~2
(84%).~2
(59%).~2
relating~36
palliative~36
Wood~3
(54%),~2
m2~13
(87%).~2
survival,~28
contraindicate~4
Fontan/Kreutzer~3
subpulmonary~1
tricuspid~50
atresia~38
ventriculoarterial~3
concordance~23
Clinic.~4
connections.~4
Waterston~1
(38%~4
17%)~2
Glenn~2
(46%~1
15%).~1
dictated~5
anatomy,~11
stenoses,~5
chamber,~5
malformations~22
(1975~1
April,~2
81%.~4
(instantaneous~1
risk)~3
merged~2
Elevated~15
post-repair~2
0.002)~7
Hypertrophy~2
0.007)~3
0.008)~3
hazard,~3
Younger~6
neutralized~8
hypertrophy,~13
contraindication~5
ml/kg/min~6
ml/kg/min.~4
arterial-sagittal~1
(0.48~1
0.10),~1
(0.43~3
0.14),~1
(0.44~4
ml/100~14
gm/min),~1
gm/min~2
ml/kg/min,~3
minutes'~2
debt~1
less.~14
833~1
1981.~18
characteristics:~4
diagonal~6
(70.1%)~1
(19.9%)~1
(3.4%);~1
unsuitable~6
(5.5%);~1
(0.6%);~1
(0.5%).~4
53.2%,~1
complimented~1
2.6%.~1
45.2%~1
(23.8%),~1
(15.2%),~1
(6.2%).~1
16.7%~3
18.5%~2
750~5
0.4%.~1
815~1
53.1~2
follow-up),~1
63.1%~1
83.4%~1
Association,~3
27.4%~1
recatheterization~1
18.9~5
87.9%~1
63.3%~1
88.6%~1
1.3%.~3
aortico-left~1
Konno~1
aortoventriculoplasty.~1
Ionescu-Shiley~2
xenograft~2
St.~28
Jude~13
angioscopy~4
detail~21
resolution.~6
endoscopes~1
1.25~10
viewing~4
cardioplegic~16
Technical~6
high-quality~9
displace~1
blood;~4
illumination;~1
Incomplete~2
scope~9
steerability.~1
angioscopy.~1
vein-to-artery~1
thrombi,~6
ulcerated~4
relevant,~1
yet,~4
unsolvable~1
bizarre~6
pneumothoraces,~1
distress,~6
Thirty-eight~17
Ages~9
tracheostomy,~2
leaks,~2
mediastinoscopy,~1
lobectomy,~3
esophagogastrectomy.~1
(24%);~2
(34%).~1
carinii,~2
cytomegalovirus,~2
Microbacterium~1
avium,~1
toxoplasmosis,~1
candidiasis,~1
Cryptococcus~1
neoformans.~1
Tracheostomy~3
Detroit~1
Receiving~1
Causes~6
Operations~3
123~17
(75%),~3
(2%),~8
(23%).~4
0%,~6
53%,~3
(15%)~19
thoracotomies,~2
thoracotomies~3
(35%)~10
abdomen.~8
(1/12).~1
met,~1
(16/16).~1
resuscitative~7
efforts~31
Endomyocardial~2
myocarditis,~3
immunosuppressive~23
"Dallas~1
Classification")~1
pitfalls~4
Today,~3
enjoys~1
armamentarium.~2
application,~8
popular.~2
masses,~9
unique.~2
highlights~3
vantage~1
point.~13
Digital~5
subtract~1
distractions~1
debate.~3
controversial,~3
Intra-arterial~2
sophisticated~6
technology~21
Enhanced~6
awareness~27
endocarditis,~9
microbiologic~10
endocarditis.~18
fibrinolytic~13
patency,~8
contraindication.~1
outlined,~2
excellent,~8
quickly~15
motor-sensory~1
clues~11
arriving~5
decisions~25
Like~2
bona~1
fide~1
process;~3
neuropathies~2
unmyelinated~5
fibers;~2
amnesia~3
amnestic~2
understood,~5
likely.~3
out,~9
migraine~8
headaches,~4
spell~1
dementia.~19
completely.~10
angiofibroma~4
1945~3
1955,~1
1971,~2
removal;~1
rhinotomy~3
expose~6
extensions~3
surgically.~9
Trends~3
adjunctive~20
approaches,~2
embolization,~3
Lateral~5
nasopharynx,~3
paranasal~11
skull~34
fossa,~3
infratemporal~4
fossa.~3
extensions,~1
managing~14
choanal~8
transnasally~1
transpalatally.~1
transnasal~5
stenting~6
choanae~3
anomalies,~9
dilations~3
neonate,~3
definitive.~2
Obstructive~5
Down~11
cranium,~1
midface.~1
adenoidectomy~2
pharyngopalatal~1
alleviating~3
pathology.~15
aborted~7
20-week~1
sections.~11
MRI's~1
Plastic~3
long,~3
branching~7
casts.~4
casts,~4
asthmaticus~2
coughed~2
tree.~5
allergies.~3
pneumonitis,~6
taken,~3
opacification~14
bronchoscopically~4
white,~8
cheesy~1
material.~21
grab~1
suction.~1
bronchoscopies~4
bronchiectasis.~3
layers~34
inspissated~2
mucus~23
9-year~3
845~1
urogenital~3
prostate,~9
bladder,~8
testicle,~1
spermatic~17
penis,~2
urethra,~6
Thirty-one~20
(3.7%)~1
supraclavicular~2
nodes,~25
cartilage,~4
retroorbit,~1
mandible,~1
sinuses.~2
primaries,~1
methodology,~3
alternatives~10
surgeon.~10
localizing~11
malignant.~8
counsel~2
location,~25
adenopathy,~3
histology.~8
specimen.~9
Parotid~1
tympanometry~4
ossicular~13
eardrum~2
scarring~21
tympanometric~1
scars~22
cats.~16
eardrums~3
myringotomies,~1
stapes~6
incudostapedial~1
discontinuity~2
immittance~1
tympanogram~1
myringectomy~2
tympanograms~2
neomembrane,~1
discontinuity.~1
otoscopy,~1
audiometry,~3
acoustic~40
angiosarcoma~3
Sites~4
forehead,~1
cheek,~1
ethmoid~1
mandible.~1
(5/10)~1
(2/9).~1
(2/11).~1
circumscribed~3
horizontally~4
distances,~1
microbial~13
flora~11
recurrently~1
inflamed~10
tonsils~11
tonsillar~5
pharyngitis~4
tonsil~2
(10.2~2
tonsil)~1
tonsil).~1
melaninogenicus~2
adult,~4
child)~1
fragilis~4
(0.4~8
child).~1
beta-hemolytic~2
adult.~8
beta-lactamase-producing~3
(BLPO)~1
BLPO~1
(1.9~5
tonsillitis~3
antimicrobials~3
Identifying~2
subtotal~27
thyroidectomy.~1
societies~4
hearing,~4
natives~5
Easter~1
Island~3
audiological~3
island~25
civilization.~1
equal,~2
civilization,~1
civilized~1
hearing;~1
(men~1
combined)~1
States;~2
natives.~1
hearing.~2
presbycusis.~1
otosclerosis,~1
Meniere's~6
exostoses~1
island.~3
Frey's~1
gustatory~1
sequela~3
parotidectomy.~1
reestablish~2
reinnervation~8
cricoarytenoid~4
(PCA)~5
motoneurons.~2
ligated,~5
abductor~2
RLN~1
anastomosed~6
Periodical~1
laryngoscopies~1
ketamine~5
abduction~6
Abduction~1
PCA~13
motoneurons,~1
electrophysiological~22
(retrograde~1
horseradish~8
peroxidase)~2
testings.~1
Mucoceles~1
Berg~1
1889.~1
crossroads~1
mucocele~2
mismanagement.~1
mucoceles~2
mucocele.~2
gymnasts~1
stress-related~2
pathologies~1
contributors.~1
performances~8
executed~1
gymnastics~2
collegiate~5
gymnasts.~1
walkover,~2
handspring,~3
handspring~3
vault.~1
Wielke's~1
(1983)~1
curvatures~4
skills.~7
platform~2
terminations~1
performances.~3
vault~6
walkover~1
walkovers~1
feet.~6
implement~3
filtering~18
dynamometric~1
smoothing~3
appraised.~1
gravitational~10
Cybex~11
dynamometers~2
pre-set~1
speeds~4
Speed~4
servomechanism's~1
tachometer~2
feedback~30
Vfb~5
max).~3
unsmoothed~1
optimized~3
low-pass~1
filtering,~1
superimposed~24
contaminating~3
influences:~1
damped~3
oscillation,~1
braking~2
servomechanism~1
system;~4
oscillatory~3
principally~16
%~9
max.~4
different,~10
reliable,~6
polynomial,~1
Unacceptable~1
induced,~3
torques,~1
filtered.~1
Over-smoothing~1
disguises~1
artefacts.~1
recorder~4
damping~2
discouraged.~3
processing.~7
(Cybex~1
Lumex,~1
s-1)~2
accelerometer~1
affixed~1
machine's~1
transducer-observed~1
voltages~3
(V0)~1
true,~1
torques~8
(Me)~1
angle,~5
valid,~4
torques.~1
calibrations,~1
Me~1
V0~2
Methodologies~1
questionable,~1
invalid,~1
inferences.~1
instantaneous~14
max~7
servomotor.~1
inertia-corrected~1
Me,~1
Unexplained~1
statically;~1
torque;~1
corrections~4
acceleration;~1
usefully~3
re-assessed~1
Stabilization~2
deterrent~1
systematic~32
subtalar~11
obstacle~6
sagittal~26
planes~19
Inman~1
Completion~1
basketball~3
court,~2
High-top~1
shoes~4
pockets~1
(stiffeners)~1
malleoli.~1
shoe~7
stiffeners.~1
eversion,~1
restriction.~3
measurably~2
pre-pubertal~2
14-wk~3
pubertal~13
(Tanner's~1
maturity~13
rating,~1
dihydroepiandrosterone~1
sulfate).~1
Effectiveness~1
pre-post~1
in:~1
isokinetic~12
(KIN~1
COM,~1
Chattecx,~1
Chattanooga,~1
TN),~1
flexibility,~3
jump,~2
parameters,~14
consumption,~15
phosphokinase.~2
Safety~4
Strength~4
16)~7
min/session,~1
session/wk,~1
91.5%.~1
Participants~5
concentric~16
(Hydra-Fitness~1
Industries,~1
Belton,~1
TX).~1
Eccentric~2
10)~19
train~12
living.~5
work/repetition~1
motions~6
tested;~3
13.1~6
45.1%~2
tested).~1
subjects)~5
(+10.4%),~1
flexibility~11
(+8.4%),~1
[+19.4%~1
(l~2
+13.8%~1
(ml~2
min-1)]~1
Musculoskeletal~3
epiphyses,~1
training-related~1
(left~2
sessions~22
missed).~1
living,~6
term,~4
brothers,~1
dizygotic~9
106~23
monozygotic~11
sexes,~9
heredity~2
(VO2~4
max),~2
(HR~1
ergocycle~5
Fat-free~2
underwater~4
weighing.~2
Aerobic~5
(brothers),~1
(dizygotic~1
twins)~1
Dizygotic~2
sibship~5
resemblance~7
Monozygotic~1
alike~2
sibs,~1
intra-class~1
coefficients.~6
Twin~4
within-pair~2
min-1.~6
max,~4
among-pairs~1
min-1,~6
kg-1.(ABSTRACT~1
(%Fat)~1
Adult~9
46)~2
athlete~12
134)~1
gender-specific~1
(%FVC).~1
(SEM~3
0.99~5
579~3
355~4
288~6
Estimating~1
%FVC~2
SEE~16
318~4
Measured~4
1.04%Fat,~1
0.87%Fat,~1
0.21%Fat~1
3.70%Fat,~1
2.85%Fat,~1
1.98%Fat~1
2.18%Fat~1
athletes.~4
introduces~5
%Fat~1
error.~12
(HDL-C)~3
subfractions,~3
HDL2-C.~1
Research~26
HLD-C~1
intensity,~5
HDL-C~6
subfractions~3
postal~1
carriers.~9
Integrated~3
miles~5
Reported~10
walked/day~1
(5.3)~1
HLD2-C~1
0.50,~5
0.003)~4
0.29,~2
0.44,~3
HDL2-C~5
0.007).~2
Controlling~3
walked~1
HDL2-C,~1
drinks~10
maltodextrin,~1
3.0%~3
maltodextrin~15
(MG5.0),~1
4.5%~6
(MF7.1).~1
Solutions~4
MG5.0,~2
MF7.1,~1
running,~4
emptied~3
drinks.~2
(221.7~1
11.0~7
(103.4~2
19.0~3
ml),~6
MG5.0~1
(153.3~1
MF7.1~2
(167.3~1
14.8),~1
emptying.~10
19.0,~1
153.3~1
16.8,~2
167.3~1
(209.3~1
12.6,~1
287.7~1
16.0,~2
271.0~1
17.8~3
jumping~1
d-1~3
jumps)~1
wk-1~2
anabolic~4
durabolin~1
sesame~6
seed~3
oil)~1
8-wk~2
placebo)~2
atria~11
Plasmas~1
(LDL-C)~1
(TC~1
HDL-C).~1
three-factor~1
(males~4
females),~1
LDL-C,~1
LDL-C~1
HDL-C).(ABSTRACT~1
genotype-dependent,~1
(MZ)~4
twins,~5
15-wk~1
lateralis~6
hexokinase,~1
phosphofructokinase,~1
dehydrogenase,~8
malate~5
3-hydroxyacyl~2
CoA~10
dehydrogenase.~7
31%,~4
intra-pair~1
(intra-class)~1
0.83.~2
Hexokinase~1
(31%),~6
(21%),~3
fiber-type~2
proportions,~1
phosphofructokinase/oxoglutarate~1
Similarity~1
confirm,~1
genotype-dependent.(ABSTRACT~1
tenable~1
hypotheses~13
(40%~4
intensity.~10
H-~1
M-wave~1
(Angel~1
Hofmann,~1
1963)~1
constituted~16
12.8%~1
max/M~2
21.5%~2
age-,~3
sex-,~2
region-matched~1
cohort,~5
vasculitis,~4
sediment~3
hypergammaglobulinemia~3
cautious~5
importance.~10
abscesses.~11
yearly~9
Infections~8
ears,~5
odontogenic~3
foci~32
abscesses,~12
hemispheres,~1
parietal~38
lobes.~6
Common~14
headache,~19
chills,~4
sensorium,~3
nuchal~3
rigidity,~2
11%.~6
established;~2
99mTc~7
scanning,~13
empirically~3
thoughtful~2
risk-to-benefit~2
Causative~1
abscesses~33
grew~15
pathogen,~2
streptococci.~3
Anaerobic~4
microaerophilic~1
"ring-enhancing"~1
enhancement,~4
attenuation.~1
Decrease~2
excised,~8
alone.(ABSTRACT~3
nosologic~1
paramyotonia~4
congenita~2
paralysis~47
blurred.~1
inexcitability~1
cooling~27
congenita.~3
(CMAP)~1
Diminution~1
CMAP~2
congenita,~1
hypokalemic,~1
hyperkalemic,~1
normokalemic~1
paralysis,~4
2-5~5
preexercise~3
thyrotoxicosis.~2
6-year~6
898~1
compressive~8
mononeuropathy.~1
nerve,~26
palmar~5
neuropathies.~4
mononeuropathies~1
appliance~3
nerve).~1
Failure~20
regenerate~1
Duchenne~14
dystrophy~30
(DMD).~4
satellite~10
DMD~7
polymyositis~2
competence.~9
Profiles~2
sectioned~12
stereologically~1
cytoplasm,~7
mitochondria,~6
(RER),~2
Micropinocytotic~1
(MPVs)~1
counted.~3
cytoplasm~21
mitochondrial,~1
RER,~1
MPVs~1
myoadenylate~1
(MADD)~1
glyco(geno)lytic~1
nonstandardized~1
myalgia.~1
Standardization~3
MADD~1
98.8%~1
myalgia~1
denervation~34
(Na)~1
microelectrodes~2
Vaseline~1
Hodgkin-Huxley~1
inactivation.~4
(7-10~1
extensor~8
longus~8
(EDL)~1
denervated~22
inactivation~16
fibers.~24
holding~6
EDL~2
denervation-induced~1
refractoriness~5
channels.~9
sprouting~6
motoneurons~6
motoneuron~3
(MND).~1
muscles,~27
extrajunctional~2
(ACh)~3
(TTX)~3
(AP).~1
MND~2
traumatically~2
Extrajunctional~1
ACh~10
ACh-sensitive~3
TTX-resistant~3
AP~10
regenerative~26
AP.~1
Histochemical~3
atrophic~19
normal-appearing~12
MMD,~1
(DMD)~3
explanted~3
organotypic~1
coculture~1
regenerating~7
develop,~4
innervated,~1
3-6~1
electron-microscopic~4
electrophysiologic~82
cross-species~1
innervation,~4
cross-striations,~1
myonuclei,~1
mature,~3
endplates.~1
myofibrillar~10
innervated~15
coculture,~1
cross-striations~2
Single-fiber~1
(SFEMG)~1
jitter~6
(99%)~6
myasthenia~10
gravis~6
(MG).~2
communis,~1
ones~11
clinically.~14
MG.~3
muscle(s)~1
myopathic~5
MG~4
weakness,~16
stimulation,~29
SFEMG~1
antiacetylcholine~1
picture.~5
recreational~5
volunteering~1
(CK)~6
eccentric~11
exercises.~5
CK~34
20-23~1
24-48~2
3473~1
U/liter,~1
1.55~4
34.71~1
mononeuropathies,~2
foot-drop,~1
myography,~1
perplexing~1
semi-quantitative~2
prognostication~2
foot-drop.~1
Thalidomide~1
disabling~14
dermatologic~10
aphthosis,~1
discoid~3
erythematosus,~9
prurigo~1
nodularis,~1
fail.~4
revealing~12
apparent,~4
sural~12
somatosensory~34
wrist.~4
thalidomide.~1
Timely~1
dosage,~11
misconception~2
reemphasized.~2
nonintravenous~1
"recreational"~1
cocaine-related~2
findings:~2
intranasally;~1
disorders;~1
well-documented~10
for,~5
of,~5
cocaine;~1
incompletely~13
defined,~6
circumstantial~6
consequences.~6
appendectomy~20
279~1
laparoscopically~4
957~1
contraception,~2
confounding~21
appendix,~3
14.9)~1
9.6)~1
appendix.~1
Eosinophiluria~3
eosinophiluria~6
Wright's~5
Hansel's~4
sediment.~1
bright~8
cystitis~7
postinfectious~2
prostatitis~2
necrosis.~27
prostatitis,~2
(DHEA)~1
(DHEAS),~1
discriminators~1
expectancy~13
aging.~9
base-line~15
DHEAS~6
12-year~10
population-based~16
deciliter~7
significant)~6
causes,~17
analyses,~9
obesity,~26
50.~5
acquire~3
abroad,~2
(ECFMG)~1
Colleges~2
10,460~1
359~6
ECFMG~2
heterogeneous:~1
birth,~14
language,~6
Puerto~13
Rico.~1
Sixty-seven~7
resided~3
York,~4
Jersey,~1
Florida,~4
Rico,~3
Mexico~4
Caribbean.~1
attempt,~1
Admission~4
Test.~2
grade-point~2
averages,~1
unaccepted~1
applicants~1
entering~15
classes.~7
belief~19
most,~6
attend~3
RU~10
486~8
(within~17
period).~3
ultrasonography~12
abortion.~6
486.~1
evacuation,~2
softening~2
cervix.~9
curettage~17
supervision.~2
spherocytosis,~1
spherocytosis~3
percent;~21
similarly.~5
Distantly~1
homozygotes~13
severities~1
correspondingly~2
offspring~21
Spectrin~1
fragility~2
splenectomy:~1
counts,~13
compensated~15
hemolysis,~7
cholera,~1
Vibrio~7
cholerae~7
electrolytes,~6
lactate,~13
rehydration,~1
convalescence.~4
134.8~1
(meq)~1
liter,~5
liter;~3
20.2~3
liter.~2
2.48~1
deciliter.~2
hyperproteinemia,~1
lactic~23
hyperphosphatemia,~1
meq~5
hyperproteinemia~1
dehydration,~4
acidemia~3
shock,~7
hyperphosphatemia~2
magnesium~78
gap.~2
beta-lipoprotein~5
92,000~1
Swedish~6
1963~3
1965~12
Register~3
1979.~5
528~1
311~5
1.65~2
276~4
(7.1~2
liter).~1
(6.5~3
liter)~4
(2.2~2
1.62~5
1.18~3
2.22)~1
1.70~2
(1.18~1
2.44).~1
adenomas,~14
1083~2
polyposis,~1
colectomy).~1
842~3
adenoma.~8
body-mass~1
top~5
quintile~7
2.0;~2
limits,~8
3.6)~1
2.2;~1
4.8).~1
adenomas;~2
conclusively~2
appeal~1
5463~1
clinics~12
surveyed.~5
verified~13
(25.9~1
percent)~98
(2.3~6
4582~1
nontwin~1
paralleling~1
oocyst~6
acquisition~25
cryptosporidium~2
parasitologic~1
contacted~7
610~1
oocyst-positive~1
7.2~12
12),~2
12.2~6
26).~1
oocyst-excretion~1
Ziehl-Neelsen-stained~1
concentrates.~1
(73~5
cryptosporidiosis~4
immunocompetent~3
oocysts~5
asymptomatic.~26
intermittently~6
stools.~2
sparse~4
inconsistent.~1
89,538~2
fat,~30
linoleic~10
quintile.~1
601~2
calorie-adjusted~1
quintile,~1
0.82~5
0.64~9
1.05).~1
(confidence~1
0.66~6
1.08)~1
(0.69~3
1.12)~1
(0.70~1
1.18)~1
adulthood~4
calories.~1
suggest,~4
T4+~7
(T8+~1
dual-color~1
anti-2H4~3
anti-T4~1
peripheral-blood~2
progressive,~5
(relapsing-remitting).~1
(T4+2H4+~1
cells),~9
midst~2
T4+2H4+~8
0.0001~3
187~9
cubic~4
millimeter~5
sclerosis;~2
353~5
14.5~8
368~3
14.6~6
402~5
15.6~3
diseases;~5
519~4
19.7~5
mitogen-driven~1
2H4~1
determinant.~4
inducers~3
satisfactorily~12
assembled~4
patients--those~1
injury--and~1
closed-head~2
constellation~10
obvious.~4
consultation,~3
dizziness,~1
hematoma,~7
laceration,~1
contusion,~3
abrasion.~1
omitted.~1
moderate-risk~2
appropriate.~6
7035~1
rooms~3
radiography,~4
savings~18
millions~2
annually.~4
cognate~3
heteroduplex~1
sequence.~12
'heteroduplex~1
mutagenesis'.~1
introducing~9
specificities~22
rearrangement~7
(monoclonal)~1
lymphoid~30
germ-line~4
rearrangements~6
Abelson~2
leukaemia~7
virus-transformed~3
grow~10
populations,~17
untransformed~3
colonizing~1
alymphoid~1
beta-chain~7
rearrangements.~2
intra-thymic~1
diversification~1
repertoire.~1
clonal~11
(EGF)~1
evolutionary~7
domains~13
tyrosine-specific~1
catalytic~13
domain,~5
EGF~4
subunits~10
heterotetrameric~1
Provoked~1
functions,~7
chimaeric~7
transmembrane~12
ligand.~3
simian~5
transduction~6
clostridial~2
neurotoxins~1
tetanus~6
botulinum~12
transmitter~9
terminals,~4
ions.~1
toxins~3
(although~2
D).~3
neurotoxin~3
intracellularly~4
capacitance.~1
internalized,~1
secretion-blocking~1
performs~4
biology,~3
calcium-modulated~1
characteristic,~2
related,~3
fold,~3
EF-hand.~1
alpha-lactalbumin~1
fold~8
resembles~14
EF-hand~1
superficially~3
homology~11
c-type~1
'parent'~1
alpha-lactalbumin).~1
resolution,~4
prokaryotes~1
eukaryotes.~1
kinetoplast~2
curved~2
'bent'.~1
Bent~1
(SV40)~2
replication~33
origins.~2
bent~6
autonomously~1
replicating~5
(ARS1),~1
40-55~1
(bp)~3
(A)3-5~1
stretches~4
poly(A)~3
stretches,~1
nucleotides~8
length)~4
phased~3
bp.~1
TRP1~1
gene,~11
nucleosomes,~1
bp~3
ARS~2
sequence;~1
nucleosome~1
assembly~12
Monocular~2
lid~9
kitten~2
disrupts~2
inputs~6
dominance~10
patterned~5
inequalities~2
higher-level~1
gating~9
striate~4
synaptic~25
behaviourally~1
inputs.~3
plasticity,~2
4-week-old~1
kittens~4
retinas~5
geniculate~1
nucleus,~7
laminae~1
shift.~1
Xq27,~1
retardation~22
(XLMR),~1
thymidylate~10
(Td~1
stress)~3
males--transmitting~1
males--are~1
transmit~6
rodent~5
hybridization,~3
Td~1
stress.~14
transmitting~6
lymphoblasts,~1
harvest.~1
chimpanzee~6
Xq27~2
constitutes~15
post-treatment~8
XLMR.~1
XLMR~1
multi-step~1
manifestation.~2
Allelic~1
oligonucleotide~7
allele-specific~1
(ASO)~1
anneal~1
match~11
perfectly,~1
mismatch~1
simplicity~6
polymerase~6
(PCR)~1
enzymatically~6
amplify~4
ASOs.~1
amplification~13
10(5)-fold~1
sequence,~7
allelic~6
'dot~1
blot'~1
hybridization.~4
simplification,~1
PCR~1
lysates,~2
purification.~2
network,~2
interconnected,~1
'cooperative~1
behaviour'.~1
behaviour,~3
order-disorder~1
transitions,~1
multi-stable~1
'hysteresis',~1
stereopsis~2
cooperative~8
networks.~1
perception.~2
hysteresis~4
excitatory~12
direction-selective~1
elements.~11
Glycine~4
gamma-aminobutyric~15
(GABA)~11
transmitters~6
GABA~44
glutamate~12
decarboxylase~15
(GAD)~2
GABA,~2
glycinergic~2
neurones.~9
glycine~9
glutaraldehyde-fixed~1
Xenopus~9
embryo,~2
anatomically~8
interneurones,~2
interneurones.~1
interneurones~1
glycinergic.~1
glycine-like~1
physiologically,~2
anatomically.~1
claw~1
Wealden~1
(Lower~1
Cretaceous)~1
Surrey~2
claypit~1
1983.~25
discovery~13
well-preserved~2
theropod~3
dinosaur.~1
century~4
ago.~5
Indeed,~7
theropod,~1
reasonably~11
complete,~8
Cretaceous~1
rocks~2
anywhere~3
dinosaur~1
resembling,~1
Allosaurus.~1
dinosaurs~1
merit~7
designation~5
genus~1
family.~12
Optical~2
dyes.~1
optical~26
architecture~11
whisker~1
barrels~1
dyes~2
recordings.~8
microvasculature.~1
dyes,~2
McDonough~1
feline~8
(SM-FeSV)~1
transforms~1
fibroblast~28
fibrosarcomas~1
SM-FeSV~1
haematopoietic~4
oncogene,~1
v-fms,~1
phagocyte~2
colony~29
CSF-1.~1
v-fms-coded~2
c-fms~3
proto-oncogene~2
CSF-1~5
specifically.~3
c-fms-coded~1
v-fms~3
Autophosphorylation~1
constitutive.~1
virus-40~1
(SV40)-immortalized,~1
renders~7
tumourigenic~1
nude~16
factor-independent~1
down-modulated~1
promoter~3
12-O-tetradecanoyl-phorbol-13-acetate~1
(TPA).~2
independence~3
non-autocrine~1
unregulated~2
(BLG)~1
enigma:~1
whey~1
physicochemical~5
interpretation.~6
orthorhombic~1
cow~1
BLG~3
7.6,~1
slabs~2
antiparallel~1
beta-sheet,~1
retinol-binding~6
model-building.~1
BLG-retinol~1
calves.~1
Mixed~4
right-handed~5
left-handed~2
conformations--A,~1
Z.~1
conformation~3
prevails.~1
solvents,~1
A-DNA~2
alternating~18
purine-pyrimidine~1
sequences,~5
Z-DNA.~1
oligonucleotides,~2
atoms~1
polynucleotide~2
B-DNA~2
6.6~16
apart~10
hydrated~3
Z-DNA,~1
A-~2
Z-DNA~1
B----A~1
B----Z~1
transitions.~1
mimic~17
described;~3
toxic.~3
Phoca~1
vitulina~1
westernmost~1
Wadden~4
Sea,~1
Netherlands,~2
collapsed~3
decades.~4
1950~9
Sea~3
pup~4
(Dutch)~2
part.~5
toxicological~2
organochlorines~1
northern~10
biphenyl~1
(PCB)~1
PCB~1
pollution~1
river~1
Rhine,~1
PCBs~2
reproduction.~2
fish~8
polluted~1
pollutants~1
marine~4
mammals.~3
accessory~41
(AOS),~1
1870~1
Gudden,~1
vertebrates.~1
non-primate~1
mammals,~5
fibres~24
project~12
nuclei:~1
(DTN),~1
(LTN)~1
(MTN)~1
nuclei.~9
AOS~3
tuned~1
directions~10
movement:~1
temporo-nasal~1
DTN,~1
LTN~1
MTN.~1
coordinates~3
motion.~21
oculomotor~6
link~20
co-ordination~1
visual-field.~1
generalization~7
primates.~3
primates~5
(prosimians,~1
Old~3
World~17
monkeys~47
apes),~1
Brain~12
topography~6
vertebrate~8
stereotyped~4
relies~4
spatially~8
(JONES)~1
ventral~17
topographically~1
(CNS).~3
postmitotic~1
quadrants~1
quadrants.~1
chloroform/methanol~1
perinatal~46
digestion.~2
[K+]o.~1
[K+]o~4
K+;~1
risen.~1
buffering~4
patch-clamp~3
currents~19
Muller~1
glia~1
endfoot~3
apposed~2
humour,~1
buffered~8
vitreous.~3
Recordings~2
inward-rectifying~4
non-uniform~2
expressing~7
pacemaking~1
driven~6
sino-atrial~2
node.~7
firing~15
if,~2
inward~20
Na-~1
K-current~1
turns~3
-40~2
mV.~1
'pacemaker'~1
photoreceptors~1
drives~1
terminates~1
light-induced~2
hyperpolarization.~2
Currents~1
hippocampal~24
DRG~2
if-channels~1
pS)~2
SA-node~1
Modulation~3
adrenaline~7
opening,~4
single-channel~6
disappears~5
anaerobiosis,~1
reappears~1
restored.~5
form--the~1
'null~1
receptor'~1
shall~1
call~5
it--that~1
idea,~1
WEHI-7~1
thymoma~6
ATP-depleted~1
(MHC).~1
clonally~2
disulphide-linked~1
non-covalently~1
stoichiometrically~1
(Mr)~7
25,000~2
(25K)~1
20K~3
(gamma~2
delta)~1
non-glycosylated~1
(epsilon).~1
clonotypic~1
26K~2
21K~4
endoglycosaminidase~1
(endo~1
F)-insensitive~1
25K,~1
16K.~1
latter,~8
zeta~4
(zeta),~1
homodimer~2
(gp26)~1
homologies~2
polypeptide.~4
thymus.~5
self~6
'altered'~1
self-major~1
(MHC)~5
selected.~5
selections~2
(TcR).~1
cloned.~2
identified;~1
gamma,~4
But~9
messages~1
functional,~5
transcripts~8
TcR~1
'functional'~1
alpha-,~1
beta-~2
gamma-chain~1
10(5)~5
messages)~1
'full-length'~2
transcripts,~2
Nucleotide~1
sequenced~5
functional.~3
prethymic~1
extrathymic~1
lineage~8
fertilization,~2
Drosophila~3
homeobox~1
caudal~23
(cad)~1
spanning~3
Mutations~2
cad~1
zygotic~1
segmentation~4
(fushi~1
tarazu)~1
restricted,~1
plasticity~3
neurones,~6
blastema~1
ciliary~18
Cholinergic~2
retrogradely~2
migration.~10
'adrenergic~1
sites'~1
histofluorescence.~1
specification~9
metameric~3
homoeotic~2
selector~2
parasegmental~1
parasegments.~1
Classical~1
embryological~4
manipulations~8
coordinated~12
pair-rule~2
proceeds~4
metameres~1
envisaging~1
maternally~4
positional~7
translating~1
homeotic~1
intermediaries~1
(see~4
ref.~2
review).~2
see,~1
tw~1
o~2
implicit~4
boundaries~2
fushi~1
tarazu~1
integrating~3
extradural~20
clip~16
T-1.~1
2-hour~5
titrated~10
(MSAP)~2
preinjury~2
levels;~4
naloxone~44
mg/kg),~15
mg/kg/minute).~1
inclined~6
MSAP~8
MSAP.~1
35.6~1
32.7~4
36.1~3
transfusion,~7
cord.(ABSTRACT~1
hematoporphyrin-derivative~1
(HpD)~1
photocytotoxicity~1
glioma~7
wavelength~6
oxygenation,~4
singlet~3
killing~14
12:1~1
violet~1
light.~10
HpD~9
photoradiation~3
densities~26
mW/cm2.~1
Cytotoxicity~2
490~7
torr~4
torr.~2
quenched~1
beta-carotene,~1
mannitol~7
experimentally~19
whereafter~1
hyperresponsive.~1
vasospasm.~15
questioned.~4
fibrinolysis~2
head-injured~6
onset)~4
(10th~1
17th~2
stages.~11
2PI),~1
(ATIII),~1
(FPA)~2
15-42~4
(FPB~1
(platelet~2
(PLT),~1
prothrombin~34
(PT),~2
thromboplastin~11
fibrin/fibrinogen~2
(FDP)).~1
2PI~10
FPA~12
FPB~3
higher;~1
ATIII~19
2PI,~3
ATIII,~1
PLT~1
epidural~91
intracerebral~26
twice.~3
PLT.~1
Fresh-frozen~1
immediately,~5
improvement.(ABSTRACT~1
(ABR),~1
postconcussional~2
ABR~3
long-lasting~9
Subclinical~2
postconcussion~2
neurovascular~12
cadavers.~2
relationships,~7
examples~22
examples,~1
compressions,~2
53.8%,~1
25.6%,~1
20.6%.~1
neuralgia~6
neuralgia.~4
operated.~2
work-up~6
endoorbital~1
because,~2
noninvasive,~4
tridimensionally.~1
solely~28
constant,~14
meningioma~16
problematic.~3
1055~2
hematomas.~5
(1.0%).~1
(10/1055,~1
0.9%).~1
278~2
removals~2
(1.4%),~2
(2.1%),~1
251~7
(0.4%).~2
hematomas,~9
regional,~1
adjacent,~1
distant.~1
locus.~3
hemostasis~4
nonperformance~1
stay~31
hypofibrinogenemia~1
subependymoma~3
Subependymoma~1
isodense,~1
hypodense,~1
postcontrast~1
Differential~7
ependymoma~2
sacrificing~2
contiguous~16
symptomatology,~2
endarterectomy,~6
consciousness,~5
CT,~8
meticulous~8
occipital~9
myofascial~6
Myofascial~1
irreversible~31
myelography.~6
films~13
mock~4
fields~19
margins.~10
invasive,~4
compression.~15
esthesioneuroblastoma~2
(olfactory~1
neuroblastoma).~1
tendencies~2
tumor's~3
cribriform~2
meninges~3
tumor,~46
Recommendations~5
examinations,~17
Aneurysms~4
extracranial~15
rarity,~2
20-year-old~9
soldier~1
C-2~4
approach;~1
continuity~26
aneurysmorrhaphy.~1
33-month-old~1
multilobulated~1
fusiform~7
midbasilar~2
occluding~11
Waves~1
III-V~2
retraction~24
thrombocytopenic~29
causation~5
paraplegia~8
malformation.~4
malformation~22
obliteration.~1
youngest~8
carotid-cavernous~3
Hamby~2
pial~6
remnant~15
reassessed~6
leptomeningeal~7
gliomas~7
Historically,~4
frequently;~1
cranium.~1
cadaveric~12
nests,~1
Until~10
now,~6
mimicking~11
neuroma.~3
extracranial-intracranial~3
unpredictably~1
observational~4
(patient~3
blinded),~1
"randomization-to-treatment"~1
(high~6
randomization~7
operation),~4
"prerandomization"~1
allocation~4
(patients~4
disease).~9
illustrating~4
thrust~3
vessel,~4
systole,~6
taut~2
pia-arachnoid~1
microoperative~1
hemispheres.~4
neural,~4
arterial,~9
cisterns~5
nonpulsatile~7
(CBF)~10
(CME)~1
electroencephalograms~2
(EEG)~6
nonischemic~9
normothermic~11
atrial-femoral~1
ml/kg/minute.~1
CBF~32
CME~2
produced,~5
19%,~7
g/minute~2
(pulse~4
4mm~1
55%,~4
EEG~36
(PRI~1
power/high~1
power),~1
brain.~34
(CHI)~1
postinjury.~3
Sickness~4
Impact~3
functioning,~6
Relatives~1
friends~5
Katz~1
Adjustment~5
CHI~2
relatives'~3
slowing~23
withdrawal.~8
unavailability~1
standardized,~1
(dose-response).~1
economy~4
availability;~1
article,~14
(weight~1
gently~2
cord)~1
one-level~1
T-12~2
Weights~1
Tarlov~3
scale,~8
performance;~3
rested~9
Pathologically,~5
semiquantitative~8
deficiencies,~4
static-load~1
injury-producing~1
posttrauma~2
deficit,~10
Sex,~1
pretrauma~2
insignificant~15
covariates.~2
Immunocomplexes~1
(SAH)~5
SAH~19
vasospasm~22
ICs~4
stays,~1
vasospasm,~3
1st~4
extracavity~1
Weiss~1
springs~1
rods).~1
seven-grade~1
herein.~9
myelopathy~12
motor-complete~1
perception,~2
neurologically;~2
nonambulatory.~2
myelopathies,~1
deficit;~1
preoperatively,~7
Reconstruction~3
appropriate,~3
conservative,~2
1,3-bis(2-chloroethyl)-1-nitrosourea~1
(BCNU)~3
Permanent~5
mg/m2,~1
BCNU~8
utilized,~1
preinfusion~4
gliomas.~2
microneurosurgical~1
unselective~1
prophylaxis~24
reconsidered.~1
perineum~3
rhizotomy~2
cancer-related~3
coccydynia,~1
rhizotomy,~1
Sacral~2
coccydynia~1
spontaneously,~5
hematoma.~8
Periodic~4
78,~2
174,~1
231,~1
326~4
transtemporal~2
clivus~1
dissections~18
heads.~2
(ICA),~1
jugular~24
base;~2
retromastoid~1
craniotomies;~1
finally,~3
petrous~6
tympanic~15
intratemporal~2
ICA,~3
sigmoid~21
sinus,~3
bulb.~1
clivus,~2
divided,~2
displaced~33
anterosuperiorly,~1
preserved.~11
Dural~2
anterolateral~10
medulla,~3
pontomedullary~1
junction,~5
spinomedullary~1
vertebrobasilar~5
6th,~2
7th,~2
8th~6
exposed.~2
labyrinth,~1
cochlea,~2
clival~2
posteroinferiorly.~1
pons,~1
5th,~2
pons~2
times.~17
retraction.~3
clipping~5
Thirty-five~14
myelopathies~1
C-4~2
C-7~1
decompressions~1
fusions~8
decompressions,~1
Substantial~3
neurologically.~1
intranasal~13
subfrontal~1
schwannomas~5
Reactive~5
gliosis~4
40-year-old~7
neoplasm.~16
T2-weighted~30
gliosis,~2
butterfly~1
(MRI),~3
modality,~2
judicious~7
caution.~7
cranium~1
simulating~9
gathered,~2
ventriculitis~1
epidermidis~7
antistaphylococcal~1
penicillin~37
vancomycin~9
rifampin.~1
Vancomycin~5
methicillin-resistant~4
misleading~7
pulposus.~1
ependymoma,~2
surgeons~42
supra-~1
infratentorial~1
(AVMs),~2
resections~28
AVMs~4
multiplicity~7
granulocytosis~1
(CSF~1
eosinophilia)~1
gentamicin~36
pertinent~9
clinicoimmunological~1
philosophers,~1
theologians,~1
public,~1
law.~4
Criteria~5
refined~4
involve~40
electroencephalography.~2
declaration~1
donation~10
desperately~2
this.~6
text,~1
Alzheimer~14
dilatation,~6
sex-matched~16
CSF,~2
Neurologists~2
enumerated~3
1935~4
bases:~1
board~8
Child~4
Neurology~1
Psychiatry~1
Neurology)~1
PG4~1
neurology~2
1970;~1
plateaued~6
385.~1
(prevalence)~1
1,500~13
1950,~2
2,400~1
1970,~4
4,600~2
8,100~1
1990,~3
11,000~1
2000.~1
12,200~1
2010,~1
certified~5
9,900.~1
notably~6
needs:~1
16,500~1
19,100~1
2010.~1
manganese~9
(Mn)~2
epileptics~4
Release~3
(PGE)~2
exacerbation,~1
PGE~9
exacerbation~16
preexacerbation~1
MS.~8
PGE.~1
hemidystonia~2
hemisphere.~9
AVM~5
dystonia.~3
subcortical~19
dystonia,~3
AVM-induced~1
dystonia~4
hemidystonia.~1
electrophysiologically~3
polyarteritis~6
nodosa,~2
Churg-Strauss~2
mononeuropathy~3
multiplex~1
nerve;~1
polyneuropathy.~1
"crack,"~1
free-base~1
cocaine,~1
territory~9
Concomitant~7
ibuprofen.~2
Search~2
Angiography~5
(ICA)~4
irregularity~6
vasculitis.~6
Crack~1
ICA~12
sympathomimetic~15
Tissues~3
probed~3
OC43~1
coronavirus~1
anovulatory~5
suppositories~2
premenstrual~19
q12h.~1
Antiseizure~1
68%~15
Wilcoxon~1
matched-pairs~2
test)~8
menses.~2
tiredness~1
well-tolerated,~3
antiseizure~1
antemortem~6
Balo's~1
hemiparesis~7
ring-enhancing,~1
myelin~17
demyelinated~4
myelinated~18
amyotrophic~8
(ALS)~4
immunoblotting~9
muscle-derived~1
preparations:~1
hemidiaphragms,~1
ALS.~5
Against~2
muscle-conditioned~1
56,000~1
(56K)~1
ALS~6
56K~1
anti-56K~1
oxide.~4
polyneuropathy~16
myelopathy.~3
serially.~1
Sensory~7
scalp-evoked~1
foveal~8
eye,~15
acuity,~9
funduscopic~1
Nitrous~1
groin~18
vulvectomy~2
lymphadenectomy~8
4500-~1
5000-rad~1
groins~1
midplane~1
detected;~2
bilaterally.~3
.03).~8
present;~5
inguinal~24
Stein-Leventhal~1
syndrome;~4
polycystic~5
well-differentiated,~2
adenoacanthomas~1
(six)~1
adenocarcinomas~16
(three)~4
endometrium.~5
adenosquamous~6
wall.~25
progestogens~1
hysterectomy~19
well-differentiated~10
endometrium,~5
4456~1
(0.29%)~1
1944~3
1968.~1
Cystosol~1
cytosol~27
82%,~6
dichotomy~1
cancers.~14
enzyme,~9
antiserum.~7
U/L.~1
U/L~2
Serous~1
adenocarcinoma,~12
endometrioid~2
amounts.~2
immunodetection~1
tocodynamometer~1
patient-activated~1
marking~5
perceived.~1
self-detection~2
tocodynamometry~4
0-78%).~1
Numerous~14
marks~1
multifetal~2
case-controlled~1
dysfunctional~7
commence.~2
cesarean~66
cervix~23
station~5
labor;~1
Time~15
Effective~7
tocolytic~5
tocodynamometry,~1
Evaluation~22
cm,~18
23%,~5
nonrandom~6
contemporary~2
parity~3
Ultimately,~2
term.~18
Comparisons~10
indeed~7
6524~1
primiparous~2
deliveries,~4
encephalopathy~31
midforceps~4
Factors~28
deliveries~21
mothers,~8
labors,~1
meconium~6
Erb/Duchenne's~1
palsy.~14
210,947~1
Washington~7
certificates~4
Erb's~3
births.~5
386~3
univariable~2
multivariable~1
Birth~3
(4001-4500~1
incurring~1
(2501-4000~1
4500~2
(OR~5
21.0).~1
18.3),~1
vacuum~16
17.2),~1
3.7)~1
Delivery~3
midpelvic~1
puerperal~1
ovarian,~3
iliofemoral,~1
thrombophlebitis,~1
antimicrobial~36
extension.~10
Through~11
elucidated~3
Papillomas~2
genotypes,~2
papillomatosis~8
section,~7
juvenile-onset~5
Papillomavirus~2
exposures.~4
electronic~11
(admission~1
concealed~7
birth.~14
(0.9%),~2
ominous~6
depression.~36
1041~1
94.3%,~1
(cesarean~2
indication,~3
Apgar~14
minutes)~33
(1.0%)~1
stethoscopic~1
auscultation~4
well-being~19
Colloid~3
regulator~4
exchange.~14
preeclamptic~9
albumin,~21
postpartum~36
antepartum.~1
antepartum~5
[colloid~2
5.21~2
protein)~7
-11.4~1
(r2~17
0.851)]~1
(serum~10
albumin)~3
-8.2~1
0.891)].~1
pregnancy-induced~5
myometrium~10
estradiol-17~6
postsurgery~1
125I-angiotensin~2
specific,~10
502~1
Receptor~2
1.72~4
nM;~2
Conization~1
intraepithelial~42
neoplasia~41
conization.~3
dysplastic~18
Morphometric~6
conization~4
endocervical~25
moist~3
swab~2
swabs~2
controlled,~9
papillomavirus-associated~1
vagina.~1
modalities,~7
biweekly~4
number,~11
appearance,~9
histology,~8
14.4~5
neutropenic~3
Vincristine,~1
actinomycin-D,~1
cis-diamminedichloroplatinum,~1
vinblastine,~3
three;~2
(gentamicin~2
clindamycin~18
resolved.~7
123/mm3.~1
septicemia~8
Ovarian~2
myomata.~1
hysterectomy,~2
laparoscopy.~8
Histologic~36
hyperplasia,~11
thickening~47
albuginea,~4
albicantia.~1
atretic~1
lutea.~1
contraceptive~38
hospital-based~12
case-control~29
521~4
interview,~7
137~11
allowance~4
(95%~18
0.6-1.5).~1
(0.2-3.9)~1
nulliparous~9
(0.3-1.3)~1
parous~2
(0.7-1.6);~1
years'~8
Paired~4
preeclampsia~13
normals.~10
fetuses.~9
Second-look~1
approximates~2
mode-locked~3
Q-switched~3
Neodymium:YAG~1
(Nd:YAG)~3
high-speed~5
hydrophone~1
incisive~1
focus.~4
Cavitation~1
bubbles~1
transients~2
generated.~4
laser-pulse~1
energies.~2
mJ,~1
bubble~17
bar~5
(130~1
psi)~2
Bubble~1
modes~29
photodisruption.~1
capsulotomy~2
neodymium:YAG~2
(IOP).~3
rise,~4
capsulotomy.~3
Eyes~4
hour,~6
IOP~18
capsulotomy,~2
meshwork~6
fibrin,~1
macrophages,~23
erythrocytes,~8
pigment.~3
hyperopia~3
keratotomy~11
(RK)~2
surgeries~5
metal-blade~3
updated~2
diamond-knife~2
uncorrected~15
determination,~2
cycloplegic~4
refractions~5
keratometry~6
hyperopic~2
spherical~12
diopter~3
(D)~8
emmetropia~4
refractive~19
RK~11
(alone~1
combination)~1
refraction~11
cornea~12
"endothelium"~1
Ultrastructurally,~4
(Weibel-Palade~1
body).~1
Immunoperoxidase~4
VIII~2
keratine,~1
vimentin,~2
S-100~5
enolase.~1
immunoreactivity.~4
should,~2
misnamed~1
"endothelium."~1
myopic~5
Acanthamoeba~3
keratitis~5
midstroma,~1
paracentrally,~1
limbus~1
stippled,~1
dendritiform~1
keratitis.~3
scrapings~1
Acanthamoebae.~1
homemade~3
(salt~1
dissolved~4
distilled~4
Acanthamoebae~2
bottle~4
Distilled~1
wearers.~1
keratoconus.~3
buttons~2
breaks~5
Bowman's~2
tetracyclines~1
anticollagenolytic~2
(oral~3
doses)~2
defects;~2
glaucoma~35
Glaucoma~1
22.2%.~1
Secondary~5
31.8%.~1
tearing~4
ophthalmologic~6
95.8%~1
53.2%~2
54.2%~1
77.3%~1
20/50~5
41.5%~1
41.4%~1
20/200~6
Intraocular~5
uncontrolled~16
19.1%~2
worst~10
30.5%~1
47.8%~2
33.3%~3
1.5-year-old~1
iris~26
stalk~4
fibrovascular~11
Histopathologically,~2
well-circumscribed,~2
melanosomes,~1
melanocytes,~3
annulate~2
lamellae.~1
capsule.~12
nonpigmented~4
adenoma,~7
hyperplastic~22
lamellae~5
osteoblastoma~5
solitary,~2
vascular,~4
osteoid-producing~1
osteoblasts.~1
orbit~11
Cyst~3
lacrimal~9
locations:~1
dacryops);~1
cysts;~2
Krause~1
Wolfring;~1
(choristomatous)~1
histopathology,~2
ductal~42
Pathologic~14
eyeliner~2
(tattooing~1
ferrous~8
oxide),~1
pigment,~2
ectropion~2
aggregates~18
coarse~1
clumps~3
granules,~9
dispersions~1
Minimal~8
orbicularis~4
clinicians.~6
construct,~1
unclear~10
precise,~5
replicable,~1
measure.~6
judging~4
research:~1
scoring;~1
responding;~1
categories;~1
power;~1
indices.~1
judge~6
kinds~22
(present,~1
average)~3
scales.~6
listed~5
above.~7
101-point~1
index.~22
analgesic~21
(either~9
amitriptyline,~3
desipramine,~1
morphine.~5
Desipramine,~1
analgesia.~17
desipramine~4
opiate~27
analgesia~50
opioid-mediated~2
neoplasm,~11
Gintzler~1
Goolkasian~1
Rimer~1
found,~30
women's~7
pressure-induced~4
labor,~13
Gintzler's~1
parturition.~8
conducted,~3
1254~1
174~6
2-3%.~1
hassles,~2
habits.~1
hassles~1
pains~2
behavior,~17
voluntarily~6
backaches,~1
pains,~3
pains.~2
preservative-free~1
(1.5%,~2
19.8~2
mumol)~6
fentanyl~37
(0.06%,~1
1.07~4
polymodal~1
nociceptive~8
(PMNs)~4
noxious~10
fields.~1
0.179~1
0.358~1
mumol/kg)~2
PMNs.~1
latencies~40
recognized,~9
preservatives~3
(chlorbutanol~1
bisulfite~2
0.1%)~2
6-15~1
unitary~7
Lidocaine~5
0.5%,~6
10.7~18
21.4~9
5-18~1
classically~2
opiates,~1
strychnine-enhanced~1
transsynaptic~6
strychnine~1
mg/kg/day)~5
postoperational~1
colchicine~8
transection,~6
dark~13
0.4%~13
vinblastine~14
0.2%~7
24.4~3
seen,~19
neurons,~11
alkaloid~1
colchicine,~2
vincristine~18
86,~2
43,~3
78%,~6
alkaloids~4
essential,~1
effective,~9
prudent.~1
Deformities~1
imbalanced~1
forces.~4
deformation,~1
intrinsically~3
constraining~1
resolve~23
counteracting~3
processes,~11
casting,~1
correction.~10
spina~3
bifida~3
cystica,~3
hip,~6
each:~3
Properly~2
alpha-fetoprotein~7
practiced.~1
dislocation.~8
peri-~3
detection,~6
specificity.~13
Efforts~4
examinations.~23
Limping~1
seeking~14
consultation.~6
limp~3
legion~1
gamut~1
orderly~4
concerned~15
overview~8
limps.~1
aches,~1
Growing~2
named,~1
nebulous~1
exclusion.~2
overlooking~1
localized,~3
quantitated,~1
"observation,"~1
forth~4
article.~5
Shoe~1
braces~13
Night~1
splints~4
Leg-length~1
maturity,~4
vigorous~15
past.~6
foot~49
pediatrician~5
parent's~1
Foot~2
problem;~2
deformities,~6
calcaneovalgus,~1
self-correcting.~1
Metatarsus~1
varus~14
Fixed~2
forefoot~1
heel~4
clubfoot,~1
Corrective~1
metatarsus~1
clubfoot~1
Flexible~6
flatfoot~2
laxity~17
ligaments~10
corrective~10
inserts~2
naturally.~1
bowed~2
femur.~6
commences~2
bowing~2
varum~1
angulation.~2
ankles.~2
giving~21
regress.~2
onset.~11
joint,~13
teenage~9
girls.~11
preteen~1
complaint.~3
complain~6
complaint,~3
carefully.~1
obvious,~1
excludes~3
Still,~4
familiarity~9
counseling~30
referral.~3
notes~7
dislocations,~6
fingertip~3
amputations~13
specialist.~3
Everyone~1
knows~2
everyone~2
growth-plate~1
disaster.~2
knowing~1
which.~1
boom~1
demand~30
cautions~1
kind~10
noncompliance~5
Mathematical~1
logarithmic~7
value)~8
(time~6
minus~9
actually~17
occurred).~1
Retrospectively,~1
end-stage~16
grouped~28
disparate~2
groupings.~1
typology~1
Cuyahoga~1
Ohio,~1
coroner's~1
pertaining~4
1958~8
city~10
6.7/100,000~1
stabilized.~3
Nonwhite~1
Assailants~1
race;~1
nonrelative,~1
home,~9
firearm.~1
firearms~2
(36.2%).~1
infant's~8
"to~1
novel"~1
pictures.~1
retardation.~8
(IQ~4
70)~5
13%.~4
Novelty~1
Validity~4
55%.~2
96%.~2
sensitive,~13
preterm.~2
novelty~4
50).~1
tapping~1
696~1
1964.~1
Participation~3
retinopathy~35
macrovascular~2
nonparticipants.~1
may,~12
experience.~15
Preventing~2
goal~27
behaviors.~5
Posterior~10
fourchette~7
lacerations~25
assault,~1
toluidine~7
rape~8
Application~9
(1/25)~1
(7/25)~1
.05,~2
Fisher~7
16.5%~4
(4/24)~1
(8/24)~1
.318,~1
lacerations.~4
Toluidine~2
.001,~2
highlight~5
four)~4
medium-chain~11
deteriorating~3
Reye~3
syndrome-like~1
hypoketotic~1
dicarboxylic~2
aciduria,~1
alarming~5
eldest~1
sibling~8
fasting,~4
octanoic,~1
decanoic,~1
cis-4-decenoic~1
"dicarboxylic~1
aciduria."~1
acyl-coenzyme~4
[14C]octanoate~1
oxidation.~11
body's~3
stores.~4
Careful~19
at-risk~5
Microcephaly~1
Virtually,~1
live-born~5
(14,724)~1
Malmo,~1
Sweden,~3
Special~10
excreters~1
(congenitally~1
infected)~1
microcephaly~6
(head~1
circumference~34
SD~35
sex)~2
-2~2
SD.~2
deceased~3
there.~3
microcephaly.~1
personal,~1
postconceptional~5
them,~13
Toxoplasma~7
gondii~3
suspected.~8
314~3
epicutaneous~4
Neomycin,~1
fragrance~1
allergens.~5
Academy~10
Dermatology~1
Kit~4
Denver~9
(DDST)~2
language~14
sector~5
DDST~6
(revised)~1
speech-language~1
expressive~2
articulation~4
language.~3
Professionals~1
Legislature~1
restraint~15
traffic~7
20,972~1
Restraint~2
usage~10
10(-6)).~3
Unrestrained~1
restrained~10
fatality~6
post-law~2
12.6%~3
Mexico.~2
ipecac~5
syrup~9
poison~2
unexpired~1
(general~1
emetic~1
bottles,~1
manufacturer).~1
emesis~6
24.8~3
Expired~1
postexpiration,~1
manufacturer,~1
postexpiration~1
date)~1
emetic.~1
osteoarticular~1
Salmonella~12
sp~3
Escherichia~11
coli~20
Enterobacter~4
aerogenes~1
aureus~41
Haemophilus~6
influenzae~7
Streptococcus~10
pneumoniae;~2
b.~6
Fever~9
5,200~1
29,700/microL~1
19,436/microL)~1
5,103/microL~1
1,660/microL).~1
mm/h~1
Needle~4
Incision~3
Recurrence~16
1/2-month-old,~1
polymicrobial~8
Cystic~4
diagnosed.~12
input.~2
catalogues~1
care-giving~1
criteria:~6
1,250~3
respirator~3
FiO2~3
arteriosus,~6
postconception.~2
infants'~1
nurses,~9
individualized~11
implemented~11
briefer~1
stays~4
mothers'~1
dates~4
confinement~2
(post-EDC),~1
Preterm~3
Infants'~1
Behavior,~1
Mental~17
Psychomotor~1
Indices~3
post-EDC,~2
Bayley~2
Scales~7
Development,~1
videotaped~10
height,~15
post-EDC~1
assessments~27
testers~1
(6~36
blind,~2
placebo-controlled,~3
micrograms/mL.~3
periods,~14
behavior/performance~1
psychologic~20
.004).~3
cautiously~8
closely,~2
reports,~9
Report,~1
(NCHS).~1
Yearbook~1
quarterly~2
Reports,~1
Office~5
Nations,~1
offices~1
dates,~1
estimates,~1
figures.~3
residence.~4
cautiously.~3
Aid~1
Families~1
Dependent~1
(AFDC)~1
metropolitan~15
36-month~2
(July~2
92,495~1
visits~54
interval.~26
1984)~7
(Citicare)~1
AFDC~1
authorization~2
census~7
targeted~7
reveals:~1
35,704~1
25,543~1
31,248~1
Citicare~1
self-pay~1
clients~3
25%,~10
(Champus,~1
Hill-Burton,~1
Crippled~1
Commission,~1
3,545,~1
3,555,~1
3,922~1
annualized~1
Medicaid~3
services.~18
Thermography~2
169~6
(21/87)~1
(6/66)~1
(false-positive).~1
pleocytosis~3
(0-10)~2
Thermographic~1
92%.~1
meningitis.~7
educating~1
resuscitations.~1
responding,~2
arrests.~1
resuscitations~1
Johns~10
Hopkins~9
hyperreactivity.~1
asthmatics,~8
deliver~9
patient-specific~3
character,~2
universal~9
cannula~10
brand,~1
gauge;~2
band,~3
style,~1
extensions;~2
20-,~1
22-,~1
24-gauge~1
faster.~1
slowest~4
6.6,~1
5.4,~2
22,~10
gauges,~1
26,000~2
chief~19
(26%)~11
pruritus,~2
discharge,~17
straddle~2
(4%),~4
suicide~28
(2%).~4
throat,~4
asthma,~16
bronchitis,~7
mastoiditis,~1
scald~4
written~12
etiologies~11
hospitalizations~9
burns,~7
charts~21
Harborview~1
PM~12
midnight,~1
(54%).~4
grafting.~7
serious;~1
well-child~1
visit~24
seven-month-old~1
resuscitated~12
pediatrics~2
follows.~4
13-year-old~3
(Periactin)~1
overdose,~3
psychosis,~2
miotic,~1
pupils.~2
supportively~1
miotic~1
pupils~4
issued~1
convulsions~10
topic.~3
drawn.~2
strategies.~7
Reliance~2
3-year-old~2
abated~3
immediately.~3
Antibiotic~3
here,~12
Leptospirosis~1
zoonotic~1
myalgias,~1
morbidity,~14
epidemic~16
doxycycline~2
Public~6
leptospirosis.~1
impairments,~4
barriers.~1
disability,~10
gratifying~1
disability.~17
Rehabilitation~2
multifaceted~2
healthcare~3
professionals~20
organizations.~4
Success~2
Cervical~13
lumbopelvic~2
Scientific~3
scant,~1
empirical~9
Antithrombotic~3
indications.~8
bases,~5
entity.~12
Parasitic,~1
bacterial,~2
cryoprecipitate.~1
Proper~8
donor~45
selection,~5
syphilis,~3
(HIV)~2
transfusion-transmitted~2
Viral~2
non-A~1
HIV~4
self-deferral~1
donated~5
Vaginal~3
empirically.~1
agents:~3
Candida,~2
Gardnerella,~1
Trichomonas,~1
Chlamydia.~2
eradication~8
health.~15
Health-risk~1
appraisals~1
(HRAs)~2
self-scored~1
risk-factor~1
guidance~11
HRAs~3
motivate~1
lifestyles.~1
physician-supervised~1
health-promotion~1
disease-prevention~1
efforts.~7
complex:~1
glenohumeral,~2
acromioclavicular,~1
sternoclavicular~1
scapulothoracic~1
gliding~1
clavicular~3
scapula~3
arm,~4
glenoid~2
humerus,~2
scapulothoracic,~1
ROM.~1
disturb~2
ligamentous~11
withstanding~1
surfaces,~3
range-of-motion~1
palpation.~4
classify~10
dysfunctions~5
noncontractile~1
"frozen~1
shoulder"~1
stiff~2
meaningless,~1
catchall~1
professionals,~2
indiscriminate~2
epidemiology,~4
therapists~21
options~6
prevention,~2
hemiplegic~3
Shoulder~3
impede~4
hemiplegia.~2
unknown,~14
preexisting~18
posthemiplegic~1
subluxation,~5
shoulder-hand~1
Resolution~3
facilitates~19
entrapment~13
triangle~5
comments~4
discussions~5
discussion~22
284~3
arthroscopically~3
athletes'~2
sport.~2
biomechanical~9
throwing.~1
synchronized~3
baseball~2
pitching,~1
swimming,~3
tennis,~1
golf.~1
palate~12
maxillary~16
palatoplasty~1
Z-plasties~2
redirection~3
palatal~2
sling~8
lengthen~3
velum~1
pushback~1
incisions.~5
velopharyngeal~11
flap.~12
rigid,~3
internal,~2
vitallium~1
Le~3
Fort~4
advancements~2
(17),~1
intrusions~2
(9),~1
lengthenings~1
(5),~4
retrusions~1
(2).~4
maxillae~2
moved~12
intermaxillary~4
elastics~1
eliminated.~11
osteosynthesis,~1
orthodontics~1
dento-osseous~1
occlusal~1
disharmony~1
pathosis,~1
sort~1
disk~15
eminence~5
mandibular~14
condyle.~1
lipectomy~2
blood-to-fat~3
noted,~8
Prophylactic~3
illnesses,~7
hydrating~1
perioperatively,~2
smaller-diameter~1
cannulas~3
bloody,~1
1750~2
mammaplasty:~1
Pontes~2
Robbins~2
low-volume~2
ptotic~1
epigastric~19
Taylor~1
al.~20
abdominis~8
superolateral~1
periumbilical~3
perforators.~2
groin,~3
wounds.~26
nonneural~1
guides~2
regenerated~2
cable~2
grows~1
reinnervates~1
fascicle~2
Y-shaped~1
guide.~2
Y.~3
2:1~7
target-specific~1
avulsed~4
skip~2
intima~17
tears~20
replantation~9
amputations.~3
monkey)~1
centimeters~3
distances.~2
30-year~3
male-pattern~1
baldness.~2
Removal~9
fibroxanthoma~1
androgenic~4
alopecia~13
table~23
pectus~6
excavatum~3
deepithelialized,~1
buried,~2
custom-made~2
trochar~2
wires~15
Dingman~2
plate-holding~1
forceps.~6
metal-to-metal~1
lingual~2
jaws~3
remote~22
canals.~2
forceps'~1
ensures~7
alignment,~2
adaptation,~1
pre-insertion~1
interpretation,~1
deals~4
perirenal~3
urinomas~1
nephrostomy~5
stent~23
urinoma~1
advocated~15
affirm~1
urinoma.~2
pyelography,~2
needle,~2
basically~2
role,~8
(cytologic~1
examination),~1
(smear,~1
culture),~1
alterations.~10
pyelography~6
diversion,~3
pyeloureteral~1
Absolute~5
simultaneously;~1
preservation.~1
fistulas,~7
manipulations,~5
radiologist~8
urologist~8
adjuncts~6
Stents~1
manipulations.~2
caliber,~3
Ureteral~3
etiology,~11
devitalization~1
projected.~1
Transluminal~1
dilatation.~11
bougie~2
postdilatation~2
restricturing~1
devascularization,~2
salutary~2
stricture,~2
ureteroneocystostomy,~1
ureteroileostomy.~1
devascularization~3
fulminating~2
these.~3
Decompression~3
evolved~16
1980s,~1
replacing~9
hospitalizations.~3
track~6
calculi.~10
few.~1
shock-wave~5
lithotripsy,~2
Extracorporeal~4
lithotripsy~19
biplanar~2
calculus,~2
waves~45
disintegration,~1
transurethral~24
enthusiasm~1
resulted.~2
adept~1
percutaneous,~1
ureteroscopic,~1
presentations.~2
Specialized~1
Access~1
urethra~22
sheaths~2
specialized~13
explained,~1
lithotripsy.~2
Interventional~2
innovation~4
radiology.~1
redilatations.~1
sparsity~1
reluctance~5
urologists~4
refer~7
strictures.~3
Every~3
impress~1
1,300~2
larger.~4
178~7
(steinstrasse).~1
Nephrostomy~1
5.3%~6
obstructed~24
flushing~7
suctioning~2
pulsating~7
jet.~1
streptokinase,~2
streptokinase-Glutamine-plasminogen,~1
urokinase~7
fibrinolysis,~1
lytic~21
streptokinase;~2
streptokinase-plasminogen~2
1:1,~1
1:2,~1
2:1,~1
urokinase.~4
occlusions~11
homogeneous~27
streptokinase-plasminogen,~1
plasminogen,~1
Streptokinase-plasminogen~1
intrathrombotic~1
Microcapsules,~1
50-350~1
micron),~1
materials~31
(monoglyceride,~1
monodiglyceride,~1
wax,~1
polymer,~1
polymer)~1
floxuridine~2
(2'-deoxy-5-fluorouridine,~1
FUDR)~1
intraarterially~1
kidneys.~11
drug-release~1
microcapsules,~1
6-hour~6
uniphasic~1
multiphasic~6
embolized~5
polymer.~3
lactide~1
capsules.~6
microencapsuled~1
transcatheter~7
Nonferrous~1
brass,~1
titanium,~1
copper,~10
alloys~1
artifact~8
0.6-T~3
magnet.~2
316)~1
tomographic-guided~1
annealing~2
gauge,~1
needle-tip~1
geometry,~5
field.~21
316~1
Amplatz~1
retrievable~1
Mobin-Uddin~1
Kimray-Greenfield~1
retrieval,~2
Filters~1
(56%)~11
filters~11
percutaneously.~2
Complications~27
filter,~6
misplacement~2
pericaval~1
retroperitoneal~32
filter.~4
retrieval~10
iohexol,~2
second-generation~7
Doses~4
iodine/ml)~1
mgI/kg~3
ml/kg).~2
Iohexol~1
well,~10
urograms~5
urogram~1
quality,~12
150-300~1
(0.5-1.0~1
iothalamate~1
meglumine~1
iodine~17
Visualization~3
calyces~1
pelvoinfundibular~1
significance,~7
ureters.~2
scans,~14
cephalocaudal~1
undulating~1
soft-tissue~28
curve,~7
posteriorly~5
arcs.~1
midline.~2
images,~17
diverges~1
converges~1
commonly,~6
irregular,~3
ill-defined,~1
Occasionally,~4
inseparable~1
Morgagni~1
hernias~4
configurations~1
pneumoperitoneum.~3
(HRCT)~1
HRCT-pathologic~1
correlative~3
HRCT~2
diameter;~3
bronchiole~1
bronchiole.~1
lobular~2
mm.~13
centrilobular~6
HRCT.~2
lobule~1
(MR)~67
Thirty-six~20
aortas~11
systemic-pulmonary~3
spiral~10
Angiographic~4
material-enhanced~6
MR~189
100%.~11
66.7%~2
volvulus~5
pneumonectomy~14
bulging~3
contour~21
hemispheric~13
snow~1
cone.~1
modified.~1
intrapericardial~5
pneumonectomy.~4
60-year-old~4
thickened~29
stripe.~1
thickening.~5
angiocardiogram~1
levorotation~1
pad~12
sign.~5
right-pneumonectomy~1
adolescence.~3
Presenting~5
rightward~5
mediastinum,~3
counterclockwise~1
right,~4
resultant~41
bronchus~11
Malacia~1
cases)~19
fluoroscopy~5
bronchoscopy.~7
crucial,~1
Postmortem~12
subsegmental~2
dilated,~6
tortuous,~1
string~3
pearls.~1
Bronchiectasis~1
emphysema,~4
bronchiectasis~12
mild.~2
Specimen~2
honeycombing.~1
bronchiectasis,~3
radiopaque.~4
fibrosis,~24
depicted~7
fibrotic~10
phantom~8
blur~1
margins~23
silhouette~2
paraspinous~1
retrocardiac~2
hypocycloidal~1
tomograms.~3
tomograms~6
phantom.~1
posteroanterior~1
misinterpretation.~1
paid~16
compartments.~6
levotransposition~1
aorta.~21
logical~8
originate~15
diameter)~7
descending,~2
circumflex,~1
branches,~4
ostial~2
(seven~25
seventeen,~1
41%)~3
("ductectatic"~1
mucinous~14
cystadenoma~4
cystadenocarcinoma)~1
indistinguishable~16
cystadenocarcinoma~1
pancreas.~12
uncinate~2
sonograms,~1
pancreas~45
lobulated~2
pancreatography~3
(ERP)~5
grape-like~1
pear-shaped~1
ERP~6
overtly~2
protal~1
hepatocellular~30
B-mode~3
duplex~12
(TAE)~1
TAE,~1
trend.~4
TAE~1
TAE.~1
periportal~5
adenitis~1
hypodense~4
porta~3
hepatis,~1
adenopathy~6
homogeneous,~1
signify~4
noncaseating~1
granulomas~22
caseation~1
adenitis.~1
Pulse~8
spins~3
Experiments~19
projected~10
spins.~1
nonmoving~2
visualized.~2
High-resolution~5
coil~11
images--both~1
nonenhanced~2
DTPA/dimeglumine~1
(Gd)--were~1
high-iodine~1
(88.1~1
(HICT)~1
(MS).~3
T1-weighted,~1
(T1,~1
density,~14
T2),~1
pre-Gd~1
T2WI.~1
Gd-enhanced~2
T1WI~2
Enhancement~2
3-minute~1
T1WI.~1
HICT~2
blood-brain~19
optimizing~5
Then~5
maximize~8
difference-to-noise~1
spin-echo~14
(TR)~3
multisection~4
msec,~15
TR~7
1,375~2
msec.~7
Age-related~6
attainment~1
accelerate~7
menopause~5
losers~1
osteoporosis.~9
(BMC)~4
47-53~1
24,~16
Fifty-four~8
1.96%;~1
losers);~1
5.61%;~1
losers).~1
BMC~11
loss--women~1
(AVN)~3
T1-weighted~14
(T1WI)~1
(repetition~4
[TR]~1
400-1,000~1
[TE]~2
20-25~2
(T2WI)~1
(TR~2
2,000-2,500~1
60-80~1
msec).~5
superoanterior~1
margin~30
21)~8
AVN~6
T1WI,~1
delineated.~3
T2WI,~1
fracture:~1
eight)~1
AVN,~1
staging.~2
ankles~6
calcaneofibular~1
ligament,~6
retinacula,~1
groove,~2
tubercle,~3
evaded~1
convex~7
Examples~5
CT-established~1
tenosynovitis~2
chondromatosis,~1
Erosions~1
extensive,~4
Synovial~5
chondromatosis~3
bones;~2
(SCMR)~1
metrizamide~12
(MM),~2
(CTM)~1
(bone~1
Twenty-eight~15
Predictions~1
SCMR~4
CTM~5
85%,~5
MM~16
67%.~3
jointly,~2
needed,~12
1.5-T~4
superconducting~1
3-mm-thick~1
T1-~8
coronal~24
planes.~3
diagrams.~1
microadenomas~2
macroadenomas.~1
macroadenomas~4
delineated,~1
Adenomas~2
hypointense~1
variable,~14
parasellar~3
chiasm~4
depicted.~2
instances.~7
physico-anatomic~1
phenomena:~1
time-of-flight~2
spin-phase~1
flow-related~2
augmentation~32
signal.~4
Flow-related~1
depiction~3
single-section,~1
diagnostically~4
conspicuity~2
calcification,~1
Physiologic~9
(CSF)~18
pulsation~3
harmonic~12
precessional~1
transform~5
(2DFT)~1
phase-shift~1
("ghost~1
images").~1
CSF.~9
entities~13
arachnoid~6
extramedullary~4
neuroma~4
pulsation,~2
arachnoiditis,~1
thin-section~3
2DFT.~1
electrocardiographically~5
gradient-echo~1
projection.~2
singly,~1
Subtraction~2
eliminates~8
protons,~1
syringohydromyelia.~1
syrinx,~2
block.~30
Charcot-Marie-Tooth~3
roots~6
DTPA,~2
infarcts.~5
white-matter~10
4-30~1
ictus,~1
500-msec~1
30-msec~1
infarct,~1
gadolinium-enhanced~1
500/30~1
Periventricular~1
deep,~2
infarcts~23
MR.~5
brain-stem~7
Usually~2
medium-aged~1
(8-14~1
(15-30~2
time-weighted~1
infarcts,~6
(SPARS),~1
SPARS,~1
selected,~3
suppressed.~3
SPARS~1
gradients,~2
image.~4
applying~17
1331~1
pulse.~6
aspartate~8
imager,~2
brain;~1
underway~2
potential.~21
erection~10
Cavernosography~2
cavernosa.~1
flaccid~5
erection.~8
leakage,~5
arterialization~1
cavernosography~5
normally;~1
impotence~8
erection,~2
intracavernous~7
inflow.~2
papaverine.~5
diluted,~1
Opacification~1
papaverine,~1
cavernometry~1
papaverine~20
elucidating~5
Impotence~2
erectile~4
cavernosograms.~1
coils.~1
leakage.~3
cystourethrography~1
uninhibited~2
Uninhibited~1
urethra.~11
urodynamic~28
92%,~2
90.7%~1
Large,~3
multiloculated~1
septations~1
lymphangiography,~1
opacified~9
lymphangiographic~2
Opacified~1
obviate~9
pitfall.~1
loop-gap~1
resonator~2
excitation~9
high,~15
radio~4
(RF)~4
uniformity~7
RF~10
pair.~1
axillae.~1
Celiac~3
blockades~1
anesthesiologists~3
department.~8
Thoracic~6
alleviate~2
narcotics.~1
desirable~19
analgesia,~8
mammographic~4
views.~5
stereotactic~2
high-osmolality,~1
ionic,~1
(HOCM),~1
low-osmolality~3
(LOCM),~1
nonionic,~1
marketplace.~2
atmosphere~6
(prospective~1
payment~5
system)~6
consumerism~1
newer~21
sparked~1
lingering~2
question,~7
"Can~2
them?"~2
LOCM~1
"expensive"~1
economically~2
constrained~3
radiologists~10
doctor-patient~3
monetarization~1
documenting~12
acceptance,~2
tolerance,~5
safety,~6
efficacy,~13
text~4
practicing~14
LOCM.~1
angiographically~22
methemoglobin,~1
(surrounding~2
lumen,~5
void),~1
methemoglobin~6
extra-aneurysmal~1
peripherally,~2
layered~2
intensities~9
clot~25
(methemoglobin~1
hemosiderin).~1
hematoma:~1
lumen;~2
laminated,~1
staged~19
hemosiderin~1
centrally,~1
located;~1
arises.~2
Hemorrhage~2
perianeurysmal~1
Leigh~2
encephalomyelopathy~1
(SNE),~1
familial,~2
putamina~1
SNE,~1
diffuse,~5
SNE~1
deter~2
context.~1
decompressing~1
disks.~2
entails~5
gaining~5
Nucleotome~1
aspirated.~2
31.~3
encountered,~5
diskectomy~2
(surface)~1
coils~6
(CT),~10
(US),~1
thallium-technetium~1
(TTS).~1
.74~1
.88,~2
sensitivity/specificity~1
74/.95~1
.59/.82~1
US,~1
.82/.98~1
TTS.~1
Enlarged~3
medium-intensity~1
(systolic~4
less)~7
fluid-pharmacologic~1
(0.5-3~1
liters)~1
satisfactorily.~4
six-beat~1
bigeminy~5
(epinephrine)~1
hydrochloride).~1
agent-induced~1
Pharmacologic~4
bronchiolitis~4
obliterans~2
organizing~6
(BOOP)~1
(UIP),~2
biopsy-proved~5
BOOP~11
(16~26
UIP~8
22.~4
independently,~5
UIP,~1
.025).~4
clubbing~2
flows,~6
diffusing~11
UIP.~1
patchy~14
air-space~3
consolidation~4
post-therapy~1
artifacts~7
Scans~5
sides~5
interpretable~4
lymphedema~3
gantry.~2
Radiation~8
overwhelming~13
pectoralis~10
axilla,~3
postirradiation~3
anatomy.~9
79-year-old~1
enlarged,~3
ill-defined~1
bronchovascular~3
markings.~2
mediastinum~12
sheaths.~2
markings~2
implications.~8
927~2
needle-guided~1
seventy~5
(29%)~9
(palpable)~1
142~14
nonpalpable~2
dissection,~17
occult,~3
inconsequential~2
mastectomy,~5
witnessed~6
metastasize~3
multicentricity.~1
attachments,~1
buoyancy~1
Gated~3
(ASD)~2
radiologists.~1
panel,~1
consensus,~1
ASD~1
97%~16
ASDs~1
(primum,~1
secundum,~1
96%;~1
atrium,~9
100%).~3
Sensitivity~7
receiver~8
atrial-level~1
than,~2
1,434~2
388~5
(27%)~10
(excluding~3
reactions)~1
pulmonale.~2
(RVEDP).~1
RVEDP.~1
weighed~13
Fentanyl~5
narcotic~15
intravenously,~12
meperidine~7
sedation~7
phase-contrast~3
(proton~1
spectroscopy)~1
sequences.~13
conspicuous~6
discerned~1
paramagnetically~2
gadolinium-DTPA~1
(diethylenetriaminepentaacetic~1
chelates~3
biodistribution~2
spleen,~18
contrast-enhancing~1
distribute~2
(ESWL)~5
ESWL~14
perinephric~3
Post-ESWL~1
symptomatic)~3
intrarenal~7
(6%)~14
Treated~2
ESWL,~1
Perinephric~1
stranding~1
fossae,~1
superparamagnetic~2
ferrite~8
T1,~10
T2-dependent~2
marrow.~17
Sequestration~2
reticuloendothelial~8
tissue-specific~8
localization,~3
warrants~14
marrow).~1
models.~12
ferrite,~1
tumor;~5
contrast.~1
Motion~1
sequestration~18
Ferrite~1
efficiently~16
predictably~3
latitude~2
promise~15
29-42~2
postconception,~2
magnet~6
devise~1
gray-white~2
myelination.~1
Myelination~1
progresses~2
cephalad~4
centrum~2
semiovale~1
Delayed~11
myelination,~1
corona~2
radiata~1
misinterpretation~3
ventricular/brain~1
(V/B)~1
horns~3
midbody~1
0.26~11
0.34.~1
V/B~2
hydrocephalus.~7
extracerebral~2
Extracerebral~1
widths~2
5-6~3
asphyxia.~4
Prominence~1
atrophy.~8
0.26-0.34~1
0-4~1
4-15~1
cineangiography~4
Correlation~16
delineated~9
dilation,~9
noninvasively~9
destructive~12
spondyloarthropathy~1
spondylitis~9
rheumatology~3
crystal-induced~2
arthropathy~7
extra-spinal~1
hydroxyapatite~6
fifty-eight~4
spines~4
correlation.~1
Macroscopic~3
well-defined,~1
yellow~14
spondylitis,~3
kyphoscoliosis,~1
spondylosis.~2
tabulating~1
8,595~1
nephrostolithotomy~3
institutions)~1
(2,262~1
Inexperience~1
faulty~6
Underlying~3
variants,~3
complication,~10
instituted.~3
neoplasms.~23
reviewing~10
(QCT)~2
nodules,~8
Commercially~1
scanners~4
high-atomic-number~1
(high-Z)~1
low-Z~1
reproducibly.~1
QCT.~1
Field~2
phantoms~1
torso.~2
high-Z~1
HU)~1
materials,~3
HU~11
HU);~1
0-15~1
HU.~2
localizer~1
gantry~1
angled~1
QCT~2
reproducibility.~4
QCT,~1
surveys~13
sources,~5
practiced~7
1964~6
1980.~10
machines~4
1970-1980,~3
57%,~5
financial~9
proposals~1
coaxial~3
steerable~6
sclerotherapy~3
varicoceles~6
matter/white~1
3,000-3,500~1
echoes~1
longest~14
120-160~1
high-contrast~3
1-month-old~2
flexible,~3
balloon-expanded,~1
stents~16
(4-8~1
weeks).~4
fibrocellular~3
20%-25%~1
stents.~1
visceral,~4
unenhanced~3
ethiodized~1
emulsion-13~1
(EOE-13),~1
Spin-echo~1
300/26~3
time/echo~1
msec)~17
95.4%~2
(IR)~2
1,500/100~2
time/inversion~1
90.8%;~1
EOE-13-enhanced~1
87.1%.~1
2,000/80~2
51.4%,~1
49.6%,~1
EOE-CT~3
300/26,~1
IR~2
1,500/100,~1
1-2-cm~1
EOE-13~1
non-contrast~2
urographic~1
isodense~3
non-contrast-enhanced~2
Non-contrast-enhanced~1
carcinoid~18
(ten~9
patient).~11
(39%)~12
liver-to-lesion~1
hypervascular.~1
(CT).~8
hemoperitoneum~3
perisplenic~1
(85%),~2
laceration~6
(71%),~4
Perisplenic~1
laceration.~2
cecal~15
diverticulitis~8
streaky~1
pericecal~2
case),~6
diverticulum~3
case).~4
Barium~3
diverticulitis.~2
appendicitis,~1
diverticula~3
Barrett~5
biopsy-confirmed~3
parameter~28
emptying,~5
(89.5%),~1
82.1%~1
Malaria~1
exacts~1
toll~1
Tropics~1
incomprehensible~1
immunology,~3
biology~9
antimalarial~2
vaccine.~6
Plasmodium~5
malaria~4
interrupted~8
vaccines.~3
vaccination~9
complexities~3
B-~1
Transformation~2
C3H10T1/2~3
(UV)~3
tetradecanoyl~1
UV-TPA-induced~1
(UV-TDTx~1
Cloned~2
UV-TDTx~2
cocultured~2
TPA,~1
UV-TPA~1
transformants.~1
communal~1
multistage~7
transformation,~1
presurface~1
(preS)~1
envelope~8
virion~2
infectivity.~1
reading~22
half.~5
Translation~1
preS~2
initiates~3
163~12
(preS1)~1
(preS2)~1
preS1~3
transfecting~1
RNA's~1
detectably~1
assembly.~2
(TCR)~2
heterodimer,~1
rearranging~2
TCR~5
carboxyl-terminal~2
Lyt2-,~1
L3T4-~1
thymocytes.~1
full-length~3
35-kilodalton~1
(kD)~1
disulfide-bonded~1
45-kD~1
partner~3
(V~1
gamma)~2
subpopulation.~1
spindle~12
orientation.~9
furrow~1
mitosis.~1
poles~5
astral~2
microtubules~8
Expected~2
placements~2
zero.~3
abl~1
c-abl~1
v-abl~1
1q24-25,~1
12-kb~1
transcript~6
c-abl.~1
haptens~2
carboxylic~3
catalysts~1
substrates.~5
substrates~17
congruence~3
haptenic~2
esterolytic~1
analogs.~4
catalyst~2
MOPC167,~1
p-nitrophenylphosphorylcholine~1
catalyzed~3
MOPC167~1
catalysis~6
(kcat)~1
specificity,~14
p-nitrophenylphosphorylcholine.~1
8.0.~1
uncatalyzed~1
770.~1
rules~10
immunogenetically~1
lipoprotein-associated~1
(allotypes),~1
Lpb5,~2
Lpr1,~1
Lpu1,~1
hypercholesterolemia~17
cholesterol-free~2
WHHL~4
apolipoproteins,~1
apolipoprotein-B.~1
(Lpr1),~1
apo-R,~1
23-kilodalton~1
(d~3
1.006~1
g/ml)~2
1.21~3
Isoforms~1
Lpr~2
alleles,~1
Lpr1~1
Lpr2.~1
segregate~3
Lpb5~1
Lpu1~2
alleles.~3
allotype~2
Lpb5.~1
rapid-freezing~1
(DSC)~1
biomembranes.~1
quick-freeze~2
DSC~1
(domains)~1
bilayers.~1
bilayers,~1
calorimetric~1
DSC.~1
county~5
society~9
council~1
co-sponsored~1
forum~1
Panel~2
psychologic,~2
economic,~2
legal,~1
stressed~12
helping~7
emotionally~2
satisfying~2
audience~3
barriers~5
dignity,~1
poverty,~2
facing~4
talking~1
ethical~19
issues.~3
Reasons~4
missing~11
opportunities~12
dependency,~2
alcoholics,~10
alcoholic's~1
denial~4
addiction.~2
above-~1
below-knee~9
ulcerations~4
gangrene~9
three-month~6
formations~2
.01),~25
WBC~13
(19,000~1
12,600/cu~1
12%,~6
non-gas-forming~1
nonclostridial~1
diabetic,~5
lethal.~1
bacteremia~24
bronchoalveolar~35
(BAL)~12
postlavage~4
Qualitative~7
BAL.~1
flora.~4
BAL~44
BAL-associated~1
gram-negative~24
Thirty-nine~9
dura-arachnoid~1
disruption,~3
episode,~8
mastoiditis.~1
35.9%.~1
intrathecal~19
abbreviated~5
doses).~2
chloramphenicol~9
Splenorrhaphy~1
traumatized~4
postsplenectomy~2
Norfolk~1
splenorrhaphy.~2
splenorrhaphy,~1
splenorrhaphy;~1
unsalvageable~1
salvageable~2
resorting~2
accrue~1
8.9%~2
3.2%,~1
anticipating~2
Availability~1
visiting~2
30.2~4
vulvectomy.~1
reexploration~3
safely,~4
staffed~6
nonoverlapping~2
Weight~8
kg;~3
marriages,~1
adjustments.~2
team,~3
jejunoileal~8
Potentially~4
iatrogenic~10
technologic~3
past,~7
reimbursement~9
Carotid~4
vascularity,~3
carotid-carotid~1
blowout.~1
(MPA)~1
polyarticular~4
flares~2
swollen~9
joints),~1
singular~4
vast~12
minimal.~11
Postbolus~1
useful,~5
inexpensive,~5
safe.~5
Asians~2
microcytic,~2
hypochromic~3
country.~6
heterozygous~13
8.4,~1
suspected,~4
agar~13
6.3.~1
relief,~4
blindly~6
Multiphasic~9
Personality~13
(MMPI).~1
MMPI,~3
worse~39
groups--those~1
surgery--and~1
rankings~5
internship~5
Intern~1
(ISC)~1
Virginia~6
faculty~34
rankings,~1
ISCs.~1
illustrative~6
world's~1
occasions,~7
actinomycosis,~1
surgeon's~5
actinomycosis~3
provision~12
dilatations~1
ultrasonography,~2
cholescintigraphy.~1
Unrecognized~1
occurrence.~7
Allowing~1
mishap~1
catastrophe~2
inexcusable.~1
mouth-to-tube~1
one's~2
intubation.~16
verification~4
intubations~4
Accelerated~1
ictus~1
hyperdensity~2
matter,~6
illusion~2
(3D83,~1
Electric)~1
reformat~1
(3D)~1
(2D)~1
3D~4
axes~2
(constituting~1
movie),~1
head-motion~1
parallax~1
reformation~2
foraminal~1
reformatting~1
hemisections.~1
Currently~3
improvement,~15
applicability.~1
20-65~1
60-65,~1
roentgenograms.~9
C5-6~4
0.52).~2
narrowing.~3
subluxation.~2
Atraumatic~1
Intractable~2
rhizopathy~1
long-tract~2
C1-C2.~2
Superior~3
magnum~1
occiput~5
brace~11
symptom-free,~1
Bony~2
pseudoarthrosis,~1
Midsagittal~1
(MSD)~1
interpedicular~1
(IPD)~2
thoracolumbar~6
junctional~22
(T10-L1)~1
canals~8
IPD~6
0.98).~2
MSD~2
0.70,~3
designs~7
hooks~2
hook~10
dislodge~2
hook.~1
plain,~1
ribbed,~1
bifid~5
lamina,~3
ribbed~1
hooks.~1
hydatid~6
kyphosis.~2
antihelmintic~1
mebendazole~3
Segmental~10
quantifying~6
rotational~12
segment)~2
tracked~7
centrode.~1
Instability,~1
erratic~1
centrode~4
determines~10
positions,~4
Acetate~4
matching~11
film.~4
radiograph,~1
digitizer~3
Centrode~1
43.7~1
55.9~1
Twice~3
right.~4
fulfilled~12
sciatica~2
topographic~3
root.~6
dominance.~2
widely.~2
diversity~14
94%.~2
delineate~19
men;~6
Duration~15
paravertebral~3
height.~10
occipito-cervical~1
Rancho~2
Amigos~2
His~14
respirator.~1
Sternocleidomastoid~1
musculature~9
support.~20
fuse~2
tongue-switch~1
trailer~1
incorporates~8
musculo-ligamentous-skeletal~1
L4-L5,~3
lifts,~1
restorative~4
bending,~2
strain,~9
kinematics~2
cine~2
models,~4
modeling,~2
kinematics,~2
estimation.~1
Estimations~1
L4-L5~1
shear~21
42.5%~1
erector~4
invoke~2
contentious~1
compression-reducing~1
sacrospinalis,~1
Ligaments~1
played~14
lifts~1
handling.~3
intradiscal~7
discitis~10
chymopapain~10
Conray~2
bactericidal~18
gram~5
antibacterial~7
suspension.~2
end-plates~2
bacteria.~13
discitis,~1
sacrifice.~1
sciatica.~1
cysteine~4
glycosaminoglycan.~1
cystatin~1
kininogen~1
collagenolytic~2
prolapsed~9
collagenase~10
substrates,~2
discs.~6
annulus~7
quantity.~1
collagen,~15
elastin.~4
elastin~13
Similarly~3
discs,~4
postmortem,~2
prolapse.~6
Degenerate~1
82-year-old~2
attainable~4
Picker~1
International~17
Imaging~6
Tesla.~1
saturation-recovery~1
magnetization,~1
infinity,~1
Images~3
fibrosus~1
clearly,~1
laminated~2
fibrosus;~1
resolved.(ABSTRACT~1
1H~1
(NMR)~6
spin-lattice~1
sectors~3
stresses,~4
pont~1
disorders:~2
chemonucleolysis;~1
91,~1
first-time~7
operations;~1
fusions;~1
Identical~4
treatable~12
judgments~8
disability--by~1
observer.~5
Return~2
reconsideration~2
442~1
478~1
40,~14
trouble~1
(LBT)~1
univariate~12
LBT~4
analyses.~11
claudication,~3
restlessness,~1
rumbling~1
"the~7
stomach"~1
feeling~7
fatigue.~10
LBT,~1
enjoy~1
Degeneration~1
Finite~1
Element~1
Method.~1
end-plates.~1
end-plates,~1
wall,~13
rims.~1
occupy~2
endplate~4
spongy~6
core.~3
Ways~2
Structural~9
multifidus~5
follow:~2
core-targetoid~2
moth-eaten~2
grouping~7
(indicators~1
reinnervation)~1
inactivity~3
certainty,~1
denervation,~3
elucidated.~5
Transverse~2
zygapophyseal~2
anterior,~10
coronally~1
oriented~17
posterior,~4
sagittally~1
imparted~1
capsule,~4
plate,~1
thickens~1
stature.~3
scoliosis,~4
"uncoiled"~1
stature~10
Stature~1
anthropometric~11
489~2
4-18~1
0.80.~2
5.9-18.4~1
span,~3
uncoiled~2
VC.~1
Mammary~1
breasts~2
classifications~6
types)~1
Cobb~2
degrees).~5
Milwaukee~5
braces,~1
constituting~7
Orthopaedics~1
Gothenburg,~1
1974,~1
6-9~2
brace-treated~2
semistructured~1
staff,~7
said~9
informed~15
38%,~5
concept,~3
laparotomy,~3
aspirations~6
97.3~2
over-all~8
71.9~3
No.~21
"skinny"~1
86.7~1
Over-all~2
61.8~3
73.3~1
sheath~19
pseudocyst~7
sheathed~2
81.8~1
passes~1
passes.~1
enlargements~1
Deep~8
breast.~11
pectoral~3
fascia.~2
fascia~12
centimeter~5
less;~3
0.92).~2
herniorrhaphy~3
789~2
Long~5
Jewish~3
evaluation;~3
sac;~1
lipoma~4
hydrocele);~1
935~1
1,020~2
(groups~3
5):~1
liposarcoma~5
lipoma.~2
(0.098~1
5.~16
Aggregate~1
$30,528.00~1
$48.00).~1
omitting~3
$18~1
million.~3
justification~3
assurance~10
herniorrhaphy,~1
(PTH),~1
(1-34),~1
basis,~14
PTH(1-34)~2
nanomoles~4
(1-34)~1
290~6
12.5~11
54.3~3
requirements.~8
(PGV)~1
PGV~2
perforated~12
PGV.~1
predominance~11
ulceration.~3
neonates.~5
nonoperatively.~4
option~16
Avoidable~1
extra-abdominal~1
ten,~6
truncal~7
drainage)~1
(Bernstein~1
tests),~1
contrasted~19
vagotomy).~1
texts~3
viscera~4
expectantly.~4
faced~6
reported;~3
policy.~2
Age,~6
gallbladder.~8
gallbladders~10
cholecystitis~11
Strips~4
Krebs~8
ethanol-propylene~1
(solvent~1
(0.1,~2
micromolar)~2
17-beta-estradiol~1
micromolar).~1
Concentration~1
rhythmic~13
cent,~38
acetylcholine.~3
Estradiol-17~1
neurohormonal~2
gender.~3
contractility.~10
rectum.~7
shaped~9
clamps.~1
suturing~2
Main~1
troubles~1
stump,~5
flabby~1
keeps~2
retracting~1
wings~1
blades~1
clamp.~1
purse-string~1
EEA~3
stapling~10
tape~12
cosmetically~3
Paper~1
expensive~19
Steri~1
Strips.~1
paracolostomy~1
colostomy~17
affixing~1
firmly~3
aperture.~1
transduodenal~3
choledochoduodenostomy~6
stoma~11
Surface-recorded~1
somatosensory-evoked~18
(SEPs)~4
dysraphic~1
malformations,~6
(4),~2
syringomyelia~7
(3),~7
(2),~7
demyelinating~15
Somatosensory-evoked~2
SEP~17
rostral~6
Prolongation~2
Correlations~9
SEPs,~1
sphincteric~8
SEPs.~1
SEPs~8
pathways,~9
technical,~1
neurotrauma.~1
(Cv2)~1
barbiturate~5
Symmetrical~1
contusions~2
recoveries,~1
outcomes.~4
Glasgow~8
time;~7
Score.~1
Cortical~3
etiology.~12
thalamocapsular~1
perirolandic~1
Patterns~11
(N1-P1),~1
waveform.~5
Premature~4
hazard.~2
hasty~1
advantage.~3
evacuated,~1
thin-walled~1
(L.S.)~1
Sixty-six~7
(35.7%)~2
65.2%~1
13.6%,~1
12.1%,~1
3%.~4
A1~9
segments,~13
neurosurgeon.~1
meningiomas~11
evolution,~2
namely,~11
interpeak~5
N14~3
N20~10
bipolar~29
Neuroleptanalgesia~1
mater,~1
Willis,~1
66-year-old~5
housewife,~2
cerebellopontine~2
aneurysm,~8
brainstem-evoked~1
(BERs)~1
BERs,~1
originates~4
colliculus,~1
(ICP)~1
BERs~1
lengthening~19
uncal~1
ICP~10
latency.~4
Spinal,~1
subcortical,~2
neurophysiological~5
sedated~1
nonsedated~1
adults;~2
maturational~6
(N9~1
equivalent)~6
(N13~1
lumbothoracic~1
junction~40
(N14~1
negativity~2
(N18~1
(P28~1
spinal,~1
N1-P1~1
identical;~1
normative~2
ploidy~25
paraffin-embedded~7
archival~2
fate,~1
Preparation~1
Hedley~1
propidium~1
Vindelov~1
histogram,~2
4C~1
(DNA~1
tetraploid)~1
histogram~3
fractionated~12
catecholamines.~3
tetraploid/polyploid~1
malignancy;~2
cytometric~10
pheochromocytoma.~3
Calcium-parathyroid~1
(Ca-PTH)~1
hypercalcemia;~1
sections,~4
Ca-PTH~3
right;~1
eucalcemic~1
cellularity~7
regulation.~9
(iPTH)~1
debated,~2
iPTH~10
parathyroidectomy~11
mid-region-specific~1
Eighty-eight~8
microliter~1
Eq/ml)~1
40%)~5
parathyroidectomy,~1
hyperparathyroidism,~3
"tiny"~1
mg).~8
(The~1
sections.)~1
frozen-section~1
"probable~1
tissue"~1
embedded~14
pathologists~19
hyperparathyroid~2
endocrinologists~1
agreed~17
masquerading~4
normal-sized~2
tiny~2
XI~5
11-year~6
Ashkenazim--18~1
women--ranging~1
neoplasia.~14
papillary-mixed~1
virtue~4
undue~3
disturbance.~8
counts.~8
Factor~22
1962~11
invasion.~24
large-needle~5
hypercellular~3
lobectomy~12
112~17
241~3
78%.~7
larger,~4
Na131I~1
castration~8
castrated~10
implanted,~1
slow-release~9
hormone-containing~1
pellets~17
(T-physiologic~1
dose).~3
(0.1T,~1
1.0T,~2
30T)~1
8%,~4
41%,~5
0T,~1
0.1T,~1
30T,~1
7%.~5
testosterone-replacement~1
age-dependent~5
irradiation-induced~3
46%),~1
oncologic~2
(reduced~1
radioiodine).~1
nonresectable~2
lungs).~1
omentum~5
suprarenal~4
pleura,~3
tissue)~1
Osteosynthesis~1
endoprosthesis.~1
49.3~1
intercurrently~1
(average,~11
99.3~1
months);~6
(Kaplan-Meier)~2
44.8~2
11.2%~1
Aggressive~6
invasive-papillary~1
Radical~2
thyroidectomy~25
laryngotracheoesophagectomy~1
(reconstruction~1
digestive~8
flap),~1
sleeve,~1
(immediate~1
one),~1
esophagectomy~13
25-year~2
(1959~1
1983),~2
Hurthle~11
Chicago~5
women;~12
46.7~1
13.2~4
(range:~6
diagnosis:~1
7.5%);~1
(partial~3
invasion)~1
18.5%);~1
appearing~9
74%).~1
low-dose,~1
non-Hurthle~1
patients--79%~1
8.4~7
years),~27
discovered--two~1
individualized.~1
(surgical~2
therapy)~6
frankly~2
cancers,~15
carcinomas,~23
single,~7
well-encapsulated,~1
(2.5%~2
literature).~1
Controversy~10
radiation-associated~2
nodules.~7
multicentricity~2
Is~4
2118~1
(36~12
cancer),~1
less,~12
cancer).~1
leave~8
unresected~2
1961~6
1986~16
(20%)~18
follicular.~1
(RAI)~1
(STT)~1
aggressively,~1
II:~3
diffusely~8
enlarge~3
goiters~5
STT.~1
RAI.~2
III:~1
palpable~15
intraoperatively,~3
(5.2%)~3
carcinoma;~5
(3.1%~1
total)~2
303~5
RAI~2
(0.3%)~3
STT,~1
left.~3
"single~1
nodule"~1
qualifiers~1
"clinically~3
solitary"~1
dominant."~1
thyroidectomies~1
22-year~1
17%.~4
goiters,~2
whereas,~6
eliminated,~3
operatively~5
goiters.~2
Fine-needle~9
415~4
hypofunctioning~1
scintiscans.~3
Specimens~5
399~3
thyroidectomies.~1
(14.5%).~1
(69%).~2
(75%).~1
complementary.~1
fine-needle~15
miss~3
April~14
thyroidectomy,~6
0.0078).~1
immunocalcitonin~1
(iCT)~1
Forty-eight~15
calcitonin~11
orange~3
juice.~3
absorptiometry~1
iCT~2
mumol/L;~1
iodine,~2
2;~9
48.5~1
4.7.~2
race~14
covariates,~1
unanswered.~1
AVP,~7
picogram/ml~1
1.7)~2
pg/ml;~5
norepinephrine,~22
5,834~1
2,564)~1
72,422~1
31,433)~1
1,033~1
405)~1
56,444~1
23,542)~1
35)~2
4,231~1
1,318)~1
pg/ml.~4
placement,~9
narcotics~7
lability~4
secretes~3
blend~2
unreported.~1
(when~2
(15/32)~1
(three~37
exclusive~6
DA-secreting~1
normotensive.~3
Without~7
(unexplained~2
features).~1
ectopic.~2
catecholamine-secreting~1
hypertensive.~4
cough.~4
alpha-blockade,~2
Predominant~2
antiadrenergic~2
amines.~1
Hypertension~11
DA/noradrenaline~1
adrenaline.~2
Memorial~12
Sloan-Kettering~2
Institute.~1
nonfunctional.~1
infrequently~18
infiltrated~5
metastasized~4
gland;~3
operation;~5
recurrences;~1
resect~1
unresectable.~1
en-bloc~1
invasion,~16
(PPNAD).~1
variably~9
lentigines,~3
neuroectodermal~5
biochemical,~7
PPNAD~3
Biochemical~10
autonomous~5
hyperfunction.~1
dexamethasone,~2
metyrapone~7
adrenocorticotropic~12
turcica,~1
ACTH-producing~4
adrenalectomy~3
Nelson's~1
occurred,~30
adrenalectomy,~1
myxomas~10
multiple,~8
recurrent,~7
locations,~5
mind.~3
Secretin~4
gastrinoma~12
paradoxic~4
Zollinger-Ellison~6
secretin~25
mol/L.~5
(sec).~1
ng/ml,~15
SEC~2
mol/L~17
706~1
798~2
([p~1
Student~2
test]).~1
dispersion.~1
Somatostatin~2
(SRIF),~1
tetradecapeptide,~1
hence~17
SRIF~4
(PC).~1
chelation~1
fundic~11
PC~23
enrichment~9
(75%~4
5%)~5
sedimentation~33
elutriator~1
rotor.~1
Acid,~1
14C-aminopyrine~1
(AP)~4
(intrinsic~1
[IF])~1
(10(-6)~6
mol/L).~2
(10(-10)~3
mol/L)~3
H-stimulated~2
14C-AP~1
Inhibition~15
IF~3
postulation~3
PC.~3
(ZES)~1
(MEN~1
ZES~3
desirable,~3
chances~6
(H2)~2
introduced,~5
enucleation,~1
pancreatectomy,~1
enucleation~6
pancreatectomy).~1
curative,~2
gastrectomy,~5
gastrectomy.~5
H2-antagonist~2
ZES.~1
metalloproteinases~1
(TIMP)~1
sputum~18
prednisolone,~3
daily).~2
TIMP~7
0.87)~1
(1.9)~1
(2p~2
(1.1)~2
2.69~1
(0.92)~1
inactive.~3
complexing~1
(27,500)~1
(28,000-28,500).~1
ng/ml-2.1~1
Collagenase~1
metalloproteinase-inhibitor~1
predicted),~1
loud~3
snoring~5
sleep--mean~1
(SaO2)~4
92.9%~3
83.2%~1
(2.1%)~1
transient,~3
(non-REM~1
91.5%,~1
90.4%;~1
sleep--21.1~1
(1.8)~1
17.3~3
(1.5)~1
Nasal~9
mucociliary~15
Teflon~8
99mTc,~2
nose.~3
Tracheobronchial~4
radioaerosol~3
(rs~6
-0.94,~1
-0.79,~2
202~11
sarcoidosis,~8
Household~4
Surveys~4
(GHS)~1
habit.~2
(21.9%)~3
GHS~1
non-smoking~2
sarcoidosis~21
grouping.~1
ex-smokers~2
bullae~6
hilar~11
Hypercalcaemia~1
bulla~3
purulent~13
irreversibly,~1
convert~6
mucoid,~1
(though~2
useful)~1
improvements.~2
(of~2
N-isopropyl-p[123I]iodoamphetamine,~1
camera~12
technetium-99m,~1
123I-iodoamphetamine~2
iodoamphetamine~1
Addis~1
Ababa~1
49%,~2
trephine~6
decubitus~3
haemoptysis~1
pulmonale,~1
Cytospin~1
cryptogenic~6
fibrosing~5
alveolitis)~1
lysosomal~20
Phenotypically~2
reagents~9
emerged.~1
RFD1~1
(interdigitating~1
marker;~2
alveolitis~8
RFD7~1
coughing,~2
exercises~5
exercises,~4
percussion,~1
Mucociliary~1
cilia~8
mucus;~1
secretions.~4
saccharin~2
photometric~2
studied:~11
mucopurulent~5
Cilia~1
(mucopurulent~1
12.1~3
Hz,~10
Hz),~1
(14.3~1
organism~29
isolated.~7
Ciliary~1
1973-85~1
times).~1
emphysema.~3
(blood~7
100/60~1
Hg),~11
barotrauma~2
theoretical~28
small.~6
abolishes~2
drive,~8
relaxants.~2
443~5
bronchoscope.~2
brushed.~1
(90.3%)~1
brushing~2
287~4
(64.8%)~1
(93.7%).~1
Histologically,~13
(83.7%)~1
(81.5%)~2
necropsy~19
purely~6
1820~1
1962-77~1
reclassified~4
TNM~6
924~1
exploratory~26
thoracotomies.~1
(8.4%),~1
T1-2,~1
N0-1,~2
M0~2
tumours.~13
re-evaluated~5
pathologists.~4
descent~7
inertia~1
result,~32
expansion.~8
displacement,~4
tetraplegic~5
posture,~3
detrimental~10
ciliotoxicity~1
minutes;~13
(9.3)~1
(3.8)~1
lifelong~7
cigarettes~10
exhaling~1
nostrils.~1
Unless~4
ciliotoxic~1
viscoelastic~5
mucus.~1
keeping~13
Smoking~9
bronchiolar~1
mucus-cilia~1
coupling.~2
(peripheral)~1
symptomless~11
non-smokers~3
subjects).~4
Gamma~1
Alveolar~7
particle~12
smokers.~6
conducting~8
defence~2
non-smokers)~1
nevertheless~7
Lungs~3
coalworkers~1
coming~3
Increasingly~2
macroscopically,~2
erosion~10
changes)~2
assessments,~6
scores.~15
accumulating~2
sending~1
laden~1
bird~3
breeder's~3
breeders~7
Sterilised~1
lyophilised~1
birds~14
intradermally.~2
Skinprick~2
0.0005);~2
0.09).~2
Intradermal~4
0.001);~7
breeders,~1
possessing~5
agonist)~7
phenylephrine~20
tone,~8
refrained~1
0.085,~1
2.0,~1
phenylephrine.~4
nmol/l,~1
clearcut~4
40-50/25-30~1
(sGaw),~1
(PEF),~1
agonists,~3
(phenylephrine)~2
(noradrenaline),~1
amoxycillin~3
diary~5
card~2
secretions:~1
sputum,~2
purulent;~2
purulent.~2
exacerbation.~1
1/2,~2
1-11~2
mucopurulent-purulent~1
purulence~1
9,~12
4-31~1
sachets~1
day)~17
responded.~7
nebulised~1
amoxycillin,~1
Improvements~7
protriptyline~2
hypoventilation~2
restrictive~12
retired~3
0.67,~1
diurnally~1
kPa~2
(67.5~1
Anticholinergic~2
mined~1
barytes~2
pneumoconiosis~4
died;~4
industry.~5
men's~1
silicosis~6
quartz~5
mortem.~1
mines.~1
miners~3
pneumoconiosis,~2
baritosis,~1
crushed~3
salts.~6
mining~1
minerals~4
pneumoconiosis.~2
compounded~4
when,~2
happens,~1
silicotic~1
ceased.~4
miners.~1
"definite"~4
(91)~1
"probable"~5
(66)~1
Unmatched~1
odds~27
2.84~2
3.79~2
0.0006)~2
non-significant~3
5.00~1
0.0003)~4
silicosis,~1
r).~1
discover~2
foams~1
shell,~1
thoraces~1
loaves~1
bread~2
submerged~3
(true~2
250-12,500~1
+0.2~1
68)~3
72-3125~1
+30~1
(78)~2
capacities,~2
(TLC),~1
431~3
(64)~1
427~3
(63)~1
Throughout~8
mid~7
RV/TLC~1
constant--mean~1
(5%).~4
graphically~4
(SACE)~1
(S~2
(LACE)~1
LACE~3
SACE~5
SACE.~1
partly,~3
sporadic,~1
legionnaires'~4
seasonal~26
male.~4
Pre-existing~1
unproductive~1
dyspnoea,~2
confusion,~5
diarrhoea.~3
absent,~6
Localising~1
lymphopenia,~2
hyponatraemia,~2
hypophosphataemia,~1
hypoalbuminaemia,~1
haematuria.~2
(16%),~6
erythromycin~12
(23%),~1
Sporadic~1
non-adrenergic~1
isoprenaline.~3
Incremental~3
pmol/kg/min~4
beats/min.~4
(sGaw)~1
Isoprenaline~1
(400~14
sGaw~1
50%.~10
Infused~1
portable~13
meter~14
turbine~1
Wright~2
meter.~3
(PEF)~3
PEF~8
coded~14
uncoded~3
order.~10
stronger~11
regressions~7
PEF.~1
poorest~4
calibre~2
wheeze~3
occasions:~1
night,~6
electroencephalogram.~2
(40)~2
pm~3
(46)~1
morning,~1
(PEF~1
465~3
(43),~1
371~4
(43)~2
0.1)~2
slept~2
(asleep~1
(6%),~3
(4%);~1
(57~6
(750~2
VP-16~6
folinic~1
given.~21
(30-40~2
(3000-4000~1
rads]~1
(86%)~8
remissions.~4
(66%)~3
non-responders.~2
Mucositis,~1
49%~16
eight).~1
Ladakhi~1
yaks,~1
4500m,~1
yaks~1
bred~2
yak~1
indigenous~1
Himalayan~1
yaks.~1
dzo~1
(cow~1
yak)~1
yak.~1
stols~1
(dzo~1
bull)~1
yak,~1
cow.~1
dominant.~1
611~1
(6.7%)~1
extradurally,~1
deciding~9
urease~2
propionohydroxamic~1
(PHA)~3
anti-urease~1
Thirty-three~13
staghorn~3
calculous~2
bacteriuria,~3
constituent,~1
concrements.~2
Twenty-four-hour~6
CaOx~2
Stone~4
Lauderdale,~1
226~5
July,~4
258~2
Outpatient~4
AMS~1
M700~1
inflatable~7
Eighty-six~8
cylinders~2
nonabsorbable~2
reservoir~30
malfunctions.~1
nonkinking~2
tubing.~2
September,~3
leaks.~1
97.9~1
satisfaction~33
Section~1
Urological~1
scrotal~18
distends~1
accommodate~3
scrotum,~2
distensibility~11
vesicoureteral~10
manometry.~3
nonfortuitous~1
Cholesteatoma~2
keratinized~2
desquamative~2
metaplasia.~6
ablative~3
cholesteatoma~7
evacuation.~6
Rectourethral~2
ejaculation~4
rectourethral~1
Dihydrotestosterone~1
frequently.~9
nephrotoxic~8
tobramycin~14
sacrifice~5
tobramycin.~1
angiomyolipomas~3
angiomyolipomatosis,~1
hypernephromas~1
totally;~1
angiomyolipoma~4
recognizable.~2
hypernephroma.~1
Calcification~2
pathologically.~6
transplants.~1
varicella~10
zoster~9
suffers~1
atonic~1
Attention~7
vesicouterine~1
fistuli~1
Retroaortic~1
Recently~7
uroflowmetry~1
urethrocystometry~1
resume~1
Presence~8
Pseudomonas~17
aeruginosa~16
cefsulodin~5
Gm)~1
aminoglycoside~20
(amikacin~1
mg/Kg~2
mg/Kg)~1
aminoglycosides~14
completing~11
aminoglycoside.~1
Cefsulodin~1
penicillin,~7
rash.~3
aminoglycosides.~1
neurogenic~17
rhabdomyosarcoma~6
Roswell~1
Park~2
(RPMI).~1
(XRT),~1
(10/16)~1
Herein~5
Uroflowmetry,~1
cystometry,~1
postvoid~1
urologist.~1
supplies~4
asymptomatically~1
urodynamics~1
individualization~4
progress.~7
diethylstilbestrol~5
lipoproteins)~2
hyperaggregability~1
DES-treated~1
polyestradiolphosphate~1
etinylestradiol.~1
DES-treatment~1
atherogenic~8
Prostate-specific~1
(PSA)~1
(PAP)~2
(BPH),~1
prostatitis.~2
PSA~6
PAP~8
cancer:~2
95.0~1
60.0~1
97.1~1
65.7~2
holds~10
early-stage~3
disease:~10
71.4~1
96.8~1
98.9~1
precedes~5
relapse.~19
BPH~8
sub-population~1
precancerous~3
PAP,~4
PSA,~1
Systems~2
(AMS)~1
(day)~1
Ninety-one~9
satisfied~14
prosthesis,~5
concealment.~2
Jonas~1
hypogastric~6
perianeurysmatic~1
Mentor~1
postimplantation,~1
twenty-one~7
failures.~14
attractiveness~1
semirigid~3
cecoappendiceal~1
exstrophy.~1
vesical~11
continence~14
Rhodamine-123~2
mitochondriacide~1
transplantable~3
R3327-H~1
Rhodamine~1
fifty-two~4
acinar~12
vacuolization~5
Laboratory~17
endocrinopathy~1
hyperglycemia~20
paraneoplastic~2
endocrinopathies~1
Foley~8
genitourinary~8
presented;~3
Japanese~33
cystic.~1
schwannomas,~1
cysts.~12
necessity~12
Focal~8
spongious~1
certitude~1
(PEFR)~2
hand-held~3
PEFR~3
timely~6
aids~12
Marfan~5
ago,~5
burdensome~1
musculoskeletal,~1
counseling.~4
Colposcopic~1
Papanicolaou~10
colposcopy~8
cryotherapy,~3
cryotherapy.~2
mean)~5
amiodarone~63
Inducible~2
263~6
305~6
.05~10
study).~3
237~1
1).~11
2).~16
therapy.(ABSTRACT~3
tachyarrhythmia~5
Wolff-Parkinson-White~8
(WPW)~2
(256~1
9),~10
intra-atrial~2
interatrial~3
se)~1
extrastimuli.~2
(ventricular~3
discordance~2
Accessory~1
(despite~1
division)~1
pre-ablation).~1
tachyarrhythmias~12
WPW~3
susceptibilities~4
mexiletine~7
depolarizations~3
(VPDs).~1
mg/min)~3
VPD~3
mg/kg/min.~1
VPDs~3
suppression)~1
suppression).~1
responders,~4
respond.~1
suppression,~3
33/5~1
S.D.)~5
0.9/5~1
47/5~1
4.7~14
2.2/5~1
Mexiletine~1
(96%~1
68%,~5
micrograms/ml).(ABSTRACT~1
predetermined~9
transmitters.~1
patients--all~1
15-month~3
discharged~28
titration~5
arrhythmia.~5
checks~2
transmission.~8
coexistent~10
(12)~3
(eight)~1
(16),~2
diuretics~13
vasodilators~15
(seven).~1
(10)~2
(10).~1
One-year~1
89%.~3
Combination~3
beta-blocking~14
cibenzoline~10
propafenone~9
efficacy.~8
Propafenone~3
(269~1
bpm).~4
Procainamide~2
propafenone.~2
Cibenzoline~3
terminating~4
dogs).~2
thirds~23
(38.5~1
7.8%~4
RV)~1
ECG,~5
second-~8
third-degree~8
intra-His~2
45).~1
second-degree~6
block,~14
Wenckebach~3
beats.~4
Electrophysiologic~3
infra-His~1
bradycardia-dependent~2
permanently~7
substitute~17
perfluorochemical~2
Fluosol-DA~6
(H~3
hours),~10
(C~3
postmyocardial~1
colored~5
beds,~2
sectioning~12
Mallory's~1
trichrome~3
Fluosol-DA-treated~1
heparin-treated~2
53.3~1
67.2~1
12.8,~2
73.6~1
11.4:~1
(3F,~1
6H,~1
7C),~1
(6F,~1
2H,~1
2C)~1
modifies~2
Prevalence~7
three-vessel~4
462~1
(403)~1
69).~1
Three-vessel~1
(4-year~1
0.22,~3
0.59,~2
Cox's~1
EF.~1
Four-year~1
23),~1
66),~1
thallium-201~24
12-lead~9
ECGs.~1
33)~5
(54~5
S.E.M.]~1
2%;~3
(3.1~4
L/m2;~1
(2.0~11
Hg/ml;~1
34).~3
inferior,~1
apical,~3
phenomenon.~15
hypoperfusion~7
(CO)~9
CO.~3
(CCS)~1
2-minute~2
CO~34
dogs:~1
CSS~1
exhausted~1
patent,~3
18.0%~2
pre-CO~2
(postischemic~1
hypercontraction)~1
CCS,~1
hypercontractility~2
CCS.~1
diltiazem~42
hyperemia~13
flow-limiting~5
(hyperemic~1
ratio).~2
(1.45~1
2.02~2
0.24,~1
(1.36~1
1.45~4
(-33%;~1
blunts~2
jeopardized~3
A).~4
(ATP)~9
sarcoplasmic~10
30-minute~8
mechanics~10
echocardiography,~15
miles/week)~1
nonrunners.~2
nonrunners~3
volume/mass~2
Noninvasive~4
peak-systolic~1
meridional~7
area/cavity~1
'average'~1
radius/thickness~1
view),~1
Basilar~1
view,~4
elevations~31
views,~5
overload.~5
Race~1
marathon~5
Borderline~2
(99~1
11)~9
(72~6
(90~6
8).~4
(during~3
diastole)~1
(0.96~2
0.85~11
cm;~5
(0.98~3
borderline~34
conduits,~1
Rastelli~1
truncus~5
arteriosus~21
transposition~14
Porcine-valved~1
conduits~5
homograft~5
0.11)~1
(0.60~3
0.10)~1
RVEF~5
0.714;~1
(EDV)~2
(0.56~3
0.08;~1
LVEF~4
taurine~15
(CHF),~2
mouth)~2
guanidinoethyl~1
(GES)~1
taurine-treated~3
CHF~18
nontreated~3
GES-treated~1
(max~1
dP/dt)~1
Taurine~2
GES~1
expectancy.~2
Echocardiographic~11
48),~2
51).~1
dimension,~4
valve,~10
(77%)~10
(44%).~2
Right-sided~1
3);~2
innominate~3
2DE~3
vegetations~4
debated.~2
54-month~1
cm2.~10
vegetation~3
new-onset~4
embolus,~3
vegetations.~2
vegetations,~1
24%,~8
embolus~12
48%,~4
21%,~11
defines~10
inapparent~4
1046~1
210~10
premortem~2
death)~2
(10%),~9
(ECG~1
distribution)~2
(80%),~2
(10%).~7
injury:~3
preterminal~3
aspergillus~1
0.0005~2
0.00001,~1
(96%,~1
0.000001)~1
ambulation~7
(min/mile)~1
ergometry~5
(kpm)~1
GXT.~1
345~4
GXT~7
Bruce~9
154)~1
191).~1
pace~7
output)~4
output).~1
cross-validate~1
equations.~2
cycle-cycle.~1
equation.~4
bevantolol,~3
1-adrenoreceptor~1
twice-daily~14
(titrated~1
Within-patient~1
hourly~13
BPs~4
bevantolol~26
(rest,~2
tilt,~1
exercise).~1
tiredness,~1
lending~1
first-line~5
once-daily~14
drug's~7
paraaminohippuric~2
150-mg~1
"priming"~1
bevantolol.~8
daily,~14
Bevantolol~6
international,~1
atenolol~12
(diastolic~1
[BP]~1
Adverse~6
checklists,~1
electrocardiography~6
funduscopy.~1
comparably~3
atenolol.~1
BP;~1
drugs;~4
effect.(ABSTRACT~1
chronic,~11
ST-segment~46
10.6~7
placebo;~1
rate-pressure~6
CM5~1
6.89~1
2.50~4
3.72~1
days.(ABSTRACT~2
cardioselective,~2
beta-adrenoreceptor~1
membrane-stabilizing~1
3,4-dimethoxyphenylethylamino~1
moiety,~1
cardioselectivity,~1
isoproterenol-induced~2
muted~1
histamine-challenged~1
antiasthmatic~1
isoproterenol,~15
totally.~1
Bevantolol's~1
reserpinized~2
mg/kg.~10
Metabolite~1
dogs;~2
angina:~1
stenosed.(ABSTRACT~1
35%),~3
chronotropic~17
actions,~2
25%.~4
(15%),~5
(maximum~9
beds.~6
kidneys,~13
IV)~6
(LAD)~3
midpoint,~1
arterial-coronary~1
pCO2.(ABSTRACT~1
(AMI)~13
820~2
867~1
Multicenter~2
Post-Infarction~1
Program.~2
unsustained~2
(0.2%)~1
seconds).~1
recording.~11
(28%);~1
(61%)~14
complexes;~1
240).~1
wave.~3
recording;~1
728~2
group:~1
AMI,~11
pectoris,~11
30%,~13
rales~2
bibasilar~1
Kaplan-Meier~6
0.67~8
infarct.~4
all-cause~2
Adjusted~2
indicators,~2
(PGE1)~1
streptokinase.~2
PGE1~10
A),~5
B),~5
PGE1.~2
recanalization,~2
0.0008),~1
ml/m2~5
recanalized~6
Reocclusion~1
deserves~15
feasibility,~1
2-dimensional~11
(2-D~2
echo)~2
(CAD)~13
AMI.~16
2-D~7
micrograms/kg/min,~4
multilead~1
Echocardiograms~2
observers.~7
Dobutamine~3
tolerated;~2
observers~11
perfect~8
CAD,~9
asynergy~14
88%).~1
(sensitivity~8
85%).(ABSTRACT~1
Day~17
non-Q-wave~9
Q-wave~16
(AMI).~8
non-Q~4
infarction:~2
single-segment~2
multiple-segment~3
25)~5
"missed"~1
anterior;~1
inferior;~1
AMI~64
Q~26
17)~9
infarctions~8
Q-zone~1
integral,~3
sigma~8
integrals,~1
ST-integral~1
maximum,~4
distinct,~4
heterogeneous,~3
entity.(ABSTRACT~1
1,977~1
"insignificant"~1
narrowing)~2
electrocardiogram.~4
98%~17
insignificantly~3
narrowed~7
rate:~5
21.5,~1
4.93,~1
0.026),~2
hospitalizations,~5
job~6
krypton-81m~4
pacing-induced~4
pacing,~13
simultaneously,~4
control).~5
(extraction~1
-15~1
-2.64~1
Krypton-81m~1
Angina,~1
-1.41~1
control).(ABSTRACT~1
Prodromal~1
227~6
sudden--with~1
hour--in~1
Nonsudden~1
death--death~1
symptoms--occurred~1
nonsudden~1
nisoldipine~4
pectoris.~14
instituted~15
beta-blocker~11
continued.~4
Nisoldipine~4
7.9~10
liters/min,~4
nisoldipine,~2
rate-systolic~4
depressant~11
outlast~1
4.5-micrograms/kg~1
microgram/kg/min~6
trends.~4
maintains~17
(74~3
men),~2
older,~15
echocardiographically~7
murmurs,~1
Infective~3
chordae~18
tendineae~6
33.~1
Congestive~3
localized.~2
Streptococcal~1
("unstable")~1
"indeterminate"~1
Unstable~5
20%.~6
organism)~1
account.~5
compromised,~2
persistent,~4
high-temporal-resolution~2
(filling~3
phases,~3
uniform.~1
2.21~2
2.88~3
Gorlin~3
0.95).~1
0.14~12
cm2~30
formula,~4
excrescences~8
(Lambl's~1
excrescences)~1
Valve~3
endocardium~7
excrescences,~1
filiform,~1
Lamellar~1
boundary~3
lunulas~1
Filiform~1
nodulus~2
Arantius~1
free-margin~1
cusps.~1
numerous.~2
Free-margin~1
filiform~2
fibrils~9
arranged~6
fibril~5
excrescences.~1
3-dimensional~1
(3-D)~1
topology~2
fixing~3
3-D~2
relations.~1
facets~6
hypoplastic~15
palliation~14
Norwood~1
sequelae--restrictive~1
inter~2
communication,~7
confluence--served~1
anomalies.~11
refinement~3
QTc-interval~1
valvuloplasty~33
(BPV),~1
0.380~1
0.027~2
BPV~3
0.429~1
0.377~1
0.026~1
catheterization-dilation~1
0.382~1
0.041~1
0.427~1
0.043~1
0.002).~16
semilunar~1
prolongation;~1
afterload~6
R-on-T~1
postprocedure~1
2-site~1
brain-type~1
(CK-BB),~1
heart-type~1
(CK-MB)~3
muscle-type~1
(CK-MM)~1
20-hour~1
CK-MB~32
CK-BB~6
CK-MM~3
1,220~1
274~3
1,322~1
127~20
(149~2
Arteriointernal~1
CK-MB.(ABSTRACT~1
(typical~3
[at~2
depression],~1
48-hour~5
(ECG)~8
unrestricted~5
Fifty-eight~12
testing:~1
(48%)~12
anginal~10
(52%)~8
magnitude,~2
shifts,~2
28%.~2
(98~3
(exceeding~1
testing)~1
shifts.~1
life;~2
(LV~2
mass/body~1
(linear~2
regression)~1
0.00321~1
(physical~2
activity)~4
82.8~2
0.00335~1
+88.4~1
divergent~6
kcal/week~1
g/m2~4
Concentric~1
asymmetric~9
lifters,~2
filling,~4
ventricles,~7
inflow,~4
M-mode~27
lifters~6
Doppler-derived~2
velocities,~3
(181~4
dimension~25
(5.6~8
0.05);~15
29,~3
(114~2
g/m2,~2
fraction.(ABSTRACT~1
(ASA)~5
single-blind,~6
dipyridamole,~3
ASA,~2
adhesin~1
Dipyridamole~3
ASA.~1
ASA~18
arachidonic~8
modifying~9
stature,~7
(BMIs),~1
NHANES~3
(1971-74)~1
(1976-80)~1
BMIs~3
0.89-0.98)~1
fatness~1
leanness~1
W/S2~1
W/S~1
W/S1.5~1
subscapular~4
skinfold~11
0.78-0.80),~1
0.83-0.89),~1
0.71-0.83).~1
6-mo~2
15-mo~1
stimulus;~2
27-mo~2
counterparts,~4
shifts~9
Older~6
compensate~5
Subcutaneous~4
depots~2
Adipose~4
(density~3
Hansfield~1
units)~7
planimeter.~1
(S:V~1
ratio)~7
Ratios~4
60.~3
S:V~3
0.65;~1
0.61;~2
hypocaloric~1
kcal/day)~2
(force:frequency~1
fatigability)~1
malnourished~13
snack~2
Carbohydrate~3
cravers~6
snacks~1
carbohydrate-rich~2
accessibility~4
protein-rich~4
snacks.~1
Noncarbohydrate~1
protein-~1
foods.~9
questionnaires,~2
high-carbohydrate~1
lunch~2
(104~2
CHO).~1
significantly:~1
noncarbohydrate~2
alert,~2
fatigued~3
sleepy,~1
mood.~1
snacking~1
obesity.~14
French~7
corpulence~1
(wt/ht2~1
thickness),~1
traditionally~9
contradiction:~1
capacities;~1
socially~6
Socially~1
Nutritional~4
(g/1000~1
kcal)~3
3-day~9
triglyceride,~6
(LDL),~2
intermediate-density~3
(IDL),~1
(VLDL)~7
free-living~3
Polyunsaturated-fatty~1
triglycerides,~14
LDL-~1
VLDL-cholesterol,~2
total-lipoprotein~1
smaller-LDL~3
(Sf0~3
0-7),~1
IDL~6
12-20),~1
20-400)~1
Animal-protein~1
plant-protein~1
VLDL-mass~1
dietary-cholesterol~1
crude-fiber~1
diet-lipoprotein~1
cross-culturally~1
samplings~1
leucocytes~7
Brocca~1
cholesterol:HDL~1
high-fat~5
feeding,~6
leucocyte~7
cholesterol:phospholipid~1
elevated,~23
(G6PD~1
6PGD)~1
(CEH~1
CES)~1
Erythrocyte~5
(low-fat)~1
feeding.~9
branched-chain~14
keto~7
(BCKA)~2
glucose-alanine~2
cycle-related~1
BCKA~11
pyruvate~15
Alanine~1
(BCAA)~3
vary.~1
liberated~2
BCAA~6
analogy~2
alanine,~1
ketone~12
Cahill~1
hypercatabolic~1
ketoanalogues~1
leucine~15
(KICA)~1
valine~2
(KIVA)~1
KICA~4
KIVA~1
substitution,~2
Doubling~1
anorexia.~1
KIVA,~1
Low-KICA~1
plasma-leucine~1
level;~2
antagonism.~1
2-ketoacids~1
BCAA.~2
uremia,~2
Ketoacid~1
uremia.~2
BCKAs,~1
KICA,~1
protein-deficient~1
6%,~4
casein,~5
0.3%~4
larvae~14
Nippostrongylus~1
brasiliensis~1
nutritionally~8
expelled~4
worm~7
burden.~4
expulsion~5
Methionine~2
burden~14
32.4~2
0.0408)~1
162~6
0.0002)~3
overcame~1
Phagocytosis~3
iron-deficient~11
6-23~1
hemoglobins~1
Neutrophil~2
3-5,~2
90.~1
oral-calcium~3
(1500~1
Ca++/day~1
wk)~1
consuming~20
low-calcium~3
Ca++/day)~1
restricting~4
dairy~11
calcium-~1
placebo-supplemented~1
habitual~11
Diastolic~3
0.31,~2
young,~9
Stimulated~4
supply.~5
waters~4
mg/L,~5
community;~2
375~3
community.~13
absorptiometry,~2
so;~1
Young~8
IU/day,~1
Conflicting~2
copper~71
published.~4
serum-copper~3
serum-ceruloplasmin~2
depressed;~2
ceruloplasmin~2
depressed,~4
reactant~2
poststress.~1
postburn.~2
Depressed~6
urinary-copper~1
losses.~5
mechanism(s)~8
accompanies~7
hypocupremia.~1
tocopherol~3
day-1)~2
tocopheryl~2
(TPGS)~1
cholestasis~6
(unresponsive~1
dl-alpha-tocopheryl~2
acetate)~1
emulsified~1
triglycerides~26
polysorbate~1
(MCT-E)~1
alpha-Tocopherol~1
absorption,~18
duct-cannulated~1
intraduodenal~6
soybean~5
TPGS,~2
MCT-E,~1
acetate;~1
gamma-tocopherol~2
alpha-tocopherol.~1
TPGS~1
alpha-tocopherol~3
micellar~2
delivers~2
enterocytes,~1
slum~1
post-measles~1
measles~17
mo;~1
measles.~4
Corneal~4
RBP~2
4-7~1
Pantothenic~1
(411.9~1
102.8~1
344.5~1
113.6~1
566~1
preschool~9
income~7
households~7
county.~1
Underweight~1
1.8%,~1
15.4%,~1
13.1%~1
4.3%,~1
6.9%,~1
protoporphyrin~5
6.0%~3
EP~19
non-Southeast~1
Oriental~5
Hawaii.~2
Premenopausal~1
30-75%~1
Hawaii,~2
urinary-to-fecal~1
calories,~5
energy-providing~1
nutrients,~3
Intakes~3
Council~5
zinc~117
allowances~2
(RDA).~2
Caloric~2
RDA~10
miles/day.~1
marginal~13
(PAA)~1
PAA~5
total-body~6
oxygen,~7
carbon.~2
4.2%,~1
wk,~14
ages,~8
Nutrition~6
niacin-tryptophan,~1
vitamins.~3
projects,~3
B-6~6
antioxidants~1
delaying~5
oncogenesis~3
Whole~7
head-fold,~1
pre-somite~1
9.5~10
gestation)~3
varyingly~1
(3,~1
mg/mL),~3
D,L~1
beta-hydroxybutyrate~8
(2,~3
mg/mL~1
D-glucose~1
beta-hydroxybutyrate).~1
extraneural~1
organogenesis~2
Synergistic~2
dysmorphogenic~1
teratogenic~8
combined.~3
somatomedin~8
bioactivity~1
ketones~1
teratogenic.~1
fuels~2
fuel-related~1
post-implantation~1
fuel-mediated~1
teratogenesis~1
interactions.~7
immunohistochemistry~4
(2-D)~5
cytoskeletal~9
immunofluorescence,~5
filaments~16
desmosomal~1
contacts,~1
adenocarcinomas.~6
immunoperoxidase,~1
anti-actin~1
doublet~5
immunoblotting,~4
consist~18
polypeptides,~4
sinusoids~6
IgA-subclass~1
(assessment~2
[hidden]~1
J-chain~1
component-binding~1
capacity).~1
anti-IgA-subclass~1
applied,~3
blastoid~1
jejunum.~9
IgA1~4
83)~2
31)~3
Macromolecular~2
one-fifth~3
pool,~4
semiautomated~1
Remote~2
Systems,~3
Inc.~1
(IRIS)~1
urinalysis~8
workstation~1
(IUW)~1
(QMU).~1
technologists~3
172~11
urinalyses~2
IUW~5
QMU~5
analytes~2
QMU,~1
ninefold~2
analytes.~1
duplicate~9
analyte.~1
Objectives~4
(MBO)~1
results-oriented,~1
participatory~1
era~4
keen~1
resources.~7
MBO~5
divisions~3
decidedly~2
Benefits~1
organizational~5
clarity,~3
deadlines,~1
participants,~3
productivity.~3
Projects~1
visualize,~1
track,~1
coordinate.~1
evolved,~2
worked~5
two-year-long~1
solving~4
innovation.~1
expects~1
laboratories,~3
commits~1
install~1
loose,~1
philosophy,~3
technology.~5
(JP)~1
(epitheliosis)~1
42.~1
Carcinoma~10
JP.~1
co-existing~2
JP~1
relatives~30
Coulter~5
S-Plus~6
precision,~3
100-cell~2
differentials,~1
flagging,~1
differential.~2
instrument's~1
category.~5
lymphocyte,~7
mononuclear,~1
0.54,~4
V-generated~1
flags~3
preset~2
differentials~3
Three-fourths~3
low-frequency~3
questionable~4
Sickledex~1
(Ortho~1
Diagnostics,~1
Raritan,~1
NJ)~2
(%Hgb-S)~1
dithionite-induced~1
sickled~2
%Hgb-S.~1
+10%~1
+5%~1
30-45~3
%Hgb-S~1
293~8
(ELISA)~11
agglutination~10
Rubascan~2
(97.6%)~1
Rubaquick~1
(95.2%).~1
read,~1
low-positive~1
C-reactive~15
(CRP)~6
nephelometry.~2
peritonitis~26
portal-hypertension-related~3
miscellaneous~12
CRP~23
ascites~28
ascites.~3
Ascitic~1
technic.~2
water-clear~1
(PTH)~8
C-terminal/midmolecule~1
N-terminal-specific~3
rendered,~1
speculations~1
detailing~3
cytologic~40
(ADB),~1
nephrotoxicity.~8
ADB~6
immunochemically~4
nonnephrotoxic~1
doxorubicin,~5
nephrotoxins,~1
ifosfamide,~2
cisplatin-~1
ifosfamide-induced~1
creatinine.~4
N-acetyl-beta-D-glucosaminidase~2
aminopeptidase~1
142,~1
0.21;~1
Dysmorphic~1
dysmorphic~8
5,128~1
erythrocytic,~1
exfoliated~2
(RTCs).~1
RTCs,~3
2-year,~1
deafness.~1
Immunofluorescent~3
anti-sera~1
(GBM)~5
(prepared~1
GBM~17
Steblay's~1
antigen(s).~1
splitting~12
thinning~6
GBM.~1
Indirect~4
Goodpasture's~5
anti-GBM~1
anti-sera,~1
anti-types~1
collagens,~5
laminin,~9
actomyosin~1
GBM,~3
Indigent~2
"blinded"~2
indigent~4
(VLBW)~2
(Bayley~1
Index,~3
VLBW~5
ventilator-treated~2
attrition,~1
unavailable~5
one-year~11
deserve~3
reascent~2
unequivocally~5
descended~1
testis~21
Chorionic~2
diligence~1
scrotum~1
hypophosphatemic~5
rickets~7
update~2
calcitriol~10
(1,25-dihydroxyvitamin~1
D3)~1
42.0~1
12.3%~2
17.3%~1
15.3%~2
18.6%,~1
length/height~1
-2.7%~1
-2.4%~1
4.4%.~1
61.7%~1
101.2%~1
mmol/L).~6
mL/min/1.73~2
(2.12~1
mL/s/1.73~2
(2.13~1
0.41~3
Unprocessed~1
unprocessed~1
milk;~1
nipple~14
Klebsiella~3
Pseudomonas,~1
140,000~3
colonies).~2
Bacterial~7
refrigeration~2
epididymitis~2
swelling,~6
erythema.~3
coagulase-negative~2
staphylococci~6
polymicrobic~1
Urologic~1
adolescents,~9
pediatrics.~1
in-office~1
42-item~1
youths~3
discriminated~10
paper-and-pencil~2
discriminate~21
fetal,~1
intrapartum,~1
perinatal,~1
19,117~1
sociohereditary~1
nothing~5
happened~3
antenatal~10
births,~7
impairments~6
community-based~4
project.~2
concerns.~4
concerns,~4
second-grade~1
problems;~4
youngsters~2
instance,~7
attainment.~1
attention-problem~1
project,~2
maternity~4
(1976~2
1978),~1
low-birth-weight~3
2251~1
City.~2
knowledgeable~2
caries,~2
prescribe~7
supplements.~7
intensive,~2
caries~1
Wayne~1
Medicine,~1
Detroit,~1
survey,~9
(RDS)~2
middle-class,~1
low-birth-weight,~1
Cognitive~3
36,~4
RDS~5
3-month-old~3
holoprosencephaly~2
insipidus~6
switched~6
desmopressin~2
decided~5
administer~10
sublingually,~2
microgram/kg)~1
antidiuresis,~1
lessened~8
small-polypeptide~1
impractical.~1
overload~17
transfusion-dependent~1
beta-thalassemia,~1
Biventricular~1
multigated~3
symptomatic.~3
transfusions,~4
extrasystole.~2
(63.0%~1
7.6%).~1
(RVEF)~1
9.4%.~1
40%);~1
phenobarbital~16
(SEp-IVH)~1
prematurity~10
patients);~24
SEp-IVH~1
SEp-IVH,~1
methylxanthines.~1
examiners~7
connotation~1
assisting~4
scientists~4
firearm~2
wounds,~18
abraded~1
Exit~2
irregularly~8
lacerated~1
interruptions,~1
protruding~9
undamaged~3
papillae.~1
tattooing.~1
Evident~1
powder,~1
Particles~2
[gunshot~1
(GSR)]~1
entrapped~7
assaults~5
Nail~1
guns~2
Steel~1
ricochet~1
accidental~13
Straight-nail~1
co-workers~2
nail-gun~1
over-penetration~1
nailed~1
mid-air~1
firing;~1
Extremity~1
gun~8
anatomic--including~1
forensic--pathologic~1
microcomputer.~2
SNOMED~1
software~9
Pathologists~1
RAM-disk~1
clerical~2
versed~2
terminology.~1
interaction,~6
Equipment~3
TV~3
photograph~2
face,~3
superimposition~5
computer-aided~2
Shape~1
Analytical~2
Morphometry~4
(SAM)~3
kth-order~1
poly-nominal~1
point-cross~1
amplitude.~7
noncongruent~1
superimpositions.~1
succeed~1
anthropological,~1
dental,~1
investigative~7
adds~6
enforcement~3
expert~6
Identi-Kit.~1
victim,~3
Identi-Kit~1
anthropologist,~1
news~4
likeness~1
before.~3
expertise~8
"Jane~1
Doe."~1
corpses~2
Athens~1
Piraeus~1
Morgue~1
abroad~3
autopsies.~2
Lack~7
mistakes~4
useless~2
effort,~3
disappointment~1
anxious~6
relatives,~2
attorneys~1
"well-meaning~1
friends"~1
loved~2
ship~1
abroad).~1
corpse~1
undergoes~8
Greece.~1
Deliberate~3
paint~3
intra-alveolar~1
particulate-laden~1
sniffer~1
finds~2
unenviable~1
political~5
pathologist~9
ethically,~1
morally,~1
legally.~1
ourselves~2
compromising~12
"you~1
pay~6
for."~1
tragedy~1
conclusions,~1
What~3
jeopardy~2
in--defenseless,~1
friendless,~1
disgraced,~1
tarnished~1
reputation.~1
Malignant~7
hyperthermia~15
triggers~5
documents,~1
necropsy,~2
hyperthermic~3
evening~14
shotgun~4
casing~1
muzzle~2
"dust~1
cover"~1
intermediate-~2
distant-range~1
butts,~1
patterned,~1
muzzle/sight~1
impressions~4
discharging~2
firearms.~2
blow~1
.32~1
revolver~1
masturbation~2
endourethral~1
piece~3
spaghetti~2
cicatricial~4
foreign-body~2
exsanguinated~1
swallowed~4
chicken~14
toxemia~3
Armed~1
Forces~1
Pathology.~1
transaminases.~1
Jaundice~1
eclampsia~2
confronting~3
midly~2
abnormal.~15
wholly~2
Fibrin~4
histopathology.~1
toxemic~1
vasculopathy~1
microbiological~5
Diagnoses~3
11/21~1
(57%).~4
Granulomas~2
10/21~1
Mycobacterium~25
avium-intracellulare.~2
gastrostomies~4
gastrostomy~14
4%,~11
gastrostomies.~2
1%,~11
stayed~7
outpatient.~1
safer~9
gastrostomy.~1
Sulfur~2
(SAA)~2
relapsing~20
cholelithiasis,~4
excretions.~1
SAAs~1
Initially,~5
SAAs,~1
N-acetylcysteine~2
mercaptolactate~1
SAAs.~1
Reduced~3
CRP,~3
anisakiasis~3
45-yr-old~3
eaten~12
States.~26
popularity~9
restaurants~2
sushi~1
bars~1
postgastric~2
megaloblastic~5
Parietal~1
titer,~2
bypassed~2
Varices~1
varices,~4
61-yr-old~1
Splenic~3
CAT~6
nonvisualized~1
portography~1
pancreatectomy.~1
Oral-gastric~1
ingestions.~2
impaction~5
oral-gastric~1
documented.~18
82-yr-old~1
ileoileal~1
intussusception~9
intussusceptum~1
adenomyomatous~2
hamartoma~8
diverticulitis,~2
Final~3
tuboovarian~1
Bacteriology,~1
pathophysiology,~3
Difficulties~5
Takayasu's~6
35-yr-old~1
Sri~1
Lankan~1
methodologic~7
simplest~2
ruthenium~4
homogenizing~1
mitochondria.~4
gentamicin-~1
mercuric~2
chloride-induced~1
drawing~6
lethally~1
Maneuvers~1
highlighted.~3
exciting~8
schedules~8
33.3~3
amikacin~5
drug-dependent.~1
administrations.~1
amikacin,~1
gentamicin.~3
Elevations~2
"efficient"~1
Amikacin~1
six-hour~3
Michaelis-Menten~6
kinetics.~6
Gentamicin~3
15.0,~1
73.9,~1
135.7~1
micrograms/mL;~2
149.9,~1
213.7,~1
239.2~1
cortex/h,~1
mg/dL.~4
micrograms/mL,~2
interactive~6
nephrectomy.~8
Cyclosporine~3
intramuscularly~5
(IM)~2
cyclosporine-induced~1
(IP).~1
(65%~1
17%),~2
Pair-fed~2
pair-watered~1
castor~4
commercial~17
microscopy,~19
pale~1
vacuoles~5
cyclosporine-treated~2
dense~35
IP~10
mL/min).~2
mL/min),~1
model.(ABSTRACT~1
steroid-resistant~1
Ataxia-telangiectasia~1
(A-T)~1
recessive~24
Vigorous~1
casefinding~1
1970-72~1
1980-84~1
231~4
black,~4
A-T~5
A-T.~1
1965-69.~1
Michigan~6
1965-69,~1
.0017.~1
Pedigree~1
probands,~2
.007~1
.0012-.02.~1
complementation~5
A-T,~1
heterozygote~4
0.68%~2
7.7%,~2
2.8%~5
estimate.~2
[CL(P)]~1
unresolved.~1
confounded~2
Japanese.~2
CL(P)~1
2,998~1
Danish~4
627~1
segregation~9
inheritance.~7
best-fitting~2
(t)~1
.035.~1
heritability~2
.97.~2
Aa----a~1
1/2.~2
.77.~1
mating.~1
inconsistency~1
Roberts/SC~2
phocomelia~2
repulsion~1
heterochromatin~1
chromosomes.~4
EBV-transformed~1
lymphoblasts~5
PHA-stimulated~1
fibroblasts,~6
Cocultivation~1
immortal~1
t(4;6)(p14;q21)~1
translocation~7
diffusible~1
metaphase~3
spreads~2
chromatid~4
repulsion.~1
perfectly~4
genome.~2
HbH~2
Sardinia,~1
Italy.~3
deletional~1
nondeletional~3
alpha-thalassemia~6
haplotypes,~2
Mediterranean~10
(--Med,-(alpha)20.5,-alpha~1
I,-alpha~1
NcoI~1
HphI~1
zeta-alpha~2
T),~4
extents~2
evenly~9
[-(alpha)20.5~1
cluster]~1
(-alpha~3
mutations)~1
GM~7
HLA-defined~1
(IDDM)~6
HLA-dependent~2
IDDM~18
susceptibility.~2
circumvent~5
patient-control~1
sharing~8
HLA~32
informative~6
IDDM.~3
sib-pairs,~1
Mendelian~2
expectations,~6
studies;~4
concordance)~1
types;~2
sib-pairs~2
.018).~1
Atlanta.~1
Paternal-age~1
certificates,~2
mothers;~2
certificates.~2
paternal-age-birth-defects~1
Logistic~7
fathers~17
combined;~2
category~25
chondrodystrophy~1
(largely~3
sporadic~16
achondroplasia)~1
situs~6
inversus.~1
inversus~6
before;~1
chondrodystrophy.~1
fixative~2
leukocytes,~5
nitrocellulose~3
agarose~5
hybridized~9
sampling.~9
reporting~22
spontaneous.~1
Problems~12
Administration,~1
biases~6
corrected.~4
stigmas~1
infertile.~1
Seventy-three~7
endometrium-like~1
stroma;~1
uterosacral~2
peritoneum~9
Nonpigmented~1
(endometriosis~1
specimens),~1
flamelike~1
(81%~4
16),~3
hysteroscopy)~1
(67%~3
subovarian~1
adhesions~22
19),~3
(45%~1
11).~5
oil-based~1
salpingographic~1
"unexplained~1
infertility"~1
exclusive.~1
Mesometrial~1
ewes.~3
mesometrium.~2
micrograms/24~12
Contracture~1
(electromyographic~1
seconds)~13
mesometrium~1
contracture~12
mesometrial~1
paracrine~10
ewes~5
systemic,~6
uterine,~1
amnion,~1
chorion,~1
Amnion~1
Chorion~1
chorion~4
decidua,~1
prostaglandins,~2
oxytocin,~2
estrogen,~7
excursion~7
trimesters~5
partum.~6
Cosignor~1
pregnancies,~8
(24-hour~1
mean,~9
nadir,~3
nadir-peak~1
excursion)~1
(expressed~7
blunted.~3
nonhypoglycemic~1
rhythm.~13
pregnancy-associated~1
blunting~3
adrenocorticotropin.~1
Asymptomatic~3
insulin-requiring~4
Antipyrine~1
antipyrine~10
days'~8
Prostaglandins~3
13,14-dihydro-15-keto-prostaglandin~3
6-keto-prostaglandin~9
669.3~1
161.3~1
pg~13
306.5~1
104.0~1
744.2~1
256.8~2
105.0~2
24.2~4
alpha/13,14-dihydro-15-keto-prostaglandin~2
86.0~1
31.6~3
37.0~2
11.5~7
flurbiprofen~7
reanastomosis~4
(controls),~2
reunion,~1
regeneration,~5
disruption.~2
compared,~5
thickness.~13
oophorectomized~1
quiescence~2
junctions,~2
coordination~10
ultrastructure~7
gonadotropin-stimulated~1
gonadotropin.~7
points.~7
gonadotropin-induced~1
consistent.~4
smooth-surfaced~1
gonadotropin-treated~1
Cytosolic~5
oligoovulatory~1
Clomiphene~1
cycle)~1
nondetectable~2
dated~2
5-second~2
Moreover~3
near-term~1
one-kidney,~1
one-clip~1
output;~1
weekly.~3
phases;~1
cryopreservation~4
unfertilized~1
oocytes,~3
mare~4
Oocytes~1
straws~1
Hepes-buffered~1
Tyrode's~6
dimethyl~13
sulfoxide~6
(method~10
cooled~5
-6~1
C/min~3
-0.5~3
-0.3~1
-80~1
plunged~1
-196~6
thawing~3
C/min,~1
diacetate~2
Comparable~6
95%,~6
Frozen-thawed~1
(17/66)~1
(51/67)~1
spermatozoa~8
frozen-thawed~1
penetrated~5
(14%~2
18/129~1
21/95~1
Naloxone~7
Premarin-Provera~5
Premarin~3
(46.0~1
28.4~6
(154~3
(135.1~1
57.5~1
Follicle-stimulating~2
118.7~2
mIU/ml,~2
follicle-stimulating~3
(135%~1
144%~1
8%),~2
(150%~1
133%~1
11%),~2
(149%~1
128%~1
(139%~1
132%~1
13%)~2
softening,~1
ripe~2
unripe~2
cervices.~2
ripeness.~1
asphyxiated~4
platelet-rich~8
aggregometry)~1
aggregating~4
diphosphate,~1
arachidonate,~1
beta-thromboglobulin,~4
B2,~3
1,6-keto-prostaglandin~2
visits,~6
B-thromboglobulin~2
three).~1
25-hydroxycholecalciferol~5
24-hydroxylase~13
1,25-dihydroxycholecalciferol;~1
1,25-dihydroxycholecalciferol-responsive~1
substance.~4
endometrial,~1
cervical,~3
nmol/L)~1
2,4-~1
49-fold~1
1,25-dihydroxycholecalciferol.~1
replication.~9
Third-order~1
arcade~1
myograph~1
tension-internal~1
Prolactinoma~1
microadenectomy~1
invasiveness,~2
microadenoma~3
conceived,~4
bromocriptine-treated~1
conceived;~2
amenorrhea~12
regarded~27
flowmeter,~3
[7-3H]dehydroepiandrosterone~1
[4-14C]estradiol~1
imposed~16
snare~8
240~15
[3H]dehydroepiandrosterone~1
[14C]estradiol.~1
snare.~2
decelerations~1
flow;~5
three-~4
aromatizable~1
hypoxemic~11
androgen.~1
L-isoproterenol~2
receptor-adenylate~2
28,~5
animal.~9
cyclase,~3
chloride.~5
hypoxemia~35
pituitary-adrenal~1
(adrenocorticotropic~1
cortisol)~1
Hypoxemia~1
added.~3
Induced~5
(microsphere~1
technique)~4
(7.2~3
hypoxemia.~9
(prehypoxemia)~1
acidemia.~1
Amniotic~8
ml/10~1
(302~1
mosm,~1
(146~1
262~3
mosm)~1
(35.8~1
76.5~1
Eq/ml),~1
(0.68~1
reached:~2
secretion;~1
vasopressin-induced~1
hyperosmolality.~1
Acetaminophen~2
lacking.~10
ingest~1
acetaminophen~15
(3.7~5
hours).~12
23.7~1
acetaminophen.~3
hepatotoxic~7
acetaminophen,~3
error,~6
nonproliferative~4
myopia,~3
phenotypes~7
4/0,~1
3/0,~1
X/X~1
(HLA~2
susceptible)~1
3/4,~1
3/X,~1
4/X~1
nonsusceptible).~1
Odds~1
equalled~3
myopia~10
Myopia~1
HLA-susceptible~1
.09~1
.09,~1
HLA-nonsusceptible~1
Virus~11
immunosuppressed.~1
other.~22
immunopathology~1
chiasm,~2
tracts,~2
endoretinal~1
retinas.~3
vitrectomies~3
detachments~7
detachments.~2
(43%)~13
reattached.~2
synechiae,~1
open-funnel~1
retinas,~2
acuities~8
better.~11
operate~9
funnel~1
open.~2
transvitreal~1
cyanoacrylate~4
retinopexy~3
rhegmatogenous~6
oil.~9
air-filled~4
Glue~1
chorioretinal~4
transscleral~2
cryopexy~4
stronger.~1
adhesive,~1
transmittance~2
implantable~10
ultraviolet-absorptive~1
pseudophakic~4
photic~3
ultraviolet-protective~2
misleading.~3
histologic,~3
cataract,~2
cardiomyopathy,~13
exercise-related~2
nystagmus~25
strabismus.~3
Corrected~3
20/40~10
visited~5
diopters~10
decade.~11
humor~8
open-angle~3
intracapsular~4
neuromyotonia~2
paroxysmal~11
third,~10
fourth,~2
axons.~4
neuromyotonia.~1
caruncle~4
Wills~1
Pathology~4
caruncular~3
Squamous~4
papillomas~14
nevi~8
masses.~7
Pyogenic~2
(7%),~2
oncocytomas~1
cytogenesis~1
(GCT)~3
GCT~4
immunoalkaline~1
reacting~6
(MPs)~1
marker,~4
8.~6
MP-associated~5
(LCA),~1
HLA-DR,~1
C3bi~1
well-characterized~2
Constituent~1
panel.~5
MP~1
LCA~1
EBM11.~1
Giant~6
(KB90~1
UCHM1)~1
unreactive~3
Spindled~1
lineage,~2
precurser~1
lose~7
some,~5
senescence-accelerated~1
Microdensitometrically,~1
SAM-R/3~1
SAM-P/6,~1
ancestry~2
pedigree,~1
(SAM-R/1,~1
SAM-R/2,~1
SAM-P/1,~1
SAM-P/2).~1
Mineral~2
osteopenia~3
diet-induced~4
adhere~11
endothelium~28
emigrate~1
intima.~5
Atherosclerotic~1
lipid-laden~3
(BAECs)~1
(VSMCs),~1
chemoattractants~8
VSMCs,~1
superoxide.~1
hypercholesterolemia-induced~1
phi~4
hypercholesterolemic~12
BAECs~1
VSMCs.~1
phi-secreted~1
VSMC~2
7-fold,~1
M0s~1
2.5-fold.~1
phi-conditioned~2
5-fold,~1
2.5-fold~5
Dade~2
Examiner's~1
(ME)~1
morgue~1
Jackson~3
(JMH).~1
Parathyroid~4
(JMH~1
series)~4
(ME~1
series),~1
42.6~1
22-103~1
73.1~1
91.6~1
Gland~2
41-60~1
till~1
70.~3
0.15)~1
Glands~2
unevenly~1
90%,~5
unaccounted~1
weights;~1
determinations,~4
nonligated~2
lobe(s)~1
PBL,~1
Portal-deprived~1
atrophy,~7
10-fold.~1
15-24%~1
lobe(s).~1
resorbed~2
novo.~1
collateralization.~1
encephalitis~13
(HSE),~1
HSE~3
Parenchymal~1
interleukin-2~2
(HLA-alpha~1
beta-2~5
microglobulin),~1
(HLA-DR,~1
HLA-DQ)~1
endothelium,~5
HSE.~2
xanthomatous~2
cholesterol-fed~8
xanthomas~1
marked.~1
pellets,~1
unesterified~2
6-fold,~1
cholesteryl~17
30-fold.~1
esterification~5
A:~1
acyltransferase,~1
markedly;~1
hydrolase~6
4-methylumbelliferyl~1
oleate~9
cholesterol-esterifying~1
hydrolytic~4
ester.~2
xanthoma~5
Instead,~9
precondition~1
xanthomas.~1
surface-connected~2
intracytoplasmic~2
(SCIM)~1
proliferates~1
"coated"~2
microdomains~2
budding~3
proliferated~8
Five-day-old~1
tracers,~1
Lucifer~3
ferritin,~5
endocytotic~2
electron-opaque~1
photoreacting~1
DAB.~1
ultrastructurally.~3
diffused~3
SCIM~2
network.~2
finding,~7
suspect~9
metabolically~5
emigration~2
myristate~9
(PMA)~3
nonchemotactic~2
adherence.~6
PMA.~2
PMA~12
(0.1-5.0~1
C5a-treated~1
PMA-treated~1
neutrophil.~1
coincubation~2
Alteration~3
cytochalasin~4
PMA-stimulated~3
microfilaments.~1
carcinogenic~5
choline-deficient~2
ethionine~2
(CDE)~1
Short-term~8
"oval~1
cells"~1
Livers~4
freeze-fracture~1
canalicular~20
CDE~3
Gap~1
disorganized.~1
Tight~1
oval~5
directly.~5
complexity,~1
(charge~1
CSs)~1
(puromycin~1
aminonucleoside~4
[PAN]~1
rat)~1
induction.~6
CSs~1
(known~1
sulfate-rich~1
proteoglycans)~1
polyethyleneimine~1
(PEI)~1
PAN,~1
lamina~24
rara~1
externa~3
CSs:~1
22.0~3
nm~24
PEI~2
17.2~4
21.1~4
coincided~9
organelles~4
reticulum)~1
broadening~3
albuminuria~2
(suggested~1
36-48~1
CS-heparan~1
PAN~7
subendothelial~5
populated~1
shapes.~1
Round~2
ovoid~2
lymphocyte-~1
bulk~7
(over~5
95%)~4
elongated,~2
stellate,~1
shaped.~1
forms,~10
microfilament~1
bundles~16
micropinocytotic~1
ultra-structure~1
biosynthetic~6
stellate~9
utterly~1
alcoholic-alkaline~1
prefixed~1
multiplied~2
substantially,~1
above-mentioned~2
(correlation~6
0.732,~1
0.800~1
0.953,~1
atherogenesis.~1
experiencing~17
painful.~1
Videothermographs~1
celsius~1
exactly~6
supposedly~3
desenate~1
41-year-old~3
suprascapular~2
improper~7
usage.~6
Suprascapular~1
crutches~2
Above-knee~1
amputees~7
foot.~6
12-15~1
metatarsal-phalangeal~2
(MTP)~1
"felt~1
best."~1
single-axis~1
foot,~4
foot:~1
a)~2
ground;~1
b)~2
inclines~1
easier;~1
c)~2
declines;~1
d)~15
stairs~1
ladders~1
inclinations~1
treadmill.~1
soft-soled~1
shoes.~2
MTP~1
toes.~1
symmetrical~6
sides,~2
above-knee~5
amputees.~2
obsessive-compulsive~5
vignettes~3
delusions~5
schizophrenic~23
paranoid~7
psychoses,~1
transient.~2
phenomenologic~1
psychopathological~4
insight.~1
"obsessive-compulsive~1
psychosis."~1
DSM-III~27
revisions.~1
object~9
distinguishes~4
schizophrenia~12
nonborderline~1
lowest.~4
psychodynamic~4
homovanillic~11
(HVA)~2
41).~1
5-hydroxyindoleacetic~8
(5-HIAA)~2
HVA~10
5-HIAA~2
HVA/5-HIAA~2
nonsuppression~1
counterbalanced~2
Navy~1
P3-C~1
Orion~1
pilots~2
fly~9
flights~1
hangover)~1
hangover~3
drank~8
flew~1
piloting~1
aircraft~4
ingesting~10
nonchronic~1
"transitional~1
treatment"~1
treatment--weekly~1
posthospital~2
dropout~3
besides~4
hospitalization.~24
1-month~4
abilities,~1
self-esteem,~2
perceptions~20
others,~14
reflect,~2
lives,~2
panic~26
Epidemiologic~8
Catchment~3
Area~6
(NIMH).~1
Haven,~1
Conn.~1
5,034),~1
Baltimore~3
3,481),~1
Louis~3
3,004),~1
Durham,~1
N.C.~1
3,921),~1
3,132).~1
NIMH~1
DSM-III.~2
Panic~1
somatization~2
Litigation~1
Court~1
1970s~4
inefficient~3
lawyers~1
psychiatrists~9
court~4
legislative~3
reform~2
radically~3
Arizona.~1
revolutionary~1
principles,~2
4-year~6
trainees~5
wherever~5
(residents~1
services),~1
orientation,~6
inpatients,~2
variants.~5
Affective~2
tranquilizer~1
benzodiazepine~5
abruptly),~1
buspirone,~1
nonbenzodiazepine~1
substituted.~2
lessen~4
depressive~34
Epstein-Barr~19
viral-specific~1
(N=43)~1
Desipramine~1
2-hydroxydesipramine~1
mother.~5
nighttime~7
desipramine.~1
benzodiazepines.~2
depression)~4
misused~1
Derealization~1
depersonalization~1
drug-free~4
hallucinations~13
factitious.~1
Health-sponsored~2
(ECA)~2
Program,~2
nonusers,~2
abuse/dependence,~1
phobias.~2
(DIS)~2
ECA~6
21.7~1
(slightly~2
rates)~1
16.7~5
nonusers;~1
nonusers~2
users,~7
sites:~1
females:~1
users:~3
9.3~11
nonusers:~2
males:~1
phobias~3
nonusers.~1
Substance~4
users)~1
nonusers).~1
underscore~5
Youth~1
Cohort~2
Longitudinal~7
(NLS)~1
Labor~1
Market~1
childbearing~4
White,~2
Black,~1
Mexican-origin~1
Rican~7
21.~7
Latino~2
Whites~5
Blacks.~2
Mexican~4
premarital~3
Mexicans~2
Ricans.~1
Whites,~1
marriage,~1
Blacks,~4
out-of-wedlock.~1
racial/ethnic~1
birthplace~1
respondents'~1
controlled.~6
tuberculosis~37
(TB)~2
migrant~3
farm~7
Delmarva~1
peninsula.~1
Relevant~1
migrants;~1
709~2
completed,~4
239~5
acid-fast~9
bacilli~7
(AFB)~2
AFB~4
nontuberculous~2
mycobacteria.~2
Thirty-seven~8
migrants~1
5-14~1
45-54.~2
national/ethnic~1
Haitians~3
Blacks~7
US-born~1
Latinos~3
(CDC)~1
TB~2
camp~1
on:~1
agencies,~3
Crouse~1
Irving~1
Syracuse,~1
operates~2
freestanding~3
8,348~1
aegis~1
aggregate,~3
differed.~3
Physician~10
procedure-specific~1
case-by-case~1
non-institutionalized~1
1976-81,~1
Canadian~18
20-64~1
Overweight~1
Quetelet~1
25.1-30,~1
30.~3
obese,~4
excessively~8
survivor~2
20-24;~1
64.~1
rabid~2
raccoons~2
617~1
Maryland~6
rabies~14
raccoons.~1
raccoon~1
epizootic~7
postexposure~4
4,797~1
registering~1
kindergarten~1
districts~2
Canada.~5
screeness;~1
screenees;~1
conference~3
teacher~1
nurse;~1
counseling;~1
nurse.~4
screenees~1
intervention"~1
achievement,~1
cognitive,~8
Parents'~1
mental,~1
worry~1
DDSTs~1
screening.~9
federal~5
government~7
workplaces.~1
Often~3
utilize~5
posteriori~1
official~1
clusters.~2
pragmatic~1
(NIOSH)~1
1978-84~1
employers~1
Seasonal~1
(SAD)~3
SAD~6
sunlight~3
[SAD~1
workplace.~1
nonetheless~2
Lighting~1
workplace~2
psychobiological~2
light.]~1
presentation.~29
Conceptually,~2
political:~1
Monroe~1
Doctrine~1
1823.~1
America~8
US-Latin~1
relations,~4
euphemistic~1
"Spanish~1
surname."~1
"Latino",~1
"Latin~1
American,"~1
origins~7
US.~1
operationalized~1
descent,~4
Specifically~1
Spanish~4
Hemisphere.~1
derived,~3
"Latino~1
(Spanish~1
surname)."~1
"Mexican~1
Latinos."~1
medical/occupational~1
Eastman~1
Kodak~1
Ektachem~1
(desk~1
top)~1
analyzer.~2
finger-stick~1
1,081~1
screenees,~1
moderate-to-high~2
screenee~1
$3;~1
$16.~1
Turn-around~1
check-in~1
large-scale~7
bicycle-related~4
Diego,~1
Incidence~7
10-14~1
collision~2
vehicle,~4
motor-vehicle~2
collisions~1
bicyclists~1
legally~1
intoxicated.~1
method;~2
Leishmaniasis~1
amastigotes~7
long-haired~1
Uvalde,~1
Texas.~2
propagated~3
Syrian~7
hamsters,~5
NNN~1
organism,~2
owl~5
(Aotus~1
trivirgatus)~1
leishmanial~3
leishmanin~2
panamensis~4
(WR~2
WR~3
539).~1
128).~1
Reactivity~3
PHA,~1
Con~1
PWM~2
post-infection~2
(PI),~1
PI~7
DTH~3
PI,~2
PI.~1
nonhuman~5
immunology~2
Methylbenzethonium~1
(MBCl)~1
ml-1.~1
MBCl~1
parasites.~3
C57BL/6~5
donovani~9
glucan~3
harvested~14
log~17
post-immunization.~1
glucan-killed~1
vaccine,~9
(GPL)~2
(GPS),~1
amastigote~1
GPS~1
GPL.~1
Leishmania,~2
infecting~5
lizards,~1
Sudanese~1
donovani,~1
tarentolae.~1
exoenzyme~2
L(+)~1
tartrate.~1
nondenaturing~3
panamensis,~1
tropica,~1
presently~11
taxonomic~2
characteristic.~5
(3%~3
7%)~5
Entamoeba~3
histolytica~7
isolates.~11
used:~5
(PGM),~1
hexokinase~1
(HX),~1
glucosephosphate~1
isomerase~1
(GPI),~1
(ME).~1
axenic,~1
monoxenic,~1
carriers,~2
rigorously~4
endoscopic,~3
axenic~1
PGM,~1
HX,~1
GPI~2
nonpathogenic~2
GPI.~1
Rf~2
harbor~4
amebas~1
prevalence,~3
Giardia~8
lamblia~5
histolytica,~1
expatriates~2
Bangladesh~2
enrollment,~1
saliva~23
(IgG~2
SIgA).~1
G.~7
5.2%~6
11.8%.~1
newcomers~1
lamblia.~1
3.2%~5
8.6%,~1
Bangladesh;~1
(90%).~2
dysentery~2
titers.~2
seropositive~8
ameba~1
David~1
Livingstone~1
tsetse~2
flies~2
Okavango~1
swamps~1
Botswana.~1
Rhodesian~1
Trypanosoma~7
rhodesiense~1
visitors~4
refused~9
Melarsoprol~1
(Mel~1
parasitemia~2
Suramin,~1
hazardous,~3
curing~2
Rhode~2
Pennsylvania,~1
autochthonous~1
brugian~1
filariasis.~1
worms.~3
worms~8
node,~5
Female~10
worm,~1
gravid.~1
worms,~1
Brugia~2
Human-biting~1
instar~1
Simulium~1
damnosum~1
ecologically~2
simuliid~1
breeding~2
habitats~4
Firestone~1
Plantation~1
Harbel,~1
Liberia,~1
electrophoretically~5
(PGM)~1
trehalase~1
(TRE).~1
Enzyme~7
identifications~4
characters.~2
identifications.~2
yahense~2
human-biting~2
sampling,~4
sanctipauli~6
biting~2
larval~16
shaded,~1
waters,~1
watercourse~1
Normally~1
allopatric,~1
sympatry~1
May-October.~1
Biting~1
yahense.~2
fostered~1
specie's~1
zoophilic~1
tendency.~3
Circumstantial~2
PGM~2
TRE~1
"hybrid"~1
TRE,~1
inversions.~1
(IgG,~2
IgA)~1
(C3,~2
C4)~2
immunodiffusion~5
Nigerian~2
tropical~8
pyomyositis~2
(TP).~1
Nigerians,~1
(CS).~2
CS.~2
Microbiological~1
pus~3
(primary~5
acquired)~2
Nigerians.~1
infestations~1
red-legged~1
ticks~7
(Rhipicephalus~1
evertsi~1
evertsi).~1
ticks.~1
Immunity~1
tick~3
hosts~7
Antibody~7
salivary~49
tests:~3
hemagglutination,~1
Rabbits~4
50-~2
100-tick~1
quantum~3
Thogoto~1
(THO)~1
candidate~6
orthomyxovirus,~1
replicated~5
larvae,~1
nymphs,~1
tick,~2
Rhipicephalus~1
appendiculatus.~1
Larvae~2
viremic~6
(10(7-8)~1
PFU/ml~2
blood)~5
10(2.5)~1
PFU~3
tick.~2
engorgement~3
10(1.9)~1
10(3.3)~1
PFU.~2
transstadially~2
moulted~2
nymphs~5
contained,~1
10(3.5)~1
PFU/tick.~1
viremia~10
10(6.7)~1
THO,~1
THO~1
Uninfected~1
10(4)~12
PFU/nymph.~1
post-engorgement.~1
post-engorgement~1
(10(4.7)~1
PFU/nymph).~1
10(3.4)~2
(5-6~1
ticks/group)~1
10(2.8-3.5)~1
PFU/ml.~1
engorged~3
nymphal~1
engorgement.(ABSTRACT~1
Dispersal~2
Aedes~8
aegypti~10
Shauri~3
Moyo,~1
village~6
Rabai~1
Mombasa,~1
Kenya,~2
mark-release-recapture~1
920~3
mosquitoes~18
captured~7
uniquely~8
marked,~5
828~1
(40%)~14
recaptured.~1
recaptured~2
once,~2
houses~5
(40.8%,~1
44.9%,~1
houses.~1
Mosquito~1
summarized~10
tables.~1
0.592~1
0.433.~1
m,~2
57.0~1
m/day~2
44.2~2
mosquito~8
Moyo~2
331.1~1
146.5~1
Lincoln~1
533.3~1
Ford~2
270.3~1
179.5~1
Bailey's~1
catch~2
380.1~1
92.9~1
Jolly-Seber~2
0.825~1
0.693,~1
0.852~1
0.532~1
Longevity~1
dengue~15
viruses.~8
recapture~1
survivorship,~1
Ae.~16
gonotrophic~1
Africa~3
dengue-like~1
Pemba,~1
Mozambique,~1
Dengue~1
serotype~9
flavivirus~2
dengue,~1
epidemic.~2
Collections~3
hematophagous~1
Diptera~1
Kingsbury~1
Fish~1
Wildlife~1
Indiana~1
118,972~1
Jamestown~4
Canyon~4
trivittatus~2
stimulans,~1
transovarially~1
stimulans.~2
came~11
trivittatus.~1
4,000~3
tabanids~1
Transmission~5
field-collected~4
stimulans~2
midgut~4
44%,~3
16%,~2
Precipitin~1
bloodfed~1
white-tailed~1
deer~4
vector~15
transovarial~1
overwintering~2
virus.~18
Vertical~2
Florida:~1
Culex~2
quinquefasciatus,~1
Cx.~4
nigripalpus,~1
salinarius,~1
restuans,~1
opisthopus,~1
Anopheles~2
quadrimaculatus,~1
An.~1
albimanus,~1
taeniorhynchus.~1
Relatively~4
taeniorhynchus~2
venereal~1
Larval~1
rearing~2
transstadial~1
taeniorhynchus,~1
abundance~7
SLE~24
locality.~1
vector,~2
aegypti,~1
Trinidad~1
Peru~1
BHK-21~3
Mosquitoes~2
unpassaged~1
viruses~8
1899/81~2
Peru)~1
(109/177)~1
(61/176),~1
(60/94)~1
(22/49).~1
fingerprint~1
(45/46)~1
T1-resistant~1
oligonucleotides~1
uncloned~1
competence~8
bronchogenic~14
institutions.~7
mediastinoscopy~2
guarantee~3
regression,~6
cited~13
Adenocarcinoma~3
thyroglossal~5
Oklahoma~2
Sciences~3
Sistrunk~4
hyoid~13
midportion~5
wound-related.~1
excise~4
suprahyoid~1
duct.~9
epithelium-lined~1
cecum~4
removed,"~1
hypocalcemia.~5
Eighty-three~5
hypocalcemia,~3
Inadvertent~2
0.63,~3
percent.~44
hypoparathyroidism~3
(69~9
transhepatic~8
cholangitis~18
U-shaped~2
inexpensive~13
perform.~3
Recurrent,~1
frustrating~3
cholangiopancreatography,~3
hepatobiliary~13
papilla~6
Wirsung.~2
sphincteroplasty~5
stressing~2
transampullary~1
definitely~6
percent).~46
(17.5~2
Multisystem~1
Cholecystectomy~5
406~2
percent),~29
0.16).~2
occult.~1
efficacious~24
automobile~11
pedestrian~3
emergent~7
laparotomies.~2
Pericardial~2
tamponade,~4
(63~4
Plain~3
missile~3
traverse.~1
heroic~1
revived~2
1960s~3
thorax,~4
justifies~2
(71~6
salvaged.~1
Intermountain~1
full-thickness~16
1.06~3
mEq/kg~2
burned.~2
in-hospital~13
unselected,~1
covariance.~2
Appropriately~1
Parkland~1
omental~11
celiotomy.~4
Serious~14
injured.~3
portends~1
expeditious~3
cephalosporin~5
(cefotaxime,~1
cefoxitin,~3
moxalactam)~1
recoveries~3
cefoxitin-treated~1
enterococci~6
Enterococci~1
moxalactam-treated~1
Intraabdominal~1
planned~22
cleanse~3
clean.~1
expectantly,~1
hole~9
appendiceal~3
Planned~1
laparotomies~4
expectantly~1
clean~7
medications.~12
outcomes,~7
bupivacaine~37
(Marcaine)~1
Systolic~13
vasopressor~4
infarctions.~5
did,~5
obliteration~15
bypasses~19
(B-mode~1
oculoplethysmography).~1
reoperative~6
hemoclip~1
diuretics.~2
Indomethacin~5
Patent~1
extubation,~4
arteriosus.~8
suprainguinal~4
infrainguinal~12
lyse~3
(89~4
Arteries~1
(79~5
Arteries,~1
reopened~3
reocclusion~5
gastroplasty~4
morbid~10
pouch~26
gastroplasty.~2
1,463~1
gastroplasties~1
ring,~3
63.4~2
safest~2
side-to-side~13
variceal~2
consecutive,~3
splenorenal~5
(along~1
time)~5
electrocautery.~1
El~4
Paso~1
younger,~7
Hispanic~2
asthmaticus.~2
bronchospasm.~6
hours;~12
regained~14
Ketamine~1
consciousness.~6
Anaesthesia~5
steal~8
hyperventilation.~8
anaesthetist~4
(Model~1
1846~1
thigh-arm~1
Arm~7
approximated~10
mask~11
sensitively~1
cyanosis.~2
cyanosis~8
develops.~4
993~1
destined~3
Caesarean~9
started.~4
systemically,~2
top-up,~1
Satisfactory~13
87.8%.~1
bupivacaine,~9
Hartmann's~3
(1971-85).~1
Characteristics~4
top-up~2
anaesthesia.(ABSTRACT~1
intracranial,~2
thiopentone~10
Intracranial~5
pre-induction~4
tracheas~1
atracurium.~3
Intubation~2
Transoral~1
craniocervical~5
nasotracheal~3
Peroperative~1
solved~5
(Travenol)~1
(Ca++)~2
realised~1
Oxyhaemoglobin~1
electroconvulsive~3
anaesthetised~7
methohexitone~1
(40-100~1
suxamethonium~5
(25-50~1
(40-50%)~1
47),~2
convulsion~5
subside~1
recommencing~1
oxygen-enriched~1
hypoxaemia.~2
herniotomy,~1
orchidopexy~1
processus~1
vaginalis~2
analgesia;~1
ilioinguinal~1
Analgesia~3
Ilioinguinal~1
double-dummy~1
buccal~14
premedication.~3
pre-anaesthetic~1
premedicant~1
anxiolysis~1
wakefulness,~2
Pharmacokinetic~9
efficacies~1
per-~1
obtainable~3
premedicated~2
paraesthesiae~3
Evoked~4
droperidol~4
1.25-5.0~1
epidurally.~1
Parkinsonism.~1
colic~4
premedication~8
jet~29
Labour~3
decompression.~8
Schwannoma~1
vagus~17
parapharyngeal~8
plethymograph~1
monitor,~3
(AR-8800),~1
apnoea~6
alarms~1
15-20~2
AR-8800~1
dependable~3
ward~6
(26),~1
(32).~1
analgesics.~5
night's~2
toilet~3
itching~2
easy.~1
pancuronium,~4
hypothenar~1
(T4/T1)~1
T4/T1~2
postreversal~2
(atracurium-edrophonium);~1
(vecuronium-edrophonium);~1
0.44~10
(pancuronium-edrophonium);~1
0.95~8
(atracurium-neostigmine);~1
0.89~5
(vecuronium-neostigmine);~1
(pancuronium-neostigmine).~1
20-30~3
elapse,~1
pancuronium~8
Increasing~18
Neostigmine~1
vecuronium-edrophonium~1
neostigmine.(ABSTRACT~1
(TOF)~1
(TD)~1
train.~1
TOF~9
SD).~14
TD~4
recover,~1
recovering~4
74.9~1
15.7~5
86.2~1
15.4%~2
"effect~1
compartment."~1
(SEP)~5
unpremedicated~3
Erbs~1
(N10),~1
(N14),~1
(P15,~1
N20,~1
P23~3
latencies,~3
P15-N20~2
N20-P23~1
amplitudes).~1
thipental~1
bolus),~2
etomidate~11
bolus).~1
Thiopental~2
N10,~1
N14,~1
N20.~1
N10-,~1
N14-,~1
thiopental.~1
P15-N20.~1
Etomidate~1
N10~2
N20-P23,~1
thiopental~7
SEP,~2
waves.~5
glycolysis~5
acid-induced~3
glyceraldehyde-3-P~1
Fructose-1,6-diphosphate~1
(FDP)~1
FDP~2
normoxemia~1
(FIO2~3
0.21)~2
pentobarbital.~2
hypoxemia,~9
10),~4
sugar~3
FDP-treated~3
hypoxemia;~1
glucose-treated~3
saline-treated~7
rabbits;~1
(FDP~2
arrest.(ABSTRACT~1
hemodilution,~2
neuropathologic~7
hemodilution~9
conditions;~2
(0.8~5
vol~2
inspired)~1
mechanically.~1
trimethaphan~2
[MABP]~1
Hemodilution~1
lactated~7
Ringer's~22
superimposing~1
MABP).~1
undetermined~4
neurologic)~1
Neuropathologic~3
pallidus~4
MABP~2
mmHg.(ABSTRACT~1
minipumps.~2
day-1);~2
day-1).~2
1,040~2
offspring,~4
(retinoic~1
external,~2
lidocaine-treated~1
(UBFV)~1
(0.2,~2
epinephrine)~1
(MHR),~1
(MMAP),~1
UBFV.~2
Epinephrine,~2
MHR.~1
MMAP~1
UBFV~2
0.2,~8
boluses~5
aminophylline~19
MAC~7
24)~9
aminophylline,~3
ip,~3
neurotransmission~5
halothane-anesthetized~3
ml-1)~5
1.0%)~1
(1.04~1
1.01~3
0.14%)~1
Commensurate~1
anticipated~9
materialize.~1
(MH)~3
MH-susceptible~1
MH.~3
caffeine:~1
MH~10
(MHS;~1
19);~1
(controls;~1
31);~1
intermediate-reaction~1
(K-type:n~1
18).~5
(normal,~5
MHS,~1
K-type:~1
13.20~1
13.74~1
14.42~1
(16.30~1
16.94~1
15.06~2
triphospate~1
(3.75~1
3.98~1
3.89~1
(3.73~1
3.65~1
Angiographers~1
encounter~11
helium-neon-laser~1
quantifiable.~1
Fontaine~1
II-IV,~1
endangiitis~1
obliterans.~1
(which~8
described),~1
intraindividual~2
Laser-Doppler~1
angioplasties~3
(PTCA),~1
(3.6%)~3
Lesion~1
(12.7%).~1
difficulty.~4
Intimal~6
(32.7%)~1
restudied~3
angiographically,~1
38%.~4
Intrapulmonary~2
(86.8%).~1
(10.5%)~2
gr/liter~1
(57.8%)~1
cut-down~1
(2.6%)~1
"classic"~1
obtainment~1
Felodipine~2
"third-line"~1
hydralazine.~4
Nifedipine,~1
demerits~1
appraised,~1
20-60~2
drug-resistant~2
felodipine~3
chlorthalidone~2
daily.~13
felodipine,~1
(supine~1
4.13,~1
reestablished~3
reintroducing~1
greater.(ABSTRACT~1
extracts.~11
Epicutaneous~1
implication~7
adenoidectomy,~1
(sIgA)~1
sIgA~3
afterwards.~1
palatine~1
long-term,~4
post-adenotonsillectomy~1
recommend,~1
0.49~7
Subsensitivity~1
develops,~2
Nebulized~1
albuterol~21
(salbutamol)~1
wheezy~1
Albuterol~5
extubated,~1
reinstitution~3
(VI),~2
(f)~2
ventilator,~1
f~7
successful,~6
398~3
32.3~4
breaths/min~2
PaCO2~9
alveolar-arterial~4
shallow~5
weaning,~3
VT/TI)~1
(TI/Ttot)~1
VT/TI,~2
ml/s~2
VI,~3
5.82~1
0.53~5
7.32~1
L/min~4
trial;~3
change.(ABSTRACT~3
Tension~3
subatmospheric~1
swing~3
fatiguing~6
(IES)~1
nonfatiguing~2
duty~13
fixed.~1
electrode.~8
IES~5
Borg~1
(Pes)~2
(Pes/Pesmax~1
%)~1
0.88,~3
Pes/Pesmax~1
separately.~5
breathlessness~5
indexes-such~1
Pneumoconiosis~4
index-the~1
taxing~1
tasks~12
task,~5
Dyspnea~3
Index~14
score,~20
(COPD),~1
(Spearman~1
rho~1
-0.62)~1
(Pearson~2
0.71)~1
0.69).~2
Ratings~6
function.(ABSTRACT~4
Extracellular~7
endothelial-dependent~1
precontracted~2
(COPD).~4
(successive~1
mumol/kg~8
(H;~5
nonhypertensive~2
(N;~4
(C;~1
ANOVA.~1
reached,~3
-14.2%~1
H;~1
-13.8%~1
N;~1
(Ppa),~2
-31.7%~1
-20.7%~1
(PVR),~3
hypoxemia:~2
-6.9%~1
-11.8%~1
(n;~1
rebound~9
(above~2
values)~3
+10.9%~1
+4.4%~1
+24.9%~1
+10.2%~1
PVR.~1
short-acting,~1
vasolidating~1
COPD,~3
premature.~1
collagens~2
bleomycin-induced~2
175~13
intratracheally~7
bleomycin-treated~2
intraalveolar~9
hydroxyproline,~1
[3H]proline~2
collagenase-sensitive~2
[3H]proline,~1
homogenized~4
NaCl,~1
guanidine-HCl~1
alkylation.~2
procollagen,~2
nondialyzable~1
[3H]hydroxyproline.~1
residue,~2
proline~5
procollagen~8
collagens.~2
asbestos~6
retention,~3
alveolitis,~5
phosphate-buffered~6
(PBS)~1
UICC~2
chrysotile~4
PBS.~1
(PFT),~1
(CR),~3
(BAL),~1
transbronchial~2
(TLB).~1
Month~1
asbestos-exposed~5
TLB,~1
CR,~3
Cst,~1
air-flow~4
peribronchiolar~2
asbestosis.~3
profile,~8
exposure-dose-related~1
dust.~2
(CB),~1
(BA),~1
(CPE),~1
alveolobronchogram~1
(SAB)~1
14).~5
SAB~4
(C-II)~1
(P-II),~1
SAB,~1
CB,~5
BA,~1
C-II~2
P-II~3
(RL)~6
FEV/VC%~1
C-II.~1
BA~8
CPE,~1
RL~15
FEV/VC%.~1
Chlorine~2
gas,~4
derailment,~1
sublethal~3
hospitalized.~1
spill,~1
FEV~3
-34~2
ml/yr~2
-18~3
never-smokers.~1
discernible~8
accords~1
pre-exposure~1
persisting~6
decline.~4
(NO2),~2
pollutant,~1
NO2-induced~1
peroxidation~3
NO2~12
fluidity,~1
(5-HT),~2
(LDH)~5
peroxides~2
3-~3
1,6-diphenyl-1,3,5-hexatriene~2
(DPH),~1
hydrocarbon~10
partitions~1
interior~7
bilayer~2
DPH~1
spectroscopy.~6
rho.~1
5-HT~46
14C-5-HT~1
LDH~16
spectrophotometric~2
rhoDPH~1
NO2.~1
Exposure~20
NO~1
potentiates~9
bronchospasm,~1
provocation,~2
(560~1
micrograms/m3)~1
asthmatics~15
mouthpiece~2
workload~6
kpm/min,~1
(SE)%~1
(air)~1
bronchoconstrictor,~1
-11~2
(PD10RHE).~1
FEV,~1
PD10RHE,~1
exposure.(ABSTRACT~1
toluene~2
diisocyanate~2
(TDI)~1
PMN~36
mechanistic~3
hydroxyurea~7
cyclophosphamide.~3
untreated,~4
hydroxyurea-treated,~1
cyclophosphamide-treated~2
tracheostomy.~1
TDI~1
TDI-induced~5
hydroxyurea,~1
bloodstream~3
200/mm3,~2
mechanically~21
responsiveness.~6
depletion.~5
nonsmoking~4
phagocytosis,~2
killing,~4
theophylline-treated~1
(intracellular~1
60.2~3
peroxide.~4
defenses~4
(IgM-RF)~1
(IgG-IC)~1
mycoplasmal~2
pneumoniae~7
ELISA.~10
IgM-RF,~2
IgG-IC.~3
IgM-RF~3
IgG-IgM-RF~1
thromboendarterectomy~4
(PAT)~2
(RPE)~2
anecdotally~1
fully,~3
RPE~6
PAT~10
Particular~4
operated,~2
roentgenograms,~4
PAT.~5
Regions~2
spared.~3
RPE.~2
peculiar,~1
(LPR).~1
LPR,~2
cell-dependent~3
(1-8~1
neutrophil-rich~1
(8-24~1
cell-rich~1
infiltrates.~6
IgE-dependent~4
[IgE~1
anti-ovalbumin~1
antibody]~2
[mouse~1
hybridoma~8
anti-dinitrophenyl~1
(DNP)~1
trachea,~5
anti-DNP~1
(PCA~1
1:10,000)~1
DNP-BSA~1
aerosols.~3
Numbers~4
peribronchiolitis~1
infiltrate.(ABSTRACT~1
Paraquat,~1
paraquat~3
transvascular~7
fluxes,~1
Lymph-plasma~1
TXB2)~1
(6-keto-PGF1~3
6-keto-PGF1~9
perivascular~11
cuffing,~1
neutrophilic~6
infiltration.(ABSTRACT~1
apoprotein~14
oligomer~5
peptide:~1
N-glycosidase~1
31,000~1
recombined~2
dipalmitoylphosphatidylcholine~1
phosphatidylglycerol~2
(3:1)~1
1:100.~1
dyn~2
cm-1~2
18.0~3
bonds~3
instilled~15
phospholipids,~2
apoprotein,~3
surfactant.~1
fixed,~5
disulfide-dependent~1
oligomeric~2
glycosylation.~1
recombination~9
biophysically~1
gold,~2
[125I]-LDL~1
[3H]-cholesterol~1
Competition~5
receptor-bound~4
receptor-independent.~1
3H-cholesterol~1
LDL-gold~1
(LDL-Au),~1
recirculated~1
(coated~1
lysosomelike~1
structures)~1
transcytosis~1
(plasmalemmal~1
vesicles).~1
receptor-independent~4
moiety;~1
schemes~3
preestablishing~1
isoniazid,~1
rifampicin,~1
pyrazinamide~3
restrictions~5
fixed-triple~1
multiplying~6
overdosing~1
purchasing~1
Third~1
Strains~1
pyrazinamidase~2
(PZA).~1
avium~6
(MAC),~1
pyrazinamidase-positive,~1
PZA~2
7H12~1
broth~5
radiometric~1
(BACTEC)~1
intubation,~16
"prophylactic"~1
persisted.~8
foam~6
(ERPF),~3
metabolites,~4
(CLP)~2
(sham).~1
adenine~19
freeze-clamping~1
ERPF~4
p-aminohippuric~3
than;~1
peritonitis.~6
pyruvate/lactate~1
septicemic~6
ARF.~3
interrupted.~1
30-cm~1
jejunum~25
ileum,~7
fluorescein.~2
Viability~2
sustain~10
devascularization.~2
intestine,~13
jejuno-ileal~5
ileum.~11
vasodilator,~6
intestine.(ABSTRACT~1
Impedance~4
cardiography~3
reproducible,~5
(SV),~1
(EDV),~1
(ESV)~2
tilt~10
(measurements~1
CO,~5
SV,~2
EDV,~1
ESV)~1
supine.~3
CI~8
L/min/M2~5
CIs~1
0.83~5
L/min/M2,~1
0.78~5
EDV~2
degrees:~5
cc/M2,~4
Supine:~2
cc/M2),~1
cc/M2).~1
noncompliant~4
12,000~1
fire-related~1
annually~1
furnishings~1
"supertoxin"~1
date.~8
escape,~1
children)~3
25-month~1
scene,~3
Position~1
Carbon~4
"lethal"~1
(=~6
21/39~1
Cyanide~1
24/29~1
mg/L)~6
Ethanol~8
21/26~1
0/12~1
(0%).~4
18/26~1
statutory~1
mg%).~1
Victims~1
attempt)~2
mg%,~3
exit~10
smoke-related~1
(PSF)~1
(%SW)~1
poststenotic~2
PSF,~1
continuous-wave~6
(CW)~1
velocimeter,~2
frequently,~6
microprocessor-driven~1
%SW.~1
MHz~4
CW~1
probe,~8
Doppler-shifted~1
nonaxisymmetric~2
(CSA)~2
%SW~4
(Y)~1
CSA~4
(X)~1
(Y~1
MX~1
-0.052,~1
-1.538,~1
Beyond~1
comparisons.~4
stenoses.~7
evolved:~1
acute--to~1
chronic--to~1
Catheters~2
buried~4
pocket~8
exteriorized~6
harness,~1
measured:~3
extraction,~12
osmolar~9
paramino~1
hippurate~1
cuff.~3
plans~8
met.(ABSTRACT~1
agonist,~23
(MS),~2
Langendorff~3
pentobarbital~11
chloral~2
hydrate~2
(CH),~1
anesthetic-morphine~1
occurring.~3
bursting~5
incised~2
angiogenesis~1
(PTFE)~5
2-cm~2
PTFE~15
pannus~6
types:~4
irregular.~1
smooth,~3
irregular-shaped~1
thrombi.~6
smoothly~2
graft;~1
proximally.~4
anastomoses.~3
pannus,~1
remainings~1
pannus.~1
interstices~1
56-day~1
nondenatured~1
4-step~1
preclot~1
autogeneic~3
heat-coagulated~1
autoclaving~2
blood-soaked~1
Healing~3
materials.~3
co-occurrence~1
Reiter's~7
HLA-B27.~2
helper~10
spondylarthropathy~1
menopause.~5
low-dosage~1
9.0%~2
0.002~5
baseline)~2
estrogens,~3
mg/d,~1
2.3%.~3
appendicular~5
Collagenous~2
watery~5
watery,~1
noninfectious~6
Roentgenographic~3
subepithelial~11
(three),~7
(six),~2
eosinophilia~12
(three).~2
diarrheal~5
malabsorption,~6
steatorrhea,~3
small-bowel~2
abated,~2
propria~15
autoimmune,~1
Hyperamylasemia,~1
bulimia,~1
hyperamylasemia,~2
amylase,~3
lipase,~4
isoamylase~8
hyperamylasemia~7
bulimia~3
salivary-type~1
452~4
one-vessel~1
V5~2
V6~1
high-grade,~1
proximal,~6
health-care~4
T-lymphotropic~2
III/lymphadenopathy-associated~1
(HTLV-III/LAV)~1
[now~1
virus],~1
(AIDS).~3
HTLV-III/LAV~3
vaccine-preventable~4
community,~6
situation.~10
residing~5
pertain~2
reassessment~3
HTLV-III/LAV-infected~1
HTLV-III~7
Nephritis~1
erythematosus.~8
Accumulations~1
best-described~1
Inbred~2
lupus-prone~1
imprecise~2
imperfect~1
hazardous.~3
Certain~10
well-recognized~8
precarious~2
equilibrium.~3
Everything~1
endoscopy-anesthesiology~1
tends~18
Cooperation~1
well-disciplined~1
outlines~5
tempered~1
comfort.~1
16-year~3
laryngectomy~7
imbrication~2
eradicating~4
glottic~6
full-thickness,~1
voice~11
cordectomies~1
hemilaryngectomies.~1
full-course~1
Imbrication~1
laryngoplasty~1
laryngectomies.~1
larynges.~1
glottis~8
neutral,~1
adduction,~3
abduction.~2
portions:~1
glottis,~2
fold.~3
closes~2
supraglottis,~1
conic~1
below.~2
accounts~15
ciliated~4
epithelium.~14
glottis.~2
1973,~3
subglottic~15
laryngotracheal~3
postintubation~1
cricotracheal~1
resected.~3
shell~7
Postoperatively,~8
Montgomery~1
T-tube~3
cords.~6
Tension-relieving~1
tolerance.~14
Voice~4
deteriorated~17
pathologic,~6
connotations.~1
1972.~1
Ear,~1
Nose,~1
Throat~1
Padua~1
3,284~1
brings~5
66.~1
argyrophilic~1
Kulchitsky~1
carcinoid,~4
fungoides,~2
estrogen-receptor~2
intranuclear~4
baboons;~1
One,~1
Two,~2
mesenchymal~17
propria,~1
Three,~1
perichondrium.~1
hormone-receptor~5
dimorphic~1
organ,~6
phonation~5
Vocal~1
singly~5
tracheotomy,~1
lateralization~2
folds,~8
paralyses~3
predominance,~2
bilateral.~3
idiopathic.~2
Tracheotomy~1
paralyses.~1
stressed,~2
laryngoscope.~2
Endotracheal~1
securing~3
remains,~1
"prolonged"~1
"safe"~1
tracheotomy~7
Neonatal~8
Columbus~1
3-year~16
343~5
56.2~3
(1/245).~1
intubation-related~1
minimized.~3
Krupp~1
2,986~1
Zeiss~1
Anesthesia~5
focusing,~2
movable~4
microscope~17
semi-Fowler's~1
best.~4
turbinates~2
binocular~2
mirrors~1
endoscopes.~2
Caldwell-Luc~1
ethmoidal,~2
sac,~3
epistaxis~7
intranasally.~1
osteoplastic~1
ethmoidal~3
roof~1
conically~1
wedged~11
Having~1
skill,~2
eustachian~5
electrocauterization~1
Mongolian~4
gerbils.~2
retracted~1
retractions,~3
cholesteatomas.~3
cholesteatomas;~1
bulla.~1
aural~2
cholesteatomas~2
hemangiomatous,~1
malignant,~7
Saccades~2
flashed~3
Latencies~3
hypometric.~1
impersistence~1
gaze~3
large-amplitude~3
saccadic~3
gaze.~2
saccades~6
target,~1
reflexive~5
attribute~6
grasp~1
perforant~4
arises~15
entorhinal~1
parahippocampal~5
neurofibrillary~11
tangles~6
pathway,~10
gyrus,~6
neuritic~3
disconnect~1
limbic~4
cortices.~2
learning,~1
precluding~2
somatostatin-like~4
(SLI)~1
SLI~5
lobe;~2
Characterization~2
somatostatin~28
0.6-~1
1.5-Tesla~1
superconductive~2
42%.~2
great.~1
electroencephalographic~10
shunting,~3
(49~8
12%)~3
1.1%).~1
(PCr/Pi)~1
PCr/Pi~5
ratio;~3
decreases.~6
Postictal~1
postictal~2
Interictal~1
31P~8
NMR~12
acquisition,~4
1.2.~2
PCr~10
exacerbate~4
Dendritic~1
Down's~8
infantile,~1
late-infantile,~1
Camera~1
lucida~1
drawings~7
Golgi-impregnated~1
dendritic~10
aspects:~1
intersections~2
branching,~2
orders,~1
(older~2
arborization~1
atrophies~1
neuropathies,~2
Sjogren's~10
debilitating~9
neuronopathy.~1
biopsy-documented~2
ganglionitis~1
immunopathogenic~1
corticospinal~4
neuropathological~8
Gerstmann-Straussler-Scheinker~1
neocortex,~3
hemispheres~7
astrocytic~5
9.~2
Multicentricity~1
large-cell~3
immunoblastic~6
noncleaved~5
B-cell~5
Neurological~5
radiosensitive,~1
poor,~8
subacute,~1
encephalopathies~1
antifolate~2
myotonic~9
catabolism.~1
androgens,~2
enanthate~2
dystrophy.~6
L-[1-13C]leucine.~1
ribonucleic~7
"event-related"~1
long-latency~3
(stimulus-synchronized~1
(response-synchronized~1
average).~1
(P165~1
P3)~1
belief,~3
P165-N2-P3~1
separately~25
Glutamate,~1
aspartate,~2
taurine,~3
(GABA),~1
regions,~3
hippocampus,~5
thalamus,~6
brains,~4
lobe.~6
cortices~5
acidergic~1
Bell's~7
Rochester,~7
Minnesota,~4
25.0~1
22.8~2
26.9,~3
(14%)~21
non-ear~1
results;~3
94)~2
112)~1
fared~6
(mixed~2
Ficoll-Hypaque~1
gradient)~2
(SDAT)~1
antimuscarinic~3
SDAT,~3
Foix,~1
Chavany,~1
Marie~1
faciopharyngoglossomasticatory~1
diplegia~2
opercular~2
milestones,~1
retardation,~11
drooling,~1
gag~1
protrude~1
brisk~4
jaw~4
jerks,~2
gait.~6
polymicrogyria~1
movements.~13
obscure.~2
(ocular~1
bobbing,~1
dipping,~1
bobbing),~1
implying~8
hemiplegia~4
(PMH)~1
lacunar~2
monoparesis~1
(PMM),~1
spasticity~8
PMM~2
PMH.~1
unclassified~4
botulism.~1
Her~14
S-1~10
(EP)~5
abnormalities).~1
abnormalities),~1
single-modality~1
EPs,~1
EPs~1
yield.~2
brainstem~28
(BAEPs),~1
brainstem.~3
BAEP~7
MRI,~5
agent)--a~1
nonantiseptic~1
antiseptic~4
isopropyl~1
(IPA)~1
emollients~2
(Alc~2
IPA~5
chlorhexidine~2
(CHG),~1
IPA--washed~1
Microbiologic~2
CFU~3
Alc~1
CHG,~1
IPA.~1
washes),~1
2-log~1
antiseptics,~1
soap.~1
Subject~2
alcohol-based~2
rinses~1
efficacious,~3
wash,~1
sink~1
inaccessible.~1
cefonicid.~1
unbound~22
(non-protein-bound)~1
cefonicid~7
Saturable~2
vivo;~1
17.6~6
6.1%~2
10.8~8
Dosage~2
pharmacokinetics.~5
Norfloxacin~1
Chlamydia~11
trachomatis~23
urealyticum,~2
norfloxacin~5
nongonococcal~3
urethritis.~2
reisolated~1
posttreatment,~1
inclusion-forming~1
posttreatment.~3
follow-ups,~2
attains~1
penetration,~7
chlamydial~6
urethritis~5
better,~9
incomplete,~3
urealyticum.~1
quinolones~1
trachomatis,~3
MICs~13
spotted~1
ciprofloxacin.~4
perorally~1
ciprofloxacin~4
Rickettsia~1
conorii.~1
2b~3
Interferon~1
(chills,~1
fatigue,~9
leukopenia),~1
indication.~2
aeruginosa.~1
1.27~3
mg/liter~3
3.16~2
1.27),~1
0.9).~3
sulfoxide.~4
Beta-lactamase-negative~1
Neisseria~4
gonorrhoeae~1
single-dose~8
cefoperazone~13
spectinomycin~2
Anogenital~1
cefoperazone,~2
spectinomycin.~1
0.028~1
microgram/ml.~5
Cefoperazone~2
anogenital~1
gonorrhea~2
mimicus~1
Environmental~3
streptomycin,~1
kanamycin,~2
trimethoprim-sulfamethoxazole;~1
susceptible.~5
(44%),~1
"Acinetobacter~1
anitratus"~1
cleanly~1
gentamicin-susceptible~1
strains)~4
gentamicin-resistant~2
10(4)-CFU~1
inoculum,~2
norfloxacin,~1
ciprofloxacin,~4
A-56620,~2
tobramycin,~2
Antimicrobial~1
A-56619,~1
imipenem,~1
SCH-34343,~1
ceftazidime,~2
aztreonam,~2
carbenicillin,~1
ticarcillin,~3
piperacillin.~1
aminoglycoside-susceptible~1
-resistant~1
"A.~1
anitratus."~1
SF~10
86-327,~1
allylamine~1
antifungal~13
86-327~1
trough,~1
non-lactose-fermenting~1
typhimurium~2
Shigella~3
flexneri~1
sonnei~1
1949~2
14,237~1
grenz~2
eczema,~1
14,140~1
(99.3%)~1
diagnoses,~6
average.~3
searched~3
Registry,~1
Stockholm,~1
(incidences~1
registered).~1
sex-standardized~1
Registry.~3
grenz-ray~3
melanomas,~3
17.8,~1
26.9.~1
carcinogens.~3
eighty-one~2
000~1
[greater~2
Gy])~1
malignancies,~9
scheduled~14
Epinephrine-containing~1
dermatologists;~1
anticoagulant~27
hypocoagulability,~1
Thrombotest)~1
(International~3
Ratio~1
5.4).~1
specimen,~3
K-dependent~2
coumarin-induced~1
palmar-plantar~2
desquamation~5
fingers~8
mercaptopurine~4
allopurinol.~2
mg/d~7
livid~1
fingertips~1
fluocinonide~1
entirely.~1
eighth~8
desquamating~1
xanthine~18
oxidase,~2
mercaptopurine,~1
hemangioma~5
nevi.~2
cricket~1
ball~4
cheek~1
port-wine~4
Discussion~1
centered~7
scleredema~4
neonatorum,~1
Cetylpyridinium~1
Peculiar~1
erythematosquamous~1
M-subunit~1
myoglobulinuria~1
nonpruritic~1
papules~7
childhood,~6
soles.~2
summer.~1
63-year-old~5
Nodules~2
chance,~1
anti-lambda~1
light-chain~1
Amyloid~1
biochemically,~2
immunologically,~1
29,000-,~1
20,000-,~1
17,000-~1
29,000-dalton~1
22-year-old~6
keratotic~4
incontinentia~3
pigmenti.~3
Scalloped~1
phalanges~5
uncertain;~1
verrucae,~1
keratoacanthomas,~1
fibromas.~1
alkalosis~7
apnoea.~2
Gross~11
'mild'~1
8-10~2
formulas~6
Organisation~1
(WHO).~1
zinc:maternal~1
WHO~4
wrong.~1
thiopentone.~1
electroencephalograph~1
continuously.~5
Thiopentone~3
Hg;~10
prematurely~6
pharmacodynamic~10
non-linear~1
handicap.~2
coma;~1
prospectively.~12
haemorrhage~8
(PVH)~1
ventricles;~1
26)~5
PVH~3
(none~1
hydrocephalus);~1
52),~2
occipitofrontal~2
circumference,~3
biparietal~5
(PVH~1
alone)~5
18)~9
famine~1
Ethiopia~1
refugee~2
camps~1
Sudan~5
centres~5
Ethiopia.~1
1325~2
ophthalmologist~4
Bitot's~1
xerosis~1
xerophthalmia~1
xerophthalmia.~1
prolong~9
chloramphenicol.~1
mg/kg/day).~4
(-9.7~1
(3.2)~4
mg/l),~1
(+225~1
(162)~1
ml/kg),~4
(-1.9~2
(+236~1
(94)~1
ml/kg/h),~1
(-83.5~1
(33.0)~1
mg/l/h),~1
(+0.34~1
(0.13)~1
h-1)~3
Acetaminophen,~1
chloramphenicol,~6
glucuronidation.~2
re-emphasises~1
together.~4
apnoea,~1
stridor~8
(infantile~1
larynx)~1
stridor.~2
L-rhamnose~2
Intestinal~8
sugars~2
lactulose:~1
raised,~1
ileus~7
equivalent.~3
Gastrografin~1
outpatients.~6
fontanelle,~1
subhyaloid~4
haemorrhages,~1
anaemia.~4
shaking~6
(280~2
Losses~1
formula.~3
ileus,~3
organomegaly,~2
emergency.~2
(Meckel's~1
sarcoma);~1
ileitis.~5
Burkitt's~5
Laparotomy~2
proctocolectomy~5
continence-preserving~1
Kock~3
pouches,~1
ileoanal~9
anastomoses)~1
Frequency~4
intercourse~2
dyspareunia~2
impaired.~17
pre-illness~1
Weight-losing~1
weight-stable~2
weight-losing~1
kilocalorie~1
lean~47
cachexia.~2
osteomyelitis,~3
Amputation~1
boot~2
Osteomyelitis,~2
3.8%~5
Antibiotic-sensitive~1
enteric~20
gram-positive~9
antibiotic-resistant~2
receipt~4
bactibilia~1
Bacteria~4
prophylaxis.~9
252~5
world~13
pylorus-preserving~2
pancreatoduodenectomy.~1
2.8%.~1
Anastomotic~1
fistulae~10
Pancreatic,~1
biliary,~1
11%,~7
Peptic~2
antrectomy.~1
30%.~9
remedy~4
Pylorus-preserving~1
pancreatoduodenectomy~1
Whipple~3
impact.~5
guidewire~7
tip,~4
threading~2
guidewire.~3
Correct~3
(superior~2
[SVC]~1
RA)~1
78)~2
(PACs)~1
(2.4%).~1
distress.~13
pleurectomy,~1
9-22~1
thoracoscopy~1
talc~3
poudrage.~1
Thoracoscopy~2
5.5-mm~1
trocar,~1
Pharmacopeia-certified~1
insufflated~2
pneumothorax~19
poudrage~1
(normal)~6
(NS)~7
(ICP),~1
(HS)~1
Beagles~1
ventilated,~2
pCO2~2
positioned.~3
bolt.~1
dog's~1
5),~9
HS~4
dextran-40~1
(D-40,~1
Intravascular~2
NS.~1
3.13~1
D-40~2
5.83~1
16.2~8
1.73~5
elevates~3
ICP.~1
16,16~1
(dm~1
PGE2)~1
N-acetyl-cysteine~1
(NAC),~1
mucolytic~1
Fasted~1
dm~5
PGE2,~1
NAC,~1
NAC.~1
stomachs~4
mL~10
(EtOH)~1
EtOH~2
NAC~3
spare~3
EtOH.~1
PGE2.~1
EtOH,~1
verifying~3
prostaglandins.~1
EtOH-induced~1
thickness,~17
Descriptions~1
fasciae~2
puzzling~3
descriptively~1
practitioners,~3
cervicofacial~2
fasciae,~2
intraoral~4
simplify~6
sympathectomy~3
(UDS)~1
hyperhidrosis.~1
(LVF)~1
Electrocardiograms~1
UDS.~1
LVF~3
Submaximal~1
UDS,~1
UDS~1
overt~30
beta-blocker-like~1
apex~19
annular~12
supravalvular~2
apex,~2
Extrapleural~2
pericardium,~3
female)~5
epithelial,~1
mixed,~2
sarcomatous.~1
palliation,~4
(9.1%),~1
extrapleural~3
Palliation~3
survivor.~3
Medtronic-Hall~2
379~1
(AVR),~1
(MVR),~1
(1,225~1
patient-years)~1
42.01~1
error]).~1
53.8~1
ninety-three~3
(50.9%)~1
annuloplasty,~1
grafting,~2
(NYHA)~3
13.5%~2
(51~8
74.1~1
69.0~1
AVR,~1
81.0~1
MVR,~1
67.0~1
sodium.~8
(2.1/100~2
patient-years):~1
MVR~1
(2.3/100~1
patient-years),~2
AVR~1
(1.4/100~1
patient-years).~1
fatal;~1
survivors,~14
Classes~5
valve-related~16
minimal.(ABSTRACT~1
closed-heart~2
cryoablation~13
(74),~1
(23),~2
(11)~1
Electrophysiological~4
ablated.~1
incident~9
cryoablation.~3
warm,~3
efficacious.~1
Fontan-type~1
post-Fontan~1
N1;~1
N0;~1
N0.~1
(T2~5
N1)~4
N0)~2
postoperation.~2
nonoperatively~3
30-month~1
sternotomy~7
1,204~1
(1.7%)~2
Hospital.~8
17.0~3
epidermidis,~1
clindamycin.~3
cephalosporin-containing~1
Trials~2
penicillin-allergic~1
minimizes~5
potassium-induced~5
ameliorating~4
hearts,~9
curves)~1
warmer~6
.025)~2
hyperemia.~4
preserves~7
energy-efficient~1
myoprotective~1
Subendocardial~4
septal,~2
Localization~3
presystolic~3
(100%).~2
Resectability~2
Induction~5
VT:~1
nonresectability~1
CGS-13080~4
(imidazo[1,5-alpha]pyridine-5-hexanoic~1
blinded,~3
.001),~22
CGS-13080-treated~2
.03)~2
"endoperoxide~1
shunt"~1
.5,~1
.18,~1
.10)~2
intraaortic~6
lodged~3
repaired.~2
bronchioloalveolar~2
So-called~1
(IVBAT)~1
histogenesis~8
"miscellaneous~1
malignant."~1
misdiagnosed.~1
oncocytoma~2
cricopharyngeus~1
Exploration~1
Enucleation~2
Pathological~6
Blalock-Taussig~1
(BT)~1
systemic-to-pulmonary~2
shunt.~15
BT~4
(PAI),~1
(7.5%)~4
postoperatively)~1
shunt,~13
reconstruction,~10
25.15~1
PAI~8
mm2/BSA~2
pre-shunt~1
286.1~1
post-shunt~1
tetralogy~9
Fallot~3
Calculation~4
femoro-popliteal-tibial~1
Angiographically,~1
patent.~5
successful;~2
ankle/brachial~3
90.2%~3
83.8%~1
Graft~6
72.6%~1
54.5%~2
leiomyomatosis~1
(FNAB)~2
FNAB~6
(53.0%)~1
Coexisting~2
refusal~3
(true-positive~1
(true-negative~1
Pneumothoraces~2
(13.6%~1
group),~8
(10.6%~1
furnished~1
cardiologists~2
angiograms.~8
computer-based~1
observers,~2
stenosis),~5
obstructions~6
operability~1
4000~5
(4000~2
cGy)~1
cGy).~2
tolerated,~3
epidermoid~9
anus.~2
protocol,~7
fluorouracil~4
mg/m~2
3000~9
Gy)~2
excisions~8
abdominoperineal~9
(59%)~6
(29.9%)~1
(11.7%)~1
(4.5%)~1
Smaller~2
disease),~5
Controlled,~1
prospective,~15
multi-institutional~2
stratify~5
(MAb)~2
17-1A~2
radioimmunodetection~2
gamma-detecting~1
(GDP),~1
GDP~3
tumor-tissue~1
1.5:1~1
averaging~25
2.3:1~1
3.4:1~1
palpation~4
local/regional~1
probe-directed,~1
"Limited"~1
axilla~3
recommended,~4
277~1
mastectomy.~6
interpectoral~3
Skip~1
nodes;~2
(1.6%)~1
transitional-cell,~1
neodymium-YAG~1
75.6~1
rectosigmoid~10
candidates,~3
rectovaginal~3
fistula.~17
Autologous~3
(PBLs)~1
tumor-affected~2
immunoregulatory~4
circuitry~1
51-release~1
microcytotoxicity~1
PBLs,~1
interleukin-2,~1
solid-tumor~1
PBLs~1
(LNLs).~1
suppressions,~1
suppressor-inducer~3
suppressions~1
Clarification~1
immunotherapeutic~1
aerodigestive~4
correlating~5
middle-stage~1
gum,~5
Thickness,~1
aggressiveness~7
organospecific,~1
1,2-dimethylhydrazine-induced~1
chow,~1
powdered~3
7%/wt~1
supplement,~2
pelleted~2
1%/wt~1
beta-carotene~12
beadlets.~1
16-week~1
placebo-beadlet~1
sum,~2
developments~10
governing~6
315~3
operable,~2
nonmetastatic~2
ten-year~10
elsewhere.~8
knee,~7
grade.~4
limb-sparing~1
(LSS),~1
outnumbered~4
LSS,~2
neurofibrosarcoma.~2
LSS.~1
failure:~1
margins,~6
rhabdomyosarcoma,~1
sarcomas.~4
"curative"~2
relapse-free~2
Logistics~1
aneuploidy,~1
"abnormal"~1
chemoinfusion~1
clotting.~1
sclerosing~23
cholangiolitis~1
dismotility~1
gastroenterostomy~1
carcinoembryonic~21
consequently,~1
88%.~2
sarcomas,~2
cardiomyopathic~7
cardiotoxicity~2
high-~2
(EF),~2
regimen,~11
treatment-induced~1
sixty~7
transitional-cell~6
Boston.~3
High-risk~3
anything~1
cystoscopy~6
frequent,~1
hypertropia~2
gaze,~2
Bielschowsky~1
tilting~3
excyclotropia~1
V-pattern~1
esotropia~7
Complaints~2
cyclotropia~1
Cyclotropia~1
side,~7
Overshoot~1
accommodative~3
disappearance.~2
convergence/accommodation~1
persistence;~1
thereafter,~8
overaction~1
deviation,~5
strabismus,~2
convergence-accommodation~1
computer-averaged~3
recessions~1
deviation.~3
strabismus~2
competent~8
grating~4
correction,~2
cataract.~5
operant~2
53.~1
Grating~1
amblyopia.~3
lagged~1
flat~17
proliferations~4
nonkeratinizing~4
Koilocytosis~1
(60%).~2
Atypia~1
(20%).~8
immunoperoxidase~16
dysplasias~2
(8.2%)~2
papilloma,~3
"tight"~2
photographs~7
Deterioration~3
glycemia~2
(ie,~14
"early~2
changes")~1
"overall~1
changes").~1
apocrine~3
hidrocystomas~1
hypodontia,~1
onychodystrophy.~1
condylomata~11
(genital~1
warts)~1
papilloma~9
(HPV-6)~1
paraffin~13
intraocular-lens~1
abrasion~2
viscous~7
hyaluronate~8
(Healon),~1
(AmVisc),~1
(Viscoat),~1
methylcellulose.~2
Wide-field~1
specular~2
pachymetry,~1
Endothelial~5
solutions.~12
Ablation~3
excimer~6
(argon~1
fluoride),~2
248~7
(krypton~1
308~4
(xenon~2
chloride),~1
351~3
fluoride).~1
ablated~3
craters~6
nm.~8
smoothest~1
crater~1
193-nm~1
absorbance~7
thresholds.~3
peak-power,~1
lens.~2
sclerectomies~1
antimetabolite~3
examination:~1
(days~5
limbal~6
gonioscopically,~1
Proliferation~4
slitlike~2
sclerectomy~1
dwindling~1
nationally.~1
otologists.~1
stapedectomies~1
retrospectively,~1
generalized.~1
institutionalized~3
untestable~1
audiometry.~1
include:~5
showed,~4
decibels~1
(12%~4
sensorineural~13
loss);~1
15.6%~4
7.37%~1
30-~1
50-dB~1
8.19%~1
dB~4
greater;~1
otologic~5
audiologic~2
habilitative~1
(10-~1
40-kHz),~1
(115-dB)~1
noise~8
cochlear~23
(CoBF)~1
CoBF~3
dissected~14
counting.~2
cochlea.~1
(second~1
turn).~1
School,~1
Norfolk,~1
pharyngoesophageal~1
techniques:~1
deltopectoral~1
43),~3
36),~2
pull-ups~1
autografts~7
Guidelines~8
otolaryngology~1
Fewer~8
authors,~1
journals,~1
educators~5
imparting~1
Epithelial-lined~1
sialocysts~1
subtypes~32
prevalent,~1
predilection.~2
oncocytoid~1
mucosa-mandibular~1
vestibule~3
favored~6
Mucopapillary~1
mucoepidermoid~4
Closed-suction~1
drains.~2
inexpensive.~3
ablate~3
laryngopharyngectomy~1
oncologically~1
parastomal~3
innovations~2
tailor~2
paddle~2
pedicle.~5
valuable.~2
weaknesses~3
Occasionally~3
advocate~10
decompression;~1
windows.~3
(16.2~1
(5.9)~2
(3.9)).~1
cardiogenic~9
(19.2~1
(4.2)).~1
(6.1).~1
(15.7~1
(6.9)~2
(5.3)).~1
(3.3%)~1
88%,~4
86%,~4
61%,~5
97%.~1
sustaining~9
hyponatraemia.~2
[1(beta-mercapto-beta,beta-cyclopentamethylene-propionic~1
2-(0-methyl)~1
tyrosine]~1
hyponatraemic~5
mmol/l)~4
normonatraemic.~1
resistances.~1
antagonist.~9
pmol/l).~1
normonatraemic~1
slightly,~9
comparability~2
interchangeability;~1
directions.~3
individual.~12
valvar~4
programmable~5
pacemakers~9
modes:~2
(VVI)~1
synchronous~28
(DDD~2
150)~1
100).~2
Medications~1
blockers.~9
mode.~15
DDD~6
modes.~7
dizziness~5
VVI,~1
pacemaker~24
150.~1
pectoris~13
Stricture~1
Constrictive~1
pericarditis.~6
Pericardiectomy~1
frank~3
haemopericardium,~1
dermatomyositis~2
autoantibody,~1
anti-Ro,~1
crosses~5
Anti-Ro~1
Thoracopagus~1
caesarean~8
section.~17
needed;~1
conjoined~1
(20-30~2
trimester.~10
relaxation,~9
intubation;~3
yoke~1
rig.~1
centrally.~2
rounded~8
holes.~3
Pressures~2
positions.~9
centrally).~1
Atracurium~2
(0.3~10
peritoneum.~6
48-166~1
50-Hz~1
antagonized.~1
mystery.~1
mechanism;~2
excitable~3
(halothane,~1
diethyl~3
ether)~2
vapours~1
crayfish~1
neurone.~1
I.v.~1
kg-1;~1
litre-1~5
seven-barrelled~1
mini-electrode~1
sweep~2
potentials.~14
nitroprusside~32
adenosine.~5
synergistically-induced~1
suxamethonium.~5
(quinacrine,~2
spermine~3
indomethacin),~1
dantrolene~4
contractures.~2
Contractures~2
(0.26~2
bathing~5
Suxamethonium-induced~1
(0.22~2
(0.51~2
Spermine,~1
halothane-~1
suxamethonium-induced~2
Quinacrine~1
tubocurarine;~1
tubocurarine.~1
synergistically~3
halothane-induced~5
(PLA2)~2
indomethacin)~1
PLA2.~1
PLA2~5
susceptible,~3
liberation~4
Pre-exposing~1
bee~2
venom~5
synergism~2
suxamethonium,~2
plasma:erythrocyte~1
trichloroethylene~2
0.56-0.74).~1
pocket-size,~1
battery-powered~1
featuring~3
floating~11
(max.~1
mA)~2
unanaesthetized~3
Modes~3
on-demand~1
0-250~1
0.2-ms~1
mA,~2
dial~1
5%.~5
allowable~1
40-mA~1
omega--that~1
mA~3
current,~5
Datex~2
Relaxograph~2
transducer.~2
(GU),~1
eczema~3
(GE),~1
(EE)~2
(MPV),~1
EE).~1
thrombocytosis~2
EE~7
Ulcer~2
non-gravitational~1
MPV~5
co-variance~1
(PHF)~1
foetal~1
(FBS).~1
Explants~1
PHF,~2
FBS.~1
PHF-supported~1
protein/ml.~2
PHF~10
destroyed~6
heating~8
undescribed.~1
'high~2
weight'~1
kd).~1
FBS~1
outgrowth,~1
concentration-dependent;~1
micro-organisms~1
mol/l~6
(8.4%~1
w/v)~1
azelaic~2
40-fold)~1
Pityrosporum~1
ovale.~2
Minimum~7
(MICs)~1
fungicidal)~1
(MBCs)~1
mol/l;~1
MBCs~1
molluscum~4
contagiosum~4
unique,~3
enclosing~2
keratinocyte.~1
ago~8
micro-dissection,~1
favours~1
virions~3
privileged.~1
unimpeded~1
shell.~1
virus-packed~1
virus-induced~3
Sixty-two~8
(58~5
carcinomas)~4
intention.~2
formalin-fixed~4
re-excisions~1
margin.~4
6-60~1
2-12~1
depth.~2
re-epithelialization~4
0.73)~1
tattooed~1
39-62%~1
Poor~8
distortions~1
e.g.~2
indicated.(ABSTRACT~1
651~2
Bazex~1
acrokeratosis~2
neoplastica~1
Tigason,~1
livedo~2
reticularis~1
nodosa~4
florid~4
angioendothelial~1
angiosarcoma.~1
angioproliferative~1
nodosa.~1
protracted~10
multitudinary~1
cheilitis~1
(GC)~2
Kveim~3
lithium~36
(Lazarus~1
Gilgor,~1
1979),~1
destabilize~2
anti-depressant~1
trazodone~1
(Molipaxin,~1
Roussel),~1
(GPP).~1
papulo-nodular~1
eruption~8
Histopathology~4
mucin,~3
hyaluronic~2
This,~6
clinico-pathological~1
eponym~2
mucinosis~1
Gold,~1
observer~6
phenytoin,~5
epileptics.~3
Saliva~2
saliva:plasma~1
(S:P)~1
2-8~1
rose,~5
puerperium.~3
667~2
70,000~2
(0.95%)~1
726~2
221~4
haemolytic~8
placentation~1
myometrium.~4
pre-eclampsia~4
small-for-gestational~1
(SGA)~1
SGA.~2
placentas~2
Intraluminal~2
endovascular~4
trophoblast~2
SGA,~2
cardiotocograph~1
(57%)~15
cardiotocographic~1
acidosis;~2
intrapartum~2
labour~9
(FHR)~1
labour.~5
Ominous~1
FHR~2
7.26)~1
(17.4%~2
10.9%,~3
liberal~12
conceptual~5
subfertile~2
'apparent'~1
non-pregnancy~1
listeriosis~1
listerial~3
ended~6
prodromal~4
macerated~1
born.~1
681~1
invited~2
96.6%~2
(IDDs)~2
non-insulin~3
(NIDDs)~2
Cataracts~1
40.8%~1
IDDs~3
46.2%~1
NIDDs,~1
NIDDs~1
Cataract~3
Retinopathy~1
43.4%~2
20.1%~1
NIDDs.~1
Sight~1
threatening~6
13.3%~1
IDD~2
NIDD~2
658~1
photocoagulation~18
vitreoretinal~4
supervision,~1
(52~3
photocoagulation,~2
maculopathy~8
eyes,~23
overlooked.~3
17/416~1
(4.0%)~2
28/899~1
(3.1%).~1
5/416~1
(1.2%)~3
7/899~1
(0.8%)~4
Vitreoretinal~1
(0.5%)~2
detachment.~9
universally~8
departments,~2
UK~11
consultant~8
junior~2
(lipofuscin,~1
melanin,~3
segments)~1
non-biological~1
(latex~1
microspheres)~2
degradable~1
non-degradable~1
ruptured.~2
degrade.~1
senescence~2
foveomacular~3
retinitis.~2
sun~4
gazing.~1
retinitis~14
sun.~1
retinitis,~1
synonymous~2
electroretinograms~3
(FERG),~1
(PERG),~1
(VEP)~4
cystoid~4
(ACME).~1
aphakics,~2
FERG~2
53%--over~1
responses--showed~1
PERG~3
ACME~1
ophthalmologically~1
glaucoma,~9
suspects.~2
exfoliation~2
(POAG)~1
trabeculoplasty~3
(LTP)~2
(uncontrollable~1
POAG~3
(IOP)~3
'failed'~1
LTP,~1
awaiting~4
recessions,~1
augmented~46
recessions.~1
recession~4
subconjunctival~4
106Ru/106Rh~2
applicators~2
7-14~1
216~6
(69.9%)~1
(17.2%)~1
enucleated,~1
(12.9%)~1
(52.8%)~1
(22.7%)~1
1.5-0.5.~1
Radiogenic~1
pole.~3
enucleated.~3
Ray~1
cheap~1
save~6
endangering~1
lives.~8
tumour,~5
canaliculi.~2
recanalisation~1
canaliculi~2
Singapore~1
Coxsackie~3
A24~2
haemorrhagic~7
(AHC).~1
outbreaks,~1
involvements~2
herpes-like~1
eyelids~2
lips~2
wild~6
(non-Sabin)~1
poliovirus~7
conceivable~2
polio-like~1
radiculomyelitis~1
AHC~2
enterovirus~1
A24.~1
(HU),~2
hopes~1
augmenting~2
hemoglobin.~4
willing~7
clastogenic~1
avoided.~11
Hb~14
microcytic~5
hyperchromic~1
reticulocytosis.~1
microcytosis~4
alpha-thalassemia,~1
endonuclease~3
alpha-genes~1
alpha/alpha~1
alpha),~3
dehydration~15
xerocytosis),~1
corpuscular~15
RBCs,~4
pump.~7
Ouabain-insensitive~1
efflux~28
Stractan~2
ektacytometry.~1
AC~17
hyperchromic.~1
interrelationship~4
hematopoiesis~5
stromas~3
marrow-fetal~1
recharge,~1
(BFU-e)~1
myeloid~16
(CFU-GM)~6
nonadherent~4
nucleated~12
BFU-e~3
erythropoiesis.~3
paucity~6
myelopoiesis~1
IXAlabama~2
IX~17
hemophilia~3
kilobases~9
(kb)~4
arrangement~10
base-pair~2
codon~3
(GGT)~1
aspartic~2
(GAT).~1
zymogen~3
IXAlabama.~1
nitrate~10
transferrin,~1
transferrin-gallium~1
(Tf-Ga)~1
Friend~1
erythroleukemia~2
benzidine~1
heme,~1
Tf-Ga.~2
Tf-Ga~2
transferrin-iron~1
(Tf-Fe)~1
iron-pyridoxal~1
isonicotinoyl~1
hydrazone,~1
reticulocytes~4
heme~3
mediator.~2
gallium's~1
incorporation.~2
spherocytic~2
[(46,XX,del(8)(p11.1p21.1)].~1
resides~4
A2,~5
(TxB2),~4
synthase~17
(TxSl),~1
3-(1H-imidazol-1-yl-methyl)-2-methyl-1H-indole-1-propanoic~1
(UK-38,~1
485)~1
2,3-dinor-thromboxane~1
(Tx-M),~1
TxSl,~1
Tx-M~2
TxSl~2
1%;~4
disproportionately~4
7%;~2
Consistent~4
4%;~3
TxB2)~1
(Tx-M)~1
departed~1
identity.~3
approached,~1
thromboxane-dependent~1
Single-chain~1
(SC-UK)~1
amidolytic~2
(Kabi~1
S-2444;~1
pyro-Glu-Gly-Arg-pNitroanalide),~1
plasmin-activated~1
two-chain~1
(TC-UK).~1
SC-UK~6
plasmin,~1
reactants.~2
TC-UK~6
Lys-plasminogen~3
augment~9
confine~2
contaminants,~1
Glu-~2
aprotinin~1
KIU/mL)~1
dansyl-glutamyl-glycyl-arginyl-chloromethylketone~1
mumol/L),~1
irreversibly~4
SC-UK.~1
plasminogen-activating~1
TC-UK.~1
Glu-plasminogen.~1
Glu-plasminogen~1
lysine~6
fibrin.~1
Lys-plasminogen.~1
nucleic~5
right-angle~1
scattering.~1
Erythroid~1
markers--HLe-1,~1
glycophorin--allowed~1
erythrocyte.~2
HLe-1~2
matured.~1
Transferrin~2
BFU-E~5
glycophorin~3
CFU-E~3
normoblast~1
light-scattering~2
Normoblasts~1
HLe~2
Leu~9
11,~11
extrusion~5
reticulum,~3
surface-bound~3
anti-IgG~2
260~5
IgG/platelet~1
nonimmune~7
338~3
IgG/platelet,~3
4,120~1
494~9
IgG/platelet.~2
amount.~1
idiopathic,~3
secondary,~6
platelet-bound~2
2,100~1
670~1
broader,~1
thrombocytopenia.~6
Quantitation~1
acetylcholinesterase-positive~1
(SACHE)~1
(3H-TdR)~1
antimouse~2
(APS)~1
3H-TdR~2
(LI)~1
LI~10
APS-treated~2
acetylcholinesterase~10
(AChE)~3
labeled,~1
polyploid,~1
SACHE~2
megakaryocytes.~1
grain~5
count.~9
Heterogeneity~2
morphologies~6
pivotal~3
megakaryocytopoiesis~1
mitosis~2
endomitosis~1
(HbS)~1
ektacytometer,~1
diffraction~4
couette~1
viscometer,~1
Sickle~2
(MCHC)~2
resuspended~1
polyvinylpyrrolidone~2
gas-porous,~1
pO2~14
spectroscopic~1
MCHC~4
Noguchi~1
Schecter,~1
HbS~3
MCHC.~1
g/dL,~1
(HbF)~1
(SS).~1
SS~20
genes)~1
reticulocytes,~2
non-F~6
replicate~3
%HbF~1
4.9,~1
four-,~1
three-,~1
two-alpha-globin-gene~1
(%~1
cell/%~1
reticulocytes)~1
-0.407,~1
10(12)/L)~1
intragenic~2
females).~2
High-molecular-weight~1
endonuclease,~1
Ddel,~1
Mspl,~1
Taql~1
Xmnl,~1
probe.~8
detects~6
In(Lu)~6
trait~10
Lutheran,~1
P1,~1
i,~2
Aua~1
(L21)~1
agglutinates~1
In(Lu),~1
42,000~2
lectin~13
lectins.~6
acanthocytosis.~1
proposita~1
poikilocytosis,~1
diminished.~4
L21~1
anti-Lub~2
antisera.~4
lymphoma-leukemia~2
agent's~2
purging.~1
Tumoricidal~1
(SK-DHL2~1
Reh)~1
(HL-60)~2
One-hour~1
ID50~2
mumol/L~11
clonogenic~9
line;~1
rare-to-zero~1
mumol/L.~1
CFU-Mix,~1
BFU-E,~1
(ID50s25~1
Marrows~1
colony-forming~9
(LTMCs).~1
CFU-F~1
(ID50~1
mumol/L)~11
unperturbed~1
LTMCs.~2
co-culture~1
(two-stage~1
LTMCs).~1
autotransplant~1
either.~2
data:~2
karyotypically~4
comprise~9
cytogenetics~2
far,~4
associations,~3
gains,~2
breaks,~2
translocations,~1
deletions~1
lymphomas.~8
(eg,~3
8q24,~1
14q32,~1
18q21)~1
dealing~10
breakage~3
etiologically~2
visibility~9
infants:~1
DiGeorge~3
(DGS),~1
(TOF),~1
(IAA)~4
non-DGS~2
IAA.~3
(HOC)~2
75.7%~1
(CHD)~4
DGS.~1
Autopsied~2
DGS,~2
IAA~6
DGS~4
HOC.~1
IAA)~1
HOC~4
post-natal~2
Radiological~7
CHD~17
CHD.~5
antero-posterior~2
(DS)~2
15;~2
(TGV),~1
10;~4
Ivemark~1
asplenia~2
(IS),~1
17;~1
Fallot,~1
arch,~6
left-heart~4
(HE),~3
16.1%.~2
TGV,~1
IS~5
DS~6
(100%);~2
HE~6
(71.4%)~1
TGV~2
CHD,~8
non-organic~2
dysphagia~11
per-endoscopic~2
MBq~3
microCi)~1
99Tmc~1
sulphur~4
oesophagus.~1
dysphagias.~1
Hytrast~1
Hytrast,~1
HU,~4
transparent,~1
light-weight~1
lead-plastic~1
collimator~2
housing.~2
underpenetrated~1
artefacts,~1
Hilar~1
visualised.~1
visualisation~2
calcifications~8
hardening.~1
overcoming~3
externally~3
single-subject~1
cylinder.~1
Pharmacological~2
vasodilatation~7
cooled.~1
single-sensitising~1
advocated.~3
intercurrent~7
practical,~8
issue.~3
antioxidant~11
combat~9
pre-treatment.~1
goitre~1
(Grave's~1
"ablative"~1
550~6
intention~6
Outcome~7
ablative,~1
linear-quadratic~1
(LQ)~1
dose-effect~2
straightforward~4
formalism,~1
radiotherapy,~12
solve~3
wider~16
LQ~2
graph.~1
extrapolated~2
fulcrum~1
quantity,~1
property.~2
simplifications~1
examples.~1
Britain~2
(41~3
1374~1
attack,~1
hardly~5
bruit.~1
endarterectomies~5
USA.~1
controversies~2
phlebography,~1
plethysmography~19
volumetry~2
13-75).~1
thrombectomy,~1
restitution~4
phlebography~1
aorto-enteric~1
bowel.~10
suture.~2
1-5~3
regrafting~1
axillo-bifemoral~2
oversewn~1
ischaemia~12
connected,~1
cannula,~1
endarterectomies,~2
reconstructed~10
fault.~1
anaesthetist.~1
faults,~1
(PtcO2)~1
failures;~4
healed.~5
Hg/min~3
healed;~1
amputation.~8
musculovenous~1
lymphoedema.~2
oedema.~1
sixty-seven~1
theatre~2
87.5~2
(i.e.~8
profuse~2
pulse,~8
resuscitation).~1
knife~3
(towards~1
vessels).~1
156~11
precordium~1
non-operatively.~1
Massive~6
self-controlled~2
formulated~3
neurosurgeons~1
administrators~5
seminar~2
convened~1
Social~10
Security~1
(DHSS).~1
Radiologists~1
admitting~7
X-rays~3
possessed~9
warranting~3
admitted.~3
unconsciousness,~1
ten-fold~1
Implementation~1
sixty-three~2
goitres~1
T0/T1~2
glucose-insulin-potassium~1
(GIK)~1
GIK~5
(10.1~2
(14.2~1
mmol/l,~6
Lactate~2
non-GIK~2
(1.32~1
0.09~18
Non-esterified~1
(NEFA)~1
(0.47~3
mmol/l~22
NEFA~1
3-hydroxybutyrate~3
(0.04~2
non-esterified~1
risen~2
Conservative~7
circumcision~9
glansplasty~2
Circumcision~2
preputial~1
clearance;~2
refashioning~1
phallic~1
phallus~1
attractive~7
(RND)~1
therapeutic.~1
dissections,~2
infrequent.~2
RND~2
RND.~1
Surgeons~3
bacteriology,~3
morphology,~16
pouch-anal~5
s.e.m.)~2
overgrowth.~3
Pouch~1
metaplasia~22
azotorrhoea,~1
absorptive,~1
morphological,~1
fissure~3
cmH2O,~1
4-6~5
sphincterotomy.~3
fissure.~8
completeness~7
irksome~1
time-consuming~4
affair.~1
hypoglycaemia~1
(Hollander)~1
tedious,~1
risky~4
objections,~1
feed~14
centres.~1
tide~2
prevagotomy~2
postvagotomy~2
vagotomy.~10
validated,~4
puborectalis~4
reputed~2
creating~6
flap-valve~2
occludes~1
synchronously~4
intensifier~2
displaying~3
barium.~2
Valsalva~13
manoeuvre.~1
manoeuvres~3
proctography~1
defaecate.~1
cytokinetic~2
60)~2
weighting~3
356.7~1
resuture~1
crypt~12
(CCPR)~2
CCPR~9
4.49~1
crypt-1~1
h-1;~1
51-61~1
enterectomy,~1
conceivably~3
tropic~2
inoperable~14
malignancy,~9
Nd~1
YAG~1
(88~6
6-8~6
1-39~2
39-54~1
non-surgical~7
electrocoagulation,~1
cryotherapy~7
upset~2
uriculture~1
dipslide~2
dipped~1
coliforms~1
(CFU)~1
123,~2
70).~1
cefuroxime~3
IV/8~1
(5.7,~1
41.2~2
povidone-iodine~6
gangrenous~5
deep.~2
Povidone-iodine,~1
guaiac~2
double-contrast~7
rectosigmoidoscopy~1
cm).~3
unaware~4
others'~1
Altogether~1
fifty-six~4
enema~9
Neoplasms~3
Rectosigmoidoscopy~1
cm)~7
(CEA)~5
(C46)~1
gate~1
8.6:1~1
immunoglobulin.~4
immunohistological~1
pre-operatively~5
111In-labelled~1
C46~2
tumour:non-tumour~1
5.8:1.~1
(1.7-7.6:1).~1
targetting~1
antitumour~1
517~3
non-transfused~3
Dukes'~18
differ.~4
lesions:~2
anus~3
incontinence;~1
constipation.~4
Electromyography~2
sphincters~2
anorectum~3
re-routed~1
Continence~3
contra-indication~2
hidradenitis~6
suppurativa~4
gluteal~4
'deroofing'~1
tracts.~7
epithelialized~1
contaminated~8
in-patient~3
deroofing~1
(14/23)~1
(23/23).~1
steatorrhoea~4
(means~4
21-37)~1
disappointing~2
antiperistaltic~2
explosive~5
onlay~2
creates~6
undesirable~9
Leicester~1
Hospitals~10
(ES).~1
69.7~1
(CBD)~3
(28)~1
ES(43).~1
(6/28)~1
ES~11
(2/43)~1
cholecystectomy,~4
frailty.~1
ES.~2
Elective~2
frail.~1
cardiothoracic~2
incisional~5
herniae.~1
582~2
475~1
(81.6~1
(4.2~4
herniae~3
(70~8
(notably~1
replacement),~1
Herniae~1
non-absorbable~2
Southampton~1
attendance.~3
referral,~1
depression:~1
difficulties.~10
(7~17
antiemesis~1
antiemetic~1
(2.8~5
mumol/l)~1
fewer)~1
combines~6
hemiplegia,~2
hemianaesthesia,~1
hemianopia.~1
situated~9
thalamus~2
encroaching~1
laterally,~2
Left-sided~1
neglect~6
accompany~8
Clinical-anatomical~1
'cortical'~1
'subcortical'~1
dementias,~1
demented~28
Huntington's~9
(combined~2
notion~11
Guillain-Barre~8
(GBP)~1
inexcitable~1
quadriplegic.~1
demyelination.~4
GBP~1
veterans~17
orbitofrontal,~1
dorsofrontal,~1
nonfrontal~1
cognition.~4
orbitofrontal~1
'edginess'/anxiety~1
dorsofrontal~1
anger/hostility.~1
thesis~3
expressions~1
extremity,~5
reflexes.~7
hypotonia~2
gravity,~2
'hypotonic'~2
fall,~2
spikes.~1
'normal~1
tone'.~1
rigidity.~3
parkinsonism~8
precuing.~1
manipulated.~1
forthcoming~1
used)~1
selection.~7
parkinsonians.~3
serially,~1
parkinsonians~2
normals,~5
slowness~1
'input'~1
'output'~1
Proprioceptive~1
interphalangeal~10
(PIP)~3
(MCP)~1
static-position~4
(Clark~1
detect.~1
MCP~1
PIP~4
deformed~14
sensibility~2
fingers.~3
finger.~1
observable~3
bradykinesia~4
bradykinesia;~1
(severe)~1
bradykinesia.~3
open-loop~1
build-up~1
anomia~1
12-year-old~6
drawing,~1
lag,~1
naming~1
qualitatively.~1
semantic~3
remembered~2
relevance.~5
sustained.~5
Von~2
Hippel-Lindau~8
haemangioblastomas~3
cerebellum~7
phaeochromocytoma.~2
considered,~9
wrongly~1
1985;~2
retrospect~2
7/8~1
biennial~2
strides~1
reorganizing~1
financing~2
obstacles~3
implementation,~1
nurses.~2
schools,~5
Red~9
Society~12
organizations~2
fill~7
gaps.~1
cooperate~3
interests~6
rewards~1
worth~3
while.~1
MD~2
McMaster~6
University,~3
Hamilton,~1
Ont.,~2
choices~10
408~4
1620~1
English-language~5
CMA's~1
Manpower~1
Bank.~2
classroom~1
salaried~1
educationally~1
innovative~1
midclavicular~1
beat,~3
interobserver~14
locating~4
MCL.~2
build~1
0.004).~6
towns~4
self-administered~7
involvement:~1
help,~3
specialist,~2
life-cycle~2
interpersonal~5
English-speaking~1
French-speaking~1
(median,~18
Philadelphia~7
neurofibromatosis~1
(NF).~1
retroperitoneum-pelvis~1
(6),~5
sarcoma;~2
visible,~2
(4000-6000~1
rad)~2
(doxorubicin).~1
variably.~1
tumor-free~4
(37.5%).~1
high-power~6
NF,~2
chemoradiotherapy~2
unresectable~13
cytophotometry~2
Feulgen-stained~1
aneuploid,~3
diploid.~5
make-up~1
content),~1
(abnormal~2
proportion,~1
cytometry.~4
histogenetic~1
aneuploid.~2
classification.~2
(IRS-I),~1
nonorbital~2
parameningeal~2
neuraxis~1
compared:~4
nonintensive~1
(preintensive~1
(intensive~1
(dactinomycin)~1
(doxorubicin),~3
5500~1
craniospinal~2
preintensive~1
(65/95);~1
(52/68);~1
comparisons).~5
sign,~7
57%)~1
involvement;~1
filterable~1
(AUC)~2
nonprotein-bound~1
dose-limiting~2
mg/M2/day~2
leukopenia:~1
5-day~7
cells/mm3.~1
Nausea~2
ear,~4
otitis.~1
Irrespective~2
November~4
dead.~1
Filter~3
longevity,~2
CIS~11
tract;~1
nonpapillary~6
rule,~3
(transurethral~1
[TUR]~1
chemotherapy)~1
primary,~7
irradiation)~1
Five-year~4
concurrent,~1
(invasion~1
TUR,~2
CIS.~1
ab~3
initio.~1
inhabitant~1
India~4
filarial~4
lymphangiosarcoma~2
III-IV~1
(45%)~12
(PR).~3
72%.~4
76%.~3
37%.~1
tolerable.~1
3A~2
staged)~2
mantle~5
multiagent~3
83%.~3
failures:~2
concurrently~14
infield~3
unirradiated~4
(concurrently~1
groups).~6
relapses,~1
salvaged,~2
nonlymphocytic~8
elemental~25
however.~5
3H~13
intraperitoneally.~3
48,~9
72,~2
mid,~4
elemental,~9
(IVC)~7
(PV)~3
(IVC),~1
(PV),~1
unpredictability~1
lymphoblastoid~1
typing.~2
frozen,~2
thawed~2
regrown.~1
(MuMTV)~1
MuMTV~2
Radioimmunoprecipitation~1
retroviruses~3
(avian~1
myeloblastosis~1
virus).~1
MuMTV-human~1
(SCCL)~1
15-year~2
institution,~10
508~2
(66~4
limited-stage~6
extensive-stage~3
category)~1
small-volume~1
49-66)~1
COPP~1
(1968-1974);~1
(180~2
stage)~1
multidrug~1
large-volume~1
73-89)~1
(1975-1982).~1
1968-1974~2
1975-1982,~2
(MST)~1
locoregional~4
(1975-1982)~1
MST,~1
figures,~2
local-tumor~1
employed:~2
(112);~1
(36);~1
(17);~1
(15).~1
1981-1982,~1
CT.~7
MST~1
8%.~7
10.5%,~2
(29/36)~1
(28/112)~1
RT.~5
SCCL.~1
uroporphyrinogen~7
(URO-S)~1
(NHL)~2
porphyrin/mg~1
protein/hr)~1
24),~2
31.7~4
19.8,~1
27.2~3
29.4~3
18.5,~1
(14.1~1
4.0),~2
(14.5~1
3.8).~3
Abnormally~2
65.4%~1
URO-S~4
0.048),~1
0.65,~1
Excessively~1
NHL~4
extensiveness~2
(LPHD)~1
Ann~3
Arbor~3
III;~1
reaction;~1
advanced-stage~3
(III~1
0.017).~1
0.031).~3
nodularity~4
months-18~1
non-hematologic~1
malignancies).~2
LPHD~1
manifests~4
thought.~1
histiocytes,~2
low-stage~1
derivation~4
LPHD.~1
leukemias,~3
cytogenetically~2
subsets.~4
causation.~1
(embryonal)~2
bilobar~4
55+~1
73+~1
CEA~19
(258~1
temporary,~1
Hydrazine~3
hydrazine~7
times/d)~1
appetite~2
(63%~1
hydrazine-treated~1
spectrofluorometric~2
definitively~5
2400~1
605~1
traced~4
back.~4
alive,~4
257~2
radiation-induced~6
radiodermatitis.~1
recall.~3
carcinomas/10(4)~1
persons/Gy~1
radiodermatitis~2
(HPV)~6
low-stringency~1
crosshybridization~1
HPV~29
DNAs,~1
cecum,~6
HPV-16-related~1
HPV-related~1
whole,~4
invasions~2
distance,~3
ones)~2
cytologically~5
fasciitis~11
precocious~13
regulation,~2
cross-sectioned~1
circularly~1
stretched,~1
tumor-supplying~1
non-muscularized~1
explainable~3
carcinogen~11
heterotopically~1
(HTBs).~1
Fischer~3
bladders,~1
N-methyl-N-nitrosourea~1
(MNU)~1
HTBs~1
Separately,~1
0.05%~4
N-butyl-N-(4-hydroxybutyl)nitrosamine~1
(BHBN)~1
weeks;~5
MNU~2
urothelium,~1
situ.~4
carcinogen(s)~1
tumor-related~4
IRS-I~1
IRS-II.~1
subtype~17
subtype.~6
Parameningeal~1
subtypes,~2
(NPCs)~1
tumor-associated~1
(TATE)~1
TATE~2
(NKC,~1
38%)~3
(23%)~11
predilection~10
intratumor~1
Stromal~1
NPCs~1
NPC,~1
ascertained.~2
Neurosecretory~1
melanosomes~4
electronmicroscopy.~1
42-year-old~6
histiocytoma~9
bland~1
periphery.~4
histiocytoma.~3
preparing~5
5-mm~10
step-wise~3
IV),~2
Oddi~11
boundary,~1
valid.~2
unclassifiable~2
Vater.~1
sarcomatoid~10
clinicopathologically.~2
30-81~1
Eight,~1
Stages~6
identified:~8
histiocytomatous~1
fibrosarcomatous~1
pleomorphism,~3
cellularity,~3
carcinomatous~2
Clinicopathologic~2
49.7~2
sarcomatous~4
histiocytoma-like~1
(sarcomatoid~1
carcinoma)~2
(leiomyosarcoma)~1
cisplatin-based~3
non-seminomatous~1
atypia~7
elements,~4
(which,~1
pattern)~2
(23%~3
non-teratomatous~1
teratoma-derived~1
alpha-chain~1
(alpha-CD)~1
Taiwan,~1
ran~3
lymphoplasmacytic~5
alpha-CD~1
immunoselection~1
alpha-CD.~1
hemangiopericytoma~2
non-calcified~1
Morphologically,~2
counterparts.~7
hemangiopericytomas~2
nylon~3
mesh,~1
abrasive~2
attempts,~2
(34)~1
(13),~1
sampling;~1
(31)~1
25.~1
false-positives.~1
well-tolerated~5
Tokyo~1
Geriatric~4
nonglandular~1
(2-5)~1
intramucosal~6
0.065%~1
86,589~1
Princess~1
Margaret~1
anaplastic,~1
24;~2
squamous,~2
11;~2
nine;~2
27%.~2
37.5%~2
35,~2
Excisional~2
treatment-related~4
nonseminomatous~3
(NSTGCT)~1
orchidectomy~3
roentgenography~7
NSTGCT~1
wait-and-see~1
57-77~1
glans~4
prepuce~3
urethra;~1
Penile~1
Necrobiotic~2
xanthogranuloma~3
paraproteinemia.~3
yellowish-red~1
ulcerated,~2
xanthogranulomas~1
necrobiosis.~1
dysglobulinemia~1
Hyperlipidemia~1
necrobiotic~1
46-year-old~3
extenuating~1
394~3
one-vessel-disease~1
(PTCA).~2
preangioplasty~5
Matching~3
angiograms,~2
Preangioplasty~1
(34/37~1
24/37,~2
(2.6~2
angiogram.~3
(coronary~1
infarction)~1
(42/50~1
infarction;~3
PTCA,~3
advisable.~2
potent,~4
short-acting~3
(Student's~1
t-test~2
observations).~1
6.2%).~1
short-lasting~3
"maximum"~1
vasodilation.~4
(ioxaglate),~1
cardiomyopathy.~13
(4.01~1
0.24)~1
0.846,~1
0.844~1
ratios).~1
13/25~1
20/25~1
(56%~1
dipyridamole).~1
(ABSTRACT~2
(ejection~3
deviation),~1
symptom-limited~6
ergometer.~6
end-points~1
(n:5),~1
(n:16),~1
(n:42).~1
(n:28)~1
(9.5~3
minutes),~5
(n:18)~1
(5.8~2
(n:17)~1
end-point,~1
Stepwise~6
6.0).~1
dysfunction;~1
intolerance.~3
anemometry~1
(FOLDA).~1
flattening~3
recurred,~3
dextroposition~1
loop-like~1
embryologic~2
cannulation~12
preformed~3
polyurethane~2
Teflon-lined~1
(spasm~1
1-16~1
restenosis.~4
preshaped~1
publications,~1
stasis~6
triple-lumen~2
preexistent~1
parameter,~3
critical,~2
sec,~3
registered.~1
valve-dilatation~1
single-lumen~1
now.~1
Na-loading~1
frog~4
creep~7
Na-loaded~1
Purkinje~16
ionophore,~1
monensin,~3
Na-Ca~3
sarcolemmal~3
Dodecylamine,~1
quinacrine,~2
amiloride~8
analog,~4
3',4'-dichlorobenzamil~2
Na-dependent~1
vesicles.~9
Ki's~1
dodecylamin,~1
3',4'-dichlorobenzamil.~1
carrier.~2
dodecylamine~1
Na+-K+~2
(aiNa)~1
K+-free~3
tetrodotoxin.~6
Tyrode~1
5.4mM~1
[K+]o,~1
aiNa,~1
aiNa.~1
aiNa~7
8.8~10
strophanthidin~1
Blockade~2
3':5'-cyclic~4
monophosphate,~4
N6,~1
2'-0-dibutyryladenosine~1
8-(4-chlorophenylthiol)-adenosine~1
norepinephrine.~7
accumulation.(ABSTRACT~1
newborn,~4
lambs~18
normoxia~5
(P/Q)~1
micropipette~3
servonulling~1
20-80~2
subpleural~4
venules~6
radiolabelled~2
drops~4
microvessels,~3
Hypoxia~4
P/Q~1
lamb~4
filtration.~2
(SOD)~1
SOD~12
Ficoll~11
(mol.~1
400,000)~1
microembolism~2
alpha-thrombin.~1
fistulas.~13
SOD-thrombin~3
Ficoll-SOD-thrombin~3
Ficoll-thrombin~2
control-thrombin~1
(pulmonary~3
lymph/plasma~1
(PVR).~1
PVR;~1
(sigma),~1
SOD-treated~1
SOD.~1
Ficoll-SOD~1
thrombin.~3
ferricytochrome~2
xanthine/xanthine~1
monolayer.~1
neutrophils.(ABSTRACT~1
Lysophosphoglycerides~1
afterdepolarizations~8
lysophosphatidylcholine~1
(10(-9)~3
mg/l)~2
Mn++~1
l-propranolol~1
1-adrenergic~13
BE-2254~1
(pH~5
6.7)~1
hyperkalemia~3
([K+]o~1
superfusion~5
LPC,~1
dromotropic~7
hypoxia-induced~6
adenosine-induced~4
block;~3
deamination~4
concentration-negative~1
atrionodal~2
inexcitable.~1
7),~13
prolongation,~5
nodal-to-His-bundle~1
atria-to-His~1
(AH)~3
(arterial)~1
(venous)~1
erythro-9-(2-hydroxy-3-nonyl)adenine~1
EC50s~1
0.28~10
(perfusate)~1
0.32~8
(effluent).~1
nucleoside~3
inhibited,~8
rank~11
AH~16
N6-cyclopentyladenosine~1
N6-(L-2-phenyl-isopropyl)adenosine~1
5'-N-ethylcarboxyamidoadenosine~1
2-chloroadenosine~2
adenosine,~6
A1-type~1
summary:~1
A1-type.~1
effluent,~1
atria-to-His-bundle~7
-0.85~2
-6.3~1
pmol/min/g/torr.~1
-0.180~1
0.013~1
msec/torr.~1
microM.~9
deaminase,~1
deaminates~1
inosine~1
hearts.~14
8-phenyltheophylline,~1
8-(p-sulfophenyl)theophylline~3
pA2~9
values:~3
5.30~1
5.28~1
8-(p-Sulfophenyl)theophylline~1
prolongations~2
delay,~3
Voltage-clamp~1
(Rana~1
catesbeiana~1
Rana~1
pipiens)~1
voltage-contraction~1
(phasic)~1
(tonic).~1
phasic-tonic~3
sodium-calcium~2
isomyosin~4
V3~8
ATPase~13
V1~16
isomyosins~3
(35%~2
V3),~1
V3).~2
Ca2+-regulated~1
Mg2+-dependent~2
pCa~1
activation).~1
submaximum~2
Ca2+-concentrations~1
(pCa~1
6.9-5.9)~1
V1.~1
cooperativity~1
Ca2+-activation~1
(Hill-coefficient~2
V1)~1
myosin~20
isoenzymes~7
migrating~25
(S2)~1
(S1)~1
isomyosins.~1
S2.~1
1-~14
reconcile~2
(i.c.)~1
transducers,~2
occluders~2
i.c.~1
Isoproterenol~4
(0.0025~1
5.80~1
0.58~2
prenalterol~2
1.4%)~1
pirbuterol~2
(8.1~4
1.2%).~1
constrictor,~1
attenuated.~2
125I-cyanopindolol~1
(125I-CYP)~1
(predominant~2
1:~3
1.5-2.0:1.0.~1
blood-flow-mediated~1
serosa~5
suffused~1
protein/ml)~1
suffusing~3
nl/sec~1
serosal~6
suffusate~2
Ringer's;~2
suffusion~1
theophylline.~5
Diameter~1
7-12~1
hyperemia,~2
10(-2)~5
baseline.(ABSTRACT~1
echocardiograms~15
654~2
height-,~1
race-,~1
decile~2
biannual~1
Echocardiography,~1
.42,~1
.31,~1
(systole)~1
.20~1
.22,~1
.14)~1
.14,~1
groups.(ABSTRACT~5
Anomalous~1
(ALCA)~1
mechanics,~1
ALCA,~1
ALCA~4
ALCA.~1
comparison.~2
Preoperatively,~2
CM;~1
CM.~5
volume/end-diastolic~1
hypokinesis~2
"overshoot~1
hypertrophy,"~1
surgery.+~1
(IDL)~1
(Sf~1
12-60~1
sixty-five-year-old~1
58)~2
(diabetes,~1
hyperuricemia,~3
hypercholesterolemia)~1
52).~5
Smokers~4
variations);~1
.003)~2
.007),~2
.016),~1
.04);~1
(HDL)~8
.04).~3
Chi-squared~1
.006),~1
.032),~1
.006)~1
bottom~6
rejection~11
triglyceride.~1
IDL.(ABSTRACT~1
2203~1
refuting~1
hypotheses,~2
expiration,~3
29.4%~2
26.1%~1
End-systolic~3
18.8%~1
ejection.~1
anterior)~2
branch.~3
collaterals~6
artery.(ABSTRACT~1
timolol~14
maleate~3
(73.7%)~1
(timolol~1
Fibrinopeptide~2
aggregates,~4
ADP~9
(0.455~1
1.82~3
medication,~7
(geometric~3
SEM,~8
32;~1
9.3;~1
.04~1
admission).~1
ergonovine,~2
pacing;~2
iv),~3
(0.79~1
min/ml;~1
(134~2
ml/min;~1
ergonovine-induced~2
ergonovine.~4
dipyridamole-induced~1
prearteriolar~1
tonus~4
subendocardium,~2
(parasternal~1
axis,~9
view)~2
(RJA)~1
planes)~1
(LAA)~1
RJA/LAA~2
.78)~1
dimensions,~7
LAA~1
single-chamber~3
piezoceramic~1
"physical~1
activity."~1
(based~3
table)~1
(VVI,~1
rate-variable~1
(VVI-Act)~1
mode,~4
mph)~1
Balke~1
commencing~4
0.0%~1
fixed-rate~1
VVI~9
VVI-Act~3
(VVI-Act~3
min;~12
1617~1
656~3
O2/min~2
451~3
O2/min;~1
1208~1
1064~1
377~4
O2/min:~1
modes,~2
(assessed~5
grading~24
pacing.(ABSTRACT~1
detail.~15
Prevalvuloplasty~1
calcified~19
peak-to-peak~4
Fick~4
Individual~8
considerably,~1
increases.~6
Supravalvular~1
1+)~2
(113~1
ml/m2,~2
.003),~1
stroke-volume~1
(1.49~1
1.35~3
0.33,~3
.04),~2
(2.05~2
counts/sec,~1
phonocardiography~1
upstroke~3
0.42~10
.001).(ABSTRACT~2
beta-blockers~8
(atenolol,~1
metoprolol,~4
pindolol)~1
Latin-square~1
habits;~1
polysomnographic~5
lipophilic~9
awakenings~1
(pindolol~4
5.0;~1
3.2;~1
metoprolol~12
4.7;~2
2.9;~2
2.7)~1
20.6~1
27.0~1
23.0~2
24.3~2
74.5~3
pindolol~4
54.5~3
175.0~1
60.7~1
95.4~1
43.8~1
restlessness~1
beta-blockers.(ABSTRACT~1
(PAP)-cardiac~1
plots.~2
PAP-CO~5
dogs)~4
clots.~2
.964~1
.032).~1
min-1;~2
Vasoconstriction~2
.002)~3
(X~5
10(6)/cm2)~1
.77,~1
(58.8~1
6.9,~1
.0001;~1
mg/kg/day~7
58.8~2
19.6,~1
deposition.(ABSTRACT~1
simulates~4
anger~4
circulations.~2
electrocardiogram,~4
Anger~2
provocation~11
215~9
preanger~1
baseline;~5
(557%~1
.002),~3
aVF.(ABSTRACT~1
cauterization~1
distinguished,~1
mesenchyme~5
(branchial)~1
arches~2
(PTA)~4
arch.~5
Dextroposed~1
(DPA)~1
Anomalies~2
ablations~2
PTA~15
DPA~2
desethylamiodarone.~2
desethylamiodarone~9
Amiodarone~5
frequency-dependent~6
fast-~1
slow-channel~1
differed,~3
fast-channel~1
amiodarone.~8
olive-shaped~1
cylindrical~6
Electrical~8
endocardial,~1
midwall,~1
septum.~8
On-line~1
equipotential~2
midwall~6
minima~5
"Pseudoisochrones"~1
electrograms~11
extrasystoles.~1
"isochrone"~1
array~9
semidirect~1
(location~1
depth)~1
reperfusing~1
"reperfusion~1
injury."~1
radicals.~3
Superoxide~1
scavenges~2
dismutation~1
catalase,~2
(37~10
reperfusion,~17
IU/ml~2
II),~5
catalase~10
(PCr)~4
7.11-7.18~1
5.58-5.80~1
Likewise~1
preischemic~5
h-SOD/catalase-treated~2
I).~5
reflow,~1
hearts.(ABSTRACT~1
occlusion-reperfusion.~1
cholesterol-enriched~2
329~6
mg/dl),~7
mg/dl).~4
planimetry~4
tetrazolium-stained~1
(hypoperfused~1
zone)~1
"cold~1
spots"~1
autoradiograms~4
99m~4
Tc-labeled~1
hypoperfused~5
42.8~2
1.3%~2
83.7~1
2.0%~5
reflow)~1
thioflavin~2
demarcate~1
animals:~2
chow-fed~5
microgram/kg/min,~1
no-reflow~5
phenomenon.(ABSTRACT~1
"late"~2
transmurality,~1
transmurality~1
beings,~2
alpha-receptor-mediated~4
hypoperfusion.~2
Adrenergic~3
alpha-receptor~1
microspheres.~5
hypoperfusion,~1
steal,~1
inner/outer~1
alpha-receptors~2
blocked.~3
lessening~2
(DOC/salt).~1
DOC/salt~2
tetraploid~2
9.7~6
26.6~2
DOC/salt.~1
scatter.~1
tetraploidy~4
polyploidy~2
fluoroprobe,~1
3,3~1
dipentyloxacarbocyanine,~1
distributes~1
potential-dependent~1
(10(-6)M~1
10(-3)M)~1
yohimbine.~4
1-mediated~1
autoregulatory~7
venules,~3
(BBB).~1
attenuates~6
protects~13
BBB.~2
protecting~9
downstream~6
attenuate~13
expect~12
BBB~1
Protection~6
nonhemodynamic~2
pursued~2
contractility,~5
Too~1
know~3
goal.~7
convinced~1
emanating~5
unexpressed~1
hypertrophy),~1
"nonhemodynamic"~1
afterload,~3
renopressor~1
participate.(ABSTRACT~1
morphometrically~3
strenuous~6
preconditioning~2
myocytes.~3
(Na+)~1
baroreceptor~12
assesses~2
low-~5
baroreflexes.~2
distensibility,~3
equipotent~8
distensibility;~1
cadralazine~1
dinitrate.~1
distensibility.~1
demand.~8
compliant~4
caliber.~3
nitroglycerin~5
channel-blocking~3
depending,~1
calcium-channel~7
prototypic~3
moderate-to-severe~4
subsystemic~1
micrograms/min/100~1
3.57~2
7.54~1
(echo~2
LVH)~1
855~1
Framingham~10
Offspring~1
(1718~1
1892~1
LVH,~1
indexed~3
(women)~1
(men)~1
g/m2.~1
LVH~5
6.6%~4
(offspring~1
(original~1
cohort)~1
(8.6%~1
23.7%,~1
men)~5
forms--eccentric-dilated,~1
eccentric-nondilated,~1
concentric,~1
thickness--which~1
age-sex~1
LVH.~1
(wall~1
mm).~5
[endocardial~1
VCF]~1
(4.8~3
sec-1,~1
area;~2
assumes~4
sec-1~4
.01);~3
Phase-plane~1
(dimension~1
dD/dt)~1
reuptake~2
Physiologically,~2
rate/emptying~1
rate),~2
head-up~6
arithmetic~3
Pressure~8
(systolic)~1
arithmetic.~1
driving~9
populations.(ABSTRACT~1
subepicardial~1
Pacing~2
half,~1
Strenuous~1
quadruple~1
physiologic,~5
hypotheses:~1
biochemistry;~1
myoplasmic~1
excitation.~2
amidst~1
isozyme~8
afterload.~7
hypertrophy).~1
hypertension.(ABSTRACT~1
beating-drained~1
arrested-drained~1
argued~5
"garden-hose~1
effect."~1
myosin.~1
Myosin~2
(HC)~2
Change~4
Transitions~1
HCs~1
HC-specific~1
biology.~3
Structure~1
Polyploidy~1
Wistar-Crea~1
mumol/hr~1
minipump~2
(10(-7)M~1
10(-5)M)~2
slightly.~4
0.7%).~2
(10(-6)M)~1
octaploidy~1
14.2%~1
2.1%,~1
nonexposed~1
(8.1%~1
0.2%).~1
replenishes~1
hydrolyzed~1
rapidly,~8
Elegant~1
regulates~6
magnetization~3
Hearts~1
18-month-old~1
couple~8
splint~7
levering~1
dislocated~4
phalanx~8
palmarly,~1
dorsally~3
Kirschner~8
band.~2
hand.~7
gamekeeper,~1
mallet,~1
Intraarticular~3
trapeziometacarpal~1
Bennett,~1
Rolando,~1
trapezium.~1
Bennett~1
advisable~5
Rolando~1
T-~2
L-shaped~1
trapezium~1
chip~2
Malunited~1
reestablished,~1
Extensile~1
tenolysis~1
occasion.~2
Perilunate~1
incisions~10
scaphoid~5
styloid~2
K-wires~1
(Herbert~1
[ASIF]~1
screws).~1
lunate~3
follows~11
scapholunate~2
torn.~1
capitate,~1
triquetrum~1
K-wires.~1
Ligament~2
lunotriquetal~1
Palmar~1
required,~10
perilunate~1
fracture-dislocations~2
fracture-dislocation~3
realignment.~1
patience,~1
views)~1
pathomechanics~1
nonanatomic~1
comminuted~5
Ligamentous~1
"joy~1
sticks"~1
Plates~2
traumatic,~3
transfers~5
body-powered~1
Subjectively,~1
replanted~6
return,~1
blindfolded~2
satisfactory.~7
reexamined~5
nonsurgically~2
plaster~6
plaster.~2
17,~6
elbows~6
nonsurgically.~3
elbow.~3
Idiopathic~6
(ISRH)~1
symptomatically~3
ISRH~2
dome-shaped~3
ulna,~4
ISRH,~1
(CDRH).~1
Remodeling~1
Trauma~8
tractions,~1
Stryker~2
frame,~2
Gardner-Wells~1
tongs,~1
Cadaver~2
closed.~3
Frankel~1
trocar-~1
diamond-shaped~1
tips~5
pin~5
obliquely~1
cutters.~1
metacarpals~4
rpm.~1
servohydraulic~1
(Materials~1
Minneapolis,~1
MN)~1
loads,~2
torque,~4
pull-out.~1
three-week~3
pull-out~4
trochar-tipped~1
drilling,~2
speed.~2
diamond-tipped~1
trochar.~1
speeds.~2
osteophytoses~1
(posterior~4
osteophytes)~1
C6-7,~1
vertebrolisthesis,~1
retrolisthesis,~1
C3-4~2
C4-5,~1
narrower~2
C2-3.~1
C6-7~2
retrolisthesis~2
C4-5~1
spondylotic~2
above-noted~1
myelopathy,~4
77-year-old~1
numbness~5
unsteadiness,~1
proprioception~2
C2-3,~1
T6-7,~1
L2-3,~1
L3-4.~1
dorsal,~1
epidural,~2
ligamentum~4
flavum~2
C3.~3
gout,~4
parathyroid,~1
decompressive~5
laminectomy,~1
(C2-4)~1
birefringent~1
crystals,~1
dihydrate~1
(CCPD).~1
CPPD~1
spinae~3
semispinalis~1
(AIS).~1
sex-~1
Boys~2
convexity~2
AIS,~1
curvature.~3
34-year-old~5
cleidocranial~2
dysostosis~1
adolescence~4
orthoses~6
34.~1
dysostosis,~1
undiagnosed~13
supposed.~1
Stable~2
metacarpal~15
(PIP),~1
shortening,~7
nonunion~3
phalanx.~4
158~10
head.~11
heads~7
necrosis:~2
ringlike,~1
focal,~6
MRI-positive~1
hips;~2
99mTc-diphosphonate~1
diphosphonate~4
symmetric.~1
expensive,~1
costly~3
central,~1
obturator.~1
delayed).~1
Pin~1
percutaneously,~1
Neurovascular~1
section)~1
shells~1
(THARIES)~1
resurfacing~1
THARIES~4
replacements.~4
definitions~7
(JRA)~1
non-RA,~3
non-JRA~3
highest-risk~2
loosening.~2
acrylic-fixed~1
THRs~1
loosenings~1
younger-than-30,~1
inadvisable.~2
Girdlestone~2
arthroplasty,~5
(TKA)~1
TKA;~1
retested~6
(THA)~1
energetic~5
penalties~1
Walking~2
33-46~1
m/minute).~1
travelled~1
walkers.~1
TKA~1
THA.~1
anticipate~2
torsion-transmitting~3
outward~11
linear.~3
ankle.~4
fork~1
fork,~1
calcaneus,~1
cuboid,~1
navicular,~1
piece,~3
talus,~2
three-arm~1
configurational~2
uneven~3
rotations~3
malalignment~2
supinating~1
supports.~2
tricalcium~1
(TCP)~2
nonimmunogenic~1
biodegradable~1
morphogenetic~3
(BMP).~1
BMP/TCP~2
unhealed~3
91%-100%~1
TCP~7
impregnated~2
(BSA/TCP)~1
0%-8%~1
incorporation,~2
unabsorbed~3
formulation~18
Osteocyte~1
osteocytes.~1
osteocyte~2
dead;~2
osteocytes~2
dead,~1
nonviable.~1
chondrocalcinosis~1
Paget's~11
chondrocalcinosis.~1
Uncooperative~1
setting;~1
hospitals.~15
Behavior~2
Special,~1
immobilization.~7
Plate~4
Screws~2
unstable,~3
phalanges,~1
comminution,~3
condylar,~4
T-condylar,~1
Y-condylar~2
diaphyseal~5
phalangeal~8
diaphysis~1
Screw~1
osteosynthesis~1
inflicting~1
interference~15
essentials~1
aftercare.~1
minicondylar~1
metaphyseal~4
(MP)~2
osteotomy,~3
transfer.~9
deference~2
tenolyses/capsulotomy.~1
irritation~5
Disadvantages~2
implant's~1
unforgiving~1
tolerances~1
nonunions.~1
cancellous~6
malignments~1
Aseptic~2
fixations,~1
nonunion,~1
replantation,~1
Kirschner-wire~3
Kirschner-wires,~1
pegs,~3
double-headed~1
screws,~2
plates.~4
nonunions~1
digits~4
"H"~2
Fracture~2
unimportant.~3
considerations,~2
Ordinary~1
Familiarity~1
standard,~5
applicable.~2
Nonunion,~1
tolerates~1
disuse~2
poorly,~3
expandable~4
reexpansion~1
immobilize~4
osteotomies,~2
replanted.~1
prohibit~2
adjunctively~1
wires,~1
provisional~3
osteosynthesis.~2
(DI),~1
surrogate~3
parenting,~1
Technological~1
secrecy~1
participants.~10
donor,~1
recordkeeping~1
insemination,~1
"family~2
secret"~1
addressed.~7
parenting~1
practices~22
extrauterine~1
summed~2
immaturity.~1
full-term~7
Dinamap.~1
subsiding~1
diverged~4
systolic,~3
diastolic,~3
6-day~2
caretaker~2
posed,~1
PRN~2
nurse~13
(TLCs)~1
medication;~1
caretakers~1
settings,~7
fear,~1
blaming~1
wish~5
Radbound~1
Nijmegen,~1
Netherlands.~2
omphalocele.~1
omphalocele,~1
omphalocele~2
Sepsis~4
applications,~2
regularly,~1
povidon-iodine~1
poisoning.~5
(younger~1
duplications.~1
meatus.~2
pit~1
hypospadias.~3
ureters,~2
hypospadias~8
duplications~2
glanular~1
epispadias~2
phimotic~1
broad,~1
spadelike~1
glans,~1
prepucial~1
raphe~4
cavernosa~2
epispadias.~1
units/h~1
68.5~2
(7.0)~1
Forearm~1
interdigital~3
skin-fold~4
laser-Doppler~4
thermocouple.~1
pallor~2
34.2~1
(0.2)~4
(0.1)~4
33.7~1
(0.02)~2
flow:~2
46.1~2
(1.0)~1
(0.7)~1
throughout.~4
skin.(ABSTRACT~1
urea,~8
resetting~3
erythropoietic~5
(PCV).~1
PCV,~1
PCV~5
[K+]RBC.~1
[increased~1
ouabain~19
(Fo)~1
(ko)]~1
([Na+]RBC)~1
[K+]RBC~2
ko~1
(TXA2)~4
OKY~7
1581~2
frusemide.~4
TXA2~9
29548~1
L-640,035~1
frusemide-induced~1
words:~1
frusemide~2
diuresis,~3
thirst~6
Thirst~2
thirst,~1
Linear~11
(cm)~1
osmolality-281)~1
+0.92,~1
(pmol/l)~1
osmolality-285)~1
+0.96,~1
(281~1
mosmol/kg)~1
(285~1
mosmol/kg).~1
subserving~1
osmoreceptors~1
uraemia,~2
dissect~3
microns)~5
viable.~1
uraemic~7
noradrenaline,~2
uraemia~1
vasculature.~6
Na+-free~4
balances~7
adrenalectomized~4
75%;~1
(-9.2~1
+5.3~1
(designated~4
balances.~2
aldosterone,~1
(selected~1
unmeasurable~1
hyperkalaemic.~1
animals.(ABSTRACT~1
flexors.~2
46.4~1
18.7~1
%,~1
[35.7~1
%]~2
27.9~2
16.4~5
10(2)~3
flexors~4
extensors.(ABSTRACT~1
corticosteroids.~6
(right)~2
knee-extension~1
Rheumatoid~6
35.7~3
17-66)~1
non-prednisone~1
respect.~3
extensors~5
0.48,~1
0.58,~1
extensors.~1
0.68,~1
Quadriceps~4
femoris~11
(COLD)~1
acid-labile~2
COLD~2
increment.~1
derangement~5
arginine-vasopressin~1
(AVP),~2
220~10
conscious,~7
intra-arterial~14
local,~4
compact~3
Intramesenteric~1
intra-arterially~3
rate.(ABSTRACT~1
Krebs-Henseleit~2
3H2O.~1
livers.~4
lipogenesis~3
portosystemic~7
encephalopathy.~6
Dogs~8
(intra-~2
extra-hepatic)~1
tryptophan,~2
pmol/ml)~1
pmol/ml).~1
GABA-ergic~1
neurotransmission,~1
gut-derived~1
starved~12
D-3-[14C]hydroxybutyrate.~1
Efflux~3
temperature-dependent,~2
alpha-cyano-3-hydroxycinnamate~1
phloretin.~1
"away"~1
analytic~5
bench.~1
non-analytic~1
"located"~1
Reference~4
Log~1
decisions,~6
actions.~3
Calibration~2
Work~2
Record,~1
cusum,~1
contingent~2
issuance~2
jeopardized.~1
Again,~3
organization.~3
commitment~11
service.~2
domination~1
industries.~1
system-wide~1
Currently,~7
organization's~2
non-revenue~1
expenditures.~1
realized~4
pursuit~6
offset~8
salable~1
commodity.~1
costly.~2
Westgard~1
appraisal~5
Prevention~5
sound~19
Appraisal~1
out-of-control~1
repeated.~6
assigning~2
dollar~2
repeating~4
productivity~3
profit.~1
profitability~1
assurance,~1
provided.(ABSTRACT~1
review,~5
compelled~1
thoughts~2
pre-eminent~1
assuring~2
quality.~6
crucial.~2
answer~11
asked.~2
thinks~1
Yet,~1
"markets"~1
repetitively~1
Inherent~2
enforce~1
mandatory.~2
suspects~1
self-testing~1
mandated~1
request~6
evolution.~6
sophistication~1
ideal.~1
"Will~1
Rogers"~1
phenomenon:~2
(stage~5
I-A1,~1
I-B1,~1
differentiated)~2
impacted~7
debulking~1
dramatic,~3
bacteriuria~14
expectations~15
stones,~9
continuous,~4
on-line,~2
real-time~4
ICU.~4
(acute~3
syndrome).~4
crisis.~5
selected;~2
mix~5
postresuscitation~2
rhythm,~6
gases.~3
54.0~2
beat/min~2
BP.~3
(68%)~13
iv.~1
32.5~2
gas-exchange~1
derangement.~2
hyperdynamic~4
shock.~15
413~2
535~2
perfusion-limited~1
(primarily~4
peritonitis).~1
flush~2
domes,~1
diaphragms,~1
fluids;~2
catheter-aspirate~4
30.6%~3
20.4%~1
32.7%~2
different).~1
5.7%~1
catheter-related~6
(55~9
false-positives,~1
588)~1
true-positives.~1
Catheter-related~1
catheter-segment~2
10.2%~2
Disturbingly~1
600-bed~1
(37.5%)~3
defibrillation,~3
cardiotonic~3
withheld.~1
"No~2
CPR"~8
(DI)~2
pituitrin~3
IU/24~2
syringe~8
uniform,~5
DI~5
mIU/kg~1
(diuresis~1
gravity~9
1.018~1
0.002),~4
Polyuria~1
discontinued;~2
overhydration.~1
Pressor~1
Broviac~4
1733~1
(69%)~7
1/48~1
catheter-associated~2
Urokinase~2
hygroscopic~2
condenser~1
humidifier~1
Humidification~1
10-~11
tidal-volume~1
Leakage~2
g/m3~2
(volume~2
leaked/volume~1
Y-piece)~1
15%.~7
repositioning~4
humidifying~1
(AHA)~1
ACLS,~1
refresher~5
AMA~1
retraining;~1
retraining~1
recommendations.~2
Mega~3
Code~3
ACLS.~1
life-support~2
pretesting.~1
sessions,~5
session,~9
weak.(ABSTRACT~1
Oliguria~1
oliguric~3
exenterative~1
armamentarium~3
cervix,~10
radionecrosis~5
sloughing~1
diversion.~3
exenteration~6
viscera.~3
dreaded~2
well-planned~1
hoped~2
postoperative,~3
reflection,~1
ultraradical~1
limit.~3
refinements~2
technicalities~1
judgment~9
Multimodal~1
39-78~1
49.5~5
micrograms/ml).~6
cardiovascular--major~1
(asystole,~1
(central~2
system--major~1
[seizures],~1
[confusion,~1
agitation]);~1
(nausea,~1
diarrhea).~1
prophylactically~2
reserving~1
(ATS)~1
(FVC)~4
(Hewlett-Packard),~1
end-point.~2
spirometric~10
diagnoses:~2
airways'~2
(SAO);~1
(MAO);~1
(COPD);~1
ATS~5
standards,~3
(FEV)~1
algorithms.~1
Hewlett-Packard~1
(HP)~3
HP~6
SAO~3
observed;~4
underevaluation~1
overevaluation~1
(17/60)~1
tuberculosis,~9
laboratory,~13
(5/26)~1
postprimary~1
(reactivation)~1
effusion.~11
helpful.~6
first-strength~1
tuberculin.~2
Lymphocytosis~1
exudates,~4
Pleural~4
exudative~4
asbestosis,~2
(anthracosidero-silicosis).~1
OKT3~1
(pan~1
OKT4~4
(helper/inducer),~1
(suppressor/cytotoxic),~1
B1~9
(B-cells),~1
OKIa~1
(HLA-DR~1
antigens),~1
Leu-7~1
(natural~1
killer).~1
OKT4/OKT8~2
SPN.~2
gratitude~1
told~8
thoracotomy,~3
happy~1
gratified~1
delicate~1
disrepute.~2
SPN~1
payers.~1
incidentally~4
radiated~1
IIA~3
Peritoneovenous~2
(PVS)~4
well-described~2
PVS~10
37-year-old~9
chylous~2
Intracardiac~2
deflated,~1
fenestrated~2
(CAO)~1
Duty~1
Pdi/Pdi~1
deflated~5
cannulation.~3
communications.~1
excision,~16
Multilesion~1
repeatedly~17
patient-friendly~1
pearl-oyster~1
pneumonitis~14
worker.~2
ornaments.~1
workplace-related~1
pearl-oyster.~1
bands;~1
lectin-like~1
Nasotracheal~2
retrieval.~1
COLD,~1
DODS~4
minute.~4
211.4~1
1,610.9~1
7:1.~1
allergen-induced~1
Kentucky~3
bluegrass~1
plethysmograph~3
(SRaw)~2
SRaw~3
(PC200His)~1
interpolation~2
PC200His~2
(PC200His~1
1.42~5
SE],~1
1.23~4
initially).~1
dual-responding~1
shares~3
killer-cell~2
interstitium~3
(FEV1/FVC)~1
variation)~1
mornings.~1
medications,~7
enforced.~2
(1.06~2
L;~2
(2.56~1
(MVV)~1
dioxide.~1
(PaCO2)~2
(MIP)~2
mouth.~2
FVC,~4
MVV,~1
MIP~1
COPD.~5
COPD~3
34)~2
plexogenic~2
arteriopathy~2
"musculoelastosis,"~1
(1),~10
Yamaki's~1
operable.~2
candidacy~1
operability.~1
pre-mortem~2
AIDS-associated~2
Center;~1
homosexual~14
sarcoma.~4
Seventy-nine~8
(24~18
interstitium,~2
textile~2
dusts~2
inhalational~4
bracts~1
(CBE).~1
CBE~3
(MEF~2
[P])~2
recoverable~5
0.69~10
Glycopyrrolate,~1
anticholinergic~14
bronchodilator.~3
glycopyrrolate,~2
glycopyrrolate~1
(100,~2
200,~4
600,~3
1,200~6
predicted)~4
Glycopyrrolate~1
converts~4
inactivates~2
bradykinin.~2
sloughed~1
injured,~3
lining~14
(ARDS),~1
Total,~1
(MAT)~3
admixture.~3
MAT,~1
Signs~4
nonoperated~5
hemopericardium,~1
constrictive~10
bicuspid~8
lifesaving~1
decubitus)~1
"good"~1
(down)~1
ventilation-perfusion~8
distribution;~1
right-to-left~4
equality.~1
Variability~2
nonhomogeneity~2
hemoptysis.~6
(46.9~1
clarifying~2
(15.6~1
(88.5~1
bronchoscopy,~3
(65.4~1
yield,~2
93.7~2
hemoptysis~10
bronchodilatation~4
bronchodilator,~2
ipratropium~10
fenoterol,~1
circuit.~3
bronchodilatation.~4
megacolon~6
university-affiliated~3
Toxic~3
(61~4
colitis:~1
salmonellosis,~1
two;~4
ischemic,~1
pseudomembranous,~1
(6/56),~1
(2/50)~1
(4/15).~1
retained,~1
well-selected~1
plea~1
ileostomy.~3
consecutively~10
horseshoe~2
Fifty-nine~8
fistulotomy,~1
fistulotomy~3
counter-drainage,~1
seton.~2
curettage,~3
fistulotomy.~1
seton~2
precludes~2
Cancer-specific~1
prospects~7
1306~1
72.5~3
72.3~1
61.5~2
explains,~1
sphincter-saving~1
Analyses~6
median,~10
cephalosporins~8
(21/43).~1
106,~1
74,~5
pseudomembranes~1
response),~1
stasis.~1
preventative~1
short-chain~2
proctocolitis~2
Lowering~5
proctocolitis,~1
Short-chain~1
Postirradiation~2
Parks~1
introduced.~6
coloanal~1
sleeve~15
vesicovaginal~2
stripping~3
nonoperatively;~1
sessile~4
pedunculated~3
piecemeal~2
polyps)~2
(4.5~4
syndrome),~2
Colonoscopic~3
polyps,~9
colectomy~11
Melanosis~1
anthraquinone~1
laxatives.~1
Colonoscopies~1
constipation,~1
distention~12
discoloration~3
sigmoid,~1
pigment-laden~1
procidentia~2
Ripstein~2
continent~10
Defecation~2
dissatisfaction.~1
cancers)~1
re-examined~2
0.05-0.01),~1
Mucinous~1
adenoma-carcinoma~1
supported,~2
aggressivity~1
advancement~10
England,~1
Germany,~3
Scandinavian~1
predominance.~2
Depth~1
resections.~2
extension,~9
forty-three~4
Gy,~1
higher).~1
symptom-free~5
80.4~1
17.5~4
time/patient~1
30.2,~1
31.8,~1
31.9~2
microtip~1
anorectal~14
manometry~10
hemorrhoids.~1
(80.7~1
cm/H2O)~2
sphincterotomy,~2
(19.3~2
hemorrhoidectomy.~1
(success~1
75.3~1
spermidine~2
Polyamine~2
polyamines~2
sigmoidoscopies~1
colonoscope.~1
lecture~2
instructions,~1
trainee~1
instructor~6
attachment.~1
sigmoidoscopic~2
examinations).~1
sigmoidoscope~5
inexperienced~4
endoscopists.~1
colonofiberscope~1
improvements,~2
unchanged;~4
pushing~1
inevitable.~1
factors;~1
Over-elongation~1
overextension~1
ptosis.~4
"leading~1
cord"~1
colonofiberscopy.~1
fiberscope~1
hardened~4
straighten~1
scope,~1
ptosed~1
straightened.~1
colonofiberscopy~1
(TA-55~1
staplers)~1
Curative~3
0-43~1
recurred.~3
Disturbances~3
acceptable.~5
schistosomal,~1
tuberculous,~1
schistosomal~3
polypectomy~8
any.~1
colon:~2
friability,~1
firmness,~1
dunce~2
cap~4
lobulation,~1
asymmetry,~3
color.~1
endoscopically.~4
lipomas~1
endoscope.~3
unsettled~1
office-based~2
specialities~1
(NDTI)~1
publishes~1
steeper~1
statistics~8
High-amplitude~1
contractions,~10
nutcracker~6
myotomy~5
high-amplitude~2
recalcitrance~1
Manometry~1
bipeaked~1
sphincter.~7
Peristalsis~1
myotomy.~3
200-ml~1
denitrate~1
Iced~1
denitrate.~1
iced~5
cold-induced~5
distension.~2
Neurotensin-like~1
(NTLI)~1
NTLI~5
Intralipid)~1
(CRF),~1
(PCS),~1
showed:~2
PCS,~1
CRF.~2
PCS~1
CRF~9
PCS.~1
NTLI.~1
(PC)~6
Excretion,~1
aqueous-phase~2
gas-liquid~1
2.26~3
3.34~3
mmol/24~1
malabsorption.~11
dihydroxy~1
chenodeoxycholic~2
deoxycholic~8
exception,~7
solubility,~1
cholestyramine,~2
subsecretory~1
inconsistent~9
acid-induced.~1
Weight-matched~1
Rodent-Blox~2
ad~16
libitum;~1
Nutrition-76~1
(AIN-76)~1
(weight/volume)~1
libitum~10
AIN-76~9
trypsinogen,~2
chymotrypsinogen,~1
lipase;~1
chymotrypsinogen;~1
trypsinogen~11
proteases~1
"high"~6
carbohydrates.~1
neurotensin,~2
tridecapeptide~1
neurotensin~16
indirect.~2
CCK-8~8
lobules~4
acini~5
-10(-6)~2
10(-9)~18
(maximally~1
Amylase~2
Neurotensin~3
pM/kg~1
potentiate~10
acini,~1
CCK-8.~1
megaesophagus,~1
(UES)~2
swallowing,~2
UES~19
intraesophageal~5
(10-40~4
cc)~4
(0.1-0.4~2
HCl)~3
Fasting~10
(MMC)~1
80-100%~1
megaesophagus:~1
swallowing~14
pressures;~3
MMC~2
(75-80%~1
respectively);~2
Conclusion:~1
megaesophagus.~2
Absence~4
lactose-free~2
carbohydrate,~6
10-day~5
stool,~2
ostomy~2
absorptions~1
62%,~2
32%,~6
34%,~5
diets,~9
meals.~1
35-40~1
kcal/kg~2
80-100~1
protein/day~2
safety.~7
substantia~9
nigra~4
(SN)~2
kindling,~1
SN~7
amygdala~3
(AM)~3
pyriform~5
kindling~4
Ipsilateral~5
afterdischarge~1
(AD)~6
AM-~1
cortex-kindled~1
AD~7
kindled~3
intensity-dependent~1
picrotoxin.~2
picrotoxin~4
foci.~3
GABAergic~6
GABA/benzodiazepine/picrotoxinin~2
16-19~1
Benzodiazepine~1
(using~2
[3H]flunitrazepam~1
ligand;~1
FLU),~1
[3H]muscimol;~1
MUS),~1
picrotoxinin~1
[(~2
35S]t-butylbicyclophosphorothionate;~1
TBPS)~1
bindings~2
glass-implanted~1
TBPS~2
FLU~1
MUS.~1
perifocal~1
cobalt-induced~1
16-day-old~1
amygdala.~1
ACTH-treated~1
tonic-clonic~5
seizure-related~1
spasms~6
near-drowning~2
late.~6
NFS~1
10-40~3
BSA.~2
Phenytoin~2
phenytoin.~3
weights,~2
hematocrits.~2
immunomodulatory~2
antiepileptic~6
offspring.~2
sister~5
(SCE),~1
mutagenicity,~1
mutagenic~3
SCE~4
26-50~1
mutagenicity~1
agrees~4
Endocervical~1
(ER)~9
(CM)~2
Cytosol~1
ERs~2
[LH]~1
surge)~1
CM~7
Fmol/mg~1
dextran-coated~1
(New~1
Kit,~1
Boston,~2
MA).~1
concomitantly.~1
123.4~1
[SEM])~1
123.3~1
15.0~4
0.27~6
KCl~7
[3H]-R5020~1
uteri.~5
perimenopausal~3
Oviductal~1
salpingitis~10
tube;~1
Chlamydial~4
microimmunofluorescence~3
1:32).~1
(78.9~1
13.1).~1
bicarbonate-glucose~1
ml/minute~2
Arteriovenous~2
perfusate,~1
light-~2
secretive~1
gonadotropins,~3
(January~1
1985)~5
2.53~1
1.57~2
1.58,~1
harvested,~1
younger.~6
23.4%~1
27.7%~1
counseled~4
cryptorchidism~9
(AC)~6
oligoasthenozoospermia~1
spermatozoa.~1
thin,~6
tails.~1
AC.~1
single-cell~3
(BSA)-supplemented~1
770~2
BSA-supplemented~2
(HCS)-supplemented~1
HCS~3
earlier,~6
hatching~2
492~3
HCS-supplemented~1
(10,000~2
cutoff),~1
1109~1
HCS,~1
(SMCS),~1
(LMCS)~1
SMCS.~1
SMCS~1
Nonsurgical~3
preimplantation~4
conceptus~1
lavages,~1
ova,~1
aborted,~1
donating~2
sister,~3
Donation~1
infertility;~1
nonsurgical,~1
inconstant~2
individually.~1
(IVF-ET),~1
IVF-ET.~1
69.3%.~1
workable~1
(controls,~2
56);~1
36);~1
Cumulative~13
(danazol).~1
Abortion~1
6.3%,~1
14.3%.~1
contemplated.~3
suppository~4
suppositories,~1
Toward~1
goal,~3
microbiochemical~1
stromal)~1
(LDH),~2
beta-hydroxyacyl-CoA-dehydrogenase~1
(beta-OH-acyl-CoA-DH),~1
(CS)~2
enzymes.~8
LDH,~1
39.9~1
15.4;~1
CS,~2
1.2;~1
beta-OH-CoA-DH,~1
mol/kgD/hour.~1
moles~2
(mol/kgD/hour).~1
eastern~2
registry~3
Midwest~1
Poland~1
1970-1984.~1
Polish~2
registry.~1
1982;~1
3.5/100,000~1
1970-1981~1
6.6/100,000~1
1982-1984.~2
starvation~11
fuels.~2
conserving~2
antilipolytic~1
nicotinic~6
tetradecylglycidate~1
(TDGD),~1
long-chain~6
hindquarter.~1
TDGD~3
corticosteroid.~2
release)~5
3-methylhistidine~5
breakdown,~1
nonmyofibrillar~1
altered).~1
counterregulatory~4
non-glucose~1
R-R~5
(GH),~1
15-fold~2
150-400%~1
upper-body~2
non-insulin-dependent~5
uncorrelated~2
(BMI),~1
subscapular-to-triceps~1
(STR),~1
waist-to-hip~1
(WHR),~1
738~2
Americans~5
25-64~1
Antonio~1
Study,~9
Diabetes~9
STR~3
WHR~6
STR.~1
BMI,~1
WHR,~1
cholesterol;~1
body-fat~2
Investigators~1
preferable.~1
(IA)~1
immunospecific~1
insulins~2
beads.~1
IAA-containing~3
insulin-naive~1
nondiabetics~1
(B)~3
insulins.~1
B-chain~3
desalanated~3
threonine~2
B30.~1
H,~8
P,~9
insulins,~2
B-chains.~1
IA-containing~1
insulin-treated~4
porcine)~2
B-chain.~1
ovine,~2
(threonine~1
B30)~1
B30~1
dominant,~3
exogenously.~1
IA~12
A-chain~2
insulin-specific~1
IA-diabetic~1
affinities.~1
20-yr-old~2
hypertension;~5
Diets~5
day-1~1
(1.86~1
(2.17~1
.043).~1
(GFR)~7
(RPF).~1
diabetics.~6
diets.(ABSTRACT~1
554~1
(insulin-dependent)~3
probands'~1
Stromgren's~1
Lifetime~1
(risk~6
first-degree~7
generations~13
1.7%.~1
probands~4
probands.~1
twice)~1
(4.1~1
0.6%,~2
proband~4
probands),~1
clustering~8
families.~14
siblings.~8
mixed-function~1
oxidase~30
cytochrome~32
P450,~1
b5,~1
P450~5
b5~2
microsomes~16
cholestasis.~5
p-nitroanisole~2
O-demethylation~2
P450-dependent~1
(0.29~3
(0.41~3
nicotinamide~5
dinucleotide~3
phosphate-~1
dinucleotide-cytochrome~1
reductases~1
glutamic~6
oxaloacetic~1
transaminase~12
bilirubins~7
conjugation.~2
conjugates~20
1-O-acyl~1
glucuronides.~2
Gilbert's~6
Crigler-Najjar~2
undetectability~1
diconjugated~2
bilirubins.~1
monoconjugates~1
diconjugates~2
R/APfd-j/+~1
bilirubin,~9
mono-~2
bidirectional~4
sinusoidal~15
hyperbilirubinemia,~1
self-limited~7
(ASLC)~1
(CUC)~1
microbiologic,~1
quickly.~1
ASLC,~1
[CUC(F)],~1
[CUC(R)]~1
F),~6
discriminatory.~1
ASLC.~3
CUC~2
ASLC~3
vice~4
versa.~2
Plasmacytosis~1
CUC(F)~1
CUC(R),~1
cryptitis~1
mandates~6
CUC.~1
coagulation,~3
Monocyte~7
lipopolysaccharide-stimulated~1
0.89)~3
generation.~4
benzalkonium~3
choline~26
acetyltransferase,~1
ablation,~2
leucine-enkephalin~2
jejunum,~6
caerulein~2
carbamylcholine~2
biphasic.~2
secretagogues,~1
exocytotic~4
intergranule~1
autophagic~2
vacuoles.~4
(pro)enzymes~1
whereupon~1
intraperitoneally,~2
Varying~6
polysaccharide~8
(0%,~4
50)~6
survivorship.~1
polypeptide)~1
Chow~3
polypeptide,~6
bile.~16
alleviated~5
enteral~2
enterocytes.~3
noncholinergic~3
sheets~8
Ussing~3
short-circuit~3
stimulated,~4
evoked.~1
isobutylmethylxanthine~2
forskolin.~4
cholinergically~1
bethanechol.~2
3',5'-adenosine~2
enterocytes~2
calcium-dependent,~1
samples)~1
(egg~1
salad~2
sandwich,~1
peaches,~1
milk).~1
Bile~13
acid-like~2
aliquots~6
(limit~2
hydroxysteroid~1
cholecystokinin-octapeptide~1
(CCK-OP)~1
antrum.~2
curvature,~1
CCK-OP~4
atropine,~15
Propranolol,~3
phentolamine,~3
adenosine-5'-triphosphate,~1
CCK-OP-induced~1
Cholecystokinin-octapeptide~1
channel-independent~1
Malabsorption~5
fermentable~7
Breath~4
oats,~2
wheat,~2
corn,~1
baked~2
beans.~1
Rice~1
hamburger~2
lactulose.~1
fermented~1
100-g~2
beans;~1
corn;~1
rice.~1
oats~1
wheat~9
flours.~1
homogenates,~2
carbohydrates,~2
rice,~2
escapes~1
malabsorbed~1
hypocholesterolemia~1
(64.3~1
lipoprotein,~3
Lipoprotein~5
apoproteins,~1
vesiculating~1
well-individualized~1
lacteals.~1
recessively~1
hypobetalipoproteinemia~1
exocytosis.~1
maximal.~2
confluent,~1
replenishment~1
ascorbate~1
strictured~1
V).~1
somatostatinlike~2
achlorhydria~5
benzimidazole~1
BY~3
308.~2
atropine-resistant.~1
Hypergastrinemia~1
stores~10
somatostatin;~1
(a)~2
(b)~3
(24%),~4
laxative~2
historical~14
Anal~3
distention.~2
Generalized~3
Rectosigmoid~1
pentagastrin~14
oxyntic~4
Interaction~4
Pentagastrin~3
pentagastrin-induced~3
pentagastrin.~3
mycobacteria~2
noninflammatory~3
slow-growing~3
(Runyon~2
rapid-growing~2
mycobacterial~7
Slow-growing~1
Isolates~2
avium-complex.~1
kansasii.~2
fortuitum-complex.~1
mycobacteria,~1
spheroplasts~1
(cell~1
wall-defective~1
forms)~3
colon)~3
colitis;~2
non-inflammatory~2
presence,~6
mycobacterium~2
enkephalin,~2
gastrin-releasing~4
Y,~2
somatostatin,~6
pylorus~4
richly~2
plexuses~3
Recirculation~2
diverted~2
bile-pancreatic~1
biliary-pancreatic~4
diversion~18
pmol/L).~1
Biliary-pancreatic~1
50-100~2
pmol/L)~7
CCK.~5
pmol/L,~2
CCK-8,~3
CCK-33~2
CCK-22.~2
CCK-33/39.~1
15)~12
de-emphasis~1
Owing~2
physiology.~6
Intraesophageal~2
recording,~4
ate~3
Recording~1
epoch.~1
Electroencephalogram~2
Periods~1
tracings.~1
postprandially~3
reflux.~20
restfulness~1
(0.075,~1
i.v.).~2
Motility~2
methods:~6
radiochromium~1
(Na51CrO4).~1
spike~9
vincristine.~1
transit.~8
Disrupted~1
hastened~1
G,~4
isotypes~5
alpha-lactalbumin,~1
1-acid~7
Stool~6
Clinitest,~1
anthrone~1
oligosaccharides,~3
quantitation.~1
0.79,~2
throughout,~2
Chloride~1
Neural~3
colon;~3
cecum.~3
transmitter(s)~1
Pseudo-Zollinger--Ellison~1
afflict~2
Hypergastrinemia,~1
nonhealing~2
7-yr-old~1
hypergastrinemia~2
200-500~1
fundal~4
gastritis.~5
Workup~1
Zollinger--Ellison~1
pseudo-Zollinger--Ellison~2
Disappearance~4
B-associated~1
e~3
Gardner's~8
polyps.~10
papilla.~2
ovalbumin-sensitised~1
gamma-glutamyl~5
transpeptidase,~1
lactase,~1
sucrase,~2
glucoamylase~1
(brush~1
microvesiculation.~1
cholestyramine.~2
sterols~6
lathosterol,~2
squalene~2
desmosterol,~1
sterol~5
lathosterol~1
sterols.~1
sterols,~2
desmosterol.~1
Cholestyramine~2
proportionate~4
synthesis).~1
synthesis)~2
enteropathy.~2
malabsorption.(ABSTRACT~1
anaesthetised,~1
Damage~6
extrapolation~4
caution,~1
loxtidine~1
250,~1
746~1
fundus.~4
foveolar~1
unsurmountable~1
triolein~3
14CO2~6
Acceptable~1
'within-day'~1
'between-day'~1
Johne's~1
(paratuberculosis)~1
ruminants.~1
paratuberculosis~4
aetiologic~1
seroreactivity~2
paratuberculosis.~1
paratuberculosis,~1
steatorrhoea,~3
non-pancreatic~3
micrograms/l~1
(47.0~1
22.1~2
(31.4~1
steatorrhoea.~2
0.2-17.0~1
-2SD~1
micrograms/l),~3
0-8%~1
15-183%~1
steatorrhoeic~1
aetiology.(ABSTRACT~1
Kingdom.~3
1845~2
1915~1
generations.~3
1835~1
1955.~1
1875-1885.~1
Pruritus~1
pruritus.~3
pigmentation~10
Autoimmune~3
sicca~1
hepatoma~5
Wilson's~17
penicillamine~6
(22%)~11
epistaxes~1
hepatomegaly~6
transplantation,~3
Non-steroidal~1
(NSAIDS)~1
hepatotoxicity.~2
Diclofenac,~1
NSAID,~1
diclofenac~1
periesophageal~1
i.v.)~10
11.5%~1
(+1.4%,~1
metoclopramide,~3
cholestasis,~1
losses,~2
cholylglycine~3
E;~1
inborn~3
intramitochondrial~2
beta-oxidation~3
Reye's~11
lethargy,~4
transaminases~4
Long-chain~1
Hepatic~17
macro-~1
microvesicular.~1
microvesicular~5
steatosis~6
Reye's.~1
defect(s)~1
antimitochondrial~16
1/40,~1
cirrhosis;~5
phosphatase.~5
(predominantly~1
IgG3)~1
exhibited.~1
1/40~1
delta-virus~6
Yucpa~1
Indians~7
Venezuela,~1
Colombia,~1
viscerotomy.~1
"Santa~2
Marta~3
hepatitis,"~1
"hepatitis~1
Sierra~3
Nevada~1
Santa~10
Marta,"~1
immunocytochemically~3
hepatocytes,~3
sluggishly~1
cytolysis.~1
intraacinar,~1
macrophagic,~1
ductular~1
delta-hepatitis~3
Europe~2
microsteatosis~1
toxins.(ABSTRACT~1
Marta"~1
Colombia~3
1930.~1
historic~4
viscerotomy~1
Gast-Galvis~1
delta-virus.~1
picture,~3
morula~1
delta-antigen~1
Marta,~1
inhabitants~2
1940's.~1
delta-antigen.~1
Venezuela~1
Amazon~1
basin~1
delta-superinfection~1
hybridization-based~1
1.75~6
(pKD3~1
DNA).~3
replication;~1
antihepatitis~1
antigen-positive~6
chronicity.~1
conforming~3
Characteristic~2
intralobular~4
hepatocytic~1
cytoplasms~1
conducive~1
acidophilic~1
bridging~4
chronicity~2
late-stage~1
anti-HBc~8
Corzyme-M~2
(Abbott~1
Chicago,~2
Ill.),~2
inasmuch~5
galactosamine-induced~2
AST.~1
Brainstem~3
encephalopathy;~1
encephalopathy,~5
(I-V~1
interval)~4
downregulation~2
(only~5
1.16~1
(heavy~1
lipoprotein)~1
lipoprotein.~4
lipoprotein-mediated~1
preincubation.~1
overruled~1
notwithstanding~1
cystine~10
sulfobromophthalein.~4
dose-dependent,~2
Actinomycin~1
time-related~3
Na+-independent~1
glutamate.~3
Na+-independent,~1
(System~1
x-c)~1
cystine.~1
electrophilic~2
x-c~1
detoxication~2
hypophysectomized~8
Alcohol~19
microgram~16
Corticosterone~2
elimination,~4
corticosterone.~1
046,~1
046~4
glomerulosa~16
primates,~1
sodium-induced~1
primate,~3
(Macaca~4
fascicularis).~2
sodium-restricted~2
(93~3
fmol/mg)~1
sodium-loaded~2
(171~1
fmol/mg).~1
zona~5
(344~2
fmol/mg,~5
18-hydroxylase~1
fmol/mg/min)~1
fmol/mg/min).~1
occupancy.(ABSTRACT~1
angiotensin-mediated~1
nonclipped~6
two-kidney,~4
(SQ~2
20881),~1
(0.2-mm~1
1.24~2
ml/min),~2
777~2
nEq/min),~1
0.14%),~1
microliter/min).~1
1.12~4
clipped~1
1384~1
nEq/min)~1
kidney;~2
min/ml).(ABSTRACT~1
Ca2+-activated~5
(Goldblatt~1
Goldblatt~3
killed.~4
15-week-old~3
(3.84~2
2.75~1
10(-2);~1
5.93~1
2.65~2
10(-2].~1
(2.90~1
10(-2]~1
0.59~5
0.06;~1
0.48~11
0.05).(ABSTRACT~9
1-hour~11
sinoartic~1
electrolytic~1
tractus~6
solitarii,~1
Sinoaortic~1
solitarii~4
phenylephrine-induced~3
sinoarotic-denervated~1
variability;~1
sinoaortic~5
sinoaortic-denervated~2
movement-related~1
depressor~6
skew~2
baroreceptor-denervated~2
6589~1
(4.7%)~1
(0.6%)~3
ouabain-sensitive~3
(231~1
students;~1
10-week~1
self-monitoring~1
(chloride)~1
titrator~3
reduction:~1
mEq/day~1
nonpharmacological~1
ouabain-resistant~2
-0.82,~1
12).~3
hr-1;~2
10);~1
Na+-Li+~11
countertransport~14
Clinic,~3
MN,~4
20.6%~2
interindividual~7
countertransport.~1
concomitants,~1
[SD]~3
Li~1
efflux/L~1
cells/hr;~5
107).~1
cell/hr;~1
104)~1
(0.31~1
(0.35~2
(0.42~1
111)~1
(0.37~1
76).~1
birthplace,~1
dihydroergotoxine~5
3,4-dihydroxyphenylacetic~3
deaminated~2
metabolite)~2
32-68~1
I-II).~1
238~4
1.22~5
Dihydroergotoxine~2
domperidone,~1
presynaptic~4
dihydroergotoxine-induced~1
Domperidone~1
variables.(ABSTRACT~1
hypertensive,~3
Wistar-Kyoto,~2
(norepinephrine,~2
phenylephrine)~1
(prazosin)~1
(rauwolscine).~1
semilog~2
nanograms)~1
k,~1
nanogram.~1
(clonidine,~1
guanabenz)~1
(fractional~2
nanogram:~1
0.011;~1
phenylephrine,~2
0.003;~1
clonidine,~6
0.00087;~1
guanabenz,~1
0.000037).~1
clonidine~28
guanabenz~1
rauwolscine~2
prazosin.~6
antidiuresis~1
antinatriuresis~1
antinatriuretic~1
rauwolscine.~3
rats.(ABSTRACT~2
5-year-old~2
Siberian~3
husky~1
pressure:~1
(representatives~1
cadmium~6
chemistry~11
huskies~1
6-week-old~1
17-~1
19-week-old~1
spindle-shaped~1
wrapped~1
vessel's~1
cell's~2
mechanoreceptors~3
chemoreceptors~2
ureteropelvic~3
renorenal~3
natriuresis.~3
(WKY).~4
resets/min,~4
Stimulating~1
receptors.(ABSTRACT~2
sodium-lithium~5
sodium-proton~8
exchanger,~2
put~8
amiloride-sensitive~2
amiloride.~2
proton-stimulated~1
(amiloride~1
sensitivity)~4
countertransporter~1
detract~1
border.~3
salt-sensitive~5
Dahl~7
salt-induced~2
salt-resistant~2
[3H]norepinephrine~3
[3H]tyrosine,~1
dihydroxyphenylacetic~2
3-methoxytyramine,~1
off,~2
(DOCA)-salt~2
uninephrectomized~1
DOCA~1
tap~6
Sympathetic~2
turnover,~6
alpha-methyl-p-tyrosine,~1
DOCA-salt~4
hexamethonium~11
ganglionic~9
overactivity~6
housed~5
62,~3
0.0003).~2
1.41%~1
(wt/vol)~2
K2HPO4~1
KH2PO4~1
16.2,~1
36.3,~1
phosphate-supplemented~4
WKY.~4
1.2,~6
0.41).~1
SHR;~1
0.0003).(ABSTRACT~1
containment,~2
competition,~1
forcing~1
insurance~15
ways,~3
hastening~1
cottage~1
corporate~2
provider~5
(PPO),~1
embraced~1
employer~3
sector,~1
phenomenal~1
PPO~2
option,~1
Hospital-health~1
affiliations~1
idle~1
containment~4
adversarial~1
Meaningful~1
alliances~1
Hospitals,~3
employers,~2
employees.~2
Cost~2
packages~2
business~3
employers.~2
Business~1
do.~2
administrator,~1
bundles,~3
sternocostal~2
subclavicular~1
tunnel.~1
musculature.~3
bundle.~2
depressions~3
infraclavicular~2
downhill~1
resurface~1
(HPT)~1
"Brown~1
tumor"~1
Brown~3
transethmoid~1
chloride/phosphate~2
normocalcemia~2
erosion.~2
HPT~4
osteitis~5
fibrosa~3
reparative~1
granuloma,~4
chordoma,~2
chondrosarcoma.~3
Dent~3
Hypercalcemia~10
parathormone,~1
fibrosa,~1
parathormone~4
assay.(ABSTRACT~2
binding-inhibiting~1
(TBIAb)~1
(TSAb).~1
(EBV)~7
TBIAb~3
TSAb~6
EBV~11
TSAb,~1
EBV-infected~1
wells~8
24-well~1
372~3
TBIAb,~1
TSAb.~1
(94.7%)~1
(TBIAb~1
TSAb)~1
multifunctional~4
(both),~1
conclude,~2
1324~1
(papillary,~1
follicular,~2
cell)~3
groups'~1
have,~2
hypothyroidism:~1
myxedema)~1
(Hashimoto's~1
impalpable~3
(TBII),~2
(TSII),~1
(TGII)~1
Porcine~1
(FRTL-5~1
TSII~3
TGII~6
(IgG;~1
mg/ml)~8
2-h~5
[14C]thymidine~1
are:~7
TBII,~4
TSII,~4
TGII;~1
thyroiditis;~1
FRTL-5~12
acromegaly,~2
(BBB),~1
L-dopa~7
BBB,~1
acromegaly.~1
pituitary)~1
BBB).~1
iv,~3
orally),~2
[maximum~1
decrement,~1
SEM);~1
21]~1
(44.1~2
5.6%;~1
23;~4
(58.9~1
5.0%;~1
mg/min,~4
L-dopa.~2
137.3~1
10.8%~1
100.2~1
3.9%,~2
138.8~1
19.7%~2
106.5~1
3.1%,~3
domperidone-L-dopa~1
sulpiride~3
(DA~1
BBB;~1
somatotrophs,~1
hypothalamus;~1
GH-releasing~2
(G-IgG)~1
(Tg)~3
antithyroid~10
drug-treated~1
monolayers;~1
Tg,~1
micrograms/dish~2
Tg~10
15.~3
G-IgG-induced~1
12th~3
18.~5
G-IgG~1
12-day~1
release-stimulating~1
(Tg-RSA)~1
mg/dish)~1
G-IgGs~1
Tg-RSA~5
varied.~3
clarified.~4
transdermally~1
hypogonadal~2
polymeric~11
scrotum.~3
(5,~2
testosterone-containing~1
h/day.~1
60-80%~2
22-h~1
(placebo,~2
ng/dl;~5
348~6
455~4
624~3
13.9%.~1
transdermal~10
hypogonadism.~2
glucosylated~2
(GSA)~1
out-patients,~1
8-12~1
GSA~7
(GHb)~1
fasted,~2
preprandial,~1
7-day~7
GHb~2
28-,~1
56-,~1
84-day~1
determination.~3
ranges,~2
0.40-0.64~1
0.46-0.64,~1
56,~3
0.54-0.74).~1
0.72)~1
0.65)~1
GHb,~1
interchangeably.~2
(hPP)~1
Parasympathetic~1
hPP~6
(beat~1
maneuver)~1
RIA)~1
(59~5
meal-induced~1
12;~3
412~1
76;~1
446~2
57;~1
325~7
SMM~1
nonstressful~2
ACTH-,~1
(AII)-,~1
K+-mediated~1
Ca)~1
ACTH-~1
AII-mediated~1
hypoparathyroid~2
(HypoPTH)~1
mIU/30~1
ng/kg~6
3-8~1
HypoPTH~5
(5.4~2
(10.6~2
ng/dl).~2
(25.1~1
(28.9~1
ng/dl.~3
0.475;~1
anti-beta~1
1D12.~1
hCG;~1
4%.~4
hydatidiform~4
mole~13
15),~7
29),~5
choriocarcinoma~15
28).~5
progressed,~6
choriocarcinoma,~3
immaturity~2
(Fn)~1
subunits,~2
230K.~1
Fn~10
Essential~1
confluence,~1
thyroidectomized~8
microCi/dish)~1
harvesting.~2
combined,~9
35S~5
antihuman~3
immunoglobulin,~1
immunoprecipitated~3
230K~1
Fn.~1
acid-precipitable~4
anti-Fn~1
7.4%~1
10(-12)~2
31.3~1
5.8%~3
degradation,~3
chased~1
methionine.~2
[35S]Fn~1
chase.~1
mU/min,~1
octadecasilyl-silica~1
7.4,~5
(defined~11
90%).~2
microU/ml.~1
OT.~1
microunits~1
0.93).~2
(OT~1
clearance/creatinine~1
3.6%~7
0.43%~1
MCR).~2
OT-related~1
antihormone~1
idiotypic~3
receptor-binding~3
Equilibrium~2
ER.~1
cytosol-Blue~1
ER,~3
18-h~1
MCF-7~1
mg/ml),~1
[3H]E2~6
2.52~1
fmol/microgram~4
selective,~4
anti-ER~1
revealed,~4
E2-binding~1
sites;~1
27.5~3
Enriched~1
antireceptor~1
competitor,~1
thyrotrophs~1
50-micrograms~1
S-transferase,~2
T4-binding~1
microU/ml)~1
(33%),~8
(26%),~3
overtreatment.~1
Arginine~2
hemofiltration.~3
liters~16
isoosmotic~1
AVP-secreting~1
substance,~4
PRL-producing~1
hypogonadism~5
impotence.~7
200-mg~2
(BRC)~1
37-yr-old~1
60-mm~1
13,969~1
BRC~2
5,103~1
1,446~1
13,471~1
Visual~17
(height,~1
40-43~1
6,900~1
12,995~1
aromatized~4
lactotrophs,~2
prolactinomas,~1
Brief~1
microelectrode~4
(0.78~1
m/s,~2
(1.05~3
0.004),~2
61.7~1
mV,~4
(94.1~1
64.1~1
dV/dT~2
(164.7~1
37.3~2
52.6~1
V/s,~2
velocity;~1
postischemic,~1
Endotoxemia~2
(DIC);~1
(TF)~1
thrombomodulin~1
(TM)~3
microgram/ml)~6
TF~3
1.52~3
11.89~1
8.12~1
mU/ml-10(6)~1
renewed~4
TM~11
55.0~1
6.4%~5
septicemia.~3
(IMCDs)~1
(PSE)~1
Urea~2
IMCDs~4
medullas~2
cm/s)~1
(IMCD1),~1
0.5;~2
(IMCD2),~1
46.6~3
10.5;~1
(IMCD3),~1
3.6.~2
IMCD1,~1
0.1;~2
IMCD2,~1
2.8;~1
IMCD3,~1
1.8.~1
PSE~3
mounted~11
urea.~2
cm/s~2
rabbit.~6
IMCD~1
two-thirds;~1
interstitium.~2
rotaviruses~5
rotaviral~2
glycoproteins,~5
ovalbumins~1
ovomucoids~1
turkey~2
eggs,~4
mucin~11
submaxillary~3
MA-104~2
virus-glycoprotein~1
oligosaccharides.~2
rotavirus~5
Bovine~5
ovoinhibitor~1
Hypophosphatemia~1
(Hyp)~1
25(OH)D-1~1
alpha-hydroxylase~7
hypophosphatemia,~3
tubules.~4
Hyp-mice,~1
calcitonin.~3
Hyp-mouse~1
homogenates.~6
time-course~1
dose-dependence~2
calcitonin-sensitive~1
12-hydroxyeicosatetraenoic~1
(12-HETE),~1
chemokinetic,~1
cell-cell~2
12-HETE~3
12,20-dihydroxyeicosatetraenoic~1
(12,20-DiHETE)~1
omega-hydroxylation~1
P-450~7
B4,~1
12,20-DiHETE.~1
proteases,~2
diisopropylfluorophosphate~1
omega-Hydroxylation~1
6.6-fold~1
sonicates.~1
NADPH~12
cofactor.~1
metabolizes~2
12,20-DiHETE~1
monooxygenase.~1
(ADX)~1
microgram/100~1
d.~5
ADX~1
adaptation).~1
potassium-loaded,~1
adrenal-intact~1
Decay-accelerating~2
(DAF)~1
direct-binding~1
(polymorphonuclear~2
[PMN])~1
DAF~17
Upregulation~1
upregulation~3
(CR1~1
CR3),~2
hemoglobulinuria~1
CR3~1
packaging~2
Translocation~1
inositol~8
opossum~3
bisphosphate~1
diacylglycerol,~1
4'5-bisphosphate.~1
4'~1
phosphatidylinositol.~1
Inositol~1
saponin-treated~1
nucleotides.~2
diacylglycerol.~1
gluten-sensitive~2
enteropathy~3
HLA-B,~1
DR,~2
BF,~9
C4A,~1
C4B~1
[HLA-B8,~1
DR3,~3
SC01]~1
[HLA-B44,~1
DR7,~2
FC31]~1
nonextended~2
HLA-DR7,~1
HLA-B8,~1
DR7.~2
HLA-DR3~3
DR7~3
complex-linked~1
DR3~1
DR3/DR7~1
heterozygotes,~1
Soluble~1
(SIRS),~1
lymphokine~1
SIRS~9
steroid-responsive~2
(SRNS).~1
SRNS~3
(10(-6)-10(-7)~1
interferon,~2
pathogeneses~1
vasodilators.~3
Ischemia~3
(KCl),~1
acetylcholine,~5
endothelium-dependent~8
endothelium-independent~3
nondenuding~1
augments~9
Lowe~1
oculocerebrorenal~1
(LS)~2
subregional~1
LS~3
Xq24-q26.~1
Probes~1
(RFLPs)~1
Xq24-q26~2
LS.~2
(theta)~1
0.00~4
DXS10~1
logarithm~2
(lod)~1
6.450.~1
DXS42,~1
theta~2
lod~1
5.087.~1
Assignment~1
erythropoietin~10
megakaryocytopoiesis,~1
(AchE)~1
megakaryocytic~2
serumless~2
Erythropoietin~2
AchE~1
426~3
megakaryocytes~7
colonies,~2
Bayesian~1
ploidy.~4
lineage.~4
beta-receptors~4
meq/d)~1
meq/d).~1
beta-receptor-stimulated~2
beta-agonist~2
4%)~7
nonsequestered~1
(46~5
5%).~6
(T4)~3
triiodothyronine~15
(T3)~9
(UCP)~1
Thyroidectomized~2
UCP~5
cold,~2
normalize~6
UCP,~1
Mere~2
corrects~6
UCP.~1
BAT.~1
5'deiodinase~1
(cDNA)~4
phospholamban~2
library.~3
deduced~8
6,080~1
6,000,~2
Phospholamban~1
domains,~1
terminus~4
(domain~2
carboxy~1
phosphorylatable~1
chloride/formate~2
recycling~3
diffusion.~4
S2~2
HCO-3~5
formate~5
(0.25-0.5~1
(JV)~1
60%;~2
JV~3
4,4'-diisothiocyanostilbene-2,2'-disulfonate.~1
Formate~1
miniature~2
microelectrodes,~2
alpha+-thalassemia~1
Melanesia.~1
Homozygotes~1
leftward,~1
4.2-kilobase,~1
4.2)~1
Bart's~2
rightward,~1
3.7-kilobase,~1
3.7).~2
nondeletion~1
-alpha~1
3.7III,~1
removes~4
1-gene~1
4.2-kilobase~2
deletes~1
2-gene,~1
2-globin~1
1-gene,~1
alpha-gene~2
[9,10(n)-3H]palmitate~1
Activities~3
control):~1
(CoA)~1
(115%),~1
acyl-CoA~9
(18%),~4
dehydrogenation~4
(49%~2
palmityl-carnitine~1
dehydrogenase-deficient~2
complemented~1
31-83%.~1
flavoprotein~1
flavoprotein:ubiquinone~2
oxidoreductase.~1
unreported~15
oxido-reductase-deficient~1
(CF).~2
CF~19
microelectrodes.~1
(-11~1
mV)~7
(-29~1
(-26~1
permselective~1
Amiloride,~1
hyperpolarization~3
epithelia.~2
aluminum-associated~1
piglets~1
parenterally,~1
d,~3
(Al,~1
(C,~1
0.001.~5
Al-treated~1
Mineralized~1
osteoblasts,~1
inhibit,~2
indirectly,~3
(CIN)~1
(koilocytosis,~1
binucleation,~1
multinucleation,~1
dyskeratosis)~1
CIN.~1
mitoses~4
CIN~4
mitoses.~2
Clinicopathological~1
caucasian~2
(stages~2
19-81~1
sectionally~1
digitiser.~1
(IEL).~1
enclosed~1
IEL~1
unwrinkled~1
601-1200~1
1201-1800~1
1800~4
IEL.~1
arteries;~2
artery:~1
Necropsy~7
myocarditis~8
housewife~2
sixteenth~3
round~8
myogenic~11
atriums~1
myofibrils~1
myoglobin.~1
Though~6
mountaineering~1
Necropsies~2
42,~5
(haematomas,~1
contusions,~6
lacerations)~1
prevented.~4
climbers~1
oedema,~3
haemorrhage,~6
catheterisation,~3
lymphadenopathy,~5
hepatosplenomegaly,~1
immunosuppression~10
pneumonias~1
teetotallers.~1
Ex-alcohol~1
beer~3
drinkers~11
users.~5
(clinical~1
recurrence)~1
Mohs~3
multifocality.~1
illustrated.~6
4.0-mm~1
Orentreich~1
minigrafts,~1
untufted~1
Syringoid~1
(SECs)~1
adnexal~11
micrographic~2
Transepithelial~1
rids~1
endogenously~4
waste~8
mycoses,~1
granulomas.~3
dermatofibrosarcoma~2
protuberans~2
10-year-old~4
37.6~1
9.8~6
(20.3~1
(18.2~3
sapphire~2
tunnels~2
sapphire.~1
neodymium~1
yttrium~1
garnet~5
(Nd-YAG)~2
circulated~2
emissions~1
walls,~5
cadaver,~2
agar-embedded,~1
emissions.~2
Dimensions~1
probe-created~1
bare~5
exit,~1
unmodified~8
(seconds~1
watts),~1
probe-formed~1
holes~4
mm2,~1
mCi~8
3%;~3
6%;~3
9%;~2
reflow."~1
Transmural~3
triphenyltetrazolium~2
histologically,~4
tesla.~1
sacrifice,~4
tesla~4
(transverse)~1
spectrometer)~1
visualized,~3
Imaged~1
tesla,~1
transmurally~1
relaxation.(ABSTRACT~1
Progressive~6
pressure-wall~2
loops.~2
reproducible.~4
dobutamine,~5
displaced,~1
intercept.~1
afterloads,~1
preload~5
load-independent~2
extrastimuli,~2
impulses/s.~2
prematurity.~3
(-34~1
16%)~1
I-85%~1
couplets~7
complexes/h,~1
tachycardia/24~1
II-abolition~1
III-85%~1
complexes/h~3
IV-85%~1
in,~1
51,~6
arrhythmia-free~1
84,~3
61,~2
39%,~5
inefficacy~4
0.015~3
all).~3
criteria.(ABSTRACT~1
amiodarone-induced~4
60).~2
amiodarone,~10
32)~7
62).~1
thyrotropin~6
(reverse~1
T3),~1
L-thyroxine~3
amiodarone:~1
micrograms/day.~3
Normalization~3
high.(ABSTRACT~2
cardiotoxicity,~1
(Adriamycin)~2
5.17~1
4.18~1
units/s~2
1.32~5
cardiotoxicity.~1
longer-term~1
Streptokinase~2
211,000~1
88,000~1
Reperfusion~1
Fibrinolytic~1
activators,~3
tissue-type~3
Alpha~5
2-antiplasmin~1
19%;~2
disappeared.~9
0.7%~7
Fibrinogen~2
Computer~7
broadly,~1
technology,~2
economy.~2
undercurrents:~1
miniaturization~1
millionfold~1
silicon,~1
technology:~1
computation,~1
databases~1
interface.~5
Microelectronics,~1
networks,~1
amenities~1
technologies~2
Future~12
computational~1
workstations~1
scene~9
Medically~1
pump,~4
myxomatous~5
Mitral~7
uneventful~9
Contrast~5
redundant~2
orifice,~2
intercepting~1
spinnaker~1
focus,~5
Colorado~3
placing~6
anticoagulation.~7
aortoventriculoplasty~2
Manouguian~1
enlarging~8
adult-sized~1
anulus,~4
anular~2
supraanular~2
late)~1
784~1
patient-months~2
warfarin,~2
sulfinpyrazone,~1
suboptimal~6
follow-up.(ABSTRACT~1
Omniscience~4
219~2
536~2
patient-years~4
97.6%~1
linearized~5
87.9~1
overall,~5
90.4~2
(aortic~8
93.3~1
freedom~15
95.7~2
3.5%,~1
100%),~4
periprosthetic~2
96.2~1
2.6%,~1
95.2~1
90.9~2
4.6%,~2
3.3%),~1
98.7~1
anticoagulant-induced~1
90.3~1
79.4~1
78.8~2
3.6%,~1
85.9~1
4.5%).~1
patient-year.~1
Existing~2
volume;~1
scar,~4
exercise:~4
72)~1
41)~2
(EDVrest)~1
0.002).(ABSTRACT~3
impulse~9
overdrive~4
Shifts~3
387~2
92)~1
negativity,~1
sinoatrial~8
extensively.~4
interrelations~2
(pre-ejection~1
period/ejection~2
pressure-large~1
(intracardiac~1
manometer~2
recordings)~1
[1~2
SE]~1
-13.4~1
3.48~1
(-7.6~1
-0.9~3
-10.4~1
-1.7~1
pre-ejection~6
(0.03~2
(-8.8~1
-17~1
3.87~1
ms).(ABSTRACT~1
Marfan's~4
NMR-derived~1
validating~2
0.95,~2
cc).~1
Intra-~1
cc),~1
practicality~1
angiography;~1
stenosis)~6
Thallium~3
electrocardiography.~3
digitalis,~3
exercise-thallium~1
Orthodromic~1
[AV]~1
node-His-Purkinje~1
His-Purkinje~10
orthodromic~11
linking~6
methodologic,~1
Exchange~3
List~1
Meal~1
Planning.~1
understood~11
rewriting~1
diabetes;~2
lists~8
high-carbohydrate,~1
high-fiber~3
menu~6
planning;~1
adding~19
symbols~1
sodium;~1
nutritive~2
starch/bread~1
fruit~4
lists;~1
foods,~7
use;~2
tool,~2
Choices,~1
"survival"~1
poster~1
format,~3
Approximate~1
listed.~2
Blank~1
counselor~1
write~2
client.~1
booklet~5
"diabetes"~1
specifically,~5
listing~2
Education~4
Group.~2
utilization,~4
provider,~3
54.~1
unadjusted~2
(vitamin~2
polyunsaturated~6
cholesterol).~1
0.60.~1
Coefficients~3
macronutrients~2
Osmolalities~1
defined-formula~1
Osmotic~2
behaviors~24
modules~4
L-amino~2
Osmolality~1
Wescor~1
osmometer~1
(model~1
5100~1
Phenyl-Free~1
kcal/oz~2
osmolalities~3
Lofenalac,~1
Phe/Tyr~1
Powder,~2
MSUD~1
Powder~3
percents~2
osmolality;~1
Formulas~2
osmolalities,~1
corn~9
highest.~4
Polycose,~1
Moducal~1
osmolalities.~1
Peritonitis,~2
(CAPD),~2
appetite,~1
supplement.~1
Anthropometric~1
15.1~4
(IBW)~2
IBW.~1
managerial~3
rotations.~2
roles,~2
responsibilities,~5
dietitians,~1
instructors~3
meetings~4
strategies,~3
effectiveness.~2
unstructured~2
rotations,~2
instructional~3
coordinator~1
participation.~1
traditional,~1
non-structured~1
gastroenterology,~2
obesity/diabetes,~1
dietitians.~1
structured,~3
non-structured,~1
dancers~11
non-dancers~1
29).~2
Three-day~1
Eating~1
Attitudes~4
(EAT).~1
Allowance~1
(RDA)~1
dance~3
(28.6%~1
10.3%,~1
nutrient,~1
13.8%~1
EAT,~1
nervosa.~4
(fasting~3
atherothrombotic~1
(ABI)~1
391~3
ABI~8
Obesity~7
mellitus,~14
(PT)~3
(POW)~1
degrees/s~3
degrees/s)~2
Isokinetic~1
dynamometer~1
extensors,~1
flexors,~3
dorsiflexors.~1
PT~13
POW~3
fallers~3
decrements.~2
Dorsiflexion~1
value).~3
dorsiflexors~1
pills~12
calendar~5
mealtime~1
blister-pak;~1
bottles.~1
over.~3
Pill~1
compliance.~14
(9.17~1
2.04)~1
blister-pak~1
mini-mental~1
overcompliance,~1
Rate~5
Blessed~2
(BDS).~1
bimodal,~1
65.~2
shorter,~1
senile-onset~1
greater)~2
presenile-onset~1
65)~4
Histories~1
.002~1
.006,~1
438~3
.005,~2
86.2%,~1
drinkers,~3
(62%)~3
Formerly~2
Medication~3
rural,~1
3,467~1
older.~14
9,955~1
nonprescription~8
respondents.~6
respondent~2
2.87,~1
Directions~1
(39.7%)~1
specialty.~4
(54.7%),~1
(11.4%),~1
(9.4%).~2
(39.6%),~1
(32.9%),~1
laxatives~1
(14.1%).~1
Frequently,~1
(physical,~1
economic),~1
reliability,~9
consideration.~5
Indexes~2
dissimilarity~1
residential~8
above,~5
disaggregate~1
life-strain~1
impairment)~2
2,146)~1
noninstitutionalized~2
whites,~8
moderating~1
(resting~2
training)~2
(21.5~3
344~4
days/week~2
handled~3
Weeks~1
homeostasis,~2
cardioinhibitory~1
vasodepressant~1
aged.~3
self-appraisal~1
460~4
pessimistically~1
aged,~5
aged's~3
categories:~8
rheumatism~1
(Db),~1
(LBW),~1
(PBF)~1
Hydrostatic~1
(M~8
62.1,~1
being:~1
Db~1
.857,~1
0.0047~1
g/ml;~1
LBW~1
.954,~1
2.08~2
PBF~1
.842,~1
2.36%,~1
commensurate~3
hypothalamic-neurohypophysial~1
releasability~1
hypervasopressinemia~1
(MMS)~2
Rating~9
(mDRS)~1
"transitional"~1
outpatients,~2
MMS~7
mDRS~3
physician-~1
advocate-rated~1
MMS,~1
mDRS,~1
American-Japanese~1
factorial~9
(PGC)~1
Morale~4
Scale.~5
PGC~2
adequately.~2
Factorial~1
invariance~1
nested~2
equivalence~1
constraints.~3
11-item~1
old-old~1
dimensions:~1
Purpose~1
(LP),~3
Acceptance~2
Goal~1
Seeking~1
(GS),~1
Meaning~2
(FM),~1
Existential~1
Vacuum~3
(EV).~1
LP~3
GS~1
FM~2
EV~2
(LC)~2
Will~1
(WM).~1
meaning~10
FM,~1
LP,~1
LC~10
well-being;~1
EV,~1
GS,~1
attest~1
wellness.~2
Maturational~1
Survey~6
(NHANES)~1
Followup~1
4,942~1
cross-~1
time-sequential~1
4,986~1
Affect,~1
subscales~3
Well-Being~2
representativeness~1
adulthood,~2
dispositions~1
desirability~3
people,~5
82,~3
MUNSH,~1
LSI-Z,~1
PGC)~1
Edwards~3
Desirability~2
Scale,~5
Marlowe-Crowne~1
happiness,~1
desirability,~2
zero-order~2
criterion/well-being~1
helplessness~7
reformulated~3
depressed/nondepressed~1
guessing~5
nonveridical~1
ability;~1
luck.~1
luck~1
ability.~8
model's~1
helplessness.~1
hypothesis;~1
personally~2
helpless~2
outcomes;~1
task).~1
interactionist~1
self-efficacy~6
correlational~1
Luria-Nebraska~1
Battery~1
(LNNB)~1
(nonalcoholics~2
alcoholics).~1
LNNB~1
nonalcoholics.~1
alcoholism.~9
chemosensory~3
pleasantness~2
hydrolysate,~2
soup~1
(BUN).~1
Elderly~3
matching.~2
BUN.~1
C3B10RF1~1
kcal/week)~2
(middle-aged~1
aged).~1
(rotorod)~1
(complex~2
maze)~1
regime.~2
locomotor~2
runwheel~1
arena.~2
framework,~1
speeded~1
pretested~1
two-choice~2
(S-R)~1
compatibility,~1
videogame~3
play,~2
posttested~1
videogames~1
S-R~1
compatibility.~3
play.~1
Gaylord~2
Marsh~2
Cerella~2
(1981)~2
Jacewicz~2
Hartley~4
(1979)~3
late-middle~1
74.~1
(1981).~1
slowing,~1
letter-number~1
"A42G").~1
auditory.~1
Gains~1
Signal~2
visual.~1
age-bias~1
adopt~8
practiced,~1
hypochondriasis,~4
later-life~2
satisfaction,~3
geropsychiatric~1
scales;~1
Mini~3
State,~2
Beck~6
(somatic~1
components),~1
State-Trait~1
Anxiety~2
Paranoia~1
Harris-Lingoes~1
subscales),~1
Hypochondriasis~2
(Institutional~1
Geriatric),~1
Satisfaction~1
Scale-Z,~1
self-rated~3
MACC-Behavioral~1
Illness~6
Independent~3
hypochondriasis~3
anxiety;~1
depression;~2
hypochondriasis;~1
interstate~2
inmigration~2
outmigration~2
determinants,~3
Perhaps~3
earnings~1
unemployment~1
people--these~1
nonelderly.~1
divergence~4
reallocation~1
(through~4
government)~1
earmarked~1
(ISH)~1
Cranial~1
falx~1
cerebri~6
leaf~1
tentorium~1
cerebelli.~1
recovered.~5
ISH~2
ours.~1
ISH.~1
"falx~1
syndrome,"~2
gather~3
paramedics~7
Utah~1
Response~10
65%,~3
willingness~2
order,~5
Physicians'~2
paramedics'~2
procedures;~1
(455/557).~1
affiliated~7
Paramedics~1
procedural~2
refers~2
nonconducted~1
impulse,~2
beat.~1
rule.~2
Practical~2
earthquake~1
earthquakes,~2
casualties~1
buildings,~1
nonstructural~1
vulnerabilities~1
retrofit~1
suggestions,~1
earthquakes.~1
ideally~4
prominences,~1
stability.~7
supplant~3
Aspiration~5
purposes,~5
Arthrocentesis~1
Heimlich~3
maneuver,~3
exception.~3
effects;~1
practicable.~1
11.2%.~1
Noncentral~1
noncentral~1
declared~1
delayed.~3
etiologies.~3
hypokalemia.~5
hypokalemic~2
Giant-cell~2
arteritis~13
large-~1
pulselessness,~1
giant-cell~2
lip,~2
strokes,~3
(steroids)~1
blindness.~4
coins~1
8-year-old~2
coin~2
radiograph.~5
Series~1
totaling~4
294~5
experts,~3
films,~4
safeguards~1
nonobvious~1
with,~9
Nitrates~1
mainstay~6
methylisocyanate~1
Bhopal,~1
India,~3
150,000~2
2,500~2
gas.~4
People~2
vicinity~6
Rescue~1
"toxic~1
conditions."~1
thousands~2
"satellite~1
hospitals"~1
kind,~2
differ,~2
standardized.~1
fields,~2
missions.~1
Leadership~1
motivating~3
think~6
leadership~5
immunoassays~4
bioassays,~1
cytolysis~3
(DRSA),~1
(killers~1
targets)~1
(counts).~1
methods'~1
robustness~2
design),~1
DRSA~4
500%~1
replot-of-plots~1
biochemistry,~3
replot-of-plot~1
antiquated~1
microcomputers.~1
variable),~1
(RSM),~1
RSM.~1
immunochemical~6
(SF)~2
IC.~2
Anti-IC~1
(VCA)~1
Epstein~1
Barr~1
(EBV),~1
preimmune~1
Fc-mediated~2
anti-VCA~5
non-rheumatoid~1
SF.~2
probing~3
idiotype/anti-idiotype~1
VCA.~1
VCA~1
Collagen-induced~1
(CIA)~1
rodents~3
CIA~1
eicosapentaenoic~1
(PG)~3
arthritis-susceptible~1
B10.RIII~1
B10.G~1
anti-type~1
CIA.~1
Females,~1
eicosanoid~1
(Ig)~1
gammopathy~3
myelomas,~1
myeloma,~2
gammopathy,~1
lymphoma)~1
anti-idiotype~2
(Id)~1
paraproteins.~3
Ig~3
Id~1
micrograms/ml;~7
0.004~3
RF.~1
Id-bearing~1
3.9%)~1
IgA.~6
paraproteins~1
IgA+~1
lacrymal~1
Id+,~1
(98%)~4
Id+.~1
transudation~1
saliva,~1
histones~3
lupus.~2
trypsin-resistant~5
histone~4
amino-~1
nucleosomes.~2
SLE,~5
anti-histone~2
trypsin-sensitive~2
histones,~1
(Pr)-induced~1
H2A,~1
H2B,~1
H2A-H2B~2
Pr-induced~4
lupus,~2
hydralazine~21
(Hy)~1
H3~2
H4.~1
Hy-induced~1
determinants.~4
autoantigen~1
nucleosomes~1
Hy~1
immunogenic~10
MAb,~1
IFN~13
anti-IFN-alpha~1
assaying~1
anti-IFN~2
IFN-mediated~1
IFN.~1
Site~3
NK-mediated~1
cytotoxicity,~2
IFN-boosted~1
125I-IFN~1
U-937~1
myelomonocytic~2
anti-depressants~3
anti-nortriptyline~1
noncompetitive~4
N-methyl-scopolamine~1
Connective~1
(CTMC)~1
WBB6F1-+/+~2
cell-deficient~2
WBB6F1-W/Wv~1
CTMC.~2
heparin-containing~1
bromodeoxyuridine,~1
i.p.~24
CTMC-like~1
characters~2
L-Arginine~2
effector~20
aconitase~2
L-arginine~15
cocultivation~5
Cytotoxic~1
macrophage-induced~1
D-Arginine~1
L-arginine-dependent~6
agmatine,~1
argininic~1
hydroxamate,~1
tosyl-L-arginine~1
L-homoarginine,~1
L-arginine.~1
NG-monomethyl-L-arginine~3
NG-monomethyl-L-arginine.~1
overridden~2
NGNG-dimethyl-L-arginine~1
NGN1G-dimethyl-L-arginine~1
guanidino~1
Guanidine~1
ribosylation~1
L-arginine,~1
dependency~6
lipopolysaccharide.~2
arginase,~1
competing~4
microorganisms.~4
oxidants,~2
burst.~3
unprimed~3
heat-killed~2
yeast-to-macrophage~1
ratios.~8
spheres),~1
unopsonized~1
zymosan,~1
Ingestion~3
opsonized~10
circumvented~2
antigen-1~1
(EBNA-1)~1
glycine-alanine~3
antigenic.~1
EBNA-1~5
immunoblotting.~5
immunoblots~6
EBNA-1.~1
1000-fold~2
Peptides~1
anti-EBNA-1~1
anti-EBNA-1,~1
coat~10
conformations~3
epitope(s)~2
sex-limited~1
(Slp),~1
(C4),~1
all;~1
wild-derived~1
H-2w7,~1
H-2w16,~1
H-2w19~1
haplotype,~3
Slp~4
C4.~1
testosterone-independent~2
Slp,~1
C3H.W7~3
(H-2w7)~1
cosmid~2
C4-related~2
(C4w7)~1
C4-specific~1
Slp-specific~2
(Slpw7a,~1
Slpw7b,~1
Slpw7c,~2
Slpw7d)~2
Restriction~1
sequencing~1
5'-flanking~2
(H-2d)~1
B10.BR~1
(H-2k).~1
(Slpw7b,~1
C4-Slp~2
5'-region~1
3'-region~1
dinitrochlorobenzene~4
4-ethoxymethylene-2-phenyloxazolone~1
hyposensitization~4
unresponsiveness~6
hapten-specific.~1
painted~2
hapten-specific~3
hapten~1
hyporesponsiveness~4
unresponsiveness.~1
dissolves~2
week).~3
microcarriers~1
(cytodex~1
trypsinization~2
cultivated~1
96-well~1
inoculation.~2
7.75~1
10(4)/well,~2
3.6-fold~2
1.69~1
10(4)/well~1
2.1-fold,~1
hemocytometer.~1
(on~2
inoculation)~2
inoculation,~4
keratohyaline-like~1
loose.~1
supposed~7
fibronectin.~1
Loose~2
harvest~1
biochemistry.~5
retinol-~1
acid-binding~2
(CRBP~1
CRABP)~1
foreskin~4
Ligand~1
trans-[3H]retinol~1
trans-[11-3H]retinoic~1
cytosols~3
CRABP~2
CRBP~3
(60.9~1
7.3~9
(61.8~1
2.5,~4
CRBP.~1
(LIs)~1
periderm~2
8-11%~1
7.5-9%.~1
16-20%,~1
epidermis.~4
thymidine,~1
(7%).~8
(EGA)~1
EGA~1
EGA.~1
rodents.~2
label-retaining~1
(LRCs)~1
Embryonic~1
LRCs~3
suprabasal~2
cystine-rich~1
Tris-HCl~1
7.3.~1
preparative~1
focusing.~1
spinosum,~1
granulosum,~1
lysine,~1
glycine,~2
residues.~6
16,000.~1
cyclosporin~7
one-tenth~2
Cyclosporin~3
entactin~4
(Matrix),~1
M1536-B3~1
Matrix~10
plastic,~5
(137%~1
control)~6
(158%~1
160%~1
control),~3
anti-entactin~3
anti-laminin~5
Matrix.~2
laminin.~1
Matrix,~2
substrata.~1
entactin,~2
(SCC-25)~1
faster-growing~1
L1210~9
leukemia,~4
S91-A~1
SCC-25~1
enzyme--methotrexate~1
(MTX),~2
3,4-dihydroxybenzylamine~1
(3,4-DHBA)--acted~1
dUMP.~1
dUMP~2
synthase.~1
5-Fluorodeoxyuridine~1
(FUDR),~1
synthase,~1
3,4-DHBA,~1
FUDR.~1
fundamentally~1
epidermally~1
Assay~4
Hair~7
benzo[a]pyrene~1
(BP),~3
benzo[a]pyrene-7,8-diol~1
(BP~1
7,8-diol),~1
enzyme-mediated~2
[3H]-BP~1
coal~4
tar~1
(CCT)-containing~1
shampoo,~1
polycyclic~3
(PAHs),~1
shampooing~1
CCT-containing~2
shampoo.~2
P-450-dependent~2
aryl~8
(AHH)~1
0.6-17.6~1
fmol~1
metabolites/h/hair~1
shampoo~1
AHH~3
(50-148%)~1
7,8-diol,~1
Benzo[a]pyrene-7,8-diol~1
Clotrimazole,~1
carcinogenicity~1
7,8-diol~1
follicles.~7
imidazole,~1
PAHs~1
carcinogen-activating~1
imidazole~4
anticarcinogens~1
Phenol~1
catechol~3
melanocytotoxic~1
4-S-cysteaminylphenol~1
(4-S-CAP)~1
4-S-cysteinylphenol~1
(4-S-CP),~1
antimelanoma~2
hydroquinone~1
(HQ)~1
Topical~5
4-S-CAP~3
4-S-Cysteinylphenol~1
depigmenting~2
potency.~5
2-S-Cysteinylhydroquinone,~1
HQ,~1
Depigmentation~1
from:~1
functioning~31
melanocytes;~1
keratinocytes;~1
keratinocytes,~5
Irradiation~2
keratinocyte~4
Glucose-6-phosphate~2
UVA.~2
(193~1
wavelength,~2
ns~1
pulsewidth)~1
(3H2O)~1
ablates~1
micrometer~5
3H2O~1
mJ/cm2~3
124-fold~1
tape-stripping~1
170-480~1
45-fold~2
re-epithelization~1
cationized~1
heparitinase-sensitive,~1
built~2
periodontal~3
Periodontal~1
tying~2
silk~3
ligatures~2
molars~2
Sterile~4
transaortic~5
extracted.~1
extractions.~1
29)~2
spp.~5
aureus).~1
teeth~1
periodontium~1
extracted,~1
plague~5
septicemic.~1
plague.~1
(fever,~2
malaise,~8
symptoms)~1
(tachycardia,~1
tachypnea,~2
hypotension)~1
persons,~7
Deaths~4
septicemia,~1
(HBV)~9
(FH)~1
HBV~22
FH,~2
multiplication~2
AH.~1
FH~1
multimeric~3
FH)~1
infectivity~3
(HDV)~1
chimpanzees.~3
HDV~3
inoculum~10
10(11)~1
(CID).~1
CID.~1
HBV-infected~1
chimpanzees~3
HDV-positive~1
superinfected;~1
HDV-infected~1
aminotransferase~10
calciuric,~1
phosphaturic,~1
magnesiuric~1
NH4Cl~1
pair-fed~12
7.28.~1
calciuria,~1
magnesiuria,~1
phosphaturia.~1
Acidification~1
proton-translocating~1
triphosphatase~5
(ATPase),~1
aldosterone.~3
microassay,~1
N-ethylmaleimide~1
(NEM)-sensitive~1
gm/day~1
(259~2
pmol/mm/hr,~2
(274~1
(255~1
pmol/mm/hr).~1
mineralocorticoids~1
NEM-sensitive~1
acidification,~1
reversibility,~1
weanling~6
aluminum-treated~3
labeling)~1
endosteal~2
periosteal~5
aluminum,~2
humans;~2
peritonitis,~7
osteomalacia.(ABSTRACT~1
(CA++)~1
PTH-stimulated~3
parathyroidectomized~1
(PTX)~1
(1.27~1
mmol/L;~1
(543~1
395~6
micrograms/gm;~1
mg/dl;~4
p-aminohippurate~2
PTX~3
2.12~2
mumol/mg~2
[pretreatment]~1
16.86~1
2.07~1
day;~2
PTH-mediated~1
both.(ABSTRACT~2
propeptide~1
(P-III-P)~1
P-III-P~8
(CAH)~1
Coded~1
CAH~3
radioimmunoassays,~1
regard,~3
(TBT)~1
steatorrhea.~1
co-exist~1
alcoholic,~2
(alcoholic~1
(steatosis)~1
Inasmuch~1
alcohol-induced~4
extract,~3
steatorrhea~2
(CMC)~1
(ADR),~2
dactinomycin~1
(ACT),~1
plicamycin~1
(MIT),~1
35-labeled~1
Tris~2
Triton~9
X-100,~1
Aliquots~1
(SDS-PAGE).~3
dimension.~2
autoradiographed.~1
ADR,~3
ACT,~2
CMC~5
Autoradiographs~1
isoforms~4
ACT.~1
ACT~5
alpha-actin~1
gamma.~4
Synthesis~3
ADR.~1
ADR~5
pressors.~1
hyponatremia~6
hyponatremic~5
(127~2
mEq/L)~5
dialyzing~1
low-sodium~1
normonatremic~7
(150~7
(hyponatremic~3
2284~1
2306~1
significant),~2
preultrafiltration~1
24.6~2
(24.7~1
(22.9~1
ultrafiltration,~1
1871~1
1821~1
267,~1
ensues~2
weight.(ABSTRACT~1
Agency)~1
14.0~3
(Hybritech)~1
(Wellcome~1
Co.)~1
Hybritech~1
Wellcome~1
heparin-like~1
(ATIII)~2
concentrate~6
concentrate,~2
sulfate--gel~1
125-labeled~1
three-exponential~1
noticeably~2
47.5~1
62.3~3
Assuming~3
supposition~1
ototoxicity~1
microdissection~2
cochlea~5
artefactual~1
tinnitus,~6
temporarily.~1
refractory,~1
disturbing,~1
vestibulo-ocular~2
electronystagmography~2
lidocaine:~1
pendular~4
unaffected;~1
suppressed;~1
reversed;~1
chair~1
reversed.~4
vestibulo-spinal~1
stepping~1
craniocorpography.~1
lend~4
Atresia~1
trans-nasal~2
trans-palatal~1
Habitual,~1
Apnoea~1
uvulo-palato-pharyngo-plasty~1
(UPPP),~1
snoring.~1
snoring,~1
altogether~2
photography,~1
ENT~5
Ljubljana~1
Olympus~3
OM-1~1
OME-J~1
T-32~1
short-lived.~1
safer.~1
devastating~4
Ivalon,~1
polyvinyl~3
foam.~1
indications,~7
Close~7
early.~1
button-sized~1
batteries~1
batteries.~2
Urgent~1
dangerous~10
mid-line~1
embryology~4
'u'~1
cosmetically.~1
fronto-ethmoidal~1
craniofacial~6
retrospective,~2
Bronchitis~1
bronchitis.~2
unresolved~3
Cefonicid~1
(Monocid)~1
ceftriaxone~3
(Rocephin)~1
Sufficient~2
pyelonephritis,~2
Cefonicid,~1
erythromycin,~3
community-acquired~5
pneumonias.~1
Ceftriaxone~1
gonococcal~2
audit.~2
accomplishing~3
Downstate~2
Brooklyn,~2
efforts,~1
groups)~2
enrollment.~1
Moonlighting~2
little-studied~2
moonlighting~4
directors,~1
nonmilitary~1
directors~6
third-year~6
moonlighting.~2
spend~5
rooms,~1
approval~6
extracurricular~1
privileges~2
denominator~2
denominator-based~1
market.~1
neurofilaments~2
(RT97,~1
BF10~2
147),~1
(RT97~1
BF10),~1
phosphorylated~7
neurofilament~1
recognise~2
structurally~13
tangles.~1
angiopathy~8
ageing.~1
82%.~3
non-demented,~1
Disruptions~1
overestimation~7
pre-injury~1
associative~2
agnosia~1
spatial,~1
visual,~1
perceptual~4
recognising~2
objects.~2
disconnection~3
Behavioural~1
(MRI~1
scan)~1
demyelination~11
cryptic~3
telangiectasia,~1
haemorrhage.~2
emphasise~2
telangiectasia~4
non-demented~2
visuo-spatial~1
forecast,~1
ideomotor~1
apraxia.~2
Imitation~1
visuoperceptive~1
abilities.~2
imitation~1
copying~1
off~27
Nm~3
added,~4
levodopa~7
rating.~2
(VEPs)~1
electroretinogram~3
(PERG)~2
P100~2
interocular~1
extra~6
stimulated.~1
musculo-skeletal~1
dorsolumbar~3
nosological~1
myositis.~1
primitive~12
macroadenoma~1
suprasellar~5
craniopharyngioma.~1
8180~1
mU/l.~1
hyperprolactinaemia~2
mU/l~2
craniopharyngioma~2
prolactinoma.~3
oligoclonal~9
banding~8
unconcentrated~2
beta-interferon~1
intrathecally~5
"fingerprint"~1
inflammatory-angiopathic~4
multiplex.~1
75.8%~1
Prednisone~3
aetiology.~3
(SP)~7
neocortex.~1
Senile~3
microtubule-associated~1
dendrites~3
SP.~3
fascicular~1
pyramidal~12
dendrites.~1
interfascicular~1
architectural~2
diaphorase~3
(NADPH-d),~1
striatum~11
(HD).~1
striatal~4
histochemically~5
NADPH-d~2
AChE~6
Y-like~1
end-product~1
aspiny~1
interneurons.~1
NADPH-d,~1
coexisted~4
putamen~5
accumbens~1
striatum.~6
AChE-rich~1
intact;~2
Topographic~1
(AD).~1
AD,~6
viz.,~1
Rose's~7
subiculum~3
(46%).~1
tangle-bearing~1
(endplate,~1
field)~1
(Rose's~1
field,~14
subiculum)~1
accentuation~1
silver-stained~1
perikarya~2
normal-looking~2
chromatolysis-like~1
intimate~7
pathomorphological~1
shrunken~3
axons,~6
branchings~1
tapering~5
portion.~5
Aggregates~3
lipofuscin~4
perikaryal~2
arose.~1
argentophilic~1
separates~4
merges~1
prominently~1
spheroids~1
chromatolytic~1
implicate~8
soma~1
Immunohistochemical~10
filament~8
arachnoidal~1
meninges),~1
hemangiopericytoma,~1
pericyte.~1
Arachnoid~1
granulations~1
similarly:~1
vimentin~2
keratin.~2
pericytes~1
"hemangiopericytoma"~1
pericytic~2
hemangiopericytic~1
(HM)~1
immunostaining,~1
(TEM),~1
VIII-related~2
anti-glial~1
fibrillary~3
(GFAP)~1
anti-S-100~1
TEM~5
membrane-like~4
(BMLM),~1
(IF)~2
rough-surfaced~1
BMLM,~1
interdigitation~1
punctate~6
SEM~9
shell-like~1
reticular~11
branched~1
ellipsoidal-~1
carrot-shaped~1
pseudolumens~1
whorls.~1
nucleolar~1
hillocks.~1
HM~1
mesenchyme-related~1
meninges;~1
histogenesis.~1
PNU~1
(N-3-pyridylmethyl-N'-p-nitrophenylurea;~1
Vacor)~1
PNU.~3
terminals~11
hindfoot~1
twigs,~1
thigh.~2
mid-thigh,~1
(27%~2
Autoradiography~2
hindfeet.~1
Correcting~1
photons~2
nongeometric~1
(0.15/cm)~1
chambers.~5
flow-directed~2
biplane~10
fluoroscopy.~1
mu,~1
0.12/cm~2
blood-pressure~4
cuffs~4
tourniquets,~1
artifact.~4
tourniquet~7
blood-pool~2
skeletal-phase~1
hands,~3
wrists,~2
forearms,~2
elapse~1
Asymmetry~1
53-yr-old~1
Thallium-technetium~1
arteriography,~6
34-yr-old~1
delineating~7
transposed~2
A-V~3
appendages.~2
appendices~2
testis.~2
testicle.~1
torsions~1
serves,~1
sequentially,~1
torsed~1
appendage.~2
hexakis(isonitrile)technetium(I)~1
[99mTc]carbomethoxyisopropyl~1
isonitrile~1
(CPI)~1
[99mTc]CPI~3
10-15~6
Planar~1
76.1~1
(s.d.)%~1
planar~5
reinjection~1
CPI~3
injection).~1
reinjection,~1
Technetium-99m~1
Radioimmunolocalization~2
(MoAb),~2
ZME-018,~1
single.~1
MoAb~5
111In~13
chelating~3
DPTA.~1
Total-body~1
liver/spleen,~1
bowel,~5
testes,~7
axillae~1
mg/5~2
111In-MoAb~1
(19%).~6
anti-murine~1
ZME-018~2
12.4%~1
anti-melanoma~1
(Fab)~3
(neck,~1
groin)~1
co-administered.~1
nondiseased~1
tumored~2
removed,~19
directed.~3
intranodal~6
T101~1
(s.c.)~1
web~4
toes~8
Computer-assisted~1
inguinal-femoral~1
Contrasting~2
efficient,~2
Misonidazole~1
congeners~1
77Br,~1
75Br,~1
18F,~1
[82Br]-4-bromomisonidazole,~1
[3H]-4-bromomisonidazole,~1
[3H]fluoromisonidazole~1
[3H]misonidazole~4
radiopharmaceuticals~3
lipophilicity~1
brominated~1
misonidazole~3
background,~4
incompatible~4
Hydrogen-3-fluoromisonidazole~1
tumor-to-blood~1
fluorine~1
bromine~1
ring.~8
[18F]~1
fluoromisonidazole~1
chelate~1
benzyl-EDTA~1
benzyl-TETA~1
111In,~1
57Co,~1
67Cu~3
111In-benzyl-EDTA-antibody~1
111In-DTPA-antibody.~1
Cobalt-57~1
antibody;~1
67Cu-benzyl-TETA-antibody.~1
radiometal~2
excretion)~1
(trial~2
beef-based,~1
soy-based~1
swine~6
diets.~13
per-kilocalorie~1
soy~13
(0.09%~1
0%)~1
(40-50%~1
8-9%)~1
Dried~1
Beef-~1
soy-fed~5
conventionally~7
pigs;~1
beef-fed~3
HDL-to-LDL~1
Neutral~1
(soy,~2
conventional)~2
(soy~2
conventional),~1
beef)~2
(conventional~1
soy,~1
Weanling~3
nonfat~1
oleic,~1
linoleic,~1
linolenic~8
erucic~3
phosphatidylcholine,~3
phosphatidylethanolamine~1
cardiolipin~1
C16:0~1
sn-1~1
sn-2~2
C20:1~1
C22:1~1
palmitylcarnitine~3
omega~6
C20:4~1
per-gram-wet-weight~1
palmitic~3
lauric~1
palmitate~2
2.85~2
kcal/g~2
3.99~1
[0-5%~1
(BW)/d]~1
fingerling~1
catfish~2
(Ictalurus~1
punctatus)~1
aquaria~1
8.75~3
protein/(kg~6
99.75~2
kcal~7
energy/(kg~6
d).~1
Regressing~1
15.08~1
Net~4
0.93)~3
17.00~2
17.33~1
lactation~18
Milk~3
Thoroughbred~1
mares~2
mares.~1
solids,~1
ash,~2
zinc.~4
mare.~1
ash~6
0.61%~1
lactation,~3
0.45%~5
0.38%~1
0.32%~1
1345,~1
943~1
wk;~2
1070,~1
659~1
831,~1
574~2
700,~1
Copper~6
3.1,~1
0.55~14
Nonpregnant~1
65Zn;~1
equilibration,~2
mated~1
Calculations~2
zinc-deficient~6
zinc-calcium-deficient~3
organogenesis.~2
accrued~2
(0.4%-1.2%)~2
two-factor~1
(T5)~1
(T10)~1
(T15)~1
slaughtered,~2
(F)~4
(MT3)~1
(MT4)~1
metatarsal~2
(force,~1
modulus~2
elasticity),~1
(ASHW),~1
(PASH)~1
absorptiometry.~1
best-fit~1
ASHW~1
MT3~2
0.41),~1
0.29)~2
PASH~1
0.17)~1
withstood~3
0.90),~1
BMC,~1
strength.~12
digestive,~1
indispensable~3
homologues~2
L-Tryptophan~1
(Trp)~1
tryptophol~1
(Tpl)~1
L-Histidine~1
(His)~1
(Imd)~1
Imd~1
(His,~1
31;~1
Imd,~2
937~2
pmol/min~3
Proline~1
(Pro)~1
pyroglutamate~1
(Pyr)~1
(Pro,~1
559~1
19;~1
Pyr,~1
352~3
L-Cysteine~1
N-acetyl-L-cysteine~1
(508~1
non-amino~1
nonmediated~2
homologues.~1
element.~1
Fe-deficient~7
pups~23
triacylglycerol~5
(TG)~6
pups.~7
Carnitine~3
ketogenesis~3
(KG),~1
KG~4
15-d-old~1
Litters~1
(-Fe)~1
Fe-adequate~1
(+Fe)~1
L-carnitine~2
(beta-hydroxybutyrate~1
acetoacetate)~1
-FeW~3
+FeW~1
-Fe~1
+Fe~3
TG~11
Iron-adequate~1
Fe~10
(d)~1
DL-carnitine~3
(Carn)~1
treatments:~1
CcCarn,~1
DdCarn,~1
Cc,~1
Cd,~2
Dc,~1
Dd.~1
Males~8
30-60%~1
dams.~3
49-d-old~1
ketoacids~2
(basal)~1
(45-58%)~1
(7-12%).~1
extraction;~1
great;~1
ketomethylvalerate~1
(KMV)~1
ketoisovalerate~1
(KIV)~1
ketoisocaproate~1
(KIC)~2
intraportal~2
KIV~1
KIC~3
KMV~1
utilization;~1
interorgan~1
ileostomy~13
meat,~5
rice~11
flour,~1
isolate,~1
2-d~2
Ileostomy~2
deep-frozen.~1
phytic~1
contents,~6
digestibility~5
fed.~4
meat~7
ameliorated~2
starch,~5
copper-deficient~10
64Cu.~1
64Cu~6
loop.~1
steers~2
80:20~1
concentrate:roughage~2
kg.~9
45:55~1
390~3
461~1
Digestible~1
Digestibility~3
0.0054~1
Mcal~1
life-prolonging~1
CD2F1~1
12-h~6
lighting~2
darkness;~1
light;~2
darkness.~1
10th-decile~1
Telemetered~1
rhythms.~2
lipotropic~2
0.1%,~1
0.4%,~2
0.8%,~1
1.2%,~2
(wt/wt)~1
DL-carnitine.~2
carnitine,~2
carnitine.~1
saponins,~1
triterpenoid~1
glycosides~1
steroidal~3
glycoside,~1
Gypsophylla~2
saponin,~2
carrier-mediated~4
galactose~7
L-isomer~1
4000,~1
saponin~3
sacs,~1
glucose-stimulated~1
Saponaria~1
alpha-tomatine~1
soya~1
saponins~2
impermeable.~1
Observer~2
physicians)~2
74-89%~1
conversely,~2
11-26%~1
(55%~5
observations)~2
self-consistent~1
(kappa~4
0.20-0.49).~1
examiner's~2
Dichotomous~1
(wheezes,~1
crackles,~1
rubs)~1
0.30-0.70)~1
(tympany,~1
dullness,~2
intensity),~1
0.16-0.43.~1
dichotomous~1
reliance;~1
disconcertingly~1
intraobserver~9
5-point~2
"very~2
life"~3
"possible~1
life."~1
scenarios~1
1.40~4
"definitely~2
yes"~1
no."~1
13,979~1
46-month~1
763~1
hyponatremia,~3
757~3
Hyponatremic~1
in-~1
Hyponatremia~4
confronted.~1
stereotypical~2
texts.~2
assertion,~1
member,~3
preselected~3
History-based~1
dyspneic~1
preceptor~4
encounters.~1
six-month~16
Continuing~2
non-feedback~2
item,~1
satisfaction.~3
disastrous~3
infirmity,~1
invisible~2
Disability~2
frustration~3
under-utilized.~1
suggestions:~1
Well-trained~1
audiologists~1
supportive.~1
varieties~4
steadily.~1
desperately.~1
(HB-PU)~1
thrombogenic~1
(PVC).~1
(power~2
80%)~2
(UA)~1
UA~2
HB-PU~1
PVC~3
chronology~1
(superoxide~1
dismutase,~3
disaturated~2
("surfactant")~1
species:~1
gestation,~9
150%~1
200%.~1
(like~1
"preparation~1
birth,"~1
oxygen-rich~1
nebulized~5
metaproterenol~4
(birth~2
1060~2
nebulization~2
tcPO2,~1
tcPCO2.~1
contradictory~1
recurrent.~1
Cure~4
Single-dose~1
Cyproheptadine~2
(Cp),~1
appetite-stimulating~1
Cp~2
(HV)~2
cm/yr~1
GH-Cp~2
(WV)~1
kg/yr~1
8-month~1
HV~9
WV~1
0.64,~4
(biw)~1
(tiw)~1
(0.24~2
hGH/kg~1
weight/wk~1
hypopituitarism.~3
tiw~5
biw~2
inconvenience~4
responsive,~1
schedules.~2
(CMV)~4
middle-income~1
13.6%~2
seroconvert~1
seronegative~8
seroconversion~5
breast-feeding.~1
CMV~13
seroimmune~1
Attacks~2
aphthous~2
stomatitis,~2
pharyngitis,~3
6-week~3
neutropenia.~3
isotypes,~1
hypogammaglobulinemia~4
prodrome~2
lgA~1
sinopulmonary~1
gammaglobulin.~1
misnomer,~1
accepted,~3
retrospect.~1
suggested,~4
"with~2
recovery"~1
dysgammaglobulinemia,"~1
isovaleryl-coenzyme~1
L-(2H3-methyl)-leucine~1
Metabolites~2
counterparts~3
leucine.~2
endonucleases~1
phenylalanine~17
allele.~5
phenylketonuria.~3
haplotypes.~2
hyperphenylalaninemic~1
genotypes.~1
phenylketonuria~7
unambiguous~2
Rapp-Hodgkin~1
craniofacies,~1
nails,~2
reminiscent~3
imperfecta,~1
proptosis~2
craniosynostosis,~1
demineralization~2
birthday.~2
imperfecta.~1
craniosynostosis~1
unimpaired~2
pathogenesis;~1
teratogenicity~3
offspring:~1
only;~3
polydrug~1
abusers;~1
340~3
free.~3
ethnicity.~1
Gravidity~1
stillbirth~3
6.89,~1
stillbirths~4
abruptio~2
placentae.~1
7.07,~1
placentae,~1
(HSV)~3
HSV~6
(12),~2
chorioretinitis~2
(eight),~1
(seven),~2
hydranencephaly~1
(five),~3
microphthalmia~1
(two).~3
case;~1
HSV-2.~3
blind.~3
baths~2
pre-exposed~1
adrenoceptors.~10
dose-relaxation~1
beating~6
atria:~1
(ISO)~3
fenoterol~3
(FE)~1
salbutamol~8
trachea:~1
ISO~8
FE~2
NE.~3
practolol~2
butoxamine~2
butoxamine,~1
respective--log~1
KB~1
beta-1~5
(LCX)~1
pentobarbital-anesthetized,~1
vagotomized~3
adrenoceptor~30
LCX~8
alpha-2~47
idazoxan~7
alpha-1~27
spinally~1
transectioned~1
slowly.~1
Idazoxan~1
prazosin,~4
postjunctional~7
adrenoceptors~16
stimulation.(ABSTRACT~1
alpha-2-adrenoceptors~1
Rhesus~4
(PE)~1
methoxamine~3
(M),~1
B-HT~6
920,~5
(hexamethonium),~1
(propranolol)~1
(atropine~1
bromide)~1
dog,~7
microgram/kg~5
i.v.),~6
PE~1
(NE,~4
mmHg;~1
PE,~4
Hg/l/min;~3
23.1~2
18.2~2
Hg/l/min).~1
-54~1
8%;~4
-43~4
-49~1
-56~1
8%)~1
-66~1
11%;~4
-52~1
-60~2
13%;~1
-57~1
alpha-adrenoceptor~1
agonists.~3
monkeys,~6
adrenoceptor-mediated~2
celiprolol~4
S49~8
[3H]CGP-12177,~1
[125I]iodopindolol,~1
sequestered~1
Pindolol~1
(WT)~1
WT~2
(down~1
regulation).~1
[cyc-~1
(variant~2
Ns~4
UNC~1
receptors)]~1
(Ns)~1
cells.(ABSTRACT~1
Dextromethorphan~3
(DM)~1
levomethorphan,~1
levorphanol,~3
codeine~2
loperamide.~1
DM~7
DM,~4
codeine,~2
naloxone.~6
(8,~3
I-isomer~1
levomethorphan~6
KCl.~1
dextrorphan~1
KCl-induced~1
(pA2~3
5.3),~1
5.3)~1
loperamide~2
6.6).~2
Codeine~1
levorphanol~1
calcium-induced~3
calmodulin-dependent~2
(IC50~3
trifluoperazine~3
calmidazolium~2
antagonists)~1
nonopiate~2
antagonizes~2
"stabilizing"~1
N-tyrosinated~1
[e.g.,~1
Tyr-Pro-Leu-Gly-NH2~1
(N-Tyr-MIF-1)~1
enkephalins]~1
intraventricularly~2
nM/mouse~1
intraventricularly)~1
Tyr-MIF-1~1
consistently,~1
nM/mouse)~1
uncompetitive~1
modulation,~2
carrier-ligand~1
D-leucine~1
nM/mouse,~1
nM/mouse.~1
arginine,~1
methionine,~3
2,3,7,8-Tetrachlorodibenzo-p-dioxin~1
(TCDD),~1
contaminant~1
Agent~1
Orange,~1
[3H]TCDD-labeled~1
kinetics,~4
efficient.~1
TCDD~4
Alpha-1~2
[125I]labeled~1
BE~1
2254~1
(125IBE)~1
125IBE~4
pM~1
Antagonists~1
competitively,~1
ARC~7
methoxamine.~2
inactivate~2
(clone~1
N1E-115),~1
(PGE1)-mediated~1
[3H]PGE1~4
PGE1-mediated~1
(10-13%)~1
PGE1-~1
forskolin-stimulated~1
5'-guanylimidodiphosphate~1
155%~1
Kd.~3
N1E-115~1
PGE1-stimulated~1
discrete-trial~1
paradigm.~2
Stimulus~1
caffeine)~1
Novel~1
caffeine.~1
methylxanthine~3
derivatives,~3
1,7-dimethylxanthine,~1
3-isobutyl-l-methylxanthine,~1
8-phenyltheophylline~1
8-chlorotheophylline,~1
nonxanthine~1
apomorphine,~2
occasioned~1
saline-appropriate~1
lever,~1
d-amphetamine~3
ephedrine~5
partially,~3
methylphenidate~2
completely,~3
2-(2-chloro-5-trifluoromethylphenylimino)imidazolidine~1
discriminative~8
dose-dependently~2
(phentolamine,~2
yohimbine)~1
(diazepam,~1
analogs,~2
R-(-)-N6-(2-phenylisopropyl)adenosine,~1
cyclohexyladenosine,~1
2-chloroadenosine).~1
surmounted~3
caffeine-like~1
2-(2-chloro-5-trifluoromethylphenylimino)imidazolidine.~1
phenylisopropyladenosine~1
(PIA)~1
PIA~3
(FFA)~4
(-)-PIA~6
(+)-PIA~1
concentrations;~2
also,~4
8-(p-sulfophenyl)theophylline.~1
WR1339~1
hypertriglyceridemia~4
stretozotocin-induced~1
hypertriglyceridemic~1
electrophysiologic,~4
SCH~6
19927,~5
R,R-isomer~1
labetalol,~1
urethane-anesthetized~2
(decreased~3
times),~1
rate-corrected~2
atrial,~4
19927~1
dosages,~3
depress~8
(AAG)~2
[3H]~6
[14C]butanol~1
(0-7.5%)~1
AAG~11
(0-3.0~1
exchangeable~10
severalfold~1
8.6~11
1.1,~5
barrier,~7
AAG-bound~2
capillaries.(ABSTRACT~1
Intraventricular~3
bradycardia.~6
HA~7
pyridylethylamine,~1
impromidine,~1
tachyphylaxis.~3
HA,~1
impromidine~2
pyridylethylamine~2
HA-N-methyltransferase~1
SKF-91488~1
(homodimaprit)~1
AVP-induced~3
(V1)~2
[d(CH2)5~3
1Tyr(Me)2]AVP~1
(SK&F~3
100273)~1
(KB~2
2.23~1
V1/V2~1
1D-Tyr(Et)2Val4desGly9]AVP~1
101926),~1
AVP-mediated~1
contraction;~1
nonparallel~1
(V2)~1
1D-Ile2Val4]AVP~1
101485)~1
100-fold~3
1.37~2
methionine-enkephalin~2
(met-enkephalin)~1
(5-80~3
met-enkephalin~11
Electrically~1
CoCl2~1
CaCl2~2
(-)-naloxone~1
(+)-naloxone~1
antiluminal~1
(AL)~1
0.0.~1
0.1.~1
nonfiltering~1
Papaverine~2
cis~1
sec)~6
[3H]adenosine~4
AL~5
trans~1
[14C]~2
(HSA).~1
15.2~4
0.567~1
0.009~1
colorimetric~2
immunologically.~1
delipidized~3
HSA~9
Kd/N~1
AAG,~1
proteins.(ABSTRACT~2
cooling-induced~2
cooling.~1
Rings~2
suspended~14
gassed~2
O2-5%~2
CO2.~3
Cooling~2
37-24~1
purinergic-receptor~1
(alpha,beta-methylene~1
ATP).~1
evoke~5
6-hydroxydopamine.~1
alpha,beta-Methylene~1
concentration-effect~5
(UK~1
14,304)~1
ATP.~5
purinergic~1
(4-28~1
potentiated.~4
potassium-~1
nifedipine.~7
depolarization-induced~1
potentiation~17
themselves,~3
norepinephrine-induced~2
mu-receptors~2
fully.~3
sympathoadrenal~5
(PVN)~1
mu-selective~1
enkephalin~1
D-Ala2-NMe-Phe4-Gly(ol)5enkephalin~1
(DAGO),~1
PVN~7
picomolar~1
DAGO~4
(0.01-0.3~1
nmol)~2
Tachycardia~1
nmol).~1
mu-receptor~1
adreno-medullary~1
microinjections~1
stress-induced~12
nitrate.~1
Trans-2,5-bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran~1
(L652,~1
731),~1
(PAF)~3
(Hwang~1
J.~9
Biol.~1
Chem.~1
260:~1
15639-15645,~1
1985),~2
potently~4
PAF-induced~9
Intravenously~2
p.o.~14
L-652,731~7
extravasation~11
ED50~21
Inhibitions~1
5-mg/kg~1
20-mg/kg~1
leukopenia~5
inhibitions~1
antagonists/inhibitors~1
cyclooxygenase.~1
(PBZ)~1
alkylate~1
PBZ~2
PBZ-resistant~2
"extraceptors"~1
PBZ.~1
endothelium.~6
alkylation~2
benextramine~3
dibenamine).~1
adrenoceptor,~1
gamma-adrenoceptor.~1
extraceptor~1
NE,~2
prazosin.(ABSTRACT~1
backcross~2
nicotine-induced~4
Nicotine~7
C3H~3
DBA~1
F1,~1
(F1~1
DBA)~1
Nicotine-induced~1
infusing~11
mg/kg/min~1
clonic~1
seizure.~3
alpha-bungarotoxin~1
(BTX)~1
regions:~1
hippocampus.~5
BTX~3
Genetic~7
convulsant~2
Ouabain~1
one-to-one~3
hr)-1~1
effects:~2
Na+,K+-pump~1
furosemide-sensitive,~1
Na+,K+-cotransport~2
quinidine-sensitive,~1
K+-efflux.~1
Ca+-dependent,~2
K+-channels~1
cytosolic-free~1
Ca+~1
Canrenone,~1
digitalisreceptor~1
Na+,K+-pump.~1
canrenone~4
concentrations)~1
depletion;~1
counterbalances~2
depletion)~1
reverses~5
K+-channels.~1
two-step~2
glucuronidation~7
UDP-glucuronic~3
UDP-glucose~2
tripled~1
4-methylpyrazole~1
Acetaldehyde~1
(250-50~1
morphine-3-glucuronide~2
added)~1
(UDP-glucuronic~1
NADH/NAD~1
fascicularis)~1
(10-15~1
(25-30~1
24-hr~4
Caffeine~3
parturition,~3
alpha-bromoisovalerylurea~2
(BIU)~2
racemic~4
BIU~15
gamma-glutamyltranspeptidase~1
(presence~2
moiety),~2
(isovaleryl~1
glutathionyl~1
moieties)~1
atom~1
bombardment~1
pattern),~2
BIU.~1
diastereomers.~1
diastereomeric~8
diastereomers~1
mercapturates.~3
mercapturic~1
Electrochemical~1
thioethers~1
paper.~1
hypnotic~3
(bile)~1
mercapturates~2
(urine).~1
conjugation:~1
[14C]BIU~1
rate-limitation~1
flow-limited~1
low:~3
0.23),~1
plasma)~3
22-270~1
mumol/kg).~1
Water~4
solubility~8
(almost~1
conjugates)~1
(mostly~6
mercapturates).~1
duct-ligated~1
hemoglobin-free,~1
recirculating~4
(16%~1
hr).~4
stereoselectivity~4
3-fold,~3
closed-chest,~1
25.2~3
33%,~5
LVdP/dt~1
secretin,~3
initially,~4
pharmacokinetic-pharmacodynamic~3
modeling~4
lymphocytopenic~2
(Cth)~1
(HCt~1
O)~1
investigated,~4
Cth~2
8:00~4
(data~4
P.M.~7
reanalyzed~5
HCt~2
O.~3
prednisolone.~4
cation,~2
blood-cerebrospinal~2
(Km~1
nmol/ml/min)~1
(p-hydroxymercuribenzoate),~1
(KCN~1
2,4-dinitrophenol)~1
(Q10~1
4.5),~1
Organic~2
1N-methylnicotinamide,~1
tetraethylammonium,~1
choline,~2
tetraethylammonium.~1
quinine~2
anion,~1
benzylpenicillin,~2
millimolar~1
anions,~4
cimetidine.~5
anions~4
(benzylpenicillin~1
saturability~1
mutual~2
Oligopeptides~1
oligopeptides,~1
9-tetrahydrocannabinol~3
(THC)~1
auditory-evoked~1
two-tone~2
Conditioned~4
9-THC~8
mg/kg:~1
rewarded~1
Concurrent~4
THC~4
distort~3
waveform,~1
N1~7
behaviorally~4
converging~1
psychoactive~4
marijuana~1
9-THC)~1
Intraperitoneal~2
(pretone)~1
tone-evoked~1
colliculus~1
9-THC.~2
sensory-evoked~2
gentamicin-induced~1
subclinically~1
(intact-gentamicin)~2
(nephrectomized-gentamicin)~1
12-hr~1
infusions,~3
intact-~1
nephrectomized-control~1
(untreated)~1
intact-gentamicin~1
nephrectomized-gentamicin~1
(microgram/ml)~1
0.01(hr-1)~1
S.E.M.).~1
Postinfusion~1
histopath~1
(0-30,~1
severe)~1
(nephrectomized-gentamicin),~1
(nephrectomized-control),~1
(intact-control).~1
Gentamicin-induced~1
nonindividualized~1
oliguria~9
Hormone-sensitive~1
diterpene~1
compound,~6
subunit.~2
Guanine~1
[3H]forskolin~1
analog.~1
[3H]Forskolin~1
densely~5
accumbens,~2
olfactory~7
nigra.~3
[3H]guanylyl-5'-imidodiphosphate~1
([3H]Gpp(NH)p)~1
oriens,~1
radiatum,~1
lacunosum~1
hilus~2
CA3~1
CA4~1
Gpp(NH)p~1
[3H]Gpp(NH)p~1
allosterically~2
prolactin-secreting~4
microadenomas.~2
perphenazine~1
(nontumor)~1
hyperprolactinemia~12
perphenazine,~1
orally.~4
prolactins~1
hyperprolactinemic~5
translaparoscopic~2
single-puncture~1
Concern~3
laparoscope~1
obstruct~1
14.6%~1
curtailment~1
double-puncture~1
Peripartum~1
enigmatic~2
demise~1
twin,~2
maternal,~2
neonatal,~2
teachers'~3
rank,~1
trainees,~1
(student~1
resident),~1
clerkship~9
(elective~1
required).~1
4,050~1
430~1
ranks,~2
members'~3
clerkships.~1
did.~8
"gatekeepers"~1
formidable~2
specialties.~2
internists,~4
surgeons,~6
version~7
alcoholics;~1
versions~2
personalities.~1
treatability~1
alcoholics'~2
personalities,~1
personalities~1
treatability.~1
module~1
second-year~2
goes~2
wrong~1
histories.~3
Skills~2
interviewer,~1
both;~1
"poor~1
historian";~1
competency-based~1
psychiatry~4
competencies~8
competencies.~4
curriculum,~2
curriculum.~9
members.~11
four-session~1
school-~1
home-based~1
therapists,~1
handicapped~4
agencies.~2
six-week~2
preentrance~1
courses,~4
topics,~1
sociomedical~1
Medicine~13
matriculation.~1
nonparticipants~2
first-year~2
honors~2
Questionnaires~5
adjustment.~6
pneumo-~1
therapy:~5
cefoxitin~2
q~4
(pneumonia~1
empyema)~1
(3%).~6
0.0227).~1
penetrating,~1
(N.S.T.)~1
N.S.T.~1
(ISS)~1
adjunct,~1
Classic~2
(IVP)~1
liberal,~1
reassess~3
IVP~12
post-traumatic~10
Center,~6
(86%).~2
Chi-square).~1
insignificant,~1
IVP's~1
Traumatic~4
Meperidine~2
(TBC)~1
IM~11
nonseptic~8
TBC~2
684~1
0.735;~1
27.75;~1
(AGP),~2
mg/dl/day~1
0.828;~1
42.30;~1
IBW~1
debridement.~3
shunted~4
hospitalized,~2
825~3
hospitals,~9
work-related.~1
contributor~6
Scalds~1
Pneumatic~5
antishock~5
garments~3
(PASG)~4
myoglobinuric~1
anoxia.~5
(TcPO2)~2
applied:~2
TcPO2~10
70.6~1
equation:~6
2.3x~1
65.7,~1
(25-35).~1
(Ender~1
united~4
Nonunion~2
Three-point~1
Nailing~2
reaming.~3
brace.~3
biomechanically~2
favorable.~3
equipment.~6
classified,~1
sacral~14
segments;~1
plafond~4
prognostically~8
compressive.~1
A-O~1
dubious.~2
Alcoholism~3
blight~1
implicates~2
Polytrauma~1
ISS~1
nonalcoholics,~1
drinkers),~1
two-wheeled~2
amongst~7
13.3%,~2
offenders~8
polytraumatology~1
gm/L,~2
gm/L.~1
traumatology.~1
fasciotomies~1
fracture/dislocations,~1
coronoid~1
split-thickness~2
degloving.~1
Industrial~1
low-energy~3
wringer~6
washer~1
MacCollum~1
(11).~1
stabilization,~1
machines,~1
radiographed~2
tenderness,~2
crepitation,~1
radiographed.~3
Repair~4
Displaced~3
pancreatectomy~9
tributaries~2
(ERCP)~2
stabwound.~1
(immediately?)~1
pericardio-pleural~1
ordinarily~3
cecoureterocele~1
cystourethrogram~1
clearly.~2
elusive~3
triplication~1
amastia,~1
excavatum,~2
ptosis,~6
epicanthic~1
folds~8
antimongoloid~1
slant~1
hypertelorism,~2
arched~3
bridge,~1
digits,~1
cubitus~2
syndactyly.~1
pole~12
shadows~2
tooth-like~1
retroperitoneum~1
Sagittal~2
incompetent~2
trigonal~1
Trigonal~1
knot~2
mersilene~1
ligature~5
cyst.~13
ml.)~4
intravascularly~2
enhancement)~1
Persistent~6
bladder.~13
hemangiomas~13
hemangioma.~2
testicle~3
untwisted~2
manipulative~4
detorsion.~1
detorsion~1
detorsion,~1
orchiopexy~4
Melioidosis~1
pseudomallei~2
pus,~1
co-trimoxazole~1
Genitourinary~1
cisplatin,~5
promptly,~2
nonresponsive~1
cryptorchidism,~2
endocrinological~2
impregnate~1
(impregnation~2
(88%).~1
without).~2
(30%~4
0%);~1
peristalic~1
intraureteral~5
Acetylcholine~2
avidin-biotin~1
lectins~8
carcinogenesis~5
N-butyl-N-(4-hydroxybutyl)-nitrosamine~1
(BHBN).~1
Concanavalia~3
ensiformis~3
(Con~1
Triticum~3
(WGA),~1
Ricinus~2
communis~2
(RCA)~1
Arachis~4
hypogaea~3
(PNA)~2
spotty~1
BHBN~2
Dunning~4
R3327H~1
Copenhagen~2
castration.~3
dry-autoradiography~1
castration-induced~1
castration,~1
3H-dihydrotestosterone~1
(DHT)~1
labelling~4
3H-DHT~2
DHT~5
histograms~5
dihydrotestosterone-induced~1
castrate~3
androgen-induced~1
intracorporeal~2
venular~7
papaverine-induced~1
corrosion~4
casting~4
Low-power~2
albuginea~4
spaces.~10
subalbugineal~2
impeded.~1
low-power~1
emissary~1
penis.~1
Along~4
smooth-muscle~1
erection:~1
three-fourths~2
ideal,~1
68.8~2
(Robson~3
IIIA),~1
735~3
reservoir.~3
urostomy~1
reservoirs~6
receptacle~1
(ulcerative)~1
(nonulcerative)~1
cystitis.~2
perineural-perivascular~1
Mast~10
aldehyde~7
demonstration.~1
washings,~1
nonulcerative~2
uncharacteristic.~1
Transurethral~2
Ta,~6
(4.08)~1
(32.5~2
multiplicity,~2
cylindroid~1
lining.~4
ureter,~3
erosion,~2
reimplantation~6
reimplantation.~4
difficulty)~1
(598~1
micrograms.~7
(429~1
(368~1
ml.).~2
Immunosuppressive~2
(44~7
staging,~8
Atrophic~3
prostates~7
adenocarcinoma.~10
prepubertal~19
prostate.~6
antecedents~3
Catheterization~2
cystoscope~2
lithotomy~1
cystoscope.~1
easily.~1
2-tiered~1
symptoms:~3
hyperreflexia~2
Predictive~2
Urodynamically,~1
detrusor-sphincter~2
dyssynergia,~1
hyperreflexia.~1
dyssynergia.~1
sympathectomy,~2
clitoris~1
35.3~5
reflex.~9
obtain.~2
collar~3
phallus.~1
subglandular~1
Barcat~1
balanic~1
neourethra~1
prune~4
belly~4
pyeloureterography~1
leukocytosis,~3
atherosclerotic,~1
deposit~7
carcinomatosis,~2
(I.D.)~1
I.D.~1
25).~1
Unexpected~2
Arteriograms~1
(DPM)~1
I.D.).~1
300.4~1
147.4~1
43.2~1
58.6~1
ASA/DPM~2
0.0005).~8
indium~3
oxine-labeled~1
(GPAI)~1
graft:~1
GPAI~1
69.3~3
34.3~1
Neointimal~1
seeding~4
(ECS)~1
antiplatelet~8
Endarterectomies~1
(325~2
day),~9
seeded~3
10(6))~1
perfusion-fixed~4
millimeters)~1
neointimal~5
planimetry.~3
endarterectomized~3
ECS~3
Vein~2
adapt~7
(SMC)~1
dimensional~6
perianastomotic~1
denuded,~1
(thymidine~1
index)~4
pretransplant~1
twelfth~2
SMC~2
Deoxyribonucleic~3
thirty-five-fold~1
transplantation~15
reconstructions,~3
repairs.~1
(116~1
(13)~4
(76),~1
(5)~1
nonreconstructed~2
unrepaired~1
(14),~1
(donor~1
nephrectomies)~1
(6).~2
Duplex~2
sleeve.~1
(Vs)~2
(Vm)~1
meters~7
(SB)~1
thrombus).~1
repaired,~3
Confirmatory~1
89%)~1
studies--all~1
77%).~2
Tau~1
SB~1
(Tau~1
0.21,~1
0.07),~2
(Vs,~1
Vm,~1
inflow)~1
Leg~3
(milliliters)~1
air-plethysmography.~1
(VV),~1
recumbent~4
ejected~1
(EV)~1
(EF~1
100/VV)~2
tiptoe~2
(RVF~1
incompetence,~1
graduated~6
stocking~1
SVI~1
stockings~1
DVD.~1
air-plethysmography~1
ejecting~1
Dec.~1
31,~9
Prosthetic~5
5.84;~1
operations:~1
(132~1
patients)--a~2
reconstruction--and~1
0.019),~1
4.68;~1
obtained;~2
available;~3
389~3
Including~3
reoperations,~2
591~1
(rest~1
gangrene)~1
(97%).~1
(7.4%),~1
(5.6%),~1
247~4
profundaplasty~1
59%.~4
(1.0%),~1
12.3%,~1
6.4%.~2
(28%).~1
re-operation~2
1454~1
assistance.~1
balloon-dependent~3
femorofemoral~3
(FFG)~1
(5%~5
36%)~1
(46%);~1
arteriosclerosis;~1
FFG;~1
ending~7
drop,~2
paresthesia;~1
FFG~3
limb-saving,~1
durable,~2
(RP)~1
transperitoneal~5
(TP)~1
aortoiliac~12
[AIOD]~1
[AAA])~1
AIOD~1
AAA)~1
RP~8
(1950~1
(1296~1
(5994~1
296~1
(4455~1
(1235~1
(853~1
Nasogastric~1
Budd-Chiari~14
diuretics,~6
paracentesis,~3
peritoneal-venous~1
portocaval~2
(four),~3
mesocaval~3
(one),~8
(two),~6
transatrial~1
membranotomy~1
(IVCR)~1
(one)~2
IVCR~2
azygousatrial~1
splenopulmonary~1
(one).~6
0.089).~1
(A2R)~1
Platelets~3
A2R~7
femtomoles~2
milligram~5
(fmol/mg~1
fmol/mg;~1
(ns).~1
17.4~1
675~3
Leather~1
valvulotome~1
incise~1
449~2
63%.~1
femoroinfrapopliteal~1
infrapopliteal~5
superiority~8
1043~2
supra-aortic~3
thirty-four~4
(innominate,~1
25;~2
subclavian,~1
103;~1
(36%).~1
reasons.~4
(innominate~2
95;~1
(TT)~2
8;~2
subclavian-carotid~1
(SCT)~1
carotid-subclavian~1
SCT.~1
end-arterectomy~1
procedures.(ABSTRACT~1
coarcted~1
sonomicrometry.~1
noncoarcted~1
coarct,~1
diminished;~1
stenosing~1
systemically.~1
reperfusion-induced~2
relevant.~1
scavengers,~1
scavengers~2
(LMD)~1
LMD~4
coagulation.~5
platelet-graft~1
Indium~3
111-labeled~2
knitted~5
21/2~1
ml/hr.~2
bolus.~5
dextran.~1
LMD.~1
(Laserprobe)~1
watts~1
Laserprobe~2
(indicated~1
perforation,~4
means.~5
(DTS)~1
(MI).~1
MIs~2
DTS~3
MI~15
8.5%~4
DTS,~1
cost-effective;~1
imperative~7
(ERT)~1
registries~2
Dec~3
digit~5
dialing~3
1369~1
1645~1
oophorectomy,~1
ERT~2
1.3,~1
ERT.~1
1.1;~2
menopause,~4
expenditures,~1
costs--population~1
prices~2
("the~1
basket"),~1
Aging~4
attention;~1
tenths~1
Gradual~3
inpatient-days,~1
billions~1
dollars,~1
reemerge~1
rationed.~1
metastasizes.~1
Metastatic~3
syndrome-related~1
variously~4
linear,~4
J-shaped,~1
U-shaped.~1
recommendations,~3
biases:~1
hyperglycemia,~2
underestimate~6
0.3%)~1
Cesarean~1
19.0%~3
0.2)~4
rates;~2
95th~2
(14%).~3
leveling~1
(RAD)~1
174)~2
187).~1
atherosclerosis,~6
10.4%),~1
(87%~3
73%),~1
(36%~3
14%).~1
(26%~2
41%).~1
(70%~2
RAD~1
correctable~4
RAD.~2
methodological~2
diagnosed;~1
pathophysiologically~2
Miami~2
Creole-speaking~1
interviewers~1
control-persons~1
(164~1
homosexual,~2
hemophilia,~1
control-men~1
gonorrhea,~1
prostitutes.~1
voodoo-priest~1
money~2
Acquired~7
heterosexuals.~1
4661~1
staffing,~2
reusers~1
dialyzers.~3
for-profit~1
not-for-profit~1
hood~5
calorimetry.~1
(REE)~2
REE~6
Lean~1
REE.~2
three-stage~4
emulsion,~2
Intralipid,~1
normolipidemic~3
nephelometry;~1
TG,~1
tryptophan~7
(TRP)~1
exogenous,~1
particulate,~1
TG.~1
(K2)~1
(K1)~2
K1.~2
Intralipid~4
TRP~2
cirrhotics~6
bloodstream;~1
liver;~2
discouraged~2
HE.~1
3-hr~1
changed,~3
drastically.~2
(IP)~4
have.~1
(CG)~1
glutaraldehyde~4
(GTH)~1
(GOT),~1
pyruvic~1
(GPT),~1
microscopes~2
gone~4
emulsion~12
Kupffer's~4
ligating~1
(septic-glucose~1
(septic-lipid~1
(septic-fasted~1
phagocytotic~4
engulf~1
septic-glucose~1
septic-lipid~1
insofar~2
concerned,~1
72-hr~1
aggregate-level~1
countermeasures~1
driver~2
individual-level~1
situational~1
drink~4
driven,~1
weather~1
police~6
roadblocks,~1
roads,~2
incidents~3
drunken~1
transportation.~2
856~1
unmarried~1
southeastern~4
524~1
(61.2%)~1
occasionally.~3
subsample,~1
drink,~2
student.~2
Racial~2
drunkenness~1
undergraduates~1
undergraduates.~1
(MSI)~1
alcohol-focused~2
(AFSI)~1
(ABMT)~1
ABMT~2
AFSI~1
conjoint~1
homework~1
MSI~1
personality."~1
subtypes.~2
Alcoholics~3
Anonymous~2
(A.A.)~1
A.A.~10
Improving~2
(MMPI)~5
elected~8
attend.~1
sorted~2
sober~1
contrasted.~1
attenders~1
nonmembers,~1
unsuccessfull~1
28-31~1
midcycle~2
(.65~1
words,~3
steadiness,~1
vigilance~3
(BAL).~2
rounds:~1
BALs~1
mg/d1~1
vigilance,~1
logic~2
nonsubstance-abusing~1
outpatients~16
normals--female~1
students--to~1
impressively~1
cross-validation.~1
intercorrelation~2
Agitated~1
Depression,~4
Familial~6
Dissatisfaction,~1
Hypersensitivity~2
Irreligiosity.~1
Expectancy~1
Questionnaire~9
assertiveness,~1
pleasure~3
expectancies~6
birth-order~1
(first-,~1
middle-~3
last-born)~1
psychopathology~4
sons~6
(ANOVAs)~1
borns~1
borns.~2
generalizations~1
Perceptual~1
Comparing~8
Breathalyzer~2
DUI~1
presentencing~1
(26.4%)~1
arrests,~1
coronary-to-aortic~1
baffle~3
(Takeuchi)~1
(two-one~1
(one-asymptomatic).~1
(three-two~1
Takeuchi~2
pharynx,~3
jejunostomy~1
Alimentary~1
substernally~1
stentless~1
monopatch~2
sheet~11
glutaraldehyde-treated~1
years);~4
13.8~8
tetralogy;~1
atresia,~7
transposition,~1
(nonsurvivor),~1
22.2~5
1.05~4
2.74~2
L/min/m2~1
1.92~1
L/min/m2).~1
oxygenator~6
wean~4
Mediastinitis~1
weaned.~2
oxygenator.~1
withdrawn.~4
5.5%,~2
normal)~3
[p~4
0.001],~1
218%~1
0.001]).~2
ventricle-pulmonary~1
(regurgitant~1
transannular~2
1.31~4
(end-systolic~1
122%~1
isovolumetric~2
either,~2
leaflet(s)~1
severed~12
assigned.~1
intact),~1
severing~2
intact)~1
0.017)~1
0.021)~2
(anterior~3
intact);~1
0.140),~1
attachments~2
chordae;~1
detrimental.~2
nonfunctional~3
(2.8%)~3
(left)~1
class.~7
Prosthesis~1
struts,~1
justify~5
Starr-Edwards)~1
replaced.~3
4.7%.~4
mortality)~2
subgroup),~1
patient-years.~2
thrombosed.~2
warfarin.~5
fatal)~2
dehiscence.~1
Thromboembolism~2
uptakes~4
bone-seeking~1
isotopes,~1
85Sr~2
99mTc-methylene~2
42K~3
(VD)~2
VD~5
0.83;~1
99mTc-MDP~1
plot,~2
85Sr,~1
99mTc-MDP.~1
decrease,~3
42K,~1
99mTc-MDP,~1
85Sr.~1
712~2
1965,~1
postinflammatory~6
floppy~4
(31%).~2
73%~15
530~6
spanned~6
heredity,~1
carcinomas).~1
phototherapy~6
Orbital~2
sheeting~1
migration,~4
otosclerosis~2
30,000~2
stapedectomy~2
stapedectomy.~1
Funen~2
inhabitants.~2
Computation~1
geographical~7
(WHO)~4
Warthin's~1
27.5%.~1
Intramuscular~3
myxomas.~3
pathological,~2
amoxicillin~7
(AOM)~1
AOM~1
participate.~2
tympanocentesis~1
mg/kg/D)~1
post-treatment.~2
enrolled:~1
Middle~4
included:~8
catarrhalis~1
terminated.~2
Videofluoroscopy,~1
quantitates~4
(transit~1
times)~1
transoral~6
transorally~1
symphysis~3
parasymphysis~1
Cochlear~1
insertion,~3
intracochlear~5
Fresh~5
free-fitting~1
multichannel~5
array.~1
Tips~1
embed~1
scala~1
tympani.~2
partition~12
UCSF/Storz~2
processors~1
medical/surgical~2
understood;~1
such,~2
(ASNHL)~1
autoimmunity.~2
perilymph~1
Histopathological~2
infiltrates,~4
erythrocytes.~12
ASNHL~1
Ninety-nine~2
(overall~2
rate-74%)~1
(21%~2
10%).~4
speaking~2
nonavailability~1
sizes,~3
assistant~3
whole-organ~1
serial-sectioning.~1
arytenoid~7
invade~3
T2.~6
ala~1
1,713~1
1957~4
Capsular~1
lymphatics,~1
invaded~7
Classification~6
UICC.~1
migraine,~4
remainder,~4
rationally.~1
Germ~1
Biologic~1
HCG~3
AFP,~1
pseudoprecocious~2
(choriocarcinomas~1
germinomas~1
syncytiotrophoblastic~3
(together~2
HCG)~1
seeding,~1
aqueductal~1
massively~5
Rarely,~2
nonparenchymal~1
nonspecifically~1
LHRH~2
plexus,~4
CVOs~1
endings,~1
barrier.~5
appreciate~4
integrator~1
interpret.~2
predates~1
Often,~1
comingled.~1
gradual-fixation~1
method:~1
haploid~3
second-metaphase~1
chromosomes),~1
analyzable,~1
bivalents~1
metaphase.~1
totals~2
certainty.~2
(nearly~1
karyotype.~2
clomiphene,~1
Bedouin~1
tribe,~1
hypercalciuria~12
(HHRH).~1
"idiopathic"~2
HHRH,~3
milder.~1
hypercalciuria,~2
tribe.~1
Tubular~1
hypercalciuria.~6
(1,25-(OH)2D)~1
milliliter~12
HHRH~2
110).~1
1,25-(OH)2D,~1
(ICUs)~1
service,~4
(emergency~1
scheduled),~1
seriousness~2
physiology-based~1
measure,~1
mortality-risk~1
ICUs~3
nonsurviors~1
(logistic~1
model)~2
822~1
medians,~1
ICUs.~1
parvovirus~4
infectiosum,~1
northeast~1
midtrimester~1
abortions,~1
abortuses~1
microscopical~1
features--a~1
leukoerythroblastic~1
Dot~2
parvovirus-specific~1
nidation~1
ovum,~1
486,~1
menses~2
kilogram)~2
experimental,~1
stroke-associated~5
859~1
California.~3
tertile~1
tertiles~1
0.16)~1
10-mmol~1
Arabia~2
(hemoglobin~4
F,~6
(G~2
gamma).~1
(base~2
pairs)~2
single-base~1
cytosine-to-thymidine~1
(C----T)~1
-158~2
5'~4
(preinitiation)~1
high-hemoglobin-F~1
C----T~2
Saudis~3
trait,~1
Saudis.~1
Homozygosity~1
(AChR)~2
(refs~3
1-5).~1
AChR~6
Torpedo~3
channel.~10
Replacement~4
delta-subunit~4
locate~5
cDNAs~1
conductances~3
delta-subunits~1
M2~3
bend~3
M3~2
benefited~10
lpr~2
(lymphoproliferation)~1
gld~2
(generalized~1
autoantibody~2
rearrange~2
transcribe~2
receptor-like~1
anti-receptor~9
rearranged~1
non-covalent~1
chains;~1
(26K),~1
epsilon~1
(25K),~1
(gp21)~1
homologue~1
(CD3),~1
16K~1
(zeta)~1
dimer~5
(p21).~1
multichain~1
lectin,~3
p21~2
gp21~2
serine~1
phosphorylated.~1
Transcriptional~1
(GREs)~1
1-3,~2
Deletion~1
oestradiol~6
footprinting~1
protein-DNA~2
GREs~1
(TAT)~1
TAT~4
expressed.~2
dimethylsulphate~1
unoccupied~1
controversy:~1
reside~1
hormone-bound~1
(HRE)~1
hormonally-inducible~1
promoters~3
(LTR)~1
(MMTV).~1
tackled~1
HRE.~1
heat-activation~1
steroid-free~1
HRE~2
MMTV.~1
DNaseI-footprints~1
hormone-free~1
complexed~18
RU486.~1
IIIA~3
(TFIIIA)~1
5S~2
laevis~2
7S~6
7-11~1
atoms.~2
amino-acid~5
TFIIIA~3
invariant~3
histidines~2
cysteines,~1
zinc-binding~2
Here,~3
EXAFS~2
(extended~2
structure)~1
sphere~2
dehydrogenases~1
'loop'~1
(residues~1
98-110)~1
rearrangement,~2
dehydrogenases)~1
guanidinium~2
bonding~5
carbonyl~8
Fig.~1
Whilst~3
commented~3
experimentally.~1
glutamine.~1
stabilizes~1
active-site~1
(rate~2
sulphite~1
NAD+),~1
hydride~1
arginine----glutamine~1
substitution.~3
sounds~8
birdsong~2
resonances~4
sound-producing~1
evidence,~8
birdsongs~1
helium~5
atmosphere,~1
contradicts~1
songbird's~1
syrinx.~1
Songbird~1
thought,~1
phosphoinositide~2
quantal-transmitter~1
Transmitter~1
liberation.~2
signalling~2
(PKC),~1
esters,~8
PKC~2
ways.~4
currents;~1
hydrozoan~1
coelenterate~1
Obelia~1
geniculata,~1
emission~9
photocyte~3
obelin,~1
calcium-activated~1
photoprotein.~1
luminescence~2
voltage-gated~2
emission.~1
photocytes~3
luminescence.~1
voltage-dependent~7
non-luminescent~1
photocyte.~1
Surprisingly,~3
osteomalacia,~2
subtropical~2
calcium/high~1
cereal~2
unifying~1
Ha-ras-1~6
locus,~3
(11p)~1
nevus~7
(DNS).~1
located.~1
contradicting~1
Krontiris~1
cell-specific~2
trans-acting~1
promoter/enhancer~1
refs~1
reviews).~1
Sequence~3
oestrogen,~1
unpublished~2
results)~1
site-directed~1
Region~2
(Fig.~1
1a),~1
domain;~2
66-amino-acid~2
(Figs~1
1a,b)~1
zinc-stabilized~1
'DNA-binding~1
fingers'~1
TFIIIA.~1
receptor's~2
DNA-binding~6
cysteines~1
(hER)~1
hER~1
(hGR)~1
glucocorticoid-inducible~1
oestrogen-inducible~1
oestradiol.~1
trypanosome~3
coat.~2
(VSG),~1
repertoire~1
coats~2
evade~2
host's~2
brucei~5
ILTat~1
1.24,~1
crystallography.~1
crystallized~1
N-terminal~8
VSG~6
(60K).~1
alpha-helical~2
MITat~1
(ref.~1
(ILTat~1
1.24)~1
(MITat~1
1.2)~2
VSGs~3
39-year-old~3
genu~5
splenium.~1
(SMA)~1
praxis~2
battery.~1
apraxia~2
SMA~5
Liepmann's~1
propose,~1
left-hand~2
verbal,~1
visuomotor~2
(lCMRgl)~1
(lCBF)~1
whiskers~1
(vibrissae)~1
carbon-14~1
double-label~3
lCMRgl~3
lCBF~2
forebrain~7
metabolism/blood~1
22%)~2
barrel~2
intracortical~1
tremor,~5
tremor.~6
cricothyroid~1
vocalis~1
phonation,~2
inspiration,~3
(breathing~1
rest).~1
innervating~3
Clonazepam~2
neurophysiologists~1
eliciting~6
globe~4
cornea.~3
(VEEPs)~1
transcorneal~1
photoreceptors,~3
VEEP~3
hamper~1
Preserved~1
Absent~1
enucleation.~2
Epidural~3
Back~2
corticosteroids,~4
(CsA)~1
debilitated~3
polyradiculoneuropathy.~3
CsA-induced~1
reversible,~5
nephropathy,~3
nontransplant~1
aphasia,~2
bifrontal~2
headache.~7
lymphocytosis~5
OKT-8+~1
anti-cytomegalovirus~1
(anti-CMV)~1
1:1,024~1
1:64.~1
anti-CMV~1
1:8,192.~1
dystrophy,~2
diesters~2
(PDE)~1
(Pi),~2
PDE;~1
PCr/Pi,~1
PDE,~1
shaky.~1
endoneurial~3
microvessels~7
Microvessels~1
Enlargement~4
AIDS-related~9
(ARC)~3
hemichorea-ballismus,~1
myoclonus,~2
Besides~6
hyperkinesias,~1
parkinsonism,~1
toxoplasmosis~3
autopsy),~1
encephalitis,~5
Carrier~2
(DD)~2
Becker~2
(BD)~1
(RFLPs).~1
DD~1
BD~1
kinase/pyruvate~1
RFLP~1
probes,~2
unavailable.~2
uninformative.~1
Norepinephrine,~1
3-methoxy~1
4-hydroxyphenylethyleneglycol~1
ceruleus~6
parkinsonians,~1
3H-desmethylimipramine~1
3H-rauwolscine~1
paraparesis,~1
(SMU)~1
paresis,~3
nonpainful~1
(SNS).~1
SMU~1
SNS~5
SNS,~1
SNS.~1
paresis~12
(VOR).~1
oscillopsia~1
blurred~3
VOR~5
velocity/peak~1
velocity)~2
normal).~3
("suppression")~1
olivocerebellar~1
projections.~3
Physostigmine~2
cholinergic.~1
Friedreich's~12
dysarthria,~2
titubation~1
cholylglycine,~2
Mitochondria~1
"paradoxical~2
lateralization"~2
dipole~1
matches~1
proprioception.~1
(rCBF)~3
(MABP)~1
metaraminol.~1
rCBF~14
14C-iodoantipyrine.~1
Autoregulation~5
heterogeneous.~3
Hyperperfusion~1
striatum,~3
eighty~3
vertex~4
periventricular/intraventricular~2
delivery)~4
vaginally.~2
hemangiopericytomas,~1
substantiated.~1
Reviewed~1
disease-free.~1
hysterectomy;~1
45%.~5
cis-platinum-based~1
pair-matched~2
(mg/dL)~1
0.86~5
(lifetime~1
occurrence)~1
5398~1
alumnae,~1
2622~1
athletes,~2
2776~1
nonathletes,~2
reporting)~1
nonathletes~2
(40.5~1
31.9%,~1
menopausal~17
nonathletes.~1
fracture-free~1
99.5F~1
"therapeutic~1
response,"~1
aborted.~1
overly~2
copies~3
articles~9
reprints~1
file.~1
publications~4
obstetrics~6
gynecology,~2
categorizing~2
subspecialty~6
macrocytic~1
hematologic,~2
colposuspension,~1
introduce~6
(Pdet~1
colposuspension.~1
16-month~2
one-hour~4
pad-weighing~3
0.68;~3
0.93;~2
voiding-cystourethrography~1
acuminata~6
postpartum.~9
Cryotherapy~1
(ONO-802)~1
obstetricians~4
Papiernik-Creasy~1
purpose,~7
Adjusting~1
reweighting~1
demographic,~7
socioeconomically~2
resting,~1
nulliparas~2
multiparas~1
10-cm~2
multiparas.~1
supplementing~3
Intermittent~2
Pre-~4
Montevideo~1
.005),~5
stimulation-rest~1
hyperstimulation.~1
nicardipine~14
HCl,~1
24-26~1
tocolysis.~3
Nicardipine~3
tocolysis,~1
uteroplacental~6
begin.~1
nicardipine,~5
calcium-entry~1
nicardipine.~2
degree,~12
ritodrine.~1
tocolysis~5
terbutaline~6
(cases)~1
1278~1
never-users.~1
22);~1
15);~1
Confidence~3
distorted~3
adequacy.~3
milieu~3
Antitumor~4
antifibroblast~2
periocular~1
(57Co-bleomycin).~1
Sub-Tenon~1
sponge~6
silastic~3
microhole~1
sub-Tenon~1
(0.5%~1
hyaluronate).~1
theorize~1
bleb~7
transorbital~3
suspecting~1
membranous-changed~1
extracapsular-planned~1
hyaluronate.~2
punctiformly~1
retrolenticular~1
widened~2
hyaluronate,~1
too.~1
microscissors~1
face.~1
Integrity~1
opacities~6
glaucoma.~8
sclera~3
pars~15
plicata.~1
haptics~1
erode~1
plicata,~1
lenses.~4
polymethylmethacrylate~1
(PMMA),~1
melting,~1
vacuolization,~1
Polypropylene~1
PMMA~2
haptics.~1
trichiasis.~1
cilia.~1
200-micron~1
0.1-~1
mW~2
eyelashes.~1
oculoplastic~2
expander~3
cosmesis.~1
exciting.~1
ridges~2
effectivity~1
ridge~4
post-operatively,~1
.35~1
ridge,~3
.25~1
.15~1
ridge.~1
non-angulated,~2
non-ridged~2
claims~9
ophthalmologists~5
allegation,~1
litigation,~2
indemnification.~1
Allegations~1
indemnity~1
alleging~1
negligent~2
Dislocations~1
tarsometatarsal~2
pain-free,~2
surveyed,~2
Anatomy~1
pertains~2
olecranon~3
Implant~1
Rewarding~1
judgment.~1
Comminuted~1
bracing.~3
locked~2
multiply-injured~1
anticipated.~5
8-hour~3
Peroneal~1
solved,~1
congruity~1
knee.~14
pendulum~1
swung~1
surely~1
panacea~2
alter.~1
remains:~1
Which~2
achieves~3
morbidity?~1
skillful~1
remembered,~1
orthopedics.~1
exhaustive.~1
rely~6
midshaft~1
orthopedist~1
plating,~1
Kuntscher~1
nailing,~1
interlocking~1
nails.~2
Approaches~1
intertrochanteric~1
pilon~1
manage.~1
talus~4
manners,~2
fibula~4
anteriorly~3
achieved,~6
parotidectomy~1
Salivary~4
defy~2
mucoepidermoid.~1
Recurrences~6
fatal.~6
editor.~1
JNA~1
preadolescent~1
invaluable~4
angiofibroma,~1
promise.~2
decade,~6
up-to-date~2
cryopreservation,~1
Nonchromaffin~1
paragangliomas~3
posed~5
Chordomas~1
subtotal.~1
Described~3
transcervical-transmandibular~1
finite~4
flaps.~12
VAS~4
algometer~1
pre~2
stretch.~2
algometer,~1
urgency,~3
hostility~3
Bs~3
assessments.~2
A-B~1
cat's~2
subnucleus~2
caudalis~2
(medullary~1
horn)~1
convergent~9
chloralose-anaesthetized~1
decerebrate~3
cats,~12
premolar~1
tooth~8
low-threshold~1
mechanoreceptive~1
(LTM),~1
wide-dynamic-range~1
(WDR),~1
nociceptive-specific~1
excited~3
inputs,~3
oral-facial~1
WDR~2
antidromic~1
thalamus.~1
terminology~4
distinctions~2
afferents,~2
capsaicin,~1
algesic~5
veratridine~2
pigeons~11
guinea-pigs.~1
guinea-pigs,~2
g/ml~2
pigeons.~1
Veratridine~1
nocifensive~1
10,000-fold~1
guinea-pigs~2
(0.02~3
micrograms).~3
(bradykinin,~1
5-HT,~6
KCl)~1
Slow~1
desensitizing~1
deplete~3
pigeon.~1
quotas~1
monetary~4
placebos~1
quota~3
Self-efficacy~2
ample~2
comprehensively~1
Children.~1
Contained~1
herein,~5
advice~8
restraints,~1
travel~3
Legislation~1
restraints~5
Australia,~2
comparatively~2
restraining~1
dislike~1
restraint,~1
disruptive~6
preschools:~1
coercive~2
preschools~1
60.6%~2
75.0%:~1
restraints.~2
diagnosable~1
disharmony.~1
mother's~9
Affect~1
child-rearing~1
Pediatricians~1
parasites,~1
addressing~4
teenagers,~3
Control's~1
immunizations,~1
(prevalence~1
Cambodians),~1
anemic.~2
hemoglobinopathies,~1
teenagers.~1
adolescent,~1
antigenemia~3
hemoglobinopathies~1
assimilation~2
32%.~4
cystography.~3
Vesicoureteral~2
cystography~5
mrads.~1
(symptomatic~2
asymptomatic)~1
nurseries~2
Columbia~3
Vanderbilt~5
Universities,~1
Universities~1
Dallas,~1
Seattle,~2
Francisco,~2
Brigham~2
Women's~4
Houston,~2
Mt~1
Sinai~3
Toronto.~2
1,625~1
Servocontrol~1
nursed~5
convection-warmed~1
incubators.~1
warming~3
overhead~1
warmers~1
servocontrol~2
heater~1
servocontrolled~1
35.5~3
37.5~5
Skin,~1
rectal,~1
(8.62~1
0.73~5
mL/kg/min,~1
(7.30~1
mL/kg/min).~1
Changing~2
(7.41~1
mL/kg/min),~1
supranormal~3
beds.(ABSTRACT~1
Risk~15
Atlanta~3
Mothers~4
575~2
random-digit~2
day-care~8
breast-feeding~2
.02,~2
1.6),~1
full-time~12
attendees~3
related.(ABSTRACT~1
municipal~2
surveillance,~6
3,009~1
(2.82/100~1
year).~4
Elementary~1
(2.85)~1
(2.78).~1
nature,~10
Playgrounds~1
elementary~14
classrooms~1
Contusions~1
abrasions~1
sprains,~2
(1.21~1
student-hours)~1
(0.65~1
student-hours).~1
Malpractice~1
pediatricians~3
bradycardia;~1
"familial~1
disorders"~1
seizures;~2
"supraventricular~1
aberration"~1
appropriately.~2
provisions~1
Handicapped~1
Act~3
(PL~1
94-142)~1
doctor~3
(adjusted~3
1.76,~1
.05);~3
disabilities~3
3.63;~1
blacks~9
whites;~1
publicly~2
insured~1
privately~3
insured.~1
low-prevalence~1
disabilities,~1
insured,~1
visits.~10
(grams~2
(days)~1
deposits,~3
C),~7
tendency,~1
warming,~1
warming.~1
warmed,~1
Hypothermia~5
today,~1
departments~11
census,~2
staffing~1
44,615~1
15,650).~1
triaged~1
emergent,~1
urgent,~2
nonurgent~1
13.4%),~1
35.4~2
13.1%),~1
8.7%),~1
certified,~1
(7.6%)~2
certified.~1
standing,~4
salaries,~1
x-rays,~5
56%.~2
Obtaining~1
pediatrician-in-training.~1
PL-1,~1
P1-2,~1
PL-3~1
(38.3~1
Uniform~1
replies~1
impression~13
PL-3s~1
PL-1s~1
PL-2s.~1
database~4
phone~3
utilizers,~1
department,~3
venipuncture~5
cutdowns,~2
cutdown~4
surveyed:~1
surgeon,~5
resident,~2
pediatrician,~1
cutdowns~1
olds.~1
unrealistic~2
cutdown,~1
noncardiogenic~3
phencyclidine~1
neurologic,~2
(100%),~1
ataxia~16
(57%),~4
constricted~11
stupor~2
blank,~1
expressionless~1
stare~1
Notably~1
aggression,~2
PCP~3
(preferably~1
immunoassay~5
methods),~1
unresponsiveness,~1
dyskinesis,~1
dystonic~2
posturing,~1
pupil~5
hallucinations.~3
six-year-old~2
Traumatically~1
VSD~2
accomplished.~2
misadventures.~1
lawn~4
darts~3
darts,~1
Parents~8
neuromotor~1
Movement~1
(MAI),~1
Peabody~1
Motor~12
Frostig~1
Eye-Motor~1
Coordination~1
Subtest.~1
MAI~3
4.5-year~2
Spearman's~1
dynamometer,~1
Torque~1
degrees/sec.~1
Gravity-corrected~1
(calculated~3
torque)~2
repetitions~2
Volitional~1
stretching~12
procedures--static~1
(SS),~2
relax~4
(isometric~1
stretch),~2
contract~2
(dorsiflexor~1
relax-agonist~1
(HR-AC)--were~1
physically~8
excitability~5
Hoffmann-reflex~1
(H-reflex)~1
HR-AC~3
H-reflex~1
stretch,~2
ROM~5
(MVCs),~1
MVCs~5
Hz.~12
asymmetrical,~1
bidirectional,~1
nonionizing~1
1-msec~1
MVC~1
Superimposing~1
comfort~7
(minimal~1
discomfort)~1
(CPM)~2
(TKR).~1
knees)~1
TKR~1
CPM~4
CPM:~1
(LOS),~1
(PODs)~1
LOS~1
PODs~1
CPM,~1
CPM.~1
(CAS)~1
examiners.~1
full-wave~1
rectified~1
Percentages~1
agreement,~4
Pearson~3
product-moment~2
correlations,~1
(ANOVAs),~1
intraclass~6
(ICCs)~2
between-rater~1
Within-rater~1
CAS.~1
examiners'~1
within-rater~1
.78~1
.82).~2
ICCs~1
.46~1
.60,~2
CAS~4
deleted~4
ANOVAs~1
facility-specific~1
examiners,~2
judgment,~2
ensured~1
multi-channel~1
VALAD~1
devices,~5
PAAL~1
crutch)~1
FAD~1
crutch).~1
adaptable~2
crutches,~1
touches,~1
decorative~1
stickers.~1
Meeting~2
Carolina~8
Chapter~1
Asheville,~1
NC,~1
18,~17
my~9
colleagues~5
therapists.~1
am~3
profession~3
graduation.~1
Questionnaires,~1
graduating~3
entry-level~8
master's~2
baccalaureate~2
categories--biographical~1
experiential~4
(7),~1
attitudinal~4
factors--plus~1
Chi-square~2
participants'~1
biographical,~1
experiential,~1
attitudinal).~1
encourage~14
synthetic,~1
"labeling"~1
hyperpermeable~1
Monastral~1
hyperpermeability~1
Perfusion~7
hyperpermeability.~1
implied~5
stagnant~2
nevus,~1
Distant~2
canthus~3
zygoma,~1
orbit,~6
zygomaticofrontal~1
subciliary~1
skin-muscle~1
transconjunctival.~1
canthus.~1
Reattachment~1
zygomatic~5
generous~2
Predictable~1
aesthetic~3
craniosynostosis.~1
Three-dimensional~2
skulls~2
Miniplates~1
craniomaxillofacial~1
maxilla,~1
mandible~7
repositioning,~1
frontofacial~1
advancement,~1
miniplates~2
reposition~1
elastics.~1
mandatory,~4
myriad~2
reestablishing~3
Traditionally,~3
reconstruction;~1
alloplastic~4
extrusion,~1
displacement.~5
20-year~7
glossectomy~2
expected.~7
audiotaped~1
spoken~3
words~11
listeners~2
five-point~2
intelligibility~2
connected-speech~1
wedge-excision~1
intelligibility;~1
speech.~2
alar~8
Meyer~1
Kesselring,~1
high-arched~1
nostril,~3
asymmetrical~6
Mestizo~1
columella,~2
feels~1
sacrificed.~2
unfurling~1
caudally.~1
septum,~8
Through-and-through~1
latissimus~4
dorsi~4
insetting~1
fair,~2
69,~3
Flap~1
predictable.~2
cc.~3
retaining~4
aesthetically~2
scapular~4
Microfil~1
fascia,~1
scapular/parascapular~1
intercommunication~1
perforators~5
Revascularization,~1
bipedicle~1
supply,~5
underneath~3
vascularization,~1
osteoclasts~8
surrounded~11
impervious~1
revascularizing~1
energy-rich~1
triphosphate,~1
phosphocreatine,~1
Hyperbaric~2
atm~4
Fluorocarbons~1
properties:~1
microcirculation.~3
McFarlane~1
hemodiluted~5
Areas~4
Necrosis~3
14.96~1
10.12~1
Fluosol,~3
4.76~1
fluorocarbons~2
surgical-pathologic~1
hysterectomy.~4
92%;~2
Demonstration~1
suboptimal.~1
(IUD)~2
IUDs~1
IUD~12
(2,000/30~1
[repetition~1
msec/echo~2
msec],~1
500/30),~1
MR,~2
IUD.~2
high-field-strength~2
(1.5-T)~1
planes,~2
rectum);~1
low-intensity~5
loculus~3
capsule;~1
fluid;~2
(shading)~1
surgical/pathologic~1
Periprostatic~1
periprostatic~3
97%,~1
prostatectomy~13
Surgical-pathologic~1
"truth~1
measure."~1
65%.~2
urography.~2
screen-film~3
receiver-operating-characteristic~1
Readers'~1
30-72~1
(SRCC)~1
SRCC;~1
leiomyosarcoma;~1
liposarcoma;~1
fibrosarcoma;~1
hypovascular~1
liposarcomas~1
Sarcomas~1
SRCC~1
nonlymphomatous~1
referable~2
Urinalysis~1
Radiologically,~1
multifocal;~1
4:1.~2
noncurable~2
(1.5-mm)~1
(pathologically~1
clinically)~2
lymphangitic~4
Thin-section~2
(1-2~3
arcades~4
(reticular~1
Polygonal~1
Fissures~1
1.5-mm-thick~1
(seen~1
radiographs)~1
(midapex,~1
hilus,~2
diaphragm)~1
(UIP)~1
(0%-100%~1
parenchyma)~1
.71).~1
honeycombing~2
.62,~1
.64,~1
.39).~1
Small-bore~1
(22-~1
23-gauge)~1
458~2
(312~1
323~6
98.7%.~1
reclassification~1
misclassification~3
(misdiagnosis~1
categorized,~1
96.6%.~1
small-needle~1
contrast-material-enhanced~1
depict~4
retroesophageal~1
traverses~2
aorticopulmonary~2
window,~2
fibroadenomas~5
fibroglandular~2
inhomogeneity~2
inhomogeneous~4
fibroadenomas.~1
gallstones,~4
ultrasonographic~6
(US)~1
state-of-the-art~1
cholelithiasis.~1
(79.1%~1
sensitivity).~2
89.8%,~1
(48.3%)~1
(11.5%)~2
calcified,~1
(21.8%),~1
(14.9%),~1
(3.4%).~3
incrementation,~1
pericholecystic~1
cholelithiasis~9
CBD~7
nonobstructed~3
(76%);~1
(11%),~6
(32%).~5
Abrupt~3
involvement),~1
peripancreatic~1
"CT~1
score"),~1
abscess,~7
dilemmas~4
colloid,~2
midabdomen.~1
Diminished~3
quadrant,~2
(retrorenal~1
colon):~1
1.9%,~2
10.0%~3
intersect~1
retrorenal~1
poles,~1
unusual,~3
positioned,~2
lobes,~5
overstaging~1
bruit~2
murmur,~3
nonexpanding~2
unwarranted~1
self-expanding~1
stents,~3
4-mm~3
3-mm~5
inserted.~1
Stent~2
stent/artery~1
(SAR)~2
diameters.~2
SAR~2
75.5%~1
54.4%~2
93.7%~2
72.9%~1
long-segment~2
23.1%.~1
patencies~1
attempted,~2
arteritis;~1
(86.4%)~1
Original~1
Gianturco~1
(EIPCA)~1
stent,~3
EIPCA.~1
2.5-cm-long~1
skirts~1
EIPCA~2
creation.~1
Well-positioned~1
0.5-1.0~1
(85.7%)~1
77.8%~2
90.2%.~1
Supraglottic~1
(SSL)~1
radical,~3
voice-conserving,~1
larynx.~5
pharyngograms~1
SSL~1
epiglottis,~3
aryepiglottic~4
mucosal,~2
extramucosal.~1
larynx/pharynx~1
pharyngograms;~1
pharyngography~1
lymphoma;~1
hyperkeratosis.~2
SSL.~1
intrasinus~1
encephalocele~1
Nondisplaced~1
Patchy~2
20%-30%~1
verifiable~2
serial,~1
microscopic,~1
52-72~1
brains.~2
thrombotic,~1
embolic,~2
ovale~2
Wallerian~1
Schilder~1
Theoretical~3
flip~6
flips.~1
signal-to-noise~3
(S/N)~1
S/N~1
TR,~4
acne,~3
suppurativa,~1
triad.~1
HLA-B27~1
spondylarthropathies.~1
articulocutaneous~1
meniscal~3
tears,~7
menisci~2
arthroscopy.~1
infrapatellar~2
bursa.~1
Injuries~3
high-resolution,~1
dissecans,~1
osteonecrosis,~1
osteochondral~5
fragments,~5
Osgood-Schlatter~1
nonossifying~1
fibroma.~1
arthroscopic~5
dissecans.~1
(pigmented~1
villonodular~4
synovitis)~1
amateur~3
interfered~7
arthrography.~2
glenohumeral~3
multidirectional)~1
arthrography~4
labral~3
parasuperior~1
Other,~2
labra~1
(everted~1
labrum).~1
arthrographic~5
paraspinal~5
spondylitis;~1
ribs,~1
vertebrae,~2
hydatidosis,~1
Radioimmunoimaging~1
fibrin-specific~1
armored~1
misinterpreted~5
pitfall,~1
363~3
(CRS)~2
Ryukyu~1
Islands~1
CRS~5
children;~3
(height~1
circumferences~3
60th~2
mutilating~2
harvesting~5
factory-related~1
agricultural~5
corn-harvesting~2
wound.~10
Gram-negative~7
rods~5
wounds;~3
Xanthomonas~1
maltophilia.~1
factory-wound~1
rods.~1
rods,~1
machinery.~1
bursa~2
Prototheca~1
wickerhamii.~1
intrabursal~1
protothecal~1
bursitis.~1
sporangia.~1
1958-1983,~1
986~3
outbreaks~4
botulism~6
China,~5
4,377~1
548~1
Xinjiang~1
province,~1
Outbreaks~1
provinces~2
China.~2
northwest~2
China~3
A;~1
northeast,~1
home-made~1
strong-smelling~1
bean~3
curd,~1
outbreaks.~1
(1950s)~1
7.6%~1
(1983).~1
sulbactam~25
Noncompartmental~1
terminal-phase~2
ml/kg.~5
70%-80%~1
12.5-25~1
sulbactam/kg~1
beta-lactam~8
drug/kg~1
concentrations:~1
sulbactam,~3
mg/liter;~2
ampicillin,~10
dosing;~1
310~5
(sulbactam,~1
hr;~3
hr),~1
7%-91%;~1
5%-132%),~1
newborn.~3
Compatibility~1
sulbactam/ampicillin~21
diluents~7
sulbactam/ampicillin.~1
ampicillin.~2
91%-101%),~1
84%-95%).~1
82%-99%).~1
governed~4
hospital-isolated~1
isolates),~1
Streptococcus,~1
Haemophilus,~1
Neisseria,~1
Branhamella,~1
Bacteroides,~1
coli,~2
Klebsiella,~2
aerogenes,~1
Proteus,~1
Acinetobacter~3
calcoaceticus~2
(1:2)~1
micrograms/16~1
g/2~1
ampicillin-resistant~2
Ampicillin-resistant~1
anaerobes.~1
sulbactam/ampicillin,~2
(aerobe-anaerobe)~1
single-blind~4
endometritis.~2
abscess;~4
pyeloperitonitis;~1
sepsis;~1
tubo-ovarian~2
removal,~8
cystocele,~1
curettage.~6
dose;~2
Pus~1
Enterobacteriaceae~3
Peptococcus~1
(nine),~1
Peptostreptococcus~2
anaerobes~5
(five).~1
anaerobic;~1
mixed.~3
Parenteral~2
(sulbactam/ampicillin)~1
(gentamicin/clindamycin)~1
assessable~4
gentamicin/clindamycin~3
microbiologically~4
gentamicin/clindamycin,~1
beta-lactamase~6
producers.~1
ampicillin/sulbactam~1
nontoxic~7
alterative~1
(471~1
0.5-1~1
Biliary~4
0.24%~2
Respective~1
15.9~2
open,~5
(sulbactam/ampicillin,~1
cefotaxime~8
cefotaxime.~5
chloramphenicol/ampicillin~5
(78%~2
Pathogens~1
ampicillin),~1
pneumoniae,~3
meningitidis,~2
aeruginosa,~2
Listeria.~1
N.~4
parainfluenzae,~2
Citrobacter.~1
pathogens,~1
(S.~5
pneumoniae)~1
(18%)~15
(two,~1
influenzae;~1
Citrobacter).~1
Sulbactam/ampicillin~1
Sulbactam~1
appendicitis.~5
perforated,~1
appendectomy.~6
excitotoxin~1
ibotenic~3
striatonigral~1
transneuronal~2
reticulata.~1
nigral~2
terminals.~6
Neuronal~2
muscimol.~1
disinhibition~1
UDP-Gal/UDP-GalNAc~1
4-epimerase.~1
4-epimerase~2
cocultivated~1
enzyme's~1
communication.~3
rectifier~2
Aplysia~4
3',5'-monophosphate.~1
Voltage-dependent~1
cesium~2
shapes~1
conductance-voltage~1
serotonin-induced~1
channels,~4
open-channel~1
HER-2/neu~4
erbB-like~1
from,~3
amplified~4
189~7
Amplification~2
hormonal-receptor~1
node-positive~1
Mengo~5
cardio~1
picornaviruses,~1
rhino-~3
polioviruses.~1
rhinovirus~4
approximation.~1
icosahedral~1
symmetry.~1
isomorphous~1
VP1,~2
VP2,~1
VP3~1
polioviruses,~1
deletions,~1
"canyon"~1
"pit"~1
VP1~1
canyon.~1
VP4,~1
poliovirus.~1
poliovirus,~1
autocatalytic~1
VP0~1
VP4~1
VP2~1
picornaviruses.~1
MerR~2
bacteria;~1
metal-ion~1
prokaryotic~1
16-kilodalton~1
overproduced~1
milligrams~15
Complementation~1
deoxyribonuclease~2
merR~1
palindromic~1
-35~1
promoter.~3
metalloregulatory~1
operator~8
mer~1
operon.~1
axotomy~1
neurotrophic~3
(NGF).~1
NGF~3
projecting~3
acetyltransferase~5
(350%)~1
axotomized~3
NGF-like~1
Xuan~2
Wei~1
Yunnan~1
Province,~1
China's~3
"smoky"~1
coal,~2
wood~3
"smokeless"~1
Indoor~1
smokeless~6
emissions,~1
smoky~2
submicron~1
organics,~1
Wei.~1
lobster~2
collect~5
axons;~1
microtubules.~1
microtubule~4
microtubules--transport~1
simulation~5
myoglobin~2
thermally~1
neighborhood~2
300-picosecond~1
trajectory).~1
helices~1
side-chain~3
interior.~1
globins.~1
Glasslike~1
trajectory~1
satisfy~1
ultrametricity.~1
(fura-2~1
fluorescence)~1
([Ca2+]i)~3
[Ca2+]i~16
low;~1
[Ca2+]i,~2
propagating~5
[Ca2+]i;~1
hypercontracted~1
(rounded~1
up)~2
Behavioral~6
opisthobranch~1
mollusk~2
Tritonia~1
diomedea~1
cues~3
earth.~1
nudibranchs~1
geomagnetic~1
recurring~6
lunar~1
magnetism~2
circa-lunar~1
giant,~1
reidentifiable~1
tubulin~4
photobleaching~2
PC12~1
coherent,~1
nondiffusing~1
neuroplasmic~1
neuron-like~1
intruder.~1
intruder~1
anions.~1
scattering,~2
acidification.~1
acidified~3
propionate.~1
light-scattering,~1
N-formyl-L-methionyl-L-leucyl-L-phenylalanine~1
(fMLP).~1
fMLP-~1
propionate-induced~1
uncouplers.~1
seems,~2
fulfill~5
chemotaxis.~3
Second~2
activators~1
AMP-dependent~2
(FOR)~1
12,13-dibutyrate~1
(PDBu)~1
single-electrode~1
FOR~4
PDBu~1
conductance.~5
Bright~1
chronobiologic~1
shortens)~1
evening).~1
(shift~1
AtT-20~1
forms:~1
(9.1S;~1
319,000),~1
(4S;~1
96,000),~1
expression;~1
(6S;~1
132,000),~1
(tRNA).~1
tRNA's~1
acid-accepting~1
[arginine~1
(9%)],~1
tRNA~1
tRNA-binding~1
post-transcriptional~2
synthesizing~2
L-citrulline~2
nitrite,~1
Murine~1
nitrite~3
D-arginine.~1
L-Citrulline~1
NG-monomethyl-L-arginine,~1
deiminase~2
imino~1
guanido~1
nitrite.~1
L-Homoarginine,~1
deiminase,~1
L-homocitrulline~1
flanks,~1
(15%).~3
(60%);~1
celiotomy;~1
(1.9%).~1
hemorrhage;~3
thoracoabdominal~6
stabbing,~1
flanks~1
celiotomy,~1
celiotomy~2
5%;~3
platysma,~1
claim~3
reasonable.~2
Cooper~2
Green~2
Birmingham,~1
Alabama,~2
esophagography,~1
explorations~1
1/2-year~4
needle-localized~2
nonpalpable,~1
mammographically~3
mammography~10
microcalcifications~2
(12.4%),~1
(0.8%),~1
(2.7%)~2
suggestive,~1
four-month~2
Olympics.~2
atlantoaxial~1
pathomechanics.~1
engage~4
alternatives.~1
Defects~1
sq~1
Transsphincteric~1
transanal~2
transabdominal~4
disks~7
work-up.~1
studies--electromyogram,~1
myelogram,~3
venogram--were~1
abnormal;~2
venography~7
(PPDs)~1
(PPD-S),~1
kansasii~3
(PPD-Y),~1
scrofulaceum~1
(PPD-G),~1
(PPD-A),~1
intracellulare~4
(PPD-B),~1
fortuitum~5
(PPD-F)~1
roentgenologically~2
mycobacteriosis.~1
attained,~2
non-M~1
(atypical)~1
varied:~2
three-drug~2
inappropriate,~1
five-drug~2
mastocytosis~9
pigmentosa~5
urticaria-angioedema~2
saw,~1
urticaria-angioedema,~2
PGD2,~1
male:female~1
1:4~1
mastocytosis.~2
flushing,~1
cramping/diarrhea,~1
syncope,~5
cyclo-oxygenase~3
Chart~2
anemias~1
unnoticed~2
undiagnosed,~1
incorrect.~1
Pseudallescheria~1
boydii~4
synovectomy~4
arthrodesis,~2
ketoconazole,~8
hypercortisolism.~2
resolved,~2
afterward~1
air-fluid~2
pathognomonic~7
(ESWL).~2
preprocedural~1
dislodged~3
stone-free~4
(impacted),~1
disintegrate~1
noncontact~1
disintegrated~1
Lithotripsy~1
ureteroscopy.~2
Avulsion~1
vascularization~4
1.77~4
Michael's~1
cent);~1
rate).~3
antireflux~9
counterpart~1
cystoprostatectomy~2
urethrectomy~1
Variations~5
enterovesical~5
colovesical~7
ileovesical~1
rectovesical~1
appendicovesical~1
pneumaturia~1
fecaluria.~1
series;~1
pyelogram~4
none.~3
Cystoscopy~1
cystogram~2
instrumentation.~5
paravesical~1
intestine.~11
kilogram).~1
Prenodal~1
hindpaws~1
hindpaw~1
tightening~3
57,~3
cholangiolithiasis~1
sump~10
reinterventions~2
papillotomy),~1
biliodigestive~1
52,~1
cholangiogram~2
cholangiography,~1
(perforation,~1
pancreatitis).~1
choledochal~11
regurgitate~1
choledochus~1
pancreatobiliary~1
choledocus~1
thickest~1
IRHV~2
posteroinferior~1
IRHV.~1
hepatectomies~2
milliliters.~1
widen~1
hepatectomy~2
successfully,~2
sonography~3
indispensable.~1
vascularized~11
myouterine~1
scaffold~2
pedicle,~2
constructing~1
enterostomy~2
Robinson~1
"rod"~1
exits~1
appliance.~1
appliances~1
stapled~6
esophagojejunostomy~1
Sengstaken-Blakemore~1
gun.~2
simplifies~2
atraumatic~6
cartridges.~1
52-year-old~5
red,~3
uveitis~6
iris.~3
(Wermer's~1
48-year-old~1
parathyroidectomy.~1
45.4~3
mmol/hr~2
50.4~3
Ectopically~1
sheath,~3
ileorectal~2
stump.~3
(Actuarial~1
colectomy,~1
polyposis.~2
Billroth~8
(BII)~1
(without~9
vagotomy)~2
BII~8
porridge~2
pancake~1
meal)~1
(45.3%~1
4.3%)~1
(79.4%~1
2.6%).~1
semisolids~1
(28.1%~1
hour)~2
(47.8%~1
7.2%~2
fullness~2
nausea.~1
strain-gauge~7
capacitance~4
plethysmography.~4
Capacitance~1
sulfadiazine~4
1100~3
sulfadiazine.~1
excision.~15
sheep,~6
(CSTAT~1
CDYN),~1
PaO2/FiO2,~2
lymph,~3
(chemotaxis/chemikinesis),~1
preburn~1
950~1
980~1
peroxidation,~1
malondialdehyde~2
(MDA)~3
CDYN,~2
organisms/gm~1
MDA~4
CSTAT,~1
PaO2/FiO2~1
protracted.~1
organisms/gm.~1
radical-induced~1
diabetes,~31
TcPO2.~2
(slow~2
limb).~1
trouble-free~1
drugs'~1
Vinca~1
(VER)~2
(VCR)~2
B16~1
F10~1
VER,~3
VCR,~1
VCR~5
VER.~1
VER~6
colonies;~2
40.4~3
53.7~2
(GM-CFC)~1
GM-CFC~1
5-FU.~1
oncolytic~2
(43.8%)~1
(30.2%).~1
hypermetabolism~1
Enflurane~3
ileus.~1
bioartificial~1
chimeric~6
synthetics~1
urodynamicist,~1
experimenter~1
identification,~6
cystometrogram,~1
History~4
urgency~4
cystometrogram~1
penis:~1
bladder;~1
infundibular~2
pancalyceal~1
ileal-ureteral~1
Epidermoid~2
Simple~6
coincidental.~1
neodymium:yttrium-aluminum~1
(CIS);~1
lesions;~5
TINxMo,~1
T2NxMo,~1
T3NxMo~1
Calmette~1
Guerin~1
instillation.~2
CIS,~2
select,~1
refuse~4
mullerian~5
differently,~1
(DT)~2
volume-doubling~1
(DTcv),~1
(DTt),~1
needling~1
DTcv~1
DTt~4
doublings~2
DTs~2
ADRs,~1
doublings/year,~2
torsion,~2
(15-19~1
(15-40~1
testes.~4
myoglobinuria~2
testis,~8
flutamide~6
estramustine~3
(CV)~1
randomization,~1
flutamide.~1
icterus,~1
CV~2
flutamide-treated~1
initially.~6
estramustine-treated~2
nonresponder.~1
libido,~2
libido~2
estramustine,~1
unacceptable.~1
watershed~2
seventy-two-year-old~1
alkaline-encrusted~1
struvite~4
urology.~1
seventy-one-year-old~1
mitoses,~2
(TURP)~2
Pathogenesis~2
transurethrally,~1
clinicoradiologic~1
knowledge.~2
nonintervention,~1
trauma-related~3
signet~2
(NOS,~1
Immunohistochemically,~2
likewise~2
M1~3
herein~12
Urodynamic~1
3/4~3
188~2
20%,~5
44.3%~1
response".~1
SAA~4
SAA-response~1
(CRP),~2
good.~12
electrolytes~9
peroral~6
handle~7
hyperglycaemia~1
mmol/l.~5
(HbA1c)~1
(9/198).~1
50-year-old~10
Uppsala,~2
2322~1
non-participants~2
Registration~1
Temperance~4
Bureau~2
Services~7
non-participation~2
registration~8
Services,~3
Board,~1
(IHD),~1
intemperance~2
IHD~3
(classified~3
Board.~1
IHD,~1
IHD.~1
(GCA)~1
9-16~2
Corticosteroids~1
men).~2
GCA~1
members,~5
HLA-haplotype~3
B15,~1
Cw3,~2
DR4.~1
74-year-old~2
tongue.~3
Legionnaires'~3
64-year-old~1
hairy~10
Immunological~2
monocytopenia~2
hyperthermia,~5
petechiae~1
Neurologic~9
posturing~2
fluffy~1
Parental~1
parent.~2
self-concept~1
empathic~2
327~5
unacceptably~4
Pyoderma~2
gangrenosum~9
stressful~2
Pseudotumor~1
papilledema,~1
lives~7
turmoil,~1
conflict.~1
treat.~4
psychodynamics~2
Obstruction~4
mononucleosis.~3
mononucleosis~9
infrequently,~5
unmonitored~3
Telephone~1
"real-time"~1
transmissions~3
"nonlife-threatening"~1
(PVCs)~2
log-transformed~1
PVC,~1
couplet,~1
ECG.~3
87%;~1
PVCs~2
PVCs/hour~2
ventricular,~1
(corrected~1
obstructive,~1
nonobstructive)~1
(HOCM,~1
m/sec)~4
nonobstructive~3
(HNCM,~1
(AS,~1
m/sec;~1
comparisons),~3
HOCM~5
55.7~1
HNCM~5
(84.5~1
8.9~11
AS~9
52.5~2
(348.2~1
91.1~1
(328.8~1
30.4~1
(198~1
21.0~1
(233~1
28.3~1
(44.5%~1
5.9)~1
(49.4%~1
2.5)~1
(36.2%~1
5.4;~1
values.(ABSTRACT~2
sonomicrometric~1
26.47~1
6.20%~1
(S.D.)~6
(control)~7
22.05~1
5.73%~1
(mild~3
5.86%~1
(moderate~2
11.46~1
3.56%~1
(severe~3
3.69~1
2.57%~1
(30-second~1
occlusion),~1
1.08~6
0.894,~1
0.662,~1
harmonic,~1
asynchrony~3
harmonic.~1
phosphorylation,~1
99mTc-labeled~3
mCi)~1
C-treated~1
(NS),~4
BTS~3
49465,~2
oral,~5
direct-acting~2
49465~1
(26%,~1
(-12.6~1
44%),~1
(-13.2~1
31%),~1
(-7.7~1
63%),~1
(-28%,~2
(-24%,~1
0.85).~4
cardiocirculatory~2
0.11;~1
0.58-0.78)~1
349~1
125%~2
Hydralazine~5
intravenously)~4
12.0~6
(3.24~1
4.71~1
L/min/m2;~3
(122~3
bpm;~1
(26.9~1
34.5~3
ml/beat/m2;~1
Beta-thromboglobulin~1
(BTG)~1
platelet-specific~1
BTG~5
50-year-old,~2
(1.22~1
39,~4
(0.82~1
31).~4
0.47,~1
0.14)~1
0.08).~2
atherogenesis~2
ambulant~1
night-to-day~1
22%,~5
26%,~5
"progressive"~1
28%)~1
single-plane~4
transverse,~2
(ES)~3
area-length~2
algorithm.~5
multislice~3
LVEDV~3
LVESV~1
Simpson's~2
NMR-determined~1
LVV~2
(LVEDV:~1
0.75;~2
LVESV:~1
LVEF:~1
0.76).~1
LVESV.~1
underestimation~4
off-axis~1
constraints~10
LVEDV,~1
LVESV,~1
LVEF.~1
High-frequency,~1
low-amplitude~3
QRS,~2
syncope~10
17%,~2
palpitations~3
LP.~2
conclusion:~3
LP;~1
Judkins-type~1
femoral-coronary~1
perforation.~7
territories~4
coaxially.~1
(VF)~3
telemetric~2
739~1
61%),~1
VT/VF~2
(incidence~1
24%).~1
51%,~3
58%,~3
84%,~2
monitor.(ABSTRACT~1
64.5~1
gm,~2
S.D.),~1
(58%),~2
desethylamiodarone,~2
tetraiodothyronine,~1
triiodothyronine,~2
amiodarone.(ABSTRACT~1
indecainide~3
Programmed~3
Indecainide~2
indecainide.~1
slowed,~1
281~3
bpm~10
224~3
tachyarrhythmias.~6
"defibrillation~1
threshold"~1
(DFT),~1
spring/patch~1
DFT~2
(10.3~1
J).~1
trials).~3
increments.~2
DFTs~1
87.5%~5
26%).~2
sigmoidal~1
(E50)~2
(E80)~2
E50~2
(5.0~1
J)~5
E80~2
(6.3~4
trabeculated~1
moderator~2
pulmonic~1
overload,~4
(regular~1
irregular)~1
(reperfusion~1
nonreperfusion)~1
(previous~1
tobacco,~3
hyperlipidemia),~1
0.1),~3
(MI),~2
predischarge~4
postinfarction~4
arrhythmias)~1
MI.~3
(1-year~2
age-predicted~2
(predictive~2
98%).~1
13%),~2
bpm.~1
(CO),~4
Doppler,~1
Gauges~1
preload,~5
micrograms/kg/min.~2
Percent~6
0.5).~3
2%).~4
2%)~3
0.48),~1
0.4),~1
0.46).~1
deuterium~2
(2H~1
(2H2O)~1
2H~1
2H2O~1
fast,~3
2H2O,~1
Jersey~5
vegetables~4
fruits~4
carotenoids.~1
900~11
eat~5
seasons,~1
in-season~1
out-of-season~3
asking~2
all-year-round~1
seasons~1
Substituting~1
Carotenoid~1
winter-fall~1
summer-spring.~1
pumpkin-seed~2
oxalcrystalluria~1
hyperendemic~1
Ubol~1
Thailand.~2
treatment),~1
5mg~1
day-1,~2
orthophosphate~5
wt-1~1
Causal~1
crystalluria,~1
phosphorous,~1
oxalate,~4
glycosaminoglycans,~3
pyrophosphate.~1
pumpkin~1
seeds,~1
Pumpkin~2
seeds~4
calcium-oxalate~1
pyrophosphate,~1
bladder-stone~1
Zinc~6
iron-folate~2
iron-folate,~1
prevalence.~2
ethnicity~1
Hawaiians~1
part-Hawaiian~1
taller~2
Chinese,~1
Filipinos,~1
Japanese,~1
Koreans.~1
combined).~1
sodium:potassium~2
Quetelet's~2
electrical-conductivity~1
(TOBEC~1
convolution~1
instrument,~3
isotopically~2
(TBW)~2
densitometrically~2
(LBM),~1
LBM,~1
TBW,~1
19-35~1
zero-,~1
first-,~1
second-order~1
(FC0,~1
FC1,~1
FC2)~1
LBM~2
0.99,~2
TBW~6
0.96,~4
LBM:~1
(kg)~2
22.998~1
0.102FC0~1
0.062FC1~1
0.29FC2(R2~1
0.983~1
255~4
Paffenbarger~1
Paffenbarger,~1
(LSI),~1
Baecke~1
survey.~8
Activity~11
leisure-time~2
pursuits~1
walking)~1
Unselective~1
baby.~2
Birmingham.~1
(distance)~1
etc)~1
predictors.~1
predictive,~2
laying~1
anticipation~2
Interpregnancy~1
703~1
0-2~1
birthweight~7
(131~1
birthlength~1
2500~7
Ca,~2
K,~7
Na,~6
Cu~4
Mg,~1
quadratic~1
low-mineral~1
milk-based~1
Se/L.~2
Se-supplemented~3
mo).~1
unsupplemented~2
micrograms/L~5
formula-fed~4
(PUFA,~1
LO)~1
GLC,~1
ileostomates.~1
PUFA~1
LO~4
28%,~3
PUFA.~1
LO,~1
blood-lipid~1
hyperlipidemia.~7
Nutrient~3
repeatedly.~1
Hypertensive~4
HDL-cholesterol~8
Mildly~2
hyperlipidemic~6
L4~1
circumferences,~1
0.84).~1
waist:hip~1
waist:thigh~1
dextrin~1
maltose~4
lipogenesis.~1
RQs~1
RQ~1
Glycemic~1
10-g~1
apple,~2
banana,~2
grapes,~2
honeydew,~2
orange,~3
strawberries~2
beans,~2
turkey,~1
margarine~1
fat).~1
Blood-glucose~1
apple~5
banana~1
blood-glucose~1
fruit.~1
[that]~1
(specific~1
action)~2
obligate~1
(basal~1
growth)".~1
carcass~7
Atwater~1
aromatization.~3
estrogenic~2
estrogen-sensitive~1
leaner~1
androgen,~1
energy-restriction~2
fat-composition~1
Carefully~2
revealing,~1
hyalinizing~1
whorled~2
Hyalinizing~1
mediastinitis~4
develop.~10
cataracts.~2
i~4
cataracts)~1
traits~3
phenotypes.~3
MB~3
nonuremic~2
QuiCK-MB~2
Immunoassay~2
Labs),~1
Tandem-E~1
(Hybritech,~1
Inc.).~1
died)~1
died).~1
transplant.~2
contingency~1
tables,~2
5.47;~1
EU/L~1
6.56;~1
immunocompromised~13
protean~2
(HT)~1
nodule,~1
77;~1
5;~1
goiter,~2
erroneous~2
uncovered;~1
inexperience~1
mistakes.~1
disappear~8
sorting~4
corroborative~1
discard~2
HT.~1
Secretory~1
lobules.~2
Hormonal,~1
anti-psychotic,~1
anti-hypertensive~1
lactational~1
(GER)~3
Intraepithelial~4
(31.5%)~1
(33.3%)~5
quantitation,~2
pyloridis.~1
pyloridis~13
hematoxylin~7
eosin~6
(95.5%)~1
ulcers.~6
amoxicillin,~2
cephalothin,~1
gentamicin,~3
tetracycline,~1
coumermycin,~1
novobiocin,~1
clorobiocin,~1
nitrofurantoin.~1
nalidixic~1
anti-arrhythmic~1
(APT).~1
(6.4%)~1
APT~3
Mural~2
pneumocytes~3
phospholipidosis.~1
Technicon~1
H*1~2
computerized,~2
linearity,~1
carry-over~2
(white~1
[WBCs],~1
[RBCs],~1
[Hgb],~1
[Hct],~1
[MCV],~1
[MCH],~1
[MCHC],~1
[RDW],~1
[Plts]).~1
0.98~8
greater,~7
MCV~3
RDW~2
0.93,~2
Plt~2
ranges.~4
WBCs~1
10(3)/microL~2
10(9)/L)~1
10(9)/L).~2
CBC~1
analyzer~4
report),~1
hematology.~1
headspace~3
isopropanol,~2
n-propanol,~1
t-butanol~1
acetonitrile.~1
partitioning,~1
volatiles~1
(5:1)~1
Fires~1
precautions.~1
fires,~2
Vitreous~3
(SIDS),~1
succumbing~1
Chief~1
Examiner~1
neuropathology,~1
bedroom.~2
anticonvulsants~5
decedents~1
infiltration,~4
basophilic~3
concerned.~3
Fibrosis~2
Opinions~1
identity,~2
verify~7
helium-neon~1
exposition~1
Segments~2
decapitation~2
(perceptible~1
examination)~1
cyanide,~1
albino~7
exhaust~1
fires~2
cars~2
(complete~2
combustion,~2
5.2%,~2
1.95%,~1
(870~1
(0.6-1.3%)~1
(PCO2)~1
(CO-Hb)~1
(91.2~1
8.1%~3
(PvO2,~1
PaO2)~1
CO-Hb~1
(57.7~1
16.0%~1
61.2~1
CO-Hb,~1
cyanide~10
True~6
occurrences~4
weapon~3
customs~2
classifying~7
vehicular-related~1
"hit-and-run"~1
manslaughter~1
manners~1
County.~1
essence~3
scientist~1
untested~1
aftermath~1
Delta~2
Airlines~1
Flight~1
D/FW~2
Airport~1
Friday,~1
plans,~3
untried~1
odontological~1
Abu~1
Dhabi~1
aviation~1
accident,~4
misguidedly~1
teams.~3
6.24%~1
Toxicology~1
485~4
24-year~1
procuring~1
xylene.~1
xylene~2
(880~1
(3,300~1
covers~7
murder~1
Washington,~3
19,~5
patrons~3
gambling~1
club~2
murdered~1
robbery.~1
microscope,~1
dermo-epidermal~1
Cut~1
reconstitution~1
crests~1
creases~1
reappeared.~1
15th~1
(instantaneous)~1
passenger~1
Scene~1
medicolegal~2
smothering~1
chromogenic~2
Limulus~2
(92.3%)~1
endotoxemia~4
caval:~1
1st,~1
2nd,~2
3rd~4
esophagogastric~7
well-compensated~1
cirrhotics:~1
coma:~1
survived:~1
bilirubin:~1
activity:~1
-0.59,~1
paraesophagogastric~1
pyloroplasty,~1
(410~1
912~1
hypertension).~3
hypertension),~2
gastro-~1
additionally.~1
1586~1
pancreaticobiliary~6
(AJPB)~1
(1.5%).~1
(66.7%)~2
AJPB~2
cholangiography.~1
(53.5~1
AJPB.~1
pancreatic-biliary~1
(92.3%).~1
Gallstones~1
(17.5%).~1
AJPB,~1
roentgenographically~3
Prognosis~8
gastroparesis~3
neuropathy;~2
Solid~1
Visceral~2
sucralfate~13
three-way~4
phases:~2
prednisone;~1
(active~2
prednisone)~2
Bioavailability~1
half-life.~4
prednisone.~11
alteration.~1
food;~2
liquids.~1
extraluminal.~1
treated,~11
cardia,~3
infiltrating.~1
obturation~1
Garren~1
bubble,~3
gastroscopy,~2
balloons.~4
Mastocytosis~2
myelofibrosis,~1
hemochromatosis~6
phlebotomy-treated~1
hemochromatosis.~2
varices.~3
65-yr-old~1
achalasia,~2
Heller~2
myotomies.~1
tortuous~7
defeated~1
improvised~1
Brown-McHardy~1
endoscope~9
radiological,~2
radiating~4
esophagogram,~1
Nodular~1
rims,~1
"nodular~2
liver"~1
leiomyosarcoma.~2
66-yr-old~1
cystadenocarcinoma.~1
cystic,~2
ribbon-like~1
enolase,~3
chromogranin,~1
7-epitope.~1
innumerable~1
neurosecretory~3
genetics~4
convention,~1
conditional~1
pairing~2
assortment~2
mates~1
assortative~2
adoptees.~1
matrices~2
genetics.~1
Czechoslovakian~1
HbA2~1
beta-thalassemia.~2
possibility,~5
mapped,~2
cloned,~3
4,237~1
IVS-2.~1
delineates~2
nonhomologous~1
goiter.~3
adenomata~3
calcification.~4
penetrance~2
C1R~2
subcomponent~1
codominant~1
C1R*1~1
C1R*2~1
.934,~1
.066,~1
.899,~1
.101,~1
salts)~1
osmole.~1
UNa+K.~1
Making~1
vancomycin.~1
200/microliter.~1
vancomycin-induced~1
agranulocytosis,~1
Vancomycin-related~1
mucormycosis~1
pancytopenia.~1
debridement,~4
alpha-2-interferon~1
Hairy~2
lymphoreticular~2
Opportunistic~1
Listeria~2
monocytogenes~3
cerebritis~1
Putative~1
lineages.~1
breast/ovarian~1
consonant~2
extra-ovarian~1
mesothelium.~1
nuances~1
IIIB~5
IVB~2
fifth,~1
pursue~2
Asplenia~1
agenesis,~1
51-year-old~4
vasodepressor~2
Establishment~1
"swallowing~2
syncope"~2
bradycardia,~5
A-H~2
maneuvers.~3
Demand~1
esophageocardiac~1
Orthostatic~3
65-year-old~6
Quinidine~2
alerted~1
hemangioblastoma~3
obex~1
cervical-medullary~1
12-hour~5
0.81,~2
sleep-related~1
university-based~3
oncology~4
Determining~2
delirium~2
Consultations~1
medical-legal~1
supradiaphragmatic~2
(CAV)~2
hexamethylmelamine.~1
293).~1
histoplasmosis~3
Republic,~1
endemic.~2
Gomori-methenamine~1
awaited~1
Amphotericin~1
ketoconazole.~6
Caribbean~2
101),~1
upper-class~1
dysuria~3
(incontinence,~1
fever)~2
(anorexia,~1
asleep,~2
staying~2
weakness)~1
bacteriuria.~4
spontaneously;~1
nonbacteriuric~1
(especially~1
incontinence)~2
bacteriuric~1
nonbacteriuric.~1
4.25~3
4.08~1
mmol/liter~6
18.1~4
51.6~1
(70.4~1
46.9~2
tachyarrhythmias,~2
mirror~2
despite,~1
empiric.~1
emerging;~1
determines,~1
Vasodilators~1
conceptually~2
Nonspecific~1
kidney--including~1
release--that~1
retention;~1
renin-angiotensin~7
vasodilators;~1
favors~3
dissolution~6
contents;~1
bite-and-swallow~1
Monotherapy~2
3/111~1
(50.0~1
(460~1
day);~1
(89.5~2
25.7~3
enalapril~4
(29.5~1
verapamil;~1
3/83~1
5/85~1
monotherapy,~1
counter-regulatory~2
short-~6
cardiomegaly,~2
Belfast,~1
Ireland,~1
gastroenteropancreatic~1
Carcinoid~5
non-carcinoid~1
insulinomas,~1
gastrinomas,~1
remediable~2
underdiagnosed~2
explanations,~2
(H2)-receptor~1
streptozotocin~3
(neurotensin,~1
motilin,~1
peptide),~1
tumors;~4
non-tumor~1
positive)~1
negative)~2
flushing.~1
overproduction--such~1
excretion--are~1
Gallup~2
surveys,~2
Diuretics~2
(76~8
physicians),~1
physicians).~1
trends,~1
fees~4
much"~1
"somewhat"~1
payments~1
parties~1
government.~1
price~1
(Health~2
Organizations~1
Preferred~1
Provider~1
Organizations,~1
others)~2
alike.~2
spiralling~1
$8~2
billion~2
cost-conscious~2
chooses~2
patronage~1
upper-income~1
lower-income~1
prescribing~8
noncompliance.~3
guard~1
incursions~1
stepped-care~2
stepped~2
"profiled-care"~1
Profiled~1
disproportionally~1
physical,~8
profiled~1
affluent~2
communities.~2
economically.~1
"low-cost~1
strategies."~1
uncertainty~4
risk-benefit~1
diastolic)~2
worthwhile?~1
trade-offs~1
confronted~3
30.9~2
31.4~1
adrenoreceptor~2
(oxprenolol)~1
(nitrendipine).~1
Cardiovascular~5
(ultrasonic~4
device),~1
(electrocardiography),~1
stoke~1
(impedance~1
cardiography).~1
blockers,~6
Prescriptions~1
pharmacies.~3
university-associated~1
"slow~1
release"~1
"enteric~1
coat"~1
pharmacies~2
Veterans~7
pharmacy.~1
Adding~3
phrase~1
"not~2
enteric-coated"~1
supplied.~1
Prices~1
generic~4
cheaper~1
brand-name~1
pills,~2
"supermarket"~1
owned~1
Corynebacterium~8
JK~2
leukopenic.~1
perirectal~3
consumptive~2
Heparin~6
thrombus.~6
excisional~8
atypical,~2
reactive,~1
lymphadenopathy.~7
cryptococcosis~2
Haitian~3
cryptococcosis.~2
ill-advised.~1
paraplegia.~3
(Sandoglobulin)~1
four-week~7
Coombs'~3
positivity,~4
host.~4
flavescens~1
flavescens.~1
beta-lactamase,~1
cefotaxime,~4
Hansenula~1
anomala~1
anomala,~1
ascomycetous~1
yeast,~1
alimentary~1
tetrad~1
demyelinative~3
(pre-~1
post-therapy)~1
readings.~3
"overshoot"~1
Painless~2
osteodystrophy~2
Radiologic~3
"bone~3
ends"~1
osteonecrosis.~1
sclerosis."~2
"rugger~1
jersey"~1
osteosclerosis~1
variant.~2
Osteonecrosis~1
Hemophilus~1
epiglottitis,~1
conjunctivitis,~3
Rarely~1
parainfluenzae~2
infects~3
immunodeficient~6
(SLE).~1
PVCs,~2
(28.3~1
(18.7~1
(36.5~1
0.00001).~2
Cox~12
mU/liter~4
Prolactin~2
intrasellar~1
craniopharyngioma;~1
(maximum,~2
5,260~1
mU/liter)~1
prolactinomas~1
hyperprolactinaemia,~1
mU/liter;~1
mU/liter).~1
enlargement,~4
shrink~1
Gastroesophageal~1
scleroderma,~11
Pennsylvania~4
manometric,~2
79,~1
esophagographic~1
so-studied.~1
end-expiration~1
mid-respiration~1
(13.0~1
16.9~2
Discrimination~4
CREST~4
(calcinosis,~1
sclerodactyly,~1
telangiectasis)~1
mid-respiratory~1
scleroderma;~1
metaplasia;~3
adenocarcinoma.(ABSTRACT~1
(102~1
beats/minute)~1
beats/minute;~1
mm;~8
11th~2
That~8
SD:~2
account:~2
polyneuropathy,~3
weakness.~3
ought~2
schedule:~1
hydrobromide,~1
fenoterol.~1
one-second~4
liters),~1
ipratropium-fenoterol~1
liter),~2
bronchodilatation,~1
Noncompliance~3
multifactorial,~1
collective~3
encompasses~3
person's~4
Simply~1
stated,~1
society,~1
person.~4
Prazosin~4
Antihypertensive~2
Agents,~1
Service~10
Party~1
Pooling~1
intolerance,~3
hypertriglyceridemia,~1
arguably,~1
personality.~2
life-style,~1
adverse.~1
unsolved~1
tailoring~2
post-junctional~1
1-adrenoceptor~2
Stamler~1
hydrochlorothiazide.~1
Inouye~1
al~2
hydrochlorothiazide~5
Okun~1
hypertension--mild,~1
Okun's~1
captopril~3
Lowenstein~1
Neusy~1
Thiazide~1
thiazides,~1
High-density~1
atherogenicity--the~1
cholesterol:total~1
atenolol,~3
11.7~5
25.8~2
choosing~11
calcium)~1
vasodilator.~3
important:~2
demography,~1
reduction;~2
concern.~8
available:~2
antisympathetic~1
whole-day~4
between-group~5
dampened~2
untoward~6
co-administered~1
unfavorably~1
Diuretics,~1
vasodilators--the~1
hypertension--have~1
(positive~7
Hypokalemia,~2
(lower~2
levels)~2
(prevent~1
hypertrophy)~1
differently:~2
sympathetics~1
(negative~2
impact),~1
impact).~1
(NYHA~1
class)~1
MVA),~1
catheterization-derived~1
classes,~2
(cath~1
MVA).~1
MVA~2
cath~1
Estimation~1
64copper~3
D-penicillamine,~1
trien,~1
6.04~1
2.74%,~1
1.05%~1
Microbubble~1
microbubbles.~1
agitated~1
postulated.~2
microbubbles~2
remotely~1
chambers,~2
AIDS/AIDS-related~1
abusers,~3
hypercellularity~1
(86%),~2
plasmacytosis~2
(63%),~2
(50%),~2
histiocytes.~1
Granulocytic~1
(77%).~1
Erythrocytic~1
(43%).~2
Megaloblastic~1
59-year-old~6
prosopagnosia~2
anosognosia.~1
cortico-limbic~1
Prosopagnosia~1
material-specific~1
motivational~1
faces:~1
alternatively~1
(visual)~1
basalis~1
innominata~1
(Meynert's)~1
Cat~1
lymphadenitis~1
pursues~1
supranuclear~11
(PSP)~2
torticollis~6
Blepharospasm~1
dysfluency~2
extrapyramidal~2
antedated~1
torticollis.~1
PSP~2
reinforces~3
notions~1
blepharospasm~3
"focal~1
dystonias"~1
Postmenopausal~2
gynecologist.~1
Predicting~1
Jefferson~6
Davis~2
Hermann~2
urine-to-plasma~1
osmolality)~1
prerenal~1
oliguria.~1
replete~3
hyperosmolar~5
preeclampsia-associated~1
gonadotropin,~5
131-labeled~1
(5F9.3)~1
scarring.~4
counting~10
cortisone~4
fetoscopy~1
midgestation,~1
midgestation~1
miscarriages).~1
miscarriages.~1
anticardiolipin~4
abortion,~2
Determination~4
Kell~5
Kell-hemolytic~1
dystocia~12
allegedly~2
mediocre~1
flawed~1
practices,~6
abdominally.~1
vaginally~3
intra-amniotic~1
taste~5
tasteless~1
0.62,~1
1956~1
epoch,~1
unplanned~1
Harlem~1
sociodemographic~2
child-rearing,~1
416~3
planned.~1
married~4
boyfriend~1
husband~1
broadly~1
periconceptional~1
bleeding)~1
gamma-emitting~1
isotope,~1
27.7~1
gm/min,~1
menstruation.~1
labial~3
vulvovaginitis,~2
injury).~1
Fusion~1
soiling~2
coitus.~1
Foot,~1
Negro~3
smoother~2
centimeters:~1
4.5261~1
11.937(F)~1
4.4895(F2)~1
0.71583(F3);~1
5.9957~1
5.7279(L)~1
1.2246(L2)~1
0.11880(L3);~1
5.4007~1
5.0305(A)~1
0.93540(A2)~1
0.079022(A3).~1
acetylsalicylic~2
(Hypertensin,~1
Ciba-Geigy~1
Limited,~1
Basel,~1
Switzerland)~1
(17.4~1
(35.1~3
ng/kg/min).~1
pregnancy-acquired~1
A2/prostacyclin~1
levonorgestrel~3
desogestrel.~1
estradiol-levonorgestrel~2
estradiol-desogestrel~2
each),~1
Ethinyl~1
(+175%)~1
(+330%)~1
(+92%~1
+160%).~1
non-protein-bound~1
contraceptives.~4
protein-protein~1
multicenter,~2
population-based,~2
(leukemic~1
reticuloendotheliosis)~1
thrombocytopenia,~6
acetowhitening~1
Papillomaviral~1
197~5
218~2
papillomaviruses~1
condyloma~4
hybridizations~1
viruses).~1
Differing~1
papillomavirus-induced~1
papillomaviral~1
isovolemic~4
uterus,~10
fetus?~1
metabolism?~1
lambs,~8
extractions,~2
consumptions~1
various,~1
radionuclide-labeled~1
maintained,~5
Triiodothyronine~1
gonadotropin-~1
mediated.~5
mm),~5
Crude~2
125-triiodothyronine~1
pmol/mg~1
affinities:~1
triiodothyronine.~1
Gonadotropins,~2
compete~5
125I-triiodothyronine~1
salicylism~1
Graded~1
(low-dose~1
24.1~1
(high-dose~1
Pups~2
hysterotomy~3
29.~1
Fetal/maternal~1
39.7~2
gm;~3
34.4~1
crown-rump~3
weight/fetal~1
Bioavailabilities~2
suppositories.~1
alcohol-related~10
Craniofacial~2
striking,~1
ounces~1
alcohol,~6
drinks,~2
overinterpreted.~1
thirty-fifth~3
vertex-breech~4
vertex-transverse~3
parturient~4
vertex-transverse).~1
section;~1
presentation).~1
second-born~2
Firstborn~1
1-minute~1
(40.7%~1
11.1%,~2
augmentations),~1
59.2%.~1
augmentation,~1
cm/hr~2
vaginally,~1
delivery:~1
(25%,~2
Discriminant~1
85.3%~1
augmentation.~1
breech~4
vulva.~3
Fryns~2
sibs~2
conformed~1
hernias,~2
polyhydramnios~1
heterotopic~3
unicornuate~2
Laparoscopy~2
six-month,~1
one-year,~1
vitreoretinopathy.~3
5/200~6
(47%),~3
(36%),~4
(30%).~3
buckle~3
decompensation~2
Silicone~3
(47%).~3
Perfluorotributylamine,~1
fluorochemical~3
perfluoropropane.~1
perfluorotributylamine~5
tamponade.~2
interfacial~3
breaks.~3
(foam~2
optically~1
interfacila~1
perfluorodecalin~1
turning~5
vitreoretinopathy,~1
retinotomy~1
subretinal~10
Endophotocoagulation~1
mulberry-like~1
excresences~2
disk,~1
pigmentosa.~3
drusen~4
hamartomas.~1
Confirmation~3
iodine-125~2
pipe~2
pipe.~1
ophthalmoscopy,~2
episcleral~8
plaque.~5
transillumination.~1
uveal~6
cryoenucleation~1
cryoring~1
clumped~1
chromatin~7
ice~2
plasmalemmal~1
matrix,~2
organelles,~1
enucleated~2
cryopexy.~1
necrotic.~2
regress~3
(noted~1
755~1
narcolepsy~1
405~4
ophthalmologists,~3
strabismic~1
contradiction~2
amblyopia~5
nystagmus.~3
(TNF)~2
Experimentally,~2
TNF,~3
TNF.~4
(AMs)~1
TNF~29
AMs,~1
AMs~7
LPS,~2
sarcoid~7
AMs.~2
(84.9~1
units/million~1
immunohistologic~5
cytochemical~5
cryostat~1
glucose-oxidase~1
(EPO).~1
T-immunoblastic~1
EPO~3
fibrillar~2
degranulate~2
cholesterol-rich~3
ostia,~1
Smooth~1
replication,~4
autoradiography,~1
lipid-rich~2
glomerulus~2
cell-conditioned~1
60-70%.~1
1:9,~1
antiproliferative~7
heparinase;~1
protease-sensitive.~1
heparin-mediated~1
Samoyed~1
(SHG)~1
(HN)~1
(GCBM)~1
(LM)~1
capillaries,~7
(EM),~1
GCBM~3
LM,~1
split.~1
EM,~1
bilaminar~1
multilaminar~1
ensued.~5
nonprogressive~2
GCBM.~1
SHG~1
speculation~2
HN.~1
nonterminal~2
20,000-fold~1
45,000~1
7.6.~2
trypsin-sensitive,~1
heat-labile,~1
alkali.~1
"aproliferin."~1
aproliferin.~1
aproliferin~1
coxsackievirus~1
(CVB3o~1
CVB3M)~1
Balb/c~2
equally,~1
(CVB3M)~1
myocarditis.~5
CVB3o-infected~2
CVB3M~1
CVB3o~2
CVB3M-infected~1
recipients,~5
belongs~1
Lyt~1
2+~2
CVB3-induced~2
T-cell-mediated~3
encephalomyocarditis~1
SDS-PAGE~5
overlay~1
lectin-gold~1
Helix~1
pomatia~1
(HPL)~1
glycoconjugates~4
HPL~5
podocyte~3
HPL-gold~1
(adjacent~2
space)~1
overlays,~1
neuraminidase-dependent~1
desialylated~1
podocalyxin.~2
glycoconjugate~2
speculative,~1
strategically~1
architecture,~2
nephrosis-associated~1
podocytes.~1
(ECM)~1
nitrogen-cooled~1
Necrotic~1
lysozyme.~3
Ito~4
desmin~1
Interstitial~4
Types~7
laminas~1
1-day~2
ECM~1
cholangiolar~1
iron-supplemented~2
glutaraldehyde.~1
paraffin,~1
6-mu~1
Myelin~3
Luxol~1
(hematocrit,~3
30.8%),~1
11-day-old~1
11.9%)~1
17-day-old~2
8.5%),~1
myelinogenesis.~1
value--that~1
assign~1
DSM-III's~1
Alaska~1
1-million-acre~1
trust~1
fund.~1
constituency~1
lawsuit~1
trust.~1
legacy,~1
struggle~5
benefits,~2
psychopolitical~1
time-sampling~1
signaled~2
switches,~1
amnesia,~2
alternates~1
discrepancies~5
phenomenology~1
psychobiologically~1
(semantic~1
memory).~1
amnesias~1
framework~8
(DST)~3
DST~8
postdexamethasone~3
DST's~1
great,~1
929~1
954~1
Psychobiology~1
Depression.~1
suicides~2
Hopelessness,~1
interest,~2
subcategories,~1
Hamilton~6
Sandoz~2
Assessment-Geriatric~1
intrapsychic~1
underline~1
chorioretinopathy~2
distressing~2
ridden,~1
combat-related~2
Experienced~2
psychiatrists,~2
reactivated~2
delineated:~1
heightened~4
vulnerability.~1
war-related~1
spiritism~1
spiritist~1
healers.~1
spiritists'~3
therapists',~1
Rogers~1
(1983-1984)~2
criminally~1
insane.~1
probate~1
heard.~1
heard~3
Hearings~1
petitions~1
signed~1
testimony~1
precedents~1
Tarasoff~1
clinicians,~1
laws~2
restrictively.~1
courts~2
rethink~1
liability~4
informed.~1
specify~1
notifying~1
absolve~1
psychotherapists~2
antidepressants,~2
benzodiazepines).~1
underappreciated~1
psychopharmacologic/psychotherapeutic~1
unipolar~7
8.5%.~1
15%-22%,~1
tumescence~4
neurophysiology.~1
"organogenic"~1
impotence,~1
mania~7
amnesia),~1
manic~11
euphoria~2
assaultiveness.~2
Psychosis~1
Bipolar~2
mania,~2
delineation~6
lithium-resistant~1
medication-free~1
inpatients:~2
nonparanoid~3
drug-~1
alcohol-abuse~1
judges~1
videotape,~1
blinks,~1
scored.~1
spoke~2
eyebrow~1
2,268~1
Maryland,~1
9th~2
Diseases~2
(ICDA-8,~1
Adapted~1
ICD-9).~1
Certifier~1
(IHD)~1
ICD~2
differently.~2
decedent~1
10th~4
psychological,~8
three-day~4
record,~3
grams~4
income,~7
functioning.~5
enforcing~1
belt~7
Applying~2
Poisson~3
averted~3
2,600~1
comparisons,~2
announcements~1
understated~1
two-round~1
meeting,~2
nationally~3
influential~3
indications;~1
discussion,~2
864.~1
unanimity;~1
uncover~2
procedure's~1
panelists~1
864~2
rationale.~1
detailed,~3
agenda.~1
amendments~1
grounds~4
6.0/1000~1
9.9/1000~1
13.2/1000~1
age/marital~1
Collection~2
fatherhood~2
21.2~1
conceptions~2
fathers.~1
parenthood.~1
siblings'~1
parents'~1
rebelliousness.~1
cope~3
founded.~1
dissuaded~1
viability,~1
intrasynovial~2
milieu.~1
autograft~4
grossly,~1
inhabiting~2
repopulated~1
Autografts~1
ACL;~1
posttransplant~1
metamorphosis:~1
PT;~1
grafts;~1
ACL.~3
Collagen-reducible~1
dihydroxylysinonorleucine~1
histidinohydroxymerodesmosine~1
"ligamentization"~1
metamorphosis~1
extragraft~1
Ballet~1
stand~2
pointe~3
demi~1
impingement~7
trigonum~5
Stieda's~2
dancer~1
impinged~2
nondancing~1
well-pointed~1
ballet~5
toe~4
dancing.~1
dancing~2
calcaneonavicular~1
bars,~3
talocalcaneal~3
talonavicular~1
Calcaneonavicular~1
synostosis~2
bar.~1
subcalcaneal~2
Running/jogging~1
Subcalcaneal~1
tenets:~1
blocks;~2
review;~1
athletics;~1
runner.~1
contemplating~2
bunion~1
elite~6
athlete,~2
forefoot.~1
chevron~1
bunionectomy~1
middle-distance~1
physiology,~2
walking,~2
jogging,~2
sprinting.~3
620~2
jogging~1
midsupport.~1
toe-off~1
toe-off,~1
push-off~1
hamate~4
authors.~5
accountant.~1
baseball;~1
swinging~1
bat,~1
outstretched~2
hook,~2
refracture~1
defunctionalizing~1
ileostomy,~2
ileostomy;~1
Dehydration~1
readmission~1
Septic~1
nonocclusive~2
vasoconstriction,~3
axis.~7
cholecystostomy~5
Hawkins'~1
cholecystitis,~6
cholecystostomy.~1
cholecystojejunostomy,~1
cholecystitis.~3
cholangiographic~2
Pigment~4
Harlan~1
semipurified~2
animal).~1
amorphous~3
Infrared~2
composition:~1
26.7~4
bilirubinate~1
cholesterol)~1
lithogenic~5
bile,~6
diamine-alcian~2
examination;~2
enema,~4
C2)~1
more)~2
specimens)~2
specimens).~1
imminent~3
concerted~3
stapler~3
encouraging.~5
41.3~1
architecture.~1
Glucan~1
trypsin-binding~1
interleukin-1,~2
glucan-treated~1
immunomodulators~1
1,440~1
tubulovillous~3
diameter),~2
rectum),~1
aspirin-induced~3
phospholipid,~1
back-diffusion~1
cerulein-induced~1
washings.~2
thousand~5
twenty-nine~4
pancreatograms~1
divisum~10
divisum.~2
Hexosaminidase,~1
hydrolase,~2
hexosaminidase~6
recipients;~3
rejection.~1
Diverticulitis~1
electively,~1
proctosigmoidoscopy~1
Morbidity~3
Intermediate~2
hepaticojejunostomy~3
51.5~2
demonstrate,~3
cannulas.~1
six-lumen,~1
radially-oriented,~1
pullback~1
hydrochloric~5
plotting~1
coordinates,~1
vectors.~2
7,963~1
2,469~1
720~4
6,786~1
3,334~1
acid-sensitive~1
atropine-sensitive.~1
bombesin-stimulated~4
proglumide.~1
cholecystokinin,~1
bombesin~6
probability,~2
analogue,~3
peptide)~1
cholecystokinin.~3
methoxyflurane~2
End-tidal~1
mixed-expired~1
washin~2
3-9~2
Multiexponential~1
(multicompartment)~1
studies),~1
metabolized.~1
paresthesias~4
23,827~1
Winnipeg~1
9-yr~2
(1975-1983)~1
18.9/10,000~1
deliveries.~7
primiparas,~1
forceps-~1
vacuum-assisted~1
regard.~3
streptozotocin-induced~1
Halothane,~1
Ca2+)~1
potentiated-state~1
reticulum).~1
(0.6%).~2
counteracted~7
T-10,~1
L-1,~1
dermatomes~2
L-1~4
dermatome.~2
dermatome~2
Arnfred's~1
O2)~1
anoxia,~2
Arnfred~1
13.9~6
anoxia~2
sec).~3
barbiturates~2
anoxic~1
0.75%~10
1:200,000~1
T-6,~1
T-8,~1
T-10~1
head-raising~1
(analgesia~1
Allis~1
dermatomes)~1
(Bromage~1
scale).~1
T-4.2~1
T-8.8~1
0.5.~1
4-hr~1
two-segment~2
(MN-SSEPs)~1
thiamylal~1
isoflurane.~10
MN-SSEPs~1
EP,~1
N13,~1
EP-N13,~1
N13-N20,~1
EP-N20~1
N13~3
EP-N13~1
Isoflurane~8
N13-N20~1
Amplitude~3
time.(ABSTRACT~3
Bupivacaine,~1
30-50~2
randomized.~1
(beta)~1
hepatocyte.~1
bupivacaine.~2
to--and~1
during--cerebral~1
pigtail~3
Monkeys~1
preparatory~1
1/70~1
preestablished~2
preischemia~1
dextrose-treated~1
dl-1)~1
(140~3
dl-1;~1
0.07).~2
Dextrose~1
postischemia~1
insular~2
dl-1~2
0.76;~2
56.7~2
244~1
5.11~1
g-1~8
hyperoxia~9
(fraction~3
[FIO2],~1
nitrogen)~1
0.125~5
(CI)~2
(PVRI)~1
FIO2~6
0.125.~1
Hypoxia-induced~2
PVRI~4
CI,~5
PVRI.~1
inflations~2
PVRI.(ABSTRACT~1
chemiluminescence~4
(0.0156~1
washing.~1
Transesophageal~1
(TEE)~1
TEE~2
(midcavity).~1
Global~3
(FAC).~1
FAC~4
(SWT)~1
digitization~1
SWT~1
(RWM)~1
RWM~1
intracutaneous~1
pollen-sensitive~1
1-mL~1
rows.~1
row~2
eg,~2
Nystagmus,~1
head-deviation,~1
degranulation,~2
endolymphatic~2
(SULFITEST;~1
Laboratories)~1
sulfiting~2
SULFITEST~2
strip~10
product)~2
food)~1
sulfite-containing~1
sulfites.~1
Dependence~1
sulfite~1
acid-containing~1
mL/kg~1
solution)~1
0.025%~1
solution),~2
single-dose,~1
Spirometric~2
180,~3
240,~1
300,~1
half-dose~1
full-dose~3
indistinguishable.~2
Procaterol~2
non-blinded~1
post-dose~1
Spirometry~2
hydrochloride's~1
Tremor~1
electrocardiograms,~1
birch~5
standardization~5
(Betula~1
verrucosa)~1
Union~2
Societies,~1
Allergen~6
Subcommittee.~1
(IS)-candidate~1
mg/mL,~1
precipitates~3
immunoelectrophoresis.~1
radioimmunoelectrophoresis~3
(CRIE)~2
radioallergosorbent~2
(RAST)-inhibition.~1
CRIE,~1
RAST-inhibition~2
qualify~2
non-allergenic~1
unjustified~1
endotracheally~10
IV-administered~1
greatly.~1
midaxillary~1
hemidiaphragm.~1
tense~2
venogram~3
periscopically~1
Delay~4
resuscitability~2
fibrillating~1
resuscitator.~1
resuscitated.~2
epinephrine-~1
phenylephrine-treated~2
venous,~4
Phenylephrine-treated~1
127.8~1
83.8~1
129.4~2
87.4~2
areflexia.~1
17-year-old,~1
breakdancer~1
crescendo~1
papilledema.~1
separate,~2
collections.~2
0.484),~1
micrograms/mL~16
62.5%~3
20.8%~1
sustained-release~2
subtherapeutic~1
micrograms/mL),~1
(PPI)~1
(67.4%)~2
(20.2%)~1
wheezing,~5
post-respiratory~1
PPI~2
variables:~4
sounds,~1
incorrectly~7
discharged.~3
5,100~1
overdoses~3
(SVT)~3
aberration.~3
wide-complex~4
SVT~6
66%,~1
SVT;~1
tachycardias.~1
ankle,~2
landmarks,~2
basilic~1
(interns,~1
cutdowns.~1
first.~1
random-source~1
rewarmed~1
humidified~2
(43~7
watts/kg).~1
interhospital~2
interventions,~4
aeromedical~3
nurse,~3
(90%),~4
(72%).~4
transport;~1
transports~1
northeastern~1
round-trip~1
miles.~2
21.8%.~1
helicopter.~1
scene.~2
extrication~1
making.~3
consent~14
purporting~2
authorize~1
deems~1
inadequacy~5
comprehension~7
authority.~1
microcomputer-assisted~1
audit~10
spreadsheet~2
format.~3
tabulates,~1
sorts,~1
updates~2
depicts~1
graphics~4
departmental~1
turnaround~1
audited~2
confidentiality~1
Taser~3
shot~3
criminal~8
.38~1
Specials.~1
"tasered"~3
abrasions,~1
(38%);~1
(1%);~1
Tasers~1
shooting~1
weapons.~1
unsuspected.~1
Quinine~1
18.6~2
(therapeutic~1
micrograms/mL).~1
acuity.~20
bystander~4
cities~2
resuscitability,~1
"Early~2
317~2
seconds),~1
560~3
J),~1
countershocks~1
(1.3~5
incision,~6
expansion;~1
resuscitation;~1
lacerations,~2
garment~2
microcuries~1
Technetium-99-labeled~2
macroaggregated~3
10-mL/kg~1
thorax.~2
trouser~1
80.5%~1
99.6%,~1
91.3%.~1
seizing~2
pentylenetetrazol-seizure~1
Epileptogenic~2
pentylenetetrazol~1
craniotomies~1
electrocortical~3
intraosseously~2
5);~1
routes;~1
(TCA)-overdose~1
indicators.~1
TCA~4
(VAs)~1
(QRS)~1
.10~2
VAs.~1
VAs~2
TCA-overdose~1
ED.~4
(Betadine)~1
scrubbing~1
scrubbing.~1
60-second~1
scrub~1
contamination;~1
closure;~2
intoxication;~1
Wounds~1
clean,~1
infected,~3
wound;~1
reexamination~5
infected;~1
(5.4%)~2
(15.46%)~1
beagles~7
shaved~2
#11~1
blade.~1
(deep)~2
(superficial).~1
reflected,~2
z~2
binomial~2
proportions.~3
superficial.~1
correctly;~1
.59~1
(z~2
1.432,~1
.5);~1
.93~2
5.466,~1
nonpenetration.~1
violation~1
curricula~2
sporadic.~1
arrests~3
attended,~1
(helicopter~1
fixed-wing)~1
in-field~2
team's~1
perspective,~1
concisely~1
colleagues,~1
formal,~1
planned,~1
enrich~2
graduate~2
apprehension~3
(systolic,~1
discern~3
"type~1
II"~1
"beta."~1
Journal~1
(JACEP)~1
(1972-1979)~1
Annals~2
(1980-1984).~1
JACEP~1
(1972)~1
(1984)~1
calculated:~1
clinically;~1
endpoints~3
analyzable.~1
(7.1%)~2
.60~1
difference.(ABSTRACT~1
widow~1
spider~1
(Latrodectus~1
Mactans)~1
envenomation,~1
six-year~8
envenomation~1
bite~13
(79%),~1
(71%).~2
antivenom~1
briefly,~1
evacuation~16
fire.~1
reopen~1
"fire-safe"~1
elevators~1
succinylcholine-induced~1
organophosphate~4
succinylcholine~5
pseudocholinesterase~1
insecticide.~1
eyesight~1
EEGs~3
Barotraumatic~1
disturbances.~10
subtle.~2
sulfamethoxazole~1
(SMX),~1
microdilution~2
(RMP)~1
(INH)~2
(EMB)~1
cavitary~4
RMP-resistant~2
SMX-containing~1
INH~11
(900~1
mg),~5
EMB~2
streptomycin~16
amikacin).~1
INH,~1
RMP,~1
kansasii,~1
SMX~3
99m-labeled~1
(Tc-HF)~1
lung:heart~4
Tc-HF~4
(2.9~2
(1.1~6
(0.7~2
(Tc-HSA),~1
Tc-HSA,~1
study.(ABSTRACT~2
(VT/TI),~1
(TI/Ttot),~1
discontinuing~11
(Time~1
0),~1
wean,~1
AV.~1
VT/TI~1
wean.~2
Tachypnea~1
TI/Ttot~1
weaning.~2
Ketanserin~2
Hg/L~2
ketanserin.~3
60.5~2
66.5~2
admixture~3
PVO2~1
ketanserin~16
VE/delta~4
PaCO2)~3
P0.1/delta~2
(FEV1,~1
L)~2
hydralazine,~3
177%~1
145%~1
17.1~5
hydralazine.(ABSTRACT~1
solubilization~3
tannic~2
fixation-staining,~1
dyskinesia.~3
dyskinesia,~1
"shortened~1
dynein~5
arms,"~1
arms.~3
microtubule,~1
A-tubule~1
spokes.~1
motile,~2
motility;~1
microtubules,~1
microtubular~2
motility.~4
transtracheal~7
PaCO2,~2
spirometry.~2
acceptance.~2
requirement.~3
Oropharyngeal~3
inhaler~5
(MDI)~5
aerosols~7
actuator~3
auxiliary~9
devices;~1
open-end~3
tube,~7
Aerochamber,~3
Nebuhaler,~2
InspirEase.~1
actuator,~1
Aerosol~5
depositions~1
oropharynx~3
MDI~6
aerosols,~1
bronchodilators,~2
L/s,~1
aerosol.~4
72%)~1
Nebuhaler~1
18%)~3
InspirEase,~1
Nebuhaler.~1
(isoflurane,~1
N2O-40%~1
O2;~1
1.56~2
recoil~4
elastance,~3
induction).~1
Resistance~3
pneumotachygraph~1
connectors~1
subtracted~2
elapsed~3
time-dependent.~1
6-wk-old~1
BALB/cByJ~1
(IT)~3
conidia~4
Blastomyces~4
dermatitidis~2
(FW~1
CR)~1
2-wk-old~1
(Pine-Drouhet~1
hyphal~2
polycarbonate~5
micron).~5
Inocula~1
nonpyrogenic~1
(NPNS)~1
viability.~2
(FW)~1
extrapulmonary~4
FW~2
44,~2
55.~1
NPNS~1
blastomycosis~4
Variation~5
92,~1
10(6),~2
10(5),~1
10(4),~2
10(3)~2
conidia,~1
Dissemination~1
cachectic~1
pathogenesis,~4
blastomycosis.~1
BAY~15
K8644~4
(VDC).~1
KCl,~1
VDC~2
K8644.~1
Contractile~9
carbachol-induced~2
carbachol.~4
factories~1
Shanghai~2
439~1
nearby~5
mill.~1
postshift~1
(FEV1)~3
mg/m3)~1
Endotoxin/m3).~1
FEV1/FVC%,~1
FEV1%),~1
byssinosis,~1
FEV1%,~1
FEV1%~1
models.(ABSTRACT~1
influences,~2
twinship~2
(DZ)~3
Greater~7
intrapair~4
anthropomorphic~3
adjusted.~1
0.76,~1
MZ~6
DZ~5
shipyard~1
roentgenogram,~3
(VO2).~1
66)~2
VO2,~5
predicted,~6
49.~1
DLCO~2
AaPO2,~1
dead-space/tidal~1
transsexual~1
silicone.~3
PaO2,~2
brawl.~1
history).~1
pleomorphic,~1
inclusions,~2
degree.~6
parasympathetic/cholinergic~1
intranasally~3
methonitrate~1
colds.~2
sprays~1
dryness~1
(AM~2
39.~1
colds~1
(CFA)~2
lavages~4
improve,~1
deterioration.~5
Consecutive~1
responders.(ABSTRACT~1
(PC20),~1
PC20)~1
(skin~3
titration).~1
(APC20)~2
(HPC20)~1
(SS)~3
formula:~5
Log10~3
(HPC20~2
SS)~3
developed:~1
(APC10)~1
log10~3
0.82)~1
8-fold~2
investigator's~1
(10-fold).~1
(SS,~1
RAST)~1
methacholine~8
4,417~1
graduation~2
bacille~1
tuberculin-positive.~1
1,088~1
unimmunized,~1
tuberculin-negative~2
tuberculin~12
unimmunized~4
reactors~7
BCG-vaccinated~1
1,460~1
chemoprophylaxis,~1
age).~3
graduation,~1
antituberculosis~2
Bronchoalveolar~4
(EAA)~1
asbestosis~1
EAA~3
BAL-cell~1
anti-IgE.~2
"mucosal"~1
"connective"~1
formaldehyde.~1
"blast"~2
after,~3
(BIP).~1
parameters:~6
alveolocapillary~1
BIP.~1
133Xe~5
BIP~1
BIP,~1
growth-arrested~1
1.023~1
1.035,~1
1.036~1
1.049,~1
1.052~1
1.059~1
growth-inhibiting~2
traverse~3
noncycling~1
cycling,~4
densest~1
lavaged~6
arrested~8
1.83%~1
antibody-forming~1
(AFC)~1
(SRBC).~1
performed:~2
AFC~7
adoptive~6
(HLN)~1
HLN~6
SRBC~2
AFC-responses~1
left,~5
Priming~1
AFC;~1
preserved.(ABSTRACT~1
tracheoesophageal~5
corrosive~1
esophagogastrectomy,~1
esophago-colon~1
prognosticate~2
been:~1
Anastomosis~2
preferable;~1
dilates~1
adequate;~1
isoperistaltic~3
used;~4
acid-peptic~1
"sump~2
bariatric~6
diseased.~1
cholecystectomies~1
724~3
drained.~2
choledocholithiasis.~2
echogenic~2
bacteriology~3
sequestration.~4
monomicrobial~2
mentioned,~1
(PEG-ELS)~1
whole-bowel~1
(97%)~8
lavage.~6
Unpleasant~1
PEG-ELS~1
rare;~2
slings~4
ingrowth.~2
Gore-Tex~1
pulling~2
posteriorly,~1
distend.~1
Georgia~1
Perforation~1
Levin~2
close:~1
25.29~1
Levin,~2
26.56~1
20.49~1
25.14~1
Output~2
Drainage~2
"tube~1
fever"~1
Mesenteric~5
Agnes~1
mesocolon~2
(88%),~2
hemicolectomy~1
1460~1
(96%).~2
275~3
(105~1
meq/L)~1
pg/mL,~2
low-normal~2
fludrocortisone~1
AS),~1
intensify~2
altitudes~2
AS.~6
("cases")~1
AA)~1
simulations~6
(ranging~2
1524~1
7620~1
[5000~1
ft])~1
hypobaric~1
(DLco),~1
midexpiratory~1
Altitude~1
DLco~4
cumulatively~1
nonexercising~2
(6.6%)~1
episode.~6
Serologic~2
1668~1
IU/L~4
convalescence,~1
1027~1
Stools~2
32P-labeled~1
cDNA-hepatitis~1
mg/wk).~1
worsen,~1
mg/wk),~1
disappeared,~4
worsened,~1
hepatotoxicity~9
suprofen,~1
country,~2
IgM-reducing~1
cold-reactive~4
IgG;~1
Mycobacterial~1
complex;~1
commoner.~1
Extrapulmonary~2
noncavitary,~1
nonapical~1
four-drug~1
rifabutine~1
clofazimine,~1
infectious,~3
infection-control~1
contact-tracing~1
Persons~8
397~2
61.1~2
(87.3%~1
cm2).~4
("prefailure~1
symptoms");~1
signifies~1
malfunction.~2
units'~1
based,~3
(47%)~10
later;~3
then.~1
geriatrics.~2
targets,~4
humanistic~7
marred~1
ambiguous~1
goals.~2
humane~3
qualities:~1
attitude,~2
concepts,~1
humanities~2
teaches~1
ends.~1
areas;~1
consent,~4
(Emr)~1
plasmid~5
pNE24~4
epidermidis.~2
26.5-kilobase~1
encodes~4
14-membered~1
macrolide~1
oleandomycin.~1
macrolide-lincosamide-streptogramin~1
(MLS)~1
MLS~1
Plasmid~1
(62.5~1
erythromycin.~2
erpA,~1
14C-labeled~2
958-2~2
(containing~2
pNE24)~1
erythromycin-susceptible,~1
isogenic~4
958-1.~1
[14C]erythromycin~1
ribosome~1
ribosomes~1
958-1,~1
ribosome.~1
pNE24;~1
60,000-dalton~1
(958-2)~1
Norfloxacin,~1
quinolone~1
identical-appearing~1
traveler's~2
Prophylaxis~2
unformed~2
norfloxacin-treated~2
bacilli.~3
discontinued,~4
Mezlocillin~1
mezlocillin~1
5-g~1
4-g~1
nitroheterocyclic~1
aerobic,~3
microaerophilic,~1
Nitronaphthofurans~1
(MIC~3
[MIC50],~1
mg/liter).~3
rough,~2
repair-deficient~1
nitroreductase-deficient~1
resistant.~4
Microaerophilic~1
(MIC50,~3
mg/liter)~1
nitronaphthofurans~1
Nitrothiazole~1
nitronaphthofurans.~1
Metronidazole,~1
nitroimidazole~1
nitrofurans~1
Nitrobenzofurans~1
MICs.~1
difloxacin~3
400,~3
200-,~1
400-,~1
600-mg~1
2.17,~2
4.09,~1
20.6,~2
27.1,~1
28.8~1
h;~5
one-compartment~4
glucuronide,~2
N-desmethyl~1
filtrate.~2
dose-normalized~1
ME1401,~1
haloprogin,~1
clotrimazole,~1
miconazole,~2
tolnaftate,~1
ciclopirox~1
olamine~1
ME1401~4
428~2
yeasts~2
haloprogin~1
tolnaftate~1
rubrum.~1
cross-resistance~1
fungicidal~1
pyrrolo[2,3-d]pyrimidine~1
nucleosides~1
tubercidin,~2
toyocamycin,~1
sangivamycin,~1
xylosyl~1
xylotubercidin,~1
(HSV-2)~1
host,~3
xylotubercidin~3
HSV-2~2
(intraperitoneally)~1
herpetic~3
therewith~1
hairless~4
intracutaneously~1
Xylotubercidin~1
streptomycin-susceptible~1
(MIC,~2
enterococcal~3
(3.5~1
flucloxacillin~5
volunteers)~2
monitored.~12
penetration.~3
Flucloxacillin~2
Penetration~2
rapid.~1
blister~7
60.4%.~1
Penetration,~1
38.2~3
11.7%~1
liters.~2
albumin.(ABSTRACT~1
[14C]teicoplanin~2
10,000-U/kg~1
three-exponent~1
76.3%~1
feces.~4
carcasses~3
11.1%.~1
Teicoplanin~1
hemoglobin-supplemented~1
Polyvitex~1
Capnocytophaga~1
Clindamycin~5
Amoxicillin-clavulanic~1
imipenem~1
[MIC90],~1
microgram/ml);~1
BMY~2
28142,~2
cefpirome,~2
(MIC90,~2
Ciprofloxacin~2
quinolones,~2
Ampicillin,~1
temocillin~1
polymyxin~4
vancomycin,~2
trimethoprim,~1
beta-lactamase.~1
19F~1
flucytosine~1
(FC;~1
5-fluorocytosine)~1
tropicalis~1
FC.~2
fluorinated~2
F-nucleotides~1
(Fnt),~1
F-nucleosides,~1
(5FU).~1
Fnt~3
5FU~3
peaks;~1
5-fluoro-2'-deoxyuridine-5'-monophosphate.~1
strain;~2
UMP~2
pyrophosphorylase.~2
FC~2
(8%);~1
[3H]streptomycin~1
faecalis,~2
sanguis,~1
mitis)~2
Moellering~1
Weinberg~1
(R.~1
Moellering,~1
Jr.,~1
Weinberg,~1
Clin.~2
Invest.~2
50:2580-2584,~1
1971).~1
beta-lactam-induced~1
viridans~4
sanguis~1
beta-lactam-aminoglycoside~1
potentiation.~2
subsp.~1
anitratum~1
lwoffi~1
4-quinolone~1
BRL~1
36650,~1
lwoffi.~1
pseudoestrous~1
cornification~1
candida~1
LY146032~4
staphylococci,~3
streptococci,~2
oxacillin-resistant~2
strains;~2
streptococci);~1
enterococci.~1
oxacillin~1
persister~1
plate-count~2
standardization.~1
oxacillin,~3
killing.~1
Aeromonas~4
caviae,~1
hydrophila,~1
sobria~1
cephalothin.~1
active;~2
subinhibitory~1
A-rich~1
moxalactam,~1
clindamycin,~3
Cefoxitin,~1
gentamicin).~1
Gardnerella~1
vaginalis,~1
agalactiae,~1
spp.,~1
Mobiluncus~1
tetM~2
agalactiae~1
genera~1
areata~2
(AA)~4
AA~8
universalis~1
(AU)~1
(nude)~1
hair-bearing~1
hairs~4
AU~6
AA.~1
AU,~2
humorally.~1
minoxidil-induced~1
antiandrogenic~4
minoxidil~21
androgen-dependent~2
hamster.~3
Minoxidil~2
spot,~2
enlargement.~4
clinicians'~1
minoxidil,~2
Dermatology.~1
dermatologists,~1
prescribers~1
underreporting~1
noncutaneous~1
Ehlers-Danlos~7
procollagen.~1
hypermobility~2
hyperextensibility~1
worldwide,~2
nevi,~2
color,~3
Dysplastic~1
multiples~2
heritable~3
Intraepidermal~1
fulfilling~4
contiguity~1
nonfamilial~1
curable~6
hypothyroidism,~6
hypertrichosis,~1
hyperpigmentation,~2
Terry~1
Discovery~1
Crow-Fukase~1
hyperlipidemia~5
xanthoma,~1
(MF).~2
MF~3
histiocyte~2
MF,~1
Xanthomas~1
normolipemic~1
chloroform~2
welder.~1
nonflammable~1
intratracheal~3
chrysotile,~1
time-dependent,~3
10(4);~1
micron)~1
10(5);~1
pleura.~1
(Pb)~1
teratogen.~1
(Pb-B)~1
mother-infant~3
Brazelton~1
(NBAS),~1
Graham/Rosenblith~1
(G/R)~1
Pb-B~2
Pb-B.~4
scales--the~1
NBAS~1
Reflexes,~1
G/R~2
Sign,~1
Tonus~1
Scales--were~1
Pb-B,~1
Sign~2
Pb~1
(NO2)~1
Exposures~1
1-wk~2
humidity~5
preexposure,~1
normocapnic~3
subfreezing~1
ppm.~4
unexplained,~2
productive~4
29.0%~2
flour~7
mill,~1
26.0%~1
phlegm.~1
phlegm~1
22.0%~1
tightness~3
(FEV1.0)~1
FEV1.0~1
17.0%~1
6.6%.~1
Circadian~2
vegetarians.~1
copper.~1
0600~2
0.185~1
0.106~1
0300~1
Remarkably~2
(64.49~1
15-100~1
(0.134~1
deviated~1
phasing~1
particulates~4
interiors~1
condominium~1
homes~12
conditioning~15
open-type~1
Hawaiian~1
homes.~3
Andersen~1
samplers~1
enumerate~1
respirable~2
residences.~2
contaminants~3
outdoors~1
fungi,~3
Cladosporium~1
sp.,~1
sp.~3
outdoors.~1
Gram~5
cocci~8
air-conditioned~2
outside.~1
sneezing,~1
congestion,~2
Lead~3
3-15)~1
finishing~1
infinity)~1
metallothionein~6
(MT),~1
(Cd),~1
(Zn),~1
(Cu).~1
Cd/Zn~1
mid-age~1
Cadmium~1
Cd~6
40.1~2
79.0~2
MT~7
Ag-hem~1
Cd-hem~1
(lead,~2
cadmium,~1
arsenic,~2
manganese,~3
chromium,~3
cobalt,~3
tin,~2
aluminum)~1
female).~2
iron);~1
(cadmium,~1
nickel);~1
(manganese~1
mercury);~1
(aluminum).~1
(iron,~1
cobalt)~1
Accounting~1
metals,~1
1953-1983~1
(71%~4
36%,~4
oophorectomy~2
1974-1984.~1
31.2%.~1
20.8%,~1
28.3%~1
36.9%~1
(60.8%~1
47.3%~1
syncronous~1
oophorectomy.~3
predictivity~1
22.3%,~1
(36.6%).~1
longstanding~6
93.8%~1
(6.2%)~4
error).~2
45.5%,~1
none,~1
good-risk~2
perforations~6
Truncal~2
re-evaluation~2
dismal~2
(13.4~2
pmol/L~3
Gallbladder~7
attaining~1
(62.7~1
area),~2
CCK,~4
refilling~2
1963-1985.~1
HBs~3
42%,~4
Prognostic~5
cm),~2
diverting~5
megavoltage~1
rad/fraction,~1
continuous-course~1
3500~1
6000~2
4800~1
rad.~3
patient),~11
determinate~3
nonparasitic~1
(NPHC)~1
Roux~1
1970-1984~1
NPHC~2
unroofing~6
Roux-en-Y~5
stained.~1
interposition.~3
only)~1
(3.5%).~1
scleroderma.~7
(3.6~2
(10.4~2
condensed~2
1-second~1
peristaltic.~1
Paneth~1
Penetrating~7
(PCTI)~1
(PTTI),~1
(PATI)~1
Moore~1
(PTI),~1
(Physiologic~1
PI),~1
(1973-1983)~1
PCTI~1
0.827~1
0.928,~1
(PTI).~1
PTI~1
(PCTI~1
PTI)~1
(PI)~3
1058~1
1980-1984,~1
373~2
685~1
(8.8%).~1
midrange~1
independent,~3
(68.1%).~1
in-situ~2
(ISVB).~1
(RVB)~1
1980-1986.~1
RVB~3
splicing,~1
93%.~5
ISVB.~2
metastasizing~3
leiomyofibroma~2
holder~3
graft-to-coronary~1
graft-to-aorta~1
forceps,~2
Pancoast~1
margin,~1
56.1~1
12.7%~2
514~3
2,601~1
(238/452)~1
Valve-related~1
event-free~1
first-event~1
patient-year)~1
anticoagulant-related~2
0.2;~4
0.2.~1
October,~2
December,~3
Puig-Massana-Shiley~2
triangular-shaped~1
(49%),~1
(6.3%)~4
(8.7%).~2
Murmurs~1
demanding.~1
climate~2
quality-assurance~2
policies,~2
rigorous~3
assignment~4
(emergent,~1
elective),~1
Class,~1
Artery~2
(CASS)~2
manager~2
computer.~7
1,303~2
913~1
(CABG).~1
(Table:~2
text).~1
CABG,~1
(2/329);~1
(5/450);~1
(7/134).~1
assurance.~2
CASS~1
male)~2
Aortography~2
arteriosum~1
20.~3
endocardiectomy~2
mitral,~8
Sree~1
Chitra~1
Tirunal~1
Kerala~1
postoperation~1
21.7%~2
13%,~3
Non-fatal~1
inclusive~3
dismal.~1
mediastinotomy~1
64.5%~1
98%.~2
1.6%,~1
apical-aortic~1
conduit.~4
Sixty-four~4
omicron)~1
non-small~4
2.4-29~1
cardioplegia~11
aorta)~2
sinus)~1
thermograms.~1
thermographic~3
antituberculous~1
anti-D~2
(740~1
MBq)~1
Tc~5
99m;~1
Favorable~3
(AOPE)~1
ATP,~4
AOPE~2
639~1
535.~1
80%,~6
admit~2
(IPG)~1
(DVT),~1
IPGs~3
IPG~2
five-month~1
(81/425)~1
IPGs).~1
(VFI),~1
VFI~5
DVT.~2
IPG.~1
209~5
room:~1
stimuli;~2
(tension)~1
sinus;~1
s;~1
overutilized.~1
49)~4
"everyone~1
x-ray,"~1
missed,~1
dissatisfaction,~3
Antithrombin~1
deficient.~2
theoretical,~1
thromboses.~1
cimetidine-induced~1
preconstricted~1
sympathetically~7
vasodilatation,~2
cardioversion.~1
transvenous~3
lidocaine.~1
Reversion~1
cardioversion~2
Later,~1
1001~1
(12.1%)~2
uncatheterized~4
(0.7%)~4
(8.6%)~1
airspace~2
opacities,~2
well-localized~1
foamy~3
Foamy~1
lamellated~3
protean,~1
eight-week~2
cards.~1
Objectively,~1
0.1N~1
(RS)~2
RS~7
aminotransferases~2
(transaminase),~1
hypoglycemic.~1
entertained~1
non-Reye's~1
antigenemia.~1
RS,~2
vomiting.~4
earlobe~10
crease~9
261~2
175)~3
86)~1
crease,~1
tension)~1
Supplemental~2
PO2.~2
Measuring~2
dementing~3
sensitivities,~1
specificities,~3
Prediction~2
87.5%,~1
37.2%~1
77.9%,~1
23.5%~1
60.8%.~1
misclassification.~1
critique~1
purports~1
erroneous.~1
Thyroxine~2
authorities~2
advise~1
nonresponding~1
nodules;~1
246~4
surgery;~7
benign.~6
thyroxine.~1
Thought~4
Disorder~3
Criteria,~3
(St~1
Louis)~2
extravagantly~1
combinatory,~1
humor,~2
flippancy,~1
playfulness.~1
disorganized,~2
confused,~1
ideationally~1
schizoaffective~8
schizoaffective-manic~4
schizoaffective-depressed)~1
Criteria.~2
tag~1
Manic~1
combinatory~1
playfulness~1
manics.~1
verbalizations,~1
autistic~2
thinking,~3
confusion.~3
schizoaffective-depressed~1
absurd~1
thinking~3
smooth-pursuit~1
eye-movement~1
schizophrenics,~3
manics,~1
4.22%~1
thought-disorder~1
tracking,~2
eye-tracking~1
Electroencephalographic~1
never-medicated,~1
nonschizoaffective~1
schizophrenics~10
(delusional~1
nondelusional)~1
Schizophrenics~1
delusional~1
depressives.~2
Slow-wave~1
intranight~1
non-rapid~1
depressives~1
schizophrenics),~1
Minutes~1
never-medicated~1
NREM-REM~1
criticisms~2
explicitly~3
lenient~1
Chronically~3
latencies;~1
nightmare~3
sufferers,~1
vivid~3
dreamers~1
nightmares,~4
nightmares~5
dreams~1
"psychotic"~1
"boundary~1
deficit"~1
Rorschach~1
first-~1
nonvivid~1
dreams.~1
"schizophrenic~1
disorders,"~1
artistic~1
creative~1
interests,~3
sufferers.~1
Forty-nine,~1
nonbipolar~3
Tanner~6
polysomnographically~1
nights.~1
nonendogenous~1
condylomatous,~1
preneoplastic,~1
(CEA),~3
involucrin,~2
dysplasias.~1
condylomas~2
6/11,~1
condylomas,~1
dysplasias,~1
involucrin~2
involucrin.~1
Carcinoembryonic~1
HPV.~1
peroxidase--antiperoxidase~1
fibrocystic~6
adenosis,~1
papillomatosis,~1
intraduct~2
ducts,~3
adenosis.~1
epitheliosis~1
ducts.~5
Apocrine~1
adenosis~1
stain,~5
demonstrable.~2
corroborated~1
myoepithelial~1
Aside~2
impart~3
osteoclast-type~1
stromal,~1
histiocytic,~2
keratin~15
osteoclastlike~1
(lysozyme,~1
1-antichymotrypsin,~1
Zymogen~1
desmosomes,~1
zonulae~1
occludentes~1
ultrastructurally~2
derivation.~1
knowledge)~3
gangliocytic~1
paraganglioma~5
(GPG)~1
71-year-old~2
GPG~2
gastrin,~5
glial-fibrillary~1
glucagon,~5
Hepar~1
lobatum~3
hepar~3
desmoplasia~1
demographically~1
biased.~1
Kansas~4
City,~3
7393~1
4122~1
(56%),~2
younger:~1
necropsies~4
whites~6
nonwhites~3
(51%).~4
"statistically~1
significant,"~1
parapsilosis~1
encompass~3
broadened~3
definition,~2
extracolonic~5
Small-bowel~1
coli.~4
Urogenital~1
vestigial~1
obscure,~3
mesonephric~1
metanephric~1
endosalpingial~1
two-layered~1
interlaboratory~1
peer~5
laboratories'~1
human-enzyme-supplemented~1
merging~2
interconversion~1
8000~3
user-specific~1
rehabilitative~2
meningomyelocele.~2
therapists;~2
3,084~1
Therapists~1
1,282~1
Spearman~3
confident~3
older;~3
approached;~1
independence,~1
(SCI).~1
Sports~3
7.6)~1
hours/wk.~1
rehospitalizations,~1
SCI~13
rehospitalizations~1
pursuits.~1
reintegration~1
drooling~3
Drooling~1
overflow~3
hypersalivation.~2
orofacial~5
do,~3
drool,~1
swallowing.~1
(MMD).~1
MMD~6
able-bodied~3
(CON),~1
nonprogressively~1
paraplegics~2
(SCI),~1
limb-girdle~2
(LGS).~1
(MMPI),~1
Ability~2
(IPAT)~1
Suicide~1
(SPS),~1
Psychological~4
(CPI).~1
IPAT~1
Test,~4
SPS~3
Hopelessness~1
subscale,~2
CON~2
Ego~1
LGS~2
MMD.~1
Million~1
(MBHI),~1
MBHI~1
attempt.~2
shaping,~1
incontinence,~6
screaming~1
combative~1
undressed~1
toilet.~1
encouragement~1
wheelchair-confined~3
ergometry,~1
(TM),~1
crank~6
ergometry.~1
ergometers,~1
(CUBE)~1
Schwinn~1
Air-Dyne~1
(SAE),~1
T-3~1
amputee~2
volitional~2
exhaustion,~1
Monark~1
(MAE),~1
CUBE,~1
SAE.~1
(CUBE~1
MAE,~1
SAE~2
MAE).~1
CUBE~1
MAE~1
89),~1
electrocardiogram~26
minute)~4
workload.~1
1.9W.~1
frame.~2
45W~1
45W.~1
below-elbow~2
hyperinsulinemia.~1
maturity-onset~2
limbs.~7
locked-in~1
anarthria~2
"locked-in"~1
Gastrostomy~1
Electronic~1
carefully,~1
Gait~2
parkinsonism.~2
kinematic~5
(Fz)~1
motor/sensory~1
(MNAP)~1
(SNAP)~1
Intranerve~1
internerve~1
SNAP/MNAP~1
2SD.~1
fastest,~1
MNAP~3
49.5m/sec~1
2SD~2
mean.~5
SNAP~1
45.5m/sec~1
59.7~1
3.8m/sec.~1
electrodiagnostic~7
monopolar~5
(MUPs).~1
teflon~1
TECA~1
MG37~1
MF37,~1
electromyography,~4
denuded~5
MUPs~1
turns,~2
MUP~1
denudation.~1
Duration,~2
MUP,~1
Muscular~2
poliomyelitis.~3
late-onset,~1
postpolio~3
weakness--age~1
severity--and~1
modification,~1
aids,~1
orthoses.~1
ambulation,~3
limb/s.~1
late-onset~3
polio~2
(8.3~1
(42.3~1
(34.8~1
Fasciculations~1
(51%)~5
long-bone~1
bulbar~4
Bracing~1
steplike~1
plateaus.~2
health.(ABSTRACT~1
Holt-Oram~2
(HOS)~1
2-year-old~5
HOS~1
plan.~1
balancing~1
Brachial~2
hemidiaphragmatic~1
shoulders.~1
shortness~5
hemidiaphragms.~1
bilaterally,~3
respirations.~1
Comprehensive~6
hemidiaphragms~2
Weakness~3
girdle~6
bicep~1
Fibrous~1
pentazocine~2
pentazocine-induced~2
deltoid~2
triceps,~2
myopathy.~2
triceps.~1
neurolysis~1
stumps,~1
removable~2
waist~3
belt.~2
bandaging,~1
moisture~4
building,~1
dressings~3
shrinkage.~1
(UE)~1
(LE)~1
Vignos~2
LE~4
Brooke~4
UE~5
UE/LE~3
grades,~3
DMD,~2
fascioscapulohumeral~1
(FSH),~2
(MMD)~1
(Becker's~1
myopathies~2
(PM).~1
equivalence.~1
(FSH)~2
observing~3
chemotaxins,~2
chemotaxin~1
formyl-methionyl-leucyl-phenylalanine~2
(FMLP).~1
FMLP~8
saline-infused~1
(9.9~2
chemotaxins~1
immunosuppressed~9
cytomegaloviral~1
wound,~5
banks~3
proline,~1
phenylalanine,~3
alpha-aminobutyrate,~1
alanine.~1
challenged.~3
pure),~1
got~3
(WI).~1
"high-risk"~1
(44%~1
pure,~3
anaerobes).~2
cefazolin~1
WI,~1
WIs,~1
cholangitis,~4
(88%~4
WIs~1
validated.~1
immunosuppression,~2
endotoxin-resistant~1
C3H/HEJ~1
splenocytes~3
Immunosuppression~1
mortalities~3
sham-hemorrhage~1
clean-contaminated~3
dirty~1
nephelometer~1
(11),~1
reductions.~2
(tyrosine)~1
(6.8~2
chow),~1
fertility,~1
tyrosine-supplemented~2
nonsupplemented~1
9032~1
leukocyte-inhibitory~1
18-hour~1
filtrate~1
mmol/L)~17
filtrate,~1
(ALS).~1
mitochondria;~1
paracrystalline~3
inclusions;~1
disorganization~2
reticulum;~2
parasinusoidal~1
Above~4
ALS,~2
subtleness,~1
(HD)~6
phenotypes,~3
(instead~1
chorea),~1
transmission,~2
parsimonious~2
continuum,~1
Binswanger's~1
rejected,~1
label,~1
"leuko-araiosis"~1
Greek~1
etymology~1
Hippocratic~1
multi-infarct~7
Ontario~3
neuroradiologists.~1
sulci~3
six-point~2
Infarction~2
items,~5
leuko-araiosis,~4
agreement.~2
psychometric~6
(Extended~2
[ESD])~1
lucencies,~1
leuko-araiosis.~5
sulci.~1
leuko-araiosis~13
ESD~4
227.1~1
14;~1
237.1~1
gait,~4
rooting~1
palmomental~1
Leuko-araiosis~3
London,~2
[ESD]),~1
(ischemic~2
lucencies~3
ESD,~1
109.7~3
61.2,~1
148.5~1
78.0~1
without.~3
extensor-plantar~1
AD.~2
4.4%,~1
bruits.~1
(dementia~1
[ischemic~1
7])~1
Electroencephalograms~2
EEGs.~1
(subcutaneous)~1
alpha-interferon~9
1.33~2
beta-interferon.~1
motor,~2
earliest,~1
cryptic.~1
Wernicke's~9
aphasia~3
region)~1
anterior-inferior~1
(SOE)~1
acknowledged~3
"clinical~2
criteria."~1
SOE~4
(106~2
Cross-tabulations~1
rapidity~2
SOE,~1
711~1
eight-year~2
Barthel~3
100-point~1
self-care~8
subscores~1
37.7~1
74.4~1
poliomyelitis~5
Corticospinal~1
(CST)~1
CST~2
cytoarchitecture,~1
demyelination,~2
unworn~2
hydrogel~3
(CLs)~1
daily-wear~1
polymacon~1
(38.6%~1
extended-wear~1
lidofilcon~1
10(8)~3
attach~2
Attachment~1
CLs.~1
keratophakia~1
corneas.~1
impurities~1
lenticules.~1
microkeratome~1
eye).~1
lenticules~1
decentered,~1
extruding~1
rubbed~2
excessively.~1
overcorrection~1
undercorrection~1
diopter.~2
lenticule~1
Argon~3
endophotocoagulation~7
goggles~1
ophthalmoscope~1
plana~6
scleral~6
buckle,~1
panretinal~6
photocoagulation.~8
trephine,~1
"trabecuphine,"~1
trabecuphine~1
iris,~1
sclerotomy.~1
hyphemas~1
iridodialysis,~1
buttonhole,~1
trephination~1
Radial~5
Keratotomy~3
(PERK)~2
4.0,~2
3.5,~3
411~3
keratometric~1
predictability~3
keratotomy,~2
estimated,~1
2.49~2
diopters;~2
3.38~2
D;~2
4.12~2
3.50~1
wide.~2
corneal-relaxing~1
light-absorbing~1
I/4e,~1
I/2e,~1
I/1e~1
Goldmann-equivalent~1
SQUID~1
perimeter.~2
degrees/s.~2
(target~1
locations)~3
observers'~2
velocities.~4
keratotomies~1
-5.0~1
-0.10~2
emmetropia.~1
Uncorrected~3
20/20~5
Refractive~1
(H.S.).~1
-4.3~2
diopters,~2
44.11~1
20/400~1
3.71~1
40.96~1
41.16~1
-3.00~1
+3.00~1
keratotomy.~5
1-D~1
Snellen~19
20/16~1
20/50,~1
-2.00~1
-2.50~1
20/125~1
20/63~1
angioid~2
streaks~5
Bruch's~4
brittleness~1
streaks.~1
(PB).~1
SF,~2
PB~18
PB.~3
anti-Leu-11b~1
Leu-11b~1
down-regulate~1
Hypochondriasis,~2
Hysteria~3
(RA).~3
scales,~4
"disease-related"~2
rheumatologists~3
RA-associated;~1
statements.~2
hysteria~1
(O2-)~3
monosodium~2
urate~14
(MSU)~2
gout.~2
Coating~1
MSU~12
supernates,~1
lysate,~1
sonicated~6
Lysate~2
lysate~5
Immunoelectron~3
self-limitation~1
gouty~5
nontophaceous~1
aspirated,~2
crystal-positive~1
intercritical~1
consented~1
unilaterally.~3
DBA/1~1
collagen-induced~2
(SS-RA),~1
(nonrheumatoid~1
[SS-CTD])~1
SS-RA~1
DRw53~1
SS-CTD;~1
SS-CTD~2
DRw52.~1
SS-RA.~1
fibromyalgia~1
diagnosis),~1
transitory.~1
granulomatosis,~1
microangiopathic~1
(Westergren),~1
aeration.~1
tracer,~1
peroxidase,~1
Horseradish~3
peroxidase-labeled~2
subnuclei~1
aeration~3
(tensor~1
palati~2
muscle)~3
ambiguus~2
(levator~1
muscle).~2
Ossicular~1
homologous,~2
costochondral~3
presculpted~1
transplants~8
suit~2
tympanoplasty.~1
airbone~1
gap,~1
dB).~1
extrusions~1
occurred;~4
96.7%~1
Homologous~2
resorb~1
extrude~2
cholinoceptor~2
spray,~1
air-~1
hot~11
soup-induced~2
rhinorrhea~3
reflex-mediated~2
hypersecretions~1
air-induced~1
rhinorrhea.~1
reflex-mediated,~1
ipratropium.~1
dysosmic~2
Odorant~2
Confusion~4
smell~4
grounded~2
psychophysical~1
dysfunctions.~3
Smell~2
smell.~1
flowed~1
infuse~2
scintillation~5
camera.~1
midnose.~1
ventrocaudal~2
ventrocranial~2
rhinosurgeon.~1
septoplastic~1
Cottle's~1
untolerably~1
decortication~2
(external)~2
cartilages.~2
mucoperichondrium~1
reconstruct~4
straightened~1
cartilages~4
septospinal~1
Pneumocele~1
expanding,~1
air-containing~1
pneumoceles~2
far;~1
seventh.~1
one-way~5
blowing.~1
trap-valve~1
revascularized~4
protagonists~2
Video-fluoroscopic~1
integrates~1
Shiley~1
(Silastic),~1
Endodermal~1
(yolk~1
tumors)~2
gonads.~1
endodermal~5
familiarize~1
otorhinolaryngologists~1
tracheitis~3
laryngoscopy~11
Roentgenograms~1
debris,~6
ulcerations,~2
Especially~2
biosensors~2
envision~1
ventriculograms.~2
hypercholesterolaemia,~1
discriminators.~1
categorised~4
(eccentric~1
concentric)~1
(recanalisation).~1
arc~4
Plaques~1
tipped~3
51.8~1
angina;~3
silent)~1
feature.~4
Silent~8
Ergometrine~1
monitoring.(ABSTRACT~2
transducer-tipped~2
miniaturised~1
57.7)~1
night;~1
night)~1
episodes)~4
Painful~2
dicrotic~2
pulsations,~1
sound.~3
sound,~3
micromanometers~2
incisural~2
ejection,~2
15-35~1
alive.~4
(9)~1
(ability~1
index).~2
extracardiac~1
Arrhythmias~2
verapamil.~5
cardiological~2
excised;~2
embolisation~1
banding,~1
univentricular~2
False~2
Septal~3
myxoma.~4
catheterisation~5
frequency;~1
(test~1
interval).~2
duration;~3
(QTc)~2
prevailing~2
days-16~1
1.0-58~1
catheterisation.~2
agreements~5
orifice~33
valvotomy.~1
unequivocally.~1
encasement~2
ornithosis~1
pheasants~1
oxytetracycline~1
psittaci~2
over,~1
616~1
(59.2%)~1
keratoses,~1
(36.4%)~1
keratoses.~2
(25.9%)~1
1873~1
21.8%~1
keratoses~10
1040~1
keratosis~5
remitting~1
keratosis,~2
questionable.~4
(DNCB).~1
micrograms/cm2~2
62.5~1
cm2,~3
(66,~1
Laugier-Hunziker~2
melanonychia~2
Hutchinson's~1
melanotic~5
lips.~1
hypertrichosis~1
pseudo-Darier's~1
clinicohistopathological~1
Becker's~1
naevus.~1
cholestatic~4
hyperlipoproteinaemia~1
reddish,~1
indurated~1
unmyelinated,~1
named~4
perineural~3
xanthoma.~1
lichen~3
planus~2
sisters~9
(HAO),~1
Aetiological~1
Acropustulosis~1
pruritic~5
acral~2
vesicopustules.~1
London.~1
U.K.,~1
scabies.~1
Consultation~2
epidemiologists~1
Perinatal~3
Authority~2
Sir~1
Dugald~1
Baird~1
utility,~2
unintentional~2
threatened~3
precisely.~1
continuity,~4
retained;~1
conformity~1
birthweight.~2
subclassification~1
exploring~1
ignore~2
been.~1
96,~2
automatically.~1
meets~3
Korner~1
approved~6
Policy~1
Committee.~1
file~3
midwives~1
secretaries~1
microcomputers~1
operational~2
mainframe~2
London~3
University.~1
amniocentesis~7
41.3%~1
Refusal~1
booking~1
One-third~2
chromosomally-abnormal~1
antenatally~1
Storz~1
hysteroscope.~1
paracervical~1
hysteroscopic~2
10,059~1
Canton~1
Ticino~1
(Switzerland)~1
1979-1982~1
practices.~7
night-time~2
(+127%,~1
very-low-birthweight~1
19.00~1
06.59~1
(tc-Pco2)~2
glue~2
tc-Pco2~3
reapplication~1
tonsure~1
(MRI).~2
norethisterone~3
hysterectomized~2
Norethisterone,~1
Psychological,~1
Menstrual~1
Distress~1
Questionnaire.~1
dose-related.~2
(pain,~1
affect)~1
progestogen.~1
(IOM)~1
pathogenesis.~1
preventable.~4
iridocapsular~1
synechiae.~1
Synechiae~1
myofibroblastic~1
minimised~1
cosmetic,~1
lenses,~5
lenticulus~1
ophthalmoscopically.~1
melanomalytic~1
macrophagic~1
iridocorneal~1
melanomacrophages.~1
Immunohistochemistry~3
hexafluoride~7
non-randomised~1
tamponades~1
seven-month~1
reattached~7
detachments;~1
retina,~6
45),~1
33),~1
non-recovered~1
67%,~3
illuminating~2
polarised~2
oculars~1
analysers,~1
darkens.~1
quarter-wave~1
lenticular~3
discontinuities~4
accentuated.~1
Epitarsus~1
cicatrising~1
epitarsus~1
denote~2
varieties.~1
conforms~1
interfornix~1
epitarsus.~1
agranulocytosis~2
chlorpropamide~1
(Chl)~1
precursors;~1
1800/mm3~1
neutrophils;~2
500/mm3~1
Chl.~1
Chl~5
AP);~1
(convalescent~1
CP)~1
22nd~1
Antineutrophil~1
granulopoiesis.~2
complement-mediated~2
(74%~1
marrows.~1
CFU-GM.~4
micrograms/mL)~2
immunoabsorbent~3
Chl-dependent,~1
antibody-mediated~3
malaria,~1
(CFU-S)~1
vinckei~1
vinckei,~1
berghei,~1
chabaudi~2
adami~1
22,000~2
ft.~1
(RIA).~2
radioiron~1
erythropoiesis,~1
plasmodia~2
nonlethal~3
adami.~1
Marrow~2
femurs~2
CFU-S~6
parasitemias,~1
erythron~1
malarial~1
Depletion~3
malaria.~1
(Cs)~1
(UV)-irradiation~1
platelets;~2
Cs-loading~1
11/12~2
UV-irradiated~1
Cs-loaded~1
alloimmunized~1
tolerant~1
alloimmunization,~2
donor's~3
(MoAbs),~1
H-25~5
H-366,~1
monocytes,~5
FACS~2
rosetting~3
H-366~4
promyelocytes~1
(day-7~1
CFU-E),~1
(day-14~1
BFU-E).~1
day-7~1
day-14~1
granulocytic/monocytic~2
leukemias.~1
2-plasmin~1
2PI)~1
JTPI-1,~1
reative~1
antiplasmin~1
2PI-plasmin~3
avidity~2
JTPI-1~1
JTPI-2,~1
(11,000~1
[11~2
K])~1
noncovalently~2
JTPI-2~2
26-residue~2
plasminogen-binding~1
2PI.~2
JTPI-3,~1
K)~2
12-residue~1
XIII-catalyzed~1
JTPI-3.~1
terminus.~3
plasmin.~1
(rH-TNF)~1
(L-CFU),~1
(CFU-GM),~1
(BFU-E)~1
L-CFU~5
myelogenous~2
hematologically~2
rH-TNF~3
U/mL.~1
rH-TNF.~1
U/mL~4
anti-rH-TNF~1
poikilocytic~1
elliptocytosis~2
(HE)~1
spectrin-band~1
tryptic~6
digests~6
wts~2
43,000~1
(5.75~1
5.85)~1
Tryptic~1
Immunoblots~5
43,000-~2
42,000-dalton~2
Coomassie~2
blue-stained~4
gels.~2
Limit~1
chymotryptic~1
(PAT).~1
(SDS)-electrophoresis~1
7.5%~5
180,000~1
blue-~1
thrombospondin.~2
Tritium~1
periodate-borohydride~1
PAT,~2
pl~1
Nitrocellulose~1
replicas~1
one-dimensional~1
glycocalicin~1
ristocetin.~1
GPIb~3
PMN)~1
H2O2~6
metabolizing~2
H2O2,~2
1,3-bis~1
(2-chloroethyl)~1
nitrosourea~2
(BCNU).~2
(GRED),~1
BCNU.~2
hexose~1
H2O2-generating~6
GRED~3
BCNU-treated~4
sulfhydryls~1
glutathione,~3
peptide-induced~1
degranulation.~3
cyanide.~2
BCNU,~1
GRED-inhibited~1
coexistence~5
blast~17
lineages~6
phytohemagglutinin-stimulated~2
(PHA-LCM)~1
methylcellulose~3
stainings,~1
micromanipulation~1
proliferate~3
basophils,~2
PHA-LCM.~1
colony-stimulating~3
(GM-CSF).~1
Recombinant~4
GM-CSF~1
basophils.~2
neutrophilia,~1
basophilia,~1
thrombocythemia~1
Substances~1
circulate~1
hematopoiesis.~1
WBC.~1
Generated~1
(HSA)~1
(HIA),~1
maturation,~4
Split~1
(CY)~1
HSA-HIA~1
HIA~2
busulfan~1
(BU)~1
BU~1
die,~1
(CFU-S),~1
HIA.~1
hematopoiesis,~2
drug-perturbed~1
maturing~3
megakaryocyte~2
pseudopodia,~2
proplatelets,~3
"Stress"~1
Nondiscoid~1
citrated~1
spherical.~1
proplatelets~1
autoantibody-mediated~1
hematocytopenias~1
inaccessibility~1
(SPA),~1
promyelocytic~2
("pure~1
aplasia,"~1
PWCA)~1
gained,~1
conserved,~2
submembranous~1
(GP)~4
Ib~7
filaments.~5
membrane-bound~8
X-100~5
(Sigma,~1
spectrin.~1
240,000~2
235,000)~1
220,000).~1
(SDS)-polyacrylamide~1
actin-binding~2
250,000)~1
P235~1
235,000).~1
X-100-lysed~1
X-100-soluble~1
A23187,~1
hydrolyzed,~1
160,000~2
170,000.~1
bis(beta-aminoethyl~1
ether)-N,N,N',N'-tetraacetic~1
(EGTA),~1
N-ethylmaleimide,~1
Ca2+-dependent~4
protease.~1
protease~10
(EPO)-containing~1
nonhemoglobinized~1
Cytogenetic~2
hypotetraploid~1
karyotypes.~2
leukocyte-conditioned~1
(PHA-LCM).~1
EPO-dose~1
BFU-E.~1
siderosome~1
rhophecytosis~1
invaginations.~1
feature,~1
(M6)~1
myeloblastic~1
GP~10
IIb-IIIa.~1
IIIa~2
(SDS)~2
(HPLC).~1
IIIa.~2
lysyl~1
endopeptidase~2
(Achromobacter~1
cleaves~1
oligopeptides~2
reverse-phase~4
gas-phase~1
sequencer.~1
IIIa)~1
prothrombin,~2
Tokushima,~1
"prothrombin"~1
Xa-catalyzed~1
Tokushima~7
"prothrombin."~1
Subsequently~2
CM-Sepharose~1
CL-6B~2
Xa.~1
"thrombin."~1
Thrombin~2
kcat/Km~1
(mumol/L-1~1
second-1)~1
tenth~4
"thrombin"~4
Boc-Val-Pro-Arg-4-methylcoumaryl-7-amide~1
p-nitrophenyl-p'-guanidinobenzoate~1
SDS-PAGE.~2
SZ~9
IX,~1
Triton-X-100-solubilized,~1
periodate-labeled~1
Ib.~1
formaldehyde-fixed,~2
15,200~1
4,100~1
Intact~1
(Fab')2~2
ristocetin-dependent~1
ristocetin-induced~1
(PAF).~2
ristocetin~1
ADP,~2
collagen-~3
Bernard-Soulier~5
fluorescence-associated~1
sorting,~1
steric~2
(TNF),~1
Buffy~1
(rTNF)~1
nitroblue~3
tetrazolium~5
polarization,~2
microgram/mL)~1
gamma-interferon.~1
TNF-specific~1
125I-rTNF~1
bactericidal/permeability-increasing~1
(BPI),~1
population(s)~1
BPI,~1
BPI~10
punctate,~1
BPI.~2
(N2~1
cavitation~3
(cytochalasin~1
f-Met-Leu-Phe)~1
granule-associated~2
lactoferrin~6
(pro)myelocytelike~1
lactoferrin,~3
promyelocytelike~1
KG-1)~1
25%)~3
(rosetting~1
IgG-sensitized~2
RBC,~1
proliferation-associated~1
antigen).~1
monocytic~2
caused,~2
Dipyridamole,~1
deposition.~9
240%~1
543%~1
21.3%~1
cotreated~1
lymphokines.~1
thromboplastin.~1
kilodaltons)~2
activator.~3
dissimilar~8
dipyridamole;~1
pyrimidopyrimidine~1
platelet-platelet~3
cohesion~4
(aggregation).~1
AP3,~1
GPIIIa,~1
Tab,~1
GPIIb,~1
(ADP)-induced~1
AP3~3
Tab~4
Unexpectedly,~4
divalency~1
thrombin-activated~1
aggregated~5
post-fibrinogen-binding~1
event(s)~1
inhibitable~3
amorphous,~1
gelatinous,~1
cryoglobulins~2
cryoglobulin~3
disorganized~3
clumps.~1
cryogels~1
thin-walled,~1
well-organized,~1
strawlike~1
clusters,~2
cryocrystals~1
compacted,~1
Crystals~1
rouleaux,~1
thick-walled,~1
nets~1
trap~2
self-associated~1
(24.3~1
(28.6~1
(30.9~1
(functionally~1
active)~2
C4b-binding~3
temporo-mandibular~2
(TMJ)~1
TMJ~2
coil.~1
meniscus,~1
brighter~1
post-trauma~1
mammography:~1
simply,~1
mammography)~1
xeromammography.~2
analysing~2
xeromammography~3
mammograms~2
0.88.~1
0.75.~1
visualise~2
1272~1
(10.4%).~1
(43%),~3
non-visualisation~1
artefacts~3
non-visualisation.~1
3-22~1
strut,~1
fissure,~5
localisation~2
calcifications,~3
macrodacryography~1
venography.~2
rare-earth~1
screens~3
high-sensitivity~1
antiscattering~1
grid,~1
eyeballs,~1
Particularly~2
(macrodacryography~1
venography,~1
fractures),~2
mGy/radiograph.~1
postero-anterior,~1
140-180~1
kcounts.~1
krypton~2
xenon.~2
587~1
cumulative.~1
Claims~1
unfounded.~1
reconsidered~2
construed~1
non-specificity~1
(false~1
positives/true~1
negatives)~1
0.78.~1
irreducible~3
negatives~1
applicator~1
(APA).~1
Heat~2
APA~2
promising,~2
randomised~8
ICRP~5
compositions,~1
(adipose~2
muscle--skeletal~1
skin)~2
compositions~2
lithotripter~1
Thomas'~5
Authority,~1
referrals~2
accepted.~4
shockwave~3
(44.1%)~1
(48.9%),~1
"stone-free"~1
few,~2
septicaemia,~1
"Steinstrasse"~1
nephrolithotripsy~1
(PCNL)~1
PCNL~1
ESWL.~2
mortality;~4
nephrolithotomy~1
Intrarenal~1
centres,~1
facilities.~6
893~1
Urography~1
non-kidney~1
Variables,~2
etc,~1
statistically.~2
rice-bran~1
dramatically,~2
"active~1
formers".~1
Rice-bran~1
hyperabsorptive~1
refluxing~1
paste;~1
sub-ureteric~1
reflux;~1
Microproteinuria~1
(RBP)~1
midstream~1
(VUR)~1
VUR~2
VUR.~1
microproteinuria~2
anti-reflux~1
ureteroscopes.~2
Short~6
ureteroscopes~2
telescope~1
anaemic~2
haematuria,~3
(67%).~3
ureter.~7
ureteroscopies~1
arise.~1
splintage~2
thirty-eight~2
placed.~4
hydronephrosis~1
undiverted~1
undiversion~1
intelligence~4
proposition.~1
53%).~1
mismanagement~1
hypovolaemic~1
post-obstructive~1
diuresis.~4
0.0001:P~1
cystometric~1
H2O)~1
H2O:~1
45%).~2
cavernosa,~1
cystoplasty.~1
potent.~1
Cystectomy~1
(TURP).~1
irrigating~3
21.5~4
ml/g~3
shivering~1
TURP~2
operator.~2
bags~7
economical.~1
instilling~1
two-component~1
post-operatively.~3
Eighty-nine~4
89,~2
centre,~1
catheterised~3
multiresistant~1
non-catheterised~1
Multiresistant~1
microflora~1
(irrespective~1
catheter)~1
year;~5
10.9%~2
balanitis~2
erythroplasia~1
Queyrat.~1
circumcision.~1
Intracorporal~1
embarking~1
self-injection~4
programme~7
inguinoscrotal~1
4/36~1
favourably~1
(18%).~3
scrototomy~1
deferens~2
million/ml)~1
three-quarters~2
titres.~1
Spermatogenesis~1
(Johnsen~1
score-count~1
8.0)~1
titres,~2
partners,~2
million/ml,~1
irreparably~1
marriage~2
microorganisms,~2
trachomatis.~1
Leucocytes~1
Micro-organisms~1
micro-organisms.~1
deferens,~2
paraplegic~3
ejaculatory~1
reservoirs.~3
AIH).~1
fertilising~1
visually-guided~2
ramp~7
undulations~2
(Beppu~1
1984).~2
errors.~3
halves~3
displayed.~1
(T,~1
target)~1
voltage.~1
(D,~1
handle)~1
potentiometer~1
screen,~1
deg~2
handle.~1
deg/s.~1
erased~1
pursuit,~1
depriving~1
undulation~3
pursuit.~1
erase~1
conveying~1
Spatial~4
(unilateral~2
neuritis)~1
presenile~1
conclusions.~3
P2~2
geniculostriate~1
nongeniculate~1
Lathyrism~1
Lathyrus~1
sativus~1
(chickling~1
pea).~1
Indian~4
subcontinent~1
lathyrism.~1
Europeans~1
lathyrism~2
Israel.~1
Hallmarks~1
adductors~1
balls~2
lurching~1
scissoring~1
Extensor~1
clonic.~1
jerks~1
perverse~1
subacutely~1
insidiously.~1
somatic,~2
(LVF),~1
occupies~3
extinction~5
(RTs)~1
RVF,~1
RTs~5
LVF,~1
RVF.~1
RVF~4
Experiment~7
coordinates.~1
tilted~1
mark.~1
reference.~2
encephalitic~1
Economo.~1
Electroencephalographic,~1
Serological~1
Tolosa-Hunt~3
closest~4
palsies.~4
receding~1
sixth.~2
sensory.~1
Corticosteroid~1
hasten~1
aetiologies.~1
Historical~1
perspectives,~1
coherent~3
Brucellosis~2
neurobrucellosis~2
meningoencephalitis.~2
brunt~1
myelitis~2
'peripheral'~1
'central',~1
immune-related~2
neurosyphilis.~1
Alloaesthesia~1
putaminal~6
alloaethesia.~1
alloaesthesia.~1
alloaesthesia~1
arhinencephaly~1
agenesis~7
callosum.~3
dentato-olivary~1
dysmorphism,~1
trisomy~5
7(7q+).~1
categories,~5
(de~1
novo);~1
symptoms);~1
(significant,~1
'on-off'~1
phenomena)~1
Involuntary~1
Movements~1
(dyskinesias);~1
('secondary~1
failure'~1
mnemonic,~1
mesocortical~1
Multifocal~2
D.B.,~1
(Weiskrantz~1
1974)~1
scotoma~3
calcarine~4
plane.~8
D.B.'s~2
'form'~1
orientations~3
stray~1
discriminations~1
D.B.~1
'same-different'~1
discrimination.~3
Haemorrhagic~1
evolves~2
Journal;~1
photodisruption~1
(AEC),~1
(AIC)~1
phakic~6
(PHA).~2
(average:~2
Irreversible~2
AIC~1
rubeosis,~1
iritis,~1
opacification.~1
angiomas,~1
Tumours~4
Scleral~1
Tumour~3
4-year-old~3
de-novo~1
life-time~1
angiomas~1
familial.~1
ophthalmologist's~1
ophthalmoplegia,~5
fourth-generation~1
astigmatism~15
anisometropic~1
coloboma-microphthalmos.~1
coloboma-microphthalmos~1
disturbingly~1
confront,~1
nonoffending~1
incest.~1
Badgley~1
Report~1
(SIgA)~1
(SIgM)~1
(SC),~1
SIgA~2
SIgM~2
SIg~3
0.94.~1
instead,~2
angioimmunoblastic~6
(AIL),~1
adenopathies~1
rash~14
lymphomatous~3
AIL,~1
AIL~1
Cisplatin~6
mg/M2-intravenously~1
(followed~2
[if~1
possible]~1
(RTOG)~2
(39%),~3
nasopharynx~4
(22%),~7
finished~2
6450~1
cGy~3
31%;~1
renal,~9
dye,~4
rhodamine~1
(Rh123),~1
intracerebrally~2
avian~5
Rh123.~1
Rh123~4
meninges,~1
dye.~3
neuropil~1
Gliomas~1
photochemotherapeutic~1
alpha-Neoendorphin-like~1
immunoreactivities~2
(alpha-NE-IR)~1
(MCT).~1
alpha-NE-IR~2
molecular-weight~2
alpha-NE-IR:~1
[125I]-alpha-NE~1
(Pharmacia~1
Chemical,~1
Sweden)~1
G-50~2
C-cell~1
alpha-NE,~1
preproenkephalin~1
MCT.~1
progestins,~2
were.~1
estrogen/progestin~1
promoters,~1
user,~2
XY~3
dysgenesis~1
streak~3
gonads~3
genotype,~1
gonadectomy~1
(serum,~1
erythrocytes)~1
E-rosette~1
dinitrochlorobenzene,~1
streptokinase-streptodornase,~2
anergy~6
proposed,~5
immunostimulant~2
flowcytometry~1
Federation~4
Gynecology~3
Obstetrics~4
[FIGO]~1
2B,~1
progression-free~2
FIGO~1
bulk,~1
Melbourne,~1
(MLB)~1
Ewing's~3
(ES),~1
MLB.~2
(1963).~1
MLB~3
quoted~3
reticulin~1
glycogen,~4
ultrastructure.~3
168~8
(CLL).~3
Splenectomy~4
59.4~2
43-75).~1
corticotherapy~2
28.6).~1
splenectomy,~3
100,000/mm3~2
counts),~1
100,000/mm3,~1
50,000/mm3.~1
thrombocytopenia);~1
thrombocytopenia)~1
1780~2
938.7~1
160-4300~1
9-28).~1
splenectomy;~1
26,~7
11-71~1
CLL~3
(Stage~9
IE),~1
IIE).~1
differentiated,~2
months-14~1
months-11~1
locally.~1
Survival,~1
pTN~1
eighty-two~1
pT1~2
collectives.~1
pT3,~2
pN0,~1
pN1,~1
pN2~1
epidermoid-adeno~1
carcinoma--large~1
pN0~1
Two-year~2
pT1pN0~1
pT2pN0~1
pT1pN1~2
pT2pN1~2
Illinois.~1
Fibrosarcoma~1
(150.8~1
98.2~1
2-,~3
5-,~1
choice;~1
983~2
Columbia-Presbyterian~1
(MPMN)~1
283~5
(11.3%)~1
MPMN~2
636~2
(11.6%)~2
SEER~1
cystoscopy.~2
interferons~1
modifiers,~1
RPMI-8226~1
alfa-2b~8
(Intron~1
Schering~1
Corp.,~2
Kenilworth,~1
NJ),~2
melphalan,~2
(international~1
activity),~2
Additive~1
interferon-melphalan~1
alfa-2b,~2
IU/m2,~1
Leukemia-Myeloma~1
Force.~1
anticellular~1
re-exploration.~1
parenterally~8
intraductal~6
(EIC).~1
EIC~8
EIC.~1
re-excision~2
thirty-nine~1
11,082,~1
20.5~6
13.8,~1
4.5,~2
2.2.~1
20.7~1
Halsted~1
quadrantectomy~2
3259~1
micrometastases;~1
797~2
441~4
(58.2%)~1
(21.7%)~1
(16.3%)~1
skipping~1
positive,~10
40.0%.~1
III-IV,~1
melphalan-doxorubicin~2
24.5%.~1
Responders~1
thrombocytes~1
thrombocyte~1
(Karnofsky's~1
(DDP)~1
VX-2~1
(IV),~1
(IA),~1
stopflow,~1
isolation-perfusion~1
(I-P).~1
DDP~4
DDP.~1
I-P~1
IA,~2
stopflow~2
mitomycin.~1
16/18~3
Berkson-Gage~1
cystitis,~4
proctitis.~1
fifty-three~4
forty-seven~1
(22.5%)~1
(60.5%)~1
noninvasive.~1
(10.3%)~2
(36.7%)~1
(63.3%)~1
lumpectomy,~1
(99Tc)~1
dilemma.~1
nonrevealing~1
extra-osseous~1
(TFA)~1
nonlymphoid~3
TFA~6
DIC.~4
non-M3~2
M3,~1
APTT~10
AcCT~1
97000X~1
9000~1
units/day~1
TFA)~1
(MFH)~4
noninvolved~3
tumor-involved~2
(89.4~1
SEM]~1
6.0,~1
0.008),~1
(12.1~2
(70.0~1
4.8,~1
lined~6
(36.4~1
Osteoblast~1
laid~4
MFH;~1
invasion;~2
altered;~1
aneuploidy~11
14q~2
rearrangements,~1
t(6;14),~1
5(1;15),~1
t(17;19).~1
nonclonal,~1
t(14q+;18q-).~1
nonclonal)~1
translocations~3
7q~1
nonlymphoblastic~1
Petrosal~1
ACTH.~2
endorphin,~1
corticotropin-releasing~1
(CRF).~1
beta-endorphin,~6
Hydrocortisone~2
Agarose~1
poly-(A)~1
32P-cDNA~1
kb)~2
kb);~1
tumor-POMC~1
Cytoplasmic~2
dot~3
blotted.~1
(RIA)~5
Aromatase~4
beta-[3H]androstenedione~1
aromatase~9
5-70.5~1
formed/g~1
protein/hour.~1
pmol/g/h)~1
(12.0~1
pmol/g/h).~1
assayed.~3
ER-~1
PR-~1
pmol/g/hour.~1
(30.2%)~1
intra-epithelial~6
68.0%~1
submucosa,~4
adventitia~6
neighboring~4
87.5,~1
65.0,~1
18.8,~1
17.7%,~1
85.7%~2
84.6%~1
71.4%~1
50.0%~2
adventitia,~2
9.1%~3
Intra-epithelial~1
Prostatic~3
(PIN,~1
dysplasia)~1
anaplasia~4
PIN,~4
49,~4
kd~8
1093~1
PIN~5
decorated~3
PIN.~1
Disruption~1
(IEF)~1
(pI~5
3.9-6.0)~1
3.7.~1
mole.~3
9-11)~1
IEF~1
medulloblastoma,~1
menarche.~1
evidences~1
hormone-releasing~2
(LH-RH).~1
thyrotrophin~2
Immune~6
Deficiency~4
Syndrome.~1
Endobronchial~2
evolutive~1
operability,~1
resectability,~1
survival;~4
(FIGO)~3
adenoacanthoma~2
radium~1
retreated~4
adenoacanthoma,~1
irradiation).~1
383~2
nontransfused~1
0.007,~1
log-rank~3
3.42~1
non-opioids~2
opioids,~1
need.~4
Collaborating~1
Centre~2
Milan~2
ladder~2
Weak~1
Neurolytic~1
analgesics,~1
WHO,~1
underuse~1
Rico~1
13,600~1
Formulation.~2
Hispanics).~2
Low-grade~1
low-or~1
intermediate-grade~2
High-grade~2
Netherlands~3
spatula~2
smear.~1
thousand,~1
preinvasive~1
screening,~6
urbanization.~1
Ayre~1
cholesterol-feeding~1
(Circ~1
Res~2
1986;~1
58:552-564),~1
dipyridamole-treated~1
Velocity~2
(diameter~2
17-32~1
microvessels.~1
Easy~1
visualizing~2
intravital~1
illumination.~1
Pairs~2
flashes~2
flashes,~1
flowing~4
parabola,~1
parabola~1
1.39~2
1.50),~1
(DCD)~1
isolated-buffer-perfused~2
(hypoxemic~2
contracture).~2
contracture.~4
DCD~3
phosphorus-31~3
7.03~1
6.87~1
6.99~3
6.88~1
redevelopment~2
Ca++-activated~1
resequestration~1
rigor~1
"erectile"~1
culturing~1
oculo,~2
Innervation~1
light-activated~1
beating.~2
ng/implant~2
SEM),~4
atria.~1
(2.22~1
1.19~3
mm2);~1
noninnervated~3
(2.35~2
oculo),~1
unanesthetized.~1
dark-adapted~3
(289~1
methylatropine~2
micrograms/kg).~3
Sympathetically~1
213~4
somites~1
conotruncal~2
vitelline~1
lesioned~4
morphogenesis~3
venosus~1
midpoints~1
filar~1
eyepiece~1
Embryos~2
embryos.~6
micrographs~1
looping~1
embryos;~1
4th~8
arches.~1
ablations.~1
isoformic~1
sarcomere,~1
myosin,~1
isoactin~2
alpha-skeletal~2
alpha-cardiac~1
(2-4~3
8-15~1
30-40~3
0.16%),~1
(4.6~2
(8-15~2
8-day-old~1
(2.27~1
0.3%,~1
sarcomeric~2
actins~1
g/mm2,~1
g/mm2/sec,~1
(336~1
401~8
(6,~1
stimuli/min),~1
2.54~1
6.35~1
isozymes~4
(V1,~1
V2,~2
V3)~1
extrapolations~1
29.2~3
34.7~1
.005)~3
postures;~1
postures,~3
(ESVI).~1
(SBP)~2
recumbency~2
SBP/ESVI~1
(Gmax),~1
Gmax~1
nonfailing~1
milrinone,~1
acetylstrophanthidin~2
(HDFP)~1
[group~4
1],~1
-19~1
2],~1
3],~1
4])~1
factors--age,~1
end-organ~3
weight)--in~1
shape,~5
adjoining~4
Ebstein's~9
Paradoxic~2
eccentricity~1
1.02~3
0.30),~1
8%).~2
eccentricity.~1
tangible~1
saturations~5
98%),~1
diphosphoglycerate~1
(2,3-DPG),~1
P50~7
(SOT),~1
VO2/SOT~1
extraction)~1
O2-hemoglobin~1
broad:~1
Po2~6
P50,~1
2,3-DPG,~5
ml/liter~1
SOT~3
Po2,~4
P50.~2
SOT,~2
ml/min/m2.~2
plateauing~1
ml/liter.~1
directly,~3
fluctuate~1
chronically,~3
rises,~2
falls,~3
ceases~1
reentrant~12
orthodromically~3
reentry~4
loop,~2
(site~3
entrained)~1
entrainment:~1
electrogram~3
(St-A~1
(St-B~1
entrainment~6
entrained~1
St-A~2
rate(s)~1
St-B~2
entrainment)~1
entrainment).~1
repolarization;~1
(MAPs)~1
MAPs~1
(AT)~3
deflection~7
upstroke,~1
(APD)~1
repolarization,~4
APD.~1
APD~2
epicardium.~1
apicoseptal~1
APD,~2
anteroapical~2
transventricular~2
70.8~2
80.7~1
97.8~2
87.1~1
4.4)~2
Kawasaki~14
persisted,~2
25.7).~1
50%;~3
42%;~3
Fusiform~1
18%;~1
253).~1
evening.~2
15%;~2
angina.(ABSTRACT~1
Interobserver~4
3+~2
prevalance~1
94%,~3
Myocarditis~1
(fetal~1
Bernoulli~2
(gradient~1
4V2)~1
.99,~1
0.6),~2
.97),~1
mid-diastolic~1
.85).~1
Ductal~2
image-directed~1
cm/sec~1
cm/sec)~1
.50).~1
cm/sec.~2
fetuses.(ABSTRACT~1
(0.61~2
(0.49~1
0.71~3
m/sec).~1
.64)~1
.84).~1
(2-~1
23-day-old,~1
[SD])~1
septostomy~1
"satisfactory"~1
48.~1
arrest;~2
Lecompte's~1
patch.~2
supravalvar~3
[SD]).~1
four).~1
(CHF)~4
constriction.~6
(beta-blockade)~1
(alpha-~1
beta-blockade).~1
receptor-antagonist~1
nalmefene~2
dP/dt/P,~1
CHF,~2
beta-Receptor~1
nalmefene,~1
nalmefene.~1
unmasking~1
vasoconstriction.(ABSTRACT~1
hand-drawn~1
edge-detection~1
algorithms~8
cineangiograms.~2
automatic,~1
precision-drilled,~1
high-fidelity~1
1.83~1
Biplane,~1
cineangiograms~1
nonsubtracted~2
Cineangiograms~1
.87~1
.98,~1
.90~1
.97,~1
cineradiography.~1
videometric),~1
videometric)~1
cinemetric~1
parametric~5
phase-matched~1
Summation~1
.96x~1
.90.~2
unoxygenated~3
Plasmalyte~3
Ischemic~2
hypokinetic~2
10%),~3
14%),~1
9%).~2
ameroid~3
run,~2
Poststenotic~1
sonomicrometry)~1
(CPR),~1
(ml/min/100~1
67.4,~1
58.8;~1
46.2,~1
38.5;~1
82.3,~1
66.9;~1
125.5,~1
99.1;~1
2.8,~4
182.8,~1
109.5;~1
mesointerventricular~1
142.2,~1
79.2;~1
epicardium,~1
19.2,~1
98.5~2
108.7;~1
mesocardium,~1
22.8,~1
135.0,~1
115.8;~1
endocardium,~1
176.1,~1
132.9).~1
.05).(ABSTRACT~2
Thumper~1
inch~1
60/min~1
Unsuccessfully~3
defibrillated~1
(14/14~1
5/14;~1
(12/14~1
4/14;~2
(11/14~1
Open-chest~1
redefines~1
puncture.~5
Pre-biopsy~1
(44%)~8
biopsy:~1
pre-biopsy~2
biopsy;~4
g/24~2
h),~5
nephropathy~26
Hypoglycemia~1
(log-transformed)~1
Hemodialysis~2
gluconeogenesis~9
prime~6
propranolol-induced~1
glucagon-stimulated~5
Subclavian~4
hemodialysis,~14
Venograms~1
venograms~2
cannulations~1
(1.87~1
0.08,~1
time-length~1
damages~4
Oxalosis~1
pyridoxine,~1
thiamine~7
100,~12
34.1~1
3.7,~2
0.755,~1
oxalate.~3
0.582,~1
hyperoxalemia~1
unusual:~1
(GIN)~1
nephrocalcinosis~1
own,~2
(15/19)~1
infrequently.~4
comprises~6
sediments.~2
Bartter's~14
(0.55~1
mEq/l.~2
Non-Bartter's~1
mEq/l~5
Normokalemic~1
Hypokalemia~3
obligatory~4
Chloruresis~1
phenacetin~1
FRG~5
(AN).~1
wholesale~1
statistics,~2
per-capita~2
compounds.~7
ranks~1
EDTA-registry~1
(4.6%~1
endstage~2
population)~1
underestimates~2
AN.~3
AN~7
north-to-south~1
Berlin.~1
Switzerland~1
Belgium.~1
normotensive,~1
(AII),~1
(Aldo)~1
AII,~2
Aldo~5
non-nephrectomized~1
renin-angiotensin-aldosterone~1
RenNew-D~4
(Alcide),~1
demand-release~1
sporocidal~1
formaldehyde~5
reprocessing~3
reuse~1
cuprophan~9
(Gambro)~1
dialyses~3
manufacturer~3
(Lixivitron),~1
(16.7~1
uses)~1
reuse.~2
bleach,~1
biocompatibility~4
3.0).~2
reprocessing.~1
Dialyses~1
Volunteers~3
mg/l~3
exchanges~3
bioassay.~3
(3.94~1
ug/ml)~2
(7.35~1
CAPD-related~1
Mantle~1
protrusio~1
acetabuli~1
pubis~2
ilium~2
sacroiliac~3
symphysiolysis~1
pubic~5
ramus~2
Altered~2
Freeze-dried~1
allograft~7
ws~1
arthroplasties.~1
Allografts~1
deficiencies.~3
ambulated~1
cane~1
Functionally,~1
allografts~2
date;~2
16-30~1
patient-controlled~4
enthusiastically~1
29-year-old~2
manipulation,~2
athlete.~1
dorsoradial~1
coracoid~7
subcoracoid~4
impingement.~2
Forty-seven~9
flexion/internal~1
adducted~1
Modifications~2
coracohumeral~1
Subcoracoid~1
laterally.~1
acutely,~1
subacutely,~1
Hematoma~1
volarly~1
retinaculum.~1
eight.~2
postreduction~1
roentgenogram.~4
Carpal~2
decompression,~4
insufficient.~1
1963,~1
3735~1
replantations~1
popularization~1
amputated~6
locking~1
Arthroscopic~1
tenosynovial~1
fibroma,~1
Chung~1
Enzinger~1
(UCLA)~1
KT-1000~2
arthrometer~3
knees.~6
UCLA~1
correlation,~5
laxities.~1
laxities~2
scatter~2
90%-95%~1
insole~2
stood~3
board,~2
tibiocalcaneal~1
tensile~11
cryoglobulinemia,~2
intense,~1
monoarticular~3
pyrogenic~1
synovitis,~3
characterized,~2
(C1q)~1
D-penicillamine~3
chloroquine,~2
chloroquine~16
Posterolateral~1
plateau.~3
(arcuate~1
pull.~1
subluxor~1
popliteus~3
reducer.~1
subluxate~1
voluntarily.~2
pull~1
(14-31~1
delayed-treatment~1
(78.8)~1
immediate-treatment~1
(78.4%).~1
malreduced~1
syndactylization,~1
valgum~1
coalition,~1
anomaly.~6
Unicameral~1
unicameral~1
three-year-old~1
myositis~9
septicaemia.~1
designate~2
un-necessarily~1
Pseudoallescheria~1
boydii,~1
soil,~1
mycetoma.~1
5-fluorocytosine~2
nontraumatic~3
Nontraumatic~1
aspirate.~1
Multiplane~1
correctional~2
varus/valgus,~1
anterior/posterior~1
bowing,~1
internal/external~1
planing,~1
disappointing.~4
(CT~2
myelography),~1
(SEP),~2
(NAP),~1
(M-response).~1
Microsurgical~3
avulsion.~1
electro-diagnosis~1
Patellofemoral~1
facet,~2
deviate~1
alignment.~1
arthrotomy.~1
arthrotomy,~3
retinacular~1
genicular~2
patella.~4
Histomorphometric~1
20-90~1
indices)~1
trabeculae;~1
chilling~2
monomer,~3
cement-on-cement~1
intrusion~8
porosities~1
(Low~1
Viscosity~1
Cement~2
[LVC],~1
Simplex-P,~1
Palacos)~1
intruded~1
(20,~1
PSI)~1
plugs~5
cements,~1
PSI,~1
Palacos~1
Simplex-P~3
4.2,~2
LVC~1
8.0,~3
12.0,~2
Ambient~1
Chilling~1
monomer~3
5.8,~2
8.2,~1
PSI~1
tested.(ABSTRACT~3
(MM)~4
considerable.~1
MM.~3
soften~1
methacrylate.~1
monoxide,~1
methane,~2
acetylene,~1
unsaturated~4
hydrocarbons.~1
evacuator~1
vaporization~3
methylmethacrylate.~1
labrumectomy~1
acetabulum,~2
labrum.~1
acetabulum~2
shallower~1
oriented,~1
subluxed~2
dislocated.~1
labrum~2
violating~1
flexion-extension~2
(AAR).~1
AAR~2
flexion-extension.~1
trochlea.~1
hinge-distractor~1
(67.7%)~1
36.4%-42.6%~1
original.~1
kyphoscoliosis~1
protruded~4
76.8%~1
(14.1%)~1
protrusions.~1
proficient~1
protrusions~3
2221~1
(1300~1
921~1
right)~1
(1167~1
1972,~4
2117~1
1161~1
(52.3%);~1
ulna~4
(15.4%);~1
Monteggia~1
(11.7%);~2
(10%);~1
Galeazzi~1
(10.6%).~1
immobilization,~2
1054~1
0.5-6.5~1
(69.7%);~1
153~7
(14.5%);~1
(7.5%);~1
(8.3%).~1
21-258~1
separation;~1
separator~3
pads~2
economical,~1
painless,~4
effective.(ABSTRACT~2
Cruciate~1
one-plane~7
lateral)~1
(ML)~1
genuine~5
ML~7
medial,~1
drawer~1
partial.~1
1965-1982.~1
impossible;~1
debrided~1
sequestra,~1
transference~2
vertebrae.~1
strut~2
rumination~1
(99%),~1
(49%,~2
crying~6
"colic,"~1
Sutcliffe-Sandifer~1
42%),~1
thrive~3
hematemesis~2
Feeding~3
(posture,~1
feeds,~1
antacids,~1
bethanechol),~1
34,~3
0.27%).~1
age);~1
fundoplication~3
(1%~1
surgery).~2
apneas/aspiration~1
Esophagitis~1
self-limiting~3
majority.~4
anecdotal.~1
conceptualized~1
transaction~1
(CF)~3
thrive.~2
reliable.~1
CF.~3
underweight~1
Relief~1
adenotonsillectomy~1
cigarettes.~2
Smokeless~2
chewers~1
craving~3
eating,~3
awakenings,~1
checklist~2
observer-rated~1
sorbitol~13
Theo-24~2
(1200~1
mg/70~1
AUCs~1
charcoal,~3
mg-hr/L~1
SE),~1
Heidelberg~2
(GRT)~1
enteric-coated~5
tablets.~1
(648~1
(breakfast,~1
lunch).~1
Salicylic~1
salicyluric~1
HPLC.~3
GRT~4
(TL)~1
equivalents)~1
[P~3
0.005]~1
0.025]).~1
TL~2
(TL~1
1.95;~1
0.94;~2
GRT,~1
Esmolol~6
ultra-short-acting~3
esmolol~14
dose-ranging~1
0.868~1
1.47~1
(192~1
0.00002).~1
bolus,~2
Giving~1
depolarizations/hr.~1
comparison).~2
Atenolol~1
ectopy.~1
gradual-rise~1
gradual-~1
rapid-rise~1
carvedilol~7
(BM~2
14190),~1
Carvedilol~5
(-32.3~1
(-13.6~2
labetalol~7
mg/ml,~3
(25%~3
1-and~2
acebutolol~5
40-week~1
blacks.~1
(414~1
mefruside~2
monotherapy.~3
acebutolol,~1
acebutolol.~1
5-hydroxytryptamine-2~1
coadministration~1
b.i.d.~5
(5.2~1
L/kg),~2
(9.7~1
ml/min/kg),~1
72-hour~1
(0.7%~1
dose)~6
ketanserinol~1
(21.8%~1
24.9%~1
dosage)~1
(169~1
233~5
ml/min/kg);~1
interpatient~4
intrapatient~5
552~1
ml/min/m2,~1
weeks),~2
646~2
Interpatient~2
(first~3
month)~5
0.39).~1
(726~1
ml/min/m2;~1
0.001;months~1
antipyrine.~2
quinidine.~5
(every~3
3-hydroxyquinidine~7
61.2%~1
70.6%~1
nonsulfhydryl~1
delapril,~3
Orally~2
delapril~13
prodrug~1
deesterified~1
diacid~10
5-hydroxy~3
diacid.~1
diacid,~1
respectively:~6
0.30,~1
1.21,~2
Cmax~7
489,~2
635,~1
572,~2
1859,~1
948~3
hr/ml.~1
Delapril~1
endogeneous~1
high-extraction~1
investigators,~4
midazolam,~2
fistuala~1
bile-cannulated~1
interspecies~1
nomifensine,~2
3-methoxy-4-hydroxyphenylglycol~2
(MHPG),~1
powerfully~1
prolactin.~1
30%)~2
MHPG~3
agonistic~2
(NT)~1
NT~6
NT,~1
E-10-hydroxynortriptyline~1
(E-10-OH-NT).~1
Equimolar~1
E-10-OH-NT~3
NT.~1
delta-Aminolaevulinic~1
(ALA)~3
g.l.c.~1
electron-capture~1
nmol/l~2
24-270~1
nmol/l).~3
ALA~11
6-36~1
10-30%~1
Erythrocytes~4
impermeable~6
entry.~4
mumol/l.~1
Haematin~1
ALA.~1
neurotoxic.~1
Km,~2
Vmax..~1
(20:1~1
ratio),~2
Vmax.~1
Baroreceptor~1
baroreceptors~5
baroreflex~7
(HP)/delta~1
(MAP).~1
HP/delta~1
reset~1
(MAP50),~1
dose-related,~1
MAP50~1
weakened~3
baroreflexes~1
favour~3
microangiopathy~1
133Xe-xenon~1
paralysed~2
tilt.~3
microangiopathy,~1
hyalinosis~2
0.57,~3
impeding~1
hyperaemic~1
hypermagnesaemia~1
Microperfusion~1
Beta-Adrenoceptor~1
isoprenaline~3
(0.01,~2
isoprenaline-induced~3
125I-iodohydroxybenzylpindolol.~1
2-mediated~1
Isoprenaline-induced~1
isoprenaline-stimulated~1
beta-adrenoceptor~1
treatment.(ABSTRACT~3
blockade;~1
manoeuvre~4
neuropathy)~1
cardioacceleratory~2
(handgrip).~1
cardioacceleration.~1
cough-induced~1
cardioacceleration~1
control;~2
muscles;~1
integrity.~1
Adaptation~2
ammoniagenesis~2
nonexistent~2
former.~4
(RBF)~3
(GFR).~1
Exogenous~6
ammoniagenic~1
acidotic~7
Infusing~1
NaHCO3~5
(247~2
GFR:~2
(111.8~1
perturbations.~1
[3H]ouabain~7
86rubidium~5
dialysed~1
dialysable~1
5'-nucleotidase~3
gamma-glutamyltransferase,~1
anisomycin,~1
gamma-glutamyltransferase~1
lymphoblasts.~2
Lithium~2
Micromolar~1
vegetables,~6
24.5~2
lithium/kg~1
spinach~1
aubergines~1
lithium/day.~1
cooking.~1
sodium/lithium~1
50:1.~1
lithium.~1
cooked~7
lithium-enriched~1
lithium-tagged~2
fusing~1
grinding~1
salt,~3
faeces.~1
1.4%~5
equivalently~1
routes.~2
mmol/day~1
exponential,~1
collection.~3
salt.~2
town~2
March,~2
Cambridgeshire,~1
(0.77~1
g/day)~2
(0.46~1
g/day).~1
Discretionary~2
Salt~6
pouring~1
Cooking~1
foods.(ABSTRACT~1
Imbalances~1
norm.~1
improves,~1
protein-wasting~1
malnutrition.~4
emulsions~2
Vitamins,~1
minerals,~1
society.~2
motivation,~2
weight-loss~3
weight-maintenance~1
fuel-source~1
Ir192~1
projector~1
(1-phenylazo-2-naphthol)~1
(S-9).~1
4'-hydroxy-1-phenylazo-2-naphthol~1
(GC-MS),~1
carbon-13~2
allergenic.~1
para-hydroxylation~1
phenyl~3
allergenicity.~1
Kathon~3
January-August~1
(ROAT)~1
creams~2
7-15~1
isothiazolinones~2
ROAT-positive~1
CG,~1
Atopic~2
1985-1986~1
moisturizing~1
ppm,~1
(Euxyl~1
unsaponifiable~2
forearm.~4
sasamin~1
sesamolin,~1
costus-sensitive~1
sesquiterpene~2
lactones~3
alpha-methylene-gamma-butyrolactone~1
Cross-reactions~1
(germacranolide~1
guaianolide~1
pseudoguaianolide~1
lactones)~1
costus,~1
costunolide~1
dehydrocostus~1
lactone.~1
4.8%~4
pet.~6
3.0883%,~1
25.3098%.~1
4.6324%~1
9.6334%.~1
refrigerated~1
dermatoses~1
factory,~1
interviewed,~3
chromate,~1
mixes,~1
melamine~1
conplasts.~1
(38/272);~1
(22/38)~1
39.5%~1
(15/38)~1
allergy);~1
(1/38)~1
gloves.~1
(23/272),~1
concreting~1
bays~1
factory.~1
engagement~1
34.8%~1
(8/23)~1
17.4%~2
(4/23)~1
antigens:~1
mumps,~3
candidin,~1
Catheter~3
embolism,~9
(HFJV)~1
HFJV~2
CMV.~1
PaCO2.~1
tonicities~1
0.225%,~1
0.45%,~1
0.9%,~3
3%)~5
chlorine.~1
PaO2/fraction~1
0.225%~3
injurious~6
(isotonic,~1
saline),~1
vasodilated~1
overwhelming.~1
advocates,~1
cognizant~1
prefer.~1
72),~2
to)~1
parallel,~2
sick.~1
member)~1
38)~3
(RVEF).~1
RVEF.~1
[r~1
.92~1
(first-pass~1
technique),~3
.81~1
(gated~1
technique)].~1
cricothyrotomy~1
Submucosal~1
untrained~6
installed,~1
shortcomings~2
Air-fluidized~1
debility.~1
Fluidized~1
float~1
silicone-coated~1
monofilament~2
polyester~2
sheet.~1
air-fluidized~1
nomogram~3
fluidized~1
Pentoxifylline~1
malleability,~1
pentoxifylline~3
(injected~2
pentoxifylline)~1
saline)~1
Simultaneously,~5
(MAP)~6
pentoxifylline-treated~1
Statistically,~1
PaO2.~4
rheological~2
hypopharynx.~1
vibrations~2
vapor.~1
nonpermeable~1
ventilator's~1
stream.~1
Maximal,~1
viscosimeter.~1
vibrations,~1
maximal,~1
rheology.~1
Observed~2
subphase~1
HFV.~1
regime~1
84)~2
ICU,~1
bacilli,~3
subsequently,~4
nosocomial~3
neodymium-yttrium-aluminum-garnet~1
(Nd:~1
YAG)~1
(91.4~1
89.7~1
treatments;~1
83.4~1
mainstem~1
intermedius~2
calibers~1
bronchi.~4
Nd-YAG~4
Tracheal~2
50I~1
FVC.~1
micrograms/kg/min).~2
successively,~1
267~1
Diltiazem~6
hypoxia;~2
(AIDS),~3
extrapulmonic~1
CDC-defined~1
retroviral-induced~1
benzodiazepines~3
sleep-disordered~4
dilating~4
Narcotics~1
wakeful~2
We,~2
hydromorphone~3
(minute~1
chemoresponsiveness).~1
4-mg~1
narcotic.~2
upper-airway~1
Cough~2
inhaling~4
beclomethasone~4
dipropionate~2
(BA)~1
puffs~3
(Plc)~1
metered~3
Plc.~2
Forced~2
22.6~2
FEV1.~3
attenuating~3
rhinitis~12
atopy~4
immune-mediated~2
pneumonitis.~5
inclusions:~1
phagolysosomes~1
Sputum~1
smear~6
fibrostenosis,~1
fibrostenosis.~1
non-involved~3
infiltrate.~6
(cfu)~1
non-pneumonia~1
cfu~1
(woman,~1
(atrial~1
(boy,~1
ten).~1
Saccular~1
multiple)~1
Carbachol~1
volume-1~1
(FEV1),~2
(SGaw),~1
(PD-20)~1
SGaw~1
(PD-35)~1
hyperthyroid,~2
SGaw.~1
55-year-old~5
runner~2
25-mile~1
cavitating~2
Reed-Sternberg~1
33-year-old~8
farmer~1
chills~2
farmer's~4
Valvular~2
Bioprosthetic~1
bioprosthetic~3
echocardiogram,~3
DMM~1
ceroid~1
histiocytosis.~2
pigmentation,~3
(TLC~1
histiocytes~1
intrabronchial~7
leiomyomas~2
bronchotomy~2
bronchoplasty.~2
aspergillosis~6
(ABPA)~2
oryzae~1
fermentation~1
starter~1
father's~1
workshop~1
lived.~2
ABPA~3
Regeneration~3
mucosectomy~1
jeopardize~2
construction.~2
islets~2
pull-through~4
reepithelialization~2
Up~5
IAA,~1
(63.3~1
(22.4~1
colonoscopy.~4
Foundation~2
exenteration.~1
hernias.~2
mesh~15
Marlex~3
periosteum~1
secured~1
clips~4
backwash~4
ileitis~5
pouchitis~2
pouchitis.~3
Pouchitis~2
pouchitis,~2
colostomy.~3
infection:~1
Necrotizing~4
myonecrosis.~1
debridements~1
derivations~1
(Bacteroides~1
spp,~1
cocci)~1
aerobes~6
(microorganisms~1
faecalis).~1
Fournier's~1
source.~6
Undigested~1
vegetable~4
barium-enema~1
Urecholine~1
Urecholine.~1
antitumor~4
(indomethacin)~1
lipoxygenase~1
(nordihydroguaiaretic~1
methylazoxymethanol.~1
nordihydroguaiaretic~1
proctectomy~2
interposing~1
neorectum.~3
Colorectal~1
Pentax~1
sigmoidoscope.~3
polyp~10
harbored~2
aborting~1
polyp-cancer~1
uninvolved~13
across),~1
farther~1
across).~1
granulomas,~2
microgranulomas,~1
Bowenoid~1
reddish-brown~1
violaceous~2
papules.~2
squamous-cell~3
genitalia~2
premalignant)~1
unclear,~5
straining,~1
defecation~5
straining.~1
feedback,~3
oatmeal~1
porridge.~1
instructions~9
generalize~1
generalization.~2
receives~2
psychotherapy.~2
hepatomegalia~1
adenocarcinoid~2
carcinoidosis.~1
carcinoidosis~1
adenocarcinoids~1
Nonocclusive~3
secondarily.~2
shock-associated~1
reasons,~4
sonogram,~1
cause-and-effect~3
however;~1
arguments~2
spread;~1
often,~3
presacral~3
retrorectal~2
hemorrhoids~2
toxemia.~1
Osseous~1
Hartmann~4
Fecal~4
continence.~3
(J)~1
J-pouch~3
S-pouch)~1
soiling,~1
Tc-99.~1
Ileal~1
preevacuation~3
S-pouch~2
(J:~1
S:~1
5%),~3
3%,~2
stools,~2
Rebanding~1
cutout~1
rebanding~1
stands~2
colocutaneous~3
(x2~1
12.75,~1
hypoalbuminemia~2
cc/day)~1
(48~6
(77~5
stomas.~4
entertained.~1
examination).~1
obstipation~2
complaint).~1
(length~1
1-cc~1
28/50~1
6/30~2
(24/28)~1
distention,~4
cutoff.~1
balloon-negative~1
acid-perfusion~1
secretin-pancreozymin~2
(17.7%),~1
(40.5%)~1
22.7%~1
selenium~62
micrograms/liter,~3
mumol/liter;~2
14.7~4
mumol/liter).~1
0.91).~2
(AST),~1
0.40,~2
Lactose~2
Italian~8
"low~2
consumers"~2
(0-250~1
82.5~2
eight-month~1
diet),~2
52.5%~1
Myoelectric~2
Ag-AgCl~1
sigmoidoscopy.~2
aborad~1
spiking~5
(RSB)~1
(SPB)~1
(SNPB).~1
bursts.~3
nonpropagating~1
(9.4~1
(21.6~1
bursts,~2
propagating,~1
propulsive~3
movements;~1
goats~1
Linda~3
littermate~2
stablemate~1
postinoculation.~1
caseation,~1
germinal~2
mucosae.~1
confluence~7
lymphangitis~1
(CCK),~1
(PP)~2
Denervation~5
(antral~1
ganglionectomy,~1
PP~6
cachexia~2
stasis,~4
atony,~1
Fluoroscopically~1
manometrically,~2
Antral~3
Hirschsprung's~4
colectomy.~1
Klotrix~1
jejunostomy,~1
wax-matrix~1
542~2
(EGC)~2
(15.3%).~1
EGC~5
(AGC).~1
Single-contrast~1
EGCs~1
(80.0%)~1
85.9%~1
AGC~1
43.8%.~1
prognosis;~2
doubts~1
assemblies,~1
contract.~2
side-hole~5
(station~1
zero),~1
stations~3
zero,~5
sensor.~1
suceptibility~1
stationary,~1
Sleeve~3
swallow-induced~1
swallows.~1
Augmentations~1
cc/min)~1
g/liter),~1
lg-1~1
(320~1
mosm/liter)~1
trypsin,~3
Duodenogastric~1
cannulae,~2
phenol~10
antropyloric~1
duodenogastric~10
interdigestive~6
red.~1
DGR~1
Pyloric~2
DGR.~1
Meat~1
Heidenhain~1
peptone~3
gastrin-induced~1
heptadecapeptide~2
somatostatin.~2
Irish~2
setter~2
cereal-containing~1
leucyl-2-naphthylamidase~1
disaccharidases~2
(basolateral~1
membrane)~2
wheat-free~1
border:~1
modal~4
brush-border~6
wheat-sensitive~1
wheat.~1
wedged-free~1
venule~2
radicles.~1
Peliosis~1
hepatis~2
malnutrition,~6
21-year~1
(CSII),~1
CSII~5
registrees,~1
20-29,~1
person-months~1
(CPOP)~1
continuance~2
CPOP~2
Continuance~1
mechanical,~1
CPOP.~1
queried~1
latest~2
update,~1
users;~1
CSII.~3
Devices~1
+131/person-month~1
use.(ABSTRACT~1
Tecumseh~1
(NIDDM)~1
364~1
acquiring~4
(relative~10
1.9,~3
succeeding~2
hypothetically~2
coronary-risk~1
recalculated~1
realistic~7
Non-insulin-dependent~1
(IHS)~1
collects~1
Alaskans.~1
(fiscal~1
IHS~1
fiscal~1
lower-extremity~4
19.9~2
Alaskans,~1
(compliance)~1
(medication~1
taking,~3
exercise),~1
diabetes-specific~2
beliefs,~2
beliefs~10
Diabetic~5
overzealous~1
GH.~2
HPLC,~2
adipogenic~7
purified.~1
derivatization~1
acetylation,~1
C-21~1
monoacetyl~1
-cortisone~1
GH)~1
bone-resorbing~6
Processed~1
explants.~3
[8Nle,18Nle,34Tyr]bovine~1
PTH-(3-34)~1
[34Tyr]bPTH-(7-34)amide~1
bPTH-(1-34).~1
tumor-derived~3
PTH-like~4
(ACSA)~1
ACSA~2
(b),~1
(o),~1
(h)~1
hTSH.~1
bLH,~1
oLH,~1
hLH,~1
TSH.~4
[125I]iodo-bTSH~1
(ED50~2
mitogenesis~1
bovine,~1
hen,~1
[3H]estradiol-17~1
fraction;~1
(sum~1
Choline~1
renocortical~1
streptozotocin.~2
[14C]choline~1
acid-soluble~1
acid-insoluble~1
betaine~2
phosphocholine~3
1.9-fold~1
1.4-fold~1
Kennedy~1
choline-containing~1
phospholipids;~1
lysophosphatidylcholine,~1
sphingomyelin.~1
kinase.~1
signals,~4
Hyp~10
D3-1-hydroxylase~1
(1-hydroxylase)~1
D-24-hydroxylase~1
(24-hydroxylase).~1
(25OHD3)~1
D-~2
calcium-deprived~2
24-hydroxylase)~1
1-hydroxylase~3
20-fold,~1
6-fold~5
1,25-(OH)2D3-treated~2
littermates;~1
mice;~1
genotypes~4
1,25-(OH)2D3.(ABSTRACT~1
(E2)-induced~1
E2-filled~1
(CB-154).~1
AP,~2
15-microns~1
(arteriogenesis).~1
APs~1
radioenzymatic~1
173-,~1
142-fold,~1
ED50.~1
CB-154~1
arteriogenesis,~2
MSH~22
laevis.~1
superfused~3
Xenopus.~2
melanotropes.~1
(GABAa)~1
homotaurine~3
isoguvacine~2
(GABAb)~1
melanophores.~1
release-inhibiting~1
GABAa~2
bicuculline.~1
bicuculline~5
GABA.~4
GABAb~1
fluorogenic~1
UV-absorbing~1
Guinea~4
adrenocortices,~1
fasciculata,~1
reticularis,~1
Aldosterone~1
(Aldo),~1
18-hydroxycorticosterone~1
(18-OH~1
(DOC),~2
beta-OH~4
And),~1
(And),~1
deoxycortisol~1
Aldo,~1
18-OH~3
DOC~3
prominent.~1
Fasciculata~1
And~1
fasciculata~11
And.~2
LDL,~3
And,~1
(rcGH)~1
wt,~3
purity,~1
immunocross-reactivity~1
methionyl~2
pituitary-derived~1
cGHs~1
bioactivity.~1
sc~3
rcGH~5
(480-960~1
chickens,~1
Thrice-daily~1
2-24~1
broiler~1
chicks.~1
24-day-old~1
saline-injected~3
productivity-enhancing~1
cows~9
(28).~1
chickens~3
selenium-intoxicated~1
somatotroph,~1
selenite/liter~1
69.4~2
selenium-treated~3
vertebrates,~1
lake~1
trout~5
sea~5
lamprey.~1
T3-binding~2
lamprey~3
coefficients,~2
Stokes~1
radii,~1
ammocoete,~2
36-fold~1
ammocoete~1
trout,~1
cytosol,~2
interchange~2
kinetically~2
equilibrating~1
decaying~1
malic~1
alpha-glycerophosphate~1
vertebrates~1
unloading~4
retards~1
D-deprived~1
tibiae~2
fractions,~6
unloading,~1
[3H]Proline~1
Fallopian~3
GAD~10
oviduct~3
(CX)~1
CX~4
benzoate~2
(EB)~1
EB~4
progesterone;~1
diestrous~5
values;~5
(PMS~1
hCG).~1
decarboxylation~1
ovariectomy~1
estradiol-containing~1
0.001-6.4~1
0.001-0.2~1
estrogenization~1
opening).~1
(0.01~6
unidentified,~2
hypothalamus-pituitary-gonadal~1
proenkephalin~1
proopiomelanocortin,~1
autocrine~6
glucagon-like~1
(GLI)~1
nonfasted~2
weight;~1
GLI~2
Immunoreactive~1
[32P]IGF-I~1
radioimmunoassayable~2
(mAbs)~2
solubilized,~1
300-~1
500-fold~1
(E21~1
E29)~1
E21~7
E29~5
[125I]ovine~1
(oPRL)~1
[125I]human~1
(stimulation)~1
Specificity~3
mAbs~6
(mammary~1
adrenal)~1
(rabbit,~1
pig,~2
cat)~1
[125I]oPRL-labeled~1
immunoprecipitating~1
44,000~1
[125I]oPRL-receptor~1
oPRL~1
Immunoblotting~4
immunoprecipitation;~1
E21,~1
distinguished.~3
lactogen-binding~1
species;~1
subunit)~1
42-46K,~1
linkages;~1
oPRL.~1
2-week-old~1
(Ka~1
10(7)~4
M-1).~1
(Ka)~1
(kd),~1
steroid-receptor~2
DNA-cellulose.~1
cooperativity,~1
Hill~2
3.39~1
3.44~1
Collectively,~1
(biosynthetic~1
Thr59-IGF-I)~1
IGF-I.~6
Ka~1
10(9)~5
M-1~2
pm/100~1
(rIGF-II)~1
125I-Labeled~1
rIGF-II~3
potency,~3
[125I]IGF-II.~1
Disuccinimidyl~1
suberate~1
[125I]IGF-I~4
135,000,~1
Cross-linking~1
[125I]IGF-I.~1
receptor)~1
receptor),~1
vis-a-vis~2
(bFGF)~1
contain,~1
bFGF.~2
bFGF~7
self-stimulating~2
Y-1~2
(C/P)~2
0.6:1.6~1
coupled.~1
C/P~1
cAMP.~4
[32P]-labeled~1
(8.0,~1
kilobase)~2
nutritionally-induced~1
(8.0~1
Refeeding~2
8.0-kb~1
refeeding,~1
(cog),~1
Thyroids~1
hypertrophied,~1
perchlorate~1
cog~1
Tg.~1
transplanting~1
WR-6~1
[3H]testosterone.~1
113mindium~1
transferrin.~2
globulin-bound~4
Thaw-mount~1
protein-bound~5
exiting~3
[3H]testosterone~1
epiandrosterone/androsterone~1
dihydrotestosterone.~1
implicated,~1
Ca-specific~2
Corpora~1
10(-3),~1
58,~2
166,~1
183);~1
100K~8
2.33~1
0.2-fold~2
estradiol-treated~2
6;~3
Phosphorylation~1
(CaM).~1
Phosphopeptide~1
CaM-protein~1
100K,~2
CaM-kinase~2
Immunochemical~1
7-fold~2
100K.~1
1.8-fold~2
CaM-kinases~1
cAMP-PK.~1
luteum;~1
Ca-CaM-dependent~1
protein;~4
III-100K~1
restraint.~4
-33~1
-42~2
3%),~1
+55~1
+75~1
-23~1
availability.~2
-9~2
-51~1
Either~4
nonstress~1
iodothyronine~6
200-fold~1
albumin-~1
pass,~1
operationally~1
occupancy.~1
BASIC~1
nucleus;~1
T3)~1
adipocytes.~1
deiodinase~2
alprenolol~1
cannulated,~1
beta-endorphin-like~1
Ei).~1
receptors;~1
Ei~5
4-h~3
Hypothyroidism~4
1-,~4
iopanoic~1
(IOP),~2
5'-monodeiodination~1
GH1~2
T4),~1
IOP.~2
nM.~5
IOP,~1
monodeiodination~1
adluminal~1
(apical)~1
(bicameral)~1
Millipore~2
baso-lateral~1
Sertoli-Sertoli~1
molecules,~4
matrix-coated~1
(Tf),~1
apical/basal~1
Tf~2
bicameral~1
(AE),~1
37,000~3
receptor-containing~2
(MCF-7,~1
receptor-negative~1
MDA-MB-231~1
32,000~3
AE.~2
Proteins~4
[35S]cysteine~1
4-fold)~1
trans-hydroxytamoxifen~1
trans-tamoxifen~1
cis-tamoxifen,~1
52,000~1
estrogen-free~1
charcoal-dextran-treated~1
AE,~1
estrogen-antagonistic~1
tunicamycin~2
glycoproteins.~2
alpha-1-adrenergic~1
norepinephrine-stimulated~1
Phorbol~1
cAMP-mediated~2
hormones;~1
MA-10),~1
(oLH)~1
Na+.~4
LH/CG~1
oLH.~1
Na+)~1
Na+).~2
oLH~6
Na+;~1
Na+),~1
internalization.~3
Glutamine~1
dexamethasone-mediated~2
RU38486~2
beta-(4-dimethylaminophenyl)17~1
beta-hydroxy-17~1
alpha-(prop-1-ynyl)estra-4,9-dien-3-one],~1
glucocorticoids;~1
glutaminase~1
steroid-treated~4
2-adrenergic,~1
antiprogestin~1
38486~2
melanotroph,~1
polyhedral~1
melanotrophs~2
tinctorial~1
cytoplasm;~1
darker,~1
lighter,~1
shades~1
melanotrophs,~1
Dopaminergic~1
POMC-related~1
melanotroph~1
levels).~2
180%~1
IL.~1
Bromocriptine~1
[3H]thymidine.~1
mechanisms:~2
subchronic~1
Digitonin-permeabilized~1
8-bromo-cAMP~1
(8-Br-cAMP),~1
efflux.~1
phase)~3
TMB-8~1
Forskolin~5
8-Br-cAMP~3
(ED50,~1
nonmitochondrial~1
nonendoplasmic~1
Apparently~1
nonreceptor-mediated~1
(forskolin~1
8-Br-cAMP)~1
thermogenesis~2
ob/ob~13
db/db,~2
deiodination~5
acclimated~1
5'-deiodination~8
14.5-fold~1
2.29~1
db/db~5
cold-stimulated~1
Cerebrocortical~1
5'-deiodination.~1
ob/ob,~1
hepatic,~7
heptic~1
BAT,~1
thermogenesis.~1
cerebrocortical~3
28,000~2
(CaBP),~1
CaBP,~4
serum-free,~2
hormone-supplemented~1
Confluent~3
1,25-Dihydroxyvitamin~1
(10(-10)-10(-7)~1
50-240~1
ng/mg~9
600-1200~1
blotting~3
CaBP.~1
25-Hydroxyvitamin~1
alpha-hydroxylated~3
bioresponses~1
1,25-(OH)2D3-inducible~1
voltage-recording~1
-78.9~1
-77.8~1
Cl-.~1
[K]i~2
138.5~1
PNa/PK~2
112.4~1
0.011~1
Depolarizing~1
rectifying~3
Sr2+~2
Ba2+,~2
Mn2+~2
Co2+.~1
Regenerative~1
K+.~1
steroidogenesis.~4
115,000~1
65,000.~1
inhibitory.~2
c-myc~9
c-ras~4
protooncogenes~2
polyadenylated~2
v-myc~8
v-ras~1
nick~1
translation.~3
nononcogene~1
beta-actin~2
dispersion,~2
kilobases)~3
detectable,~2
430%,~1
670%,~1
330%~1
c-myc,~3
beta-Action~1
560%,~1
810%,~1
460%~1
c-ras,~1
beta-Actin~1
(AGF)~1
900-fold~1
precipitation,~3
AGF~4
25,000-30,000,~1
(3T3~1
(NRK~1
(Y1~1
(BAC~2
BAC~2
boiling.~1
immunoactivity.~1
accomplished,~1
tried.~1
ACTH-like~1
(63-144~1
(7-150~1
ovine(o)CRF-(1-41)~1
ACTH-(1-24).~1
B-ALA~2
I-ALA.~1
B/I~3
1.A~1
120-~1
126-day-old~1
I-ACTH~1
corticotropic~1
prepartum~4
adrenal.~1
immunoactivity~2
(gestational~2
116-138~1
proopiomelanocortin-derived~1
N-acetyl-beta-endorphin~1
(N-acetyl-beta~1
EP),~1
lobe,~4
[35.6~1
pg/ml].~1
Metoclopramide~2
N-acetyl-beta~3
45.2~3
20.1~2
lamb.~1
photoaffinity~2
azido~2
glyoxal~1
arginyl~1
([Az~3
Bz~5
Arg12-14]VIP)~1
Arg14]VIP).~1
Arg14]VIP)~1
glyoxal.~1
(Kd,~1
[125I-Tyr,Az~2
Arg14]VIP~1
VIP)~1
(production~1
Photolysis~1
Arg14]~1
peptide-receptor~1
photolabeled~1
neurohypophysial~3
[3H]OT~2
[3H]arginine~1
epididymis,~5
2-16~1
Membranes~2
[3H]AVP~3
peptides.~3
Millimolar~1
self-~1
cross-displacement~1
LIGAND~1
OT,~1
vasotocin,~2
[Thr4,Gly7]OT~1
[Asu1,6]OT,~1
ornithine~9
vasotocin~1
(OVT),~1
d(CH2)5Tyr(Et)OVT~1
dEt2OVT.~1
d(CH2)5Tyr(Me)AVP.~1
V2~6
[1-deamino,4-valine]8-D-AVP~1
Isotocin,~1
desglycinamide~1
[Arg-8]AVP~1
tocinoic~1
displacing~2
[3H]OT.~1
mammals~6
(HFA)~1
80-85%~1
HFA~2
HFA.~2
abortuses.~1
Krebs-Ringers~1
3-h~3
(10(-8)~2
(TFP),~1
chlorpromazine~4
(CPZ),~1
(CAL)~1
5-100~1
(DS),~1
pregnenolone,~1
TFP,~2
CPZ,~3
CAL~2
DS,~1
near-control~1
Bu2cAMP-stimulated~1
22R-hydroxycholesterol~1
TFP~1
CAL.~1
radical-scavenging~2
hypoinsulinemia~1
(CAT),~1
(SOD),~2
(GSH-PX),~1
(GSSG)~2
GSH-PX~1
GSSG~6
H2O2-induced~2
2890~1
(1607~1
1283~1
1933~3
emigration,~1
Steno~1
2658~1
(92%).~1
1942~1
1953~1
1962,~2
(U/kg)~1
15-17~1
hyperglycemia.~3
Midaglizole~1
(DG-5128),~1
2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-phenylethyl]pyridine~1
dihydrochloride~2
sesquihydrate,~1
antidiabetic~1
2-adrenoceptor-antagonizing~1
midaglizole~5
(NIDDM).~1
sulfonylurea~1
insulin),~1
150-250~1
(some~1
(FPG)~1
midaglizole.~2
Glycosylated~2
sulfonylureas~1
midaglizole,~1
FPG,~1
FPG~1
levels.(ABSTRACT~2
galactosemic~3
alloxan-induced~1
immunohistochemically~2
galactosemics,~1
glomeruli,~3
insulin-deficient~1
galactosemia~1
diabetic-like~1
polyol~2
galactosemics~1
galactosemics.~1
expansion,~1
obliteration,~1
nephromegaly~1
galactose-fed~1
respiration-related~1
(RRSD),~1
(R)~2
nondiabetes-prone~1
RRSD~3
nonanesthetized~1
arrythmia~1
Seasonality~1
(IDDM),~1
seasonality~5
nondiabetics.~1
autumn~1
spring~5
10(-4)).~1
counterinsulin~2
insulin-producing~2
infiltration--a~1
formative~1
wounding.~1
malnutrition:~1
aldose~2
sorbinil,~1
(PMA),~1
provokes~6
fraction),~2
downregulating~1
PMA)~1
glycemia-induced~1
Sheffield.~1
norms.~1
glucocorticoids,~4
anti-insulin~10
anti-insulin-receptor~1
anti-idiotypes.~1
hypoglycemic~9
antibodies.(ABSTRACT~1
guanidine~2
noncollagenous~1
denaturing~1
HCl-solubilized~1
DEAE-cellulose~3
proteoglycans~4
350,000~1
210,000)~1
higher-molecular-weight~1
predominant.~1
110,000,~1
Radioimmunoassays~1
orthograde~1
streptozocin~4
(3-day)~1
SP~19
unligated~1
Transport~3
quantitate.~1
3-mo~1
STZ-induced~1
(STZ-D)~1
weight-~1
controls:~3
474~3
pg/24~2
STZ-D~3
.03;~1
.02.~1
reduced:~1
pg/3-mm~1
.01.~1
.07),~1
(1.41~1
mm/h.(ABSTRACT~1
legitimate~1
discipline~5
It,~1
agenda~1
encounters~2
requests~5
ideas~1
helped.~2
seeing~3
doctor;~1
25-item~1
population?~1
newly-developed~1
doctor.~2
factors--'medical~1
information',~1
'psychosocial~1
assistance',~1
'therapeutic~1
listening',~1
'general~1
advice',~1
'biomedical~1
treatment'--partially~1
twenty-six~1
4012~1
Inadequate~2
sub-optimal~1
Patients'~4
re-examine~1
organized.~1
57)~3
fits.~1
fits~2
yearly.~2
Hemoccult~2
776~1
screened;~1
restrictions.~1
3/776,~1
screened.~2
preceptorship~2
fifth-year~1
Students~3
preceptors~2
tutor.~1
preceptors.~1
colonoscopies~2
upon.~2
juvenile.~1
(PEG)~1
pneumoperitoneum~2
PEG.~1
PEG~9
pneumoperitoneum,~1
(280)~1
cardia~3
(89)~2
peritoneum,~2
omentum,~2
(9.7%).~1
Laparoscopic~2
4.4%~4
(2.8%~1
omentum).~1
14.3%~1
pretherapy~3
failure.)~1
140/90~2
lowered,~1
Degenerative~1
spondylitic~1
radiculopathy~6
climacteric~1
woman's~5
alertness.~1
juncture~1
doctors.~1
Hyperthyroidism~1
disguised~1
apathetic~1
nervousness.~1
impaction.~2
"malignant"~2
metastases),~2
different-aged~1
hosts.~4
fibrotic,~2
angiogenic,~1
"soil"~1
medicine;~1
unraveling~2
endoscopical~1
9-46~1
Dysplasia~1
incurable~1
carcinoma:~2
non-cancer~1
1.0962,~1
0.295).~1
non-dysplastic~1
1.0747,~1
0.299).~1
0.005~5
premalignancy~1
LIM1215,~1
butyrate~7
dipeptidyl~3
peptidase~3
Butyrate~1
0.054%.~1
Alkaline~2
six-fold.~3
butyrate.~1
herpetiformis~2
IgA-~1
IgM-containing~1
postchallenge~1
dapsone/sulphapyridine~1
preplanned~1
former,~2
IgA-containing~2
raised.~3
alpha-glycosidases~1
(BAY~1
m1099~2
o1248)~1
deoxynojirimycin.~1
maltose,~1
glycaemic~2
o1248~1
glycaemia~2
micrograms/kg/h)~1
ng/kg/h)~2
cerulein~1
Bicarbonate~2
(maximal~1
22%).~3
diminish.~1
Transdermal~3
scopolamine~7
mg/patch)~1
randomised,~1
interprandial,~1
409.4~1
mmol/day;~1
scopolamine,~1
364.0~1
mmol/day)~2
231.8~1
235.3~1
HBe~1
(HBeAg)~1
anti-HBe~3
(HBeAb)~1
oligo~1
2-5A~3
HBeAg~5
(HLA-I)~1
HLA-I~1
(gamma)~1
dyskinesia~4
ceruletide.~1
Oddi;~1
prestimulatory~3
III):~1
(seven)~2
11-16~1
ceruletide~1
disclose~4
sulpiride.~1
9,000-fold~1
100,000-fold~1
Procion~1
HE3B,~1
DEAE~2
G75~1
purest~1
HTC~1
pH's~1
12,400~1
17,500~1
conjectured~1
portal-systemic~1
396~2
infection;~6
carriers;~1
microlymphocytotoxicity~1
DQw1~1
DQw1,~1
technique).~1
acids/creatinine~4
biopsy-confirmed,~1
included,~1
improve.~3
acids/creatinine,~1
weight/height~1
test:~1
urine.(ABSTRACT~1
(ascites,~1
hemorrhage)~2
(probability~1
follow-up)~1
Decompensation~1
(Cox's~1
prognosis:~1
bilirubin;~1
gamma-globulin~1
stigmata;~1
sex;~2
probability.~1
Antimitochondrial~1
54,~1
kd.~2
PBC~1
(94%)~5
(antimitochondrial~1
antibodies)~1
dl~1
labeling.~2
appositional~1
calcium/creatinine~3
peritoneovenous~2
recirculation~4
para-amino-hippurate~1
0.08),~1
Perioperatively,~1
equalize.~1
fallen~6
ranges:~2
1,477.6~1
194.6~1
62.9~1
74.2~1
325.6~1
175.2~1
47.9~1
ml.(ABSTRACT~1
Adenine~2
arabinoside~7
ducks~3
duck~7
supercoiled~1
(noncoding)~1
strand~2
hepadna~2
polymerase.~1
virus-infected~2
immunomodulation~1
ducklings~2
virus-positive~1
3rd,~1
4th,~1
27th~2
44th~1
Duck~1
[3P]-labeled~1
Immunoreactivity~3
DHBV~1
sporadically~3
cisternae~4
reticula.~1
immunoelectron~3
hyaloplasm~1
peroxisomes~1
cores~4
anti-delta~2
delta-infected~2
delta-infection.~2
anti-delta-negative~1
delta-agent~1
delta-infection~1
16-~2
21-week-old~1
livers,~3
microsomes.~6
fluorophore~1
1,6-diphenyl-1,3,5-hexatriene.~1
microviscosity~1
(eta)~1
2.17~3
poise,~1
poise~1
"fluid"~1
phospholipid/cholesterol~1
phosphatidylcholine/sphingomyelin~1
"rigid"~1
unsaturation~2
unsaturated/saturated~1
eta~5
perturbants~1
[3H]taurocholate~1
Anisotropy~1
(0.2287~1
0.0014)~1
(0.2612~1
0.0012),~1
anisotropy~2
domains.~1
"intact"~1
"sick"~2
endo-~1
xenobiotics,~1
tetrachloride.~1
[14C]taurocholate~1
Hepatocytes~2
hepatocytes--as~1
release--but~1
(3.16~1
nmoles~2
cells-1;~2
(2.16~1
Mutant~3
(TM~1
dibromosulfophthalein,~1
tributylmethyl~1
ammonium,~2
cholate~5
taurocholate.~2
dibromosulfophthalein~3
[14C]tributylmethyl~1
cations.~2
ethanol,~9
presaturation~1
ATP/ADP~6
ATP-beta~1
ATP-gamma~1
methodology.~3
bioenergetic~1
freeze~5
discrepancy,~2
batches~1
(42.2~1
interexperiment~1
3.0%,~2
consistency,~3
all-or-none~2
kg),~4
batch~2
variation.(ABSTRACT~1
serum-supplemented~2
mRNAs.~2
genes),~1
substrata~2
life-span~1
hyaluronates,~1
sulfates,~1
4-sulfate~1
6-sulfate~1
coupled)~1
heparins~2
hyaluronates.(ABSTRACT~1
fibrogenesis~1
ethanol-rich~1
RNA-DNA~2
methodologies~2
fibrogenesis.~2
chemistry.~1
polysomal~1
enterocyte~2
hepadnavirus~1
(HBV),~2
woodchuck~1
(WHV),~1
squirrel~4
(GSHV)~1
(DHBV).~1
ultrastructural,~3
numerically~2
world,~2
hepadnaviruses~2
(HCC)~1
woodchucks~2
squirrels.~1
HCC~12
squirrels,~1
Hepadna~1
oncogenic~5
Integration~1
integrations~3
aberrations.~2
deletion,~3
translocation,~1
integrations.~1
HCC,~1
HCC.~2
HCCs~1
identified.(ABSTRACT~1
cube~1
ellipsoid~1
revolution~2
Penn~1
slices,~1
algorithm,~1
well-validated~2
simplest.~1
M-mode,~2
Optimization~1
grams)~3
([~1
(diastole)~1
(diastole)]~1
[left~1
dimension]).~1
(body~4
intercept;~1
g);~1
meters.~2
(younger)~1
mean.(ABSTRACT~1
fatness,~1
6148~2
root,~2
4947~1
age),~1
echocardiograms,~2
Consideration~4
achieved:~1
averages~2
0.66,~2
-0.24).~1
-0.67,~1
Sympatholytics~1
methyldopa~1
reserpine),~1
(captopril~1
enalapril),~1
(hydralazine,~1
trimazosin,~1
minoxidil)~1
passive,~2
coexist~2
prolapse,~5
generalizations.~1
irreversible.~2
(IVRT,~1
opening)~1
IVRT~4
(91~2
cm/m2,~1
0.46,~4
assumptions,~1
coordinate~1
contouring,~1
assumptions.~1
calibration,~1
two-dimensional,~1
Multiday~1
CD-1~2
He-O2~10
atmospheres~5
(t1/2)~4
Pc~3
ATA.~2
Pc.~3
reserpine~2
monoaminergic~4
habituation~8
inert-gas~2
redox~4
lactate-to-pyruvate~3
NADH/NAD)~1
acceptor,~1
blue.~1
incline,~1
6.70~2
(dP/dt)/P.~1
Treadmill~1
(6.0~1
9.97~1
(dP/dt)/P,~1
snared~1
thermistors~2
ewes,~1
4.46~2
cal/ml~1
uteroplacenta,~1
Commonly,~1
data)~1
data).~1
Zhuang~1
55:~2
1341-1348,~1
1983)~3
morphometry~2
simulations,~1
elasticity.~1
proposition~2
(Circ.~1
Res.~1
57:~3
903-905,~1
interstitium-to-luminal~1
pulmonary-artery~1
transendothelial~3
luminal-to-abluminal~2
abluminal-to-luminal~2
gelatinized-polycarbonated~1
abluminal~2
g/100~2
equalize~1
double-isotope~1
symmetrically~3
(lipotrophic)~1
lipotrophic~2
choline-phosphate~1
cytidine~1
5'-diphosphocholine~1
Lipotrophic~1
[14C-methyl]-choline~1
[1-14C]-palmitic~1
diglyceride~1
D-[U-14C]glucose~1
CDP-choline~1
cytidyl~1
manifest,~1
myoclonic~6
convulsions.~2
(HPNS).~1
particular.~2
synaptosomes~3
67.7~3
ATA~3
[3H]GABA~2
intraterminal~1
(AR)~4
aerosolized~7
carbachol,~2
citric~4
Awake~1
(Cdyn),~1
(RL),~1
(FRC).~1
(Pao)~1
Cdyn,~1
RL,~2
AR~17
noncumulative~1
(ED65Cdyn),~1
(ED200RL),~1
(ED150FRC)~1
whole.~4
ED65Cdyn~1
bronchoconstrictors~1
antigen-dependent~1
Ascaris~5
suum~2
sit~1
quietly~2
chairs~1
masks.~1
(Cdyn)~1
60-90~3
(41%)~5
mg/ml).~1
Bypass~1
Ventricles~1
fibrillated.~1
Left-heart~1
outflow.~7
multiple-breath~1
(MBNW)~1
diffusion-dependent~1
maldistribution~2
convection-dependent~1
predominates~3
MBNW~1
0-,~1
4-s~1
end-inspiratory~1
(BH0,~1
BH1,~1
BH4,~2
10-12~2
(Sn),~1
Bohr~1
(VDB),~1
Fowler~1
(V50).~1
Sn,~1
VDB,~1
V50~1
holding,~1
Sn~2
Sn/delta~2
VE)~1
BH1~2
BH0.~2
BH4~1
diffusion-independent~1
inhomogeneity.~1
units.(ABSTRACT~1
(Ppa50)~1
(PIO2)~1
44-60~1
6-ketoprostaglandin~1
prostacyclin,~1
PIO2~6
Ppa50.~1
Ppa50~4
attenuation,~3
Torr,~2
hypoglossal~6
electroneurograms~1
almitrine~11
genioglossal~8
(GG,~1
airway-maintaining~1
unanesthetized,~1
instrumented,~1
1.0-6.0~2
(f),~2
almitrine,~1
Almitrine~2
vagotomized,~1
tracheostomized,~3
alpha-chloralose-urethan-anesthetized~1
f,~1
heliox~1
(Pc)~2
N2;~1
neutralizes~1
Pc,~1
PN2~1
ATA,~2
IG/HP~1
(W),~1
nares~2
midtrachea~1
tracheostoma.~1
respiratory-related~1
(Pua)~1
SWS,~3
inspiratory-related~1
Pua~3
-1.2~1
swings~2
Pua.~1
uncoupled~2
(QL),~1
half-equilibrium~2
(t1/2).~1
radio-albumin~2
subsegments~1
luminal-lining~1
(gravimetric~1
water-to-dry~2
QL,~2
Gravimetric~2
(4.94~1
(4.13~1
0.09,~3
Tour~1
France,~2
18O~2
2H.~1
isotopes~2
2.25~1
3.80~1
7.9,~1
9.8,~2
3.4-3.9~1
4.3-5.3~1
ceiling~1
birds.~4
Intersubject~1
(Q)~1
l/min)~1
K(VO2~1
r)~1
Qr,~2
r,~1
Qr~1
Q,~1
l/min.~1
Q-VO2~1
low-compliance~1
righ~1
22-32~1
20/min~1
torque).~1
slit-catheter~1
(236~2
(157~3
eccentrically~3
(10.5~3
concentrically~1
"eccentric"~1
Soreness~1
soreness~1
close-arterially~1
greyhounds~2
Bradykinin,~1
(-39.3~1
-47.3~1
-22.5~1
(119.0~1
25.0,~2
46.3~1
(-31.4~1
5.0,~1
-34.3~1
-21.9~1
-31.5~1
2.4%)~1
(12.3~1
3.9,~1
13.0~1
3.4,~2
6.5,~1
Phenylephrine~1
(19.8~1
1.7%)~1
(-23.9~1
directions,~2
vasodilatations,~1
lambs.~1
micropuncture~3
80-micron-diam~1
paralyzing~1
Complement~3
cobra~1
(CVF)~2
iv).~3
sheep:~1
CVF~6
bromophenacyl~1
(Qlym)~1
(Qlym~1
(L/P)~2
Qlym.~2
L/P~1
Qlym~1
CVF-induced~2
111In-oxine~1
CVF-treated~1
lung-lymph~1
(Qlym).~1
meclofenamate,~1
gelatinized~1
micropore~1
Boyden~1
PAF.~4
iv)~6
Leukocyte~4
(E),~3
demargination~1
(MEFV)~4
volume-displacement~1
MEFV~6
(H).~1
(SR-V)~1
Flows~1
VC's~1
(bumps)~1
bumps~1
SR-V~1
SR's~1
I-~1
H-induced~1
bronchomotor~2
configuration.(ABSTRACT~1
thermodynamics.~1
Simulation~1
intrathoracic,~1
(tidal~1
frequency)~1
inspiratory-to-expiratory~1
(I/E)~1
I/E~1
Vs)~1
indicator-dilution~2
(Vtr)~1
flowmeter.~2
Least-squares~1
51.0~1
104.6~1
(V1~2
-347.65~1
3.35~2
slope:~4
1.89-4.81)~1
70.2~1
768.8~1
4.92~2
-2.55~1
-7.30).~1
Vs~3
ml/h~8
(Vs~2
-72.35~1
0.21-1.14),~1
159.07~1
-0.56~1
-1.57).~1
Vtr~6
Vs.~1
free-moving~1
caged~1
calvarial~2
headpiece~1
push-pull~1
(PPC),~1
tether,~1
four-channel~1
swivel,~1
multisite~1
PPC~1
eminence,~1
14-70~1
perfusates~3
tether-swivel~1
gonadotropin-releasing~1
radioimmunoassays.~4
neurosecretions~1
simian.~1
Istituto~3
Rizzoli,~1
metaphysis,~1
Extension~2
grading,~2
Enneking~1
266~2
excisions,~2
fifty-one~2
surgery.(ABSTRACT~3
twenty-two~7
staples~1
seventy-one~2
players.~2
Over-all,~2
porous-coated~4
knee-rating~1
Surgery,~1
osteotomy.~6
"burn~1
bridges"~1
closing-wedge~1
non-union.~3
Osteotomy~1
tibiofemoral~5
Charnley~1
(methylmethacrylate)~1
complement,~2
anaphylatoxins~4
(C3a~1
C5a),~1
whole-complement~1
dose-correlated~1
monomethylmethacrylate~1
non-cemented~1
(film)~1
lots,~1
(heel~1
effect),~3
femora~1
cadavera~3
step-wedge.~1
densitometric~3
non-uniformity~2
unreliable.~1
(351~1
feet),~1
Akin~2
procedure)~1
hallux~4
objectively.~4
metatarsophalangeal~4
dissatisfaction~6
unsound~1
deformity:~2
hallucis~2
intermetatarsal~1
Arthrodesis~2
(sixteen~1
feet)~1
Keller~2
threaded~1
Steinmann~1
fix~1
arthrodesis~5
Interposition~1
hallux.~1
metatarsalgia~1
Cock-up~1
stainless-steel~2
Range-of-motion~1
Osteoarthritis~1
shoulder,~2
seizure,~1
electroshock~1
undisplaced~1
twelve;~1
subscapularis~3
four;~2
tuberosity,~1
treated;~2
hemiarthroplasty,~1
revision);~1
shoulders,~2
charts,~1
(Risser~1
seventy-five~1
received.~4
unfused~2
pseudarthrosis~4
scoliosis.(ABSTRACT~1
Lyme~5
Arthritis~2
consulted~2
chronicum~2
migrans,~2
recollection~1
bitten~1
Bell~1
oligoarticular~2
Effusion~1
Longer~3
Metatropic~1
dwarfism~3
endochondral~4
ossification.~2
perichondral~3
metatropic~3
spongiosa~1
metaphysis;~1
chondro-osseous~1
dumbbell-shaped~1
zone;~2
clumping~2
chondrocytes~4
pericellular~1
metachromatic~5
chondrocytes;~1
alcian-blue-positive~1
calcification;~1
islands~5
chondrocytes,~1
ink~1
chondrocyte~1
epiphysis.~1
Grade-IV~2
spondylolisthesis~5
incapacitating~4
pseudoclaudication,~2
upright.~1
lumbar-nerve~1
outweighed~1
forward-bending~4
recorded,~5
Raster~1
stereophotography,~1
postures:~1
erect,~1
(forward~3
limb-length~2
(thirty~1
kyphosis~3
Qualitatively~1
toes.(ABSTRACT~1
institute~3
appraising~2
sixty-five~2
ninety-two~2
dipotassium~1
ninety-five~3
milliliter.~2
milliliter,~3
milliliter.(ABSTRACT~1
non-visualized~2
caudad~3
myelographic~3
twenty-three~5
spine;~2
disc;~1
arachnoiditis;~1
threefold.~1
fifteen,~1
uncemented~2
prosthesis)~1
non-consecutive~1
popliteus-arcuate~1
cut,~3
Gairns~1
nerve-endings~1
slow-adapting~2
Ruffini~1
Pacinian~1
corpuscle.~1
Rapidly~3
subserve~3
acceleration.~1
nerve-endings,~1
wrists~3
ulnar-nerve~2
6,538~1
nerve-conduction~1
ninety-six~2
top-level~1
volleyball~1
teams~4
Championships,~1
infraspinatus~2
Cybex-II~1
dynamometry.~1
cocking~1
follow-through~1
Synovectomy~2
elbows,~1
pronation-supination~3
fourteen.~1
elbow,~1
hemophiliacs~2
non-operative~1
failed,~4
tri-institutional,~1
enchondromas~1
(Ollier~1
(Maffucci~1
Ollier~2
chondrosarcoma~4
astrocytoma,~1
one;~1
granulosa-cell~2
Maffucci~2
chondrosarcomas,~3
osteosarcoma,~1
astrocytoma.~1
non-skeletal~1
certainty~3
enchondromatosis.~1
leaflets.~3
subannular~1
bifurcated~1
aorto-femoral~2
causes:~1
18),~3
30),~2
2);~2
out-flow~1
profundoplasty~2
femoro-popliteal~2
rethromboses~1
(9.6%).~1
reoccluded~4
(9.4%),~1
(4.2%).~1
aorto-bifemoral~1
profunda~3
under-estimated~1
thrombosis;~1
re-establish~2
uneventful,~1
41st~1
78th~2
thromboendarterectomy.~1
forty-two~4
unpatched~3
patched~7
neutralising~1
(HNA)~1
(ACT)~1
(PTT).~1
PTT~3
HNA~3
infrarenal~5
syphilitic~1
aortitic~1
aortoarteritis.~1
aorto-arteritis~1
rarer~2
aorto-arteritis.~1
peri-aortic~1
disease'~1
engenders~1
CFA~3
tandem~4
instance.~4
profundaplasty.~1
Amelioration~1
fibre-optic~1
endoscopy,~5
bores~1
thrombo-embolectomy~1
reamer~2
compliant,~1
impaling~1
bristles~1
intra-luminal~1
Broadly~1
speaking,~1
radioisotopic~2
(liver~3
lungs),~1
lungs)~2
21.5%.~1
Transposition~1
(TGA)~2
septostomy.~1
(VSD)~1
aortoplasty~4
banded~1
Conduits~1
coronaries~1
Trivial~1
mmHg).~5
case.(ABSTRACT~1
etiopathogenesis,~1
diagnostics~1
1967~4
plication.~1
dyspnoea.~1
9%.~4
(N.Y.H.A.)~1
promptly.~1
etiological~4
postpericardiotomy~2
outset.~1
loculated~1
pericardiocentesis~2
(subxiphoid~1
pericardiotomy,~1
sternotomy,~4
thoracotomy).~1
Cerebro-vascular~1
as:~1
tortuosity,~1
"C"~1
"S"~1
shape;~1
coiling,~1
loops;~1
kinking,~1
ageing~2
(TEA)~4
elongation.~1
Authors~1
bedside~5
Re-thoracotomy~1
dramatically.~1
(terbutaline,~1
terbutaline.~1
Thrombin,~1
Ca2+-ionophore~1
(ADP-mediated)~1
(cyclooxygenase-dependent)~1
alkoxyether~2
plasmalogen-type~1
Zellweger~2
A23187-induced~1
(patients,~1
PAF/10(8)~3
(PMN);~1
249-2,757~1
PMN;~1
291-5,433~1
PMN).~1
thrombin-induced~2
[1-14C]oleate~1
[1-14C]palmitate~1
microCi/h.~1
Oxidation~1
(84~4
0.82,~1
palmitate;~1
0.77,~1
oleate).~1
nmol/ml~2
1-beta-D-arabinofuranosylcytosine~1
(ara-C)~2
ara-C~10
nitrobenzylmercaptopurine~1
riboside~1
(NBMPR).~1
ara-C,~1
NBMPR~1
(67-85~1
explain,~3
opsonization~5
polysaccharide.~1
serotype.~2
Secondly,~1
pathway-mediated~2
opsonization;~1
anticapsular~3
opsonization.~1
(125I)iodoTyr10-glucagon~1
NH2-terminal~2
hepatocyte,~1
COOH-terminal~1
understimulation~1
Cholesteryl~1
(CE)~2
J774~4
CE~2
(LDL).~1
A:cholesterol~1
(ACAT)~1
chloroquine-inhibitable~1
125I-LDL~1
ACAT~4
LDL-treated~2
10-30-fold~1
acetyl-LDL~2
(matched~1
LDL)~1
macrophages;~1
Milrinone,~1
amrinone,~3
milrinone~5
calvaria~5
bones.~11
Threshold~1
Milrinone~1
milrinone-stimulated~1
runoff~1
(3.25~2
3.25~1
(GHRH)~1
nM)-stimulated~1
Transcription~3
transcription,~1
GHRH-stimulated~1
transcriptional~5
granulocyte-monocyte~1
monocyte-macrophage~3
multinucleated~5
recruit~4
osteoclasts.~1
vivo-aged~1
hypertransfusion.~1
erythropoietically~1
4.1a:4.1b~2
hypertransfused~1
(MSNA)~1
command~6
Nonischemic~1
MSNA,~1
MSNA.~1
MSNA~2
metaboreceptor~1
mediation.~1
(muscle~1
chemoreflex~1
stimulation)~1
(elimination~1
command).~1
chemoreflexes~1
gossypol,~1
rhodamine-123,~1
lonidamine.~1
(T47-D),~1
(MiaPaCa,~1
RWP-2),~1
(DU-145),~1
(HCT-8),~1
(HeLa)~1
cathodal~2
(LDH4~1
LDH5)~1
gossypol~3
rhodamine-123.~1
agar,~1
rhodamine-123~1
phosphates~7
12-O-tetradecanoyl~2
phorbol-13-acetate~2
(TPA),~2
1-oleoyl-2-acetyl-glycerol~1
(OAG)~1
OAG,~2
DOC,~1
Retinoic~1
DOC-,~1
TPA-,~1
OAG-induced~1
OAG.~1
outputs,~1
food-stimulated~2
eating.~1
Meal-stimulated~1
sialoglycoprotein~1
gpL-115)~1
gpL-115~8
(115~2
kD)~2
kD,~3
95,~1
115,~1
gpL-115,~1
(IDDM;~1
79),~2
(CD;~1
46),~2
(DH;~1
53),~2
86).~1
Preferential~1
DR~4
DQ~4
DRw6,~2
DR2~1
CD~3
3.8-kilobase~1
DQw3,~1
DX~1
UU~1
(IDDM~1
59%,~3
DH~11
45%,~2
DR3-DX~1
DQ-DX~1
subregion.~1
surface-expressed~1
unseparated~3
pulse-labeled~1
virus-exposed~2
monocytes-macrophages~1
countercurrent~1
elutriation.~1
Cell-free~3
macrophage-derived~1
abortive~1
sought.~5
adipocyte~5
Adipocyte-precursor-derived~1
factor(s).~1
Sephacryl~1
S-200~1
adipocyte-precursor-derived~1
25,000-40,000.~1
precursors.~1
dysproteinemia~1
(AILD)~1
supervening~1
AILD~3
Lymph~6
immunoregulation~1
lymphomagenesis~1
calmodulin-binding~4
Calmodulin~1
microgram/mg~1
Calmodulin-binding~1
230,~1
212,~1
204,~1
164,~1
139,~1
59,~1
46.5,~1
59-kD~1
Ca2+/calmodulin-dependent~1
125I-calmodulin~1
46.5-kD~2
reflecting,~1
Hep~4
transporter~8
2.8-kilobase~1
fetal)~1
2.8-kb~1
insulin-sensitive~1
-insensitive~1
Hepatocytes,~1
transporter.~1
antioxidative~1
(Hb)~1
alpha-thalassaemia~5
(alpha-thalassaemia~1
1/2)~2
1/Hb~2
Spring~1
(HbCS).~1
(GSH-Px),~1
GSH-Px~3
cervicitis~1
non-gonococcal~1
reticulate~3
(MOMP)~1
MOMP~2
antigens--with~1
difference:~1
lectin-peroxidase~1
histochemistry~1
carcinomata,~2
adenomata,~2
(PNA),~1
Griffonia~2
simplicifolia~1
(GSII),~1
europaeus~1
(UEAI),~1
Hyperplastic~3
typing,~2
(serous,~1
mucinous,~1
endometrial).~1
Gynaecology~1
Obstetrics'~1
indicator,~1
65%;~1
micrometers.~1
value;~1
tumours,~8
technician:~1
objectivity~1
Chemotactic~3
51Cr-labeling~1
Exacerbation~1
Psoriatic~1
chemotaxis-enhancing~1
vulgaris.~3
vulgaris,~4
intradermally~1
merely~5
methoxsalen~1
(PUVA)~1
159%~1
irradiance,~1
sensors,~1
manufacturers.~3
unsatisfactory.~5
Manufacturers~1
dosimeters~1
Ideally,~1
engaged~4
erythrodermic~4
erythroderma,~1
eruption,~1
monotonous~1
bandlike~3
dermis,~2
cerebriform-mononuclear~1
Pautrier's~1
microabscesses~1
erythroderma;~1
erythroderma.~1
dubious~1
piroxicam-induced~1
photosensitivity~6
photopatch-tested~1
piroxicam~1
(2%,~1
concentrations);~1
test-positive~1
thimerosal.~1
reactors.~1
Reusable~1
electrodesiccation~3
dermatologists.~2
electrodesiccation.~2
(HBsAg+)~1
virus),~1
rinsing~4
HBsAg,~2
reusable~1
etretinate~5
hyperkeratotic~3
1/2-year-old~2
nonbullous~1
ichthyosiform~2
Shortness~1
systematized~1
epiphyses~3
Pellagra,~1
oldest~5
Cutaneous~4
B6,~1
biotin,~2
B12,~2
riboflavin~2
fat-soluble~3
(vitamins~1
confusing.~2
hair,~1
weathering.~1
acquired,~4
fragility.~1
keyed~1
irregularities,~1
twisting,~1
extraneous~1
shaft.~2
1,643~1
3,175~1
(forty~1
sixteen-center~1
psoralens~1
(PUVA),~2
joules/cm2~1
phototoxic~3
Kyrle's~1
forties.~1
female/male~1
6:1.~1
Straw-colored~1
calf,~1
koebnerization~1
invaginated~1
orthokeratosis~1
parakeratosis,~1
keratinization.~2
dodecylsulfate~2
bands.~1
seborrheic~4
symmetrical,~2
backs~2
melanosome~1
macrocomplexes~2
packed,~1
melanosomes.~1
Langerhans~8
phagosomes.~1
melanin~4
macroglobules~1
("giant~1
melanosomes")~1
nonpatterned~1
nevoid~1
(HBsAg)~5
guttate~9
hypomelanosis~7
leukodermic~1
dermatosis~4
achromic~2
hypopigmented~3
macules,~1
cause-effect~1
Epithelial~4
rete~1
basket~4
weave~1
hyperkeratosis~6
hypomelanosis.~1
Minigrafts~1
triamcinolone~1
cataracts,~3
pilaris,~1
linked.~3
Psoriasis~1
genodermatosis.~1
follicularis~1
spinulosa~1
decalvans~1
ichthyosis~3
follicularis,~1
paraproteinemia~1
subcutis.~1
Variable~2
interfibrillar~1
[35S]sulfate~2
paraprotein,~2
blepharoplasty~1
electrocautery~4
ecchymosis~2
laser-treated~3
bloodless~5
laser,~4
lasers,~2
He-Ne~3
summarizing~1
laser-induced~1
telangiectasia.~1
577~2
xanthelasma~1
palpebrarum~2
far.~2
rhinophyma~1
defocused~1
contouring.~1
fruitful,~1
deferred~4
cooperating~2
remedied.~1
sebaceum~1
interlude.~1
dipyridamole-thallium~3
69)~2
redistribution,~1
reciprocating~10
palpitation,~1
"skipped~1
beats"~1
hypokinesia~4
hypokinesia,~1
hypokinesia;~1
Midventricular~1
mid-ventricular~1
hypokinesia.~1
Exercise-induced~5
269~1
Thallium-201~4
overestimate~4
interim~3
worsening.~3
overestimates~1
Unipolar~1
mid-right~1
domain:~2
slew~5
(1.31~1
(1.15~1
mV).~1
Amplitudes~1
(0.21~1
smallest.~1
(17.1~2
(bipolar~2
sensing~5
(P/QRS~1
15:1).~1
rate-response~1
17/83~1
risk-free~1
cm/s;~2
mass),~1
trabeculations~4
trabeculations,~2
more;~1
582.~1
493~2
septoparietal~1
Trabeculations~1
posteromedial~2
misinterpreted,~1
-0.5;~1
less),~2
"operability."~1
muscularized~2
Cor~1
triatriatum~3
dexter~1
venosus.~1
Now~2
kHz~1
radiofrequency~6
electrosurgical~3
generator~10
ablation)~2
(unipolar~2
(watts)~1
conduction;~1
Chloralose-anesthetized,~1
tachycardia;~4
liters/min~5
ms.~6
intracoronary,~1
slows~4
0.044~1
epicardium~4
"wave~1
front"~1
nonflow~1
overriding~3
dictate~2
91)~1
disabled;~1
Valvuloplasty~2
proarrhythmic~6
beats)~6
extra-stimuli~1
disopyramide~14
Proarrhythmic~1
fibrillation;~3
quinidine,~6
disopyramide)~1
characteristics;~1
0.06).(ABSTRACT~1
(935~1
(Holter~1
therapy).~1
Arrhythmia-free~1
Diltiazem,~1
(155~1
(163~1
(87~2
alleviation~4
digoxin-treated~1
inspection.~1
bradycardia-~1
tachycardia-dependent~1
branch).~1
ventriculoatrial~2
(VA)~4
Resumption~1
RH~1
escapes)~1
"in~1
vitro"~1
valvulitis~1
myalgia,~3
glucocorticosteroids~1
Subthreshold~1
subthreshold~3
incessant~1
posteroseptal~2
histamine-releasing~2
(HRF)~1
HRF~2
(SpHRF)~1
(BHR),~1
histamine-release~1
BHR~1
(PC20).~1
mg/ml.~2
SpHRF~3
-0.86;~1
PC20.~1
cell-~1
basophil-derived~1
BHR,~1
BHR.~2
spices~5
coriander~2
curry,~1
mace,~1
celery,~1
spice~2
RASTs~1
mugwort-pollen~1
mugwort~1
Leukocytes~1
venoms~1
jackets~2
Vespula~1
flavopilosa,~1
V.~21
pennsylvanica,~1
squamosa,~2
A1.~2
squamosa~4
cross-reaction~3
ELISA,~6
jacket-sensitive~1
accidentally~4
anaphylaxis.~7
chymopapain,~1
vasovagal~1
health;~1
ecology~4
therapy."~1
litigation~1
arisen,~1
Eustachian~1
(ETO)~1
provoking~5
ETO.~1
nostril).~1
nonallergy~1
seasons.~2
ETO~4
nine-step~1
rhinomanometry~1
AR,~5
Saline~3
AR.~1
(MCGs),~1
high-molecular-weight~2
(HMW)~1
daltons)~4
(LMW)~3
(LPRs).~1
LPRs~1
neutrophil-dependent~4
chemoattractant~4
HMW~8
LMW~8
48-well~1
microchemotaxis~1
attracted~2
Checkerboard~2
chemokinetic.~1
MCGs~1
XM300~2
daltons),~3
YM100~2
(300,000~1
XM50~1
(100,000~1
YM10~1
(50,000~1
inflammation-provoking~2
retentate~1
chymase,~1
chemoattraction.~1
MCG~2
400,000~1
separable~1
chymase~1
nonatopic~3
rhinitis,~1
tonsurans~3
immunosorbent,~1
26/30~1
anti-IgE~1
Trichophyton.~1
(SO2)-induced~1
(FEV1~3
[RT])~1
SO2-induced~3
albuterol,~3
2-agonist,~1
trimellitic~2
anhydride~4
(TMA)~1
TMA~2
micrograms/m3,~1
trimellityl~1
(RSA-TM)~1
TMA.~1
RSA-TM~1
foci,~2
RSA-TM,~1
clarifies~2
disease-anemia~1
3-month,~1
(52%~1
histamine-induced~5
sundown~1
Inventory.~3
Physiologic,~1
Pfeiffer's~2
Portable~2
Questionnaire,~2
Face-Hand~2
sundowners,~1
sundowners~1
restless~1
approached.~2
Sundowners~1
demented,~1
nonsundowners.~1
odor~2
awakened~2
shift,~2
sundowning.~1
facility,~3
(TSH),~1
(T4),~1
(FT4I),~1
(T3),~2
(FT3I)~1
(TSH~2
microU/mL~2
FT4I~2
findings)~2
116)~2
findings),~1
(4.3%)~1
(1.8%~3
0.01]).~1
microU/mL)~1
FT4I,~1
made;~4
FT3I.(ABSTRACT~1
nondepressed,~1
depressed/not~1
demented;~1
demented/not~3
geropsychiatrists~1
DSTs~1
postdexamethasone,~1
48.7~1
METS)~1
rate-blood~2
inhospital~1
recruiting~1
(ANLL)~2
Duke~2
0.0002),~1
nonspontaneous~1
0.003),~3
care;~2
palliated~3
cross-sectional,~1
(SDB)~1
in-lab~1
polysomnography.~1
somnolence~2
parasomniac~1
(snoring,~1
gasping~1
sleep)~1
SDB~3
insomnia~4
not;~2
status)~1
complication-rate~1
(49%)~3
(59%);~1
booster~3
candida,~1
trichophyton.~1
Nonresponders~1
Tuberculin-positivity~1
43%;~1
pre-employment~1
employees,~3
funded~5
Aging.~1
administrator~1
telephoned~1
requested.~2
packet~1
promotional~1
qualifications,~1
strata~2
beds)~1
proprietary~1
domiciliary~2
backed~1
temples.~1
temple~2
frontal,~2
vertex,~1
headaches.~3
Temporal~3
sero-negative~1
90-year-old~1
glomerulo-nephritis~1
75-year-old~3
female.~3
predilection,~2
esophagus/esophagogastric~2
7:1~1
Clear~3
white.~2
sphincter,~1
g/day~2
S,~3
habit,~3
Spiral~2
pseudoobstruction.~6
sixth,~1
seventh,~1
"aging~1
gut."~1
nongangrenous~1
stricturing~4
62.2%~1
86.4%~1
ileocecal~3
erythrocytic~1
ESRs~2
(Crohn's~1
40.7~1
3.3,~1
31.0~1
3.9),~1
(ulcerative~1
proctitis~3
proctosigmoiditis~1
2.1).~2
(ileitis~1
jejunoileitis),~1
ESRs,~1
severe;~1
tripartite~1
selected:~3
2-globulin,~2
-12.168~1
0.333X1~1
0.022X2~1
0.018X3~1
0.337X4~1
0.056X5~1
0.033X6,~1
X1,~1
X2,~1
X3,~1
X4,~1
X5,~1
X6~1
1.52;~1
2.44;~1
2.44.~1
Siblings~1
17-35~1
35-70~1
fibersigmoidoscope~1
colonoscope~2
anoscopy~2
Straight~1
retroflexion~1
anoscope~1
Anoscopy~1
fibersigmoidoscopy~1
Instructions~1
gastritis,~3
2-test),~1
cabbage~1
bread,~3
coffee,~2
meat.~1
One-half~1
RDA.~3
inform~3
(ALF)~1
ALF~2
Rajgarhia~1
All-India~1
(AIIMS)~1
85.4%~1
female-to-male~1
1.3:1.~1
59.7%~1
pregnant.~2
57.2,~2
39.3,~1
28.9%~1
coma,~2
22.8%~1
(10.6%),~1
cramps~3
sleep),~1
cramps.~1
5-fluorodeoxyuridine~1
(5-FUDR).~1
profited~1
nonbiliary~1
unremitting~1
1-year.~1
links~1
extraintestinal~3
sulfasalazine,~1
anicteric~1
zonal~1
(centrolobular)~1
featured~1
inclusions.~1
cimetidine-related~1
re-exposure~2
well-known.~1
hypersplenism,~1
aspiration--a~1
Food-dependent~1
anaphylaxis,~3
celery-dependent~1
allergies,~1
serious,~2
Ludwig's~2
pneumoniae.~1
constricting~4
strands~3
turbinectomy.~1
Anaphylaxis~2
catastrophe.~1
immediate-type~1
based.~2
incriminated~3
razor,~1
antiperspirants~4
deodorants,~2
pyogenic~4
axilla.~1
transepidermal~2
nicked,~1
irritated~1
razor~1
axilla).~1
dysrhythmias,~2
rarely,~5
carditis.~1
tachycardic~5
"irreversible~1
shock."~1
hypovolemia.~1
represents,~1
nonpuerperal~1
Bartholin's~1
absolutely~1
carbamazepine-intoxicated~1
TLI-treated~1
GVHD~2
GVHD:~1
sublethally~1
GVHD,~1
HT-2~1
(T~5
origin)~1
GVHD.~1
recipient.~3
imprint~3
electroimmunofixation~1
EAE~1
(MBP).~2
MBP~3
proteolipid~2
myelin-associated~4
glycoprotein.~6
delipidated~2
electroimmunofixation,~1
homogenate.~1
non-myelin~1
myelin,~2
electroimmunofixation.~1
Antigen-~1
mitogen-stimulated~1
(TNF-alpha)~1
lymphocyte-derived~2
(TNF-beta)~1
(lymphotoxin),~1
TNF-alpha~4
TNF-beta.~1
TNF-beta~2
osteoclasts,~2
Half-maximal~1
TNF-beta,~1
antifibronectin~1
individuals)~1
individuals).~1
antigenicity~5
antigenicity.~2
(Leu-4,~1
Leu-3,~1
OKT8)~1
substratum-dependent~2
antigen-bearing~1
150/55~1
Culture~5
plastic.~4
(PMN-myeloperoxidase~1
convertase~2
later-acting~1
C6,~2
C7,~2
C8.~1
C7~5
convertase-cleaved~1
cell/large~1
(NK/LGL)~1
choriomeningitis~1
(LCMV),~1
(MCMV),~2
(MHV),~1
Pichinde~2
vaccinia~1
NK/LGL~5
(PEC)~2
postinfection~1
(p.i.)~1
p.i.~2
MHV.~1
LGL~4
phenotype:~1
asialo~2
GM1+,~1
Thy-1.2~1
+/-,~1
Lyt-2.2-,~1
J11d-.~1
cell-resistant~1
LCMV.~1
lymphocyte/LGL~1
(CTL/LGL)~1
NK/LGL.~1
MHV~1
p.i.,~1
CTL/LGL~1
MHV-CTL~1
Virus-induced,~1
unidirectional~3
5-microns~1
Wash-out~1
virus-1~1
(HSV-1)~1
HSV-1~2
(HFEM~1
strain),~1
poly~1
I:C-treated~1
beige~1
engender~1
transferring~2
NK1.1+,~1
GM1+.~1
Transfer~1
anti-tumor~2
(rHTNF)~1
(MCA-101,~1
-102,~2
-105,~2
-106)~1
(MCA-38)~1
rHTNF~12
Tumor-bearing~2
(41/86)~1
MCA-101,~1
-106~2
MCA-38~1
MCA-105,~1
-106,~2
-38~1
pre-treatment~3
excipient-treated~2
non-immunogenic~2
MCA-101~1
-102~1
cures~1
MCA-38,~2
-101,~2
-102.~2
MCA-105~2
excipient~1
MCA-106~3
MCA-102~1
morphologically,~1
MCA-102.~1
"ghosts".(ABSTRACT~1
periodate~3
aldehydes~4
termini~1
sialoglycoconjugates.~1
moieties~3
(N-AN~2
borohydride~4
oxidation,~2
periodate-treated~1
[3H]borohydride~1
Oxidized~1
sialyl~2
periodate-activated~1
sialyl-glycoconjugates~1
gangliosides,~1
gangliosides~4
B54.2~8
quantified,~2
epitope-bearing~1
(S-MC),~1
culture-derived~3
(BM-MC),~1
(FTL-MC),~1
FTL-MC~1
(ABFTL-MC).~1
ABFTL-MC~2
nontransformed,~1
antibody-binding~2
110,000~2
130,000~3
BM-MC.~2
[35S]methionine,~1
("B54.2~1
antigen")~1
Labeling~1
BM-MC~2
93,000~3
N-linked~2
carbohydrate.~3
Endoglycosidase~1
110,000-Mr~2
130,000-Mr~2
"high~2
mannose"~1
93,000-Mr~1
imbalances~2
zoster.~2
(PBMC)~1
PBMC~6
for:~2
varicella-zoster~6
(VZV)~1
Leu-3~1
(helper/inducer):Leu-2~1
(cytotoxic/suppressor)~1
coexpression~1
Leu-2~1
OKM1~1
VZV~2
Leu-3:Leu-2~1
Leu-2+~3
OKM1+~1
Cryopreserved~1
fluorescence-activated~1
sorting.~1
radiosensitive~1
Immunologically~2
Trichinella~2
spiralis~2
cell-derived~3
mediators,~5
antigen-inducible~1
transferable~2
anti-trichinella~1
homocytotropic~1
PCA-detectable~1
correlate,~1
(Isc).~1
Isc~1
Immunization~2
06~3
pili~4
5.0-fold~1
6.3-fold~1
(MLN)~1
patches.~1
serum:milk~1
serum:bile~1
homing~3
Antibody-forming~1
MLN~1
transferred.~3
mucosal-glandular~1
125I-monoclonal~1
anti-paternal~2
anti-MHC~2
fetoplacental~1
proper,~1
interphotoreceptor~1
retinoid-binding~1
(IRBP)~1
uveoretinitis~2
(EAU)~1
S-antigen~1
(S-Ag).~1
IRBP-induced~1
EAU.~2
IRBP~4
EAU~1
(lymph~1
(spleen~1
only).~1
Recipients~2
pinealitis~1
S-Ag~1
sensitization.~2
system:~1
Theiler's~1
(TMEV)~1
SJL/J~4
unlinked~1
H-2~2
(susceptible~1
BALB/c)~1
(H-2s~1
H-2d,~1
recombinant-inbred~1
(R-I)~1
H-2s~1
H-2d~1
H-2s/H-2d~1
heterozygotes),~1
non-H-2~3
TMEV-induced~2
R-I~2
loci--only~1
"functionally"~1
accent~1
anti-myelin-associated~1
(MAG)~1
anti-MAG~5
immunizing~4
Immunoenzymatic~1
cross-inhibition,~1
coating,~1
cross-inhibition.~1
MAG~1
(observed~1
(FMLP,~1
anti-TNF~2
lymphotoxin~1
phagocytes,~1
anti-lymphotoxin~1
chemotactically~1
lymphokine,~1
(LIF),~1
neutrophil-mediated~1
antibody-dependent~2
(ADCC)~1
K562~4
LIF~3
ADCC~2
54.9%~1
0.99)~2
neutrophil-target~1
LIF-treated~1
3.3:1~1
effector:target~1
4.8:1~1
LIF),~1
ADCC.~1
3I~2
kappa-chains~2
82/706~1
double-stranded~3
charge.~2
IgG-associated~1
3I-reactive~1
kappa-light~1
mutation,~1
GM2,~1
GD2,~1
GD3~1
astrocytomas,~4
GM2.~3
(Cy),~1
(JB-RH)~1
GM2~8
JB-RH~2
Freund's~4
adjuvant,~1
immunogenic.~3
minnesota~2
BCG,~1
monophosphoryl~1
R595~2
Cy~1
C5b-9~9
override~2
survive.~4
physiochemical~1
C5b-9,~2
C9.~1
cytolytically~1
[Ca2+]o,~1
[Ca2+]o~1
deregulation.~1
maleyl-BSA~4
radiolabeling~2
SDS-polyacrylamide~3
(38,~1
75,~5
80,~6
kD).~1
algal~1
fucoidan.~1
(LPS),~1
co-migration~1
p57~1
p85)~1
ligand-receptor~1
Chloroquine,~1
maleyl-BSA,~1
fucoidan~1
tumoricidal~1
Receptor-mediated~1
(RBL)~1
potential-sensitive~1
bis-oxonol.~1
Depolarization~2
bis-oxonol,~1
RBL~1
aggregated.~1
lanthanum,~1
antigen-stimulated~3
bis-oxonol~1
fura-2.~1
Antigen-stimulated~1
(h-r-TNF).~1
propensities~1
h-r-TNF~2
cultivation~1
h-r-TNF.~1
(NC)~2
(TNF).~1
NC~18
NC-sensitive~1
TNF-sensitive~1
NC-resistant~1
TNF-resistant.~1
51Cr~7
effectors~1
interact.~1
10ME~1
B/C-N~1
NC-mediated~2
TNF-mediated~2
synthesis-dependent~1
lysis,~1
Leukotriene~2
3.1-200~1
pmol.~2
LTD4-induced~3
LTD4.~3
reflex,~5
133xenon~1
0.2-200~1
whealing~1
whealing.~1
itching.~1
(FEH)~1
Greenlandic~1
Eskimos,~1
HPVs~2
genomes~2
molecularly~1
HPVs,~1
HPV13,~1
FEH~2
HPV13~1
tentatively~3
HPV32.~2
papillomas,~6
specimens:~1
HPV6~1
uncharacterized~1
HPV32~1
FEH.~1
HPVs--HPV13~1
(tricolored)~1
Melanocytes~1
dopa~2
freezing.~2
hyperpigmentation.~1
hyperpigmented.~1
hyperpigmentation~5
ultraviolet-B~1
(UVB)-induced~1
Hairless~1
Nonirradiated~1
6-24~3
(nonirradiated)~1
dorsal/ventral~1
(D/V~1
D/V~1
revert~1
sun-exposed~1
(GM2995)~1
xeroderma~3
pigmentosum~3
(1:4~1
dilution),~2
anchorage-independent~2
round,~2
smooth-edged~1
agar.~1
passages,~1
35-50%~1
aneuploidy.~2
late-passage~1
GM2995~2
early-passage~1
IgG-anti-keratin~1
(KIF)~1
damaged,~1
graft-versus-host~3
opsonins~1
IgG-anti-KIF~5
KIF~16
(PMN).~1
Keratin~1
0.3-2.5~1
aggregates.~2
nonopsonized~4
autoantibodies.~2
Monocytes~3
Nonopsonized~1
avidly.~1
230,000~1
(SIFM)~1
heat-stable,~1
SIFM~2
serum-derived~1
cell-directed~1
fibroblast's~1
migrate.~2
keratins~7
keratin-enriched~1
interfollicular~1
variations,~1
constituent~4
interindividually~1
nonequilibrium~1
electrophoresis:~1
1a~1
1b~1
5a~1
5b~1
10a~1
10b.~1
doublet,~1
(1a~1
1b)~1
(5a~1
5b)~1
(10a~1
10b)~1
concurred~2
Hardy-Weinberg~1
(25%),~7
(25%).~2
bilayers~1
unilamellar~3
stoichiometric~2
corneocytes.~1
detergent-solubilized~1
mU/g,~3
64.7~1
88.5~1
7.04~1
mU/mg,~2
4.28~1
5.02~1
mU/mg.~1
Elemental~2
PIXE~1
(proton-induced~1
emission)~1
freeze-dried~2
Ca-induced~1
DNA-~2
RNA-polymerases~1
necrobiosis~2
lipoidica~2
cross-striation~1
fibrils.~1
hydroxy-proline,~1
collagen-specific~1
lesional~6
I/III~1
healthy-looking~1
clone.~2
MCMV~7
three-week-old~1
0.003%-0.185%~1
Coincident~1
perfringens~1
debridement~10
objective,~1
perfringens,~1
rifampin,~2
penicillin-treated~1
77-1,800~1
metronidazole/kg,~1
(8.6-86~1
mg/kg).~9
inocula~1
fimbriae~1
homografts~2
postinoculation~1
fluorescent-antibody~1
trachomatis-specific~1
Organisms~3
E-specific~1
vulnificus~4
bacterium~2
edema;~3
bundles;~1
accumulations~4
proteins;~1
phagocytized~3
digested.~1
(CP)~2
.71,~1
bacteremic~7
aureus,~6
"rheumatic"~1
non-T~1
compartmentalization~3
(RHD)~1
RHD~4
83S19.23~1
256S.10,~1
tonsils,~1
organ-specific~2
parasitism~1
Hookworm~1
Strongyloides~2
stercoralis~2
test's~1
parasitological~1
(CSD).~1
usual,~2
1,038~1
CSD,~1
eruptions,~2
splenomegaly).~1
neuroretinitis,~1
pleurisy,~1
arthralgia~2
peptidoglycan~2
1960s.~1
Staphylococci~1
divide~3
glycan~3
connecting~4
parallelogram.~1
doubles~1
deform~1
spiral,~1
twisted~1
disaccharide~1
turn.~2
Insights~1
peptidoglycans~1
division,~1
penicillin-binding~1
methicillin,~1
growth-dependent~1
Lassa~17
Leone,~1
Mastomys~3
natalensis,~2
50%-60%~1
10%-20%~1
agriculture~1
bush~1
90.2,~1
10(-6),~3
df~3
most-important~1
5%-14%.~1
Eightfold~1
1%-18%~1
antibody-positive~3
reinfection.~1
1%-2%,~1
Africa.~3
Leone~1
case-fatality~4
10%-16%~1
16.5%.~1
retrosternal~5
.81);~1
5.5).~1
eighth-nerve~1
deafness~7
more-common~1
TCID50/ml~2
1.9-7.2).~1
IU/liter~1
5.2-99.0).~1
nonviremic~1
.002);~1
TCID50/ml.~1
viruric~1
acid-glycine~1
pyloridis,~1
(EU).~1
EU,~1
EU.~3
EU~2
99%.~1
(485~1
E),~1
EU),~1
Discriminating~2
charged,~1
multilamellar~2
broad-spectrum~1
ribavirin~4
(RIB)~1
(MTP-PE)~1
Liposome-encapsulated~2
MTP-PE~3
(L-MTP-PE)~1
LD50~3
(HSV-1).~1
liposome-encapsulated~3
RIB~3
(L-RIB;~1
mouse),~1
mouse)~1
L-RIB~2
L-MTP-PE~1
Exopolymer-free~1
cages.~1
exopolymers,~1
Exopolymers~2
cage.~2
exopolymer~1
exopolymers~2
fibronectin-coated~1
exopolymers.~1
toxoplasmic~3
tachyzoites.~1
tachyzoites~3
Immunosuppressed~1
even-larger~1
destruction,~1
detectable.~2
Brains~2
cortisone-treated~2
tachyzoites,~1
scant~3
encephalitis.~3
couples,~3
antispermatozoal~3
partner's~2
semen,~5
subclassified~2
normospermic~1
oligospermic~2
immunobead~1
IgA/IgG~1
hyperstimulation~3
fragmentation,~1
triploidy,~1
sister-chomatid~1
E2-peak~1
luteal-phase~1
failures),~1
E2/P~3
Ultrasonically~1
Superovulation~1
(hMG)/human~1
(hCG).~1
Oocyte~1
ultrasonically~1
guided,~1
(PBS),~1
trocar~1
smaller-bore~1
anonymous~2
donation,~1
recipient,~2
posted~2
donations~1
altruistic~1
withhold~1
names~1
identification.~7
donate~3
asynchronously.~1
recipient's~3
Synchronization~3
manipulating~1
inseminated~1
concert~2
vaso-occlusion~1
leukoembolization,~1
alprenolol,~1
N-formyl-methionyl-leucyl-phenylalanine~3
C5a.~3
Lysosomal~1
-65~1
VIII,~1
hemostasis.~2
CCl4-induced~2
defenses,~1
CCl4~3
Peroxidation~1
evaporated~2
peroxidation.~3
chymotrypsin~1
thrombogenicity~1
boron~2
neutron~7
spectrometer.~2
(Li~1
2.64~2
ng/gm~2
weight),~3
rubidium~1
biophysical~3
pretreating~1
anti-C5~3
activated,~2
inactivator,~1
Activated~6
inactivator~2
nonphagocytic~1
polyphosphatases~1
diphosphatase~1
[ADPase])~1
ADPase~4
intraglomerular~3
(ADP)~1
x-irradiation~3
(2000~2
rads)~1
(PAN)~2
weight).~6
doxorubicin-treated~1
x-irradiated~1
PAN-treated~1
microscopy)~2
(immunofluorescence~1
fluorescinated~1
proteoglycans,~1
dispose~2
dipalmitoyl~1
(DPPC)~2
(CHOL)~1
intratracheally,~1
60-minute~2
DPPC~4
CHOL~6
0.5%)~1
Labeled~2
DPPC,~1
DPPC/CHOL~1
(2:1~1
DPPC.~1
fashions~1
(AN)~1
1:100~2
(K+)~2
Oxygenated~1
leakier~1
Scavengers~1
AN-induced~1
oxidants~1
"nutcracker~1
esophagus"~1
Manometric~2
(-0.65;~1
nonperistaltic~3
sealing~1
water-borne~1
ears.~3
plugs,~1
petroleum~1
jelly,~1
moldable~1
otological~1
witnesses~1
fierce~1
cholesteatomatous~2
ears--closed~1
(McCabe,~1
Sade,~1
1982a).~1
years--a~1
aerate--a~1
'Eustachian~1
function'~1
IP).~1
cochleas~2
dispersive~4
microanalysis.~1
Cisplatin,~1
stereocilia~2
disarrayed,~1
fused,~1
sulphur,~1
post-cricoid~1
chordomas~1
Mersey~1
paediatric~7
endoscopist~2
Alexandra~1
Sydney~1
reluctantly,~1
paediatrician~1
laryngoscopy,~2
used!~1
How~3
now--the~1
intra-thoracic~1
papilloedema~2
neurofibroma~2
Horner's~4
Recklinghausen's~2
hoarseness~1
node;~1
mind,~2
immigrant~2
provinces.~2
ten-day~3
earache,~1
fussiness,~1
30-day~8
reevaluation~1
compress,~1
pad.~1
self-treatment.~1
injury-prevention~1
cautioning~1
self-care.~1
(obstetrics~1
medicine)~1
6,856~1
301~3
468~1
insurance,~1
1.42)~1
1.75,~1
2.49).~1
obstetricians)~1
obstetricians.~2
reviewed:~1
cohorts,~1
suggests,~1
appropriately,~3
technologically~1
normal-weight~2
babies.~2
answer.~1
Continuity~1
Commonly~4
(UPC),~1
(COC),~1
(MCI),~1
modified,~2
(MMCI),~1
MMCI~3
1.0).~1
COC~2
.41~1
MCI~3
.44.~1
MCI,~1
resolving.~1
distracts~1
physician-patient~6
wishes,~1
fears~7
psychotherapeutic~2
attunement~1
advice,~1
accepting~2
psychiatric,~1
sector.~1
programs:~1
psychopharmacology,~1
care)~2
prepaid~5
fee-for-service~9
cost-containment~2
26-item~1
Sociodemographic~1
health-related~1
constructs~1
"physician~2
conduct/humaneness"~1
Assessed~1
standpoint,~2
realm~4
conduct/humaneness."~1
hundred++~1
panic,~2
attacks,~4
phobias,~2
self-rating~3
frightening~1
anxiety.~2
fears,~1
Attitude~2
nonpatient~1
nonhypochondriacal~1
Hypochondriacal~1
sensations,~2
distrusted~1
hypochondriasis.~3
Somatization~1
systems:~1
Feighner~2
Duke,~1
Hopkins,~1
Yale~1
fewest~1
respondents,~3
birthrate~2
schizophrenics.~2
spring-fall~1
winter--i.e.,~1
preschizophrenic~1
winters~2
exaggerated.~2
tentative~3
formulation.~2
low-disease~1
winters,~1
reactive)~1
process-reaction~1
anhedonia~1
reforms~2
Federal~2
Republic~2
Germany~1
stigmatization.~2
tenure~1
stigmatized~1
modern,~1
stigma~3
matters.~1
perceive~8
stigmatization,~1
opposite.~1
devalue~1
Nor~2
stigmatization~1
well-intentioned~1
unanticipated~2
"Daily~1
Living~1
Groups,"~1
feared~2
hallucinatory-type~1
suggestibility.~1
hallucinate,~1
Launay-Slade~1
Hallucination~1
(LSHS-A).~1
hallucinating~3
nonhallucinating~2
LSHS-A~3
scorers~2
hear~1
suggestibility~1
Barber~1
Suggestion~1
SCL-90R~1
phobia~2
Liebowitz's~1
DSM-III-R~3
defeating~1
(masochistic)~1
82)~1
40)~3
(PDQ).~1
(18.3%)~2
Overlap~1
borderline,~1
avoidant,~1
Validation~2
masochistic~1
imagery~1
(PTSD)~1
intrusive~2
recollections~1
flashbacks~1
PTSD.~1
veteran~1
PTSD~1
capitalizing~1
flashbacks.~1
abreaction~2
neuroleptic-induced~2
confound~2
Neuroleptic~1
Associations~2
Monoamine~1
(MAOIs)~1
MAOI~3
palpitations,~1
psychosis.~1
Withdrawal~1
phenelzine~1
alprazolam.~1
drastic~2
trade~1
inadvertently~2
nortriptyline.~1
bioavailability,~1
Bioinequivalence~1
Reigning~1
nosology~3
"too~1
subjective"~1
respected~1
"mysteries"~1
nosology:~1
praecox~1
feeling.~1
demystify~2
mysteries~1
explicating~1
workings~1
"typification"~1
manuals,~1
DSM-III,~1
presuppose~2
typifications.~1
typification,~1
preconceptual~1
objective.~1
panic.)~1
Relationships~3
Coping~2
Checklist,~1
(SCL-90~2
Zung~2
scales),~2
problem-focused~2
wishful~3
thinking.~1
cognitions~1
(score~1
55)~1
24.~1
MMS.~1
Seventy-eight~3
postrape~1
seekers~2
raped~1
"friend,"~1
assailant.~2
rape-related~1
fearful~1
Triethyl~1
tin(TET)-induced~1
cerebrum~3
perfusion-fixation.~2
T1.~2
magnetisation~1
slowly-relaxing~1
rapidly-relaxing~1
detoxified~2
age-stratified~1
Halstead-Reitan~1
abstinence.~4
unrecognised~2
cognition~1
slowed.~2
VM/Dk~1
P497~1
P540~1
P560~1
VM~1
astrocytoma~2
chemosensitivity~6
35S-methionine~1
P497,~1
chemosensitive.~1
cisterna~6
magna~4
advanced.~3
transtentorial~2
Conduction~1
tentorial~2
Transtentorial~1
Acetylcholinesterase,~1
immunoreactivity,~2
neurochemical~3
mover,~1
immobile,~1
Photosensitivity~1
precipitation.~1
age-related,~1
epilepsies.~1
1062~1
4007~1
Versive~1
photosensitivity.~2
grand~1
mal~1
poly-spike~1
evening,~2
remarkably,~1
epilepsies~1
pathoplastic~1
absences~1
pattern-reversal~1
normalisation~1
half-field~1
ionised~1
pudendo-anal~1
(MUPD)~1
38.5~2
reflexes;~2
ms)~5
MUPD~1
(tau~2
polysynaptic~1
leucodystrophy~1
arylsulphatase~1
nmol/h/mg~3
heterozygote,~1
60-160~1
Sural~1
Schwann~4
humeroperoneal~1
pseudohypertrophy,~1
life-saving~2
dysarthria~7
radiata.~1
cervicalis~1
hypertrophica,~1
C8-T1~1
radiculomyelopathy~1
Queckenstedt~1
partial,~3
tomogram~2
hemiatrophy~2
beaking~1
C7.~2
durotomies.~1
compromizing~1
phaeochromocytoma~3
normotension~1
chlorocresol~3
oris~1
hyperreactive~2
2-25~1
sonographic~2
stiff-man~2
exteroceptive~2
Clonidine,~1
tizanidine~1
effect:~1
Correspondingly,~1
alpha-stimulator,~1
tizanidine,~1
trans-sylvian~1
myofilaments~4
disintegrating~1
myelin-like~1
well-developed~5
myofilament~8
dissolution,~1
swelling.~1
pyknotic~1
fibres.~3
immunoglobulins.~1
extra-cellular~1
communicate~4
Extradural~2
blood-CSF~2
marker.~5
cryptococcal~2
non-specific.~2
thyroid-stimulating-hormone,~1
somatomedins,~1
Advancing~1
3,872~1
Trunk~1
primaries~1
lentigo~1
maligna~1
Clark's~2
Breslow~4
spread,~2
rapidly.~6
5.3;~1
Stanford~1
(75.5%),~1
(4.5%),~1
(12.6%),~1
(27.5%),~1
(45.5%)~1
.0118)~1
.0091).~1
(Broviac~1
Hickman,~1
Houston).~1
607~1
7,198).~1
Clotting~2
Hickman~4
1,700~1
rad,~2
61+).~1
134+~1
Univariate~7
1,015~1
Involved~1
defense,~1
ER-negative~1
ER-positive~1
receptor-positive~1
1,230~1
asymptomatically.~1
appealing~2
offered,~1
Mastectomy~2
(47%);~2
conservation--tumor~1
chose~8
electing~2
psychosexual~1
(Profile~1
[POMS],~1
[HLCS]~1
Locke-Wallace~1
Marital~1
[MAT],~1
Psychosocial~2
[PAIS],~1
Derogatis~1
[DSFI],~1
Millon~2
Multiaxial~2
[MCMI],~1
[BCIT]).~1
conservation.~1
conservation,~3
introverted~1
dejected~1
valued~3
self-interested~1
cytosine~1
(ara-C)/anthracycline~1
(HDara-C)~1
toxins,~1
anthracycline~3
antibiotic.~1
Menogaril~2
(7-con-O-methylnogarol)~1
semisynthetic~1
nogalamycin~1
menogaril~4
(Baltimore).~1
28-day~3
nadirs~2
Nonhematologic~1
malaise~1
postinfusion~1
limiting.~1
1,400~2
schedules,~1
schedule-dependent~1
OH)~3
Dosing~2
mg/m2/d~3
escalated~3
toxicities.~1
(CRs)~3
proven,~2
CRs,~2
Cardiotoxicity,~1
459~1
mg/m2;~2
celite~1
shorter.~2
Dexamethasone~2
lymphoblastic~4
(ALL).~1
pelvic,~1
(TR600/TE~1
40).~3
(short~1
time).~3
patchy,~1
discrete,~4
biopsies;~1
confirmation.~1
bank.~1
determine:~1
spermatogenesis,~2
cryopreservation.~1
postthaw~2
10(6)/mL~2
cryopreserved~3
537~1
(SCLC)~2
(PRs)~1
(NRs).~1
PRs.~1
(PCl)~1
nonexistent.~1
PCl~1
MTX.~3
unresectability~1
preoperatively;~1
preradiation~1
postradiation~3
DFS~1
1.0)~1
.61).~1
(thus~1
.38).~1
Hydroxyproline~1
(OHP)~1
hydroxyprolinuria~1
Ionized~1
phosphorous~2
each).~6
1,25~1
(OH)2-vitamin~1
25-OH-vitamin~1
Ultrafilterable~1
(UP)~1
UP~6
Creatinine~2
mL/min.~2
.831),~1
.727,~1
.488,~1
.025~1
r2~1
.623,~1
justified.~1
candidiasis~1
fungus.~2
liposomal-amphotericin~1
(L-AmpB)~1
AmpB~1
(Fungizone;~1
Squibb~3
Son,~1
Princeton,~1
antifungals.~1
(88.8%)~1
L-AmpB.~1
L-AmpB~1
anti-fungal~1
graft's~1
intima,~4
coagulability~2
perfection~1
principles.~3
"arterialized,"~1
baclofen.~1
spasms,~1
antispasmodic~1
short-duration~1
spasms.~3
malfunctions~1
Baclofen~1
indefinitely~1
varix~2
Galen~1
subpial~1
infratentorial.~1
Galen.~2
conservatively.~3
Staging~3
endocrinological,~1
surgical,~4
(ACTH)-dependent~1
Microadenomas~1
Macroadenomas~1
hypercortisolism;~1
ACTH-secreting~1
optional,~1
(1-(2-chloroethyl)-1-nitrosourea,~1
injuries;~3
neurobehavioral~5
(baseline)~1
Quantified~1
information-processing~2
Surviving~1
dexamethasone-treated~1
1.0041).~1
retractor.~1
required;~2
retractors~2
retractor;~1
timed-pregnant~1
craniectomy~1
ultrasonography.~1
sedative~3
stillborn.~1
stillbirth,~1
Newborns~1
nursery,~1
Weight,~2
inhibition;~1
oxygen;~1
transillumination~1
localization;~2
opening;~1
cranium;~1
minimization~2
loss;~2
site;~3
multilayered~1
watertight~1
halo~11
occiput-C1-2~1
aspects,~1
microcystic~2
distracted~1
flavum.~1
Fistulous~1
nongerminomatous~1
germ-cell~2
bleomycin.~2
combined-modality~1
feeder~3
burr~1
therapy-resistant~1
[111In]~1
[111In]granulocyte~1
86.5%~2
87.8%,~1
(73.1%),~1
(66.7%).~1
true-positive~2
true-negative~1
accumulations.~1
ESR,~3
tracheo-bronchial~2
[99mTc]MAA~1
cinescintigraphic~1
ascendence~1
boli~1
time-activity~1
s.d.~1
mm/min.~1
mm/min~1
bronchiectatic~1
mm/min)~1
(SV)~2
LVSV~2
7%).~2
RVEDV~2
RVSV~1
RVESV~1
interdependence.~1
radiocolloid~3
"blind"~3
Agreement~10
0.80,~1
"saturated"~1
[99mTc]sulfur~1
liver-spleen~2
(colloid~1
shift).~1
N,N,N'-trimethyl-N'-[2-Hydroxy-3-methyl-5-iodobenzyl]-1,3-~1
propanediamine~1
(HIPDM)~2
single-pass~2
[125I]HIPDM~5
Iodine-125~3
HIPDM~3
2-min~4
98.6%~1
[125I]HIPDM,~1
chlorpromazine,~2
43.0%~1
51.4%~1
49.8%~1
0.8,~1
(each~1
Cold~2
(77.7%~1
sodium-free~2
amines,~1
imipramine,~1
physico-chemical~1
autoradiograms.~1
charge-coupled~1
digitize~2
2,000~7
pixels~1
pseudo-color~1
monitor.~4
Software~1
linearity~2
solid-state~1
detectors,~1
analyzers.~2
label's~1
chelator~6
mitogen-mediated~1
blastogenesis~1
(tropolone)~1
tropolone,~1
111In)~1
tropolone.~1
(tropolone).~1
tropolone~2
111In's~1
cadmium.~2
radiobiologic~1
metal-to-cell~1
(cadmium).~1
Engelmann's~2
Ribbing~1
Ribbing's~2
Radiographic-scintigraphic~1
Freiberg's~1
infraction~1
photopenic~1
pinhole~2
C18:2(9,12)~1
Glucagon-stimulated~1
(ZD)~1
ad-libitum~1
30.6~4
[14C]cholesterol~6
postdosing~1
ZD~2
(SPE),~1
SPE~6
nonnutritive~2
ingredient.~1
oil,~3
SPE,~2
hydrogenated~1
palm~4
(HPO),~1
HPO.~1
HPO~2
absorbed,~2
digestible~1
nitrogenous~3
[15N]ammonia~1
cockerels~1
7.00~2
7.00-g~1
47.1~1
0.05-0.01).~1
Ammonia~1
N,~4
6-9%~1
[14C]glycine.~2
10.53~1
beans~3
4-d~1
Radioactivity~3
-0.9805,~1
bean-containing~1
underestimated,~1
"real"~1
Creatine~2
pyridoxine-deficient~3
6-7~1
(S-adenosylhomocysteine),~1
libitum-fed~3
guanidoacetate~1
arginine-glycine~1
transamidinase~1
(NAM)~1
NAM-treated~1
B-12.~2
(expt.).~1
Eight-day-old~1
Columbian~1
Hampshire~1
(expt.~2
A-deficient~1
beta-carotene-supplemented~1
arenaceous~2
expt.~2
hemicellulose,~1
lignin~1
citrus~2
pectin,~3
polygalacturonic~2
chick,~1
methoxyl~4
pectin~4
Zn/g~4
diet)~4
Cu/g~4
diet).~1
(CRL)~1
CRL~2
zinc-~1
head-to-CRL~1
selenite~4
sucrose;~1
15MO~1
molybdenum~3
molybdate~1
water;~4
45MO~1
distilled-deionized~1
methylbenzylnitrosamine~1
(MBN)~1
intragastrically~2
MBN~1
12-wk~1
promotion.~1
excised.~4
MBN-induced~1
Se.~2
Mn;~1
Mo.~1
papillomas.~3
selenium.(ABSTRACT~1
48)~4
(deficient,~2
microgram/g,~1
adequate,~5
micrograms/g)~4
micrograms/g),~1
(sucrose~1
Copper-deficient~1
Iron-deficient~1
starch;~1
Selenium-deficient~1
selenium-supplemented~3
selenium-deficient~7
adriamycin-induced~1
Selenium~6
uninephrectomy~1
heminephrectomy~1
(starting~1
Normal,~1
sham-operated,~1
pair-fed,~1
(casein)~1
isoenergetic~2
CRI),~1
CRI~3
8-d-old~1
(Fa/?)~2
preobese~4
(fa/fa~1
"fatty")~1
Zucker~2
(24-35~1
33-34~1
thermoneutral~2
(fa/fa)~2
thermogenic~2
off.~1
casein)~2
(8%~4
Malnutrition~2
[2-3H]Mannose~1
20-d-old~1
[2-3H]mannose~1
(61)~1
(53)~1
assigned,~1
21-d~2
(27)~2
Feed~2
efficiencies~3
expending~1
gain.~7
menhaden~2
n-3~2
(n-3~1
PUFA)~1
coconut~1
PUFA-enriched~1
oil-enriched~1
568~1
symptom,~3
"Catalyst"~1
deepest~2
mm);~2
(1.13~1
1.28~3
eventuated~1
.80~1
Initiation~2
quasi-experimental~2
(where~2
clinic,~4
24-hour,~1
day/week~1
telephone;~1
Resource~1
ordered~11
charts.~1
50/50~1
gamble~1
feedings~9
feedings,~2
cereal.~2
unthickened~3
postprandial),~1
(17.8%~1
22.4%~1
2.4%),~2
(11.7~2
(45.2~1
feedings.~2
emesis,~1
feeding:~1
prone-board~1
30-degree~3
juice,~1
0.006).~3
(LLAM)~1
esophagram,~1
esophagoscopy;~1
GER.~2
LLAM~3
(PILBD)~1
cholestasis:~1
syndromic~3
nonsyndromic~1
PILBD~1
features:~1
facies~1
(95%),~1
embryotoxon~1
butterfly-like~1
(87%),~1
"complete"~1
"partial"~1
syndrome:~1
high-pitched~1
voice,~2
PILBD.~1
phenobarbital.~1
penetrance,~1
methanolysis-high~1
Bilirubin-protein~1
bilirubin-protein~3
diazo~1
Gilbert~1
monoester~2
diester~2
nonspecific,~1
ERCP~8
side-viewing~1
Oddi,~2
(three);~1
choledochocele,~1
pseudocyst,~1
stone,~2
supportive,~1
Dumping~1
(Nissen~1
Inappropriately~1
1,25(OH)2~5
fast.~3
(IH)~1
(urinary~3
mg/kg/24~1
calcium/urinary~1
IH~2
(35.3~1
IH.~1
Absorptive~1
(0.27~1
0.07,~3
(0.95~2
1.14~1
0.0005),~3
calciuria~1
46,XX~7
hermaphrodites~2
propositus~2
hermaphroditism.~1
daughter~4
hermaphroditism;~1
mosaicism~3
testis-determining~1
jacket~8
canister~4
nebulizer~3
flashlight~1
actuated.~1
conventionally,~3
beginners~1
beginning.~1
999~3
impaired,~8
neurobehavioural~2
Sensorineural~1
91.1,~1
mean;~1
Wechsler~2
Preschool~1
Intelligence~2
(WPPSI)~1
101.8.~1
full-scale~1
WPPSI~1
0.7),~2
reordering~1
impairment:~1
underrated~2
Term~1
(TXB2)~2
TXB2/10(6)~1
U/ml),~2
unfractionated~1
TXB2~9
2.87~1
2.81~1
pmol,~1
(1.14~1
proaggregatory~1
Thresholds~2
4300~1
microgram/mL~7
48,000~2
benethamine~1
children),~2
79,000~2
children).~1
benzyl~3
penicillin.~1
(Sawchuck-Zaske~1
method).~2
"peak"~2
mg/kg/d~3
"peak,"~1
microgram/mL.~1
mitigating~1
carmustine~4
O2.~8
air-breathing~4
(12.5,~1
whole-brain~5
lomustine~1
carmustine,~1
Atropine,~3
pirenzepine~7
(PZ)~1
[11-~1
[[2-(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-~1
pyrido[2,3-b][1,4]benzodiazepine-6-one~1
(AF-DX~1
subclassify~1
carbachol-mediated~2
[3H]N-methylscopolamine~3
PZ~8
AF-DX~6
9.1,~1
5.7.~1
constants:~1
2.38~1
3660~1
pancreas:~1
440~3
KH~1
PZ,~1
1.55,~1
subtype,~2
116.(ABSTRACT~1
mediatory~2
[3H]inositol-1-PO4.~1
LiCl~1
[3H]inositol-1-PO4~2
(0-60~1
13-fold~1
Potassium~5
Sgd~2
101/75~1
inositol-1-PO4~1
101/75.~1
0.966)~1
U-62,066E,~1
U-62,066E~2
Kappa~1
water-only~1
ilea~1
naloxazone,~1
(KA)~3
942C,~2
naloxazone~7
incubation-60~1
washout)~1
942C~3
KA~3
pKB~4
8.34~1
6.23~1
0.08.~2
Modeled~1
(experimentally~1
determined)~1
6.0.~1
autoreceptors~4
oxotremorine-induced~1
[3H]ACh~6
8.92.~1
pirenzepine,~2
M1-selective~1
7.14.~1
[oxotremorine,~1
(CARB),~1
McN-A-343~3
pilocarpine]~1
Oxotremorine~1
weak.~2
"low"~3
(M2)~1
vivo)~1
[3H]quinuclidinyl~3
CARB.~1
Fourteen-day~1
physostigmine~6
CARB~2
quinuclidinyl~1
trans-synaptic~1
mephenytoin~2
4-hydroxylation~4
enantiomers~5
S-mephenytoin~1
4-hydroxy~1
N-demethylation~1
enantiomers.~1
(Vmax/Km)~1
4-hydroxymephenytoin~2
150-~1
N-demethylation.~1
Competitive~4
ethotoin,~1
mephobarbital,~1
methsuximide~1
phensuximide,~1
ethosuximide,~1
phenobarbital,~3
primidone.~1
N-alkyl~3
lactam~1
6-membered~1
4-hydroxylase.~1
Warfarin,~1
diazepam,~4
iodochlorohydroxyquin,~1
anticonvulsants.~3
(30-350~1
mephenytoin's~1
biotransformation.~1
(28-35~1
(80-110~1
(135-161~1
month)-old~1
beagles,~3
vasoconstrictors~1
K+,~4
beagles.~3
Equipotent~1
Contractions~3
stimulation-evoked~1
senescence.~4
prejunctional,~1
postjunctional,~1
(MNL)~1
desensitizes~1
changes:~2
CGP~1
12177~1
[4-3-tertiarybutylamino-2-hydroxypropoxy)-benzimidazole-~1
2-on-hydrochloride])~1
(receptor~2
redistribution);~1
down-regulation).~1
MNL~3
redistribution:~1
nadolol.~2
down-regulated~1
age-groups.~2
(4-month-old)~1
(12-month-old)~1
(26-month-old)~1
open-field~1
down-regulation,~1
26-month-old~1
oxotremorine-M~1
(Ki)~1
GTP~1
(D50-GTP)~1
[3H]N-methylscopolamine.~2
Ki~1
D50-GTP~2
oxotremorine~7
BM5~1
[N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide].~1
benzilycholine~1
mustard,~1
pharmacologyically~1
etomidate,~1
hormone-stimulated~2
Desoxycortisol~1
etomidate.~2
17-hydroxy-progesterone~1
(IC50,~4
beta-hydroxylase,~1
(10(-7)-10(-6)~1
inhibited;~1
weaker~3
inhibitor;~1
21-hydroxylase~2
17-hydroxylase.~1
Etomidate,~1
monooxygenase~1
corticosteroidogenesis~1
N-methylformamide~1
(NMF)~1
CBA/CA~1
mice:~1
N-ethylformamide~1
(NEF),~1
dimethylformamide~1
(DMF),~1
formamide~2
N-methylacetamide~1
(NMA).~1
NMF~3
NEF~4
NMF,~1
DMF,~1
NMA,~1
thioesters~1
1H-NMR~2
thioester~4
S-(N-ethylcarbamoyl)-N-acetylcysteine.~1
S-(N-methylcarbamoyl)-N-acetylcysteine.~1
ethylamine;~1
biotransformed~1
methylamine.~1
DMF~2
dimethylamine~1
methylamine~1
NMA.~1
NMA~1
N-(hydroxymethyl)acetamide.~1
N-hydroxymethyl~1
derivative.~3
N-alkylformamides~1
Hydroxylation~1
alpha-carbon~1
formyl~1
moiety.~1
hepatotoxicity,~1
conjugate,~1
mercapturate.~1
aminopyrine~8
demethylation~2
Aminopyrine~2
vivo-in~2
[14C]aminopyrine~1
Ci/kg,~1
(48.9~1
(1.99~1
liters/kg~1
demethylase~1
diabetes-induced~1
aminopyrine,~1
C1-fragments.~1
(5-HT)~7
5-HT2-receptor~2
Ca++-channel~1
5-HT-concentration-effect~2
verapamil's~2
justifiably~1
displacements.~3
property,~1
concentration-ratios~3
Quantification~1
5.73.~1
indicating,~1
presumably,~2
Ca++-antagonism~1
antagonistic~1
decentralized~4
deafferentation~11
waned~2
deafferentation).~1
pergolide~3
(30.0~1
undertaking~3
(sham-operated)~1
denervated,~1
matched,~2
saline-pretreated~1
(intact~1
innervation),~1
deafferentation.~2
pergolide,~1
dogs.(ABSTRACT~1
[3H]acetylcholine~1
([3H]ACh)~1
prelabeling~1
[3H]choline.~1
[3H]ACh.~1
Muscimol~1
[3H]ACh,~1
(+/-)-baclofen~1
(-)-baclofen~1
SK&F~3
89976A~1
[N-(4,4-diphenyl-3-butenyl)-nipecotic~1
acid],~1
100330A~1
[N-(4,4-diphenyl-3-butenyl)-guvacine]~1
100561~1
[N-(4,4-diphenyl-3-butenyl)-homo-beta-proline],~1
hemicholinium-3~4
beta-alanine.~1
Nipecotic~1
substrate-inhibitor~1
transporter,~1
[14C]Taurocholate~1
mumol/min.~1
mechanically,~1
flow-independent.~1
antagonised~1
propanolol.~1
vectorial~2
tetraethylammonium~4
[14C]TEA~1
(pHi~1
pHo~5
7.4)~1
TEA~12
overshoot~3
Na+/H+~4
K+/H+~1
nigericin.~1
electroneutral,~1
temperature-dependent~1
[Km,~1
0.328~1
(CL~2
.05:~2
0.250-0.425)~1
mM;~3
Vmax,~2
2.13~1
1.98-2.32)~1
nmole/mg~1
sec].~1
mechanism:~1
mepiperphenidol~1
cis-inhibited~1
trans-stimulated~1
Quinine,~1
(57%~1
trans-stimulate.~1
cis-inhibit~1
trans-stimulate~1
H+/TEA~1
(Cd-MT)-induced~1
ZnSO4/kg~1
b.wt.)~1
Cd-MT~6
Cd-MT/kg~1
b.wt.~1
i.p.).~2
(ALP)~1
gamma-glutamyl-transpeptidase~1
(GGT),~1
(NAG),~1
ALP~2
NAG~2
Cd-MT,~1
injection.(ABSTRACT~2
myoelectrical~1
i.c.v.~8
duodeno-jejunum~1
"minute~1
rhythm."~1
tolazoline~1
pattern.(ABSTRACT~1
endings~7
3,4-dihydroxyphenylethyleneglycol~1
(DOPEG)~1
(an~13
turnover)~1
autoreceptors.~1
bodies)~1
postsynaptic~5
somatodendritic~1
autoreceptor-mediated~1
ng)~2
hydrate-anesthetized~1
i.p.)~9
DOPEG~3
terminals)~2
postsynaptically)~1
ibotenate-lesioned~1
septal-~1
hypothalamic-free~1
attested~1
depopulation~1
hypothalamic-~1
septal-free~1
Altogether,~3
(0.0625-2.0~1
(0.0625~1
mepivacaine,~1
slope.~1
piperoxone,~1
i.p.),~2
Reserpine~1
opioid-induced~3
isoflurane-anesthetized~1
fentanyl,~4
analgesic/anesthetic,~1
CO2,~3
anticholinesterase,~2
physostigmine,~1
fentanyl-induced~1
hydrobromide~1
opioid-cholinergic~1
microinjection~4
ventrolateral~5
medulla.~4
obtunded~1
chemosensor~1
Manipulation~1
5-fold.~1
Mature~4
(endogenous~1
estrogen)~1
estrogen-treated~2
pre-estrogen~1
ovariectomy.~1
subtype-selective~1
adrenoceptors,~1
events.(ABSTRACT~1
[3H]pirenzepine~1
([3H])PZ)~1
(-)-[3H]quinuclidinyl~1
((-)-[3H]QNB)~1
radioligands,~1
[3H]PZ~2
(-)-[3H]QNB~3
pM.~1
nucleotide,~2
guanyl-5'-yl~1
imidodiphosphate,~1
bronchoconstriction,~3
bronchodilators.~3
fixed-consecutive-number~1
equated~2
Tolerance~1
behaving~2
doses;~2
Establishing~2
patas~2
repeated-acquisition~1
left-~3
right-key~1
(learning).~1
(performance).~1
agonist-antagonists~1
dezocine,~1
GPA~2
1657~2
nalbuphine~5
rate-decreasing~2
dezocine.~1
dezocine~2
within-session~1
buprenorphine~4
(0.01-3.2~1
agonist-antagonist,~1
diethylaminoethoxyhexestrol~1
(DH)~2
di[1-14C]oleoylphosphatidylcholine.~1
experiments)~2
Hydrolysis~3
enzyme-substrate-drug~1
enzyme-substrate~1
drug-enzyme~1
drug-substrate~1
angularis~1
oculi~2
tone.~9
tributaries,~1
betaxolol,~2
118,551,~1
thermoregulation.~1
anxiolytic~2
two-key~1
isolating~2
anticonflict~2
pecking~1
30th~3
injection-appropriate~1
(1.0-3.0~1
MJ~1
13805~1
5-hydroxytryptamine-1A~2
8-hydroxy-2-(di-n-propylamino)tetralin~1
(8-OH-DPAT)~1
(0.3-1.0~1
buspirone-appropriate~2
(0.03-1.0~2
(0.03-1.7~1
apomorphine~1
clozapine~1
(0.1-3.0~2
5-hydroxytryptamine-1B~1
1-[3-chlorophenyl]piperazine~1
(0.3-10.0~1
anxiolytics.~1
N-[4-(2-bromoethylmethylamino)-2-butynyl]-2-pyrrolidone~1
(BR~2
401)~1
N-[4-(2-chloroethylmethylamino)-2-butynl]-2-pyrrolidone~1
123)~1
oxotremorine.~1
BR~9
(LD50,~2
kg-1).~3
401,~2
75-~1
100-fold.~1
(tremor~1
analgesia)~1
(salivation)~1
aziridinium~2
401A),~1
cyclization~1
salivation~3
cyclizes~1
cyclize~1
cyclization,~2
2-haloethylamines~1
oxotremorine.(ABSTRACT~1
Clara~1
resynthesize~2
sulfur-containing~1
cysteine,~2
Cysteine~1
14-fold~2
resynthesis~1
fastest~4
cystathionine~1
oral-caudal~1
strips,~1
strips.~2
(0.1-1.0~1
30-300~1
2-26~1
Krebs'~2
atropine-resistant~2
Contraction~3
supplies,~1
Levomethorphan~2
emptying;~1
dextromethorphan~2
(10,~2
dextromethorphan.~1
2-deoxy-D-glucose,~1
stimulant;~1
hormone;~1
equiactive~1
food-induced~1
stimulants.~1
interdependent~1
prototypical~1
N1-methylnicotinamide~1
(NMN),~1
Sperber~1
chickens.~1
NMN~2
potency:~1
quinine,~1
NMN.~2
(Tm).~1
(quinine,~1
NMN),~1
quinine.~1
TEA,~1
Desensitization~2
postdesensitization~1
derived.~2
phenoxybenzamine.~2
calculated,~2
overestimations.~1
anesthetic,~2
[3H]bupivacaine~5
[14C]5-hydroxytryptamine~1
[14C]5-HT,~1
green.~1
amine;~1
[14C]5-HT.~1
(100-250~1
[14C]5-HT~1
uptake)~2
(8-SPT)~1
peripheral)~1
8-SPT~5
2-chloroadenosine,~2
R-phenylisopropyladenosine~2
N-ethylcarboxamidoadenosine.~2
(EC50~2
1.74~2
(predominating~2
heart)~1
vessels)~1
peripheral.(ABSTRACT~1
angiotensins~3
enhanced.~1
III-induced~3
Yohimbine~7
II-induced~2
Rauwolscine~1
angiotensin.~1
(1-128~1
repolarization.~1
(dV/dtmax).~1
use-dependent~2
monoexponential~1
bath,~1
dV/dtmax~2
(first)~1
(second)~1
hyperpolarizing~1
slow-response~1
[K]o~1
la~1
Bath~1
methylmercury~1
(MeHg)~1
EPPS,~1
MEPP~5
(MEPPf),~1
MeHg~2
Ca++-specific~1
Sr++~6
Ba++~3
Ca++,~3
MeHg-induced~1
MEPPf~4
(asynchronous~1
MeHg.~3
hemidiaphragm~4
EPPs~1
EPP~2
Ca++.~2
MeHg.(ABSTRACT~1
i.m.;~1
endothelium)~1
extraneuronal~2
blockade),~1
14,304~3
agonist).~1
(under~1
conditions)~1
phenylephrine;~1
vessel.(ABSTRACT~1
A-4,~1
4-methylpiperidine~2
hemicholinium-3,~1
(i.p.)~1
A-4~4
Reversal~1
A-4-induced~1
eserine~1
A-5,~1
A-5~1
menadiol~1
(K3),~1
dicumarol,~2
K3,~2
cysteine.~1
Isobolographic~1
K3-dicumarol~4
K3~3
KCN-resistant~2
dicumarol~3
dicumarol-mediated~1
K3-semiquinone-free~1
Dicumarol~1
K3.~1
contributed.~1
45Ca++~3
glutathione.~2
methiodide~3
muscimol,~1
tonically~2
muscimol~2
counters~2
caudal)~1
N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline~1
(EEDQ),~1
autoreceptor~4
([3H]NE)~1
EEDQ~3
[3H]NE~2
UK-14304.~1
double-reciprocal~1
1.41~2
KA.~1
repopulation~3
reserve;~2
UK-14304~1
(TTx)~1
TTx.~1
Na+-dependent~1
desensitization,~2
TTx~1
LTD4,~2
(5-HT).~2
brom-D-lysergic~3
diethylamide,~1
diethylamide~2
serotonergic~7
benextramine.~1
reserpine-pretreated~1
bioluminescence~1
(LT)~3
(0.02-0.5~1
(NE;~1
0.06-0.6~1
(AVP;~1
microU)~1
LT~4
FPL-55,712,~1
NE-induced~2
phentolamine.~2
vasodilation,~4
LTD4-~1
(AcS)~1
AcS~7
micrograms/kg/min~4
5.99~2
2.99~1
components:~2
puff~5
microcomputer-based~1
experiment)~1
manipulated~2
Biological~1
8-puff~1
(inhalation~1
boost~3
(post-~1
presession~1
9-fold~3
(puff~1
capacity),~1
breathholding.~1
breathholds.~1
(Experiment~4
(PB)~3
N-acetyl-para-aminophenol~1
(APAP)~1
P-450,~1
APAP-reactive~1
APAP~11
post-APAP~2
oxalacetic~1
mercapturate,~2
Covalent~1
[3H]APAP~1
pretreatment.~3
uridine~2
glucuronic~1
induction;~1
Theophylline,~1
bronchodilating~3
life-threatening,~2
neurotoxic~4
theophylline-induced~3
uranyl~2
Sham-operated~1
2.06~1
(unbound)~2
neurotoxicity.~3
nitrate-induced~1
ureter-ligated~1
azotemic~1
pentobarbital,~1
L7.~1
5-week~1
(denervated)~1
(innervated)~1
tyramine.~4
(16.7-fold~1
curve)~1
(3.8-fold~1
curve).~1
(5-fold~1
curve),~1
16-day~1
birth;~2
litter~2
18th~2
shortfalls~1
(RNA,~1
nicotine-exposed~1
maturation)~1
regionally,~1
(cerebellum)~1
early-developing~1
(midbrain~1
brainstem).~1
nicotine)~1
(30-300~1
(nitrendipine,~1
verapamil)~1
(Tx)B2~1
factor-4~2
collagen-epinephrine~1
aspirin-treated~1
Aspirin~1
Tx~3
beta-diethylaminoethyl-diphenylpropylacetate~1
(SKF~2
525A),~1
monooxygenases,~1
oxprenolol~1
SKF~3
525A~3
tris(2-butoxyethyl)phosphate,~1
displacer~1
fenoprofen~3
(S.E.M.)~3
(0.07)~1
R-fenoprofen~3
S-fenoprofen~5
50.3~1
(4.5)~1
ml/kg,~3
fenoprofen.~1
min/ml/kg,~1
min/ml/kg.~1
S-enantiomer~2
2.1-fold.~1
glucuronides~3
1.6-fold~1
R-~5
2.3-fold~1
S-fenoprofen.~1
2.1-fold~1
(0.01)~1
R-ketoprofen~2
S-enantiomer.~2
S-ketoprofen~3
(7.4)~1
(76)~1
R-enantiomer~1
ml/kg/hr~4
enantioselectivity~1
inversion,~2
glucuronidation,~1
process(es).~1
R-dose~1
290%,~1
renally~1
183%~1
spironolactone,~1
antimineralocorticoid~1
alpha,11~1
alpha-epoxy-derivatives~1
(spironolactone,~1
prorenone~1
mexrenone)~1
spironolactone~3
epoxy-group~1
500-fold.~1
epoxy-derivatives~1
progestagenic~1
epoxymexrenone~1
epoxyprorenone,~1
epoxyspironolactone~1
alpha-position~1
aldosterone-antagonists~1
OPC-8212,~2
3-isobutyl-1-methylxanthine~1
(IBMX),~1
OPC-8212~5
IBMX~3
current.~6
intra-~6
Cs+,~1
Co++~1
asialoorosomucoid~1
(ASOR)~1
N-methyldeptropine,~2
ASOR.~2
560%~1
380%~1
coendocytosis~1
Isolation~5
hepatocytes;~1
ASOR~2
drug-protein-receptor~1
asialoglycoprotein~1
(5-HT2)~1
cyproheptadine,~1
mianserin,~1
interrupt~2
(CFRs)~1
CFRs,~1
abolition.~1
CFRs~3
Mianserin~2
potent;~1
5-HT-induced~4
2.21,~1
7.38~1
ADP-induced~4
mianserin~1
3.18~1
RX~1
781094,~1
epinephrine-stimulated~1
6.10,~1
5-HT2~2
(5-HT2~1
notwithstanding)~1
importantly~1
surrounds~2
(ACh).~1
complexities,~1
pressure-ejected~1
urethane~1
interneurons~2
Locally~2
single-unit~1
Pressure-ejected~1
(50/51)~1
(22/22).~1
curare-sensitive~1
(neuromuscular~1
type)~4
nicotine,~2
hexamethonium-sensitive~1
(ganglionic~1
scopolamine.~1
interneurons,~2
curare~2
(Purkinje~2
(interneurons).~1
(488~1
nm)~6
lesion's~1
laser's~2
neosalpingostomy,~1
fimbrioplasty,~1
salpingo-oophorolysis,~1
adhesiolysis~1
conceived.~1
Adhesion~2
ibuprofen,~2
blindly.~1
presterilization~3
contentment~4
sterilized.~3
1,716~1
clinics.~4
487~2
replied,~1
physician;~2
480~3
regretted~2
backgrounds~4
Nipple~2
Adnexal~1
556~1
Dermoid~1
unproven,~1
Ethical~2
couple's~3
Responsible~1
striving~1
desperate~1
weighs~1
pros~1
cons.~1
truth~1
telling~1
conflicts~3
interest.~2
inevitable~4
raped.~1
coitus~1
percreta.~1
(DPL)~1
(28.3%)~1
DPL~5
(71.7%)~2
DPL,~1
(96.5%)~1
(3.4%~1
(0.9%~1
11.6%~1
DPL.~1
hetastarch,~1
hetastarch~4
hemodilutional~1
prehemorrhagic~1
Exsanguination~1
pale,~2
mottled,~1
respirations~2
noncranial~2
exsanguination~1
expertise.~2
exsanguination,~1
re-establishing~1
repairing~1
swine.~2
7.5%,~1
5.0%,~2
(b.w.~1
25-30~2
Hemodynamics,~1
alcohol-pretreated~2
434~1
803~2
clients.~1
13.4%~2
17.7%~2
3.474;~1
14.0%~2
supervened~1
34.6%~1
admonition~1
third.~4
quadricepsplasty~2
comminuted.~1
sequestra~2
grafting;~1
heal.~2
cease~1
(0-14~1
seatbelted~2
protective,~1
flying~1
glass,~1
etc.~3
seatbelt,~2
optional~1
oversensitivity~1
auto~1
fevers.~1
(100%)~4
hemialloplastic~1
long-stem~1
Non-ophthalmologists~1
detect,~2
diagnose,~1
lids~4
Uniformed~1
Sciences.~1
perilunar~3
Baptist~1
"crowded~1
carpal"~1
illustrations~2
carpectomy,~1
unconscious~2
cold.~1
collapse,~2
below,~1
eclampsia,~1
manubriosternal~1
clavicle~4
subluxations.~1
subcapularis~1
clavicle.~2
discoveries~1
neuroscience.~1
addictions.~1
imagine~1
addiction,~1
most?~1
chemicals?~1
production?~1
Immunizations?~1
therapies?~1
Who~1
knows?~1
Today's~2
heterogeneity.~2
dependence,~2
psychiatric/psychological~1
conceptualization~1
craving,~1
methadone-maintained~1
settings:~1
self-reports~3
methadone~13
(clinic~1
sessions)~1
inter-relationships~1
among,~1
abusers~4
Two-hundred~2
addicts~11
leaving,~2
reentering~3
abstinence~10
adjustment,~3
precipitants~1
Traumatized~1
self-medicating~1
chemical-dependency~2
treatment-completion~1
(treatment~1
efficacy)~1
trauma-oriented~1
dependency.~1
combat.~1
combat-level~1
Levo-alpha-acetylmethadol~1
(LAAM)~1
orphan~1
959~2
LAAM~5
methadone,~1
opioid-addicted~1
2,394~1
on-site~1
confidential~2
program's~2
postulates~1
functions:~1
agency~2
misunderstood~1
politics.~1
Lastly~1
manager.~1
wake~1
governmental~2
departure~2
Britain.~2
felt.~1
initiatives~1
rib.~2
hydrothorax.~1
supracostal~1
endourological~2
tetradecyl~7
Polyinosinic-polycytidylic~1
Anorexia~1
lethargic,~1
(pleural/pulmonary~1
progressed.~4
Metastases~2
(liver,~1
fossa)~1
microhematuria~2
Cystography~1
Presently,~2
cystography,~1
(29),~1
(51)~1
(21).~1
developing,~1
tumor)~5
protocol)~2
nonvasectomized~1
ml.),~2
vasectomized~2
(144~2
vasovasostomy~4
gm.~9
fulguration~1
undilated~1
Vesical~2
(0.87~1
Iliac~1
transrectally~1
nephroureteral~1
5F~1
kidney-to-bladder~1
Edema~2
wrap~5
reflux/dysfunction~2
Reflux~2
videourodynamic~1
urinate.~1
irritative~2
urgency)~1
equals~11
enucleative~1
gm.,~3
(469~1
subgroups:~1
(526~1
10(-9)).~1
541~1
10(-7))~1
void.~1
micturition,~1
floor/external~1
electromyography.~2
trochlear-shaped~1
sponge.~1
electromyograms.~1
secures~1
compressibility~1
Ischial~1
ischiectomy~9
bulbous~5
urodynamically~2
ischial~4
tuberosities~1
reclining~1
nonischiectomy~1
pseudodiverticulum,~1
Bourneville's~1
tuberous~7
exstrophy~2
function)~1
1--patients~1
exstrophied~1
2--children~1
cc,~1
0.006),~2
0.18).~1
undescended~4
intersex~4
cytogenetic,~1
pseudohermaphroditism~1
gonadal/genetic~1
dysgenesis,~1
dysgenetic~1
pseudohermaphroditism,~1
46XX~1
hermaphroditism~1
Klinefelter's~1
ureteroscope.~2
ureteropyeloscope~3
calix.~1
9F~2
stone.~1
localizations.~3
nodular,~2
cortical.~1
ureteroileal~4
nephroureteroscopy~1
lumina.~1
frightened,~1
unprepared~2
friability~1
urethroplasty~1
technically,~1
re-established~2
outlet,~1
Goodwin~1
urethrotomy~2
transpubic~2
urethroplasty.~1
Incontinence~2
tubae~1
profluens.~1
Pemphigus~2
bullous~7
cohesion.~1
vegetans,~2
pemphigus,~2
vegetating~1
intertriginous~1
pemphigus~8
Intracavernous~1
priapism~1
intra-abdominally~1
eroded~2
seminoma~3
Paratesticular~1
Orchiectomy~1
2,8-Dihydroxyadeninuria~1
urolithiasis~2
Excretion~3
hydroxylated~1
phosphoribosyltransferase.~1
urolithiasis.~2
2,8-dihydroxyadenine~1
penile-brachial~1
(PBI)~1
thermography.~1
thermography~2
vasculogenic~1
Length~2
ribosomal~3
"spacer"~1
chromosomally~1
UM-UC-2~1
(modal~3
chromosomes)~3
rDNA~2
spacer~1
(7.6,~2
karyotypes,~1
UM-UC-3~1
UM-UC-4~1
latter),~1
intrachromosomal~1
Uncharacterized~1
copy~3
(HESW)~1
HESW~3
R3327AT-3~1
cristae~1
HESW.~1
fibroadipose~1
HESW-induced~1
histomorphological~1
gamma-carboxyglutamic~1
(Gla)~1
K-requiring~1
calcium-containing~2
Gla~6
EDTA-soluble,~1
non-dialyzable~1
urate,~2
Bladder~5
(struvite)~1
non-calcium-containing~1
bridge.~1
adriamycin-monoclonal~2
(LNCaP),~1
adriamycin-normal~1
adriamycin.~1
xenografted~2
anti-PAP~1
reagent~4
immunochemotherapy~1
Intravesical~3
(BCG),~1
parvum~1
(CP),~1
hemocyanin~2
(KLH),~1
Allium~1
sativum~1
(AS)~5
intravesically~1
(MBT-2).~1
C3H/He~1
MBT-2~1
transurethrally~1
electrocauterized.~1
Immunotherapy~1
CFU),~1
micrograms),~2
KLH~1
weighed,~1
worthwhile.~3
postservice~2
9324~1
Army~4
8989~1
Vietnam-era~2
Korea,~1
veterans.~3
1.45;~1
1.96)~1
homicide,~2
poisonings.~1
veterans,~1
Korean~1
War.~1
(OC)~2
433~1
registries.~2
3191~1
OCs~4
OC~2
OCs.~1
conferred~5
Orphan~1
passed.~1
rider~1
foundation~2
compensating~2
Radioepidemiological~1
Tables.~1
computation~1
"probability~1
causation"~1
(otherwise~1
"assigned~1
share")~1
computations~2
Affairs~1
Inspector~1
General's~1
financially~3
penalizing~1
Medicare~2
boards'~2
licensure~3
disciplinary~1
boards~1
revocations~1
suspensions,~2
consumers~3
organizations,~1
rectify~1
license~1
renewal~2
fund~2
good-faith~1
referrals.~2
Statistics,~2
Hyattsville,~1
Md.~1
Abell-Kendall~1
Age-adjusted~3
(0.16~1
mmol/L),~8
surveys.~1
(5.61~1
(5.46~1
(5.77~1
(5.56~1
(361,662)~1
Intervention~3
Trial.~1
inference~2
(12,866~1
22.7~1
foregoing~1
inference.~1
1968,~1
Honolulu~1
6908~1
80th~1
20th~2
(199~2
[11.0~1
mmol/L])~4
1.8).~1
glucosuria~2
4.5).~1
hyperglycemic~3
imparts~1
employs~4
computer-linked~1
same-sized~1
20-minute~3
three-hour~4
(term,~1
ewe~1
0.5-,~1
1.0-,~1
2.0-mg/kg~1
52%,~3
96%,~3
168%,~1
fetus;~1
elder~5
perpetrator~1
Broad~2
definitions.~1
ties,~1
violence,~3
abuser,~1
(TSS)~1
influenzalike~2
onsets~1
Jan~2
Feb~2
23,~1
exotoxin~1
production;~1
toxin-1,~1
enterotoxin~1
Control-confirmed~1
TSS.~1
CDC~1
TSS,~1
TSS~2
nonsuppurative~1
(ID~1
HDCV)~1
licensed~5
HDCV~3
ID,~2
(IM),~2
1.0-mL~1
0.1-mL~1
ID~14
immunization.~8
Uniformly~1
postbooster~1
boosters~1
vaccination.~2
inadvisable~1
places.~1
20/100~4
vision-dependent~1
modest.~1
Timed~1
nonhospitalized~2
85.8~2
68.3%~1
cured)~1
(16.4%)~1
(34.5%)~1
(63.6%)~1
short-course~1
two-week~2
(FPPs).~1
FPPs~2
FPP,~1
leaders,~1
administrative~3
responsibility,~2
Topics~1
FPP~1
Questions~2
yes-no~2
(MgSO4)~1
mmol/min~1
MgSO4~5
Soon~2
began,~3
117%~1
118%~1
piping~1
attack.~3
theoretical.~1
(HBsAg).~1
Documentation~4
pernicious~7
(20.7%)~1
(22.3%)~1
subsequently.~2
identifiable,~1
Reducing~2
(CCU)~1
CCU~14
full.~3
4479~1
2931~1
.0005),~1
drop.~3
725~2
proving~3
823~1
growing,~1
inviting~1
moderate.~1
donation.~4
hominis,~3
1204~2
Navajo~1
enrolling~1
endometritis,~1
18.3).~1
(IgM~1
1:32~1
seroconversion)~1
(19%~2
[3/16])~1
(4.5%~1
[6/133];~1
4.2),~1
classifiable~1
infection).~1
megestrol~3
(480~1
mg/d).~1
reversing~1
1672~1
6615~1
frozen.~1
1938~1
125,105~1
(0.80),~1
reinfused~4
934~1
8.4%~7
community's~1
available--his~1
computer's~1
marketing~4
computers~5
microcomputers,~1
postresection~2
13-week~2
7-week~1
Stratification~1
general;~1
Olfactory~3
Scan,~1
cracks~1
Herein,~2
alternative,~3
Situs~1
8,000.~1
totalis~1
Uneventful~1
70-year-old~2
MFH~3
lymphadenectomy.~1
lymphadenectomy,~1
four-field~1
(delayed~1
manipulation).~1
seromas,~1
edemas.~1
leiomyosarcomas~3
adrenals,~2
right-lower~1
flank,~1
right-upper-quadrant~1
cavography.~1
(Metastases~1
obsolete.~2
primarily,~1
"primary"~1
description,~1
"junctional~1
activity"~1
undetected,~1
(67~3
(surgery~3
only),~1
chemotherapy),~1
chemotherapy).~2
43%:~1
32%:~1
briefly.~3
(HPD)~2
oxygen-mediated~1
biomolecules.~1
HPD~7
refining~3
Intraarterial~1
HPD,~1
C1300~1
reject~1
lymphocyte-tumor~1
PHA~4
lymphoblastogenesis.~1
haematoxylin-eosin~1
vacuoles,~3
cilia,~1
subnuclear~2
(Merkle~1
exophytic~2
Merkle~2
alluding~1
victim.~2
fellow,~1
oncologist,~1
merge~1
art.~1
oncologists~1
hints~1
nonacademic~1
Try~1
first;~3
fails,~2
other--the~1
dogma,~1
formed:~1
versa,~1
say~3
Regarding~4
points);~1
"home"~1
"elsewhere"~1
(55%).~3
Nt.~1
(79.6%),~2
(49.4%),~1
(30.1%),~1
blastoma~2
rarest~2
one-fourth~1
morphogenesis,~1
"cystic~1
lesions,"~1
teratogenic-oncogenic~1
2-1/2-year-old~1
fornix,~2
corpus.~2
columnar~9
mucus-producing~2
cuboidal,~2
singled~1
pseudostratified~1
metaplastic~5
intimately~2
perfused,~1
piglet~1
protection:~1
cooling;~1
mOsm)~1
cardioplegia;~3
citrate-phosphate-dextrose~1
(calcium~3
tromethamine;~1
work)~1
82.9%~1
86.7%~3
35.7%~1
43.7%~1
76.1%~1
77.7%~2
67.4%~1
110.7%~1
100.6%~1
Yale-New~2
Haven~2
anticoagulation-related~1
(328~1
482~2
Carpentier-Edwards,~1
Hancock,~1
Ionescu-Shiley,~1
other),~1
2,571~1
2,935~1
valve-years.~2
479~1
(330~1
Starr-Edwards,~1
Medical,~1
Bjork-Shiley,~1
others),~1
2,247~1
2,392~1
Venoarterial~1
cannulating~2
salvaging~3
hernia.~2
esophagogastrectomy~1
esophagogastrectomies~1
fibromyomatoses~1
thoracotomy;~2
hand-sewn~3
totaled~2
38.9%~1
5.44%~1
35.57%~1
6.06%~1
deviation).~2
41.43~1
4.62~1
dilations.~1
double-lumen~5
self-retaining~1
(myograft)~1
neuroelectrically~1
penetrations~1
myograft~2
seroma~3
myografts~2
myoventriculoplasties~1
neoventricle~2
Myoventriculoplasty~1
Neoventricles~1
Transpulmonary~2
generators~7
Extrapericardial~1
slush~4
18.7%,~1
14.3%,~1
differences).~1
observed:~1
Phrenic~3
C;~4
(649~1
259)~1
(MacCarthy)~1
(Plegisol,~1
Abbott~3
multidose~2
Solution~3
respects.~1
defibrillation),~1
(74.3%~1
6.9%~1
18.7%~2
8.9%,~1
98.0%~1
63.0%~2
9.0%,~1
(19.7~1
IU/15~2
min/gm~2
oxygen/air/high-dose~1
afterward.~5
Chemotaxis,~1
unaffected,~1
opsonizing~1
kinking~3
Lecompte~2
kinked~1
("neo-coarctation")~1
relocation~1
foreshortened~3
"neo-coarctation"~1
bioprostheses~5
Xenomedica,~1
Carpentier-Edwards~20
Hancock~5
T6-treated)~1
Mitroflow~1
profile)~1
bioprostheses),~1
(8/15~1
(1/31~1
3%).~3
Xenomedica~3
T6-treated,~1
(mitral~1
27),~2
9.8%)~1
79.1%~1
71.8%,~1
85.2%,~1
3.8%,~1
3.4%,~2
18.8~1
15.4~3
prosthesis;~1
suboptimal,~1
photoresections,~1
Gruentzig~1
help.~3
Transtelephonic~1
(TTM)~1
TTM~5
526~2
near-syncope~1
121),~1
light-headedness~1
248),~1
281),~1
321).~1
episode;~2
46).~1
non-life-threatening~1
(38%),~1
(senile)~2
(presumably~2
rheumatic)~1
322~1
synchrony~3
pacemaker,~1
pacemaker-mediated~2
Gold~2
auranofin,~2
auranofin~2
gold-induced~2
eosinophilia.~1
cromolyn~2
attempts.~2
limbs;~1
dismissed~4
PTA,~1
operation)~1
monitored,~4
style.~1
chapter.~1
elsewhere,~2
outweigh~1
declining.~2
Ectopic~1
Schmidt~1
1805.~1
presence.~1
odynophagia~2
unremarkable~4
esophagram~1
Debate~1
embryology,~1
esophagoscopy~6
Inflamed~1
First~5
branchial~3
mesodermal~6
cleft.~1
pinna~4
concha.~1
mesotympanum.~1
concha~1
openings~6
Millions~1
aids.~3
Stimulator~1
(TBS)~1
malfunction,~1
open-cavity~1
mastoid~3
Implantable~2
Hearing~3
Device~1
(IHD).~1
stimulates,~1
fidelity,~1
disclosure~1
glossopharyngeal~3
meningitis,~5
paretic~2
cricopharyngeal~4
voice.~1
full-therapy~2
decision-making~4
adenocystic~1
acinic~3
66%.~1
stylomastoid~1
foramen,~1
retrosigmoid~3
(IAC)~2
3-cm~2
IAC~3
labyrinth~2
vertigo~6
MFVN~1
RVN.~1
vertigo.~2
laryngocele~2
Europe,~3
America.~5
saccule~5
ruler.~1
Saccules~1
Larynges~1
"cancer"~1
"normal",~1
uninvaded~1
larynges,~2
17.8%.~1
0.04),~2
saccules~2
larynges~1
Munchausen~1
factitious~4
well-rehearsed~1
ear-nose-throat-maxillofacial~1
proxy.~1
subentity~1
fabricate~1
malingering,~1
rebreathe~1
slow-developing~1
Firstly,~1
(CAP)~1
intensities.~1
GP.~2
24.66~1
14.92~1
CAP~1
elicited,~1
click~5
SPL.~1
"critical~1
level"~1
starts~3
deteriorate~4
thermostable~1
angiofibroma.~2
DHT,~1
text.~1
Ear~1
Infirmary~2
Otology~1
(CWD)~2
(CWU)~1
precholesteatoma,~1
infection),~2
(CWU).~1
Neurogenic~1
intraparotid~1
schwannomas.~1
Schwannomas~1
neurofibromas~1
electroneurography.~1
adventitiously~2
sensorineurally~1
deaf~5
speakers.~2
cristae,~3
align~1
axis;~1
predominate.~1
semicircular~5
utricle~1
anterosuperior~2
Schwann's~1
ensheathing~1
primate's~1
anuran.~1
phylogenetic~1
nerve's~1
cervical/occipital~1
maxillofacial~2
prosthodontist.~1
(LELI)~1
HeNe~1
reaffirmed~2
J--associated~1
4-10~2
J/cm2~9
transcutaneously--was~1
Neodymium-YAG~1
1,064~1
nm,~3
nanosecond~3
(TEMoo,~2
ns)~1
9-11~1
ps,~1
50-70~1
ns).~1
energies~3
bracketing~1
tabulated.~2
(hereafter~1
threshold)~1
eg--66~1
(2,200~1
GW/cm2)~2
picosecond~2
pseudophakics~2
aphakics;~1
trains.~1
nonuniformity,~1
haze,~1
haze~1
approximation~5
dosimetry~2
photodynamic~2
photosensitizer,~1
J/cm3~1
irradiance~1
tabular~1
Laryngeal~3
equine~6
customarily~2
laryngotomy~1
recumbency.~1
arytenoidectomy.~1
Arytenoidectomy~1
chondritis~1
(CBA)~1
perihilar,~1
solid,~2
mass--the~1
hyperinflated.~1
obviates~3
terminating,~1
mucus-filled~1
bronchocele~1
tree,~5
Distally~1
noncollapsible~1
hyperinflation~3
aspergillosis,~3
Animal-to-human~1
salmonella~4
4.9-fold~2
newport~1
isolations~3
Californians~1
antimicrobial-resistance~1
resistance)~1
plasmid.~1
Interviews~2
0.052).~1
abattoirs~2
dairies~1
slaughter~2
culture-positive~1
processed,~1
cows.~2
0.60,~1
chloramphenicol-resistant~1
farms~1
dairies.~1
antimicrobial-resistant~1
farms.~2
Gaucher's~10
neuronopathic~5
form),~1
glucocerebrosidase~5
(T----C)~1
X.~5
444~3
NciI~3
endonuclease.~1
restriction-fragment-length~2
(RFLP).~1
mutation.~6
(444leucine----proline)~1
RFLP,~1
heparin-associated~2
heparin-dependent~1
reexposure~1
preadsorption~1
cell-bound~1
glycol.~1
Weekly~1
deoxyadenosine~1
S-adenosylhomocysteine~1
deoxyadenosine,~1
standpoints~1
convenience,~4
red-cell~4
Aluminum-associated~2
uremia~7
deferoxamine,~4
coronary-artery~3
0.3.~3
encroachment~1
Epidemiology~2
arts.~1
"low-technology"~1
science,~1
nonspecialists.~1
arcane~1
cultivate:~1
analogic~1
deductive~1
reasoning,~1
constraints,~1
1021~1
5606~1
enrollees.~1
hypnotics-anxiolytics~2
1.8;~1
2.4),~1
1.9;~1
2.8),~1
antipsychotics~1
2.6).~1
noncurrent~1
proved,~1
Encephalitis~1
polyneuritis~1
brain-derived,~1
Semple~1
Assays~2
systems).~1
cerebroside~3
GD1b~1
GT1b.~1
encephalitogen~1
augmentative~1
defensive~1
acid-stimulated~1
bulb~3
(185~1
bulb,~2
(263~1
642~1
Pacific~2
(Czechoslovakia)~1
(United~1
States)~1
childbirth~2
obstetrical~2
Norway,~1
converging.~1
intermountain~1
Lake~2
Utah.~1
Carditis,~1
outbreak,~2
carditis~2
middle-class~2
incomes~1
schoolchildren~1
(chosen~1
random)~1
518~4
("secretory"~1
media),~1
decongestant-antihistamine~2
middle-ear~1
decongestant-antihistamine,~1
69.8~1
amoxicillin-treated~2
sucrase-isomaltase~3
monosaccharides,~1
sucrase-isomaltase,~1
Pulse-chase~2
immunoprecipitation,~1
sulfate-polyacrylamide-gel~1
fluorography~4
205,000.~1
225,000~1
endo-beta-N-acetylglucosaminidase~1
peptide-N4-(N-acetyl-beta-glucosaminyl)-asparagine~1
amidase~2
sucrase-isomaltase.~1
early-appearing~1
205-kd~1
(kilodalton)~1
high-mannose~2
asparagine-linked~1
later-appearing,~1
225-kd~1
(mature)~1
sucrase.~1
meta-analysis,~1
meta-analyses~2
meta-analyses,~1
areas--study~1
combinability,~1
2.7).~1
searching,~1
687~1
Minnesota.~1
feature--i.e.,~1
generalized-onset~2
Monosomy~1
blood-cell~1
monosomy,~1
7-specific~3
polymorphisms,~1
Granulocytes~2
(No.~4
Chemotaxis~1
Danazol~2
(ITP).~1
ITP~2
vinblastine.~1
platelet-associated~2
(Fc~1
receptors).~1
2.7-fold~1
(cytosolic)~1
ultrafiltrates~1
SEM])~1
calcium-influx~1
smooth-muscle-cell~1
clear-cell~5
Transplacental~2
Carcinogenesis~1
diethylstilbestrol-exposed~1
27.~2
("predeposited")~1
predonation~5
4996~1
Cross-matched~1
1287~1
predepositing~1
(32)~1
predeposited~3
predeposited,~1
558)~1
predeposit~2
predonated~1
transfusion-associated~1
fraud~1
lapses~1
(lateralization)~1
macaque~4
emitted~5
conditioning,~3
innate~1
perceiving~1
left-hemisphere~1
readily-available~1
Angiogenesis,~1
(bFGF),~2
angiogenic~3
luteum,~1
So~2
bFGF-producing~1
(Glossina~1
spp.).~1
Trypanosomes~1
procyclic~3
(VSG)~1
trypanosomes~2
(equivalent~2
midgut)~1
repeats~3
dipeptide-Glu-Pro-.~1
Related~1
leishmania.~1
cruzi.~1
under-used~1
polymers:~1
infusibility,~1
backbone~2
true.~1
Barnacle~1
Teflon)~1
mussel~1
clam~1
byssus,~1
cross-linking.~1
gelatin,~1
epoxidized.~1
plastics.~1
modifiable~3
purpose.~2
flagella~1
ATP-induced~1
flagellar~4
axoneme,~1
doublets~4
axoneme~1
propulsion.~1
vibrating~2
micropipette.~1
rotating~3
rotate~1
pigmentosum,~1
ataxia-telangiectasia,~1
Fanconi's~1
Bloom's~7
exchanges,~2
forks,~1
DNA-damaging~1
ligase.~1
ligases~2
ligase~2
sister-chromatid~1
replicon-fork~1
DNA-chain~1
S-phase~5
polymerases~2
semi-conservative~1
Diacylglycerol~1
(DG)~1
oncogenes~7
ras-encoded~1
G-proteins~1
G-protein~1
polyphosphoinositide~2
ras-transformed~2
ras~2
Ha-ras~2
Ki-ras~1
DG~2
80,000~1
(80K)~1
gelsolin~4
sever~4
filaments,~2
polymerization~8
[Ca2+]~4
activations.~1
actin-gelsolin~1
binary~1
gelsolin-actin~2
Ca2+-independent~1
profilin-actin~1
4,5-bisphosphate,~1
filament-severing~2
gelsolin,~1
nucleating~2
Glucocorticoids,~1
enhancers~1
(GREs).~1
GRE~2
'receptor~1
transformation',~1
two-phase~2
coefficient.~2
glucocorticoid-receptor~1
enhancer~6
transfected~1
unmask~1
eukaryotic~1
protein-coding~1
cis-control~1
interspersed~1
govern~2
(hMTIIA)~1
TATA-box,~1
GC-box,~1
(BLE)~1
hMTIIA~3
(MRE)~1
(GRE).~1
hMTIIA.~1
(AP1)~1
BLE~1
72-base~1
Sp1~1
GC-box~1
site-specific~2
other's~2
Transgenic~1
c-fos~3
deregulated~1
land-bridge~4
islands.~1
Land-bridge~2
mainland~2
ocean.~1
supersaturated~3
island,~4
islands,~1
habitat~1
reserves,~1
follow.~1
extinctions~3
colonizations~1
reverse;~1
post-establishment~1
parks~2
fauna.~1
formalized~2
game~1
Prisoner's~2
Dilemma~1
selfish~1
defection~1
rewarding~1
cooperation.~2
TIT~3
player~1
cooperates~1
opponent~1
move.~1
predator,~1
Dilemma.~1
mirrors,~1
three-spined~1
sticklebacks~1
(Gasterosteus~1
aculeatus)~1
predator~1
companion~2
defecting~1
evolve~4
egoists.~1
interplexiform~1
cyclase.~3
Exogenously~1
whole-cell~4
light-responsiveness~1
photoreceptors.~1
AMP,~4
kainate,~2
L-glutamate,~2
transmitter.~1
computes~1
excitations~1
cones.~1
cones~3
'green'~1
'red'~1
cones,~1
old-world~1
Macaca~2
fascicularis.~1
photopic~1
luminosity~1
cone-mediated~1
cones:~1
dim~1
undershoot~1
(pHi)~2
pHi~16
pumping,~1
Na/H~4
Cl/HCO3~3
cotransport,~1
Na/H/Cl/HCO3~1
obligatorily~1
homogeneously.~1
disaggregation~1
destroys~1
environments.~4
pH-sensitive~1
BCECF~1
(2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein)~1
(CC)~4
CCs~2
(Nao),~1
Nao,~1
Cl.~1
Oxyntic~1
Nao.~1
(Clo),~1
Clo~1
Clo.~1
CCs,~1
OCs,~1
outweighs~1
alkalinization.~1
ethylisopropyl-amiloride~1
monensin~1
sensitizes~2
aggregability.~1
1947,~1
filariases~1
diethylcarbamazine~1
(N,N-diethyl-4-methyl-1-piperazine~1
carboxamide;~1
DEC),~1
microfilariae~9
DEC~2
(FEA).~1
antibody-independent~1
(DAF),~1
phosphatidylinositol,~2
C4b,~1
HeLa~1
splicing~2
frameshift~1
'intron'~1
Alu~1
hydrophobicity.~1
polysomes,~1
translated.~1
spliced~1
unspliced~1
encode~2
fog~5
clouds~1
analysing,~1
fog,~2
rain.~1
sulphonates.~1
pesticides~4
rainwater~1
air-water~1
thousandfold~1
Henry's~1
Law~2
Blooms~1
dinoflagellate~1
Gonyaulax~1
tamarensis~3
(synonyms~1
Protogonyaulax~1
Alexandrium~1
tamarense)~1
shellfish~1
coastal~3
Gulf~1
Maine,~1
November,~2
alternations~1
overwinter~1
Newly~2
2-6~1
dormancy~1
germination~4
unfavourable~2
waters--an~1
clock~4
germination.~1
estuaries.~1
conclusive~4
circannual~1
sediments,~1
terrestrial~1
Glucagon~3
(Ki~3
glucagon.~3
post-translational~1
dibasic~1
(Arg~1
17-Arg~1
glucagon(19-29)~1
glucagon(19-29),~2
[Ca2+-Mg2+)~1
ATPase)~1
1,000-fold~1
Glucagon(1-21)~1
inactive;~1
glucagon(18-29)~1
glucagon(22-29)~1
glucagon(19-29).~1
intramolecular~3
proteins:~1
NMR,~1
Raman~1
quenching,~1
Mossbauer~1
hydrogen-deuterium~1
calculations.~1
hen~1
egg-white~1
scattering~2
(scattering~1
Bragg~1
reflections),~1
displacements,~2
Rigid-body~1
nm2).~1
recoil.~1
bouncing~1
along.~1
memorable~1
'chunks'~1
remember.~1
Memory~2
chunks~2
informaton~1
chunk.~1
ingenuity~1
chunks,~1
recalled~4
correctly.~3
paradigms~1
non-verbal~1
non-human~1
memorize~1
lists.~2
'chunk'~1
5-element~2
(colours~1
achromatic~1
clustered~5
colours~1
clustered.~1
chunk~1
boundary.~1
chunking~1
profitably~1
linguistic~3
point-to-point~1
somatotopic~1
terminate.~1
periphery,~4
Excitatory~1
facilitations~1
Neurotransmitters~1
messengers,~1
GMP~5
second-messenger~2
molluscan~1
neuropeptide,~1
FMRFamide,~1
channels)~1
FMRFamide~1
channels;~2
closures~1
inwardly~2
diode,~1
hyperpolarization,~1
rectification,~2
rectification~2
currents.~1
ohmic~1
Rabbit~5
sequenced.~3
(673,~1
671~1
672~1
Kinases~1
621~1
RNAs~3
kinases.~1
specificities.~3
ubiquitously~1
predominate~2
Phe-Tyr-Met-Glu~2
phosphorylcholine~1
(PC)-binding~1
complementarity-determining~1
(CDR1)~1
anti-PC~1
854~1
2,260~1
tetrapeptide~2
PC-binding~2
McPC603~1
HOPC8.~1
surface-simulation~2
McPC603.~2
non-specifically~1
modelling~1
saccular,~1
fusiform,~1
broad-based,~1
serpentine~2
operation:~1
broad-based~2
cases:~2
trapped,~2
transcortically~2
PCA.~2
hemiparesis,~2
hemihypesthesia,~1
PCA,~1
sellar~4
(computed~1
puncture).~1
four-vessel~1
Endocrinological~1
panhypopituitarism.~2
Insufficient~2
ballooned~1
sella.~1
apoplexy~2
SAH.~5
sella,~2
6-month-old~1
circumference.~3
frontotemporal~1
craniotomy.~1
ganglioglioma~1
gangliogliomas~1
accident.~6
myelogram-computed~1
tomogram,~1
callous~1
tethering~2
L-5~2
hemilaminectomy,~1
L-4,~1
L-5,~1
facetectomy,~2
foraminotomy~1
meningioma;~1
oculopathy~1
dysesthesias~1
fracture/dislocation~1
(consecutive~2
series).~1
bleeding:~1
(MSAH)~1
0.00001);~1
(IVH)~2
0.008);~1
(ICH)~1
MSAH~1
ICH~1
MSAH,~1
IVH,~1
ICH,~1
(11%).~1
Documented~1
T-12,~2
(Tarlov~1
plane).~1
naloxone-treated~1
morphometrically;~1
megadose~4
mg/kg/hour~2
epicenter~2
naloxone,~4
(HRP)~3
(normals).~1
HRP~6
nonclot~1
TEM).~2
adventitial~7
tunnel-like~1
vasa~2
vasorum~1
stomas,~1
numbering~1
10/mm~1
connect~1
intraadventitial~1
dense,~2
well-organized~2
clots,~3
magna,~1
Virchow-Robin~2
(intraadventitial)~1
epithelium-like~1
fibroblasts;~1
Vasogenic~1
stomas~2
wastes~1
regrowth~8
gliomas,~5
(between~2
autopsy)~1
(Td)~1
Hounsfield~2
necrosis),~1
glioblastomas.~1
Td's~6
glioblastomas~2
65.1~1
48.1~1
895~1
130.6~1
50.5~2
(0.97).~1
grades.~1
Radiotherapy~4
retarding~1
astrocytomas~2
glioblastomas.(ABSTRACT~1
toy~1
modernized~1
BBs.~1
rifles~1
myelomeningocele.~1
meningocele.~1
primordial~1
(benign~1
malignant),~1
cholesteatoma,~2
aided~2
petroclival,~1
intracavernous,~1
subtemporal~2
preauricular~4
pseudoaneurysm~2
ICA.~2
Nonvascular~1
temporary),~1
mastication~1
solved.~1
proven.~1
tubercular,~1
pyogenic,~1
fungal.~1
hematogenous,~1
nonimmunocompromised~1
tuberculomas.~2
tuberculoma~1
glioma.~1
neurologically,~1
Doubtful~1
(STA)~1
(MCA)~3
STA-MCA~1
MCA~9
nodules)~1
ependymomas,~1
oncocytoma,~1
hamartoma,~1
well-enhanced~1
vascularity~4
extirpation~3
(meningioma,~1
case)~1
firm.~1
cortically~2
neuralgia,~2
Meckel's~1
cave~1
Physics~1
Sheffield~2
painless.~2
(5-fold)~1
hyperthenar~1
magnetoelectrical~1
noninjurious,~1
(MEPs)~4
MEP~16
Latency~1
volume-conducted~1
C-8:~1
56.0~1
20.0~3
MEPs~4
anodal~2
T-10.~1
waves,~6
I1~1
I4.~1
56.0-g~1
transections~1
20.0-~1
1.5-g~1
peaks.~2
Somatosensory~3
(SSEPs)~1
corticomotor~1
(CMEPs)~1
Rats,~1
parasagittal~3
craniectomies~1
midthoracic~1
laminectomies.~1
SSEPs~2
CMEPs~2
50-g/cm~2
SSEP~5
CMEP~5
Neurohistopathological~1
Acutely,~1
vocalization.~1
(MEP)~2
regain~4
attained.~2
predictor.~2
0.55.~1
microC/cm2~1
ph).~1
corticocortical~1
input,~2
transcallosal~2
(TCR).~1
by:~2
anode~2
cm2)~3
F4~1
nomenclature)~1
located,~1
away;~1
interconnected~2
resistors~2
away.~1
Transcranial~1
microseconds~1
diphasic~2
(latency,~1
ms),~3
microV.~1
temporalis~3
interpolar~1
(epicranial~1
stimulation);~1
furthermore,~2
zygomas~1
brows~1
dulled~1
wave.(ABSTRACT~1
(Grade~1
"Good"~1
21%;~1
"Bad"Grade~1
40%;~2
downgrading~1
(93%),~1
ballooning~2
horns,~1
rostral-caudal~1
(edema)~1
transcranially~1
somatotopy~1
homunculus~1
transcranially.~1
facilitation,~2
supratentorial,~1
Reversible~1
weakening~3
warn~2
Supratentorial~1
monitoring;~1
pitfall~1
Cerebellar~2
pericranial~2
spaced,~1
Collision~1
antidromically~1
prestimulus~1
premovement~1
facilitation.~1
volley~1
trunk.~3
CCTs~2
myelomeningocele~6
Sick~4
coughing.~1
Arteriography~1
rupture;~2
clinoid~2
coincidental~3
orthosis~4
wrestling.~1
wrestlers~1
illegal~1
thrown~4
mat.~1
moyamoya~4
32-year-old~3
craniotomy,~3
encephaloduroarteriosynangiosis~1
trouble.~2
AVM.~2
cervicomedullary~1
pigmented,~1
schwannoma.~1
eleventh~1
choriocarcinoma.~4
cephalic~6
headaches~4
Raeder's~2
oculosympathetic~4
signs;~1
Angiograms~2
recovery;~1
insipidus.~2
apoplexy.~1
Willis.~1
obliterate~1
cisternal~3
hypervolemia~1
transcranial~2
electrodeless~1
(HSE)~2
vigabatrin~1
(VGB)~1
CPS~5
VGB,~2
(principally~1
drowsiness,~1
headache)~1
efficacy:toxicity~1
Coadministration~1
VGB~2
VGB.~1
lorazepam~1
(LOR)~1
LOR~4
(excepting~1
benzodiazepines)~1
Tachyphylaxis~1
meralgia~1
paresthetica~1
Wernicke-Korsakoff~7
embolic.~1
(MCA),~3
sylvian~1
Nonembolic~1
(FIM)~1
(MEPP)~1
abnormally,~1
FIM~6
nonweak~1
10-Hz~1
hemicholinium~1
FIM,~2
2-adrenoreceptor~1
(BPM)~1
BPM~1
HR,~6
0.61,~2
1,013~1
ever-smoked~1
(RR~2
1.2).~1
ever-smokers~1
(68.8~1
never-smokers~1
(73.8~1
IPD.~1
psychoneurosis~1
Parkinson~1
open-label~1
controlled-release~3
carbidopa/levodopa~2
(Sinemet~1
CR3).~1
"on"~1
interdose~1
"off"~1
Sinemet.~1
unsustained.~1
Demyelination~2
intraneural~2
M-protein~3
(MAG).~1
M-proteins~1
MAG.~1
myelinolytic~1
M-protein.~1
Immunofluorescence~4
sheaths,~1
31P-NMR~3
heterogeneity,~3
612~1
"optico-cerebral~1
Gerstmann-Straussler~1
(GSS)~1
(NFTs)~1
neuraxis.~2
spinocerebellar~3
GSS~1
pathologically,~1
NFTs~2
GSS.~1
spongiform~2
encephalopathies,~1
cloud~1
deployed~1
workplace,~1
pharmaceuticals,~1
neurotoxicology~1
alarm~2
(AVMs)~2
AVMs,~1
bled.~1
(47/58)~1
private-sector~1
consultative~1
neurodiagnostic~3
Eight-four~2
(41/49)~1
("local"~1
"artery-to-artery~1
embolism").~1
Occipital~1
prominent,~2
fluctuating~3
six;~1
minor,~2
vowels~1
consonants~1
hypernasality.~1
anarthric~1
pauses.~1
prolactin,~4
after-discharge~1
After-discharges~1
Stimuli~2
after-discharges~1
endoneurium~1
Scanning-integrating~1
microdensitometry~1
azure~1
B-RNA-~1
Feulgen-Schiff-stained~1
neostriatal~2
oligodendrocyte~1
23%)~3
putamen.~1
oligodendrocytes,~1
(RNA~1
loss)~1
(SNAPs)~1
microV,~1
elicited.~1
(SEP-derived)~1
SNAPs,~1
misleadingly~1
"myopathic,"~1
glycogen.~1
myophosphorylase~2
glutamate-induced~1
(gamma-D-glutamyl~1
glycine)~1
Markers~1
(CAT)~4
mesencephalon.~1
diminished,~2
[3H]-spiperone~1
D2-dopamine~1
biceps,~1
digiti~1
minimi~1
radiculopathy,~2
(56%).~2
serologically~5
Legionella.~1
gammopathy.~1
biclonal~1
paraprotein~1
appeared.~3
hemifacial~3
worse,~1
Glomerulonephritis~2
myoclonus~3
serotoninergic~1
neurochemical,~1
Scopolamine,~1
event-related~4
Physostigmine,~1
callosotomy~3
callosotomy,~1
(prior~1
scanning).~1
shadow~3
splenium~1
splenium,~1
anisomorphic~1
gliosis.~1
transection.~3
Assessing~1
thrombosis:~1
varicosities,~3
nonwhite~4
significant:~1
followed,~3
37-~1
72-month~1
37-72~1
wide-spread~1
hand-sutured~1
(EEA~1
instrument)~1
stomal~3
peristomal~2
Colostomy~2
fit.~2
Naval~1
Bethesda,~1
colposcopy,~2
colposcopically~1
(11.1%)~3
13.7~3
(15.6%)~1
diameters,~4
transvalve~2
Diameters~3
Transvalve~1
381~3
mL/minute~3
286~3
410~1
mL/minute,~1
1.3:1).~1
1980s~1
(diabetic~2
"strict~1
management,"~2
euglycemic~1
1.5-hour-postprandial~1
mg/dL);~1
"customary~1
"as~1
community"~1
mg/dL).~2
(III)~1
13.4%,~1
.01)(ABSTRACT~1
(PROM)~2
deliver.~1
Expectant~1
(19%),~5
indigent,~1
intraamniotic~4
aerobes,~2
anaerobes,~3
mycoplasmas.~2
bivius,~1
bivius~5
micro-enzyme~1
isolate.~1
1236~1
414~1
cystadenocarcinoma,~1
dysgerminoma.~1
burden,~1
[3H]leucine~1
cisplatinum,~1
adriamycin,~1
thiotepa,~1
chlorambucil.~2
Chemosensitivity~1
danazol.~1
chemosensitivities.~1
plate),~1
adenocarcinomas,~4
adenoacanthomas,~1
carcinosarcomas,~1
chemosensitivities~2
x-ray,~2
(IVP),~2
cystoscopy,~3
sigmoidoscopy~9
cyproterone~4
(SHBG),~2
hyperfunction~1
(premature~1
pubarche,~1
amenorrhea)~1
proband,~1
aunt~2
(twin~1
sisters),~1
great-grandmother.~1
hirsutism~7
Glucocorticoid~2
amenorrheic~8
leucocytic~1
(HLA)~3
salpingitis.~1
continuity.~4
low-risk,~1
four-day~1
acetoacetonuria~1
Ketonuria~2
salpingectomy,~1
salpingectomy~6
(midtube~1
resection),~1
salpingotomy.~3
"Preventive~1
hemostasis"~1
salpingotomy~1
Ruptured~1
trying~2
pregnancies;~2
Tubal~2
norms~4
plaques;~1
(VII)~1
puerperium~2
meningocele~2
gestations,~1
contraceptive.~2
Postpartum~2
nephrosclerosis~3
gravida~3
para~3
1-0-8-1,~1
involute~1
Myositis~2
ossificans~4
progressiva~4
ossifying~1
flexure~1
fibrosing,~1
Remarkably,~2
advisability~2
diffusion,~1
Subtherapeutic~1
vaginitis~1
25.5~5
utero-ovarian~1
Placenta~1
accreta~1
previa~1
percreta~1
13,000~1
Advances~3
credited~1
sisters.~2
Real-time~1
bilobed~1
asplenia.~1
Broad-spectrum~1
begun,~2
uterus.~2
Anaerobes~3
cover,~1
catamenial~1
"nonfunctional."~1
theorized~4
catastrophic,~1
leading,~1
vulva,~3
pseudoneoplastic~1
hallmarks~2
epidermolysis~5
bullosa~4
Scarring~2
hematometra.~1
salpingostomy.~1
reverted~3
beta-hCG~1
vaginoplasty.~1
neovagina~1
transplanted.~1
McIndoe~1
neovagina.~1
virologic~1
warty~1
papillomavirus-6.~1
colo-ovarian~3
oophoritis.~1
discomfort;~2
salpingo-oophorectomy;~1
colovaginal~1
oophoritis~1
Malacoplakia~1
malacoplakia~3
tumorlike~2
invade,~1
bowels.~1
Healon~5
(sodium~4
hyaluronate)~1
trabeculectomy~3
Healon.~2
cleft,~1
sclera.~1
Stallard-Worst~1
triangular~3
Cairns'~1
Tenon's~1
maintenance,~2
clefts,~1
synechiae~2
(5/59~1
8.5%)~1
(33/55~1
60%).~1
"clogging"~1
tonographic~1
hyaluronidase~5
cleave~1
histopathologically.~2
Descemet's~3
(Healon)~1
diamox~1
timoptic~1
protractor~2
post-injection~1
myectomy~1
ptosis~10
Extraocular~1
(simultaneous~1
circulations)~1
Ophthalmoscopic~3
pole;~2
cherry~1
Fluorescein~5
encompassed~4
(RPE).~1
Electroretinography~1
(ERG)~3
a-~1
b-waves.~1
grim~1
Goldblatt's~1
ophthalmoscopy~2
eyes).~1
choroidopathy,~2
(RD)~1
ophthalmoscopic~2
bed,~4
(due~2
infarction),~1
RD~1
choroidopathy~3
detail;~1
suprachoroidal~2
lasts~1
hole.~1
Suprachoroidal~1
macula~8
buckling~2
0.014).~1
worrisome~1
0.043).~1
(ARN)~1
ARN~2
(Ramsay~1
Hunt~1
(CMV),~1
(VZ)~1
VZ~3
reactivation.~1
(ROP)~2
(moderate)~1
(fibrovascular~1
proliferation)~1
(confluent~1
extension)~1
birth-weight-matched~1
preterms~1
ROP,~1
cryopexy,~1
ROP)~1
cryotreated~1
fans)~1
(PCRP)~1
nonperfusion.~1
fans~1
De~1
neovascularization~9
(1.4%).~2
20/30~2
nonresolving~2
PCRP~1
PSR.~1
Terson's~4
dome-shaped,~1
echography,~1
epiretinal~8
hyaloid~4
Echographically,~1
B-scans,~1
A-scan.~1
histopathologic,~1
cone-rod~2
macula,~2
equatorial~1
lipofuscin-like~2
atrophic.~1
Laurence-Moon~2
Bardet-Biedl~1
polydactyly,~1
low-average~1
"Laurence-Moon-Bardet-Biedl~1
phenotype"~1
neuroradiologic~1
ataxia.~2
Electroretinograms~1
ERG~4
b-wave~3
flicker~1
cylinder~12
refraction.~1
shortcoming~1
little-known~1
cylinder,~1
refinement.~1
eligibility~1
photographic~5
commendable~1
photographers.~1
confines~2
guideline~3
Intracarotid~3
countered~1
supraophthalmic~1
infraophthalmic~2
retinopathic~1
retrobulbar~6
4-ml~1
ampule~1
opthalmoplegia,~1
blindness,~4
Epikeratophakia~1
glare,~1
vacuolations~1
Hemidesmosomes~1
trephined~1
Excess~1
levator~4
ptosis)~1
Ptosis~1
bridle~1
sutures,~4
Knapp~1
speculum~3
diamond~2
knife.~1
lid,~1
aponeurosis~1
disinsertion~1
(ATD)~2
autoantibodies:~1
(ANA)~1
(SS-A~1
SS-B).~1
keratitis,~2
bilateral,~4
autoantibody-positive~1
ATD~5
5-35~1
Krukenberg~1
spindle,~1
transillumination,~1
Disc~5
prognoses.~2
[IOPs]~1
medication[s]~1
medication)~1
non-neovascular~4
glaucomas,~1
glaucomas~1
neovascular~7
(NVG).~1
7.5).~1
NVG.~1
(50%);~1
(36%;~1
repair);~1
(9%);~2
(3%);~2
endophthalmitis~1
(2%);~1
prognoses;~1
impression.~1
lymphangioma~1
superficial,~2
multicystic~2
lymphangiomas~2
hemorrhages.~3
hamartomas~2
diaphanous~1
serous-filled~1
lymphorrhages,~1
bundles.~1
1007~1
(35%);~1
(36%);~1
traction-rhegmatogenous~1
(17%);~1
(12%).~2
22%.~1
traction/rhegmatogenous~1
48%;~1
27%;~2
24%;~1
Drusen~2
(ARM).~1
ARM.~1
drusen.~1
6.1%,~1
duplicates~1
Digitization~1
(AMD)~1
Salient~2
(sub-RPE)~1
neovascularization;~1
retina;~2
walls.~6
AMD~1
Coumadin~1
(warfarin)~1
AMD,~1
antithrombotics~1
(ROP).~1
myopia.~4
powers,~1
22.20~1
44.13~1
31.27~1
D),~1
fellow~4
rubeosis~1
(RP),~1
manually.~2
perimeter~3
perimetry~1
RP.~1
fluorescence,~2
phosphorescence~1
instantaneous,~1
afterglow.~1
decays~1
emitting~3
electrons~2
bloodstream,~1
Optimalization~1
exciter~1
pseudofluorescence.~1
extraocular~3
droop~2
Toxin~1
life),~1
P-32~1
154%~1
Pigmented~2
globe.~2
polygonal,~1
hyperpigmented~3
spindled~1
emissaries,~1
eyeball,~1
well-melaninized~1
macromelanosomes),~1
melanocytoma.~1
uvea~1
Proptosis~2
neurocutaneous~2
melanosis~1
pigmentation).~1
Shortly~4
oculocutaneous~1
melanosis,~2
nevus.~4
clinician's~2
perspective.~2
pole,~2
equator,~1
calotte~1
correlations.~2
nonselected~2
(218~2
retinoschisis~3
periodically,~1
deliberately~2
withholding~1
formulated.~3
postequatorial.~1
nonprogressive.~1
"schisis-detachment".~1
choriocapillaris.~1
vitritis~1
parafoveal~2
neovascularization,~7
noncontributory.~1
arteriolitis~1
obstructions.~2
(CRVO)~2
Included~4
CRVO~2
CRVO.~1
0.021),~1
intraretinal~3
(CRN)~1
choriovitreal~1
(CVN)~1
CVN).~1
CRN~1
CVN~2
fluorophotometry~4
blood-retinal~3
Midvitreous~1
pre-retinal~1
CRN.~1
Acuity~1
Meter~1
(PAM),~1
interferometer~3
(LI),~1
white-light~1
(WLI),~1
entoptic~1
PAM,~2
LI,~1
WLI~1
overread~1
interferometric~1
octaves~2
WLI.~1
Blue~7
equivalents,~3
20/40)~1
PAM~1
(PVD)~1
PVD.~2
Photocoagulation~2
no-PVD~1
PVD~1
vitreoretinopathy~1
tractional~4
incarceration,~1
tacks,~1
fluid-gas~3
traps~1
counteraction~1
D1~1
tears.~2
periretinal~2
578~2
iris-fixated~1
(48%).~2
receptionist~1
obtains~4
appointments.~2
photographer-technicians~1
photographers~1
in-service~1
meetings.~1
treats~3
CNV~3
Ophthalmologists~2
cameras~1
videoangiography.~1
tally~1
misdiagnoses~1
misdiagnoses.~1
macroaneurysms~1
talented~1
seroepidemiologic~1
(hepatitis~2
myiasis~4
6-year-old~5
Dermal~5
Dermatobia~1
furuncle~2
travelers.~1
Invasion~1
dipterous~1
myiasis.~2
screw-worm~1
Chrysomyia~1
bezziana~1
Villeneuve.~1
myiasis,~1
intraorbital~1
ophthalmomyiasis~1
bezziana.~1
Neoplastic~1
angioendotheliomatosis~1
(NAE)~1
predominate,~1
NAE~4
nystagmus,~5
pancorporal~1
factor-VIII-related~1
maker~1
extranodal~3
contention.~1
optics~1
examiner.~1
biomicroscope~1
object.~1
unfamiliar~2
(Humphrey~1
Vision~3
Analyzer,~1
Moller/CooperVision~1
Visutron,~1
Reichert~1
SR-IV,~1
Rodenstock/Coburn~1
Phoromat).~1
remote-controlled~1
phoropters~1
Phoromat~1
Visutron.~1
SR-IV.~1
irrigated~1
barb~1
zonules~1
cleanup.~1
Ophthalmic~3
Rods,~1
2-inch-long~1
drug-coated~1
conjunctiva,~1
comfort,~2
Rods~2
eyedrops,~2
citing~1
cleanliness,~1
advantages.~1
accommodation.~2
non-painful~2
Two-point~1
two-point~4
40.3~1
(S.D.,~2
30.8~2
tactual~1
well-established~4
McGill~3
(MPQ)~2
MPQ~4
Pittsburgh~2
Montreal.~1
descriptors.~1
descriptors~1
oralis~5
magnus~1
(NRM)~1
digastric~1
jaw-opening~2
7-140~1
NRM~1
deafferented~2
NRM-induced~2
(0.08-0.15~1
NRM.~1
thoraco-lumbar~1
Tonic~1
piperidine-4-sulphonic~1
microliter)~1
-7,~1
-8~2
-10.~1
fear-defence~1
PAG~3
pyrazolone~1
metamizol~4
(dipyrone),~1
analgesic,~1
antipyretic,~1
spasmolytic~1
acting.~1
antinociceptive~1
tail-flick~3
heat,~2
periaqueductal~1
grey~1
Metamizol~3
(i.p.;~1
(i.t.;~1
i.t.~4
(40,~1
(15-100~1
fibre-evoked~1
PAG.~1
Borg's~1
Category~1
Perceived~1
(BRPP)~1
(1982)~1
adjectives~9
adverbs~1
0-10),~1
Analogue~1
(VAS)~3
line).~1
set-up,~1
periods;~2
moments~2
Nm,~1
Nm),~1
BRPP~1
VAS.~2
BRPP.~1
moments.~2
restrictions,~1
collection,~3
reporting.~1
menu,~1
ECMO~8
ECMO,~3
lipoprotein-cholesterol~1
(World~1
Organization-recommended~1
(mmol/L):~1
citrate3-~2
110;~1
(Pedialyte~1
RS;~1
Chicago),~1
mmol/L):~1
139.~1
collected:~2
urine;~1
hypernatremia.~1
Pedialyte~1
glucose/electrolyte~1
Infrequent~1
sibling,~4
vanillylmandelic~1
(VMA)~2
neuroblastoma.~1
VMA~5
levels),~1
(false-negative~1
7.5%).~1
27.5%~1
(2.5%)~2
shown,~2
reviewed;~1
Lesser~2
unheeded~1
historical,~3
hear,~1
Deleading~1
improperly~1
already-lead-poisoned~1
apartment~1
deleading.~1
Supportive~2
vacate~1
apartments~1
deleading~1
lead-poisoning~1
shelter~1
deleading,~1
reality.~2
576,~1
upper-middle~1
socialized~1
behaviors,~3
bathe~4
daughters~1
cross-sex~1
aversion~1
incest~1
taboo.~1
development-related~1
offense~1
offense.~1
Fathers,~1
crimes~1
partners.~2
single-parent~1
graduated)~1
nonoffenders.~1
maladjustment~1
delinquency~1
adjusted,~1
preschool,~1
adolescence,~3
Schwachman~3
home-visiting~2
only:~1
nourished~6
Griffiths~2
Stanford-Binet~2
catching~1
caught~1
cessation.~2
subscales.~2
nonintervention~1
microwave~7
ovens.~1
Well~2
demarcated~3
microwave-emitting~1
streaming~1
Psychologic~3
dart~1
Consumer~1
(neurologic~1
5/10~1
injuries)~1
game.~2
formula-fed).~1
(three-~1
five-fold)~1
trivial.~1
glycuronyl~1
transferase,~1
factors)~1
repress~1
P-450.~1
Arousal~1
catecholamine-mediated~1
(PiO2~1
arouse~2
4.1-fold~1
3.4-fold~1
.02),~3
3.5-fold~1
5.3-fold~1
3.2-fold~1
12-fold~1
would,~1
believe,~1
will,~1
advocates~2
regulations~3
policies.~1
mind:~2
adhered~3
Resetting~1
crying.~1
Thereby~1
unjustly~1
antihistamines,~2
decongestants,~2
allergist~1
immunotherapy.~3
condition:~2
thyroid-related~1
reassurance.~1
acalculous~1
early:~1
postherpetic~2
Zoster~1
Ongoing~1
Taste~2
Connecticut~2
Chemosensory~1
taking;~1
otorhinolaryngologic,~1
olfactory:~1
Healthcare~1
public's~2
commonsense~1
proponents~1
unorthodox~3
well-educated,~1
media-conscious,~1
salespersons.~1
unconventional~1
tragic~1
informed,~2
quackery.~1
multivitamin-with-mineral~1
nonnutrients~1
well-balanced,~1
additives~3
harmful.~2
breastfeeding~9
fluoride,~5
decision.~1
mononucleosis,~2
serious.~1
Performing~1
heterophil~1
(VCA),~1
VCA,~1
(anti-D)~1
(EBNA).~1
IgG-VCA,~1
IGM-VCA,~1
EBNA~2
IgG-VCA~1
indefinitely.~1
interpreted.~4
riding~2
terminated~7
returned.~2
riding.~2
bicycling~3
yellowing~1
lens,~3
lids,~1
Preventive~4
forestall~2
advice.~2
"emergency"~1
caller's~1
powerlessness~1
perceives~1
health-related.~1
therapeutically.~1
five-step~1
strategy--including~1
listening,~1
clarification,~1
self-help,~1
advice--can~1
Korotkoff~2
loud.~1
Loudness~1
manometer,~1
muffling~1
nearest~3
time-consuming.~1
Hazardous~1
ubiquitous~3
real,~2
Soviet~2
Union.~1
governments,~1
industry,~1
(UTI)~1
UTIs~1
reinfections~1
prophylaxis,~2
self-start~1
postintercourse~1
achlorhydria,~1
exciting,~1
well-known,~1
Manifestations~1
pyuria,~2
cylindruria,~1
azotemia.~1
Legionella~3
pneumophila~2
microvasculature,~1
intertester~2
goniometric~2
table's~1
15-cm~1
perpendicularly~1
board.~1
arbitrary~4
goniometer~2
trochanter,~1
condyle~6
fibula,~2
landmarks.~1
moved.~1
(r's)~1
.98;~1
.99)~1
.97-.98;~1
.98-.99)~1
vara~5
positions:~1
double-limb~2
(DLS)~1
(Condition~3
single-limb~1
Intraclass~1
raters~2
Newman-Keuls~1
post-hoc~1
Condition~1
Conditions~2
L-tryptophan~2
pretest-posttest~1
L-tryptophan,~1
(Groups~1
Burning~1
250-W~1
lamp~2
"intense~1
sensation."~1
500-mg~1
14th~2
remeasured.~1
interrater~4
Ashworth~2
Kendall's~2
tau~1
.847~1
raters'~1
(SWD)~1
SWD~3
myotoxic~1
sectioned,~2
(LJM)~1
LJM~3
adult-onset~9
(DM).~1
DM)~1
flatten~1
Intrarater~1
.98.~1
Student's~5
LJM.~1
ROM,~1
independent.~2
DM.~1
orthoses,~1
thermoplastic~1
(TMBJ),~1
TMBJ.~1
TMBJ,~1
stabilization.~2
postbaccalaureate~2
Perceptions~2
Mann-Whitney~2
concepts.~1
socialization~2
accredited~3
programs;~1
79%.~3
(96%)~3
affirmed~1
curricula.~1
aging-related~2
behavioral-social~1
sciences.~2
Content~1
credits~1
study),~1
(direct~1
10,264~1
funding~3
Scintigrams~1
contralateral,~4
scintigrams,~3
Retention~1
Unquestionable~1
lymphatics~3
scintigrams~2
anastomosing~5
nonparalytic~1
nondenervated~1
cross-striated~1
sarcomeres,~1
organelles.~1
26);~1
surgically--by~1
transmastoid~1
Facial~4
rehabilitated~1
crossover,~3
transfers.~1
hopefully~1
neurotmesis,~1
tattoos~3
"French~1
method"~1
tattoo~2
artists.~1
dermabrasion~2
"rubbed"~1
wheel.~2
"painted"~1
stick.~1
tattoos,~1
Details~3
microreservoir~1
desired,~1
Accurate,~1
settled~1
design;~1
methacrylate~3
nonvascular~2
corroded~1
periumbilical.~1
Thinning~1
Scarpa's~1
combination;~1
rejoined~1
free-tissue~4
transplantations~1
tenodesis~5
tenodesis,~2
overrides~1
subdivides~1
"direct"~1
"crossed"~1
tenodesis.~1
axes.~1
"reciprocal"~1
resurfaced~1
preaxial~2
polydactyly~5
configuration:~1
1--ray~1
duplication;~1
2--completely~1
phalanges;~1
3--incompletely~1
metatarsals;~1
4--incompletely~1
phalanges.~1
thereof~2
pathomechanism~1
big~1
varus.~1
maxilla~3
uvulae,~1
hypertelorbitism,~1
Theories~1
morphopathogenesis~1
liposuction.~1
inframammary~1
rhinoplasty~4
noses,~1
textual~1
judgement~1
rhinoplasty.~2
suspensory~1
insensate~1
summarized,~1
(nephrostomy,~1
dilation),~1
collections,~2
gastroenterostomy.~2
obviating~4
(6%);~1
splenoportography,~1
(Gelfoam)~1
splenoportography.~1
has,~2
stacks~2
Simpson~1
incompatibility~2
ioxaglate~1
(Hexabrix)~1
Extreme~2
pharmacoangiographic~1
mixing~5
stopcock~1
flushed~1
Torsion~2
circumstances:~1
abnormality;~1
pneumothorax;~1
consolidated~1
bronchography;~1
vasculature;~1
radiographs;~1
mass;~1
2,048~2
bits,~1
number)~1
Striking~2
enabling~5
(ROC)~1
"truth"~1
mediastinum.~2
ROC~1
0.779~1
0.039~1
0.781~1
0.038~1
interpretations~3
seldom-mentioned~1
pathognomic~1
gravity-dependent~1
layering~1
tree-like~1
(dermoid~1
plugs),~1
fat-fluid~1
globular~1
problematic~1
lin~1
anatomy-and~1
fluid-containing~1
(US).~1
26-year-old~3
infiltrative~8
radiographically,~2
cases/million/year,~1
cases/million/year.~1
observer-performance~1
+8.6~1
+430,000~1
dosimetric~2
56),~3
Tc-99m~1
41),~2
(radiographic~1
III-V).~1
"double~1
sign"~1
isointense~2
I-II)~1
low-signal~2
TRs~2
TEs.~1
TR/TE~1
chronologic~4
hips)~2
heads,~1
AVN.~1
arthrograms~2
Pseudocapsule~1
bursae~1
Arthrographic~1
pseudocapsule~1
nonbursal~1
receive-only~1
reduced-field-of-view~2
Experimentally~1
(Achilles)~1
tenosynovitis,~1
tendonitis,~1
inherently~5
multiplanar~1
troublesome~2
neuromas~2
lipoma,~3
cryomicrotome~1
time/short~1
gyri~1
inferomedial~2
cingulate~3
occipitotemporal~2
gyri,~2
gyrus;~2
rhinal~1
sulci,~1
sulcus,~1
sulcus;~1
pes~1
hippocampi,~1
subiculum,~2
subsplenial~1
alveus,~1
fimbria,~2
fornix;~1
dentatofimbrial~1
fissure;~1
sulcus~3
confidently~2
Ungated~3
(TRs)~2
echo-delay~2
(TEs)~1
ungated~3
1,500-1,800~1
Gating~2
CSF-gated~1
mismapped~1
(TEs),~1
quantitatively.~2
1,500-1,800-msec~1
(S/N),~1
S/N.~1
interpretations.~1
Cushing~4
derives~3
(ACTH).~1
Fifty-seven~5
(SST);~1
lacking,~1
hypotheses.~1
(112~1
manifestations)~2
SST~1
SST-related~1
sinovenous~1
(28.6%)~1
SST.~1
endothelial-~1
nonendothelial-lined~1
leaf.~1
lacunae,~1
(dural~1
spaces),~1
tributaries.~1
pallidi~1
abnormalities;~4
embolization)~1
Spectrometric~1
pseudarthrosis,~3
fusions,~1
hardware)~1
seat,~1
Three-millimeter~1
reformated~1
higher-resolution~1
reformations.~1
ribs~1
physiotherapy~4
vibrator.~1
vibrator~1
nurseries,~1
low-attenuation~1
3d~1
distributions,~1
gyral~2
scars,~3
erosions,~2
Double-contrast,~1
full-column~1
9%-18%~1
sclerosant~2
hemorrhoids,~2
electrocoagulation~3
lipomas,~1
leiomyoma.~1
lipomas.~1
Thickening~1
Extraluminal~2
extramural~2
overweight.~1
low-calorie~1
glutamic-pyruvic~1
Radiography~1
iodized~3
VX2~1
Iodized~1
ringlike~2
correlated,~2
peritumoral~1
sinusoids.~1
microemboli~1
Kupffer~7
vasculature,~2
circulates~1
Pixel~1
laser-printed~1
resolution;~2
readers~2
expected;~1
multiple-tuned~1
hydrogen-1,~1
phosphorus-31,~1
lithium-7,~1
fluorine-19)~1
integrity,~3
testicles~3
ischemia;~2
hormone-treated~2
monophosphoester~1
phosphodiester~1
(PD),~1
phosphocreatine;~1
(ATP).~1
MP/Pi~1
0.70).~1
MP/PD~1
MP/beta-ATP~1
P-31~1
spermatogenesis.~1
exudate)~1
buffer-perfused~1
ion,~1
destroying~2
Itraconazole,~1
triazole~1
(recurrent)~1
dermatophytosis.~4
corporis/tinea~1
cruris~1
pedis/tinea~1
manuum~1
itraconazole~15
corporis~1
cruris,~1
pedis~2
manuum,~2
sooner~2
100-mg~2
(2.9%)~1
Hematologic~2
blood-biochemical~1
dermatophytoses.~1
dermatophytoses~2
itraconazole.~3
versicolor~3
mycologically~3
cured,~3
mycologic~2
cure;~1
dermatomycoses.~1
Itraconazole~2
dermatophytosis~7
rubrum~7
(five)~1
candidosis~5
(eight).~1
relapses.~3
candidosis;~1
candidal~4
mycoses~3
seven-day~2
Malassezia~1
furfur~1
cytopathic~4
Cell-surface~1
slowly--maximal~1
itraconazole;~2
itraconazole,~3
triazole,~1
Endocrinologic~1
coccidioidomycosis;~1
chromomycosis~3
(Fonsecaea~1
pedrosoi);~1
sporotrichosis~7
lymphangitic,~1
disseminated).~1
coccidioidomycosis~3
sporotrichosis,~1
triazole.~1
coccidioidal~6
coccidioidomycosis,~2
onychomycosis~2
epididymitis,~2
histoplasmosis,~4
blastomycosis,~1
oral-sinonasal~5
alternariosis,~1
chromoblastomycosis,~1
onychomycosis.~1
respond,~1
unassessable.~1
211.8~1
mycotic~3
Torulopsis~1
glabrata~3
assessable.~1
candidosis,~1
aspergilloma.~2
1964-82~1
48.8~2
49.0~1
65).~1
51.1%~2
41.7%.~1
13.4).~1
open-heart~8
refixation.~1
refixation~2
sternum.~2
sternum~2
plasty,~1
unexpectedly~6
subsiding.~1
Coarctation~2
days-3~1
1.6-4.2~1
2.8)~3
aortoplasty.~1
commissurotomy~2
10.7%~2
infants)~1
recoarctation.~1
Pentoxifylline,~1
hemorheologic~2
b.w.~1
5-10~8
(+22.6%)~1
(+19.5%)~1
dsc-5~1
(+22.3~1
+18.3,~1
(-20.6~1
-15.5%).~1
pentoxifylline.~2
'pure'~1
forecast~1
c.~1
time-independent~1
(endocarditis),~1
("pure"~1
regurgitation)~1
cross-clamping~2
cross-clamp~1
Transcervical~1
thymectomy~2
13-year~2
nonthymomatous~1
gravis.~2
theoretic~2
thymectomy.~1
transsternal~2
One-hundred~1
stricture-forming~1
oesophago-gastric~1
survival-time~1
cardia.~5
hemodilution.~3
intracellularly.~1
hypoxanthine-xanthine~1
SOD,~1
Dulbeccos~1
deformability.~1
erythrostasis~1
(RFR)~1
microfiltration~1
(CPB)~1
RFR~4
influx.~3
CPB~7
K+-Na+~1
K+/Na+~1
heart-lung~4
K+/Na+.~1
granular-cell~2
oesophagus,~3
infiltratively~1
myoblastoma~2
tracheo-oesophageal~1
tumour-bearing~1
fistula-bearing~1
retrosternally.~1
thermolysin~3
phosphorus-containing~1
carbobenzoxy-Gly-Leu-X,~1
Gly-Leu~2
phosphonate~3
(-PO2(-)-O-).~1
phosphonamidate~2
(-PO2(-)-NH-~1
840~1
phosphonamidate,~1
kilocalories~5
crystallographic~2
Cbz-GlyP-(O)-Leu-Leu~1
crystallography~1
angstrom)~1
Cbz-GlyP-(NH)-Leu-Leu.~1
enzyme-inhibitor~1
thermodynamic~1
perturbation~4
dynamics,~1
4.21~1
"mutation"~1
suitably~1
represented.~2
right-hand~1
premotor~2
brief,~2
"preparatory~1
sets,"~1
somesthetic-motor,~1
integrative~3
Arthropod-borne~1
(arboviruses)~1
vector-vertebrate~1
vector-virus~1
Crosse~1
(LAC)~1
triseriatus,~1
LAC~5
ingested.~3
(V22)~1
triseriatus~2
V22~2
revertant~1
V22M3,~1
V22M3~1
virus-vector~1
G1~1
arthropod~1
vector.~1
epileptogenesis~1
voltage-activated,~2
inactivating~3
Appearing~1
neurite~1
dendrites,~1
labile~1
voltage-activated~3
"DNA~1
fingerprint"~1
hypervariable~2
minisatellites~2
hybridize~1
blots~1
individual-specific~1
insert-free,~1
M13~4
bacteriophage~1
competitor~1
15-base~1
bacteriophage.~1
fingerprinting~1
laboratories.~2
mollusc~1
voltage-clamp~1
neocortex~1
G-peroxidase~1
inundated~1
Blood-borne~1
occurring,~3
vivax~6
trypanosomiasis,~1
hinders~1
livestock~4
continent.~1
posing~1
industries~1
congolense.~1
(VSGs)~1
stock~1
(46,000)~1
[3H]myristic~1
trypanosomes.~1
Hin~2
recombinase~1
inversion.~1
synthesized.~1
31mer~1
helix-coil-helix-binding~1
26-base~2
52mer~3
Hin-mediated~1
14-base~1
"half~1
site."~1
Nuclease~1
epitope.~1
acetylation~2
c,~1
discontiguous,~1
discontiguous~1
Deregulation~1
plasmacytomas,~1
immunocytomas,~1
Burkitt~1
retrovirus~2
(J-3)~1
plasmacytomas~2
pristane-primed~1
BALB/cAn~1
karyotyped~1
translocation-negative~1
J-3~1
transcribed.~1
plasmacytomagenesis~1
3.5-kilobase~1
Overexpression~1
(trisomy~1
disease-like~1
possibly,~1
reservoir,~2
injection;~1
assured.~3
expanded,~1
postgastrectomy~1
bilious~1
enterogastric~1
constituents.~2
diversionary~1
gastritis;~1
modification.~2
cytoprotective~2
symmetrically.~1
audiometry~3
unremarkable.~1
FDA~2
reality~1
Cincinnati~2
coinvestigator~1
reaming~5
reamed~1
diaphyses~1
reamer.~1
pass.~1
(~2
8.3)~3
piriform~1
Jacksonville~1
(Fla)~1
(48.7%)~2
Florida.~3
(56.75%)~1
Substernal~1
lye~2
injurious;~1
steroids;~1
2,325~1
1,517~2
underlay~1
mesh.~3
concern,~4
cost-effectiveness~3
by-products~1
Bowman~1
Gray~1
infradiaphragmatic~3
seminoma.~1
preorchiectomy~1
beta-HCG~1
folk~3
Root~1
thriving~1
philosophies~1
supernatural.~1
(G6PD)~1
1,478~1
(728~1
girls)~2
G6PD~2
(5.6%)~1
(2.2%)~2
engendered~1
anxieties~1
fears.~1
rushing~1
emotions~1
adversity.~1
cross-cultural~2
"humanistic~3
attributes"~1
culturally~1
Totalitarian-Authoritarian-Dogmatism~1
Faculty~1
traditions~1
attitudes:~1
traits"~2
self-reported~5
scores;~1
Baylor~1
"age-drag"~1
fulminans.~1
1,870~1
130%).~1
vitamin-K-dependent~1
VIIIC,~1
Presently~1
(Coumadin)~1
Munchausen-by-proxy~2
costly,~2
dangerous,~1
artery-middle~2
penumbra~1
concept.~3
(PVCM)~1
stridor,~3
PVCM~2
dense-core~1
endocrine-type~1
hypereosinophilic~1
Smoldering~1
hypereosinophilia~1
MAT~6
paroxysms~3
Components~1
kyphosis,~1
lordosis,~1
40-year~1
skeletally~1
progression:~1
thoracolumbar,~1
Pre-brace~1
20-59~1
Cobb.~1
in-brace~2
discontinuance,~1
pre-brace~2
5-15~3
bracing;~1
apexes~2
T8~4
L2~1
best,~3
superstructure~3
T7.~1
quadraplegia~1
bradycardic~1
unopposed~2
C1-C2~1
instability:~1
reducible,~1
irreducible,~1
subaxial~1
dens~2
latencies.~4
complication);~1
non-union~2
unpreventable~1
treatable);~1
nonsurgery-related~1
(unavoidable~1
irreversible).~1
Countermeasures~1
T11~1
sacrum.~2
frustrations~1
single-stage~3
Failures~1
decompensation,~1
lordosis.~1
chylothorax~9
years:~1
VDS,~1
Chylothorax~1
corsets~2
corset,~2
chairback~3
molded~2
thoracolumbosacral~2
(TLSO)~2
(flexion,~1
twisting)~1
sitting.~2
no-orthosis~1
TLSO~2
corset.~1
orthosis.~2
corset~1
worn,~2
worn.~1
discectomy~2
(Hs),~1
(D),~1
(Hy),~1
Psychopathic~1
Deviate~1
(Pd),~1
Psychasthenia~3
(Pt),~1
Schizophrenia~2
Important~6
unduly~3
Contralateral~4
Vertebrobasilar~1
IIIAB~3
metastases)~2
treatment--those~1
(PLND)~1
PLND~1
PLND;~1
hypercalcemic.~1
0.38.~1
hypercalcemic--7.5~1
505~3
roentgenography;~1
jaundice;~2
centimeters;~1
compositional~2
milliequivalents~2
(HSL)~1
HSL~4
Hypernatremia~2
sodium:~1
hyperosmolarity~1
osmolarity:~1
milliosmoles~1
kaluresis.~1
osmolarity~2
aggressively.~2
thrombogenesis.~1
metal,~1
silver.~2
Silver~1
biphasically.~1
885~1
Nazionale~2
Tumori~2
4.7,~1
nonradical~2
unilobar,~1
hemihepatic~2
intrabiliary~1
plication~1
Heartburn~1
parts.~2
conveniently~2
Menghini~1
Jamshidi~1
plunger~1
throw~1
adjustable,~1
marble,~1
stenoplasty~1
secured.~1
pulseless~1
hypesthetic~1
periodically.~1
1925;~1
predicability~1
needless~1
dehydroepiandrostenone~1
6,600~1
transdural~1
electrodense~1
adventitia-tunica~1
stemming~1
Sarcomatous~2
9-18~2
electively;~1
malformation--a~1
preoperational~1
ventriculo-peritoneal~1
hematoma;~1
admission;~1
another--a~1
pregnancy--was~1
(SFCs)~1
1013~2
SFC~5
(17%).~4
SFC.~1
SFCs~1
glioblastoma~7
microspectrophotometric~2
Cytofluorophotometric~1
neurinoma~1
lifting,~1
Preexisting~1
referrable~1
One-fourth~1
recoveries.~1
surmised~1
lenticulostriate~2
chondromyxoid~2
fibroma~2
heralded~1
abducens~2
syringomyelic~1
Tomograms~1
nasoseptal~1
craniopharyngiomas,~1
transbasal~2
T6-7.~1
receiver-stimulators~2
cages~1
encircling~2
antennae.~1
cavitation,~1
ependymal~2
myelin.~2
beyond.~1
ventriculitis.~2
Children,~3
Toronto,~3
myelodysplasia.~1
overdrainage~1
Monro~1
discussing~2
90th~1
ventriculomegaly~3
meningomyelocele~1
shunting;~2
shunting.~4
spasmogen~1
xanthochromic~1
spectrophotometrically.~1
spasmogenicity~1
greatly,~4
antagonistic,~1
angiospasm~1
level--whether~1
rise--seems~1
hemorrhage--perhaps~1
leukotrienes--will~1
roots.~1
disclosing~1
calvarium~3
squama~1
craniometaphyseal~1
quadriparesis.~1
tall~5
craniomegaly,~1
valgum,~1
46,XX,t(12;18)(q13;q12)~1
Subluxation~1
C-3~2
laminectomies~2
glioblastoma.~1
aware,~1
feeders~1
embolization.~7
(ICSC)~1
ophthalmologist.~2
ICSC~4
typifying~2
ICSC,~1
improperly.~1
bored~1
Partially~1
norms,~2
testable~1
15-~2
35-month-olds~1
(RASBI).~1
RASBI.~1
cebus~2
polyglycolic~1
(PGA)~1
sewn~1
apron,~1
bowel's~1
PGA~2
gone.~1
RASBI~1
pancreatectomies,~1
duodenopancreatectomies,~1
pancreatectomies)~1
Puestow~1
cysts).~1
21%.~3
pseudocysts,~2
procedures).~1
diversions,~1
Reoperations~2
duodenopancreatectomy.~1
Hemorheologic~1
nailfold~6
(RBC)~5
phenomenon;~1
acrocyanosis~2
twofold),~2
(fourfold~1
fivefold).~1
Nailfold~1
acrocyanosis,~1
nomenclature~3
(AAA).~2
1.4%;~1
revascularization,~3
surgery--almost~1
double-~3
triple-vessel~2
interest;~1
bothersome~1
needle-to-suture~4
3:1.~1
polypropylene,~1
1:1.~2
Theoretically,~1
needle-hole~2
midpoint~1
end-to-end,~1
graft-to-graft~1
12.46~1
polypropylene~3
4.32~1
polypropelene~1
1.94~1
(5-0~1
prolene~1
needle),~1
33.35~1
two-tailed~1
indicate,~2
pull-off~1
sutures'~1
qualities.~2
Tense~1
(nephrogenic~1
ascites)~1
(DPVS).~1
DPVS,~1
Ventilatory~2
Shunt-related~1
DPVS.~1
nephrogenic~4
mesoatrial~5
vexing~1
hypercoagulable~1
retrohepatic~2
cavoplasty~2
26-month~1
submit~1
Harvey~1
(MSV)~1
MSV~2
1,2~1
(DMH)-induced~1
DMH,~1
base/kg,~1
Moloney~1
(MSV-M)~1
focus-forming~1
DMH~7
MSV-M~2
MSV-M.~1
tumors/rat,~2
pedal~5
Orthopedic~1
country's~1
Cardiothoracic~1
34%.~1
conveys~1
message.~1
"unnecessary"~1
supplier-induced~1
inbalance.~1
gallstones.~4
(CCK).~1
cholecystography~1
CCK-22,~1
nonsulfated~1
gastrins.~1
Emtobil~1
sorbitol)~1
"test~1
meal."~1
gallstone~19
1722~2
(13.5%)~3
Candidemia~1
candidemia,~1
(15.7%)~3
population).~1
candidemia~1
Norepinephrine-induced~2
intimal-thickened~1
deendothelialization~1
unsedated~1
(2.4%~2
(7.6%~1
1.7%).~1
0.0025.~1
cross-section~1
1.9%.~2
14.5%~1
denudation,~2
(2%~2
hypocalcemia)~1
glycerol~10
stores,~2
bearing.~2
Catecholamine,~1
(NTB)~1
bearing,~1
NTB~1
regrew;~1
Reconstructive~1
well-accepted~2
Double-,~1
triple-,~1
quadruple-loop~3
debatable.~1
antidiarrheal~1
takedown~1
pouches~2
disadvantages,~1
cystoenterostomy~1
superseded~1
hepaticoenterostomy~1
devastated~1
Suppurative~1
pylephlebitis~3
era,~2
nonspecificity~1
pylephlebitis.~1
rebleeding,~1
undoubtedly~1
panacea.~1
antifibrinolytic~5
predicated~3
good-condition~1
complaining~6
keystone~1
pre-dating~1
154),~1
cardiomegaly~1
154).~1
16,204)~1
5.7).~1
7.9).~2
4.4),~2
22),~1
"hypertensive~1
hemorrhage"~1
Subcortical~3
(ILs)~1
ILs~5
Multivariable~2
Diabetes,~1
nonneurologic~2
cutting.~1
arteriosclerosis,~1
spaces,~2
ectasia~1
"etat~2
crible"~1
Shrinkage~1
atrophy)~1
ectatic~1
Gliosis~1
crible,"~1
cardiologic~1
post-stroke~1
non-depressed,~1
(CVD)~2
Taiwan~2
Japan,~4
CVD~7
1972-1983.~1
(5.0%-12.7%),~1
(47.1%)~1
assessment),~1
(40.1%)~1
Districts~1
infarcted~8
shaped,~1
("pseudo-infarct~1
islands").~1
chylomicron~1
non-embolic~2
Frederickson's~1
hyperlipoproteinemia~2
(12%),~4
normolipidemic).~1
family)~1
perfluorocarbon~4
FC-43~4
solubilities~1
twenty,~1
ten.~3
acepromazine~1
FC-43,~1
2/5~1
5/5~1
3/10~1
hetastarch-treated~1
FC-43-treated~1
.035).~1
survivability~1
(1H-NMR)~1
gerbils~12
(T1)~2
(T2)~1
FT-NMR~1
wet/dry~2
Naruse~1
vasogenic~3
(1/T2)~1
TET~1
edemas~1
Glycerol~2
(B-TG)~1
(PF4)~1
(TIA).~2
B-TG~3
PF4~3
7th~2
alpha-granule~1
133Xenon~1
analyser,~1
(meriones~1
unguiculatus)~1
("symptom-negative"~1
gerbils)~2
CA1~2
CA2~1
plasticity.~1
I);~2
pronounced,~1
post-ischemic~5
glycolysis,~1
H+/Na+~1
antiporter~1
ganglioside~1
GM1~5
(lCMRgl),~1
cat.~2
insult,~2
GM1-treated~1
non-treated~1
moderate)~1
flow-metabolism~1
pentothal.~1
(Co57,~1
Sn113,~1
Ru103,~1
Sc46).~1
neosynephrine~1
MAP.~2
mirrored~3
59.2~1
g/min~5
(SCBF)~2
SCBF~6
brainstem,~1
intraspinal~2
non-sympathetic,~1
non-cholinergic~1
VIP-immunoreactive~2
Well-innervated~1
nerve-mediated~1
VIP-containing~1
VIP-specific~1
P-specific~1
neurodilator~1
(SEP's)~1
SEP's~7
14%)~4
micro-emboli~1
baboons,~1
99-Technetium~1
size)~2
(LA),~1
trifurcation~2
(CA),~1
(CCI).~1
(CA~1
L).~2
0.032)~1
0.016).~1
ipsi-~1
microaggregates~1
TIA.~1
(TIA)~2
Endothelium~1
(pial~1
venules)~1
light/dye~1
Aggregation~2
arachidonate.~1
superfusing~1
antiaggregating~2
doppler~1
Xenon~1
reestablished.~1
outward.~1
upstream,~1
hypocapnia~2
prestenotic~2
ticlopidine~7
dual-tracer~1
indium-111~3
(PAI,~1
index),~1
(baseline~1
studies)~5
(aspirin~1
bid~1
22.3~2
tid~2
21.8~2
bifurcations~2
(%)~3
+13.9,~1
13.9%;~1
scintigram)~1
13.9%).~1
29.5~5
7.0,~4
baseline),~1
respectively.(ABSTRACT~2
hypercapnia,~7
iodo-[14C]antipyrine~1
6-hydroxydopamine~2
unlesioned~2
Hypercapnia,~1
hypercapnia.~3
non-relatives.~1
unit;~1
spouses.~2
in-law.~1
diabetes),~1
20.9%~1
in-law~1
barrelled~1
mini-electrode.~1
Determinations~5
(PCr),~1
DCR.~1
operation-associated~1
Angiography,~2
(18.5%);~1
take-off~1
(LSA).~1
Inflation~2
stereotypic~1
hemiparesis.~4
cm3~2
pressure-perfusion~2
formalin.~1
Evans~8
LSA~1
111In-platelets~1
MCA,~2
perfused-fixed~1
111In-platelet~4
2.8.~1
ml;~2
(10.8~1
units;~1
animals;~3
brain.(ABSTRACT~1
dolichoectatic~3
Vertebro-basilar~1
incidentally.~1
post-infusion~1
Recanalization~2
oxidase-linked~2
allopurinol,~1
righting~4
24-72~2
(SOD)-inhibitable~1
(NBT).~1
NBT,~1
SOD-inhibitable~1
(0.05-1.0~1
microgram/ml).~1
VIP.~2
(ml/min~1
S.E.)~1
cerebrum,~1
microM/min~1
2,3,5-triphenyltetrazolium~1
(TTC)~1
TTC~2
hematoxolin~1
E);~1
quantified.~3
TTC,~1
S.D.,~1
4.4%).~1
Staining~1
(CeBF)~1
(BCL).~1
autoregulation,~2
CeBF~7
52.1~2
58.9~1
autoregulations~1
BCL,~1
48.0~1
53.9~1
g/min.~2
abolished,~1
autoregulation.(ABSTRACT~1
hypoxia-ischemia~3
sham-ligated~1
hypoxic-ischemic~1
Hypoxic-ischemic~1
Hypoxia-ischemia~1
boy,~2
scan's~1
Lacunar~1
chorea,~1
hemichorea-hemiballismus.~1
"painful~2
spasms"~2
well-associated~1
Ophthalmoplegia~1
splint,~1
conversations~1
patient?~1
essay~1
so:~1
experiences;~1
abdication~1
authority~1
articles;~1
deduction~1
fallibility~1
frontline~1
Barnett,~1
Plum~1
Walton,~1
moratorium~1
striata~1
ligations.~1
3-hour~3
alpha-methyl-p-tyrosine~1
ergotamine~5
dihydroergotamine~5
migraine)~1
xenon-133~3
single-photon-emission~1
Strain-gauge~1
toe-arm~2
g/min):~1
ergotamine,~1
dihydroergotamine,~1
ergot~2
withheld~2
venae~5
cavae~2
chelator,~1
postischemia.~1
deferoxamine-treated~1
damaged.~3
multiinfarct~1
stroke-like~2
Hachinski~1
dementias.~1
(cortex,~1
nucleus)~1
7.13~1
0.02.~4
26.2~2
0.97).~1
Extrapolation~2
22Na~1
[3H]sucrose~1
80.8~2
(1.65~1
2.79~1
microliter/g/min,~1
hemisphere,~1
diencephalon.~2
Lumped~1
deoxyglucose~1
(Ci*(t))~1
[18F]-2-deoxy-2-fluoro-d-glucose~1
(18F-2-FDG).~1
(Cp*(t))~1
Ci*(t)~1
Cp*(t)~1
routine.~3
lumped~6
18F-2-FDG~1
nonweighted,~1
fitting.~1
4-hour-occlusion~2
k1*~1
k3*~2
1-hour-occlusion~2
(48%~1
Radiolabelled~1
misonidazole,~1
radiosensitizing~1
Biodistribution~1
right/left~1
hemispheral~1
ligations~4
congener~1
gamma-~2
positron-emitting~1
[15O]water~1
[11C]butanol~1
1.71~2
(SEP's~1
AEP's),~1
fore~1
AEP's~1
AEP's.~1
Remarkable~2
ischemia.(ABSTRACT~2
Survivors~2
(42%).~2
nimodipine~8
4-vessel~1
nimodipine)~1
3-point~2
Grades~1
nimodipine-treated~1
1,3-Butanediol~1
ketosis.~1
1,3-butanediol-induced~1
1,3-butanediol~2
mmol/kg)~2
Levine~1
exposure)~1
1,3-butanediol.~3
(241%~1
Scheffe~2
butanediol,~1
beta-hydroxybutyrate,~1
ask~1
central-nervous-system-derived~1
3-methoxy-4-hydroxyphenylethyleneglycol~3
(noradrenaline,~1
adrenaline,~2
dopamine),~2
Catecholamines~1
without,~3
noncomatose~4
3-methoxy-4-hydroxyphenylethyleneglycol,~1
strengthened~1
permanganate~2
monoamine~12
cored~1
29.2%~1
adventitia.~2
oxidase-containing~1
31.4%.~1
periadventitial~2
intervaricose~1
angiopathy.~2
beta-blockers.~2
0.60:1.00~1
0.14).~1
0.57:1.00;~1
0.12).~4
beta-blocker-treated~1
initiated.~2
ataxic~2
pontis.~3
son.~1
Fibromuscular~1
arteriopathies~1
Pulse-synchronous~1
1978-1985~1
alike,~1
panarterial~1
ectasia,~1
cerebri.~1
cascade,~2
enthusiastic~3
potentiators~1
provocative,~1
Recent,~1
stringently~2
drinking.~4
Submerged~1
reoxygenated.~1
Synaptic~1
Hyperexcitability~1
bath;~1
DC~3
neurons;~1
posthypoxic~1
hyperexcitability~1
Lehigh~3
Valley~4
Register.~2
600,000~1
Meterological~1
Oceanic~2
Atmospheric~2
Administration.~1
1,944~1
sine-cosine~1
wavefunction~1
65-74~2
75-84,~1
sine~2
June-August,~1
February-April.~1
computed.~7
2-month~1
-0.64,~1
premorbid~4
[14C]iodoantipyrine.~1
microns/ml,~1
noted;~3
hindbrain~1
normoglycemia~1
microns/ml~1
microns/ml.~1
Standardized~1
deformability,~1
filtered,~1
adhesiveness~1
Slowed~1
(PSC)~1
PSC~7
contractility)~1
Open-heart~1
1,377~1
occlusion)~1
(extracranial-intracranial~1
bypass)~2
55.8~1
382~1
g/l).~1
662).~1
(MEP's),~1
(SEP's),~1
(VEP's),~1
(AEBR's),~1
MEP's,~1
VEP's~1
AEBR's~1
ictus.~1
MEP's~1
ectosylvian~1
33.8~1
contralaterally~1
4-12~1
magna.~1
10(-7),~1
whole-mounted~1
photoelectric~2
K+-or~1
(10(-5)M)-induced~1
(10(-6),~1
Phentolamine~1
extraluminal~4
pressure's~1
K+-~1
(10(-7)~1
5-HT.~3
Ca++-induced~3
Hg.(ABSTRACT~1
granulocyte-platelet~5
concentrates~10
agitation,~1
storage,~3
lysozyme,~2
oxine~1
18.4~2
676~1
525~1
38.9~2
MNSs~3
anti-M~2
anti-N~2
125I,~1
MN~1
anti-M,~1
-S,~1
-s~1
absorption-elution,~1
washed,~1
centrifuged~3
phthalate~3
MM,~2
NN~2
anti-S~1
anti-s~1
Ss~1
ss~1
platelet.~1
Colony-forming~1
units-granulocyte/monocyte~1
byproduct~1
plateletapheresis~4
vials~2
polyolefin~1
vials,~1
handle,~1
store,~2
thaw~1
convenient.~1
Cryopreservation~1
thrombocytopenic,~1
leukopenic~1
heidelberg~1
heidelberg)~1
bags.~3
low-grade,~1
(CGD)~1
chemiluminescence.~1
Transfused~1
granulocytes.~2
continuous-flow~1
leukapheresis~1
CGD.~1
husband,~2
2100~1
2-aminoethylisothiouronium~1
dithiothreitol-papain~1
electropheresis~1
blotting,~1
"new"~1
K23.~1
agglutinated~1
anti-B.~2
deacetylation~1
leukemia;~1
(UDP)-N-acetyl-D-14C~1
crenation~1
knisocytes~1
dacryocytes.~1
C3-independent~2
(RBC),~1
C5b-9-dependent~1
antiglobulin~10
ghosts)~1
anticoagulated~6
IgA),~1
(IgA~3
C8,~1
C9,~1
serums~5
plates,~3
61-year-old~2
anti-Ge~2
alloantibody.~1
agglutinated,~1
Ge~1
autoantibody.~1
Anti-Jka~1
8-month-old~2
CLX~2
51Cr-labeled~5
well;~1
43.6~3
thin-film~2
8.52~1
bag,~3
bag.~1
container~1
Lu(b+)~1
kd,~1
Lub~1
N-glycosidically~1
bonding.~1
Uzbekskaya~1
SSR~1
south~1
Union,~1
anti-Dra~1
Dr(a-)~3
Cra,~1
Tca,~1
Esa,~1
IFC,~1
Cromer-related~1
Dra~1
Anti-Dra~1
Dr(a+),~1
Dr(a-),~1
Panels~1
computer-driven~1
panels.~2
donors,~5
numeric~1
databases.~1
menstruating~1
(nontoxic~1
powder),~1
Fe++);~1
(MCV),~1
protoporphyrin,~1
(TIBC),~1
TIBC.~1
TIBC~2
0.027)~1
Carbonyl~1
Percoll-Renografin~1
(PR),~2
2.6,~1
13.5,~1
quickest~1
perform;~1
centrifuge.~1
allergic-type~3
Serums~1
IgE-antibodies~1
oxide-human~1
oxide-protein~1
alloimmunization~3
Alloantibodies~1
phenotyping~1
matching,~1
Autoantibodies~3
Economic~1
payers~1
shifting~4
discussion.~3
diversify~1
reorganization~5
Marketing~1
consumer-oriented~1
"core"~2
transperineal~1
transrectal~2
routes,~2
Rectal~4
cleansing~3
shipped~1
akin~2
venipuncture.~1
Nonpalpable~1
biopsied~4
cost-effective,~1
Accreditation~3
fee~5
companies.~1
JCAH~1
AAAHC~1
accreditation~2
accreditation,~1
efficiently,~1
economically,~1
abbreviated-stay~1
lasers.~1
varicocele~8
varicocele.~3
embolotherapy~1
334~2
cost.~3
elected,~1
elect~1
vasoepididymostomy~3
huge~1
hydrocele~2
obscures~1
anesthesic.~1
injected,~1
Vasectomy~2
contraception~2
sterility.~1
epididymitis.~2
cut-fulgurate-and-cover~1
vasectomy~4
Manhood,~1
pleasure,~1
vasoepididymostomy,~1
My~1
Tables~2
Testicular~4
azoospermic~1
gonadotropins).~1
"no-touch"~1
Vasography~1
vasography~3
deferring~1
inordinate~1
ensue,~1
implantation,~4
poor-risk~4
qualified~4
anesthesiologists,~1
printed~10
telephone.~1
infrastructure~1
pleasant~2
intend~1
mandate~1
Simplified~1
Transvaginal~1
Pereyra~5
Probably~1
Raz,~1
cost-saving~2
nursing.~1
suite.~1
In-office~1
optimized,~1
happier,~1
scheduling~1
(premedication,~1
intravenous,~2
inhalational,~1
regional)~1
met.~1
readiness.~1
advantages,~2
"routine"~2
ever,~1
Long-acting~1
drowsiness~1
"light"~1
Composition~1
cystine,~1
monohydrate,~1
brushite~1
Perirenal~1
endourologic~1
ureterorenoscopy,~1
nephroscopy~1
Others,~1
nephrostomy,~1
nephrostolithotomy,~1
patient-management~1
Buffalo~3
1976-1985~1
nephronia~3
Gierke~1
hepatorenal~1
cystourethrograms~1
Lobar~3
predominated.~1
(staghorn~1
(A-V)~1
armamentarium,~1
Spongiosography~1
spongiosography~1
rechannel~1
pudendal~7
divert~1
spongiosal~1
fifty-year~1
applicability,~1
sophistication,~1
bench~1
eosin-stained~1
micrometer,~1
extravasated~2
Flexible,~1
deflectable~1
cystoscope,~1
introducer~3
Irrigation~2
distending~6
MAGPI~2
(meatoplasty~1
glanuloplasty)~1
Videoprostatectomy~1
avenue~1
noninvasively.~1
undefined.~2
shocked.~1
1,776,~1
4,500,~1
shocks,~1
18-24~3
kV.~1
1,600~1
(18-24~1
kV).~1
4,538~1
2,490.~1
Modest~1
(hematoma~1
(fibrosis)~1
forty-nine-year-old~1
skin-colored~3
verrucoid~1
acuminatum,~1
keratosis.~1
Seborrheic~1
acuminata.~1
Prader-Willi~3
hypotonia,~2
varies.~1
Individualization~1
Cryptorchidism~1
seventy-five-year-old~1
pyelogram,~1
ureterogram~1
midureteral~1
ureterectomy~1
uroepithelial~2
(HIS)~1
HIS~1
(117.5)~1
(61.1)~1
bladder).~1
Micturition~2
euthyroid.~3
Hyperthyroid~1
nocturia~1
debatable,~1
(IVU).~1
prone-position~2
filming~1
IVU.~1
elapsing~1
wave)~3
Goteborg,~1
Sweden.~1
reassessment.~1
(MPV)~2
(AMI),~6
non-coronary~2
(NCE),~1
(8%).~3
(LDH))~1
15-34~1
million,~1
10.1,~1
2.9.~1
(15-19,~1
20-24,~1
25-29,~1
30-34~1
Oslo~1
(1925-64)~1
(1970-77).~1
oncological~1
hypercalcemias~1
squamocellular~1
31%.~3
0-12.8~1
1.25-10~1
withdraw~1
flare-ups~1
Pyuria~1
microhematuria,~1
angiology~1
Danderyd~1
acrodermatitis~3
chronica~1
atrophicans~2
(ACA).~1
ACA~2
bluish,~1
discoloration.~1
subpapillary~2
augmented.~1
Borrelia~6
Borrelia.~1
Stillbirth~1
bereaved~1
Providing~2
pictures~1
certificate~2
grief.~1
traveler~2
ailment.~1
boil~1
punctum~1
seropurulent~1
serosanguineous~1
crawling~1
maggot~1
Ethylene~1
sensitizers~2
backup,~1
saves~2
Akathisia~3
Diphenhydramine~1
akathisia.~2
purpuric~1
thrombocytopoiesis~1
nonendothelialized~1
osteochondromatosis~1
recur,~1
synovectomy.~2
nonpathologic~2
astute~2
nodosum.~2
Sustained,~1
569~1
attempts;~1
VT.(ABSTRACT~2
nonsalvaged~3
(T1/2~5
Watanabe~1
(WHHL)~1
lumens~3
occluded,~2
afterdepolarization~1
(DAD)~1
automaticity~5
Triggered~2
amiodarone-superfused~2
Tween~1
80-pretreated~1
amiodarone-pretreated~1
DAD~2
(800,~1
1.8,~1
2.3,~2
(values~1
millivolts~1
Superfusion~1
micrograms/gm).(ABSTRACT~1
postcountershock~1
ectopy,~1
Shock~1
externally.~1
overdrove~1
shock-induced~4
break~3
postshock~3
mEq/L~12
reentry.~1
3-hydroxyquinidine,~1
trough.~1
3-hydroxyquinidine:~1
0.66).~1
3-hydroxyquinidine.~2
403~1
individualize~1
512-point~1
amplitude-frequency~1
single-rate~3
dual-chamber~4
Dual-chamber~1
excerise~1
L/min/m2)~1
dysrhythmias~8
Axial~1
filmed~2
posteroanterior/lateral~1
(PA/Lat),~1
oblique/60-degree~1
RAO/60~4
LAO)~1
angulated~2
35-degree~1
oblique/55-degree~1
oblique/30-degree~1
RAO/55~3
LAO/30~3
Cr)~1
Tracings~1
5.3,~1
PA/Lat,~2
LAO,~2
(SEE)~2
5.2,~2
LAO~1
SEE.(ABSTRACT~1
coordinate,~1
indexing~1
idealized~2
silhouettes~2
22).~1
globularity~1
systole.~1
Excessive~3
inferoapical~1
regions)~1
(diaphragmatic~1
zones)~1
dysfunction.(ABSTRACT~2
measurement.~4
52)~2
circumferences.~1
ponderal~3
habitus.~1
auscultatory~1
(WI)~1
hypervolemia,~1
WI~3
seated,~1
0.0020~1
atrium).~1
WI.~2
0.36.~1
defer~1
postradiotherapy~3
post-cardiac~1
postinfective~1
disease-related~6
Post-cardiac~1
1980-1985.~1
Postradiotherapy~1
1980-1985~1
4.75~1
Effusive~1
noneffusive~1
overall:~1
(21%).~3
likelihood,~1
S-T~4
T-wave~5
(NSA-ECG)~1
5127~2
NSA-ECG~3
non-ECG~1
ECG-MI~1
VPBs~1
influence.~4
Inclusion~4
chow-~1
counterpart.~1
compositions.~1
baboon.~2
lard~2
fat-containing~1
animals'~1
VLDL.~1
Peanut~2
VLDL-associated~2
lipid-poor~1
A-II.~1
Apolipoprotein~1
B100~4
spans~2
13,689~1
codon.~1
4563~1
510,000.~1
amphipathic~2
alpha-helix~1
beta-structure.~2
hydrophillic~1
beta-structure~1
alpha-helix,~1
chase~1
6%/min.~1
B100,~1
pathway.(ABSTRACT~1
receptor-dependent~5
LDL-cholesterol~11
Jm,~1
animal;~1
Jm~2
proportionality~1
overproduction~3
metabolism:~1
(HMG~1
CoA)~1
(regulating~1
biosynthesis),~1
(governing~1
formation),~1
acyl-CoA:cholesterol~1
acyltransferase~2
(ACAT;~1
esterification).~1
phosphatidic~1
125I-~1
131I-labeled~1
subfractions.~2
B-specific~1
hyperapobetalipoproteinemia~1
hyperapobetalipoproteinemia,~1
cholesterol-depleted~1
subfraction.~2
(H-TGL)~1
trioleoylglycerol~2
phosphatidylcholine.~1
mN/m,~1
H-TGL~2
mN/m.~1
2.6-fold~2
oleate;~1
(FHTG)~1
TG-enriched,~1
(VLDL),~1
(FCHL)~1
FCHL~3
subfraction,~1
denser,~1
buoyant~3
subfraction~2
catabolized~1
Lipid~4
frequently)~1
cholestanol~4
n-6~1
sterol,~1
etiopathogenesis~1
(SK)~1
inclusion.~1
(33%~2
(42%~2
multiple-vessel~1
kinase-MB.~1
SK,~1
SK.(ABSTRACT~1
1,730~1
454~1
2,151~1
dynes~3
cm-5~2
g-m/s2~1
significantly;~1
liters/min/m2~1
1,011~1
1,106~1
CHF.~3
predrug~2
CHF.(ABSTRACT~1
(IE)~1
(MVP)~1
MVP~7
IE.~2
murmurs~2
IE~6
murmur.~2
"semiopen"~1
noninstrumented~2
inactivity.~1
accelerate.~1
semiopen~1
2.6),~1
criss-cross~2
superoinferior~2
mirror-image~1
streams,~1
double-outlet~1
(EGG)~1
vectorcardiogram~1
(VCG).~1
VCG~4
3,266~1
entities:~1
538),~1
557),~1
323)~1
437)~1
390),~1
657)~1
364)~1
2,446)~1
820).~1
69.6%~1
69.4%~2
VCG.~2
set:~1
66.3%~1
67.1%~1
deleted,~1
entities,~2
classifiers.(ABSTRACT~1
lateral,~3
slit-like~1
equivalent:~1
diameters--23~1
(right),~2
(supine)~2
(left);~1
areas--4.1~1
(left).~1
0.85,~1
pressure).(ABSTRACT~1
nonrespiration.~2
(MTV)~1
MTV~2
MTVs~2
interception~1
(12.4~1
cm-2)~2
(9.2~1
orifices~1
(7.7%~1
9.0%)~1
nonrespiration~1
(14.5%~1
13.2%).~1
5.0%.~1
Interception~1
0.90).~2
(305~1
ml/s)~1
cm/s).~2
electrocardiograms.~2
Degree~2
atheromatosis~1
near-simultaneous~1
(Pulmonary~1
liter/min.~1
thinning,~1
images.(ABSTRACT~1
nonexercise~2
dipyridamole.~2
9-beat/min~1
12-mm~1
Noncardiac~1
lightheadedness~1
reocclusion.~1
aVR)~1
quantified;~1
(99%).~1
Leads~1
V1,~1
(MI)~2
0.15-Tesla~1
0.62).~1
High-fidelity~1
hemiaxes.~1
(29%,~2
(27%,~1
t1~2
[both~1
0.005],~1
(end~1
systole)~1
t2,~1
t2~1
(difference~12
videodensitometry.~1
Lucite~2
(AEM)~1
ischemic-type~2
anti-ischemic~2
1,154~1
hours/patient)~1
AEM~4
(episodes~1
longer)~2
AEM.~1
AEM,~1
CAD;~1
nondiagnostic~3
antianginal~2
CM5,~1
CC5~2
77%,~2
(reduction~2
amplitude)~1
(increase)~1
(39%~4
(54%~1
47%).~1
nitrates,~1
Dipyridamole-echocardiography~1
(echo)~1
administration):~1
1--early~1
2--late~1
3--negative~1
4a--negative~1
4b--negative~1
Rate-pressure~1
1/100,~1
4a~1
4b~1
(284~1
298~1
1/100);~1
overlapped.2+~1
dipyridamole-echo~1
mapping-guided~2
15-W~1
300-mu~1
ventriculotomy~2
Visually-~1
kinase-MB~2
IU.~2
mEq/liter)~3
(potassium~1
normalization.~1
unknown;~1
(Narula~1
method)~3
(decrease~2
(standing)~1
proarrhythmia~5
495~2
(VPCs)~2
VPCs.~1
VPC~2
VPCs/hour,~2
VPCs/hour~3
(0.04%)~1
VPCs/hour.~1
496~2
1%.~3
luminescent~2
aequorin~1
Isometric~1
stroke-prone~3
bis-(beta-aminoethyl~1
N,N,N',N'-tetraacetic~1
topics~3
detail:~1
myosins~1
hormone's~1
pretranslational~2
run-off~1
endocrine,~1
particularly,~1
myocyte.~2
micrococcal~1
II-exposed~1
chromatin,~3
extracorporally.~1
GFR,~2
diltiazem's~1
arteriole.~1
modulators,~2
groups--1,4-dihydropyridines,~1
phenylalkylamines~1
benzothiazepines--has~1
reversibly,~1
stereospecifically~1
Non-dihydropyridines~1
[3H]202-791~1
[3H]PN200-110~1
drug-receptor~1
inactivated.~1
openings.~1
entry-blocking~2
pharmacologic,~1
modulators.~2
posthemorrhagic~1
hyperlipidemia,~4
imposes~1
coincidentally~1
relegated~1
step-care~2
pressure-lowering~4
(verapamil~1
analogs)~1
(dihydropyridine~1
compounds).~1
Dihydropyridines~1
dihydropyridines,~1
entail.~1
guidelines,~2
first-choice~1
pharmacotherapy~2
provokable~2
expanding;~1
vasoprotection.~1
calcinosis~1
Postpacing~1
uptake/release~1
dipyridamole--2-dimensional~1
consensus.~1
Angina~4
Endocardial~1
472~1
dipyridamole--2-D~1
valuable,~1
(HR),~3
subanginal~2
workloads~2
Prinzmetal's~1
interruption.~1
reappear~1
arteries.(ABSTRACT~1
(PTT)~1
(associated~1
15-mm~1
changes),~1
PTTs.~1
transfusions.~2
doubled,~2
IU/liter)~2
AMIs~1
AMIs,~1
CK-MB.~1
erroneously~2
(2%).(ABSTRACT~1
acute-care~2
Worcester,~1
2,596~1
admission)~1
34%)~1
(13%~1
12%).~2
tapes~2
808~2
RR~3
inferior).~1
collateralized~1
68),~2
58),~3
nondilated~1
1,659~1
(CAD),~7
1,451~1
(area~2
72%).~1
58%),~1
PVS,~2
VF~6
(53%).~1
noninducible~1
concordance);~1
suddenly.(ABSTRACT~1
circus~4
electrophysiologists~1
tracing,~3
reviewer~2
alternation,~1
reviewers'~1
predefined~2
correct,~2
alternation.~1
alternation~3
(AF).~1
Anterograde~1
0.001];~1
Retrograde~2
diltiazem.~2
preexcited~3
AF~5
administration:~2
0.20),~1
minute.(ABSTRACT~1
(drug-free)~1
0.009),~1
infrequent--6%~1
respectively--and~1
SVT.~1
(mm~2
Calculated~3
valvuloplasty.~1
wire-guided~3
12Fr~1
2+/4+~1
conical~2
sizer,~1
valvuloplasty,~4
407%).~1
-0.57;~1
prevalvuloplasty~1
splitting,~1
commissures,~1
commissurotomy,~2
(AS).~1
echodensities~3
procured~1
Etiologic~2
radiodensities~2
planimetered.~1
Sensitivities~1
etiologies,~1
degenerative,~1
heaviest~1
lightest~2
cusp~2
0.82.~1
curvilinear;~1
transesophageal~10
AS,~1
Gorlin's~2
AS:~1
0.92,~1
0.0~1
0.1).~3
post-stress~1
85%).~1
86%).~1
handgrip.~1
nitroglycerin.~1
anuloplasty.~1
(MR).~1
anuloplasty~2
Carpentier~2
Duran~1
semiquantitate~1
half-time,~1
spectra.~2
249~1
(26%).~1
38,~2
24%)~1
originally.~2
25%).~1
307~2
14/101~1
17/89~1
14/103~1
13/93~1
ml/min/kg~2
mild-to-moderate~1
(101~2
ml/kl/min,~1
1-12~3
Rest~4
subgroups,~1
amyloid.~2
echogenicity~4
V6)~1
block),~1
echocardiogram.~1
(DSS)~1
DSS~1
cineangiography.~1
"membrane"~1
164)~1
40);~1
177)~1
DSS.~1
Senning~4
TGA~3
late;~1
operations)~1
TGA.~2
subpulmonic~1
obstruction).~1
Obstructed~1
(TAPVC)~1
TAPVC~1
212).~1
fenestration~1
Van~2
Praagh.~1
converged~1
underdevelopment~1
valve/mitral~1
aberrantly~1
(APSD)~1
APSD~5
halfway~1
trunk;~1
helix;~1
(distal)~1
preductal~1
TA~4
APSD,~1
TA.~3
pathogenetically~1
crest.~2
signal-averaging~1
electrograms,~1
status.(ABSTRACT~2
perioperatively.~1
double-orifice~1
developed;~2
acceptable,~1
3,996~1
6.39~1
teratogens,~1
mendelian~1
proceeds.~1
transmitral,~1
transtricuspid,~1
waveforms~8
Transmitral~1
transtricuspid~2
velocity/transmitral~1
(97.8%).~1
velocity/transaortic~1
hemodynamics.~2
overweight)~1
Preload,~1
kdynes/cm2)~2
Afterload,~1
persons:~1
kdynes/cm2~2
very-low-calorie~1
(420~2
kcal/day),~1
realimentation~3
kg/wk).~1
(LBM)~1
Best~1
very-low-calorie,~1
expenditure,~2
(RMR),~1
30-54~1
126%~1
kg/wk~1
RMR,~1
pre-diet~1
RMR~1
(kcal/h)~1
pre-study~1
1719~1
kcal/day~2
nutrient.~1
long-~2
(MCFA).~1
MCFAs~3
transesterification~3
energy:~1
reesterified~1
elongation,~1
normoglycemic~1
fat-poor~1
(diet~2
protein-poor~1
fat-rich~1
hyperglycemic,~1
diabetes-associated~1
Digestion~1
nonstarch~1
(NSP)~1
(dietary~1
fiber)~1
polysaccharide-free~1
NSP~1
Starch~1
digested,~1
recovered;~1
escaped~3
alpha-amylase~5
reheating.~1
cooked,~1
cooled,~3
reheated~1
potato,~1
lumps~3
finely~1
sieved~1
potato.~2
pancreatin~1
mid-small~3
5th~2
post-resection~1
(RBCs),~1
Finnish~9
glycerolphospholipids,~1
samples;~3
PUFAs~1
USA~1
glycerolphospholipids~2
fatfolds~1
Heavy~2
selenium,~3
10,532~1
1975-1978~1
37-87~1
exam,~2
selenium.~2
micrograms/L)~1
0.8-3.2).~1
0.5-2.6)~1
0.8-12.1).~1
strong,~1
615~1
Hawaii~2
Magnesium,~1
cautiously,~1
fruits,~1
grains,~1
iron-fortified~3
fortified~4
nonfortified~2
ashed,~1
ashes~1
bathophenantroline~1
disulphonate.~1
25.7%~1
iron/100~2
stool)~1
22.2%~2
stool).~1
(NOS)~1
carcinomas--they~1
NOS.~1
French-American-British~1
(FAB)~1
blasts,~1
dyserythropoiesis,~1
sideroblasts,~1
dysmegakaryopoiesis,~1
dysgranulopoiesis,~1
"abnormal~1
precursors".~1
(biopsies)~1
(marrow~2
smears)~1
FAB~2
cytopenia.~1
(MCV)~4
(RDW),~1
(ESR),~1
[a~1
further]~1
(iron~1
(anemia~1
disorders).~1
nonheme~2
0.55;~1
0.0004)~2
0.41;~1
0.37;~1
nonactive~1
store~3
Standards~2
Method~2
H20-T~1
Counter~1
Toa~1
E-5000,~1
checking~1
Geometric~1
Hematrak~1
eye-count~1
Neutralization~1
protamine~8
protamine.~2
"heparin~1
rebound"~1
heparin-protamine~1
hemolyzed~2
(PAIgG)~1
hemolysate~3
PAIgG.~1
Centrifugation~1
PAIgG~3
IgG-bearing~1
microspherocytes~1
co-isolate~1
Caution~1
semiautomated,~1
(FIA)~1
(CRP).~1
FIA~5
0.890,~1
nephelometric~2
0.886,~1
Westergren~4
0.356,~1
RF,~2
kits~1
kit~2
PregnaSTICK~1
Concept~1
Testpack,~1
mIU/mL~5
[IU/L]);~4
Icon,~1
Quest,~1
Nimbus,~1
Sensi-Chrome,~1
[IU/L]),~1
Icon~1
Branch~1
koilocytic~1
cytomorphologic~1
appears.~1
koilocytosis~2
Enolase~1
(E.C.~1
4.2.1.11)~1
permutations~1
sandwich~4
antirat~1
cross-reacts~1
avidin-biotin-peroxidase~2
alloantibody~1
2-35)~1
alloantibodies~6
"Type~1
Screen"~1
crossmatching~2
low-incidence~1
actuality~1
happening~1
define.~1
100,177~1
25,744~1
Febrile~1
nonhemolytic~2
51.3%~1
36.7%,~1
delayed-type).~1
non-oncology~1
half-year~1
(1976-1984),~1
12,652~1
lymphocytotoxicity~2
crossmatch~4
21-37~1
proficiency~2
South-Eastern~1
Procurement~1
Foundation.~1
336~3
(82.4%)~1
samples:~1
10,410~1
649~2
discordant.~3
(false)~1
(6.1%,~1
6.4%,~1
dispensing~1
trays~3
locally;~1
one-wash~1
three-wash~1
methods;~1
(monospecific)~1
(polyspecific)~1
(anti-HBc~1
IgM).~1
(SP-PHA)~1
(HBcAg)~1
SP-PHA~3
microtiter~2
HBcAg-sensitized~1
1:1,000~1
dilution,~1
68.18%~1
anti-HBc-positive~1
HBsAg.~1
End-point~1
I-converting~1
germinoma.~1
ACE.~2
tumoral~1
germinomas,~1
protocols,~2
start,~1
stop.~1
making;~1
treating.~1
Oct~2
nonmotorized~1
bicycles.~1
street.~1
stunt~1
going~3
bike~1
bicyclist~1
bicycling.~1
Accidents~1
asphyxia,~1
(32.1~1
(50.4~1
22.9~2
nonasphyxiated~1
9.9~3
(59.3~1
27.1~1
expanders.~1
beta-endorphins~1
abstracted~1
consenters~1
nonconsenters.~1
requester.~1
physician-requester,~1
prematurity,~1
requesting~2
permission~1
(HRV)~1
Rotazyme~2
HRV~1
(HRV+~1
HRV-negative~1
(HRV-)~1
Vomiting,~1
HRV+~2
HRV-~2
(590~1
HRV+.~1
2123~1
enterocolitis~2
(NEC)~1
(5.7%)~1
birth-weight~1
749~1
NEC.~1
NEC,~1
NEC~1
exposes~2
addicting~1
drug-dependent~2
prenatally~2
drug-exposed~1
very-low-birth-weight~1
(28.2~1
(986~1
1037~1
Calcium,~2
60-day~1
(104.4~1
mg/cm),~1
(7440~1
1090~1
7420~1
826~1
(66.9~1
(45.1~1
44.0~1
BMC.~2
Babson~1
(fra[X])~1
unrelated,~1
fra(X)~2
fra(X),~1
2133~1
Tucson.~1
Vehicular~1
playground~1
EITHER~1
OR~3
"marker"~1
recommendation.~1
retropharyngeal~2
specimen).~2
Fusobacterium~1
gamma-hemolytic~1
beta-Lactamase~2
(HI)~2
postnatally~2
17-year~2
HI~2
2(5.4)~1
2(6.9)~1
(3.4%)~3
reversion.~1
(HLH)~1
Turner~3
(45,X)~1
fortuitous~1
HLH,~2
HLH~1
nondysmorphic~1
HLH.~1
Branch,~1
possession~1
loaded,~1
unlocked,~1
choking~2
(58%~2
[11/19]).~1
Posteroanterior~1
(12/13)~1
(9/20);~1
(6/9).~1
croup~1
deteriorates~3
busy~2
(PICU)~1
PICU.~2
3.4%.~1
PICU-acquired~3
pathogen.~3
Klebsiella-Enterobacter-Serratia~1
(20.5%)~1
mortalities.~1
Infected~4
PICU~2
King's~5
carinatum~1
syndrome's~2
Noonan's~1
mL/kg/h~1
effecting~2
523~1
contacted.~1
18,728~1
(children~1
credit~2
92,640~1
child-days.~1
7.02%~1
4.29%~1
11.30%~1
non-day-care~1
pediatricians.~2
(PDA)~1
[mean,~3
weeks];~1
1680~1
g])~1
constricted,~2
PDA~4
infants;~2
PDA.~1
(580~1
reopening~5
foreign-born~3
third-world~1
adoptees~3
immunizations~1
scabies~1
lice~1
anomales~1
lactose~6
rubeola,~1
varicella,~1
mumps.~1
lip-palate~1
repair;~1
preadoption~1
visit,~2
CMV-infected~2
(12/32;~1
38%).~1
Stepped~1
(0.1%)~2
vital-capacity~1
Histograms~2
bimodal~5
distribution:~1
nonasthmatic~1
asthmatic.~1
bronchoconstrictor~3
autosomal-dominant~2
heartburn,~1
half;~1
corticosteroid-dependent~1
tapered,~1
course:~1
dinner~3
asthmaticus;~1
benzocaine~1
spray~2
pharynx.~2
no-signal~1
exterior~3
stone's~1
1979-1985~1
(nasogastric~1
tube/rectal~1
tube/enemas)~1
(CDT)~1
13/17~1
(3/7~1
cicatrization~1
lobatum.~1
Radioisotopic~1
submassive~2
42-yr-old~1
propylthiouracil~7
Microscopy~1
(there~1
products),~1
propylthiouracil-induced~1
hepatomegaly.~1
dysautonomia~2
hiatal~2
fundoplication,~1
subsided,~2
Power~2
(Talwin)~1
tripelennamine~1
(pyribenzamine)~1
midwestern~1
convulsions,~2
heroin~3
"heroin-associated~1
nephropathy."~1
effacement~2
non-heroin-using~1
addicts.~1
IgA-IC~3
(simultaneously)~1
IgA-IC,~4
IC,~1
IgG-ICs~2
Raji~1
Multimeric~1
(polymeric~1
monomeric)~1
IgA-ICs~4
intermittency~1
Polymeric~1
IgA-IC.~1
dialytic~7
discontinuation.~1
(I),~2
(II),~1
(HPTH)~1
(PTx).~1
PTx.~2
HPTH,~1
(1.51~1
(1.01~1
Io~2
HPTH~6
PTx~4
TGs~1
2.22~2
1.46~2
(1.17~1
(1.61~1
PTx.(ABSTRACT~1
histologies~2
iPTH,~1
OHD,~1
hemodialyzed~1
osteodystrophy.~1
histology;~1
69.0%,~1
osteoidosis.~1
30.1%,~1
hyperosteoidosis,~1
Hyperosteoidosis~1
(20.9%),~1
aluminum-containing~1
binders~1
hydroxide.~1
hyperosteoidosis~2
micrograms/L.~1
exit-site~1
(ESIs)~1
(2,052~1
ESIs~3
ESIs.~2
cryoprecipitate,~1
epsilon-aminocaproic~3
Discontinuation~3
nonhemophiliacs~1
nephrograms~2
Dyazide~2
nonoliguric~1
(weeks)~1
crystal-laden~1
triamterene-induced~1
(6.1%~1
surface).~1
2/mm2/d).~1
g/d~2
mucormycosis.~1
Echocardiogram~1
transplants,~1
pseudotumors~1
fistulae.~2
exudate.~2
prevalent.~4
exist,~1
(ADPKD)~1
ADPKD,~1
90.8%~1
24.1%~2
Nonneoplastic~1
pyelonephritis.~2
(indocyanine~1
dye)~1
triplicate;~1
formulas.~1
Hemodynamics~3
Furosemide~1
-13%~1
2.2%~4
6.76~1
6.17~1
.10).~2
mL/min,~1
furosemide.~1
Persistently-elevated~1
14-year-old~4
streptozocin-induced~3
glomerular,~1
L/24~1
rechallenge,~1
beta-glucosidase~1
colinear~1
beta-Glc~2
cDNAs.~1
67,000,~1
64,000-61,000,~1
58,000)~1
(CRIM)~1
CRIM~9
non-Jewish~1
N-Glycanase.~1
[3H]Br-conduritol~1
epoxide,~1
beta-Glc,~1
immunoblots.~2
beta-Glc.~1
Ataxia~1
multi-system~2
6-phosphate~2
nonhemopoietic~2
2-deoxy~1
double-enzyme~1
Mediterranean-type~1
stem-cell~2
enjoyed~2
adenosyltransferase~1
odd~2
716~1
15-40~2
methionine-oxidation~1
0).~2
high-Km~1
MAT.~1
hypermethioninemia~1
Autonomic~2
correspond,~1
Quiet~1
beats/minute~1
(11.1~1
78.2~3
four-hour~1
(220~2
(KL/KH~1
supercoupling~1
dysalbuminemic~2
hyperthyroxinemia,~1
euthyroidism~1
hyperthyroxinemia~1
Hypervitaminosis~1
(25-OH~1
D)~2
(1,25-OH2~1
Vitamin~8
CAGE~4
questionnaire--a~1
mnemonic~1
drinking,~3
annoyed~1
guilty~1
opener--was~1
transpeptidase~2
CAGE-negative~1
answering~2
"yes"~1
consumed.~3
Manual~2
abusers.~1
ambulatory,~2
retirement-home~1
Wintrobe~3
globulins.~1
mm/hour~1
0.55,~2
0.93.~1
hypoalbuminemia.~1
467~2
Non-Hodgkin's~2
1969.~1
Formulation,~1
Rappaport,~1
Kiel,~1
Lukes-Collins~1
plasmacytoid~1
cleaved,~1
non-cleaved~2
(Lukes-Collins);~1
organs--kidney,~1
pleura;~1
IE);~1
4,920~1
(8.7~1
City's~1
files)~1
peaking~2
anytime~1
daybreak,~1
A.M.,~1
somehow~1
subsamples.~1
Cerebrovascular~1
82),~1
Hyperparathyroid~1
nephrocalcinosis.~1
polyuria,~3
antedating~1
Randomized~2
morally~1
ethically~1
Alternate~1
designs,~2
practitioner's~1
risk/benefit~1
1,708~1
Bellevue~1
81.6~1
fl.~2
Literature-derived~1
(below~1
fl~1
73-year-old~2
normalized,~1
wasting.~3
Henoch-Schonlein~2
him~4
Pretibial~1
hyperthyroidism,~3
ophthalmopathy~8
pretibial~4
exophthalmos.~1
thyrotropin-releasing~2
Typically~1
keratinized,~1
dermatophytoses,~1
eruptions.~1
hosts,~2
multivisceral~1
dissemination,~3
subcutaneous,~1
rechallenge~5
Nephrotic~2
80-year-old~1
naproxen,~1
remitted~3
naproxen~2
minimal-change~1
polydipsia.~1
pancytopenia,~1
hypothalamic-pituitary~2
pancytopenia~2
microgram/kg/minute~2
(0.004~1
microgram/kg/minute)~1
vasopressin;~1
osmoreceptors;~1
mucositis.~1
methotrexate-induced~2
"subaortic~2
bump"~1
ankylosing~9
bivalvular~1
bump,"~1
polyserositis~1
plaquelike~2
fibrofatty~1
pericardium.~1
transfusion-induced~1
hemosiderosis~2
anephric~2
Dialysate~1
biliary/fecal~1
deferoxamine-induced~1
24-year-old~4
gynecomastia,~1
galactorrhea,~1
beta-human~3
nonrevealing)~1
search,~2
"cured."~1
(5.7%~1
Anticholinesterase~1
(anti-ChEs)~1
surfeit~1
hypotension;~1
anti-ChEs.~1
62.6~1
pyridostigmine.~1
anti-ChEs~2
beats/min),~2
near-syncopal~1
inflammatory,~1
infiltrative,~1
APGAR~1
59.1~1
25-93);~1
M:F~1
1:4;~1
(blacks:~1
Hispanics:~1
48%:31%:21%).~1
Categorizing~1
44.1,~1
inferolateral~2
myoglobinuria.~3
0.071~1
0.052~1
postdialysis~3
predialysis~2
(0.029~1
protein-energy~1
undernutrition~3
0.62;~1
midarm~1
0.71;~3
cases.(ABSTRACT~1
Estelle~1
Doheny~1
(67.0%)~1
(27.8%)~2
(38.4%)~2
(18.4%)~1
panuveitis.~1
(pars~1
planitis)~1
uveitic~1
(15.4%).~1
endophotocoagulation,~1
aphakia,~1
Psychophysical~1
Usher's~1
pigments~6
light-catching~1
pigments,~1
photoproducts.~1
photoreceptor-pigment~2
vision,~3
closed;~1
keratoconjunctivitis~1
sicca,~1
keratopathy,~2
keratopathy.~1
previously),~1
unobtrusive~1
eyedrop~1
electronically~2
S.D.~4
82.7%~1
pilocarpine.~2
84.3%~1
.012,~1
van~1
der~1
Waerden~1
defaulting~1
cocaine-intoxicated~1
slit~1
collarette~1
blowout~6
orbit:~1
"hydraulic"~1
"buckling~1
force"~1
69-year-old~1
Downbeat~1
downbeat~2
Neuroradiologic~1
parabrainstem~1
sheath.~2
beta-very~1
(beta-VLDL)~1
cholesterol/saturated~1
fat-fed~1
beta-VLDL~2
0-120~1
(U937)~1
beta-VLDL.~1
w-6~2
immunosuppressive,~2
B10.D2,~1
DBA/2,~1
C3B6F1~3
acids:~1
(POLY),~1
(MONO),~1
(SAT),~1
eicosapentanoic~1
(FISH).~1
B10.D2~2
DBA/2~2
methylcholanthrene~1
quarters,~1
POLY~5
pulmonis,~1
tractinoin,~1
methylcholanthrene.~1
immunosuppressed,~1
Antibody,~1
(ethylnitrosourea)~1
instillation,~1
MONO~1
pulmonis~1
FISH~1
"triggered"~1
tetrachloride~2
(pro-I~1
pro-III)~1
SGPT~3
pro-III~7
pro-I~1
(1028~1
0.886)~1
0.116).~1
extracellularly~2
alveoli,~5
immunohistochemical,~1
light-microscopic~2
myofibroblasts~2
gaps~3
coalescence~1
remodeled~1
Albumin,~1
Metaplastic~1
single-layered~1
keratin-positive~1
apoprotein-negative.~1
alveoli~4
alveoli.~1
AR2-20~1
AR1-28~1
RWP-1~1
RWP-2~1
200-kd~1
histochemistry.~1
E4~2
(LTE4)~1
LTE4~7
precursor,~1
LTE4,~3
ng,~1
ng.~1
blank~1
nonpeptidyl~1
venules;~1
bulged~1
wrinkled~1
thymomatous~1
monoclonals,~1
Hassall's~1
corpuscles),~1
epitope,~1
anti-cross-striational~1
biotinylated~1
visualant~1
acinar,~1
islet,~1
agglutinin-I,~1
glycoconjugates,~1
G-6-PD~1
monoclonality,~2
315),~1
steak~1
64)~2
[Z]~1
monoclonal,~1
Monoclonality~1
streaks,~2
monoclonality~5
0.016)~1
monoclonality.~1
unravel~1
endocular~1
(CECs)~1
(LCFs)~1
Hydrogen~1
(H2O2)~3
(MEM).~1
corneas~8
C/in~1
atmosphere.~3
Supernatants~2
Corneas~1
(G)/glucose~1
(GO)~1
(cytoplasmic~1
nuclei)~1
(via~1
checkerboard~1
[MCR])~1
MCR);~2
GO~1
LCFs~5
(5-15%~1
cornea-derived~1
G/GO~6
10,000-15,000~2
daltons).~1
daltons);~1
(1200-6000~1
CECs~3
corneas,~1
MCR)~1
LCFs.~1
wall--endothelial~1
monocyte/macrophages--secrete~1
factor-like~1
(PDGF-like)~1
30-kd~1
PDGF~4
c-sis~1
Hybridization~5
(HUVE)~1
HUVE~1
transcripts.~1
anti-PDGF~1
31-kd~1
16.5~7
PDGF,~1
homodimer.~1
distributional~1
return;~1
reoxygenation~1
subepicardium;~1
energy-requiring~2
(active)~1
reperfusion;~1
sarcolemma's~1
(this~1
scavenged~1
irreversibility);~1
flocculent~1
cognitive-developmental~2
Piaget~1
Werner.~1
blends~3
feelings.~1
temperamentally~2
temperament~2
IQs,~1
well-replicated~1
"doom~1
anxiety,"~1
confusional~1
contend~1
doom~1
mistakenly~1
"understandable"~1
random-sample~1
1,423~1
therapist-patient~1
29.6%~1
Psychiatrists~1
peers~2
attitudes.~1
termination;~1
rationalized~1
Jamison-Farabee~1
decree~4
psychiatrist's~1
rights~7
refusal,~1
Outside~2
denial;~1
competency~3
justice~1
proceedings~1
Commitment~1
Statute,~1
responsibilities~3
makers~1
dangerousness~2
commitment.~1
involuntarily~1
danger~4
Diverse~1
interpersonal,~1
environmental,~3
switches~2
insomnia,~3
self-reinforcing~1
1,006~1
905)~1
362)~1
Fagerstrom's~1
875~1
184)~1
403)~1
Concordance~2
overinclusive~1
unnatural~1
diagnoses;~2
inpatients.~1
(88.2%)~1
1-mg~1
Inventory,~1
15-24-year-olds~2
(35-64~1
preadolescents,~1
propositions.~1
(voices~1
acts,~2
hallucinations,~3
commands.~1
seclusion.~1
commands~1
voices~1
subvocalization.~1
hallucinated~1
suggestion.~1
subvocalized~1
120)~2
62)~1
hyperserotonemia,~1
akathisia~3
tartrazine~2
(FD&C~1
antidepressants.~1
weight-for-age~5
height-for-age~5
679~1
22-59~1
Companiganj,~1
Bangladesh.~1
Overreporting~1
(proportion~1
identified)~1
height-for-age,~2
artifactually~1
95,647~1
widowed~2
1972-76~1
cause-of-death~1
files,~1
1976.~3
7,635~1
225,251~1
Cause-specific~1
bereavement~2
bereavement.~1
two-fold~3
women),~2
widowhood.~2
widowed,~2
26-day~1
person-to-person~1
Norwalk~2
gastroenteritis,~1
Norwalk-like~2
immune-electron~1
Whites.~3
Inferences~1
nutrition)~2
Promoting~1
Health,~1
Nation,~1
specifies~3
1990.~1
Territorial~1
Directors~1
territorial~1
funds~1
Women,~1
Infants,~1
(WIC)~1
Grant.~1
objectives.~1
Achievement~1
programming~2
householders~2
(HHW)~1
disposal.~1
HHW~2
fining~1
disposal~2
HHW,~1
endorse~1
tax~1
finance~2
disposal,~1
Alameda~2
(California)~1
60-94~1
deviating~1
breakfast.~2
dentists,~1
dentists~1
advice-only~1
four-step~2
smoking;~1
reminder~2
stickers~1
charts;~1
gum~16
reminders~2
gum.~3
1,091~1
647~1
dentists.~1
thinness~2
Kaiser~2
Permanente~2
checkups~1
"thin"~1
(decile~1
"average"~1
(deciles~1
40-79~1
Thin~1
2.6)~1
(R.R.~2
2.1,~3
C.L.~1
Unmeasured~1
Thinness~1
(HCHO)~1
(eye~1
nose/throat~1
rash)~1
HCHO~4
respondent,~1
manufactured~4
Housing~1
Urban~2
(HUD),~1
part-time.~2
person,~2
confidants,~1
post-injury~1
brucellosis~2
biologicals~1
Girona,~1
Spain.~1
Brucella~7
melitensis,~1
Rev-1~1
serology,~2
(attack~1
melitensis~2
Employees~2
windows~1
extracting~2
39.5~3
oven~3
exterior.~1
oven.~1
Brucellae~1
spouse,~1
veto~4
Guidance~1
Ethiopia,~1
Courts~1
violate~2
privacy~2
judgements~2
reinforce~2
nondiscrimination~1
constitutions~1
Convention~1
Forms~2
Women.~1
rights,~1
remedies~2
ministerial,~1
legislative,~1
judicial~1
initiatives.~1
pet~1
deworming~2
customers.~1
Toxocara~2
canis~6
Isospora~2
anthelminthic~1
store.~2
555~1
deaths/1,000~1
reproductive,~1
contraceptive,~1
Socioeconomic~1
bra~1
abortions~13
.72~1
.54~1
smaller.~1
484~3
Vail~1
Aspen/Snowmass,~1
Colorado,~2
giardiasis.~2
Vail,~1
giardiasis~3
filtrates~2
Aspen/Snowmass~1
Aspen~1
Snowmass~1
waterborne~1
Patient's~3
ex-smokers.~1
Montreal:~1
33.4~1
10,000,~1
pedestrians,~2
passengers,~2
bicyclists.~1
MAIS~1
pedestrians.~1
Pedestrian~1
passenger)~1
Varus-valgus~1
(DOF)~1
varus-valgus~4
DOF~3
(varus-valgus~1
proximal-distal,~1
medial-lateral~1
translation),~1
(171%)~1
anterior-posterior~3
translation).~1
MCLs~1
femur-MCL-tibia~1
(FMT)~1
(healing~1
site)~2
FMT~1
Ice~1
hockey~3
scan-positive~2
(49.1%),~1
tarsals~1
(25.3%),~1
metatarsals~2
(8.8%),~1
(7.2%),~1
(6.6%),~1
(1.6%),~1
sesamoids~1
16.6%~1
oldest,~1
youngest.~1
mileage~1
96).~1
Tarsal~1
Varus~1
Radiographs~2
9.8%.~1
206)~1
180),~1
military~7
recruits.~1
realized.~1
site-dependent.~1
Technetium99~1
Gymnastics~1
wrestling,~1
softball.~1
gymnastic~1
(1982-83)~1
conducted.~4
clubs~2
(2,558~1
participants)~1
student,~1
warm-up~1
2,016~1
(5.3~3
competitors~1
beginners).~1
chronic.~2
vault,~1
springboard.~1
dismount.~1
(fatigue)~1
gymnast~1
breaststroke-related~1
kick~4
rearward~1
thrust.~1
Disagreement~2
derangement(s)~1
"breaststroker's~1
knee."~1
pathobiomechanics~1
breaststroke~2
Descriptive~3
surveying~1
nonbreaststrokers~1
hamstring~3
cinematographic~2
noninjured~2
initiation,~1
breastroke~1
diskogenic~1
down-lineman.~1
weightlifting~1
Tentative~1
skiing,~1
skiing-triggered~1
reactivations~1
(SPF)~1
Reactivation~1
Tampere~1
Station~1
(TRSSM)~1
sports,~2
DEC-2060~1
Tampere.~1
814~1
soccer,~1
long-distance~2
orienteering.~1
totalled~2
337~1
(62%);~1
top-ranking~1
(266~1
33%),~1
(80,~1
(71,~1
sprains~1
751~1
filing.~1
TRSSM.~1
activity-induced~1
strained~4
Remaining~2
70.5%~1
74.5%~1
92.5%~2
Aggressive,~1
soaks,~1
buddy~1
taping~1
followups~1
Rio~5
provinces,~1
Argentina,~1
1982-1983~1
(WEE)~1
epizootic.~4
Totals~1
153,084~1
Province~2
2,351~1
WEE,~1
Venezuelan~4
Antequera,~1
Maguari,~1
Melao,~1
vesiculovirus~1
(Calchaqui),~1
Gamboa.~1
WEE~2
albifasciatus,~1
albitarsis,~1
Mansonia~1
Psorophora~1
pallescens.~1
49,707~1
15,961~1
Negro,~1
2,019~1
Chubut~1
mosquitoes,~1
Turlock~1
(TUR)~1
TUR~1
bait~1
trap.~1
(DEN)~2
Bangkok,~1
Bangkok~1
DEN-2~4
Blood-engorged~1
25-day~1
temperature-induced~1
Bangkok.~1
antigen-specific.~1
anti-dengue~1
(IgM-IC).~1
IgM-ICs~4
DEN-1,~1
-2,~1
-3~1
1:20~1
DEN-4~1
react.~1
type-specific.~1
post-exposure~1
immunity,~3
rabies-endemic~1
practicable~2
vaccines,~1
(HDCSV)~1
Vero~1
(PVRV).~1
HDCSV~1
single-site~2
eight-site~1
economy,~1
stomatitis~4
(VS)~1
VS~3
1982-1983.~1
Epidemiological~2
herds~1
Junction,~1
Colorado.~2
Entomological~1
premises~2
northwestern~1
Insect~1
Culicoides~1
midges,~1
variipennis,~1
stellifer~1
(Selfia)~1
Culicoides.~1
1982-1983,~1
Veterinarians,~1
Insight~1
antibody-negative~1
sneezing~2
serosurvey~1
horses~4
cattle.~1
Neutralizing~1
VSNJ~1
stomatitis-affected~1
Rocky~1
Mountains~1
veterinarians~1
ranch.~1
pasture~1
Horses~1
pens~1
barns~1
foals~1
foal~1
dam's~1
(Melanoconion)~1
taeniopus~1
"enzootic"~3
allopatric~1
"epizootic"~2
bloodmeals~2
20-22~1
refeed~1
(CECPFU),~1
10(5.5)~1
IABC~1
CECPFU;~1
10(5.0)~1
CECPFU.~1
sympatric~1
subspecies~3
isomerase,~2
phosphogluconate~1
CAE~1
identities~2
intracomplex~1
pairings.~1
ecology,~2
trophozoites.~1
gerbils;~1
post-infection;~1
trophozoites~1
post-infection,~4
Gerbils~1
post-infection.~5
recrudescence~2
unsuccessfully~3
nonsterile.~1
rangeli~4
cruzi,~1
hemoflagellates~1
epidemiologically~4
stocks~9
sylvatic~1
Rhodnius~1
prolixus,~1
cruzi~3
sympatrically~1
transmitted.~1
isocitrate~1
(ICD),~1
stocks.~1
ecologic~2
malayi~1
mosquitoes.~1
microfilariae's~1
to:~3
midgut,~1
exsheath~1
mosquito.~1
2-day-old~2
larva-infected~1
Circulatory~1
excretory-secretory~2
Excretory-secretory~1
biotin-conjugated~1
antigenemias.~1
Ixodes~3
dammini,~1
white-footed~2
Peromyscus~1
leucopus,~1
spirochete,~1
burgdorferi.~3
Nymphal~1
dammini~3
xenodiagnosis).~1
spirochete~1
prepatent~1
Hamsters,~1
too,~1
dammini.~2
formally~2
burgdorferi~6
spirochete.~1
A/g~1
rads).~1
colons~1
mitigated~1
evacuability~1
pressure-sensitive~2
scintigraphically.~1
volume)~1
-0.70;~1
-0.41,~2
Inefficient~1
Wirsung~5
Oddi.~3
sphinteroplasty~1
Tonometry,~1
tonometers~1
Intramural~2
429~3
Nissen~1
fundoplications~1
29;~1
18;~2
enterocutaneous~2
each;~1
dehiscence,~1
Fundoplication~1
(8.8~2
archived,~1
mucosae~2
segmentectomy~2
Infectious~2
resections;~1
Roux-Y~1
pancreatojejunostomy~11
pancreatojejunostomy)~1
pancreatojejunostomy,~1
claimed.~1
mucosa-to-mucosa,~1
pancreatojejunal~1
Restoration~1
pancreatojejunostomy.~1
appendectomy,~4
haemodilution.~1
irrigant~1
619-1582~1
1360~1
glycine.~1
dilutional~1
hyponatraemia~1
salts,~2
prilocaine,~1
12-13~1
8-9~2
400-mg~1
prilocaine~1
elective,~1
313~4
emergency,~2
Ranitidine~1
alkalinisation~1
8.9).~1
labouring~1
antacid~1
between-patient~1
pethidine~5
Nalbuphine~1
pethidine,~1
vein/maternal~1
(0.78,~1
(0.61,~1
nalbuphine,~1
Vecuronium~2
pumps~5
investment~1
Travenol~1
infusor~1
ml/hour,~1
infusor.~1
(NP)~1
equieffective~1
NP~6
m-2)~1
(14.4~1
m2).~3
pressure-diameter~1
(Ees),~1
(231.6~1
81.7~1
g-1).~1
NP,~1
Controlled~5
acting,~3
NP.~1
Onset~2
(+/-SD)~1
pollicis.~1
(TH)~1
TH~1
min.)~1
Bupivacaine-induced~1
HEPES-Liley~1
supramaximally~1
anesthetic-induced~1
isobaric~4
pin-prick~1
[body~1
height-squared~1
(m2)],~1
PEF,~1
undisturbed.~1
nitroprusside.~2
(microgram~1
"sensitivity."~1
slope),~1
0.766,~1
-0.791,~1
vasodilating~4
Whatever~1
Advisory~1
(Forane)~1
1981-1984.~1
nonanesthetic~1
infection)~1
intubated;~1
(MAP),~1
(PCWP),~1
5-French,~1
thermistor-tipped~1
(EVLW).~1
(COP),~1
COP-PCWP~2
(Qsp/Qt)~1
ml/15~1
parameters--cardiac~1
PCWP,~4
MAP--were~1
MAP,~1
EVLW~1
EVLW.~1
protonation~1
pKa~5
octanol:buffer~1
(P+)~1
(Po)~1
spectrophotometry~2
strengths,~1
Corroboration~1
potentiometric~1
(7.61~1
7.94~1
(8.06~1
0.165~1
(8.28~1
buffer).~1
Octanol:buffer~1
protonated~3
fractions)~1
warning:~1
2666~1
202,~1
3210~1
272,~1
Ionic~1
octanol~1
cooling,~1
MAC)~1
30-60~2
preinduction~4
HR),~1
HR.~5
morphine)~1
plain;~1
Observations~3
extraarachnoid~1
spinaloscopy~1
ease,~1
bevel~2
18-gauge~5
Tuohy~3
reemphasize~2
transportation~3
50:50~2
oxygen-air~1
Preoxygenation~1
(iv~1
isoflurane-induced~4
(electromagnetic~3
probes)~3
(PR,~1
intervals)~1
pancuronium.~3
282~4
0.2%),~3
(1.15-1.35%~1
Catecholamine~2
(dP/dt),~2
6/6~1
verapamil-propranolol~1
4/6~2
diltiazem-propranolol~1
block.(ABSTRACT~1
Sufentanil~2
(heart~1
(cortisol,~1
alertness~1
[PETCO2],~1
[delta~1
PETCO2]).~1
sufentanil~4
sufentanil-N2O~1
fentanyl-N2O~1
hypocapnea~1
drive.(ABSTRACT~1
(newborns)~1
23.8~1
(0-7~1
carotid,~2
(1.2%,~2
(2.4%,~1
4.0%),~1
(1.6%,~1
3.0%)~2
500-700~1
(300-400~1
(clinical)~1
methohexital~3
(helium~2
dilution)~1
lubricant.~1
significance).~2
rebreathing,~2
l/min/%~1
Respitrace~1
ribcage~4
(end-tidal~2
FCO2~1
9-10%).~1
dimunition~1
ribcage/diaphragm~1
(atelectasis)~1
ventilation/perfusion~1
2-5%~1
(unchanged~1
state)~2
1-19%~1
0.84,~2
3.7%,~2
PEEP~3
solitarius~1
(NTS)~1
decerebrate,~1
NTS~2
(spikes/s)~1
severed.~2
55.3~1
Hypercapnia~1
NTS;~1
H2-receptor~4
famotidine~1
pD2~1
relaxation)~1
n;~1
eq~1
3.20~3
2.95~2
0.14,~2
(10(-5)M),~1
low-concentrations~1
H2-antagonists~1
(potentiated).~1
H2-receptors~1
morphine,~3
(pethidine),~1
rigidity)~1
subcutaneous-to-epidural~1
lipid-to-water~1
solubility.~2
reexamine~1
postinduction~1
continuously,~3
wash-out~1
half-times~1
Procaine~1
rate-responsive~2
TX~4
senses~2
Implantation~3
implantation:~1
Bicycle~1
bpm,~1
(rest:~2
liters/min/m2,~1
7.34~1
liters/min/m2)~1
hypocalemia~1
sotalol~2
bretylium,~2
N-acetylation~2
(NAPA).~1
NAPA~22
(NAPA)~1
chloralose-urethane~1
Walton-Brodie~1
infusion)~3
involved;~1
discounted.~2
NAPA's~1
vagolytic~1
catecholamine-mediated.~1
Dreyfus~1
(NAPA),~1
Drayer,~1
Reidenberg~1
Sevy~1
elimination-phase~2
standpoint~2
NAPA,~1
individualizing~1
Antiarrhythmic~1
N-acetylprocainamide,~1
H-V~1
protected.~1
breakthrough~1
titration.~1
platinum-multiwire-surface~1
Kessler~1
Lubbers~1
tissue-pO2-pressure;~1
8-wire~1
Pt-wire-diameter~1
Pt-wire~1
microns.~4
proportioning~1
measuring;~1
histograms.~1
pO2-histogram~1
quasi~1
inquiry~3
(sterilization,~1
presentation)~1
bypass-surgery.~1
R-wave~5
Precordial~2
V1-6~1
2.0mm~1
19.03~1
5.81mm;~1
2.0-1.0mm,~1
11.42~1
5.99mm;~1
1.0mm,~1
5.21mm~1
1.0.~1
V1-6,~1
0.5mm~1
0.537~2
0.883)~1
twenty-five-year-old~1
Kearns-Sayre~1
torsades~1
pointes~3
"ragged-red~1
fibers"~1
Gomori~1
mitochondria:~1
gian~1
(NMI),~1
NMI~6
Heparin,~1
hyperaggregable~2
TXA2;~1
hyperaggregable,~1
AMI;~1
hyperaggregability;~1
sixty-nine-year-old~1
arteritis,~1
(KS)~1
cytomegalovirus.~3
KS~1
expectoration~1
broncholiths,~1
varix,~1
Agenesis~1
hemoptysis,~1
twenty-nine-year-old~1
lymphangiograms.~1
zone:~1
incoagulable~1
lymphagogues,~1
CLS~2
2210.~2
lymphagogues~1
1.51~1
.93;~2
Coughing~1
ignored.~1
Asthma~2
pollens~3
pre-seasonal,~2
seasonal,~3
post-seasonal~2
non-atopic~1
ferns~1
ferns.~2
ferns,~1
non-atopic,~1
hyposensitization.~1
olive~1
buffy~9
intracardially~1
reinjected~2
degranulated~3
clinician.~1
773~1
291~3
MI;~1
ED,~1
IU/L).~1
(DAP),~1
(DAVD),~1
(MAVD).~1
vasopressors~1
two-minute~1
high-compression~1
(HCF)~1
IAC-CPR,~1
HCF~1
DAP~1
HC-IAC-CPR~1
MAVD~1
HCF-IAC-CPR~1
IAC-CPR~1
DAVD.~1
asystole~1
DAVD~2
appreciably.~1
unnecessary,~2
Northwestern~2
Spine~1
neuroradiologist.~1
tenderness;~2
mobility;~1
neck;~1
54%.~2
sample).~1
specialists.~1
certification.~1
internists~2
indexes:~1
autonomy,~6
satisfied,~1
Expectation~1
certification,~1
recency~1
square,~1
0.35;~2
internists.(ABSTRACT~1
Support,~1
Prehospital~2
557,700.~1
3,184~1
runs.~3
weekends.~1
1:00~1
9:00~1
PM.~1
1,196~1
bypassing~1
30-month-period,~1
498~1
score;~3
(ISS);~1
TRISS~1
times;~2
(discharge~2
hospital).~1
square-mile~1
(TPT)~1
arbitrarily~1
(1,~2
TPT~1
(0-20,~1
21-30,~1
31-40,~1
min).(ABSTRACT~1
untreatable.~1
mumol/g~1
dichloroacetate~1
(DCA)~1
(PGI).~1
PGI.~2
DCA~3
studied--PGI~1
PGI~4
lactate.~2
ischemia-induced~2
DCA-treated~1
(12.5~2
mumol/g)~2
(22.8~1
mumol/g,~1
necrosis.(ABSTRACT~1
20-gauge,~1
1/2-inch~2
13-gauge,~1
puppies~1
mL/min~6
20-gauge~3
endotracheally.~1
diazepam.~3
pathologist.~1
endotracheally,~1
Agitated,~1
threatening,~1
jeopardizes~1
IM,~1
Haloperidol~2
ED;~1
trauma;~2
inebriated.~1
110,~1
Disruptive~1
Methemoglobin~2
1-mg/kg~1
1.2%.~1
methemoglobin.~1
as-yet-undetermined~1
lidocaine-toxic~1
(TCA)~2
.86;~1
.89).~1
(QRS~1
59;~1
.76).~1
radiopacity~4
formulary~3
radiographing~2
radiodensity~3
radiodense~1
cadaver.~1
mnemonics~1
Chloral~1
hydrate,~2
iron-containing~1
carbonate,~1
acetazolamide,~2
busulfan,~1
Antihistamines,~1
phenothiazines,~1
radiopacity.~1
Merely~1
cassette~1
Visibility~1
KUB~1
pill,~1
pillmatrix,~1
pills.(ABSTRACT~1
(x-rays).~1
nine-year~3
nonpenetrating~1
dosimeter~1
badges.~1
Film~1
badge~1
86.2%~1
mrem/month~3
discipline.~2
expectation~3
seminars,~1
readings,~2
journal~1
clubs,~1
exhibits,~1
conferences.~1
care--field~1
aid,~1
casualty~2
clearing,~2
Disaster~1
System.~3
pneumomediastinum~1
Vasodilator~1
Urapidil~7
1-blockade~1
fostering~1
cis-4-hydroxy-L-proline~1
(cHyp),~1
(weighting~1
O2-90%~1
air-exposed~2
cHyp,~1
cHyp.~1
(RVP)~1
desmosine~1
RVP~3
cHyp~6
mg/artery~3
mg/artery.~1
hypoxia.(ABSTRACT~1
55.2~1
Uniphyl~4
Theo-Dur~2
15%)~6
Days~2
"trough"~2
Theo-Dur,~2
PEFR,~1
Uniphyl.(ABSTRACT~1
electrophysiology,~1
(theophylline~1
ethylenediamine)~1
522~1
(81.4~1
73.0~1
(40.7~1
(199.0~1
148.2~1
(391.0~1
325.0~1
(224.0~1
201.0~1
ERP.~1
presyncope~1
pain)~1
tone.(ABSTRACT~2
bronchitics,~1
GE~5
scintiscanning.~1
bronchitics~3
bronchitics.~1
scintiscan~1
(0.1N~1
HCl).~1
E4(LTE4)~1
(V30-P~1
V30-M)~1
(GSEM)~1
V30-P~2
(1.46)~1
0.058~2
(1.63)~1
39-fold~1
basenji-greyhound~7
aerosol,~2
nonvagal~5
Disodium~1
cromoglycate,~1
humidity)~1
(ventilation,~1
L/min)~2
(preexposure~1
exercise)~2
14.7,~1
H2O/s.~2
0.018)~1
alae~2
nasi~2
pressure/flow~5
W.~2
Erect~2
erect~2
plot;~1
steepens~1
(Vtr).~2
Vtr,~4
+14.4~1
+14.1~1
+14.2~1
Voluntary~2
-1.3~1
L/min).(ABSTRACT~1
nasopharyngoscopy~1
(72.2%)~1
eminences,~1
interarytenoid~1
boggy,~1
edematous~3
posture.~2
tetraplegia~1
(C4-C7)~1
(Th4-Th7).~1
(16.0%~1
(11.2%~1
consistent,~3
(29.1%~1
(37.6~1
Inflating~1
straps~1
changes.(ABSTRACT~1
(OSAS).~1
OSAS,~1
nonrapid~1
(NERM)~1
one-night~1
time/cycle~1
(Tl/Ttot)~1
swing),~1
(TTdi)~1
TTdi~2
0.195~1
0.045~1
0.153~1
0.037);~1
genioglossus,~1
protrusor~1
(Vl),~1
(EMGdi),~1
(EMGgg)~1
goats;~1
Vl/delta~1
0.087~1
L/min/mm~1
0.069)~1
(0.57~1
0.078,~1
awake).~1
EMGdi/delta~1
NREM,~2
NREM).~1
EMGgg~2
(49.3~1
awake,~1
REM),~1
EMGgg/delta~1
(phasic~1
REM).~1
subject:~1
progesterone)~3
apneas.~1
"compliance"~3
snorers,~1
weight-matched,~1
(0.12~1
H2O-1;~1
cm2;~2
(ART)~1
infer~4
yr;~1
ART~3
area-distance~1
aligned,~1
2.45~1
2.56~1
Z~1
0.92;~2
0.0001.~1
(Mo)~1
Mo-T~2
cocultures~2
Mo~5
Generation~1
ACE-inducing~1
T-dependent~2
CM-dependent~1
go~5
Mo-derived~1
evokes~1
pyogranulomatous~1
Macrophages~3
collected,~1
donors'~1
Antigen-induced~1
avium-intracellulare~3
nonresponders.~6
(2.4~1
(7.3%)~1
(15.9%)~2
appear.~1
(29%~2
overall).~1
(proved~1
biopsy)~1
implication.~1
bronchoscope~8
aeroallergen~1
challenge)~1
relavaged~1
T-lymphocytes.~1
Characteristically,~1
eosinophiles~1
T-cells~2
Peroxidase-staining~1
phagocytized,~1
subjects.(ABSTRACT~1
O2-exposed~1
emphysematous~3
leftward~2
fluid-filled,~1
lathyrogen~1
beta-aminopropionitrile~1
hyperoxia,~4
3',5'-guanosine~1
GMP)~2
GMP,~1
GMP.~1
mesothelial,~1
endothelial,~1
histamine-stimulated~1
32-yr-old~1
dusty~1
T-lymphocyte~3
sarcoidlike~1
mineralogic~1
blastic~2
berylliosis~1
(aluminum~1
lung).~2
(MCBN)~1
MCBN~2
sympathomimetics~1
asthmatics.~1
histoplasmoma.~2
histoplasmoma~1
re-exploration~3
2,271~1
(3.1%)~1
re-explored~2
crossclamp~2
Sternal~4
ml/hr~1
tumors:~1
female;~2
surgery--three~1
sternotomy.~2
survived;~1
metatarsals,~1
heel,~1
(47.8%)~1
(96.6%).~1
hopeless.~1
Thomas~3
Nashville.~1
(distal~1
80-91;~1
85).~1
neurospinal~3
non-arterial~1
obscured~8
(CCA)~1
CCA~1
phlebographically~1
floating,~1
free-floating~6
(13/26)~1
(2/13)~2
(7/26)~1
(1/8)~1
non-Hodgkin~1
leukemia-lymphoma~2
immunophenotypic~1
classifications,~1
helper/inducer~3
leukemia-lymphoma,~1
27,~5
HTLV-I.~1
smoldering~1
leukemia-lymphoma.~1
Tucson,~1
coccidioidomycosis.~2
Coccidioides~3
immitis~3
immunosuppressing~1
1:2048~1
Tucson~2
staging:~1
0.153).~1
0.074).~1
endoprostheses~2
percutaneous-transhepatic~1
similar-sized~1
percutaneous-endoscopic~1
(PEBS)~1
clogged~1
Pyrimethamine-sulfadoxine~1
pyrimethamine-sulfadoxine~2
pyrimethamine-sulfadoxine.~1
preadmission~3
biostatistical~1
"normality"~1
testing),~1
post-test~1
12-test~1
battery,~1
endorsed~1
Osteoporosis~1
journals~5
articles.~2
Assessments~2
explicit~2
syntheses.~1
articles,~2
criteria;~2
37).~1
identifying,~1
selecting,~1
43);~1
directives~1
identify,~1
assess,~1
chalazia~3
injections;~1
15.8%~1
Intralesional~1
easy,~2
medium-size~2
iridocyclitis.~1
amelanotic~1
workup,~1
see-saw~4
redness~3
sinusitis.~2
frontonasal~1
fovea~1
hole,~1
pseudovitelliform~1
maculopathy,~2
"null~1
zone"~1
(NCS),~2
dampen~1
(NBS).~3
orthotropia~2
large-angle~2
(NCS).~1
Radionecrosis~1
(grades~1
Chandler~1
classification)~1
radionecrosis.~1
(SGS)~1
(CHNMC)~1
decannulated~1
tracheotomy.~3
SGS~4
CHNMC~2
collated~1
SGS.~1
meaningfully~2
denervation.~2
Subglottic~3
Ulcerations~1
posterior-lateral~1
enough,~1
precise.~1
reservations.~1
frontiers~1
Just~1
fiberbronchoscope~1
neodymium:yttrium~2
laryngologist,~1
otolaryngology.~1
poliomyelitis,~1
exanthemata.~1
laryngotracheitis~1
supraglottitis~1
neuroectodermally~1
gastro-omental~2
self-cleaning~1
distensible.~1
tracheotomies~1
pharyngoesophagectomy~1
6,100~1
6,400~1
endarteritis~2
Myocutaneous~1
otolaryngologists~1
desires~1
unobstructed~3
ignition-free~1
relaxant,~2
besylate~1
microlaryngeal~2
pitfalls,~2
advantages:~2
emergencies;~1
turbinates,~1
Dysphonia~1
plica~1
ventricularis~1
phonation.~2
laryngoscopy.~3
dysphonia~1
(vicarious~1
unaccompanied~2
(usurpative~1
phoniatric~1
dysphonias~1
Bronchogenic~1
foregut.~1
bronchoesophageal~2
(gestation~1
(PT-VLBW).~1
PT-VLBW~2
deglutition~4
Contribution~1
classification;~1
dissection;~1
symmetry~4
cartilages,~1
folds;~2
epiglottis~1
cartilage;~1
myotomy;~1
Laryngomalacia~1
thrive,~2
cyanosis,~3
hyomandibulopexy~1
epiglottoplasty,~1
arytenoids,~1
corniculate~1
Epiglottoplasty~1
laryngomalacia.~1
Indications,~1
Stridor~2
Pittsburgh.~1
(17.5%)~1
Laryngoscopy~2
453~2
laryngomalacia,~1
paresis.~1
1,943~1
bronchocentric~1
acetylcysteine,~1
learning-~1
memory-related~1
interna.~1
oscillations~5
masticatory~1
oculomasticatory~1
myorhythmia~1
(OMM).~1
disjunctive~1
degrees/sec)~1
OMM.~1
olivary~1
pseudohypertrophy~1
OMM~2
presumptively~1
anterior-middle~1
recanalizing~1
sickling.~2
(JE)~1
Thailand;~1
4.2:1~1
suppressor/cytotoxic~1
roentgenography,~1
Myelograms~1
myelograms~2
ports~1
(93%).~1
strokes.~1
persistence,~2
details.~1
Attenuation~1
irregularity.~1
longitudinally.~1
nonhemoglobin~1
ghosts.~2
Chloroform-methanol~1
lipid-soluble~2
Non-lipid-associated~1
Shoulson-Fahn~1
dressing,~2
finances,~1
evolves,~1
Intellectual~1
Averaged~1
jerking~1
symptomatology.~2
workup.~2
willed~1
1-year-old~1
Werdnig-Hoffmann~2
longer-chain~1
(C10~1
C12)~1
3-hydroxydicarboxylic~1
Dicarboxylic~1
aciduria~1
Neuropathological~1
penicillamine-induced~1
anti-acetylcholine~1
serum-induced~1
AChRs,~2
AChRs.~1
AChRs~1
recovered,~3
penicillamine.~1
compacta~1
Leptospira~1
interrogans~1
serovar~1
bataviae~1
110-~1
bacampicillin,~2
cyclacillin,~2
piperacillin,~4
mezlocillin,~2
doxycycline,~3
chlortetracycline,~3
moxalactam.~2
Cephalexin,~1
cefadroxil,~1
cefamandole,~1
Leptospires~1
cephalosporins,~2
leptospirosis~1
(kala-azar)~1
parasitization~1
donovani.~1
Pentavalent~1
chemotherapy;~1
(AmB)~2
AmB~6
macrophage-directed~1
(liposomes)~1
(L-Amb)~1
hepatosplenic~2
L-AmB~3
parturient.~1
169.9~1
60.4~1
74.3~1
87.7~1
bregma~1
micromethods.~1
(chloramphenicol,~1
gentamicin)~1
days:~1
intravenously;~2
[standard~1
deviation]~1
liter):~1
(5.5),~1
(2.6),~1
(0.9)~1
3.12~2
(0.86),~1
(0.18),~1
(0.05)~1
bacteriostatic~1
(SBA)~1
JK,~1
Mycobacterum~1
fortuitum.~4
SBAs~2
indifferent.~1
antibiotic,~2
LY146032,~1
oxacillin-susceptible~1
LY146032.~1
MBC/MIC~1
4X~1
60-mg/ml~1
hematology-oncology~1
colonized,~1
carriage~2
ICR/CD-1~1
trichinosis~4
Susceptibility~2
serotyping~1
avium-M.~2
non-AIDS~3
brucellosis.~3
recreation,~1
petrochemicals,~1
pesticides,~1
insecticides,~1
Compositae~3
tanning~1
Personal~2
morphea.~1
(grade~4
scleroderma)~1
scleroderma).~1
morphea~1
well-defined.~1
pilosebaceous~4
(fT),~1
androgenicity.~1
fT~7
(12.7~2
pg/mL~4
[44.1~1
19.1~4
pmol/L])~1
(7.4~1
[25.7~1
pmol/L]),~1
(10.7~2
[37.1~1
pmol/L]).~1
hirsute~3
fT.~1
hirsutism)~1
acne.~4
hyperandrogenemia~1
eroded,~1
bacteremia,~6
Tohoku~1
Sendai,~1
gingiva.~2
male-to-female~3
lentiginous,~1
(MNCs)~2
MNCs~4
angiogenesis-enhancing~1
MNC~1
indurated.~1
(k-type)~1
Procollagen~1
1(l)~1
anagen-telogen~1
circumstantially~1
Preservation~2
telogen~2
pseudopelade~1
areata.~1
alopecia.~2
acantholytic~2
(TAD)~1
defervescence.~1
TAD,~1
TAD~1
borders.~1
eradicate~3
excising~1
well-demarcated~1
presurgical~1
genitalia,~1
velvety~2
(HPV-16).~1
HPV-16~1
scrofulaceum.~1
pyoderma~7
ulcerating~1
undermining~2
orbitectomies~1
canthal~3
morphealike~1
eyelids,~1
brow,~1
extramammary~3
fed,~1
mineral,~1
intergroup~2
rickets,~1
IU,~2
normalise~1
hypercalcaemia~3
quotients~1
(IQ)~1
spelling~1
Verbal~2
deviant~1
(unlike~1
paralysis)~1
neonate's~1
timing.~2
end.~2
(-0.71,~1
0.90,~1
Kuwait.~1
boiled~3
once.~3
re-admission,~1
re-admission.~1
re-admissions~1
unboiled~2
(unfiltered~1
mineral)~1
endocrinopathy.~1
Critically~1
stabilisation.~1
stabilisation~2
52.9%~1
Pakistani~1
typhoid~2
excretors~1
typhi.~2
dermatomyositis.~1
corticoid~1
(SM-C)~2
(Laron~1
dwarfism).~1
SM-C~4
Kd)~1
retinoblastoma~4
(8%),~1
41%.~1
retinoblastoma,~4
cancers;~1
radiochemotherapy,~1
handicaps~1
centiles~3
20,713~1
Electively~1
non-convulsive~1
regressing~1
epilepticus.~2
Scrotal~3
Edinburgh,~1
2818~1
hydroceles,~1
aetiology,~1
swellings~3
standardised~2
(3.5)~1
(3.6)~1
-2.8~1
(0.7],~1
2:~1
(2.8)~1
(1.4)~1
SDS~6
(0.8],~1
3:~2
(3.4)~1
-0.4~1
(0.8].~1
pre-exercise~3
(2.3)~2
mU/l,~2
(2.5)~2
mU/l).~2
mU/l)~1
(17.8~2
(3.0)~1
(20.8~1
Post-exercise~1
(34%~1
total;~1
post-exercise~2
stature:~1
stage;~1
SDS.~1
puberty.(ABSTRACT~1
Height~2
(SDS),~2
Pubertal~1
Somatomedin~1
interferences~1
54,041~1
38,102~1
2252~1
1158~1
subsided~2
taller,~1
heavier,~2
fatter~1
tachypnoea,~1
compliance;~1
Chloroquine~2
aspects--namely,~1
Roughly~1
prezygotic~1
inheriting~1
karyotype,~1
sub-band~1
13q14.~1
soaked~1
nursery.~1
(53.8%)~1
(69.2%)~1
cholangitis;~1
hospitalized;~1
requirements;~1
Cleveland.~1
21-73~1
prolonged,~2
25-122~1
disconnection,~1
secure,~1
choledocholithiasis~4
evisceration,~1
(completely~1
27.6%~1
(IMCS),~1
(DSRS),~1
gastrocaval~1
(GCS),~1
IMCS~1
DSRS,~1
foreshortened,~1
(INS)~1
INS~7
(INS~1
0.133~1
0.085~1
ex-vivo~1
Baboons~1
34.6~1
in-vivo~1
(Lewis-Tanner~1
operation).~1
Mediastinal~2
encroached~1
warranted,~1
(Tx)~2
(ATN)~1
(PG).~1
Anesthetized,~1
500-g~1
(I.V.)~1
mL/h~1
with:~2
101.9%~1
92.0%,~1
108.0%~1
105.4%~1
ATN~1
cyclo-oxygenase-treated~1
In-Service~1
Exam~1
(ABSITE)~1
curricular~1
(known)~1
(unknown)~1
Level~3
(entry)~1
(exit)~1
ABSITE~1
known-known,~1
unknown-unknown,~1
unknown-known,~1
known-unknown.~1
exit.~2
Weaknesses~1
incorrectly.~1
fibrillatory~1
(21.2%)~1
0.49,~2
0.35.~1
Intraaortic~1
(85.8%).~1
Nitroglycerin~1
(76.3%),~1
(48.0%),~1
preinfarction~1
(34.6%),~1
(11.0%),~1
(6.3%).~1
(0.8%).~1
90.8~1
2.9%.~1
1.12.~1
cryoablative~2
(Kent~1
bundle)~1
paraseptal~1
Cryoablation~1
abolishing~1
appendage,~2
(83.3%).~1
appendage~7
tachycardia.(ABSTRACT~1
417~1
non-drug-addicted~2
drug-addicted~3
methicillin~2
nafcillin~1
abstained~2
returns~3
reinfects~1
cure,~2
contraindicated.~2
June,~3
stations.~2
Three-year~1
Tulane~1
Charity~2
Orleans~1
esophagus;~1
wound).~1
bronchoscopy;~1
esophagoscopy,~1
esophagrams,~1
underwent,~1
(12.5%)~2
suture,~1
closed-tube~1
survived.(ABSTRACT~1
Neodymium-yttrium-aluminum-garnet~1
malignancy-induced~1
atelectasis/pneumonia,~1
27)~3
postlaser~1
17),~2
(3.4~3
months).(ABSTRACT~1
cocarboxylase~1
acetylcoenzyme~1
(acetyl-CoA)~1
(Tyers'~1
glucose),~1
ml/L~1
ml/L,~1
ml/L.~1
(83.3%)~1
1.(ABSTRACT~1
2,474~1
mitral-aortic~1
11.945~1
0.6-14~1
0.08%~2
replacements)~1
0.25-85~1
invasively~1
clotted~1
Rethrombosis~2
replacements).~1
low-profile~1
implanted.~1
cleaned~2
DeVega~2
85.3~1
8.2%.~1
annuloplasty.~1
(0.68%~1
annum).~1
organically~1
impalement~1
large-diameter~1
pipes~2
recuperated~1
Orderly~1
(TAPVD)~1
1;~5
TAPVD~4
faint~1
severe).~1
3-16~1
47-year-old~1
web,~1
atriocaval~1
Typical~2
emboli,~2
Intraoperatively~1
Recoarctation~1
Coarctectomy~1
noncircumferential~1
behind,~1
guidewires~2
implementation.~4
destination.~1
post-CT~1
hypouricemia~2
pyrazinamide-suppressible~1
uricosuric~1
probenecid~1
anyone~2
hypouricemia.~1
hyperuricosuria,~1
probenecid,~1
Postmyocardial~1
reinfarction.~2
infarct)~1
narrowed,~1
Armand~1
Trousseau~1
nonconcurrent~1
(DVT)~2
19.0).~1
phosphokinase-MB~1
False-positive~1
depressions.~1
tularemia~2
ulceroglandular~1
tularemia.~1
[58%]~1
waited~2
phosphokinase~1
Francisella~1
tularensis~1
(12.5%).~1
aminoglycoside;~1
(Chicago)~1
hepatoma.~1
(50.1~1
0.8s.~1
(4.3~3
(2.93~1
0.075~1
5.41~1
(1.35~1
0.088~1
nmol/L).~2
nonhyperparathyroid~1
hypervitaminosis~1
in-and-out~2
contaminated.~1
ecthyma~3
uncharacteristically,~1
nonbacteremic~1
narrowing,~3
(FNA)~1
nonthyroidal~2
Breast,~1
FNA~2
FNA.~1
atypical).~1
events:~2
(0%~1
(11.5%).~1
Aztreonam~2
aztreonam~1
superinfection.~1
exfoliative~2
(cis-platinum)~1
cancer-associated~2
cisplatin;~1
amebocyte~1
(LAL)~1
LAL~3
(sensitivity,~2
86%)~1
(cefazolin~1
ticarcillin~2
disodium,~1
piperacillin~1
trimethoprim/sulfamethoxazole)~1
CAPD,~2
Aug~1
Idaho;~1
fatalities.~2
station.~2
hepatitislike~1
threatening.~1
livestock.~1
underdiagnosed.~2
antisocial~6
personality,~2
"moderate"~1
Knowing~1
(cholesterol)~1
venograms,~1
entirety,~2
Jewish-Georgian~1
tartrate,~1
precrisis~1
labetalol.~2
hyperadrenergic~1
subtypes-manic,~1
bipolar,~2
depressive-were~1
(demographic,~1
premorbid,~1
morbid)~1
dimensions.~3
Schizotypal~1
(SPD~1
BPD,~2
Chestnut~1
Lodge~1
(pure~1
SPD,~2
81;~1
SPD/BPD,~1
cohorts.~1
(core)~1
suspiciousness/paranoid~1
ideation,~1
illusions/depersonalization/derealization;~1
impulsivity,~1
self-damaging~1
aloneness;~1
SPD~4
BPD;~1
psychoses~1
(GHQ),~1
(DIS).~1
GHQ~2
(major~3
dysthymia,~1
disorder).~1
nonpsychiatric~2
medical-surgical~1
amitriptyline~3
263,000~1
single-hospital~1
however:~1
Consultation-Liaison~1
System,~1
"early-onset"~1
diabetes:~1
course;~1
psychotropics~1
consultants'~1
consultees'~2
gestalt-seeking~1
Perturbations~1
breakdowns~1
"schizophreniclike"~1
"maniclike."~1
misperceptions,~1
associations.~1
randomness~1
"jumps"~1
gestalt~1
13q-chromosomal~1
[46,XY,del(13)(q22q31)].~1
atelencephaly~1
"lamellar~1
bodies"~1
adrenoleukodystrophy,~1
hypoadrenalism.~1
adrenoleukodystrophy~1
hemizygote~1
Baltimore,~1
1945.~2
grossly.~1
8-micron~1
"kink"~1
hydroureter,~1
hydronephrosis,~1
unopened~1
Exstrophy~1
cloaca~1
vestige~1
mesenterium,~1
knock-knee.~1
cloacal~1
Acetylcholinesterase~2
Auerbach's~1
aganglionic~3
envelope,~1
interspace~1
cell-to-extracellular~1
immunocytolocalization~1
Sirius~1
red;~1
fibronectin;~1
Disse's~1
numerous,~1
discontinuous,~1
piled~1
perisinusoidal~2
myofibroblasts;~1
fenestrae~1
junctions;~1
rarefaction~3
disputed~2
antigenemia,~1
Hong~1
Kong.~1
hepatitis-induced~1
(ITEC)~1
Minimal,~1
ITEC~3
proteinuria;~1
proteinuric~2
Intraglomerular~1
ITEC,~1
leukoencephalopathy~2
myelinolysis,~1
pontocerebellar~1
derangements,~1
intriguing,~1
lipodystrophy.~1
peroxisomes.~1
peroxisomal~1
Intramucosal~1
Adenomatous~1
5200~1
1983-1985~1
reader~1
knowledgeably~1
journals.~2
fatigue-related~1
plot.~1
remedial~4
self-control~1
self-instructional~1
verbalize~1
faded~1
verbalization.~1
off-task~1
problem-solving~1
postmeasures~1
Self-control~1
plan-ahead~1
self-verbalization~1
remediation~1
Generalization~1
real-life~1
(RSD)~1
watts/cm2~1
insert.~1
RSD,~1
sympathectomy.~2
(TCM),~1
TCM~3
handheld~1
expresses~1
gauge.~2
spasticity,~1
lumps,~1
(SCI)~1
(AB)~1
couples.~3
nondistressed~2
distressed~5
AB~2
couples'~1
recreational-social~1
posthoc~1
marriages~1
communications~7
substantive~2
videofluorographically~1
peristalsis.~4
videofluorographic~1
capability.~4
(vital~1
volume),~1
Minimally~2
sighted~2
Wheelchairs~2
knee-ankle-foot~1
(KAFOs)~1
KAFOs,~2
permitted.~1
KAFO~1
Former~1
(DRS)~1
Functioning~1
(LCFS)~1
LCFS,~1
DRS.~1
DRS~5
LCFS~4
raters,~1
Stover~1
Zeiger~1
(S-Z)~1
S-Z,~2
(GOS),~1
GOS~1
(EGOS)~1
GOS,~1
EGOS.~1
reliabilities,~1
validities,~1
surpasses~1
Rivermead~1
Inattention~1
(RBIT),~1
(20)~2
non-brain-damaged~1
RBIT~3
neglect.~3
RBIT.~2
Interrater~2
random.~1
inattention~1
noninattention,~1
21-month~2
2181~1
gown~3
spun-laced~1
(2.83%~1
6.5%)~1
3.8%)~1
(4.8%~1
11.4%)~1
Developed~1
Society,~1
stratifying~1
believability~1
404~2
hypersensitivity,~1
(culture-positive~1
17.3%).~1
70.3~1
0.8;~1
deciles).~1
(delayed-type~1
hypersensitivity),~1
(albumin~1
(contamination~1
immunoresponsiveness.~1
(DTH~2
coli);~1
carrageenan~1
(Vd)~1
immunoassay.~3
Vd,~2
Sawchuk-Zaske~1
0.121~1
L/kg~4
Vd~6
L/kg,~2
gradient-purified~1
(gating)~1
light-scatter~1
Subpopulations~1
subpopulations,~1
Burned~1
(HSR)~1
HSR~2
(Psqo2)~1
trials)~1
tonometer.~1
Psqo2.~2
Psqo2~2
reaffirm~2
mitogen-induced~2
(macrophages)~1
(macrophages),~1
monocytes/macrophages~1
(ICA).~1
emboli;~2
unproven.~1
opinions,~2
Bank~2
parietal,~1
putamen,~2
low-flow~5
migraine.~3
(Compton~1
scatter)~1
mL/100~1
g/min)~1
Armaly-Drance~1
Goldmann~1
(Octopus).~1
77.5%~1
perimetry.~2
perimetry,~2
paired-associate~1
(NC).~2
Mattis'~1
unequally~1
subgroup.~3
neuropsychologic~1
performance:~1
unimpaired,~1
"focal"~1
scans;~1
differ;~1
single-fiber~1
heart-rate~1
responsivity~1
acts.~1
leukodystrophy~2
(MLD)~1
MLD~3
MLD,~1
Metachromatic~1
arylsulfatase~2
porencephalic~1
4-month-old~2
(congenital)~1
(hypoplasia)~1
hemihypoplasia~1
nonclearing~1
bubble.~2
vitreopapillary~1
traction,~5
break.~1
tonometric~1
eye-bank~1
lensectomy/vitrectomy~2
Perkins'~2
applanation~4
tonometer,~1
tonometer;~1
tonometry~4
Schiotz'~2
indentation~2
tonometry.~1
delamination.~1
Balanced~3
Plus~2
(33/36).~1
double-masked~1
nonperforating~1
hyphema~1
aminocaproic~10
(Amicar),~1
g/d,~1
rebled,~2
rebled.~1
light-headedness,~1
hyphema.~2
(CNVMs)~1
(study~1
CNVMs~5
(comparison~1
CNVMs,~1
subfoveal.~2
subfoveal~4
size).~1
photographs)~1
769~1
(1486~1
extramacular~2
SS,~2
SB+~1
thalassemia,~1
3.7%.~2
78.2%~1
pucker~1
extra-macular~1
Epiretinal~1
stereo~2
(graded~1
exudates),~1
(evaluated~1
[FAZ]),~1
(whereby~1
calculated).~1
acuity;~3
FAZ~2
grading.~4
Cross-correlations~1
gradings~1
fluorophotometry,~1
maculopathy:~1
keratoscope~3
photographs,~2
photographs.~1
astigmatism.~4
blue-green~1
lamina.~1
vitrectomy,~1
attached.~1
reattachment,~1
five-day-old~4
14-day-old~4
laser-created~2
equator.~1
choriocapillaris~1
Muller's~3
14-month~1
choriocapillaris-filling~1
9-THC),~1
8-tetrahydrocannabinol,~1
cannabinol,~1
cannabidiol~1
miosis.~1
Bolus~3
ventriculocisternal~1
maleate,~1
vanadate,~2
(nonproprietary~1
colforsin),~1
photocoagulating~1
9:30~1
3:30~1
pneumatonometer~1
timolol,~1
pilocarpine,~2
reformulation~1
15-minute~4
0.01%~1
Ringer~2
Continued~4
180-minute~1
perfluoropropane~5
perfluoropropane,~1
retrocorneal~1
hexafluoride.~1
opsin~3
(1N~1
rabbits).~1
[20~3
eyes])~3
intramuscularly;~1
[22~1
mg/kg/d.~1
Ulceration~1
(17/20)~1
(9.1%~1
55%).~1
ulcerate.~1
Systemically~1
683~1
humor.~1
equipment/instrumentation~1
cart~4
accessibility,~1
mobility,~4
multiple-shelf~1
shelves~1
irradiation;~1
24-week~1
mg/kg/day,~1
12-week~3
assessments;~1
painful/tender~1
joints).~1
videotapes~3
Trained~2
Rheumatology~1
fellows~10
unpleasantness~2
fellows'~1
idiotype,~2
16/6.~1
anti-16/6~1
idiotype.~1
crossreact~2
single-stranded~1
polynucleotides,~1
cardiolipin).~1
16/6~1
(ml/minute)~1
(ml/minute).~1
calculate:~1
(mg/minute);~1
(ml/minute);~1
(protein~1
permeance).~1
(MRL/l)~1
arthritic~5
hindlimbs~1
MRL/l~2
Mac-1~1
(Mas~1
034)-positive,~1
macrophage-like~1
Ia-expressing~1
Ly-1,~1
Lyt-2,~1
GK~1
1,5,~1
antiimmunoglobulin~1
(2.5-3~1
50-foot~1
Ritchie~1
investigator,~1
(AIMS)~1
dexterity,~1
AIMS.~1
subscale~1
immunopathologic~2
RNP~1
(nRNP)~1
(ICs)~1
nRNP~1
coalitions,~1
tendinitis.~1
strikes~1
thiamin.~1
thiamin~7
beverages~2
transketolase~4
Thiamin~1
nontoxic,~1
beverages,~2
taste-testers~1
inter-subject~1
thiamin-requiring~1
disease.(ABSTRACT~2
1-Methyl-1,2,3,4-tetrahydro-beta-carboline~1
(1-MeTHBC)~1
6-methoxy-1-methyl-1,2,3,4-tetrahydro-beta-carboline~1
(6-M-1-MeTHBC)~1
chemically-bonded~1
glass-capillary~1
1-MeTHBC~4
6-M-1-MeTHBC~2
6-M-1-MeTHBC;~1
Salsolinol,~1
THBCs~1
acetaldehyde~1
Ethanol-induced~1
myocyte,~1
hypotonicity~1
(FAS)~1
Leiber-DeCarli~1
protein-derived~1
isocalorically~1
ethanol-fed~1
cytoskeleton:~1
Z-band~1
disarray,~1
granulofilamentous~1
Teratogenic~1
re-education~1
disulfiram~3
prescribed.~1
risked~1
disulfiram,~1
200-300~1
disulfiram.~2
treatment--usually~1
partner--and~1
sabotage~1
out-manoeuvre~1
maximised.~1
non-violent~2
offence.~1
drinking/drinking~1
crime~4
crime.~1
beverage,~1
companionship~1
Chacma~1
(Ca),~1
(Mg),~1
(Fe),~1
(Na),~1
Mg.~1
K.~1
system's~2
beats,~3
ml/kg/min;~1
44.5~1
oxygen/min/m2).~1
regionalization~1
28.~3
region's~1
department's~1
inadequacies~2
widespread.~1
teams,~1
parotitis~1
forceful~2
hay~3
(Tc)~1
hospitalization;~1
0.047~1
Nortriptyline,~1
advocating~1
overdoses.~2
(Quantab~1
titrators)~1
inflicted~2
methanol.~1
over-the-counter~3
inhaler.~1
Hypotension~2
systolic.~1
leads.~1
proportion.~1
medical-dental~1
Cephalometric~1
Frontal~2
cephalometric~4
condylar-only,~1
condylar-body,~1
noncondylar~1
clinical-dental~1
dentition~3
Pterygoid~1
nocturnal,~1
matures.~1
dentures~1
splints.~1
badly~2
"mini"~1
single-point~3
minicompression~1
Affiliated~2
Seattle.~1
trapezius~5
superior,~3
dependable,~1
Shaw~5
scalpel~6
Concerns~1
7-week-old~1
piglets.~1
Tensile~2
ultimately,~2
Varicosities~1
blemishes~1
electrothrombosis~1
insulated~1
27-gauage~1
Microfibrillar~1
(Avitene)~1
"tissue~1
clay,"~1
sculpted~1
contour.~1
clay~2
solidifies~1
palpably~1
Long-standing~1
esthetic~1
Xeroderma~1
superiorly~1
nasolabial~1
infraorbital~3
William~1
House,~1
Illinois'~1
far-advanced~3
otosclerosis.~1
tympanotomy~1
Case~4
palsy:~1
tick-borne~1
spirochetal~3
spirochetes,~1
ricinus~1
ticks,~1
95th-percentile~1
IgG-positive,~1
December.~1
(NED).~1
NED~2
aggressively~2
laser-related~1
Venturi~6
low-pressure~1
corroborates~1
viewpoint~2
expressed;~1
CHARGE~2
Mondini~1
CHARGE.~1
labyrinthine~7
alkaloids,~1
dioxide/oxygen~1
inhalations,~1
parotidectomy,~2
submandibular~5
non-efficacy~1
rhinoscleroma~1
ceforanide,~1
half-life,~2
ceforanide~2
bacteriologically~2
Second-~2
third-generation~1
rhinoscleroma.~1
impracticality~1
penems~1
monobactams,~1
ventilating~1
attic~2
retractions~3
tensa~3
membranae~3
tympani~2
tympanosclerosis~4
pexi~2
58.05%~1
cholesteatoma.~1
gauges~1
gerbilline~1
Cholesteatomas~1
11.88~1
Osteoclastic~1
Stapedial~1
(SEMGs),~1
electrocochleography,~1
SEMG~3
(Bell's~1
tumor),~1
stapedial~6
SR.~1
SEMGs~1
varicella-zoster,~1
rubella,~1
pneumatization~4
digitizing~1
tablet,~1
Nonpathologic~1
pneumatization.~1
narrowest~1
nasally~1
otolaryngologic~1
(ARc)~1
(ARn)~1
cancerous~2
ARc~2
ARn~1
ARc,~1
ARn,~1
ARn.~1
Deep,~1
(TDCs),~1
dermoid~3
TDC,~2
dermoid,~1
"mixed"~1
appendages)~1
TDC~1
(epithelial~1
follicles).~1
totipotential~1
"thyroglossal~1
anomalies,"~1
Jugulotympanic~1
things,~1
"paraganglioma~1
bone"~1
"bleeding~1
polyp"~1
Osteoradionecrosis~1
orocutaneous~1
sequestrectomies~1
mandibulectomy~1
osteoradionecrosis~2
repolarisation~2
aVF,~1
V2-V5~1
extrasystoles~3
post-pacing~1
died:~2
gallop~2
Downsloping~1
predictive.~1
(collateral~1
morning.~1
(midnight~1
am)~1
am.~2
groups--that~1
(1SD)~2
(17)~1
(14)~1
raising.~1
indices--fractional~1
change--were~1
dimensions;~1
fullterm~1
subjects),~4
ductus.~1
dome-like~1
mid-systole;~1
Dilated~1
leaflet,~1
offsetting~7
(septal)~1
offsetting.~1
leaflet.~2
akinesia~4
tachypnoea~1
aortogram~1
Senning's~1
underside~1
diazoxide~2
acrosclerosis,~1
acrosclerosis-diffuse~1
acrosclerosis~1
Antibody-dependent~1
(XP),~1
areflexia~1
254~3
XP~3
reactivate~1
UV-damage~1
adenovirus~2
cell-fusion~1
UV-damaged~1
multiforme~3
multiforme.~3
porokeratosis~4
'peeling~1
syndrome'~4
keratohyalin~3
four-fold~2
erythematous,~1
foliaceus~1
'tin-tack'~2
feature;~1
undersurface~1
foliaceus.~1
poxvirus~1
stranded~2
DNA-containing~1
somatomedin-C,~1
plaque-type~1
somatomedin-C~3
polycythaemia~1
vera.~1
Itching~2
myelosuppressive~1
(H1~1
H2)~1
Fusobacteria~1
facultative~1
Spirochaetes~1
cultured.~1
kilovoltage~1
X-rays;~1
(plaque~1
tumours;~1
erythroderma)~1
footpad~1
CBA/H~1
X-rays.~2
anti-macrophage~1
F4/80~1
Birbeck~2
dendritic.~1
granule-containing~1
F4/80-positive~1
rounded,~1
ATPase-positive~1
pre-malignant~1
(FN)~1
FN~1
pre-malignant.~1
arthropathica~1
sclerosis-like~2
Langerhans'~7
(T6)~1
(ATPase)~1
T6,~2
ATPase,~2
subpopulation,~1
(MPA:~1
Depo-Provera,~1
Upjohn)~1
non-metastatic~1
non-hormonal~2
contraception.~1
(21.4%)~1
(9/45)~1
(7/26).~1
(PMT)~1
(beta-E)~1
oestradiol,~1
PMT~3
beta-E~2
(10.7,~1
(14.6,~1
endorphin~7
PMT.~2
Rando~2
Phantom~1
antenatally.~1
thermoluminescent~1
chips~3
(TLD~1
chips)~1
Phantom.~1
scanogram~1
TLD~1
Births~1
1380~1
(women~1
marriage)~1
13,845~1
youth,~1
primiparity~1
blood-stained~2
7238~1
mid-trimester~1
tap.~1
unavoidable.~1
systolic/diastolic~2
A/B~7
velocity-time~1
bupivicaine~1
(A/B)~1
midcavity~2
arose,~1
extractor~1
2659~1
(umbilical~1
7.20)~1
post-ejaculatory~1
spermatozoal~1
area-under-curves~1
nostrils~2
area-under-curve~1
Mooren's~2
Suppressor~2
helper/suppressor~1
keratoconus~2
progressive.~1
February.~1
haemostasis~2
minimised.~1
fluorescein,~3
revealed.~1
circulations,~1
arcades,~1
deficient,~1
Watershed~1
circulations~1
overlap.~1
fluoresce~2
dystrophies,~2
rod-cone~1
(Stargardt's~1
flavimaculatis,~1
vitelliform~1
Leber's~2
amaurosis.~1
focal.~1
receptors-namely,~1
amacrine,~1
Mueller,~2
cells--in~1
hyphaema~2
Healonid~2
opacity~4
Primary,~1
neurotropic~4
temple.~1
rib,~1
neuroid~1
trunks.~2
atypism~1
metastasised~1
melanogenesis;~1
Fontana~1
Bodian's~1
amblyopia:~1
('grating~1
acuity')~1
Bupivacaine~1
lignocaine~3
evulsion~1
(dry)~1
Nikon~1
Auto~1
Refractometer~1
NR-1000F~2
homatropine~1
postmydriatic~1
myopes~1
hypermetropes~1
aphakia~5
CR.~3
(depending~1
medium)~1
cone-plate~1
rheoscope~1
(PH)~2
density-fractionated~1
diamide-treated~1
ellipsoidally~1
ex(eta~1
ex/eta~1
in)alpha,~1
viscosities,~1
(Hts)~1
ellipsoidal~2
suspending~1
Ht.~1
glutaraldehyde-treated,~1
disturbed.~3
laminar~1
flow-lines~1
shape-transformed~1
echinocytes~1
stomatocytes~1
chlorpromazine.~3
discocyte-echinocyte~1
discocyte-stomatocyte~1
salicylate-treated~1
rheology~1
erythropoiesis~5
succession--the~1
clones.~3
variabilities,~1
60-~2
136-day~1
8.4%.~1
45-day~1
reticulocytes.~1
maybe~1
scanty,~1
agranular,~1
nucleoli.~1
lineages,~1
colonies.~1
replating~4
pluripotent~1
hundred-nine~1
reticulocytopenia,~2
reticulocytopenic~4
mL/dL,~1
mL/dL.~1
basal.~3
marrows~4
glucocorticoid-treated~2
reticulocytopenia~1
gamma-carboxyglutamyl~1
(des-gamma-carboxy)~1
K-sufficient~1
prothrombin;~1
Morris~2
no.~2
7777~2
carboxylase~2
9618A~1
5123D~1
prothrombin.~1
Carboxylase~1
(ARC)-associated~1
t(8;14)(q24;q32).~1
aberrations,~1
prelymphomatous~1
(HCL)~2
(IFN).~1
therapy),~1
HCL;~1
(OCS),~1
OCS~3
egress~1
Others~1
mystery~1
(often~1
membrane),~1
puts~1
survival:~1
hepatosplenomegaly;~1
count;~1
BUN,~2
distinctively~1
Rai~4
cytochemistry,~1
counterflow~2
elutriation~2
segmented~3
thymidine.~1
(CR1,~1
NBT~1
endotoxin,~1
receptors----immune~1
phagocytosis----complement~1
receptors----oxygen-independent~1
killing----oxygen-dependent~1
killing----chemotaxis.~1
NBDphallacidin-stained~1
microfilamentous~2
27).~1
(fMLP)-induced~1
Adult,~1
fMLP~3
27;~1
58.7~1
(2.37-fold)~1
(1.28-fold).~1
content--approximately~1
disappear.~2
572-574~1
Arg-Gly-Asp~1
carboxyterminal~1
Arg-Gly-Asp-Ser~2
(RGDS)~1
RGDS~3
plasmic~1
(8D-50)~1
Gel-filtered,~1
HEPES-buffered~1
8D-50~3
mg/mL)~2
RGDS.~1
lymphoblast~1
C5MJ.~1
Nonadherent~1
Ficoll-Paque~1
panning~3
anti-My-10~1
plated~6
lecithin,~1
C5MJ-conditioned~1
dish.~1
Blast~1
7,800~1
single-lineage~1
multilineage~1
dormant~1
Polyarthritis~1
Monoarthritis~1
Hip~2
Hotness,~1
Tissue-typing~1
Iraq,~1
unpasteurized~1
authorities.~2
sacroiliitis~3
spondylolysis~1
spondylolisthesis,~2
vertebral-arch~1
spondylolisthesis.~1
Circumferential~2
CAT-scan~1
sulphasalazine~2
(SASP)~1
SASP~6
(DPA).~1
antirheumatic~1
second-line~5
'responders'~1
SASP/DPA~2
dyspepsia~12
dysgeusia~1
withdrawals~1
Microwave~1
Microwaves~1
consecutively-admitted~1
assessor~1
specialty,~1
to.~1
pseudogout~2
temporomandibular~2
Panhypogammaglobulinaemia~1
hypogammaglobulinaemia~1
ventriculo-cardial~1
radial-head~1
Joint~3
(EDS),~1
(OI),~1
(GOA),~1
achondroplasia~1
pseudoachondroplasia.~1
Caucasians.~1
EDS~5
hypermobile~1
laxity.~1
pseudoachondroplasia~1
grosser~1
GOA~1
(COL2A1).~1
(ICRP),~1
"Stochastic"~1
"non-stochastic"~1
non-stochastic~2
dose-equivalent~2
achievable,~1
account,~3
including:~2
public;~1
detriment~2
provide.~1
ionising~1
radiations,~1
public.~1
Congress~1
Radiology,~1
(ICRP)~1
legislation,~1
clarity~1
enforceability,~1
codes,~1
incorporated.~1
drafter~1
acceptability,~1
unfortunate~1
offset.~1
L5/S1~1
discograms~1
L4/L5~3
Retrolisthesis~1
discography.~3
discographic~1
Min~2
(Kodak),~2
Fuji~1
(Fuji)~1
MR3~1
(Agfa-Gevaert),~1
highly.~1
Medichrome~1
bipedal~1
lymphography.~1
lymphogram~2
lymphography~1
blood-flow~1
Anatomical~2
computer-processed~1
imperfections~1
Nigeria.~1
also.~2
non-ionic~3
(iohexol)~1
(meglumine~1
iothalamate)~1
muscle-compression~1
(DSA)~1
millilitres~1
iopamidol~1
DSA~1
non-hepatic~1
99Tcm-colloid~3
"templates"~1
inaccurate,~2
imprecise,~1
Observers~1
I/ml~2
(Omnipaque,~1
Nycomed~1
Ltd)~1
iopamidol,~1
(Niopam,~1
Merck~1
Ltd).~1
(proximity~1
(reproducibility)~1
deriving~2
(cat)~1
bottles~4
MnCl2~2
CuSO4~2
imager~1
(T1~1
T2s),~1
T1/T2~1
(SDs)~2
(animal~1
protocols)~1
protocols).~1
SDs~7
protocols;~1
phantoms.~1
Noise~1
Non-uniformity~1
asses~1
Friuli-Venezia~1
Giulia,~1
North-east~1
Italy~1
1,250,000~1
region-wide~1
survey;~1
facilities;~1
Frequencies~1
0.848~1
mSv~1
0.253~1
mSv,~1
Publication~1
26.~1
detriment.~1
area-exposure~1
6532~1
radiologists,~1
Low-energy~2
Amersham~1
137Cs~1
encapsulation~2
prepyloric,~1
standardization,~1
prepyloric~2
hyposecretion~2
Curtis-Fitz-Hugh~1
manifestation,~1
perisplenitis~1
perihepatitis~1
Perisplenitis~1
perinephritis~1
'TNM'~1
Curability~1
(conservatively~1
T1-3,~1
M0)~1
incurability~1
minimally.~1
Pharyngolaryngo-oesophagectomy~1
pharyngogastric~2
hypopharynx,~1
pharyngolaryngeal~1
Wooden~1
arrows~1
tribal~1
fighting~1
Highlands~1
Papua~2
Guinea.~1
arrow~1
Mt.~1
Hagen~1
arrow,~1
incompetence.~2
Bush~1
let~1
empyema~2
(40),~1
(4).~3
(1983-84)~1
(1984-85).~1
decortications~1
thoracoplasty~1
sicker~1
(DFI)~1
DFI~3
s.d.)~1
Francis~2
Ifakara~1
(Kilombero~1
District),~1
Tanzania,~1
non-bowel-resective~2
nmol/ml).~1
hyperbolic~1
1.9.~1
3.77~1
h-1,~2
vagus.~1
supersensitivity.~2
intra-operatively.~1
oesophagectomy~1
aorto-oesophageal~1
(85~1
End-to-end~1
Exoskeletal~1
granulation.~1
Fucidin~1
ointment.~1
granulating~2
friction~2
dressings.~1
filled.~3
audits~2
Oxford~3
1975-85.~1
(other~2
carotid),~1
sympathectomies.~1
cards,~1
In-patient~1
Enquiry,~1
Lothian~1
audit,~1
cycloplegics,~1
French-Canadian~1
cousins~1
Norrie's~1
microcephalic.~1
L1.28~1
blepharospasm.~2
treated:~1
pimozide~1
benztropine~1
mesylate,~1
clonazepam~2
amantadine~1
eyebrow-eyelid~1
improvement;~3
lagophthalmus,~1
low-vision~3
Canada;~1
morphologic,~1
histochemical,~4
thyroglobulin-related~1
rectus-levator~1
orbits~1
3-week-old~1
neuro-ophthalmic~1
stem,~2
radiations~1
metalic~2
changing.~1
relegate~1
cellulitis.~3
(CO2)~1
hard-driving,~1
competitive,~1
hurried.~1
inconsistencies~1
subcomponents~1
reconceptualization~1
twofold:~1
Hyperinflation~1
hyperventilating~1
10,173~1
southwestern~3
drinkers.~4
562~1
Manitoba~2
States:~1
nonurban~4
practise~1
equitable.~1
(clinically~1
exophthalmos)~1
14.3~3
9.1)~1
12.1%~1
6.7%.~1
bottle-fed~1
(27.0%~1
7.0%;~1
7400~1
Joseph's~1
Apr.~1
Mar.~1
1671~1
$892,000;~1
revenues~1
$449,000,~1
$443,000.~1
$534.~1
$431.~1
2737~1
115/1000.~1
350%,~1
6/1000.~1
56%,~3
73%.~2
721~1
summoning~1
summon~1
rehearsals~1
Nurses~1
Alberta.~1
biopsy-proven,~1
40-56~1
Gy),~1
post-treatment,~1
irradiate~1
waiting~6
promise,~1
mesenchymoma~1
pleomorphic~7
follows,~1
options,~1
68%.~1
suggested;~1
sarcoma's~1
Census~1
Bureau.~1
2.1.~1
equally.~1
Richter's~3
(CLL)~3
CLL.~2
(56%);~2
(93%);~1
(53%),~1
non-T-cell~1
phenotype;~1
IIE~1
21%),~2
regimes.~1
56-92~1
(men:~1
women:~1
varied,~2
bruise-like~1
dusky~1
cellulitis,~4
pyoderma,~1
poor;~1
wide-field~1
electron-beam~1
tumor-free.~1
CFPMV~3
(Cytoxan~1
[cyclophosphamide],~1
vincristine)~1
(Cytoxan,~1
[doxorubicin])~1
CFP,~1
three-arm,~1
CFP~2
26/46~1
(57%);~1
31/48~1
26/47~1
9.5,~1
regimens:~1
4/46~1
6/48~1
5/47~1
11/33~1
third-line~2
7/21~1
8/25~1
(32%),~5
(CFPMV----CA----CFP)~1
(CA----CFP----CFPMV)~1
(CFP----CFPMV----CA)~1
0.24).~2
arm:~1
0.13).~1
diuresis)~1
adenoid~4
(107+~1
stabilized,~1
20-108+).~1
well-matched~1
CCNU~5
frontal-lobe~1
multiforme,~2
parietal-lobe~1
4650~1
1050~1
coagulative~1
calcifications.~1
hyalinized~1
Synergism~1
"radioresistant."~1
radiosensitizers~1
(carcinomas,~1
lymphomas),~2
radiosensitizers,~1
14-cm~1
(-96H)~1
sonography,~1
9-cm~1
(-66H)~1
Sonography~1
echolucent~1
Angiomyolipoma~1
cytophotometric~1
intramucosal,~1
submucosal,~1
muscular,~1
subserosal~1
(homogeneous~1
ploidy),~1
ploidy,~2
Cytophotometric~1
(FCC)~1
non-Burkitt's~3
re-evaluated.~2
Ten-year~1
83%;~2
47%;~1
(NPC)~1
(UD)~1
correlation:~1
keratinizing~1
(KS),~1
(SP),~1
(RC),~1
(Mix,~1
NK);~1
51.8%,~1
(SP,~1
RC,~1
Mix)~1
pleomorphism:~1
pleomorphism),~1
anaplasia).~1
(33.3~2
38.6%),~1
71.8%).~1
NPC~3
emerged:~1
(KS;~1
30%-40%),~1
60%-72%).~1
A/pepsinogen~3
341~2
gastroscopy~4
1.5),~1
ng/l).~1
95.1%~1
20.4%.~1
precursors,~4
(25),~1
(23).~1
(65%).~2
(TCT)~1
capillarosclerosis,~1
TCT~3
Capillarosclerosis~2
patient-months)~1
4.8%,~1
patient-month.~1
preferably~2
three-piece~1
silicone-rubber~2
spinal-level~1
exteriorization~2
self-administration.~1
3891~1
catheter-days~1
Hospitalizations~1
unrelieved~2
entailed~1
dissected.~1
triangle.~1
(IBC)~1
nonrandomized~2
chlorambucil,~1
doxorubicin.~1
Locoregional~1
cytoreduction.~1
pejorative~1
Considerably~1
focussed~2
Whereas,~1
currently.~1
vindesine,~1
ifosfamide~1
(EVI);~1
(PAV);~1
(7,~1
(CMC).~1
Responsive~2
302~5
evaluable,~1
CAV~1
preferring~1
Progression-free~1
SCLC~2
CAV.~1
Addison's~2
discontinuance~3
9-alpha~1
fluorohydrocortisone.~1
5-8).~1
bolus)~2
leucovorin~1
rescue.~1
(FUDR)~1
sixty-eight~2
extracorporeally~1
(TBHT)~1
(29.5%)~1
TBHT~2
hyperthermia.~1
(21.4%).~1
TBHT.~1
(108~2
paraaortic~2
presentation;~1
adenopathy;~1
extramediastinal~1
pleura~2
(43%-60%)~1
(70%-85%).~1
relapses:~1
irradiated.~2
nonmediastinal~1
Fonar~1
Beta-3000~1
(Fonar~1
Co.,~1
Melville,~1
(T).~1
MRIs~1
spinal-epidural~2
MRI;~2
ossified~2
Radiated~1
Morphologic~3
Pilocarpine~1
xerostomia.~2
(DU),~1
(21%);~1
(DH),~1
LB~6
stages;~1
DU~4
lymphomas;~1
divisible~2
subtypes:~3
nonconvoluted~1
(NC),~1
(LCV).~1
LCV~1
Group's~1
clinicopathologically~1
irrelevant~1
(B;~1
(NB;~1
noncleaved,~1
not-otherwise-specified~1
(NOS;~1
NB;~1
NOS;~1
NB~2
postsurgery.~1
(IgA)~2
patterns;~2
expansive~3
tubular,~2
expansive,~1
growths~2
well-,~2
differentiated.~1
growths,~1
narrowly~2
III),~5
periparotid~1
join~1
lactalbumin~1
445~1
fmol/g)~2
1059~1
nipple,~2
anal).~1
protein-15,~1
Intracytoplasmic~1
(ATL)~1
ATL~1
patients--one~1
normocalcemic.~1
osteoclast-activating-factor-like~1
635~2
7877~1
1954~3
1399~1
false-negative,~1
86.3%~2
(6.5%~1
65.7%,~1
expedite~1
(CHP)~1
(Vc)~1
D+~1
(ACAdr);~1
(P),~3
(B),~1
(Vb),~1
ACAdr;~1
(Adr).~1
(PBVb)~1
ACAdr~1
Vc,~1
ACAdr,~1
granulosa-theca~1
beam),~1
Adr.~1
PBVb~1
Adr~1
log-linear~2
1920~1
1930,~1
(pancreas,~1
(cervix)~2
Period~1
(chiefly~1
males)~1
1970s,~1
intestines,~2
Downward~1
cloacogenic~1
20-years-old,~1
styles.~1
mono~1
verifies~3
879~1
Munich,~1
(Breslow~1
millimeter.~1
thickness).~1
(1.50-3.49~1
84.1%~1
57.6%.~1
lactase~2
(RAAL)~1
high-dose,~1
continuous-infusion~1
cytarabine,~2
(Hi-COAP).~1
cytarabine~8
(CNS),~2
Hi-COAP~1
RAAL~1
multiinstitutional~1
firstline~1
mg/m2).~1
205,~1
51+~1
Cardiotoxicity~1
Extending~1
tolerable~2
polymorphous~4
rad),~1
medulloblastomas.~1
seeds.~1
59.1%)~1
33.3%).~1
hematogenously~1
fluids)~1
Feulgen~5
cytophotometry.~1
fluids),~1
diploid)~1
histograms,~2
hypertetraploid~1
lymphotropic~3
(HTLV),~1
DR5~1
HTLV-III.~1
pseudolymphoma~2
nonreactive~3
submucosa.~1
GPLs,~1
GPL~2
Pineocytomas~1
pineocytomas.~1
pineocytomas~4
inadequate;~1
35-years-old~1
1948~1
1710~1
2.9:1.0.~1
Obstruction,~1
scirrhous~1
(Evans'~1
urothelial~1
ABC,~1
TS~7
adopted.~2
multicentricity,~1
homolaterally~1
(ureter~1
pelvis)~1
pT2,~1
pT4.~1
pB~1
pA~1
Ollier's~2
neoplasms:~2
dedifferentiated~1
osteosarcoma.~1
(1978~1
1982)~1
4067~1
10,366~1
Ontario.~2
reverse.~1
(SCC)~1
SCC~4
collected.~3
keratinization,~2
(ALL),~2
(REST).~1
Non-keratinizing~1
CRs~4
(REST),~2
non-keratinizing~1
ALL~1
translate~1
subset.~3
o,p'DDD.~1
inoperable,~1
beta-hydroxy-5-ene~1
tetrahydro-11-deoxy-cortisol.~1
o,p'DDD~2
16-oxygenation~1
androst-5-en-3~1
beta,17~1
beta-diol,~1
immunopotentiator,~1
OK-432,~1
eluates~2
eluated~1
IgG1-lambda.~1
immunopotentiators.~1
OK-432.~1
(XLP)~1
hypogammaglobulinemia-~1
agammaglobulinemia,~1
virus-associated~2
(ML).~1
XLP~3
2-19~1
1-216~1
ML.~2
"B"~1
ileocecal,~1
76.5%~1
(Stages~2
(41.2%),~1
(17.6%),~2
(11.8%),~1
12-192~1
survivors;~1
XLP,~1
post-EBV~1
Zhong~1
Shan~2
People's~1
(HCC),~1
cholangiocarcinoma.~1
(Hepatitis~1
80.0%~1
(32/40).~1
97.5%~1
(39/40).~1
82.5%~1
(33/40)~1
35.0%~1
(14/40)~1
25.0%~1
(10/40)~1
(3/40)~1
65.0%~1
(26/40)~1
(4/40)~1
(30/40)~1
(16/40)~1
0.056);~1
HBV.~1
iron;~3
ferritin;~1
hepatocarcinogenesis~1
China;~1
japonicum~9
Fifth~1
Workshop~1
hematopathologists~1
(WF)~1
WF~2
choices.~1
(78.9%).~1
WF,~1
excepting~1
(73.3%),~1
(64.2%),~1
(76.5%),~1
(70.2%).~1
(39.0%)~1
(12.3%)~1
(8.0%)~1
primaries.~1
palliation.~2
pancreatic,~1
thymomas,~1
tomographic-surgical~1
Hematogenous~1
x-rays.~1
portal.~1
3600~1
4200~1
cGy,~1
prostatectomy.~5
90.6%~1
83.7%.~1
(20.4%)~1
98.4%.~1
0-14~1
1976-1983.~1
surname)~1
(148~1
(leukemias,~1
lymphomas).~1
excesses~2
surname~1
whites.~3
thermodilution,~2
catheter-tip~1
manometer.~1
mono-exponential~1
pressure(PP),~1
volume(SV),~1
pressure(SBP),~1
output(CO)~1
quotient~2
SV/PP~1
SV~1
PP.~1
postextrasystolic~3
(PESP)~1
postextrasystole~1
(isolength~1
subscribing~1
ventriculogram,~1
"jeopardized,"~1
PESP,~1
(paced~1
beat)~2
(postextrasystolic~1
PESP~2
non-jeopardized~1
revascularized)~1
isolength~1
noncardiovascular~1
Mosul~1
Iraq.~1
injection-corrosion~1
unaided~1
sample)~1
conus~2
preponderant,~1
Schlesinger~1
[Schlesinger,~1
Arch~1
Pathol~1
30:403-415,~1
1940].~1
intrapopulation~1
non-Europeans~1
non-Caucasian~1
racial,~1
sexual,~1
ontogenetic~1
(Tl-201)~1
scintigraphy;~1
2.5%)~1
8.9%).~1
time-constant~1
I;~4
l;~1
mumole/min~2
productions~3
(-7.5~1
-4.6~1
homocoronary~2
perforator~1
twirled,~1
winding~1
Unsuspected~1
cinearteriography,~1
positionally~1
visualization.~2
predilatation~1
12%;~1
disengagement~1
unhurried~1
Tandem~6
single-balloon~1
catheter).~1
calibers,~1
predilate~1
handy~1
money,~1
Simmons~1
1,117~1
transstenotic~1
(2.8%),~1
(3.0%),~1
(0.4%)~3
inclusive.~1
event)~1
patterns:~1
54),~1
restenosed~2
60),~1
32).~1
dilated).~1
217),~1
dilated;~1
277)~1
dilated.~1
488~2
PTCA)~1
92%.(ABSTRACT~1
(APTT)~1
84.1~2
27.4~1
0.7-5.5~1
Neovascularity~1
pre-positioned~1
wires.~1
manifold~1
overcomes~2
kissing~1
[1,2].~1
paraprosthetic~1
end,~3
unwound~1
wire.~1
hiterto~1
(EBD)~1
(blue~1
areas).~1
EBD~2
"blue~1
areas"~1
avulsions,~1
elastica,~1
67-89%~1
catheter-induced~3
re-endothelialization,~1
thrombogenicity,~1
cardiomyopathies~1
glucose-perfused~1
180-200-day-old~2
Cardiomyopathic~2
phosphocreatine/inorganic~1
triphosphate/inorganic~1
acidity~3
hamsters.~3
Verapamil-treated~1
phosphocreatine.~1
Arterioles~1
microvessel~3
myofilaments.~1
intimal-medial~1
periluminal~2
"ridges"~1
32P-labelled~1
1.1kb~1
SacI~1
specifying~2
meromyosin~1
untranslated~2
alpha-MHC.~1
(lambda~3
HCMHC8)~1
stringency~2
skeletal,~1
Probe~1
HCMHC8~5
31S~1
Heteroduplex~1
12/1).~1
rescreening~1
hybridize,~1
HCMHC9).~1
HCMHC8.~1
HCMHC9.(ABSTRACT~1
M-10(-4)~1
verapamil-sensitive~2
Verapamil-sensitive~1
(pmol/cm2/sec)~1
10.45~1
1.44~2
24.34~1
2.41~1
32.57~1
2.35~2
fibrillated~1
respirator,~1
cyclically~1
pentolinium.~1
[3H]tyrosine~1
[3H]catecholamine~1
[3H]normetanephrine~1
catechols~1
catechol-O-methyltransferase~1
epimyocardial~3
cinematography,~1
epimyocardium~1
midsystole~2
venules.~2
momentary~1
arteriole~3
phase;~3
subepimyocardial~1
dilazep~1
potentiator,~1
myocardium-sparing~1
exploit~1
thrombolysis.~2
sulphonic~1
DoCA-salt-treated~1
SE;~2
test),~1
(NE).~1
nonsurvivors.~4
Expressed~2
substrates:~1
shock.(ABSTRACT~1
reinitiated~1
preexcitation~4
(1/5~1
isoproterenol).~1
Oscillations~2
(SB-SB)~1
(S'-S')~1
(VERP)~1
lengths,~2
VERP~7
(S'1,~1
S'2,~1
S'3)~1
S'1~2
S'2~2
VERP),~1
S'3~1
VERP).~1
beats.(ABSTRACT~1
Jatene~1
D-transposition~1
(D-TGA),~1
D-TGA~2
D-TGA.~1
1);~3
2).(ABSTRACT~1
valvotomy~4
neurohumoral~2
(local~1
87.8~1
18.9%~1
SD])~1
20.7)~1
arteriograms,~1
31.6)~1
6.5%~5
nonspastic~2
(20.5~1
13.8%;~1
.7).~1
Ergonovine~1
perpetuation~1
umbrella~4
Rashkind~2
occluder,~1
[PDA])~1
post-Glenn~1
cava-right~1
cava),~1
"interatrial~1
defects"~1
("coronary~1
sinus"~1
ovale,~2
atrium),~1
non-PDA~1
postoperative).~1
successfully;~1
lower-lobe~1
PDA,~1
expands~3
(BCA)~1
9.5)~2
(PSG)~1
BCA~3
PSG~1
Bordeaux,~1
Leiden,~1
reoperations.~1
reoperated~2
Separan~2
AP-30,~1
polyacrylamide,~1
Atherogenesis~1
wall-atheroma~1
(intravenous)~1
polyelectrolyte~1
antiatherogenic~1
drag~3
deendothelialized,~1
(39.5~1
platelets/1~4
56.4~2
Restenosis~1
chemoreflex.~1
pathway(s)~1
paw,~2
Interruption~1
(perfused~1
Gregg~1
reservoir)~1
(Bezold-Jarisch).~1
automaticity,~2
(infarct~1
preparation)~2
(noninfarct~1
preparation).~1
Transmembrane~1
(spontaneous~1
depolarization)~1
noninfarct,~1
noninfarct~3
(10(-10)M~1
10(-6)M)~1
(10(-9)M~1
10(-7)M~3
afterpotentials~2
10(-5)M~1
cardioselective~1
chronotropism.~1
bradycardiac~1
(UL-FS~1
constrictor.~1
(sonomicrometers,~1
thickness)~2
(microspheres)~2
UL-FS~3
(%WT)~1
1.04~1
ml/min/g,~1
ml/g,~1
ml/min/g).~1
(35.7~1
28.9~1
%WT~1
run),~1
run.(ABSTRACT~1
heart-blocked~1
(LHP)~1
pericardiectomy,~3
LHP~3
(0,~3
Hg/sec~1
zero-flow~1
(Pf~1
.98~1
Pf~2
pericardiectomy~1
0.(ABSTRACT~1
"asymptomatic"~1
provoking,~1
demand,~2
2-monthly~1
swam~1
protection)~1
dry.~1
Swimming~2
swimmers.~1
oestrogen-receptor-like~1
(1-16~1
Immunocytochemical~2
'evaluation'~1
'remediation'~1
Cardiff.~1
travelling~1
organization,~3
angiofibromata~1
resonance.~3
sphenopalatine~1
foramen.~1
enlarges~1
erodes~1
'antral~1
sign'~1
X-ray,~1
3-plane~1
pre-operatively.~2
post-onset~1
thirty-sixth~1
seventieth~1
interaural~1
retrocochlear~2
incus~3
malleus~3
footplate~6
(columella)~1
imaginary~2
stapes.~1
malleus,~1
footplate,~1
columella~3
works~3
female:~1
Ninety-three~2
(9.6%)~1
bothered~1
(38.5%)~1
Tinnitus~1
hypocalcaemic~1
normocalcaemic.~1
glands)~1
developing.~1
looks~4
electronmicroscopic~1
Juvenile~1
Alpha-interferon~2
antroscopic~2
antra~1
opaque~1
Antroscopy~1
ostium.~1
antroscopy~1
Otolaryngology,~1
Linkoping~1
14-year~1
(1971-1984).~1
(N1)~1
1-13~1
(N3)~1
fibrinoid~2
arteriolosclerosis~1
(MAP~1
115-124~1
0.036~1
mg/dl/month,~1
mg/dl/month~4
0.046~2
Normotension~1
nephrotoxics~1
(aminoglycosides,~1
anesthesia)~2
function:~1
concomitance~1
toxics~1
(UF)~1
nephrotics~2
139%~2
UF~10
PV~6
l,~1
refilling.~1
Hemodynamically,~1
(TPRI)~1
TPRI.~1
(Fragmin,~1
mol.~1
4-6000~1
d),~1
(dose~1
anti-Xa~1
U),~1
(WBACT)~1
125-175%.~1
WBACT~1
Fragmin.~2
Anti-Xa~1
Fragmin~1
auto-immune~5
sodium-~1
potassium-losing~1
seven-week~1
(spinous~1
arch)~1
schematic~1
myelogram.~1
37)~3
44).~1
herniation,~2
Ransford~1
nondiscogenic~1
sciatica,~1
ski~8
Wyoming,~1
120-day~1
season.~2
570~2
skier's~2
evolutions~1
styles,~1
intercondylar~1
notch.~1
Soldiers~1
army~1
army.~1
recurvatum,~1
lengthening.~1
Untreated,~1
stiff,~1
tibia;~1
supine;~1
cruciate-deficient~1
sublux~1
arthrometric~1
millimeters.~1
arthroplasties,~1
peg~1
plateaus~3
1-mm~1
metal-backed~1
Tibialis~1
dorsiflexion.~1
middiaphyseal~1
unite.~1
hypercortisolism,~1
pathogenicity,~1
hypodermic~1
inflammations,~1
Routinely~1
734~1
Aspen,~1
1968-1978,~1
527~1
16-40.~1
(proximal,~1
distal)~1
(Class~1
Compartment~1
1982-1984~1
continual~1
12.9/100,000~1
skier~2
2.9/100,000~1
1983).~3
philosophy~3
retroversion~2
nonconstrained~1
Supernumerary~1
bellies~1
(SMBs)~1
forearm,~3
variant,~2
tendon-muscle~1
SMB~1
excursion,~4
palmaris~1
superficialis,~1
superficialis~1
carpus.~1
muscle-tendon~1
relieves~3
Observation~3
SSMB~1
gout~6
tophaceous~1
antigout~1
cobalt-chromium-bearing~1
ceramics~1
exists,~2
hip.~4
(OA).~1
microfractures.~1
OA,~1
microfractures~6
porotic~1
Tricalcium~1
overreamed~1
press~13
TCP-stabilized~1
osteoconductive~1
ailment,~1
total.~1
Rotator~1
acromioclavicular~3
separations~1
rotator~1
skier.~1
(10/13)~1
separations.~1
tuberosity~2
injuries),~1
Immobilization~2
Metaphyseal~1
widespread,~2
amenorrheic,~1
Phosphorus~1
Deposition~1
radioopaque~1
Os~1
calcis~3
monotonic~1
0.009)~3
Pustulotic~1
arthroosteitis~1
pustulosis~1
palmoplantaris~1
(PPP)~1
PPP~1
aponeuroses~1
(malignant~1
parts)~1
juxtacortical~1
16-61~1
16-46~1
(96%),~1
straps,~2
skiers~1
1981-1982~1
skiers.~1
excellent;~1
pleased~1
overlooked,~1
Skiing~1
fitness.~6
conditioning.~2
Strength,~1
preseason~3
Thoracolumbar~1
snowmobile~1
Alpine~1
freestyle~1
requires:~1
(specifically~1
dysfunction)~1
stability),~1
4%-5%~1
noncontiguous~1
occur;~3
instrumentation;~1
wedge-compression,~1
flexion-distraction,~1
etc.);~1
(bilateral~1
distraction,~1
distraction)~1
mountain~1
sickness,~2
edemas,~1
sojourners~1
elevations.~1
altitude;~1
Diamox~1
(Lederle,~1
Pearl~1
River,~1
York)~1
cornerstones~1
frostbite,~1
handling,~2
Frostbite,~1
degrees-42~1
frostbitten~1
refreezing~1
frostbite~2
afflictions~1
skiing:~1
tendinitis,~1
tendinitis~2
glenoplasty,~1
coracoacromial~2
1972-1985,~1
coracoclavicular~1
breakage,~1
anterior.~2
Neer~1
degrees-50~1
swathe~1
limited-goals~1
redislocations~1
100-unit~1
interscalene~1
notoriously~1
ossificans,~1
varus/valgus~1
packs~5
Virginia,~1
Formula~2
powder)~1
objected~1
nonformula~1
packs.~4
voted~1
approve~1
intent~2
3,000,000~1
dispense~1
enclose~1
pack~2
endorsement.~1
erythromycin-induced~1
ethylsuccinate~1
cogwheeling~1
use)~1
mg/L.~1
Erythromycin~1
(2.5-21~1
(82%),~1
(94%),~3
(76%).~2
life-threatening.~2
(SIADH).~1
SIADH.~2
(serial~1
discharge).~1
SIADH,~1
Childhood~2
Graves~5
0.0039).~1
ophthalmopathy,~3
mcg/dl,~2
relapsed;~1
0.039).~1
Hence~1
unilateral,~2
nonpenetrance~1
thenar~1
Fromont~2
anomaly).~1
anomaly)~1
triphalangeal~1
polydactyly.~1
anomaly,~2
diaper~5
Epidermophyton~2
floccosum~2
Dermatophytosis~1
rashes~1
12-month-old~1
allergy,~2
phenylpropanolamine~2
(PPA)~1
PPA~6
guessed~1
Appetite~1
PPA,~1
been,~1
study's~1
unblinded.~1
unblinding~1
fenoldopam~9
(capsule)~1
times/day~1
(+32%~1
+50%,~1
(+73%~1
+66%,~1
fenoldopam's~1
Fenoldopam,~1
0.025,~1
microgram/kg/min.~1
Fenoldopam~3
congestion.~2
mg/kg/hr)~1
(2.32~1
500,000~1
250,000~2
S-2251.~1
1.10~2
l.~1
2-hydroxylation~1
desmethylimipramine~1
(DMI)~1
hydroxylation.~2
hydroxylators~1
DMI~2
2-hydroxydesmethylimipramine~1
hydroxylators.~1
hydroxylations~1
Sparteine~1
([EM]~1
[MR]~1
([PM]~1
5-dehydrospartein~1
PMs~2
sparteine~1
2-dehydrosparteine~5
thirtyfold~1
(Km)(1880~1
1044~1
EM~4
(58.3~1
38.8~3
(658~1
pmol/min/mg).~1
5-dehydrosparteine~1
trimethoprim~2
7.55~1
9.70~1
(27.07~1
44.62~1
Thereafter~4
(means:~1
(0.86~1
l/kg;~2
l/kg)~1
ml/min/kg;~2
ml/min/kg).~1
nonrenal~2
(metabolism).~1
D-Xylose~1
D-xylose~4
77.4%~1
14.8%~2
Ticlopidine,~1
carbamoyltransferase~1
orotate~1
(Kendall~1
alanine/kg~1
pre-load~1
(10(-4)-100~1
intravenous).~2
intravenous),~1
Coeliac~1
recirculates~1
chyme~1
sluggish~1
recycling.~1
lactulose-labelled~1
mouth-caecum~1
(M-C~1
TT)~1
M-C~1
TT,~1
transit,~1
Synchronous~2
0.97),~1
Fingertip~1
(VOP)~1
(PPG)~1
0.92~4
VOP~1
PPG)~1
lag.~1
neurotransmitters.~1
throxine~1
neurotoxin,~1
neurotransmitters,~1
secretomotor~1
propylthiouracil.~2
sessions:~2
weight);~1
(-13~1
(-9~1
rte~1
(neonatal)~2
organ/body~1
known:~2
'haemodynamic~1
stimuli',~1
growth-promoting~4
hyperprolactinaemic~2
(radii~2
3.0-3.6~1
5.1-7.8~1
porosity/charge~1
(theta~1
D3.6/theta~1
ALB,~1
D5.1/theta~1
IgG).~1
deteriorates.~1
contemporaneous~1
crypts~4
(CCPR),~1
robust~2
withstand~3
scrutiny.~1
hyper-proliferative~1
'steady~1
state'~1
hypophysectomy~1
absorption.(ABSTRACT~1
Standing~1
tilting,~1
ovo~1
interference.~1
Flexor~1
glutaraldehyde,~1
phosphotungstic~1
micrographs,~1
Magiscan~1
Mk~1
Tendon~1
ethylenediamine-sensitive~1
cross-sensitivity~1
aliphatic~1
pesticide~1
fungicides~1
thiophthalimides,~1
captan,~1
difolatan~1
folpet.~1
bis-dithiocarbamates~1
benomyl~1
1.0%,~2
1.5%,~4
2.0%.~1
++~1
atopy;~1
triphenyl~5
spectacle~4
tri-m-cresyl~2
tri-p-cresyl~2
tricresyl~1
Trolab~1
triaryl~1
phosphates,~1
Contact~1
(OH)3,~1
cosmetics,~1
ointments~1
(FCAT)~1
4-Methylesculetin~1
Esculetin,~1
dihydrocoumarin~1
daphnetin~1
sensitizers,~1
fraxetin~1
7-methylcoumarin~1
catecholic~1
disubstitution~1
benzene~1
esculetin,~1
4-methylesculetin,~1
daphnetin,~1
ortho-quinones~1
oxidizing~1
AlCl3~1
excoriated~1
papules,~2
aluminium-bound~2
(Di-Te-Pol).~1
Aluminium~1
clonidine.~2
clonidine-inducing~1
48-h~2
petrolatum~1
Foods~5
scratch-chamber~3
handlers.~2
balsam~1
Peru,~1
onion~3
leek.~1
lemon~1
peel~1
Wet~1
handler~1
Open,~1
NiCl2~2
patch-test-proven~1
NiSO4~1
non-toxic~1
Finn~2
Chambers~2
roughness~3
dermatitic~1
(RDS).~1
(TEWL)~1
(CBFV).~1
TEWL~3
CBFV~2
8.127~1
2.89~1
gr/m2/h)~1
SLS,~1
2.717~1
2.165)~1
objectivated~1
CBFV.~1
masseur~2
famous~2
company~2
result:~2
colophony,~1
Colophony~1
wooden~1
slipping.~3
tin~1
nickel-sensitive~1
irritancy~1
unlikely.~1
(CH50)~1
ARDS.~2
CH50~3
post-surgical~1
C3a.(ABSTRACT~1
(Vo2)~2
(Do2)~2
Vo2~4
Do2~3
m2.~3
crystalloids,~1
(WP)~1
WP~1
3.59~2
ml/dl~1
above-normal~1
Do2.~1
51)~2
(0.09~2
131I-albumin~1
(RISA)~2
extravascular,~1
(EVECW)~1
(RISAL/RISAPL).~1
EVECW~1
(ml/g~1
lung)~1
24Na,~1
(TLW)~1
(g/g~1
Air-breathing~1
4.53~2
TLW~4
RISAL/RISAPL.~1
RISAL/RISAPL~3
8.32~1
0.16,~2
inclusive,~1
OA-injured~1
Breathing~3
1,997~1
goodness-of-fit,~1
multihospital~1
Glascow~2
(GCS)~1
orotracheal~1
(OTI)~1
(NTI)~1
tracheally~1
intubated.~1
Paranasal~2
(AFL)~1
GCS~1
NTI,~3
OTI~2
AFL,~2
.1).~1
polymicrobial.~1
Sinusitis~1
"blunt~1
contusion."~1
contusion.~1
plurality~1
contusion~2
(ECMO)~3
neonates'~1
ECMO.~2
ml/cm~3
0.3),~1
1.7).~1
1.5).~1
-.66,~1
.0001,~2
-.52,~1
ventilate~1
balance;~1
(ARDS)~3
nonsurvivors;~2
(nonsignificant).~1
18-yr-old~1
T-piece~3
(IRT),~1
(IMV).~1
850~1
-28~1
-50~1
IRT~1
lumens.~1
ranging,~1
+9%~1
-12%,~1
beat/min,~1
+23%~1
-30%~1
beat/min.~1
brands.~2
dextrose,~2
dextrose.~1
hemopericardium.~1
2-ml~1
performed;~2
idioventricular~4
(tcEMG)~1
technical/experimental~1
Reliable~2
shielded~1
cables~1
non-electrophysiologic~1
tcEMG~2
ventilator-induced~1
pneumothorax.~4
TcEMG~1
volume-cycled~1
(VCV)~1
uncuffed~1
(Paw)~3
mechanical-lung~2
Jet~2
cycle/min~1
uncuffed,~1
5.9-mm~1
(OD)~1
jet-drive~1
psi.~1
H2O.~4
VCV~3
Paw.~1
Paw~5
ventilations,~1
9-mm~1
newborns.~2
superior-inferior~1
undercompensated~1
(89%),~1
dysrhythmias.~2
NaHCO3,~1
hydrogen-gas~1
pre-arrest~1
postischemia,~1
NC.~1
CBF,~1
re-circulation,~1
re-establishment~1
near-normal~3
(Hct)~1
exchanged~1
oxygen-carrying~3
ml/dl.~2
2.96%~1
7.05~1
Invasive~1
phycomycotic~1
(HBO)~1
HBO~1
defenses.~1
Phycomycetes~1
(Apophycomyces~1
elegans)~1
(DLL).~1
Lavage~1
cytocentrifuged~1
carinii.~1
(13/30),~1
DLL.~1
Herpes~1
viruses,~1
gondii.~1
(12/14).~1
instilled.~1
prelavage~1
(PFTs)~1
three-minute~1
0.49L,~1
FEV1/FVC~1
(PaO2/VO2)~1
-23.0~1
VO2/min.~1
PFTs~1
%DCO~2
(SL~1
-59.3~1
0.501~1
%DCO,~1
0.851,~1
-0.25),~1
0.898~1
0.857)~1
inaccurately~1
oximetric~4
carboxyhemoglobin,~1
effusions:~1
tuberculosis;~1
neoplasias;~1
transudates;~1
parapneumonic,~1
complicated;~1
empyemas;~1
miscellaneous.~1
(PL/SL~1
PL/SL~3
empyemas~1
empyemas,~1
94.9~1
94.7~1
Enalapril~1
cardiopathy,~1
cardiopathy.~1
(COPD)~1
(MPAP)~1
hypertension)~1
MPAP~2
(RVPEP)~1
(RVEP),~1
TPV)~1
TPV/RVPEP~1
TPV/RVEP.~1
deceleration.~1
TPV~3
-0.77;~1
-0.84;~1
inhalers~1
(MDI).~1
marketed~2
mouthpiece,~1
(InspirEase,~1
Bag)~1
(double~1
blind).~1
InspirEase~1
Aerochamber.~1
(Theo-24)~1
(bid)~1
(Theo-Dur).~1
(Cmax)~2
(Cmin)~1
microgram/ml,~1
Cmin~4
(84.1~1
79.6~2
predicted).~1
changeover~1
beta2~1
albuterol.~1
gargling~3
nonmedicated~2
MDI.~1
gargle~1
Aerosol-administered~1
Mouth~2
delivered,~2
bronchodilation.~1
sedated,~1
ventilated.~4
(BASELINE),~1
(ALM~4
(POSTALM~1
(BASELINE)~1
P(A-a)O2~1
QVA/QT~1
ALM~1
(57.9~1
(64.7~1
perihilar~3
sarcoidosis;~1
heights~3
(FVC~1
(common~1
O2-transport~1
(PFC),~1
transfused,~2
O2-ventilated~1
oleic-acid~1
Rounded~1
Coexistence~1
homozygote~2
metabolic,~3
81-year-old~1
mercury-zinc~3
powered~1
explosion.~1
gastrinoma.~3
GIH~2
(L-cysteine,~1
exaggeration~1
paradoxical.~1
categorical~1
0.75)~1
0.75).~1
0.65),~2
Dupuytren's~1
spiders~2
0.64).~1
0.27)~1
0.11).~1
realized;~1
cannulate~1
2-hr~2
59-191~1
units/liter~1
units/liter;~1
12-46~1
units/liter).~1
54-118~1
units/liter,~1
78.4)~1
S-type~1
isoamylase.~1
speculative~1
methane~6
methane--42.1%~1
57.9%~1
(6.1%)~1
(31.4%)~1
(34.4%).~1
producers~2
nonproducers,~1
methane-producing~1
gentamycin~1
cephazolin~1
nonproducers~1
10-25~1
[3H]polyethylene~1
(PEG~1
900)~1
gavaged~1
1-1.3%~1
900.~1
35-102~1
1.8-2.4%~1
animals).~1
(serosal~1
anesthesized~1
(SP).~1
SP,~4
(G)~1
Thiry-Vella~1
after:~1
meal;~3
propanolol,~1
propanolol~2
Effluent~1
intraluminally~1
neurocrine/paracrine~1
cysteamine.~1
cysteamine~7
16,16-dmPGE2~2
86.8%,~1
49.7%,~1
67.8%,~1
16,16-dmPGE2.~1
hypermotility~2
cysteamine-induced~1
hydrolases,~1
gallstone-induced,~1
(354~1
(1840~1
elastase~3
(1492~1
beta-glucuronidase~2
1-protease~1
2-macroglobulin~2
(61.7~1
trypsin-alpha~1
protease-to-inhibitor~1
Coupled~1
ribonuclease~1
(27.4~1
units),~1
methemalbumin~1
hematin/100~1
paracentesis~2
gastroparesis,~1
tumor-induced~1
extrapancreatic~2
metastasis-induced~1
rashes,~1
arthralgias,~1
cephamycin~1
pentoxifylline,~1
Indomethacin,~1
dialyzability~1
dialyzability,~1
dialyzable,~3
po.~1
Cpmax,~1
tmax,~1
t1/2,~2
AUC0-infinity~1
[NS]),~1
bags,~1
two-drug~1
(D5W)~1
0.9%.~2
clarity;~1
D5W~1
mixing,~1
reexamined.~1
chromatography;~1
periods.(ABSTRACT~1
Outpatients~1
(APTT).~1
PT.~1
Hematology~1
(30.79~1
(55.10~1
0.821)~1
(median:~1
mg/h.~1
diaphoresis,~1
calculation,~3
insure~3
wounded~1
Cimetidine-treated~1
Closure~1
cimetidine-treated~1
cells/cm2~2
mm2~3
half-lives,~1
cefonicid,~1
pharmacy~11
saved.~1
200-bed~1
compounding~1
expenses.~1
habits,~3
GRASP~1
(Grace~1
PETO)~1
debates.~1
debate~4
lively~1
reimbursement.~1
pharmacist's~1
though,~3
Quebec~1
providers,~2
665~1
3283~1
libraries~1
Compendium~1
Pharmaceutical~2
Specialties~1
Goodman~1
Gilman's~1
Basis~1
Therapeutics,~1
pharmacists.~3
59.9~1
Quebec.~1
pharmacy,~1
scholarship~1
"research~1
mindset"~1
production/extraction~1
information-based~1
Pharmacy~1
scientists.~1
UNC/BW~1
fellowship,~2
industry/academia~1
collaborative~3
fellowships,~1
academia~1
doors~1
it?~1
sponsors,~1
pharmacy?~1
fellowship.~1
fellowship~6
interests.~2
comments,~1
researchers?~1
really~1
literature;~1
papers~2
abstracts~2
fellowships~2
(Appendix~1
fellows.~1
publication.(ABSTRACT~1
Fellowship~1
pharmacodynamics,~2
pharmacokinetics,~2
pharmacodynamic-pharmacokinetic~1
modeling.~1
Liability~1
notwithstanding,~1
bright.~1
inception~1
Formalized~1
biostatistics~1
Pharmacodynamic~1
academic-industrial~1
pursue.~1
text)~1
publication~1
publish~1
scientists,~1
author.~1
Articles~1
researchers.~1
work.(ABSTRACT~1
duties,~1
Director,~1
challenging,~2
stimulating,~1
director,~1
entails.~1
duties~2
benefit--but~1
tactful~1
cooperation,~1
sense.~1
director~1
find,~1
Spinoza~1
thing~1
aspires~1
centers,~2
well-trained~3
tracks~2
jumps.~1
corporations,~1
don't~1
satisfactions.~1
mission~1
threat,~1
Medicine.~1
mission,~1
future,~2
career.~2
Administrators~1
serve.~1
leadership,~1
misrepresentation~1
intent,~1
pricing~2
insurers,~1
billing~1
Department.~1
professionally~1
contractual~2
"minor~1
players"~1
burgeoning~1
(WPSI).~1
epilepsy-related~1
minimise~1
Refractory,~1
Results,~1
Taltrimide~1
anticonvulsive~2
taltrimide~4
photoconvulsive~2
Discharges~1
(IPS)~2
paroxysms.~1
Homovanillic~1
(HVA),~1
(BBB)~1
15-54~1
phenobarbitone~1
diphenylhydantoin~1
(PHT)~2
3-32~1
B-vitamins~1
B6~3
normoblastic,~1
ramifying~1
2.5-3.5~1
PHT~5
PHT.~1
neocortical~3
SDs.~1
epileptogenicity~1
SDs,~1
Electroshock~1
(ES)-induced~1
facilitative~1
pentylenetetrazole~1
shrew.~1
Kw~1
915~2
MHz.~2
Phosphocreatine~1
Community-based~1
quarters~1
continue,~1
handicaps,~1
laparoscope.~1
(UFs),~1
ampullar~1
three-puncture~1
thermocoagulation~1
isthmus,~1
mesosalpinx,~1
voluminous~1
hematocele,~1
complication-free.~1
(CC)-induced~1
transvaginal~3
(E2);~1
(Tambrands~1
Palmer,~1
MA)~1
Ovustick~3
(Monoclonal~1
Antibodies,~1
Mountain~4
View,~1
CA)~3
kits;~1
(BBT).~1
mIU/ml~1
(961~1
53.3%~1
BBT~1
IUDs.~1
oligomenorrhea~1
hypothalamic,~1
disturbed,~1
androstenedione.~1
(fallopian~1
periadnexal~1
adhesions)~1
(SE2)~1
repeatable~2
SE2,~1
plateau,~1
menstruation,~1
13/day~1
Gamete~1
pickup~1
gametes~1
PMS~5
sweats~1
flushes,~1
flush-like~1
PMS.~1
ohms~1
flushes~2
reanastomosis,~1
1-15~2
insulin-receptor~3
IM-9~1
(one-tailed~1
.002,~1
autoantibodies,~2
receptor-antibody-negative~1
(Fisher's~1
.0415).~1
Insulin-receptor~1
IDDM.(ABSTRACT~1
48-h-starved~1
Lipase~2
organs)~1
LPL.~1
.018)~1
ketonuric~2
nonketonuric~1
very-low-density~1
(IDDM).~1
aliquot~3
.35,~1
.40,~1
.45,~1
mg/L;~2
.56,~1
10-5)~1
mg/L),~2
nonglycosylated~2
.54,~1
.0005~1
.63,~1
mg/L).~2
glucose-clamp~1
slow-fall~1
(48-74~1
physician-diagnosed~1
(IGT)~1
(NDDG)~1
20-74~3
1976-1980~1
Survey.~2
demographic/medical~1
participant's~1
scheme.~1
17,390~1
15,357~1
(88.3%)~1
11,858~1
exam.~2
5901~1
examinees~1
75-g~1
(OGTT)~1
examinees,~1
OGTT~2
3772~1
IGT.~2
instructions.~3
OGTT,~1
1970-1980~1
NDDG~3
(3.2%)~2
20-44~1
(11.2%)~1
(4.6%).~1
post-75-g~1
dystrophia~2
myotonica~2
(skeletal)~1
gastrinlike,~1
somatostatinlike,~1
cholecystokininlike~1
Gastrin~2
8-wk-long~1
pregnancy;~2
suckling,~2
propagation~3
intestino-intestinal~2
T-shaped~1
10-15-cm-long~1
Migrating~1
transducers.~1
90-150~1
4-diphenylmethoxy-N-methylpiperidine~2
Pirenzepine~1
Pirenzepine,~1
spasmodic~3
histomorphometry.~1
0.037),~1
enteroglucagon,~1
azoxymethane,~1
resuture,~1
azoxymethane~2
enteroglucagon~9
trebled~1
bypass;~2
(defunctioned)~1
beta-lactoglobulin.~1
Biophysical~1
Affinity~2
G-(IgG)-rich~1
G-depleted~1
G-rich,~1
G-depleted,~1
mediated,~3
swallows,~1
(2-8~1
(1.5-20~1
7-lumen~1
(3-8~1
swallow.~2
beyond,~1
shortens~4
portions.~1
dysmotility.~2
sobriety.~1
abstinence,~3
Nutcracker~2
Motilins~1
7-8-12-13-14.~1
(guinea~1
dog)~1
motilins.~1
motilin~8
4.82~1
(10(-5)~4
hexamethonium,~1
(10(-4)).~1
species-related~1
bioactive~2
motilin.~2
(relief~1
discharge)~1
Lille~1
Multidisciplinary~2
[90%~1
mo)~2
mo)].~1
photoablation~1
(routine~1
xylose~2
4-wk~1
surface-cell~1
Self-filling~2
methods)~1
3-o-methyl-glucose-induced,~1
phlorizin-reversible~1
glucose-coupled~1
Km.~2
chloride-induced,~1
bumetanide-reversible~1
rheogenic~1
self-filling~1
10(-15)~1
(NT),~2
1-8~1
1-11,~1
(10(-11)~1
D-Phe11~1
[3H]thymidine)~1
(labeling~1
3.86~2
Eq/cm2~2
(pH-stat~1
4.39~1
51.8%~1
villi.~1
(+25%~1
+37%,~1
(-27.7%~1
-25.3%,~1
NH4Cl,~2
(-31%,~1
-52%,~1
-50%,~1
(+18.5%,~1
+19.3%,~1
+19.6%~1
30%-50%~1
lesions),~1
(vasopressin)~1
103-15.8x)~1
Omeprazole,~3
H+,~1
K+-adenosine~1
videorecorded~1
off-line~1
omeprazole~7
15-25~1
mumol/kg,~1
h)-stimulated~1
acid-inhibitory~1
estrogens.~1
high-cholesterol~1
prairie~2
excitation,~1
excitation-contraction~1
coupling,~1
catheterizations,~2
99mTc-macroaggregated~1
disinfection,~1
cleaning~1
machine,~2
Contamination~1
cholangiopancreatography.~1
desulfated~3
CCK-gastrin~1
Sulfated~1
CCK-7~4
pmol/kg)~5
Desulfated~1
(80-400~1
CCK-3~3
(10-80~3
nmol/kg)~4
CCK-2~2
(10-160~2
5-2000~1
CCK-7.~2
(10-400~1
nmol/kg).~1
(5-20~1
guanosine~8
(250-1000~1
located:~1
noncholinergic,~1
postcontractile~1
(vent),~1
[14C]polyethylene~1
vent~1
2.5-min~1
cholecystokinin-octapeptide,~2
(PP),~1
intragallbladder~2
cholecystokinin-octapeptide.~1
PP10~1
64.1%~1
17.1%,~1
PP50.~1
cholecystokinin-induced~1
Jewish-Iranian~1
radiologic,~2
recessive,~2
anastamosis~1
Sepsis,~1
oysters.~1
positivity.~1
oysters~2
restaurant~5
visited.~1
seafood~2
warned~2
undercooked~1
seafoods.~1
somatostatinoma~1
hypersomatostatinemia~1
calcium-pentagastrin~5
somatostatinoma,~1
tolbutamide~3
hypersomatostatinemia.~1
somatostatinomas~2
pseudoobstruction,~1
16-yr-old~1
High-dose~5
prevention.~5
forgotten~2
wishes~2
hemorrhage--particularly~1
benefit/risk~1
prudent~6
units/24~1
1.5.~3
Appendicitis~1
caecum~4
continental~1
sleep;~1
awakening.~1
peristaltically~1
awakening,~2
4.4/subject/24~1
defecate~1
defecation,~1
(superimposed)~1
fundic,~1
(+2SD)~1
re-examination~2
initially),~1
0-3)~2
(0-3)~1
(0-5)~1
(0-11)~1
seven-fold~1
Crypt~3
cells/crypt/h~1
non-ulcer~2
dyspepsia;~1
ulcers);~1
pseudo-obstruction~1
individuals:~1
duration)~5
non-propagated~1
incoordinated~1
pseudo-obstruction.~1
edentulous~1
neutralisation~1
refluxed~1
dentition.~1
(v/v),~1
haemoconcentration,~1
cobalamin~23
Simultaneously~1
binder~6
albendazole~5
sulphoxide,~1
(E~1
granulosus)~1
diffuses~1
Cyst/serum~1
pan-proctocolectomy,~1
anticipation,~1
reorientation,~1
selfimage~1
social-psychological~1
elaborated.~1
other)~1
hindquarters~2
(cellophane~1
wrap)~1
methoxamine,~1
(acetylcholine,~1
serotonin)~1
mecamylamine~1
dose-vascular~1
range),~1
precapillary~1
amplifier~2
"sensitivity"~1
unimportant~1
(SHR).~2
1.5-microliter~1
(i.c.v.)~2
(i.c.).~1
(i.c.~2
i.c.v.)~1
injected.~1
(i.c.),~1
i.c.v.).~2
8644,~3
(1%),~1
(0.1%),~1
(0.01%)~1
(SHR),~3
intraerythrocytic~1
magnesium-deficient~1
(DR).~1
(0.1%~1
Acetylcholine,~1
5'-diphosphate,~2
endothelium-derived~3
factor(s),~1
contribute;~1
spinotrapezius~1
nondimensional~1
treatment)~1
Tone~1
(so-called~1
arterioles)~1
(DOC)-salt~1
DOC-salt~6
week:~1
dimorphism~2
2061~1
graders~2
Rating)~1
brain-damaged~1
ignored,~1
2-day~3
nurse's~1
46.7%~1
42.1%~1
fura~1
48).~2
0.3;~3
33;~1
quin~1
167.4~1
143.2~1
nmol/L;~1
0.025-0.1~1
agonist-mediated~1
skinfold)~2
3784~1
biracial~2
Bogalusa,~1
Louisiana.~1
0.12;~2
(fourth~1
fat-blood~1
0.15),~1
0.12),~1
quartile~4
100.4~2
108.9~1
hypertension-central~1
(PAF;~1
acetyl~4
phosphorylcholine)~1
mg/kg)-anesthetized~1
(0.2-0.8~1
([Sar1,Ala8]angiotensin~1
micrograms/kg/min),~1
Methysergide~1
micrograms/min)~3
Alprazolam,~1
artery)~2
(dpm/mg/hr).~1
(centrifuged~1
(4.02~1
leucine/microgram~1
protein/hr;~1
monoamines~3
(ED25:~1
DOCA-treated~1
5-hydroxyindole~5
5-hydroxytryptophol~1
5-methoxytryptamine~1
N-acetylserotonin.~1
5,6-dihydroxytryptamine~1
6-hydroxytryptamine~1
3-hydroxytryptamine~1
DOCA-hypertensive~1
monoamines,~1
moieties.~1
(WKY),~2
permeant~2
acidification;~1
1164~1
paroxysm.~1
microneurographic~1
130/88~1
164/100~1
88/56~1
Yet~2
short-dwell~1
long-dwell~2
prohibitively~1
(HCTZ)~1
(ERBF),~1
HCTZ~2
HCTZ.~1
beta-blocker-HCTZ~1
ERBF~2
.05.~3
lactate-buffered~2
multivitamin~1
vitamin.~3
Discontinuing~1
Ultrafiltrates~1
membranes:~1
cuprophan,~2
polyacrilonitrile~3
polysulfone.~2
Hemofiltration,~1
polysulfone,~1
ultrafiltered,~1
Plasmapheresis~2
plasmapheresed.~1
Walter~1
Reed~1
enroll~1
phlebotomies~1
hip-replacement~1
chosen,~1
Transfusion-related~1
banked~2
sulphate,~1
scheduled,~1
Shepeard~1
Community~3
milliliters,~1
half-unit~1
(CPDA-1)~1
adenine,~2
(ADSOL)~1
preservative.~1
opening-wedge~1
Alignment,~1
hip-knee-ankle~2
undercorrected~2
gonarthrosis~2
Hernborg~1
Nilsson.~1
rigidly~2
Two-plane~1
osteons~1
porosity,~1
non-union;~1
shaft;~1
allograft;~1
ten-centimeter~1
centimeters.~1
pronation~2
millimeters,~1
radio-ulnar~2
(Hermodsson~1
Hill-Sachs)~1
(twenty-two~1
younger).~1
demonstrated.(ABSTRACT~1
occipito-atlantal~1
torticollis,~1
vertigo,~1
projectile~1
(twenty~1
knee)~1
had,~2
urokinase,~1
nitrendipine,~3
subintimal~1
fibrin-platelet~1
ensues,~1
Relevance:~1
(23.5%),~1
brachioradialis~1
(19.5%),~1
tenderness.~1
Bleeds~1
2.00)~1
winged~1
scapula.~1
gainfully~1
functioned,~1
serratus~1
Magnuson-Stack~1
Bankart~1
Hill-Sachs~1
irregularities~4
osteophytes.~1
Herbert~1
screw.~1
trans-scaphoid~1
Corticocancellous~1
immobilisation~1
jig~1
Gurd's~1
Cotrel~1
sublaminal~1
Luque~2
braced~1
unbraced~1
cholecalciferol~1
wire,~2
unfixed~3
[25(OH)D3]~1
24,25-dihydroxycholecalciferol~1
[24,25(OH)2D3]~1
callus.~2
osteocartilaginous~1
monarticular,~1
Mullins,~1
Berard~1
Eisenberg~1
(1965)~1
Dunn~1
(1974)~1
Antihelmintic~1
Echinococcus~1
granulosus~1
albendazole;~1
civilian~3
parachutists~1
civilians~1
parachutists,~1
(81.8%).~2
landing~2
first-stage~1
Dwyer~1
obliquity~1
worse),~1
432~1
stilette~1
stiletted~1
two-needle~1
0.7%.~1
fusion;~1
initiators~1
chondromalacia~2
patellae~1
osteophyte~1
patellae.~1
virus)-positive--that~1
AIDS--presented~1
radiculography~1
HIV-positive.~1
fasciitis.~3
vegetarian~2
haemochromatosis.~1
polyarthritis~3
joint-space~1
haemochromatosis~1
suspicion;~1
iron-binding~2
synovium.~2
cobalt-chrome~1
excellent.~6
resorptive~1
86%.~2
peroperative~2
sockets~1
socket~3
articulating~1
socket.~1
metal-polyethylene~1
inserted,~1
(10.7%)~1
value:~1
peak-flow~1
Derby~1
weight-bearing.~1
intoeing~2
anteversion.~1
widely;~1
medial.~2
anteverted~1
second.~2
Clearly~2
anteversion~1
gait;~1
Ahlback~1
(1968).~1
occupation.~1
meniscectomy.~1
scans).~1
adversely.~1
Osteochondritis~2
hump~1
guaranteed~1
hump.~2
C2;~3
C1-2~1
C2~3
started;~1
(failure),~1
(good)~1
(excellent);~1
neuralgic~1
amyotrophy~1
fair.~1
Ulnar~1
carpus~1
Colles'~1
fixator.~1
fixator~2
forgo~1
splintage.~1
carpometacarpal~1
adduction~2
"myelopathy~1
hand"~1
mediolateral~2
unfixed,~1
undecalcified~1
subcapital~3
trochanteric.~1
fractures;~1
Catterall~4
coverage,~5
head-at-risk~1
Stulberg,~1
Cooperman~1
Wallensten~1
Iowa~9
Stulberg~6
class;~1
age-groups~1
693~1
mobilised~1
displaced.~1
Rosen~1
Pavlik~1
harness.~1
splinted~1
hips.~1
splintage,~1
4.0%;~1
85.7%.~1
venographic~1
deep-vein~1
Custom-made~1
fully-constrained~1
now-outmoded~1
high-velocity~1
road~2
low-velocity~2
"vibration~1
arthrography",~1
prominences~1
types--physiological~1
crepitus,~1
clicks,~1
lateralise~1
tear,~1
promises~1
logical,~1
pivot~1
"unblocked"~1
microcapillary~1
133-xenon~1
(74%).~2
uneventfully~2
(carbon~1
fibre,~1
composite,~1
xenograft)~1
intra-osseous~2
portion,~1
osteochondritic~1
crater,~1
joint;~1
impermanent~1
necessary;~2
serum-~1
gonadotropin-free~1
elapsed.~1
[very~1
(LDL)]~1
Granulosa~1
HDL-esterified~1
HDL-free~1
preferentially.~1
(phospholipase)~1
Hypothalamic-pituitary~1
3979~1
6167~1
centiGrays,~1
RT,~1
Hyperprolactinemia~1
oligomenorrhoea~1
FSH,~2
progestational~1
alpha-subunit-specific~1
nonreceptor~3
nonreceptor-bound~1
Conceivably,~1
0.0001);~1
Thyroglobulin~2
(200K~1
320K)~1
(105K).~1
64K~1
73K,~1
50K,~1
ophthalmopathy.~3
(LPD),~1
LPD~4
(PgR)~1
13-15,~1
PgR~5
(HSA-bound~1
nonsex~1
(non-SHBG-bound~1
SHBG-bound,~1
HSA-bound,~1
non-SHBG-bound,~1
0.5-14~1
2-binding~1
(HSA~1
SHBG)~1
SHBG-T~1
HSA-T~1
SHBG~15
SHBG-bound~2
HSA-bound~3
1.9-fold.~1
30.4%,~1
maturative~1
polyglandular~1
1.2-12.1~1
(SCA)~1
Adrenocortical~1
SCA~6
(so~1
far)~1
sensitivities/specificities/predictive~2
0.77/0.78/0.90~1
0.92/0.89/0.92~1
adrenal-binding~2
SCA)~1
1.0/0.56/0.50~1
0.86/0.83/0.86~1
1.0/1.0/1.0~1
Somatomedins~1
(Sm)~1
normal-statured~1
Laron-type~3
(IGF-I;~1
Sm-C)~1
[3H]alpha-aminoisobutyric~2
short-statured~1
dwarfism.~1
hyporesponsive~1
hypogonadotropic~1
placebo).~1
hyperprolactinemia,~1
hyperprolactinemia.~2
(Sm-C)~1
Sm-C,~1
Sm-C~6
Glucocorticoids~1
aminoisobutyric~1
20-h~1
Sm-C.~1
hydrocortisone.~1
RU486~1
[125I]Sm-C~1
trypsin-dispersed~1
preincubation,~1
[3H]aminoisobutyric~1
gt11~2
Grave's~1
1:10(6).~1
(IL-28~1
IL-33)~1
IL-28~5
IL-33~3
(antimicrosomal~1
titers,~2
1:6400).~1
(kb),~2
0.6-kb~1
poly(A)+~1
subcloned~1
dideoxy~1
572~1
basepairs~1
GenBank~1
Dayhoff~1
banks,~1
characterized;~1
thyroglobulin,~1
TSH-binding~1
[19~1
increment,~2
0.53,~1
0.35,~1
Last,~1
alpha-cell~1
gynecomastia~2
(PSFG)~1
(PSFC).~1
[3H]androstenedione~1
Estrone~1
(E1)~1
crystallization,~1
metabolites:~1
16-hydroxyestrone~1
alpha-OHE1)~1
(E3),~1
epiestriol~1
(epiE3)~1
(ARE2)~1
(ART~1
alpha-OHE1~2
E3~2
epiE3/microgram~1
ARE2~1
PSFC;~1
PSFG~4
striking:~1
PSFC,~2
3.15~1
PSFC.~1
4.17~1
3.70~1
epiE3~1
PSFC~1
androgen-estrogen~1
gynecomastia.~1
alpha-reduced~2
alpha-androstanediol~5
hGH-N~2
GH-V,~1
silent.~1
(hPGH),~1
mid-pregnancy~1
hPGH~2
GH-V~1
hGH-V~3
dot-blotted~1
pregnanediol-3~1
alpha-glucuronide~1
(PdG),~1
beta-glucuronide~1
(E2G),~1
nonbreastfeeding~1
Ovulation~1
PdG,~2
E2G~1
PdG~8
smoothed~3
anovulatory,~1
E2G,~1
adequacy,~1
complexed.~1
MCRs,~1
(Vd),~1
GH-binding~1
immunoprecipitable,~1
mL/kg),~1
4.5-fold~1
(13.2%~2
59.9%/15~1
hGH-binding~1
hyperestrogenism~2
estrogen-secreting~1
11-43~1
spermatogenesis~2
hypothalamo-pituitary~1
irreversible)~1
adrenorphin~9
(3-7771~1
Adrenomedullary~1
(2295~1
1092~1
pg/mg,~1
pg/mg).~1
Adrenorphin~2
(IC50)~1
met-enkephalin,~2
dynorphin-(1-13)~1
BAM-12P~1
Renin~1
monkey.~1
saralasin.~2
calcium-calmodulin~1
R2471~1
renin,~1
angiotensinogen,~1
(TSAb),~1
stimulation-blocking~1
TBII~5
hypothyroid.~2
positive;~3
(SHBG)~3
HDL2~2
A-I.~2
girth~1
(WHR).~1
(Sms)~1
Sm-C/insulin~1
Membrane-enriched~1
[125I]insulin~1
5.1-7.2%~1
[125I]Sm-C/IGF-I.~1
12-20~1
1:1,000)~1
135,000-dalton~1
(QTc),~1
Bazett's~1
(447~1
(468~1
meta-iodobenzyl-guanidine~1
imbalance;~1
unexpectedly.~1
pulsatility~1
10-month~2
studies).~1
[1.0~1
pulses/8~9
h]~1
HA.~2
alpha-Adrenergic~1
2-agonist~1
0800~2
(3.3~2
(4.9~1
naloxone-responsive~2
sleep.(ABSTRACT~1
(strength~1
surge-initiating~1
ovulating~2
4-17~1
cycles/woman).~1
(concentration~2
979~1
pg/mL.~1
variance,~3
(concentration,~1
feedback.~2
(peak:~1
dose:~1
0.60;~1
diiodotyrosine~1
(DIT)~1
DIT~11
noncompartmental~1
MCRs.~1
L/day~1
nmol/day~1
DIT.~1
nmol/24~1
(533~1
ng/24~1
0.108~1
0.048~1
nmol/nmol~1
thyroidal~2
1.2-17.7~1
nmol/mmol~1
DIT-like~1
hepatocarcinoma~1
(T),~2
absence,~1
antiestrogen~4
antiandrogen~1
Pregnanediol~1
E2-related~1
T-related~1
D-binding~2
LD~2
17-hydroxycorticosteroid~1
androstenediol~2
insignificantly,~1
10-23~1
postburn~10
C19-steroid~2
glucocorticosteroid~1
athyreotic~7
(suppressive~1
(BW)/day~1
BW/day~3
25th-75th~1
2.5-2.9~1
1.9-2.3~1
(FT3),~1
(FT4)~1
FT3~1
FT4~8
FT3,~3
FT4.~1
13/26~1
4/30~1
1/25~1
FT3.~1
Melatonin,~1
antigonadotrophic~1
Melatonin~1
hCH~1
[36.5~1
pg/mL]~1
(10.0~3
pg/mL).~1
0.770;~1
Free-flow~1
reabsorbed~1
NH3~1
PCT,~1
backflux~1
detracts~1
(MPCs).~1
Immature~1
MPCs,~1
rosetting.~2
[3H]5-formyl-FH4~1
folates~1
5-methyl-tetrahydrofolate~1
(5-methyl-FH4)~1
10-formyl-FH4~2
(41.4%),~1
5-formyl-FH4~1
(12.3%),~1
FH4~1
(10.3%).~1
10-formyl-FH4,~1
5-formyl-FH4,~1
5-methyl-FH4,~1
FH2~2
10-formyl-FH2~1
Paralleling~1
folates,~1
FH2,~1
antipurine~1
polyglutamates.~1
Hereditary~3
angioneurotic~2
(HANE)~2
(C1~1
INH).~1
HANE,~1
5-30%~1
HANE~3
message~3
kb).~1
defect(s),~1
pretranslational,~1
rearrangement.~1
(RCCT)~1
immunodissection,~1
5'-N-ethylcarboxamideadenosine~1
(NECA),~1
N6-cyclohexyladenosine~1
(CHA),~1
R-N6-phenylisopropyladenosine~1
(PIA).~1
RCCT~3
NECA~1
CHA.~2
CHA~2
NECA.~1
1,3-diethyl-8-phenylxanthine~1
isobutylmethylxanthine.~1
AVP-~1
toxin.~2
(A1)~1
(A2)~1
nucleotide-binding~1
Ni,~1
interrelated,~1
calcitriol-replete~1
aluminum-related~1
1%)~1
reaction-activated~1
hypoestrogenemic~1
intravaginal~2
pulsatility.~1
fractional)~1
modeled~4
(RF+)~1
(7S)~1
19S~2
RFs~2
pentameric~1
crossreactive~1
(RCRI)~1
RFs.~2
(PWM)~1
RCRI~2
anti-RCRI~3
RF+~4
RA-derived~1
Waldenstrom's~1
macroglobulinemia.~1
107-kD~5
Solubilized~1
Reacti-gel.~1
Eluates~1
blot.~1
107-~1
101-kD~1
7.0.~2
xanthinuria.~3
[8-14C]adenine~1
5-d~2
9.7%~2
enzyme-deficient~2
7.96~1
9.16~1
cpm/g~2
4.73~1
487%~1
Degradation~1
(TSP)~1
125I-TSP~1
saturably,~1
U937~3
6.7-14.5~1
TSP~7
rosetted~2
anti-TSP~1
Arginine-vasopressin~1
(Ir)~1
PlatAVP~4
Ir~2
platelet-poor~1
(Pavp).~1
PlatAVP,~1
Pavp,~1
suppression-stimulation~1
Pavp~2
(Posm,~1
mosmol/kg~1
H2O);~1
(pg/ml)~1
(Posm~1
-274.4),~1
Posm~1
intraplatelet~2
BMax~1
sites/platelet;~1
typhi~3
mutants,~2
541Ty~1
(Vi+)~1
543Ty~1
(Vi-),~1
auxotrophic~1
p-aminobenzoate~1
10(8),~1
10(9),~1
Vaccine~2
coprocultures~1
vaccinees~3
O,~2
Vi,~1
meager.~1
vaccination,~2
postvaccination,~1
plasma-dependent~1
(dd)~1
cinchona~1
F(ab')2,~1
Fab,~1
dd-IgG.~1
dd-IgG~1
8:1~1
50:1~1
1.6-3:1~1
44-75:1~1
dd~1
Bombesin,~1
EDTA,~3
(10(-3)~1
poikilocytosis~3
resealed~2
elliptocytic~1
2,3-diphosphoglycerate~1
(DPG)~1
(0-8~1
dissociates~1
skeletons,~1
ektacytometer.~1
pyropoikilocytosis~1
(HPP).~1
2,3-DPG~2
(2.55~1
ghosts,~1
HPP~1
2,3-DPG).~1
Nonphysiological~1
(6-8~1
HbF,~3
fragmentation.~2
diminishing~2
abatement~1
stunned~5
(DP)~1
[Ca]0~2
(0.5-7.5~1
Langendorff-perfused~1
ferret~1
(stunned~1
[Ca]0,~1
DP~12
(MCAP),~1
tetani~1
ryanodine,~1
stunning~1
DP-[Ca]0~1
MCAP~2
(Ca0~1
stunning,~1
low-[Ca]0~2
[ATP]~1
Ca0~1
transient).~1
stunning.~1
C.M.~3
Glanzmann's~3
thrombasthenia.~2
surface-labeled~1
Ca2+-washed~1
(CIE)~3
electrophoresed~1
125I-fibrinogen,~1
AP-2~1
T10~1
(anti-GP~2
IIb).~1
thrombasthenia~1
alpha-MHC~1
beta-MHC~3
coarctated~1
deinduction~1
alpha-MHC,~1
elliptocytosis.~1
cell-membrane~1
beta-spectrin~2
anti-alpha~1
alpha-spectrin~3
mutant,~1
9.9-45.2%~1
dimers~2
0.92)~1
-0.98).~1
dimer-dimer~1
intra-assay~1
Rose-Waaler~3
+0.58;~1
+0.27;~1
Minute~3
18,000~1
histopathogenesis~1
erosions.~1
globoid~1
zygomycosis~3
alpha-interferon.~1
Clonal~1
(GM-CFCs)~1
T4:T8~3
0.036).~1
0.0001;~2
glomic~5
67.5/mm2.~1
96/mm2.~1
12/mm2~1
VII,~2
lowest,~1
(BCR)~1
thromboplastin,~1
thromboplastins~1
Microsieving~1
(HbSS)~1
piracetam~2
HbSS~2
vaso-occlusive~1
crises~2
Instead~1
multipotential~1
airway;~2
generally,~1
invariably,~1
non-alcoholic~3
microbiology,~1
radiology,~1
stillbirth.~1
typified~1
Nauomenko~1
Feigin's~1
haematomata~1
Fatal~1
biotype~3
milleri~2
trephines~3
IgA2~3
haematological~1
IgA1,~2
IgA2,~1
nucleate~1
cavities.~1
1.18%~1
0.18%,~1
1.41%.~1
subclass.~1
Concepts~1
mounting~1
harmful,~1
uncertainty,~1
processes:~1
overgrowth,~1
alpha-thiol~1
(alpha-TPI)~1
(448~1
75)~1
mg/l,~1
oestrogens~1
666~1
(87)~1
mg/l.~1
Inconsistent~1
alpha-TPI~2
Crossed~3
mobilities.~1
antiprotease~1
prealbumin~5
amyloid,~2
(SSA),~1
amyloidotic~1
(FAP).~1
ASc1~1
AF,~1
paradox~3
SSA~1
FAP~1
bronze~2
Suspected~1
photodegradation~2
copper-porphyrins.~1
biliverdin.~1
biliverdin~2
"bronze"~1
paraneoplastica~1
Bazex.~1
helices,~1
palmoplantar~1
eruption.~2
improving,~1
soft,~1
chin,~1
panniculitis~1
reagent.~1
Flegel's~1
lenticularis~2
perstans,~1
perstans~1
5-fluorouracil.~1
blistering~1
bullosa.~1
lipodystrophy~2
membranoproliferative~5
(dense~2
deposit)~1
2.5-cm~1
microprobe~1
blue-black~1
argyria.~1
argyria~1
Similarities~1
darkening~2
colorless~1
(collagen~1
gelatin)~1
tattooing~1
light-exposed~2
melanophages~4
intraepidermal~1
cell-activating,~1
(T6-~1
DR+~1
OKM5+~1
OKM1-)~1
(Mo3e+),~1
(Mono~1
My7).~1
clean-appearing~1
Dermatologists~1
Subungual~1
baleful~1
banal~1
list.~1
hypohidrosis~1
overheated~1
sunlight,~2
perspiring.~1
fissuring~1
cheilitis.~1
methacholine.~2
1951~1
telangiectases~2
macularis~1
eruptiva~1
perstans.~2
telangiectases.~1
Reflex~2
dissuade~1
Pigmentary~1
poikiloderma~1
vasculare~1
pruritic,~1
fungoides.~2
dermatology~4
palpation,~1
hypergranulosis,~1
papillomatosis.~1
enteropathica,~1
enteropathica.~1
infraocular~1
milium-like~1
syringoma~2
Fontana-Masson~1
melanin-containing~1
biomaterial~3
manufacturer.~2
anti-bovine~1
avidin.~1
0.40%~1
64.3%,~1
avidin~2
Lymphomatoid~1
lymphomatoid~2
papulosis.~1
Bronx,~1
(Castellani)~1
Sabouraud,~1
1911~1
(57.5%),~1
Malmsten,~1
(18.5%),~1
(Robin)~1
Blanchard,~1
(11.5%),~1
Bodin~1
var.~1
Matsumoto,~1
Padhye,~1
Ajello,~1
1902~1
(Harz)~1
Langeron~1
Milochevitch,~1
1930~1
(3.9%),~1
audouinii~1
Gruby,~1
1843~1
(2.8%).~2
anetoderma~2
anetoderma,~1
ocular,~1
Photoprotection~1
sunscreens~4
8-methoxypsoralen~2
anthracene.~1
Parsol~3
1789~2
Eusolex~3
8020~2
oxybenzone~3
xenon-arc~1
photoprotection~4
3.0)~1
2.0)~2
anthracene~1
unsensitized~1
1.8)~2
1.4)~1
sunscreens,~1
UVA-induced~1
ectothrix~1
canis.~1
cross-sectioning~1
cuticle.~2
cuticle~8
broken.~1
sulfide~1
shampoos~1
myriads~1
hidden~1
(IBM~1
7350/4361)~1
slides.~1
slide~3
chromatic~1
standardize~3
perceivable~1
conferences~1
conferences,~1
redefine~1
lips,~1
Literature~2
acquisita~2
pemphigoid.~2
pemphigoid~1
Birt-Hogg-Dube~1
fibrofolliculomas,~1
trichodiscomas,~1
acrochordons.~1
firm,~2
infarctive~1
prostacyclin-thromboxane~1
glucagonoma~2
necrolytic~3
erythema,~2
dacarbazine.~1
acantholysis~2
(HTLV-III)~2
T-helper~1
corticosteroid-azathioprine~1
alive;~1
azathioprine-corticosteroid~1
safe;~1
some.~1
nodosum,~1
Papular~1
Lupus~1
pernio,~1
mottling~1
(DNCB)~1
pernio~1
unsightly~2
telangiectatic~1
K1~2
preeclampsia.~2
eighty-nine~2
Full-thickness~1
Occasional~1
flowers~1
bimodality~1
seen.(ABSTRACT~1
730~3
hyperactivity~2
Dermatological~1
sponsors~1
1,909~1
patient-participants.~2
4,431~1
demarcation~4
Separation~1
annulare~3
hereditarily~1
substances).~1
Melanoma/Skin~1
Week,~1
356~2
Referrals~1
numbered~1
exemplifies~1
pedicled~1
diagrams,~1
commentary.~1
facial,~1
eruptive~1
vellus~2
Halo~1
hypopigmentation~1
816~2
Limitation~1
Size~1
(MILIS)~1
674~2
variables;~1
(48%);~1
MILIS~1
drug-free,~2
(couplets,~1
salvos~1
phenomenon)~1
alternans~12
alternans.~1
gradually.~1
(369~1
rate-related~1
"strain"~1
cineangiographic~1
sever,~1
(431~1
(128~3
dynes-cm2~1
10(3),~1
Insertion~1
artery),~1
counterpulsation,~1
2.0),~1
1.9),~1
postinsertion~1
ankle-brachial~1
(10.5F/12F)~1
balloon-related~1
electrocardiography,~2
dB/octave)~1
corner~1
satisfied:~1
(late~2
potential)~1
(chi-square~1
93.2,~1
Extraparenchymal~1
shunt).~1
Reversed~1
descent.~1
turbulent~2
extraparenchymal~1
Two-dimensionally~1
Mustard~1
repair),~2
repair)~1
m/s~1
two-dimensionally~1
ms/s.(ABSTRACT~1
Valsalva.~1
(78%).~1
effort-limited~1
289~1
1,614~1
ventriculograms~2
Thrombolytic~2
Nisoldipine,~1
readmitted~2
1,781~1
1,306~1
cm-5,~1
nisoldipine's~1
cardioverter/defibrillator~1
fibrillation-defibrillation~1
defibrillating~1
spring-patch~1
32.~1
1,524~1
571~1
microscopically,~2
Endothelialization~1
Arteriosclerotic~1
(Photofrin~1
arteriosclerotic~4
aortas.~2
Photofrin~3
laser)~1
porphyrins~2
atheromas~1
(zone~1
141-cerium-labeled~1
staining)~1
terms.(ABSTRACT~1
commissures~2
oversized~1
Liberation~1
midleaflet~1
Embolic~2
presume~1
injects~1
"excess"~1
Computers~1
display,~1
concludes~3
myxoma,~1
half-times,~1
(Ag~1
ELISAs~1
(culture~1
filtrate)~1
92.3%~1
Ag~6
(21)~2
aspergilloma~1
ELISAs,~1
87%.~1
prick~1
Alternaria~1
alternata~1
ABPA.~1
Aspergillus-related~1
foodstuffs.~1
embarked~1
esterase-inhibitor~1
ascaris~1
H2O/L/sec~2
Trapping~1
(functional~1
rebreathing~6
Upstream~1
BAL,~1
10(4)/ml~1
Eosinophils~1
season,~2
(48.1%).~1
aspecific~1
rhinitis.~3
mast-basophiloid~5
31),~3
(IPF)~1
0.0,~1
IPF~3
1315~1
737~1
0.655~1
cytocentrifuge~1
reason(s)~2
lumenal~1
(IT),~1
ryegrass~2
(RGGI)~1
allergen-controlled~1
grass-pollen~3
IT~5
preseasonally~1
midseason~1
IT.~1
RGGI-specific~1
(sIgE)~1
RGGI~8
sIgG~1
thirteen-fold~1
IgG-blocking~1
IgG4.~1
sIgG1~3
sIgE~1
sIgG4~3
IgE-binding~1
ryegrass-polypeptide~1
ubiquitous,~1
IgG-binding~1
symptom-medication~1
-0.62,~1
carmine~1
maleic~2
colophony~1
active-challenge~1
prechallenge~1
0.72;~1
p,~1
significant).(ABSTRACT~3
hemacytometer~1
sulfonamides~2
(SM)~1
N4-sulfonamidoyl~1
(N4-SM).~1
Sulfamethoxazole~1
(SMX)~1
CNBr-activated~1
isourea-linked~1
N4-SMX~1
IgE.~3
(counts~1
disks)~1
1.11~1
SM~4
SMX,~1
sulfamethizole,~1
sulfamerazine,~1
sulfanilic~1
trimethoprim.~1
N4-SM~1
(Ags)~1
farinae~3
(DF)~1
media-free~1
CIE~5
DF~8
Ags,~3
CRIE~2
mite-sensitive~3
Ags~8
Ags.~2
Homologous,~1
heterologous,~1
Heterologous~1
(Ags).~1
mite-specific~1
feces-specific~1
allergenicity~1
interspecific~2
cephoperazone,~1
wheal-and-flare~1
penicilloylpoly-L-lysine.~1
penicilloylpoly-L-lysine~1
desensitize~1
Wheezing~1
aminoglycoside-allergic~1
pentamidine.~2
antiparasitic~2
readministration~3
drug-allergic~2
85.~1
Readministration~1
pentamidine~5
sulfamethoxazole-trimethoprim~1
readministered~1
maculopapular~4
azulfidine~1
suprainfection.~1
pollens,~1
(GpI),~1
(meadow~1
fescue,~1
grass,~3
sweet~1
redtop~1
perennial~2
ryegrass).~1
GpI~3
immunize~1
hybridoma-derived~1
anti-GpI~1
grass-allergic~1
allergen:~1
12/18~1
2/135~1
be,~1
hyperimmunoglobulin~1
(HIE)~1
HIE~4
(23.7~1
97).~1
(159~1
anti-Staphylococcus~1
eczematoid~1
(42.4~1
life-endangering~1
phenoxymethyl~1
abandonment~1
resensitization.~1
2,820~1
servants~2
scoring.~1
46.8%~1
68.6%~1
25-year,~1
yogurt,~1
trend,~1
inconsistent,~1
airline~6
932~1
passengers.~2
packets~1
dinner,~1
packet,~1
(362~1
Na).~3
discretionary~1
234~2
(232~1
dinners~1
(786~1
menus~1
"captive"~1
packets.~1
762~1
Utahns,~1
iron/2,000~1
kcal,~1
Allowances~2
(RDAs)~2
kcal:~1
8.99~1
iron/1,000~1
kcal.~2
vegetable,~1
fruit,~1
products;~1
low-iron~1
pastries,~1
sweets,~1
fats,~1
high-calorie~1
breakfast~2
cereals~2
cereals,~1
16%;~1
poultry,~2
18%.(ABSTRACT~1
Managers~1
Title~1
managers~2
aversion,~1
Manager~1
transportation,~1
menus.~1
protein-calorie~1
Anthropometry~2
does.~1
anthropometry~1
Heymsfield's~1
tomography-generated~1
Anthropometrics~1
Anthropometry,~1
impractical~1
scarcity~1
cost-accounting~1
$72~1
$121~1
References~1
plan,~1
item.~1
Code,~1
36,255~1
Agriculture's~1
1977-78~2
Mean,~1
minimum,~1
Codes,~1
compiled~1
items.~2
(beef,~1
pork,~1
chicken,~1
eggs)~1
assumption.~2
"Higher~1
[77%]~1
respondents),~1
vanadium~1
burn-injured~1
lunches~1
non-participating~2
table,~2
boys'~3
chemically.~1
35%)~1
+11%~1
-15%).~1
Alabama~2
nonsequential~1
recalls.~1
Coenzyme~1
cravings~2
("craving~1
sheets").~1
cravings.~1
stages:~1
premenstrual.~1
Cravings~2
chocolate~1
high-sugar~1
high-starch~1
postpartum,~1
self-report,~1
letting~1
suckle~1
"let~1
down,"~1
feeds~1
pediatrician.~1
coped~1
maternal-infant~1
Oregon.~1
Discards~2
householder's~1
amount,~1
Households~1
discarded~3
1,587~1
($2.88)~1
vegetables;~1
poultry;~1
non-use~1
leftovers~1
dishes;~1
cost)~1
unsafe~1
householder.~1
Aesthetic~1
discard.~1
refrigerator~1
Consumers~1
(CUPs)~1
Association.~1
CUPs~3
(77%),~2
geriatric-related~1
geriatrics,~1
diet-related~1
benefiting~1
72%,~2
Nursing~1
histories,~1
SHAPEDOWN~1
no-treatment~2
sustainable.~1
Very-low-calorie~1
adolescents'~1
weight-related~1
Self-esteem~1
-9.9~1
14.9%~1
13.2%.~1
-5.15~1
Drop-out~1
cortical)~1
trabecular)~1
(BMC),~1
free),~1
estradiol-17B~1
92.~1
-.57,~1
.458,~1
.0002)~1
cares,~1
(SDAT).~1
(BDS)~1
(SPMSQ).~1
(FHT).~1
SDAT~2
(BDS,~1
SPMSQ,~1
FHT)~1
(CDR)~1
univariate,~1
ANOVAs,~1
indicate:~1
measures;~1
measure;~1
bacillary~1
four-year-period~1
489-bed~1
(40.4%)~1
Urosepsis~1
hospital-acquired~2
bacteremia-related~2
nonfatal/ultimately~1
(NF/UFUD),~1
NF/UFUD~1
neutropenia-associated~1
nonurinary~1
multiple-drug~1
mesylate~1
(DEM,~1
Hydergine)~1
twelve-week~1
amnesic~2
pseudodementia,~1
Psychic~1
Somatic~1
(IPSC-E),~1
DEM~2
3.34;~1
1,39;~1
symbol~1
Zahlenverbindungs~1
(ZVT)~1
Haloperidol-induced~1
predisposed.~1
Neuroleptics~1
dyscrasias.~1
(ESWL),~1
Urology~1
Clinics~1
nonverbal~3
pressing~2
key.~1
Positively-accelerated~1
.99).~1
exponent~1
allometric,~1
(Botwinick,~1
Cross-sectional~2
age-group~1
Formulae~1
(WAIS),~1
check~1
underarousal~1
hyperarousal~1
sleepers.~1
Vasoconstrictions,~1
44.~2
Bunker~1
(BHHC),~1
64,~3
underfed~2
Diet-restricted~1
hang~1
descend~1
Underfed~1
Undernutrition~1
startle~2
sensory-motor~1
Life-prolonging~1
retard~2
70.4~2
tachistoscopically~1
completeness.~1
persons'~1
completeness,~1
elaborative~1
(Kunen~1
1979).~1
(1986)~1
pictorial~1
elaboration.~1
speakers~2
peers,~4
paradigm,~1
listened~1
taped~1
speaker~1
Communication~1
speaker's~1
benevolence~1
trustworthiness,~1
kindness),~1
retirement~9
retirees,~1
retirement,~1
self-esteem.~1
Retirement~1
Retirees~1
adjustment;~1
externality~1
equivocal.~1
dressed~1
(Ta).~1
exposures,~2
1,680~1
(GEU)~1
geriatrics~2
affective,~1
GEUs~1
(hypoxic/hyperoxic);~1
0.11,~1
PCO2/lower~1
PCO2)~2
3.14~1
multiplicative~1
senescent~3
Relaxant~1
declines.~1
versa~1
Cross-temporal~1
older)~1
"oldest-old"~1
(those~1
over)~1
Markides~1
Martin's~2
disabilities.~1
(3C-7)~2
carboxy-terminus~1
(P505-582)~1
multispecific~1
3C-7~1
anti-BSA~2
MOPC~1
Idiotype-binding~1
reconstitute~2
Lyt-1-2+.~1
antibody-induced~2
Mesocestoides~1
corti~2
isotypic~2
corti,~1
Lyt-2+~2
G-10-adherent~2
anti-parasite~1
parasite-infected~1
Bluegrass~1
(KBG-R)~1
4B.~1
KBG~1
pollen,~1
anti-KBG~1
KBG-R~2
arg~7
(FMLP)~2
pure)~1
plasma-Percoll~1
elutriation,~1
endotoxin.~1
(unstimulated)~1
111Indium-tropolonate-radiolabeled~1
1.3.~1
47.2%~1
43.8%~1
serum-coated~3
FMLP.~1
peptides)~1
circumstance.~1
stimulus-specific~1
arg-stimulated,~1
FMLP-stimulated~1
monocyte.~1
Methylxanthines,~1
B-treated~1
biphasic,~1
1-Methyl-3-isobutylxanthine~1
8-Phenyltheophylline,~1
potentiation,~1
methylxanthine-induced~1
MLC,~1
"HLA-identical"~1
MLC.~1
Bgl~1
II-digested~1
kb),~1
HLA.~1
SstI-digested~2
DO~3
beta.~2
kb,~1
crossovers~1
loci.~2
allorecognition~1
MLR~1
graft-vs-host~1
60,000)~1
95,000)~1
Polypeptides~2
oncofetal~1
lactoperoxidase-catalyzed~1
iodination.~1
galactopyranoside,~1
galactopyranoside~1
isolectin~1
simplicifolia.~1
galactopyranosyl~1
galactopyranosyl-binding~1
disaccharides~1
galactosyl~1
NKH-1~3
subepidermal~3
immunogen.~1
NKH-1,~1
subbasement~1
oxytalan~1
elaunin~1
microfibrils~1
(elastofibrils)~1
nonreactive.~1
arrector~1
follicle,~1
NKH-1-positive~1
Species~1
nonprimates:~1
skins~1
NKH-1.~1
subbasal~1
(subbasal~1
proteins)~2
microfibrils.~1
Skh:HR-2,~1
pigmentation.~1
darkness),~1
(melanocyte~1
density),~1
(melanin).~1
lighter.~1
quantifiable~2
(HPD)-induced~1
phototoxicity.~2
kJ/m2~1
400-410~1
after.~1
time-points,~1
ear-thickness~1
125.7~1
14.4%~2
HPD-~1
irradiation-treated~1
HPD-induced~1
(line~1
SV-K14)~1
envelopes~2
ionophore.~1
140K,~1
90K,~1
61K,~1
53K,~1
36K,~1
noncompetent~1
SV-K14~2
anti-involucrin~1
transglutaminase,~2
(AKH1~1
AKH2)~1
filaggrin~3
flattened,~1
keratohyalin.~2
AKH1~4
reacts~2
profilaggrin~1
kD),~1
AKH2~5
filaggrin.~1
keratinization~4
profilaggrin/filaggrin;~1
profilaggrin/filaggrin~1
electron-induced~1
420,~1
[3H]-thymidine~1
3H]Thd)~1
Ci/g~1
meV~1
rads/min.~1
radioautographs~1
singlets~1
[3H]Thd)~1
show,~1
(pubescent)~1
420-day~1
(adult)~1
728-day~1
(senescent)~1
taut,~1
shiny,~1
Prominent~1
hyperplastic,~1
hyperkeratotic,~1
parakeratotic.~1
Keratohyaline~1
keratohyalin-derived~1
high-molecular-weight,~1
differentiation-specific~1
antikeratin~1
hyperproliferative~1
underdeveloped,~1
facies,~2
Congenitally~1
"nude"~1
(RNU/RNU)~1
cutaneously~1
mentagrophytes.~2
Nude~1
thymus-grafted~5
euthymic~1
(+/RNU)~2
adoptively~1
PEC-recipient~2
mentagrophytes-induced~1
(4/4),~1
trichophytin~1
PEC~3
+/RNU~3
trichophytin-sensitized~1
non-sensitized~1
cell-dependent,~1
Photodamaged~1
glycosaminoglycans.~1
subepidermally.~1
repair:~1
continued;~1
Westinghouse~1
FS~2
sunlamps~1
Sunscreens~1
sun-protection~1
prevented,~2
topically,~1
preirradiated~1
acid-treated~1
ceramides,~1
Interlamellar~1
linkages~2
30-carbon~1
omega-hydroxyacids~1
corneocytes~1
squalene.~1
sebocyte~1
subjecting~2
comedo~1
irritants.~2
Polymorphous~1
(PLE)~1
photodermatosis~1
afflicts~1
fair-skinned~1
papular,~1
vesiculo-bullous,~1
multiforme-like,~1
(strophulus)-like~1
sunshine,~1
monomorphous~1
subsides~1
scars.~3
corium~1
spongiosis~1
PLE~2
Reproduction~1
UVB,~1
UVA,~1
UVA-~1
UVB-effective~1
Phototherapy~1
(psoralen~1
UVA;~1
PUVA)~1
alkyldimethylbenzylammonium~1
(ADB)~1
(beta-glucuronidase)~1
0.02%,~1
cytotoxic,~2
exclusion,~2
beta-glucuronidase-release,~1
0.002%~1
0.001%.~1
10(-8)%.~1
pathomechanisms~1
surfactants.~1
(MCMV)~1
lumina~4
heat-inactivated~1
MCMV-infected~1
maldeveloped~1
unclosed~1
underdeveloped~1
Ectodermal~1
poxlike~1
morphogenesis.~1
.002).~2
resistant,~1
kDa~4
serum-resistant~1
serum-sensitive~1
.007).~1
low-passaged~1
82-40,~1
100-kDa~2
125-kDa~1
nonlipopolysaccharide~1
(non-LPS)~1
12-including~1
biotypes~1
serotypes-express~1
non-LPS~2
Tor~1
biotype,~1
lamblia-infected~1
-uninfected~1
Titers~1
(higher~1
OD)~1
Giardia.~1
OD;~1
image-analysis~1
(PMNLs)~1
PMNLs~2
Zigmond~1
n-formylmethionylleucylphenylalanine~1
(f-Met-Leu-Phe).~1
videotape~1
videocamera~1
PMNL~2
10-sec~1
microns/min~2
25.3~1
f-Met-Leu-Phe.~3
McCutcheon~1
41,000-dalton~1
spirochetes~1
0.03%~1
(OE)~1
protoplasmic~1
pellet.~1
Shearing~1
pellet~2
flagellin-enriched~3
OE~1
flagellin-rich~1
66,000,~1
41,000,~1
31,000/34,000~1
41-kilodalton~1
(kDa)~1
flagellin~1
Antigens~1
31/34~1
0.25-1.0~1
AmB/kg~1
AmB,~1
AmB.~1
microgram/ml;~3
regimens--cyclophosphamide,~1
(C);~1
antiestrogen,~2
(CTBCG)--in~1
(product~1
rank)~1
sixty-six~1
5700~1
Adolescents~1
postfeeding~1
seven-eighths~1
two-kidney~1
GFR)~2
GFRs~1
gm/24~2
obsolescence~1
reduction.(ABSTRACT~1
oxine.~1
0.71%~1
1.77%~1
chemotaxis-under-agarose~1
0.07%~2
genitalia.~1
protein/180~7
vesicle,~1
27.8~2
Castration~1
biosynthesis:~1
6.05~1
(noncastrate)~1
PGF2~3
slice,~1
methemoglobinemic~1
primaquine~5
biotransformation~2
erythroleukemic~1
Primaquine~1
carboxyprimaquine~1
(CPQ)~1
CPQ,~2
Xc~1
6-methoxy-8-aminoquinoline,~1
CPQ~2
nitrosourea,~1
1,3-bis-(2-chloroethyl)-nitrosourea~1
Xc.~1
toxicology,~1
pharmacogenetics~1
8-aminoquinolines.~1
cromolyn-binding~1
E-dependent~2
1.1)~2
mol/L,~1
(41.8%~1
7.1%)~1
nitrendipine.~1
A23187.~2
dihydropyridines~4
secretion.(ABSTRACT~2
normoblastic~1
methylmalonic~2
homocystine.~1
dUST~2
dUST.~1
MTHF,~1
MTHF~1
"stress~1
test"~3
malabsorptive~3
streptozocin.~1
(normoglycemic)~1
(Hb~1
mosm/kg~1
Po2.~1
flotation~1
di-n-butyl~1
phthalates~1
gravities~1
1.062~1
1.142.~1
(SEM),~1
(L/W)~1
elliptical~1
interfaced~1
1.090~1
1.118~1
gm/ml~2
(T60)~1
0.0067~1
0.0007~1
1.064~1
1.134~1
gm/ml,~1
T60~3
0.0139~1
0.0022~1
gm/ml.~1
1/MCV~1
Ponder's~1
media.(ABSTRACT~1
(VWF)~1
(GPIb)~1
(GPIIb-IIIa)~1
(thrombasthenia)~1
(Bernard-Soulier~1
2600~1
sec-1.~1
thrombasthenia,~1
VWF,~1
(10E5~1
PLT-1)~1
(6D1),~1
10E5~1
binding.(ABSTRACT~1
Cohocton~1
Tri-County~1
1974.~4
inactive,~1
unscreened~1
acalculus~1
speculative.~1
"depression"~1
single-visit~1
physicians;~1
underrecognition~1
care:~1
convenience.~1
1,017~1
2,155~1
plans.~1
cardiology,~1
neurology,~1
board-certified~1
practice),~1
Room,~2
ordered.~1
appointments~3
consultants.~1
nonprimary~1
dermatology,~1
Hypertension-aid~1
(HTN-APT)~1
assists~1
HTN-APT~2
critiques~1
indication-contraindication~1
computer-generated~1
judgmental~1
culminate~1
sudden,~1
arteriosclerosis~1
concentration:~1
decedents,~1
Obliteration~1
indicator.~1
predominately~1
Mandatory~1
Accompanying~1
deluge~1
automobiles.~1
abroad.~2
incident.~2
party,~1
forth.~1
crash,~1
portraits~1
Swiss~1
Pedagogue~1
Johann~1
Heinrich~1
Pestalozzi,~1
shown;~1
setup~1
transjurisdictional~1
hotel~1
motel~1
hotel/motel~1
check-in;~1
drove~1
hometown~2
day's~1
divorced~1
(HCl)~1
KBr~1
pellets.~1
sugars,~1
mannitol,~2
noninterfering~1
growing.~1
privatization~1
"policy~1
authorities,~1
profit/loss~1
barometer~1
pluralistic~1
defined?~1
vicarious~1
Amendment~1
prisoners,~1
forth?~1
researched~2
offender~1
man's~1
land"~1
prison~2
prisons.~1
York.~2
origins,~1
interagency~1
Prison~1
Force's~1
promulgation,~1
Correctional~1
Facilities~1
enacted~1
Correction,~1
murder.~1
victimization~1
allegations~1
victimization.~2
Factitious~1
police,~1
convicting~1
assailant~2
murders.~2
fired~4
decomposed~1
conviction~1
incisal~2
marks.~1
registration.~3
(NFN)~1
rampant~1
NFN~1
bullets~2
(EDXA)~1
ricocheted~1
fireplace~1
shots~1
officer's~1
burglar.~1
SEM-EDXA~1
bullets,~1
science.~1
gel,~1
perchlorate,~1
analyzers~3
Verifier,~1
Intoxilyzer~1
5000,~1
Intoximeter~1
3000),~1
900A,~1
GC~4
Mark~1
0.000~1
0.250~1
g/210~1
42/instrument,~1
0.99).~2
radiative~1
(REA)~1
573~1
(DWI~1
532~2
(PM~1
REA~4
"Negative"~1
GC)~2
"positive"~3
DWI~2
0.943~1
1.54;~1
0.980~1
2.76.~1
0.99.~1
(GSR)~1
microscope/energy~1
(SEM/EDX)~1
unattended~1
GSR~9
sizing,~1
aquisition~1
verification.~1
lift~3
test-firings~1
.38,~1
.32,~1
.25,~1
.22~1
handguns~1
Unique~1
firing.~1
handblank~1
operator-free~1
analyst-time-per-case~1
breeds~1
such.~2
Gjerde~1
arousal.~1
Gjerde's~1
proposals,~1
investigation:~1
records;~1
not?~1
feasible;~1
unimportant;~1
diagnosis--even~1
well--did~1
(.19)~1
con~1
low-income,~1
unacculturated~1
Mexican-American~2
households,~2
emotion~2
hostile,~1
overinvolved~1
stressors~3
Anglo-American~1
intrafamilial~1
genealogical,~1
multidimensionally~1
cooperated~1
psychometric,~1
.63~1
.78).~1
disposition,~1
subdiagnosis,~1
prediction.~1
assaultive~3
dangerous.~1
Assaultive~1
nonassaultive~1
pseudobulbar~1
diseases--one~1
"physiopharmacological"--may~1
(83)~1
"major~1
depression"~1
"neurological~1
sample"~1
(44)~1
guilt,~1
nonfocal~2
hyperreligiosity.~1
(TLE)~1
pseudoseizures~2
16-channel~2
TLE~3
hyperreligious~1
Sinemet~1
presymptomatic~1
state?~1
Lasegue's~2
Lassegue's~1
electrically-induced~1
ependymomas~1
circumscribed,~1
electrogustometer~1
Electrogustometric~1
electrogustometric~1
Electrogustometry~1
taste.~1
1-70~1
Hydrocephalus~1
Axonal~1
crush.~1
"double-crush"~1
Short,~1
interosseus)~1
(triceps~1
surae,~1
dorsiflexions~1
(toe~1
stood.~1
surae.~1
responses)~1
ataxia).~1
interosseus~1
domicile,~1
elastolytic~1
amyl~1
sub-group~1
levodopa-treated~1
"on-off"~2
fluctuations,~1
clioquinol.~1
clioquinol~1
overdosage~1
amygdaloid~1
boxers~3
neuropsychometry.~1
fights,~2
neuropsychometric~1
Neuropsychometry~1
Exposed~2
14C-3-O-methyl-D-glucose~1
HRP.~2
interendothelial~1
clefts~3
astrocytes~2
CNS,~2
astrocyte~1
clumping,~1
polyribosomal~1
tangled~2
(min)~1
astrocytes,~2
axonomas~4
lieu~1
non-myelinated~1
neuromas.~1
Axonomas~1
tegmental~1
compact,~1
regenerate.~1
sprouts~1
permanently,~1
wobbler~3
labeled.~1
tangles,~1
Congophilic~3
unprecedented~1
(CSF),~1
pan~1
T-cells,~2
cytotoxic/suppressor~1
Ia-positive~1
neuroimmunological~1
(NID),~1
(INF)~1
T/suppressor~1
NID~2
(Guillain-Barre~1
vasculitis),~1
petrosus~1
haematoma,~1
dealt~2
crocodile~2
paradox,~1
hyperaemia~2
ephaptic~1
petrosal~1
(SPN)~1
intensified~1
neuritis,~2
radiculoneuritis,~1
deteriorate.~1
borreliosis~1
tick-bite~1
parenteral,~1
glucocerebrosidase,~1
anti-~1
(rabbit~1
IgG)~1
gold.~1
lysosomes,~2
Labelling~1
(RER)~2
(CRM)~1
CRM~2
kDA~1
sarcolemma~1
arachnoiditis~2
neurobrucellosis.~1
asthenia,~1
anorexia,~2
papilloedema,~1
turcica.~1
[MELAS]~1
Q10~1
(CoQ)~1
CoQ~1
MELAS.~1
electromyographically,~1
prerelaxant~1
Times~1
distraction.~1
(rested)~1
in-house~1
(fatigued).~1
fatigued,~1
(57.2~1
65.9~2
10.9,~1
intuitive~1
Thromboelastography~3
thromboelastogram,~1
thromboelastography~1
replacement)~1
thromboelastography,~1
accuracy)~1
incremental,~1
exhaustive,~1
capacity;~1
Symptom-limited~1
VO2max.~1
threaten~1
believes~1
"wake-up"~1
function).~1
"optode"~1
quenching~2
optode~5
reading.~1
-10.3~1
designers~1
single-channel,~1
arrhythmia-monitoring~1
expound~1
comment~1
depths:~1
on-patient,~1
analysis;~2
pseudocode~2
detector;~1
"footnotes"~1
(FINAP)~1
volume-clamp~1
Penaz.~1
FINAP~5
ipsilaterally~1
catheter-transducer~1
(intraarterial~1
[IAP])~1
thumb,~2
-4.8~1
1.49~1
FINAP/IAP~3
0.979,~1
0.963,~1
0.996,~2
intercepts~2
7.499~1
0.802~1
0.083~2
0.945~1
(systolic),~1
0.884~1
(diastolic),~1
0.949~1
(mean).~1
0.502~1
0.922~1
0.757~1
0.932~1
0.767~1
0.892~1
finger-cuff~1
32.387~1
1969,~1
balloon-tipped~1
fluorouracil,~2
OH),~1
(FAC)~1
260%~1
FAC)~1
escalation~1
nonsignificantly)~1
Hematologic,~1
(GI),~1
infection-related~1
Stomatitis,~1
dose-limiting.~1
Desu~1
1,777~1
(BM;~1
50%),~2
(PB;~1
60,000/microL)~1
lymphocytosis,~2
[Hb]~1
g/dL),~1
100,000/microL),~1
Hb,~1
covariates~1
ifosfamide-VP-16~2
methyl-gag~1
(VP-16).~1
MIME.~1
MIME~2
front-line~3
non-cross-resistant~1
nodularity.~1
(NN),~1
nodular-diffuse~1
(ND).~1
68.2~2
39.6~1
ND~1
NN-lymphocytic~1
(LPD)~1
77.2~2
44.3~1
ND-LPD.~1
NN-M~1
ND-mixed~1
(M).~1
(HU)~1
ara-C.~1
Concomitantly~2
Cycles~1
10+~1
30+~1
2,200~1
cells/microL,~1
80,000/microL.~1
(VAB-6)~1
"poor-risk"~1
(GCT).~1
GCTs~2
seminoma,~1
extragonadal~1
CRs.~1
tolerable,~1
VAB-6~2
GCTs.~1
continue.~1
(TCCB)~1
chronobiologically~1
Cytoxan~1
(Mead~1
Pharmaceuticals,~1
Evansville,~1
IN),~1
(5-FU),~1
(PRs).~1
diaziquone~1
(AZQ)~1
AZQ~5
procarbazine.~1
(AA).~1
GBMs~4
AAs.~2
AAs~1
procarbazine~2
PRs~1
(11.9%)~1
(47.4%)~1
Karnofsky~2
performance-status~1
(KPS)~1
.031).~1
hematologic.~1
AZQ-based~1
AA,~1
(SCLC).~1
alpha-1-acid~1
SCLC.~1
AGP~1
limited-disease~1
CEA,~1
(AGP~1
LDH)~1
brachytherapy~5
(BRT)~1
BRT~5
non-BRT~4
41,~2
44%)~1
.0006).~1
597)~1
BRT,~1
170)~1
.0005);~1
BRT-associated~1
tenuous,~1
(CCBs)~1
CCBs~1
(DOX),~1
(VBL),~1
units-granulocyte-monocyte~1
[CFU-GM]).~1
co-incubated~1
(CHOP),~1
contracts~1
(NCI)~1
(PMGs)~1
PMGs~1
(POC)~1
CHOPs~1
CHOP~1
CHOP,~1
1,922~1
nidus~4
"radiculomeningeal~1
fistula"~1
(RMF),~1
multilevel~2
nidus,~1
disconnecting~1
RMF's~1
non-hemorrhagic~1
RMF~1
rheumatological,~1
painlessly.~1
Oil~2
protrusion,~1
facets.~1
herniations.~1
(AVM's)~2
AVM's.~1
temporary.~1
hemianopsia~1
hemisensory~1
Parinaud's~1
thalamocaudate~1
AVM's~3
striatothalamocapsular~1
microsurgically~1
Hau~1
Shanghai.~1
bleed~1
hemianesthesia,~1
hemianopsia.~1
Angiographically~1
Reil.~1
Anticoagulant~1
neurocysticercosis~2
(24.8%)~1
Cysticercus~2
normal-pressure~2
out)~1
lumboventricular~1
Hg-1~1
moderate-sized,~1
map,~1
agreeing~1
overnight-fasted~1
(fasted~1
polytrauma~1
(stressed~1
lactate/pyruvate~1
velocimetry~1
cord-injured~2
Nervous~1
Centers'~1
Health.~1
rotobed~1
uncommon--4.9%~1
unstable.~1
(HTSCCA)~1
receptor-positive,~1
receptor-positive.~1
HTSCCA~2
HTSCCA.~1
meningiomas.~1
"shaken~1
analyzed;~2
uncontrollably~1
Models~2
accelerometers~1
shaken~2
padded~1
unpadded~1
Angular~1
accelerations~3
shakes~2
impacts~2
subhuman~2
scaled~2
concussion,~2
sham-operation~2
(sham-operated~1
(clot~1
(clot-removal~1
arachnoid.~1
clot-removal~4
evacuated.~1
(MRI);~1
post-SAH.~1
caliber)~1
Evacuation~1
nimodipine,~1
SCBF,~1
53.0-gm~1
T-1~1
(whole~1
angiotensin,~2
adrenaline)~1
Nimodipine~1
microgram/kg/min)~1
nimodipine.~2
(metabolite/transmitter)~1
Turnover~1
alpha-methylparatyrosine~1
5-hydroxyindole-3-acetic~1
raphe-spinal~1
microangioarchitecture~1
coursed~1
wavelike~1
(fungal)~1
Intradural~1
myolipoma~1
lipomatous~1
long-recognized~1
"Saturday-night~1
palsy,"~1
43-year-old~1
(CCF).~1
CCF~2
unsuccessful,~2
large-sized~2
vanillyl~1
mandelic~1
123I-labeled~1
(MIBG).~1
[123I]MIBG~2
0.01-0.22%~1
pathophysiology.~2
[54Mn]DTPA~2
[153Gd]DTPA~2
dimeglumine~1
ion-DTPA~1
[Mn]DTPA~1
(SPECT),~1
iodine-123~1
(123I)-labeled~1
N,N,N'-trimethyl-[2-hydroxy-3-methyl-5-iodobenzyl]-1,3-propanediamine~1
[123I]HIPDM~1
condensation~2
2-hydroxy-3-methyl-5-iodobezaldehyde~1
N,N,N'-trimethyl-1,3-propanediamine,~1
[123I]HIDM~1
reductant~1
bisulfite),~1
iodate).~1
iodine-iodine~1
kcal/mole.~1
1+~2
reductant,~1
bisulfite.~1
single-plasma~1
(SPS)~1
diatrizoate~2
(Hypaque)~1
(ERPF)~1
(Sapirstein~1
Method).~1
(Vt)~1
(Ct)~2
liters,~1
counter.~2
Vt~2
(Sy.x)~1
Sy.x~1
quadratic,~1
hypomotility~1
Kinevac~1
radionuclide.~1
mol/d~2
forages~1
concentrates)~1
4.375~1
(near~1
balance)~1
MJ/d~1
(kf)~2
(0.58-0.70)~1
(forage)~1
concentrate).~1
kf~12
acetyl-CoA~3
propionate)~1
repartitioned~1
ruminants~1
metabolizable~1
acetyl-CoA.~2
Predicted~4
0.47.~1
absorption;~2
oxidized.~1
NADPH,~1
NADPH.~1
cycles)~1
Boiled~1
cassava~2
oven-dried~1
(soybean-cottonseed)~1
(172~1
g/d),~1
g/d)~2
(6.9~1
intake)~3
Cassava~1
hydrocyanic~1
19-22,~1
Mn-adequate~1
(2.59~1
Mn/d,~1
P:S~1
0.86)~1
Mn/d~2
(depletion),~1
(repletion).~1
Diets,~1
feces,~1
integument~1
Mn,~2
repletion.~1
fleeting~1
Miliaria~1
crystallina,~1
repletion~3
began.~1
2.11~1
dams,~1
Ornithine~1
per-gram~1
wet-weight~1
decarboxylase.~1
putrescine.~1
Postprandial~1
(SLI),~1
(IRI)~1
(BG)~1
bran.~1
BG~2
bran,~2
prebran~3
IRI~2
bran~7
ingestion),~1
3,5,3'-triiodothyronine~1
Obese~2
triglycerides.~1
Thyroidectomy~1
T3.(ABSTRACT~1
Gluconeogenesis~1
dihydroxyacetone~1
(DHA),~1
glycerol,~4
2-48~1
DHA,~1
plateaued.~2
(2-11~2
DHA~2
pyruvate.~3
1.35-fold~1
pathway:~1
triose~1
(PVP).~1
(ID),~2
(PF),~1
anemia),~1
(R-14),~1
(R-7),~1
(R-3)~1
(R-0).~1
(ln)~1
cpm~1
postadministration~1
PVP),~1
Repletion~2
NZB~7
autoimmunity~2
(zinc-deficient)~1
(zinc~1
copper).~1
inanition~1
(restricted~1
intake).~1
antierythrocyte~1
restricted-intake~1
extremes.~3
(lm)~1
(MT)~1
uninduced~1
zinc-treated~2
0-~1
160-microM~1
MT-1~1
wild-type.~1
lm/lm~10
twofold-reduced~1
6-h~1
65Zn~1
wild-type,~1
zinc-induced~1
dishes.~1
(1-3),~1
heavy-metal~1
(4,~1
cross,~2
B-6.~1
40-50%~3
60-75%~1
nonpurified~3
proteoglycans.~2
broiler-type~1
dyschondroplasia.~2
Birds~3
dyschondroplasia~3
(5-11%~1
59-68%).~1
20-d~2
ultrafilterable~1
dialyzable~3
19th~1
pregnancies)~1
(low)~1
(high)~1
homeostasis.~4
Jugular~1
calcitonin,~2
phosphorus.~2
Heifers~1
Cows,~1
heifers,~1
colostrum~1
parturition.(ABSTRACT~1
RCS~1
mix.~3
vitamin(s)~1
litters~4
grandmothers~1
RRR-alpha-tocopheryl~2
First-week~1
(born~2
alive)~1
72.3%~1
IU/kg~2
Three-~2
9-mo-old~1
cottonseed~1
lecithin~1
(LCAT)~1
(3-mo-old)~1
(9-mo-old)~1
(soybean~1
cottonseed).~1
(FR)~1
casein-fed~1
(NR)~1
casein.~1
5-hydroxyindoles~2
[serotonin~1
(5HIAA)]~1
(LNAA~1
threonine,~1
phenylalanine)~1
fed;~1
Lysine~1
Leucine~1
tyrosine.~1
(norepinephrine~1
state).~1
self-selected~2
Self-selected~1
Balances~1
lower-than-usual~1
adequate.~3
Microbial~1
rumen~6
15N~2
fistulated~1
alfalfa~1
haylage~1
dosed~1
(15NH4)2SO4.~1
cheesecloth.~1
Particle-associated~1
squeezed~1
32.1~1
59.9%~1
15N.~1
(mg/mL~1
particle-associated~3
47.5;~1
35.5;~1
30.1;~1
26.1;~1
26.7;~1
70-80%~1
50-65%~1
17-27%~1
ruminal~1
(young)~1
(middle~2
aged)~1
cal%)~2
(LST)~1
(HST)~1
LST~2
middle-aged,~1
HST.~4
(proximal~1
one-third)~2
DNA)~1
(disaccharidase)~1
(pancreatic~1
alpha-amylase)~1
(disaccharidases)~1
(alpha-amylase).~1
adaptability~1
lactase.~1
butylated~2
hydroxytoluene~2
(BHT)~1
BHT,~1
retinyl~2
1-d-old~2
(lm/lm)~1
milk-induced~1
lm/lm-nursed~1
foster-nursed~1
4-20~1
gel-filtration~1
EDTA-dissociated~1
micelles,~1
(II)~1
(II)-binding~2
glutamate,~1
(Se)-deficient~1
selenite,~1
selenocystine~1
(SeCys)~1
selenomethionine~1
(SeMet)~1
ether,~1
(GPx)~1
selenocysteine~2
lyase~1
lyase.~1
GPx~1
Se-deficient~1
SeCys,~1
SeMet~2
SeCys.~1
SeCys~1
1.3-~1
(GSH-Px)~1
S-transferase~1
(GSH~1
S-Tr)~1
S-Tr~2
refeeding~1
(0.015~1
ppm)~1
MDMA~8
harm.~2
(if~2
sparingly~1
episodically)~1
Certainly,~1
unsafe.~1
MDMA's~2
long-range~1
anecdotal~1
unsupervised~1
MDMA,~1
growth-retarded~1
(SmC)~1
SmC~3
puberty;~1
non-GH-deficient~1
GH-deficient~1
age/chronologic~1
Precocious~1
(54.5~1
encephalomalacia~1
Thyrotropin~1
(TRAb)~1
Hashimoto~1
(TBII)~1
TRAb~8
thyrotoxicosis;~1
antiidiotypic~1
(TSI)~1
TSI~3
patient:~2
glucose-regulating~1
(glycerol~1
galactose)~1
glucose-6-phosphatase~1
phenylalanine-restricted~1
L-tyrosine~1
mumol/L,~1
trimester;~1
trimester,~2
microcephaly,~1
hemihypertrophy,~2
careful,~1
Kawasaki-like~1
polycythemic~1
hyperviscosity~1
2.5%.~1
centipoise.~1
ml/kg/min),~2
(1.56~1
1.89~1
(cutaneous)~1
(+80%)~2
Hg/ml/min/kg-1.~1
(+32%)~1
polycythemia.~1
polycythemia,~1
28-162~1
1140~1
2325~1
pneumotachography,~1
water-filled~1
25th~1
10(9)/L~1
97)~1
weight-,~1
disease-matched~1
nonthrombocytopenic~6
80).~3
122)~1
integrity:~1
-0.56,~1
10(9)/L.~1
-0.58,~1
IVH~2
Relations~1
Adolescent~2
self-image~1
(Offer~1
Self-Image~1
Adolescents)~1
(Child~1
Checklist).~1
(luteinizing~1
hormone),~1
(testosterone~1
estradiol),~1
(dehydroepiandrosterone~1
androstenedione).~1
testosterone/estradiol~1
stronger,~1
maturers:~1
(androstenedione)~1
girls;~1
self-comparisons~1
same-age~1
advertisement~2
experimentation~1
brand.~1
61.6%~1
advertisements,~1
33.2%~1
advertising~2
causally~3
NAD+,~3
NADH,~1
NADP(H),~1
"rheumatoid~1
diathesis"~1
antedates~1
tympanossicular~1
(70.50%).~1
Conductive~1
stapedius~1
(1.40%).~1
(29.40%)~1
dB)~1
loudness~1
unfinished~1
transacetylations~1
vitro:~1
-0.50,~1
-0.83,~1
-0.61,~1
(k/Hb~1
[min-1~1
dl]~1
(24.2~1
(18.6~1
3.1),~1
(k/10(6)~1
(7.72~1
0.81).~3
(8.50~2
(9.08~1
1.04).~1
hydrolyzing~1
esterase.~1
citizen.~1
4137~1
9162~1
same-sexed~1
pairwise~4
expectancy,~1
64.76;~1
18.23~1
68.29;~1
18.24~1
hypothesis:~1
steps,~2
longterm~1
widefield~1
capillaroscopy.~1
(retinopathy)~1
lentigines~1
lymphedema.~1
kindreds~1
Brazil~1
heredofamilial~1
Brazilian~1
Swedish/American,~1
Portuguese~1
syndesmophyte~1
Ankylosis~1
laterofixation~1
pauciarticular~1
(JRA).~1
laryngoscopic~2
Cricoarytenoid~1
JRA.~1
hemosiderosis,~2
Polyarteritis~1
nonseasonal~1
immunotherapy,~1
Penicillamine~1
49-year-old~2
hydrarthrosis~1
Cholestatic~1
pneumophila.~1
(MCAT)~1
1,859~1
matriculants~1
MCAT.~1
Science~3
subtest~2
MCAT~4
First-year~2
school's~4
dismissal~1
graduated,~1
probation~2
dismissal,~1
residencies;~1
directors.~1
column-isolated~1
trauma-induced~1
(SAP)~2
SAP.~1
(ELISA),~1
SAP-induced~1
anti-SAP~1
25,000-mw~3
injury-induced~1
immunodiagnostic~1
cc/kg~1
Mason~1
42.4~2
37.7%),~1
0.921;~1
burned)~1
Surface~3
postburn,~1
4,425~1
nonsurvivors.(ABSTRACT~1
full-~1
partial-thickness~2
Sampled~1
(2''~1
2'')~1
square-inch~1
rinsed~1
wash.~1
mg/cm2/hr)~2
mg/cm2/hr.~1
(gm)~1
(m2)~1
(%).~1
antithromboxane)~1
zone-of-stasis~2
oxygen-derived~4
16-hour~1
received:~1
PO~5
(DMSO)~1
yeast-derived~1
(PEG-SOD,~1
Pharmacia)~1
(Fridovich)~1
U/cc~1
'blinded'~1
hair-follicle~1
inhibitor),~1
DMSO~2
radical),~1
PEG-SOD~1
radical)~1
supply-demand~2
hypermetabolic-hyperdynamic~1
septic.~1
pentothal~1
Crystalloid~1
hydrophila~1
29,548~1
(TXA2~2
infusion;~4
U46619~1
microanatomic~1
(TBSA)~1
TBSA~1
TBSA),~1
(PLNA)~1
(HVG)~1
(GVH)~1
GVH~1
HVG~1
14-21,~1
PLNA~1
(MEE)~1
Curreri~3
(CEE)~1
(MCEE),~1
(UUN)~1
MEE's,~1
CEE's,~1
MCEE's~1
MEE's.~1
UUN's~1
MEE's~1
18-month~3
Stones~1
Filling~2
Double-J~1
over-all).~1
127.~1
ureteroscopy,~1
mastering~1
endourologically~1
microsecond.~1
silicon-coated~1
9.5F~1
transureteral~1
passable~1
extractable~2
otherwise,~1
ureterscopic~1
"shock~1
wave"~1
Ureteroileal~1
dilators~3
choledochonephroscope~1
Turner's~2
dysuria.~1
trigone~1
portend~1
cystectomy.~1
1978--before~1
1983--during~1
averages.~1
staged,~1
(thymolphthalein~1
substrate)~1
extraprostatic~4
(53~1
chi-square)~1
radioimmunometric~1
enzymatically.~2
PAY~1
276,~1
antiprostatic~2
radioimmunological~1
mCi.~1
111indium,~1
cent):~1
(21.8~1
mg.),~1
(53.4~1
mg.)~1
(75.4~1
132)~1
134),~1
Radioimmunological~1
2,750~1
unnecessarily~1
dilatory,~1
peel-away~1
set,~1
Universal~1
basketing~1
negotiation~1
ureteropyeloscope.~1
retropubic~3
neomycin~1
coverage.~2
Savings~1
laxative-enema~1
micturitional~1
profilometry~1
post-prostatectomy~1
vesicourethral~2
Micturitional~1
acontractile~1
detrusors.~1
99mtechnetium~3
dimercapto-succinic~2
diethylenetriaminepentaacetic~1
subfertility.~1
subcostal~1
adrenalectomy.~1
psoas~4
intrapelvic~1
retroperitoneum.~2
meningomyelocele,~1
Pasteurella~3
multocida.~1
self-catheterization~1
uroflow,~1
mishap.~1
describe-2~1
paralyzation.~1
atony~1
Crede~1
dedifferentiation.~1
perhaps,~4
epispadiac~1
Post-traumatic~1
self-dilation~1
Echinococcosis~1
Electroejaculation~1
IIB~2
Electrostimulation~1
anejaculation~1
necrotic,~1
syncytial~2
cytotrophoblastic~2
alpha-fetoprotein.~1
23-year-old~2
azoospermia.~1
epididymides~1
deferentia.~1
flagellum~2
aplasia.~1
Young's~1
(bronchiectasis~1
azoospermia),~1
immotile~1
alum~2
Hematuria~1
methysergide,~2
3H-NA~1
counteracts~1
R-3327~1
AT-1~1
AT-2,~1
AT-3~1
MAT-Lu~1
sublines,~1
videomicroscopy.~1
ruffling,~2
pseudopodal~2
vectoral~2
translation,~1
(gestalt)~1
graded.~2
Intra-assay,~1
intra-observer,~1
inter-observer~1
sublines.~1
JHTK-1~4
persistently.~1
septaploidy,~1
G-band~1
karyotyping~1
Dibutyryl~2
heterotransplanted~1
subcutis~1
stereologic~2
alpha-dihydrotestosterone~6
stereological~3
(androgens,~1
(BPH).~1
25);~1
0.7;~1
0.059~1
0.022,~1
0.005;~1
0.03;~1
0.02;~1
epithelium;~2
BPH.~2
alpha1~2
alpha2~9
[3H]prazosin~1
[3H]rauwolscine,~1
yohimbine,~1
[3H]rauwolscine.~1
Kd,~1
fmol./mg.~1
midportion,~1
(UUO)~1
(TxA2)~1
OKY-046~1
micrograms./kg./min.~1
UUO~1
RBF~3
TxA2.~1
TxA2~1
UUO.~1
(AAA)~1
50s~1
60s~1
0.003,~1
70s~1
80s~1
Delineation~1
penile/brachial~1
(PBPI);~1
bulbocavernosus~1
(BCR);~1
(AE);~1
hypogastric-pudendal~1
PBPI;~1
BCR~1
Impotent~1
(138)~1
(215)~1
Covert~1
ischiopudendal~2
4047~1
(3.8%)~1
9.2%~2
(occluded)~1
(stenotic)~1
8.8%~2
permanent.~2
not),~1
nonhemispheric~2
xenon-enhanced~1
(Xe/CT~1
CBF).~1
territories.~1
Xe/CT~2
(vertigo,~1
lightheadedness,~2
vision).~1
pneumoplethysmography~1
Gee~1
ocular/brachial~1
flow-augmenting~1
subclavian-external~1
relieved.~1
femoral-above-knee-popliteal~1
(F-AKP),~1
femoral-below-knee-popliteal~1
(F-BKP),~1
(F-D),~1
(Ax-F),~1
(F-F).~1
thrombectomy.~1
F-BKP~3
F-D~3
F-AKP~2
reproduces~1
virginal~1
fails.~1
fabric~1
forever~1
velour~3
dogs),~3
(DVD,~1
(SVD,~1
(WD,~1
5-0~3
Prolene~1
Dexon~1
DVD,~1
WD~3
midgraft~1
resutured~1
Dexon.~1
tensiometer.~1
graft-to-artery~1
(absorbable~1
suture)~1
pounds,~1
(14.3)~1
DVD~2
(12.6)~1
SVD~1
(7.2)~1
Graft-to-graft~1
17.3)~1
9.0;~1
7.9;~1
DVD.(ABSTRACT~1
arteriographically~2
bypasses.~1
0.98)~3
successes~1
(32.5%~1
1.5%)~1
(34.6%~1
0.57).~1
(13.3%).~1
seven-~1
2052~1
(13,911~1
dpm/ml~2
(2049~1
plasma).(ABSTRACT~1
embolectomy~2
aortorenal~1
60.10~1
6.82~1
5.31~1
3.91~2
4.59~1
5.73~1
4.98~1
36.14~1
11.41~1
Amputations~1
(81%,~1
limbs),~1
procedures),~1
(11%,~1
aortofemoral~3
(11%);~3
durability,~3
Femorofemoral~1
advantage,~3
runoff;~1
reoperations),~1
digitalis-induced~2
digitalized~5
isoperfused~1
autoregulated~1
(millimeters~1
[0.89~1
0.07;~1
0.05],~1
[0.92~1
0.09].~1
(-14%)~1
(-9%).~1
Digitalized~1
MIH.~1
SMC-PR~5
49).~1
3H-thymidine~2
3H-labeled~2
0.25)~1
vaccine-associated~2
(OPV),~1
OPV~6
OPV.~1
distributed.~2
520,000~1
Vaccine-associated~1
bismuth~4
subsalicylate~6
(262~1
tablet)~1
symptom)~1
subsalicylate.~1
enterotoxigenic~1
Bismuth~3
blackening~1
tongues~1
travelers'~1
exclusively.~1
801~1
1138~1
updated.~1
fall-related~1
Alzheimer-type~1
walk;~1
(69/1000/y)~1
sex-adjusted~1
comorbid~2
4.9;~1
13.3),~1
wandered~1
3.6;~2
10.4)~1
1.66~1
28.6)~1
wandering,~1
freeze-preserved~1
reinfused,~1
reinfusion.~1
g/dL~2
[13.6~1
g/L]),~1
(0.357~1
0.216~1
L/min),~1
3,4-Methylenedioxymethamphetamine~1
(MDMA,~1
"Ecstasy"),~1
3,4-methylenedioxyamphetamine,~1
Enforcement~1
3,4-methylenedioxyethamphetamine~1
(MDEA,~1
"Eve")~1
MDEA~2
(Annual~1
Trustees,~1
officials~1
nonresidential~1
buildings~2
rapid-response~1
sprinklers~1
detectors~1
installation~1
high-rise~1
stringent.~1
(CBV)~1
double-balloon~2
CBV,~1
Oximetry~1
1.4:1~1
1.3:1~1
CBV.~1
CBV~1
stay;~1
Indwelling~1
"transient"~1
"nosocomial"~1
often-ignored~1
54)~2
(calcium,~1
mg/d)~2
sphygmomanometer.~1
repeated-measures~1
(RBD)~1
parasomnia~1
atonia~1
Punching,~1
kicking,~1
leaping~1
dream~6
enactment~1
videotaping~1
RBD~1
psychopathologic~1
olivopontocerebellar~1
(slow-wave)~1
aperiodic~1
twitching~1
confrontations~1
(chickenpox,~1
illness)~1
(black~1
black),~1
case-patients~1
dialing.~1
40;~1
5.8).~1
nonaspirin~2
26;~3
6.4);~1
732~1
Rand~1
Experiment,~1
45.4%~1
(For~1
73.5%).~1
matured,~1
general-family~1
physician,"~1
quit.~3
cessation,~1
5875~1
quit~4
(73%~1
43%).~1
Colchicine~2
venerable~1
strictly,~1
surveillance.~4
hospital's~3
incidence)~1
benefit-to-toxicity~1
nonpregnant,~1
nonlactating~1
Vitamins~1
nonnutritional~1
rests~2
tachycardia/fibrillation.~1
Frank~1
(CF),~1
possibilities,~1
nutriture.~1
undernourished,~2
0.025),~2
weight-for-height~2
(TSF)~1
0.56:~1
TSF).~1
(IVFTT)~1
Lipofundin~1
MCT~1
IVFTT~3
proband.~1
(K2~1
8.84~1
3.45%/min).~1
0.941~1
0.285~1
1.753~1
0.306~1
0.792,~1
K2.~1
g/hr).~1
hormonal-stimulated~1
Guar~1
guar~6
layer;~2
stir~2
concentrations--when~1
catheter--than~1
week;~2
processing,~4
drug-monitoring~1
patient-monitoring~1
(SGA),~1
Illustrative~1
SGA~3
wasting,~1
0.624~1
0.944,~1
(residents,~1
nurses),~1
gastrostomy,~1
gastrocolic~1
antiglomerular~2
(antiGBM-GN)~1
desferrioxamine~3
(DFX)~1
[24~1
SEM):~1
antiGBM-GN/DFX~1
antiGBM-GN~2
271.5~1
92.2~1
DFX~2
[superoxide~1
(OH.)]~1
antiGBM~1
OH.~1
immunologically-stimulated~1
(ISN)~1
[nM~2
diphenol/hr/10(6)~1
ISN/DFX~2
ISN~2
0.01]~1
O2-/hr/10(6)~1
29.1~5
32.6~1
0.05].~2
dimethylthiourea~1
antiGBM-GN.~1
nephrons~1
micropuncture.~1
sectioning,~1
nephrons.~1
S3~3
S1-S2~1
atrophied.~2
Tubule~1
reabsorptive~2
Micropuncture~1
Starling~3
benzolamide~5
mg/kg/hr,~1
(APR,~1
3.6,~1
hydraulic-pressure~1
nullify~1
benzolamide-induced~1
hyperoncotic~2
high-hematocrit~1
continued,~1
APR~2
(25.6~1
nl/min)~1
rats).(ABSTRACT~1
(MC)~1
adhere;~1
(dimethylpolysiloxane)~1
(DMPS),~1
contracted,~1
DMPS~2
wrinkled;~1
relaxed,~1
wrinkles.~3
detached,~1
wrinkles~7
rounder.~1
10(-1)~1
azide~1
II-treated~1
ionophore-treated~1
DMSO,~1
actin-translocating~1
detachment;~1
wrinkles,~1
(BJPs)~1
(LOU/m)~1
BJPs~2
6.7.~1
Myeloma~1
5.2),~1
4.3),~1
6.7).~1
BJP~3
non-tumor-bearing~2
LOU/m~2
millipore~1
3500.~1
indwelling-venous~1
BJPs.~1
Polyfructosan~1
(Cin)~1
Cin.~1
Cin~1
alpha-ketoisocaproate~1
leucine,~2
leucine-free~1
isotopically:~1
14C-KIC~1
3H-leucine~2
p.o.;~1
injectate,~1
Perfusion-fixation~1
(autoregulatory)~1
juxtamedullary~1
Arteriolar~1
somewhat,~1
perfusion-fixation~1
clamp,~1
reclamation~1
(mEq/liter~1
maneuvers:~1
(6.61~1
5.39~1
0.26,~1
(U-B~1
(ischemic:~1
control:~1
(40.1~1
U-B~2
PCO2/UHCO3~1
glomeruloesclerosis~1
mg%),~1
(150/100~1
proteinuria).~1
3,242~1
pre-term~2
(2,170~1
gestational-age~1
(2,340~1
abortions.~1
(10.6%)~1
(5.5%~1
9.6%,~1
gravidas~1
(reversible~1
them)~1
hemodialyses~1
Minute-ventilation~1
mass-spectrometer~1
dialysate;~2
[H+]~1
dialysates~2
(poorly~1
bound)~3
(highly~1
hemofilters~1
Colton~1
Henderson~1
0.00001~1
protein-binding~2
doubtful.~2
protein-drug~1
protein-membrane~1
drug-membrane~1
sieving.~1
drug-protein~1
CCPD.~1
641~1
178%~1
dialysate:~1
deferoxamine.~5
1521~1
339,~1
1120~1
232,~1
Algerian~1
early-onset~1
AP50,~1
C4-bp~1
nephritic~3
cousins,~1
half-normal~3
intramembranous~2
C3/C5~1
convertases,~1
discriminations,~1
abnormally-delayed~1
N1-P2~1
Lutheran~4
adoptee~2
agency--the~1
influence:~1
adoptee,~2
roadside~1
2044~1
nondrinking~2
drinking-driving~2
roads~1
leaning~1
problem-drinking~1
subordinates~1
(EAPs)~1
supervisors~4
supervisor's~1
supervisors'~1
EAP's~1
subordinate.~1
EAP~1
egalitarian~1
stigmatized,~1
drinker~1
EAP.~1
Al-Anon~4
self,~1
spirituality,~1
chapter~1
Members~1
self.~1
(members~1
start).~1
spirituality~2
interviewees~1
Al-Anon.~1
antidotes~1
helpfulness.~1
scenes~1
prime-time~1
aired~1
10.65~1
Dramas,~1
behavior--11~1
Put~1
terms,~1
viewer~1
dramas~1
abstainers,~1
relapsers~3
abstainers~2
aftercare~1
Relapsers~1
prematurely,~1
limits;~1
beverage~2
mixed-age~2
elder-specific~1
liquor-by-the-drink~1
(LBD)~1
counties.~2
Time-series~1
LBD~1
police-reported~1
LBD.~1
non-LBD~1
sale~3
shut~1
outlawed~1
discouraged,~1
fuels,~1
kind.~1
focused,~1
Prohibition,~1
alcoholic.~1
public-health~1
drinker.~1
addiction)~1
coalesced:~1
unified~1
addiction~1
interindividual,~1
moreover,~1
control-of-supply~1
backfire~1
overpowering.~1
Auditory~1
Potentials~1
(BAEP)~1
(11.3/sec~1
31.3/sec),~1
I/V~2
components)~1
kill,~1
"tumor~1
stabilization"~1
960~1
thermoradiotherapy,~1
thermochemotherapy,~1
1-34~1
1-32~1
(46%),~1
1-22~2
accumulative~1
Colony-Forming~1
(HTCFA),~1
HTCFA~2
retracing~1
1971-75~1
1976-80~1
Usage~1
Tamoxifen~1
Tamoxifen-induced~1
("tamoxifen~1
flare")~1
4-20%~1
subside.~1
durable.~1
Endocrine~1
Persistence~2
antagonist-agonist~1
deprive~1
67-year-old~2
(73%).~1
"at~1
risk,"~1
instituted,~1
oncocytic,~1
lobectomy.~2
"mesenchymal"~1
oncocytic.~1
oncocytic~2
oncocytosis,~1
lentiginous~1
surgical.~2
spur~1
bronchus.~3
insular,~1
trabecular,~1
aergenous~1
carcinoid.~1
aerogenous~1
Temperatures~1
endocardium.~1
snares;~1
venting~1
venting);~1
roentgenography:~1
shadows.~2
Thoracotomy~1
shadow,~1
(81%).~1
without)~1
Applicability~1
bronchostenosis~1
undifferentiated)~1
error),~1
suitability.~1
bronchostenosis,~1
unload~1
(-56.3%~1
-19.1%,~1
(-45.8%~1
+2.1%,~1
endocardial/epicardial~1
(27.6%~1
-6.5%,~1
subvalvular~3
reimplanted~1
Allograft~1
Serratia~1
marcescens~1
(acute),~1
(chronic).~1
resuspension~5
resuspension.~1
dissections.~1
possible)~1
Double-chambered~1
bundles(s).~1
(August~1
1986)~1
double-chambered~2
spontaneously),~1
(4/6).~1
checked~2
step-up~1
atrial-pulmonary~1
ventriculotomy.~2
recatheterized.~1
bundle(s)~1
arteriotomy~1
744~1
774~1
8.8)~1
8.2)~1
(Bjork-Shiley~10
7.6%;~1
6.0%),~1
patient-years;~1
py),~6
py;~8
periporsthetic~1
0.78%~1
1.68%~1
1.22%~1
py).~1
0.023).~1
(1.78%~1
py)~2
(0.48%~1
0.85%~1
0.29%~1
0.085).~1
35.9%~1
62.6%~1
71.0%~2
Postischemic~1
cardioplegia,~1
26.8%~2
35.4%~2
6.3%~2
58.0%~1
64.4%~1
protection;~1
79.7%~1
80.7%~1
cardioprotective~1
additively~1
intramembrane~1
postcardiotomy~2
54.6)~1
resuming~1
"cardiac~1
cripple"~1
heparin-bonded~1
decompress~1
Shunts~1
Computer-enhanced~1
cannulation,~1
Tricuspid~1
hypoplastic.~1
diphenylhydantoin.~1
HemoQuant~3
nightly)~1
975~1
will.~1
mismatching~1
Anatomically,~1
orthodeoxia~1
platypnea~1
orthodeoxia.~1
angiographic,~1
echocardiographic,~2
bismesylate,~1
[MS]~1
signaling.~1
exacerbations.~1
signaling~2
affirmatively~1
"perfect."~1
complications--most~1
87.2~1
99.5~1
person-years).~1
0.01)--from~1
immunocytologic~1
adenohypophyseal~1
hypertension:~1
family-centered,~1
nurse-coordinated~1
Cognitive-behavioral~1
(Aspergillus~1
species),~1
Charcot-Leyden~1
Mycetomas,~1
aspergillosis.~1
aeration,~1
mucus,~2
Complication~1
precaution~2
fasciitis,~1
orbits,~1
antimicrobial,~1
therapy-based~1
midfacial~1
LeFort~7
(26.5%)~2
(83.9%)~1
steroid-hormone~2
acceptor~1
(nuclear~1
written,~1
multivariant~1
(OSAS)~1
uvula-soft~1
(UPPP,~1
ppp)~1
cine-CT~4
(Imatron~1
Scanner~1
pharyngoscopy~2
exam~4
UPPP~1
May,~1
otocyst~3
anlage~1
otic~4
epithelial-mesenchymal~2
otocyst/mesenchyme~1
(O/M)~1
periotic~2
perilymphatic~2
organizes~1
chondrogenesis~1
Hemangiomas~3
neodymium-yttrium~1
cavernous,~1
capillary,~1
(ARA)~1
canine.~1
subtended~2
picks~1
sensor's~1
modulator~2
amplifier,~1
tubed~1
strap~2
effector.~1
Tolusa-Hunt~1
(THS).~1
THS~2
tonsillitis.~1
tonsillectomy.~1
3-year-10-month-old~1
septoplasty~1
Corti,~1
stria~1
vascularis~1
Reissner's~1
Trichinosis~1
pork.~1
68-year-old~2
tectorial~1
Quick-freeze,~1
deep-etch~1
microfibrillar~1
proteoglycans;~1
endolymph.~1
myringoplasty~1
perforations,~2
glued~1
seal.~1
Gelfoam~1
balls.~1
take-rate~1
warble-tone~1
hypoplasias,~1
partition.~2
deafened~1
malformed~2
rudimentary~8
audiovestibular~1
Intracochlear~1
interscalar~1
modiolus,~1
(lateral~1
posterior)~1
aqueduct~1
(incomplete~1
vestibule-semicircular~1
"Mondini's~1
dysplasia."~1
unwarranted.~1
embryogenesis~2
(8.5%,~1
(11.1%,~1
(3.2%,~1
(2.1%,~1
(3.9%,~1
beta-blockade.~1
(BHR).~1
16-wk-old,~1
10-wk-old~1
signaled,~1
unsignaled,~1
non-exercised~1
[eight~1
normotensives,~2
(N1);~1
(N2);~1
hypertensives,~1
familiarization~1
120;~1
142.~1
Wilcox~1
3-min~1
(N1~2
-12~2
-5~2
-7~1
post-exercise.(ABSTRACT~1
wetting~2
120-min~1
sec-1)~1
humidity).~1
run.~2
Spraying~2
(Tre),~1
exertion,~1
humid~8
(Tre~2
Tsk)~2
Tsk.~1
cyclists~12
"depletion~1
ride"~1
VO2max,~4
-1).~1
24-min~1
(artificially~1
flavored~1
sweetened);~1
ml-1);~2
(7.7~2
ml-1).~1
(185.35~1
3.26~3
91.93~1
3.39,~1
(5.70~1
mmoles~1
l-1),~1
(6.05~1
0.54),~1
(6.03~1
0.42)~1
(4.97~1
0.35)~1
effort.(ABSTRACT~1
ultraendurance~1
triathlons,~1
triathletes~8
IRONMAN~1
triathlon~3
treadmill,~2
physique~1
cyclists.~3
treadmill;~1
49.1~1
swimmers,~3
adaptations.~1
(TR),~1
(CE),~1
(TS)~2
6-wk~1
half-triathlon~1
mile~4
swim/56~1
bike/13.1~1
run).~1
CE,~1
averaged:~1
formula;~1
well-trained,~1
95.7%~1
non-cyclists~1
92%)~1
105%).~1
86.6%~1
cyclists,~1
82%)~1
95%).~1
-0.78,~1
-0.50).~1
VO2max.(ABSTRACT~1
runners,~2
sprint~2
junior-level~1
s-1,~1
Wingate~1
11.67~1
sprinters~2
sprinters).~1
competition.~1
Wheelchair~1
Games.~1
tetraplegics,~1
paraplegic,~1
paraplegics,~1
classifications.~1
30-s~2
all-out~1
(PO)~1
5-s~1
3.43~1
(16.9~1
PO,~1
740~1
4345~1
1A~3
reserve)~1
(VO2,~1
(23.9~1
1.60,~1
(19.5~1
2.40,~1
36.6~2
2.65,~1
2.35)~1
39.8~1
2.04,~1
33.2~2
2.64)~1
(beats~1
3.5)~1
(184~1
1.3)~1
untrained,~1
pre-synaptic~1
(338~1
receptors/platelet~1
receptors/platelet,~1
(2.53~1
2.24~1
barefoot~1
mps~1
pace).~1
membership~2
(55%),~3
(21%,~1
abusers),~1
(27%),~2
Hypoglycorrhachia~1
18%.~1
(15.4%~1
mortality).~1
obtundation~1
shunt-associated~1
bacteremia.(ABSTRACT~1
Arsenic-induced~1
axonal-loss~1
electrodiagnostically~1
polyradiculoneuropathy~1
dying-back~1
produce,~2
myoinositol~1
(EDN).~1
(RICF)~1
(HDN),~1
HDN,~1
RICF,~1
insulin-related~1
vicious~1
escalating~2
Electroencephalography~1
electrophysiologically.~1
redox-active~2
manganous~1
copper-zinc~1
(Mn~1
CuZn~4
SOD)~1
norm~1
polymyositis,~1
peroxidase.~4
disease-specific~1
DMD.~2
Cockayne's~1
remyelination~1
remyelinated~1
internodes~1
internodes.~1
hypomyelination~1
maldevelopment~1
clarified,~2
7-month-old~1
R-aVL~1
amplitudes,~2
S-III~1
S-aVR~1
PR-I,~1
QT-I,~1
QRS-I~1
DH.~2
centronucleation,~1
appendixes,~1
Hepatoerythropoietic~1
decarboxylase,~1
hepatoerythropoietic~3
proband's~1
mildness~1
oral-contraceptive~2
546~1
4228~1
ended;~1
(We~1
nonepithelial~1
cases.)~1
restriction-enzyme~2
200,000-fold~1
A-globin~1
"duplexes"~1
endonucleases.~1
S-globin~1
A-hybridization~1
anneals~1
mismatch.~1
(90.2~1
(46.5~1
four),~1
(specificity,~1
0.952)~1
0.780)~1
three-month-old~1
886~1
partum~2
("maternal~1
deaths")~1
(suicide,~1
accidents)~1
3.2).~2
sharply,~1
endoprosthesis~2
self-expandable~1
restenoses~2
coronary-bypass~2
thrombolysis,~1
unfound~1
stented~1
304,000~1
1.0);~1
postulating~1
consenting~1
leukemia-related~1
preeclampsia,~2
(313~1
(248~1
hypocalciuria~2
overlapped~1
organophosphorus~1
fenthion,~1
monocrotophos,~1
dimethoate,~1
methamidophos.~1
post-tetanic~1
levothyroxine~1
Synthroid~1
(Flint)~1
formulation--169~1
day--used~1
(Stock~1
JM,~1
Engl~1
Med~1
1974;~1
290:529-33).~1
overestimated.~1
[1.87~1
nmol~7
liter]),~1
(11.3~1
[145~1
liter],~1
Corpus~1
Christi,~1
1806~1
1806)~1
1732~1
vaccinated,~1
immune.~1
nephropathic~1
cystinosis,~2
photophobia.~1
cystinotic~1
eyedrops~2
cysteamine-treated~1
Cysteamine~1
cystinosis~1
autotransplanted~1
(respectively)~1
Rigidity~1
autografting~1
presyncope,~1
pygmy~3
pygmies.~2
Prepubertal~1
pygmies~3
435~2
milliliter;~2
(278~1
ambulate,~1
(VP-16-213),~1
1000-rad~1
"boost"~1
426,~1
evaluable.~1
0.0013).~1
Failure-free~1
0.0099).~1
effects--chiefly~1
neutropenia--were~1
complete-response~1
Axons~1
regrow~1
alpha-motoneurons~1
'supernumerary'~1
cell-body~1
supernumerary~2
trajectories~1
boutons~1
dense-cored~1
alpha-motor~1
kinases~1
peptidergic~3
covert~1
pS.~1
(E-C~1
coupling)~1
(SR).~1
voltage-sensing~1
(T)-membrane,~1
varies,~1
'intramembrane~1
movements',~1
sensors.~1
Ca-channel-blocking~1
T-tubular~1
parallel.~1
dihydropyridines.~1
generates~1
blood-borne~1
cell-attached~1
cation-selective~1
pS~1
saline).~2
mechanotransducing~1
disturbs~1
neurohypophysis.~1
neurohypophysis~1
depolarized,~1
Antennapedia~1
(Antp)~1
gain-of-function~1
antennae~2
overexpression~3
Antp+~1
inserting~1
Antp~3
heat-shock~1
(scutum)~1
poly(dA).poly(dT)~4
arouses~1
dAn.dTn~2
bending.~2
heteronomous~4
Arnott~1
poly(dA)~1
poly(dT)~1
bivalent~1
(Ca-poly(dA).poly(dT))~1
structure:~1
Ca-poly(dA).poly(dT)~1
B-type~2
sugar-phosphate~1
Na-poly(dA).poly(dT),~2
Ca-~1
form:~1
peculiarity~1
antibiotics).~1
furrow,~1
cytokinesis.~1
actin-filament~2
(solid-like)~1
fluid-like.~1
repolymerization;~1
filaments;~1
crosslinks~2
alpha-actinin,~3
amoeba~1
alpha-actinin~1
Frey-Wyssling~1
alpha-actinin.~1
recoils~1
elastically~1
insults~1
deforms~1
2AR),~1
(MAR).~1
rhodopsin,~1
helices.~1
2AR.~1
'professional'~1
microbicidal~1
non-mitochondrial~1
Cytochrome~1
b-245~1
(CGD),~1
(PAGE)~1
127,000~1
(10-127K).~1
23K~1
76-92K~1
haem~3
CGD~1
monogenic,~1
polygenic~1
sub-chromosomal~1
ankyloglossia~1
(tongue-tied)~1
Icelandic~1
neural-crest~1
clathrin~2
LCa~1
LCb~1
brain-specific~1
Covering~1
paralysed.~1
ketamine-xylazine~1
millimetres~2
plexiform~1
birds,~1
amacrine~1
topographical~2
unprecedentedly~1
non-established~1
two-genes~1
oncogenes,~1
v-mil,~1
neuroretina~1
neuroretina.~1
faithful~1
leukaemogenic~2
transduced~1
retroviral~3
leukaemogenesis.~1
leukaemias~1
(FeLV),~1
myc~1
FeLV~2
leukaemogenesis~1
clonality~1
FeLV/v-myc-induced~1
FeLV/v-myc~1
proviruses~1
v-tcr)~1
v-myc.~1
v-tcr~1
lymphosarcoma.~1
impediment~2
heterozygote.~1
conform~1
dominance,~1
D4S10~1
G8~1
(HD),~1
neurodegenerative~1
heterozygotes.~1
amphibian~1
morphogens,~1
ventrovegetal~1
(VV)~1
VV~1
heparin-binding~1
vulval~2
nematode~1
Caenorhabditis~1
elegans.~1
fates~1
fates.~1
Embryonal~1
peri-implantation~1
blastocysts,~1
colonize~2
transgenic~1
possibility:~1
mutations,~1
realization~2
(HPRT;~1
2.4.2.8),~1
germline~1
chimaeras~1
HPRT-deficiency,~1
HPRT-deficient~1
Lesch-Nyhan~1
self-mutilation.~1
vectorial,~1
Golgi-associated~1
(termed~1
NSF)~1
stack~1
ATP-dependent~1
acylation~2
deacylation~2
rounds~3
(DAT).~1
DAT;~1
DAT,~1
etiologically,~1
saccade~3
distractibility~1
posited~1
Saccade~1
abnormalities--especially~1
distractibility--are~1
oculographic~1
(BPV).~1
head-hanging~1
(ENG).~1
(122/240)~1
neurolabyrinthitis~1
bithermal~1
ENG.~1
BPV.~1
preprandial~1
(performed~1
jaw,~1
nonuniformly~2
Tongue~1
jaw-closing~1
spindles~1
monosynaptic~1
Seemingly,~1
fusimotor~1
phenylpropanolamine-containing~1
Angiogram~1
"beading"~1
phenylpropanolamine.~1
questioning~3
pathologies,~1
(NSHS),~1
Ammon's~1
(AHS)~1
AHS~1
NSHS~1
Epigastric~1
Generators~1
short-latency~1
orthodiagonal~1
N11~1
volleys.~1
subcomponents,~1
dipoles~1
(N13a)~1
axially~1
(N13b).~1
N13a~1
N13b~1
(bipolar)~1
P14~1
far-field~1
(noncephalic~1
reference)~1
cuneate~2
lemniscus.~1
Olmsted~1
33.6%,~1
Preselected~1
autopsies;~1
Incontinentia~1
pigmenti~1
hyperreflexia;~1
flaccidity~1
neuropathology~1
neurosarcoidosis~1
(NP-SLE)~1
vasculopathy,~1
antineuronal~3
NP-SLE~2
NP-SLE,~1
antibody-positivity~1
NP-SLE.~1
coterminous~1
north-south~2
sophisticated--and~1
expensive--prevalence~1
place-related~1
tremors~2
clonazepam.~1
still,~2
disputes~1
(6-~1
8-hour)~1
Daytime~2
disorientation~2
WAIS~1
PD.~1
myotonia,~1
myotonia~3
carbohydrate-containing~1
2A,~1
2B~2
Acetazolamide~1
antimyotonic~1
paramedian~2
perihypoglossal~1
upbeat~3
Pentobarbital~1
Age-specific~1
41.4,~1
8.4.~1
5.6;~1
4.5.~1
85+-year-old~1
CHOL)~3
(LDL~1
(HDL~1
CHOL:HDL~1
Normotensive~1
lipoprotein(a)~1
[Lp(a)]~1
(ICVD)~1
62.2~1
11.1;~1
63).~1
Lp(a)~2
ICVD~2
hemispatial~1
memories,~1
imagined~2
east~1
head/eyes~1
Recall~1
hemispace~1
head/eye~1
hemispace.~1
engrams~1
memories~1
destroyed,~1
Shy-Drager~1
(ALS),~1
SDS,~1
small-sized~1
Glossolaryngeal~1
glossolaryngeal~1
(Alzheimer's,~1
Pick's).~1
SUNY-Health~1
Brooklyn~1
symptomatic;~1
34),~2
repeat.~1
(3241~1
2712~1
722~1
perinatally~1
ARC)~1
21.6~1
ARC.~2
T4/T8~5
100,000/microL)~1
149,000/microL~1
(4.2%)~1
150,000/microL~2
100,000/microL~1
50,000/microL~1
(prematurity,~1
aspiration)~1
preeclampsia-eclampsia~1
thrombocytopenic.~1
60,456~1
3457~1
postdate~4
8135~1
dystocia.~2
Hopkins-related~1
comprehensive,~1
Enrollees~1
9.9%,~1
1970-1974,~1
1974-1979,~1
1980-1984.~1
nonwhite,~1
regionalized~1
delivery).~1
20-35~1
36)~3
ritodrine-only~1
lidocaine;~1
37%),~1
Halogenated~1
awareness.~1
halogenated~3
halothane)~1
vol%~2
postdelivery~2
%.~1
pregnancy-related~4
5221~1
rising,~1
declining;~1
depend,~1
4.9%~2
preapplication~1
(occiput~1
81.2%~1
Preapplication~1
59.8%~1
+1~1
stations,~2
2%),~1
cephalohematoma~1
(3.9%~1
forceps).~1
Cosmetic~1
(ecchymoses,~1
abrasions)~1
29.5%).~1
Dye~2
peritubal~1
Larger~3
trophoblasts~1
preanesthetic~1
Aneuploidy~1
condylomata,~1
IB~2
11.3%.~1
(17.4%)~2
(9.2%).~1
sidewall~3
26%.~1
3.2%.~1
Hysterectomy~1
D.C.~1
hysterectomies~2
abdominally~1
cytoreductive~1
III/IV).~1
Occult~3
appendices.~2
III/IV)~1
Burch~3
colposuspensions~1
(53.3~1
low-urethral-pressure~1
.0005).~1
.0002).~1
disease's~2
hematocolpos~2
hematometra,~1
37%,~2
hematometra~1
hematometra/hematocolpos~1
Postovulatory~1
roles.~2
paravaginal~4
neurolemmoma,~1
neurofibroma,~1
Cherney~1
pubococcygeus~1
pounds~2
(113.6~1
"lengthened"~1
instruments.~1
electrogenerators.~1
mismatched,~1
coagulate~1
control--except~1
Kleppinger~2
forceps--matched~1
mismatched.~1
IVP,~1
pyelograms~1
(60.6%).~1
IVP;~1
Endometriosis,~1
non-IVP~1
(revised~1
procedure).~2
index;~1
694~1
Chemstrip~2
LN,~2
69.6,~1
83.4,~1
96.9%;~1
Bac-T-Screen,~2
96.4,~1
56.0,~1
16.1,~1
99.4%.~1
71.9,~1
75.7,~1
46.0,~1
90.3%;~1
84.4,~1
65.8,~1
41.5,~1
93.6%.~1
LN~1
Bac-T-Screen~1
Exfoliated~1
6/11~2
16/18.~2
German~5
condyloma,~1
(cervical~3
I/II),~1
dysplasia-carcinoma~2
papillomavirus-positive~1
Toxic-shock~1
(TSST-1)-producing~1
MN8~1
broth,~1
Today~2
sponges.~1
sponges~2
sponge,~2
2276~1
1854~2
50-g~1
fifty-seven~1
carbohydrate-loaded,~1
institution)~1
11.9%~1
.0086).~1
macrosomia~3
(advanced~1
gestation),~1
macrosomic~1
Wilford~1
Hall~1
(8.5%)~2
special-interest~1
relaxin.~1
postlaparoscopy.~1
drunk~1
ethanol)~1
weekly)~1
Beer~1
consumed,~1
liquor.~1
4440~1
Pharmacokinetics~1
nursing,~1
Clonidine~2
easily,~1
colposcopy;~1
colposcopy.~2
endocervix~2
additional,~1
conization,~1
pyelograms.~1
(1.3%)~1
transections,~1
Florida~1
5.3%.~1
floor,~2
drain,~1
1975-1982~1
(complete)~1
mole,~2
resubmitted~1
intra-pathologist~1
(K).~1
Albert~1
Mathieu~1
Chorionepithelioma~1
Registry's~1
abstracted.~1
Trophoblastic~2
Gynecology,~1
(USC)~1
begun),~1
chemotherapy-alone~1
(cine~1
hysterosalpingography).~1
fluorographs~1
113.4~1
52.4~1
mR~1
one-eleventh~1
plume~2
char~1
valving~1
Microcolpohysteroscopy~2
magnifications~1
1:1-1:150.~1
squamocolumnar~2
endocervix.~1
microcolpohysteroscopy~2
smears.~1
microcolpohysteroscopy,~1
geographically~1
menorrhagia~2
Nd:Yag~1
93.9%~1
Amenorrhea~1
preplaced~1
9-0~1
postplaced~1
10-0~1
1.60~2
with-the-rule~1
against-the-rule~2
Pterygium~1
pseudopterygium~2
"dynamic"~1
astigmatism,~1
pseudopterygium's~1
canthus,~1
wrinkling~1
anchoring~2
perilimbal~1
phthiriasis~1
200-microns~1
destroy~3
nits.~1
stinging~1
slicing~1
eyelash~1
nit.~1
eyelashes~1
cystitome~1
iridocyclectomy,~1
iridochoroidectomy,~1
interno~1
retinochoridectomy~1
Uveal~1
tapetoretinal~1
uveitides.~1
(HRBVO)~1
(close~1
vein-vein~1
HRBVO~1
Sclerosing~1
ineffectiveness~1
pseudotumor.~1
deformations,~1
deformations~3
cup.~1
substained~1
'Creep'~1
reaccommodate~1
pressure'~1
perimetric~1
novice~1
Humphrey~1
sure~1
dB/decade~3
-0.6~2
(30-2)~1
-06.~1
(30/60-2)~1
hill~1
Tear~1
fast-migrating~1
globulins~1
postgamma~1
Postgamma~1
pointed~2
cutting,~1
inflamed,~1
decerebrated~1
turpentine,~2
croton~1
leucocytes,~1
hyperexcitable~1
irritants,~1
nociception.~1
tail-withdrawal~1
Potentiated~1
Yohimbine,~1
alpha-methyl~1
p-tyrosine,~1
zimelidine,~1
p-chlorophenylalanine~1
Pseudo-cocaine~1
(dextro-cocaine),~1
several-fold~1
baclofen,~1
62-item~1
Behaviour~1
(AHD,~1
SI)~1
reconsider~1
Varni/Thompson~1
(PPQ)~1
PPQ~2
generalizability~1
3.33~1
micrograms/dl,~2
post-dexamethasone~1
paresthesias,~1
sensations.~1
vividness~1
experienced.~1
chordotomy~1
Dercum's~3
(adiposis~1
dolorosa)~1
Placebo~1
Hereafter,~1
polyarthritic~1
tail,~2
butyricum~1
oil;~1
(3-4~1
hyperaesthesia~1
(60.8%)~1
'typical'~1
(13.2%),~1
non-noxious~4
(34.4%)~1
(13.2%)~1
'atypical'~1
oedematous~4
modifications:~1
fields;~1
C-fibre~3
suprathreshold~1
spikes;~1
after-discharges.~1
convergent,~1
discussed;~1
vocalization~2
paws~3
forepaws)~1
min-96~1
intraplantar~1
carrageenin~3
forepaw.~1
hyperalgesic~2
Xylocaine~1
paw.~2
paw~1
hyperalgesia~1
non-injected~1
paws.~1
'collateral~1
sprouting'~1
brought.~1
arrived,~1
reinnervated~1
(BMS)~2
toothache~2
BMS~11
Tactile,~1
discrimination,~1
stereognostic~1
warmth~2
psychogenic~4
German.~1
psychologists,~1
raters.~1
intensity:~2
dropping~2
retained.~2
triads~2
(Berne)~1
(BPQ)~1
(VRS)~1
(LO),~1
(conventional)~1
(HO)~1
(placebo)~1
(PL)~2
arteriovascular~1
HO~2
HO,~1
PL~3
scales:~1
VAS,~1
VRS,~1
RaW~1
(scale~2
words),~1
NoW~1
words).~1
VAS/VRS~1
RaW/NoW~1
BPQ~1
torsade~2
adjuvant.~2
(15-21~1
adjuvant),~2
post-acute~2
(28-42~1
(benserazide)~1
bites)~1
(2.8/specimen):~1
(1.8/specimen);~1
(1.0/specimen).~1
(5.4/specimen):~1
(2.4/specimen);~1
(3.0/specimen).~1
multocida,~1
fluorescens~1
M-5.~1
aerobic-anaerobic~1
varicella.~1
Varicella~2
capitis~2
kerion~1
griseofulvin~3
KOH~3
griseofulvin-treated~1
Citrobacter~1
diversus~4
suburban~1
abscesses)~1
microbiology~2
3431~1
diversus;~1
colonized~4
b-CAPSA~1
87,541~2
13,500~1
uncommon:~1
F);~1
elevation;~1
homosexuality~2
adolescent's~1
self-described~1
gay~5
bisexual~3
homosexuality,~1
sexuality~2
fantasies,~1
Homosexuality~1
sexualities.~1
teenagers~1
employment,~1
sexuality,~1
drop-out,~1
Ad~1
Hoc~1
427,698~1
steady,~1
70.5%.~1
uncircumcised~2
11-fold~1
circumcised~3
boys).~1
onward.~1
reversed,~1
circumcisions~1
population.(ABSTRACT~1
IQs~1
IQ.~1
(off~1
source,~3
face-to-face~2
congregate,~1
cyclohydrolase~3
Guthrie~1
pteridine~2
neopterin~1
biopterin.~1
tetrahydrobiopterin-loading~1
hyperphenylalaninemia~1
20-month-old~1
adenoids~2
mg/dL),~4
hypomagnesemia~4
mg/kg/d),~1
(21.7%),~1
mEq/L),~1
hyperkaliuria~1
mEq/L).~1
N-parathyroid~1
pg/mL)~1
cystica~2
(magnesuric~1
hypomagnesemia)~1
rickets.~1
calcitriol,~1
hormone-deficient~1
ectrodactyly-ectodermal~2
dysplasia-clefting~2
lobster-claw~1
hands;~1
blond,~1
enamel~1
hypoplasia;~1
philtrum.~1
pellucidum.~1
pellucidum~1
septooptic~1
Liquid~3
packaged~1
child-resistant~1
containers.~1
sold~1
safeguards,~1
pipeline~3
(liquid~1
NaOH/KOH~1
farm/industrial~1
nonintentional~1
Farm~1
drain/pipe~1
Dairy~1
toddlers~1
nonchild-resistant~1
containers~1
glasses~1
milking~2
ingestions,~1
consumer~2
redirected~2
farm-related~1
31.04~1
hours);~1
780,000~1
pediatricians'~1
micrograms/dL~7
micrograms/dL.~1
urges~2
lead-based~1
gasoline.(ABSTRACT~1
Diego~3
709).~1
Brain-injured~1
coroners'~1
Abbreviated~1
Concussion~1
permissible~1
abused.~1
0.83).~1
otoscopy~1
well-baby~1
briskly~1
pink~2
Tympanic~1
translucence~1
luster,~1
vitally~1
was:~2
0.7x~1
27.2;~1
.9.~1
instantaneously,~1
5,356~1
(0.9%)~1
3,375~1
Intracerebral~1
five-minute~1
audiovisual,~1
Inactivation~1
flora-mediated~1
product-forming~1
Maturation~1
Oahu,~1
HI,~1
Sept~1
2.5.~1
polyarthritis,~2
carditis,~1
chorea.~2
Polynesian/part-Polynesian~1
Hawaiian/part-Hawaiian~1
Samoan~1
Rheumatic~1
Polynesian~1
albumin/bilirubin~1
1,860~1
NY.~1
cafeteria~3
Nov~1
174/214~1
noncase~2
10(-8),~1
french~1
fries~1
hamburgers~1
acute-~1
convalescent-phase~1
Snow~2
.04,~1
suspect,~1
conclusively,~1
Implicated~1
EMS-C~1
identify.~1
macroregions~1
acknowledging~1
agreements.~1
strive~2
keeping,~1
reviews,~1
remedies.~1
Life),~1
life-threatened~1
expeditiously~2
self-hypnosis~4
mg/kg/d)~1
.045).~1
neonates;~1
g;~2
Nellcor~1
N-100~1
oximeter,~1
co-oximeter~2
19.41~1
0.79X)~1
.90,~1
9.72~1
0.92X)~1
.78.~1
(SD);~1
-14~2
78%.(ABSTRACT~1
abrasions.~1
subtle,~1
Table~1
palpated~1
Overlooking~1
malocclusion,~1
ankylosis~1
vicissitudes~1
Overcompliance~1
overcompliance.~1
overcompliance~1
listen~1
rapport~1
self-help~1
(viral)~1
postnasal~1
oroantral~1
mobile,~2
superficial-appearing~1
lump~1
dizzy~1
dysequilibrium,~1
Vertigo~1
electronystagmography,~1
partnership,~1
environment--including~1
personnel--sets~1
allied~1
reminded~1
faces~1
eluded~1
coryneform~1
culture-negative~2
"contamination"~1
recommending~2
Possibly~1
behooves~1
blame~1
loneliness~1
suicide.~3
(manifested~1
apathy),~1
hopelessness.~1
friends,~1
campaigns~1
launched~1
starting.~1
hazards,~1
threat.~1
unusual--in~1
remains.~1
Nonparametric~1
pair-wise~1
.007)~1
100),~1
108),~1
(2,500-Hz~1
unexercised~1
Intensities~1
(MVC)~1
electrically.~1
MVC.~1
hypomobile~2
hypomobility.~1
Groups.~1
cinematographically~1
immobilization:~1
PROM~1
(A-P)~1
A-P~3
arthrometer,~1
laxity,~1
interexaminer,~1
intraexaminer,~1
edema-effusion,~2
[corrected]~2
(LBP)~1
LBP.~1
"significant"~2
(SLBP)~1
(NSLBP),~1
intrarater~2
NSLBP~3
therapist.~1
(ICC)~1
.95;~1
SLBP~1
Group,~2
.94.~1
Kolmogorov-Smirnov~1
Schober~1
goniometry~1
loyalty~2
agent."~1
threatened.~1
double-agent~1
theories--egoism,~1
utilitarianism,~1
formalism--are~1
paternalism.~1
autonomous,~1
responsibility.~1
obligation~1
confront~1
Resolving~1
IPS~5
32-item~1
(BS),~2
(CERT),~1
107)~1
(67.2%)~1
BS~2
(64.7%),~1
CERT~2
(83.3%),~1
(76.9%)~1
(97.2%,~1
classroom,~1
(74.3%,~1
(87.7%)~1
Predominantly,~1
(MIS)~1
fulfillment~1
MIS~1
placements,~1
Applications~1
anophthalmic~2
enophthalmos.~2
room-temperature~3
vulcanized~3
Indepth~1
enophthalmos~1
ingenious~1
mesial~1
crura~1
Goldman~4
rhinoplasty,~1
Cartilage~1
bifidity,~1
theme.~1
mini-abdominoplasty~1
miniplasty~1
musculofascial~1
abdominoplasty~1
much.~1
ibuprofen-treated~4
(lactated~1
Ringer's)~1
(ibuprofen)~1
ischemia:~1
microrevascularization.~1
6-,~1
10-hour~1
14-hour~2
cyclo-oxygenase,~1
sludging.~1
buttock~1
reversal.~3
Outflow~1
mmol/liter),~2
7.11~1
splinting.~1
reconstructible~1
Flaps~1
tissue-transfer~1
including,~1
disadvantages.~1
perfuse~1
interseptal~1
malleolus,~1
peroneus~1
brevis~1
arborizing~1
fashioned~1
demonstrative~1
uniqueness~2
two-fold.~1
circumpennate,~1
herewith~1
mid-third~1
sensate,~1
heel.~1
flap).~1
(RTIl)~1
ACI~1
(RTIa)~1
allografts.~1
Short-term,~1
longer-term,~1
higher-dose~1
(Lewis/ACI)~1
(Lewis/Lewis).~1
1075~1
994~1
Three-hundred~1
job.~1
splinting~2
(pyridoxine)~1
b.i.d.).~1
vary,~1
nonreplantable~1
degloved~1
replantation.~1
skeleton,~2
"global"~1
cineradiographically~1
velar~1
covered,~1
bone-graft~1
temporaiis~1
hemicoronal~1
bicoronal~1
donor-site~1
commonplace,~1
Avulsed~1
obstacles.~1
reattachments~1
Medicinal~1
leeches~1
(Hirudo~1
medicinalis)~1
hemangiomas,~4
Klippel-Trenaunay~1
Koch~1
pouch,~4
intralesionally~1
Ariyan~1
Krizek,~1
Analgesic~1
Uncomplicated~1
unrestrictive,~1
decubiti~1
Hemovac~1
mastectomy)~1
objectively,~1
etiopathologic~1
nipple-areola~3
IIa),~1
IIab).~1
Zyderm~12
internationally~1
States).~1
Zyderm,~1
Examining~1
anticollagen~1
subcutaneum:~1
collagen-derived~1
anti-implant~1
(titers~2
640),~1
(bony~1
defect)~1
model:~1
anterogradely~1
agglutinin-horseradish~1
Reinnervation~1
hyperinnervation~1
reverse-flow~4
peroneal,~2
tibial,~1
flaps;~1
comitantes~1
cmH2O.~7
comitantes,~1
slough~1
heals.~2
longstanding,~1
expander,~1
saline-gel~1
expander.~1
rasp~2
dismantled~1
renewable~1
blade~1
rasps~1
Salmonella,~1
Shigella,~1
Yersinia;~1
Extraintestinal~1
diseases:~1
osteoarthropathy.~1
even,~1
overshadowing~1
uroradiologic~1
discovery.~1
radiolographic~1
pathognomonic.~1
Enteric~1
enterocolitides.~1
Gastroduodenal~1
Optimum~1
perivesical~1
proton-density~1
well-performed~1
extravesical~1
2,100/90~2
mass/liver~1
mass/fat~1
neoplasms)~1
cavography~1
portography.~1
pseudoaneurysms~1
Transcatheter~3
pseudoaneurysms.~1
gadolinium-DTPA,~1
diatrizoate,~1
Depiction~1
arthrography,~1
confidently.~1
transaxial~5
Coronal~2
superior.~2
(sigmoid~1
closure)~1
safely.~1
implications,~2
obviated.~1
Adventitial~1
noninvasiveness.~1
(similar~1
Phleboliths~1
visible.~2
Photodynamic~2
photosensitizer~2
(hematoporphyrin~2
[HpD])~2
fiberoptics~4
intratumoral~4
(630-nm~1
wavelength)~1
CT-guided~1
Crohn~2
quadratus~1
lumborum~1
iliopsoas~1
paracolic~1
gutter~1
evacuated~2
avoided,~1
masticator~4
ambiguous.~1
pterygoid~1
masticator,~1
prestyloid,~1
poststyloid~1
prestyloid~1
(sinusitis)~1
nasomaxillary~2
sinusitis,~1
walled.~1
eroded;~1
eroded.~2
(semilunar~1
canal)~1
thinned~1
expanded.~1
ranulas~1
glands;~1
enlarge,~1
herniate~1
plunging~1
ranula).~1
ranulas.~1
unilocular,~2
ranula~3
Arthrograms~1
derangements.~1
arthrogram~1
clicking~1
reexploration.~1
near-homogeneous~1
metrizamide.~1
(82%).~1
(91%).~1
periappendiceal~2
drainages~1
(follow-up~1
1/2-3~1
drainage;~1
temporization~1
elective;~1
obviation~1
disease);~1
high-signal~5
CSF-dura~2
refocusing~1
(SSRGR),~1
(GRASS).~1
single-section~1
multi-section~1
SSRGR~2
GRASS~2
circumventing~1
nitroxides,~1
uncharged,~1
Nitroxide~1
nitroxide~2
nitroxides~2
uncharged~1
stem)~1
nonenhanced,~1
1,830~1
(0.4%),~1
(0.2%),~2
Temperature,~1
W/kg.~1
imaging)~1
SARs.~2
35.1~1
High-field-strength~1
SARs~1
0.42-1.2~1
W/kg~1
temperature-~1
hemodynamic-related~1
(MSAD)~1
descriptor.~1
MSAD~1
2.2-6.8~1
(22-68~1
mGy).~1
user's~1
(desired~1
quality)~1
(caused~1
collimation,~1
geometry).~1
understands~1
asks~1
truthfully.~1
mmol/kg~3
gadolinium-diethylenetriaminepentaacetic~1
(present~1
[71.4%])~1
precontrast~1
fill-in~1
(42.8%)~1
pericatheter~1
drawback~2
heavy-duty~1
corners,~1
Heating~2
heated.~1
template.~1
expedited~1
"Nutcracker"~1
RES~5
emptying)~1
dyspepsia.~4
Methodologically~1
Hui~1
Walter,~1
chance.~2
endoscopy;~1
merit;~1
Intratumor~1
multiple-side-hole~1
landmark.~1
equivocally~1
cholangiograms;~1
46.~1
Thymic~4
3-14~1
Rebound~1
4+~1
lavaged,~1
Consolidation~2
beveled~1
Cores~1
lost).~1
histopathology)~1
57.1%);~1
(same);~1
64.3%~1
46.4%).~1
diagnostically.~1
hamartoma),~1
Paraspinal~2
lipomatosis~2
excess.~2
Noncardiogenic~1
recompression~1
seawater~1
dive~1
campaign~1
mammography,~1
mammography.~1
recorders,~1
positioning.~1
month-long~1
9,000~1
mammograms.~1
metastatically~1
chrysotherapy.~1
intratesticular~3
extratesticular~1
Epididymal~1
characterization.~1
testosteroni~3
cases);~1
testosteroni,~2
esophagoscopy.~1
odynophagia,~1
esophagograms~1
episodes:~1
enteroviral~1
postesophagoscopy~1
compromised-host~1
instructive~1
hierarchical~1
levels--the~1
molecular,~1
nano-,~1
micro-,~1
macrolevels--and~1
semicrystalline~1
liquid-crystalline~1
hierarchies~1
biocomposite~1
disk.~2
Bilirubin,~2
excreted.~1
peroxyl~1
(physiologically~1
concentration).~1
liposomes,~2
alpha-tocopherol,~1
"beneficial"~1
physiological,~2
chain-breaking~1
antioxidant.~1
(ADH).~1
ADH-induced~1
antidiuresis.~1
transcellular~2
spaces;~1
blood-facing~1
one-child~3
abandoned.~1
policies'~1
macrodemographic~1
aging;~1
microdemographic~1
family's~2
capabilities,~1
Han~1
policy;~1
two-child~1
Phosphate~1
anhydrides~1
dominate~1
Phosphoric~1
ionize;~1
Phosphates~1
metaphosphate~1
PO3-~1
intermediate.~1
Stable,~1
enzymes;~2
chemists,~1
phosphates.~1
Ribonuclease~1
endoribonuclease~1
primer~1
copurification~1
135-nucleotide~1
genome,~1
endoribonuclease.~1
nucleus-encoded~1
organelle~1
myohemerythrin~1
homologs~1
antigenic,~1
narrow,~1
grooves~1
superassemblies~1
myohemerythrin.~1
solvent-exposed~1
Cross-polarization~1
magic-angle-spinning~1
sclerotization~3
tanning.~1
Unsclerotized~1
ecdysed~1
pupae~1
hornworm,~1
Manduca~1
sexta~1
L.,~1
chitin.~2
chitin,~1
nitrogen-15~1
nitrogens~1
histidyl~1
carbons~1
carbon-nitrogen~1
adduct~1
chitin~2
quinonoid~1
[1,25(OH)2D3].~1
receptor-specific~1
gag-erbA~1
erythroblastosis~1
immunoprecipitable~1
(mRNAs)~2
cross-hybridizing~1
3T6~2
eukaryotes,~1
(ANF)~1
guanylate~3
transduction.~1
ANF~3
273,000-fold~1
4.01~1
5.55~1
cyclase-coupled~1
180-kilodalton~1
GMP-mediated~1
homelessness~1
scientifically~2
homeless~3
undomiciled~1
literal~1
Chicago.~1
unaffiliated~1
Homelessness~1
poverty~1
housing~1
thrombin-binding~1
thrombomodulin,~1
Va~1
VIIIa.~1
C--deficient~1
Am4~1
ets-2~1
subsection~1
13q14~1
(RB)~2
tumor-specific~2
retinoblastomas~1
examined:~2
RB~4
kb.~2
medulloblastoma.~1
metal-binding~1
bioorganic~1
complementarity~2
Structures~1
inside.~1
construction;~1
microenvironments~1
(Ad12).~1
tumorigenic~1
run-on~1
Ad5-~1
Ad12-transformed~2
virally~1
Fujinami~1
(FSV)~1
Five-~1
FSV-transformed~1
nonpermissive~1
Estuarine~1
snails~2
Ilyanassa~1
obsoleta~1
trematode~1
Gynaecotyla~1
adunca~1
singularly~1
conspecifics~1
parasite.~2
tides,~1
beaches~1
sandbars.~1
Semiterrestrial~1
crustaceans~1
shore~1
(induced)~1
snail~3
cercarial~1
crustaceans.~1
host-to-host~1
predation,~1
Weissenberg~1
rheogoniometer.~1
indeterminate,~1
semidilute~1
hydrolyze~1
undetermined.~1
448~1
3'-terminal~1
polyadenylation~1
(PHF),~1
insolubility~1
(DF2)~1
ubiquitin~3
lysylendopeptidase;~1
ubiquitin-derived~1
digest~1
sequencing.~1
acrosomal~2
Urechis~1
sperm.~1
sperm-oocyte~1
Acrosomal~1
opens~1
radiometer~1
Administration's~1
polar-orbiting~1
meteorological~1
satellites~1
ecological~3
Rift~1
(RVF)~1
Kenya.~1
enzootic.~1
satellite-derived~1
forecasting~1
sub-Saharan~1
2,062~1
linitis~1
plastica.~1
12.5%;~1
registered,~1
lengthens~1
"incidental~1
appendectomy"~1
Randomization~1
habitus,~1
gallbladders.~1
.47).~1
paramount,~1
Hulka~2
Missouri~1
3.7%;~1
violence.~1
embolectomy,~1
heparinization,~1
fasciotomy,~2
organism-specific~1
50-patient~1
reinfusing~1
autotransfusion~3
tremendously~1
posttransfusion~1
transfusion-related~1
Interest~1
citations~3
Adenine-Saline~1
(AS-1)~1
donor-patient~1
polycythemia~2
vera,~2
phlebotomy~2
hydroxyurea.~1
55.7).~1
64.9).~1
Hydroxyurea~1
Cytopenia~1
Phlebotomy~1
Hydroxyurea,~1
desoxyribonucleic~1
leukemogenic~1
myelosuppressant~1
Triglyceride~1
49.2~1
Maintaining~3
socioeconomic,~1
appointments,~1
taking.~1
inquire~1
nonthreatening~1
athletics~1
4A)~1
65.8%~1
orthopedists~1
girls'~1
4A~1
schools.~3
trainer~1
outranked~1
Copiah~1
Mississippi.~1
participated,~1
23,842~1
other).~1
neurologist~1
CF,~1
preconception~1
Furuncles~1
pathogenic,~1
furuncles~2
vulvovaginal~1
buttocks.~1
plagued~1
climatic~2
reinfection,~1
debility,~2
immunodeficiency.~1
furunculosis.~1
hemolytic-uremic~1
Kluver-Bucy~1
agnosia,~1
distractability,~1
placidity~1
sexuality),~1
hyperphagia.~1
beings.~1
Dialysis-induced~1
hemofiltration,~2
chiasm.~2
nonbronchogenic~1
coiling~1
hyperdense~2
parapelvic~2
Mucous~2
plugging~1
Cholescintigraphy~1
DISIDA~1
genesis.~1
Intrafascicular~1
perivasculitis~1
0.9-1.5~1
head-neck~1
cadavers,~1
3,000-7,000~1
9,800-14,600~1
restrained,~1
nonrestrained~1
biomechanic~1
cryomicrotomography~1
Cord~1
Barrow~1
Phoenix,~1
subgroup:~1
hangman's~1
Odontoid~2
mishaps,~1
occupant~1
backseat,~1
Motorists~1
Posttraumatic~2
disabling.~1
syringoperitoneal~1
syringosubarachnoid~1
least.~3
sequestrations~2
uncoforaminotomy~1
drop-attacks.~1
one:~1
sequestra.~1
Autotransfusion~1
autologous,~2
Saver~1
chromium51~1
coporectomy~1
methylmetacrylate~1
paraparesis~1
corporal~2
wedging~1
pericordal~1
profusion~1
Specifically:~1
flexion--distraction~2
flexion--axial~2
(burst)~1
reductions;~1
Sublaminar~1
cut-through~1
Mersilene~2
L2-3~1
nonlinearities~1
moving-contact~1
incompressible~1
inviscid~1
annulus.~1
Torque,~1
backrest~2
inclination~1
driving.~2
3.5-hour~2
repeated,~1
inclination,~1
13.5-18.5~1
inclination.~1
Electromyogramatic~1
seating~1
juxta-free~3
compression-torsion~1
three-motion~1
nm/degree.~1
compression-torsional~2
bilateral-lateral~1
compression-bending~2
nonunion),~1
two-level~1
job-related~1
42.7~2
minorities~1
14.035,~1
Nonsmokers~1
78.5%~1
95-97)~1
above).~1
chymopapain-induced~1
involved-level~1
Safranin-O~2
hexuronic~1
facet-joint~1
osteoarthritic-like~1
(LBP).~1
(SIP),~1
subscales,~1
SIP~3
Roland)~1
Walk-in~1
LBP~1
136)~1
Roland~2
Drawing~2
(BPCS)~1
psychologically~3
disturbed"~1
"psychologically~1
disturbed."~1
"return-to-work~1
status"~1
BPCS~1
intractable,~1
sequential,~1
50-100%~1
morphine-induced~1
myelographically.~1
"minor"~1
laminectomies,~1
clip.~2
clips.~2
Crow's~1
Latarjet,~1
branch,~3
Voltage~1
(TUR).~1
procedures:~2
generator;~1
Resectional~1
resectional~2
(CDD)~1
(TDS)~1
(1972~2
1981)~2
CDD~6
TDS~5
TDS.~1
(60.5~1
lithiasis~1
microlithiasis.~1
microlithiasis~2
echographically~1
microlithiasis,~1
bruising~1
one-third.~1
(56.7~1
phosphokinase-myocardial~1
mandating~1
undertake~2
embedding~1
venipuncture,~1
lubricant~1
L3-L4,~2
unavoidable~1
mislead~1
unwary~1
"safe~1
distances"~1
22.2%,~1
19.4%,~1
8.3%,~1
Montefiore~2
8.2%~2
stigmata~1
neurofibromatosis.~1
perivenous~3
feeders,~1
drainage--single,~1
dual--were~1
4-24~1
irrecoverable~1
disappears,~1
recovers~1
obtained:~1
(51.7%).~1
collection:~1
hygroma~1
hygromas.~1
complains~1
Video~1
tabulated,~1
publication.~2
hydatidosis~1
Paravertebral~1
uncalcified~1
vertebra,~1
Roentgenograms,~1
vertebrectomy~1
(Kayexalate)~1
Kayexalate~6
enemas,~1
Enemas~1
enemas.~2
sorbitol.~1
beings~2
Presumably,~2
myointimal~1
smoked,~1
Oxygen-derived~2
(WBC)~2
leukocytes;~1
pancreatitis;~1
hyperamylasemia.~1
neomucosa~6
short-bowel~3
neomucosal~5
serosa,~1
[14C]-glucose.~1
villi~3
patching~8
(0.067~1
0.103~1
0.020~1
0.012~1
microCi/min)~1
(0.264~1
0.142~1
microCi/min,~1
(13.0%~1
6.2%~1
1.33%,~1
Colon~1
Neomucosa~1
absorbs~1
cuff-occluded~1
(CORRP)--a~1
parameter--in~1
(TBV)~1
(AP),~1
(CVP),~1
(PWP),~1
CORRP~5
change"~1
(CSC)~1
CSC~6
PWP~1
TBV,~1
TBV~4
PWP,~1
15.5%~1
CVP.~1
CORRP.~1
CVP,~1
PWP;~1
Nephrotoxicity~1
(CyA)~1
CyA~6
(ATP)-MgCl2~1
Kidneys~1
albumin-Krebs-HCO3~1
3H-inulin~1
(glomerular~4
marker)~1
14C-cytochrome~1
(cyt)~1
(marker~1
absorption).~1
ATP-MgCl2~4
CyA.~1
Cyt~1
[Na+]~1
[K+],~1
cotreatment~2
desirable.~1
supraceliac~2
fluorometry~3
Fluorometry~1
dual-channel~1
guide--one~1
transmits~2
excite~1
photomultiplier~1
fluorometric~2
(dye~1
[DFI]~1
ANOVA).~1
oxidase--apparently~1
model--and~1
(allopurinol~1
(FFA~1
(pretreatment~1
allopurinol),~3
(concurrent~1
(posttreatment~1
60-month~1
incompetence;~1
muscle-pump-generated~1
in-place~1
calibration.~1
was.~1
subcardial~1
juxtacardial~1
27.4%;~1
communicated~1
juxtagastric~1
sharply.~2
Branching~1
1974-84~1
control-study~1
Auckland~1
(records~1
breath)~1
4.4,~1
getting~2
sleepiness~2
hypnotics.~1
0.44)~1
hypoxaemia~2
arousals~1
14)/h).~1
(17%))~1
hypoventilation;~1
Arousals~1
(arousals/h~1
spent:~1
0.71,~1
Hypoxaemia~1
bulla;~1
bullae,~1
(residual~1
(RV)/total~1
volumes;~1
tensions.~1
amen-able~1
litre.~1
peribullous~1
non-bronchial~1
1955-80,~1
chylothoraces~3
Blalock~1
Fallot's~1
tetralogy.~1
ligated.~1
lymphangioleiomyomatosis~1
chylothorax.~1
fibrothorax.~1
hexadimethrine~1
(Polybrene)~1
(P-AHG)~1
albumin-antiglobulin~1
saline-antiglobulin~1
10,084~1
pretransfusion~1
P-AHG~2
antigen-negative,~1
crossmatch-compatible~2
anti-K.~1
alloantibodies.~1
unit's~1
anti-Lea),~1
Polybrene~2
antiglobulin.~1
technique;~1
ABO~1
hematopoeitic~1
hemapheresis,~1
Prolonging~1
(CS-3000,~1
Fenwal).~1
Donors~1
reprogrammed~1
(pump~1
0.187~1
10(9]~2
0.331~1
pooling~3
(Leukotrap,~1
Cutter~2
Berkeley,~2
tab~1
single-donor~1
(WBCs~1
93%;~1
77-99%;~1
Posttransfusion~1
Granulocyte~1
rpm).~1
agitated.~1
unagitated~2
immunoglobulin-coated~1
sedimented~1
agitation.~1
H2O2-dependent~1
nonfluorescent~1
2'-7'-dichlorofluorescein~3
(DCFH),~1
(DCF)~1
DCFH~1
(DCFH-DA)~1
DCF~1
radiolysis~1
Non-A,~1
octanohydrazide-Sepharose~1
IX/HBV~1
chromatographed.~1
Storage~1
nutrient-additive~2
AS-3~2
(Nutricel,~1
Biological,~1
CA),~1
(0.72~1
85.1~1
single-label~2
(single-label~1
(double-label~1
AS-1~1
(Adsol;~1
Fenwal~1
Deerfield,~1
IL)~1
Nutricel~1
71.8~1
Adsol.~1
Chemicals~1
leached~1
B6C3F1~1
injections:~1
ethanol;~1
solution;~1
blastogenic~3
allogenic~1
P1k~1
fourteenth~1
anti-P~3
titer.~1
Pk~1
anti-PP1Pk~1
ABO,~1
Rh,~1
cryoprecipitate~1
Deferral~1
give.~1
1247~1
deferral~2
excuse~1
donating.~1
attractants.~2
Allogeneic~1
PTC~4
PTC.~1
trifluoroperazine,~1
"passageway."~1
intiate~1
channel-related~1
Fig~1
educate~1
(hypertension)~1
received;~1
"Gift~1
Life"~1
Walsh~4
Campbell~3
persuaded~1
Dornier~1
HM-3~1
x,~1
y,~1
operators~1
knowledgeable,~1
Snap-Gauge,~1
(NPT)~1
Snap-Gauge~4
NPT~3
(CCT),~1
A1,~1
generally.~1
III-IV.~1
(12/52),~1
prostatectomies,~1
Jansen.~1
noninjected~2
ABO-Rh~1
suffice~2
phenol.~1
cystolitholapaxy~2
XY,~1
folded~1
perineum.~1
neovaginal~1
teenager~1
(loupes)~1
hypospadiac~1
mouth-controlled~1
(Zeiss~1
OPMI~1
6CH~1
Contraves~1
Stand)~1
flip-flap,~1
MAGPI,~1
Hodgson~1
XX~1
Asopa),~1
meatal~1
Bouin's~1
orchialgia,~1
extravasation,~1
ureterolithotomy.~1
6.0F,~1
8.5F,~1
11.0F.~1
polyorchidism.~1
polyorchidism~1
monodermal~1
discloses~1
"traumatic"~1
"nontraumatic."~1
"spontaneous,"~1
misnomer.~1
utricular~1
twenty-seven-year-old~1
cystourethroscopy~1
occurrences.~1
invasive/recurrence~1
metastasizes~1
fifty-three-year-old~1
ureterovesical~1
Later~1
uroflow~1
nonimpotent~1
erections.~1
inter-pudendal~1
superselective~1
fulfilled,~1
Interdependence~1
image,~1
grief~2
nonjudgmental~1
stance,~1
liaison~1
caregivers~1
consent.~1
next.~1
Insomnia~1
somnolence.~1
partner.~1
supplanted~1
hypnotics~1
insomnia.~1
Occlusive~1
Films,~1
foams,~1
hydrocolloids~1
hydrogels~1
commend~1
dyadic~1
nonejection~1
SAM.~1
neglects~1
SAM,~3
equal-sized~1
SAM~5
edges;~1
leaflets,~4
prominence.~1
slack~1
anteriorly.~2
orient~1
margins.(ABSTRACT~1
thallium,~1
40-degree~1
70-degree~1
angiogram,~2
reversal;~1
narrowing,;~1
[FPA]~1
(asymptomatic,~1
time-concentration~1
4.68~1
IU/kg)~1
extravascularly.~1
outbursts~1
"remote"~1
(radiolabeled~1
(gradient:~1
unstenosed~1
unoccluded~1
ml/min/gm~1
ml/min/gm,~1
endocardial:epicardial~1
(anterolateral~1
10.3%~1
48.4~2
55.6~1
7.8%,~1
low-level~2
finishers~1
nonfinishers~1
(NF)~1
NF~2
workload,~2
(NF~4
F)~4
anaerobically.~1
(95.4%),~1
(multiform~1
extrasystoles,~1
pairs,~2
tachycardia).~2
(600~1
chronically),~1
cause;~1
0.022).~1
chagasic~3
ECGs,~1
Mitochondrial,~1
nuclear,~1
glycoprotein-like~1
stripped~1
cylinder-ellipse~1
0.95.~2
over-~1
rest/exercise~1
6.1;~1
9.2;~1
7.0;~1
-0.18;~1
(-47~1
-24~1
fatigue-limited~1
(SVO2)~1
(CHF).~1
SVO2~3
Dose-dependent~1
0.37).~1
SVO2.~2
tricuspid)~1
natal~1
mitral).~1
(m~2
E/A~1
1.17~3
thereafter.(ABSTRACT~1
Postnatal~1
(Ao)~1
(FVI)~1
left-to-right~5
Ao~3
FVI,~2
PA,~1
(PEP/ET)~1
Ao,~2
AT,~1
PEP/ET~1
Fallot.~1
6.25%.~1
61.1%,~1
27.8%.~1
ventricular-pulmonary~1
flow/systemic~1
acceptable;~1
reoperate~1
lipid-soluble,~1
beta-adrenergic-blocking~1
workloads;~1
2,591~1
die.~1
triage;~1
recanalization.~1
vessel).~1
(23%):~1
asynergy,~2
asynergy.~2
Wall~3
(7.8~1
28),~2
0.05).Of~1
reoccluded;~1
pmol/liter~1
13.5).~1
mol/liter~1
19.5)~1
-0.4,~2
absence)~1
endorphins~2
515~1
[AMI]).~1
(1.4%~1
1.3%)~1
guidewire/dilatation~1
(69%~1
minor;~1
medically.~2
successful:~1
worse.~2
exercise-echocardiography~1
(EET)~1
dipyridamole-echocardiography~1
(DET,~1
DET~4
EET~2
interpretable,~1
EET,~2
76%)~1
87%)~1
(operator,~1
instrumentation),~1
ostia.~1
traversed~1
Provocative~1
stress--exercise,~1
testing--allows~1
(RV~1
LV)~1
Inducibility~2
noninducibility~1
undocumented~1
(VF).~1
67-month~1
57),~1
2.6.~1
Six-month~2
extrastimulus~4
(PES)~1
Extrastimuli~1
micrograms/min),~1
(recordings~1
Coupling~1
extrastimuli).~1
provoked.~1
(twice~1
(part~2
(68%~1
94%),~1
VTs~1
extrastimuli)~1
studied).(ABSTRACT~1
(ECG),~1
(76%),~3
inducible,~1
ms).~1
aneurysmectomy~3
recording:~1
(torsades~1
pointes-type~1
tachycardia)~1
mEq/liter.~1
delta-wave~1
free-wall~1
Pathway~1
(Medtronic)~1
P-wave~3
V/s~3
(QRS).~2
different:~1
V/s.~1
Orthogonal~1
noncontacting~2
electrographic~1
contacting~1
0.007~1
mg/kg/min)~1
(BPs)~1
21/102~1
19/95~1
0.005);~2
counts/s,~1
420~2
28-month~1
risk:~1
S3,~1
preservation,~1
662~1
analyzes,~1
aspects.~1
embolus;~1
subendocardium;~1
comparatively,~1
catheterization-determined~2
gradient:~1
mm/Hg~1
(regression~2
0.63x~1
1.41),~1
0.64x~1
0.52),~1
Doppler-calculated~1
1.4);~1
Doppler-determined~1
1.15~1
0.3).~3
malfunctioning~1
bioprosthesis,~1
angiocardiography.~1
acceleration,~2
dW/dt~3
high-fidelity,~1
catheter-mounted~1
(IDC)~1
IDC,~1
(454~1
ml/s,~2
(569~1
916~1
IDC~3
0.04;~3
IDC.~2
regurgitation;~1
Consecutively~1
nonsignificant.~1
7.09)~1
(8.02~1
4.75)~1
Provided~1
deviation]),~1
"dome-like"~1
more),~1
(acceleration~1
midsystole.~1
"spike~1
dome"~1
(0.62~1
(WR)~1
unloaded~1
pedaling~3
VO2/delta~3
WR)~1
constant:~1
10.29~1
ml/min/W~2
W/min,~1
WR,~1
8.29~1
(3-OHQ),~1
rate-corrected,~1
endpoint.~1
3-OHQ~8
ultrafiltration.~5
1,362~1
3,480~1
(largest~2
0.0184~1
0.0128~1
0.0297~1
0.0111~1
rubidium-82~1
(supply)~1
benefits.~1
"stable"~1
redirects~1
result--angina--to~1
fundamental,~1
ischemia),~1
(secondary~2
ischemia)~1
ischemia).~1
episodes--with~1
pain--constitutes~1
thereby,~1
2,982~1
456~2
471~1
(88%,~1
Naughton~1
abnormalities)~1
(silent~1
(VF),~1
VF.~2
hours/patient).~1
episodes/patient/48~1
noon.~1
98),~2
120).~1
3-vessel~1
1-vessel~2
juvenile-onset,~1
modifiers~1
Isosorbide-5-mononitrate~1
(IS-5MN)~1
Once-a-day~1
IS-5MN~5
once-a-day~4
IS-5MN.~1
(hazard~2
deaths/patients~1
(invasive~1
noninvasive),~1
non-operated~1
product/100~1
carvedilol,~4
Relative,~1
counts-based~1
first-third~1
carvedilol.~1
10%;~2
propranolol;~1
544~1
(CK)-MB-confirmed~1
Reinfarction~1
(9.2%)~1
(V1-V4).~1
pain),~1
R:S~1
V2.~1
reelevation~1
sampling)~1
(1,051~1
663~1
0.0004).(ABSTRACT~1
Myocardium~2
(2-week)~1
(subtotal~1
(reperfused~1
(occluded~1
Biplane~2
monoplane~1
complementary,~1
stage:~2
infra-Hisian~1
I--16~1
results);~1
II--34~1
III--39~1
IV--21~1
tachydysrhythmia~2
Modal~1
service:~1
upgrade~1
asynchronous~3
batteries;~3
rechargeable~1
114)~1
deaths.(ABSTRACT~1
(TI-201)~1
TI-201~4
akinetic~1
dyskinetic~1
Redistribution~1
thyrotoxic~4
(TT3).~1
TT3~1
3,348~1
(Lown~1
bivariate~1
Nonsustained~1
suddenly),~1
phase-dependent~1
parasystolic~10
nonparasystolic~1
parasystole~2
1,800~2
151%~1
decelerating~1
Transition~1
supernormal~5
"window"~1
VPCs~2
interectopic~1
trigeminy.~1
Bigeminy~3
trigeminy~6
reentry,~1
electrotonically~1
electrotonic~1
3:1~1
entrainment.~2
Kuopio~1
East~2
Finland.~1
33,655~1
14,990~1
eligible.~2
disopyramide.~1
(quinidine,~1
combined),~1
(AF)~1
cryosurgical~5
42%)~1
different;~1
pacemakers.~1
diuretic-treated~2
open-label,~1
esmolol,~1
(esmolol,~1
micrograms/kg/min)~1
[NS]).~1
1--oscillators~1
2-intermediate~1
oscillators~1
14);~1
3--nonoscillators~1
(change~3
liters/min)~1
38.0~1
wasted~1
ventilation;~2
(ventilatory~1
Oscillatory~2
ml/kg/min)~2
(17.9~3
14.7),~1
(Qp/Qs)~1
relation,~2
volume/diastolic~1
pressure-time~3
ml/s).~1
nutriture~3
RDAs~6
B-12~1
Peruvian~1
weight-for-height.~1
67.4~1
9.4-18.5%.~1
Equations~1
well-nourished~1
doubly-labelled-water~2
(2H2~1
18O)~1
max)~2
kcal/h~2
daytime,~1
nighttime,~1
two-pair~1
decay-curve~1
lean,~1
(AOO),~1
child-onset~1
(COO)~1
subject-keypunched~1
diaries.~2
(2472~1
(1979~2
moderate-to-strenuous~1
vigorously.~1
AOO~1
COO~1
vigorousness~1
weight-supported~1
phylloquinone~4
Notwithstanding~1
prophylactics~1
high-fat,~1
low-calcium,~1
low-fiber~1
low-fat,~1
high-calcium,~1
microM;~3
detergents~1
fat:~1
lean.~1
ephedrine-aspirin~1
percentiles,~1
(62~1
F).~1
midparent~1
Suboptimal~1
flesh~1
Percentage~1
selenoproteins~1
(Sephadex)~1
Glutathione~1
15-30%~1
nutrient-based~1
(Diet~1
Guide)~1
food-group~1
(Exchange~1
Lists)~1
diet-planning~3
3-session~1
workshop.~1
postworkshop.~2
Guide~1
Lists~1
preworkshop~1
distinctive-type~1
cardiac-type~1
dysplasia;~1
candidates.~5
DNA-aneuploid~1
villoglandular~2
(CIS),~1
polyps;~1
CIS).~1
lipofuscin.~1
neuromelanin~1
Marschalko~1
grades:~1
T11,~1
T8,~1
T11+~1
(IL-2).~1
B1+~1
sizers~1
thrombocytic~1
platelet-crit~1
(PCT).~1
447~1
inverse,~2
Platelet-crit~1
adsorbable~1
hydroxide,~3
anticoagulants.~2
(kU/L),~1
persist.~1
atypia.~4
single-agent~1
point-counting~1
quantities,~1
Alpha-thalassemia~1
(HbB)~1
deletion.~1
HbB~1
HbB.~1
fL.~1
three-gene~1
alpha-thalassemia.~2
one-gene~1
(SBT)~1
SBTs~1
SBT~2
calf.~1
preaspirin~1
0.50),~1
0.50).~1
Cefinase~2
(BBL~1
Microbiology~1
Cockeysville,~1
M.D.)~1
5-micrograms~1
Penicillin~1
Cefinase-negative~1
saprophyticus~1
MICs,~1
saprophyticus,~1
expertise,~2
hyposplenism~3
pneumococcemia~1
asplenic~2
pneumococcemia.~1
natural-valve~2
Hemoglobins~1
mononuclears~1
differentials.~1
asymmetrical.~1
"R"~1
flags,~2
backlighting,~1
(Thromb~1
1983;~2
32:605-613)~1
eluate,~1
reagents.~2
72-130%~1
(0.7-1.30).~1
Hepatocellular~1
(0.25)~1
(0.35).~1
deferrals.~2
(RBC~1
ZP)~1
deferrals~2
fingerstick~1
microhematocrit~3
requirement,~2
ZP~3
[0.943~1
mumol/L]~1
RBC),~1
(5u~1
column),~1
(Sandoz,~1
Hanover,~1
(substituted~1
3H-tracer~1
Immuno~1
Corporation,~1
Stillwater,~1
MN).~1
cumbersome~1
belli~2
trimethoprim-sulfamethoxazole.~1
Isosporiasis~1
protozoa~1
(CMV).~1
enterocolitis,~1
bacteremias~1
species).~1
CMV-induced~1
belli,~1
lymphohematogenous~1
infestations.~1
Doxycycline~1
1984-1985,~1
inter-ethnic~1
0.5%;~1
1.0%;~1
Indians,~1
2.6%;~1
coloreds~1
(Eur-African-Malay),~1
2.2%;~1
Afrikaans~1
13.4%;~1
9.9%.~1
10-19~1
postpubertal.~1
Dietarily,~1
17.9-26.1~1
16.3-22.3%,~1
32.7-39.5%.~1
Clearly,~2
aminotransferases.~1
existed,~1
Perl's~1
nonulcer~2
Brunner~1
siderosis~1
39-yr-old~1
Garren-Edwards~2
31/2~1
maneuvers,~3
deflate~1
Transampullary~1
remnant.~4
Pancreas~1
Santorini.~1
Extended~1
cystduodenostomy~1
29-yr-old~1
microhamartomata.~1
hemobilia.~1
nasobiliary~1
Choledochoduodenal~1
antrectomy~1
scleroderma-like~1
aperistalsis~1
steroid-dependent~2
teens~1
twenties.~1
steroid-induced~1
-0.93~1
Cyclophosphamide~1
-0.84~1
-0.28~1
-2.29~1
-0.43~1
(MPGN~3
ultrastructure,~1
perturbation,~1
MPGN~11
63%;~1
never,~1
pallor,~1
hypocomplementemia~1
hypocomplementemia,~1
compelling~1
same,~1
cytostatics,~1
H11~2
elaborated~2
immunogold~1
debris-containing~1
filament-like~1
association,~1
drug(s).~1
Drug-induced~2
pain-relieving~1
glomerulocystic~1
(GCKD),~1
Ultrasonographic~1
similar-appearing~1
ultrasonograms~1
GCKD~2
0.27%~1
idolent.~1
(ACKD)~1
ACKD~1
hypergammaglobulinemic~2
urine-concentrating~1
immunopathologic,~1
Moderate-to-severe~1
enalapril.~1
fell.~1
suspected:~1
furosemide-insensitive~1
short-lasting.~1
converting-enzyme~2
hemodialysis).~1
g/d).~3
108.8~1
121.8~1
patient.(ABSTRACT~1
.51,~1
undialyzed~1
mEq/L.~1
microcytosis,~2
protoporphyrins,~1
bone-related~1
Increase~1
54-year-old~3
foundry~2
glomerulonephritis;~1
silica-exposed~1
silicosis.~1
silica-induced~1
(GBMs)~1
(EM)~2
congo~1
red-negative~1
amyloidosis-like~1
glomerulopathy.~1
calciuresis~1
plicamycin,~1
diphosphonates.~1
diphosphonates,~1
etidronate~1
disodium~1
(etidronate)~1
etidronate.~1
"catheter~2
31.8~2
("blockers")~1
("nonblockers"),~1
urea-splitting~1
encrustations.~1
Encrustations~1
obstructed.~1
specimen)~1
cfu/ml~1
30,147~1
human-years~1
2,046~1
Normative~1
hydroxychloroquine~6
chloroquine/hydroxychloroquine~2
toxicity:~1
toxicity;~1
myotoxicity.~1
neuromyotoxin~1
hydroxychloroquine.~1
doctors~5
cross-national~1
"should~1
order"~1
percent:~1
ordering,~1
expectations.~3
ordering.~1
ventures.~1
typify~1
ventures:~1
partnership~1
syndication,~1
venture~1
company,~1
cheese-alkalosis~1
milk-alkali~1
risk-free,~1
electroencephalography,~1
polychemotherapy~1
encephalopathic,~1
pleocytosis.~1
toxic/metabolic~1
zoster-associated~1
Variant~1
5-fluorouracil-associated~1
4,065~1
Grady~1
11-week~1
1,194~1
spirochetosis~8
eosin,~1
spirochetosis.~3
spirochetosis,~1
gonorrhoeae.~1
DF-2~5
(bacteremia,~1
cellulitis)~1
bites.~2
multocida~1
scratches~1
periodontitis.~1
mutans.~1
anti-A~1
cytopenia,~1
husband's~1
trimethoprim/sulfamethoxazole~1
hemolyticum.~1
nondiphtherial~1
coryneforms~1
non-immunocompromised~1
nine-year-old~1
C2.~1
properdin~4
father,~1
coping,~1
Couples~1
cohesive,~1
menstrual,~1
luteal,~1
dexterity.~1
Crawford~2
Dexterity~2
Test--Part~1
0.015).~1
Test-Part~1
logarithm-transformed~1
advances.~1
Consequently~1
Gestational~1
57.6%~2
33.7%~1
44.2%~1
chlamydia~3
culture-positive.~1
mycoplasma.~1
procedure:~1
salpingostomy~1
gestations.~1
convenience~2
(night,~1
7:59~1
AM;~1
5:59~1
PM;~1
11:59~1
PM)~1
commitments~1
routines~2
obstetrician.~1
3458~1
13.1%,~1
18.5%,~2
28.2%,~1
multiparous~1
4.7%,~1
10.1%,~1
meconium-stained~1
Toronto~3
acyanotic~8
Eisenmenger's~1
19.2%~1
developments,~1
(1.1%)~1
computer-derived~2
childless~1
2.8).~1
careers.~1
intimacy,~1
incomes,~1
Maffer~1
Feminine~1
Identity~1
Sociotrophy-Autonomy~1
Symptom~1
Checklist~1
troubled~1
0.23%.~1
Fundal~1
corkscrew~1
placentas,~2
43%,~1
104%,~1
redistributed,~1
(myometrium).~1
lamb,~1
gynecologist~1
pathologist,~1
encouraged.~1
1970-1985.~1
tumor-positive~2
47.4%~1
29.4%,~1
nonhairy~3
chorioamnionitis~4
70.8%~1
Chorioamnionitis~1
gestations~2
pyrexia.~1
chorioamnionitis,~1
chorioamnionitis.~2
posthysterectomy~1
Mount~2
sacropexy,~1
anchor~2
promontory~1
retroperitonealization~1
(93.3%)~1
Molar~1
Hormones~1
581,829~1
112,581~1
3187~1
mlU/ml~1
182-fold~1
amenorrhea.~1
trophoblast,~1
estrogen-androgen~1
injection)~1
low-density/high-density~1
Trophoblast~1
8-bromoadenosine~3
Gs-GTP~1
continually~1
rights.~1
Representative~1
2.16~1
"estrogenic~1
bias"~1
denominator.~1
anovulation~1
hoping~1
59)~1
Phospholipid~1
lecithin/sphingomyelin~1
phosphatidylglycerol,~1
phosphatidylserine,~1
lysolecithin~2
1420~1
obstetrician-gynecologists~2
inseminations~1
sterilizations.~1
sterilizations~1
practice-related~1
syncytiotrophoblast.~2
A-gold~1
cell;~1
Golgi-derived~1
(95.7%)~1
oviducts~1
(52.6%),~1
intelligent~1
superinfection,~1
nephrotoxicity,~1
Tocodynamometry,~1
(8.2~2
Braxton~2
Hicks'~2
Two-hour~1
1F~1
non-state~1
1F.~1
chairmen~3
113)~1
599)~1
department).~1
funding.~1
fellows,~1
gynecology;~1
subspecialty;~1
Employment~1
60.8%~1
devote~1
49.1%~1
clinical;~1
56.6%~1
40.3%~1
grant~1
grants~1
63.5%~3
34.5%~1
funded.~1
hysteroscopy~4
hysterosalpingography.~1
hysteroscopy,~1
flashes.~1
Frequency,~1
8-week~2
flashes;~2
severity;~2
(frequency,~1
Obstetricians~1
Gynecologists~1
polyhydramnios,~1
debilitation~1
progressiva.~1
vulvovaginitis~1
negate~1
fitness,~1
non-oral~1
(ml/kg1~1
min1)~1
(2.34~1
ml/beat).~1
lipoprotein/cholesterol,~1
2a~1
(coherent~1
U/ml;~1
impinge~1
lipid-lipoprotein~1
Pedersen~1
White's~3
2.9%,~1
14.9%,~1
21.1%,~1
(12.5%,~1
22.4%,~1
42.4%,~1
76)~1
17.1%~2
7.3%~1
(31.6%~1
16.3%,~1
4.1%,~1
Pedersen's~1
fivefold,~1
gestation;~1
abortion-related~2
laminaria~1
tents~1
Emergence~1
equate~1
attrition.~1
17.6%.~1
69.7%~1
dysplastic:~1
Confirmed~1
62.1%~1
ectocervix.~1
"atypia"~1
atypia,~3
Colposcopically~1
endocervical,~1
2-sympathomimetics~1
(tocolysis)~1
tocolysis;~1
delivered.~1
symphysis-fundus~4
primigravid~4
multigravid~2
(symphysis-fundus~2
ninetieth~1
centile),~1
centile).~1
Adriamycin-based~1
IB,~1
adenomyosis~1
microscopically.~2
56.~1
adenomyosis,~1
adenomyosis.~1
Unruptured~1
metrorrhagia,~1
fertility;~1
Auscultation~1
bradyarrhythmia~1
ripeness~2
parity.~1
corpus,~1
picked~1
cervices~1
chemoprophylaxis~1
1:200,~1
1:500.~1
mycoplasmacidal~1
ELISA-positive~1
mycoplasmacidal-negative~1
A400~1
(ELISA~1
hominis.~1
81.6%~1
82.9%.~1
proopiomelanocortin-related~1
(beta-lipotropin,~1
gamma-endorphin)~1
pregnancy)~1
embryos)~1
prostaglandin-induced~1
(four)~1
beta-Endorphin~2
beta-lipotropin~3
gamma-endorphin~2
acetylated~1
1-31~1
beta-Lipotropin~1
"fetus-related"~1
twenty-fifth~1
hematocrit;~1
compensation.~2
hematocrits,~1
time-dated~1
ritodrine-treated~1
Starting~2
(term~1
L-Isoproterenol-dependent~1
triphosphate.~1
fluoride-dependent~1
(7.4%)~1
Ophthalmoscopically,~1
.03),~1
centering~3
properly.~1
sight~2
sighting~3
sighting.~1
fixate~1
pupil,~1
ignoring~1
nonhemorrhagic~2
pseudophakic.~1
20/400,~1
papillitis~1
alpha-N1,~1
units/m2~1
Mu/m2),~1
11a~1
examine,~1
suppressive,~1
preretinal~1
scissors.~1
Fibrovascular~1
eyes),~1
(retrolenticular)~1
preeclamptic,~1
-.32,~1
.34,~1
spots,~1
Elschnig's~1
detachment).~1
(Kaposi's~1
ganciclovir~2
(dihydroxy~1
propoxymethyl~1
guanine),~1
acyclovir,~4
epikeratophakia,~4
adults:~1
diopters.~3
epikeratophakia~6
335~1
illiterate~1
Allen~1
card,~1
contact-lens~1
intolerant,~1
permanence~1
myopia;~1
decay,~1
reepithelialize,~1
aphakia.~1
predictability,~1
lenticule.~1
972~1
(67.5%)~1
638~1
emmetropia;~2
diopter,~2
+0.12~1
-1.00~1
overcorrected~1
concanavalin-A~1
66-month-old~1
keratectomy~1
pseudomembrane.~1
transparency~1
argon-fluorine~1
podocytic~2
(PAN).~1
expanses~1
droplets,~1
ruptured,~1
(GBM).~1
Polymorphonuclear~2
superoxide,~1
per-cell~1
diethyldithiocarbamate,~1
monolayer,~1
neutrophil-generated~1
thymectomized~1
(D3TX),~1
pellucida,~1
cell-sperm-differentiation~1
(TSDA),~1
oophoritis,~1
orchitis~1
epididymovasitis),~1
anti-oocyte/zona~1
anti-TSDA~1
anti-parietal~1
Anti-oocyte/zona~1
antizona~1
anti-oocyte~1
acrosome~1
anti-sperm~1
organ-specific.~1
5-10%~2
D3TX~1
D3TX,~1
anti-nuclear~1
(SWR/J~1
A/J)~2
(SWRAF1)~1
(C57~1
BL/6J~1
(B6AF1)~1
D3TX.~1
(GECs)~1
5/6~1
nephrectomy)~1
(SHAM)~1
(SHRs).~1
SHAM~6
(195~1
GEC~2
(10),~2
SHAM.~1
(0.6%~1
glomeruli).~1
(158~1
(outside~1
SHAM).~1
represent,~1
proximate~2
mesothelial~1
(PMCs)~1
(CH)~2
crocidolite~1
fibers:~1
(LM,~1
PMCs~1
CH~3
LM~1
blebbings~1
CH.~1
Metaphase~1
Chromosomes~2
entangled~1
pierced~1
asbestos.~1
CR-treated~1
intricate,~1
PMCs.~1
Alpha-hemolysin~1
110,000-dalton~1
engineered~1
extracellularly.~1
(QO2)~1
(RTCs)~1
QO2~3
150%.~1
nM/mg~1
RTCs~4
Na-K~1
ouabain-treated~1
AH,~1
ouabain-pretreated~1
protected,~1
RTC:~1
(O2-~1
modulators~3
RTC~1
toxicant,~1
4-ipomeanol~1
(4-IP),~1
Sendai~2
4-IP-treated~1
4-IP~1
Adriamycin-induced~2
abrogate~2
coxsackievirus,~1
(CVB3),~1
(PFU).~1
PFU)~1
PFU,~1
125I-CVB3~1
125I-bovine~2
apoptosis.~1
membrane-bounded~1
apoptotic~2
immigration~1
ductules~2
Atherosclerosis~1
Carneau~1
bifurcation,~1
Ten-week-old~1
lesion-prone~3
cholesterol-containing~3
foam-cell~2
780-1080~1
140-240~1
group(s)~1
nonsusceptible~1
(nonlesion)~1
pooled,~1
pigeon~1
nonlesion~1
monocyte-specific.~1
pronase~1
chemoattractant(s)~1
heat-stable~1
protein(s).~1
chemoattractants.~1
pathogen-free~1
Cloned,~1
DNP,~1
DNP35-HSA.~1
progranular~1
vesicles)~1
Degranulation~1
pits.~1
microthrombi~2
alpha-adrenoreceptors~1
Shwartzman~1
(GSR).~1
(0.5-0.66~1
microgram/kg/min),~1
cortisone-sensitized~1
Alpha-adrenergic~1
dibenzyline~1
renal-hypertensive~1
microthrombi,~1
D-adrenergic~1
endotoxemia,~1
Miniature~1
triaxial~1
shoe-borne~1
amputee's~2
pylon~1
amputee,~1
misalignments~1
amputee.~1
"stage~1
unchallenged~1
exaggerate~1
misperceptions~1
Staff~1
over-estimate~1
under-estimating~1
optimism~1
sincere~2
faked~1
(hand~1
Jamar~1
dynamometer.~2
sincere,~1
fake~2
grip.~1
indicated;~1
alternatives:~1
dismantling.~1
answerable~1
deception.~1
(HMO)~1
enrollees~3
HMO~4
specialist;~1
EEG-recorded~1
Schneider's~1
first-rank~2
1-8).~1
Intrusive~1
military,~1
postmilitary,~1
Alprazolam~1
(4-5~1
7-13~1
372)~1
hypomanic~1
hypomania.~1
Cycling~2
clerkship.~6
Intercorrelations~1
data-gathering~1
end-of-course~1
phobic~3
(none,~1
extensive).~1
instruments:~1
Structured~1
Disorders,~1
Phobic~1
third-cluster~1
nonphobic~1
right-unilateral~3
ECTs~1
melancholic~1
ECT.~1
ECT~4
Accentuation~2
ECT-induced~1
slowing.~1
nortriptyline,~2
phenelzine,~1
(MAO)~1
MAO~2
biopsychosocial~3
consultations,~1
consultee~1
inquiries~1
Consultants~1
psychopharmacologic~1
consultees,~1
deemphasis~1
(because~1
"awake"~1
"movement"~1
periods),~1
REM-~1
non-REM-related~1
REM-related~1
diagnoses)~1
preschoolers~1
field-tested~1
(DSM-III-R)~1
cross-system~1
Discrepant~1
DSM-III-R,~1
demographics.~1
help-seeking~1
psychiatrists'~2
same-gender~2
opposite-gender~1
genders~1
manpower~2
hyponatremia.~2
HRA~1
Update~1
Project.~1
Geller/Gesner~2
questionnaires.~1
1950s,~1
1950s.~1
Probabilities~1
probabilities~2
persuasive~1
tools.~1
factual~1
misconceptions~2
II);~1
separated/divorced~1
unhappy~1
marriage;~1
two-to-threefold~1
9,514~1
(GCU)~1
(NGU)~1
NGU~2
GCU.~2
soldiers~1
CI:~1
1.37-2.00).~1
1990~2
18-65~1
diaries~4
kcals/week~1
DHHS~1
financed~1
copaid~1
(health~1
organization).~1
(urban~1
rural),~1
copayments~1
(cl)~1
.88)~1
.83~1
cl~1
.41)~1
fee-for-service.~1
$20,000~1
breastfeed~2
breastfeeding.~2
Statewide~1
1979-81~1
1.13/1,000~1
0.97/1,000~1
person-years,~1
Extrapolating~1
254,250~1
3,382~1
$6,764,000.~1
$20,340,000~1
surgeons'~1
charged.~1
initiative.~1
rubrics~1
community-oriented~1
(COPC).~1
Nicaragua,~1
Costa~2
Rica~1
highlighted,~1
faculties.~1
1945-49~1
1950-54~1
1935-39,~1
stop,~1
stopping.~1
six-fold~1
multimammate~2
Inoculations~1
nonulcerating~1
inoculations~1
burdens~2
leishmaniases~1
(AVL)~1
cross-panel~1
braziliensis,~1
mexicana,~1
braziliensis;~1
widest~1
(Brazil:~1
Amazonas,~3
Bahia,~3
Ceara,~3
Espirito~1
Santo,~1
Goias,~2
Minas~2
Gerais,~2
Para,~2
Paraiba,~1
Janeiro,~2
Sao~1
Paulo;~1
Honduras:~3
Barbara~1
Yoko;~1
Peru:~2
Ancash,~1
Piura,~1
Ucayali;~1
Venezuela:~3
Cojedes,~1
Distrito~1
Federal,~1
Lara,~1
Portuguesa,~1
Vale~1
Hondo,~1
Yaracuy,~1
Zulia).~1
guyanensis~1
Brazil:~3
Amapa,~1
Rondonia).~1
Rica:~1
Alajuela,~1
Guanacasten,~1
Limon,~1
Puntarenas,~1
Jose;~1
Paraiso,~1
Olancho).~1
m.~7
amazonensis~1
Bolivia;~1
Maranhao,~2
Mato~2
Grosso~2
Norte,~1
Para;~1
Pasco~1
Forest~2
Humboldt;~1
Carabobo,~1
Guarico,~1
Merida).~1
venezuelensis~1
Lara).~1
Belize;~1
Mexico:~1
Campeche~1
Quintana~1
Roo,~1
Yucatan).~1
AVL~1
Sul,~1
Piaui,~1
Sergipe;~1
Valle).~1
stocks)~1
amazonensis.~1
Parasite~1
"prototype"~1
L-leucine~1
Time-lapse~1
phase-dense~1
broke~1
down.~1
Ammonium~1
ethylamine~1
L-Leu-OMe.~1
leishmanicidal~2
effect)~1
mM):~1
(0.62),~1
Trp~1
(0.96),~1
Met~1
(1.13),~1
Glu~1
(2.0),~1
Phe~1
(2.5),~1
Tyr~1
(3.8).~1
Ile,~2
Val,~2
Ala,~4
Gly,~2
Ser,~1
His,~1
Pro~2
Benzyl~1
homologs:~1
Leu,~1
Ranks~1
amastigotes,~1
enzyme(s),~1
amastigotes.~1
sand~2
fly,~1
Lutzomyia~1
abonnenci,~1
suprapylarian~1
bloodmeal~2
midgut),~1
cardia/stomodeal~2
Flagellates~1
armature~1
cibarium~1
proboscis.~1
hindgut~1
Malpighian~1
gut:~1
nectomonad~1
paramastigotes.~1
Nectomonads~1
digestion,~1
interdigitated~1
flagellum.~1
nectomonads,~1
kinetoplast,~1
gel-like~1
cuticular~1
stomodeal~1
hemidesmosome~1
Paramastigotes~2
hemidesmosomes.~1
Lu.~1
abonnenci~1
adaptations;~1
Marshallese~2
1981-1982.~1
cases/year/100,000~1
Seronegativity~1
110-190~1
fallout~1
1954.~1
amebiasis~3
(GDP)~1
Treponema~1
pallidum~1
(TPHA)~1
nontreponemal~2
TPHA~2
GDP-negative~1
syphilis.~1
bisexuals~1
homosexuals~1
amebiasis.~1
Bisexual~1
Cryptosporidium~5
824~1
Oocysts~1
dispensary~1
22-month~1
Cryptosporidiosis~1
cryptosporidiosis.~3
oocysts.~1
5-31~1
center-wide~1
(28/84)~1
(4/18)~1
submitting~1
12-35~1
Cryptosporidium-positive~1
1-44~1
adults).~1
Electrophoretically-detected~1
allozyme~1
Philippine~1
strains),~1
mekongi~4
(Laos),~1
anthropophilic~1
japonicum-like~1
schistosome~4
Peninsular~1
Malaysia.~1
Result,~1
japonicum,~1
Formosa,~2
Philippines;~1
mekongi,~1
substrains;~1
Malaysian~3
schistosome,~1
schistosomes~1
10-50~1
snails.~2
mansoni~2
(0-0.33),~1
loci,~1
sexually,~1
inhabits~1
coevolved~1
Leyte~1
Luzon~1
(Philippines),~2
Mindoro~1
multilocus~1
electromorphic~1
Nei's~1
interstrain~1
divergence.~1
Interstrain~1
(D~5
D(max)~1
(Mindoro)~1
Leyte-Luzon~1
loci).~1
China-Philippine~1
loci)~2
conspecific~1
distantly~1
0.275,~1
Biomphalaria~1
alkylphosphonic~1
2-aminoethylphosphonic~1
alkylphosphonate-phosphorus~1
phosphonate-phosphorus~1
alkylphosphonates~2
Parasitological~1
Pongo~1
Nuer,~1
Bahr~1
Ghazal,~1
Sudan.~1
Onchocerca~1
volvulus.~1
Microfilarial~1
intensities,~1
mf/mg~1
shoulder;~1
Nodule~1
microfilarial~2
eruptions~1
individuals;~1
Microfilariae~1
chorioretinitis,~1
hyperexposed~1
savannah~1
snips.~1
Microfilaremia~1
volvulus;~1
Mansonella~1
miliary~1
cysticerci~1
Cysticercotic~1
Cancun,~1
toxigenic~1
01~1
non-01~2
persons;~1
sewage~1
tank~1
seafood.~1
toxigenic.~1
Smith~1
matched-pair~1
5/0)~1
4/0).~1
Conidiobolus~1
coronatus,~1
priest~1
Ivory~1
Coast,~1
(Peromyscus~1
maniculatus)~1
spirochetemia~1
maniculatus~7
(AI)~1
log2)~2
AI.~1
Nymphs~1
maniculatus.~2
tick-infected~2
burgdorferi,~1
ruffled~1
inappetence,~1
move,~1
lameness~1
spirochetemias~1
larvae.~1
Curran~2
Phebe~1
Liberia~1
one-month~2
"swollen~1
arenavirus~1
Junin,~1
Machupo,~1
fibrin-fibrinogen~2
arenaviral~1
serologically.~1
BHK~1
PRNT~1
Dengue,~1
travelers~1
dengue-receptive~1
immunobinding~1
E-glycoprotein~1
dengue-infected~1
C6/36~1
E-glycoprotein-reactive~1
E-glycoprotein,~1
antigenicities~1
heat/detergent~1
denaturation.~1
(45AZ5)~1
mutagen,~1
5-azacytidine,~1
45AZ5~2
Viremia~1
candidate.~1
troublesome.~1
gastroepiploic~2
Stomal~2
gastroplasty,~1
gastrojejunostomy,~1
20.4~1
ng/g,~2
extragastric~1
extraduodenal~1
Yorkshire~1
appetites~1
83.3~1
Cystosarcoma~1
phylloides~1
nulliparity,~1
figure,~1
Quadrantectomy~1
Transitional~1
Sialomucin~1
(15.9~1
inference,~1
colostomy,~2
perfluorocarbons~2
dissolving~1
Identically~1
devascularized~4
(perfluorotributylamine)~1
nonshunting~3
(-21~1
-8.9~1
(statistically~1
hemodialysis:~1
conduit,~1
Poiseuille's~1
liquids~1
based:~1
R4/8~1
escaping~1
flowing,~1
ameliorated.~1
recorder,~1
Taipei,~1
Taiwan.~1
56.3~1
97.4~1
accuracies,~1
85.5~1
95.5~1
spares~2
sternocleidomastoid~1
triangle,~1
easier,~1
safer,~1
(PVT)~1
(NST)~1
quality:~1
blocks.~1
PVT~2
NST~2
anaesthetists.~1
ion-selective~1
anaesthetists~15
(anti-HBsAg).~1
disregarded~1
analgesia/anaesthesia~1
twin.~1
epidural.~1
bearing-down~1
cover.~1
fluphenthixol~1
depot~2
phenothiazine)~1
phenothiazines~1
butyrophenones,~1
likened~1
(bromocriptine,~1
amantidine~1
L-dopa)~1
prune-belly~2
Ormond~1
Street.~1
relaxants~4
Analgesics~1
4843,~1
meptazinol~5
pethidine.~1
midwives.~1
babies'~1
historically~1
post,~1
1966-83~1
Ill-health~1
retirements~3
ill-health~1
retirements,~1
puerperium,~1
primigravidae~2
Pre-oxygenation~1
Magill~1
litres/minute.~1
13-26~1
26-42~1
gas-tight~1
denitrogenation~1
quicker~1
origin;~1
alcuronium.~2
cross-reactivity.~1
epidurally~1
103,500~1
hyercarbia~1
oedema/atelectasis~1
mismatch,~1
fuel~1
analysers~3
Fuel~1
Portex~1
Minipack~1
bevel.~1
radio-opaque~1
16-gauge~1
Newtons~1
force)~1
breaking.~1
radio-opaque.~1
Thames~1
cyclopropane~1
(92%~2
Cyclopropane~1
room;~1
favoured~2
glycopyrronium~1
bradydysrhythmias~1
Glycopyrronium~1
somatosensory,~2
anaesthetics,~1
150,~2
72.4~1
25-G~1
postdural~1
16.8%~1
24.5%~1
postlumbar~1
surface-cooled,~1
(27.5~1
L/kg).~1
surface-cooled~1
weight-matched~1
(CPB).~1
[determined~1
(VR)]~1
VR~2
capacitance)~2
inotrope~1
2.1-2.2%~1
1.7-1.8%~1
3.4-3.5%~1
3.0-3.1%~1
(SVR)~1
dP/dtmax~1
(LVdP/dtmax),~1
SVR,~1
LVdP/dtmax~1
Amrinone~1
halothane-associated~3
outbred~1
Amana,~1
Hartley,~1
exposed,~1
SGPT.~1
Outbred~1
Amana~1
anoxic/ischemic~1
(exposure~1
affected,~2
persistent.~2
neurolept~1
(214~1
sevoflurane~8
sevoflurane,~2
anesthetics.~1
MAC,~2
CBD.~1
coronary,~1
dP/dt,~2
1.2%),~1
1.8%),~1
RV,~2
dyssynchrony~1
resistances,~2
(unchanged)~2
(reduced)~2
isoflurane-associated~1
fentanyl-pentobarbital~1
0.75%,~1
2.25%~3
123Xe~1
gm-1~4
.004)~1
intramyocardial~1
intercoronary~1
collateral-dependent~2
while,~1
steal.~1
(anesthetized~1
pancuronium)~2
(micrometer-controlled~1
snares)~1
akinesis,~1
postsystolic~1
non-ischemic~1
afterloads.~1
(MAC)~1
(SE).~2
AD95~2
(anesthetic~1
ED95)~1
2.07%.~1
0.06%~1
61.4%.~1
0.94%.~1
lidoflazine,~1
(CBF).~1
cavae.~1
lidoflazine~4
(CMRO2)~2
pre-ischemia,~1
post-ischemia.~3
post-ischemia~3
post-ischemia,~1
CMRO2~5
pre-established~1
nitrogen.~1
(QT)~2
infused,~1
(SF6).~1
QT.~2
kPa)~1
(13.5~1
kPa).~1
1.5%.~2
(DHE)~1
etilefrine~1
99mTc-marked~1
venoconstrictor~1
T4/5,~1
DHE~2
(-5.9~1
muscle/skin~1
(-16.9~1
(+7.0~1
2.3%),~1
(+4.2~1
(-5.4~1
0.7%)~1
(+2~1
0.6%).~1
replenished~2
Unchanged~2
Kety-Schmidt~1
hypocapnia.~1
CBF.~2
phenobarbital-pretreated~1
thiopental,~3
oxygen)~1
microspheres;~1
supply/consumption~3
sub-MAC~1
(ipsilateral~1
P.S.~1
II-III~1
isoflurane-50%~1
Preocclusion~1
(18-20~1
Opticath~1
(three-wavelength)~1
(two-wavelength)~1
anaerobically~1
cooximeter~3
(Sv-O2)~1
Pre-insertion~1
three-wavelength~2
cooximeter.~1
Sv-O2~1
.994;~1
2.2%).~1
two-wavelength~3
.808;~1
10.6%).~1
5-31%~1
.003~1
Pending~1
Ohmeda~1
3700~1
(version~3
60-98%)~1
(y)~1
(x)~1
(y~5
1.05x~2
6.38,~1
0.96).~1
1.21x~1
19.1,~1
oximeter's~1
XJ1),~1
0.96x~1
4.59,~1
XJ1)~1
Finger~1
0.55x~1
45.2,~1
0.78).~1
"arterialize"~1
finger;~1
resaturation,~1
ear-~1
finger-probe~1
24.0~1
non-exposure~1
ft~1
candles~2
791~1
microwatt~1
[muWcm-2]),~1
cyanide-specific~1
light-protected~4
non-exposed~1
polyvinylchloride.~1
one-minute~2
mmol/liter;~1
neuroradiologists~1
8.8%,~1
disagreement.~1
Intraobserver~1
(IASD)~1
echocontrast~1
IASD.~1
Echocontrast~1
IASD~1
aretriography,~1
(0.55%).~1
fifty-two,~1
0.8-1.2%~1
focuses,~1
RCA~1
thirty-four-year-old~1
Sneddon~1
reticularis.~1
(EMIT)~1
mono-N-dealkyldisopyramide.~1
mcg/ml.~1
"positive~2
history"~3
"unknown~2
history,"~1
bronchus-obstructive~3
ingested,~1
late),~1
delayed)~1
self-management~3
pamphlets,~1
Pre-interviews~1
post-interviews~2
(recognition~1
Control).~1
Nurse~1
(Theo-Dur)~1
(Theo-Beads)~1
Theo-Dur.~1
Theo-Beads~1
p-phenylenediamine.~1
N'N'-bis-(4-aminophenyl)-2,5-diamino-1,4-quinonediimine.~1
"tilt~2
dehydrated:~1
enrolled;~1
10.7)~1
8.5)~2
(0.38~1
Hg).(ABSTRACT~1
(HEMS)~1
obtainable,~1
HEMS~2
inaccurate.~1
(ATLS)~1
expedient~1
(minutes~1
0.27.~1
On-scene~3
0.62.~1
0.4.~1
extrication,~1
94),~1
114),~1
ATLS~2
106),~1
69),~1
procurement~2
2.94;~1
2.38;~1
13),~1
1.36.~1
successful.(ABSTRACT~1
(15.2%)~1
hemopneumothorax,~1
eight-hour~1
Single-dose,~1
Admixture~1
(packed~1
bloodwarming~2
One-day-old~1
admixture,~1
34.0~1
35-day-old~1
60-C~1
cervical-spine~1
(pC-S),~1
(pCXR),~1
anteroposterior-pelvis~1
(pAP-pelvis)~1
beam.~1
inches)~2
pC-S~1
pCXR~1
pAP-pelvis~1
employee.~1
FAMA~1
High-risk,~1
0.~2
35.8~1
Done~1
1c~1
(133~1
muffled~1
exhaustive~1
"unroofed"~1
bronchoscopes.~1
mucoceles.~1
Thrombectomy~1
steering~1
wheel~1
guarding.~1
abdomen;~1
Gall~1
Spigelian~2
strangulation~1
incarceration.~1
coexist,~1
additive.~1
therapies,~1
tracheostomies~1
consented,~1
0.056)~1
tracheostomized~2
tracheostomy.(ABSTRACT~1
Sleep-associated~1
acid:creatinine(UA:Cr)~1
UA:Cr~4
sleep-associated~4
normoxemic~1
polysomnography,~1
(+31.2~1
10.9%),~1
4.6%;~1
(-23.2~1
5.8%).~1
nonhomogeneous~1
2.82~1
2.90~1
19.5%~1
N-formyl-methionyl-leucyl-phenylanine~1
(f-Met-Leu-Phe)~1
f-Met-Leu-Phe~1
(10(-12)~1
depolarization,~1
N-formyl~2
t-boc-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine,~1
f-Met-Leu-Phe-induced~1
SP-induced~1
1.34~2
households.~1
dollars)~1
helium-20%~1
(He-O2).~1
([Vmax50(He-O2)--Vmax50(air)]/predicted~1
Vmax50)~1
Vmax50~1
prebronchodilator~1
bronchodilator.(ABSTRACT~1
effort-independent~1
helium-oxygen~1
(He-O2)~1
exposure:~1
ex-smokers,~1
(one-way~1
variance).(ABSTRACT~1
steelworkers~1
smokers:~1
"obstructive"~1
FEV1/VC~3
66.6%~1
(59.8%~1
37),~1
"small~1
disease"~1
32),~1
"resistant"~1
36).~1
(74.9%).~1
2.67~1
2.46~1
SAD,~2
1.30%~1
N2/L~3
2.43%~1
4.20%~1
OS.~2
OS,~1
Closing~1
uneveness~1
physiopathologic~1
interest.(ABSTRACT~1
exhalation~1
(partial,~1
(maximal,~1
M-P~2
(DI).~2
DI.~2
euhydration~1
(Days~3
hypohydration~2
Hypohydration~1
chlorthalidone,~1
hypohydration,~1
Diffusing~1
surprising,~1
Pco2~1
surfactant-saturated~1
0.90)~1
Distention~1
changed.(ABSTRACT~1
pseudoglandular.~1
duct,~1
intercept)~1
compensates~1
(polyalveolar).~1
intraacinar~1
growth:~1
seen--the~1
overnutrition~1
(118%);~1
weight/body~1
snout-to-anus~1
(141%);~1
triglyceride/DNA~1
(217%).~1
(64%),~1
protein/DNA,~1
RNA/DNA,~1
lipid/DNA,~1
cholesterol/DNA;~1
content;~1
phospholipids.~1
Physicochemical~1
Sephadex.~1
hypoxic-conditioned~1
6,000~1
mitogen(s)~1
prone.~1
Oleic~2
end-inspiration)~1
(Qs/QT)~1
technique.(ABSTRACT~1
(PFB),~1
likewise,~1
PFB~1
fluid.(ABSTRACT~1
phagocyte,~2
macrophage,~1
chemoattractant(s).~1
(C5)~1
epifluorescent~1
Fab'~1
blindwell~1
anti-C3~1
soluble,~2
inactivator.~1
HLA-A,B,C,~1
immunogenetic~2
HLA-A,B,C~2
HLA-D~1
HLA-DRw52~1
79.2%~1
53)~1
50.9%~2
9.66,~1
pc~2
3.69).~1
DRw52~2
DRw52-positive,~1
(96.9%~1
19.74,~1
29.93),~1
lymphocytosis.~3
2-yr~1
55.20~1
41.10~1
(69.5~1
43.01~1
10(6)).~1
20%)~1
(47.2~1
19.2).~1
subsets,~1
(IPF).~1
(BALF)~2
BALF~12
IPF.~1
(quantitated~2
(BOOP),~1
43.~1
membraneous~1
(MB)~1
Clubbing~1
consolidation,~1
SAD.~1
(M-1~1
subtype)~2
(M-2~1
nonclassic~1
receptors),~1
3H-quinuclidinyl~1
pirenzepine.~1
(mucosa,~1
cortex)~1
KI~1
(KI~1
(Kl~1
M-2~2
pentamidine,~1
(iv)~1
34-fold~1
Concurrently,~1
3-fold.~1
Liposome-mediated~1
Decreasing~1
90-fold~1
(PEFV)~1
MDI-holding~1
(MDI-HC)~1
Premetaproterenol~1
MDI-HC~3
PEFV~3
postmetaproterenol~2
0.02);~1
premetaproterenol~1
hysteresis.~1
77-yr-old~1
5,400~1
debated~1
PPD,~1
PPD.~1
Mycobacteria~1
lymphocyte-mediated~2
(VUH)~1
Cushing's,~3
virilization,~3
Feminizing~1
17-KS~1
feminization,~1
Beckwith-Wiedemann~1
uncompromised~1
Esophagectomy~1
Multi-variant~1
transhiatal~1
705~1
Nashville~1
(57.7%)~1
Wake~1
primary-level~1
intermediate-level~1
812~1
588~1
rectosigmoid,~2
Cecal,~1
ascending,~1
1115~1
histogenesis,~1
multifocal.~1
1970.~1
41.8~1
skin;~1
gluteus~2
eyelid,~1
bronchus,~1
Jackson-Pratt~2
(American~1
Heyer~1
Schulte~1
Goleta,~1
injectable~1
narcotics,~1
2.9),~1
Drains~1
seromas~1
savings.~2
(66%),~2
chemo-~1
Beach,~1
perigastric~1
I--four~1
II--five~1
III--eight~1
IV--three~1
65.(ABSTRACT~1
Project,~1
Multitubular~1
prototypes,~1
L-phenylalanine~2
ammonia-lyase,~1
trans-cinnamic~1
coenzyme.~1
ammonia-lyase~1
5.5.~1
hemodialysis-like~1
hyperphenylalaninemia.~1
kindreds.~1
80%;~1
survive,~1
virus;~1
hypogammaglobulinemia.~1
hemodiafiltration~4
three-times-weekly~1
Abstinence~1
37.6%~1
35.8%~2
enzyme-inducing~1
transcarbamylase,~1
hyperammonemia.~1
(encephalopathy~1
deficits)~1
910~1
provocation.~1
chest-pain~2
655~1
tracings,~1
("definite"~1
pain);~1
("probable"~1
pain).~1
Achalasia~1
Innovations~1
implemented,~1
vocabulary~1
quickly,~1
searches,~1
expect.~1
high-density-lipoprotein~1
eyelids.~1
second-most~1
right-side~1
Raised~1
iodine-125,~1
emits~1
gamma-rays~1
keV.~1
ophthalmologist,~1
radiotherapist,~1
physicist.~1
(CRAO)~1
CRAO~2
20/80~1
O2,~4
foveola-sparing~1
cilioretinal~1
Chitosan,~1
chitosan~1
sets,~1
chitosan-treated~1
palpebralis~1
superioris~1
dysthyroid~2
(Graves's)~1
Hering's~1
fixating~1
retinal,~1
preretinal,~1
Arnold-Chiari~1
hyperflexion~1
paraparesis.~1
laminectomy.~1
hypersomnia,~1
(CPS).~1
82).~1
records-linkage~1
polyneuropathies~1
(IDP)~1
IDP~3
cells/mm3),~1
macrophage-mediated~1
plasmapheresis.~1
immunopathogenic.~1
dopamimetic~1
GABA-utilizing~1
GABA-mimetic~1
(progabide,~1
4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin--3-01)~1
100330-A)~1
apomorphine-induced~1
turning.~2
mimetics~1
guanacline~2
fasicularis~1
guanethidine,~3
guanacline,~2
(SAG)~1
SAG~1
infiltrate,~4
neuropil.~1
guanethidine-induced~1
electrooculography~1
Tobacco~1
primary-position~2
dark,~1
obeyed~1
Alexander's~1
Tobacco-induced~1
slow-phase~1
Poliovirus~1
tropism~2
forebrain,~1
synaptosomes,~1
endings.~1
motoneurons;~1
viremia.~1
4-aminopyridine~1
(4-AP)~1
5-mg~1
flicker-fusion~1
(power,~1
gait)~1
4-AP.~1
4-AP~2
lessens~1
(WE)~1
alluded~1
WE~4
dysequilibrium~1
alimentation.~1
Preventable~1
curable,~1
atherostenosis~3
sensory,~1
flashing~1
lights.~1
spells~2
paresthetic,~1
territory,~1
TIAs.~1
stenosis--preponderance~1
TIAs--distinguish~1
Long-latency~1
antiparkinsonian~1
N1,~2
N2,~3
uncertainty.~1
factor's~1
nonneuronal~1
caloric-induced~1
7,000~1
radiotherapy;~1
hemianopia~1
and/or,~1
(FEF),~1
FEF.~1
saccades,~1
colliculus.~2
FEF~2
triggering,~1
colliculus)~1
decussating~1
(EEGs)~1
Bioccipital~1
impairments.~1
stroke;~1
bioccipital~1
Pelizaeus-Merzbacher~3
myelin-specific~1
2',3'-cyclic~1
nucleotide-3'-phosphodiesterase.~1
(lipophilin).~1
jimpy~1
myelin-deficient~1
lipophilin~1
Dihydropyridine~1
0.2-ml~1
[14C]nicardipine~1
[3H]water~1
30.7%~1
42.3%~1
hippocampi.~1
Folate~1
Lactobacillus~1
casei,~1
(20.4%):~1
(12.2%).~1
anticonvulsants,~1
folate,~3
Sardinia~2
Alghero,~1
78,000~1
Sardinia.~1
100,000.~2
dorsomedial~1
isointensity~1
Tears~2
immunoblot.~1
atopy,~1
emotion,~1
heat.~1
Atopy,~1
G)~1
(Slidex~1
Streptokit~1
bio-Merieux~1
Streptex~1
Wellcome)~1
erysipelas,~1
fasciitis)~1
hypodermis.~1
(0.63)~1
(LCs)~1
LCs~2
paracoccidioidomycosis.~1
paracoccidioidomycosis~1
(LCs,~2
135/mm2)~1
689~1
204/mm2)~1
LCs.~1
Paracoccidioides~1
brasiliensis.~1
sclerosus~1
atrophicus~1
(LSA)~1
HLA-B40,~1
LSA.~2
Prolidase~1
iminodipeptides~1
prolidase~1
connective-tissue~1
packed;~1
Elastin~1
atopy.~1
dandelion~1
(Taraxacum~1
officinale),~1
(Ambrosia~3
acanthicarpa),~1
trifida),~1
artemisifolia),~1
sagebrush~1
(Artemisia~1
tridentata),~1
feverfew~2
(Parthenium~1
hysterophorus),~1
yarrow~1
(Achillea~1
millifolium),~1
tansy~1
(Tanacetum~2
vulgare)~1
Dahlia~1
ivy~1
(Hedera~1
helix).~1
plants,~1
cocklebur~1
(Xanthium~1
strumarium),~1
fennel~1
(Anthemis~1
cotula,~1
fleabane~1
(Erigeron~1
strigosus),~1
sneezeweed~1
(Helenium~1
autumnale),~1
parthenium).~1
boy's~1
clears~1
oleoresins~1
plants;~1
inhalants~1
1/2-month-old~1
hemidysplasia~1
(CHILD)~1
meningocele,~1
Shone's~1
arciform~1
erythemas~1
Videourodynamic~1
haemodialysis~4
Scribner~1
polyvinylchloride~1
cannulae.~1
2.5-16~1
7.7-60~1
kg))~1
cloacae~2
Stopping~1
cohorting~1
colonised~1
fontanometer~2
fontanelle~1
(2.2)~1
hypoxic-ischaemic~1
(4.3)~2
post-haemorrhagic~1
accurately,~1
non-invasively~1
auxological~1
knemometer~1
Knemometry~1
interchangeable~1
knemometry~1
(atresia),~1
diisopropyl~1
iminodiacetic~2
methylbrom~1
5.03~2
14.9,~1
scintiscan.~1
4.26~1
1.85~1
3.69.~1
mumps~2
haemophilus~1
Lecithin:sphingomyelin~1
Phosphatidylglycerol~1
lecithin:sphingomyelin~1
Carney's~2
Triad~3
extra-adrenal~2
functional),~1
chondroma.~1
Triad.~1
paraganglioma.~1
(GAN)~1
paragangliomata~1
upon,~1
Subtotal~1
prolamine~2
pancreaticojejunostomy~1
entities.~1
20-month~1
collagen)~1
0.008).~2
unilobar~2
2-70~1
In-hospital~1
40.5%~1
24.9%,~1
Duke's~1
"secondary"~1
resection:~1
Encouraging~1
agressive~1
go.~1
surgery),~2
4-45~1
extra-abdominal)~1
(classification~1
Milan)~1
Retroperitoneal~1
subspecialists.~1
insidious,~1
extraperitoneal~3
published,~1
double-ligation~1
situ)~1
(dissected)~1
dissected,~1
slower,~1
completion.~1
Full-wall~1
(56.8%)~1
uncontrollable~1
perihepatic~1
(50.0%)~1
Angeles.~1
siblings).~1
cautioned~1
Junior~1
positively.~1
realistic,~1
clerkship,~2
Ulcerative~1
(Barrett's~1
ulcer)~1
columnar-lined~3
(gastroplasty~1
fundoplication).~1
Valvar~1
underperfusion~1
Open-chested,~1
preocclusion~1
1961,~1
Peking~1
recur.~1
(CK),~1
MB,~1
CK.~2
Isoenzyme~1
isoenzymes.~1
February,~1
(3.3%;~1
[CL]~1
10.9%).~1
(17.2%;~1
27%),~1
(24.1%;~1
35%).~1
Hemiparesis~1
(3.5%;~1
chacma~1
agonal~1
(blast~1
injury);~1
postpneumonectomy~1
bronchopleural~1
gluing~1
shield~1
ice.~1
Diaphragm~4
reintubations,~1
simplified,~1
Supraventricular~1
dysrhythmia~5
cools~1
146.3~1
Meanwhile,~1
aconitine,~1
bilobectomy;~1
atrioplasty,~1
hypoventilation.~1
Weaning~1
accomplishes~1
expeditious,~1
coagulum~1
occurrences,~1
39.2%~1
22.5%~2
39.6%~1
(nursing~1
homes)~1
Isosorbide~1
sublingually~2
8/131~1
9/106~1
8/130~1
11/122~1
placebo-pretreated~1
7/105~1
"control"~1
(203~1
12/132~1
rest;~2
isosorbide.~1
Sublingual~1
B12)~1
dementia).~2
anemia;~1
borderline.~1
deoxyuridine~1
survey)~1
Sharp~1
Prothrombin~1
-1.60~1
+0.8~1
-5.5~1
unpredictable,~1
32/65)~1
19/65).~1
Ancillary~1
(22%,~1
14/65).~1
prognostically.~1
organophosphate-induced~1
generations,~1
micronodular~3
corticotropin-independent~1
fibrolamellar~1
hepatoma,~1
seventy-four~1
74%,~1
77%.~1
13-month~1
42%).~1
Hypomagnesemia~1
hypomagnesemia,~1
[1.03~1
HLA-A,~1
-B,~1
-C~1
-DR~1
microdoplet~1
cytotoxins.~1
race-matched~2
kinship~1
HLA-DR5~3
envisaged~1
cofactors.~1
high:~1
malnourished,~1
(5/18);~1
(14/26);~1
(4/15);~1
continence,~1
(5/12).~1
small-dose~1
(ITT)~1
Hahn~1
radioiron,~1
"mucosal~1
block"~1
ITT,~1
radioactivity.~2
10-mg~2
30-mg~1
high-biologic-value~1
protein-limited~1
2105~1
1355~1
(2.11~1
g/L).~1
(DHS),~1
DHS~1
mOsm/L~1
53%),~1
nursing-home~2
(28%~1
15%),~1
DHS:~1
DHS.~1
single-drug~1
variable:~1
31.4%~1
21.6%~2
comatose,~1
bezoars~2
3247~1
esophagoduodenoscopies~1
(EGDs).~1
Bezoars~1
(PUD).~1
(Billroth~1
another).~1
mellitus;~2
(9,~1
gastropathy~1
bezoar~1
PUD.~1
lactase-deficient~2
absorbers.~1
Vertebral~1
absorbers~1
(CRF)~1
[CHD]~1
[CAPD]),~1
fractionation,~1
amylase.~2
Wales,~1
ban~1
Zealand,~1
epidemic,~1
depended.~1
concluding~1
diagnostic-exchange~1
titrate~1
accordingly.~1
Rifampin,~1
digitoxin,~1
sulfonylureas,~1
barbiturates.~1
beta-blockers,~1
itching,~1
subsided.~1
decompensation.~1
89-year-old~1
pilocarpine-related~1
radionuclear~1
"neurogenic"~1
abruptness~1
amphotericin,~1
tubuloglomerular~3
cardioembolic~2
tomography-documented~1
pendulous~2
contractions;~1
echolucency~1
then,~1
thiazide~1
3693~2
quartiles~2
[458~1
mumol/L])~3
[291~1
(97~1
thiazide-type~1
quartile.~1
acid-lowering~1
risk).~1
injures~1
gouty.~1
unanswered~1
liquid-filled~1
Vasculitis~2
hairy-cell~1
HCL,~2
HCL~4
remittance~1
880~1
"toxic"~1
39.4~1
(103~2
15,000/mm3~1
10(9)/L);~2
1500/mm3~1
mm/h.~1
(1/21),~1
(15/45),~1
(15/38),~1
(17/31),~1
(PWS)~1
hypomentia,~1
hypogonadism,~1
dysmorphism.~1
prometaphase~1
heterogeneity;~1
15q12~1
PWS~3
PWS.~1
deflazacort~4
diabetogenic~1
[7.7~1
(8.81%~1
1.19%~1
10.71%~1
1.17%~1
hemoglobin)~1
(29.3~1
47.3~1
U/d).~1
deflazacort,~1
Norethindrone~1
calcium-creatinine~1
hydroxyproline-creatinine~1
(bezafibrate)~1
(Salbutamol)~1
mL/min)~1
Albuterol,~1
hyperkalemia.~2
(6.2~1
audible~2
(S4),~1
persons),~1
55.4~1
cardiologists,~1
officers).~1
Audibility~2
phonocardiographic,~1
S4~6
(68.6%)~1
(S1),~1
(72.5%).~1
recordable~3
S1.~1
S4,~2
palpability~1
likelier~2
graphically.~1
confuse~1
hydrochloride-induced~1
Amiodarone-induced~1
times:~1
22;~1
cysticercosis.~1
praziquantel.~1
(111~1
hemoperfusion)~1
recently.~1
fracture;~1
inadvisable,~1
optimal.~2
(MyD).~1
MyD,~1
MyD.~2
(HSP)~1
HSP~2
tetramethylthiuram~2
disulfide.~1
vasculitides~1
disulfide,~1
delayed;~1
(RSV)~1
uninstitutionalized~1
RSV~3
1:256~1
macronodular~1
lymphocutaneous~1
Pierre~1
Janet's~2
Obsessions~2
(1903),~1
unappreciated~1
psychiatry,~1
dated,~1
discoveries.~1
called,~1
obsessions~1
compulsions~1
"forced~1
agitations");~1
psychasthenic~1
century,~1
1-24~1
(cosyntropin)~1
medicated~1
(MDD)~1
MDD~3
cosyntropin~2
nonsuppressors~1
suppressors.~1
MDD.~1
corticotropin~1
arsonists,~1
habitually~1
offenders,~1
arsonists~3
(MHPG)~1
fire-setting~1
hypoglycemia)~1
Myoclonus~1
myoclonus.~4
drug-associated~1
TCAs.~1
TCAs~2
bundle-branch~2
(0.7%).~1
2.5-year~1
addicts,~1
methadone-treated~1
Prognostically,~1
methadone-~2
"drug-free"-treated~1
drug-free-treated~1
abuse;~1
cytomegalovirus-infected~1
integumentary~1
botryomycosis~1
ischiorectal~1
cryptosporidial~1
Grains~1
grains.~1
T4-inducer~1
blot-confirmed~1
immunoblasts~1
(HCM)~1
myofiber~2
disarray~5
HCM~1
myomectomy~6
HCM.~3
Myofiber~1
septectomy~1
HCM;~1
8033~1
0.037%.~1
(coronary)~1
excavation~1
infundibulum~1
paraffin-embedded,~1
streak,~1
64.6%~1
pale-staining~1
insudative~1
(UC)~1
B-D-galactose~1
(1-3)~1
N-acetyl-D-galactosamine,~1
T-blood-group~1
MN-blood-group~1
PNA~5
nascent~1
UC,~2
glycocalyx~1
"regenerating~1
hyperplastic"~1
colons,~1
UC~3
neoplasms;~1
quiescent.~1
Villous~1
well-formed~1
Distinguishing~2
distinction.~1
embryonic,~1
oophorectomies.~1
cyst-ovarian~1
undegraded~1
I-cell~1
(ICD)~1
mucopolysaccharides,~1
ICD.~2
podocytes),~1
vacuolated.~1
fibrillogranular~1
wheat-germ~1
succinylated-wheat-germ~1
alpha-mannosyl,~1
beta-N-acetylglucosaminyl,~1
Immunohistologic~1
milk-fat~1
globule~1
(MFG)~1
separation,~1
conflicting,~1
mesotheliomas~1
anti-MFG,~1
anticarcinoembryonic~1
immunomarker~1
MFG~2
CEA;~1
MFG.~1
Mesotheliomas~1
MFG,~1
Pilomatrixoma~1
usually,~1
anucleated~1
basaloid~1
pilomatrixoma.~1
Calcific~1
lamellations,~1
psammoma~1
cavities,~1
histoplasmosis.~1
drains,~1
collapsed,~1
intramedial~1
Discrepancies~1
(Coulter~1
Counters)~1
centrifugally~1
Template~1
pseudosarcomatous~1
hyperchromatic~1
gelatinous~2
1921~1
Atherosclerosis,~1
bronchopneumonia~1
centenarians~1
small-vessel~1
anti-double-stranded~1
[3.24~1
(28,400/mm3~1
[28.4~1
10(9)/L]).~1
mediators.~1
acid-rich~1
(gelatinous~1
transformation)~1
acanthocytes~1
Paragangliomas~1
perithyroidal~1
adenomyoma~1
adenomyoma,~1
interlacing~1
adenoleiomyomatous~1
adenomyomas~1
neoplastic.~1
diverticulosis~1
Beale~1
1571~1
10cm~1
0.3ms,~1
0.2ms.~1
1ms~1
(BAEPs)~1
neurosurgeon~2
Cz~1
(vertex)~2
earlobes.~1
intraauricular~1
suboccipital~1
preincision,~1
dura,~1
mobilization,~1
BAEPs~2
interference,~1
cautery~2
braiding~1
suppressor;~1
polarity,~1
structures.(ABSTRACT~1
soccer~2
degree;~3
dorsiflexion,~1
(tested~1
newton~2
meters,~1
newtons~1
1721~1
newtons.~1
warmup~1
underlines~2
sprain~1
injury.(ABSTRACT~1
(MMT)~1
MMT~3
fastion,~1
MMT.~1
(FG)~1
FG~4
4;~1
FG.~1
S-shaped~3
4w~1
three-grade~1
six-grade~1
substitutions.~1
nonparetic~1
Zero~1
Calcaneal~1
Compton~1
(SMF),~1
(NCV)~1
(EI),~1
submaximally~1
39),~1
SMF~2
NCV~4
EI~4
1T.~1
(GXT)~1
(MRS).~1
(MET)~1
cardiologist.~1
164);~1
46);~1
cardiologist~1
(VEA),~1
(STTC),~1
(SBP),~1
(RPP),~1
METs~2
10.1%~1
STTC~1
VEA.~1
GXT;~1
SBP,~1
RPP.(ABSTRACT~1
postlaminectomy~1
piriformis~1
P40(P1)~1
pronator~7
teres~5
Struthers~1
teres,~1
through.~1
Struthers.~1
spiked~1
100.5F~1
102.5F.~1
Ventilation/Perfusion~1
afebrile.~1
wireless~1
communication/environmental~1
controller~1
(ICECS)~1
parts:~1
remote-control~1
modules.~1
radio,~1
intercom~1
button~1
soft-touch~1
mouthstick.~1
(prothrombin~1
2.5-~1
3.3-mm~1
angioscopes~1
Radiologically~1
membranelike~1
Angioscopy~1
angioscope~2
(PTAs)~1
Limb-threatening~1
PTA.~1
outcome:~2
.001);~2
.02);~1
(33/36)~1
AFP~1
(17/302)~1
(17/61)~1
EGC.~1
(FS)~1
(99%~1
FS.~1
Diverticulosis~1
3.6%.~2
reconstructions)~1
reconstructions).~1
found;~1
interval;~1
gastroscopic~1
hyperperfusion,~1
photoplethysmography,~1
photoplethysmography~2
waveforms,~1
(NFH),~1
NFH~4
early-recurring~1
Late-recurring~1
later)~1
patching,~2
(95.2%~1
94.2%~1
1.6%),~1
(36.2~1
cm2),~1
(56.2%~1
51.9%~1
9.7%)~1
disaccharidase~1
Neomucosal~1
impossible,~1
material;~1
bioenergy~2
energy-charge~1
ligation/puncture~1
CLP~1
corticomedullary~1
charge,~1
operation's~1
Equal~1
1,2-dimethylhydrazine~1
(DMH)~1
(CMI)~1
(PZS)~1
preneoplasia.~1
CMI~2
PZS~2
preneoplastic~1
crypt.~1
validates~1
(SFH)~1
inconclusive.~1
persistence.~2
SFH~4
toxic,~1
(ATP)-SFH~1
m-Dansyl~1
cadaverine,~1
halflife~1
ATP-SFH~2
(210~2
MDC~2
SFH.~1
Regressions~1
insonation~1
insonation,~1
insonation.~1
(intimectomy~1
excision).~1
vein-patch~4
angioplasty;~1
(9/13~1
[69%])~1
(12/13~1
[92%]).~1
reendothelialization~1
patching.~1
Durability~1
higher-risk~1
(1974~2
oversewing~1
died--five~1
85%;~1
(pulse).~1
75.7~1
stride,~1
sway,~1
hydrocephalic~1
cadence~1
counterrotation~1
cocontraction~1
conclusive,~1
(L-dopa)-carbidopa~1
fluctuations.~2
low-protein~1
L-dopa-carbidopa.~1
trimodal~1
(GBS).~1
GBS~1
predictor,~1
plasmapheresis,~3
GBS.~1
gliotic~1
cerebellum;~1
language-related~1
"clot"~1
3225~1
nonpsychotic~1
diastematomyelia~2
autism~3
(Kanner's~1
lentiform~1
(current~1
112),~1
declive,~1
folium,~1
tuber~1
vermis,~3
Clarke's~1
XII,~1
tegmentum,~2
nigra,~1
pontis,~1
olives,~1
"Azorean~1
disease,"~1
dysesthesia~1
taste,~1
undiscovered~1
dysgeusia,~1
dyslexia~2
paralexias,~1
boy)~1
dyslexic~2
penicillamine,~2
(97%),~1
(65%),~1
dysdiadochokinesia~1
Chorea~1
caudate,~1
pallidus,~1
Dystonia~1
manic-depressive~2
Brain-stem~1
(BAER)~1
BAER~2
Delusions,~1
(MID).~1
MID:~1
MID,~1
Delusions~1
misbeliefs~1
theft~1
infidelity.~1
MID~4
DAT.~1
deducted~1
Hallucinations~1
common:~1
task:~1
(TOL),~1
primates;~1
(TRL),~1
perseveration.~1
TOL~2
TRL,~1
perseverative~1
TRL~1
butyrylcholinesterase~1
11S~1
(TIAs).~1
backgrounds.~2
(3-methoxy-4-hydroxyphenylethyleneglycol~1
[MHPG],~1
[HVA],~1
(SAH).~1
HVA,~1
MHPG,~1
SAH,~1
poststroke.~1
high-signal-intensity~1
flubendazole.~1
boxing~6
professional)~1
post-concussion~1
devastation~1
boxing.~2
Amateur~1
ring-side~1
iridectomy.~1
iridectomy~5
iridotomy~1
vigilant~1
watching~1
proptosis,~1
chemosis,~1
"Posterior"~1
sphenoethmoidal~1
overshadows~1
intracanalicular~2
panparanasal~1
ductional~1
amphiphilic~1
papillopathy.~1
radon~1
Ohio~2
(69.6%)~1
(86.7%)~1
telangiectasias,~1
microaneurysms,~1
fundi.~1
nummular~1
keratoconus,~1
nyctalopia,~1
(+9.50~1
+16.00)~1
nanophthalmos~1
(axial~1
angles;~1
synechial~1
electroretinographic~1
extinguished~1
electroretinograms.~1
autosomal-recessive~1
Antiretina~1
(cancer-associated~1
[CAR]~1
23,000~1
CAR~2
pigmentosa,~1
CARs.~1
Schirmer~1
(ascorbic~1
acid).~1
"basal"~1
1310~1
mumol/L);~1
(110~1
Ascorbic~2
(GCF)~1
Hyderabad,~1
India.~1
children:~1
appearing,~1
keratitis),~1
[less~1
mumol/L]).~1
GCF~4
measles,~2
1.1%,~1
1.7%,~1
hyperproliferation~1
Strabismus,~1
dystopia,~1
nasolacrimal~1
plagiocephaly.~1
Ptosis,~1
Bascom~1
Palmer~1
Miami,~1
intervene~1
orbitography,~1
echography.~1
worsen.~2
infrequent,~1
Optic~1
compressible~1
retro-orbital~1
low-density,~1
hemangioma,~1
encephalocele.~1
Medial~1
orbitotomy~1
choristomatous~1
craniotomies,~1
fluoropyrimidines~3
fluorocytosine,~1
Fluorouridine,~1
deoxymetabolite.~1
deoxymetabolites~1
Fluorouridine~1
multivesicular~2
nonliposome~1
liposome-treated~2
blepharitis~2
Crusting~1
lashes,~1
lashes~1
leukocytic~1
meibomian~1
Gram's~1
cocci.~1
ribitol~1
teichoic~1
contains,~1
blepharitis.~1
Dutch-belted~1
phased-array~1
semiconductor~1
817~1
portable.~1
mW,~1
diode~1
Bradykinin~1
carboxypeptidase~1
desArg9-bradykinin~1
(DBK)~1
pentapeptide~1
Arg-Pro-Pro-Gly-Phe~1
Ser-Pro-Phe.~1
kinin~2
Carboxypeptidase~1
salicylate,~1
ACE;~1
carboxypeptidase.~1
DBK~2
hepatosplenomegaly.~1
antihistone~2
anti-total~1
Anti-H2A/H2B~1
anti-H4~1
Still's~1
monocyclic~2
remittive~1
ABC-digested~1
redness.~1
7-9~3
Synovitis~1
exacerbations,~1
imaging).~1
naproxen.~2
endotracheal,~1
administration;~1
administrations,~1
rape.~1
ISS,~2
23.5%),~1
traumas~3
altercations.~1
trousers~1
(MAST).~1
Henry~1
maneuver.~2
(SSH)~1
diathesis~2
SSH~1
nonmajor~1
SSH.~1
hypercoagulability.~1
Blindness~1
cricothyreotomy~1
Phenylpropanolamine~1
(PPA),~1
anorectics,~1
congestants,~1
PPA.~1
(6.49).~1
(1.36,~1
2.27,~1
(0.85,~1
1.40,~1
(KBD)~1
Radioisotopically~1
RISA~2
KBD~2
isovolemia.~1
ultrafiltered~1
human-sized~2
pumps,~1
cannulations,~1
precautions,~1
Commentary~1
infusate~1
single-cuff~1
Tenckhoff~3
double-cuff~2
Oreopoulos-Zellerman~2
(Toronto-Western)~1
Single-cuff~1
dermatomes.~1
extensively,~1
intrapleurally.~1
bacteraemia~1
45.3%~1
naso-tracheal~1
9.4%~1
(v.~1
mouth),~1
(CPB),~1
sternostomy~1
oligaemic,~1
overperfused,~1
deadspace~1
(VD/VT)~1
(PE'~1
CO2)~1
CPB,~1
VD/VT~2
CPB.~1
vecuronium.~4
(MPF)~1
ECAP~2
ED95~2
(0.23~1
(0.055~1
MPF~1
MPF.~1
Alcuronium~1
normocarbia.~1
disconnected~1
apnoeic~1
23.6~1
laudanosine,~1
nerve-hemidiaphragm~1
(0.6-2.9%~1
end-tidal)~1
(AER)~1
AER:~1
Nb,~1
MAC-based~1
AER~1
Stereo-photograms~1
-846~1
+505~1
("abdominal")~1
-0.87)~1
("ribcage")~1
weight/expected~1
thiopentone,~3
re-instituted~1
Intubation,~1
laryngoscopy-only~1
gynaecological~1
Forrester~2
Spray;~1
"Laryng-o-jet";~1
Spray.~1
tea~1
toast~1
"gently"~1
"on~1
demand",~1
(0.5%,~1
0.375%~2
0.25%).~1
0.125%~1
(Marcain)~1
labour,~1
"top-ups"~1
top-ups~1
top-up.~1
T6.~1
2-chloroprocaine~1
pinprick~1
5-min~1
semi-upright~1
diamorphine~5
phenoperidine~2
(5.96~1
(8.39~1
(3.40~1
extradurally~1
seizure-like~2
vapour~1
(2-6~1
vol%;~1
0.5-1.5~1
litre-1).~1
Burst~1
radiatum~1
(approx.~1
litre-1),~1
neurones;~1
Input/output~1
post-synaptic~1
(EPSP)~1
enflurane-induced~1
amino-ester~1
amides~1
amide.~1
elapid~2
snake~2
bite.~1
antivenine,~1
antivenine~1
'PUVA~1
lentigines'~1
ophthalmological~1
opacity.~1
omega-oxidation~2
20-hydroxy-~1
20-carboxy-LTB4~1
[14C]arachidonic~1
[14C]LTB4~1
[14C]omega-oxidation~1
(KOH)~1
Teepol~3
(EFA)~1
EFA~1
adrenic~1
UVC,~1
'latent~1
period'~1
(Zyderm~1
ice-pick~1
acceptability-but~1
retinoid~1
Age-~1
hyperostoses~2
anteroinferior~1
calcanei~1
accretion~1
acetabula.~1
isotretinoin~1
Hirudoid~1
ingredients~1
1,3,5-trihydroxyethylhexahydrotriazine~1
thymol~2
triazine~1
3-(hydroxyethyl)-5-methyl-8-(2-methylethyl)-3,4-dihydro-2H-1,3-benzoxazi~1
ne.~1
reticulohistiocytosis~1
tricho-dental~1
anagen~1
arthralgia.~1
(Tigason)~1
prurigo-like~1
S-beta-thalassaemia~1
2-10~1
oestrogen-norethisterone~1
bleedings~1
oestrogen-progestogen~1
valerate~1
anti-androgenic~1
(CPA)~1
oestrogen-CPA~2
Bonney~3
discarded.~1
tumour-associated~1
(HMFG~1
123I-labelled~1
radioimmunoscintigraphy~1
staged.~1
min-22~1
HMFG~1
surgically-removed~1
acuminata;~1
Cryosurgical~1
out-patient~1
condylomata.~2
condylomata;~1
transantral,~1
Koornneef's~1
avoidance.~1
Pearce~1
tripod~1
6/5~1
6/12~1
neurosensory~2
interferometry.~1
ophthalmology,~2
activities:~1
preventive,~1
promotive.~1
pioneering~1
Professor~1
Barrie~1
recognised.~2
sclerokeratitis.~1
Infiltrative~1
sclerokeratitis~1
shutdown.~1
dacryocystorhinostomy~2
Lacrimal~1
Moorfields~1
Lens~1
retrodots~2
oblong,~1
perinuclear~4
Retrodots~1
birefringence~1
resisting~1
retinal/macular~1
N95~1
cyclocryotherapy~1
extrasclerally~1
intracranially~1
haemodilution~1
(pressure~1
tolerate.~1
Arden~2
ethambutol.~1
humour~4
o'clock~1
Rotterdam~1
Nagoya~1
microcornea~1
ROP~1
microphthalmos~1
entropion~1
kink.~1
Keratometry~1
pachometry~1
keratoconjunctivitis.~1
low-powered~1
vaulted~1
D);~2
-1.0~4
Sjogren-Larsson~2
tetraplegia,~1
ichthyosis,~1
glistening~2
dots~2
melanolipofuscin~1
ophthalmoscopically~1
'windows'~1
midperiphery,~1
Unilateral,~1
non-pigmented~1
non-pigmented,~1
Goblet~2
ectoderm~1
congenital.~1
Hemopoietic~1
self-renewal~1
repopulating~3
CFU-S;~1
repopulate~1
mutational~2
(haplotypes)~1
Senegalese~2
Beninian~2
Bantu,~1
haplotype.~1
Senegal~1
haplotype-bearing~2
Beninians~1
Bantu~2
subhaplotypes~1
(CNBr),~1
fibrin-derived~1
NDSK,~1
Thrombin-releasable~1
fibrinopeptides~1
1-42~1
NDSK.~1
fibrinogen-derived~3
aortas,~1
atheromas.~1
Thrombocytopenic~1
Cytochalasin~2
plasma-induced~1
antitubulin~1
rings.~1
3-isobutyl-1-methyl-xanthine~1
(MIX).~1
cAMP,~1
MIX~1
(50-~1
100-fold)~1
(HPFH).~1
overexpressed~2
HPFH~2
Sardinian~2
zero-thalassemia).~1
1,560~2
noncoding~1
deleted.~1
HPFH,~1
beta-thalassemic~1
39CAG----TAG)~1
zero-thalassemia.~1
sialoglycoproteins~1
(SGPs)~1
SGPs~1
SGPs,~1
SGPs.~1
SGP~3
(MCH)~1
(HbF)-containing~1
MCH~4
imidodiester,~1
dimethyl-3,3'-dithiobispropionimidate~1
(DTBP).~1
(MoAb)~1
fluorescein-conjugated~1
epifluorescence.~1
Coulter-derived~1
0.96)~1
antibody-treated~1
fixed-permeabilized~1
nondistinguishable~1
(22%~1
heterocellular~1
(HPFH)~1
aciduria.~1
Cyanocobalamin~1
homocystine~1
Cobalamin~1
methylcobalamin~1
adenosylcobalamin~1
(thiol)~1
Lebanon~1
Cooley's~1
IVS1~2
G----C~1
Indians)~1
IX.~1
Chlorotetracycline~1
(CTC)~1
(PMN),~1
CTC~7
video-enhanced~1
emanates~1
CTC.~1
cytoplasts.~2
anti-Mo1~4
(binds~1
[gp~1
155.94]~1
adherence)~1
(PMA).~1
Anti-Mo1~1
(anti-Mo5)~1
crosslinked~1
acid-alcohol~1
elastin,~2
tropoelastin~1
desmosine/isodesmosine~1
crosslinks.~1
U937.~1
HL60~1
(PK)~1
(oxidized~1
reduced)~1
(NAD)~1
NAD,~1
NAD~8
PK-deficient~3
PK~3
5'-triphosphate~1
Fluoride~1
peroxides.~1
Fc(IgG)~1
heat-aggregated~1
F-Met-Leu-Phe.~1
peroxides,~1
intra-observer~1
'worst'~1
inter-relationship~1
'stiffness'~1
complain.~1
sulphydryl~1
(AS),~1
osteoarthritis,~1
spondarthritides~1
CRP.~1
out-patients~2
(FMF)~1
hyperglobulinaemia,~1
leukaemoid~1
FMF.~1
carbonated~1
apatite,~1
labile.~1
postero-medial~2
paravascular~1
(micron).~1
blood-vessels,~1
Nigerians~1
sickle-cell~1
66-month~1
predominated,~2
84%.~1
Salmonella.~1
hip-joint~1
renography~2
non-obstructive~1
(22)~1
renogram~2
obstructed,~1
pelviureteric~1
lacerations;~1
(hypertension~2
29%).~1
49.6~1
microcolonies~1
biofilms~2
apatite~1
aggregate.~1
nidi~1
mucroproteins,~1
mineralised,~1
infection-induced~1
calculogenesis,~1
biofilm~1
glycocalix~2
aetiologically~1
calculogenesis~1
enkephalins~2
presynaptically.~1
Methionine-enkephalin~1
leucine-enkephalin.~1
Phentolamine-resistant~1
bladders.~1
(FDPs)~1
(pT2-4)~1
Microalbuminuria~1
creatinine)~1
pT2-4~1
FDPs~3
invasive.~1
rhinosporidiosis~1
extravaginal~1
orchiectomy.~1
chordee~2
in-patients.~1
22/100,000~1
28/100,000.~1
Wales.~1
56/100,000~1
Canterbury~1
15/100,000~1
Burton-on-Trent.~1
hardness~1
7000~1
Scotland.~1
ninety-eight~1
X-rayed~1
3.5%~2
Socio-economic~1
backache.~1
(1.03:1)~1
contour,~1
complementing~1
pyelocaliectasis.~2
pyelocaliectasis~1
calculi,~1
km)~2
marathon.~3
normomorphic~1
Haematuria~1
non-glomerular~1
calculus.~1
ureterorenoscope~1
ureterolithotomy~1
1985-86),~1
ureteroscopic~3
Electrohydraulic~1
perforation;~1
Perforations~1
extravasation.~1
Extra-ureteric~1
customary~2
sulphoxide~1
(DMSO).~1
Mitomycin~1
(57.1%)~1
ileocaecal~4
contracting.~1
Flutamide~1
(SCH~1
13521).~1
symptom-free.~1
Flutamide.~1
Encrusted~1
diffraction,~1
infra-red~1
(EXAFS)~1
hexahydrate,~1
NH4MgPO4~1
6H2O,~1
struvite.~1
Infra-red~1
crystalline.~1
intracavernosal~1
erections~2
erections,~1
(PIPE)~1
PIPE~1
hydroceles~1
(46.7%)~1
Bristol~1
1970-1985,~1
1970-1979.~1
10-13~1
microdensitometer~2
immunomodulating~1
'curative'~1
(right-~1
tumours).~1
7.01,~1
d.f.~2
4.23,~1
colo-anal~1
defaecation~1
Longmire~1
nesidioblastosis.~1
work;~1
Duodenum-preserving~1
morbidity;~1
(EIS)~1
ethanolamine~1
(EO),~1
(B~1
15-42).~1
EIS,~1
38.1~1
pre-EIS~1
EIS.~1
EIS~1
fibrinolysis.~1
EO~2
Ca2+-chelating~1
ethanolamine,~1
decapsulized~1
125I-labelled~1
fibrin(ogen).~1
EO,~1
oleate,~1
U-tube~4
hepaticojejunal~1
areolar~1
sub-nipple~1
Modern~2
'unprecedented'~1
(Civetta,~1
1981),~1
(Frank~1
Wachtel,~1
fight~1
haematopoiesis~2
Smoke~1
smoker.~1
(n=6),~1
venovenous~3
0.0015~1
Splinting~1
tries~1
humour.~1
splints,~1
static,~1
Mediplast,~1
Hexcelite.~1
Betadine~7
Aserbine~1
Aserbine.~1
ointment/Aserbine~2
pre-discharge~1
'delayed'~1
neuroticism,~1
Pre-burn~1
sabbaticals~1
underfunding,~1
Montreal,~1
1982-83~1
neighbourhood~1
work:~1
absenteeism~1
Californium-252~1
(252Cf)~1
(2-year~1
61%;~1
34%).~1
IC)~1
(HN),~1
(NPC),~1
(LC),~1
(PEG),~1
redissolved~2
7.2.~1
(intra-assay~1
4.0%).~1
(HN~1
11.38~1
12.54~1
13.36~1
17.56~1
17.39~1
13.04~1
26.50~1
4.60~1
(5.12~1
4.09~1
(5.92~1
(SCC~1
H/N)~1
efficiency.~3
H/N~1
24%.~1
desmosomes~1
preponderant~1
17:4.~1
Melena~1
depressed-type~1
23-year~1
grade,"~1
subclassifying~1
glandularity~1
Charts~1
41-month~1
splenectomies~1
27.5%;~1
46,000/microliter.~1
postsplenectomy.~2
261,000/microliter~1
177,000/microliter~1
(DCIS)~1
Intraductal~1
(730~1
kin,~1
Saskatchewan~1
63.5~1
67.6~1
(42.0%)~1
(25.6%)~1
(41.0~1
47.4~1
exsmokers.~1
exsmokers~1
pack-year~1
DT~1
Backward~1
M-component~1
plasmocytes~1
M-component,~1
L-glutamine,~1
(technetium)~1
(MAA)~1
area-normalized~1
(Qmax)~1
tumor/liver~2
Qmax~4
MAA~1
vein;~1
nutritive;~1
colloids~1
1597~1
(L-PAM)~1
(NSABP~1
ERPR~3
(well~1
elastica~1
69%.~1
ER-PR+~1
ER+PR-.~1
concordant.~1
ER+PR+~1
ER-PR-~1
propriety~1
fm/mg~1
PR.~1
arterially~1
oily~2
anticancer~4
targeting~1
copolymer~1
(styrene~1
neocarzinostatin~1
(SMANCS)~1
lymphographic~1
Lipiodol~1
(SMANCS/Lipiodol).~1
SMANCS/Lipiodol~3
pleuritic~1
character.~1
Evaluations~1
unrevealing~1
levamisole~3
two-arm~1
8/101~1
precursors:~1
pro-opiomelanocortin~1
(POMC),~1
pro-dynorphin,~1
pro-enkephalin.~1
beta-Endorphin,~1
POMC-derived~1
pmoles/g~3
pro-dynorphin-derived~1
pro-enkephalin-associated~1
(0.6-2.1~1
opioid-positive~1
opioids.~2
cold-punch~1
0.029~1
0.038,~1
0.003);~1
Phenazone~1
phenazone~4
(t0.5)~1
(8.880~1
2.5585~1
(12.024~1
3.8486~1
(K,~1
0.063~2
0.0197~2
(MCR,~1
54.968~1
20.3476~1
41.832~1
14.7153~1
Slides~1
microcysts,~1
pseudopalisading,~1
glioma,~1
homogeneously~2
infiltration"~2
"diffuse~1
infection-associated~1
[HL],~1
[NHL]).~1
HL~2
NHL.~1
granulocytopenia~1
0.035),~1
0.034).~1
Advance~1
(34%);~1
histocytologic~1
(19/41,~1
46%)~1
(4/27,~1
irradiation:~1
(cigarette~1
smoking),~1
implicated.~1
upstate~1
(PSIL)~1
Beirut~1
(AUBMC)~1
immunoproliferative~1
(IPSID)~1
IPSID;~1
non-IPSID;~1
IPSID~5
non-IPSID.~1
(AHCP)~1
IPSID,~2
(MCI)~1
non-IPSID,~1
plasmacytic~1
(DLP).~1
(FL).~1
DLP;~1
FL;~1
AHCP~1
PSIL~1
AHCP,~1
DLP~1
FL~1
nonsecretory~1
Registry-based~1
1979-1983~1
farmers,~1
forestry~1
armed~1
1.38~2
0.98-1.93)~1
0.80-5.79),~1
6.50,~1
1.29-32.6);~1
2.85,95%~1
1.00-8.13);~1
2.02,~1
0.93-4.42).~1
occupation)~1
1948-1979.~1
blood/gas~3
anaesthesia:~1
awake;~1
haematocrit~1
postanaesthetic~2
anaesthetic-related~1
1.95)~1
2.53),~1
3.36)~1
5.53)~1
2.14)~1
"occlusion~1
pressure"~1
(MnSSERs)~1
fentanyl.~1
MnSSERs~2
postinduction.~1
(53.2~1
63.6~1
MnSSER~3
21.18~1
22.18~1
2.04~1
0-65~1
lest~1
halothane-anaesthetized~1
L2-T11.~1
(period~3
P1);~1
(periods~1
P2,~1
P3,~1
P4)~1
P5).~1
(LV),~1
oblongata~1
Nepal~2
Nepali~3
anaesthetists,~2
Diploma~1
Anaesthesiology~1
Nepal.~2
Kathmandu,~1
supervise~1
Canadians~1
[EsEs]~1
Caesarian~1
aorto-caval~4
hypoxaemic,~1
haemodynamically~3
anaesthetist's~1
methaemoglobin,~1
sulfhaemoglobin,~1
methaemoglobinaemia~1
dapsone~1
Dapsone,~1
sulfone,~1
herpetiformis.~1
methaemoglobin~1
four-month-old~1
haemangioma~1
10.6)~1
9.25.~1
Pancuronium~1
9.90.~1
pH-dependent~2
bumetanide,~1
furosemide,~1
vasoactivity,~1
at:~1
bumetanide~4
(Bumetanide~1
Group)~1
(Control~1
Group),~1
post-oleic~1
Bumetanide~2
13.6,~2
54.7~1
38.6~1
Controls:~1
45.1~1
8.8,~2
48.3~1
7.8,~1
Controls.~2
Oedema~1
(wet~1
0.3)~1
bumetanide-induced~1
vasoactivity.~1
daycare~1
bromosulphthalein~1
(RGV)~1
(20.6~2
(29.9~1
RGV~3
14.1,~1
(6.71~1
6.31~1
1.81)~1
1.41;~1
0.33)~1
non-fluid~1
sip~1
cremophor~5
EL~4
anaesthetized,~1
hr-1.~1
thoracopulmonary~1
(SAP),~1
(PAP,~1
RAP),~1
EL,~2
SAP,~1
Cremophor~1
(-68,~1
-71,~1
-70~1
RAP~1
(-78~1
-32~1
infusion).~1
(+734,~1
+548~1
+439~1
-30.5~1
respectively).(ABSTRACT~1
Equianalgesic~1
butorphanol~4
(ASA~1
(butorphanol~1
fentanyl)~1
succinylcholine,~1
Induction,~1
post-intubation~1
drowsy~1
(SNP)~1
SNP~3
(10-16~1
Haemodynamic~1
Polygeline~1
haematocrits.~1
ISO.~1
Qs/Qt,~1
Qs/Qt.~1
breath-by-breath~1
(Crs)~1
Crs~3
manoeuvres.~1
Retraction~1
Crs,~1
70.0~1
cmH2O-1~1
0.0069).~1
pentobarbitone~2
Antinociception~1
"Analgesymeter."~1
Pentobarbitone~1
subanaesthetic~2
changes).~1
regaining~1
concentration-vs-time~1
(3-10~1
(1-9~1
(18-41~1
pancuronium;~1
adults)~1
60-240~1
haemoptysis.~1
37F~1
Shortening~1
bradyarrhythmias.~1
climb~1
unabated~1
immunoassay,~1
digoxin.~1
Paraplegia~1
Laminectomies~1
(Oxycel)~1
pledget~1
(TURP),~1
outset~1
tensely~1
Uraemic~4
anaemia,~2
cardiovascular,~1
haemodialysis.~1
Anaesthetic~1
IVAC~1
$2200.~1
catheter-based~1
67%)~1
semiquantitatively~1
3+,~1
(3+).~1
(25/26)~1
Pathogenic~1
viral-induced~1
hamartoma.~1
multisensor~1
manometers,~1
Reflection~1
disadvantageous.~1
Nitroprusside~1
(CFR)~1
(mCSA),~1
(%AS),~1
Brown/Dodge~1
3F~1
CFR~8
translesional~2
(peak/resting~1
8.2).~1
%AS~1
.85),~1
mCSA~2
.79),~1
.83).~1
discrepancies.~1
posterior-inferior~2
prenodal~3
suprahisian~1
362~1
47)~1
38;~1
(41%;~1
117)~1
postmortem.~1
Balloons~1
distend~1
DeBakey~1
oppositely~1
angiography/surgery,~1
aorta),~1
outflow)~1
view;~1
intersecting~2
euclidean~1
long-axis~3
leaflet-annular~2
distortion.~1
nonplanar,~1
saddle-shaped~1
reproduced:~1
nonplanar.~1
nonplanar~1
posteriorly.~1
anteroposteriorly.~1
10.8).~1
nonvital.~1
frail~1
Incompetence~1
(low-risk~1
(PMV).~1
87).~1
transseptal~1
PMV~3
ventriculographic~1
PMV.~1
pacemaker.~2
pliable~1
debrisoquine~3
pharmacodynamics~2
[EMs]~1
[PMs]~1
debrisoquine).~1
EMs~5
(Cp)~1
ng/ml/mg~1
(1115~1
1238~1
5-hydroxypropafenone,~1
PMs.~2
debrisoquine's~1
4-hydroxylation,~1
preexcitation,~1
duplicator~1
controllable~1
jets'~1
(immediately~1
plane)~1
velocimetry);~1
jets~1
pandiastolic~1
low-output~2
ml/min/kg,~3
ml/min/kg)~1
.03~1
(prepacing~1
Latex-induced~1
interrupts~1
phenol-painted~1
supersensitive~3
(denervation~1
supersensitivity).~1
arrhythmogenic.~1
ansae~3
subclaviae~3
mA),~1
microgram/kg/min).~1
nontransmural~1
painting~2
decentralization~2
ligation-induced~1
maximum)~1
fibrillation.(ABSTRACT~1
ATDs~1
transpericardial~1
antibradycardia~1
pacemakers,~1
programmed.~1
operating-room~1
AICDs,~1
scheduling.~1
rhinomanometry.~1
aromatics,~1
camphor,~1
menthol,~1
pine~1
aromatics~1
Palpation~1
retching~1
1.0-1.5~1
Ceramic~2
stems,~1
modelled~1
ossicle,~1
cap-shaped~1
1982-1985.~1
well-aerated~1
extruded.~1
missing.~1
'field~1
cancerization'~1
12.9%~1
(30/232).~1
Carcinomas~1
(19/232)~1
followed-up,~1
nasopharyngoscope,~1
cauterized~1
S-carboxymethylcysteine~1
radio-labelled~1
solutes.~2
Inlet~1
Hysolated~1
hysolated~1
Sievings~1
(BUN~1
(MC,~1
cellulosic~3
OH-groups~1
(RC,~1
(CA,~1
MC/RC/CA,~1
162/169/150~1
143/143/124~1
104/107/84~1
(QB~1
QD~1
UFR~1
6/10/8~1
3/3/3~1
MC/RC/CA~1
1312/3486/3099~1
67/24/47%~1
81/86/91%,~1
Elastase~1
RC~1
1936~1
extracorporal~2
circuits.~2
heparinoid~2
heparin(oid)s;~1
myeloperoxidase,~1
1-proteinase~1
(E-alpha~1
1PI)~1
polymethylmethacrylate,~1
ethylene-vinyl~1
copolymer,~1
polycarbonate,~1
polyacrylonitrile~6
Polymethylmethacrylate~1
(712.5~1
165.9~1
E-alpha~4
1PI~4
(681.8~1
102.6~1
dialyzers,~1
(1,6590~1
Polyacrylonitrile~1
(267.6~1
lactoferrin.~1
myeloperoxidase~1
anaphylatoxin~1
Cuprophan,~1
biocompatibility.~2
Cuprophan~5
leucopenia~1
disfunction.~1
Nevertheless~2
cellulose-based~1
objective:~1
cellulose.~1
engineer~1
aerospace~1
hemodialysate.~1
REDY~5
Sorbent~4
portability~1
plumbing",~1
Economically,~1
l),~1
acid/base~1
disposable.~1
set-up~1
wearable~2
being,~2
pyrogen-free~1
Cartridge~1
"uremic~1
toxins"~1
SRUF~3
Recycling~1
Ultrafiltrate~1
A-B-A,~1
B-A-B~1
periods)~1
ESRD~3
cramps,~2
being.~1
routine,~1
machinery~1
SRUF,~1
cramping~1
hemodialysis.(ABSTRACT~1
uremics~1
Redy~1
cartridge~1
ultrafiltrate,~1
l)~1
urea/day)~1
extra-corporeal~1
status:~1
uf~1
interdialytic~2
balance.(ABSTRACT~1
dialysates,~1
Organon~1
Teknika~1
AKZO~1
Chemie~1
ninhydrin~1
non-toxic,~1
non-pyrogenic,~1
organ-system,~1
measurable,~1
stratification,~1
(RPGN)~1
RPGN~2
man;~1
surround~1
Extra~1
Corporeal~1
(ECBT)~1
pathogenic)~1
ECBT~1
plasma-exchange,~1
hemofiltration),~1
binders.~1
immobilizing~1
membranes).~1
kallikrein~1
membrane;~1
Cuprophane~1
blood-membrane~1
C5a-induced~1
DGCUF~6
(mmol/l)~1
-67~1
(mmol/l).~1
(delapril~1
diacid)~1
(CRF:~1
(37-64)~1
Ccr~2
(EH:~1
(28-61)~1
79.3~1
CRF,~1
5-OH-delapril~2
4.69,~1
12.88~1
([AUC]24(0))~1
414,~1
658,~1
5068~1
h/ml,~2
EH,~1
[AUC]24(0)~2
1859~1
EH.~2
(Casilan)~1
Casilan~2
GN),~1
GN~2
sodium-dodecylsulphate~1
(200-1890~1
weight/high~1
(MMW/HMW)~1
40-200~1
(characterized~1
(MGN)~1
D-penicillamine;~1
MGN.~2
osmium~1
tetroxide~1
HLA-type~1
B27~1
DR3.~1
MGN~1
hips).~1
nailed/pinned~1
reexamination.~1
Arthrosis~1
slipping~1
29-year-old,~1
malposition,~1
repositioned,~1
Valgus~1
weight-bearing,~1
removal)~1
plaster,~1
fasciotomy;~1
nailguns~1
ensue.~1
nail,~1
Arthroscopy~1
(EX-FI-RE)~1
EX-FI-RE~2
telescopic,~1
single-frame~1
angular,~1
retainers~1
Hoffman-Vidal~1
Adrey~1
quadrilateral~2
0-1000~1
Nm;~1
Nm.~1
player.~1
curiosity~1
Keck~1
(TTS)~1
TTS~3
neurilemmoma~1
relieved,~1
Symes~1
amputations,~2
nourishment~2
(progressive~1
nonprogressive)~1
halo-vest~1
collar,~1
Halo-vest.~1
halo-femoral~1
suggest.~1
1293~1
referred-pain~1
Referred~1
33.5%~1
17.7%.~1
above-outlined~1
Designed~1
osteogenetic~2
(BMP-HAP).~1
(BMP)~1
(HAP)~1
sac.~1
BMP-HAP~5
HAP~5
90-200~1
bead~4
welds~2
implant-bone~1
implant-cement-bone~1
quasistatic~1
implant-porous~1
cobalt-chromium~1
(CoCr)~1
alloy~1
(Ti)~1
bead-substrate~2
interfaces~1
CoCr~1
bone-bead~1
strengths.~1
welds,~1
(CAT).~1
Inheritance~1
valproate~1
PNDC.~1
PNDC~1
CAT.~1
doves~2
dove~1
droppings~1
(MAS)~1
Pneumonia~1
fulminant.~1
Nonparasitic~1
vague~1
dermoids,~1
lymphangiomas,~1
Lactation~2
Mother,~1
Mothers'~1
(MMB)~1
Jose,~1
founding~1
acknowledges~1
MMB~1
banking,~1
Surgeon~1
Pediatrics,~1
high-tech~1
touch~1
curtains~1
nurturing~1
pharmacology.~1
program:~1
guidance;~1
assistance;~1
service;~1
couple,~1
"hands-on"~1
(M.D.~1
R.N.)~1
(NDA)~1
NDAs.~1
NDAs~1
follow-on~1
17.9~2
expeditiously.~1
(Varea)~1
Varea~1
0.089,~1
(hepatic)-extraction~1
high-clearance~2
low-clearance~2
carbohydrate/low~1
carbohydrate/high~1
156%;~1
woman)~2
methoxy~1
methylthioacetaminophen.~1
methylthioacetaminophen~1
methylthiometabolite~1
3'-phosphoadenosine~1
5'-phosphosulfate~1
N-acetylcysteine.~1
Meptazinol~2
meptazinol,~1
Meptazinol,~1
Valid~1
liking,~2
dysphoria~1
miosis,~1
morphine-like~2
dysphoria.~2
Dysphoria~1
meptazinol.~1
Doxazosin~3
1-receptors.~1
doxazosin~4
(steady~2
[Cmax]~1
[C~1
min],~1
O-24-hour~1
[AUC(p-24)],~1
(19.4,~1
18.7,~1
(3.4,~1
(2.2,~1
unbound,~1
(tmax)~1
1-Acid~1
(tmax).~1
Dizziness,~1
biguanide-treated~1
metformin~3
phenformin~4
Metformin~1
718~2
-0.55;~1
HbA1,~1
pyruvate,~2
0.49;~1
0.50;~1
tiapamil~2
digoxin-induced~1
primed-constant~2
Digoxin~1
Tiapamil~1
vasoconstricting~1
polacrilex~1
chewing~2
Extraction~1
chewer~1
twofold)~1
Disproportionately~1
metabolite-to-nicotine~1
Habitual~1
abstaining~1
again.~1
(1-4)-linked~2
maltotriose~2
sugar-saline~1
maltotriose,~2
maltotetraose,~1
maltopentaose~1
maltoheptaose.~1
maltohexaose~1
(haemoglobin~1
g/dl);~1
iron/day),~1
'lactate~2
turnpoint'~2
(placebo-treated)~1
runners;~1
runners.(ABSTRACT~1
Beat~1
Valsalva's~2
bioimpedance~1
straining~1
lows~1
-21~1
+17~1
manoeuvre,~1
(ANG~1
ANG~6
non-filtering~2
servo-controlled~1
75-80~1
Postglomerular~1
unchanged.(ABSTRACT~1
expiration.~4
estimates)~1
5.42~1
litres/min~2
pairs).~1
(Fick)~1
18-62~1
(DBP)~1
130.4~1
non-coffee~1
82.2~1
128.4~1
81.4~1
cups~3
124.9~1
124.1~1
78.7~1
(analysis~1
covariance:~1
SBP~2
3.46,~2
df,~2
DBP~2
Thyroparathyroidectomy~1
(TK),~1
PH.~1
PH,~2
TK~3
PH~1
TK.~1
Ca2+.~1
tri-iodothyronine~1
h-regenerating~1
ulcerogenic~3
(range)~1
ten)~2
unmilled~1
milled~1
one)~1
zero)~1
ulcerogenesis.~1
(AMPD)~1
AMPD~5
(TAN)~1
peptide-activated~1
trappable~1
Quin2.~1
formylmethionyl-leucyl-phenylalanine~1
(fMet-Leu-Phe)~1
stimulant.~1
fMet-Leu-Phe~5
post-absorptive~1
L-[1-13C]leucine~1
13C.~1
[13C]leucine~1
alpha-ketoisocaproate,~1
0.012%/h~1
0.034~1
0.007%/h~1
RNA)~1
microgram-1~2
69.5~1
immobilized,~1
81.1~1
10.6%;~1
8.3%.(ABSTRACT~1
bromine,~2
rubidium,~2
WKY,~4
leukemias~1
genetics,~1
heretofore.~1
(French-American-British)~1
"Working~1
Formulation"~1
(Working~1
Non-Hodgkins~1
Lymphoma~2
Usage)~1
cell-type~1
hematopoietic,~1
lymphoid,~1
pathologist's~1
hematologist's~1
acumen~1
granulocytopenic.~1
bronchopneumonia,~1
under-diagnosed~1
pharyngitis.~1
granulocytopenia.~1
bulge~1
tachydysrhythmias~3
34/53),~1
12/53)~1
7/53).~1
tachydysrhythmias.~1
electrocardioversion~1
(9/29)~1
dysrhythmia.~3
(VI)~1
CO2-stimulated~1
succeeded,~1
intralobar~1
non-resolving~1
sequestrum.~1
bioprosthesis~1
(POR;~1
293)~1
bileaflet~1
(SJ;~1
363).~1
POR~7
SJ~6
(3.0-4.5~1
percent/pt-yr~1
percent/pt-yr);~1
percent/pt-yr,~4
Warfarin-related~1
percent/pt-yr)~1
anticoagulation;~1
warfarin-related.~1
SJ);~1
percent/pt-yr;~2
(26.4~1
108,~1
bioprosthesis.~1
valve.(ABSTRACT~1
205)~1
Shorter~1
information:~1
colleague,~1
Hypergammaglobulinemia,~1
IgG1-4~1
subclasses)~1
(LPS).~1
Hyperimmunoglobulinemia~1
+0.70,~1
Rainbow~1
Babies~1
Childrens~1
Cleveland,~1
cepacia.~1
cepacia~4
Case-control~1
cepacia,~2
colonization.~1
colonization,~1
2,187~1
Airways~1
41.4~1
(DIMS)~1
(NM)(p~1
(EDS)~1
DIMS~2
Nightmares~1
DIMS,~1
nightmares.~1
Sensations~1
Steven's~1
Anxious~1
contrivances~3
Conduit~1
horizontally.~1
nonvalved~1
handmade~1
(Gore-Tex,~1
Inc)~1
spirally~1
built-in~1
(IMPRA,~1
Inc).~1
curving~1
underfeeding~1
overfeeding~4
clearer.~1
(4.86~1
kcal/L~1
REE,~1
(Charcot-Marie-Tooth~2
roots,~1
Transdiaphragmatic~1
catheterization-proven~1
flail~4
Atypical~1
Mobitz~1
deaths;~1
2.28~1
specimen);~1
36-year~1
Two-dimensional,~1
consolidation.~1
Churg~1
Strauss~1
IHSS~1
hypercontractile~1
pericardiocentesis,~1
proctocolectomy,~1
construction,~1
twist~1
obstruct.~1
emergently~1
stoma,~1
nonperforated~1
stoma.~2
(colonic~1
(inflammatory~1
$6,500.~1
left-colon~2
ileotomy~1
ill-prepared~1
bowels~1
(in-hospital~1
small-bowel,~1
large-bowel,~1
ileocolic~2
proctocolectomies~1
ileostomies.~2
relentless~1
Illinois~1
707~1
late-appearing~1
polypectomy.~1
(50.3~1
polyp.~1
Peutz-Jeghers~1
hamartomas,~1
profunda.~1
Duhamel~1
Duhamel-Martin~1
colorectum.~1
routinely.~1
strictureplasty,~1
tapering.~1
strictureplasty~1
Serosal~1
J-pouch.~2
S-pouch,~1
S-pouch.~1
simplified.~1
mobilizing~1
Lahey~1
(cecum~1
nonpolyposis~1
(HNPCC),~1
counterpart,~1
(FPC).~1
HNPCC,~2
Lynch~1
clinical-genetic~1
confidence.~1
(accurate~1
tags~2
mucosae,~1
undermines~1
hemorrhoidectomy~1
(itching~1
moisture)~1
whitish~1
lesion).~1
Colostomies~1
midcolon~1
DMH-treated~3
defunctioned~3
stathmokinetic~1
nonmitotic~1
mitomycin-C~1
quantified:~1
Romanian~1
6275~1
(1973-1982).~1
"crude"~2
6.9%.~1
Age-standardized~1
(1873-1882),~1
1538~1
town.~1
11.3%;~1
civilization."~1
(CDAI)~1
albuminemia~1
CDAI~3
zincemia~1
zincuria~2
CDAI.~1
ultrafiltrable~3
Eosinophil~2
(5.80~1
5.49)~1
(2.81~1
2.19)~1
(3.01~1
1.67).~1
(6.36~1
5.95)~1
5.84)~1
discriminatory~1
6.36~1
5.95~1
3.19~1
mucosal-submucosal~2
acid-extracted~1
Mucosal-submucosal~1
Muscularis~1
met5-enkephalin~1
Truelove's~2
endoluminal~3
SP;~1
ganglionectomy~1
cholinergic,~1
adrenergic;~1
indeterminant.~1
cholecystectomized~1
arginine.~1
choleresis~1
secretion--the~1
achlorhydria.~1
Omeprazole~2
intraduodenally~2
1.725,~1
2.625,~1
acidity.~1
Pancreaticojejunostomy~1
nonopaque~1
concretions~1
concretion~2
serine,~1
valine,~1
diffractometry~1
protein-carbohydrate~1
vitamin-mineral~1
Supplemented~1
ecchymoses~1
substituted,~1
1/2-2~1
therapeutics~1
committee-based~1
formularies.~1
serum-concentration~1
(Squibb~1
Ascot)~1
conventional-release~1
PA.~1
dose-adjusted~1
peak-trough~1
0.972~1
0.59.~1
Ascot~2
tmax~1
Generic~1
applies~1
troughs~1
antibiotics)~1
individualization.~1
Logically,~1
postantibiotic~1
(PAE),~1
Simulations~1
PAE).~1
troughs.~1
H2-blocker~1
extubation~1
Haen's~3
Use,~1
(IDIS),~1
Abstracts~1
(IPA),~1
1980-81.~1
citations,~1
drugs),~1
IDIS~3
Haen's.~1
consultation;~1
Neuroblastoma~1
20-200~1
3,5,3'-triiodo-L-thyronine~1
(IGFs)~1
IGFs~1
0.7-1.1~1
kilobases,~1
kilobases.~2
barely~1
vitellogenin.~1
vitellogenin~3
4-hydroxytamoxifen,~1
4-Hydroxytamoxifen~1
(800~1
cell).~1
4-hydroxytamoxifen~1
estrogen-binding~1
Phodopus~1
campbelli.~1
proestrus,~1
mammal.~1
(8046~1
1063~1
(720~1
2504~1
Ovariectomized~1
benzoate/kg~1
2200~1
0500~1
(new~1
lutea)~1
proestrus.~1
Preovulatory~1
0.6/ovary~1
shed.~1
surgical/anesthetic~2
(AU),~1
nucleoplasmic~1
(NP;~1
KCl-extractable)~2
chromatin-bound~1
(CB;~1
hepatectomy,~1
(N6)~1
Surgical/anesthetic~1
N6~1
(S6).~1
S6~1
(N6-N),~1
(S6-N6),~1
(AU-S6),~1
(RL-S6)~1
-17.3~1
-4.0~1
-4.5~1
(N,~4
micrograms/dl)~1
CB~2
(NP,~1
sixths~1
(NO)~1
(NOO)~1
libitum:~1
DNA):~2
NO-N,~2
-40%~1
NS);~1
NOO-N,~2
-59%~1
-19%~1
-41%~1
CU,~1
LR~1
LR,~1
loss.(ABSTRACT~1
elucidated,~1
estrogen-primed~1
(1-30~1
micrograms;~2
library,~1
estradiol-stimulated~1
pBR322.~1
estrogen-regulated~1
clone,~1
pERU3,~1
pERU3~2
1(I)-procollagen.~2
hybrid-selected~1
beta-Blocking~1
solvent.~1
beta-1-blocking~1
miniosmotic~1
50-60%~1
Metoprolol~1
T3-treated~1
T3-induced~1
beta-receptors,~1
(DHT),~1
-10(-9)~1
chondrocytes.~1
Chondrocytes~1
5-30~1
32-55~1
40-52~1
female-derived~1
male-derived~1
Puromycin~1
antimanic~1
(I5'D),~1
3.3-5~1
15'D~1
NB41A3~1
3-24~1
LiCl.~1
I5'D~2
lithium,~1
[3H]R5020~7
sulfatepolyacrylamide~1
85,600~1
109,600~1
(A/B~1
photolabeling~2
hydroxylapatite~2
72.0~1
relabeling~1
(Rf~1
photolysis~2
94.3~1
photolysis,~1
[3H]R5020-binding~1
R5020.~1
molybdate,~1
(dithiothreitol~1
thioglycerol),~1
(phenylmethylsulfonylfluoride~1
leupeptin),~1
vol/vol),~1
EGTA,~1
ratio's~1
unity.~2
0.1.(ABSTRACT~1
active:~1
beta-endorphin-(1-31),~1
beta-endorphin-(6-31),~1
beta-endorphin-(1-5)-(16-31).~1
Structure-activity~1
[longer~1
beta-endorphin-(27-31)]~1
lipolytically~1
starved,~1
libitum-fed,~1
starved-refed~1
LTW(m)~2
aromatize~1
minces~3
[7-3H]T,~1
[3H]estrone~1
beta-3H]T,~1
[3H]H2O~1
(3.30~1
0.15%~1
testis).~1
aromatizing~1
actitivity~1
pmol/h~1
aromatization~1
(Bu)2cAMP,~1
4-hydroxy-4-androstene-3,17-dione.~1
cyclase-cAMP~1
4-hydroxy-4-androstene-3,17-dione,~1
competitive-suicide~1
enzyme(s).~1
estrogen-progesterone-primed~1
(5HT)~1
quipazine,~1
(5HT2)~1
(5HT1~1
5HT2)~1
beforehand~1
quipazine~2
1210,~2
1220,~2
1230~2
0900~2
5HT2~1
intriguing~2
BeWo~1
activator,~1
(16-fold)~1
(2.8-fold),~1
alpha-phorbol~1
12,13-didecanoate~1
27-fold)~1
36-~1
54-fold)~1
2.0-fold~1
CT-induced~2
C3H3-methylated~1
6-27~1
glucagon-binding~1
[125I]iodopindolol~2
18-19~1
24-27~1
beta-receptor-adenylate~1
(25-27~1
receptor-Ns~1
nonhormonal~1
F-~1
unaltered,~1
nucleotide-sensitive~1
orchidectomized~1
micrograms,~3
sc)~1
90-130~1
neonatally~5
gonadectomized,~1
testosterone-~1
im)~1
PULSAR~1
(50-75%)~1
gonadectomized~3
bromocriptine)~1
mRNA-S14.~1
Regulation~1
(S14)~1
(peak,~1
photoschedule.~1
photoschedule,~1
hypophysectomy,~1
mRNA-S14~2
Photoreversal~1
Oscillation~1
receptor-saturating~1
photoperiod,~1
antagonizing~2
T3-inductive~1
photoschedule~1
gamma-Aminobutyric~1
iontophoretically.~1
organ-cultured~1
hypothalamo-neurohypophyseal~2
(HNS).~1
HNS~3
(10(-8)-10(-3)~1
GABA-activated~1
omitted~1
nipecotic~1
release;~2
neurotransmitter.~1
-94~1
II-mediated~2
Ca2+-free~1
conductances,~1
depolarize~1
Action~1
depolarization;~1
(rT3)~1
rT3.~1
[125I]T4~3
T4/day~4
(BW),~1
T4/day.~1
[125I]T4,~1
rT3,~1
G-25,~1
[131I]T4,~1
[125I]rT3~2
BW,~1
3:1,~1
[0.50~1
pmol/ml~1
0.018~1
T3/ml],~1
P-containing~2
postimplantation~1
(0800~1
1200-1300~1
0900-1200~1
capsule-implanted~2
pregnancy.(ABSTRACT~1
ATP-Sepharose.~1
antiestrogen-binding~1
[3H]4-hydroxytamoxifen~1
[3H]tamoxifen~1
aziridine.~1
[3H]4-hydroxytamoxifen,~2
ATP-Sepharose~2
[3H]estradiol,~1
overshadowed~1
1/4~1
(normally~1
10-h)~1
Oxytocin~1
decapitation,~1
thoracic,~1
Sep-pak~1
diestrus,~1
D-2~2
5-hour~1
(MTC)~1
MTC.~1
MTC~2
(17-OHP),~1
17-OHP~1
Estrone,~1
(CC).~1
(mean)~1
ovulations~1
noncommunicating~1
noncavitary~1
(58.6%),~1
(10.3%),~1
(27.6%),~1
(54.5%)~1
(81.8%)~1
salpingooophorectomy~1
"milked~1
out")~1
three-phase,~1
backup~1
3546~1
35,036~1
2688~1
(7.7%)~1
use-effectiveness~1
woman-years.~1
Cycle~2
predictable,~1
well-classified~1
pieces,~1
Incubations~1
([OT],~1
mIU/ml).~1
antigonadotropic~1
intraluteal~1
(PID)~1
classed~1
adhesion-free~1
cancelled~1
retrievals~1
regime,~1
zona-free~1
(SPA)~1
SPAs~1
postcapacitation~1
SPA.~1
SPA~2
postincubation~1
varicocele,~1
varicoceles,~3
indexes,~1
oligospermia~3
husbands~1
oligospermia,~1
10(6)/ml,~1
oligospermia.~1
varicoceles.~1
epididymovasostomy~1
postpathologic~1
macrosurgery~1
misinterpretations~1
IUD,~1
expense.~1
unrepaired,~2
OHSS~1
hypoalbuminemia,~1
audiotaped.~1
conversation~1
family-related~1
closed-end~1
declarative~1
empathy~2
verbally.~1
relative,~1
gathering~2
didactic,~1
(1976-1981)~1
affiliate~3
faculty,~1
predoctoral~1
affiliate-faculty~1
(1981-1983)~1
psychology~4
proposed:~1
obstetrics-gynecology;~1
family-centered~1
obstetrics;~2
member.~1
updating~1
specialization~1
Specialty~1
selections.~1
modest,~1
intuitively~1
worthy~2
note.~1
vague,~1
"The~1
things~1
way"~1
"being~1
emergencies,"~1
doctor's~1
reasonable."~1
36.5%~1
subcategories~1
self-evident,~1
convey~1
one-week~1
rain~1
forest~1
ICD-9~1
residency-based~2
Oklahoma.~1
contexts~1
live.~1
anthropology--the~1
"anthropology~2
medicine"~1
focus)~1
practice"~1
focus),~1
anthropological~2
micro~1
(practitioner-patient~1
relationship),~1
(family),~1
macro~1
(community)~1
STFM~1
Curriculum~1
Cross-Cultural~1
Unresolved~1
clinician-teacher's~1
Bowen~1
Theory,~1
asserts~1
emotion-based~1
doesn't~1
noncompliant.~1
unwitting~1
complicity~1
partnerships~1
intensifying~1
party~1
focused.~1
struggles~1
defuse~1
profession.~1
espoused~1
reductionistic~1
espouse.~1
cooperatively~1
biomedical~3
Colleagues~1
acuteness~1
priorities.~1
forced-choice~2
non-physician~1
illness:~1
comprehensiveness,~1
intragroup~1
(COPC)~2
pragmatics~1
COPC~4
projects.~1
lessons~1
"Family~1
Advisor~1
Booklet"~1
25-minute~1
talk~2
interviewer~1
booklet.~1
96.8%~1
71.6%~1
appointment~2
no-show~2
behavior:~1
ethnicity,~2
payment,~2
house,~1
associations:~1
capability,~1
(SMAC)~1
SMACs.~1
opportunities.~1
(98%~1
Chicago-area~1
(39%).~1
Developing~1
Viewing~1
insider~1
outsider~1
asserted.~1
Delaware~1
responsibilities)~1
Residency~1
(NRMP)~1
77%),~1
41%),~1
(82%~1
52%)~1
NRMP.~1
exams~1
(conferences~1
sheet)~1
notes.~1
(11.8%~1
15,739~1
Atlantic~1
percentages.~1
FP~1
mediation--the~1
divorce~2
divorcing~1
Goals~1
impulsive~1
self-discipline~1
self-disciplined~1
impulsiveness~1
stayed,~1
sick-role~1
(N-29)~1
(N-30)~1
91.8%~1
85.6%~1
externs~1
preinternship-level~1
third-~1
fourth-year~1
trained,~2
post-clerkship,~1
interviewing.~1
Home~1
trainees'~1
nonphysician~1
well-structured~1
medicine's~2
philosophical~2
naturalistic~2
inquiry,~1
rationalistic~1
inquiry.~1
specialty's~1
courage~1
agency.~1
postdoctoral~1
cosponsoring~1
cisapride.~2
dual-headed~1
gamma-camera~2
(half-emptying~2
50-191~1
half-emptying~1
22-80~1
(BDP)~1
Enteric-coated~1
BDP~6
postcolectomy~1
BDP,~1
monopropionate~1
(BMP),~1
Cellulose~1
BMP~1
(43.0%~1
24.1%)~1
(13.5%~1
8.5%,~1
t-test).~1
phthalate-coated~1
ileocolitis~1
(slope~2
forestomach,~1
acid-synthesizing~1
antrum,~2
somatostatin-producing~1
gastrin-producing~1
(essential)~1
variable)~1
grade),~1
(analgesics,~1
nonsalicylate~1
tea),~1
Prospectively~1
recorded:~1
Adenosquamous~1
Noteworthy~1
tonofibrils~1
porphyria,~1
biopsy-verified~1
(87.5%)~1
nucleation~2
gallbladder-to-hepatic~1
straightforwardly~1
beta-methyl-cholate~4
alpha-methyl-ursocholate,~1
bile;~1
Amidation~1
alpha-methyl-ursocholate~3
Cholate~1
7-dehydroxylated~1
deoxycholate,~1
ketonic~1
7-hydroxyl~1
7-methyl~1
amidation~1
7-dehydroxylation~1
meals,~4
bethanechol,~1
99mTc-HIDA~1
Somatostatin,~1
93.2%~1
57.1%~1
91.3%~1
somatostatinomas.~1
gastrinomas~4
98%,~1
gastrinomas.~1
gastrinoma,~4
extrahepatically~1
83%-95%~1
correct;~1
reliable;~1
caudad.~1
defecation:~1
guanethidine~1
(i.v.),~2
(p.o.),~1
(into~1
ileum),~1
defecation.~4
caudad-migrating~1
barostat~2
inter-digestive~1
phase-locked~1
gastroparetic~1
postcibal~1
(epigastric~1
fullness,~1
nausea).~1
pouch.~1
titration,~1
mmol/h.~1
mmol/h,~1
162%~1
ischemia-reperfusion~1
iron-catalyzed~2
Haber-Weiss~2
(hemorrhage~1
60-80-min~1
(reinfusion~1
blood).~1
(100-fold)~1
tungstate~1
oxidase),~1
agent)~1
scavenger).~1
oxy-radicals~1
2'7'-bis(carboxyethyl)-5(6)-carboxyfluorescein~1
(BCECF)~1
stirred~1
cuvet~1
slip.~1
HCO3-free~1
gassing)~1
(pHo).~1
7.15~1
7.1-7.8.~1
Chloride-free~1
SITS~1
(pHo~1
7.3-7.8).~1
pHo,~2
Ringer's,~1
pHo.~1
Cl/OH~1
exchanger;~1
protons~1
exchangers.~1
Gallstone~1
29%)~1
3.46~1
1.08-11.24).~1
6-keto~1
endoscopically,~1
50-mg~1
50.2%~1
69.4%,~1
40.0%~1
81.4%~1
60.9%~1
64.2%~1
57.5%~1
98.3%~1
sympathectomized~1
38.17%~1
26.3%~1
23.9%~1
sympathectic~1
junction)~2
opossums~1
Abe~1
Tomita.~1
half-amplitude.~1
mV;~3
513~1
36.0~1
mV/ms;~1
half-amplitude,~1
cm/s.~1
dysrhythmia,~1
dysrhythmic~4
10.5,~1
77.0,~1
35.0,~1
407.0~1
meclofenamate.~1
met-enkephalin;~1
non-prostaglandin-mediated~1
Capsule~1
thicknesses.~1
0.95;~1
"vessels"~1
rhodamine-conjugated~1
(18-22~1
(22-26~1
hypogaea,~1
Formalin-fixed~1
coded,~1
blindly,~1
intensely~2
(4+).~1
I-positive~1
38-yr-old~1
Antimycobacterial~1
avium-intracellulare,~1
antimycobacterial~1
T84~2
collagen-coated~5
confluency,~1
"monolayers"~1
multifocally~2
unpolarized~1
abound,~1
macromolecules.~1
impermeant~1
backing~1
polypectomy,~1
(operative~2
0.5%.~1
unchanging~1
grounds.~1
"social~1
drinking"~1
nonalcoholics~2
3.94~1
6.46~1
protooncogene~1
c-erbB-2~1
c-ras-Ha~1
c-myb~2
S10~4
S20,~1
immunoneutralization~1
meal-stimulated~1
fat-induced~2
Eq/30~4
alone:~1
S20~1
preinfusion.~1
unicenter,~1
antisecretory~1
site-protective~1
sucralfate.~1
79%,~1
sucralfate,~2
(63%).~1
24-mo~1
2-mo~1
4-mo~1
cimetidine-~1
sucralfate-healed~1
spell,~1
hastens~1
YY~4
(PYY),~2
cephalic,~1
2-deoxyglucose~1
PYY~9
pmol/kg~3
Peptide~2
2-deoxyglucose.~1
PYY.~1
pentagastrin-~1
bethanechol-stimulated~1
PYY,~1
mechanism)~1
(SMA).~1
micropheres~1
SMA.~1
63%)~1
mucosa/submucosa~2
muscularis/serosa~2
(tissues~1
arteries).~1
30%-65%~1
(preocclusion)~1
(G-17)~1
G-17,~2
C-~1
N-~1
unsulfated~4
G-17.~4
G-17~4
desulfation~1
sulfation~1
triphosphate-dependent~1
prelysosomal~1
clathrin-coated~1
acridine~2
morphometry.~2
dissipated~2
primaquine,~1
monensin.~1
internalization)~1
fluorescein-dextran.~1
dextran-storing~1
phosphatase-~1
arylsulfatase-negative~1
lysosomes.~2
delta-agent)~1
delta-superinfection.~1
panendoscopy~3
limited-consultative,~1
UGI~3
provides,~1
non-critically~1
dyspeptic~1
Mary's~1
Center's~1
esophagogastroduodenoscopies~2
panendoscopies~1
esophagogastroduodenoscopies.~1
$150.00~1
$50.00,~1
$117,000.00~1
gastroenterologists~1
1980s.~1
(ERCP).~1
ERCP.~2
choledochoscopy.~1
Peroral~1
choledochoscopy~1
Wolf~1
(grasping)~1
(cutting)~1
proctoscopic~1
propria.~2
wait~2
peritoneoscopy~1
opisthorchiasis.~1
Peritoneoscopic~1
Opisthorchis~1
viverrini~1
cholangiocarcinoma~1
peritoneoscopic~1
bile-stained~1
duodenoscope~2
PJF~1
cannulated.~1
sludge~1
Gruentzig-type~1
IU;~1
iatrogenesis~1
exacerbating~1
selectivity.~1
minoxidil.~2
ACE-inhibitors~1
ACE-inhibitor.~1
arts~1
Fortunately,~1
sought,~1
hyperbilirubinaemia~2
penultimate~1
protoporphyrinogen~1
(PROTO)~1
PROTO/g~1
protein/h~1
ISD)~1
delta-aminolaevulinic~1
866~1
ALA/g/protein/h~1
variegate~1
PROTO~2
rifampicin~1
flatulent~2
postcholecystectomy.~2
postcholecystectomy,~1
intra-gastric~1
'sump~3
choledochoenterostomies.~1
Reviewing~1
6-60)~1
1-126)~1
suprapapillary~1
interdefecatory~1
looseness~1
constipated~3
bloating,~1
practitioner.~1
Stressful~1
Bedford~1
pmol/l.~1
mins~6
(kaolin)~1
(purified~2
cellulose)~1
CCPR.~1
bran)~1
CCPR,~1
anti-oxidant~2
(salicylazosulphapyridine,~1
SASP)~1
(5-aminosalicylic~1
5-ASA;~1
sulphapyridine,~1
SP)~1
(ROS)~1
zymosan-stimulated~1
xanthine-xanthine~1
Salicylazosulphapyridine,~1
5-ASA,~1
OH,~1
5-ASA~1
relatedly.~1
(5ASA)~1
5ASA~5
unrecordable.~1
atropinisation.~1
Acidic~1
atropinised~1
characterising~1
non-healing~3
0.4679.~1
relapsing,~1
0.6027.~1
singling~1
N-nitroso~2
controversy,~1
nitrosation~2
N-nitrosoproline~2
Polya~1
beetroot~1
proline.~1
(N-Pro)~1
synthesised~1
(collection~1
clearance).~1
N-Pro~3
ng/day)~2
(18.0~1
ng/day),~2
polya~1
ng/day).~1
hypoacidic~2
acidic.~1
-0.53,~1
bacterially~1
nitrosamine~1
couplets,~1
reorganization.~1
reseal~1
Normal-appearing~1
Mg++-ATPase,~1
Mg++-ATPase~1
reorganizes~1
microfilament-dependent~1
synthesis.(ABSTRACT~1
Hepatobiliary~1
cysteinyl~2
[3H]leukotriene~4
[3H]leukotrienes~1
mutants.~1
Enterohepatic~1
N-acetyl-[3H]leukotriene~2
E4,~1
intestinally~1
[3H]Leukotriene~1
C4.(ABSTRACT~1
7-methyl-deoxycholic~5
14C-Labeled~1
mumoles~7
Deoxycholic~1
cholic~1
lithogenic.~2
hamster;~1
bile-Metrizamide~2
(unsaturated~1
bile)~1
(supersaturated~1
bile).~1
w/v),~1
undiluted~1
1.020~1
1.300~1
1.060~4
1.075~2
1.100~1
taurocholate,~1
(biliary~1
3.45~1
gm%).~1
6-nm-thick~1
bilayer.~1
comicellization~1
salt-associated~1
calcium-mediated,~1
Washed~1
45CaCl2~1
25-fold--the~1
300-fold~1
(C57BL6J)~1
Tepperman~1
agouti~6
(CBA/J)~1
biles~1
[24-14C]cholic~1
pools,~1
[1,2-3H]cholesterol~1
strains.(ABSTRACT~1
cerebrotendinous~4
xanthomatosis~3
75:448-456).~1
26-hydroxylase~1
steps:~1
alpha-hydroxycholesterol----7~1
alpha-hydroxy-4-cholesten-3-one----cholesta-4,6-~1
dien-3-one----4-cholesten-3-one----cholestanol.~1
alpha-hydroxy-4-cholesten-3-one~3
cholesta-4,6-dien-3-one~2
dilution-mass~1
xanthomatosis.~1
cholesta-4,6-dien-3-one.~1
Duct~1
Host~1
strain-related~1
C57BL~1
proteinase~1
Lipids~1
chloroform:~1
activity.(ABSTRACT~1
auto-antibodies~1
(63.1%)~1
(6.9%)~1
(37.9%),~1
(45.6%)~1
(52.2%),~1
(38.7%),~1
(13.8%),~1
(9.5%)~1
(42.9%)~1
(53.6%),~1
(15.8%),~1
(14.3%)~2
antismooth~1
troponin,~1
calmodulin.(ABSTRACT~1
Glutaraldehyde-polymerized~2
trimers)~1
nonsaturable~1
polyalbumin~1
saturably.~1
avid~1
transiently.~1
31.4%,~1
nonaggressive~2
63.6%~1
mitigation~1
(5.4%).~1
Anti-HBe~1
custom~1
Williams'~1
L-ornithine)~1
48-hr~1
alpha-aminoisobutyric~3
Na+.(ABSTRACT~1
nondestructively~1
80.9~1
orthophosphate,~1
7.25~1
Concomitantly,~2
7.02~1
mumole~1
(2.15~1
phosphomonoesters~1
sn-glycerol~1
3-phosphate)~1
acids--valine,~1
isoleucine--or~1
acids--alpha-ketoisovaleric~1
alpha-ketoisocaproic~1
alpha-keto-beta-methylvaleric~1
acid--on~1
[35S]~1
dish)~1
35S-protein~2
Immunoaffinity~1
35S-albumin~1
35S-fibrinogen.~1
35S-labeled~2
unlabeled)~1
acids;~1
insulin-dependent.~1
46.3%~1
(25/54)~1
hypertetraploidy.~1
hyperploid~1
8.1).~1
(6.1~1
5.6,~1
Aryl~1
Macrophage~1
1-antitrypsin~2
deficiency-associated~1
(Laennec's)~1
volunteers.(ABSTRACT~1
(SCl)~1
decaffeinated~1
noon~1
p.m.,~1
immunoassay)~1
arising.~1
SCl~4
(1.53~1
18);~1
0.47),~1
(Rs~2
0.80)~1
innocuous~1
a.m.~1
-0.94)~1
SCl,~1
6-Deoxyacyclovir,~1
6-deoxyacyclovir~7
monoexponentially,~1
6-deoxyacyclovir,~1
S.E.,~1
photoproducts,~1
photomixtures~1
GOT~1
GPT~1
photoproducts~1
Photoproducts~1
irradiations~1
oxygen-dependent~1
photoreactions~1
phototoxicity,~1
5-week-old~2
Microvascular~1
WKY.(ABSTRACT~1
d(CH2)5Tyr(Me)arginine~1
osmopump.~1
(F1,~1
10.18,~1
teprotide~1
20881)~1
analogue-treated~1
rat.(ABSTRACT~1
angiotensinogen~1
(Ao-1~1
Ao-2)~1
Ao-1~6
Ao-2~7
C-50~1
Wistar,~1
2.6:1.~1
4.1-fold,~1
1.1:1.~1
2.4:1~1
2.8:1,~1
1.1:1~1
0.78:1~1
8.2-fold~1
nM/hr,~1
amounts,~1
nephrectomy),~1
Ao-1.~1
ng/min)~1
postrema~2
(5-10~2
postrema-ablated~6
sham-lesioned~6
(1-3~1
shaker~1
96-week-old~1
Shaker~1
cerebral,~1
decremental~1
splanchnic,~1
age.(ABSTRACT~1
96.6~1
attractive.~1
(1-100~1
10-mEq~1
200-mEq~2
133Xe.~1
Restricted~1
subpressor~1
Correlates~1
inner-city,~1
Customary~1
girl's~1
Vertex-corrected~3
(uncorrected)~1
BPs.~1
vertex-corrected~2
0.53).~1
Seated~1
0.54).~1
Vertex~1
mEq/day)~1
macrophotography~1
anteriolar,~1
venular,~1
repletion,~1
2.44~1
(2.50~1
sodium-sensitive~1
(32.2~1
Hg/ml/min/100~1
(4.42~1
7.47~1
(3.72~1
5.18~1
mm/mm2;~1
0.39,~1
(MAP;~1
-0.26,~1
-0.31,~1
-0.33,~1
0.42,~1
0.38,~1
-0.34,~1
-0.36,~1
Biofiltration~5
(BF)~9
BF.~8
BF~29
(HD,~1
biofiltration~22
(BF,~1
180-210~1
BUN~3
predialytic~1
depuration~2
Acidosis~1
(Biospal~1
3000S)~1
Cr,~1
postdilution~1
(PreHDF,~1
PostHDF)~1
PostHDF.~1
PostHDF,~1
convection~1
Beneficial~1
alkalosis.~3
mEq.~1
post-dialysis~1
mEq~2
Clearances~1
intradepurative~1
(diffusive~1
convective)~1
depurative~5
(10.5-12~1
h/week)~1
(ABB)~1
checked.~1
ABB.~1
CH,~1
biofiltration-PAN~1
acetate-cuprophan~1
post-dialytic~4
pre-dialytic,~1
intra-dialytic,~1
Biofiltration:~1
Usual~1
intolerant~1
biofiltration.~4
mEq/l).~3
Hypotensive~1
(24.5~1
(BF):~1
AN69-S~4
(BF-4h)~1
AN69-S,~1
(BF-3h).~1
intradialytic~7
HCO3,~2
BF-4h~1
BF-3h.~1
postdialytic~1
(Bic.~1
HD)~1
(BF),~2
(Vfm).~1
Bic.~2
(WBV),~1
(RCV)~1
(RISA).~1
Vfm~2
min.,~1
Vfm.~2
interdialysis~1
phosphate).~1
biofiltration,~5
calcium/total~1
hemo-diafiltration~1
(acrylonitrile~1
metallylsulphonate~1
sodium)~1
(HF).~1
instabilities~1
HF~3
postdilution),~1
min/session)~1
differences:~1
HF.~1
Puglia.~1
9-10.5~1
3.5-4~1
(35-40~1
mEq/l)~2
(NCV).~1
Favourable~1
hyperhydration.~1
Biofilter~3
Hospal~1
(Cc)~1
(Cd)~1
dialyzers),~1
RDT~1
principles:~1
reinfuse~1
bicarbonate-saline~1
Ct,~1
Cc~2
S;~1
progressively.~1
Ct~1
ensuring~1
"physiological"~1
biocompatible~1
"biofilter"~1
Hospal.(ABSTRACT~1
plasma-perfusion~1
bauxite~1
cartridge,~1
rebound.~1
90.5~1
49-132).~1
AN69~4
adolescents).~1
inter-dialytic~1
monthly.~1
Multimodality~1
pre-dialysis~2
bicarbonates~1
Hard~2
Hemodiafiltration~1
(HDF).~1
32-month~1
"soft"~1
"hard"~1
HDF.~1
HDF~3
1.2m2~1
hollow-fibre~1
1.8m2~1
calcium-phosphate~1
(Cuprophane~1
biofiltration;~2
(HDA).~1
ultrashort~1
(Na+~1
mEq/l,~1
HDA.~1
disturbancies~1
AN69.~1
postdilutional~1
(BHD)~1
(BUN,~1
hematocrit)~1
BHD.~2
Hemorheological~1
AN69S~1
pre-dialytic~1
hemorheological~1
Biofiltration,~1
hemodiafiltration,~1
Oxalate~1
(Ox),~1
AN69,~1
Ox~7
hollow-fiber~1
dialyzer.~1
End-dialysis~2
Predialysis~1
Pre~1
98.8~1
depurated~1
hemodialyzers.~1
DBW~1
haemodialytic~1
l-ascorbatemia~4
superfluous~1
bicarbonate.~1
biological.~1
acetate-containing~1
reinfusate.~1
(better~1
equilibrium,~1
predilution~1
predilution,~1
acid-basic~1
HCT,~1
lasting.~1
Strategic~2
proactive~1
stance.~1
budget~1
advertising.~2
Planning~1
Cambridge,~1
corporations~1
businesses.~1
Decision~1
rules,~1
budgeting~1
earn~1
wage~2
jobs~1
reward~1
promotion,~2
(Kf)~1
LT's~2
cell-depleted~1
constant-flow~1
Kf's~1
[Drake~1
(KfD),~1
Am.~2
(Heart~2
Circ.~2
3):~1
H266-H274,~1
1978;~1
Goldberg~1
(KfG),~1
8):~1
H189-H198,~1
1980]~1
no-flow~1
(Tyrode's~1
alone),~1
KfD~2
KfG~2
1.239~1
0.169~1
1.586~2
0.223~2
mmHg-1~3
lung-1,~3
(W/D)~1
1.6.~1
2.071~1
0.234~1
W/D~2
1.417~1
0.200~1
1.851~1
0.244~1
alone).(ABSTRACT~1
hyperoxia-induced~1
durations.~2
preconfluent~1
Thymidylate~1
hyperoxia.~3
Thymidine~1
(exercise~2
reflex)~1
lesioning~1
stimulus-induced~1
(selective~1
stimulus),~1
probing.~2
contractions:~1
(slowly~1
adapting),~1
capsaicin.~1
(possible~1
outflow).~1
ozone~1
(O3)~1
O3~6
(VT/TI,~1
VT/TE,~1
state),~1
(nonvolume-related)~1
(volume-related)~1
Histamine-induced~1
tachypnea~1
inductance~2
plethysmograph.~1
176%~1
793%~1
ml/cmH2O~1
ml/cmH2O.~1
(DBcAMP)~1
(Em)~1
-59~1
-45~1
(AP's)~1
DBcAMP~2
TEA-induced~2
Em~1
AP's~1
electrogenesis~1
tomograph~1
scanner.~1
magnetometers.~1
inspiring~2
680~1
Meridian~1
sagittal,~1
coronal,~1
6.7-7.2~1
4.0-4.3~1
Lines~1
meridian~1
saddle~2
domes.~1
inspirations~1
single-motor~1
Electromyograms~1
end-expired~1
Single-motor~1
Hyperventilation~1
excursions,~2
[approximately~2
min]~1
(VO2max~2
(29.8~1
mmol,~1
(50.2~1
6.61~1
mmol).~1
(42.6~1
14.08~1
32.37~1
begins,~1
drift).~1
drift.~1
(VE),~2
pretraining~1
substantially;~1
training-induced~3
end-exercise~1
whole-lung~2
(14.6~1
ml/h)~1
1.3),~1
cmH2O)~1
(0.07~1
granulocytes/100~1
2.3).~1
bronchiolus~1
radiobiology~1
(HFO).~1
HFO~2
[frequency~1
2-32~1
Hz;~1
5-80~1
ml]~1
(Pao),~1
(Ptr),~1
Pao~6
oscillator~1
wherein~1
Ptr~2
(averaged~1
PL's,~1
f's,~1
VT's,~1
(PA~1
Pao)~1
overdistension~1
PA's~1
10-35~1
coloring~1
anastomose~1
traveled~1
costophrenic~1
diaphragms.~1
singing~3
singers~2
subglottal~3
punctually~1
octave~1
note,~1
/p/~1
explosion,~1
trillo~1
glottal~2
phrase,~1
phrase.~1
phonatory~2
oscilloscope~1
nonsingers,~1
coactivation~2
closed/open~1
glottogram~1
transglottal~1
wave-form~1
filtering).~1
formant~1
Cutz,~1
Bryan~1
131-138,~1
barotrauma.~1
mustard.~1
nondepleted~1
margination~1
shuttle~1
crews.~1
(L+0)~1
preflight~2
30.5%,~1
(12%,~1
(34%,~1
(EDVI)~1
(-23%,~2
(SVI)~1
EDVI~1
(-11%,~1
(ESVI)~1
ambulate~1
postflight~1
spaceflight~1
(TTI)~1
duration).~1
TTI~5
20-30%~2
TTI.~1
postcontraction~1
intermittent.~1
curvilinearly~1
impeded,~1
(Pm)~1
(TI/TT)~1
Pm/Pmax~1
TI/TT)~1
maximum.~1
(Borg)~1
centroid~1
Loaded~1
pressure-short~1
pressure-long~1
fatigue.(ABSTRACT~1
(Ppl)~1
Pes/delta~6
Pm)~1
Pm~5
5-cm~1
Mueller~1
1.00-1.08).~1
1.14).~1
0.91-1.04),~1
volume-dependent~1
seated.~1
Qualitatively,~1
compliances).~1
Quantitatively~1
inhomogeneities~1
Ppl.~1
pliometric~3
(being~1
miometric~1
shortening)~1
(Agostoni~1
Fenn,~1
15:349-353,~1
1960).~1
plethysmographic~2
(miometric),~1
(isometric),~1
(pliometric).~1
Pes~1
heart's~1
stenosed.~1
(Sw),~1
(H),~1
(Sw-H-Sd);~1
(Sw-H-Sw).~1
Sw,~1
Sw-H-Sd,~1
Sw-H-Sw.~2
Sw~3
(Vcf)~1
Sw-H-Sd~1
Sw-H-Sw~1
adenosinetriphosphatase~1
Sw-H-Sd;~1
Sw-H-Sw.(ABSTRACT~1
Vs,~1
isotope-dilution~1
low-voltage~1
(16.98~1
1.98~1
(8.69~1
ml/h).~1
197)~1
LV,~1
235).~1
(11.83~1
216)~1
(13.61~1
2.34~1
(146.9~1
bursts/5~2
432)~1
(26.5~1
348),~1
Vtr.~1
LV.~1
Dog~1
(LUL)~1
Lobe~1
(Qth)~1
Qth~1
1.27)~1
LUL~1
Qth,~2
(EFP)~1
(LA)~1
(Rus)~1
(Rds)~1
Rds~1
EFP~1
LA~1
Pam)~1
(Vaw).~1
(TGV)~1
(Im)~1
Pam/Vaw~1
relationship:~1
PB/[2~1
Im(delta~1
Pam/Vaw)],~1
large-stroke-volume~1
Pam~1
Vaw~1
digitally~1
plethylsmography~1
0.959,~1
(6.96~1
1.38).~1
(QT),~1
(QF)~1
QF~3
Dextran~4
colorimetrically~1
632~1
632-nm~1
815-nm,~1
887-nm~1
Dextran,~1
(Fahraeus~1
effect).~1
estimator-model~3
inhomogeneity,~1
(exhaled).~1
training;~1
(PImax)~1
prestudy~1
PImax~2
endured~1
trainers~2
(Clanton~1
87:~1
62-66,~1
TLC,~1
tert-butyl~6
hydroperoxide~7
(t-bu-OOH),~1
buffer.~1
t-bu-OOH.~6
hydroperoxide.~1
glutathione-dependent~1
wt-1.~2
perfusate;~1
(Reff)~1
(Eeff)~1
Reff~4
Eeff~3
(0.5-0.9)~1
l-1)~1
magnetometers~1
forcing.~1
deflates~1
nonuniformities~1
rate-independent~1
flowmeters~1
hemithorax~3
superior)~1
hemithorax,~1
(Zin)~1
(Ztr)~1
4-32~1
six-element~3
inertance)~1
inertance,~1
Zin~7
Ztr~3
suspect),~1
4-32,~1
4-64,~1
4-110~1
32-Hz~1
64-Hz~1
110-Hz~1
Ztr,~1
impedances~1
(A.C.~1
34-39,~1
impedance)~1
five-element~1
Eyles~1
Pimmel~1
(IEEE~1
Trans.~1
Biomed.~1
Eng.~1
28:~1
313-317,~1
realistic.~1
DuBois~1
8:~1
587-594,~1
1956),~1
compressibility,~1
fit,~1
nine-element~1
Peslin~1
39:~1
523-534,~1
1975)~1
(10-20~1
(HPNS)~1
0.2(Pc~1
60)1.2.~1
isofluidity~1
surfactometer~1
55,000-dalton~2
Surfactant~3
6.25~1
weakest~1
pulsating,~1
protein-containing~1
13-17~2
(sedentary~1
h/day~1
m/min~1
incline~1
ET).~1
(papaverine)~1
51Cr-ethylenediaminetetraacetic~1
(51Cr-EDTA).~1
high-oxidative~2
(100-500~1
ID)~1
(constriction,~1
change)~1
parallel-arranged~1
300-400~1
ID.~2
H2-blockade,~1
300-500~1
beta-blockade,~1
parallel-~1
series-arranged~1
nonuniformity~1
H2-~1
(DLCO),~1
(QL)~1
turtle~2
(Chelonia~1
mydas)~1
(49-127~1
wt).~1
(VL)~1
acetylene~1
DLCO,~1
Torr-1~1
mydas~1
diving:~1
breathing:~1
assures~1
migrations.~1
hypoferremia~1
160-km~1
canoeing,~1
finish,~1
haptoglobin,~1
haptoglobin~1
hypoferremia.~1
iron-related~1
Intracisternal~1
veratrine~2
alpha-chloralose-anesthetized~1
(NPE).~1
fluid-to-plasma~1
(A/P)~1
(37-114~1
veratrine,~1
alloxan~2
(permeability~1
edema),~1
(hemodynamic~1
edema).~1
A/P~6
(0.54~1
(0.48-0.84)~1
Veratrine~1
NPE.~1
HP);~1
O2-60%~1
(supraoxemic~1
SP);~1
suction.(ABSTRACT~1
(EPOC).~1
(R),~1
durations,~1
EPOC~3
(EOC).~1
EPOC:EOC~1
(RIP),~1
freedom.~1
RIP~3
20-80%~1
(Pmmax).~1
isovolume~3
loop-area~2
Pmmax,~1
91%,~1
Pmmax~1
deteriorated.~1
(TI/TT).(ABSTRACT~1
(-23%),~1
(+47%),~1
on-switch~1
hyperventilated~2
humidity,~1
(rh)]~1
(-22~1
rh)~2
3/group)~1
inspired,~1
calculated.(ABSTRACT~1
eucapnic~1
[100%~1
(rh)],~1
(-12~1
rh),~1
rh).~1
15-micron~2
diam~1
50-micron~1
bronchovasculature~1
diam.~1
Warm~1
[9,10-3H]oleic~3
reacylation~1
oxygen-induced~1
overfeeding.~2
surplus~1
overfeeding-induced~1
interpair~1
genotype-overfeeding~1
short-term,~1
Mg/1,000~1
kcal).~1
(-6.8%;~1
(131.5~1
0.84;~1
intercompartmental~1
high-level~1
quadriplegics~2
ventilator-delivered~1
Quadriplegic~1
quadriplegic~1
emphatically~1
geniohyoid~7
sternohyoid~5
sonomicrometry~1
shortened)~1
rebreathing;~1
cats;~1
Sternohyoid~1
cat,~1
End-expiratory~1
(Vthx)~1
Reconstructor.~1
Untrapped~1
anesthesia-paralysis.~1
anesthesia-paralysis,~1
Vthx~3
Vthx)~1
(blood)~1
(Vtt)~1
Vrc)~1
Vdi).~1
Vrc~1
(0.17~1
Vthx,~1
Vdi~1
Vrc,~1
Vdi,~1
Vtt~1
anesthesia-paralysis~1
agent;~1
ia~5
mol)~2
(INDO),~1
(HEX).~1
g/cm~2
5.74~1
INDO~1
HEX~1
(28.5~1
endurance-trained~1
(30.5~1
88.2~1
29-~1
19-fold~1
(83.3~1
(61.5~1
ml-1),~1
(trained)~1
(sedentary).~1
Muscles~1
102.4~1
16-contraction~1
6.12,~1
2.56,~1
muscle-1~2
s-1~1
Glycolysis~2
16.~1
55,~1
ATP/kg~2
(76.8~1
Equivalent~1
Glycogenolytic~2
Glycolytic~1
(PFK)~1
1.26~1
glucosyl~1
0.03.~1
glycogenolytic~1
6.45~1
0.04.~1
PFK~2
6.45.~1
6.70-6.45.~1
(beta-EP)~1
(beta-LPH)~1
eumenorrheic~4
exhaustion]~1
beta-EP~6
beta-LPH~6
bout.~1
Exhaustive~1
precold~1
thermoregulatory~2
exercise-~1
Hubmayr~1
54:~1
1048-1056,~1
Olson~2
1710-1714,~1
inefficiency~1
Exercise,~1
50-W~1
water-perfused~1
NE)~1
(20%~1
body),~1
(WB)~1
O2-91%~1
WB~4
(gut~1
deficit)~1
curtailed~1
obligating~1
Extrinsic~1
(PO2),~1
reduced/oxidized~1
aa3,~2
Seizures~1
(0.2-1.2~1
curare.~1
Briefer~1
aa3.~1
76.2~1
83.6%.~1
aa3~2
preseizure~1
reductive~2
seizure-free~1
cyclist's~1
(SA).~1
(VO2/BW)~1
former's~1
SA/BW.~1
VO2/BW~2
(BW~2
84.4~1
bicycled~1
SA/BW~1
(FA)~1
racing~1
FA/BW~2
VO2/BW,~1
biophysics.~1
reared~1
(O-2)~1
cyanide-sensitive~1
O-2~2
cyanide-insensitive~1
AM,~1
Vmax)~1
He-20%~1
Vmax),~1
(choke~1
(VL),~1
(VC).~2
wave-speed~2
VL,~1
Resistances~1
0.3-cm-diam~1
0.6-cm-diam~1
main-stem~1
air-dried~1
HeO2~1
(generations~1
0-5)~1
tantalum~2
bronchography.~1
mol/kg~2
(MCh)~1
(FRC)]~1
bronchography~1
diam)~1
fifth-generation~2
(49.8~1
3.0%;~1
Length-tension~1
MCh.~1
Frank-Starling~1
FRC)~1
TLC)~1
parasympathomimetic~1
expiratory-flow~1
(IVPF)~1
IVPF~1
plethysmography)~1
master~1
10-yr~1
(50-82~1
10.1-yr~1
(T2).~1
(COMP)~1
(post-COMP)~1
COMP~2
post-COMP~2
(54.2-53.3~1
52.5-45.9~1
20.7-20.8~1
22.4-20.0~1
ml/beat~1
(70.0-68.9~1
(13.1-15.1%),~1
(61.0-59.0~1
(ECV)-induced~1
(ALI)~1
sodium-anesthetized~1
ECV~4
XAD-7~1
(pre-ECV)~1
post-ECV,~1
35.2~1
ALI~1
pre-ECV~1
ECV-induced~2
chlorisondamine~1
Pressure-volume~1
inflation)~1
P-induced~1
capsaicin-induced~1
TTX~1
chlorisondamine.~1
region-specific~1
SHR's~4
WKY's~1
8.62~1
M0.67.~1
tails~1
WKY's.~1
0.022;~1
0.017;~1
0.040;~1
0.100;~1
0.826.~1
premeability~1
solute,~1
(CLSE),~1
posthyperoxic~1
postexposure,~1
CLSE-treated~1
phospolipids~1
weight-to-dry~1
(PaO2~1
Torr).~1
mitigates~1
(LLL)~1
divider~1
LLL~6
N2-5%~1
CO2-5%~1
O2).~1
(QLLL)~1
QLLL/QT~1
degassed,~1
intrabronchially~1
225,~1
micropipettes,~1
punctured~1
servo-null~1
air-liquid~4
Laplace~2
(released~1
neurotransmission.~1
bretylium~1
tosylate,~1
Metoprolol,~1
2-Adrenergic~1
prejunctional~1
1-adrenoceptors~1
tungsten~1
polymerized,~1
27-micron~1
suspensions.~1
dual-wave-length~1
microspectrophotometer,~1
O2-N2~1
mm/s.~1
capillary)~1
(heme)~1
deoxyhemoglobin~1
s.(ABSTRACT~1
thick.~1
parabolic~1
deoxygenation~2
intracapillary~2
(16-160~1
half-saturation~1
(Raw)~1
(Vtis)~1
open-chested~1
sinusoidally~1
350-ml~1
(PGF2~1
Vtis.~2
Raw~2
Vtis~1
Raw,~2
overrode~1
Vtis,~1
elastic.~1
suprasystemic~1
Suprasystemic~1
Morphometrical~1
muscularization~1
calves,~1
pedals,~1
conditioned,~1
amplified,~1
12-bit~1
analog-to-digital~1
converter,~1
Hz/channel,~1
mathematically~2
noise.~1
rectangular~1
disregard~1
incomplete;~1
12-year-period,~1
Thirty-day~1
(13.9%);~1
arm-to-leg~2
23.9~1
M-Mode,~1
ball-like~1
47.~1
(5.8%)~1
hygiene,~1
(2.3%)~1
resuturing~1
(3.3%).~1
minor.~1
Wound~1
diabetic--or~2
re-opening~1
simplicity,~1
roller.~1
69.4%.~1
(55.5%)~1
(69.4%).~1
(80.5%),~1
(13.9%)~1
(89.2%)~1
(10.8%)~1
(46.4%)~1
(25.0%),~1
(10.7%),~1
(80.5%)~1
re-amputation~2
(bk,~1
196),~1
transgenicular~1
(tg,~1
93)~1
(ak,~1
124)~1
ak~4
bk~5
30.5%),~1
(85%~1
66%)~1
(walking~1
limb:~1
tg~1
disarticulation~1
(ak:~1
resp.~3
tg:~1
bk:~1
16%).~1
disarticulation.~1
octogenarians.~1
Extremely~1
become,~1
(8.6%),~1
(3.7%~1
auricular~1
caroticum~1
regains~1
revision.~1
ACF,~1
ACF~2
diagnose.~1
limb)~1
revascularisation~1
Recognized~1
6-20~1
ankle/arm~1
non-dissecting~2
AAA.~1
aetio-pathology~1
FFAs~2
calcium-albumin~2
ether-extractable~1
albumin-calcium~2
2-28%~1
molecule)~1
(number~1
six).~1
[4.6~1
mg/dL;~1
hyperandrogenism.~1
(SaT),~1
(fT)~1
SaT~6
237.6~1
pmol/L]~1
T/SHBG~1
54.8),~1
fT,~1
0.45;~1
SHBG.~2
0.36;~1
[130~1
mg/mL]~1
(167~1
g/cm2)~1
(0.73~1
g/cm2).~1
(150K)~1
(IGF)-binding~1
(70K)~1
IGF-binding~2
Cohn~2
IV-1~2
Concanavalin~1
A-Sepharose~1
IGF-I-Sepharose.~2
Con-A~1
Sepharose,~1
IGF-I-Sepharose~1
(Coomassie~1
staining),~1
iso-mol~1
furthering~1
IGF-II.~1
thyrotoxicosis,~1
(TPP).~1
TPP~4
HLA-A2,~1
DRw8~2
PP,~1
(62.8%~1
28.6%).~1
HLA-DRw8~1
sex-hormone~1
fat/day)~2
19-nortestosterone~1
(detection~1
19-norsteroids~1
weight-reducing~1
Cal/kg~1
protein/kg~1
8-10,~1
2.14~1
g/day]~1
(2.21~1
g/day;~1
weighing)~1
(3.06~1
vehicle;~1
U/mL,~1
Somatomedin-C/insulin-like~1
(3.42~1
(4.16~1
glycosuria~1
accelerated.~1
(22-45~1
(65-85~1
0600,~1
1100,~1
1600,~1
2100,~1
0200~1
(CS),~1
nonaldosterone~2
mineralocorticoids,~1
19-nor-deoxycorticosterone~1
(19-Nor-DOC).~1
19-Nor-DOC~5
pituitary-dependent~1
K+/day).~1
mineralocorticoid,~1
19-Nor-DOC,~1
8);~1
mol/mol,~2
T4/T3~3
1.4;~1
0.15,~1
0.7.~1
atoms/mol~2
Cl/base~3
tubule,~1
fluorometrically~1
microperfused~1
(2',7')-bis(carboxyethyl)-(5,6)-carboxyfluorescein.~1
chloride-free~1
4-acetamido-4'-isothiocyano-(2,2')-disulfonic-stilbene~1
pH),~1
(4,4')-diisothiocyano-(2,2')-disulfonic-stilbene.~1
Cl/formate~1
thiamine-dependent~1
transketolase,~1
alcoholism-associated~1
Amish~2
Menton~1
pyrophosphate),~1
pyrophosphate)~1
Hybridomas~1
lipopolysaccharides~1
BALB/c,~1
MRL/lpr,~1
VH7183~4
slot~1
self-epitopes.~1
(TSP),~1
450-kD~1
88-kd~1
TSP.~1
thrombin-~1
ionophore-stimulated~1
OKM5.~1
C32~1
HT1080~1
fibrosarcoma~1
OKM5~1
88-kD~2
saturable.~1
OKM5,~1
(0.14s-1).~1
dissociation-limited~1
unshunted~4
gastrin-17~1
(G17),~1
peptone,~1
G17~1
gastrin.~1
HMG~2
Reductase~1
dichloroacetate,~1
(modelled~1
surfactant)~1
[3H-methyl]dipalmitoylphosphatidylcholine~1
cytidine-5'-diphosphate-choline~1
phosphorylcholine,~1
reutilization~1
"soluble,"~1
-5.27%/h)~1
0.67).~1
([3H-methyl]choline-[14C]palmitoyl)~1
degrade~1
intraversus~1
Tracer~1
biliverdin,~1
monoglucuronide~1
(BMG)~1
diglucuronide~1
(BDG)~1
Gunn~2
BMG~7
BDG~4
deconvolution~1
(hepatic)~1
(extrahepatic)~1
BDG,~1
intrahepatically,~1
Exercise-training~1
"muscle~2
efficiency"~2
output/muscle~1
mass)~1
sarcoplasm,~2
(HDL),~1
(CETP).~1
apoB-containing~2
CETP,~3
CETP-like~1
Incubated~1
dysbetalipoproteinemic~1
(threefold)~1
lipoprotein-free~1
dyslipidemic~1
CETP~1
ligand-independent~1
fMet-Leu-Phe.~2
Scatchard-Plot~1
[Ca2+]i.~1
up-~1
toxoid~1
(ID)~1
anti-TT~3
(idiotype)~1
"idiotype"~1
TT~1
Idiotypic~1
crossreactivity~2
anti-ID~1
[35S]BSP~3
5-10-fold~1
isosmotic~1
Li+~1
gluconate-~2
Substitution~1
NO-3~1
[3H]bilirubin~1
gluconate-.~1
Goresky,~1
Cl-/organic~1
anion-exchange~1
Na+-HCO3-~3
cotransport.~1
cotransport~2
Nernst~1
valinomycin,~1
thermodynamics~1
(Na)i/(Na)o~1
[(HCO3)o/(HCO3)i]n[(K)o/(K)i]n-1,~1
HCO3-:Na+~1
stoichiometry.~1
impose~1
HCO3-,~1
3-s~1
n.~1
HCO3-:1~1
thermodynamically~1
inside-negative~1
1260~1
(BNLI).~1
Eosinophilia~2
leucocytosis~2
(DAGTs)~1
immunohaematology~1
haemolysis~2
haemolysis.~1
Immunoglobulins~1
DAGTs~1
negative;~1
hyperplasia;~1
erythroblasts~3
dyserythropoietic~1
Amastigote~1
1-20~1
rhopheocytotic~1
dyserythropoiesis~1
gondii,~1
microtitre~2
CIE3,~1
throughput~1
(EIUs)~1
robust,~1
Units~1
Aberdeen,~1
milleri.~1
(MgUF)~1
7.6%,~1
MgUF~2
-0.269,~1
hypomagnesaemia,~1
Ames~1
Seralyzer~2
range;~1
lipaemia~1
450:1.~1
photometry~1
+0.10~1
25D~1
0.26)~1
+0.11~1
(0.27)~1
photometry,~1
(0.06~1
nurses'~1
doctors'~1
analyst,~1
technicians;~1
inflamed:~1
(nu~1
non-inflamed~2
hypotensive.~1
Alport's~1
necrotising~1
Excised~1
similarities,~1
Haemorrhage~1
cultured,~1
chippings~1
leukaemic~2
subcultured.~1
germinative~1
subcultured~1
postconfluence~1
Minoxidil's~2
postconfluent~2
subcultured,~1
mitogens,~1
perifollicular~3
Responder~1
pretreatment-increased~1
phytohemagglutinin-induced~1
blastogenesis,~1
approximating~1
responder,~1
nonresponder,~1
solutions)~1
bald~1
stump-tailed~1
arctoides).~1
hairiness~1
folliculogram~1
(regrowth~1
prebald~1
periadolescent~1
(prevention~1
reinstituted.~1
minoxidil-treated~1
keratinocytes.~1
vasodilation)~1
(averaging~1
minoxidil).~1
androgenetic~1
(male~1
baldness)~1
(In~1
period.)~1
literature--and~1
years--revealed~1
effluvium.~1
predict,~1
preclude,~1
regrowth.~1
recuperative~1
valve)~1
remainder.(ABSTRACT~1
micromanometer~1
triphosphate/protein~2
(nanomoles)~1
0.81),~1
-0.73)~1
0.79).~1
-0.74)~1
0.76)~1
diameter.(ABSTRACT~1
Subgroups~1
consumption/rate-pressure~1
beats/min)-1~1
poststress~1
image;~1
stress-redistribution~1
2SD).~1
noncritical~1
(1.12~1
symptomatic:~1
synchronism~2
"time~2
contraction"~1
relaxation,"~1
biharmonic~1
(360~1
entraining~1
(anterograde~1
pathway)~1
entrain~1
macroreentrant~1
Rather~1
Age-matched~1
lifters.~1
phonocardiogram~1
stress-time~3
Runners~1
lifters.(ABSTRACT~1
(DDD)~1
(VDD).~1
reprogramming~1
Sensing~1
balloon-aortic~1
cm2/m2~1
transvalvular~1
used.(ABSTRACT~1
diagnosis-matched~1
stenosis/pulmonary~1
3.5);~1
0.075).~1
diagnosis.(ABSTRACT~1
(g~1
m/m2)~1
(33%,~1
preload.~1
desethyl~1
analog:~1
26.9~1
Desethylamiodarone~1
parenchymatous~1
saturate~1
5,125~1
(integrated~1
score),~1
dosage-related~1
Subdivision~1
induce,~1
harder~1
similarities.~1
Videodensitometric~3
density)~1
Reproducibility~1
(flow~1
rest)~1
microsphere.~1
(microgram/mg~1
radical-mediated~1
pressure.(ABSTRACT~1
resurgence~1
stress-rate-corrected~1
gated,~1
pressure-~1
volume-controlled~1
nonsonicated~1
Renografin-76,~1
hand-agitated~1
Renografin-76/saline~3
Off-line~1
Renografin-76~1
Nonsonicated~1
Hand-agitated~1
cardiomyopathy).~1
normal),~1
dynes/cm2,~1
methods.(ABSTRACT~1
Esophagoatrial~1
atrial-esophageal~1
hydropneumopericardium~1
esophagoatrial~1
diammonium~1
suxamethonium)~1
antiragweed~3
RPM1-1640~1
2b-depleted~1
(SRW)~1
PRIST~1
supernatant.~1
2-positive~1
SRW~1
produced.(ABSTRACT~1
azatadine,~1
antihistamine,~1
azatadine~2
(CDA)~1
(sneezing,~1
rhinorrhea)~1
CDA,~1
N-tosyl-L-arginine~1
ester-esterase~1
CDA~1
differs,~1
sickness-like~1
arthralgias.~1
leukocytoclastic~1
contaminant.~1
beta-propiolactone-modified~1
percoll~1
normal-~1
Ca-ionophore-induced~2
normal-density~2
electron-microscopy~1
major)~1
elucidate,~1
hyperrhinorrhea~1
house-dust~1
vidian~2
neurectomized~1
spirograms,~1
diesel-exhaust~1
(DEP)~1
DEP~4
DEP.~2
anti-OA~2
1-week~1
DEP,~1
districts,~1
cutaneous,~1
intestinal,~2
Immunology~1
(ST)~1
IT).~1
(x~1
Known~1
22/30,~1
3/30,~1
5/30.~1
14/16~1
respiratory.~1
yearly,~1
homebound~3
methodologies.~1
leader~1
name~1
intake;~1
entry,~1
non-counseled~1
establishments)~1
3,500~1
putting~1
Teenagers~1
inadequacies.~1
mid-upper~1
observer's~1
9.8%~1
day).~1
modeling-derived~3
noted:~1
.685,~1
.001;~2
nitrogen:~1
.799,~1
albumin:~1
.485,~1
recommendations.(ABSTRACT~1
Noninsulin-dependent~1
overeating.~1
priority,~1
meals;~1
adhering~1
calorie-restricted~1
postponed.~1
spending~1
dining~1
family-style~1
restaurant.~1
Restaurant~1
small-size~1
portions,~1
chefs~1
recipe~1
Nutritious~1
fare~1
theme~1
attributes.~1
Infection,~1
High-calorie,~1
(GI)~1
immunocompetence.~1
Kotler~1
Gaety~1
quality-controlled~1
purchase~1
Administrative~1
788,~1
tertiary-care~1
trayline~2
layout~1
resentment,~1
self-esteem~1
Employee~1
documentation.~1
tray~1
dietitians'~1
Fairview~1
computers.~1
bedridden~3
summing~3
(humerus,~1
height).~1
Recorded~1
Restraints~1
Restrained~1
lines)~1
mentation,~1
detoxified.~1
nondetoxified~1
chemically-dependent~1
supposed,~2
(Folstein~1
[MMS],~1
15.3)~1
(PADL),~1
(IADL),~1
(ADL)~3
daycare,~1
caregivers,~1
(ICU)~2
nonelective~9
13.0%~2
47.4%,~1
survivors)~8
excessive.~3
Nonelective~2
(UI)~1
(NH)~1
NH~2
UI~3
Sexuality~2
programmatic~1
cyproheptadine-induced~1
gammaglutamyltransferase~1
Chlorpromazine~1
ring).~1
Barrett's.~1
diary,~1
abate,~1
bethanechol~4
squamo-columnar~1
gastroenterologist~2
cytologies~2
nematodes~2
stercoralis.~1
Strongyloides.~1
cancer,"~1
(4.9%)~4
duodenitis.~1
1,480~1
(DF),~2
3-10~2
DF.~2
DF,~2
Soroka~1
diverticulosis,~2
stercoral~1
female:male~1
outstanding~3
3-11~1
Extrahepatic~3
5-11~1
21-36~1
icteric~2
prehepatitic~1
Shinshu~1
(6.8%)~3
(20.0%)~1
hyperproduction~1
portent~1
Mallory-Weiss~1
snores.~1
Seat~2
belt-induced~1
75.6%,~1
needle-induced,~1
7-year-old~6
Hyperkalemia~2
rises.~4
recluse~1
(Loxosceles~1
reclusa),~1
responding.~4
Generally~1
enjoyable~1
helmets,~2
fire-retardant~2
transports,~1
shoulder-harness~1
underutilized~3
alpha-blocking~1
unconfirmed.~1
(SC5b-9),~1
SC5b-9,~2
SC5b-9.~2
SC5b-9~2
self-antigens~1
Subsets~2
NZB/NZW~2
nonpathogens~2
(IdX,~1
IdGN1~3
IdGN2)~1
dominating~1
30-wk-old~1
IdGN2~1
IdX~3
idiotypy~1
"spreading"~1
Id,~1
IdGN,~1
pathogenic.~1
anti-IdX;~1
"escape"~1
IdGN2,~1
Id-negative~1
Defining~3
NZB/W~4
(ng/microgram~1
anti-RNA~4
70-fold)~1
0.9962)~1
(microgram/g~2
I/anti-RNA~1
53.6~4
Mitogen~1
53.6.~1
biosynthetically~3
KG-1A~1
34,000.~1
mouse-human~1
immunodominant~2
helix~5
apolar.~1
procedures)~2
hydrophobicity~3
matches,~1
Fauchere-Pliska~1
sinusoid~2
immunodominance.~1
Babesia~1
bigemina~4
hemoparasitic~1
climates.~1
babesiosis~1
Viable~1
merozoites,~1
gradient-separated~1
merozoites~3
Surface-reactive~1
merozoite~1
72,000,~1
58,000,~1
55,000,~1
45,000,~2
36,000~4
co-precipitated~1
36,000,~1
35,000,~1
33,000,~1
58,000~1
surface-exposed~1
co-migrated~2
surface-reactive~1
co-migrating~1
radio-labeled~2
immunogens~1
(scid)~1
scid~2
NK-2.1.~1
NK-2.1+~3
(B6D2F1)~1
Sorted~1
(r-IL~1
(Asialo-GM1+,~1
Thy-1.2+,~1
L3T4-,~1
Lyt-2-)~1
TCR-gamma~1
TCR-beta~1
TCR-gamma,~1
TCR-beta,~1
TCR-alpha~1
immunopathic~3
Coxsackievirus~1
B3~9
(CB3).~1
CB3-infected~1
(heart,~1
myosins)~1
A.CA~1
A.SW~1
B10.PL/SgSf~1
B10.A/SgSf~1
isoforms.~1
heart-specific~2
antidinitrophenol~1
nonprecipitating~7
DNP-bovine~1
IgG2b~1
isotype,~1
(IgG1,~1
IgG3,~1
IgE)~1
precipitating.~1
Nonprecipitating~3
valence,~1
precipitable~1
antibody:antigen~1
precipitate.~2
isotype-specific.~1
solubilization.~1
antibody-antibody~1
isotype.~1
(CxRP)~1
pneumococci~8
xid~1
anti-pneumococcal~2
postpone~2
(15TD3)~1
(EBV)-producing~1
15TD3~8
genome-positive~1
superinfection~8
12-0-tetradecanoyl-1-phorbol-13-acetate~1
n-butyrate~2
EBV-induced~2
(EA)~2
genome-activated~1
EA~3
EA+~1
anti-EA+~2
anti-EA-~1
phosphonoacetic~1
methanol)~1
EBV-specific~2
-nonspecific~1
two-color~1
EBV+~1
views:~1
EBV-specific,~1
filament-associated~1
sites/(E)~1
Yz-1~3
sites/E~3
457~2
553~4
HindIII~4
(GVHD)~1
Brown-Norway~1
(BN)~1
BN~4
[methyl-3H]thymidine~1
inoculum.~2
LI)~1
GVHD-DA,~2
BN,~1
GVHD-BN.~1
GVHD-BN~3
6-14~1
(proliferation~1
degranulation)~1
complement-derived~2
(BMF).~1
BMF~5
cytopenia~3
Avidin-fluorescent~1
Giemsa~4
BMF,~1
anaphylatoxin.~1
Cathepsins~1
aminoendopeptidase~2
cathepsins~3
cathepsin~14
pepstatin~1
(FPLC).~1
Substrate~2
proteinases~1
catheptic~1
proteinases.~1
enzyme(s)~2
[3H]retinol~2
(retinyl~1
esterifying~1
palmitoyl-CoA~2
dithiothreitol,~2
Saturation~6
acyl-CoA:retinol~1
(ARAT;~1
2.3.1.76).~1
absolute;~1
ARAT~2
Terminal~1
(cornification)~1
retinol.~6
Retinol~5
(RBP),~1
transthyretin~10
(TTR).~1
RBP.~3
radiobinding~1
TTR~8
TTR.~1
apoform~1
retinol)~1
holoform~2
retinol).~1
holoforms~1
products)~3
Retinol-binding~1
Franz-type~1
25-41~1
Gestation~1
10(2)-10(3)~1
ligand-coated~3
substrata,~1
adhesion.~3
HR-9~1
Cyclobutyl~1
pyrimidine~13
dimers,~2
dimer-specific~1
Micrococcus~4
luteus,~1
(320-400~2
photoreactivation~1
endonuclease-sensitive~1
photoreactivating~1
perilesional~4
trypsinized~1
passages.~3
passaged.~1
hyper-pigmented~1
manifesting~6
defective.~4
accessible.~2
fills~1
circulation;~2
[14C]benzoic~2
nonvolatile~1
reused,~1
Arachidonic~1
(AA),~2
leukotrienes,~5
Keratome~1
sonication,~1
Phospholipase~3
formed/min/microgram~1
13;~1
7.29~3
1.06,~2
14.44~1
2.50,~1
kinetics)~1
alcohols:~1
propanol,~1
butanol,~1
pentanol,~1
2-methylpropanol,~1
3-methylbutanol,~1
2,2-dimethyl-propanol.~1
1-Pentanol~1
2,2-dimethylpropanol~1
erythemogenesis~2
alcohols.~1
provoked,~1
aldehyde.~1
stumptail~3
arctoides),~1
paratuberculosis/g~2
79%-84%~1
liquid-chromatography~1
isethionate~1
presurgery~4
6-hr~2
80%--to~1
azotemia~8
Bacteriologic~2
(obtained~4
catheterization)~1
(47.3%)~2
clean-catch~2
midstream-void~2
uncleansed~1
first-void~2
0.924~2
0.906,~1
species/ml;~1
0.97.~1
Uncleansed~1
(0.97)~1
(0.91-0.92)~1
leukocytes/mm3)~1
pneumonia;~1
70.7,~1
microbial-related~1
culture;~3
fiber-optic~2
lower-respiratory-tract~2
"study"~1
SECs~2
20-micrograms~1
(rHBsAg)~1
(HEPTAVAX-B),~1
rHBsAg~2
(rHBsAg:~1
HEPTAVAX-B:~1
reactogenicity~1
beta-propiolactone~4
tri(n)butyl~2
booster,~1
postimmunization~2
nonreactors.~1
(anti-HDV-positive)~1
anti-HDV-positive~3
more-rapid~1
mefenamic~2
rabbit-adapted~1
rinderpest~1
antipyretics~1
Antipyretic~1
preopsonized~1
host-defense~1
microbes.~1
cohort.~6
seventy-six~1
(69.7~1
recorded).~1
minerals.~6
three-phased~2
constancy~2
(APGAR~1
unknown)~1
unknown).~2
Dane~3
(Madison),~1
Wisconsin,~4
closed-panel~2
(HMOs).~1
literally~1
employer,~1
24,000~2
HMOs;~1
Fee-for-service~1
HMOs~1
Inpatients~1
nonacute~1
Dream~1
Staged~2
Technique,~1
6-point~7
"meaning"~1
Sober~1
education-equated~1
face-name~3
quantity-frequency)~1
Conceptual~1
Analogies~2
(CLAT),~1
well-constructed~1
analogical~1
CLAT~2
generalized-diffuse~1
prediction,~2
analogies~2
analogies,~1
year),~2
retest~2
(ECT)~6
1159~1
nonresponders,~2
4.93~1
trimipramine.~1
rapid-cycling~1
above-elbow~1
(twitch~1
averaging.~2
misdirection~3
re-established.~1
innervate~3
n-hexane~2
printing~3
Taipei~1
(pVEP)~1
pVEP~1
(BAEP),~1
I-V~1
(SEPs),~1
Tyramine~2
neuropaths~3
super-sensitivity~1
post-denervation~1
bulbo-spinal~1
unreported,~1
atrophies.~1
"juvenile~1
extremity"~1
1959.~3
musicians~1
uncoordinated~1
pianists,~1
guitarists,~1
clarinetists.~1
activity-specific,~1
non-progressive.~2
dystonias,~1
30N~1
12-18~2
(OFF)~1
(ON).~1
movements)~1
movements).~1
(interonset~1
latency)~1
OFF~1
slowness,~1
interonset~4
programmes,~2
programmes.~1
oligodendroglioma~2
Addenbrooke's~1
Cambridge.~1
Indies.~1
Indies~1
one-eighth~1
Ireland.~1
Kingdom-born~1
(A10)~1
(A9)~1
(senile~2
plaques)~1
levodopa.~4
(Hoehn~1
Yahr).~1
Intolerance~2
Neck~2
recognised,~1
myeloradiculitis~1
mislabelled~1
(NFT)~1
(60)~1
temporal,~3
NFT,~1
midfrontal~7
NFT~1
ordinal~3
peduncle~1
(NCPP).~1
by,~2
Ayer~1
"Marker"~1
myofibers~9
myosatellite~1
urination,~1
24h,~1
hemiplegics.~3
hemiplegics~2
urination~2
24h~2
co-existed~1
Mollaret's~1
immunocytological~1
Mollaret~1
leucoencephalopathy~1
Anergy~1
non-enhancing~1
papovavirus~1
oligodendrocytes~5
(THS)~1
(fifth~1
sides).~1
(Mb)~1
hypokalaemic~2
Mb~1
Mb,~1
hypokalaemia~2
ischaemia,~5
sarcolemma.~3
haemorheological~2
(haematocrit,~1
(SAE,~1
("solid~1
body")~1
(SAE~1
infarcts).~1
microrheological~1
Short-~1
Rolandic~4
P40.~1
P40~1
(N75,~1
N135)~1
mid-latency~1
EEG.~3
(LH;~1
42)~2
(TGH;~1
TGH~3
(TGH~1
67%;~1
48%)~1
(LH~1
TGH.~1
Alertness~1
TGH,~1
Ideomotor~1
(5-HIAA),~3
non-depressive~1
Epileptic~4
(some-times~1
lability,~1
"organic",~1
"deterioration",~1
disregarded.~1
"well-behaved"~1
individuation~1
(increasing~1
drug)~2
(e.g.~4
schooling~1
psychotherapy)~1
(FFR)~1
intent.~3
(methyl-GAG,~1
etoposide).~1
(MOPP)~2
WR-2721~5
thiophosphate~1
(MRs).~1
(IORT)~4
IORT~7
4,960~1
cGy.~5
sensitizer,~1
423~2
(1968~2
status;~2
liposarcoma,~2
fibrohistiocytoma,~1
prognosticators.~1
(LSS).~1
53,~1
stratifications~1
(UT)~1
cisplatin-containing~3
96-hour~4
mg/m2/d,~2
myelosuppression.~3
chemoradiotherapy.~1
completion,~2
49%.~2
(HAI)~2
intensification.~1
HAI~6
mitoxantrone,~1
Survivals~2
Granulocytopenia~2
1,000/microL~2
500/microL~1
50,000/microL.~1
mitoxantrone.~2
Mitoxantrone~2
HAI.~1
cross-resistant~1
OH).~2
(3,000~3
1,273~1
2,767).~1
atropine-responsive~1
cardiotoxic~2
excoriation.~1
axillary-subclavian~1
thromboses~6
(CVC).~1
U/kg/h.~1
phlebitis.~2
CVCs~1
90).~1
pterional~2
transsylvian~1
itself;~1
pyrimidal~1
adopted,~1
(243~1
families)~3
42.3~2
decennial~2
48:52),~1
(21.5%),~1
(2.2:1).~1
oligodendroglioma.~1
antiedema~1
retiform~3
oligodendrogliomas,~2
astrocytomas.~3
oligodendrogliomas~4
multiforme)~1
microhemorrhages~1
53.0%~1
glioblastomas,~3
56.7%~1
axial,~6
retiform,~1
glomeruloid.~1
Glomeruloid-type~1
CHI.~2
destroyed.~1
ICP,~9
tonus,~1
parvocellularis.~1
tonus.~1
Halothane~9
carotid-jugular~1
metaraminol-induced~1
microballoon~2
hydrogen-clearance~1
Carbon-14-iodoantipyrine~1
inflation:~1
sham-treated~3
(balloon~1
inflation).~1
(17.1%~1
transependymal~3
intracisternal~6
kaolin~3
dry/wet~1
microgravimetric~1
opened,~6
gradually,~2
Meningiomas~2
steroid-binding~1
antiprogesterone~3
RU-38486~1
suspension)~2
0.041).~1
antiprogestational~1
ethidium~2
mithramycin~1
(DNA).~1
G0/G1,~1
G2/M~1
estrogen-~1
progesterone-receptor~1
cytosol-enriched~1
cryostat-cut~2
meningiomas,~6
meningiomas).~1
G2/M-phase~1
0.69,~4
ganglion,~2
ring-enhancing~2
chocolate-colored~1
settling~1
invagination~2
medullospinal~1
syrinx~2
craniovertebral~1
Chiari~5
spinal-cord~2
Cytological~1
misleading,~2
(SPI),~1
(EW)~1
pancreata~1
EW~4
SPI~4
Chymotrypsin~1
EW.~1
(Cercopithecus~1
aethiops~1
ssp~1
vervets)~1
psyllium~15
husk~2
(cellular~2
microvillar~1
disarray)~1
psyllium-fed~3
SEM.~2
villus.~1
scrapings.~1
Psyllium~1
Atwater's~2
Merrill~3
Watt's~3
ME~8
monosaccharide~1
3.75~4
kcal/g.~2
DF-rich~1
carbohydrate-derived~1
disappointing,~3
6-d~1
infused.~3
g/d.~1
micronutrients~1
enterally.~1
grow.~3
Glycogen~2
66.4~8
4.3%.~2
excreted,~2
maltotetraose~1
oligosaccharide-bound~1
100.3~2
(Icatalurus~1
catfish.~1
fishes,~1
catfish,~1
flavin-containing~1
(FMO)~1
FMO~2
acid-deficient~1
acid-supplemented~1
food-restricted~5
libitum.~2
drug-metabolizing~2
chemicals.~3
0.076,~1
acid-free~1
0.076%~2
controls.(ABSTRACT~3
Sedentary~3
(EGRAC)~2
EGRAC~2
riboflavin-dependent~1
postweaning~4
deficient)~2
1-10~2
Mn-deficient~4
iron-dextran,~1
colloidal-iron-carbohydrate~1
Piglets~1
iron-dextran~2
Fe/kg~5
(Kupffer~1
iron-treated~2
(uninjected)~1
atomic-absorption~1
ferritin-protein~2
ferritin-iron~2
ion-exchange~1
62-~1
54-fold~1
iron-dextran.~1
meals:~1
sauce~3
whole-meal~2
bread.~2
sturgeon~1
(Acipenser~1
transmontanus).~1
(SPD)~1
casein:wheat~1
gluten:egg~1
(6.2:3.0:0.8)~1
rainbow~2
casein:gelatin~1
(7:3)~1
spray-dried~1
(SPD-C)~1
sturgeon.~1
(NH3),~1
N-balance~1
postabsorptive~3
(cecum)~1
Cecal~3
nonantibiotic~1
CP.~1
recycled~3
interscapular~2
decapitated~1
Virgin~1
nonesterified~6
(NEFA).~1
Soleus,~1
(EDL),~1
virgin~10
24-mo-old~2
kcal/wk)~2
(R,~1
xenobiotic~1
metabolizers,~1
(catalase,~1
peroxidase),~1
(xanthine~1
palmitoyl-CoA)~1
glucose-6-phosphatase.~1
(LP)~7
decrease)~1
12-mo-old~1
beta-naphthoflavone~1
(beta-NF~1
(40-44%)~1
(43-46%)~1
beta-NF-injected~1
vehicle-injected~4
(T3).~1
(LP-5),~1
(LP-8)~1
LP-5,~1
LP-8.~1
LP-5~2
LP-8~2
LP-5.~1
(LP-5,~1
LP-8)~1
Lifelong~1
B6CBAF1~1
long-lived~5
genotype.~2
clinging,~2
denaturation~2
solubility;~1
cycling.~9
longevities~3
(C57BL/6J)~1
denaturation,~1
(ob/ob)~3
(11-12~1
fa/fa~2
9-10~1
postobese~2
no-drug~1
(O-ND),~1
(O-FR)~1
ephedrine/methylxanthines~1
(O-E/Mx)~1
O-FR~3
O-E/Mx~3
25-33%.~1
O-ND~2
4-fold,~1
fat:protein~1
single-gene~1
Four-week-old~2
85-110~1
9):~1
motor-driven~3
(EOD)~1
EOD~2
feed,~1
Fasted-EOD~1
fasted-EOD~2
exercised,~3
episodic,~1
Inappropriate~1
Appropriateness~1
pre-intervention~2
post-intervention~1
choices,~1
Funding~1
decision-making,~1
sciences,~2
investigator-initiated~2
grants.~1
Technology~2
awards~2
consortium~1
foundations~1
foundations,~1
consortia~1
endowments~1
pre-test~2
lessons:~1
textbook~2
lesson~3
pre-test.~1
bathtub~1
stair-climbing~1
77.9~2
$11,052.~1
outliers~4
60.6~4
$28,190~1
charges.~3
prefracture~3
high-cost~1
curtail~1
consultant/surgeon~1
consultant.~2
SCL-90-R,~1
inventory.~3
SCL-90-R~1
interviewed.~7
Older,~1
antiarrhythmia~3
compromising.~1
Table.~1
(tachycardia~1
bradycardia),~1
atlanto-dens~2
roentgenographic,~1
neurophysiologic~5
investigations,~4
achondroplastic~3
spells,~1
compression;~2
Reconstructed~1
4305~2
(19.6%)~1
popularized~2
Marden~1
(J~2
Pediatr~1
1964;64:357).~1
cyanosis)~1
80)~1
"appropriate"~1
correctable.~1
veno-occlusive~12
aplastic~14
consanguinity~6
hypogammaglobulinemia;~1
mitogen,~5
phytomitogens,~1
(9.8~2
mg/dL)~11
(242~1
(98.1%~1
calcium/phosphorus~1
prematurity;~1
postnatally;~1
1365~1
30.1~3
inositol,~1
feeds.~1
(CBFV)~1
beat-to-beat~6
heartbeat~1
6.92%,~1
13.1%.~1
CBFV,~1
encourages~4
suggestively~2
struggle,~3
persist;~1
(42%:~1
waking,~2
sleep-disturbed~2
non-sleep-disturbed~2
Co-sleeping~1
(sleeping~1
sibling)~1
Prescreening~1
(PDQ),~1
parent-answered~1
Revised~1
PDQ~1
(R-PDQ)~1
nonnormal~1
Test-retest~2
94.1%,~1
parent-teacher~1
R-PDQ,~1
1434~1
Start~1
R-PDQ~3
complete;~2
ligands,~2
[3H]Ro~1
5-4864~4
[3H]PK~1
11195,~1
aldosterone-sensitive~1
micrograms/kg/day)~1
micrograms/kg/day,~1
week)~5
demedullation~1
stripe~6
Ro~2
duct)~1
2033~1
Hg/sec,~1
88.4~2
148.0~1
134.5~1
1.96~1
ml/mm~1
Hg/kg.~1
inotropy,~1
venodilatation~1
[3H]-5-Hydroxytryptamine~1
([3H]-5-HT)~1
decomposes~1
decomposition~4
(apparent~5
100-1000~2
"specific"~1
ligand/receptor~2
[3H]-5-HT~8
[3H]-5-HT,~1
15-2000~1
5-HT1~1
Radioligand~1
15-250~1
(PEN)~1
PEN~7
(probenecid,~1
phenylbutazone,~1
chlorothiazide,~2
sulfamethoxypyridazine~1
inhibitor-transport~1
0.38-74.8~1
p-~1
aminohippurate,~1
PEN,~1
p-aminohippurate.~1
(drug~2
concentration/Ki~1
ratios)~1
drugs.(ABSTRACT~2
[14C]diphenhydramine~2
[3H]sucrose,~1
[14C]diazepam.~1
[14C]diphenhydramine,~1
[14C]diazepam,~1
diphenhydramine,~2
cirazoline,~2
933,~3
equipressor~1
cirazoline~3
Cirazoline~1
933~2
613~1
mOsmol/kg~1
933.~1
933-induced~1
euvolumic~1
nephron.~5
phosphoinositides~2
[myo-3H]inositol~1
1-phosphate~1
(IP);~1
1,4-bisphosphate~1
(IP2);~1
1,4,5-trisphosphate~2
1,3,4-trisphosphate~1
(IP3).~1
Termination~4
(CHCl3-MeOH).~1
IP2~4
IP3~2
veratrine.~1
IP3.~2
4-phosphate~3
convulsant,~1
[35S]t-butylbicyclophosphorothionate~2
([35S]TBPS),~1
picrotoxin-sensitive~2
phenylquinolines~1
8165~1
9084,~1
isoquinoline~1
11195~3
(BZ)~1
Ro5~3
4864.~2
[35S]TBPS~3
submicromolar~2
(+)-bicuculline-sensitive~1
BZ~3
"antagonist"~1
Ro15~1
1788.~1
acid-A~1
[35S]TBPS-labeled~1
"Ro5~1
4864~1
site"~1
4864,~1
8165,~1
9084~1
(TD),~1
M520/N~2
(TD-sensitive)~1
(BEC),~1
BEC~5
(even~3
F344/N~2
(TD-resistant)~1
BEC.~1
TD.~1
ethanol's~1
avitaminosis~1
reserpine.~1
1.0-mg/kg/day~1
chronotropic,~1
tyramine-releasable~1
pronounced.~4
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP)~1
bioassays:~1
(GPI)~1
(MVD).~1
[Me-Phe3,D-Pro4]morphiceptin~1
(PL017)~2
MVD.~2
PL017~6
(Schild~3
-0.97~2
MVD~3
-1.4~1
[D-Pen2,D-Pen5]enkephalin~3
CTP.~1
GPI,~2
(trans-3-4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl)benzenea~1
cetamine~1
(U50,~1
488H).~1
U50,488H~1
MVD,~2
inhibition)~3
somatostatin-tolerant~1
N,N-diallyl-Tyr-AIB-AIB-Phe-Leu-OH~1
(ICI~1
174,864).~1
174,864~1
PL017.~1
vitro.(ABSTRACT~1
Inward~1
(8-12,000~1
(12-48,000~1
SR,~5
Amount~2
oxalate-facilitated~2
acetamide~1
oxotremorine,~4
Compounds~3
(3,4-[8-3H]dihydroxyphenylethylamine)~1
methyl-14C]choline~1
Cl).~1
isethionate,~1
methanesulfonate~2
Apomorphine~1
nM),~6
Krebs-Ringer-bicarbonate~2
(KRB;~1
125.4~1
Cl-).~1
(isethionate~1
KRB).~2
(125.4~1
KRB),~1
Cl-).(ABSTRACT~1
etorphine~7
AD50~1
naloxone-precipitated~1
[3H]diprenorphine~3
bound,~1
nonwashed~1
[3H]-D-Ala2,~1
DLeu5-enkephalin~1
morphiceptin,~1
Thiopurine~2
(TPMT)~2
catalyzes~7
S-methylation~2
heterocyclic~1
6-mercaptopurine.~1
TPMT~14
monogenic~2
(B6)~1
AKR/J~1
(AK)~1
like-sexed~2
DBA/2J~1
AK~10
Breeding~1
(hybrid)~1
matings~5
102)~1
27.1%~1
nonserotonergic~1
(10-day-old)~1
Ten-day-old~1
(CYPRO),~1
5,7-dihydroxytryptamine~2
(5,7-DHT).~1
CYPRO~2
5,7-DHT~5
5-hydroxytryptophan~1
potentiated,~2
5,7-DHT-treated~1
antinociception~3
CYPRO.~1
dimethylnitrosamine~1
(DMN)-induced~2
kidney)~1
(peripheral~1
spleen)~3
[methyl-14C]~1
DMN.~2
enumerating~1
Fractionation~2
B-lymphocytes~1
aminoacetonitrile~1
disintegrations~1
N-nitroso(acetoxymethyl)methylamine~1
dinitrophenylated~1
DMN~2
Aroclor-induced~1
pithed~9
(i.a.,~1
dose-pressor~2
(-)-phenylephrine~2
equieffective.~1
Phenoxybenzamine~2
(3-1000~1
-log~2
ID50,~1
(-)-phenylephrine.~2
potentiating~7
agonists)~4
blockers)~2
stimulants,~1
transmembranous~1
(sensitive~1
(insensitive~1
blockers).(ABSTRACT~1
ulcerogens~2
propionitrile~3
time-response~3
alpha-methyl-p-tyrosine.~1
propionitrile,~1
324%~1
it.(ABSTRACT~1
(51.2~1
s.c.)~5
valine)~2
Gastric,~1
s.c.).~1
Dose-~1
lergotrile~2
Aggravation~3
(-)-butaclamol,~1
(-)-sulpiride,~1
effectively,~1
antiulcerogenic~1
proulcerogenic~1
antiulcerogens~1
proulcerogens~1
(-)-N-(2-chlorethyl)-norapomorphine~1
cysteamine-~1
propionitrile-induced~1
(pancreatic/biliary)~1
([D-Ala2,NMePhe4,Gly-ol]enkephalin,~1
DAGO),~1
D-Pen2,D-Pen5]enkephalin,~1
DPDPE)~1
(U-50,488H,~1
U50)~1
writhing~5
(morphine),~1
D-Ala2,D-Leu5]enkephalin,~1
DADLE)~1
(ketocyclazocine,~1
KC)~1
(intrathecal),~1
(mouse~2
hot-plate~3
DADLE~3
DPDPE;~1
KC~11
U50~2
DPDPE~5
U50.~1
supraspinal~12
kappa-acting~1
sedation.(ABSTRACT~1
growth-related~2
(ODC)~1
alpha-acetyl-beta-endorphin~4
ODC~8
alpha-terminus~1
9-day-old~2
25-day-old~1
Centrally~1
6-day-old~4
opioid-sensitive~1
subjective,~2
ciramadol,~1
agonist/antagonist,~1
nondependent~1
ward.~2
4.5-hr~1
ciramadol~3
"liking,"~1
"good~1
effects,"~1
"any~1
effects"~2
Pentazocine~1
"bad~1
pentazocine,~1
ciramadol.~1
(22.5,~1
liking~1
(30,~1
agonist/antagonist.~1
(CHA)~2
A1-selective~1
(8-[4-[(2-aminoethyl)-aminocarbonylmethyloxy]phenyl]-1,~1
3-dipropylxanthine),~1
CHA-induced~1
(saralasin)~1
9-day~1
s.c.,~2
flurbiprofen,~1
mg/kg/b.i.d.~2
alpha.~3
Conversion~3
1-[14C]arachidonic~2
PGs~8
S.E.M.)~4
41.6~2
ng/6~1
flurbiprofen-~1
indomethacin-treated~2
[3H]nitrendipine~14
dibucaine~4
proadifen~1
tetracaine~10
meproadifen~1
RAC-109~2
benzocaine.~3
Lidocaine,~2
procaine,~2
piperocaine~1
Dibucaine~1
[3H]nitrendipine.~1
(Li+~1
Rb+;~1
EC50,~2
(Ca++,~1
Mg++~1
Mn++;~1
occupancies,~1
occupancies~1
allosteric~3
conjugation,~3
harmol,~1
harmol~5
80%),~3
20-mumol~1
reoxygenation,~3
reoxygenation.(ABSTRACT~1
(full~2
M-7,~1
UK-14,304~1
indanidine~3
(Sgd~1
101/75:~1
indanidine.~4
M-7~2
organs;~1
preganglionic~6
(distribution~1
elimination)~1
(biochemical~1
systems)~1
E-0663~4
(10-[3-(3-hydroxypyrrolidinyl)-propyl]-2-trifluoromethyl~1
phenothiazine),~1
triflupromazine.~1
phenothiazine~3
(0.01-100~1
monoamine-related~1
(3,4-dihydroxyphenylacetic~1
promethazine~3
triflupromazine~1
(3-methoxy-4-hydroxyphenylethylene~1
glycol)~1
E-0663.~1
phenothiazines.~1
(MBF)~2
MBF.~2
sulpiride,~1
Dopamine-induced~1
MBF~7
dopamine-induced~1
[noradrenaline~1
ST-91]~1
biting,~1
licking,~1
90-minute~2
long.~3
ST-91.~1
naltrexone~10
flunarizine~5
(smooth~2
ball)~1
Flunarizine~2
exponentials~2
voltage-~3
flunarizine,~2
inactivations~1
+20~1
water-loaded~1
beta-funaltrexamine~1
(beta-FNA).~1
Fentanyl,~1
d-propoxyphene,~1
profadol,~1
bromadoline,~1
beta-FNA,~2
beforehand.~2
U-50,488,~3
tifluadom,~2
Mr2034,~1
proxorphan,~1
ethylketocyclazocine~2
beta-FNA~2
Mr2034~1
proxorphan~1
kappa-selective~1
butorphanol,~1
10,047~1
dose-levels,~2
(EPI)~3
(NOR)~1
perfused/superfused~1
(0.1-10~2
NOR~3
idazoxan,~2
(GABA)ergic~1
Intracisternally~1
bicuculline-sensitive~2
Bicuculline~2
vesico-vesical~3
Aminooxyacetic~1
catabolism,~4
aminooxyacetic~1
pinching~3
(spinal~2
somato-vesical~1
(SPROM)~1
elected.~1
Antepartum~1
SPROM.~1
SPROM~1
amnionitis~1
reaccumulate.~1
SPROM,~1
notoriety~1
tampon~3
nonmenstrual~2
nonmenstruating~1
resorbable~2
(TC-7)~1
TC-7,~1
TC-7~1
(E3)~1
34-36~2
E3.~2
gonad.~1
(CVS)~1
CVS.~1
Retained~1
didelphys,~1
hematocolpos,~1
dysmenorrhea~1
nutmeg.~1
second-trimester~2
23-day~1
clomiphene-induced~1
triplet~6
74-day~1
abortion-delivery~1
belted~2
High-dose,~1
vestibulitis~2
metergoline~4
bromoergocriptine~2
83%,~8
metergoline).~1
(TRH)~2
Spermatozoa~1
lithopedion~2
tuboplasty~1
Hyskon~2
tendineae.~2
Post-cesarean-section~1
fevers~3
wards.~1
post-cesarean-section~2
Hematomas~1
defervesced~1
abuser.~1
Psammoma~1
cervicovaginal~4
smear,~5
Colposcopy,~1
washings~2
Alphaprodine~1
alphaprodine.~1
filed~7
Wisconsin~6
negligence.~1
adjudicated~1
plaintiff,~1
$25.1~1
$1~2
extra-ordinary~1
injudicious~1
postterm~3
negligence,~1
breast-stimulated~1
curettings.~1
Limiting~1
jeopardizing~1
curettings~4
hooded~3
piroxicam,~2
(NSAID),~1
salicylate.~3
(GAG),~1
noncollagen~1
Salicylate~1
withdraw.~1
sphygmomanometer~4
Greco-Latin~1
96.4%~1
76.6%.~1
portable,~1
anti-HBs.~1
Typing~4
(JCA)~1
non-Ashkenazi~1
Bw50~1
Cw6~2
(Bf)~1
glyoxylase~1
(GLO)~1
Bf~1
GLO~1
ethnically~2
JCA~1
synovianalysis~1
(JRA),~1
enteroarthritis,~1
JRA~1
74%),~1
JRA,~1
enteroarthritis.~1
40,000/mm3~1
sulindac,~2
sulindac~9
concomitantly,~1
histomorphologic~1
panoramic~1
TMJ.~3
637~1
13.2%~4
7.5%.~1
Wear~1
37.8%.~1
asymmetries,~1
radioimaging~1
111indium-chloride~1
(111InCl3)~1
ankles,~1
111InCl3~1
azathioprine.~1
rechallenge.~1
isoxicam~3
isoxicam.~1
permeate~1
sonophoresis~1
iontophoresis.~3
Amuno-Gel~1
(MSD~1
Dohme)~1
(indocid~1
gel)~1
iontophoretically~1
inline~1
fluorimetric~1
Nonassisted~1
Iontophoresis~2
mA/cm2)~1
181.1~1
ng/cm2~1
Sonophoresis~1
iontophoretic~2
(1380~1
97.6~1
ng/cm2.~1
indomethacin/cm2~1
microgram/cm2~1
internuclear~5
Discoid~2
problem-based,~1
student-centered~1
inquisitive~1
rote~1
memorization~1
careers~2
scholarships~1
indebtedness~3
Receipt~2
scholarship,~2
(public~1
private),~1
nonfederal~1
agency,~1
nonclinical~5
Indebtedness~1
reasoning~3
aptitude~3
(MRAT)~1
(GPAs)~1
(MCAT),~1
MRAT~2
GPAs~1
MRAT.~1
km/hr~2
Hyge~1
sled.~1
xyphoid.~1
Wheel~1
impacting~2
hub~2
organ-system~1
(CPAP)~1
(PAW)~1
11-75).~1
time-cycled~1
38-42~1
eucapneic.~1
CPAP~3
2.4.~2
High-frequency~2
solenoid-based~1
(HFPG).~1
HFJV;~1
HFPG.~1
t-test.~1
HFPG~2
CPAP/PIP.~1
PAW~1
'optimal'~1
(HCT)~2
(29.7~1
(38.4~1
(FIO2,~3
PEEP,~1
mode)~2
HCT~3
m10(2)/dl,~2
m10(2)/dl;~2
HCT.~1
3.64~4
ml/min/m2),~1
bpm),~1
(1,058~1
dyne-sec/cm5),~1
dyne-cm/m2).~1
HCT;~1
Number~2
Low-risk~1
Nontrauma~1
prostatomembranous~1
Impacts~1
m/sec~2
post-impact.~2
Intragastric~4
ethanol/distilled~1
dp/dt~3
electrical-mechanical~1
dp/dt,~2
piglets,~2
fast-rotating~1
burn.~2
dressings:~1
Duoderm~2
(Squibb),~1
Op-Site~3
(Smith~2
Nephew)~1
[corrected],~3
semiocclusive~1
(Datascope~1
Corp.).~1
moistened~1
epithelization~1
planimetric~1
Duoderm.~1
macerated;~1
Duoderm's~1
paste-like~1
Duoderm,~1
Op-Site,~1
dressing.~1
radioactively~5
1-protein~1
(also~6
T1-kininogen)~1
8-fold,~1
9-fold.~1
prealbumin)~2
burnt~3
hemipelvis.~1
foramina,~1
sacrum~2
hemipelvis~2
hemothorax.~1
drained,~1
autotransfused.~4
PTT;~2
fibrinogen;~1
FDP;~1
V;~1
XI,~3
VII.~1
incoagulability~1
Post~2
fabrics~4
(SN~1
HRS)~1
electrolytically.~1
HRS~1
venous)~1
(FES).~1
FFA,~1
FES,~2
Hospitalization~3
2,058~1
EC-IC~2
Dramatic~3
ascend~1
prototypes~2
nephroureteroscope,~1
(Teflon)~2
dilators.~2
fiberscopic~1
electrohydraulic~5
bidimensionally~1
mucositis~3
ineligible~2
(21.2~2
80.~3
deactivation~5
post-activation~1
(83.5~1
(7.3~2
incontinent.~1
revisions,~2
kink~2
(81.7~1
continent,~4
incontinent,~1
Peyronie's~9
tunica,~2
plaque-derived~1
(chordee~1
scar)~1
additions~4
(45X,-Y),~1
inversions~1
seminomas~4
pT~2
restricted.~2
gm.)~1
Twelve-hour~1
(spinach)~1
(controls~3
mmol.~1
3.1)~1
post-load~1
supersaturation~3
transparencies.~1
flash,~1
spotlights~1
lens/film/filter~1
diaries,~1
diary.~4
0.4938,~1
void,~1
1-stage~6
strip.~1
labia~1
minora~1
vaginoplasty~2
ectopia~4
dysmorphogenesis~1
banking~1
hitch,~1
transureteroureterostomy~2
Boari~1
hypospadias,~3
dribbling.~1
megalourethra~2
megalourethra.~1
2-stage~1
popularity.~2
cosmesis~3
Varicocelectomy~1
varicocelectomy~7
post-ligation~1
varicocelectomy.~4
Smith-Lemli-Opitz~1
dysmorphism~1
spherically~1
urography,~4
(Gore-Tex)~1
hilus.~3
180/90.~1
carcinosarcoma~1
ureteronephrectomy~1
carcinosarcoma,~1
prompt,~4
corrected,~2
hemiscrotum~1
plasmacytoma~7
cis-platinum,~2
Schwannomas,~1
neurilemmoma,~1
Cystitis~1
Secretory-type~1
Microvilli~1
Rough~1
apparatuses~1
secretory-type~1
cystica.~1
N-[4-(5-nitro-2-furyl)-2-thiazolyl]~2
(FANFT),~1
catgut~2
FANFT~7
sulfhydryl-reducing~1
mg./kg.~1
weight/day).~1
FANFT,~1
FANFT-induced~1
veno-occlusion~1
Veno-occlusive~2
pharmacocavernosography~2
(PCG)~1
pharmacocavernosometry~1
(PCM)~1
(regitine),~1
ml./sec.~1
PCM~1
PCG~1
cavernosal~9
non-pharmacologic~2
regards.~1
venogenic~1
mm./second~1
urothelium~5
ECM.~1
epodyl~1
cisplatinum~1
thiotepa~1
testosterone-filled~1
furthermore~2
growth-retarding~2
promotor~1
Bay~6
nominally~3
calcium-free~7
(rabbit)~2
(man).~2
EGTA),~1
8644.~3
evoked,~1
internodal~3
unreinforced,~1
interpositions.~1
27.8%~2
thrombus-free~2
planimetrically~1
55.1%~1
weeks.(ABSTRACT~1
Small-diameter,~1
blood-simulating~1
simethicone~1
chloride)~3
tissue-mimicking~1
graphite~2
45-degree~1
transversely~2
motorized~1
mm/sec.~1
(nine)~1
(four).~1
bedridden.~1
semicontinuous,~1
autotransfused~1
11.91~1
gm/dl~4
11.90~1
gm/dl,~1
0.73).~2
(SWMAs)~1
distal,~3
gastroscope~1
SWMA~3
SWMAs.~1
normalized.~10
infarct;~2
SWMAs~1
pharamcologic~1
"fit,"~1
U/kg)~2
Anastomoses~1
grafts),~4
grafts).~1
antihypertension~1
awaken~1
perfusion;~1
hyperperfusion~5
Intraoperatively,~1
xenon-labeled~2
postocclusion~5
lateralizing~4
event;~2
angioscopy-assisted~1
vaporize.~1
laser-welded~1
Angioscopy-assisted~1
hot-tip~1
valvulotomy~4
1819~1
trivalent~3
23-valent~3
HIV-seronegative~2
HIV-seropositive~3
9N~1
18C~2
HIV-infected~1
mount~4
group-practice~4
medicine-clinic~1
2299~1
11-month~2
encounters),~1
voluntary,~1
(20.2~2
sessions).~1
decentralized,~1
(93.2~1
109.9~1
utilizers~2
(3.27~1
3.05~2
visits),~1
walk-in~2
(0.14~1
visits).~2
Hospital-wide,~1
productivity,~2
unscheduled~4
tachyarrhythmia,~1
$1.4~2
fourths~2
persists,~1
$2.18~1
prevention/control~1
necrolysis~1
2415~1
falling--perhaps~1
g/L)~4
(136~4
Dipyridamole-thallium~1
Events~1
0.624,~2
0.256).~1
0.592,~1
0.148).~1
subset,~1
hypernatremia,~1
mL/kg,~1
pediatric-sized~1
non-oliguric~1
(434~1
(597~1
m2),~2
(C5a,~1
f-Met-Leu-Phe-Lys~1
[fMLPL],~1
hemodialyzer.~1
fMLPL,~2
133.8%~1
128.2%~1
C5a-receptor-positive~1
aluminum-intoxicated~1
iPTH-release~3
aluminum-insensitive~1
aluminum-free~1
"less-sensitive~1
aluminum"~1
anti-glomerular~2
(Steblay's~1
nephritis)~1
(Goodpasture's~1
Sheep~1
Expectedly,~1
M2,~1
nephritogen~1
(Ver)~1
Ver~6
bid,~2
(2.29~1
(318~1
microliters/min,~1
0.0025~1
(1.68~1
Anionic~1
Fenestrated~1
fenestral~4
neuraminic~1
diaphragms~2
phosphoinositides,~1
accumulate.~1
32P~2
(PI-P)~1
4,5-bisphosphate~2
(PI-P2)~1
[gamma-32P]~2
neomycin,~4
(50,~1
32P-PI-P2~2
32P-PI-P,~1
32P-PI-P.~1
neomycin.~3
moreover~2
Phosphoinositides~1
membranes.(ABSTRACT~1
IE/kg~1
drawn:~3
Spermine~1
(CFU-E~1
BFU-E),~1
granulocyte-macrophage,~1
non-specific,~1
non-erythroid~1
spermine-~1
spermidine-induced~1
spermidine,~1
granulopoiesis~1
thrombopoiesis~2
+0.23,~1
246);~1
169)~3
-0.10,~1
193).~1
Fivefold~1
mgCa/100~1
(SCr~1
[Ca]~2
[P]~1
(5.19~2
3.92~2
P/dl~1
mg2/dl2,~1
(85.3~1
Ca/100~1
0.06),~1
+0.52,~1
Quantity-Frequency~2
778~1
nondrinkers~1
10.51~1
drinks/week)~1
drinks/week).~1
QF,~1
1070~1
provincial~3
Zealand.~1
1509~1
interview).~1
attitudinal,~2
motivational,~1
cross-tabulated~1
situations:~1
Drinkers~6
Evening~1
Hotel-Tavern~1
Club~2
Solitary~4
postdischarge.~2
locate,~2
missing,~3
residentially~2
unwilling~3
locate.~1
Carolina,~3
Vermont~4
prices,~1
county,~1
disruptions~5
drinking-related~6
1-5%,~1
audiences~1
have:~1
Assortative~1
Drinking-driving~1
18-24-year-old~1
alcohol-associated~1
seatbelts~2
health-risk~1
482)~1
Contra~1
forever.~1
Respondents~4
ambivalence~2
opera~1
rock~4
music~2
ostensibly~1
commercials.~1
Refreshments,~1
wine,~2
Suspiciousness~1
content-analyzed~1
scorers.~1
commercials~1
three-wine-commercial~1
nine-wine-commercial~1
soft-sell~1
hard-sell~1
appeals~1
males).~2
variables--Adolescent~1
(AAIS),~1
(QF),~1
friend~4
alcohol--were~1
self-drinking~1
reciprocal,~1
friends.~4
AAIS~1
AAIS.~1
Dysthymic~1
(GDS)--in~1
GDS~1
1312~1
Psychiatry,~1
Lund,~1
alcohol-dependent~1
Abstainers~1
abstinence;~1
Granulomatous~3
enigma;~1
anatomopathological~1
prevalently~1
disclosed.~2
salpingo-oophorectomy.~4
Mullerian~5
adenosarcoma~2
Eaton-Lambert~1
myasthenic~5
connotes~1
resectable.~3
immunosuppressed;~1
indolent,~1
Single-organ~1
multiple-organ~1
tumors--each~1
Cures~1
small-animal~1
90Sr~1
applicator.~1
cures.~2
(cyclophosphamide)~1
levan)~1
Levan~1
splenomegaly.~3
antitumoral~3
levan.~1
Palo~2
Alto~2
nonmyxomatous~2
79)~1
"inoperable"~1
200.1~1
patient-years,~2
incomplete.~1
reparable~1
Fontan-Kreutzer~3
(82.3%)~1
(5.8%).~1
Extracardiac~1
cavopulmonary~1
intratrial~1
baffles.~1
error],~1
ventricular-left~1
(0.58~1
1.8%;~2
whatsoever,~1
(Case~2
Transventricular~2
Hegar~1
Postvalvotomy~1
fibroelastosis~1
empyema,~2
fibroelastosis,~2
intentionally~4
Warfarin~1
thromboembolism.~1
Tissue-valved~1
ventricle-to-pulmonary~1
valve;~1
generous-sized~1
Taussig-Bing~1
juxtapulmonary~1
valves),~1
infundibulum.~1
pneumonectomy,~6
subdivisions~2
conclusions:~4
adaptational~1
volume/functional~1
39.4%.~1
(b/c),~1
(b'/b),~1
flatness~1
(a/b)~1
b'~1
(b~3
b'),~1
b/c~3
b'/b~1
(6/7)~1
a/b~1
a/b,~1
struts~1
cineangiocardiography~1
Cineangiography~1
anulus-enlarging~1
apico-aortic~2
23.2~1
measurements;~3
3.5%),~1
0.025%).~1
Imperfect~1
deformed.~1
(cardiac~3
massive,~3
1-hour-old~1
preembolism~1
noncoronary~2
apicoaortic~1
conduits;~1
obliquely,~1
supracoronary~1
Danielson~1
colleagues.~1
Campylobacter-like~1
(provisionally~1
pyloridis)~1
Iatrogenic~2
phosphate-binding~2
0.57;~4
52.8~1
(47.3~1
39.2~3
Paraffin-embedded~2
leiomyosarcomas,~4
leiomyomas,~2
leiomyoblastomas).~1
leiomyoblastomas~1
histograms:~1
tetraploidy/polyploidy~1
leiomyosarcomas)~1
diagnosis--that~1
(encompassing~1
cusps,~1
annulus,~3
(immunoblot~1
Tonsilloadenoidectomy~1
340,000~1
insurers~2
tonsilloadenoidectomy~2
2,944~1
98.2%~1
overestimating~1
cerumen,~1
mucous.~1
rami~3
conveyed~2
stated.~5
(SFF)~1
phonational~2
SFFs~1
pitch~4
Pharyngoesophageal~1
myotomy,~1
laryngectomees~3
rehabilitation,~5
breathy~1
injection-esophageal~1
nonmyotomized~1
laryngectomees.~1
pseudoglottis~1
myotomized~2
tracheo-esophageal~1
laryngectomees,~2
laryngectomized~2
fluency~4
post-TE~2
(SIADH)~1
SIADH~2
pureed~1
well-masticated~1
complication;~3
Manofluorography~1
videofluoroscopy~1
manofluorography,~1
Dysfunction~1
incoordination,~2
deglutition.~3
otoscope~4
tympanometry,~2
myringotomy,~1
ears)~3
MEE.~2
reflectivity~1
(AOR)~1
93.14%~1
MEE~1
MNDs,~1
PBP,~1
PMA,~8
PLS.~1
1.5:1.~2
corticobulbar~1
fasciculations,~2
LLE~1
tending~4
RLE~1
LUE~1
RUE~2
bulbar.~2
MND.(ABSTRACT~1
education-support~1
group's~1
fearful,~2
empowerment~1
caretaking~1
"motor~1
(MED).~2
3,4-diaminopyridine,~1
MED~3
heminode.~1
electrogenesis.~1
paranodal~1
dysmyelination~1
contradictory,~1
(495.0~1
muscle/hr)~1
muscle/hr).~1
tenotomy.~2
tenotomy~3
soleus,~2
tenotomy,~1
myofibril~4
disrupted.~2
proteases.~2
isoforms,~1
college-age~2
(10-second~1
contraction/20-second~1
MM1~5
MM3~5
flatbed~1
(IEF).~1
isoform~6
MM2~2
MM3.~1
fatiguability~5
10(3]/(0.0699~1
0.00725~1
t).~1
unimodal~4
calcium-requiring~1
[3H]acetylcasein~1
Variance~2
Dystrophic~2
fatiguable~1
(cross-sectional~1
area).~3
(mononeuropathy)~1
(mononeuropathy~1
multiplex).~1
antebrachial~1
"Neuralgic"~1
29.7~2
117.0~1
myoblast~1
2.22-2.78,~1
2.85-3.26~1
micrograms/mg~8
2.64-2.94,~1
2.54-3.60~1
1.97,~1
2.18~3
biopsy).~1
Ca2+-selective~1
dantrolene.~2
vinca~1
Microtubule~1
vincristine-exposed~2
(0.67~1
cross-sections,~1
portion(s)~1
malorientation~1
neurofilaments,~1
axoplasmic~4
(NMJ)~1
dynamic,~1
(5-111~1
NMJ~3
composites~3
(ChE)~1
mounts.~1
maturation;~2
12-48~1
48-82~1
NMJs;~1
82-111~2
NMJs~2
remodeling;~1
ChE~1
abruptly.~1
double-step~2
(Ca2+~2
Mg2+)-ATPase~2
Besides,~1
(CNEMG)~1
(MNEMG)~1
CNEMG~5
MNEMG.~3
MNEMG~2
134%~2
25-30%~1
CNEMG,~1
(CAPs)~2
conductor~2
CAPs~3
CAPs,~2
CAPs.~4
diameter-velocity~2
polyphasic~3
GBS)~1
demyelinates~1
demyelination;~1
Duchenne's~6
DNA-sequence~1
(probability,~1
greater),~1
DNA-marker~2
grandparents~3
unavailable,~1
uncertainties~3
Pitfalls~1
Crossover~1
Dakota~1
Iowa.~2
offices.~3
trimmings~3
slaughtering~1
19.0;~1
beef.~1
"gullet~1
trimming,"~1
harvests~1
cases--or~1
outbreaks--of~1
factitia~1
umbilical-cord~1
prenatal-exposure~1
deciliter),~2
deciliter).~2
semiannually,~1
Capillary-blood~1
confounders.~1
high-prenatal-exposure~1
low-exposure~2
high-exposure~2
7.3).~1
medium-~1
6.3).~1
deciliter,~1
benzene.~2
air-sampling~1
100)~4
641),~1
409~3
1047).~1
322,~1
1186,~1
6637~1
million-years~1
(ppm-years),~1
399,~1
ppm-years~1
lifetime;~1
enforceable~1
exposure-response~2
logistic-regression~1
benzene-induced~1
azotemia,~3
(AIDS-associated~1
nephropathy;~1
"failure~1
thrive"~1
(NGF)~1
NGF,~1
inflexible~2
'lock~1
key'~1
change;~3
handshake.~1
bill~4
platypus~3
Scheich~2
electroreceptors~2
platypus.~1
bill.~1
prey~1
fresh-water~1
electroreceptors.~1
germline-specific~1
parthenogenetic~3
term;~3
androgenetic----parthenogenetic~1
intermingling~1
Support-free~1
semiconservative~1
fission~1
mating-type~1
SV40~10
large-T~2
plasmids~8
36,000)~1
cell-cycle~3
(PCNA)~4
cyclin.~2
gonochoristic~1
vertebrates:~1
fishes~1
reptiles);~1
mammals).~1
sex-determining~2
evolve?~1
non-existent~1
latitudes~1
Chromaffin~1
catecholamine-~1
peptide-containing~1
exocytosis,~1
alpha-fodrin~1
permeabilized~3
detergents,~1
immunoaffinity-purified~1
anti-alpha-fodrin~1
Ca2+-induced~2
fodrin~1
eukaryotes~1
Cis-acting~1
TATA~3
box,~3
proto-oncogenes~8
transforming~5
FBJ-murine~1
osteosarcoma~2
Adenovirus~2
E1A~5
promoters.~2
(transactivation)~1
E1B~2
transactivation.~1
Sp1;~1
E1A-transactivation,~1
TATA-box~1
cyclin~6
36K),~1
polymerase-delta~3
templates~4
primer/template~1
(large-T~1
antigen),~1
cellular.~2
immunopurified~4
36K)~1
PCNA~4
polymerase-delta.~2
anti-PCNA~1
equivalent;~1
processivity~1
polymerase,~2
polymerase-delta,~1
replicative~3
Lignin~2
phenylpropanoid~1
woody~1
microbes;~1
nevertheless,~1
white-rot~1
catalyse~2
biodegradation~1
cellulose,~1
Earth.~1
depolymerization,~1
catalysed~2
(ligninases).~1
Phanerochaete~1
chrysosporium~1
Burds,~1
(nitrogen)~1
Ligninases~1
biodegradation,~1
pollutants.~1
ligninase~6
enzymology.~1
28-residue~1
leader,~1
37K).~1
peroxidases.~1
Charged~1
C-peptide~15
charged-group~1
dipole.~1
Zimm-Bragg~1
Light-modulated~1
39,000~1
39K)~1
cGMP-dependent~4
fluxes.~2
neuroeffector~3
unambiguously~2
intermittence~2
varicosity~2
varicosity.~2
115,000-155,000~1
115K-155K)~1
relatedness~1
'very~1
antigens'~1
VLA-1~2
210K/130K)~1
VLA-2~1
160K/130K)~1
VLA~4
discovered,~4
VLA-2,~1
130K~1
VLA-3~1
VLA-5~1
unidentified.~1
pointer~1
cosegregation~2
(M.N.,~1
J.D.,~1
Hayward,~1
F.~6
Northrop,~1
D.J.H.B.,~1
Walker,~1
D.S.S.,~1
manuscript~2
(CML)~2
550-bp~1
CML~2
HL60.~1
papova~1
uncoating~1
encapsidated~1
polyoma~4
myristic~2
myristylated~2
nonenveloped~2
encapsidation~1
scaffolding~1
tissue-specific,~1
gamma-crystallins.~1
delta-crystallin~2
reptiles.~1
epsilon-crystallin,~1
epsilon-crystallin~3
(EC~3
1.1.1.27)~1
LDH-B4.~1
crystallins~2
Ricin~1
sugar-binding~3
ribosomes.~2
ricin~13
ancient~2
galactose-binding~4
salesman~2
combinatorial~2
optimization,~1
cities,~2
tour~2
once?~1
iterative~5
non-uniformly~1
tour.~1
extendable~1
mappings~2
geometrical~4
anthropoids~1
fossil~4
Miocene~1
Venta,~1
(Myr~1
BP),~1
Tertiary~1
rocks.~1
Neogene~1
Aotus,~1
crepuscular-nocturnal~1
anthropoid~1
primate.~3
Venta~1
dentitions~1
genera.~1
ancestral~3
extant~1
Ventan~1
Aotus~1
platyrrhine~1
traceable~1
Miocene,~1
Myr~1
right-eye,~1
left-eye~1
whiskers.~1
trimming~1
Catecholaminergic~1
sleep-wake~1
Tyrosine~1
RNAs.~2
subfamily~1
alpha-globin-like~2
galago~1
horse.~1
subfamily,~1
1-globin~3
orang-utan,~2
galago,~1
orang-utan~5
codons,~1
boxes~2
CCAAT~1
1-gene.~1
1-genes~2
Proudfoot~1
baboon,~3
orang-utan.~1
implication,~2
subfamilies~1
10.5-base-pair~1
periodicity~6
dinucleotides~1
co-orientation~1
spaced~4
'wedges'~1
stacked~3
roll~2
AA-TT~2
dinucleotides.~1
wedge,~1
textbooks,~1
nomenclature.~2
(15.6%).~1
(meningohypophyseal~1
Parkinson)~1
(65.8%),~1
McConnell~1
(28.1%).~1
(trigeminal~1
divisions,~2
branches)~1
inconstant.~2
ophthalmic,~1
meningeal,~1
destinations.~1
kaolin.~1
AERs~2
clicks~1
P0~1
P3-P5~1
P4/N5~1
P1-P3~1
neuropraxic~1
Incidental~1
leukomalacia~2
detail.(ABSTRACT~1
(PCoA).~1
PCoA~9
Infundibular~1
OD~1
superiorly,~1
cinereum~2
(16.8%),~1
(14.4%),~1
circuminfundibular~1
mamillary~4
peduncles~2
(7.6%),~1
(5.7%).~1
premamillary~1
(IAs)~1
(SAH),~1
IAs,~1
IAs~1
IAs.~1
acepromazine-ketamine~1
expose,~1
divide,~2
polyene~1
filipin,~1
replicas.~2
filipin~1
vibratome~1
filipin-cholesterol~2
protuberances~1
pits~2
P-~1
E-faces~1
Distinct~1
filipin-treated~1
astroglial~1
(PCoAs).~1
Hemodynamically~2
PCoAs~3
thrombose.~1
chronically.~1
hunterian~1
0.6;~5
1.0;~3
0.45.~2
thrombose~1
hyperalimentation~1
frames,~1
kneeling~1
positioning,~3
fulfills~1
distract~1
lightweight~2
fiberglass~2
elevator~1
cushions,~1
hemicylindrical~1
troughs,~1
ergonomically~1
cushions~1
buttocks~3
cushioned~1
face-down.~1
machete~1
Autogeneic~1
cranioplasty~1
here)~1
(57%].~1
(26%],~1
(17%].~1
Myelography~5
(15%].~1
myelopathic~1
neurologically.(ABSTRACT~1
halted~3
(pHe)~1
pHe~3
acid-based~2
postmetrizamide~1
hypertropic~1
cortical/leptomeningeal~1
C-6,~1
predated~1
moribund.~1
Buckling~1
Semple-type~1
relapsing-remitting~1
encephalomyelitis,~1
Meningitis~1
polyradiculopathy~2
microglial~2
multinucleation~1
(PSP),~1
(32.8%)~1
PSP.~1
MI-PSP~1
(12.9%~2
MRI)~2
"active"~2
Amitriptyline~3
lancinating~1
nightly.~1
audiogenic~3
stimulus-sensitive~1
oromandibular-cervical~2
60.7%~1
self-assessment,~2
video-rating;~1
anticipatory~4
foreperiod~1
blink~3
masseter~5
jerk~4
microcompression;~1
Trigeminal~1
microcompression~1
thermocoagulation.~1
chorea~3
spheroid~1
chorea-amyotrophy-acanthocytosis~1
Acanthocytosis~1
N18~1
N22~2
P38~1
cuneatus.~2
movement-induced~1
(FL),~1
56',~1
28'~5
(pts)~1
non-MS~5
(19).~1
probable,~2
56'~2
pts.~1
abnormal),~1
probable)~1
PR,~5
myoblasts,~1
myoblasts~1
(G6PD),~1
G6PD-A~1
G6PD-B~1
mute,~1
about.~1
MRI-verified,~1
callosally~1
consciously~3
(GBS)~1
1976-77~1
A/New~1
Jersey/1976~1
vaccinations~1
levodopa;~1
city,~2
delusion~1
dorsolateral~7
tegmentum.~1
novel,~3
small-scale~1
Prealbumin~2
prealbumins~1
FAP.~3
left-handers~1
left-biased~1
male-handedness~1
McNemar's~1
Terguride,~1
lisuride,~1
cataplexy,~1
stereotypies~3
terguride~2
Terguride~2
agents;~3
(ECCE)~1
(IOL).~1
reblock~1
capsulotomies,~1
liquefied~3
tarsoconjunctival~1
coloboma.~1
20/15~1
19-year~1
cryocoagulation~1
cryocoagulation,~3
cryocoagulation;~1
choroidal-retinal~2
iris-ciliary~1
intravitreally~1
420,000,~1
210,000,~1
105,000,~2
52,500,~1
26,250~1
units/0.1~1
scotopic~2
electroretinography.~1
angulates~1
step-zoom~1
(GRIN)~1
microns,~3
macrovessel~1
Ophthalmoscopy~1
amplitude/pressure~1
calcofluor~1
(CFW),~1
brightener~1
Acanthamoeba.~2
CFW~2
sp,~2
Phycomycetes,~1
Fusarium~3
solani,~2
capsulatum,~1
neoformans,~1
Rhinosporidium~1
seeberi,~1
Trephine~1
methanol-fixed~1
greenish~1
reddish-orange~1
smears,~1
vitreal~3
subconjuctivally.~1
cetotaxime~1
Cefotaxime~2
(AVCR).~1
AVCR~3
detection;~1
affected;~1
(AVC);~1
fundus;~1
papillomacular~1
superotemporal~2
quadrant.~1
AVCR.~2
AVC~2
(ALD)~3
relentlessly~2
operative.~2
(NLP).~1
exotropia,~2
(EOG)~3
Macular~1
Visual-evoked~1
cuts~8
ALD~4
(APDs)~1
dimmer~1
denser~2
specified.~2
APDs~1
forniceal~1
conjunctiva.~5
melanosis.~2
mucopolysaccharides.~1
neuroidal~1
neurofibroma.~1
88-year-old~1
cystadenomas~1
creamy~1
secretion),~1
surmounting~1
clearer~4
inferiorly,~1
Moll~1
double-layered~1
cuboidal~3
lining,~3
plump~1
hobnailed,~1
plasmalemmas~1
widenings~1
canaliculi,~2
election-dense~1
swirls~1
myofilamentary~1
Moll.~2
injection-molded~3
(IOLs)~2
iridescent~3
neodymium:~3
lathe-cut~2
mJ~3
(Standard~1
injection-molding~3
IOLs,~1
mJ.~3
Iridescent~1
bluish~1
coloration~4
canaliculus,~1
mucin-producing~2
nonectatic~1
canaliculus.~2
Inflammation~5
canaliculus~1
canaliculops,~1
dacryops.~1
103-diopter~1
iridotomy-sphincterotomy~1
mid-peripheral~3
fasicularis)~1
iridotomies~5
Oozing~1
Abraham~1
spot.~1
Vascularized~1
nonvascularized~3
concise~4
demineralized~2
multistep~1
osteogens~1
chosen.~2
Harris~7
Transplantation~2
Functional,~1
outperformed~2
autograft,~1
hydroxyapatite,~1
TCP.~1
Diaphyseal~1
osteoinductive~1
subsumed~1
title~2
dysmyelinating~1
myelin;~1
myelinoclastic,~1
remember~2
clinician,~3
compulsive~2
inpatient,~4
residential,~1
summarize,~1
door~5
involves,~1
genetic,~2
subcategorize~1
youngsters.~1
marijuana),~1
turmoil~1
youngster~3
alcoholism),~1
catalogued.~1
aftercare,~1
Fourth,~1
categorized.~2
philosophic~1
Fifth,~1
confrontational~1
honestly~1
Essentially~1
Sixth,~1
laudable~1
goal.(ABSTRACT~1
controversy--thus~1
viewpoints.~2
abuser~3
pleasure-driven~1
discouraging~1
counterproductive~1
hopeful~1
Promising~1
highways,~1
encounters,~1
school-based~2
society-wide~1
gateway~1
drugs:~2
marijuana,~1
nation~2
counsel,~1
preconditions~1
prompter~1
Greatest~3
ribavirin-treated~1
bronchopneumonia.~2
(HRVs)~1
40/100~1
episodes/100~2
HRVs~1
non-illness~1
April.~1
reservoirs,~3
WA,~1
Propionibacterium~1
acnes~1
(19.7%)~1
infection).(ABSTRACT~1
meningitidis~2
37.8~4
Afebrile~1
Bacteremia~1
disease--outpatient~1
disease--three~1
disease--admission~1
hospitalized:~1
retractions.~1
hyperpyrexia~1
[106~1
F]~1
greater).~1
roseola,~1
(binomial~2
0.15.~1
priori~1
temperature)~1
temperature),~1
0.59).~2
kilograms~5
intussusception.~3
10-month-old~1
miosis~2
pneumothoraces.~1
toxidromes~1
gestures.~3
decontamination,~1
intubations,~1
charcoal/cathartic~1
nonatherosclerotic~1
cervicocephalic~1
problems)~1
Antibiotics~4
leaders~3
lobbying~1
circumspect~1
microabscess,~1
1.2%);~1
indurated,~1
conjunctivae~1
Desquamation~1
finger,~3
enlarged.~2
soles,~1
sway~3
mandibles,~1
Frames~1
10-second~2
landmark~4
Approximation~1
.18~3
.06.~1
.32.~1
(H-N)~1
Head-neck~2
(static)~1
(dynamic)~1
H-N~2
(horizontal~1
concluded,~3
hemiparetic~2
(CVAs).~1
CVA.~2
(HVS)~1
(BFV)~1
20-MHz~1
BFV~4
voltage,~1
polarity.~2
BFV,~2
20-pulse-per-second~1
HVS~1
prototypal~4
sacrum,~3
Small,~1
intimately.~1
disabled.~4
postures.~4
commonplace~3
audiovisual~3
audiovisuals.~1
audiovisuals~1
(anastomotic~1
perianastomotic)~1
(distant~2
88%;~2
colostomies,~1
intravasation~2
mesentery.~3
(rupture,~1
(calcified~1
spleen).~1
pericolonic~1
portal,~2
mesenteric,~3
poppyseed~1
(Lipiodol)~1
chemoembolization~3
stent.~2
11-F~1
7-35~1
neo-intimal~1
ml/day.~1
225)~1
Embolization~8
velour,~1
macroaggregates,~1
(90.8%),~1
36.~1
strangulation.~1
(UPJ)~2
pyeloplasty.~1
22-gauge~8
Chiba~3
UPJ.~1
UPJ~5
stenting.~1
pyeloplasty~4
"cystic-appearing"~1
extraparotid~1
thallium-201/technetium-99m~1
retrospectively)~1
retrospectively).~1
adrenocorticotropic-hormone~1
(ACTH)-producing~1
(DTPA)~2
lesion/pituitary~3
mmol/kg).~1
neurosurgeon's~1
extraaxial~2
even-echo~3
rephasing,~1
determine.~2
(stroke),~1
sulcal~1
Ependymal~1
(15-24~1
mgI/ml~1
(41%),~4
routine-dose~1
conventional-dose~1
multi-level~1
reactions),~1
detectability~2
mastectomies~2
1-cm~3
whole-breast~1
mammograms,~1
40-69-year~1
70-year~1
Wolfe~3
Transillumination~5
1,110~1
(SNR)~1
Min-R/OM1~1
4.5-cm~1
kV~3
target-beryllium~1
0.03-mm~1
SNR~3
target/filtration~1
0.051-mm~1
rhodium~1
Tomography~1
indeterminate.~1
opacities.~3
aortographically~2
"erect"~1
autopsy-proved~3
Kaposi~5
Premortem~1
PE.~3
met:~1
kilovolt~3
milliamperage,~1
targeting,~1
(25-cm~1
noise,~6
milliamperage~1
thin-collimation,~1
high-spatial-frequency~1
milliamperage.~1
(IFTO)~1
salpingography~2
intratubal~5
IFTO~2
recanalization:~1
soft-tipped~1
3-F~1
diagrams~2
surrounding,~1
zone);~1
leiomyoma,~2
diffuse)~1
adenomyosis);~1
low-signal-intensity~2
marginated~3
imaging:~1
(CMJ),~1
CMJ~1
Struvite~1
abdominopelvic~10
remission--eight~1
.026).~1
(PVNS)~1
PVNS~1
(TR)/echo~1
(equal~2
fat)~9
appointed~2
Agenda~3
People.~2
science;~1
education;~1
resources;~1
mechanisms;~2
coalitions~3
radiologist-patient~1
understandable~1
small;~2
triangulation~1
lesions--especially~1
breast--to~1
sagging~1
needle-catheter~1
[Au(I)]~1
Au(I)~2
(O-2.),~1
(O1(2)delta~1
antiarthritic~1
deactivators~1
O1(2)delta~1
gli,~1
(q13~1
q14.3).~1
gli~1
past:~1
"During~2
liquor,~1
have?"~1
dentist?"~1
"When~1
job?"~1
autobiographical~1
complying~3
answers.~5
H-540~2
3215.~1
skinned~4
nicely~1
(diprotonated)~1
depresses~6
diprotonated~1
histochemistry,~4
(somatomedin~1
perichondrium~4
hybridizing~4
IGFs,~1
grasp.~2
meaning.~1
technologies.~2
policy-making~2
decision-makers.~1
understanding,~1
well-intended~2
priorities~8
Agency~4
priorities,~1
regulations,~2
pursuing~1
jobs,~1
"Risk-risk"~1
"How~2
safe"~2
manage,~2
fuzzy~1
rhetoric.~1
Regulatory~3
Statement~2
commission's~2
societal~2
electricity~1
polyuridylic~2
acid-paper~2
step,~3
phosphoribosyltransferase~2
Distinctive~1
fictive~1
swimming.~3
monosynaptically~1
reticulospinal~1
LCB.~1
triskelion,~1
LCB~1
heptad~1
coiled~2
coils,~1
tissue-dependent~1
(SMVs)~2
SMVs,~2
generator,~1
pumped~4
free-running~3
SMVs~8
ergs,~1
animal's~2
neuropsychopharmacological~1
neurobiological~2
adopted-away~1
alcohol-seeking~1
begins.~2
Alcohol-seeking~1
appetitive~1
neurogenetic~1
antianxiety~2
neurophysiological,~1
neuropharmacological~1
795-amino~1
stably~4
86-amino~1
150-amino~1
123I-radiolabeled~1
biolabeled~1
bomb~1
Hiroshima.~1
(GPA)~1
VFs~2
mutagenesis~2
systems;~1
nonprimate~3
faces,~1
faces.~3
561~2
horns),~1
breed~3
familiarity,~1
gold-conjugated~1
domainal~1
pinpointing~1
supramolecular~2
antigen-binding~1
(Fab')~1
11-atom~1
nanometers~1
undecagold-Fab'~1
immunolabel.~1
S-49~1
immunoadsorption~1
antibody-coated~6
immunoblot,~1
(binding~1
[3H]dexamethasone~1
mesylate)~1
kilodaltons.~2
antigen-deficient~1
Spiritual~1
spiritual~3
rabbi-physician.~1
Overdilution~1
juices~1
diaphoresis~1
papaverine-phentolamine~2
IU/L)~1
IU/L.~1
Expansion~2
1954,~1
tendinosis,~1
microinvasion~2
serviceable~2
tympanoplasty~1
stapedectomy,~1
Farrior~1
Virginia.~1
2,892~1
2,232~1
thrombocytaphereses~1
contemplate~1
pseudocysts~9
cyst-related~1
18.9%.~1
57.4%~1
cholelithiasis--before~1
(IAT)~1
angiodilatation~1
IAT.~3
IAT~2
IAT,~2
IAT-related~1
interruption,~1
Spironolactone~1
arteritis.~3
(joints~1
vasculature)~1
taper~1
division.~2
polydipsia~2
polyuria.~2
penicillin-resistant~5
multiglandular~4
Livaditis~1
"long~1
gap"~1
(SLI-a),~1
corpal~1
(SLI-c)~1
(SLI-f)~1
(DU)~1
(GU)~1
GU~3
(52.3~1
Arimura's~1
Chromatographic~2
(SLI-a,~3
0.45,~3
SLI-c,~3
SLI-f,~3
0.21);~1
0.13,~2
SLI-a~2
(DU,~1
GU,~1
SLI-c~1
SLI-f~1
(6-3H)~1
(FUdR)~1
99m-technetium~1
Nuclide~1
fluoropyrimidine~1
metabolites)~2
99mTc-MAA~4
nuclide~1
3H-FUdR~1
repercussions.~1
antitoxin~2
revaccination,~1
revaccination~3
Antitoxin~1
sigmoidally~1
morphovolumetrically~1
funnel,~1
mountain.~1
seeding.~2
varians~3
Subcutaneously~1
micrococci~1
Cytologic~3
hexosamines~1
uronic~2
cleanliness~2
vitamins,~5
2,221~1
cholecystectomies,~1
supraduodenal~2
(adult~1
form)~1
hypersplenism~4
Choledochoscopy~2
choledochotomy~2
V-Y~1
Cholangioclip~1
complication-free~1
[as~1
(GCS)]~1
return)~1
(GCS~3
speed,~5
Unemployment~2
Mayo-Adams~1
retractor~1
fast-Fourier~1
(FFT)~2
Interindividual~1
(ACA)~1
45.3~2
ACA,~1
58.4~1
44.7~4
34.9~3
30.5~5
Choroid~4
preponderance.~1
meningotheliomatous~1
parietooccipital~1
rachidian~1
mandibuloauricular~1
auricle.~1
(MVT)~1
MVT,~1
MVT~1
gangrene.~2
MVT.~1
Serosanguineous~1
(BCAAs)-enriched~1
kcal/kg/day~1
protein/kg/day~1
ketoacid~1
(+13.1~1
+18.0~1
BCAA,~2
glutamine,~2
ketoacids,~2
ketoisocaproic,~1
ketoisovaleric,~1
ketomethylvaleric.~1
BCAA-enriched~1
economics.~1
stapler,~3
(U.S.~1
Norwalk,~3
Conn.),~1
ILS~5
(Ethicon~1
Ltd.,~3
U.K.).~1
(6/174);~1
(4.7%~1
ILS).~1
leakages~1
8.7%-EEA~1
14.5%.~1
staplers~4
32.5%~1
131/2~1
bougienage~1
half-volume~1
foot;~1
"venous~2
sufficiency~4
indices"~1
uninfluenced~2
halftime~1
indices."~1
variances~5
duodenums~1
(HCl).~1
2.03~2
0.12,~2
ml/gm/min~1
normotension.~1
H+-dependent~1
III-oxine~1
FN-coated,~1
(Persantine)~1
gamma-camera,~1
fivefold.~2
FN-coated~1
(27.2%).~1
hemangioma:~1
live-threatening~1
thermal-green~1
(TGD)~1
double-indicator~1
liquid.~3
(PLa)~1
PLa~6
PLa,~1
mm/kg,~1
Microporous,~2
PU],~1
poly-L-lactide~1
PLLA]~1
scaffolds~1
small-caliber~5
neoarteries~3
PU/PLLA~2
[ID])~1
inspection,~1
patent;~1
ID),~1
aneurysmal.~1
pulsations~1
neointima~3
neomedia~4
implants:~2
arranged.~1
neoadventitia~1
lattice,~1
fibrohistiocytic~1
microporous,~1
Arteriosclerosis~1
arteriosclerosis.~4
(79%~2
(83%~4
82%),~1
(86%~2
74%;~1
(systole~1
L/day.~2
lymphography,~1
lymphangiectomy~1
lymphorrhagia~1
chylorrhagia,~1
papillar~1
venorraphy~1
aortorraphy~1
fibrinous~3
Oligoarticular~1
urethritis,~2
(Reiter's~1
Calcified~1
unlikely,~3
65.8~1
validities~2
50.12~1
5.76~2
(6.5%)~1
(9.3%)~2
(16.8%)~2
69.9~1
(32.5%)~1
(17.2%).~1
True,~1
0.147~1
embodying~1
payment.~1
0.051)~2
Matched~1
24-month~3
aneurysms).~1
hypervolemic~4
(35.6%)~1
aiming~3
33-38%,~1
15-18~1
160-200~1
(120-150~1
unclipped~1
aneurysms)~1
47.6%~1
rebled~3
diencephalic~2
triad:~1
hypersomnolent~2
apathy,~3
apathy~1
affect,~1
confabulation,~2
apathy.~1
Speech~2
hypophonia~1
handwriting~3
legible~1
script~1
scrawl.~1
recall,~1
(Canis~1
familiaris).~1
air-only~2
58.3~1
recompression;~1
flows;~2
(TIA),~1
Daisen~4
Ama~4
319.6~1
314.5~1
2,168~1
Akita~1
Prefecture,~3
winter;~1
Putaminal~1
(SHRSP).~2
MCA.~3
microspheres,~4
SHRSP,~8
SHRSP~18
vasodilatation.(ABSTRACT~1
bioluminescent~1
7.04-7.09~1
ATP-~1
glucose-induced~1
Phosphatidylinositol~1
phosphatidylserine~1
sphingomyelin~3
20:4~1
22:6~2
(20-fold~1
increase).~2
Na+,K+-ATPase~5
(-21%)~1
Lowry~2
(-36%)~1
pentane,~1
pentane~1
Cystatin~1
proteinases,~1
(pHa),~1
pHa,~1
pHa.~1
18-19-week-old~1
reserpine,~6
Increments~2
WKY;~1
129.7~1
inevitably~3
mm/sec~3
[pi~1
(diameter/2)2~1
velocity]~1
67.1~1
129.8~1
25.4~1
(85.0~2
hypercapnia.(ABSTRACT~1
worsens~2
Normoglycemic~1
convulsive~2
Hyperglycemic~1
Cl-,~1
contract,~1
(150-200~1
o.d.)~2
stretch-dependent.~1
(10(-6)-10(-4)~2
ACh-~2
suppressed,~2
hydroxy-eicosatetraenoic~1
(HETEs)~1
15-HETE~3
11-HETE~1
appeared,~2
8-,~1
9-,~2
11-,~1
12-,~4
15-HETEs~1
HETEs~1
5-HETE~6
exams.~1
prehensile-traction~1
butanediol-treated~1
butanediol~1
5-lipoxygenase,~1
2-(12-hydroxydodeca-5,10-diynyl)-3,5,6-trimethyl-1,4-benzoqu~1
inone~1
(AA-861),~1
AA-861~3
5-lipoxygenase~5
telangiectasias~1
mirabile~1
Moya-Moya~1
PIH)~1
PIH,~1
PIH~5
criterion.~5
(43.7%)~1
(37.7%)~1
(12.6%)~2
reserved,~1
calyx~1
C-arm~1
fluoroscope~1
sacrosciatic~1
(Javadpour)~1
ureteroiliostomy~1
Appreciation~2
Javadpour,~1
Sigmoid~2
U-~1
J-shaped~4
tunneling~4
Enuresis~1
condom~3
high-stage~1
cystostomy,~1
redescent~1
Snap-Gauges.~1
nonfunctioning~7
ureterorenoscopy~3
4F~1
ureterorenoscope.~1
twenty-three-year-old~1
twenty-four-week~1
urosepsis.~1
pyelocalyceal~1
epididymis-testis~1
[Hpd])~1
Hpd~2
renal-carcinoma-derived~1
defecating~1
papillae~3
Medullary~4
angiomyolipoma.~1
anuria~2
ureterorenal~1
pain-induced~1
eighteen-year-old~1
aplasia,~2
embryology.~1
behaves~2
Image-guided~1
Marshall-Marchetti~4
urethrovesical~2
invalidated~1
Urodynamics,~1
anesthetic)~2
cystolysis~1
supratrigonal~1
colocystoplasty~1
ruling~3
anesthesia).~1
although,~1
demonstrable,~1
(unless,~1
encountered).~1
profilometry,~1
etc.),~2
cystourethrography,~2
tomography),~1
appropriateness.~1
Catharantus~5
vindesine.~1
albumin-coated~1
4-54%~1
microtubule-dependent~2
ECG-changes~1
p.a.,~1
p.a.~2
inversion)~2
Endocarditis~3
electro-~1
V6,~2
sparkling~3
reclassify~1
(0.075-0.675~1
rest:~1
0.5-8.7~1
rest-obstruction,~1
embolectomized~2
anamnestic~1
mmHg/l/min),~1
affection~1
Ergometer~1
anaerobic,~1
learns~1
talk.~1
habilitative/rehabilitative~1
radiocapitellar~1
extended,~1
pronated~1
Self-destructive~2
often-asked~1
again?"~2
debriding~1
Ciguatera~1
foodborne~1
Indo-Pacific.~1
Ciguatoxin,~1
algae,~1
self-limited.~1
publicity~3
anguish~1
homes:~1
unesthetic~1
privacy,~1
exemplary~1
compassion.~1
Knowledgeable~1
dispel~1
myths~2
Codependency~1
family-system~1
"shameful~1
codependent~1
visibly~1
atherocardiovascular~1
prohibiting~2
surgically-excised~2
(2DE)~3
anuli~3
separation/AC~1
Chordal~1
(4.2)~1
(3.1,~1
random,~6
unequal~6
MVP.~5
0.0025).~2
MVP,~5
0.00002),~2
Echocardiographically~1
"of~1
significance."~1
(2D-ECHOs)~1
2D-ECHO~3
686~1
563~2
12.0%~1
arteriosclerosis-related~2
ancrod,~1
viper,~1
Agkistrodon~2
rhodostoma,~1
Open-chest,~2
Ancrod~1
ancrod.~1
ancrod~4
U/kg);~1
single-vessel~2
micromanometers,~3
subcritical~1
nonstenotic~4
near-critical~1
computer-aided:~1
interval:~1
outperforms~1
P-P~3
(733~1
(884~1
15:~2
IV:~2
N.S.).~2
propafenone,~1
M-4.10(-5)~1
5.10(-6)~1
(5.10(-5)~1
fiber-ventricular~1
(APD),~1
depressing~4
automaticity;~1
40.2~1
(14%;~1
(27%;~1
(12%;~1
(8%;~1
dp/dtmax~1
(9%;~1
(17%;~1
venodilator~1
subsidiary~1
bradycardia/tachycardia~1
DVI~1
SLE);~1
(inactive~1
SLE).~1
(-dD/dt)~1
(2.57~1
3.37~2
cm/sec,~4
(+dD/dt)~1
4.41~1
-dD/dt~3
dD/dt~1
3.29~2
4.23~1
+dD/dt.~1
+dD/dt~1
-0.71~1
bullet.~1
WFW~1
subjects).(ABSTRACT~1
1.5-cm3~1
(VS).~1
counting;~1
9%),~1
fluoroscopically~1
disordered.~1
0.0055).~1
(BDA)~1
1.1).~1
BDA~2
Aneurysm~2
arch.(ABSTRACT~1
atm.~1
4.3).~1
obstruction.(ABSTRACT~3
VSDs~6
subarterial~3
membranous,~2
anomalies:~1
twist,~1
malaligned~2
VSDs.~1
effusive~3
all)~2
recordings,~3
beam-flow~1
deceleration,~1
Womersley's~1
0.54)~1
-0.47)~1
0.30)~2
-0.11)~1
deceleration.(ABSTRACT~1
(color~2
4-chamber~3
-0.64).~1
septum.(ABSTRACT~1
cardioactive~1
suprasternal~1
folate/kg~1
absorbability~1
(0.89~1
d-1)~2
neomycin-treated~1
(RDI)~3
76-kg~3
62-kg~3
phylloquinone,~1
K-producing~1
(5.11~1
mmol)~4
scurvy,~1
1-mo~1
(227~1
mumol),~1
RDI~2
Advisable~1
[0.07~1
mumol/g])~1
506~6
caliper~7
Subcutaneous-fat~1
Lange~1
2130~1
weighing,~1
g/mL~2
41.7%~1
7.8).~1
0.820)~1
calipers~3
0.633).~1
low-carbohydrate,~1
3-d~1
carnitine-rich~1
abetalipoproteinemia.~1
salt-activated~1
(omega~2
(MHD)~1
MHD~3
nonfasted)~1
nonfasted).~1
homocystine,~2
cysteine-homocysteine-mixed~1
(MDS),~1
homocysteine~2
MDS,~2
taurine;~1
Protein-bound~1
predialysis,~1
pervasive~1
xylitol,~2
pentose-sugar~1
solid-food~1
scrambled-egg~1
(T-1/2~1
xylitol~4
preloading~2
xylitol.~1
unrelated.~1
grandparents'~1
northern,~1
malabsorbers~1
tocopherols~1
6.02~1
micronutrients;~1
28-86~1
uncontrolled,~1
micronutrients.~1
folacin~7
Folacin~1
morning;~1
1300-1450~1
0.74-0.93)~1
Arsi~1
Bale~1
monocrop~1
farming.~1
villages~6
settlements~2
low-vitamin~1
omnivores~2
vegetarians~2
omnivores.~1
vegetarians,~3
Pyridoxine~3
(PDM)~1
PDM~2
0.90454~1
0.9266~1
8.3%~3
prepubescent~1
six-county~1
7,100,000~1
inhabitants)~1
inclusively,~1
nonteaching~1
endemically~1
1.58:1,~1
Hispanics,~3
62%;~2
32%;~1
Asians,~1
half-white/half-Asian,~1
overrepresented~4
old;~4
Japanese-American~3
zip~1
84.7~2
2.75:1.~1
outfits~1
dress~4
outfit~1
intern~1
enteroviruses,~1
swab,~2
Enteroviral~1
virology~1
tray.~1
hydrolyse~1
(ammonia).~1
"microtiter~1
bacterium;~1
colonizes~2
chronic-only~1
bacterium.~1
achalasia.~2
postdilation~1
dilatations,~1
(1-6~1
(duct~1
Wirsung)~1
typical;~1
ileocolonic~2
717~4
YY.~1
excreta,~1
ileostomies~1
interdicted~2
juice)~2
ileostomates~2
excreta~1
constipated,~1
senna~5
moisture.~1
evident;~2
laxation~2
Bacteremic~1
immunodeficiency,~1
Shigellemia~1
require,~1
reabsorption,~3
500-1000~1
93.67~1
102.47~1
15.22%,~1
89.33~1
25.4%~2
127.48~1
28.44%,~1
2362.19~1
845.08~1
3085.1~1
837.92~1
4675~1
1204.09~1
5791.56~1
1033.99,~1
70.1~1
12.79%,~1
77.74~1
9.18%,~1
achalasic~1
nasoesophageal~1
trichobezoar~1
"tail"~1
bezoar.~1
trichobezoars~1
non-acquired~1
62-yr-old~2
paucimobilis~1
(GDH;~1
E.C.1.1.1.47)~1
Malays,~1
(GDH4~1
GDH5)~1
GDH~2
GDH1,~1
GDH2,~1
GDH3~1
nearer~1
Amniotic-fluid~1
leucine-aminopeptidase~1
positives~7
96.5%~2
25%-at-risk~1
tempting~1
gametogenesis.~2
assignments~3
cytogeneticists.~1
multipoint~2
linkage,~1
likelihoods,~1
Markovian~1
Morton~1
MacLean~1
multiple-region~1
nine-locus~1
Morgan~1
seven-locus~1
Weinstein~1
Rao~1
.33~1
meiosis~1
robust.~1
recombinants.~1
Diuretic-induced~1
potassium-sparing~3
quinidine-related~2
Torsades~2
pointes,~2
Hypomagnesemia,~1
pointes.~1
digitalis.~4
Refractory~2
repleted~2
Potassium-/magnesium-sparing~1
risked.~2
(Maxzide,~1
triamterene/50~1
hydrochlorothiazide)~1
Neurohormonal~1
structural,~1
(Maxzide).~1
switch.~1
Maxzide~1
Memphis~1
Redundancy~1
redundancy.~1
"pill~1
electrode"~1
swallowed,~1
preamplifier~1
three-channel~1
"pill"~1
(renal)~2
enterics~1
sensitivities.~1
infections;~3
wards~3
non-neutropenic~2
faecalis~3
CDC-JK~1
CDC-JK,~1
Neutropenic~1
sequentially.~3
single-organism~2
(MEN-1).~1
deceased,~1
MEN-1~3
MEN-1,~1
natural,~1
MRC~2
2.96~2
2.57~2
2.86~1
sputum.~4
Exudative~1
Bronchoscopy~5
rigors,~1
leukopenia.~2
flare,~4
Collected~1
Armenian-born~1
panniculitis,~1
quiescence.~1
61-year-woman~1
periarteritis~3
Thrombotic~2
Alcohol-induced~1
pseudo-Cushing's~3
17-hydroxysteroids~1
lupus-like~1
36th~2
antibody-sensitized~2
monocyte/platelet~1
rosettes~2
Anticytomegalovirus~1
(VHLD)~1
erythrocytosis:~1
hemangioblastoma,~1
VHLD~1
erythrocytosis~1
VHLD.~1
erythrocytosis.~1
propellants,~2
(IVIG)~1
12F,~3
toxoplasma~1
diphtheria,~1
tetanus.~1
IVIG~3
(febrile~1
work/school,~1
hospitalizations)~1
alkylated~2
scaled-down~1
filters:~1
(80-90%)~1
(10-30%)~1
remixed~1
longitudinally,~4
sickness),~1
hematinic~1
process:~1
Leukocyte-conditioned~1
1.4-3.0~1
Chemotherapy-induced~2
droperidol.~2
cisplatinum.~1
phenobarbital/droperidol~1
(read~1
radiologists)~1
0.70.~1
Receiver~4
Pursuit~1
MM-CK~2
MB-CK~1
MM3-CK,~2
MM2-CK,~1
MM1-CK~1
(8.65~1
(18.50~1
6.67~1
MM3-CK~2
MM2-CK~1
MM1-CK;~1
MM3-CK:MM1-CK~3
amplifies~1
(5.51~2
H)~1
(10.74~1
3.28~2
reperfuse~1
SK~1
CK,~3
MB-CK.~1
pressure/end-systolic~2
[PSP/ESV],~1
load-insensitive~1
4,829~1
PSP/ESV~8
.09)~2
101)~1
2.292.~1
.0026)~1
1.237~2
(3-year~1
79.2%,~2
2.292~1
89.3%,~2
54.1~2
(197~2
30.3~4
(226~1
(LDL):~1
3.78,~1
3.24,~1
dialyzed,~1
undialyzed,~1
Lecithin:~1
nmol/ml/hr),~1
(73.3~1
112.8~1
nmol/ml/hr).~1
(RCT)~1
order:~3
(1.85~1
mg/dl/hr)~2
(2.41~1
(4.83~1
mg/dl/hr).~1
HDL3~2
Apoprotein~1
0.9501)~1
-0.148).(ABSTRACT~1
containment.~2
ascertaining~3
insensitive.~1
trabeculectomies~1
kW/cm2.~1
preultrasound~1
postultrasound.~1
postultrasound~1
neuroretinal~2
.75)~1
glaucomatous~13
Cup~1
cup-to-disk~1
3.1-year~1
indices:~1
scotomas~2
decibels,~2
decibels).~2
S.E.M.,~3
mm2)~2
(1.33~1
mm2).~1
rims~1
hexagonal~2
head-down~3
Gonioscopy~2
.80,~1
Schlemm's~1
gonioscopy,~1
lacquer~1
cracks,~1
Lacquer~1
staphyloma;~1
spider-web~1
curved,~1
perineural,~1
temporally.~1
Retinal~6
Contusive~1
hypoparathyroidism,~1
manifested.~1
self-limited,~3
Keratitis~1
Branhamella~3
catarrhalis,~2
gonorrhoeae,~2
nonpathogenic.~1
paracentral~1
diplococci~1
convergence,~1
accommodation,~1
(cerebellar~1
malformation),~1
vestibulopathy,~1
Black/New~1
(B/W)~1
omega-3~4
(fish~1
FO).~1
FO~6
(lard,L)~1
(CIC)~1
anti-ds-DNA~1
CICs~1
B/W~6
T-independent~2
(DNP-dextran)~1
(sheep~1
YAC-1~3
Arteritis~2
immune-complex-induced~1
Immaturity~1
(myofibroblasts)~1
fibrocytes~4
microfilaments,~2
NBD-phallacidin,~2
mushroom~1
f-actin~1
oligomeres~1
g-actin,~1
(1-7~1
fibrocyte,~1
microfilaments~1
NBD-phallacidin~1
myofibroblasts,~1
cell-cell,~1
cell-matrix~1
attachments.~2
isoactins~2
fibrocyte~1
fibroblastlike~1
myofibroblast,~1
carbon,~1
extraglomerular~2
Electron-microscopic~1
scarcely~3
(immune~3
mesangium,~1
lacis~1
Chronicity~1
charge-mediated~1
amidated~1
(aBSA)~1
polycation~3
aBSA~2
aBSA.~1
noncartilaginous~1
protamine,~2
Protamine~2
apposition.~1
Umbilical~4
pseudopods~2
indenting~1
(M199~1
Gey's)~1
indented~2
25-35%~2
single-cell-derived~1
Wide-ranging~1
"mixed~2
epithelial-mesenchymal"~2
hepatoblastomas.~1
"sarcomatous"~1
myofibroblasts.~1
"sarcomas"~1
ultrastructurally,~2
carcinosarcomas~1
hepatoblastoma.~1
transiently,~2
pseudopregnant~3
DI,~5
apoptosis~1
(97.5%),~1
(2.5%).~1
21-54~1
dating,~1
endometritis).~1
Leu-1~1
PD7/26),~1
pan-T-cell~1
(UCHT1),~1
(Leu-3a~1
UCHT4,~1
pan-B~1
(To15~1
Leu-12),~1
(UCHM1~2
Leu-M3).~1
TAL-1B5~1
(anti-HLA-DR),~1
1/34~1
(anti-T6/Langerhans/interdigitating~1
(occupying~1
stroma),~1
secretory/pre-menstrual~1
(20-25%~1
stroma).~1
periglandular~2
HLA-DR+)~1
Leu-7+~5
dendritic-appearing~1
1/34+~1
5/30~1
T6+~6
Langerhans/interdigitating~1
contribution,~1
HDLM-1~3
(ECM)-coated~1
flasks.~1
ECM-induced~3
HeFi-1-negative~1
2H9~1
1E9~1
acid-phosphatase~1
H-RS~1
interdigitating~1
mucosubstances~2
Bonnet~3
hr/day)~1
exsanguinated.~1
Karnovsky's~1
fixative,~2
decalcified,~1
2.5)/periodic~1
diamine.~1
Quantimet~1
mucosubstance~2
Nasopharyngeal~2
terminators~1
dynamically~2
dropouts,~1
conceptualizing~1
dropouts.~1
evaluate.~1
symptom.~3
"essential"~1
delirium;~1
cry~6
War,~1
fought~1
battles~1
impact;~1
testifying~1
molestation.~1
omission,~1
authoritative~1
ingratiating~1
attorney~1
attorney's~1
preconceived~2
notions,~1
age-inappropriate~1
harmed~1
testifying.~1
traumatization~1
judge's~1
screens.~1
predictions.~1
histrionic~1
paranoid,~3
compulsive,~1
psychoanalysis~1
transference.~1
unfolded~1
phenelzine.~1
self-referred~1
Asians;~1
torture.~1
health-seeking~1
providers.~2
Cambodian,~1
Laotian,~1
Vietnamese~1
Checklist-25.~1
psychiatry.~3
advising~2
hostility,~1
irritability,~4
derealization,~1
bulimic~3
diet-restricting~1
anorexic~4
Familiar~1
Figures~1
schizophreniform~1
contexts,~2
machine-estimated~1
(expired-air~1
thiocyanate)~1
713).~1
cigarette,~3
ultralow-yield~2
higher-yield~1
expired-air~2
thiocyanate.~1
thiocyanate~2
Machine~2
underrepresent~1
4,652~1
(ELISA).~2
seropositivity~3
(inverse~1
seronegatives~1
time-of-screening~1
(RRs)~1
geophagia~1
3.14;~1
5.64)~1
5.22;~1
1.63,~1
16.71).~1
anti-hemagglutinin-A~1
confounders~1
practitioners'~2
requests,~1
prescriptions,~1
Doctors~6
patient-physician~1
incurs.~1
Pontiac~1
building~6
Manhattan~1
City).~1
overall);~1
tower~2
Pneumophila~1
Airborne~1
settle~1
serogroup~1
tower.~1
skinfold,~4
Brownsville,~1
14-17,~1
fatness.~1
Brownsville~1
Americans.~2
745~1
(acquired~2
non-ill~1
alpine~1
villages,~1
bacteria:~1
coliforms,~2
thermotolerant~1
(fecal)~1
gastro-intestinal~1
(AGID)~1
29,272~1
teachers.~2
loglinear~1
streptococcus~2
predictor;~1
contributions.~2
AGID.~1
Hitchcock~1
(OR)~2
(95%CI)~1
1.3-3.2)~1
95%CI~4
1.3-3.7)~1
7.4-37).~1
3.2,~2
1.5-7.2)~1
camping~1
0.9-3.2)~1
barnyard~1
proximity.~1
non-response~1
materially~3
(Black-White)~1
1,490~1
two-to~2
14-year-olds.~1
(TRSF)~1
Rohrer~4
(weight/height3)~1
levels:~2
TRSF~2
0.57)~1
85th~3
TRSF,~1
Severe,~2
obesity/overweight~1
percentile)~1
obese/overweight.~1
malleable,~1
Maine~1
penalties,~1
crashes.~2
single-vehicle~2
crashes~11
Maine's~2
pre-law~3
Massachusetts'~1
arrested,~1
convicted,~1
penalties.~1
But,~1
spouses'~1
609~1
781~2
spouse.~1
smokes~1
(Cuba,~1
Rico).~1
Numerators~1
(NCHS)~2
tapes,~1
certificate.~2
Denominators~1
census.~1
Cuban-born,~1
Mexican-born~1
Rican-born~1
Aged~2
migrants,~1
licit,~1
illicit,~1
State.~1
cigarettes,~1
pills.~2
marijuana.~2
polls,~1
Michigan,~4
contradicted~1
commissioned~1
polls~2
phrasing,~1
rotated,~2
prejudicial.~1
Nicaragua~1
1979-82.~1
Nicaraguans~1
Nicaraguan~1
contra~2
troops.~1
settlements,~1
76/1,000~1
Internationally~1
protections~1
intensity"~1
epidemics,~1
await~4
hostilities.~1
notification~4
statue~1
statute~1
statute.~2
non-Hispanic~5
Albuquerque,~1
Southwestern~1
Hispanics~2
cigarette-related~1
Reporting~1
(cleft~1
palate;~1
palate)~1
2.39,~1
clefting.~1
clefts.~2
cue~3
2217)~1
1984/85.~1
91,651~1
30-55~1
1963-73~1
1948-58.~1
1969-80,~1
Whites;~2
four-fold.~1
(Texas)~2
13.7).~2
facilitators~1
Peer~1
facilitated.~4
poor:~1
perforations.~3
telescoped~3
month;~2
three-score~1
centralization~1
clinic;~3
incarceration;~1
services;~1
anesthesia;~1
protocol;~2
herniorrhaphies~2
Syria.~1
Explorations~1
gastrectomies,~1
conjugated,~1
remnant,~2
(N-carboxymethylnormorphine~1
(201~1
meperidine.~1
(0.8%,~1
oxide/oxygen/muscle~1
relaxant.~2
chlorodifluoroethylene~1
(CDF),~1
chlorotrifluoroethane~1
(CTF)~1
Indocyanine~1
CDF~1
CTF~1
postanesthesia~1
(halothane).~1
(ALT)~1
necrosis;~2
normoxia.~3
(SCh)~1
SCh,~3
SCh~7
fasciculation~1
SCh-induced~1
(SCh:~1
increments)~1
(0.94%,~1
tidal)~1
SCh.~1
304%~1
115%.~1
360%~1
290%~1
watch~1
Bucking~1
Intubating~1
"excellent"~1
"Fair"~1
flunitrazepam~3
Trieger~1
aminophylline.~1
Aminophylline~4
flunitrazepam.~1
mepivacaine~9
1-hr~6
intervals;~2
epinephrine-containing~4
mepivacaine.~2
(MCAO).~1
N2O/fentanyl~1
MCAO.~1
MCAO,~2
O2/air)~1
(2.0%~2
SD);~2
(O2/air)~1
total);~1
N2O/40%~1
nitroprusside/hydralazine~1
phenylephrine/metaraminol,~1
(isoflurane)~1
hemiplegic,~2
7/7~1
(thiopental)~1
2/6~1
(N2O/fentanyl)~1
(3/6~1
infarctions).~1
0.055.~1
Infarctions~1
compared).~1
vasodilators).~1
ionization~4
(14,~2
3:1),~1
[Ca++]~3
(minutes);~1
gluconate;~1
pyridostigmine,~3
thiopental-nitrous~1
oxide-enflurane~1
Train-of-four~2
(0.005,~1
pyridostigmine~7
(0.02,~1
allocation.~1
ED50's~1
0.013,~1
0.017,~1
d-tubocurarine,~1
flatter~2
relaxants,~2
postconception~1
pneumocardiograms~1
(6-15~1
(72%);~1
-0.70)~1
pneumocardiogram~1
83%).(ABSTRACT~1
epoch~6
64-s~1
Epoch-to-epoch~1
bins~1
ANOVA~2
hierarchal~1
epoch-to-epoch~1
epochs~5
(4-s)~1
epochs.~1
burst-suppression~1
16-s~1
epochs).~1
preferability~1
Intrathecally~1
(50-750~1
mcg),~1
clonidine-morphine~1
(clonidine~1
mcg~2
mcg.~1
clonidine's~3
Antinociception,~1
idazoxan.~3
Epidurally~2
glands.(ABSTRACT~1
Ephedrine,~1
(MMAP)~1
(1.5-6.0~1
ug~1
(MHR)~1
prebleed~3
enflurane/nitrous~1
oxide/oxygen;~2
enflurane/air/oxygen;~1
isoflurane/nitrous~1
isoflurane/air/oxygen.~1
N2O,~2
(180-210~1
176-201~1
190-209~1
cerebrovasodilation~1
catheterized,~1
862~2
normocapnia~3
decubitus;~1
(LFRC)~1
Costal~2
LFRC~1
non-dependent~1
post-inspiratory~1
7-8%~1
crural,~1
costal,~1
(vecuronium,~1
d-tubocurarine)~1
multiwire~1
(pO2)~1
exerting~2
extraintracranial~1
microcirculation,~2
Swelling~1
Venography~1
User~1
"friendly"~1
(SICU)~1
quantify,~2
(A.S.)~1
Trending~1
custom-designed~1
designs.~4
Sarcoidosis~1
granulomatous,~1
(usually)~1
Preexercise~1
"zona~3
glomerulosa,"~1
fasciculata,"~1
innermost~1
recticularis."~1
neuroectoderm,~1
Adrenal~9
pheochromocytoma)~1
Brassica~2
coleslaw~1
cabbage,~1
cauliflower,~1
broccoli~1
ultraviolet-absorbing~1
Allergenic~1
pollinosis~2
exhausts.~1
Emphysema~2
saving.~1
(1:1~2
dilution;~1
dilution).~1
(microgram/mL)~1
0.64;~2
3.4;~1
undiluted;~1
paced.~1
metropolitan-rural~1
(pulses)~1
capture,~4
scuba~6
divers.~3
dysbaric~2
(DAE)~1
diving-related~1
DAE~2
dysbarism~1
multiplegia~1
usefulness,~2
(CPK)~2
CPK~3
isoenzymes,~2
echocardiograms.~3
echodense~1
post-catheterization~1
Catheterizations~1
house-staff~2
RBC/hpf.~1
rigorous,~1
semi-annual~1
audits.~1
manuevers~1
succinylocholine~1
97.~1
pCO2.~1
Narcotic-induced~1
intralingual~1
unobtainable.~1
misread~2
ambulating~1
Crural~1
Mycoplasmal~1
imported~4
shining~1
coins.~2
rheumatological~1
Baker's~2
(Baker's)~1
male):~1
ceruloplasmin,~7
(AIBC),~1
(AOA);~1
AIBC~5
AOA;~4
AIBC,~2
AOA,~3
AIBC.~2
additively,~1
AOA~4
ceruloplasmin;~1
it;~1
constituent(s)~1
nonsmokers;~1
FEV1/Ht3.~1
"slope"~1
"level"~1
"horse-racing~1
effect"~1
FEV1/Ht3~1
predictors,~2
prognosis.(ABSTRACT~1
1,705~2
Ex-smokers~1
quitting~1
(DL)~1
non-Mexican-American~1
ATS-sponsored~1
DL,~1
(VA),~1
DL/VA.~1
DL~1
DL/VA~1
asbestos-related~1
pleuroparenchymal~1
Restrictive~1
ventilatory,~1
circulatory)~1
(49.2%)~1
(EIA)~1
hypertonic-saline-induced~2
EIA~2
EIA,~1
inhaled.~1
interchangeably,~1
hypertonicity~2
SO2.~1
dogs'~1
bronchoconstrictors.~2
ppm),~10
MBP.~3
Tapes~2
axonemes,~2
axonemes~1
alteration.(ABSTRACT~1
PMN,~2
Catalase~1
(25,000,~1
100,000,~2
3-aminotriazole,~1
catalase.~3
PMN-dependent~1
scavenging.~1
inadvertantly~1
catalase-treated~1
ng/kg,~1
pneumococcus~1
incite~2
pneumococci,~4
polysaccharide,~1
subcomponents.~1
Leukocytosis~1
penicillin-induced~1
noncomplement-mediated~1
bronchiolitis.~2
(TRAIIFR)~1
pmol/min)~1
nonedematous~1
(19.9~2
pmol/min),~1
TPAIIFR~3
AI~1
(HVR),~1
climbers.~1
Denali~1
(Mt.~1
McKinley)~1
4,400~2
(PB~2
HVR~3
SAO2%~1
SaO2%~1
SaO2%)~1
acetazolamide.~2
hyperbolically.~1
4.10~1
48.70~1
21.00~2
cmH2O/L/s~1
hyperoxic-induced~2
(PtcCO2),~1
(VCO2),~1
(VD/VT).~1
SaO2,~1
VCO2,~1
VCO2~1
VCO2)~1
VCO2.~1
VD/VT.~1
(FLS)~1
upstream.~1
FLS.~1
closed-circuit~2
rolling-seal~1
spirometer~5
(expiratory~1
assistance,~3
EA).~1
H2O/L/s)~4
C2).~1
Sense~1
-0.2~1
(-0.3~1
(+2.25~1
(+1.5~1
(SIP).~1
(SIPmax)~1
SIP.~1
inspire.~1
PETCO2.~1
(MIP).~1
(PmPeak)~1
PmPeak/MIP~1
Two-minute~1
(I-O),~1
(cum~1
I-O),~1
cum~4
I-O~4
I-O.~1
125I-fibrinogen.~1
ensued~6
particle-bound~1
9.3-fold~1
referenced~3
(PA/PC)~1
17.8-fold~1
inert.~1
minced~1
(LGL)~3
11b~2
anti-Leu~1
7+~1
11+~2
compartmentalized~1
NK-active~1
cooperative,~1
height;~1
(ml)~3
-457.3~1
0.662),~1
0.0052~1
[height~1
(cm)]2.44~1
0.827).~1
elevations,~1
scavenger,~2
(DMTU)~1
DMTU.~1
neutrophil-derived~2
Salla~2
intralysosomal~2
nonsmoker~3
alpha-1-antitrypsin~2
lobules,~1
965~1
oriental~1
descent).~1
"giant"~1
patients--that~1
waves).~1
succession~1
axillary,~2
Bacteriuric~1
nonbacteriuric;~1
(52%,~1
(change,~2
-32%,~1
+40%,~1
Objective:~1
Design:~1
Randomized,~1
double-blinded,~2
Setting:~1
Patients:~1
Volunteer~1
Interventions:~1
Aerosols~1
manufacturers'~2
canisters,~1
triamcinolone.~1
(beclomethasone~1
acetonide),~1
propellant~1
(trichloromonofluoromethane~1
dichlorodifluoromethane,~1
dichlorodifluoromethane~1
dispersant~2
(oleic~1
Results:~2
beclomethasone,~1
(difference,~2
16.9;~1
12.36~1
21.34;~1
Coughs~1
puff.~1
coughs~1
triamcinolone,~1
35.3;~1
22.62~1
47.98,~1
Asthmatic~1
inhale~2
wastage;~1
spectrum;~1
misdiagnosed,~2
characterizations~2
Dallas~2
textbooks~1
pattern;~3
fever;~2
eosinophilia;~1
1985-86.~1
foreign-trained~1
Graduate~2
shortage~2
survivors'~3
gift~1
Histocytology~1
30-150~3
binucleated~1
(tarda)~1
pseudo-achondroplastic~2
vitiligo,~3
Ticks~1
infest~1
Amblyomma~1
americanum~1
woodsman's~1
truck~2
tire~2
inferonasal~1
two-year-old~2
blow-in~1
ophthalmicus.~1
limbal-mass~1
20/200.~3
Subretinal~1
Coats's~4
ten-month-old~1
aqueous:serum~1
(6:1).~1
retinoblastoma.~6
compassion~1
result/litigious~1
patient"~1
ora~2
serrata~2
angiomatous~3
retinopathies,~2
classification's~1
Harrison's~2
newborns,~4
inverting~4
11a.~1
spondylosis~6
hyperostosis~4
hyperostosis.~1
Laryngotracheal~1
perceptual-physiologic~1
collectively~5
speech-otolaryngology~1
videolaryngoscopy,~1
biofeedback~9
(tubal~2
tensor~3
veli~4
palatini~4
1-day-old~3
chinchillas~1
audiometric~1
Al2O3~1
Pneumosinus~1
dilatans~2
anatomic,~3
hypercoagulability~3
Audiometric~2
striae~1
coexistent,~1
Metastasis~3
Fungal~2
9-deazainosine~2
pentavalent~1
antimony,~1
(Ansamycin)~1
Killing~1
clofazimine~1
nitrocefin~1
porin~2
nS.~1
Saccharomyces~2
boulardii~2
difficile,~1
difficile-associated~3
"persister"~1
0.01%.~1
Resultant~1
strain-dependent~1
deviation];~1
dose-interval~1
cephalosporin,~6
BMY-28142,~1
acetonitrile~3
dichloromethane.~1
discarded,~1
4.25)~1
BMY-28142~3
38.7~4
enterobacteria~1
Lanka.~2
dihydrofolate~4
antifolates.~1
plasmid-borne~1
Cloning~1
sulfonamide~3
Lanka~3
transposon~1
Tn7~1
dominate.~1
sulfonamide.~2
ducreyi~1
chancroid.~1
(RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine~1
(2HM-HBG)~1
2HM-HBG,~1
kinase-negative~1
2HM-HBG.~1
VZV.~1
2HM-HBG~2
deoxythymidine~1
deoxycytidine~2
ribo-~1
deoxyribonucleosides.~1
Sch~11
34343,~1
penem~1
34343~7
eq/ml~1
7.52~1
23.6%~3
34343.~1
3-day-old~1
(13.1~1
[dry~2
wt];~1
20-day-old~2
(MICs,~3
microgram/ml),~4
Enterococcus~1
efficacy;~1
symptomatically,~1
nonhematogenous~1
Enterobacteriaceae,~4
salivarius~1
(MBC,~4
(CD50s)~1
CD50s~1
CD50~2
197.5~1
15-mg/kg~2
30-mg/kg~3
slowly,~3
91.7~1
28.1~1
end-dwell~1
infusion-related~1
dialysis-related~1
Broth~1
(0.13~1
anaerobius~1
(0.11~2
tinidazole~2
nitroimidazoles~1
positively,~2
extreme,~2
2,727~1
8,840~1
teicoplanin,~2
glycopeptide~2
cures,~2
teicoplanin~5
cured;~1
streptococcus)~1
methicillin.~1
drug-accumulation~1
(D.L.~1
Stevens,~2
K.A.~2
Maier,~1
B.M.~1
Laine,~1
J.E.~1
Mitten,~1
Infect.~1
Dis.~1
155:220-228,~1
1987)~1
perfringens.~1
toxin-suppressing~1
macrobroth~1
MBC~4
ATCC~1
13124.~1
(micrograms~1
milliliter):~1
0.69;~1
MIC/MBCs~1
1.50/3.10~1
(micrograms/ml).~1
alpha-toxin~7
MIC.~3
log-phase~1
Clindamycin,~1
turbidity,~1
turbidity~2
(62.6%~1
Tetracycline~5
viability;~1
detectable.(ABSTRACT~1
curtisii~5
mulieris~5
virginiamycin,~1
imipenem.~1
josamycin.~1
colistin,~2
cycloserine,~1
hydroxy~4
tinidazole.~1
alizarin~1
Nile~2
mulieris.~1
metronidazole-resistant~1
vaginosis.~1
tinidazole,~1
A-56619~4
aryl-fluoroquinolones,~1
nafcillin.~3
A-56620~6
beta-lactams~2
expanded-spectrum~1
noninfected,~1
1.0-g~2
liter/kg.~1
(10(5)~1
CFU).~1
40.~5
acyclic~1
S-enantiomers~1
9-(3,4-dihydroxybutyl)guanine~1
[(R)-~1
(S)-DHBG],~1
9-(4-hydroxybutyl)guanine~1
(HBG),~1
9-(2-hydroxyethoxymethyl)guanine~1
(ACV)~1
triphosphates~4
Ad.169.~1
0.0076~1
(R)-DHBG,~1
(S)-DHBG,~1
HBG~1
dGTP.~2
poly(dC)oligo(dG)12-18~1
poly(dA)oligo(dT)12-18.~1
dGTP,~1
antipseudomonal~4
cefuroxime,~1
ceftriaxone,~2
ceftizoxime,~2
latamoxef,~1
ceftazidime.~1
aztreonam.~1
Vancocin~1
(vancomycin~1
hydrochloride;~1
Eli~1
Lilly~1
macrotube~1
subculture.~1
adenoviruses~1
(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine~1
[(S)-HPMPA]~1
9-[(2-hydroxy-1,3,2-dioxaphosphorinan-5-yl)oxymethyl]guanine~1
P-oxide~1
(2'-nor-cyclic~1
GMP),~1
(S)-HPMPA~1
2'-nor-cyclic~1
lipopeptide~3
bile/serum~1
micrograms/g.~1
L-[U-14C]valine~1
delta-(L-alpha-aminoadipyl)-L-cysteinyl-D-valine~1
DL-methionine~1
Acremonium~1
chrysogenum~1
broths,~1
DL-Norleucine,~1
nonsulfur~1
norleucine.~1
'idiopathic'~2
post-irradiation~4
retesting~1
leukaemia,~3
5)).~1
(permanent~2
2)),~1
(0.5)~3
cm/year~4
(1.75)~1
Moslem~1
centiles,~1
babies--that~1
centile--in~1
cousin~1
tolazoline.~1
Tolazoline~1
4-14~1
enmeshed,~1
chaotic~1
disengaged~1
non-steroid~1
(long~1
Heredity~2
Atopy~1
atopy:~1
(1/18)~1
(5/13).~1
Diarrhoea~1
hypercholesterolaemia~4
textured~1
-21.8%~1
afterwards,~3
triglyceridaemia~1
counselling.~1
Pink~1
teething~1
powders~1
vapour.~1
spilled~1
povidone~1
1000.~2
year-old,~1
unforthcoming.~1
airborne~8
(neutral,~1
acidic,~1
basic)~1
carcinogenicity.~1
Mutagenicity~1
TA100~1
TA98~1
4/25;~1
7/25;~1
0/20;~1
1/11;~1
2/39;~1
uninjected,~1
3/47.~1
1.90~2
videomicroscopy~1
cigarette.~3
pre-smoke~1
3/sec.~1
post-smoke~2
3/sec~1
low-,~1
medium-,~1
high-nicotine~1
exhaled~4
acatalasemic~3
reoxidized~1
Mercuric~1
nitro~1
NADH~4
kerosene~3
kitchen.~1
glycosaminoglycans-rich~1
kerosene,~1
glare~8
Professional~9
nonprofessional~2
non-driver~1
(VES)~1
VES~1
(PPs);~1
(ABs)~1
(UMFs)~1
Turin~1
large-size~1
PPs~3
bilateral)~1
UMFs/g~1
unilateral),~1
ABs~2
UMFs~2
10,000/g,~1
500/g~1
UMF~1
100,000/g.~1
municipalities~2
fluoridation~2
chlorination.~1
depth-associated~1
226,~1
strontium,~1
Atlas~1
localizations,~1
clusterings~2
wealth~3
28.1%,~1
69.5%,~1
93.1%,~1
ozone.~2
function-sparing~1
LSS~1
(LSS~1
angiosarcoma,~2
(p2~11
isosignal~1
auspices~1
Surgeons.~1
1977-1978~2
(2355~1
645~1
1983-1984~1
(3457~1
(AJCSS)~1
AJCCS~1
locoregional,~1
Salvage~2
favored,~1
esophagogastrostomy~2
8.9%.~1
39.4%~1
30.2%,~1
restricture~1
(PTD).~1
"accordion"~1
cholangiogram;~1
PTD,~1
PTD~4
(3/42)~1
mono-octanoin~1
dilatation),~1
maltreated.~1
aspiration;~1
(persistent~1
cysts),~1
cystenterostomy~1
watched~3
pancreatography,~1
chambered~2
nonulcerated~2
hour),~3
non-ulcerated~1
value"~1
nonrecirculating~1
steady-state,~1
Piperacillin~1
taurocholate)~1
mumol/h,~2
(perfusate~2
micrograms/h,~1
salt-independent~3
choleretic~4
multiple-valve~1
Preoperative,~1
intraoperative,~1
5.6%,~2
16.7%.~1
.03,~1
improvement-of-fit~1
square)~1
(mortality~1
esophagopleural~2
coaptation~1
cusps~4
Starr-Edwards~3
(SE~4
6120~2
6400)~1
replacement:~2
33.4%~1
32.3%~2
2400)~1
(97.8%)~1
(2.54%~1
patients/yr)~2
(3.47%~1
double-valve~5
proved.~1
prosthesis-based~1
(LEA)~1
LEA.~1
32-channel~1
(Part~1
LEA~6
(means,~2
94.8~1
121.4~1
glutaraldehyde-preserved,~2
prosthesis-to-epicardium~3
peel.~1
ethanol-fixed~1
prosthesis-to-sternum~1
fixatives.~1
prosthesis-epicardium~1
easing~1
(SSEP);~1
snap-frozen~1
SSEP.~1
m-2(p~1
.0003).~1
.028)~1
.028),~1
m-2.~4
(Q~1
m-2.(ABSTRACT~1
nonoxygenated~1
(F-K)~1
F-K~1
Multidose~2
conserves~3
KCl/L)~2
mEq,~1
potassium"~1
207%,~1
390%,~1
681%~1
23.8%~3
138%~2
170%~1
postcardioplegic~1
(1965~1
(124~2
(175)~1
(58)~1
interpositions,~1
antiperistaltic.~1
reexaminations~2
.2751,~1
postperfusion~2
decompressed~6
aorto-bi-common~1
comments.~3
Situations~1
194)~2
Archives~1
109)~2
1953,~2
.82)~1
(cohort,~1
sectional,~1
non-review~1
journal.~1
schizoaffective,~2
post-1940~1
predexamethasone~4
nonsuppressors;~1
unimodally~1
hypothalamic-pituitary-adrenocortical~2
(CAs)~1
CAs.~1
metabolic-dispositional~1
normetanephrine~6
(NM),~1
metanephrine~1
(VMA),~1
(MHPG).~1
CAs~3
precursor-product~2
NM,~1
synthesis;~3
random-assignment~1
nonpharmacologically~1
agoraphobic~1
Panicking~1
1343~1
fibrosus,~2
calcareous~4
fibrosus.~2
degranulating~2
pseudopods,~1
platelet,~4
(0.14%)~1
27-year~2
TB.~1
(cellular)~1
(JCF)~1
JCF~2
neuropathologists~1
gemistocytic~1
astroglia~1
hematoxylin-eosin,~1
cuspid~1
strut.~1
Dissection~2
cerebellocortical~1
kurulike~1
congophilic~1
underused,~1
tan-brown~1
innovation,~1
21st~3
Century--the~1
report--often~1
faculty's~2
handicapping~2
(poor~1
income)~1
educated,~1
earned~1
Pattern~2
Indicators~2
high-resource~1
high-resource,~1
nondisabled~1
recreation~2
tempo~2
SCI.~2
"cortical"~2
grasping~1
"raking,"~1
prehension~3
three-jaw~1
chuck~1
casting.~1
toes,~2
transmetatarsal~1
Successfully~1
(forefoot~1
nonforefoot~1
Torticollis~1
Sternomastoid~1
38.6%,~1
Tenotomies~1
25.3%~2
11.8%~4
bathing,~1
aphasic~3
signing~3
wants~1
signed,~1
pictured~1
Programming~1
electroglottograph~1
nonimpaired,~1
parkinsonian,~1
dysphagic~3
Low-frequency~2
EGG~3
nonimpaired~2
videofluoroscopic~1
supraspinatus~7
Alexia~1
agraphia~2
alexia~1
territory.~2
agnosia.~2
Prosopagnosia,~1
simultanagnosia,~1
visual-motor~2
worldwide.~2
arm-leg~3
arm-single~3
wheelchairs.~1
air-braked~1
Select~1
(PO),~1
(+3.8~1
(+25W)~1
propulsion~4
Prototypes~1
Inflatable~1
ganged~1
battery-operated~1
(SMV-PV)~1
SMV-PV~2
(4/14)~1
(10/14).~1
"Delayed"~1
"immediate"~1
"delayed"~1
complicated:~1
gangrene,~1
phosphate;~1
appendectomy;~1
Transperitoneal~1
(VPs)~1
(AHVECs)~1
Polymers~1
Mylar,~1
Teflon,~1
bioabsorbable~1
(BR1~1
BR2),~1
(EBN).~1
BR1,~1
BR2,~1
EBN~1
AHVEC~3
(56%,~1
AHVECs~2
Mylar~2
VPs~1
VPs,~1
attachment,~2
(ICO)~2
ICO.~3
ICOs.~1
ICO,~1
(1.8%).~2
ICO~1
overestimated,~1
Burlington,~1
Mass.~1
Cystadenoma~1
(3.8%).~2
cystadenomas,~2
somatostatin-14,~1
tetraprenylacetone,~1
somatostatin-14~3
tetraprenylacetone~3
17%).~2
pmol/2~1
Tetraprenylactone~1
oncologists.~3
re-resection.~1
resections,~7
exenterations,~1
(following~1
resection)~2
well-vascularized~3
transferred,~1
distance.~2
extirpative~2
postthrombotic~2
saphenofemoral~1
(SFB)~1
valve-to-popliteal~1
(PVTs)~1
SFB~2
PVTs~1
Electrocoagulation~2
(34/58).~1
(5/16)~1
electrocoagulation.~1
coagulated.~1
"dry-mouth"~1
Ideally~1
(colorectal,~1
gynecologic,~1
Endoscopically~1
radiotherapy)~1
capsulotomies~2
2-mJ~1
4-mJ~1
timolol-pretreated~1
Pretreating~2
Nonpseudophakic~1
(373~3
occludable~2
angles,~2
bombe~1
uveitis,~2
iridotomy,~1
argon)~1
iridotomies.~3
Alaska's~1
Eskimos~5
1686~2
(0.65%)~2
Eskimo~3
Narrow~1
2.65%~1
gonioscopy.~1
countering~1
mydriasis,~2
cycloplegia,~1
tropicamide~4
slight.~2
6/36~1
Unfavorable~1
(combined,~1
buckle);~1
break(s);~1
break;~2
premacular~3
fibroplasia~2
macula.~3
neovascularization.~4
lensectomy,~1
bubbles.~1
younger-onset~2
Retinopathy.~1
Prince~1
susceptible;~1
retinopathy;~3
a-wave~1
verified,~1
Spasmus~1
nutans~2
oscillations,~2
nodding,~1
oculography,~1
spasmus~1
dissociated,~1
disconjugate,~1
uniocular.~1
rim,~1
Whitnall's~2
frontozygomatic~1
intermingled~2
pretarsal~3
esotropic~1
Upgaze~1
upgaze~1
iridis~2
Iridocyclectomy~1
rubeosis.~1
(Nd)-YAG~1
Scheimpflug~1
(Zeiss)~1
iridotomy.~2
Emulsification~1
intravitreal~4
emulsification~3
viscosities~3
centistokes~1
[cs],~1
cs,~1
12,500~1
cs)~1
(benzalkonium~1
emulsify~1
(viscosity)~1
Diamagnetic~1
ferromagnetic~3
fetromagnetic~1
moved,~2
Subconjunctival~3
nonneovascular~1
conjunctiva;~1
touch;~1
extrascleral~1
gutter;~2
gutter.~1
Revision~6
(38%).~1
"cyclodialysis~1
approach"~1
"trabeculectomy~1
approach")~1
cyclodialysis~2
eyelid.~5
recessed~1
avoided;~1
lamella~6
tarsus,~1
substitute,~1
suspend~2
retraction,~3
ectropion;~1
immunohistopathology,~1
Castroviejo~1
contemporaneously~1
transposition.~2
C-17~1
closely.~1
androgens:~1
exocrinopathy~2
exocrinopathy,~1
Salivary,~1
lacrimal,~1
Antinuclear~1
RNP,~1
SS-A,~1
SS-B,~1
HLA-B8~2
inservice~2
(training)~1
Stronger~2
polymyalgia~4
rheumatica,~1
21.5/10(5),~1
76.6/10(5)~1
Symptoms,~1
37.8/10(5),~1
(depleted~1
strain-specific~1
haplotype-specific,~1
sex-related.~1
ABC-treated~1
proteoglycan.~2
spondylitis.~2
collagen).~1
(JDMS)~1
heterogenous~6
JDMS.~1
JDMS,~1
JDMS~1
methylprednisolone.~3
viral,~1
first-aid~1
plasmapheresis/prednisone~1
12-36~1
Mseleni~3
Durban~1
antigens;~1
Dysphagia~2
.80)~1
.65);~1
.011).~1
(NPC-KT)~1
(Ad-AH)~1
(BJAB,~1
Raji,~1
A2L)~1
superinfected~1
EBV,~1
Ad-AH~4
EBV-associated~2
thymidine-labeled~1
EBV-mediated~1
mastoiditis~1
otorrhea~2
postauricular~2
mastoidectomy~2
(91.4%);~1
Aerobes~1
(11.4%);~1
(17.1%)~1
anaerobes;~1
(62.8%)~1
(80.0%).~1
paresthesia~2
sensoritrigeminal~1
Otoscopic~1
gerbil,~1
Meriones~1
unguiculatus.~1
artist's~1
rendition~1
Cavitron~1
aspirator~1
perineurium,~2
endoneural~1
anosmia~3
(nasal~1
inhalant~3
anosmia),~1
smell,~1
electron-optically~1
biochemical.~1
septate~2
hyphae.~1
Zygomycetes~1
(formerly~2
Phycomycetes).~1
Entomophthora~1
coronata.~1
Coccidioidomycosis~2
non-disseminated~2
curative;~1
lesion"~1
straighter~1
chin.~1
dysphonia.~2
(resection~1
nerve)~1
postweanling~1
puppies,~6
operated-on~3
Cricotracheal~1
Bakamjian's~1
Rhabdomyolysis~1
round-window~5
layers:~1
ear),~1
(inner~1
ear).~1
"defense~1
system."~1
Cationic~1
niche~3
perilymph,~1
RWMs~2
Passage~1
RWM.~2
niche,~1
chronological~7
well-epithelialized~1
rebuilt,~2
2-cyano-butyl-acrylate~2
(Histoacryl)~1
ossicles~1
ossicles.~1
ossicle~2
Negligible~1
adhesive.~2
ossiculoplastic~1
Computer-aided~1
Boundaries~1
(reconstructions)~1
topography,~3
tenia~3
tela~1
choroidea~1
peduncle.~1
electroauditory~1
Tarsorrhaphy~1
tarsorrhaphy~1
tarsorrhaphy.~2
saprobic~1
immunocompromised,~1
immunocompetent.~1
(debridement~2
irrigation)~1
humidification~1
laryngectomee~2
mist~1
1352~2
uncomplicated.~2
non-cardiac)~1
77.9%~1
86.2%.~1
74.3%~3
gallopamil~3
mg/kg/min).~1
Gallopamil~1
(2.6)~1
(2.4]~1
(142~3
(134.1~1
(57)~1
112.9~2
(38)~2
(0.6)~1
Hg/ml/min),~1
(6)~2
electrocardiographic,~2
vasospasm).~1
(9.2)%~1
57.4~2
(13.0)%.~1
(8.5)%~1
(9.8)%~2
63.2~2
(14.8)%~1
Dyskinetic~1
(2.1)~1
finding.(ABSTRACT~1
ventriculograms,~1
(9.1)~1
narrowing).~1
transvalvar~1
Syncope~3
this.(ABSTRACT~1
(5.8);~1
(6.3);~1
(6.9].~1
(4.7);~1
(4.9);~1
(6.2].~1
"sporadic~1
myxoma".~2
Clinic)~1
"syndrome~1
freckling~1
(68%),~1
non-cardiac~1
(syndrome~1
sporadic):~1
0%;~3
99%;~1
0%.~1
region;~1
Imbibition~1
organisation~4
chorda~2
surgery)~2
unstained~3
Movat's~1
pentachrome,~1
imbibition~1
chordae,~2
organisation.~1
valves;~2
chordae.~1
Dangerous~1
K-pumps.~1
Dehiscence~1
Milder~1
hoarseness.~1
Botalli~1
aneurysmectomy.~1
LR:~1
3.7-16~1
RL:~1
3.4-12~1
VE/VCO2~1
Temazepam~2
elixir~3
(Euhypnos~1
Elixir),~1
trimeprazine~1
tartrate~4
(Vallergan~1
Forte~1
Syrup),~1
theatre,~1
ward,~3
anaesthesia)~2
temazepam~5
0.002,~2
applied),~1
non-ophthalmic~1
(PCO2~1
4.7-5.3~1
enflurane;~1
anaesthesia;~2
(0.75%~1
booked~1
confinements.~1
fertility).~1
miscarriages~3
temazepam,~1
propylene~6
(capsule~2
elixir)~1
(train-of-four~1
"neostigmine~1
vecuronium-induced~3
neostigmine).~1
antagonism,~3
dorsalis~2
post-cannulation~1
velocimeter~2
arteries--three~1
group--flow~1
(NAP)~2
intransinus~1
NAP~3
(aerosol~2
(s.~1
Glaw)~1
Glaw~1
salbutamol.~1
patient-controlled,~1
Micropalliator~2
Cardiff~2
Palliator~2
(LMM)~2
sources:~1
LM;~1
Surveillance,~1
Epidemiology,~2
End~1
melanoma;~1
LMM~3
LM.~2
foreskins~2
wart-derived~1
'transformed'.~1
HPV-DNA~3
(5-100~2
HPV-DNA/cell~1
equivalent).~1
virus-cell~1
(VIP)-stimulated~1
cytochemically~1
cerium-salt~1
vera~1
(PRV)~1
water-induced~4
PRV~2
aquagenic~1
PRV.~1
Hyaluronate~1
(2.9-10.5~1
2.4-7.8~1
(24-30~1
mg/l).~2
4.6-12.4~1
nicotinate-treated~1
aspirin-pretreated~3
atopics.~1
onwards~1
Leucocytoclasis~1
chloroacetate~1
OKM~1
neutrophilia~3
nicotinate~1
non-allergenic,~1
leucocytoclastic~1
angry~1
(ABS)~1
Trafuril~3
naevus~6
A-type~2
heavily,~1
C-type~1
naevocytes.~1
protein-positive~1
strongly.~1
finer,~1
kinky~2
cutanea~4
tarda~3
617-618~1
S-adenosyl-L-methionine~1
(SAM);~1
120-150~1
child-bearing~4
seroprevalence~5
non-pregnant)~1
Rubella~3
Arabian~3
District~8
28-30~1
97.5th~1
centile,~1
graphs~2
low-birthweight-for-gestation~1
(LGA)~1
(78-84%)~1
(84-88%)~1
LGA~1
(PIH).~1
(PRA)~3
3.7)/108~1
BP-levels~1
141-145/90-95~1
(free,~1
oestriol~4
oestrone~4
E3,~1
718,~1
370,~1
214%,~1
149,~1
E3:progesterone~2
quoting~1
'uterine~1
integral'~1
nulliparae~1
multiparae.~1
75th~2
centile~5
titrating~2
equi-analgesic~1
Heel-prick~1
pethidine:~1
7.13,~1
9.11,~1
kPa;~2
22.3,~1
mmol/l).~2
7.23,~1
6.83,~1
20.9,~1
Falope~4
expel~1
halve~2
worst.~2
(AT-III)~1
Rouen~3
heparin-Sepharose~1
AT-III~4
antithrombins~2
V8~1
carboxymethylated~1
histidine.~3
Toyama,~1
AT-III.~1
Platelet-associated~2
(ITP),~1
nonimmune.~1
antirabbit~1
Nonimmune~1
aregenerative~2
(ADP).~1
(SpA).~1
SpA~2
168,~1
39).~2
consumptive,~1
spans;~1
Indirectly~1
Mepacrine~2
(SPD).~1
mepacrine~1
granule.~1
Colony~1
(PHA)-stimulated~1
PHA-LCM~1
PHA-LCM;~1
Colonies~1
recloned~1
(EBV)-negative~1
0.0009).~1
0.0014).~1
phagocytosing~1
(MLC).~2
MLCs~2
crowded~3
round-bottomed~2
wells,~3
flat-bottomed~1
nonproliferating~1
platelet/megakaryocyte~1
IIb/IIIa~4
(GPIIb/IIIa)~1
(roughly~1
megakaryocytes)~1
(threefold~3
fivefold)~1
megakaryocyte/platelet-specific~1
GPIIb/IIIa~3
accrual~3
PHA-LCM)~1
facilitory~2
(ADA)~1
ADA-specific~3
ADA-immunoreactive~1
XII~7
Hageman~2
TaqI~3
propositi~2
polymorphism,~2
constructed,~2
PLA1~4
(PTP),~1
PLA1-negative~3
PTP.~1
(PLA1-positive)~1
platelets:~1
120,000~2
[glycoprotein~1
120],~1
90,000),~1
140,000).~1
Leka~1
(Baka)-negative~1
F(ab)2~2
PTP,~1
(PLA1-negative)~1
alloantigen~2
IIb-related~1
thrombin-thrombomodulin~5
antithrombomodulin~1
125I-thrombin-thrombomodulin~1
125I-antithrombomodulin-thrombomodulin~1
125I-thrombin~2
diisopropylphosphoryl~1
(DIP)~2
(A549).~1
(EPO)~1
cDNA.~3
[35S]EPO,~1
radiochemical~7
homogeneity,~1
[35S]-labeled~1
EPO,~1
azide,~2
Asialo-EPO~1
sialated~1
asialo-EPO~1
[35S]EPO~1
[125I]EPO~1
Ib-IX~4
X-100-solubilized,~1
trypsinized,~1
FMC~2
(epitope~1
IX)~1
beta-subunit.~1
recombined,~1
reformed~1
Cross-blocking~1
(congruent~1
25,000)~1
(GP150/135)~1
(FN-R)~1
(GP135)~1
FN-R~1
138,000~3
Polytomography~1
meatus~7
(IAM),~1
IAM~1
pneumatisation~1
medium;~4
16.25~1
medium),~1
examined;~2
concern;~1
reinforcing~3
opinion;~1
haematomas~1
adenomatoid~4
sequestration,~1
varicography,~1
medium).~2
reduplication~3
varicography~1
conclusive.~1
MHz)~3
15-week~2
copper-sulphate~1
dilutions.~1
standardising~1
55%;~1
lesion:~1
leukaemia.~2
mosmol/kgH2O~1
evaporation)~1
evaporation.~1
post-micturition~1
dribble~1
(PMD)~1
PMD,~2
videocystometric~1
(Padtest~2
sanitary~2
towels~2
cystometrograms~1
contemplated~2
(detrusor~1
mastocytosis)~1
1,4-methyl-imidazole-acetic-acid~1
(1,4-MIAA),~1
ion-pair~1
1,4-MIAA~4
1.47-4.66)~1
0.18-4.30)~1
mastocytosis,~1
(0.72-2.34~1
48.9%~1
aminoglutethimide~2
(AG)~2
orchiectomised~1
hydrocortisone-treated~1
AG~8
lasted,~2
excluded;~1
urethroscopy~2
penoscrotal~1
mobilising~1
4/0~1
chromic~7
Intracorporeal~1
fascio-cutaneous~1
testosterone-induced~1
post-vasectomy~1
Post-vasectomy~1
spermatoza~1
(LOS)~2
(FNP)~1
gastrooesophageal~1
(84.8~1
FNP,~1
(76.2~2
(87.8~1
length-pressure~1
diagram~4
FNP~1
1978-1984,~1
Gy/4~1
Roux-en-Y-oesophagojejunostomy~1
postresectional~1
non-advanced~1
(1080~1
kJ~1
1810~1
sour~2
cheese,~1
Vegetable~1
antrum;~2
Automobile~1
herniating~1
Loculi~1
autografted~2
orthotopically~1
myo-electrical~2
non-transplanted~1
autograft.~1
extra-pancreatic~2
(duodenal~1
paraduodenal)~1
shelling~1
b.d.~1
ultrasonogram,~1
surmise~1
12-44~1
since,~1
choledocholithotomy~1
cleared.~1
unresectable,~2
cent;~19
(35.5~1
centroblastic~1
49,573~1
self-examination~6
DHSS~2
'UK~1
Cancer'.~1
319~2
district.~1
mastalgia~4
risk'~2
'low~1
I-II~1
283)~1
10-60)~1
MCF7~1
(MCF7~1
6-8-week-old~1
(127/135~1
52/106,~1
(tumour~1
s.e.m.,~1
stimulatory.~1
Glutaraldehyde-killed~1
mdx~7
cholinesterase-silver~1
impregnations~1
Z-lines.~1
calibres~1
vermis~2
foliae~1
39%)~2
pericerebral~1
Nagano~1
Ogawa~2
kinships~2
FAP,~4
prealbumin.~1
opposition~5
('squeeze'),~1
('flex')~1
'Squeeze'~1
'flex'~3
Isotonic~3
('cut')~1
'squeeze'~1
self-paced.~1
pause~2
slower.~1
400-500~1
amusia~1
destructions~1
auditory,~1
sphere.~1
nonlinguistic~1
supramodal~2
rate-dependent.~1
modalities;~2
loudness,~2
consideration;~1
(fluorescein~1
sheathing~1
8/14~1
5/32~1
without;~1
perivenular~3
cycle/deg~1
sinewave~1
gratings~4
orientation;~1
horizontal.~2
hint~1
extrastriate~1
carpi~3
radialis~3
'stretch'~4
'short'~1
'long'-latency~1
short-latency,~1
spastics~1
amplitude;~1
vibration,~2
spindles,~1
Ia~3
afferent-mediated~1
(Matthews,~1
1984a)~1
postcentral~6
precentral~3
eminence.~2
lemniscal~1
P27~1
P22,~1
N30~1
P45.~1
thalamocortical~1
P22~1
generators.~2
concluded.~2
centripetal~4
Circular~1
gratings,~1
eccentricities~3
(papillomacular~1
luminance~1
Injecting~2
recurs~1
Learning~1
commissural-CA3~1
Microcomputers~1
part-time~3
Ont.~2
mention~2
questionnaire).~1
18,940~1
episiotomy.~2
wait.~1
24,439~1
reactor~4
clean-up~1
Chalk~2
River~3
Base.~1
cause-specific~1
1980-81~1
Newfoundland~1
5729~2
John's~1
5005~1
(87.4%)~1
involuntary.~1
unemployed~2
tranquillizers~1
neuroleptics~5
parens~1
patriae~1
Fecal-oral~1
strongyloidiasis~4
climates,~1
152.3~1
infertility,~10
Counts~2
Paediatric~1
Society's~1
1984-85~6
Montreal~1
breast-feed~3
workplace)~1
smoked;~1
analyzed:~3
(NSE),~1
Shimada.~1
Kaplan~2
Meier.~1
NSE,~2
vanilmandelic~1
(VMA):~1
ferritin.~2
recursive~1
subdivide~1
g/m2/day~3
neoadjuvant~8
N3~3
32%)~3
g/m2/day.~1
infusional~5
responders;~1
mechlorethamine,~1
MOPP-courses.~1
MOPP-course.~1
"small"~1
69.7+~1
87.5%.~2
62+~1
19+~1
78+~1
debulking,~1
whole-abdomen~1
antigranulocyte~1
K562,~2
thyrocyte.~1
NK-cell~2
100:1~2
20:1,~1
lyses~2
NK-cells~1
(FP).~1
nonencapsulated~1
subareolar~4
(SSDH)~1
(26-73~1
nipple.~1
areola~1
areola.~1
SSDH~2
reexcised~1
SSDH.~1
proclivity~1
Keratan~1
microspectrophotometrically~2
histogram.~1
(Types~1
81.7%,~1
19.8%,~1
45.7%,~1
57.1%,~1
16.1%,~1
nationality~1
Fundic~1
argyrophil~4
eroding~2
enterochromaffin~1
enterochromaffin-like~1
(EC-L)~1
A-like~1
D1/P~1
Naproxen~3
antipyretic~2
400/microliters~1
10(3)/microliters,~1
(ANC)~1
4514/microliters.~1
(Cooper~1
Lasersonics,~1
8000,~1
Clara,~1
CA).~1
(40.6%)~1
loculations,~1
symphysis.~1
2173~1
Cancers~1
intestinal-diffuse~5
60s,~1
(MCF)~1
mg/m2/day~2
(DV).~1
MCF.~1
DV~1
upgraded.~1
(TTP),~1
TTP~5
MCF~2
DV,~1
MCF,~1
doxorubicin-based~1
(GITSG)~1
GITSG~1
replicated.~1
25.0.).~1
[CI],~1
0.28,~1
0.36)~1
asparaginase~1
(10-30~2
[IP]~1
weekly--20~1
PEG-asparaginase~7
(vincristine,~1
prednisone),~1
IU/kg,~1
weekly--17~1
resistant)~1
(NR),~1
(CR~2
PR)~2
chemotherapy-resistant~1
L-asparaginase)~1
PR).~1
NR.~1
840+~1
126+~1
16+,~1
21+,~1
26+,~1
28+~1
(DIC--one~1
dog),~2
IIIM0~1
(PCI)~3
PCI~12
PCI;~2
0.6).~3
PCI.~3
non-PCI~1
sessile,~1
Supplementary~1
(Leu-1,~1
Leu-2a,~2
Leu-3a,~2
Leu-9,~1
T-3,~2
T-11,~2
TQ-1),~1
pre-B~2
B-cells~1
(BA-1,~1
B-1,~1
B-2,~1
B-4,~1
J5),~1
(Leu-7~1
Leu-11b),~1
(T-9,~1
HLA-Dr,~1
Tac).~1
Leu-1,~1
Leu-9.~1
NK-,~1
pre-B-,~1
HLA-Dr~1
similar;~1
immunophenotype~1
lymphadenectomies~2
teratocarcinomas~6
(teratoma~1
teratocarcinomas.~1
Recrudescence~1
Cushings~1
Unimodal~1
metastasized,~1
Paraffin~1
(dysplasia~1
Condylomatous~1
G-banded~1
oncocytomas.~2
stemline~3
karyotype~4
45,X,-X,rcp(8;19),der(13)t(X;13)~1
sidelines~1
pseudodiploid~1
46,XY,del(1q),der(13)t(1;13)~1
karyotype;~1
telomeric~2
(TIS),~1
(TA),~1
(T1).~1
category;~2
TIS~2
TIS,~1
64.6~1
enzymoimmunologic~1
hyaluronate-hyaluronectin~1
micrograms/l;~3
5833~1
micrograms/l)~2
micrograms/l).~1
semiparametric~1
(Cox's)~1
Prevalence,~1
27.5%,~1
ASAT~1
(N),~2
2N~1
89.7%,~1
trials;~1
tobacco-~1
"myogenic"~1
pressure-dependent~4
(intracellular)~1
ligature.~1
externalization~6
intracoronarily.~1
hypercontraction~1
ECG-ST~1
pharmacophysiological~1
nondenuded~3
topologically~2
i.c.)~1
areas.(ABSTRACT~1
open-chest,~3
Autoregulatory~1
O2/min/100~2
flow-oxygen~1
pipette~1
tetrodotoxin-insensitive~1
voltage-dependent,~3
overshoots,~1
milliseconds.~1
restitution.~1
Co2+~1
overshoot.~1
4-aminopyridine-sensitive~1
state-dependent~1
interpolated~3
courses;~1
restitutions~1
populate~1
ectomesenchyme~1
premigratory~1
quail~1
homotopically~1
septa.~6
acetylcholine-induced~3
norepinephrine-contracted~2
pulse-labelled~1
calcium-45~1
potassium-chloride-induced~1
lanthanum~2
agonist-releasable~1
relaxes~2
calcium-independent~1
subfragment-1~4
subfragments.~1
(S-1)~1
Ka(ATPase),~1
Ka(binding).~2
dissociating~4
actin;~2
"nondissociating"~2
S-1.~2
S-1,~1
Ka(ATPase)~3
Ka(binding)~1
Ka(binding),~1
actoS-1~2
subfragment-1.~1
(LAD,~1
(LC,~1
0.96X~1
0.53X~1
EF,~1
1.31X~1
0.83X~1
LAD,~1
LC,~4
5.1.~1
(cGMP)~4
unrubbed~5
endothelium-denuded~5
Methylene~1
M&B~3
22,948,~2
cGMP-phosphodiesterase,~1
Unrubbed~1
22,948.~1
vasodilators,~5
bed.(ABSTRACT~1
6.8),~1
milliseconds)~2
Purkinje-ventricular~1
(PVJ~1
delay)~1
[K+]~7
PVJ~3
nonworking~1
10-microliter~1
transudates~3
effluents~2
chloroacetaldehyde,~1
(1,N6-ethenoadenosine)~1
(normoxic)~1
pmol/ml,~2
O2),~1
1,178%,~1
641%~1
flow.(ABSTRACT~1
[Ca]i~17
fura-2~5
BCECF,~1
[H+]).~2
ethylisopropylamiloride,~1
Na-H~1
potassium)~1
pHi.~2
(lithium)~1
22-fold~3
6.60).~1
subtoxic~1
24Na~1
ethylisopropylamiloride.~1
Ca-H~1
cell.(ABSTRACT~2
dihydroxyphenylglycol~5
depletion:~1
Anoxia~2
energy-depleting~1
uptake1~3
nonexocytotic~3
overflow.~2
overflow,~1
(cyanide~1
oxidase.~3
anisotropic~6
potentials:~2
upstrokes~7
propagation.~6
directionally~1
propagation,~2
experimentally:~1
Vamp~1
capacitance,~1
resistivity,~1
chlorothiazide.~1
prehypertensive~4
age-associated~2
thyroxine,~4
Ca2+-myosin~3
thyroxine-treated~3
monotonically~1
Pi/mg~2
prot/min~2
529~1
24-month-old~1
(microprobe~1
Ultrathin~1
cryosections~1
(mmol/kg~1
Cl,~5
Myofibrils~1
bathed~2
for)~1
precontraction~2
(-6.0~2
mol/l).~1
reconstituting~3
lymph-flow~1
pumping)~1
pumping.~1
pump;~1
propelled~1
"isolated"~1
models'~1
capacitance-free~4
perturbing~1
Hg/sec.~1
Capacitance-free~1
constant-pressure~1
model-independent).~1
decay.~2
dPLC/dt.~1
resolves.~1
myocardium:~1
myofibril,~1
70-80~2
Injections~4
aggregatory~1
(29.4~1
4.7%)~1
85)~1
constrictive/restrictive~3
diagnostic/therapeutic~1
liters/min/m2),~1
59%).~1
myocarditis).~1
(verapamil-SR)~1
catecholamines;~3
venoconstriction.~1
verapamil-SR~4
sympathetic-adrenergic~1
0.17.~1
pace-mapping.~1
Pace-mapping~1
(cathode)~5
(anode).~2
anode)~1
35).~3
(240~2
sotalol,~2
sotalol.~2
freeze-clamped~2
creatine.~2
dP/dt.~1
frequency-~2
orientation-dependent~2
mexiletine,~2
sodium-channel~1
Quinidine,~1
effects.(ABSTRACT~1
(CBN)~1
CBN,~2
(CN),~1
CBN~4
CN,~1
CN~4
CBN.~1
antineutrophil~1
subepicardium.~1
(40.0~2
(21.7~1
(spontaneously~1
collaterals).~2
(recruitable~1
recruitable~6
collaterals.~6
collaterals,~1
1782~1
(0.64~1
(+41~1
(+54~2
UCP)~1
LCP).~1
UCPs~3
atrium-His~1
LCPs~2
LCPs.~1
(UCP~1
LCP),~1
LCP~2
open-catheter~1
(IPP)~1
(TMFP).~1
(RAP)~3
IPP~7
RAP,~2
TMFP~5
TMFP1~4
(PWP~3
IPP);~2
TMFP2~2
1/3~5
2/3~3
TMFP3~2
RAP).~1
pulsus~2
paradoxus,~1
expiration)~1
beat-by-beat~1
(810~1
tamponade)~2
Encompassing~1
.59)~1
.52)~1
TMFP3.~1
equalization~2
("inspiratory~1
tracking").~1
paradoxus.~1
hypothesizing~1
Frame-by-frame~1
(sigma)~4
micromanometry:~1
(AR),~2
(maxEav)~1
(es)~1
stress-strain~5
End-systole~2
loge~3
(Dm/Dom),~1
Dm~3
Dom~1
(V/Vo),~1
Vo~2
extrapolating~6
es~3
maxEav~2
(Ves/Vo),~1
MaxEav~1
(1575~1
565)~1
(1877~1
544;~1
(1320~1
268),~1
"unloaded"~1
(SFo)~1
.24),~1
potential.(ABSTRACT~1
spheres~9
.37),~1
.23),~1
.55),~1
ventriculogram~3
.31).~1
SD]~1
risk.(ABSTRACT~1
0.8/patient,~1
(77%~2
1.1/patient,~1
.0002),~1
.0008),~1
.0027),~1
.017).(ABSTRACT~1
(RVMI)~1
RVMI~1
Deviations~3
drawback,~1
hypothesis--that~1
Nitrates,~1
quest~1
inotropic-vasodilator~1
survival?~2
Should~5
trials?~1
used?~1
initiated?~1
Answers~1
2270~1
40-69~1
1677~1
593~1
1.10).~1
(Fa~1
Fd)~1
Fa~4
Fd~1
liter/min/m2~1
-.69)~1
-.87).(ABSTRACT~1
shelf.~1
.00001)~1
defect;~1
tract)~1
(32/39).~1
arch--coarctation~1
VSD,~1
shelf,~1
(PDA).~1
(L-R)~1
L-R~3
Fick's~1
demonstrations~1
(MM3)~1
IA),~1
1.25%/hr~1
2.37~1
1.11%/hr~1
IB)~1
1.46%/hr~1
IA).~1
3.1%/hr~3
48/55~1
IA).(ABSTRACT~1
XIII,~4
epsilon-(gamma-glutamyl)-lysine~1
XIIIa-catalyzed~1
.8%,~1
0.1%).~2
XIIIa~2
enoximone~12
enoximone.~1
(LVEDP)~1
(LVEDV)~1
LVEDP~1
LVEDV.~1
method),~5
Enoximone~1
897~2
1135~1
enoximone,~1
aortopulmonary~5
dobutamine.~2
(hydrostatic)~1
(sonomicrometry)~1
constrictors~1
reapproximated~2
(recorded~2
balloon)~1
(.O2-)~1
U/kg/min~1
.40).~1
"area~1
echocardiography),~1
ventricle),~1
.42).~1
(autoperfusion~1
autoperfusion~4
-0.02~2
(-0.03~1
-0.01~1
subepicardium~2
subendocardium~5
metallic-capped~1
restenosis,~4
[22%]~1
[100%];~1
relaxation;~1
steps)~1
microcomputer-controlled~1
servo-pump~1
beats;~2
single-beat~1
beat),~1
value);~1
(just~1
systole.(ABSTRACT~1
(ESPVR)~1
afterload-insensitive~1
descriptor~1
ESPVR~7
(Emax)~3
Vd.~1
Emax~19
unblocked~1
ESPVR.~2
ESPVRs~2
afterloads~2
(sonomicrometry~1
techniques)~1
(Emax),~2
(ESPVR),~1
stress-volume~1
(ESSVR)~1
(4.63~1
3.54~4
Hg/ml,~1
ESSVR~2
Emax,~2
ESPVR,~1
(MB~1
fraction)-confirmed~1
(QMI)~1
(NQMI)~1
NQMI~5
QMI~1
reinfarctions~2
.009),~3
.034),~1
establish.~3
transsarcolemmal~5
flux;~1
convincingly.~1
po~1
75.9~2
13.7%~3
11.1%~2
37.9~1
-.83)~1
drug-treatment~1
"salvage~1
index".(ABSTRACT~1
5070~2
CVD.~2
biological,~3
glomerular/tubular~1
EPH-gestosis~1
EPH-gestosis.~1
(urea-creatinine~1
78.4%~1
urea-creatinine~9
(lowest~1
tertile)~1
(highest~4
tertile).~1
goodness~1
g/1.73~7
glucosuria.~3
75-105~1
148-153~1
112-160~1
72-82~1
inulin-clearance.~1
261-342~1
Norway~2
1972-1973~1
1983-1984.~1
semirural,~1
Account~1
self-locking~1
(Muller)~2
cup,~1
2.0-4.6~1
Swanson~1
Evarts,~1
Radiolucent~3
acetabula,~1
Zones~1
26.5%~1
subsidence~3
revised.~1
histiocytosis,~2
microfracture~1
detritus~1
mantles~1
predispositions~2
loosened~2
reinterpreted~1
well-functioning~1
cm-3.7~1
cm-5.1~1
1983-1985.~1
Namaqualand~1
(NHD)~1
Overhead~1
radiolucent,~1
sterilizable,~1
(Y/S)~1
knees),~1
squatting.~1
patellectomy~1
Marmor~3
osteoligamentous~1
stabilizer~1
flexions~2
378~4
0.16%~1
0.13%~1
sternomastoid~3
soft-tissues~1
neck)~1
realignment,~1
64%).~1
33%).~3
component),~2
hemophilic~2
arthropathic~1
Hemophilia.~1
hemarthroses~1
Hemorrhages~2
52.6%.~1
76.6~2
morphometry,~1
Singh~1
cortical-shaft~1
negated~4
azathioprine-immunosuppressed~1
recompiled.~1
months:~1
freeze-drying~2
allografts;~2
microradiographic~1
graft-host~1
strength;~1
incorporation;~1
Endochondral~1
stainability~1
Feulgen-Schiff~1
Epiphyseal~1
bowleg~1
knock-knee~1
Blount~1
stapling,~1
sulfate/keratan~1
nonstapled~1
Canine~4
250-300~1
low-viscosity~7
300-900~1
Pressurization~2
plugged~4
pO2,~1
pCO2,~2
pressurization~1
pO2.~1
cementing~2
finger-packing.~1
proximal.~1
Rachitic~1
(0.02%~1
Proteoglycans~1
lowermost~3
enchondral~1
2289~1
764~1
3053)~2
1975-1977~1
Stockholm~3
(2418~1
Mondays~1
Sundays~1
(1492)~1
2937~1
(1465~1
Hessel/Nystrom~1
(674~2
Thornton~3
(380~1
Rydell~2
(224~3
hemiarthroplasties~1
resource-consuming~1
(orthopedic~1
surgical)~2
(conservative,~1
hemiarthroplasty~5
[HAP]).~1
(von~2
Bahr,~1
Hessel/Nystrom,~1
Thornton,~1
nails),~1
2418~1
HAP.~1
redisplacement~3
departments.~2
reoperated.~1
reoperated,~1
risky.~1
flanged~1
pins.~3
Scandinavia,~1
hook-pin~1
redisplacement,~1
survivors).~2
malhealing~1
(25%;~1
ambulators.~1
ratings,~4
diverticulum.~1
Leinbach~2
decubiti,~1
(ORIF)~1
(0.8-11.9)~1
(36-86)~1
"unstable"~1
Smith-Petersen~1
Deyerle~1
unrecorded~1
endoprostheses,~1
ORIF.~1
ORIF,~2
simpler,~1
30%-70%.~1
"developed"~1
dilemma,~3
minimum.~2
world-wide~1
high-technology~1
daunting~1
indeed.~1
sophisticated,~1
direction;~1
championed~2
nonoperative,~1
nonacute-care~1
nonambulatory~1
indefinite~3
unanimity~2
nonambulatory,~1
Triage~1
(VLBW,~1
diplegia,~1
Neurologically~1
postneonatal~1
Plans~1
educator,~1
interprofessional~2
educators,~1
(cortical~2
blindness).~1
handicaps:~1
(CDRS)~1
Poznanski,~1
Cook,~1
Carroll~1
12-year-olds.~1
CDRS~1
well-adjusted~1
CDRS.~1
founders~1
problem(s)~1
viewpoints~2
Ranging~2
retrospect,~3
non-hyperactive~1
school-failure~1
laypeople~1
school-aged~3
(ADD)~2
ADD~3
seniors~3
cannabis-dependent~1
self-assessment~2
harmony,~1
attendance,~2
convincing~4
"marijuana-naive"~1
someone~4
unmotivated~4
lazy~1
(49%).~2
academically;~1
behind.~1
(SES)~1
(Chi~2
(51%~1
Chi~1
6.14~1
pseudodementia~1
cerumen~1
cerumen.~1
(HTN)~1
HTN~2
657~1
905~1
cm-5)~2
(2002~1
988~1
1089~1
HTN,~1
4.47~2
1.01;~1
0.05]),~1
gm/kg~1
1/2-hour~1
Goldberg's~1
"Finger-Finger"~1
"Serial~1
Sevens"~1
Farnsworth-Munsell~2
Hue~1
Hourly~2
Arachidonate-induced~1
aggregations~4
flurbiprofen.~1
Ibuprofen~1
t.i.d.).~1
L/kg.~1
autoinduction,~1
-0.88~1
-0.91;~1
coadministered~4
autoinduction~4
Vaughan-Williams~1
cibenzoline.~1
disopyramide,~1
ml/m2)~4
(2.65~1
L/min/m2).(ABSTRACT~1
Ribavirin~3
ribavirin,~3
1200,~4
19.7,~1
beta-phase~1
administration)~1
5.1,~1
9.9,~1
threefold)~1
Ketorolac~1
tromethamine,~1
nonnarcotic,~1
synthesis-inhibiting~1
ketorolac,~1
(verbal~1
analog)~1
Ketorolac,~2
ketorolac~1
bromazepam~7
(0.88~3
(34.8%~1
28.8%~2
unbound).~1
Bromazepam~1
Propylene~2
(42.1~2
41.9~3
pentopril~6
(CGS~2
13934)~1
Pentopril~1
(CLR)~1
CLR~2
200%),~1
AUC).~1
(1749~1
1774~1
ml/6~1
(757~1
mEq/6~1
glucuronide)~1
coadministration.~2
(raising~1
stature).~1
Multistage~1
abnormalities.(ABSTRACT~1
coatings~3
resins.~3
Spray~1
Frullania~2
compositae~1
lichens.~1
Parmelia~2
caperata~1
reticulata~1
positivity:~1
Pseudovernia~1
furfuracea,~1
Evernia~1
prunastri,~1
Usnea~1
Ramalina~1
lusitanica.~1
d-Usnic~1
evernic~1
atranorin~1
2-component~1
w/w),~1
diluents:~1
1,4-butanediol~1
diglycidyl~1
(BDDGE)~1
glycidyl~2
ethers~2
(Epoxide~2
0.01%;~1
fillers.~2
BDDGE,~1
BDDGE~3
PGE,~1
glue.~1
Permeation~2
perfume~7
fragrances~1
Roma,~2
Italy,~1
3.6%).~1
contactants,~1
whitening~1
tapes.~1
musk~3
ambrette~2
incense.~1
olden~1
incense~4
worshipped~1
ancestors.~2
perfumes~1
volatilized~2
burnt,~1
sebum,~1
neutron-irradiated~1
Ni~2
immunodeficient.~1
function),~3
structures).~1
zymosan.~3
9.71~1
.995)~1
.994).~1
lactates~2
12.99~1
.998)~1
open-plan~1
policy,~3
Gram-positive~3
sleeves~2
exchanging~3
introducer.~1
PAC~7
PACs~1
(CRB),~1
underestimated.~1
CRB~1
.009)~2
CRB.~1
(arrest~1
decompensation)~1
residents;~2
Munchausen's~3
masqueraded~1
(cardiopathia~1
fantastica);~1
catheterizations~4
cardiopathia~1
fantastica~1
(arteritis~1
factitia).~1
private,~1
nonprivate~1
university/university-affiliated~2
subdivision~1
bed-size~1
(71.6%).~1
nonuniversity~2
(APP).~1
(HPT),~1
(TRF),~1
antitrypsin,~2
(CER)~1
(MAT).~1
APP~2
hemoglobin-HPT~1
TRF~1
CER~1
Explanation~1
Diuresis~1
many,~3
(EMD)~1
asystole/EMD~2
(Ao),~1
Ao-RA~1
electrically;~1
400-J~1
Countershock~1
EMD~1
countershock~3
adenyl~2
nondisposable~2
domes~1
prefilled~2
Flush~1
set-up.~2
contaminants.~2
Binomial~1
preassembled~1
plastics,~1
readiness~2
preassemble~1
gastroduodenal~7
perforate~7
Perforated~1
Hypoxia,~1
hypercarbia,~1
142.3~1
131.4~1
86.9~1
(ScsO2)~1
ScsO2~3
countershock,~1
cyclic-AMP.~1
nitroglycerin,~1
(Amp)~1
Amp~2
Amp/ICP~1
thermal-dye~2
(EVLW)~3
13.6%.~1
(16.1~3
6.8%)~1
4.2%).~1
nonbreathing~1
combitube~2
(ETC)~1
ETC~7
(ETA).~2
oxygenate~1
ETA~2
32-day-old~1
methemoglobinemia~2
aniline~2
monograph~1
aggressive.~1
(OSA)~3
OSA.~3
OSA~7
hypercapneic,~1
bronchoscopically.~1
(Legionella).~1
(MDL~2
17,043).~1
64.8~1
(0-2);~3
Q-peak~1
(0-3);~3
T-time~2
(0-1).~1
Range~4
0-16.~1
(AVA)~1
AVA~2
100/107~1
mild-moderate,~1
(AVG)~1
84/88~1
AVG~1
desaturates,~1
desaturate.~1
(DCO),~1
DCO~4
Gallium~4
2.88)~1
2.75)~1
(neutrophils~1
patients):~1
replacement;~3
Lambert-Eaton~3
non-COPD~3
.320~1
.055~1
TLC),~1
(FBs)~1
tracheobronhial~1
(78.8~1
FBs~1
nuts.~1
(meat,~1
cucumber~1
peels)~1
nonorganic~2
(toys,~1
thermometer)~1
FB~5
(FBs~1
Stiff~1
peanuts~1
unresolving~1
pneumonic~1
Expert~2
neodymiumyittrium~1
Joules~2
bronchograms~1
26-year~1
rapidly-growing~1
Transbronchial~2
profound,~1
lymphangioleiomyomatosis.~1
lymphocytes)~1
(SRUS)~1
F:~2
19-41~1
(35-66)~1
visualizes~1
intrarectal~3
SRUS~3
SRUS.~1
radiochemotherapy~1
(222~1
split-course~3
iridium~3
1918~2
(postoperative~1
included)~1
brushings.~1
(86.4~2
Brush~2
91.5~2
Brushing~1
brushing,~1
brushings~2
lesion;~3
obviously,~1
125)~2
visit;~1
lump,~1
ani~1
bimanual~3
hematogenic~1
mucosectomy,~1
angulated,~1
spout~1
J-pouch,~1
S-~2
vascularization.~1
reach.~1
Vascularization~1
2.3:1.~1
sigmoidoscopy,~3
verge,~1
endoanal~6
muscosectomy.~1
mucosectomy.~2
60cm~1
H20,~1
H20).~1
descendants~2
adenomatosis~2
Turcot~3
adenomatosis.~1
Undoubtedly~1
adenomatosis,~1
pleiotropic~3
expressivity.~1
cyst-hamartoma.~1
rectocutaneous~1
parasacrococcygeal~1
11,657)~1
factories,~1
2269),~1
2.38%~1
1.37%~1
2111),~1
1.52%~1
6525)~1
1.03%~1
0.69%~1
752~1
operate.~1
pentagastrin,~1
pmol/kg/hr~6
pmol/kg/hr,~2
11.25~1
meq/hr~2
pmol/kg/hr)~3
8.78~1
6.37~2
pmol/kg/hr).~1
ng/min/ml~1
humans.(ABSTRACT~2
(MCT)~2
(LCT)~1
GIP~2
15(R),~1
15-methyl~1
15(R),15-Methyl~1
15(R),15-methyl~1
(chronic~4
pancreatitis)~1
temperature-dependence~1
degrees/180~1
sequence)~1
0.05-1.6~1
0.952/40~1
0.965/60~1
0.988/80~1
quantification.~1
lyophilized~1
contents/day~1
(secretin-pancreozymin~1
0.983)~1
45;~1
0.867),~1
0.946),~1
0.992)~1
sprue.~2
Heat-labile~1
sprue,~1
(NPY)~2
Exceptionally~1
NPY~20
30-40%,~1
colocalized~3
presynaptically~1
NPY,~1
(1-19)~1
fed-type~1
mid-jejunum~1
pM,~8
abolish)~1
MMC.~1
III-like~1
w/w)~1
diets:~1
well-balanced~2
restricted),~1
protein-restricted~5
(pair-fed~1
pups).~1
pups'~1
acaloric~2
Billroth-I~3
Acaloric~1
gastrectomized~4
Medium-viscosity~1
preserved;~2
LeVeen~1
carbamazepine-induced~2
broadens~1
immunoallergic~1
hyperamylasemic~1
(P-type)~1
(S-type)~1
22-79~1
4.5-mm-diameter~1
Amplitude,~1
fifties.~1
Double-peaked~2
(18.1%)~2
triple-peaked~1
1%).~3
Nonperistaltic~1
(18.1%~1
4.1%).~1
(12.6%~1
0.4%).~1
Triple-peaked~1
wet-swallow-induced~1
0.0125)~1
intrinsic,~1
glycoprotein(s)~1
promotility~2
expectorated~1
os:~1
PL,~1
(PIR),~1
propantheline~1
(PRO),~1
(CIM),~1
(RAN),~1
(BET),~1
(MET),~1
(STIM)~1
sucking~4
peppermint~1
lozenge~1
ice,~2
(CAN)~1
microequivalents~1
PRO~1
STIM~1
CAN~1
PIR~1
CAN.~2
CIM,~1
RAN,~1
MET~1
CIM~3
RAN~1
BET~1
Prairie~1
[14C]cholic~1
(8.66~1
(4.76~1
3.21~1
0.34),~1
(6.42~1
0.46),~1
(6.22~1
0.43).~2
forming,~1
mid-lumbar~1
mumol/hr).~1
mumol/hr),~1
mumol/hr)~3
Cefoperazone's~1
mumol/hr.~1
micelles~2
micelle~1
presecretory~1
ferric~2
nitrilotriacetate~2
iron-overloaded~1
mumol/100~3
overload;~1
4-prolyl-hydroxylase~2
glucosyltransferase~1
galactosyltransferase~1
overload:~1
effect;~3
(8-12~1
Intracolonic~1
Intracerebroventricular~3
(15-20~1
(2-hr)~1
chyloperitoneum,~1
chyloperitonium~1
pruritis~1
serologies~1
(VSTs)~1
vibrameter~4
biothesiometer~2
VST~5
1.87~1
(arbitrary~1
70.7~1
Biothesiometer~1
742~2
.01;~4
exudates)~1
microaneurysms~4
exudates~5
nonproteinuric~3
(nonproteinuric:~1
55.5~1
proteinuric:~1
minitablets~1
sulfonylurea,~1
ultralente~1
5-19~1
prediabetic~3
9-~1
14-yr-old~1
macroangiopathy)~2
multiplace~1
HBO.~1
healed,~4
non-HBO-treated~1
2-test~1
thioridazine~7
(14.8~2
(77.8~1
first-dose~1
(Staphylococcus~1
(ke,~1
(n)~1
nth~1
0.018).~1
First-dose~1
q8h~3
(AUC24)~1
AUC24~1
pharmacokinetically~1
q6h.~1
lodge~1
dissolve,~1
#00~1
(99mTc)~3
chaser.~2
(DUR)~1
Operating~3
Pharmacy.~2
DUR's~1
colloids.~1
formulary,~1
$12,346.00~1
ultrashort-acting,~1
Carbamazepine's~1
succinate.~1
treatment-resistant~3
ten-week~1
nonblinded,~1
benzydamine~3
(HSC)~1
mouthwash~3
(nystatin~1
ml/ml~1
0.9%)~1
antineoplastic-induced~1
q2h~1
Stomatitis~1
HSC~1
stinging,~1
psychoses.~1
thioridazine,~1
innovator~1
Mellaril.~2
bioequivalent~1
(FDA).~1
bioequivalence~2
FDA.~1
Sandoz,~1
bioequivalence.~1
reassessment,~1
rejects~2
assertion~2
bioequivalent.~1
FDA's~1
rhythmicity~2
"cold",~1
(Tgb).~1
Tgb~3
Tgb,~1
overfilling~1
autoradiographs.~1
thyroids,~1
life-long~1
bicuculline,~1
GABA-A~2
bw).~1
3.9-fold~1
7.0-kilobase~1
6-12~2
bw,~1
ip).~3
25-dihydroxyvitamin~1
25-(OH)2D3]~1
(activation)~1
25-(OH)2D3.~1
25-(OH)2D3~5
[14C]acetic~1
[14C]oleic~2
triacylglycerol.~2
acylations~1
25-(OH)2D3,~1
lypopolysaccharides~2
(IGF)-I~1
Singleton~1
125.~1
(HXT4~1
L-T4/day)~1
hypophysectomy.~3
(HXNR~1
HXNR~1
147.~1
SE.~2
Hypophysectomized~1
HXT4~3
sham,~1
HXNR,~1
ngeq~4
(h)IGF-I/ml,~1
656.3~1
59.2,~1
635.3~1
56.3,~1
645.5~1
hIGF-II/ml,~2
(88.0~1
hIGF-I/ml,~1
(362.4~1
concentrations.(ABSTRACT~1
PRL-responsive~1
[125-I]iodo-PRL~1
slab~3
autoradiographs~3
microdensitometry.~1
lactogenic~4
viz.~1
[125I]iodo-PRL~4
nonlactogenic~1
viz~1
cerebroventricular~2
PRL-brain~1
Estradiol-binding~1
matrix-associated~1
estradiol-binding~1
H222Sp~1
67,000~2
[3H]estradiol-binding~2
1,25-(OH)2D3-dependent~1
3H-glycerol~1
(o)~1
[125I]oGH~5
mid-~1
[125I]oPL~4
Unlabeled~2
(0.9-9~2
oGH~4
[125I]oPRL~1
oGH,~1
[125I]oGH.~1
oPL.~1
20-30%.~1
liver:~1
oPRL.(ABSTRACT~1
(ROS~1
17/2.8).~1
ROS~2
17/2.8~2
hormone-depleted~2
pM;~2
nucleus].~1
MIT,~1
osteoblast-like~2
proto-oncogene,~1
N-myc,~1
17beta-estradiol~1
(A)+~2
0.8-fold~1
E2-stimulated~1
(3-~1
6-fold)~1
proestrous-estrous~1
N-myc~16
kilobase~3
0.4-fold~2
stringency,~1
transcript.~1
autocrine,~1
paracrine,~1
estrogen-dependent~1
cardiomyocytes~2
myo-[2-3H]inositol~1
(IP1)~2
biphosphate.~1
Norepinephrine-stimulated~1
IP1~4
subselectivity:~1
Pertussis~1
ADP-ribose~1
ADP-ribosylate~1
norepinephrine-dependent~1
ADP-ribosylated~1
phosphoinositol~2
IGF-II-secreting~1
(18,~1
54-SF)~1
many-fold~1
(296~1
groups),~1
[4-14C]~1
NADPH-generating~1
diol~7
fast:~1
alpha-hydroxyprogesterone,~2
alpha-hydroxypregnenolone~1
Androstenedione~1
androstenediol.~1
[3H]dihydrotestosterone-receptor~1
L-cells.~1
[3H]dihydrotestosterone,~1
DNA-Sepharose,~1
L-cells~1
Flow-through~1
transformable~1
dihydrotestosterone-receptor~1
Unoccupied~1
L-cell~1
6-8S~1
4.6S.~1
nontransformed~1
receptor;~1
subunits;~1
(RI)~1
mU/ml)~4
RI~11
fluorescein-coupled~1
ultra-structural~1
prepubertal,~2
26-day-old~1
(rGH).~1
BW),~3
sc,~3
rGH~7
69-fold~1
19.8%~2
32.0%.~1
rGH-treated~1
(RIA),~2
1.63~1
rGH/day.~1
amiodarone-treated~3
E-domain~8
proinsulin-like~1
(pro-IGF-II)~1
BRL-3A~3
pro-IGF-II~1
[rat~1
pro-IGF-II-(117-156);~1
peptide]~1
40-amino~1
pro-IGF-II.~1
41-residue~1
[Tyr116]pro-IGF-II-(117-156)~1
pg/tube.~1
hIGF-II,~1
pro-hIGF-I-(71-105),~1
EGF,~1
[Phe117]pro-IGF-II-(118-156)~1
E-peptide~3
blot)~1
polyestradiol~1
(DRN),~1
(MRN),~1
raphe-pontine~1
(MRN-RPn)~1
1100-2100~1
hypothalami~2
DRN~3
MRN~2
surge;~1
RPn~1
arcuate,~1
ventromedial,~1
suprachiasmatic,~1
MRN-RPn~1
MPN~1
(PCPA)~1
1700~5
PCPA~1
PCPA-injected~1
Cornell~1
iodine;~1
(HI-Tg)~1
(LI-Tg)~1
atoms/molecule~1
immunogenicity,~1
adjuvants.~1
radioassays~1
RIAs.~1
HI-Tg~3
LI-Tg.~1
LI-Tg~2
LI-Tg,~1
HI-Tg.~2
neuromedin~1
(NMN)~1
NH2-enriched~1
putrescine-thyroglobulin.~1
(TG-B),~1
Lys8,Asn9-NT8-13,~1
xenopsin,~1
(iNMN)~1
(iNT).~1
iNMN~3
iNT~2
adrenal,~6
Feline~1
NMN-related~1
acid/acetone~1
acid-proteases.~1
synaptosome-like~1
vesicle-like~1
heptapeptide~1
dermorphin~1
intracerebroventricularly~1
Dermorphin~1
amides,~1
[D-Met2]DM,~1
[Sar4]DM,~1
[Trp5]DM,~1
[Phe5]DM,~1
[Gly7]DM,~1
[Ser(Bzl)7]DM,~1
deamidated-DM~1
secretion:~1
D-isomer~1
Ala~1
[L-Ala2]DM~1
amide;~1
[Gly7]DM~1
[Pro4]DM~1
[Gly6]DM;~1
([125I]hGH)~1
[125I]hGH~11
intracellular.~1
Internalization~1
(noncultured)~1
interior,~1
degradative~4
(binding,~1
wt:~1
669,000)~1
DNAase~1
(SEHPLC).~1
(DA)-mediated~2
Wistar-Imamichi~2
[neonatal~2
(NC)]~2
sulpiride-induced~1
(estrogen~1
Sulpiride-induced~1
[3H]spiperone~1
(20.4~1
fmol/pituitary)~1
fmol/pituitary,~1
(E2;~1
(P;~1
secretion(s)~1
Sulpiride~1
(postnatal~2
3-9)~1
22-28).~1
[3H]spiperone.~1
NC.(ABSTRACT~1
1-Adrenergic~1
Autoradiographic~1
slide-mounted~1
[125I]2-[beta-(4-hydroxy-3-iodophenyl)ethyl-aminomethyl]tetralone~1
([125I]HEAT)~1
[125I]HEAT~3
[125I]HEAT-binding~3
prazosin-displaceable~1
phentolamine-displaceable~1
binding)~2
stalk-transected~2
ganglionectomized~1
neurohypophyseal~3
coho~1
pH-stat~2
FA~9
glucose-free,~1
(titrimetric)~1
(colorimetric)~3
manner;~4
alpha-agonists~2
beta-antagonist~1
NE-~2
beta-agonist-stimulated~1
NE-stimulated~2
(IGF~1
(FGF),~1
(PDGF),~1
[125I]PDGF~2
FGF,~1
[6-3H]thymidine~1
Dulbecco's~3
Eagle~2
FGF~3
[125I]IGF~2
PDGF.~2
(P)-induced~1
2.5-mg~1
benzoate.~2
BIA-LH~4
bioassayable~2
(BIA-LH)~1
(204~1
(174~5
(376~1
pulsatile.~1
(57.1~1
(55.0~1
(62.9~1
(35.0~1
(34.6~1
(45.0~2
(125.3~1
(253.9~1
(44.7~1
Radioimmunoassayable~1
BIA-LH,~1
BIA-LH.~1
surge,~1
(10-12~1
(22-24~2
1730~1
Middle-aged~1
dexamethasone-pretreated~1
ACTHAR,~1
post-ACTH~1
Multinucleated~1
(10(-10)-10(-8)~1
tartrate-resistant~3
osteoclast-like~2
TPDMT-4~4
pregnancy-dependent~1
virgin,~1
T4-OR26,~1
T4-0I96,~1
T4-0I320,~1
outgrowths~1
virgins~1
(E2)-~1
T4-OR26~1
ovarian-responsive~1
E2-dependent~3
T4-OI320~3
T4-OI96~1
autonomous.~1
neither.~1
cytosolic,~1
microsomal,~2
translocated~4
dextran-charcoal~1
4S~2
5S,~1
E2-ER~1
autonomy-specific~1
[3H]E2-ER~1
Hormone-dependent~1
statuses~1
environments,~2
[125I]iodo-Tyr0CRF~4
noniodinated~1
(10(-11)-10(-7)~1
suberate,~1
iodo-Tyr0CRF,~1
gel.~2
[125I]Iodo-Tyr0CRF~1
sauvagine.~1
GnRH,~1
[Arg8]vasopressin,~1
CRF-stimulated~1
coenzyme-A~1
(mass)~1
4.7-fold,~1
4.4-~1
3.1-fold,~1
58-69%~1
65-86%~1
iodoacetamide,~1
102K~1
102K.~1
intraovarian~2
catecholestrogens~1
[e.g.~1
2-hydroxyestradiol~1
(2-OH-E2)],~1
(GC).~1
2-OH-E2~11
GC.~3
10-fold,~1
Saturating~1
EPI.~1
beta-antagonist)~1
alpha-antagonist)~1
2-OH-E2,~3
0.7-~1
U-0521,~1
O-methyl~1
EPI,~3
metanephrine,~1
2-OH-E2.~1
synergizes~1
unknown.4+owever,~1
catecholamine/2-OH-E2~1
paleocortex,~2
Nonfractionated~1
(1.04-1.38~1
Eadie-Hofstee~2
(666~1
caudo-cranial~1
(1628~1
266,~1
paleocortex~1
(357~1
phylogenetically~1
caudo-rostral~1
suckling-induced~3
(rNHA).~1
rNHA~4
decapitated.~1
suckling.~2
(non-H-2)~1
graft-vs.-host~1
(GVHR)~1
(DBA/2~1
B10.D2)F1~1
Syngeneic~1
(F1)~1
(enzyme~2
assay)~4
GVHR~6
(0.03,~1
microgram/mouse).~1
(saline~3
injected)~1
1-acetyl-1,2,3,3a,8,8a-hexahydro-8a-hydroxy-5-methoxypyrrolo[2,3-b~1
]indole,~1
2-hydroxymelatonin.~1
(a-MT-K1)~1
(melatonin~1
indoles~1
2-hydroxymelatonin~2
indoles,~1
6-hydroxymelatonin~1
HPLC),~1
beta-glucuronidase-arylsulfatase~1
liberate~1
phosphoenolpyruvate~3
carboxykinase~1
(PEPck)~1
multi-hormonal~1
occupancy,~2
PEPck~8
thyroidectomized,~1
(pPCK10).~1
Translational~1
(transcriptional)~1
T3-receptor~1
(NTPase),~2
nucleocytoplasmic~2
Mg2+-ATPase~2
dose-,~1
time-,~2
Heat-denatured~2
NTPase~7
hCG's~3
(prepropressophysin)~1
suprachiasmatic~1
(SCN)~1
prepropressophysin~1
day-night~1
SCN~2
Sucrose~5
(1,25-(OH)2D3~1
sedimenting~1
6-fold;~1
insulin-primed~1
functionality~1
nonsteroidogenic~2
(nanomoles~2
protein-1)~2
2-month-old~3
5-cholesten-3~1
beta,25-diol~1
(25-hydroxycholesterol;~1
protein-1~9
Microsomal~1
5-3~1
beta-hydroxysteroid~2
dehydrogenase-delta~1
5-delta~1
4-isomerase~1
(2-month-old,~1
12-month-old,~1
amytal~2
transuteroplacental~3
(F)-cortisone~1
(Papio~1
anubis).~1
F-E~3
mid-gestation~1
100;~3
(fetectomy)~1
ethamoxytriphetol~1
[1-(p-diethylamino-ethoxyphenol)1-phenyl-2-p-methoxyphenolethan~1
ol~1
(MER-25)].~1
fetectomized~2
mid-gestation,~1
MER-25~1
E)~4
poly(2-hydroxyethyl~1
methacrylate)~1
(polyHEMA)~1
rounding~5
(10(-5)-3~1
poly-D-lysine~1
(polylysine)~1
alpha-dihydroprogesterone,~2
poly(HEMA)~7
rounding),~1
poly(HEMA),~1
alpha-dihydroprogesterone~1
Polylysine~1
polylysine~3
incubated,~1
(OXT)~2
OXT~10
(SRIF-14)~1
somatostatin-28~2
(SRIF-28)~1
SRIF-like~1
syntheses~2
cysteine-containing~1
SRIF-14~1
SRIF-28~1
sizeably~1
Na125I~1
iodothyronines~1
euthyroidism.~1
nonmetabolizable~4
(600-700%~1
half-maximum~1
microU~2
TSH/ml,~1
TSH/ml.~1
3-O-methyl-D-glucose~1
(Bu)2-cAMP~1
micrograms/ml);~2
phloretin;~1
stereochemical~2
3-O-methyl-glucose,~1
L-glucose;~1
66.0~2
fmol/min~5
mM);~1
transporters~2
D-glucose-sensitive~1
[3H]cytochalasin~1
Mediocre~1
(hGH),~2
bioassay's~1
(bGH)~1
hGH.~2
bGH.~1
sc.~2
bGH~2
pinpointed~1
growth-neutralizing~1
31-32~1
specifications~5
hGH;~1
bGH)~1
lambda,~1
hovered~1
respectable~1
reliably.~2
immunogenicities~1
invalidates~1
beclouds~1
Thyronine~1
growth-stimulating~2
Estrogens~1
(MCF-7).~2
[3H]5~1
([3H]DHT)~1
[3H]DHT~3
Occupancy~1
125-fold~1
DHT.~2
estradiol-mediated~1
dependent;~4
withdrawn;~1
estrogen/androgen~1
5'-deiodinating~1
(5'D)~1
hatching,~2
5'D~3
5-deiodinating~1
(5D)~1
3,3'-diiodothyronine.~1
5D~3
effects)~3
deiodinases~1
T3-sensitive~1
overexposure~1
Edman~1
horse,~1
buffalo,~1
beta-lactoglobulins.~2
beta-lactoglobulins~2
PP14~1
(beta-EP),~1
(beta-LPH),~1
perimenstrual~2
(PMS)~1
midcycle.~1
(MDQ)~1
Beta-EP~1
MDQ~1
swings.~1
(GA)~2
GA~7
GA.~1
GA,~2
oil-base~2
hysterogram~1
fecund,~1
clinic-based~2
45,X/46,XY~1
dysgenesis.~1
(serial),~1
gonad~2
45,X~4
endocrinologically~3
agonadal.~1
chimerism~1
+5.0~2
(seeding)~1
nonfrozen~4
postthaw,~1
seeded,~2
fertilizability~4
Seeded~2
nonseeded~3
microdiathermy~1
electrosurgery.~1
immunoactive~3
analysis:~2
Comhaire~1
Irvine~2
Aitken~2
HEPA.~1
nidation,~1
organogenesis,~1
3H-estradiol~1
Ligands~1
(OCs)~1
reproductive-age,~1
provisionally~1
lognormal~1
Truncated~1
range"~1
Fifty-microgram~1
estrogen-containing~2
Thirty-five-microgram~1
beta-lipotropin,~2
amenorrhea-galactorrhea~2
(PRL).~2
adenomectomy,~2
corticotroph~2
wife~2
fertilize~4
wife's~1
IVF-GIFT~4
GIFT.~1
(6.25%)~1
(8/16)~1
Fertilization~1
(12/30)~1
(2/12)~1
insemination.~1
wives~4
Infertile~2
10-cm-long~1
syringes~5
prefreezing~1
postthawing~1
Postthawing~1
stored-frozen~4
straws.~1
postinsemination~1
syringes.~1
Donor~3
cycles;~1
(EPAT)~1
EPAT~1
(EPAT-factor)~1
ovum.~1
EPAT-factor~1
1-cell~1
blastocyst~9
fertilization-treated~1
transfers,~2
ET),~1
transfers).~1
(12.7%)~1
(24.7%)~1
ET,~1
(29.1%)~1
ETs~1
(27.1%,~1
zonae~1
pellucidae~1
zona-intact~1
fimbriae,~1
drop-out~2
gynecologists~1
regretting~1
(GCW)~1
isoporous~1
nondiscriminatory~2
Kf~4
(r0)~1
.72)~1
.73).~1
invariable~1
(20-25%).~1
barrier-size~1
51Cr-EDTA~2
16-50~1
electron-microscope~1
24-67%).~1
still-functioning~1
[647~1
(C.V.)~1
0.22]~1
(310~1
C.V.~3
0.08);~1
(352~1
0.06);~1
614%,~1
Glycosaminoglycans~1
(GAGs)~1
(17.22~1
6.56~1
micrograms/10(5)~3
(43.71~1
16.05~1
(26.11~1
3.30~1
diabetic).~1
(GBM),~1
water-insoluble~1
Heparan~2
GAGs~2
water-~1
8006~1
ancestry,~1
45-70~1
6394~1
(157-189~1
1,5-anhydro-D-glucitol~1
9.6-38.8~1
(13.3~3
multidisciplinary,~2
(Nisei)~2
1910~1
1939~1
King~5
1746).~1
volunteered,~1
Nisei~6
(IGT),~2
IGT,~2
61.4~2
IGT;~1
50.3%~1
undiagnosed)~1
nephropathy)~1
(11.5%~1
diabetes--40.0%~1
17.2%~2
sulfonylurea-treated~1
IGT)~1
63.8%~2
19.4%~2
72.7%~1
5-9~2
20.5%~1
Nephropathy~1
IGT.(ABSTRACT~1
Diabetes-prone~1
(BBdp)~1
(BBn)~1
glycosuric,~2
beta-cells.~3
cyclosporin-treated~1
hypoinsulinemic~1
BBn~4
OX19+~1
(pan-T)~1
W3/25+~2
W3/13+~1
OX19-~3
BBdp~4
OX8+~1
Suppressor/cytotoxic~1
(OX8+)~1
Ia+~1
cyclosporin,~1
beta-cell~2
heparinase.~3
beta-mercaptoethanol~1
125I-fibronectin.~1
"galactose~1
neuropathy."~1
gravimetrically~1
sorbinil~5
NMR-spectroscopic~1
AR42J~1
neglect,~3
lower-class~2
570)~1
Louisville~2
entitled~2
"team~1
teach"~1
germane~1
565~3
Libya.~4
7.1.~1
overcrowded.~1
98.1%~1
gainful~1
psychogeriatric~3
Charles~3
4.8%.~2
offices,~1
Verona~1
(18.3~2
cyclical,~1
tape-recorded,~1
coded.~1
Talk~1
something~2
engaging~3
queries~1
Sydney,~2
Australia.~2
12-item~1
initiative~2
Trent~1
Practitioners.~1
35-64~1
Practices~2
Becoming~1
'walks~1
door'.~1
informal~1
comprehensive.~1
Cognitive,~1
tutors~1
grounding~1
draws~3
tutor~1
Tasmanian~1
Director~1
Education.~1
trainee,~1
negotiated~1
tutors.~1
tune~1
trainee's~1
vision;~1
tarda.~1
(diminished~1
A3,~1
allele,~2
(22.2%),~2
(24.5%).~1
A3~1
non-A3~1
(16.6%)~2
1-75~1
5-yr~2
(HBeAg)-positive,~1
49.2%~1
HBeAg-negative~1
HBeAg-positive~2
HBeAg.~3
virus-deoxyribonucleic~1
reversions~2
"e-window"~1
38.7%~1
reversions.~1
821~1
(Corzyme-M),~1
carriage.~2
507~2
(4.4%),~2
(26.7%),~1
anti-hepatitis~1
agent(s)~1
(13.4%),~1
tauro-23[75Se]selena-25~1
homocholic~1
ileoscopy,~1
hypocomplementemia.~1
nonascitic~1
928~1
545~3
pre-S~4
pre-s2~4
pre-s1~3
Possibly,~1
1.4:1.~2
microclimate~1
juxtamucosal~2
4.48~1
4.84~1
3.52~1
7.16~1
cap,~1
6.84~1
6.74~1
Juxtamucosal~1
"mucus-bicarbonate"~1
(IBS)~1
ultraluminal~1
IBS.~2
Periodicities~1
IBS~6
IBS--ileal~1
propulsive;~1
5-aminosalicylic~8
dropouts~1
"much~1
improved"~1
20-40~2
initiation.~5
5-Aminosalicylic~1
q.i.d.~1
progastrin~4
glycine-extended~6
heptadecapeptide.~1
forestomach~1
pylorus.~3
pylorectomy,~1
pylorectomy~1
Neuropeptide~3
(0.3-30~1
dimethylphenylpiperazinium~1
ceruletide,~1
Nerve-mediated~1
alpha-adrenoceptors,~2
purinoceptors~1
nonnoradrenergic~1
pylorus,~2
cycles/min,~1
potential-associated~2
voltages.~1
Bethanechol~1
Hydrochloric~2
Sodium-dependent~1
low-affinity,~1
high-capacity~1
high-affinity,~1
low-capacity~1
zero-trans,~1
cis-NaSCN~1
Postresection~1
(low-affinity~4
177.5~1
3.73~1
267.8~1
post-transection~1
280.4~1
271.7~1
4.69~1
recorder.~4
[median~1
0.4-7.1)~1
0.0-1.7)~1
0.0-2.1)~1
0.0-0.7)~1
0.01],~1
smoker~2
pH-metry.~2
Sulfasalazine~3
deoxycholate.~2
oxidase-induced~1
Sulfapyridine,~1
deoxycholate-induced~1
sloughing,~1
chemiluminescence,~2
scavenge~2
performed).~1
Welch-Allyn~1
Fujinon~1
microchip~2
tract:~2
endoscope;~1
"bench"~2
electronics~1
brightness~1
(luminosity),~1
(chroma).~1
619~1
adrenalin~1
chiefs~1
gastroenterology~1
Reluctance~1
respondent's~3
attendings,~1
assistants.~1
restaging.~1
Verification~3
colonoscopes~2
newport.~1
disinfection~2
cross-contaminate~1
colonoscopes,~1
Implemented~1
Sphincter~2
sphincterotomy;~1
Schatzki~2
retractable~1
sphincterotome.~1
25,000,000~1
diuretic-based~1
Lichen~1
Michael~1
Reese~1
(dilated)~1
(Meptid)~1
non-cirrhotic~5
(NCLD)~1
h:~1
NCLD~3
(cirrhotics~1
l/h;~2
l/h).~1
vomited~3
(cirrhotics:~1
5.3%:~1
NCLD:~1
1.3%).(ABSTRACT~1
Lactitol,~1
metabolised~1
lactitol~4
radiotelemetry~1
-6.51~1
-5.63~1
-5.18~1
Neomycin~1
antagonises~1
(25.8~2
mmHg),~4
intrasplenic~5
(25.0~1
intravariceal~4
NCPF,~1
intraphepatic~1
(15.4~2
(23.96~1
(8.9~3
0.93),~1
varices.(ABSTRACT~1
effective--only~1
shattered.~1
fragmented.~1
aborally~1
micrograms/kg/h).~1
feeding-induced~2
pancreas).(ABSTRACT~1
58.9%;~1
9.6%;~1
23).~2
-0.85,~1
pre-existent~1
dose/response~1
mg);~1
gastroduodenoscopy~2
characterise~1
stomach)~1
(91.3%)~2
81.3%.~1
95.9%~1
biopsied.~1
hydrolases~4
CU).~1
(IRE2)~1
non-smokers,~4
(IRCT)~1
IRCT~1
IRE2~1
155%,~1
200%,~1
(PF4),~1
seven)~1
Radioimmunoassay~2
Abbott's~1
(nv~2
0.324~1
nmol/ml),~1
4.625~1
(142.5~1
0.189~2
(Z~1
5.396,~1
Olsalazine~1
(ADS)~1
azo-linked~1
(5-ASA).~1
ADS~3
ADS,~2
5-ASA).~1
ADS.~1
2-aminoisobutyric~1
(66-87~1
(19-55~1
ERCP,~1
marsupialisation~1
diligently~1
edema)~1
15-liter~1
"colloid"~2
post-large-volume~1
9.89~1
paracentesis)~2
hr.(ABSTRACT~1
embolization--a~1
(Toshiba~1
SAL50A/SDL-01A).~1
25-gauge~1
transhepatically.~1
708~1
807~1
419~4
nonselectively~1
galactosamine.~1
diffusion-limited~1
methylaminoisobutyric~1
stuporous,~1
comatose.~1
precomatose~1
(measuring~2
sham-surgery~2
(83%).~2
[cirrhosis~1
(17.0~3
gm)].~1
cirrhotics.~2
N-demethylase~1
obstruction)~2
precirrhotic~1
(11.5~4
acetaldehyde,~3
(inflammation-induced)~1
cyanamide,~1
cyanamide~3
Nonfasted~1
[3H]Fucose~1
[14C]leucine~1
inflammation-stimulated~1
[35S]glutathione~2
Uptakes~1
ethanol-withdrawn~1
22.30~1
3.06~1
(13.51~1
2.04),~1
(16.96~1
2.22).~1
detoxification,~1
determined.(ABSTRACT~2
dihydroxyfumarate~5
prolyl~4
dihydroxyfumarate.~1
Cu(Lys)2~1
proliferators,~1
ciprofibrate~4
clofibric~5
acylCoA~3
laurate~3
Ciprofibrate~2
97%),~2
49%),~2
(484~1
614%),~1
(529~1
931%)~1
(624~1
671%)~1
125I-immunoglobulin~1
component-dependent~1
Primate~2
component-specific~1
intolerant.~2
alpha)-glyco-allodeoxycholic~1
kanamycin~1
acid-fed~2
cholestanol.~1
glyco-allodeoxycholic~1
Kanamycin~3
alpha-dihydroxy~1
beta-trihydroxy~1
cholesterogenesis.~1
cholestanol,~1
alpha)-glyco-allocholic~1
alpha)-allodeoxycholic~1
dehydroxylation.~1
cholic,~1
chenodeoxycholic,~1
deoxycholic,~1
lithocholic~1
dehydrocholic~1
step-wise,~1
carrier)~1
Sulfation~1
acid-dependent~2
acid-independent~2
(KMCH-1)~1
cholangiocellular~2
KMCH-1~4
pave~2
24th~2
98,~1
adrenocarcinoma,~1
spot-blot~1
NaOH,~2
detergent,~1
virus-hepatitis~3
coinfection~2
coinfection.~1
(burst~1
0.72,~2
norepinephrine.(ABSTRACT~1
random-zero~1
potassium-treated~4
3.4/1.8~1
19/13~1
1/0~1
91.5%~1
Li+-Na+~3
subject-determined~1
0.27,~4
one-kidney~1
pinacidil,~1
(+97~1
(dP/dt;~1
+1447~1
367~3
Hg/sec)~3
(+376~1
isoproterenol-stimulated,~1
fluoride-stimulated~2
Blunted~1
cellophane~1
cradle~1
(SHRSP)~3
(4-week-old)~1
(SHRSP-T),~1
(WKY-T).~1
norepinephrine)~2
SHRSP-T~1
WKY-T.~1
SHRSP-T.~2
Isoproterenol-induced~1
Relaxation~3
(membrane~1
stabilization)~1
beta-adrenergic-mediated~1
polyamines,~2
dialysate,~1
polyamines;~1
Monitors~1
(vs~2
postdilution)~1
(Amicon~1
D-20's~1
Renaflo's).~1
(Qp)~1
cc/min~1
cc/hr,~2
(Qb)~1
cc/min,~1
(UFR)~1
Qp,~1
Qb~1
(TMP)~1
(gravity,~1
Gomco,~1
suction,~2
IMED).~1
Gomco~1
TMP's~1
Costs~2
harness~1
Institution~3
(CT-AVIS,~1
PAVIA)~1
ascertain:~1
equipment;~1
(Plasma~1
System-Haemonetics)~1
FILTRA~1
(Dideco)~1
PLASMAPUR~1
(Organon~1
Teknika).~1
AUTOPHERESIS~1
CTM-(Hemascience).~1
single-needle~1
post-procedure~1
leads,~1
80-T)~1
(412-S)~1
S80-T~1
412-S~1
S-80-T~1
conductors~1
electrode-patient~1
80-T~1
'high-performance'~1
(TE),~2
(VI).~1
TE,~4
(braking)~1
Exponential~1
f.~1
mechanoreceptor-mediated~1
(Tcw)~1
(2-3~3
ergometer)~1
4.83~1
VO2),~2
(Hsk~1
Tre),~1
Tcw~1
(SE),~1
(28.8~1
2.66~3
[Ibody~1
Tsk/Hsk]~1
[Itotal~1
TW)/Hsk]~1
Itotal~2
Ibody~1
(Isuit~1
Ibody)~1
(Rcoll)~1
(Tcoll)~1
(2-10~1
mo),~4
(16-24~1
(6-13~1
Rcoll~2
Tcoll~2
(21,~1
9%)~4
ewe.~1
hypoxia),~2
hypoxia).~1
(CaO2)~1
7.18~1
5.19~1
3.27~2
ml/dl,~1
CaO2~1
2.00~3
(MSEs)~2
(TOs)~2
allobarbital-anesthetized~1
Impeded~4
TOs~4
MSEs.~3
MSEs~5
bulbospinal~3
Intercostal~2
forearms~2
(RHBF)~1
posttraining~4
(before,~5
22.4;~1
32.1;~1
6.4;~1
4.1;~1
RHBF~2
33.5;~2
43.7;~1
31.0;~1
NS;~1
35.7;~1
34.0).~1
(RHBF).~1
marrow-induced~3
(90-120~1
triglyceride-containing~1
acids).~1
U-60,257~2
blood-formed~1
remeasured~1
0.343~1
0.017~4
microliter/min.~1
diffusional~2
0.528~1
microliter/min~2
0.330~1
carbohydrate-poor~2
(FP)~3
mid-FP~1
mid-LP,~1
[means~1
2.0%]~1
(glucose,~1
glycerol)~2
catecholamines).~1
FP,~1
FP),~1
LP),~1
LP).~1
dissociations~1
gonadotrophic~1
(Cao2)~1
Cao2~3
7-day-old~4
oxyhemoglobin-containing~1
animals)~1
methemoglobin-containing~1
(15.1~3
vol%),~1
Cao2,~1
(CBF~2
Cao2)~1
g-1)~2
afterloaded~3
shorten.~1
Fatigue~4
(EEV)~1
(EMG),~1
EEV~5
Breaths~1
(braking),~1
Expiratory~1
mid-lung~1
hyperpnea~2
M-to-P~1
(M/P~1
V30).~1
M/P~5
V30~3
Blunting~1
beta-agonists~1
V30.~2
Antimuscarinics,~1
bronchodilation,~1
(capillary~1
[direct:~1
indirect:~1
0.7].~1
(PM),~2
(effective~2
EFP),~1
isofiltration~1
(VC);~1
expiring~1
(RV).~1
Inspirations~1
expirations~1
(phase~1
beta-agonists,~1
washouts~1
somatocardiovascular~1
omocervical~1
intactness~1
occlusion).~2
funiculus~1
funiculus,~1
funiculus.~1
double-occlusion~2
(Pc,f).~1
(Ra,~3
Ca),~1
(Rv,~1
Cv),~1
(Rmc,~1
Cmc)~1
(Pdo)~1
Pc,f~6
Pdo.~1
Rmc~2
Cmc~1
Rmc/RT~1
Cmc/CT~1
cmH2O-1.~2
4.2-~1
Rv,~1
Cmc,~1
Cmc/(Ca~1
Cv).~1
acclimatization~6
(FIo2)~1
hypoxia:~1
72.2~2
113.2~1
140.0~1
FIo2~1
intraperitoneally)~2
(ventilation~1
4:~1
endurance-type~1
days/wk~2
bouts).~1
119,~1
172,~1
163,~1
posttraining.~2
115%~1
(PCE~1
PCE~5
(2.72~1
3.56~2
(XYZ)~1
l/min),~1
fast-twitch~7
Hemidiaphragm~1
isozymes.~2
Trends,~1
wk),~1
constrain~2
hundreds~2
650)~1
hypohydration.~1
(SG)~1
540).~1
sodium-to-potassium~2
SG~3
(2,000~1
sojourn~2
(Pdimax)~1
(Tlim).~1
(Tr)~1
(Ts).~1
Ts/Tr],~1
Tlim~2
unfatigued~1
Pdimax~2
drive;~1
(9-10~1
(2.8-3.0~1
(6.7-6.9~1
(9.6-9.8~1
(13.6-16.2~1
immature,~2
microembolism.~1
tranexamic~1
alpha-thrombin~1
U/kg).~1
Control-thrombin~1
Clym).~1
Clym.~1
CVF-thrombin~1
O-2-generating~1
zymosan-treated~1
(-30~1
(-25~1
Pressurizing~1
C-fibers~2
C-fiber~1
constant-diameter~1
nonsymmetrical~1
waveforms.~2
(15-80~1
resident-trace~1
symmetry,~1
unacclimated~1
NaCl-glucose-phosphate~1
reinfusion)~1
2-wk~2
antechamber,~1
HST~1
euhydrated.~1
(RCV,~1
51Cr)~1
(PV,~1
125I)~1
HST,~1
RCV~2
F-cell~1
exercise-heat~3
triangularis~6
sterni~5
(transversus~1
thoracis)~1
nonrespiratory~3
uninformed~1
(external~1
abdominis)~1
expulsive~1
"belly-in"~1
laughter.~1
sterni,~1
expiration;~1
abdominals.~1
chamber:~1
subjects);~2
antisymmetric~2
leg)~1
leg),~1
W/leg~1
boxes,~1
evaporation~5
(experiment~1
evaporation,~1
declaring~1
feature:~1
VT)~2
bifurcations.~1
VE,~5
Sympathectomy~2
f;~1
eupneic~1
baroreceptors.~1
0.01-10~1
rootlet~2
8-30~2
C4-C6~1
low-stimulus~1
Decerebration,~2
decerebellation,~2
phrenic-to-phrenic~1
(DRG)~1
(VRG)~1
(CPNS)~1
respiratory-modulated~2
non-respiratory-modulated~1
CPNS.~2
afferent.~1
DRG,~1
VRG~1
CPNS~1
paucisynaptic~1
PNS.~1
Acclimation~2
(Columba~1
livia)~1
(CECM),~1
dissipation.~1
48-60~1
(Tb)~1
panting~1
gular~1
fluttering.~1
Ta's,~1
(42,~1
nonpanting~1
pigeons'~1
(46.2~1
W/m2)~1
CECM~2
Tb~2
Ta's~1
(20-56~1
(RECM)~1
hatching.~2
altricial~1
nestling~1
multitrait~1
preeminence~1
powerful,~1
contending~1
1.0-cm-ID~1
(LLTS)~1
(hs)~1
LLTS~5
cm/min~1
(VEp)~1
LLTS.~1
VEp,~2
VEp~3
26-40%~1
hs~1
5-20%~1
T-O~1
gestation:~1
4-7,~1
6-9,~1
9-12~1
(ATA)~1
autopsied.~1
(Litter~1
resorptions,~1
fetal-to-placental~1
(weight,~1
resorptions~1
embryogenesis.~7
4.35~2
l/min)]~1
ride~2
(LCHO),~1
confectionery~2
(SCHO),~1
high-CHO~1
SCHO)~1
SCHO~3
LCHO,~1
(194,735~1
9,448~1
m),~3
LCHO~1
(175,204~1
11,780~1
176,013~1
10,465~1
(159,143~1
11,407~1
m).~1
cycling.(ABSTRACT~1
(U).~1
(smaller~1
accumulation).~1
8.5,~2
3.8,~2
rotating-hinge~2
Lucent~1
lucent~7
distressing,~1
(840~1
arthroscopy,~2
96.5~1
81.3~1
91.0~1
gibbus~4
bx,~1
bone-grafting~1
rotation;~1
filled;~1
violated~2
straight-leg-raising~1
straight-leg~4
raising,~2
Eventually~1
elbows.~2
Alternatives~1
foot)~2
obliquus~3
obliquus,~1
force-vector~1
eighty-six~3
Non-union~1
malunions.~1
radial-nerve~1
degrees;~2
non-compliant~1
antiglide~3
fibulae~1
restressing~1
64.3~1
fracture.(ABSTRACT~1
ligaments,~3
epicondyles.~1
29.5)~1
mg/h~1
beta-endorphin.~1
mg/h)~1
glucoregulatory~2
[3H]oxytocin~1
3H]OT)~1
[3H]lysine~1
3H]LVP)~1
radioligands~4
[Kd,~2
(Bmax),~1
protein],~1
[3H]LVP~3
(Bmax,~2
5794~1
1616~2
Although,~1
(beta-AR)~1
beta-AR~1
2-AR)-binding~1
receptor-linked~1
2-AR-AC~3
19-34)~1
63-85)~1
antagonist-binding~1
AC,~2
epinephrine-mediated~1
2-AR~1
[3H]yohimbine~1
Adrenarche~1
hypothalamic-pituitary-gonadal~1
(gonadarche).~1
adrenarche~3
gonadarche,~1
preadrenarchal~1
adrenarche.~2
gonadarche~1
(CPON)~1
26),~3
ganglioneuroblastomas~2
95)~1
38).~2
pheochromocytomas,~2
C-terminal-directed~1
antisera,~1
CPON~5
somatostatinomas,~1
insulinomas~2
NPY.~1
(0.35-1.25~1
unextracted~1
ganglioneuroblastomas;~1
pheochromocytoma;~1
adiposity,~2
morbidities~2
antilipolysis~1
Lipolysis~1
alpha/beta-adrenergic~1
Within-site~1
(antilipolysis)~1
(CSII)~2
(ICT).~1
18-32~1
4-23~1
ICT~1
(MNCV~1
SNCV)~1
(E/I~1
(30/15~1
(Valsalva~1
CSII,~1
MNCV~2
SNCV~1
E/I~2
30/15~1
ICT,~1
ICT.~1
erythrocyte-associated~4
(erythrocyte-associated~1
corticosteroid-binding~1
2.62~3
albumin-bound.~1
comply~3
hypothyroidism;~1
1-11.7~1
Western-style~1
3H]E2)~1
[14C]E2~1
glucuronides,~1
96-h~1
sulfates~1
alpha-hydroxyestrone~1
alpha-OHE1),~1
2-hydroxy~1
2-methoxy~1
16-hydroxylated~1
alpha-OHE1,~1
[14C]E2,~1
MCRs~2
[14C]E2.~1
role(s)~1
nonaromatizable~1
[dihydrotestosterone~1
(DHT)]~1
[androstenedione~1
(A'D)].~1
A'D~7
3-12~3
A'D.~1
ovulation-inducing~1
Digoxin-like~1
(DLI)~1
beta-glucuronidase,~2
DLI~3
protein-bound,~1
glucuronidated,~1
230.~1
glucuronidated~1
testosterone-estradiol-binding~1
4-androstenedione~2
nonhirsute~2
(IC).~1
DHEA~8
(BMI;~1
WHR.~2
DHEA;~2
DHEA,~1
servo-mechanism~1
adjusts~2
MCR.~1
C-19~3
androst-5-ene-3~2
androstane-3~3
alpha,17~3
beta-diol~3
11-12~1
beta-diol.~1
(R5020)~1
29K,~1
128K,~1
150K~1
60K~2
70K~1
R5020~3
51,000~1
51K~3
progestin.~1
receptor-reactive~2
43K).~1
octadecylsilyl~1
cartridges~2
(Sep-Pak~1
cartridge),~1
Yale,~1
abort~2
(conception~1
ultrasound).~1
8-14,~1
15-21,~1
22-28~1
29-35~1
post-ET~3
0.01-0.49),~1
(0.05-4.7),~1
(0.68-27),~1
(0.35-59),~1
(0.01-5.5),~1
(0.33-20),~1
(0.46-25),~1
(0.76-335)~1
1E5~1
(0.02-3.0~1
post-ET.~1
Ovulatory~1
Naltrexone~2
(SCADH)~1
Neonate~3
ethylmalonate~2
methylsuccinate;~1
ethylmalonate,~1
butyrate,~1
3-hydroxybutyrate,~1
adipate,~1
[1-14C]butyrate~1
(29-64%~1
[1-14C]octanoate~1
(43-60%~1
palmitate,~1
succinate,~2
sonicates~1
dehydrogenated~1
[2,3-3H]butyryl-CoA~1
[2,3-3H]octanoyl-CoA~1
butyryl-~2
octanoyl-CoAs~1
Monospecific~1
(MCADH)~1
MCADH~2
octanoyl-CoAs,~1
SCADH~3
99mTc-Pertechnetate~1
(99mTcO4-)~1
radionuclide,~1
99mTcO4-~7
Na+/K+/Cl-~3
co-transport~3
(Hanks'~1
salts),~1
co-transporter~1
scintiscans),~1
inflammation-associated,~1
fibroblast-stimulatory~1
fibroblast-inhibitory~1
(IFNs),~1
deactivators,~1
(40-60%)~1
hypercollagen-producing~1
IFN-alpha,~8
subculture~1
IFNs,~1
doublings)~1
IFNs~1
Menkes~1
hemizygotes~2
mottled~1
metallothionein-I~4
(mouse)~2
metallothionein-II~2
(human)~2
(metallothionein~1
inducers).~1
blotchy~1
flavin~5
(FAD),~1
[14C]riboflavin~2
[14C]FAD~2
[14C]riboflavin.~1
ethanol-impaired~1
nonradiolabeled~1
FAD.~1
pyrophosphatase~1
mononucleotide~2
(FMN)~1
(FMN~1
FAD)~1
readily.~2
alpha-keto~2
(BCKAD)~1
BCKAD~5
phosphorylation-dephosphorylation.~1
postabsorptively~1
postprandially.~1
meal-feeding.~1
oxidize~2
125I-DBP,~1
125I-G-actin,~1
DBP-G-actin~1
DBP-actin~2
indistinguishable,~2
slopes.~2
125I-G-actin~1
(nanomole)~1
DBP-actin.~1
DBP,~1
actin,~4
oligomers.~3
125I-apo-DBP~1
holo-DBP~1
ventilator-plethysmographs~1
Surfactant-TA,~1
[131I]albumin~1
intravascularly.~1
albumins~1
betamethasone)~1
Unpurified~1
immunopurification~2
400-fold~3
incubate,~1
microU/0.5~1
Immunoaffinity-purified~1
bioactivity-to-immunoactivity~1
(B/I)~1
-0.7237,~1
-0.6650,~1
-0.6382,~1
(XSCID)~1
XSCID~4
Carriers'~1
Nonrandom~1
XSCID.~1
Sacrifice~1
slippage.~1
slippage~2
unexpectedly,~2
(beta-VLDL),~1
ester-rich~1
apolipoprotein-E~1
(apoE)~2
liposomes;~1
apoE-phospholipid~1
apoE,~2
infusions:~1
(B19)~2
(erythema~1
infectiosum)~1
anemias.~1
1-2-g~1
erythropoietin.~6
burst-forming~3
Granulocyte-macrophage~1
progenitors.~2
phlorizin~3
pancreatectomized~2
intolerance;~1
tolerance;~1
phlorizin-treated~3
phlorizin.~1
euglyemic~1
hyperinsulinemic~1
Insulin-mediated~1
Phlorizin~1
reemergence~2
phlorizin,~1
normalizes~2
(HEP)~2
(URO)~1
URO~2
HEP~3
newcomer~1
market,~2
tan~2
accelerator,~1
Readings~3
companies'~1
Dapsone~1
(necrotizing)~1
elevatum~1
diutinum~1
(palpable~1
purpura)~1
(100-150~1
reached)~1
Amiodarone,~1
non-sun-exposed~1
amiodarone-associated~2
lipidosis.~1
Sun~2
Porphyrin~1
phototested,~1
UVB.~1
phototesting~1
dermatologist~2
830~1
Hospitals.~1
nonblacks).~1
mongolian~2
Wood's~1
melanoma/dysplastic~1
Westragel~2
Westrastick~1
Franz~2
danthron~3
dianthrone,~2
anthralin,~3
microemulsion~1
Westragel.~1
danthron,~2
dianthrone~2
dianthrone.~1
Westragel,~1
short-contact~2
Drionic~3
unit)~1
hyperhidrosis~4
(axillae,~1
palms,~1
soles)~1
Persprint~1
necessitate~5
profundus,~1
profundus~1
antimalarials,~1
Electrosurgery~1
electrophysical~1
fundamentals~2
mosaicism.~1
zygote~3
gametic~1
Schimmelpenning-Feuerstein-Mims~1
McCune-Albright~1
Sturge-Weber~1
Proteus~7
gigantism~1
macrocephaly,~1
papillomatous~1
anomalies),~1
Delleman-Oorthuys~1
(orbital~1
porencephaly,~1
appendages,~1
commentary~1
"banner"~1
multidirectional~3
occipito-parietal~2
bitemporal~1
minigrafts~1
atrophicus.~1
undesired~2
fragility,~3
post-inflammatory~1
(incontinence~1
pigment),~1
alteration,~1
hemosiderin.~1
(hydroquinones),~1
Mutilating,~1
horrifying,~1
(BCC)~2
BCC~6
metatypical~3
BCC,~2
thickness;~1
10.2,~1
syncope:~1
(syncopal)~2
(non-syncopal)~1
syncope;~1
A.(ABSTRACT~1
Jamaican~3
4.70~1
(79.4~2
60.8~3
(116.3~1
stress-systolic~2
12.5,~3
Einthoven~1
electrocardiographer's~1
littered~1
shattering~1
reassembling~1
induction:~1
induction),~1
induction)~1
injected;~1
(97%;~1
Anticoagulants~1
infarcted.~1
hematoxylin-eosin~1
perfluorochemical,~2
perfluorochemical-treated~1
(15.3~1
retroperfusion~5
diatrizoate)~1
subserved~1
retroperfusion,~2
presynchronized~1
monastral~3
retroinfused~1
dye).~1
half-time.~4
640~3
480).~1
subdividing~1
filling:~1
asynchrony.~1
MDL-17,043)~1
0.22).~2
fidelity~2
micromanometer-tipped~1
Afterload~2
1,030~1
1,381~1
Hg/s~2
piroximone~8
(MDL-19,205),~1
inotrope-vasodilator~1
m2;~6
(1,633~1
1,183~1
dynes.s.cm-5;~1
g.m/m2;~1
piroximone.~2
piroximone,~2
ml/m2;~1
vasopressin)~1
desmopressin)~1
units/patient;~2
(4.8-~1
4.3-fold,~1
10(3)/mm3,~1
increased:~1
(VIII:C)~1
units/ml~2
(VIII:vWF)~1
undefined,~1
turbulence,~1
color-coded~1
ultrafast~1
(cine)~1
(size,~1
cine-computed~2
bradycardia-tachycardia~2
seconds;~2
Multiple,~1
repetitive,~2
deflections,~1
deflections~3
electrogram.~1
0.087).~1
dilation;~1
Norris~2
(METs)~1
(1,235~1
1,037~1
942~2
mumol/min~2
pollution:~1
engineering,~1
smoke,~7
buildings.~1
Bermuda~2
94,000~1
34,000~1
nondissociating~2
Electrophoretic~2
somatoform~1
underscored.~1
heterogenicity~1
fiberoptic-assisted~1
anti-PA~1
PA-protein~1
Bitolterol~2
closed-port,~1
intermittent-flow,~1
compressor-driven~1
(CPIF)~1
nonsteroid-using~1
bitolterol~9
7.3,~1
preprednisone~3
dust-mite~1
bedding,~1
carpet,~1
sofas~1
monthly,~4
mites.~1
Der~14
pteronyssinus,~1
(AgP1Eq).~1
twentyfold,~1
sofas,~1
AgP1Eq~6
gram),~1
gram)~1
humidity.~1
May.~1
counted,~2
July;~1
Ryegrass-pollen~1
pollen-allergen~1
mite-allergic~1
seasonally~3
mite-allergen~3
cedar,~2
hobbies.~1
(59.6%)~1
Methacholine~1
(1.46~1
3.96~1
4.52~2
Race,~3
intermittently.(ABSTRACT~1
immunotoxic~1
urea-formaldehyde~1
(UFFI)~1
asthma:~2
differential,~1
(E-rosetting,~1
B73.1,~1
lymphocytes),~1
formalin-treated~1
(Form-RBC),~1
Thomsen-Friedenreich~1
Form-RBC,~1
(NK),~1
(IFN)-boosted~1
(IFN-NK),~1
UFFI-insulated~4
(home~1
formaldehyde,~3
UFFI~5
UFFI-containing~1
NK,~2
IFN-NK~2
L-649,923~7
capacity)~4
(0.3%).~1
parallel-group,~1
repetitive-dose~1
intermittent-flow~1
Productivity~1
measuring,~2
Self-evaluation~1
worth.~1
her/his~1
self-examined~1
dietetic~10
professional.~1
Well-defined~1
accomplishments~1
jointly~3
Heart,~2
Lung,~2
(NHLBI)~1
Agriculture~1
fats.~2
One-day~1
5,640~1
(LRC)~1
LRC~2
Guidelines.~1
34-day~2
Army.~1
wartime~2
rations)~1
nonpoor~4
nonwhites,~1
nonpoor,~2
promotion/disease~1
patterns)~1
26-~1
45-year~1
accountability~2
Procedure~1
supervisory~1
delegation~2
assistants,~1
Lifestyle~4
Assistant~3
Wisconsin-Stevens~1
majoring~2
dietetics)~1
wellness:~1
occupational,~1
spiritual,~1
intellectual,~1
emotional.~1
Assistants,~1
wellness~2
Assistants~2
wage.~1
assistants~6
flexibility;~1
appraisal;~1
University's~1
campus~2
cafeterias;~1
athlete's~3
recommendations:~1
late-life~2
(PDE),~1
DSM-III-R*~1
PDE~2
PDE.~1
22-day~1
(dyspnea,~1
overutilizers~1
stressful,~1
caregiver~1
Caregivers~4
vacations,~1
church~2
wide-ranging~1
caregiving,~1
caregiving~1
(SPMSQ)~1
SPMSQ~3
accepted)~1
errors,~2
99.0%~1
delirium.~2
SPMSQ.~1
faller~1
sedatives/hypnotics,~1
drug/diagnosis~1
high-odds~1
85;~1
Electroconvulsive~2
.26;~2
.22;~2
.008)~2
.50;~1
laterality~5
medico-surgical~1
nonpsychiatric,~1
TRH.~1
(1.9%~1
2.3%.(ABSTRACT~1
(PDB)~1
1,078~1
PDB~3
Dunedin~1
cholesterols,~1
(218)~1
Weight-for-height~2
elders.~1
(SIP)~1
3.12,~1
.029)~1
.28~1
4.39,~1
.011),~1
SIP,~1
clarification~4
prevaccination,~1
post-~1
postvaccination.~2
6A,~1
9N.~1
post),~1
6A~1
(SNS)~1
outflow,~3
arterialized~4
m/kg~1
(-51~1
-58~1
(-60~1
-62~1
(-20~1
(NPH)~2
NPH:~1
NPH~8
scan;~2
NPH.~3
NPH;~1
multigenerational~2
intercohort~1
curvilinear,~1
upturn~1
approval,~1
unconditional~1
coresidence.~1
streams~3
county-group~1
destinations,~1
destination,~1
Arizona~4
Illinois,~4
suburbs~1
Repeatedly~1
story~2
Distance~3
factor;~2
1-in-100~1
microdata~1
streams.~1
(RAMMS)~1
wounding~2
wounding,~2
punch,~1
leucopus).~1
(Mus~1
musculus),~1
(Cohen~1
1987),~1
Peromyscus.~1
C/insulin-like~1
(SM-C/IGF-I)~1
[125I]SM-C/IGF-I~1
SM-C/IGF-I.~2
SM-C/IGF-I~5
SM-C/IGF-I's~1
lost,~3
concreteness~3
concrete~4
abstract~4
words.~2
Adults'~1
syntactic~2
complexity.~1
1856~1
1876,~1
cohort-sequential~1
1829~1
1860~2
1869~2
1900~6
1909~2
1949.~1
Sentences~1
longest,~1
entries~1
half-decade~1
right-branching~1
embeddings~1
subordinate~1
phrases~1
sentence~1
sentences~2
clauses.~1
adults'~1
sentences.~1
heterochrony~1
hemispheres?~1
hemisphere)~2
imagery-based~1
executing~3
electrooculogram.~1
task;~1
attention-engaging~1
hemi-aging.~1
Psychometric~2
OARS,~1
(SPES),~1
2015)~1
SPES~1
factors--alienation,~1
endorsement~6
room)~1
map.~3
distinctiveness~4
map-room~1
college-aged~1
speed/accuracy~1
64-card~1
Card~1
Sort~1
(WCST)~1
95),~1
80-~1
64-~1
800-1,600~1
(Barrett's)~1
double-barrelled~1
cytotoxin.~2
Biotyping~1
bacteriophages~1
bacteriocins~1
reinfection~4
antibiotic-associated~2
(TMC),~1
TMC.~2
(complications,~1
hematochemical~2
TMC,~1
excess,~6
gaseous~2
TMC~3
1969-1983)~1
Gammaglobulin~1
2.8-year~1
4-234)~1
fluid/serum~1
0.10-1.55).~1
(sterile~1
cirrhotic,~1
1,957~1
1,093~1
5.59~1
0.02--both~1
Gastroenterology~1
Giovanni~1
Battista~1
Torino,~1
person-year~1
Piemonte~1
Region.~1
manifold.~1
Sex-~1
Cutler-Ederer~1
Proportional~2
Hazard~1
Model.~2
clue.~1
Talc~1
SGOT,~3
SGPT,~3
Leukemoid~1
leukoerythroblastosis~2
pneumatosis~2
intestinalis~2
smooth-surfaced,~1
polyp,~3
remove.~1
(consequences~1
thermocautery)~1
endosocopic~1
esophagomyotomy.~1
esophagomyotomy,~1
month's~2
battle~2
peace~1
mind),~1
both),~2
un-American~1
(avoidance~1
suits).~1
(DR,~1
DQ,~2
DP)~1
(Th)~1
subtypic~2
Dw~6
alloresponses.~1
CMV-specific~1
Th~1
Clones~2
DR-,~1
DQ-,~1
DP-reactive~1
DR-~1
DQ-restricted~1
antigen-presenting~7
(APC)~1
DR-DQ~1
APC~1
Unrelated~1
determinant(s)~1
polymorphic.~1
Fabricius~1
bursal~2
involution.~1
(IgG-RB,~1
IgG-G3,~1
IgG-RB2)~1
abundant.~2
ORG~3
2058~2
progestin)~1
2058,~1
progestin-binding~1
(studied~1
HPLC)~1
estradiol-sensitive~1
post-transplantation,~1
immunogen~1
deaminase-deficient~1
(SRP),~1
7SL~3
72,000~1
32P,~1
deproteinized~2
35S-methionine-labeled~1
54,000~4
SRP~4
particle.~3
non-fatal~4
C57Bl/6~3
A774~1
Semliki~1
(SFV)~1
(MBP)~5
MBP-primed~1
SFV.~1
myelin-reactive~1
spectrotype~1
pauciclonal,~1
spectrotypic~1
(PC-BSA)~1
C-carbohydrate~1
spectrotypes~2
PC-BSA~1
associate.~1
75/3B12,~1
75/3B12~5
galactose-containing~1
M-1,~2
asialofetuin,~1
lactose,~2
N-acetylgalactosamine--molecules~1
site--but~1
fetuin,~1
1/50~1
1/80~1
Abrin~1
N-acetylgalactosamine~1
nontarget~1
immunotoxins~1
lactose.~1
collagen-like~3
peptide's~1
selective.~2
platelet-interactive~2
immunodeterminant~2
anti-S.~4
fibrillogenesis,~1
sanguis.~1
mesenteroides~1
(G6PDH)~1
enzyme-antibody~1
G6P,~1
inter-heavy~1
disulfides~3
G6PDH-F(ab')2~1
G6PDH~1
anti-G6PDH~1
anti-digoxin~1
cytoplasts~4
(eosinophil~1
(ECP)~1
schistosomula.~2
ECP~3
Cytoplasts~1
cytoplast:schistosomula~1
neutroplasts~1
eosinoplasts,~1
43.9%~1
24.7%~2
synergism,~2
ECP.~1
ECP,~1
10(-5)M).~1
inflict~1
(X/Y)~1
C3d~1
(CR2),~1
(C4bp),~1
(Il~1
encode,~1
known;~1
(PBC),~1
gt~1
11-Amp3~1
1370-base~1
pBTA224,~1
lambda-Amp3.~1
pRMIT,~1
pRMIT~1
J101~1
anti-mitochondrial~1
PBC,~1
1591-RE~3
UV-induced~3
C3H/HeN~1
trinitrophenol~2
(TNP)~1
TNP-haptenated~2
3152-PRO~3
MCA-induced~1
TNP-1591-RE~1
TNP-3152-PRO~1
TNP.~2
TNP-hapten~1
regressor~1
progressor~2
Lyt-1-2+~1
Lyt-1+2-~1
Vicia~1
villosa~1
adherent,~1
noncross-reactive~2
co-express~1
hapten,~1
(Ts)~3
CY~1
noncytotoxic~1
Ts~24
Ts-inducing~1
2,4-dinitrofluorobenzene~2
agranular~1
plastic-adherent~1
Raji.~1
Leu-11,~1
NK-9.~1
Leu-11-positive~1
ML-2.~1
Raji-ML-2~1
heat-~2
(2D-PAGE)~1
(Dw2,~1
Dw12,~2
FJO)~2
(referred~2
(DR~1
migrates~3
Dw12~2
FJO~3
(HTC~1
DHO~1
(FJO-13,~1
DHO-8,~1
FJO-6,~1
DHO-7)~1
sequenced,~1
DR2-Dw2HTC.~1
2D-PAGE~1
(DHO-8~1
FJO-13)~1
(DHO-7~1
FJO-6)~1
Dw2,~1
RL)~1
RPMI~5
8866,~1
8866~3
RL-positive~2
hindrance~6
RL.~3
4.9.~2
immunoabsorbent.~2
20-positive~1
MHM~2
Tu~2
23/Fc~1
RL-specific~1
H3N2~1
H7N2~1
H7~1
primed,~1
NA,~2
reassortant~1
H7N1~3
H1N1~3
boosted~2
immune-suppressed~1
(cyclophosphamide-treated)~1
nonsuppressed~6
(donors)~2
non-antigenically~1
Sarcoma~2
webs~2
infection-mediated~1
(wing~1
web)~1
trachoma~3
formalin-~2
UV-inactivated~2
lipopolysaccharide,~1
triton~1
antigen(s)~2
Levodopa-carbidopa~1
Levodopa,~1
carbidopa~1
catechols,~1
(NSC~1
263475),~1
L-3,4-Dihydroxyphenylalanine~1
(L-dopa)~1
cysteinylcatechols~2
L-dopa,~2
4-S-~1
3-S-Cysteinylcatechols~1
2-S-cysteinylhydroquinone~1
melanocyte-specific~1
tyrosinase,~1
4-S-Cysteaminylphenol~1
tyrosinase~2
dimorphism.~1
glabrous~2
ethylenediaminetetraacetic~1
(EDTA)~2
(823~1
20/mm2)~1
(1689~1
66/mm2)~1
(1363~1
52/mm2,~1
2249~1
105/mm2,~1
(465~1
24/mm2)~1
(542~1
17/mm2,~1
(sham~2
564~3
27/mm2;~1
1179~1
49/mm2,~1
B5~4
(LTB5)~1
(EPA),~1
acid-derived~1
chemokinesis.~2
LTB5~4
LTB5.~1
LTB5;~1
(FMLP)-elicited~1
EPA,~1
epidermopoiesis~1
(back)~2
(arm,~1
postauricular,~1
forehead).~1
absorption:~1
benzoic~3
forehead.~1
human/hairless~1
[14C]Diazepam~2
14C-label~1
twin-chambered~1
triplicate~1
Fluxes~1
(stratum~2
dermis)~1
epidermis):~1
0.35-0.61~1
microgram/cm2/h~2
0.24-0.42~1
1.4-2.4~1
10(-2)cm/h~2
0.8-1.4~1
(0.76-3.31~1
cm2/h~2
0.12-0.27~1
coefficients)~1
microgram/cm2/h.~1
(ECMs)~1
ECMs~1
(HSPG)~1
(La).~1
7-8~1
HSPG,~1
La.~1
Morphology~1
larger;~1
matrices.~3
8-day~2
substratum.~1
promoter,~2
differentiative~1
histidine-rich~3
(HRP),~1
3F6-6,~1
(HRPII)~1
HRP-positive~1
TPA.~1
cultures;~1
stratification.~1
(maturation)~1
(stratification).~1
nonlesional~5
Goeckerman~2
Multiparameter~1
RNA/DNA~2
"uninvolved"~1
lamina-associated~1
Cytochemical~1
tracer-positive,~1
thiourea.~1
charge-selective~1
Profilaggrin~1
spinous~8
coordinately~1
keratins.~1
Virological~1
"sentinel"~1
(ARD)~1
ARD~4
(1981-1982~1
1982-1983).~1
(1981-1982,~1
zooepidemicus~2
fingerprints~3
prints.~1
bacteriocin~2
zooepidemicus;~1
untypable~1
biotyping~1
fingerprints.~1
incidents,~1
zooepidemicus,~1
Bacteriuria~1
patient-days.~1
overestimate.~1
(101.0~1
(102.0~1
3-,~3
4-specific,~1
rotaviruses.~1
VP7,~1
1975-1985,~1
serology-~1
culture-confirmed~1
(Danderyd,~1
Sweden).~1
whooping~2
Israel~2
rickettsial~3
(until~1
.0001);~2
covariables.~2
dublin~2
Lane~1
LD842,~1
avirulent~2
80-kilobase-pair~1
pSDL2.~1
spleen;~1
plasmid-cured~1
plasmid-free~1
LD842~2
Sublethal~1
organism's~3
serovars~1
pig-tailed~1
macaques.~1
Monkey~1
F;~2
J;~1
microorganism~1
endosalpinx~1
microimmunofluorescence.~1
Peritubal~1
endosalpingeal~1
(confirmed~2
salpingitis,~1
unfed~2
diverticulae.~1
Spirochetes~3
Naturally~1
polysaccharides.~2
Wiscott-Aldrich~1
IgG2-deficient~1
reaccumulates~1
micrograms/gm~2
reaccumulation~2
nonceruloplasmin~1
(FSGS),~2
(PAN),~1
FSGS~2
hallmarks.~1
preimmunization~1
2.8-fold~1
higher),~1
Defective~2
mitogen.~2
(AT~2
(Ag)~1
heparin-agarose~1
(H-CIE)~1
immunoelectrofocusing~1
(CIEF)~1
isoantithrombin~1
H-CIE~1
runs;~1
H-CIE,~1
CIEF~2
4.5)~1
4.6);~1
inactivation,~3
macronutrients,~1
diet-restricted~5
maltase~3
sucrase~2
villus/crypt~1
(acetate,~1
propionate,~3
butyrate)~1
isobutyrate~2
isovalerate,~1
Isobutyrate~1
isovalerate~2
Glucose-~1
sucrose-containing~1
incubates~1
myelocytic~2
aggregometer.~1
leukergy~1
zymosan-activated~4
formyl-methionyl-leucyl-phenylalanine,~1
Leukergy~1
(GSSG-R)~1
GSSG-R~6
acetylphenylhydrazine~2
diamide.~1
Pentose~1
GSSG-R.~1
diamide~2
reagents,~5
GdA-~1
"deficiencies"~1
pathogenically~2
phenocopy~1
Labetalol~2
meglumine/sodium~1
Tympanometry~2
school-children~1
Kuwait~1
otoscopic~2
radiotracer~3
Inhalers~1
99Tcm-labelled~1
(simulating~1
particles)~3
chlorofluorocarbon~1
chest)~1
19-29~1
(vial~2
upwards)~1
upwards~2
(82.5~1
one-position~1
two-position~1
vestibule.~1
MDIs~1
telecobalt~1
Material~2
(Cheesman~1
Charing~1
1983-4.~1
post-surgery,~1
pre-requisites~1
oral-oropharyngeal~1
rhinotomy,~1
wide-based~1
Lasix~1
Pyrogastrone~1
tympanotomy.~2
antero-inferior~1
overhang~2
crista~1
postero-superior~1
Tanzania~3
Muhimbili~1
Dar~1
Salaam.~1
Otitis~1
40-60~2
dB.~3
H.L.~1
otorhinolaryngology~1
otology~1
Meniere~1
underpressure~1
Bekesy~1
underpressure.~1
(8/43).~1
vertiginous~1
crippling~1
near-total~2
glossectomies.~1
quilted,~1
split-skin~1
hemiglossectomy~1
cartilagenous~1
discussed:~4
Chondrosarcomas~1
oesophagoscopic~1
Hundred~1
unhelpful~1
oesophagoscopy~1
oesophagoscopy,~1
teleangiectatic~1
granuloma.~1
ganglioneuroblastoma~1
Multiparous~1
rewarding.~2
vasectomy.~1
knew~5
machismo~1
(rural~1
residency)~1
problems:~1
Desired~1
.291)~1
Belief~3
want.~1
Flexner~1
(GPEP).~1
convincingly~2
low-cost~1
user-friendly~1
genogram~1
list,~2
prescription,~2
notes,~1
package,~1
package.~1
redevelop~1
software.~1
C-1,~1
breath-ethanol~2
blood-ethanol~1
Spectra-Physics~1
171-19~1
Mineralight~1
multiband~1
lamp,~1
UVSL-58~1
Fotodyne~1
Foto~1
410,~1
3-4100.~1
stains.~3
semen-5~1
(MHS-5)~1
(immunoglobulin~1
[IgG1])~1
N-biotinyl-w-aminocaproic~1
acid-N-hydroxysuccinimide~1
antibody-biotin~4
semen.~4
Immunodominant~1
11.5,~1
biotinylated-MAb~1
streptavidin~1
Cross-reactivity~2
antibody-peroxidase~1
vesicle-specific~1
Ninhydrin~1
spotting~1
Shime-waza~1
"choke~1
hold",~1
subdue~1
choke~5
unconsciousness~1
shime-waza~2
judo~1
1882.~1
"control~1
holds"~1
judo.~1
hold,~1
holds.~1
Jonestown,~1
Guyana~1
myelinolysis~4
liability.~1
metamorphosis.~1
Phases~2
30s,~1
overaged~1
interracial~1
embankments~1
launch~1
free-fall~1
evaluators.~1
testify~1
hearings.~1
proffer~1
fifty-nine~2
Police~1
drug-screening~1
Candidates~2
Inwald~1
(IPI).~1
IPI~1
Drug-Positive~3
Drug-Negative~3
candidates'~3
Item-level~1
(PMI).~1
1427~1
PMI~1
6.342,~1
(r2)~1
0.374.~2
PMI.~2
crystallizable~1
(Fc)~1
125I-Protein~2
-B.~1
dihydrocodeine~1
Sep-Pak~1
cleanup,~1
(Novopramine),~1
Imipramine,~1
2-hydroxyimipramine~2
2-hydroxyimipramine,~1
blood--9.0,~1
urine--92,~1
(acetaminophen~1
urine).~2
imipramine-related~1
(PCP)~7
myoglonin~1
PCP,~1
underground~3
pit.~3
frequents~1
"Confined~1
Space-Hypoxia~1
Syndrome"~1
tanks,~1
ships,~1
mines,~1
bins,~1
oxygen-deficient~1
kidnapping~2
paternity~1
daughter.~2
smeared~1
unsmeared~1
"cutaneous~1
import.~1
soldiers:~1
382);~1
334);~1
combat-ready~1
88).~1
postwar~2
tornado~1
(HSCL)~1
(PTSD).~1
PTSD,~2
HSCL~2
disasters~2
Marines~5
impatient~1
active-duty~1
Vietnam,~2
wounded.~1
applicants,~1
widowers~1
escort.~1
unescorted.~1
"dangerous~3
others."~2
Sunday~2
Saturday,~1
(DES).~2
54-year~1
clomipramine~1
cats:~1
triethyl~1
tin.~1
T1'~1
T2'~1
conclusion.~1
signified:~1
deterioration;~1
medullaris~8
brachii,~2
Prominent,~1
realised,~1
Hippocampal~1
tumour-like~2
976~1
confirmed:~2
inter-rater~2
Neurobehavioural~2
hospitalisation~1
utilising~1
aetiologies~1
levodopa-carbidopa,~1
levodopa-carbidopa~1
melatonin.~2
dysautonomic~1
hyposympathetic~1
Gliomas,~1
non-alcoholic,~1
fits,~1
tetraparesia,~1
Post-mortem~1
Leigh's~4
haemorrhages~2
Pupil~2
darkness~2
dull~2
migrainous~4
headache-free~3
nonheadache~1
non-headache~1
habitually-affected~1
etoposide.~1
(ten)~1
(1,200~1
mg/m2),~3
(HDCEP).~1
HDCEP~6
(1,000~2
(CAV).~1
Reevaluation~1
1,000/microL),~1
20,000/microL),~1
(59%),~1
45+%~1
yet.~1
MOPP~1
CHAP~1
(cyclophosphamide,~1
hexamethylmelamine,~1
OH],~1
cisplatin)~3
CHAP,~1
remitters).~1
regimens).~1
L-asparaginase~6
(ALL)~1
(PTT),~2
(CNPE),~1
CNPE~2
radiation/chemotherapy~1
chemoradiotherapy,~1
radiation/chemotherapy-related~1
effusion/tamponade~1
Moyamoya~1
(autoexcitation)~1
(spasm)~1
mentalis~2
autoexcitation~1
spread)~1
decompressed,~1
craniectomy.~1
7-month~2
totally,~3
cysticercotic~2
("autofusion")~1
autofusion~2
flexion-distraction~1
retropulsion~1
(Gd)-diethylenetriaminepenta-acetic~1
meningioma.~2
Gd-DTPA-enhanced~1
(85%);~1
CT;~1
kinase-BB~1
(CK-BB).~1
"extrapolated"~2
"observed"~1
Glasgow-Liege~3
Scales).~1
"Extrapolated"~1
Neuraxis~1
volume-buffering~1
(pressure-volume~1
PVI)~1
PVI~11
Hg/ml/min~4
ICP's~2
220.0~1
40.5~1
Corroborating~1
inexorable~1
shunt-dependent~1
thrombotically~1
bengal~3
dye-sensitized~1
514.5-nm~2
joule~1
fluences~1
(energy~1
kJ/sq~2
coagulum.~1
Vessels~2
electronic-state~1
photothrombosis~1
photocoagulation)~1
photothrombotic~2
permanency~1
mechanisms)~1
autoregulation:~1
carbon-14-labeled~1
iodoantipyrine~1
gm/min.~1
boundary-zone~1
craniectomies.~1
air-rifle~1
Classically,~2
chemonucleolysis,~1
injector~3
Vancouver~1
Hypersecretion~1
somatotroph~1
macroadenomas,~1
extrasellar~1
Gel-chromatographic~1
chromophobic~1
myelomeningoceles,~1
younger;~1
difficulty;~2
quadriparesis,~2
oscillopsia,~1
opisthotonos.~1
malformation:~1
surviving,~2
ischemic/hypoxic~1
Neurosurgical~2
postoperatively;~3
clot),~1
(backflow~1
heparin),~1
(significant~2
living);~1
(requiring~1
activities);~1
ICA/CCA~2
longer-lasting~1
(AVM's).~1
intramedullary,~1
dural,~1
Serpentine~1
avulsive~2
avulsions~2
(DREZ)~1
shock-like~1
dermatomal~1
pseudomeningocele~1
avulsion,~1
DREZ~1
Spondylotic~1
tandem.~1
myelographically~1
motor-neuron~1
chromium-51-labeled~1
(GOS).~1
(NE:~1
E:~1
0.0025;~1
DA:~1
worsened.~3
CA's~1
randomize~1
autocorrelation~1
cross-correlation~1
sacrifice:~1
ACh.~1
SAH;~1
floor.~2
15-foot~1
roof,~1
landed~1
abducted~3
Axillary~1
"tight~1
mechanism."~1
Neuroradiological~1
informational~1
(PCS)~1
vertebrae),~3
vertebrae).~1
short-segmental~1
end-plate,~1
board-like~1
end-zone~1
sandwich-like~1
transcortical~2
(IV).~1
scintigraphies~2
[99mTc]MDP~3
shin-splints~1
(HPT).~1
(D/S-index)~1
D/S~2
3.66~1
HPT-patients~1
1.64.~1
values).~4
secondary)~1
(NLSQ)~1
Sokoloff~1
al.'s~1
LC.~3
2-[18F]fluoro-2-deoxy-D-glucose~1
(2-[18F]FDG).~1
(+/-s.e.m.)~1
0.443~1
k2*~1
0.124~1
0.024~2
[201Tl]diethyldithiocarbamate~1
(DDC)~1
(LCBF).~1
DDC~4
tracer(s):~1
[123I]isopropyliodoamphetamine~1
(IMP)~2
(IAP).~1
LCBF~3
DDC,~1
IMP,~1
(LCBF)~1
IMP~2
IAP,~1
IMP.~1
SPECT~1
153Sm~1
multidentate~1
[153Sm]~2
ethylenediaminetetramethylenephosphonate~1
(EDTMP)~1
[153Sm]EDTMP~2
[99mTc]~1
(MDP).~2
Lesion/normal~1
17:1.~1
EDTMP~2
Samarium-153~1
[153Sm]EDTMP.~1
(bladder~1
voiding).~1
inhomogeneously~1
iodine-131~3
([131I]MIBG)~1
[131I]MIBG~4
arteriographically.~1
radio-~2
Iodine-131~2
MIBG~9
radiopharmaceutical.~1
Chernobyl~9
vacation~1
nationals~1
subpopulations--adult~1
burdens,~1
nCi~2
Bq)~1
(33,300~1
Bq).~1
mrem~2
(51.8~1
mSv).~3
rem~2
(370~2
Sv).~1
131I.~1
Radioactive~4
Radiocolloid~1
defects).~1
appreciated,~3
males;~3
(PSS).~1
(end-expiratory)~1
PSS~4
150-200~2
[99mTc]triethelenetetraamine~1
polysterene~1
(GET).~1
GET~2
GET,~2
GET.~2
left-ventricular~2
(2.67~1
EDV/sec,~1
40-65~1
(0%-9%)~1
([Gd]DTPA)~1
[Gd]~1
DTPA~3
mM/kg~1
[Gd]DTPA~4
zones;~1
83Rb~3
Paired-indication~1
201Tl,~1
83Rb,~1
permeation,~1
atrial-aortic~1
ventricular-aortic~1
Assisted~1
18F-2-fluoro-2-deoxy-D-glucose~1
(FDG)~1
FDG,~2
131I,~6
FDG~3
FDG.~2
effusive-constrictive~1
nutritionist's~1
advisor~1
scientist's~1
drug-nutrient~1
Space~3
1990s~1
90-d~1
earth~1
morale.~1
in-flight~4
synopsis~1
(LSRO),~1
FASEB,~1
spaceflight.~1
extravehicular~1
microgravity~1
menus,~1
packaging,~1
wastes.~1
LSRO~1
countermeasures.~2
(LL)~2
(FL)~2
lipogenesis,~1
LL~3
(+73%,~1
experiments).~1
LL.~1
Starvation~5
triacylglycerols,~1
refed~7
(TTR)~1
Yolk~4
(moles)~1
20-21~1
TTR-RBP~1
20,000-40,000~1
40,000.~2
TTR,~1
RBP-TTR~1
40,000-20,000~1
tissue.(ABSTRACT~1
pantothenate~6
Lieber-DeCarli~1
maltose-dextrin~1
19-36~1
51-78%~1
78-90%~1
ethanol-treated~6
[1-14C]pantothenate.~1
0.5-2.5~1
ethanol/kg~3
[1-14C]pantothenate~3
4-28%~1
(NPA)~1
Selenium-~1
VE-depleted~1
Se,~2
all-rac-alpha-tocopheryl~1
Se-dependent~2
(SeGSHpx)~2
VE/kg~1
NPA~4
of)~2
antioxidants.~1
SeGSHpx~5
SeGSHpx.~2
15-20-fold~1
Riboflavin~5
riboflavin/g~2
succinyl~2
sulfathiazole~2
[2-14C]riboflavin~1
lumichrome~1
hydroxymethylriboflavins~2
(FMN),~1
lumiflavin~1
10-hydroxyethylflavin.~1
Carboxylumichromes~2
flavin-derived~1
riboflavin-deficient~3
85-90%~1
extracts;~1
carboxylumichromes~2
oxidations,~1
hydroxymethyl~1
flavin.~1
poults~3
refeeding.~4
starvation,~2
(MT).~1
MT-bound~1
Zinc,~1
resumes.~1
(200,~1
magnesium-containing~2
magnesium.~3
molars.~1
level-dependent~1
Five-day~1
(safflower~1
Hb).~1
g/dL)~2
Fe)~2
Nonheme~2
safflower~3
gains.~6
baking.~1
L-ascorbic~1
casein-ascorbate~1
180-215~1
1-20%.~1
protein-ascorbate~1
niacin-deficient~1
L-leucine.~1
[methylene-14C]tryptophan.~1
niacin-free~1
isonitrogenous~3
tryptophan.~1
L-tryptophan.~1
pellagra~1
niacin/tryptophan.~1
biotin~5
[Km~1
33.9~1
pmol/(mg~1
min)].~2
(antimycin~1
biocytin~1
DL-thioctic~1
thiophane~1
biotin.~2
Counterflow~1
L-tyrosine,~1
L-aspartate,~1
L-asparagine,~2
L-glutamate~1
L-glutamine)~1
L-alanine,~1
L-phenylalanine.~1
2-amino-[1-14C]isobutyric~1
(hg),~1
C57B1/6~1
Ch)~1
CH).~1
hg~1
Efficiency~2
(multicollinearity).~1
subjectivity~2
accommodated~3
explicitly.~1
(ACAP)~1
Swiss-Webster~1
EtOH-containing~1
EtOH-fed~1
non-EtOH-fed~1
ACAP~5
diphosphoglucuronosyltransferase~1
methionine-deficient~2
methionine-sufficient~2
TCDD/kg~1
(PND)~1
Dams~1
weanlings~4
PND~7
Thymus~2
TCDD-treated~2
TCDD-exposed~5
21-fold,~1
(-32.1%),~1
(-26.9%),~1
(-13.9%)~1
(-8.3%).~1
water-fed~1
(+215.4%),~1
(+120.8%),~1
(+69.2%)~1
(+57.5%).~1
fructose-fed~1
Hens~2
photophase~1
scotophase.~2
overwhelmingly~5
albumen~1
Albumen~2
magnum.~2
continuous;~1
oyster~13
accrues~1
scotophase~1
feedstuff,~1
photophase.~1
protein-based~3
isolate-based~1
(Isomil~1
Iron);~1
(Similac~2
Iron).~1
(midshaft)~1
postnatally.~2
Baby~1
BMC/BW~2
(BPD),~2
Pre-exercise~1
tcPCO2~1
hyperinflation,~1
hyperreactivity,~2
nondelayed~2
athyrosis~1
Perceptual-motor,~1
visuospatial,~1
temperamental~1
perceptual-motor,~1
emotional-behavioral~1
balloons;~1
(repeat~1
undercorrects,~1
brain-dead~5
repeatable,~1
mL/min/m2,~2
Premeal~1
(7.6~2
diabetes)~2
postmeal~1
mL/min/m2;~2
mL/min/m2~2
g/kg/d~5
kcal/kg/d~4
(formula~7
protein/fat~2
(g/g)~1
energy;~1
3070~1
systemic)~1
Meconium,~1
meconium,~1
(palmitic,~1
stearic,~1
acids)~3
Wilhelmy~2
atelectatic~1
dynes/cm,~2
Ophthalmologic~1
interburst~1
Fewer,~1
suck~1
sucking,~1
Breast-feeding~1
preadolescents~1
(H2O2).~1
(generated~1
oxidase)~1
microgram/min)~1
H2O2-injured~2
(5S)-5-hydroxy-6,8,11,14~1
eicosatetraenoic~1
(RIA,~3
14.7;~1
54.8~1
13.5)~1
1.6;~1
8.3;~2
7.6).~1
glucose-glucose~1
5'-lipoxygenase~1
L-364,718,~1
Administered~2
p.o.,~3
L-364,178~1
(CCK-8)-induced~1
micrograms/kg),~5
CCK-8-induced~1
L-364,718~8
CCK-like~1
(1.0-5.0~1
acid-~1
atropine-induced~1
motilin-induced~1
secretin-induced~1
cats.(ABSTRACT~1
pouches.~2
(L-364,718)~1
oleate)~1
(vagally~1
innervated)~1
(interdigestive)~1
function(s)~2
threo-methylphenidate~1
(MPH)~1
recrystallization~1
binaphthyl~1
dl-threo-MPH~1
d-threo-MPH~2
l-threo-MPH.~1
enantiomeric~3
trifluoroacetylprolyl~1
d-isomer~1
l-isomer~1
l-norepinephrine~1
synaptosomes.~6
Destruction~3
catecholaminergic~3
d-threo-MPH,~1
d-enantiomer~1
l-norepinephrine.~1
stereoselectively~1
threo-~1
erythro-MPH~1
preferences.~1
(faded)~1
HCI~1
two-lever~2
food-reinforced~1
retrained~1
0.375~1
fading~2
selections)~1
PCP's~2
non-DM~6
[3H]netilmicin~2
92.4~2
(96.4~1
106.7~1
Henle,~3
free-flow~4
netilmicin~10
recta.~1
wt.)~2
wt).(ABSTRACT~1
(0.625-10~1
102922~2
FPL~2
55712~2
mg/kg/min),~2
88046~1
microgram),~1
mimetic,~2
U-46619~1
agonists.(ABSTRACT~2
nmol/side)~2
ethylcholine~1
(AF64A)~1
AF64A,~1
AF64A~6
nmol/side~1
clenbuterol,~1
[125I]iodopindolol.~1
agonist-binding~1
clenbuterol~16
clenbuterol-induced~2
89,406.~2
89,406~2
118,551.~3
isoproterenol-~2
clenbuterol-stimulated~1
118,551~12
[3H]cyanoimipramine~1
([3H]CN-IMI)~1
[3H]CN-IMI~4
chlorimipramine~2
[3H]CN-IMI.~1
stereoselective~3
stereoisomers~6
norzimelidine.~1
Lesioning~1
4-methyl-alpha-ethyl-metatyramine~1
isomazole,~1
imidazopyridine,~1
isomazole~8
Isomazole~1
LVdP/dt/P~2
transcoronary~2
mecamylamine.~1
demand/supply~1
mesolimbic~1
photocell~2
morphine-~1
locomotion,~1
rearing,~1
sniffing,~1
grooming~1
bursting.~1
methobromide~3
(VTA;~1
A10~5
(limbic~1
intra-VTA~1
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol~2
VTA~1
striatum.(ABSTRACT~1
Prostaglandins,~1
thromboxanes~1
eicosanoids,~1
N-formylmethionyl-leucyl-phenylalanine~2
(416~1
ng/5~2
colons.~2
proinflammatory~2
rolipram~3
retardant~2
N6-(L-phenylisopropyl)adenosine~1
(L-PIA)~1
Pavlovian~1
nictitating~1
800-msec~1
tone-~2
light-conditioned~2
100-msec~1
unconditioned~3
L-PIA~8
(50-200~1
mumol/kg),~2
(3-100~1
(0.03-3.0~1
tone-conditioned~2
db.~1
L-PIA.~1
(VIP)-responsive~1
High-affinity~1
protein),~3
3.3-fold~1
I-isoproterenol~1
(Ka,~1
(sequence~1
10-28)~1
VIP-stimulated~1
MgCl2~1
MnCl2.~1
VIP-~1
forskolin-activated~1
Intravitreous~1
VIP-responsive~1
adrenergic-responsive~1
(nonpigmented~1
(pD2)~1
(pKA)~1
arteries:~1
basilar,~1
mesenteric.~1
pKA~2
0.74,~2
antilog~1
pD2-pKA.~1
0.9;~3
.001.~1
(0.17)~1
Fengabine~6
79.229)~1
benzylidene~2
bulbectomized~1
fengabine~6
5-hydroxytryptophan-induced~2
reserpine-induced~2
bulbectomy~1
wide-spectrum~1
proconvulsant~2
(50-1000~1
alpha-methyl-p-tyrosine-induced~1
pargyline-induced~2
b.i.d.),~1
serotonine~1
[3H]imipramine~1
GABAA~7
GABAB~1
[Arg8]vasopressin~1
[AVP-(1-9)]~1
[Cyt6]AVP-(5-8)~1
[Cyt6]AVP-(5-9)~1
postlearning~2
(consolidation)~1
preretention~2
(retrieval),~1
Pentylenetetrazol-induced~1
AVP-(1-9)~2
[Cyt6]~1
AVP-(5-9)~1
[pGlu4,Cyt6]-AVP-(4-9)~1
pole-jumping~1
[pGlu4,Cyt6]AVP-(4-8)~1
[OXT-(1-9)]~1
[pGlu4,Cyt6]-OXT-(4-9),~1
[pGlu4,Cyt6]OXT-(4-8)~1
[Cyt6]OXT-(5-8)~1
[Cyt6]OXT-(5-9)~1
behaviors.(ABSTRACT~1
[3H]dopamine~1
([3H]DA)~1
K+-evoked~1
[3H]DA.~2
[3H]DA~4
(isolated~1
ether)-N,N'-tetraacetic~1
quinpirole~1
l-sulpiride~1
superfusates~1
tritium~6
Ca++-evoked~3
interval-dependence~1
time-dependence~2
lidocaine-induced~1
Lidocaine-induced~1
mexiletine;~1
amitriptyline;~1
30-sec~1
pause,~1
procainamide)~1
quinidine).~1
4.02~2
(before/after)~1
bisoprolol,~1
(pD2~6
7.69)~1
7.41)~1
5.30).~1
bisoprolol~3
procaterol.~1
procaterol-induced~1
9.11~1
9.20~1
6.50~1
6.63.~1
bisoprolol.~1
attention-deficit~1
dl-threo-methylphenidate~1
(Ritalin,~1
Ciba-Geigy,~1
Switzerland).~1
Enantiomers~1
heptafluorobutyryl-1-prolyl~1
enantiomer~3
d-methylphenidate~2
l-enantiomer~1
level-time~1
24.48~1
7.62~1
ng/hr/ml~2
l-methylphenidate.~1
enantiomer.~2
synthetically~2
3+)2~1
(I).~1
(HbX)~1
2+)2~1
valency~1
HbX~5
ferricyanide.~1
2+)2.~1
hexaphosphate~2
difference-binding~1
three-line~1
hyperfine~2
unpaired~1
iron-centered~1
nitrosyl~1
i.a.~3
[met]enkephalin~2
prepared,~2
[Met]enkephalin~1
(3-300~3
(18-42%~1
preinjection~3
sec.~3
[met]enkephalin.~1
hindquarters.~1
opioid-dependent~1
Depressions~1
dexoxadrol,~2
metaphit,~1
acylates~1
isothiocyanate~2
levoxadrol,~1
metaphit.~2
metaphit's~1
dexoxadrol-~1
PCP-mediated~1
acylate~1
isothiocyanate,~1
dexoxadrol.~1
tyramine,~2
metaphit~1
dexoxadrol~1
accumbens.~1
subtype(s)~1
Try-D-Ala-Gly-NMe-Phe-Gly-ol,~1
[D-Pen2,5]-enkephalin,~1
naloxonazine,~1
mu-1~4
isoreceptor,~1
motor-stimulant~1
intra-ventral~1
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol.~1
microinjected~1
[D-Pen2,5]-enkephalin~1
isoreceptor~1
(+/-)-3,4-Methylenedioxymethylamphetamine~1
(MDMA)~2
decapitation.~1
40-mg/kg~1
Fink-Heimer~1
Degenerating~1
(neocortical~1
neurons)~1
lethality~12
lacrimation,~3
salivation,~2
mg/kg;~1
lacrimation~1
atropine-treated~1
benactyzine~1
atropine-insensitive~1
arecoline.~1
atropine.(ABSTRACT~1
barbiturate-like~1
acidA~1
receptor-chloride~1
beta-reduced~1
pregnane~1
C20.~1
hormones:~2
alpha-pregnane-3~2
-ol-20-one~1
alpha,21-diol-20-one,~1
deoxycorticosterone,~1
GABA-mediated~2
synapses~13
Deaconness~1
damage)~3
(involvement~1
sampled),~1
pheochromocytoma,~8
CM,~1
(135~2
(166~2
Timolol~1
(phenoxybenzamine~1
pheochromocytoma.(ABSTRACT~1
climbing~5
opiate.~2
levorphanol.~3
naloxone-induced~2
jumping,~1
[3H]spiroperidol~4
Levorphanol~1
sites.(ABSTRACT~1
ibopamine~10
epinine~7
autoperfused~1
Heparinized~1
epinine.~2
ibopamine.~1
ibopamine,~7
intraduodenally,~1
epinine,~4
adrenoceptors.(ABSTRACT~1
2-Hz~2
(prejunctional~1
(postjunctional~1
gallamine.~1
(pKB~3
9.2,~1
gallamine~2
converse~1
postjunctionally~1
prejunctionally,~1
prenalterol,~3
differential-reinforcement-of-low-rate~1
72-sec~1
30-response~2
fixed-ratio~7
Dose-effect~1
5'N-ethylcarboxamide~1
(NECA)~2
(2-CA)~1
N6-R-phenylisopropyladenosine~1
(R-PIA)~1
N6-S-phenylisopropyladenosine~1
(S-PIA).~1
CPA~5
2-CA~2
R-PIA~5
S-PIA.~3
(HR).~1
MPB~1
R-PIA,~2
CHA,~1
HR.(ABSTRACT~1
quinidine-N-oxide,~1
O-desmethylquinidine,~2
2'-oxoquinidinone,~1
impurity,~1
dihydroquinidine,~2
(BCLs)~1
Vehicle~1
upstoke~1
(APD90).~1
BCL~3
quinidine-N-oxide.~1
APD90~1
BCL.~1
dihydroquinidine~1
[2,6-dimethyl-3-carbomethoxy-5-carbomethoxy-4-(3-nitro)phenyl-1,~1
4-dihydroxypyridine]~1
enatiomeric~1
202-791~1
[isopropyl-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2,~1
6-dimethyl-5-nitro-3-pyridinecarboxylate]~1
(+)-202-791~1
(1:1)~1
antiulcer~4
[1-(2,-dimethylphenyl)-3-isobutoxyamidinourea]hydrochloride~1
(WHR1582A),~1
WHR1582A~7
18-hr~2
pylorus-ligated~5
lumen-perfused~1
RX781094A~1
corynanthine,~1
2-deoxy-D-glucose~2
dimaprit.~1
antiulcer-antisecretory~1
presynapitcally~1
(dorsalis~1
palmer~1
hand)~2
(digital~1
low-maximum~1
(+)-S202-791~2
(-)-Bay~1
(-)-R202-791~2
(+)-Bay~1
nitrovasodilator~1
dihydropyridine-induced~1
(-)-R202-791,~1
(+)-S202-791,~1
[(+)-S202-791]~1
[(-)-R202-791]~1
processes.(ABSTRACT~1
beta-hydroxy-11~1
beta-[4-dimethylamino~1
phenyl]-17~1
alpha-[1-propynyl]estra-4,9-dien-3-one)~1
754~1
1184~1
N-mono-~1
N-didemethylated~1
[3H]RU~1
CGS~12
15943A,~1
triazoloquinazoline,~1
adenosine-stimulated~2
synaptoneurosomes.~1
A-1~3
[3H]cyclohexyladenosine,~1
15943A~4
A-2~3
[3H]5'-N-ethylcarboxamidoadenosine~1
cyclopentyladenosine~1
synaptoneurosomes,~1
[3H]nitrobenzylthioinosine,~1
receptor-stimulated~2
[3H]inositol~9
([3H]InsPs)~1
[3H]InsPs~3
(1477~1
basal)~2
(428~1
basal).~1
M1-muscarinic~1
(adults)~1
(7-day-old~1
adulthood;~1
serotonin),~1
carbachol-~1
acetylcholine-stimulated~1
hydrolysis,~3
75.~2
receptor-effector~2
exhypoxic~1
postinjection.~1
Trimoprostil,~1
Trimoprostil~4
(drainage)~1
trimoprostil~1
trimoprostil.~1
[3H]nicotine~4
(0.75-3.0~1
(0.5-2.0~1
lost.(ABSTRACT~1
(METH)~1
neurotensin-like~1
METH~2
METH-induced~1
5'-guanylylimidodiphosphate~1
Mono-~1
dimethoxysubstituted~1
tolazolines~1
3,5~1
dimethoxy-,~1
methoxy-,~1
agonists;~1
kynurenine~2
L-kynurenine,~1
kynuramine~2
5-hydroxykynurenamine~1
(5-OH-kynurenamine)~1
5-OH-kynurenamine~4
5-HT3~3
(neuronal~1
"M")~1
LY53857~1
ICS~1
205-930~1
1-(1-napthyl)~1
piperazine~3
Kynuramine~1
5-HT).~1
ileum.(ABSTRACT~1
chamber-organ~1
micrograms/2~1
(65.13%)~1
(18.0%)~1
(10.58%)~1
(2.45%).~1
alpha-dihydrotestosterone,~1
alpha-androstanedione~1
Cortisone~1
cigarettes/day)~1
(510~1
3-methylxanthine~1
1-methyluric~1
beta-hydroxycortisol~1
P2-Purinergic~1
beta-methylene-ATP~3
ADP.~2
2-methylthio-ATP~1
relaxation),~1
P2-purinoceptors~2
beta-Methylene-ATP~1
2-methylthio-ATP;~1
beta-methylene-ATP.~1
relaxations,~1
Volatile~1
pharmacology,~1
depressants.~2
(PB),~1
oxazepam~4
inhalants.~3
(500-8000~1
1,1,1-trichloroethane~4
(500-12000~1
isoamyl~2
(150-1050~1
flurothyl~1
(562-1300~1
(0.1-20~1
Isoamyl~1
flurothyl,~2
PB-like~2
Toluene,~1
delta-9~1
(11)-tetrahydrocannabinol~1
9-11-THC),~1
delta-9-tetrahydrocannabinol~1
9-THC).~1
9-11-THC~9
cannabimimetic~4
hyperreflexia,~2
prancing~1
tail-tuck.~1
noncannabimimetic-like~1
N-acetyl-p-benzoquinone~2
imine~2
3-(cystein-S-yl)acetaminophen.~1
biotin-amplified~1
3-(N-acetyl-L-cystein-S-yl)acetaminophen~2
keyhole-limpet~1
hemocyanin.~1
derivatized~2
(acetaminophen-bound~1
metallothionein)~1
acetaminophen-derivatives~1
acetaminophen-bound~2
metallothionein.~1
3-(N-acetyl-L-cystein-S-yl)acetaminophen,~1
supernatant,~3
microsomes,~4
fmol/well.~1
6200~1
pmol/well.~1
acetaminophen-protein~1
adducts~4
NADPH-dependent~2
(DHPG)~1
DHPG~9
synapse.~1
desipramine;~1
intraneuronal~2
rerelease.~1
(DBH)~1
102698~9
[1-(3,5-difluorobenzyl)imidazole-2-thiol]~1
1-benzylimidazole-2-thiols~1
DBH~4
DA/NE~2
520%,~1
quinacrine~4
postocclusion.~2
P/mg~2
creatinkinase~1
9.84~1
6.93~1
I.U./mg~2
quinacrine-treated~2
initially;~1
(phospholipids:~1
CK:~1
7.76~1
4.99~1
sham-operated.~1
higher.(ABSTRACT~1
nonapeptide~1
(OXT),~1
desglycinamide9-OXT~1
Z-prolyl-D-leucine,~2
prolyl7-leucine8~1
N-alpha-Acetyl-(2-0-methyltyrosine)-OXT~1
(penicillamine1-2-0-methyltyrosine)-~1
lysine8-vasopressin,~1
desglycinamide9-OXT,~2
Z-prolyl-D-leucine~1
N-alpha-acetyl-(2-0-methyltyrosine)-OXT.~1
oxytocinergic~2
thereof)~1
organochlorine~1
insecticides~5
chlordecone,~2
mirex,~1
1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2,2-trichloroethane~1
1,1-bis(4-chlorophenyl)-2,2,2-trichloroethane~1
intrasynaptosomal~2
Ca++]i),~1
synaptosomal~5
Chlordecone~3
(10-50~1
extrasynaptosomal~2
valinomycin.~1
chlordecone~4
K+-stimulated~1
chlordecone.~1
mirex~1
voltage-sensitive~3
chlordecone-induced~1
(0.09-180~1
metoprine,~1
HA-N-methyltransferase,~1
H1-receptor~4
mepyramine~4
(0.5-2~2
(1-4~2
HA-induced~2
i.c.v.),~1
H1,~1
H2,~1
cefixime,~5
cefixime~5
intravesicular~1
extravesicular~1
protonophore,~1
carbonyl-cyanide-4-trifluoromethoxy-phenylhydrazone,~1
5.0),~1
nmol/30~1
sec/mg~1
Cefixime~1
glycyl-L-proline~1
dipeptide.~1
valinomycin-induced~1
K+-diffusion~1
dianionic~1
cefixime.~1
carrier-mediated,~1
Proglumide~1
nonsteroid~2
cytodestructing~1
Cimetidine,~1
NaOH.~2
antisecretory,~1
usefulness.~3
coinheritance~1
hydroxylation~12
debrisoquine.~1
R-enantiomers~1
5-(4-hydroxyphenyl)-5-phenylhydantoin~1
(HPPH;~1
metabolite),~1
chiral~1
HPPH~6
S/R-ratio~1
S/R-values~1
hydroxylation-deficient~1
S/R-ratios~1
product-stereoselective~2
NIH-shift~1
pro-S~1
Substrate-stereoselective~1
S-HPPH~1
hydantoin~1
enantiomers.(ABSTRACT~1
116.~1
vivo"~1
muscarinic-mediated~1
(pA2)~1
hundred-fold~1
acetylcholine-mediated~1
Transcortical~1
fiber),~1
5,7-dihydroxytryptamine)~1
magnocellularis)~1
postsynaptically,~1
somatodendritically~1
triethiodide~1
artificially.~1
supranodose~3
hexamethonium-resistant~2
mu/kg~1
(D-Pro2,~2
D-Trp7.9)-substance~1
nodose~4
ganglion;~1
Fluorometric~1
Auriculotemporal~1
neurotomy~4
(parasympathectomy),~1
Lobules~1
intact.(ABSTRACT~1
[14C]alpha-aminoisobutyric~1
(AIB),~1
[14C]AIB~1
parasympathectomized~4
AIB~4
(150%)~1
(200%).~1
Acceleration~2
[3H]Norepinephrine~1
tracer-radioactive~1
36Cl-~6
shallow,~1
RU5135~1
(potency~1
Ro15-1788.~1
6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate~1
muscimol-activated~1
anthelminthic-insecticide~1
avermectin~3
B1a~1
Thin-layer~1
[5-(p-hydroxyphenyl)-5-phenylhydantoin]~1
5-(p-hydroxyphenyl)-5-phenylhydantoin~1
coinjections~1
(4-10~1
dopamine-containing~1
potassium-evoked~1
monoamines.~2
reuptake,~1
(BAR)~1
[125I]iodocyanopindolol~3
steresospecific~1
BAR~4
subtype-specific~1
betaxolol.~1
BAR.~1
42-hr~1
Ligand-receptor~1
phospholipid-rich~1
receptor-independent,~1
concentrative,~1
sequester~1
S49)~1
80-min~1
9-aminoacridine-propranolol~1
(9-AAP).~1
surfactant-containing~1
(LB)~1
acid/osmium~1
9-AAP~2
LB.~1
9-AAP,~1
9-aminoacridine~1
side-chain.~1
microM);~1
chlorquine~1
inhibition.(ABSTRACT~1
serotonin2~2
chloralose-anesthetized~5
LY~1
53857,~1
antifibrillatory~2
dilevalol,~3
dilevalol~5
suppression:~1
[16%]~1
[7%]~1
vehicle).~1
(mortality:~2
[80%]~1
[100%]~3
vehicle),~1
fibrillation:~1
[25%]~1
[75%]~1
dilevalol).~1
methylscopolamine,~1
i.m.,~1
[40%]~1
methylscopolamine~2
large-for-gestational-age~1
sensor,~1
"hot~2
predominant;~1
osmolarity.~2
UF,~1
reproductive-age~1
3,582~1
(SAT)~1
(SIT)~1
(IBA)~1
Immunobeads~1
Hepes~1
SAT~1
SIT~2
IgG-IBA~2
SAT.~1
89.0~1
Parenting~1
lesbians~1
1,921)~1
424)~1
sexual-orientation~1
Lesbians~1
unsuspecting~2
Polymyositis~1
myositic~1
polymyositis.~5
Modanlou~1
Freeman~2
34-week~1
demise,~1
funisitis~1
transfer--specifically,~1
tissue-soluble~1
ribonuclear~1
antigen-A--has~1
initiator~1
amniocenteses,~1
Amniocentesis~1
uneventful.~3
resectable,~2
Megacolon~1
disimpaction.~1
fetomaternal~1
(FMH)~1
FMH~2
Kleihauer-Betke~2
dermatitidis.~1
syndesmophytes,~1
rheumatoid-like~1
apophyseal~1
13/21~1
8/21~1
(PM)~3
coxsackieviruses~2
(CVB)~1
CVB~3
(CVB~1
Myocytes~1
regenerated,~1
Anti-CVB~1
"AM~1
Symptoms"~1
(nocturnal)~1
Complaint"~1
mononeuritis~1
polyneuropathy;~1
symmetric,~1
(C4bp)~1
convertase.~1
C4bp~1
Wissler-Fanconi~2
metastasize.~1
mutilans,~1
polychondritis.~1
polychondritis~4
Relapsing~2
polychondritis,~1
common;~1
dermatoses.~1
Hemarthrosis~1
hemarthrosis~4
exostosis~2
talus.~1
heighten~1
Articular~2
extraarticular~3
rheumatism.~1
Outcomes~3
(TLI)~1
immunosuppressant~1
TLI~3
staphylococcus~1
Rheumatism~2
(y)--E~1
[39.1~1
mg/kg/day]~2
[49.8~1
vomiting)~1
(63.8%),~1
(9.7%),~1
Are~1
ability?~1
Walk~1
physiotherapists~1
polyarthritis.~2
0.23).~1
workups,~1
Week~2
72.5%.~1
cultural,~2
contacted,~2
descriptions,~2
curriculum;~1
emphases~1
dean.~1
residency.~8
premedical~3
Rasch~1
data"~1
graduates;~1
residency:~1
obstetrics-gynecology,~1
score)~1
clerkships~2
clerkship).~1
graduates'~1
(CHC)~1
CHC.~1
pretests~2
posttests~2
lectures~2
small-group~1
endocrinopathies,~1
illnesses).~1
behaviors:~1
delinquency.~1
conflicts.~3
competency.~1
pertained~1
obstetrics-gynecology.~1
homemaker~1
advisers,~1
biomechanics,~2
ICU-associated~1
decontamination~4
(polymyxin~1
(Gram-positive)~1
decontamination.~2
Superinfections~1
land~3
rotorcraft~1
Scores.~1
1972-1983,~1
3,564~1
fatally~2
seatbelt.~1
fatality,~1
wearers~3
collisions.~1
endoprosthetic~3
coupling-piece~1
angulatory~1
malalignment.~1
Rush~1
plating.~2
jumped~1
stories.~1
disruptions,~3
pseudoaneurysm,~1
multiply~3
salvageable.~1
Ancrod,~1
viper~1
trypsin-like~1
proteinase,~1
clot.~3
defibrinogenized~1
Burn-Specific~1
hematocrit.~3
four-point~3
Ultralight~2
aircraft,~2
ultralights~1
popularity:~1
flying,~1
unattainable~1
unproven~2
ultralight~4
crashes,~4
licensing~13
aircraft.~1
stricter,~1
far-reaching~3
regulations.~3
Stricter~1
enforced~5
must,~4
noncompromised~1
(Thompson~2
Epstein)~1
Epstein's~1
Pipkin's~1
criteria).~1
suspicion.~5
arthroscope~1
"second-look~1
procedure"~1
renorrhaphy~1
11.4%~2
15.6%,~1
(4.4%).~1
purview~1
subspecialties,~1
otolaryngology,~2
neurosurgery.~1
interdisciplinary,~1
Interdisciplinary~1
subspecialties.~2
pupils)~1
(5.3%).~1
pupils,~1
(Evans~1
(145~2
degrees-150~1
nail-plate~2
(McLaughlin)~1
88.2%.~1
Oakland~1
Tomographic~1
scan.(ABSTRACT~1
open-flame,~1
hyperphagia~3
hyperphagic~2
hypermetabolism.~3
anorectic~4
hyperphagic-hypermetabolic~1
hyperphagia,~2
hyperphagia-hypermetabolism~1
nonvisualization~1
nephrectomies~2
causalgia~2
missiles.~1
T12-L1~1
backboard~1
Scoop~1
stretcher~4
logroll~1
evacuates~1
incising~2
Postoperatively~2
Sorenson~3
congruency~1
results).~1
dome,~1
luxation~2
thoracolaparotomy,~1
laparotomy:~1
'chyloma'~1
Supradiaphragmatic~1
chyloma.~1
hemipelvectomy~2
circumduction~1
(Bigelow's~1
Buck's~1
injure~4
nonpelvic~1
legs;~1
4-Methylpyrazole~1
MP)~1
MP.~2
unmeasurable.~2
14.5,~2
14.75~1
MP,~1
blue-ringed~1
octopus~1
Paralysis~1
toxins:~1
toxins.~1
Noradrenaline,~1
d-amphetamine,~1
a-receptors,~1
tilidine~3
185.5~1
charcoal).~1
Ethanol,~2
cacao~1
adsorption.~1
Federa~1
Charcoal~2
Norit~1
Merck.~1
intoxications.~2
poisoned,~1
246,~1
mumol/l;~2
10.3-48.6~1
40-80~1
47.3-79.4~1
mumol/l/day~1
37.7-63.6~1
mumol/l/kg/day.~1
hydrotalcite~1
(Ultacit)~1
algeldrate~2
(Algeldratum~1
des-acidans)~1
(AlS)~1
AlS~1
hydrotalcite--a~1
acid-neutralizing~1
capacity--in~1
(disseminated~1
paraparesis/paraplegia)~2
coagulation),~1
Neurohistochemical~1
(testicular)~1
(urethral)~1
acetylcholinesterase-containing~1
(carbachol)~1
(scopolamine)~1
3H-labelled~1
prejunctionally~1
Remodelled~1
intussuscepted~1
uses.~2
Ureters~1
nonrefluxing~2
infection-free~2
sphincters.~1
difficult-to-use~1
stereoscopical~1
EDAX.~1
(28.4%).~1
(71.6%)~1
non-papillary~1
Papillary~5
calculi),~1
intrapapillary~1
crystalluria~5
stones).~2
whewellite~1
Randall's~2
uropathy~1
priapism,~1
cavernosum~5
clamped.~1
tumescence,~2
sub-threshold~1
neurostimulation.~1
microneural~1
intraspinally.~1
recentralized~1
recentralize~1
Subpressor~1
(consisting~1
albuginea)~1
polypeptide-like~4
causes;~2
'non-neuropathic'~2
VIPergic,~1
azide)~1
disintegrator~1
urology~1
Lawson~1
set.~2
Tract~1
0.017-inch~1
radiologist.~2
calices~1
51chromium-ethylenediaminetetraacetic~1
renography.~2
renography,~2
caliceal~2
planimetrical~1
calices.~1
Caliceal~1
Intrapelvic~1
nonparametric~2
nonparametric)~1
Spread~5
lumbotomy~3
dismembered~2
cost-effectiveness.~1
(78),~1
renaissance~1
Introduction~3
ureteroscope~5
Ureteroscopy~2
cm.)~1
intraintestinal~1
cystoplasty~2
supravesical~2
ureter),~1
ureters).~2
84.8~2
acuminatum~1
anoscopy.~1
Brunn's~4
nests~4
supramontanal~2
pitted~1
verumontanum~1
(97.5~1
acinar-type~1
intestinal-type~3
papilloma.~1
nonmicrosurgical~2
Gleason~8
Treatment-related~1
cancer)~3
testings~1
urinalysis.~1
urinalysis,~2
system(s)~1
Insignificant~1
urovaginal~2
gynecological~1
radiotherapy:~2
urethrovaginal,~1
ureterovaginal~1
rectovesicovaginal~1
transvesical~4
hydroureteronephrosis~2
loopogram~1
microtransducers~1
fragile,~2
microtipped~2
(4F),~1
lithotriptor.~1
shielding~2
omphaloceles~4
ureterosigmoidostomy~2
enterocystoplasty.~1
urethroplasty,~1
fibroepithelial~2
pitfalls.~3
cis-platinum~3
epipodophyllotoxin,~1
dimethyl-tri-azeno~1
carboxamine.~1
Gartner's~1
nephroureterectomy~2
luteum.~3
ureterolysis.~1
dysuria,~2
lipomatosis.~1
prevesical~1
xanthogranuloma.~1
leukoplakia~2
Irritative~1
pentosanpolysulfate.~1
Merkel's~1
misplaced~2
hypoadrenalism~1
angiocentric,~1
inception.~1
angiocentric~1
radiologic.~1
(12.7%),~1
2043~1
(LSV)~1
LSV~4
(GSV)~1
femoroperoneal~1
(LSV/AUTO)~1
(LSV/SYN)~1
(13).~1
LSV/AUTO~1
LSV/SYN~1
GSV~1
56)~2
180/90~1
(7.1%).~2
runoff),~1
myofibrillae.~1
revascularizations~1
polytetrafluorethylene~1
improved).~1
(ePTFE)~1
bacteria/ml~1
[CFU]/cm2).~1
Colonization~2
ePTFE~3
(589~1
733~2
CFU/cm2).~1
(225~1
CFU/cm2,~2
CFU/cm2),~1
CFU/cm2)~2
(371~1
CFU/cm2~1
CFU/cm2.~1
aortomesenteric~1
"retrograde"~1
femoral-infrapopliteal~1
bypasses,~8
Stenotic~1
collections;~1
angiodysplasia.~1
Nevada.~1
control-persons,~1
unclear;~1
"chronic~2
infection,"~1
"severe"~2
headaches;~1
bedridden;~1
sleeping.~1
"physical"~1
preexcitation.~5
better-directed~1
3833~1
collaborating~1
religion,~2
menarche,~1
condoms~3
spermicides~2
caps,~1
spermicides,~1
clearest~2
final-year~1
clerks.~1
Tutors~2
specialty-specific~1
clerks~4
tutorials.~1
"clinically"~1
state's~2
"new~2
entrants"~1
93%).~2
$10,937~1
households).~1
insufficient:~2
Powerful~1
hepatoblastoma~3
immunoprophylaxis~1
mother-to-infant~1
352,721~1
450,585~1
(HBsAg);~1
62,359~1
infectious.~2
27,375~1
55,620~1
Taiwan;~1
seropositives~2
seropositives.~1
fighters)~1
yeast-recombinant~4
immunoprophylaxis,~1
Corps~1
corps~1
Justifications,~1
administrative/legislative~1
Corps.~1
10-km~5
2,3-diphosphoglycerate,~1
400-m~2
track:~1
deglycerolized~1
split,~1
minute),~2
Erythrocythemia~1
affiliation,~1
chart-based~1
374~2
(109/121)~1
home(s)~1
nonprofit~1
(101/121)~1
(66/121)~1
policymakers,~1
substantial.~2
$13.7~1
$12.1~1
billion,~2
respectively--or~1
premiums,~2
insurance.~3
classmates.~2
Examiners,~1
intervention/prevention~1
1000)~1
(92.0%)~1
specialties,~1
addicted~5
encounter.~3
Addictions~1
sobriety,~1
ended.~2
impaired-physician~1
committees.~2
House~3
Delegates~1
resolutions~1
Bivariate~1
framework.~3
verbalized~1
intentions,~1
self-prescribed~1
Cardiokymography~2
anterolateral,~1
posterolateral,~1
DATTA~1
(8/20)~1
Panelists~1
specialty:~1
surgery/thoracic~1
(18)~2
ATP-ase~5
(ADR).~1
cerium-based~1
ADR-treated~3
injection),~2
non-nephrotic~1
X-irradiation~1
X-irradiated~1
Uninephrectomized~1
drinking;~2
desoxycorticosterone~1
(DOC)~2
(SALT)~1
SALT~2
hydrochlorthiazide,~1
UNX.~1
DOC-SALT~3
(RBF),~1
(NE-ARF)~1
NE-ARF~3
(autoregulatory~3
3.49~1
0.25),~1
0.09),~1
NE-ARF,~1
instillations,~1
g%.~1
ml/ex~1
Al-induced~2
(OB)~1
limb-bones.~1
OB,~1
OC.~2
OB~2
bPTH~2
(i)~1
proliferation;~1
(ii)~1
4.05~1
(1,25(OH)2D3)~1
(Ca~2
MT)~1
47.7~1
pg/dl~1
L-triiodothyronine~1
8.14~1
6.08~2
1.59~2
Ipodate~1
9.59~1
1.91~2
6.68~2
3.67~1
2.91~2
ml/kg/min).(ABSTRACT~1
MAC-related~4
neoantigen(s),~1
IgA-glomerulonephritis~1
(IgA-GN)~1
(HSP).~1
(Clq~1
IgA-GN~2
HSP,~1
(mesangial~1
mesangio-peripheral)~1
C3b/iC3b~1
neoantigens~2
co-localization~1
mesangio-peripheral.~1
non-sclerosing~1
C3d,~1
IGA-GN~1
HSP.~1
Lymphoproliferative~2
cell/macrophage~1
171%,~1
tumor-bearing,~1
(PAS)~3
diastase,~1
mucicarmine,~1
(Coll~1
embedded.~1
hyaluronidase-sensitive~1
Coll~1
PAS-D~1
(diastase)~1
mucicarmine.~1
PAS-D.~1
mesotheliomas.~1
confidence,~1
77-year-old-woman~1
Faisal~1
Specialist~1
Arabia.~3
(NSTT)~1
NSTT,~1
NSTT~2
(51.6%),~1
hemangiopericytoma.~1
TA3Ha~5
1/10~1
7/12~1
Tail~2
Hines~1
all-male~3
micromensurative~1
"thin~1
strands"~1
Intraduct~1
sheets,~3
darker~2
vesicular.~1
sarcoma-bearing~1
post-tumor~1
parameter.~1
cancer-bearing~1
Fibromatosis~1
(en~1
bloc)~1
dozen~3
fibromatosis~2
extra-mammary~1
disease-en~1
manifest.~2
prebypass~2
ameliorates~3
0.3:~1
Left-to-right~1
oximetry,~2
pulmonary-to-systemic~3
xenografts,~3
18.1%,~1
nonobstetric~2
valvotomies~1
Tubbs~1
trimester).~1
3.01~2
(average)~3
(7.3%),~2
(87.8%).~1
dismaturity~1
valvotomy:~1
pregnancies),~1
26.7%~1
26.2%~1
9.3%~2
poly-L-lactic~1
polyurethane/poly-L-lactic~4
harvesting,~1
pulsations.~1
onward,~2
lattice~2
platelet-fibrin~2
regenerated.~1
lattices.~1
Fibroblasts,~1
perigraft~1
lattices~2
neoadventitia.~1
neoarteries,~1
thromboresistance~1
49.4%~1
thymoma.~5
(NP~1
micromanometers.~1
postarrest~1
pressure-length~3
increments).~1
mEq/kg/min,~1
0.984)~1
slope).~1
energetics~3
0.939)~1
(0.047~1
0.070~1
oxygen/beat/100~1
nutrient-antibiotic~1
accordingly,~1
(76.6~1
ventricular/left~3
mature.~1
patched.~1
(unrepaired~1
fetuses)~1
Intrauterine~1
palliating~3
oligemia~1
evolve.~1
aorta-pulmonary~3
disfavor~1
polytetrafluoroethylene.~1
remedied~1
gm/m2~6
approach:~1
arterioplasty~1
supra-valvular~1
hilum~1
trifurcated~1
cryogenic~5
free-sewn~3
premounted~3
(lipopolysaccharide)~1
Lipopolysaccharide~1
(preanesthetic~1
0.128~1
0.032~5
mean];~1
0.136~3
0.347~1
0.227~1
0.428~1
decayed~2
0.839,~1
0.0030X~1
0.173~1
nonpulsatile.~1
glucose-containing~1
nitrogenated~1
acalcemic~2
Oxygenation~3
mg/hr~2
mg/2~1
functions;~1
964~1
661~1
multivalve~1
(mortality,~1
events)~2
89.3%~1
died),~1
toxicity)~1
"honeycomb"~1
septae,~2
pump-oxygenator~1
tachycardia:~2
97.7%~1
nodoventricular~1
transatrial-transpulmonary~2
52.9~1
104.2~1
postrepair~1
22.6)~1
0.13.~1
Ottawa~2
standard-profile~1
suture/alignment~1
stitch~1
valve's~1
tear.~1
homogeneous.~2
death).~2
(IFA)~2
(screening~2
aminoethyl~1
(QAE)-Sephadex~1
A50~2
factor-negative~1
(yielding~2
(confirming~1
IFA~2
1:80~2
1:80.~2
QAE-Sephadex~1
B-subunit~1
(CKB)~1
CKB~2
Intravascularly~1
critical-care~1
arena~2
machines.~1
neuroreceptor~1
specificity;~1
silica-cartridge~1
extraction-concentration~1
sample-volume~1
silica-extractable~1
calcium-infusion~1
carboxylation~3
Willebrand's~1
findings).~1
(geodes)~1
pseudocyst.~3
(complement~1
immunodiffusion)~1
(89%);~1
(25%);~2
lysis-centrifugation~2
(brain-heart~1
nongranulomatous~2
siphon~1
Adenocarcinomas~1
histomorphology.~1
Videostroboscopy~1
airflow.~2
Stroboscopic~1
frame-by-frame.~1
two-mass~1
(P3)~2
514.5~2
dosimetry.~1
chemosensitizing~1
hydrops.~1
(LSC)~2
Vestibular~3
LSC~3
obscure;~1
aminoglycoside-induced~3
(VOR)~2
Probable~1
enlarging,~1
tender,~1
mutilation~1
94.7%~1
36.3%~1
Caldwell~2
Magnification~2
Videoplan~1
99th~1
aerated~2
namely:~1
hypersinus,~1
pneumosinus~2
dilatans,~1
pneumocele.~1
paper)~2
hypersinus.~1
pneumocele~2
Radium~1
Odense.~1
locale.~1
hyperfrequency~1
6.73.~1
Croup~1
had:~1
15,000~3
stabs,~1
20,000,~2
stabs.~1
Ampicillin~2
AJCC~1
nasofrontal~3
transects~1
gets~1
laser-irradiated~2
Beer's~1
Kubelka-Munk~1
approximation,~1
seven-flux~1
phototherapy,~2
useless,~1
spectrophotometer~1
Tt,~1
reflectance,~1
Rt,~3
on-axis~1
collimated~2
(1-D)~1
Tt~2
Rt~4
absorbance,~1
anisotropy,~1
cm-1,~2
wavelength.~2
488-nm~1
Green's~1
degrees-70~1
Arrhenius~1
(molar~1
entropy~1
cal/mol-degrees~1
enthalpy~1
kcal/mol).~1
W/cm2~2
krypton-fluoride~1
Incisions~1
re-epithelialization,~1
re-formation~1
bandwidth~1
piezoelectric~2
polyvinylidene~1
time-resolved~1
stress-wave~1
far-ultraviolet~1
fluence~4
mJ/cm2),~1
photothermal~1
avalanche~1
Shielding~1
backscattered~1
Brillouin~1
W/cm2.~1
narrows~1
small-spot~1
repetitions,~1
retina--as~1
assumed--than~1
repetitions.~1
(Nd):YAG~1
pointillistic~1
One-~2
blanched~2
interspaces~1
Scar-prone~1
fading.~1
dentistry~1
considered:~1
restoration,~2
Dental~6
biostimulation~1
dentistry.~1
transmyocardial~4
vaporization,~1
carbonization,~1
path.~2
wattage,~1
assistants'~1
cleansed~1
copious~3
sclerostomy~1
millijoules.~1
millijoules~2
sclerostomy.~1
dihematorporphyrin~1
ether),~1
Previous,~1
Hyperthermia~4
(2,450~1
(PDT)~2
SMT-F,~1
EMT-6,~1
RIF~2
PDT~5
argon-pumped~2
tunable~6
(630~1
post-PDT~2
SMT-F~2
independent)~1
EMT-6~1
vaporizing~1
LI.~1
Argon-ion~1
microlens-tip~1
64.2~2
PTA-treated~1
(48.4~1
13.5%,~1
.0125).~1
(4.55~1
Post-PTA~1
31.2~3
8.1%,~1
.0125);~1
carbonization~1
transtenotic~2
.40~2
.07~1
.005);~1
.37~1
.14~1
.11~1
.16~1
.12~1
.06~1
PTA)~1
bronchoscopically,~1
peribronchial~5
poorer.~1
awaits~3
biostimulating~1
reparation~1
He/Ne~1
microscopy).~1
Potentially,~2
osteocytes,~1
degenerate~1
8-14~1
mW)~1
(74%);~2
photosensitization~1
photosensitizers.~1
tetraphenylporphinesulphonate~1
(TPPS),~1
vehicled~1
azone.~1
up;~2
workshops~1
(1982~1
incentives~2
(menses)~1
[mid-luteal~1
(ML)].~1
(VR)~2
menstruating,~1
non-athletic~1
mid-point~1
VRs~1
(ventilatory)~1
pHa~4
(VE/VCO2)~1
(VCO2/VO2)~1
R),~2
VE/VCO2.~1
MPA,~1
hypercapnia;~1
MPA.~2
Ventilation,~2
joggers~3
6.63~1
(37.5~2
39.0~2
79%)~2
59%)~1
0.97)~1
(4.46~1
Post-exercise,~1
(DR)~5
(30.3~1
speed)~1
(treadmill~1
160,~1
acclimatization.~1
segment:~1
13.97~1
10.19~1
1.19,~1
31.38~1
27.91~1
1.45,~1
44.97~1
41.24~1
38.4~2
hottest~1
(running~2
first-cycling~1
second;~3
first-running~1
second).~3
10-ml~1
sexes;~1
hemoconcentration~1
(-6~1
-8%~1
-10%~1
(-3~1
-4%~2
tapings~3
tangent~2
Loadings~1
wraps~1
moment,~1
shrinking~1
tape.~1
running-related~1
shod~3
unshod~1
deflect~1
(foot~1
"pseudo-neuropathic"~1
obesity;~1
fitness;~1
psycho-social~1
employability~1
include,~1
inter-individual~2
manifestly~2
unfair~1
fascinating~2
medico-legal~3
Bona~1
Fide~1
Qualifications~1
Complicating~1
lawsuits~1
Act.~1
fighting,~1
enforcement,~1
military.~1
incumbents.~1
lifestyles,~2
execute~1
Med.~3
Sci.~2
Exerc.,~2
Vol.~2
pp.~3
78-82,~1
1987.~2
Adjective~4
Check~2
kilopond~2
post-exercise.~2
(38.8~1
(B-EN)~1
54;~1
59).~2
mode-specific~1
post-exercise,~1
centrifuged,~2
separated,~2
B-EN.~1
B-EN~3
B-EN,~2
submersion.~1
87-90,~1
submersion~4
motionless~4
buoyancy,~1
(beta-EIR),~1
beta-EIR~5
buoyancy.~1
Venipuncture~1
pre-restriction~1
dieting~2
pre-training~1
crescents,~1
Cavitary~1
otorhinological~1
Arthralgias,~1
(vasculitis~1
Goodpasture~1
crescents.~1
mesangial,~1
mesangium.~2
Immunosuppression-related~1
miner,~1
soil~1
company.~2
blastomycoma~1
blastomycomas~1
thought;~1
121,700~1
mailing~1
Again~3
1.3).~2
4.2).~2
1.6).~1
estrogen-replacement~1
Normally,~3
isoelectric-focusing~1
dead)~1
SIDS,~2
conception:~1
Survey,~7
7188~1
relative-risk~3
2.2).~1
highest,~1
2.3),~1
2.7),~1
beer,~1
week),~1
Mantel~1
+4.2;~1
liquor~3
Viewed~1
collectively,~1
40s~1
male-to-male~1
court-ordered~2
solicited~1
detentions~1
Asian,~1
Hispanic,~2
unmarried,~1
teaching-hospital~1
detained.~1
obstetrics.~3
grounds,~2
Scale),~1
(dexamethasone~1
47;~1
10.89,~1
strings~1
readers.~2
"masking"~1
task-directed~1
adenohypophysis~3
prolactinoma,~1
two:~2
8281~1
13,453~1
ataxia-telangiectasia~4
non-Amish~1
0.032];~1
0.013]).~1
0.014)~2
0.028];~1
0.006]).~1
ataxia-telangiectasia.~1
arterial-end-tidal~1
dead-space/tidal-volume~1
predicted;~5
Cities~2
restriction-endonuclease~2
excreting~2
toddler-aged~1
cytomegalovirus;~1
seronegative,~1
(lesion)~1
9.26~1
(lesion~2
(age)~2
area/internal~1
-0.73,~1
0.23;~2
100-fold;~2
Esmeralda~1
Nevada,~1
km2),~1
558~1
Manhattan,~1
64,000~2
speeds,~1
seat-belt~1
contributors~2
five-hour~2
biogenic~7
neuropeptides.~3
neuromodulators~1
efferents.~1
non-synaptic~1
crustacean~1
neuroactive~2
neuroamines,~1
octopamine,~1
proctolin~1
mechano-receptor~1
asexuality~1
kingdom~1
Queen~3
Tangled~2
biotic~1
'contrary',~1
organism;~1
Bank,~1
chiasmata~1
fecundity.~1
crossing-over~1
sib~4
thread,~1
superprecipitation~1
fluorescently~1
one-headed~1
detectibility~1
fovea.~3
phase-encoding~1
eccentricities.~1
two-channel~1
even-~1
odd-symmetric~2
peripherally.~1
Transforming~1
factor-alpha~2
(TGF-alpha)~1
mitogenically~1
TGF-alpha~4
proTGF-alpha.~1
proTGF-alpha~5
cotranslationally~1
prohormones~1
50-amino-acid~1
phosphatidylinositide~1
Ca2+/phospholipid-dependent~1
agonist-stimulated~1
nucleotide-~1
ion-stimulated~1
phosphorylate~1
ester-induced~2
Extrachromosomal~1
extrachromosomal~4
uniparentally~1
chloroplasts,~1
symbionts.~1
paternally~3
(psr)~1
wasp,~2
Nasonia~1
vitripennis.~1
psr~2
venereally~2
families),~2
psr,~1
fertilizes~1
divisions.~2
Resulting~2
'selfish'~1
deoxyguanosine~1
8-hydroxydeoxyguanosine~1
(8-OH-dG)~1
reagents-O2,~1
ions-O2,~1
polyphenol-H2O2-Fe3+,~1
asbestos-H2O2~1
carcinogenic;~1
8-OH-dG~6
(Klenow~1
fragment).~1
oligodeoxynucleotides,~1
misreading~1
pyrimidines~4
tested)~1
misread.~1
H3-receptors~4
parentage~1
loci:~1
mortem,~1
wild.~1
Jeffreys~1
'minisatellite'~3
sparrows~1
(Passer~1
domesticus)~1
Nottingham.~1
minisatellite~2
sparrow~3
'fingerprint',~1
minisatellite-derived~1
Segregation~2
Fingerprint~1
nestling,~1
pair's~1
fingerprints,~2
extrapair~1
copulation.~1
Extrabond~1
copulations~1
sociobiology,~1
demography~1
(GCL)~1
P-like~3
ramify~1
beaded,~1
varicosities~7
tachykinins)~1
H1-~2
H2-receptors,~1
H3-receptor,~1
H2-receptors.~1
guinea-pig~4
cell-surface~3
species)~3
outbreeding~1
allelomorphs~1
copied.~1
T-to-C~1
A-to-G~1
strand;~1
strand-inequalities~1
'compartmental'~1
insects.~2
zebrafish,~1
gastrula~1
zebrafish~1
compartmentation~1
(50K)~1
BHK21~1
(CPP).~1
CPP.~3
peels~1
fibrin-red~1
"raw"~1
paints~1
AL.~4
end-arteries~2
infra-~1
supradiaphragmatic,~1
diaphragma~1
sellae.~1
metrizamide-enhanced~2
extrusions,~1
spondylosis,~5
Naloxone,~2
20-g~1
traumatize~1
(2-mg/kg~1
(VPT),~1
Pcsf).~1
VPT~1
infusion--infusion~2
ml/second,~1
injection--injection~1
(Pcsf-d)~1
Pcsf;~1
Pcsf-d~5
Pcsf~2
volume:~2
Pcsf,~1
VPT.~1
(DAI),~1
(good~3
recovery)~1
DAI.~2
(HpD),~1
Photoradiation~1
joules/cm2.~1
mm.(ABSTRACT~1
Fourty-four~1
9.6],~1
(Grades~3
deceased.~3
0.0036).~1
0.15).~2
(16.5~1
0.0511).~1
survival.(ABSTRACT~1
retracted.~1
Wave~2
P13~2
studies).(ABSTRACT~1
Gangliogliomas~2
Russell~1
Rubinstein~1
ganglioglioma.~1
makeup.~1
tumor-free,~1
seizure-free.~1
makeup~2
syringomyelia,~1
neuroradiographic~2
minidose~1
endomyelographic~1
(PMDMECT)~1
PMDMECT,~1
pre-computed~1
pneumoencephalography,~1
(total,~1
ependyma~1
brightly~2
sideward.~1
paper-like.~1
(TEPs)~1
TEPs~1
side:~1
P19~1
N28~1
TEP~1
neurinoma,~1
parafornicial~2
(PAG)~1
crus~4
osteopetrosis~3
33.4%.~1
MN.~1
intra-axonal~1
Organelle~1
(organelles~1
perikarya.~1
meningoradiculitis~2
(Ixodes).~1
Infiltrations~1
pericapillary~2
endoneurium,~1
epineurium~1
neuropathologically~4
(Lewy~2
nuclei),~2
hypoceruloplasminemia,~1
blepharospasm,~1
Immunofixation~1
apoceruloplasmin~2
Kinetic,~1
Ceruloplasmin~1
hypoceruloplasminemia~1
Ganglioside~1
(A2B5)~1
tangle~1
preabsorbed~1
(carpal~1
syndrome--CTS)~1
backfiring~1
F-wave~3
CTS,~1
backfired~1
Repeater~1
CTS~4
wrist-to-palm~1
CTS.~1
dopamine-beta-hydroxylase~1
dystonics~1
nondystonic~1
learned,~2
reasoning.~1
previously--abilities~1
scopolamine:~1
hemifield~4
midoccipital~1
neuroanatomic~1
asymmetries~1
gravis,~3
force-time~2
outstretched-arm~1
hyperammonemia~5
thereon.~1
Acetylcarnitine~1
acylcarnitines~2
hyperammonemias,~1
hyperammonemia,~1
Selectively~1
neurocytoprotective~1
AVMs.~3
Education;~1
Osteopathic~1
Association)~1
2,700~1
3/5~2
full-time.~1
postgraduates~1
(PG4s);~1
PG4s~1
3,000;~1
projection,~1
2,400.~1
levodopa,~6
peak-dose~3
dyskinesias,~1
end-of-dose~1
dyskinesias.~1
scintillations.~3
trihexyphenidyl.~1
waxed~2
trihexyphenidyl,~1
plexopathies~1
mononeuropathies.~1
cis-dichlorodiammine-platinum~1
(cisplatin;~1
CDDP)~1
intra-arterially,~1
conundrum,~1
answers;~1
(FVER)~1
(OCB).~1
periventricular/subcortical~1
matter),~1
FVER~1
OCB~1
ambiguous,~1
autonomic,~1
oculomotor,~1
(0.95)~1
(0.90)~1
IgG%~2
(0.47)~1
low-sensitivity~1
dimensionless~2
suppressors;~1
Suppressors~1
isoelectrofocused~1
silver-stained,~1
immunofixated~1
8.3),~1
bands,~3
3-O-methyldopa~2
(OMD)~1
on-off~6
OMD~1
wearing-off~5
14-month-old~2
accented~1
Ciladopa~1
ciladopa~5
(added~1
levodopa)~1
Dyskinesias~1
ciladopa.~1
hyperpyrexia,~1
Dantrolene~2
amnesia.~2
physostigmine.~2
levodopa/carbidopa~2
(CR-4-Sinemet)~1
(Sinemet)~1
"wearing-off"~1
CR-4-Sinemet,~1
Sinemet,~1
CR-4-Sinemet~2
CR-4~1
(helper/suppressor)~1
Cinnarizine~2
tremor;~1
Childbirth~1
14.7%~1
21.2%~1
1974-1978~1
cesareans,~2
Deliveries~1
(2.8-2.3%),~1
version.~2
stabilize.~2
dystocia,~6
15,399~1
0.88%.~1
race-specific~1
0.56%~1
Orientals.~1
Identifiable~1
percentile).~1
artery/internal~2
"brain-sparing"~1
83,~1
Growth-retarded~1
(86-1184~1
mU/mL)~1
transformed)~1
percentages,~1
5.2-43.6).~1
(5.4%~1
3037~1
Ochsner~1
Hospital)~1
Gynecologic~2
ovaries;~1
58.8%)~1
potential;~1
41.2%).~1
Ileus~1
Prescription~3
nystatin,~1
candicidin,~1
aminacrine~2
(cardiovascular~1
bifida).~1
4264~1
2236~1
55,736~1
1.2-1.5).~1
1086~1
1.1-1.6).~1
nystatin~2
tocolytics,~1
tocolytics.~1
1-63).~1
clindamycin-gentamicin).~1
clindamycin-gentamicin~1
tachysystole~2
apart),~1
decelerations.~4
malposition.~2
twin-pairs~1
vertex-vertex~1
10.4%~3
neoplasia;~1
42.8%.~1
Vulvar~1
Feulgen-deoxyribonucleic~1
sites--tumor~1
labia,~1
perineum--there~1
Committee's~1
scarce,~2
nonroutine~1
resent~1
Programs~2
residency-fellowship~1
abdominally,~1
preventability.~1
0.91;~2
preeclamptics~1
preeclamptics.~1
2256-648~1
dyne~5
cm-5.~1
13.2-3.9~1
L/minute.~1
Smith-Kline~1
Ekoline~1
Ultrasonoscope.~1
effusion:~1
albumin/globulin~1
20-455~1
adnexectomy~2
12-204~1
nongynecologic~2
short;~1
reoperation)~1
Queens,~1
Nassau,~1
Suffolk~3
(DES)-exposed~1
DES-related~1
18-81~1
16-31.~1
Mycotic~1
Reservoirs~1
(IUGR)~1
axoplasm,~1
polyribosomes.~1
IUGR~1
Progestins~1
oppose~2
estrogen's~1
1-28;~1
1-28,~2
17-28.~1
postdrug~1
estrogen-progestin.~1
poststudy~2
0.625~5
ng/mL):~1
17-19,~1
folliculogenesis~2
membranitis,~3
3:00~1
membranitis.~2
2:00~2
64%.~2
4:15~1
hours'~2
35-hour~1
4:00~2
membranitis~1
reaffirmation~1
26-35~1
135)~1
(11%;~1
73).~2
collaboration,~3
fmol/mL).~1
(21.1~1
fmol/mL)~1
1-6~3
unobstructed,~1
averted.~1
etidocaine~2
(final~2
0.375%,~1
etidocaine-treated~1
etidocaine,~1
etidocaine.~1
gonioscopy~2
Intravitreal~1
pre-injection~1
Limberg's~1
"rhomboid~1
flap"~2
embodies~1
inflammations~1
hemaglobinopathies~1
S-thal~1
Retina~1
Proliferative~3
(HbSS),~1
nations.~3
electrically-powered~1
1935.~1
sight-threatening~3
Noorden.~1
dacryocystitis~3
refracted~1
(RK).~1
refraction,~1
BALB/3T3~1
subablative~1
mJ/cm2/pulse~2
4.2%.~1
98.8%.~1
excimer-treated~1
radiation-treated~1
optotypes~2
numerals~1
(LCDs)~1
light-emitting~1
diodes~1
(LEDs).~1
optotype~1
gradation~1
decimal~1
notation.~2
Sloan~2
optotypes.~1
bag;~1
haptic~7
decentered~1
Erosion~2
(PMMA).~1
sulcus).~1
instrument-induced~2
IR-blocked~1
instruments'~1
incandescent~1
lamps,~2
envelopes,~1
emitters~1
Manufacturers'~1
Triamcinolone~1
acetonide~2
subconjunctivally~2
trabeculectomy.~3
subconjunctiva~1
euthanized~1
(ciliochoroidal)~1
hyperopia,~1
suppressant~2
trabeculopuncture~2
(YLT)~1
trabeculotomies,~1
extent;~1
trabeculotomy~2
extent)~1
trabeculopuncture,~1
YLT~1
goniotomy~1
(thermal~2
corneal-like~1
trabeculum~1
intertrabecular~2
(viz,~1
juxtacanalicular~1
collagen-phagocytosing~1
four-generation~1
choroideremia~2
choroideremia.~1
(glial)~1
(collagenous)~1
hypoproduction~1
pseudoxanthoma~5
elasticum~6
(PXE).~1
mottling,~1
peau~1
d'orange,~1
PXE,~1
(VAS~2
sensory)~1
affective)~1
contextual~2
Scales.~1
Rational~2
Thinking~2
(CSQ)~1
CSQ~1
oneself,~1
acupuncture.~1
chronic-pain~1
traits,~2
acupuncture~1
resting.~1
follow-ups.~2
defined:~1
Description~1
loadings~1
somatically.~1
somatically~1
(convergent,~1
multireceptive)~1
barbiturate-anesthetized~1
dearth~2
swells~1
Touch,~1
noxious.~1
leucocytes.~3
instigated~1
heel-lance~1
sleep/waking~3
gate-control~1
Awake-alert~1
cry.~2
Fundamental~1
'stress',~1
unwell~1
heel-lance.~1
developmentally,~1
664~1
cultures:~1
Staphylococcus,~1
influenzae,~3
Bacillus~5
subtilis~1
diphtheroid~1
000/mm3~1
(hypoxia,~1
permethrin~2
creme~1
lindane~2
(Pediculus~1
humanus~1
capitis).~1
Nezahualcoyotl~1
louse-free~1
nonindex~1
permethrin-treated~1
lindane-treated~1
MMU~1
18006~1
(PFU),~1
Fevers~2
vaccinating~1
seroresponse;~1
(10(3)~1
PFU).~1
vaccinee.~1
prevaccination~1
transplacentally~1
9.75~1
new-born~1
BCG-immunized),~1
BCG-immunized~1
16.1).~1
Tuberculosis~2
non-BCG-immunized~1
parents.(ABSTRACT~1
Cicatricial~1
(intracranial~4
ventilation)~2
ventriculomegaly,~2
leukomalacia.~1
prematurity).~1
Forward~1
stomachache~1
stomachaches.~2
stomachaches~5
birthdays.~1
challenges,~2
juices).~1
reproduced.~1
incrimination.~1
non-immunoglobulin~1
less-educated~1
infant-feeding~2
inner-city~5
breast-feeding,~3
"probably"~1
"definitely"~1
breast-fed,~1
888~1
Percentiles~1
clinodactyly~1
100-patient~1
orders.~3
Orders~1
hyperalimentation,~2
Involving~1
hypoxic-induced~2
neuromotor,~1
Bruininks-Oseretsky~1
Proficiency~1
(BOTMP)~1
BOTMP~1
NA1~1
16-month-old~1
poison,~1
Phytonadione~1
pralidoxime~2
(2-PAM)~1
carbamate~2
insecticide,~2
Pneumootoscopy,~1
reflectometry~2
surburban~1
relectometry,~1
77.5%.~1
Left-hand~1
Russell-Silver~1
clinodactyly,~1
ivory~1
pseudoepiphyses~1
cyst(e)ine;~1
1,750~1
caseins~2
18:82);~1
60:40).~1
kcal/kg/d.~1
casein-predominant~1
whey-predominant~2
cyst(e)ine~3
nephrolithiasis.~3
hypercalciuric~3
hyperphosphaturia~1
CaHPO4~1
-16%.~1
algebraic~1
calculations,~1
incubator~2
humidification.~1
premature,~1
noteable~1
popular,~2
119),~1
127),~1
hymen~7
forchette~2
.0003),~1
hymenal~1
.0009).~1
Hymenal~1
molested~1
23-month-old~1
toddler~2
miliarial~1
bulbs.~3
Acrodynia~1
bulbs~3
instigators~1
nonsmoking.~1
Interventions~6
social-psychologic~1
smoke-free~3
pediatrician's~1
Bradycardia,~1
"athlete's~1
heart"~1
nontrained~1
associating~1
3,294~1
ill-health.~1
retinoscope.~1
underreferral~1
overreferral~2
99.96%.~1
ophthalmoscope.~1
860~1
misinformed~1
(having~4
contact)~2
Psychoactive~1
misinformation~2
confusion.(ABSTRACT~1
vitamin,~1
(nonproliferative)~1
proliferative.~2
penicillinase-resistant~1
penicillin),~1
roentgenography.~2
(prazosin),~1
(nifedipine~1
diltiazem)~1
bipyridine~2
pulselessness.~1
distinguish,~1
(Lipo-Hepin,~1
Liquaemin)~1
(Coumadin,~1
Panwarfin)~1
Fibrinolysis~2
against,~1
Location,~1
Thyroglossal~2
hygromas,~1
Laryngoceles~1
intracorporal~2
Gadgets~1
helped,~1
sometimes,~1
dystrophic,~3
feeling,~1
(Adalat,~1
Procardia).~1
simple.~2
(Minipress)~1
emerging.~1
decent~1
3,020~1
(2,350~1
Flexibility~2
excessive,~1
consecutively.~2
dropped,~1
goniogram~1
reversal)~1
27.2,~1
27.0,~1
26.3,~1
.96.~1
intratester~4
reliabilities~3
goniometers.~1
(internal)~2
.99.~1
.26~1
.55.~1
.84~2
Goniometric~1
(SS~2
US)~1
51-lb~1
cardioperipheral~1
bent-knee-inversion~1
corrected)~1
bent-knee-inverted~1
straight-leg-inverted~1
adaptable,~1
unbalanced,~1
cavus~2
planus.~1
dissipation,~1
Compensatory~1
Fincher~1
Corb~1
Job~3
osteomyocutaneous~4
postablative~1
hardy~3
thyrocervical~1
microopaque~1
Prussian~1
Panorex~1
hemitongue~1
midlateral~1
Mobility~3
alveololingual~1
relining.~1
Anthropologists~1
contouring~3
spinoff~1
sculpturing~3
foreheads~1
subdivisions.~1
cranioplasty;~1
osteotomies.~3
Palpebral~1
Inclinations~1
Transconjunctival~2
canthopexy~1
stigmatizing~1
anchorage~4
episthesis,~1
osseointegrated,~1
951~1
epistheses~1
Gynecomastia~1
unaesthetic.~1
laser--that~1
deepithelialization.~1
Deepithelialization~1
deepithelialization~2
mammaplasty.~2
epidermis--a~1
deepithelialization--with~1
deepithelializing~1
maximus~3
sore,~1
trochanter~8
undermined~2
limb-saving~1
Tubed~1
interpositional~1
Morphology,~1
reclamped~1
reclamping.~1
reapplied~1
(cps)~2
256-cps~2
tuning~1
neurilemoma~3
ansa~3
cervicalis.~1
recollect~1
wrench~1
lipectomy.~1
dependable.~1
globe,~1
(meningioma~1
glioma)~1
"pseuduotumor"~1
immeasurably~1
compartments,~3
interconnecting~1
cholescintigraphy~1
disofenin~1
92%).~1
(beyond~1
cholescintiscans.~1
Orient~1
irrigation-suction,~1
67.6%.~1
22-55~1
Lasting~2
biliary-enteric~4
Serious,~1
transhepatically;~1
arteriobiliary~1
Tc-99m-labeled~1
(RBCs).~1
(Bilharzial)~1
Implants~1
up).~2
"take"~1
schistosomiasis~1
ailment~1
canines.~1
8-20~1
Significant,~1
20-mm~2
10-mm~4
urethrography,~1
sedatives,~1
prostatism~1
ineffectual~2
hypertrophy--a~1
925~1
(1,222~1
treatments)~1
calyceal,~2
ureteral,~1
nephrolithotripsy,~1
nephrostography,~1
irrigations~3
retrievals.~1
Staghorn~1
staghorn)~1
8,478~1
2,149~1
adrenal/liver~1
hemorrhage),~1
graph~2
beryllium~2
commonly.~1
Misinterpretation~1
side-by-side~2
contours,~1
azygoesophageal~1
recess,~1
Upright~2
Cine~2
acquires~1
end-systole.~3
Multispectral~2
Aeronautics~1
TR/long~1
TR/short~1
TE.~1
system-imposed~1
Image~1
intercase~1
intensity-based~1
Mammographic~1
Radiographically~1
craniocaudal~2
radiography-aided~1
C-2,~1
foramina~2
strontium-89.~1
radiophosphate~1
remineralization~1
Treatments,~1
lesion-to-nonlesion~1
hour/4~1
(MDP)~1
four-phase~1
nonquantitative~1
29.7%~1
54.7%,~1
15.6%.~2
surface-coil~2
0.5-T~1
Menisci~3
fibrocartilaginous~1
posterior-horn~1
meniscus.~2
Volumetric~2
surface-rendering~1
Pixar~1
fast-computing~1
somersaulting~1
axis)~2
animated~1
Editing~1
translucent~2
surface-rendered~1
(Gianturco)~1
(64.1%)~1
89.5%~1
58.8%~1
69.1~1
Cataclysmal~1
neovascularity,~1
Postembolization~1
isobutyl-2-cyanoacrylate,~1
noncholesteatomatous~1
processes)~1
(TORPs),~1
(PORPs).~1
TORPs~1
PORPs).~1
discernible,~1
revolutionized~1
Meticulous~1
otolaryngologist,~1
"microanatomic"~1
locales.~1
familiarizing~1
msec:~1
("asymmetric");~1
("symmetric~2
TE");~1
TE").~1
rephasing~3
Even-echo~1
short-TE~2
train,~4
long-TE~1
Switching~1
gradients)~2
(CSF)-gated~1
artifacts.~3
constant-velocity~1
cardiac-dependent~1
short-echo~1
nongated~1
excitations.~1
mm/sec),~1
vascular-driven~1
diencephalon~1
Glomus~2
tympanicum~2
chemodectomas~2
Jacobson~1
(tympanic)~1
3.5:1,~1
Tinnitus,~1
chemodectoma,~1
chemodectomas.~1
trapezoidal,~1
hypervascular,~1
middle-to-late~1
(N3).~1
70-Gy~2
Gy/day~1
regression;~1
over-treated~1
self-closing~1
30-F~1
introducer-sheath~1
(MR)-guided~1
5-mm-diameter~1
500-microM~1
MR-guided~1
5-F~1
perinates~1
solvation~2
supercomputers.~1
Phosphorescence~1
lifetimes~3
millisecond~1
indole~1
microseconds.~2
photoluminescence~1
muscle-specific~1
BC3H1~3
Differentiated~1
surrogates~2
transfection~5
v-erbB,~2
Val12~1
c-H-ras~1
cotransfection~1
oncogenes.~1
meridians~1
Cones~1
computer-reconstructed~1
mounts~1
2.9-fold~2
foveas~1
Cone~2
radially~3
isosensitivity.~1
nasotemporal~1
sialylation~1
1-6-linked~3
complex-type~2
asparagine~5
(Asn)-linked~1
-GlcNAc~1
1-6Man~2
1-).~1
transformation-related~1
gp~2
130,~1
Glycosylation~1
GlcNAc~1
Mile~5
complacency~1
negation~1
operators,~1
reactors,~1
squid~2
calcium),~1
homogeneity.~1
Mutation,~1
gametes,~1
populations--collectively~1
flow--will~1
Gene~1
species'~1
N-CAM,~1
collectives~1
CAM~1
N-CAM~7
superfamily,~1
immunoglobulin-like~1
homophilic~1
(682~1
N-CAM's~1
stearothermophilus~1
angstroms~2
30S~1
angstroms.~1
bat~1
Pteronotus~1
parnellii~1
echolocating~1
bats~1
suprageniculate~1
peri-olivary~1
aversive~1
(CCK-8),~1
memory-enhancing~2
(angiogenesis).~1
Walker~2
micropocket~2
desorption-electron~1
Microgram~1
chorioallantoic~1
Readthrough~1
leukosis~2
retroviruses.~2
AAUAAA~1
readthrough~3
intermediates:~1
genomes)~1
Midway~1
centralis~1
central-to-peripheral~1
20-fold.~1
retina-peripheral~1
Nonuniform~1
neurogenesis~2
topography.~1
512-cell~2
criticized~2
mingling~3
intermingle~1
interclonal~1
controversies.~1
vanishing,~1
inequality~6
1947.~1
1973-74.~1
slowdown~1
wages~1
wages,~1
birthrates.~1
elegans~1
unc-79.~1
unc-79~3
unc-80,~1
Nematodes~2
unc-80~1
unc-9,~1
unc-80.~1
postulate,~1
E-associated~1
E-containing~2
neurites,~1
Pheochromocytoma~1
(PC12)~1
neurites~4
cones;~1
unmetabolized~2
B,E(LDL)~1
nucleoprotamine~7
85%)~1
nucleohistone~7
sequence-specific~5
spermatozoon~1
Sequence-specific~1
0.65M~1
Bam~1
nucleoprotamine.~1
size-selected~1
single-copy~1
spermatozoon.~1
methanes~1
(CBrCl3,~1
CCl4,~1
CHCl3).~1
halomethanes~1
(CCl4)~1
525A,~1
beta-mercaptoethanol.~1
Halomethane~1
gap-junctional~3
unhealthy~2
Dictyostelium~3
discoideum~1
(MHC~1
mhcA~2
(antisense~1
RNA).~1
transformants~1
progeny,~2
ameboid~1
locomotion.~2
starving~1
antisense~2
mononucleate,~1
recombination,~1
discoideum.~1
G418~2
transfect~1
Dictyostelium.~1
G418-resistant~1
cytokinesis~2
multinucleate.~1
hmm~4
karyokinesis.~1
Whole-cell~2
current)~2
Drosophila.~1
myotube~4
picosiemens,~1
picosiemens.~1
coherence~2
spurts~2
Piaget.~1
albopictus,~2
Hemisphere,~1
cold-hardiness~1
Trade~1
imports,~1
introduction,~3
arboviral~1
infesting~1
DNA's,~1
673~1
COS~6
untransfected~1
Preneoplastic~1
multidrug-resistant~1
(mdr)~1
mdr~3
P-glycoprotein,~1
multidrug-resistance~1
carcinogen-initiated~1
fifths~3
ideation.~1
kills~2
nonorganized,~1
nonintegrated~1
incidence--up~1
studies--of~1
triage,~1
medically,~3
financially.~1
overcrowding~1
co-morbidity~1
1,565~1
2,837~1
917~2
Demography~1
teenaged~5
abortions)~1
oligohydramnios~3
Potter~1
sib.~1
encysted~3
(Potter~1
6,250~1
Tennessee,~1
browplasty~2
rejuvenative~1
brow~2
camouflaged~1
nosocomial,~1
pneumonias,~2
41-year~1
enteroclysis~1
BACOP~1
"bleomycin~1
lung,"~1
teratoma,~2
Periaortic~1
neuroglial~2
mycetomas~1
air-crescent~1
boydii.~1
myelomatous~1
IgD-positive~1
(IgD~1
effusion)~2
Follicular~8
continuing.~1
furcal~6
L4-root~1
discectomy,~2
accelerates,~2
osteolysis~2
Craig~1
osteolysis.~1
chiropractors~3
malalignments~1
subluxations,~1
L4-5.~1
radiologist,~1
chiropractors,~1
(driving~1
surface),~1
indispensible,~1
pin-bone~2
Instron~2
load-to-failure~2
pin.~1
insertional~2
in-lb.~2
in-lb~1
spondylectomy~1
interspinous~2
radiograms.~1
unite~1
tactics~2
L-rod~1
flexural~3
Nondestructive~1
Southwell~1
Attaching~1
L-rods~3
3.2-mm~1
uninstrumented~1
halting~1
4.8-mm~2
outcome;~1
compass~1
xiphisternum~1
ventrally~1
0.11),~1
Kyphosis~1
Kyphectomy~1
kyphectomy~2
6-57~1
99,~1
111,~1
neuroarthropathy~1
fibroblast-like~2
notochordal~2
zones:~2
Containing~1
metrizamide,~1
withdrawal:~1
73%).~2
4.25%~1
(L1-L4)~1
(I-IV),~1
(I-II)~2
trabeculae.~2
(OPLL),~1
(kyphotic~1
meandering-type~1
curvature).~1
OPLL~2
Sciatica~1
sequestrated~2
hookwire~2
29.6~3
79.2~2
nil.~2
31Phosphorus~3
(MRS),~1
nondestructive~2
phosphodiesters.~1
PCr.~1
MRS~2
accumulated.~1
(SMV)~1
SMV~3
Cachectin/tumor~1
Cachectin~4
cachectin~2
endotoxemia.~2
pounds)~1
nonsplenectomized~2
preliminarily~1
splenectomized~2
trypsinization.~1
G-75~1
protein-like~2
60,000.~1
enteroumbilical~1
debrided.~1
12,317~1
33.0~1
$10,657.~1
xeromammographic~1
Xeromammography~1
eighty-seven~1
unimproved~2
0.088.~1
transbrachial~2
drier~1
Infusaid~5
transaxillary~1
tunneled,~1
Lidoflazine,~2
6.8%,~1
consciousness;~1
strong.~3
Coenurus~1
cerebralis~1
cistern~2
fluid-like~1
frontotemporoparietal~2
T-2~1
two).~2
iodoventriculography~1
(TIP)~1
TIP~2
vascularization;~1
floaters.~1
nontender~1
pallisading~1
pseudorheumatoid~2
rebleeding;~1
sclerotherapy,~3
splenopneumopexy~2
29-month~1
portopulmonary~1
sclerotherapy.~1
(PHPT)~1
(SHPT)~1
(73%),~3
HPT.~1
four:~1
grafting),~1
euparathyroid.~1
(whose~1
fat),~2
graft-dependent~1
transplant,~2
Autotransplantation~1
HPT,~1
Incorrect~1
euparathyroidism,~1
monoglandular~2
avoidable.~2
(XOD)~1
(SOD).~1
XOD~2
(rats,~1
beings).~1
XOD;~1
SOD:XOD~4
(kidney~3
10(3))~1
10(4))~1
10(5)).~1
10(5].~1
CHF-B4~1
choledochoscope~3
(16.9%)~1
stones;~1
(4.6%);~1
(88.6%)~1
choledochoscope.~1
(52.3%).~1
achieve.~1
diameter:4~1
precoated~1
10(5).~1
laminin-treated~1
fibrin-~1
fibronectin-treated~1
cm-2,~1
RPMI-1640-HEPES~1
collagen-precoated~1
Thoracoabdominal~1
volemic~1
(IS)~1
(NaCl)~1
unclamping.~4
HS,~5
unclamping,~1
44.5%~1
reader's~1
80.5%.~1
(PGY-5)~1
antrectomy,~2
(PGV).~1
Mann-Williamson~2
ulcer-producing~1
stomachs,~1
pentagastrin-stimulated~1
mEq/hr~1
mEq/hr,~1
after;~1
min/ml~3
antrectomy).~1
FS,~1
FNAs~1
"suspicious"~2
"suspicious"--but~1
malignant--were~1
suspicious,~1
Fistulas~2
arterial-enteric~1
Discussed~1
failure).~1
uropathogens,~1
antimicrobials.~2
"urinary~1
infections"~2
"difficult~1
forthcoming,~1
neurophysiology,~1
endocrinology,~1
averting~3
Uric~2
hyperuricosuria.~1
nonobstructing~1
Cystinuria~1
excretes~1
cystinuria~1
Hippocrates~1
wrote~1
"infection~1
stones"~1
urease-producing~1
Parenchyma-sparing~1
Excretory~2
injuries).~1
consorts~1
condylomatous~1
soaking~1
qualities;~1
connector~1
separations,~1
(COFk)~1
Uncoated~1
COFk~3
Biocath~1
postcatheterization~1
obturator~3
lithotriptor~2
quarters.~1
2-55~1
(rad),~1
Strychiomel~2
(Mellaril),~1
multiaction~1
(Strychiomel)~1
polled~2
replied~1
Intraurethral~1
Suprapubic~1
intraurethral~1
Perineal~1
urethrostomy~2
agenesis.~2
(2.7%).~1
(24.9%),~1
(18.6%).~1
ureterolithotripsy~1
solid-wire~1
disintegration.~1
"steinstrasse."~1
nitrofurantoin~3
histochemistry)~1
(Triton~1
X-100).~1
Columnar~1
"cake"~1
Ureteric~1
Chemo-immunotherapy~1
cystourethrectomy~1
prostatectomies~2
1904,~1
suggest:~1
fourteen-month~1
497~2
patient-completed~1
(8.7%)~1
gender-dysphoric~1
cm--a~1
(CCF)~1
resectoscope~2
renal-sparing~1
(MPSS).~1
Hemangiomas,~1
infrequency~2
dedifferentiate~1
Ask-Upmark~2
(segmental~1
hypoplasia)~1
detubularized~1
Continent~1
diversions~3
cystoprostatectomy.~1
1978-1983,~1
(trying~1
[Zn],~1
[Var/Zn],~1
[Zn]~2
[Var/Zn]~4
sub-divisions:~1
wives,~1
emigrated~2
Urinalysis,~1
chyluria.~1
intrascrotal~2
paratesticular~1
eighty-two-year-old~1
thirty-eight-fold~1
hypospermatogenesis~1
alpha-sympathicolytic~1
Providers~1
exploitation~1
Toxoplasmosis~2
Pyrimethamine~1
"Unprepped"~1
dietary-induced~1
microbiology.~1
Instrumentation~3
yesterday's~1
remedies--medicinal~1
herbs.~1
Plants~1
medicinal~5
herbs~3
Drug-plant~1
herbal~2
remedy.~1
Precise~4
underreported~1
abortus~1
herds,~1
alcohol-abstinent~1
benzodiazepines,~2
consult~3
(sham),~2
4-,~1
618~1
1422~1
occlusion);~1
(1282~1
384;~1
thinning.~1
myocardia~1
Excitability,~1
refractoriness,~1
2-antagonist~1
catecholamine-depleted~1
antidigoxin~1
polyacrolein~1
macrospheres~1
(APAMB).~1
posthemoperfusion~1
cardionuclear~1
R/S~1
aVL,~2
V5,~1
repeatability,~1
year's~3
(CM5~1
CC5)~1
83.6~1
78.9~1
CC5.~1
downsloping~1
dynes/cm2~1
10(3],~1
ergometric~3
watts,~1
kg/min~1
(2821~1
783~1
[SEM]~2
(957~1
(612~1
half-filling~7
Half-filling~1
0.77)~1
size.(ABSTRACT~1
(DCM)~1
(MPI).~1
MPI~1
normokinesis~2
DCM~2
(SWMA)~1
(DWMA).~1
DWMA~2
0.58)~1
SWMA.~1
DCM,~1
flowprobe)~1
(drained~1
initiated).~1
Radionuclide-determined~1
(VD),~1
VD.~1
(Rp/Rs)~1
Qp/Qs~1
Rp/Rs~1
VSD.~2
Interatrial~1
(IASA)~1
(2DE).~1
IASA~2
2DE.~1
IASAs~4
involution~2
stress.,~1
(TAPVC),~2
Abandoning~1
2444~1
mixed-type~1
TAPVC,~1
(supine:~1
upright:~1
60];~1
[31%]~1
stenosis).~1
circumference)~1
tendineae;~1
ramipril~46
(HOE~6
498),~1
ramipril,~14
ramipril.~6
Ramipril~14
Ramipril,~1
Efficacy,~1
dihydralazine,~1
non-sulphydryl~2
ramiprilat.~1
Converting~1
77,~2
84).~2
498)~2
pro-drug~1
ramiprilat)~1
HOE~7
498,~1
498-glucuronide,~1
diacid-glucuronide,~1
diketopiperazine~4
62.4~2
Ramipril's~1
(daily~1
498).~1
76.4~2
85.6~1
98.4~2
(72.1~1
(71.7~1
sodium-replete~2
Sulfoconjugated~1
daily),~1
(trough~1
a.m.,~1
transaminase,~3
mmol/liter)~1
(ramiprilat),~1
Ramiprilat~1
ramiprilat~5
84.5%~1
ramiprilat,~2
Nonrestricted~1
noninvasively,~1
17-day~1
once-~1
19.57~1
15.20~1
18.78~1
14.57~1
scatter,~1
unexperienced~1
Arrhythmogenesis~2
1,287~1
Arrhythmia~2
proarrhythmia,~1
tachyrhythmia~1
JT~2
arrhythmogenesis~1
U.S.,~1
Mexiletine,~1
mexiletine.~1
within-patient~2
2/70~1
3/78~1
caffeine-naive~1
velocity),~2
E/peak~2
(CAD~5
m/s),~2
0.32),~1
0.010~2
area/A~1
0.69),~1
(MPIP),~1
code,~1
653~1
MPIP~3
4-digit~1
53%;~2
apply,~1
events--acute~1
discharge--was~1
(non-AMI~1
non-AMI~4
(intraventricular~1
(electrocardiographic~1
dyskinetic,~1
(13.8~2
microV)~1
II.(ABSTRACT~1
pericatheterization~1
(stenosis~1
[24%]~1
[3%]~1
(femoral~1
brachial),~1
(-12%,~2
(-7%,~1
(-16%,~1
densitography.~1
Electromechanical~2
systole-heart~2
time-heart~2
(electromechanical~1
1206e-0.02~1
transition,~1
aVF~1
aVR,~1
V3-V5~2
regionalizing~1
mean).~2
dyssynergy~2
pattern).~1
0.10);~1
0.08)~2
orally.(ABSTRACT~1
attesting~1
cardiodepressant~1
nisoldipine.~2
CI-930,~2
1,999~1
1,471~1
CI-930.~2
CI-930~5
0.51).~1
0.78)~2
(DCMV)~1
(DOAV).~1
recent-onset,~2
DCMV~5
DOAV~6
Near-constant~1
pacing).~1
2-dimensionally~2
discordant,~1
(VSD),~1
(AVR)~2
flowmetry~1
subgroups;~1
A-II~3
B-I~2
B-II~2
AVR.~1
(Sellers~1
classification):~1
isomerism~9
isomerism,~1
0.049).~1
isomerism.~1
isomerism)~1
(VEST),~1
VEST~1
(baseline);~1
walking;~1
stairs;~1
eating;~1
urinating.~1
urinating~1
stage.(ABSTRACT~1
time-velocity~4
hypertrophy;~1
origin);~1
0.77;~3
Age-corrected~1
nomograms~4
Radius~1
75),~1
78).~1
-0.905,~1
-0.823~1
0.810,~1
0.625,~2
0.752~1
-0.631,~1
augmented,~2
inversely,~3
radioligand-binding~1
neuronally~2
Radioligand-binding~1
minority,~1
cardioselectivity~2
"vascular~1
sparing"~1
1-selective~9
(ISA),~2
ISA~6
respects:~1
selectivity);~1
(ISA);~1
(lipophilicity).~1
cardio-depression,~1
ISA,~2
Beta-adrenoceptor-blocking~1
metoprolol.~1
gluconeogenesis,~1
glycogenolysis.~1
Nonselective~1
diferric~1
tied-off~1
thus.~1
2H:1H~1
18O:16O~1
(580%)~1
(256%)~1
200)~4
0.97%~1
-0.32~1
0.87%~1
200),~1
microL~1
undistilled~1
Water-CO2~1
100-microL~1
post-obese~2
respirometer.~1
Slimmed-down,~1
finished.~1
comfortably~2
Molybdenum~2
graphite-furnace~1
spectrophotometry,~2
test-weighing~1
microgram.~1
2-linoleoyl-1,3-dioctanoyl~1
(8L8)~1
2-oleoyl-1,3-dioctanoyl~1
8L8~1
octanoic~1
decanoic~1
2-[1-14C]linoleoyl-1,3-dioctanoyl~1
2-[1-14C]linoleoyl-1,3-dioleoyl~1
glycerol.~3
1,3-dioctanoyl~1
gluten-free~6
flour.~1
breath-H2~1
starch-protein~1
glycogenesis,~1
D-[U14C]-glucose~1
dose/100~1
second-meal~1
14C-glucose~1
Preschool-age~1
Indonesian~1
3228~1
perpetuates~1
haptocorrin~4
binder),~1
cobalamin,~2
corrinoids~1
Corrinoids~1
prematures~5
(110,100~1
10,100)~1
(3.67~1
undergraded~2
meconium.~2
Cobalamin-binding~1
22.13~1
15.50~1
prefectural~1
animal-protein~1
intake:total~1
Wistar-Slc~1
buds,~1
video-based~1
(CIM).~1
send~1
touch-sensitive~1
categorizes~1
nodular.~1
instrumentally~1
circularity~1
"diagnosis,"~1
hierarchic~2
classificatory~1
hypercellular,~1
nuclear/cytoplasmic~2
Round,~1
oval,~1
nucleoli,~1
azurophilic~1
hyperleukocytotic~1
2'-deoxycoformycin.~1
trabecula~1
microvillous~1
tonofilaments~1
cardioexcitatory~1
somatastatin,~1
Met-enkephalin,~1
Leu-enkephalin,~1
YY,~1
enolose,~1
hormone/follicle-stimulating~1
Reverse-phase,~1
chromatograms~2
pinpointed,~1
aminoacidopathies~1
contortrix~1
anti-protein~2
gamma-carboxylated~1
valvular,~1
(helper)~1
Viral-induced~1
(HTLV)~1
half-minute~1
labor-intensive~1
blasts.~2
"three-part~1
differential"~1
cell/antibody~1
Weakly~1
PEG,~3
Polybrene,~1
(LISS);~1
LISS,~1
LISS.~2
technics;~1
titrations,~1
DuPont~1
aca~4
analyzer,~2
RA-1000~1
diazotized~1
(used~1
instruments)~1
RA-1000.~1
spuriously~1
1-nitroso-2-naphthol~1
97.4%,~1
92.3%,~1
(Mellaril~1
Prolixin).~1
Phenothiazines~1
lymphedematous~2
lymphedema,~1
syringocystadenoma~1
papilliferum~1
lactiferous~1
Spain~1
summertime~1
eschar,~2
(MSF)~1
antirickettsial~1
serology.~2
lymphohistiocytic~1
rickettsiosis~1
rickettsiae~4
MSF~1
computer-simulated~1
classifies~2
result)~1
Slipped~1
(SCFE)~2
SCFE~2
SCFE,~1
energy-absorptive~1
single-photon~2
absorptiometric~1
Humerus~2
densitometer~1
(HM),~1
(FHM),~1
[SSC])~1
(pColl-I-C)~1
FHM~3
SSC~3
HM,~1
pColl-I-C~3
first-week~1
correction)~2
Graphic~1
Hotelling's~1
Bonferroni~2
appropriate-for-gestational-age~2
small-for-gestational-age~3
(glucose~2
polymers)~1
sucrose).~1
25-hydroxycholecalciferol,~1
(LBW)~1
length-for-age~1
(L/A),~1
374554~1
L/A~3
10.4%,~1
12.0%,~1
28.9%,~1
27.6%,~1
21.3%.~1
LBW.~1
skinfolds~2
Superobese~1
percentile.~1
superobesity.~2
"low-dose"~1
falloff~1
stockier~1
(ICGH)~1
ICGH~2
ICGH.~2
expense,~1
hormonal-stimulation~1
(CHST)~1
sequentially-administered~1
thyrotropin,~1
heights,~1
cm/y~1
fruitful~1
(Wyler~1
Philadelphia)~1
11-~1
midpuberty,~1
1.46)~1
acromegalic~7
commingling~1
curves;~1
abnormalities:~3
leukomalacia,~1
3828)~1
1.8%)~1
Ipecac~1
callers~2
childhood/adolescent~1
semi-structured~1
"worst~1
thing"~1
unpleasant~1
state-matched~1
Hydrohematometrocolpos~1
hymen,~3
fundoplication-gastrostomy~1
extubated~3
0.22.~1
growth)~1
microcephalic~6
nonketotic~4
43).~1
eight),~5
L-carnitine.~1
chaperone~4
mailed,~1
chaperone.~1
seductive~1
uncomfortable~1
"near~1
miss"~1
"aborted"~1
"emergency~1
apnea")~1
Emotionally,~1
lives;~1
intervened.~1
"vulnerable~1
children."~1
premailed~1
(1470~1
mL/d)~1
macronutrient~2
handwashing~3
overgown.~1
your~1
no-gown~1
834~1
1056~2
1073~1
1714~1
technicians.~2
Gown~1
gowns~2
Handwashing~2
heme-positive~1
coincidently~1
enterocolitis.~3
thromboxane.~1
masks~7
goggles;~1
goggles.~1
mask/goggles~1
Alagille~1
hepatocarcinoma.~1
Disabling~2
circles~2
Shelby~1
Tennessee.~1
sociological,~1
drownings~7
U.S.A.,~2
incident,~1
Essentially,~1
"found~1
floating".~1
"tired~2
life".~1
clustering.~2
hangings~1
oneself~1
aside~2
jail~1
defibrillation;~1
beta-active~1
synergistic,~1
dentin~6
200-1,000~1
incineration~3
incinerated~1
200-600~1
Temperature-dependent~1
predentin~1
incongruous~2
stylet~2
guard-adjustment~1
malpractice.~2
Controversial~1
entomological~1
Jung's~1
writings~1
mandalas~1
Mobile,~1
Alabama.~2
Cysts~2
asphyxial~4
suspicions~2
foul~2
simple-appearing~1
expand.~2
Edrophonium,~1
Hypertonic~1
Gastrin-releasing~1
iron-deficiency~5
streaking~1
("watermelon~1
stomach")~1
Laminated~1
enteroliths~2
enterolithiasis~1
hemobilia~4
better-trained~1
entertain~1
nonsurgeons,~1
gallstone.~1
Cholangiography~1
hemispherical~2
methyltestosterone~5
36-yr-old~1
chyluria~1
evidenced.~2
encapsulating~2
loops,~4
hunger~1
satiety.~1
deploy~1
aligning~1
55-yr-old~1
hypo-gamma-globulinemia,~1
B-immunoblastic~1
(diffuse~1
Condyloma~1
Famotidine~3
thiazole~1
Pharmacologically,~1
famotidine's~1
syringe.~1
parameters;~3
bovis~5
noncolonic~3
Wilsonian~1
pallidum.~1
Osmium~1
rupturing~1
Fasciola~1
hepatica~1
5-yr-old~1
fascioliasis--ulceration~1
parasite,~1
hematobilia.~1
fascioliasis~1
hatches~1
pierces~1
opportunistic,~1
mycotic,~1
Nesidioblastosis~2
insulinoma.~1
insulinoma,~1
nesidioblastosis~1
work-up,~2
distinct.~1
(PIN),~1
nullipara~1
Nephrosclerotic~1
arteriolar,~1
interlobular,~1
step-sectioned~1
crescents~3
SCr~1
occasions)~2
50.0~3
.8575,~1
oxalosis~3
radiographical~1
trabecules~1
Trabecular~1
analgesics;~1
pointers~1
COMBIN.~1
(Bf).~1
COMBIN~3
disequilibrium~9
modifier.~2
locus--and~1
TM,~1
QM,~1
theta,~1
recessivity~2
liability,~1
models;~1
B-BF-DR~1
linked,~2
B8-BfS-DR4~1
B15-BfS-DR4,~1
B7-BfS-DR2,~1
B8-BfS-DR3,~1
B18-BfF1-DR3,~1
B40-BfS-DR4.~1
HLA)~1
modifier~1
polygenes)~1
Automatic~2
pedigrees~2
contrived~1
counter-example~1
pedigrees.~1
fumaric~1
skin-fibroblast~1
fumarase~4
digitonin~2
pI's~1
5.53~1
5.60~1
5.65-6.8.~1
fumarase-deficient~1
antifumarase~1
(35S)-methionine-labeled~1
fumarases~1
proalbumin~2
(8.6,~1
6.9)~1
variants'~1
fast-moving~1
(Gent,~1
Vanves,~1
Reading)~1
slow-moving~1
(Sondrio,~1
Christchurch,~1
Lille,~1
alloalbuminemia~1
.0004~1
Christchurch~1
Lille.~1
resolutive~1
plasminogen.~1
6q26-q27~1
somatic-cell~1
extinct~2
walks~4
(RFLP)~3
0.9-kb~1
0.5-2.0~2
RFLPs~1
insertion/deletion-size~1
0.1-kb~1
three-generation~2
repeats.~2
Hartnup~11
alpha-amino~1
nonessential).~1
sibs.~1
manifestations--impaired~1
"pellagrin"~1
other--who~1
(transport)~1
family),~1
recessives~1
form).~1
"Hartnup"~1
genotype)~1
polygenic.~1
Cause~1
multifactorial.~1
(PWS).~1
translucency~1
hypopigmented.~1
hypopigmentation.~1
Hairbulb~1
cysteinyldopa~1
periodontitis~3
model-choice~1
mistaking~1
masking~1
range)~3
uninflamed~1
(Cmax),~2
beta),~1
(CL/f),~1
(Vd/f)~1
5.97~3
mg/liter,~2
3.83~2
ml/kg/minute,~1
3.63~1
Vd/f~1
(8.56~1
5.87~2
0.138,~1
3.23~1
liters/kg,~3
CL/f~1
catarrhalis.~1
ampicillins,~1
tetracyclines,~1
motivates~1
pre-infectious~1
fusidic~6
methicillin-susceptible~5
[MIC]~1
anti-staphylococcal~2
anti-streptococcal~1
carboxyquinolone~1
fragilis.~2
Patients,~3
fibrosis;~1
Infecting~1
Serratia,~1
Acinetobacter.~1
emerged;~1
Resistant~1
liters/hour/1.73~1
66.6~1
desethyl-ciprofloxacin~1
(M1),~1
sulfo-ciprofloxacin~1
(M2),~1
oxo-ciprofloxacin~1
(M3),~1
formyl-ciprofloxacin~1
(M4).~1
Multiple-dosing~1
ml/minute/1.73~1
every-12-hour~1
Disks~1
Mueller-Hinton~3
(NCCLS)~1
Deutsches~1
Institut~1
fur~4
Normung~1
(DIN~1
58940).~1
breakpoints~2
(susceptible,~1
(limited~1
NCCLS~1
recommended:~1
DIN~1
diagnostic-related~1
New,~1
broad-spectrum,~2
phlebitis)~1
purchases~4
expediting~1
Decisions~2
hospital-associated~1
empirically,~1
streamlining~1
initial,~2
Streamlining~1
post-antibiotic~1
(PAE)~1
PAE~10
PAEs~1
mirabilis,~2
marcescens,~2
techniques--filtration,~1
dilution--were~1
faecalis.~3
(MBC)~1
pseudomonal~2
ceftazidime~2
combination:~1
difficult-to-manage~1
(MRSA)~1
MRSA~4
Azlocillin~1
Antagonistic~1
500,~2
microbiologically.~1
dose-independent~1
d,area,~1
2.76~2
liters/hour.~1
42.2~1
42.5~1
proteinosis~5
proteinosis.~3
(rheumatoid~1
Felty's~2
myositis).~1
papulovesicular~1
myelofibrosis.~2
dynes/second/cm5~1
421~1
dynes/second/cm5,~1
angioedema.~2
1:2,560~1
antiribosomal~1
indepth~1
propositus,~1
anti-SS-A,~1
anti-SS-B,~1
anti-Sm,~1
anti-ribonuclear~1
underproduction~1
phlebotomy.~1
tranylcypromine~1
cheese.~1
Electrocardiography~1
Paroxysmal~4
hemoglobinuria~7
(Donath-Landsteiner)~1
complement-fixing~2
autohemolysin~1
steroid-responsive.~1
anti-IgM~1
autohemolysin.~1
cytopenias~2
widens~1
hemoglobinuria.~4
Hypophosphatemic~1
Judicious~2
females;~3
Shwachman~1
Kulczycki's~1
(S-K)~1
Brasfield~1
height-adjusted~1
percentile,~3
clubbing,~1
(1955~1
S-K~1
noncomparable~1
symptom-matched~1
66,~2
vagally-mediated~1
-0.44,~1
44-month~1
pneumonia:~1
(12).~1
Community-acquired~2
centers;~2
"alert"~1
"lethargic"~1
"stuporous."~1
pyrimethamine~1
Leukopenia,~1
Ring~3
catheter/feeding~1
Carey-Coons~1
bacteribilia,~1
(66.7~1
episodes).~1
Metro~1
Exclusion~1
ml/second/1.73~1
glomerulosclerosis.~2
non-azotemic~2
para-amino~1
inulin,~1
ml/minute,~1
ml/minute),~3
ml/minute).~1
1,176~1
mOsm~2
874~1
92).~1
(trend~1
Bisphosphonates~1
diphosphonates)~1
fragmentary.~1
bisphosphonates~1
aminohydroxypropylidene~1
bisphosphonate~1
(AHPrBP~1
APD),~1
AHPrBP~2
AHPrBP's~2
tolerated:~1
rehydrated,~1
AHPrBP,~1
(myocardial~3
two-group~1
activity-related~1
mg/hr)~3
radioactive-labeled~1
carbohydrate-supplemented~2
(hypertensive)~2
term-pregnant~2
control-fed~3
(normotensive)~2
micrograms/min,~2
257.8~1
212.7~1
[14C]deoxyglucose~1
autoradiographs,~2
washed-out~1
cerebellar,~2
ketamine-treated~1
Resident~2
gynecology~1
Queries~1
anesthesiology~1
staffs.~3
capping~1
endometriosis-related~1
maturation-activation.~1
156%~1
oxytocin.~3
endotoxin-induced~1
Thrombocytopenia,~1
explicable~1
(preeclampsia).~1
endothelium-mediated~1
Endothelium-mediated~1
0.0135).~1
near-significant~1
II-serotonin~2
tosylate.~1
pig;~1
persist,~1
notching.~1
cardiotachographic~1
"riding~1
on"~1
"horrible"~1
"excruciating"~1
anesthesiologic~1
Jarcho-Levin~1
triphasic),~1
(monophasic),~2
desogestrel~1
biphasic)~1
gestodene~1
(triphasic).~1
embryopathy,~2
(endosalpingosis)~1
endosalpingosis~1
5399~1
medical--among~1
Declining~2
Transcapillary~1
"wick"~1
"wick-in-needle"~1
(thorax~1
(biparietal~1
length).~1
derivate,~1
enprofylline,~1
myometrium,~4
monophosphate-and~1
monophosphate-dependent~4
Enprofylline~2
[inhibitory~1
mol/L]~1
mol/L),~2
enprofylline~2
Heparin-associated~2
panhypopituitarism~1
FEMCEPT~1
(BioNexus~1
Raleigh,~1
Carolina)~1
1279~1
hysterosalpingograms~1
89.4%.~1
hysterosalpingogram-demonstrated~1
two-application~1
nonradiopaque~2
cyanoacrylate.~1
IIB,~2
parametrial~2
parametria,~1
step-serial~1
parametrium~2
88.1%~1
Parametrial~1
large-tumor~1
70.9%.~1
(31.1%~1
nodes)~2
(44.1%~2
(82.2%~1
76.9%,~1
hydrogelic~1
P-block,~1
hysteroscopically~1
Hysterosalpingography~1
checkup~1
P-blocks,~1
P-blocks~2
Endeavors~1
Distension~1
isthmus.~1
sonographer~1
regurgitation).~2
1931~1
0.0041~1
age-standardized~1
85+~3
leiomyomas.~1
hemostasis;~1
myomectomies;~1
brevity~1
nil;~1
capillary-venous~1
equations,~3
venous-capillary~1
mg/dl/150~1
mg/dl/114~1
mg/dl/211~1
mg/dl/183~1
mg/dl/157~1
third-trimester~2
7.1);~1
9.0).~1
(preinfusion)~1
Argentina~1
Uruguay;~1
gain;~1
multiparous)~1
Gordon's~1
dentition,~1
Rigid~1
labors~1
(30.3%~1
12.9%,~1
(21.2%~1
7.1%,~1
oligomenorrheic~1
lie.~2
mildest~1
summits~1
H/L~1
oligomenorrhea.~1
(42.1%)~1
7500,~1
10,000/U~2
11-hour~1
5000/U~1
7500~1
10,000/U,~1
heparin-neutralizing~2
two-cell~4
N-formylmethionyl-leucylphenylalanine~1
Russo~1
amnion.~2
N-formylmethionyl-leucylphenylalanine.~1
permeation.~1
hyperemesis~5
gravidarum~3
registration,~3
836~1
vomit~2
hyperemesis.~1
binding-globulin~1
Scalp~3
cordocentesis~1
Obstetric~2
in-born~1
nonpreventable~1
midsegment~1
third-look~1
(35%),~3
microinvasive~1
capillary-like~2
clitoral~1
nonmidline~1
47.1%~1
24.8%~2
births;~1
(26.7%)~2
(33.7%)~1
(13.8%~1
23.0%,~1
Heme~1
(2.72%~1
(98.5~1
(66.1~1
partum,~1
(1.38%~1
Disparity~1
preeclamptic-eclamptic~1
coagulopathy,~2
530/1000~1
transarterial~2
Shands~2
Gainesville,~2
0.54%.~1
laboring~2
unwashed~2
recommendation).~1
immunoprophylaxis.~1
municipality~1
Amsterdam~2
Statistics.~2
underregistration~1
(14.3%).~1
Underregistration~1
bookkeeping.~1
Underreporting~1
Sepharose-treated~1
anti-beta-endorphin~1
(21.3~1
(15.5~1
(22.7~1
clostridia~2
clostridium~1
phonocardiography,~1
fell,~1
obstetrician~1
blood-sampling~1
duly~1
nonpulsating~1
velocimetry.~2
oligohydramnios,~1
dilatation)~1
lie,~1
caput.~1
hyperthecosis.~1
hyperthecosis~1
baroreceptor-mediated~1
viremia,~3
inoculation),~1
Agents~3
Fetuses~2
abruption,~1
105).~1
cells/4.0~1
ng/10(5)~1
cells/24~2
five-fold~2
ever-increasing~1
target-tissue~1
Hot~1
opiates.~3
flush.~1
oxidated~1
nonestrogens.~1
nonovarian,~1
estriol.~1
penetration;~1
nonestrogens,~1
injectable,~2
topical,~2
vasomotor,~1
goat.~1
estrogen;~1
mid-1970s~1
estrogen-progestogen~2
(49.0~1
100,000)~3
(390.6~1
100,000;~4
(245.5~1
(66.8~1
(343.5~1
(188.3~1
229.2~1
Progestogens~1
nonhepatic,~1
nonorally,~1
(comparable~1
preparations)~2
(25,~2
nonhepatic~1
tablet.~3
circumvents~2
osteoporosis-related~1
Noncompliance,~1
forgetting~2
tolerability;~1
progestogens.~1
lifetime,~3
preferential.~1
keratomycosis~1
fumigatus,~1
Fusarium,~1
Aspergillus,~1
unremarkable,~2
choroiditis,~1
planitis~1
eyes);~2
tacks~7
atrophy;~1
phlebitis;~1
corneal,~3
redetachment~1
tack~1
sclera,~2
tack,~2
choroid,~3
reproliferation~1
meridian,~1
series:~4
Analyzer's~1
purportedly~1
hypotony,~1
midvitreous~1
aphakic,~2
vitrectomized~1
20/400.~1
20/100,~1
disorganization,~1
5-month-old~2
coloboma~2
blepharoptosis.~1
brachycephaly,~1
coloboma,~1
neuroepithelium~2
close,~1
(PVI)~3
multicentric.~1
HPV-6/11,~1
HPV-18~1
tissues;~1
DNA-positive~4
cytopathology.~1
PVI.~3
HPV-6/11~1
instances;~3
HPV-16.~2
antibody-cell~1
(ACE),~1
Divalent~2
(antigen~2
disappearance)~1
reexpression~1
intravascular,~1
interstitial,~1
lethal,~3
cultivation,~1
ectoplacental~1
embryogenesis,~1
("Ewing's~1
sarcomas")~1
extraskeletal~1
plaque-bearing~1
desmoplakins~1
desmosomes.~1
IFs.~1
simple-epithelium~1
neurofilaments.~1
primitive,~1
pluripotential~1
differentiate,~1
mesenchymal,~1
blastoma,~1
cholinephosphotransferase~1
(CPT)~2
ethanolaminephosphotransferase~1
Ethanolamine~1
CPT,~1
EPT,~1
transmethylation~2
myocytolytic~3
non-necrotic~1
impregnation~3
"tethering"~1
Ler-vit/vit~1
depigmentation.~1
lightens~1
molt.~1
melanophagosomes.~1
clump~1
Koganei~1
Macroscopically,~2
iridial~1
melanin.~1
Interactions~2
powerful.~1
m/sec.~1
m/sec,~1
strike~1
100-500~1
sounded~1
Fugl-Meyer~3
Assessment.~1
non-paretic~1
conflicts,~2
anticipates~1
transferences~1
nondynamic~1
psychopathology,~1
33,384~1
69.8%~1
16.6%.~1
ECT,~3
Russian~2
roulette.~1
citizenship,~1
witnessed.~2
roulette~1
bedroom,~1
conflict,~2
wisdom,~1
revolve~1
partners'~1
externalizing~1
marriage.~1
trihexyphenidyl~1
amantadine,~1
atrocities~1
stressors,~2
disorder's~1
reexperienced~1
stressor~2
long-debated~1
paraprofessional~2
nonsuppression.~1
hypercortisolemia,~1
"modified"~2
81%).~1
First-order~1
DST.~2
psychiatry's~1
neuroscience~1
restructured~1
PGY-3~1
agoraphobia~3
(VPCs),~1
Polygraphic~1
dreaming~1
("white~1
dreams")~1
(nights~1
(night~1
narrations,~1
conflictual~1
repressed~1
Postdexamethasone~1
1982-1984,~1
molestation~3
acquaintances~1
threats~2
coercion.~1
molesters~2
dysfunctional,~1
homosexual.~3
traumatic.~1
phobia.~2
folie~2
famille~2
veteran.~1
paranoia.~1
crises,~1
membership.~2
veteran's~1
nonretarded~1
self-destruction~1
aggression.~1
atypical.~1
readmissions~1
213)~1
204)~1
reinterviewed.~1
maintain,~1
2.4-~1
non-elective~1
proxy~4
ramifications~2
restricts~2
Empirical~1
1,367~1
fathers'~2
after-effect~1
Antonio,~1
acculturation~1
Americans,~3
Epidemics~1
1976/77~1
1978/79.~1
influenza-associated~1
1972/73~1
1980/81~1
rubella.~3
(15-44~1
Financial~1
urged~5
vaccinate~1
susceptibles~1
Seattle-area~1
(cardiopulmonary~1
resuscitation)~1
1984-85.~1
short-stay~1
23,000.~1
510,000~1
screenings~1
1,012~1
1979-80~1
(NIDR)~1
year-olds~1
Non-refugee~1
Biomechanically,~1
(internal-external~1
rotation)~1
(flexion-extension)~1
games.~1
football.~1
coaches~2
remind~1
numerator-denominator~1
sport,~1
I/Type~1
Angle-specific~1
torque-velocity~1
explanation,~1
dives~3
athletics.~2
Dynamometer.~1
diagnostic/surgical~1
(DJD)~1
obligatory.~1
subscapularis,~1
supraspinatus,~1
infraspinatus/teres~2
throwing~2
Instron.~1
(ALRI).~1
antirotational~1
Hanger,~1
Canada).~1
Triathlons~1
(races~1
running)~1
triathlons~1
Triathlon~1
(USTS)~1
starters;~3
Ironman~4
Qualifier~1
(622~1
Championships~1
(4,583~1
USTS~4
(17/1,000)~1
starters~2
(61/622)~1
Ironman,~2
(794/4,583)~1
Prerace~1
postrace~1
(17/64)~1
race.(ABSTRACT~1
long-distance/marathon~1
injury-provoking~1
runners:~1
sprinters,~1
backache~3
fractured.~1
biofeedback.~1
trainers,~1
(165)~1
Tumaco~1
Cali,~1
Colombia.~2
(histological~1
scraping~2
slits~1
margins)~1
(aspiration~1
macerate,~1
macerate).~1
aspirate-culture~2
biopsy-hamster~2
Montenegro~1
Montenegro-positive~1
aspirate-hamster~1
biopsy-culture~1
57%.~2
Promastigotes~1
Senekjie's~1
Kenyan~1
Mitogens~1
(phytohemagglutinin~1
leishmania)~1
twice),~1
purification,~3
excystation~1
oocysts,~1
sporozoites.~1
Cryptosporidium.~2
Cesium~1
"fresh"~1
Seemingly~1
Panamanian~1
lemurinus).~1
tombstone~1
Disintegration~1
gambiense~2
virulence.~1
(LD50)~2
trypanosomes/ml~1
gambiense,~1
trypanosomal~1
parasitemias~1
organisms/ml~2
blood.(ABSTRACT~1
onchocerciasis~3
Simuliid~1
(May-Oct),~1
(Nov-Apr)~1
captured,~1
Farmington~1
River.~1
yahense,~1
January-April.~1
"tolerable"~1
94,~1
1,877,~1
4,900,~1
trichinella~1
inciting~1
(AHD)~1
Alaska.~1
multilocularis~4
(Em2~1
ELISA).~1
(1979),~1
histologically;~1
cestode~4
red-backed~2
voles,~1
Clethrionomys~1
rutilus.~1
impression,~1
Em2~1
AHD~1
salmincola~1
Anthelminthic~1
2-g~1
niclosamide~1
bithionol~1
counterimmunoelectrophoresis~2
East.~2
Counterimmunoelectrophoresis~1
Ponceau~1
(95.5%~1
93.2%)~1
(99.2%~1
89.9%)~1
hemagglutination.~1
counterimmunoelectrophoresis.~1
Diarrheal~1
Bangui,~1
51.6%~1
jejuni,~2
enteropathogens~1
Inner~1
Mongolia,~1
rickettsiosis.~1
Dermacentor~1
nuttalli.~1
rickettsia~1
Hemolymph~1
nuttalli~1
ultra-low~1
malathion~3
(L.)~1
Orleans,~2
Replicates~1
5.5-day~1
captures~1
oviposition~2
pesticide.~1
emergence.~1
Venereal~1
cage-mating~1
1-4,~1
transovarially-infected~1
(24%-31%)~1
F7~1
5B~1
5B,~1
filial~2
progeny.~2
TO~1
Alagoas~4
(Rhabdoviridae:~1
Vesiculovirus)~1
phlebotomine~1
(Lutzomyia~2
spp.)~1
arthropod.~1
Replication~1
laboratory-reared~1
longipalpis)~1
Bite~2
flies.~1
Cocal,~1
Maraba~1
serogroup.~2
difficult;~1
ecology.~1
excel~1
mime~1
mentors,~1
torch~1
handicraft~1
euphemistically~1
operate,"~1
caseloads,~1
faculties~2
teacher.~1
6,494~1
1,467~1
Restenting~1
misplaced.~1
restenting,~1
silon~2
chimneys~1
escharotic~1
chimney~1
Presentations~2
graft-to-enteric~1
aortography,~2
transabdominally.~1
redo~1
4,941~2
database,~1
1,823~1
scans),~2
Portland~2
explorations,~3
decide~2
Implanted~1
Long-arm~1
distance)~1
porosity~2
splicing.~1
trimetaphan/sodium~1
intra-ocular~8
antiemetics~2
droperidol,~2
prochlorperazine.~1
antiemetics;~1
prochlorperazine~1
Vomiting~1
cf.~2
Squint~1
(35%).~2
non-depolarising~2
tetrafluoroethylene~1
Falsely~2
non-stimulator~1
drawover~1
inspiration:expiration~1
corrugated~3
litres/minute~1
57,176~1
24-32%~1
Mallinckrodt~4
50;~1
Anesthetic-induced~1
hyperthermia-susceptible~4
quin2.~1
halothane-mediated~1
halothane-dependent~1
(TEDCFM)~1
TEDCFM~1
Paravalvular~1
U-50488H,~1
kappa-analgesic,~1
(halothane)~1
U-50488H~4
U-50488H-induced~1
MAC.~14
mu-receptor.~1
kappa-receptors~1
kappa-analgesics~1
venous/maternal~1
arterial/umbilical~1
0.30.~1
2,6-pipecolylxylidine~1
(PPX),~1
transplacental~5
0.02%~1
perineurally~1
intramuscularly.~1
Perineural~1
abdominoplasty.~1
antagonism;~1
atracurium--0.06,~1
mg/kg--followed~1
fade.~2
fused.~1
fontanel~3
(AFP),~1
Ladd~1
ketamine.~4
open-sutured~1
1:800,000,~1
1:800,000.~1
UA,~1
UV,~1
(MV)~1
MV~1
concentration-low~1
1:800,000~1
conflicting.~1
1:300,000~2
bupivacaine:~1
fatal/anesthetic~2
(FAR)~1
numerator~1
FAR)~1
"anesthetic"~1
(denominator)~1
FAR.~2
FAR~5
FAR,~1
subparalyzing~1
d-tubocurarine.~1
lucid~1
Disorders~3
(DSM-III)~1
epigastrograph~1
four-electrode~1
detector)~1
epigastrium.~1
(T0.5)~1
promethazine,~1
T0.5~1
triorthotolyl~1
(TOTP),~1
acrylates~2
TOTP~2
TOTP.~1
(0.008-0.8~1
metocurine~3
(0.015-0.85~1
LDH.~2
TOTP-pretreated~1
TOTP).~1
Metocurine~2
ester-type~1
Acrylates~1
intramuscularly,~2
nociception,~2
(DRL~1
lidocaine-exposed~1
reinforcements~1
shock-titration~1
inter-group~1
(bupivacaine~1
0.5%/20~1
0.5%/15~1
(tetracaine~1
-19.4~1
14.8%)~1
(T5-6)~1
(T7-8).~1
Polyethylene~1
neurodysfunction~1
sheathed-nerve~1
(3-40%)~1
Liley~3
PEG.(ABSTRACT~1
balloon-occluded~1
(109~1
(39.6~1
(194~1
components-the~1
(PAOP),~1
Bedside~2
PAOP.~1
effort-related~1
solution).~1
pressure-end~1
redistributed~4
(SPVR)~1
(LVEF:~1
(SPVR:~1
mmHg/ml,~1
2.(ABSTRACT~1
adrenocorticosteroid~1
benzodiazepine,~1
methohexital.~2
etomidate/fentanyl~1
midazolam/fentanyl~1
methohexital/fentanyl~1
Midazolam~3
(Te)~1
ketamine,~2
Te~2
(tau)~2
(V/V)~1
Te/tau,~1
(Vrs)~1
(FRC-Vrs)~1
V/V~2
FRC-Vrs.~2
0.73-2.29~1
Te/tau~4
0.24-0.65~1
FRC-Vrs~4
115-392~1
1-71~1
845.0e-1.28(Te/tau)~1
1-1~2
dermatome,~1
TEA.(ABSTRACT~1
fentanyl-pentobarbital-oxygen.~1
mm2.~2
4.57~1
(dTC)~2
(2.0%)~2
pieces.~1
oxygen-anesthetic~1
Supernatant~1
fluorometry.~1
boiled.~1
13.9%~2
d-tubocurarine-induced~1
SNO~1
Dangers~1
anesthesiologist.~1
inevitable,~2
Processes~1
Wherever~1
customizing~1
loosen~1
couplings,~1
homeostatic~4
(awake~1
anesthesia);~1
buffers~1
(titration~1
effect);~1
pre-treatments~1
(pre-oxygenation,~1
etc.).~1
promoted.~1
problem.(ABSTRACT~1
monoxide.~2
oximeters.~1
IL-282~1
Co-oximeter~1
(O2Hb)~1
(COHb)~3
COHb,~2
(SpO2)~1
O2Hb~2
COHb~11
0-75%~1
oximeters~1
SpO2~1
O2Hb,~1
O2Hb.~1
Ca45~2
Mabuchi~1
Sreter~1
frozen-biopsy~1
halothane/caffeine~1
(AOD)~1
AOD~2
noncorrectable~1
refusal.~1
tid,~1
(Fontaine's~1
T/C-C/S~1
(T/C~1
C/S~1
delta(C/S)-delta(T/C)~1
Paraclinical~1
(SI)~2
(Student~1
+58%~1
T/C),~1
C/S),~1
digit-to-brachial~1
(DBI),~1
Instant~1
DBI~2
thirteen-year-old~1
Viremia,~1
"Moya~1
Moya"~1
unilaterality~2
Cushingoid~1
(cataracts~1
.025),~2
(compression~1
osteopenia,~2
HEPP~2
(IgE~1
pentapeptide)~1
Cryptogenic~1
septae~1
crepitations~1
(urticaria~1
angioedema)~1
allergic.~1
pseudo-allergic~1
(PSAR).~1
anti-H1~1
placebos,~1
PSAR~1
ketotifen~4
anti-histamine~1
azelastine~7
(experimental~2
Azelastine~1
challenge),~1
synthesis/release~1
etc~1
bronchospastic~3
incur~1
indiscriminately~1
buffer-challenged~1
corticosteroid-induced~1
(AIB).~1
Aspirin-intolerant~1
39.4%).~1
euglobulin~3
AIB.~1
recalcification~1
ASA-tolerant~1
allergists'~1
anitratus,~1
cloacae,~1
beta-Streptococcus~1
hemolyticus.~1
immunoglobulin-bearing~2
Tac+~2
thymic-dependent~1
thymic-independent~1
Thymostimulin~2
TP-1)~1
IgA-bearing~1
IgM-bearing~2
IgG-,~1
IgA-,~1
thymostimulin~1
(ROSC)~1
priming,~1
scenario).~1
ROSC.~1
ROSC~2
ROSC,~2
ROSC)~1
.037),~1
CPR)~1
.025).(ABSTRACT~1
field-to-hospital~1
scenario~1
four-minute~1
(BLS).~1
34-minute~1
(ROSC).~1
heparinization;~1
CPR-BLS~2
CPR-ALS~3
weaning),~2
viability.(ABSTRACT~1
veno-arterial~1
(NDS)~1
Prearrest~1
NDS~2
CPB.(ABSTRACT~1
cervicothoracic~4
(C7-T1);~1
Barrow's~1
spine-injured~2
Films~2
C6-C7~1
C7-T1~1
Ocean~1
diversity.~1
non-fermentative~2
trimethoprim/sulfamethoxazole,~1
orotracheally~1
nasotracheally.~1
intubate,~1
(SAI)~1
(BNI).~1
intubate~4
SAI~5
BNI~4
three)~3
epistaxis,~1
counterpressure~2
legislated~1
vehicles.~1
alternate-day~1
104;~1
PASG,~1
claims,~2
suites~1
fluoroscopy).~1
high-use~1
suites.~1
praised~1
ACLS/ATLS~1
anonymous,~1
post-course~1
ACLS;~1
ATLS.~1
(AED)~1
AED~1
AEDs~1
fairness~1
liked~1
chaplain~1
chaplains~1
grieving~2
witnessing~1
wish.~1
necks.~1
biostatistics,~1
review--40~1
Medicus~1
Citation~1
research-related~1
Division,~1
post-testing~1
trioxide.~1
dimercaprol~1
arsenic.~1
Hemodialysis,~1
fluphenazine~3
decanoate-induced~1
IM.~1
lability.~1
Inpatient~2
lung-to-body~2
(NPSH)~1
NPSH,~2
CAT,~2
room-air~1
GPx,~1
NPSH~1
oxygen-exposed~1
65%)~2
1981-83,~1
5,469~1
(NTM)~1
NTM~3
fortuitum,~1
scrofulaceum,~1
chelonae.~1
(1.3/10(5)),~1
fortuitum-M.~1
chelonae~1
(0.2/10(5)).~1
clindamycin-phagocyte~1
mini-osmotic~1
thetaiotaomicron~1
(clindamycin-resistant)~1
clindamycin-treated~3
(sensitive,~1
organisms)~1
theta.(ABSTRACT~1
(FMLP)-activated~1
luminol-enhanced~3
(occurring~2
(PMNL)~1
PMNL,~1
oxidants.~2
Smokers'~1
PMNL-activated~1
PMNL-derived~1
FMLP-activated~1
mucilloid,~1
laxative.~1
Workers~1
times/yr,~1
125),~1
118),~1
plantain~1
psyllium.~1
antibodies;~1
bronchoconstrictive~1
reaction.(ABSTRACT~1
Basophils~1
anaphylactoid~5
radiocontrast~2
1,050~1
mOsm/kg,~1
mOsm/kg.~1
(PGE2,~1
IBMX,~1
db~1
cAMP).~2
contribution.~1
(RMF)~1
(MIP),~1
(MEP),~1
(MSVC).~1
RMF.~1
formulas,~1
(87.6~1
hyperinflation.~1
MIP,~1
MEP,~1
MSVC.(ABSTRACT~1
combinations:~1
placebo-placebo,~1
placebo-salbutamol,~1
placebo-theophylline,~1
salbutamol-theophylline.~1
0.19.~1
(RR),~1
(190~1
0.8),~2
BPM;~1
(9.0~1
H2O;~4
Crs/FRC~1
(0.049~1
1/cm~1
constant-load~3
(LT),~2
LT.~3
(6-3)]~1
(term-3)],~1
sub-LT~1
work-rate~1
asymptotes.~1
(6-3)~1
VO2(term-3)~1
LT,~1
92.5~1
right-shifted~1
(P50,~1
mumol/g).~1
(VA/Q)~3
VA/Q~10
QT,~3
alveolar-endcapillary~1
values),~1
(HPV),~1
spiders.~1
(NH3)~1
Challenges~3
dose-dependently,~1
1.6%.~1
NH3,~1
remained.~3
i.a.)~1
D-Trp7,9)~1
capsaicin-sensitive~1
arc,~1
Chloroform:methanol~1
(2:1)~1
LH-20~2
6,000-dalton~7
sequencing,~2
kDa.~1
hydrophobic,~1
35,000-dalton~1
surfactant-associated~1
35,000-~1
pneumocytes).~1
185,000~1
170,000~2
coprecipitated~2
Cyanogen~1
(CNBr)~2
PC,~3
1(IV)~1
2(IV).~1
non-disulfide-bonded,~1
19,000,~2
standards;~1
26,000,~1
standards).~1
coeluted~3
CM-cellulose.~1
apoprotein.~1
macro-molecules~1
pneumocyte-derived~1
Ozone~2
diethylene~1
triamine~1
pentacetic~1
(99mTc-DTPA)~1
double-blinded~2
66.8~1
99mTc-DTPA~3
0.43%/min~1
Iatroepidemics~1
constructive~2
sanitoria~1
Translating~1
forefront~1
alveolarization,~1
dexamethasone/kg~2
Starved~2
rations~2
lavageable~1
(Sa),~1
(DmO2)~1
Sa~1
(Sc),~1
DmO2.~1
Sa,~1
Sc,~2
DmO2~1
S.(ABSTRACT~1
140-day~1
non-breathing~1
24-h-ventilated~1
Etiology~1
crepitus~3
clothesline~1
Subcommittee~1
Trauma.~1
tibial-fibular~2
985~2
71-month~2
cases--two~1
amputated.~2
stabilization;~1
doomed~1
(PATI).~1
definitively,~1
resection-ileocolic~1
Exteriorized~2
PATI~1
PATI).~1
Jacksonville,~1
fistula;~2
(8),~3
(22),~2
handgun~1
rifle~3
stabbed.~1
noncontributory~1
(MSBOS)~1
MSBOS~3
specifies,~1
crossmatched~2
crossmatches~1
$6000.~1
anesthesiologists.~2
4350~1
grams;~1
grams.~1
primarily;~1
("spontaneous")~1
("spontaneous").~1
ventilators.~1
paracentesis.~2
"negative"~1
(PVG)~1
(NEC),~1
PVG~6
(13%,~1
PVG.~4
(62%~1
0.184),~1
knit~1
cytopathologists.~1
73.7~1
parasacral~3
transsphincteric-translevatoric~1
fascias~1
translevatoric-transsphincteric~1
Luzern,~1
Switzerland,~1
urethrorectal~1
Winslow~1
(HFW).~1
HFW~4
hepatoduodenal~2
curled~1
stooped~1
epiploic~1
Organs~1
(63%);~1
(30%);~1
1966,~1
two-thirds.~1
lady~1
exteriorizing~1
Martell~1
imposed,~1
deteriorates,~1
reexteriorization~1
linkages.~1
Algorithms~1
stick~3
figure.~1
piano~1
automobile.~1
"upward"~1
"downward"~1
thereof.~1
avulsed.~1
stripping.~1
artery-based~1
oblique-iliac~1
temporals,~1
meningeals,~1
inches~2
retinopathy).~1
(width,~1
texture,~2
(depth,~1
intraclinoid~1
tuberculum~1
sellae)~1
blocks,~2
skulls,~1
(carotid~1
nerves)~1
(1963-1983)~1
extremis;~1
extremis~1
ideally,~1
extraabdominal~1
desmoids~1
incarcerated~2
obstruction;~4
ulcerations;~1
ulcerations.~3
(diagnosis~2
hospitalization)~1
(spleen,~1
extremities).~1
transabdominally~2
(TIAs),~1
aspirin's~1
ASA/DIP~4
908~1
DIP~1
ASA/DIP.~1
ASA/DIP,~1
combating~2
unequaled~1
postendarterectomy~1
perspectively~1
(Kehr)~1
choledochostomy~2
digitalization.~1
variations.~3
digitalization,~1
choledochostomy.~1
FNABs~1
342~2
89.5~1
suppuration.~1
MTC,~2
Jehovah's~1
Witnesses,~1
assurances~1
religious~12
respected,~1
orients~1
diverts~1
2842~1
time--(5~1
deviation)--(4~1
risk;~3
fraction:~1
+7~3
severer~1
Doxorubicin~1
predictions,~2
(viral~1
pyrogen~1
reaction)~1
hospitalize~1
0.55).~1
9.4)~1
previously;~2
Notably,~3
mortal~1
Policies~1
ethics~8
committee.~1
Depo-Provera~1
(depot~1
[DMPA])~1
why,~1
U.K.~1
Inquiry~2
destination~1
"discreet~1
housekeeper,"~1
secretions,~5
homocarnosine,~1
Phosphoethanolamine~1
innominata.~2
Hydrocephalus,~1
good:~1
(St14),~1
(Xq27-28),~1
13.766~1
very-long-chain~3
electrophysiological,~2
b,~1
meningitic~1
flinch-jump~1
b-treated~1
epileptogenic~4
inferomesial~1
conflicted~3
stereotaxically~1
Extracranial~1
Rett's~3
purposeful~2
(hand-washing)~1
regular,~1
voluntary/behavioral~1
abducting~2
innervation:~1
postsaccadic~1
INO.~1
4-hydroxyphenylglycol~1
5-HIAA,~1
Morganella~1
morganii,~1
Providencia~3
rettgeri,~1
alcalifaciens,~2
Cefoxitin-resistant~1
monoanionic~1
zwitterionic~1
(cephaloridine),~1
(cephalosporin~1
(Proteus~3
mirabilis)~1
porins~2
Porin~1
mirabilis),~1
vulgaris),~1
(Providencia~1
rettgeri),~1
(M.~1
morganii),~1
porins.~1
Ion~4
trailing~1
ion-pairing~2
(46:54),~1
K2HPO4,~1
hexadecyltrimethylammonium~1
Moxalactam~1
silica-packed~1
precolumn~1
long)~2
0.999)~1
0.990).~1
intrarun~1
interrun~1
21.4%.~1
moxalactam~3
cefazolin,~1
cephapirin,~1
cephalexin),~1
cefazolin.~1
sums~3
squares.~1
1,000-~1
(33.7~1
1,000-mg~2
86.1~1
red-man~1
interval.(ABSTRACT~1
ereA,~1
ereB,~1
ermAM~6
ereA~2
ereB~4
esterases~1
macrolides~1
rRNA~5
methylase~1
macrolide,~1
lincosamide,~1
streptogramin~1
coresistant~1
methylase.~2
codissemination~1
Enterobacteriaceae.~1
beta-Lactam~1
N-(3-dimethylamino-propyl)benzylpenicillinamide~1
(ABP),~1
(Ci)~1
(Ce),~1
Ci/Ce~1
isopycnic~2
Duve~1
(C.~1
Duve,~1
Barsy,~1
Poole,~1
Trovet,~1
Tulkens,~1
Hoof,~1
Biochem.~1
Pharmacol.~1
23:2495-2531,~1
1974),~1
prodrugs~1
Intercalation~2
mol%~1
drug/lipid~1
deoxycholate-solubilized~1
(LD50~1
sterol-containing~2
cerevisiae~1
inocula,~1
penicillin-gentamicin~1
ciprofloxacin-gentamicin~1
enterococci,~1
ciprofloxacin-procaine~1
orphanage~1
pathogens;~1
orphanage-acquired~1
284,635),~1
cefaclor~2
taken;~1
cefaclor,~3
flora,~4
spp.;~1
decreases,~1
logs~1
counts;~1
Wilkins-Chalgren~1
ampicillin-chloramphenicol~1
ceftetrame~1
(Ro~2
19-5247)~1
cefetamet~2
15-8074),~1
990~1
cephalexin.~1
cephalexin~5
Flavobacterium~1
meningosepticum.~1
Ceftetrame~1
aureus;~1
Livedo~1
rosacea~2
split-face~1
paired-comparison~1
36.7,~1
48.5,~1
(hematology,~1
chemistry,~2
urinalysis).~1
rosacea.~1
Membrane-associated~2
(Fitzpatrick~1
VI)~1
piebaldism,~1
albinism,~1
leukoderma~1
individuals'~2
(HL)~3
(HTLV-III).~1
"hairy"~1
hairs),~1
acanthosis.~1
malpighii,~1
koilocytes~1
Little,~1
HL.~1
HL,~1
immunochemical,~1
Scleredema~1
IgG-lambda~1
paraproteinemia,~1
scleredema,~2
hyperlipoproteinemia.~1
adultorum.~1
EKH4~1
50-kd~1
Dylon~1
T;~1
(NKH1~1
(C3);~1
10-nm~1
dermoepidermal~1
desired.~3
Tissue-expansion~1
antihistaminic,~1
anticholinergic,~1
(beta-1-3~1
polyglucose)~1
keratoderma~2
blennorrhagica~1
keratoderma.~2
fungus,~1
plaque-phase~1
open-labeled~1
(KID)~1
Skinner~1
ours~1
ichthyosis.~1
reticulated~1
peribuccal~1
grooves,~1
heavy-grain~1
leatherlike~1
Etretinate~1
anti-intercellular~2
middermal~1
tuberculoid~1
1969-1972~1
1978-1982~1
analytically~2
38-75~1
decreases)--25/30,~1
angina--23/30,~1
response--18/30.~1
(carboxyhemoglobin~1
[COHb]~1
0.05%)~1
ppm-COHb-average~1
(air~6
sec),~3
702~2
nonsignificantly~1
53.9%,~1
55.2%).~1
57.4%,~1
57.1%).~1
.049.~1
trails,~1
dexterity~1
pegboard,~1
sharpened-Romberg,~2
writing,~2
pegboard~1
trails.~2
story.~1
non-Virginia~1
harvesters~1
"green~2
symptoms."~1
cotinine~7
symptoms,"~1
leaf-sap~1
(78.5%).~1
Cotton~1
nondurable~1
comfortable.~1
perterbation~1
hypothalamopituitary~1
cells/cc,~1
(alcohol,~1
intercourse,~2
donation)~1
Environment~1
high-cancer-risk~1
epidemiology.~1
blue-collar~3
typographers~1
lithographers~1
enterprises,~1
birth-cohorts,~1
wastes,~1
disposed~4
improperly,~1
automotive~1
ground,~2
sewer,~1
landfill.~1
Annually~1
quarts.~1
Improper~2
(41.5%)~1
Paint~1
dumped~1
sewer~2
landfills~1
Reading~2
Prong~2
granite~1
(1950-1979)~1
granites.~1
Fraction~7
granite,~1
fringe~1
(BPbL)~1
controllers~4
Alexandria~3
intersections.~1
delta-aminolevulinic~1
dehydratase~1
BPbL.~1
BPbL~1
68.28~1
13.22~1
30.00~1
beta-Aminoisobutyric~1
(beta-AIB),~1
thymine,~1
beta-AIB.~1
beta-AIB~2
marmosets,~1
Callithrix~1
jacchus,~1
lead.~2
fibromatosis,~2
"aggressive~1
fibromatosis,"~1
myofibromatosis,~1
keloid,~1
protuberans,~1
tumefactions~1
Oncogenic~1
fibromatoses~1
regresses.~1
resectability.~1
Location~1
abdomino-pelvic~3
(35),~2
(8).~1
(96.2%~1
75.5%,~1
0.0034)~1
three-dimensional,~2
(95.6%~1
73.3%,~1
0.125).~1
re-resection~1
fungating~1
tumor).~2
3000-11,000~1
efforts)~1
abdominosacral~3
S1-2~1
S2-3~1
S4-5~1
(12%);~1
(23.8%).~1
74%.~1
Drug-free~1
deinnervation~2
augmentations,~1
deinnervated.~1
(221~1
reconstructions),~1
mound~1
Symmetry~1
(272~1
278)~1
Kopans~1
ninety-nine~2
mastopathy~3
1971-1986,~1
extrapancreatic,~1
1979-1986,~1
Transhiatal~2
(30-day~1
43-76~1
4500-6000~1
rads.~3
esophagogastrostomy.~1
esophagogastrostomy,~1
RV-left~1
septal-RV~1
(adenosine,~2
ml/min/gm;~2
high-preload~1
arteriotomy.~1
2.5-4.3~1
(tripartite)~1
(absent~2
portion)~1
portions)~1
subclavian-pulmonary~1
neonates.(ABSTRACT~1
sutureless~1
survival).~2
(CVA).~1
CVA,~1
reestablishes~1
obliterates~1
friable~1
1.97~5
gm/dl.~1
(TVR)~1
TVR,~1
TVR).~1
1,076~1
patient-year).~1
(AVR,~6
1%);~1
0.6%);~1
3%);~1
99.4%~1
(AVR~1
100%);~1
anti-coagulant-related~1
2%);~1
patient-year.(ABSTRACT~1
(BCP)~1
(CCP)~1
ligated;~1
clamped,~2
BCP~3
CCP~3
Silicon~1
Avalanche~1
Detector.~1
BCP.~1
plunge~1
Plunge~1
fundoplication.~3
esophagomyotomy~1
son~1
outlook~3
(TGA).~1
Jatene's~1
milestone~1
(RVH)~1
RVH~2
disadvantaged.~1
Late-onset~1
alpha-hydroxyprogesterone~2
(10.4%)~1
393~2
Iodine~5
protirelin~1
131.~2
toxicosis~1
iodine-containing~1
episodes;~2
captopril,~1
dictum~1
drug-refractory~5
manifestations:~1
Neurophysiologic~1
Neurotoxic~1
connections)~1
mitis~3
five),~5
(dRTA)~1
dRTA~2
back-leak~1
dRTA;~1
dRTA.~1
hyporeninemic~1
hypoaldosteronism~1
hypoaldosteronism.~1
sediment,~1
chronicity,~1
(lung,~1
Sicca~1
trihydrate~1
("patient-quarters").~1
10(3)/mm3~3
10(9)/L),~1
8.0%),~1
(1.58~2
unimpaired.~1
flurazepam~1
1797~1
-0.34~1
-0.40.~1
lower-weight~1
155)~1
milligram-per-kilogram~2
declines,~1
overmedication.~1
low-weight~1
floxacillin~1
floxacillin.~1
Floxacillin~1
urinary-free~1
venal~1
1.5-cm~1
corticotropin.~1
corticotropin-producing~3
Pick's~1
(AD),~2
(nLC),~1
AD-1,~1
nLC~2
AD-2,~1
AD-2~2
AD-1~1
0.25-mg~2
Behaviorally,~1
euphoria,~2
2225~1
subtype).~1
bipolar)~1
relative.~2
Multifactorial~2
brother-sister~2
correlations),~1
transmissibility~1
co-occur~1
(3798~1
pairs),~1
955~1
Depression:~1
Louis.~1
3423~2
schizoaffective-bipolar~2
151),~1
76),~1
330).~1
career,~3
intending~1
specialize~1
10,516~1
designating~1
preferences,~1
classmates~1
27.8%),~1
20.7%).~1
publication,~2
research-oriented~1
alcohol-dependence~1
Interval~2
(LIFE)~1
Instruction~1
booklet,~1
sheet,~1
LIFE~1
psychopathologic,~1
("psychiatric~1
ratings")~1
symptom-based~1
LIFE,~1
accommodated.~1
kappa-statistic,~1
Opinion~1
"Adjustment~1
Disorder"~1
ill"~1
(NI),~1
NI~2
biosocial~1
seeking,~1
avoidance,~1
novelty,~1
punishment,~1
reward.~1
tridimensional~1
low)~1
reconciles~2
description.~2
maladaptive~2
schizotypal~6
Francisco;~1
nonexperts.~1
Automated~4
Analyzer~2
4000/mm3~1
10(6)/mm3~1
10(12)/L);~1
"left~1
shift"~1
myelofibrosis~3
glomerulus,~1
Fever,~2
Early,~1
hyperplastic.~1
hemophagocytosis.~2
Terminally,~1
dyserythropoiesis.~2
cytometer~2
technologists.~3
midaxillary,~1
livers;~1
Density~2
0.5-~1
(0.005~1
1.25%).~1
1.051~1
1.017~1
1.077~1
g/mL).~1
micrograms/g).~2
(wedge~1
(Y-B)~1
Hamazaki-Wesenberg~1
"budding"~1
"screening"~1
(Grocott~1
methenamine~1
acid-Schiff),~1
Y-B~2
fungi.~1
51-labeled~1
nonlysis~1
H6000~2
(Tarrytown,~1
scattergram~1
Homozygous~1
In-house~1
breadth~1
budgets.~1
Bobath~1
early-severe~1
late-mild~1
nine-month~2
recheck~1
Ease~1
thermograms~1
0.5C~1
pained~2
Thermograms~1
ten-member~1
(efficiency,~1
elbow);~1
toe);~1
disarticulations.~1
40.53,~1
df).~1
Wrist~2
prognosticating~1
overwork~1
(BWF)~1
(year~1
BWF~2
self-intermittent~1
(SIC)~1
(IND)~1
knees;~1
hamstring/quadriceps~2
(IK)~1
isometric).~1
66.8%~1
61.7%.~1
(37.4~1
(28.7~1
IK~1
hamstrings;~1
EMG.~2
tendoachilles~2
bursitis~1
bursitis,~2
tendons,~2
customized~1
inserts,~1
Jewett~1
degrees/yr~1
degrees/yr.~1
Heterotopic~2
paraplegia,~5
ossification,~2
hyperinflated~1
hyperexpanded~1
calculates~1
(Ps)~2
3394~1
(8.3%)~2
Ps~5
pancreaticoduodenectomy.~1
99m-tagged~1
stew~2
pancreaticoduodenectomy,~2
"fixed"~1
incurable.~1
sacropelvic~1
exenterations~1
(adenocarcinoma,~1
primary;~1
resection).~1
Gy).~3
recurrence),~2
metastasis).~1
Astler-Coller~1
extrapelvic~1
recurrence).~1
12+~1
53+~1
1966.~1
fundoplication;~2
approximation;~1
"gas~1
bloat"~1
abdomen)~1
fundoplications,~1
faster,~1
Pancreatitis~5
1256~1
scrutinized~1
choledocholithiasis,~4
choledochoscopy,~3
choledochoduodenostomy,~2
sphincteroplasty.~2
(8.4%).~2
sphincteroplasty,~1
970~1
embolectomies,~1
bedridden,~2
ambulatory.~2
immediately;~1
laryngotracheoscopy,~1
explorations.~2
849~1
(14.5%)~1
(9.7%)~1
(16.1%)~2
subxiphoid~2
tamponade;~2
window.~3
(two)~3
Payne~1
Scott~1
bypasses)~1
postbypass~4
34%;~2
0.8%.~1
excisions.~3
pharyngoesophagus;~1
postcrioid~1
"pull-up"~1
pancreaticopleural~1
pseudocysts.~1
aneurysm;~3
thoracostomy.~2
difficile-positive~1
antimotility~1
(LPJ)~1
LPJ.~1
LPJ~1
sympathectomies~1
causalgic~2
Postsympathectomy~1
(97%~2
677~1
(thyroid-stimulating~2
hormone)~3
permanently.~1
lumpectomy~2
192.~2
axillary-node~1
involvement)~1
SD]).~1
(undrained)~1
(drained).~1
phytochemagglutinin-induced~1
laparotomies;~1
observed)~1
phytochemagglutinin~1
label.~1
(ELND)~1
ELND~3
ELND.~1
55.7%~1
48.9%,~1
Thickness~1
basing~1
(FAA)~1
intimectomy~2
Endarterectomized~1
endartectomized~1
60.7%,~1
70.1%,~1
79.7%,~1
(94.3%).~1
FAA~2
(0.91%~1
tactic~1
(BDL),~1
BDL~3
BDL,~1
(ICHs)~1
lobar,~1
putaminal,~1
thalamic,~1
pontine,~1
intraventricular,~1
pallidum,~1
(76.4%)~1
(21),~2
arteriograms.~1
ICHs~1
compilation~1
diary;~1
Spielberger~2
Replicate~1
decoppering~1
viewpoint,~2
Holland,~1
education-matched~1
perceptual-motor~1
Attentional~1
uncompromised.~2
(17.5%),~1
innervations~2
childbirth.~2
"primary~1
dementia"~1
astrocytosis~1
temporal)~1
(motor~1
neglect)~1
dextral~1
(LH)-damaged~1
aphasics~2
dysarthrics,~1
(RH)-damaged~1
nonaphasic~1
dysarthric~1
nonaphasic,~1
RH-damaged~1
(ISM)~1
ISM~3
noncompressive~1
ISM,~3
Oncologic~1
supervenes.~1
Intramedullary~1
solitary;~1
whole-cord~1
acetylcholine-receptor-antibody~1
(A-AChR)-negative~1
AChR.~2
A-AChR-negative~4
(A-Ret)~1
A-Ret~3
myasthenia.~1
epiphenomenon.~1
(szs)~1
(BTs).~1
electrode)~1
sharp-wave~1
discharges,~1
sz,~1
szs,~1
double,~3
discriminative,~1
szs~1
(VB~1
TIA)~1
VB~3
Nocardial~1
Nocardia~2
asteroides~1
stereotaxic~1
Xenon-enhanced~1
insidiously~1
Sylvius~2
tectum~2
mammillary~3
MRI-identified~1
biochemically.~1
(interferon~1
exacerbating-remitting~1
blinding.~1
diseases)~1
mathematic~1
(Tourtellotte's~1
Tibbling~2
coworkers,~2
Schuller~3
Sagar's~2
formula)~1
Sagar~1
coworkers~3
Tourtellotte's~1
neuroimmunologic~1
antibody-specific~1
(HTLV-I)-associated~1
(HAM)~1
Upper-limb~1
N9-N20~1
lower-limb~1
N20-P40~1
HAM~1
bioenergetics~1
Phosphoglycerate~1
mutase-deficient~1
evidence:~1
Postexercise~3
Tasks~1
right-hemisphere~2
right-hemispheric~1
extrapersonal~1
minority.~1
Genuine~1
Amnestic~1
left-handedness,~2
dyslexics~2
nondyslexics~1
dyslexia,~1
mixed-~2
left-handedness~1
overreporting~1
arguing~1
Geschwind's~1
testosterone-mediated~1
dyslexia.~1
prepiriform~1
(PPC)~1
early-~1
PPC,~1
relay~1
Language~1
Porch~1
Communicative~1
Ability.~1
(HTLV-I),~1
(ATLL)--or~1
retrovirus--has~1
Martinique,~1
Jamaica,~2
Tobago,~1
Seychelles,~1
Zaire.~1
ATLL.~1
ATLL~1
endemicity~2
HTLV-I~2
(areas~1
endemicity)~1
lentiviruses--visna~1
particular--may~1
neurotropic.~1
Tropical~1
MS-like~1
rhombencephalitis~4
monocytogenes.~1
listerioses,~1
aprosodia~1
prosody~2
gesturing~1
Wernicke-type~1
functional-anatomic~1
propositional~2
myelinolysis.~1
antiphospholipid~3
eyes;~1
23.4~3
nonglaucomatous~2
(glaucoma~1
trabeculectomy).~1
pseudophakos.~1
hyaloid.~1
vitreolysis~1
Inversion~2
(gravity~1
(preinversion)~1
biosynthesis)~1
double-masked,~1
two-period,~1
seven-hour~1
metyrapone.~1
24).~4
lights~2
blue-sensitive~1
panuveitis~1
vitritis,~1
scleritis~4
scleritis.~1
Inventory)~1
scales-both~1
pathologic.~1
passive-aggressive,~1
hypomanic.~1
Callender~1
type-the~1
(Epi/HPF)~1
(ISDNA)-were~1
Epi/HPF~3
ISDNA.~3
Larger,~1
Worse~1
Cox'~1
melanoma-related~1
ISDNA~1
nonperfusion,~1
nonperfusion~3
jet-black,~1
"leiomyoepithelioma~1
epithelium."~1
yellow-white~1
lipidic~1
evagination,~1
fluorescein-labeled~4
different-sized~1
leaked~2
tell~1
larger-molecular~1
keratoplasty~1
reimplant~2
keratoplasty.~2
endocapsular~3
capsulectomy~1
zonule.~1
capsulectomy.~1
(DHFR)~2
MTX)~1
slow-acting~1
DHFR~5
amplification.~2
Phytohemagglutinin-stimulated~1
pathways;~2
(IBM)~1
IBM~6
retinoids~5
(synthetic~1
retinoids,~1
all-trans-retinoic~1
13-cis-RA,~1
retinoid,~1
RO-10-9359,~1
all-trans-RA~1
13-cis-RA~1
RNAs,~1
RO-10-9359~1
intra-erythrocyte~1
arylesterase~1
HSA.~1
acid:HSA~1
hydrolyzed.~1
SA,~4
5-amino~1
4-amino~1
137%,~1
deacetylation.~1
anti-platelet~1
Centrifuged~1
sediments~3
apple-green~1
birefringence.~1
(PX)~2
cannulation;~1
catheter;~2
PX,~1
shunt-site~1
PX~1
access-related~1
PX.~1
migrans~2
Tumoral~1
normocalcemia,~1
formes~1
frustes~1
TC,~1
capsulitis,~1
nationality,~1
C5-normal~1
B10.D2/new~1
C5-deficient~1
B10.D2/old~1
(Chediak-Higashi~1
thoroughly.~2
(18.4%),~1
(34.5),~1
(6.8).~1
prone-anti-Trendelenburg~1
Carre).~1
(17.8%)~1
(7.8)~1
(56.6~1
Antigen-negative~1
(Hu-IFN-alpha~1
Hu-IFN-alpha~2
(44.5%)~1
(66.4%)~1
option.~3
(SCV)~1
electrically,~1
SCV~3
Thumper.~1
(prematurely~1
discharged).~1
91.9~1
97%).~1
discharge:~1
.017);~1
.0004);~1
.0003);~1
.0017).~1
winter-heating~1
(18.9%)~2
14.0%.~1
heaters~2
kitchen~3
stoves~5
cohabitants~5
3.2%),~1
(13.3%)~1
.0045).~1
(85.7%),~1
uvula~2
uvular~2
airway-related~1
manipulation;~1
non-traumatic~2
myelitis,~1
polyneuritis.~1
laryngotracheobronchitis.~1
tracheitis,~1
reemerged~1
(ASB)~1
pliable,~3
small-to~1
moderate-sized~1
ASB.~1
ASB~1
unexplored~1
ambivalence,~1
himself.~1
tips.~2
Supramid~3
pocket,~1
(PEPSI)~1
Bossae~1
floor-of-mouth~1
workhorse~1
bulky,~2
non-hair~1
wired~1
browpexy;~1
paresis;~1
abound.~1
protracted,~1
fruitless~1
videofluoroscopy,~1
oblique,~1
longitudinal,~1
transverse.~1
hemotympanum~1
(2.67%);~1
(1.33%);~1
(1.33%).~1
epistaxis.~2
HHT~1
(III,~1
withdrew.~1
Desu.~1
septorhinoplasty~4
devitalized~3
tooth.~2
incisor,~1
premaxilla,~1
septorhinoplasty.~1
nonfatty,~1
symblepharon.~1
maximizes~1
"take,"~1
relining~1
contractures,~3
Audiologic~1
Electronystagmography~1
(Selvester),~1
ray.~2
post-infarction~3
post-infarct~1
result),~1
doubt.~2
fissuring.~1
stenosis;~1
220/pressure~2
28(9)%~1
(8)%~1
(0.19)~1
(0.12)~1
stenosis.(ABSTRACT~1
Follow~2
cloth~1
valvectomy,~1
Inspection~2
commissure.~2
(case~2
echographic~3
leaflets;~1
systole;~1
supra-annular~1
narrowing.(ABSTRACT~1
arteriosus).~1
(4-16~1
100,000/mm3)~1
7000/mm3~1
cusp,~1
(pheochromocytoma)~1
aorto-cardiac~1
Ligation~2
thiocyanate,~1
nitroprusside-induced~1
0.21-0.70~1
50-160~1
thiosulphate~1
10.6-38.5~1
0.11-0.85~1
59-197~1
antidote.~2
premedications~1
i.m.:~1
paracetamol~3
Trait~2
proneness.~1
Paracetamol~1
apprehensive~1
(BrP)~1
(LOS-GP).~1
BrP~1
BrP,~1
(483~1
(1.94~2
(trough)~1
Disposition~1
triexponential~1
135.5~1
Vss~3
149.7~1
(MRT),~1
1095~2
(ClP),~1
159.9~1
(Vss)~2
207.1~2
beta).~1
(pneumonectomy,~1
One-lung~1
(OLV),~1
two-lung~1
re-established,~1
OLV.~1
OLV~1
fasciculations~5
(0.83~1
litre-1)~4
118551~2
alpha-stimulation~1
solution:~1
propionic~1
7.4).~1
nucleophile~1
(nucleophilic~1
reaction),~1
(Michael~1
addition)~1
Org~2
6368,~1
6368~1
Cross-contamination~1
air-oxygen~1
mixtures.~3
(EDX).~1
EDX~1
prickle~1
intra-epidermal~1
NH4OH.~1
naevi,~2
perilesional,~1
Anthralin~1
Harpenden~1
6-48~1
thicker.~1
sudanophilic~1
remained,~1
urticaria)~1
eruption)~1
anaesthetic.~1
(FDE)~1
(1-10%)~1
petrolatum,~1
FDE~6
sulphonamide,~1
chlormezanone,~1
barbiturate,~1
sulphamethoxazole~1
phenazone,~2
aminophenazone~2
propyphenazone~1
propyphenazone.~1
FDE.~1
FDE,~1
female),~1
harlequin~1
foetus,~1
(AIDS)-related~1
folliculitis~2
prodromes.~1
pilomatrixoma~2
anti-smoking~2
educative~1
atenolol;~1
trace.~1
(Tampere,~1
Finland)~1
register.~1
denominators~1
catchment~2
age-distribution~1
(884)~1
abruption~6
pre-eclampsia,~2
smaller-for-gestation~1
liveborn~2
post-episiotomy~1
episiotomies.~1
'slack'~1
urogram,~1
uroflowmetry,~2
microtransducer~1
multipara~1
66,974~1
Dublin~1
1980-1982.~1
Wednesdays~2
Saturdays.~1
Sundays.~2
intra-uterine~2
Tuesdays~1
Saturdays~2
Wednesdays.~1
Monday~1
Fridays~1
Fridays.~1
primiparae~1
multiparae~1
0.023,~1
7.31~1
41,090~1
Nulliparity,~1
hydramnios,~1
post-term~1
Manchester~2
Breech~1
longer;~3
commended~1
(PID).~1
Salpingitis~1
PID.~3
vaginosis~1
Non-chlamydial~1
PID~1
pre-chemotherapy~1
positive);~1
Marker~2
(CIN~1
PAS~2
Gonadal~3
POMB/ACE~2
(cisplatin,~1
[Oncovin],~1
bleomycin/actinomycin~1
etoposide)~1
(9-38)~1
41/2~2
non-glaucomatous,~1
'chain'~1
lasing~5
(19,~1
application;~1
applications),~1
non-progressive~1
polydimethylsiloxane~1
Trifluorsiloxane~1
neovascularisation~1
limbus.~2
polydimethylsiloxane.~1
colobomatous~1
peripapillary~10
naevus,~1
sensitised~1
subconjunctivally.~1
histiocytoma,~1
desmoplastic~3
lids)~2
frontalis~3
props~1
lubricants,~1
lids).~1
ophthalmia~4
neonatorum~2
(9.1/year),~1
uni-~1
bilaterality,~1
established:~1
negative/normal~1
gonococci~1
chlamydiae.~1
goniophotography~1
Optiflex~1
3-38~1
75.9%~1
push.~1
Iris~1
tuck~1
angles.~3
(sleeving~1
burial~1
25.5%~1
looped~2
burial,~1
burial.~1
lids.~2
Ophthalmology,~2
Paris,~1
children--32~1
Tanzanian~1
medicines,~1
neonatorum.~1
postenucleation~1
20-year-woman~1
thinned.~1
Pseudocyst~1
ectasia.~5
(67Ga)~1
18/23~1
13/16~1
67Ga~6
parotids~3
alveolitis.~2
lid.~1
76-month~1
trachoma.~1
Malawi~1
graders.~2
commotio~1
retinae.~1
described).~1
prism~5
dioptres~5
esotropia.~3
esotropia,~1
exotropic.~1
bimedial~2
83.5%.~1
Judgment~1
adduction.~1
uveitis.~1
toxocara~1
larva~2
amnionic~3
diapedesis~3
(5HT),~1
phalloidin~1
(ECs)~2
reduces,~1
ECs~6
5HT~4
agents'~1
Evan's~1
blue-labeled~1
(IFN)~2
alpha-IFN~2
p80,~1
(r-Hu-IFN-alpha~1
[35S]methionine-labeled~1
p80~2
cytochemically.~1
alpha-naphthyl~1
leukapheresed~1
(pl)~1
solubility:~1
5.7-6.3~2
bands)~1
6.6-7.6~1
bands).~1
Isozymes~1
Sepharose-concanavalin~1
(Con-A)~1
solubilization,~1
phenylmethylsulfonyl~1
(PMSF),~1
B-esterases~1
3.1.1~1
well-studied~1
168%~1
residues),~1
adsorb,~1
coverslip-transfer~1
migrate,~1
proliferate,~1
fibroblastoid~2
(GM)~1
anti-fibronectin~1
coverslips~3
Petri~1
cell-binding~2
(CFU-G/M)~1
molecule;~1
(U-1957,~1
U-1958,~1
U-1996)~1
EBV-carrying~1
(U-1957~1
U-1958)~1
(U-1996)~1
plasmablasts-plasma~1
U-1958~1
PCA-1~3
OKT-10~3
IgG/10(6)~1
U-1957~1
LB-1~2
secreted.~2
U-1996,~1
producer,~1
plasmablast~1
14q+~1
Pluronic~7
F-68~1
(Green~1
Cross,~1
Osaka,~2
Japan)~2
5-vol/vol%~1
5-micron-diameter~1
dyne/cm2.~1
extensional~1
gravity-sedimented~1
lubricating~1
WCB6F1-Sl/Sld~5
cells/mm2~1
(NKCF)~1
51Cr-release~3
40:1~1
80:1~1
polyinosinic-polycytidilic~1
(IFN)-alpha,~1
(IL~2
Leu-11+~1
cell-in-agarose~1
(TBCs),~1
"large~1
lymphocytes."~1
TBCs~1
NKCF~2
NKCF,~1
(GPIIIa)~1
Glanzmann~3
GPIIIa~1
90,000~3
81,000,~1
64,000.~1
Iraqi-Jewish~3
Arab~2
absent;~1
47,000~1
(MCA)JTC-4,~1
(APC).~1
antiprotein~1
C-IgG~1
MCAJTC-5,~1
APC.~1
MCAJTC-1,~1
domain-related~1
MCAJTC-1-recognized~1
140,000/microL)~1
(PRP).~1
ethylenediaminetetraacetate,~1
iodoacetate,~1
PRP~1
immunoprecipitate~1
restriction-fragment~1
(126~2
Orissa.~1
-++-),~1
haplotype).~1
(+-----[+/-];~1
--++-++).~1
beta-chain.~2
elliptocytes.~1
(beta'-chain)~1
kilodaltons,~1
ankyrin.~1
beta'-chain~1
antispectrin~1
tetramerization~1
self-association~3
tetramer~1
beta'-chain.~1
74,000-dalton~2
80,000-dalton~2
vesiculate~1
citrate-phosphate-dextrose-adenine~2
Vesiculation~1
thiol-disulfide~1
.92)~1
spectrin-free~1
DA-1~6
interleukin-3~1
(IL-3,~1
multicolony-stimulating~1
[multi-CSF])~1
(GM-CSF)~1
erythroid-specific~1
(Epo).~1
Epo,~1
Epo.~1
Epo~19
Epo-stimulated~1
multi-CSF.~1
GM-CSF,~1
(RA+)~1
(RA-)~1
RA+~1
large-joint~1
(HLA-B27~1
carpal-tunnel~3
commonest.~1
2-microglobulin~1
(EBNA-2)~1
consanguineous~2
anti-EBNA-2~1
(LSH),~1
(PSH)~1
LSH~1
PSH.~1
PSH~1
thiol,~1
thiol~7
Rheumatologists~1
sizeable~2
Prescribing~1
Formulary~1
Sheet~1
Compendium.~1
(RTA).~1
RTA~1
bicipital~2
atrial).~1
relaxation-time~1
non-calcific~1
pancreatitic~1
characterisation~1
Hexabrix~2
(May~1
Baker)~1
toxaemia~1
ultrasound-guided~3
Eight-six~1
899~3
indications:~1
(Surecut).~1
undistended~1
0.022),~1
(65.5%)~1
"slight"~1
"marked"~1
asymmetry.~1
vesico-vaginal~1
ovoids~2
greatest,~1
portals~2
Displacements~2
malrotation~2
(MRS)~1
localising~1
MRS.~1
Phosphorus-31~1
cm-3~2
phosphocreatine/ATP~1
phosphate/ATP~2
0.9.~1
gamma-ATP~1
diaphanography,~1
(3HTdR)~1
xenografts~8
efficiencies.~1
disaggregated.~1
radiation-response~1
3HTdR~2
(NCI-H69,~1
COR-L51)~1
(COR-L24,~1
COR-L31).~1
Altering~1
radioresponsiveness~1
Growth-curve~1
COR-L24~2
NCI-H69,~1
cerebrospinal-fluid~2
volume-flow~1
(C2).~1
plotted,~1
R-wave.~1
4.13~2
s-1.~2
dehydrate~1
Antidiuretic~1
practised~1
contrast-agent~1
dwarfed~1
superfluous.~1
pelves~2
sterile.~2
ureteritis~1
Mammograms~1
11-17)~1
32-75)~1
DY~4
perilobular~1
period)~2
Cohort,~1
(MZ),~1
(DZ]~1
(control).~2
breast-cancer~1
similarity,~2
discordance,~1
Interdepartmental~1
intradepartmental~1
pyelographic~1
Selectron~2
neurovesical~1
Stamey~1
Neurophysiological~1
gripping,~1
(SRL)~1
disconcerting~1
Potency~1
TURP.~1
urethrotomy.~4
post-operatively~3
Intracavernosal~1
diabetic)~1
(Achromycin,~1
Lederle)~1
satisfactorily,~1
re-treatment~1
haematocele.~1
Relapses~2
orchiectomy,~1
micro-aerophilic~1
swabs.~1
cystoscopies~1
non-autogenous~2
fashioning~1
(GORE-TEX)~1
non-reversed~1
arterio-enteric~1
Axillofemoral~2
peroperatively~2
(t~3
Pre-operative~2
Hypoperfusion~1
suboptimally~1
vein)~2
technetium.~1
ml)-1~1
surviving.~1
Delays~1
118)~2
N-methyl-N'-nitro-N-nitrosoguanidine~1
shams,~2
shams~1
shams;~1
(66.4~1
(96.7~1
(96.6~1
FNAB.~1
99.4~2
directs~3
haematocrit,~1
bedrest~2
'autohaemodilution'.~1
'autohaemodilution'~1
kinesis~1
Extravasation~1
ranula.~2
mylohyoid~1
1910,~1
marsupialization,~2
intra-oral~3
multicentre~2
appendicectomy.~1
Libya,~1
tubercular~1
absence.~2
Ramadan.~1
oligaemia~2
(bled)~1
bled).~2
([3H]thymidine),~1
([3H]leucine).~1
Bled~1
([3H]proline)~1
hepatectomies),~1
Leucocyte~1
centile.~1
nmol/10(9)~3
229.5~1
71.9%,~1
81.8%).~1
unemployment,~1
committees~8
unemployment.~2
enclosed.~1
(255/331),~1
(127/255)~1
something--33.3%~1
(3/9)~1
(101/158)~1
boards,~1
(23/88)~1
doing.~1
Britain's~1
self-paced~2
forefinger~2
performances,~1
hyperkinesias~1
anomic~1
word-finding~3
confrontation~1
Howard~1
Orchard-Lisle,~1
1984),~1
phonological~2
sought-after~1
word,~1
'tip-of-the-tongue'~1
word-finding.~1
retrieving~1
anomia.~1
semantically-based~1
phonologically-based~1
anomias.~1
facioscapulohumeral~3
telangiectasis,~3
microaneurysm~2
FSH.~1
'sporadic'~1
preventable,~2
presyncopal~1
existence.~3
reexamines~1
leucodystrophy.~1
(axon~1
diameter/fibre~1
diameter).~2
extraspinal~1
plexus)~1
watchmakers'~1
(numbers~2
brackets~1
misplaced):~1
cryoinjuries.~1
Explanations~2
misrouting~1
'musculotopic'~1
tetraplegia.~2
tetraplegics~2
Head-up~1
tetraplegics.~3
Tetraplegics~1
Neurohypophyseal~1
pmol/l,~1
prohormone/carrier~1
neurophysin~1
desamino-8-D-arginine~1
pmol/h)~1
pmol/h).~1
(IMA)~1
postonset.~1
apraxic~1
IMA.~1
(Token~1
Matrices~1
Apraxia~1
scores)~1
IMA~2
faring~1
better);~1
(EAD)~1
339~5
0.6%:~1
EAD~2
atherosclerosis).~1
Sweating~2
cheeks~1
heating,~1
Emotional~4
neuron)~1
sudomotor~1
Gustatory~3
blushing~1
Severely~2
(MOF)~1
MOF.~2
76.9~1
MOF~3
non-MOF~1
Septicaemia~1
'shock'~1
endotoxaemia~1
pooled.~1
286.94~1
51.35~1
30-95~1
(TBSA),~1
(112.56-185.85~1
(44.03-298.0~1
non-survivors,~1
TBSA,~1
digging~1
4094~1
84.9~1
43.3~2
flame,~3
36.3~1
electrical,~3
scalding,~2
58.0~1
silver-nitrate-incorporated~1
3477~1
outpatients:~1
82.9~1
liquids,~2
chemical,~3
fern-shaped~1
'so-called'~1
fractals.~1
'fractal~1
burns'~1
strike.~1
silver-incorporated~1
manageability,~1
discourage~1
re-epithelization,~1
nitrate-incorporated~1
Monday,~1
Area,~1
LPG~2
(Liquid~1
Petroleum~1
Gas)~1
Juan~2
Ixhuatepec,~1
Pemex~1
Company,~1
tanks~4
m3~2
m3)~1
propane~1
butane.~1
Ixhuatepec~1
40,000,~2
hills~1
village.~3
one-story~1
pillars~1
bricks~1
roofs~1
north-east~1
ground-placed~1
5:40~1
seismograph~1
05~1
BLEVE~1
(Boiling~1
Expanding~1
Vapour~1
Explosion)~1
tanks.~2
Richter~1
Unburned~1
everything.~1
exploded~1
tons,~1
(SHL)~1
Edmonton.~1
SHL~3
hemoperitoneum.~2
six),~2
hypovolemia~1
Venoms~1
Hymenoptera~1
stings;~1
venom.~3
sting.~2
vespid~2
venom(s)~1
skin-testing~1
angiopathy,~1
(63.4%)~1
(53.9%).~1
(33.9%);~1
(20.1%)~2
ten;~1
postcosyntropin.~1
symptoms/signs~1
insidious;~1
subfertility,~1
Extragonadal~1
complexion~1
thermometry~2
capacitive~6
deep-seated~3
equipments~1
Yamamoto~1
Vinyter~1
Company~1
(Osaka,~1
Japan).~1
thermocouples~2
angiocatheters~1
microthermocouples.~1
Thermometry~1
Temperature~2
heating.~1
8-MHz~1
13.56-MHz~1
regression),~3
PRa~2
(80%-100%~1
PRb~2
(50%-80%~1
NR~3
TDF~1
Time-dose~1
(TDF)~1
thermoradiotherapy.~1
Douglas~2
acylureido-penicillin,~1
azlocillin~2
granulocytopenic~2
chemotherapy-treated~1
chemotherapy-induced~1
granulocytes/ml)~1
cephalothin~2
preantibiotic~1
granulocyte/ml~1
499~2
Tobramycin~3
(obstructive~1
uropathy).~1
antibiotic-related~1
"intermediate"~2
program;~4
peptichemio,~1
peptichemio~1
restarted~1
IIb,~1
evaluate,~1
radiation:~1
silhouette,~1
pericardectomy.~1
(HNPCC).~1
genetic/pathologic~1
HNPCC~1
macrophagia,~1
sialo~1
sulfomucin,~1
microfluorometric~1
diploid-near~3
euploid~1
diploid,~2
semimalignant~1
Ploidy~1
originally,~1
plasmacytoma.~1
rosettes,~1
background).~1
Gremilus~1
(immunoperoxidase~1
esthesioneuroblastoma.~1
onset;~1
denying~2
1/6)~1
obstructions,~3
iliopudendal~1
Compression~5
Subselective~1
countershocked,~1
Postresuscitation~1
Antianginal~1
(sidewinder)~1
maneuvered~1
angiographers~1
(Chandler~1
port),~1
Malfunction~1
malfunctioned.~1
PTCAs.~2
(restenosis)~1
includes:~1
documentation,~1
dirth~1
procedural),~1
pharmacologic.~2
trans-stenotic~1
eccentric,~1
calcified.~3
balloon/vessel~1
graft)~1
(uncomplicated)~1
"intimal~1
dissection."~1
angioplasty)~1
addressed,~2
restenosis;~1
angioplasty.(ABSTRACT~2
proximal"~3
(CABG)~1
88.3%~1
75-99)~1
0-60)~1
47.2~2
20-80)~1
0-20).~1
90.9%~2
(18.2%)~2
post-PTCA.~1
(TR).~1
100-150~1
probe;~1
TR.~1
(HFV),~1
(QLLL),~1
pseudomonas~1
[(A-a)DO2]~1
(Qs/Qt),~1
QLLL~2
SB.~1
haemodynamics,~2
(A-a)DO2,~1
Succinylcholine~2
24-year-old,~1
(ECT).~1
atracurium-edrophonium~1
succinylcholine.~3
isorhythmic~1
ischaemia.~2
arthrogryposis~1
(AMC)~1
pyelolithotomy~1
sedatives~3
haemopericardium.~1
22,925~1
infants).~1
72.8~1
82.6~1
3,585~1
(URIs).~1
(1.64~2
100);~1
URI~2
(5.31~1
URIs.~1
"leak"~3
"croup~1
epidemic"~1
extubations;~1
accidental.~1
extubations~1
reintubation~1
reintubation.~1
"Leak"~1
extubation.~2
(tmax),~1
(Tlag),~1
(t1/2el),~1
Cmax,~2
Tlag,~1
t1/2el,~1
4.15~2
838~1
"honeycomb~1
lung."~1
set-point~1
vascularly~4
cut.~2
nerves;~2
C-fibers.~1
([Ca2+]cyt)~1
quin2~1
chlorotetracycline~1
(CTC).~1
calcium-CTC~2
(0.40~2
accident;~1
([Ca2+]dt)~1
[Ca2+]cyt.~1
[Ca2+]cyt~2
[Ca2+]dt~2
collagen-activated~1
Channel~1
"resting~1
state."~1
aggregation-inducing~1
(NIF)~1
(NTG)~1
[M])~1
NIF:SHR~1
NTG:SHR~1
7.35~1
7.26~1
Aortas~1
NIF~4
blockage,~1
Chemically~1
5.91~2
6.20~1
NR,~2
5.62~1
6.07~1
(10-minute)~1
PBN~6
(N-tert-butyl-alpha-phenylnitrone),~1
Studied~1
5-1,000~1
microM/L,~1
microM/L~1
Investigating~1
microM/L)~1
time-reperfusion~1
vulnerability).~1
PBN.(ABSTRACT~1
neglecting~1
microphotometric~1
V3.~1
10-11~1
dropping.~1
periureteric~1
hilum.~1
downstream,~1
9,11-epithio-11,12-methano-thromboxane~1
(STA2)~1
STA2~6
thromboxane(Tx)-antagonist,~1
(9,11),~1
(11,12)-dideoxa-9~1
alpha-dimethylmethano-11,12-methano-13,14-dihydro-13-aza-14-oxo-15~1
cyclopenthyl-16,17,18,19,20-pethanol-15-epi-TxA2~1
(ONO-3708),~1
STA2-induced~2
STA2-vasoconstriction~1
pCa-tension~1
12-o-tetradecanoyl~1
1,2-diolein,~1
agonist(receptor)-dependent~1
caffeine-sensitive~1
crossbridge~2
"latch".~1
vapor-phase~2
beams~2
ArF~1
XeF~1
8-40~1
mJ/pulse.~2
air-tissue~1
ethylene,~1
propyne,~1
allene,~1
propylene,~1
propane,~1
butene.~1
351-nm~1
torching~1
PBZ-pretreated~1
Ca2+-channel~1
(MLC)-phosphorylation~1
MLC~4
35-40%~1
Unloaded~1
Lo/sec)~1
second),~1
dephosphorylation~1
(Hill~1
equation).~2
hyperbolae~1
20-25%~4
Postextrasystolic~2
(46.9%).~1
20.7%~2
ruptures,~2
re-exploration,~1
rhinomanometric~1
Aalborg~1
re-examined.~1
packing.~1
resorption;~1
deformities;~1
betahistine~7
Electronystagmographic~1
time-intervals~1
ENG-controlled~1
65.3%~1
Rhinoplasty~1
numbness.~1
Jakobsson~1
(S-phase)~1
mastoid.~1
superstructure,~1
otoscopy.~1
myringotomy~1
effusion(s)~1
(RT3)~1
(IPD).~1
RT3~6
TBG~2
(OGTT),~1
T3/T4~2
RT3/T4~1
RT3;~1
paramesangial~1
precipitins.~1
Transmigration~1
transmigration~1
formation)~2
abortions-of~1
origin-seem~1
summarize:~1
amniotomy~1
cm/h~1
Efficient~1
quantitated.~3
mU/m,~1
incrementation~1
40-minute~1
period.(ABSTRACT~1
single-exposure~2
overexposes~1
leaded~1
wedges,~1
(collimator),~1
fast-speed~1
Guided~1
film/screen~1
prechymopapain~1
discectomy.~1
(ON)~1
ON~2
spherocylindric~1
Luck.~1
(minimum,~1
Merle~1
d'Aubigne~1
hypercortisonism.~1
trochlea~2
spica~6
immobilizes~1
90-90~1
pin--the~1
pontoon~3
spica--allows~1
$13,334.~1
rotationally~1
unconstrained~1
cruciate-sacrificing~1
Rotational~3
tensioned.~1
tensioned~1
tight,~1
fatigability~1
exponential.~1
elongational~1
TKAs~3
antithromboembolic~1
radiolucency,~1
(1.5%)~2
TKA,~1
tilting.~2
(TKAs)~1
McIntosh,~1
Marmor,~1
Attenborough,~1
Guepar,~1
tricompartmental~1
roentgenographically.~1
McIntosh~1
Attenborough~1
Guepar~2
(DSFH),~1
varus,~1
DSFH,~1
pinning.~1
Baumann's~2
pinning,~1
DSFH.~1
internation~1
bicondylar~1
TEAs.~1
Custom-designed~1
polyethylene-bearing~1
yolk-type~1
well-fixed~1
TEA.~1
prefabricated~2
braces.~2
worker's~2
selective;~1
hamstrings.~1
Nociceptors~1
hamstrings~8
quadriceps.~1
considerable,~1
orthopedist's~1
suture-line~1
5-fluorocytosine,~1
6903~1
(21/105~1
catheters).~1
11/105~1
0.16/100~1
10/105~1
0.14/100~1
insertions.~1
chondroosseous~1
energy),~1
anlage.~2
ossific~1
nonload-bearing~1
ossified.~1
obturated~1
14-20~1
(BSA).~1
(bBMP)~1
poly(lactic)~1
poly(glycollic)~1
high-viscosity~3
sequences:~1
chondrogenesis,~1
BMP-induced~1
50-ms~2
500-ms~2
Impulsive~1
gentamicin-loaded~2
paris~1
Staphylococcal~1
culture-proven~1
paris,~1
"ulceration"~1
cartilage-cartilage~1
Sharpey's~1
energy-absorbing~1
bone-ligament-bone~1
reducible~2
radiostrontium~1
(SrC)~1
(tetracycline~1
Drilling,~1
stripping,~2
SrC~4
Strontium~1
pounds),~1
(equals~1
tetracycline-labeled~1
surfaces)~2
bone/min,~1
bone/min.~1
drilling.~1
nontubular~5
aldolase~2
(tubular~1
bone)~4
(nontubular~1
achondroplasia.~3
rheumatologist,~1
Medication,~1
parts,~1
Spasticity~2
motoneuron.~1
Paresis,~1
fatigability,~1
etc.,~1
Ablative~1
(53.5%).~1
Yoga~1
paschimottansana~1
ushtrasana~1
craniocerebral~3
impedes~1
(81%),~2
welfare~2
Hemophilic~1
hemarthroses.~1
physiotherapy,~1
Slo-bid~3
Gyrocaps~1
Theo-dur~3
Sprinkle~3
Gyrocaps,~2
pre-dose~2
aganglionosis~1
dating~4
(TSE)~1
TSE~3
TSE.~1
TSE,~1
(60.6%)~1
90.3%~1
25.8%~1
Malabsorptive~1
hyperoxaluria,~1
hyperoxaluria.~1
hyperoxaluria~1
Imperforate~1
aperture,~1
congenitally,~1
"acquired"~1
imperforate~3
Intra-abdominal~1
distension,~1
enveloping~2
falciform~1
(PNH)~2
PNH~8
(HUS).~1
PNH,~1
HUS.~1
L/kg-hr~2
2.31~3
2.47~1
oxipurinol,~1
calorie)~1
protein/day)~1
protein/day).~1
oxipurinol~3
51.1~1
45.7~3
oxipurinol.~1
carteolol,~1
metipranolol,~1
(I25).~1
I25~1
metipranolol~2
carteolol~2
eyedrops.~1
Lorazepam,~1
green,~1
(9.97,~1
(11.5,~1
t.i.d.~2
(repeated-measures~1
(ADM)~1
ADM~6
mg/m2/24~1
Tricyclic~1
fewer.~1
increase;~1
expected).~3
consequence.~1
glands:~1
carbacholine;~1
pilocarpine;~1
'paradoxical'~1
metacine~1
chlorosyle;~1
Secretions~1
saliva.~1
(ISA)~1
ISA)~2
pindolol.~3
HDL2/HDL3~1
ISA.~1
anastomic~2
(correlated~1
n.m.r.~3
Well-resolved~1
3-D-hydroxybutyrate,~1
Resonances~1
meningitis;~1
Intense~2
N-0),~1
N-2),~1
N-4)~1
N-8)~1
N-0,~4
N-2~4
N-4~4
N-8~4
uninephrectomy.~2
N-4.~1
Hypoproteinaemia~1
hypoalbuminaemia~1
N-0~1
(TTKG)~1
TTKG~2
Hyperkalaemia~1
'aldosterone-like'~1
hyperkalaemia~1
mineralocorticoids.~1
1900-7000~1
dyspnoeic~1
LTD4.(ABSTRACT~1
125I-crude~1
(Frazer's~1
FF-III)~1
125I-concanavalin~1
125I-FF-III~3
saccharides.~1
FF-III~1
alpha-methyl-D-mannoside,~1
lectin-mediated~2
gliadin~6
2-bromoethylamine~1
(BEA)~1
BEA-treated~1
(2.87~1
(39.9~3
BEA~1
renomedullary~2
homoeostasis,~1
sympatho-adrenergic~1
homoeostasis~1
goitrogen~1
Methimazole~1
'chronic~1
bronchitis'~1
Fucose~1
plasma-type~1
transudate.~1
fucose~4
(microgram/30~1
collection)~2
'bronchitic'~2
9;~2
1082~1
385;~1
520;~1
bronchitic~2
blown~1
laryngo-tracheal~1
fucose,~1
gradedly~1
two-three~1
477.4~1
57.2~2
774.2~1
961.6~1
(cuff~1
measurement)~1
96.0~1
aiding~1
campaign.~1
bowel-associated~1
CA125,~1
alpha-fetoproteins,~1
comfortably.(ABSTRACT~1
Well-differentiated~1
Anaplastic~1
Stomadhesive~1
Gantrez~1
(N-butylmonoester~1
polymethyl~1
vinyl~3
Stomadhesive.~1
(10.5%).~1
(5.0%~1
Sofia~1
Erfurt).~1
schoolgirls~1
costume~1
jewelry~1
(31.8%),~1
watches~1
(23.3%),~1
buckles~1
jeans~1
buttons.~1
(36/51~1
9/176~1
sex-indifferent~1
adornment.~1
(TEWL).~1
TEWL.~1
photocontact~1
ambrette.~1
Photopatch~1
Department,~1
cobalt-sensitive~1
housewives.~1
78.6%~1
cobalt.~2
(tc-PO2)~1
tc-PO2~1
Tc-PO2~2
1+,~3
2+,~1
"edge~1
effect",~1
water-ethanol~1
(Finn~1
Chamber;~1
Test;~1
Chamber).~1
"ring-shaped"~1
chrysanthemum,~2
chrysanthemum~2
co-existence~1
Transepidermal~1
Eczematous~1
scaling,~1
nickel-positive~2
-negative~1
Cobalt~1
Chromate~1
PPDA~1
Erythematous~1
tars,~1
glycol,~2
tars~1
overpresented~1
Diazolidinyl~2
(Germall~2
preservative~3
preservative,~1
maximization~1
imidazolidinyl~1
115)~1
diazolidinyl-urea-sensitized~2
Rechallenge~1
diazolidinyl~1
weeds~1
trees.~1
Anthemis~1
cotula~1
(dog~1
fennel)~1
Xanthium~1
strumarium~1
(cocklebur)~1
Ambrosia~1
artemisiifolia~1
(ragweed)~1
weed.~1
single-bind~1
population:~2
between-test~1
nebulizers~3
inhalers.~1
Transthoracic~3
(TNAB)~1
TNAB,~1
cytopathologist,~1
98.6~2
TNAB.~1
thoracocentesis~5
thoracocentesis.~5
categorizations~1
upgraded~2
Anxiety,~1
tap,~1
Whole-lung~1
episodes/night)~2
Allographic~1
Therapy-related~2
dismantling~1
opted~1
interpose~1
Gore-tex~1
ml/minute.~1
285~6
re-explorations~1
antihistaminic~3
azelastine,~1
ketotifen,~1
Ketotifen~1
(S3)~1
statistic,~1
0.40-0.50)~1
0.10-0.30)~1
intervals:~1
(31.5~2
rCBF.~1
simultaneous,~2
Doershuk~1
Shwachman-Kulczycki~1
Birmingham~1
1.6-2.9~1
4.5-6.0~1
Coefficient~1
Coil-spring~1
hepatogenic~1
angiodysplasia~1
("pulmonary~1
spiders")~1
rheumatica~4
loud,~1
harsh~1
precordium.~1
pedicellated~1
bronchoscopies.~1
France~1
Polynesia~1
Paris~11
(68,179~1
university's~1
affirmative~2
"Have~1
asthma?"~1
general/family~1
two-peaked~1
Denmark,~3
8,806~1
Study),~1
(AW)~1
tonsillectomy/adenoidectomy,~1
pain/vomiting~1
psycho-immunologic~1
brain-controlled~1
adopting~1
prosperity.~1
quasi-isotonic.~2
hyporesponsiveness,~1
Implicit~1
West,~1
blacks;~1
(IUAT)~1
worded)~1
Uruguay,~1
Chile.~1
Brazil.~1
Pre-coded~1
Pan~1
Organization.~1
(allergic~1
dermatitis).~1
environmental.~1
(samples~1
0300,~1
night-to-morning~1
dawn~1
profiles),~1
(51-100~2
(0300~1
profiles)~1
Somogyi~1
free-insulin~2
(18-25~1
(WIB)~1
Jamaicans~3
Jamaica.~1
WIB~4
WIBs~4
Jamaicans.~2
Effort~1
angina)~1
(45%);~1
obese).~1
duration.(ABSTRACT~2
modernization~4
5222~1
Random~3
higher-income~1
(2.9%;~1
41.2%~1
.004,~1
.045,~1
Yekatit~1
Ababa,~1
3453~1
305-bed~1
Ethiopian~1
Ethiopia's~1
Basement~1
creatinines,~1
(3346~1
262)~1
(2660~1
177).~1
uricemia,~1
metabolism;~1
kalemia~1
spans,~1
HbA1c~2
diabetologists~4
excellent).~1
diabetologists.~1
diabetologist~1
diabetologists'~1
variable.(ABSTRACT~1
profiling~1
digoxin-like~2
(DLIS)~2
DLIS.~2
DLIS,~1
DLIS~5
nonjustifiable~2
Eliminating~1
25-34~1
mg/kg/h~1
61-190~1
train-induced~1
(STIB)~1
STIB~3
underpinnings~2
stimulus-triggered~2
STIB.~1
Concentration-response~2
bursting,~2
acid-mediated~1
circuits,~2
collicular~5
amygdala,~2
wet-dog~2
shake~1
"naive"~1
AM.~6
19-day-old~1
correlatively~1
postlesion.~1
"epilepsy"~1
"epileptic~1
seizures"~1
"epilepsies"~1
Epilepsies~1
Syndromes.~1
commonality.~1
door-to-door~1
Igbo-Ora,~1
20,000.~2
1963.~1
nondoctor~1
neurosurgeons,~1
cases/1,000)~1
13.0,~1
epilepsy:~1
hemoglobinopathy,~1
(CBZ),~1
CBZ~11
10,11~1
(CBZ-E)~1
CBZ-E~1
CBZ-E/CBZ~1
polypharmacy~1
postdose.~1
magazine~2
Spanish,~1
English,~1
announcement~1
repetitively,~1
comic~1
legends,~1
"communication"~1
"lower~1
evoking~2
(non-insulin-dependent)~1
Nonenzymatic~1
colorimetry~1
streptolysin~1
ASO~1
hemagglutinin-inhibiting~2
nonenzymatically~1
glycosylated,~1
"Introduction~1
Medicine,"~1
interviewing,~1
gaps,~1
84.4%,~1
Teachers~1
supervising~2
surplus,~1
(AAFP)~1
membership,~1
AAFP~1
states:~2
Iowa,~2
Wisconsin.~2
profits~1
chapters~3
assistantship~1
Heartsounds,~1
mentally.~1
evaluator~5
evaluators~5
simulations.~3
predysplastic~1
ahd~1
G2/tetraploid~1
(aneuploidy)~1
uphill~1
Na1+-dependent~1
rightside-out~1
electroneutral.~1
Gramicidin~1
transstimulation~1
Na+-phosphate~1
metenkephalin~4
Hoe~1
postdeglutitive~1
component)~1
flow-dependent~3
opossums.~1
Loperamide~2
distention-induced~1
neuron).~1
mimicks~1
recto-anal~1
99m-macroaggregated~1
29.0%,~2
P450.~1
C19-steroids~1
alpha-hydroxylation~2
14%-38%~1
(P(450)16~1
P450-mediated~2
hydroxylases,~1
P450-independent~1
beta-oxidoreductase,~1
alpha-hydroxylation,~1
catalyze~1
hepatectomized~2
1/3-hepatectomized,~2
2/3-hepatectomized~3
flow-pressure~1
plotting.~1
1/3-~1
increases:~1
2/3-hepatectomized,~1
transfusion)~1
wt-1)~1
hemorrhaged~5
hemorrhaged-transfused~1
portal-hypertensive~1
hepatonecrosis~1
Placebo-controlled~1
t.i.d.)~1
14-week~1
(frequency~1
severity)~1
(51Cr~1
(third~2
trimester)~2
orad~1
force-generating~1
heat-denatured~1
(disease~1
(7.0~3
ppm).~2
(58.8%)~1
(43.7%).~1
(Zollinger-Ellison~1
hypergastrinemia.~2
CU/kg~1
secretin.~1
pentagastrin-fast~1
achlorhydria-related~1
hypergastrinemic~1
1200-mg~1
pH-metry~1
pH-metry,~1
(92.9%)~1
"pathological."~1
listening~7
+1.14~1
+1.5~1
stress-free~1
monooctanoin.~2
ethanol/ether~1
monooctanoin~6
2-mercaptoethanol~4
solubilize~1
0.558).~1
(16.7%~1
(230~1
methods).~1
L/H~1
body-water~1
Diabetes-related~1
history-taking,~1
debilitated,~1
sores.~1
amputation;~1
71%)~1
79%).~1
sporting,~1
unemployed.~2
disablement~1
pension.~1
controls).(ABSTRACT~1
Utilising~1
1960-79.~1
1-1-80,~1
225.2~1
'definite'~1
'probable',~1
Pancolitis~1
Proctitis~1
'severe'~1
'moderate'~1
'transient'~1
over-representation~1
distorts~1
Osteoporosis,~2
(30.6%).~1
amenorrhoeic~1
multifactorial;~1
non-malignant,~1
closeness~1
hypnotherapy,~1
hypnotherapy.~1
psychopathology.~2
hypnotherapy~1
deconjugation~4
pteroyl-L-glutamyl-gamma-L-glutamyl-gamma-L-glutamic~2
oestradiol-17~1
alpha-DHT),~1
dehydroepiandrosterone-sulphate,~1
oestriol-3-glucuronide~1
(E3-3G)~1
oestrogens,~1
E3-3G~1
E2/E3~2
aglycones~1
diarrhoea,~2
0.18;~1
0.05-30.75~1
0.09;~1
0.01-0.19~1
mumol/l,~3
(0.10;~1
0.01-6.83~1
0.01-0.39~1
(cholic~1
ph-metry,~1
(1800~3
(2200~2
interquartile~1
(1.4-1.7)~1
(2.05-3.2)~1
(2.5-3.85)~1
1.5)~1
'cases~1
histories'~1
(independently)~1
disquieting~2
(IOIBD)~1
beta-endorphinlike~5
clonidine-induced~1
Na+,K+-adenosine~1
ouabainlike~1
anteroventral~1
(AV3V)~1
Cryoblockade~1
AV3V~2
cryoblockade~2
cardioregulatory~1
axonally~2
4346~1
952~1
Hg/ml/min,~1
3575~1
Buffering~1
(16%);~1
(-22%).~1
carcass,~1
Liver,~2
Rh~5
pairings~1
sharing,~1
hypertensive-normotensive~1
normotensive-normotensive~1
groups--stepped~1
care--or~1
(inversely)~1
(again,~1
level),~3
pmol/kg/min,~1
uptake-inhibiting~1
8.4%;~1
63.3~2
4.4%;~1
57.1~1
corticosteroid-sensitive~1
1002~1
1006~2
sodium/potassium~1
calcium/magnesium~1
negatively.~2
within-population~1
gm/L~1
30.0~7
UF.~1
Ultrafiltration~1
collodian~1
spheres,~3
aim,~1
plexiglass~2
stagnation~1
channelling~2
stagnation.~1
Cascade~1
paraproteinemic~1
dead-end~1
(QD~1
CF),~1
albumin-rich,~1
globulin-poor~1
Postprocedure~1
cryocrit,~1
A/G~1
antiatherogenic/atherogenic~1
plasmafractionation~1
washouts,~1
entrapping~1
Scalva~1
(PMMA)~2
(anionic~1
(Cu),~1
PMN.~4
(NCP),~1
elastase,~2
cationic,~2
(40-43%),~1
anionic,~1
PMMA,~1
inert,~1
indicative,~1
(Al)-~1
Al-~1
Diarrhoeal~1
49.8%,~1
34.1%,~1
-6-phosphate~1
2.2%,~1
5.4%.~1
endocapillary~1
27.4%.~1
diarrhoeas~1
socio-economic~2
hygienic~1
Loyal~1
business,~1
spokespersons~1
word-of-mouth~1
legally,~1
exaggerated,~1
suboptimum~1
employees'~2
business.~1
Profound~2
manager,~1
hospitals'~1
"Baby~2
Doe"~1
Committees~1
Entrepreneurial,~1
innovative,~1
energetic,~1
enterprises.~1
trochanter.~4
un-united~1
1542~1
low-friction~1
gentamicin-containing~2
1.72%~1
1.65%~1
(conversions~1
revisions)~1
results--a~1
0.81%~1
3.46%.~1
enclosure~1
haematogenous~1
painless;~1
1964,~2
3573~1
breakage.~1
variable;~1
Re-fracture~1
re-fractures~1
697~1
Flexion~1
Walldius~1
chair,~1
unexacting~1
Fellows~1
Orthopaedic~1
VY-plasty~1
Loosening~1
triplane~4
stabilises~1
Cadaveric~1
Discs~1
unrestricted.~2
Syme's~1
spondylolysis,~1
immobilisation.~1
Excision,~1
trial:~2
crepe~1
bandage;~1
mobilise~1
Discomfort~2
conventionally.~2
hammer~2
elastofibroma,~1
Stretching~1
slow;~1
head-tilting~1
dermofluorometry~1
(FDF)~1
transcutaneously~1
(NaFl),~1
dermofluorescence~2
(DFU).~1
NaFl~1
decaying.~1
FDF~2
cross-clamping.~4
(LD)~1
counterpressure.~1
Radioisotope~1
(SPP)~1
SPP~5
thigh,~1
toe.~2
(iliac~1
(subclavian~1
artery).~1
stemmed~1
1836.~1
Transabdominal~1
aneurysmorraphy~1
infra-renal~2
2-5%.~1
Dubost~1
Rob,~1
Stipa~1
Shaw,~1
Helsby~1
Moosa~1
Williams~3
over-sewing~1
phlebotome~1
Numbness,~1
invades~1
aberrant,~1
retroaortic~1
"en~1
bloc"~1
dacron~1
iliolumbar~1
AVR;~1
MVR;~1
accountability.~2
(thromboembolism,~1
leak)~1
%/patient-year~1
(endocarditis~1
1.5;~2
pannus/tissue~1
(thromboembolism~1
thrombosis)~1
NYHA,~1
coronary-coronary~1
ringed~1
DAA~2
LPA~1
pseudoaneurysmal~1
mineralocorticoid-binding~2
(aldo)~1
hyperaldosteronism.~1
aldo~3
[144~1
SD;~1
sites/cell~1
respectively]~1
(292~1
sites/cell;~1
dexamethasone-suppressible~1
hyperaldosteronism,~1
sites/cell).~1
keratinocyte-conditioned~3
(2.4-~1
3.8-fold~2
PTH-(1-34).~1
Nle8,18,Tyr34-bPTH-(3-34).~1
malignancy-associated~2
PTH-induced~1
PTH-responsive~1
keratinocyte-derived~1
unmineralized~4
(matrix)~1
[61~1
0.02].~1
osteomalacic~2
chelatable~2
Pituitary-testicular~1
glucose-monitoring~1
pituitary-testicular~1
NPT,~1
amitriptyline.~1
ACTH-cortisol~1
hypersecreted~1
chronobiological~1
HDL.~2
(LPL),~1
(HTGL),~2
HDL,~6
(low,~1
[122~1
group].~1
HTGL.~2
(4-MA)~1
4-MA~2
baldness,~1
4-MA-treated~3
[46~2
4],~1
macaque,~1
ng/dL).~2
Sertoli-Leydig~2
(hNT)~1
methadone-addicted~1
hNT~3
(hNT~1
3MSH~2
(IR-hNT)~1
137,~1
183,~1
85,700~1
IR-hNT~2
hNT-(1-76)~1
10-16%~1
(61-69%)~1
hNT-(1-76).~1
NT-(1-76)~1
(K),~2
(DA).~1
secretogogues.~1
secretogogues~2
PRA,~3
(PAC),~1
(10-mg~1
dose),~1
mU/h~1
PAC,~1
ng/dL~2
ng/dL,~3
11-deoxycortisol~3
(Formula:~1
[1,25-(OH)2D]~1
following.~3
D-replete~2
premarin~1
(SRIH)~1
SRIH~10
endocrine-inactive~2
GH-producing~1
SRIH.~1
[15N]Glycine~1
(GHD;~1
(pGHD;~1
(CGD/FSS;~1
GHD~2
66.09~1
14.12%~1
27.64~1
5.33%~1
IU/m2~1
pGHD~2
47.19~1
13.42%,~1
22.69~1
4.58%~1
CGD/FSS~2
37.27~1
5.68%,~1
3.53~1
4.50~2
[15N]glycine~1
(50-100~4
(0.5-1~1
(start,~1
(1900-0300~1
(T3,~1
0.025;~1
T4-dependent~1
[basally,~1
pulses/24~3
Cluster~1
program]~1
(dex)~2
(PULSAR,~1
dex;~1
Cluster,~1
dex).~1
Dex~1
dex~3
administration),~1
suprapituitary~2
(Pliquid)~1
(Pairway).~1
(P-V)~4
Pliquid~3
Pairway~1
intercept,~1
phospholipid/g~1
P-V~12
Pliquid,~1
210,000-mol-wt~1
(GP~2
210)~2
agglutination.~1
(KLH)-anti-KLH~1
(OA)-anti-OA~1
chymotrypsin-treated~1
Ib).~1
anti-GP~2
210.~1
nonparietal~2
Gastrin-17~1
Hypoalbuminemia~1
[14C]carbonate~1
turpentine-induced~1
mRNa~1
fibrinogen-,~1
fibrin-degradation~1
(PBDHT)~1
(PUDHT)~1
PBDHT~2
788~1
micrograms/d);~1
PUDHT~1
micrograms/d,~1
diol)~1
diolG)~1
non-testosterone~1
diolG~1
lumirubin,~1
lumirubin~3
photoproduct~1
(Simpson,~1
R.U.~1
Circulation.~1
68:239.).~1
prohormone~1
D3-deficient~1
D3-depletion,~1
D3-depletion.~1
D3-endocrine~1
Reverse~1
3,3'-diiodothyronine~1
(3,3'-T2)~1
Metabolism~2
3,3'-T2~7
Deiodinase~1
(PTU)~2
sulfotransferase~1
salicylamide~1
dichloronitrophenol.~1
3,[3'-125I]T2~1
[3',5'-125I]rT3.~1
PTU~8
E-recurrent~1
(HIE;~1
Job's)~1
125I-IgE~1
-0.851;~1
L-Triiodothyronine~1
T3-responsive~1
(GH)-secreting~1
T3-stimulated~1
T3-depleted~2
anti-T3~3
T3-containing~2
50-70%.~1
40-70%.~1
45-70%~1
Growth-promoting~1
cel~1
(nephrocalcin)~1
nephrocalcin~5
Pulverized~1
8.0;~1
nephrocalcins~2
stone-forming~1
densa~2
densa.~1
290,000-D~1
gelatin/collagen-binding~1
60,000).~1
fibronectin-epidermolysis~1
epidermal-dermal~1
disadherence~1
Steinberg~1
normotriglyceridemic~1
(1979.~1
64:292-301).~1
kindred,~2
B-37~10
(203,000~1
wt),~2
kindred.~2
B-48.~1
B-37,~1
B-100.~3
B-100,~1
B-48,~1
Lp-B37,~1
31P-nuclear~2
resonance,~2
mmHg/min,~1
26.0~3
4.6,~2
gangliosides.~1
gangliosides),~1
tumorigenicity~1
coagglutination~1
pneumococci.~2
colonisation~2
coagglutination,~1
(14.37%),~1
(12.27%)~1
(26.82%)~1
(2.43%),~1
(70.73%).~1
recognise,~1
draughtsman~4
(factor~1
V),~2
heparinase~4
ovatus,~1
thetaiotaomicron,~1
uniformis~1
fusobacteria~1
Veillonella~1
peptococci~1
peptostreptococci)~1
spp~1
Interregional~1
imprecision~1
haemolysate~1
radioassay~1
Intrinsic~2
polymorph~1
hypersegmentation.~1
(20%);~1
1,2-dimethyl-3-hydroxypyrid-4-one,~2
chelators~2
"cold"~1
alpha-ketohydroxypyridines~1
(XGC)~1
(1.8%),~1
annum.~1
duodenum;~1
XGC.~1
XGC~1
fatal),~1
11,443~1
enterobiasis,~1
schistosomiasis,~1
mucocele,~1
trichuriasis,~1
ascariasis,~1
cystadenoma,~1
neuroma,~2
clonorchiasis,~1
cytodiagnosis~1
takers~1
cytotechnologists~1
goitre:~1
adenoma;~1
perimeters,~1
sections)~1
hypophosphataemia~1
curetted,~1
haemangiopericytoma.~1
"vascular"~1
extraosseous~1
(IBAS-1).~1
(traumatic~1
planus,~2
leucoplakia,~1
"risk~4
group")~1
(area,~1
perimeter,~2
leucoplakia~1
group"~1
group."~2
nucleo:cytoplasmic~1
(form~1
(DAP)~1
paracortical~1
areas)~1
unstained,~1
Touch~1
imprints~1
haemagglutination~1
(PHI)~1
(AIHA)~1
5.783~1
(6.183)~1
ng/10(6)~2
0.433~1
(0.349)~1
(DAGT)~1
DAGT~1
AIHA.~1
PHI~1
interrupted,~1
(PCV)~1
(HbS%),~1
HbS%~2
2,3-dinor-6-keto~3
detoxification.~2
unusually,~1
treatable.~1
(Whickham).~1
14.0%,~1
differed:~2
cholecystectomy)~1
Real~2
14C-cholesterol~1
3H-dextran~1
nmol/cm2/minute).~1
solubilisation.~1
diseased,~1
dyskaryosis,~1
dyskaryosis.~1
mastitis~4
ectasia/periductal~1
(DE/PM),~1
DE/PM,~1
centred~1
"granulomatous~1
mastitis"~1
pluriglandular~1
carcinoids~16
non-antral~1
metastasising~1
PGP~1
Rhodococcus~1
equi,~2
bacteraemic,~1
equi.~2
1976-86~1
unit:~1
necrotica~2
obscuring~1
(varioliformis)~1
excoriations,~1
folliculitis,~1
comedogenic~1
acnitis.~1
keratoacanthomas~2
Mohs'~3
fresh-tissue~1
keratoacanthoma~2
2.4%.~1
Micrographic~1
keratoacanthoma,~1
patents~1
expire.~1
Sometimes~2
prescriber~1
dispenser~1
chronicles~1
miscommunication~1
noncommunication~1
"equivalent."~1
gangrenosum.~1
pachyonychia~2
waist,~1
dappled~1
axillae,~1
thighs,~1
buttocks,~1
fades.~1
noncongenital~1
brittle~1
cystine-deficient~1
curious~1
sociable~1
Fertility~2
evaluated;~1
47,~4
"other."~1
graying~2
long-wave~3
[SDs]~1
sera)~1
Patch,~1
multiple-antigen,~1
predispensed~1
Chamber~3
keratocysts,~1
soles),~1
horror~1
Lassar's~2
paste,~1
Unguentum~3
Merck,~1
Preparations~2
oxalic~1
paraffin.~1
(ichthyosis,~1
keratoderma,~1
52,596~1
mg/kg/day.~3
reticuloid~4
photopatch~1
allergy;~1
Azathioprine,~1
skin's~1
photosensitizer(s)~1
unproved.~1
Sneddon's~1
(PUVA).~1
macules~2
PUVA-induced~2
macules.~1
Yemen~1
hematoxylin-and-eosin~1
leishmaniasis,~1
Alaska,~1
bifonazole~1
regions;~1
fatiguability.~1
Esophagogastroduodenoscopy~1
inverted,~1
Antituberculous~1
minocycline~1
fraise~3
dermabrasive~1
abrasiveness~1
full-faced~1
full-face~1
power-driven~1
rotary~1
brush.~4
fraises~1
exacting~1
extra-coarse~1
grit~1
fraise,~1
widths,~1
grits,~1
cutis~1
dermabrasion-Loo-punch-excision~1
lidocaine-bipuvacaine~1
(50:50)~1
hairline~2
jawline.~1
cutis.~1
Loo~2
2.0-~1
2.5-mm~1
punch)~1
bluish-gray~1
7-0~1
Aloe-vera-soaked~1
(Vigilon)~1
compress.~1
Sutures~1
"dot"~1
refrigerants~1
Frigiderm~1
Fluro~1
colder~1
Cryosthesia~2
Biobrane~1
(Woodroof,~1
Ana,~1
milia~1
dermabrasion.~1
fraction?~1
resistance?~1
exercise?~1
0.66;~1
0.00005)~2
-0.51;~1
-0.37)~1
liter-1.~1
aortocoronary~3
intact:~1
diphosphate/adenosine~2
phosphate/adenosine~1
adenylates~1
accumulated;~1
inosine.~1
0.021~1
0.660~1
Ultrastructure~1
relaxations.~3
methiothepin~1
(serotonin),~1
radionuclide-derived~1
double-buffered~1
acquisitions~1
elderly:~1
(2.7/patient).~1
(0.6%),~1
(0.2%).~1
Cardioversion~1
arrhythmia),~1
refractoriness.~2
pre-excitation,~1
Supernormal~3
ajmaline.~1
pre-excitation.~1
deleterious.~2
A-SVT)~1
A-VP).~1
A-SVT~3
A-VP~2
coxsackie~6
B3-induced~1
A/D~6
Plaque~1
(pfu)~1
(10(2)~2
U/g~5
(10(4)~1
pfu/mg,~2
pfu/mg).~1
5.(ABSTRACT~1
(1.75~1
mg/cc)~1
ethanol-water~1
ethanol-verapamil~1
excitability,~1
excitability.~2
Stunned~1
sarcomere~2
mEq/min~1
cardioverter-defibrillator~7
(AICD)~1
cardioverter-defibrillators~1
(AID-B~1
AID-BR~1
models)~1
countershocks.~1
cardioverter~1
16.8%.~1
AID-B~1
5.62%~1
depletions.~1
surpassing~1
arrhythmias.(ABSTRACT~1
reinduction~4
reinducible~1
HV,~1
distorting~1
repository~1
information;~1
decisions;~1
logic.~1
biotin-avidin~1
ragweed,~1
gourd~3
(watermelon,~1
cantaloupe,~1
honeydew~1
melon,~1
zucchini,~1
cucumber),~1
(120/192)~1
ragweed.~1
gourd-specific~1
gourds~1
0.79.~1
watermelon~3
cross-reactive.~1
watermelon-specific~2
throat)~1
"caine"~1
(urticaria,~1
exposure),~2
breathlessness,~2
sensitization),~1
(nonanaphylactoid~1
exposure).~1
(Xylocaine;~1
Astra~1
Products,~2
Westboro,~1
Mass.)~2
budesonide,~2
glucocorticosteroid,~1
ragweed-pollen~2
ragweed-induced~1
dipropionate,~1
actuation.~1
blinding,~1
canisters~1
adaptors~1
dissimilar.~1
troublesome,~1
Budesonide~1
Ptychodiscus~2
(PBTX)~1
brevis.~1
tide.~1
"triggering"~1
PBTX~10
(PG),~1
PBTX.~2
(PGA2,~1
PGB2,~2
PGI2)~1
(worsening~1
menstruation).~1
4-month,~1
Day-by-day~1
Meclofenamate~2
IU/ml).~1
hydroxyzine,~3
25.12~1
hydroxyzine~4
subsensitivity~1
honeybee~1
beekeeper's~1
Hyperimmune~1
beekeepers~1
(Cohn~1
HBV,~1
16/20~1
Test)~1
dose.(ABSTRACT~1
centimeter)~1
31.0)~1
U/gm~1
53.4~1
319.7)~1
U/gm.~3
cat-allergic~2
(0.0013~1
1.33)~1
64.3)~1
70.8)~1
present.(ABSTRACT~1
cosyntropin.~1
test-dose~1
corroborating~1
liberalization~1
references.~2
gm/day).~3
allowed,~2
endosperm.~1
sweeteners,~2
1,080~1
135%~2
lb.~1
One-minute~1
USDA's~3
handbooks,~1
(thiamin,~1
folacin,~2
B-12)~1
fast-food~2
0.062~2
0.078~1
0.122~1
0.176~1
0.205~1
0.249~1
6.32~2
8.46~1
5.57~1
0.315~1
0.390~2
0.271~1
8.00~1
0.459~1
0.596~1
1.58~2
Pressure-fried~1
crispy,~1
open-vat~1
cities.~1
Cereal~1
Chemists~1
gas-liquid-chromatographic~1
basis).~1
Moisture~1
crispy~1
recipes~1
recipes.~1
cuts.~3
Ohioans~1
Meat,~1
Dakota.~1
Retail~1
interregional~3
Ohio.~2
pasta~1
candies,~1
beverages.~2
low-sodium,~1
nutrient-dense,~1
sodium-dense~1
2,991~1
1,142~1
(Light,~1
Moderate,~2
Heavy,~2
Heavy)~1
Light,~1
Users~3
personalized~1
log.~1
bedsides.~1
"lost"~1
trays.~1
Unreported~2
served.~1
redesigned~1
Seroconversion~2
1,621~1
Hisayama~1
dress,~2
fundi~1
infarctions,~2
post-ictal~1
impediments~1
725-bed~1
incontinence).~1
radiodilution~1
transcobalamins~1
QUSO~1
binding/affinity~1
II-B12~1
1,024~2
(Hgb)~1
difference;~1
(17.7%)~2
Hgb~3
(-0.10)~1
(-0.21).~1
(-0.01)~1
(-0.04).~1
fallers,~1
injured).~1
chair.~3
noninjurious~1
latter).~1
faller,~2
injury-prone~1
Supreme~2
Judicial~1
4-3~1
decision,~1
"substituted~1
judgment"~2
sustenance~1
honored.~1
wishes.~1
publishing~1
amicus~1
curiae~1
Die,~1
Brophy~1
incompetent,~1
well-prepared.~1
merit.~2
Geriatrics~1
(AGS).~1
AGS~1
Conroy~1
(published~1
Journal).~1
ethicists~1
caveats~1
Thomasma,~1
PhD.~1
editorial~1
Journal.~1
invite~2
Villonodular~1
Huge~1
painfree~1
aneroid~3
sphygmomanometers~2
readings).~1
maeters.~1
Y-tube~1
advisors~1
Etiologies~1
cardiomyopathies,~1
antidysrhythmic~1
medications),~1
imbalances,~1
Exceptions~2
dentistry,~1
invested~1
incarceration~1
can't~1
risks)~1
qualification~2
not)~1
Las~1
Vegas~1
movie~2
Deer~1
Hunter"~1
talotibial~1
exercising.~1
boney~1
exostoses.~1
underventilated~1
94.6~1
91.4~1
-3.4~1
.01,~2
metaproterenol-induced~1
SaO2.~1
moon's~1
Lunar~1
(BILE)~1
moon~1
lunacy~1
consuming.~1
prothymocytes,~1
TdT+~10
motheaten~2
(me/me)~1
(mev/mev)~1
rat-~1
mouse-origin~1
lymphopoiesis~1
me/me~8
mev/mev~9
(+/-)~1
(NZB,~1
NZB/W),~1
(nu/nu),~1
(W/Wv,~1
Sl/Sld)~1
basophilic,~1
nonvacuolated,~1
eosinophilic,~1
pre-TdT+~1
(PnC)~1
R36a.~1
PnC-specific~2
(formed~2
excess)~2
PnC~3
(TEPC-15)~1
challenge;~1
(PnC),~1
TEPC-15/PnC~1
interferon-alpha,~1
(IFN-alpha,~1
Antigen-specific~1
(TDH)~1
(BM-MA)~1
2,4-dinitrobenzene~1
(DNBSO3).~1
TDH~5
BM-MA~3
(BM-MA~2
d5-7)~1
(Thy-1+,~2
Lyt-1+2-);~1
d10)~1
Lyt-2+),~1
U/10(8)~1
U/3~1
Cultivation~1
DNP-BM-MA~1
d6~1
beta-producing,~1
antigen-presenting,~1
osmotical~1
anti-sheep~1
(SRBC)~2
(C57BL/6~2
BALB/c)F1~1
anti-SRBC~3
preadministration~2
SRBC.~1
anti-Thy-1.2~1
MC.~2
(Ab)~2
IC-induced~1
(MCP~1
gp45-70)~1
iC3~1
mononuclear-derived~1
63,000~1
58,000.~1
two-allele~2
MCP.~1
Kas~1
glycopolypeptide~1
Lys20~1
Arg37,~1
Cys27~1
competes~1
125I-C5a~1
"recognition~1
domain",~1
Thy-1~13
aureus-derived~1
phosphatidylinositol-specific~1
(PI-PLC).~1
PI-PLC-treated~1
lectin-binding~1
ThB~1
Qa~2
PI-PLC~2
Qa-2,~1
Qa-4,~1
Qa-6,~1
Qa-1,~1
TLa,~1
ThB.~1
Qa-2~1
Qa-2-positive~1
anchoring.~1
Glycosyl-phosphatidylinositol-linked~1
beta-glucan-inhibitable~1
17.8%~2
N-acetylglucosaminidase,~1
N-acetyl-glucosaminidase~1
beta-glucan~3
N-acetylglucosaminidase~2
mannan~1
monocyte-phagocytic~1
beta-glucan,~1
Opiate~1
(beta-END)~1
beta-END~7
N-acetylated-beta-END.~1
monocyte-resting~1
opioid-triggered~1
SFR20-DQ~1
alpha-chains,~1
beta-chains.~1
locus-specific~1
5-negative~1
"blank."~1
5+~1
DR5,~2
DQw1;~2
DR8,~1
DRw13,~1
uterine-ligated~1
complement-~1
Complement-mediated~2
hypocomplementemic~1
shrimp~9
(Peneaus~1
indicus),~1
DEAE-Sephacel~2
BioGel~1
P-100.~1
Brilliant~1
allergen-specific~1
shrimp-sensitive~2
microELISA~1
(SPRIA)~1
antigen-coated~1
shrimp-derived~1
reaginic~1
aminoacylation~1
SPRIA~1
tRNA(Tyr)~1
tRNA(Arg).~1
post-recognitive~1
latticed~1
Ag2Ab2).~1
Established~1
charge-charge~2
antiHSA~1
cationized,~1
small-latticed~1
five-~2
MEL-14,~1
MEL-14~7
eosinophils;~1
neutrophil-endothelial~1
immunoprecipitates~2
PPME,~1
mannose-6-phosphate-rich~1
MEL-14-defined~1
PPME~1
(HA).~1
792~1
(tetrasaccharide)~1
pmol/liter,~1
N-acetyl-D-glucosamine~1
(NAGA)~1
NAGA~3
N-acetyl-D-mannosamine,~1
D-glucosamine.~1
glucopyranosyl~1
glucomannosyl~1
NAGA.~2
rodent-human~1
hemadsorption~1
(mAb),~1
K117~2
L127,~1
COS-7~1
L127.~1
Hybrids~1
Thy-1+~4
Thy-1-~6
RAG,~1
Thy-1.~1
dipeptide,~1
MTP-PE,~2
micelles.~1
[3H]-labeled~1
twice-weekly~1
immunomodulator~1
SG3/5~1
nonproducing~1
(SP2/0)~1
2a,~2
kappa)~1
IgG(Fc)~1
Native~3
human/mouse~1
17-1A,~1
express,~1
paf-acether~5
(platelet-activating~2
factor)~3
beta-hexosaminidase~1
nmol/min/mg~2
acetyl-coenzyme~3
uneffective~1
antigen-challenged~1
Jel~4
poly[d(AT)]~1
241.~1
base-pairs~1
(K(O))~1
K(O)~3
60-fold~1
antibody/DNA~2
(platelets)~1
Complexation~1
(ds)~1
(ss)~1
ds-~1
ssDNA~3
ssDNA.~2
IgG-~1
immunochemistry~1
subregions~1
DP.~1
Swei.~1
DQw3.~1
DQw3~5
DR4,~3
DQw2~2
mutations;~1
additions/deletions~1
chi-like~1
membrane-related~1
[125I]calmodulin~1
Calcium-dependent~1
affinity-binding~1
(Bt)~1
cytoplasmic-free~1
phytomitogens.~1
W-7,~2
chloropramazine,~1
phytomitogens~1
TFP-inhibitable,~1
"trigger"~2
R-bearing~1
two-target~2
conjugates,~3
NK/K~3
(MG),~1
anti-AChR~1
mAb,~1
endplates~1
CBA/J~5
emerge:~1
resorptions;~2
multigravid,~1
nonpaternal~1
Intentional~1
(LTB4)~1
(paf-acether)~1
histoenzymologic~1
Hanks'~1
(HBSS)~1
Paf-acether,~1
HBSS~2
(HBSS-BSA).~1
Histoenzymologic~1
Paf-acether~3
paf-acether,~1
HBSS).~1
proteins/cm2/2~1
paf-acether.~1
reintroduction~1
undecapeptide~2
wheals~2
fluorimetry~1
(25.1%).~1
chelation.~1
(ACH),~1
trinitrochlorobenzene~1
(TNCB).~1
TNCB,~1
(30.2~1
(117%~1
(131%),~1
(133%).~1
(1+)~1
(2+)~1
hypogranulated~1
ACH,~1
ACH.~1
urticating~4
Hylesia~3
moth~3
hairs.~2
moths,~1
hairs,~1
radioenzyme~1
moths~1
HE-injected~1
moths.~1
(LC).~1
(0.9-2.7J/cm2),~1
ATPase-stained~1
(0.02-0.2~1
(37-40%~1
density).~1
D-mannitol,~1
L-histidine~1
0.3-0.6~1
amounting~1
chloroform/methanol.~1
liberates~2
C30-C34~1
sphingosine,~1
corneocyte~3
omega-hydroxyacylsphingosines.~1
envelope.~1
hydroxyacylsphingosine~1
corneocyte.~1
uppermost~3
MCGs.~1
I-B4~8
(GS~1
I-B4)~1
(alpha-D-galactosyl~1
specificity).~3
(UEA)~1
(alpha-L-fucosyl~1
UEA~8
I-B4.~1
30-40%~3
UEA.~2
Raising~4
UEA-Sepharose~1
4B,~1
I-B4-Sepharose~1
binding;~1
stratification;~1
morphea,~1
collagenoma,~1
keloids;~1
[3H]hydroxyproline,~1
procollagen-specific~1
keloid~2
collagenoma;~1
abundance,~1
resilience~1
oxyhemoglobin.~2
(fair)~1
(dark)~1
1.5-microsecond~1
electron-lucent~1
heat-fixed~1
molds~1
Smyth~1
integumental~2
amelanosis,~1
(NEMCs)~1
morphometrically,~1
MOP~1
(8.09~1
microns),~4
(26.51~1
(36.87~1
microns2)~2
(0.626)~1
(5.08~1
(18.74~1
(12.54~1
(0.452)~1
nuclear-cytoplasmic~1
(0.5595),~1
nm),~2
(7.02~1
granules/micron2).~1
94.23~1
5020.05~1
nm2,~1
NEMCs~1
(286.9~1
interkeratinocytic~1
(385~2
nm).~3
(spine-like~1
(1.39~2
cold-knife~1
Excimer~2
66.7%,~2
stylette~1
Modifying~1
fentanyl-supplemented~1
oxide-oxygen~2
(ir~1
beta-E),~1
ir~2
progesterone-estradiol~1
unsolved,~1
distillation.~1
conductivities~1
Milli-Q~1
distillation,~1
glassware~1
"resolved"~1
pregnancy!~1
(331~1
vacuum.~1
follicle.~4
(9.3%).~1
HP,~3
(Micropolyspora~1
faeni~11
adjuvant)~1
(peritoneal~1
exudate,~1
(PPD),~1
noncultured~3
antibody-containing~2
Randomly~2
animal)~1
high-efficiency~1
accumulator-filtered~1
faeni,~2
PPD~1
Xa~6
HTGL,~3
phospholipid-binding~1
-0.87,~1
albumin-heparin~1
(arteriovenous~1
(8.2%~1
warmed~2
(tumor~1
39,401~1
cpm,~4
12,153~1
preincubating~2
coincubating~1
5474~1
sphingomyelin,~1
phosphatidyl~1
Dexter-type~1
"busulfan-marrow"~1
busulfan-treated~1
(TX)~1
proaggregator~1
(UTXB2)~1
One-step~1
UTXB2~3
octadecylsilyl-silica~1
eluate~1
(UTXB2V)~1
UTXB2V.~1
UTXB2V~4
94.5~1
ng/day~1
(224.4~1
postsinusoidal~1
(HVL)~1
HVL~5
ml/hr)~1
nonsignificant,~1
(PGE2)~1
mEq)~5
(-124~1
mEq).~1
-82~1
hypotympanum~2
promontory;~2
hypotympanic~3
hypotympanum.~1
protrudes~1
73.4~2
protympanum,~1
fossula~3
vestibuli~1
exceptionally,~1
45.5~1
canal;~2
cochleariformis;~1
eminentia~1
pyramidalis.~1
recesses~1
frequently:~1
subfacialis~1
retrofenestralis~1
subrostralis~1
Unfortunately~1
silently~1
irresectable~2
Habituation~1
(VHT)~1
(ppv).~1
ppv.~1
ppv~3
Dix-Hallpike~1
VHT~2
(VHT-test-battery).~1
Ppv~3
repercussion~1
vestibulospinal~1
posturographic~1
pleads~1
non-allergic,~1
turbinates.~1
non-allergic~2
Tonsillectomy~5
crypts.~2
tonsillitis,~2
inductor~1
pus.~2
nerve-muscle~1
arytenoids~1
site-of-lesion~1
ectomesenchymoma~1
4:5.~1
ectomesenchymomas~1
was/were~1
ectomesenchymomas.~1
'pull-up'~1
pharyngo-laryngo-oesophagectomy.~1
(NBS)~1
Migraine~2
bracket,~1
accompaniments.~4
migraines,~1
scintillating~1
marching~2
paresthesis~1
bracket~1
varying,~1
ordered,~1
anyway.~1
human-model~1
protectant,~1
antiseptics~1
hydroxide-induced~1
forearm)~1
(neomycin,~1
bacitracin)~1
epithelialization)~1
Contaminated~1
neomycin-polymyxin~1
B-bacitracin~1
"difficult"~2
referrals,~1
"thick-chart~1
generics.~1
representatives,~2
advertisements~1
Letter.~1
overutilization.~1
chest-related~1
off-site~1
abdominal-related~1
1.34,~1
.5)~1
overinterpreted~1
radiologists'~1
Pruritus,~1
goal-directed~1
centuries,~3
philosophers~2
themes~3
Vocational~1
inventing~1
roadblocks~1
interfaces.~2
data-based~1
measure's~1
(divided~1
nonpatients)~1
23-item~1
nonpatients'~1
multiaxial~1
3455~1
dysthymic~3
7837~1
nondepressive~4
"anxious/fearful"~1
unspecified~2
arthropathies.~1
conjugal,~1
deviantly~2
Aberration-Magical~1
Ideation~1
(Per-Mag)~1
slippage--a~1
referential~1
Per-Mag~3
(GBI)~1
deviant.~1
GBI~1
Freud's~1
(SOA)~1
foveal,~1
SOA~2
out-of-body~5
narcissism,~1
paranormal~1
self-concept,~2
desirability.~1
nonreporters~2
Paranormal~1
Reporters~1
precognition,~1
psi,~1
spiritualism,~1
witchcraft~1
nonreporters.~1
reporters~1
proneness~1
dysphoric~2
hysterical~2
professions,~2
downgoing~1
oculocephalic~4
vestibuloocular~2
(independent~1
coma)~1
non-neurological~1
shuttlebox-analog~1
validation,~1
mm3~2
0.995~1
measurements).~1
(spectacles~1
lens)~1
almost-complete~1
Obvious~1
unstabilized)~1
6/9~1
Migraineurs~1
lateralised~1
under-responsiveness~1
habituation,~1
over-responsiveness~1
habituation.~1
Bipolarity~1
myometer~1
myasthenia,~1
tourniquet-induced~1
(35.2~2
m/s)~2
(39.8~1
m/s).~1
(FCR)~2
H-reflexes~4
FCR~3
re-innervation.~1
depolarisation~1
hardness,~1
vibrotactile~1
hardness.~1
(50-500~1
contractor~2
(1-3N).~1
skewed.~1
areflexic~1
milestones~1
("Triton")~1
mesulergine~2
pergolide.~1
(BChE)~1
(dementing~1
non-dementing,~1
BChE~2
(degeneration~2
interneurons)~1
AChE,~2
globally~2
pathology-induced~1
reflected.~3
bradykinetic~1
Bradykinesia~1
corollary~2
clinical-anatomical~1
aprosodias.~1
utilised~1
aprosodia,~5
affect.~1
Functional-anatomical~1
affective-prosodic~1
aprosodic~1
Amplitude/frequency~1
accelerometric~1
Intra-subject~1
0.1-0.015~1
young)~1
downwards~1
"pathological"~1
into,~1
demodulated~1
spring-mass-system.~1
synchronisation~1
tremors.~1
(VIII-ST)~1
(otolith~1
(ST).~1
Backwards~1
VIII-ST~1
sternomastoid,~1
EMG/tilt~1
position)~2
F-response~6
(MND)~1
M-response~1
30.8%,~2
76.3%,~1
6.3%)~1
macular-sparing~1
altitudinal~1
visuo-psychic~1
imagery.~1
visuo-limbic~1
disconnection.~1
diplopia,~3
uniocular~1
intra-orbital~1
ponto-medullary~2
E:cholesterol~1
hemianaesthesia~1
else's~1
inter-digitated~1
touched,~1
touching.~1
rimmed~6
medius~3
minimus~1
gastrocnemius,~1
femoris,~1
elevated;~2
myopathic,~1
features;~1
"neuropathic"~2
clumps,~2
noticeable,~1
Golgi's~1
T-system~1
(autophagosomes)~1
Autophagosomes~1
coalesce~1
Gently~1
(tubulomembranous~1
heel-cord~1
(ringbinden)~1
apnoeas~2
trichlorethane,~1
parieto-occipital~4
saccades.~1
full-field~1
pursuit;~1
intrahemispheric~1
pseudohypertrophic~2
(MD),~1
chairbound.~1
Erfurt~1
Warsaw~1
(BMD)~2
BMD~2
chairbound~1
MD.~3
paediatrics~1
"same/different"~2
interfield~1
half-fields.~1
cueing~1
Interfield~1
hemi-space~1
attracts~2
processed.~1
pre-attentional~1
releaser,~1
sympathomimetic,~1
histological,~1
biometric~1
crico-arytenoid~1
motorneuron~1
essayist~2
says,~1
says~1
(Qs/Qt)~2
Qs/Qt~4
tutorial~1
Qs/Qt:~1
(oxygen~5
uptake),~1
Qt~1
output),~1
Cc'O2~1
capillaries),~1
CvO2~1
equations:~1
[(VO2/Qt)/(Cc'O2~1
CvO2)].~1
representations~2
self-inflating~2
analogous)~1
controller.~2
relexants~1
(non-relaxant~1
non-depolarizing~1
(relaxant~1
nonrelaxant~1
one-lung~5
CO-Oximeter~1
5,230~1
warmer,~1
infants),~1
(81),~1
(98),~1
(91).~1
([Adr]~1
Adria~2
sarcomas:~1
carboxamide~5
(DTIC)~1
DTIC~8
Adr-DTIC~2
pathologists;~1
on-study~1
affirmed.~1
(1,2-benzopyrone)~1
coumarin,~1
daily;~1
status).~1
14.3%),~1
4+,~1
9.5+~1
21+~2
(organ~1
Coumarin~1
gut-associated~2
(GALT)~1
loco-regional~1
(XRT)~2
GALT~2
Waldeyers'~1
lymphomas)~1
non-gut-associated~1
(ENL).~1
(GALT-L)~1
.017)~1
GALT-L~1
(ER)-positive~1
ER-unknown~2
(CAF)~1
CAF~4
(O~1
CAF).~1
CAF.~1
.33)~1
.70)~1
semi-solid~1
"aggressive"~1
(RFS)~1
46.8~3
RFS~1
.0043,~1
Peto-Pike),~1
.1175)~1
III-A~1
0.5-cm~1
.0205).~1
(no,~1
favorable,~3
gross).~1
III-B~1
no,~1
postremission~1
amsacrine~2
(ANL),~1
ANL~1
(induction),~1
daunomycin,~1
arabinoside,~4
6-thioguanine,~1
(VCR),~1
42;~3
fungal).~1
amsacrine,~1
4'-(9-acridinylamino)~1
sulfon-m-anisidine~1
(m-AMSA),~1
develop;~1
(26/137,~1
9/281,~1
.0005,~1
[CR]~1
courses),~1
Clin~1
Oncol~1
5:941-950.~1
35%.~5
MS-contin~1
(MSC;~1
Purdue-Frederick,~1
CT)~1
immediate-release~1
(IRMS)~1
MSC~7
Tmax~1
IRMS.~1
(.70~1
IRMS,~1
IRMS~1
bifunctional~2
radioimmunodetection.~1
BCA,~1
p-carboxyethylphenylglyoxal-di(N-methylthiosemicarbazone)~1
(CE-DTS),~1
(56C)~2
conjugating~2
CE-DTS~2
phosphorylazide~1
6.2.~1
Technetium-99m-labeled~1
(56C),~2
[99mTc]CE-DTS-IgG~1
(111In)~1
DTPA-IgG~1
(56C).~1
99mTc.~1
N-bromosuccinimide~1
postlabeling~1
L-~3
D-[methyl-11C]methionine~2
carbon-11~1
(11C)~1
one-carbon~1
one-pot~1
two-pot~1
40%-90%~1
yields.~1
[11C]carbon~1
(RN)~1
CVD,~1
First-pass~1
radiocardiographic~1
Regurgitant~1
9.6%~2
RVEF,~3
LVEF).~1
LVEF(FP)~1
(corrected)~1
0.77),~1
0.88),~1
0.91)~1
0.52-0.71).~1
bones)~1
0.58-0.61~1
s.e.e.~1
Septo-optic~2
[99mTc]IDA~1
[123I]metaiodobenzylguanidine~1
(MIBG)~3
paraganglion~1
Iodine-123~1
0.001%~1
I-III.~2
Metaiodobenzylguanidine~1
locates~1
neuroblastomas.~2
(APUD)~2
[131I]MIBG.~2
Views~1
(positive/total~1
cases):~1
ten),~1
nonsecreting~3
granules)~1
scintigraphically,~1
paragangliomas)~1
Nutriture~1
(NHANES~2
southwest~1
(SW~1
HHANES).~1
quality-control~1
20-24~2
25-29~1
Response-surface~2
three-variable~1
3-5%~1
6-10%~1
54-55%~1
26-30%~1
cocoa~8
butter~8
(59-72%)~1
(93-97%).~1
27-34%~1
(16:0),~1
22-32%~1
(18:0)~2
25-37%~1
(18:1).~1
Palmitic,~1
oil-fed~2
31-37%~1
58-64%~1
triolein-supplemented~2
(EFAD)~1
EFAD~3
esters.~2
methionine-free~3
isoleucine,~1
histidine,~1
Deprivation~1
28S~3
45S~1
pre-rRNA~1
18S~1
(NP).~1
LP-fed~2
salt-dependent~4
invert~4
(50:50~1
fructose)~1
cornstarch~1
[1,2-3H]aldosterone.~1
56-d-old~1
cornstarch;~1
libitum,~3
[1,2-3H]aldosterone~1
(mg/d)~1
cornstarch-fed~3
sucrose-fed~2
fecal)~2
sugar-~3
(ROH)~1
(disposal~1
DR)~1
(MAR)~2
ROH~8
(6.8,~1
micrograms/dL).~1
input-output~1
[3H]ROH~3
(LO~1
MAR)~1
(residence~1
MAR~4
(0.92~2
(7-9~1
recycled,~1
metabolized,~2
(LO)~1
micrograms/d~1
(HI).~1
DR.~4
ROH-dependent~1
Ethambutol,~1
[CH3CH2-CH(CH2OH)-NH-CH2]2~1
(EMB),~1
casein-based~2
adequate-Zn~1
(AZn)~1
marginal-Zn~1
(MZn)~1
MZn~2
EMB.~3
EMB,~1
AZn~3
EMB-treated~1
cross-fostering~1
(Zn-D)~1
suckled~1
Zn-sufficient~1
(Zn-S)~1
65Zn,~2
zinc-depleted~1
(Zn-Dp)~1
zinc-repleted~1
(Zn-Rp)~1
Zn-Rp~2
Zn-Dp~1
dibasic,~1
dolomite~1
magnesium)~1
magnesium-fortified~1
(Se),~2
(Se-methionine)~1
Se-yeast~3
Se-methionine,~1
Se-yeast.~1
slope-ratio~2
Se-methionine~2
dam~1
(GSH-Px,~1
1.11.1.9)~1
GSH-Px,~2
Se)~1
Na2SeO3)~2
torula~1
yeast-based~1
Anti-GSH-Px~1
GSH-Px.~1
exponentially,~1
anti-GSH-Px~1
antibody-reactive~1
tumorigenesis~1
micronutrient~3
tumorigenesis.~2
[Sprague-Dawley~1
Fischer-344~1
(F-344)]~1
nutrient-energy~1
2HCl~1
carcinogen.~1
F-344~2
Lactating~6
light-dark~1
Diurnal~3
middark~2
meal-feeding~1
cross-bred~1
Fast-growing~1
(broiler)~1
lighter-weight~1
(White~1
Leghorn)~1
(325%~1
Leghorns~1
233%~1
broilers)~1
Leghorn~1
protein-deprived~1
(Leghorns)~2
(broilers)~2
Antisera~2
caseins,~1
sulfate--polyacrylamide~1
regimes~1
lactation:~1
intake),~1
caseins.~1
chondrodystrophy,~2
shortened,~2
Manganese,~1
Tibial~1
prehypertrophic~2
spongiosa.~1
subsystems--intestine,~1
calcium-regulating~1
subsystems.~1
1,25-dihydroxycholecalciferol[1,25(OH)2D3]~1
24R,25-dihydroxycholecalciferol[24R,25)OH)2D3]~1
metabolites;~2
seco-steroid~1
gene-induced~1
28,000-dalton~1
calbindin-D28K.~1
D-induced~1
calbindin;~1
24R,25(OH)2D3,~2
Avian~1
(Ca)~3
coregulated~1
minute-to-minute~1
conserve~1
eggshell~1
replenishment.~1
Ca:Pi~1
(MO)~1
wt%~3
MO~5
(HCO)~1
MO-induced~1
HCO~3
(PUFA),~1
20:5n-3~1
22:6n-3~1
phosphoglyceride~1
22:5n-3~1
PUFA,~1
20:4n-6,~1
22:5n-6~2
18:2n-6.~1
20:4n-6~1
18:2n-6~2
n-6/n-3~1
MO.~1
consumption.(ABSTRACT~2
energy)~1
[kJ/(kg0.75~1
d)]~1
protein-fed~1
(mitochondrial~1
fat-cholesterol~3
HDL-serum~1
adaptative~1
colipase~1
germ-supplemented~1
Norwegian~2
Hooded~1
(B2-)~1
(B2+)~1
B2-~2
dam,~1
Iron-mobilizing~1
maternofetal~1
folate.~3
coprophagy~2
Bioassays~1
pentaglutamate~1
reserves.~2
retinol/g~1
(11-fold~1
27-fold~1
87-91%~1
stearate~2
mercaptans,~1
beta-mercaptocarboxylic~2
(Se)-dependent~1
postmitochondrial~1
mercaptans~3
E-deficient~3
E-~1
E-,~1
Se-deficiency~1
(ED).~1
D-(-)-Penicillamine~1
compound),~1
beta-mercaptopyruvate,~1
t-butyl~1
mercaptan~1
S-methylglutathione~1
(nonmercaptan~1
analogue)~1
postmitchondrial~1
mercaptosuccinic~1
N-(2-mercaptopropionyl)glycine~1
thioglycolate~1
hinderance~1
zinc-metallothionein~1
(Zn-MT)~1
(+/?)~1
22-wk-old~1
Heth~1
Hoekstra,~1
libitum--fed~3
Unrestricted~1
mice.(ABSTRACT~1
oxygens~2
P-450-oxy~1
NADPH-cytochrome~3
Zn-adequate,~1
Cu-adequate,~1
cooper~1
Mn)~2
10-wk~1
1.050-1.1963)~1
triticale~5
phytase~5
phytate~10
corn-~1
triticale-based~1
component;~1
phytic.~1
balances,~1
hypophosphaturia~1
bone-mineral~1
1,25-(OH)2-cholecalciferol~1
25-OH-cholecalciferol.~1
25-OH-cholecalciferol,~1
25-OH-cholecalciferol~6
(1-OHase)~1
(24-OHase)~1
(P).~1
1-OHase~3
fmol/(mg~2
(0.014%)~1
interrelating~1
Alfalfa~3
intraruminally~1
wethers~1
ruminal,~1
roughage~1
isoenergetic.~1
saponins.~1
protozoal~2
hemicellulose~1
Saponins~1
(Fe)~1
feline.~1
casein-based,~1
fiber-free~1
105,~3
(supplied~1
FeSO4~1
7H2O)~1
10-d~1
one-slope~1
broken-line~1
puppy,~1
kitten,~1
casein-dextrose~1
(ER).~2
deprivation;~1
(ECF).~1
ECF~2
compartment;~1
[100~1
micrograms/(kg~1
h)]~1
(SBTI)~1
atropine-sensitive~1
atropine-nonsensitive~2
atropine-administered~1
SBTI,~1
(SBO)~2
tumorigenesis,~2
C3H/OUJ~1
SBO~9
SBO.~2
splenocyte~2
E55:B5,~1
P815~1
phosphatidylethanolamine.~2
thiuram~4
tibia)~1
supplementation:~1
Al,~5
Sr,~1
Br,~1
Si,~1
Mo,~1
Li,~1
47Ca~3
chick.~1
Anticonvulsants~1
primidone~4
pteroylpentaglutamates~1
Primidone~1
(and/or~1
phenobarbital)~1
carbohydrate-to-fat~1
opiate-stimulated~1
naloxone-,~1
cholecystokinin-~1
bombesin-suppressed~1
(cornstarch)~1
(corn~1
lard)~1
(administered~1
ketocyclazocine~1
preferentially,~1
postinjection;~1
overeating~1
breeder~2
diet-exercise~2
diet-sedentary~2
(HS),~2
normocholesterolemic~2
mph,~4
CAO~3
planners~2
bone-marrow~1
non-macrocytic~1
Re-reading~1
(TIBC)~1
predict.~1
58.1%;~1
medium-risk,~1
40.2%;~1
26.6%,~1
(1.47~1
utilities~3
Physicians,~1
forget~1
euglycemic-hypoglycemic~1
chidren~1
(625~1
(811~1
Ministry~1
Genetics,~1
Columbia.~3
Permission~1
observance~1
oath~1
nonstatistical~1
1341~1
1952-1981~1
76.3%;~1
61.8%;~1
57.1%;~1
53.1%;~1
49.9%.~1
90.7%;~1
87.2%,~1
84.9%,~1
81.9%,~1
millicurie~1
technetium-labeled~1
diisopropyliminodiacetic~1
(DISIDA)~1
DISIDA,~1
granulocyte-derived~1
(elastase/antielastase~1
complexes)~1
(elevated~1
beta-thromboglobulin).~1
hyperglycinemia~1
(NKH).~1
NKH,~1
NKH.~2
NKH~1
1246~1
511~1
Hct.~1
randomizing~2
leukopheresis.~1
(AGC~1
1500/mm3),~1
mortality:~2
multiple-dose~3
dosing).~1
binders,~2
Perceived-Benefit-of-Drinking~1
scalable,~1
34-month~1
12,647~1
cervicitis.~1
Collecting~1
Simple,~1
Q-tip~11
incontinency~1
(SUI),~1
SUI~2
SUI.~1
absolute.~1
ultrasonographically~1
post-vaginal-delivery~1
3,127~1
[4.5%]).~1
(51.1%)~1
persistent/recurrent~1
(LAG).~1
Tru-cut~2
parametrium.~1
disposable,~2
(47.8%).~1
FNA/LAG,~1
65.6%;~1
93.5%;~1
validation.~1
malformation;~1
four-chambered~1
May-Hegglin~2
previa.~1
70-minute~1
salpingectomy/cornual~1
"removal."~1
lyrics~4
mood-altering~1
pervasiveness~1
lyrics,~1
Drug-related~1
songs~2
chart,~1
chart.~2
aggression~2
youth.~2
disagree~1
sequence:~1
consolidating~1
styles;~1
recovery-related~1
issues;~1
shaping~1
Driving~1
Intoxicated~1
(DWI)~2
installation.~1
DWI.~1
Vaillant~1
MacAndrews~1
Mortimer-Filkins~1
questionnaire;~2
cofactors~1
grief,~1
agoraphobic,~1
signalled~1
Longituding~1
attract~3
charcoals.~1
(w/v).~2
(14C)~1
Darco~4
G-60,~2
USP,~1
SuperChar~4
charcoal.~5
drug-charcoal~1
Equilibrium,~1
G-60~2
USP~3
(mumoles/gm)~1
(1141),~1
(580)~1
(381),~1
Kd's~1
Sorbitol~1
(717)~1
SuperChar.~1
Hacettepe~1
Ankara~1
1188~1
self-poisoning~6
(12.8%).~1
95.4%,~1
tranquilizers~1
Optalidon.~1
79.0%~1
thiosulfate~1
antidote~1
15.68~1
mcg/mL.~1
toxicokinetic~1
mL/minute),~1
L/kg)~1
nitrite/thiosulfate~1
boric~5
charcoal)~1
eighties.~2
intoxications~2
epilepticus,~1
allusions~1
3,4-methylene-dioxy-methamphetamine~1
amphetamines.~1
MDMA.~1
Sympathomimetic-MAO~1
serotonin).~1
sympathomimetic-MAO~1
Rondec~1
Mushroom~1
Amanita~3
mushrooms~1
("death~1
cap",~1
"destroying~1
angel").~1
carboxyl-~1
assays)~1
pituitary-hypothalamic~1
euthyroid-illness~1
non-prescription~1
hypnotic.~1
1982-1985~1
14-30~1
(0.1-4.7/micrograms/ml)~1
Psychotic~1
catatonic~1
stupor--often~1
anxiety--was~1
diphenhydramine.~1
benzoylecgonine,~1
metabolite--a~1
methamphetaine,~1
phencyclidine.~1
8.7,~2
dialysance~2
103,~1
30-66%~1
serum-osmolal~1
89.4~1
Hemodialyzer~1
osmolal~2
0.998,~1
hypercalciuria).~1
(intestinal)~1
hypocalciuric~3
kidneys)~1
Sound~2
GmbH~1
noise-induced~1
nephroscopy.~1
Cecoileal~1
Tunneled~1
Plication~1
re-configured~1
Heineke-Mikulicz~1
(unit)~1
1984:~1
enteric-Kock~1
refuses~1
conduit),~1
(Kock~2
pouch)~2
ileography~1
suspicious.~1
(urothelial)~1
cavernosometric~1
(54.1~1
Insufficiency~2
cavernosography,~1
albuginea.~1
stumps~2
mesh-wrapped~1
urethra-sparing~1
B2/C~1
post-chemotherapy~2
Hernia~1
preperitoneal~5
cystoprostatectomies.~1
Manitoba,~1
2,699~1
1976).~1
urologists)~1
prostatectomy,~4
Dilation~4
692~1
ureterorenoscopic~1
6-foot,~1
6-inch~1
hemoglobinopathy~3
Cystourethrography~1
voiding:~1
subvesical~2
pre-voiding~1
tightened~1
Voiding~1
enkephalins.~1
suprasacral~1
complete),~1
dyssynergia).~1
cystometrographic~1
dyssynergia~1
(electromyographic)~1
(cystometrographic)~1
liver/spleen~2
bucrylate,~1
nonHodgkin's~1
breath,~3
Azoospermia~1
ventriculoseptal~1
malascended~1
rachischisis~1
60-year~1
pseudohermaphrodite~1
paraurethral~4
endocrine-paracrine~6
urethras~3
Churukian-Schenk~1
chromogranin~1
Scattered~1
(luminal~1
extensions)~1
engrafted~1
(FANFT)~1
purpurin~1
nm.,~1
joules/cm.2).~1
micrograms./gm.~3
purpurins~1
NT1~2
NT2,~1
Purpurins,~1
photosensitizers~1
(300-mg./gm.~1
131I-6-iodomethyl-29-norcholesterol,~1
131I-sterol~2
second-site~1
620%~1
electrosurgically~1
electroresection~1
(FTIA)~1
(RCC)-reactive~1
A6H~3
AFP-22~2
RCC~11
non-RCC~2
FTIA~2
xenografts.~4
Radioimmunoscintigraphy~1
contractant~1
spongiosum~1
vasopressin-like~1
107.2~1
fmol./gm.~1
(UPV)~1
elucidation.~3
UPV~3
asleep.~1
UPV,~1
intravesical-(IVP)~1
electroencephalography~2
persistance~1
Cystometries~1
infravesical~2
anti-testicular~1
supernates~1
(5F9)~1
esophageal,~2
MOPC-21,~1
(8:1~1
tumor:~3
MOPC-21.~1
(testicle)~1
fmol/mg.~1
femtomol/mg.~1
3.6S~1
TSU-Pr1,~1
Karyotypic~1
Y-chromosome~1
Examinations~1
tortuosity~1
(FD)~1
[ASV]~1
[PTFE])~1
FD~6
ASV~2
PTFE).~1
Revascularization~1
aortobifemoral~3
axillounifemoral~2
axillobifemoral~4
errors)~1
(log~5
3.882,~1
2.213,~1
(disabling~1
salvage)~1
0.0005,~2
profundaplasty)~1
2.011,~1
double-velour~1
111.~1
Hypothenar~1
hammer.~1
unilaterality,~1
Gangrene~1
limb;~3
(EC-IC)~1
(CVA)~1
(2.1%).~1
(9.2%),~1
reopened,~1
nonoccluded~2
angioscopic~3
(stable~1
venotomy~2
harvested.~2
Prostacyclin~1
(PAD)~1
bruits~2
PAD~3
oculoplethysmography~1
phonoangiography~1
(OPG/CPA)~1
5.5-year~2
difference).~6
fighter~1
diapering~1
afflicted.~1
abnormality--detrusor~1
(DHIC)--that,~1
Detrusor~1
empties~1
ineffectively.~1
imparied~1
trabeculation,~1
DHIC~2
Ehrlichia~3
Ehrlichia:~1
Rigors,~1
guns,~1
toys,~1
Handguns,~1
Inexpensive~1
reputation~1
5732~1
24-km~2
radius)~1
patient-day~1
neighbors.~2
nonprice~1
policymakers~1
markets.~1
nurse/flight~3
paramedic-staffed~1
kJ)~2
160/100~1
monounsaturates~1
polyunsaturates~1
18.2%~1
23.2%~2
causality~3
(Favor)~1
test-marketed~1
puffed~1
puffing~1
(107.3~1
[67.6~1
188.5~2
nmol/L]).~1
cross-table~4
31%).~1
suicides,~1
Allegheny~1
1.7-fold).~1
46.0%~1
adolescence)~1
misinformed,~1
industry's~1
"informed~1
choice"~1
midsized~1
residence,~2
unawareness~1
boyfriend,~1
Inner-city~1
unintended~1
teachers,~1
ministers~1
churches,~1
([live~1
abortions]~1
county's~1
sociodemographically~1
laws,~3
prohibition~2
minors,~2
sale,~2
vending~2
violators~1
laws.~2
Violence~1
communicable~1
currently,~1
risk-taking~1
physical/sexual~1
insufficiently~1
center-based~1
(169)~1
denied.~1
wars~2
seropositive.~3
8%])~1
Administration-operated~1
Alaskan~1
year-long~2
(114/493),~1
(31/80)~1
(34/115)~1
(7/15)~1
teens,~1
(8/19)~1
nonculture~1
wearers,~1
(21/27~1
[78%]~1
14/81~1
[17%];~1
[OR],~1
infinity),~1
(17/27~1
[63%]~1
24/81~1
[30%];~1
OR,~2
6.2).~1
disinfect~1
(18/25~1
[72%]~1
26/81~1
[32%];~1
nonsterile~1
developers,~1
logistical~1
ahead.~1
decision-support~1
Activities,~2
1004~1
0.78/100,000~1
0.84/100,000~1
(4.8/100,000).~1
Council,~2
AMA's~2
undertaking,~1
AMA,~1
finances.~1
prime)~1
6,6-d2-glucose~1
15N2-urea.~1
(ip)]~1
lethargic~1
8-hr~1
mortality.(ABSTRACT~2
nasoenteral~3
alimentation~1
malplacement.~2
small-bore~2
(properdin).~1
neoantigen~3
[iC3b-C3d~1
neoantigen)~1
C3d.~1
iC3b-C3d~2
plasmas.~1
mitochondrial/lysosomal~1
lysosomes:~1
1.235~2
co-sediment~1
light)~1
dense).~1
lysosome-like~1
subfractionated~1
'microsomes'~1
Cd-thionein,~1
endosome~1
Cd-thionein~1
(109Cd)~1
PG,~1
stopped-flow~1
systolic-hypertension~1
Semiquantitative~1
diabetes.(ABSTRACT~1
Henle's~1
-replete~2
Unidirectional~1
45Ca.~1
calcidiol~1
Al-related~1
(AL,~1
(TPTX-AL,~1
(TPTX-C,~1
(Rbf)~1
TPTX-AL,~1
Rbf~2
TPTX-AL~2
TPTX-C;~1
(CCD),~1
(OMCD)~2
(IMCD).~2
(pHs)~1
(EH)~1
double-barreled~2
CCD,~1
pHs~4
7.71~1
7.72~1
7.27~1
EH~5
equilibrium)~1
-15.3~1
-31.3~1
(peritubular~1
6.8)~1
HCO3-concentration~1
pHs,~1
OMCD~2
6.57~1
6.58~1
6.47~1
57.7~3
5.51~1
5.67~1
7.36~1
OMCD.~1
CCD~2
gradient.(ABSTRACT~2
biologically-inactive~1
(i-PTH)~1
syn~5
b-PTH~5
i-PTH.~1
prehypertensive,~1
Superimposition~1
sodium-excretion.~1
mmol/day,~1
normalized;~1
potassium-remediable~1
AII-dependent~1
(LVEDiD)~1
(5.58~1
5.05~1
wall-thickness~1
(r/Th)~1
(3.65~1
0.44;~1
(LVPWT)~1
r/Th~4
LVPWT~3
double-labeled~1
(i.m.)~2
micrograms/liter~1
flameless~1
124.7~1
192.4~1
micrograms/liter.~1
76.8~1
35.3%~1
23.2%,~1
1.61~1
deferoxamine.(ABSTRACT~2
thicker/ulcerated~1
Clinical/pathologic~1
supraclavicular,~1
mediastinal,~1
prostatic-specific~1
cytopathology~1
(TCC)~1
TCC,~3
chalazion.~2
(396~1
Comparably~1
(SCS)~1
small-tumor-bearing~1
(STBM)~1
large-tumor-bearing~1
(LTBM)~1
S13~1
foot-pad~1
SCS~6
takes.~1
STBM~1
LTBM~1
small-tumor~1
large-tumor-resected~1
(LTRM)~1
faded.~1
Enhancing~1
S13-tumor-bearing~1
(TBM)~1
S13-tumor-resected~1
(TRM)~1
magnetic-loop~1
(popliteal~1
prefemoral)~1
(popliteal).~1
anesthesiologist,~1
interdepartmental~2
IORT.~1
mammaplasty~4
mammaplasty,~2
silicone-gel-filled~1
open-lung~3
lung;~1
Chromosomally~1
myxomas;~1
45,X,-Y,+7,-18~1
45,X,-Y.~1
telomere-to-telomere~2
telomeres~1
2qter~1
12pter~1
Yqter~1
chromosome),~1
tetraploid.~1
neoplastic;~1
"Does~1
legs?"~1
Track~1
touch-pressure,~1
vibratory,~1
(coronal,~1
transverse).~1
(yttrium-aluminum-garnet)~1
(SNO2)~1
dangerously~1
SNO2~1
accurate;~1
ensue~2
matching)~1
transfusion--even~1
cases--if~1
inexpensively.~1
"chronotropic~1
incompetence"~1
adnexa~3
conservative--that~1
Lastly,~3
staffs~2
laboratorians,~1
consultant,~1
F9~2
3.10~1
angina-like~1
edrophonium-stimulation~1
irritability~2
akathisic~2
non-akathisic~1
-0.42)~1
(AIO)~1
fertilisation~1
ova.~2
Flanders~1
AIO~3
(0.45%)~1
triplets.~1
twinning~1
Finland,~1
Iceland,~2
organised~4
(0-74~1
also;~1
Nordic~1
prospects.~1
flexible.~1
Polymorphic~1
Huntington~1
informative,~1
Partly~1
non-alcoholic-related~1
steatohepatitis,~1
desferrioxamine,~1
inconvenient.~1
1,2-dimethyl-3-hydroxypyrid-4-one~1
(L1).~1
Gelatin~1
desferrioxamine.~1
categories--the~1
Dukes~2
(OG),~1
OG~7
non-survivors~1
(arterial~2
hepaplastin~1
non-aminoacid~1
aminoacid~1
Labelled~2
bronchiectatic.~1
inflamed.~1
chiasmal~3
76-160~1
nmol/l)~1
0.5-5.0~1
rice-growing~1
Philippines,~1
smallholdings~1
link:~1
unsafely;~1
exposed;~1
underestimate.~1
out-of-hours~1
on-call~1
house-surgeon,~1
firms.~1
house-surgeon~1
registrar~1
firms~1
ward-rounds~1
weekends~3
weekend~1
alcohol-fixed~1
antibody-positive.~1
luteinising~1
non-antigen-specific~1
Fc-receptors~1
corticotropin-cells~1
corticotropin-cell~1
adenectomy.~1
epidermal-growth-factor~1
(EGFR)~1
EGFR+~3
EGFR-~1
ER+~2
EGFR-.~1
"double-negative"~2
EGFR~3
divides~1
lymph-node-negative~1
lymph-node~2
sexing~1
(15),~4
gene-probe~1
(among~1
cultured]~1
miscarried~1
fulfil~1
eclamptic~1
pre-eclampsia.~1
(7-20~1
refinement,~1
marginal,~1
utilisation~1
legumes,~1
cereals.~1
anterior-lateral~1
amperages.~1
autoinflation~2
preinflation~1
postinflation~1
tympanometry.~1
(MRT)~2
(equivocal)~1
infradermal~1
MRT~4
1:500~1
wt/vol~2
HPV-6~1
Latent~1
(78.5%)~1
radiotherapist~1
portals.~4
perichondritis~1
laryngectomy,~1
"standard"~1
extrameningeal~1
exceptional.~3
Meningioma~1
deficits;~1
intracranial-extracranial~1
pinnacle,~1
priority.~1
audio~4
translabyrinthine~1
removals.~1
hypoglossal-facial~2
Grading~1
(H/N~1
ca~5
LMWFs),~1
P15E,~1
(MuLV).~1
LMWFs~4
DNFB~4
neutralizable~1
P15E.~1
P15E-like~1
(homosexual~1
prostitutes,~1
hemophiliacs,~1
immigrants),~1
microsomic.~1
Lymphocytic~1
otolaryngologist~2
(PAIDS),~1
Otolaryngology.~1
Thorough~1
supraorbital~2
nasoethmoidal~1
orifices.~2
(phototubometry).~1
photodiode~1
phototubometric~2
phototubometry~1
(TVP)~1
judges,~1
proficiencies~1
12);~2
electrolarynx~2
11);~3
rated.~2
pitch,~1
intelligibility,~1
communicative~1
tympanostomy~3
earplugs,~2
earplugs~1
nonodontogenic~1
intralaryngeal~2
Postulated~1
hyperfusion~1
resistor,~1
widely-used~1
telescopes.~1
Nagashima~1
SFT-I,~1
4450.57,~1
Karl~1
8702~1
JVC~1
GX-N8U~1
Panasonic~1
8600~1
one-tenth-inch~1
zoom.~1
telescopes~1
stroboscopic~1
fogging,~1
laryngologists~1
buying.~1
(mto)~1
mto~2
Tubocurarine~1
myotonic.~1
(dy/dy)~1
"myotonic"~1
(CPEO).~1
"myopathic"~1
Jitter~1
CPEO~2
(NMJs)~1
micron2~2
terminal.~1
nonbifurcated~1
nitric~1
Immunodeficiency~1
(ARP)~1
(RRP)~1
RRP.~2
RRP~4
ARP~2
3000-8000~1
Years~2
gastrocnemius.~1
Miyoshi~1
C-protein~6
slow-~1
fast-type~2
C-proteins~1
coexpressed~1
posthatch.~2
PM,~1
slow-type~2
posthatch~1
Duchenne-type~1
sites)~2
adynamia~1
episodica~1
hereditaria~1
myotonia.~1
[K]e,~1
-63~1
inexcitable,~1
paralyzed.~1
[K]e~1
Hydrochlorothiazide,~1
hamartomatous~5
percent)--gastrointestinal~1
nongastrointestinal~2
(interval~1
64).~1
arose)~1
arose).~1
aggregability~5
increased)~1
mornings~2
cause--effect~1
pylori~5
SD],~1
campylobacter.~1
pylori,~1
urease-screening~2
pylori.~2
gastritis)~1
gastritis).~2
unrecognized.~1
kinase;~1
remit~1
myoneuropathy~1
vacuolar,~1
neurosyphilis~3
meningovascular~1
neurosyphilis)~1
(HIV).~1
benzathine~1
Meningovascular~1
Neurosyphilis~1
(1,25-(OH)2D3)~1
[3H]1,25-(OH)2D3~1
Nmax~2
receptors)~1
recombinant-DNA~1
multigeneration~1
restriction-site~1
penicillin-sensitive~1
0.0038),~1
0.0032),~1
0.010),~1
condition)~1
0.0030).~1
0.0298).~1
episodes),~1
0.0012).~1
electromyographic,~1
muscle-biopsy~2
poliomyelitis--13~1
myofibers)~1
neural-cell~1
motor-unit~1
cardiogenesis.~1
genetically,~1
2343~2
preexcitation;~1
dihydropteridine~1
(DHPR)~1
tetrahydrobiopterin,~1
DHPR~5
biopterin~2
7.7)~1
aluminum-chelating~1
c-Ki-ras~1
RNAse~1
K-ras~1
Intrastriatal~1
excitotoxic~2
kainate~1
ibotenate)~1
3-5-fold.~1
sub-class~1
co-localized~1
NADPH-diaphorase.~1
Beal~1
intrastriatal~1
quinolinic~2
quinolinic-acid-induced~1
Phenylketonuria~1
(PKU)~2
(PAH,~1
4-monooxygenase,~1
1.14.16.1).~1
PKU~3
PKU,~1
C-to-T~1
Trp)~1
PAH.~1
glycerolipid~1
organelle,~1
megaterium,~1
phospholipid-translocating~1
Bretscher~1
'flippase'.~1
flippase~1
self-replicate.~1
complements~2
mononucleotides,~1
self-replicating~1
condense~1
ribonucleotides.~1
purines~2
3'-amino-3'-deoxynucleotides~1
dimers.~1
tetranucleoside~1
triphosphoramidate~1
GNHpCNHpGNHpCN3~1
GNHpCNH2~1
pGNHpCN3,~1
autocatalytic,~1
(streptomycin,~1
spectinomycin,~1
edeine,~1
hygromycin~1
neomycins)~1
16S~2
rRNA.~1
Ivermectin~1
(22,23-dihydroavermectin~1
B1)~1
unpredecented~1
cattle,~3
horses,~2
nematodes,~1
warble~1
mites,~1
ivermectin~4
insecticidal~1
dung-breeding,~1
haematophagous~1
Diptera.~1
cowpat~1
fauna~1
rumenal~1
dung-degrading~2
Faeces~3
invertebrate~1
pastureland.~1
'point-to-point'~1
'paracrine'~1
neurotransmitter,~1
circuitry.~3
(pcd)2,~1
primordia~1
Grafted~1
timetable~1
clock.~1
recreating~1
(MTX)-resistant~1
frm~1
BU25,~1
250-~1
300-fold).~1
cell:~1
(HeLa~1
BU25-10B3)~1
pulsed-field~1
field-inversion~1
(kb).~2
wanes~1
boosted,~1
contagiousness.~1
picornavirus~1
picornaviruses~2
alpha-bungarotoxin,~1
(mAb35)~1
Electrophorus~1
(mAb270)~1
(P.J.W.,~1
Liu,~1
Shimasaki,~1
Esch,~1
Morley~1
J.M.L.,~1
preparation),~1
rat-neuron-like~1
PCA48)~1
mAb270~1
ion-channels~1
sub-conductance~2
partially-occluded~1
equally-conductive~1
K-selective~1
Amphiuma.~1
gate,~1
two-state~1
(open~1
closed)~1
unison.~1
obeying~1
(BaP)~1
epoxide-deoxyguanosine~1
carcinogen,~1
7,12-dimethylbenz[a]anthracene~1
(DMBA)~1
carcinogen-deoxyadenosine~1
bay~1
epoxides~1
benzo[c]phenanthrene~1
(BcPh)~1
initiators,~1
configurationally~1
isomeric~1
1,2-epoxides~1
BcPh~1
(Parameter~2
R)~1
0.69)~1
0.65).~1
occluder.~1
absolute)~1
four-grade~1
HBO-treated~1
Prompted~3
oblate~1
spheroid,~1
("facet~1
rhizotomy")~1
(SERs)~1
SERs~2
g-cm.~1
lidocaine-~1
antiischemic~1
(DID),~1
DID.~2
complicated,~1
DID~2
vasoreactivity.~1
collagenous,~1
reticular,~1
coarser~1
(30-minute),~1
mg/kg/minute~1
Monitored~1
(EEG).~2
normocarbia~1
(PCWP)~1
"preload"~1
PCWP~2
preload).~2
bursts/minute)~1
PCWP.~1
38.6%~1
allowed.~1
scans--suspected~1
neurotrauma,~1
1,3-bis-(2-chloroethyl)-1-nitrosourea~1
territory;~1
BCNU;~1
BCNU-related~1
cubicle~3
removable,~1
iridium-192.~1
shields~1
routines.~2
mR/hour/mg~1
radium-equivalent~3
192Ir.~1
mR/mg~1
192Ir~4
0.26.~1
nurse-hour)~1
teams;~1
radioisotope~3
Narrowing~1
laminar,~1
T10-T-12~1
indriven~1
Iran-Iraq~1
war.~1
debridements,~1
(62)~1
Nemazee~2
(38.4%,~1
19.5%,~1
albus~1
30.8%~2
gram-negative.~1
mater.~1
penetration).~1
abscess),~1
centers.(ABSTRACT~1
Craniometaphyseal~1
cerebellar.~1
Intratumoral~1
temporal-middle~1
Klippel-Feil~2
neuroschisis~1
etiological,~1
pathoetiology~1
(OXY)~1
OXY~3
heatstroke~3
Mecca~1
pilgrimage.~1
areflexia,~1
(chewing,~1
smacking)~1
pancerebellar~1
Dystonia,~1
"off-period"~1
dystonias~1
(ALD).~1
26-week~1
lecithin.~1
nondrug~3
spectrally~2
protanopia~1
segregated.~1
Genotypes~1
close;~1
(VCO2)~1
(40K~1
(-9%),~1
(+17%).~2
hypometabolism~1
lipofuscinosis~2
CTs~1
fugax,~1
gaze-evoked~4
sprouting.~1
(SAS)~1
(brainstem~1
[BAERs])~1
BAERs~1
SAS~1
SAS.~1
transience~1
(CIIP)~1
CIIP~1
(SFM)~1
oscillate~1
spillover~1
somatostatin-containing~1
neurotransmitter)~1
scleromyxedema.~1
IgG-type~1
Carboxyl~1
alpha-amidation~1
alpha-amidating~2
peptidyl-glycine~1
alpha-amidated~1
slurred~1
weakness;~1
operculum.~1
Sturge-Weber-Dimitri~1
cardiopathy~1
expressivity~1
chlorpheniramine,~1
immunization-induced~1
1,704~1
(FSP).~1
alpha-gamma~1
PGM1~1
FSP~2
globulin)~1
(4q11-q13)~1
(1p34-p36).~1
(A9/A10),~1
[3H]diazepam~1
(CVT)~1
neurovisual~1
CVT~5
(PVER)~1
PVER~4
papilledema~1
pseudopapilledema.~1
corticofacial~2
platysma~2
Descending~2
carbidopa.~2
3-O-Methyldopa~1
limbic-cerebellar~1
trimethyltin~1
(TMT).~1
disorientation,~1
organotin~1
undemented~1
proprioception,~1
organize~2
arousal,~1
institutionalization~2
23.9%,~1
9.5%.~1
62.8%.~1
(free-running)~1
bent-tipped~1
endolaser~2
fornix-based~3
ciliochoroidal~2
hypotony.~1
Saint~1
Lucian~1
limbal-based~3
(NVG)~1
12-14~2
NVG~1
glaucoma:~1
excavation,~2
externo~1
Fiberoptics~1
tips,~1
(333~1
corneoscleral~3
Corneoscleral~1
created,~1
IOLAB~1
AZAR~1
91Z~5
hyphema,~2
UGH~1
vaulting,~1
notified~2
traumatizing~1
manufacture,~1
blepharoptosis~2
(sea~2
fan)~1
Multifield~1
(PCRP).~1
stratified,~2
Amsler~1
(44).~1
Hippel~1
nystagmographic~1
[123I]-5-iodo-2-thiouracil~1
(123I-ITU)~1
radiopharmaceutical~2
123I-ITU~3
collimator,~1
123I-ITU.~1
thiouracil~1
67Ga-citrate,~1
Granular~2
(Myoblastoma)~1
adnexa.~1
trabeculectomy,~1
juxtafoveal~4
monochromatic~3
73.2%~1
93.4%~1
carboxyfluorescein~2
photocoagulated~2
M/kg~1
probenecid-treated~1
antenna~1
funduscopic,~1
visual-evoked~1
resulting,~1
6/24~1
pallor.~2
incidious~1
orbita.~1
Severin-type~1
2.4%,~1
unplugging~2
Gaze-evoked~1
amaurosis,~1
alarming,~1
(MG)~2
ophthalmoplegia.~2
MG,~3
(CNP),~1
(PEO)~1
ductions~1
EOG,~1
(outliers).~1
CNP~2
PEO~1
PEO.~1
antiaggregants,~1
horizontal,~2
vertical,~2
cyclorotary~3
diplopia.~2
Reproducible~2
transpositional~2
lamella.~1
standpoint.~1
Midfacial~1
dacryocystitis.~1
(RMS)~1
(1461~1
(clinicopathologic~1
RMS~1
salvaged)~1
palisading~1
(neuropil),~1
rosettes.~1
(gemistocytoid)~1
processes;~1
perikaryon~1
interweaving~2
(neurites);~1
Nissl~1
neuroblastic~2
plasmacytomas.~1
IgG-kappa;~1
IgG-kappa.~1
melphalan/prednisone,~1
plasmacytoma,~1
hematic~1
nonenhancing,~1
Feuerstein~1
Mims.~1
Jadassohn,~2
necessarily,~1
Juxtalimbal~1
epibulbar~1
plical,~1
caruncular,~1
invaginations~1
push~4
Mucus-producing~1
(Schneiderian)~1
Hemifacial~2
(HFS)~3
(cranial~1
VII).~1
compresses~1
advocated,~2
exacerbated.~1
HFS~12
unforseen~1
pseudophakia,~1
reattached,~1
retinopexy.~1
buckling,~1
new/missed~2
endophthalmitis,~1
retinopexy,~1
buckling.~1
reattachment.~1
fish-egg~1
pearly,~1
sheen.~1
cinemicrography,~1
lamellipodia.~1
sailors~1
sal~1
hand-over-hand~1
manner.)~1
engulfed~1
reel~1
Exchanging~1
controllable.~1
(61%).~1
Choroidal~3
MRIs.~2
58%.~3
Proximity~1
(64.6%)~1
20/200,~2
electro-oculogram~1
ramifications.~1
accountable~4
Retinoblastoma,~1
bilaterality~1
"trilateral~1
retinoblastoma."~1
(WCRHs).~1
WCRH~1
WCRHs.~1
WCRHs~3
thrombocytosis,~1
Microaneurysms~2
WCRHs,~1
meningo-encephalopathy~1
placoid~1
epitheliopathy~1
(APMPPE).~1
APMPPE~3
meningo-encephalopathy.~1
meningo-encephalitis,~1
hazy~1
subterminal~1
spores.~1
septicum,~1
gas-forming~1
(RPE),~1
septicum~1
panophthalmitis.~1
(ROP),~1
case);~1
fibrous-appearing~1
ROP.~1
retrolental~2
sky~1
(34.7%).~1
(CLBP),~1
CLBP~2
Composite~1
statistically:~1
(PFS)~1
non-pain~1
Self-Rating~3
PFS~2
'depressive~1
PFS.~1
(31.0%)~1
'action-proneness'~1
HAB~1
questionnaire),~1
'non-organic'~1
'action-prone'~1
(CLBP)~1
Attrition~2
dysesthetic~2
(McGill~1
Sternbach~2
Scale)~1
function-limiting~2
(DPS).~1
'cutting,'~1
'burning,'~1
'piercing,'~1
'radiating'~1
'tight.'~1
DPS~1
dysaesthesias~1
spondylopathic~1
paraesthetica,~1
pyriformis~2
allodynia~1
musculocutaneous,~1
in-patients~3
out-patients;~1
out-patients.~1
0-100~2
methadone)~1
3-821~1
'transgression'~1
laboratory/radiologic~1
nephrologist~1
kL/Pcr~1
habitus~1
Pcr~1
36,729~1
3200~1
2282~1
(C-S)~1
line-associated~1
Apnea/bradycardia~1
Slime~1
C-S~4
phage~1
Mucocutaneous~1
slime-producing~1
slime~5
noncomparative~1
temporarily)~1
(immune)~1
(non-immune)~1
H1-specific~2
(HIV),~1
toddlers.~1
givers~1
(779~1
pediatricians).~1
life-styles.~1
chloride-deficient~2
-.55,~1
-.51,~1
-.75,~1
McCarthy~1
Abilities~1
.59,~2
.58,~1
.74,~2
mentions~1
aspiring~1
flu~1
chickenpox~4
81-mg~1
analgesic/antipyretic~1
outgrown~1
(epilepsy)~1
"benign~1
epilepsy"~1
Japan's~1
mass-screening~1
near-miss~2
mouth-to-mouth~1
revive~1
disputed.~1
72-hour-old~1
beagle,~1
hypercarbic.~1
sodium-treated~1
Yates~2
correction).~1
Dinamap~4
oscillometric~4
(ranges~2
coefficient)~2
5.36~1
.97)~1
1.10x~1
.903)~1
1.06x~1
.917)~1
1.60x~1
68.23~1
.872)~1
1.38x~1
16.47~1
.874)~1
-0.24~1
4.74~1
4.56~1
-1.65~1
8.70~1
method.(ABSTRACT~1
Diffusive~1
Respirator,~1
(pH,~1
PO2),~1
diatheses,~1
tracheobronchitis~1
endrin~3
subdistrict~2
Talagang,~1
Attock~1
District,~1
Punjab~1
Pakistan.~2
surveyed;~3
152)~1
September.~1
Endrin~1
thermometer-manufacturing~1
nonworkers'~1
Mercury-in-air~1
mucolipidosis~2
mucolipidoses.~1
hemangioendothelioma~1
hemangiomatous~1
anemic,~2
long-lasting,~1
Prensky's~1
migraines~2
migraine;~1
(killed)~1
(live)~1
hemoglobinopathies.~2
infections--especially~1
odor,~2
upset.~1
dietary,~1
affliction~1
humanity.~1
formulating~2
Sometimes,~1
hinder~2
Clues~2
35;~1
ever";~1
bruits,~1
Referral~1
Headaches~1
(HPDP),~1
healthcare,~1
HPDP~1
level:~1
broaden~1
organizational,~1
lobbyist).~1
misinformation.~1
cardioverter-defibrillator.~3
"problem"~1
"masked~1
depressives"~1
category--those~1
person"~1
productively.~1
legitimizing~1
delusions,~2
lethargy~1
calm~1
Anorectic~1
(lean)~2
blunted,~1
Bulimic~1
Hyposensitization~2
Vasomotor~1
calipers,~1
.62~1
.85~1
.79~1
.91~1
sit-in~2
Hubbard~2
Massage~1
rotators,~1
.94~1
rotators~1
extensors)~1
dynamometry~1
time-rate~2
tension-maintaining~2
isometrically~2
isokinetically~1
degrees/sec~1
(EEFT)~1
(MVIC)~1
MVIC.~1
.83)~1
.92,~1
EEFT~1
Coordinator~1
ACCE's~1
ACCEs~4
burnout.~8
inventory,~1
ACCE~1
169).~1
(66.3%)~1
ACCEs,~1
creativity~1
outweight~1
doctoral~1
dissatisfaction;~1
tenure-track~1
syringe,~1
breast-fed.~1
lip.~2
mucoperiosteal~2
sling.~1
pared~1
palates~1
show.~1
lax~2
malar~2
blepharoplasty.~1
tarsus~1
blepharoplasty,~1
scalp-reduction~1
Juri~1
natural-appearing~2
forward-growing~1
inartistic~1
ala.~2
fat;~1
flipped~1
book.~1
gracefully~1
twists~1
sculpture~1
thoracic-wall~1
endeavors.~1
recontouring~1
chest-wall~1
carinatum,~1
(Poland's~1
submuscular~1
lawyers,~1
(AMA)~1
book~1
Guides~2
Impairment,~1
grafted;~1
whole-man~3
(WMI)~1
Impairment.~1
contradict~3
perichondrial~2
fluorochrome~2
Enveloping~1
(partially~1
devascularized),~1
16.72~1
16.45~1
devascularized)~1
10.97~1
24.02~1
47.75~1
free-flap~1
(fibula,~1
disease--occlusion~1
arteries--was~1
"moyamoya~1
vessels"~2
(CT)-guided~1
non-diagnostic~1
brushings,~3
hili~1
lymphadenitis.~1
paratracheal~6
specialists,~1
obstetricians-gynecologists~1
Internists~2
overdilation,~1
severed,~1
neomedia,~1
vasorum.~1
transjejunal~1
jejunobiliary~1
placed;~1
(94.0%),~1
spermatic)~1
pampiniform~1
(88.8%),~1
IVb).~1
(6.0%),~1
Peyronie~1
impotence),~1
venocclusive~2
Pharmacomanometry,~1
(PMEF)~1
Pharmacocavernosography~1
(key~1
cinecavernosography~1
corpora.~2
(n),~1
(cardiac,~1
artifacts)~1
degrading~1
(n)b~1
-0.42,~1
ghosting~1
0.40).~1
breathhold~1
artifacts,~2
spacing~2
specified,~1
low-and~1
meta-iodo-benzylguanidine~1
scintiscanning~1
carcinoids.~4
I-131~2
scintiscans~1
narrowings,~1
pseudocapsules.~1
600/25~1
hyperintense~1
2,000/60~1
Pseudocapsules,~1
Paget~3
archives~1
blastic,~1
flame-shaped~1
demonstrated:~1
preodontoid~1
overtake~1
osteosclerosis.~1
arcs~4
Autosomal~2
L-3~1
L-4~1
(perfect~2
specificity)~1
single-energy~1
Scoliosis~4
misrepresent~1
histographic~1
endosteal/periosteal~1
sequences;~1
96%).~1
non-oat-cell~1
5,000-5,900~1
Paraaortic~2
4,200-5,000~1
(42-50~1
150-180~1
(1.5-1.8~1
anteroposterior-posteroanterior~1
23-120~1
thermoradiation~2
20-70.2~1
(50%-80%),~1
compensation,~1
claimants~1
head-capitellum~1
capitellum.~1
typical,~2
(ionic~1
58.9%)~1
(4-~1
5-F)~1
Ferrites~1
magnetically~1
miscible~1
ferrites~3
studies--plain~1
examination--revealed~1
thumbprinting~1
spiculation.~1
"fistula"~1
cryosections.~2
Disk~2
Lower-space,~1
single-contrast~6
dual-space,~3
arthrotomography~3
84%)~2
arthrograms,~1
lower-space,~2
clicking,~1
catching,~1
locking,~1
hemorrhagic,~1
(TR)/short~1
long-TR/long-TE~1
deposition;~1
evolution;~1
cryomicrotomy~1
10-69~1
meniscuslike~1
impingement,~1
coil,~3
5-mm-thick~1
pulsing~1
(herniation/bulge)~1
45-54~1
intraforaminal~1
nonmyelinated~3
garfish.~1
garfish,~1
protons.~2
Double-contrast~1
oropharynx.~1
cisterns,~1
herein;~1
100-~1
1,000-fold.~1
left-lower-limb~1
left-iliac-artery~1
enteroprosthetic~2
flora;~1
aortoduodenal~2
Uruguay~2
1956.~2
Coxiella~2
burnetti,~1
swine,~2
fowl~1
1,358~1
(814~1
confirmed)~1
meat-processing~1
plants.~1
agglutination,~1
microagglutination~1
oversupply~6
exists;~1
imminent.~1
waste,~1
opportunity;~1
radiospirometry~1
non-shunt~2
Palliative~2
136.7~1
106.1~1
W/min.~1
(116.7~1
W/min)~1
paracorporeal~1
Supplementing~1
(CK-MB).~1
(AMP)~1
(GMP)~1
additives,~1
freeze-clamped.~1
oesophagojejunal~1
Celestin~2
Pull-through~1
gastrotomy~1
Helsinki~2
leiomyomata,~1
1973-1982.~1
(38-76)~1
(29)~1
(20),~1
"surgical~1
survivors"~1
(4/29~1
(squamous~1
0.80).~2
(VC,~1
0.64)~2
(TLC,~1
0.71).~1
So,~1
MPAP.~1
monostrut~1
cineradiography~2
0.04-0.067~2
0.052)~1
0.046)~1
29/31~1
2.0-2.5~2
27/31~1
closing.~2
(12/20),~1
0.053-0.106~1
0.073)~1
0.040-0.106~1
0.061)~1
17/20~1
valves)~1
35-50~1
Messenger~1
Cell-cell~1
(INF-C)~1
9-O-acetyl-N-acetylneuraminic~1
receptor-destroying~1
(RDE),~1
9-O-acetyl-esterase.~1
RDE~2
di-isopropyl~1
fluorophosphate~1
(DFP).~1
[3H]DFP-labeling~1
DFP~1
DFP-treated~1
INF-C~1
9-O-acetylated~1
(dissociation~1
picomolar)~1
alpha-helix.~1
Design~1
fibroblast-populated~1
hertz.~1
amplitude-dependent~1
remodeling,~1
Crystallins,~1
taxon-specific~1
invertebrates~1
argininosuccinate~1
lyase,~1
tau-crystallin~1
SIII-crystallin~1
S-transferase;~1
pragmatism~1
role).~1
marriages.~1
first-cousin~1
platelet-secreted~1
promote,~1
cell-substratum~1
adhesion-promoting~1
vitronectin,~1
unthinkingly~1
calculatingly~1
suicidal;~1
manipulator~1
life's~1
safeguarded~1
Suicidal~1
hurt~1
patronize~1
"gay~1
bars"~1
T-helper/T-suppressor~1
nitrites~1
routinely,~1
penile-oral~1
55.5%~1
inapparent,~1
Farm,"~1
spiritually~1
Summertown,~1
Tenn,~1
vegan~4
vegetable)~1
vegans~1
protein-complementing~1
Preeclampsia~1
delta-6-desaturase.~1
775~1
"fast~1
foods"~1
(foods~1
testosterone-binding~1
Neoplasm~1
lymphoma).~2
(Eight~1
follow-up.)~1
(14%);~1
Erroneous~1
inexperience,~1
thyroidologist~1
cytopathologist~2
Shigella.~1
Campylobacter-associated~2
(ineffective~1
therapy);~1
Campylobacter.~2
diarrhea;~1
campylobacteriosis,~1
7a~2
definition),~1
Onsets~1
swum~1
trend).~1
Throat-swab~1
chlorinator~1
malfunctioned~1
July.~1
chlorination~1
nonsmoking)~1
(nonsmoking)~1
compartment-open~1
(Cl~1
(Vdarea)~1
Vdarea~1
Tetraplegic~1
11-beta-hydroxylation~2
step;~1
hypothalamic-pituitary-adrenal~2
insufficiency;~2
alkalemia~1
10,811~1
4,427~1
(40.9%)~1
7.44,~1
2,577~1
(23.8%)~1
7.48.~1
(213~1
7.48;~1
(61.9%)~1
(29.3%)~1
27.9%~1
48.5%~1
7.60.~1
(36.6%)~1
(44.2%~1
alkalemic~1
(27.9%~1
Alkalemia-associated~1
businessman,~1
governor~1
philanthropist~1
1937~1
Troy,~1
trust,~1
enormously,~1
interns.~1
actors~1
interns'~2
call.~2
interns~3
empyema.~1
wide-scale~1
hyperphosphatasemia~2
macroamylasemia,~1
pseudotumor,~1
endocrinologic,~1
allergic,~1
ophthalmopathies,~1
dual-lumen~1
strength-endurance~1
isometric-isokinetic~1
19-109~1
38-168~1
17-191~1
14-208~1
Sorensen~1
back-muscle~1
medium-high-frequency~1
Translatory~1
spondyl-~3
retro-olisthetic~3
translatory~2
L5,~2
L4,~2
L3,~1
L5.~2
retro-olisthesis.~1
Traction-compression~1
spondylolisthesis).~1
spines.~3
inclinometers~1
afternoon.~2
creep.~2
spine's~1
disc)~1
laborers~1
lifted~7
crate~1
lordotic~3
kypohotic~1
lift.~1
L3~3
kN.~1
0.82).~2
load-deformation~1
(T12-sacrum)~1
potted~1
topmost~1
Selspot~1
injured)~1
(Luque~1
rectangle)~1
decompression)~2
motion--in~1
modes--indicating~1
behavior).~1
2,905~1
T1-L5.~1
Pedicles~1
L5~5
T5~1
width.~1
T12.~3
cephaladly~1
L3-T1.~1
T12~1
T11.~1
halo-vest,~1
1976-1984,~1
(comprising~1
18.7%)~1
tetraparesis.~1
Anderson-d'Alonzo~1
flexion-rotation~1
Instituto~1
Ortopedico~1
Rizzoli~1
2-6),~1
halo-thoracic~2
placed,~2
atlanto-dental~1
occipito-atlanto-axial~1
versa)~1
vulnerable,~1
flexed.~1
whiplash~2
overstretching~2
2035~1
wage-loss~1
claims.~3
high-hour~1
feedback-oriented~1
(spondylosis,~1
post-laminectomy~1
postmyelography-proven~1
postmyelography-possible~1
(PID),~1
catalogued~1
interview;~1
(27/61)~1
(35/61)~1
(33/62)~1
(9/62)~1
(3/62)~1
postoperatively).~2
(14/33)~1
(5/33)~2
(15/33).~1
.57,~1
however.(ABSTRACT~1
Rotation~2
occiput-atlas~2
atlas-axis~1
one-sided~1
atlas-axis.~1
(irreversible~1
ligaments)~2
syringography~2
Cotrel-Dubousset~1
Diplomyelia~1
spur.~1
sign-and-symptom~1
spur,~1
diastematomyelia,~1
tether~1
derotation~1
(VDS)~1
VDS~1
centralized~1
midsacrum.~1
"saving"~1
interarticularis.~1
spondylolysis.~3
Scheuermann's~2
(clindamycin,~1
oxacillin)~1
Cephalothin~1
repetition,~1
echo,~2
timings~1
planners,~1
makers,~1
13.8%.~1
orthopaedists~1
nonbiologic~1
LBP,~1
Balans~5
semi-kneeling~1
flowimetry.~1
Comfort~1
Pedal~1
abdominis,~5
psoas,~1
spinae,~1
spinae.~1
(T2-weighted)~2
spondylolithesis.~3
discography,~2
Discography~1
fusions.~1
myelograms.~2
CT/discography~4
discogram~3
Discogram~1
(disc~1
protrusion/leaking).~1
CT/discographic~1
fourpoint~1
scale:~1
CT/discogram~1
subgrouping~1
(degeneration)~1
(disruption).~1
anteroposterior,~1
plication,~2
French.~1
(early~4
hypoglycemic)~1
occasional,~1
suffice.~1
proctectomy,~1
endorectal~1
pseudoaneurysm.~1
Variceal~1
1,953~1
(FNAC)~1
FNAC~2
FNAC,~1
mu/T4~1
Before,~1
Leu7~2
granulocytosis.~1
Leu7+~1
1,418~1
Florid~1
disease-induced~1
Nonthoracotomy~1
esophagostomy~2
Transpleural~1
nonthoracotomy~2
(relatively~1
(widely~1
pancreaticoduodenectomy~3
pancreaticocutaneous~2
Penrose~2
210.4~1
305.~1
bypasses).~1
guide,~1
exsanguinating~1
abdominal-right~1
tidy~1
Kocher~1
duodenotomy~1
ratchet~2
antesternal~2
esophagostoma~1
colostoma~1
protector~1
esophagogastrotomy~1
cutter~2
cutter,~1
dislodgement~1
thromboses,~2
tibioperoneal~1
related)~1
(technique~1
related).~1
thrombectomy;~1
postexploratory~1
Calibration,~1
cholangiogram.~2
ampulla,~1
moonlighting,~1
Debt~1
responsibilities.~4
Subspecialists~1
(loading~1
kilogram,~1
pattern--colon,~1
breach~2
enterococcus~1
Mezlocillin,~1
(polypropylene)~1
herniorraphy~1
kilograms.~1
IIIb~1
(lidocaine)~1
(viscose~1
faintness.~1
millimole~1
postprandially,~1
Hyperglycemia~1
faintness,~1
(dysphagia~1
distension)~1
symptomless.~1
anorectum.~1
sentinal~2
96.4~1
(209)~1
(117)~1
assess.~2
(66).~1
history;~1
Kline~1
Diagnostics)~1
device;~1
(Dukes'~1
curable.~2
Obesity,~1
non-obese~2
11.7.~1
intended.~1
impact,~3
Bridge~1
Harbor~1
25,650~1
fibroadenoma~3
(19)~1
gigantomastia~2
cystosarcoma~1
phyllodes.~1
childhood).~1
nears~1
tubing,~1
adapter.~1
17-beta~1
(b-HCG)~1
b-HCG,~1
(4,893~1
5,435~1
S.E.M.~14
milli-international~2
picograms~3
(b-HCG~2
22,173~1
2,696~1
0.00001;~1
20,310~1
1,688~1
milliliter),~1
"elderly,"~1
myeloradiculopathy~3
5.4%,~2
6.5%,~1
special-care-facility~1
population),~1
(11.6%),~1
neuralgias~1
(MPA,~1
Depo-Provera)~1
cytosols.~1
meningioma-PR:~1
0-69)~1
338.3~1
fmol/g~2
0-1190),~1
0-586)~1
2813~1
0-17,168),~1
PRs,~1
macroprolactinoma~1
macroprolactinomas,~2
attenuates,~1
YC-170~2
carotid-ophthalmic~3
intraaneurysmal~1
isobutyl-2-cyanoacrylate.~1
isobutyl-2-cyanoacrylate~1
clivus.~2
transoral-transpharyngeal~1
retroauricular~1
chordomas,~1
overemphasized.~1
tegmentum~1
supracerebellar~1
schwannoma,~1
cave,~1
"dumbbell"~1
calcium:~2
mg/dl);~1
adenomas--all~1
(nephrolithiasis,~1
nephrocalcinosis,~1
Anemia,~1
Warren~2
(expanded~1
polytetrafluoroethylene)~1
20.0%~2
3.4%;~1
month:~1
death:~1
3.4%).~1
metastatic,~1
used--nine~1
electrocautery,~1
188/113~1
(ERA)~1
ERA,~1
ERA.~1
ERA~1
(CEPA)~1
CEPA~6
Preanesthetic,~1
nitroglycerin-induced~1
3570~2
3463~1
4341~1
6350~1
CEPA;~1
3080~1
Eighteen-hour~1
3156~1
CEPA.~1
2.80~1
L/min-m2~4
3.07~2
gm-m/m2~2
unclamping~1
onward~1
technique-related~1
(PYY)~1
(23.4~1
pmol/L;~1
subserosa~2
carcinoma--present~1
subserosa--had~1
Incidences~1
lymphatic,~1
musculature;~1
graft-independent~1
(0/8~1
4/5~2
high).~1
parathyroids~2
fossae).~1
Gradients~1
Autonomous~1
(lipopolysaccharide,~1
[LPS])~1
(CoQ10)~1
LPS-administered~1
69.7%.~1
CoQ10~2
42.9%,~1
antioxidants,~1
endotoxin-administered~1
(LeVeen)~1
centrifugation:~1
low-speed,~1
VIII-deficient~1
VII-deficient~1
ethylenediaminetetra-acetate~1
precipitate,~1
sedimentable~1
thromboplastin-like~1
death--compared~1
population--appeared~1
procedures--particularly~1
nature--are~1
47%.~2
(PIB)~1
18-week~1
C-free,~1
hypercholesterolemia-inducing,~1
PIB~9
alfalfa,~2
(FA),~1
nonsaponifiable~1
(NSL)~1
14C-acetate~1
unweighted~1
(161%)~1
alfalfa;~1
NSL~2
alfalfa.~2
suppresses,~1
synergistically,~1
FA.~1
depilation~2
injections).~1
17.2%),~1
atheroembolism~5
atheroembolism,~1
atheroembolism.~2
atheroembolism:~1
irretrievably~1
asthenia~1
large-bowel~1
tomograms,~2
(preferentially~1
leukocytes)~2
coagulase-positive~2
Staphyloccus~1
mg/kg/8~2
7);~1
aureus/gm~1
organisms/gram~1
sterile--a~1
commendable.~1
multiple-system~1
clearing.~1
SACE,~4
indices).~1
(radiograph,~1
comparison;~1
two.(ABSTRACT~1
silos~1
mycotoxicosis)~1
3.3)~1
mould~2
10(9)/l.~1
done;~1
silage~2
mis-diagnosed~1
mycotoxicosis~1
(organic~1
silo~1
mouldy~1
unloading.~1
(transfer~1
factor).~1
increasing,~2
(82)~1
407~1
(84)~2
lungs--that~1
(RV/TGV)~1
(0.246~1
(0.036)~1
(0.114~1
(0.026)~1
(0.126~1
(0.017)~1
g/ml).~1
sniff~3
(sniff~1
Pdi),~1
(PImax),~1
OKY-046,~3
AA-861,~2
(PC20~1
(1100~1
OKY-046.~1
AA-861.~1
first-ever~1
"inappropriate"~1
0.33/1,000.~1
1977-1983,~1
TIA,~2
TIAs),~1
accessed~1
1961-1973.~1
arrhythmias;~2
2,077~1
Pennsylvania-western~1
Jersey.~1
lacunes~1
0.029);~1
30-36%)~1
47%)~1
22:5,~1
poststroke,~2
fluctuated--with~1
remits~2
Fundus~1
(45Ca)~1
nifedipine)~2
calcium-deficient~3
near-maximal~2
loading;~1
nmol/g,~1
nmol/g.~1
potassium-stimulated~4
potential-operated~1
(potassium)~1
receptor-operated~2
(serotonin)~1
noninsulted~2
insulted~2
ice-cold~1
hemispheric,~1
(ml/100~1
g/min,~2
108.4~1
123.8~1
115.0~1
50.9~1
differences.(ABSTRACT~1
Recessed~1
(tip~1
stereotactically~1
(35.4~1
(33.6~1
(-dPO2/dt)~1
(23.8~1
torr/sec,~2
gerbils).~1
8.28~1
6.13~1
O2/100~1
torr).~1
iodoacetate~5
Hyposmotic~1
excitotoxins~1
medium-to-cell~1
nonetheless,~2
hypotonically~1
iodoacetate.(ABSTRACT~1
phenoxybenzamine-treated,~1
88,~2
phenoxybenzamine-treated~1
(2.3-fold~1
(2.9-fold~1
beta-wave~1
microgravimetry~2
osmotically-balanced~1
reproducibility,~2
34-year-old,~1
subclavian-left~1
artery-to-artery~2
outdating~1
Distribution,~1
outdate~1
99,251~1
group-specific~2
shortages;~1
differences;~1
importing~2
43,757~1
2050~1
outdated,~1
3908~1
36,501~1
(36.8%~1
509~1
donor-recipient~2
ABO-mismatched~1
outdating.~1
(FFP),~1
FFP~2
one-on-one~1
viscosimeter~1
HT:eta~2
HT:eta)~1
HS:HT~3
lowered:~1
steeply~2
(Hb),~1
(ZPP)~1
ZPP~6
-0.580)~1
donors)~1
-0.667;~1
iron-depleted~1
(hypoferritinemic)~1
bloodmobile~2
anti-HBs~1
464~1
4.25,~1
lymphocytotoxic~1
(LCTAb)~1
LCTAb~2
random-donor~2
alloimmunization.~1
nomifensine.~1
nomifensine-dependent,~1
metabolite-specific~1
purpura,~2
PlA1~1
(AET),~1
cephapirin~1
cephalosporin-coated~1
AET.~1
Co(a-b-)~3
Colton-phenotypes~1
proposita's~2
anti-Co3.~1
Co3~1
proposita.~2
8024~1
(BFU-E),~1
(CFU-MIX~1
CFU-GEMM)~1
1.5-hour~1
apheresis.~1
reconstitution.~1
leukocyte-poor~3
spin-cool-filter~2
RBC.~6
400-ml~1
bg~1
tested:~2
3-ml~1
tht~1
(390~1
shelf-life~2
open-system~2
small-volume,~1
marketed,~1
software,~1
unwise~2
euglobulins~1
kringle-4-binding-protein,~1
2-antiplasmin.~1
Nightly~1
CNS-symptoms~1
25),~1
key-questions~1
"difficulty~1
food"~1
"pain~1
chest"~1
"heartburn~1
night"~1
hypothetic~2
"70-year-old~1
Sweden".~1
82.~1
29%),~2
20%),~2
56%),~1
overmortality~1
(S-creatinine~1
cytostatics~1
melphalan-prednisolone~1
bed-side~1
non-coagulating~1
clumsiness~2
born,~1
adipositas~1
dolorosa~1
Dercum.~1
mexiletin,~1
jaws,~1
intelligibility.~1
eye-movements~1
non-participant~2
Welfare~1
non-participants.~2
304~3
utmost~2
1/1~1
restart~3
16-19)~1
syncopes,~1
21,000~1
(CVD,~1
ICD-8~1
nos.~1
430-438)~1
1970-1980.~1
17,629~1
(430-433)~1
1970-1975~1
cases/100,000~1
inhabitants,~1
(430-432),~1
(433,~1
434)~1
(435)~1
precerebral~1
hospitalised~2
(Sus~2
domesticus),~1
LCAT~4
lecithin:cholesterol~3
HDL3.~3
(alpha-LCAT)~1
arcus~1
cornealis~1
(LCAT),~1
hypoalphalipoproteinemias.~1
15-36)~1
exercise-induced,~1
1,25(OH)2D~1
1,25(OH)2D.~1
calcium-metabolic~1
Hyperlipoproteinemia~1
monozygotic,~1
brothers.~1
hypertriglyceridemia.~1
lipid-lowering~3
"atherogenic~1
index"~1
numerator.~1
xanthomata~1
hypercholesterolaemia.~1
troponin-I,~1
troponin-I~8
5384~1
IU/L),~1
cardiac-specific~1
13080~2
(imidazo~1
[1,5-a]~1
pyridine-5-hexanoic~1
streptokinase-induced~1
microA~2
oscillation/min~1
SEM)].(ABSTRACT~1
data);~1
bolus/5~1
(2350~1
1839~1
2583~2
1517~1
90.0~1
88.6~3
4021~1
(AMIS).~1
(1824~1
AMIS~1
(univariate~1
relationships).~1
Ligated~1
risk")~1
(37/1000~1
8/1000~1
infarct-and~1
noninfarct-related~2
antiprocainamide~1
immunostaining.~1
radiolabelling~1
pirmenol~32
QTc,~1
Electrode~1
(RAFW).~2
RAFW~3
ECA.~1
RAFW,~1
puppy~1
fulgurate~1
RAFW.~2
puppies),~3
puppies);~2
puppies).~3
(CD)~3
ECT:~1
puppy),~2
(AVB)~1
AVB~1
puppies;~1
infarct--a~1
"dead"~1
between.~3
CD.~2
Inferolateral~1
(apical~1
Doppler-defined~1
enlargement).~1
cc/sec,~1
(Q),~1
(DE).~1
(An)~1
(Pl)~1
(Rl).~1
(Ql).~1
Pl~2
152An,~1
Rl~2
1722An,~1
Ql~4
1.21Qn,~1
Pl,~2
Rl,~2
adequate)~1
3.51~1
8.39~2
0.80P~1
0.75R~1
0.87Q~1
DE~1
(doxorubicin)~1
(651~1
(668~1
worsens,~1
(IDC).~1
preejection~3
period/left~1
(PEP/LVET)~1
(0.637~1
0.457~1
0.097,~1
PEP/LVET~1
-0.76,~1
PESP.~1
Myotonic~1
(Wenckebach~1
type),~2
1876~1
all-cause,~1
biennially.~1
Shocks~2
Medtronic~2
6880~1
5350~1
configurations,~2
Transvenous~1
circuit,~3
"excitable"~1
termination.~2
"excitable,"~1
doxazosin,~3
C57BR/cdJ~1
lipases.~1
once-daily,~1
long-acting,~1
doxazosin's~2
doxazosin-treated~1
HDL/total~3
52-week~1
(5%;~1
(3.9%;~1
(5.4%;~1
O-demethylated~1
C-hydroxylated~1
liters/kg)~1
doxazosin;~1
Munster~1
(PROCAM)~1
PROCAM~1
cholesterol/high~1
women.(ABSTRACT~2
x-ray).~1
Calculators~1
5,209~1
limiting,~1
adequate-sized~1
(CK-MB),~1
Selvester~1
dyssynergic~1
(A/E)~1
A/E~4
(0.80~2
-0.60,~1
occlusion.(ABSTRACT~1
semisupine~1
[difference~2
significant])~1
significant]).~1
responses.(ABSTRACT~2
alpha-lipoprotein~1
alpha-lipoprotein),~1
(HDL-C%).~1
1,454~1
1,481~1
HDL-C%.~1
HDL-C%~6
669~1
853~1
Dyspnea,~1
nondyspneic~1
644~1
akinesia,~1
dyspneic.~1
Akinesia~1
(inferolateral~1
0.0001])~1
akinesia.~1
films.~4
1,344~1
1,350~1
equivalent),~1
S-wave~7
specific)~1
Vasodilatory~2
levels--2,~1
valve--by~1
planimetered~1
Distensibility~2
[2~1
(changes~2
diameter)/(diastolic~1
pressure)].~1
maneuver.(ABSTRACT~1
suddenly)~1
bruce~1
event.(ABSTRACT~1
(criterion~1
induce;~1
induce).~1
inefficacy,~3
Specificities~1
inefficacy.~1
(nonspecificity).(ABSTRACT~1
(CMT)~2
CMT~8
[CL]).~1
Entrainment~2
pathway;~1
(manifest~1
CL,~1
CLs;~1
CLs~1
leg-crank~1
nonlinearly~1
dobutamine);~1
(1,390~1
Hg/s,~1
ng/ml/hour),~1
inter-study~1
variabilities~1
differences)~1
+0.02~1
+0.01~1
ml/beats/m2,~1
(-614~1
-406~1
cm-5).~2
(CWD).~1
200-meter~1
jog.~1
CWD,~1
CWD~2
sedated.~1
sedated.(ABSTRACT~1
normal-term~1
mm/s)~1
mm/s).~1
0.87).~1
s-1).~3
56).~1
multivalvular~2
0.788,~1
(DC)~2
echograms~1
(h/R~1
Independently~1
(228~1
h/R~2
kdyne/cm2,~2
(meridional~1
DC.~2
(279~2
noninvasive/invasive~1
suddenly;~1
penetrance.~1
Pirmenol~11
pyridinemethanol~2
Preclinical~2
wastage.~1
2-compartment~1
Pirmenol,~1
chemically,~1
artery-ligated~1
(Harris)~1
pirmenol,~3
infusion-slow~1
utility.~2
pirmenol's~1
decreased.(ABSTRACT~1
pirmenol.~2
61);~1
half-lives)~1
times/day)~1
drug.(ABSTRACT~1
Reentry~1
paroxysm~2
Dosages~1
Oxylog~2
(PK~1
Morgan,~1
Kent,~1
UK)~1
Bag~1
(RMR)~2
+0.904~1
+0.934~1
Oxylogs~1
expenditure:~1
canopy,~1
noseclips.~1
hood,~3
(0.809~1
(0.837~1
0.043)~1
(0.847~1
0.045)~1
kcal/min~3
(17%~2
CHO,~1
loss:~2
workloads.~1
(736-1020~1
kcal/meal~1
EE)~2
kcal/min,~2
Body-fat~1
(weight--total~1
water/0.73)~1
Gambian~1
subsistence~1
farming~1
preharvest~1
shortages.~1
(gas,~1
diarrhea)~1
lactose-maldigester~2
lactose-digester~1
lactose-intolerant~1
milk-rejector~1
milk-related~1
pyridoxal~10
5'-phosphate~1
(PLP)~3
apodecarboxylase~1
(TDC)~1
PLP~14
14C-tyrosine~1
micro-modified~2
0.995,~1
(finger~1
prick)~2
Sumatran~1
(200,000~2
9776)~1
2447)~1
12,173).~1
nonrecipients~2
intent-to-treat~1
RRR-alpha-tocopherol~2
(d-alpha-tocopherol),~1
Aquabiosorb~1
(SEG)~1
standard-SEG~1
SEG~3
modified-SEG~1
bioavailability.~2
Histidine~1
zinc-histidine~3
1:12~1
serum-zinc~2
Influence~2
mated;~1
zinc-deprived~2
Endotoxin-activated~1
Marginal~1
midgestation.~1
mating,~1
(PHA),~1
ultrasound),~1
2248~1
56.6~2
phytate:zinc~7
1973-74~2
1980-82.~1
total-cholesterol~3
1980-82~1
1980-82,~1
cholesterol-intake~1
extracellular,~2
Warthin-Starry~1
(3PD).~1
3PDs,~1
3,861~1
3PD~2
0.883~1
0.868,~1
(0.492).~1
flag~1
blasts;~1
(NRBC)~1
WBCs;~1
monocytosis~1
1,600/microL~1
bands/microL~1
600/microL~1
10(9)L);~1
ochronosis~1
ochronosis.~1
probe-positive,~1
probe-negative,~1
2-4,~1
(1.3-123.7~1
(0.72-1.25~1
Methanol~1
aspartame~1
(Ohio)~1
diphtheria-tetanus-pertussis;~1
measles-mumps-rubella;~1
signature~1
variation),~1
[40~1
pg/mL])~2
pyrazinamide,~1
ethionamide~1
(TBM).~1
jaundiced,~1
(ALT),~1
U/L,~1
TBM~1
dies~1
terrible~1
overwhelm~1
rationalization~1
mourning.~1
reinforced.~1
anxiety-provoking.~1
frustration,~1
sadness,~1
regret,~1
hurt,~1
inadequacy.~1
blamed~1
sincerity,~1
mourning~1
blame.~1
neuroregulatory~1
taps~2
Calcitonin~2
ng/L~1
[14~1
pg/mL]).~1
"Deleading"~1
deleaded.~1
[Pb-B]~1
[33~1
micrograms/dL])~3
4.34~2
6.27~1
[90~1
scraping,~1
sanding,~1
paint.~1
mask-bag~2
mannequin~1
self-inflatable~2
hyperventilate~1
staff's~1
1988~1
$33,370.~1
inconveniences~1
outliers,~1
1852~2
8.46;~1
1358~1
6017~1
Antibacterials,~1
antifungal-anti-yeasts~1
amoxicillin.~1
1147~1
(CLD)~1
(NICUs).~1
NICUs~2
CLD,~1
CLD~3
881),~1
7.7%).~1
135,~1
13.3%),~1
non-chromosomal~1
embryopathies~1
embryopathy~2
cardiofacial~1
(subsibs)~1
subsibs.~1
subsibs~2
monitoring:~1
alarm),~1
22-item~1
fifth-grade~1
city.~2
grabbing~1
afraid~1
friendly~1
HBsAg-negative~2
HBsAg-positive;~1
34.4%,~1
1.2/patient/yr),~1
patient/yr).~1
(SGOT)~1
SGOT~1
micron/mL).~1
(DDS).~1
(spectral~1
analysis),~2
[CT]~1
brain)~2
HDF).~1
cuts),~1
post-HD,~1
post-H~2
HDF,~2
pre-H~1
post-HD~1
bicaudate~1
in-between-~1
within-treatment~1
EEG%~1
(3-7/7-13~1
Zuni~6
Zunis~1
(ESRD)~1
immune-complex~2
mesangiopathic~1
educed~1
Mesangiopathic~1
Indians'~1
ancestry.~2
jewelry-making,~1
potting,~1
ARF,~1
nephropathy-XY~4
phenotypical~1
sisters,~2
(Drash~1
(HDL-C).~1
1,146~1
483~1
HDL-C,~2
4,279,~1
1,807~1
735,~1
strata.~1
within-family~1
dyslipoproteinemia~1
HDL-C.~1
Path-analytic~1
Multiparity~1
pregastrin~1
1970)~1
post-gastrin~1
pre-RIA~1
"cure"~3
disseminating~1
absenteeism,~1
pneumonia-influenza~1
Influenza~5
aches~1
lassitude,~1
small-airways~1
Laryngotracheobronchitis,~1
Elizabeth~2
1889,~1
infamous~1
plagues.~1
influenza.~2
calculated--and~1
Special-risk~1
1930s.~1
Killed~2
immunosuppressants,~1
Vaccines~1
Target~1
Control.~1
discovered:~1
changed;~1
camouflage,~1
glycosylated.~1
recognize.~1
reassortment.~1
coinfecting~1
reassort~1
ribonucleoprotein~1
recombinations~1
unmatched~1
pandemic~1
perpetually.~1
polyvalent~1
hexavalent~1
12F;~1
octavalent~1
19F;~2
nonavalent~1
prevaccine~1
(t-test,~1
cultures).~1
amylases~1
Angiotensin-converting~2
476~1
exclusions~1
40.3%.~1
76.2%~1
69.2%~2
usage;~1
Astrand~1
exercisers~1
(19/453,~1
4.2%)~1
(21/1000,~1
2.1%).~1
(1/1000,~1
inconvenience,~1
schemes,~1
949~2
(22.1%)~1
Abstaining~1
Vasa~1
laparoscopies~2
free-standing~2
surgicenter~1
obstetrician-gynecologists,~1
free-standing,~1
clinical-pathologic~2
postmenopausal.~1
stored.~1
Dimethylsulfoxide~1
cryoprotectant~1
Embryo~1
1970s.~2
County/University~1
(Premarin,~1
micronized~3
(Estrace,~1
Estradiol,~1
Ever~1
4750~1
amniocenteses~2
Davis,~1
fifteenth~3
(transplacental~1
nontransplacental),~1
(96.8%).~1
(3.6%),~1
(0.7%),~1
(0.3%),~1
postprocedural~2
(14/298).~1
preamniocentesis~1
(7/211).~1
Miscarriage~1
(5/298).~1
nontransplacental~1
amniocentesis.~2
prismatic~1
intolerable,~1
intracameral~1
identically.~1
dampened,~1
bystanders.~1
photocoagulator~1
eyepiece),~1
Reflected~1
bystanders~1
nonischemic,~1
reviewer.~1
Intraexaminer~1
interexaminer~1
gas-fluid~1
aerial~3
ophthalmoscopy.~1
prism,~1
high-minus~1
cutter.~1
vacuolation~2
trilateral~1
neural-associated~1
(S-antigen~1
rhodopsin),~1
rhodopsin~5
360-degree~1
retinectomy~1
edge.~4
capuchin~1
ischemic-proliferative~1
pericytes.~1
away,~1
deeper,~1
Intraretinal~1
Rubeosis~1
fugax.~1
hemianopsia;~1
caruncle)~1
pagetoid~2
exenteration;~1
Histopathologically~2
sunburst~1
chloride-fixed,~1
specific-activity~1
(Mg)-sufficient~1
Mg-deficient~4
gnotobiotic~1
Mg-sufficient~1
unstressed,~1
seizure-shock.~1
seizure-shock~3
petechiae.~1
membranes;~2
(SMCs)~1
"hills"~1
"nodules,"~1
SMCs~6
adhesivity,~1
"multilayered"~2
agglomeration~1
"spheroids,"~1
low-adhesive~1
substratum,~2
agarose,~1
autodigestion~1
extracellularly,~1
SMCs.~1
spheroids.~1
Proteases~1
Homeostatic~1
amidine-type~1
(5-amidino-2-benzimidazolyl)methane~1
1,2-bis~1
(5-amidino-2-benzimidazolyl)ethane,~1
neuroepithelioma~1
microscopy;~1
uraniffin-positive~1
(NSE,~1
NFTP,~1
cholinesterase)~2
Askin,~1
(GPHLV)~1
(Cy).~1
Cy-treated~2
GPHLV~4
Cy-immunosuppressed~1
Cy-sensitive,~1
mg/kg/48~1
CyA-induced~2
vacuolization.~1
CyA,~1
manned~2
missions~1
crews~1
Earth,~1
missions,~1
spaceflights.~1
suggestions.~1
cruelty~2
32-year~1
back-ward~1
deinstitutionalization~1
mid-1950s.~2
mark,~1
recidivists.~1
rediagnosed~1
rediagnostic~1
covary~1
8-16)~1
Kiddie-SADS~1
(Schedule~1
Schizophrenia)~1
unipolar)~1
bisexual,~1
paraphilias.~1
(phototherapy).~1
gamblers~2
informants~1
Avoidant~1
Critics~1
schizoid~2
covariation~1
schizoid,~2
Items~1
avoidant~2
covaried~1
(DSM-III-R).~1
definition.~2
1088~1
1428~1
75-6186~1
(1688~1
1284~1
low-potency~2
phenelzine-treated~1
Phenelzine~1
anorgasmia~2
(MAOI)~1
Precipitously~1
late-night~1
early-night~1
American-Chinese~1
(75.9%)~1
blackouts,~1
naltrexone.~3
vignette.~2
Harsh~1
portrayals,~1
unreasonable~2
prejudicial~2
homosexuals.~1
non-aged~1
DPT~1
polio;~1
shot,~1
17-44~1
45-65~3
Pap~12
mammogram.~1
kinds,~1
cost-sharing~1
$22~1
$9~1
$97~1
mammogram~2
provider-initiated,~1
minimal-contact~1
(PI);~1
(PI/M);~1
(C).~1
(self-efficacy).~1
stopping,~1
PI/M~1
(skull~1
disability),~1
1977-81.~1
disability;~1
biases.~1
offspring's~1
birth/fetal~1
9,411~1
Natality~1
Surveys)~1
residence-based~1
Sacramento~1
0-19~1
1974-84.~1
15-19~1
alcohol-associated.~1
childbirth,~1
1,083~1
751.~1
35,89,~1
contraceptive-associated~2
sterilizations,~1
contraceptive-related~1
legalization~1
abridged~1
3,132~1
non-somatizers;~1
somatizers~3
non-somatizers~2
trend;~1
quitters~1
quitters,~1
1969-80~1
workplaces~2
486,400~1
102,700~1
376,200~1
shipyards,~1
insulators.~1
(FSP),~1
Nonpsychiatric~1
nonobstetrical~1
inmates~1
lifestyles~1
World's~1
Fair.~2
Heat-related~1
Fair~1
fountains.~1
gatherings.~1
End-Stage~1
160.1,~1
49.28,~1
Sex-specific~1
1980-85.~1
(CPHA-PAS)~1
hila,~1
deaths),~2
57.8~1
Hackensack~1
restaged~1
complications)~2
selectively.~1
periareolar~2
(choledochoscopy)~1
learned.~1
pre-oxygenation~2
mask.~3
facemask.~1
2.7,~3
mg/kg/hour).~1
(0.01-0.065~1
metronidazole.~1
(6-37~1
epiglottic~1
bullae.~1
(core~1
Clinitron~2
internal)~1
fluidised-bead~1
rewarming,~1
Read~1
kPa,~3
buprenorphine,~1
Pall~1
Ultipor~1
(BB50T)~1
moisture-exchanging~1
sterilise~1
decontaminate~1
13,380~1
welcomed,~1
fatality.~1
peri-operative~1
opiate,~2
pretreatments~3
radio-immunoassay.~1
micrograms/litre~1
mediastinitis,~1
pyopneumothorax~1
mg/hour~1
hepatic)~1
haemofiltration;~1
litres).~1
stormy,~1
atony.~1
tracheopathia~1
osteochondroplastica.~1
anaesthesic~1
fail-safe~1
gas-loaded~1
pipelines~1
cranially.~1
13th~2
5.7-11.1~1
Infusions~2
dissociation,~1
"septa"~1
bubble-like~1
Latex~2
radial,~1
(1.5-2.0~1
U44069~5
3.0%.~2
post-induction~1
oxide-based~1
Barbiturates~1
chiasmatic~1
cistern.~1
d-glucose~1
injection--usually~1
catecholamine-induced~1
anti-vasoconstriction~2
azepexole~3
agonist),~1
Ca+2~1
vasoconstriction;~1
3-4-week~1
VAP,~1
VPA,~2
PVA.~1
(amrinone)~1
(propranolol,~2
VAP)~1
propranolol-verapamil~1
PVA)~1
dP/dtmax,~1
AVP).(ABSTRACT~1
inspired.~1
85Sr-labeled~1
(cerebellum,~1
(GI~1
(CFCO)~1
(EMCO)~1
(TDCO)~1
arterio-venous~1
oximetry.~1
1748~1
EMCO~5
CFCO~6
.89,~1
.99~1
.16).~1
TDCO~4
.85,~1
.89~2
1.25,~1
139).~1
.87,~2
1.01,~1
251).~1
measurement;~2
60-75~1
7.20-7.40,~1
37.5-38.5~1
(muMol/ml~1
7.45~1
/-~1
.62;~1
6.95~1
10.11~1
1.00.~1
(muMol/gm~1
weight):~1
.20;~1
3.04~3
.31.~1
brain/plasma~1
malate,~2
alpha-ketoglutarate,~1
arteriovenous,~1
Event-free~1
(TcpO2)~1
Dorsal~1
TcpO2~7
oxygen-sensing~1
(submaximal~1
vasodilation),~1
vasodilation).~1
(TcpO2~1
C/TcpO2~1
(vasodilation~1
decreases).~1
62.1~2
0.61);~1
chilled~1
blanket~1
tone)~1
0.29.~1
0-0.77);~1
dressing).~1
worsens;~1
(syn.~1
fibroplasia)~1
string-of-beads~1
(LMCA)~1
LMCA~1
observer-blind~1
(SNRT)~1
seventy-two,~1
fifty-three).~1
bundle-to-ventricle~1
SNRT~3
5.3%,~1
0.007;~1
10.6%,~1
nebivolol~3
nebivolol,~4
nebivolol.~1
(PEPc)~1
(LVETc),~1
0.009.~1
PEPc~1
LVETc.~1
LVETc~1
beneficially~2
intervals.(ABSTRACT~1
infarctional~1
"3-D~1
VCG"~1
"MI~1
index."~1
(X-rot)~1
(Y-rot).~1
spheric~1
colors~2
circles.~1
"Bite"~1
X-rot~2
+90~1
Y-rot~2
leftward.~1
substantiating~1
extremities)~2
Fontaine,~1
(still~1
(II,~1
half-recovery~1
sixty,~1
ninety,~1
fifty-five-year-old~1
year-old~1
(Osler-Weber-Rendu~1
Osler-Weber-Rendu~1
tyrosine-bound~1
timothy~1
(A-F)~1
elatior)~1
companies~1
radioimmunoelectrophoresis,~1
Extract~1
immunoelectrophoresis,~1
producer.~2
antihistamine/decongestant~3
sonotubometry.~1
navicular~5
(snuffbox~1
navicular),~1
Snuffbox~1
98%;~2
reported.(ABSTRACT~1
straightening,~1
.08)~1
749)~1
roentgenographs~2
cortices,~2
(CPZ)~1
CPZ~2
(23.5%)~1
systolic)~1
congesting~2
(rotating~1
tourniquets)~1
Congesting~1
(ETC),~1
twin-lumen~1
(EOA),~1
ETC.~2
EOA~1
seal,~1
ETA.~1
prep~1
mEq/mL/kg~1
stained,~1
NaHCO3.~2
roentgenographs,~1
Fluoride-induced~1
NaF~1
(r,~1
0.886;~1
fluoride-induced~1
influenza-like~1
flu-like~2
eligible)~1
Carboxyhemoglobin~1
Fundoscopy~1
collapsing~3
witnessed,~1
comorbidity,~2
bystander-CPR~1
dispatcher-assisted~1
survivor's~1
they,~2
regrets.~1
unsympathetic,~1
reassuring.~2
Cryptococcal~2
Blot~2
Maisonneuve~1
Rentograms~1
syndesmosis~1
uneventfully.~2
gonadotrophin~2
torsed,~1
Diamondback~1
rattlesnake~1
atrox).~1
envenomation.~1
antivenin,~1
Rattlesnake~1
(MRC)~1
Oxygen-Cost~1
Diagram~1
(OCD),~1
(BDI)~1
(OAD)~1
10.5%.~1
observers;~1
OCD~1
BDI~1
12.0)~1
Exponents~1
(0.63~2
0.18)~1
FVC;~1
OAD,~1
loads.(ABSTRACT~1
miner's~1
(host~1
factors),~1
miners,~1
rhonchi~2
(abstracted~1
reports)~1
life.(ABSTRACT~1
railroad~1
diesel~4
exhaust.~1
Employed~1
15,059~1
Railroad~1
(RRB).~1
(1,256)~1
hygiene~3
RRB~1
retirement.~1
Asbestos~1
1959,~1
locomotive~1
kin.~1
1.41,~1
1.88)~1
diesel-powered~1
locomotives.(ABSTRACT~1
Formaldehyde~1
pollutant~1
(VE~2
exposure;~1
air:~1
FEV3.~1
produced:~1
FEU1~1
three-fold~4
9.45~2
SE:~1
pack-years).~3
marijuana;~1
(149.1~1
102.7~1
joint-years)~1
(MTS)~1
(43.3~1
joint-years~1
cytopreps.~1
MTS,~2
TS,~2
pack-years)~1
MTS~2
Marijuana~1
fluid)~2
(ELF)~1
ELF~3
protocols--a~1
100-ml~1
300-ml~2
BAL--performed~1
aliquots.~4
ELF,~1
aliquot,~2
aliquot.(ABSTRACT~1
(OPA)~1
bupivocaine~2
hypopneas~2
(OAH)~1
[13(3.8),~1
OPA~3
3(1.8)~1
7(2.5)~1
NA;~3
ANOVA]~1
[19(3.9)~1
8(2.1)~1
14(3.9)~1
ANOVA].~2
[21(6.1)~1
12(3.6)~1
14(4.6)~1
ribcage-abdominal~1
(RC-Ab)~1
RC-Ab~1
Konno-Mead~1
(Isc)~1
paracellular~5
immunoprecipitated,~1
BM.~2
tunicamycin,~1
N-glycosidic~1
phagocytize~1
(WGA)~1
spheres.~1
WGA~3
(C-Fe)~1
ricin,~1
prebound~2
C-Fe~1
spheres.(ABSTRACT~1
-0.71,~1
lung.(ABSTRACT~1
multiwell~1
endotoxin-activated~1
(EARS)~1
(DSM)~1
EARS.~1
EARS~1
malmoense~2
malmoense,~1
5-hydroxyeicosatetraenoic~1
(5-HETE)~1
perfusates.~2
(GC-MS)~2
oxygen-18-labeled~1
pentafluorobenzyl~1
(PFB)~1
trimethylsilyl~1
5-m~1
carboxylate~2
(RCOO-)~1
fragmentation;~1
(s/n~1
10:1)~1
1,1-[18O]2-5-HETE.~1
perfusate)~1
U/ml).~1
piriprost,~1
1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine)~1
IgE-sensitized~1
platelet-dependent,~1
cyclooxygenase-independent~1
arachidonatic~1
cognizance~1
illustration~1
vasoactive/spasmogenic~1
sulfidopeptide~1
richness~2
"vasodilator"~1
Salbutamol~2
Incorporated~1
(USAI)~1
"optimal~1
nutrition"~1
"optimal"~1
diet?~1
products--a~1
fatty-acid~1
calorie-control~1
ingredients--raise~1
USAI~1
"grants"~1
heavily.~1
thrombus)~1
threefold,~1
30.0).~1
sepsis-associated~1
hypocalcemic,~1
Hypocalcemia~2
parathyroid-vitamin~1
diathesis.~2
[SD],~1
(170%~1
(0.76;~1
sense,~1
dessicated~1
ox~1
alpha-tocopheryl~1
(we~1
adenomatosis).~1
fibromas~1
hypercalciuric,~1
91,000,~1
1998~1
141,000.~1
121%~1
19%.~1
internist~2
2464~1
1401.~1
1998,~1
206%,~1
internists.~1
"target-sign"~1
patulous~1
perioptic~2
hypertelorism~1
pterygium~2
Lima,~1
Peru.~1
31.06%~1
Sthal~2
sunburst,~1
eight-year-old~1
lymphangioma.~1
chalazion;~1
toxocariasis~2
elisa~1
1:2)~1
elapsed,~2
ointment,~1
designations~1
20/160~1
(6/48)~1
(6/37.5)~1
neovascularizations~2
microthrombus~1
fluorangiography,~1
eyeball~2
recession,~1
tied~2
disinserting~1
reason.~1
(Table).~1
intermediolateral~2
failure)~2
synapse~2
sclerosis).~1
efferents~3
attends~1
(GCS,~3
(2,176~1
531~1
(544~1
medullaris.~3
thighs~1
(S3~1
S5~1
segments).~1
Cysteamine,~1
depletes~3
dissipating~1
dose-dependent.~2
precysteamine~1
viruria~1
dissimilar,~1
ingestants~1
wheeze.~2
wheezed~1
Advice~1
Pulmonary-Allergic~1
(cough,~1
rhinorrhoea,~1
wheezing),~1
(irritability,~1
disorders),~1
(abdominal~1
anorexia),~1
abbreviating~1
(Pancrex~2
weight/day~1
surface/day)~1
microgranules~1
acetatephthalate.~1
(Krebsilasi)~1
Pancreas-Prolipase)~1
Pancrex~1
palatability.~1
Acarboxyprothrombin~1
antagonist-II~1
(PIVKA-II]~1
19,029~1
PIVKA-II~4
AU/ml),~1
AU/ml).~1
(0.51%)~1
(0.18%).~1
0.04%~1
resuscitaire.~1
1966-77~1
5-15).~1
Accident~2
attendances~1
non-attendances~1
immunisation~2
immunisations;~1
signified~1
antimuscarinic,~1
Rotavirus~1
Colostrum~1
anti-rotavirus~2
sucked~1
dummies~2
dummies,~1
dummy~2
hyper-reactivity~1
Dextrostix~1
Benzidine~1
hyper-reaction.~1
i(6p),~1
nedocromil~2
nedocromil,~1
Nottingham~1
91%.~1
pupils;~1
school;~1
Carboxyhaemoglobin~1
carboxyhaemoglobin~1
"Blinded"~1
ulceration"~3
sarcoma)~2
"curative~1
resection,"~1
survival--independent~1
factors--when~1
proportional-hazards~2
gallstones:~1
("contractors")~1
("noncontractors").~1
overnight.~2
Lipomul.~1
CCK-8-SO4.~1
contractors~3
noncontractors.~1
noncontractors~3
min/ml.~1
Contractors~1
CCK-binding~1
(27.6~2
1.149,~1
scarring;~1
age--56~1
age--24~1
reanastomoses,~1
choledochoduodenostomy.~1
hepaticojejunostomies~1
choledochojejunostomies.~1
guaiac-negative~1
(colon~1
microscopic):~1
stalk,~1
pancreatoduodenal~4
(80.6%)~1
gastrojejunostomy~2
61)~2
(14.8%)~2
pancreatoduodenectomies~1
(25.9%),~1
(16.6%),~1
(6.5%).~1
protein-malnourished~1
(MLNs)~1
glucocerebroside~1
hypersplenism.~1
Vicryl~1
10-72~1
10-53~1
cryothermic~1
cryoablation,~1
9-72~1
re-entry~1
cryothermia~1
(PS)~4
(RVEDV~1
RVEDV.~1
valvotomy;~1
reoperation:~1
valvectomy~1
PS~6
wisdom~1
bloodflow~1
Dissatisfied~2
Saphenous~1
splenic,~1
femoral-tibial~1
branched,~2
nonreversed~4
iliorenal~1
Nebraska~2
August,~3
aortoventriculoplasties,~1
(Carpentier-Edwards,~1
(St.~1
Jude,~1
Valves~1
aortoventriculoplasty;~1
young-adult~1
perfected~1
atriotomy.~3
Charlotte~1
Technically~1
atriotomy~2
septotomy~1
impedance,~2
pneumonectomy):~1
761~1
1.76~1
J/min~1
.006);~1
bed)~1
(14.7%)~2
(7.8%)~1
(8.9%)~1
nonemergency~1
1.8%.~2
97.7~1
randomizable~1
Hypothermic~1
pulmonary-systemic~1
infracristal~1
vital-organ~1
Aortocoronary~1
undiseased~1
cylindroma~1
fibroelastoma.~1
fibroelastoma~1
cardiotomy~1
de-airing~1
rehabilitated.~1
orthotopic~1
unbundling~1
Reassessment~1
attuned~2
inefficiencies~1
Financially~1
bundled~1
licensure.~3
shortcomings.~1
non-physicians~1
realistically~1
biologic,~1
32.5%,~1
(25.5%)~1
DC:~1
(male),~1
SCCL~2
compiled.~1
2902/10(6)~1
722/10(6)/y.~1
Hypotheses~1
2570~2
1010~1
5003~2
225.~1
resolving,~1
measles-specific~1
tetany.~1
(15.4%)~1
related;~1
(9.9%),~1
(DRA)~1
(divorced)~1
DRAs~2
(17/45,~1
37.8%)~1
(14/45,~1
31.1%),~1
pharmacoepidemiologic~1
2b)~1
61),~3
61).~2
Papanicolaou-stained~1
hyclate~1
Polysomnography~1
100-proof~1
(scotch~1
vodka)~1
pound~1
vodka,~1
mL,~1
scotch,~1
mL.~4
scotch~3
vodka~3
nights,~1
lower;~2
hypopnea.~1
protein-losing~2
sarcoma--an~1
Protein-losing~1
reticulocytosis~1
immunocompromised.~1
nonendemic~1
fungemia,~1
(paraplegics/quadriplegics)~1
Measure,~1
List,~1
Indicators.~1
paraplegics.~3
Interactive~1
travel.~1
quadriplegic,~2
Checklist-90,~1
(Brooke~1
scales)~2
Base~3
hours/week~1
hired~1
assistance/day.~1
rehospitalization,~1
prevocational~1
Self-Observation~1
Technique~1
(SORT).~1
injury-related~1
(activities~1
help)~1
postdischarge~1
independence:~1
discharge;~1
entered;~1
52.68~1
16.3;~1
149.76~1
lbs,~1
64.4~1
29.29~1
environs;~1
Beckman~1
MCC~4
Hans-Rudolph~1
Quinton~1
electrocardiograph.~1
SD):VO2max~1
26.3~2
HRmax~1
VEmax~8
62.8~1
L/min;~1
.07.~1
Dermatomal~2
(DSEP)~1
FZ.~1
DSEP~3
Side-to-side~1
DSEP.~1
Epidemiologists~1
man),~1
2300~4
assistive~1
ambulation;~2
ft;~1
12/16~1
diagnosis-related~1
wheeled.~1
L3-4,~1
deficit).~1
0.81)~1
wheeled,~1
wheeling~1
Wheeling~1
(amputation~1
first),~1
double-disability~1
BK~1
good-to-fair~2
"inverted"~1
stride~6
Deformity~1
dwarfs~2
polyform~1
4-1/2~1
11-2/3~1
alleviates~1
(HCCs)~1
Daughter~1
(15.6%,~1
solutions).~1
beta-Hydroxybutyrate~1
Branched-chain~2
acid-enriched~1
BCAAs.~1
staple~7
Pavlov~1
staples.~2
Staple~1
stapler.~1
fibroconnective~1
fabric,~1
(LR)~1
(D5LR).~1
D5LR~4
(387~1
(363~1
30-hour~1
attacks).~2
Separating~1
coordinates;~1
needle;~1
multiperforated~1
1.0%.~1
Nonfatal~1
1.25%.~1
magnesium-activated~1
sodium-potassium~1
energy-generating~1
(mitochondria)~1
energy-utilizing~1
cytoprotection~1
Crushing~1
"kissing~1
lesions"~1
pathognomonic,~1
mycotic.~1
pyloromyotomy,~3
bulimia.~3
undernourished~1
anorexic,~1
progresses,~2
loses~1
interfered.~1
gastrin-~1
Zollinger~1
neoplasias~2
Insulinomas~1
contradistinction,~1
indefinitely,~1
EEA,~1
GIA,~1
Corp,~1
Conn).~1
Hunt-Lawrence-Rodino~1
GIA~2
TA;~1
times);~1
esophagojejunostomy,~1
TNM-matched~1
(pouch)~1
(Roux-en-Y~1
reconstruction)~1
staplers.~1
linea~1
alba~1
environmentally~2
electrocorticographic~1
mesial/basal~1
Hypercholesterolemia~1
Storandt~2
dementias~1
beta-permanent~1
hyperintensity~1
Ill.~1
PVH,~1
PVH.~1
cognition,~1
hypokinetic-rigid~1
nicotinamide-adenine~2
encephalomyopathy~1
Eventually,~2
angiectasia,~1
neuromyopathy~1
(enzyme-linked~1
(MTX).~2
MTX-treated~3
non-MTX-treated~1
IgM-RF:IgM~1
as-yet-uncharacterized~1
Fc.~1
(RSC)~2
RSC~4
RSC-RF~5
pFc'~2
IgG1;~1
IgG3.~1
CH3~1
IgG-RF~1
monocyte-associated~1
IgG-containing~1
698~2
rheumatologists.~1
698,~1
306,~1
discretion~2
microheterogeneity~3
(2.70~1
A-bound~1
CL-4B;~1
excluded).~2
bradykinin~9
6-7-day-old~1
3-nM~1
Bradykinin-stimulated~1
meclofenamic~1
14-eicosatetraenoic~1
osteoclast-mediated~1
bradykinin,~2
BPP5a.~1
DesArg9-bradykinin~1
mumole/liter)~1
35S-sulfate~1
polymyositis/dermatomyositis~1
(EMC)~1
(EMC-D),~1
(EMC-221A)~1
muscle-associated~1
EMC-221A.~1
EMC~1
genomes.~1
UV-B~2
(280-320~1
long-wavelength~1
UV-A~6
white)F1~2
joules/cm2/day~1
UV-A-irradiated~1
Splenomegaly~1
(HCQ)~1
HCQ,~1
HCQ~3
[facets]),~1
morganii~1
(Morganella~1
morganii)~1
deforming~1
5898~1
27,687~1
(0.8-1.2)~1
(0.8-1.5)~1
(0.9-1.5)~1
(0.8-1.9)~1
(0.3-40~1
(5-40~1
4-methylpyrazole,~1
[NADH]/[NAD+]~1
(PGL)~1
PGL~1
heavy,~1
non-alcoholics~1
C57~1
BL/6~1
blood-monocyte-derived~1
ethanol-dependent~1
non-dialysable~1
pyrazole,~1
4-iodopyrazole~1
3-amino-1,2,4-triazole,~1
(ADH),~1
ethanol-oxidising~1
system--namely,~1
tetrahydrofurane.~1
millilitre~2
tlc~1
acetaldehyde-treated~1
isoleucine.~1
acetaldehyde.~1
28th~1
(59.5~1
S.E.M.),~1
(v/v)~1
5-hydroxyindol-3-ylacetic~1
(MAO-A)~1
SMAST~1
shopping~1
Perth,~1
(E1S),~1
(AFTC)~1
(patients)~1
E1S~1
AFTC~1
feminization.~2
feminization~1
T/E2~1
E1S/E1~1
CFLP~1
tert-butanol~1
tendencies.~2
OXT-treated~1
(0.2-2.0~1
IU).~1
576~2
glutamyl~2
transferase.~1
Courses~1
AECs~2
clients,~2
(CPR).~1
Operator~1
two-handed~1
(923~1
(775~1
H2O),~1
H2O).~2
skill.~1
operators.~1
(DCA),~1
(PGI)~1
PGI,~1
Physiology~3
(RAPS)~1
transports.~1
RAPS~8
(APACHE-II)~1
Scale).~1
eighty-three~3
helicopter;~1
Pretransport~1
3.85;~1
APACHE-II~6
14.98;~1
(X2(1)~2
57.09,~1
pretransport~1
92.53,~1
.8472,~1
abruptly,~1
Akron,~1
fires.~1
furnishings.~1
smoke-inhalation~1
Stenoses~1
distal.~1
atherosclerosis:~1
1840~1
lamina).~1
cardioneuropathy,~1
onwards.~1
21-64~1
Wednesday,~1
Thursday,~1
Friday~1
weekday,~1
(vena~1
cava)~1
leftwards~1
131mI-iodobenzylguanidine~1
etretinate,~1
electromyogram.~1
etretinate-induced~1
reminders,~2
drop-outs~2
invitation.~1
haemangiomas~3
pre-school~1
case-notes~1
haemangioma.~2
Haemangiomas~1
development;~1
centripetally.~1
(LTB4)-induced~1
LTB4-induced~1
pinnae.~1
parakeratosis~2
spongiotic~1
(SPF),~1
(UVR)~1
sunscreen.~1
protoporphyria~1
(EPP)~1
EPP.~1
encircled~1
micaceous~1
pseudoepitheliomatous~1
balanitis,~1
glans.~3
extracutaneous~3
morphoea~1
vasoocclusion~1
Erythrocyte/human~1
"high-reticulocyte~1
control"~1
ten-minute~2
Mechanically~1
(sheared)~1
Less-dense~1
high-reticulocyte~1
less-dense~2
(IOV),~1
(spx)~1
(non-spx)~1
intermedia~3
Ghosts~1
spx~2
6-globin~1
Triton-extracted~1
thalassemic~6
IOV~1
precipitates.~1
IOV,~1
beta-thalassemics~1
deranged.~1
2-mL~1
180.~1
(biologic):~1
high-molecular~1
kininogen.~1
XIII~6
2-antiplasmin,~1
2-macroglobulin,~2
Plasminogen,~1
prekallikrein,~1
infant;~1
near-adult~1
megakaryocyte-specific~1
two-color,~1
16N.~1
microL)~1
16N~3
32N,~1
64N~2
0.100~1
10(6)/microL)~2
32N~2
Chronic,~1
10(6)/microL~1
0.400~1
dissociated.~1
Setif~2
pseudosickling~3
hemolysates,~1
accentuates~1
A/Setif~1
HLA,~1
W6/32~1
anti-HLA~4
intraassay~1
interassay~2
fg/platelet,~1
fg/platelet~2
Chloroquine-elutable~1
chloroquine-elutable~2
HLAs~1
allosensitization~1
terminator~1
zero-39~3
nontranslatable~2
stabilities~3
pre-mRNAs~2
SP6~1
promoter-polymerase~1
(Epo)~1
type(s)~1
paralleled,~1
tuft.~1
(RCC)~4
plasticizer~1
di(2-ethylhexyl)phthalate~1
(DEHP).~1
DEHP~8
leaches~1
(PVC)~1
ektacytometer~1
RCC.~2
Pooled~1
aliquoted~1
PL146~2
(PVC),~2
PL732~4
(polyolefin),~1
DEHP)~1
DEHP.~1
(El~2
(Omax)~1
Omin,~1
flexibility.~2
transferrin-bound~1
Belgrade~3
125I.~1
phenylhydrazine-treated~1
transferrin-receptor~1
abovementioned~1
cytosol.~3
69,000~1
neuraminidase-galactose~1
oxidase-NaB3H4,~2
periodate-NaB3H4~1
particle,~2
AHN-1,~1
AHN-1~2
140,000,~1
(XGP)~1
XGP~2
Nephrectomy~1
acid/creatinine~1
thrombus;~1
4-144);~1
11.6)~1
remission:~1
(systemic~1
cystometries~1
micturition.~2
unrecognised,~1
non-cholinergic,~1
non-prostaglandin~1
strips;~1
(BGA)~1
BGA~6
anti-BGA~2
(O)~3
anti-H~1
prostates,~1
lipid-based~1
(orchiectomy~1
diethylstilboestrol).~1
criteria)~2
"flare".~1
Megestrol~1
elsewhere:~1
notice~1
maldescent~1
untreated)~1
orchiopathia,~1
"blood-testis"~2
spermatogenic~2
membrana~1
twitch-like~2
guanethidine.~1
(EJPs)~1
EJP.~1
NA-induced~1
(VIP),~1
dose-dependently.~1
non-adrenergic,~1
cavernosum.~1
overlay.~1
prolymphocytic~3
'spleen-saving~1
procedures'~1
omentoplasty.~2
omentoplasty,~1
spleen-saving~1
Aberdeen~1
co-operation~1
haematologist.~1
zeal~1
Mark's~2
Hospital;~1
6.52~1
(mg~1
protein)-1,~1
0.006.~1
3.58,~1
Miles'~1
Anorectal~1
aganglionosis.~1
defaecate~2
(102.7~2
79.5~1
(118.4~1
Polyposis~1
(familial~1
coli)~1
registry,~1
neorectum~1
proctocolitis.~1
postanal~1
intersphincteric~1
Ivalon~1
rectopexy.~1
(28),~1
track.~1
rerouting~1
(BAS)~1
BAS~2
BAS,~1
I-ST)~1
II-ST)~1
I-ST,~1
leak;~1
II-ST~1
(1959-83),~1
hyperamylasaemia.~1
choledochopancreatography~1
units/l~1
(196~1
1977-1985,~1
20-69~1
unskilled~1
labourers~1
76,~3
Teesside,~1
UK,~2
where,~1
Amylase,~1
(17.3~1
hypertrypsinaemia,~1
hyperlipasaemia~1
fraction);~1
(92.3~1
69.2~2
amylase).~1
hypertrypsinaemia~2
urged.~1
55.8,~1
Pa,O2~2
poached~1
pertechnetate~3
transit)~1
activity-time~1
aboral~2
thirds.~1
differentiates~1
outlining~2
intra-operatively~1
tricipital~1
skinfold;~1
dynamometry;~1
(ALB);~1
(TFN);~1
(DH);~1
(PNI)~1
99)~1
DH,~1
TFN~2
PNI~2
(mPNI),~1
ALB~1
mPNI~1
Bayes'~1
theorems,~1
5-25~1
Joule~1
lasers;~1
N-acetylserotonin~2
330,~1
aqueous.~1
low-tension~2
deteriorating.~1
0.000).~1
846~3
(46.0%),~1
(11.0%)~1
(30.6%)~1
forward.~1
dermolipomas.~1
(squint~1
(adenoidectomy)~1
participated.~1
out-of-pocket~1
compassionate~2
Opening~1
52,854~1
Calgary,~1
factor:~1
Long,~1
0.001]),~2
nonbarrier~1
0.030])~1
0.046]).~1
Canada,~5
trait),~1
E-beta-thalassemia).~1
E-beta-thalassemia~1
623-bed~1
documented;~1
producing.~2
isolates;~1
Methicillin~1
speciation~1
nonorganic,~1
ultra-low-dose~1
coin)~1
means;~1
coins)~2
esophagotomy~2
stone).~1
blunt,~1
4801~1
15.8.~1
10(9)/L,~1
155.5~1
Single-donor~1
1110~1
49.4~1
[MCC])~1
[ECC]),~1
0.684,~1
0.922,~1
ECC.~1
inaccuracy~1
(ECC)~1
(Ara-C)~2
(ANLL),~1
vomiting;~1
conjunctivitis;~1
mucositis;~1
neutropenia,~1
AML~1
Ara-C,~1
Ara-C~6
manageable~1
chemo-resistant.~1
labium~1
majorum~1
preliminary,~2
citation~1
villous-like~2
scatterplots~1
less:~1
6549~1
3.53)~1
(cancer~1
mg/m2/d;~1
rad;~1
4400~1
6900~1
11/13~1
hand-foot~1
3/13~1
(AVCI)~1
(35/44)~1
(39/44)~1
(26/41)~1
(33/41)~1
AVCI~2
AVCI's~1
(DCPAV)~1
(CYVADIC)~1
postoperatively),~1
means),~1
multi-institutional,~1
Contracts~1
options:~1
radiotherapy);~1
0.021,~1
Myelopoiesis~1
colony/cluster~2
E-(PGE)~1
exchanges;~1
monocytes;~1
anti-cancer~1
Pasteur~3
(flu)~1
contracture,~1
Extravesical~1
epithelial)~1
multipotentiality~2
submesothelial~1
125,~1
[lipid~1
LASA-P~1
(Dianon~1
Stratford,~1
)],~1
19-9,~1
[CEA])~1
19-9~1
(6/15).~1
Heterogeneous~2
subset-specific~1
Leu-1+~1
T-cells),~1
Leu-2a+~1
Leu-3a+~1
(T-helper/suppressor-inducer~1
Leu-12+~1
Leu-M3+~1
(monocytes)~1
evidence)~1
(13/57)~1
(1/19)~1
(ERc)~1
(PRc)~1
ERc~7
PRc~5
seven-point~1
PRc.~2
cervices,~1
0.063)~1
(ECMF)~1
IVA).~1
IVB).~1
(NED)~1
ECMF~3
relapse),~1
Tabulation~1
(COP-Bleo)~1
endpoint,~2
covariates:~1
IVA~1
Extramedullary~2
myelolipomas~3
myelolipoma~2
myelolipoma.~1
masses;~1
laparatomy.~1
Microscopically,~3
Winston-Salem~1
44.4%~1
Population-based~1
sinonasal~4
1865~1
1875~1
consistent:~1
(rate)~2
malignancies;~1
(age).~1
"Clemmesen's~1
hook"~1
Malignancies~1
Hokkaido~3
Prefecture~2
Sapporo~3
48-month~1
improved--from~1
87.5%).~1
(Sapporo~1
excluded),~1
(48-month~1
21.1%~2
28.1%).~1
symposium~2
Society.~1
Columbia,~1
justify,~1
anticipations~1
unreliability~1
militated~1
nonseminomas~1
nonseminoma~1
migration"~1
Postchemotherapy~1
nonseminoma,~1
RPLND.~2
Sadly,~1
nonreporting~1
Adjuvant,~1
RPLND~1
tumor(s),~1
"seen~1
cystoscopy"~1
histopathologist~1
External-beam~1
Gerota's~1
(T1-2~1
N0~4
M0).~1
angioinfarction~1
accumulated,~1
seminomatous~1
spouse/partner~1
openness~1
sexuality.~1
nerve-sparing~1
vasocongestion~1
Infertility~1
penile,~1
urethral,~1
Cancer,~1
goal-directed.~1
(Dudas,~1
emotional,~3
nutritionist,~1
(Frank-Stomborg~1
Wright,~1
Dietz~1
(1980)~1
restorative,~1
palliative.~1
well-being,~1
happiness~1
QL~3
(objective~1
parameters)~2
(subjective~1
QL.~1
incapacitation~1
sequela,~1
suspect.~1
epidemiologically.~1
sweeteners~1
proto-oncogenes,~1
cancer-causing~1
nonprisoner~2
(IVDA).~1
IVDA,~3
IVDA.~1
(2.28)~1
21.5/10(5)~1
67.2/10(5),~1
164/10(5),~1
IVDA~1
hyperkalemia,~1
(119~1
extragonadal)~1
Therapy.~1
anasarca,~1
sided,~3
0.019).~1
(Framingham~1
amplification,~2
unadvanced~1
IV-S,~1
copies.~1
ganglioneuromas~1
ganglioneuroblastomas,~1
round-cell~1
rosette~1
[SCLC],~1
(NSG)~1
non-NE~3
epidermoid,~1
isoenzyme,~2
cytometrically~2
carcinoma),~1
multiclonality,~1
multiclonality~1
washing):~1
48/77~1
way:~1
(tumors~2
(DT),~2
(DT~1
(5-year~1
DT.~1
substages~2
1117~1
accessioned~1
Substaging~1
(NHL).~2
anti-early~1
anti-viral~1
(HLA)-identical,~1
anergic;~1
T-cells.~1
(yes~1
no)~1
Infusor~2
(Travenol~1
Laboratories~1
Illinois)~2
lightweight,~1
1378~1
non-obstructed~1
Hematology/Lymphoma~1
NHL,~2
Supervening~1
Co-60,~1
leukocytosis.~1
thrombocytosis.~1
Tumor-associated~1
mechanism(s),~1
(CYVADIC),~1
citrovorum~1
rescue,~1
aziridinobenzoquinone~1
(AZQ),~1
dibromodulcitol.~1
diffuse-type~1
Lauren~1
dialect~3
Singapore.~1
648~1
(62.5%)~1
(31.8%)~1
Hokkien~1
Online~1
spectorphotometric~1
77.6~1
62.0~1
0.0007),~1
cardiocoronary~1
(GFP)~1
ventriculography;~1
(ANGIO)~1
(table;~1
ANGIO~1
.88).~1
"aortic~2
root"~1
grown.~1
"pseudonormalization"~1
T-waves~1
bioptome~3
thickwalled~1
gleaned~1
multi-angled~1
J-wires~2
wire-reaching~1
(RD),~1
sin~1
angulations--double~1
angles--were~1
J-wire~1
57.90~1
angled,~1
significant.)~1
obtuse~1
commercial,~1
unshaped~1
frames)~1
Judkin's~1
torquability,~1
pig-tail~1
alpha-antagonists.~1
2-selective~3
BHT-920,~1
NMR-detectable~1
Phosphonic~1
phenylphosphonic~1
31P-NMR-detectable~1
phosphatic~1
PPA's~1
downfield~1
ppm/pH~1
pK'~1
7.09~2
0.972;~2
wash-in~1
(0.039~1
(0.038~1
extracellular-to-intracellular~1
spaces.(ABSTRACT~1
Myocyte~1
myocytes)~1
Wistar-Kyoto.~1
ryanodine~15
Ryanodine~5
(10(-10)-10(-5)~1
10-70%~1
5-12%~1
9-76%~1
Positron~1
positron-emitter~1
13N-labelled~1
[13N]~1
([13N]glu)~1
13NH3~5
[13N]glu~5
13N-label~4
[13N]alanine~1
([13N]ala),~1
[13N]aspartate~1
([13N]asp),~1
[13N]glutamine~1
([13N]gln),~1
1.0:0.4:0.5:0.01.~1
[13N]ala~1
[13N]glu.~2
transamination~1
[13N]ala.~1
[13N]gln~1
13NH3.~1
Time-activity~1
-90~2
(called~1
threshold).~2
Single-channel~1
barium)~1
depolarizations.~3
(KR~1
(-)Bay~2
potential-dependence~1
calcium/barium~1
PVC-valinomycin~1
minielectrodes~1
(0.6-0.8~1
microgram/min),~1
beta-agonist,~1
(0.15-0.43)~1
(79-202)~1
pafenolol.~2
1-agonist~1
2-blockade~1
118,~1
551.~1
(1-20)~1
global,~1
+dP/dt,~1
+dP/dt~1
Ischemia-reperfusion~1
(5-16~1
5-16~1
postrest~2
(40-80%)~1
(postrest~1
contraction)~1
restimulation~1
monoexponentially~1
reinduced~2
758~1
ryanodine-induced~1
diastole.(ABSTRACT~1
nonsubtype~1
[125iodo]cyanopindolol~1
stereoselective,~2
displaceable~2
myocytes;~1
myocytes,~1
45Ca,~2
indo1,~1
quin2,~1
uncoupler~2
17.08~1
Ca/mg~1
indo1~1
79.8~1
nM/min~1
82-84%~1
indo1.~1
Quin2~1
influx:~1
calmodulin-stimulated~4
calmodulin-Sepharose~1
Spherogel~1
TSK~1
5PW~1
61,000~1
calcineurin.~1
Ca2+-calmodulin~1
calmidazolium.~1
calcineurin,~1
dephosphorylated~1
pseudofirst-order~1
0.23,~1
0.115~2
Ca2+-regulation~1
dephosphorylation.~1
antithrombogenic~1
(ATECD)~1
ATECD~3
computer-operated~1
aggregometer-like~1
ECs.~2
EC).~1
(ISDN)~1
2-isosorbide~1
mononitrate~2
(2-ISMN)~1
5-isosorbide~1
(5-ISMN)~1
ADP)~1
nitrate-treated~1
ADP).~1
ISDN~5
2-ISMN~1
5-ISMN,~1
ATECD.~1
5-ISMN~1
ATECD.(ABSTRACT~1
attenuations.~1
nmol/100~3
beta-attenuation.~1
attenuation.(ABSTRACT~1
Preischemia~1
0-3%~1
(3-5~2
deoxyglucose.~1
2,4-dinitrophenol~1
hypoxia/anoxia~1
(serotonin~1
transport)~2
prelabelling~1
[2,8,5'-3H]~1
5'-N-ethyl-carboxamide-adenosine~1
(-)-N6-(R-phenyl-isopropyl)-adenosine~1
(R-PIA),~1
(+)-N6-(S-phenyl-isopropyl)-adenosine~1
(S-PIA)~1
63.7~1
Ci/mol,~1
cardiomyocyte~1
radioactivities~2
Elastic~3
(dyskinetic)~1
modulus.~2
Error~2
motion)~1
beta-myosin~1
RV/day,~1
RV/day)~1
RV/day).~1
alpha-myosin~1
beta-synthesis~2
beta-mRNA~1
ejections~2
(flow-clamps)~1
Pressure-flow~1
flow-clamp~1
time-varying~4
E(t),~1
elastance.~1
3-component~1
Qmax,~1
p(t);~1
V(t);~1
Q(t),~1
flow-clamped~1
E(t).(V(t)-Vd).(1-Q(t)/Qmax)~1
(ameroid~1
constrictor).~1
sonomicrometers).~1
(SD,~2
Ba2+~1
Steady~1
twitches,~1
contractured~1
oscillated~1
(amplitude~1
(0.05-30~1
(90-100%~1
(Ba2+~1
0.3-1.0~1
atria,~3
Ba2+.~2
0.05-50~1
steeply,~1
(fmin).~1
2.9).~1
(fmin~1
fmin~1
1-week-old~1
Propagation~1
transversely,~1
(Vmax),~1
heptanol~1
corners~1
corners.~1
"notched."~1
5-hydroxy-tryptamine,~1
5-hydroxytryptamine.~2
(PVA),~1
FTI,~1
VO2.~6
(isovolumic)~1
cross-circulated~1
PVA~3
servo~1
force-equilibrium~1
FTI.~1
PVA,~1
FTI~2
Sarcomeric~1
(MHC),~1
multigene~1
beta-cardiac,~1
IIA,~1
MHC.~2
beta-MHC.~1
sheds~1
context,~2
(+dL/dt,~1
lengths/sec)~2
Physiologically~1
12/min).~1
(preload,~1
load)~1
+dL/dt~4
(0.93~1
lengths)~2
lengths/sec.~1
lengthening)~1
(g/mm2)~1
(milliseconds~1
lengths/sec.(ABSTRACT~1
(0.5-msec~1
electrodes)~1
dilatory~1
scorpion~1
reflexes)~1
[3H](-)dihydroalprenolol,~1
[125I](-)iodocyanopindolol,~1
[3H]prazosin,~1
[3H]yohimbine,~1
sarcolemma-enriched~1
beta-,~1
258,~1
525,~1
1,000,~1
[3H](-)dihydroalprenolol~1
(-)isoproterenol~2
(-)norepinephrine~1
(-)epinephrine~2
(+)isoproterenol.~1
(-)norepinephrine.~1
(+/-)bisoprolol~1
[125I](-)iodocyanopindolol~1
Hofstee~2
1:beta~1
90%:10%).~1
1-type,~1
2-type;~1
beta-dominant~1
(beta/alpha~2
alpha-dominant~1
(nitrendipine/alpha-adrenoceptor~2
euvolemic~2
flowmeter);~1
intrapericardial,~1
(radionuclide~1
microspheres);~1
Decompensated~1
(DCT)~1
(baseline,~1
(DCT,~3
lactate-pyruvate~1
(7.56~1
2.31),~1
0.23)~1
occluders.~1
(L0).~1
L0,~1
hyperfunction,~1
cremaster~3
airtight~2
+10,~2
+20,~2
(5%,~1
(phentolamine),~1
non-neural,~1
vasoregulation~1
cremaster.~1
periarteriolar~1
metabolic)~1
Normoxia~1
7.37~1
39.3~1
epicardial,~1
isochronous-activation~1
43-62~1
capture.~1
VTs.~1
Sodium-channel~1
Aldrich,~1
Corey,~1
Stevens.~1
batrachotoxin~2
ensemble~1
exponentials.~1
relaxation:~1
gating.~1
starvation-induced~1
myofibril.~1
vagal-sympathetic~1
alpha-chloralose~1
(varying~1
frequency).~1
subclaviae-vagal~3
Atrioventricular~1
(AH~1
(HV~1
(TXA2)/prostaglandin~1
(PGH2)~1
TXA2/PGH2~5
45Ca2+~6
mimetic~2
I-PTA-OH~2
45Ca/+~1
explants,~1
U46619-induced~1
conduit-branch~1
conduit-pulmonary~1
intervention).~1
121)~1
110)~1
(21.5%)~1
(10.7%).~1
(11.8%;~1
.07)~1
(1.8%;~1
thrombus:~1
.008),~1
.013),~1
information.(ABSTRACT~1
Rheologic~2
sec-1),~1
(Myrenne~1
aggregometer).~1
16%),~1
constant)~2
increase),~1
preconditioned~1
SMVs.~1
LVADs~1
(LCx)~1
flow-function~1
LCx~2
111In-oxine.~1
labeling,~1
(ATP;~1
micrograms/min).~2
(endo/epi)~1
endo/epi~1
quinacrine.~1
(NCC),~1
(RCC),~1
(LCC)~1
(LAD),~1
NCC~3
LCC~3
capillaries/mm2~4
premyocytolic~1
3289~1
(3349~1
3383~1
myocytolysis.~1
RP'~2
(RP'/RR,~1
0.71);~1
(fast-slow)~1
SVT,~1
(iK)~1
hyperpolarizes~1
Ek~1
(-90~1
mV),~1
slow-inward~2
(0.10~1
fast-slow~1
Decremental~1
Pathways~1
fast-Na+~1
nonnecrotic~1
(longitudinal)~1
(APD-60~1
APD-60~2
wavefronts~1
(longitudinal~1
collision)~1
wavefront,~1
band-pass~1
Signals~1
isochronal,~1
(maxPV),~1
(minPV),~1
(-)dP/dtmin~1
[(-)dP/dtPV],~1
(AodiPV).~1
(+)dP/dtmax~1
Isochronal~1
6.73~1
Hg/ml~1
5.48~2
Hg/ml)~1
volume-axis~4
isochronal~5
.97~2
maxPV,~1
minPV,~1
(-)dP/dtPV,~1
AodiPV~1
.69,~2
Emax.~1
-.68~1
-.91,~1
.75).~1
443)~1
162)~1
dead).~1
82.9)~1
59.0)~1
46.6),~1
fitted,~1
"intention~1
treat"~1
emitter~1
Prestimulation~1
liter/min~2
stimulation).~1
micromanometry~1
pressure/volume~5
nonsimultaneous~1
(AVP~1
[CVP]~1
coined~1
"postinflammatory~1
prolapse"~1
(PIVP)~1
PIVP.~2
PIVP~1
stress-shortening~1
mass/volume~1
1.81~1
0.18,~1
tufts~1
Henoch-Schoenlein~1
pentose-phosphate~1
malonyldialdehyde~2
pantrapezial~2
colleague~1
ossiculum~1
spondyloschisis.~1
bend.~1
osteonecrosis~2
metacarpal.~2
ridge),~1
trapezial~2
slopes),~1
(pronation)~1
retroposition~1
(supination)~1
drill.~1
illumination,~2
Materials~1
(Instro~1
Engineering~1
Kenton,~1
(physiolysis~1
colli~1
femoris;~1
PCF)~1
coxarthrosis.~2
PCF~1
unfavorable,~1
spica.~1
68.9~1
114.4~1
femurs.~1
femora.~1
recess.~1
semitendinosus~1
Lachman's~1
Anteromedial~1
straight,~1
anteromedial,~3
menisci,~1
Chondromalacia~1
aching~3
occupations;~1
intercollegiate~1
soccer.~1
(+).~2
(Lachman~1
sign).~1
Lenox~5
ligament-deficient~1
Newton-meters~1
(Nm)~1
ligament-sectioned~1
degrees.(ABSTRACT~1
Stanmore~1
Worst~1
revising~1
bulkier~1
recruits,~1
nondiscrete~1
recruits;~1
evertors~1
compartments)~2
Cleidocranial~1
Fasciotomy~1
venogram.~1
clenched-fist~2
Tendon,~1
(20.3%),~1
(67.8%),~1
articular-bone~1
(16.5%).~2
subjectively,~1
Redisplacement~1
59%;~2
functionally.~2
Comminution~1
(macrophages);~1
(BMG).~1
BMG,~1
(composite~1
(osteoclast)~1
(osteoprogenitor)~1
(BMP)-induced~1
Biomechanical~2
30%-60%~1
(Upjohn~1
Kalamazoo,~1
Michigan)~1
thumbs.~2
Adduction~1
quadriceps,~1
hamstrings,~1
1.96).~1
(BRIV).~1
tibiotarsal~1
roosters.~1
Chondrocyte~1
reorganized~1
multitudinous~1
(TMC)~1
space-occupying~2
spacers~2
Key-type~1
(replacement)~1
error-free~1
biomaterials,~1
Bennett's~3
Rolando's~2
routing~1
"prearthritic"~1
scaphotrapezial~2
hand--termed~1
"basal~1
syndrome"--is~1
medialization~1
Balance~3
articulations~1
facets,~1
trapezium,~1
bone-ligament~1
conspicuous.~1
sake~2
groundwork~1
practitioner,~1
neonatologist~2
ml/Kg/h)~1
(Period~2
prematures,~1
hypothyroxinemia~1
hypoactivity,~1
hoarse~1
hypothyroxinemia,~1
dependents~1
Forces.~2
(PKU),~1
galactosemia,~1
maple~2
(MSUD).~1
5.9/10,000~1
livebirths~1
gestation).~1
pitocin,~1
undercounting~1
ICH.~1
(PIE)~1
PIE~6
PIE).~1
puncta~3
99mTcO4~1
disbelief,~1
cerebelli,~1
fontanelle.~2
147)~1
(DOE,~1
13.2)~1
2D-echocardiogram.~1
DOE~1
DOE.~1
Implications:~1
exertion;~1
Temperament~1
1,855~1
temperament.~1
(CHPS)~1
CHPS~1
604~1
first-born~2
.43~1
.34~1
.091~1
(CHPS).~1
subarachnoid-pleural~4
forgotten.~1
deliberations~1
Kingdom),~1
first-generation~3
Conflicts~1
defended~1
justification,~1
concern--which~1
degree--with~1
pretext~1
equality~1
obligations~3
not-yet-born~2
abyss~1
temptation~1
debates~1
Doe~1
era,"~1
Historic~1
infanticide~1
peril,~1
euthanasia.~1
Congress,~1
alludes~1
confront.~1
smallest--those~1
grams--have~1
crossfire~1
administrators,~2
beliefs.~4
centuries.~2
exhortation~1
Appeal~1
Bouvia:~1
"Provide~1
respect,~1
number"~1
entrusted~1
bioethical~1
bioethics~2
deliberation~1
exigent~1
optimally.~1
amazingly~1
pace.~1
brilliant~1
tragedies~1
well-meaning,~1
clamor~1
designed,~1
risk-limiting~1
(randomized~1
miracles,~1
heroics,~1
editorial,~1
review)~1
citational~1
amphetamine.~2
Publications~1
10-hydroxy-NT~1
(10-OH-NT)~1
10-OH-NT~4
688~1
0.469;~1
30.9%~1
4-hydroxy-3-methoxyphenylglycol~2
(HMPG)~1
(CSF).~1
10-OH-NT,~1
HMPG~3
0.397;~1
0.623;~1
nonadditive~1
10-OH-NT.~2
10.0%.~1
noradrenergic,~1
serotoninergic,~1
redistribute~1
(?~1
internalize)~1
terbutaline,~3
redistributed.~1
(QTc).~1
linear-effect~1
biophase.~1
NAPA.~1
suppression;~1
desmethyldoxepin~1
doxepin:~1
zinc-sparing~1
[range~2
10.0]~1
2.5]~1
[range];~1
fed)~1
[0.5~2
1.0]~1
1.5]~1
4.3]~1
[2.0~1
6.0]~1
isosorbide-5-mononitrate~1
551~1
376~2
(5.88~1
1.85;~1
5.08~1
(6.17~1
1.88;~1
5.78~1
(4.57~1
(Procardia),~1
(high-carbohydrate)~2
GLC/electron~1
78.9,~1
42.2,~1
1.89,~1
Insofar~1
medroxalol~4
medroxalol,~2
Medroxalol~1
prodrug,~3
biotransformations:~1
sulfone~5
biotransformation,~1
AUC(0-12)~3
4.85~1
hr/ml~4
Anirolac,~1
anirolac,~5
Highest~1
metabolizers.~1
constitution~2
parent/offspring~1
mephenytoin,~1
diallelic,~1
(GHR)~1
(CEI).~1
GHR~3
CEI~8
(teprotide,~1
non-clipped~5
(ANG)~1
finger-nails~3
hydroxylysine.~1
cross-links,~1
hydroxylysinonorleucine~1
(+31%)~1
histidinomerodesmosine~1
(+42%)~1
allysine~1
aldol~1
cross-links~2
pindolol,~2
operator-controlled)~1
breathlessness.~2
covariance,~2
uracil~2
thymine~3
Uracil~1
D-galactose~2
perfusions.~1
(CBG)~1
CBG~6
CBG.~1
01.00~1
23.00~2
Superimposed~1
ultradian~1
(23.30-00.30~1
dilutions,~1
Mass~2
ingredients;~1
2-methyl-4-isothiazolin-3-one~1
5-chloro-2-methyl-4-isothiazolin-3-one.~1
5202~1
(medication,~1
hobbies~1
associated,~1
11.7%.~1
irritation.~1
Soaps~1
fragrances,~1
preservatives,~1
Primula~1
obconica~1
Hance~1
primula~1
19.6%~1
purple~3
"dye"~1
multicolored~1
tattoos.~2
Atomic~2
UVA)~1
(Brassica~1
nigra)~1
vinegrette,~1
Cruciferae.~1
Cruciferae~1
condiments~1
isothiocyanates.~1
handlers~1
isothiocyanates~1
lipsticks~1
diisostearate~3
diisostearyl~3
malate.~1
Impurities~1
impurities.~1
monoisostearate~1
isostearyl~1
liquidity~1
EE,~2
sling-type~1
(36%,~2
(1.1%,~1
22.3%~1
Benedict~1
2.6(SD)%~1
EE.~1
(EAP)~1
posterior.~1
(RVEDV)~1
end-inspiration.~1
Holt~1
RVEDV)~1
thermodilution.~1
Thermodilution~1
2.09~1
1.79~1
(5315~1
sec/cm5)~1
(7892~1
sec/cm5).~1
SVR~2
epinephrine's~1
Methoxamine,~1
compressor.~1
p-value~1
(HFO-IMV)~1
type-2~5
HFO-IMV~2
HFO-IMV-treated~1
CMV-treated~1
(ARI)~1
1--Qsp/Qt)~1
(L).~1
dissolved)~1
(Qt),~1
oxygen-hemoglobin~1
isopleths~1
E).~1
Qt,~1
ARI~1
(BVCP)~1
BVCP~1
decannulation.~1
commode,~1
(PFT)~1
(Dsb),~1
PFT,~1
Dsb.~1
lavaging~1
airway-sampling~1
asthma),~1
spaces).~1
"pill-electrode"~1
flutter,~1
pill-electrode~2
(interelectrode~1
flutter)~1
reverting~1
flutter.~2
rub,~1
embolism;~1
nonglycosidic,~1
nonsympathomimetic~1
posicor~1
physician-operated~1
prehospital-treated~1
inhospital.~1
phosphokinase,~1
broncholithiasis.~1
pedunculary~1
untrue.~1
cylindric~1
hot,~1
body)~1
radicality~1
orthopnea~1
echo-dense~1
mediastinitis.~1
nonbacterial~3
valvulitis,~1
moderated.~1
deviations,~1
sternectomy,~1
sternectomy~1
valvula~1
foraminis~1
ovalis~1
Bernoulli's~1
(ILD)~1
ILD,~1
(radiographic,~1
scintigraphic)~1
Computer-generated~2
ILD~1
(LVH)~2
ECG;~1
A2;~1
murmur;~1
pulse;~1
(valve~2
(PF-CVD)~1
PF-CVD.~1
43.58~1
ICU-treated~1
tetanus,~2
complicated.~1
(TBNA)~1
TBNA~5
endobronchial/transbronchial~1
75);~2
84);~1
89);~1
TBNA,~1
91).~1
Carinal~1
aspirates,~3
23);~1
parabronchial~1
28);~1
endobronchial,~1
42).~2
extrabronchial~2
extratracheal~2
Flow-volume~1
(BRM)~1
(Il-2)~2
gamma-interferon~1
IFN)~1
BRM~2
BRM-treated~1
BRM-stimulated~1
(LAK)~2
antileukemic~1
5-fluorocytosine.~2
IPA,~1
Scan~1
disease--80~1
colitis--from~1
(ICJ)~1
coloileal~1
ICJ's~2
intracecal~1
Competent~1
restudied.~2
ICJ.~1
1578~1
elsewhere;~1
colonic,~1
seepage~1
improvements?~1
undiscovered.~1
undrained.~1
undrained~1
leaked,~1
drain.~1
sigmoidostomies,~1
border,~1
blue-Alcian~1
carcinogenetic~1
0-acylated~1
sialomucins~1
polyp(s)~3
anus,~1
Juxtaposed~1
midline,~1
arteriomesenteric~1
skin-grafted~1
31st~1
tenets~2
defunctionalized~2
IU/1~4
447,800~1
189,000~1
nondiploid~2
Multi-Test~1
age-complicating~1
minor).~1
Ascorbate~1
Diseased~1
infective,~1
developmental,~1
mesonephric,~1
paramesonephric~3
location;~1
parovarian,~1
vaginal.~1
embryologic,~1
1121~2
1119~1
(9.4%)~1
(1.8%)~2
viscus,~1
hemoperitoneum,~1
manometries~1
(sPIIIP)~1
sPIIIP~7
(CPH)~1
weaker.~1
low-extraction~1
capacity-limited~1
(antipyrine~1
aminopyrine)~1
(ICG~1
lidocaine).~1
varices),~1
(-31%)~1
(-53%),~1
(-49%),~1
ICG~1
(-54%).~1
HBV-related~1
(gastrin,~1
GIP)~1
nmol/kg/min~1
(MSP)~1
multilumen~1
mechanized~1
MSP~7
-0.099,~1
-0.123,~1
-0.614,~1
-0.372,~1
0.0006).~1
-0.333,~1
-0.196,~1
(FI)~1
MSP.~2
FI,~1
Antroduodenal~1
antral,~1
antroduodenal~1
neodecortication~1
dynograph~1
Neodecortication~1
neodecortication.~1
neodecortication,~1
DMH-~1
Colonic,~1
Ia-induced~1
D-sorbitol,~1
D-sorbitol~1
dose-independence~1
Day-to-day~1
(911~1
(456~1
aminotransferase.~1
Work-up~1
4-cm~1
hepaticojejunostomy.~1
0.8-mm-diameter~1
periductal~4
(CIT)~1
CIT~6
(5.9~1
arginine-infusion~1
CIT.(ABSTRACT~1
Adipocyte~1
area/ml).~1
(non-insulin-stimulated)~1
(tracer~1
pmol/90~1
(half-maximally~1
(.2~1
.1,~1
.1~1
2-by-2~1
(race-by-sex)~1
.012).~1
IDDM,~2
0.43)~1
(2.80~1
circumferences/s).~1
welcome~1
overwhelmed~1
helpless.~1
(SED)~1
consistency)~1
SED~3
self-efficacy,~1
Isolab~1
(Akron,~1
whole-blood~2
.93,~2
microliters)~1
16.3,~1
1.3-fold~1
self-monitoring.~1
strips:~1
Haemoglukotest~2
20-800~2
(HGT~3
1/1;~1
Boehringer-Mannheim,~1
Mannheim,~1
halved~1
scissors~1
SC).~1
20-360~1
test-strip~1
(Beckman~1
analyzer):~1
HGT~3
1/1,~1
.950;~1
.966;~1
.966.~1
.98).~1
(HMBGs)~1
HMBGs~2
claiming~1
"user~1
friendliness,"~1
unsubstantiated.~1
ever-expanding~1
HMBG~1
(YSI~1
23A).~1
Precision~1
Accuchek~3
bG~2
Glucoscan~2
Glucokey,~1
Glucochek~1
Glucometer~1
Trendsmeter~1
Diascan~1
precision.~1
HMBGs.~1
kilodalton~2
(kd)~1
(CaBP)~2
CaBPs~3
kd)~2
0.005-0.001)~1
Minipumps~1
13-week-old~1
33-52%.~1
C3H+~1
PRL-treated~1
ER-enhancing~1
bromocryptine~1
(CB-154)~1
estrogen-stimulated~2
C3H,~1
0.25-5.0~1
immature)~1
estrogen-replaced~2
PRL-independent~1
redistributing~2
cytosol;~1
PRL-suppressive~1
uncovering~1
otherwise-masked~1
insolubilized~1
neuraminidase.~1
Desialylated~1
bioassays~1
alpha-beta)~1
equipotent.~1
(alpha-as~1
(asialo-hCG)~1
affinity;~2
asialo-hCG,~1
alpha-as~2
alpha-beta.~1
asialo-hCG~1
alpha-beta,~1
desialylation~1
Desialylation~1
nonagonist~1
phosphoproteins~1
K-19~6
TPA-induced~1
TPA-stimulated~1
(8-diethylamino)-octyl-3,4,5-trimethoxybenzoate~1
(TMB-8)~1
(TFP)~1
Ionophore~1
TMB-8-~1
TFP-stimulated~1
TSH-~1
TPA-reduced~1
32PO4-labeled~1
kinase(s)~1
Ca++-calmodulin-dependent~1
(CSCC)~1
(cytP450scc)~1
(25-200~1
Paramagnetic~1
Resonance~1
(EPR)~1
cyt~2
P450scc~2
EPR~4
signal)~2
6.2-7.3.~1
Aminoglutethimide~1
(competitive~1
CSCC)~1
near-UV~1
(UV-A,~1
320-400~1
14-h~1
10-h~1
(lights~1
1700-0700~1
irradiances~3
fluence-response~1
0.022~1
microW/cm2~2
10(13)~1
photons/cm2)~1
10(14)~1
photons/cm2),~1
360-nm~1
500-nm~1
UV-A,~1
wavelengths,~1
(1.6%~2
phosphorus)~2
16-23)~1
sacs)~1
Nonlactating~2
lactation-associated~1
Bu2cAMP~2
[125I](Phe2,Nle4)ACTH-(1-38)~1
polymyxins~1
progesterone-directed~1
anisomycin~1
proceptive~1
antiprogestin,~1
nuclear-bound~1
progesterone-facilitated~1
msc,~1
827~1
-596~1
fmol/min,~2
11,972~1
pg/min~4
5,518~1
-6,454~1
1,932~1
pg/min,~2
ng/min~5
stimulation-induced~2
-532~1
22,777~1
7,082~1
12,764~1
-10,013~1
2,399~1
SPV~1
outputs.(ABSTRACT~1
Insulin-like~2
IGF-I's~1
20-3.5~1
[125I]iodo-LDL~1
[3H]cholesterol~1
[3H]cholesteryl~2
linoleate-labeled~1
[3H]progesterone~1
lipoprotein-borne~2
sterol.~1
effectual~1
PTH-(1-34)~1
phosphodiesterase)~1
188.2~1
8.15~1
766~1
127.9~1
455.6~1
tetracycline-based~1
osteoblast-mediated~1
0.01-0.025).~1
(woven)~1
Al-associated~1
osteoblasts.(ABSTRACT~1
(Met14hGH),~1
Nb2-11C~1
somatotropic~3
Nb2~2
Met14hGH~3
77-93%~1
[125I]hGH,~1
[125I]Met14hGH~1
down-regulation.~1
(VAD)~1
preleptotene~1
spermatocytes.~1
synchronization,~1
spermiations.~1
(hPL),~1
isobutyl~3
methylxanthine,~1
hPL~8
hPL-producing~1
Perifused~1
75-95%.~1
hPL.~1
esterases,~1
co-enzyme~1
(CoA)-cholesterol~1
CoA:~1
acetoacetyl~2
thiolase~3
4-aminopyrazolo-[3,4-d]pyrimidine,~1
intraadrenal~1
4-aminopyrazolo-[3,4-d]pyrimidine~1
alpha-ethinyl~1
hydroxysterols~1
collagenase-dispersed~1
studied.(ABSTRACT~1
hepatic-portal~3
lyophilized,~1
reconstituted,~1
Column~1
radioimmunoassayed~2
12-38~1
fmol/ml~1
afternoon,~4
fmol/ml.~1
13-32~1
noon;~1
nyctohemeral~2
pineal,~1
6-hormone~1
(6H~1
bTSH.~2
pmol/ml.~1
1B-6),~1
bTSH-sensitive~1
1B-6,~1
Hypophysectomy~2
IV1-4.~1
7.5K~4
15K~5
buffalo~1
ED50,~1
Chylomicrons~1
chylomicron-associated~2
cholesterol-labeled~1
diabetic:~1
(0.05%~1
weanling,~1
mellitus-~1
(LT)-prone~1
Biobreeding~1
Worcester~1
(BB/W)~3
iodine-induced~4
iodine-treated~2
BB/W~6
hemithyroidectomy~2
30-day-old~1
antithyroglobulin~2
BW;~2
(T4,~1
micrograms/dL;~1
25.1~1
ng/dL;~2
microU/mL;~2
non-diabetes~1
mellitus-,~1
non-LT-prone,~1
(W-line),~1
W-line~2
(71.5~1
hemithyroidectomized,~1
(mPL-II),~1
(mGH),~1
(mPRL),~1
(hPL)~1
mGH~4
mPRL~3
mPL-II~1
theophylline;~1
mPRL,~1
mPL-II,~1
Angiotensinogen~3
Reuber~1
H35~1
(H4IIE)~1
beta-estradiol.~1
Acc~2
(1097~1
basepairs)~1
(serum-free~1
conditions).~1
(Roussel-UCLAF)~1
L-T3~2
hypothalamo-neurohypophysial~1
urethane.~1
dehydrates~1
g/kg,~1
ip)~1
(2.5%;~1
relevancy~1
fluctuate.~1
(P2)~2
S-adenosyl-[methyl-3H]methionine~1
3H-methyl~1
phosphatidyl-mono-~1
dimethylethanolamine~1
proestrus;~1
estrus,~1
metestrus,~1
diestrus.~1
diestrus~1
mediobasal-hypothalamic~1
Ovariectomy~1
Attempting~1
methylation,~1
CsA,~2
LH;~1
(orange~1
CsA-treated~6
creatinines~1
POMC-like~10
immunostainable~1
(bFGF).~1
7.0-~1
3.7-kilobase~1
bFGF-like~1
bioactive,~1
anti-bFGF~1
theca~1
interna~1
adenohypophysial~1
believed,~3
mammotrophs~4
somatotrophs.~1
gonadotrophs~1
colocalize~2
somatotrophs~3
distalis.~1
Pituitaries~1
grids~1
PRL)~1
immunolabeled~1
mammosomatotroph,~1
colabeled~1
bihormonal~1
unspecific~1
6-n-propyl-2-thiouracil~1
(PTU-insensitive)~1
(DTT)~1
DTT~2
DTT.~1
noncompetitive.~2
enzyme/substrate~1
DTT,~1
uncompetitive,~1
Deiodination~1
PTU.~2
concentrations),~2
microsome~1
Ketononestrol~1
aziridine~2
[(6R,TS)1-(N-aziridinyl)6,7-bis-(4-hydroxyphenyl)5-nonamone~1
(KNA)],~1
hexestrol,~1
KNA~3
tritium-labeled~1
tritium-iodine~1
aziridinylation;~1
Ci/mmol.~1
[3H]KNA~3
concentration-,~1
[3H]KNA.~1
66,000.~1
receptor-agonist~1
physiopathological~1
(Cy)~1
(0.5-8~1
Cy.~1
-0.8128)~1
Cy;~1
preproIGF-IA~1
preproIGF-I~1
105.~1
preproIGF-I,~1
hybridizes~1
(quadriceps~1
femoris)~1
(hypox)~1
IGF-1~1
(9.7-~1
9.5-fold~1
hypox~3
0.95),~1
0.92),~1
microgram/rat~1
tuberoinfundibular~1
(TIDA)~1
TIDA~3
EV-treated~5
3,4-dihydroxyphenylalanine~2
(DOPA)~1
3-hydroxybenzylhydrazine~1
(NSD~1
1015),~1
DOPA~8
NSD~1
1015,~1
veratridine,~1
facilitatory~1
Ca2+-dependent,~2
Oxyntomodulin~1
(OXM),~1
glucagon-containing~1
octa-peptide,~1
immunoreactants~1
enteroglucagon.~2
OXM~6
Reversed-phase~1
RRA~2
N-terminally~1
(GOL),~1
GOL~2
peaks:~1
coeluting~2
glicentin~3
intestine)~1
OXM,~5
glicentin,~1
picomoles~1
GLI,~1
GLI)~1
GLI),~1
accounted,~1
totality~1
GLI.~1
h-fasted~1
(2-fold),~1
(GOL~1
antiserum)~2
(GOL--C-terminal~1
immunoreactivities)~1
totality,~1
[131I]Thyroglobulin~1
131I]Tg),~1
[131I]~1
iodoamino~4
(MIT,~1
DIT,~1
[131I]Tg~1
HCl.~2
4000.~1
degrades~2
perifused~1
(HGP)~1
HGP~7
[125I]glucagon~1
0.13)~2
isobutyl-methylxanthine~1
0.36).~2
cascade;~1
ketosis~2
14-min~2
Life-long~2
Recipient~1
oxygen).~1
organifying~1
30-36~1
methimazole.~1
energy-deficient~2
substimulating~1
prazosine~1
1-agonist,~1
(S-28)~1
(S-14),~1
S-28~4
anti~2
S-14/S-28~1
(1000-1700~1
sera:~1
(reacts~1
S-28,~1
S-14;~1
pmol/ml),~1
anti-S-14/S-28~1
S-14~1
S-28/ml),~1
anti-S-14/S-28-treated~2
3.25-fold~1
anti-S-28-treated~1
anti-S-28~1
S-14)~1
S-14.~1
(LID),~1
LID~14
KI,~1
mated.~1
age-paired~1
cretinism~1
cypionate~1
(%FT)~1
(%non-SHBG-T)~1
non-SHBG-T)~1
Non-SHBG-T~1
largest-fold~1
Luteinizing~1
thelarche~1
pubarche~1
menarche~1
luteolysis,~1
P/E2~1
minimal;~2
galactose-1-phosphate~1
uridyl~1
(transferase),~1
(Rokitansky-Kuster-Hauser~1
menopause--an~1
high-galactose~1
big-big~4
galactorrhea-hyperprolactinemic~1
5800~1
dividends.~1
embryo-derived~4
embryo;~1
Postthaw~1
thawed,~2
adenosinetriphosphate~1
ejaculates~2
(TCA~1
bioluminescence).~1
luciferin-luciferase~1
98.5%.~1
intrassay~1
nmol/living~1
thawed.~1
thawing.~1
freezing;~1
4-cell~1
videotaped.~1
CellSoft~1
(CRYO~1
Resources~1
(HOP)~1
penetrability~1
(PD).~1
HOP~2
non-PDs,~1
PDs.~1
non-PD~1
28.4%,~1
48.8%,~1
69.3%,~1
87.2%~1
22.7%,~1
37.8%,~1
52.4%,~1
57.9%,~1
cautery.~1
ampullary-isthmic~1
(PRL),~2
(FF)~3
hormone(FSH)-primed~1
(hCG;~1
ng/ml)-stimulated~1
FSH-supported~1
luteinization,~1
FF,~2
LI-like~1
hyperprolactinemia-associated~1
effect(s)~1
SDT~1
OPU~6
goals:~1
recurrence;~1
peritonitis;~1
SDT,~1
endometriosis-associated~2
fecundity~2
two-parameter~2
"monthly"~1
pregnancy"~2
immediate,~1
"buttoning"~1
iatrogenic.~2
Cul-de-sac~1
(PGE2),~1
F2a~1
(PGF2a),~1
13,14-dihydro-15~1
keto-PGF2a~1
(PGFM),~1
prostanoids~4
(WA)~1
(attempt~1
[RR]~2
2.5;~2
[CI]~1
1.7-3.7).~1
2.1-16.4)~1
1.3-8.5),~1
3.1;~1
1.1-9.1),~1
drug(s)~3
microprolactinomas~1
(microPRL).~1
microPRL~1
(hMG)~2
hMG.~1
estradiol/testosterone~1
(286~1
0.107,~1
dysynchrony~1
informing~1
BioBreeding/Worcester~1
Nondiabetic~1
(9.3~1
(168.8~1
165.7~1
(148.3~1
nm;~1
Endothelium-dependent~3
relaxative~1
(-8.0~1
(-7.0~1
-3.0~1
center-sponsored~1
suggestion,~1
budgets~2
revenues.~1
experts.~1
life-cycle,~1
child-bearing.~1
psychologist~2
Comprehensibility,~1
reciprocity,~1
mutuality,~1
credibility,~1
nurturing,~1
motherhood~2
tenet~1
competently~1
(Doctors~1
Ought~1
Care/DOC)~1
Seventh-grade~1
(DOC~1
talks)~1
talks~3
semester~2
criterion-based~1
print,~1
three-year,~1
Sample~1
pages~1
program-level~1
with.~1
stroke-rehabilitation~1
Rural~1
obstetrics,~1
fees.~1
states;~1
preceptors;~1
inventories~1
symptomatology;~1
(DACL),~1
DACL.~2
Maslach~3
Burnout~1
burnout,~2
psychologists~1
burnout~1
ethnographic~4
outlined:~1
desk~1
newspapers,~1
maps,~2
informant~1
Flashlamp-pumped~1
small-diameter~3
fragmenting~1
3-44~1
g/day),~2
nonclassifiable~1
0.014~2
trend)~1
acid-independent.~1
monoconjugates,~1
diconjugates,~1
alcohol-fed~1
calcium/bile~1
uridine-5'-diphosphate-glucuronosyltransferase~1
enterotoxin,~1
blood-to-lumen~1
[3H]mannitol.~1
micrograms/10~1
[3H]mannitol~1
A-exposed~1
discernable~2
transecting~1
Radiologic,~1
Erosive~1
postsclerotherapy~1
biofeedback,~1
intraanal~1
plug,~1
electromyometer.~1
Apple~1
electromyometer~1
"keyhole~1
deformity"~1
Gut~1
Sucrase~1
q.i.d.,~1
p.o.)~1
4.1,~2
exsmokers,~1
precedence,~1
intermediates,~1
6-G(Tyr-Gly-Trp-Met-Asp-Phe-Gly).~1
(gastrin~1
G).~1
109-21~2
6-G~1
Cross-reactivities~1
des(SO3)~1
6-G-R-R~1
gastrin-G~4
cosecreted~1
5-4864,~1
"peripheral"~1
"central"~1
mg/250~1
micrograms/250~1
intracerebroventricular~1
intracerebroventricularly.~1
benzothiazepine~1
Agonists~1
29.4%).~1
reflux)~1
624.9~1
mumol/h~2
CyA/kg~1
Miglyol~1
(24.6~1
graphed~1
CyA-treated~1
ordinate~1
bile-independent~1
Sucralfate~2
octasulfate~1
(SOS),~1
1.4-1.6).~1
levels--an~1
SOS.~2
octasulfate,~1
acid-titrated~1
SOS~1
SOS-treated~2
(injury~3
(0.003~1
Littermates~1
calories)~1
radioautographs.~1
(13.2~2
BICAP~6
spurting~1
oozing~1
nonbleeding~1
1:10,000.~1
1-sec~1
watt~2
2-sec~1
pouchoscopies~1
GIF-XP~1
retroflexion)~1
(56),~1
(47),~1
(18),~1
pouchograms~1
fistulograms~2
choledocholithotomy.~1
obliteration;~1
non-ostial,~1
interventive~1
anti-convulsant~1
independence.~1
reassure~1
diabetes-related~1
revolves~1
oesophagitis.~4
closet~1
(r=0.92:~1
Recumbent~1
oesophagitis,~2
58.2%~1
NSAID.~2
NSAIDs.~1
breakup~1
under,~1
Proven~1
nocte~1
nocte.~1
Tablets~1
2115~1
Breakfast,~1
lunch,~2
standardised.~1
Means~2
medians~1
smoking:~1
nmol/kg/h),~1
Vg~1
(ml/h)~1
(mmol/h).~1
standardisation~2
standardisation,~1
800,~2
bd~1
(given~1
(2300~1
anacidity~1
(speed~1
km/h,~1
(635~1
spirochaetosis~1
spirochaetes~1
harmless~2
commensals~1
(MTT)~1
Senokot~3
codeine/loperamide~1
63.9~2
g/day.~2
(dry~1
Codeine/loperamide~1
allotypes~2
Gm,~1
Am,~1
Gm~1
mesalazine~1
sulphapyridine~1
colitic~1
(Wistar-Kyoto~1
WKY).~2
presumption~1
tacit~1
mating),~1
inbred.~1
suppliers~2
F6~1
strain"~1
(tobacco~1
mellitus),~1
probability),~2
contends~1
10,059).~1
2.29,~1
2.83~3
g/cm2,~3
leanest~2
(age-adjusted~1
18.2%).~1
(1963-1965).~1
men:~1
74/1000.~1
19/1000~1
29/1000~1
ones.(ABSTRACT~1
50-degree~1
orthostasis.~1
humoral,~2
95-114~1
b.i.d.)~2
(120-180~1
(-10,~1
-20,~1
I/ml/hr)~1
diltiazem-treated~1
hydrochlorothiazide-treated~1
resistance.(ABSTRACT~1
fenoldopam,~2
dopamine1~1
163/103~1
147/76~1
BP)~1
121/81~1
123/65~1
BP);~1
-16~1
Fenoldopam-induced~2
765~1
634~1
3.8%;~1
dopamine-receptor~1
prostaglandin-mediated.~1
BP-lowering,~1
vasodilating,~1
multifiber~1
ramp.~1
[SE]mm~1
DS.~1
6-OH-dopamine.(ABSTRACT~1
baroceptor~1
Baroceptor~1
(relationships~1
Ethanol-fed~1
g/kg),~1
alpha-blockade.~2
carbochrome~1
(+5-10%)~1
(-24%)~1
(-17%),~1
(+13%).~1
reserve).~1
hypertrophy.(ABSTRACT~1
figure-of-eight~1
ligatures.~1
Plexiglas~2
(arteriolar~1
gains)~1
(0.155~1
0.030~2
acid/mol~2
40-week-old~3
(0.035~1
(palmitic~2
29%;~1
76%),~1
(servo~1
null)~1
Leaky~1
venular.~1
Six-week~1
DOC-salt-treated~2
hypertension-induced~1
microiontophoretically~1
deoxycorticosterone-acetate~1
(prehypertensive~1
stage).~1
microiontophoretic~1
nA~1
current-dependent~1
DOCA-salt-treated~2
arithmetic)~1
Microelectrodes~1
(leg)~1
(arm)~1
sympathoexcitatory~1
arylamine~2
carboxamides~1
carboxylate.~1
[3H]rauwolscine~12
4-aminophenyl~1
rau-AMPC)~1
Radioiodination~1
rau-AMPC~1
125I-rau-AMPC,~1
k2/k1~1
0.016~2
min-1/2.1~1
125I-rau-AMPC~2
photolabile~2
arylazide~2
alpha-hydroxy-20~1
alpha-yohimban-16~1
beta-(N-4-azido-3-[125I]iodophenyl)~1
(125I-rau-AZPC).~1
photolabels~1
62,000)~1
125I-rau-AZPC,~1
prazosin-treated~4
receptor-selective~2
BHT~1
(0.3-1~1
extra-junctional~1
Nai,~1
Nai/Ki~3
86Rb~3
(K~1
Nai~1
ouabain-binding~1
pressure-natriuretic~1
9-week-old~2
denervating~1
microEq/min/g~2
x-intercept~1
pressure-natriuresis~1
resetting).~1
resetting.~1
chloralose.~1
Single-unit~1
Arg-Pro-Hyp-Gly-Phe-Ser-DPhe-Phe-Arg-trifluoracetic~1
(B3852),~1
micrograms/0.1~1
phospholipid-sensitive,~1
Helical~1
(responses~1
KCl;~1
(168~1
12-O-tetradecanoylphorbol-13-acetate.~3
mezerein,~1
non-phorbol~1
EGTA)~1
-60%)~1
EGTA~3
minutes).(ABSTRACT~1
(3.3%~1
(4.0%;~1
(0.4%;~1
(-2.79~1
-1.34~1
delta/delta~1
blockade.(ABSTRACT~1
(DOC)-salt-treated~1
(SHR-S)~1
Okamoto~1
SHR-S,~1
SHR-S~4
(1.97%~1
2.93%~1
Cl-;~2
NaCl),~1
(2.93%)~1
(0.39%)~1
(0.39%~1
NaCl).~1
NaCl-fed~1
salt-depleted~2
Phosphoinositide~1
polyphosphoinositides~1
trisphosphate~3
alkalinization,~2
II-receptor~2
II-stimulated~1
catecholamine-containing~1
receptor-rich~1
overlie~2
gene-related~1
ganglionectomy.(ABSTRACT~1
(two-kidney,~2
current;~1
once-weekly~1
pivalate~3
mg/wk)~1
6-28)~1
12-28),~1
Deoxycorticosterone-treated~1
17-28).~1
postrema-ablated,~1
sham-operated;~1
ablated)~1
non-angiotensin-dependent~1
glioma-neuroblastoma~2
32P-labeled,~1
(1650-base~1
pair)~1
(cDNA).~1
Steroids~2
Actin~1
poly(A)+RNA~1
expressed,~1
(chronic)~1
43.1~2
feral~1
first-generation,~1
colony-born~1
parentage.~1
subspecies,~1
breeding.~1
5819~1
oxprenolol.~3
pressure-related,~1
"intermediate,"~1
"other"~1
pressure-related~3
tallies~1
cremasteric~2
figure-8)~1
Grollman~2
superfusion.~1
adenosine),~1
phenylephrine-contracted~3
(cGMP).~1
cGMP.~1
ester-contracted~2
vessels;~1
ester-treated~1
potassium-free~1
vehicle)~1
(ED50)~2
A-treated~1
Lame~1
(c~1
moduli~2
Lai-Fook~1
40:~1
508-513,~1
1976)~1
translobar~1
250-1,500~1
2-20~1
c-c~1
[air~1
(SF6)],~1
underdetermined,~1
infinite~2
assumption,~1
smoothing.~1
log-normal~1
blood-free~2
(5.24~1
4.89~1
(3.85~1
(15.33~1
Poly-L-lysine,~1
polycation,~1
U/mg~1
6.24~1
nonaerobic~1
(pHm).~1
(pHh).~1
High-~1
7.063~1
6.33.~1
prefatigue~2
ANOVA),~1
pHh~4
7.219~1
0.023~1
pHm,~1
5-Hz~5
Micropolyspora~1
ponies,~2
ponies.~2
pony~1
Untrained~1
m/min,~3
Run~1
48:30~1
intercostals~3
vastly~1
superimposed,~1
(sedentary,~1
joggers,~1
miles/wk;~1
marathoners,~1
miles/wk)~1
125I-fibrin,~1
125I-euglobulin~1
(IEL)~1
125I-plasma~1
(IPCL),~1
Marathoners~1
(76%~1
IEL;~1
427%~1
418%~1
309%~1
IPCL;~1
(IEL:~1
0.441~1
0.425,~2
IPCL:~1
0.294~1
0.544,~1
Bio-Breeding/Worcester~1
volume-pressure~2
(V-P)~1
midportion.~1
protein/DNA~1
4-hydroxy-L-proline,~1
V-P~2
(WGM),~1
(MGM)~1
([TCr]).~1
creatine,~2
WGM~1
[TCr].~2
Horse~1
MGM~1
(BB)~2
(Tes)~1
37.66~1
38.14~1
38.13~1
38.41~1
core-to-skin~1
(FBF)-Tes~1
FBF.~1
(PP).~1
elevated),~1
m/min.~3
Alpha-~1
(phentolamine)~1
alpha-blockade~1
slow-twitch~3
(fast~1
slow)~1
beta-Blockade~1
(0.2-3.3~1
Vp30~1
(airflow~1
27%).~2
mumol,~1
Alveoli~1
(approximating~1
microns3,~1
11,529~1
microns2,~1
72.7~1
91.8~2
microns).~4
(100.3~1
alveolus~1
beta-neurons.~1
monosynaptic)~1
beta-neurons~1
vagus,~2
(monosynaptic)~1
among-treatment~1
(120-158~1
kcal/mile)~1
(120-130~1
kcal/mile).~1
nonweighted~1
(kcal/mile)~1
inspiratory-shortening~1
expiratory-prolonging~1
parabrachialis~1
medialis~1
(pentobarbital,~1
cats).~1
0.2-0.4~1
(19-40~1
prolongation.~1
prolongation)~1
(12.2~2
Transvascular~1
(Pi).~1
(Blue~1
Dextran)~1
Fahraeus~1
(Qf).~1
Qf~1
fast-phase~2
(Kf).~1
Slow-phase~1
Fast-~1
plasma-perfused~1
(VE/VO2)~1
rpm)~1
(210-330~1
VE/VO2~3
(SEC)~1
(SEC~1
Stiffnesses~1
(slopes~1
(constant-stress~1
stiffness)~1
stiffness-stress~1
monotonically.~1
limit)~1
limit).~1
(1-11~1
pHi;~1
130-33~1
pHi,~2
box-balloon~1
(25-50%~1
[their~1
impulses/s~1
11-15~3
s].~1
77.3~1
(26.3%~1
(88.5%~1
low-nicotine~1
[HCO3-]~3
isonatremic~1
pedicles.~1
[Cl-]~2
meq/l,~2
meq/l.~1
acetazolamide-treated~1
meq/l)~1
pedicles,~1
ions;~1
(Rcs)~1
microliters,~1
1:10,000~1
Rcs~3
365%~1
(41.8~1
UK-37,248~1
(U-46619)~1
Hyperthermia,~1
heat-exchange~1
(SVI),~1
9.6,~2
169-173,~1
113-120,~1
148-117%~1
160-162%~1
87-102~1
105-120%~1
[tidal~1
(f)]~1
airways).~1
2.6-microns~1
monodisperse~2
Tyndallometry~1
(RC)~1
(Gebhart~1
51:~1
465-476,~1
1981).~1
expired/aerosol~1
1.0-micron~1
hold)~1
0.04-0.44~1
[0.25~1
(SD)].~1
1/f,~1
[coefficient~1
0.12].(ABSTRACT~1
perturbation.~2
thixotropic~4
Thixotropic~1
exceeded,~1
short-range~4
thixotropy~1
(0.2-0.3%~1
length),~2
kg/cm2),~1
extraalveolar~1
(Palv~3
inflation;~2
deflation)~1
Pa),~1
Pm),~1
Pv).~1
Palv~1
midlung~1
perimicrovascular~1
3.5-3.8~1
(metabolic,~1
insulative,~1
hypothermic).~1
immersions/wk~1
Thermoregulatory~3
acclimation~1
(Tdb):~1
(rh):~1
25%].~1
(32.7~2
7.99~1
5.25~2
min);~1
[rectal~1
(Tre):~1
37.06~1
37.31~1
(Tsk):~1
24.83~1
26.86~1
(Tb):~1
33.03~1
34.16~1
C);~2
thermoneutrality~1
37.16~1
37.39~1
31.29~1
32.01~1
35.92~1
36.22~1
(5.66~1
8.33~1
kJ/kg).~1
(VO2max).(ABSTRACT~1
Inert~1
(1,000Pc)~1
60Pc).~1
narcosis~5
multiday~1
60Pc~2
1,000Pc~1
annullment~1
regresses~1
1,000Pc.~1
N2O.~2
First-breath~1
(DMD),~1
MD,~2
efforts;~1
defenders~1
airflows~2
defenders;~1
Quantitatively,~1
phenomenon).~1
(COS)~1
(CRU)~1
(RC/AB)~1
CRU~2
RC/AB~3
-0.48~1
-0.46~1
equalized~1
Pab),~1
after)~2
CRU,~2
deflating~1
action);~1
Pab~1
inflating~1
action).~1
proprioceptors~1
Pes,~1
12-stage~1
(GXT).~1
group);~1
NF.~1
Pdi);~1
(TI).~1
TI.~1
manuscript,~1
(HGM)~1
HGM~1
(RLL).~1
Bloodless~1
RLL~1
(FIO2)~2
RLL.~1
(Pc),~1
0.50-1.0~1
light-to-moderate~1
O3,~2
NO2,~1
Two-way~1
intercostals,~2
transversus~2
Fiber~7
[6~1
notably,~1
(47-50~1
(PSN)~1
PSN~7
(30-60~1
(CSN).~1
CSN~2
PCO2.~1
O2-sensing~1
chemoreceptors.~2
25-beats/min~1
(CD25)~1
stimulation:~1
CD25~3
foxhound.~1
posttraining;~2
pretraining.~2
foxhound~1
microprocessor~2
rejecting~1
samples/s),~1
zero-crossing~1
breath-to-breath~1
282)~1
(2nd~1
SDV~2
SDQ,~1
SDQ~1
2.0).~1
pair,~2
8.6%~1
0.2-0.5~1
cmH2O/cm~1
ht,~1
59:~2
597-602,~1
cmH2O/cm).~1
"pleural"~1
blue-dyed~1
container,~1
hydrostatic.~1
container.~1
8-cm-long~1
99mTc-diethylenetriamine~1
"costal"~1
bottom,~1
gravity.(ABSTRACT~1
5-hydroxytryptamine,~4
dihydrochloride.~1
occupancy-response~1
receptor-reserve.~1
receptor-reserve~1
integer-multiple~1
(entrainment)~1
Nepalese~2
porters~1
Annapurna~1
Himalayas~1
915,~1
2,135,~1
3,200,~1
4,420,~1
5,030~1
[fraction~1
20.93,~1
17.39,~1
14.40,~1
11.81%]~1
consumption).~1
PDP~1
11/73~1
subharmonic~1
spectrum),~1
modeled.~1
(bottom~1
111In-oxine-labeled~2
audioradiograms~1
overdestruction~1
releasable~2
reinnervate~1
musculus~4
(E1~1
bodybuilders~1
degrees/s,~2
Biceps~2
brachii.~1
0.60)~1
W/CSA~1
0.67)~1
0.58),~1
IT/CSA~1
PT,~2
CSA.~1
F.(ABSTRACT~1
(QO2~1
QO2.~1
(P50)~1
low-P50~1
end-capillary~1
Torr)~1
dependency.(ABSTRACT~1
(diethylcarbamazine,~1
DEC)~1
(FPL-55712)~1
(rPBF)~1
rPBF.~2
FPL-55712~1
deep-penetrating~1
radio-frequency~1
600-MHz~1
waveguide-type~1
(SAR).~1
SAR's~2
Friesian~2
double-muscled~1
Belgian~1
(BWB)~1
(Ptp),~2
quasi-sinusoidal~1
(amplitude:~1
(Rc),~1
(Rp),~1
(Rt).~1
Ptp~2
Ptp.~3
Rc,~1
Rp,~1
BWB~2
(SWS).~1
SWS-tracheal~1
SWS-nasal~1
(N:~2
T:~2
0%).~1
gastrocnemius-plantaris~1
phenoxybenzamine,~3
isotonic,~1
(L),~1
0.3-0.4~2
Coinfusion~1
concentration.(ABSTRACT~1
1,3-[14C]propanediol~1
(Pr)~1
Indicator~1
125I-albumin,~2
51Cr-red~1
3HOH,~1
Pr~3
alloxan,~1
alloxan.~1
Indicator-dilution~1
PS,~1
diffusivity~1
(D1/2S),~1
(VW).~1
D1/2S~2
Pr,~1
VW~1
desiccation.~1
Interpretation~1
Inspiration~1
2-29~1
Airflow,~1
(DIA~1
EMG)~1
DIA~3
Hering-Breuer~2
subgross~1
(Lm)~1
Quasi-static~1
(%V10)~1
%V10~2
Lm~2
pig),~1
dyn/cm)~1
tomographical~1
3-7~1
bucket~1
reinflation.~1
microdroplet~1
mN/m~2
(gamma-V~1
hysteresis).~1
area-volume~1
(SA-V)~1
(2.19~1
gamma-SA~1
determinative~1
Twitch~2
0.7).~2
-0.58~1
shortens,~1
(STE)~1
nonfatiguing,~1
(8.9-35.7~1
Stevens~3
n,~1
phi.~1
(PAO).~1
(Qbr)~1
Qbr,~1
PAO~2
[Qbr(s-p),~1
pressure-1]~1
PAO,~1
Qbr~2
Qbr(s-p)~2
correlated:~1
(ml/min)~1
0.978Qbr(s-p);~1
0.912.~1
nonanastomotic~1
PAO.~1
0.007).(ABSTRACT~1
Breuer-Hering~1
(BHR)~1
1451-1456,~1
postdenervation~1
Multifiber~1
Sectioning~1
postsurgery,~2
stroking~1
(Sol)~1
Sol~2
half-relaxation~1
Po~2
S-Sol~1
S-P,~1
force/cross-sectional~1
Polycations,~1
polylysine,~1
(50-1,000~1
Blocking~2
protamine-treated~1
polycations,~1
[peak~1
(VO2peak),~1
l/min].~1
(120%~1
VO2peak)~1
rest);~1
(beats/min)~1
(l/min)~2
[HCO-3]~1
hypervolemia-induced~1
10-11%~2
non-steady-state~1
dTC~5
(0.165~1
+/-0.008~1
0.143~1
0.168~1
dTC.~1
recurarization.~1
La-])~1
incremented~1
loadless~1
50-W/min~1
[La-]~4
Beaver~2
1936-1940,~1
La-~1
b[exp(cVO2)].~1
(MSE)~1
MSE~1
residuals~1
[La-]-VO2~1
(d[La-]/dVO2~1
2.241~1
0.081~1
(Pcrit).~1
Pcrit~4
backpressure~3
(Ppv)~1
(P-Q)~1
100-micron~2
pump-perfused~1
Rus/PVR,~1
isogravimetric~1
(Kf),~1
nonembolized~1
Rus/PVR~1
37.13~1
37.37~1
36.99~1
36.66~1
emitter-collector~1
voltage-current~1
transistors,~1
two-generation~1
nonhomogeneity.~1
Properties~3
paths.~1
bronchoconstriction;~2
area-transmural~1
opening-pleural~1
interdependence~3
("knees"~1
"bumps")~1
benzoyl-phenylalanyl-alanyl-proline~1
(BPAP),~1
Accordingly~1
(2-171~1
(DLCO)~2
stereology~1
BPAP.~1
DLCO.~1
Vmax-ACE~1
isotropic~1
2-171~1
angtiotensin-converting~1
Krebs-perfused~1
[3H]benzoyl-phenyl-alanyl-alanyl-proline~1
([3H]BPAP),~1
(recruitment~1
derecruitment).~1
(VET)~1
constant-run~1
online~1
open-circuit~1
VET~6
68.0~1
Across~2
transformation).~1
(knee~1
jerk).~1
Capsaicin~1
75-Hz~5
protocols.(ABSTRACT~1
multiplication.~1
normo-,~1
hypo-,~1
(inorganic~1
phosphate)~1
7.10~1
6.83~1
PCr/Cr~1
ADP/ATP~1
7.25.~1
[ADP]~1
7.10)~1
6.83)~1
7.17).~1
mM-1~2
Km;~1
normocapnia.~1
7.25),~1
V/Vmax~2
(V),~2
(ROAD),~1
(CLD).~1
Intermittently,~1
(EVC)~1
apneas).~1
expression:~1
aP2~1
bP~1
chord~1
(Crs),~1
ROAD~1
weight-specific~2
a/kg,~1
b/kg~1
c/kg~1
Crs/kg~1
Crs20/kg),~1
rs)~1
relationship;~1
(Grs/kg).~1
Crs20/kg~1
rs,~1
Grs/kg,~1
(HeO2).~1
bag-in-the-box~1
(isovolume).~1
isoflow~1
(Viso)~1
intrasubject~1
Viso~1
Viso.~1
time-interval~2
(forty-five~1
(both,~1
subluxations~3
occurred.(ABSTRACT~2
self-image,~1
H.)~1
gradations~1
over-all,~1
lessened,~1
ninety-four~1
transferring,~1
subacromial~3
wheelchair,~1
Grade-III~1
Grade-I~1
Avascular~1
diaphyses,~1
orthoroentgenograms.~1
femora,~2
tibiae,~1
poliomyelitis;~1
hemangiomas),~1
polyostotic~2
Zickel~1
scanograms.~1
loaded.~1
tibiofibular~1
syndesmosis.~1
retro-acetabular~1
6.5-millimeter~1
pylons~1
ten-millimeter~1
compressive,~1
torsional,~1
half-frame~2
(half-pinned),~1
half-frame,~2
full-frame~2
(transfixion-pinned)~1
connecting-rod~1
superior;~1
triangulating~1
half-frames~2
another)~1
newtons,~1
pin-cluster~1
one-millimeter~1
newtons;~2
rigidity.(ABSTRACT~1
unfortunately~2
newton-meter~2
inch-pounds).~2
non-unions~5
clavicle,~2
Radiographically,~1
hypertrophic.~1
pseudarthrosis.~2
fourteen,~1
(93.7~1
plate;~1
sculptured~1
clavicectomy.~1
apron~1
averaged.~1
millirems~2
millirems,~1
millirems.~1
Precautions~2
coxarthrosis~2
ninety-one~1
hip-scoring~1
(fifty-two~1
7,222~1
Type-III~1
IIIA,~1
IIIB,~1
non-union,~2
Type-IIIB~1
non-unions,~1
Type-IIIC~2
(twenty-nine~2
stage-III~1
wound-healing~1
Conclusions~3
Radiculopathy~1
athetosis.~1
Herniation~1
athetoid~1
hyperactivity.~1
athetosis~1
osteophytes,~1
bone-grafting,~1
implant;~1
occipitocervical~2
atlanto-occipital~1
Occipitocervical~1
Iliofemoral~1
triradiate~1
Nes~1
rotationplasty~1
Syme~2
epiphyseodesis~1
above-the-knee~1
side-bend~1
side-bend,~1
sublaminar~1
broke.~1
xenograft.~2
eleven,~1
Neer-II~1
non-metal-backed~1
better;~2
revision:~1
components.(ABSTRACT~2
(functional)~1
epicondyle.~1
interepicondylar~1
neck-shaft~1
proximally,~1
distally).~1
interspecimen~1
transcondylar~2
distally,~2
(described~1
digit,~1
congruous~1
digit.~1
Semmes-Weinstein~1
(grade-3~1
grade-4~1
bulk.~1
Bristow-Helfet-May~1
(212~1
shoulders),~1
redislocated~1
(96.2~1
fifteen-week~1
(Schwinn,~1
intra-cardiac~1
Resuspension~1
multi-dose~2
Arrest~1
13-minute~1
86.1%~1
Thromboembolic~1
Re-operation~1
(asymptomatic~1
murmur)~1
homograft.~1
Bjork-prosthesis~1
Starr,~1
Bjork~1
followed;~1
pluripharmacological~1
epi-~1
Guiraudon's~1
(EEV),~1
EEV,~1
(ER),~1
(1-68~1
non-VT~1
non-sustained~1
miles),~1
(shrapnel,~1
gunshot),~1
logistics,~2
(208~1
microporous~1
2.36~1
Werner's~2
(CSFP),~1
(RSPP),~1
cross-clamped.~1
RSPP~4
6):~3
lusoria~2
Aortobifemoral~1
(PTFE),~1
bordered~1
side),~2
patency.(ABSTRACT~1
tanned~1
endothelialization,~1
saphenectomy~1
meanwhile.~1
attempting,~1
Lymphatic~3
lymphorrhea~1
(TCM204~1
Radiometer,~1
America).~1
27-yr-old~1
End-organ~1
(GR)~1
GR~5
(Kd).~1
(PCO)~1
(0800-2000~1
midfollicular~1
(MF)~1
PCO~3
pulses/12~3
mIU/mL)~1
(EF,~1
mIU/mL;~1
mIU/mL).~1
(GRTH)~1
GRTH.~3
GRTH~3
anti-Fn-precipitable~1
8.2%,~1
GRTH,~2
overlap;~1
125%,~1
thymulin~7
thymus)~1
(AGA)~1
AGA.~1
Persistently~1
AGA~1
8.6-13.3~1
3.09~1
4.03~1
[goitrous~1
4.41-9.03);~1
2.58-5.78);~1
28.7-70.5)~1
24.4-45.2);~1
mU/L;~2
0.05-1.6)~1
0.36-5.1;~1
0.70;~2
hyperproduction,~1
EGF-binding~2
PRL-~1
GH-secreting~1
SD)]~1
[125I]EGF~1
EGF-like~1
(DEX),~1
DEX,~5
45-60~2
[N-(1-phenethyl-4-piperidyl)propionanilide]~1
Isokalemic~1
[400~1
pg/mL;~2
pmol/L].~1
(DEX,~2
(183~3
DEX~8
(hPRL)~1
(70-90~1
(1.39-2.9~1
15.2-25.4~1
802~1
(75.6%)~1
45K~1
(16.1%~1
radioimmunoreactivity),~1
68.1%~1
22.5K,~1
45K,~1
160-180~1
200-220~1
220-240~1
discomfort.(ABSTRACT~1
hCG/human~1
(hLH).~1
hLH~1
hCG-~1
hLH-stimulated~1
steroidogenesis,~2
18-hydroxycortisol~11
aldosteronism~1
glucocorticoid-suppressible~1
aldosteronism.~1
adrencorticoids.~1
microgram/24~1
HPLC-RIA~3
18-oxocortisol~1
0.42;~1
19-nordeoxycortisosterone~1
18-oxoglucuronide~1
0.25;~1
0.15942).~1
mmoles/day)~1
mU/L).~1
dopamine-treated~1
pituitary-thyroid~2
ovulatory,~1
(TSAb)~1
(FT4I).~1
FT3I,~1
FT3I~2
Intrathyroidal~1
71-yr-old~1
570-g~1
micrograms/dL,~1
microU/mL,~1
iodinase~1
guaiacol~1
[131I]Iodide,~1
monoiodotyrosine,~1
71.6%;~1
diiodotyrosine,~1
26.7%;~1
1.05%;~1
0.65%.~1
[131I]iodide~2
(tracer)~1
(basal),~1
(GO),~1
(NA-K3).~1
basal:~1
0.8%;~1
GO:~1
15.1%;~1
3.1%;~1
NA-K3:~1
16.7%;~1
1.14%.~1
organification~1
factor-I~1
(MEM)~1
equalling~1
MEM~1
(FCS~1
(HbSS~1
(rbc)~1
crisis-free~3
deformable~1
rbcs~1
Velocities~1
rbc's~1
(Vrbc)~1
postocclusive~2
(PORH)~1
Vrbc~3
mm/s,~1
Crisis~1
PORH~1
leukocyte-to-endothelium~1
(PIP2)~1
PIP2~5
F(-)-stimulated~1
F-.~1
PIP2-specific~1
(-alpha/alpha~2
alpha).~1
segregates~1
cluster.~1
(GAG----UAG).~1
116UAG~1
nonsense~1
acetylcholinesterase,~1
acetylcholinesterase-negative~1
complement-sensitive~1
complement-insensitive~2
Hemolytic~1
(PNH~1
cytokine~1
micrograms/200~1
spectrins~3
(N-terminal)~1
80-kD~1
46-50~1
65-68~1
(T50a~1
T68~2
terminology).~1
HE;~1
IT80~1
50-kD~1
(T50b)~1
T50a~2
I125~1
IT80.~1
spectrins.~1
IT80;~1
255,~1
T50b~1
19-kD~1
464;~1
T19b)~1
68-kD~1
cleavages,~1
(EPS)~1
microperfusion~2
4-methylumbelliferone~1
(4MU).~1
4MU~1
superfusion,~1
365-nm~1
EPS~3
star~2
Midproximal~1
darkest~1
LPS.~1
M21~2
C9:C8.~1
C5b-8~3
C5b-8/cell;~1
C9:C8~2
6.6:1;~1
nonlytic~1
10(5)/cell),~1
2.8:1~1
C9/cell~1
1:1;~2
(e)~1
C5b-8(1)9(1),~1
(TBCa).~1
TBCa~2
0.52,~1
nephron,~1
saralasin~1
-187~1
68-99~1
(hence~1
nephron),~1
(AITP).~1
(CFU-Meg)~1
CFU-Meg,~1
CFU-Meg~1
[3H]TdR~5
thrombopoietic~1
spleen-liver~1
AITP.~1
GSH,~2
(BCKDH)~1
(MSUD)~1
BCKDH~3
MSUD,~1
(PNH),~1
lost:~1
PNH-erythrocytes~1
(PNH-E)~1
(huE)~1
C8-binding~2
(C8bp).~1
PNH-E~3
C8bp.~1
C8bp,~1
huE,~1
polymerization.~1
C8bp~2
PNH-E.~1
3H-PN200-110~2
3H-CGP12177~2
nifedipine-sensitive~2
Time-averaged~1
([Ca]i)~1
fura-2,~1
2.85-~1
2.16-fold~1
l-Isoproterenol~1
1.53-~1
1.28-fold~1
[Ca]i.~3
keratoacanthoma.~1
undifferentiated,~1
epidermotropism,~1
Pautrier-like~1
microabscesses.~1
paranuclear~1
intermediate-sized~1
(oriental~1
sore)~1
lesion(s)~2
noduloulcerative,~1
scar(s)~1
Arabia,~1
61.72%;~1
35.37%;~1
volcanic~1
30.32%;~1
19.37%;~1
11.37%;~1
"iceberg"~1
4.63%.~1
tenderizer~3
papain~1
sting~2
ant.~1
stings~3
tenderizer.~1
ant~1
Lipoid~1
proteinosis,~1
hyalinlike~2
lipoid~4
"onionskin"~1
35SO4(2-)~1
[3H]glucosamine~2
pro-alpha~2
1(III)~1
interrelation~1
Especially,~1
butanilicaine,~3
reactions;~1
dermatitides.~1
shave~7
electrodesiccation,~1
adapts~1
digits.~1
dual-running~1
W-plasties~1
orienting,~2
reexcision~2
autografts,~1
reductions,~1
sun-damaged~1
predermabrasion~1
valley-like~1
pre-,~1
postdermabrasion~1
follow-ups~2
unapparent~1
(BCC).~1
admixed;~1
unanalyzable~1
1,103~1
Ridit~1
minutes/24~4
recovered).~1
17.8)~1
42.3).~1
Catheterization-determined~1
velocities)~1
(catheterization~1
-0.03~1
0.163~1
0.134~1
0.161~1
"either~1
both."~1
(85%).(ABSTRACT~1
deepening~1
reenter~1
hypocontractility.~2
hypocontractility~2
hypocontractile~1
leads;~1
Being~2
silicone-rubber,~1
displacement:~1
(RV):RVNMR~1
RVcast~1
1.62;~1
(LV):LVNMR~1
LVcast~1
(CONMR~1
COTD~1
liters/min;~4
SVNMR~1
SVTD~1
1.95~2
5.58~1
(LVSVNMR~1
RVSVNMR~1
1.75;~1
variance)~3
mEq/dl~2
assessment:~1
(disarray~1
myofibers,~3
myofibrils,~1
fibers)~1
myofibers.~2
ductus;~1
valve-incompetent~3
ovale;~1
receded,~1
clues:~1
"matchhead"~1
exclusively;~1
(14.6%)~2
(12.2%)~1
Lown~2
Sotalol~2
dextrorotatory~1
d-sotalol,~2
d-Sotalol~1
d-~2
d,l-sotalol~2
d-sotalol~3
d,l-sotalol.~1
uncoiling~1
(large~1
136%.~1
Gensini~1
"normalcy~1
rate"~1
B2.~2
0.00001),~7
min/ml,~1
oxygen/min,~1
15,609~1
2,386~1
0.0001).(ABSTRACT~1
54);~1
4);~1
intervention)~1
multilesion~6
74)~2
Patient-related~1
restenotic~1
(87%);~1
11%).~2
each.(ABSTRACT~1
patient);~2
recatheterized~1
postangioplasty~1
Hazards~1
(post-angioplasty~1
0.039)~1
0.0007).~1
0.026).~1
preinterventional~1
Noninducibility~1
noninducible,~1
death.(ABSTRACT~2
Beta-adrenergic~3
celiprolol,~1
celiprolol.~1
oxygen/kg~1
blockade--reduced~1
pressure--must~1
(HDL)-cholesterol~1
cholesterol/HDL-cholesterol~1
myectomy.~1
0.89X~1
0.91X~1
filtering)~1
depolarizations/h~1
these)~1
0.0007)~1
30.1).(ABSTRACT~1
infranodal~1
0.00003),~2
0.0003),~2
0.00006),~1
increased.(ABSTRACT~1
pre-excited~1
(shortest~1
48.3%~1
pre-excitation~3
71.4%,~1
91.2%,~1
defibrillations~3
interpericardial~1
rate-sensing~1
defibrillations,~1
defibrillations.~2
electrode.(ABSTRACT~1
cryoprobe~1
cryoinjury~1
heart;~1
deaminase-resistant~1
N6-R-1-phenyl-2-propyladenosine~1
(RPIA),~1
RPIA,~4
RPIA~1
shocking~1
anodes),~1
(anode),~2
current-induced~1
20.2,~1
21.3,~1
(configurations~1
(configuration~1
T2)~2
seeks~1
MHz,~1
doughnut~1
Subaortic~1
bulboventricular~1
disadvantageous~1
conduit;~2
recruited.~1
Doppler-estimated~1
liters/min).~3
musical~1
striated.~1
striations~1
fluttering~1
vortices~1
hyperkalemia-induced~1
Intrasubject~1
mild/moderate~1
(Cl),~1
33.3%)~1
24.3%)~1
11.1%).~1
(LAR),~1
LAR~2
Cetirizine,~2
H1-antagonist~1
cetirizine~6
postdiluent~1
cetirizine.~1
hydroxyzine.~1
O-Glycosidically~1
(Gp-1~2
beta-b)~1
(Gp-1)~1
Pronase~3
squirt~3
Gi-rep~2
NaOH~3
NaBH4.~1
Gp-1~3
beta-b~1
N-Glycoside~1
beta-a~1
Gp-2~1
alkali-resistant~1
GPs~1
(Gp-2)~1
digest,~1
Chemically,~1
allergenically~1
glucosamine,~1
O-linked~1
O-~1
alkali,~1
"angioedema."~1
Melkersson-Rosenthal~1
"bursts"~5
(HPAA)~1
HPAA~1
(nadir~1
micrograms/1.73~1
"burst"~3
0.2);~1
IC;~1
beta-agonists;~1
cromolyn.~1
troleandomycin.~1
HPAA.(ABSTRACT~1
emigrating~1
2',7'-dichlorofluorescein~1
(DCFH-DA),~1
2',7'-dichlorofluorescein.~1
DCFH-DA~2
(PBNs),~1
acetate-stimulated~1
PBNs.~1
noncellular~1
PBNs~1
(CACh)~1
CACh~1
[ECACh]).~1
(V25)~1
"recovery"~1
(FEV1:~4
V25:~4
V25~1
V25,~1
-5%~1
-50%~1
-77%~1
"recovery."(ABSTRACT~1
loratadine~5
1:30~1
fuel.~1
continues,~1
(FFAs)~1
ketosis,~1
(NIDDM);~1
prescription.~2
Researchers~1
telephone,~1
mail-~1
telephone-assisted~1
reporting;~1
documents;~1
nonconsecutive~1
Adequacy~1
(MAR)--an~1
3,701~1
Variety~1
MARs~1
sugar,~1
se--either~1
adequacy;~1
Snacks~1
very-low-protein,~1
low-phosphorus~1
Acceptability~3
(unacceptable)~1
acceptable).~1
Products~2
vanilla~1
wafers~1
(4.0),~1
(3.97),~1
cookies~1
(3.78).~1
unfortunately,~1
cents~1
People,~1
Health/Preventing~1
Disease:~1
Nation.~1
mid-course~1
national,~1
federal,~1
Iron,~1
USDA~6
NDB~4
(avoiding~1
data),~1
Handbook~1
E/total~1
ever-growing~1
"head~1
household"~1
urbanization~1
achievements~1
Turkey.~1
founded~1
promising--particularly~1
cities;~1
nonmetropolitan~1
retirement/recreation~1
counties'~1
young-old~1
religiosity~1
devotions.~1
Texans~1
religion~1
(health,~1
income).~1
Multiple-regression~2
compensatory;~1
nonorganized~1
kin/friend~1
devotion.~1
affirms~1
wholeness~1
Michigan's~2
Income~1
Dynamics~1
multiple-equation~1
frameworks~1
logit~1
wealth,~3
pension~1
spouse's~1
car,~1
voting~1
Objective,~1
functionings~1
Multidimensional~1
(MOSES)~1
MOSES~2
norming~1
2,391~1
.8~1
.58~1
Robertson~1
Status,~1
Kingston~2
Dementia,~1
Impairment-of-function~1
(PAMIE)~1
(g)~1
headdown~1
(-0.17~1
headup~2
(+0.94~1
+g~1
unchanged)~1
institutionalization.~1
Passages~1
implied,~1
facts,~1
inferred.~1
compatible.~1
factorially~1
cuing~1
digit-monitoring~1
divided-attention~2
well-being:~1
(LSIA).~1
Senior~1
Citizens~1
Myths~1
Reality~1
LISREL,~1
LSIA.~2
(26.1~1
(66.0~1
5.85~1
(B-EP)~1
B-EP~4
(31.8~1
Checklist.~1
omohyoideus~1
impulses.~1
18-,~1
24-,~1
27-month-old~1
(493~1
Isoproterenol-stimulated~1
cAMP/mg~1
8.9,~1
5.1).~1
rotifers~1
(D:D),~1
D:D,~2
malonaldehyde,~1
Paramecia,~1
rotifers,~1
rotifer~1
(mab)~1
(TsF)~1
(AC)-associated~1
(ACAID),~1
TNP-coupled~1
(TNP-Spl).~1
mab~3
(14-12)~1
ACAID~1
TNP-Spl.~3
(14-30)~1
TNP-ACAID.~1
14-12+,~1
TsF~1
TNP-ACAID,~1
TNP-ACAID~1
[2-3H]myoinositol~1
Ins(1,4,5)P3~3
Ins(1,3,4,5)P4~1
Ins(1,3,4)P3~1
Ins(1,4,5)P3,~1
InsP3~1
Quin~1
Fura~3
2-loaded~1
paradoxically,~2
(PKC)~2
pp28,~1
pp33,~1
pp67~1
PKC.~1
PIP2.~1
(Bam~2
Bg1~2
Eco~2
RI,~2
Hinc~3
Hind~2
Pvu~2
DR1~2
DR9~1
RFLP.~1
Bands~1
DR1,~2
DR2,~1
DRw52,~1
DRw53,~1
Subtypes~1
DR1.~1
consanguinuity~1
non-polymorphic~1
DR6.~1
DQw2.~1
DR6~1
DQw1-~1
DQw2-associated~1
Subdivisions~1
MVL~1
(DR1),~1
Akiba~1
(DR2),~1
QBL~1
(DR3),~1
FPF~1
(DR5),~1
(DR6)~1
PD6,~1
PD6~6
SLA~3
family;~1
exon/intron~1
frames;~1
PD6-specific~1
(NK)-enriched~1
(MNC)~1
Chang,~1
Molt-4~1
5-HT1-specific~1
8-OH-DPAT,~1
5-HT1/5-HT2~1
5-HT2-specific~1
Monocyte/NK~1
NK-enriched~1
2-dependent~2
IFN-gamma~1
monocyte-containing~1
NKCC-enhancing~1
IFN-gamma,~1
(RBL-2H3)~1
ionophores.~1
ionomycin~2
Na+/Ca2+~2
ionomycin;~1
RBL-2H3~1
C-regulated~1
competitively.~1
diphosphate-induced~2
myocarditic~1
(CVB3m)-induced~1
CVB3m~5
(MNSF)~1
CVB3m,~1
anti-asialo~2
anti-Lyt-2~2
anti-CVB3m-neutralizing~1
CVB3m-infected~1
MNSF~4
LGL.~2
(cAMP)-dependent~1
RII~4
kinases)~1
[8-azido-32P]cAMP.~1
retinoids.~1
(L-SOD).~1
L-SOD~1
photodermatologic~1
Non-Langerhans~1
T6-~8
(MED)~1
cm-2),~2
0.397~1
cm-2).~1
blister-derived~1
UV-exposed~2
0.2%;~1
0.1%;~1
UVC;~1
0.2%)~1
(DNFB,~1
picryl~1
(PCl,~1
1%),~1
tolerogen~1
2,4-dinitrothiocyanatebenzene~1
(DNTB,~1
(LCs).~1
nonsensitized~1
adsorptive~1
DNFB-sensitized~1
DNTB~1
LCs,~1
(PGs)~1
7-PGA1~4
24-~1
D2,~1
9-deoxy-delta~1
9,12-13,14-dihydro-PGD2~1
12-PGJ2),~1
PGD2~2
PGD2;~1
12-PGJ2~2
PGA2~1
PGE1,~1
PGI2~1
cyclopentenone~1
cyclic-AMP,~1
cyclic-AMP~1
melanocytes:~1
thio-conjugates,~1
indolic~2
(dopa),~1
5-S-cysteinyldopa~1
(5-S-CD),~1
5-hydroxy-6-methoxyindole~1
(5H6MI)~1
5-hydroxy-6-methoxyindole-2-carboxylic~1
(5H6MI2C)~1
melanin:~1
tyrosinase-negative~1
albinism.~1
Dopa~1
5-S-CD~1
Indolic~1
fragmentography~1
deuterium-labeled~4
melanin-related~1
5H6MI2C~1
culturable~1
sebocytes~1
substructures~1
stating~1
seborrhea)~1
(PDGF)~1
([3H]Thd)~1
0-5~1
PDGF/ml~1
[3H]Thd~1
35SO4~1
pericellular,~1
CL4B~1
GAGs.~1
(DS')~1
parakeratotic~1
orthokeratotic~2
interscale~1
orthokeratinizing~1
30-microgram~1
nonresponsiveness,~1
parakeratosis.~1
hyperproliferation,~1
scale-associated~1
A-specific~1
pyrethroid~1
cypermethrin,~1
Cypermethrin~1
Volpo~1
cypermethrin~2
(cal/cm3)1/2.~1
(cal/cm3)1/2,~1
cal/cm3)1/2.~1
5-methoxypsoralen~1
(5-MOP)~1
5-MOP,~1
electroretinography~1
5-MOP.~1
5-MOP~3
wheal,~1
61.6%,~1
71.1%,~1
57.5%,~1
antipsoriatic~2
theories,~1
(UV)-excimer~1
heat-damaged~1
"shielding"~1
Epitestosterone~2
(EpiT)~1
alpha-hydroxy~2
epimer~1
EpiT~6
One-centimeter~1
Golden~1
sectioning.~1
(656/382%),~1
(210/315%),~1
(80/56%).~1
DHT-dependent~1
Toxic-shock-syndrome~1
(TSST-1),~1
(PBMs).~1
TSST-1-target~1
receptor-ligand~1
PBMs~1
(5-50~1
(25-10,000~1
ng).~1
Scatchard.~1
Toxin-specific~1
PBM~1
2.58~1
spleen-sensitive~1
parvum;~1
complement;~1
resection;~1
10(2))~1
10(5))~3
parvum,~1
extrasplenic,~1
splenomimetic~1
(UTI;60%).~1
(encrusted~1
cystitis).~1
UTI.~1
encrusted~1
(ID90):~1
ID90.~2
10-1,000~1
ID90~1
inocula.~1
B19~13
B19.~1
IgM-positive~3
stillborn~4
outcomes--no~1
(CB3)~1
CB3~2
pfu/g)~1
(3%-13%)~1
(4%-41%)~1
(14%-68%).~1
CB3,~1
(EBNA)~1
BamHI~1
mononucleosis,"~1
"fatigue~1
(EBNA~1
immortalized~1
antigen:~1
rhinovirus-associated~1
Tecumseh,~1
1966-1971.~1
Rhinoviruses~1
Rhinovirus-associated~1
completed;~1
typed.~1
evolving,~1
(HDCV)~1
(id)~1
smaller-than-recommended~1
HDCV,~1
id~3
1:11)~1
(IFN;~1
Scrape~1
Blinded~1
.057).~1
subepithelium~1
(Leu-3):T~1
(Leu-2)~1
5:1.~4
(Leu-14)~1
(Leu-7)~1
14.9%.~1
mini-epidemics.~1
10-30~2
Travelers~2
Canary~1
pretravel~1
vaccinations,~1
journey.~1
10,524~1
travelers;~1
73.8%.~1
doctor,~1
giardiasis,~1
7/1,000;~1
amebiasis,~1
4/1,000;~2
3/1,000;~1
helminthiases,~1
1/1,000.~1
cholera.~2
virology,~1
environments:~1
crowded,~1
(337~1
(293~1
nurses;~1
CMV,~2
patient-to-patient~1
seroconverted,~1
diapers~1
(UGTI)~1
Nairobi,~2
UGTI~2
20.3%.~1
4.4;~1
1.7;~1
2.6;~1
UGTI,~1
Capnocytophaga,~1
capnophilic~1
subgingival~1
nonoral~1
38.3%;~1
14.4%-113.3%).~1
mobilities~4
(LPSs)~1
(CB5)~1
CB5~4
epidemicity~1
coxsackieviruses.~1
fingerprinting.~1
1967.~1
monkeypox~2
Zaire~1
smallpox.~1
Lymphadenopathy,~1
smallpox~2
chickenpox.~1
unvaccinated~6
Pleomorphism~1
"cropping"~1
pg/ml-42,000~1
1:640.~1
10(5)-10(7)/ml,~1
(10(6)-10(7)~1
virions/ml).~1
(10(-2)-10(-4)~1
virions/ml)~1
corticoadrenal~1
panophthalmitis,~1
capsulatum.~1
histoplasmin,~1
(phospholipase~1
(oxygen-labile~1
hemolysin),~1
(PMNLs).~1
zymosan-induced~1
Toxin,~1
PMNLs,~1
chemiluminescent~1
Tuberculostearic~1
[(R)-10-methyloctadecanoic~1
(TBSA)]~1
(SIM)~2
m/e~2
Kong,~1
smear-positive,~1
specimens;~2
smear-negative,~2
sputa~1
GC-MS/SIM~1
Unit.~1
aerogenes.~1
aerogenes;~1
Enterobacter.~1
Enterobacter,~2
doses);~1
dose);~2
carumonam~1
28142~1
Oxytocin-like~1
ng/liter.~1
169;~1
nonpregnancy~1
(Spearman's~1
-0.50;~1
mumol/liter,~1
progestogenic~1
superovulation~1
CBA/Ca)~1
mare's~1
(PMSG)~1
superovulated~1
[73~1
nonusers]~1
IVF,~2
laypersons~1
ethical/social~1
"a~1
own"~1
"spare"~1
(POST)~1
transabdominovesical~1
(endometriosis,~1
ureaplasma~1
transferrin-like~1
Levo-norepinephrine~1
[ring-2,5,6-3H]~1
levo-norepinephrine,~2
O-methylated~1
4-hydroxy-3-methoxymandelic~1
normetanephrine.~1
VMA.~2
0.821~1
0.020,~1
0.020.~1
0.634~1
0.030,~1
0.507~1
0.025.~1
[8-14C]~1
monocyte-mediated~2
(Leu~2
3a)~1
2a)~1
tuberculin-specific~1
Acid-denatured~1
Concentrated~1
G-50-80~1
ethanol-ether~1
freeze-thawing,~1
PMN-prominent~2
(In-PMNs).~1
(early)~1
(late)~1
In-PMNs.~1
lung/spleen~1
6-phosphogluconolactonase.~1
6-phosphogluconolactonase~1
49.6%~1
Fn;~1
Fn-coated~1
(Gc,~1
(FHN).~1
acetaminophen-induced~1
FHN~1
(AST)~4
Gc~5
transblotting~1
anti-Gc.~1
Gc,~1
Densitometric~1
PAGE~1
Gc.~1
Dimethyl~1
scavenger.~1
(DMSO2),~1
quench~1
hypochlorous~4
DMSO2~2
chloramine,~1
monochloramine~1
DMSO2.~1
anion.~2
H+.~1
Amiloride~4
Na+-H+~3
phospholipid-dependent~2
C-kinase,~1
(FMLP),~1
FMLP,~2
22Na+~6
exchange;~1
uridine)~1
oxypurines~3
deoxyribonucleosides~1
(deoxycytidine,~1
deoxyuridine,~2
thymidine)~2
Hypoxanthine~2
near-linear~1
Covariance~1
iron-induced~3
kilogram),~2
Solubilization~1
K-deprived~1
N-methylthiotetrazole~1
(NMTT)~1
NMTT~1
K-free~3
NMTT:~1
(Bactrim),~1
NMTT-containing~1
antibiotics:~1
cefoperazone.~1
K1)~1
des-gamma-carboxy~1
(abnormal)~1
Gelsolin~1
severs~1
"nucleating"~1
"cutting"~1
oligomers,~1
dextrans,~1
(PAH),~1
permeability-area~1
"open"~1
thermometer~1
muscles:~1
sternohyoid,~1
sternothyroid,~1
ceratohyoid,~1
thyrohyoid,~1
geniohyoid.~1
-9.8~1
-4.9~1
NA+-Li+~1
(urea,~1
potassium),~1
vertical.~1
fenestra~2
Fisch~1
1968-1979,~1
(40-50~1
maxillectomy,~1
exenteration,~1
maxillectomy.~1
adenoidal~1
adenoids.~1
Hopefully~1
adenoidectomy.~1
uvulectomy,~3
palates.~1
palates,~2
sounds;~1
Transnasal~1
nasopharyngoscopy;~1
Azzam~1
Kuehn~1
(1977)~1
uvulae~1
Kleinsasser's~1
1963-1981,~1
(carcinoma~1
hyperplasia)~1
(hyperplasia~1
atypia),~1
postcricoid~2
cytopathologist.~1
Mononucleosis.~1
Mononucleosis~1
tonsil.~1
Leiomyoma~1
spindle-cell~1
(.58~1
$23.28~1
$14.44~1
month).~2
(3076~1
unexamined~1
underrecognition.~1
883~1
CAGE,~2
.0039).~1
(Pap)~1
Gaudette~2
Keeping~2
"An~1
Attempt~1
Comparison"~1
Forensic~4
(Vol.~1
599-606)~1
1/4500,~1
Quantico~2
(Proceedings~1
Symposium~1
Comparisons,~1
25-27~2
VA)~1
mark~13
perimortem.~1
aggressor's~1
evidence.~2
jury~1
rugae~2
nonmatching,~1
Unequivocal~1
equivocation~1
phlebography.~1
weapon,~1
weapons~5
weapons,~3
guns.~1
embracing~1
anachronistic~1
unpopular~1
scrutiny,~1
uncertainties,~1
answers,~2
Mariel~1
Boat~1
Lift~1
Communist~1
Cuba~1
shores~1
freedom,~1
Cuban~1
Government~1
prisons~1
Literal~1
interned~1
camps.~1
"Marielitos"~1
Criminal~1
mid-1980~1
mid-1985.~1
electrodermal~2
murder,~1
"lie~1
detector"~1
feedback's~1
respiration's~1
self-inflicted.~1
Self-biting~1
counterirritation~1
odontologist.~1
F-14~1
(CADS)~1
cockpit~1
energized~1
CADS~2
detonate.~1
projectile.~1
ordnance~1
(Ritalin~1
Talwin)~1
Missouri's~1
lakes.~1
sunken~1
adipocere~4
skeletonized~2
leather~1
bondage~1
Revolutionary~1
smokehouse~1
brutal~1
tale~1
sadomasochistic~1
ritual~1
biomedicine~1
elementary,~1
enterprise~3
objects,~1
symbolic/cultural/historical~1
ascertainment,~1
illustration.~1
conceptualize~2
culled~1
conjunctions~1
disjunctions.~1
antisocial,~1
redefined.~1
Parent,~1
refusers~2
nonrefusers~1
nonrefusers,~1
school-related~1
peers).~1
Categories~1
phobia,~1
refusers.~1
Kiresuk~1
Attainment~3
Scaling~3
critics.~1
detracting~1
Abuse~1
Client-Oriented~1
Acquisition~1
Process~1
[NIDA-CODAP]~1
NIDA-CODAP~1
2,532~1
cross-validation~2
client,~1
"partialed~1
out"~2
degree:~1
counselors~3
(client~1
contact);~1
counselors'~1
expressiveness,~1
staff-client~1
"autonomy"~1
self-sufficient~1
decisions);~1
clients'~1
subsamples~1
court-referred~2
substance-abusing~1
delinquent~1
finding:~1
self-evaluative~1
self-revealing~1
trusting,~1
ready,~1
abusers:~1
having,~1
addicts;~1
delinquents;~1
thoughts.~1
distractibility,~1
misidentification,~1
Fregoli~1
misidentification~1
neurological,~2
toxic-metabolic~1
paranoia~1
disorder)~1
(NINCDS-ADRDA~1
(4.6%)~1
(15.5%)~1
10(-2)).~1
(DPH)~1
dysregulation~1
perchloric~2
phosphodiesters~1
antedate~1
"molecular~1
neuropathology."~1
Scrapie~1
prion.~1
scrapie-infected~2
stalks~1
scrapie~2
varicosities.~1
Creutzfeldt-Jakob~1
Electrolyte-induced~1
(EID),~1
Teniposide~1
(VM-26)~1
VM-26~5
leukemia/lymphoma~1
blasts).~1
(Css),~1
Css~5
(Css)~1
(VP-16)~1
5-azacitidine~1
(5-Az)~1
(ANLL).~3
VP-16,~1
5-Az,~1
5-Az.~1
(refractory~1
relapsed).~1
days);~1
VP-16/5-Az~1
anthracyclines~1
ANLL.~1
(SUMC)~1
(JCRT)~1
(FFR).~1
(MMR).~1
FFR~5
(CMT).~1
MMR~1
XRT,~1
.12).~1
XRT~1
(7-year~1
89%).~1
1,616~1
Freedom~1
teratoma;~1
IIb)~1
surgery/radiotherapy~1
(septicemia,~1
aplasia).~1
Cisplatin-based~1
explored,~2
IIb/limited~1
IIc).~1
N-phosphonacetyl-L-aspartate~1
(PALA)~1
L-alanosine~1
16+~1
PALA~1
L-alanosine.~1
alfa-2a~1
(rIFN~2
Roferon-A;~1
Hoffman-LaRoche,~1
Nutley,~1
U/d~2
escalations~1
17+).~1
advance.~1
hydroxymethoxyphenylethyleneglycol~1
(HMPG),~1
nonneuroectodermal~1
remission),~1
(extracranial~1
(neuroectodermal~1
glial),~1
(neuroectodermal),~1
(neuroectodermal)~1
VMA,~1
Nonresponding~1
solitary)~1
nausea/vomiting~1
(L-2)~1
21-succinate~1
(Solu-Medrol~1
MP;~1
mg/kg/hr~2
12-point~1
stair-climbing.~1
cats)~2
-0.88).~1
MP-treated~1
brain-tumor~1
(92%);~1
(lasting~2
nonpostural~1
less).~2
somatomotor~1
concussive~2
cavitation.~1
Valuable~1
Subependymomas~1
intracranially,~1
cord;~1
wing.~2
AVM,~1
breakthrough,~1
(CBF),~2
excisable~1
(CT)-proven~1
rebleed~7
Apnea~1
Rebleeding~3
0.005)).~1
(47%:~1
(RFE).~1
RFE~1
retrogasserian~1
rootlets~3
gasserian~1
transclival~1
eased~1
human-derived~1
malocclusion~1
pseudomeningoceles~1
(preradiotherapy)~1
(vinblastine,~1
(GCT's)~1
non-germinoma~2
GCT's.~1
germinoma~4
(cyclophosphamide~1
rads,~1
20+~1
89+~1
GCT's~1
fo~1
chemosensitive~1
Germinomas~1
disseminate~1
pre-therapy~1
"penumbra"~1
transmantle~2
kaolin;~1
Plateau~1
(ICP).~1
plateau-like~1
(CPP),~1
CPP~16
(Infusaid)~1
Chemonucleolysis~1
workmen's~1
success).~1
1112~1
self-assessed~1
finger-tapping~1
reaction-time~1
injuries:~1
suffered,~1
17%;~1
"total"~1
0.0089).~1
mg/gm~2
ml/gm~1
corticosteroid-treated~1
cuffing~2
entrance.~1
whole-head~1
aperture~1
connected.~1
lacunae~1
epispinal~1
funiculi~1
L-2~1
S-2~1
interconnections~2
intersegmental~1
Asphyxia~1
(PG's)~1
pup.~1
tracheotomized,~1
carbon-14-iodoantipyrine~1
Laser-assisted~1
(LAVA)~1
arteriotomies~1
milliwatt~1
(4/17~1
25/28,~1
chi-square:~1
0.5-mm~1
(4/17)~1
(14/14)~1
stay-sutures~1
LAVA's~1
supports,~1
exploited~1
laser-sealed~1
reexplored~1
LSA,~1
pre-scan~1
scanners.~1
subchiasmal~1
(STA)-middle~1
STA.~1
cervico-occipital~1
Lipomas~1
retrochiasmatic~1
(RERF)~1
Hiroshima~1
Nagasaki~1
bomb.~1
(TG),~1
anti-TG~1
Nontoxic~1
uninodular~1
477)~1
501).~1
100+~2
(chi-squared~3
6.584,~1
7.919,~1
krypton-81m,~1
volume--(VA/VA)cal--from~1
(VA/VA)cal~1
mercaptoacetylglycylglycylglycine~1
(MAG3),~1
[99mTc]triamide~1
mercaptide~2
(N3S)~1
stereochemistry~1
dimercaptide~1
(N2S2)~1
MAG3~1
N3S~2
mercaptoacetylgylcylglycyl-glycine~1
99mTc]MAG3),~1
mercaptoacetylgylcylglycyl-L-alanine~1
99mTc]MAG2-Ala),~1
mercaptoeacetylglycylglycyl-L-asparagine~1
99mTc]MAG2-Asn)~1
mercaptoacetylglycylglycyl-L-glutamine~1
99mTc]MAG2-Gln),~1
[131I]OIH~1
[125I]iothalamate.~1
triamide~1
(123I)~1
chlorine-36~1
(36Cl)~1
pudic~1
perchlorate.~2
123I~2
60%-66%,~1
36Cl~2
123I,~1
nuclides~1
20-53~1
20-45~1
300-g~1
Technetium-99m-(99mTc)~1
pate~1
111In]DTPA)~1
crosstalk~1
(solids,~1
0.00097;~1
0.00038).~1
radioiodines~2
biokinetic~1
cumulated~2
submicronic~1
(CLE),~1
CLE,~1
CLE~1
Neurenteric~1
[99mTc]pertechnetate~1
sonographic,~1
lipoprotein-catabolizing~1
[lipoprotein~1
(HL)]~1
equienergetic,~1
oil:fish~1
triacylglycerol,~1
(HDL2),~2
(triacylglycerols)~1
L-cystine,~1
L-cysteine,~1
L-methionine~2
(unheated)~1
(PER).~1
vitamer~3
B-6-free~1
(PN~1
HCl)/kg~1
PN~5
HCl/kg)~1
HCl/kg~1
Neocortices~1
B-6-restricted~1
neocortex;~1
vitamers~1
imposed.~1
neurogenesis.~1
Eimeria~1
acervulina~1
coccidiosis~1
MgO~2
7H2O.~1
Gain,~1
(BAP),~1
coccidiosis-infected~1
coccidial~3
BAP~1
Gain~1
7H2O,~1
Coccidiosis~1
h/d~1
(CpA)~1
(CpB)~1
leveled~1
Zn/g,~1
CpA~1
CpB~1
7-wk-old~1
copper-supplemented~1
(+Cu)~1
(-Cu)~1
cuproenzymes~1
cytochrome-c~1
zinc-superoxide~1
dismutase.~1
-Cu~5
(APDE-I),~1
thymus,~1
APDE-I~1
+Cu~3
yellow-appearing~1
74,000,~1
16:0,~1
18:0~1
20:3n-6~1
18:1n-9,~1
20:4n-6),~1
3.65%~1
Three-week-old~1
(2.2%~1
6.25)~1
thrifty~1
well-groomed~1
specific-pathogen--free~1
latin~1
tyrosine-free~1
phenylalanine/kg~5
tyrosine/kg~1
Intra-adrenal~1
(AsA)~1
(ACL),~1
AsA~11
scorbutic,~1
acid/100~1
Scorbutic~1
NaF-stimulated~1
NaF-responsive~1
scorbutic~2
NAF-stimulated~1
(glucose)~1
fat/carbohydrate~1
diet-dependent~2
negates~1
obesity-producing,~1
(KC)~1
(+70-100%)~1
Adrenalectomy~1
evident)~1
vadrenalectomized~1
(NZB~1
NZW)F1~1
autoimmune-based~1
carbohydrate-free~1
autoimmune-prone~1
autoimmune-prone,~1
glomerulonephritis-prone~1
protein-low~1
exercise-retirement~1
allotted~2
40-d~2
wheel-running.~1
(2175~1
lunch.~1
single-pregnant~2
73-97~1
119-141~1
twin-pregnant~1
73-140~1
VO2/kg~2
brain).~1
kcal/kg/d;~2
micrograms/dL),~1
calcium-stimulated~1
primidone,~3
L-thyroxine.~1
Ca-stimulated~1
(indicating~2
conservation)~1
resorption)~1
Placentas~1
l-leucine~3
(fetal/maternal~2
fetal/maternal~2
unity;~1
(0.50~2
gradient-dependent~1
HgCl2~1
p-chloromercuribenzoate,~1
p-chloromercuribenzene~1
(PCMBS)~1
N-ethylmaleimide.~1
p-chloromercuribenzoate~1
PCMBS.~1
PCMBS~2
carrier,~2
bunazosin~3
Contributions~1
8.21~1
noncholinergic-nonadrenergic~1
nonadrenergic-noncholinergic~1
(6.75~1
mEq/kg,~1
(muscarinic),~1
(H1)~1
(5-hydroxytryptamine2)~1
myo-inositol.~1
(alpha-1)~1
EC50.~1
mM]~1
inositol-monophosphatase,~1
phosphoinositides.~1
HA1077,~1
two-hemorrhage~1
HA1077~9
Ca@-induced~1
6.71.~1
(PHE)~1
PHE~3
PG.~1
HA1077.~1
antivasospasm~1
7.30;~1
7.18)~1
(-)-isoproterenol~1
(5.59)~1
(5.29)~1
[125I]cyanopindolol~3
36.2~2
mg-1~1
20712A~3
[125I]Cyanopindolol~1
K-1~1
(24-32~1
(-)-propranolol~1
Beta-2~1
emulsion-coated~1
aprindine~7
4.81~1
[3H]idazoxan,~2
[3H]idazoxan~11
[3H]clonidine~2
Densest~2
parabrachial~1
Calleja,~1
parasubiculum,~1
radioligand.~2
thiosulfonates~1
CH3SO2S-(CH2)n-SSO2CH3(SS1~1
thiosulfonate)~1
hypolipidemic~3
acetoacetyl-CoA~1
thiolase,~1
thiosulfonate~1
hypocholesterolemic~2
hypotriglyceridemic~1
P-450MP,~1
tolbutamide.~2
Tolbutamide~1
copurified~1
P-450MP;~1
homogenous~2
P-450MP~2
anti-P-450MP~1
hydroxylate~2
mephenytoin.~1
intranigral~3
dopamine-2~1
(-)-[125I]iodopindolol~1
(IPIN)~1
IPIN~6
butylpindolol~1
CGP-12177~1
IPIN,~1
Isoproterenol,~1
salbutamol,~1
salmefamol~1
CGP-12177,~1
Unextracted~1
(LT)-like~1
FPL-55712.~1
counting,~1
[3H]LTC4~2
[3H]LTD4~1
serineborate.~1
monohydroxyeicosatetraenoic~1
(5-,~1
15-HETE)~1
HETE~1
HETE,~1
(alpha-1~2
alpha-2)~1
gepirone,~1
isapirone~3
1-(2-pyrimidinyl)-piperazine~3
buspirone).~1
Buspirone,~1
gepirone~2
prazosin)~1
ST-587),~1
tissue-~1
species-dependent~1
(isapirone~1
gepirone)~1
(buspirone~1
isapirone).~1
ST-587~1
rauwolscine).~1
S-pentobarbital.~1
N-crotonic~1
enantiomerically~2
asymmetric'~1
cross-reaction.~1
secobarbital,~1
thiamylal.~1
R-enantiomer,~1
(1.96~1
liters/h)~1
R-isomer~1
(2.58~1
liters/h).~1
(73.5%~1
63.4%~1
R-enantiomer),~1
S-warfarin,~1
S-phenprocoumon~1
S-glifumide.~1
Dendrotoxin~1
(DTX)~1
voltage-clamped~2
Myxicola~2
DTX~3
conductances.~1
prepulses.~1
(aquaresis)~1
(Saimiri~1
sciureus).~1
vasopressin-stimulated~1
D-tyrosine~2
(alkyl)~2
Aquaresis~1
aquaretic~3
0.7880~1
desGlyd(CH2)5D-Tyr(Et)VAVP~1
aquaresis~1
123A)~1
2-chloroethylamine~1
N-[4-(2-chloroethylmethylamino)-2-butynyl]-2-pyrrolidone~1
123),~1
123A~6
N-[3H]methylscopolamine.~1
Alkylation~1
N-[3H]methylscopolamine~2
N-methylscopolamine~1
16-fold~1
periarterial~1
(PNS).~1
PNS~4
release/stimulus,~1
perfusion-pressure~2
PNS-induced~1
release/stimulus~1
glucagon's~3
mg/ml/hr);~2
Normocalcemic~1
(5.24,~1
8.35~1
(3.62~1
hypo~1
mg/dl)-~1
(15.2~2
hypocalcemia),~1
dependent.(ABSTRACT~1
(saturated~1
acids),~1
sunflower~3
(unsaturated)~1
Purina~1
Rodent~1
Chow.~1
Sunflower~1
adrenoceptor-adenylate~1
[cAMP~1
(adenosine~1
monophosphate)]-independent~1
3-isobutyl-1-methylxanthine,~1
N6,2'-O-dibutyryl~1
phosphodiesterase.~2
micrograms/kg/hr)~1
(+/-)-dobutamine~2
(-)-dobutamine-mediated~1
(+/-)-~3
(-)-dobutamine,~1
(+)-dobutamine~4
(-)-Dobutamine~1
(+/-)-Dobutamine~1
isoproterenol-infused~3
(-)-dobutamine~3
prazosin-sensitive~2
(+/-)-,~1
(+)-~1
(+)-dobutamine.~1
Chronotropic~1
straightforward,~1
Deaconess~2
chlorisondamine,~1
beta-3-iodo[125I]-4-hydroxyphenyl-ethyl-aminoethyl-tetralone~1
[125I]HEAT,~3
(AHR).~1
AHR~6
(7.9~3
unaltered:~1
AHR.~1
(0.1-10.0~3
micrograms/40~2
corynanthine~1
(0.5-5.0~1
(0.01-0.2~1
antiepileptogenic,~1
anticonvulsant,~1
end-tidal.~1
Awake,~1
(1.63~1
liters/min),~1
(741~1
(-19~1
(-290~1
Hg/sec).~1
(chlorisondamine,~1
(11.6~1
liters/hr)~1
Nicardipine-induced~1
purinoceptor~2
N6-phenylisopropyladenosine~1
2-fold.~1
NECA,~3
D-PIA.~1
8-phenyltheophylline.~1
Terbutaline~2
purinoceptor.~1
overfed~4
semisynthetic,~1
energy-dense~1
710~1
(alanine~1
urine)~1
pellet-fed~2
Contributing~1
80-mg~1
muCi~1
4-[3H]propranolol~1
nonsmoking,~1
naphthoxylactic~2
(AAG).~1
0.175~1
0.090,~1
(CLu)~1
CLu~2
CLu.~1
low-to-medium~1
VUss,~1
cell/plasma~1
AAG.~1
peripheral-type~1
(PBR)~1
autoradiographically~2
PBR-specific~1
(R05-4864,~1
11195)~1
(13,000~1
R05-4864~5
metolazone~3
indacrinone~2
indapamide~3
(HCTZ;~1
trichloromethiazide~1
furosemide),~1
K+-sparing~1
triamterene),~1
acetazolamide)~1
(IC50S~1
stereoselective.~1
Thiazide-like~1
rank-order~2
(metolazone~1
trichlormethiazide~1
chlorothiazide).~1
metolazone,~2
indacrinone,~2
PBR~1
efficacies.~1
mg/mg~1
protein)-solubilized~1
HCTZ.(ABSTRACT~1
19,205),~1
2220~1
2815~1
2.6-16.3~1
2615~1
3760~1
2730~1
1905~1
vasorelaxant~2
vasoconstrictory~4
deficiency-induced~5
vasorelaxation~3
dichlorobenzamil,~2
Na+/Ca++~1
voltage-operated~1
endothelium-independent.~1
Hemoglobin,~1
accentuating~1
constrictory~1
WEB~7
2086,~1
thieno-triazolodiazepine,~1
kadsurenone,~1
thiazinamium~1
2086~6
111Indium~1
[30~1
ng/(kg~1
min)]~2
anti-PAF~2
ng/site)~1
(0.025-2~1
micrograms/site)~1
triazolodiazepines,~1
triazolodiazepine~1
(0.1-30~1
half-amplitude~1
decelerated.~1
(7-30~1
(0.1-480~1
furosemide-induced~1
Bed~1
noncephalic~1
46.5%,~1
Falope-Ring~2
spillage~1
(5.6%).~1
inexperience.~1
postcesarean~1
metronidazole-tobramycin.~1
Ideal~1
package-insert~1
parovarian~2
intraligamentous~1
(23/125)~1
fertilization/embryo~1
One-ovary~1
two-ovary~6
one-ovary~6
5.3).~1
ampules~1
Pergonal~1
(8.3%~1
laparoscopy)~1
laparoscopy).~1
(17OHP)~1
(298-3,170~1
ng/dL),~1
ng/dL)~2
(751~1
complete:~1
pregnanetriol~1
(235-537~1
21-deoxycorticoids,~1
CAH.~1
paracortex~1
androstenedione:~1
17OHP~2
(PCOS)~1
suppressible.~1
tomography.(ABSTRACT~1
mosaicism,~1
subseptate~1
subseptum~1
minilaparotomy~1
Dark~1
Agouti~1
Wistar-Hooded~1
Genetically~1
Leukopenia~1
deacetylated~1
10(-9)M.~1
hydroxychloroquine,~1
10(-5)M.~1
88)~1
DR4+~1
(pc~1
DR4~1
(III-IV),~1
ARA~3
(SCAT)~1
latex)~1
latex.~1
comorbidities,~1
cineesophagram~2
cineesophagrams~1
cineesophagram.~1
Raynaud's,~1
CREST)~1
Photoelectric~1
plethysmogram,~1
Longterm~1
(16-20~1
(plethysmography).~1
anaphase~1
telophase~1
HEp-2~1
antimidbody~1
1:160~1
1:1280.~1
DNase~4
RNase~1
Osteophyte~1
sacrifices~1
safranin-O/fast~1
synovial/periosteal~1
nubbin-like~1
spurs~1
synovial,~1
perichondrial/periosteal~1
periphery;~1
CsCl~1
CL-2B,~1
hydrodynamically~1
macromolecule.~1
CL-2B~1
A1D1~2
A1D2~1
14C-glucosamine~1
proteoglycan/mg~1
diflunisal,~1
diflunisal~2
Diflunisal~1
etodolac,~1
etodolac~2
trisalicylate~1
salicylate:~1
0.31);~1
tolerability~2
1,178~1
tolerability,~1
Predisposing~1
Heightened~1
arteritis-polymyalgia~1
recognized:~1
mononeuropathy,~1
neuropathy--C-5~1
bipyramidal~1
9,540/mm3~1
Proteinuria,~1
Pathophysiological~1
(ITP)~2
Malignancy,~1
lymphoreticular,~1
ABIM's~1
humanism)~1
indebtedness,~1
loan~3
moonlight~1
$20,500),~1
payments.~1
moonlighted,~1
debt,~1
payments,~1
dependents.~1
vaccinations.~1
taught.~1
postsecondary~1
nonminority~2
Certification~1
Physician's~1
Minority~2
shortage.~1
responded;~1
satisfaction:~1
clear;~1
members;~1
Lecturers~1
lecturer's~1
lecturers,~1
lecturer~1
lecturers~3
Harvard~1
School.~1
acknowledged.~1
reluctant~1
applicant's~1
(pediatrics,~1
applicant.~1
manipulated,~1
qualifications~4
applicant~3
pediatrics,~2
vignettes.~1
heterosexual.~1
portrayed~1
prejudiced~1
stigmatizing,~1
documentary~1
roundtable~1
advocacy~1
wrap-up~1
physics,~1
subtests.~1
sociodemographic,~1
educational,~1
1,994~1
freshman~3
freshmen~2
course's~1
attitudes;~1
students--both~1
students--had~1
Phagocytic~1
(PMN-CL)~1
0.81;~1
oxygenating~1
PMN-CL~5
opsonic~2
(Tf)~1
humoral-phagocyte~1
(PMN-CL,~2
OI,~2
3.55~2
01.5~1
10(3);~1
10(3).(ABSTRACT~1
Makiya's~1
Transaminase~1
chloric~1
R-value~1
Ps.~1
10(8)/20~1
kg/minute).~1
Neutropenia~1
cephalosporins.~1
substance(s)~2
140-290,000.~1
tracheocutaneous~1
reapproximation~1
Z-plasty.~1
Z-plasty~1
Combat~1
Netz~6
tension-absorbing~2
pins;~1
borehead.~1
Supported~1
hemorrhagic-traumatic~1
scrofa)~1
(DIC).~1
ml/kg-1~1
mg/kg-1)~1
(AVF)~1
AVF~3
post-traumatic,~1
hepatosclerosis~1
ascertain.~1
Misdiagnosis~1
Fossa~1
navicularis~2
penourethral~1
dilations,~1
meatotomy~1
open-sided~1
duplication.~1
retroiliac~1
pyonephrotic~1
malrotated~1
ureterocaliceal~1
Castleman's~1
Calculi~3
through-and-through~1
basket.~1
Aberrant~3
retrocaval~1
undiverting~1
cystoplasty:~1
detubularization.~1
mirabilis.~1
struvite/carbonate~1
apatite.~1
epididymectomy~1
brushite.~1
Buren~1
21.2F.~1
pre-dilation~1
11.3F,~1
10.6F.~1
dilated/nondilated~1
Glucose-loaded~1
Cytoplasts,~1
polyanion.~1
countercharges~1
R3327~1
musculovascular~4
tumescence.~1
Bursts~1
detumescence~1
bulbocavernosus-ischiocavernosus~1
proCedure.~1
dosimeters.~1
(location,~1
opacity),~1
heparin-coated~1
Urothelial~1
non-coated~1
anti-adherence~1
erectogenic~1
cavernosographies~1
papaverine;~1
intracavernously)~1
neuroendocrine-reproductive~1
microsecond~1
fiber;~1
cladding~1
utilises~1
fine,~1
miniaturization.~1
0.0027).~1
0.0026).~1
pelvicalyceal~1
0.0056)~1
fragmenter.~1
24F~2
36F~3
semi-rigid~1
(Amplatz~1
design)~1
cross-sections~1
Masson's~1
24F.~1
(-)3H-noradrenaline.~1
superfusate~4
neck--alpha-adrenergic~1
excitement~1
six-week-old~2
24.3,~2
ventral,~1
non-castrated~1
methyltestosterone,~1
Ureterorenoscopy~1
Creation~1
vesicostomy,~1
defunctionalization~1
(20).~1
Clot~1
cystotomy,~1
vesicorenal~2
advised,~2
mesylate.~2
Auto-injection~1
Priapism~1
Bulbocavernosus~1
msec.,~1
absent)~1
organogenic~2
Curvature~1
wedges~1
3-zero~1
polydioxanone~1
epidermidis),~1
Surgical/pathological~1
interaortocaval,~1
paracaval~2
precaval,~1
precaval~1
preaortic~2
retroperitoneum,~2
Hilar/suprahilar~1
(162~2
intermembrane~1
Manganese~2
Roy~1
thymolphthalein~1
0.0002,~3
(0.0~1
IU/l.)~1
penetration--serum~1
involvement--clinical~2
minor),~1
contusions.~1
nonurological~1
Burden~1
(pelvis,~1
infundibula~1
calices).~1
(upper,~1
juxtavesical).~1
(sand,~1
fragments)~1
piridoxilate,~2
glyoxylate~1
580~3
glyoxylate.~2
727~1
mumol.~2
Whewellite~1
arrangement,~1
trihydrate,~1
Piridoxilate-induced~1
hemiacidrin~3
paretic)~1
365.~1
101F~1
Rehospitalization~1
post-perfusion~1
Whitaker~1
signifying~1
Anderson-Hynes~1
ureteropyeloscopy~1
ureterostomy~2
antirefluxing~2
antimesenteric~1
sandwich.~1
multifocal,~1
ureterectomy,~1
nephroureterectomy,~1
fulguration.~1
bladder:~1
prophylactic/adjuvant~3
m.2)~1
inevaluable~1
m.2~3
m.2.~1
ototoxicity,~1
transections.~1
quadriplegics)~1
mm.).~2
(95.7~1
(87.2~1
hemorrhage).~1
tissue-diagnosed~1
post-transurethral~1
infrared,~1
spherules~1
calcium-to-phosphate~1
spherule~1
1.19.~1
Lactobacilli~1
lactobacilli~2
lactobacillus~5
uropathogens~3
casei~2
GR-1~2
(GR-2,~1
GR-3~1
A-60)~1
lymphangiography.~1
(lymphnodegram).~1
lymphnodegram~1
Interpretations~1
lymphnodegrams~1
microscopic.~1
cysto-vesiculo-prostatectomy~1
acclaimed~1
hospital-related~1
indoctrination~1
Transureteroureterostomy~1
undiversions,~1
reimplants/reconstructions~1
ureterostomy,~1
Hamartomas~1
designation,~1
rhabdomyosarcomas~1
Devine-Horton~1
paper-thin~1
meatus,~2
reconstructed.~2
subcoronal.~1
meatal-based~1
(flip-flap)~1
chordee,~2
add-on~1
nonhair-bearing~1
interscrotal~1
chordee-causing~1
Duckett~1
Thiersch-Duplay~1
(63.6~1
Muir-Torre~2
jejunectomy~1
(Duke~1
i)~1
ii)~1
iii)~1
osmoles,~1
volumetrically~1
frequency-graded~1
curtailed,~1
"resistance~2
shunt-like~1
VIP-ergic~1
vessels."~1
rTNF~6
topoisomerase~2
(VP~2
topoisomerase-targeted~2
teniposide~1
(VM~1
C3H/HeJ~1
implantability~2
MBT-2.~1
(TNS)~1
TNS,~1
(seven-day~1
implantability.~1
(3,700~1
cystectomized~1
quantities.~1
Damaging~1
regenerates.~1
ionically-bound~1
intercalated~9
nm.2~1
60-ml.~1
electrostimulation~1
spasmodically~1
ureterointestinal~1
ureterosigmoidostomy.~2
(nitrosamines)~1
ureterosigmoidostomy,~1
urine-feces~1
slurry~1
Nitrosamine~2
(N,N-dimethylnitrosamine)~1
(11/28)~1
0.275~1
micrograms./ml.~1
nitrosamines~1
(RSVs),~1
femoral-popliteal~1
(SF-PVs),~1
SF-PVs~4
RSVs~3
Obligatory~1
SF-PV~5
(RSVs,~2
SF-PVs,~2
Continuation~1
untenable~1
inflammatory.~1
(AES)~1
sham-seeded~1
ECs/cm2),~1
AES-treated~1
(AVFs)~1
AVFs~2
(loss~2
nonsmooth~1
side-to-side).~1
623~3
(50.2%).~1
walls;~1
spectrographic~1
J/mm~1
J/mm,~1
devices:~1
bird's~7
nest~7
81.3%~1
hooked~2
pre-shaped~1
trapped.~1
reopened.~1
anesthetics;~1
venacavography~1
intracaval~1
Coverage~1
[TSH])~1
mU/L~2
(microU/mL)~1
(thyroxine~1
[4.5~1
(microU/mL),~1
high-titer~3
(regardless~1
1:1600~1
Minn,~1
(PPS),~1
care-intensive~1
institutionalized.~1
PPS~1
PPS,~1
48%),~1
39%).~1
practice:~1
payers,~2
reimbursement,~4
poverty.~2
"screened"~1
"undetected~1
reservoir"~1
(Conn)~1
"epidemiologic~1
necropsy"~1
2067~1
nosologist~1
Diseases.~1
deaths)~4
certifiers.~1
Omission~1
certifiers~1
DT-60~4
tabletop~2
(Ore)~1
Throughput~1
claim.~1
$1.20~1
$5.49~1
secretary,~1
residents)~1
purchasers,~1
manufacturers,~1
(MT[ASCP])~1
Licensed~1
noncertified~2
30%).~1
discernible.~1
technologists,~1
rs~1
ventures~1
pathologists,~3
Labrea~2
Basin,~1
Boca~1
Acre~1
Basin.~1
nonfulminant~1
Venezuela.~1
Basin~1
25-mg~2
active-treatment~1
lower-dose~1
15-mg~1
Lactic~3
Hyperlactatemia~1
prohibited~1
careers,~1
defensibility.~2
defensibility~3
arbitrators.~1
Experts~1
Arbitrators~1
Commercial~1
stippling~2
edetic~2
Basophilic~1
(HTSCA)~1
HTSCA~1
L-glutamine~1
L-asparagine~1
interacromioclavicular~1
"Pitt"~1
semi-synthetic~2
(Zn)~1
P):Zn,~1
Fe:Zn.~1
(mg/g~2
mid-arm~1
0.019)~1
(ELD)~1
(BEE)~1
Harris-Benedict~1
ELD~4
BEE~1
(1580~1
1575~1
(1755~1
330)~1
1180~1
expenditure/g~2
(EEE)~1
EEE~1
(AVP)-sensitive~1
dihydrotachysterol,~1
watered~1
2478~1
(IMCD)~1
(MAL)~1
MAL~2
AVP-stimulated~2
OMCT~1
cyclase.(ABSTRACT~1
cuprophan-induced~1
cuprophan-activated~2
OKY1581.~1
thromboxane,~1
(OMCDi).~1
(IMCD1)~1
IMCD.~1
IMCD1~2
OMCDi.~1
OMCDi~1
cpk~2
(PKD)~1
nmol/liter)~2
(cpk/cpk)~1
(cpk/+)~1
PKD.~1
PKD~1
chloruretic~1
FeCl~1
5.20~1
0.49%~2
CIn,~1
2.3%;~1
hydrochlorothiazide's~1
doubt,~1
H+-ATPase~1
export~2
Na+/HCO3-~1
symport~1
chloride-dependent~1
bis-(carboxyethyl)-carboxyfluorescein~1
acid-loaded~1
H+/K+~1
nigericin,~1
7.1)~1
HCO3-/CO2,~1
4-acetomido-4'-isothiocyano-2,2'-stilbene~1
(SITS).~1
bis-(1,3-dibutylbarbiturate)~1
trimethine~1
oxonol,~1
HCO3-/CO2~1
hyperpolarization.(ABSTRACT~1
microcatheterization~1
amiloride-induced~1
antikaliuresis,~2
Smaller,~1
reabsorptions~1
alpha-galactosyl~1
determine,~1
anti-galactosyl~1
1:80)~1
micro-~1
(4/5~2
Coli~1
alpha-galactosyl-glucoside~1
anti-alpha-galactosyl~2
alpha-galactosyl-glucoside,~1
D-glucose.(ABSTRACT~1
(84.0%)~1
2530~1
narrow.~1
cord-like~1
bisected~1
hemisections~1
(27.3%).(ABSTRACT~1
build,~2
arcuate/interlobular~1
nonsclerotic~1
(23,700~1
mu)~1
(19,600~1
3,700~1
glomerulosclerosis.(ABSTRACT~1
(FSS).~1
FSS~1
MH,~2
FSS.~1
co-factors~1
(PHPT),~1
(taken~1
mass).~1
nephrogenous~3
(NcAMP),~1
NcAMP~1
25(OH)D~1
clinically-well~1
0.583,~1
0.512,~1
0.715,~1
0.717,~1
0.803,~1
0.440,~1
Deficient~1
(CRC)~1
chronically-hemodialyzed~1
CRC~5
0.0065).~1
Transfusions~1
CRC,~1
2,3-diphosphoglycerate-poor~1
EP-HCT~1
persisting,~1
oxy-deoxyhemoglobin~1
(LCSG)~1
1,121~1
nonsmall~1
N0,~1
expectations;~1
yttrium,~1
Fleischer~1
distally;~1
retrogradely.~1
aliment~1
CBC;~1
films;~1
(PPNET)~1
"PPNET"~1
ganglioneuroma.~1
non-beta~1
pyloroplasty.~2
hypersecretion.~2
"cimetidine~1
failure."~1
(ER~1
PgR)~1
PgR-positive~1
Peroxidase~1
"virgin"~1
debulking.~1
Serum-mediated~1
(3H)-thymidine.~1
blastogenesis.~1
noncardioplegic~2
(118%~1
(114%~1
IU/L/gm,~2
retrospectively;~1
antibiotic-sterilized~1
homografts,~1
valveless~2
heterograft~1
statistically,~1
Repairs~1
difference),~1
sinus),~1
266)~1
(porcine,~1
126,~1
pericardial,~2
(86%,~1
12/14)~1
5/14)~1
Monostrut~2
replacements,~2
mitral)~1
valved,~1
870~2
patients-years~1
survivor).~1
excluded)~2
89.2%,~1
82.5%).~1
97.5%,~1
92.8%,~1
definition)~1
96.0%,~1
93.9%,~1
89.7%.~1
(26.1%)~2
(229)~1
tertiary,~1
2.60%~1
1.04%~1
(4.34%~1
patient-year),~1
(0.35%~1
(0.52%~1
6.08%~1
(7.33%~1
(3.29%~1
staged;~1
(151),~1
Sensitivity,~3
mediastinum;~1
abutting~2
(52.3%)~1
(59.1%),~1
(irradiation~1
(gradients~2
(S,D,D)~2
switch,~1
banding;~2
banding.~2
patient-months.~1
123%~1
107%~1
unassisted~1
assistance:~2
0.0004,~1
(153%~1
operating,~1
Duffy~1
(HMSN~1
IA)~1
HMSN~1
disease-type~1
Aschoff~1
HMSN.~1
Rhinophyma~1
rosacea,~1
vaporize~1
rhinophyma,~1
Aspartate~3
macroenzyme~1
immunoglobulin-complexed~1
macro-AST~1
5-phosphate.~1
Self-Administered~1
(SAAST)~1
SAAST~5
patient-spouse~1
patient-collateral~1
76.5%.~1
Patient-spouse~1
84.7%~1
problems"~1
68.5%~1
"loss~1
control."~1
SAAST,~1
1,771~1
3,322.~1
(2.98~1
(3.57~1
Appearance~1
anxiety-provoking~1
carbidopa-levodopa~1
beta-fibrinogen~1
BclI.~1
B1B1~1
g/l;~1
B2B2~1
B1B2,~1
2.98~2
g/l.~2
fetal-like~2
0.015;~1
signed-rank~1
0.009;~2
Kigali,~1
Rwanda,~1
(12.4%):~1
enteritidis~1
nonbacteraemic~1
falciparum~1
parasitaemia.~1
Bacteraemic~1
bacteraemic~1
(9.3%~1
7.3%).~1
Rwandese~1
(GR38032F),~1
Nausea,~1
vomited.~1
Polyarticular~1
OA--generalised~1
OA.~2
Joints~2
underdesigned,~1
overdesigned~1
45-64~1
(CHD).~1
first-two~1
converged.~1
life-span.~1
self-defined~1
UCCA~1
candidate's~1
alphabetical~1
50-base~1
nucleocapsid~2
(AICAH).~1
AICAH~1
hypercholesterolaemic~1
(LDL;~1
0-12),~1
(VLDL;~1
20-400),~1
non-lymphocytic~1
(t-ANLL)~1
preleukaemia.~1
t-ANLL.~1
t-ANLL~2
levelled~1
rubella-like~2
(269)~1
(160),~1
(17).~1
11-14-year-old~1
intensification~1
eradication.~1
60-95~1
A9~1
Complexes~1
14C-acetaldehyde~1
borohydride,~1
post-alcohol~1
acetaldehyde-albumin~2
double-labelled~1
starch-derived~1
16,800)~1
[SEM~2
1.3]~1
mOsm/kg)~2
(332~1
[1.0]~1
1.36%~1
28.1%~1
83.0%~1
glucose;~1
ultrafiltrate.~2
7-9-fold~1
osmosis.~1
(FBA),~1
(9.86~1
[SE~1
0.81]~1
FBA)~1
(7.51~1
[0.24]~1
mg/g).~2
Lister~1
Guineapigs~1
immunised~1
viraemia,~1
non-manual~2
7735~1
(fatal~1
Programme.~1
laboratory-proven~1
16th~1
31%)~1
(demographics,~1
cats'~1
Grafting~1
"pulseless~1
myoelastic~1
omohyoid~2
investing~1
epithelialize~1
tracheosophageal~1
fluent,~1
intelligible~1
duckbill~1
Dedo~1
Sooy~1
commissure,~1
subglottic,~2
microtrapdoor~3
Rhinitis~1
medicamentosa~1
Neonates~1
breathers,~1
edematous,~1
deaf,~1
ototoxicity.~2
deafening~1
radiograph;~1
Phillips~1
Ruh~1
(1912)~1
Sweetser~1
hemangiomata~2
Sweetser,~1
supraglottic,~1
late,~2
Photoglottographic~1
(PGG),~1
electroglottographic~1
(EGG),~1
stroboscopically~1
photographing~1
PGG,~1
EGG,~1
vibration.~1
vibrates~1
margin)~1
glottographic~1
(PARA,~1
ectomorphic~1
mesomorphic~1
[density~1
(Db)]~1
generalized,~1
(tested)~1
(PARA).~1
over-predicted~1
PARA~3
0.0039~1
0.0166~1
(under-predicted~1
7.4%).~1
SAS-STEPWISE~1
hydrostatically~1
0.0164),~1
skinfolds,~1
0.0064).~1
Lohman,~1
131I-human~2
20.3%~2
sub-maximal~7
post-training~1
wk-1)~1
somatotype~1
amenorrhea;~1
yr-1~1
yr);~1
gynecologically~1
menarcheal~1
mileage,~1
same:~1
runners).~1
quietly,~1
post-VO2max~1
(1.07~1
(ir-BE)~1
8-min~1
+15,~1
Ir-BE~2
kits.~1
ir-BE~3
(pg~1
intensity;~1
(27.1~1
2.4)~1
(74.1~1
8.6).~2
8.1)~1
5.2)~1
ir-Be~1
(predicted~1
248.2~1
VO2max;~1
-0.397,~1
rowing.~1
variable-resistance~1
rowing~4
re-breathing,~1
rowers~1
0.58;~1
ergometers~1
(140/90~1
160/95~1
post-training.~1
one-repetition~1
(4,374~1
6,866~1
(64.0~1
65.4~1
(40.9~1
95.8~1
91.3~1
endurance.~1
Circuit~1
one-mile~3
165,~1
178)~1
mile.~1
(best~1
sub-sets)~1
walk-1~2
(T1);~1
1-4);~1
(yr);~1
(lb);~1
6.9652~1
(0.0091*WT)~1
(0.0257*AGE)~1
(0.5955*SEX)~1
(0.2240*T1)~1
(0.0115*HR1-4);~1
0.325~1
0.355~1
sub-maximum~1
(HWs),~1
HWs~5
(151.1~1
160.1~1
(252.1~1
237.3~1
25.1)~1
HWs.~2
(719.3~1
98.1~1
784.4~1
118.9~1
HWs).~1
3-lb~1
MET,~1
HW~1
supra-maximal~3
platform.~2
Supra-maximal~1
towing~1
telemetrically~1
Pre-activity~1
post-contact~1
strides.~1
9.7%).~1
supra-maximum.~1
non-significantly.~1
Post-contact~2
talocalcaneal/talocrural~3
eversion/inversion~1
motion;~1
shank~3
calcaneus;~1
categorize~1
"Rearfoot~1
motion,"~1
rearfoot~2
inversion-eversion~2
system"~1
plantar-dorsiflexion~1
pronation;~3
heel-toe~1
running;~1
flare).~1
shoes);~1
heels~1
pronation,~1
electrogoniometrically.~1
physician:~1
non-injury~1
lesion/laxity~1
brace;~1
Marquette~1
Stabilizer~1
photoelectrically~1
(3.33~1
electrogoniometer~1
foreaft~1
(UDO)~1
UDO~3
action--downhill~1
40-min~1
Delayed-onset~1
soreness,~1
(viz.~1
dominant)~1
-0.50~1
-0.22~1
succumbed.~1
(Xq).~1
Chromosome-banding~1
Xq~3
DNA-hybridization~2
46,XX,del(X)(pter-q21.3::q27-qter)~1
equipoise--a~1
merit,~1
obliged~1
"treatment~1
preference"~1
insuperable~1
equipoise,~1
equipoise,"~1
community--not~1
investigator--about~1
surgical-wound~1
face-lift~1
augmentation-mammoplasty~1
office;~1
gentian~4
skin-marking~2
violet,~1
mammoplasty~1
chelonae,~1
abscessus,~1
c-sis,~1
"competence"~1
trientine~2
accidentally)~1
radiator~4
soldered~1
heated,~1
shops~1
radiators,~1
deciliter;~1
respirators~1
indicated)~1
working.~1
(11,712~1
1.94;~1
2.78).~1
0.01])~1
strata,~1
7547~1
contacts)~1
postintervention~1
doubled)~1
RSV,~1
Pseudoxanthoma~1
unliganded~1
trp~2
aporepressor~1
repressor~1
symmetrically-disposed~1
bihelical~1
motifs.~1
'DNA-reading~1
heads'~1
alpha-helices~1
somatotopically~1
organized,~4
noradrenaline-containing~2
coeruleus~1
neuromodulator~1
Johnston~1
mossy~1
LTP~2
beta-adrenoceptors~1
All-trans-retinoic~1
bud.~2
(234)~1
mirror-symmetrical~1
432234~1
bud~1
polarizing~1
ZPA)~1
ZPA.~2
buds~1
high-point~1
bud,~1
excretable~1
accordingly~1
Catalysed~1
lecithin-cholesterol~1
(phosphatidylcholine-sterol~1
acyltransferase)~1
lipoproteins;~1
VLDL)~1
(CETP);~1
endocytosis.~1
(Mr),~1
74,000~1
1.9-A~1
periplasmic~1
D-galactose-binding~1
nine-residue~1
(amino-acid~1
134-142),~1
beta-turn~1
beta-strand,~1
residue.~1
205.~1
Ca2+-binding~1
adopts~1
'helix-loop-helix'~1
'EF-hand'~1
trg~1
Glutamate~3
non-vesicular~1
bacteriocidal~1
(X-CGD),~1
plasma-membrane-associated~1
X-CGD~6
linkage.~2
(90K)~1
90K~1
22K~2
(b-245),~1
heterodimer~1
(23K)~1
beta-chain;~1
'reverse~1
genetics'~1
19-147~1
non-coding~1
Karyotypes~1
non-hereditary~1
devising~1
X-autosomal~1
non-random~1
techniques),~1
enzyme-positive~3
enzyme-negative~1
X-inactivation~1
nonshocked~1
shock;~1
stimulus-withdrawal~1
pre-exists~1
nonbinding~1
(MCD),~1
electrocorticogram~1
MCD~3
quasi-permanent~1
MCD-like~1
serotonin-containing~1
5-HT)~1
K-conductances~1
Ca-independent~1
K-conductance~1
neurons:~2
K-conductance,~1
Im~1
inhibitory,~2
fate.~1
vegetal~2
Vg1,~1
oogenesis.~1
Vg1~3
oocyte,~1
translocating~1
Vg1.~1
evidently~2
highly-polymorphic~1
PUM~2
mucin-type~2
SDS-gel~1
PUM-coded~1
mucins.~1
immunohistology~1
translated,~1
Enhancers~1
enhancer.~1
polyomavirus~2
enhancers.~1
F441~1
positive-acting~1
Base-pair~1
acceptors~2
lifetimes,~1
(AAC~1
exchange).~1
catalyst.~1
Retrovirus-mediated~1
Hunter-Schreger~1
(HSB)~1
prisms.~1
insectivores~2
multituberculates.~1
HSB~2
arctonic~1
condylarths~1
Palaeocene~2
(Puercan)~1
herbivores~1
carnivores~1
oligodendrocyte--type-2~1
(O-2A)~1
axolemma.~1
type-1~4
astrocyte,~1
(E16),~1
P0),~1
P8~1
P10.~1
Type-1~1
O-2A~3
myelinated.~1
astrocytes.~2
(19F-NMR)~1
19F-NMR~1
spin-spin~2
(T2),~1
halothane;~1
mdx,~1
locus;~1
Hprt~1
chromosome,~2
Emery~2
Dreifuss~2
Xq28-qter~1
domesticus/spretus~1
segregating~2
provocatively~1
fur,~1
spf,~1
OTC~1
(ornithine~1
transcarbamylase)~1
mutated~2
Duchenne/Becker~1
cross-hybridize~1
centimorgan~1
St14-1~3
(DxPas8)~1
phosphorylase~2
(Phk).~1
X-chromosome,~1
G6pd~1
myopathies:~1
lymph-nodal~1
phosphorylating~2
8-10-fold~1
30-nucleotide~1
(CRE)~1
cAMP-responsive~1
CRE.~1
CRE~2
43K)~1
43K~1
(CREB)~1
3-4-fold~1
CREB~1
sequence-directed~1
protein-induced~1
A-tract~1
deducing~1
bends.~1
Amino-acid~1
GABA/benzodiazepine~1
ligand-gated~2
super-family~1
ion-channel-containing~1
Co-expression~1
vitro-generated~1
supercooled~1
subzero~1
hysteresis,~1
colligative~1
insects~1
supercooling~1
antifreeze~1
(AFGPs).~1
imprinted~1
gametogenesis;~1
propagated,~1
extraembryonic~2
imprinting,~1
undermethylated.~1
faithfully~1
pronuclear~1
'genome~1
imprinting'~1
imprinting~2
pronucleus;~1
division;~1
gametogenesis~1
enhancers,~2
246-base~1
BclI-PvuII~1
Py~3
subdomains~1
Host-range~1
mutants)~1
endoderm,~1
A2(TXA2),~1
RCS-RF2~1
A2-inhibitory~1
'lipocortins'.~1
lipocortin~1
Lipocortin~1
anti-phospholipase~1
Receptor-operated~2
(ROCs)~1
Bolton,~1
Breemen~1
Somlyo~1
Somlyo,~1
near-physiological~1
Mg2+,~1
NMDA~1
(N-methyl-D-aspartate)-activated~1
ATP-activated~1
spectrin-based~1
Spectrin,~1
assembly,~1
membrane-skeleton-associated~1
Ca2+-~1
adducin:~1
Adducin~1
(EPs)~1
Arbitrary~1
false-positive/false-negative~1
mitosis,~1
nonbenign~2
fringes~1
(suggesting~1
substance)~1
736~2
fleece~1
(OC),~1
Hemostasis~1
OC,~2
inward.~1
polynucleated~1
(CVP).~1
60-g~1
(SCBF).~1
dextran,~2
MSAP,~1
isothiocyanate-labeled~2
formalin-fixed,~1
lectins,~1
Solanum~1
tuberosum~1
N-acetylglucosamine~1
abundantly~3
hydromyelia~1
STA~1
0.962)~1
reapplication.~1
rebleeding.~2
(DACA)~1
composes~1
angiography:~1
DACA~3
azygous~1
DACA.~1
morbidity/mortality,~1
(37),~1
(37.1%)~1
(18.8%)~1
(digoxin,~1
support).~1
55.6%~1
37.4%~1
worst,~1
(91.4%)~1
31.7%,~1
HFS.~3
school-age~1
Seeding~1
adenohypophysitis~1
petroclinoid~1
meningioangiomatosis~1
meningocytic~1
ventricle-peritoneum~1
Work-up,~1
cisternography,~1
Occupant~1
publicized.~1
Wrenching~1
attenuated,~2
lacerating~1
marketplace~1
1,500,000~1
Comedication~1
(toxicity:efficacy~1
NINCDS-ADRDA~2
lexical-semantic~1
Bradyphrenia~1
inattentive~1
thinking,"~1
intellect,~1
vigilance.~1
bradyphrenia.~1
CSF-MHPG,~1
bradyphrenia~2
CSF-MHPG~1
mid-20s.~1
X-chromosomes.~1
99.2%~1
monozygotic.~1
Xp21~1
pERT87.~1
Theta~1
neuroimaging~1
aphasia.~1
anatomic-clinical~1
scholastic~1
achievements,~1
handicap~2
Anatomic-clinical~1
centered,~1
(CPT-I)~1
(CPT-II)~1
CPT~4
CPT.~1
isotope-exchange~1
sonication:~1
CPT-II~1
all-glass~1
homogenization,~1
CPT-I~1
Ross~1
(RRV),~1
togavirus,~1
A/D)~1
anti-RRV~1
RRV-induced~1
abulia,~1
Neuropsychologic~1
Excluded~1
neurosyphilitic~1
weight/24~1
treponemicidal~1
(Wmax)~1
O2/kpm)~1
hyperhidrosis,~2
dysreflexia.~1
dysreflexia~1
propping~1
upright,~1
counterproductive.~1
pseudoepileptic~1
pseudoseizures.~1
succession.~1
attenuations,~1
(LDME)~1
LDME~2
Conception~1
6.1)~1
miscarriages,~1
miscarriage.~1
afternoons~1
responsive.~1
bodies),~1
Lewy~1
(CPSs)~1
(IMS)~1
CPSs~1
IMS~2
video-EEG-recorded~1
Transthyretin~1
plexus-specific~1
21-41~1
fibrillation/flutter~1
post-extrasystolic~3
growth-discordant~1
discordancy:~1
Twins~2
discordancy~2
disparity.~1
handicaps.~2
(96.5~1
90.1~1
18.3)~1
(95.5~1
16.8),~1
11.5%),~1
myometria~1
PAGE),~1
carbamylation~1
34,500~1
(34K)~1
-21(P34a-d)~1
-23(P56a-d),~1
tissue:~1
P34,~1
myometria;~1
P56a&d,~3
(65.3%);~1
P56b&c,~3
(0%);~1
(46.1%)~1
myometria.~1
P34~2
P56~2
(P34~1
phase:~4
92.3%;~1
15.3%;~1
P56a-d~1
30.7%,~1
53.8%).~1
14,028~1
38,645~1
NST.~1
(primiparas~1
multiparas)~1
(lumbar~1
peridural~2
oxide).~1
Primiparas~1
-6.4~1
primiparas~1
3.9%;~1
7.21~1
-9.5~1
4.5;~2
recent,~1
Puget~2
1977-1981.~1
healthiest~1
nongenital~2
assailant,~1
weapon.~2
"gang~1
rape."~1
self-reporting~3
urethroscopic~2
urethrocystometry.~1
24.6%~1
59.3%~1
cystometry.~1
(94.4~1
82.4%,~1
(10.9%)~1
3461~1
(25.8%)~1
Q-Tip~1
Coexistent~2
Diethylstilbestrol-Adenosis~1
DES-exposed~6
high-stringency~1
Insulin-dependent~1
malformations)~1
(class~1
RT)~1
glycohemoglobin~3
.039)~1
(75)~1
"successful~1
.012)~1
.037)~1
"successful"~1
4116~1
936~1
135-139~1
(SAP-35)~1
SAP-35~5
(L/S)~1
30-43~1
protein-35~1
L/S~2
(diabetic)~1
(control);~1
protein/creatinine~2
0.9936;~1
gonadotrope~1
carbidopa,~1
dopamine/norepinephrine~1
Follicle~1
protein-related~1
22-23~1
anovulatory.~1
(granular)~1
(26.1%),~1
deglycosylated-asialo~1
choriogonadotropin~1
(AHF-hCG)~1
AHF-hCG~4
(LH)-like~1
minces,~1
gonad,~1
85.45%.~1
18.4%~1
76.9%~1
(1-3+)~1
(95.1%)~1
high-virulence~1
67.6%~1
18.6%~1
6%),~1
22%),~1
RDS.~1
7.2)~1
second-stage~2
63),~1
129)~1
acidemic~1
respiratory-metabolic~1
(mEq/L)~1
.0005)~1
(-15.9~1
(-9.6~1
(-6.4~1
1.9)~2
(artery~1
vein).~1
7.20~1
test,"~3
71,~1
breathing;~1
colposcopic,~1
microspectrophotometry.~1
"Q-tip~1
medium-fill~1
(stress~1
mobility).~1
upstaging,~1
.022).~1
postperitoneal~1
reperitonealization~1
24-34~1
PTT,~2
fourth-degree~2
3400~1
warmth,~1
Mother~1
primigravida~1
(case/control)~1
primigravidas~1
Mother.~1
.000001).~1
nephrostomy.~1
neovascularized~1
Miya~1
Hook~1
sacrospinous~2
coccygeus~1
duration:~1
1.5-6~1
blasted~1
energies,~1
laser-treatment,~1
monovision~1
keratomileusis,~1
asphericity~1
photograph.~1
Contour~1
keratomileusis.~1
entoptoscope.~1
entoptoscopy~1
consequences,~1
simplex,~2
zoster,~1
pox,~1
conjunctivodacryocystorhinostomy.~1
autoclavable~1
Aqueous,~1
transconjunctivally~1
[aqueous~1
2-tailed~3
t-test);~1
5408.8~1
357.3~1
228.0~1
0.004,~1
t-test)].~2
[32.0~1
0.026,~1
suture-tagging~1
hemostasis,~1
crushing)~1
post-enucleation~1
Zonular~1
pseudoexfoliation~2
Simcoe~1
aspirating~1
(Storz)~1
zonular~3
zonules.~1
disinsertions~1
(ECCE).~1
(Phaco-Ersatz)~1
Refinements~2
discission~1
discission.~2
IOLs~2
Modification~2
mobile.~1
pressure-reduction~1
plausibly~1
3065~1
(ECCE-PC~1
IOL)~1
(44/3065)~1
(40/2330).~1
3065)~1
0.0013)~1
(AEL)~1
IOL~1
phacoemulsification~2
(PKE),~1
RDs~1
Punctal~1
aqueous-deficiency~1
Bengal~1
supplements;~1
punctal~2
(keratograms)~1
pellucid~1
mire~1
steepening~1
meridians.~2
[Trobicin])~1
(NVI)~1
designates~1
numeral.~1
"+"~1
NVI.~1
(PEX)~1
PEX.~2
PEX~9
469~1
(actuarial)~1
trabeculoplasty,~1
fluorescein-filling~2
fibroproliferation~1
(34.4~1
13/15~1
11/17~1
downgrowth~1
cicatrizing~1
bilaminar,~1
trilaminar,~1
bodyfold~1
arches,~1
evolving.~1
fetor~1
peritonsillar~2
dyscrasias;~1
fail,~2
"grow~1
(14.9~1
immature/total~2
micro-erythrocyte~1
four-part~3
8500~1
adoptions~1
domestically.~1
(prevalence,~1
2.8%)~1
orphanage.~1
tuberculin-positive~1
complicated)~1
skin-tested~2
whoops~1
(ethylsuccinate~1
well-tolerated.~1
3959~1
2385~1
2791~1
Aminoglycoside~1
16,279~1
16,070~1
(98.7%)~1
amikacin.~3
1017~1
Amikacin-resistant~1
amikacin-resistant~2
6'-N-aminoglycoside~1
(VZIG).~1
VZIG~3
undecided).~1
(43,~1
DC,~1
Commonwealth~1
scoring,~1
optional.~1
footprinting.~1
Clamping~1
etiologic,~1
0%),~1
burned,~1
(89/106)~1
(90/125)~1
Baltimore.~1
dissatisfied~1
delegate~1
solo~1
reach,~2
(involuntary~1
nonsmokers)~1
209;~1
presport~1
(FEF25-75).~1
FEF25-75~5
68.4%~1
exposed:~1
(13.6%)~2
[80/108]~1
[52/85]~1
),~1
Washington.~2
(3.02~1
crowding~1
sewers.~1
endemic,~1
"body~1
language,"~1
psychiatry/pediatric~1
Unnecessary~1
perpetuating~1
Connecticut,~1
63,399~1
(36,891~1
26,508~1
1.4).~1
57.6%,~1
11.4%.~1
parainfluenza,~1
Counseling~1
1,438~1
27.0%~1
157.2~1
148.4~1
pauses,~1
neurodevelopmental,~1
recognized;~1
(sicca~1
own.~2
cholesterol-HDL~1
carotene~1
accomplish,~1
inconclusive,~1
megadoses~1
cruciferous~1
common),~1
3,008~1
lengthened.~1
"acute"~1
expeditiously,~1
effort-induced~3
subclavian-axillary~2
tried,~1
(Abbokinase)~1
(Kabikinase,~1
Streptase)~1
catheter-directed~1
bronchofibroscopic~1
Popliteal~1
dissect,~1
pseudothrombophlebitis).~1
properly,~1
Optimally~1
outpaced~1
repetitious~1
questioning.~1
unrewarding.~1
path,~1
fixations~1
instructing~1
Adaptive~1
(ASDs)~1
parent-guardian~2
programming.~1
preequipment~1
postequipment~1
Friedman's~1
Sitting~1
Parent~1
muscles'~2
covarying~1
Clinicians,~1
muscle's~1
Diastasis~1
recti~4
scientifically.~1
diastasis~3
flexed-knee~1
umbilicus.~1
sit-up,~1
abdominis;~1
(WI),~1
(CGPs)~1
CGP.~2
cranking~1
(RPP)~1
Duncan's~2
(IPE)~1
IPE~2
RPP~2
SBP.~1
60-rpm~2
90-rpm~2
30-rpm~1
heel-up-heel-down~1
retroactive~1
Mat~1
hypomobility~1
heightens~1
unfamiliarity~1
free-muscle~1
pens.~3
skin-preparation~2
(Betadine,~1
pHisoHex,~1
Hibiclens).~1
toxin-mediated~1
Antistaphylococcal~1
fabrication~2
contrivance~1
headband~1
goniometer.~1
Frankfort~2
plane),~1
ectropion,~3
ectropic~1
bipedicled~1
ectropion.~1
good/excellent~1
texture~1
match.~1
creases.~1
"blepharoplasty~1
Tennison~1
isosceles~1
interdigitate~1
noncleft~1
rotation-advancement~1
philtral~1
pout,~1
diagrammatically~1
prominence,~1
Shave~2
paler~1
repigment~1
1313~1
maxillomandibular~1
(576~1
breasts)~1
146.6~1
lbs.,~1
1313.6~1
infra-mammary~1
crease.~1
arthrolysis,~1
Fowler's~1
slip~3
mallet~3
rebalancing~1
Dissection,~1
suprafascial~1
nonaxial~1
vulvectomy,~1
sensate~1
rhinoplasties,~1
stairstep~1
transcolumellar~1
Surgically,~1
intercartilaginous~2
Basically,~1
Brown-McDowell~1
Undermining~1
chondrocutaneous~2
(vestibular~1
hinging~1
counterrotates,~1
ala,~1
transfixion~1
craniosynostoses~1
subgrouped~2
unilateral)~1
(bilateral)~1
symmetrical.~1
(category~2
devastating.~1
dysostoses~1
sanctuary~1
tract--especially~1
care--preferably~1
barrier-nursed.~1
Langenbeck~2
Toronto-Bayview~1
lymphangiogram.~1
Dissections~1
embalmed~1
Gray's~1
fuses~1
paralumbar~1
gluteal-thigh~1
vessels--the~1
Unilink~2
device--has~1
thrombotized,~1
endothelialization~2
chordee.~1
relocated~2
meatoplasty~1
glanuloplasty.~1
raphes,~1
bifurcate~1
dogears~1
prepuce.~1
nonexistent,~1
raphes.~1
pleasing~1
"functional"~1
(Table~1
bossing~1
Mobius~1
transcoronal~1
bossing.~1
Sulfamylon~2
chondritis,~1
confused.~1
hidradenoma~1
thoracodorsal~1
enters.~1
insulate~1
accidently~1
cauterization.~1
foresight~1
ophthalmology~1
PHPV~1
PHPV.~1
leucocoria,~1
microphthalmos,~2
opacity,~1
colobomas,~2
lenticular,~1
vitreal,~1
glory~1
Thin-needle~1
rapid-sequence~1
intricate~1
patient-tailored~1
neuroradiologist~1
gadolinium-diethylene-triaminepentaacetic~1
(DTPA).~1
mmol/kg.~1
signal-enhancement-to-noise~1
400/30)~1
sequences--that~1
200/20~1
1,500/35/400~1
msec/TE~1
msec/inversion~1
msec)--showed~1
(signal-difference-to-noise~1
[SD/N])~1
SD/N~1
recrudescences~1
radiographic-fluoroscopic~1
fluoroscopic-television~1
Radiologic-endoscopic~1
Polyps~2
infirm~1
teleradiology~1
digitized,~1
concordance.~1
Teleradiology~1
4-27~1
urograms.~1
3-18~1
endopyelotomy~1
times/echo~2
(TR/TE).~1
(TRs/TEs).~1
defect--1~1
zone--that~1
nodularity,~1
Masses~1
Intratesticular~1
Eq/ml~2
[2,210~1
pM])~2
[553~1
juxtametaphyseal~1
46-80~1
compressions)~1
21-45~1
-2-SD~1
"fracture~2
threshold."~1
discovertebral~2
Undecalcified~1
(endochondral~1
disk-space~1
pulposus)~1
Anatomically~1
functionally,~1
beam-hardening~1
(ROI),~1
Dual-energy~2
Contour-detection~1
ROI~2
tissue-equivalent~1
6%-10%~1
inaccessible,~1
plafond,~1
scintigraphs~1
physes~1
deformity).~1
0.74-0.98~1
0.98-1.20~1
below-normal~1
low-SI~2
high-SI~2
intrameniscal~2
menisci.~1
palpatory~2
pseudomass~1
(PVE)~1
PVE,~1
encephalopathic~1
PVE~1
prophylactically.~1
"hypoperfusion~1
complex,"~1
mesentery,~2
pancreas;~1
cava;~1
"healthy"~1
(TEs).~1
Adjacent~1
TRs/TEs.~3
multinodular,~1
thyroid-muscle~1
131,~2
pseudocapsule,~1
pseudocapsules~1
(hemorrhagic~1
degeneration)~1
(TR/TE)~1
coils;~1
gliomas;~1
voxels~1
delineation,~1
misregistration~1
artifact;~1
junction;~1
objectification,~1
capacious,~1
(suboccipital~1
blood-ocular~2
102%~1
Dixon~2
water-fat~1
inhomogeneities,~1
phase-correction~1
non-chemical-shift~1
spin-warp~1
technique:~1
sinc~1
homospoil~1
771~1
Growth-dependent~1
630-910~1
68-185~1
multiexponential~1
("magnetic~1
fingerprint")~1
section-selection~2
cancels~1
frequency-encoding~1
encodings.~1
streaklike~1
voids~1
interleaved,~1
phantom,~1
volunteer,~1
imaged.~1
imagers.~1
rationing~1
trees,~1
algorithmic~1
pursued,~1
designer,~1
economics,~1
universality~1
algorithms,~1
promulgation~1
radiologist-consultant-decision~1
maker.~1
recognizer~1
1,000-word~1
lexicon~2
900-word~1
lexicon.~2
lexicons~1
(gastrointestinal~1
neuroradiology,~1
mammography),~1
vocabulary,~1
translations~1
print~1
sentences,~1
Dictation~1
high-dose-rate~1
semiautomatically;~1
interpolation.~1
implants;~1
pelvic-inguinal~1
isodose~1
szulgai~7
non-tuberculosis~1
ethambutol,~1
worldwide;~1
actinomycetoma~1
actinomycetes~1
Streptomyces.~1
Antecedent~1
culturing,~1
shunt-related~1
survey-based~1
stringent,~1
Austria,~1
decontaminated~1
Soviets~1
magnificent~1
grateful~1
superimpose~1
resampling~1
pixel-by-pixel~1
Monte~1
Carlo~1
ruthenium-modified~1
"line-of-flight."~1
swept~1
electron.~1
Phototransduction~1
phototransduction.~1
cation-suppressed~2
light-suppressed~1
L-cis-diltiazem~1
cGMP-activated~1
act,~1
cGMP,~1
Wald~1
11-cis~3
isomerized~1
all-trans~4
bleached,~1
isomerization~1
enzyme-mediated,~1
isomerized.~1
eye-specific,~1
(retinol~1
isomerase)~1
dark.~1
modifications.~1
(Mab)~2
G-class~1
neuron.~1
diopters)~1
deprived;~1
nondeprived~1
emmetropic.~1
deprived.~2
nonfoveal~1
page;~1
impoverished~1
nonspeech--a~1
duplexity~1
phonetic~1
precedence~1
quasi-sensory~1
scalar~1
relays.~1
Alopex,~1
Low-stringency~1
107-kilodalton~1
(hMR).~1
glucocorticoid-responsive~1
hMR~1
hGR~1
angiogenin~10
Angiogenin~1
regulated;~1
HT-29~1
SK-HEP~1
humans'~1
array).~1
object's~1
spatio-temporal~1
(preattentively),~1
attentive~1
computations.~1
eubacteria,~1
Double-stranded~1
49-kilobase~3
ospA~1
ospB~1
B31.~1
Molecules~1
reannealed~1
denaturation;~1
renaturation~1
nuclease.~1
100-kilobase~1
transcarbamylase-deficient~1
enzymological~1
transcarbamylase~2
transversion~1
117.~1
somesthesia~1
Fragile~1
nonstaining~1
Hybrid~1
breakpoint~2
Fragility~1
hybrid.~1
elastogenic~1
orchestrated~1
gelation~4
photolytic~1
photodissociation.~1
photodissociated~1
carbonmonoxyhemoglobin~1
reoxygenation.~2
reoxygenated~6
Chamorro~2
Guam~2
Rota,~1
hereditable~1
Cycas~2
circinalis~1
Americanization~1
Macaques~1
beta-N-methylamino-L-alanine,~1
N-methyl-D-aspartate~1
corticomoto-neuronal~1
cycad~1
Ganglion~1
retinorecipient~1
connectivity~1
(H-1)~1
Spiroplasma~2
mirum,~1
Mollicutes~1
H-1~1
spiroplasma~1
mirum~1
sphingomyelin-rich~1
late-to-lateral~1
(PL-to-LP)~1
stomatogastric~1
voltages,~1
negativity.~1
cesium-134~1
cesium-137~1
Greenland~1
Arctic~1
glaciers,~1
Regenerating~1
elongating~1
axons?~1
elongating.~1
axo-glial~1
buccal-buccal~1
bag-bag~1
buccal-bag~3
hatching).~1
tonotopic~1
(EIRA)~1
EIRA~1
laity~1
true;~1
Abortions~1
"significant~1
nonschizophrenic~3
16,621~1
0.24%.~1
(SH)~2
normophosphatemic~1
SH~2
(Tm~1
PO4/GFR~1
GFR).~1
dermatologist.~1
corticosteroid).~1
Nonsteroidal~1
sulfones,~1
antimalarials~1
plaque-like~1
leg-raising~1
Bariatric~1
misconceptions.~1
willpower,~1
3,237~1
objections.~1
0.2%.~1
diligence,~1
(CTS).~1
B6.~2
"rootwork,"~1
slave~1
antebellum~1
South.~1
rootwork~2
magical~2
sorcery~1
tradition~1
medicines.~1
Adherents~3
"folk"~1
doctors,~1
7,671~1
4,449~1
17,660~1
Encounter~1
nigricans,~2
A29,~1
Bw45(w6),~1
B13(w4),~1
(DQw1).~1
bronchobiliary~1
appendicovaginal~1
Abundant~1
filariform~1
thiabendazole~3
four-valve~1
I1.~2
Corynebacteria~1
risking~2
Blastocystis~1
infested~2
crampy~1
chills.~1
"experimentation"~1
hospitalizing~1
consumer.~1
hospital-owned~1
Anesthesiologists.~1
intensiveness~1
Explicit~1
solvable~1
cohesiveness,~1
superb~1
facts:~1
participants;~1
payor~1
lymphoscintigraphy,~1
Lymphangiography~1
Lengthening~1
esophagoplasty.~1
1,724~1
Extra-anatomic~1
drainages.~1
Sphincteroplasty~1
hyperaklalinphosphatemia,~1
choledochoenterostomy~1
avert~1
(SR,~1
(PTRA,~1
PTRA,~1
PTRA~1
(100.0~1
68.4~1
coloprotectomy~1
intractability~1
"femoral~1
umbrella"~1
cited,~1
Cauterization~1
gastrostomies,~1
extraperitoneally.~1
excellently~1
nonreversed,~1
Appendectomy~2
(40.6~1
(39.1~1
3.27,~1
readmission.~1
marsupialization~1
chondromyxofibroma~1
hypophysitis~1
(LYHY)~1
(viral?)~1
LYHY~1
(Ogilvie's~1
transfemoral~1
7.7%.~1
angiographically.~3
I-V.~1
I-IV,~1
is.~1
81-year-old-woman~1
Tetanus~1
Cephalic~1
trismus~1
risus~1
sardonicus.~1
33-50%~1
neuro-ophthalmologic~1
(15-45~1
high-yield,~1
24-96~1
0.5-24~1
noncarotid~1
1.2-3.5)~1
endarterectomy).~1
branch:~1
parieto-occipital,~1
calcarine,~1
8.3%.~2
(SHRSP),~1
4-52~1
fibrin)~1
hopping~1
eicosanoids~1
TxB2:6-keto-PGF1~1
TxB2,~1
deteriorating,~1
(MCAo)~1
frontoparietal~4
MCAo~1
MCAo,~2
MCAo.~4
0.992~1
Entry~1
(MCAo).~1
30.79~1
2.90)~1
29.19~1
3.28)~1
sham-occluded~1
0.9722)~1
5.88~1
beta-endorphin-,~1
met-enkephalin-,~1
A-related~1
dynorphin-containing~1
cell-mossy~1
Paco2,~1
Pao2,~1
Pretreated~1
46619,~2
Pial~1
46619~3
predilated~1
in-which~1
venous-stasis~2
low-ionic~1
centrifuged.~1
75-fold,~1
destabilizes~1
Disaggregation~1
disperse,~1
serums,~2
sialoglycoproteins--beta~1
C)--are~1
delta,~2
En(a-)~1
S-s-U-~1
Gerbich~1
(Ge)~1
beta-like~1
Ge-Yus-~1
agglutinins.~1
Apae,~1
Apae~3
absorption-elution~1
-A,B~1
bromelinization,~1
seaweed~1
Codium~1
atlanticum,~1
anti-Apae~1
Anti-Emm,~1
Emm-propositi~1
Emm-brother~1
"naturally~1
occurring."~1
Emm-siblings~1
Emm~1
Kx~1
Kx-positive~1
McLeod~1
hemorrheologic~2
Wrb~1
e,~1
Leb,~1
Fya,~1
Fyb,~1
Jka,~1
Jkb,~1
Yta).~1
(sodium-dodecylsulfate~1
stain)~1
Wrb.~1
"spin,~1
cool,~1
filter"~1
(SCF)~1
(FNHTR).~1
microaggregate~1
(MAF).~1
MAF.~1
SCF~2
6700~1
FNHTR;~1
prepares~1
"map"~1
(first-dimension)~1
second-dimension~1
(2D).~1
lower-molecular-weight~1
metaperiodate-[3H]NaBH4~1
lactoperoxidase-H2O2.~1
2D~1
[3H]NaBH4-labeled~1
half-disappearance~2
Glutathione-dependent~1
avenues~1
storage-dependent~1
alloimmunized,~1
cytapheresis~2
(FAB~1
M5)~1
leukostasis.~1
diathesis,~1
incentives.~1
2859~1
same-day~1
CS-3000,~1
6.51~1
Disposable~1
counter-centrifugal~1
underlaid~1
concentrated.~1
(99.9%~1
(59.8~1
67.3~1
lymphokine-activated~1
(albeit~1
neoplasms),~1
88.3~1
mIU/cc,~1
Subcapsular~1
papaverine/phentolamine~1
30/1~1
causations.~1
twenty-one-year~1
(1963-1984)~1
ureterostomy.~1
allows.~1
(TUURS)~1
(85/95).~1
iatrogenic,~1
psychologically,~1
(BPH)~1
(beta-TG)~1
beta-TG~1
thirty-two-year-old~1
fluctuant~1
ureterocele~1
dyspareunia.~1
post-ejaculation~1
hemospermia,~1
Fulguration~1
neurilemomas.~1
periurethral~1
(spirits,~1
wine)~1
(SCD),~1
4,532~1
40-64~1
self-filled~1
SCD~8
consumers.~1
spirits~3
SCD.~1
CHD-free~1
spirits,~1
2:1.~1
assistant,~1
0.46.~1
duty,~1
subarachnoidal~1
BMDP's~1
327.1~1
432.8~1
71.0~1
Diet-treated~1
post-glucagon~2
477~2
goitre;~1
atoxic.~1
(16.0%)~1
1-25~1
atoxic~2
hydroxocobalamin~2
transcobalamin~1
cobalamins~1
(UB12BC)~1
UB12BC~1
(TB12BC).~1
extra-pulmonary~1
(SAE)~1
(Binswanger's~1
probable.~2
1350~1
self-poisoning,~1
self-poisonings~2
poisonings~1
hypnotics,~1
non-medical~1
clodronate~5
(dichloromethylene~1
bisphosphonate)~1
4.43~1
BW/day).~1
(800-3,200~1
clodronate.~1
Cockroft~1
Gault~1
Siersbaeck-Nielsen~1
al,~1
GFR.~1
Brochner-Mortensen~1
laparocentesis~1
dissolve~1
unconscious,~1
Alpha-hemolytic~1
Far-reaching~1
participant.~3
handicapped.~1
embarrassed~1
awkward.~1
penile-vaginal~1
Odynophagia~1
esophagogram~1
74).~1
0.038).~2
0.009).~1
9.3%.~1
0.00005).(ABSTRACT~1
Nonsurgically~2
cardiomegaly.~1
nonsustained)~1
Epicardial~1
tachycardias,~1
direct-current~1
desiccation~1
microbipolar~1
kHz)~1
tripolar~1
well-delineated~1
round-shaped~1
(62/71)~1
(9/71).~1
(14/62).~1
(13/52)~1
sialidase~4
neuramin~1
0.060~1
mumol/sample~2
0.05]).~1
7.17~1
15.45~1
Sialidase~1
fiberscope.~1
Laminar~1
Usually,~1
denudated~1
sited~2
144,000~1
(UK)~1
recanalize~1
3-hour-old~1
20-day~1
stiffens,~1
inward.(ABSTRACT~1
micrograms/min~1
Pericardiocentesis,~1
pericardiocentesis.~1
(DF~1
6.30~1
hydralazine-digoxin~2
Dose-related~1
patient-oriented~1
Self-administered~1
interviewer.~1
questionnaires--the~1
boxes--can~1
life-quality~1
Psychosomatic~1
neurogenic,~1
psychosomatic.~1
hyperreact~1
way;~1
size--indicative~1
arousal--higher~1
(-2.7~1
-2.3~2
SD/chord,~1
(-2.4~1
SD/chord;~1
depolarized.~1
radius/posterior~1
0.59)~1
radius/wall~1
0.55)~1
energy-terminating~1
attempts).~1
septum)~1
weighed.~1
tachycardia/fibrillation,~1
(cycle~1
antitachycardia~1
[one~2
patient],~1
[two~2
patients],~1
patient]).~1
30/hour)~1
Open-label~1
323,~1
22.7).~1
-70%~1
-95%.~1
(fatigue~1
Noncapturing,~1
(inhibition).~1
cathodal,~1
noncapturing~1
MA.~1
Sc.~1
apex.(ABSTRACT~1
msec.(ABSTRACT~1
Momentary~1
(SND)~1
(SCL;~1
SCL)~2
Age-stratified~1
SND,~1
Kent~3
midday~1
nodal,~1
(SR),~1
Simonson~1
Ashman~1
(70%).~1
QS2~2
QT:QS2~2
155-~2
170-day-old~2
270/min,~1
interstimulus~1
unmasks~1
VO2).~1
(LVEDD)~1
75.4%,~1
70.2%,~2
0.0026),~1
LVEDD,~1
ml/min/1.73m2,~1
Filtration~1
1978-86,~1
aortic-mitral)~1
lost;~1
complete).~1
(30-day)~1
0.55),~1
Embolism~1
2.1%/patient-year)~1
(1.5%/patient-year;~1
492)~1
(3.2%/patient-year;~1
(18.9%/patient-year;~1
Warfarin-treated~1
0.4%/patient-year)~1
2.9%/patient-year);~1
warfarin-treated~1
2.5),~1
(2.9%/patient-year)~1
(1.5%/patient-year).(ABSTRACT~1
reassessing~1
PPH,~1
PCWPs~1
COs~1
RVedp,~1
PVR/SVR~1
0.583;~1
2873~1
atherogenic,~1
total-to-HDL~1
equalizes~1
LDL/HDL~1
especially.~1
for;~1
dihydropyridine,~1
ischemia--angina,~1
exercise--were~1
low-level,~1
operations).~2
contractility.(ABSTRACT~1
29,000~1
(barometric~1
[PB]~1
end-diastolic,~1
60-W~1
torr,~2
(rest)~1
(exercise),~1
examined--ejection~1
rest--were~1
Everest.~1
Diabetics~1
period/LV~1
"dropout"~1
Choice~1
revascularization),~1
T1-201~1
infart~1
zone.(ABSTRACT~1
rating-scale~1
dyskinesia)~1
observer)~1
normal/abnormal.~2
observers)~1
Disagreements~1
grow,~1
(sigma~2
es)~2
(Vcfc),~1
Renografin-76)~2
Vcfc~1
0.12);~1
afterload.(ABSTRACT~1
0.14):~1
IU/liters,~1
63)~1
[90%]),~1
aneurysms;~1
calcifies~1
Cardiogenic~1
(APE)~2
Harmonic~1
1,357~1
cadian~1
(91%~1
(1,713~1
1,253~1
self-monitored,~1
Moderate-intensity~1
75%).~1
Self-monitored,~1
moderate-intensity,~1
group-based~1
inconvenient~1
obstacles,~1
self-monitored~1
moderate-intensity~1
cal/kg~1
108%~1
Training-induced~1
week.(ABSTRACT~1
periodicity:~1
left-axis~1
fanlike~1
partitions,~1
(ECW)~1
ECW,~1
ECW~3
NaBr~1
Bromide~1
ECW.~1
60-89~1
(0.016~1
mumol)/10(9)~4
4.06~1
(0.062~1
(0.060~1
(0.0081~1
0.0060~1
(3.39~1
mumol)/g~1
41%;~1
(GD)~1
GD~1
GLC~2
(aware~1
condition),~1
cholecystectomies.~1
gallstone-related~1
linoleic:saturated~1
unexplainable.~1
GD.~1
Bangladeshi~1
diarrheal,~1
dinitrochlorobenzene.~1
calorimeter.~1
8.88~1
(2123~1
kcal/d)~2
(2419~1
(overweight).~1
(24hEE)~1
(8.58~1
(10.70~1
2558~1
kcal;~1
24hEE~1
24hEE.~1
20-50~1
Taiwanese~4
undernutrition,~1
714~1
25-44~1
Orleans.~1
palmitoleic~1
(16:1)~1
(TOBEC)~2
hydrometry.~1
TOBEC~7
1240~1
Coagulation~1
Fructo-oligosaccharides~1
sweeteners.~1
nonabsorbed~1
fructo-oligosaccharide~2
tid)~1
flatulence~2
tid).~1
lactulose,~3
fructo-oligosaccharide.~1
12-d~1
food-grade~1
xanthan~1
locust~1
(X/LBG)~1
xanthan,~1
locust-bean~1
gums~2
reneutralized~1
X/LBG~1
pyridoxal-5'-phosphate~4
3.85~1
2.0%)~1
(SCD)~1
(ASTAC).~1
(42.5%)~1
(54.5%).~1
ASTAC.~1
(PPO).~1
18-35~1
Cross-validation~1
0.974~1
(cm),~1
-36.410~1
(-1.324~1
(0.01185~1
(FC1(0.5)xht))~1
(12.347~1
FC2(0.5))~1
(0.0627~1
FC0)-(0.9232~1
LBM.~1
preschool-aged~1
(RDR)~1
RDR~2
postsupplementation,~1
RDR,~1
postsupplementation~1
(Se)~1
(GSH-Px).~1
0.51,~1
LJ~1
Filer,~1
Jr,~1
PhD,~1
additives.~2
methylxanthines,~1
Needs~1
designing,~1
funding,~1
Industry~2
formalize~1
openness,~1
soundness,~1
protections.~1
Contracts,~1
officials,~1
Negotiating~1
patience~1
goodwill~1
existing,~1
cumbersome,~1
bureaucracies~1
university-industry~1
societies,~1
advisory~1
chondroblastomas~1
chondroblastomas.~1
cyst-like~1
reexcisions~1
(94),~1
(92),~1
Latin-American~2
anemia)~1
(76.1%),~1
isolates:~1
cohesive~1
type:~1
lymphocytic.~1
obliterans,~1
nodosa-like~1
Endarteritis~1
E-5000~2
carryover,~1
precisions,~1
first-phase~1
third-phase~1
(HPP)~1
anisopoikilocytosis.~1
HPP.~1
HPP,~1
(Sp~1
1/74).~1
Sp~2
1/74~2
(cobalamin)~1
Latin-Americans~3
0.0029).~1
"parameters,"~1
nonquestionable~1
crime,~1
assailants.~1
(p)~1
(p),~1
(means),~1
perpetrators~1
day-of-the-week~1
accident)~1
Erie~1
3,787~1
restrictive.~1
airguns)~1
license.~1
0.074/100,000/year,~1
hunting~4
hunting,~3
shotguns,~1
moose~2
hunting.~1
shooters~1
autumn.~1
Firing~1
inebriation~1
them;~1
ones;~2
rifles,~2
Shooters~1
dehisced~1
decompositional~1
(pink~1
teeth)~1
1973-1984.~1
putrefaction~1
exudation~1
dentine~1
1977-1984.~1
(13/56)~1
gramoxone;~1
Toxicological~1
multiorgan~2
sprayed~2
parked~1
car.~1
discolorations~1
chloropicrin~2
car's~1
console~1
mat,~1
ng/g~1
police.~2
assault.~3
(subependymal~1
glomerate~1
astrocytoma)~1
Sudden,~1
(TTP).~1
Shwarzman~2
coincidence.~2
necrophilia~1
disinterred.~1
genitals~2
breasts,~1
unyielding,~2
forward,~1
(55-~1
hot-biopsy~1
(PN);~1
multipeaked~1
PN,~1
gastroenteropathy~1
choledochocele~1
A-E)~1
cele~3
cele.~2
choledochocele.~1
steatohepatitis~2
transminase~1
ductules,~1
Wilcoxon's~1
rank-sum~1
Zonal~1
steatohepatitis.~1
Dialytic~1
67-yr-old~2
1530~1
Zahn's~1
Paucity~1
40-yr-old~1
epigastralgia~1
roentgenological~1
yellowish-whitish~1
I-type~1
43-yr-old~2
jejunitis~1
alleviated,~1
megacolon.~1
starchy~3
ileostomate~2
representative.~1
0.885,~1
-0.867,~1
-0.611,~1
broad.~1
substrate:~1
420-450~1
ml/h.~1
pmol/l)~2
hyperchlorhydria~1
hypersecretinemia~1
"how~1
enough?"~1
Peristaltic~1
(Newman-Keuls)~1
Retrosternal~1
Emepronium~1
medication-induced~2
taxonomically~1
entity;~1
lesion(s),~1
prepylorus,~1
caseating~1
Bilroth~1
else.~1
gastroscopic,~1
lues.~1
impregnation.~1
cholangiograms~1
Zenker's~1
Hemobilia~1
74-yr-old~1
centri-~1
midzonal~1
calcium-phosphorus~1
fistulogram~1
amenorrhea,~2
hypogonadotropism,~1
chromophobe~1
polypeptide-producing~1
polypeptide-oma~1
scan),~1
Pericarditis~1
1,058~1
pretamponade~2
Tamponade~1
89.7%~1
foreseen~1
benefit/cost~1
mm/h,~2
mm/h),~1
mm/h).~1
Midweek~1
ESR.~1
in-center~1
gamma-globulins~1
1,029~1
patient-monthly.~1
double-bag~1
dislocations).~1
peritonitis-related~1
Membranoproliferative~1
(crescentic~1
glomerulonephritis)~1
posttransplantation.~1
mucormycosis,~1
siderophores~1
nonmodulators.~1
nonmodulation~1
nonmodulators~1
(CEIs)~1
(CEI),~1
triple-drug~1
(TRX)~1
TRX~1
abdominal-wall~2
scintigrams.~1
Postdrainage~1
potomania~1
Vichy~1
anion-gap~1
acidemic,~1
(urine~1
mmol/d),~1
chelonei~2
peculiarities~1
Uremic~2
deep-body~1
thermolabile~1
people;~1
thermolability,~1
(NO),~1
(NX),~1
sham-nephrectomized~1
NX~4
.02~3
thermolabile,~1
accesses~1
rethrombosed.~1
Postthrombolysis~1
allele(s)~3
Sandhoff~5
22,043~1
32,342~1
heat-labile~2
finer~1
1979-84.~1
Central-American~1
genealogies~1
researched.~1
kinships,~1
pedigree.~1
birthplaces~4
grandparents,~1
great-grandparents~1
ancestors~2
scattered.~1
founder~1
gene(s)~1
settlers,~1
influenced.~2
data--with~1
log[IgE]~1
Bernstein's~2
estimators,~1
Nam~2
Gart~2
ABO-like~1
Huether~1
Murphy~1
Haldane's~1
estimator~1
blanks;~1
recessive-gene~1
(30.4~1
populations);~1
percent);~1
mg/liter),~1
1,487~1
mg/m2);~1
1,095~1
Decline~1
settings.(ABSTRACT~1
snack.~1
(baseline).~1
10:30~3
0.015)~1
hemodialysis-treated~4
double-tetracycline~2
labels)~1
(2.82~1
Amino-terminal~1
Osteomalacia,~1
0.171~1
0.035~1
micrograms/dl),~1
microIU/ml)~1
(0.667~1
0.733~1
0.055~1
Deficiencies~1
milieu,~1
coagulants~1
perpetuated.~1
cerebro-spinal~1
meningitis:~1
blood-contaminated~1
justified,~1
1973.~1
colchicine-treated~2
non-colchicine-treated~2
putida~2
phlebitis,~1
lymphoplasmocytic~1
"purple~3
microembolization~1
microembolization.~2
warfarin-related~1
Acanthosis~1
accompaniment~1
Hydroxychloroquine~2
Pancoast's~1
fluoroquinolone~2
antibacterials,~1
(rat,~1
carcinogenic,~1
norfloxacin-related~1
dyspepsia,~1
UTI~5
fluoroquinolone,~1
"compassionate"~1
pathogen(s)~1
guidelines;~1
checklists~6
record;~1
trimethoprim/sulfamethoxazole.~1
ceftriaxone.~1
Tube~1
1:512.~1
bacillus,~1
DF-2.~1
(PAS)-positive~1
bacilliform~3
PAS-negative~2
bacillus.~1
faculty.~2
multiple-station~1
case-to-case~1
examinee's~1
per-student~1
$21.00.~1
Hemofiltration~1
ml/hour~2
girth.~1
(-70~1
(-45~1
cavities)~1
subtraction.~2
overhydration;~1
microadenomas,~1
(cobalt-60)~1
Normoprolactinemia~1
Hypopituitarism~1
macroprolactinomas;~1
regression:~1
42.8);~1
23.7);~1
38.9);~1
19.7);~1
dying--the~1
14.9)--and~1
warfarin-sensitive.~1
non-blind~1
extra-skeletal~2
99m-diphosphonate~1
hyperlactatemia~1
Child's~4
mentation.~1
9.6).~1
l-thyroxine~2
thickened,~2
U/day)~1
tolazamide,~1
(HgA1,~1
2hpp~1
tolazamide~1
Pneumonias~1
mycoplasma,~1
chlamydiae,~1
6-35%~1
1-17%~1
(TWAR)~1
mycoplasma-like~1
Developments~1
organogenetic~2
(Starling~1
wicks~1
(wick~1
wick-in-needle~1
Obstetricians.~1
anencephalic~2
hydramnios~1
1271~1
753~1
Hyperstimulation~1
phase).~1
octadodecasilyl~1
(methionine~1
(beta-endorphin~1
beta-lipotropin)~1
G-75.~1
utero"~1
preeclampsia;~1
21-fold~1
nonoxytocin~2
Freezing~1
(16.7%)~1
(41.0%)~1
(19.7%~1
18.8%,~1
15.5%.~2
mU/L)~1
micrograms/L).~1
time-integrated~1
(time-integrated~1
hemarthrosis.~1
(Picker~1
International,~1
Northford,~1
Connecticut)~1
inversion-recovery~1
manganese.~2
neurulation~1
development)~1
Pharmacopeia~1
Pregnancy-induced~1
135;~1
U-63,557A;~1
5-(3'-pyridinylmethyl)~1
benzofuran-2-carboxylate,~1
monohydrate~1
U-63,557A.~2
U-63,557A~1
U-63,557A,~1
allantoic~1
binge-type~1
utero;~1
acetaldehyde-oxidizing~1
"early"~1
quadrants,~1
"cone"~1
(791T/36).~1
111-~1
overcome.~1
Risks~1
nonstatistically~1
systolic/end-diastolic~1
systolic/end~1
(N.S.).~1
erythroblastosis.~1
93.1~1
Growth.~1
Self-reported~1
adolescents;~1
race:~1
nonblack~2
33.2,~1
(31/34),~1
(103/159),~1
(31/87),~1
2.49,~1
Mucopurulent~1
erythema-edema~1
Meir~1
Kfar-Sava,~1
Israel,~1
(39.4%).~1
Arias-Stella~2
(Pittaway~1
DE,~1
Reish~1
Wentz~1
Am~1
Obstet~1
gynecol~1
1985;152:299-302),~1
9.7%.~1
1025~1
obstetricians,~1
residency,~1
Pregnancies~1
123.70~1
12.21~1
22.66~1
6.16~1
glycolysis.~1
placentas.~1
dinucleotide/nicotinamide~1
dinucleotide)~1
phakic,~1
Postvitrectomy~1
Daunorubicin~1
reproliferation.~1
daunorubicin~2
Step-level~1
bleb,~1
fornix-~1
choriocapillaris,~1
Presumed~1
(chlorhexidine~1
detergent)~1
gross,~2
biomicroscopic,~1
amblyopic~5
nonamblyopic~3
anisocoria~3
128)~1
anisocoria.~1
hemianoptic~1
congruous.~1
mg/sq~4
treatment-free~2
(12-16~1
238-340~1
19-week~1
regressed.~1
doxorubicin-induced~1
A2G~2
alpha/beta.~2
alpha/beta~2
TNF-treated~2
interferon-treated~1
stereomicroscopy~1
1-mu~1
(43-90%~1
(O3)-induced~1
0.00,~1
hours/day.~1
Hilltop~4
Madison~1
preacinar~1
could,~1
(histone,~1
polyhistidine,~1
polyarginine)~1
(polyanetholsulfonate)~1
polyelectrolytes~5
Arthus~2
26-43%~1
glycol-conjugated~1
40-68%~1
chemiluminescence)~1
(IgG-bovine~1
O-2,~1
Trend~1
(IEMG)~1
IEMG~1
(ANOVA,~1
acromion~1
GCS.~3
(GCS-O/O)~1
(NO-GCS).~1
GCS-O/O~2
NO-GCS~2
ascribable~1
ethics,~1
solving,~1
committees,~1
ethics.~1
vitality~1
Legal~1
receiving,~1
Double-blind~1
Demented~1
"increased"~1
(HPA)~1
HPA~4
3-methoxy-4-hydroxyphenylglycol,~1
psychiatrists.~2
"Kraepelinian"~1
Kraepelinian~1
Solvent-inhalant~1
existent~1
solvent-inhalant~1
pharmacological,~1
assaulted~1
assaults,~2
therapists'~1
"dynamic-organic~1
continuum."~1
megavitamin~1
optimism.~1
Mexican-Americans,~2
acculturated,~1
outpatient,~1
acculturated~2
Mexican-Americans~1
leaders).~1
Mexican-Americans.~1
Motto~1
colleagues'~1
Estimator~1
593)~1
Motto's~4
deciles~1
destructiveness~1
builds~2
safeguards.~1
therapist's~3
mobilizes~1
confrontation,~1
countertransference~4
3.3%,~1
L-dopa-induced~1
BPRS~1
138.4~1
meq/liter)~1
(141.8~1
meq/liter).~1
serially.)~1
carbamazepine-lithium~1
lithium's~1
gene-environment~1
influence--rural~1
upbringing~1
home--predicted~1
biennially~1
63.~1
mental--but~1
physical--health~1
physical--but~1
mental--health.~1
partialled~1
perseverance~1
stoicism.~1
stay:~1
$6,400~1
yohimbine-induced~1
decade's~1
undersupply~1
manpower,~1
nonpsychiatrist~1
underemployment~1
commonplace.~1
consultants,~1
fewer,~1
aura~5
(DSM-III).~1
panic-like~1
meperidine-induced~1
normeperidine.~1
nonsuppressors.~1
Unit-1~1
subcohort~1
postrestart~2
restart,~1
pregnancy's~1
Catatonia~1
psychiatrist.~1
catatonia~1
neuroleptic-respondent~1
(cranial)~1
hypothesizes~1
habituating~1
"constant"~1
sleep-dream~1
(GPU,~1
GPR,~1
(OS,~1
105)~1
motives~2
consult.~1
consulting~2
534~3
6-15)~1
DMFS~3
non-migrant~1
dates.~1
respondents);~1
malathion,~1
4,054~1
3,645~1
3,067~1
8.59~1
33.19~1
expected)~2
physician-attended~1
attendants~2
4.42~1
expected),~1
nurse-midwives,~1
Midwife~1
midwives,~1
29.69~1
server~5
patron~1
("pseudopatrons")~1
servers~2
Pseudopatrons~1
blood-alcohol~1
(BAC)~1
pseudopatrons~2
BACs~2
servers.~1
patrons.~1
851,000~1
cesareans~2
deliveries;~1
22.7)~1
records:~1
pre-AIDS~1
refugees.~1
Paulo,~1
1984/85,~1
1973/74~1
2,550~1
(HHANES)~1
1982-84~1
molars;~1
caries.~1
sealants~1
Filled~1
(decayed,~1
teeth.~2
gingivitis~1
(76.9~1
Control/Health~1
(CDC/HRA)~1
3,135~1
1959-79~1
25-60~1
CDC/HRA~3
habits).~1
age-sex-race~1
clients"~1
"protected"~1
client's~1
allocating~1
"drop-outs"~1
(1,150)~1
(33,909)~1
$2.1~1
Minnesotans,~1
Alcohol-related~1
$216~1
$630~1
$1.2~1
billion.~2
Podiatric~1
(DPMs)~1
DPMs~2
DPM;~1
stays;~1
DPM/orthopedist~1
(actual~1
141-170~1
ideal)~3
100-110~1
ideal).~1
21.5)~2
($25,692~1
$19,576)~1
(30.1~1
($26,447~1
$19,576).~1
hospitals).~1
beta-amino~1
chloramines~1
lifetime.~1
hypobromous~1
bromamine.~2
chloramine~2
schistosomula,~1
bromamine~1
mansoni.~1
dracunculiasis~3
Supply~1
Sanitation~1
Decade~1
(1981-1990),~1
Africa,~1
anti-dracunculiasis~1
Assembly~1
dracunculiasis-the~1
Smallpox~1
Eradication~2
Worm~1
Cote~1
d'Ivoire~1
(Ivory~1
Coast),~1
4,971~1
592~1
3.32~1
Necator~1
americanus~1
parasite-specific~2
6-10~1
Eggs~1
35-40.~1
38-64~1
1,350-3,828~1
eosinophils/mm3.~1
hookworm~1
capillariasis~1
fisherman~1
Malihan~1
Village,~1
Khoozestan~1
Iran.~1
borborygmus,~1
Eggs,~1
Capillaria~1
philippinensis~1
ferrets~3
malayi.~1
microfilaremic~1
ferrets.~1
lymphostatic~1
microfilaremia~1
pahangi~2
reinfected~1
sources--Brugia~1
microfilaria~1
products--were~1
reinfection:~1
amicrofilaremic;~1
microfilaremic;~1
microfilaremia;~1
amicrofilaremic.~1
anti-adult~1
amicrofilaremic~2
anti-mf~1
amicrofilaremic,~1
Midazolam,~1
Diethylcarbamazine~1
Mazzotti~2
parasitologically~1
IHA~5
ratti.~1
sero-reactors~1
(83.8%),~1
ratti~2
(55.9%).~1
filariasis~1
schistosomiasis.~1
Albendazole~2
Vesicles~2
voles~1
post-inoculation.~1
cellulosae~1
neurocysticercosis.~2
128-1,024).~1
128-512).~1
Streptomyces~1
somaliensis~2
cocco-bacillary~1
PAS.TCH~1
grain,~1
actinomycete~1
mycetoma~1
distinctive.~1
June-September.~1
May-August.~1
White-footed~1
leucopus)~1
chipmunks~1
(Tamias~1
striatus)~1
60/371~1
5/104~1
chipmunks,~1
squirrels~1
(Sciurus~1
carolinensis),~1
0/8~1
(procyon~1
lotor),~1
(Didelphis~1
virginiana);~1
leucopus~2
west-central~1
9/23~1
nymphs.~1
Transovarial~1
black-legged~1
pacificus.~1
ovarial~1
ovarially~1
BSK~1
(H5332)~1
aegypti.~1
arbovirus~1
microfilariae.~1
cistron~2
gambiae~3
gambiae,~1
arabiensis,~1
melas,~1
polytene~1
sympatric)~1
vectors,~1
EcoRI-SalI~1
cistron,~1
EcoRI~2
nontranscribed~1
pupae.~1
Alexandria,~1
Egypt,~1
laboratory-bred~1
longipalpis~1
CHAT~2
stroke-free~1
(transient~1
attack)~1
deficit),~1
militating~1
pyloroplasty~6
high-normal~1
Comorbid~1
bilioenteric~1
Buerger's~5
mucosa-lined~1
Carcinoids~2
MEN,~1
Analyzing~2
foregut~2
(thymus~1
Sawaguchi~2
hepatoportoenterostomy.~1
transconduit~1
take-down~1
biliostomy.~1
anicteric,~1
reccurrence~1
cataloged~1
(41.9~1
rerepair~1
(Candida)~1
thromboemboli~1
palliatively.~1
H222~1
Spy,~1
Unacceptably~1
Roentgenologic~1
opacification,~1
Claviculectomy~1
Principal~3
4,787~1
Samuel~1
Merritt~1
counterpulsation.~1
anticholinesterases--neostigmine,~1
edrophonium--were~1
diaphragm-phrenic~1
anticholinesterases~1
Supraclinical~1
(SCBF),~1
tetracaine,~1
tetracaine;~1
hypovolemia.(ABSTRACT~1
oxprenolol-induced~1
(critical~1
preconstriction~1
inspired),~1
(PETO2~1
88.8~1
(PETCO2~1
40.8~1
49.8~1
(SaO2),~1
SaO2)~1
(hypoxic~1
eucapnia,~1
(25.7%~1
eucapnia~1
(SPESB).~1
SPESB~1
electromyographically~1
(ED95,~1
offset,~1
"ganglion~1
score".~1
interspace,~1
(0.25%,~1
Caudal~2
pruritis,~1
8-24~1
rapid-acting~1
sevoflurane.~1
I-III~1
0.686~1
saline/gas~1
0.370~1
0.016;~1
oil/gas~1
2.7.~1
Dial-A-Flo~1
Stat~1
Master~1
(SM),~1
CorrectFlo~1
(CFLO),~1
Arm-A-Flow~1
(AAF).~1
DAFs~1
SMs~1
CFLO~2
AAF,~1
dial.~1
30-ml/hr~1
-25.1~1
-23.4~1
3.5%.~1
-0.1~1
25.2%~1
-4.08~1
DAFs,~1
SMs,~1
CFLOs~1
0.82-0.88,~1
AAF~2
DAF,~1
SM,~1
(positive,~1
Tetrodotoxin,~1
R05-4864,~1
midazolam-induced~1
0.1-1~1
tyramine-like~1
(2-CP)~1
(BS)~1
2-CP~3
BS,~1
BS.~1
dermatomes,~1
(pin~1
T-3.5~1
L-2.9~1
cephalopelvic~1
disproportion~1
T-2).~2
nonpretreated~3
(C-2~1
C-3).~1
C-1).(ABSTRACT~1
Sevoflurane,~1
soda~5
lime~5
lime,~1
1-MAC~1
Sevoflurane~1
Soda~1
(NMS)~1
MH-susceptibility~1
NMS~4
(1-3%),~1
(0.2-25.6~1
NMS,~1
MH-susceptible,~1
1-3%~1
MH-susceptible.~1
midazolam-pentobarbital~1
midazolam-thiopental~1
probit~1
isobolographic~1
(supra-additive).~1
synergism.~1
II-III)~1
90-120~1
po;~1
N2O/O2~2
32/95~1
lidocaine-fentanyl~1
predetermined,~1
computer-controlled~2
Efflux,~1
iteration~1
25.35e-.145t~1
4.85e-.0148t~1
kgLBM-1,~1
methohexital,~1
22.21e-.092t~1
5.09e-.0121t~1
kgLBM-1.~1
(end-tidal)~2
(63.5%),~1
(16.3%).~1
(67.9%),~1
(19.1%).~1
(70-84~1
(30-57~1
halothane-nitrous~1
ion-monitoring~1
(179~1
pharmacokinetic/pharmacodynamic~1
"defasciculating"~2
(Sch),~1
25-79~1
bolt~2
tensions,~1
(PaCO2~2
MTC),~1
(MTC~1
pretreatment),~2
Sch,~1
Forebrain~1
trimethaphan,~1
re-infusion~1
(rCGU)~1
3H-2-deoxyglucose~1
rCGU~2
Hemispheric~1
18).(ABSTRACT~1
1.51%.~1
non-vital~1
organs.(ABSTRACT~1
(MH).~1
fascicles,~1
Product-Moment~1
(GLC)~1
0.5-50~1
"depth-pulsing"~1
Fluorine~1
non-NMR~1
emulate~1
means:~1
end-expired),~1
(CMRO2).~1
2.32~1
(cerebral~1
g-1).(ABSTRACT~1
phenobarbital-treated~2
(+PB~1
-PB~3
+PB~3
MAC),~1
(metyrapone)~1
triphosphate/adenosine~1
(ATP/ADP).~1
O2/N2O/halothane~1
25-75%~1
(31.9~1
(0.02-0.06~1
(0.10-0.25~1
O2/N2O/fentanyl,~1
ED95.~1
parallel;~1
right.(ABSTRACT~1
paradox.~2
215%~1
myocardium).~1
non-halothane~1
days-32~1
Lactated~1
Ringers~1
(isoflurane~1
MAC).~2
(128.7~1
142.5~1
(124.6~1
119.4~1
(36.9~1
ml/m2).~1
isoflurane).(ABSTRACT~1
(EEG~2
suppression),~1
(25-29~1
normothermia~1
thiopental-induced~1
1.74%).~1
(A/V)~1
A/V~1
ascribing~1
Isolated,~1
(ETT)~1
ignition.~1
flammability~5
(Si),~1
ETTs~5
(O2)~1
(N2O)~1
flammability.~2
candle-like~2
ignition~5
0.263,~1
Si~2
0.189,~1
0.176.~1
0.456,~1
0.414,~1
Flammability~1
beta-2-agonist~1
1,167~1
(Fadel-Nalebuff~1
modification),~1
RASTS~1
Reagents~1
characterization,~1
(extract,~1
disks,~1
pool)~1
freeze-drying.~1
alum-adsorbed~1
spore~2
mycelium~1
Epicoccum~6
spore-A/mycelium-A),~1
spore-A/spore-B),~1
(spore-A/mycelium-B).~1
skin-reactive~1
spore/mycelium~1
rhinitis).~1
(asthma~1
RAST-Candida~1
APE~4
pollen-specific~1
aeroallergen.~1
Asthmatics~1
allergology~1
multispecificity~1
cola,~1
coffee.~1
(ERL).~1
ERL~4
(resistance,~1
isoabsolute~1
volume-matched~2
ERL,~2
volume-time~2
hand-operated~1
cursor~1
"hand-read"~1
FEV75,~1
FEF25-75;~1
0.989),~1
0.589).~1
Configurational~1
"bumps"~1
mumol/lung~2
saline-filled~2
interface;~1
(PIF)~1
(TNP),~1
hapten.~1
Primed~1
(dinitrophenol).~1
Unimmunized~1
(ip)~1
S).~1
L-[3H]~1
([3H]~1
DHA),~1
3H-DHA~1
ovalbumin-exposed~1
Hemosiderin~1
Prussian-blue-stained~1
"hemosiderin~1
Orthodeoxia--arterial~1
recumbency--has~1
(AVM),~1
6.5F~1
LOC~1
non-LOC~1
0.33).~1
(empyema,~1
(9.1%)~1
50-yr-old~1
smelting~1
potrooms,~1
15,000,000,000~1
nonfibrous~2
1,300,000,000~1
oxide/g~1
methadone.~1
"freebase"~1
permeability-related~1
promulgated~1
timely.~1
Assemble~1
(Cl)~2
Five-point~1
Ppa/Cl~3
rectilinear~1
FIO2.~1
L/min/m2,~1
FIO2,~2
aerosolization~1
(Vmax25)~1
Vmax25~2
(+214%~1
(+21%).~1
reactivity).~2
fan.~1
air;~1
1,905~1
phlegm,~1
wheeze,~1
attacks.(ABSTRACT~1
1,511~1
non-Mexican-Americans~1
observations),~1
biggest~2
Vmax50,~1
size-compensated~1
(Vmax50/FVC).~1
(Vmax50,~1
Vmax50/FVC)~1
(Cdyn).~1
250%~2
(diluent)~1
Removing~3
(8.14~1
(8.11~1
consumption;~1
111Indium-tropolonate-labeled~1
(111In-neutrophils),~1
unlabeled,~1
endotoxic~1
111In-neutrophils~4
suprahilar~1
111In-neutrophils.~1
discretely~1
neutrophils)~1
(Hgb,~3
g/dl),~1
g/dl,~1
p50,~1
hypoxanthine.~1
(18.9~1
124%~1
152%~2
subventilatory~1
two-team~1
3-42~1
ileostomy.(ABSTRACT~1
(IND),~1
IND~4
preceding,~2
well-publicized~1
impinging~1
improvement:~1
extra-hepatic~2
ampullary,~1
hepatis.~1
diverse:~1
Hodgkin's,~1
(cholecystojejunostomy,~1
stenting,~2
(42%);~1
palliative,~1
methyl-prednisolone~1
alter,~2
Butterworth~2
Rapids,~1
1971-73~1
1981-83~1
low-yield.~1
"selective"~2
$70.~1
nationwide,~1
overused.(ABSTRACT~1
(U/A)~1
(ED),~1
U/A.~1
(IVPs)~1
parenchyma),~1
bleeding),~1
Cholecystoenterostomy~1
(CCE)~1
(stones~2
cholecystojejunostomy~1
(CDJ)~1
(CCE~2
CDJ~3
65%),~1
CCE~1
CDJ.~1
Cholecystoduodenostomy~1
Cholecystojejunostomy~1
(15/42).~1
(27/44).~1
(12/13).~1
(51/102).~1
(51/92).~1
(42/94).~1
(FFP)~1
(33/62).~1
(24/43).~1
oncologist.~2
breast-sparing~1
nodal-positive~1
non-center~1
demographics~1
typical:~1
ailments.~1
Anticipated~1
delays,~1
hemicolectomy,~1
thyroidectomies,~1
credence~1
femoral-level~1
Operatively,~1
(fewer~1
(PCD)~1
PCD~2
temporizing~1
pus;~1
(PGV-AP)~1
PGV-AP~1
131I-19-iodocholesterol~1
isotope.~2
(nonautomatic)~1
multiprogrammable~1
automatic.~1
permanent-burst~1
Sedative~1
antihypertensives,~1
2.87%.~1
0.471;~1
0.252,~1
0.278,~1
0.427,~1
13.939~1
[3,~1
85];~1
55.3%).~1
excellent-good~1
omit~1
Entered~1
81),~1
1.7:1~1
syncope)~1
Raynaud~1
(forced~1
[FVC],~1
Hg/L/min~1
(handwashing,~1
example),~1
gloving,~1
labyrinths~1
subject;~1
exhaustively~1
signal-processing~1
(ASP)~1
commercially.~1
ASP~3
hearing-impaired~2
(ASP~1
(quiet,~1
+5,~1
noisy~2
corditis.~1
Hirano~3
surveyed).~1
otolaryngologists.~1
tympanoplasties~2
ears).~2
1.07%~1
Silastic,~1
shavings,~1
mastoid,~1
transtympanic~1
Corti~2
(Nomarski)~1
Corti.~1
cytocochleograms.~1
degenerate,~1
(Meniere's~1
(ABR)~1
latency-intensity~1
interwave~1
latency-repetition~1
rotatory-linear~1
linear-oblique.~1
rotatory-linear,~2
horizontal;~1
ear;~1
Hanhart's~1
onlooker.~1
dysmorphia~1
(F0)~1
postlingually~1
F0~2
normal-hearing,~1
Osteochondrosis~1
(joint~1
mice)~1
click,~1
motion).~1
pre-auricular~1
microprojector,~1
bronchospasms,~1
vascularis.~3
(conductive~2
sensorineural)~1
(ossicle)~1
multiunit~1
magnocellularis~1
(sensorineural~1
lymphoepithelial~1
disease--primary~1
Adrenoleukodystrophy~1
(VLFA),~1
hexacosanoate~1
(C26:0).~1
carriers)~1
(C18:1)~1
C26:0.~1
C26:0~3
VLFA~5
VLFA,~1
(DNA)-alkylating~1
methylmethane~1
sulfonate-induced~1
AChE-containing~1
Bw61,~1
DRw9~1
[CP]~1
2.88;~1
3.60;~1
4.63,~1
(CP~3
5.40).~1
(AChR~1
Ab)~2
(2.77~1
4.61,~1
4.53,~1
HLA-DRw9~1
8.26,~1
4.08,~1
embolism"~1
Gadolinium~2
Twenty-mu-thick~1
midfrontal,~1
editing~1
Neuroectodermal~1
three:~1
neuron-glia~2
parietal;~1
thinning)~1
supposed;~1
liposome-entrapped~1
copper-zinc-superoxide~1
injury-enhanced~1
magnetoencephalogram~1
(MEG)~1
MEG~6
biomagnetic~1
magnetometer~1
tastes~1
auriculotemporal~1
(Frey's~1
("angiomas")~1
cavernous;~1
probands)~1
inconsistant~1
(3OMD)~1
3OMD~4
Portuguese,~1
unchecked~1
Enumeration~1
coumermycin~8
coumermycin)~1
regimens),~1
cloxacillin~7
Coumermycin~2
Coumermycin-resistant~1
coumermycin-resistant~2
(MBC~1
ciprofloxacin.(ABSTRACT~1
arabinosyl,~1
2'-deoxyribosyl,~1
ribosyl~2
pyrrolo[2,3-d]pyrimidines~1
ara-tubercidin,~1
ara-toyocamycin,~1
ara-sangivamycin,~1
deoxysangivamycin~1
indexes)~1
sangivamycin~1
Ara-sangivamycin,~1
arabinosyl~1
deoxyribosyl~1
DNA-DNA~1
[3H]amikacin.~1
[3H]amikacin~2
2,535~1
2,262~1
6,216~1
neamine~1
membrane-binding~1
habekacin,~1
hemodialysis)~1
3-mg/kg~4
(1-h~1
habekacin~1
tobramycin-related~1
nephro-~1
acousticovestibular~1
7,644~1
kHz),~1
1.0-mg/kg~1
Netilmicin~1
(161~1
(accumulation)~1
(Shiley~1
Infusaid,~1
Norwood,~1
Teichomycin~1
ototoxic,~1
teichomycin~2
ethacrynic~1
(A-56619)~1
much,~1
sub-MICs~1
Cefoxitin~1
lozenges~1
antirhinovirus~1
lipopeptide,~1
(methicillin~1
resistant),~1
cocci,~1
teicoplanin.~1
30-micrograms~1
15-micrograms~1
interpretive~1
BMY-28100,~1
BMY-28100~1
cefazolin).~1
(A.~1
Pont,~1
Graybill,~1
Craven,~1
Galgiani,~1
Dismukes,~1
Reitz,~1
Arch.~1
Intern.~1
144:2150-2153,~1
paldimycin,~1
Paldimycin~1
6.8.~1
(dialysis~1
staphylococci.~3
intraphagocytic~2
sultamicillin~4
enterobacterial~1
2''-O-adenylyltransferase~1
[ANT(2'')],~1
ANT(2'')-specific~1
ANT(2'')-encoding~1
narrow-spectrum~1
liters/h,~2
"Streptomyces~1
avermitilis"~1
avermectins~1
CR-1,~2
CR-2,~1
CR-3,~1
CR-4,~1
methylate~2
O-methyltransferase~1
(B2OMT)~1
oleandrose~3
C3'~1
C3''~1
demethylavermectin~3
CR-5~1
(derived~2
"S.~1
avermitilis"),~1
B2OMT~3
CR-6~1
3"-O-demethylavermectin~1
B2a~1
S-adenosylmethionine~1
3''-O-demethylavermectin~1
A2a~1
C5)~1
C3)~1
Intranasal~1
haemolytica~1
viral-bacterial~1
4-quinolones~3
(trichloroacetic~1
precipitable)~1
ofloxacin,~2
amifloxacin,~1
enoxacin,~1
pefloxacin,~1
antibacterially~2
(nalidixic~2
cinoxacin,~1
flumequine,~1
pipemidic~1
phytohemagglutinin.~1
cycle.(ABSTRACT~1
eucaryotic~1
uridine,~1
orotic~1
4-quinolones.~1
HAT~1
(hypoxanthine,~1
aminopterine,~1
[14C]hypoxanthine~1
N-(Phosphonacetyl)-L-aspartate,~1
cefepime~2
(BMY-28142)~1
chromatography-UV~1
(CL;~1
1,502~1
inordinately~1
liters/kg.~1
cefepime.~1
CP-62,993~3
0.031~1
desacetyl~5
mg/liter);~1
error]~1
desacetylcefotaxime,~2
desacetylcefotaxime~2
Ciprofloxacin,~1
rimantadine~5
freundii~2
netilmicin,~1
enoxacin.~1
FCE~3
22101~3
bacitracin.~1
Pustular~1
Pustules~1
4.8:1.~1
euhidrotic.~1
psoralen~1
erythroderma-type~1
(MF),~1
MF.~1
(Mustargen)~1
PUVA,~1
(SCC)-related~1
(SCC-RAG)~1
assayed,~1
kit,~1
SCC,~3
dermatoses,~2
SCC-RAG~2
smaller-sized,~1
non-SCC~1
amelanotic,~1
fascicles.~1
Queensland,~1
bottle,~1
(breast~1
bottle)~1
milks,~1
milks~2
Bottle~1
(milk)~1
semi-liquid~1
(pudding)~1
LL-SH~3
(1.98)~1
(0.545).~1
disproportion.~1
Galway~1
mid-70s~1
IU/ml.~2
5353~1
October.~1
N-acetyl-beta-glucosaminidase~1
(NAG)~1
preterm,~1
NAG:creatinine~2
5914~1
walkers~1
overreliance~1
3657~1
non-lymphoblastic~1
taught,~1
'minor~1
ailments'~1
nebulisers~2
Nebulisers~1
nebuliser~1
intranebuliser~1
wasted,~1
stunted.~1
catch-up.~1
immunisation.~1
1971-84~1
haemosiderosis~1
avian,~1
gliadin,~1
enteropathy,~1
'soft'~1
'tense'~1
(14.0~1
fontanelles,~1
psychotherapist~1
2,3,7,8:tetrachlorodibenzodioxin~1
(TCDD)~1
pets~3
sentinels~1
owners~1
pets'~1
owner-reported~2
Mantel-Haenzel~1
Owner-reported~1
TCDD-contaminated~1
unconfirmed~1
(1,1,1-TCE)~1
1,1,1-TCE~2
Opposite~1
pre-administration~1
cystoides~1
5-yr-period~1
1979-1983.~1
(56.1%)~1
PCI,~1
(15/21),~1
(20/21),~1
(16/21)~1
degreasing~1
trichloroethylene.~1
smelter~2
Dividing~1
quintiles~1
(PbB)~1
spoke,~1
1000,~1
PbB~2
hyperactive.~1
borosilicate~1
capacitor~1
resistor~1
lead-related~1
clothes.~1
Tap~1
households)~1
tapwater~1
0-791)~1
171.5~1
0-1036),~1
macrominerals~2
(mg/day):~1
16.5,~1
13.2;~1
2.3.~1
0;~1
31.0,~1
24.4.~1
Intake~1
(RNI)~1
RNIs~1
Sigmoidoscopic~1
Origin~2
cineangiography,~1
sham-Tx~4
(CLP).~1
14C-phenylalanine~1
SOL,~3
113%~1
Abolished~1
colorectum~1
Klatskin~1
56.7.~1
Mitosis~1
Postrecurrence~2
postrecurrence~1
(BSHGH)~1
BSHGH,~1
BSHGH~6
N)~2
(2287~1
(42.7~1
(3049~1
LBM/24~16
kJ/kg~2
1-6.~1
(BSHGH~4
N/kg~3
prot/kg~4
5.90~1
BSHGH.~1
hyperviscosity,~1
atresia)~1
Esophagogastrectomy~1
esophagogastrostomies~1
2062~1
962~2
thymectomy,~1
thymomas.~1
thymomas~1
"unit"),~1
12-unit~2
18-unit~1
flush,~1
mid-gut~2
tachykinin~1
(NPK)~1
tricuspidal~1
(SBO).~1
(PSBO)~1
(CSBO)~1
(UGI)~1
(NGT)~2
nasointestinal~1
(long)~1
(NIT)~2
PSBO~3
CSBO,~1
CSBO.~1
NGT~7
NIT),~1
CSBO~1
NIT).~1
Need~1
pylorus;~1
NIT~4
NIT,~1
SBO.(ABSTRACT~1
cholangiovenous~1
choledochoscopic~1
1.4%.~1
(9.6~2
(preoperative~1
pancreatoduodenectomy,~3
CCK:~3
pmol-120~4
min/L),~2
901~1
min/L)~1
min/L).~1
abolishment~1
re-evaluating~1
tourniquets~3
17):~1
(Ono~1
Pharmaceutica,~1
(DEC)~1
Louis,~1
MO)~1
SRI~2
(Sandoz~1
63-072~2
695~1
PMN/20~5
(HPF)~1
HPF~2
HPF,~1
1419~1
leukosequestration~1
moderates~1
leukotriene-induced~1
Reconstructions~1
59),~1
"take~1
off"~1
(6-14~1
lodgment~2
three-dimensionally.~1
carina,~1
hitherto.~1
extraesophageal~1
torn,~1
derivative)~1
J/cm2.~1
(mediastinitis~1
Atelectasis~1
(PRLND)~1
micrometastatic~1
9.6%.~1
Clark~2
optimistic,~1
PRLND~2
14.3%;~1
positive-node~1
hydroxyethyl~3
Oncotic~1
(OP)~1
(EVLW),~1
pressure-pulmonary~1
[D(A-a)O2]~1
OP~1
D(A-a)O2~1
1-13C-palmitate~1
d5-glycerol~1
H2(18)O~1
boluses,~1
foxhounds~1
2,000-cGy~1
carinal~1
IORT,~1
right-heart~1
20-ml~1
(all,~2
crystals)~1
40-ml~1
technetium-99~1
(40-ml~1
volume).(ABSTRACT~1
2,570~1
(IABP).~1
64.9~1
IABP.~2
(2.5%),~1
IABP~3
revascularize~1
end-to-side.~1
hydrauler~1
(sonomicrometry).~1
acid-enhanced~1
vented~2
45.8%~1
(78.6~1
(39.3~1
(bypass,~1
(cardioplegia)~1
(DCRV).~1
deviation]).~1
DCRV~6
atriotomy,~1
unileaflet~1
tilting-disc~2
Hall)~1
by-pass~1
stuck~1
unraveled~1
evoked-response~1
Expedient~1
subadjacent~1
parahiatal~2
counterincision.~1
colopericardial~1
corrosion.~1
midsternotomy.~1
plugs.~2
historians~1
shirt~1
tie,~1
nylons,~1
physician-identifying~1
tag.~1
suits,~1
clogs,~1
socks.~1
feminine~1
ruffles~1
dangling~1
earrings~1
fashionable~2
earrings,~1
hose~1
(CI).~1
43;~1
48;~1
U/L),~3
(282~1
[1.7~1
mg/dL]).~1
995~1
Hospitalized~1
stercoralls~1
stool-positive~2
stool-negative~1
bloating.~1
guaiac-positive~1
antacids.~2
Tonsillar~1
adenotonsillar~1
tonsils.~1
"minimal"~1
surgery-induced~2
(focal~1
options;~1
unification~1
3783~1
(Scotland)~1
(7.9%).~1
hyperaldosteronism~1
[ICD]~1
589)~1
(ICD~2
458)~1
208;~1
239)~1
creators~1
executed.~1
kinase-myocardial~1
nonsyncopal~1
U/L)~1
"cholerheic~1
enteropathy."~1
resin.~1
OSA,~1
Behavioral,~1
methylphenidate,~2
tardive~3
blink-rate,~1
pulse-rate~1
dosage-reduction~1
(Sum~2
DA),~1
NE),~1
Sum~1
DA/Sum~1
stereomorphometric~1
Nissl-stained~1
Xe~1
gray-matter~2
(gray~1
matter)~1
(monozygotic)~1
co-twins,~1
co-twins~2
Maudsley~1
(1948~1
1965)~1
Gottesman~1
Shields.~1
MZ/DZ~2
mood-incongruent~2
"more~1
genetic"~1
(7.68)~1
(paranoia)~1
P300~1
depressives,~1
neurointegration.~1
schizophrenic,~1
psychotic,~1
Schizophrenic~1
(16/41)~1
(15/41)~1
non-thought-disordered~1
(16/65)~1
(24/65)~1
epiphenomena,~1
posttraumatic,~1
"lesion"~1
neuro-ontological~1
necessity,~1
wanted,~1
imperative.~1
aspirates),~1
(blood,~1
fluids).~1
(fine-needle~1
biosensors,~2
real-time,~1
biosensor~1
microelectronic~1
Biosensors~1
configured~1
envisioned.~1
charge-related~1
record-keeping~1
departmentally~1
patient-centered~1
physician-level~1
institution's~1
officer,~1
care-related~1
tools,~3
"artificial~1
intelligence"~1
Telepathology~2
telepathology~2
camera;~1
monitor;~1
telecommunications~1
"equivocal"~1
Rapid,~3
emerges?"~1
analyte~1
networking~1
telecommunication~1
pathologists-in-training,~1
pathologists-in-training~1
raphe,~2
(sliding~1
reward).~1
parafascicular~1
maze~2
learning;~1
inhabit~1
"subcortical~1
dementia."~1
abled-bodied~1
(MVO)~1
59.3~2
mL/min/100mL~1
0.13mL/100mL.~1
MVO~1
2.57mL/min/100mL~1
0.17mL/100mL.~1
auscultated~1
-0.8~1
-12.7~1
diastolic.~1
Advancement~1
Uncontrolled~1
69.~1
stair~1
homemaking~1
(PDI)~1
pain-related~1
PDI.~2
PDI~2
.86),~1
(59.3%~1
discretionary,~1
(14.3%~1
workbook-based~1
(OT).~1
log,~1
workbook~2
monomelic~1
amyotrophy,~1
girdle,~1
longus.~1
intraexaminer~1
5.1%~1
-0.20~1
11.3%~1
CV,~1
legging~2
instep.~1
tightened,~1
nonelasticity,~1
Unna~1
boot,~1
fibroplasia.~1
positive-action~1
serrated~1
Delicate~1
shredding.~1
(T1)-~1
(T2)-weighted~1
100-hue~1
(ERGs)~1
(a-wave,~1
b-wave,~2
potentials)~1
a-wave,~1
lymphomatosis~1
choriocapillaritis~1
choriocapillaris-retinal~1
epithelium-outer~1
-13.00~1
anisometropia~4
maculae~1
-3.75~1
maculae.~1
overlapped,~1
beading.~1
exudation,~1
Band~2
BSS~1
(balanced~1
Viscoat~5
(chondroitin~1
sulfate-sodium~1
hyaluronate),~1
intracamerally~1
Viscoat.~1
energy-dispersive~1
(ESRs)~1
presentation:~1
mm/h;~2
proptosis.~1
electron-microscopically~1
neovasculature~1
photothrombosis,~1
sulfamethoxazole,~1
tobramycin)~1
broadest~1
microgram/mL),~3
microgram/mL).~1
avidity.~1
Anti-DNA~2
cardiolipin.~4
Anticardiolipin~2
rare:~1
classes:~1
Atlantoaxial~1
counters.~1
"unknown"~1
2,467-12,000/mm3~1
6,683~1
1,992).~1
0-30%~1
Cusum~1
DLCO/lung~2
DP-treated~2
test);~1
Hydroxyapatite~1
(40.7%,~1
(6.0%,~1
needle-like~1
electron-dense,~1
calcifying~1
Myoadenylate~1
(MADA)~1
postexertional~1
MADA~2
ammonia,~1
inosine,~1
hypoxanthine)~1
MADA-deficient~1
4-B-5,~1
(ssDNA)~1
thymocytes,~2
4-B-5~2
DNase-treated~1
Coincubation~1
procainamide-induced~1
hydralazine-induced~1
chromatin.~1
anaerobic.~1
Margaria~2
50-yd~2
dash.~2
cranialization.~1
doctrines~1
Auricular~1
columellar~1
minicomposite~1
length-width~1
allografts,~1
(5/16).~1
nonpatent~1
diagrammed~1
III);~1
IV);~1
trunks,~1
transected,~1
fibrin-based~1
suturing.~1
Tisseel.~1
transmissible~1
cocoon,~1
insulated.~1
(MEO)~1
(7/11)~1
(7/10)~1
MEO~1
Ben~1
Taub~1
(CMN)~1
CMN~1
CMN,~1
otolaryngologist.~1
Deep-neck~1
Epidermoids~1
blastomatous~2
Intradiploic~1
epidermoids~2
intradiploic~1
diploic~1
Arthritis,~1
Digestive,~1
15.9%.~1
(0.27%)~1
premedicants~2
Trimeprazine~1
Pre-charged~1
dilutions)~1
(suxamethonium,~1
gallamine,~1
thiopentone)~1
anaesthetics:~1
Prick~1
(79.6%)--a~1
(97.3%;~1
(96.6%;~1
weals~1
pretreated,~1
Bronchospasm~1
monoquaternary~1
2-10%~1
3-4%~1
hyperglycaemic~1
145)~1
(253)~1
(159)~1
(preoperative)~1
987~2
(474)~1
(MHS)~1
MHS~13
MHS.~1
Difficult~1
lubricants~1
75.1~1
hyperoxia)~1
(4-fold~1
peroxidation)~1
2-fold).~1
Disopyramide~1
biventer~1
cervicis~1
erabutoxin-b~1
Equieffective~1
magnesium-blocked~1
twitches.~3
tubocurarine-induced,~1
disopyramide-induced,~1
non-parallel~1
litre-1.~3
costo-cutaneous~1
garter~1
concentration-~1
endplate-currents~1
(EPC)~1
EPC.~1
non-competitive~1
acetylcholine-activated~1
receptor-ion~1
10(-7)-1.3~1
10(-8)-1.3~1
10(-8)-6.4~1
Sweden;~1
extradural,~1
intrathecal,~1
1:1100~1
(0.09%)~1
1:275~1
(0.36%)~1
benefit-low~1
prethrombotic~1
coagulability.~1
subnanomolar~1
F1+2~3
scission~1
Nossel~1
1-42,~1
nonanticoagulated~1
diatheses.~1
Virus-treated~1
under-agarose~1
10-micron~1
deactivation,~1
chemotactic.~1
(fMLP)~1
fMLP.~1
parvovirus,~1
Wright's-Giemsa~1
encapsidation,~1
30,000/infected~1
(moi);~1
moi,~1
200x~1
50x~1
supernatants.~1
parvovirus.~1
anti-Rho(D)~1
Clq-binding~1
20,000/microL~1
81,000/microL~1
CCGG~1
antibody),~1
ANLL,~2
hypermethylation~1
agglutinate~1
VIII:von~1
postsurgically~1
pseudo-Bernard-Soulier~1
(MoAbs)~1
cCLLa,~1
69-kilodalton~1
leukemia-associated~1
(B-CLL)~1
variants:~1
(PLL)~1
(HCL).~1
B-CLL~2
MoAbs~3
MoAbs.~2
cCLLa~3
inhibition-absorption~1
10(6)/cell,~1
anti-cCLLa~1
t(14;18)~2
del(6q)~1
7q.~1
translocation.~1
t(14;18).~2
c-fos,~1
FBJ~1
plasmalogen~1
(SV40).~1
subcloning~1
pan-hematopoietic~1
T-200~1
CD-3,~1
1G10~1
12.8.~1
blastlike~1
obligately~1
stromalike~1
(monovalent~1
fragment)~1
(LJ-CP8~1
LJ-P9).~1
ADP-stimulated~2
LJ-CP3,~1
LJ-CP3~1
"strong"~1
surface-oriented~1
IIb/IIIa.~1
VII-agarose~1
HTF1-7B8,~1
HTF1-7B8~2
VIIa,~1
blots,~1
quenched-flow~2
47-kiloDalton~1
20-K~3
47-K~3
phosphorylations.~1
depolymerizes~1
(F-)actin.~1
pyrene-labeled~1
monomers.~1
(DBP).~1
depolymerize~1
Depolymerization~1
DBP.~1
Fibrin(ogen)~1
depolymerization.~1
G-actin~1
actin-DBP~1
depolymerizing~1
sulfate-labeled~1
heparanase-mediated~1
Kav~1
6B).~1
heparanase~8
nonanticoagulant~2
bloodborne~2
low-sulfated~1
low-mol-wt~2
heparins,~1
N-sulfate~1
O-sulfate~2
resulfated.~1
25-fold~1
pentasaccharide,~1
carboxy-terminal~4
411).~1
411)~1
triethylene-tetramine~1
384,~1
cross-linking,~1
site).~1
(dCyd)~1
1-B-D~1
arabinofuranosylcytosine~1
(L-CFU).~1
Leukemic~1
myeloblasts~1
dCyd~5
72.2%~1
CFU-GM,~1
L-CFU.~2
dCyd-mediated~1
(Ara-CTP)~1
(dCTP)~1
Ara-C.~1
fibrogenic~2
fibrin-stabilizing~1
a2b2,~1
a-chains~3
b-chains;~1
a2,~1
a-chain.~1
a-chain,~1
a-chain~1
4.0-kilobase~1
uncultured~1
Rsa~1
Cap~2
IVS-I.~1
XeCl~1
nsec~1
(UVB308).~1
MW/cm2~2
J/cm2,~3
UVB308~2
MW/cm2),~1
log10.~1
MW/cm2)~1
"window~1
efficacy"~1
zero-thalassemia,~1
cluster,~1
autofluorescent~2
epifluorescence~3
deparaffinized~1
dezenkerized~1
autofluorescence~2
identifiable.~1
marrows,~1
chemokinesis,~1
bisglycinate~1
[Cu(II)gly]~1
bishistidinate~1
Cu(II)gly~2
self-perpetuating~1
D-Penicillamine~1
Cu(II)gly.~1
aurothiomalate~1
'incomplete~1
CREST'~1
'diffuse~1
algodystrophy~3
notable.~2
posters~1
poster.~1
viewers~1
hyperuricaemia~1
cobalt-60~1
radiotherapy-surgical~1
palliatively~2
lactating.~1
mastitis.~1
mastitis/mammary~1
metronidazole;~1
Mammillary~1
mastitis/duct~1
granulate.~1
(6/72)~1
Peripherally~1
(13/28)~1
(Hadfield's~1
unreviewed~1
1:8.~1
anti-tumour~1
essential;~1
(thirteen~1
retarded.~1
Presentation~1
haematemesis~1
'normal'~1
'retarded'~1
'Gas-bloat'~1
well-perfused~1
evanescent.~1
(sixty~1
55-84~1
Laurence's~1
Micro-embolization~1
(42)~1
favourable.~1
run-off,~2
defibrinogenation~3
Arvin~2
run-off.~1
gl-1~2
0.7s-1)~1
defibrinogenated~2
solid.~1
thermode~2
mid-rectum~1
(B16~1
C57/BL6~2
UV-2237~2
transfusing~1
azoxymethane)~1
Enterectomy~1
60-106~1
0.002-0.005)~1
70-86~1
halving~1
10-90~1
bacteraemia.~2
(COPi)~1
non-injured~2
(COPp)~1
wick-technique~1
COP.~1
hypoproteinaemia~2
COPp~2
12h~2
COPi~2
(COPp~1
COPi).~1
pseudo-~1
post-burn,~1
(Price~1
et.,~1
Frohlich,~1
1977).~1
reasons:~1
who--following~1
failure--developed~1
IC-type~1
'backwards~1
flap'.~1
lawn-mowers.~1
cupping~2
"near-vision"~1
aid(s),~1
head-borne~1
dioptric~1
orthoptic~1
photography.~2
1020~1
iritis~2
perforated.~1
photophobia,~1
redness,~1
collaborated~2
(FOB)~1
complied.~1
180.4,~1
58.5%~1
complying.~1
Restricting~1
(FAS/FAE)~1
psychoeducational~1
FAS/FAE~2
Ethambutol~2
dosages.~1
Kingston,~1
motorbikes,~1
snowmobiles~1
all-terrain~1
(ATVs).~1
dirtbike~1
ATV-related~1
(ABH)~1
(TUR~1
BCG).~1
(aneuploidy~1
ABH-negative~1
reactivity)~1
(diploidy~1
ABH-positive~1
ABH~1
undifferentiation~1
BCG.~1
columnar/mucinous~3
nonurethral~1
XXY~1
choriocarcinomatous~1
rhabdoid~1
affiliation~1
MRT.~1
DTIC.~1
plasmablastic~3
(Kaplan-Meier~1
0.0000).~1
granuloma/fibrous~1
1952~1
histiocytoma/plasma~1
6:1~1
esophagocardia~5
extensive)~1
1946~2
Tokyo,~1
21.7%.~1
56.5%~1
closely--the~1
99%,~1
dryness,~1
flashes."~1
tumors).~1
posttherapy~1
hormonal)~1
interinstitutional~1
(alpha-tocopherol)~1
(0.116~1
(0.111~1
(0.122~1
age-ratio~1
(11.85~1
(AJC~1
(cisplatin~1
non-cisplatin~1
based)~1
40.6%~1
32.4%,~1
combined-treatment~2
(111+~1
combined-therapy~2
Site-~1
"isoeffect~2
dose"~2
isoeffect~1
ANLL~3
units-granulocyte~1
occlusive,~1
platelet-vessel~2
Adhesion,~1
jeopardy.~1
Finding~1
come.~1
(fat)~1
(ESPL)~2
(0.77-2.6~1
(0.70-2.13~1
ESPL~3
b/(MAC~1
"a"~1
"b"~1
(69.04~1
25.83~1
mm-1)~1
(63.19~1
17.36~1
mm-1).~1
(38.66~1
9.73~1
mm-1:~1
B:~1
PvO2.~1
PvO2~4
receded~1
postspinal~1
recedes~1
T10.~1
mesosalpinx~2
Yoon~1
Kruskall-Wallis~1
H-Test~1
Wilcoxen's~1
Rank-Sum~1
One-way~1
(ANOVA)~1
Multiple-Range~1
postanaesthesia~1
(halothane~1
isoosmolar~1
Haemolysis~1
hypoosmolar~2
(V/Q)~1
Landrace~1
Landrace/large~1
kg-1--a~1
(intermittent~1
(total)~1
IPPV~1
anaesthetic,~1
7.06),~1
mmole~1
L-1.~1
re-intubation~1
post-extubation~1
stridor).~1
coproporphyria.~1
coproporphyria~1
bullosa,~1
letalis~1
Hypoglycaemia~1
Gravid~1
"accelerated~1
starvation."~1
post-blockade~1
meantime,~1
preanaesthetic~1
(throbbing~1
recumbency)~1
post-dural~1
ventriculo-spinal~1
transducer-tubing~3
configurations;~1
pole-mount~3
(60-inch~1
tubing)~1
patient-mount~2
(12-inch~1
tubing).~1
additions.~1
pole-~1
overshoots~1
42K+~7
(application~1
25-150~1
depolarization-mediated~1
(Vmax,~1
force/mm2,~1
23%;~1
+dF/dt~1
max/mm2,~2
-dF/dt~1
1/2).~1
Exocytotic~1
chromatography)~2
reuptake.~1
cyclohexyladenosine~1
S-phenylisopropyladenosine,~1
glucose-free~1
(GX)~1
postpubertal~1
(SH).~1
MSH;~1
MGX;~1
MGX~10
(MGX~1
FGX~11
(FGX~4
P),~1
T).~1
FTX~1
EP.~2
MGX,~1
FGX.(ABSTRACT~1
Aftercontractions,~1
afterdepolarizations,~2
substrate-free~1
W-shaped~1
dependencies~1
(200-1,000~1
M-shaped~1
dependencies.~1
extrasystolic~2
subthreshold.~1
delayed-afterdepolarization~1
aftercontractions,~1
ryanodine.~1
overloaded~1
Ultrarapid~1
freeze-fractured~1
30/micron~1
18/micron~1
unpretreated~1
Discrete~1
ultrarapidly~1
Particle~1
adherens~1
alongside~1
arrays.~1
Caveolae~1
transients,~1
fura-2/AM,~1
bell-shaped~1
ryanodine-sensitive~1
"tail~1
transients"~1
release.(ABSTRACT~1
myocardium)~1
Superoxide-radical-induced~1
agranulocytic~4
Leukopak~1
filters)~1
(granulocytopenia).~1
reperfusion),~1
granulocyte-related~1
no-reflow,~1
enzyme-induced~1
Ca]i)~1
(choline-substituted)~1
Nao-free~3
(1,280~1
Nao-~3
Cao-free~2
(540~1
Sodium-free~1
preexposed~2
Brief,~1
preperfusion~1
La3+~1
Nao~2
Ca-free~1
CCCP~1
CCCP,~1
[Ca]i,~1
release).(ABSTRACT~1
(0.02-0.04~1
mu/ml)~1
superfusate-modified~1
Locke's~2
mol/l/min.~1
-79.3~1
-70.9~1
110.9~1
101.7~1
254.1~1
V/sec~2
weight-to-body-weight~1
(2.45~1
3.40~1
micrograms/right~2
(1.80~1
(32.6~1
nmol/hr/right~2
ventricle).(ABSTRACT~1
microsphere-assessed~1
mid-LC~1
(LADP)~1
(AoP)~1
(LADP~2
AoP),~2
implantation)~2
(6-7~1
pithing.~1
subsensitive~2
Arg-vasopressin~1
angiotensin-II~1
(homologous~1
desensitization).~2
(heterologous~1
[3H]Yohimbine~1
155/100~1
136/84~1
atenolol-induced~1
Regurgitation~1
fifties,~1
.81,~1
apoproteins~1
4045~1
(APOB)~1
(APOA1)~1
APOA1/APOB~1
APOB~2
HDL3,~1
561)~1
(HDL2-C)~1
HDL3-C~3
HDL3-C.~1
black-white~1
(sexual~1
triglycerides).~1
HDL3-C,~1
covariate-adjusted~1
1973-1984~1
nonwhites.~1
black/white~1
(denoted~2
Vmin),~1
Vmin~3
turbulent.~1
111-monoclonal~1
antimyosin~4
Antimyosin~1
VTs),~2
VTs]~1
[nine~1
VTs])~1
initiated;~2
distant)~1
VTs)~2
nonsites~1
Suga-Sagawa~2
Eav),~1
Preload~1
(slope:~1
Eav)~1
Eav~4
afterload)~1
(ESPVRs),~1
(Vom)~1
(Vop)~1
Vom~3
Eav.~1
fraction-afterload~1
equals,~2
compressions.~2
(high-impulse)~1
deformed,~1
mid-chest~1
low-velocity,~1
(low-impulse)~1
compressed.~1
low-impulse~1
norepinephrine/g~1
(437~1
pg/g~1
Supersensitivity~1
([125I]-cyanopindolol)~1
(268.6~1
(253.5~1
(58.7~1
17.4%)~1
(49.6~1
10.9%)~1
.068).~1
(oxotremorine~1
wide).~1
eight-level~1
midmyocardial~1
reperfusion).~1
nonreentrant~4
(AVCT)~1
(AVERP)~1
AVCT~3
AVERP~1
Slow-channel~1
interval-dependent~1
Amiodarone's~1
balloon-expandable~2
main,~1
(longest~1
(Fluosol-DA)~1
Gottingen~1
FPL-55712,~2
LTD4-receptor~1
LTs~1
Diphenhydramine,~1
LT-induced~1
spasm.(ABSTRACT~1
relevance,~1
debatable~1
Bologna~1
(facial~1
meatography~1
(1976-1986).~1
laryngitis.~1
high-flux~2
backfiltration~1
F-60~1
(Fresenius~1
AG).~1
limulus~1
HNK-1+~4
(non-DM)~1
experimentation,~1
non-DM.~1
(27.9%).~1
TPRI~2
0.730,~1
Yugoslavia.~1
Glomeruli~1
Henle~1
phosphocysteamine,~1
limitation;~1
living:~1
traveling,~1
socializing,~1
footwear.~1
McBride~1
quickness~1
security,~1
employability,~1
equating~1
earnings,~1
clouded~1
sympathy~2
attorney,~1
"private"~1
injury?~1
function?~1
(Nurick's~1
dove-tailed~1
50.1~1
30-75);~1
59.3%;~1
3.8%.~1
caudocranial~2
Tangential~1
hernial~1
(main~1
tear);~1
herniation;~1
sharpness~1
discs;~1
slips~1
slips.~1
facetectomy~1
interarticularis~1
destabilized~1
insole,~2
anodyne~2
(Indomethacin~1
test-negative~4
candidates;~1
360.~1
structural.~1
spondylolithesis~2
ala-transverse~1
dissipated.~1
musculoligamentous~1
Sciatic~2
neurocirculatory~1
olecranon.~1
(infection~1
permissible.~1
(THA),~1
conversions~1
nontotal~1
(Two~1
THAs~1
Girdlestones).~1
six-118~1
prognosticators~1
(ESR).~1
chondromatosis.~1
bursography~2
musculotendinous~2
snapping~1
straight-stem~1
Locking)~1
valgus;~1
fluted~1
1808~1
T-28~1
TR-28~1
Trapezoidal-28~1
Lock~1
referred.~1
Periarticular~1
Southwick~1
slip,~1
degrees-94~1
well-encapsulated~4
lipofibromatous~1
aseptic-hinge~1
total-knee~1
Condylar~2
postrevision~1
radiolucency~1
median.~1
(center~1
mortise)~1
three-foot~1
(Zone~2
Cartier~1
Villers'~1
templating~1
Zone~2
metarsophalangeal~1
degrees-30~1
dorsoflexion~1
Indium-111~3
images);~1
nonarthroplasty-related~1
images).~1
true-positive,~1
true-negative,~1
false-positive,~1
copes~1
construct.~1
"ruptured~1
disc"~1
precipitant,~1
"trauma"~1
compelling.~1
heuristic~1
Workers'~3
Compensation~3
compensable~1
backache;~1
"injures"~1
sufferer~1
contest,~1
counselor.~1
Sensibility~1
quantification,~1
simulator~1
nonathlete~1
return-to-play~1
leagues~1
insurance:~1
program),~2
state-regulated~1
$16.8~1
$16.1~1
billion;~1
$5.2~1
$40~1
Ergonomically~1
Workplace~1
employee:~1
be.~2
impairment/disability~1
Speculation~1
reinforcer~2
Preference~1
weight-concern~1
pain-rating~2
now-employed~1
comprehended~1
antipyrine,~2
norantipyrine~2
rifampin;~1
4-hydroxyantipyrine~1
102%,~1
desmethyl-~2
3-hydroxydiazepam~2
400%.~1
(iso)zymes~1
smoke)~1
steroids).~1
paraxanthine~3
7-demethylation~1
8-hydroxylation~1
7-demethylation/8-hydroxylation~1
Torasemide~1
torasemide~1
Probenecid~1
0.0016)~1
L/kg;~3
(AMX)~1
isocaloric,~1
AMX~4
12.17~1
9.65~1
ouabain-~1
frusemide-sensitive~1
efflux,~2
normoglycaemic~4
(hereditary~1
IGT~3
Na+/K+-ATPase~1
(CIn)~1
isosthenuric~1
CIn.~1
CIn~2
pre-ischaemic~1
(CaA)~1
citrate-free~1
CaA~3
47Ca-85Sr~1
post-load,~1
54.6~1
76.3~1
CaA,~2
complexation~3
32P-labelling~1
risen,~1
acyltransferases~1
octanoyltransferase~1
1.7-2.4~1
Acetyl-CoA~1
octanoyl-CoA~1
(42-57%)~1
acetylcarnitine~2
acylcarnitine~7
intermediately~1
litres/kg~1
(beats/min~1
propranolol/ml)~1
pregnancy:~1
-0.61~1
-0.39~1
6.64;~1
integrities~1
Perfused~1
hydrolysis-resistant~1
glycylsarcosine~3
Na+:~1
Li+,~2
Tris,~2
mannitol.~2
Cs+~1
Kt~2
substituent~1
non-metallic~1
substituents.~1
interpreted,~1
unqualified~1
'Na+-dependent'.~1
Na+-dependence~1
[10].~1
fulfilled.~1
Adrenaline,~1
(ARH).~1
1471~1
335,~1
nmol/g~2
glomerulosa.~1
3030.4,~1
339.8~1
ARH~1
cortex.(ABSTRACT~1
GC-MS~2
PFT~1
hallmark,~1
Intrathoracic~1
(END)~1
END~3
fixed-pressure~1
shock),~1
(NAL),~1
(MP),~1
NAL~1
nonsteroid-treated~2
Scatterplots~1
END.~1
.75,~1
anoxic-ischemic~1
(SMC/IGFI)~1
(NB)~1
SMC/IGFI~4
.50,~1
.46,~1
.39,~1
NB.~1
greatly;~1
random-source,~1
shaved,~1
(32-Fr)~1
orogastric~1
fan~1
blowing~1
Evaporative~1
evaporatively~1
lavage-treated~2
post-termination~1
3.78~1
administers~1
revolutions~1
Noble-Collip~1
drum.~1
(MDF)~1
(191~1
MDF~2
sump,~1
(IAIS)~1
suction-induced~1
NG~1
IAIS~2
expelling~1
Blockage~1
IAIS.~1
(LDV).~1
LDV~5
Heated~1
decompensations~2
DO2,~1
compensations~1
nonsurvivor~1
(17-19).~1
Cytomegalovirus~1
14-valent~1
vaccine)~1
(47/1,000~1
41/1,000~1
Nonpneumococcal~1
pneumonias;~1
pneumonias).~1
nonvaccine~1
nonpneumococcal~1
hoped.~1
widely-accepted~1
Fr~1
smaller).~1
1,737~1
subacute;~1
unsuccessfully.~1
133Xe,~1
woman;~1
0.51),~1
COLD.~1
pen~4
Mantoux~1
indurations~1
post-thoracotomy~1
"biopsy~1
only"~1
34+~1
56+~1
42+~1
13+~1
37+~1
Post-chemotherapy~1
pneumotachygraphy)~1
plethysmography).~1
0.8687)~1
MVV~3
VEmax.~2
watts/min.~1
.81)~1
.81),~1
.78),~2
.68),~1
.67),~1
.65)~1
.64).~1
post-bronchodilator~1
37.69~1
0.98.~1
oxygen-conserving~1
efficiency--transtracheal~1
demand-pulse~1
delivery--are~1
(VWT)~1
VWT~3
(2.88~1
(1.77~1
SA.~3
Moist~1
rales,~1
Aging,~1
.5~1
exudates.~1
transudates.~2
fluid-to-serum~1
transudates,~1
classified.~1
transudative~1
hemoglobin-oxygen~2
(experimental)~1
(recovery)~1
efficiently;~1
(R6)~1
(R26).~1
(R6-R26)/R26~4
Rrs.~1
R6~3
uninstructed~1
Tape~1
play-back~1
physiotherapists.~1
adventitious~1
fashions.~1
hyperimmunoglobulinemia~1
3,179~1
solderers~1
fumes~2
galvanized~4
soldering~4
metal.~1
fume~1
nonenzymatic~2
beta-glucuronidase.~1
(TSBA)~1
simulation,~1
TSBA~1
TSBA,~1
CCA.~1
CCA,~1
Orocecal~1
os),~1
os)~1
(128.8~1
32.9)~1
(85.5~1
35.7),~1
(88.8~1
46.2),~1
(84.4~1
40.6).~1
orocecal~3
secoverine~2
(SWSA).~1
cycles/minute)~1
SWSA~1
FFT.~1
Secoverine,~1
1000-kcal~1
potential/30~1
gastrocolonic~3
Secoverine~1
loose/watery~1
urgency.~1
race-~1
arbacet~3
arbacet-treated~2
60.4%~1
(Difference~1
"pancreatic~1
barrier,"~1
(JCl-,~1
JHCO3-)~1
transductal~1
JCl-,~1
+0.92~1
mumol/cm/hr;~2
JHCO3-,~1
-1.71~1
Glycodeoxycholate~1
cerulein,~1
72-year~1
Hyperbilirubinemia~1
feathery~1
plugging,~1
microvilli,~1
Widening~1
pericanalicular~1
ectoplasmic~1
oxytetracycline,~1
pseudopyloric~1
gland-type~1
atypism,~1
hamartomatous.~1
(pocket~1
spirometer,~1
Buhl~1
homebased~2
pharmacist.~1
(FEV1:FVC)~1
t-test,~1
0.718.~1
morbilliform~1
tartrazine-free~1
Tartrazine,~1
desipramine-induced~1
tartrazine,~1
nonassociation~1
tartrazine.~1
270/160~1
Ketoconazole,~1
nitrogen-substituted~1
P-450-mediated~1
18-40~1
(TDx)~1
(two-tailed~1
t-test)~1
(0.797~1
0.201~1
0.722~1
primary-care~1
X-rays,~1
Dunedin,~1
2834~1
1978-80~1
1983-85.~1
hydrochlorothiazide-triamterene~1
(EID)~1
inspections~1
EID~2
inappropriately.~1
non-intensive~1
+178,000~1
+460,000~1
(Clren).~1
Clren~1
(Clcr)~1
Clcr~1
rational,~1
bulletin~1
pays~1
(GMS).~1
GMS~5
1982-83.~1
wholesalers~1
carbocysteine,~1
delisted~1
error]),~1
phytohemagglutin~1
(88.6~1
cpm)~2
(44.0~1
(0.125~3
(0.625~1
hyper-reactive~1
laboratory)~1
(1/2~1
tablet)/day~1
manufacturer-recommended~1
P.M.)~1
6:00~1
A.M.).~2
castrate,~1
4A),~1
(DEX)~2
DHEAS,~2
DEX-suppressed~1
spironolactone.~1
coital~2
Coital~1
(0.72)~1
coitus,~1
fecundability.~1
lynestrenol~1
progestative~1
microsurgery,~1
(living~1
births)~1
[35S]methionine-radiolabeled~1
220,000,~1
dibutyryladenosine~1
([Bu]2~1
immunoadsorbant~1
protein/24~1
(Bu)2~1
25,000-dalton~1
(19.4%/trial).~1
Granulosa-lutein~1
(G-L)~1
G-L~6
Spent~1
hormone/human~1
(LH/hCG)~1
fertilize.~1
"luteinization"~1
foreward~1
(HEPA)~1
oocyte/human~1
SPA,~2
(IVF~1
(1C),~1
(2C),~1
(4C)~1
sperm-penetrated~1
oocyte.~2
(complement).~1
vitrification~3
(VS1)~1
VS1~4
HEPES~1
agonadal~1
U/S-guided~1
LA,~1
AG,~1
SVB~5
varicocele;~1
dyspermia~1
smoking)~1
hypofertile~1
VB1),~1
chlamydia,~1
mycoplasma~1
dehydroascorbate~4
tissue-transport~1
(BUI)~1
tissue-sampling~1
ascorbate,~2
7.4),~1
(0-10,000~1
BUI.~1
BUI~5
0.67%,~1
Masseter~1
injectate.~1
Dehydroascorbate~1
(7500~1
[14C]phenylalanine~1
(55.2~1
glucose.(ABSTRACT~1
(VRBC)~1
4.7-micron~1
(0.76~1
RBC/min;~1
hyperviscous~1
sorbinil's~1
Siperstein~1
(tSIP)~1
minimum-points~1
Williamson~1
(tWIL)~1
(tTRUE)~1
tSIP~3
tTRUE~3
tWIL,~2
collapsed-ellipse~1
(tEA).~1
hundred-twenty~1
tWIL~2
tTRUE,~1
tEA~3
tSIP,~1
40-60%~1
manner:~1
3-O-methylglucose~1
hexose.~1
(RPF)~1
mumol.min-1.kg-1)~2
acetoacetic~2
insulin-glucose~2
Acetoacetic~1
0.7-1.5~1
0.1-0.3~1
ml.min-1.1.73~2
0.5-0.8~2
(total),~1
Mg2+-(ouabain-resistant),~1
Na+-K+-(ouabain-inhibited)~1
C57Bl/Ks~2
(db/db)~2
(db/+)~1
(16,~1
Na+-K+-ATPase~1
morphometrical~1
[3H]N-succinimidyl~1
3H]NSP)~1
[3H]NSP~4
family/household~2
titles~1
(ICHPPC-2-Defined)~1
tired~1
over-represented,~1
wakening~1
household.~1
'reducing'~1
Cronbach's~1
sub-scales~2
about:~1
'Rand~1
battery',~1
'sickness~1
profile'~1
questionnaire'~1
books~1
unimportance~1
paramedicals,~1
representatives:~1
Yugoslavia~1
bills~1
teamwork.~1
74.2%~1
(Ayurvedic)~1
single-handed~1
Practitioners~2
3.1.~1
Multifactor~1
WONCA~1
Solo~1
surroundings.~1
Teamwork~1
intersectoral~1
louse,~1
Pediculus~1
capitis,~1
Jeddah.~1
lice:~1
contagious~1
typhus,~1
(hospital~1
notes)~1
attenders,~1
Na-Cl~3
microEq~1
microEq/h~2
(Na-H~1
Cl-HCO3)~1
sodium-chloride~1
Na-K-2Cl~1
Necturus~1
5501~1
3789~1
(Rb,~1
3805~1
2594~1
(Rs)~1
4303~1
1914~1
Rb,~1
1034~1
213,~1
urea-containing~1
Rs~1
germ-free~2
amino-grams~1
arterioportal~1
111In-leukocyte~1
90)~1
discontinuation,~1
-0.29,~1
tauro~1
(75Se)~1
selena-25-homocholic~1
58-labeled~1
cyanocobalamine.~1
pedigrees,~1
polyp-free~1
5-10-yr~1
Jaw~1
tetrachloride-induced~2
retention)~1
chronologically~1
AM)~1
(53.6%)~1
(GABA)-containing~1
[3H]GABA.~1
tetrodotoxin-sensitive~1
tetrodotoxin-sensitive.~1
Scopolamine~1
GABA-evoked~1
GABA-containing~1
sideholes~1
straddled~1
dichotic~2
incentive,~1
stressor.~1
46.5~1
4.7).~1
(11.8~1
beta-valerate.~2
[14C]sucrose~3
[14C]inulin,~1
hemoglobin-free~1
taurocholate-stimulated~1
(k~1
neodymium:yttrium-aluminum-garnet~1
intrahepatically~1
50-2400~1
Microthermocouples~1
severity:~1
6-31~1
gravidarum.~1
Steatorrhea~1
transaminase.~1
92.6%~1
2.8%,~1
(GABA)-like~1
GABA-benzodiazepine~1
GABA-like~5
vein-ligated~2
disproportional~2
triazolam~5
(-23%).~1
(-26%),~1
antiserotonergic~1
Child-Turcotte~2
(1-year)~1
Pugh~8
"original~2
unit"~1
receiver-operating~1
units"~1
(At~1
80%).~1
lactosylated~8
Ashwell~1
Dibromosulfophthalein~1
blue-shifted~1
neoglycoprotein.~1
off-and-on~1
off-rate~1
dibromosulfophthalein.~1
virus-encoded~1
HBsAg-negative,~1
pre-S-encoded~1
(pre-S1~1
HBsAg-positive,~1
pre-S1~1
always,~1
HBsAg-~1
pre-S1,~1
Fatigue,~1
1,212~1
Virus,~1
hepatocytolysis~1
Ground-glass~1
Pekin~3
duck,~1
virus-free~2
flock~2
Muscovy~1
hatchlings~1
geese~1
ducklings,~2
geese.~1
goslings~2
uninjected~1
midmenstrual~1
icterus~1
aflatoxin.~2
Aflatoxin~3
ppb)~1
peanuts,~1
ppb~1
(S,~1
episomal~2
quantity;~1
(177~1
DOC-treated~1
elusive.~1
(DR),~1
(wt/wt).~1
microliters~1
(+287%)~1
(+89%)~1
(+107%)~1
effluxes.~1
furosemide-sensitive~1
(K0.5)~1
(Vmax).~1
(mmol/L~1
K0.5~3
RBCs.(ABSTRACT~1
better).~1
race-sex~1
assemble~1
contracts.~1
25-45~1
Hennepin~1
themselves;~1
decision.(ABSTRACT~1
post-dilution~1
(Diafilter~1
D-20,~1
AMICON),~1
asymptote~2
(filtration~1
equilibrium),~1
Darcy's~1
pre-asymptotic~1
hemofilters.~1
corollary,~1
middle-molecule~1
solute.~1
PSGN~1
Amongst~1
ferroxidase~2
(ceruloplasmin)~1
Ferroxidase~2
(Plasmaflux~1
(TT3)~1
(TT4)~1
(FT4),~1
(TBG)~1
polyneuritis)~1
Pre-exchange~1
TT4~1
TBG,~1
(M)-,~1
(NLX)-treated~1
M-treated~2
NLX-treated~3
space-to-tissue~2
leakiness,~1
25%;~1
leakiness~1
nonsubmersed~4
submersed~3
diving,~1
surface)~1
diving.~2
Submersed~1
entail~1
(lesser~1
drop)~1
overloading~1
(larger~1
pooling)~1
(Pt)~1
Pt/Po~1
(Osm)~1
Osm~4
freezing-point~1
mosmol~2
H2O-1~2
base-1~1
Osm.~1
pK~1
H2CO3.~1
hemoglobin;~1
Osm/delta~1
nonbicarbonate~2
synergist~1
unweighting~1
(suspension)~1
7/group)~1
normal-control~1
(NC);~1
(OV);~1
normal-suspension~1
(N-SUS);~1
overload-suspension~1
(OV-SUS).~1
OV~5
OV-SUS~3
N-SUS~2
Myofibril~1
(mg/g)~1
(Fm1)~1
myosins,~1
s);~2
(RL~2
16-48~1
(31-89~1
hypopnea~1
(90-96%)~1
l/s)~1
(81-93%)~1
hypopnea,~1
high-resistance~1
EMGdi,~1
atonicity~1
snorers)~1
apnea).~1
2-wk-~1
1-mo-old~1
3-mo-old~1
elliptic~1
ellipse~1
8-25~1
[90.6~1
predicted],~1
capacity/total~1
0.3-W/kg~1
TI/TT~1
(follicular~1
altitude-specific~1
(2,596~1
(4,575~1
(Tes),~1
(Tsk,~1
sites),~1
(ms)~1
dew-point~1
(SkBF)~1
(slope)~1
ms/Tes~2
SkBF/Tes~2
lavagable~1
pneumocytes,~1
[3H]choline~2
phosphine-3R~1
hemicorpus~1
(flow-through~1
(1.28~1
(13.7~1
U/g,~1
bloodstream.~1
29548.~1
tension),~1
Methacholine-induced~1
46619.~1
pump-induced~1
Hemolysis~1
LLL's~1
sigma's~3
forelimbs.~1
sigma.~1
LLL.~1
contraction-induced~2
barodenervation~1
alpha-(4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol,~1
THIP)~1
beta-(baclofen)~1
THIP~3
THIP,~1
Baclofen,~1
"apneustic"~1
glycine-sensitive~1
(5.6-56~1
lumped-element~1
[with~2
inertance~2
(Iaw)]~1
(Rt),~1
(It),~1
(Ct)]~1
(Cg).~1
frequency-independent~2
Iaw,~1
Iaw~1
asymmetrically~1
Cg,~2
Ct.~1
multiple-tube~1
(Zrs).~1
Zrs~1
0.148~1
materials:~1
Batson's~1
(rami~2
tracheales~1
cervicales)~1
(bronchus~1
trachealis)~1
(lobus~1
cranialis~1
dexter)~1
(ramus~4
bronchalis~1
trachealis),~1
(truncus~1
brachiocephalicus).~1
carina~1
trachealis~3
thoracica),~1
(arteria~1
bronchoesophagea)~1
bronchalis)~1
pleurales~1
pulmonales)~1
esophagea)~1
(w),~1
platform,~1
cycloergometric~1
(VO2max);~1
VO2max).~1
w~5
([Lab])~1
([ATP]).~1
[ATP].~1
[50%~1
[3H]dipalmitoyl~1
(DPPC),~1
(PC),~1
(PG)].~1
progressively;~1
0.63%~1
dpm~3
lyso-PC,~1
[choline,~1
glycerophosphorycholine,~1
5'-diphosphate~1
(CDP)~1
(CDP-choline)~1
(8-BrcAMP)~1
8-BrcAMP~1
cAMP.(ABSTRACT~1
immunoglobins~1
small-pore~1
Basenji-Greyhound~1
crossbred~1
(B-G)~1
B-G~3
Large-volume~1
(NS~1
43.9~1
impalements~1
(Lmax),~1
Lmax~1
Stretch-induced~1
reversible;~1
atropine;~1
nonstretched~1
trachea;~1
runway~1
(u~1
0/g)~1
mass-spring~1
u~2
unity,~1
deep-flexed~1
0/g~1
49%).~1
(staining~2
atrophied~2
darkly~1
8.8).~1
(GPD)~2
(SDH)~2
suspension-induced~1
(Roy~1
SDH,~1
oxidative-glycolytic~1
SDH~3
GPD~3
Hindlimb~1
(away~1
(CON)~1
Fibers~1
HS.~4
(Sao2)~1
PETo2)~1
(wt/ht,~1
kg/cm).~1
PETo2~1
consumption/FRC.~1
Vo2/FRC~1
nonobese,~1
Sao2~1
PETo2.~1
Vo2/(initial~1
collaterally~4
dusted~1
tantalum,~1
Intrasegmental~1
extrasegmental~3
nonhomogeneously~1
reciprocally~1
intrasegmental~2
nonhomogenous~1
acylcarnitines.~1
PVD,~2
acid-soluble,~1
postexercise,~1
-0.51,~1
wheezes~3
(FEW)~1
high-impedance~1
Ptp,~1
Olafsson~1
Hyatt~1
48:~1
564-573,~1
1969).~1
FEW~3
(isoproterenol)~1
FEW,~2
collapsible,~1
thick-walled~1
(HFO)~1
HFO.~4
pendelluft,~1
(QLV)~1
Low-resistance~1
42.9~1
cmH2O),~1
QLV~2
microliters/min~1
microliters/min.~1
(extrapulmonary~1
(0.042~1
microliter-1)~1
(0.026~1
0.027).~1
hypoproteinemic~1
(saline),~1
(albumin),~1
(hetastarch)~1
postplasmapheresis~1
law")~1
(1-P)-n1~1
assumed.~1
n1~6
Dissipative~1
Viscous~1
"hook")~1
hooks,~1
(Pentothal)~1
Moving-time-averaged~1
(EMGma)~1
spinalization,~1
rhizotomy.~1
C7-spinalized~1
EMGma~2
C7-spinalized,~1
non-iron-containing~1
iron-dependent~1
iron/kg~1
sufficient).~1
min/day,~1
days/wk).~1
tricarboxylic~3
Endurance~1
iron-sufficient~1
geared~1
beta-agonists.~1
(22Na~1
[14C]sucrose)~1
(amiloride,~1
terbutaline)~1
regulable~1
passively.~1
carotid-denervated~1
(23-25~1
(5-8~1
reinstituted~1
shivering,~1
in-line~1
photon-emitting~1
phoswich~2
Pulses~1
counter-timer,~1
(99mTc-sulfur~1
colloid)~1
N-[1(S)-carboxy-(4-OH-3-[125I]-phenyl)~1
ethyl]-L-alanyl-L-proline~1
(125I-CPAP),~1
flow-cell~1
cuvette~1
detector.~1
Single-pass~1
125I-CPAP~1
(1-10~1
cross-transplantation~1
cross-innervation.~1
(vascularized~1
graft),~1
graft).~1
Callus~1
"myositis~1
ossificans"~1
"heterotopic~1
callus"~1
Ischaemia~1
picture:~1
instants~1
MN/m2.~1
Howse~2
0.79%.~1
1.38%,~1
(1.78%),~1
miles;~1
three-quarters,~1
Trendelenburg~1
Odense~1
hip;~1
modulus,~1
ductility~1
recurred)~1
recurred),~1
Tethering~1
distractor~2
Ilizarov~1
bearings~3
backwards~1
lateral;~1
Bearing~1
duplication,~1
realignment~1
giving-way.~1
31-month~1
kneel~1
force-displacement~1
injured-normal~1
N/mm,~1
malleolar~2
using,~1
polylactide-glycolide~1
(polyglactin~1
910).~1
united,~1
demanding,~1
radiocarpal~1
over-correction~1
reposition.~1
pin,~1
Hoffmann-type~1
half-pins~2
pin-track~1
refractures~1
deltoid,~1
Endoprosthetic~1
ampullae.~1
postejaculatory~1
(semenogelin).~1
gel-bound~1
semenogelin~1
kallikrein-like~1
(prostate-specific~1
liquefaction.~1
Lactoferrin~1
(I-VI)~1
I-VI~1
30-h~1
(IV~1
2.0-2.6-fold~1
lipemia~4
lipoprotein2~1
lipemia,~2
HDL2,~2
apoA-I/apoA-II~1
HDL2.~2
glucocorticoid-induced~2
(0.5-50~1
RU26988,~1
eq/min~1
Kms~1
units-erythroid~2
(CFU-E)~1
rarity.~1
CFU-E,~1
rosetting,~1
immunoglobulin-positive~1
0.368%,~1
panned~1
(rEp)~1
nucleolus.~1
rEp~1
rEp.~1
125I-rEp~1
(Ep),~1
erythroblasts,~1
Ep.~1
gamma/beta~3
-408~2
-137~3
127-bp~1
hemin.~1
zeta-globin~1
orientation-specific~1
-259~1
H2O2/10(6)~2
sarcoid,~1
rIFN~5
PMA-triggered~1
[1-13C]glucose~1
13C~2
Dilution~1
oxaloacetate~2
enrichments~1
dehydrogenase/TCA~1
flux/total~1
Pyruvate~1
calvariae~1
(UMR106)~1
osteoblastlike~1
UMR~1
hyperlipoproteinemic~1
E-2/2~1
Arg----Cys.~1
Arg----Ser.~1
Arg----Cys)~1
Arg----Ser)~1
Arg----Cys),~1
hyperfunctioning~1
double-labeling~1
Xenografts~1
intensely.~1
stimulators.~1
(B,E~1
VLDL,~2
B,E~3
delipidation~1
delipidation,~1
IDL,~1
twenty-twofold~1
Chymotryptic~1
Relationship~1
E4/3~1
E4/4,~1
E3/3~1
subscripts~1
apoE~2
E2/3~1
0.40;~1
-0.48;~1
pump)~1
antierythropoietin~1
insulin)~1
(AVP)-stimulated~1
(Lp)~1
Lp~10
centimeters/atmosphere~1
166.0~1
10.4.~1
dioctanoylglycerol~1
(DiC8)~1
Lp,~2
3.1).~1
beta-phorbol~1
beta-myristate~1
alpha-acetate~1
Inactive~1
beta,13~1
alpha-didecanoate~1
8-p-chlorophenylthio-cyclic~1
(CcAMP):~1
169.4~2
165.1~1
Phosphatidic~1
CcAMP-stimulated~1
Lp:~1
10-microU/ml~1
159.6~1
88.9~1
15.8,~1
CcAMP~1
7.7.~1
PKC,~1
hydroosmotic~2
CCT;~1
post-cAMP~1
DiC8~1
post-AVP~1
"pouchitis".~1
sulphation,~1
substituents),~1
sugars.~1
UEA-1,~1
PNL,~1
HPA.~1
(representative~1
triploid,~1
triploid~1
moles,~4
abortions);~2
mole);~1
mole).~1
moles.~3
Hyaluronic~1
10.38~1
(0.66~1
death),~1
pmol/l),~1
nmol/l);~1
(73.7~1
nmol/l),~1
(FTI)~1
(83.2~1
56.6),~1
(SIDS).~1
(chicken~1
serum),~1
apparent).~1
thalassaemia,~1
haematology~1
Thrombocytosis~1
10(12)/1.~1
-0.54,~1
non-linear.~1
scale;~1
readjustment~1
Chemexfoliation~1
(chemical~1
peeling)~1
keratoses)~1
rhytides)~1
Phenol,~1
exfoliation,~1
Trichloroacetic~1
keloids~2
pores),~1
rhytids~1
depomedroxyprogesterone~1
condom)~1
Port-wine~1
(sympathetic)~1
high-strength~1
tar-anthralin~4
impetigo~1
streptococcus.~1
mandate,~1
photoresponsive~1
badges~1
volunteer.~1
cabinet.~1
Portions~1
shaded~1
cabinet~3
Dosimetry~1
Evidently~1
works,~1
0.31;~1
chemomediator~1
(trans-8-methyl-N-vanillyl-6-nonenamide),~1
IgE-antibody~1
crustacea~5
oyster-sensitive,~1
oyster-~2
crustacea-sensitive,~2
crustacea-sensitive~3
(ratios~1
oyster-tolerant~1
(crab~1
ragweed-~1
Phase-contrast~1
serum-dependent~1
N-formyl-methionyl-leucyl-phenylalanine,~1
(5/17)~1
TMA-conjugated~1
Venom~2
venom-specific~3
Venom-specific~1
efficacy).~1
optimistically~1
(immunoblotting)~1
nitrocellulose,~1
Alternaria-sensitive~2
Alternaria.~2
55,000~1
60,000,~1
Monoclonal,~1
(RIAs)~1
farinae.~1
Microtiter~1
(nanogram~1
[AgP1Eq]).~1
0.5-fold).~1
0.86;~1
mites~2
0.89;~1
Mab-based~1
(Cl).~1
zymozan.~1
Dr.~1
Aas.~1
tetrachlorophthalic~1
(TCPA),~1
TCPA~2
TCPA,~1
Nedocromil~2
sneezes.~1
(TM-RSA)~1
TMA-exposed~3
TM-RSA~4
class-specific~2
TM-human~1
(TM-HSA)~1
TM-HSA~1
TM-HSA.~1
serum.(ABSTRACT~1
(Lol~1
X)~1
(Lolium~1
perenne).~1
double-antibody~1
anticytochrome~1
Ab;~1
c-specific~1
densities,~1
WIC,~1
height),~1
variance;~1
stamp~2
nonpoor.~1
nonparticipants,~1
coursework.~1
Interns~1
internships.~1
Role~1
Entry-Level~1
Positions~1
Dietetics~1
Completed~1
representatives'~1
internship.~1
internship,~1
hands-on,~1
iodine.~1
(0.002~1
0.094~1
iodophor~1
sanitizing~1
134;~1
106;~1
83;~1
9.8;~1
0.004;~1
0.034;~1
117%)~1
8-fl~1
oz~1
calcium:zinc~6
omnivores,~1
omnivorous~1
Beliefs~1
vitamin/mineral~1
Subjects'~1
uncertainties.~1
clientele.~1
RDA,~1
nmol/:]),~1
nmol/L]),~1
nmol/L])~1
B-12;~1
Passive,~1
agitated,~1
self-centered~2
two-thirds,~1
one-third,~2
50-month~1
SDAT)~1
(383~1
mosm/L,~1
137.4~1
mEq/L,~2
(1068~1
mg%;~1
(H3N2)~1
Douglas,~1
Wyoming.~1
older).~1
Nosocomial~1
(32%;~1
44%;~1
26%;~1
summaries~1
population;~1
sleep/wake~3
inter-day~1
individuality~1
Governing~1
councils~1
Sciences,~2
Engineering,~2
chartered~1
enlist~1
Academy's~1
1863~1
congressional~1
charter~1
adviser~1
requisites~1
gerontology~1
Barriers~1
ageism,~1
disincentives,~1
underdevelopment,~1
legislatures~1
gerontology,~1
legislatively~1
Kansas,~1
Kentucky,~1
decisional~1
incapacity.~1
can:~1
self-determination;~1
understandings~1
self-determination~1
emphasis,~1
agent-proxy~1
appointing~1
Steakhouse~1
impacts,~1
72-96~1
"Steakhouse~1
spasm."~1
(5.2%),~1
epiphenomenon~2
Nonucler~1
conceals~1
heading.~1
"epigastric~1
EDS,~1
cholecystograms,~1
India)~1
(71.8~1
(109.5~1
47.8~1
pinpoints~1
milk)~1
sugar.~1
misclassified~1
91.7%;~1
malabsorber,~1
(IBS).~1
semistructural~1
(nonpatients),~1
nonpatients~2
IBS,~1
stomachaches,~1
nonpatients.~1
hypothetical,~1
colonoscopists.~1
interphysician~1
asterixis,~1
aortoesophageal~2
exsanguination.~1
timely,~1
hematemesis,~1
esophageal-atrial~2
telangiectasia)~1
burnetii~1
persists.~1
relapse).~1
epitheliochorial~1
decidua.~1
PHA-responsive~1
remixing~1
Developmentally~1
(HPP-CFC),~1
lineage-specific~1
factor-1~1
(CSF-1)~1
hemopoietin-1~1
(H-1),~1
Qa-m7~4
Qa-m7.~1
Qa-m7-positive~1
(5-FU).~1
HPP-CFC-sparing~1
HPP-CFC~3
post-5-FU~1
(FU8d)~1
purities~1
FU8d~1
(H-1,~1
CSF-1)~1
co-fractionate~1
HPP-CFC,~1
post-transplantation.~1
erythroid,~1
(MoAb);~1
CR11-462,~1
Q5/6,~2
Q5/13~5
anti-HLA-DR1,4,w6,w8,w9~1
AC1.59,~1
anti-HLA-DRw9~1
AB7ae9,~1
anti-HLA-DQw3~1
AC6G.~2
AB7ae9~1
AC1.59~2
CR11-462~2
idiotypes,~1
Q5/6~3
idiotypes.~1
anti-MoAb~6
127,~1
CR11-351,~1
Q1/28,~1
Q6/64,~1
6/31,~1
melanoma-associated~1
adherence).~1
antibody/dsDNA~1
Leukotrienes~1
LTB4,~1
monocyte-macrophages,~1
LTs,~1
wool-purified~1
CD4+,~1
CD4-~1
phytohemagglutinin,~2
(AA);~1
CTLL2~1
EL4~1
Jurkatt~2
adherence-purified~1
"breakthroughs"~1
(VZV).~1
(Oita-1)~1
virions.~1
(Oita-2)~1
freeze-thawed~1
Neurovirulence~1
Oita-1~1
Oita-2~2
immunoprecipitation)~1
Rhinovirus~1
laboratory-infected~1
(recipients)~1
cards~1
[56%]~1
(12[67%]~1
fomite~1
0.468,~1
.494).~1
fomites~1
Enterococcus,~2
oliguria;~1
hypothermia;~1
(male)~1
Coagulase-negative~1
API~1
STAPH-IDENT~1
(Analytab~1
Plainview,~1
peritonitis-associated~2
(lap)~1
(TV)~1
pickups~2
(OPUs)~1
lap~2
OPU,~1
transvaginally.~1
(HCS)~1
30,000;~1
30,000-10,000;~1
10,000-5,000;~1
5,000-1,000;~1
1,000.~1
TYH-280~1
BSA/ml~1
column:~1
70,000-100,000;~1
30,000-70,000;~1
5,000).(ABSTRACT~1
(TALP)~1
eight-cell~2
TALP~2
diversities~1
fertilizable~1
gametes.~1
uncleaved~1
4A,~1
preclinical,~1
term).~1
(chi2~1
(AID)~1
cleavage:~1
4.78~1
Bess~1
(BLU),~1
BLU,~1
Fluids~1
cleaved.~1
sole,~1
peak).~1
stool.~1
gm/day),~1
gm/day)~2
Lactulose~2
165%~1
5-N-ethylcarboxamide~1
33,000~1
(2-CA;~1
3.68~1
L-phenylisopropyl~1
(L-PIA;~1
Kis~1
monophosphate.~1
2-CA,~1
Procoagulant~1
A2-mediated~1
nitrobenzylthioinosine~1
2.94~1
nonexercised~1
micrograms/m3~1
026:B6-LPS,~1
afterwards~1
endotoxins~1
dusts,~1
defense.~2
(CFI).~1
CFI~12
immunoadsorbent~1
CFI.~2
saturation),~1
antiglobulin-positive~1
alloanti-D~1
alloanti-D,~1
125I-autoantibody~2
anti-D,~2
41,500~1
53,300~1
mol-1.~1
Dog,~1
adsorbing~1
D--red~1
adsorb~1
alloanti-D.~1
nonadsorbable~1
autoanti-idiotypes~1
azocasein~1
amyloid-enhancing~1
CL6B.~1
protease,~1
73-residue~1
1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine,~1
Homogenates~1
1640~1
Alkyl-ether~1
3H-PAF~2
3H-lyso-PAF~1
3H-acetate/3H-acetyl-coenzyme~1
3H-lyso-PAF,~1
fluorophosphate.~1
chelation,~1
59Fe-ferric~1
Ham~1
MDA.~2
(lipid~1
56-fold~1
iron-loaded~2
(TBBM)~1
DPA,~1
TBBM~3
TBBM,~1
menopause-adjusted~2
polynomial~1
(premenopausal)--exponential~1
(postmenopausal)~1
(0.2%~1
0.44%,~1
debriefing.~1
0.925).~1
.0096)~1
Debriefing~1
analog),~1
abstracts.~1
patient-reported~1
physician-reported~1
imperatives~1
interviewer-administered~1
mortality--low~1
birthweight--among~1
sociocultural~2
1,564~1
dialogue~1
drinking).~1
Shortage~1
1.275~1
1.415)~1
unfavorable.~1
Residents'~1
Frequently~1
well-designed~1
intervene.~1
antidepressive~1
mesotheliomas,~1
Litigious~1
paranoids~2
fantasies~1
preoccupations.~1
Imaginary~1
grievances,~1
accusations~1
irrational~1
vindictiveness~1
persecutors~1
contexts.~1
defeat~1
enmesh~1
innocent~1
nightmarish~1
entanglements,~1
subvert~1
justice.~1
"hypercompetent"~1
defendant,~1
proceeding,~1
witness.~1
ends);~1
"day~1
court."~1
Examiner,~1
Allo~1
beetle,~1
beta-D-galactose~1
allo~1
Florence~2
(84.6~1
40.3%).~1
chiropractic~2
vertebral-basilar~1
diver~1
drowning.~1
lapsed~1
refilled~1
"oxygen"~1
"argon."~1
argon.~1
criminalist,~1
carpipramine~3
(Prazinil)~1
Carpipramine~1
carpipramine.~1
endosulfan~2
endosulfan,~1
ether.~1
Xylene~1
(solvent)~1
mL).~1
39-year~1
shotgun.~1
ballistics~1
Sheridan~1
rifle,~1
handguns.~1
Ours~1
triazolam,~2
benzodiazepine.~1
Duluth,~1
harbor.~1
[21~1
C])~1
adipocere.~1
Artifacts~1
soot~1
"pseudo-soot"~1
"pseudo-tattooing."~1
bites,~1
graphite,~1
pseudo-soot~1
pseudo-tattooing~1
asphalt~1
pavement,~1
pseudo-scorching.~1
Questioned~1
swabbed~1
5-bromo-4-chloro-3-indolyl~1
(BCIP).~1
BCIP~4
anti-Le(a)~1
anti-Le(b)~1
(ABC).~1
Morphine,~2
heroin,~1
Unconjugated~3
(pharmacologically~1
kit.~1
morphine-glucuronide.~1
deuterated~1
(HCl),~1
decanted.~1
(unhydrolyzed)~1
(hydrolyzed),~1
4:1~2
chloroform:isopropranol.~2
(NaHCO3)~1
evaporated,~1
trifluoroacetic~1
(TFA),~1
GC/MS.~1
unhydrolyzed~1
GC/MS~1
N-ethyl-1-phenylcyclohexylamine~1
(PCE)~1
d2~1
N-ethyl~2
d3~1
d4~1
cyclohexyl~1
d5~1
Structurally~1
N,N-dimethyl,~1
N-propyl,~1
cyclopentyl~1
PCE.~1
inflict.~1
determiners~1
Galaxy~1
crashed~1
takeoff~1
Reno-Cannon~1
Jan.~1
perished~1
driving,~1
stricken~1
weekdays~1
even.~1
Property~1
unconscious.~1
stressed--natural~1
committee,~1
Lateralisation~1
handedness~2
"Simple~1
primitive"~1
auras~3
Exclusively~1
"intellectual"~1
Penfield~1
Ashkenazi~1
Hexosaminidase~1
Tay-Sachs~1
gangliosidoses~1
manipulandum,~1
mechanically-induced~2
stretch-reflex~4
(separated~1
randomisation~1
apraxia,~1
anatomo-clinical~1
Frenchay~4
Hole~3
Peg~3
measureable~1
sensorium~1
Lacunes~1
lacune~1
lacunes.~1
thalamo-geniculate,~1
C2/3~1
(NA),~1
(5HIAA)~1
(ChAT)~1
ChAT~1
mirror-wrote~1
directionality~1
decussate~2
Cell-type-specific~1
Galactocerebroside+~1
(GFAP)+~1
GFAP-~1
Tardive~1
acetyltransferase)~1
Neurology,~1
high-prevalence~2
Isles~1
Scandinavia~1
Cobrotoxin-binding~1
dodecylsulphate.~1
5.2-5.6~1
cobrotoxin-binding~1
13b~2
13a,~1
13a~2
13b),~1
(C7)~1
C6/7~1
(C2)~1
[1-14C]pyruvate~1
osteochondrodysplasia,~1
son,~1
dysontogenetic~1
phakomastoses.~1
gliomas"~1
phakomatoses.~1
syndrome".~1
"hereditary~1
glioma"~1
sibships~1
tennis.~1
Craniotomy~1
concentrate.~1
burr-hole~1
(VIS)~1
Onuf's~1
osteosclerotic~1
neglect),~1
hemi-inattention~1
neglected,~1
modality-specific~1
cancel~1
10/s~1
PCIs,~1
Component~2
PCIs~1
(AIPFP)~1
(Garin-Bujadoux~1
Bannwarth's~1
(BCB)~1
AIPFP.~3
BCB~2
meningopolyradiculitis~1
(LMR)~1
monosymptomatic~1
LMR~1
oticus~1
(extent~1
deflexions)~1
deflexion,~1
deflexion~2
deflexions~1
covariate~1
deflexion.~1
ST.~1
neuroticism~1
H-M~1
electronystagmographical~1
(VOR),~1
hypertonia~1
(supraspinal~1
sclerosis)~1
antispastic~1
Intrathecal~1
Miller-Fisher~2
(male:~1
61.5%;~1
30.8%)~1
(PetCO2)~1
(PaCO2T)~2
(PaCO2).~1
(r),~1
PaCO2T~2
211),~1
233).~1
Bias~1
PaCO2:~2
-7.8~1
PaCO2T:~2
-5.8~1
-1.6~1
+0.7~1
PETCO2,~1
PtcCO2.~1
heartbeat),~1
120/80~1
Hg/beat,~1
Echoencephalograms~1
Subependymal-intraventricular~1
echoencephalographic~1
subependymal-intraventricular~1
"O"~1
sort,~3
bubblesort,~1
insertionsort,~1
descendant,~1
shellsort.~1
in-memory~1
quicksort~1
descendants),~1
mergesort,~1
mass-storage~1
oximeter.~1
1076~1
department;~1
rebleeds~3
2.1%.~1
(Day~1
V:~1
(CMRL),~1
ml/gm/min),~1
mumol/gm/min~1
(CMRL~1
-0.06~1
mumol/gm/min)~1
CMRL~1
(CPP)~3
N2O:O2~2
(70%:30%)~2
10-torr~1
0.0019~1
(PVI~2
0.0013~1
CPP).~2
Below~1
CPP;~1
0.0071~1
CPP,~1
phosphorus-31-~1
hydrogen-1-enhanced~1
Nimodipine,~1
channel-associated~2
(ia)~1
enflurane-anesthetized~1
pentylenetetrazol.~1
ia).~2
diphenylalkylamine~1
ia)~1
glycol-400)~1
gm/min).~1
(STA-MCA)~1
clipped,~1
Reopening~1
preocclusive~1
(SSEP's)~1
SSEP's.~1
SSEP's~1
"maturation")~1
myelin-sheath~1
Reinnervated~1
representation.~1
postlesional~1
Desmoplastic~1
calvaria.~1
ectodermal,~1
mesodermal,~1
(rarely)~1
endodermal,~1
mixed-cell~1
buttock,~2
mesoderm~1
audible,~1
visibility.~1
Topographical~1
(UTS)~1
UTS,~1
Radiotracer~1
(SVS)~1
SVS.~1
SVS~2
(streptavidin)~1
10(-15)M),~1
DTPA-coupled~1
streptavidin.~1
target/nontarget~1
technetium-99m-(99mTc)~1
8.56~1
8.96~1
0.978~1
cardiographic~1
Externally~1
biased,~1
(131I).~1
radiation).~1
linseed~2
(LSO)~1
(18:3~1
7.48,~1
0.32,~1
SBO,~1
SBO/5%~1
LSO~1
LSO.~1
(20:4~1
0.21.~1
2-series~2
6/omega~1
casein-amino~1
gelatin.~1
wool~2
450%~1
caffeine-treated~1
rat;~1
calciuric~1
35-50%,~1
prostaglandin-mediated~1
polyribosomes~2
aminoacyl-tRNA~2
zinc;~2
59-69%~1
54-59%~1
Acylation~1
69-90%~1
zinc-sufficient~1
2-hydroxy-4-methylthiobutyric~1
(DL-MHA).~1
L-methionine,~1
D-methionine~2
L-lactate,~1
DL-MHA~3
Na+-gradient~1
L-lactate~3
Michaelian~1
[KappM~1
Vappmax~1
nmol/(g~1
[Kd~1
microL/(g~1
DL-MHA.~1
fatty,~1
lipid/g~1
mammary,~1
(mu/mg~1
(343-464~1
tumor-like~1
incisor~1
mesenchyme.~1
Lakes~1
predentine,~1
odontogenesis,~1
pulpal~2
dentin-secreting~1
odontoblasts~1
perforates~1
dentine,~1
sufficiency)~1
overfed,~1
DHEA-treated~1
946%~1
DHEA.~1
phosphorylation;~1
NAD/NADH~1
prepregnant~1
(ALP),~1
ALP.~1
PLP-PL~1
homeostases.~1
hydroxymethylglutaryl~1
housestaff~3
rounds,~1
disinterest~1
subspecialists,~1
reasons).~1
mailings~2
rescheduling.~1
(0.371~1
0.340,~1
(0.040~1
0.041,~1
0.9),~1
(0.443~1
SREPCIM~1
research),~1
pre-x-ray~5
(observation,~1
post-x-ray~1
"ruled~1
in"~1
Columbia's~1
Aerosolization~1
Nebulizers~1
reintroduce~1
perpetuate~1
(36.8%)~1
furfur.~1
Colonized~1
noncolonized~1
(32.4~1
(1.76~1
(Wilcoxon~1
ammonia.~1
di-15N-urea~3
15N)~1
(excreted~1
bioavailable)~1
mono-15N-urea~1
(urea~1
ammonia).~1
di-15N-urea.~1
bioavailable.~1
guidance,~1
microsomia~2
(AF),~1
(AC),~1
(FC).~1
(AF/AC)~1
0.07.~1
labioscrotal~2
Tennessee~3
43,891)~1
4499~1
(5.9%~1
blacks).~1
2499~1
1499~1
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2~1
(hot-plate~1
[MePhe3,~1
D-Pro4]morphiceptin~1
antitransit~2
trans-3,4-dichloro-N-methyl-N-(2-(1-pyrolidinyl)cyclohexyl)benz~1
eneacetamine~1
[D-Pen2,~1
D-Pen5]enkephalin~1
(DPDPE),~1
DPDPE,~1
PL017,~1
N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH~1
(mu~1
DPDPE.~1
-1.0),~1
-0.5).(ABSTRACT~1
area.(ABSTRACT~1
5-hydroxytryptamine2~1
antagonist-induced~1
([agonist]~1
KA)~1
spiperone,~1
5-methoxygramine~1
5-methoxygramine.~1
(k-x/kx)~1
3-methoxytyramine~2
15855A)~1
(apomorphine)~1
15855A~1
apomorphine.~2
3-Methoxytyramine~1
Easson-Stedman~4
(-)-EPI~1
(+)-EPI~1
Epinine.~1
catecholimidazolines~1
catecholamidines~1
stereoisomerism~1
desoxy~3
-OH~1
benzylic~1
(-)-isomer~3
(+)-isomer.~1
imidazoline~1
nonglucocorticoid~1
U-72099E~2
(17,21-dihydroxy-11~1
alpha-t-butylacetoxy-1,4-pregnadiene-3,20-dione-~1
21-hemisuccinate,~1
salt)~1
peroxidation-induced~1
glucocorticoid-related~1
U-72099E,~1
LY171555~9
AVP-deficient~1
Brattleboro~1
LY171555-induced~1
vasopressinergic~1
system.(ABSTRACT~1
[D-Ala2,~2
D-Leu5]-enkephalin~2
MePhe4,~2
Gly-ol5]-enkephalin.~1
naloxonazine~3
buffer)~1
[3H][D-Ala2,~2
Gly-ol5]-enkephalin~1
"LIGAND"~1
"competitive,"~1
(concentration-effect~1
relationship)~1
starvation-associated~1
(fed)~1
(R)-nipecotic~1
[(R)-NAEE]~1
cholinomimetic~1
(R)-NAEE~7
5.62,~1
5.40)~1
GTP-stimulated~1
5.0).~1
fixed-interval~3
electric-shock~1
6N-[1-methyl-2-phenylethyl]-adenosine~1
(-)-PIA-antagonist~1
(+)-amphetamine~1
15.0-mg/kg~1
caffeine.(ABSTRACT~1
phosphatidylinositols~1
phosphatidylinositols,~1
bisphosphate.~1
modulator,~1
phosphatidylinositols.~1
Ca++-dependent~2
Pigeons~1
naltrexone-appropriate~1
withdrawal-precipitating~1
morphine-treated~2
30-hr~1
morphine-abstinent~1
diprenorphine~1
Nalorphine,~1
naltrexone,~1
agonist-antagonist~1
Mutual~1
0.5-hr~1
arylcyclohexylamine~1
dissociative~1
cross-dependence~1
(6-MP)~1
thiopurine~1
polymorphism.~1
6-MP~5
([3H]TdR)~1
(1.37~1
0.340~1
(0.529~1
0.068~1
0.327~1
0.064~1
cases).(ABSTRACT~1
Acetazolamide,~1
chlorothiazide~2
nephrotoxicant.~1
Six-day~1
toxicant~1
chloride-treated~1
2-Butoxyethanol~1
(BE)~2
Butoxyacetic~1
(BAA)~1
BE.~1
BE,~2
BE-glucuronide~3
BE-sulfate~3
BE-induced~5
hematotoxicity~5
pyrazole~2
(alcohol~1
BAA.~2
Pyrazole~1
BAA~4
(aldehyde~1
pyrazole.~1
butoxyacetaldehyde,~1
hematotoxic~1
Cyanamide~1
butoxyacetaldehyde-induced~1
hematotoxicity.~2
(1,1-dideuterio-2-BE)~1
hematotoxicity;~2
forming.~1
nicotine's~1
(cerebellum),~1
teratologic~1
[3H]myoinositol.~1
lithium;~1
biphosphate~1
[3H]IP1.~1
(mAChR)~1
mAChRs~1
[3H]IP1~1
mAChR~3
benzilate,~1
60%.(ABSTRACT~1
urokinase-type~1
(scu-PA)~1
scu-PA),~1
(CALU-3)~1
scu-PA)~1
(scu-PA-32k).~1
b.wt.,~1
T1/2,~2
scu-PA~5
hippocampal,~1
M1,~1
4-diphenylacetoxy-N-methylpiperidine~1
(11-2[[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,~1
11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one)~1
2-[N-acetyl-N-(2-methoxy-3-octadecylcarbamoyloxypropoxycarbonyl)~1
aminomethyl]-1-ethylpyridinium~1
(CV-6209)~1
CV-6209~6
104,~1
CV-3988,~2
ONO-6240,~2
Ginkgolide~2
etizolam,~2
[3H]serotonin~1
i.v.)-induced~2
0.0046~1
i.v.);~1
(CV-6209,~1
CV-3988~1
ONO-6240)~1
nonPAF~1
(Ginkgolide~1
etizolam)~1
CV-6209.(ABSTRACT~1
711389-S,~1
micro-electrode~1
sucrose-gap~1
externally,~1
711389-S~7
Use-dependent~1
711389-S-treated~1
Acivicin~2
(AT-125;~1
6.25-200~1
acivicin~3
cysteinylglycine~1
(Cys-Gly),~1
Cys-Gly~2
(Cys)~1
(63-99%),~1
glutathione-derived~2
390-fold~1
7200-fold),~1
Cys~2
acivicin-treated~2
34-fold.~1
methylmercury.(ABSTRACT~1
S-(N-Methylcarbamoyl)glutathione~1
hepatotoxin~1
N-methylformamide.~1
methylamine,~1
N-acetyl-S-(N-methylcarbamoyl)-cysteine~1
S-(N-methylcarbamoyl)glutathione~2
(kH/kD~1
N-acetyl-S-(N-methylcarbamoyl)~1
thiocarbamates~1
(tetraiodothyronine;~1
T4)-~1
(T3)-treated~1
(33.4~1
45.0~1
T4-treated~2
(26.2~1
37.4~1
VERP.~1
stereo-selectivity~1
R-(-)-YM-12617(5-[2-[[2-(o-ethoxyphenoxy)ethyl]amino]propyl]-2-~1
methoxybenzenesulfonamide~1
(+/-)-YM-12617~2
S-(+)-YM-12617~1
R-(-)-~1
(+/-)-YM-12617,~1
R-(-)-YM-12617~1
S-(+)-isomer.~1
YM-12617~1
stereospecific;~1
MR-2034~1
MR-2035,~1
Bremazocine~1
bremazocine~1
bremazocine,~3
ethylketazocine~1
U-50,488~2
hydration:~1
water-deprived~1
(ethylketazocine,~1
tifluadom~3
MR-2034)~1
(nalorphine~1
butorphanol)~1
1-naphthol~3
cubes~1
(1.69~1
min/g~1
hypophyseal~1
hypophysectomy.(ABSTRACT~1
1,25-dihydroxy-vitamin~1
normalization,~1
bromobenzene~1
(BB).~1
volumic~2
1,25(OH)2D3-treated~1
(SHRs)~1
SHRs~3
SHRs.~1
alpha-methylnorepinephrine~2
SHRs,~1
sniffing~1
dopamine-stimulated~3
[3H]cis-flupenthixol~1
stimulant-induced~1
stereotypies.~1
alkaloid,~1
Ruthenium~1
lock~1
dual,~1
fast-reaction~1
noncompetitive,~1
antithetical~1
mechanistically~1
(LTD4;~1
0.1-10~1
LY171883~6
LTD4-LTE4~1
LY171883.~1
toxicologically~1
CN.~1
CO/CN~1
formers:~1
advisable,~1
carboxyhemoglobin.~1
ICR~1
KCN~1
0.35%~1
antidotal~1
dimethylaminophenol~1
McN-5707~9
[trans-6-(2-chlorophenyl)-1,2,3,5,6,10b-hexahydropyrrolo-~1
(2,1-a)isoquinoline]~1
antidepressant.~2
tetrabenazine-induced~1
nM);~1
(p.o.)~2
Spiperone~1
WB4101~1
CGS-13080,~2
CGS-16617,~2
CGS-16617~4
postoligemic~1
shocked~2
postreinfusion~2
alone).~1
antiproteolytic~1
(CGS-16617~1
CGS-13080)~1
0.17%~1
protoplasmic,~1
accretion.~1
supraspinally~2
i.c.v.,~1
(i.t.),~1
subantinociceptive~1
(i.t.)~3
(i.t.).~2
spinal/supraspinal~1
Interspecies~1
[1-(1-phenylcyclohexyl)piperidine]~1
allometric~2
aBx~1
a).~1
77,000~1
126B0.32,~1
0.799),~1
10B0.96,~1
(CLs~1
50B0.64,~1
0.891).~1
(MLP)~1
[CLs~1
MLP~1
10(5))B1.0,~1
0.991].~1
ritodrine-infused~4
1.7-fold,~2
calcium-calmodulin-dependent~1
(phosphorylase~1
kinase)~1
calcium-phospholipid-dependent~1
1.6-fold.~1
kinases,~1
Ritodrine~1
6.9-fold~1
3.0-fold.~1
3.0-fold~1
curves:~1
1.7-fold~2
self-administer~1
lip-contact~1
solenoid-operated~1
spouts.~1
reinforcer.~1
Food-maintained~1
food-maintained~2
reinstated.~1
(0.062,~1
0.125,~1
(milligrams~1
(upon~1
access),~1
Pellet~1
available.(ABSTRACT~1
ethylketazocine,~2
monkeys;~1
ethylketazocine.~1
2033,~1
ethylketazocine-appropriate~2
quadazocine~1
(WIN~1
44,441)~1
U-50,488.~1
ORF~6
17583,~1
intraduodenal;~1
betazole~1
tetragastrin,~1
0.11-0.26~1
p.o.).~1
17583~5
Antisecretory~1
famotidine.~2
alpha-methyldopa~3
(Aldomet)~1
alpha-Methyldopa~2
Corrections~1
(14C).~1
everted.~1
(parallel~1
Epinine~3
propranolol-sensitive,~1
AKS~1
spasmogenic~1
tremorolytic~1
Efficacious~1
P-450-generated~1
scavengers.~1
(0.39~1
142%~1
NADP+.~1
l-(S)-propranolol.~1
imidazole-histidine~1
alkylxanthines~1
A533U~6
A1433U,~1
adenosine-~1
125I-aminobenzyladenosine~1
A1433U~5
(0.91~1
A1433~1
7.70~1
pKd~1
6.94,~1
prolongation.(ABSTRACT~1
Naphthalene,~1
cytotoxicant~1
naphthalene~8
naphthalene,~1
[3H]glutathione~1
adducts.~1
effluxing~1
incubation;~1
intracellularly,~1
extra-cellularly~1
cocaine-sensitive~1
[3H]-5-hydroxytryptamine,~1
indoleamine~2
[3H]norepinephrine.~1
methiothepin,~1
cotransmitter.~1
doing,~1
citalopram,~1
amfonelic~1
tetrahydrobiopterin~3
pterins~1
chromatography-fluorescence~1
chromatography-electrochemical~1
pterins.~1
tetrahydropterins~3
cofactors,~1
tetrahydropterins.~1
aortae~3
(Tris~1
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic~3
bicarbonate-buffered~3
bicarbonate;~1
Tris-~1
acid-buffered~1
(STZ)-diabetic~1
STZ-diabetic~2
(8-10~1
bethanechol;~1
Agonist~1
chronotropism~2
[3H]batrachotoxinin~2
20-alpha-benzoate~1
([3H]BTX-B)~1
[3H]BTX-B~3
[3H]BTX-B/receptor~1
[3H]saxitoxin~1
neurotoxin-stimulated~1
A20-alpha-benzoate~1
disordering~1
38.~1
cpm.~1
2066~1
631.~1
668~2
148.~1
(5-HT)-stimulated~1
5-HT-2~4
5-HT-1c~4
6-chloro-2-[1-piperazinyl]-pyrazine~1
(MK-212)~1
m-Trifluoromethylphenylpiperazine~1
(TFMPP),~1
m-chlorophenylpiperazine~1
(MCPP)~1
1-(1-naphthyl)-piperazine~1
(1-NP)~1
TFMPP~4
MCPP,~1
MK-212~4
MCPP~3
1-NP~2
1-NP,~1
curare-induced~1
4-6).~1
Curare-induced~1
Curare~1
mepyramine,~1
FPL55712,~1
mepyramine.~1
LY171883,~1
curare,~1
pretreatment.(ABSTRACT~1
(PSS)~1
Myogenic~1
stretch-induced~1
zero-Ca++~1
stretch-induced,~1
C-dependent~1
fenoldopam.~2
R-83566~1
resistance),~1
R-83566,~1
Opioid~1
microassay~2
(beta-END).~1
10(-14)~2
peroxidase-mediated~1
formyl-methionine-leucine-phenylalanine~2
N-acetyl-beta-END~1
naloxone-sensitive~1
Clenbuterol~1
5-min,~1
benzodiazepine-mediated~1
relaxation/sedation)~1
9896~3
nonsedating,~1
non-muscle~1
challenged,~1
(anxiolytic~1
rotorod~1
relaxant/sedative~2
(vehicle~1
pretreatment)~1
motor-decreasing~1
9896,~1
motor-impairing~1
tolerates,~1
muscle-stripped~1
4-diphenyl~3
acetoxy-N-methylpiperidine~3
1,1-Dimethyl-4-phenyl-piperazinium~1
Wy-45,727,~1
8.23,~1
(dog)~1
(rat).~1
Wy-45,727~2
9.35~1
9.09,~1
Cyproheptadine,~1
(tonic)~1
potassium.(ABSTRACT~1
response);~1
yohimbine;~1
adrenally~1
(PHEO),~1
PHEO~3
H-Tyr-D-Ala-Phe-Gly-OH,~1
H-Tyr-D-Arg-Phe-Gly-OH~2
H-Tyr-D-Arg-Phe-sarcosine(Sar)-OH~1
510.0,~1
tail-pressure~1
(dermorphin~3
676.8,~1
214.3~1
138.50,~1
28.00~1
[3H]naloxone~1
enkephalin-degrading~2
H-Tyr-D-Arg-Phe-Gly-OH,~1
H-Tyr-D-Arg-Phe-Sar-OH~2
H-Tyr-D-Ala-Phe-Gly-OH~1
(bestatin~1
1.18,~1
D-Phe-2S-,~1
3R-3-amino-2-hydroxy-4-phenylbutanoic~1
cleaving~1
Gly3-Phe4~1
benzylpenicillin~8
(p-hydroxymercuribenzoate~1
N-ethylmaleimide),~1
(4-acetamide-4'-isothiocyanatostilbene-2,2'-disulfonic~1
4,4'-diisothiocyanatostilbene-2,2'-disulfonic~1
phenoxymethylpenicillin~1
cefpiramide~1
dipeptides,~1
minaprine~4
Nissl's~2
taxol~4
taxol,~1
baccatin~1
7-epitaxol,~1
microtubuli~1
polymerization,~1
Baccatin~1
7-epitaxol~1
taxol.~1
sufentanil,~2
opioid,~1
(GVR)~1
GVR~3
(RU),~1
RU)~1
RU).~1
mechanisms.(ABSTRACT~1
(Vp)~1
Vp~2
Vp,~3
acyano-Vp~4
nor-Vp~2
sigmoidal.~1
3350~1
7140~1
S.D.;~2
Quaternary-Vp,~1
amphiphilic,~1
nonionizable~1
Tetrahydroxy-Vp,~1
ionizable~1
membrane-bound,~2
"apparent"~1
ionizability~1
amphiphilicity~1
nor-Vp;~1
nor-Vp,~1
real.~1
cocaine-induced~2
phenobarbital-induced~1
B6C3/F1~1
Hepatotoxicity~1
60-mg/kg~1
lethality.~1
metabolite(s)~1
hepatotoxic.(ABSTRACT~1
S-(2-chloroethyl)glutathione~1
(CEG;~1
S-(2-chloroethyl)cysteine~1
2-bromohydroquinone.~1
AT-125~4
[L-(alpha-S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic~1
acid].~1
2-bromohydroguinone-induced~1
CEG-induced~2
CEG~2
probenecid-sensitive~1
2-bromohydroguinone.~1
[S-(2-chloroethyl)cysteine]~1
iodothalamate~1
medullary-papillary~1
Histoautoradiographic~1
tubules.(ABSTRACT~1
Premenstrual~1
emotional/behavioral~1
50-200~1
tablet),~1
rectally~1
(suppositories)~1
non-parenteral~1
progestins.~1
Wharton's~1
taenia~1
newborn's~1
Bailey~1
(45,X/46,XX)~1
multivitamin/multimineral~2
noniron~1
36-week~1
16-20~1
anti-Ro(SSA)~5
anti-La(SSB).~2
Scl-70~1
hydroxylation,~1
Sjogrens~1
HLA-DR3.~1
(U~1
ribonucleoproteins,~1
snRNP)~1
B'/B~3
U1~2
snRNP~2
U1-U2~1
snRNP,~1
anti-U1~1
68k,~1
Reblotting~1
Anti-Sm~2
synonymous.~1
Ro/La~1
Hypocomplementemia~1
Prematurity~1
(C9RP)~1
C9RP~1
Subepithelial~2
Charge-charge~1
planting~1
Precipitating~1
(C5fr).~1
C5fr~2
leukostatic~1
desarg~2
desarg.~1
(Bb~1
Antinucleolar~2
"mitogenic~1
cascade."~1
(PCNA),~1
nucleolus~1
G1-S~1
"fibrillarin"~1
kD/pI~1
antinucleolar~1
p145~1
windows"~1
immunogens.~1
PCNA,~1
antipeptide~1
libraries.~1
answers,"~1
multiple-choice~3
2,713~1
percent-correct~1
Anesthesiology~1
(ABA)~1
answers"~1
board's~1
"truly,~1
potentially"~1
1,036~1
1,413~1
"smart~1
dangerous"~1
ABA~1
unfairly~1
punitive.~1
alumni~1
scholarly~2
chose,~1
funders~1
Self-report~1
466~2
(now~1
Pritzker~1
Medicine)~1
"false~1
negatives"~1
graduate.~1
tests--consisting~1
tests--were~1
immaturity,~1
compulsivity~1
passivity,~1
are.~1
(PIs)~1
enact~2
Third-year~1
Dentistry~1
realism~1
interassessor~1
write-ups~1
assessors~1
prevention/protection~1
pandemic,~1
belts,~4
Germany.~1
incurs~1
(noncompliance~1
fined).~1
fines,~1
Belt~1
seats~1
incontestable,~1
Underarm~1
Loads~1
underarm~3
belts.~2
Lacerations~1
survivable.~1
motoring~1
survivable~1
U.S.A.~1
75-80%.~1
Voters~1
Secretary~2
Austin,~1
advocate,~1
State's~1
keeper~1
elections~1
supervisor,~1
licensing.~1
chairman~1
commission.~1
election~1
Austin~2
opposed.~1
re-election~1
opportunity,~1
legislation.~2
Austin.~1
time-series~1
crash-induced~1
1973-1981.~1
somewhat.~1
51-52%,~1
63-67%.~1
43-44%~1
53-55%~1
technique--the~1
double-pair~2
meant~1
unbelted~2
rigor,~1
lap/shoulder~2
vehicular,~1
roadway,~1
3)%.~1
single-car~1
multiple-vehicle~1
size),~1
(travel~1
speed),~1
roadway~1
(posted~1
limit),~1
(light~1
dark).~1
lap-shoulder~2
belted.~1
crash.~1
precrash~1
submarine~1
1970's~1
subchondral,~1
supply;~1
caseload~1
resident.~1
(blunt~1
manages~1
accrediting~1
(784).~1
Truncal,~1
stabwounds.~1
(1,500~1
ms-1)~1
Transducers~1
KPa,~2
joules.~1
shot.~1
blood-nerve~1
hits~1
missiles~1
(ALT~1
AST)~1
18.62~1
67.44%~1
25.58%~1
neopositivity~1
toxic-infective~1
Non-A~1
Non-B~1
pronation-external~1
bimalleolar~1
Rolled~1
toe-to-thumb~1
wraparound~1
pneumopericardium~1
paraxiphoid~1
Pneumopericardium~1
Heel~1
dependability~1
PICA~1
arteriogram;~1
embolization;~1
unroof~1
nontrauma~3
administrating~1
timeliness~1
nonpreventable,~1
salvageable,~1
1984-30~1
7,936~1
audited.~1
violations~1
595~1
6,564~1
(9.1%).~1
7,200~1
person-hours~1
$300,420.~1
bulbous)~1
self-catheterization,~1
urethrotomy).~1
ml/second~1
urethras.~1
take;~1
paramedic's~1
monitored;~1
Paramedic~1
runs,~1
Distortion~1
closed-drain~1
no-drain~1
closed-drainage~1
no-drainage~1
post-transfusion~1
scrutinized,~1
Ender's~1
6.8%.~1
Osteitis~1
8.35%.~1
result;~1
dens,~2
D'Alonzo.~1
united.~1
Posteriorly~1
sparing.~1
Layered~1
unburned~1
litigation.~1
preoccupied~1
"suicide-like"~1
possibilities.~1
"death~1
wish"~1
unseasoned~1
provider.~1
ignorance~1
witness~1
first-hand.~1
non-absorbed~1
SuperCharR~1
prior,~1
20:1~1
charcoal:tobramycin~1
34.9%~1
(0-12~1
(0-24~1
(2,3-dinor-6-keto~1
PGF1~2
carbimide~4
(PRP)~1
aggregation-associated~2
Hamsters~1
sprout~3
sprouts,~1
marc~2
euthanasia~1
Zeeman-AAS~1
efflux)~1
Al/l.~1
(1419~1
2265~1
2049~1
86.5~1
(574~1
(pat.~1
819~1
(pat.B),~1
micrograms/l.~2
balance).~1
Treating~1
iron),~1
dihydrogen~1
15,3~1
SERALYZER~1
ARIS*)~1
(PChE)~1
IU/mL~1
7-19)~1
PChE.~1
Vincent~1
Indianapolis,~1
unseeded,~1
e-PTFE~1
Occlusions~1
(COHgb)~1
93.3%~2
84.0%~1
unseeded~3
COHgb~2
multiple-institution~1
Kinked~2
oculoplethysmographic~1
envisioning~1
vertebral,~1
kinks~1
2.8%;~1
uncomplicated,~1
repeatability;~1
precision)~1
ankle-arm~2
aortography;~1
without:~1
0.04);~2
10.6%.~2
blurring~1
knob,~1
rupture.(ABSTRACT~1
(TOS)~1
TOS~2
(N9),~1
(P/N13),~1
(N18-P22).~1
N9-P/N13,~1
P/N13-N18,~1
N9-N18.~1
neurocompressive~1
aorta-left~1
(ALRVF)~1
Incidence,~1
straightening~1
Marshall~2
Islanders~2
BRAVO~2
thermonuclear~1
7266~1
islanders~1
atolls,~2
2273~1
atolls~2
fallout,~1
atoll~1
cases/Gy/y/1~1
cases/rad/y/1~1
atolls;~1
radioiodines,~1
dispersed.~1
convey.~1
contextual.~1
Radon~1
inhabitants'~1
dwellings.~1
pCi/L~1
Bq/L),~1
Agency.~1
exchangers~1
radiogenic~1
Architects,~1
contractors,~1
designers,~1
physicists,~1
dichotomized~1
white-collar~1
Edwards'~1
White-collar~1
nonstroke~1
scenarios,~1
high-risk,~1
low-efficacy~1
Resource-Based~1
Value~1
(RBRVS);~1
(S/Ps)~1
S/P~1
pre-S/P~1
post-S/P~1
RBRVS~2
denominated~1
nonmonetary~1
S/Ps.~1
convene~1
profession,~1
pseudoepidemic~2
suite~1
floors~1
gordonae,~1
0.2-micron~1
water-deionizing~1
diagnostic-therapeutic~1
Pseudoepidemics~1
tampons~4
Absorbency~1
tampon-associated~1
year-matched~1
non-tampon~1
32.8;~1
15.5,~1
69.6).~1
tampon,~1
absorbency~2
Polyacrylate-containing~1
absorbency,~1
rayon,~1
cotton/rayon~1
tampons.~1
low-absorbency~1
user.~1
22,874)~1
Centralized~1
21.9%~1
48.7%,~1
44.5%,~1
40.3%,~1
age-stage~1
6332~1
muscle-invading~1
T4)~1
external-beam~1
disease--57%~1
cisplatin-based,~1
very-advanced~1
neuroscientists~1
"jet~1
lag,"~1
31,323~1
1986-1987~4
17,092~1
16,779.~1
16,206.~1
66,142;~1
22,082~1
(33.4%)~1
15,872.~1
ethnic/racial~1
6650~1
(10.1%),~1
3853~1
1679~1
(10.4%),~1
63,991;~1
130,379~1
college-medical~1
obstetrics/gynecology.~1
GY-1~5
"number~1
offered"~1
ACGME-accredited~2
FMG~1
hesitation~1
appoint~1
FMGEMS,~1
duty.~1
disciplines,~1
obstetrics/gynecology,~1
psychiatry.(ABSTRACT~1
jurisdictions~1
licensing,~1
Applicants~1
licensed.~1
FLEX~1
Boards~1
licenses,~1
within-~1
between-day~1
RMR.~1
RMRs~1
B6:~1
B6-deficient~2
B6-replete~1
NSTs~1
NST,~1
repositor~1
(Clinical~1
Nutrition)~1
glucose-6-phosphate,~1
(PCT,~1
PST)~1
(DCT),~1
DCT,~1
High-energy~1
roughly-equal~1
papilla,~1
L-652,731,~1
(anti-GBM)~1
(GN).~1
sheep-anti-rabbit~1
intra~1
extracapillary~1
GN,~1
(GSC)~1
(Series~4
GSCs~6
125I-anionic~1
(aIgG-molecular~1
[mol~1
wt]~1
150,000,~1
4.9)~2
131I-neutral~1
(nIgG-pI~1
GSC~5
(Crp-mol~1
137,000,~1
125I-nIgG.~1
deiodinated~1
(HDM),~1
(Adriamycin-Adria)~1
aIgG~1
Crp~1
nIgG~4
native,~1
(0.0029)~1
(0.0025),~1
nIgG.~2
recently-described~1
HDM~3
HDM,~1
equal.(ABSTRACT~1
Heymann~1
Fx1A~1
Heymann's~1
(PHN)~1
anti-Fx1A~2
(anti-Fx1A~1
(LpA)~1
PHN.~1
PHN~1
(SNGFR),~1
LpA~3
micrograms/7.6~1
(ACZ)~1
ACZ~9
NH4Cl.~1
mumoles/100~2
alphaketoglutarate,~1
citraturia~1
fumarate,~1
alphaketoglutarate~1
synthetase.~1
(glutaminase,~1
GLDH,~1
PEPCK)~1
ACZ.~1
(Pila)~1
corticotomy.~1
Pila~2
83.9~1
11.9)~1
113.1~1
12.8)~1
Pila.~1
Rila~3
(RAP~1
Pila)/RBF,~1
RAP.~1
corticotomy,~1
RBF.~1
209%~1
RBF,~1
131%~1
(Bayliss);~1
bone-surface~2
labels,~1
(HFAK)~1
heparin-free~1
dialyses.~1
vascular-access~1
dialyser~1
alkalosis-producing~1
Group).~1
net-acid~1
restriction),~2
(399~1
Group:~1
[HCO3-]p,~1
[H+]p,~1
nEq/liter~1
nEq/liter,~1
0.003.~1
negligibly~1
(355~1
mEq).(ABSTRACT~1
Hyperlipemia~2
12.61~1
m2/day,~1
(265~1
17.60~1
m2/day~1
little;~1
accounts,~1
Na.~1
governed,~1
(KPTT)~1
significantly-reduced~1
heparin-sensitivity~1
(LH),~1
placebo-control~2
180-min~1
alcohol's~1
naloxone-stimulated~2
22.6%~1
v/v)~1
estradiol;~1
antepartum,~1
drinking-group~1
cognitive-perceptual~3
prefrontal-type~1
socialization.~1
computer-administered~1
correlates.~1
moderate-only~1
Heavy-drinking~1
heavy)~1
abstaining,~1
antialcohol~1
friends'~1
taverns~1
.70,~1
BALs.~1
replicates~1
(family~1
behaviors)~1
Depression-Proneness~1
Self-Concept~1
eating)~1
at,~1
offsprings'~2
brown-bagging~1
purchased,~1
on-premise~2
establishments~1
Adoptees~1
pharmacokinetics:~1
caffeine-free~1
drink.~1
abusing~1
disinfectants.~1
nicknamed~1
"Montana~1
Gin,"~1
(273)~1
(142),~1
8-96~1
1974-1983.~1
52.5).~1
60-65%~1
Alpha-fetoprotein~1
peplomycin.~1
Cis-platinum~1
peplomycin~1
alopecia,~1
myelotoxicity,~1
1973-1983:~1
(45.7%)~1
(31.9%)~1
(Dukes~1
34.4%~1
ileosigmoidostomy~1
ileoproctostomy.~1
hilum,~1
primary.~1
leiomyoblastoma~1
counterpulsators~1
cartilage-perichrondrium~1
neotracheal~5
polyglactin~1
subepithelial,~1
microm.~1
pervaded~1
one-layer~1
succeeds~1
0.0047).~1
postmetastasectomy~4
0.0019)~1
0.0295).~1
Caustic~1
cervicotomy~1
(23%,~1
13%-36%).~1
(9/17).~1
ever.~1
lessens,~1
74.7%~1
mitral-aortic).~1
paravalvular~1
78.9%~1
(Multivariate~1
[n~1
210]~1
factor.)~1
modified-orifice~2
durability.~1
(206~1
120),~1
153),~1
(1.9%/pt-yr),~1
(0.6%/pt-yr),~1
(0.8%/pt-yr).~1
(0.8%/pt-yr)~1
Method:~1
Data:~1
fractions).~1
Inferences:~1
minute;~2
(infusion~1
reperfusion)~1
Submitral~1
submitral~2
(roof~1
aneurysm).~1
commissures.~1
ungrafted~1
antilipid~1
(short-term~1
(long-term~1
(evoked~1
(6/9)~1
cross-clamping).~1
(radioactive~1
T7)~1
cross-clamps,~1
Progressively~1
(T7-10,~1
T10-L1,~1
L1-3,~1
L3-6,~1
L6-7)~1
shunt/bypass~1
15.1%~1
(5/16,~1
31.2%)~1
71.2%~1
(5/7)~1
(0/26)~1
cross-clamping,~1
(patches)~1
(1984~1
glutaraldehyde-stabilized~2
formaldehyde-preserved~1
photographically,~1
hand-up~1
(elbows~1
flexed)~1
bilateral).~1
plexus:~1
hypesthesia~1
improving.~1
plexopathy~1
hands-up~1
chylopericardium~1
Blalock-Hanlon~1
atriotomies~1
electrothermal~1
atomisation/atomic~1
phenanthroline~1
phenanthroline-copper~1
copper-catalysed~1
"AMS~1
800'~1
know.~1
462.5~1
Goitres~1
51),~1
orchidectomy.~1
yolk-sac~1
5125~1
7363~1
(398~1
cholesterol-cancer~1
dismiss~1
diarrhoeal~1
Part-weaning~1
weaned,~2
0.4).~1
Cow's~1
23.3).~1
Blood-pressure~1
2]/104~1
'Copal~1
231/251'~1
visits;~1
day-time~1
(155/94~1
(154/97~1
home-monitored~1
bodies;~1
myeloma-associated~1
post-herpetic~2
synchronised~1
synaptically~1
Gypsies~1
hypertriglyceridaemia~1
consanguineous,~1
inbreeding~1
0.017.~1
Gypsies.~1
person-days~1
Sound.~1
5.1;~1
2.6-10.0).~1
1,208~1
41.6%~1
39.8%,~1
31.8%,~1
11.5%.~1
actuarially~1
sebaceus~1
Jadassohn~1
(SNJ)~1
congenitally-occurring,~1
waxy,~1
pulsion~1
SNJ's~1
Cable~1
solution-soaked~1
cottonoid~2
pledgets~3
saline-soaked~2
rubber,~1
silicone,~1
Xomed~1
Laser-Shield~2
cuffs.~1
2,985~1
drill-out~2
beyond),~1
(1984-1986)~1
pleuridirectional~1
"Pinocchio"~1
unaesthetic~1
undesirable,~1
crura.~1
over-projecting~1
(AmpB)~1
(L-AmpB).AmpB~1
dimyristoyl~2
phosphatidyl-choline~1
7:3~1
AmpB.~1
neurorrhaphies,~1
connections,~1
epineural~1
(14/49)~1
Bulimia~1
fibroblast-collagen~1
pharyngotracheal~2
shrapnel.~1
war,~1
antigenicity,~1
epithelialization.~1
Rendu-Osler-Weber~1
Postpoliomyelitis~1
polio.~1
post-poliomyelitis~1
reinnervation.~1
laryngeal,~1
endocochlear~1
(perilymph-like)~1
Ostial~1
antrostomy~2
ostiomeatal~1
antrostomies~1
water-steam~1
etch~4
fluences,~1
fluence.~1
beams--with~1
precooling--were~1
Precooling~2
chlorethyl~1
precooled~3
bloodless.~1
charring~1
cleaner~1
(shelf-life)~1
ingredient-containing~1
tough~1
demarcated,~1
infocus,~1
(CW).~1
more-or-less~1
invasion--eg,~1
glioblastomas-vaporization~1
out-of-focus,~1
CW]~1
ultrasound-microsuction~1
fibrocartilage~2
invaginations,~1
fibrocartilage,~1
contraside~1
Capillary/cavernous~1
Epistaxis~1
gallium-arsenide~1
mJ/cm2,~1
10.85~1
mixed-lymphocyte~1
Kurtzke~1
2.65.~1
mid-periventricular~1
(thalamo-cortical~1
radiations).~1
Dimethyl-4,~1
4'-dimethoxy-5,~1
5'-6'-dimethylenedioxybiphenyl-2,~1
2'-dicarboxylate~1
(DDB)~1
Schizandrin~1
herb,~1
Fructus~1
schizandrae.~1
DDB.~1
DDB~1
accompaning~1
Z-lines~1
curiously~1
diagonally~1
myokymia,~1
unsupportable~1
mg/Kg/day)~1
(DEX-DEN),~1
DEX-DEN~9
plantares~4
DEN~3
plantares.~1
solei~2
solei,~1
solei.~2
twitch-tetanus~1
(extensor~1
longus)~1
30-35~1
6.5)~1
(MUP)~1
C-5,~1
cottons.~1
prescreened~1
cottons~1
session:~1
meter)~2
779~1
elutriators,~1
+0.5~1
-9.1~1
-0.08;~1
-0.74;~1
Logarithmic~1
-0.85;~1
opposing,~1
stable-isotope~1
(triglyceride-fatty~1
cycle).~1
triglyceride-fatty~3
glycolytic-gluconeogenic~1
gluconeogenic-glycolytic~1
cells--i.e.,~1
F-reticulocyte~3
glucose-appearance~1
beta-receptor-mediated~1
Lancet,~1
clonally,~1
nonclonal~1
clonal,~2
neural-tube~1
3442~1
period),~3
pregnancy),~1
1.3);~1
bounds~2
spermicides.~2
(limb~1
cause),~1
spermicidal~3
trisomy,~2
dispute.~1
trisomy.~2
13,729~1
trisomic~9
(case)~1
matched-sample~1
maximum-likelihood~6
spermicide~2
use:~2
combined-trisomy~1
stroke:~1
0.007),~2
0.0004),~1
gluconate,~2
mediums,~1
solubilities.~1
(dual~3
hypercalcitoninemia.~2
Bone-density~1
Z-scores~1
sex),~1
0.15;~1
0.17).~1
bone-density~1
(-0.26~1
0.39),~1
(-0.75~1
Would~2
rate?~1
'Hebbian'~1
calcium/diacylglycerol-dependent~1
(PKC]~1
(e.p.s.p.)~1
(BMD),~1
X-linked.~1
X-autosome~5
Xp21.~3
t(X:21)~1
(pERT~1
87)~2
DXS164~10
(XJ)~1
DXS206~3
Subclones~1
16-kilobase~1
16-kb~1
centromeric~6
t(X;21)~1
DMD/BMD~2
'XX~1
males',~1
Yp,~3
Xp,~1
Xp~3
pseudoautosomal~14
XX-male~1
Yp~4
(and,~1
unequal)~1
Xp.~1
small:~1
Streptomyces;~1
SCP1~1
coelicolor~1
methylenomycin~2
orthogonal-field-alternation~1
lasaliensis~1
coelicolor.~1
rectifies~1
strongly,~1
voltage-dependence~1
rod-rod~1
homologue.~2
phaeochromocytomas~1
(MEN2)~1
MEN2.~1
neuroblastomas,~3
MEN2~1
neuroectoderm.~1
2A~4
(MEN2A)~2
p9-12A~1
MEN2A.~1
MEN2A~4
10p11.2-q11.2.~1
neoplasis~1
autosomally~1
(D10S5).~1
D10S5~4
sublocalized~2
10q21.1~1
p11.2----q11.2~1
q24----q25.~1
Ordering~1
single-copy,~1
ruminants,~1
Myosin,~2
filament,~2
coiled-coil~2
rod,~1
filament.~3
Hynes~1
(HMM),~1
Nitella~1
myosin-coated~2
Kron~1
Spudich,~1
Harada~1
single-headed~1
two-headed~1
HMM~1
S1,~1
1.8-turn~1
solenoid.~1
dyad~4
outwards~1
Richmond~1
bends~2
analogue.~1
intercalating~2
West.~2
(FAP;~1
coli).~1
osteomata~1
Adenomata~1
Knudson~1
non-familial~1
5q21-q22.~1
B-chains~2
interchain~6
(SSV).~1
(D-1)~1
(BT-1)~1
BT-1~1
D-1~1
(ECGF).~1
Platelet-derived~1
30K)~1
v-sis.~1
C-terminus.~2
carboxy-terminal,~1
endothelial-type~1
liganded~1
receptor-HRE~1
HREs.~1
oligomer,~1
unliganded,~1
8S-form~1
hetero-oligomer~1
(4S-GR),~1
non-steroid-binding,~1
non-DNA-binding~1
8S-R~1
(hsp~1
8S-GR~1
4S-GR~3
antiglucocorticosteroid~1
8S-GR,~1
TA-~1
486-~1
8S~2
hsp~1
4S-GR.~1
isoprenaline,~3
tetramethylammonium.~1
interestingly,~3
beta-receptor(s)~1
unclamped~2
depolarizes~1
(ACTH),~4
thyrotropin.~1
Enkephalin~1
parvocellular~3
thence~1
enkephalinergic~2
colour,~1
'form',~1
object?~1
separately?~1
'capture'.~1
random-dot~1
colour-border,~1
stationary.~1
dominates~2
colour.~2
rivalry,~1
undiminished~2
rivalry.~1
rivalry~2
Counterphased~1
dichoptically~1
stripes~2
(luminance)~1
(chrominance).~1
percept~1
red-green~1
yellow-black.~1
affording~2
cyclopean~1
perceptually~2
(filled~1
in)~1
vimentin.~4
Vimentin~3
nonphosphorylated~1
assembly-disassembly~1
disassembly.~1
stoichiometrical~1
phosphorylations,~1
site-specific,~1
phosphorylation-dependent~1
disassembly~1
fruitfly~1
Per~1
phylogenic~1
fos~5
fos.~1
stage-specific~4
web-forming~1
differentiation-dependent~1
virus)~5
governments~1
embark~2
median)~1
(1.90)~1
(0-4~2
yrs~3
8.23~1
(7.97)~1
(5-59~1
5.50~1
(5.44)~1
transposable~10
Transposons~1
transpose~2
'genomic~1
shock'~1
maize~13
transposons,~2
'cytotype'~1
Tn5~3
transposon-like~1
A-particles~1
Tc1~8
undetectable,~2
Bergerac~1
Bergerac,~1
germ/soma~1
mutator~1
mutator-induced~1
Tc1.~1
antibody-antigen~2
(SDM)~1
Gloop2,~1
(HEL)~2
were;~1
(CDRs),~1
CDRs~1
SDM~1
predictions;~1
closely-related~1
electrostatics~1
Seed~3
cis-regulatory~2
(60K)~1
berries,~1
monellin~4
thaumatin,~2
sweeter~3
sweet,~1
thaumatin~1
non-sweet~1
monellin)~1
Monellin~1
thaumatin.~1
(BAERs)~1
33-minute~1
isoelectricity~1
BAER,~1
MnSSER,~1
(N20-P25)~1
(brachial~1
spine)~2
reconnect~1
(He-Ne,~1
other.(ABSTRACT~1
(PaO2,~1
5-atmosphere~1
insult;~1
impact-injured~3
(P-31~1
MR)~1
impact-hypoxic~1
beta-adenosine~2
(beta-ATP)~2
beta-ATP,~2
antibiotics--moxalactam,~1
piperacillin--and~1
bacitracin~2
epileptogenetic~1
Moxalactam,~1
centimetre~1
25-,~2
50-,~2
75-g/cm~2
hindlimb.~1
25-g/cm~1
SSEPs.~1
obese)~1
rhizolysis~1
fluoroscopy,~2
Meckl's~1
rootlets,~2
"destructive"~1
dysesthesia,~1
neurosurgeon,~1
(MVD)~1
infirm,~1
willingly~1
neurostimulation~1
inoperable;~1
adjunct.~1
next,~1
moribund,~1
berry~3
reirradiated~1
interstitially~1
teletherapy.~1
regressed;~1
brachytherapy.~1
teletherapy~1
teletherapy,~1
meningiomas)~1
coagulator,~1
irrigator,~1
dissector,~1
eyepieces~1
exchanged.~1
striking.~2
CT?~1
1512~1
vegetative.~1
neurosurgery,~1
Anteriorly~1
"look-alike"~1
encountering~2
dedifferentiation~5
inconclusive;~1
dogmatic~1
neuroradiological~1
pilocytic~1
rads.(ABSTRACT~1
intracerebellar~1
cyst-ventricular~1
ventriculoscope.~1
hemoglobinemia~1
hemoglobinemia.~1
(AVMs).~1
honeycomb~3
(extraganglionic)~1
(glioblastoma~1
astrocytoma),~1
oligodendrogliomas.~1
extraganglionic~1
blended~2
conglomerate~1
(5460~1
(XO)~1
XO~1
(UA),~1
XO,~3
(i.v.,~1
respired.~1
(VCSF),~1
VCSF~6
mmol/litre,~2
talked~2
"favorable"~1
(40%).~1
"talk~1
deteriorate"~1
Somatotropic~1
Rathke's~2
cystic-appearing~1
Crouzon's~2
kleeblattschadel~1
kleeblattschadel,~1
"sylvian~1
AVMs"~1
subdivisions,~1
insula,~1
deficits),~1
transcortical-transventricular~1
clipped.~1
skull--the~1
cervicodorsal~1
osteochondroma~2
central-peripheral~3
myelinopathy~1
inflammatory-demyelinating~1
myelinopathy,~1
manifestation)~1
(CIDP)~1
CIDP.~1
periventricular,~1
MS;~1
CIDP~2
prenatal,~2
(GTCS).~1
GTCS~2
neurologists.~1
53).~1
postmaturity~2
Seychelles.~1
(14/21)~1
6/21~1
Seychelles~1
"due~1
to"~1
"with"~1
nonwhite.~1
1971.~1
esotropias,~1
conspicuous;~1
ataxias.~1
life-supporting~2
"quality~1
burdens.~1
(SMA),~2
neurite-promoting~2
synkinesis.~1
Side-effects~1
"state-dependent"~1
1/2-fold~1
125I-insulin~5
monocytes)~1
affinity)~1
"down-regulation"~1
EEG-VTR~1
automatisms~2
spiky~1
Myasthenic~1
left-handers.~1
Callosal~1
left-handers,~1
less-lateralized~1
unvarying~1
(SF-EMG).~1
SF-EMG~2
ulnar,~1
artery-antecubital~1
(5.1%)~1
30s.~1
near-nerve~1
tunnel,~2
Tinel's~1
(ELS).~1
ELS.~1
"overlap~1
syndrome."~1
apply.~2
enteritis.~4
synapse-dependent~1
(N29)~1
N29~4
volley.~1
(PDT),~1
photosensitized~2
(HPD).~1
2.5-3.0~1
Joules/cm2,~1
perifoveal~1
Subperiosteal~2
thiphenamil~2
(Trocinate),~1
eight-incision~1
(RK),~1
Overcorrection~1
RK.~3
steepen~1
RK,~1
21.63~1
unappealing~1
iridopupillary~1
20/60,~1
Neodymium:~2
membranectomy~1
Kelman~1
Irrigating~1
Cystatome~1
Youens~1
Manipulating~1
Cannula.~1
broadened,~1
drops.~1
endo-vitreous~1
vitro-retinopathy.~1
17-year-history~1
glaucomatocyclitic~1
flavimaculatus,~1
flavimaculatus~1
(CRABP)~2
(CRBP)~3
(emmetropization).~1
refractions,~1
89.1%~1
cheat~1
emmetropization~1
fovea,~1
Obviously~1
well-observing~1
ferning~3
[1984].~1
Liotet~1
[1983]~1
clog~1
contactology.~1
'spontaneous'~1
vibrations.~1
emmetropic~4
(908~1
(0-9),~1
(10-14),~1
584~3
(15-19).~1
detachments,~5
four-quadrant~1
Holes~1
degenerations~1
malignancy-related~1
cordotomy,~1
pharmacotherapy.~1
'pain'~1
painfulness~1
unpleasantness.~1
exp.~2
cross-modality~1
'slightly~1
painful,'~1
'somewhat~1
painful'~1
painful.'~1
'definite~1
value'~1
(VAS).~1
German-speaking~1
unidimensional~1
lumbo-sacral~1
(SSQ)~1
SSQ:~1
guarding,~2
rubbing,~1
cognitive-behavioural~1
vocationally~1
70.9%~1
neurosis~1
(24.3%).~1
neurosis.~1
MAO-A~1
MAO-B~1
MAO.~1
5-2500~1
catecholamine-O-methyltransferase,~1
hydroxylase,~5
dopamine-beta-hydroxylase.~1
Tetracaine~1
non-incident~1
(P0.1;~1
VE;~1
VA;~1
Ti/Ttot;~1
VT/Ti;~1
RR),~1
(delta(A-a)O2;~1
VD/VT;~1
pAO2;~1
(paO2;~1
paCO2;~1
pH;~1
HCO3-).~1
buprenorphine-treated~1
galvanism,~1
Maxillofacial~3
galvanism~1
currents,~2
restorations~7
(TMD)~1
TMD~9
repression-sensitization~1
pain/dysfunction~1
spurious.~2
ABA,~1
Depressive~2
symptoms--memory~1
difficulties--than~1
drawings,~1
Margolis~1
[10],~1
(44.3%)~1
trazodone.~1
non-depressed~3
Carrageenan~1
mechano-heat~1
(CHM)~1
(sensitization).~1
CMH~3
Frey)~1
(NRD)~1
(clock-like)~1
(non-clock-like)~1
Hardly~1
clock-like~2
(0.25,~3
non-clock-like~2
Morphine-induced~1
NRD~1
Non-clock-like~1
swim-induced~2
footshock,~1
non-opioid~5
footshock~3
nociception~2
hindpaw.~1
licking~2
nefopam,~1
orphenadrine,~1
nociceptors~1
(force)~1
(PTM)~1
Trigger~1
fibrositis,~1
myalgic~1
PTM.~1
interdependency~1
conceptualizations~1
'do~1
pain?,'~1
'does~1
problem?,'~1
'is~1
family?'~1
sciatalgic~1
(N150-P220)~1
(BEP)~1
Lasegue~2
discal~1
BEPs~1
monopolarly~1
vertex.~1
liminal~2
knee-flexor~1
N150-P220;~1
N150-P220~1
affected)~3
dolorimeter~1
(HBD)~1
HBD~5
algological~1
pre-surgical~1
excruciating~1
single-shot~1
non-phantom~1
antero-lateral~2
cordotomy~3
side;~2
cordotomy.~1
(RCA~1
autotomy~1
autotomized~2
I-injected~2
autotomized,~1
I-treated~1
autotomy.~1
Individually,~2
chromosomal,~1
gonadal,~3
fronts.~1
type/group~1
anti-CPS~3
anti-type-specific~1
anti-CPS,~1
type-specific~13
Hemophagocytosis~1
stormy~1
(DCC)~2
Tulsa,~1
OK,~1
Giardia,~2
Campylobacter,~1
enterovirus,~1
DCC~5
Cryptosporidium,~1
(62.6%),~1
Gram-stained~4
(ETAs)~1
ETAs~6
girls),~3
junk~1
unhealthy.~1
vogue~1
147%~1
kg/mo~1
kg/mo,~1
cm/mo~2
Exaggerated~1
Foster~1
fragmented,~1
Medicaid-reimbursed~1
spiral-shaped~1
dys-gamma-globulinemia~1
lymphonodular~1
hyperplasia).~1
knee-chest~1
notion,~1
slack,~1
folded,~1
stretchable~1
sons'~1
circumcise.~1
misunderstanding~2
circumcision,~1
myelodysplasia~7
Flattening~1
precipitously~2
type-I~1
syringomyelia.~3
Radiant~1
(0.06)~1
(0.4)~2
awkwardness~1
XYY~2
composites.~1
visual-perceptual-motor~1
auditory-processing~1
(siblings),~1
(ALTE)~1
evaporimeter~1
ALTE~2
(20.1~2
1.93,~1
ALTE,~1
mg/m2/h~1
10/190~1
(5.3%)~1
11/36~1
ALTE.~1
anemias,~1
age-appropriate~1
Mentzer's~1
colonoscope,~1
colonoscopic,~1
(Crohn~1
13.7/1,000~1
10.8/1,000~1
melena,~3
lethargy.~1
roaches,~1
wads,~2
earring~1
eraser~1
otorhinolaryngologic~1
grasped~1
paraldehyde~2
(66%).~1
confusing,~1
"rule~1
sepsis."~1
72%;~1
5.53%.~1
cells/HPF,~1
1.005.~1
trousers.~1
pericardiotomy.~1
elusive,~2
organisms--pneumococci,~1
influenzae--are~1
meningism,~1
perimeningeal~1
Listeria),~1
schistosomiasis),~1
saccharin,~1
phenylketonuric~1
aspartame.~1
cariogenic~1
Sugar~1
remarkably.~1
anemia--subtle~1
deficiency--remains~1
Pericarditis,~1
rub.~1
head-erect~3
wedge.~1
hypertonia,~1
hypotonia)~1
torque.~1
.83,~2
concentric-eccentric~2
inclination).~1
cue.~2
0-degree~1
15-degree~1
multisensory~3
(auditory,~1
tactile,~1
kinesthetic)~1
curl-back~2
(eccentric)~1
curl-up~1
unsupported.~1
unsupported~1
(KET)~1
(KEVs)~1
KET~2
Torques~1
forcefully~1
deviations.~3
4,670~1
81,047~1
2,192~1
2,478~1
10,551~1
visually.~1
girl-boy~1
needlessly~1
plaintiff~2
negligence~1
"uninformed"~1
nonisokinetic~1
(TMJ).~1
abate~2
36;~1
pericolic~2
phlegmon~1
bouginage,~1
esophagography~2
lymphangiograms~1
(kidney,~1
bladder)~2
restaging~2
(hematoma,~1
fracture).~1
(COE)~1
COE~2
unopacified~1
Superiorly,~1
Inferiorly,~1
diverge~2
abdomens~1
(30.3%)~1
(36.4%),~1
(54.5%),~1
lymphocysts~1
(6.1%).~2
(51.5%)~1
nonbronchial~3
59.5%~1
embolized.~1
proximally)~1
(206.7-310.1~1
waist.~1
Double-balloon~1
(206.7~1
310.1~1
kPa),~1
Radiologic-surgical~1
sarcoma-melanoma~1
solitary.~1
(19.4%)~1
(88.9%),~1
(27.8%),~1
(5.5%).~2
wives.~1
low-probability~2
high-probability~5
nonembolic~2
shrinkage,~1
Horner~2
otherwise.~2
reminding~1
(CHESS)~1
(FLASH)~1
CHESS-water~1
FLASH~3
CHESS,~1
arthropathy,~3
(presumed~1
inflammation)~1
hypointensity,~1
irregularity,~1
flattened.~1
intratendinous~1
tendinous~6
discontinuity,~1
(PDD)~1
hereditary,~2
PDD~1
mid-diaphyses~1
six-stage~1
PDD.~1
inhomogeneous.~2
Endosteal~1
PDD,~1
acroosteolysis.~1
paranasopharyngeal~1
pharyngobasilar~1
foramina.~1
amalgam.~3
0.3-T~2
permanent-magnet~2
(glomus~1
hemangiomas)~1
(salivary~1
sarcomas).~1
Hypervascular~1
"channel~1
voids"~1
high-flow~1
63-81~1
radiculomeningeal~1
signal-intensity~2
T1/long~1
diskectomy.~1
diskectomy,~1
rent~1
pulposus,~1
Schmorl~1
artifact,~3
radiologist's~1
gonads,~3
60%)~1
(AAD)~1
AAD~1
repositioning.~3
Concomitance~1
2,139~1
by-pass.~1
28-56~1
4-46~1
smallness~1
ventricular.~1
sutured.~3
post-operatively).~1
Endarterectomy~1
52-62~1
viz,~1
Q-waves.~1
time-enzyme~1
480-min~1
Contrastingly,~1
4.7%/patient~1
Ominiscience~1
thoracoscopically~1
non-trial,~1
2-64)~1
pathoanatomic~2
dibenzo-p-dioxins~1
incinerators~1
refuse.~1
surface-catalyzed~1
incinerators.~2
Dioxins~1
catalytically~4
non-chlorinated~1
dioxins,~1
chlorides.~1
dioxins~2
[13C6]pentachlorophenol~1
amoebae~1
prespore~2
prestalk~1
cell-autonomous~1
differentiation-inducing~5
prestalk,~1
Thousands~1
cofeeding~1
veterinary~2
appendiculatus~1
arthropod-borne~2
Humoral~6
prepro~2
endfeet~3
mandibulate~1
milkweeds,~1
latex-producing~1
counteradaptation~1
plant's~1
severance~2
milkweed~1
edible~1
generalist~1
vein-cutting~1
milkweeds~1
(Ds)~1
Ds~8
waxy~1
(wx)~1
wx~2
4.3-~1
1.5-Ds~1
Splicing~1
splice~18
dimer.~4
glucose-inhibited~1
Crystallographic~1
Jurassic~2
present)~1
tetrapod~3
assemblage~1
(Fundy~1
basin,~1
Newark~1
Supergroup,~1
Nova~2
Scotia)~1
Triassic-Jurassic~4
tritheledont~1
mammal-like~1
reptiles,~1
prosauropod,~1
ornithischian~1
dinosaurs,~1
protosuchian~1
sphenosuchian~1
crocodylomorphs,~1
sphenodontids,~1
hybodont,~1
semionotid,~1
palaeonisciform~1
fishes.~1
Triassic~1
spore,~1
radiometric,~1
geochemical~1
Hettangian~1
assemblages.~1
"typical~1
Triassic"~1
assemblages,~1
invertebrates,~1
Manicouagan~1
extinctions,~1
histoincompatible~1
autoamputated.~1
chimeras~8
rejected.~3
Li-Fraumeni~1
noncancerous~4
c-raf-1~2
radiation-resistant~1
(SQ-20B),~1
NIH/3T3~5
six)~3
raf~3
SQ-20B~4
c-raf-1.~1
c-raf~7
clones;~1
autosomes~1
clone-1~1
double-minute~1
transition-state~1
six-membered~1
enzyme-like~1
delta-lactone~1
delta-hydroxyester~1
170,~1
catalytic-antibody~1
endocrinology~3
pheromone~1
pheromones~1
disruptants~1
candidate,~1
(CARCS)~1
preinterview~1
ranking.~1
thereof,~1
CARCS~2
equitable~1
previews~1
toxoid.~2
disease-associated~1
HLA-B8.~1
nonrelapsing~1
Streptococcus.~1
Watsky~1
Drechslera,~1
Drechslera~1
observed),~2
12,686~1
non-overlapping~1
obesity:~1
hunger,~1
overeating,~1
guilt~1
preoccupation.~1
preoccupation~3
S+IV~1
10,000+~1
CBCs~1
monocytosis,~1
macro-ovalocytic~1
hematologist~1
(pain~2
"fair"~1
(improved),~1
"poor"~1
worse).~1
valgus,~1
Supraglottitis~1
supraglottitis.~1
operatively.~1
Kleptomania,~1
kleptomania.~1
kleptomania~1
shoplifting.~1
kleptomania;~1
compulsively~1
promiscuous.~1
discogenic~1
membrane-invested~1
wall-bound~1
precipitates;~2
teardrop~7
kyphotic~1
fracture-dislocations,~1
(SER).~1
postdistraction~1
(1.20-.633~1
.567).~1
"transient~1
hyperesthesia"~1
paramedical~2
.116~1
.167~1
thoracoplasty,~1
rib-bone~2
L1-L2~1
morseled~1
Spanning~1
articulations.~2
25.5%)~1
-.08~1
(T2,~2
T7,~1
T12)~1
(L1-L5)~1
Hamann-Todd~1
Osteological~1
Collection.~1
caudal.~1
caudally,~1
24-36~3
baby's~1
45.5%~2
Standing,~1
(AME).~1
AME~4
4-week,~1
Erection,~1
(DSEPs)~1
DSEPs~1
(predecompression)~1
post-decompression~1
9-msec~1
3-msec~1
8-9-msec~1
antispasmodics,~1
(meperidine~1
lament,~1
1926,~1
adnexae~1
models:~1
Low-flow/hypothermic~1
-63.3~1
-87.0~1
([Na]i)~1
(pNa/pK),~1
0.067~1
-86.4~1
mv~1
normal-flow/hypothermic~1
low-flow/normothermic~1
-75.2~1
[Na]i~1
pNa/pK~1
low-flow/hypothermic~1
Asperlicin,~1
CCK-induced~2
asperlicin~1
CCK-~1
carbachol-stimulated~1
lipase.~2
(17.9%~1
(27.3%~1
2.1%)~1
Asperlicin~4
stereospecificity~2
d-isomer,~1
dextrorphan,~1
(impH)~1
L),~1
impH~5
7.22~2
(6.58~1
(6.55~1
(7.34~1
(7.26~1
(6.47~1
6.75~2
cholecysto-sphincter~1
(SO)~1
SO~11
alpha-chloralose.~1
side-hole,~1
pressure-monitored~1
degassed~1
ng/kg/min.~3
(MI~1
175%~1
single-processing~1
hertz~1
(f0),~1
(w0),~1
eigenvalue~1
signal's~1
(e0).~1
f0,~1
w0,~1
e0~2
3256~1
Neyman-Pearson~1
normality.~2
w0~1
f0~1
energetics.~1
biobreeding~1
rats--the~1
mellitus--by~1
(induction~1
(maintenance~1
(nephrotoxicity,~1
(dAVF)~1
dAVF~1
dAVF.~1
(3.46~1
Tumor-producing~1
Cachexia~1
halted.~2
inducer.~3
lipolysis.~1
lipolytic,~1
fibroblast-conditioned~1
(128%~1
287%~1
adenocarcinomas)~2
phenomena;~1
teratocarcinoma)~1
tumor-producing~1
immunodepression,~1
host-tumor~4
C1300-NB~4
nonimmunizing~1
TBJ-NB~2
lines;~2
TBJ-NB;~1
weight/carcass~1
(T/C)~1
T/C~1
(0.0033~1
0.0229;~1
host;~1
strikingly,~2
0.0186~1
0.1657,~1
problem-oriented~1
(POSGS)~1
(DL).~1
POSGS~4
(MCQ)~1
between-within~1
0.095).~1
best)~1
attributes:~1
2356~1
Abscesses~3
CLP,~1
pair-feeding~1
(sham/dep).~1
wound-disruption~1
sham/dep~2
(iron-198~1
(CHO~1
iron-220~1
(iron-56~1
(CHO-FeD~1
CHO-FeD~3
pressure-segment~1
region-at-risk~2
(3600~1
(20,000~2
tension;~4
cava-to-left~1
pressure-dimension~1
work-end~1
volume).~1
(stroke~1
7.0),~1
epithelium's~1
(2-DG)~1
fragments).~1
2-DG~3
gm/kg,~3
[14C]-2-DG~1
2-DG.~3
(G-6-Pase),~1
dephosphorylates~1
2-DG-6-phosphate,~1
solution-treated~1
2-DG,~1
[14C]-2-DG,~1
G-6-Pase~1
healing;~1
Intima~1
(I/M)~1
nonpaired~1
I/M~2
nicotine-treated~2
(alpha-agonist)~1
(beta-agonist)~1
(alpha-antagonist)~1
(beta-antagonist)~1
Methoxamine~1
5492~1
electromanometric~1
humidifier.~2
humidifiers~1
thermophilic~2
(EVTV)~1
(0.59)~1
EVTV~3
-3.43~1
Reproducibility,~1
percentage,~2
non-smoker~2
wheezes.~1
non-respiratory~1
approach--a~1
sternotomy--was~1
thymomas)~1
39.5%,~1
Fibreoptic~1
Bronchograms~2
bronchograms.~1
bronchographic~2
bronchography:~1
bronchitis".~1
insensitive,~2
agreeing)~1
(TLCO),~1
(KCO)~1
TLCO~1
KCO~2
28.7%~1
81mKr~1
(VEmax)~1
cytology/cell~1
FNAs.~1
FNAs,~1
TEM.~1
negatives,~1
positives,~2
6.6%))~1
1.0-1.3~1
(9.8%))~1
(0.74~1
aortoplasty,~1
reader.~2
capacitation~1
capacitate~1
disperse~2
cumulus~2
pellucida~5
"false-positive"~1
138).~2
impressed~1
"specific."~1
reevaluation.~1
frontier~1
sperm/egg~1
male-factor~3
fecundability~1
WIUI.~1
WIUI~11
oligoasthenospermia,~2
capacitated~1
bypassed,~3
therein)~1
inseminating~1
holidays.~2
WIUI,~1
asthenospermia,~2
"cervical~1
factor"~5
oligoasthenospermia~1
(drop-out~1
meticulousness~1
holidays),~1
AIH~1
AIH.~1
sperm-cervical~1
interaction.(ABSTRACT~1
mandates.~1
awesome~1
record-keeping.~1
Camey~3
Night-time~1
trade-off~1
prostate;~1
peritriploid~1
semiprone~1
ureteroscopically~1
pyelolithotomies,~1
exstrophy,~1
cross-trigonal~1
reimplantations~1
vasectomies~3
Neo-tubules~1
neo-tubules~2
57/154~1
unilateral.~1
methotrexate-5-fluorouracil~1
Triamterene~1
antihypertensives~1
retro-internal~1
Teardrop~1
peripelvic~3
Amphetamines~1
diethylpropion,~1
psychotomimetic~1
irreversibility~1
"sexual~1
revolution,"~1
Anisakidae~1
(cod~1
herring~1
worms)~1
coasts~1
grocery~1
Chigger~2
"chigger~1
bite."~1
chigger-borne~1
antipruritics,~1
repellents.~1
detrimentally~1
(endothelial~2
denudation).~1
platelet-thrombus~3
Regrowth~1
(related~1
flow);~1
(thromboxane~3
Platelet-membrane~2
VIII-von~1
Fragments~5
wil~1
caliper,~1
video-densitometric~1
Calipers~1
Border-recognition~1
cul~1
reports;~1
magnification,~3
lesion-specific~1
Lesion-specific~1
branching.~1
Procedural~2
"Silent"~1
most.~3
narrowings~1
reangiography~1
289).~2
post-PTCA~4
(98%).~1
PTCA:~1
monocytes/macrophages,~3
weld~1
thermally,~1
Restenosis,~1
non-infarct-related~1
non-infarct~1
1,336,~1
97,~2
VPCs,~2
rhythm.(ABSTRACT~1
reviewers,~1
(technetium-99m~1
1-receptor~2
intravenously).~2
(-5%~1
(-15%~1
-9%~1
metoprolol),~2
fatigued.~1
(323~1
(10%,~1
(triplets~1
(246~1
0.2195).~1
(217~1
(277~1
0.8036)~1
(151~2
VT-modified~2
VT-unchanged~2
nonsustained,~1
[PCr]/[(~1
PCr]~1
[Pi]),~1
(0.36~2
(6.38~1
6.85~1
narrowed.~1
resynthesis,~1
2+)~3
catheter-derived~1
1/2),~1
[2-D~1
echo])~1
line-drawing~3
revalidate~1
1.0-cm2~1
"mid-diastolic"~1
"anatomic"~1
"hemodynamic"~1
ms/T~1
quantifies~1
(MR~3
3+)~1
Angle-corrected~1
exponentially.~1
2p~3
1,735~1
ml/min/kg.~1
orifices,~1
intermediate-term~1
extrastimulation,~1
younger)~1
E-F~2
).~3
0.26).~1
inotropism~1
histaminic~1
Ca++-adenosine~1
triphosphatase,~2
Mg++-adenosine~1
triphosphatase.~1
preparation;~1
monophosphate-phosphodiesterase~3
IV-phosphodiesterase~1
papaverine)~1
phosphodiesterases.~2
inotropy~4
-49%).~1
88%)~1
-59%)~1
(-18~1
+33%).~1
(sulfoxide);~1
sulfoxidation~2
nonlinearity~2
sulfoxidation.~1
myocardial)~1
congested~1
Enoximone,~1
years.(ABSTRACT~3
(WG),~1
(WGLT),~1
WG,~1
WGLT,~1
WG~3
biliopancreatic~5
cfu/mL~2
cfu/mL.~2
Candida;~1
appetite.~1
satiety~2
im,~3
palmitate.~3
(56.78~2
mg/d;~1
(22.71~1
dehydroascorbic~1
conjugase~4
(pteroylpolyglutamate~1
3.4.22.12)~1
pteroylglutamyl-gamma-glutamyl-gamma-(U14C)~1
Conjugase~1
breast-tumor~1
fibroadenoma.~1
mastectomies.~1
(Na-carboxymethylcellulose,~1
karaya~1
gum)~1
Food,~1
carboxymethylcellulose.~2
Karaya~1
1,25-(OH)2D.~1
mg/d),~3
high-Ca~1
Curry~2
fortification,~1
NaFeEDTA,~1
curry~3
palatability,~1
2.716,~1
3.126,~1
Fe-depleted~1
dhal~1
low-Fe~1
0.224,~1
powder's~1
housebound~1
70.0-85.1~1
-1.1~1
(Am~1
Nutr~1
1984;40:~1
1096-120).~1
3.0-9.0~1
y.~1
non-AC~2
A:RBP~1
DPH.~1
2228~1
6-59~1
Guinea-Bissau.~1
0.62/100~1
child-months~1
1756~1
deaths).~1
periurban~1
(HG),~1
(NG),~1
(FG),~1
(E2R)~2
(LN)~3
conjunction,~1
E2R~2
MG1~3
MG2,3~2
prognoses,~1
(GF)~2
GF.~1
P).~1
(10(-14)~1
microCi/mL~1
(3H)-thymidine~1
GF~12
0.0074~1
0.3852,~1
0.0550,~1
GF,~2
0.0550;~1
0.0550.~1
tumors'~1
skepticism~2
nonneuroendocrine~1
(Mab~1
NSE)~2
(Het~1
nonneuroendocrine,~2
Het~3
NSE;~1
glucagon-producing~1
(MEN-I)~1
microadenomas)~1
Gastrin-producing~1
antigastrin~1
Extrapancreatic~1
A-cell~1
MEN-I~1
H6000,~3
Instruments~3
Tarrytown,~1
request.~1
Positivity~1
lobularity~2
H-1,~1
intercorrelations~2
Antithrombin-III~1
thrombophilia,~1
antithrombin-III~3
semiautomated.~1
automated,~1
Kabi~1
Chromogenic~1
S-2238~1
COATEST~3
MULTISTAT~5
Protopath~2
(r-sq)~1
antithrombin-III.~1
III/Kabi~2
r-sq~3
immunofixation~3
(IFE)~1
(IEP)~1
IFE.~2
IFE~2
IEP~1
paraprotein-containing~1
dipstick-negative~3
1,079~1
dipstick~3
esterase,~5
CFUs/mL~1
(10(6)/L)~1
dipstick-negative,~1
urines.~1
Amplified~1
(c-~1
N-myc)~1
SCLC,~2
describe,~3
(MRSA),~1
MRSA.~1
Angiolymphoid~1
(AHE)~1
AHE~2
AHE.~1
1.5-3%~1
(coloboma,~1
anomalies)~2
(tetralogy~1
arteriosus),~1
(vascular~1
arch).~1
Speciation~1
surgical;~1
openings,~1
urorectal~2
calling~1
flushing)~1
(DTP)~5
(lymphocytosis~1
hemagglutinin)~1
(redness~1
swelling)~1
(fever~1
fretfulness)~1
DTP~14
postvaccine~1
diphtheria~8
Acellular~1
reactogenic~1
constitution,~2
committee's~1
minors.~1
Orange~1
prelaw~2
postlaw~2
call-in~1
2082~1
Tucson's~1
KIDLINE~1
2208~1
Baltimore's~1
KIDSLINE.~1
calling.~1
Loneliness~1
calls,~2
40th~1
percentile;~1
resumed,~3
receivers.~1
occurrence/recognition~1
A-IV~6
APO~5
.909~1
.088~1
.961~1
.035~1
Apert,~1
Crouzon,~1
Pfeiffer~1
high-rate-of-increase~1
age--that~1
low-rate-of-increase~1
ages;~2
age-independent~3
Apert~3
neurofibromatosis,~1
"copy-error"~1
sperone~1
syndromes;~2
febrile-convulsion~1
1935-64.~1
record-linkage~1
single-major-locus~3
likelihoods~2
environment)~1
mixed-leukocyte~2
polymorphonuclear-leukocyte~1
cystinosis.~1
neutropenic,~1
commensal~2
normoglyceridemic~1
Hypertriglyceridemic~1
sweetener~2
(11.57~1
10.20~1
intrahepatic-type~1
(DLIS~1
Syx~1
-0.43,~1
0.37,~1
Denver,~1
1961-1962~1
catastrophically~1
era.~2
Esophagography~1
Histoplasmosis~2
pyomyositis,~1
costochondritis~3
post-CPR~1
underused~2
perinatologists,~1
Going~1
"utility~1
ethics,"~1
consent,"~1
"universal~1
equality."~1
(ethical)~1
apart)~1
(amniocentesis~1
telemetry~1
8240A,~1
Alto,~1
California),~1
decelerations,~2
fixed-wing~1
cabin~1
workups~1
bruising,~1
Importance~1
5967~1
vulvar,~1
4.9%).~1
1675~1
(-20%)~1
(-17%)~1
(-18%),~1
(-6%)~1
(-16%).~1
fetal-neonatal~2
livebirths.~1
vaporization.~1
outreach~1
Third-trimester~1
gm/L)~1
apogee~1
99.7~1
(36.6~1
(37.0~1
morning)~1
outliers)~1
0.0115~1
0.0064~1
labor)~2
nulliparous,~1
beta-estradiol-17-glucosiduronate.~1
(hypertrophy~1
lactotropes~1
anovulation.~1
11-dehydro-thromboxane~2
(731~1
creatinine;~1
Selectivity~1
2,3-dinor-6-keto-prostaglandin~1
samples).~1
(138~2
31.7%~1
59.1%~1
10.8%,~2
17.2%,~1
40.2%,~1
38.3%~1
61.5%,~1
2.51.~1
40.9%,~1
2.40.~1
Decidua~1
chorion.~1
Postterm~1
decelerations)~1
atherosis~2
vasculopathy.~1
atherosis.~1
0.1452).~1
-0.5079,~1
sickest.~1
"digoxin"~1
"treated"~1
digitalization~1
(presampling~1
0.736;~1
presampling~1
14,367~1
parity-matched~1
17/291~1
5/279~1
endomyometritis,~1
placentation.~1
"infertility~1
Lancaster~1
genealogic~4
1700s.~1
inbreeding.~2
(tenth~1
retardation;~2
reemphasizes~1
fetuses:~1
iliohypogastric~4
Pfannenstiel~2
relief;~1
(A-locus,~1
B-locus,~1
C-locus,~1
DR-locus,~1
Cw7~7
DRw8,~3
carcinoma--diabetes~1
mentioned;~1
non-B,~1
non-C~1
Afterward,~1
15,306~1
(23.2%),~1
(21.3%),~2
(19.8%),~1
[1-(beta-mercapto-beta,beta-cyclopentamethylene~1
2-(O-methyl)tyrosine]~1
Bradycardia~2
earphones~1
Broadband~1
noise-exposed~1
Lambs~2
Piperacillin,~1
"bumping~1
things,"~1
acuities.~1
dyschromatopsia,~1
transvitreally~1
1,054~1
3,923~1
preretinopathy~1
Tono-Pen~3
masked,~1
tonometer~6
Torre's~2
(sebaceous~1
malignancy).~2
colonic).~1
insulitis,~1
Langerhans.~1
diabetes-prone~4
diabetes-resistant~4
BB/Wor~4
Light-~1
(marginating)~1
(PPE)~2
"thromboangiitis"~1
"thromboangiitis."~1
PPE~3
cytochemistry.~4
Foam~1
cu~1
lysosome~2
5.75~2
mu.~1
multichambered~1
maximized,~1
(immunoerythrocytes)~1
Subconfluent~1
Permeabilization~1
(0.2-0.4~1
Immunoerythrocytes~2
anti-endothelial~1
0.3-1.2~1
Proteoheparan~1
fractionations.~1
proteoheparan~6
(HS~4
6B~1
Sephacel,~1
Nu-Sieve~1
Sephacel~1
intensely,~1
matrix;~1
(devoid~3
factor-induced~3
pharmacologically.~1
hyperplasias,~5
(Figure~3
near-triploid~2
47-month~1
hyperplasias~4
neoformans~13
antiserum-treated~3
reagent,~4
anti-NK~3
1.1-treated~1
2,002~1
home-delivered~1
3.8)~1
minorities.~1
(2.7,~1
3.4),~2
(2.1,~1
non-hip~2
(2.0,~1
cook~1
5.7,~3
32.1),~1
HBsAg;~2
HBeAg-positive.~1
(22.2~1
Laotian-Hmong~1
Ban~3
Vinai~2
Thailand~1
Green-Hmong~1
Migrants~1
re-studied~1
(reflecting~2
Liquid-crystal~1
thermometers~1
cost;~1
post-program~1
318,~2
325)~1
requesters~1
58.1~1
60.9~1
54.4~1
thermostat.~1
injury-control~1
behavior;~1
thermostats~1
government-funded~1
shelters~4
(focusing~1
illness).~1
(9/73)~1
basics~3
counselors,~2
(4/73)~1
shelter.~1
shelters,~1
(WiSSP),~1
stillborns.~1
underreported:~1
WiSSP.~1
submitted,~1
unreported:~1
stillborns~1
WiSSP~1
FDF.~3
placental/cord,~1
maternal/environmental,~1
inaccuracies~2
Placental/cord~1
underreported.~1
nonperformers:~1
self-examination,~1
Fulton~1
991~1
Tijuana,~1
unbridled~1
(CES-D).~1
Risk-for-caseness~1
8,837~1
4.9/100,000.~1
(11/100,000),~1
(8/100,000);~1
non-student~1
Michigan.~1
transmissions.~1
outbreak's~1
Measles~1
illnesses;~1
trapezoid~1
meniscoid~1
macroscopically.~1
(No~1
interconnects~1
acromial~1
excites~1
(hamstrings)~1
stabilizers~1
muscle-conditioning~1
notches~2
designed.~5
Notch~1
(ANT)~1
(TOTAL)~1
ANT/POST,~1
POST/TOTAL,~1
(POST-ANT)/TOTAL.~1
POST/TOTAL~1
Mississippi~3
Organized~2
pick-up~1
games).~1
Collisions,~1
Offensive~1
receivers)~1
varsity~2
emission,~1
ondermatomal~1
blown,~1
Wolin~1
"meniscoid"~1
Methodist~1
Indianapolis.~1
taping,~1
Elbow~1
pitchers.~1
pitching~2
pitchers~3
brachioradialis,~1
radialis,~1
longus,~1
supinator.~1
threw~1
pitch.~2
cocking,~1
ball.~1
flexor-pronator~1
Cleland's~2
lumbrical~6
aponeurosis,~1
league~1
laps~1
panniculus~1
Lang~1
(Graham~1
Co,~2
Tibiofibular~1
midstance~1
preswing~1
athletically~1
disabling,~1
pregnanolone~5
Althesin.~4
(AD50)~1
Althesin,~1
Althesin~1
recollections,~1
unaware,~1
prerecorded~1
chin~2
chins~1
Sentence~4
salience~1
hypnosis.~1
corroborated.~1
cued~1
conversation.~1
1-OH~3
midazolam;~1
metabolise~2
cumulation~1
haemoglobinuria~2
Phaeochromocytoma~1
Predominantly~1
adrenaline-secreting~1
Labetalol,~2
pernasal~2
day-case~2
herniotomy~1
ilio-inguinal~2
(pinprick)~1
T8,9~1
attributed,~4
23-66~1
thrombelastography~1
(TEG).~1
TEG~1
(EBL)~1
EBL~2
crystalloid.~2
Thrombelastography~3
thrombelastographic~1
(PTC)~1
(NCPB)~1
NCPB~1
neurolytic~1
anesthetics--0.75%~1
ketamine--with~1
197%.~1
PCO2(L.min-1~1
%CO2(-1)]~1
2.42~2
butorphanol.~1
Butorphanol~1
nalbuphine.~1
perianesthetic~1
saline;~1
epinephrine:~1
14-21~2
treatment's~2
time:~1
(5.0,~1
mg/ml;~2
metal-tipped~1
angiopyroplasty~1
1SD)~1
ninety-second~1
fifteen-minute~2
grade).~1
thirty-one-day~1
telethermographic~1
(T')~2
thromboischemic~1
Schwartz,~3
washing-out~1
waves)~1
"staccato~1
phenomenon."~1
66.1~1
(fresh~1
infarct:~1
23.7%;~1
scarring:~1
25.9%;~1
35.0%;~1
15.2%).~1
Roberts~1
Friedmann~1
bedding~2
Caracas,~1
Mites~1
mites/mg~1
Pyroglyphid~1
abundant,~2
Blomia~1
Tyrophagus~1
Tarsonemus~1
nonpyroglyphid~1
dust-sensitive~1
dandruff~1
cat-sensitive~1
CIE/CRIE~1
dander-specific~2
serum-specific~2
serum-related~1
dander-related~1
dandruff.~1
radiostained~1
CRIE.~1
(intermediate~4
allergen).~1
1,445~1
childhood)~1
dismissed.~1
perenne,~2
cereale,~2
pratense,~1
dactylon,~1
Ph.~2
communis.~1
pratense~1
dactylon~1
grasses~1
3-propylxanthine,~1
canines~1
(IV-PB)~1
IV-PB~5
598~1
192)~1
4.7)~2
AW.~1
tremulous~1
AW~3
over-sedation~1
AWS,~1
Myoglobin,~1
Myoglobin~1
CPK-MB~3
billing,~1
"complaint~1
frequency"~1
(complaints~1
64,910~1
3.8.~1
(135),~1
nonemergency.~1
(25)~1
billed~1
1.1.~3
Expressing~1
EDs~1
1986-87~1
1987-88~2
configurations.~3
phone,~1
1987-88.~2
(PGY-4)~1
PGY-1,2,3~2
1987-88;~1
PGY-1,2,3,~1
PGY-2,3,4.~1
1986-87,~1
long;~2
PGY-I~1
5,944~1
King/Drew~1
self-adhesive,~1
dual-function~1
monitor/defibrillation~2
paddles~6
self-adhesive~6
71%;~1
(30%;~1
pads;~1
Self-adhesive~1
post-exertional~1
tented~1
(PcjO2),~1
post-resuscitation~1
PcjO2,~1
PcjO2/PaO2~1
PcjO2/arterial~1
reperfusion/hypoperfusion~1
gallop,~1
phosphoric~1
pill.~2
Esophagoscopy~1
Asbestos-exposed~1
amosite,~1
(Lm).~2
Lm.~2
synergistic.~4
Smoke-exposed~1
smoke-exposed;~1
asbestos,~2
L-proline,~1
(GuHCl).~1
Re-extraction~1
GuHCl~2
nondisulfide~3
pepsin-sensitive~1
bonds,~5
"7S-collagen").~1
insolubilization~1
noncovalent~5
IPF,~2
lavage).~1
(trypan~1
exclusion)~1
Antibacterial~2
v/s~3
-16.2~1
2,029~1
1,360~1
3.2),~2
2.1),~2
4.0).~3
(Cyto~1
Cyto~6
(cfu),~2
clearance),~2
cfu).~1
culture-proved~1
II(a),~1
II(b),~2
(INH),~1
(RIF)~1
RIF.~1
II(a)~1
[Group~1
113],~1
SM.~3
Rifabutin~2
(ansamycin~1
427)~3
C57B1/6,~1
S/W~2
rifabutin~4
(established~1
infections),~2
(LM~1
intracellulare,~2
(ansamycin,~1
intracellulare.~1
persisters~1
smegmatis,~1
phlei,~1
vaccae~1
aminoglycoside-acetylating~1
Acetylating~1
3-N-acetyltransferase.~1
fortimicin~1
malonyl-~1
(34.7%),~2
propionyl-~1
(3-N-acetyltransferase-III)~1
acetyltransferases~1
auramine-O,~1
(MAIS)~2
spread-plate~1
groundwaters~2
state-monitored,~1
undisinfected~1
incidence),~3
incidence).~1
5,367~1
groundwaters,~1
groundwaters.~1
auramine-O~1
(region~1
(isoniazid,~1
ethionamide,~1
ethambutol)~1
streptomycin)~1
7H11~1
broth-determined~2
Grass~1
time-limited~1
rhinorrhea,~1
(Ru)~1
(Rlo)~1
order;~1
Ru~4
0.057~1
1.342~1
0.504~1
Rlo~3
0.099~1
0.269~1
0.938;~1
0.089~1
sensitized,~1
airways;~3
(AMP),~2
terfenadine~4
astemizole.~2
bronchoprovocation~4
Terfenadine~1
terfenadine.~2
Astemizole~1
challenges.(ABSTRACT~1
micromoles/kg~1
BDE-rats~1
A2-type.~1
ketotifen.~1
Xanthines~1
(PAM)~2
lavaged.~2
hemocytometer~1
(mitotic~1
8.38~1
(Dt)~1
Dt~1
"free"~2
Normobaric~1
restructuring~3
preacinar,~1
(KCl-induced)~1
tension:circumference~2
dimensions)~1
(AAI)~2
N-nitroso-N-methylurethane.~1
(27,000~1
Phospholipids,~1
(DSPC)~1
DSPC,~1
lysoPC~1
PC-to-sphingomyelin~1
(L/S~1
38,000~5
dyne/cm~1
nitrosourethane-induced~1
AAI.(ABSTRACT~1
(LRT)~1
colonizer~1
(acyclovir,~2
inhales.~1
Servo~2
IPS,~3
(CFS).~1
CFS,~1
SVC~3
(Pdi),~1
IPS.~2
(RIP)~2
(He)~1
SF6-20%~1
(SF6)~1
insufflating~2
L/s),~1
SF6.~1
PaCO2/Pb~1
V-0.64~1
v0.23,~1
(cm2/s).~1
AaPO2~1
SF6~2
He.~2
2-zone~1
jet).~1
He,~1
premortem,~1
reanalysis~3
arrangements,~2
gas-powered~2
nebulizer.~1
(FVC,~1
spirometers~1
"tests~1
Technicians,~1
"minimum"~1
inspected~1
(84%),~2
TCNA~1
valuation~1
Neutrophil-mediated~1
(proteases~1
radicals)~1
"prime"~1
vasoamines~1
prostanoids.~1
anaphylatoxin-induced~2
histamine-receptor~1
hypotension).~1
(PGI2)~4
TGxB2,~1
Alpha-thrombin~1
fibrin-neutrophil~1
adhesivity.~1
Lipid-derived~1
HETEs)~1
(PVR,~1
PAOP~1
31.6%.~1
Antioxidant~1
oxyR~1
regulon~1
hypomethylation~8
Ebselen~1
selenoorganic~1
GSH-peroxidase~1
compounds)~1
(HBsAg)-positive~2
parturients,~1
4399~1
(5.2/1000~1
deliveries).~1
(18/2231,~1
8.1/1000~1
deliveries)~2
(non-Hispanic~1
5/2168,~1
2.3/1000~1
5.95;~1
68%).~2
nebulized,~1
methylprednisolone,~3
unblinded~2
(tremor,~1
vomiting).~1
analyses).~1
PCO2).(ABSTRACT~1
15,187~1
meq/L.~1
162,~1
hypernatremic~2
hospital;~3
meq/L~1
182),~1
infirmity~1
vertebras~1
dual-photon~2
osteocalcin~47
(NaCl,~1
high-sodium~4
lower-renin,~1
18.8/17.7~1
-11.4/-8.7~1
5356~1
(1.2%).~3
menstruated~1
hemoperitoneum;~1
anovulant~1
plasmapheresis-induced~2
heterosexually~3
(licensed~1
exceptional;~1
Housestaff~1
time-motion~1
bills.~1
Charges~1
Medicare's~1
Visits~1
limited;~1
inefficiencies,~1
debts,~1
(Omniderm)~1
High-intensity~1
(HIFU)~1
HIFU~1
insonification~1
HIFU.~1
plana.~1
78-year-old~2
pupil.~1
paracentesis-induced~1
miosis;~1
diclofenac,~1
Diclofenac~2
mydriasis~2
Floret~1
pyknosis~2
bubbly~1
atrophying~1
midperiphery.~1
Bietti's~2
Occidentals~1
Orientals~1
Phakoanaphylaxis~1
phakoanaphylaxis~1
portray~1
depicted,~1
Beta-aminopropionitrile~1
(aphakic,~1
neovascular).~1
40.0~2
blebs.~1
retinoscopy~1
retinoscopy,~1
tumor-growth~1
(lymphosarcomas)~1
1.5-V~1
potable~1
(mucoviscidosis;~1
pancreas)~1
Polypectomy~1
ethmoidectomy,~1
ethmoidectomy~1
endolymph,~1
epilaryngeal~1
extralaryngeal~2
laryngectomies~1
pyrosis~1
manometrics,~1
Bernstein~2
Pyrosis,~1
laryngoceles~3
suggests.~2
otolaryngic~1
laryngoceles,~1
parainfluenzae-induced~1
ampicillin-susceptible~3
influenzae.~7
70+~1
phonosurgical~1
phonosurgery.~1
laryngomicrosurgical~1
specimen),~4
isolates).~1
(Ig)E,~2
"blocking~1
antibodies"~1
Endolymphatic~1
(22/22)~2
(13/22)~1
saccule,~1
utricle,~1
basalward~1
Aminoglycosides~1
ototoxic~2
spermine,~1
imino).~1
One-tenth~1
intratympanically.~2
cochleotoxic~1
Endolymph~1
g/kg).~1
Sound-evoked~1
endolymph~4
unmated,~1
19-nandrolone~1
phenylpropionate.~1
female's~2
(tobramycin~1
respirators,~1
drug).~1
liters/h~4
(CLS)~1
(CLCR)~1
CLCR~2
13.23,~1
0.697;~1
CLCR,~1
0.845.~1
law)~1
Woodman~2
known)~2
Vesterdal.~1
(cefotaxime~1
ceftriaxone)~1
MIC,~6
Vesterdal~1
(dilution,~1
example).~1
Peritonitis~1
elastomer~1
biomaterial.~1
biofilm-encased~1
vancomycin-exposed~1
Vancomycin-exposed~1
silicone-associated~1
3.125~2
(bactericidal)~1
203.6~1
50-mg/kg~2
171.7~1
80-mg/kg~3
(P,~2
(108.9~1
h/ml~1
h).(ABSTRACT~1
enterobacteria.~1
iothalamate,~1
3.08~2
3.24~1
41821,~1
leukocytes).~1
41821~3
luminol-dependent~1
mouse-pathogenic~1
single-trial~1
CFU.~1
steeper,~1
clavulanate~2
timentin~1
clavulanic~18
postadministration.~1
corticalis~1
70.5~1
cefoxitin.~3
Clavulanic~2
(Campylobacter~1
(skin)~1
organisms:~1
flucytosine,~2
(E.~1
Fougera~1
N.Y.)~1
gluceptate~1
similar:~2
69.1%~2
200-~1
750-mg~3
Demethylavermectins,~1
avermitilis,"~1
bioconversion~1
demethylavermectins~1
C-5~1
methylated.~2
Avermectin~1
tylosin~1
(Mustard's~2
Mustard's~2
(plus~4
Blackburn~1
offensive~1
vomited,~1
shigella.~1
Oka~2
revaccinated,~1
generalised,~1
intersex.~1
consanguinity.~1
thyrocalcitonin~3
hypocalcaemia~2
normocalcaemic~4
Hyperthyrocalcitoninaemia~1
Aplastic~1
Jamaica~2
epidemics.~2
0.5-12.5~1
viraemia~1
Parvovirus~1
kwashiorkor~1
analysed;~1
thoracocentesis,~1
chyle~2
chylothorax,~1
pleurectomy~3
Lymphopenia,~1
bedside.~3
'intermediate~1
ward'~1
amenorrhoea,~1
Summary~1
(phenytoin,~1
valproate,~2
phenobarbitone)~1
anginose~1
1966-85.~1
lanugo~1
Helena,~1
Montana.~1
1,834~2
3,027~1
U.S.A.)~1
spirometry;~1
(FVC),~4
(MMEF~1
25-75%)~1
nuisance~1
"dipping"~1
polyurethane-coated~1
molten~1
solder~1
isocyanates.~1
piecework.~1
distributors~1
following-back~1
reminds~1
pieceworkers~1
hygienists~2
(BSFTPM)~1
coke~2
1622~1
OSHA~1
BSFTPM~3
stationed,~1
0.150~1
mg/m3,~1
exsmoker~1
Ankara.~1
11.17~1
5.41;~1
6.44~1
5.48;~1
45.68~1
53.36,~1
(Pb-b)~1
(Ht),~1
cable-producing~1
Pb-b,~1
Ht,~1
Pb-b~2
Ht~1
2018~1
posterior-anterior~1
18.8%.~2
Ivor~3
34.1%~1
.052),~1
3.4).~1
thoracotomy);~1
(temporary~1
reasonable,~1
(QB)~1
QB~4
QBS~1
(QB/QS)~1
9.7%,~1
QB/QS~1
11.4%,~2
QB/QS,~1
(BW,~1
kilograms)~1
(BSA,~1
meters)~1
formulas:~1
In(BW)~1
In(BSA)~1
(MVR~1
AVR)~1
bioprostheses.~1
(linearized~4
54.2~1
patient-year);~2
explanted,~1
44.6~1
Double-outlet~1
Torino~1
(1.86%)~1
2,579~1
(different~1
reexploration,~1
rewiring~2
.041),~1
.031),~1
reintervention~4
arch-cerebral~1
parasitized~7
triatriatum.~1
valvectomy.~1
fortunately~1
evacuate~1
eject.~1
exercised.~1
Survivors,~1
Bashall~1
(RBFA)~1
self-care,~1
Criticism~1
(content,~2
validity)~1
undressing,~1
RBFA~1
H/M~1
T-reflexes~1
18.4C~1
12.1C,~1
Peak-to-peak~1
covariant~2
H-reflex;~1
T-reflex,~1
Motivation~2
homemakers,~2
unemployed,~2
semiobjective~1
(touch);~1
esthesiometer~1
(two-point~1
discrimination);~1
Pfizer~3
tester~2
(temperature);~1
(vibration);~1
Optacon~1
(vibration).~1
two-alternative~1
UE.~1
LE,~1
ulnar)~1
LE.~1
Optacon)~1
dermatome.(ABSTRACT~1
Problem~1
family-rated~1
poststroke~4
gastroenteric~2
glycol-labeled~1
(filleting)~1
Set~1
(RSAS)~1
RSAS~2
66.9~2
5692~1
5515~1
12,052~1
RSAS.~2
(15/16)~1
(TS~4
perigeniculate~1
125,000~1
55.2%~1
counselors.~1
cramping,~1
valvoplasty~1
anorectoplasty~2
atropine-sensitive,~1
bicuculline-sensitive,~1
Progabide,~1
progabide~4
Vigabatrin~1
"temporal"~1
Tolerability~1
drowsiness.~1
Ictal~2
video/electroencephalographic~1
upper-extremity~2
stiffening.~1
chewing,~1
mouthing,~1
blinking~2
electroencephalograms,~1
night),~1
postural,~1
tremorgrams~1
(MMSE)~4
Orientation-Memory-Concentration~1
(BOMC),~2
six-item~1
Information-Memory-Concentration~1
MMSE~2
BOMC~1
-0.83~1
(BOMC).~1
BOMC,~1
stereognosis~1
graphesthesia,~1
border-zone~2
bibrachial~1
dyslexia/dysgraphia~1
parietotemporal~1
middle-posterior~1
nerve-fiber~1
Loyola~3
Maywood,~1
Ill,~1
sleep-like~1
spindle-like~1
cortex;~1
alpha-like~1
(monotonous,~1
unreactive,~1
predominant,~1
(68%,~1
21/31)~1
(19%,~1
6/31).~1
(20/21)~1
MELAS~1
stroke)~1
acrocephaly,~1
syndactyly,~1
ammonic~1
callosum,~2
acallosal~1
Heschl's~1
PES,~1
PES~1
phakodonesis,~1
(ciliary~1
block)~3
coincidental,~2
colforsin)~1
maleate.~1
microL/min~3
microL/min,~1
forskolin-treated~2
microL/min.~1
(POAG).~1
POAG.~1
POAG,~2
Jeune's~1
dark-~1
light-adapted~1
30-Hz~5
metoclopramide-treated~2
bright-flash~1
flickering~1
assigned)~1
(paired~1
microangiopathy.~1
inherits~1
Microangiopathy,~1
off-spring~1
neovasculogenesis.~1
subnuclei.~1
angioarchitecture~2
joining~22
latently~14
McKrae.~1
tear-film~1
RK-treated~1
Slit-lamp~1
wedge-shaped~2
sleds~3
enophthalmic~2
sled~2
adhesives~1
orbits.~3
encapsulated.~1
Butyl~1
2-cyanoacrylate~1
(Histoacryl~1
Blue)~1
(Crazy~1
Glue)~1
extraocular-muscle.~1
Heat-induced~1
tendinoplasty-treated~1
heat-treated~1
compaction~2
tendinoplasty~1
Prednisolone~1
arthritis;~2
arthropathies~2
Casting~2
(stifle)~1
tidemark~1
6-25%~1
condyles.~2
condyles;~1
(JA).~1
(AIMS),~1
JA~10
JA;~1
AIMS~2
JA.~1
Cryoproteins~1
RNP.~2
DR1;~1
52.2%~1
78.3%~2
diuretic,~3
48.1%~1
70.4%~1
headache;~1
alcohol-preferring~1
alcohol-avoiding~1
Sleep-wake~2
movement-sensitive~1
mattress.~1
ANA~6
alcohol-exposed~4
foetuses~1
(ETOH)~1
contributes,~1
(retinol)~1
(retinal);~1
spermato-genesis.~1
ETOH-induced~1
malonaldehyde~3
dextrimaltose-fed~1
ETOH~1
testes/body~1
(ETOH:~1
0.0114~1
0.0004~1
ISO:~1
ETOH-fed~4
radio-immuno-assays~1
TRH-induced~1
non-preferring~1
cold-exposure~1
ANA,~3
breath-acetone~1
antiketogenic~1
carbohydrate-deficient~1
CDT~6
CDT.~1
Drunken~1
believing~2
socio-demographic~1
Cattell~1
16PF.~1
Score,~1
initial)~1
transport).~1
80.94,~1
76.98,~1
15.02,~1
pentobarital~1
defibrillated.~1
CPR;~1
66.67~1
74.00~1
9.91~1
postresuscitation.~1
delivery/utilization,~1
group):~1
methoxamine.(ABSTRACT~1
pulseless,~3
"flu-like"~1
Palor,~1
orthostasis,~1
typifies~2
(CTFs)~1
CTFs,~1
here:~1
welders,~2
sunbathing~1
boating~1
CTFs~1
CTFs.~1
dipstick,~1
uK,~1
uK~1
ketonemia~1
Acetest~1
.94;~1
hatchling~1
Chicks~1
100-microM~1
apically~1
25-~3
higher-frequency~2
Audible~1
wall-mounted~1
chinchilla.~1
disarticulation,~1
disarticulated~1
strial~3
120-dB,~1
700-~1
2800-Hz~1
chinchilla~3
Electric~3
middle-latency~1
(EMLRs)~1
candidacy.~2
EMLRs~2
MLRs.~1
EMLR~2
stroboscope~1
0.6-mm~1
bimorph~2
holder.~2
Gluing~1
vibrator-induced~1
90-dB~1
.42~1
12.64~1
"hormonally~1
dependent"~1
hormone-dependent.~1
Melanoma~1
(3/12).~1
voices.~2
applicable,~1
200/100~1
(intravenous~2
nitroprusside).~1
anesthesia-induced~1
Stripping~1
postmeningitic~1
Preoperation~1
otolaryngologist-head~1
supranasal~1
chondromucosal~1
reaugment~1
vomer~1
lengthening,~1
pug~1
stigma.~1
(CPPD)~1
primary)~1
HPV-11,~1
multiple-electrode~1
magnets~2
headset.~1
electrotactile~1
Perilymphatic~1
servomechanical~1
nulling~1
perilymph.~1
BIOCEM~2
bisphenol-a-glycidyl~1
("epoxide~1
methacrylate")~1
pentacalcium~1
("tricalcium~1
phosphate")~1
bioceramic~1
vitality.~3
interdigitations~1
BIOCEM.~1
croup.~1
vasoconstrictor,~2
oxymetazoline~1
oxymetazoline.~1
uvulopalatopharyngoplasty.~2
tonsillectomies,~1
septoplasties,~1
turbinectomies.~1
desaturation,~2
thermocouple~1
J/cm2),~1
630-nm~1
laser;~1
g/kg.~1
DMSO-treated~2
panendoscopy.~1
Acoustic~2
microphone~1
electroacoustic~2
flap)~1
versatility.~1
choking,~1
uvula,~1
ST/HR~3
angio-cardiographic~1
narrowing:~1
accorded~2
Underestimation~1
white;~1
Maori.~1
labourers.~1
sudden.~1
16-36~1
aortic.~1
1-20)~1
Juxtaductal~1
non-functioning~1
impeccable~1
20%;~2
0-8%.~1
propantheline,~1
72.~1
beta-enolase~5
catalyses~1
2-phosphoglycerate~1
phosphoenolpyruvate.~1
beta-enolase,~1
1-7~2
13-43~1
2-75~1
transoesophageal~4
echo-free~1
(non-operated~1
(operated~2
leucocytosis,~1
Vegetations~1
non-operated,~1
anticoagulants--either~1
8-59~1
micro-organism,~1
micro-organism~1
squeezing~1
130/90~1
initially)~1
42nd~1
67th~1
266th~1
mV/pH~1
0.120~1
Ischaemic~1
(alkalosis)~1
34-69~1
effort),~1
(warm~1
effort).~1
29.5%.~1
timolol.~1
phonocardiograms,~1
Isovolumic~2
offsets~1
104(30)~1
24.3(6)~1
Theoretically~1
Brockenbrough~2
transseptally~1
retriever~3
aorta;~1
Schneider-Medintag~1
Gruntzig~3
inflated)~1
Mansfield~1
inflated).~1
wire;~1
wire.(ABSTRACT~1
15-27~1
(41%);~1
pioneer~1
impeller~1
haemofiltration~1
haemopericardium~1
(DeBakey~1
embolise~1
discordance.~1
concealed)~1
(sinus,~1
multiform~2
arrhythmias:~1
pre-excitatory~1
misadventure.~1
recompense~1
Corporation.~1
punitive~1
immediacy~2
keeping.~1
thiazide-induced~1
waveband.~1
photoactive~1
Near-UV~1
(365~2
nm)-induced~1
lethality,~1
far-UV~2
Trolox-C,~2
pre-irradiation~1
Plating~2
Trolox-C~1
(adrenalin~1
noradrenalin)~1
standing).~1
adrenalin,~2
noradrenalin~2
mulatta,~1
nemestrina~2
fascicularis,~1
dermographism~4
(factitious~1
urticaria),~1
dermographometer~1
nemestrina.~1
agglutinins~5
Agglutinins~2
Anti-P.~2
17-42%~1
(4-17%).~1
13-14-year-olds~1
titre~16
exocellular~2
Dissolution~1
flow-through~2
psoralen-UVA~1
8-MOP~2
10(3)/mm3)~2
10(4)/mm3).~1
cell/tumour~1
10(2)-10(4)~1
scratched~1
mite.~1
(XP124LO)~1
(XP~1
125LO),~1
XP-G.~1
monochromator~1
XP124LO~1
XP125LO,~1
XP2BI~1
XP3BR,~1
idiosyncratic,~1
'delay-to-delivery'~1
(uterine~1
UAI)~1
kPas/15~4
UAI~5
logarithmically~4
labour;~1
sound-provoked~1
non-stress~1
(N-S)~1
N-S~2
mid-luteal~2
3075~1
mU/l:~1
201-400~1
sperm-mucus~2
coincide,~2
'unexplained~1
infertility'~1
anti-atherogenic~1
HDL-2~3
desogestrel,~2
levonorgestrel,~2
gestoden~1
androgenicity~2
PVB~6
bleomycin)~1
non-responders~6
4544~1
(HRT).~1
HRT~1
'opposed'~1
reassuring:~1
1.43,~2
0.62-2.82)~1
2.53,~1
1.26-4.54).~1
bias--thus~1
HRT.~1
reassuring,~1
proviso,~1
2.84,~1
1.46-4.96);~1
1.59,~1
1.18-2.10);~1
ethinyl-oestradiol~1
babies:~1
(birthweight~1
1973-79),~1
161/1000~1
haemochorial~1
placentation,~1
30-33~2
on-line.~1
3.4)~3
4211~1
adenocarcinoma-in-situ~1
Midland~1
pre-diagnosis~1
(cone~1
hysterectomy).~1
Colposcopy~2
hypermetropic~1
nitrate,~1
cyclosporin.~2
Tubinger~1
isoptres~3
redundant.~2
pupil;~1
iridocyclitis~1
sector;~1
tendency;~1
aggravates~2
(occlusio~1
pupillae).~1
(say~1
Transscleral~1
ruby~3
cyclocoagulation~1
macroaneurysm~1
secondly,~2
hyalinization~2
Contusion~1
pheasant.~1
presenile)~1
6/18~1
(71.8%)~1
hypermaturity~1
Specular~1
shrank,~1
haemoglobin-C~1
(PSR),~2
PSR,~2
keratometer~1
mires~1
(IOL)~2
situ).~1
convex-plano~2
ophthalmometer~1
Javal-Schiotz~1
(Haag-Streit),~1
McCarey-Kaufman~1
(MK)~1
stabiliser)~1
rabbit)~2
MK~1
unstored~1
unused~1
acid.(ABSTRACT~2
SPD.~1
(vWd).~3
collagen;~3
platelet-to-platelet~3
apyrase.~1
Mg2+.~1
chymotrypsin,~3
low-Ca2+~4
13.177~2
Aspirin-treated~1
U46619,~2
endoperoxides.~1
thrombin-independent~2
transglutaminase~1
porcine,~3
alpha-chains~4
anti-guinea-pig~1
(ABAE)~1
Ca2+/Mg2+~1
codistributed~3
ABAE~1
plasminolysis.~1
progenitor-derived~1
globin.~1
(++-~1
+-),~1
zygosity~1
A----G~1
Ncol~1
5'-p-Fluorosulphonyl~1
benzoyladenosine~1
(FSBA),~1
p-chloromercuribenzenesulfonate~1
(pCMBS),~1
FSBA~7
pCMBS~2
(SpD)~1
HE,~1
(HPP),~1
self-association,~1
SpD~4
extract;~1
spectrin;~1
5'-p-fluorosulfonylbenzoyl~1
(FSBA)~1
ADP-mediated~1
FSBA-induced~1
SBA~2
5'-fluorosulfonylbenozoyl~1
(FSBG)~1
[3H]-FSBA~1
[Ca]i),~1
(Quin~1
(beta-thal)~1
beta-thal.~1
beta-thal~4
(siEp)~1
siEp~4
clones,~30
2.28,~1
125I-2.28~1
molecules/platelet,~1
12,600~1
molecules/platelet~1
Immunoelectrophoretic~1
53,000-mol~1
Immunocytochemistry~2
Double-labeling~1
cytofluorometry,~1
2.28-positive~1
porto-systemic~1
para-umbilical~1
proliposomes.~1
proliposomes~1
extraliposomal~1
pancreatogram~1
"shrunken"~1
Miller-Abbott~1
catastrophic.~2
investigations--chest~1
catheterisation--accounted~1
5.6-fold~2
radiographers'~1
16,000,000~1
annum~1
mannose.~2
microSv/MBq~2
tumour-directed~1
Gy/h)~2
(0.1-0.7~1
slopes,~2
(SLDR)~1
SLDR~1
Gy.~4
SLDR,~2
0.1-0.7~1
Gy/h~1
Gy/h.~1
radiobiological~2
CHO-K1~1
radioprotective~1
radiosensitising~1
split-dose~4
neutrons~4
rays,~2
(NNXXX,~1
XXXNN~1
NXXXN).~1
(NNXXX)~1
pharyngo-oesophageal~1
tonicity,~1
cricopharyngeus.~1
ahead~1
non-dysphagic~1
19-66)~1
123I-hippuran~1
99Tcm-thiodiglycolic~1
(TDG).~1
Deconvolution~1
renograms~5
radiopharmaceuticals.~3
estimations.~1
99Tcm-TDG~1
123I-hippuran.~1
Iopamiron,~1
Hexabrix.~2
Hexabrix,~1
Iopamiron~3
Iopamiron.~1
opacifying~1
89Sr~5
strontium~10
11.81~1
99Tcm-MDP~1
superscan.~1
(IRF)~1
IRF,~1
HWB(t),~1
RWB(t),~2
P(t).~1
HWB(t)~2
HO(t),~1
IRF~3
P(t)~1
convoluting~1
P(t,k)~1
(1-beta)HO(t)~1
HS(t),~1
superscan~1
Impulse~1
1781~2
ureteropexy.~1
intra-ureteric~1
submucosally.~1
enuretic~1
"failure"~1
alkalinisation,~1
16/21~1
(81.9%)~1
92.2%.~1
Ileocaecal~1
(epidural~1
randomly.~2
ml/s;~1
recatheterisation,~1
prostate-specific~2
BPH,~1
(66.6%)~2
(94.5%)~1
52.7%~1
(PMDS).~1
adrenogenital~1
masculinisation~1
position:~1
1-8)~1
Antidiarrhoeal~1
Restorative~1
Since,~2
calculable~1
geometrically~1
('J')~1
('W')~1
encroach~1
4131~1
2975~1
85.9.~1
ani,~1
colectomies~1
Nigeria,~1
Ife~1
fibro-adenoma,~2
gynaecomastia,~1
oligo(dT)-cellulose.~1
oligo(dT)-cellulose~2
(activated~1
ER):~1
non-activated~1
(non-activated).~1
'late'~1
(T3-4,~1
N2-3~1
M1).~1
Portopulmonary~1
48-72~4
flatus~1
(EGC).~1
EGC,~1
multilocular~3
PAD,~2
PAD.~1
(AISO)~1
AISO~2
AISO,~1
'acute~1
scrotum'~1
orchidopexies~1
1979-1981~1
'ascending~1
testicle'~1
tobacco-induced~1
"regularly"~1
1908~1
Canada's~1
merchants~1
sell~1
coffers~1
hypnosedative~1
(FAM),~1
FAM~1
arrhythmogenicity~1
postdoxorubicin~1
postinfusion.~2
local-regional~10
(gross~1
breasts.~1
Multi-agent~1
multi-agent~2
censored~1
Local-regional~1
residual,~2
(SVCS)~1
maximum-tolerance~1
(GEWS)~1
SVCS~2
GEWS~1
Orcein-positive~1
(OPHM),~1
OPHM~4
orcein~1
preoxidized.~1
rhodanine~1
rubeanic~1
microanalyzer~1
copper-protein~1
mucosa)~1
postmenopausal)~1
(ten-fold)~1
(seven-fold).~1
ODC;~1
pleomorphism.~2
1809~1
equidistant.~1
reconsideration.~1
carcinosis~1
carcinosis.~1
Imprint~1
translates~1
CYVADIC)~1
CYVADIC~1
RCC,~1
mitoses;~1
vaginectomy~2
excision)~2
(PLAP)~1
histochemically,~1
PLAP-positive~1
glycogen-rich~1
multi-potential~1
tumor-adjacent~1
middle-aged.~1
9062~1
Missouri.~1
Stage,~1
Johannesburg~1
locoregionally~1
15/23~1
19/26~1
Mucoepidermoid~1
(MUO)~1
(37)~1
(98)~1
MUO~2
(PN),~1
appliances.~1
MUO.~1
Myxoid-type~1
Enneking's~1
1.95-kg~1
enormous,~1
protuberant~1
(GCMN),~1
arisen.~2
leptomeninges,~2
Pathologic,~1
overrisk~1
12.1).~1
painters,~1
554).~1
36.8%~3
non-Mexican~2
Racial,~1
4658~1
2038~1
cholangiocarcinoma,~1
hepatoblastoma,~1
2286~1
(49.1%)~1
anti-HBs,~1
(angiogram,~1
scintiscan,~1
purposive~1
oncologists,~2
radiotherapists.~1
role--physicians~1
"self"~1
regulations;~1
autonomy--physicians~1
accountability;~1
relationship--physicians~1
incongruities~1
Radiumhemmet~1
(bleomycin,~2
5-fluorouracil)~1
BCF~1
BCF.~1
73.6%,~1
A-binding~1
A);~3
damaged-appearing~1
rarefied~2
ragged~1
indistinct~3
B);~3
spindling~2
51;~2
seven;~2
(1.9%)~2
predominance;~3
(84.3%)~1
(43.3%)~1
macrophage-histiocytes~1
Incisional~1
5250~1
4770~1
Low,~1
(RT~1
CT).~2
immunohistochemically,~2
(TH),~2
(CA)-synthesizing~1
sarcoid-like~1
Sarcoid-like~1
botryoides~3
rhabdomyosarcomas.~2
(38.0%)~1
(24.7%),~1
(9.4%;~1
(7.1%;~2
(2.4%;~1
(2%;~1
(1.6%;~1
(ACC),~2
ACC~9
epithelial-membrane~1
globules,~1
(SKVA)~1
ACC.~3
immunophenotypes~4
myoepithelial-cell~1
epithelial/myoepithelial~1
SKVA~1
immunophenotypically~2
undifferentiated.~1
myoepithelium.~1
(diminutive),~1
diminutive~2
1987,~1
29.8%.~1
HPT)~2
(0.15%~1
0.14%,~1
(L.J.T.)~1
demographics,~2
(41%,~2
45/109)~1
(14/45)~1
play-performance~3
parent-rated~1
75.4~1
97.4).~1
42.3,~1
90.7,~1
98.2.~1
concise,~1
reporters.~1
quantifiable,~1
Leukemia~3
(CALGB)~1
protocols:~2
7781~1
165)~1
8083~1
139)~1
7782~1
151)~1
extensive),~1
(POMS).~1
Gender,~1
(PSR~1
ED)~1
regressions.~1
POMS~3
(Overall~1
postthrombolytic~1
(+~1
re-infarction~1
(re)-percutaneous~1
Transseptal~1
puncture;~1
Fellows.~1
cardiologists.~2
readers,~1
(NLVF).~1
frames/sec~1
NLVF~4
(PFR)~1
volumes/sec~1
(EDV/S)~1
3.00~1
EDV/S~1
EDV/S,~2
.05;~5
PFR's~1
peri-apical~1
Apical~3
cineventriculography.~1
Sones~1
Postdilation~1
system).~1
V5.~1
Superflow~4
(5F)~4
[2.8~1
0.027]~1
maneuverable~1
(LAT)~1
LAT~8
cranial,~1
RAO~2
19/40~1
19/44~1
post-PTCA,~2
(48/56,~1
(18/33,~1
12/27~1
14/24~1
(58%).~1
descending.~1
nonsegmental~1
(DADs)~1
DADs~6
(acidosis,~1
DADs.~2
3',~2
(dB-cAMP,~1
Acidosis,~1
(pO2~1
Acidotic~1
pH0~1
-86.2~1
-58.6~1
together)~1
(0.04-0.10~1
(microsphere)~1
Defined~3
(-28%)~1
i.d.)~1
media-thickness-to-lumen-diameter~1
(force~1
[pD2(+cocaine)~1
pD2(-cocaine)~1
0.53)~2
0.044,~1
4.197~1
0.050~1
4.381~1
0.068,~2
130%~1
carboxamido~1
(NECA,~1
A2-selective~1
2-chloro~1
(2CA,~1
(CHA,~1
8-phenyl~2
2CA~3
hundredfold.~1
(200-220%~1
400%~3
nitrobenzyl-6-thio~2
guanosine.~1
(200%~1
dipyridamole.(ABSTRACT~1
electromagnetically.~1
decapsulation~1
Decapsulation~1
decapsulated~3
reflexively~1
beta-LIPO).~1
nonsurvival~1
microvasculatures),~1
(dP/dt)max,~1
(dP/dt)max~1
[delta(dP/dt)max/delta~1
t].~1
beta-LIPO~1
delta(dP/dt)max/delta~2
t.~1
after-loading~1
servo-pump.~1
intercepts,~1
VO(t),~3
E(t)~4
VO(t)~2
underlain~1
semiempirical~1
micropunctures.~1
gain),~1
172%~1
quinidine's~1
intracellular-current~1
strength-duration~2
current-voltage~2
strength-~1
charge-duration~1
overshoot,~1
excitability;~1
(ro~1
ri),~1
H2O-saturated~1
insulator.~1
(94%~1
N2-6%~1
ro,~1
ri~3
ro~3
uncoupling,~2
ro:ri,~1
ro:ri~1
(TQ-segment~1
shifts).~1
prereplicative~3
(G1)~2
(twenty-three-fold)~1
[3H]thymidine-labelled~1
lysophospholipids~1
diacylphospholipids~1
mitochondria)~1
acyl-CoA:lysophospholipid~1
sulfhydryl-sensitive~2
glutathione:~1
glutathione)~1
glutathione:oxidized~1
20:4)~1
11-OH,~1
12-OH,~1
15-OH~1
glutathione-protein~1
lysophosphatide~1
acyltransferase.~1
HgCl2-induced~1
-43%)~1
-38%)~1
PVP-sieving~1
HgCl2.~1
EFP,~1
Kf,~1
+5~1
0.94-0.98);~1
integral.~1
shortening),~1
energetics,~1
isozymes,~1
14-36~1
days-2~1
terminalis~2
auricles).~1
Preceding~1
alpha-containing~2
heart).~1
9-month-old~2
aortic-constricted~2
(LVDW)/body~1
LVDW/tibial~2
22-month-old~1
LVDW/body~1
Diet-induced~1
(regression)~1
Hg/ml/min)~2
atherosclerotic).~1
endocardial-to-epicardial~1
midmyocardium,~2
1.8-3.0~1
(reentrant~1
nonreentrant)~1
mechanism.(ABSTRACT~1
1,4-dihydropyridine~1
stereoisomers,~1
(+)202-791,~2
(+)Bay~1
(+)PN~3
200-110,~2
(+)[3H]PN~2
(+/-)[3H]nitrendipine,~2
(+/-)[3H]Bay~2
dihydropyridine.~1
(5-19~1
200-110~3
("agonists"),~1
entropy.~4
("antagonists").~1
(BIO~2
53.58)~1
14.6)~1
(F1B)~1
g/kg/day~1
[LV]~1
carnitine-treated~2
peak-positive~1
(index~2
free-carnitine~1
convertible~1
(ATP)/(ADP~1
adenosine)~1
(creatine~1
phosphate)/(creatine)~1
(BRs),~1
discharging,~1
arch/aortic~1
(10(-6)-10(-5)~1
(10(-10)-10(-6)~1
Excitation~1
passive)~1
active).~1
burst,~1
complement-induced~1
ng/min/kg)~1
90-100~1
(7%,~1
pertussis-toxin-treated~2
acetylcholine;~2
responses;~4
(30-100~1
nifedipine-like)~1
(NE)-induced~1
(PA).~2
PI-P2~3
(nifedipine-like)~1
PI-P2.~1
V0,~1
Sarcomere~1
embedded,~1
reextension,~1
enveloped~2
myofibrils.~1
corbular~1
Restitution~1
calcium-release~1
Low-density~2
cholesterol-carrying~1
(mevinolin~1
compactin)~1
(cholestyramine~1
colestipol),~1
streak.~1
grows,~3
.92.~1
edge-to-leading~1
.75~1
.96,~2
echocardiography.(ABSTRACT~1
VO2)~1
intermediate-energy~2
cardioverting~1
(25J)~1
tow~1
anodes~1
reoperation),~1
68).~1
cuspal~7
("alignment~1
stitches")~1
insudation,~1
design-related~1
(MVA)~1
.08).~2
cm2;p~1
.8,~1
.3,~1
cm2).(ABSTRACT~1
strip,~1
[CSA]~1
(ERP;~1
(PCL)~1
PCL~3
-.84,~1
dyne/cm2~4
BAEC~1
high-stress~1
prealigned~1
125I-LDL.~1
lipoprotein-deficient~2
stensosis~1
(0.20~1
relaminarization~2
Continuous-wave~1
contracta~1
time-controlled~1
(ICSO)~1
ICSO)~1
ICSO,~1
ml/g/min)~1
arterial-arterial~1
ICSO~2
66.2~1
ligation).~1
oxypurinol,~2
oxypurinol~2
Oxypurinol~1
(36.3~1
(-6.6~1
1.0%).~1
oxypurinol-treated~1
-3.2~2
1.7%;~1
(LCx).~1
demand-dependent~1
angioplasty-induced~1
catheter:~1
denudation;~1
LADs~1
work-length~1
minor-axis~1
probe-measured~1
.969)~1
.960),~1
.973)~1
.967),~1
(Mw)~1
(Lw).~1
Mw~4
Lw~3
.04)~5
Lw.~1
Mw,~1
Ultrafast~2
frames/sec)~1
interrogate~1
SE]).~1
.94,~3
0.66%,~1
4.73%,~1
16).(ABSTRACT~1
83%).~1
(18%;~1
(56.9%;~1
(50/53)~1
(14/15)~1
"V"~1
(absolute~1
.45)~1
-.15,~1
(leak,~1
(2/5),~1
(3/10).~1
making.(ABSTRACT~1
atrial-ventricular-arterial~1
(1962~1
1986).~1
(Van~1
Praagh)~1
components;~2
exclusive)~1
supramitral~1
parachute~1
seven),~2
[CL];~1
24.6%),~1
CL;~1
postoperatively.(ABSTRACT~2
.28).~1
covariance).~1
prohibitive~2
(Coumadin),~1
99.5%~2
0.67%~1
97.4%~1
94.4%,~1
76.7%~1
1175.4~1
(1368~1
valve-years).~1
Linearized~1
limits)~1
(0.00~2
1.03);~1
1.49);~1
3.052);~1
0.77);~1
4.14).~1
71.7~1
4.9%;~1
(1982-1986).~1
SCI,~1
SEP;~1
judiciously.~1
(PBV)~1
PBVs~3
PBV~4
PBV,~1
dysfunctioning~1
.0154)~1
.0110)~1
.7620)~1
factors.(ABSTRACT~3
(SLV)~1
(SRV)~1
(VMI)~1
VM/EDV.~1
shunt)~1
SLV~2
SRV~3
EDVI,~1
VMI,~2
VM/EDV~5
SRV.~1
SRV,~1
aortotomy,~1
aortotomy~2
Avoidance~2
unifocalization~1
Symmetric~1
arteriopulmonary~1
(SAPS)~1
SAPS.~2
Choussat~1
Fontan,~1
SAPS-induced~2
SAPS~1
double-inlet~5
(DIRV),~1
DIRV,~3
Intra-atrial~1
38.5%~1
(DIRV~1
DIRV~1
drainages;~1
confluence.~2
(UVH)~1
TA,~4
atrial-to-right~1
Fontan-switch~1
18.3%)~1
37.0%)~1
UVH,~2
15.4%)~1
(PAB),~1
PAB,~1
PAB.~1
TA.(ABSTRACT~1
ventricle).~1
triple-balloon~2
inflate~2
inflates,~1
atrium-to-pulmonary~1
1:2.~3
13.0%)~1
(4.4%~1
5.3%)~1
(fibrinopeptide~1
FPA)~1
(beta-thromboglobulin,~1
beta-TG),~1
venoarterial~1
beta-TG.~1
6800~1
52%).~1
75).~1
Determinants~1
canal).~1
transaortically.~1
14.3).~1
16.6),~1
40.2%~1
68.2%~3
49.0%),~1
83.8%).~1
dextrocardia~2
mesocardia~1
Transaortic~1
subendocardially~1
defect),~1
location).~1
(PAP).~1
PAPs.~1
1.48(PP)~1
.61,~1
PAP.~1
(OMC)~1
OMC~5
64),~2
209)~1
99),~2
OMC.~1
Reoperation-free~1
reoperation-free~1
(61%~3
(CAPD).~1
Orthostasis~1
1.45-1.65~1
iodocyanopindolol~1
sites/cell,~3
(2080~1
sites/cell),~1
cAMP/10(6)~1
MNL/10~1
ERPF.~1
(+22%).~1
Tamm-Horsfall~9
pelvis:~1
ilium,~1
ischium,~1
pubis.~1
crutches.~2
fracturing~2
20,538~1
sex-dependence.~1
Menopause~1
19-75~1
(OA),~1
37;~1
(ON),~1
shells)~1
sockets,~1
chrome~1
chamfer-cylinder~1
acetabulum.~1
biologic-in-growth~1
stem-type~1
unions.~1
radiolucencies~2
Reaming~1
chamfered~1
bone-component~1
porous-ingrowth~1
reaming,~1
Marcy~1
Gibson~1
Watson-Jones~1
Tc-99m-MDP~1
nidus.~1
(regional~1
enteritis)~1
"quiescent"~1
subgluteal~1
fistulized~1
capricious~1
self-evident.~1
(migratory~1
osteolysis,~2
osteoporosis).~1
intraepiphyseal~1
joint-related~1
localizes~4
physeal~2
cumbersome.~1
notching~2
unions,~2
malunions,~2
fabella,~2
sesamoid~1
fabella~3
fragment;~1
(TTA)~1
TTA~4
(HTO).~1
Patellar~1
HTO~1
fabricated.~1
21-79~2
supination,~2
nondominant.~1
supination.~1
groove.~3
(CPM),~1
Thymidine-labeled~1
hyaline-like~1
Sorbothane~4
(I.E.M.~1
Orthopaedics,~1
Aurora,~1
substantiation~1
absorbing~1
insoles~1
Durometer~1
insoles.~1
unplanned,~1
Vulnerability~1
Repeating~1
"accident~1
proneness,"~1
predisposition.~2
holistic~6
samarium~1
220-260~1
midcallus~1
magnetized~1
nonmagnetized~1
Hospital-based~1
(RMSF)~1
RMSF,~1
Hemostatic~3
RMSF~1
Scottish~2
Clean-catch~1
10,960~1
cells/microliter~2
13,300~1
3,970~1
glucose/blood~1
sulfinpyrazone~3
mentioning~1
Inclusion,~1
beta-adrenoceptor-mediated~2
alpha-adrenoceptor-mediated~2
enantiomorphs.~3
hypoprothrombinemic~2
hypoprothrombinemia~8
S-warfarin~2
R-warfarin~1
nonstereoselectively~1
Clopamide~1
AUC.~1
clopamide,~3
Chlorothiazide,~1
"warfarin~1
alone"~1
pseudoracemic~1
phenprocoumon~2
Phenprocoumon~1
7-hydroxymetabolite~1
conjugated.~1
Sulfinpyrazone~1
(R)-~1
(S)-enantiomers.~1
7-hydroxylation~2
(S)-phenprocoumon~1
sulfinpyrazone.~1
(cis-diamminedichloroplatinum~1
ml/min/m2~1
L/m2.~1
(24.4~1
56.9~1
1.2),~1
debrisoquin.~1
interphenotypic~1
Michaelis-Menton~1
(Km).~1
hydroxylator~1
dihydrodiol~1
para-phenolic~1
smokers).~1
(26.8%~1
(48.0%~1
39.7%~1
polymorphisms.~7
quinidine-N-oxide~1
L/hr.~1
0.83%.~1
quinidine-like~1
acetohydroxamic~1
AHA.~1
fibrin-split~1
microaggregates.~1
AHA~6
toxic-allergic~1
methylenedianiline~1
(syn:~1
4-4'-diaminodiphenylmethane)~1
para-group.~1
cross-sensitization~1
8021~1
lipstick,~1
creams.~2
8021,~1
(chemically~1
unrelated)~1
constituents:~1
4-isopropyl-dibenzoylmethane~2
3-(4'-methylbenzylidene)~1
camphor;~1
Alloys~1
microgram/cm2/week~2
microgram/cm2/week.~1
Additives~1
Some,~1
colouring~1
flavouring~1
Antioxidants~1
pharmaceuticals~1
Dodecyl~1
gallate~4
propyl-~1
octyl-gallate~1
gallic~1
phenols~2
patch-test-positive.~1
anti-DR~1
perivascularly~1
mastocytes.~1
itchy~1
depigmented~1
manus,~1
ceremony~1
incenses~2
sandalwood.~1
volatized~1
burnt;~1
sebum;~1
ethylenediamine~1
re-patch~1
retesting,~1
(OCB)~1
SV)~2
(OCB/VO2~1
(-11.6~1
OCB,~1
.79;~1
-12.6~1
293.1~1
OCB/VO2~1
.84,~1
hypomagnesemia.~1
Glasgow-Pittsburgh~2
(k2)~1
k2~1
zero-time~1
(y0)~1
y0~1
passes,~1
(ECMO).~1
(HFOV).~1
HFOV~3
HOFV.~1
(alveolar-arterial~1
HFOV,~2
confining~1
microthromboses~1
pattern:~1
(PB)-50,~1
propranolol-0.5~1
cocaine-5~1
epinephrine-0.5~1
carbachol(CA)-5~1
pirilamine-20~1
cimetidine-30~1
lidocaine-20~1
(AT)-40~1
intra-AH~1
CA-10~1
AT-20~1
intra-PH~1
PB-10~1
norepinephrine-0.05~1
cybernetic~1
(SVRI).~1
SVRI~1
core/peripheral~1
(PDCO)~1
5.16~1
.58.~1
(TDCO~1
PDCO).~1
estimate;~1
dextran-40)~1
(Kf~1
translaryngeal~1
protector.~1
slid~1
well-lubricated~1
stylet.~1
insufflates~1
47-yr-old~1
Ca-channel~1
(COPD-CP).~1
(Vo2~1
(delta)~4
(CLTO)~1
CLTO,~1
PAH,~2
[including~2
phenomenon])~1
dynes.s.cm-5,~1
dynes.sec.cm-5,~1
vasodilator-reversible~1
snore~1
desaturation.~4
half-night,~2
Apneas~1
mixer/tonometer~1
precision;~1
100.0~2
published),~1
switchboard~1
(delay:~2
sent.~1
(Xrs)~1
(Th-TMT)~1
Th-TMT.~3
Th-TMT~2
(TMCR),~1
fiberbronchoscopic~1
brush,~1
TMCR,~1
TMCR~1
Categorization~1
asbestos-associated~1
(restrictive,~1
restrictive-obstructive,~1
airtrapping~1
categorization,~1
pleurisy~3
562.~1
localized).~1
Anti-Scl~1
pitting~3
pitting,~1
Anticentromere~3
(CAM)~1
bronchioles,~3
CAM,~2
tomographic,~3
Cartilaginous~1
Empyema~1
(36.7~1
Pneumococcus~1
(15.8~1
Enterobacteria~1
(segmentectomy,~1
lobectomy)~1
(52.5~1
tripling~2
(PWP)~1
(EVLW:~1
ml/kg:~1
(triple~1
EVLW),~1
Cardiology~1
bpm)~3
electrophysiology~1
impulse.~3
barogenic~1
(Gastrografin)~1
communicate.~1
six-view~2
new.~1
sulfasalazine-induced~1
autosuture~1
(CFPR)~1
Treatment,~1
(single,~1
synchronous,~1
metachronous),~1
2(1)~2
self-selection~3
Melbourne~1
Anticarcinoembryonic~1
rocket~4
A4/6,~1
B6/8,~1
C6/7,~1
D0/1)~1
CEA-positive~1
anti-CEA~4
whipworm~1
(Trichuris~1
trichiura)~1
Trichuris~1
(Vermox),~1
anorectum,~1
dialysis-dependent~1
discolored~3
duodenocolic~1
verge.~1
knife,~2
endoscope,~2
Paradoxical~2
(anismus)~1
Electromyogram~1
defecating;~1
anismus.~1
bowel-related~1
worries~1
cytodiagnosis.~1
Colonogastric~1
"gastrocolic,"~1
halitosis~1
"colonogastric"~1
gastrojejunocolic~1
Angiosarcoma~2
histiocytoid~1
hemangioendothelioma,~2
72-year-old~3
erythrophagocytosis~2
alpha-1-antitrypsin,~1
alpha-1-antichymotrypsin.~1
Debulking~1
meal).~1
(IPPPR)~1
IPPPR~3
enteropancreatic~1
pattern-recognition~4
emulates~2
smoothes~1
rescore~1
36-71%~1
42-88%~1
dilator.~1
psi).~1
belches.~2
0.71.~1
(5-37~1
well:~1
81,~1
tracehoesophageal~1
(CDCA)~1
ursodeoxycholic~3
(UDCA)~1
preneoplasia,~1
CDCA,~1
UDCA,~1
UDCA~4
CDCA~1
mepirizole~4
subcutaneously)~4
mepirizole.~2
duodenoulcerogenic.~1
16,16-dimethyl~2
nonantisecretory~2
(0.5-5~1
mepirizole-induced~1
mepirizole,~1
develop:~1
earlier),~1
hyperacidity~1
isoinsulinemic~1
free-insulin,~1
bolognese~5
euglycemia~2
(435~1
sauce.~1
insulinemia~1
restricted-protein~1
0.7-1.9~1
normal-protein~1
(NPD)~1
5-8~2
determinations/day~1
reincrease~1
(689~1
diet.(ABSTRACT~1
(microalbuminuria)~1
microalbuminuria~3
24-h,~1
overnight,~3
single-void~3
(mg/24~1
Single-void~1
microalbuminuria,~1
nl/s,~1
micrograms/min.~1
albuminuria:~1
progressing,~1
[neuropathy~1
(NSS)~1
(NNSP)],~1
[neurologic~1
(VDT)~1
thresholds],~1
[nerve~1
(NC)].~1
Abnormality~3
Setting~1
NSS~2
NNSP~2
VDT~1
Small-~1
large-fiber~2
diabetics)~1
(MPSAP).~1
(Pfizer~1
tester)~1
(Somedic~1
vibrameter)~1
MPSAP.~1
threshold:~1
sensitivity;~1
MPSAP~3
MPSAP).~1
MPSAP,~1
(vibration~1
sensation)~1
small-fiber~1
.02).(ABSTRACT~1
insulin-pump~1
20-39~1
insulin-dose~1
self-measurements~1
SC-~1
IV-pump~1
SC-pump~1
systems.(ABSTRACT~1
needles.~1
contaminated,~1
i.e,~1
needle-insertion~1
disinfectant~1
Nose~2
(30.5%)~1
(30.0%).~1
waist/hips~1
waist/thighs~4
arms-to-thighs~1
skinfolds.~1
1370~1
eighty-four~1
older-onset~1
50-item,~1
Etzwiler~1
validity),~1
(Cronbach's~1
.88),~1
readability~1
layperson~1
7th-~1
8th-grade~1
(EOD),~1
(LOD),~1
achievement.~2
EOD,~1
LOD.~1
Sexually~2
(STDs)~2
STDs~4
STDs,~3
vaginitis,~1
cervicitis,~1
abreast~2
STDs.~1
extragenital~1
perihepatitis,~1
Porsolt~1
(0-5~1
immobile;~1
70%).~1
antiglucocorticoid~3
anticholinergics~1
MR2266~1
synthetase)~1
alpha-bromoandrostenedione~1
alpha-BrA)~1
beta-BrA~2
mechanism-based~1
kinact~1
[1(-3)H,4(-14)C]androstenedione~1
aromatase.~2
Time-dependent~2
epimers~1
6-BrA~1
cytochromes.~1
6-substituted~1
estrogen-untreated~1
preembedding~2
PR-positive~2
hens,~1
thecal,~3
steroid-producing~1
ovary),~1
Immunocytochemically,~1
ACTH1-24-~1
forskolin-induced~1
ACTH1-24~3
1-methyl-3-isobutylxanthine.~1
ACTH1-24-induced~1
(IFC)~1
streptozotocin-diabetic~3
(STZ-DM)~1
IFCs~1
200-g~1
STZ-DM~6
Holtzman~3
(EPI),~1
0.01-0.1~1
0.01-1.0~2
(ADA),~1
(bGH),~1
IFC~8
STZ-DM,~1
perifusion,~1
(STZ-DM~1
STZ-DM.~2
7-,~3
28-day-old~2
agarose.~1
(colony~1
efficiency).~1
10-80~2
assymetric~1
prechondrocytes,~1
36-day-old~2
microns/1000~1
GH-pretreated~3
0.4;~2
GH-treatment~1
GH-treated~1
IGF-I-independent~1
3T3-preadipose~1
peptide-1~1
(GLP-1)~1
GLP-1~11
(GLP-1-IR),~1
(LMT-01),~1
thalamus-hypothalamus,~2
oblongata.~1
GLP-1-IR.~1
thalamus-hypothalamus.~1
GLP-1-IR~2
thalamus-hypothalamus~2
(1-37);~1
GLP-1-IR,~1
(1-37).~1
[disocciation~1
nM].~1
neurosignal~1
inositol-containing~1
myo-[3H]inositol~1
Z,Z-dienestrol,~2
DES.~1
corticosterone-binding~1
(CBG),~1
[125I]CBG~1
0.745;~1
(2.5-5~1
END-LI)~1
END-LI~7
flushings.~1
Extracted~1
lipotropin~2
(0.23).~1
(Kav~2
oil),~1
(Prog),~1
Prog~3
(E2~1
Prog).~1
ovariectomy,~1
532%~1
ng),~1
beta-Sympathomimetic~1
glycerophospholipid~1
(Bt2cAMP)~1
Bt2cAMP~4
Bt2cAMP-induced~1
translatable~3
Bt2cAMP,~1
prealveolar~4
interalveolar~1
Bt2cAMP-treated~4
point;~1
[125I]L-T3~2
D-T3.~2
[125I]D-T3,~1
[125I]L-T3.~1
porous.~1
(50-100%)~1
protein-mediated~1
albumin-binding~1
[125I]D-T3~2
12%),~1
(5.1)~1
(5.0),~1
(LEL)~1
lymphocyte-conditioned~1
(LCM)~1
LEL~5
LCM~2
(LCM-E)~1
LCM.~1
LCM-E~2
LCM,~1
gamma-interferon,~4
LCM-E.~1
alpha-E~1
casein-synthesizing~1
currents:~1
Co2+,~3
Tetraethylammonium~1
4-aminopyridine,~1
receptor-DNA~2
DNA-cellulose-binding~1
DNA-cellulose~9
histone/ml~1
histone-binding~3
histones.~3
itself)~2
transcriptionally~20
(haPL;~1
haPL-II)~1
haPL-II~6
haPRL~2
[12.3~1
6]~1
(term).~1
10-12.~2
(37,000)~1
haPL-I.~1
haPL-II,~1
2-mercaptoethanol.~1
haPL-II.~1
[125I]iodocalmodulin~1
240,000,~1
(Mr).~1
calmodulin-Sepharose.~1
(trifluoperazine).~1
alpha-spectrin,~1
calcineurin~4
calmodulin,~7
406,000~1
0.4S;~2
237,000~1
0.3S;~1
10S~3
5.5S~1
7S,~1
steroid-~1
5.5S.~1
mosM,~2
mosM.~1
fmol/10(5)~1
(0.5mM).~1
secretogogue~1
[2-3H]E2,~1
IU/h~4
feminizing~1
2-hydroxylase~1
testosterone-treated~1
[4-14C]E2~1
2-hydroxylase,~1
neurodeficit,~3
neurodeficit~1
(IIEA)~1
EEGs,~1
IIEA~1
1,201~1
IIEA,~1
isoelectric.~1
methohexitone,~1
quadrantanopsia~1
"manipulation~1
hemiplegia."~1
games,~2
draughts,~1
"punchi."~1
bisynchronous~1
3-Hz~1
(impulsive~1
petit~1
mal),~1
Myoclonic~1
clobazam.~1
Attendant~1
hostility.~1
(CBZ)~4
anxious.~1
(PHT),~1
veratrine-stimulated~2
ethosuximide~1
(ESM)~1
(VPA)~2
ESM,~1
VPA~2
ESM~1
electroshock-induced~2
(i.p.),~1
kilogram.~2
PHT,~1
CBZ,~1
xanthines~1
temperatures;~1
agonist/antagonist~1
antagonists;~1
[3H]cyclohexyladenosine~1
[3H]diethylphenylxanthine~1
(DPX)~1
[3H]CHA~1
GppNHp,~1
[3H]DPX~1
nucleotide.~6
homotopic~1
forebrain-bisected~1
commissure)~1
transhemispheric~2
kindling.~1
parentally.~1
(PTZ)-induced~1
PTZ~2
(i.v).~1
epileptogenecity~1
(mg/kg)~1
50-60%.~1
LD50)~1
videorecording,~1
split-screen~1
filmed,~1
fits;~1
Fits~1
"because~1
there,"~1
nonfebrile~2
Stroke,~2
NCPP.~1
NCPP~2
nonsymptomatic~1
noncerebral;~1
Maldevelopment,~1
endometrioma~1
(mild,~1
52%;~1
uterotubal~1
miu/ml)~1
Hysterosalpingograms~1
hydrosalpinx~1
spillage.~1
-3/-2~1
+7/+8,~1
regularity~2
(Concanavalin~1
phytohemagglutinin)~1
immunosuppressive.~1
(DHT).~1
(7.06%~1
1.72%,~1
(2.30%~1
0.26%)~1
(3.53%~1
0.74%~1
0.14%).~1
4.59%)~1
(4.17~1
1.07).~1
(12.8%~1
(59.7%~1
12.0%)~1
chromopertubation~1
microanastomosis.~1
Resected~2
"plugs,"~1
outpatient-based~1
ultrasound-directed~1
(TUDOR)~1
1226,~1
960.~1
TUDOR~1
30.0%~1
learn,~1
4.29~2
Hysteroscopic~1
PTO,~1
HSG~8
reanastomosis/reimplantation~1
PTO.~1
head-directed~1
spermiograms~1
spermatogonia,~1
spermatids,~1
spermatids~3
quantitations,~1
hypospermatogenesis,~1
hypospermatogenesis.~1
spermiogram~1
stethoscope~1
2,481~1
teacher-learner~2
Teacher-learner~1
non-family~1
(785/1,409)~1
stress."~1
menses,~1
"less~4
compassionate,"~1
efficient,"~1
accurate."~1
physicals~1
addictive~3
self-identified,~1
Holistic~3
(FPs).~1
"holistic"~1
interactional~1
FPs.~1
logbooks~1
anticipations,~1
satisfactions,~1
frustrations.~1
administrators.~2
frustrated~1
biomedical.~1
handshake~1
greeting)~1
interruptions~1
greeting~1
magnify~1
touched;~1
weaknesses.~1
honesty,~1
(anti-HBs)~2
Concurrence~2
(36/57~2
13/38,~1
24/133,~1
Subtyping~1
subdeterminant~2
ay~1
homotypic~1
heterotypia~1
heterotypic~2
canrenoate~2
canrenoate,~1
mg/day);~1
(MEB),~1
androgen-responsive~1
MEB,~1
MEB~2
spironolactone-treated~1
multicompartmental~1
insoluble,~1
"soluble"~1
DCA,~1
(ABT-k)~1
0.10/h~1
(NCR)~1
ABT-k~1
(PCR).~1
NCRs,~2
PCRs.~1
Morphometrically~1
PCRs,~1
PCRs~1
NCRs~1
milliliters),~1
aminopyrine.~1
electrocutaneous~1
cancer-prone~1
Extracolonic~1
propelling~2
125-s~1
ml/s.~3
Analogous~1
29.0~1
parasitism.~1
serum-stimulated~3
concentration-related~3
Noncollagen~1
(5-21~1
heparinlike~1
25-yr-old~1
gurgling~3
noises~2
belch~3
Fluoroscopic~1
UES.~1
"chest~1
origin."~1
Neurotensin-stimulated~1
"Ca2+-free"~1
5.1)~1
K+]o)~1
8-Bromo-guanosine~1
mediation,~1
[cGMP]i.~1
81.0%~2
95.2%,~1
75.0%~2
87.0%,~1
58.9%~1
55.0%~2
ASA-treated~2
SA-treated~2
16,16-Dimethyl~1
pseudoobstruction)~1
antineurofilament~1
NF2F11.~1
unstained.~1
(radiology,~1
morphometry).~1
palisade~2
propria;~1
"treble~1
clef"~1
g/dl.~3
decreased;~3
"catch-up"~1
corticosteroid-unresponsive~1
pain--both~1
extrinsic--and~1
elderly--age-related~1
(ARMD)--and~1
ARMD~1
monomer.~2
Angiosarcomas~1
haemangioendotheliomas~1
(EHAE)~1
crucial:~1
fallible~1
transplantation),~1
EHAE~1
14C-deoxycholate~1
(SD:~1
13.8)~1
mumol/kg/d~1
%-change~5
0.89).~1
[14C]-triolein~1
preprepared~1
discriminates~3
(TEA;~1
site.(ABSTRACT~1
7.56~1
6.72.~1
7.06~1
6.64,~1
6.09~1
6.39.~1
CO2/bicarbonate~1
7.51~1
5.96~1
6.80~1
6.26.~1
Secondly~1
juxta~2
pH-microclimate~1
n-acetyl~1
Proximally,~1
'peristaltic~1
reflex',~1
caecum.~2
water),~1
lentil~6
carbohydrate)~1
carbohydrate),~2
21%)~1
(lactulose~1
swallowed),~1
(non-fermentable~1
mouthwash.~1
contents:~1
bd,~1
Albino~2
Carcinogen~1
mg/kg/week).~1
fibre.~1
1-10.9%,~1
2-3.6%,~1
3-63.7%,~1
4-21.8%.~1
fibre).~1
Stathmokinetic~1
S-phospholipase~2
FFA/ml~3
50-60~2
Hg/ng~1
II/kg/min).~1
(Na,~1
Na),~1
II-DBP~3
-0.78)~1
-0.70).~1
Ionic,~1
renin-sodium~1
-20.0~1
mEq/L;~1
omicron-iodohippurate~2
exercise-mediated~2
catecholamine,~1
scintigraphed~1
renogram),~1
renogram).~1
Renography~1
exercise-mediated,~1
NaCl-induced~2
WKY)~1
strain.(ABSTRACT~2
Vasoconstrictor~1
nmol),~2
[3H]5-hydroxytryptamine,~1
SHR:~1
anococcygeus~1
Nonhuman~2
hypertensive),~1
echocardiography-determined~1
baboons.(ABSTRACT~1
pg/kg/min~2
microliter/hr)~1
allocate~1
program-related~1
Client~2
loyalty,~1
communications,~1
service-specific~1
Liability/recovery~1
liability/recovery~1
"advanced"~2
Verrucous~1
(Ackerman's~1
Ackerman's~1
radioresistant,~2
postlaryngectomy~2
(mano,~1
manometry;~1
fluoro,~1
videofluoroscopy;~1
graphy,~1
picture)~2
manofluorography~2
Pharyngeal~2
propulsion,~1
evolved.~2
professors~1
tobacco-associated~1
Cigar~1
Pipe~1
sternocleidomastoid,~1
Branches~1
glottic)~1
(5-yr~1
survival)~1
80-85%,~1
Drs.~1
Biller~1
80-90%~2
Bryce~1
regrew~1
parotid,~1
salivary,~1
(31),~1
(zygoma)~1
anteriorly,~2
(mano:~1
fluoro:~1
graphy:~1
lingual-laryngeal~2
inlet.~1
triggered,~1
(SDC),~1
SDC~2
petrotympanic~1
resumes~1
medially,~1
(brain)~1
MacFee~3
horizontal)~1
these;~1
(ASPS)~1
ASPS~1
Hemangiopericytoma~1
Injected~1
1:400,000~1
1:100,000~2
ameloblastoma~4
malignant;~1
insiduous~1
capillary/cavernous~1
seventy-eight~1
(MTX)-5-FU.~1
33).~2
(EGFR1)~1
111indium-labeled~1
EGFR1.~1
Hibernomas~1
hibernating~1
nonhibernating~1
hibernomas~2
hibernomas,~1
(FVR)~1
unfit~2
[UF,~1
kg-1]~2
(F,~1
FVR,~1
FVR~1
baroreflex,~1
-2.42~1
U/mmHg,~1
U/mmHg.~1
FVR;~1
adaptations,~1
(228%)~1
Lobes~1
resistance-training~2
builders~1
(BB),~1
weight-trained~1
one-arm~1
presses~1
one-leg~1
extensions.~1
RM)~1
RM~1
presses.~1
weight-training~1
thoroughbred~1
800-m~1
2,000-m~4
gallop.~2
800-~2
gallops,~1
gallops~1
units.kg~1
muscle-1.s-1,~1
123.5~1
3-phosphate.~2
flow/mouth~1
(magnitude~1
difference)~3
third-order~1
(S).~1
(1.96SE)~4
mg/pair~4
days-1~1
[half~1
days].~1
(kd~3
days-1,~2
h/day)~1
grade)~3
unweighting.~1
(mg),~1
(mg/muscle~1
muscle),~1
mg/muscle~1
sulfhydryl-containing~1
(GSH).~1
GSSG)~1
140-fold~1
phosphagens,~1
phosphorylase.~3
contraction).~1
Pi.~1
cross-bridge~1
723~1
vol%).~1
(CAO).~1
(Pga)~1
CAO,~1
Ppl~2
cmH2O).~1
Pga.~1
(671~1
17.2,~1
cmH2O.l-1.s~2
(Qc)~1
Qc~3
(COID)~1
1-s~1
[Qc(C2H2)]~1
COID~5
Qc(C2H2)~3
(VRD/VI).~1
Rebreathing~1
VRD/VI~1
L1).~1
[end-tidal~1
Torr],~1
Hyperoxic~1
Isocapnic~1
NaCN~1
neuraxis,~1
inputs),~1
potentiates,~1
tracheostomized.~1
fine-wire~1
Bronchoconstriction~2
eucaloric~1
meat-free~2
glycosyl~2
units/kg~1
ultrastructures~1
exercise-training~1
18-mo-old~1
60-69~1
(ABD)~1
oscillations.~2
Sinusoidal~1
ABD~5
(VT~1
ABD/RC,~1
ABD/RC~2
progressively,~1
comparable.(ABSTRACT~1
(HET),~1
(UN-HET)~1
(ACC-HET)~1
(67.0~1
(75.15~1
64.80~1
g/h)~1
ACC-HET.~3
(15,~4
ACC-HET~1
(4.64~1
4.80~2
l/min).~2
acclimation.~1
(treadmill,~1
times/wk,~1
[rested~1
killed].~1
times/wk~1
D-carnitine,~1
beta-Hydroxyacyl-CoA~1
exercise-trained~1
carboxymethycellulose)-treated~1
(Te)-treated~1
(Co)-treated~1
(Te,~1
wt;~1
Co.~1
[3H]triamcinolone~1
acetonide,~1
glucocorticoid,~2
(52.9~1
Te-treated~1
acetonide-receptor~1
(RSBP),~1
[40-70%~1
(VO2max)]~1
Postexperimental~1
[SR:~1
SS:~1
ml.min-1~1
RSBP~2
(NT~3
(LT50)~1
Hyperoxia~1
H2O2-mediated~2
3-amino-1,2,4-triazole.~2
air),~1
(normobaric~1
air).~1
catalase-H2O2~2
3-amino-1,2,4-triazole~1
[H2O2]~1
ATA-1~1
[O2],~1
[O2]~1
O2-induced~1
Oxidant~3
xenobiotics~4
paraquat.~1
631%~1
surface-associated~1
(Zrs)~1
(ZL),~1
(ZW)~1
ZW~2
ZL.~1
dependent:~2
kPa.l-1~1
mildly,~1
ml/kPa~2
monotonously~1
4.19~2
1.93~2
non-Newtonian~1
(AN),~1
(GG),~1
(Di)~2
laryngectomized,~1
z-scores~1
Emerson~1
cuirass,~2
transrespiratory~1
(DNP).~1
Arterial,~1
DNP~2
energy-using~1
pumps.~2
Pikes~1
18-44~1
4-12)~1
400-450~1
(msw).~1
alpha-activity,~1
microsleep~1
traces)~1
4-5%~1
(Na+),~1
(K+),~1
(Ca2+),~1
(Mg2+),~1
(Cl-)~1
(soleus,~1
plantaris,~2
gastrocnemii)~1
(INAA)~1
(AAS).~1
(ECFV)~1
[3H]mannitol,~1
[14C]mannitol,~1
(PEG,~1
900,~1
PEG-900)~1
(ICFV)~1
biopsied,~2
freeze-dried,~1
PEG-900~2
mannitol;~1
ECFV.~1
(TTW),~1
ECFV,~1
ICFV,~1
plantaris)~1
TTW~2
(758~1
(6.5-8.5%~1
TTW)~2
ICFV;~1
(766~1
(10-15%~1
ICFV.~1
INAA~1
(VmaxFRC)~1
jacket.~1
VmaxFRC,~1
VmaxFRC~6
(ml/s)~2
2.47,~1
FRC-corrected~1
FRC's/s~1
FRC's/s)~1
(2.51~1
FRC's/s).~1
lung-size~1
12.2%,~1
20.0%.~1
dysanapsis.~1
dysanapsis~1
equidimensional~1
acetylcarnitine.~2
acetyl-CoA/CoA~1
(Aubier~1
460-4,~1
mg.kg-1~2
Plasmatic~1
extra-alveolar~1
ferrets,~1
(-5~2
ml.kg-1~2
(Palv)~1
[inspired~1
Torr]~1
(PIO2~1
Palv.~3
Ppa/delta~3
Q),~2
pressure-axis~1
(Ppa0),~1
Ppa0~2
(LBV)~1
LBV~2
Torr;~1
LBV.(ABSTRACT~1
microphotometrically~1
urethan~7
smoke-induced~1
(FITC-D)~1
FITC-D~1
days/wk)~2
[1,335~1
1,414~1
SE)]~2
(1,155~1
Myofibrillar~1
(hPTH)~1
antiamino-terminal~1
hPTH,~1
antimidregion~1
acridinium~1
luminometer.~1
Luminescence~1
hPTH-(1-84)~1
rapidity,~2
28K~2
nonreduced~2
amino-terminus~1
(BP-28)~1
[Ka,~1
6.55~1
L/nmol~2
IGF-II],~1
sites/mol~1
BP-28~6
53K~2
(BP-53)~1
BP-28,~1
BP-53.~2
BP-53~4
Transsphenoidal~1
18-hydroxydeoxycorticosterone~1
(18-OHDOC),~1
(Cosyntropin)~1
ACTH-dependent~2
17-deoxypathway,~1
18-OHDOC,~1
subnormally~1
18-OHDOC~2
Supraphysiological~1
ARC,~2
17-deoxysteroids~1
harbinger~2
arterial-venous~3
C-peptide.~2
107%,~1
(67%,~1
278%,~1
328%,~1
19-26~1
64-74~1
[3H]EPI~1
microCi/m2~1
microCi/m2/min~1
(1.38~1
cabergoline~1
adenoma).~1
600-micrograms~1
400-micrograms~1
puerperal,~1
chips,~1
cold-sensitive~2
mouths~2
dispersal~1
Tritiated~3
cDNA,~17
cDNA-probed~1
spermatozoa/mL.~1
endotoxin),~1
3-aza-lipid~3
diamino-analogue,~1
LPS-induced~5
(0.25-0.75~1
dP/dtmax-end-diastolic~1
(dE/dtmax),~1
dE/dtmax~2
inotropes~1
plasma-replete~1
volume-expanded~1
(dDAVP)~1
end-proximal~1
dDAVP,~1
somatostatin-infused~2
micropuncture,~1
dDAVP~1
secretion)~2
(BBM)~1
L-alanine~1
(1913~1
sidedness~1
BBM~4
sphingomyelin-to-phosphatidylcholine~1
(SPH/PC)~1
cholesterol-to-phospholipid~2
pmol/mg;~1
(418~1
46;~2
ischemic-induced~2
SPH/PC~1
fluidity.~2
BBM.~1
(HFF).~1
(MCCM)~1
MCCM~3
HFF.~1
Anti-PDGF~1
MCCM,~1
(33-41%)~1
coelutes~1
Cation~1
PDGF-like~10
MRL/Mp-lpr/lpr~4
anti-Sm.~2
5-mo-old~2
MRL/lpr~17
C57BL/6-lpr/lpr~1
MRL~4
variable-region~4
transmute~1
pteroylmonoglutamate~1
5-methyltetrahydrofolate~1
5-formyltetrahydrofolate~1
amethopterin.~1
Age-dependent~1
proteins),~4
(T3S)~1
(PTU)-sensitive~1
deiodinase.~1
T3S~6
T3S.~2
nonconjugated~1
iodothyronines,~1
TCA-soluble~1
T3S,~1
PTU-treated~1
Flux~2
8.3,~2
16.7,~1
Branched~1
counter-regulated~1
acids.(ABSTRACT~2
energy-based~1
operator-dependent~2
(electrode-subject~1
interface),~1
energy-~1
current-based~2
(protocol~2
impedance),~1
redefining~1
(NB),~1
(paNE),~1
(iaNE)~1
(FAVR)~1
(NE-EC30,~1
FAVR,~1
alpha-tone,~1
-21.3~1
-14.9~1
hypertensives.~2
alpha-tone.~1
iaNE~1
FAVR~1
(reactivity)~1
"nonspecific"~1
five-sixths~1
(MP).~1
benzazepril.~1
postictus~1
[K]0~1
(gk).~1
nicorandil~2
(10(-9)-10(-7)M)~1
gk)~1
hyperpolarized~4
(dmPGE2),~1
(MHV-3).~1
Fully~1
BALB/cJ~5
MHV-3~1
1,402~1
IU/liter).~2
dmPGE2~3
ALT,~1
dmPGE2-treated~1
-untreated~1
(10(-4)-10(-8)~1
10.0.~1
mU/10(6)~2
dmPGE2.~1
dmPGE2,~1
desmopressin,~2
spray.~2
velocimetry,~1
desmopressin;~2
Desmopressin~1
(520~1
(potassium,~1
messenger,~2
(cAMP),~1
(scc)~1
adrenodoxin.~1
8-bromo-cAMP,~3
8-bromo-cAMP-stimulated~1
adrenodoxin~1
machinery,~1
aspirator,~1
mammographical~1
microdissection.~1
cytokeratin,~1
transformation;~1
semi-automated~1
unfavourably~1
coliform~1
(72.5%)~1
polymorphs~1
(lipofuscinosis),~1
systematic,~2
ceroid.~1
Seltzer.~1
Triceps~1
papulosquamous~2
dactinomycin,~1
decarbazine.~1
polydactylous~1
Seven-eighths~1
piezogenic~3
heels.~1
consecutively,~2
(47.0%),~1
seen:~2
eruption"~1
versicolor,~1
dermatophyte,~1
butyl~4
methoxydibenzoylmethane~4
padimate~5
erythemogenic~3
8-methoxypsoralen.~1
(indoors)~1
(outdoors).~1
octyl~2
oxybenzone,~1
Sunscreen~1
sunscreen-protected~1
indoors~1
hypoacusis~1
Kauai~1
123/100,000,~1
latitude,~1
Nonmelanoma~1
reportable~1
overdiagnose~1
pyodermas,~1
scabies,~1
underdiagnose~1
rosea,~1
mandatory:~1
Tzanck~1
ectoparasite~1
handles~1
pilomatrix~1
"shadow~1
incompletely,~1
Rothmund-Thomson~1
order)~1
poikiloderma,~1
sparseness~1
epithelioma,~1
Phototesting~1
Thomson~1
traits.~2
Cowden's~1
genodermatosis~1
dyscrasia~1
panniculitis.~1
bright,~1
uncombable~1
trianguli.~2
HCL.~3
pathergy.~1
Superpulsed~1
emit~1
superpulsing~1
vaporizational~1
superpulse~2
ELC~8
nonsun-exposed~1
(COPD-S),~1
(COPD~1
(1024~1
167)~1
COPD-S~1
(1072~1
(910~1
211,~1
trichloracetic~3
peeling.~2
epilation.~1
Anginal~1
inflations.~2
monitor-detected~3
(visible)~1
(recruitable)~1
cardiac-related~2
ml/m2.~2
ventricle;~1
13%).~2
(aVF:~1
-1.8~1
300.1~1
117.4~1
poststreptokinase~1
(49.2~1
cardiomyopathy),~1
(%/h)~1
(anterior,~2
0.0005;~1
0.13;~1
0.047).~1
right-sided,~1
awake.~4
Predictors~3
induced)~1
0.0089~1
induced).~1
atheroma)~1
undistensible~1
intraintimal~2
nonthrombosed~1
canal-like~1
(534.4~1
425.6~1
(believed~1
hyperventilation)~1
cardiomyopathy;~2
endomysial~1
Slightly~2
acylcarnitine.~1
tachycardia);~1
amiodarone)~1
angiocardiogram.~1
ventricles)~1
rhabdomyomas~1
multiple).~1
oldest).~1
normal.(ABSTRACT~1
inhibitor--slow-release~1
hours)--on~1
placebo:~2
pyridostigmine:~1
101.9~1
pyridostigmine.(ABSTRACT~1
lensed~2
craters,~1
(rim~1
vacuolization)~1
Postreperfusion~1
(sonomicrometers)~1
released;~1
ml/(min~1
holosystolic~6
6.0%).~1
45.9~2
(72.7~1
(3.34~2
beta-ATP~1
0.39)~1
PCr,~1
echo-pulsing~1
(1.05)~1
nonbeating~1
slices:~1
image)~1
0.99X,~1
3.14.~1
(SEE~5
13.03~1
19.03)~1
(A/V~1
arrhythmogenicity,~1
preshock~1
mA).~1
J);~1
asynchrony,~2
(relaxation~1
constant),~1
(segment)~1
(minor~1
dimension)~1
(micromanometer)~1
aeroallergens~2
rat-sensitive~1
2-euglobulin~1
"prealbumin"~1
fur.~1
monomethoxy~1
(mPEG)-modified~1
HBV-specific~1
sting;~1
mPEG-HBV-treated~2
HBV-treated~3
mPEG-HBV~2
SRs.~1
(31.2%),~1
dust-induced~1
chopped~1
(B4,~1
D4,~1
grain-dust~1
hormone-related~5
anti-IgE-induced~2
0.088).~2
Solenopsis~1
invicta~1
(PCN)~1
PCN~2
penicilloyl~1
buret~1
desensitizations~1
(H2),~1
5'-guanylylimidodiphosphate,~1
12-myristate~28
13-acetate~27
PMA-induced~9
4,5-diphosphate.~1
(V30P),~1
(PC35SGaw)~1
V30P~3
(PC30V30P)~1
PC35SGaw~1
PC30V30P~1
lately~1
Laennec~1
"epidemic"~1
3.6/100,000~1
0.35/100,000~1
0.39/100,000~1
"corticophobia,"~1
homeopathy~1
dies,~1
underuse,~1
overuse,~1
gesture~1
hypotheses.(ABSTRACT~1
implementors~1
barriers,~5
fiber's~1
touted~3
ills~2
Water-soluble~1
gums,~2
Water-insoluble~1
Wheat~2
hemicellulose;~1
unrefined~1
breads~1
vegetables.~1
Vegetarians~1
laxation;~1
simplistic~1
causality.~2
weight-control~1
lb)~1
for.~2
no-dairy-products~1
cider~1
vinegar,~1
honey~1
harmless,~1
videodisc~1
learners~2
LIFESTEPS:~1
Management,~1
programmming~1
feeding;~1
cues--physiological,environmental,~1
cognitive--are~1
self-regulating~1
Inputs~1
communicators~1
(Nutrition~1
Communicator~1
Inputs)~1
receivers~2
(Receiver~1
Inputs).~1
communicator~2
receivers'~1
(knowledge),~1
(attitude),~1
student-student~1
educator~2
marketer~1
consumer,~1
"pay,"~1
gathering,~1
formulated,~1
segmenting,~1
budget,~1
commitment,~1
ingenuity,~1
creativity.~2
receiver-assisted~5
pamphlet~3
sender-produced~1
garnered~1
continuation,~1
miscue~1
neighborly,~1
sensible,~1
Semantic~1
version,~1
racially~2
audience.~1
You,~1
beautiful~1
inabilities~1
"be~1
be."~1
Your~1
mine~1
minds~4
Challenges,~1
Change--a~1
heroes.~1
yours?~1
Mine~1
Pogo,~1
said,~1
"I~1
insurmountable~2
opportunities."~1
involutional~2
(macrofollicles)~1
hyperplastic-dysplastic~1
(microfollicular)~1
certain.~3
(micronodular)~1
microfollicular~4
micronodules~1
microfollicles.~1
micronodules.~2
involuting,~1
microfollicles,~1
Involuting~1
(cystic)~1
microfollicles~3
micronodules,~1
involuting~3
macrofollicles.~1
cytokines~21
macrofollicles~1
follicles.(ABSTRACT~1
underidentified~1
(MAST)~2
(UMAST),~1
versions:~1
MAST~9
(BMAST)~1
(SMAST)~1
UMAST~2
BMAST~1
pap~1
uncovers~2
protein/100~4
protein/g~1
proline-rich~1
Culture-passage~1
uracil-DNA~2
glycosylase,~1
presenescent~2
dysregulated~1
glycosylase~2
G0~2
Werner~1
(WS)~1
thermolability~1
WS~1
(Nv),~1
(Sv)~1
E-PTA~1
supragranular~1
month),~1
Hydergine-treated~1
Nv~1
Sv~2
Hydergine~2
(Codergocrine~1
mg/Kg/day~1
differentially.~1
Hydergine,~1
hexosemonophosphates~1
(HMP)~1
HMP~2
dephosphorylate~1
(G6P).~1
(G6Pase),~1
domain-specific~2
moderated~2
controllability~2
Domain-specific~2
attribution~2
self-blame,~1
Controllability~1
self-blame~2
(traditional~1
sex-role~1
(nontraditional~1
knowledge).~1
impression-formation~1
nontraditional~2
schema~4
(CT,~1
noisier~1
(CNSs)~1
picture-identification~1
Kahn~1
Antonucci~1
718)~1
closeness,~1
proximity,~2
received)~1
objectivity/subjectivity~1
1975-1980~1
Census.~1
(SMSAs)~1
(NonSMSAs)~1
movers~3
Suburban~1
movers'~1
locational~1
45-~1
youthful~1
364),~1
822),~1
209).~1
(SHEP)~1
protocol--pill~1
assay--all~1
randomization.~2
Pill-taking~1
Ambulation~1
doors,~1
Capitalizing~1
doors.~1
tape)~1
exit-door~2
wandering~2
famotidine,~2
1,031~1
h.s.,~4
b.i.d.,~5
crater.~1
h.s.~3
"per~1
protocol"~1
ulcer-related~1
attests~1
Nonantisecretory~1
hiccups~2
Hiccups~1
vasoactive-agent-induced~1
metaraminol~1
"Valium~1
tablets"~1
ambulances~2
Ambulance~1
Portland,~1
facilities'~1
ecchymoses.~2
John~2
Bryant,~1
turn-of-the-century~1
Guy's~2
Inhibited~1
actin-containing~1
conjugate-forming~1
NK-resistant~11
NK-sensitive~7
contact-mediated~2
4-hydroxy-3-nitrophenyl~2
Inducer~1
(Tsi)~1
(old)~1
NP-conjugated~2
(SC).~2
NP-SC-injected~1
(Tst).~1
(Tse).~1
(HRBC)~1
HRBC-primed~1
anti-NP~2
anti-HRBC~1
PFC.~2
NP-specific~3
Tsi~2
Tst~3
age-matching~1
Tse~1
(Nbr).~1
IgE/ml)~2
(17,000~1
27,000~2
Nu/nu~1
IgE/ml~1
Nbr~3
C57BL/6-beige~1
Nbr-infected~1
Xid+~1
(CBA/N;~1
(CBA/N~1
Xid-~1
preinfection~2
nu/nu+~1
Nu/nu+~1
SJL~9
myelomas~2
RF/total~1
myelomas.~1
pepsin-digested,~1
RF-containing~1
farinae,~1
(BALB/c)~4
(Mab),~1
2/53~1
Epitope~2
nonrepeated,~1
(25/35)~1
anti-Der~2
(16/18)~1
cross-inhibition~1
Mab,~4
10B9,~1
4C1,~2
79.5%~1
10B9~1
repertoires~1
(C4)~2
(Slp)~1
Slp.~1
(C4-like)~1
Slp-constitutive~1
B10.WR.~2
C4-like~2
B10.WR~2
C4/Slp~1
t62~5
allotypes,~3
t63,~2
alloantisera~3
(t61,~1
t63)~1
t-locus.~1
PAGE,~2
allotype;~1
t61~2
allotype.~2
t63~1
t61.~1
C1-INH~2
C1s~8
Kinetics~4
C1r~5
C1s.~4
PMSF,~1
PMSF~2
C1-INH.~3
complexes:~1
IgM-human~1
Neutrophil-derived~1
HRA-N,~1
PMN/ml~1
RBL.~2
HRA-N~9
(EOS)~1
EOS,~1
release).~1
EOS~1
Filarial~1
fractionate~1
lymphocyte-stimulating~1
(Superose-12).~1
filaria-specific~1
mitogenic.~2
host-parasite~2
(SAA1~1
SAA2)~1
introns~15
CA/GT~1
(SAA4)~1
SAA1/2~1
(SAA3)~1
(NK~1
CMC).~1
(NKCF).~1
NKCF-binding~1
NKCF.~5
rigidification,~1
fluidization~2
Rigidification~1
abrogates~3
casein-treated~6
Splenocytes~1
DNP-Ficoll~1
dinitrophenyl-Ficoll~1
lymphokine-containing~1
(NWL)~1
5-mo-old,~1
(CN)~2
NWL~5
A-stimulated~7
splenocytes,~1
leads--concomitantly~1
peak--to~1
A-mediated~1
immune-neuroendocrine~1
"forbidden"~1
C5b-7~3
C5b-8.~1
C5b,~1
alpha-subunit.~3
C5b~5
C5b6.~1
C5b-8,~1
C5b.~1
Neuraminidase-treated~1
(NT)-PMN~1
[3H]FMLP~1
NT-PMN,~1
[3H]FMLP-associated~2
Subcellular~3
NT-PMN~2
Golgi-containing~1
reexpress~1
recycle)~1
FMLP-induced~2
recycling)~1
trafficking~2
desialated~1
(LPS)-responsive~1
(Lpsn)~1
aged"~1
(IFN)-alpha/beta~1
LPS-hyporesponsive~1
(Lpsd)~1
C57BL/10ScCR~2
Lpsd~6
IFN-alpha/beta~4
Lpsn~4
cellfree~5
LPS-treated~1
anti-NA~1
anti-H3~2
H3N1,~1
H3N2,~1
H3N7~1
anti-N2~1
HA-influenced~1
N7~1
NA.~2
piebaldism~1
take.~1
isobutylmethyl~1
xanthine.~1
P3U1~1
(BALB/c~6
biodistribution.~1
(tumor:blood~1
4-hydroxylase~1
galactosylhydroxylysyl~1
keloids,~1
secretagogues~5
Lesional~2
31.1%~2
anaphylotoxin~1
39.8%~3
melanocyte-stimulating~1
(alpha-MSH)~1
melanogenesis~2
(C57BL/6JA~1
[Nle4,~1
D-Phe7]-alpha-MSH~1
Ac-[Nle4,~2
D-Phe7]-alpha-MSH4-11-NH2~1
D-Phe7]-alpha-MSH4-10-NH2,~1
pheomelanogenesis~1
eumelanogenesis~3
alpha-MSH.~1
melanotropin~2
melanotropins~1
nonbiodegradable~1
hypopigmentary~1
sulfoxide's~1
(ara-A)~1
Solubilities~2
ara-A~4
DMSO-water~1
ara-A's~2
configuration)~1
(asymmetric~1
configurations),~1
cross-currents~1
exaggeratedly~1
DMSO's~1
brown,~1
Q-switched,~1
nsec,~3
(EM).~2
ash-white~1
Dermal-epidermal~1
lucida,~1
hemidesmosomes~2
melanosomal~2
melanin-specific~1
melanin-dependent,~1
epicutaneously~1
urushiol~3
3-n-pentadecylcatechol~1
(PDC),~1
antigen-specific,~11
PDC-immune,~1
contaminants)~1
phosphatase-negative~1
[41%]~1
adherent;~1
shunt--38%~1
(CNST)~1
most-common~1
slime-like~1
CNST~8
non-slime-producing~4
CNST.~1
Shunt~1
Discriminate~2
radiometrically~1
Vaccinia~2
[3H]thymidine-labeled~2
Hexose~1
[14C]1-glucose~1
intraphagolysosomal~1
Pock~1
(CMV)-encoded~1
higher-molecular-mass~1
(50-215~1
kDa)~19
Regulators~1
Inhibitor~4
(OMI)~1
Meiosis~1
Inducing~1
intrafollicular~1
echoes,~3
four-cell~5
pregnancies/transfer~2
pregnancies/transfer)~1
pregnancies/transfer).~1
postinsemination.~1
fast-cleaving~1
slower-cleaving~1
anucleate~1
pellucida.~1
50.7,~1
Fertilized~1
(81.0~1
53.3)~1
47.3).~1
inseminate~1
zonae,~1
correlate.~1
gonadotropin/human~1
oocyte-corona-cumulus~1
(OCCC)~1
resort.~2
infertility's~1
coaster~1
surprisingly,~2
shaker-1~1
(ABEP)~1
ABEP~4
dBHL~1
10/sec~1
40/sec.~1
psychoacoustic~1
psychoacoustically~1
ABEP,~1
Walkman~1
mini-stereo~1
masker.~1
[ADH]~1
hypothyroid-induced~1
Pseudodysphagia~1
throat--commonly~1
Otolaryngologist~1
investigations--provided~1
supraglottis.~1
hystericus~1
outdated~1
pharyngeus~2
keratinising~1
footplate.~1
cerebello-pontine~1
sensori-neural~1
goitre.~2
Perchlorate~1
Pendred's~1
Bithermal~1
jugulo-digastric~1
hypernephroma~1
1966).~1
haemangiopericytoma~2
invest~1
Stout~1
ultramicroscopic~1
otolaryngological~1
(Ballantyne,~1
Groves,~1
actinomyces~2
israelii.~1
Actinomyces~1
commensals.~1
gram-positive,~1
acid-fast,~1
(Walker~1
1981;~2
Bennhoff,~1
hemophilus~5
symbiosis~1
furthers~1
(Bennhoff,~1
Topographically,~1
favorite~1
localizations:~1
Cervico-facial~1
Abdomino-pelvic~1
Pulmo-thoracic~1
spheno-ethmoidal~1
vasectomies.~3
vasectomies,~1
sedative;~1
(FEF25-75),~2
five-week~1
(NAMCS),~1
Specific,~2
drafting~1
suicidal,~1
nonsuicidal,~1
nonsuicidal~2
Ideation.~1
suicidally~1
(UNI,~1
(BPD,~1
55),~1
(UNI/BPD,~1
UNI~3
noncomorbid~2
syndromal~1
comorbidity.~2
(HRSD)~1
(HARS)~1
cross-validated~1
(TCA),~1
Mein~1
Cambodians~2
Mien.~1
"therapeutic"~2
Asians.~1
Eighth~1
(POWs)~1
imprisoned~1
(non-POWs).~1
non-POWs~1
POWs.~1
present-day~3
Moods~1
(FMI)~1
FMI~1
(chocolate~1
73),~1
172),~1
"self-medicating"~1
hysteroid~1
dysphoria,~1
compulsively,~1
chocolate,~1
nonwork~1
ruminations,~1
VEPs.~1
administer)~1
ganzfeld~1
(ERG):~1
short-wavelength~1
tracking.~1
(CCT).~1
square-wave~5
stimulator.~1
phalange~1
Edinburgh~1
right-handers~1
73.5%~3
lateralization.~1
neuromyotonia,~1
"late~1
response"~1
(LRR),~1
myokymic~1
melancholics,~1
manics~1
bifrontal,~1
non-dominant~1
affectively~1
temporo-parietal-occipital~1
hypersomnolence~2
subside,~1
mammillo-thalamic~1
prosodic~2
lachrymation~1
SS-A~1
(SDAT),~1
Brodmann~1
neuro-ototoxic~1
SJL/J)~2
(immunized)~1
myotubes.~4
myopathies.~1
cell-skeletal~1
(Ia)~7
qua~1
HCl-induced~1
caveolae~3
myotoxin.~1
Tangier~2
syringomyelia-like~2
61.~1
cytons~1
uncolored~1
meat-type~1
1-40~1
droplets'~1
Remyelination~1
37.~2
riboflavin-based~1
coenzymes~1
flavin-adenine~1
(FAD)~1
DNA:DNA~2
JC~8
(JCV)~2
JCV~10
(PML).~1
PML~2
orthochromatic~1
(OLD)~1
OLD~1
oligodendrocytes.~1
ceroid-lipofuscinosis.~1
OLD.~1
Galactolipids~1
plasmalogens.~1
Morsier~1
septo-optic~1
adenohypophysis.~1
neurophysin-containing~1
CMF~2
fluorouracil).~1
CMF.~1
(surgery,~2
CMF,~3
1.8%).~1
mitoguazone~1
(THE).~1
esophagrams~1
adenocarcinoma)~1
adenocarcinoma).~1
NRs~1
histologies,~1
(RT).~1
vindesine~1
(CCNU),~1
(CTX),~1
overall)~3
limited-field~2
(RT),~1
Southeastern~1
(SECSG)~1
78-GU240~1
(PVB),~1
doxorubicin;~1
81-GU332,~1
(VP-16),~1
(PVP16B).~1
Goldie-Coldman~1
Price-Goldie-Hill~1
(vincristine~1
[VCR],~1
CCNU,~1
[Ara-C]~1
dacarbazine)~1
nonpolar~5
phase-specific~1
antineoplastics~1
protocol-specified~1
Taxol,~1
Priority~1
(Roferon-A,~1
Hoffmann-La~1
Roche,~1
Roferon-A~2
(TIW).~1
(gp240)~1
(ZME-018)~1
(diethylenetriamine~1
111In.~1
ZME-018.~1
(DFI),~1
52.3~1
11.6,~1
11.4,~2
17.9,~1
27.9,~1
cytosol);~1
(PMGCT)~1
(KS).~1
KS.~2
(IVAP)~1
forcipal~1
longsheath.~1
IVAP~1
(SLL)~1
SLL.~3
SLL~5
SLL,~2
(BCRP)~1
(WBC~4
50,000/microL)~1
68%;~1
65%).~1
(minimum~3
seventy-three~1
(SWOG)~1
(TF~2
.29).~1
SWOG~3
stricter~1
1,010~2
(Cox~1
N2-3,~1
forms),~1
important)~1
histoprognostic~1
Scarff~1
Bloom~2
radioimmunologically~1
Laminin~3
3F8,~1
(ADCC),~1
3F8~5
GD2~2
Toxicities~1
postantibody~1
IVS~12
(P-glycoprotein)~1
P-glycoprotein~9
P-glycoprotein;~1
P-glycoprotein.~3
1,000/microL).~1
noncancer~1
myelosuppressed~1
packages,~1
restructuring,~1
packages.~1
Interim~1
"trends"~1
Accrual~1
"group~1
trials,"~1
redesign~1
131I-6~1
beta-iodomethyl-19-norcholesterol~1
asymmetric,~2
(AVC)~1
(NP-59~1
AVC)~1
0.733)~1
(RAIU)~1
0.656),~1
0.494)~1
RAIU.~1
hemangioma/infantile~1
hemangioendothelioma)~1
technetium-99m-labeled~2
(GBPS)~1
GBPS~5
"halo"~3
150-500~1
(3/9).~1
GBPS.~1
Microfiltration~1
[99Tc]sulfur~1
cannot,~1
biotin-ureido~1
N-hydroxysuccinimidobiotin~1
chloramine-T~1
N-[beta-(4-OH-3-125I-phenyl)ethyl]~1
N-[beta-(4-OH-3,5-di~1
125I-phenyl)ethyl]~1
(n-butanol:~1
NH4OH:~1
3:1:1,~1
v/v/v).~1
avidin-binding~1
radioassays.~1
high-greater~1
Ci/mmol-and~1
(201Tl)~2
Monolayers~2
201Tl.~1
Perfusates~1
CO2-95%~2
formulae.~1
t-tests.~1
(N.S.);~1
Yttrium-90~1
radioimmunotherapy~1
90Sr.~1
90Y-labeled~2
90Y~4
radiolytic~2
Dowex~1
0.003M~1
ethylenetriaminetetraacetic~1
eluant,~1
0.002%.~1
0.5M~1
mCi/mg~3
labeling).~1
Triple~2
stannous~5
([Tc]SFC).~1
(LRP)~1
MP-gradient~1
[Tc]SFC.~1
"solubilize"~1
[Tc]SFC,~1
[Tc]SFC~2
Technetium-labeled~2
reoxidation~1
pertechnetate.~1
Biomedical~3
E.I.~1
du~4
Pont~3
Nemours~1
cobalt-57~2
NBS~3
5-ml~2
ampoules,~2
syringes,~2
Du~2
27-ml~1
Vial~2
epoxy-~1
solution-filled~1
containers,~1
Capintec~1
Radcal.~1
radionuclides~5
ampoules~1
calibrator~1
radionuclides,~1
ampoule~1
49-yr-old~1
sciences~1
repeatability~3
omega-6~3
N/kg,~1
N-free~2
Soybean~1
excreta.~2
(diets~2
34.8,~1
N/kg).~1
1-3)~2
(calculated),~1
(calculated)~1
tested),~1
hyperproliferation.~3
gamma-linolenic~1
(18:3n-6)~1
(20:5n-3)~1
primrose~3
18:3n-6)~1
20:5n-3)~1
(EFA)-deficient~1
5-desaturase~1
hypergranulosis~1
EFA-functional~1
18:3n-6~1
A-depleted~1
(REq)/d~1
REq/d~1
A-deprived~1
A-replete~2
Yearling~1
(Salmo~1
gairdneri)~1
Transketolase~1
thiamin-deficient~2
12-151~1
Zn/kg~2
65Zn-labeled~1
ZnCl2.~1
interacted,~1
(33-35~1
Fe/g~2
(15-25~1
(2441-2470~1
(1408-3042~1
65Zn.~1
(cornstarch~1
Zn/g)~1
29-d~2
copper/kg~2
F-Cu~1
F-Cu-fed~1
copper-deficient,~1
(HgCl2)~1
(CH3HgCl)~1
[Na2(75)SeO3,~1
Na2(75)SeO4,~1
L-[75Se]methionine~1
([75Se]Met)]~1
3-wk-old~1
75Se,~1
0-1.0~1
75Se~1
[75Se]Met~2
Methylmercury~1
[75Se]selenite~3
Precipitation~3
75Se-selenite~1
(0-500~1
[75Se]Met,~1
manyfold~1
pups)~2
(14-16~1
Underfeeding~1
mild-IUGR~2
non-IUGR~1
severe-IUGR~1
dams;~1
immunocompetence~3
sufficient)~1
(MOSF)~1
MOSF~7
MOSF.~1
sepsis)~1
male).~1
bimodal;~1
28.8),~1
91.6).~1
variables--microcephaly,~1
chorioretinitis--when~1
intelligence.~1
Knowles~1
co-workers.~2
(PDmax)~1
(PDmean)~1
palm,~2
PDmax~1
PDmean~1
non-CF~2
1978-1984~1
resolution:~2
cardiac-induced~1
obstruction-induced~1
sighs~1
(PVLs)~1
PVLs~2
36.30~1
33.53~1
noninfiltrated~1
Infiltration~2
verus~1
0.014),~2
gravity-controlled~1
0.51)~1
infiltrations.~2
(VI~1
nonsurvivors)~1
37.3%~1
phosphorus;~2
fortifier,~2
0.104~1
Xanthine~1
waiving~1
primipara~1
kaliuresis~1
(13.6%).~1
early-second-trimester~1
25-28~3
(17/21)~1
Anesthesiologists~1
mesosalpinx.~1
Postoperative,~2
1.13-1.24~1
kg/24~2
0.7-0.9~1
anti-bacterial~1
lactoferrin)~1
46,XX,~2
transphalangeal~1
(Holt-Oram~1
pericardiectomy.~2
lymphangiomyomatosis,~1
(beta-hCG)~2
mIU/mL.~1
tenuous~1
ecosystem~1
Toxins~1
defences~2
non-RA.~1
plaminogen~1
weights:~1
90,000,~1
33,000.~1
dominantly.~1
urokinase-type.~1
beta-Methasone~1
activators.~3
chloroquine.~2
chloroquine/day~1
Seropositive~2
(Western~2
blotting),~1
bindable~1
(SPBIg)~1
(7.0-60~1
Ig/platelet)~1
kDa).~7
HLA-Bw35~1
S2-serotonergic~2
synoviocytes.~1
synoviocytes,~1
synovitides.~1
synoviocytes~1
phlogistic~2
(Mn),~1
(Fe).~1
(Sr)~1
(Cu)~1
conspiciously~1
Sr~3
Mn.~1
Fe.(ABSTRACT~1
innominate,~1
(osteoarthritis,~1
GOA),~1
etiopathogenetic~1
lubrication~1
hindfoot,~1
enquiry~1
footwear~1
r(18)(p11.3;~1
q23)~1
del~1
(18)(q21.2;~1
q22)~1
Pathogenetic~1
polysynovitis~1
(PMR)~1
PMR.~1
midback~1
spondylodiscitis~3
Monoarthritis,~1
monoarthritis,~1
insults.~1
conjectural~1
destabilization~2
Macroscopic,~1
perichondrocytic~1
hyaluronate:~1
richer~2
(CSRPG);~1
(KSRPG).~1
CSRPG/KSRPG~1
Proteoglycan~1
(CAPAGE).~1
CAPAGE,~1
CSRPG,~1
contusive~1
patella,~1
condyles,~3
post-contusion~1
Synovium~1
tendotomy.~1
polysulfuric~1
(GAGPE)~1
osteoarthritis-like~1
Pond-Nuki~1
antidegenerative~2
macroscopical~1
antiosteoarthritic~1
hens~1
Salicylates~1
chondrocyte.~1
non-reparative.~1
proteoglycan-rich~1
cartilage-derived~1
(90-95%~1
cartilage-specific~1
1-2%~4
short-helix,~1
herald~2
L-ascorbate,~1
CTAP~1
Ib,~3
("matrigenin"~1
matrigenin~2
chondroitin-6-sulfate~1
400-600~1
Kdaltons.~1
(repair)~1
moieties,~1
Autoimmunity~1
"arthrogenic~1
epitope(s)",~1
Deposits~2
autoimmunity;~1
sulfate-rich.~1
fastening~1
geodes~1
Variabilities~1
(AAMC)~1
AAMC~1
coordinators~3
clerkships,~1
rank-ordering~1
Rank-ordering~1
mid-1980s.~1
(HMOs)~2
"gate-keeper,"~1
eligibility,~1
1985-86~1
preceptorships,~1
outpatient-oriented~1
students)~2
CPS.~1
CPS,~2
call,~1
bleakest~3
"High~1
quality"~1
night-float~1
slept.~1
freshman-level~1
Analytic~2
decision-making.~1
organizers~1
acknowledge~3
"addictive~1
disease."~1
denotative~1
"disease"~1
symbolic~1
turpitude~1
"diseases."~1
athletics,~1
legalities~1
"New~1
Roads"~1
connects~1
intends~1
(DUI)~1
(out~1
140)~1
"client's"~1
"client"~1
bases.~9
psychoanalytic-developmental~1
freebase~1
articulate~2
post-detox~1
Residential~1
(TCs)~1
crack~1
inheritability~2
(genetic)~2
nonalcoholic,~1
predisposed)~1
drinking)~1
therein~1
pre-urology~1
diplomates,~1
urologists.~1
8,236~1
angiomyolipomas.~1
angiomyolipomas,~1
revolutionizing~1
982~1
(percutaneous~1
nephrostolithotomy.~1
Re-treatment~1
Post-treatment~1
(cystoscopy~1
nephrostomy)~1
complimentary~2
5.54,~1
enuresis~4
continence)~1
abacterial~1
cystitis)~1
mm.2)~1
urgency),~1
belongs,~1
Marshall-Marchetti-Krantz~1
urethrolysis~1
urethras,~1
epispadias,~1
ureteroceles~1
retraining.~1
pubovaginal~2
medication:~1
wet.~1
detrusor-related~1
compliance).~1
sphincterometry~2
post-distension~1
reconfirmed~2
hematuria)~1
fractionally~2
pyelography.~1
lithotriptors~1
pre-clinical~1
Sachse~1
urethrotome~1
impacted.~1
renographic~2
(18.5~1
intestinocystoplasty~4
(ileocecal,~1
patch)~1
Hyperchloremic~1
hyperchloremia~1
tubular-shaped~1
cystoplasties.~1
Intestinocystoplasty~1
priapism.~2
Surprisingly~2
sicklemic~1
nephrolithotripsy.~1
nephrostogram~2
pyelolysis.~1
Pyeloplasty~1
ureterocalycostomy~1
pyelolysis~1
carcinogens,~3
phyllodes~5
stuartii,~2
stuartii~6
uropathogenicity.~2
(factors~2
expressed)~1
uropathogenic~2
expressed),~1
non-uropathogenic~1
uropathogenicity,~1
uropathogenicity~1
CBA~15
(RPCT)~1
RPCT~3
(COM)~1
(COD)~1
rounded-up~1
microdiffusion~1
ng./mg.~1
apatite/struvite~1
zeolithic~1
antigen-antibody.~1
alpha-glycerolphosphate~1
(alpha-GPDH).~1
(wellferon)~2
microgram./ml.~1
IFN-beta~20
K+-solution~1
electrophoretograms.~1
corpora,~1
crossed.~1
ml./min.~1
undescribed,~2
antispasmotics.~1
flavoxate~2
oxybutynin~3
uM~2
bethanechol)~1
In-vitro~1
5.0+/-0.4~1
Flavoxate~1
uM),~1
uM)~1
50's~1
Imipramine~1
fmol./min.~2
VIP-release~1
might,~1
short-distance~1
(ACD)~1
(49.5~1
ACD~4
profundapopliteal~1
femoroprofunda~1
aorto-~1
ilioprofunda~1
axilloprofunda~1
(Dacron~1
(polypropylene~1
PTFE)~1
"healing"~1
watts).~1
CEs~1
hemisphere;~1
CE.~1
artery-related~1
Em.~1
2614~1
0.92%.~1
ileostomies,~3
stomata.~1
cystostomy.~1
high-riding~1
tensional~3
flexible-bottomed~1
point)~2
vacuum-operated~1
stress-providing~1
bottom.~1
deformation.~1
Core~2
AVF.~1
Angiodynography~1
(ADG)~1
ADG~3
(EMF)~1
EMF~1
ADG.~1
y-intercept~1
Veins~2
Leather's~1
situ"~1
(reversed)~1
pressures.(ABSTRACT~1
blurry~1
scotomata~1
distended.~1
(IRJV,N~1
(SRJV,N~1
(denudation~1
alterations).~1
IRJVs~3
endothelialized,~1
SRJVs~2
neutrophil,~3
popliteal-anterior~1
popliteal-posterior~1
popliteal-peroneal~1
tibial-peroneal~2
tibial-anterior~1
two),~3
vein-PTFE~1
PTFE-vein~1
(RVH).~1
fibrodysplastic~4
orificial~1
"temporarily~1
successful"~1
PTAs~1
nonorificial~1
Orificial~1
(FAAs)~1
FAAs~4
braided~1
FAAs.~1
5779~1
OCs;~1
nation's~1
teacher-to-learner~1
immense~1
critics~1
premises,~1
CME's~1
age-old~1
mission--to~1
care--has~1
unwieldy,~1
flawed,~1
strayed~1
mend~1
flaws~1
learner-oriented~1
6962~1
patient-days~1
PICUs.~3
groups--low-risk~1
early-discharge~4
patients--were~1
day(s)~1
0.894~1
0.547~1
Incidents~1
$200.~1
injury-accident~1
Darkness~1
intersection~1
heeded~1
obeyed.~1
Likert~2
cardiology)~1
non-internal~1
throat),~1
underemphasis.~1
knowledge/skill~2
interviewing)~1
assurance).~1
unmet~5
ambulatory-care~1
1979-1980~3
1984-1985~1
isolates)~2
1984-1985.~2
26%),~2
serotype,~2
heidelberg,~1
childbearing,~1
Teenaged~1
parenthood~3
programmatic,~1
N,N-diethyl-m-toluamide~1
(DEET)~1
repellent.~1
repellents~1
DEET.~1
(47.5%~1
(16.8~1
community-living,~1
125).~2
10.7%.~1
(24/175),~1
(8/125).~1
coral~3
snakebite~1
nonpoisonous~1
scarlet~1
king~1
snake.~2
precipitous.~1
Envenomation~1
Antivenin~1
snake,~1
preenrollment~1
SES~2
896%~1
(25/29~1
(3/29~1
(1/29~1
neurourologic~1
reinjury~1
reinjury.~1
in-study~2
(leukoaraiosis)~1
Binswanger~1
(SDBT)~1
SDBT~3
small-artery~1
Delirium~1
states),~1
anticholinergic)~1
sparse.~4
g/L~2
(anti-HBc)~2
pattern's~1
low-titer~1
(anti-HBs,~1
anti-HBs-positive~2
Price~1
Act,~1
(FDA)~1
approving~1
fraternity.~1
straw~1
fraternity~1
82%).~1
party.~1
hay,~1
silage,~1
fourfold.~3
Reuse~1
paO2~2
93.0~1
reused~1
Intradialytic~1
(DLCO,~1
30.70~1
8.89~1
23.77~1
(KCO,~1
5.65~1
reuse,~1
Percentual~1
paO2,~1
conditions.(ABSTRACT~1
CaCO3,~1
ketoacids.~1
changeover,~1
unabated.~1
bimonthly~1
phosphaturia~1
moderately-severe~1
halt~2
(HSAED)~1
fifty-fold~1
HSAED~4
(antiHSA)~1
HSAED-antiHSA~1
(AVP)-contracted~1
lyotropic~2
properties;~1
(CoA),~1
malonate.~1
nonfatty-acid~1
CoA,~1
DIDS,~1
diuretic-induced~3
-1162~1
microEq/100~1
(65.0~1
mg/day/100~1
(GEC)~2
poly-L-lysine~1
10-fold)~1
8-fold)~2
(LY)~1
(HP).~1
sulfide.~1
(C20:4)~1
masked.~1
C20:4.~1
(TXB2~1
supernatant).~1
stimulate--although~1
degree--TXB2~1
monoenoic~1
abundance:~1
palmitic,~1
tissues.(ABSTRACT~2
lisinopril~3
lisinopril,~3
Lisinopril~1
40%),~1
nearly-significant~1
lisinopril.~1
antiproteinuric~2
(postglomerular)~1
monthly;~1
IU/liter.~1
wt/day,~1
"set~1
point"~1
osmosis~2
treated-water~1
water-treatment,~1
aluminium,~1
Width~1
lipid)~1
sharpen~1
intussusception,~2
post-surgery.~1
neurosecretory-like~1
axon-like~2
1,673~1
1,497~1
node(s)~1
node(s).~1
node(s),~1
gliomatous~1
5/8.~1
temporoparietooccipital~1
(IOHT)~1
thoraco-abdominal~1
IOHT~1
LCF~1
25Gy.~1
Nb~2
noble~1
subrenal~1
(pleomorphic~1
adenoma)~1
(10:1)~1
expired;~1
blue-gray~1
nevus-cell~1
Adriamycin.~1
Somatostatinomas~1
somatostatin--diabetes,~1
maldigestion,~1
cholelithiasis--were~1
(Whipple~1
(21/31~1
Vater,~1
Chemotherapeutic~1
somatostinoma~1
Commissurotomy~1
stenosis:~1
(25.1%)~1
(17.6%).~1
(3.5%),~2
94.6%~1
(5.0%)~1
88.9%~1
91.7%~2
82.6%~1
tubes:~1
Neville~1
Tracheoflex~1
fasten~1
disease-free,~1
postresection,~1
surgically/pathologically~1
uniformity.~1
nonsquamous,~1
(346~1
nonsquamous~4
disfiguring~1
Dead~1
intraoperatively).~1
Phlebograms~1
cloth-covered~1
(Ionescu-Shiley~1
(size~1
cloth-covering~1
posts~1
ingrowth,~1
549~1
6120)~1
Louvain~1
(Belgium)~1
3,130~1
1.25%~1
1.08%~1
0.26%~2
(deaths~1
reoperations)~1
7,670~1
(6.7%),~2
(6.2%),~1
(5.9%),~1
(5.1%).~1
paralysis:~1
5.5%.~1
15.7)~1
reoperation;~1
septuagenarians~5
(27.3%)~1
(nontuberculous)~1
decortication,~1
thoracentesis,~1
(thoracostomy),~1
decortication.~1
Eloesser~1
Morphologic,~2
trileaflet~1
sheaths;~1
regurgitant.~1
ten-ring~1
reanastomosed~1
eight-ring~1
malacia~1
4,5,~1
inoperable.~1
719~1
lifesaving.~3
suicide--particularly~1
"accidents",~1
well-disguised~1
possessions,~1
Empathic~1
Cautious~1
conservatism~1
pollution.~3
nonconvulsive~2
pathophysiological,~1
pathopysiological~1
(HPRT),~1
(carrier)~1
haematoma.~1
cues.~1
broad-complex~2
asystole),~1
Gujarati~2
Muslim~2
sons.~1
doubt)~1
deduced.~5
blood-group~1
loci),~1
red-cell-enzyme~1
X-chromosome~11
non-maternity~1
Thai-Kampuchean~1
Khmer~1
small-intestinal~2
necroticans~2
(pigbel)~1
Beta-toxin-producing~1
hypoalbuminaemic~1
fluid-retaining~1
(sitting)~1
head-low~1
hypoalbuminaemia;~1
carcinoma-in-situ~1
Germ-cell~1
Archival~1
(DCBE)~1
DCBE~5
DCBE,~1
(SRSV)~1
ill-effects~1
"phenanthroline~1
copper"~1
metal-catalysed~1
antifertility~2
(mifepristone)~1
syncytiotrophoblasts~1
(hCG),~2
nmol-10~1
Karawa~2
Wasolo~2
laparotomies,~1
supracervical~1
hysterectomies.~1
nurse-surgeons~1
nurse-surgeons,~2
(10.5)~1
22(16)~1
(HIV)-1~1
1-anti-chymotrypsin,~1
ghee,~1
prized~1
cooking,~1
oxides~4
ghee~2
(12.3%~1
sterols),~1
butter,~1
high-performance-liquid~1
pontobulbar~1
(PBB)~1
(CN).~1
Kluver-Barrera~1
globular,~2
Neurons~4
PBB~4
angular.~1
took;~1
(medial~1
treatable,~2
(hypercarbia,~1
movement)~1
fraught~1
pharyngoesophagram~4
(94.1%)~1
pharyngoesophagram.~1
Delphian~4
(T1-T3),~1
laryngectomy;~1
"lethal~1
granuloma."~1
reticulosis~1
(NACE).~1
Uvulopalatopharyngoplasty~1
ARP's~1
cartilage-perichondrium~1
(SISI)~1
SISI~1
T1-characteristics)~1
Spin~1
Echo~1
nonossified~1
pharyngocutaneous~1
varicosities/telangiectasias~1
microtechnique,~1
Completeness~1
Sharplan~1
0.2-mm-diameter~1
sec/10~1
sec/mm~1
temperature-time~1
reconnected~1
Coherent~1
(1,700~1
W/cm2).~1
semithin~1
Re-endothelialization~1
myofibroblast~1
endoscopist.~1
aluminium-foil-wrapped~1
photoresection~1
laser-vaporizing~1
(6,500~1
cm3)~1
0.04%.~1
million;~1
45.6%~1
neglected.~1
(22/44),~1
(13/44)~1
infections.(ABSTRACT~1
hyperthermia).~1
Felty~1
characteristic;~1
hypergammaglobulinemia,~2
CD2+,~3
CD3+,~5
CD8+,~3
HNK-1+,~1
CD16-.~1
LGL,~3
uncertain:~1
antibody-mediated.~1
lymphoproliferation~5
spondylytic~1
(CSM)~1
abnormalties~1
C5-C6~1
radiculopathies~1
CSM~1
teased~1
VEPs,~1
heterozygotic~1
neurotization.~1
neurotization~3
(feeder~1
hypogravity~2
aboard~1
Spacelab~1
subsarcolemmal~4
myofilaments;~1
autophagy~1
Tripeptidylaminopeptidase~1
spaceflight,~1
3623~1
lone~4
illness),~1
thromboemboli.~1
1440~1
chronic).~1
88.0~2
19.4,~1
121.0~1
milliliter)~2
(24.0~2
6.5).~2
low-density-lipoprotein~3
Canadians,~1
cross-breeding~1
Canadians.~1
immunoglobulin-derived~1
8903~1
present);~1
1.22;~1
1.59).~1
1.35).~1
black:white~1
(black:white~1
secular~7
AS)~1
enlisted~1
non-sudden~2
recruits),~1
non-hemoglobin~1
Gould~2
Shaffer~2
fictional~3
televised,~1
broadcast~1
Pennsylvania.~1
televised~2
mediums~1
6763~1
(methylprednisolone,~1
two-dose~2
one-dose~1
hives,~1
0.055).~2
699~1
PSA--but~1
PAP--appeared~1
(294~1
Condylomata~3
acuminata,~1
(64.4~1
(42.5~1
(41.2~1
(32.8~1
condyloma.~1
Genomic~8
codons~10
H-ras,~1
K-ras,~1
N-ras~6
metastasized.~3
unmutated~2
H-ras~1
geneticists~1
expectation,~2
Flynn~1
12.42~1
Morphogens~1
(DIF)~2
morphogen~1
prestalk/prespore~1
DIF-1,~1
microchemical,~1
1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone,~1
pattern-forming~1
Exocytosis,~1
'fusion~1
pore',~1
lumen-positive~1
a.c.~1
admittance~1
milliseconds,~1
H3.2~2
32-nucleotide~1
(nt)~2
nt~1
DNA-protein~5
cis-acting~11
alpha-keratin,~1
links.~1
radicals,~2
parings~1
Waals~1
Hydrophobic~4
bury~1
sinking~2
euphotic~1
sea.~1
abyssal~1
benthic~1
Stokesian~1
zooplankton~3
grazing~1
particle-reactive~1
sank~1
141Ce~1
144Ce,~1
grazing.~1
tall,~1
giraffe,~1
Giraffa~1
camelopardalis,~1
(gravitational)~1
giraffe~2
Briefly,~1
giraffes~1
(oedema)~1
radiotelemetry,~1
(treponemes)~1
widely-held~1
Columbus's~1
Inca,~1
Aztec~1
Mississippian~1
treponemal~3
Pleistocene~2
(dated~1
11,500~1
gill-~1
siphon-withdrawal~1
courses:~1
ion-channel~3
endures~1
post-translational.~1
magnocellularis,~1
septal-diagonal~2
septo-hippocampal~1
viral-associated~2
Euphorbiaceae~1
Thymelaeaceae,~1
gene-transfer~3
Nothing~1
DNA-bound~1
uteroglobin~1
helix-loop-helix~2
Myxococcus~1
xanthus~1
internally-duplicated~1
beta-sheet~2
erythraeus"~1
motifs~4
prokaryotes.~1
Careers~1
lists,~3
leavers~1
hard-headed~1
proton/oxygen~1
disagreements~1
H+/O~2
('slip'~1
pumps)~1
direct.~1
charge/O~1
respiring~1
octamer~9
ATGCAAAT~1
ATTTGCAT~1
well-conserved~2
non-tissue-specific~1
regions--like~1
U2~6
H2B~1
genes--where~1
canonical~3
motif~8
lymphoid-specific~1
lymphocyte-specific~3
decipher~1
intertwining~1
neuron-free~1
kainic~1
slice.~1
(12-O-tetradecanoyl-phorbol-13-acetate).~1
Protons~2
lipid-water~1
interfaces,~1
timescale~1
unbinding~1
L-type~2
deprotonation~1
protonatable~1
deprotonated~1
helix.~3
Tight,~1
overtwisted.~1
interconvert~1
folding~8
distinguishable.~1
cis/trans~1
multiplicity.~1
collagen-binding~2
cation-independent~2
mannose-6-phosphate~1
(InsP)~1
dihydropyridine-sensitive~5
co-infecting~1
(HBV).~2
co-infection~1
36-nm~1
(HDAg)~1
viroid~1
virusoid.~1
HDV.~2
delta-hepatitis.~1
chimpanzee-adapted~1
(ORFs)~1
anti-genomic~1
antigenomic~1
HDAg.~1
RuBisCO,~2
D-ribulose-1,5-bisphosphate~1
carboxylase-oxygenase~1
4.1.1.39),~1
photosynthesis.~1
L8S8~2
keg~1
keg.~1
RuBisCO~1
tabacum,~1
near-atomic~1
sliding-layer~1
Nature~5
Alcaligenes~1
eutrophus.~1
supervened.~1
dysphasic~1
forebrain.~3
3H-GABA~1
(contractures)~1
trichrome-stained~1
Electron-microscopy~1
ends,~6
Trimodal~1
Miller~1
(ataxia,~1
areflexia)~1
Electrodiagnostic~1
thenar,~1
lumbrical,~1
palm-to-wrist~1
(PTM).~1
PTMs.~1
PTM~1
(retinitis~2
ophthalmoplegia),~1
KDa~2
vaginam~1
nondopaminergic~2
timber~1
"fasciculations"~1
antivenin~3
(PSP).~1
50-90~2
counterclockwise,~2
around.~1
parasites;~1
ten-~2
3437~1
Walnut~1
Creek~1
Contraceptive~1
2656~1
woman-years)~2
(2.06~1
suggestive.~1
noncervical~1
6/11.~1
"condylomatous~1
vaginitis."~1
16-positive~1
Virologic~1
grayish~1
Papular,~1
spiked,~1
(6.9%).~2
Intravasation~1
intravasation.~1
AID,~1
AID~1
AID.~1
hospitalization-alone~1
stillbirths,~1
paracoagulation~1
-0.524)~1
Gas-liquid~1
byproducts~1
amnionitis,~1
GLCs~1
extra-amniotic~1
obstetrician-gynecologist,~1
obstetrician-gynecologist.~2
obstetrician-gynecologist~2
community-dwelling~1
investigator-designed~1
restrooms~1
proportionate.~1
Urogynecology~1
26-56~1
hysterectomy-oophorectomy~1
pistol-aspiration~1
1974-1981~1
Molluscum~1
contagiosum.~1
suppository,~1
hypan~2
dilator,~1
Laminaria~1
tent.~1
tents.~1
Full-time~1
obstetrics-gynecology~1
Chairmen~1
35,900~1
2447~1
non-radioactive~1
hemagglutination-inhibition~2
(Hi-Estrotec)~1
17-beta-estradiol,~1
0.885~1
gonadotropin-human~1
universally,~1
crying,~1
cried~1
0.1-1.6),~1
vitellointestinal~1
mid-therapeutic~1
3(S)-3-hydroxyquinidine~1
(3-hydroxyquinidine).~1
metabolism"~1
unbalanced~1
46,XX,der(5)t(5;11)~1
(p15;q25)mat~1
cri~3
chat~3
subtlety~1
bradyarrhythmia.~1
phosphosoda.~1
eclampsia.~1
(530~1
U-333~1
U/24~1
euglycemia,~1
(4530~1
(30-minute~1
71%).~2
macrosomia,~1
immigrants.~2
unsupportive.~1
Nonovarian~1
21.5-kg~1
pseudocapsule.~1
nonovarian~1
fibromatosis.~2
menorrhagia,~1
monoplegia~1
intromission~1
calyceal~2
fibro-osteochondroma~1
proliferation--fibroblastic,~1
cartilaginous,~1
osseous--all~1
intermingled,~1
fibrio-osteochondroma.~1
pseudosarcoma~1
(atypical~1
mitoses)~1
pseudosarcoma.~1
lacunaelike~1
endothelium-lined~1
Autoerythrocyte~1
(Gardner-Diamond~1
ecchymoses,~1
copper-containing~2
non-copper~1
Taping~1
penny~1
Gardner-Diamond~1
Whole-blood~1
(100-mg)~1
(Organon,~1
UK).~1
0.799~1
1982-1986,~1
16-related~2
11-related~2
18-related~2
25-55~1
vaginectomy.~1
vaginectomy,~1
palpated,~1
Ultrasonic~3
scanned.~1
21-33~1
164-395~1
Retroplacental~1
diphosphate.~1
placentae~7
Unimpeded~1
retroplacental~5
2564~1
obstetrically~1
phonocardiogram,~1
congestion)~1
small-for-dates~1
-187.02~1
12.7x.~1
198.629~1
2.24x)~1
mL/minute/kg~3
(systolic/diastolic~1
0.12x)~1
(5.6,~1
(5.1,~1
2.1)~1
(4.6,~1
1.6)~1
(4.1,~1
(3.6,~1
(89.4%)~1
(27.7%);~1
(73.9%)~1
Postdate~1
Nonmedical~1
dystocia-specific~1
resectoscopic~1
resectoscope,~1
dyscrasias,~2
amenorrheic.~1
fibroids~2
fibroid~1
Myomas~1
nonreproductive~1
"climacteric~1
counter-arguments;~1
separable.~1
gynecic~1
adherents~1
antiphysiologic~1
antipharmacologic.~1
synergestic~1
contraphysiologic.~1
vel~1
atrophicus,~1
infantilism~1
perimenopause.~1
staphyloma~1
(hourly)~1
four-time-a-day~1
limbus-based~1
O'Brien~1
(BSS).~1
Healon-treated~1
BSS.~1
Outstanding~1
wall-like~1
layers;~1
rolled-in~1
Gass~1
sight.~1
epitheliopathy.~2
cryotreatment~1
vitreo~1
6-42~1
(16/25).~1
(9/25~1
cryo~1
phakic.~1
myopes,~1
hyperopes,~1
(IAL)~1
pigmentosa)~1
electron-microscopical~1
post-gamma~1
melanocytoma~3
meshwork,~1
chlorate~1
Eye,~1
boxers.~2
Vision-threatening~1
subcapsular.~1
right-handedness,~1
bouts.~1
vision-threatening~2
aide~1
cyclocryotherapy.~1
clot,~6
IU/cc~1
Reopacification~1
35-month~1
post-vitrectomy~1
20/100.~1
(PDR)~1
[SI])~1
birthweights~4
(55.6%)~1
(7.6%).~1
regressed,~2
SI,~1
ROPsc:ROPcm~1
Neovascular~1
(FPL)~1
inter-technique~1
Karyotype~3
(female/male~1
4:1).~1
3-92).~1
chalazion,~1
Paralytic~1
Advocates~1
quote~1
exoplants~2
Eyelid~1
reanimation~1
epiphora~1
(EOM)~1
blow-out~2
EOM~2
ductions,~1
enophthalmos)~1
(EOM),~1
exophthalmos~4
upgaze)~1
chemosis~1
levator,~1
spill-over~1
nonocular~5
dacryostenosis~1
Philadelphia.~1
dacryostenosis,~1
54.7%.~1
76.4%~1
intracanalicular,~1
chiasmal,~1
post-chiasmal~1
advisability,~1
(hemispheric)~1
(TIAs);~1
suspected;~1
32,870~1
(77.3/1,000)~1
(83.2/1,000)~1
(78.1/1,000).~1
premise,~1
1,559~1
6,162~1
2,432~1
47-month-old~1
48-~2
83-month-old~1
mild--most~1
anemia--and~1
protoporphyrin.~1
end-of-treatment~1
salary~2
reimbursed~2
fee-for-services~1
(3.69~1
(1.42~1
Evaluating~2
Pediatrics'~1
well-childcare~1
(86.6%~1
.48,~2
polysomnogram~2
pneumogram~2
ipecac.~1
7.65,~1
4.04,~1
Accessibility~1
center's~1
4.60,~2
.13).~1
sticker~1
Syrup~1
Proof~2
postingestion.~1
ipecac-induced~1
postingestion,~1
postingestion;~1
overdosages~1
children.(ABSTRACT~1
vanishing.~1
Mercy~1
diligent~1
able,~1
Complications,~2
plug.~2
vasoocclusive~1
Bicetre,~1
France.~2
occular~1
(palpebral,~1
nasal)~1
(maxillofacial,~1
auricular,~1
malformations]~1
spinomedullary).~1
(potentially~1
involutive~1
hemovascular~1
(hemolymphangiomas)~1
High-flow~1
embolizations.~1
lamps.~1
prove,~1
lamps~2
user-tested~1
812);~1
180);~1
through,~1
nurse/counselors~1
Repetitive,~1
nonmigrating~2
(fasting)~1
milk-fed~1
nonpropagated~1
insect,~1
Radioallergosorbent~1
cardioembolism~1
nonvalvular~2
embolism)~2
rabies,~1
Rabies~1
bite;~1
licks~1
nonbite~1
skunks~1
raccoons)~1
rabid.~1
urethrotrigonitis~1
nonglomerular~1
pseudohematuria~1
undesirably~1
High-carbohydrate,~1
methodical~1
heeded.~1
Noncontraceptive~1
noncontraceptive~1
high-efficacy,~1
adequately,~1
clues,~1
alignments~2
squat~2
lifting.~2
"back-bowed-in"~1
(BBI),~1
"back-bowed-out"~1
(BBO),~1
BBI~2
lift,~2
excursions~2
cadence,~2
excursion.~2
dynametric~2
(DMT),~1
DMT.~1
dynametrically~1
DMT~1
discuss.~1
palsied~1
sagittal-plane~1
conserved.~4
segment;~1
wheelchairs~1
wheelchair-bound~1
Steady-rate~1
(L/min)~1
0.614~1
0.510~1
single-case~2
hemophilia.~2
factor-VIII~1
arthroses~1
pedal,~1
16-mm~1
cine-film~1
[BW])~1
rpm,~1
patellar-tendon~1
quadriceps-tendon~1
938~1
Orthotic~1
custom-formed~1
director's~2
setter.~1
underemphasized~1
directed,~2
rheumatologist~1
midface-malar~1
Proplast.~1
6-mm~1
repositioned.~2
velocardiofacial~2
hypernasality~1
carotids~2
auricle~2
functioning:~1
attractiveness,~2
sensual~1
self-image.~1
attractive,~1
underscored~1
Suction~2
2.4-mm~1
reinserted~1
saucer~1
retropectoral~2
Gentle~1
prepectoral,~1
retromammary~2
retropectorally~1
musculoaponeurotic~1
1431~1
Donor-site~1
Nebraska.~1
(19.29~1
mellitus)~2
(33.33~1
18.59~1
nondisplaced~1
antihormonal~2
guillotine-type~1
markings,~1
pencil~6
indelible~1
osteotomies).~1
suppliers.~1
Epidemic~1
(policy~1
ampicillin;~2
Augmentin~1
(ampicillin~1
clavulinic~1
ampicillin)~2
acute/rehabilitation~1
pre-policy~1
trimethoprim-resistant~2
plasmid-mediated~5
(25/29)~1
HBV-DNA~6
ex-service~1
brucella~1
Rose~1
Bengal,~1
Br.~1
meningoencephalitis~2
non-Parkinsonian~1
hyperdense,~1
myopericarditis~1
pleurisy.~1
anti-thrombocyte~3
haemochromatosis,~1
anti-diabetic~1
'autonomic~1
score',~1
(30.7~2
non-surviving~1
programmer~1
Deterrents~1
overdiagnosis,~1
realities.~2
Radiology~1
Mammography~3
abnormality)~2
biopsies).~1
chronicled~1
diversification,~1
strengthens~3
mammographers'~1
UK-treated~2
63%).~1
lysis);~1
UK.~3
Electrocardiographically~2
(3-mm)~1
spongework~1
obliterating~4
immobile.~1
Forming~1
aspergillomas~1
sponge-work~1
episternal~1
ossicles,~1
(men,~1
Episternal~1
C-7,~1
diskovertebral~1
osteophytosis~1
C-7.~1
Subaxial~1
images;~2
(DCL)~1
acetabula~1
nonparalyzed~2
DCL~3
arthrograms.~1
bulbous,~1
Concavity~1
0.91.~1
(parotid~1
masses),~1
"masses."~1
likely;~1
50-msec~1
delineate,~1
pseudodensity~2
(proportional~1
Pseudodensity~1
0.28.~1
hemorrhage-white~1
(2,500/0-20~1
[TR~1
msec]),~1
20-msec-TE~2
600/0-20,~1
600/0-20~1
600/20~1
"T1-weighted".~1
"short~1
T1"~1
partial-flip~4
109%~1
alba,~1
grisea~1
susceptibility;~2
undermine~1
image-guided~1
hydrogen-1~1
phosphocreatines.~1
(93%~2
94%).~1
section-selective~1
rephase~1
reformatted~1
Dixon's~2
water/lipid~1
exploits~1
contributions,~1
reception~2
whole-section~1
uniformly,~1
dual-coil~1
scatter-to-primary~1
High-contrast~2
(NEMA)~1
focal-spot~6
pinhole.~1
spots.~1
direct-exposure~2
NEMA~2
slit,~1
pinhole,~1
Brachytherapy~1
radium.~1
implantations,~1
iridium-192~2
ribbons~1
noncontinuous~1
two-planar~1
Seeds~1
seed/cm),~1
nonstandard~1
seed/6mm),~1
(P-32)~1
11-77~1
(82.1%)~1
(61.5%)~2
mandril~1
optimum.~2
Hemimegalencephaly~1
nonesophageal~3
gastroenterostomies,~1
antral-pyloric~1
enteroenterostomies,~1
strictures).~1
esophageal),~1
Malignancy~1
colonic);~1
non-esophageal~1
strictures)~1
esophagocolonic~1
Transhepatic~1
Transcholecystic~1
opacify~1
Thick~1
(I-131~1
MIBG),~1
paraganglioma)~1
mammographers,~1
single-view~4
two-view~3
oblique-cephalocaudal~1
"call-back"~1
(PPV)~1
(rodlike~1
PPVs~1
(0.11,~1
1,000;~1
30-39-year~1
over-59-year~1
(0.5-1.9~1
1,000).~1
(Coturnix~1
coturnix)~1
syllable-initial~1
[d]~1
vowels.~2
syllables~3
[d],~1
[b],~1
[g]~1
vowels,~1
generalization,~1
posit~1
capacities.~2
mobilizable~1
permeabilization~3
density-gradient~2
gelatinase~2
translocates~1
N-formylmethionylleucylphenylalanine.~1
tectum.~2
tectum,~1
toponymic~1
(TOP)~1
dorsoventral~1
inverted.~1
TOP~2
retinal-tectal~1
retinotectal~1
genotoxic~1
furan~1
furfural~1
non-ras~2
metric~3
metrics,~1
regularities~1
derivable~1
probabilistic~2
sentient~1
puzzle~1
HIV-1~20
HIV-2.~2
group-common~1
(HIV-1)~3
cytopathicity~1
CD4~30
syncytia~1
CD4+~27
post-binding~2
Contemporary~1
nonconscious~1
perceptual-cognitive~1
motoric~1
automatized~1
subliminal~1
remembered.~1
preconscious~1
subconscious.~1
Transduced~1
Biomaterials~1
biomaterial-centered~1
biomaterials~1
physics.~1
cell-to-substratum~1
BMD,~1
Accumulating~2
t(X;21)(p21;p12)~1
restriction-mapped,~1
chromosomes;~2
illness-related~3
(ADAS-COG)~1
-.90~1
(38.8%)~1
inquired~1
Alcoholism,~1
ulcer(s)~1
ASA/NSAID-associated~1
Plagiocephaly~1
Esthetic~1
plagiocephaly~1
craniectomies,~1
orbitocranial~1
Sclerotherapy~2
subdermal~1
trauma).~1
genitourinary,~1
reimbursements~1
hospice~1
facility),~1
Hospice~1
"aggressiveness"~1
hypointensity~2
industry)~1
1983-1984,~1
(PMRs).~1
PMR~7
(whites,~2
1.20,~1
(PMR~1
1.51,~1
PMRs~2
(buccal~1
farmers.~1
Midwest.~1
team-care~1
(simulated)~1
audiotaped,~1
unscripted~1
simulators~2
audiotape~1
Teams~1
"pseudopedicle."~1
Diazinon~1
lice,~1
pleiocytosis.~1
carcinomatosis;~1
bronchiseptica~2
journal,~1
T13~1
14-27~1
intermyelin~1
exuded~1
TXB2,~1
compression.(ABSTRACT~1
vest.~4
(Sunny-brook)~1
dismounting~1
perceivability~1
Schmorl's~8
T10-11~1
T11-12~1
(corresponding~4
discograms.~2
costovertebral~4
(osteophytosis)~1
T11-12,~2
T10-11,~1
osteophytosis,~2
degeneration).~3
T12-L1,~1
35-55~1
LPB.~1
Thoracal~1
1,205~1
1.4-3.9)~1
(1.6-8.6),~1
(1.0).~2
neurographic,~1
psychophysic~1
sack.~1
28-63~1
multisegmental~1
L3-L4~1
postmyelographic~1
sleeves.~1
pincers~1
posture-dependent~1
tensing~1
tensed~1
dose-time,~1
state-of-art~1
Pleuroscopy~1
(thoracoscopy)~1
pleuroscopy~1
Prevalent~1
dogma~1
10,040~1
cigarette-smoking~1
4-monthly~1
post-screening~2
squamous)~1
resectable).~1
early;~1
radiotherapeutic,~1
fruition~1
Economical~1
T1N1~1
T2N1~1
non-squamous~1
recurrences--especially~1
brain--remain~1
miniresective~1
29-year~1
En~3
Non-small~1
invasion--both~1
plasty~1
Tottori~1
grays~2
hepatectomies,~1
Metachronous~1
(70.3~1
Borrmann~1
15.76~1
-0.999~1
desobstruction~1
disassembling~1
reassembly~2
thumbtack~1
ovary--staging~1
laparotomy--must~1
cytoreduction~4
fumarate~6
APN),~1
lathyrogenic~1
chemical.~3
APN.~1
APN~3
56.8~1
Dandy~1
Blackfan's~1
Dandy-Walker~1
tentorium.~1
Myelogram-computed~1
foraminotomies~1
inferiorly.~1
Subdural~3
subtentorial,~1
suprasubtentorial.~1
taps,~1
lambdoid~1
low-positioned~1
medullaris,~1
lipoma--cord~1
cisternography~3
5-minute,~1
1.5-ATA~1
ligation:~1
infarcts;~2
wiring,~1
Gough-Cooper~1
Diseases,~1
Square,~1
hemianopia,~2
scotomata.~1
mixed-density~1
blush.~1
pneumocephalus~2
technetium99m~2
lymphoscintigraphy.~2
lymphoscintigraphy~2
(gastrogastrostomy).~1
reviewed--Fogarty~1
wound-related~1
34.4%.~1
(P2~2
0.029)~1
(REE),~1
(BCM),~1
noncachectic~1
REE),~1
K40~1
BCM),~1
BF)~1
BCM~13
REE/BSA~1
-0.782;~1
vital,~1
21.7,~1
reactivity;~1
(athymic)~1
H-2-incompatible~3
engraftment--saline~1
recipients:~2
13.2,~2
2.97,~1
Difference~1
peritoneum).~1
ventilation--an~1
cepharanthin~1
fluorocarbon~1
Cepharanthin~1
cepharanthin-treated~1
semitransparent~1
RAD-treated~1
therapy--whether~1
surgical--for~1
esophagus--frequently~1
esophagitis--had~1
patients--20~1
"nonacid"~1
GER--a~1
secretions--causes~1
hypovolemia,~1
toxemia,~1
remained:~1
syndrome?~1
ATP--it~1
glucose-depleted~2
mMol/L~1
glucose-repleted~1
Thrombofibrinous~1
shuntogram~1
Relocation~1
infection--and~1
sarcoma--was~1
rub~2
155),~1
fatalities--2~1
234),~1
(morbidity~2
1975-1979~1
Rankin~1
disability)~1
(Rankin~1
(physiatrist)~1
in-hospital,~1
Hisayama,~1
Facilities.~1
1,603~1
watershed,~1
aneurysm-associated~1
hypodensity~5
hypodensity,~3
IC-M2~1
hypodensity.~3
anti-free~1
apnea-induced~1
minutes:~1
arrest-related~1
tomography-verified~1
Hyperfrontality~1
leukoencephalopathy.~3
Leukoencephalopathy~1
19/96~1
primary-tertiary~1
(0.67%)~1
disease--characterized~1
strokes;~1
regulation--hypertension,~1
1.0396~1
0.0011~1
1.0442~1
31/2-4~1
vacuolation,~1
blebs,~2
lucencies).~1
Hypoglycemic~1
Michaelis-Gutmann~1
Morphologically~2
malacoplakia.~1
malacoplakia,~1
hemorrhages;~1
nontransfusion~3
para-Bombay~2
immunohematologic~1
(IBM/COBE~1
2991).~1
plasticized~1
tri(2-ethylhexyl)~1
trimellitate~1
agitators~1
(shakers)~1
6.43.~1
10(10).~1
shakers~1
inch)~1
button.~1
shaker.~1
(PRC)~1
170-mu~1
(Sepacell~1
R-500).~1
1550~1
PRC~3
multitransfused~1
(PRR)~1
(TRR)~1
buffy-coat-depleted~1
PRC.~1
PRC,~1
PRR~1
TRR~1
ranges)~1
(83-92),~1
(0-100),~1
(0.6-9.7),~1
filter)~1
leukocyte-free~1
refrigerate~2
shipment.~2
1000-ml~1
-78~3
(PRBCs).~1
PRBCs~3
PRBCs.~1
-22~2
PRBC~1
refrigerating~1
(CPD)~1
(CPDA-1).~1
CPDA-1~2
CPD.~1
CPD~1
(Nutracel)~1
51Cr:99mTc~1
1.23.~1
single-isotope~1
(extrapolation)~1
51Cr:111In~1
radiolabels.~1
Stroma-free~1
20-I~1
3-I~1
batches,~1
2-nor-2-formylpyridoxal~1
(NFPLP)~1
Hb/HbNFPLP~2
(PO2~3
nonmodified~1
oxygen-binding~1
HbNFPLP,~1
tetramers,~2
NFPLP~1
Clotted~1
Unseparated~1
vigorous.~1
Platelet-free~1
(PFP)~1
subfertility~1
orchiectomies~1
Non-seminomatous~1
(laceration,~1
renorrhaphy,~1
1.6/patient;~1
thirty-second~1
(here~1
skinny~1
(80%);~1
ESWL-induced~1
nephrostomies.~1
longest.~1
(3/27),~1
(8/27),~1
(1/27),~1
(12/27).~1
Rubinstein-Taybi~2
(broad~1
toe)~1
Anuria~1
intravesically.~1
VATER~1
Curiously,~1
oocyte)~1
47.6~1
(beta-HCG)~1
Wedge~1
beta-HCG.~1
antiadherence~2
cocarcinogens~2
glycosaminoglycan-deficient~1
3-hydroxykynurenine~1
3-hydroxyanthranilic~1
cyclamate,~1
saccharin.~1
fistulization~2
perinephritis.~1
supratesticular~1
forty-six-year-old~1
uro-dynamic~1
tabes~2
(FED)~1
Glomset-Wright~1
alpha-LCAT~1
beta-LCAT~3
FED~6
autoincubation~1
lecithin:~1
(alpha-LCAT~1
deficiency),~4
waist/hip~1
gel-forming~1
fiber--guar~1
beta-cells~2
tularemia,~1
Pediculocides~1
immunocompetence,~1
"overkill"~1
newer,~3
flatulence,~1
adolescence;~1
Dysfunctional~1
post-teenage~1
Amebic~1
hypochondrium~1
epigastrium~1
46,351~1
six-through~1
21-year-olds~1
horse-related~1
horses.~1
Bruises~1
riders~1
headgear.~1
carcinoma's~1
listen,~1
educate,~1
mastery~1
"emotional~1
upset"~1
worry,~2
etc.,)~1
(RCPP)~1
RCPP~3
pressure/aortic~1
0.09)~1
inflation.(ABSTRACT~1
dyskinesis~3
dyskinesis.~1
intimal,~1
(Tx)A2~1
thermodilution)~2
TxA2)~1
aspirin),~1
Hg/ml/min;~2
postulates:~1
Distensible~1
(diameter)~1
(disappearance~1
([maximal~1
diameter-minimal~1
diameter]/minimal~1
D-sotalol~4
(406~2
PVC/hr~3
(211~1
dog;~2
(RVI)~1
(VM)~1
IZ~2
layer)~1
SEPF~2
24-hour-old~1
RVI;~1
inductibility;~1
normalcy.~1
(MVR).~1
(C-E),~1
(S-J),~1
(I-S)~1
C-E,~1
S-J,~1
I-S~1
S-J~1
C-E~1
MVR.(ABSTRACT~1
(HR);~1
(PEP);~1
(STI~1
PEP/ET)~1
(TMS~1
STI~3
TMS,~1
0.559~1
0.447~1
0.018),~1
measurements.(ABSTRACT~1
dopamine)~4
titrations.~1
7.8)~1
dopamine).~1
bacteremias,~1
stopped),~1
Defect~1
large-restrictive~2
51%;~1
agents--the~1
drugs--have~1
tocainide~1
complexes/hr)~1
agent.(ABSTRACT~1
supraventricular,~1
incessant,~1
"mechanism"~1
catecholamine-dependent~1
reentrant,~1
(concealed~1
catecholamine-facilitated~1
flutter/fibrillation.~1
(SVT),~1
nadolol,~3
SVT.(ABSTRACT~1
(SVT).~2
non-inducible~1
(11%).(ABSTRACT~1
2,599~1
U/liter.~1
1,897~1
(2,707~1
U/liter)~1
AMIs.~1
chemistries,~3
receiver-operator~2
individually,~1
aVF).~1
(aVL,~1
V1-V3~1
reperfusions~1
revascularization:~1
2-mg~1
(IS-5MN),~1
IS-5MN,~2
dopadecarboxylase~1
vasomotion~1
hyperventilation-induced~1
Levodopa~1
disregulation~1
dopamine.(ABSTRACT~1
Prinzmetal~5
silent;~1
PM);~1
Cosinor~1
acrophase~2
arteries),~1
(age-~1
sex-matched)~1
(-36%,~1
-40%,~1
(-37%,~1
-35%,~1
0.391,~1
-1%,~1
0.818).~1
depression),~1
hyperkinesia~1
(QMED~1
Monitor~1
OneTM)~1
QMED~5
CASE-II~1
(ECGM)~1
wander~1
discounted~1
ECGM.~1
inspect~2
Tl-201~9
(intervention~1
scans:~1
scans.(ABSTRACT~1
Urografin~1
windows)~1
6,218~1
869.~1
380.)~1
(DVI)~1
(VDD),~1
sequence.(ABSTRACT~1
(alive~1
(maintaining~1
Completely~1
(ART).~1
1--AF;~1
2--ART;~1
3--palpitations~1
ART;~1
4--AF~1
ART.~1
21%).~1
AF.~1
WPW.~1
Beta-blocking~1
(V2),~1
(V3)~1
(V4)~1
VTs,~1
extrastimuli;~1
14-day)~1
12-month)~1
tachycardia-related~1
Alternans~4
(66%~1
short.~1
aVL~1
0.0005).(ABSTRACT~2
sequential-pulse~4
single-pulse~4
Single-pulse~1
leading-edge~2
position;~1
678~1
(466~1
length:~1
conduction.(ABSTRACT~1
weight-for-height,~1
preschool-age~2
(15th~1
[NCHS])~1
(60th~1
NCHS).~1
Skinfold~1
NCHS~1
cutoffs~1
Maastricht~1
Zeist,~1
Tromso,~2
mackerel~1
interrelationship,~1
Anorectic-restrictor~2
anorectic-bulimic~2
sweetness~1
Normal-weight~1
disliked~1
sugar:fat~1
(S:F)~1
regain.~1
(overweight)~1
(underweight)~1
actometers~1
hypoactive.~1
navy~2
unleavened~1
dephytinized~1
legumes~2
Alpha-tocopherol~2
(pigment~1
choroid).~1
epithelium-choroid~1
donors).~2
Gamma-tocopherol~1
3H-alpha-tocopherol,~1
3H-all-trans~1
Adipocytes,~1
membranes),~1
debris).~1
tocopherol:cholesterol~2
tocopherol:triglyceride~1
adipocytes,~6
(oil~1
tocopherol,~1
lipids;~1
bulk-lipid~1
25-32~1
low-methionine~2
PII),~1
adequate-methionine~1
(725~1
PIII).~1
PII~1
PIII.~1
PII,~2
PIII,~2
(NAM,~1
NAM~1
PIII)~1
(59.8,~1
56.7,~1
mumol/(kg~1
Plasma,~1
formiminoglutamic~1
(FIGLU)~1
FIGLU~1
3H-folic~1
coenzymes,~1
enterohepatically~1
(Tryp)-deficient~1
Zn-deficient~1
picolinic~1
compensate.~1
Tryp~4
Tryp-adequate~1
plasma:bone~1
Zn.~1
pellagra.~1
Trimethoprim~2
pyrimethamine,~1
(DHFR),~1
intestinal-loop~1
methotrexate;~3
(SHML)~1
immunohistologically.~1
SHML~3
alpha-1-antichymotrypsin~1
histiocyte-like~3
alpha-1-antichymotrypsin,~1
histiocyte-related~1
SHML.~1
coexpress~2
(10-57%)~1
("R-flags")~1
computed;~1
out-of-range~1
Flash-frozen~1
(FF),~1
(positive-A)~1
non-HD~1
positive-B~1
Rebiopsies~1
Simplicity,~1
quickness,~1
neocyte~1
atop~2
(arabino-galactan~1
polysaccharide)~2
enriches~1
neocytes~1
0.96/slope~1
assay's~1
within-run~1
between-run~1
technics.~1
(WB-PIA).~1
WB-PIA~2
accounting,~2
"protection"~1
not-definite~3
chylomicronemia.~1
infranatant~1
Postheparin~1
(apolipoprotein~1
C-II).~1
diet-derived~1
less-than-optimal~1
perennially~1
sunny~1
Diego.~1
direct-reacting~2
indirect-reacting~2
Diazo~1
Soy~1
dextrimaltose,~1
soy-lactose~2
maltose.~1
(TSH)-blocking~1
TSH-blocking~1
propylthiouracil,~1
unwittingly~1
MSP,~1
adult)~1
prick-tested~1
(MMR)~1
cow's-milk~2
examinees;~1
diphtheria-pertussis-tetanus,~1
(Salk)~1
nonreactivity~1
prick-test~1
MMR.~1
vaccinees.~2
nurseries.~1
1846)~1
oscillometrically~1
deformations.~1
(1368)~1
negotiations,~1
corruptive~1
(rat~1
pup)~1
extrinsically~1
milk-cereal~1
26%)~1
(oatmeal~1
varieties)~1
ready-to-serve~1
cereal-fruit~1
54%).~2
54%)~2
rice-fruit~1
McKusick-Kaufman~1
(MKS),~1
prenatally,~1
postaxial~1
hydrometrocolpos~3
consistently.~1
MKS~1
panethnic~1
(57.6%)~1
(42.4%)~1
prematurely.~3
(69.6%),~1
(17.1%),~1
(1.27%),~1
precaution,~1
electrical-seizure~1
(78.9%)~1
1011~1
(64/93)~1
phenytoin-induced~1
Cleft~3
Athabaskan~1
Indians.~2
Apache~2
equates~1
health--indeed~1
itself:~1
Can,~1
health?~1
home-care~5
discharge-planning~2
givers'~1
vendor~4
(54%,~1
91%),~1
(80%,~2
(65%,~1
76%).~1
85%),~1
Institute's~1
Setleis~2
"forceps~1
marks"~1
marks;~1
puffiness~1
eyebrows;~1
eyelashes;~1
tip;~1
Sebastian~1
Aguadilla~1
Rico;~1
unhappy,~1
unhappiness~1
sadness~1
aspiration-positive~3
Bipeaked~1
postrelaxation~1
trimoprostil,~1
trimethyldesoxy~1
trimprostil~1
push-type~1
enteroscopy~2
(SIF-10L)~1
duodenojejunal~3
23-yr~1
Sheva~1
1961-85.~1
1981-85~1
youthfulness~1
Mama~4
Yemo~4
Kinshasa,~2
Zaire,~1
cryptosporidia~1
benzothiadiazine~1
(chlorothiazide,~1
phthalimidine~1
(chlorthalidone)~1
(G34)~1
G34~1
barrier;~1
G34.~1
"peptic~1
hepatitis"~1
regeneratory~1
tissues)~1
brushing/washing~1
abrupt,~2
side-lying~1
fluvialis.~1
fluvialis~1
seafoods~1
serendipitously,~1
-C,~2
FPC~5
haplotype;~2
A24(9)-B51-X-DRw8~1
HLA-C~1
locus).~1
albuminuria/gamma~1
globulinuria~1
migration."~1
(focal,~1
segmental)~1
lamellation~1
L/d)~1
4.51~2
L/d.~1
.86,~1
(five,~1
(23,~2
(11,~1
mesangioendothelial~1
(six,~1
(LN).~1
LN.~2
LTS),~1
STS).~1
STS,~3
LTS~4
65.3~1
STS~11
LTS.~3
LTS,~1
Non-PD-related~1
PD.(ABSTRACT~1
underutilization.~1
outpouring~1
HLA-associated~3
allele;~1
haplotype-sharing~1
(ATD),~1
ATD,~1
alphoid~11
tandemly~7
(D6Z1),~1
3-kb~2
centromere~8
Sequences~6
2-kb~3
homologue,~1
XC,~2
hybridizes,~1
173-bp~4
latters'~1
replicating.~1
Leprechaunism~1
(Ark-1,~1
Atl,~2
Minn)~1
leprechaunism.~1
Ark-1~6
Atl~2
leprechaun~1
250-kD~1
(alpha-alpha~1
dimer)~2
125-kD~1
monomer)~1
Minn.~1
alpha-alpha~1
Beta-subunit~1
insulin-enhanced~1
autophosphorylation.~4
Orosomucoid~1
(ORM)~1
ORM~4
focusing-immunoblotting~1
isoprotein~1
orosomucoid~3
(ORM2).~1
ORM2~1
North-~1
South-American~1
Aleuts,~1
Highlanders.~1
.958,~1
.025,~1
.011~1
ORM*1,~1
ORM2*2,~1
ORM2*3,~1
ORM2*4,~1
progeroidal~1
deciduous~5
teeth,~8
proteodermatan~1
chain-bearing~2
asparagine-bound~1
Xylosyltransferase~1
p-nitrophenyl-beta-xyloside.~1
pentadecapeptide~2
glycosaminoglycan-free~1
unambiguously,~1
(SMRs)~1
Genetics~1
SMR~4
2.27~2
1.7-3.0).~1
5-24~1
SMRs~1
25-54-year-old~1
2.5-9.6).~1
achondroplasia--i.e.,~1
stenosis--may~1
Honolulu.~1
unexpected,~3
trisomies~1
(20-24,~1
30-34,~1
35-39,~1
40-44,~1
45+~1
golden-hamster~1
hyperhaploid~2
hypohaploid~2
complements,~1
complements.~1
Rigshospitalet~1
processor~2
hard-copy~2
printer~2
4,691~1
metaphases,~1
"eyeball"~1
"machine"~1
karyotyped.~1
(amniotic-cell~1
cultures)~1
"karyotyping-only"~1
karyograms~2
4,773~1
17%-20%~1
clot-specific~1
ST-segments,~1
perspectives:~1
skeptical~1
group-successful~1
unsolved.~2
IU/minute~3
repositioned~1
500,000-IU~1
clot's~1
traversal~1
intra-thrombus~1
IU/hour~1
glipizide,~1
glipizide~4
glipizide.~1
25-mg/dl~1
Glipizide~1
comparably,~1
antisickling~2
deoxygenation-induced~4
N,N'-p-phenylenedimaleimide~2
(PMD).~1
PMD~3
sickling~5
PMD-treated~1
deoxygenation,~1
monofunctional~3
vancomycin-dependent~2
leukoagglutinins~1
septoplasty.~1
legionella~3
legionellosis.~1
pneumophila,~2
Georgia,~1
cervigrams,~1
coloposcopist~1
Colposcopists~1
Cervigrams~1
(uninterpretable).~1
time-honored~1
condemned.~1
cervicography~1
repetition.~1
20-county~1
Carolina.~3
17,370~1
23%).~1
(62%,~1
carcinomas),~1
therapy-associated~1
deserving~1
collapse;~1
ileus;~1
proliferations.~1
Obstetrics)~1
32/60~1
15/60~1
reanastomosis.~1
hysterosalpingography,~1
(contralateral~1
7.20,~1
5.42).~1
149.8~1
52.6%~2
(33.1%~1
(102.2~1
145.2~1
sonographers~1
1022~1
99.7%~1
95.8%,~1
cerclage.~4
24.40~1
614.00~1
441.73~1
3.3).~1
16.1),~1
3261~1
2098~1
811~1
vessels:~1
1627~1
memory-based~1
predictability.~1
1335~2
crown-heel~1
Angioscan~1
weighed;~1
Dubowitz~1
adequate-,~1
small-,~1
large-for-gestational~1
Readily~1
hemoconcentration.~1
silent,~1
fasting;~1
(Chemstrip~1
pyrexia~1
(Michaelis~1
(183)~2
malpresentation~1
2598~1
accelerations,~1
cord-to-maternal~1
0.44.~1
(59.0%~1
(macrosomia~1
(tricuspid~1
(2.15:1)~1
(1.33:1,~1
30.7~1
Octopus~1
G-1.~1
ametropia,~1
+1.00~1
+2.00~1
skew,~1
fluctuation,~1
0.25-mm~1
sclera-encased~1
extrusions.~1
Gotland,~1
(8.4%)~2
20/20,~1
90-diopter~1
follicle-associated~1
(FAE)~1
cell-labeling~1
FAE~3
mesothelium~2
stereomicroscopy,~1
stomata~4
(90.6%~1
silica,~2
(60.3%~1
5.5-fold~1
detached.~1
5.8-fold~1
regions.(ABSTRACT~1
adenosinemonophosphate~1
nucleotidyl~1
phosphohydrolase~3
(LM),~1
(FN),~1
equivalents:~1
neuronal--none;~1
melanocytic--FN~1
cell--large~1
FN,~1
epitheliomas~4
(BCEs),~1
BCEs~3
Behind~1
carpet~1
higher-energy~1
107%),~1
Extrapyramidal~2
nonrecognition~1
anxiety-neurotic,~1
rehospitalization.~1
nonsituational~1
Agoraphobia~1
self-exposure~1
2,902~1
Oaks~1
Gambling~1
Screen~1
20-item~1
gambling.~2
interviewers.~1
development:~1
gambling,~1
Gamblers~1
Anonymous,~1
(500-2000~1
cognitive)~1
imprisonment~1
ventricle-to-brain~1
delirious~1
sulfonylureas.~1
Dyspepsia~1
(86.7%~1
25.0%),~1
lorazepam.~3
ownership~1
nation;~1
profits;~1
competition;~1
ideological~1
posed.~1
epidemiologically,~1
File,~1
"injury~1
work,"~1
external-cause-of-death~1
codes.~1
male-to-female-rate~1
4.2:1.~1
guards~2
senseless~1
1975-84~1
2.1/100,000~1
workers/year.~2
taxicab~1
78.2/100,000~1
retail~1
industries,~1
private-security~1
workplace-homicide~1
eating-and-drinking~1
homicides.~1
janitors~2
cleaners,~1
printers.~1
3,778~1
1,486~1
ever-smoking~1
non-tobacco-related~1
Quitters~1
ex-smokers/no.~1
smokers)~1
Jews~2
non-Jews,~1
Sentinel~1
Event~1
(Occupational)~1
[SHE(O)]~1
decedent's~1
SHE(O)~5
selects~3
work-related,~1
City),~1
Island.~1
rigorously.~3
assimilation:~1
"language~1
preference",~1
"country~1
birth",~1
"contact~1
homeland",~1
"attitudes~1
friends."~1
Hispanics.~1
pre-adolescent~1
(10-year-olds:~1
56,)~1
(15-year-olds;~1
B6)~1
10-year-olds~2
15-year-olds.~1
pre-adolescents,~1
15-year-olds).~1
pre-adolescents.~1
"blood~1
building"~1
Smoking-related~1
scombroid~2
scombrotoxins~1
18-43,~1
Latino,~1
Black).~1
battering~2
pregnancy).~1
sustained;~1
contest~2
postcontest~3
24,995)~1
city's~1
demography.~1
sustains~1
preventability~1
(ACIP)~1
(PHS).~1
(EFR)~1
1,488~1
EFR~4
pantry~1
Iliocaval~1
iliocaval~4
Transstenosis~1
selection:~2
oxygen-to-transcutaneous~1
foot-to-chest~1
xenon-133,~2
abandoning~1
sparing,~1
coolness~1
shoelace~1
augur~1
dual-complex~1
Extraanatomic~1
Expeditious~1
preventing,~1
FITC-dextran-150~1
splayed~1
lucite~1
suffusion,~1
incompetent.~1
same;~1
preangiographic~1
popliteal-tibial~1
ankle-brackial~1
creature~1
comforts~1
read.~1
equation;~1
research;~1
faculties;~1
physician-sparse~1
scanner,~2
(71.6~1
gastrectomies~1
effusions;~1
pleurodesis;~1
this;~1
thoracostomy;~1
node-negative.~1
self-breast~1
paramount.~1
Chulalongkorn~1
Cutting~1
County-University~1
irrigations.~1
pararenal~2
homogenated~1
6-0~4
436.9~1
knotting~1
316.9~1
transversalis~2
displaces~2
waste.~1
mumol/litre,~2
2.9)~1
cardioventilatory~1
nalbuphine-medicated~1
pethidine-medicated~1
Siemens~1
SV900C~1
Bench~1
breaths/minute,~1
(0.2-0.3~1
Mapleson~1
graphical~1
hypernatraemia~1
Eusol~1
Eusol.~1
hyperpyrexial~1
clomipramine.~1
laryngoscope~2
impinges~1
adaptor~1
Penlon~1
swivelling~1
buzzer~3
synthesizer.~1
synthesizer~2
Halothane-induced~1
preincubation;~1
extubation-induced~1
tissue:blood~1
systematically,~1
myocardial:blood~1
(8.1-16.2~1
size-related~1
chloroprocaine~1
10(-3)-0.4~1
10(-3)-0.08~1
CP;~1
ability-CFA)~1
20-hr~4
72-92%~1
SB-1~1
57-72%~1
SB-2.~1
Air-Shields~1
Ventimeter~1
I-653.~2
0.424~1
0.225~1
I-653~7
I-653,~3
5.72~1
0.40%.~1
0.036%~1
centigrade~2
redetermined~1
0.75%)~1
(5.84~1
0.36%).~1
(0.69),~1
(2.5).~1
flasks~3
sevoflurane;~1
isoflurane;~2
biodegradation.~1
IM)~1
PO)~1
(PPX)~1
vein/cord~1
PPX/bupivacaine~1
0.78%.~1
300-mg~1
single-orifice~2
Bunegin-Albin~4
multi-orifice~1
(SVC)~1
SVC-RA~2
mid-RA,~1
multiorifice~1
mid-RA.~1
mid-RA~1
seven).(ABSTRACT~1
(penoscrotal~1
inguinal),~1
yrs.~1
halothane/N2O/O2~1
419),~1
32-37~3
move-no~1
"up-and-down"~1
0.17%,~1
0.18%~1
MHS-subjects~1
(6-month-old)~1
(28-month-old)~1
N2O/30%~1
micrograms.kg-1.h-1)~1
GABA-benzodiazepine-barbiturate~1
(1.2%),~3
ng.ml-1,~1
micrograms.kg-1.min-1~1
micrograms.kg-1,~1
(-494~1
mmHg/s).~1
verapamil--changes~1
anesthetics.(ABSTRACT~1
mg.kg-1)~1
(onset~1
(T25)~1
(T100)~1
(T25-75)~1
T25~1
T100~1
morphine-thiopental~2
fentanyl-thiopental~2
(expected/observed~1
opioid-barbiturate~1
2223~1
2196~1
2010~1
Chronologically,~1
1972-1974;~1
1975-1981;~1
(703~1
(467~1
shunted,~1
possible.(ABSTRACT~1
(set-point).~1
stimuli).~1
stimuli)~1
0.5-2~1
46.0~2
command)~1
(10.7-44.5~1
(4.7-8.4~1
model-based~1
halothane/14%~1
higher:~1
(bpm)~1
maintained:~2
NS,~2
6.6-7.6.~1
1.3%;~1
SEM:~1
nmoles/mg)~1
nmoles/mg).~1
VA,~1
(7-32%)~1
6.6-6.8,~1
(52-78%)~1
7.2-7.6,~1
10(-6)M,~1
7.0-7.6.~1
VA.~1
1,326~1
distributed;~1
69%)~1
78%)~1
(nonsymmetrical~2
range).~1
skewness~3
photoplethysmography),~1
thrombelastogram),~1
(decrease).~1
thrombelastogram~1
(POAD)~1
Leriche-Fontaine,~1
mesoglycan~1
velocitographic~1
index);~1
protodiastolic,~1
variations;~1
1.5-tesla~1
sixty-six-year-old~1
monoparesis,~1
angiitis.~1
Okihiro's~1
Okihiro~1
Duane's~1
panhypoglobulinemia~1
deficiency).~2
etiopathogenic~2
(bronchiectasis,~1
immunodeficiency).~1
disc-based~1
(Phadebas~1
PRIST)~1
(RAST).~1
(Phadezym~1
PRIST/RAST).~1
Phadezym~4
inter-assay~2
absorbances~1
'Phadezym~1
Unit'~1
(PRU)~1
ELISA-dedicated~1
microplate~3
('MacPRIST'~1
'MacRAST')~1
ionizer~1
(Bionaire~1
Biotech~1
Electronics,~1
mold~4
ionizer.~1
spores,~2
Thai~3
1.54:1.~1
rainy~1
precipitant~1
(61.25%)~1
29.15%~1
9.60%~1
32.45%~1
6.85%~1
63.15%~1
79.25%~1
cells/mm3~1
epidermals,~1
mite,~2
molds,~1
weeds,~1
cockroach,~1
grasses,~1
kapok,~1
formylated~1
Polarization~1
non-aspirin-sensitive~1
aspirin-sensitive~2
Dehra~2
Dun~2
(1980-81).~1
February-April~1
August-October,~1
Pollen~1
Pinus~1
Broussonetia,~1
Rosaceae,~1
Poaceae,~1
Debregeasia,~1
Rumex,~1
Morus.~1
Cladosporium,~1
Alternaria,~1
smut~1
Curvularia,~1
Ascospores,~1
Nigrospora,~1
Aspergilli/Penicilli,~1
antimicrobials,~2
Freshwater~1
Recommendation~1
cardiovascular-respiratory~1
multireflex~1
apnea;~1
measured);~1
(resulting~1
heart);~1
volume);~2
submersions,~1
g%~1
(legal~1
intoxication).~1
pre-immersion~2
shivering.~2
cycles/min)~1
thermal-induced~1
Cold-induced~1
cold-stressed~1
oscillators.~1
30.57~1
(1.08~1
C/hr)~1
C/hr).~1
30.27~1
296)~1
(315~1
mg%)~1
non-CPR~1
(outdoors),~1
30.94~1
third-hour~1
(2.28~2
C/hr),~1
(17.1%).~1
84.9%~1
"serious"~1
(30),~1
(ten),~1
first-hour~1
above;~2
antiprostanoids,~1
anti-thromboxane~1
Aloe~2
methimazole,~1
34.3%~2
28.2%~3
frostbite.~2
67.9%~1
Weather~2
(NWS)~1
issuing~1
forecasts~1
NWS~3
warnings,~1
weather-related~1
preparedness/awareness~1
disaster-associated~1
post-impact~1
Well-documented~1
epidemiologists.~1
disasters.~1
(NDMS)~1
geophysical~1
disasters,~1
Catastrophic~1
forces;~1
evacuating~1
stabilizing,~1
NDMS~1
assets,~1
time-proven~1
antivenins~1
IgG(T)~2
antivenin.~1
biotechnical~1
dapsone,~1
antivenom,~1
phalloides~1
amatoxin-containing~1
mushrooms,~1
amatoxin~1
(ARD),~1
ARD.~2
(87.5~1
thousand),~1
Death,~1
Intensified~1
Orebro~1
Compromised~1
Protected~1
(PTBNA)~1
(PSB)~1
PSB~6
PTBNA~6
PSB.~1
organisms/brush~1
culture)~4
(expectorated~1
bronchoscoped~1
(definitive~1
presumptive)~1
PTBNA.~1
streptococci.(ABSTRACT~1
Registries~1
non-Asian-born~1
American-born~1
Nonsignificant~1
(RHL).~1
EIA.~2
RHL~2
RHL,~1
H2O/L.~1
H2O/L).~1
FEV2~1
airflow-induced~1
(AIB)~1
bronchoscope,~1
(Taw)~1
dry-air~3
Taw~6
Rcs,~1
(EHL)~1
EHL~1
rose.~3
challenge.(ABSTRACT~1
(OKT4)~2
(OKT8)~2
(early-~1
late-phase)~1
(Dil)~1
(SER)~1
Dil~2
SER.~1
SER~4
FEV1/FVC,~1
FEF75,~1
moment)~1
(0.60)~1
Bimodal~1
0.76),~2
nonadrenergic,~3
epiglottis.~2
sharp,~1
H2O.L-1.s,~1
H2O.L-1.s~1
(ANOVA).~1
methacholine,~6
(OSA),~1
(PCSA)~1
[AHI],~1
AHI,~1
hour).~1
PCSA~2
PCSA,~1
AHI~2
-0.38,~1
naso-oropharynx~1
(UDP)~1
(SWS),~1
UDP~1
(PACO2).~1
PACO2~2
Uncertainty~1
flooded~1
(labeled~1
blue)~1
3.95~1
mEq/L.(ABSTRACT~1
ruminant~2
sepsis-induced~1
trypsin-activated~1
(C5').~1
C5'~2
C5'-treated~1
C5'-treated,~1
C5-treated~1
C5.~2
C5',~1
protease-activated~1
vivo.(ABSTRACT~1
aerosolization.~1
papain-treated~1
panlobular~1
histamine-aerosol-induced~1
chloralose~1
parainfluenza~3
exhalation.~1
0.94),~1
triathalons~1
ultramarathons.~1
42-km~1
noncardiogenic.~1
(ASA),~1
(DIP),~1
femoropopliteal-tibial~1
(UV),~1
(DuPont,~1
Wilmington,~1
DE).~1
(SV~1
.25).~1
Below-knee~1
Femorotibial-peroneal~1
(31%);~1
recuperation,~1
warfarin.(ABSTRACT~1
0.86.~1
pre-bypass~1
(8.8%)~2
(67.6%)~1
PTFE.~1
GEE-OPG.~1
OPG~2
(24.7%,~1
74/300)~1
(22.3%,~1
25/112)~1
(3/374).~1
nonhemodynamically~1
(3/19).~1
(synchronous)~1
(metachronous)~1
Dysphagia,~1
endarteritis,~1
liquid-to-soft~1
Trapped~2
enterostomies~1
Apudomas~1
apudomas~4
Piedmont~2
paragangliomas,~2
pinealocytoma.~1
pinealocytomas.~1
(RUQ)~1
RUQ~1
cystadenomas.~1
unilocular~3
(SSD)~1
SSD~1
SSD-treated~1
sulfadiazine-induced~1
infraumbilical~1
performer~1
mammaplasties.~1
(desmopressin)~1
micrograms/m2~1
coagulant~4
(547~1
mL;~2
1075;~1
1.65;~1
(34.0~1
-5.2~1
72.7;~1
0.105),~1
desmopressin.~1
referral-based~1
Intervention:~2
fluorodeoxyuridine~2
infusaid~1
Intrahepatic~2
0.092).~1
2-nitropropane~3
coworker.~1
Neurobehavioral~2
(NCSE),~2
constructions,~1
Capacity~1
(CCSE)~1
CCSE~1
MMSE,~1
NCSE,~1
NCSE~1
design:~1
remission;~2
relapse;~3
(50.7%)~1
1987~2
influenza-related~1
intensive-care~1
organ-transplant~1
upcoming~1
dynes/s.cm-5~1
dynes/s.cm-5.~1
major-vessel~1
Sixteen-week~1
Subjects:~1
Pre-intervention~1
internists),~1
4683~1
5942~1
5946~1
8148~1
Post-intervention~1
faculty),~1
2571~1
2858~1
workstations,~1
visits:~1
$12.17~1
$13.99~1
contrasts.~1
contrast-sensitivity~1
(0.5,~2
cycles/degree)~1
Nicolet~1
asteroid~8
Bayadi-Kajiura~1
liquefaction~1
hyalosis~1
hyalosis.~1
Strabismus~2
ultra-pure~1
nonantigenic,~1
noninflammatory,~1
7-pound~1
Ante~1
hemodynamically-significant~1
(LEM)~1
Low-~1
just-dried~1
flame)~1
semi-gel,~1
meshes~1
granules;~1
transparent.~1
(subretinal)~1
sub-~1
hard,~1
inimical~1
threatens~1
oculogyric~2
gaze-holding~1
saccade.~1
pedunculopontine~1
(PPNc)~1
rostrocaudal~2
PPNc~3
12-microns-thick~1
midlevel~1
68.7~1
PSP,~1
mnemic~1
meaningless~1
drawings.~1
pathway's~2
corticolimbic~1
Hoehn~1
Yahr~1
electroculogram~1
scanpaths~1
"predictable"~1
scanpath~1
nonfamiliar~1
possessor~1
"phosphate~1
stuttering~4
stuttering.~1
peduncle,~4
unsteadiness~1
incapacitated~1
ataxia;~1
Rosenthal~1
axonopathy~1
peduncles,~1
columns,~4
3,689~1
observed-to-expected~1
1.43;~1
Observed-to-expected~1
2.63~1
(MOX)~1
N-methyltetrazolethiol~1
NMTT,~1
[NMTT-14C]MOX~4
[14C]NMTT.~1
MOX~6
MOX,~2
[14C]NMTT~2
MOX.~1
biliary-excreted~1
1:60~1
1:252~1
1:256,~2
1:5~2
cefotaxime)~1
antibiotics),~1
(1:3~1
cefotaxime).~1
poly(ICLC)~1
(stabilized,~1
polyriboinosinic-polyribocytidylic~1
proportional-hazard~1
mouse).~1
Kill-kinetic~1
(0.5x~1
MIC),~2
(1x~1
suprainhibitory~1
(4x~1
MIC)~1
kill-kinetic~1
4x~1
isocratic~1
fluorescamine,~1
0.999);~1
(M);~1
1.03M~1
7133,~1
postinfusion;~1
well-agar~1
azoles~1
polyenes.~1
9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine~1
(BRL~1
39123)~1
herpesviruses~2
(ACV).~1
(HSV-1),~3
(HSV-2),~1
(IC50S)~1
39123~7
IC50S~1
equid~1
bovid~1
felid~2
(IC50S,~1
MRC-5~3
HSV-infected~2
39123,~1
ACV.~2
(9.3,~1
0.973,~1
(62,~1
6-mg/kg~1
Edwardsiella~1
tarda,~1
piscicida~1
conjugative~1
110-megadalton~1
Mastocytosis,~1
avidin,~2
160-fold~1
preponderantly~3
macule~1
opossum,~2
Monodelphis~1
domestica,~1
desquamation.~1
Post-ultraviolet~1
tape,~1
hydrocolloid~1
(HCD).~1
14/34)~1
(47%,~1
16/34)~1
HCD;~1
HCD~1
fluocinolone~1
(MM).~1
1130~1
(86.3%)~1
(74.8%)~1
"prophylactically"~1
nevocellular~1
futile.~1
papule~1
light-microscopic,~1
fibroxanthoma.~1
"fibrohistiocytic"~1
Hopital~3
Henri~2
Mondor~1
Creteil,~2
Stevens-Johnson~3
Necrolysis~1
Staphylococus~1
necrolysis,~3
(TEN)~2
Mondor,~1
culpable~2
TEN.~2
TEN~5
culprit~2
sulfonamides,~1
(barbiturates~1
only);~1
phenylbutazone~6
oxicam~2
Aspirin,~2
antipyretics,~1
sulfonamide-related~1
basement-membrane~4
readdress~1
disparity,~2
type-IV~1
KF-1~6
pemphigold~1
neoantigen.~1
Perivascular~2
aurothioglucose.~1
0.25-mL~1
0.25%,~1
polidocanol~4
(Aethoxysclerol~1
[France]),~1
(Sotradecol~1
(0.25%)~1
polidocanol-injected~1
sclerosants.~1
Long-lasting~1
antibody-producing~4
plasmaphereses~1
immunoglobulin-free~1
postexchange~1
Hypozincemia~1
enteropathica~1
hypozincemia~1
paediatricians~2
losers.~1
non-salt~1
losers,~1
Midlands,~1
endocrinologist.~1
virilisation.~1
ascertained,~3
SBLA~1
(sarcoma,~1
$64.72~1
employee,~1
$8.42~1
0.64%,~1
9856~1
9251~1
(GFD).~1
GFD~3
15,608~1
1979-82~1
(9.1/1000)~1
(10.1/1000)~1
(23.2/1000).~1
European,~1
Pakistani,~1
'light~1
dates'~1
pre-eclamptic~1
Malformations~1
1974-85.~1
lip;~1
(alone)~1
Clefts~1
teratogen~1
atypically~1
average;~2
hypocalcaemia.~1
anticoagulant.~1
Swivel~1
Glamorgan.~1
haemolysed.~1
Paediatricians~1
Glycocalyx~1
glycocalyx.~1
glycocalyx,~1
solids.~1
223).~1
73.4%~1
Baffle~1
Dysrhythmias~1
unreconstructable~1
(ex~1
(51/52)~1
(FPC)~1
spectacular~1
FPC,~1
18.1%~2
24.2%~1
emerges,~1
apply:~1
"direct~1
line"~1
Greenville~1
Preoperative:~1
lbs~3
(196-535);~1
(110-300);~1
(140-320).~1
(97.5%~1
intensively.~1
Caterpillar~2
Corporation~1
Peoria,~1
reimburse~1
CPT-4~1
unbundled~1
rebundled,~1
"degree~1
difficulty"~1
(DODRVS)~1
DODRVS~1
pay,~1
fee.~1
access-oriented,~1
market-driven~1
resource-based~1
RBRVS)~1
formula-driven~1
50),~1
34-84~1
47).~2
operations/surgeon~1
operations/surgeon).~1
pancreatectomies~2
39%),~1
vagotomies~1
pyloric-preserving~1
(1694~1
3271~1
mL),~2
microfocal~1
Preoperatively~3
cystadenocarcinomas,~1
microadenocarcinoma.~1
Cystadenocarcinomas~1
1967,~1
series.(ABSTRACT~1
(13,~1
sternotomy;~2
approach).~1
alveolar-postductal~1
"honeymoon"~1
abdominal.~1
transmediastinal.~1
(SvO2)~1
SvO2~4
(0.19~3
(maintained~1
95.13~1
38.76x~1
278.71x2~1
milliliters)~1
lingula~2
lingular~2
nonimmunocompromised.~1
inferior.~1
(VSD).~1
angina).~1
(pretreatment)~1
(MEI)~1
MEI~4
oxygenators~3
Duromedics~1
Vienna.~1
(21.5%).~1
6.25%~1
Austrian~2
citizens;~1
(2.3%).~1
Endoaneurysmorrhaphy~1
tracheobiliary~2
skeletonizing~1
prebinding~1
Desorption~1
desorb~1
enalapril-hydrochlorothiazide~2
mL/s~2
[80~1
mL/min]),~1
Reimplementation~1
chiefs,~1
chairmen,~1
self-learning~1
expert.~1
malnourished.~3
posteducation~1
posttest,~1
latrogenically~1
Philadelphia,~3
(NMS),~1
hematochezia.~1
Sigmoidoscopy~1
hydrophila;~1
neuro-osteoarthropathy~1
Charcot's~1
contributory,~1
nonanginal~3
CAD)~1
(Mg++)~1
0.965~1
(1.93~1
mEq/L);~2
triamterene-containing~2
(2.01~1
Mg++.~1
(HBM)~1
intervention:~1
HBM~3
make,~1
keep,~1
5184~1
14.7%,~1
36.2%~1
reocclusion,~1
(27/76)~1
(27/100)~1
-4.1%~1
6.0%)~1
(11.0%~1
Posthospitalization~1
herself~3
prostration~1
staring,~1
postanginal~2
Postanginal~1
(HLR)~1
(Mich)~1
HLR~7
36.1%~1
[calcinosis,~1
dysmotility,~2
telangiectasia]~1
variant)~1
reflux-related~1
"impression~1
smears"~1
plate).~1
(SPEP)~1
SPEP~4
decide,~1
"patient,"~1
shame~5
humiliation~4
inadequacies,~1
shortcomings;~1
complaining,~1
suing.~1
counterhumiliation~1
(berry)~1
SAH-triggered~1
hemorrhages)~1
Infrequently,~1
maltophilia~4
(Xanthomonas~1
maltophilia)~1
gangrenosum,~1
addict.~1
earlobe.~2
prescribed,~2
Conn,~1
Louis).~1
mental-health-care~2
Schedule/DSM-III~1
social-interpersonal~4
DSM-IV)~1
School-aged~1
Children-Epidemiologic~1
Version~1
informants.~1
under-report~1
parent-child~1
informants,~1
felonies~1
felony~1
jurisdiction,~1
incompetency~1
offenses,~1
postrelease~1
always.~1
"factors,"~1
melancholia,~1
melancholia~1
"psychological"~1
worthlessness,~1
helplessness,~1
hopelessness,~1
PM).~1
Dexamethasone-induced~1
corticosteroid-catecholamine~1
"escaper"/"suppressor"~1
escapers~1
suppressors~5
micrograms/dL)~2
DST).~1
Afternoon~1
retested,~1
age--the~1
"MHPG~1
age"--was~1
(SCID).~1
GAD;~1
.79.~1
SCID~6
GAD.~1
(CGAS),~1
CGAS~2
categorization.~1
therein,~1
immunogenetics.~1
(gross,~1
ultrastructural)~1
vague.~1
article's~1
storm,~1
first-described~1
(Atlanta)~1
(indicative~1
chloroquine-induced~3
hematoxylineosin-stained,~1
fibroproliferative~1
atheronecrosis~2
atheronecrosis,~1
non-atherosclerosis-related~1
atherosclerosis-related~1
(DCHs)~1
(PBs)~1
PBs,~1
DCHs~3
DCH~1
PBs~1
hinted~1
Banks,~1
Arlington,~1
Va,~1
ALT.~1
alkaptonuric~3
ochronotic~7
leaflet:~1
endothelial-lined~5
embryologically~2
digoxin-specific~1
dilemmas,~1
(4100~1
12,900/mm3).~1
neutrophilia.~1
Heterosexual~1
4.87.~1
Multilocular~1
locule.~1
protothecosis~1
protothecosis.~2
sporangia~1
endospores~1
Vaginitis~2
emphysematosa~2
"popping~1
sound"~1
body-type~1
cyst's~1
self-healing~2
epidemiologic,~5
(male:female~1
1:3).~1
(axilla~1
inguinal,~1
"uncombable~1
immunofixation,~2
Enterobius~1
vermicularis~1
Ova~1
helminths~1
vermicularis.~1
neuroectoderm~1
palisading,~1
cylindromas~2
(aPTT)~1
Responsiveness~4
aPTT~2
photo-optical~1
(WHO~1
interpretations,~1
skewing~3
misconstrued~1
combine,~1
individualistic~1
art,~1
taxonomy,~1
inculpate~1
gamma-subunit~2
enolase)~1
nonargyrophilic~3
ng/mg),~1
ng/mg).~3
Neuron-specific~1
well-recognized,~1
vasitis~1
deferens;~1
epithelial-neural~1
next-of-kin.~1
(Finland),~1
rhombencephalic~1
Diencephalic,~1
metencephalic,~1
myelencephalic~1
embryopathology~1
Brenner~1
nonregressive~1
phylloides.~1
gastric-type~1
heterotopia.~1
Intratubular~1
refractile~1
Sertoli's~1
"ring"~1
plastination~1
Plastinated~1
(CTS)~3
midpalm~1
32C.~1
msec/degree~2
electromyographer~1
overlies~2
Pneumatosis~2
types--idiopathic~1
secondary.~1
Locked-in~1
mutism,~1
Specially~1
port.~2
wheelchair-based~1
Reoperative~1
axilloaxillary~2
Tufts-New~1
Dacron,~1
(pHI)~1
pHI.~1
pHI~2
6.86~1
(opposite~1
Aspirin-dipyridamole~1
(U-63557A)~1
downward.~1
complication/mortality~1
reconstructable~1
"cryptogenic"~1
antibody-tagged~1
urinalysis;~1
guillotine~1
Lisfranc's~1
Chopart's~1
(BIH)~1
BIH~1
37-kg~1
BIH.~1
0.12%~1
herniorrhaphy.~1
groins.~1
peritoneography~1
lateralize~1
levodopa/carbidopa.~1
(LNAAs)~1
LNAA~2
supper~1
(Merck,~1
Dohme),~1
videotape-recorded~1
factor-analyzed~1
animation.~1
methylmercury-treated~1
methylmercury.~1
hair;~1
3192~1
migraineurs,~1
migraineurs~1
tranquilizers,~2
amphetamines,~1
thrombosis/phlebitis,~1
odors,~1
progabide.~2
Progabide~2
progabide's~1
Unconcentrated~1
(AIF)~2
immunolabeling,~1
avidinbiotin-peroxidase~1
(avidin-biotin~1
AIF).~1
Oligoclonal~2
1014~1
(OND)~2
AIF~4
avidinbiotin~1
AIF,~1
Avidin-biotin~1
OB.~1
neuro-imaging,~1
involvements.~1
OND~2
Neuroretinitis,~1
"macular~1
star."~1
lipoproteinaceous~1
Demyelinating~1
star.~2
neuroretinitis~3
manifestations;~1
staggered;~1
star,~1
resolve.~1
militates~1
Meige's~1
(blepharospasm-oromandibular~1
dystonia)~1
drifting~2
blinks~1
synkinetic~1
penicillin-responsive~1
pontis~1
mania)~1
ventricle/brain~1
non-manic~1
limbic-connected~2
(severely~1
abnormal)~1
retract~1
intraplaque~2
Reanalysis~1
(ulceration)~1
asserted~2
ambulate.~1
prednisone-treated~4
JHM~3
viral-like~1
AC)~1
AC).~1
1944.~1
(dysphasia,~1
dysgraphia,~1
(perceptual~1
memory)~1
video-electroencephalographic~1
(carbamazepine~2
mg/L])~2
eye-hand~1
memory-scanning~1
Carbamazepine~1
4874~1
migraine-associated~1
5131~1
federally~1
86.7%.~1
22.7%.~1
20.78~1
nonspinal~1
upset,~1
(Sanders,~1
Retzlaff,~1
Kraff~1
[SRK])~1
SRK~2
Wilmer~1
Ophthalmological~1
measurement-predicted~1
20-D~2
4.00~1
"implanted"~1
"predicted-emmetropic"~1
photo-coagulation~1
ARN.~4
Multilinear~1
suspects,~1
6.8;~1
16.0)~1
5.8;~1
Suggestive~1
self-tonometer~3
(PXS)~1
(PXM)~1
PXS~5
"pseudoexfoliation~1
suspects"~1
PXM~2
Inferior~2
PXS,~1
PXM,~1
30-2~1
Instruments,~1
Leandro,~1
Calif).~1
dB,~3
(choroidal)~1
microperforation~1
Riolan.~1
"gray"~1
(Fra[X])~1
(Xq27-28)~1
Phenotypic~3
Fra(X)~2
(64.8~1
[6480~1
rad]~1
treatments).~2
bengal,~2
(550~1
bengal)~1
bengal.~1
wings.~1
subretinal,~1
mate~1
(PLRK).~1
Cryolathing~1
lenticule,~1
PLRK~2
lyophilization.~1
lata~5
"iliotibial~1
tract."~1
stripper~1
iliotibial~1
stripper,~1
nine-member~1
Ophthalmology.~1
voluntarily),~1
probation,~1
granted~2
accreditation.~1
Ophthalmology~1
"Special~1
Requirements~1
Ophthalmology."~1
"end"~1
exoplant~1
(cortical,~1
subcapsular)~1
helicoid~1
(GHPC)~1
serpiginous~3
choroiditis)~1
GHPC,~1
(eventually~1
GHPC~1
laser-based~1
Photographs~2
193-~1
248-nm~1
nanoseconds~1
supersonic~1
decelerates~1
Plume~1
B16F10~1
enucleation-induced~1
chemomyectomy~1
chemodenervation~2
"suicide~1
transport")~1
silicone-,~1
perfluoropropane-,~1
fluid-filled~4
silicone-filled~2
perfluoropropane-filled~1
(12-0-tetradecanoyl-phorbol-13-acetate)~1
Strain~5
aponeurotic~1
tear-producing~1
overcorrections~1
undercorrections~1
endoillumination,~1
microforceps,~1
infusion/aspiration,~1
(KTC)~1
HLA-DR+~11
KTCs~4
(PA);~1
KTC~1
KTCs.~1
Auranofin~1
(2.5-10~1
(50-250~1
(250-1,000~1
4-bromophenacyl~1
azurophil~4
eighteenth~1
1,424~1
1,805~1
63-94~1
specializes~1
Kellgren~1
Lawrence.~1
(definite~1
osteophytes),~1
31%);~1
flares,~1
perceptions;~1
(24.4%),~1
(22.8%),~1
(22.8%).~1
searching~2
"Why~1
me?"~1
(45.5%),~1
(34.0%),~1
(34.1%).~1
(49.4%)~1
(21.0%).~1
illness'~1
providers'~1
Pneumococcus,~2
steers.~2
libitum)~1
[pituitary-derived~1
IU/d~1
excipient].~1
9-10-11th~1
Restricted-fed~1
(FFA),~2
steers,~1
"regular"~1
any)~1
"modified~1
diets"~1
nutrition-care~1
magnified.~1
insists~1
ignores~1
neighbor~1
87-lb~1
dietitian's~1
technician's~1
individualized,~3
(MPO)~4
MPO~26
pMP401~1
(AML)~14
start/termination~1
diethylstilbesterol~1
DES-induced~2
lactotrophs.~1
(2-13~1
Ppl,c).~1
Ppl,c.~1
firmer~2
Ppl,c~2
elastase-induced~3
circumferential,~1
anterior-posterior,~2
sternochondral~1
26-27~1
239%~1
lambda-gammopathy~1
prekallikrein~9
payor,~1
two-tiered~1
Questioning~1
excellence~3
self-growth~1
benefited.~1
scant.~1
acinetobacter~1
sentinel~2
thunderclap~1
sclerae~6
equivocal,~1
(40/46,~1
anaemias~1
(2/28,~1
(5/95,~1
5.3%;~1
0.87.~1
preponderance;~1
"crops"~1
aneuploidy;~1
1991~1
102,000~2
projected,~1
135,000~6
73)~1
non-users~1
oestradiol:~1
happen~1
non-users,~1
Wmax~1
Hydraulic~1
16-80~1
21-40;~1
ex-cigarette-smokers~1
cigarettes;~1
("smoking-years")~1
abstention.~1
abstention,~1
frankness~1
sabutamol~1
hypo-osmolar,~1
iso-osmolar~1
nebulisation~1
argued,~1
ignorance,~1
non-compliance.~1
"narrative~1
reconstruction".~1
anti-anginal~1
200,000)~1
N-(4-azido-2-nitrophenyl)-2-aminoethyl~1
(NANDP).~1
NANDP~1
Exclusive~1
actin-activated~1
Mg-ATPase~1
photolabelling~1
gizzard)~1
3H-NANDP~1
vanadate~3
labelled.~1
Splice~1
Mutagenesis~2
E1a~2
adenovirus,~2
site:~1
hierarchy~5
archetypal~1
beta-globin:~1
Introns~1
(pre-messenger~1
RNAs)~1
pre-mRNA~1
(lariat)~1
lariat~3
accepts~1
branch-accepting~1
acceptors,~2
Mutation~3
neurotrauma~7
disfigurement,~1
amnesia--in~1
helmet~1
motorcyclists,~1
handguns,~1
challenging.~2
inexhaustible.~1
neuromedical~1
Principles~1
Creative~1
alterated~1
fear.~1
Assisting~1
arduous~1
journey~1
Bond,~1
victim's~1
geared,~1
"cured"~1
Let~1
paved~1
Coordinator.~1
asses,~1
Continual,~1
judiciously~1
hypocarbia.~1
Paramedics,~1
realize,~1
wisdom.~1
docosahexaenoic~1
(DHA)~1
phospholipids:~1
Anaesthetists~1
pertinent.~1
(CCB).~1
neutrophil-specific~2
CCB~1
TG),~1
platelet-specific,~1
microgram/mL,~1
5.13~1
1.86~1
(1.57~1
(p34)~1
pol~9
endonuclease/integrase~1
p64~1
p53~8
p34~3
p64/p53~1
HTLV-IV,~2
retrovirus.~5
HTLV-III/LAV,~3
p64/p53.~1
HTLV-IV~5
elastase-1~2
80),~1
72.1%,~3
98.3%,~2
85.9%,~1
83.6%~1
60.0%,~1
asthmatic's~1
panic-fear.~1
hispanic.~1
clinic:~1
nontuberculosis~1
Esophagopericardial~1
esophagopericardial~1
education-orientation~1
time-sequenced~1
PNH.~2
DAF.~2
111Indium-labeled~2
1760~1
1636~1
1385~1
epileptic,~2
hypercalcaemia,~3
hypercalcaemic~1
synovial-fluid~2
saturated,~1
low-molecular-mass~2
("bleomycin-iron").~1
oxidised~1
(dehydroascorbate)~1
iron-catalysed~1
genital-tract~1
Synovium,~1
(SARA)~1
fluorescein-labelled~2
('Micro~1
Trak';~1
Syva).~1
SARA~2
inclusion-like~1
Official~1
1971-80~1
professions.~2
means-weight~1
(MUAC).~1
Stunting~1
MUAC~4
wasting)~1
(sensitivity)~1
operate,~1
fish-allergic~2
fish.~1
(ACS)~1
tracheotomy;six~1
ACS~1
Substantive~2
ACS.~1
Surface-spreading~1
surfactant-treated~5
TA-treated~1
washes.~1
measured.(ABSTRACT~1
physician-directors.~1
physician-director~1
startling~1
headings:~1
Description,~1
Requirements,~2
Standards;~1
Standards,~1
Deficiencies,~2
Impact;~1
Causes,~1
Solutions.~1
(item~3
trouble-shooting~2
interwoven~2
heterophil-negative~1
Acute,~1
dipstick.~1
sediment;~1
customers~2
analyst's~1
automation,~1
avail~1
choose.~2
reflectometer~1
Machines~1
price.~1
Considerations~2
strains:~2
(penicillin-resistant~1
penicillinase;~1
NaCl;~1
MR1~1
(methicillin-resistant~2
latter;~1
MR2~2
6538~1
sulbactam.~3
bacteriostatic.~1
homosexually~3
HTLV-III/LAV-seropositive~1
involution,~1
virus-replicating~1
virus-antibody~1
HTLV-III-infected~3
trapping,~2
cytopathogenic~1
HTLV-III-associated~1
NHS~3
title,~1
Kallikrein~4
10.2-~1
90-~2
22-fold,~1
(B-1-A-2)~1
124958-R)~1
B-1-A-2~2
10(-9)-10(-8)~1
[32P]orthophosphate~4
10(-10)-10(-9)~2
vanadate.~1
phosphorylation-dephosphorylation~1
anti-HBe.~1
clearance/seroconversion~1
HBeAg,~1
antielastolytic~1
beta-D-glucose~1
pressures)~1
GO.~1
scavenger)~1
methoxy-succinyl-L-alanyl-L-alanyl-prolyl-L-valine-chloromethyl~1
aminotriazole-inactivated~1
N-tosyl-L-phenyl-alanine~1
chloromethyl~7
N-alpha-p-tosyl-L-lysine~1
NE-mediated~1
GO-~1
oxidant-resistant~1
(Eglin-C),~1
oxidant-sensitive~1
1PI).~1
Eglin-C~1
HA4-1B~1
HA4-15~1
kappa),~2
Bb~7
HA4-1A~3
FD3-20~1
Ba.~1
anti-Ba~3
Ba~6
anti-Bb~2
EC3bBb~1
Bb.~3
[125I]B~1
EC3b~1
Fab.~1
(LIF)~2
f-met-leu-phe-mediated~1
(antibody-dependent~1
cytotoxicity).~1
57.2%)~1
(124.4%)~1
(59.9%).~1
anti-neutrophil~4
51.6%.~1
Responsibility~2
Words~1
captivate~1
compel,~1
hobble~1
executives~9
subtleties~1
paradoxes~1
unit-based~1
Hospital's~2
privileging~1
Elizabeths~1
criteria-based~1
granting~1
olive-oil-rich~1
complex-carbohydrate-rich~1
non-HDL~1
Edmonston-Zagreb~4
Schwarz~4
platelet-membrane~1
(1.1-1.3)~1
dopamine-beta-hydroxylation.~1
Dopamine-beta-hydroxylase~1
noradrenaline.~1
Acute-phase~2
Penang,~1
Malaysia,~1
P388D1.~3
(81.7%)~1
1972-81,~1
time--age-period-cohort~1
symptom;~1
alanine:glyoxylate~1
(AGT,EC~1
2.6.1.44)has~1
(PH),~1
AGT~2
glutamate:~1
(GGT,~1
2.6.1.4)~1
1.11.1.6).~1
GGT.~1
AGT,~1
Anti-SLA-positive~1
liver-kidney-microsomal~1
autoimmune-type~2
CAH,~2
anti-SLA-positive~2
hypergammaglobulinaemia~1
g/l,~4
1.8-5.3~1
g/l);~1
Anti-SLA~3
species-specific,~2
(0.05-0.25~1
Adenosine,~2
droppings.~2
roost;~1
guano~1
Sennar~1
bat-related~2
case-histories~1
(RAST)~1
bat.~1
Droppings~1
hypoxaemic~1
(27-42~1
meningococcal~3
TNF)~1
baselines~1
entailing~1
(NDPH)~1
1:32.~1
hybridisation~8
NDPH.~1
NDPH~1
25-50%~1
manufacturers;~1
leukemia/lymphotropic~1
(HTLV-III),~1
courts,~1
monopoly~1
demanded~2
supreme~1
cattery~2
immunodeficiency-like~1
Tentatively~1
lentivirus,~2
cat-to-human~1
Kittens~1
leukopenic,~1
polylactic~1
(PLA)~1
Elastase.~1
Elastase),~1
(covering~2
PLA~1
P-E~2
"PLA"~1
Elastase"~1
membrane).~2
(2-12~1
Scar~1
(anti-HBc),~1
107,473~1
6.38~1
159,500~1
factor-specific~1
antibody?~1
disclosed?~1
doctrine~1
"right~1
privacy"~1
"duty~1
warn"?~1
Hemolytically~1
C1,~4
rabbit's~2
EAC423~3
EAC42~1
C5-9~1
cervical)~2
Quinolone~1
time-kill~3
ciprofloxacin-containing~1
Macrobroth~1
Replica~1
ciprofloxacin-supplemented~1
Replica-plated~1
Amifloxacin~1
heteroresistant~1
mutate~1
MIC;~1
survival),~1
gradual,~2
self-extubation~1
(EPO)-hydrogen~1
(H2O2)-halide~1
H2O2),~1
halides~4
injurious,~1
EPO.~1
target-cell~3
EPO-H2O2-halide~2
EPO-catalyzed~1
halide~2
EPO-coated~1
112,000~1
(HMW)-kininogen.~1
HMW-kininogen~6
Cleavage~3
kininogen,~4
Philosophical~1
addict,~1
(premotivation,~1
Believing~1
85%-90%~1
re-entry.~1
multifaceted,~1
hospital?~1
morale~2
high?~1
enlisting~1
credentialing~1
competencies,~1
Forbes~1
credentialing.~1
articulates~1
"vision"~1
empower~1
proactively~1
corporation,~2
beneficiary~1
gifts~1
behalf~1
executives.~2
decimating~1
communique~1
hospital-wide~1
clinical-administrative~1
Purpose,~1
Philosophy~1
microliter/ml)~1
HD-antigenaemia~1
anti-HD~4
seroconversion,~6
antigenaemia,~1
co-infection.~1
(PSS),~1
617,913~1
non-rheumatic~1
studies--the~1
Whitehall~1
Civil~2
Servants~1
yersiniosis,~1
serologically,~3
Yersiniosis~1
yersiniosis~1
pseudotuberculosis~3
enterocolitica,~1
yersiniosis.~1
sodium-propionate;~1
'Channelyzer'.~1
normotensives;~1
[SE]~1
10(-3))~3
(0.6);~1
(0.7);~1
(0.9);~1
(2.8),~1
octadeca-9,11-dienoic~1
diene-conjugated~1
automated.~1
hospital--a~1
birthweight).~1
Christmas,~1
prison,~1
affirmative,~1
Broadmoor~1
answer),~1
entitlement,~1
902~2
6.1).~1
V);~1
85-90~1
PP14.~1
anti-PP14~1
immunoadsorbent.~2
67.~1
harassment~1
Harassment~1
observe.~1
Derogatis'~1
Well-controlled~1
Well-adjusted~1
hypertension-related~1
eat,~1
pessimistic~2
worry;~1
overall;~1
stressed;~1
Self-Assessment~1
1979;~1
(BSE)~1
upper-middle-class~1
BSE~3
BSE,~2
self-concept.~1
susceptibility/seriousness~1
(susceptibility/seriousness)~1
hierarchically;~1
.27.~1
detective~1
health-promoting~3
Health-Promoting~2
Self-Actualization,~1
Responsibility,~1
Nutrition,~1
Interpersonal~1
Management.~1
48-item~1
Second-order~1
Lifestyle.~1
.922;~1
.702~1
.904.~1
Howard's~2
irreplaceability,~1
selves,~2
equality,~2
empathy,~1
163-item~1
empathy.~1
Humanistic~1
Behaviors~1
search.~1
Billings~1
Moos~2
(CRS;~1
Moos,~1
Cronkite,~1
Billings,~1
Finney,~1
(PAIS;~1
Deragotis~1
Lopez,~1
analyses:~2
Foci~1
(Indices~1
Responses),~1
(1984),~1
(PAIS,~1
PAIS~1
.49,~1
.37,~1
.47.~1
CRS.~1
Lazarus'~3
(1966)~2
appraisal,~1
(perceived~1
support)~1
appraisal.~1
(use~2
reappraisal,~1
emotion-focused~2
coping)~1
disabled,~1
wheel-chair-bound~1
problem-~1
coping.~3
nonmarried~1
EKG.~1
anticipating,~1
sighing~1
respirations,~1
(malnutrition)~1
(first-degree~1
(second-degree~2
(BBB~1
hemiblocks)~1
physiologic--those~1
workload--and~1
psychological--those~1
(LAP)~1
A-crystallin~5
(-366~1
+46)~1
oncogenesis.~1
Large-T~1
beta-crystallins~1
gamma-crystallin~5
Accessibility,~1
neomycin/niacin,~3
cholestyramine/neomycin,~1
lovastatin~6
lovastatin/neomycin.~1
cholesterol/high-density~1
hyperlipoproteinemia,~1
(HTLV-III/LAV).~2
HTLV-III/LAV-specific~1
(ECP),~1
MPO,~2
(PaO2/inspired~1
NC).~1
digesting~1
elastase).~1
antileukoprotease,~1
eglin-c,~1
eglin-c.~1
eglin-c~4
cfu),~1
cot~1
sodium-resistant~1
1000-bed~1
Methicillin-resistant~2
Bacteriophage~2
profiling.~1
cross-transmission~1
vesico-vagino-rectal~1
Lehoczky's~1
pudendum,~1
(amylase~1
43)~1
pancrease,~1
low),~1
low).~1
investigate,~1
immunoassays.~4
m2:~3
650%~1
biocompatibility,~1
cholagogic~1
frustrated,~1
99Tcm-EHIDA.~1
Duplicate~2
0.959).~1
(Lo)~1
%Lo)~1
oblique.~4
198%~1
Lo~1
sarcomeres~2
rhodamine-phalloidin~1
formylpeptide~7
shorter-lived.~1
N-formylhexapeptide.~3
elastase.~10
N-formylhexapeptide~1
N-formylhexapeptide-induced~1
oligodendroglial~4
Budding~1
bar-shaped~1
nucleoids~2
retrovirus,~11
gaps),~1
replicate.~1
myelin-forming~1
multiple-resistant~1
penicillin-streptomycin~1
penicillin-kanamycin~1
penicillin-gentamicin.~1
adenylylated~1
3''~1
streptomycin-resistant~5
streptomycin/ml)~1
penicillin-susceptible~4
contempt~1
"Thinly~1
contempt,"~1
Peters~1
Passion~1
Excellence,~1
nurse?~1
Lillian~1
settlement~2
house.~1
Kinney~1
Did~1
ex-nurses?~1
Nightingale~1
biostatistics.~1
pioneers~1
You~1
non-university~2
research?~1
Motivational~1
explicated.~1
needs?~1
programs?~1
management-level~1
staff?~1
NEs~1
computers,~1
marketing.~1
It's~2
(AK1)~1
0-0.10).~1
(66%,~1
52-80%)~1
ectocervical~1
(35%,~1
16-53%)~1
age-adjustment~1
age-mediated~1
(WG)~1
6.2,~1
calf-intestinal~1
W8,~1
autoantigen,~2
neurosurgery~2
mid-1986.~1
72.8%~1
4.6),~1
2.2)~1
thrush,~4
amoebiasis,~1
(tinea)~1
thrush~2
zoster;~1
1028~1
1038~2
Agbave~1
2850~2
Kati,~1
village,~1
1381~1
carbohydrate/cassava~1
(84%~2
1916~1
supply)~1
malnutrition-related~1
theorem,~1
mortality--an~1
practical.~2
oversimple~1
31,224~1
Midlands~1
adenoids,~1
sterilisation~1
(SSF),~1
7692~1
SSF.~2
SSF,~1
tertile,~1
SSF~1
BMI.~2
Proteolipid~2
ribonuclease.~1
glycolipid~15
fucosylated~1
(a),~1
(UDCA,~1
13-15~1
(PBC).~1
gamma-glutamyltranspeptidase,~1
(respectively~2
UDCA.~1
A-gliadin~1
early-region~2
(Elb)~1
leucocyte-migration-inhibition~1
non-occlusive~1
(continuous~2
echotomography-B~1
0-50%~2
50-75%~2
(crude~1
9.57%).~1
0.23%~1
2.48%~1
1.71%~1
75-99%~1
non-bolus~1
(oral)~1
0.61-0.80).~1
0.70-0.86),~1
Humidified~1
twin)~1
blood-velocity~2
acidotic.~1
hyperoxygenation,~1
hyperoxygenation~1
(IBS),~1
suggested--72%~1
high-fibre~1
bulking~1
hyalinised~1
tremolite~2
whitewash~1
asbestiform~2
tremolite.~1
Metsovo~2
amphiboles~1
amosite~1
crocidolite.~1
risky,~1
cons,~1
adult-adolescent~1
gratification~1
weaknesses,~2
collaborate~2
talents,~1
users/abusers~1
polio,~1
immunizations.~2
travel,~1
parenthood,~1
Legal,~1
minors~1
Seeing~1
scheduling,~1
enumerated.~1
teenager's~1
disengage~1
liberally~1
lymphotrophic~1
virus-III~2
Department-Tuberculosis~1
Haitian,~1
lymphatic),~1
thrush).(ABSTRACT~1
(HMD)~1
HMD~4
(BPD).~2
%PMN~3
%MAC~2
HMD,~1
%MAC,~1
HMD.~1
HIV-related~4
cephradine,~1
microdilution.~1
cephradine.~1
cephradine~1
Cefamandole~1
Cephradine,~1
inter-regional~1
burst),~1
MPO.~1
dosage-form~1
radiotelemetric~1
coatings,~1
unification,~1
customer's~1
kaleidoscope~1
horizon~2
me.~1
(GL).~1
GL~1
(SGL)~1
anti-GL~1
(NHS),~1
2-deficient~1
(C2d-HS),~1
C4-deficient~1
SGL~4
Mg-EGTA.~1
C1.~1
C2d-HS~2
C1q~51
B-depleted~1
SGL.~1
SGL,~1
(H2O2),~1
neptrotoxicity~1
Myeloperoxidase~2
(MPO),~2
MPO-H2O2-halide~2
chloride-containing~1
MPO-H2O2-perfused~2
effacement,~1
(p40)~1
p40~1
(mab~2
IV.3).~1
inter-donor~1
IV.3~2
aggregometry.~1
CD2+/CD16+/CD3-~1
anti-Thy-1.1~1
Thy-1.1+~1
SL2~1
IgG2b.~1
anti-Fc~8
5.14)~1
IgE-antigen~1
5.14~2
IgE;~1
R's~1
IgE-Fc~1
zymogens~1
proteolysis,~3
laborious~1
H-D-Pro-Phe-Arg-p-nitroanilide-HCI~1
(S-2302),~1
microplate,~1
kallikrein.~9
marketplace,~1
renovating~1
hotel-like~1
downsizing~1
self-esteem?~1
relocated,~1
executives,~2
climate,~2
non-nursing~3
corporation.~1
productive.~1
hired.~1
nursing?~1
kallikrein-kininogen-kinin~1
(KKK)~1
KKK~3
kallikrein,~5
36-60~1
Coxsackie-B-virus-specific~1
slot-blot~2
hybridisations~1
dermatomyositis,~3
Coxsackie-B-virus~1
RNA;~1
oesophagogastroduodenoscopy~1
litres/min)~1
21-65~1
echocardiographs~1
age/sex~1
95-120~1
107,~2
hydroureter.~1
(HPA),~1
Roman~2
snail,~1
pomatia,~1
N-acetyl-galactosaminyl~1
infectiousness~1
partnership.~1
losers"~1
annually)~1
losers".~1
"remission-inducing"~1
fallacious.~1
necessity.~1
inconvenience.~1
(YE)~1
Belgium,~2
YE~4
O:3~1
O:9~1
gastroenteritis;~1
$451~1
$889,~1
685,400~1
$300~1
discretionary.~1
40,635~1
1978-85,~1
quarter)~1
39-40~1
41-42~1
undelivered,~1
undelivered~1
ATP-requiring~1
1-3).~1
ubiquitin-mediated~1
alpha-NH2~1
(tRNA)~1
(aspartate~2
glutamate).~1
Tumour-specific~1
(TSA;~1
anti-TSA~1
Vaccination~2
copresentation~1
Polyoma~1
(PY)~1
rodents;~1
PY-transformed~1
PY-specific~1
Tumorigenesis~1
PY~2
middle-T~1
small-T~1
(ST),~1
TSAs~1
Rejection~2
MT.~1
unparalleled~2
3-acetoxymethyl-7-alpha-chloro-3-cephem-4-carboxylate-1,1-dioxide~1
(Porcine~1
elastase.)~1
(T.-Y.L.~1
Ser~2
57.~1
(1976-1986),~1
peaked.~1
roomed-in~1
nursery-at-night~1
full-term,~1
bassinet~1
rooming-in~1
25.4%),~1
11.2%),~2
7.5%)~1
nurse-administered~1
Krantz~1
Survey;~1
7-point~1
Profile;~1
Bi-polar~1
Bandura's~1
framework;~1
purposively~1
Set,~1
(HOS),~1
do-not-resuscitate~1
(DNR)~1
mid-Atlantic~1
13-item~1
replications~1
DNR~3
parent(s)~1
avoidance-active~1
parent-doctor~1
130)~1
Linkages~1
passage,~2
(HOL),~1
HOL,~1
HOL.~1
HOL~3
HOL;~2
4.202,~1
.026.~1
0.412,~1
.666,~1
.3271,~1
.083.~1
6.79,~1
.034.(ABSTRACT~1
working-class,~1
progressed;~1
(Verran~1
sociological~1
R2s~1
.34.~1
R2.~1
diligent,~1
allay~1
toileting.~1
"accept"~1
lifestyle.~2
Long-term,~2
lease~1
Competence~1
Physical,~1
Informed,~1
assertive~1
ostomy,~2
ostomate.~1
urostomies~1
pouching~1
ostomate~1
Pouches~1
Damaged~2
$3~2
$5.~1
Ostomy~1
bed-ridden~1
commonalities.~1
circumference;~1
fold;~1
research-based~1
sores,~1
Well-designed~1
span;~1
augment,~2
replace,~2
learner~1
"caring"~1
Pacemaker~1
Cardiology/American~1
subcommittee~1
macrophage/monocytes.~1
brain-derived~3
nonproductive,~1
tropisms~1
tight-binding~1
double-radioiron~1
Washing~1
phytates~4
Removing,~1
dephytinization~1
monoferric~1
phytate,~1
well-absorbed.~1
full-blown~2
HPX~2
peroxidase]~1
peroxidase-positive~1
granulations.~1
dysgranulopoiesis~1
(FFC;~1
fat/100~1
FFC~2
(FFC~2
4.7%),~1
elastase-1,~1
Elastase-1~1
trypsin;~2
6-fluoro-7-piperazino-4-quinolone~1
Hemophilus,~1
Obligate~1
(Leu-2-positive)~1
anergy,~1
1,034~1
kilometer~1
homosexual/bisexual~6
48.6~2
peroxide-dependent~1
explantation,~1
myeloperoxidase.~1
O2-/mg~3
782~1
O2-.~1
antiprotozoa~1
centriacinar~1
(EIC)~2
NO2-exposed~3
chondrocyte,~1
fluoride-inactivated~2
bind.~2
AKD~3
(ELF).~1
(O.2)~1
(ELISAs)~1
(STD)~3
(VRL)~1
Colindale.~1
97.3%~2
VRL~1
Mangabey~2
Mangabey-origin~1
leprae.~3
Dharmendra-type~1
lepromin,~1
OKT4-~2
OKT8-enriched~1
(FcR+)~1
FcR-~7
phi)~4
OKT4+~12
lepromin-responsive~1
OKT8+~14
T-enriched~1
monkeys'~1
Dharmendra~1
lepromin~1
FcR+~4
lepromin.~1
leprosy.~1
Clare's~3
Coast~4
country)~1
contradictions:~1
Cardinal~1
O'Connor~1
Archdiocese~1
life-styles~1
(gays~1
abusers)~1
bankrupt~1
earlier;~1
stumbling~1
anywhere.~1
midwest~1
Fio2)~1
26-fold,~1
six-fold,~1
micrograms/lung.~1
arteries/mm2,~1
alveoli/mm2,~1
(IVS)~2
self-splicing.~1
Tetrahymena~6
self-splice~1
catalysis.~1
GpN~1
CpU.~1
self-splicing~2
IVSs.~1
coexisted.~1
newborn;~1
1149~1
(CD4~1
CD8)~1
seroconversion.~7
Extravascular~2
51Cr-labelled~2
3H-water,~1
14C-urea.~1
[23.2~1
wt].~1
14C-urea~2
Permeability-surface~1
derecruitment~1
apnea/bradycardia~1
Unclear~1
(NCP)~1
(HNE),~1
HNE~8
chloromethylketone~1
oligopeptide~1
(CMK)~1
1-PI).~1
HNE,~1
CMK-complexed~1
1-PI~9
NCP.~1
(C5)-derived~1
cochemotaxin.~1
Immunoelectrophoresis~1
anti-factor~4
(IFN-alpha),~2
interferon-beta~2
(IFN-beta),~1
interferon-gamma~6
(IFN-gamma).~2
-beta,~1
-gamma~1
(pre-rRNA)~1
(alpha,~5
45S,~1
41S,~1
36S~1
pre-rRNA.~1
32S~1
pre-RNA~1
28S,~1
5.8S,~1
(L929~1
(GG2EE)~1
H9~6
shapes;~1
shells.~1
budded~1
(replication)~1
cow,~1
20-28%~1
selenoprotein~1
skim~2
diameric~1
suctioning.~1
.003.~1
hygiene;~1
Affects~1
husbands'~1
husbands.~1
43-item~1
nonprobability~1
inpatients'~1
seclusion-room~1
88-item~1
seclusions~1
seclusion~3
equity,~1
prebirth~1
postbirth.~1
postbirth~2
inequity~2
Fathers'~1
mothers'.~1
father's,~1
equity~1
Dyadic~2
(DMC)~1
infant-adult~1
Videotapes~1
Cohen's~1
agreement;~1
.86~1
Monadic~1
(Tronick,~1
Als,~1
Brazelton,~1
validity;~1
bi-serial~1
rpb~1
4.878,~1
(1-tail)~2
Construct~1
dyads~1
4.071,~1
DMC~1
(CNRs).~1
CNRs~2
CNR's~1
scientist,~1
associate,~1
facilitator.~1
CNR~1
engaged.~1
Nurses'~1
sector:~1
submission~1
intramurally~1
$3,000~1
proposals.~1
well-written~1
plethora~2
granulocytopenia,~1
kallikrein-induced~1
kinins.~1
kallikrein-kinin~2
kinins~3
polyethyleneglycol.~1
Fragment~1
erotic~2
deposition?~1
(intratracheal~2
(0.45~1
sliced~1
evenness~1
uniformity,~1
EIs~1
emphysematous,~1
apex-base~1
nonventilated~2
(MLI)~1
MLI,~1
EI,~1
submicrometric~1
weight]~1
CFU/g~2
ciprofloxacin-treated~1
carbenicillin~2
microbiota~1
antileprosy~1
phenazine~3
myeloperoxidase-mediated~1
iodination,~3
prooxidative~2
nitrogen-containing~1
force-frequency~2
subtetanizing~1
abdominis.~1
5(S),~1
12(R)-dihydroxyeicosa-6,~1
14-cis,~1
8,10-trans-tetraenoic~1
(leukotriene~2
LTB4)~1
5(S)-hydroxy-6(R)-L-gamma-glutamyl-L-cysteinyl-glycinyleicosa-7,9-~1
trans,~1
11,14-cis-tetraenoic~1
LTC4)~1
"peaks"~1
ABR.~1
ABR,~1
five-month-old~1
scalds,~1
bronchides~1
hydrofluoric~1
debridgement~1
treacherous~1
behind-the-back~1
girdles,~1
Requiring~1
ruler~1
pen,~1
Salmonellae~1
O-antigen~1
(C3b)~1
O-antigen.~1
tail.~4
DAF-A~3
63,000,~3
DAF-B~2
55,000.~1
convertases~2
decay-accelerating~4
450,000,~1
DAF-A,~1
DAF-B,~2
inositol-specific~1
papain.~1
inefficiently~1
64,000)~1
DAF-A.~1
Papain~1
DAF-B.~1
leukocyte-induced~1
papain,~2
papain-derived~1
phospholipases~5
hyperestrogenemia~1
XII)~1
surface-mediated~5
XI)~1
pig:~1
wheat);~1
WBS~1
starch);~2
WFS~3
(wheat~1
cellulose).~1
(nonstarch~1
WBS,~2
(g/kg),~1
40.8,~1
101.8;~1
63.7,~1
201.2;~1
20.5,~1
50.3;~1
39.0,~1
60.7.~1
(mL/24~1
FC,~1
4108,~1
4560,~1
2556~1
1757.~1
noncellulosic~3
urgent.~1
lentiviruses~1
D-type~1
retroviruses,~6
(STLV-III),~1
(SIV)~2
CD4-bearing~2
SIV~9
macaques,~3
sooty~1
mangabeys~2
SIVMAC~1
HIV-2,~4
HIV-2~9
Microtubules~1
microtubule-based~2
meiotic~9
spindles.~1
arrays,~2
assembly)~1
intermicrotubule~1
Reticulomyxa.~1
force-producing~1
ascertain,~1
overview,~1
intrusive,~1
accommodations~1
discovering~3
feat~1
unwary.~1
self-management,~1
lays~1
Stoll,~1
concern:~1
God;~1
hope;~1
rituals;~1
strengthen,~1
despair~1
Discussing~1
God-related~1
position.(ABSTRACT~1
over-protective~1
Feelings~1
support--especially~1
reciprocate~1
decisions:~1
values?~1
myths,~1
restrictive,~1
comforting~1
Spiegel~1
hypnosis,~1
ironically~1
daring~1
trance~1
"Do~1
pain?";~1
hurt?";~1
"Move~1
leg."~2
tonight?"~1
"Your~1
warm";~1
"It~1
hypnotherapeutic~1
Erikson~1
Barber.~1
Hypnosis~2
workshops,~1
self-control.~1
Technologic~1
Prolonged-release~1
difficult-to-enter~1
pain-management~1
acceleratory~1
antithrombin,~1
nonthrombogenic~1
hundredfold~1
heparin-antithrombin~1
(SIV),~3
neuroleukin~1
(NLK)~1
NLK~3
gp120~26
antigen-negative/antibody-negative,~1
antigen-negative/antibody-positive,~1
antigen-positive/antibody-positive.~1
immuno-compromise~1
MT-4~3
HTLV-IIIB.~3
thousands.~1
HTLV-IIIB~11
(ENV-80)~1
gp41~6
(STLV-III[AGM])~2
(HTLV-III/LAV-1/HIV)~1
(HTLV-III[BH10]).~1
STLV-III(AGM)~1
LTR~20
HTLV-III(BH10)~1
bp)~1
U3~11
U5~3
homology.~5
U3,~2
TATAA~1
AATAAA~1
polyadenylation/termination~1
3'-most~1
U5.~1
STLV-III~4
homolog~5
LTR.~8
LTRs~5
homologous.~1
HIV-2/LAV-2.~1
HIV.~30
HTLV-III.(ABSTRACT~1
Defensins~1
acid-urea~1
acid-extractable~1
H5)~1
L8),~1
H5~3
methanolic~1
acetate-lead~1
rim-staining~1
diaminobenzidine.~1
rim-stained~1
promyelocytes,~1
(149)~1
Hemophilia~1
seroprevalence,~1
seropositive,~2
(CDC~2
(ARC),~4
moderate),~3
(1977~1
77)~1
[T~1
assay])~1
declined;~1
26/mm3~1
1193~1
3851~1
387)~1
100/mm3~1
8/mm3)~1
seropositive)~1
threads~1
Executive~2
Officer~2
(CEO)~1
(CNO)~1
explored;~1
12.2%~1
CEOs~1
CNO~3
appointment.~1
CEO~2
succession,~1
contingencies,~1
like?~1
hold?~1
authority,~1
relax,~1
hybrid--a~1
businessperson.~1
executive,~1
articulated~4
forwarded~1
nursing's~1
leaders.~1
(WIM)~1
rutabaga,~1
digesta~5
bran-~1
rutabaga-based~1
WIM~2
rutabaga~4
digestible.~1
Extractable~2
(anti-invasion~1
[AIF])~1
(Trasylol)~1
matrix-derived~1
Suramin~2
transcriptase~5
suramin~3
g/wk~1
g/wk.~1
Suramin-induced~1
hemo-pneumothorax~1
kininogenase~4
fluid-samples.~1
(Mr54K)~1
(SRP).~1
SRP-receptor~1
(docking~1
preprolactin,~2
SRP,~1
(SSR),~1
35K).~1
deans,~1
encouragement.~1
universe~1
risk-reducing~1
weight-reduction~1
curvilinear.~1
payoff~1
52-item~1
Self-Care~2
refactored~1
parsimony~1
629~1
Varimax~1
parsimony.~1
15-item~2
goodness-of-fit~1
(GFI)~1
(0.848)~1
variances.~1
GFI~1
orientations,~1
meta-analysis~2
(NNS)~1
cumulate~1
NNS.~1
NNS~2
cheerful~1
communicative.~1
minister.~1
rival~1
mainframes~1
mainframe.~1
(HCWs):~1
(LE),~1
HCWs~3
serologic,~2
HCW~2
seropositivity.~3
HIV,~17
(HNE)~1
granulated~4
(Ng)~1
(Ac),~1
(Vv)~1
Ng,~2
Ag,~4
Vv~2
Ac~1
HNE-treated~2
nongranulated~1
ciliated,~1
preciliated,~1
rationales~1
aminoglycoside-(3)-N-acetyltransferase~1
(aacC5)~1
TEM-type~1
IS26,~1
IS140,~1
IS15-delta.~1
Tn2922.~1
Dealing~2
handled,~1
"tinned"~1
"reduction"~1
28-32~2
source:~2
lactose:~1
(LAC~1
GP).~1
44-239~2
ppm/5%~1
microL/L~1
mL/L~1
CO2).~1
arctocyonid~2
Chriacus,~1
Eocene~1
mammal~1
climb,~1
musculature),~1
plantigrade~1
claws,~1
semiprehensile~1
artiodactyls~1
Chriacus~1
Artiodactyla,~1
urban/rural~1
(nausea)~1
2451~1
(12.0%)~1
(25.2%),~1
pneumonectomies.~1
(9.4%~1
uromodulin,~4
616-amino~1
85-kilodalton~1
uromodulin~19
(PGK)~3
(ATP:3-phospho-D-glycerate~1
1-phosphotransferase,~1
2.7.2.3)~1
Embden-Meyerhof~1
PGK~4
PGK-1~4
premeitotic~1
PGK-2~3
Szabo~1
'retroposon',~1
bounding~1
non-functional~1
pseudogenes~1
pseudogene~4
(psi~6
PGK-1)~1
frames.~5
intronless~1
pseudogene,~2
meiosis.~2
Cockroft-Gault~1
180%.~1
(GB)~1
phenylcarbamomethyl~1
iminodiacetate~1
(99mTc-HIDA)~1
GB~5
101%~1
(89%~2
'simultaneous'~1
bellows~4
Inv(16)(p13q22)~1
t(16;16)(p13;q22)~1
juxtapose~1
16q22~3
16p13.~1
inv(16)~2
t(16;16).~1
(M4Eo).~1
M4~6
6%)~2
16p13~2
juxtaposition~3
16q22,~1
t(16;16),~1
heteroantisera~1
(AL).~1
AML,~5
M4,~1
M5~7
morphology/cytochemistry~1
subtyping.~1
immunophenotyping~2
"gold~1
standard"~1
immunophenotyping.~1
(Ph1)~3
(CML),~3
Ph1~3
bcr~15
Ph1-positive~5
CML;~1
CML.~14
(MEL)~4
nonerythroid~4
hybrids.~6
11-linked~1
11-containing~1
fibroblasts)~1
MEL~18
HEL~2
(HMSN)~1
fasciculus~1
gracilis.~1
Vancouver,~1
enrolment~1
seroconversion:~1
enrolment,~1
aminopeptidase,~2
deaminase-binding~1
g/m2).~1
combined-drug~3
CA-125~13
Cisplatin/Adriamycin~1
cytofluorometric~1
(3H-TdR~1
LI).~1
"null"~1
(Cy~1
CALL~1
mu).~1
(SIg)~1
(8.5%-15.5%).~1
cytostatics.~1
naphthol-ASD-chloroacetate~1
(6MP)~1
6MP~1
0.866;~1
6MP.~2
myelotoxicity~2
4-demethoxydaunomycin~1
(D-DNM)~1
(nucleated~1
D-DNM~6
t1/2s~1
4-demethoxydaunomycinol~1
(D-DNMol)~1
D-DNMol~2
plasma;~1
Antileukemic~1
cell-permeable~1
JEG-3~3
30-fold,~1
8-Br-cAMP.~2
[1.5~1
(Kb)]~1
Kb)~1
reporter~2
1.5-kb~1
0.3-kb~1
Oxytocin,~1
oxytocin-associated~1
(neurophysin),~1
(UOV)~1
UOV~2
(UOV/CL).~1
neurophysin,~1
UOVs~1
UOV/CL,~1
UOV/CL~2
deamino-8-D-arginine~2
DEX-treated~4
PGs.~1
day-1),~1
anti-diuretic~1
[hPTH-(1-34)]~1
hPTH-(1-34)~4
hPTH-(1-34)-treated~1
calvariae.~1
remodeling.~6
CA-125,~1
4.1)~1
Eicosanoid~2
Methylprednisolone~1
adjunctive,~1
(nosocomial~1
urosepsis)~1
seventy-three,~3
metastasis;~1
limb-salvage~4
(Mantel-Cox~1
statistic:~1
0.8)~1
(PIIIP)~1
PIIIP~7
SMS~58
201-995,~8
adenomectomy.~2
201-995~40
(SMS)~1
SMS-induced~1
(promyelocytic)~1
rTNF.~4
rTNF),~1
rTNF).~1
interferon-gamma.~5
1,500-2,100~1
NH4+.~1
ALL.~18
count)~2
hypercalcaemia.~2
E-speed~11
xeroradiographic~5
cassettes,~1
.011,~2
.007,~1
carious~6
sealant.~1
Sealant~1
sealants.~1
self-referral~1
bulimia--enamel~1
xerostomia,~2
cheilosis--are~1
Eyeglasses~1
light-curing~2
sharing.~1
sharing)~1
deft~1
73,~2
dentists'~2
informally~1
Dentists~1
"office~1
organization"~1
"finances"~1
"personal~1
growth"~1
"recognition"~1
567~1
microprocessor.~1
(subject~2
(necrotic~1
Holland~1
dentist.~2
Submission~1
HLA-B~6
Bw4~3
Bw6~3
HLA-Aw23,~1
Aw24,~1
A32,~1
HLA-Cw3.~1
puzzle.~1
A32~1
MoS39.~1
MoS39~1
anti-monocyte~1
Mo2,~1
My4,~1
Leu-M3~1
(MoP9),~1
MoP15,~1
MoS1,~1
63D3,~1
MoS39-expressing~1
molecules:~2
SG133,~1
MoU26.~1
SG185~1
lineages:~1
SG134,~1
MoU48.~1
IJ~12
Abolition~1
anti-IJ~2
(allo)~2
thru~1
anti-donor~2
anti-host~4
anti-third~3
mab.~2
mab,~4
tolerogen,~2
antidonor~1
tolerogen-specific~2
Coincidentally,~2
16,16-dimethyl-PGE2~1
(dmPGE2)~1
+/-18~1
pg/10(5)~1
Nondamaging~1
BHAC-DMP~1
(N4-behenoyl-I-beta-D-arabinofuranosyl-cytosine,~1
daunorubicin,~3
6-mercaptopurine,~2
prednisolone)~1
(HDMTX)~2
g/m2)~1
hemogram,~1
HDMTX.~1
([111In]N)~1
(67Ga).~1
[111In]N~5
67Ga.~4
Seven-day-old~1
celebrated~1
507-bed~1
Akron~1
revenue~3
Actinobacillus~4
actinomycetemcomitans~5
judgement.~1
sialometaplasia~1
metachronously~1
apertognathia,~1
xanthofibromas~1
(fibrous~1
histiocytomas)~1
arthrographic,~1
extraoral~1
malocclusions.~2
retrodiscal~3
histometric~1
post-extraction.~1
photodensitometry~1
maxillas~1
photodensitometry.~1
Segment~1
(45.7~1
2384~1
(Kinshasa,~1
Zaire)~1
2492~1
5.2%);~1
29-year-olds.~1
administrative,~1
(6.5%,~1
6.0%,~2
10(-12)M~1
(10(-6)M),~1
(10(-6)M).~1
(4R,5S,6Z-nor-LTD1).~1
LTC4-induced~1
non-sulfidopeptide~1
Mesangial~5
responded)~1
responded).~1
shape-change~1
wrongly.~1
improbable.~1
denominator,~2
Kouska's~1
fallacy,~1
disprove~1
Alkylating~1
mustard:~1
1,000,000/mm3.~1
thrombocythemia.~2
32P.~1
(mithramycin)~1
pancytopenic~2
morphology).~1
nonmyeloid,~1
Continual~1
cytomegalovirus-antibody~1
PDBu,~2
(HIV-1,~1
HTLV-III/LAV),~2
env~23
gp130,~1
HIV-1-infected~1
(HTLV-IIIB),~1
(HTLV-IIIRF).~1
cross-neutralized~2
Uganda,~1
HTLV-IIIRF,~1
titres).~1
DXYS1~6
nonlinkage~2
hyperlaxity~1
condyle/ascending~1
hypothesis--the~1
orientation--one~1
clockwise~1
Amalgam~1
cephalograms~3
0.1-0.3).~1
zygomaticofacial~1
deep-space~1
inaccurately,~1
names,~1
innocuous.~1
Gregory~1
Shafer.~1
20s~1
30s~2
linings~1
canine-premolar~1
Onchocerciasis~1
organisms'~1
maxilla.~4
pathosis~3
energies;~1
kVp~4
Masking~1
Artifact-reduction~1
xeroradiography~4
56.4%~1
single-image~1
retake~3
mandibles.~1
apices~6
buccolingual~2
molar,~3
apices.~1
bone-specific~2
sialoprotein~2
17/2.8)~2
1473-base-pair-long~1
AUG~3
Ser-Xaa-Glu~1
O-glycosidically~1
Asn-Xaa-Ser~1
oligosaccharide.~2
Gly-Arg-Gly-Asp-Ser~1
sialoprotein.~3
Arg-Gly-Asp-containing~3
sialoprotein-coated~1
sialoprotein--we~1
"osteopontin"~1
Neurohypophysial~2
([3H]AVP)~1
[1-deaminopenicillamine,~1
2-(O-methyl)tyrosine]Arg8-vasopressin~1
[1-deamino,4-valine]D-Arg8-vasopressin~1
(dVDAVP)~1
[1(beta-mercapto-beta,~1
beta-cyclopentamethylene~2
2-(O-ethyl)tyrosine,~1
8-ornithine]vasotocin~1
dVDAVP~1
[1-(beta-mercapto-beta,~1
acid),2-(O-methyl)tyrosine]Arg8-vasopressin~1
[d(CH2)5Tyr(Me)AVP],~1
(pressor)~1
d(CH2)5-Tyr(Me)AVP~1
vesicle.~4
nucleoprotein~10
(20-~1
25-fold)~1
dehistonized~1
5-fold).~1
nuclease-resistant~1
nonradioactive~4
laccase~3
(benzenediol:oxygen~1
oxidoreductase,~5
1.10.3.2)~1
Neurospora~3
crassa~4
laccase-specific~1
deoxyundecanucleotide~1
21-mer~1
crassa.~1
1.36-kilobase~1
Sal~4
laccase.~1
multicopper~2
plastocyanin~1
azurin.~1
oxidases~1
(ASGP-R)~1
Fluorescence-activated~4
ASGP-R.~2
transfections~1
ASGP-R~3
ASGP-R,~1
phosphoprotein~3
serotype)~1
pGEM4~1
transcription-reconstitution~1
N-RNA~1
247,~1
protein-RNA~1
10-J/m2~1
20-kilobase~1
25-kilobase~1
50-kilobase~1
DHFR-containing~2
repair-proficient~3
Glucocorticoid-stimulated~1
769-base-pair~1
transcripts;~1
virus/POMC~1
ADH).~1
glycols~1
3,4-dihydroxyphenylglycol~1
4-hydroxy-3-methoxyphenylglycol,~1
3,4-dihydroxymandelaldehyde~1
4-hydroxy-3-methoxymandelaldehyde~1
17,000~5
210-fold~1
benzaldehydes.~1
benzaldehyde,~1
3,4-dihydroxybenzaldehyde~1
4-hydroxy-3-methoxybenzaldehyde~1
29-fold~1
isozyme,~1
ADH.~3
(ethanol)~1
ADH-catalyzed~1
"unidirectional"~1
A2780~1
(5FUra)~1
5FUra~2
(dThd,~1
5FUra,~1
5,10-methylenetetrahydrofolate~1
5-fluorodeoxyuridylate~1
(FdUMP)-thymidylate~1
(dTMP)~1
(FdUrd)~1
FdUMP~1
dTMP~1
prothymosin~13
503-base-pair~1
completes~1
Asp-109,~1
ISG-54K)~1
beta-interferons~1
adenoviral~1
ISG-54K~1
imitating~1
post-separation~2
"direct-labeling"~1
"indirect-labeling"~1
neutron-activatable~1
(55Mn),~1
europium~1
(151Eu),~1
dysprosium~1
(164Dy),~1
neutrons.~1
direct-labeling~1
indirect-labeling~2
neutron-activatable,~1
attomole~1
(10(-18)~1
efflux:~1
carbonylcyanide~2
p-trifluoromethoxyphenylhydrazone~1
(FCCP)-depletable~1
FCCP-insensitive~1
Maximally~1
polyadenylylated~11
UV-irradiation~1
46-kDa~4
pBR322~6
supercoiling~7
topoisomers.~1
supercoiling.~1
[cholesterol,~1
reduced-adrenal-ferrodoxin:~1
oxidoreductase~8
(side-chain-cleaving),~1
1.14.15.67].~1
P450scc,~1
1626-base-pair~1
gt10.~2
Primer~1
1850~1
preP450scc~1
60189.65.~1
midgestation;~1
(VZV~1
gpI;~1
98,000)~1
monolayers,~2
(gpII~1
gpIII)~1
gpI~3
glycosylation,~6
phosphoryl~1
endoglycosidases.~1
Phosphoamino~1
phosphoserine~2
phosphothreonine~1
backbone.~1
50,000),~1
32Pi~1
[gamma-32P]ATP~2
gpII~1
gpIII.~1
gpI,~1
VZV-infected~1
lima~1
ps~5
quencher~1
quencher.~1
inhibitor's~1
ns.~1
N-acetyl-L-tyrosinamide~1
40-ps~1
tyrosine-69~1
vibrational~6
chromophore.~3
530-nm~1
vacuo~1
nonexponential~2
ps.~1
sub-ns~1
geminate~1
recombination.~5
resinless~2
embedment-free~1
centrioles~1
pericentriolar~1
centriole.~1
anaphase/early~1
telophase.~1
interphase~2
lagging~1
co-translational~1
ribosome).~1
intrachain~2
ribosome;~1
unfolding~1
proposal,~1
ribosome,~1
reducing.~1
post-translationally~2
EBER~2
EBV-harboring~2
U1,~2
7SL,~1
EBERs~1
adenovirus-associated~1
VAI~2
localized;~1
nuclear-localized~1
EBERs.~1
MB1,~1
hemangioblast,~1
MB1~1
125-200~1
MB1-bearing~1
quail,~1
alpha-MB1-positive~1
L-3,5,3'-tri[125I]iodothyronine~1
-290~1
-129.~1
(HDF)~1
periodate,~1
40-transformed~2
Quiescent~3
remaining)~1
post-stimulation~1
HDF)~1
newt~2
Epon-embedded~1
0.25-micron-thick~1
+50~1
back-projection~2
12-nm~1
spokes,~1
urchin~13
(Strongylocentrotus~1
purpuratus)~1
indo-1.~2
jelly~3
210-kDa~2
23-fold~1
glycoconjugate),~1
mAb-induced~2
spermatozoan.~1
experiments;~1
nonisotopic~1
DP,~1
streptavidin-horseradish~1
3,3',5,5'-tetramethylbenzidine~1
nick-translation.~1
Drosophila,~5
180-base-pair~1
"homeo-box."~1
homeo-box~6
motazoan~1
dipteran~1
6-specific~1
Hox-1~1
p14-p21~1
Hox-3~1
15F1-3~1
12q11-q21.~1
syntenic~2
neu~7
185-kDa~1
p185.~1
p185~1
anti-p185~2
neu-transformed~1
Ha-ras-transformed~1
oncogene-encoded~1
R24~2
(adriamycin).~1
complement-resistant~1
Immobilized~2
complement-activating~2
complement-enhancing~1
(Burkhart)~1
(ISK).~1
first-domain~2
pre-S(2)~3
pre-S(2),~1
(amino~3
14-32~1
terminus)~3
hydrophilicity~1
adr,~1
ayw,~1
ayr;~1
adw.~1
chimpanzees,~6
nondefective~2
(SNV),~1
replication-competent~4
reticuloendotheliosis~1
SNV-derived~2
Viruses~2
overgrown~1
encapsidation.~1
"mediatophore,"~1
proteoliposomes~1
marmorata~3
soluble;~1
17-kDa~6
Broca~1
(VDB)~1
fornix~2
supracallosal~1
striae.~1
posttransection,~1
VDB.~1
hippocampus-derived~1
neuronotrophic~1
MS/VDB~1
transection-induced~1
microgram/wk)~1
transection;~1
VDB~1
NGF-affected~1
noncholinergic.~1
"cage"~1
t-butylbicyclophosphoro[35S]thionate~1
([35S]TBPS)~1
(GABA)-gated~1
GABA-gated~4
dodecapeptide~2
185-196~4
193,~1
Sepharose-linked~2
1-20,~1
126-143,~1
143-158,~1
169-181,~1
185-196,~2
193-210,~1
394-409~1
toxin-binding~4
Naja~2
naja~2
siamensis~1
decamethonium~1
carbamoylcholine.~1
carboxymethylation~1
187,~1
Gaussians~1
Rodieck.~1
delays;~1
orientational~2
selectivities.~1
chromosome-linked~3
(PLP).~2
PLP.~4
(SMS~3
201-995)~2
201-995.~1
(.05~1
U/day~1
readministration.~1
hyperglucagonemia~6
diets--(I)~1
(HCO),~1
HCO,~1
HCO--were~1
EFAD.~1
ring-shaped~1
Myelodysplastic~2
pyrexic~1
(CRI).~1
paraaminohippurate~1
NA+~1
5p~4
5p15.2-5p15.3~1
propositions~1
bathes~1
24-hydroxylase,~2
4-aminoantipyrine~2
I2~8
13,14-dihydro-15-ketoprostaglandin~1
strikingly.~1
laeve,~1
E2-9-ketoreductase.~1
9-ketoreductase,~1
9-ketoreductase~2
9-ketoreductase;~1
9-ketoreductase.~1
Rotameters.~1
Enoxacin~4
quinolone-azaquinolone~1
enoxacin~32
(47.8)~1
(45.9).~1
colistin~2
colistin.~1
p58-1~1
(DXS14)~1
p58-1,~1
HTLV~12
ceftizoxime~6
Sch-34343~1
roseola-like~1
exanthema~2
chilblain~1
(CMML)~1
CMML~1
(PGD2)~4
4-840~1
Cyclical~1
Rauscher~4
anti-Rauscher~1
ERY-1,~1
CFC-E.~1
ERY-1~2
erythropoietin-induced~1
(APL)~3
APL~7
regimens;~1
23/27~1
transfusions;~1
2/27~1
5/27~1
cis-retinoic~2
(cisRA)~1
10(-6)M~1
cisRA.~2
cisRA~4
differentiate.~6
CRABP.~1
cautionary~1
HL-60,~4
ribonucleotide~7
(GTP)~3
ribonucleotides~3
tiazofurin.~2
ribonucleotide-dependent~1
McArdle's~6
(adaptation~1
('second~1
wind'~2
glucose).Changes~1
'second~1
(HMSN);~1
MyD~3
'common'~1
unexpected.~2
male;~1
trigone.~1
Osteosarcoma~1
(CGL)~4
Cytarabine~1
CGL~7
0.006);~2
thioguanine,~2
desacetylmethylcolchicine,~1
trimethylcolchicinic~1
CGL,~2
(APL).~1
Cytocentrifuge~1
promyelocytes.~1
posttherapeutic~1
14q11~3
46,XY,-15,t(11;14)(p15;q11),~1
+der(15)t(15;?)(p11;?).~1
Pancytopenia~1
t(11;14)(p15;q11)~1
ALL,~10
conceivably,~1
osteosarcomas.~3
non-receptor-mediated~2
Lubrol~1
S-GTP,~1
(3.3-172~1
mEq/h)~1
Natriuresis~1
5.5-76~1
mg/h,~1
peptidoma~1
peptide-related~1
demonstrated;~1
lasting,~1
(1.2+1.2~1
(400+400~1
(75+50~1
51chromium~2
ethylenediaminetetraacetate~1
pBR~1
322.~1
Subcloning~2
McArdle~1
(alpha:beta~1
2.43.~1
transformed.~1
N-methyl-thiotetrazole~2
(cefotetan)~1
descarboxyprothrombin~1
(PIVKA~1
hypoprothrombinaemia~1
depths.~1
overhanging~1
Probing~1
gingival~9
Tehran,~1
(Heck's~1
large-diameter,~1
Knoop~1
wide-tip~1
narrow-tip~1
20-second~1
amalgam~8
restorations.~2
offered:~1
Lost~1
behind-the-ear~1
90kV(p)~1
5.465~1
5.516~1
vendors~1
company's~1
warranty~1
verruciform~1
rougher~1
warty,~1
innocuous,~1
adherence-related~1
immunoprecipitations~1
(DMSO,~1
monocyte/macrophages~1
(PMA,~1
D3).~1
monocyte/macrophage~4
Triggering~1
DMSO-differentiated~2
twofold.~2
(5-30~1
[99mTc]gluceptate~1
(48-72~1
Gallium-67~2
nonfibrotic,~1
[99mTc]GH~4
Dysesthesia~1
odontectomy~1
mesioangular~1
crown~6
cemento-enamel~1
molar;~1
burs~6
Neurosensory~1
(BSD),~1
(2-P),~1
two-alternate~1
(19/42)~1
(22/42)~1
BSD,~1
(14/42)~1
2-P~1
dense.~1
edentate~1
60Co~1
osteogenesis.~1
(LNs)~1
packing,~1
Dentinoma~1
osteodentin~1
Mesenchymal~1
chemo-therapy~1
naftidrofuryl~2
Naftidrofuryl~3
potency),~2
uridine-5'-triphosphate.~1
[3H]norepinephrine,~2
cause:~1
factor(s);~1
neurotransmission;~1
EC80~1
(10(-7)-10(-5)~2
MK-761~2
(10(-7)-10(-4)~3
Spirendalol~1
10(-8)-8.1~1
L643717~1
10(-7)-3.6~1
MK-761,~2
Eicosatetraynoic~1
(LAS)~3
LAS.~1
LAS~3
(five-year~1
Hispaniola~1
Haiti,~1
Dominicans~1
Haitians,~1
(19%);~1
heterosexuals,~3
Haiti~1
heterosexual,~1
enrolled,~2
HTLV-III,~2
seroconverted.~7
63Ag8.653~1
osteosarcoma-associated~1
(OSAA)-immunized~1
OSAAs~1
(TE-85).~1
OSA1,~1
OSA2,~1
OSA3,~2
OSA4,~2
OSA5.~1
OSA1~2
OSA2~2
OSA5~1
(PBMC).~1
TE-85~1
92,000.~1
cisplatin-resistant~1
"KFr,"~1
cisplatin/ml.~1
cisplatin/ml,~1
KFr~5
LDH-3~1
LDH-4,~1
nucleoli~2
twenty-fold~1
[N-(6-aminohexyl)-1-naphthalenesulfonamide~1
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide]~1
3p14~2
3p21~1
del3(p14~1
3p25~1
t(11;22)~1
del(22).~1
1q,~1
19p13,~1
3p~1
6q,~1
Anatomists~2
anatomists~2
2,317~1
1888~1
[95%~3
0.1-0.5],~1
0.7-2.7),~1
1.3-5.0)~1
1925-79,~1
referent.~1
1900-69,~1
referent,~1
0.2-1.1)~1
2.3-15.6).~1
1925~2
glioblastoma).~1
(HT-29~1
line)~5
tumor-secreted~1
FR3T3~1
repolarized~1
nontumorous~2
hydroethidine~2
ethidium,~1
intercalates~1
Hydroethidine~1
uniformly.~1
microfluorimeter~1
(SFs)~1
(ACR)~1
PAb421.~1
SFs~1
ACR~5
mock-infected~1
SV40-transformed~4
over-expression~1
Over-expression~1
hydroxyanisole~3
[(BHA)~3
CAS:~30
25013-16-5]~1
dose--2%~1
BHA--induced~1
forestomach.~1
BHA,~1
BHA~3
N-Nitrosobis(2-oxopropyl)amine~1
(BOP;~1
CAS;~1
60599-38-4)~2
(GSHPX)~1
BOP~12
GSHPX~1
5.0-ppm-supplemented~1
Adenoma~2
BOP-treated~1
(DBA/2J)~1
nonsaturable,~1
unactivated~6
maturity)~1
Mos~1
(HCC-P4733),~1
(HCC-M14328),~1
(HCC-M1410)~1
HCC-M1410~1
HCC-M14328~1
HCC-P4733~1
90-day~2
Isozyme~1
[125I]IdUrd-labeled~1
(15-39~1
0.72-1.4).~1
(40-54~1
(0.67-3.3),~1
(1.3-6.9),~1
WO~1
nitrosamine-ductular~1
Secretin,~1
U/kg,~2
N-nitrosobis(2-oxopropyl)amine~2
[(BOP)~1
60599-38-4]~2
(secretin~1
BOP,~1
cocarcinogen~1
(F344)~2
vivo-produced~1
(CAS:~15
70-25-7)~1
684-93-5)~1
hypercellularity,~2
transplants;~2
carcinogen-induced~5
phagokinetic~1
ddy~1
(sp~1
U/mg,~1
(BCE)~1
BCE~1
TNF-positive~1
migration-inhibitory~1
Mice,~2
A/J~14
Webster,~1
urethan/kg~1
Webster~6
61-74%~1
urethan.~1
9-38%~1
urethan-treated~1
interesting,~3
urethan,~2
Inoculation~4
Cationized~1
electrostatically~1
Ehrlich~2
(DNR),~1
2.04%~1
(recycling)~1
resistance-linked~1
[MuLVs;~1
ecotropic,~1
xenotropic,~1
mink~1
(MCF)],~1
MuLV~8
(F-MuLV)-~1
(M-MuLV)-induced~1
xenotropic~2
C58~1
ecotropic~4
(F-MuLV~1
M-MuLV).~1
F-MuLV~1
M-MuLV~4
leukemogenesis,~1
ABH,~1
Lewis,~1
sialylated-Lea~1
Chromatogram~1
upper-phase~1
A-active~3
blood-type~1
8-sugar~1
H-active~1
Lea-active~1
Leb-active~1
glycolipids.~2
Leb~5
(cALLa)-positive,~1
pre-B-cell~4
low-antigen-density~2
subculture,~1
heavy-chain~9
cALLa-specific~1
(SSM),~1
sun,~1
sunburn,~1
suntan~2
neck:~1
SSM~4
NM~1
NM.~2
(GM3,~1
GD3,~2
alkali-labile~3
ganglioside)~1
cells/mouse.~1
0.927~1
GM3,~2
formylpeptides~1
hexapeptide~7
N-formyl-nor-leucyl-leucyl-phenylalanyl-nor-leucyl-tyrosyl-lysine,~1
formylhexapeptide~2
N-formyl-nor-leucyl-leucyl-phenylalanyl-nor-leucyl-[125I]tyrosyl-lysine~1
Surface-adherent~1
(RM-HS1)~1
mesenchymal-epithelial~1
18s~1
28s~1
(pX1r101),~1
"borderline~1
tumors,"~1
invasive).~1
1975-83,~1
1970's,~2
4',6-diamidino-2-phenylindole,~1
(FN).~1
FN-positive~1
(FN+)~1
GFAP~4
nuclear-to-cytoplasmic~4
(0.192).~1
(1,252~1
(8,376~1
FN+~6
GFAP-positive~3
(GFAP+)~1
GFAP+~6
(0.245)~1
(0.176).~1
(1,350~1
hyperchromasia,~1
histologic-type~1
52.1%~1
"other~2
malignancy."~1
histiocytomas,~1
length-of-follow-up~1
(ROH),~1
13-cis-retinoic~7
(13-cRA),~1
4-oxo-13-cRA.~1
plasma-~1
serum-enriched~1
decapentaplegic~1
(DPP-C)~1
DPP-C~3
dorsal-ventral~1
specification.~1
imaginal~1
(kb]~1
4.5-kb~3
C-terminus~1
(25-38%~1
identity)~1
C-termini~1
factor-beta~8
(TGF-beta),~3
(MIS).~1
TGF-beta~51
non-mammalian~1
Joseph~2
Machado-Joseph~2
inherited,~1
multisystem,~1
conduction-refractory~1
virus-I~2
(HTLV-I)~14
(11.1%),~1
beta-chains~7
hexosaminidase,~1
alpha-chain,~2
beta-locus.~1
Substrate-specific~1
arthrosis,~1
arthroscope.~1
arthroscopically,~1
specificity),~1
underdiagnosing~1
bark~1
Juglans~1
regia,~1
Derum~1
Dendasa.~1
self-induced~2
gingiva~3
Cheilitis~1
glandularis~1
observant~1
sialography,~1
vacuole~2
periapicalesion--apical~1
granuloma--of~1
epon-embedded~1
neutrophil-dominated~1
periapex,~1
delimited~2
envisage~1
endodontic~13
radiopacity,~1
Mandibular~1
nonconcentric~1
condyle-fossa~1
intermethod~1
interarticular~2
concordance,~1
1685~1
full-month~1
(fourteen~1
periapical~12
bitewing~8
radiographs).~1
Temex~1
shield.~2
apolar~4
zervamicin~1
crystallizes~4
triclinic~2
10.206~1
12.244~1
15.049~1
93.94~1
95.10~1
104.56~1
C60H97N11O13~1
2H2O.~1
intrahelical~1
3(10)~1
N(3)~1
O(0),~1
alpha-helix-type~1
solvent-shielded~1
head-to-tail~3
antiparallel.~1
inefficient,~1
Waals'~1
(VSV)~3
(VSV~1
G),~1
VSV~6
cDNAs,~2
basolateral,~1
signal(s)~2
(H1GA)~2
CV1~2
MDCK~2
ectodomain~1
(PtdIns)~1
(Ins-1,4,5-P3),~2
(Ins-1,3,4-P3),~1
Ins-1,4,5-P3,~2
(Ins-1,4-P2)~1
PtdIns~4
4-phosphate,~2
Ins-1,4,5-P3~6
4-monophosphate~1
(Ins-4-P),~1
1-monophosphate~1
(Ins-1-P)~1
PtdIns-4,5-P2~1
angiotensin-stimulated~1
Ins-1,3,4-P3~3
Ins-1,4-P2~3
Ins-4-P~1
Ins-1-P~3
Ins-4-P,~2
Li+.~1
Ins-P~1
Ins-1,4,5-P3.~1
Ca2+-mobilizing~3
presurface-antigens~1
(pre-S)~1
(pre-S2)~2
(pre-S1)~1
22-nm~1
pre-S2~2
coinjecting~1
lit/lit~1
repressor,~8
represses~1
operator,~1
(OR1,~1
OR2,~1
OR3)~1
OR2.~1
OR2~1
(touches)~1
ethylation~1
functionalized~1
4-N-t-butyloxycarbonyl-aminoaniline,~1
(Rau-AmPC).~1
Rau-AmPC~1
beta-[N-(4-azido-3-[125I]iodo)phenyl]~1
(125I-Rau-AzPC),~1
diazonium~1
125I-Rau-AzPC~1
yohimbine-agarose~1
125I-Rau-AzPC,~1
(Mr,~7
NaDodSO4/PAGE~9
non-subtype-selective~1
alpha-antagonist,~1
1-antagonist,~1
(-)-alprenolol.~1
62,000~1
Antilles,~1
2(6~1
Glu----Val,~1
Val----Ile),~1
A/S~3
Antilles~5
carriers'~1
S/C~1
deoxy-Hb~2
(saturating~1
Dilute~1
7.00).~1
S/S~1
Thermodynamic~1
free-energy~3
duplexes.~2
nearest-neighbor~2
well-represented~1
duplexes~2
Free-energy~1
mismatches,~2
hairpin~1
bulges~1
(fluidizes)~1
tolerance).~1
disordering,~1
Multilamellar~1
(fluidized)~1
(66.5~1
%),~2
2.5-8.5~1
disordering.~1
(2.5-8.5~1
1198-base-pair~1
"hormone"~1
thymosin~9
(B-cell~1
lineage).~1
Prothymosin~1
inducible;~1
serum-deprived~2
phosphate/receptor~1
GTPase~2
Ns.~1
recycle~3
recouple~1
membrane-spanning~5
folding.~1
(OrnDCase)~1
(papillomas)~1
initiation-promotion~2
OrnDCase~9
inactivated,~2
OrnDCase.~2
heat-inactivation~1
non-OrnDCase~1
L-ornithine,~2
L-ornithine~1
OrnDCases~1
OrnDCases,~1
OrnDCase,~1
Pi/phosphocreatine).~1
work-cost~5
(Vm~1
Pi/phosphocreatine)~1
hyperbola,~1
1/(1~1
phosphocreatine/Pi)~1
NADH;~1
range--a~1
V/Vmax.~1
Sequence-generating~1
memories.~1
Assembly-competent~1
sulfhydryl-specific~1
fluorochromes~1
5-(2-[(iodoacetyl)-amino]ethyl)aminonaphthalene-1-sulfonic~1
(IAEDANS)~1
5-iodoacetamidofluorescein~1
(IAF)~1
IAEDANS-labeled~1
IAF-labeled~1
KCl/10~1
6.9.~1
myosin--i.e.,~1
unassembled~1
filaments--was~1
FET~1
(t1/2,~2
turning-over~2
endosomal)~1
regurgitated~1
JAR~3
32PO4~4
32PO4,~1
uncombined~1
self-phosphorylation~1
autophosphorylation~10
Autophosphorylated~1
reaction--inhibited~1
ATP--even~1
Ca2+/calmodulin-independent~2
signal-recognition~1
(SRP)~1
(K562)~3
54-kDa~2
(HEp-2)~1
Bombyx~1
mori~2
fibroin~3
-72~2
-32,~1
Antheraea~2
silkworm~1
-238~1
-73,~1
28-36~10
(SP~2
28-36)~1
28-36,~1
preculture~3
(treated/control~2
Hox~3
homeo~18
753-base~1
753-bp~2
H-2Ld.~1
1.4-kilobase~2
H-2Ld~9
-210~1
-135~1
constructs,~2
-195~2
-161.~2
constitutively.~2
repressive~1
All-female,~1
Mating~1
Cnemidophorus~3
uniparens,~1
inornatus~2
gularis.~1
uniparens~2
inornatus.~1
male-like~2
pseudosexual~1
all-female~1
unisexual~2
male-typical~1
2-(N-acetoxy-N-acetylamino)fluorene~3
acetylaminofluorene~3
revertants~5
adducts,~2
quasipalindromic~1
(NTPase)-I~1
0.72-~1
2.5-kilobase-pair~1
(kbp)~1
beta-galactosidase~2
NTPase-I~2
HindIIID~2
16-kbp~1
1896-base~1
631-amino~1
COOH~4
NH2~12
termini,~3
Orthopoxviruses.~1
Sympatric~1
mule~4
(Odocoileus~1
virginianus~3
Odocoileus~1
hemionus,~1
ranch~1
Phylogenetic~1
hemionus.~1
(1.3%~1
divergence),~1
hemionus~1
divergence).~1
bucks~1
Introgressive~1
RecA~8
Titration~2
RecA-coated~1
thousandfold.~1
homology,~7
Biotinylated~2
streptavidin-agarose~1
cleavable~2
cupric~3
acid-agarose~1
10(4)-~1
10(5)-fold.~1
plasmid,~8
cosmid,~1
constant-region~2
nonallelic~2
sites).~3
exons,~6
BALB/c-H-2dm2~2
Ld~5
low-copy~1
Dd~7
Ld.~3
misalignment~1
mtDNAs~2
Alleles~3
tRNAs,~1
rRNAs,~1
(assuming~5
model),~1
Departures~1
purifying~2
mtDNA~5
6-thioguanine)~1
efficiency)~1
CHO-K1-BH4~1
(K1-BH4),~1
radiation-hypersensitive~1
transformant,~1
AS52.~1
AS52~4
xanthine/guanine~1
(gpt)~2
hypoxanthine/guanine~3
(hprt)~1
K1-BH4~2
radiomimetic~1
streptonigrin~1
methanesulfonate,~1
191,~1
mutagenicity.~1
hypermutability~1
(DHFR;~1
5,6,7,8-tetrahydrofolate:~1
1.5.1.3),~1
270-fold~1
manufactures~1
E19,~1
subgenera~1
subgenus~2
Chicken~1
mannose-binding~6
kDa),~6
kDa,~7
mercaptoethanol,~1
specific-binding~1
gamma-chain-specific~1
NaDodSO4/polyacrylamide~14
cochromatography~1
Fractogel~1
HW-55(F)~1
nononcogenic~3
(Ad)~1
Ad2~1
Ad5,~1
nontumorigenic~5
Ad12~1
Ad2-~2
Ad5-transformed~2
Ad2-transformed~1
serotypes.~2
methylisobutylxanthine~1
dibutyryl-cAMP~4
cAMP-elevating~2
colchicine.~1
beta-melanocyte-stimulating~1
(h~2
MSH)~1
22-amino~1
(LPH)~1
35-56).~1
18-amino~3
MSH-(5-22)~5
corticotropin-secreting~1
nonpituitary~4
G-50,~1
LPH~6
LPH)~1
LPH,~1
MSH,~1
mid-portion~1
MSH-(5-22).~1
LPH.~1
radioimmunoassay;~2
(Ve/V,~2
0.60);~1
MSH.~1
LPH-(39-56),~1
flanked~8
synchrotron~2
photochemotherapy.~1
cyanine~1
carcinoma-specific~1
N,N'-bis(2-ethyl-1,3-dioxolane)kryptocyanine~1
(EDKC),~1
light-dependent~2
1-0.01~1
(CV-1).~1
phototoxicity~1
70-1000~1
100-175~1
trans-activation~6
trans-activator~3
extension).~1
trans-activated~1
Ca/high~1
(RGCs)~1
RGCs~3
(P2-10),~1
Ca/20~1
RGCs,~1
P11-13~1
TTX,~1
rescued~3
TTX-treated~1
RGCs.~1
(ir)~1
morphinans~2
[Goldstein,~1
A.,~4
Barrett,~1
W.,~4
James,~1
F.,~4
Lowney,~1
I.,~1
Weitz,~1
J.,~7
Knipmeyer,~1
Rapaport,~1
(1985)~9
Proc.~12
Natl.~12
Acad.~12
5203-5207].~1
codeine.~4
(GC/MS):~1
activity-dependent~1
SCPA~5
SCPB~3
SCPB.~3
SCPs~3
neurites.~3
(5-hydroxytryptamine,~2
(ENS).~1
interganglionic~1
connectives,~1
ENS~1
II/AH~3
5-HT1P,~1
[3H]5-HT~2
6-hydroxyindalpine~1
2-methyl-5-HT.~1
5-HT1P-mediated~1
5-hydroxytryptophyl-5-hydroxytryptophan~1
5-HT2P,~1
[3H]5-HT.~1
2-Methyl-5-HT,~1
5-HT1P~1
5-HT2P~1
MDL~1
72222,~1
(TyrOHase)~1
TyrOHase~7
L-3,4-dihydroxyphenylalanine~1
TyrOHase.~1
0.533~1
PLP-specific~1
introns.~3
exon-intron~2
Exon~2
ATGG~1
trans-~1
cis-membrane~1
Homology~1
PLPs~1
human-rodent~3
q13-q22.~1
improbable~5
1/6000th~1
(iii)~10
anti-triplets,~1
quadruplets~2
quintuplets~1
improbably~1
numbers;~1
eye;~2
(v)~3
doublet)~1
decoding~1
(observations~2
i-iii);~1
symbolize~2
(observation~1
iv);~1
v);~1
Arg-Phe-NH2~1
(RFamide).~1
cation-exchange~2
RFamide~2
anemone~3
Anthopleura~2
elegantissima.~1
(Antho-RFamide)~1
pyroGlu-Gly-Arg-Phe-NH2.~1
Antho-RFamide~3
Anthopleura.~1
anemones.~1
intracellular-domain~2
(ld)~1
160,000)~1
(sd)~1
130,000)~1
ld~6
sd~4
N151,~1
ssd~6
surface-domain)~1
N151~5
2437~1
(bp).~1
N208,~1
N208.~1
637-bp~1
AATACA~1
polyadenylylation~6
55-bp~1
anchor.~1
modulated:~1
oligodeoxyribonucleotide~1
mesencephalon~2
mRNA-containing~2
mesencephalon)~1
dopamine-innervated~1
blot-hybridization~4
Leucine-enkephalin,~1
methionine-enkephalin,~1
neuroblastoma-glioma~1
(NG108-15).~1
leucine-enkephalin,~1
enkephalin-induced~1
delta-opiate~2
stoichiometry,~1
(NA;~1
3.2.1.18)~1
signal-anchor~4
oligonucleotide-directed~2
mutagenesis.~2
CV-1~1
anchor,~3
phenotypes:~1
(aspartic~1
(arginine~1
traffic)~1
(LM2)~1
transfer-effector~1
LM2~8
LM2,~1
(cyt~1
b5)~2
Amax)~1
benzphetamine~1
b5.~3
Reconstituted~1
LM2-cyt~2
(LM2-cyt~1
b5-dependent~1
NADH-cytochrome~3
(NADH-cyt~1
reductase)~2
3-hydroxy-3-methylglutaryl-coenzyme~1
(NADPH)~1
[(S)-mevalonate:NADP+~1
(CoA-acylating),~1
1.1.1.34].~1
cholesterol/phospholipid~2
cholesterol-poor~1
12-nitroxystearate~1
Enrichment~1
"nonfluid"~1
hydroxymethylglutaryl-CoA~4
phase-separation~1
Tc,~1
Swiss-Webster,~1
Philly,~1
(Swiss-Webster~1
Philly)F1~1
Philly~4
beta-casein~5
Engelbreth-Holm-Swarm~2
(EHS)~1
beta-casein.~2
EHS~2
(1.5-~1
(CyIIIa)~1
(CAT;~2
acetyl-CoA:chloramphenicol~1
O3-acetyltransferase,~1
2.3.1.28)~2
blastula~2
CyIIIa~3
mRNAs);~1
CyIIIa-CAT~2
topoisomerase,~1
underwound~1
circle.~1
unwinding~9
T-antigen~5
helicase,~1
T-antigen-associated~2
unwind~1
[ability~1
poly(dT)-stimulated~1
helicase].~1
helicase~1
sequence-specific.~1
eubacteria~1
phylogeny.~1
spacers)~1
Facts~2
T/G~2
selection)~1
frameshifts,~1
EJ-ras~1
(SOD2)~1
pUC9~3
oligode-oxynucleotide~1
612-base-pair~1
SOD2~1
Sod2~3
Hybrid-selection~1
lymphosarcomas~2
myb~12
myelomonocytic,~1
lymphosarcoma~4
13-acetate-induced~1
signal(s).~1
nonpolymorphic~6
Dw4.~1
DR4-positive~4
ancestor.~1
picornaviral~1
polyprotein.~1
cleavages~5
capsid,~1
protomer~1
protomeric~1
1AB)~1
protease-type~1
proton-abstractors~1
(5Z,13E)-(15S)-9~1
beta,15-trihydroxyprosta-5,13-dien-1-oic~1
beta-PGF2)~1
11-ketoreductase~1
beta-PGF2~11
constrictors.~1
15-hydroxyprostaglandin~2
beta-PGF2.~2
dehydrogenases.~3
[8-norleucine,18-norleucine,34-tyrosine]PTH-(1-34)~1
([Nle]PTH-(1-34)-NH2),~1
(HPLC),~3
tissues:~3
(affinity)~1
radioligand,~2
Nonidet~2
P-40~2
glucoside.~1
anti-PTH~3
1-34,~1
IgG-PTH-receptor~1
A-Sepharose.~1
NaDod-SO4/polyacrylamide~1
69-70~1
PTH-Sepharose~1
70-~3
28-kDa~3
[Nle]PTH-(1-34)-NH2-containing~1
(mdr1)~1
mdr1~4
rectum;~1
(apoC-II)~2
apoC-II,~1
apoC-IIToronto.~2
apoC-IIToronto~1
apoC-II~3
1-68.~1
Asp69-Gln70-Val71-Leu72-Ser73-Val74-~1
Leu75-Lys76-Gly77-Glu78-Glu79~1
Thr69-Lys70-Phe71-Phe72-Leu73-Cys74.~1
Thr68~1
Asp69~1
Phyllanthus~1
niruri~1
(WHV)~2
WHV~8
(Marmota~2
monax).~1
WHV-carrier~1
woodchucks,~1
WHV,~2
WHV.~1
respond;~1
34-kDa~15
8-benzylthioadenosine~2
(AcChoEase;~3
acetylhydrolase,~1
cholinesterase,~1
3.1.1.7)~2
(BtChoEase,~1
acylcholine~1
acylhydrolase,~2
pseudocholinesterase,~1
3.1.1.8)~2
BtChoEase~8
AcChoEase~11
(E3-E5,~1
BtChoEase.~2
AcChoEase.~5
Patches~1
11-hr~1
thymidine-uptake~1
spatiotemporal~1
neuroblasts~1
cholinesterases~2
transition.~2
bioelectric~1
neurons--the~1
potential--at~1
anti-NGF~1
NGF.~1
toad~3
Rb+,~1
NH4+~1
amiloride-insensitive~2
Sr2+,~1
Lorentzian~2
Methohexital~1
A/chicken/Pennsylvania/83~1
Asn-Xaa-Thr/Ser~1
HAs~1
HA1~3
HA1s~2
(413~1
residues)~4
identical)~2
identical),~1
pigments.~3
q31-q32~1
FMS~6
protooncogene,~2
intergenic~1
(ATP:protein~2
phosphotransferase,~2
2.7.1.37)~2
immunoscreening~2
gt11.~6
cAMP-binding~4
lysogenized~1
1195-base-pair~1
nontranslated~2
36,794.~1
Dictyostelium,~1
High-pressure~1
galactosamine-rich~2
high-charge~1
beta-turns.~1
terminus,~7
well-characterized,~1
(28-36~1
(5-18~1
bilayer-spanning~1
oxygen-labile,~1
glycolicum~1
sonication~3
2-(N-cyclohexylamino)ethane-sulfonic~1
(CHES)~1
8.6-9.0)~1
ultracentrifugation,~2
2.02.~1
NH2OH~1
hydroxy-urea.~1
(rASVs),~1
rASV157~4
rASV1702,~1
tumorigenicity.~1
src~11
rASV1702~2
myristoylated,~1
rASV1702.~1
termini:~1
Ser-6~1
Ala-76~1
Rous~5
rASV~1
Hybrid-arrested~2
403-amino~1
44,539),~1
45,000)~1
N-glycosylation~7
41,183.~1
41,000~2
1132~1
thymidine-rich~2
cytosine.~3
"leader"~1
domains:~4
linker~4
(3T6)~1
(LLC-PK1)~1
52-kDa~1
(T47D).~1
[35S]methionine.~2
thermophila~1
shock-inducing~1
translationally~2
(ca.~1
nucleotides),~1
proteolytically~5
20-kDa~8
20-kDa/80-kDa~2
Ca2+-requiring~1
(calpain,~2
3.4.22.17)~2
calpain~1
Spectroscopic~1
sR-II~1
Halobacterium~1
halobium,~1
repellent~1
hydroxylamine~3
NaCNBH3~1
bleached~2
retinylidene~1
bacteriorhodopsin,~4
halorhodopsin,~1
earlier-discovered~1
phototaxis~1
renamed~1
sR-I587.~1
sR-II480,~1
photoreaction~1
photocycle~1
spectroscopically~1
sR-I587~3
450-nm~1
phototactic~1
retinal.~1
23-24~1
23-,~1
50-kDa~4
subfragment~5
G-100~1
A-50~1
23-~2
23-kDa~1
epsilon-N-monomethyllysine~1
epsilon-N-trimethyllysine~1
550,~1
3-N-methylhistidine~1
754.~1
glycolysis),~1
ATP-driven~1
pump's~1
minima)~1
nonlipid~1
scaled-particle~1
free-volume~2
free-area~1
in.~2
disappears.~1
("autonomous")~1
"random"~1
(Huh6-c15)~1
neomycin-resistant~2
G-418~1
pregenome~1
Dane-like~1
Anucleate~1
(cytoplasts)~1
activatable~2
granule-poor~1
(O2-.)~1
microirradiation~1
(zymosan-activated~1
serum);~1
preheating~1
silkmoth~1
choriogenesis~2
polyphemus~3
Hyalophora~1
cecropia.~2
aeropyle~2
crowns,~1
Aeropyle~1
crowns~4
substructures--lamellae~1
filler.~2
Filler~1
cecropia~1
choriogenesis,~1
cecropia,~1
period-specific~1
abundance.~1
polyphemus,~1
(8pter-8q22).~1
free-ranging~1
cheetahs~3
(Acinonyx~2
jubatus~3
raineyi)~1
reproductively~1
jubatus).~1
ejaculate)~1
raineyi,~1
(2-4%)~1
(0.0004-0.014)~1
cheetah~2
(0.004),~1
subspecies.~1
bottlenecks~1
ancient,~1
(circa~1
ago);~1
century)~1
Antigen-exposed~1
antigen-plus-Ia-specific~2
T-T~4
antigens--ovalbumin,~1
poly(LGlu56LLys35LPhe9)~1
[(GluLysPhe)n].~1
alloreactive~9
corecognized~1
enzyme-treated,~1
"processing~1
independent"~1
biotin-insulin.~1
Biotin-insulin-exposed~1
biotin-insulin~2
Avidin~1
biotin-insulin-exposed~1
allospecific~7
Sonicates~1
(PBMNC)~2
quiescent-confluent~1
PBMNC~10
erythrocytosis,~1
K-562~4
Polycythemia~1
T-lymphocyte-depleted~1
NaDodSO4/PAGE,~4
13-,~1
17-,~1
65-kDa.~1
13-kDa~2
mitogenic,~1
transforming,~1
65-kDa~1
oxidatively~3
copper(II)~1
cell-induced~3
copper-catalyzed,~1
delipidated,~1
resolubilized~1
n-octyl~1
beta-D-glucopyranoside.~1
125I-labeled,~1
cell-modified~1
minicircle~4
probe-based~1
(kDNA)~1
subfragments~3
Leishmania.~2
minicircle.~1
kDNA~1
(EBV)-determined~1
(EBNA-1~1
EBNA-5)~1
EBNA-2~7
ushered~1
GMP-dependent~4
NaDodSO4/gel~1
bilayer,~1
GMP-stimulated~1
l-cis-diltiazem,~1
cryofixed~1
1-ms~2
-190~1
Freeze-fracture~2
denoting~1
terminals;~1
low-Ca~1
nerve-electroplaque~1
crossreacted~2
subunits--apparent~1
79,000.~1
270,~1
49,000~3
286,~1
44,700,~1
52,300,~1
56,600,~1
65,200.~1
(alpha)2~1
elasmobranches~1
(alpha)2(beta)2~1
(alpha)3(beta)2~1
Myelin-associated~1
MAG,~1
hypomyelinating~1
p1B236,~1
brain-specific,~1
Sutcliffe~1
[Sutcliffe,~1
G.,~2
Milner,~1
Shinnick,~1
Bloom,~1
671-682].~1
(499~1
(N-CAM),~1
granulocyte.~1
basophil-specific~1
eosinophil-specific~1
cyanide-resistant~1
pJ3.11,~5
7C22,~1
DOCR1-917,~1
COL1A2,~2
TCRB~5
7q2.1-3.1.~1
pmetH~2
pmetD,~2
(Farrall~1
Lancet~1
i:1402-1404,~1
pJ3.11-CF~1
D7S15,~1
PON,~1
D7S8,~2
TCRB,~2
D7S8~4
flow-sorted~1
741~1
PIC~1
.36~1
.16.~1
Informative~1
Kodiak~1
Lawrence~1
Aleuts~1
Pribilof~1
Amerindian~1
XIIIB~2
Caucasian,~2
Mongoloid~2
(pmetH~1
TaqI).~1
(Sandostatin)~1
shrank~1
gastrin;~1
hypoglycemia--one~1
adenomatosis--the~1
hypoglycemia-free~1
vipoma,~1
peptide;~2
secretin-~1
Gastrinoma~2
786~1
post-receptor~1
(797~1
201-995).~1
(617~1
together).~1
50-150~1
oxytocin-induced~2
midpregnancy~2
(labor)~1
dual-compartment~1
Postlabor~1
prelabor~2
chorion-decidua~1
ng;~2
Amnion-chorion-decidua~1
(2.37~1
ng);~1
Elution~3
6.8-14.2~1
injecting,~1
5.43;~1
1.08-52.5).~1
.84-8.59).~1
Seropositivity~2
(IMR-90)~1
(Anal~1
Biochem~1
1984;~1
140:478).~1
Invest~1
72:2082).~1
pg/10(6)~1
Authentic~1
AM-derived~2
(173~1
143%~1
macrophage-conditioned~1
medium.(ABSTRACT~1
U-70138F,~1
roxithromycin~3
(RU~2
965),~1
ofloxacin~17
(ORF~2
18489),~1
McCoy~1
fosfomycin,~1
(C2d)~1
(LE)-like~1
C2d~3
(SCLE),~1
anti-Ro~6
(anti-Ro~1
SS-A),~1
A25,~1
B18,~1
DR2.~3
SCLE~2
immunogenetically.~1
HLA-DR2,~1
HLA-A25,~1
-B18~1
-DR2~1
adhesiveness,~1
Coombs~1
monocytic-macrophagic~1
ribosomes,~1
cisternae.~1
astemizole~1
wealing,~1
FTF~2
148,~1
myelomal~1
(NS-1)~2
(KUT-2~1
(HTLV-I)-infected~3
KUT-2~1
ATL-associated~1
antigen-positive.~1
p50~1
p74~1
Xs~1
(envelope~1
transcriptase,~1
transactivation~2
(tat-III),~1
(3'orf,~2
sor)~1
gag,~4
3'orf,~3
sor,~5
tat-III~5
sera;~1
full-fledged~1
(ARC,~1
(homosexuals,~1
[IV]~1
(gp41)~3
(p15,~2
p24)~1
nonrisk~1
3/35~1
p15~2
p24.~4
tat-III)~1
(self-renewal);~1
self-renewal.~1
5-azacytidine~1
(5-aza)~1
6-azacytidine~1
(6-aza)~1
renewal.~1
5-aza~1
6-aza,~1
5-aza-treated~1
anti-AML~1
(Fn)-coated~1
hemin-induced~1
attaching~3
microtubule-disrupting~1
125I-Fn~1
190,000~3
Fn-binding~1
Fns~2
octylglucoside~1
190,000/185,000~1
Fn-heptapeptide-Sepharose,~1
Fn-receptor~1
(neor).~1
co-cultivation~3
producer~3
(G418r)~1
G418r~3
neor~4
stocks,~1
RDFD2-25,~1
[2-3H]~1
XMP.~1
Uninduced~2
RDFD2~1
IMPD~4
metabolized/10(7)~2
cells/min)~1
cells/min).~1
RDFD2-25~1
tiazofurin~7
(HMSN),~1
Dejerine-Sottas~1
bulbs,~1
U/ml-68,000~1
ng/ml-600~1
(20-5000~1
Lymphomas,~1
19-9)~1
specificity-sensitivity~1
chromosome-positive~6
(62.5%).~2
(mechlorethamine,~1
108.3~1
103.4~1
10(-9).~1
osteosarcomas~4
aneuploidies~2
(2-16;~1
paraosteal~2
osteosarcomas,~3
18.8%;~1
2.0.~1
hypercalcemic,~1
midregion-specific~1
glomerular-mesangial~2
angiotensin-II-induced~1
angiotensin-II-associated~1
prostaglandin-E2~1
angiotensin-II-stimulated~1
prostaglandin.~1
6-Thioguanine~1
(6-TGN)~1
6-TGN~4
6-TGN.~1
-0.474;~1
thiopurine-induced~1
activity--presumably~1
BALF.~2
physically,~1
fertilization)~1
3-100~1
nontrophoblastic~2
Disaggregated~1
excavate~1
(sCT).~1
sCT~8
bound/mg~1
PGE-binding~1
bound/10(6)~1
rats),~1
hepatocytes).~1
E-series~2
(iPG)~1
(iTx)~1
radiometrically,~1
iPE2~1
iTxB2~2
indomethacin;~2
dazmegrel.~1
carbenoxolone.~1
iPGE2~2
homogenisation~1
myelomonoblastic~1
Listeria,~1
extraperitoneally~1
OKY1581,~1
(Tripp,~2
C.S.,~2
Wyche,~1
E.R.~1
Unanue,~1
Needleman,~2
Immunol.,~2
press;~1
Ceuppens,~1
J.S.,~1
Vertessen,~1
Deckmyn,~1
Vermylen,~1
90:458-463),~1
K.M.~1
Leahy,~1
Invest.,~1
76:898-901),~1
Y'~6
(Sugiyama,~1
Y.,~2
Yamada,~1
Kaplowitz,~1
Chem.,~1
258:3602-3607).~1
alpha-hydroxysteroid~3
alpha-HSD),~1
acid-metabolizing~1
alpha-HSD~4
chromatofocusing,~1
chromatofocusing~4
alpha-HSD-I,~1
3-oxo-cholic~2
alpha-HSD-I~1
isocholic~1
alpha-HSD,~1
3-oxo-bile~1
Margin~1
microleakage~2
(commercial)~1
"excellent~1
margin"~1
microleakage.~1
Tyldesley~1
Rotter,~1
by-product~3
anomaly--macrodontia~1
noncontributory--is~1
upregulates~1
HLA-negative~2
IFN-gamma-induced~2
blot,~6
Colo~1
TNF-alpha,~2
intracytoplasmically~1
(Ii),~1
Ii~5
hybrid,~3
intracytoplasmically.~1
(PGD2),~1
mm-thick~1
48/80.~2
Released~1
ovalbumin),~1
PGD2.~2
(340~1
hypopyon,~1
15+,~1
32+,~1
34+,~1
145+~1
1-(4-amino-2-methyl-5-pyrimidinyl)~1
methyl-3-(2-chloroethyl)-3-nitrosourea~1
(ACNU)~2
ACNU-resistant~4
subline,~2
C6/ACNU.~1
ACNU~28
C6/ACNU-bearing~1
(C6/ACNU-meningeal~1
gliomatosis)~1
C6/ACNU~2
quicker.~1
Binder's~4
(maxillonasal~1
cervicospinal~1
retrusion~1
chondrodysplasia~1
punctata,~1
undisclosed~1
autorotation.~1
fascicularis~4
head-films~1
repositioning),~1
repositioning).~1
overjet~1
bisecting~1
Correlative~1
Presurgical~1
logically~1
asphyxiation~1
inconceivable~1
hemimandibulectomy~2
ameloblastoma.~2
nonarticular~1
propoxyphene~2
napsylate~1
propoxyphene-acetaminophen~1
propoxyphene-containing~1
(AMPH)~1
(Ghosh~1
Parvathy,~1
perifornical~1
(PFH)~1
AMPH~1
PFH,~1
l-dopa~1
AMPH,~2
PFH~2
synapses,~1
PFH-injected~2
nor-adrenaline~1
AMPH.~1
Leu-~3
Met-enkephalin.~1
enkephalin-like~3
Met-enkephalin-like~2
Tmax)~1
i.m.)~1
i.m.),~1
Tmax.~1
rubbed.~1
females.(ABSTRACT~1
(0.31,~1
1.125,~1
80.0~1
beagle-type~1
(dogs~1
curve-fitting~1
(KB)~1
(alpha).~1
KA,~1
KB,~2
microgram/kg;~1
245.(ABSTRACT~1
Recognizable~1
hypodiploid~3
Cytogenetically,~1
intratubular~3
servonull~2
589~1
(BMI)]~1
HL60,~2
alkyl-lysophospholipid~1
1-octadecyl-2-methyl-rac-glycero-3-phosphocholine~1
(ET-18-OCH3).~1
growth-inhibition~1
(ID50)~1
ET-18-OCH3~3
(HL60),~2
(Raji),~2
(K562),~1
(L1210),~2
(K562).~1
O-alkyl~3
ALPs,~1
elevenfold~1
LD50,~1
ET-18-OCH3,~1
(0.13-0.21~1
nmol/min/mg)~1
race-ethnic~2
groups--Spanish~1
surnamed~1
Japanese--and~1
immigrants,~1
"homeland"~1
distinctive,~1
homeland~1
natives;~1
Angeles,~1
lifestyle,~1
facts.~1
1,519~1
(ORs)~2
0.52-1.09]~1
0.30-1.08),~1
0.99-2.12).~1
1.10-1.97);~1
nondrinkers,~2
1.40-2.56).~1
ORs~1
86-54-4;~1
1-hydrazinonaphthalazine)~1
302-01-2),~1
3,419~1
3,219~1
0.5-1.7]~1
0.5-1.7).~1
1,114~1
Grain~1
Millers'~1
mills~2
Cancer-Environment~1
1961-79~1
occupations,~1
prosecutors~1
welders~1
cutters;~1
porcelain,~1
workers;~3
employees;~1
brick~1
21-day~2
Bone-derived~1
17/2.8,~1
17/2,~1
RCJ~3
3.2T.1,~1
3.2.4.1CAM,~1
3.2CE2.1)~1
non-tumor-derived~1
(RCB~1
2.2A,~1
RCB~3
2.2B,~1
2.2C,~1
2.2D)~1
subcultures~1
1376b~1
Unsaturated~1
(16:1),~1
(18:1),~1
(18:2),~2
(18:3),~1
(20:4)~1
killers~2
(18:0),~1
arachidic~1
(20:0)~1
16-carbon~1
18-carbon~1
(stearic)~1
20-carbon~1
(arachidic)~1
(18:2)-linolenic~1
(18:3)~1
(BT2C,~1
BT4Cn,~2
BT5c,~1
9L)~2
BT5C,~1
9L~6
BT2C~1
phagocytic.~1
BT5C~1
(BT5C~1
(BT4Cn)~1
BT4Cn~1
(BT2C)~1
25013-16-5],~2
[(TC)~1
59-02-9],~1
carbazole~1
[(CA)~1
86-74-8]~1
2,2'-dioxo-N-nitrosodipropylamine~1
[(DOPN)~1
enzyme-altered~1
forestomachs~1
DOPN~1
BHA-induced~1
BHA-~1
TC-treated~1
diethylnitrosamine~1
[(DENA)~2
55-18-5],~1
[(DMH)~3
57-14-7],~1
dibutylnitrosamine~1
[(DBN)~1
924-16-3]~1
DENA~2
hemangiocellular~1
DBN~1
DENA,~1
form-positive~1
"initiation."~1
(MoAb).~2
tumorigenic,~1
(C-C36)~1
NS-1,~2
phosphoribosyltransferase-deficient~1
C-C36~4
D10~19
"#71295."~1
65,000-~1
14,000-molecular-weight~1
Meth~6
#71295~2
D14,~1
subline~3
(B16-BL6)~1
B16-BL6~2
footpads~6
Footpad~1
(13/15)~1
moniliforme~4
nutritionally.~1
cornmeal,~1
1069~2
mutagen~1
fusarin~3
gamma-glutamyltransferase-positive~1
adenofibrosis,~1
cholangiocarcinomas,~2
carcinogenicity,~1
Rearrangement~4
int-1~3
int-2~1
BALB/cfC3H~2
(HPO)~1
int~1
proviral~23
HPOs~2
WiDr~3
(NCR-nu)~1
93-100%~1
cocktail~5
(collagenase,~1
DNase,~1
pronase)~1
cells/g~1
yields;~1
(PEs)~1
disaggregation.~1
(33%);~1
Single-cell~1
(D0~1
Gy;~1
(D0,~1
tumors"~1
(HRCC)~1
HRCC~5
(SN12C)~1
(SN12L1).~1
subcapsule~1
vascularized,~2
nonencapsulated,~1
SN12L1~1
1-(2-hydroxyethyl)-1-nitrosourea~1
[(HENU)~1
13743-07-2]~1
nitrosocarbamate~1
3-nitroso-2-oxazolidinone~1
(NOZ)~1
HENU~2
HENU,~1
NOZ~2
MRC-Wistar~1
HENU-treated~1
adenocarcinomas),~1
lymphoma-leukemia.~1
osteoblastomas.~1
lymphoma-leukemia,~2
(Burkitt's-like)~1
adenomas)~1
Lymphadenopathy-associated~1
(HIV~3
neurotropism~3
seroepidemiological~1
human-immuno-deficiency-virus-associated~1
3'-azido-3'-deoxythymidine~4
(AZT).~1
tomography;~1
AIDS-virus-associated~1
antiretroviral~4
LSA2L2~1
(Memorial~1
Sloan-Kettering)~1
3.0-9.5~1
Z-score,~1
Z-score~1
-0.30~1
-1.37~1
Growth-hormone~1
2507~1
(3/646)~1
(58/548)~1
insertive~1
Receptive~1
(HTLV-IV).~1
prostitutes~4
HIV-associated~2
West-Indian-born~1
caucasian,~1
HTLV-1~4
Valosin,~1
25-amino-acid~1
valosin-specific~1
endopeptidases~3
valosin~3
(valosin-containing~1
VCP),~1
valosin.~1
Valosin-specific~1
neuropathy-Ib~1
(HMSN-Ib)~1
(AT3)~1
AT3,~1
(HMSN-Ib,~1
Duffy,~1
AT3)~1
HMSN-Ib~2
AT3.~1
(EWSCL)~1
(DWHCL)~1
EWSCL,~1
DWHCL).~1
EWSCL~3
DWHCL.~1
DWHCL~2
Extended-wear~1
(EWCL)~1
EWCL~4
lensectomy~2
(polymegathism).~1
polymegathism,~1
radiopacities~1
(chin-down)~1
chin-up~1
unsharp~2
"Crack,"~1
"Crack"~1
committing~1
"crack"~1
cemento-ossifying~1
fibro-osseous~4
(PPS)~1
flexure.~3
ascends~1
periosteum,~2
crosscut~1
parotideomasseteric~1
skin-fascia~1
Dermatomyositis~1
BMS.~1
Unit,~1
sialography~2
alpha-hemolytic~2
Microbiologically,~1
Sialography~1
(43.33%)~1
(47.50%)~1
(47.61%)~2
(44.44%)~1
(6.34%)~1
(1.58%)~1
(73.00%)~1
sialoadenitis~1
(25.39%).~1
Lymphocyte-related~1
Immunoproteins,~1
C'3~1
HLA-B15~2
glossitis~5
link,~1
Gingival~3
ameloblastomas~3
evaginatus~2
disk-bilaminar~1
Paresthesia,~1
endodontic-periodontal~1
molar.~3
Kodak's~1
Ektaspeed~4
Ultraspeed~4
low-contrast~2
ventilator-assisted~1
Used~1
difficult-to-treat~1
combinations)~1
exorbitant~1
cytokinin~3
auxin,~1
rosea~2
epimeric~1
dehydrodiconiferyl~4
beta-D-glycosides.~1
quadrupole~1
Fourier-transform~2
Antisense~1
realize.~1
(13-~1
15-mer)~1
oligodeoxyribonucleotides~1
epsilon-amino~1
poly(L-lysine)~1
14,000).~1
15-mer~1
oligonucleotide-poly(L-lysine)~2
N-protein~1
computed,~1
rules.~2
probabilities.~2
formalism.~1
formalism~3
schemes.~1
scheme,~2
topological~2
decompose~1
subschemes,~1
two-entry~1
(GDCase;~1
L-glutamate-1-carboxy-lyase,~1
4.1.1.15)~1
1300-fold~1
chromatographies~1
DEAE-cellulose,~1
hydroxylapatite,~1
GDCase~4
(3.6-25%)~1
4-7.~1
NaDodSO4~4
2-mercaptoethanol,~2
40-kDa~2
80-kDa~5
5.4.~1
sulfinic~1
decarboxylated~2
carbonyl-trapping~1
beta-methylene-DL-aspartate.~1
"beta-benzyme",~1
beta-cyclodextrin,~1
chymotrypsin.~2
78-kDa~3
glucose-regulated~1
GRP78~2
stress-inducible~1
reticulum-localized~1
N-terminus~9
70-kDa~4
GRPs,~1
temperature-shift~1
(beta-D-glucuronoside~1
glucuronosohydrolase,~1
3.2.1.31)~1
153-base-pair~2
full-length.~2
kilobases).~1
isozyme.~1
endoderm~5
endoderm-like~6
down-regulated.~2
up-regulated~7
pg/micrograms~1
primer-extension~1
transfection.~4
four-state~1
oxygen-evolving~2
(OEE2),~1
Chlamydomonas~8
reinhardtii.~1
photosynthetic~1
photosystem~9
algae.~1
OEE2~5
preprotein,~1
57-amino~1
reinhardtii,~3
Anti-human~1
SJK-287-38~1
[Tanaka,~1
S.,~2
Hu,~1
S.-Z.,~1
Wang,~1
S.-F.~1
Korn,~1
257,~1
8386-8390]~1
(tsLA24).~1
220,000~5
[32P]orthophosphate,~1
Phospho~1
phosphoserine.~1
agarose-immobilized~1
nonhydrolyzable~3
5'-[gamma-thio]triphosphate,~1
polymerizing~1
220,000)~1
Mov-13~2
heterotrimers~1
human-mouse~5
comigration~2
H107.~1
24-amino~2
IgG-induced~2
IgG-immunized~1
nonsynovitic~1
anti-proteoglycan~2
6C11,~1
DEAE-cellulose-resolved~1
sulfate-containing~1
v-Ha-ras~1
MCF-7ras~4
MCF-7,~1
(insulin-like~1
bFGF,~2
microheterogenous~1
Mrs~1
17,200,~1
rhabdomyosarcoma-derived~1
Msp~1
Hpa~1
methylated,~1
HindIII,~1
episomal.~1
nonreplicative~1
hypermethylated~1
PLC/PRF/5~1
repression.~2
hypomethylated,~2
2/3),~1
receptor-expressing~3
(NIH~1
3T3)~1
oncogene.~4
c-myc-carrying~1
nontransfected~3
1,25-(OH)2D3;~1
c-myc.~5
megakaryocytes,~6
peroxidase-positive,~1
monax)~1
17-36~1
cocarcinogenic~1
well-monitored~1
pericarcinomatous~1
anaplasia,~1
hepatitic~1
antigen-carrying~1
weeks-long~1
necroinflammation~2
unestablished~1
postulated,~1
2-(4-Phenylpiperidino)cyclohexanol~1
(AH5183)~1
[3H]AH5183~7
saturably~1
Bound~1
AH5183~1
alpha,3~1
beta,4A~1
beta,8A~1
alpha)-decahydro-3-(4-phenyl-1-piperidinyl)-2-~1
naphthalenol~1
eserine,~1
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,~1
1-methyl-4-phenylpyridine,~1
(+/-)-N-allylnormetazocine~1
10,047),~1
heterogenously~1
nucleus-putamen,~1
(713-751~1
(334-516~1
transsection~1
(exons~1
(exon~1
transcript,~3
(17,257~1
Da)~4
(17,224~1
MBP,~2
"17-kDa"~1
MBPs,~1
[1-(2-chlorophenyl-N-methyl-N-(1-methylpropyl)-3-isoquinoline~1
carboxamide]~1
tritiated-drug~1
(RN1)~1
(SK-N-MC,~1
SK-N-SH)~1
(ATCC~1
HTB~1
U-87~1
MG).~1
positron-~1
isotopes.~3
4-[3-(4-diphenylmethyl-1-piperazinyl)-2-hydroxypropoxy]-1H-indole-~1
2-carbonitrile~1
(DPI~1
201-106)~1
R-DPI~3
(205-429)~2
S-DPI~3
(205-430)~2
DPI~5
201-106~5
20-alpha-benzoate,~1
.008).~1
man-made~1
biosphere.~1
biodegradative~2
alkylbenzoates~1
4-ethylbenzoate.~1
4-ethylbenzoate~3
2,3-dioxygenase~1
(C23O),~1
operon~8
C23O~1
HTLV-II,~2
HTLV-II~4
repeat,~4
hypothalamus).~1
(285%~1
hypothalamus)~1
(350%~1
320%~1
striatum)~1
23-70%~1
site-,~1
PG-specific~1
HLA-A,B~10
accused~1
paternity,~1
trios,~3
fathers)~1
(RMNE)~1
Paternity~1
trios~2
(whites~1
blacks)~1
94.4~1
93.6~1
RMNE~1
agreed.~1
blacks.(ABSTRACT~1
dysmetria,~1
(five-day)~1
sodium/volume~1
(S/V)~1
S/V-depleted~1
(CPAH),~1
inulin),~1
proteinuria)~1
mEq/d.~1
S/V-expanded.~1
KR/K)~1
(ibd)~1
disease-susceptibility~1
Namely,~2
(sharing~2
markers/both~2
R/lambda~1
ibd~1
ibd,~1
.25/lambda~1
penetrances,~1
single-locus~1
familiality~1
minor:~1
5.25-fold~1
60;~1
3.42-fold~1
leprosy,~1
1.49;~1
2.38).~1
HLA-unlinked~1
pleiotropy~2
dis-equilibrium~1
allele(s).(ABSTRACT~1
Pompe's~1
(glycogen~2
Cori~1
attractions~1
TMB-8,~1
U46619.~1
(42.0~2
8.2%)~1
7.0%)~1
3.1%)~1
6.2%)~1
TMB-8-sensitive~1
bulb)~1
pylorus)~1
844~1
person-months.~1
constant-risk~1
A-56268~23
(TE-031),~2
6-O-methyl~1
log2~4
acnes,~1
pyogenes,~4
administration.(ABSTRACT~3
cefmenoxime~3
Cefmenoxime~1
two-compartment-model~1
0.270~1
7.60~2
65.5~2
7.50~1
3.72%~1
cefmetazole~7
fosfomycin~6
methicillin-~1
cephem-resistant~1
Cefmetazole~1
2'~1
cloxacillin,~1
fosfomycin.~1
Penicillin-binding~2
2',~1
Retinoids,~1
isotretinoin,~5
consolidate~1
Modules~1
mg/m2/day),~1
1-14~1
enterotoxicity,~1
re-admitted~1
Leukaemia~1
(UKALL~1
HLA-DRw6~6
(22.9%~1
(26.0%).~1
Prolymphocytic~1
cyclophosphamide;~1
(TAD-9)~1
Refractoriness~3
TAD-9~4
HD-Ara-C~1
pericardiac~1
transplantations.~1
megakaryoblasts,~2
megakaryoblasts:~1
myelopoiesis,~4
TAM).~1
MY10~1
MY9~2
MY7,~2
MY4,~2
megakaryoblasts~6
TAM~2
CFU-GEMM.~1
alpha-A~2
(Roferon-A)~1
(bcr)~2
(Pr-1)~1
Ph1+~2
Philadelphia-positive~1
(Ph1+)~1
Stratum~3
intermediate-dose~2
(POMP)~1
POMP~1
APL,~1
coagulase~1
xanthine:~1
equilibrates~1
Form~7
NAD+~3
D/O~2
prefers~1
Interconversion~1
group-modifying~1
reagents:~1
Cd2+,~2
Cu2+,~1
NADH/NAD+~3
xanthine:acceptor~1
(NAD+-dependent~1
forms).~1
radical-ion~1
stump-lengthening~1
reduction-rotation-plasty,~1
rhombus-shaped~1
Kotz~1
Salzer,~1
midthigh~1
fishmouth-shaped~1
fittings~1
facilitated,~1
zimeldine~2
Citalopram~3
Citalopram,~2
(F1,17~2
5.27;~1
13.18;~1
neurobiologic~1
42-month~2
anti-tuberculous~1
cites~1
aformentioned~1
sperm/ml.~1
99.9%~1
aminoacyl~1
acid-starved~1
(PDGF)-like~1
c-sis/PDGF-B~1
PDGF-A~1
cell-like~2
C-11~1
alpha-PGF2~1
1.00)~1
beta-PGF2,~1
preleukaemic~1
Isotretinoin~3
corynebacteria~1
postpolycythemic~1
(Sweet's~1
nodulocystic~1
scar-correcting~1
crown-root~1
dentist,~2
developments.~2
handpieces~1
dentist's~3
handpiece~1
lighting.~1
stain-masking~1
opaquers~1
modifiers.~1
masking.~1
HSV-1,~1
HSV-2,~3
Varicella-zoster~1
pretesting,~1
fluoridation,~1
fluorides,~1
sealants,~1
interferon-gamma-treated~1
lymphokine-stimulated~1
H-2K~5
H-2D~5
(non-lymphokine-treated)~1
H-2D,~1
I-E.~1
subverting~1
protozoan.~1
Inverse~2
etretinate.~4
(13-cis-retinoic~3
(aromatic~1
retinoid).~1
p21E,~1
p41E~1
estrogen-regulated,~1
(0-t~1
0-infinity~1
0-t~1
30.3,~1
23.0,~1
[67Ga]citrate~4
Fluorine-18-2-fluoro-2-deoxy-D-glucose~1
18F]FDG)~1
[18F]FDG~3
Fluorine-18~1
tumor-detecting~1
[67Ga]citrate.~1
OST7~2
(111I),~1
(KT005).~1
radiolabels~2
111In-lableled~1
tumor-to-liver~2
tumor-to-kidney~1
OST7,~1
tumor-to-tissue~1
igG~1
53.8%~1
hemihypertrophy~1
experienced,~1
beta-propriolactone-sterilized,~1
radiation-sterilized,~1
gas-sterilized~2
histiologically~1
Beta-propriolactone-sterilized~1
radiation-sterilized~1
mulatta~1
circummandibular~1
Tantalum~1
HZ~2
Node-to-node~1
Nodes~2
node-spread~1
paracortex,~2
0-3+~1
farthest~1
(zoned~1
zoning.~1
(PDCs)~1
tumor-oriented~1
PDCs~1
([3H]dThd)~2
(DNA-LI),~1
(Tc),~2
determination;~1
[3H]dThd~3
DNA-LI~2
gland's~1
[(TPA)~1
56937-68-9],~1
21259-20-1),~1
404-86-4),~1
condensate~6
(CSC),~1
3807-77-0)~1
LHC-8~1
(population~2
(CLE)~1
CSC/ml,~1
CSC/ml~1
(A23187)~1
220%.~1
exponential;~1
475)~1
156)~2
unaccountable~1
epithelium)~1
"urogenous~1
hypothesis."~1
1950-80~1
1960's~1
1,181~2
(SCID)~2
sibships,~1
(ADA)-deficient~1
9,170~1
2-or-more-year~1
nonreferred~1
[relative~3
9-22].~1
4.8;~1
1.2-18.9).~1
alkylator~1
3,607~1
(SEER)~2
2,278~1
(CCCs)~1
(CCPDS).~1
CCPDS~3
Late-stage,~1
CCCs~1
LewisX~1
(LeX)~1
[characterized~1
trisaccharide~2
Gal~8
1----4~1
(Fuc~1
1----3)N-acetylglucosamine]~1
oncodevelopmental~1
anti-SSEA-1~3
AH8-183,~1
LeX~6
FH1,~1
FH4,~1
FH6,~2
IB9,~1
difucosylated~1
trifucosylated~1
LeX-related~1
(adenomatous)~1
nonpremalignant~1
(hyperplastic)~1
(APs)~1
(HPs).~1
AH8-183~2
monofucosyl~1
HPs.~2
APs,~1
villose~1
HPs~1
polyp-to-cancer~1
haptens,~1
[synthetic~1
(S-TAGs)],~1
S-TAGs~1
Gal(1----3)-beta~1
GalNAc~2
(TF-beta)~1
Gal(1----3)~1
(TF-alpha)~1
(Gal~1
galactose;~1
GaNAc~1
N-acetylgalactosamine).~1
S-TAG~1
Tn~3
GalNAc-O-serine.~1
TF-alpha~2
TF-beta~2
Tn.~1
TF-alpha-specific~1
Acinar~3
reexpressed,~1
(FUra)~1
doxifluridine~1
[(5'-dFUrd);~1
5'-deoxy-5-fluorouridine]~1
fluoropyrimidines.~1
5'-dFUrd~7
FUra~5
push,~2
route)~1
5'-dFUrd/kg/day~1
FUra/kg/day.~1
(25-35~1
mg/kd/day)~1
FUra).~1
5'-dFUrd/kg.~1
5'-dFUrd/kg~1
FUra.~1
arotinoids,~1
chemoprevention.~1
(E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,~2
8-tetramethyl-2-naphthalenyl)-1-propen-1-yl]benzoic~1
13-7410;~1
arotinoic~3
ethyl-(E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-~1
tetramethyl-2-naphthalenyl)-1-propen-1-yl]benzoate~1
13-6298;~1
arotinoid~3
ester),~1
8-tetramethyl-2-naphthalenyl)-1-propen-1-yl]phenylmethanol~1
13-8320;~1
methanol),~1
(E)-1,2,3,4-tetrahydro-1,1,4,~1
4-tetramethyl-6-[1-(4-methylphenyl)-1-propen-2-yl]naphthalene~1
13-9272;~1
arotinoid)~1
teratogen,~1
embryolethal~2
arotinoids~2
embryopathic~1
conformationally~3
(M-MuSV)-Moloney~1
(M-MuLV)~3
Friend-Moloney-Rauscher~1
virus-expressing~1
M-MuSV-injected~1
anti-M-MuSV~3
virus-inoculated~1
104E.~1
Virus-injected~1
M-MuLV.~2
M-MuSV-induced~1
3-methylcholanthrene~1
56-49-5)-induced~1
BMT-11,~1
leukemoid~1
(WBCs)~1
grew.~1
forty-fold~1
BMT-11~2
(Pg),~1
(C57BL~1
DBA/2f)F1~2
MXT~6
Uteri~2
25.00~1
micrograms/animal)~2
(125,~1
here;~1
dThd~1
(3LL)~2
3LL.~1
antiangiogenic~2
metastasis-promotion~1
3LL~3
case-definition~2
leukaemia/lymphoma~3
western-blot~1
(HTLV-I).~4
p19~7
p24~13
longer).~1
(self-reported~1
bulimia).~1
related:~1
amenorrheics~1
EAT-26~1
segregating.~2
Harvey-ras-1~1
(HRAS1)~1
(INS).~1
Gerhard~1
HRAS1~2
Iceland.~1
monoblastic~2
blood-tissue~1
"beta~1
subunit"~1
Catholic~1
nuns~1
19-94~1
0-574~1
(0.76%)~1
586~1
U/ML,~1
positive"~1
clinical-arthrographic~1
power-spectrum~1
bite,~2
neuroanatomy.~1
marker:~1
overactivity,~1
myxoma(s)~1
chlorhexidine,~1
benzydamine-free~1
Stinging~1
benzydamine,~2
chlorhexidine.~1
gingiva,~3
mats~1
dislodging~1
epithelium-covered~1
Terms~1
Klippel-Trenaunay-Weber~1
Plexiform~1
unicystic~1
gingivae~1
residua~2
lymphangiomas.~1
mucogingival~1
Tubliseal,~1
AH26,~1
Diaket~1
sealers~2
gutta-percha.~2
pulps~2
cementum~4
invaginatus~1
gutta-percha~3
sealer.~1
(bending,~1
(degree~2
darkroom)~1
packet.~1
(387)~1
Bitewing~1
(83.7%).~1
(89.9%)~1
unreadable~1
canines,~1
nonrestored~1
dentin.~2
reversals,~1
Pompe~1
atheromatous,~1
thromboembolic,~1
spider.~1
anti-centrosome~1
centrosomes,~1
noncentrosomal~3
36-kDa~2
centrosomal~5
lymphoblastoma~1
KE37~1
centrosomes~1
centrosomes.~1
"housekeeping"~1
26,000-36,000~1
26-36)~1
26-36~4
13-acetate,~3
26-36,~2
satisfy.~1
Newcastle~2
F0.~1
F2,~1
membrane-fusing~1
"chase"~1
m-chlorophenylhydrazone~1
Message~1
amounts)~1
53-base-pair~1
RP41,~1
224-amino-acid~1
RP41~1
RP16,~1
RP41.~2
RP16~1
serine/threonine~1
20pter----20q13~1
3p25----3qter,~1
c-src-1~1
c-raf-1,~1
SiHa~1
carcinoma-derived~1
13q14----13q32.~1
SW756~1
Ki-ras2~1
C4-I,~1
C4-I~1
cis-activation~1
nucleolus-organizing~1
enzyme-digested~1
repeats,~3
680-base-pair~2
1020-base-pair~1
Xba~10
tissue?~1
sis~5
SMC,~4
(CaM)-dependent~1
(calcineurin)~1
anti-phosphodiesterase~1
phosphodiesterases~1
Affinity-purified~2
anti-calcineurin~1
61-kDa~1
18-kDa~3
CaM,~1
CaM-binding~2
(calmodulin-dependent~1
fodrin),~1
CaM-dependent~1
neurons--e.g.,~1
Calcineurin~1
base-mispair~1
3'----5'~2
exonuclease~9
oligodeoxynucleotide~6
primers,~1
X174~5
amber~4
codon,~2
mispaired~2
3'-hydroxyl~1
nonsuppressor~2
mismatches~1
mispairs~1
primers~2
am16~1
am3~1
mispair~3
Ttemplate~1
Gprimer~1
mispair,~1
neighbors,~1
10(3)-~1
10(6)-fold~1
crossreacting~4
(NCA)~2
deglycosylated,~1
microsequencer,~1
phenylthiohydantoin~1
N-acetylglucosaminylasparagine.~1
NCAs,~1
NCA-95~2
NCA-55.~1
Cysteine-containing~1
homologies.~1
supergene~2
NCA~4
[Thompson,~1
Pande,~2
H.,~2
Paxton,~1
Shively,~4
Padma,~1
Simmer,~1
Todd,~1
Riggs,~1
(1987)~5
USA,~2
press]~1
[Zimmermann,~2
Ortlieb,~2
B.,~2
Friedrich,~2
Kleist,~2
press].~1
25-kDa~4
cap-binding~2
(CBP)~2
23-base~2
22-base~1
oligonucleotide,~1
primer,~1
phages~1
250-base~1
inserts.~1
1900-base-pair~1
CBP~8
25,117).~1
2250~1
PB2~1
topoisomerases~3
5.99.1.2)~1
5.99.1.3)~1
15-20.~1
intertwined,~1
catenated~1
unlinking~1
pPLc245~1
PL.~1
overproduced.~1
phage-type~2
lysozymes:~1
lysozymes.~1
Short-pulse~1
nitroxide-labeled~1
dispersions.~1
Nitroxides~1
14N~1
(T1e)~1
Heisenberg~3
(T1n).~1
T1e~1
T1n~1
bimolecular~2
iron-porphinato~1
[Eisenberger,~1
P.M.,~2
Shulman,~1
R.G.,~1
Kincaid,~1
M.,~6
Brown,~1
Ogawa,~1
(1978)~1
(London)~4
274,~1
Perutz,~1
M.F.,~1
Hasnain,~1
S.S.,~1
P.J.,~2
Sessler,~1
J.L.~1
Hahn,~1
295,~1
535-538].~1
Perutz~1
iron's~1
hemes.~1
Eisenberger~1
helix-coil~2
(helix-coil)~1
activated)~3
perturbed~2
meromyosin/heavy~1
hinge.~1
iodine-photodissociation~1
mus.~1
backbone,~1
thermoelastic~2
filament-released~1
rubber-like~2
(rigor~1
2-4.~1
jumps~1
glucosides~2
pith~3
zeatin~1
habituated~1
glucosides)~1
Hydroperoxy-5,8,11,13-icosatetraenoic~1
hydroperoxy-5,8,11,13-icosatetraenoic~1
C3H/10T1/2.~1
Fe-catalyzed~1
quin-2.~2
hydroxyperoxy-5,8,11,13-icosatetraenoic~1
CuZn-superoxide~1
4.1.1.32)~1
19-day~2
N6,O2-dibutyryladenosine~1
avidin-linked~1
Postnuclear~1
ATP-regenerating~1
avidin-enzyme-biotinylated~1
beta-galactosidase.~1
Ionophores~1
Caulobacter~1
crescentus~2
27-kDa~10
flagellin,~3
29-kDa~1
29-,~1
flaEY~1
crescentus.~1
-13,~1
-24,~1
-100~4
fla~4
-13~2
(C/TTGGCC/GC-N5-TTGC)~1
-12,~1
nif~1
19-base-pair~1
[designated~1
II-1;~1
Chen,~1
L.-S.,~1
Mullin,~1
Newton,~1
2860-2864]at~1
-101~1
cluster;~1
element,~6
calsequestrin~2
42,435~1
1.9-2.0~1
Hydropathy~1
structured.~1
moderate-affinity,~1
superinduced~2
Superinducibility~1
"immediate~1
early"~1
liver-specific~8
subspectra~1
multiplicities~1
simulation.~2
branch-point~1
spin-coupling~1
1,2-(cyclic)-4,5-trisphosphate~2
carbodiimide.~1
1-1.5~1
1,4,5-trisphosphate.~1
cyclized~1
Partisil~1
SAX.~1
1,2-(cyclic)-4-bisphosphate~1
5-phosphomonoesterase~1
five-membered~1
phosphomonoesters.~1
JE~1
polyomavirus.~1
Empty~2
(capsids)~1
Virions,~1
capsids,~1
dose-responsive~1
polyoma.~2
(336a)~1
signal-~1
messenger-linked~1
3-phosphoglycerate~2
3-phosphoglycerate-dependent~2
II-catalyzed~1
"nonnervous"~1
nonnervous~1
[orthophosphoric-monoester~2
(alkaline~2
optimum);~1
3.1.3.1]~2
2513~1
528-amino~1
ALP,~2
liver/bone/kidney~1
3'-untranslated~8
gaps).~1
biopolymers~1
Extremal~1
[Arratia,~1
R.,~5
Gordon,~2
Waterman,~2
Ann.~1
Stat.~1
971-993].~1
extremal~1
[Smith,~1
Burks,~1
Nucleic~3
Acids~2
645-656],~1
Tunicamycin~1
Tunicamycin-resistant~2
single-step~3
methanesulfonate-pretreated~1
leishmanias~1
Alg~1
N-acetylglucosaminyltransferase.~1
tunicamycin.~1
tunicamycin-resistant~1
50-amino~1
pSW272,~1
(NRK)~2
TGF-beta.~9
Transformed~1
(SW355)~1
NRK~1
Ca3(PO4)2-mediated~2
SP1.~1
cotransfected~3
neo~11
(pSV2neo)~1
(pT24-c3),~1
colonies)~1
pSV2neo-transfected~2
SP1~6
3/16~2
metastatic.~1
H-2Dk~1
Ca3(PO4)2~1
5/20~1
transfection,~4
Ca2+]i)~3
(CCK-8)~2
Lanthanum~1
CCK-8-stimulated~1
lanthanum-sensitive~1
glycophospholipid~1
anti-Thy-1~3
Diffusion~2
cm2/sec~1
HT29~1
[3H]adenine~1
1-adrenergic)~1
(beta-adrenergic)~1
(Wap)~1
Wap-ras~4
founders.~1
tissue-directed~1
Wap~2
founder,~1
Wap-ras-expressing~1
Wap-ras--i.e.,~1
cell-type-specific~5
testololactone,~1
neurotumor,~1
RT4.~1
RT4~2
RT4-AC~5
(stem-cell~1
RT4-B,~1
RT4-D,~1
RT4-E,~1
10(-5).~2
RT4-B~1
RT4-E~1
RT4-D~1
RT4-B8~1
RT4-E5~1
glial-cell-specific~1
RT4-D6-2~1
dibutyryl-cAMP.~1
determinational~1
(mtDNA)~2
tRNAs~6
anticodons,~1
tRNA.~2
elegans,~1
(ZEBRA)~1
2.7-kilobase-pair~1
(BamHI~1
WZhet)~1
WZhet~1
1-10%~1
immortalize~3
PME77,~1
non-autoimmune~2
(CBA/ca~1
(34,~1
PME77.~1
[MRL-lpr/lpr~1
B/W]~1
PME77~1
detects,~1
supernatants,~4
protein(s),~1
LAMP~1
[for~1
lupus-associated~1
protein(s)],~1
Anti-Gal~1
1----3Gal.~1
glycosidic~2
anti-Gal~5
1----3Gal~4
apes~1
reciprocity~1
anti-Gal.~1
Sulfhydryl~1
persulfides~3
(RSSH)~1
mercaptopyruvate,~1
donates~1
mercaptopyruvate~2
sulfurtransferase~1
2.8.1.2).~1
methylthio-group~1
methanethiosulfonate.~1
thermostability,~2
Partial-to-complete~1
methylthio~1
flow),~1
stability:~1
2.004;~1
2.033~1
2.005;~1
2.000~1
mT).~1
linewidth,~1
carbon-centered~1
semiquinone,~1
oxygen-centered~4
radicals;~1
nitrogen-centered~1
radical.~2
intense;~1
Enkephalin-positive~1
"woolly~1
Meynert,~1
enkephalin-positive~1
woolly~2
Meynert.~2
pallidal~1
subcommissural~1
Methylmalonyl-CoA~1
mutase~11
(2-methylmalonyl-CoA~1
CoA-carbonylmutase,~1
5.4.99.2)~1
heterogenous++~1
apoenzyme~2
mut-,~1
mut~1
mutase,~2
6G.~1
552,~1
Line~2
rhodamine,~2
anti-mutase~1
precursor;~1
(ALD),~1
ALD,~1
cerebrohepatorenal~3
enoyl-CoA~1
hydratase/3-hydroxyacyl-CoA~1
beta-ketothiolase.~1
Peroxisomes~3
ALD.~2
beta-ketothiolase~1
(helper/inducer)~5
(cells~2
CD4)~1
anti-HIV~6
CD8+~25
(suppressor/cytotoxic)~5
CD16+~2
killer)~2
cytolysis,~1
(diazepam-binding~1
neuromodulatory~1
acid-benzodiazepine-Cl-~1
beta-carboline-like~1
chlordiazepoxide~1
gavage.~1
DBI.~2
octadecaneuropeptide~1
(Gln-Ala-Thr-Val-Gly-Asp-Val-Asn-Thr-Asp-Arg-Pro-Gly-Leu-Leu-Asp-Leu-Lys~1
HPLC/RIA~1
octadecaneuropeptide-like~1
DBI,~1
enzyme-catalyzed~2
sulfation,~1
amidation.~1
Blot-hybridization~3
AtT20~1
enzyme-activity~1
(EIDA).~1
EIDA~1
splicing:~1
277-amino~1
DM-20~7
PLP-like~1
mutant.~4
208-232;~1
PLP-encoding~1
(GFL)~1
Somata~1
GFL~3
(INa)~1
patch-electrode~1
INa~1
somata~1
"giant~1
limb-preserving~1
Bones~2
Questionable~1
Deletions~4
(6q-)~1
6q21-24,~1
6q-~5
q22,~1
mid-fall~1
"look-back"~1
Banks~2
95,917).~1
"miscellaneous"~1
laboratory-designated,~1
(anti-HBs),~1
laboratory-designated~1
1:6561)~1
retesting.~1
kits,~2
Sorin/Biomedica~1
Electronucleonics~1
retesting;~1
Sorin~1
(M5)~2
hypocellular~4
otalgia,~1
90,000/mm3.~1
Bishop~4
(Syntocinon)~1
(FVC).~1
(LF)~2
Spleens~2
pulp.~6
cordal~1
LF~6
streptozotocin,~2
anti-Ia~8
Ia-~1
785~1
enrolled.~4
seronegative.~1
nonsteady~1
seroconversions.~1
onchocerciasis,~1
loiasis,~1
dipetalonemiasis~3
micro-ELISA~1
(OD~1
microfilariae-negatives~1
loiasis~1
Dipetalonema~1
perstans-negative~1
Loa~1
loa-negatives,~1
loiasis.~1
(CSF);~1
disturbances;~1
leukemia-like~1
HTLV-I-associated~4
(HAM).~1
p32~1
intra-blood-brain~2
HAM.~1
myeloneuropathy~1
Martinique~1
(French~1
Indies)~1
unneeded~1
(E+,~1
Leu-1+,~1
Leu-2a-,~1
Leu-3a+)~1
45,X-Y,inv(16)(p13;q22),t(11;17)~1
(q11;q25),del(21)(q13)~1
Tourette's~8
Mennonite~1
tics~8
(CMTs).~1
CMTs.~1
CMTs~1
tic~5
CII.~1
odds)~2
CII~1
Taq~10
blepharoconjunctivitis~1
Protocols~1
ventilators,~1
observations:~2
Clonogenic~1
THP-1~2
myelomonoblasts.~2
U/mL),~1
(recombinant~3
natural)~1
interferons).~1
1-B-D-arabinofuranosylcytosine~1
(ara-C),~1
(AML),~4
APS.~3
HSA-cultured~1
ara-C-containing~1
HSA-induced~1
perturbed,~1
ara-C-based~1
Sensitive~1
HSA-perturbed~1
growth-stimulated~2
ON/REL;~1
off-therapy,~1
CR/OT~3
ON/REL~1
HTLV-I-susceptible~1
cord-blood~1
MNC,~2
remission-induction~2
1:40~2
1:160.~1
HTLV-I-carrying~1
milkborne~1
stain-measured~1
Reticulin~2
49%;~2
28%;~1
46%;~1
(GSD-1a)~1
(CCC)~1
cis-diamminedichloroplatinum-II~2
(CDP).~1
6-18)~1
"rescue"~2
Deleterious~1
CDP~3
CCC~1
mg/M2.~1
(cumulative~2
mg/M2)~1
ALL),~1
reinduction-responders~3
reinduction-nonresponders~1
roots;~1
63.33%~1
84.38%~1
chemotherapy-associated~1
glucagonoma,~1
201-995),~2
H2-blockers~1
glucagonemia~1
inconstant;~1
tonsil,~2
trismus,~2
average-risk~1
6-MP.~2
catabolizes~1
thiouric~1
(TPA~1
significative~2
vaginal,~2
(HDARAC)~1
HDARAC.~2
HDARAC~3
gastroprotective~2
subcitrate~1
(De-Nol)~1
De-Nol~4
ulcerogens,~1
chemoreceptors,~1
(denervated);~1
(18.9%~2
31.5%;~1
meclofenamate;~1
297.3%~1
304.0%~1
(GC-MS).~1
cholenoic~1
allylic~3
(FAB-MS).~1
FAB-MS~1
solvolyzed~1
tetrahydrofuran,~1
hydrolase.~2
solvolysis,~1
deconjugation,~1
diazomethane,~1
beta,7~2
alpha-dihydroxy-5-cholenoic~1
3-sulfate,~1
alpha,12~1
alpha-trihydroxy-5-cholenoic~1
monosulfate,~1
Chenodeoxycholic~1
A-fat~1
(RP).~1
1,000)~2
nonchylomicron~2
6.4-fold~1
nonchylomicrons.~1
gemfibrozil~3
L4F3~5
granulocyte/monocyte~1
clonally.~1
L4F3-treated~1
nonleukemic.~1
(TGF~5
TGF~30
beta-mediated~1
3-5-fold~1
UKALL~2
Romanowsky~1
"common~1
ALL."~1
non-diffuse~1
"granular"~1
Morphologists~1
peridental~1
fluorosis~2
fluoridated~2
fluorosis,~1
molars,~1
anomalies--natal~1
notch--found~1
(PDL)~1
anesthetized.~2
pistol-pressure~1
standard-grip~1
collimation.~2
(brain,~1
breast)~1
collimation~2
nonfluoridated~1
2,776~1
three-inoculation~1
Teeth~2
cracked~1
dentin,~2
luting~6
crowns.~1
ionomer,~1
silicophosphate,~1
polycarboxylate,~2
powder/liquid~1
resembles.~1
HLA-A2~7
HLA-Aw69~1
HLA-Aw68~1
HLA-A3.~1
(aa)~1
HLA-A3~5
aa~4
mutagenized~3
HLA-A3-specific~1
HLA-A2/Aw69~1
trans-octadecenoic~1
(18:1t),~1
18:2~6
Hydrogenated~1
18:1t~4
0.98;~2
18:1t.~2
18:2.~1
displacement)~2
condyle,~1
freeing~1
securely~1
rehabilitate~1
Preinduction~1
orthognathic~4
dentoalveolar~3
prognathism.~2
particulates.~1
popularly~1
moulage,~1
masks'~1
angioblastic~2
"referred~1
pain"~1
malunited~1
zygomatico-maxillary~2
sled,~1
Proplast~2
acheived~1
five-months~1
interparticular~1
(HFOV)~1
mL/kg).~1
pneumotachograph.~1
mL/kg.~1
Inspiratory/expiratory~1
HFJV,~2
HFOV.~3
mL/kg)~2
10.3;~1
(0.118~1
immortality~1
Aberrations~1
near-diploid~2
(UK),~1
[and~1
(DT)],~1
samples'~1
postdiagnosis~1
(lactogenic~1
hormones)~1
(74.0~1
kilocalories)~1
mastalgia,~1
kilocalories;~1
biomarker~1
Uncertainties~1
Risk-assessment~1
risk-assessment~1
acts;~1
influences;~1
"biochemical~1
epidemiology."~1
intestine:~1
40-70%~1
subsites~1
"HUOCA-II"~1
HUOCA-II~3
karyological~1
karyotyping.~1
(TAF)~1
TAF~7
(NHL),~3
(FARM),~1
(WF).~1
FARM~3
(23.4%).~1
errors-9~1
subtype--30~1
Program--9~1
Program--20~1
"unclassifiable"~1
abstracting~2
nonconcurrence~1
micrograms/mouse/day)~1
(Meth~2
rechallenged~2
Winn~1
A-inoculated~1
beta-carotene-treated~1
dependently.~1
Thy-1-positive,~1
Lyt-1-negative,~1
Lyt-2-positive~1
trans-Golgi~1
cis-GA~1
Mc-29~1
enough.~1
biogenesis~2
[14C]glucosamine~1
[14C]N-acetylmannosamine~1
5-Azacytidine~1
(5-azaC),~1
hypomethylating~2
T984-15.~1
subclones~10
T984-15~2
5-azaC/ml~1
5-azaC-treated~2
49-59),~1
(68-94~1
chromosomes/cell).~1
5-azaC~4
sparsomycin~1
Sm/ml~1
(DOX)~1
DOX~5
micron;~1
(DOX-Lip)]~1
CT38LD~3
(C57BL/6J~1
CT26~2
CT26.~1
DOX-Lip,~1
life-spans~4
DOX-Lip~2
.5),~1
Exocrine~1
guppy~1
Poecilia~1
methylazoxymethanol~1
[(MAM-Ac)~1
592-62-1].~1
MAM-Ac~1
carcinogen-free~1
MAM-Ac/liter~1
less-differentiated~2
Adenocarcinomas,~1
ductlike~1
guppies~1
410.4~1
polyinosinic-polycytidylic~1
(poly~1
I:C)~1
I:C~1
metastasis),~1
(asGM1)~1
asGM1-positive~1
attributable,~1
Urethan~1
51-79-6)-induced~1
A/J,~1
SWR/J,~1
RIIIS/J,~1
BALB/cByJ,~2
129/J,~1
Clara-derived~1
mammogenic~2
outgrowths,~1
deoxycorticosteroid~1
lobulo-alveolar~1
lines:~4
B16-bladder~1
(BL6)~1
DBA/2)F1~3
RT7-4bs~3
BD-IV~1
BL6~2
antimetastatic~1
F344/Du~1
[(MNNG)~3
70-25-7]/ml~1
MNNG~9
(surface~3
(intestinal-absorptive~1
mucins~1
immunohistochemically.~1
mucin-positive~1
Changed~1
allotypes.~3
IMN~2
supraphenotype~1
DR3-B8~1
B8,~3
Bf*S~1
B18~1
(Bf*F1).~1
(anti-HIV),~1
sexually-transmitted-disease~1
(4/107)~1
(26/124)~1
(17/94)~1
April/May~1
(61/249)~1
(25/99)~1
November/December,~1
gonorrhoea~1
attempt),~1
'Ampligen',~1
zidovudine~1
(azidothymidine,~1
AZT;~1
'Retrovir',~1
AZT~7
virustatic~2
ampligen.~1
ampligen~3
q26-qter~1
(AMML)~1
cytologies,~1
AMML~1
phosphomonoester~1
debrancher~1
phosphoglycerate~2
Ataxic~1
hypermetria.~1
Cutoff~1
lens-related~2
Sahlgren's~1
Gothenburg.~1
(1981-1982).~1
over-represented~1
Nucleolin~1
C23)~1
intranucleolar~1
preribosomal~2
nucleolin~1
nucleolin.~1
Hy-Thr-Pro-Hy-Lys-Lys-Hy-Hy,~1
NH2-end~1
(serines)~1
glycine-rich~2
dimethylarginine~1
structures:~2
(NH2~2
(COOH~2
terminus).~2
stretches.~2
preribosome~1
biogenesis:~1
preribosomes~1
(Ub)~1
Ub-activating~2
Ub~10
iodoacetamide-treated~1
(E):~1
[3H]ATP~1
E----E~1
[3H]AMP-Ub~1
PPi~1
PPi----2Pi~1
pyrophosphatase).~1
Ub.~3
ubiquitin-activating~1
3.4.17.1)~1
5-benzamido-2-benzyl-4-oxopentanoic~1
(BOP)~1
0.191).~1
adduct.~2
zinc-bound~1
carbonyl.~1
immersed.~1
unglycosylated~3
53,222~1
N-glycosylation.~1
lipases~2
trehalose,~1
Lyophilized~1
palmitoyloleoylphosphatidylcholine~1
(9:1)~1
trehalose~3
trehalose-phospholipid~1
terbium~3
trifluoroethanol~1
(vol/vol)~4
trifluoroethanol,~1
A-conformation,~1
dichroism.~1
[5386~1
long]~1
172-bp~4
double-helical~3
A-form~5
d(GGTATACC).~1
dichroism~8
(-1.41)~1
low-salt~1
(-1.50)~1
A-structure~2
-1.04,~1
-1.03~1
crystal.~1
5386~1
hydei~1
conformation.~8
interbands~1
compaction.~1
anti-Z-DNA~4
ts11,~1
(ts)~1
ts11~4
non-ts~4
EMBL3~1
transformant~5
Sequencing~4
gene/pseudogene~1
serum-synchronized~1
regulated,~6
mid-G1.~1
Entactin~1
oligo(dT)-primed~1
1E,~1
insert,~4
1328~1
729~1
entactin.~1
nicktranslation~1
1E~1
29,261)~1
(41,~1
(24,~1
arginine)~1
hybrid-arrested~1
MOLT-4~6
transcriptional-regulator~1
granule,~3
precedes--and~1
initiates--secretion~1
rise-times~1
2-59~1
prosome,~3
urchin.~1
prosome~5
g/cm3~4
Cs2SO4~1
Biochemically,~1
24-35~1
erythroblast~1
prosome.~1
postribosomal~2
lysates.~5
decreases;~1
sedimenting,~1
oogenesis~1
egg.~2
Proopiomelanocortin~1
prophase~2
spermatocytes~1
caput~1
newborn),~1
prepuberal~2
postpartum),~1
spermiogenesis.~1
divergent,~1
transcriptase-mediated~1
CpG~6
import~9
extinction.~1
generality~2
hepatoma-fibroblast~1
500-1000.~1
intertypic~1
heteroduplexes~1
1123~1
Single-stranded~1
25-247~1
200-400~3
Xq26-Xqter~1
Mus~3
spretus~2
recombinational~2
Hprt-FIX-c11-G6PD-St14-1.~1
(mdx)~1
H-2Dd~6
(H-2b~1
H-2d)F1~1
H-2Kb,~1
H-2Db,~3
H-2Kd~7
H-2K,~3
17s~1
H-2Db~1
H-2Db.~1
constitutionally~1
heterozygous.~1
Ly-6-encoded~1
antigen-independent~1
Ly-6~7
blots.~5
Ly-6a~1
Ly-6b~1
15E~1
Env-54~1
probe),~2
ins-1,~1
(insulin-related~1
gene),~1
c-sis.~1
15-related~1
HLA-DP~5
markers)~1
T3-delta~2
T3-epsilon,~1
q23.~1
T3-epsilon~3
Hu-ets-1~1
11q23,~1
q23~1
gustin~9
(cAMP~2
PDEase;~1
3',5'-cyclic-nucleotide~1
phosphodiesterase,~3
3.1.4.17)~1
PDEase~6
6-fold.~1
gustin.~1
parentheses)~2
gustin,~1
PDEase.~3
Anticalmodulin~1
calmodulin-activated~1
gustin-activated~1
lubrol-PX,~1
leupeptin.~3
Lysophosphatidylcholine-activation~1
PDEase,~2
lysophosphatidylcholine-activation~1
B6E11,~3
CA1,~2
B6E11~4
synapsing~1
CA1.~1
Tetrodotoxin~1
timekeeping~2
[TyrOHase;~1
3-monooxygenase;~1
tetrahydropteridine:oxygen~2
(3-hydroxylating);~1
1.14.16.2]~2
coeruleus,~1
(OMP)~4
OMP~11
pBR322-derived~1
pMG5.~1
17-base~1
OMP.~2
1630~1
ATG-initiated~1
bulbectomy.~1
nonolfactory~1
Active,~1
D-aspartate~1
cholerae.~3
[amino~2
acid]/extracellular~1
acid])~1
mmol/liter,~2
freeze-substituted~1
calcium-rich~1
acetonitrile,~1
Fe(III)Cl3~2
N,N-dimethylaniline,~1
epoxidation~1
olefins,~1
1-phenyl-1,2-ethanediol~1
1,2-diols)~1
Fe(III)Cl3/H2O2~1
mimic,~1
dipolar~1
aprotic~1
(acetonitrile)~1
biomembrane,~1
Fe(III)-oxene~1
Fe(V)-oxo~1
Fe(IV)-oxo~1
(MMTV)~1
nitrocellulose.~2
NaDodSO4,~1
nick-translated~3
MMTV~5
[32P]DNA~3
mesylate-labeled~1
membrane:~2
least-square~1
ca.~1
cocaine-insensitive~1
dimethyl-epinephrine~1
uncouplers,~1
lambda-Tris(4,7-diphenyl-1,10-phenanthroline)cobalt(III),~1
photoactivated~1
DNA-cleaving~1
chirality,~1
B-form~1
termini.~2
purine/pyrimidine~1
enhancer,~3
crystallographically~1
3.2-A~1
folding,~3
supersecondary~1
ligands:~1
tyrosines,~1
aspartate.~1
CO3(2-)~1
HCO3-)~1
sulfate-binding~1
typhimurium.~2
base-pairing~1
promutagenic~1
O6-methylguanine~1
(O6-MeGua)~1
Nucleosides~1
triisopropylsilyl~1
nonaqueous~1
ribose~3
hydroxyls~2
hydrogen-bonding~1
dielectric~1
O6-MeGua~4
hydrogen-bonded~3
thymine.~1
wobble,~1
tautomeric~1
structures),~1
unprotonated~1
cytosine.O6-MeGua~2
thymine.O6-MeGua~1
[Gaffney,~1
Markey,~1
Jones,~1
Biochemistry~2
5686-5691].~1
O6~1
cross-strand~1
5-methylcytosine)~1
thymine).~1
(1626~1
nucleotides)~2
60,333,~1
45-nucleotide~1
58-kDa~2
beta'~1
HAFTL-1,~1
B-lymphoid~3
JH~2
chain)~5
assembly:~1
HAFTL-1~2
beta-to-J~1
neoplastically~1
fms~3
fms-related~3
9.5-kilobase~3
sequenced;~2
GGN~1
triplets,~1
oligoglycine~1
[Cobianchi,~1
SenGupta,~1
N.,~1
Zmudzka,~1
Wilson,~1
261,~1
3536-3543].~1
(Ub)-aldehyde,~1
Ub-C-terminal~1
Ub-mediated~1
Ub-aldehyde~3
Ub,~1
Ub:~1
Ub-protein~2
degradation)~1
Ub-aldehyde.~1
Ub-aldehyde,~1
Simian~4
alpha-primase~4
copurifies~1
HeLa,~1
5.2.~2
protein's~1
triacyglycerol,~1
(p31)~1
31,500~1
(p31.5),~1
p31~7
p31.5~7
heat-shocked~1
degraded.~4
poly(A)-associated~1
poly(A)-protein~1
Schonfelder~1
[Schonfelder,~1
Horsch,~1
Schmid,~1
H.-P.~1
6884-6888]~1
73,000~2
poly(A)-binding~1
hsp70)~1
3-Hydroxy-3-methylglutaryl~1
(hydroxymethylglutaryl-CoA~1
4.1.3.5)~1
isopentenyl~1
tRNA,~2
isoprenoids.~1
5'-untranslated~4
isoprenoid~2
(serum).~1
VII(a),~3
facto-X(a),~1
(TFI).~1
TFI~4
HepG2~4
CdCl2~1
diisopropylphosphoryl-factor~1
superfine~1
Mono~2
comigrates~3
X(a),~2
9800~4
units/mg~2
equilibria.~1
"nested"~1
computes.~1
Neurobiological~1
KK~2
NaDodSO4-extractable,~1
deoxycholate-soluble~2
NaDodSO4-soluble~2
compartment)~1
(pericellular~1
polymeric)~1
macroangiopathies~1
acid/Schiff~1
Peaks~1
(5-~3
50-mer)~1
32Pi.~1
gels;~1
nuclease,~3
hydrolyzate~1
oligoribonucleotides,~1
oligodeoxynucleotides~1
swell~1
"capacitance~1
flicker,"~1
pore,~1
2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein~1
6.88.~1
Ionomycin~1
Ca2+-buffered~1
stipulate~1
intercalation~3
topologies~1
alpha(2----8)-linked~1
polysialic~11
200-250~2
bud-derived~1
metanephrogenic~1
mesenchyme,~1
sonication.~1
DNase.~1
prebiotic~3
(band~4
p11.2)~1
q11.2)~1
t(X;18)(p11.2;q11.2)~1
reciprocal.~1
translocations:~1
t(X;18;21)(p11.2;q11.2;p13)~1
t(X;15;18)(p11.2;q23;q11.2).~1
X;18~1
cog/cog~1
(Tgn)~1
Gpt-1.~1
Tgn~1
(Myc)~1
single-element~1
subfamilies.~2
three-member~1
duplicated,~1
unrearranged~1
3-14.~1
347-amino~1
61-amino~1
glycine/alanine,~1
leucines/isoleucines/valines,~1
tyrosines/phenylalanines,~1
C1r,~2
2-glycoprotein~1
70-amino~1
(potential~1
O-glycosylation~2
DXS42~2
Xq24-q27).~1
5.26.~1
Haplotype~2
DXS99~1
Xq26-q27).~1
prenatally.~1
Asibi~1
17D~1
10,862~1
positions;~2
divergence,~5
0.94%,~1
NS1,~2
NS3,~2
NS5~1
substitutions,~1
ns4a~1
ns4b~1
ns2a~2
ns2b~1
substitutions).~1
ns2b,~1
flaviviruses,~1
NS5.~1
vicerotropism~1
intercysteine~1
"loop"~1
38-57)~1
lutropin~1
(hLH)~1
beta-(38-57)~3
thyroglobulin-conjugated~1
Helical-wheel~1
38-57~4
dichroic~3
trifluoroethanol)~1
hLH.~1
amphipathic-helical~1
Y-mediated~1
gel-permeation~2
lecithin/cholesterol~1
mixed-lipid~1
sulfobromophthalein,~1
hydrophobicity,~2
salt/organic~3
micelle.~1
Vesicular~1
bengal;~1
(eluant~1
anti-MPO~2
epitope-selected~1
sulfoxide,~2
tissue-cultured~1
AcChoEase,~1
(G4)~1
G4~2
Guamanian~3
parkinsonism-dementia~3
(A4~1
4.0-4.5~1
cores,~3
amyloids~1
lodgepole~3
(Pinus~2
contorta~1
Dougl.~1
ex.~1
Loud.)~1
jack~3
banksiana~1
Lamb.)~1
Sst~3
chloroplast~15
pine,~1
sympatry,~1
sympatry.~1
Chloroplasts~1
chloroplasts~1
(female)~1
(male).~1
Converging~1
microinfusion~1
picrotoxin)~1
dentate/lateral~1
interpositus~1
HVI~1
minimax~2
two-person~1
zerosum~1
minimax-prescribed~1
money.~1
Players'~1
wins~1
minimax,~1
subject-to-subject~1
opponents~1
keepers,~1
payoffs~1
organophosphate-detoxifying~1
(B1~1
A1)~2
quinquefasciatus~2
pipiens~3
70-fold,~1
chlorpyrifos~1
bioassay--i.e.,~1
800-fold~1
100-fold,~3
Antiesterase~1
(B2~2
tarsalis)~1
(A1~1
pipiens,~1
tarsalis);~1
antiesterase~1
(A2~2
A3)~1
(B1,~3
B3).~1
Myzus~1
persicae~1
Sultzer,~1
Musca~1
domestica~1
organophosphate-resistant~1
7H-pyrido[4,3-c]carbazole~1
Ditercalinium,~1
bisintercalators~1
crucially~1
self-complementary~1
tetranucleotide~3
d(CpGpCpG)~2
Ditercalinium~2
[2H]acetate~1
400-MHz~1
NMR.~1
exchangeable-proton~1
Overhauser~3
upfield~1
proton)~1
pyridocarbazole~2
monointercalate~1
bisintercalate~1
duplex.~2
intercalate~1
helix,~2
repressors.~1
7H-pyridocarbazole~1
(E2F),~1
E2F~4
E1B,~1
E1A,~1
beta-globin,~1
E2F.~2
E1A-mediated~1
E1A-inducible~1
Gruppuso~1
[Gruppuso,~1
P.A.,~1
P.,~4
Kahn,~1
Cornblath,~1
Zeller,~1
Engl.~1
311,~1
629-634]~1
hyperproinsulinemia~2
proinsulin~11
lambda-WES~1
MD41~1
MD51,~1
MD51~1
preproinsulin.~1
MD41,~1
(CAC----GAC)~1
(propositus's~1
father).~1
Elbein~1
[Elbein,~1
S.C.,~1
Gruppuso,~1
Skolnick,~1
Permutt,~1
M.A.~1
821-824],~1
[Asp10]proinsulin.~1
(BeWo).~1
enhancer)~1
1500-base-pair~1
-169~1
cAMP-induced~1
18-bp~2
-146~1
-111.~1
-169/-100~1
promoter-regulatory~1
retinoyl~4
beta-D-glucuronide,~1
Retinoyl~3
beta-D-glucuronide~6
55-75%,~1
63-80%,~1
38-50%~1
differentiation:~2
(0.1-0.2~1
retinoids;~1
granulocytes;~1
superoxide-generating~1
fMet-Leu-Phe-stimulated~1
"down-regulator"~1
Supercoiled~2
(dG-dC)16,~1
supercoiling,~3
chloroacetaldehyde.~1
Chloroacetaldehyde,~1
bromoacetaldehyde,~1
superhelical~2
chloroacetaldehyde~2
(dG-dC)16~3
215-kDa~1
4647~1
1461~1
23-amino~1
43-residue~1
13-amino~1
(PRI)~1
ribonucleolytic~1
angiogenin-PRI~2
p-hydroxymercuribenzoate~1
angiogenin.~2
PRI~2
ribonuclease,~1
angiogenin/RNase~1
constitutive,~2
peak-to-basal~1
transporters:~1
nonessential~1
up-regulate~1
nonmonotonically~1
trade-offs,~1
C6-2B~1
Diphtheria~1
ADP-ribosylating~1
A431~2
less-specific~1
toxin-treated~2
"Peripheral-type"~1
metalloporphyrin~1
hemin~3
central-type~1
[alpha-32P]GTP~3
GTP-binding~4
5'-[gamma-thio]triphosphate~2
(GTP[gamma~1
S])~1
GDP;~1
nM-1~1
(29,~1
GTP[gamma~2
S]~1
S].~1
sterically~2
(basket-handle~1
porphyrins)~1
photolysis.~1
rebinding~2
linearity.~1
energy-barrier~1
Intercellular~2
(tissue)~1
cell-to-cell)~1
De,~1
Dcyt,~1
Tenebrio~1
molitor~1
photobleaching.~1
L-mRNAs~1
polyribosomes,~3
H-mRNA~1
actinomycin-D~1
cordycepin~1
(PBt2)~1
PBt2~5
1-oleoyl-2~1
acetylglycerol~1
1-oleoyl-2-acetylglycerol~1
Vasopressin,~2
PBt2.~1
substrate--namely,~1
granule-mediated~5
1,2-cyclohexanedione,~1
48/80,~2
exocytosed~3
LDL-containing~1
1.4-1.6~1
18,400,~1
anti-basic~1
sequestering~1
holoclone~3
capacity:~1
paraclone~1
generations),~1
meroclone,~1
paraclone.~1
holoclones~1
paraclones.~1
Lentropin,~1
Lentropin~1
lentropin~3
multiplication-stimulating~5
(MSA/IGF-II).~1
MSA/IGF-II~1
better-known~1
Transcripts~3
GS17~3
midblastula~1
(MBT),~1
GS17-beta-globin~1
activate,~1
cis,~2
MBT.~1
74-base~1
pG8~3
pG2,~1
pG2~2
fluke~2
gt10~3
miracidium~2
vitelleria.~1
trematodes;~1
(myoadenylate~1
deaminase;~1
3.5.4.6)~1
sedimentary~1
Puu~2
Naio~2
Cave~2
Maui,~1
Holocene~2
radiocarbon~1
(tandem~1
accelerator-mass~1
spectrometer;~1
TAMS)~1
lava~1
7750~1
oceanic~2
TAMS~1
chronologies~1
late-Holocene~1
Chronologies~1
nonarcheological~1
sedimentation,~2
deposit,~2
Oceania.~1
computationally~1
dozens~1
(SCE)~1
EM9~6
glycol-treated~1
SCEs,~1
complementation.~1
BrdUrd-containing~2
exquisitely~2
BrdUrd.~1
low-SCE~1
high-SCE~1
BrdUrd~1
nondisjunction.~1
comedocarcinoma,~1
amphotropic~4
gamma-beta~2
spliced,~1
transduce~1
[LICR-LON-HMy-2~1
(LICR-2)]~1
(EBV);~1
NS-1~4
LICR-2~2
PBL.~3
clonability~1
NS-1;~1
clonability,~1
(unique)~1
(GD3,~1
uncharacterized,~1
heterophile~1
antigens).~3
RNA-associated~1
B'',~1
HB''-1~5
B''~2
1015-base-pair~1
25,457~1
(S-IgA)~1
mutans~4
IgA-producing~2
IgA-deficient~2
Pokeweed-mitogen-stimulated~1
S-IgA~2
Tin(IV)-protoporphyrin~1
(Sn-protoporphyrin)~1
oxygenase~6
immunoquantitation~1
Sn-protoporphyrin~2
concurrently,~2
Cobaltic(III)-protoporphyrin~1
(Co-protoporphyrin)~1
Co-protoporphyrin~1
oxygenase;~1
metalloporphyrin.~1
dideoxynucleosides~1
lentiviruses.~1
cell-specified~1
provirus~11
2',3'-dideoxynucleosides~1
retrovirus-induced~2
(SP-22)~1
(Ala-Pro-Thr-Lys-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg).~1
SP-22~3
anti-gp120~6
HIV+~1
SP-22.~2
anti-SP-22~1
HIV-induced~1
syncytium~2
nonneutralizing~1
[Sar1,Ile8]angiotensin~6
Displacement~2
des-Asp1-angiotensin~1
des-Asp1,Arg2-angiotensin~1
Autoradiograms~3
Ang~2
75-fold~1
octapeptide.~1
(Zellweger)~1
[14C]acetyl~1
[14C]palmitoyl-CoA,~1
3-oxoacyl-CoA~4
(acyl-CoA:acetyl-CoA~1
C-acyltransferase,~1
2.3.1.16)~1
rat-liver~1
beta-oxidation.~2
coprostanoic~1
HAV~3
HM-175/7~2
MK-5,~1
HM-175~1
culture-adapted~1
MK-5.~1
(propagated~1
marmoset~2
(grown~1
HM-175.~1
Cys-Phe-D-Trp-Lys-Thr-Cys~1
Cys-Tyr-D-Trp-Lys-Val-Cys~1
threoninamide~2
tryptophanamide.~1
(somatotropin)~1
octapeptides~2
D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2,~1
Ac-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2,~1
D-Trp(For)-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2,~1
D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2,~1
Ac-Trp(For)-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2,~1
Ac-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2,~1
D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Trp-NH2,~1
D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2.~1
N-terminus,~2
D-tryptophan~1
D-phenylalanine~1
hormone-release~1
D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH2~1
(RC-98-I),~1
lymphogranuloma~1
venereum.~1
serovars:~1
genus-specific~2
3-deoxy-D-manno-octulosonic~1
(KDO)~2
KDOp-(2----8)-KDOp-(2----4)-KDO.~1
KDO~1
2.8-linkage.~1
barium,~1
MgATP~1
("growth-associated~1
factors")~1
regeneration-associated~1
non-neuronal~2
nerves),~1
regenerable.~1
carp~1
([3H]thymidine~2
incorporation)~3
12-kDa~2
(myelination)~1
opiate-naive~2
ilea.~3
morphine-pretreated,~1
tolerant/dependent~1
enkephalin.~1
tolerance/dependence~1
(AcCho)~2
soma,~2
AcCho~8
cone,~2
neurite,~2
soma.~2
synapse:~1
excitation-secretion~1
neurite-muscle~1
Squirrel~1
sciureus)~1
color-vision~1
polymorphism;~1
"junctional"~1
nonsynaptic~4
type"~2
low-conductance~3
(45-pS)~1
myotubes,~2
molecules--neural~1
(N-CAM)~3
(N-Cal-CAM)--and~1
(JG22)~2
ECMs,~1
CAMs,~1
anti-ECM~1
CAMs~1
N-Cal-CAM~1
Inward,~1
anomalous,~1
EK,~1
ramps~1
EK.~1
Rectification~2
(Mg2+)~1
EK~1
closures.~1
Noninflammatory~1
postprocessing,~1
1-T~1
500/30,~1
1,500/120)~1
Weighted~1
(muscle,~1
marrow),~1
16q22.~1
(FRA16B)~1
(FRA16C)~1
cryptococcemia~1
albidus.~1
nonpathogenic,~1
albidus~3
non-neoformans~2
cryptococci,~3
fungemia.~1
dysmorphologically~1
children);~2
diuretic-responsive~1
diuretic-resistant~4
(ascitic~1
sulfatase~8
(STS;~1
E.C.3.1.6.2),~1
3-hydroxysteroid~1
arylsulfatase-C~1
(ARC;~1
E.C.3.1.6.1),~1
optima.~1
copurify~1
forms--the~1
(S)--occur~1
Thyroid,~1
male-~3
isozymic~1
sulfatase,~3
STS.~1
(ESAC)~1
(EUSAC)--often~1
"markers"--and~1
(EISAC).~1
EUSAC~1
0.64/1,000~1
(0.32-0.40/1,000~1
0.23-0.32~1
inherited),~1
EISAC~1
0.11/1,000~1
(0.07/1,000~1
0.04/1,000~1
inherited).~1
ESAC~3
0.8/1,000-0.4-0.5/1,000~1
0.3-0.4/1,000~1
inherited.~2
+0.20~1
+0.25--close~1
+21--but~1
-0.06.~2
-2.4~1
(log)~1
+0.25~1
(weak)~1
biases,~1
15p~2
Inherited~2
A3-B8-DR3~1
racquetball,~1
antiserotonin,~1
protective;~2
(father,~1
rhinitis;~1
A1-B8-DR3,~2
A3-B8-DR3;~1
A3-B8-DR3,~2
A30-B5-DR8;~1
A30-B5-DR8.~2
A30-B5-DR8,~1
A2-B7-DR5~1
A3-B8-DR3.~1
(PGE2).~3
S-25930~2
S-25932,~1
4-quinolones,~1
(A-56619),~1
A-56620.~1
quinolones.~1
S-25932~1
ofloxacin.~3
7.86~1
241.4~1
196.5~1
Ofloxacin~2
azidothymidine~3
96;~1
(A-56268)~1
roxithromycin.~1
follow-up:~1
8670~1
Rising~3
(1-17~1
(56%;~1
39+~1
Response,~1
analysis-derived~1
myelomonocytic.~1
(pre-B~2
phenotype).~1
pseudodiploid.~1
t(9;11)(p21-22;q23)~1
t(4;11)(q21;q23)~1
11q23-25~1
9p21-22~1
10p11-13.~1
11q23-25,~1
CALLA-~1
Alkyl-lysophospholipids~1
2-lysophosphatidylcholine~1
purging~5
(SRM)~1
1,000:1.~1
ALP-treated~1
SRM~1
purged~4
SRM.~1
SRM,~1
3611~1
v-raf~1
kinase-encoding~1
immortalizes~1
3.6-kb~1
c-rafRNA~1
myeloid,~1
Strontium-85~1
Absorbed~2
(FCM).~1
Tissues,~1
imipenem/cilastatin.~1
eradicated.~2
(72.5~2
coverslip)~1
Salmon,~1
eel,~1
nonosteoclastic~1
T3;~2
cyanoketone,~1
fertilizability,~1
cyanoketone~9
(82.3~1
4.6%)~1
cyanoketone-treated~1
17-hydroxypregnenolone~1
(64.5%)~1
(32.4%).~1
P-in-oil~1
endometriosis;~1
cystadenocarcinomas.~1
cystadenoma.~2
19-9:~2
125:~2
48%).~1
(0%),~2
1,1-dimethyl-4-phenylpiperazinium~1
(DMPP).~1
DMPP~1
2,625~1
1,410~1
1,540~1
(ACh),~1
1,165~1
945~1
microadenosis~1
bloating;~1
nesidioblastotic~1
micrograms/day),~1
Ovalbumin~2
sulfidopeptide-leukotriene,~1
immunoreactive-PgD2~1
cAMP-promoted~2
HL-60.~2
q,~1
v,~1
microglia,~1
(B10.S~1
B10.ASR2)~1
[B10.S(9R)]~1
co-cultured~9
sorter~6
anti-IE~1
(H2d),~1
anti-IA~4
H2d~1
H2s~1
BALB/c-derived~1
IE).~1
putatively~3
H-2k~7
anti-Iat~2
H-2k-restricted~3
H-2kxb~2
antigen-primed~6
H-2b-restricted~3
uninhibited.~1
radioresistant~1
Lyt-1+,2-~1
Iatk~1
anti-Iatk~1
Iat~3
HLA-ABC,~1
diphencyprone~1
(DCP)~1
13);~3
DCP~1
HLA-ABC~4
faintly~2
subinfundibular~3
HLA-ABC-positive~1
intrabulbar~2
DCP,~1
(PNG)~1
(1:183)~1
(1:718).~1
PNG~1
chancroid~4
gonorrhoea,~1
most-western~1
U/mmol~1
markers;~2
[99mTc]glucoheptonate~1
([99mTc]GH)~1
[99mTc]GH.~3
Maxillomandibular~2
n-butyl~1
SCEs~1
MPD),~1
(osteoarthritis/arthrosis).~1
TMJs~1
maximal)~1
click/reciprocal~1
subcategory~1
pericoronitis.~1
(COC)~1
odontoma~4
COC.~1
112%)~1
76%);~1
(12.7%~2
intravaginally~1
subcutaneously,~3
matting~1
Chondroitin~1
1970-79~1
Valley.~1
2.83),~1
2.25),~1
9.0),~1
5.75).~1
1950-79.~1
1969-83~1
1948)~1
2,120~1
[32~1
(Obs);~1
(Exp);~1
Obs/Exp~1
2.79;~1
.01].~2
Obs~2
ether-related~1
Exp,~1
Exp~1
[men,~1
3.6],~1
Fat,~1
RRs~1
(DPP)~1
3.4.14.5),~1
(HeLa,~1
K-44)~1
glycylprolyl~1
methylcoumarinamide~1
(Gly-Pro-MCA)~1
(assumed~1
DPP~7
Gly-Pro-MCA~3
hydrolyzes~4
24-fold~1
HF,~2
4.13-fold~1
blacks].~1
Proportionately~1
twofold-higher~1
age-incidence~1
(1.7)~1
NOS~1
3,346~1
30-44.~2
non-seminoma~1
carcinogen-DNA~2
mutation)~1
bio-monitoring~1
pilot)~1
experience--with~1
adducts--affords~1
understanding.~1
20-79~1
phenoxyacetic~1
herbicides~1
(STS)~2
phenoxyherbicides,~1
(0.5-1.2),~1
(0.8-1.4).~1
chlorophenol~1
(0.7-1.5)~1
(0.8-1.2),~1
phenoxyherbicide~2
(1.03-1.7),~1
applicators,~1
(1.2-19.4),~1
phenoxyherbicides~2
(1.04-2.8).~1
DDT~1
[1.82~1
(1.04-3.2)]~1
[1.35~2
(1.06-1.7)],~1
agricultural,~2
forestry,~1
(genetic~1
cultural),~1
all-cases~1
70-25-7]~2
44);~1
16,16-dimethyl-prostaglandin~1
(16,16-dm-PGE2;~1
16,16-dm-PGE2~3
Hyperkeratosis~1
51.~1
MNNG-induced~1
coal-fired~2
furnaces,~2
carcinogen-specific~1
flue~3
Osborne-Mendel~1
(PAHs)~1
thiaarenes~1
[sulfur-containing~1
(S-PACs)]~1
S-PACs~1
condensate,~2
54.6%.~1
nonaromatic~1
carcinogenic.~1
50-32-8)~1
condensate).~1
(68.2~1
54.6%)~1
2-transformed~1
(H238)~1
260),~1
(PN)~1
7.7,~2
H238~2
1.2-,~2
7.7-,~2
74.3-mg~2
PN;~1
PN.~1
5-phosphate~2
KLN~4
RA-induced~3
RA-treated~2
RA-supplemented~1
metastasize,~1
(neuraminidase)~1
.0022),~1
57-97-6)~1
sham-inoculated~1
Buccal~1
3H]dThd)~1
(TLIs),~1
2-bromo-alpha-ergokryptin~1
oPRL/animal~1
48th~1
presiding~1
(Gc)~1
30.2%~1
(Gc~1
1f)~1
1f.~1
(AH-p)~1
altogether.~1
1f~1
microanalytical~1
(GSD).~1
hypoglycaemic~3
GSD,~1
phosphate/pyrophosphate~1
translocase~1
T2;~1
GSD.~1
GSD~2
human-immuno-deficiency-virus~1
(opportunistic~1
(mother~1
addict~1
infected),~2
(helper-T-cell~1
mitogen)~2
antigen-capture~1
(HIV-2),~1
(HIV-1).~1
Retroviral~3
hybridization;~1
hirsutism.~3
peripubertal~2
HIV-antibody~2
eliminates,~1
benchmark~2
urging~1
HTF~2
adjuvants,~1
adjuvant-free~2
antigen-delivery~1
'targeted'~1
biotin-binding~1
anti-class~4
non-biotinylated~1
6/60~1
wear,~3
(MMF)~1
interincisal~1
(MIO)~1
(BSRO)~1
BSRO~5
nonrigid~2
physiotherapy.~2
MMF~1
MIO~4
(6.6%).~1
nonrigidly~1
(29.6%),~1
(26.1%).~1
Antisialagogue,~1
(ScHBr),~1
ScHBr~4
nonstimulated~3
paraffin-stimulated~1
(CL/P)~1
40,304~1
(0.206%)~1
2.06/1000~1
(CL),~1
(CLP),~1
(CP).~1
(OLP)~1
non-OLP~4
OLP~4
48.2%~1
21.4%~1
72.7%,~1
9.1%,~1
neurosis,~1
OLP,~1
disturbance;~1
q'at~3
(Khat~1
edulis)~1
Keratosis~1
mucosa--probably~1
chewing--was~1
AIDS-causing~1
leukoplakia,~3
demonstrates,~2
hemophiliacs.~2
ameloblastomas.~1
molar-ascending~1
collagenized~1
incisor-cuspid~1
1.7:1.~2
rate--16%--was~1
collagenized.~1
cementum-like~2
intracystic~1
lumina,~1
Weibel-Palade~5
Traitement~2
SPAD,~1
SPAD~4
amalgam,~1
became.~1
advertised~1
Pushing~1
choristomas~1
choristoma~1
retromolar~1
virus-seropositive~1
T4A:T8~1
nonsexual~1
proportionality,~1
troponin-tropomyosin-actin~1
(regulated~1
actin)~3
S-1.ATP~7
(turned-on~1
(turned-off~1
(pPDM~1
S-1)~1
S-1.ATP,~1
pPDM~4
(acto~1
S-1).~1
acto.S-1~1
turned-on~1
turned-off~1
(alpha-MHC)~1
-947~1
-374~1
Cardiotoxin~1
VII4~1
mossambica~2
P61~1
73.9~1
59.0~1
6715~1
3-A~1
neurotoxins,~1
six-stranded~1
Synchrotron~1
(monomer)~1
(polymer)~1
spacings~1
5.4,4.9,~1
isosbestic~5
(0.37-5~1
ets~3
ets-1~5
5.3-kilobase~2
4.0-,~1
2.5-,~1
2.2-kilobase~2
thymus;~2
splice-donor~1
-acceptor~1
intronic~1
Afrikander~1
8.4-kilobase~1
misspliced~1
7.3-kb~6
8-exon~1
translatable,~1
8.4-kb~1
DE-B~1
fractionating~1
DEAE-Sephadex~3
transcribing~1
(rDNA).~1
camptothecin~4
rDNA,~1
rDNA.~2
Camptothecin,~1
12-amino~1
serine-glycine~1
chondroitin/dermatan~1
xylosyltransferase,~1
glycosaminoglycan-substituted~2
xylosyltransferase~1
Ser-Gly-Xaa-Gly,~1
Xaa~1
routing.~1
90.5%~1
retinol-deficient~1
CRBP-specific~1
Apolipoprotein(a)~1
[apo(a)]~1
280,000~1
apo(a)~6
kringles~1
kringle~5
Apo(a)~1
(77-100%)~1
391-421,~1
4-like~1
activator;~1
plasmin-specific~1
kringle-like~1
(oil)~1
MPa~3
bar).~1
"outside-out"~1
agonist-free~1
axon,~1
(VLA)~1
(VLA-1,~1
VLA-3,~1
VLA-5),~1
(VLA-2),~1
(VLA-4)~1
antibody-Sepharose~1
LFA-1,~3
(CR-3),~1
p150,95~2
vitronectin~4
receptor-platelet~1
position-specific~2
31-40%~1
46-52%~1
Mac-1,~2
GPIIb/IIIa,~1
0.15-ml~1
bovines,~1
goats,~1
non-serum-containing~1
33-65%~1
Chromatographically~1
(BDGF)~1
specific;~1
(C57BL/10)~1
BDGF~1
Daudi~8
IFN-resistant~6
IFN-sensitive~8
(Cl2~1
Cl1,~1
IFN-receptor~3
ligand-induced~2
Triton-insoluble~2
impure~3
IGFs.~1
(2.8-~1
4.4-fold~1
increases)~2
Crithidia~2
crosslinks,~1
copolymerize~1
tubulin,~1
Nutridoma-SP~1
Boehringer~1
Mannheim),~1
PT-r~1
(secretion~1
radioimmunoactive~1
secretin)~1
epithelioid,~1
12S~4
(Ad5)~1
12S,~1
proliferate.~2
Ad5~4
dl312.~1
pea~2
ribulose-1,5-bisphosphate~1
carboxylase,~1
chloroplasts.~1
Import~1
ionophores,~1
yet-to-be-determined,~1
(HurTNF)~1
HurTNF,~1
(138,~1
(MCF-7)~2
138-kDa~3
0.05-0.8~1
5-methyldeoxycytidine~1
(m5dC)~1
m5dC~3
noncarcinogenic~2
benzo[e]pyrene~1
phenanthrene~1
(respectively),~1
benzo[a]pyrene.~1
30-38~1
28-38~1
arc-territory~1
mitotically~2
graft-derived~1
record--in~1
proximodistal~1
eye--of~1
Case-to-case~1
indeterminancy~1
"courtship"~1
subterranean~1
Spalax~2
ehrenbergi~3
superspecies~1
(2N~1
speciation,~1
homospecific~1
mates'~1
ethological~1
premating~1
mouse-Chinese~1
R4~1
4-1~1
(chromosomes~1
material)~1
pMBA14,~1
mouse-derived~2
mouse-Syrian~1
JS17~2
17-derived~1
3-4-1~1
(located~1
T122/T66C~1
wild-mouse~1
testis-specific~3
neomycin-resistance~3
Provirus~1
904~1
L-3,5,3'-triiodothyronine~1
2.5-5.2%~1
G-150~2
49,000-Da~2
6.4-14.7~1
4.2-4.9%~1
5'-phosphate,~2
liter/mol),~1
[3,5,3'-triiodothyroacetic~1
D-3,5,3'-triiodothyronine~1
(D-T3)~1
D-thyroxine].~1
49,000.~1
[125I]thyroxine~1
proteinase-digested~1
27,000-Da~1
36,000-Da~1
DXS14~1
DXS7,~1
(lod~1
WAS-DXS14~1
WAS-DXS7~1
0.00),~1
(DXYS1-DXS1)-WAS-DXS14-DXS7-(DXS84-OTC).~1
pericentric~2
Spotted~1
hyenas~2
(Crocuta~1
crocuta~1
Erxleben)~1
sexes:~1
pseudopenis~1
"male-like"~1
Androstenedione,~1
organizer~1
hyenas.~1
hypotransferrinemic~2
apotransferrin.~3
nontransferrin-bound~1
hypotransferrinemia.~1
Gastrointestinally~1
non-transferrin-bound~1
calibers.~1
(axotomy)~1
axotomy.~1
stump).~1
68-kDa~1
(NF68),~1
beta-tubulin,~1
crush,~1
NF68~1
several-fold.~1
(encoding~1
NF)~1
thymopoietin~8
(Tpo)~1
(AcChoR)~3
AcChoR-rich~2
Tpo~4
AcChoR~17
Ca2+-insensitive~1
nondesensitizing~1
Outside-out~1
[3H]phencyclidine,~1
enhances,~1
[3H]acetylcholine,~1
6-(5-dimethylamino-1-naphthalenesulfonamido)-n-hexanoic~1
beta-(N-trimethylammonium~1
AcChoR.~3
metacerebral~1
(MCCs).~1
MCCs~2
radula~2
(ARCM),~1
B15~8
ARCM~3
cotransmitters~1
(SCPA~1
SCPB)--i.e.,~1
SCP-sensitive~1
SCPB-like~1
ARCM.~1
RP-HPLC~2
B16s~1
coelute~1
SCP~1
SCPs.~1
intrinsic.~1
[QPRTase;~1
nicotinate-nucleotide:pyrophosphate~1
(carboxylating),~1
2.4.2.19],~1
QPRTase~2
tanycytes~1
QPRTase,~1
roundish~1
(0.1-0.8~1
bounded~6
brain's~2
excitotoxin.~1
(GABA)-ergic~1
goldfish~1
Dissociated~1
on-center~2
rod-dominant~2
GABA-sensitive~1
outside-out~1
170-amino~1
peptide-coding~1
paired,~1
Lys-Arg.~1
Arg-Arg~1
neurotensin/neuromedin~1
productively~3
glioma-derived~1
oligobipyridine~2
2,2'-bipyridine~1
2-oxapropylene~1
copper(I)~1
dinuclear~2
trinuclear~3
Cu(I)~3
pseudotetrahedral~1
bis(bipyridine)~1
chiral,~1
"double-stranded~1
helicates."~1
(helical~1
stacking~1
bases)~1
self-assembling~1
organic,~2
inorganic,~1
tumorigenicity,~1
gamma-actin~3
nuclear-acting~1
factor/receptor/protein~1
kinase-related~1
sis,~1
erbB,~1
ras)~1
(alcohol:NAD+~1
1.1.1.1)~1
subunits)~2
atom,~1
zinc-containing~3
step(s)~1
unit(s).~1
monokine~11
endotoxin-stimulated~1
RAW~4
264.7~4
2,6-bisphosphate~1
Photoaffinity~1
interleukin-1~27
cachetin/tumor~1
cachetin~1
cachectin/tumor~1
carboxyl-methylation~1
aspartyl~1
tetragastrin~4
(Trp-Met-Asp-Phe-NH2)~1
L-isoaspartyl~2
([iso-Asp3]tetragastrin),~1
methyltransferases,~1
[iso-Asp3]tetragastrin,~1
[iso-Asp(OMe)3]tetragastrin,~1
demethylates~1
L-succinimide~1
([Asu3]tetragastrin)~1
[iso-Asp3]tetragastrin~2
mixture;~2
succinimide~4
"repair"~1
racemization~1
(half-time~1
L-aspartyl-containing~1
[D-iso-Asp3]tetragastrin~1
[D-Asp3]tetragastrin.~1
D-aspartyl~1
"repaired"~1
L-aspartyl~1
tetrazolium-reducing~1
24-homo-~2
26-homo-1,25-dihydroxyvitamin~2
24-homoanalogues~1
26-homo~1
receptor:~2
gyrase~2
supercoil~1
minichromosomes,~1
pBR322,~1
gyrase.~1
half-saturated~1
constrained.~1
BC1~7
identifier~1
C-tailed~1
poly(A).~1
nonrepetitive~1
ID-containing~1
brushborder~1
Na/glucose~2
Poly(A)+~1
phlorizin-sensitive~1
alpha-D-[14C]glucopyranoside~1
(MeGlc).~1
MeGlc~1
(2.0-2.6~1
(2.6-2.9~1
55-kDa~3
(hIGF-I)~1
(CMV-IE)~1
hIGF-I.~1
hIGF-I~2
tRNA(tRNA(UmUGGln))~1
UmUG~1
Um~1
2'-O-methyluridine)~1
anticodon~7
UAG~2
tRNA(tRNA(CUGGln))~1
CUG~1
tRNA(UmUGGln)~1
gag-pol~2
hormone-producing~2
(intron~1
D-containing~1
polysomes~4
peptide-human~1
Relocating~1
segment-specific~6
4-8.~1
song~1
sequence-detecting~2
triads,~1
heterosynaptic~1
Hebbian~1
synergic~1
Networks~1
prerepresentations~1
percepts.~1
(apparent)~1
5.8],~1
H+-extruding~1
K+-H+~2
Multibarrelled~1
(Vm),~1
(I-V)~1
5-200~1
Vm~1
"valve"~1
export.~1
Pelargonium~1
hortorum~1
1250~1
transpiring.~1
transpiring~3
865~1
thinner-walled~1
compactly~2
PA-mediated~1
plasminogen-free,~1
plasminogen-free~1
CEE~1
semicontinuous~2
RSV-infected~1
pregastrulating~1
dark-grown~3
Zea~1
mays,~1
(H2O2:H2O2~1
oxidoreductase;~1
1.11.1.6;~1
CAT)~1
CAT-2~3
(mRNA),~1
dark-treated~3
light-treated~1
Cat2~4
leaves.~2
leaves,~2
tomato~2
(Lycopersicon~1
esculentum)~1
ethylene.~1
rapid;~2
30-120~1
ethylene-inducible~1
wound-inducible~1
ripening~3
ripening:~1
norbornadiene.~1
encode.~1
An2,~1
ATPase.~2
An2~2
(L-CAM)~1
non-neural~1
124,000~1
135,000.~1
L320)~1
L-CAM.~1
850-base-pair~1
L-CAM~8
L320~1
79,900~1
neurotransmission:~1
(ChoAcTase),~1
(AcChoEase),~1
(AcChoR).~2
ChoAcTase~2
convergence.~1
21-44%~1
AcChoEase-like~1
evolution).~1
invertebrates.~1
vertebrates--both~1
TnphoA~1
phoA,~1
(PhoA),~1
PhoA+~1
20.5-kDa~1
(TcpA)~1
pilus.~1
TcpA~2
pilus~2
pilins~1
toxR~2
hamster-human~1
q13.~1
int-2,~1
mammary-specific~1
(gamma-Phk).~1
gamma-Phk~7
387-amino~1
Phk-deficient~1
I-strain~2
(Phk)~1
Phk~1
(multiple)~1
(single).~1
Phk-mutant~1
GM2/BCG-vaccinated~1
GM2/BCG~1
GM2-positive~1
immunoglobulin--T-cell~1
anticlonotypic~2
A2B4.2~1
tetrameric~3
(H2L2,~1
interchangeable.~2
[which~2
p17~4
(AIDS)-associated~1
virus]~1
(HTLV-IIIB)~1
feline,~1
simian,~1
gibbon,~1
30-amino~3
(HGP-30)~2
p17-specific~1
HGP-30~1
Farr~1
luciliae~1
hst~3
DNA-mediated~4
NIH3T3~2
radical-catalyzed~1
photochemistry~1
merocyanine~1
(MC~2
540),~1
540-mediated~1
photooxidation~1
(singlet~1
ghost.~1
alpha-cholest-6-ene-3~1
beta,5-diol~1
intermediacy.~1
phototherapeutic~1
(MDR)~1
MDR~1
(former~1
adriamycin)~1
"MDR1"~1
MDR1~3
25-30%,~1
preprocholecystokinin~1
arylsulfatase.~1
alpha-carboxyamidated~1
pmol/g),~1
nonamidated~1
procholecystokinin~1
Mrs,~1
9000,~1
7000,~1
5000)~1
pmol/g).~1
CCK-58,~1
CCK-33.~1
Corticotrophic~1
CCK-8-like~1
region(s).~1
Invasiveness~1
amoebiasis~1
actin-encoding~1
HM1:IMSS~1
(MBP),~1
placental-site~1
insert-specified~1
ligand-binding~2
ICM-1~3
within,~3
basic,~2
phosphorylates~2
presents,~1
(AcChoEase)~1
photometry.~1
subcisternal~1
time-scale~1
[3H]batrachotoxinin-A~1
(BTX-B).~1
BTX-B~1
aconitine~1
veratridine.~1
formazan,~1
dichlorofluorescein,~1
cRNA~2
(dorsal~1
root)~1
septum-basal~1
S14~8
effectors,~2
"transkaryotic~1
implantation,"~1
(HTLV-4)~1
Senegal.~1
immunodeficiency-related~1
4248~1
Senegal,~1
Guinea,~1
Bissau,~1
Mauritania,~1
Burkina~1
Faso,~1
Coast.~1
1985-1987,~1
HTLV-4~4
radioimmunoprecipitation-sodium~1
pathogenicities~1
ribonucleocapsids~1
Chimeric~1
encapsidated,~1
(pseudoviruses)~1
assayable~1
pseudovirus~1
protoplasts~1
maculonodular~1
infiltrations~3
(Cu)-adequate~1
(6ppm),~1
Cu-deficient~2
Cu-depleted~1
8-wk.~1
2-ppm~3
Hepatomegaly~1
0-ppm~4
Cu.~4
Delayed-type~2
D7S15~1
cen----q22,~1
7q22----31,~1
7C22~3
q22----q32.~1
COL1A2~1
7q21----q22~1
7q32,~1
q22~1
q31.~1
PGY1.~1
PGY1~1
7cen----q22,~1
assignment.~1
Choroideremia~2
(McK30310),~1
Subregional~1
Xq13-22~1
(RFLPs),~1
(Xq13-q21.1)~1
DXS3~3
(Xq21.3-22).~1
Xp11.3~1
Xq26.~1
Recombination~2
0%-4%~1
(PGK,~1
DXS3,~1
DXYS12,~1
DXS72,~2
DXYS1)~1
Xq13-22.~1
LINKMAP.~1
Multipoint~2
LINKMAP~1
DXS1~1
(Xq11-13)~1
DXS17~1
(Xq21.3-q22).~1
(384:1~1
insufficient,~1
X-chromosomal~2
X/hamster~1
hybrid-cell~1
(C12D).~1
0.15-2-kb~1
cosmids,~1
Xq27-Xq28:~1
DXS102~1
(cX38.1),~1
DXS105(cX55.7),~1
DXS107(cpX234),~1
DXS134(cpX67).~1
DXYS1,~1
DXS107,~1
DXS51/DXS102,~1
F9,~1
DXS105,~2
Fra-X,~1
F8/DXS52,~1
DXS15,~1
DXS134.~1
DXS105~1
Fra-X~2
FraX~1
5.01~1
cMorgans~2
(MEN-2A)~1
Leppert~1
(D13S6)~1
(D13S3)~1
(GSD~1
Hers~2
laser-excited,~1
MspI~3
(TaqI)~1
myelin-basic-protein~1
18q22-q23~1
Restriction-fragment-length~1
BamHI,~4
PvuII,~1
PstI.~1
PvuII~1
zeta-,~1
Polynesians~1
triplicated-zeta-gene~1
restriction-enzyme-site~1
Melanesians~2
Polynesians.~1
non-Melanesian~1
Polynesia.~1
semipermeable~1
closed-space~1
(157)~1
(864,~1
876,~2
913,~2
915)~2
(833,~1
845,~1
864,~1
ceftizoxime.~2
azlocillin,~2
15-keto-13,~1
14-dihydro-metabolite~1
(ABC)~3
B-5~1
gliomesenchymal-cell~1
(Ia+)~1
PVGc~1
RTI~1
RTIc/RTIu~1
OX3~3
(anti-Ia~2
RTIu),~1
OX4~1
(anti-RTIc~1
u),~1
OXI~1
(anti-rat~1
OXI+,~2
0.23/gl;~1
OX4+,~4
0.14;~1
OX3+,~1
RTIu).~1
OX3+~6
OX3+.~2
OX1+~1
OX4+~3
depleted;~1
OXI+~1
hybrids)~1
OX1+,~1
OX3-.~1
girdle.~1
(IBBB)~1
HIV-specific~15
(PE),~2
IBBB~2
18489)~1
xanthine-free~1
TDX~1
Irving,~1
Tex.),~1
Individualized~1
Difloxacin~3
28965),~1
roxithromycin,~1
Pneumoniae,~1
A-56268,~2
nares.~1
generation)~1
unambiguously.~1
paramyxovirus~1
3-induced~2
(AchE),~1
Freeze-thawed~1
TGF-beta/L.~1
(IL3)~1
underdosage~1
mid-skull~1
Kashmiri~1
consanguinous~1
generations;~1
acropathy.~1
Sudomotor~1
kinaesthetic~1
HLA-A~9
haplotyping.~1
Likelihood~1
ag/cell~3
homozygosity,~1
(French-American-British~2
[FAB]~2
M4)~1
(CA19-9).~1
CEAs,~1
TPAs,~1
CA19-9s~1
CA19-9~5
CA19-9,~1
intermarker~1
Biomarker~1
33,600~1
nonproportional~1
Dose-dependency~1
age-dependency~1
antibody-defined~2
Periosteal~1
"cocktail"~1
(SGOT,~1
bilirubin)~1
+11.1%,~1
-38.2%,~1
+68.6%,~1
lorazepam,~1
s.c.;~1
dehydroisoandrosterone,~1
sulfoconjugates.~1
Sulfatase~1
cells/mL.~1
7.5.~1
B-37.~1
H.J.B.,~1
hypobetalipoproteinemia.~2
hypobetalipoproteinemia,~1
Unaffected~1
(Skin~1
response-associated~2
(Ia)-positive~1
(ELCs)~1
stepwise,~1
ELCs~4
Chondrogenic~1
chondrogenic~1
(87.5),~1
(86.7),~1
(90.3),~1
(89.8),~1
(83.9),~1
(83.5)~1
sedative,~2
Nalbuphine,~1
meperidine,~1
cardiovascularly~1
Microorganisms~1
("aerobic")~1
(Bacteroides,~1
Fusobacteria,~1
Peptostreptococci)~1
prognathism~1
1349~1
tobacco.~3
likewise.~1
carboxymethylcellulose~1
lubricate~1
xerostomic~1
mucin-based~1
cervicomediastinal~1
expired.~1
angiomyoma~1
(angiomyoma)~1
myofibroblast-like~1
myogenous~1
velum,~1
contact;~1
fissural~1
cyclophosphamide-induced~1
cystostomy~1
F2-alpha~1
irrigants~1
(BMR).~1
BMR~4
(kcal/d)~2
protein/d)~2
(X):~1
0.925,~1
BMR,~1
1973-84~1
seaboard~1
shipyards~1
(Seattle,~1
Francisco-Oakland,~1
Hawaii).~1
(date~2
diagnosis)~2
birth)~2
1975-79;~1
1905-9~1
Geographic~1
1968-78~1
asbestos-manufacturing~1
shipyards.~1
cytofluorography,~1
3b~4
B72.3~5
LS174T~7
beta-estradiol-pretreated~1
"metastases"~1
micrometastases.~1
Livers,~1
pad,~1
(nu/nu)~3
lymphoscintigraphic~1
IgG1),~1
pads.~1
(L.I.)~1
(specific/nonspecific~1
specific/nonspecific~1
(14-477~1
L.I.'s~2
1.5-3.5.~1
Tumor-negative~1
B72.3.~1
globules.~1
cytostatic-cytotoxic~1
thioether~1
lysophospholipid~1
Ilmofosine~2
(1-hexadecylthio-2-methoxymethyl-rac-glycero-3-phosphocholine,~1
41.440)~1
(0-16~1
myosarcomas,~1
Ilmofosine.~1
case's~1
Pokeweed~1
Phytolacca~1
americana~1
N-succinimidyl-3-(2-pyridyldithio)propionate~1
9.2.27~3
glycoprotein-proteoglycan~1
10(-11)-10(-13)~1
melanoma)~3
melanoma).~1
9.2.27,~1
abrin.~2
9.2.27.~1
Retinoids~1
3-isobutyl-1-methylxanthine.~1
8,764~1
unfiltered~3
smoker's~1
industry-wide~1
6,152~1
(2,460~1
3,692~1
nonexposed)~1
(company~1
[observed~1
(Obs)~1
(SMR)~1
430]~1
(Obs~1
603).~1
1.66-4.69)~1
(lagged~1
constant).~1
panelists'~1
"near-replicate"~1
rodent.~1
near-replicates~1
near-replicate~1
reproduced,~1
time-pregnant~1
anti-epiglycanin~2
Detergent-solubilized~1
epiglycanin~2
electroblotted~1
[125I]epiglycanin,~1
82,000.~1
fluorography,~1
borotritiide.~1
Pronase,~1
endo-N-acetyl-alpha-D-galactosaminidase~1
(Diplococcus~1
pneumoniae),~2
(Vibrio~1
cholerae)~1
[(Ni)~1
7440-02-0]~1
(PBMCs)~2
Rhabdomyosarcomas~1
subsulfide~1
[(Ni3S2)~1
12035-72-2]~1
WAG~1
Ni3S2~2
23d~2
47.5%)~1
Ni-injected~1
Ni-treated~1
determinations/rat).~1
Noncarcinogenic~1
Ni-induced~1
acetate-induced~2
robertsonian~1
nontumorigenic,~1
M3.~1
540-73-8]~2
(ICR)~1
(laboratory~1
chow)~1
beta-carotene/kg.~1
diHCI/kg~1
tumors/tumor-bearing~1
beta-carotene.~1
appeared)~1
beta-Carotene~1
(H-2b)~3
(Dd)~1
(SHN~1
C3H/He)F1~1
PGK-mosaic~1
(NTP)~1
NTP~1
39,851~1
41,102~1
C3H)F1~1
(B6C3F1)~1
cord-stromal~1
tubulostromal~1
Tubulostromal~1
II/Han~3
(OV),~1
(RB),~1
germfree~1
(GF),~1
Carcinomas,~1
phytoestrogens,~1
irritations~1
initiators.~1
prostacyclin.~2
ampligen,~1
helper-inducer~8
dsRNA-dependent~1
(2'-5'-oligoadenylate/RNA-ase~1
pre-embryos~1
pre-embryo~1
Oncogene~1
(CML).~3
(Ph)~2
chromosome;~1
Ph-positive~5
(breakpoint~1
bcr-abl~3
Ph-negative~1
bcr/c-abl~1
Thyrotropin-secreting~1
thyrotropin-secreting~2
iodothyronines.~1
hyperuricemia~2
(glycogenoses)~1
glycogenosis~7
(debrancher~1
hypoxanthine,~1
(1106~1
Leprosy,~1
leprae,~3
avium-intracellulare-scrofulaceum~1
(Bacille~1
Calmette-Guerin),~1
bovis,~1
phasmids~1
mycobacteriophage~1
phages,~1
smegmatis~1
cultivatable~1
multivaccine~1
(AMPDA)~1
AMPDA.~1
(379~1
(58.9%)~1
dermatoglyphic~1
whorls,~1
atd~1
(7.89%)~1
nonaffected~2
endosseous~1
Apertognathia~1
bite)~1
condylosis.~1
condylosis~1
PSS,~1
apertognathia.~1
gonial~2
Coronoid~2
mouth-opening~3
TMJs.~1
locking.~3
osteoradionecrosis.~2
Strictly~1
HBO,~1
(Hong~2
Kong)~2
tooth,~2
Caucasoids~4
Negroids.~1
incisors~4
premolars~3
interproximal~2
acid-etch~1
replanted,~1
Replanted~1
killings~1
microCi/g~1
ankylosis.~1
Stomatology~1
Nanjing~1
Nanjing,~1
scholar~1
stomatology~1
(MRG)~1
glossal~1
MRG.~1
Candida-related~1
MRG~1
(infiltrating~1
lipoma)~1
liposarcoma.~1
lipoblastic~1
odontodysplasia,~1
Tooth~2
irrigant,~1
intracanal~4
ultrasonication~1
hypercementosis~2
factors--including~1
trauma--are~1
Molars~1
mA.~1
matched.~1
Inter-rater~1
Pearson's~1
(peak)~1
caries-detection~1
nationalities~1
(Methods~1
vermilion.~1
vermilion~1
Reciprocal~1
abrasion,~1
blanching~1
pseudogout.~1
Migratory~2
names.~1
haemorrhagica~1
immunologic,~5
(intramucosal~1
"dentinoid."~1
"dentinogenic~1
malocclusion.~1
comedonecrosis.~1
interdigitations,~1
cementoblastoma~2
decontaminating~1
obturating~2
simulated.~1
time/related~1
Apicoectomies~1
preauthorization~1
Tremendous~1
imaging--new~1
masseteric~1
Similar,~1
(188~2
Angle~1
overlap,~3
cuspid-protected~1
balancing-side~1
deflective~1
clenching~1
Tilted~1
decalcification.~1
Osseointegration~1
ceramic,~1
osteoconductivity.~1
mesiodens~1
glossodynia,~1
glossodynia.~1
anxious,~1
rarest.~1
acinuslike~1
multipotentiality.~1
chloroma,~1
ameloblastic~1
endodontist~1
blockages.~2
endodontics~1
redone,~1
Nygaard~1
Ostby~1
instrumentation-obturation~1
apicoectomy~1
developer~1
fixer~2
developer),~1
mL)~1
D-speed~5
42.7%~1
taurodontism~1
1,581~1
taurodontism.~1
taurodonts~1
Lymphadenopathy~2
nodes).~1
3.8),~1
(HIV)-seronegative~1
5.7)~1
15.6).~1
0.14.~1
9.99,~1
14.99,~1
19.99~1
1.00,~2
varicella-like~1
"vaccine-like"~1
Vaccinees~1
Histones~1
nonnuclear,~1
GDP.~1
poly(A)-containing~2
poly(A),~2
unidirectionally.~1
splenin~6
splenin.~1
49-amino~1
48-amino~1
splenin,~2
32-36)~1
thymopoietins,~1
MOLT-4.~1
8-BrcAMP.~1
GH4~1
-272~1
+27~2
glucocorticoid.~1
-773~1
(heparitinase~1
glycuronidase,~1
sulfatases)~1
heparinum.~1
thromboplastin-activated~1
coagulation;~2
arrested.~1
Heparitinase~1
4.2.2.8),~1
4.2.2.7),~1
cleavable,~1
bifunctional,~1
photoactivable,~1
Derivatization~1
N-[4-(p-azido-m-[125I]iodophenylazo)~1
benzoyl]-3-aminopropyl-N'-oxysuccinimide~1
(Denny-Jaffe~1
reagent)~1
azo~1
Denny-Jaffe~1
nonderivatized~2
IgG-related~1
TFIIIB~1
TFIIIC,~1
TFIIIC~2
TFIIIC1~5
TFIIIC2.~1
TFIIIC2~3
VA1~2
"footprinting"~2
footprint~9
alpha-inhibin-92~4
92-residue~1
alpha-inhibin-52~1
alpha-inhibin-31,~1
disuccinimidyl~5
alpha-inhibins.~1
polymer-guided~1
Reassociation~1
polymer;~1
polymer-associated~1
(inevitably)~1
poleward~1
48-kDa~1
phosphoprotein.~2
chains)~3
calpain,~3
Leupeptin,~1
signal-directed~1
(HMG-CoA~1
277-base-pair~1
"footprints."~1
scrambled~1
bp,~1
Scrambling~1
26-bp~1
glutaminyl~6
[Gln1]gonadotropin-releasing~1
[Gln1,~1
Gly4]thyrotropin-releasing~1
(H-Gln-His-Pro-Gly-OH),~1
H-Gln-Tyr-Ala-OH~2
pyroglutamyl~3
H-Lys-Arg-Gln-His-Pro-Gly-Lys-Arg-OH~1
D-glutaminyl~1
(revealed~1
heat),~1
43,000-50,000,~1
60-130~1
390-690~1
pmol/microgram~1
Glutaminyl~1
peptidylglycine~1
amidations~1
nonenzymatically;~1
1-210)~1
californica~3
pentamer)~1
1-14,~1
25-36,~1
41-53,~1
63-75,~1
102-114,~1
128-138,~1
172-182,~1
188-198.~1
eighth)~1
immunodominant.~1
Significantly,~2
128-138~1
188-198)~1
(fragmented)~1
presynthesis~2
single-stranded-DNA-binding~2
(SSB),~1
SSB~1
unwinds~1
origin-dependent~2
21-,~1
19-,~1
17-base-pair~1
Jerne~1
"network"~1
(anti-IdAb)~1
Anti-IdAb~1
ligands'~1
anti-IdAb~2
"internal~1
imagery"~1
"auto"-anti-IdAb~1
toxin)~1
chimera~2
anti-ligand~1
"chemical~1
alphabets,"~1
DS7,~1
phosphoglucose~1
mutant"),~1
("curb")~1
D-allose.~1
curbing~1
curb~3
allose.~1
Mannose~1
023~1
glucose-mediated~1
curb.~2
intensifies~1
mannose-mediated~1
allose-mediated~1
Purple~1
deionization.~2
1.4.~1
purple-to-blue~1
deionized~1
(125I-Epo)~2
125I-Epo~6
suberate.~2
85-kDa~2
enhancer/promoter~1
Transient-absorption~1
532-nm~1
bathorhodopsin~1
(BathoR)~1
lumirhodopsin~1
(LumiR)~1
single-exponential~2
BathoR~1
(BathoR1~1
BathoR2)~1
BathoR1~2
BathoR1/LumiR1~1
BathoR2~2
BathoR2/LumiR2~1
ns,~1
phosphatidylcholines.~1
Quadrupolar~1
Liouville~1
[Meier,~1
Ohmes,~1
Kothe,~1
Phys.~1
3598-3614].~1
quadrupolar~1
motional~1
C-13,~1
C-14~1
gauche~2
1-myristoyl-2-[13-2H2]~1
myristoyl-sn-glycero-3-phosphocholine~1
protein/lipid~1
0.073~1
mol/mol.~1
spin-label~1
[Brophy,~1
Horvath,~1
L.I.~1
Marsh,~1
860-865],~1
spectroscopies.~1
cytoskeleton,~2
flattening,~3
cytochalasins,~1
cytokinesis,~2
nocodazole,~4
communication-competent,~1
compacted~1
diacetate.~1
carboxyfluorescein,~1
interembryonic~1
nocodazole~5
assembling~1
"second~1
messengers"~1
mono-,~1
bis-,~1
trisphosphates~1
(InsP,~1
InsP2,~1
InsP3,~2
InsP2~1
InsP~1
quin-2~2
alpha-induced~4
3-fold),~1
C-InsP3~1
stomatitus~1
nonpolarized~1
luminally~1
(neo)~3
[Taketo,~1
Gilboa,~1
Sherman,~1
2422-2426].~1
LTR-linked~2
C57BL/6,~5
(1.25%~1
HDL-lipid~1
C3H/He.~1
centimorgans~2
apart).~1
Ath-1,~1
Ath-1~3
Alp-2,~2
A-II,~1
centimorgans.~1
atherosclerosis;~1
hyperalphalipoproteinemia~1
ETn~2
transposon")~1
retroviral-like~1
Long-lived~1
generated;~1
Lengthened~1
postreproductive~1
reproduction,~1
supF~1
(xeroderma~2
cyclobutane~4
pyrimidine-pyrimidone~2
(6-4)~2
80-fold~1
dipyrimidine~3
cytosine,~1
17-fold~1
cytosine-containing~2
non-cyclobutane~1
mutagenesis,~3
(ACC)~1
HTLV-IIIb,~2
(gp120)~1
HTLV-IIIb.~1
high-titer,~1
ACC,~2
goat,~1
HTLV-IIIb~1
anti-HTLV-III~2
gp120-specific~1
gp120-inoculated~1
gliotoxin~2
gliotoxin-induced~1
Gliotoxin~1
cell-enriched~3
chimeras.~2
infections--e.g.,~1
toxoplasmosis.~2
(gt)~1
(gt/gt)~1
(+/gt)~1
gt/gt~6
[Sidman,~1
Kinney,~1
Sweet,~1
253-257].~1
NFS/N~9
homozygote,~1
(Cas-Br-M~1
MuLV),~1
homozygotes,~1
+/gt~1
Scrapie-associated~1
fibrils,~2
scrapie-inoculated~1
Cas-Br-M~2
disease-inducing~1
encephalomyelopathy,~1
mouse-adapted~1
complexed,~1
Intra-blood-brain~1
(9/12)~1
(8/13)~1
posttransfection~1
Heparin-agarose~1
COS-derived~1
pseudo-first-order~2
L-[3H]phenylisopropyladenosine~1
hydroxy-phenylisopropyladenosine,~1
coneurotransmitter~1
2-[125I]Iodomelatonin~1
2-[125I]iodomelatonin~5
74.0~1
2-iodomelatonin~1
6-chloromelatonin~1
6,7-dichloro-2-methylmelatonin~1
6-methoxymelatonin~1
N-acetyltryptamine~1
N-acetyl-5-hydroxytryptamine~1
(inactive).~1
(dmnX).~1
dmnX~2
10-1000~2
impaled~1
oxytocin-immunoreactive~1
dmnX.~2
contain.~1
oxytocin-like~1
Paramecium~6
pantophobiac~5
calmodulins~1
calmodulins,~1
dimethyllysine~1
calmodulins:~1
101.~1
calcium-liganding~1
suction-pipette~1
("potentiated")~1
Na+-~1
Ca+,~1
0-10~1
"staircase"~1
cycle-regulated~2
H4~3
position-~2
orientation-independent~2
(PyV)~1
antigens)~2
pattern-matching~1
ARIADNE.~1
"descriptor"~1
110-residue~1
418-528~1
565-675~1
PyV).~1
[Glu1]plasminogen~1
Glu1]Pg)~1
[EC~1
3.4.21.31)~1
epsilon-aminohexanoic~1
(epsilon~1
Ahx;~1
Ahx~3
acid's~2
[Glu1]Pg,~1
[Glu1]Pg~5
Ahx-binding~2
Ahx.~1
site(s).~1
2(IX),~2
collagen-proteoglycan.~1
Gly-Ser-Ala-Asp,~1
NC3~5
2(IX)~6
1(IX)~4
1(IX).~1
Val-Glu-Gly-Ser-Ala,~1
collagen-proteoglycan~1
P1-450~1
P3-450~1
holoenzymes~1
structure/activity~1
glucagon/secretin~1
Asp9~1
Glu9,~1
His1~1
des-His1-[Glu9]glucagon~1
amide,~1
C18-silica~1
Uncommon~1
[dimyristoyl~1
hexane/ethanol,~1
9:1~3
(vol/vol)]~1
air/water~1
constant-area~1
(pi)-surface~1
isotherms,~1
intersections,~1
pi-A~1
isotherms.~1
delimit~1
phase-transition~1
Deuterium~1
nonradiative~1
100%--i.e.,~1
deuterium.~1
(quadrupole)~1
nuclide,~1
single-compartment~1
proteoliposome~1
scattered-light-collecting~1
eigenvector~1
alpha-helices,~3
beta-turns,~1
beta-strands.~1
D-glucose,~2
lines--namely,~1
lamellas~3
microfilaments;~1
Colcemid-induced~1
Epo-responsive~1
SKT6,~1
SKT6~3
hemoglobin-positive~1
94,000,~1
119,000~1
Epo-unresponsive~1
C3H/10T1/2~5
drug-selection~1
C3H/10T1/2,~1
synergize~6
Polysphondylium~1
whorls~1
pattern-specific~1
prepattern.~1
prepattern~1
longer-range~1
freshwater~1
turtles~2
constrains~2
smaller-bodied~1
(Chrysemys~1
picta~1
Deirochelys~1
reticularia).~1
larger-bodied~1
(Pseudemys~1
scripta),~1
pSV2neo.~1
Microcell-mediated~1
(XP-A)~1
neo-tagged~1
XP-A~2
XP-F~1
XP-C~1
cloning.~4
microbeam~1
yttrium-aluminum~1
HT1080-6TG~1
G418.~1
microcell-mediated~1
10(-4)-3~1
10(-3).~1
phosphate-mediated~1
TA99~5
pigmentation-associated~1
nu/nu~12
(half-life,~1
(8.9%~1
tumor/blood~2
10(4)-10(5),~1
tumor/normal~1
426-residue~1
immunogenic,~2
carrier-free~1
16-residue~1
Hematopoietic~1
twitcher~10
(Krabbe~1
galactosylceramidase~1
galactosylceramidase,~1
psychosine,~1
cerebrosides~1
Galactosylceramidase~1
100-day-old~2
twitchers~2
psychosine~5
cerebrosides,~1
40-day-old~2
30-35%~1
twitchers,~2
post-HCT~1
HCT-treated~3
twitchers.~1
phosphorous-containing~1
rotating-frame~3
double-surface~1
phase-modulated~1
(3.5-sec~1
interpulse~1
coeruleus.~1
confined,~1
VIa~1
enkephalins,~1
Step~1
[Nowycky,~1
C.,~2
Fox,~2
Tsien,~1
316,~1
440-442].~1
N-type~4
(atropine,~1
pirenzepine)~1
Guanosine~1
irreversible),~1
5'-[beta-thio]diphosphate~1
toxin-sensitive~1
serotonin-uptake~1
barrels.~1
omega-conotoxin~2
GVIA,~1
Conus~2
geographus,~1
T-type~1
neuron-specific,~1
high-threshold~1
sympathetic,~1
channel-type~1
directness~1
neurotransmitter-receptor~1
mRNA-injected~5
hybrid-depletion~1
hybrid-selection~1
5-kilobase~2
5-HT1C~1
1B236~1
626-~1
582-amino~1
acid-long~1
axonal-glial~1
glial-glial~1
heralding~1
"viral"~1
pubis,~1
Clq~12
45,X,~1
chromosome-specific~6
centromere,~2
long-arm~1
euchromatin~2
Yq.~1
euchromatic~1
pDP105,~1
15p11.2,~1
Y/15~1
Y-chromosome/autosome~1
32,000-dalton~1
(HexA)-deficient~1
consanguinous,~1
alpha-chains.~2
endo-H~1
counterpart--i.e.,~1
HexA,~1
cis-Golgi.~1
(GEP)~1
co-occurring~1
Sandostatin~1
GEP~1
bicyclo~1
cervicoisthmic~3
(Shirodkar~1
McDonald~1
cerclage;~2
(dilatation~1
postcerclage~1
(OAV7700,~1
Ohmeda).~1
autoclaved.~1
litre/minute~1
(TNF~2
U/mL)~5
c-myc-mRNA~2
post-transcriptionally~1
alpha;~3
Cw3~2
2.64,~1
1.92,~1
2.07,~1
Cw4~3
2.01,~1
2.06,~1
2.14,~1
Aw19~2
posttransfusion,~1
7,500/microL.~1
crossmatch,~2
HLA-A,B,~1
13,300/microL~1
A/BU~1
9,700~1
BX,~1
10,000/microL~1
ABO-identical~1
5,900~1
compatible,~1
(8,200/microL).~1
"innocent~1
bystander"~1
anti-abl~2
anti-bcr~2
p210~1
abnormalities--including~1
case)--were~1
t(1;19)(q23;p13.3)~1
tdic(9;12)(p1?1;p1?2)~1
hypodiploidy~1
translocations.~4
Hypodiploidy~1
19.9,~1
1.78,~1
3.15)~1
27/78~1
(rubidazone~1
m-AMSA~1
(amsacrine).~1
megakaryoblastic~13
(HP1-1D)~1
Megakaryoblastic~1
enlarge.~2
lower-thigh~1
1,206~1
(585),~1
(204),~1
(308),~1
(109)~1
CLL,~4
quinoline-azaquinoline~1
(R)-warfarin.~1
(R)-warfarin~1
(R)-6-hydroxywarfarin~1
CA-50,~2
CA-50.~1
CA-50~2
doubtful,~1
4-steroid~1
5-steroid~1
[125I]iodohuman~1
([125I]LDL)~1
[125I]LDL.~1
[125I]LDL~1
LDL-binding~1
Bu2cAMP,~1
activin,~1
mediate,~1
17/2.8.~1
thymidine-induced~1
Stereotaxic~1
(5-200~1
norephinephrine~1
adrenodemedullated~1
Radioreceptor~2
PMSG~4
PMSG/hCG-injected~1
retinoid-free~1
pretreatments.~2
25-hydroxycholesterol,~1
gonadotropin-primed~1
TSH-beta~1
[32P]UTP~1
Hybridizing~1
densitometry.~1
occupancy;~1
[126~1
parts/million~1
(ppm)]~1
(alpha-subunit,~1
ppm;~1
115-145)~1
2-3,~2
43-44,~1
74-75,~1
95-96.~1
disulfide-bridged~1
S-carboxymethylation~1
beta-core:~1
1-43,~1
3-43,~1
44-74,~1
44-95,~1
75-95,~1
96-114.~1
beta-core~5
200-320~1
immunopotency~1
beta-core-containing~1
Oophorectomy~1
alpha-estradiol~2
(PGF~2
mIU/l)~2
(hCG)-stimulated~1
monophosphate-stimulated~1
dazmegrel~4
Dazmegrel~2
SHRSP.~5
10-week-old~2
C-prostaglandin~1
saline-loaded~1
sieves,~1
straight-phase~1
(ADP),~2
salt-loaded~1
non-pulmonary~2
dentist~2
syrups,~1
Pulpal~2
cementation~2
ionomer~5
polycarboxylate~2
varnish~2
cementation.~2
2,136~1
Panoramic~1
tungsten-carbide~1
corrode~1
autoclave,~1
anticorrosive~1
dips~1
Airport.~1
Team~1
Examiner-Coroner's~1
Office,~1
Investigation,~1
anthropologists~1
at-scene~1
jaws.~1
inexplicable~1
Extent~1
multiquadrant,~1
radiolucent-radiopaque~1
Correctly~1
Sequestrae~1
skin-derived~2
divide;~1
TAMe~1
scroll~1
oval.~1
exocytosing~1
(LTB4).~2
lung-derived~1
anti-IgE,~1
rabbit;~1
-DQ~5
-DZ~1
transcribed,~1
RLA-DR~1
-DP~2
RLA-DZ~1
HLA-DZ~1
kb;~1
beta-chain,~1
kappa-~2
lambda-light~1
spectrotypes.~1
diversity,~1
microchamber~1
attractants~1
pol,~4
synthesized;~1
aa584-609~1
aa598-609~1
gp41,~2
aa603-614,~1
aa609-620.~1
LeuGlyIleTrpGlyCysSerGlyLysLeuIleCys~1
(aa598-609)~1
code:~1
1:2),~1
92.7%~1
1:128.~1
(185%~1
470%)~1
monocyte-macrophages~1
cloning,~2
sideroblastic~2
(EFS)~2
(VM-26,~1
(ara-C,~1
L-asparaginase.~1
VM-26/ara-C~1
EFS.~1
(VAPA~1
80-035).~1
Monocytic~1
M5),~1
100,000/microL,~1
80-035,~1
cytopenic~2
c-erbB-2,~1
73-yr-old~1
Submandibular~1
sialolithectomy~1
99mTc-pertechnetate~1
sialo-scintigraphy~1
mealtimes,~1
non-growing~1
Cephalograms~1
0.015),~1
parasymphysis,~1
(polylactic~1
acid:~1
mandibles~1
copolymer-PL~1
esthetics,~1
methacrylate,~1
PAS-positive,~1
diastase-resistant~1
Ofloxacin,~1
expectation.~1
potassium-40~1
(40K)~1
(BCM)~2
(30.5%),~1
BCM,~2
BCM.~1
supremely~1
Connecticut.~1
[odds~3
1.2-6.9].~1
1950's.~1
live-births.~1
5.6).~1
multiparity~1
goitrogen-containing~1
tonsillectomy,~1
suppressants,~1
4.3)~1
1.8),~2
5.2).~1
6,860~1
.07,~2
1-(4-amino-2-methylpyrimidin-5-yl)-methyl-3-(2-chloroethyl)-3-nitr~1
osourea~1
cytotoxicities~2
ACNU-sensitive~1
(9L/R~1
9L/R~5
ACNU,~1
ACNU.~1
interstrand~2
antithymocyte~5
D-54MG.~1
blood-to-tissue~2
(En)~1
53.5~1
(50.6~2
g/min).~1
K-value~2
Regionally,~1
K-~2
En-values~1
D-54MG~1
driver's~1
files.~1
smoking-adjusted~1
Masons~1
tilesetters;~1
cleaners;~1
trucking~1
warehousing,~1
Shipbuilding~1
shipbuilding~2
burners,~1
boilermakers~1
(PTCL),~1
(HTCL)~1
Irradiated~3
PTCL~2
HTCL.~1
PTCL-inoculated~1
HTCL-inoculated~1
HTCL~1
leaned~1
tumor-macrophage~1
xenografting~1
perch~1
(Morone~1
americana)~1
estuaries~1
Chesapeake~1
(MBN;~1
937-40-6)-induced~1
Carcinogen-treated~1
MBN/kg~1
nutriture,~1
papillomas)~1
500-millisecond~1
(cis-PDD)~1
drug-containing~1
cis-PDD.~1
trans-Dichlorodiammineplatinum(II)~1
platinic(IV)~1
cis-PDD~2
Vincristine~2
3'-Deamino-3'-(3''-cyano-4''-morpholinyl)doxorubicin,~1
anthracycline.~1
Hyperproliferation~1
(UDC)~1
noninbred~1
UDC~1
5-8:~1
cells/1,000~1
cells/hr--P~1
9-12:~1
2.9--P~1
13-16:~1
2.3--P~1
(positions~2
retrovirus-associated~2
[ovine~1
(OPC);~1
adenomatosis],~1
(LIP)~1
8-28~1
OPC~2
lentivirus~2
(OvLV)~1
nonciliated~1
LIP,~1
OvLV.~1
OvLV~3
lentivirus.~1
26,000-dalton~1
p27~1
Mason-Pfizer~1
OPC.~1
Retroviridae.~1
1,3-Dinitropyrene~1
1,8-DNP~4
42397-65-9)~1
mutagens~2
frameshift-type~1
P-value~1
[(BP)~1
50-32-8],~1
1,8-DNP.~1
1,3-DNP.~1
704~2
tampons,~1
douching~1
1968-81.~1
1968-81,~1
Northeastern~1
.01],~1
78-93-3;~1
aircraft)~1
garden~3
equipment-manufacturing~1
1950-80,~1
70,030~1
Foundation's~1
Life-Span~1
E-85~1
3,046~1
1965-80.~1
(ATB)~1
ATB,~1
gonadotropic~2
(AB-2~1
AB-26)~1
Advantage~1
c-fms,~2
terminal,~1
maturation-associated~1
dedifferentiate.~1
c-fms.~1
1976-80.~1
Vegetables~1
Legumes~1
Breakfast~1
DLD-1~1
6,202~1
9.5%,~1
3.6%;~1
neoplasms"~1
20-34~1
(MuMTV),~1
immunodetection)~1
(gp55,~1
gp34,~2
p28,~2
p18,~1
p12)~1
milk-borne~1
RIII~1
isogeneic~1
mastopathies~1
gp55,~1
p12~2
p18~1
MuMTV-expressing~1
(Tera~1
SuSa,~1
NEC-8,~1
833K,~1
T3B1)~1
(RT4,~1
RT112,~1
T24,~1
HT1197,~1
HT1376)~1
Cytotoxicities~1
21-161~1
4-19~1
112-431~1
5,782~1
369~1
1.2].~1
1.57;~1
plastics~2
grinding,~2
4.6;~2
20.4)~1
heat-associated~1
15.3).~1
2.3;~2
sifting,~1
(MW/RF)~1
certificate-based~1
Next-of-kin~1
MW/RF~4
[RR~1
2.4]~1
radiation-exposed~2
1.9).~2
engineers,~1
technicians,~1
repairers,~1
assemblers~1
3.9;~1
9.9)~1
12.2).~1
electricians~1
linemen~1
(electrical~1
tradesmen),~1
duration-response~2
tradesmen~1
ultra-high~1
fumes,~2
Seattle-Puget~1
1,869~1
1974-77~1
1982-84.~1
Aromatic~1
118,404~1
246,848~1
397,460~1
0.9-1.2).~1
48,106~1
marital-specific~1
(45-54,~1
55-64,~1
65-74,~1
"married."~1
[whites,~1
2.5].~1
widowerhood~1
[(BBN)~2
3817-11-6]~1
BBN~4
sacrificed,~1
Ola:Sprague-Dawley~1
(S9)~1
(HAAs)--2-amino-3-methylimidazo[4,5-f]quinoline;~1
2-amino-3,4-dimethylimidazo[4,5-f]~1
quinoline;~1
2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline~1
(compounds~1
food)--to~1
HAAs~1
Contagious~1
(UBD)~1
UBD~3
(HaPV)~1
HaPV~4
Complete,~1
UBD.~1
(.OH)~1
(.MNNG)~1
spin-trapping~1
5,5-dimethyl-1-pyrroline-1-oxide~1
(DMPO).~1
H2O2-MNNG-DMPO~1
tungsten-halogen~1
mW/cm2~1
.OH~2
.MNNG~1
H2O2-MNNG-BHT~1
H2O2-MNNG~1
.MNNG,~1
water-reactive~2
hr/day~2
day/wk).~1
compounds:~1
[(BPL)~1
57-57-8],~1
[(MMS)~1
66-27-3],~1
ethylchloroformate~1
[(ECF)~1
541-41-3],~1
dichloroacetyl~1
[(DCAC)~1
79-36-7],~1
[(PO)~1
75-56-9]~1
compound)~1
BPL~1
DCAC~2
(LLTC),~1
(LL),~1
C-nucleoside~1
(NSC-286193;~1
2-beta-D-ribofuranosylthiazole-4-carboxamide)~1
(LLAK)~1
LLTC~2
LLAK~4
LLAK,~1
LLTC,~1
MM-96~1
G2-phase~1
tiazofurin,~1
tiazofurin-sensitive~1
estuarine~1
sheepshead~3
minnows~2
(Cyprinodon~1
variegatus)~1
N-nitrosodiethylamine~1
55-18-5]/liter~1
seawater.~1
holding.~1
pericytomas~1
cholangiofibrosis.~1
pericytomas,~1
cholangiofibrosis~1
Spongiosis~1
minnow~1
hepatocarcinogens~2
waters.~1
immunoscintigraphy~1
radioimmunotherapy,~1
MAbs~18
subcloning.~2
anti-pig~1
immunoglobin~1
liter/mol).~1
radiolabeling,~1
MAb.~1
heterofusion~1
CI-921~6
di-substituted~1
(HF)~1
13762~1
(YV)~1
YV~3
RB.~2
YV,~1
RBs~1
(ASC)~1
radioprotect~1
(MISO)~1
ASC~6
radiomodifying~1
C3H/fSed~1
(FSaII),~1
TCD50~3
RD50~2
[87.1~1
(ASC)].~1
radioprotected~1
ASC.~1
ASC-treated~1
...~2
1.34)~1
1.23),~1
(RD50~1
LD50).~1
MISO~1
MISO.~1
nonproducer~1
retrovirus-infected~3
fibrosarcoma)~1
virus-immune~1
interference;~1
provirus.~6
Possible,~1
A4)~1
Sewall~1
A4~1
(deletion~1
gene)~1
host-clonal~1
illuminated~2
TXA2)~1
(PHN).~1
(Fx1A)~1
(183%)~1
(PGE2~1
Cobra~1
UK38485.~1
UK38485~2
38485,~1
IgG-capture~1
(GACRIA)~1
(GACELISA)~1
(HAV,~1
(HIV,~3
(HBc,~1
62),~1
(30).~1
GACRIA~6
anti-rubella-virus.~1
anti-HAV~3
anti-rubella-virus~1
GACELISA~2
closely;~1
IgA-capture~1
anti-HIV.~1
anotia~1
microtia.~1
Accutane~2
306,061~1
1.84),~1
mile),~1
1.53).~1
Antibody-positive~1
Counties~1
counties),~4
presequence~5
presequences~1
(atp2-1)~1
Nicotiana~3
plumbaginifolia~1
atp2-1~1
(B1-CFC)~1
Ph+~1
(CJD)~1
(pit-hGH).~1
CJD~1
pit-hGH.~1
Palatal~1
Peritonsillar~1
Quinsy~1
criticize~1
mutational-distance~1
(profile),~1
similarity.~1
(target)~1
(probe)~1
3800~2
netropsin~6
drug-DNA~2
enthalpy-driven~1
netropsin;~1
I-C~1
pairs;~2
entropies~1
entropic~1
disruption;~1
netropsin-DNA~1
binding-induced~1
interactions;~1
AATT~1
decamer~1
[d(GCGAATTCGC)]2~1
poly[d(AT)].poly[d(AT)]~1
(LPL;~1
triacylglycero-protein~1
3.1.1.34)~1
LPL,~1
pLPL-49R2,~1
(49R2)~1
[Ben-Avram,~1
Ben-Zeev,~1
O.,~1
Lee,~2
D.,~1
Hagga,~1
K.,~3
E.,~2
Goers,~1
Pedersen,~1
Reeve,~1
Schotz,~1
4185-4189].~1
49R2~1
50,548)~1
mRNAs--3.2,~1
kb--with~1
2.5-kb~1
AR)~1
iodocyanopindolol.~1
ribozymes.~1
template-directed~1
acyclic,~1
prochiral~1
2-HS-glycoprotein~1
(AHSG)~1
AHSG~7
18-amino-acid~1
AHSG.~1
unseen~1
3q21----qter~1
Lysine-372~1
(common)~1
Naskapi,~1
Mersin~2
Eti~2
Turks.~1
Naskapi~1
mid-Asiatic~1
Adana,~1
Turks,~1
548.~1
acid-550~1
Mexico-2~1
Polyclonal~9
type-specific,~1
1,600%~1
1400%~1
6.6-kilobase~1
518.~1
410-414.~1
tetracenomycin~4
glaucescens~2
lividans,~2
pIJ702,~1
copy-number~1
tcm~1
streptomycete~1
deoxyribonucleoside~1
triphosphates,~1
aprt~1
dTTP~3
dCTP~1
misincorporation~1
altered--those~1
misincorporated~1
next-nucleotide~1
"proofreading"~1
1-like~9
11-14~2
fraction).~2
5-times~1
55-70~1
(5-15~1
low-light-intensity~1
charge-coupled-device~1
digital-image~1
processor,~2
Mn2+,~2
Zn2+,~2
Cd2+.~1
Zn2+.~2
Cd2+~1
neoglycoprotein~1
(mannose,~1
galactose,~1
fucose)~1
pyranose~1
(ring)~1
mannosyl~4
fucosyl~2
[colony-forming~2
unit(s)~2
spleen]~1
Cobblestone~1
CFU-C~1
culture].~1
Stroma~1
supernate,~1
Galactosyl~1
whole-marrow-cell~1
CFU-S.~1
(homing)~1
(p422)~1
Xp22.3.~1
Clone~5
p422~1
sulfatase-deficient~1
pCDR2,~1
pCDR2~1
pCDR~1
CDR~3
degeneration-related)~1
neuroectodermal,~1
(PLT)~1
DPw1,~1
-3,~2
-4,~2
-5.~1
DP11.1~1
ILR1,~1
PLT-defined~1
RFLP-defined~1
Tenascin~2
tenascin~4
carcinogen-treated~1
mesenchyme-derived~1
(stromal)~1
E3-region~2
WI-38.~1
adenoviruses.~2
adenovirus.~1
(hGH).~1
dwarfism,~1
Ultrogel~2
AcA~2
minicolumn.~1
125I-hGH~2
(26-46~1
101.1~1
8.6%.~1
1.95%~1
9.1%.~1
(Ang-II)~1
Ang-II~11
brains)~1
125I-Ang-II~3
Ang-II.~1
[sarcosine1,Ala8]Ang-II~1
[sarcosine1,Ile8]Ang-II~1
Ang-III~1
Ang-I.~1
Light-microscopic~1
beta-rays~1
T7~2
chain-termination~2
processive,~1
dissociating.~1
dideoxynucleotide-terminated~1
secondary-structure~1
impediments.~1
Processive~1
dITP~1
dGTP~1
cholecalciferol-induced~1
calbindin-D~2
single-chain~3
30,042)~1
S-pyridylethylated~1
calbindins~1
troponin~1
RepA,~1
overproducing~1
RepA~5
(oriR).~1
(DnaB~1
DnaC~1
SSB,~1
gyrase).~1
DnaA~4
oriR~3
I-protection~2
9-base-pair~1
DnaA-recognition~1
("DnaA~1
box")~1
136-base-pair~1
nucleases.~1
phenylacetamidomethyl-resin.~1
peptide-resin~1
1-hydroxybenzotriazole;~1
tert-butyloxycarbonyl-protected~1
side-chain-protecting~1
deprotection,~1
20.7%.~1
phenylisothiocyanate~1
post-heparin~1
apoC-II.~2
positive-strand~1
Sindbis~3
anti-CAT~1
polypeptide;~1
AUG.~1
neighbor,~2
(sex-limited~2
-2.0~1
gene-commitment~1
[four~1
(CCK)-related~1
enkephalin]~1
(CCK-7)~1
(CER-7)~1
CCK-4.~1
CER-7~1
beta-bends,~1
CCK-4~3
helical.~2
CER-7,~1
superimposable~2
indolyl~1
beta-bends~3
CCK-4,~1
gastrin-related~1
hexapeptide,~1
CCK-7/CER-7~2
CCK-4/little~1
(CCK-7~1
added).~1
gene-specific~3
USF~2
(upstream~1
promoter;~1
Brookhaven~1
(mass,~1
palindrome.~1
Non-sequence-specific~1
phenamil.~1
[3H]phenamil~2
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate.~1
QAE~1
Bandeiraea~1
1100-fold~1
NaDodSO4/poly-acrylamide~1
disulfide-reducing~1
105-kDa~1
"zinc~1
finger"~1
zinc:~1
Zn2+~4
tetrahedral~1
histidines.~1
(60-75~1
metal-peptide~1
thermostable.~1
"footprint,"~1
monoterpene~3
cyclases~1
geranyl~2
presumptive,~1
enzyme-bound,~1
linalyl~1
skeletons.~1
2,3-cyclopropylgeranyl~1
uncouple~1
homoallylic~1
intermediacy~1
cyclopropylcarbinyl~2
(pol~1
M13lacZ~1
Pol~1
polymerized.~1
proofreading~2
misinserted~1
delta.~3
excises~1
deoxynucleoside~1
exonucleolytic~1
proofreading.~1
exonuclease-dependent~1
(Mo-MuLV)~2
nonleukemogenic~1
Mo+PyF101~1
Mo-MuLV,~1
Mo-MuLV~2
leukemogenesis.~4
MF-MuLV,~1
leukemogenesis~3
necessary:~1
protooncogenes.~1
1724-base-pair~1
37,320.~1
Transfection~3
COS-m6~1
(PALPase)~1
PALPase~4
phosphatidylinositol-glycan.~2
Transfected~1
phosphatidylinositol-glycan~1
Dispersed~1
Nonstimulated~2
neighbors~1
acinus.~1
Neurotensin,~1
Heptanol~1
neurotensin-,~2
secretin-,~2
carbamoylcholine~1
(carbachol),~1
heptanol.~1
secretagogues.~4
(Dd-ras)~1
(glycine----threonine)~1
missense~1
Dd-ras-transformed~1
Transformants~2
overexpress~1
Dd-ras-Thr12~3
overexpressing~1
Dd-ras-Gly12~1
photobleaching,~2
fluorescein-labeled,~2
size-fractionated~2
dextran:~1
size-dependent~2
nondiffusible~2
(structure)~1
diffusibility~1
endosomes,~2
multienzyme~1
(HHO.c1.95~1
HHO.c8.5111)~1
c1~5
c8,~2
embryonic/fetal~2
HHO.c1.95~1
217-amino~1
homeodomain~3
melanogaster.~1
HHO.c8.5111~1
153-amino~1
AC1~1
HHO.c1~1
HHO.c8~1
blot-hydridization~1
rudiments,~2
postfertilization~1
c8~2
(c10~1
c13)~1
Maize~3
Robertson's~2
Mutator~1
(Mu)~1
transposing~2
transposons~3
(Tn)~1
Mu1~2
Mu1.7.~1
TnMu1~2
TnMu1.7~1
210-base-pair~1
TnMu1.7.~1
Mu1.7~1
maps;~1
Mu~6
pZ189,~1
160-base-pair~2
ultraviolet-treated~3
pZ189~4
excision-repair-deficient~1
pigmentosum)~1
Introducing~1
single-strand~1
170-base-pair~1
Passing~1
nicked~1
20-33%~1
plasmids.~4
error-prone~1
[rec(X)]~1
rec(X)~6
Xq26.3----Xqter~1
Xp22.3----Xpter~1
Xqter----Xq26.3::Xp22.3----Xqter.~1
4D8,~1
Hx120A,~1
DX13,~1
St14~1
rec(X).~1
Mouse-human~1
12E7~1
(MIC2);~1
113D.~1
duplication-deficiency~1
MIC2~5
inactivation)~2
rec(X),~1
q26.3----qter~1
recombines~3
"recombinogenic"~1
circularize~1
(analogous~3
integration)~1
recombination).~1
homologous-recombination~2
end-join~2
Substrates~1
sticky~1
dideoxynucleotides~1
CENP-B,~1
CENP-B.~2
CENP-B~2
anticentromere~3
(ACA),~2
polyclonal.~2
ACA.~2
type-~1
gp120,~3
killer-specific~1
channel-forming~3
killer-cell-specific~1
alpha-benzyloxycarbonyl-L-lysine~2
thiobenzyl~2
in-vivo-primed~1
(T-tubules),~1
63Ag.8.6.5.3~1
T-tubule~1
T-tubules.~1
(Ab~1
(mAb21-4)~1
mAb21-4~1
(Affi-Gel~1
mobility:~1
175,000;~1
90,000;~1
55,000;~1
gel-supported~1
vitro-grown~1
(SP-I),~1
co-storage~1
co-secretion~1
SP-I.~2
(SP4B)~1
SP4B~3
lysogens~1
SP4B/beta-galactosidase~1
cDNA-derived~1
SP-I~5
1614~1
449-amino~1
(BEN).~1
PTH-related~3
BEN~1
PTH(1-34).~1
(carrier-coupled)~1
210-223~1
eel~7
(C1+~1
C1+~3
current-inactivation~1
accessible,~1
gate.~1
Patch-clamp~1
chloride-selective.~1
receptor-controlled~1
second-messenger-mediated~1
(SCG)~1
transmitters,~1
preprotachykinin~5
(PPT),~1
PPT~3
SCG~2
beta-PPT~1
neurokinin~7
Inhibin,~1
FSH-suppressing~1
(LH)-secreting~1
androgen-producing~1
FSH-~1
inhibin-producing~1
intragonadal~3
homodimers~2
inhibin-related~3
theca-interstitial~1
LH-stimulated~1
cross-communication~1
Boc-Trp-Ile-Ala-Aib-Ile-Val-Aib-Leu-Aib-Pro-Ala-Aib-Pro-Aib-Pro-Phe-OMe~1
Boc~1
t-butoxycarbonyl~1
Aib~1
membrane-active~1
zervamycin~1
9.086~1
10.410~1
28.188~1
86.13~1
87.90~1
89.27~1
7180~1
(F0~1
sigma)~1
0.91-A~1
3(10)-helix~1
ribbon.~1
-91~1
-64~1
-1~2
-46~2
-31~1
NH...OC~1
CH3OH~1
Pro-10.~1
4-spiro[2.n]alkanols,~1
3-7,~1
FSO3H~1
SbF5/SO2ClF~2
-130~2
4-spiro[2.5]octanol~1
4-spiro[2.5]octyl~1
spirocyclopropane~1
spiro[2.5]octyl~1
bicyclo[4.2.0]octan-1-ol~1
bicyclo[4.1.0]heptyl-1-methanol.~1
spiro[2.5]-octyl~1
1-bicyclo[3.3.0]octyl~1
4-spiro[2.4]heptanol~1
1-methylcyclohexenyl~1
spiro[2.6]nonanol~1
1-bicyclo[4.3.0]nonyl~1
4-spiro[2.n]-alkanols~1
unidentifiable~1
3-spirocyclopropyl-2-norbornanol~1
2-methylbicyclo[3.2.1]oct-3-ene-2-yl~1
Hexahydro-1,4-thiazepine-3,5-dicarboxylic~1
thiomorpholine-3,5-dicarboxylic~1
cyclothionine~3
TMDA,~1
Gas/liquid~1
TMDA.~1
TMDA~2
phenylisothiocyanate.~1
multiple-ion~1
poly(U)~2
28-150),~1
poly(A.A.U)~1
A.A.U~1
or/and~2
A.A.T~1
gene-encoding~1
Down-regulation~1
(sCT)~1
sCT.~1
bone-cell~1
CT-sensitive~1
octathymidylate~1
anomer~1
anomer.~1
beta-nucleosides.~1
ribose-containing~1
deoxyribose-containing~2
(9-amino-6-chloro-2-methoxyacridine)~1
alpha-octathymidylate.~1
pentamethylene~1
9-amino~2
miniduplex~1
acridine-substituted~1
alpha-oligothymidylates~2
Acridine~1
exonucleases.~1
alpha-Oligodeoxynucleotides~1
(c-Ki-ras~1
v-Ki-ras,~1
replication-defective~2
secondary),~1
v-Ki-ras~4
Micrometastases~1
colonization/growth~1
(overt~1
microfoci~1
Poly(A)~1
ribonucleoproteins~2
(mRNPs),~1
mRNP~2
polysomes.~2
mu-globulin~5
capped,~1
uncapped~1
appreciably,~1
retrovirus-based~1
2.4.2.8)~1
"CAAT~2
box,"~3
"TATA~2
box"~1
(LTRs)~1
lactotroph-specific~1
(rPRL)~1
rPRL~7
-55~1
-160~1
promoter-selective.~1
"footprints"~1
8-base-pair~1
motif,~1
CCTGATAATA.~1
-125~1
15-base-pair~1
purify,~2
pituitary-specific~1
M412~1
bacteriorhodopsin~1
(bR)~1
"rapid-sweep"~1
(FT-IR)~1
(extending~1
8-cm-1~1
resolution)~2
bR~1
bR----M~2
FT-IR~2
rapid-sweep~1
tyrosine/tyrosinate~1
low-temperature~1
low-humidity~1
spectra,~1
features'~1
Peroxisome~1
proliferators~1
peroxisome~4
PP-binding~1
(PPbP)~1
nafenopin~1
ciprofibrate,~1
140,000-160,000)~1
PPbP~2
clofibrate.~1
PP-induced~1
repression,~2
superinduction~4
Nuclei~2
HgII-affinity~1
HgII)~1
accessible).~1
HgII-bound~1
HgII~1
(cycloheximide)~1
unfolded,~1
glycerol),~1
tubulin.~1
organization:~1
(actin~1
paracrystal-like~1
cofilin,~1
21-kDa~2
cofilin~4
buffers.~1
"actin/cofilin~1
rods."~1
(FGF)-stimulated~1
FGF-stimulated~1
noncytotoxic.~1
FGF.~1
Hexamethylenebisacetamide~1
(HMBA)~1
inducer-mediated~1
phospholipid;~1
leupeptin~2
HMBA-induced~2
accumulation;~1
HMBA;~1
(vi)~1
HMBA.~1
HMBA-mediated~1
C-related~2
Myo-intimal~1
atherogenesis,~1
(TGF-beta)~6
TGF-beta,~4
myo-intimal~1
metamorphosis)~1
nerve),~1
cells--as~1
Conversely~1
cues,~1
c-mos~7
[LDHC4,~1
LDHX;~1
(L)-lactate:~1
1.1.1.27]~1
LDHC4~5
homology)~2
LDHA4~1
LDHB4~1
homology).~2
Subunit~2
LDHC~2
LDHA~1
-B~4
human-specific~1
(Spalax~1
ehrenbergi)~1
lens-specific~1
nonsynonymous~1
alpha-crystallin~1
azaguanine-resistant~1
CH3g.~1
allozymes~1
(encoded~3
locus)~2
alpha-galactosidase~1
X-chromosome-specific~1
T(X;12)13Rl~2
T(X;2)14Rl~1
T(X;16)16H,~1
T(X;4)7Rl,~1
T(X;7)6Rl~1
T(X;4)7Rl~1
Hprt,~1
centromeric,~1
9-centimorgan~1
transcarbamoylase~3
(Otc)~1
DXPas7~1
(M2C)~1
T(X;16)16H~1
DXPas8~1
(St14-1)~1
representing,~1
Hprt-Ta~1
subchromosomal~1
provide,~1
EBS4~1
Genticin~1
(G418)~1
viral-mediated~1
Myasthenia~1
californica.~2
TH-stimulating~1
anti-AcChoR~1
39-45%~1
conformation-sensitive~1
"main~1
region"~1
(MIR),~1
AcChoR-induced~1
anti-MIR~1
conformation-insensitive~1
autosensitization~1
MIR.~1
MIR~1
ML-2~4
0.03-30~1
(THC),~2
Leu-M5~1
promonocyte~2
0.03-1~1
THC-induced~2
Pronounced~2
THC-treated~1
"incompletely"~1
alpha,25-dihydroxycholecalciferol,~1
cannabinoids,~1
THC.~1
deciphering~1
cannabinoid-induced~1
"incomplete"~1
cannabinoid~1
phenotype)~3
Pool~1
FHTG~1
were--with~1
exception--within~1
FHTG.~1
FHTG,~2
Positively~1
dequalinium,~2
mouthwashes,~1
lozenges,~1
paints,~1
anticarcinoma~2
Dequalinium~2
MB49.~1
CX-1~1
W163~1
Lipophilic~1
transmitter-synthesizing~1
(aFGF,~1
bFGF)~1
AGF-1~1
AGF-2~4
neuron-enriched~1
aFGF~1
polyornithine~1
AGFs~1
FGFs~1
isothiocyanate.~1
neurons--adding~1
cadmium-sensitive~1
omega-conotoxin,~1
geographicus.~1
omega-conotoxin-sensitive~2
Culturing~1
electroplax.~1
Mu-~1
delta-opioid~1
kappa-opioid~3
(Ptd-Cho),~1
(AcCho).~1
choline-phospholipids~1
disorders)~1
AcCho)~1
LA-N-2),~1
[methyl-3H]methionine~1
PtdCho~2
PtdCho,~1
LA-N-2~1
N-methyltransferase.~1
cochromatographed~2
Ac-Cho,~1
[3H]PtdCho~1
transverse-tubule~1
subunits:~1
175-kDa~1
N-glycosylated,~1
site(s),~1
domain(s).~2
143-kDa~1
glycopeptide.~1
N-glycosylated~1
2-specific~2
lectin-agarose~1
3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate,~1
X-100.~2
(B15~1
B16).~1
transmitter,~1
peptide--termed~1
myomodulin.~3
Myomodulin~1
myomodulin,~1
neuromodulators:~1
Rexed's~1
Antidromic~1
small-airway~1
negative),~2
(ISCeq)~1
microA/cm2.~1
ISCeq.~2
(N-methyl-D-glucamine)~1
ISCeq~1
cis-dominant~1
type--specific~2
transfection-fusion~2
heterokaryons,~1
quiescent,~2
transcriptional.~1
5'-deletion~1
30-base~1
growth-inhibited~1
growth-regulatory~2
Trisomy~1
nondisjunction~3
unpairing,~1
disjoined~1
nondisjoined~1
chiasma~1
nondisjunction,~1
Mucormycosis~1
Mucorales).~1
Entomophthoromycosis~1
Zycomycetes,~1
Entophthorales.~1
entomophthoromycosis~1
sheathes.~1
sheathes~2
Splendore-Hoeppli~1
entomophthoromycosis.~1
pseudo-Splendore-Hoeppli~1
population--megakaryoblastic--was~1
M5a),~1
cytochemistry;~1
(CD14);~1
M5b~1
(CD15);~1
CD14~1
CD15~1
cytochemical,~1
box-containing~7
c10,~1
Hox-2.1~2
17q21.~1
c1,~1
Hox-2.2~2
Hox-2.2,~1
Hox-2~1
Hox-1.1~1
12q12----12q13,~1
teratomas.~2
c13,~1
2q31----q37.~1
17q21~1
(Hox-1,~1
IgK~1
(Hox-3).~1
En-1,~1
engrailed-like~1
hemimelia~1
gene).~1
genes--c8~1
c13--maps~1
(ESD)~1
Wilson~1
(WD),~1
Middle-Eastern~1
7D2,~1
D13S10,~1
centiMorgans~1
(cM)~1
4.66~1
cM)~1
(WND)~1
D13S10.~1
WND~2
centromere-D13S10-ESD-WND.~1
Gilles~1
Infantile~1
4.67~1
euparathyroid~5
ectomy.~1
gastrinomas;~1
glucagonomas;~1
insulinomas;~1
(insulin,~2
glucagon)~1
alleviations~1
Cefotaxime,~1
O8~1
WA~1
Amoxycillin~1
WA.~1
amoxycillin.~1
(10(7)),~1
spleens,~3
agar;~1
beta-lactam-resistant~1
oxacillin-resistant,~1
gram-negative-bacterial~2
(sputum)~1
predose~1
tracheostomies,~1
postdose~2
0.34;~1
Acral~2
lividity~1
lividosis~3
nondeformable~1
myeloblasts,~1
leukostasis,~1
(50,000/mm3)~1
myeloblasts.~1
hyperleukocytosis~1
leukostasis~3
biotechnology~1
diagnostics,~1
diagnostician.~1
alpha-linked~1
beta-linked~1
D-mannose,~1
D-galactose,~1
L-fucose,~1
N-acetyl-D-glucosamine,~1
(sialic~1
saccharides~1
spoilage~1
(ROL).~1
(FACS)~1
nitrobenzoxadiazol~1
(NBD)-phallacidin-stained~1
ROL~3
microns/min)~1
(m)~1
micron/min~1
[HL-60~1
cells]~1
[PMN].~1
fMLP,~3
NBD-phallacidin-stained~1
mROL.~1
peptide-mediated~1
25S~1
PLB-985,~1
PLB-985~2
Myelomonoblasts~1
(chloromas)~1
(HTLV-II).~1
HTLV-producing~1
preactivated~2
(IL-2)~26
methylcellulose-containing~1
cocultivation.~2
IL-2-independent~1
virus-producing~2
46.6%;~1
20.5%)~1
malignant-appearing~1
(18.5%)~2
HLA-DR3,~1
HLA-DQW2~1
HLA-B45~1
influences--next~1
factors--on~1
allotyping~1
(BT).~1
five)~1
BT,~1
BT:~1
14.5).~1
.045;~2
immune-response~2
ventilator-dependent~2
transmucosal~1
Acidified~1
mumol/10~2
ASA.(ABSTRACT~1
no-added~1
Tablet~1
112/73~2
111/73~2
prostaglandin)~1
blastocysts;~1
17-yr-old~1
proctosigmoiditis.~1
jets,~1
interrupters,~1
oscillators,~1
oscillation.~1
interrupters.~1
pressure-limited~1
rolling~1
piston~1
fast-responding~1
(resistive~1
unloading),~2
(elastic~1
Logic~1
adjustable.~1
binucleate~1
multinucleate~2
Sternberg-Reed~1
(MDS).~1
summarised~1
(few~1
(many~1
(logrank~1
5.793,~1
0.016),~1
subtype;~1
sideroblast~1
13-cis~1
(CRA),~1
using:~1
(ANAE)~1
staining;~1
(ANBE)~1
nucleotidase~1
M7~2
platelet/peroxidase~1
ANAE~1
ANBE~1
erythroleukaemia~1
(M6).~1
5'nucleotidase~2
reactions--reactions~1
M6~1
pseudomalignant~1
Acne~2
ionomer.~1
Occlusal~1
bruxism.~1
splint.~1
noncrisis~1
intraligamentary~2
1:50,000,~1
1:100,000,~1
1:100,000.~1
fissures.~1
sealant~7
existence,~1
concavities.~1
concavities~1
endodontically~2
masks,~1
eyewear.~1
eyewear~1
cross-contamination~1
disinfected~2
sterilization/disinfection~1
debilitation.~1
Fredrickson~1
Gemfibrozil~1
(VLDL)--associated~1
triglyceridemia~2
(respectively-32.4%~1
-40.4%,~1
(HDL)--associated~1
HDL-cholesterol.~1
cholesterol/protein~1
non-statistically~1
hyperfiltration~3
(C/ASA),~1
(D/ASA).~1
hormone-supplemented,~1
glomeruli-free~1
immunoassayable~2
Ib-positive~2
complex-positive~4
IIb-IIia~1
complex-negative~2
Ib-negative~1
Post-haemorrhagic~1
process?~1
extra-arterial~2
PG6~2
keto-F1~2
ensheathed~1
Lutrol,~1
Tidal~1
fresh-gas-flow~1
(FGF)~1
(I:E)~1
(1:1,~1
1:3),~1
breaths/min)~2
situation:~1
breaths/min.~1
I:E~3
(FGF~2
1:3,~1
breaths/min).~1
(seconds).(ABSTRACT~1
(anti-TFR)~1
B3/25,~1
96.5,~1
B3/25~3
HSA,~2
[67Ga]~1
(anti-TFR~1
MoAb)~1
TFR.~2
TFR~1
post-whiplash~1
arthrographically~3
22/25~1
nonporous~1
laminates~1
orthodontists,~1
life-size~1
retrognathism~1
pogonion~1
prognathic~1
electrosurgery~3
tungston~1
"autosensor"~2
retruded~1
Delaire~1
2-agonist)~1
(muscarinic~1
blocker),~1
U-46619,~1
[3H]citalopram~7
equilibrium-saturation~1
8560~1
serotonin-sensitive~2
serotonin-insensitive~2
p-chloroamphetamine~2
university.~2
high-positive~4
(sufficient~2
openly~1
bisexual.~1
(16/112)~1
reagin~1
32%).~1
ejaculation)~1
partner,~3
(NBGG)~1
(CBGG)~1
NBGG~1
CBGG~3
CBGG;~1
(8.37~1
5.54~1
NBGG.~1
(2.23~1
(3.12~1
CBGG,~1
86.6~1
UK-38,485,~1
EP-092,~1
RPF.~1
CBGG-immunized~1
UK-38,485~1
TxB2.~2
(PGs);~1
immunologically-mediated~2
(GFR);~2
(gp~3
9170~1
176)~2
orthovoltage~1
megavoltage;~1
22.3),~1
HTLV-IVP,~2
prostitute.~1
LAV-2FG,~1
SBL-6669,~2
tat,~2
pathobiology.~1
LAV-2FG~2
(HIV-2)~1
STLV-IIIAGM~12
tat~24
HTLV-IVP/LAV-2FG~2
transactivated~1
Chimpanzees~1
chimpanzee-HIV~1
LAV-1~1
(v-env5)~1
LAV-1.~1
LAV-1,~1
v-env5-immunized~1
"flare-up"~1
follow,~1
sequela.~1
xeroradiographs.~3
xeroradiographs~2
"Folded~1
film"~1
arthrotomography.~1
Meniscus~1
Desquamative~1
gingivae.~1
veneers~1
esthetics~2
Chuong~1
Kaban.~1
(X400)~1
Leitz~1
Texture~1
System-Plus.~1
"jackknife"~1
nonaggressiveness~1
heterosexuals~1
xerostomia~1
depapillated~1
perioral~1
contagiosum,~1
temples,~1
1958,~2
gemination~3
dentitions.~1
succedaneous~1
/s,r,d,~1
t/.~1
arthrokinetic~1
myospasm~1
entrapment.~1
citalopram~1
amineptine~1
tail-immersion~1
amineptine,~1
inescapable~2
hypogammaglobulinemic~2
panhypogammaglobulinemia.~1
crossreacts~2
biopterin-dependent~1
hydroxylases~1
phosphoinositide-specific~1
(PLCs),~1
PLC-I~3
PLC-II.~1
PLC-II~2
PLC~4
(cytosolic~2
(particulate~1
PLC-I-like~1
anti-PLC-I~1
anti-PLC-II~1
140,000.~1
PLC-I:~1
trypsin-digested~1
glandular-like~2
hybridization/nuclease~2
kallikrein-encoding~1
(bromocryptine)~1
(haloperidol)~1
Bromocryptine~1
glandular-type~1
oligonucleotides.~1
phTPO-1,~1
3048~1
103,026.~1
phTPO-2,~1
phTPO-1~1
1-base-pair~1
6282.~1
171-nucleotide~1
GT~1
boundaries,~1
hTPO-1~1
hTPO-2,~1
cation-dependent~2
6-phosphate-specific~1
2463-base-pair~1
145-base-pair~1
831~1
30,993),~1
1487-base-pair~1
residues).~1
18,299)~1
7648)~1
extracytosolic~1
(mouse-human)~1
60S~3
Artemia~1
salina~1
2-iminothiolane~1
"diagonal"~1
(two-dimensional~1
nonreducing-reducing)~1
Crosslinked~1
urea-NaDodSO4~1
P0.~2
focusing-NaDodSO4/polyacrylamide~1
homodimers.~1
(P1)2~1
(P2)2~1
L10~3
(neuropeptide~1
NPY)~1
NPY-like~2
NZBxW,~1
BXSB)~1
blood-vessel~1
phenylalanine.~1
bacterioopsin~1
bacteriorhodopsin-like~1
chromophores.~2
chromophore~2
Phe-57~1
-83,~1
Tyr----Phe~1
bacteriorhodopsin.~2
matrices--i.e.,~1
proteins--mainly~1
55-~1
180-kDa~1
280-kDa~2
subconfluent~1
85-~2
72-kDa~3
angiogenesis.~1
NaDodSO4-resistant~1
60-80%.~1
trisphosphate.~1
(RSV).~1
intersubgroup~1
(Long~1
strain)~6
(18537~1
18537~1
divarication,~1
relatedness.~1
pCRABP-HS1,~1
pCRABP-HS1~2
1050-nucleotide~1
(Bos~1
taurus)~1
prolactin-related~3
(bPRC-I),~1
lactogen,~1
bPRC-I~1
nonprimates.~1
delete~1
pGem4~1
Run-off~1
coprecipitation~1
ribonucleocapsid~1
(FMS~1
nomenclature).~1
transformants;~3
"activated"~2
PLP-related~1
241-amino~1
35-amino~1
(116-150)~1
(pre-mRNA)~1
coregulated.~1
(rGH)~1
7-base-pair~1
Spermatogenic~1
gel-blot~1
(Leydig)~1
675-~1
750-nucleotides~1
625-nt~1
pachytene~1
testis:~1
1700-nt~1
1450-nt~1
proenkephalin-~1
50,000)~1
60,000/58,000),~1
Ca2+/calmodulin-independence.~4
ATP)~1
Ca2+/calmodulin-independence,~1
phospho~1
thermolytic~2
phosphopeptide~2
1/1',~1
Threonine~1
1/1'.~1
phosphothreonine,~1
1/1'~1
Ca2+/calmodulin-independence~1
2-Azidoadenine~1
[32P]nucleotide~1
noncatalytic~3
Tyr-368~1
Tyr-345~1
near-complete~3
axonemal~4
alpha-tubulins~4
near,~1
6-11B-1,~1
posttranslationally~1
alpha-tubulins.~1
alpha-tubulin~12
37-138~2
37-138).~1
25-50,~1
6-11B-1~1
25-50~2
N-acetyllysine.~1
yeast.~3
neighbor-exclusion~4
intercalative~1
base-paired~1
heptanucleotide~1
d(CGCGCGC)~1
d(GCGCGCG),~1
violated.~1
neighbor-exclusion-obeying~1
neighbor-exclusion-violating~2
(counterion~1
3.1.27.5)~1
glutathiones.~1
MA-10,~1
LK17,~2
subclone,~3
K9,~1
K9~2
endosomal~3
Endosomal~1
"immuno-isolation"~1
recycles~1
modulated.~1
immuno-isolated~1
fusion-competent~1
(PDGF).~1
Serum-free~2
estrogen-independent~1
16-kDa~2
PDGF/SIS~1
PDGF-induced~1
1,3,4-trisphosphate,~1
heparin-affinity~2
FPLC~1
bFGFs.~2
opsin,~2
polytopic~1
topogenic~1
stop-transfer~3
extractability~1
"weak"~1
water-accessible~1
(TEC-1)~1
P19X1~1
P19S1801A1~1
TEC-01~1
ricin.~2
TEC-1~1
glycopeptides~1
embryoglycan,~1
fucosyltransferase.~1
embryoglycan~2
Hox-1.4~7
homeobox-containing~1
(initially~1
HBT-1),~1
cell-specific.~1
10.5-16.5~1
chlorophyte~1
chrysophyte~1
Ochromonas~1
danica,~1
oomycete~1
Achyla~1
bisexualis~1
small-subunit~1
oomycetes~1
chrysophytes.~1
chrysophytes~1
chlorophytes~1
protist~1
Arabidopsis~1
thaliana~3
(Linnaeus)~1
Heynhold~1
pseudogenes.~1
Stylonychia~1
lemnae,~1
Homo~2
spaiens~1
homology;~2
protists~1
introns,~1
reinhardtii~4
Fanconi~2
difunctional~1
diepoxybutane~1
(DEB).~1
DEB-hypersensitivity~1
pSV2-neo-SVgpt.~1
Transfectants~1
DEB~2
DEB,~1
clonogenicity~1
DEB-resistant~1
(DEBr)~1
DEB-induced~1
gpt~1
DEBr~3
Alu-equivalent~1
subcultures.~1
agents)~2
bz-m13CS9~2
bronze-1~3
902-base-pair~1
Suppressor-mutator~2
(dSpm)~1
nonmutant~1
dSpm.~3
dSpm~3
consisting,~1
Heterodontus~1
francisci~1
(horned~1
shark)~1
(JH),~1
(VH)~1
Gene-specific~1
vertebrate,~1
(VH-diversity-JH)~1
C3bBb,~1
C3bBb.~1
anti-decay-accelerating~1
C3bBb~1
semipurified,~1
(A-~1
(A+~1
A+~8
immunoglobulin-secreting~7
helper/inducer-T-lymphocyte~1
high-titered~1
gp71~2
virion,~1
p15E.~1
p15E~3
[3H8]leukotriene~1
tritium.~2
D4.~1
radioimmunochromatographically,~1
endogenously.~1
nmol/kg~3
(Alb-BR)~1
Alb-BR~3
probucol~4
(41.1%~1
20.2%).~1
7.4-fold~1
(thiobarbituric~1
acid-reactive~1
substances)~1
4.3-fold~1
(Mo-MuLV),~1
(Ab-MuLV).~1
Ab-MuLV~10
(P160~1
virus-containing~2
nonthymic~1
(Mo-MuLV).~1
2)-induced~2
viral-encoded~1
P160~1
Ab-MuLV-transforming~1
(ADA;~1
aminohydrolase,~1
3.5.4.4)~1
GM2756~3
GM2825A,~1
ADA-deficient~2
GM2825A~5
codons.~2
(SAP).~2
carboxylated~2
carboxylase-catalyzed~1
14CO2,~1
radiolabeled,~2
hydrolysates.~1
laminin-immunoreactive~1
neurofilament-immunoreactivity~1
oculo.~1
action-potential~1
Clusters~1
granule-like~1
calcium/calmodulin-dependent~2
(CaM-K)~1
5.1-kilobase~1
CaM-K~2
478-amino~1
(54-kDa)~1
AcChoRs~2
22Na-uptake~1
cotransformation~1
anesthetic-protein~1
glial-type~1
tegmenti~1
pedunculopontinus~1
(NPP),~1
Mesulam~1
[Mesulam,~1
M.-M.,~1
Mufson,~1
Wainer,~1
Levey,~1
Neuroscience~1
1185-1201]~1
Ch5.~1
NPP~2
Ch5~1
innominata,~1
vulnerable.~2
Inhibitory~3
Mauthner~2
outward-going;~1
quantal~5
nS,~1
1000-2000~1
glycine--the~1
pertinence~1
(NCAM)~1
frog.~2
NCAM~8
dominates,~1
vertebrate.~1
NCAM.~1
beta-protein.~1
stain-positive,~1
"senile~1
plaque-like"~1
beta-protein~2
(1-desamino-8-rhodamine-L-lysine~1
image-intensified~1
lumen-negative~1
Double-label~2
computer-enhanced~1
micromegakaryoblasts~1
CO2),~2
ischemia/reperfusion.~1
anoxia)~1
(AHP)~1
AHP.~2
AEP.~1
AHP,~1
cytarabine.~3
(DXS~1
84),~1
pERT87-1,~1
pERT87-8,~1
pERT87-15~1
(DXS164),~1
pXJ-1.1~1
Obligate-carrier~1
noncarrier~2
two-copy~1
(DXS28)~1
(DXS43),~1
OTC,~1
Restriction-fragment-length-polymorphism~1
X;autosome~1
autosome.~1
Y-chromosomal~3
(46,X,~1
mar).~1
Molecular-hybridization~1
studies--including~1
G-,~1
Q-,~1
G-11-banding--of~1
G-11~1
chromosome-derived~1
Turner-syndrome~1
interlocus~2
seriation~6
Seriation~2
computer-intensive~1
hemochromatosis:~1
B7~6
(actually~2
CW.,~2
B7,~1
Bfs,~1
DR2);~1
B14~5
B14,~1
BfF,~1
DRW6);~1
A11,~3
B35;~1
B5.~1
B5)~1
undeniably~1
haplotypes--A3,~1
B15--were~1
disequilibrium.~1
hemochromatosis--i.e.,~1
B12;~1
B8;~1
A9,~1
B7;~1
B12--were~1
haplotypic~1
marking;~1
(TA-4),~1
Droperidol~1
antiemetic,~1
antiserotonin~1
parachlorophenylalanine,~1
aprotonin~1
octreotide~1
(Sandostatin,~1
tumour-released~1
Osteosarcomas~1
chondrosarcomas~1
approximately,~1
NY-198~6
[1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-~1
quinolinecarboxylic~1
hydrochloride]~1
difluorinated~1
C-methyl~1
maltophilia,~1
calcoaceticus,~1
norfloxacin.~1
(SBL-6669)~1
(RIPA)~1
LAV-II,~1
SBL-6669~3
LAV-II.~1
pathogenicity.~1
LAV-II~1
imminent,~1
immunoprophylactic~1
(gag,~1
env)~2
(cytolysis),~1
peripolesis~1
cord/stromal~1
HMFG2~1
thalassemias~1
(dimethylsulfoxide).~1
delta-globin~4
(T-C)~1
CCAAC~2
Tf,~1
density-dependent,~1
Tf.~1
224Ra~2
226Ra~1
mineral.~1
distribution-difference~1
4496~1
Morphology.~1
France;~1
Hemogram~1
(AMLs)~1
AMLs~1
1954).~1
hemograms~1
107),~1
(RAEB)~1
329),~1
RAEB~1
1177~1
(ALLs)~2
L2,~1
L3.~1
hemogram~1
(Ara-C).~2
Neurotoxicity~1
helper-suppressor~2
Lymphomas~1
Kumamoto~1
prefecture~1
(Kyushu)~1
Okinawa,~1
13,329~1
(IT-MTX).~1
IT-MTX~1
(Span-1)~1
Span-1~6
58.7,~1
Span-1,~1
Dupan-2~2
Lewisa-b-~1
19-9.~3
Dupan-2.~1
we,~1
12,13-dibutyrate(PDBu)~1
12-0-tetradecanoylphorbol~1
13-acetate(TPA),~1
chronotropy.~1
1,2-oleoylacetyl-glycerol~1
1,2-dioctanoylglycerol,~1
alpha-phorbol,~1
strengthened,~1
rocking~2
negative-pressure~1
(NPV)~1
NPV)~1
RB;~1
NPV;~1
NPV.~3
NPV~1
Asynchronous~1
up-and-down~1
(16.6,~1
16.6,~1
35.1,~1
(1.7,~1
11.1,~1
61.0~1
dimethyl-PGE2~1
beta-[4-dimethylaminophenyl]17~1
alpha-[1-propynyl]-estra-4,9-dien-3-one)~1
ZK~5
98734~3
beta-4[4-dimethylaminophenyl]17~1
alpha-[3-hydroxy-1-propynyl]estra-4,9-dien-3-one)~1
antiprogestins~2
15-keto-13,14-dihydro-PGF2~1
15-keto-13,14-dihydro-PGE2.~1
(AA,~1
glandular,~3
AA;~1
98734;~1
98734,~1
(SLC)~1
Interferon-gamma,~1
SLC.~1
DR-positive~1
SLC~2
SLC)~2
DR+DQ+~2
Interferon-gamma.~1
Interferon-gamma~1
125I-TGF~5
intrafemoral~1
EGF)~1
inhibitable,~1
organ-selective~1
alpha-HSD).~1
[3~3
beta-3H,~2
C24-14C]lithocholic~1
3-oxo~1
beta-3H]Cholic~1
ceased,~1
24-14C]Lithocholic,~1
prograde~2
20-40%~1
extensive.~1
glycocholate~2
sinusoid.~1
dysfunction:~1
suddenly,~1
ankylosis,~1
high-copper~1
carving~1
Tungsten~1
carbide~2
microfilled~2
Diamond~1
small-particle~2
High-speed~1
nondisrupted~1
smooth--free~1
burs.~1
radiopaque-radiolucent~1
sees~1
pathoses~1
sialoliths~1
Impacted~1
normal-size~1
represented,~1
15,783~1
15,303~1
Fibromas,~1
periodontitis,~1
mucoceles,~1
premalignant.~1
Irradiance~2
HTLV-I-related~1
anti-HTLV-I~2
anti-retroviral~1
AVID,~1
idiotype)~1
AVID~5
hexamethylene~1
bisacetamide,~1
inducer-treated~2
near-threshold~1
urticarias,~2
(Medical~1
Procedures)~1
(Victoria)~1
common-law~1
"cloning,"~1
banned.~1
amended~1
biologists,~1
cytologists,~1
cytogeneticists,~1
"clones"~1
91%).~1
77%)~1
81%)~1
.52).~1
Disparate~1
AIEOP/LAM~1
8204~1
daunomycin~1
(DNM)~1
DNM,~1
(6-TG)~1
pairs:~1
(VP-16)/Ara-C,~1
Ara-C/6-TG,~1
DNM/Ara-C.~1
marrow;~1
CNS).~1
phase),~2
Hyperleukocytosis~1
AML.~4
epirubicin~4
mg/m2/d.~1
nine).~1
[WHO]~1
pts),~1
leukocytopenia),~1
port,~2
.68,~1
drug-uptake~1
(AUC).~1
111In]96.5,~1
[111In]ZME-018)~1
p97~1
[111In]96.5~2
tumor-to-muscle~1
tumor-to-organ~1
tumor-to-intestine~1
antibody"~2
111In]CEA)~1
[111In]ZME-018~1
poly(L-lactide)~1
(PLLA)~1
setback~4
induced;~1
Ameloblastomas,~1
transfacial~2
zygomaticomaxillary~1
transfixation~1
catastrophies.~1
Immunogenetic~1
HLA-DR1~1
supertypic~2
HLA-DR6.1~1
15.4,~1
0.008,~1
Caucasian;~1
Anti-Scl-70~1
anti-Scl-70~1
fibrositis~2
(BPI)~1
curtailing~1
logistic,~1
+100~1
edition~1
Disorders.~1
inflection~1
binge~1
Acetone-fixed~1
(MAb~1
528)~1
(EGFR).~1
(4/4)~1
(13/21)~1
(SCLCs)~1
(0/9).~1
SCLCs~1
large-cell,~1
SCLCs.~1
neck--upper~1
aero-digestive~1
(UADT)--cancers.~1
UADT~1
(smokers,~1
alcohol),~1
curability~1
six-step,~1
dentist-oriented,~1
site-targeted,~1
pharyngoscope.~1
Inc.--Park~1
DuValle~1
teachability,~1
6,206~1
smokers;~1
ex-smokers;~1
Maps~1
Flats~2
Facility~2
plutonium~1
petrochemical~1
histologic-specific~1
(BGS)~1
BGS~4
Lewisa~1
(Lea),~1
Lewisb~1
(Leb)~1
metastatic).~1
islets.~6
Lea~6
centroacinar~1
BGSs~1
Incompatible~1
incompatibility.~2
(MPLC)~1
unicentric~1
(ULC)~1
prefecture.~1
MPLC~6
metachronous.~1
Brinkman~2
(BI)~1
MPLC,~1
BI~1
MPLC.~1
ULC~1
10,473~1
Leisure~1
World,~1
Laguna~1
Hills,~1
cereal,~1
643~1
31,465~1
(1970-75)~1
5,485~1
noncases~1
(g),~1
Bradford~2
(case-control,~1
temporality~1
coherence,~1
satisfied.~1
(NAs)~1
DMH-sensitive~1
DMH-resistant~1
DMH.~3
NAs,~1
NAs~2
stabilizer,~1
biscoclaurine~1
cepharanthine~7
0.1-0.5~1
cepharanthine/ml~1
cepharanthine,~1
Cepharanthine~1
P388~1
P388/VCR.~1
Diethylnitrosamine~1
55-18-5)-transformed~1
72/22~4
cytoarchitectural~2
butyrate-induced~1
26-51%~1
cytofluorimetry~1
detergent-resistant~1
monomer-polymer~1
microfilament-associating~1
Butyrate-induced~1
"normalization"~1
cytoarchitecture~1
DONRYU~2
N-ethyl-N-nitrosourea~3
N-propyl-N-nitrosourea.~1
nitrosourea-induced~1
JCV,~1
inoculated,~1
BN/Bi~1
removed;~2
inoculation;~1
6-Keto-prostaglandin~1
allophenic~1
(chimeric)~1
(GPI).~1
osmoregulatory~3
"set"~2
fuller~1
Osmoreceptor-mediated~1
human-immunodeficiency-virus~1
low-titre~1
(core,~1
non-structural~1
(3'~2
orf,~2
tat)~1
ELISA-negative~1
antigenaemia~1
16-34~1
hybridisation,~1
non-lymphoid~3
tuberculin).~1
(FIET)~1
ischemically~1
FIET~2
FIET.~1
myophosphorylase,~1
Retroviruses~3
(LTR).~2
fim-2~3
(F-MuLV).~1
5'-end~1
haemopoietic~1
(M-CSF~1
CSF-1).~1
Proviral~2
fim-2/c-fms~1
leukaemias.~1
DXYS1-p58-1~1
X-chromosome.~1
(restriction~1
pERT87)~1
(CK/PK)~1
CK/PK~2
isolated-case~1
accommodates~1
vocalizations,~1
vocalizations.~1
immunotitration.~1
ripening.~1
crepitation~1
resurfacing,~1
(retained)~1
(retrievable)~1
coronoidectomy~1
coronoidectomy,~1
exodontia.~1
(11/25)~1
(4/25)~1
herpes-type~1
Gamma-glutamyl~1
carcinoma-resection~1
dentinal~1
tissue-time~1
viewbox,~2
accessories~2
magnifying~1
x-viewer.~1
observer,~1
Xerox~1
beveled-edge~1
cassettes~6
selenium-alloy~1
xeroradiography.~1
holders.~1
complete-mouth~1
collimating~1
pathogenesis:~1
maldirected~1
capitulum.~1
Herpetic~1
whitlow~3
Acyclovir,~1
whitlow.~1
Factitial~1
factitial~2
paraoral~1
self-mutilation~1
self-destructive~2
melphalan.~1
digestibility,~1
pearl~6
millet~6
sorghum~2
maize.~1
sorghum,~1
uncooked~1
sorghum.~1
barley,~1
nutritious~1
well-digested~1
(TGF-beta).~1
lipopolysaccharide-treated~1
lipopolysaccharide-treated,~1
cosecretion~1
monocyte/macrophage-derived~1
21-base-pair~2
(LSF)~1
L325~1
L264~1
LSF~4
late-early~1
Sp1.~1
vitro-transcribed~1
(IFN-beta)~2
(UTRs).~1
undegraded,~1
UTRs~1
polylinker~1
UTR~3
UTR.~1
pMG377,~1
IX-like~1
pMG377~2
1(XII).~1
1(XII)~2
calvaria,~1
DG12~1
optimum),~1
WISH~1
[14C]ethanolamine,~1
[14C]myristic~1
myo-[3H]inositol,~1
membrane-linked~1
tumor-associated,~1
MCF-7.~1
0.1-1.8~1
1.8-kilobase~2
pUC8~1
(pMUC10),~1
T47D~3
anti-mucin~1
(HMFG-1~1
HMFG-2)~1
HinfI.~1
Glycosphingolipid~1
GD1a~5
gangliotriaosylceramide.~1
H-,~1
GM3~1
ras-transfected~2
confluent.~2
gangliotriaosylceramide~2
5'-terminal~1
"footprint"~1
21-24~1
single-nucleotide~2
7.5S~1
130,000.~2
(TMV)~1
N'~4
sylvestris~1
tabacum~1
cv.~1
Yellow,~1
TMV-OM~3
TMV-L~6
(tomato~1
TMV-OM-derived~1
annexins.~1
calpactin~1
endonexin~5
phosphatidylserine-~1
phosphatidylethanolamine-containing~1
gamma-crystallins~2
correspond.~1
G3~1
G4.~1
G4-crystallin~1
low-concentration~1
G3-crystallin~1
separating,~1
60-nm~1
part-rough,~1
part-smooth~1
Nucleoside~1
5-iodonaphthalene-1-azide~1
(Ina)~1
nitrene,~1
lipid-embedded~1
Ina~2
photosensitizing~1
3-aminopyrene,~1
8-anilinonaphthalene-1-sulfonate,~1
[125I]Ina-labeling~1
n-undecylamine~1
[125I]Ina-labeled~1
Photosensitization~1
chromophore-bearing~1
albumin-fluorescein~1
[125I]Ina~2
azides.~1
4.0-kilobase-pair~1
(EIIA-EF)~2
(-82~1
-66)~1
EIA-inducible~1
EIIA~1
(EIIF)~2
[poly(dI).poly(dC)~1
poly(dI-dC).poly(dI-dC)]~1
(salmon~1
-69~1
EIIF~2
EIIA-EF~1
severalfold.~1
Z-RNA~4
Z-RNA-like~1
anti-Z-RNA~3
IgGs.~1
Pre-or~1
determinants;~1
mung~1
Anti-Z-RNA~1
A-RNA,~1
erg,~1
363-residue~1
v-ets~1
3.2-~1
3.6-kilobase~1
erg~2
Hu-ets~2
2.1.3.3)~1
intestine;~1
gene;~4
carbamoyl~1
ornithine,~1
box"-~1
"ATA~1
box"-like~1
11-nucleotide~1
reappears,~1
heme.~1
decays.~1
conformations.~1
tryptophans~1
anisotropies~1
subpicosecond~1
nondiffusive~1
motions.~1
16-ps~1
subnanosecond~1
tryptophan-14~1
tuna~1
half-staggered,~1
polarities~1
orientation)~1
half-staggered~1
strands.~1
(Hb).~1
Fe-porphyrin~1
distance--2.06~1
(0.10)0.20~1
triangulation.~1
RNase.~1
cotranslational~2
stem-loop~3
polyadenylylated,~1
nonadenylylated~1
0.55-kilobase~1
(kb)-long~1
20-kb-long~2
genome)~2
soup/cell.~1
polynucleotide.~1
0.55-kb~1
nonstop~1
exceptions.~1
stop-codon~1
genotypic~1
2w,~1
between,~1
2b,~1
u,~2
2w~3
theta)sigma~1
coancestry~1
u.~2
perceptible~2
4Nu~1
10(-1).~1
2(theta~1
alpha)sigma~1
asymptotically~1
10(-5),~1
generations)~1
1-10.~1
marsupials~2
eutherian~3
marsupials,~1
paternal,~1
inactivity,~1
marsupial,~1
Didelphis~1
virginiana,~1
marsupial~1
nuclease-insensitive~1
(nonregulatory)~1
nuclease-hypersensitive~1
(regulatory)~1
eutherians,~2
hypomethylated~1
"lock~1
trophectoderm~2
events--rather~1
inactivation--account~1
1556A2.1~2
(GAT)-specific~1
372B3.5~1
(GAT-TsF2),~1
GAT.~1
(I-J+~1
(AB+~1
AB+~2
I-J+~6
DR1-9.~1
-9;~1
(4-7%)~1
(DR4,~1
-9)~1
(DR3,~1
-5,~1
-6)~1
Dinucleotide~1
shuffling~1
UMR106~3
S90E.~1
metabolite-specific,~1
1-34)~1
echoviruses,~1
neurotoxins.~1
electroplax,~1
batrachotoxin,~1
sodium-selective~1
PNa~1
PTl~1
PCs.~1
(N-bromoacetamide~1
N-bromosuccinimide),~1
QX-314~1
23-day-old~1
(md)~1
md~2
intraperiod~2
places,~1
PLP,~2
kinetics:~1
[IK(Ca)],~1
[IK(V)],~1
(Ia).~1
omega.~1
spikes,~1
decrementing~1
Postsynaptic~1
kDa;~1
43-kDa~10
coextensive~1
26-mer~1
deduced,~1
43,988~1
day-11~1
BC3H1.~1
egg-laying~1
(ELH)~1
R15.~2
ELH~6
R15~5
ELH,~1
Rb+~1
IR.~1
Mn2+.~1
ICa.~2
ICa~1
R15,~1
AMP-mediated~1
[32P]cDNA~1
medulla/pons~3
Lower,~1
Watanabe-heritable~1
(EtNU).~1
rat-specific~1
N-ras.~1
[Schechter,~1
A.L.,~1
Stern,~1
D.F.,~1
Vaidyanathan,~1
Decker,~1
S.J.,~1
Drebin,~1
J.A.,~2
Greene,~1
M.I.~1
R.A.~1
312,~1
513-516]~1
EtNU-induced~1
BD-IX~1
(IGF-II).~1
6.0-kilobase~1
Wilms~2
5.0-kb~1
assembles~1
co-assemble~1
Biosynthetic~1
(EC-SOD;~1
superoxide:superoxide~1
1.15.1.1)~1
G+C~1
EC-SOD~3
(Asn-89).~1
96-193~1
SODs,~2
leiognathi~1
intrasubunit~1
SODs~3
EC-SOD.~1
divergences~1
194-222~1
EC-SODs~1
hormone-specific~2
(hCG~1
mucin-like~1
IdID,~1
O-glycosylation.~1
oligosaccharide-deficient~1
(eIF-4F)~1
eIF-4F~4
trans.~1
(NO3-)~1
(NO3-).~1
L-arginamide,~1
L-arginyl-L-aspartate.~1
L-Argininic~1
L-agmatine,~1
L-citrulline,~1
nonprecursors,~1
L-canavanine~1
L-arginine-derived~1
NO2-/NO3-~5
morpholine~1
N-nitrosation~1
N-nitrosomorpholine.~1
L-[guanido-15N2]arginine~1
N-nitrosomorpholine~1
L-citrulline.~1
J774.16~1
C3C.~1
NO2-/NO3-.~1
C3C~1
protein-phosphorylation~1
beta-adrenoreceptor-stimulated~1
mannosylphosphodolichol~1
(Man-P-Dol)~1
(GDP-mannose:dolichyl-phosphate~1
O-beta-D-mannosyltransferase,~1
2.4.1.83)~1
40-80%~1
Man-P-Dol~4
GDP-mannose,~1
isoproterenol-treated~1
GDP-mannose~1
Vmax).~1
glycosyltransferase~1
dolichol~2
kinase-mediated~1
interferon-induced~3
15-kDa~1
ATG~2
Constructs~1
-115~1
-96,~1
"CCAAT~2
box."~1
shuffling.~1
virions,~1
AATTTTTAT~1
TTTTTNT,~1
somatotropin~1
(MPS),~1
2.8-A~1
K2OsCl6~1
MPS~3
Alignment~1
Proton/hydroxide~1
(H+/OH-)~1
H+/OH-~4
decane~1
diphytanoyl~1
(GH/OH)~1
nS.cm-2,~1
"net"~1
(0.4-1.6)~1
cm.sec-1.~1
GH/OH~4
(fatty~1
acid-free),~1
phloretin,~1
chlorodecane,~1
pathway(s),~1
"washing"~1
"background"~1
120-kDa~1
laminin-binding~3
NG108-15~1
proteolysis.~5
"cranin,"~1
(IgM;~1
CHON211)~1
(nucleoporins)~1
CHON211~4
envelope;~1
(GlcNAc)~1
CHON211,~1
immunodeterminant.~1
modification:~1
GlcNAc.~1
nucleoporins~1
nucleo-cytoplasmic~1
comb~4
ctenophores~1
net.~1
reorientation~1
Dual-electrode~1
protistan~1
1-mm-long~1
isopotential.~1
propagate~4
intraciliary~1
Ca2+-sensitive~2
axoneme.~1
(differentiation-inducing~1
DIF-I)~1
erythroid-inducing~1
sulfoxide-~1
hexamethylenebis(acetamide)-treated~1
DIF-I.~2
DIF-II)~1
hexamethylenebis(acetamide),~1
DIF-II~2
sulfoxide-inducible~1
cytoplast-fusion~1
MEL-cell~1
multitudes~1
eukaryotes;~1
innovativeness~1
proteins--with~1
domains--indeed~1
heptameric~2
comingled~1
Choroideremia,~1
nightblindness~1
Xq13-21~1
XL-62,~1
Xq21~1
XL-45,~1
phenol-enhanced~1
reassociation~1
48,XXXX~1
XL-45~4
XL-45.~1
XL-62.~1
submicroscopic~1
transfectants,~1
526-amino~1
50-81~1
DRw6~3
EcoRV~1
ethnic-matched~1
(FBP)~1
FBP,~2
42,000.~1
FBP~5
NaDodSO4/PAGE)~1
160,000,~1
chloroform/methanol,~1
amide-linked~1
ester-linked.~1
ZR-75-1~4
TNF-like~6
TNF-induced~5
TNF-resistant~2
ZR-75-1R,~1
ZR-75-1R~2
coronaviruses~1
peplomer~2
neuropathogenicity,~1
peplomer.~1
peplomers~1
15-amino-acid-long~1
extramembranous~1
Amphibian~1
strontium.~1
(19-26~1
vitro).~1
Forskolin,~1
20-1724,~1
phosphopeptide.~1
single-neuron~1
receptive-field~1
RF)~1
RF).~1
near-radial~1
penetrations.~1
penetrations,~2
shape)~1
area--termed~1
"RF~1
center."~1
penetrations)~1
penetrations),~1
Closely~2
350-~1
400-microns-diameter~1
hexagons,~1
columns--an~1
(HTLV-1)~1
(tat)~2
transgene~3
HLA-matched~2
HLA-typed~2
Caucasoid~5
open-wedge~1
virus/lymphadenopathy-associated~1
Trisomic~1
gene-centromere~2
chromatids~1
disomic~2
FORTRAN~1
DSLINK,~1
segregation.~1
coprolalia,~1
628~1
392~4
subdiagnostic~2
Neurokinin~1
(NKA)~1
(NKB)~1
NKA~3
lung);~1
NKB~1
NKA-immunoreactive~2
Bidimensional~1
Impressive~1
(hemoglobin,~1
g/L;~1
10(9)/L;~1
(AZT)~3
Azidothymidine~1
C57Bl/Ler-vit.vit~2
pelage~2
molts,~1
numerous)~1
(Ia+/adenosine~1
1600/mm2)~1
HLA-B12,~1
TEN,~1
Sulfonamide-related~1
oxicam-related~1
B12.~1
Nonacetylated~2
salsalate~4
[30.7~1
re-treated~2
Polysaccharidoses~1
brancher~1
amylopectin-like~1
polysaccharidosis~1
tromethamine~2
alpha-treated~1
pilocarpine-induced~1
uveoscleral~2
hyposynthesis~1
hypercatabolism.~1
apparently,~1
(TDI),~1
Hydatid~1
cystpericystectomy~1
accelerator~1
(vWF)~8
(vWD)~5
vWD~9
anticoagulant,~1
vWF~52
multimers,~3
1-Deamino-8-D-Arginine~1
multimer~2
DDAVP.~2
differentiation-associated~1
(MY9,~1
PM-81,~1
AML-2-23,~2
MCS-1,~1
MY8,~2
Mo1,~2
MY1,~1
Mo2),~1
(T101,~1
T11),~1
B4)~1
[J5~1
(CALLA),~1
HLA-DR].~1
(PM-81)~1
(Mo2).~1
naphthyl~1
(MY4~1
MY7)~1
MY4+~1
M4-~1
MY7+~1
MY7-~1
MY4~1
MY7~1
[MY4-~1
MY7-]~1
Mo1)~1
MY8~1
(rHF,~1
acidic)~1
(rLF,~1
ferritins~1
rHF~6
rLF~1
10(-16)~1
isoferritin~1
isoferritins.~1
(L-T3)~1
B-4~1
light-density~1
burst-promoting~3
(BPA).~2
BPA~6
pulse-exposed~1
BPA-like~2
(CALLA)~2
deoxynucleotidyl~3
CALLA.~2
CALLA~4
HUT-102.~1
DIF~5
HUT-102-conditioned~1
diethylaminoethanol~1
(DEAE)-chromatography,~1
MonoQ~1
DIF,~1
DIF.~2
(gamma-IFN)~1
gamma-IFN~1
Hemopoiesis~1
(LTBMC)~1
Myeloid~1
(MBMC)~2
(LBMC)~2
lymphopoiesis.~2
lymphopoiesis,~2
MBMC~6
LBMC~8
LTBMC~3
mycophenolic~1
myelopoiesis.~4
wool-passed~2
-198~1
gamma-genes~1
S1-hypersensitive~1
Chondrocalcinosis~1
1-4%~1
tissue-typed~1
(RANA).~1
anti-RANA~2
Anti-RANA~1
HLA-DR4.~2
heat-aggregated,~1
monomeric,~1
catabolin~2
Catabolin~1
5.2%.~1
microcysts~1
Interleukin-2~5
IL-2~113
(Jurkat~1
(Escherichia~1
[AIDS]~2
malignancies)~1
Jurkat~11
IL-2.~18
(RIL-2)~1
RIL-2~4
U/kg/hr.~1
(25/25),~1
(10/25),~1
(15/25).~1
(16/25)~1
dichotomy,~1
(CGRP)~8
CGRP~35
50,100,~1
ng/min.~1
angiocardiography,~1
(gn)~1
gn~2
(TXB2),~1
alpha(6-keto-PGF~1
nine-fold~1
(5.35~1
ng/mg;~1
6-keto-PGF~1
intraperitoneally),~1
(non-nephritic)~1
hypercellularity.~1
age-frequency,~1
(56.7%).~1
Epiglottitis~1
10(9)/l~3
(.1~1
.2~1
units/min)~1
(AC).~1
cells/ml),~2
cells/ml).~1
phorbol-myristate-acetate,~1
PBC.~1
synthesizes~2
5-steroidogenic~1
17,20-lyase~2
8-21~1
17,20-lyase.~1
[3H]pregnenolone~1
4-st~1
secretagogue-stimulated~1
methoxyverapamil~1
(D600;~1
corticotrophs,~2
lactotrophs~1
50-70%~1
microM)-stimulated~1
D600.~1
barium-stimulated~1
[7.52~1
micrograms/dl;~2
CRF-treated~1
(16.44~1
12.24~1
Corticotrophs~1
(191.1~1
158.6~1
196.1~1
170.1~1
corticotrophs.~1
undetectable)~1
hysterosalpingogram.~1
non-salt-losing~1
exteriorize~1
Clitoroplasty~1
Biocompatibility~3
lymphocytes:~1
subsets;~1
2,143~1
(IL-1)~36
IL-1~248
3-methylhistidine/creatinine~2
Regularly~1
Interleukin-1~13
IL-1.~25
two-vessel~2
(57.7%).~1
4.1%.~1
64.9%~1
(oCRH)~2
oCRH~9
CRH.~7
oCRH-induced~4
increments,~1
D-Ala2,MePhe4,met-(O)enkephalin-ol~1
FK~10
33-824)~1
(Cushing's~1
(hCRH).~1
hCRH~3
Bachem)~1
33-824,~1
hCRH-induced~2
33-824.~1
(ACTH,~2
met-enkephalin.~1
33-824~4
2409~1
opiodergic~1
18-23~2
29-40~1
visit)~1
7-19~1
(return~1
visit).~1
sulfate;~1
glucosiduronates~1
estrogens;~1
(DHAS),~1
(DHA).~1
DHAS~5
(noncarboxylated;~1
GLU)~1
(carboxylated;~1
GLA)~1
GLU/GLA~2
nonclassical~5
(nonclassical)~2
(classical)~1
nonclassical.~1
(21-OH~4
defsevere/21-OH~1
defmild)~1
(17-OHP)~2
defmild/21-OH~1
defmild):~1
8,131~1
4,205~1
4,468~1
2,123~1
11,067~1
5,582~1
5746~1
1565~1
17-OHP,~1
17-OHP/cortisol,~1
defsevere/21-OHnormal)~1
defmild/21-OHnormal)~1
"superinduction"~1
Endotoxin-stimulated~1
IL-1,~17
costimulation~3
anti-IL-1~6
wall's~1
dyn/cm2~1
viscometer~1
platelet-surface~1
ristocetin,~3
desialation~1
vWF.~6
Unusually~2
shear-induced~1
Shear-induced~2
vWF-dependent~1
XIIa~2
(3Cl)~1
XIa~2
(5F4)~1
3C1~3
5F4~2
XIIa;~1
Alpha-1-antitrypsin~2
epidermodysplasia~4
verruciformis~3
verruciformis,~1
Lymphocyte-induced~1
pilots.~1
10,312~1
2,326~1
renew~1
1,207~1
1,119~1
(4.0%~1
4.3%;~1
4.2%;~1
first-class~1
avidin-biotin-peroxidase-labeled~1
T-lymphocytes,~6
esterase),~1
3a~12
cytotoxic-suppressor~2
antitrypsin~4
(PiSZ~1
cell-sized,~1
(CTL).~7
detergent.~1
antigen-bearing,~1
cell-sized~3
pseudocytes~3
(artificial~2
CTL~135
alloantigen-bearing~3
lymphokines~23
Ia-dependent~1
cell-size~2
PPD-specific~3
hybridoma,~4
8B2,~1
I-Ad.~1
PPD-pulsed~1
(abbreviated~2
PGM)~1
8B2~5
Ia.~2
non-antigen-treated,~1
APC,~6
Ia-negative~1
I-Ad~2
I-Ab.~1
PPD/I-Ad-specific~1
(antigen-specific~1
non-antigen-specific)~1
ionomycin,~1
Ia-T~1
signals.(ABSTRACT~1
macrophages-monocytes,~1
(EAE).~1
Reconstitution~3
anti-I-A~3
blood-brain-barrier~2
(EAE),~1
post-inoculation~1
(dpi)~1
dpi)~2
MRL-+~3
MRL-lpr~3
(lpr)~1
Interleukin~23
abberrant~1
co-stimulating~2
Aqueous~3
Successive~1
chemokinetically~1
arg.~1
acid/acetonitrile~1
(Leu-3+)~1
Leu-3+~5
phytohemaglutinin/phorbol~1
constitutively;~1
re-expressing~1
alloantigen,~2
(tetanus~1
toxoid),~1
2-stimulated~2
cytotoxins~3
L929~3
16-hr~1
alloantigens,~1
toxoid,~1
cytotoxin(s).~1
alpha-lymphotoxin~1
LT)~2
CTL-toxin.~1
40%).~1
CD8~9
Astrocytes~1
3)-like~1
20-alpha-hydroxysteroid-dehydrogenase~1
(20-alpha~1
SDH)~1
3-dependent~7
32DCL.~1
astrocyte-derived~1
microglia~3
experiments:~1
3-like~2
32DCL~1
B27.4(B27D),~1
HLA-B27.1,~1
B27.2,~2
B27.3~5
HLA-B27.4~2
B27.1~4
aspartate-77~1
serine-77~1
valine-152~1
glutamate-152,~1
histidine-114~1
aspartate-114~1
aspartate-116~1
tyrosine-116,~1
B27.4.~1
B27.4~2
conversion-like~1
B27.1,~1
15-min)~1
(46,000/cell~1
150,000/cell)~1
GM-CSF.~8
(CTL)~24
H-2K/D~1
H-2I~1
K/D~1
detergent-releasable~1
post-lethal~1
269-residue~1
BSF1~13
mIg~2
hyper-Ia~2
BSF1-containing~1
PtdInsP2~3
PtdOH~1
InsP3.~2
anti-Ig~18
KDa.~1
Anti-Ig~1
BSF1-receptor~2
anti-leukemia~2
FBL-3~6
Winn-type~1
non-curative~1
FBL-3,~2
circumstance,~1
FBL-3.~1
"LAK-inducing"~1
Laz~3
(p45,~1
(CD10),~1
p105).~1
Ramos~1
vice-versa.~1
Immunogenicity~1
(Ts3)~1
Ts3~4
D-amino~1
(DTH).~1
hapten-Ficoll~1
xenogeneic~2
medium-density~4
DTH.~1
Precursor~2
hapten-primed~1
burro~1
(BRBC)~1
BRBC~1
(CRBC),~1
CRBC~1
BRBC.~1
DTH,~2
added.(ABSTRACT~1
Lyt-2-~12
alloantigen-specific~2
Lyt-2~6
(NK)-susceptible~1
Lyt-2.~1
membrane-directed~1
(anti-Ig,~1
LPS)~1
(8-mercaptoguanosine,~1
[8MGuo]).~1
macrophage-depleted~1
8MGuo.~2
(PGE1,~1
mitogenesis.~2
8MGuo~3
cycle-specific~1
concert,~2
surface-directed~1
A)-activated~1
CD8+.~2
A-activated~7
autorosetting~2
nonrosetting~1
(4:6),~1
autorosette-forming~1
W3/25+,~1
OX8-phenotype~1
P2-specific~2
(EAN),~1
EAN.~1
EAN~4
Lewis.~1
cells/host.~1
Lewis-~1
BN-derived~1
neuritogenic~3
bromide-derived~1
CB2~1
21-113),~1
CB2-specific~1
53-78~1
(SP4),~1
autoreactive~15
DM-20,~2
CM-Trisacryl~1
DM-20-induced~1
(rIL~7
Tac~6
Daudi,~2
1/1700~1
B73.1+~1
bouyant~1
(Ig)-secreting~2
(TGF)-beta~1
factor-dependent,~1
Unactivated~1
Cowan~11
(SAC)~5
SAC~8
(mIL~2
mIL~16
emetine,~1
paraformaldehyde-fixed~3
Ia/antigen~1
BSF-1,~5
N(alpha~1
C1(alpha~1
H-2-restricted~1
H-2Dd.~1
CTL.~22
H-2Ld)~1
fortuitously~1
pLD~1
H-2Dd),~1
Transformant~1
anti-H-2Ld~2
anti-H-2Dd~2
N/C1-specific~1
2M~2
LD.~2
CTL,~6
VSV-specific~1
H-2Ld-restricted~1
VSV-infected~1
antigens.(ABSTRACT~1
arctoides~1
suum.~1
total),~1
cell-derived.~1
fractioned~1
(MuLV)~1
antigens--the~1
FMR~3
Friend,~1
Moloney,~1
MuLV,~1
(GCSA)~1
AKV/Gross~1
MuLV.~2
MuLV-induced~3
GCSA~2
lysing~4
MuLV-infected~2
MuLV-encoded~1
AKV-infected~1
genomes,~1
influenza,~1
unsegmented~1
(RSV),~1
anti-RSV~1
Mammalian~1
populations--one~1
mature--and~1
Lyt-2-,~7
descendents.~1
lymphocyte.~1
S49.1~3
H-2Kd-,~1
H-2Dd,Ld-,~1
H-2Ld-specific~1
anti-H-2d~1
microfluorometry.~2
S49.1,~1
T-25,~1
T-25ADH,~1
Thy-1-,~1
100/0.~1
Dd,~2
T-25~1
T-25ADH~1
Ld,~2
SWR~7
(SNF1)~2
SNF1~13
Id564~2
SNF1-derived~3
idiotypically~2
Id512~1
(cationic)~1
nephritogenic~3
idiotypes-lupus~1
nephritis-SNF1~1
IdLNF1.~1
IdLNF1~2
(Lyt-1+,~1
L3T4+)~1
PLP-activated~1
encephalitogen,~1
PLP-sensitized~1
amphipathicities~1
coil),~1
helix-breakers~1
dipoles.~1
amphipathicity.~1
disjoint~1
subpeptides,~1
hydrophilic.)~1
conformations,~1
COOH-terminus.~1
vaccines:~1
significances~1
generalites~1
conformations:~1
alpha-helices;~2
amphipathicity~3
antigenicity;~1
conformations;~1
segmentally~3
amphipathic.~1
alpha-Helical~1
Lysines~1
digests.~1
lysines~1
dipoles.(ABSTRACT~1
c(cyt~1
c),~1
c-primed~1
hemocyanin-primed~1
cyts~2
bromide-cleaved~2
1-65,~1
1-80,~1
66-104~1
44-47,~1
60-62,~1
89-92.~1
reoccurrence~1
clonotypes~1
non-MHC-restricted~2
(TABM)~1
TABM~9
(MBSA).~1
Amounts~2
MBSA-immune~1
MBSA,~1
pre-desensitization~1
(NH4)2SO4~1
nonreduced,~1
MBSA~1
nonimmune/nondesensitized~1
MBSA.~1
region-encoded~1
Q10d/Ld~1
Q10d,~1
Q10+~1
H-2-unrestricted~1
Q10d~3
Q10-containing~1
semisyngeneic~1
anti-Q10d~1
H-2Ld,~1
-D,~1
-L.~1
anti-Q10~1
toleragen~1
self-tolerance~1
monocyte,~3
LPS-stimulated,~1
laboratories)~1
(HrIL~1
pyrogens,~1
Il~2
1-induced~9
HrIL~1
anti-IL~8
HA-releasing~2
non-IgE-related~1
immuno/inflammatory~1
unharmed.~1
immunostimulation~2
(CSF-GM).~1
CSF-GM~1
anti-thymocyte~3
anti-Ly-2.1~1
Ly-2~2
fetally~1
immunostimulatory~4
(MHC)-restricted~1
(NK)-sensitive~1
IEL,~1
Thy-1+,~7
Lyt-2+,~4
CT-1,~1
GM1,~3
indo-1,~1
Conjugate~1
Lytic~1
indo-1-loaded~1
indo-1~2
biexponentially,~1
liters/hr,~2
9.36~1
2,724~1
6.40~2
(Hib).~2
polyribosylribitol~1
lipooligosaccharide~1
Hib~34
PRP,~2
10,000-fold,~1
lipases,~1
Densitometry~1
radioautograms~1
d/y~1
subdeterminants;~1
subdeterminant.~1
reprobing~1
[1,25(OH)2D3],~1
reader,~2
Readers~1
Practice,~1
pleased,~1
reservations",~1
reservations,~1
dissatisfied.~1
implant-driven~1
neuropsychological,~1
cortical,~2
utilisation,~2
medio-frontal~1
(PET)~18
11C-2-deoxyglucose~1
(11DG)~1
PET~39
thiothixene~1
hypofrontality~2
hypofrontal~1
(SIg+)~1
Predictably,~1
1/2+~1
radiopharmaceutical,~1
hexamethylpropyleneamine~2
oxime~4
(99mTc-d,~1
1-HM-PAO),~1
99mTc-d,1~1
HM-PAO~3
N,N,N'-trimethyl-N'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine~1
([123I]HIPDM).~1
Technetium-99m-d,~2
1-HM-PAO~2
(SPECT)~18
cyclotron.~1
Rubidium-82~1
(82Rb)~2
82Rb~8
long-axis,~1
short-axis,~2
display.~2
single-position~1
apicoinferior~1
interpolating~2
interlaced~1
CABG~26
CABG.~5
(2.7),~1
(2.3),~1
(3.1),~1
(11.6),~1
(17.2),~1
(8.7).~1
categorically,~1
(13.9).~1
20.5:1,~1
3-0-[11C]-Methyl-D-glucose~1
(CMG)~1
CMG~2
1.11.~2
inflow;~1
KM~1
VMAX.~1
[18F]-N-methylspiroperidol,~2
butyrophenone~1
neuroleptic:~1
[18F]-N-methylspiroperidol~2
earth's~2
5-G~1
10-G~1
distorted.~1
(MGBPT)~1
99mTc-filled~1
count-threshold~1
0.87x~1
27.4,~1
7.87~1
frames/cardiac~1
endless~1
"beating~1
slices"~1
four-chamber,~1
0.79x~1
0.88x~1
MGBPT,~1
16-frame~1
MGBPT~2
0.74x~1
deadtime~3
cps~1
10/0~4
(Tissucol).~1
hyperfibronectinemia~2
RE~4
organisms),~1
B.W.),~1
Pseudomonas.~1
R.E.~1
units/rat)~1
(908.0~1
55.1~1
(548.5~1
49.9~1
24,011~1
$147,000~1
3.2)~1
21.8)~1
$46,505~1
$38,720~1
(0/3)~1
(0/1)~1
spleen),~1
(53.3%)~1
0-2,~1
(23.1%),~1
B-gene~2
XbaI~1
EcoRI,~4
X3~1
insertion-deletion~3
polymorphism),~1
ID1~2
ID2,~1
(1,2,3,~1
;5,13,21)~1
(centers~1
homes).~1
4102~1
4034~1
2612~1
chemoprophylaxis.~1
shunt-surgery~1
sclerotherapy-treated~2
Thyrostatic~1
methimazole-induced~2
HLA-DR-positive~7
8.3+1.7~1
(+SD)~1
1.0+1.7~1
2.0+1.9~1
12.6+6.4~1
2.9+3.7~1
thyroid-infiltrating~1
interferon-gamma,~2
thyrotropin-receptor,~1
thyrocytes.~1
helper-like~1
suppressor-like~1
reflects,~1
methimazole-treated~3
829,~1
rodents:~1
(MMC).~1
(IL-3);~1
IL-3~19
mast-cell~1
histamine-producing~1
P-cell~1
MMC;~1
safranin,~1
IL-3-dependent~2
CTMC~3
(BCGF),~2
(BCDF),~1
(interleukin-4,~1
IL-4)~1
2.19~4
IL-4~15
BCGF~25
BCDF~2
B151K12,~1
BCL1~12
anti-dinitrophenol~1
DNP-prime~1
B151K12~3
BCDF,~1
BCGF-II~3
lymphokine.~1
monokines~2
(BCDF~1
BSF-2)~1
BSF-2~7
BSF-2.~1
transmission;~1
bullfrog~1
catesbiana),~1
'concentration~1
clamp'~1
encephalitogenic~6
(I-A)~1
(Ala)~1
MBP-specific~2
repertoire;~1
(LAF).~1
collagenase.~2
(3,000-5,000~1
Il-1~3
Ti~11
CD3-gamma,~1
-delta,~1
-epsilon.~1
(interleukin~3
CD3,~2
(detected~2
WT31).~1
(TCR-gamma)~1
CD3.~1
WT31-T~1
CD8.~2
0.2-0.9%~1
thymocytes)~3
WT31-~4
(vWF),~3
haemostatic~1
disulphide-bonded~1
homopolymer;~1
(220K)~1
260-275K.~1
Multimer~1
C-termini,~1
pro-polypeptide~1
pre-pro-vWF~1
subdomains.~1
multimers.~1
Hepatocellularcarcinoma~1
5-50-fold~1
Rearrangements~1
break-point~1
Macrophages,~1
(Ig).~2
(FcRs)~1
FcRs~1
B-cells.~5
macrophage-lymphocyte~1
FcR~3
Ig-coated~1
ligand-activated~1
IgG1/IgG2b~2
47,000-60,000~1
(47-60~1
10K)~1
Ly-17~1
Mls~10
superfamily~4
Ly-17,~1
receptor-deficient~1
Clonal,~1
antibody-secreting~4
antigen-reactive~3
B-lineage~3
(A-MuLV)~1
ras-containing~2
(KiSV)~2
pseudotyped~2
hapten-binding~1
Immortalized~1
immortalizing~4
immortalization~1
(non-transmembrane)~1
nucleoprotein.~2
Haemagglutinin~1
(HA),~1
signal-deleted~2
short-lived,~1
unglycosylated,~1
II-restricted~9
II-bearing~1
I-restricted~4
transfectants~7
NP)~1
HLA-transfectants.~1
Translocations,~1
CpG-rich~1
(pre-B)~1
V-region~3
(VH),~1
(JH)~1
(lambda)~1
VL~1
JL~1
V-gene~5
Joining~1
recombinase.~2
unclotted~1
uncoagulated~1
preclotted~2
catheter-reservoir~2
transcerebral~1
antisiphon~1
erect.~1
spring-ball~1
ASDs.~1
histiocytosis-X~1
98%)~1
fluorodeoxyglucose~2
(FDG),~2
PET,~3
glia.~1
PET-FDG~2
(epibulbar,~1
tarsal,~1
forniceal).~1
(Leu1+~1
OKT8+).~1
(Leu3a/3b+)~1
20-fold;~1
fornices,~1
OKT10~1
Krause.~1
OKT6~2
(la)~1
allying~1
immunoregulated~1
Endophthalmitis~2
Subconjunctival,~1
endophthalmitis.~6
electroacupuncture~1
(i.th)~1
0.25-4~1
flick~1
cross-tolerance~3
i.th~1
spondyloarthropathies,~1
nonrheumatic~5
rheumatic.~1
(20/22).~1
(12/33);~1
(20/30),~1
Discovering~1
Handgun~2
fathers,~1
"accidents."~1
dbl~3
(p66)~1
cDNA-selected~1
transfectant~3
p66~3
dbl.~1
phosphoprotein,~1
dbl-encoded~1
(TS),~1
mitogenesis;~1
EGF-treated~1
EGF-mediated~1
EGF;~2
growth-supportive~1
heparin-sensitive~1
oriS~2
oriL,~1
HSV-1-infected~6
(KOS)~1
oriS.~1
pUC19,~1
(coordinates~5
0.074-0.294),~1
0.294-0.453),~1
0.453-0.641),~1
0.641-0.830),~1
0.0-0.086;~1
0.830-0.865).~1
oriL~1
cis.~1
plasmids,~5
HSV-encoded~1
(ICP8).~1
B-lymphocyte~8
(HIV;~2
lymphadenopathy-associated~5
HTLV-III/LAV)~2
Inhibitors~2
cycloheximide)~1
(pokeweed~1
(Epstein-Barr~1
antigen-mediated~5
T4-positive~3
retrovirus:~1
high-responding~2
(IX:C)~1
responder.~1
IX:C~2
modified)~1
immunocomplexes~1
(env)~2
indirectly.~1
env.~1
(NMES)~1
range-of-motion,~1
strengthening,~1
NMES~5
multiarticular~1
relatively,~2
90-degree~1
unusable.~1
transgastric~2
(0.9%-1.4%).~1
(CABGs),~1
electrocardiographic-gated~1
CABGs~2
beta-lactamases.~8
clavatus~1
(HBcAg).~1
HBc~3
T-cell-independent~1
T-cell-dependent~2
Denaturation~1
nonparticulate~1
HBeAg;~1
immunogen,~1
HBcAg-~1
HBeAg-sensitized~1
HLA-DRw6)~1
(JY:~1
-B7,~1
-DR4,~1
w6)~1
hit.~1
F1-JY~3
centimeter.~1
F1-F1~1
JY-JY~1
(Fos)~1
Fos~5
TCGCGAATTCGCG~1
ISIR~1
(iterative~1
five-stranded~1
"arm,"~1
scissile~1
Arg200~1
Glu144~1
Arg145~1
hexanucleotide~1
GAATTC~1
hexanucleotides~1
cis-active~1
hormone-dependent,~1
enhancer-like~1
(PET),~4
schizophrenia--one~1
(LESS)~2
confidentially~1
(SW).~1
"skin~1
irritation"~1
LESS~1
(scolitron)~1
0.0).~1
surprising.~1
allotransplantation~1
Pretransplant~1
(CsA).~1
CsA;~1
80.5~1
Monolayer~2
monophosphate)~1
(deoxyribonucleic~2
2',3'~1
dideoxyadenosine~1
(ddA),~1
mol,~1
membrane/passable~1
dibutyryl-cAMP,~1
stimulator,~1
ddA~1
Uncertainity~1
surmount~1
inhibitors--the~1
antileucoprotease~4
elastase--PPE)~1
inhibited/mol~2
0-1.19~1
0.10-0.80~1
half).~1
60-70%~1
81m~1
prone,~1
V/Q~4
cranial--again~1
Constraint~1
Bronchodilator~1
Q.~1
revisional~2
(peribronchial).~1
refused.~1
Thermoluminescent~1
Humanoid~1
tomoarthrography,~1
pluridirectional~1
pantomography,~2
mGy,~2
8800~3
mGy~9
Tomoarthrography~1
mGy.~1
polytomography,~1
ScoutView,~1
xeroradiography,~1
ScoutView.~1
tomoarthrography~1
plain-film~2
butterfly-pattern~1
Tc-99m-methylene~1
alae.~1
concentric-ring~1
(SPECT).~4
SPECT,~2
scalloped~1
Myometrial~1
organ-absorbed~2
nephrolithotomy,~1
hydrothorax,~1
pneumonia/atelectasis,~1
nephrostomy-tube~2
dislodgment~1
deaths--one~1
midureter~1
ureterocolic~1
stone(s)~1
disappeared;~1
friable,~1
atraumatically~1
transparenchymal~1
laceration;~1
(endopyelotomy)~1
enormously~2
dual-energy~1
human-chest~1
parallelogram~1
extraventricular~3
flow-void~3
(CFVS)~2
Magendie.~1
CFVS.~1
CFVS~5
Magendie~2
65-77%,~1
Serpiginous~1
"salt-and-pepper"~1
vascular.~2
Multiplanar~1
neuromas,~2
Low-intensity~1
turbulence.~2
Flow-void~1
Hypointensity~1
diffuse.~1
ECG-gated~7
Partial-volume~2
61-100~1
.94)~1
.94).~1
Inter-~1
imagers~2
T2-based~1
tissue-contrast~1
25-35~1
preprostatic~1
cryomicrosections~1
Weibel~1
compartments:~1
parenchymal,~1
peripheral.~1
Heitzman~1
Weibel's~1
Lymphangitic~1
parenchymal)~1
sarcoid.~3
Disruption,~1
pseudofractures~3
scout~3
pseudo-fractures~1
(non-dimensional~1
computer-analyzed~1
(77.8%)~1
4-yr~1
35-65,~1
calcium-supplemented~1
g)(S)~1
0.313,~1
0.353,~1
67).~1
bone-change~1
0.360,~1
BMC;~1
mantle,~1
T-cytotoxic-suppressor~1
(Tcs)~1
9.3,~1
Tcs~2
9.3+~1
9.3-~1
(Ts),~2
Leu-8+~1
PGL.~2
0.59),~1
TH/Tcs~1
1.44)~1
Leu-6+~1
TAC+~1
OKT-10+~1
monoarthritis.~1
enteroarthritis~1
diverse;~1
dehydrogenase)~1
sicker,~1
pyloroduodenal~1
Bouveret's~1
(NSAIDs),~3
Norway.~2
aspirin-like~1
true:~1
NSAIDs;~2
Propionibacterium;~1
acnes.~1
Pleomorphic~1
masquerade~1
cardiotropic~1
(CVB3)~2
CSA-treated~3
T-cell-mediated,~1
C57B1~1
EL4.~1
propofol~29
(2,6~1
phenol)~1
Propofol~6
(split~1
C3d/C3~4
allergologic~1
FEV;~1
FEV.~1
(RDS),~1
antiproteases,~1
alpha-1-proteinase~1
1PI),~1
(CER).~1
(TIC)~1
TIC~6
inhibited/ml~1
unstandardized~1
TIC,~1
RDS,~1
(6/6)~1
(9/12).(ABSTRACT~1
sinobronchial~1
(Kartagener's~1
doublets,~1
spokes~2
beta-lactamases~20
biovariants~2
beta-lactams.~3
penicillins.~2
inducers.~3
(scleroderma)~1
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine~6
(MPTP)~6
MPTP~18
MPTP-induced~6
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine~1
holidays~1
(fast)~1
holidays,~1
hypometric~1
velocity-amplitude~1
dopaminergic-responsive~1
(NPY),~2
adventitia-media~1
(PHM-27),~1
(NKA),~1
PHM-27.~1
(PBPs)~3
electroelution~1
PBP~24
(1b)~2
Pasteurellaceae~1
anti-PBP~1
24,000-molecular-weight~1
[35S]penicillin,~1
PBPs~7
(1a,~1
1b),~1
proportions)~1
kinase-deficient~3
9-[4-Hydroxy-3-(hydroxymethyl)butyl]guanine~1
(3HM-HBG),~1
([+/-]2HM-HBG),~1
cis-9-(4-hydroxy-2-butenyl)guanine~1
(2EN-HBG),~1
buciclovir~2
(BCV~1
[(R)-9-(3,4-dihydroxybutyl)guanine]),~1
anti-herpes~1
3HM-HBG~4
(+/-)2HM-HBG~4
BCV~4
2EN-HBG,~2
2EN-HBG.~1
growth-inhibitory~1
BCV,~1
3HM-HBG,~1
anti-HSV~2
efficacy.(ABSTRACT~1
papulonodular~1
Ki-1~1
activation-associated~1
Tac,~2
T9,~2
Leu-2a.~1
rejection,~17
allogeneically~1
syngeneically~1
[deaths/number~1
mortality)])~1
.0018),~1
.014),~1
.039),~1
.055).~1
valve-conserving~1
.05]),~1
.059).~1
Rereplacement~1
.06)~1
octogenarians~2
(CAB)~1
45-month~2
octogenarians)~1
octogenarians;~1
CAB~4
DVR~1
(August,~1
1978-May,~1
1,089~1
Margaret's~1
Montgomery,~1
(76.5%)~1
13.5%)~1
3.7%)~1
(21/1,089~1
.026),~1
.036),~1
.017),~1
(five-year)~1
.0008).~1
pectoris)~1
well.(ABSTRACT~1
bridging,~1
technician.~1
U/kg.~1
presumedly~1
cells/mL~2
2-L~1
4+)~3
chemoimmunotherapy,~1
1-butanol-extracted,~1
U/d)~1
L3T4+~20
chemoimmunotherapy.~1
BW-B759U~2
virostatic~3
BW-B759U.~1
9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine~1
B759U),~1
Rhegmatogenous~1
B759U~1
scarification~1
lamp.~2
eyewashings.~1
snout,~1
zosteriform~2
eyewashings~1
aminotransferases,~1
grafted,~1
Koebner's~1
collie~2
GM-CSA).~1
Phytohemagglutinin~1
GM-CSA~6
neutrophil-containing~1
endotoxin-treated~1
collies~1
nadir.~1
(IL2),~1
(PHA)-activated~1
HTLV-I-transformed~3
HTLV-I-producing~1
IL2.~3
IL2,~1
IL2-independent~1
"touching"~1
IL2~8
growth-helping~1
Breakpoints~1
7q32-q36~2
.0004).~1
region:~1
1p32,~1
2p21,~1
6p21.~1
1p32~1
6p21~1
protooncogenes,~1
c-L-myc~1
hpim,~1
megakaryocyte-enriched~1
aggregometer~1
Megakaryocytes~1
(ristocetin~1
aggregated)~1
(bovine~1
aggregated).~1
Megakaryocyte~2
(NIF-T~1
primes~2
(f-MLP).~1
5-lipoxygenation~1
dismutase-inhibitable~1
f-MLP,~1
desArg,~1
Thrombocytopoiesis~1
cell-replete~1
nu/+~4
immunothrombocytopenia~2
(APS).~1
Meg-CFC.~1
Hematocrits,~1
GM-CFC,~2
APS,~1
macromegakaryocytosis~1
Meg-CFC~2
APS~1
(NGpS),~1
Sporadic,~1
thrombocytopoiesis.~1
immunothrombocytopenia.~1
Meg-CFC,~1
heavy-light~1
releasate~3
gel-filtered~1
PAI.~1
platelets/mL~1
IU/mL),~1
(S2251).~1
Diisopropylfluorophosphate-inactivated~1
gla-domainless~1
thrombin-cleaved~1
Stimulators~1
(CFU-GEMM)~1
(IL-1),~7
CFU-GEMM~3
lymphocyte-depleted~2
(MCM)~1
(hrIL-1)~1
MCM~5
ROO6B~1
hrIL-1,~1
ROO6T~1
hrIL-1.~1
hrIL-1~2
(rG-CSF)~1
rG-CSF,~1
rG-CSF~1
rG-CSF.~1
(TdT)~3
(V)-joining~1
(CD7+,~1
CD5+,~2
CD1+/-,~1
CD2+/-,~1
CD3-,~2
CD4-,~2
CD8-)~1
TdT~12
T-ALL~15
B-lymphoblastoid~10
Preclearing~1
HLA-DR3,7-positive~1
continuing,~1
non-variceal~1
oesophagogastric~1
'last~1
resort'~1
diffusely.~1
afferences~1
deafferentation-deafferentation~1
diaschisis~2
1160~1
centers:~1
145;~1
87;~1
MANOVA~1
conspicuously~2
88),~1
527),~1
12-O-tetradecanoylphorbol~1
fluoride-sensitive~1
TPA-treated~1
disease-derived~1
monocytic-macrophage~1
lineage;~1
monocytoid~2
non-monocytic~1
monocyte/macrophage-like~1
monocyte-specific~1
(0.018~1
inch,~1
snapped~1
Ahlback,~1
laborers.~1
nonproductive~1
reticular-nodular~1
"prime~1
movers"~1
Kartagener's~2
immotility~1
five-hundred~1
1172~1
snare-wire~1
ensnared~1
(bloody)~1
T8-positive~3
2:1;~1
1:25;~1
gel-electrophoretic~1
DR3/4~1
DQw3-specific~1
17.15~1
alpha-chain.~1
peptide-map~1
(DQw2)-Dq~1
(DQw3)~1
DR3/DR4~2
histones),~1
U1-RNP~2
anti-U1-RNP,~1
hepatitis-associated~1
pan-T-lymphocyte~1
1-antitrypsin-deficient~1
electrophoretograms~1
1-Antitrypsin~3
(0.989~1
0.197),~1
(0.956~1
0.062)~1
(0.818~1
0.12)~1
(RNA/DNA)~1
PiZZ~5
0.225),~1
PiM~5
(RNA/DNA)],~1
(38.48~1
31.93~1
(58.36~1
12.7).~1
Cytolytic~3
icterus.~1
icterus.(ABSTRACT~1
(CRH)~5
restoration.~1
hypercortisolemic~1
weight-corrected~1
weight-restored~1
(VMD)~1
(DE)~1
(QCT).~1
VMD~6
1.14%/yr~1
1.03%/yr~1
Osteoporotic~4
1.62%/yr~1
1.17%/yr~1
99.8~1
mg/cm3,~1
Dispersion~1
intravertebral~2
SEM)/ml~1
39);~1
(28-34~1
20)].~1
(2215~1
(4409~1
1042~1
(353~1
13)].~1
0.562;~1
(70.8~1
0.384;~1
CRH:~1
CRH-sized~2
CRH.(ABSTRACT~1
CRH-stimulated~4
(m)RNA~1
nonactivated~2
Biologically~3
"common"~1
(vWf)~6
gelation,~1
vWf~35
reptilase.~1
Metabolically~1
pro-vWf~3
nonstimulatory~1
hirudin~1
vWf.~4
extract)~1
androgen-receptor~1
Monokine-stimulated~1
burst-~1
configuration).~1
balloon/graft~2
diffuseness~1
MEL-14high~6
emigrants.~3
MEL-14low~5
flow-cytometric~1
suspension-stained~1
MEL-14;~1
Ly-2-~8
nonmature~2
Ly-2+~13
(PNAlow~1
H-2Khigh~2
L3T4+),~1
MEL-14.~1
MEL-14moderate-to-high~1
medulla;~1
suspension;~1
thymocytes;~1
Two-color~1
anti-Ly-2~2
anti-L3T4~2
cloning-efficiency~1
limit-dilution~1
(PTL-p)~1
lectin-enhanced~1
(CTL-p).~1
PTL-p~5
CTL-p~8
PNA-~2
predominantely~1
MEL-14-~5
MEL-14medium-to-high~2
PTL-p.~1
MEL-14+,~1
PTL-p,~1
medium-to-high~1
(Mls)~1
a,~1
Mlsa-~3
Mlsc-specific~3
Mlsc-reactive~1
Mlsa~5
Mlsc~6
Mls-specific~1
Mls-encoded~1
Mlsa-specific~1
stimulators,~1
Mlsa.~1
Mlsd~3
engraftment~9
A-Thy~3
posttransplantation~2
A-Thy----MRL/lpr~1
chimeras,~3
MRL/+~1
(congenic~1
Exocytosis~1
cytolysin-containing~1
(BLT~1
esterase)~1
BLT~1
(Hib)~10
polyribosylribitolphosphate.~1
subclass-specific,~1
"sandwich~1
assay."~1
PS.~2
anti-PS~1
anti-IgG1~1
anti-Hib~2
postpassage~1
chemoimmunotherapy~1
(ACIT)~1
(Renca)~1
ACIT~3
(locoregional~1
bicompartmental~2
Renca.~2
thymocyte-activating~2
(ETAF)~4
ETAF~15
Trypsinized~1
nonconfluent~1
units/micrograms~2
9-12).~1
confluency.~1
146%~1
cytokines,~4
(KTGF)~2
IL-3,~7
KTGF~6
diphtheria-pertussis-tetanus~2
(DPT)~1
(PRP-D).~1
immunizations)~1
PRP-D~5
31.22~1
24.00~1
(NAb),~1
(immunoblots).~1
NAb.~1
NAb~2
HSV-specific~4
HSV.~1
MAbs--H1,~1
H3--were~1
gB~1
(HSV-1~3
HSV-2).~1
MAB~4
protective.~2
H2.~1
(calciferol)~1
hearing-loss~1
(Brookes~1
Morrison,~1
Brookes,~1
Neuro-otology~1
Throat,~1
hearing-loss.~1
Parkinsonians~1
(LVSC)~1
(RVSC)~1
(LVSC~1
RVSC)/LVSC.~1
s.d.),~1
(16/17~1
Re~2
(1+~1
(3+~2
0.700~1
0.821,~1
SPECT.~4
[18F]deoxyglucose~1
motor-sensory)~1
see.~1
110-min~1
TEST-RETEST~1
RETEST~1
[18F]N-methylspiroperidol(8-[4-(4-[18F]fluorophenyl)-4-oxobutyl]-3-me~1
thyl~1
l-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one,~1
mCi/ml,~1
Ci/mumol~1
EOB)~2
10-25%~1
N-methylspiroperidol~1
[18F]fluoride.~1
frame-to-frame~1
nonsubjective~1
sinogram~1
5-methyltetrahydrofolate.~1
decapeptide~2
(+)-inotropic~1
[Sar1Ile5Ala7]AI;~1
[Sar1Ile5~1
alpha-MeAla7]AI;~1
[Sar1Val5N-MeAla7]AI~1
[Sar1Val5Sar7]AI.~1
point-stimulated~1
decapeptides~1
enalaprilat.~3
Sarcosine~1
Acetyl~1
CoA-dependent~1
p-aminobenzoic~1
p-aminosalicylic~2
N-acetyltransferase~1
(NAT)~1
(Bio.~2
87.20)~1
(rr)~1
82.73/H)~1
NAT~4
Bio.~4
87.20~2
82.73/H~2
rr~2
parentals.~1
high)~2
intermediate)~1
genotype-dependent~1
RR,~1
Rr~1
(TENS)~4
TENS~20
thymus-dependent~7
BCG-treated~1
Adoptive~4
Seronegative~1
microliter.~1
OKT4-positive~5
(T4~1
facto,~1
fellatio,~1
methaqualone~1
herpes.~3
6.77~1
19.77~1
abrin~3
B-chains,~1
immunotoxin.~1
immunotoxin~7
internalize~2
bearers~2
bearers.~1
prostaglandin-dependent~2
C3-bearing~2
X5563~9
trinitrophenyl~8
(TNP)-modified~2
TNP-reactive~2
TNP-primed~1
anti-X5563~3
TNP-modified~4
TNP-helper~2
TNP-X5563~1
TNP~6
helpers~3
Naltrexone,~1
S20Y~1
naltrexone/kg,~1
hours/day,~1
31-92%~1
27-49%~1
(10(6)-2.5~1
(39.7~2
delta-~2
kappa-binding~1
mu-binding~1
neuro-oncogenesis~1
A-secreting~1
Co-culture~1
amoebocyte~7
immunoelectrophoretic~2
aorta-coronary~12
exchange-fluid~1
(Audimax~1
Theraband)~1
inaudible,~2
transdermal,~1
Theraband.~1
(BFER)~1
BFER~3
Leukocytic~1
(HLA),~1
3.95).~1
Cw4,~1
B35~1
salt-losing~4
introitus~3
pregnant;~1
menopause;~1
single;~2
virilization;~1
0.002);~1
introitus.~1
virilization).~1
1:20.~1
0.000148)~1
homoeobox-containing~1
segmentally-restricted~1
presages~1
Homoeobox~2
homoeobox~8
Mo-10~1
anellids~1
Xenopus,~2
(HHO.c10)~1
HHO.c13,~1
pentapeptide,~1
homoeo~1
HHO.c13~1
5-9-week-old~1
organ-~2
elements--variable~1
beta)--rearranged~1
(Ek~1
Eb~4
Ev~2
Es~1
81-104~2
c).~1
autosomes,~1
telomeres.~1
pseudoautosomal.~1
Page,~1
Mov-15,~1
germline,~1
meioses~1
(HIV-2,~1
LAV-2),~1
HIV-1,~2
HIV-1-positive~1
LAV)~1
(HSV-I)~1
(LTR),~3
post-transcriptionally.~1
HSV-I.~1
activate.~1
(URR)~1
(BPV)~1
(ORF)~2
URR.~4
E2-mediated~1
URR,~1
(H)PV16~1
nucleotides;~1
E2-URR~1
Somatostatin-like~1
PET.~4
(46.9%)~1
chemotherapy-related~1
34.2%~1
stomatologic~1
myelosuppressive,~1
stomatotoxic~1
[6]~1
pseudotherapy,~1
61/193~1
33/142~1
42/203~1
30/171~1
21/125~1
Pneumocystis,~2
7/205~1
86/187~1
17/109~1
15/25~1
predecessors~1
growth-transformed~2
(IR1).~1
26-base-pair~1
(W0)~1
CAATT-(N)34TATAAA~1
base)]~1
(W1,~1
bp;~1
W2,~1
bp).~1
"unique"~1
62-kDa~2
antiporter,~1
LTK-~3
(LAP1)~1
antiport~4
sorts~1
antiporter-deficient~1
(AP-).~1
LAP1~3
(TK-~1
AP-)~1
cotransformed~1
(TK)~3
TK+~1
transformants,~1
(AP+).~1
AP+~3
donor;~1
cosegregated~1
(glutathione~2
transferase;~2
2.5.1.18)~2
Ya~5
Goldberg-Hogness~1
("TATA"~1
box),~1
TATTA,~1
Exons~1
Yc~5
site),~1
[21-OHase;~1
21-monooxygenase;~1
hydrogen-donor:oxygen~1
(21-hydroxylating);~1
1.14.99.10]~1
(21-OHase~1
21-OHase~8
Y1~1
anthocyanin~2
aleurone~1
mutable~1
c1-m5,~1
Spm.~2
Spm~3
c1-mutable~1
methyl-sensitive~1
c1-m5~1
C1-specific.~1
insertions,~2
Spm,~1
C1-S~1
C1-I.~1
Bz1~1
(BSF-1)~6
lipopolysaccharide-activated~1
IgE-secreting~1
BSF-1~46
anti-BSF-1~2
11B11,~2
11B11-containing~1
11B11~4
IgE-inhibitory~1
T-cell-derived~5
rat-mouse~2
mouse-mouse~2
clonotypically~1
5-7)~1
29-kDa)~1
elsewhere),~1
interleukin-HP1~1
plasmacytoma).~1
H-2b-specific~1
xenoantigens~1
(HTLV-III/LAV),~3
(STLV-IIIAGM).~1
Overlapping~2
STLV-IIIAGM-infected~1
Strongest~1
pol-~1
gag-~1
STLV-IIIAGM,~4
(HTLV-I~1
-II),~1
visna~1
T200~13
subtractive~1
T200+~1
Ltk-~1
1.9-kilobase~3
5.6-kb~1
6.5-kb~1
T200-negative~1
1368-base-pair~1
L16.~1
[Wang,~1
X.-M.,~1
C.H.,~1
Waddell,~1
Wu,~1
3857-3872].~1
Sp2/0~1
alloreactive,~1
H-2Db-specific~1
(3F9)~1
3F9~5
erythrocyte-specific,~1
I-Ab-restricted~1
(LB2).~1
LB2~2
idiotype;~1
(BSF-2)~1
BSF-2-like~1
DNA-nuclear~1
mobility-shift~1
("footprints")~1
strand,~1
-68~1
-92~1
-113~1
-134~1
(III),~1
-136~1
-175~1
extracts)~1
footprints~3
-200).~1
I-hypersensitive~1
Footprint~1
light-inactivated~1
(CKS-17)~2
CKS-17,~1
CKS-17~6
CKS-17.~1
Two-fold~1
pyrene,~1
spared,~1
t(7;9),~1
SUP-T3,~2
q36~1
q34,~2
ABL.~1
t(7;9).~1
ABL~9
SUP-T3~1
rearranged;~1
Pulsed-field~1
v-abl.~1
(ld,~1
sd,~2
polyadenylation-site~1
ld,~1
superfamily.~3
poly(A)-addition~2
3475~1
13-kilobase~1
2-kilobase~2
alpha-trans-inducing~1
(alpha-TIF),~1
alpha-TIF~1
trans-induction~1
(alpha-TIC),~1
alpha-TIC~6
alpha-H1~2
homologs,~1
homolog,~1
5-methylcytosine~1
proposing~1
remethylating~1
5-methylcytosine.~1
dividing.~1
75-kDa~1
thrombin-sensitive~1
tandem,~1
beta-hydroxyaspartic~1
beta-hydroxyasparagine~1
asparagine.~1
beta-hydroxyasparagine,~1
hydroxylase(s).~1
P450c17~10
(steroid~3
alpha-monooxygenase,~2
1.14.99.9)~2
17,20~1
enzyme;~1
128-fold~2
17-mer~1
380-base~1
hac17-2,~1
1754~1
57,379.82.~1
High-stringency~1
1303~1
S1-protection~1
80.1~2
70.3%~1
160-268~1
P450c17.~1
P450c21~3
(28.9%),~1
Crithidia,~1
Endotrypanum,~1
Nei~1
shared.~1
infantum~1
(Q,~1
Coppock-like~2
[logarithm~1
7.58~1
0].~1
crystallin~1
homo-~1
heterotrimeric~1
q24.3----q31~1
q34~1
37,000)~1
42,000)~1
Qb-1.~2
Qb-1~1
histidine-methionine~2
(PHM-27)~1
PHM-27~2
VIP/PHM-27~2
brain--including~1
hippocampus--hybridized~1
PHM-27-specific~2
(Bethesda,~1
Md.)~1
Capabilities~1
angle-petromastoid~1
(CPA-PM)~1
98.7%~1
tympanomastoid~1
Size,~1
cholesteatomas,~1
CPA-PM~1
(0-3.7~1
sultamicillin.~1
(6-11~1
(6-18~1
1:4.~1
(VGF)~1
VGF~4
degree)~1
Regenerated~1
reticulonodular~1
shadowing~1
alveoli;~1
intussuscepting~1
Sugiura,~1
nonshunt~2
(DSR)~1
Sugiura~4
7.2%,~1
gradient-recalled~2
(GRASS)~2
echoes.~3
cinegraphic~1
Turbulence~1
3-17~1
second-echo~7
(43.9~1
(intensity~1
34.0%)~1
first-echo~3
18.7%).~1
(40.3~1
7.4%)~1
(15.0~1
13.3%)~1
17-96~1
radiograph:~2
knob~1
"mass"~1
retrotracheal~1
obscuration~1
venacavograms~1
return:~1
(90-100%)~2
atrium;~2
Ventilation-perfusion~1
venographically~1
macroaggregated-albumin~1
2000-2500~1
35-80~1
bicornuate~6
didelphys~2
septation.~2
Uroradiology~1
nephrotomography,~1
benignity)~1
arbiter~1
gas-producing~1
gas-containing~1
wrists.~1
retinaculum~1
0.15-T~1
Parosteal~1
parosteal~1
facet-dislocation~1
congruency.~1
anterolaterally)~1
convex).~1
laryngomalacia~1
tracheomalacia,~1
imprecise.~1
Endoscopy,~1
(Imatron)~1
Cine-CT~2
cine-CT.~1
cine-CT,~1
upper-gastrointestinal~2
strictures;~1
ulcers;~1
(PTD)~1
post-PTD~1
(41.4%)~1
malformation).~1
(27.6%)~1
T2-~1
"beaded"~1
"communicating"~1
(coiling)~1
(coiled)~1
150-250-A~1
magnetite~2
(Fe3O4,~1
Fe2O3)~1
Magnetite~1
(MAM)~1
MAM/kg~1
T1-/T2-weighted~1
MAM~10
phase-modulation~1
velocity-encoded~1
.999;~1
(12-17~1
0-30~1
obliquities~1
slice-select~1
voxel~2
perpendicular.~1
750/30~1
Philips~1
phase-flow~1
vessels'~1
.977,~1
MR-imaging~1
flow-meter~1
sham).~1
target-to-effector~1
MR-exposed~1
sham-exposed~1
redisplayed~1
lp/mm.~1
4096~2
4096,~1
2048~1
2048,~1
1024~3
1024,~1
512,~1
bits~2
"seeability"~1
discernment~1
usability.~1
lp/mm~2
(2048~1
2048).~1
seeability~1
"immature~1
histiocytes"~1
"monocytoid"~1
parafollicular~2
(28,~1
lobations.~1
Cytochemistry~2
granular,~1
alpha-naphthylacetate~1
focal/granular~1
positivities.~1
Immunophenotypically~1
TH,~3
Leukostix~5
interlot~1
Bio-Dynamics~1
89.4%~2
90.4%,~1
88.8%~1
92.4%.~1
between-reader~1
between-lot~1
68.9%~1
97.7%.~1
pJ3.11~5
(D7S8),~1
.004~1
(.012)~1
71.3~1
(.011)~1
.018~1
(.036)~1
D7S8.~2
Three-locus~1
MET-CF-D7S8,~1
CF-MET-D7S8~1
CF-D7S8-MET~1
161:1,~1
Weaker~2
MET-CF-D7S8.~1
pmetH.~1
members)~1
is:~2
(7cen;p8.33)collagen(COL1A2);DOCR1-917;paraoxonase+~1
++(PON);(MET-cf-J3.11);T-cell~1
(TCRB);qter.~1
against)~1
postzygotic~1
0.359~1
.125,~1
CF-MET-pJ3.11.~1
COL-pJ3.11-CF-MET.~1
BanI~1
pmetD~1
.009;~1
15.45),~1
10.07),~1
6.64)~1
paraoxonase~1
(PON)~1
0.76.~1
Melanesians,~1
Micronesians,~1
TaqI-digested~2
Pacific.~1
Caucasoids.~1
DRw8-positive~1
BglII-digested~1
HLA-class~3
(beta-Glc)~1
5,600,~1
2,500,~1
"epidemic~1
apprehension"~1
numerators~1
denominators;~1
registries,~1
gammaglobulin~2
monoblast~1
gammopathies~5
gammopathies.~2
mm/hour,~1
nonhematologic~1
crackles~1
81.2~1
(41.5~1
nonsurvivors,~1
(51.6~1
Pregestational~1
sialoadenectomy~1
(removal~1
anti-epidermal~1
sialoadenectomized~1
chlamydia-positive~1
200-micrograms/0.1-ml~1
(9-[2-hydroxy-1-(hydroxymethyl)~1
ethoxymethyl]guanine).~1
Wiping~1
remain.~2
(MDD),~1
MDD,~1
self-medication~1
Endogenously~1
nonoxyntic~1
39-57~1
propofol,~5
(Q70)~1
(-15%)~1
(SVR).~1
obtunded,~1
Q70~2
Meyer-Overton~1
isomers,~1
enantiomers,~1
"asymmetric"~1
plane-polarized~1
2-butanol~2
2-octanol~2
tadpoles,~4
(mM)~1
alcohols,~1
2-pentanol~1
0.27;~1
2-hexanol~1
0.079;~1
2-heptanol~1
0.011,~1
0.020;~1
0.0042,~1
0.061~1
0.0032.~1
precious~1
refinery~2
furnace~1
micrograms/M3.~1
beryllium.~1
fume.~1
habitual,~3
144)~1
smoked)~1
pack-years~2
24%),~1
37%)~1
(tests~2
ANCOVA).~1
recoil,~1
(DLCO/VA)~1
(Dm/VA)~1
(Qc/VA).~1
Kst(L)~3
Kst(L),~1
(Kst(L),~1
0.184~1
(4.62~1
ml/min/mm~1
Hg/L;~1
Qc/VA~3
(9.45~1
11.75~1
-0.32,~1
duration-related~1
MHC-restricted,~1
L3T4+,~2
helper/amplifier~1
[3H]thymidine,~1
influenza-virus-infected~1
anti-IL-1.~1
(IL-1).~4
PHA-induced~4
IL-1-induced~8
IL-2-induced~4
angiodysplastic~1
Exacerbations~2
purulence.~1
successes.~1
6315-S,~1
difluoromethyl~1
thioacetamido~1
oxacephem,~1
oxytoca,~3
diversus,~2
piperacillin-~1
cefoperazone-resistant~1
6315-S~3
cefotaxime-~1
moxalactam-resistant~1
freundii,~4
(MICs~3
Clostridium,~1
Fusobacterium,~2
peptostreptococci~1
beta-lactamases,~5
Imipenem~2
Tufts~1
Anaerobe~1
(TAL)~1
carbapenems,~1
cephamycins,~1
TAL2480~1
TAL3636~1
periplasm.~1
Mutants~3
carumonam,~1
derepressed~3
908-Ssi,~1
cefotetan.~1
AMA-R,~1
AZT-R,~1
hypersusceptible~1
Cefpirome~2
penicillinase~4
Richmond-Sykes~1
Va/b~1
cephalosporinases~2
(cephalosporinase)-producing~1
cephalosporins;~1
plasmid-containing~2
transconjugant~1
1037.~1
cefpirome~2
dependently,~2
enzyme-producing~2
cefpirome.~1
(MIEC).~1
MIECs,~1
(MIEC~1
pefloxacin;~1
MIEC~1
doxycycline;~1
charcoal-yeast~1
legionellae.~1
pefloxacin~1
Legionnaires~2
(Clostridium~1
13124).~1
MISs~1
clavulanate-sensitive~1
nitrocephin~1
(Cefinase)~1
trimethoprim-sulfamethoxazole,~6
amoxicillin-clavulanic~1
YTR~4
830,~2
clavulanate,~1
beta-lactams,~1
Anti-Sjogren's~1
antiribonucleoprotein~1
(0.96%~1
drug-prescribing~1
(historical)~1
47,136~1
44,634~1
reassuringly~1
cell-independent~3
Helper~2
17.6%~1
(boys-girls)~1
oppositional,~1
Conduct~1
overanxious~1
prevalences.~2
Pervasive~1
7.3%.~1
PBMCs~3
hydroxyanisole,~1
hydroxytoluene,~1
n-propyl~1
pre-Descemet~1
keratocytes.~1
dysproteinemia.~1
SAC,~1
Pre-irradiation~1
OKT8.~1
cocultures.~1
C4a~3
desarginine,~1
C1s-C1~8
CH50,~1
desarginine.~1
macrophage-bacterial~1
hemocyanin-induced~1
chinchillas.~2
microassay.~1
19F,~1
nontypable~2
influenzae),~1
plantar,~1
Infiltrating~1
HLA-DR-positive,~1
lymphocyte-endothelial~1
(vWd)~1
Veneto~1
1,218~2
1,281~1
IU/dL~1
standard),~1
non-O~1
(1,166~1
gaussian~1
vWd~9
vWd").~1
(0.82%).~1
(0.57%)~1
(1.15%).~1
endomitotic~2
[vol/vol])~1
2.5-fold,~1
endoreduplication.~1
endomitosis,~1
endomitosis.~1
polyploidization~1
1F5~5
(anti-CD20)~1
serotherapy.~1
(1,032~1
(2,380~1
vWF);~1
(BSS)~1
(platelets~2
GPIb);~1
GPIb;~1
GPIIb-IIIa);~1
Sheared~1
vWF-platelet~1
(Blood~1
66:204,~1
VIIa/tissue~8
EPI)~1
3H-factor~1
Xa's~2
Xa,~1
VIIa~1
GY30,~1
GY30~4
(GM-CFU)~1
(CFU-S).~1
(IL-3),~5
IL-2,~13
(M-CSF)~2
G-CSF.~2
CSFs~9
G-CSF~8
Immunologically,~2
Grampian~3
(43.3%~1
49.4%,~1
(38.3%~1
40.6%)~1
remittent~2
(C4,~1
Bf)~1
iridocyclitis,~1
insidious.~1
Intussusception~1
mid-1974~1
mid-1984~1
(CVH)~1
T-suppressor/cytotoxic~3
CVH~3
fortuitous.~1
gla-protein~2
(SBGP),~1
SBGP~7
(uncoupled~1
process).~1
hypercalcemia)~1
coupling-uncoupling~1
[CTCL])~1
U/m2,~1
CTCL,~1
intermediate-,~3
immunomodulator,~1
(CDP),~1
(MTX-CF).~1
CDP.~1
(healing)~1
request,~1
nonosteosarcoma~1
(leukemia,~1
complication).~1
(PGL),~1
(PWM)-induced~2
B-cells,~2
Interleukins~1
(IL)-1~1
PGL;~1
PGL,~2
PWM.~2
"helper"~1
"cytotoxic/suppressor"~1
B-chronic~1
nondiffuse~8
(64),~1
(34).~1
(74)~1
justified;~1
(ST-T~1
9203~1
7818~1
Industry.~1
factor-adjusted~1
cigarettes/day,~1
semi-allogeneic~2
(EAI)~1
(conventionally~1
antisera)~2
RT1-encoded~1
MHC)~3
RT1A~3
RT1B,~1
RT1C~1
(Qa-like)~1
alloantibodies;~1
(pregnancy-induced~1
DMDM~2
hydantoin,~2
trimethyl~2
aqua)~1
releaser~3
quaternium-15~1
ICDRG~1
(ECC),~1
ECC~2
(-114~1
ECC,~1
orosomucoid,~2
Overwhelming~1
Hospital-acquired~1
(BGP)~1
[cortisone~1
BW)].~1
BGP~13
(65.20~1
4.38~1
150.18~2
91.57~1
EGF.~13
pM).~2
56-72%~1
(MABs)~1
Hypopituitary~1
Snell~1
dwarf~2
mU/day)~1
MAB-GC73~3
(35SO4(2-))~1
vacuolation.~1
MAB-GC73;~1
characteristically,~1
24,25-(OH)2D3~5
24,25-(OH)2D3,~1
(LLC-PK1).~1
(kS)~1
[125I]iodo-EGF~8
conceptuses~2
(G-15,~1
G-50)~1
Tris-HCl,~1
1-30~1
[125I]iodo-EGF.~1
mince~3
[125I]MIT~3
temperature-dependent.~2
[125I]MIT,~3
(unlabeled),~1
IL-1-p)~1
Calf~1
(IGF-I),~1
FRTL5,~1
therein.~1
intrathyroid~2
short-loop~1
Aprotinin~4
[125I]hCG~3
aprotinin;~1
aprotinin,~2
hCG-mediated~1
bioassays.~1
(VP),~1
(OXY),~1
pro-ACTH/endorphin-derived~2
(CSFM)~1
VP,~2
OXY,~2
corticotrope~1
content).~1
2-14~2
0.7-fold~1
0.0025)~1
CSFM~5
pro-ACTH/endorphin~2
VP.~1
time-trend~1
post-registration~1
enquiry.~1
bleeders~2
rebleeders~2
finely-tuned~1
medication-antibiotic~1
sulfonamides.~1
factor/urogastrone~1
(EGF/URO),~1
(EGF/URO)~1
EGF/URO~4
EGF/URO,~1
qid~2
6-keto-PGE1~1
microbleeding~5
(integrity~1
indicators)~1
cirrhosis)~1
remission)~2
(histologic~1
remission.(ABSTRACT~1
(EP,~1
(Salmonella~1
typhosa)~1
monophasic.~1
12-65~1
non-cardiac).~1
Fourty~1
93.2%,~1
micro-rheological~1
(RFR).~1
(11.6%).~1
perfusionist~1
(T4).~1
pathology;~1
NKH-1+~1
hyperthyroxinemic~1
189,~2
176,~2
vWF,~5
vWD,~1
plasmin-cleaved~1
vWD.~1
idiotopes,~2
antiidiotypes,~1
antiidiotopes,~1
CDR-1~1
idiotope~9
free-calcium~1
([Ca2+]c)~1
thrombin;~1
mitogenesis)~1
Ca2+-mediated.~1
(400/480~1
cell-covered~1
microcarriers.~2
[Ca2+]c~2
[Ca2+]c,~2
pyrilamine,~1
elastase-alpha~1
PI)~2
people:~1
Moles~1
burning/tanning~1
proneness;~1
608~1
Cedars-Sinai~1
(accounting~1
ruptures)~1
1333~1
39.1%~1
50.7%~1
(22.2%~1
19.5%)~1
(6.0%).~1
In-migration~1
in-migrants~1
year-round~1
diterpine~1
(FK),~1
U266~2
betamethasone.(ABSTRACT~1
HLA-DRw13~2
A/Texas~1
DW19~1
HLA-DRw13.~1
polyclonally~1
PHA.~3
thymocyte-TE~1
(BH11,~1
T2/30,~1
AG3,~1
BC3)~1
Bp35~2
(CD20).~1
anti-Ig-induced~2
anti-Bp35.~1
anti-Ig-~1
anti-Bp35-dependent~1
co-stimulants,~1
BCGF,~2
anti-Bp35~6
anti-Ig.~3
Anti-Bp35~1
BCGF.~3
anti-Bp35:~1
co-stimuli.~1
Dense~1
HLA-DR(bri)~1
(AChR)-reactive~1
BW5147.~1
(alpha,beta,gamma,~1
delta).~1
(EAO)~1
EAO)~2
testis-sensitized~1
EAO,~2
efferentes,~2
intralymphatic~1
Vasitis~1
EAO.~2
IA+~2
F4/80+~1
efferentes~1
Ia+.~1
autoantigens~2
sequestered,~1
orchitis,~1
KLH-primed~3
tolerized~5
TNP-OVA),~1
SIg-~5
TNP-KLH~2
TNP-OVA-tolerized~1
NZB)~1
host-derived~2
anti-ssDNA~2
3.5/10(7)~1
anti-ssDNA-producing~1
1.9/10(7)~1
replica~1
anti-TNP~6
anti-TNP-producing~2
anergy/selection~1
Bp50~8
(CDw40)~1
anti-Bp50~6
anti-IgM,~3
anti-CD20,~1
co-stimulatory~3
BCGF:~1
anti-IgM;~1
Bp50-mediated~1
EL-4~15
C6VLB,~1
clone-specific~2
124-40,~2
C6VLB~5
124-40~4
tyrosine-containing~1
T3-like~1
aminoethylamide~1
(nBSA)~2
(cBSA),~1
cBSA~7
nBSA~8
1H11,~1
"head"~1
C1q,~11
antibody-combining~1
head;~1
C1-inhibitor,~1
biphasic;~1
C1r2C1S2~1
C1-inhibitor.~1
C1r2C1S2,~1
1H11.~1
1H11~3
(Fab)2~1
Plausible~1
strain-~2
macrophages)~3
B10~2
H-2k,~1
H-2u,~1
H-2f).~1
(B10.AKM)~1
H-2u~4
(B10.PL)~1
C2-specific~1
1-regulated~1
(mIgM)~1
WEHI-231~8
(PtdInsP2),~1
second-messengers:~1
(InsP3),~2
(DG),~1
DG.~1
anti-IgM-stimulated~3
DG,~1
(diC8),~1
diC8~1
mIgM-mediated~1
(IFN-alpha)~1
CKS-17-induced~1
CKS-17-mediated~1
cell/target~1
retroviruses;~2
TNF-susceptible~2
TNF-secretion,~1
Wehi~1
mastocytoma,~1
TNF-dependent~1
paraformaldehyde~1
L2C~5
univalent~1
molecules/cell~2
antibody:~1
intra-Ig~1
bridges,~1
("monogamous"~1
inter-Ig~1
("bigamous"~1
(LPC)~1
thymuses~1
(GvHR)~1
alloantigens~1
(anti-receptor~1
lymphocytes;~3
CTL).~1
(PLN),~1
GvHR.~1
anti-D2~2
PLN~2
B6D2F1~16
Thy-1+L3T4+Lyt-2-~1
Thy-1+L3T4-Lyt-2+~1
GvHR~2
wool-nonadherent~1
(FACS-purified),~1
bm1~3
alloantigen.~3
efficiency:~1
nonfractionated~1
mitomycin-treated~1
(L3T4+~1
Lyt-2+)~1
bm1-derived~1
(recombinant)~2
alloantigen-triggered~1
(wild-type)~1
Kb-allospecific~1
B6-derived~2
(EL4~1
RBL-5~1
H-2-allospecific~1
fluorescein-specific~2
prefractionation~1
(EL-BGDF-pik)~1
EL-BGDF-pik~2
(BSF~2
EL-BGDF-pik,~1
BSF~2
filler~3
(HTLV)-III~1
(LAV).~1
HTLV-III/LAV.~2
Gp120/160.~1
(PCE2)~1
PGE2-mediated~2
G2,~3
postdivisional~1
S17,~1
Lyt-1,~3
Ig,~1
Ia,~4
BP-1.~1
units-granulocytes/macrophages~1
post-seeding~1
reseeded~2
S17.~1
Whitlock~1
Witte.~1
S17~3
S10.~1
pan-specific~2
hemopoietin~2
synthesized,~1
1-29~1
123-140~4
64-82~2
91-112~2
Immunoabsorbent~1
1-29,~2
91-112,~2
anti-1-29~1
elution.~1
Anti-1-29~1
anti-91-112~1
Antipeptide~1
WEHI-274.14~1
WEHI-3B.~1
WEHI-3B~1
anti-1-6~1
lymphokines,~3
hexapeptide.~1
cyclosporins,~2
dihydrocyclosporin~1
nonimmunosuppressive~1
(PHA)-induced~1
2-induced~4
([Ca2+]i),~1
cyclosporins~1
T'~8
H-2k-bearing~1
B10.AQR~1
B10.A~11
(anti-Kk),~1
R1.1~1
H-2d-bearing~1
(anti-H-2d).~1
pseudo-second-order~1
(E-IgG)~1
(EAC3b)~1
iC3b~1
(EAC3bi),~1
E-IgM,~1
(EAC14),~1
(EAC3d),~1
Rosetting~1
HSV-1-induced~3
CR1-like~1
CR3-like~1
EAC3bi.~1
5C11~1
EAC3b~2
EAC3bi~3
anti-Forssman~1
(EA-IgG).~1
C1q-mediated~2
C1q-coated~1
anti-C1q.~2
FcR-mediated~3
EA-IgG.~1
N-formyl-methionyl-leucyl-phenylalanine-stimulated~1
non-opsonic~1
anti-angiotensin~1
(A25)~1
anti-AII~3
site-associated~1
idiotope.~1
CRI+-antibody~1
(A41),~1
anti-CRI~1
detergent-treated~1
CRI+~1
(A22).~1
Anti-idiotypic~2
[3H]LTB4,~1
[3H]N-formylmethionyl-leucylphenylalanine~1
(fMLP),~1
[3H]LTB4~1
(B6/MEF)~1
SV40-specific~2
H-2b~3
because:~1
recrudescent~1
(UV-HSV)~1
(dialyzable)~1
UV-HSV-stimulated~1
Dialyzable~2
OKM1+,~2
OKT8+,~1
OKIa+~1
sulfate-acrylamide~1
eosinophil-mediated~5
metazoan~1
IgG-dependent~1
Clq.~2
10(7),~1
10(7).~1
(38C13)~1
(Id)-specific~1
complex-restricted~7
thymus-derived~3
receptor-bearing~1
(C3.CBA/N)~1
C3.CBA/N~8
thymus-independent~4
TNP-Ficoll,~2
TI-type~2
TNP-Brucella~1
PC-KLH,~1
CFA;~1
anti-PC-KLH~1
anti-TNP-KLH~1
phenol-extracted~3
disrupted,~2
impairment;~1
(LSLC),~1
LSLC~8
Trinitrophenyl-ovalbumin~1
intraportally~2
antigen-pulsed~1
1-containing~1
Ig-secreting~5
rTNF-mediated~2
CESS~1
Combined,~1
PWM-induced~1
Cross-reactive~3
Id-anti-Id~8
liquid-phase~2
None,~1
nonautologous~1
Id.~1
diverse,~1
virus-~1
IgA1;~1
IgA2.~3
IgM+~3
(sIgM+)~1
sIgM+~3
IgA2-producing~2
IgA1-~1
IgA1-producing~1
MBP-induced~1
(REAE)~1
(SJL~2
PL)F1~1
MBP-P2~1
Lyt-1+~3
acute-stage~2
R-EAE~1
35S-methionine-,~1
[3H]leucine-,~1
chromatofocusing.~1
m.w.)~2
co-mitogenic~2
co-eluted~2
Fluorography~1
(32,000)~1
pro-IL~3
immunostimulating~1
(Pam~2
212)~2
EC-derived~1
(EC-derived~1
contra-IL~1
[EC-contra-IL~1
1])~1
EC-contra-IL~3
P388D1,~2
929,~1
immunoenhancing~1
Cytokines~1
(LT).~1
osteoclast-activating~1
(OAF)~1
bone-resorptive~1
additive).~1
Synergy~2
synergy,~1
OAF.~1
(OA)-specific~1
BDF1~9
glycosylation-inhibiting~2
(GIF)~1
GIF.~2
OA-pulsed~2
GIF~23
OA-specific~9
anti-lipocortin~1
I-Jb~2
15,000.~1
anti-hapten~4
(DNP-OA),~1
DNP-KHL-primed~1
GIF,~1
carrier-specific~3
phospholipase-inhibiting~1
TsF.~2
Framework~1
F1)~1
(PBL).~2
solubilizing~3
"hidden"~1
T3+~6
alpha',~1
alpha")~1
HPB-MLT~1
anti-Leu-4~3
(anti-T3).~1
non-alpha,~1
L24~1
L25.~1
II-specific~2
Anti-L24~1
Anti-L25~1
(II1/D1)~1
(IgM,~2
lambda)~1
II1/D1~5
(c-C1q),~1
AKR/Gross~1
multi-gene~1
AKR.H-2b~3
AKR.H-2b:Fv-1b~4
"doubly~1
congenic"~1
anti-AKR/Gross~2
MHC-encoded~5
Fv-1n~3
B6.Fv-1n~1
congenic,~1
Fv-1n-mediated~1
AKXL~1
Akv-1~1
provirus,~2
production:~1
CTL-defined~1
K1-expression~1
Basilea,~1
K1b9~1
14-kb~1
6-kb~1
copy,~2
(Cys)-immunosuppressed~1
Suspended~1
15-50~1
cm3/day,~1
(TAA)~1
subcarcinogenic~1
(UVR).~1
Foot-pad~1
UVR-exposed~4
(DLN).~1
UVR-induced~5
DLN~1
non-UVR-exposed~1
UVR-~1
splenocytes.~1
TAA.~1
Keratinocytes~5
dispase/trypsin-derived~1
subcultivated~1
lapin~1
H2O/100g~1
trichomoniasis~1
Trichomonas~4
mount,~1
trichomoniasis.~1
Diamond's~1
vaginalis.~4
trichomoniasis,~1
(cfu)/ml.~1
cfu/ml.~2
gp160~2
p55.~1
ampullae~1
osmium.~1
Crosslinks~1
displayed:~1
stereocilia,~2
bundle;~1
upward-pointing~1
stereocilium~1
stereocilium;~1
thirdly,~1
upwind~1
(EGF),~4
662.4~1
182.8~1
(SCCHN).~1
(induction)~1
(PBM)~2
PBM.~1
failure-free~2
(mycosis~1
cerebriform~1
19+).~1
anterior/apical~2
thallium-201,~1
vertical-long,~1
horizontal-long~1
diethyldithiocarbamate~2
([201TI]DDC)~1
[201TI]chloride.~1
[201TI]DDC~2
[201TI]chloride~1
201TI,~1
multidetector~1
(PnAO)~1
d,l-diastereoisomer~1
hexamethyl~1
propyleneamine~1
(HM-PAO)~1
d,l-HM-PAO~1
99Mo/99mTc~1
[99mTc]d,l-HM-PAO~1
(alleles~1
allotypes)~1
103)~2
-DR,~1
Kidd,~1
MNSs,~1
Gm(a;..;g,s,t)~1
HLA-DR8~1
two-locus~1
psychedelic~1
methylenedioxymethamphetamine~1
(MDMA),~1
p-chloroamphetamine.~1
(+)-stereoisomer~1
fluoxetine,~1
fluoxetine~5
O-ethyl~1
S-[2-(diisopropylamino)ethyl]methylphosphonothioate~1
(VX),~1
organophosphorus,~1
(anti-ChE)~1
VX,~1
EPC)~2
(EPC),~1
VX~3
EPC~4
(MEPC).~1
MEPC~2
potential-evoked~1
MEPCs~1
depolarization-evoked~1
MEPCs.~1
anti-ChE~1
conductance.(ABSTRACT~1
(DAS).~1
DAS~4
DAS.~1
sulfoconjugation~1
2,6-dichloro-4-nitrophenol,~1
sulfotransferase,~1
sulfoconjugation.~1
plexus-longitudinal~1
26-33~1
(Squibb)~1
Calmette-Guerin.~1
irritability)~2
co-morbidities.~1
volume-outcome~1
18,986~1
multiple-regression~1
Higher-volume~2
mix);~1
"non-scheduled"~1
stays.~1
temperature-related~1
leopard~1
Lucke~3
poikilothermic~1
frogs~2
temperature-mediated~1
N-butyl-N-(4-hydroxybutyl)~1
3817-11-6].~1
BBN-treated~1
"glue"~1
leaks)~1
glue-treated~3
Cardioplegic~1
venting,~1
(39%);~1
hospital);~1
7.65~1
bypass:~1
97%)~1
86.4%).~1
procedural-related~1
eventually.~2
1,980~1
12.0%.~1
(HIV-I)~1
anti-gag~1
(p24)~2
anti-env~1
HIV-I.~1
1982/3~1
1985/6.~1
HIV-I-infected~1
anti-p24~3
radioimmunoprecipitation.~2
anti-gp41~1
titre.~1
AIDS/ARC.~1
Thromboangiitis~1
(TAO),~1
TAO~1
[18F]fluorodeoxyglucose~3
(chorea-free)~1
58).~1
(33.9~1
agammaglobulinemia--i.e.,~1
agammaglobulinemia~1
1,2).~1
K),~1
Genes~1
MHC,~1
congeneic~1
intra-MHC~1
NotI~2
'jumping~1
library'~1
NotI-cleaved~1
(PFG)~1
walk,~1
('NotI~1
clone')~1
(A.-M.F.~1
T.P.,~1
non-responsiveness~1
peptide-MHC~1
('holes')~1
Protein-tyrosine~1
growth-factor~1
(reviewed~1
6-8).~1
protein-tyrosine~3
phosphotyrosyl-proteins~2
Eukaryotic~1
(AMV~1
well-translated,~1
message,~3
barley~1
(IL-1~4
AMV~2
35-fold~2
efficiency;~1
AMV-mRNAs~1
machinery;~1
Untransformed~1
(Ti;~1
molecules)~1
(CTL),~3
(IFN-gamma)~4
signalling,~1
signal-transduction~1
Ti/CD3~1
Ti.~1
Ti-~1
non-transformed,~1
T-cell,~4
Ti/CD3-mediated~1
T3-positive~1
T3-negative~1
corecognition~2
antigen-Ia~3
phosphodiesteratic~1
phosphatidyl-inositol~1
comessengers~1
(Ins(1,4,5)P3)~2
Rubin~1
32P-Ins(1,4,5)P3~1
3H-~1
100-300~1
C14,~1
Neurostimulation~1
neurectomies~1
T-6.~1
hyperreflexic~1
Radiofrequency-coupled~1
neurotomy.~1
menorrhagia.~1
ganciclovir.~5
antiCMV~1
ventralis~1
posterolateralis~1
adrenocorticotrophic~1
thalami~2
asymmetries.~1
68/100,000~1
h/wk~1
Outer~1
6U~1
anthropometrics,~1
endorsing~2
folate),~1
(gamma-glutamyltranspeptidase),~1
47S~1
endonucleolytic~2
+650~1
+650.~1
mouse/human~2
P-450ALC,~1
N-nitrosodimethylamine.~1
immunoscreening,~1
hybridization-selection.~1
1416~1
3a.~1
56,820.~1
p3a-2~1
3a,~1
subfamily.~1
dnaB~5
pUB110.~1
(dnaBI~1
dnaBII)~1
mutants;~1
dnaBI~4
pUB110~1
dnaBII~3
dnaBII,~1
DnaB~2
transcription-translation~2
[35S]cysteine.~1
"dnaB~1
dna~1
S-adenosyl-L-homocysteine~1
(AdoHcy)~1
(adenosylhomocysteinase;~1
3.3.1.1).~1
AdoHcy~2
dinucleotide-binding~1
244,~1
Gly-Xaa-Gly-Xaa-Xaa-Gly~1
219-224,~1
"pro"~1
fibronectins~1
(deminectins)~1
fibronectin-deminectin~1
deminectin~1
fibronectins.~1
(transfectants)~1
C3H/101/2~1
Rat-2~2
(oncogene)~1
radiation-transformed~1
Ki-ras,~1
Ha-ras,~1
neu,~1
trk,~1
raf,~1
abl,~1
fms,~1
x-ray-transformed~1
(IL-1)-producing~1
subclone~6
(EBV)-containing~1
(721~1
LCL)~1
84.5,~1
LCL~5
721/84.5~2
3B6,~1
3B6~2
3B6-derived~1
13,500,~1
HSB2~1
anti-monocytic~1
(IgE-BF)~1
IgE-BF~9
IgE-BF,~1
lectin.~3
OX3.~1
carbohydrate-attachment~1
(IL-2)-dependent~2
"IL-2~1
line,"~1
HT2,~1
BSF-1-secreting~1
processing;~1
sprains.~1
Thigh~1
(stimulated)~1
single-leg,~1
vertical-leap~1
Blood-flow~1
(Y-grafting)~1
competitive.~1
cI~1
I-Ed~4
I-Ed-restricted.~1
by)~1
repressor-derived~1
nonself~1
alloreactivity.~1
(chi)~1
chi,~1
transactivates~1
regulator.~2
transactivation,~1
-II~1
LTRs.~1
M-MuLVs~1
transactivating~1
Palm~1
Beach~1
Transmitted~1
ducreyi,~1
(generally~1
Trimethoprim-sulfamethoxazole~3
(Hounsfield~1
vanished~2
dedicated,~1
Photon~1
Emission~1
Tomograph~1
(massive~1
luxury~2
perfusion)~3
(rCBF),~1
(rOEF),~1
(rCMRO2)~1
(rCBV)~1
15O~1
multi-slice~1
rCBF,~1
rOEF,~1
rCMRO2~3
rCBV~1
supratentrium,~1
OEF~2
age-dependent.~1
angiographical~1
(Diamox).~1
non-occluded~1
("positive"~1
"steal"~2
("negative"~1
oxygen-15~1
(diameter,~1
Sephadex)~6
hypocapnia,~1
123I-isopropyl~1
C15O2~1
15O2.~1
"central~1
area,"~1
periinfarct~1
"peripheral~1
area"~1
hypofixation~1
H-9,~1
source;~1
(LAV)~1
Institutes'~1
CEM-F.~1
(BFP)~1
BFP~1
BFP.~1
BFP,~1
(SLE)-like~1
IgM),~1
1-antichymotrypsin~1
anti-cathepsin~1
autosomal,~1
antiprotease,~1
(antiGBM)~2
paraureteral~1
organism),~1
nonduplicated~1
nonduplex~2
partial)~2
(PAO2/FlO2)~1
min/L,~1
PAO2/FlO2~1
1.08,~1
ARDS-associated~1
Townships~1
(number)~1
nodules),~1
coalescence,~1
coalescence.~1
thymus).~1
involuted~1
compressibility.~1
Phototiming~1
(39/42),~1
(12/12),~1
(51/54),~1
capsulelike~1
counter-rotating~1
resonators~1
crest,~1
hernias:~1
fracture)~1
portrays~1
postincisional~1
0.1-mm~1
microfocus~1
x3~1
x5.~1
Gray-scale~1
high-kilovoltage,~1
short-exposure~1
high-pass~1
latitude.~1
2DFT~2
cryosection~1
labyrinthine,~1
tympanic,~1
oligodendroglioma,~1
(considered~1
roof)~1
fracture's~1
Floor~1
(body)~1
"fat"~2
refocused~1
2000,~1
nonhomogeneity,~1
Two-sec~1
SVBG~3
96.16~1
months/patient.~1
1.2%/year~1
3.4%/year~1
LAD.~1
bepridil~6
bepridil,~1
(276~1
(268~1
(251~1
(216~1
(723~1
(403~1
(288~2
(271~1
(290~1
ST-~1
T-segment~1
Redilation~1
redilation~1
Infection.~1
1,2a,3a,7~1
D1/12~1
(against~1
Dr~1
molecule),~1
"5/9,"~1
31-yr-old~1
panendoscopy,~1
colon-fiberscopy~1
cholangiopancreaticography~1
bleeder~1
hematogenous.~1
uveitis:~1
chamber;~1
mutton~1
keratic~1
spondyloarthropathies.~1
pucker.~1
(26.5%),~1
(10.2%),~2
(8.2%),~1
[11C]-deoxy-D-glucose~1
enflurane-fentanyl~2
endanger~1
beta-blocked~1
(D5W).~1
(SNP).~1
esmolol-treated~1
Acetylation~1
PA-induced~1
3-5-year~1
pharyngeo-tracheal~1
(PTL)~1
PTL~4
airway's~1
1AT)~3
1AT~29
"threshold"~1
"protective"~1
mg/d-1600~1
pyelonephritis;~1
Serotyping~1
4.0-mA~1
reaggregated~1
vidarabine,~1
bromovinyldeoxyuridine,~1
9-(1,3-dihydroxy-2-propoxymethyl)~3
Vidarabine~1
postinfection.~2
(Le~1
IF-AD)~1
IF-AD.~1
Postinfection~1
IF-AD~1
mg/1.73~1
nonrenal)~1
(CLCR).~1
CLCR.~2
30:1~2
inhibitor-based~1
7,775~1
15-8074~3
2-to~1
(P99,~1
K1,~2
K14,~1
TEM,~1
CARB).~1
Octanoic~1
Chain~2
Emulsion~1
hydroxybutyrate~1
acetoacetate~2
16-50%~1
cross-clamp.~1
(2.31~1
1.86)~1
44),~1
dual-phase~1
incrementally~1
(CK)-MB~1
refunction~1
(D-100)~1
D-100~2
D-50~1
atheroma,~1
18-F-fluorodeoxyglucose~1
region/whole-brain~1
cortical-subcortical,~1
antero-posterior,~1
subcortically,~1
"hypofrontality"~1
cortical-subcortical~1
18-F-fluorodeoxyglucose.~1
Laterality~1
(right-left)~1
subcortical-cortical~1
TENS.~4
36.2C~1
36.6C~1
nonsurviving~1
(SIS)~1
(alpha-1-acid~1
glycoprotein)-6~1
(sepsis~1
score).~1
SIS~2
Harbor/UCLA~1
Torrance,~1
(skin,~1
(10/21).~1
(4/7),~1
(6/14).~1
IL-2-dependent~2
CTLL-2.~1
5.2%),~1
5.5%),~1
(41.6%~1
6.4%),~1
95%),~1
23.8%)~1
Iofetamine~1
iofetamine~1
ocularly~1
Draize~1
ended,~1
(6/20)~1
(0.5/3)~1
(13/20~1
2.3/3,~1
(1.5/10)~1
(3.4/10).~1
(6/10).~1
locus),~1
B27,~2
sacroiliitis,~2
HLA-B27,~1
sacroiliitis.~1
arabinosine,~1
Liped~1
twenty-fourth~1
SS-B~1
(La)~1
illicitly-manufactured~1
brews~2
Lone~1
(86%);~1
hepatomegaly;~1
world.(ABSTRACT~1
ampicillin-resistant,~1
cefixime-treated~2
(anti-Ro).~1
(23/33)~1
expanding)~1
(PPH)~1
PPH~2
Primiparity,~1
amniotomy/oxytocin,~1
syntometrine~1
(oxytocin~1
ergometrine~1
maleate),~1
oxytocic,~1
re-emergence~1
p21-p22~1
"lymphomatous"~1
ALL)~2
immunophenotype.~1
9p~4
.62).~1
(t[4;11]),~1
(TC-1)~1
TC-1~1
(GM-CSA)~3
(murine~1
lung-conditioned~3
media).~1
synergized.~1
CSF-1-dependent~1
3,000),~1
30')~1
DE-52~1
G100~1
elutes~2
mannoside,~1
cell-inducing~1
non-IL~1
DA-1.~1
GM-CSA,~2
lymphohemopoiesis.~1
(CTCL).~1
T-stage,~1
CTCL~5
T2/T3~1
.051).~1
cell"~3
microns]~1
.009).~1
.074),~1
(des~1
A,B~1
fibrinogen)~1
(a2b2~1
tetramer)~1
gamma-thrombin~3
Catalytically~2
i-Pr2P-~1
D-Phe-Pro-Arg-CH2-alpha-thrombin~1
(a2~1
a2~2
b-chains,~1
XIII.~1
a2b2~2
b-chains~2
cocomplex~1
alpha-thrombin,~1
a-chains.~1
(Ep)~1
monocyte-conditioned~2
(MoCM,~1
BPA)~1
(MNC-T),~1
(nonadherent~1
NAB)~1
(NAB-T).~1
phi,~4
MNC.~2
MoCM~2
abrogation~3
NAB-T~3
NAB,~1
MNC-T,~1
NAB-T.~1
Ep~1
BPA;~1
(TTP)~1
sera-induced~2
IgG-immune~2
complex-induced~2
TTP.~1
(vWF)-rich~1
Australian-born~1
sclerodactyly~1
ACA-positive~7
ACA-negative~6
extra-oesophageal~2
CREST',~1
Ankylosing~2
punched-card~1
cheaply,~1
9-(1,3-dihydroxy-2-propoxymethyl)guanine~4
Lethal~1
(LMG),~1
relentless,~1
LMG~2
"novel"~1
immunotyping~1
LMG,~1
tartase~1
(TRAP)~1
kappa.~1
polyclonal,~2
lymphoproliferations~1
(PBLD)~1
PBLD~2
hyperplasia/lymphoid~1
(PLH/LIP~1
virus-type~2
technetium-99m-stannous~1
(99mTc-PPi)~1
99mTc-PPi~6
photon-emission~2
.89)~1
.98).(ABSTRACT~1
(PGD),~1
OKT~4
(MCNS),~1
(MPGN)~1
MCNS,~2
PGD,~1
MPGN,~1
PGD.~1
"Breakthrough"~1
preseptal~1
cefaclor.~2
[MBC]~1
hypoparathyroidism.~1
[25-(OH)D]~1
25-(OH)D3~2
25-(OH)D3,~1
25-(OH)D~1
mmol/l.(ABSTRACT~1
(CXR)~2
40/80~1
trypsin-inhibiting~1
(TIC),~1
elastase-inhibiting~1
(smokers'~1
-0.37;~1
Open-Heart~1
(OM)~1
Center:~1
OM,~1
OM~1
11.57),~1
stenoses)~1
5.81),~1
5.54),~1
5.17),~1
4.78).~1
Activity-initiated~1
(17%,~1
tolazoline,~1
co-trimoxazole,~1
alpha-IL-1~1
GLUT)~1
1p31.3----p35~1
GLUT~1
1p33.~1
peptidelike~1
(CGRP-LI)~1
CGRP-LI~5
99mTc-iminodiacetic~4
(6-10~1
'obscure'~1
melaena~1
(34),~1
non-vascularized~2
isografts,~1
spicules~1
new-bone~1
antidouble~1
T3-suppressible~2
T3-nonsuppressible~2
(10-19~1
glucocorticoid-sensitive~1
CEM~1
([3H]DEX).~1
pyrazolosteroid~1
[3H]cortivazol~1
([3H]CVZ)~1
[3H]CVZ~5
4.6S~1
CVZ~3
[3H]DEX~1
96,000~4
[3H]CVZ-receptor~1
Mevinolin,~1
mevinolin~2
5/12-15~1
1/12~2
IV-V~1
8/12-15~1
6/12-15~1
5/12~1
mg/4~1
im).~1
(Cluster),~1
ng/mL;~5
0.012),~1
amplitude-modulated~1
boys)~1
(Cortrosyn,~1
4244~1
1113~1
ng/dl].~1
5-17-hydroxypregnenolone~1
5-17P)~1
5-17P/17-OHP~1
5-17P:~1
1543~1
dehydroepiandrosterone:~1
5-17P/17-OHP:~1
pubarche.~1
Antipituitary~1
Bw58,~1
DR5.~1
(TBCa)~1
nonosteoporotic~1
[7.8~1
ng/mL]~1
(898~1
806~1
regrouped~1
21-Deoxyaldosterone~2
21-deoxyaldosterone~4
21-deoxy~1
(CT)/CT~1
CALC-I~2
CGRP-I~1
CGRP-II~3
CALC-II~4
Ewing~2
CGRP-II,~1
IARC/EW~1
CALC~1
cells/well)~3
(PMC;~1
10,000/well)~1
PMC,~3
(hTg),~1
helper-induced~1
(CD4+/4B4+)~1
(CD8+)~1
autocytotoxic.~1
autoreactive.~1
thyroid-specific~1
(antibodies),~1
intragenomic,~1
3'-flanking~2
e.~1
(PGE1)-associated~1
autoimmunity,~3
(SRTA).~1
SRTA-reactive~1
10-micrograms~1
3I,~1
40),~1
tuberculins~1
Dundee~1
Synacthen~2
microanatomical~2
induration,~1
periappendicular~1
I12~1
hypersensitivity)~1
51Cr-albumin~4
problematical~1
polycythaemia.~2
helper:suppressor~2
haemagglutination;~1
arthropathies,~1
75.4%~1
73.9%~1
haemagglutination,~2
5.40~1
4.56,~1
Mycosis~1
multistaged~1
13-6298.~1
arotinoid.~1
Pityriasis~2
lichenoides~9
varioliformis~5
acuta~4
chronica.~1
(HLA)-DR+~1
CD1+~1
HLA-DR+.~1
killer/killer~1
chronica,~1
acuta,~1
interrelated.~1
ANAs~4
pre-PUVA~1
269)~2
post-PUVA~1
pre-PUVA--positive~1
"spontaneous~1
suppressor"~1
(SSCA).~1
(OIs)~1
SSCA~3
OIs~1
soybean,~1
peanut-sensitive~1
legumes.~2
Cross-allergenicity~1
peanut,~1
pea,~2
soybean.~1
hypoallergenic~1
azobenzenearsonate~1
(ABA).~1
ABA-reactive~1
(TNP)-coupled~1
stratagem~1
ABA-specific~1
(E9).~1
E9~4
cells/mouse~1
footpad)~1
Ts.~1
Th,~3
Th-dependent~1
anti-immunoglobulin~4
(anti-Ig).~2
(TNP)-binding~3
TNP-carrier~1
anti-Ig,~1
serine.~1
TNP-specific~4
(KLH)~3
KLH.~3
HTLV-III/LAV-induced~2
PBMNC,~1
(Meg)~1
(MCM),~1
(ECM),~1
(ECMM)~1
(ECMrIL~1
ECMM~3
ECMrIL~2
Meg,~1
mixed-cell,~1
ECM,~1
MCM,~1
BPA,~1
Meg-CSA,~2
Meg~1
megakaryocytopoietic~1
Meg-CSA~1
2-activated~15
(IAK)~1
IAK~5
2-induced,~1
(EC).~1
EC.~7
sublineages~1
NKCF-containing~1
rLT~6
51Cr.~2
Na2CrO4~1
Anti-TNF~1
(sixfold~1
170-fold)~1
DRw13~7
DR-restricted~1
COT~6
beta-chains,~1
6B5,~2
6B5~3
6B4~3
6B3.~1
6B3~1
ILR2,~1
7.3.19.1,~1
6B3,~1
104.~1
A.E7~1
helically~1
isoleucyl~1
solvents.~1
helix-breaking~1
A.E7.~1
(B3B4)~1
R+~5
B3B4~9
49-Kd~3
B3B4,~1
F(ab')2-B3B4~1
Fab'-B3B4~1
ligand-specific~1
upregulation.~1
8/1~6
dual-parameter~1
Dual-parameter~1
(C1-INH).~1
C1-INH,~2
C1-INH:~1
spermine.~1
C1q-bound~1
C1r.~1
anti-CL~1
poly(ADP-ribose)~3
[14C]nicotinic~1
[14C]nicotinamide~1
[14C]NAD~1
3-aminobenzamide~1
(3-ABA),~1
3-ABA~1
deoxycoformycin~2
non-circulating~1
anaphylatoxin-dependent~1
U-46619.~2
S1/S1d~1
muscle-containing~1
anaphylatoxins,~1
Cytokine~1
co-stimulation~2
leishmania-preinfected~1
proteose~1
intracellular,~3
Elicited~1
preinfected~1
macrophage-dependent~1
evasion~1
Lyt-1+,~3
L3T4a+~3
self-class~1
(CGG)~1
anti-I-Ab~1
3JP~1
CGG-specific~2
Autoreactive~1
(RIL~1
RIL~3
anti-FcR~1
anti-B16~1
(chloroquine,~1
iodoacetamide)~1
iodoacetamide~1
4.0%,~2
T-prepared~1
solarium~3
half-hourly~1
Leu-11~1
wave-length~1
subcorneal~2
non-psoriatic~1
leukotactic~1
nonpsoriatic~1
PLF.~1
Zairian~1
HTLV-I-~1
live,~1
antibody-neutralization~1
Keratinocyte~1
IFN-alpha.~1
culture-proven,~1
cell-suppressed~1
pinna,~1
"fingerprinting"~1
STD~1
histamine-2~1
cimetidine's~1
units/10(6)~1
(LU)~1
LU~1
effector-target~1
conjugation)~1
cimetidine-exposed~1
B-CLL.~2
Hyperestrogenemia~1
cold-stored~1
(hues)~1
brightness.~1
greys~2
achromatopsia,~1
account)~1
specialisation~1
specializations~1
(IMP),~1
particles/micron2~1
P-faces~1
150/micron2~1
E-faces.~1
paranodal-like~1
500/micron2)~1
('heminodal')~1
axolemma~2
morphologies.~1
heminodal~3
1,100/micron2),~1
E-face~1
(CL-A;~1
synonym~1
BA)~2
OKT3-,~1
OKT8-positive~4
CL-A~4
OKT3-positive~2
0.014);~1
0.171).~1
0.029),~1
OKT3-~2
0.342)~1
0.443)~1
0.031);~1
0.156~1
0.281).~1
(IL-2),~4
dex,~1
dex.~1
abrogated,~1
morphine;~1
PAG-PVG~9
cross-tolerance.~2
Cross-tolerance~1
(RTB)~1
RTB~4
tagging~1
131I-TB~1
radiotracer,~1
hyperplasias)~1
Maximum-count~1
201TI~3
rest-redistribution~2
maximum-count~1
ISs~1
count-based~1
IS.~2
(QOV)~1
QOV~1
FWHM~1
nCi/cc~1
dog-sized~1
torsos.~1
(Gm)~1
Gm(1,2;21)~2
cytofluorograph~1
(OKT~1
(OKT8+~1
cells/mm3)~1
lymphocyte/T~1
(OKT4+:OKT8+).~1
OKT4+:OKT8+~2
(activated)~3
herpetiformis,~2
gluten.~1
piroxicam.~3
collagen-like,~1
Nanogram~1
enzyme-generated~1
(MLR).~2
MLR,~1
anti-C1q~1
Nathan's~1
Agar~1
(NAWD)~1
NAWD~5
60.0%~1
nitrofurazone~1
mafenide~1
92.8%~1
72.0%~1
toxoids~2
inferential~1
pertussis-~1
DTP-associated~1
pertussis--115~1
encephalopathies--were~1
1311~1
casually~1
MOLT3~1
polyadenylic~1
[poly(A)]~1
Cordycepin,~1
OKT11A~1
cordycepin,~1
tumor-neutralization~1
immunosurveillance~1
(IgAN)~2
agematched~1
IgAN~4
[macroscopic~1
(URTI)~1
6)]~1
(HPLC-ELISA)~1
URTI~1
IgAN.~1
(13/83).~1
(5.9%).~1
53.2~1
unchanged:~1
centerline~1
(intracoronary~1
13.5%.~1
16.4%~2
sensitisation~1
red-blood-cell~1
HLA-incompatible~1
chromium-51-labelled~1
RBC-specific~1
HLA-B7-incompatible~2
Cr51-RBC~2
(22.3,~1
36.9,~1
haptoglobin.~1
HLA-B7-compatible~2
serositis.~1
endocrinopathies.~2
thyroiditides~1
Serositis~1
C4AQ0~2
(C4A~1
B8~2
Serositides~1
serositides~1
tetani,~1
1-Hz~1
Tetanic~1
Hertz~1
pentostatin~2
(2'-deoxycoformycin)~1
Pentostatin~1
Lengthy~1
pentostatin.~1
(remission~1
Hypotension,~1
bolus-dose~1
(rIL-2)~3
rIL-2~9
leukapheresis.~1
millimeter,~1
rIL-2-induced~1
6000.~1
body-surface~1
rifamycin~1
polyketides.~1
synthases~2
iterated~1
thio-esters~1
methylations~1
glycosylations,~1
polyketide~3
Streptomyces,~1
(serpins)~1
darwinian~1
(manic~1
homogeneity)~1
9.17~1
heterogeneity);~1
nosology,~1
hypoxanthine-guanosine~1
(HPRT).~1
chimaeras,~1
(PtdIns(4,5)-P2)~1
Ins~4
(1,4,5)P3~1
Michell~1
Ins(1,4,5)P3-activated~2
mitogen-regulated,~1
voltage-insensitive~1
Ca2+-permeable~1
(TCRs)~1
(MHC)-encoded~2
TCRs~1
H-2Kb-restricted,~1
2,4,6-trinitrophenyl~1
(TNP)-specific~1
(H-2Kb/TNP)~1
H-2Kb/TNP~1
(CTL-p)~1
(NK-p)~1
microculture~1
NK-p~1
OND.~1
(CD4+)~1
18F-2-fluoro-2-deoxyglucose~1
Pick~1
premortem.~1
meningoencephalitis,~1
Ia-bearing~2
meningoencephalitis;~1
hormone-like~1
(CRH-LI)~1
CRH-LI~1
extrahypothalamic~1
stereotypical.~1
paraocular~1
Pars~1
(HF),~1
[9].~1
(L4-S1)~1
(ankle)~1
flexor.~1
TENS,~1
36-month-old~1
(Connaught)~1
antipolysaccharide~1
(61.7%)~1
(38.1%)~1
(Praxis).~1
(MEF)~2
AOM.~2
MEF~3
"controls,"~1
(NICHD)~1
757)~1
1,514)~1
infant:~1
NICHD~1
1AT,~3
3T3.~1
(5.8,~1
cDNA-directed~1
yeast-produced~1
1AT.~4
non-alpha~1
1AT-producing~1
retrovirus-packaging~1
ADA-fibroblasts~1
retrovirus-mediated~2
I-Ak~5
(Ak~1
3J9,~1
TA3~2
3J9~1
Ak~2
alpha-specific~1
39J~1
I-Ak-restricted~1
(G----A)~2
Ia.19~1
membrane-specific~1
chains:~1
B1,~7
5358-base~1
1786~1
alpha-helical,~2
(3.8,~1
1.4-kb~2
polynucleotides~2
A-form----B-form~1
ribosubstituted~1
riboadenosine~3
deoxyriboadenosine,~1
Ribosubstituted~1
bending).~1
riboguanosine~1
ribocytosine.~1
perturbations,~1
(pHSV-106,~1
pML-BPV-TK4)~1
TK-~1
Chromatin~1
mock-methylated~1
octamers.~1
microinjection,~1
5-azacytidine.~1
pML-BPV-TK4~1
v-sis-transformed~2
Insulin,~5
preexists~1
PB-3c~5
(IL-3)~2
([Ca2+]i).~1
12-tetradecanoate~1
(PTA),~1
phospholipid/Ca2+-sensitive~1
PB-1~6
[3H]-phorbol~1
77-kDa~1
holoenzyme~1
19,000-dalton~1
"E3/19K"~1
293.12~1
E3/19K~4
293Kd~1
HLA/H-2Kd~1
(145-2C11)~1
Armenian~1
(T3-epsilon)~1
multiparameter~1
phycoerythrin~1
PE-primed~1
anti-PE~2
PE-binding~1
Three-color~1
B220+(IgM,IgD)-~1
0.02-0.05%~1
2,4-dinitrophenyl~2
B220+-(IgM,IgD)-~1
B220+(IgM,IgD)+~1
hapten-gelatin~1
fluorescein-polymerized~2
BSF-1.~2
interferential~2
(ICS)~1
ICS,~1
Scatter~2
17.10~1
Frey~1
11.80~2
thermal,~1
(judged~1
skin).~1
era--sometimes~1
signs/symptoms,~1
(Ravasio~1
beta-lactamase-susceptible~1
sterilize~1
catarrhalis-infected~1
MEF.~1
transducing~3
pipiens.~1
neuroepithelium.~2
700-base~1
20,300~1
nonsensory~1
odorants~1
ICP-0,~1
ICP-4,~1
ICP-27~1
VP-5~1
ICP-0~4
ICP-0--related~1
(productively)~1
rectifier)~1
5'-monophosphate~1
"resolution~1
megabase-scale~1
megabase~1
4-kilobase~1
1.6-kilobase~2
uninformative~1
X-gene~1
mauritiana~1
mariner~2
peach-colored~1
eye-color~1
mosaic.~1
age-of-onset.~1
LDR152~1
(D19S19),~1
DM;~1
0.0-0.03);~1
15.4.~1
anoscopy,~1
proctoscopy,~1
Scolitron~1
56.3%~1
successes;~1
16.9%~1
nonprotocol,~1
indentations,~1
Occluded~1
hepatectomies.~1
(CFU-T)~1
CFU-T~1
vivo-primed,~1
alloimmune,~1
C-like~1
CTLL-2~4
vivo-primed~3
anti-P1~1
(nonlytic)~1
CTL;~1
"ring~1
structures"~1
"structures"~1
mechanism--employed~1
CTL--of~1
P2)~1
analogously~1
CTL-induced~2
160A~1
"holes"~1
(Poly~1
P1)~1
(channel)-forming~1
EM.~1
tumor-challenged~1
Unsuccessful~1
imperforate,~1
ECG-gated,~1
Distinction~1
(small,~1
large)~1
signs:~1
capping,~1
hemidiaphragm,~1
Decubitus~1
hemithoraces~1
67%).~1
hemithorax.~1
(anatomic~1
histologic)~1
15-33~1
Anteroposterior~2
outline.~1
flaccid.~1
membranacea,~1
flaccidity.~1
overdistended~3
0.35-T~1
(Diasonics~1
MT/S)~1
(FNH)~1
FNH~4
lesion/normal-liver~1
1.33,~1
1.41.~1
nowadays,~1
esophagography.~2
laparotomy;~2
93%:~1
In-111-labeled~1
haziness~1
contrast-filled~1
(9-28~1
French)~1
clips,~1
claustrophobia~1
bolus-contrast~1
periostitis~4
multilayered,~1
(diaphysis,~1
epiphysis).~1
thicker,~2
radiogrammetric~1
Sagittal,~1
coursing~1
Oblique-plane~1
face"~1
foramina;~1
Subependymal~1
sellar-floor~1
sellae~1
zero).~1
macroadenoma.~1
microadenoma,~1
head-coil~1
4561~1
neurologists,~1
CNS;~1
repetition-time/echo-time~1
TR/TR~1
hemosiderin-laden~1
aortofemoral,~1
femoral-popliteal,~1
femoral-femoral,~1
axillary-femoral~1
uninfected;~1
pseudointimal~1
intragraft~1
ophthalmicus~3
Uveitis~1
positron-emission~1
13N-ammonia~4
multi-slice,~1
rationally~1
implemented;~1
rubidium-82,~1
technetium-99m.~1
improvement).~1
(resolved~1
(found~1
122),~1
octogenarian~1
OKB7~5
(CLL),~2
HCL).~1
Incidentally~1
OKB7+~1
CALLA+.~1
non-T-ALL~1
(T+,~1
OKB7+,~1
CALLA+).~1
unicellular~2
taxonomy~1
settled.~1
(TEM~1
phagosomes,~1
sporulate~1
857~1
(19.5%)~1
Stigmata~1
spurts,~1
oozes,~1
"platelet~1
aggregates."~1
presumed,~1
36%).~1
myeloma),~1
homosexuals,~1
promiscuous~5
transfusions).~1
Hermansky-Pudlak~3
ceroid-like~1
ceroid/lipofuscinosis.~1
ceroid/lipofuscinosis~1
dolichols,~1
dolichols.~1
T3-negative,~1
T4-positive,~1
T8-negative.~1
seropositivity,~1
anal-receptive~1
cytomegalovirus-seropositive~2
intermittently,~1
Histoplasma,~1
Strongyloides,~1
T8-positive.~1
decidua-associated~1
Decidual~2
(43,000~1
cytolytic.~1
carriage,~1
fast-acting~2
8.40~1
9.92~1
adrenocorticotropin,~1
CR-121)~1
(Sigma).~1
Sigma~2
plots,~1
(830~1
Occupation~1
0.527;~1
0.404;~1
SIV-infected~3
D-galactosamine~2
(GalNH2)~1
1-antitrypsin.~1
GalNH2~1
1-antiproteases,~1
1-antiproteases~1
GalNH2-treated~4
1-antiproteases.~1
(AAT)~2
1-antiprotease~2
AP2~3
AAT~5
microsamples~1
Purposes~1
mycobacterial-induced~1
(CMIU)~1
125I-plasminogen~1
electrophoreis,~1
(uninhibited)~1
suspected--roughly~1
CMIU~2
vasopermeability~1
multistep,~1
chamber.(ABSTRACT~1
(PLEVA)~1
papulonecrotic~1
PLEVA~2
beta-T-cell~2
(mature~1
immature),~1
killer/natural~1
(My10)~1
involutes,~1
irradiating~1
corpuscles~1
Stains~2
anti-OX4~1
dansylated~1
(5-HTP)~1
5-HTP-induced~1
5-HTP~2
12,103~1
19-74~1
(kg)/height~1
(m)2)~1
intensity)~1
taller.~1
Sedation,~1
mg/kg/hour.~2
bi-exponential~1
concentration--time~1
Half-lives~1
(EA),~1
(IA~2
Leu-2a~5
Leu-3a/3b~1
null-null~2
1AT),~1
parallel(r~1
(AM),~1
(BM),~1
antigen-~2
Density-fractionated~1
BM,~1
erythematosus;~1
blood-to-brain~1
anti-myelin~1
(anti-MBP)~1
anti-MBP,~1
anti-MBP~4
HLA-B35~6
HLA-Cw4.~1
Cw4.~1
HLA-related~1
co-trimoxazole.~1
prosthesis-related~1
(Oregon)~1
(Stanford)~1
(Vancouver)~1
Evaluated~1
comparable;~1
improved;~1
Bad~1
(fading~1
pruritus)~1
anti-Smith~1
[29%]),~1
cavitarylike~2
(OCD)~1
OCD.~1
OCD,~1
gyrus/hemisphere~1
caudate/hemisphere~1
(PCP),~1
brushing.~1
congregate~1
X-associated~1
F-2-fluoro-2-deoxy-D-glucose~1
controls'~1
Caudate~1
N-isopropyl-p-iodoamphetamine~1
(CD4)~2
(CD8)~2
FcR+-bearing~1
(TN)~1
TN~3
(TNMS)~1
TNMS~1
Meier~1
product-limit~1
3.07%~1
Scotopic~1
emetropic~1
(SF),~1
C3H/Hej~1
IL-2-related~1
3H-double-stranded~1
3H-single-stranded~1
(ssDNA).~1
Leeds~1
Tester~1
Probit~1
limits:~2
106-167~1
(348~1
233-1296~1
EC95~1
5.92~1
command,~1
birthdate.~1
hyoscine~1
1515~1
weals.~1
re-administration~1
Hallopeau~1
razoxane.~1
stress-,~1
urge-~1
3-36~1
Intra-anal~1
non-epidemic~1
Refractile~1
C1(-)-inhibitor~1
(C1(-)-INH)~1
(SDS)-gel~1
C1(-)-INH~8
(106,000~1
106,000~1
C1-s.~2
C1-s~3
"doublet"~1
C1(-)-INH;~1
96,000;~1
C1(-)-INH,~1
midweek~1
(LTMBCs)~1
LTBMC.~2
Anti-CSF~1
cell:cell~1
divide.~1
del(6)(q21),~1
del(10)(p13),~1
ATL,~2
HTLV-I-negative~1
ATL.~1
(Incontan)~1
anally.~1
nonlymphatic~1
NHLs~1
0.32/10(5).~1
(BL)~6
(LBL)~1
(LCL)~2
(n-BL)~1
BL~18
LBL~6
(mediastinum~1
nodal);~1
tonsillary~1
poorest.~1
(3.13~1
(centroblastic~1
(235~1
comigrating~2
(SOM)~1
minded~5
1-year-olds~1
SOM~1
redefined~2
alchemist's~1
orchestrate~2
Inducers~1
Muramyl~1
(Shrinking~1
scapulo-humeral~1
microglobulin.~1
required.(ABSTRACT~1
whole-tendon~1
Tendons~2
7-microAmp~1
(14C)proline~2
(14C)hydroxyproline~2
255%~1
tenoblastic~1
14C-Triolein~1
isoamylase,~2
nongastrointestinal,~1
(hCalc)~1
(hCGRP)~1
hCalc~7
hCGRP~8
(0.01-1.0~1
hCGRP.~4
Ganglionic~1
Calc~1
crop-sac~2
proinsulin,~1
Proinsulin~1
oPRL,~1
rugae)~1
patches),~1
crop~2
Palytoxin,~1
nonphorbol~1
palytoxin~4
10(-13)~2
Palytoxin-induced~1
100-250~1
(0.5-10~1
Palytoxin~1
castrated,~1
optimizes~1
corticotrophs~4
[125I]Tyr-oCRF~1
(0.5-150~1
agnogenic~3
sinusoids,~2
fibroblasticlike~1
myofibroblasticlike~1
fragmentary~1
Corticotropin~2
CRF-induced~3
stomachs.~1
nongastric~1
(YAG)~1
electrofulguration,~1
(coaptive~1
coagulation).~1
(monopolar,~1
probes),~1
Undesirable~1
sparking~1
electrofulguration~1
immunosuppressants.~1
immunosuppressants~1
125I-EGF~7
shamoperated~1
Lymphokine~5
allogeneic,~1
(rIL-2,~1
Cetus,~1
USA)~1
killer-mediated~1
reduced-time~1
Hematochemical~1
adhesiveness.~1
granulocytosis,~1
dissector~1
(CVBG)~1
learn.~1
inflammation),~1
Microscope~1
dismissals~1
(3/79)~1
dismissal.~1
episodes/24~1
Laron~4
"two-site"~1
(IRMA)~2
(hCRH)~1
IRMA,~2
2-28~1
58].~1
[1462~1
55],~1
CRH-like~2
IRMA~1
slowly;~1
CRH-degrading~1
IRMA.~1
1462~1
CRH,~3
osteocalcin.~1
(PBC)~1
calciferol~1
Nonsuppression~1
nonsuppressible~1
ACTH-(1-24)~3
ACTH-(1-39)~1
cortico-endosteal~7
envelopes.~2
gla-protein,~1
EAU,~1
anti-S-antigen~2
anti-mu~3
CY-treated~1
vivo-activated~1
(IVS~1
3.7-kb~2
HLA-DR3/4~1
DR-identical~1
4-kb~4
HLA-DR4,~2
non-DR3/non-DR4~1
closer,~1
Euthymic~1
LEW~5
Immunodeficient~1
Histocompatible~1
euthymic,~1
(sequentially~1
Xmn~1
Dde~1
p45h~1
(Taq~2
p45d~1
(Pst~1
52a~1
kindreds)~1
offsprings~1
osteoporosis--decreased~1
resorption--is~1
bone--Gla~1
(BGP),~2
[1,25(OH)2D]~1
micrograms/d).~1
CD3(T3)~1
CD7+,~1
CD8-,~1
anti-CD3~2
43-kD~2
amegakaryocytic~1
HLA-A2.~2
necropsy)~1
anti-HLA-A2~1
Oftentimes~1
gut"~1
Lyt-2/3~2
protein-bearing~2
pseudocyte~1
(bg/bg)~1
(LCMV).~1
Virus-specific,~1
bg/+~10
LCMV~1
bg/bg~11
mediating,~1
(NPb)~1
Ly-1-~3
Ig-bearing~2
BH.~1
BH~3
idiotype-specific,~1
NPb~6
NP-Ficoll~1
Ly-1~14
anti-NPb~1
non-Ig~2
(lymphokine)~1
NP-Ficoll,~1
lymphokine(s).~1
cell-B~3
tolerance-inducing~1
DHGG~3
8-bromoguanosine,~1
circumvention~1
AHGG~2
(immunogen)~1
DHGG.~1
deliverance~1
tolerogenic~3
(concanavalin~1
hyperresponsiveness,~3
hypersecretion),~1
nonlymphoid,~1
wool,~1
bursectomy~2
(Ag)-presenting~1
myoglobin-specific~1
Ag.~1
I-Ek,~1
(detectable~1
co-culture)~1
phi-like~1
1-induction~1
T----APC~1
signalling.~1
co-mitogenicity,~1
pyrogenicity~1
lipopolysaccharide-induced~1
FS-4~12
formaldehyde-fixed~1
(MA-IL~1
MA-IL~2
1-alpha~4
endotoxicity.~1
endotoxin-associated~1
monokines,~1
(rTNF~1
(preceding~1
(2C3E1),~1
culminates~2
idiotype-negative~2
2C3E1~6
idiotype-positive~3
restimulated~4
anti-IgA~4
3[(3-cholamidopropyl)~1
dimethylammonio]-1-propanesulfonate~1
(CHAPS).~1
CHAPS~2
CHAPS,~1
Detergent~1
125I-IL~6
receptor/mg~1
(responders),~1
(nonresponders)~1
IV3)~1
focussing~1
sorts.~1
responders)~2
(mIg)~1
(Ti/T3),~1
(I-A~2
I-E)~3
I-A/E~1
(anti-IA/E)~1
L1210-specific~1
K7L,~3
L1210,~2
K7L~2
K7L-insensitive~1
(K7L-)~1
L1210-K7L-~4
(10(7)~1
L1210.~1
(L1210)-specific~1
(L1210)~1
1210-K7L-~1
K7L-reactive~1
(TCL),~1
(PBMC),~1
PBMC-derived~1
II-positive~3
TCL;~1
TCL~3
(C2F2)~1
C2F2~2
(MLR)~2
1)-dependent~1
C2F2,~1
2)-dependent~2
CTLL~3
C2F2.~1
1-dependent~4
C2F2-mediated~1
anti-TR~2
Anti-TR~1
(aBM)~2
Cytodex~1
IgM+(sIgM+)~1
fluorochrome-labeled~1
anti-mu-chain~1
aBM~13
allotype-congenic~1
(C.AL~1
allotype-specific~1
mu+~1
sIgM-~1
panning.~1
LPS-responsive~1
5-fluorouracil-pretreated~1
BM-derived~2
(31.3,~1
Macrophage-depleted~1
microcultures~1
IFN-induced~1
four-fold,~1
subfractionation~1
125I-IFN-alpha~1
organ/system~2
polymyositis/dermatomyositis.~1
(RNP)~1
dermatomyositis/polymyositis;~1
myositis;~1
pneumocystis~4
Hypogammaglobulinemia~1
(BCGF)~1
(BCDF).~1
sequellae~2
BCDF-like~1
(C5b-9)~1
C5b-9-treated~1
MC-derived~1
auto-growth~1
phospholipases,~1
"wasted"~1
(wst/wst)~1
wst/wst~7
(wst/+~1
+/+).~1
IgG2a,~1
IgG2b,~1
Ig+~2
Ig+,~1
+,~2
bright"~2
chain-specific~1
Ig-specific~1
"switch"~1
anti-T~5
8BE6,~2
anti-guinea~2
pan-T~4
(CBH).~1
8BE6~10
68,000~2
CD5~1
Lyt-1.~1
8BE6+~1
capping.~1
8BE6-treated~4
GP,~1
control-treated~2
fibronectin-receptor-positive~1
CBH~2
1-micron~1
neuro-autoimmune~1
lymphocytolysis~1
MOPC-21~1
Recoveries~1
LBRM33-1A5.~1
TY5,~1
alpha-stimulated~1
co-stimulator~1
(TE-IL~2
17-wk~1
TE-IL~8
cells/ml~1
Mr.~1
chromatography-purified~1
intrathymic~3
ROHA-9~6
1-secreting~1
co-purified~1
HPLC-purified~1
multi-colony~2
ROHA-9MC3~1
Uromodulin,~2
pronase-digested~1
(7).~1
85,000~1
Uromodulin~6
succinylation~1
carboxymethylation,~1
pronase,~1
N-glycanase~1
(N-glycosidase~1
F-,~1
N-asparagine-linked~1
oligosaccharides)~1
uromodulin.~2
down-regulating~1
mammalian,~1
glycosylation-enhancing~2
(GEF).~1
GEF~12
OA-primed~1
GEF,~1
N-alpha-p-tosyl-L-lysyl-chloromethyl~1
ketone.~1
p-aminobenzamidine~1
benzamidine.~1
protease(s).~1
DNP-OA-primed~2
DNP-KLH-primed~2
DNP-KLH.~1
KLH-specific~1
7.2,~4
CH12~2
microheterogeneous~1
S--S~1
p23,~1
p23~2
leu-pro-pro-ser-arg~2
355)~1
p23;~1
N-flanking~1
p23-induced~2
cell-replacing~1
p23-conditioned~1
leu-pro-pro-ser-arg.~1
ubiquity~1
"IL~2
1-like"~2
co-mitogenesis~1
Wil2WT~1
Molt4,~1
C1q.~3
complex-bound~1
immunoregulation.~2
cell-line~1
lysate.~2
smooth-and~1
(Re)~1
4:1:4)~1
1000-fold.~2
liposome-incorporated~1
liposome-associated~1
Re-lipopolysaccharide~1
Fc-receptor~1
IgG-coated~2
plasma-membrane~2
"activates"~1
I-A+~1
(I-Ab~1
haplotype)~1
D3137~4
anti-I-Ab,d~1
antibody).~1
Listeria-dependent~1
mg/animal)~1
MPS.~1
C1.18.4~1
(I-Ak)~1
(B10~2
B10.BR)F1~1
I-Ab~1
I-Ak),~1
anti-immunoglobulin-treated~1
Indo-1.~1
Cytochalasins~1
cytochalasin,~2
xid-defective~1
[CBA/N~1
DBA/2]F1~1
anti-immunoglobulin,~2
tumor-binding~6
recycle.~1
(doubling~1
CD16~2
Leu-19~1
(ENKAF).~1
(IL-3)-like~1
431,~2
SCC)~1
FDCP.~1
IL-3)~1
anti-IL-2-antibody.~1
17K,~1
DEAE-ion~1
HPLC-chromatofocusing~1
5.6.~1
17K~1
ETAF/IL-1,~2
IL-3-like~2
Depilatory~1
(mEGF)~1
regressive~2
(catagen)~1
Merino~1
catagen~2
Apoptosis~1
mEGF-induced~2
catagen,~1
(LPS)-stimulated~1
laboratory-adapted~1
AD169~1
immediate-early~1
AD169-infected~1
leukokine~1
Immunizing~1
virological~1
co-administration~2
HSV-2),~1
(mice~2
pigs)~1
(owl~1
monkeys).~1
Immunized~2
pfu~1
(OSA).~1
hybridising~1
papovaviruses~1
2-[18-F]fluoro-2-deoxy-D-glucose~1
(FDG).~3
Spirogermanium~1
azaspirane~1
germanium~1
anti-neoplastic~1
lamellar-bodies~1
SG-treated~1
gliomatosis~1
oxygen-15-labeled~1
fluorine-18-labeled~4
fluorodeoxyglucose.~1
(CBV),~1
(CMRO2~1
CMRGlu),~1
(OEF)~1
CBF/CBV~2
CMRO2,~2
occlusions;~1
OEF,~1
CMRGlu,~1
CMRO2/CMRGlu~2
CMRGlu/CBF~2
hypometabolism.~3
CMRGlu~2
ergocalciferol~4
supraoccipital~2
sternebrae~2
Degrees~1
ergocalciferol;~1
ergocalciferol.~3
Ossification~2
ergocalciferol,~1
retardations~2
progressions~1
relatable~1
"carnival~1
fetuses."~1
teratological~1
McN-A-343.~1
bioassayed~2
(10(-8)-10(-7)~1
concentration-relaxation~1
potencies.~1
second-phase~1
relaxations.(ABSTRACT~1
opiate-induced~1
m-chlorophenylpiperazine,~1
serotonin-releasing~1
(EBVR/CR2)~1
EBVR~3
anti-gp~1
EBVR,~1
140).~1
lymphocytotoxins~1
(LCT).~1
LCT~5
microorganism.~2
streptococcus,~1
51chromium-release~1
2-treated~1
65.2~1
K562.~1
ileoileostomy~1
barium-impregnated~1
medulloblastomas,~1
ependymomas),~1
Ependymoma~1
Electrotherapy~1
epithelial-lining~1
(1.89~1
Haematopoietic~1
(HCGFs)~1
HCGFs~4
(ECM).~1
cyto-differentiation~1
haematopoiesis.~1
HIV-1.~3
50-fold,~2
NF-kappa~2
inducibility.~1
18F-deoxyglucose~1
(PET).~4
brain-size~1
corresponds,~1
narcoleptic~2
non-DR2~1
cataplexy~1
naps,~1
(W3/13+),~1
(W3/25+)~1
MBP-reactive~1
(S-F)~1
sulfate/polyacrylamide~1
Thy-1.1-transgenic~1
development-specific~1
Senescence~1
adrenal-specific~1
Dot-blot~1
nonquiescent~1
alpha-hydroxylase.~1
alpha-hydroxylase,~2
Ia-expressing,~1
81-104,~1
NaDodSO4/PAGE.~1
nonantigenic~1
presentation--facilitating~1
B-cell-stimulatory~4
B-cell,~3
10(10)-10(11)~1
M-1.~1
cell),~6
75,000.~1
L(tk-)~1
extrachromosomally~1
papovaviruses.~1
11-cis-retinoid~2
all-trans-retinoids,~1
retina/pigment~1
all-trans-[3H]retinol,~1
11-cis-retinol,~1
11-cis-retinal,~1
11-cis-retinyl~1
13-cis-Retinoids~1
all-trans-[3H]retinol~1
11-cis-retinoids~1
all-trans-[3H]retinal~1
all-trans-[3H]retinyl~1
75-base~1
oligonucleotide.~1
pFH6~1
[Kornblihtt,~1
Umezawa,~1
Vibe-Pedersen,~1
Baralle,~1
EMBO~2
1755-1759].~1
3.7-kilobase-pair~1
31-residue~1
propeptide.~1
rich.~3
ATATAA~1
CAAT~1
-150.~1
GGGGCGGGGC~1
SP1,~1
TGACGTCA~1
-173~1
shutoff~2
host-protein~1
(vhs~1
(alpha)-viral~1
vhs-1~1
(beta)-~1
(gamma)-viral~1
G1(G0)-arrested~1
IL-1-like~1
pro-von~1
propolypeptide~7
propolypeptide,~1
equimolar.~1
pro-vWf,~1
post-Golgi~1
prosequences~1
multimerization~3
codistribute~1
"patches~1
vWf,~3
MAL,~1
Calvariae~1
resorbing~3
osteotropic~1
36-amino~1
carboxyl-terminally~1
preproneuropeptide~1
Developmentally,~1
Unexpectedly~1
Galactose~1
lividans~2
galP1~2
galP2,~2
polycistronic~1
galactose.~1
galT,~1
galE,~1
galK~2
galE~4
gal~2
operons.~1
operon's~1
UDPgalactose~1
Retrovirus~1
[direct~1
(DO)~1
vectors]~1
dominant-acting~1
phosphotransferase~3
guanine-xanthine~1
subgenomic~1
env-encoding~1
constructions~1
[3H]inositol-,3-[32P]phosphate-and~1
4-[32P]phosphate-labeled~1
1,4-bisphosphate.~1
3,4-bisphosphate,~1
3,4-bisphosphate~2
polyphosphate~1
1-phosphatase.~1
4-phosphate.~2
1,3,4,5-tetrakisphosphate,~1
1,4,5-trisphosphate,~2
1-phosphate,~1
Amber~1
anticodons~1
lysine-inserting~1
(tRNA(Lys))~1
glutamine-inserting~1
(tRNA(Gln))~1
tyrosine-inserting~1
(tRNA(Tyr))~1
aminoacylation,~1
tRNAs.~3
aminoacylated~2
tRNA(Lys)~1
tRNA(Gln)~1
(HSP70)~1
serum-regulated~3
studies--CCAAT,~1
(SRE),~1
"TATA"--correspond~1
linker-scanner~1
SRE~1
HSP70.~1
S-transferases~1
(GST)~1
GST-2~3
25,425~1
GST-2.~1
GST~1
GSTp~1
Yb~1
centromere.~2
preleukemia.~1
interfertile~1
smithii~2
zygotes~1
diploids,~1
biparentally,~1
1-kilobase~1
unidirectionally~1
21S~1
handicapped,~1
nonselectable~1
(pHHAM)~1
Harvey,~1
Abelson,~1
327-base-pair~1
HHAM~2
(tk),~1
Helper-free~1
W/Wv~1
interleukin-2-dependent~1
(C9)~1
C9-related~2
(C9RP).~1
lymphocytes--i.e.,~1
OKT3-activated~3
(monoclonal~3
T3).~1
anti-C9RP.~1
C9RP.~1
interleukin-2-stimulated~1
dendritic,~1
(Thy-1+~1
DEC).~1
(Tehy~2
184,~1
Tehy~3
245,~1
Yety~1
245)~2
lectin-lymphokine-rich~1
anti-asialo-GM1~1
DEC:~1
Ly-5+,~1
Lyt-1-,~1
Ia-,~1
sIg-.~1
DEC-derived~1
(related)~1
receptor-related~1
F23.1~2
84-88~1
44-kDa~1
[(C57BL/6~1
DBA/2)F1]~1
alum-absorbed~1
2-containing~1
(GIF).~1
ovalbumin-pulsed~2
IgE-potentiating~2
IgE-suppressive~2
ovalbumin-primed~1
35-kDa~4
ovalbumin-specific~3
dinitrophenyl-coupled~1
C3b-~1
C4b-coated~1
90,000.~1
(D).~1
crossing-over.~1
16,560~1
Da~1
(subtype~1
adw).~1
ORF,~1
0.8-kilobase~1
X-specific~1
Cytotactin~1
cytotactin~5
(Covaspheres)~1
Cytotactin-coated~1
anti-cytotactin~3
anti-neural~1
(anti-N-CAM)~1
N-CAM-coated~1
anti-N-CAM~1
cytotactin,~3
cytotactin-coated~4
proteoglycan-containing~2
chondroitinase,~1
heparitinase,~1
Mr280,000~1
HNK-1~1
couple.~1
Proteoglycan-coated~1
coaggregated~1
proteoglycan-coated~1
proteoglycan.(ABSTRACT~1
98-amino~1
Blundell~1
coworkers.~1
polyproline-II-like~1
erbB~2
v-erbB~4
32-amino~1
Rat1~2
(HER-erbB)~1
HER-erbB~1
EGF-induced~3
genomically~1
platelet-free~1
(a-1-antitrypsin)~1
(AAA),~1
(elastase/a-1-antitrypsin)~1
AAA-rupture~1
AAA-elective~1
a-1-antitrypsin~1
hematemesis.~1
6,148~1
convention)~1
g/m~2
mass/height~2
Summer~1
resampled~1
nonleukodepleted~1
exposures).~1
anti-CMV.~1
(IgG+,~1
IgM-)~1
formula-supplemented~1
colicky~1
pJN2CK-M,~1
1,160-bp~1
kinase-M~3
q13,~1
19q13.~1
G-banding,~1
19q13.2-q13.3.~1
co-morbid~1
anemia);~1
time);~1
exsmokers),~2
DR4-negative~3
post-transplantation~2
thymocyte)~1
1-6-positive,~1
9-positive,~1
Tdt-positive,~1
B-negative,~1
Calla-positive.~1
granulomatosis.~1
protease-antiprotease~1
antiproteases~1
(9-[1,3-dihydroxy-2-propoxy-methyl]-guanine,~1
DHPG).~1
Retinotomy~1
Endoretinal~1
pseudolymphomas,~1
orbital,~1
conjunctival,~1
pseudolymphomas~1
lymphocytic)~1
(Oxford,~1
B5-fixed~2
UCHL1~3
T2/48,~2
T2/48~2
(37/43)~1
(1/56)~1
(11/56)~1
mantle-zone~1
proliferations,~1
"undifferentiated"~1
R-associated~1
(H107).~1
serum-IgE~1
(Fc8R)~1
IgG-immunocomplexes.~1
(9G2),~1
(suppressor),~1
Leu-3a~2
(helper),~1
Leu-4~1
(pan-T),~1
Leu-12~1
(pan-B),~1
anti-polyvalent~1
56-week~1
small)~2
nonparamedic~2
6,405~1
Intrapleural~1
comparison)~1
0.2),~1
immunoactivation~1
0.2).(ABSTRACT~1
keratectomy.~1
Doxycycline,~1
A-56268.~1
(+)-Cyclaradine~3
(Sch~1
31172)~1
carbocyclic~1
(9-beta-D-arabinofuranosyladenine).~1
(+)-cyclaradine~2
phosphonoformate~1
acycloguanosine~1
(acyclovir;~1
ACV),~1
trifluorothymidine,~1
9-(1,3-dihydroxy-2-propoxymethyl)guanine.~1
TK-,~1
ACV-resistant~1
bioavailable;~1
(liposomes),~1
Aerosolized~2
assessment)~1
10(4)-fold~1
pneumocystosis.~1
(MIC50)~1
(MIC90)~2
MIC90~5
MIC90S~1
cefazolin-beta-lactamase~1
MIC50~1
4.0-micrograms/ml~1
[9-(1,3-dihydroxy-2-propoxymethyl)guanine]~1
Ganciclovir~6
HLA-DR3/DR4,~1
Islet~2
fixing,~1
36/100,000,~1
1978-1982.~1
revascularization)~1
hemostyptic~3
(FTCH)~1
FTCH~2
FTCH,~1
relaparotomy,~1
aneurysmatic~1
well-healed~1
resorped~1
hemostyptic.~1
pre-CPB~2
alpha-stat~1
(CPTs).~1
CPTs.~1
Non-enzymatic~1
matrix-degrading~1
catabolism-inducing~3
Piroxicam~1
(JRA-uveitis),~1
Enzyme-linked~2
JRA-uveitis~3
opsonize~1
(nontypable~1
preopsonization~1
intrabullar~1
phagocytizing~2
hypofunction~1
(UVH),~1
(VSR).~1
nontransferable~1
VSR.~1
Discordance~1
(evaluating~2
VOR)~1
VSR)~1
UVH.~1
"instability"~1
UVH~1
VSR~1
utriclar,~1
macula)~1
nerves'~1
endoneurium.~1
nonacoustic~1
cerebellopontile~2
(propofol~1
propofol.~2
GCT-conditioned~1
(mw)~1
(kd).~1
CSA,~1
hyperimmunoglobulinemia.~1
(pre)activation~1
(GM-CSF);~2
erythroid-potentiating~1
(EPA);~1
pluripoietin~2
(Ppo);~1
(Ppo~2
(MoCM)~1
Ppo~5
indistinguishable;~1
CFU-GEM.~2
CFU-GEM~3
MoCM.~2
(Ppo)~2
EPA~1
124I~1
Radioiodine~1
vaccinated.~1
6.52,~1
reminder.~1
allaying~1
(Moab).~1
48,870/microliter~1
40,100/microliter.~1
IFN,~3
3,500/microliter;~1
130/microliter).~1
2950/microliter~1
3890/microliter~1
300/microliter~1
120/microliter.~1
Moab~2
170/microliter~1
360/microliter.~1
(CALLA)-positive~1
CALLA-negative~5
T-acute~1
CALLA-positive~5
non-T,~1
erythrocyte-rosette~1
(CD9,~1
T-ALL.~4
0.055)~1
nonlymphoblastic,~1
triacetate,~1
Dilations~1
uninjured.~1
anastomosis)~1
diagonal,~1
reader-blinded,~1
(Renografin-76;~1
noncontinguous~1
density-time~1
96%);~1
ethylsuccinate.~1
half-lifes~1
time-curve~1
Marshall's~1
cumulatively.~1
(Form~3
(demography);~1
Lysholm~1
Tegner~2
elaborates~1
"computer/user~1
friendly,"~1
(Xe/CT),~1
brain-death~1
acetate-gluconate~1
dextran-70~1
(IC-SK)~1
IC-SK~1
(NSCLC,~1
(SCLC,~1
NSCLC.~1
NSCLC,~1
orogastrically~2
lysophosphatidylcholine.~3
Transmucosal~1
synergistically.~1
pmol/min,~2
+175~1
fmol/ml)~1
SLI-14~1
SLI-28,~1
nmol/min),~1
pmol/min).~1
lutea,~1
hCG-inhibited~1
alpha-hydroxylase/17,20-lyase.~1
cholesterogenic~1
alpha-hydroxylase/17,20-lyase~1
enzyme(s);~1
steroid.(ABSTRACT~1
Osteocalcin,~1
osteocalcin,~2
osteomalcic~1
CRF-containing~1
vasopressin-containing~1
(CRF+/AVP+)~1
vasopressin-deficient~1
(CRF+/AVP-)~1
post-embedding~1
precursor:~1
AVP-associated~1
(NP-AVP)~1
(GP).~1
CRF+/AVP+~4
CRF+/AVP-~4
swellings.~2
(ADX),~1
CRF+~1
ADX,~2
ADX.~1
(HHM)~1
H-500~1
HHM~1
urea/HCl~1
ethanol/NaCl.~1
hydrophobic-interaction,~1
gel-filtration,~1
bPTH(1-34)/mg~1
(1.78-fold~1
(EGF)-dependent~1
NRK-49F~1
beta)-like~1
ATP;~1
(IP3)~1
half-effective~1
PIP2-induced~1
IP3,~1
45Ca2+,~2
(oCRF)~2
(IR-ACTH)~1
oCRF~19
IR-ACTH~5
(F).~2
(P-CRF)~1
oCRF)~1
ACTH)~1
P-CRF~3
(Ca2+)~1
chelators)~1
CaCl2.~1
10(-4)M)~1
spanned.~1
KiS~1
anticalmodulin~2
(trifluoperazine~1
R24571)~1
EGTA-washed~1
MgATP2-,~1
prolactinomas).~1
pituitary.(ABSTRACT~1
honeycomblike~1
cell-filled~1
retransfusion,~1
blood-filled~1
33-yr-old~1
multimodal.~1
mainstay,~1
neuroaugmentative,~1
physiatric,~1
inclusion;~1
rebleeding:~1
HBsAg-reactive~1
A5C3~3
Staphyloccocus~1
aureus-stimulated~2
H5D3~1
immune-complexed~1
reasonable;~1
evaluators,~1
behavior.(ABSTRACT~1
bubbles,~2
C4a,~5
subnormal,~1
CRH-induced~4
adenomectomy~1
sunburning,~1
photosynthesis~1
para-aminobenzoic~2
(sun~1
Para-aminobenzoic~1
photoisomerization~1
7-dehydrocholesterol~1
previtamin~1
interferred~1
1-PI)~1
metalloproteinase~2
Pro-357~1
Met-358,~1
reactive-site~1
1-PI.~1
1-PI,~1
Met-358~1
Phe-352~1
Leu-353.~1
kinase-B~1
(CK-B)~1
UT).~1
CK-B~5
CK-M~1
UT~1
B-isoenzyme~1
14q32~1
non-SCLC~1
(EBV)-transformed~1
murine-human~1
heteromyeloma~1
core-lipid~2
(smooth)~1
O-side~1
A-reactive~1
(vWD),~1
alloantibodies,~1
3'-7.4~1
Rb-82~1
N-13~1
dipyridamole-handgrip~1
Arteriographically~1
1,3,4,5-tetrakisphosphate~1
(Ins-1,3,4,5-P3).~1
Jurkat,~3
InsP4.~1
OKIa1~1
(HLA-DR),~1
(HLA)-DR~1
OKT6+~1
(HNK-1).~1
combinations;~1
enalaprilat,~3
(-33%).~1
enalaprilat~2
myoplasm.~1
autacoids~1
(signal~2
transductors),~1
(GMP),~1
alpha-human~3
(prostaglandin~1
I2)~1
machinary.~1
messengers.~1
(13.8%)~1
(it~1
two);~1
60.2%~1
advantageously~2
short-term.~1
nucleatum.~1
cavity;~1
mitogen;~1
(OKT8+)~1
(CTLp)~2
CTLp~8
T191,~1
alpha-immunoglobulin~1
IgM)/T~1
(TRF)~2
IgM/recombinant~1
T191-mediated~1
T191~5
activation)~1
alpha-T200~3
incorporation).~1
13.3,~1
anti-T200~1
anti-L3T4,~1
clones--27.9,~1
30.7,~1
30.8,~1
30.10--were~1
proliferated,~2
(H2d/z)~1
clone-mediated~1
"cognate"~1
30.10),~1
(27.9~1
30.8),~1
Ia+,~1
antigen+~1
P388D~3
32P-probe~1
3H-IL~1
Glomerulonephritic~1
cytokine,~4
(alpha-IFN)~1
comitogenic~1
(MNC),~2
MSU-induced~1
overproduction;~1
(anti-AChR)2~1
(EP).~1
epitopic~1
D10.G4,~1
Kirsten-murine~1
Ki-ras-expressing~1
(KiSV-D10)~1
D10.G4~2
KiSV-D10~2
(BSF-1).~1
receptor-~1
oncogene-expressing~1
Hut-102,~1
MT-1,~2
MT-2~7
chromatofocussing~1
thymocyte-stimulating~1
co-eluted.~1
(400:1)~1
endotoxin/U~1
(IL-B),~1
effectors.~3
IL-B~7
T2D4,~1
immunoglobulin-binding~1
T2D4~4
T2D4.~1
(keratinocytes)~2
cytokines.~4
(PAM~1
HT-2.~2
(S4B6)~1
(11B11).~2
41,413-fold~1
desalting~2
(HEC).~1
H4/18),~1
(plateau~3
(ICAM-1),~1
HEC~2
fibroblastoid,~1
H4/18~11
reinduction.~1
LT/TNF~2
(hCT),~1
calcitonin-gene-related~2
(hCGRP),~1
preprocalcitonin~1
PQN-34)~1
amido~3
paratope-epitope~1
anti-hCT~2
CT07~1
anti-hCGRP~1
CGR01~1
hormone-ending~1
heptapeptides,~1
QPO1~2
PQN-34~1
PQN-34.~1
CT08~1
preprocalcitonin.~1
SP-2/0-AG14~1
30,000,~1
anti-IgE-binding~1
(H107)~1
factor-producing~1
k:E~4
2B4.11.~1
120-fold~1
changed:~1
(log2)~1
(log2).~1
-1.~2
-2.04~1
X/divided~2
anti-E~1
[B10.A(4R)~1
B10.PL]F1APC.~1
-1.17~1
[Ca++]i,~2
fmet-leu-phe,~1
[Ca++]i.~1
superphysiologic~1
Anti-idiotype~1
A-12~1
Ab-2~2
(Ab-2~1
anti-Id-KLH~1
Id-positive,~1
noninternal~1
anti-Id,~2
(MHV-JHM)~1
intranasally).~1
Immunodepression~1
MHV-JHM.~1
postinoculation,~1
A-unresponsive~1
MHV-JHM-infected~1
MHV-JHM-infected,~1
chlamydia-stimulated~2
(LPS)-induced~1
LPS-inducible~1
(PFC).~1
Lyb5+~1
(xid)~1
NBF1~1
chlamydia.~1
(resting)~2
ontogeny,~2
ethylmethanesulfonate~1
(EMS),~1
(FACS).~1
(Thy-1-)~1
demethylated~1
EMS-induced~1
Thy-1-variant.~1
5-azadeoxycytidine~1
(5-dAZA)~1
re-expression~2
MB3.6,~1
ganglioside,~1
gamma-3~1
perforin~1
(P1)~1
immuno-electron~2
NK-like~1
blastocoel~1
Immunoregulatory~3
(cBSA)~1
cBSA,~2
BSA-specific~1
cBSA.~1
self-regulation~1
(PC-mice)~1
PC-mice.~2
(sIg)~1
anti-mu,~1
sIgD~1
sIgM~1
PC-mice~2
large-sized,~1
sIgD+~1
PC-induced~1
bursectomize~1
E5.~1
Hatching~1
E5~1
quail-chick~1
bursaless~2
bursa,~1
heterospecific,~1
(RGG),~1
RGG,~2
(RAMG)~2
Ia-restricted,~1
RGG-specific~1
(lymphokine~1
differentiation),~1
TNP-RGG~1
10(2)-~2
10(3)-fold~2
RAMG~1
TNP-RGG.~1
(modulation).~1
(TNP-RGG),~1
T-B~2
3T3,~1
U373~3
Autocrine~1
(aBGF),~1
5/2,~1
aBGF~5
EBV-negative~7
aBGF,~1
(Tg)-binding~1
(Jurkat-AG9)~1
emetine~1
thus-prepared~1
(Tg-Ts47)~1
Tg-specific~1
Hashimotos'~1
Tg-Ts47-derived~1
Tg-Ts47~1
histocompatability~1
molecules'~1
(desetope)~1
Ii.~1
endosomes~2
polymerize~1
Anti-CR1~3
anti-fluorescein~1
semi-purified~1
KD,~2
anti-mu.~1
anti-CR2~1
antigen-activated~2
MLA-144~1
Ca++/phospholipid-dependent~1
dibutyrate~1
TMB-8.~1
quin-2-labeled~1
(0.33)~1
chrysotherapy~1
thioglycollate-elicited~2
(CSF-1).~1
absorbance.~1
CSF-1-treated~1
G-CSF,~4
WEHI-3B-conditioned~1
CSF-1,~4
cytotoxicity-enhancing~1
(M-ECEF),~1
monokine,~2
ECEF-like~1
U937-ECEF~3
M-ECEF~6
ECEF~1
32,000,~1
M-ECEF,~4
Eco-RI~2
kbp~2
C57BL/10~3
acute-type~1
chronic-type~1
exogeneously~3
mitogen-free~6
anti-Tac/IL~1
autostimulation~1
patient):~1
acute-type,~1
chronic-type.~2
CH12.~1
complex-encoded~3
immunoglobulin)~1
Nickel-specific~1
(CD~1
skin-specific~1
(Langerhans~1
LC)~1
unpurified~1
nickel-specific~1
(SIS).~1
suppressor-cytotoxic~2
CD4/CD8~1
ratio:~1
4B4+~1
2H4+~2
Intraepidermal,~1
subepidermal,~1
("free")~1
Intraepidermally~1
(Ad35)~1
Ad35~3
"normal."~1
Ad35,~1
SmaI,~1
hemagglutinins,~1
HpaI,~2
PstI,~1
prototype.~1
Ad7~1
Ad11~1
hemagglutinin,~1
(gB,~1
gC,~1
gD,~2
gE).~1
biopsy-positive~1
biopsy-negative~2
OKT4)~1
(VP176)~1
(VP221)~1
(gD)~1
(precursor,~1
type-common~1
gD.~1
VP176~1
protection).~1
VP221~1
Protection,~1
35-45~1
Asialo~2
(As-VWF)~1
(GPlb)~1
llb-llla~1
(GPllb-llla)~1
As-VWF-induced~2
5'-p-fluorosulfonyl~1
apyrase,~1
As-VWF~5
GPllb-llla~4
endoperoxide-thromboxane~1
VWF~1
Avoiding~1
Waikato~1
Island)~1
Otago~1
Southland~1
Island).~1
Maoris,~1
non-Maoris~1
south.~1
Atkinson~1
Morley's~1
haemangioblastoma~1
subclones.~1
(PTCL)~1
(IBL)-like,~1
T-zone~1
Lennert's~1
lymphoepithelioid~1
classifiable.~1
(helper~3
(suppressor~1
IBL-like~1
hypergammaglobulinemia.~1
L17M~1
less-intensive~1
regiments,~1
Immunotoxins~2
anti-TR-ricin~4
glioblastoma,~2
"target"~2
immunotoxin's~1
"non-target"~1
1380-fold.~1
glioblastoma-~1
medulloblastoma-derived~1
cystic)~1
(Gd),~1
Gd~3
Gd-labeled~2
dianhydride~1
(DTPA);~1
DTPA-protein~1
microliters.~1
(TE~1
purport~1
(CMRglc)~2
(XCT)~1
XCT~2
volumetrically,~1
CMRglc~11
atrophy).~1
(16.9%~1
proton-NMR~1
3-[18F]fluoro-5-nitrobenzimidate~1
4-[18F]fluorophenacyl~1
fluorine-18~1
(30-50%,~1
5-60~2
(8.0)~1
(25-37~1
(corrected).~1
18F-labeled~1
Proponents~1
re-infused~1
4.6-0.02~1
0.20-0.02~1
4.6-0.2~1
Slower~1
ulcers--previously~1
histology--by~1
78%).~3
(mu)~1
(rCMRglc)~3
behavior-metabolism~2
6%-12%~1
rCMRglc~6
0%-5%~1
(AtT-20/D16-16)~1
AtT-20/D16-16~3
cyclase)~1
(unbound~1
drug),~1
Kreb's-bicarbonate~1
nM-1.0~1
blocked,~3
endoperoxide~1
(2.0-10.0~1
CGRP-like~5
CGRP,~1
(hCGRP).~1
5'-triphosphate.~2
spurred~1
perinigral~1
MPTP,~3
nmol,~3
3,3-dimethyl-MPTP~1
1,3,3-trimethyl-4-phenyl-2,3-dihydropyridinium~1
pyridinium~2
2,2~1
3,3-dimethyl~1
1-methyl-4-phenyl-2,3-dihydropyridinium~2
1-Methyl-4-phenylpyridinium~1
(MPP+)~2
4-(4-fluorophenyl)~1
4-(2-pyridyl)~1
MPP+,~2
MPP+~12
sartorii~1
(nerve-stimulated)~1
neomycin-induced~1
9.0,~1
Potentiation~1
7.4.~1
Ca++-mediated~1
antibody-vinca~1
KS1/4-DAVLB~1
(LY256787),~1
4-desacetylvinblastine~1
(DAVLB)~1
P3/UCLA~2
LY256787~4
DAVLB~2
(terminal~2
redistribution-elimination~1
radioequivalent~1
DAVLB.~2
radioequivalents~1
LY256787.~1
fecal.~1
KS1/4~1
Immunobead~1
(T8)~4
microbeads.~1
Uncontrollable~1
(medical~1
trousers)~1
polymyositis-dermatomyositis~1
(PM-DM)~1
(64.3%).~1
anti-Jo-1~4
(4-6~1
continues.~1
(BA-1+),~1
(Lyt-3),~1
inducer/helper~1
(T4+)~1
blastogen~2
(60-375~1
"rib~1
imprint"~1
nozzle.~1
Trinidad.~2
HTLV-I,~4
0.19%~1
transmitted,~1
coinfected~1
HIV/HTLV-I~1
232.1~1
(normal:~1
gm/m2).~1
(6.98~1
6.94~1
(1967~1
deaths):~1
2.3%,~1
0.0006),~1
aneurysmectomy,~1
polyepoxy~2
polyglycerol~1
polyglycidyl~1
compound-cross-linked~1
suturability~1
Histiocytosis~1
(My)~1
(MCS-2~1
MY9)~1
My+~5
(B+T-My+);~1
(B-T+My+),~1
(B-T-My+)~1
T-cell-receptor~1
My-~2
(freedom~1
Exercise-stimulated~1
anti-C1-inhibitor~2
105,000).~1
105,000-dalton~1
96,000-dalton~1
HSV-2)~2
(oropharyngeal~1
genital)~1
Oral-labial~1
oral-labial~3
'growth~1
factor'~1
(BSF-1~1
interleukin-4)~1
(MLC)~1
human),~1
H-Y,~1
H-Y~3
sex-reversed~1
(XX~1
H-2Kk,~3
(Taylor,~1
HLA-B37.~1
crystallized.~1
glucocorticoid-resistant~1
CTL-mediated~5
'deathless'~1
glucocorticoid-~1
(InsP3)~2
semitendinosus.~1
Caged~2
1(2-nitrophenyl)diazoethane~1
P4-~1
P5-position).~1
Photochemical~1
InsP3-specific~1
skeletal-muscle~1
phosphatases~1
open-sky~1
entrap~1
Cryoextraction~1
nucleosclerotic~1
Antinociceptive~1
(HCAs)~1
HCAs~7
(noradrenergic~1
HCAs),~2
protriptyline,~1
(serotonergic~1
citalopram.~1
Noradrenergic~1
saline-induced~1
Serotonergic~1
SPB~1
(papilla)~1
black)~1
PH1~1
PH3~2
4.44~2
(3.00~1
4.72~5
(PH4~1
6.54~1
PH5~1
8.98~1
(B4~1
9.41~1
premenarche,~1
7.88~1
9.05~1
menarche).~1
B5,~2
[Tyr10,13]secretin~1
[Tyr10,13,Phe22,Trp25]secretin,~1
secretin-stimulated~2
(150-240~1
kinase),~1
early-late~1
(glycoprotein~1
infected-cell~1
(ICP4,~1
ICP22,~1
ICP27,~1
ICP47)~1
early-late,~1
hybridize.~1
granulocyte/macrophage~2
A)-stimulated~1
IL-3.~1
CsA-resistant~1
[phorbol~1
(PMA)]~1
Dihydropteridine~1
(DHPR;~1
1.6.99.7)~1
NADH-mediated~1
dihydrobiopterin~1
pterin-dependent~1
hydroxylating~1
DHPR.~3
1.2-kilobase~1
TAP~9
T-cell-activating~1
focusing/NaDodSO4/PAGE~1
Ly-6.1E~2
trifluoromethanesulfonic~1
2C~1
aggressor~2
noncytolytic~1
SN1~2
SN2,~2
TALLA~1
GP37,~1
Ichikawa~3
mixtures:~1
[IgG1(kappa)]~3
SN2~7
SN1-RA~4
SN2-RA~4
5.8-7.0~1
6.4-7.8~1
transplantation;~2
T4-like~1
sperm-lymphocyte~1
OKT4A.~1
immunoglobulin-related~1
"idiopeptides,"~1
EBV.~1
(EBNA-1),~1
EBNA-2,~1
EBNA-3,~1
EBNA-leader~1
(LMP).~1
CD23.~2
(cALLA~1
BLA),~1
(transferrin~2
BK19.9),~1
adhesion-related~1
(LFA-1~1
LFA-3).~1
CD23~11
anti-CD23~1
45-kDa~5
90-kDa~2
[3H]pargyline,~1
benzylamine~1
[3H]Pargyline~1
microvessels;~1
MPTP.~1
"enzyme~1
barriers"~1
HuH-7,~1
3.6-~1
virus-related~1
1.35-1.36~1
1.22-1.24~1
g/cm3,~1
heterodimer.~2
26-kDa~6
glycoprotein),~2
2B4.~1
discerned.~1
gibbon~2
(gIL-3)~1
granulocyte,~2
gIL-3~4
aw18,~1
(I-E~1
chain)--Slp~1
(H-2a)~1
B10.MOL-SGR~1
(H-2wm7)~1
H-2aw18~2
intercross~1
aw18~2
H-2aw18.~1
meiotic,~1
unequal,~1
H-2a~2
H-2wm7~1
translocation-associated~1
MYC~12
(BL2)~1
t(8;22)~2
MYC.~2
deregulation~3
BL2~1
[Gazin,~1
Dupont~1
Direchin,~1
Hampe,~1
Masson,~1
Martin,~1
Stehelin,~1
Galibert,~1
383-387]~1
188-residue~1
(ASV~1
jun.~1
jun~1
transformation-specific~1
17-transformed~1
gag-jun~1
(Ay)~1
Ay~3
(Emv-15).~1
Emv-15~1
Ay-associated~1
(Emv-15)~1
viral-host~1
interferon-inducible~1
IP-10,~1
beta-thromboglobulin)~1
(connective~1
tissue-activating~1
q21,~1
monocytic/B-lymphocyte~1
t(4;11)(q21;q23).~2
t(4;11)(q21;q23)-carrying~1
IP-10~3
ETS1~1
11q23~1
translocate~2
t(4;11)~1
(q21;q23)~1
(9;11)~1
(p22;q23).~1
ETS1,~1
nonubiquitous,~1
non-HLA-A,B,C~2
JF11,~1
HLA-A,B,C-associated~1
cosmids~2
2-microglobulin.~4
alloantiserum~2
(HA2)~1
HLA-A2-positive,~1
phytohemagglutinin-activated~1
nonubiquitous~1
oligonucleotide-probe~1
resides.~1
39(CAG----TAG)~1
lipopolysaccharide-responsive~1
1-5%~1
DNA-reactive~1
(Ighj),~1
(Igha),~1
(Ighb),~1
nu/nu,~1
(Ighe)~1
anti-denatured~3
sorter-selected~1
Ly-1-positive~2
enriched,~1
(CD2)~1
sheep-erythrocyte-binding~2
T3-Ti~2
antigen-receptor~2
microsequencing~1
prolines~1
1.7-~1
1.3-kilobase~2
COS-1~2
0.92.~1
3-5.~1
Leu-19+~2
anti-CD3-anti-melanoma~1
conjugate-independent.~1
(42-54~1
(nonspecific~1
39.2)~1
15-kilobase~1
2700-base-pair~1
boundaries.~1
NCA.~1
Zimmermann~1
2960-2964]~1
[Paxton,~1
Mooser,~1
T.D.~1
920-924].~1
ancestor~2
B-glycoprotein~1
q31~1
q35,~1
[del(5q)]~2
5q-~2
del(5)(q15q33.3)~1
[del(5)(q13q33.3)].~1
q33~2
[del(5)(q22q33.1)].~1
novo,~1
[ins(21;5)(q22;q31.3q33.1)]~1
5q33.1.~1
CSF),~1
FMS,~1
centromere;~1
5q.~1
[Shanahan,~1
Denburg,~1
Bienenstock,~1
Befus,~1
Immunol.~1
1331-1337].~1
brasiliensis-infected~1
(12.5%),~1
association:~1
membrane-membrane~1
170-nm~1
embrace~1
lamellopodia.~1
mesotocin~1
Bufo~1
japonicus~1
MT,~1
Gly-Lys-Arg,~1
neurophysin.~1
toad.~1
Mechanoelectrical~1
frog's~1
adaptation:~1
tens~1
hair-bundle~1
mN~2
m-1.~1
m-1~1
spring,~1
dashpot,~1
Exp4,~1
Con4,~1
Exp7,~1
Con7,~1
3.5-cm~1
Exp4~3
Exp7~3
tensile-strength~2
Con4~1
Con7~1
Hodgkin~2
paramediastinal~2
"radiographic~1
negative"~2
post-radiation~1
(TMP-SMZ)~2
(G-6-PD).~1
SMZ~1
TMP-SMZ~6
G-6-PD-deficient~4
Pretherapy~2
20);~1
US1~2
US12~2
US2,~1
US3,~1
US4~2
US4,~1
US1,~1
US8,~1
US9,~1
US10,~1
US11,~1
US8~1
US12,~1
dispensable~3
(L3T4~1
Lyt-2)~1
(T3+,~1
Lyt-2-),~1
T3-associated~1
34-kilodalton~1
46-kilodalton~1
art/trs~5
transactivator~1
19-kilodalton~1
antigen-committed~2
I.C.~2
HIV),~1
L.L.~1
HTLV-I-infected~4
(gp61)~1
Military~1
empyemas.~1
small-intestine~2
(GVHD).~1
(LEW)~1
(LBN)~2
LBN~2
rejection).~1
identical-sized~2
warrant.~1
(Demerol)~1
electroanalgesia.~1
costeffective.~1
Electroanalgesia~1
Cosmetics~1
nondiagnostic.~1
Initial-staging~1
.0054)~1
876~2
9-French~1
flutter-type~1
(Heimlich)~1
chest-tube~1
28-French~1
edema-producing~1
blood-volume~1
(neonate~1
malrotation.~1
pushed~1
transpyloric~1
Kevlar~3
film-screen~1
cassette.~1
Phase-shift~4
long-TR~2
CSF-spinal~1
CSF-thecal~1
conspicuity,~2
mismapping~2
gating,~3
pulsation.~1
(phase-shift~1
(temporal~1
excitations,~1
rephasing.~1
pseudogating,~1
bed:~1
C-100).~1
polysomnograms~1
collapsibility~1
2500/50-100).~1
noncontour-deforming~1
2500/50-100~1
(N1,~1
DY)~1
incorrect,~1
photon-deficient~1
panangiograms~1
(hepatofugal~1
present/absent~1
patent/occluded.~1
enteroenteric~1
reniform~4
sausage-shaped~1
intussusceptions~1
cholecystograms~1
(sonography,~1
tunneled~1
vagina;~1
(Gd-DTPA).~1
thicknesses,~1
interslice~1
Gd-DTPA)~1
Signal-intensity~1
chemical-shift~2
hemopoietic,~1
1.4-T~1
fat-~1
water-selective~2
out-of-phase~4
radiographed,~1
fat-selective,~1
Fat-selective~1
T2-weighted,~2
cryosectional~1
borderlines~1
attachments;~1
99mTc-scintigraphy~1
rabbits:~1
1.5-mm~2
cortex).~1
glance,~1
discredit~1
"occult"~1
(4.4%)~1
penumoperitoneum~1
40-month~1
kilowatts~1
(+0.2~1
(+0.5~1
minute).~1
occulusion,~1
extracanalicular~1
Gadolinium-DTPA~1
frontally~1
(47)~1
megaloencephaly.~1
Megaloencephaly~1
macrocephaly.~1
angioplasties)~1
(1.5%),~1
98.5%,~1
95.0%,~1
99.5%.~1
over-penetrated~1
mistimed~1
T2).~1
hypocellularity.~1
acellularity~1
echo.~2
multislice,~1
multiecho,~1
water/fat,~1
universal,~1
perfluorochemicals~2
immiscible~1
odorless~1
unemulsified~1
perfluorohexylbromide~1
perfluoroctylbromide.~1
(orthostatic,~2
pressor)~1
trackers~1
nontrackers,~1
6-monthly~2
dosings~1
(VAC:~1
11,889~1
22,335~1
3-71~1
VAC,~1
keratomalacia~1
(X3A/B)~1
VAC.~1
blinding~2
Tinidazole~1
MIC90s~4
226.55~1
vaginalis-associated~1
leu-3a~1
leu-2a~1
leu-7~1
cytotoxicity)~1
10(4)/ml.~1
(r-IL2)~1
r-IL2~5
Recombinant-IL2~1
Pseudoaneurysms~1
protease-inhibitor~1
immunoturbidometric~1
[EIC])~1
583~1
Specification~2
heritabilities~1
luteum-epidermal~1
femtomol~1
125I-epidermal~1
incubate.~1
12.34~1
10(-19)~1
mol/micrograms~1
mol/L;~1
L/mol.~1
metronidazole-sensitive~1
cyoctol.~1
2.7%,~2
(maternal~1
neonatal)~1
amazonensis,~1
14-16~1
(18.7%)~1
caring,~1
p.m.~1
outlier~1
constellations~1
(URI)~1
(LRI)~1
ozone,~1
URI,~1
LRI,~1
LRI~1
PEFR.~1
unexposed.~1
193,000~1
Methodologic~1
Populations~2
Ortho-mune~1
OKT3,~2
OKT4,~3
OKT6,~2
OKT8).~1
39.7%)~1
(40.5%~1
27.8%).~1
antileishmania~1
Graft-to-enteric~1
(CABG),~1
(0.075~1
vaso-~2
broncho-constriction~3
[x~1
S.D.]~1
0.7-10.4~1
(beta-blockers,~1
CS)~1
(great~1
GCV)~1
mcg/kg~1
1.0),~1
isoflurane-oxygen.~1
GCV/CS~1
(lead~1
V5)~1
(GCV)~1
GCV~1
(inspired~1
0.75-1.0%).(ABSTRACT~1
EMTs.~1
Paid~1
cite~1
Wegener~3
1965.~2
cyclophosphamide-resistant~1
5'-ethynylthymidine~2
(strain~3
KOS)-induced~1
5'-Ethynylthymidine~1
333)-induced~1
acyclovir-~1
bromovinyldeoxyuridine-resistant~1
5'-ethynylthymidine,~1
1-infected~2
dATP,~1
dCTP.~1
Ampicillin-susceptible~1
strains).~1
enoxacin-treated~1
ofloxacin-treated~1
chloramphenicol-treated~1
ampicillin-treated~1
monocytogenes,~1
Citrobacter,~2
Morganella,~1
Providencia,~1
polymyositis/dermatomyositis,~1
(MCTD)~1
acronym~1
MCTD~1
SRA~1
(swollen~1
arthritis).~1
28,790~1
(143,512~1
dispensed~3
76,118~1
(560,341~1
supervise.~1
preceptors,~1
preceptor's~1
Archives.~1
28-channel~1
bleeding;~1
volvulus,~3
Diverticulectomy~1
hyperesthesia,~1
"reverberating~1
circuits"~1
aphakic-vitrectomized~3
Aphakic-vitrectomized~1
(404~1
pericorneal~1
histopathologically,~1
S-antigen.~3
(DR+~1
6-),~1
CD8,~2
post-partum~3
post-surgery~1
'half-life'~2
(72.2~1
(64.1~1
(45.5~1
beta/SP1~1
nasociliary~1
Postherpetic~1
Nasociliary~1
pentastomiasis~2
pentastomid~1
larva,~1
Linguatula~1
serrata,~1
pupil's~1
phlebotomy,~1
cytophereses,~1
50,000/microL,~1
granulocytic/macrophage~1
(CFU-C)~1
IL-2-mediated~1
(Ph)-positive~1
recombinations.~2
polyclonality~1
(vWF:Ag),~1
vWF:Ag~4
(74.8~1
U/dL),~3
(105.9~1
(116.9~1
(123.3~1
U/dL).~1
vWd,~1
(45%,~1
(vWd,~1
orf-2~1
colony-promoting~1
(GM-CSF~1
G-CSF)~1
GM-~1
CSFs.~4
AML-CFU~2
GM-CSF-~1
G-CSF-responsive~1
antipolynucleotide~3
K30~1
134.~1
aetiopathogenesis~1
eye-head~2
utricular/saccular~1
graviceptive~2
ipsiversive~2
(OTR).~1
OTR,~1
(nonparoxysmal)~1
OTR~3
Wallenberg's~1
dysconjugate~1
hypotropic~1
tilt--a~1
OTR--was~1
vertical)~1
contraversive~1
surround,~1
IL-2-activated~1
T24~1
non-Q-wave.~1
Double-vessel~1
pharmaco-mechanical~1
collagenase-treated~2
(InsP3;~1
ACh,~1
pharmacomechanical~1
auricles~1
reflex-decay~2
VIIIth~1
enalapril,~1
Clearance/bioavailability~1
distribution/bioavailability~1
HIPDM-Single~1
(rCP)~1
rCP~2
ByJ~1
anti-T-lymphocyte~1
anti-Lyt2.2~1
anti-Lyt2.2-treated~2
EMC-infected~1
L3T4~2
Mmalton~1
dysplastic,~2
1-AT)~2
1-AT~6
1-AT,~2
serum-albumin,~1
ileocolitis.~2
ache,~1
(56.6%)~1
PABA~8
Drawbacks~1
65.6~1
volunteers).~1
PABA/PAS~3
(PABA/PAS~1
0.0149~1
PABA)~1
0.902).~1
alpha-hydroxylase/17,20-lyase).~1
9-fold,~1
ACTH-mediated~3
10(-8)-M~1
P450c17;~1
(oCRH)-stimulated~1
on)~1
off)~1
oCRH-stimulated~2
0.747;~1
0.483;~1
(3-amino-1-hydroxypropylidene)~1
1,1-bisphosphonate~1
OHP~1
(rGM-CSF)~1
rGM-CSF~4
0-22-ng/ml~1
megakaryocytopoiesis.~1
(E-RFC)~1
(EC),~1
E-RFC~1
E-RFC,~1
(rIL-1)~3
anti-LFA1~1
EC-adherent~1
factor/cachectin~1
(TNF/C)~1
TNF/C~6
IL-1-injected~1
IL-1-~1
saline-treated,~1
hyperoxia-exposed~1
trichomonal~1
97.5%.~1
99.3%.~1
sinus).~1
tachycardia-initiating~2
"preventive~1
zone."~1
(AgE)~1
AgE~2
mitogen-like~1
AgE,~1
ragweed-allergic~1
AgE.~2
nonragweed-allergic~1
atopic)~1
AgE-responsive~2
AgE-allergic~1
subcloning,~1
antigen-nonspecific,~1
immune-deficient~1
immune-competent~1
graft-vs-host-induced~1
(GVHID)~1
GVHID.~1
B)F1~1
trinitophenyl-modified~1
GVHID~2
GVH.~1
spleen-derived~2
MCA-5~1
NK-markers~1
asialo-GM1~2
(NK-LAK).~1
(T-LAK).~1
NK-LAK~1
YAC-1,~1
T-LAK~1
excerted~1
1/6700~1
1/4200~1
1/3700~1
1/1450~1
NK-1-expressing~1
(HGG)-specific~1
AB.7.D7~3
HGG-primed~1
HGG.~1
HGG,~2
tolerogen.~3
HGG~2
nontolerogenic~1
Heat-aggregated~1
nontolerogenic,~1
nondegraded~1
us,~1
prelytic~1
nucleosomal~1
[Ca+2]i~3
[Ca+2]i.~1
[Ca+2]i,~2
Paraformaldehyde~1
"pulsing"~1
ionophores~2
(T3-Ti)~1
nonantigen-specific,~1
(Leu-8~1
circulating,~1
(CALLA-positive,~1
CD10)~1
thalassemics~2
RIP.~1
post-seroconversion~1
anti-rat~3
Thy-1-like~1
(1-hr)~1
mesangiolytic~2
mesangial-proliferative/infiltrative~1
ATS-induced~2
(CVF).~1
PMN/glomerulus)~1
ATS-treatment~1
CVF.~1
mesangiolysis~1
ATS-treated~2
anti-I-MN~1
proliferative/infiltrative~1
(655.0~1
micrograms/5~1
CVF-anti-CVF~1
antibody-C3~1
relate,~1
(TMEV),~1
TMEV-specific,~1
TMEV-infected~2
neuroantigen-specific~1
TMEV~2
encephalomyelitis.~2
thereof),~1
neuroantigens,~1
TMEV-specific~1
(lymphoproliferation),~1
polyarteritis,~1
cryoglobulins.~2
non-RF~2
cryoglobulins,~1
self-associate~1
nonimmunological~1
cryoglobulinemia.~1
(PEC),~1
1-specific~1
UV-B,~1
LBRM-33-1A5.~1
incubations,~1
(Q10)~1
2-promoted~1
4.0.~1
PG-stimulatory~1
cytokine(s)~1
anticytokine~1
synergizing~1
polyanions,~1
(nonreduced~1
reduced),~2
(180,000~1
360,000~1
TEPC15~1
idiotopic~1
anti-idiotopic~2
anti-idiotopes,~1
B24-44,~1
T15~9
paratope.~2
anti-idiotope,~2
B36-82,~1
7-22~1
140.7C6,~1
B36-82.~1
B36-82~4
B24-44~2
PC-protein~1
T15.~1
(Ins(1,4,5)P3).~1
tetrakisphosphate~1
(InsP4)~1
(Ins(1,3,4)P3)~1
anti-IgM.~4
polyphosphates~2
InsP4~2
Ins(1,3,4)P3.~1
Ins(1,4,5)P3;~1
E19.~1
abrogated.~1
E19~2
proIL-1~2
repressor.~1
10T1/2~2
EJ,~1
c-Ha-ras,~1
high-inducible~1
boostable,~1
Lyt-1.1~1
NK-deficient~1
YAC.~1
Ha-ras-transfected~1
non-transfected~1
transfectants.~2
Rat-1~1
compete,~1
v-fps.~1
target-effector~1
CTLA-1~4
CCP-1)~1
CTLA-3~3
Factor)~1
esterase-related~1
CTLA-3.~1
cytotoxicity;~1
Ly-6C~4
6C3~6
NZB,~1
NOD,~1
STb/J~1
6C3+~1
6C3-mediated~1
Ly-6.1~1
CBA/J),~1
Ly-6.2~1
MRL-+/+),~1
MRL-+/+~1
Lyt-2-/L3T4-~2
lpr/lpr~6
gld/gld~3
gld/gld)~1
Tp44~6
9.3.~2
co-expressed~4
PCA-1,~1
antigen-processing~1
isotype:~1
IgM-,~1
kappa-,~1
lambda-restricted~1
Id+~1
leukemia-derived~1
MOR-h2,~1
MOR-h3,~1
MOR-h4,~1
CG1,~2
CG2).~1
idiotopes.~2
idiotopes~6
anti-CG1,~1
anti-CG2,~1
anti-MOR-h2,~1
anti-MOR-h3~1
anti-MOR-h4,~1
CG2,~1
MOR-h2~1
MOR-h3~1
MOR-h4~1
autoantibody-associated~1
(NZW~6
BXSB)F1~6
micrograms/wk),~1
micrograms/wk)~2
sub-suppressive~1
(GPMBP)-sensitized~1
(LNC)~1
GPMBP~7
GPMBP-sensitized~1
LNC,~1
LNC~1
GPMBP-specific~2
Anti-Ia~1
LNC.~1
GPMBP-induced~2
EAE-inducing~1
H34~2
H67,~1
H6~3
H21~3
[125I]IL~1
liters/mol.~1
McAb.~2
H67~2
(HMCS).~1
HMCS~3
ILB1~1
time-sensitive,~1
1R)~1
(FITC)-conjugated~1
1R~9
stimulations.~1
1R-positive~2
interferons.~2
FITC-conjugated~1
monocyte-T~1
Resting,~1
lysosome,~1
digitonin,~1
17-kda~1
Endoplasmic~1
1-producing~1
(B).~1
(SDP)~1
(low/high~1
AXB/BXA~1
proliferation).~1
SDP~3
waits~1
comitogen~1
I-Ad-restricted~1
hybridomas,~2
derived-macrophage~1
(14M1.4),~1
(mediated~1
expression).~1
14M1.4~2
IFN-gamma)~1
(BSF-1),~1
2-independent~1
D10.G4.1~6
(D10)~1
conalbumin-specific~1
TCGF~4
3D3~4
clonotype-specific~1
antibody)~2
lymphokine-dependent~1
BSF-1/IL~1
D10.G4.1,~1
"T~1
factors"~1
(TCGF)~1
(RP-HPLC).~1
(GM-CSF),~1
cytokine.~1
cytokine-dependent~2
macrophage-colony~1
(GM-CSF)--this~1
HT-2,~1
co-factor~1
factor-alpha/cachectin~1
factor-beta/lymphotoxin~1
spectrums~1
TNF-alpha.~1
TNF-beta-stimulated~1
Kk~1
H-2Kk)~1
exclusively)~2
Qc-1.~1
Qc-1~1
Forssman~1
glycosphingolipid~1
(Fo).~1
Fo-specific~1
(MAB)~2
IgG2c~1
Fo-positive~3
Fo~3
macrophage-like,~1
glass-~1
nylon-adherent,~1
esterase-positive~2
globoside~1
glass-adherent,~1
(TNP)-M1~1
(TNP-M1~1
TNP-M1~5
Lyb-3+,~4
TNP-carbohydrate~1
(Lyb-3-,~2
5-)~1
5+)~1
Lyb-3-,~1
5+.~1
TNP-Ficoll~1
anti-Dextran~1
B512~2
(17-9).~1
anti-idiotypes~2
17-9~3
Dex-binding~1
anti-Dex~2
IgCHb~2
Backcross~1
allotype-linkage~1
"recurrent"~1
anti-alpha,1-6~1
(macrophage)~2
pre-S(1)~5
HBsAg/p43,~1
HBsAg/p43-specific~1
10-amino~1
p12-21,~1
pre-S(1)-specific~2
p12-21~1
p94-117~1
H-2-linked~1
2B1,~1
2B1~1
17.3.3~1
I-Ek-restricted~1
(mAb~4
binding).~1
(M6-Ricin)~1
5-hr~1
non-antibody-directed~1
M6-Ricin~4
isotype-matched~1
L2C-bearing~1
99.999%~1
logs)~1
(BSF-1)/interleukin~1
i.v.-administered~2
dosage-dependent~1
alpha-melanocyte-stimulating~1
(alpha-MSH).~1
alpha-MSH~7
(Nle4,~1
D-Phe7~1
alpha-MSH),~1
melanotropin-sensitive~1
3)-dependent~1
FD.C/1,~1
32Dc1-23,~1
KP3~1
Replication-defective~1
v-src~3
lymphokine-independent~2
v-src.~2
GM,~1
(GM-CSF)-dependent~1
GM-CSF-dependent~4
U937,~3
PMA-treated,~1
Paraformaldehyde-fixed~1
SW-1353.~1
acetate-activated~1
60-kDa~1
cross-linkage~2
radio-attenuated~1
promastigotes;~1
membrane-free~1
Vaccinated~1
Leishmania-specific~1
CP-immunized~1
53,000,~1
vaccine-induced~1
nonmembrane-derived~1
AKTB-1b,~1
sialidases~2
sialyltransferases~1
2-6,~1
2-8,~1
linkages,~1
(NDV),~1
sialidase,~1
CP-,~1
VC-,~1
NDV-treated~1
24-fold,~1
sixfold,~1
NDV,~1
1-3GalNAc~1
1-4GlcNAc~1
desialylating~1
NDV~1
iodinatable~1
resialylation~3
CP-treated~5
CMP-NANA~2
2-3(Gal~1
1-3GalNAc)~1
2-6(Gal~2
1-4GlcNAc)~2
sialyltransferase~3
VC-treated~1
sialyltransferases.~1
46,000~1
sialidase-dependent~1
(directed~1
NKH1~1
CD16,~1
CD4,~2
CD5,~1
CD5.~1
(Daudi)~1
AM-mediated~4
nontherapeutic~1
killer-like~1
pre-effector~1
expand,~1
BL-associated~1
BLA,~1
CALLA,~1
"activation"~2
BLA~1
BLA+,~2
CALLA+,~1
B1+,~2
sIgM+,~1
sIgD-,~1
C3d/EB~1
receptor+~1
Percoll-fractionated~1
IP-stained~1
semi-thin~1
CALLA+~1
centroblasts.~1
(RadLV)-transformed~1
(ovalbumin,~1
OVA)-specific~1
(OVA)~1
anti-OVA~3
(Ig)G2b~1
boosting~1
clone-primed~1
class-related~1
non-helper~1
RadLV-transformed~1
class-restricted~1
(DNP)-bovine~1
OVA-specific~2
DNP-OVA~1
noncommited~1
clone-dependent~1
Bolton-Hunter~5
(125I~1
PSF~3
cross-linkable~1
blood-derived~1
"collagen-stimulated~1
platelets"~1
(B200~1
B205).~1
125I-vWF~1
(collagen-treated~1
platelets)~1
B200~1
B205.~1
collagen-treated~1
GPIa,~1
GPIb.~2
(GPIa~1
?),~1
GPIIb-IIIa;~1
cysticercosis,~1
(25.7~1
25-80~1
shortest,~1
longest;~1
phytohaemagglutinin~2
12.5-29.0~1
43.0-66.0~1
Carbon-11-labeled~1
N,N-dimethylphenylethylamine~1
([11C]DMPEA)~1
N-methylphenylethylamine~1
[11C]methyl~1
oxidase-B~1
11C~4
[11C]DMPEA,~1
[11C]DMPEA~1
gummas,~1
periostitis,~1
gumma~1
greyhounds,~1
hyperemia),~1
rubidium-81~1
(81Rb);~1
4.58~1
(0.84~2
81Rb~4
0.83)~1
-3.29~1
1.91,~1
potassium-rich~2
Rubidium-81~1
No-carrier-added~1
fluoroprednisone~1
([18F]21-fluoroprednisone)~1
tosylate~1
2%-8%~1
cyclotron~1
(EOB),~1
[18F]21-fluoroprednisone~1
[18F]20-dihydro-21-fluoroprednisone.~1
[18F]21-fluorocorticoids~1
C-20.~1
(hemocyanin),~1
A--deficient~1
(Thy-1,~1
L3T4,~4
Mac-1)~1
Hyperaminoacidemia~1
whey-dominant~1
casein-dominant~1
whey/casein~2
18:82,~1
34:66,~1
50:50.~1
citrulline;~1
(IL2)~1
micrograms.)~1
(5,000~1
U/injection)~1
75Semethionine-release~1
vivo-generated~1
(7/29)~1
90),~1
0.3);~1
(WR6~1
HPB-ALL,~2
CCRF-HSB-2,~1
p12/lchikawa,~1
HPB-MLT;~1
leukemia-~1
HUT102,~1
HUT-102B2,~1
MT-2,~1
MJ,~1
C2/MJ,~1
KH-2,~1
KH-2Lo,~1
HPB-CTL-1,~1
ATN-C1;~1
ATL-derived~2
ATL-BK9~1
ATL-BK10;~1
Daudi;~1
myelocytic-monocytic~1
phytohemagglutinin-P-activated~1
HTLV-I-positive~4
KH-2~1
KH-2Lo~4
HPB-CTL-1~1
(TPA)-induced~1
Tumorigenicity~1
TU1~3
TM5,~2
C.B6-H-2dm4~1
(dm4)~1
TDM4,~1
dm4~3
heterozygosity,~1
TM5.~1
TU1,~2
subline.~1
TM5~1
labelling.~1
Leukocytes,~1
(PHM1),~1
cells/glom.~1
cells/mm2).~1
(0.3:~1
10/mm2)~1
14/mm2)~1
non-proliferative~3
15/mm2),~1
30/mm2),~1
53/mm2),~1
81/mm2).~1
post-infectious~1
significantly-increased~1
diagnostic-retrieval~1
syndrome--a~1
long-limbed~1
history)~1
blood-lead~4
Edinburgh.~1
(BAS).~1
"macrophage/dendritic"~2
(30,602~1
patient-days)~1
(27,329~1
patient-days),~1
daily-treatment~1
three-days-a-week~1
0.024).~1
3720~1
rate-regulation~1
1-methyl-4-phenylpyridine~1
(MPP+),~1
Lyden~1
neuromelanin,~1
depot,~1
melanins.~1
anti-malarial~1
(HTF-islands)~1
HTF-islands~1
non-methylated~1
rare-cutting~1
(C-G)~1
C-G~2
non-island~1
HTF-islands.~2
SacII~1
(EGFs)~1
(hEGF),~1
urogastrone,~1
crystallization.~1
1-48)~1
53-residue~1
EGFs~1
Onchocerciasis,~1
Epidemiological,~1
savannah.~1
epigenetic~1
Endothelium-derived~1
(EDRF)~1
Nitrovasodilators,~1
EDRF~11
Furchgott~1
NO.~2
EDRF.~1
potentiator.~1
anaphylotoxic~1
Dementias~1
monoaminergic,~1
(CRF)-like~1
Electronmicroscopy~1
(Hyalcon)~1
subluxated~1
luxation.~1
Paecilomyces~1
lilacinus~1
uninvolved,~1
20/20.~1
antibiotic/steroid~1
Vitrectomy~1
scarred,~1
cataracts).~1
equator~1
translental~1
side-reactions.~1
(Intraocular~1
0.01-0.02~1
elastotic~2
Oxytalan~1
fibrillogenesis~1
Meesmann's~1
(HSV).~1
3H-proline~1
pre-antibiotic~1
(IRBP),~1
(S-Ag),~1
(GFAP),~1
IRBP,~1
Anti-GFAP~1
photoreceptor-like~1
(IRBP,~1
S-Ag,~1
opsin).~1
Y-79~1
retinoblasts~1
phthisis~1
bulbi~1
B759U,~1
DHPG,~1
BIOLF-62,~1
2'NDG)~1
victims).~1
Gross,~1
megalic~1
capsids~1
(30.4%)~1
Breakthrough~1
CRCS~2
calciobiotic~1
sealer~1
hydroxide-based~1
sealer),~1
Proco-sol~2
Tubliseal~1
eugenol-based~1
sealers),~1
Diaket-A~2
polyvinyl-based~1
sealer)~1
coverslip~1
sealer,~1
Tubliseal.~1
Myo-Monitor~2
(temporofacial)~1
lymphocytosis-promoting~3
diphtheria-tetanus~5
toxoids-whole~3
toxoids-acellular~2
0.00008).~1
0.00001)~1
Natives~2
(Indians~1
Eskimos)~1
non-Native~1
Caucasian).~1
cholinesterases,~1
(BtChoEase;~1
"true"~1
3.1.1.7).~1
2.4-kilobase~2
N-terminal,~1
BtChoEase,~1
cholinesterase.~1
cholinesterase-producing~1
2.5-kilobase~1
cDNA-encoded~1
Schizosaccharomyces~2
pombe,~1
pombe~3
cam1,~1
1.2-kb~1
cerevisiae.~2
cam1~2
pombe.~1
calpastatin,~1
76,964),~1
(resultant~1
68,113).~1
Calpastatin~1
(cystatin),~1
cystatin.~1
pX~3
products:~1
p40x,~2
p27x-III,~2
p21x-III.~1
p40x~1
p27x-III~3
p21x-III~1
Cotransfection~1
p40x.~1
(TGF-alpha).~1
sis/platelet-derived~1
downregulated~2
TGF-alpha-expressing~2
contact-inhibited~1
v-sis-~1
v-erbB-transfected~1
(D10.G4;~1
cachectin,~1
(gp96).~1
14-amino~1
gp96~5
Oligonucleotide~1
gp96.~1
3-kilobase~1
trinitrophenyl-modified~1
low-hapten~2
BALB.C3H~2
(H-2k)~1
F6(51),~1
anti-trinitrophenyl~1
anti-trinitrophenyl-self~1
high-responder~2
progenies~1
F6(51)-immunized~1
F6(51)-defined~1
clonotype.~1
gene-directed~1
antigen-presentation~1
repertoires.~1
ferredoxin~2
(Fd-B2)~1
determinant)~1
anti-Fd-B2~1
ferredoxin.~1
Fd-B2~1
alignments.~1
(IL-4)~1
(PNA)-negative~1
PNA-positive~1
14-17~1
LyT2-~3
double-negative~3
LyT2+~2
double-positive~1
anti-IL-4~2
anti-IL-2~1
IL-4.~2
(CSFs)--L-cell~1
(CSF-1),~2
(GM-CSF)--were~1
granulocyte/macrophage,~1
40-200,~1
10-50,~1
40-500~1
HF1.7,~1
anti-Leu-3a,~1
HF1.7~2
anti-Leu-3a~2
mAbs.~2
anti-CD4~1
anti-mAb~1
cytofluorometry.~1
Attesting~1
110,000-120,000~1
(gp350/220)~1
leader-encoding~1
gp350/220~2
(Oka).~1
bromodeoxyuridine.~1
VZV-specific~1
6000-14,000~2
ether/ethanol~1
sequencer~1
Phe-Pro-Ile-Pro-Leu-Pro-Tyr-Cys-Trp-Leu-Cys-Arg-Ala-Leu-.~1
SPL(Phe).~1
Antiserum~1
SPL(Phe)~2
(Phe-Pro-Ile-Pro-Leu-Pro-)~1
beta-galactosidase-SPL(Phe)~1
2.0-kilobase~1
Phe-Pro-Ile-Pro-Leu-Pro-Try-,~1
SPL(Phe),~1
surfactant-deficient~1
Medium-chain~1
(MCAD;~1
acyl-CoA:~1
(acceptor)~1
2,3-oxidoreductase,~1
1.3.99.3)~1
Definition~3
MCAD~12
libraries,~2
1263-base-pair~1
738-base-pair~1
3'-nontranslated~1
heavy-~1
light-strand~1
5'-Adenylyl~1
imidodiphosphate~1
(p[NH]ppA),~1
beta-gamma~1
bond,~1
p[NH]ppA~1
(formation~2
preinitiation~1
initiation),~1
1.7-kilobase~1
3.3-kilobase~1
Lyt-3~6
Leu-2/T8~1
21-amino~1
variable-~1
joining-region-related~1
super~1
brain--in~1
(EAE)--we~1
(fully~2
EAE-susceptible~1
hyperinduction~2
RT-1~2
hyperinducibility~1
xenoantiserum~1
(JY).~1
190-kilobase~1
interleukin,~3
T-cell-replacing~2
(BCGF~2
killer-helper~1
(KHF).~1
KHF~3
agglutinin-binding~1
(PNA+)~1
PNA+~3
(HPLC-TRF)~1
TRF)~1
anti-TRF~1
TB13~5
HPLC-TRF~1
TRF.~3
KHF.~1
TRF,~1
RNK-16~5
(YAC-1)~1
(EL-4,~1
K562),~1
messenger.~1
OX-34,~2
OX-34~3
(9D7)~1
(P13K)~1
118-130).~1
56-kDa~1
9D7~4
anti-P13K~4
(CVI)~1
gamma'),~1
CVI~1
Lyt2-~1
140-base-pair~1
(ATTTGCAT)~1
1-J~1
joining)~1
beta-J~1
170-kDa~1
anti-P-glycoprotein~1
MRK-16.~1
anti-P-glycoprotein-toxin~1
polyproteins~3
(gag).~1
gag-initiated~1
frames:~1
(p27gag~1
p14gag);~1
(pro);~1
transcriptase.~2
frameshifts~1
frameshifting~1
efficiently:~1
gag-X/pro~1
X/pro-pol~1
gag-related~1
frameshifting;~1
US7~2
41,366~1
(G,~2
gallium-avid~1
abortion)~1
(IMOC)~1
IMOC~3
Projection~1
80,000,~2
540,000,~1
.84;~1
.93.~1
0.6%.~1
(Gl)~1
Gl~3
elastase/PI~3
(volume-corrected~1
oxygenator,~1
(MVR)~2
4/11~1
0/39.~1
valvulopathy~1
(introduction~1
cardioplegia)~1
(intra-aortic~1
pumping).~1
bcl-2~4
Precisely~1
cycle-dependent~4
Protein-DNA~1
0.2M~1
sites--dendritic~1
electro-diffusion~1
spines,~1
Termed~1
(2/16~1
patients--two~1
Encephalopathy,~1
Encephalopathy~1
speculation.~1
Intraspinal~1
Lister's~1
definitive,~1
ray).~1
"Y"~2
oblique)~1
ischium~1
ramus.~1
postfracture~1
tenosynovitis.~1
syringomyelia:~1
pulsated~1
Pulsation~1
Nonpulsatile~2
cysts:~1
Postsurgical~1
Axial,~1
spin-echo,~2
multiphasic,~2
guideline,~1
syringo-~1
hydromyelia,~1
(syringo-~1
hydromyelia).~1
distinctness~1
Moderately~1
2000-msec~1
56-msec-echo~1
nonirradiated,~1
space-occupying,~1
Radiation-related~1
intrathrombic~1
two-catheter~1
cytosine-arabinoside~1
VP16-213~2
interstitial-alveolar~1
2-9~1
7-21~1
consolidations~1
interstitial-alveolar,~1
paracardiac~8
"matted"~1
thickening/effusion.~1
nipple-areolar~2
Needles~1
obliquely.~1
skin-to-lesion~1
Dysplasia,~1
regions).~1
colectomies,~1
apposed,~2
Abscess~1
sinograms~1
single-contrast;~1
(one-third)~1
28-71~1
cleftlike~1
fill-in.~1
Mirror-image~1
(angiography,~1
transcystic~1
cytology-negative~1
Transcystic~1
albumin-saline~1
Gd-DTPA,~1
Renografin~3
safety-tested~1
11C-palmitate~4
11C-palmitate,~1
Pneumocystis.~1
F.IX,~1
XmnI,~1
Malays.~3
"cline"~1
present--and~1
Americans--are~1
Malays~1
disequilibrium,~1
XmnI.~1
non-European~1
Gibraltar~1
Suez.~1
MstII~1
amniocyte~2
alkali-burned~1
factor-treated~1
Hydropic~1
fundi,~1
"coronary"~1
(Maddox~1
Wing~1
p-deletion~1
micrograms/kg/minute~1
micrograms/kg/minute)~1
Acid-base~1
emulsion.~1
0.5),~1
Alfentanil~1
Steward~1
methohexitone.~1
151.9~1
10/103.7~1
14.1/87.5~1
gemstone~1
grinders,~1
polishers,~1
silica)~1
cutters~1
carvers.~1
polishers~1
AIDS).~1
Hemophiliacs~1
cells/microL~1
4.4-year~1
(48/152)~1
[18F]fluoro-2-deoxyglucose~1
11.9%.~1
(1.78/100~1
(3.22/100~1
Perivalvular~1
categories--patients~1
(nonfatal~1
fatal)--were~1
MIs.~1
censored.~1
MI:~1
MIs,~2
.0019).~1
nonrandomized,~1
unobserved~1
(HATT)~1
HATT.~1
HATT~1
platelet-aggregating~1
Harvesting~1
patent).~1
88,044~1
alcohol-drug~1
Sulindac~1
non-blood~1
(12/22,~1
infection-resistant~1
N-isopropyl-p-iodoamphetamine-iodine-123~1
(IMP).~1
hypoactivity~3
"redistribution"~1
angina--defined~1
(37%):~1
Reintervention~1
5-14.5)~1
82(3)%~1
89(6)%~1
87(7)%~1
1.82)~1
1.80)~1
1.45).~1
reintervention.~1
etretin~9
10-1670)~1
(ILI)~1
[3H]-thymidine)~1
ILI~4
(LAF)~1
LAF~1
etretin.~1
T6-positive~5
(1.55~1
0.52%)~1
Sialophorin,~1
gpL115,~1
sialophorin~7
sialylated,~1
sialylated.~1
115,000.~1
lymphocyte/monocyte~1
platelet/neutrophil~1
desialylation.~1
saccharide~1
(L-BCGF)~1
L-BCGF~2
129.~1
(CALLA)/CD10~1
L-BCGF.~1
inducing,~1
L-BCGF,~1
1-deamino-8-D-arginine~1
VIII/von~1
Proteolysis~1
factor-containing~1
biphenotypic~1
B-myelomonocytic~1
(rh~1
GM-CSF)~1
(SC;~1
(IV;~1
rh~4
(WBCs).~1
fourfold,~1
daily)-administered~1
(BSF-1)/Interleukin~1
(HPC).~1
prolierative~1
CFU-e~1
(rEPO).~1
induces,~1
rEPO,~1
(CFU-mix)~1
rEPO~2
FS7-20.6.18,~1
(CFU-Mk).~1
CFU-Mk~1
HPC~2
Amyloid,~1
(dCF;~1
[iv]~1
biweekly).~1
dCF,~2
dATP~2
(maximally,~1
nmol/10(6)~1
erythrocytes),~1
dCF~2
T-lymphoblast;~1
Endothelium-denuded~1
precontraction,~1
23187,~1
(10(-5)-10(-4)~1
(10(-8)-10(-6)~2
H1-receptors.~1
precontracted,~1
(10(-9)-10(-6)~1
M).(ABSTRACT~1
dual-head~1
medium-energy~1
collimators.~1
transaxially~1
reconstructed,~1
.95,~2
(Nalfon,~1
Dista,~1
Ind.)~1
(enteric~1
q.i.d.).~1
51Cr-tagged~1
subject-reported~1
1.104~1
0.961~1
ml/day)~1
1.686~1
0.858~1
ml/day),~1
krypton-81m.~1
-0.86,~1
(RIL-2),~1
t,~1
RIL-2,~2
(sacrifice~1
u/dose~2
Leu-3a/Leu-2a~1
malaise.~1
1:320,~1
PBC-specific~1
(anti-M2)~1
mixed-form~1
(anti-M4)~1
LE-cell~1
ASMA,~1
serological,~2
(LOBEX)~1
evening;~1
SHAM,~1
LOBEX,~1
LOBEX~7
LOBEX-lactating~2
PRL-releasing~4
alpha-methyl-para~1
5-hydroxytryptophan,~1
methyltrienolone~1
3H]R1881).~1
(250-350~1
nucleus-median~3
block-dissected~1
hypothalamus-preoptic~3
estrogen-mediated~1
[42.2~1
[3H]R1881~2
radioinert~1
(MGF)~2
alpha,25-(OH)2D3].~1
reciprocally.~1
alpha,25-(OH)2D3,~1
alpha,25-(OH)2D3~2
cell-derived,~1
44-2C~3
(DEX).~1
DEX-mediated~1
antiglucocorticoid,~1
RU-486.~2
CT-~3
CGRP-specific~3
RU-486~1
DEX-inhibited~1
RU-486;~1
CT/CGRP~1
(AII).~1
firing,~1
(Li+)~1
(CRF~1
AII;~1
Li+-loaded~1
tadpoles~6
metamorphic~3
climax,~2
5-deiodinase~1
tadpole~2
3,3'-diiodothyronine,~1
prometamorphic~2
climax.~1
premetamorphic~1
5-deiodinated~1
climax~3
(240-280~1
alpha-methyl-3H-trienolone.~1
[(EB)~1
BW]~1
oil-treated~3
EB.~2
(213%~1
alpha-methyl-3H-trienolone~1
EB-~1
EB-induced~1
EB-pretreated~1
pmol/10~4
V'm~2
K'm~2
(3.9-4.0~1
37.8,~1
37.4,~1
38.2,~1
(1.1-1.2~1
(AE)~1
(19-Nor-DOC),~1
18-hydroxylated~1
19-hydroxylase~3
18-OH-DOC~2
19-hydroxylases~1
synchronicity~1
Marino,~1
23-square~1
mile,~1
Adriatic~1
1969-1983~1
Gastroscopic~1
Marinese~2
Marino~2
reside,~1
Gastroscopy~1
Marino),~1
37-amino-acid~1
65-pmol~2
2.2-nmol~3
vasodilation.(ABSTRACT~1
(EDRF).~1
nitroprusside-stimulated~1
endothelium-covered~1
microcarrier~1
melittin,~1
hydroquinone.(ABSTRACT~1
microprocessor-controlled~1
abductors,~1
knee;~1
individual;~1
walker~1
stairs.~1
aortoenteric~2
revascularisation.~1
(NC~1
21-OHD)~1
21-OHD.~2
(10,548~1
5,998~1
(saliva,~1
787~1
21-OHD~2
0700-0900~1
(828~1
0900-1100~1
(314~1
pg/mL),~1
1.3-6.9%~1
21-OHD,~1
metyrapone,~1
ACTH-intact~3
ACTH-deficient~7
[dehydroepiandrosterone~1
4-A)]~1
postmaryrapone~1
27-566);~1
4-A,~2
105-651)],~1
postmetyrapone~1
3-16);~1
3-10)].~1
0.05-0.01)~1
U/day,~2
(DHEA~1
Osteocalcin~3
[97~1
rebounds~1
Staphylococcus-A~1
(20-40-fold)~1
mitogens;~1
synthesis-independent~1
(cycloheximide-insensitive)~1
(cycloheximide-sensitive)~1
(Ins~1
1,4,5-P3)~1
nonmitochondrial,~1
ATP-dependent,~1
1,4,5-P3-responsive~1
1,4,5-P3-induced~1
-0.49)~1
0.62),~1
1,4,5-P3.~1
anti-RNA-protein~1
anti-Ro/SSA~6
Ro/SSA~4
La/SSB~1
anti-La/SSB~2
precipitin.~1
Anti-nRNP(Sm)~1
anti-kappa~1
Paraprotein~1
anti-Ro/SSA.~1
Osteoclasts~1
(CSFs)~1
CSFs,~1
factor-urogastrone~2
(EGF-URO)~2
(FEM),~1
(cephalic)~1
(CAC),~1
(COR),~1
(CAR),~1
(REN)~1
EGF-URO,~3
tachyphylaxis,~2
EGF-URO~16
(FEM,~2
SMA)~1
[Emax]~1
(CAC,~1
COR,~1
CAR,~2
REN)~1
(Emax~1
SMA,~1
COR)~1
(CAC~1
REN).~1
COR~1
alpha-transforming~1
10(-10))~1
10(-9))~1
nonreversible~1
1,156~1
1):~1
224)~1
1C~8
1A,~4
1B,~3
10.3,~1
54%;~1
(1A~1
73;~1
1C,~1
(house~1
radioimmunoassays)~1
ryegrass.~1
Anaphylatoxins~1
extract-activated~1
1-encoded~1
(Mlsa~1
Mlsc)F1-hybrid~1
nonpolymorphic,~2
(responder~1
responder)~1
(HIgG)~1
monomethoxypolyethylene~1
(mPEG)~1
(sIg-)~1
sIg-~1
HIgG(mPEG)20~1
HIgG.~1
mPEG~1
(XIg)~1
XIg.~1
tolerization~1
(TNP-HGG).~1
TNP-SRBC~1
tolerization.~1
(ACAID)~1
IA-~1
TNP-Spl~2
IA+/I-J+~1
TNP-ACAID:~1
I-J+,~1
14-30,~1
14-30+~1
exit)~1
(H-2b,~2
Thy-1.2)~1
body-irradiated,~1
B10.Thy-1.1~1
Thy-1.1).~1
reconstitution,~2
low-binding~2
(Th).~1
thymus-shielded~2
body-irradiated~1
leg-~1
tail-shielded~1
(L-T-shielded)~1
L-T-shielded~1
component(s),~1
(CFA):~1
MRL/LPR~1
KLH/CFA.~1
less-pronounced~1
priming;~1
(Ag.Ab)~1
Ag.Ab~4
(Lipid~1
(PS~1
propyl-2-deoxy-2-[(3R)-3-hydroxytetrade-canamido]-4-O-pho~1
sph~1
ono-6-O-tetradecanoyl-beta-D-glucopyranoside~1
(glycolipid~1
M9)~1
M9,~1
methanolysis~1
3-deoxy-D-manno-2-octulosonic~1
triggering.~1
Thy-1-negative~2
phorbol-12-myristate-13-acetate~1
LBRM331A5~3
co-stimulated~1
Ly-1-negative~2
neuron-rich~1
(Fd11)~1
(TsF).~1
isolable~1
Fd11~7
(B16G)~1
(Fd),~1
binds.~1
(A10~1
TsF)~1
Fd-primed~1
boost.~1
Lymphotoxin~1
lambda:mouse~1
H-2-recombinant~1
intron-exon~2
[3H]methyltrienolone~1
8s~1
99.3%~1
OKT11)~1
dihydrotestosterone-mediated~1
2-like~1
precultured~2
Legionella-infected~1
OKT11+,~1
Leu-11+,~1
Leu-M1,~1
OKT8,~1
Leu-7,~1
Leu-7-.~1
T3-~1
beta-heterodimers~1
anti-T3,~1
Ti-alpha,~1
Ti-beta~1
Ti-T3~1
D-pretreated~2
WEHI~3
lymphotoxin-like~1
YE6/6~3
MBL-2,~1
mitogen-activated~3
leukemia-transformed~1
95,000~1
65,000,~1
(SSS-III)~1
anti-IgD~1
M5/114~1
anti-I-A/E~1
SSS-III-primed~1
SSS-III.~1
(Za~2
Zi)~2
(Br-poly(dG-dC).poly(dG-dC)~1
AAF-poly(dG-dC).poly(dG-dC)~1
Z-form~1
(poly(dG-5BrdC).poly(dG-5BrdC)~1
poly(dG-5MedC).poly(dG-5MedC)).~1
(Ze)~1
(3-7.3)~1
poly(dG-5BrC).poly(dG-5BrdC)~1
"model"~1
(BSF1)~1
BSF1.~1
35S-methionine.~1
Pre-B~1
(HGF)~1
HGF~7
HGF-sensitive~2
hybridoma.~2
P388D1~1
(m.w.~2
pI)~1
2/O~1
C3a(C3adesArg)~11
Ten-~1
C3a(C3adesArg)-induced~1
LPS;~1
C3a(C3adesArg).~1
desArg~1
C3adesArg~3
(fragment~1
163-171)~1
helper-dependent~1
helper-independent~2
163-171~5
ng/kg.~1
SIII,~1
polysaccharidic~1
Plasmacytoma~1
(PCT-GF),~1
PCT-GF~4
trimethylsilyl-controlled~1
HPLC;~1
NH2-Pro-Thr-Ser-Gln-Val-Arg-Arg-Gly-Asp-Phe-Thr-Glu-Asp-Thr-Thr-Pro-Asn-~1
Arg-Pro-Val-Tyr-Thr.~1
HLA-B27-negative~1
HLA-B27.1-positive~1
HLA-B27.1;~1
B27.2;~1
B27f~1
HLA-B27f~1
B27-specific~1
HLA-B27.1~1
HLA-A2.2Y,~1
HLA-A2.3,~1
HLA-Aw68.2~1
HLA-A2.1,~1
HLA-A2.2F,~1
HLA-A2.4,~1
HLA-Aw68.1,~1
HLA-Aw69.~1
Pairwise~1
sapiens.~1
polyphosphatidylinositol~1
32P-adenosine~1
(PtdInsP2)~1
(PtdInsP).~1
Alternately,~1
3H(inositol)-PtdInsP2~1
cholate.~1
anti-H2~1
PdtInsP,~1
immunoglobulin-mediated~1
Class-switched~1
GM+~1
(T-ALL)~1
LAK-cytotoxicity~1
leukemic-LAK~1
ALL-LAK~1
T3-,~1
T4-,~1
T8-,~1
T11+,~1
2-responding~1
non-NK~1
(LC)-~1
(AD~1
HSV),~1
Antigen-presenting~1
HSV-stimulated~1
(AMCR).~1
HSV-induced~1
AMCR~2
UVA-irradiated,~1
8-methoxypsoralen-treated,~1
(2-20~1
J/cm2)~1
Ultraviolet~1
somnolence,~1
(Westinghouse~1
FS-40~1
mJ/cm2/s~1
UV.~1
post-UV~1
euthermic~1
(analogues~1
Cryostat~3
gamma-chains~1
self-Ia-specific~1
self-Ia~1
BB5,~1
epidermotropic~1
Civatte~1
C10,~1
BB5~3
C10~2
anti-Lyt~1
BB5-induced~1
immunophenotype,~1
elastolysis,~1
(BKH)~1
multipolypoid~2
BKH~4
Zumbusch~1
platelet-agglutinating~2
Ib-binding~1
hypercatabolic,~1
hypozincemia,~1
naloxone-insensitive~1
(DISH)~1
rarer.~1
extra-axial~1
DISH~3
(Forestier's~1
Barbiturate-sensitive~1
FDG-PET~4
tumor/control~2
1.48:1~1
2.69:1~1
barbiturate-enhanced~1
barbiturates;~1
(T-helper~1
CPA.~1
CAP.~1
nervorum~2
(Obersteiner-Redlich~1
Ouchterlony~1
1-AT.~2
2-macroglobulin.~1
Diffusely~1
aslo~1
Perihilar~1
alkalotic~1
no-carrier-added~1
N-(2-[18F]fluoroethyl)spiroperidol~1
N-(3-[18F]fluoropropyl)spiroperidol~1
N-alkylation~1
spiroperidol~1
1-bromo-2-[18F]-fluoroethane~1
(2b),~1
1-[18F]fluoro-3-iodopropane~1
(2c)~1
1-bromo-3-[18F]fluoropropane~1
(2d)~1
(1.1%~1
(femur)~1
[18F]-N-methylspiroperiodol,~1
butaclamol.~1
5.9.~1
Metz~3
deconvolve~1
losses).~1
count-level~1
beside~1
overlayed~2
joystick.~2
filtering.~1
cameras.~1
Fe.~2
170,000-dalton~3
copper-adequate~2
thiourea~1
PM-induced~1
beforehand,~1
influenzae-treated~1
Nonlymphoidal~1
synovium),~1
venule-like~1
nonlymphoidal~1
units/ml)~3
(18.1~1
(11.9~1
units/ml).~1
[HLA-DR];~1
antiinterleukin~1
[Tac],~1
antitransferrin~1
[TF-R]~1
0.001-0.05).~1
Edward~2
sibship,~1
halfnull~1
C4A~2
dsDNA,~1
Ro(SSA),~1
La(SSB),~1
nRNP.~1
producers,~2
homozygous.~1
dermatomyositis/polymyositis~2
(DM/PM).~1
DM/PM~1
nondeforming~1
ASP.~3
2,941~1
2,030~1
58.~1
1,769~1
1,328~1
Vibratory~2
volts.~1
frenulum~1
electro-ejaculation~1
Suppressive~1
H-2q,~1
Ly-6.2,~1
Thy-1.2,~1
Ly-23.2,~1
3+.~1
(Kq,~1
Dq/Lq)~1
B10.Q~2
(H-2q)~1
Ly-m6.2A~1
Ly-m.6B,~1
Ly-m.6C,~1
H9/25~1
DBA/1,~1
KIU~1
ketamine-pentobarbital-anesthetized~1
aprotinin-pretreated~1
hr-1,~1
aprotinin.~1
intra-glomerular~3
serum-borne~1
lymphotoxic~1
GN.~1
lymphotoxin.~2
self-regulatory~1
cross-clamped~1
"iatrogenic"~2
presented:~1
unvented.~1
reperfusion:~2
equilibrium-gated~1
(technetium~1
99m)~1
17-month-old~2
mammary-left~1
vestibular-evoked~1
(VsER)~1
VsER~4
end-organ,~1
summit~1
radioimmunoassay),~2
anti-P-peptide~1
polyphosphoinositides.~1
cyclic-cAMP-generating~1
prokaryotes,~1
hexadecameric~1
topoisomerases,~1
CD4-positive~1
HEL(46-61),~1
10-mer~1
HEL(52-61)~3
Leu56~2
immunogenicity;~1
Tyr53~1
HEL(46-61)~1
interact,~1
cytolytic-T-cell-derived~1
CTLA-4,~1
223-amino-acid~1
V-like~1
CTLA-4~1
coinduced~1
ctla-4~1
Y-specific~4
Virus-specific~2
(HIV)-specific~1
HIV-vaccinia~1
env-expressing~1
gag-specific~1
env-specific~1
CD3-specific~1
immunopathogenesis~1
apes.~1
broncho-alveolar~1
CTL:~1
dysmetabolism~1
subthalamic~2
comparative,~1
mycoplasmas,~1
agar-selective~1
(Remel,~1
Lenexa,~1
KS)~1
microenzyme-linked~1
vaginalis-positive,~2
negative).~1
(.053-.084~1
isografts~1
syngeneic,~1
tubo-oophorectomized~1
teratogenic,~1
hypotony~1
(vWf),~1
vWf-producing~1
nonexpressing~1
1.1-kilobase~2
Pst~3
Sma~1
Sac~1
I-digestion~1
re-expressed~1
testicular,~2
I-DNA~1
22-kDa,~1
(IL-1)-related~1
nonhomology~1
(r)IL-1~1
26-kDa-protein~1
rIL-1~10
H-2Dp~3
hosts)~1
Dp~3
(EBV)-carrying~1
antigen-restricted~1
(CTLs)~2
EBV-seropositive~2
(LCL).~2
HLA-A11-positive~1
HLA-A11-restricted~1
LCL,~1
HLA-A11-specific~1
EBV-seronegative~2
LCL.~1
HLA-A11.~1
EBV-encoded~1
LCLs.~1
EBV-converted~1
LCL-like~1
LMP~1
HLA-A11~1
progenitor.~1
two-member~1
120-266)~1
128-267)~1
(B151K12)~1
anti-2,4-dinitrophenyl~1
dinitrophenyl-primed~1
(TRF~1
[B-cell~1
(BCGF-II)~1
activity].~1
TB13,~1
TRF-~1
BCGF-II-active~1
pSP6K-mTRF23.~1
46,000.~1
non-Dw2/non-Dw12.~1
Dw2~2
non-Dw2/non-Dw12~1
AZH,~1
AZH~1
"family,"~1
monocyte-produced~1
4-carboxyglutamic~1
(BGP)--a~1
formation--were~1
BW301U~2
trans-activating~2
tat-responsive~2
21-nucleotide~2
trans-activator.~1
LTR-directed~1
SUP-T1~1
CD1+,~1
6-thioguanine-~1
GM1500,~1
IgG2,~1
B532,~1
(Ig+,~1
B532+,~1
EBNA+,~1
segment-immunoglobulin~1
B-cell-specific~1
(idiotopes~1
Ids)~1
Id-expressing~1
anti-isotype)~2
low-resolution~1
Ids~3
variable-constant~1
anti-isotypic~3
(10(7)-10(8)~1
HLA-A3.1~5
HLA-A3.2~6
(A3.1,~2
A3.2,~3
leucine;~1
glutamine).~1
A3.1~1
152A3.1-156A3.2~3
152A3.2-156A3.1,~1
156.~1
nonmutated~1
P815-HTR~1
HLA-A3.1-restricted~1
152A3.2-156A3.1~2
HLA-A3.2-allospecific~1
152,~1
heterohybridomas~2
heterogeneous;~1
4D6,~1
heterohybridomas.~1
retain,~1
4D6~1
L-gene~3
22-kDa~3
22K.~1
nonsegmented~1
negative-strand~1
termination/polyadenylylation~2
56-68~1
RNAs:~1
truncated,~1
attenuator~1
Phage~1
1-219;~1
220-242;~1
243-263.~1
(Washington,~1
DC).~1
VIIa)~1
47-base~1
1.113~1
Nick-translated~1
1.143~1
15-kb~1
400-amino~1
51.141~1
2.4-kb~1
6.0-kb~1
dihedral-angle~1
constraints;~1
vicinal~1
beta-sheets.~1
host-range~2
PCC4aza1R,~1
PCMV,~1
75-base-pair~1
PCMV~2
PCC4~1
Protamines~1
postmeiotically~1
spermatids.~1
Prospects~1
PAT-1,~1
Panagrellus~1
redivivus.~1
redivivus~3
C15~5
unc-22~1
4.8-kilobase~1
(PAT-1)~1
copies)~1
(tk)~1
tk~5
crosses.~1
70Z/3~1
[Saga,~1
Tung,~1
J.-S.,~1
Shen,~1
F.-W.~1
Boyse,~1
6940-6944]~1
Ly-5~4
Ex-6(B)~1
Ex-7(B),~1
5'-proximal~1
lymphocyte-determined~3
43-53)~1
p63/latent~1
Guttman~1
scalogram~1
T4-cell~2
scale"~1
cumulative,~1
(sor,~2
3'-orf),~1
reinitiation~3
3'-orf~2
sor~8
anti-3'-orf~1
anti-sor~1
nucleocapsids~3
Neutralized~1
anti-glycoprotein~1
virion-cell~1
radiotracer.~1
imaging;~1
fluorine-18-2-fluorodeoxyglucose~1
(PET-FDG)~1
mg/dl/min~2
regrowing~1
(typical)~1
brucellosis,~1
backache,~1
nonosteoarticular~1
sacroiliacs~1
(5.3%),~1
Spondylitis~1
six-weeks~1
(Rb)~1
Knudson's~1
two-hit~1
"suicide"~1
laser-stimulated~1
1/300~1
erasable~1
2.0-nanometer~1
spacing,~1
50-kilodalton~3
neuroanatomically~1
unsteady~1
brain-stem.~1
cerebellomedullary~1
orbitopathy.~1
(PiZZ)~1
AAT-deficiency,~1
1963-82~1
overconsumption,~1
(PLC)~1
AAT-deficiency~1
4064~1
30-69~1
(DMS)~1
DMS~5
5.7%.~1
(13.5%),~1
(12.4%).~1
(21.9%),~1
(21.1%)~1
221)~1
calculated-T2~1
1.61%).~1
2.0-T~1
spatial-frequency~1
(k-space)~1
90-180~1
motion-independent~1
shift-resolved.~1
optionally~1
colors.~1
msec/image~1
masslike~2
2-35~1
discontinuance.~3
wide-latitude~2
air-interspace~1
low-scatter~1
LogEtronics~1
(TWL~1
TWL~6
well-penetrated~2
reversed-contrast~1
Nonpalpable,~1
noncalcified~3
(19),~1
pelvis;~1
Romanus~1
scintiscans,~1
spinning~1
chopper~1
mrad~1
recumbent.~1
Built-in~1
protractors~1
rulers.~1
scoliosis;~1
inequalities;~1
1.5-MR~1
Punctate~2
.024).~1
Discrete,~1
High-signal~1
Abnormal,~1
Perls'-stained~1
locales~1
Heavily~1
high-field~2
substances--principally~1
iron--that~1
neostriatum~3
(caudate~1
putamen),~1
T2*~1
parkinsonism/tremor,~1
hemiballismus.~1
Parkinsonisms~1
cortico-ponto-cerebello-dentato-rubro-thalamo-cortico-spinal~1
Dystonias~1
Choreas~1
Hemiballismus~1
craniopharyngiomas.~1
Obstructions~1
motion:thickening~1
0.97;~1
bepridil.~2
vWf-binding~1
(vWd),~1
85.4~2
(subsets):~1
sclerotherapy--10,~1
endoscopy--47,~1
endoscopy--21,~1
bleeding--nine.~1
protime,~1
bleed,~2
rebleed,~1
Blakemore~1
indicators:~1
0.0124)~1
morrhuate,~1
Reendoscopy,~1
amply~1
(5-ASA)~1
reinstituting~1
Melanesian~1
Vanuatu~2
falciparum.~2
mesangiocapillary~1
glomerulonephropathy~1
Countries.~1
Cellulosic~1
co-proliferation~1
vancomycin-polymyxin,~1
(TMP/SMX)~2
vancomycin-polymyxin~2
TMP/SMX~3
hematochezia,~1
platelet-bindable~1
150,000/mm3,~1
10(-8].~1
10(-6].~1
200,000/mm3~1
0.0049).~1
immunohistopathologic~1
choroid.~1
SIV.~1
paracortex.~2
SIV-induced~1
(rLT)~1
(1589~1
5554~1
neutrophils/cu~1
(10,368~1
992~1
4636~1
878~2
lymphocytes/cu~1
rLT,~1
hemodynamic-change-related~1
rLT-induced~3
stark~1
M5+~1
CRF-like~3
manic)~1
diphtheria-tetanus-pertussis~2
gms~2
Focusing~1
non-immunized~1
DTP,~1
DTP.~2
dose-heart~1
non-cardioselectively~1
noncardioselective~1
adrenergic-mediated~1
clonidine-treated~1
pre-incision~1
shivered~1
marijuana-tobacco~1
(MTS).~1
TS.~5
Hyperplasia~1
(joint-years)~1
smoking.(ABSTRACT~1
glue,~2
"closed"~2
high-concentration~1
plasma.(ABSTRACT~2
(ganciclovir)~1
ganciclovir,~1
Mainly~1
1900/mm3)~1
1000/mm3)~2
500/mm3)~1
(TBHI)~1
nontypeable~2
(NTHI)~1
TBHI~2
NTHI,~1
NTHI~2
TBHI.~1
(CMRO2),~1
(CpH),~1
(CMRGlc),~1
(CMRGlc[N])~1
(33.1~1
2.2),~1
CMRGlc(N)/CMRO2~1
CpH~2
0.06.~1
7.12~1
CMRGlc~1
(N)/CMRO2~1
acidotic,~1
CMRGlc/CMRO2~1
31608,~2
penem,~1
31608~9
Aeromonas,~1
(MIC50s)~1
rettgeri~1
piperacillin-,~1
ceftazidime-,~1
fluorescens,~1
acidovorans~1
TEM-1,~2
TEM-2,~1
SHV-1,~1
PSE-1,~1
OXA-2,~1
PSE-4,~1
P99~2
Ic~1
31608.~2
(MIC90S,~1
cephem~1
Cell-associated~2
Chloramphenicol~1
m-chlorophenylhydrazone,~1
motive~1
SCH24893,~1
multiple-antibiotic~1
Plasmids~2
tetracycline-resistant~2
tetracycline-susceptible~1
135-kilobase~1
45-kb~1
transconjugants.~1
multiple-antibiotic-resistant~2
58-kb~1
pNR9589.~1
Nonconjugative~1
98-kb~1
pNR9131~1
pNR9581,~2
50-kb~1
pNR9589~2
Double-digestion~1
pNR9131,~1
("colonization~1
resistance")~1
microflora.~4
antibiotic-treated~1
(25-OHD)~2
thalassaemia~3
25-OHD,~1
alpha,25~1
dihydroxyvitamin~1
alpha,25(OH)2D),~1
25-OHD~6
alpha,25(OH)2D~4
June.~1
alpha,25(OH)2D,~1
(FEV1.0),~1
(MEF50)~1
1,880~1
FEV1.0,~2
FEF25-75,~4
MEF50~1
MEF50,~1
OX1~1
leucocyte),~1
W3/25~4
(helper/effector~1
OX8~4
(suppressor/cytotoxic~2
infiltration:~1
Seven-~1
(5-day~1
count).~1
36%;~2
microflora,~1
gastrojejunal~1
(222)~1
colocolonic~1
(297)~1
0.2%,~1
(PADP)~1
(PAWP)~1
PADP,~1
PAWP,~2
LVEDP.~3
PADP~2
PAWP~2
(PADP),~1
(PAWP),~1
Histocompatibility~1
Electromyographically~1
postcerebrovascular~1
skin-surface~1
Prescribed~1
substandard)~1
EMGs~1
stroke-disrupted~1
EMG-triggered~2
relearning~1
reinstating~1
time-locked~1
theory;~1
intergrated~1
low-intensity,~1
galvanic~2
tenotomized~1
10/sec.~1
rebreak~1
(FES)~1
FES~6
FES.~1
photoplethysmographic~1
insured;~1
conducting-material~1
provided;~1
32-day~1
dacryocystitis,~2
Dacryocystitis~1
nonchlamydial~1
(nCSF-1)~1
(rIL-3)~1
lactoferrin-pretreated~1
rIL-3~4
nCSF-1~3
high-proliferative~1
(HPP-CFC)~1
low-proliferative~1
(LPP-CFC)~1
nCSF-1,~1
LPP-CFC~2
(rhG-CSF)~1
rhG-CSF.~1
rhG-CSF~7
MDS.~5
fMLP-induced~1
cell-restricted~3
-associated~2
(CD19),~1
(CD20),~1
(CD21),~1
(sIg),~1
(CD5)~1
(CD35)~1
sIg,~2
sIg+~1
(IL-2R)~1
Blast-1.~1
12-0-tetradecanoylphorbol-beta-acetate~1
IL-2R.~2
60-kilodalton~1
9-abl~1
(bcr).~1
chronic-phase~1
Ph~1
bcr,~1
bcr.~1
(auto)~1
2R)~1
2R~5
2R,~1
MLR.~3
IgG-class~2
(HSV),~1
HSV,~1
CMV-seropositive~1
HNK1+~1
CMV-seronegative~1
(196)/microL~1
(89)/microL,~1
respectively],~1
CD4+HNK1+~3
[38~1
(48)/microL~1
(13)/microL,~1
CD8+HNK1+~3
[166~1
(146)/microL~1
(54)/microL,~1
respectively].~1
HNK1~1
cytoplasmatic~1
TCB~1
beads;~1
(vWf).~1
afibrinogenemia~1
6D1,~1
(LJ-CP8)~1
LJ-P5,~1
IIb/IIIa,~2
afibrinogenemic~3
glass-bead~1
(platelet-platelet~1
adhesion)~1
Ag),~1
(AIDS-OI),~1
(AIDS-KS),~1
(ARC).~1
non-AIDS-related~1
gp41.~1
AIDS-OI~1
AIDS-KS,~1
AIDS-OI,~1
helper/T~1
Ag-positive~1
anaemic.~1
(NSAID).~1
3852~1
programme,~1
Oerskovia~1
xanthineolytica~1
monothermal~3
4-test-set~1
4-test~1
Posturography,~1
(recording~1
sway)~1
Indeed~1
posturography~2
posturography.~1
WHO.~1
serositis~1
foremost~1
Security--A~1
qualification.~1
equivalency.~1
statutes~1
(illness)~1
(disease),~1
essence,~1
(P-Alb)~1
P-Alb~1
PV.~2
2-amino-4-oxo-6(D-erythro-1',2',3'-trihydroxypropyl)-dihydropterid~1
ine~1
(D-erythro-neopterin).~1
(88.2~1
[SD]%)~1
29.9%).~1
D-erythro-neopterin~1
silica-dust-exposed~1
-bearing~1
T4+/T8+~4
(One~1
syndrome.)~1
anti-intrinsic~2
prenicious~1
17-hydroxylase~1
(17-OH)~1
17-OH~4
(51Cr-RBC)~1
neutrophil-depleted~1
boosting.~3
anticholera~3
(EGF)-induced~1
hepatocarcinogenesis.~1
derangement,~1
unit-granulocyte,~1
erythrocyte,~1
(megakaryocyte)~1
(CFU-GEM)~1
unit-erythroid~1
CFU-megakaryocyte~1
(CFU-Mk)~1
CFU-granulocyte-macrophage~1
gp110,~1
p24,~1
p51/65~1
2',3'-dideoxynucleoside~2
erythro~1
3'-azido-2',3'-dideoxythymidine~1
azidothymidine)~1
2',3'-dideoxycytidine~1
gag-proteins~1
"epidermal~1
ETAF,~1
(UVB,~1
290-320~1
sunlight.~1
source)~1
mRNA;~1
UVB-injured~1
(GP)Ib~1
vWF-induced~2
anti-GPIb~1
GPIb,~1
GPIIb/IIIa.~1
52/48-kD~1
(nu/+)~1
postinfection)~1
nu/+.~1
insusceptibility~1
anti-CVB~1
gamma-T~1
hierarchy,~1
T-ALLs~4
(22/26)~1
rearranged,~1
(11/13),~1
(3/14).~1
(8/14)~1
3A-1~1
(8/17)~1
(3/17).~1
(3/25)~1
ALLs~2
duality~1
uncommitted~1
serpin~1
(position~2
358)~1
357).~1
XIIa,~1
P2.~1
Ala357~2
Arg358,~1
Arg358~1
beta-Factor~1
XIIa.~1
0.069).~1
T-helper/inducer~1
(Th),~1
(anti-Leu~2
3a/anti-Leu~1
non-cutaneous~1
pretumorous~1
jellyfish~2
envenomated~1
jellyfish,~1
envenomations~2
coelenterates.~1
subphyla~1
coelenterates,~1
(79.5%).~1
(3.1%),~1
(2.3%),~1
(7.8%).~1
nonvariceal.~1
0.55%~1
melena~3
melena.~1
1-6%~1
"helper/inducer"~1
(W~1
3/13+,~1
3/25+,~1
OX~6
8-)~1
51Cr-~1
[14C]thymidine-labeled~1
restimulation.~1
exception:~1
perithymic~1
(pt-LN).~1
pt-LN~2
3/13+~1
3/25+~1
pt-LN.~1
(AgB)-specific~1
(Tsf1)~1
mini-Marbrook~4
AgB-specific~8
anti-Ig-coated~1
petri~1
Tsf1~4
(BMDM)~1
histocompatible~2
BMDM~4
BAL17,~1
12-myristate,~1
1-(5-isoquinolinesulfonyl)-2-methylpiperazine~1
dihydrochloride,~2
(PKC).~1
1-(5-isoquinoline-sulfonyl)-2-methylpiperazine~1
dioctanoylglycerol,~1
BAL17~3
PMA-blockade~1
(desensitization~1
PKC-mediated~1
Encephalitogenic~1
PL/J(H-2u)~1
(PL/J~1
SJL/J(H-2s))F1~1
((PLSJ)F1)~1
I-Au~3
PL/J~2
(PLSJ)F1~2
SJL/J.~1
1-11-specific~1
non-encephalitogenic~1
1-11.~1
Liposome~1
antifungals,~1
antiprotozoans,~1
Liposomes~1
headgroup~1
factor-1/interleukin~1
activated-EL-4~1
costimulant~1
(100-113)~1
factor-1.~1
(IL-4).~1
Cos-7~1
preactivation~1
unresponsive.~1
TKS-1,~1
growth-enhancing~1
(BGEF),~1
nonagglutinated~1
BGEF~6
HSB.2~1
C5B2.~1
IL-1-alpha~11
IL-1-beta.~4
TKS-1~1
SV-80~3
beta-phorbol-12-myristate-13-acetate~1
reversal:~1
beta-phorbol-12,13-dibutyrate,~1
vein-derived~1
1250-fold~1
adherence-inducing~1
12-o-tetradecanoylphorbol~1
IgE-specific~1
R).~1
lysomotropic~1
Endo~1
exoglycosidase~1
endo~1
N-glycosylated.~1
side-chains,~1
(tunicamycin)~1
[3H]mannose.~1
B10,~1
B10.A,~1
B10.A)F1,~1
(Asn86~1
Asn176)~1
bisialylated~1
biantennary~1
mannose)~1
Asn176~1
H-2Kk~4
H-2Kb~2
bi-~1
monosialylated~2
Asn86~2
cross.~1
Mitogenic~1
sialylation,~1
galactosylation~1
co-dominantly~1
143-4-2~2
143-4-2-defined~1
anti-Ly-6.2~1
Ly-6.2C~4
anti-Ly-6.2C~1
antigen-non-bearing~1
(PMA~1
antigen-like~1
anti-TcR~1
extrathymically~1
hepatoma-derived~1
(Hep-3B~1
(PBMNC).~1
immunoprecipitates.~1
albumin;~1
PBMNC.~2
4.0-fold~1
1-beta.~1
(Ab1),~1
IgG1-kappa,~1
gp37~4
37,000),~1
(Ab2)~1
Ab2~5
Ab2,~1
paratope~1
JM~1
anti-idiotopes.~1
4EA2~4
4DC6~4
4DD6~1
(Ab1)~1
anti-idiotope~1
SN2.~1
gp37.~2
Ab1~3
anti-anti-idiotopic~1
(Ab3)~1
(SN2).~1
("env"),~1
"env".~1
chimpanzees'~1
"env",~1
(gD).~1
gD~3
36.3)~1
HSV-2-infected~1
5,120~1
acyclovir-treated~1
13.5%-43.7%)~1
18.7%-33.0%)~1
megadaltons.~1
(CMRGlu),~1
Supramarginal~1
retyped~1
D-region~1
tissue-typing~1
sclerosis.(ABSTRACT~1
[18F]2-fluoro-2-deoxy-D-glucose~1
plugged.~1
(CMRglc),~1
21-83~1
[18F]-fluorodeoxyglucose~1
ECAT~1
tomograph.~1
CT/T~1
IOM~1
CMRglc,~2
invariant.~1
PET;~1
juxtaventricular~1
activities;~1
IVH.~3
electro-encephalograph~1
18F-fluorodeoxyglucose~1
(18F)-methyl~1
diffusible,~1
2(18F)-fluorodeoxyglucose.~1
metabolism-to-flow~1
rCMRglc,~1
Tanimoto~1
0.56.~1
Centered~1
eight-track~1
solves~1
schemes;~1
monitors;~1
playback~1
speed;~1
1/4-inch~1
(0.64-cm)~1
microcomputers;~1
unobtrusive,~1
reconfigured~1
[1-11C]putrescine~1
([11C]PUT)~1
(GMR)~1
[1-11C]2-deoxy-D-glucose~1
([11C]2DG)~1
Blood-to-brain~1
[11C]PUT.~1
[11C]PUT~4
cc-1~2
3.11)~1
GMR~3
0.098~1
signal:noise~1
glycolytically~1
hypometabolic~1
[13N]ammonia~1
(S:R)~1
(RMPR)~1
S:R~1
(%D)~1
(%A)~1
%D~2
%A~2
RMPR~3
-0.68)~1
-0.92)~1
(TMJs)~1
(0.88)~1
(0.76)~1
(0.56)~1
TMJs,~1
rod"~1
sectors.~1
step-and-shoot~1
aliasing~1
62-156~1
postinfarct~1
[1-11C]~1
Residue~1
radio-biochemical~1
(2.9%~1
fractions),~2
73.7%~1
oxidized,~2
back-diffused~1
27.2%~1
diglyceride,~1
nonmetabolized~2
case-patient~1
2147)~1
1253~1
6.7;~1
42.5;~1
1-antiproteinase~1
noninfected.~1
congruently~1
drug-abusing~1
drug-using~1
non-drug-exposed~1
unprescribed~3
cefsulodine)~1
Recreational~1
1-methyl-4-phenyl-pyridinium~1
N1-[3H]methylnicotinamide~1
([3H]NMN),~1
H+-driven~1
86.6%,~1
harmaline~1
87.1%,~1
Mepiperphenidol~1
(Darstine)~1
80.6%.~1
elicitor~1
translocated;~1
translocated.~1
cation/H+~1
antiporter.~1
antimitotic~1
reversibility.~2
[3H]leucine,~1
agonists:~1
(KCl).~1
(130%~1
TGF-alpha,~1
EGF-URO.~1
KCl)-mediated~1
Benzo(a)pyrene~1
BaP.~1
A-elicited~1
BaP-exposed~2
nonadherent,~1
BaP~5
-3),~1
+7)~1
interleukin-1.~1
pons/medulla~1
protein-specific~1
cells/kg~1
line-mediated~1
TNS-induced~2
anti-DNA,~1
antihistone,~1
autoantigenic~1
nucleosome,~1
Antihistone~2
histone-histone~1
DNA-histone~1
4.6.3~3
IgML~1
antinative~1
endorphin-like~1
cellular,~1
Androgens~1
Ro(SSA)~2
La(SSB)~1
(CD3+~1
CD8+)~1
(snRNA)~1
U2,~1
U4,~1
U6.~1
70K,~1
A',~1
B',~2
B",~1
snRNA,~2
Anti-(U1)~1
Anti-(U1,U2)~1
A'~1
B"~1
snRNA~3
p70/p80~5
(Ku),~1
lamins~1
pores,~3
transcribable~1
nontranscribable~1
heterochromatin.~1
p70/p80,~1
(IL2)-induced~1
IL2-cultured~3
MKN-28~4
unsuitable.~1
(thermodilution)~1
218.4~1
2,049~1
dynes/sec/cm-5,~1
1,485~1
366~1
2,028~1
false.~1
femoral-radial~1
HIV-mediated~1
HIVs~1
(HIVLAV).~1
LAV,~1
(CD-4)~1
non-cytocidal~2
body-sway~1
swaying~1
impulse-noise-induced~1
(HSV1)~1
(HSV2),~1
HSV1~1
HSV2~1
macroinvasive~1
coagulate,~1
vaporize,~1
scalpel.~1
Impulse-evoked~1
3-20~1
(BoTx)~1
gentamycin,~1
bekanamycin,~1
BoTx-poisoned~1
3,4-diaminopyridine~1
BoTx~2
BoTx,~1
(biosynthetic)~1
(2225~1
4575~1
2397~1
48,700~1
effects--low-grade~1
flushing--were~1
osteoclast-stimulating~1
lymphotoxin,~1
cell-culture~1
endow~1
'sandwiched'~1
(simian~1
immodeficiency~1
(STLV-IIIMAC)~1
(STLV-IIIAGM)~1
(STLV-IIMM)~1
non-pathogenic~1
(HTLV-IV),~1
HIV-2ROD~1
LAV-2)~1
ungulate~1
lentiretroviruses.~1
Knudson.~1
(FAP,~1
coli),~1
5q,~1
5q~1
(EGF).~2
Subversion~1
SSV-transformation~1
cellularly~1
A-chain,~1
homodimers,~1
PDGF-responsive,~1
1-minute,~1
T-1,~1
subcutaneously.~3
microA,~1
mah-jongg~1
graphesthesia~1
Reis-Bucklers'~1
Lattice~1
Rifampin~1
reacquisition~1
conjunctivitis-otitis~1
(CJ-AOM)~1
leukocytes/high~1
Nontypable~1
CJ-AOM;~1
CJ-AOM.~2
42),~1
encephalomalacia,~1
(Connaught~1
Praxis)~1
Postvaccination~1
radioimmunoassay)~1
(antibody~1
0.149~1
(0.838~1
Eighteen-month-old~1
anaphylactoid-like~1
meningitis)~2
fragment-repressor~1
("footprinting")~1
17-base-pair-long~1
bac,~1
operator-constitutive~1
+418~1
+1524~1
[alpha~1
2(I)]~1
enhancer-dependent~1
299-residue~1
factor-binding~1
S-carboxymethylated~1
Achromobacter~1
299,~1
269-287.~1
hydrophilic,~1
"macroglycopeptide"~1
292.~1
29-193)~1
leucine-rich~1
2-glycoprotein.~1
Lopez~1
[Lopez,~1
Chung,~1
D.W.,~1
Fujikawa,~1
Hagen,~1
F.S.,~1
Papayannopoulou,~1
Roth,~1
G.J.~1
5615-5619].~1
mediator(s)~1
genes).~2
(Subclass~1
DO)~1
interchangeability~1
(EBV)-positive~1
(BJAB)~1
EBV-positive~1
BJAB~3
21-hydroxylation~1
P450XXIA2~4
[steroid~1
21-monooxygenase~1
21-hydroxylase),~1
1.14.99.10],~1
21-hydroxylation.~1
P450XXIA1~1
XXIA2~1
XXIA1~1
3.2-kb~1
probands;~1
EcoRI.~1
Kpn~1
"deletions"~1
conversions,~1
crossovers,~1
MRL/MP~1
Lyt-2-,L3T4-,Thy-1+,~1
Lyt-2-,L3T4-,Ia-,Thy-1-~1
q23-31,~1
5q-chromosome~1
del(5)(q15q33.3),~1
[del(5)(q13q33.3)],~1
[del(5)(q14q33.3)].~1
granulocyte-macrophage-CSF),~1
macrophage-CSF),~1
receptor).~1
5q-chromosome,~1
del(5q).~1
2-deoxy[14C]glucose~1
(MPTP).~1
L-Dopa~1
carbidopa)~1
L-dopa-treated~1
L-Dopa,~1
asset.~1
CABGs,~1
CABGs.~1
l/min/m2~1
hemolyzed,~1
retransfused.~1
autotransfusate.~1
autotransfusion.~1
psychometry,~1
(CSF-AK)~1
fatigue)~1
CSF-AK~2
U/l)~1
U/l~1
-3.4.~1
Psychometrically,~1
trival~1
supplementary,~1
lung/visceral~1
vector-infected~1
orf)~1
sor.~1
Cos-1~1
(OKT4-)~1
DNA's~1
"susceptible"~1
coculture.~1
gag-,~1
env-,~1
pol-derived~1
trs.~1
organ-resident~1
uveoretinitis,~1
uveitogenic~1
tuberculin,~1
(Muller~1
contact-dependent~1
beta-interleukin-1~1
serum?~1
cortex?~1
effect?~1
laparotomy)~1
(endotoxin-tolerant)~1
1-inch~1
conalbumin~2
(D.10.G4.1)~1
Iak~1
conalbumin.~1
(167%~1
lymphocyte-recruiting~1
footpad,~1
footpad.~1
LPS-bearing~1
footpads.~1
homed~1
hind-footpad~1
attracting~1
attracted.~1
"focusing"~1
mitogen-activated,~1
(IL-2~1
significant-~1
immunofacilitation~1
(IgG2b)~1
(30H12)~1
Thy1.2~3
deposition).~1
(SIT).~1
(Lew)~1
Lew~3
Fl~1
Lew;~1
rejection),~1
Lew,~1
GVHD),~1
LBN.~1
(PCA),~2
SIT.~1
(blunted~1
infiltration)~1
architecture)~1
18-64~1
35-44~1
summarising~1
PD20~10
FEV1-log~1
graph,~1
fitting,~2
interpolation,~1
0.03-8~1
(lymphocyte~3
17%);~1
202%~1
urethra/external~2
urodynamically.~1
reeducation~1
alpha-blockers~1
tried;~1
sacral-root~1
electro-stimulation,~1
segmental,~1
subsegmental.~1
15-47~1
transmural,~1
ileum;~1
appendicitis;~1
interspaces;~1
disk).~1
TR/TE.~1
requisition~2
radiographs:~1
hypesthesia,~1
hyperesthesia~1
hyporeflexia~1
two-sentence~1
1443~1
759~1
(C4-C6).~1
osteochondromas,~1
cap.~2
perichondrium,~2
CT:~1
Lymphomatous~1
necrotized.~1
Extranodal~1
dissipate,~1
equivocal;~1
amputations).~1
flow--a~1
exploration;~2
harvesting;~1
jurisdiction~1
legislate~1
calculator.~1
40-140~1
6.0-mm~1
0.3%.~2
well-calibrated~1
LVEFs,~1
anatomy.(ABSTRACT~1
(317~1
nmol/L),~1
income.~1
micrograms/d)~1
SCa~1
long-stay~1
immunotransmitter,~1
iron-adequate~1
PEC.~1
gonads;~1
dicentric~1
X;Y~1
breakpoints.~1
Centromeric~1
"suppressed"~1
46,X,t(X;Y)(q22;p11).~1
Y-DNA~1
(lysine~1
acetylsalicylate),~1
(epinephrine),~1
post-aspirin~1
guaiac-impregnated~1
anticoagulant;~1
poxviruses,~1
Shope~1
(MV),~1
(EGF)-like~1
Virus-free~1
SFV~3
MV-infected~1
EGF-unresponsive~1
RK-13~2
EGF-responsive~1
EGF-stimulated~1
Electroblotting~1
anti-EGF~1
EGF-EGF~1
(MN)~1
1:10),~1
(3H-thymidine~1
9,697~1
2,508~1
8,969~1
8,515~1
fumes.~1
1.60.~1
1.53,~1
1.17-2.08).~1
Participants:~1
disoriented~1
deterioration).~1
epithelium--Bruch's~1
membrane--choriocapillaris~1
(LMTK-),~1
LMTK-~3
LMTK+~1
(LH7~1
anabolize~1
LH7~5
[14C]ganciclovir~1
2',3'-didehydro-2',3'-dideoxythymidine~1
2',3'-didehydro-2',3'-dideoxycytidine~1
(DHC)~1
I-carrying~1
DHC~2
2',3'-dideoxynucleosides.~1
beta-lactamase-coding~1
3.2-megadalton~2
biotin-labeled~1
TEM-1~1
TnA~1
"African-type"~1
(IABP)~1
hemodynamically,~1
1,448~1
73.3%;~1
45.9%;~1
34.2%;~1
41.9%.~1
53.3%,~1
31.9%.~1
lectins--wheat~1
(RCA-I),~1
A)--stained~1
lectins--WGA,~1
RCA-I,~1
(SBA).~1
lectin-positive~1
red-positive~1
red-reactive~1
WGA-,~1
RCA-I-,~1
A-,~1
PNA-,~1
SBA-positive~1
consist,~1
N-acetylglucosamine/sialic~1
mannose/glucose~1
beta-galactose~1
beta-galactose-N-acetylgalactosamine~1
disaccharides.~1
(w11,w12),~1
(w13,w14),~1
(composed~1
alloantigenic~1
epitopes),~1
Antipolynucleotide~1
(dsDNA)~1
dsDNA~2
Spasmodic~1
derived:~1
(HTLV-IV)~1
(LAV-2FG~1
SBL~7
6669)~1
HTLV-III/HIV-1,~1
6669~1
HTLV-IV/STLV-IIIAGM.~1
HTLV-III/HIV.~1
-104~2
(start~1
+1)~1
Spl~1
-151~1
-80)~1
III/lymphadenopathy~1
HXB2,~1
HXB2~3
BH10~2
HXB3,~2
lymphocytopathic~1
HXB3~1
orf~1
cytopathicity.~1
(LIS),~1
(NK9)~1
NK9-positive~1
LIS.~2
(OKTII~1
ve),~3
(OKT4~1
(OKT8~1
(OKT6~1
ve)~2
(anti-Tac~1
LIS~2
DLE,SLE~1
(PFE)~1
PFE~3
faradism;~1
perineometry.~1
hospital-treated~2
perivasculitis,~1
(TRG~1
(TCR~1
TRG~4
biallelic~1
(transcripts~1
[kb])~1
anti-Ti~1
CD3-TRG~1
CD1a,~1
CD1b,~1
CD1c,~1
CD1a~2
(cALL)~1
(CD10)-positive~1
(cBMLs).~1
cBML,~3
CD10~5
CD34~4
(MY10)~1
(CLA),~2
CD20~5
(B1),~1
ctyoplasmic~1
(Cmu)~1
cALL,~1
CLA~3
Cmu~5
cBML.~1
cALL.~2
cALL~5
CD10,~2
CLA,~2
CD34,~3
cBMLs.~1
CD20,~1
cBMLs,~1
CD34-negative~1
Tyrode-albumin~2
10E5,~1
(EHPVO)~1
12-69).~1
1-17)~1
1-48).~1
eradicated,~1
3-105).~1
23.~1
EHPVO.~1
over-tube~5
re-bleeding~1
re-bleedings~1
oleate.~1
accomplish;~1
bleeding).~1
polyradiculoneuropathy,~1
immuno-compromised~1
IL-2-producing~1
11-deoxycorticosterone~1
(histologically,~1
AA).~1
B/DOC~3
F/S~2
(7.7,4.1,5.9,1.9~1
23.5,~1
median),~1
(16.2,~1
29.6,~1
graft-coronary~2
subselective~2
peak/resting~1
(Brown/Dodge~1
coronary-vein~1
hypokinesis.(ABSTRACT~1
spiculization~1
Towne~1
(4-72~1
nature/origin~1
activation/proliferation.~1
(interleukin-2~1
Ki-67~5
0.0007;~1
DR5J~3
(Corrected~1
pc.)~1
electrogalvanic~1
(EGS).~1
EGS~2
two-to-four-hour~1
hematochezia~1
Technetium-99~1
(Tc-99m)~1
microperifusion~2
hydrodynamics.~1
oCRF,~1
perifusion.~2
stopped;~1
oCRF.~1
oCRF-like~1
half-lives.~1
hypophysial-portal~3
(irCRF)~1
aminergic~1
irCRF~5
coryanthine,~2
0.1-5.0~1
coryanthine.~1
[18F]2-deoxyglucose~1
(LCMRglu)~1
(CPS),~1
LCMRglu~4
glucose/100~1
right),~1
(left,~1
(right,~1
CT/MRI;~1
0.054~1
LCMRglu,~1
-0.36;~1
-0.22;~1
centromedian~1
(CM).~1
semiflexible~2
platinum-iridium~1
Bipolar,~1
Zung's~1
Mann~1
Whitney~1
ESCM~1
outlasted~1
"kindling,"~1
pS4~3
Yq12.~2
C-banding.~1
4B-2~2
Yq11.~1
daughters.~1
46,XX,15p+~2
Amniocytes~1
46,XY,15p+.~1
daughters,~1
amniocytes~2
Mbo~1
46,XY,15p+~2
male-specific~3
8-in.~1
32-labeled~1
"classically"~1
Immunoprophylaxis,~1
(PO-AH)~1
PO-AH~2
warm-responsive~3
thermoresponsive~1
thermoresponsiveness~1
lymphoma/leukemia.~1
HTLV-II-transformed~1
HTLV-negative~1
S-LB1,~1
25OH-[3H]D3~3
[24,25-(OH)2D3],~1
1,24,25-trihydroxyvitamin~1
[1,24,25-(OH)3D3].~1
25OH-[3H]D3.~1
S-LB1~4
1,25-(OH)2-[3H]D3~1
24,25-(OH)2-[3H]D3~1
[primarily~1
1,24,25-(OH)3D3]~1
25OH-[3H]D3-metabolizing~1
25OHD3.~1
17-hydroxylase,~1
17,20-desmolase,~2
11-hydroxylase~1
dehydrogenase/isomerase~1
17-desoxysteroids~1
PRA.~3
(EBV)-induced~2
EBV-immune~2
(GD);~1
carbimazole~1
carbimazole-treated~1
[1,25-(OH)2D],~1
Gla-protein~1
7p13,~1
11q23-24,~1
12p11-13,~1
CD19~1
physiologic.~1
anti-TNF,~1
anti-IL-1,~1
(multi-CSF)~1
multi-CSF;~1
multi-CSF~5
granulocyte-CSF~1
(G-CSF).~1
multipoietin.~1
Alone~1
eosinophil,~1
2.8-11.0~1
U/dl~2
(RBC)-suspending~1
(SFM),~1
27-fold).~1
SFM~2
Vaso-occlusive~2
comitogenesis~2
Non-cytotoxic~1
(Binet~1
classification),~1
discriminating.~2
Anti-Jo-1~1
histidyl-t-RNA~1
synthetase,~2
excision(s)~1
21.74~1
non-glued~1
19.79~1
18F-2-deoxyglucose~1
C57BL/6NNia~1
escape-avoidance,~1
hostile~1
Instrumental~1
PVP,~2
PVP-specific~4
PVP.~3
culture:~1
(IgA)-bearing~1
human-human~1
anti-phosphorycholine~1
(PC-Sepharose)~1
glycine-conjugated~1
PC-Sepharose.~2
PC-Sepharose,~1
Mitogen-stimulated~1
anti-PC-bearing~1
(NZB)~1
NZB.xid~2
(mIgM)-expressing~1
LBMC,~1
mIgM.~1
(SJL/J~1
I-As,~1
MBP-sensitized~2
(I-Ad),~1
CBA/CaJ~1
(MTg)~1
(MTE)~1
(CFA).~1
CFA,~1
MTE-primed~1
MTE~2
MTE,~1
MTE-injected~1
(BB/Wor)~1
lymphopenic,~1
8+~2
19-~1
(LCMV)~1
LCMV,~1
LCMV-infected~2
(OX~1
8+),~1
Tc.~1
II-like~2
Prototype~1
PHA-P-stimulated~1
BCGF),~1
sup).~1
sup~4
cell-depleted,~2
vivo-activated,~1
synergized~1
IgM-specific~1
sup-induced~1
synergies~1
IIB.~1
foreskins.~1
foreskins,~1
mock-conditioned~1
dexamethasone;~1
immunoultrastructural~1
trafficking.~1
k)~1
93-103~1
93-104.~1
101,~3
102,~2
B10.A(5R)~1
b:E~1
agretope,~1
agretope~2
trimolecular~1
heteroaggregates~1
10(3).~1
lymphoma-hybridoma,~1
TA3.~1
glycosphingolipid,~1
3-dependent,~1
(BMMC).~1
glycosphingolipids~1
BMMC~8
3-conditioned~1
mediator,~1
beta-hexosaminidase,~1
histamine-augmenting~1
BMMC,~1
contaminant,~1
BMMC.(ABSTRACT~1
(gp57Tac)~1
(pp78)~1
co-immunoprecipitates~1
gp57Tac~3
pp78~2
(PBL-T)~1
2.8.2.~1
PBL-T~1
epsilon.~1
unmanipulated~1
epsilon,~1
Hapten-specific,~1
(TNP-ABC)~1
short-,~1
TNP-ABC~2
131),~1
4E),~1
W6/32),~1
aureus-induced~1
R3-367.~1
phorbol-12-myristate-13-acetate-induced~1
I-specific~1
(H-2s)~1
SJL/J)F1~2
(mouse,~1
BP).~1
(self)~1
nonencephalitogenic~2
(SJL/J,~1
H-2s,~1
H-2d)~1
"parentally~1
restricted"~1
Lymphokines~1
EC-specific~1
T-EC~2
paraformaldehyde,~2
function-associated~1
macrophage-colony-stimulating~1
B6D2F1,~1
C3H/HeN,~1
interferon-alpha/beta~1
(MuIFN-alpha/beta)~1
(GM-CFC).~1
(GM-CFC/M-CFC).~1
macrophage-CSF~1
(rHuIL-2~1
rMuIL-2)~1
M-CFC~1
MuIFN-alpha/beta~1
MuIFN-gamma~1
myelo-suppression~1
Myelo-suppression~1
NK-1.1+,~1
Qa-5+~1
complement-treated~1
IL-1/ml~1
Natural,~2
glycosated~1
[125I]TNF-alpha~2
receptors/cell~1
IL-1-alpha.~3
carryover~1
neutralizations~1
IL-1-beta~8
IL-1.(ABSTRACT~1
rIL-1,~1
rIL-1-treated~1
rIL-1-alpha~1
rIL-1-beta~4
rIL-1-induced~1
IL-1-inducing~1
monocyte/macrophages,~1
Mo2~1
carrier-reactive~2
ovalbumin-reactive~1
Hen-1),~1
TNP-ovalbumin~1
Hen-1~2
antigen-specificity~1
hapten-carrier~1
TNP-binding~1
TNP-ovalbumin,~1
(CSPG)~1
p-nitrophenyl~1
beta-D-xyloside~1
CSPG~4
xyloside~2
xyloside,~1
xyloside.~2
II-restricted,~1
polysaccharide-immunized~1
Anti-Hib~1
anti-diphtheria~1
neuraminidase,~1
heterosubtypic~1
(H7)~1
reimmunization.~2
H6N2~1
N2-specific~1
(intravirionic)~1
(AbSC)~1
immunosorbent-plaquing~1
anti-PRP~3
1/552~1
1/1190~1
AbSC~4
PRP.~2
postimmunization,~1
anti-PRP,~1
AbSC.~1
pR27,~1
RL-5.~1
pR27~4
Intron~1
T1a~1
11C1,~1
gp52.~1
2F10,~2
3A4,~2
nonprotective~1
2F10~4
3A4~4
idiotype-recognizing~1
3A4-immunized~1
2F10-TNP~1
transplanted,~2
MCA-1490~6
MCA-1511.~1
5.96,~2
Igh-1~1
MCA-1511~1
(4.72~1
MCA-1490.~2
tumor-reactive~1
urocanic~3
photoreceptor/mediator~1
(Thy1+,~2
Ly2+)~1
Ly2-).~1
HSV-1.~1
radioantigen-binding~1
(["Ab"])~1
childrens'~4
["Ab"]~5
intralaboratory~2
radioantigen.~2
Binding-dilution~1
radioantigen~2
["Ab"].~1
larger-sized~1
polysaccharide-diphtheria~1
(PRP-D)~1
Preimmunization~1
Lowered~1
(rHuIFN-beta)~1
rHuIFN-beta/kg~1
rHuIFN-beta~3
DHPG.~1
median-effect~1
communally~1
urban.~1
rural-metropolitan~1
minorities,~1
unpartnered~1
sociopsychiatric~1
Clr~1
(dl-CF;~1
dl-5-formyltetrahydrofolic~1
midinfusion.~1
Myelosuppression,~1
I-CF~1
5-methyltetrahydrofolic~1
(5-CH3FH4),~1
dl-CF~1
5-FU-containing~1
(M-BACOD,~1
(HD-Ara-C),~1
(HD-MTX),~1
mg/m2/20~1
multiple-site~1
(always~1
[3H]-5-bromo-2'-deoxyuridine~1
(BUDR).~1
BUDR~2
BUDR.~1
11C-labeled~1
L-[1-14C]leucine~1
L-[guanido-14C]arginine~1
Carbon-14~1
[14C]arginine~1
Kjeldahl~4
whey,~1
(NPN),~1
micro-Kjeldahl~1
(colostrum,~1
Decelled~1
skimmed~4
ultracentrifuged~1
whey.~1
NPN~2
decelled~1
dye-binding~1
(Bio-Rad)~1
Pierce~1
bicinchoninic~1
colostrum.~1
skimming~1
Bio-Rad~2
(square~1
MSE)~1
ficin~1
alpha-cysteine~1
(LAI)~1
(LAI~1
electroblotting,~1
LAI~2
Ileocolonoscopy~3
ileocolonoscopy~3
sulfasalazine;~1
transgression~1
HLA-Bw62~6
:~1
Crohn-like~3
(19/26).~1
enteritis-like~1
(48%,~2
(78%,~1
157,~1
enthesopathies~1
enterogenic~1
NS).(ABSTRACT~1
anti-SSA~2
(Ro)~3
Anti-SSA~1
15.4%.~1
"marker~1
atlantoaxis~1
slackening~1
immune,~1
grandmother~1
(satellite~1
chromosomes).~2
(JA)~1
(3/3)~2
5/7~1
(2/7)~1
JA,~3
macrophage/articular~1
35S-labelled~1
metallo-proteinase~1
metallo-proteoglycanases~1
IL-1s~2
Chondrocyte-mediated~1
Breakdown,~1
cartilage)~1
lipopolysaccharides,~1
slated~1
7-17~1
double-fluorescent~1
erythroblast-depleted~1
splenocytes;~1
Thy~3
1.2+~1
aerosolised~1
67.9~2
Aerosolised~1
1985-86,~1
1c,~1
1c.~1
(bacterial~1
[BPIG])~1
BPIG~6
353)~1
350)~1
Hib-antibody~1
(bacteremia)~1
denies~1
multiclonal~1
antiself-IgG~1
(RF]~1
harbour~1
immunoglobulin-receptor-dependent~1
TGF-alpha.~1
auto-induction~1
ligand-dependent~1
Abolishing~1
v-src,~1
v-mos,~1
v-fps,~1
(downstream~1
Site-directed~1
22-amino-acid~1
Ala-Ile-Glu-Lys-Tyr-Leu-Glu-Asp-Gln-Ala-Gln-Leu-Asn-Ala-Trp-Cys-Ala-Phe-Arg-Gln~1
Val-Cys~1
(STLV-III;~1
HIV)~1
(gp)~1
peptide-Ia~1
functions--the~1
molecules--a~1
combining-site-containing~1
receptor-gene~1
beta-gene~1
MtDNA~1
endonucleases,~1
misidentified~2
E-cadherin~5
uvomorulin,~1
cell-CAM~1
(ref.4)~1
Arc-1~1
E-cadherin.~1
(D4S10)~1
(OB),~1
(HZO)~1
HZO~1
Sheehan's~1
1-Desamino-8-D-arginine-vasopressin~1
(DDAVP).~1
1980-1984~1
vitrectomies.~1
40/200.~1
(PC-IOL)~1
gentamicin-sensitive~1
randomly,~1
gentamicin-treated~1
(BLAST-2)~1
(BCGF).~1
Substantially~1
anti-Fab~1
flux)~1
submitogenic~1
(EBV).~2
17,000;~1
predominantly.~1
Media~1
EBV-containing~1
CC-1065-[N3-adenine]DNA~1
117-base-pair~1
M13mp1~1
CC-1065~4
adenine.~4
zelensis,~1
4-base-pair~1
CC-1065-DNA~1
12-base~1
inhibition/enhancement~1
Hae~1
CC-1065.~1
mAbs,~1
LM609,~1
LM609~2
heptapeptide.~1
(3'-UTR)~1
(bIL-2)~1
3'-UTR~2
(TATT)n~2
nonhistone~1
HMG-I,~1
nuclease(s).~1
bIL-2~1
T-rich~1
3'-UTRs~1
[t(9;22)-(q34;q11)]~1
joins~1
(P210)~1
P210~6
growth-stimulatory~1
anti-nicotine~3
(-)-6-hydroxymethyl-nicotine,~1
(-)-nicotine~1
immunogens,~1
(-)-[3H]nicotine-binding~1
mineralisation~1
hyperphosphataemia~1
(845~1
10(-6)/l~1
375;~1
CD4/8~4
glucoheptonate~1
.54),~1
HM-PAO)~1
variable-region,~1
joining-region,~1
repertoire,~1
24--amino~1
(rTNF).~1
salt-precipitation~1
Tamm~1
Horsfall.~1
(Tamm-Horsfall~1
glycoprotein)~1
Caenorhabditis.~1
ectoderm.~1
[37.8~1
"sterile~1
abscess."~1
pertussis,~1
(neutropenia),~1
fungal,~1
bacterial)~1
6,452~1
pressors~1
intraspinal,~1
[3H]R~2
1881~1
5020~1
meningohypophyseal~1
T6-7~1
receiver-stimulator.~1
460-kHz~1
(width~1
receiver,~1
falling.~1
41.7~1
angioma.~1
neurinomas~1
End-to-side~1
fluorine-18-fluoromethane~1
0.941,~1
Noninfectious~1
sheath)~1
abutment~1
malpositioned~1
azygous,~1
deflector~1
Poorest~1
10L),~1
Subcarinal~1
(contralateral)~1
10L~1
(Rotter's~1
gradient-refocused~1
(VSDs)~1
(survival~2
tumor-spleen~3
Magnetopharmaceuticals~1
detectability.~1
Fe/kg,~1
Intrasplenic~1
contrast-to-noise~1
43-fold~1
capsuloligamentous~1
arthroscopic,~1
intercarpal~1
scaphoid,~1
circle,~1
midcarpal~1
scaphoid.~1
lunotriquetral~2
short-segment~2
"pinhole"~1
Plain-film~1
location:~1
nodal;~1
extranodal,~4
(Waldeyer's~1
ring);~1
extralymphatic~3
(orbit,~1
sinonasal,~1
larynx).~1
signatures.~1
Nodal~1
Extranodal,~1
CT-derived~2
unfocused~1
(chemotherapy~1
large-field~1
radiotherapy).~1
deep-tissue~1
ports.~1
Current-generation~1
unobservable.~1
Certainly~1
nerve/sheath~1
intercellular/axonal~1
disk"~1
bulge.~1
EMI~1
7070).~1
62.5%,~1
mamillopontine~2
Dilatation~1
signal-to-noise,~1
(phase-encoded~1
readout);~1
gap;~1
excitations;~1
times--repetition,~1
Parameter~1
computer-image~1
hues~2
resolvable~1
chemical-shift,~1
gradient-recalled-acquisition-into-steady-state~1
(MAM),~1
(R1).~1
Superparamagnetic~1
"fast-scan~1
techniques."~1
47-cm~1
(spatial~1
receiver-operator-characteristic~1
intensifier-based~1
pyelograms,~1
Hard-copy~1
"bones~1
black"~1
prints~6
"dry~1
silver"~1
silver-coated~1
"dry,"~1
multiformat,~1
transmitted-light~1
silver,~1
insults,~1
mid-1970s.~1
chloramphenicol-associated~1
rubidium-82.~1
blockers),~1
23,008~1
0.28).~1
(DLCL)~1
(AAT),~2
CLA.~1
staining).~1
Leu-M1~1
phagolysosomes.~1
anti-HIV;~1
LAS,~1
hyperactivation~1
[mg/L]),~1
(mg/L),~2
beta-lactamase-negative~1
nontypeable,~1
trimeprim-sulfamethoxazole,~1
non-type~6
deficiency;~1
leaks;~1
nontypable,~1
serotyped,~1
(73/122),~1
(6/20).~1
sequelae;~1
array,~1
satellite.~2
HindIII)~1
misaligned~1
wide)~1
disruptions.~1
permanganate.~1
(MHC)-specific~1
lysed.~2
Campenot~1
CTLs~2
MHC-specific~1
CTLs,~1
CTL-neuron~1
immunopathogenic,~1
helper)~1
cytolytic/suppressor)~1
CVB3~1
planfulness.~1
attempters~3
ideators~1
surveys:~1
(HANESII;~1
10,929)~1
(BRFS;~1
18,388).~1
-3.6~1
-5.6,~1
-1.5~3
HANESII~1
-4.9,~1
BRFS.~1
weight-lowering~2
antichymotrypsin.~1
purified-protein~1
(PPD).~1
phenotypically:~1
Leu-3-positive~2
Leu-2-positive~1
T-cells).~1
PPD-reactive~2
Leu-2-and~1
1,392~1
industries:~1
31.0%~1
38.0%~1
"wheeze~1
cold"~1
"persistent~1
wheeze."~1
asthmalike~1
bronchitis.(ABSTRACT~1
alpha-1-protease~1
NO2-free~1
"elastaselike"~1
elastinlike~1
succinyl-trialanine-nitroanilide~1
BAL)~1
BAL).~1
(HLE)~1
Methoxysuc-Ala3-Pro-Val-aminomethylcoumarin~1
HLE~1
(NMC)~1
Now,~1
NMC~1
plated,~1
scrapings,~1
nasal-polyp-derived~1
cell-CSA,~1
epithelium-derived~1
semiannual~1
1611)~1
2646).~1
700/mm3)~1
reduced-dose~3
(HSV~1
unifocal~2
(C57BL/6J),~1
(BALB/cByJ),~1
(A/J).~1
tissue-culture-infective~1
anti-T11,~2
anti-T11~1
anti-T4,~1
amdinocillin,~1
sonic~1
nitrocephin-disk~1
drug-produced~1
amdinocillin.~1
amdinocillin~4
enzyme-labile~1
enzyme-stable~1
(MIC90s,~3
Penicillin-resistant~1
enterococci)~1
penem.~1
derepressible~1
aeruginosa)~1
(MHA~2
LYHB)~1
IsoVitaleX~1
HGB),~1
CFU/ml.~1
MHA~6
HGB~3
LYHB.~1
LYHB~2
McFarland~1
CFU/ml~1
cefamandole.~1
ureidopenicillins,~2
Beta-~1
"histiocytic"~1
HLA-DR1,~1
HLA-DR1.~1
HLA-DR2.~1
benoxaprofen~2
syringomas,~1
isothiocyanate-Leu~1
phycoerythrin-Leu~1
annulare.~1
(DTP).~1
(SID)~1
temporal.~1
SID~4
succeeding)~1
thoracovascular~1
subset-to-total~1
lymphocytopenia~1
Rendering~1
arterial-left~1
intraconduit~1
Porosity~1
Ethnicity~1
microglobulin~1
hemodialysis-associated~1
Sound,~1
person-days;~1
person-days)~1
Non-Hispanic~2
abuse/dependence~3
Americans;~1
DSM-III-defined~1
1243~1
1309~1
abuse/dependence.~1
Dysthymia,~1
Antisocial~1
3132~1
less-restrictive~1
somatizer.~1
somatization,~1
laypersons'~2
higher-rank~1
island-wide~1
rural-urban~1
(DIS)-DSM-III~1
program)~1
3921~1
DIS,~1
confounders,~1
DIS-DSM-III~1
"rural~1
blacks"~1
2.88).~1
system-hypothalamic~1
"overdrive"~1
(CRH),~1
oCRH.~2
oCRH,~1
(conduct~1
somatization)~1
18.1%.~1
immunosenescence~1
antigen-responsive~1
concomitants~1
age-altered~1
paraparetic~1
goniograms~1
kinesiologic~3
midtherapy~1
(3.15~1
(2.14~1
reappeared,~1
six-site~1
chiropractor~1
short-wave~1
neurologist,~1
q.d.~1
p.r.n.)~1
A'Solagoft~2
Ringers'~1
1244~1
syngenic~1
non-self-histocompatibility~1
ventriculoencephalitis~1
immunohistochemistry.~2
narcoleptics~1
HLA-DR2-antigen~1
(putative)~1
homozygosity.~1
exclude,~1
narcolepsy.~1
monochromacy~1
DXS15~1
DXS52,~1
Xq28.~1
(Il-1),~1
(rIl-1).~1
rIl-1~2
biomicroscopy,~1
recede~1
rIl-1-induced~1
Heat-inactivated~1
Vitrectomy,~1
capsulectomy,~1
lentis~1
(phakic~1
aphakic).~1
5/400~1
20/70.~1
DR4-~1
0.035).~1
IgM-RF-~1
mitogen-responsive~1
4B4+,~1
SI~2
(Gm~1
man)~1
venopyronum~1
dragees.~1
(57.1%~1
26.5%,~1
(3.6%~1
19.1%,~1
1;21~3
(60.7%~1
32.9%,~1
1,3;5,21~2
(46.4%~1
25.8%,~1
pseudolupus~3
6.9).~1
b2~1
authenticity~1
(monocytelike)~1
4.0-kb~1
(cytochrome~1
1.6.2.2)~1
(pb5R141)~1
1817~1
Pro-Asp-Ile-Lys-Tyr-Pro,~1
pb5R141~1
steer~1
morphometrics~1
live-born,~1
estrogen-gestagen~1
reepithelialize~1
metroplasty~1
metroplasty.~1
advances,~1
mystifying~1
"bridged"~1
suitable,~1
welcomed.~1
morphine-6-glucuronide~1
lignocaine-prilocaine~1
(EMLA)~1
EMLA~1
scales).~1
expressions,~1
saggital~1
thiopentone).~1
Craniad~1
Scl~6
sclerosis:~1
acrosclerosis.~1
(CREST),~1
speckled,~1
scrapes~1
scraped~1
(Me2SO,~1
Capella~1
tolmetin,~1
post-cataract~1
tolmetin~2
multimers;~1
SDS-5%~1
immunoblotted~2
anti-vWF~1
(Lomustine)~1
depletion-type~1
(TdT).~1
(C').~1
Lymphoblasts~1
(TdT+)~1
"inert"~1
(BM).~1
cytospin~1
lg~1
C'-fixing~1
MoAb:~1
anti-CD10~1
(RFAL3)~1
anti-CD7~2
(RFT2)~1
(T-ALL).~1
cocktails~1
anti-CD10,~1
anti-CD19,~1
anti-CD24~1
anti-CD8~1
(CD7-,~1
HLA-DR+).~1
"clean-up,"~1
T-ALL,~1
(FXIIIa),~1
A2B2.~1
Biosynthesis~1
FXIII~9
PLC/PRF/5,~1
concentrated,~1
(SFCM)~1
PLC/PRF/5.~1
SFCM~2
zymogen.~1
MoAbs,~1
PM-81~1
cryopreserved.~1
MoAb-treated~1
21.0,~1
10.0,~1
posttransplant.~2
engraftment.~4
MoAb-mediated~1
cluster-forming~1
(CFC),~1
CFC~1
(LCM).~1
phagocyte-depleted~1
(HLA)-mismatched~1
members:~1
graft-v-host~4
family-mismatched~1
1,299~1
mismatched-family~1
HLA-mismatched~1
(BMT)~3
genotypically~1
HLA-identical~6
engraftment;~1
Binary~1
rejection:~1
(GVHD),~1
noninteracting~2
antigen-trapping~1
aetiological.~1
(Vicryl)~1
nephrotomies,~1
nephrotomies~2
microfil~1
nephrotomies.~1
(TAUS)~1
Technicare~1
Autosector~1
TAUS~2
5-fluorouracil;~1
(Inadine)~1
dressings,~1
Inadine~1
gauze.~1
Scotia~1
2/1000~1
bifida,~1
anencephaly~2
encephalocele;~1
dumoffii~1
dumoffii;~1
dumoffii,~1
legionellosis~1
1537~1
Richardson~1
(COP-BLAM)~1
Restaging~1
beard~1
vasodilates~1
Digitalis~1
chapter,~2
pulmonale?~1
rheumatic,~1
floppy,~1
(cor~1
etiology:~1
Anular~1
operatively-excised~1
more-diffuse~1
juxtaglomerular~3
viprostol,~1
viprostol~1
ng/ml/hr;~1
Trial,~1
-5.4),~1
-2.2).~1
1899~1
-3.8)~1
-0.6)~1
"suspect"~1
-2.0).~1
"ribbon~1
ribbon~1
hemodynamic-inotropic~1
-.59,~1
.67,~1
(931~1
2053~1
pindolol-induced~1
performance.(ABSTRACT~1
lumen)~1
plaques).~1
hypoechoic~8
tunicae~1
mode-determined~1
garment.~2
"autotransfusion"~1
MAST-augmented~1
(PSVT):~1
nonpharmacologic,~1
electrical.~1
Nonpharmacologic~1
PSVTs~1
Synchronized~1
electroplates~1
defibrillates~1
(VF~1
fibrillation):~1
(APLS)~1
APLS~2
decision:~1
dosages?~1
equipment?~1
(EOA)~1
"postresuscitation~1
(cell-necrotizing~1
cascades),~1
"intoxication"~1
brain-oriented~1
barbiturates,~1
circulation),~1
postcardiac~1
etiology-specific~1
rescuer~1
(BLS)~1
bradypnea,~1
BLS~1
pump,"~1
"cough-CPR"~1
Which,~1
widespead~1
teachability~1
(IACs)~1
Instructional~1
"physically~1
challenged"~1
Weisfeldt,~1
Pharmacology~1
beta-adrenergic-receptor~1
(ACLS).~1
asystolic~1
postanoxic~2
Calcium-channel~1
arteriospasm.~1
flutter.(ABSTRACT~1
1920s~1
(EMD),~1
Tampa~1
EMD.~1
no-calcium~1
EMD,~1
anoxia/ischemia.~1
effective)~1
enormous.~1
flurry~1
interferometer.~1
SPL~1
KHz~1
piston-like~1
footplate/cochlea~1
'trismos',~1
(locked~1
jaw).~1
trismus.~1
IgA-plaque~1
PFC)~1
PFC,~1
ICs,~1
C3b-mediated~1
IgA-secreting~1
prednisolone/prednisone~1
12-106),~1
endovenous~1
angiourography~1
(SAU)~1
(DSA).~1
echo-Doppler~1
SAU~2
EDV.~1
non-invasiveness~1
5-year,~1
dihydroxycholecalciferol~1
(calcitriol)~1
Calcitriol,~1
Calcitriol~1
(DNMN)~1
DNMN~2
II-III.~1
proteinuric.~1
DNMN,~2
anti-C5b-9~2
anti-IgG,~1
anti-C3d~1
DNMN).~1
"generalized~1
OA"~1
interphalangeals.~1
hyperostosis,~1
reappraisal~1
scrub-plus-paint~2
0.601~1
0.622~1
paint-only~1
hexachlorophene~2
showers,~1
showers.~1
suspended.~1
chondrocyte's~1
Heat,~1
friction,~1
Load~1
polysulfate~1
(GAGPS)~1
"osteoarthritis"~1
meniscectomy,~1
metalloprotease(s),~1
(NMPE),~1
protease(s)~2
NMPE~2
metalloprotease~1
Hexuronate~1
GAGPS~1
resurfacing.~1
stock.~1
(revision~1
12.3%)~1
sepses.~1
(CDH),~1
stock,~1
"responders,"~1
"nonresponders"~1
"placebo~1
responders,"~1
nonplacebo-controlled~1
medicating~1
Trientine~1
Hevea~1
braziliensis.~1
angio-oedema~1
glove-bag,~1
immunoenzymatic~2
trypsin-sensitive.~1
"crude~1
latex".~1
mask-mode~2
film-based~2
512(2)~1
framing~1
frames/second.~1
70-120~1
KVP,~1
10-30mA~1
5msec~1
(PC20M)~1
(PO20~1
UNDW)~1
(FEV1).~1
nebulizer,~1
PO20~1
UNDW~5
-0.66;~1
PC20M~3
-0.19;~1
-0.61;~1
Loculation~1
loculations~1
"Extreme"~1
loculation,~1
nonloculated~1
Light's~1
parapneumonic~1
(Portalung),~1
pneumowrap,~1
pneumobelt,~1
kyphoscoliosis.~1
contributes.~1
nocardiosis.~3
nocardial~3
nocardiosis~4
cycloserine.~1
nocardiosis,~2
(NBTE).~1
NBTE~3
antefinem.~1
BMT~3
murmurs;~1
hematuria;~1
NBTE.~1
Beta-lactam~1
antiinfective~1
alprazolam's~1
cross-tolerant~1
narrow-spectrum,~1
low-mortality~1
technologies,~1
ventilator-patient~1
Hct,~1
overloading.~1
heuristic,~1
heading~1
staffs,~1
formulates~1
cut-downs~2
teamwork~1
bradycardias~1
substantively~1
low-output,~1
high-output,~1
low-resistance~1
Mg2+)ATPase~6
(BLM)~1
desoctapeptide~2
PTH-(3-34),~1
hPTH-(1-34);~1
calcitonin;~1
35-52%~1
8-13%~1
3-microM~1
(10(-9)-10(-7)~3
13-25%~1
18-27%~1
8-12%~1
bPTH-(3-34),~1
hPTH-(1-34),~1
BLM.~2
BLM~7
(I-LH)~1
(B-LH)~1
(OVX)~3
(Eb)~1
I-LH~5
B-LH~6
OVX~13
LHRH-induced~2
bioactivity,~1
L-leucine,~2
L-isoleucine,~1
sulfamerazine~4
(EOP)~1
[i.e.~1
(END),~1
(DYN)],~1
kappa).~1
EOP~2
Immunoneutralization~1
Anti-beta-END~2
anti-DYN-A~1
(intracerebroventricularly~1
[icv])~1
END-(6-31)~1
icv),~1
kappa-antagonists,~1
Mr1452~1
Mr2266~1
ip),~1
(beta-FNA),~1
1-opiate~1
anti-enkephalin~1
154,129,~1
icv)~1
icv.~1
END-(6-31),~1
Anti-DYN-A~1
anti-ENK~1
delta-antagonists~1
DYN-A~1
mu/epsilon-~1
kappa-opiate~1
CRF/beta-END~1
latter)~1
glucose-responsive~1
D,L-glyceraldehyde~1
(GA;~1
[phenylethanolamine~1
N-methyltransferase~1
(PNMT)]~1
PNMT~4
medulla/pons.~1
D-glyceraldehyde,~2
(0.1-1~1
nonstimulating~1
secretagogue,~1
cells/sample~1
(FALS)~1
(PLS)~1
FALS~1
PLS~4
Agranular~1
ridges,~1
mammotrophs,~1
FALS-PLS~1
superphysiological~2
(1-250~1
(Collaborative~1
Research)~1
(progesterone~1
transnasal,~1
disconnections~1
HPD.~3
hemisected~1
beta-subunit,~1
alpha-subunit,~1
OXV~1
pre-HPD~1
(IVT)~1
IVT~4
LY134046~1
(8,9-dichloro-2,3,4,5-tetrahydro-1H-2-benzazepine~1
2-receptors~1
LHRH.~6
beta-Receptors~1
anti-PRL~3
PRL-like~1
PRL-containing~1
85-97%~1
(P-450scc),~1
PMSG-treated~1
immunodot~1
P-450scc~9
Cumulus~1
P-450scc.~1
Referring~1
Proglucagon,~1
L-cells,~1
(GLP-I~1
GLP-II)~1
(IP-II).~1
proglucagon~5
liberated,~1
GLP-I~2
[GLP-I-(1-37)~1
GLP-I-(7-37)],~1
GLP-II,~2
IP-II,~2
IP-II.~1
GLP-I-(1-37),~1
GLP-I-(7-37),~1
IP-II~1
mestranol~2
hepato-carcinoma~1
mestranol,~2
Mestranol~1
mestranol.~2
diethylestilbestrol-treated~1
cumulus-oocyte~1
populating~1
preantral~4
follicles/ovary~1
diethylstilbestrol-treated~2
atretic;~1
posthypophysectomy,~1
(MBH-POA)~1
MBH-POA~13
chamber)~1
perifusates~1
NAL;~1
NAL-induced~1
NAL-evoked~1
(CRF-LI)~1
medullary,~1
G-50.~1
rat/human~1
(r/h)~1
CRF-LI~6
CRF-immunoreactive~1
CRF-positive~1
r/hCRF.~2
r/hCRF~2
(Amgen~1
Thr59)~1
32P-Labeled~1
IGF-I-treated~1
v-fos~1
[32P]v-fos~1
(6.25~1
(18-fold)~1
renin-like~2
nongravid~1
renin.~5
antirenin.~1
38K,~1
(SZ)-diabetic~1
(ArGH)~1
(6-h)~1
SZ-diabetic~3
ArGH~3
(5-day),~1
(6-h),~1
pituitary-adrenocortical~2
sympatho-adrenal~1
hypoglycemia-induced~2
(MBH),~1
MBH-lesioned~1
1-100~1
D-(U-14C)glucose~1
Perifusion~1
alpha-reduction~1
600-microns~1
beta-3H]androstenedione~1
alpha,2~1
alpha-3H]testosterone.~1
1500-fold,~1
amygdaloid,~1
preoptic,~1
area-anterior~1
0.947;~1
preoptic-anterior~1
0.068;~1
(PEN)-evoked~1
(GLU),~1
L-aspartate~1
(ASP),~1
quisqualate~2
(QUIS),~1
N-methyl-D,L-aspartate~1
(epileptiform)~1
Intracellularly~1
PEN-evoked~1
(PDS)~1
GLU~4
6-mV~1
(AA)-induced~1
overdepolarization.~1
overexcitation.~1
(275~1
exencephaly,~1
anophthalmia,~1
teratogenicity,~1
nonteratogenic~1
Teratogenicity~1
phenytoin-protein~1
proper.~1
(euglycemic~1
groups--type~1
subjects--matched~1
0.593)~1
0.649)~1
(gamma-vinyl~1
GVG),~1
seizures),~1
(EEG),~1
visual-,~1
auditory-,~1
(23.1%)~1
Markov~1
goodness-of-fit;~1
same-side~1
Luteinized~1
follicle-like~1
(HSG)~2
hysteroscopy/laparoscopy.~1
91%)~1
94%)~1
perimenopause,~1
uninterruptedly,~1
micrograms/90~1
postmature~2
oocytes;~1
(Shering~1
Berlin,~1
(Diane,~1
(Androcur,~1
Diane~6
Androcur)~1
(facial,~1
bust,~2
abdomen).~1
Androcur~1
29.1%~1
27.8%,~1
Androcur,~4
0.10;~1
(Diane~1
Androcur),~1
(Androcur~1
Diane),~1
Organization-sponsored~1
multicentered~1
hydrotubation~1
insufflations,~1
HSG,~1
insufflation,~1
salpingography,~1
hydrotubation,~1
Buoyant~1
AB,~1
boring~1
centrifuge~3
tube),~1
bacteria-free.~1
(aged).~1
Gonadotropin~1
BCPT~1
hypothalamic-pituitary-ovarian~1
intertwined~1
perimenopause~1
preperimenopause.~1
CAm/CCr,~3
(amylase,~1
lysozyme)~1
CAm/CCr~1
proteins-a~1
phosphatase-containing~1
enzyme-containing~1
antigen/antibody~1
(HBeAg/anti-HBe)~1
cytoplasmic/membranous~3
anywhere,~1
hepatocytolysis.~1
sooner.~1
Gelusil~1
(Parke-Davis,~1
Plains,~1
N.J.)~1
pericryptal~1
Stellate-shaped~1
villar~1
contraction-associated~1
isotropomyosin,~1
isomyosin,~1
muscle-like,~1
lacteals~1
postembedding~1
A-colloidal~1
14/20~1
Addiction~2
1950's~1
Spuhler~1
Zollinger,~1
rightly~2
(Saridon)~1
colics~1
(aspirin)~1
aspirin--the~1
aminophenol~1
cause--exceptionally--the~1
(NSAID's)~1
nephrotoxic.~1
Phenacetin~1
has--in~1
mixtures--mood-altering~1
(euphoric)~1
addiction--and~1
abuse--may~1
euphoric~1
weariness~1
districts.~1
psychoneurotic~1
backpains,~1
8-10%~1
uro-epithelial~1
doggedly~1
denied,~1
hampering~1
(VLM)~1
VLM~6
chemoreception,~1
controllers,~1
answered.~3
systems?~1
chemoreception?~1
endeavor~1
VLM.~1
Lennon~1
489-495,~1
egometry~1
reabsorbsion~1
23-h~1
Homeostasis~1
113mIn-labeled~1
enteriditis~1
(41.1~1
(16.0~1
g/g~1
([14C]sucrose,~1
(125I-neutral~1
(BPT)~1
histolyticum~1
BPT~2
BPT-induced~1
morphologically.~2
diffusion-limited.~1
(transcytosis).~1
BPT-exposed~1
125I-dextran~1
nonthermoregulatory~3
held.~1
SkBF~5
SkBF-internal~2
(PCf20)~1
2.34,~1
4.27,~1
mumol/ml~1
(PCs40)~1
3.16,~1
5.01,~1
mumol/ml.~1
(PCf20,~1
PCs40,~1
[110%~1
VO2max:~1
8.73~1
3.60~1
(C)]~1
glucoregulation,~1
lypolysis~1
yearling~1
(6-ketoprostaglandin~1
(RAR's)~1
RAR~1
(PEEP)~4
RAR's~5
irregularly.~1
proportionately,~1
hyperinflating~1
stiffer.~1
monostotic~1
valves".~1
reaffirms~1
Authors,~1
reviewers~1
editors~1
escalating.~1
colonisation,~1
preincisional~1
hyalinic~1
rigid.~1
multinuclear~1
26-29~1
(IRDS)~1
atrial/aortic~1
1.9:1).~1
convexo-concave~2
antiaggregatory~1
prostacyclin),~1
2,3-dinor-6-keto-PGF1~6
beta-oxidation)~1
A2)~1
[19.8~1
pmol/mmol~5
rise)~1
(37.7~1
(80.6~1
6-25~1
nafarelin~7
pituitary-ovarian~2
(Gp)~1
(Gp~6
Gps~3
(Gps~2
Gp~6
nafarelin.~1
(progesterone,~2
nafarelin,~1
Gonadotroph~1
reduced).~1
insulinoma~3
Euglycemia~2
basally,~1
Meals~1
calories),~1
0800-1600~2
Day-long~1
nonobese.~1
day-long~2
NIDDM.~2
0.30;~1
(PHM)-like~1
(VIP)-secreting~1
1800;~1
500-6800~1
pmol/liter;~3
235;~1
50-580~1
nonendocrine~1
VIP-secreting~2
(SY1).~1
(Kav,~2
0.50-0.53)~1
PHM-specific~1
(SY2).~1
0.30-0.37),~1
SY2,~1
PHM-like~3
N-terminus-directed~1
SY1,~1
[percent~1
IBW),~1
78-202%]~1
[waist~1
0.67-0.91].~1
(HEF)~1
(M/I)~1
Androgenic~1
FT).~1
40-254~1
mU/min~1
0.78;~1
HEF~3
5-69%~1
-0.60;~1
M/I~3
PIP,~1
HEF,~1
[88~1
mg/dl]~1
180-~2
270-minute~1
270-min~1
240/120~1
hypokalaemia.~1
ambulant,~1
(0.5-0.75~1
(excretion~1
10.8,~1
micrograms/day;~1
microgram/day).~1
suppressible~1
(GnRH-A)~1
GnRH-A~6
(5-pregnen-3~2
beta-ol-20-one),~1
alpha-diol-20-one),~1
GnRH-A-treated~3
orchiectomized~1
GnRH-A,~1
IUhCG,~1
5-steroids,~1
4-P~1
GnRH-A.~2
1144~1
gonadotroph~3
Trappist~1
monks.~1
(sampling~1
pulses/h;~2
monks~2
27);~1
alpha-androstan-17~2
beta-ol-3-one~2
Euglycemic~1
mU/M2~1
ACTH-(1-13)~1
inducer).~1
(0900~1
immunofluorescence-positive~2
[25~1
deprivation).~1
stimuli:~1
ACTH-positive~1
[2(3)H],~1
[3(3)H],~1
[6(14)C]glucose~3
[2(3)H]glucose~2
[3(3)H]glucose.~2
[2(3)H]glucose,~1
[3(3)H]glucose~2
[6(14)C]~1
size-selective~1
BALF/plasma~1
(54,000-900,000~1
hyperbolically~1
BALF,~1
oxidant-induced~1
dimeric,~1
Fn,~2
Oxidant-induced~1
tissue-derived~1
prehepatic~1
posthepatic~1
insulinemia.~1
High-performance~1
insulin(s)~1
5:4,~1
4:5,~1
1:7,~1
(Val----Leu).~1
"multiple~2
anomalies"~1
attendants.~1
(TG1),~1
pHY~2
TG1~1
collagens)~1
medionecrosis,~2
unlabelled~1
Papworth~1
Paul-Bunnell~1
BBC~1
antimalarials.~1
Koebner~1
conduct.~1
comedones~2
incongruities,~1
strialike~1
comedones.~1
hydrocarbons,~1
nitrosamines.~1
mutation-like~1
Initiated~1
benzoyl~1
Collectively~1
mutagens,~1
antipromoting~1
Melanomas~1
vesiculobullous~1
disturbances:~1
gammopathies,~1
torn/separated~1
Optimizing~1
hemostatics:~1
subsulfate~3
(Monsel's~1
Yucatan~1
evaporimetry~3
Plots~1
evaporimery~1
nonoxynol~1
(Exovir-HZ)~1
scabbing,~1
scabbing~1
Permethrin~2
(Burroughs~1
investigator-blinded,~1
lotion~3
(Kwell)~2
reinfestation.~1
elegant~1
oxide-eugenol~2
1,102~1
71.9%~1
deselected~1
cannulations.~1
Thus:~1
nonobstructing,~1
mid-systolic~3
(holosystolic~3
regurgitation.(ABSTRACT~1
motion--either~1
circulation--arterial,~1
surfaces--contributes~1
(venous~2
commence~1
nonhospital~1
occulsive~1
nonthrombotic~2
referral;~1
withheld,~1
nonhigh~1
film),~1
embolism.(ABSTRACT~1
prevent,~2
thromboplastin;~1
Embolectomy~1
defibrination~1
defibrination,~1
passing-by~1
depends,~1
endeavor.~1
beneficial;~1
release-inducing~1
(standardized~1
restarting~1
cod~1
platelet-inhibitor~1
(Coumadin)-derivatives~1
arrhythmia;~1
unnecessary.(ABSTRACT~1
Typical,~1
atherothrombotic,~1
platelet-active~1
rethrombosis~1
(embolic~1
thrombotic),~1
(embolectomy,~1
thromboendarterectomy,~1
Allergen-induced~1
ozone-induced~1
fired,~1
mediator-releasing~1
sneezes~1
N-alpha-p-tosyl-L-arginine-methyl~1
One-week~1
cells/basophils.~1
Esperase~7
Alcalase,~2
licheniformis~2
subtilis,~1
laundry~2
Esperase,~2
autolysis,~2
Savinase,~1
Alcalase~3
Savinase.~3
Alcalase.~1
Savinase~1
(Pd15),~1
(RAST),~1
Pd15,~2
(explained~1
(UNDW)~1
Late-phase~1
(albuterol)~1
theophylline-containing~1
steadiness.~1
titrations~1
timothy,~1
orchard,~1
caramelized~1
IPG-treated~2
summation,~1
pollinosis.~1
Supporter~1
(SET)~1
supporters~4
meditative~1
assertiveness.~1
dramatizing~1
supporters'~1
Post-training~1
(HB)~1
HBeAG~1
A)F1~1
polyinosinic:polycytidylic~1
(pI:C)~1
pI:C-treated~2
pI:C~5
alloantigens.~1
L5178Y~1
MDAY-D2~1
radioresistant;~1
pI:C-mediated~1
GVH-induced~1
(HTLV-I)-related~1
(gag)~1
p19,~2
p24),~1
sero-positive~1
p15,~1
(1/10~1
CR2,~2
CR3)~1
Yeast~1
germinate.~1
EA,~2
EAC14,~2
EAC3b,~1
EAC3bi,~1
EAC3d.~1
Fluorescein-labeled~1
EAC3d,~1
pseudohyphae~1
stellatoidea.~1
(3D9,~1
1B4,~1
C511,~1
2B6,~1
anti-B2,~1
anti-Mac-1),~1
EAC3d~1
(anti-CR2)~2
HB-5~1
140.~1
Mo-1~1
germinated~1
(i.d.)~1
nonliving~1
(SCHLAP~1
SWAP,~1
SWAP~2
97k~3
methionine-labeled~1
schistosomes.~1
i.d.~4
95k/78k~1
97k/95k/78k~1
(Sm-97)~1
SWAP.~1
Sm-97,~1
Sm-97~2
tegumental~1
syncitia~1
(1:10,240)~1
anti-Sm-97~3
(titer~1
1:640).~1
protectively~1
nonprophylactically~1
Sm-97.~1
anti-lipid~1
base-hydrolyzed~2
cryptococci~5
cyclophosphamide-pretreated~1
Secondarily,~1
anti-cryptococcal~1
Seven-week-old~1
postinfection,~1
caseinate.~1
early-acting~1
differentiation/growth~1
c-onc~1
Separated~2
(DXS)~1
mab),~1
R-IL~2
DXS,~2
r-IL~3
costimulated~1
DXS~1
Bur-1~5
T4+,~1
HLA-DRw11~1
HLA-DR5)~1
self-MHC~1
(mH)~1
HY~1
autoreactivity~1
mH~2
marrow-grafted~1
(donor)~1
S-300~1
ICA-positive~1
7/10~2
9/10~1
PEG-purified~1
autoantigen.~1
anti-PM-Scl~5
polymyositis/scleroderma~1
PM-Scl~2
D-treated~1
5,6-dichloro-beta-D-ribofuranosylbenzimidazole~1
(DRB)~1
clawed~1
frog,~1
xenoantisera~1
MHC-linked~1
(endotoxin~2
hyporesponsive)~1
responsive)~1
butanol-extracted~2
N-acetyl-~1
N-glycolylneuraminic~1
N-acetylneuraminic~1
Oxidative~1
N-glycolyl~1
(CS-A)~1
CS-A~3
6B2+~3
CS-A.~1
[B10----AKR],~1
Ly-2-,~1
anti-recipient~2
[B10----AKR]~1
allo-antigens.~1
Ly-1+2-,~1
125I-laminin~1
activation-dependent~1
fluorescein-visualized~1
granule-plasma~1
granule-deficient~1
granule-depleted~1
Electroblot~1
secondary/tertiary~1
(GAC)~1
(125I-HGAC~1
(GAV;~1
anti-GAC~5
125I-HGAC~10
GAV~1
(GAVsp)~1
GAVsp,~2
400%)~1
GAVsp.~4
anti-gamma~1
(2E.6)~1
700%)~1
anti-C~2
(187.1),~1
(anti-IdX)~1
anti-IdX~1
HGAC~3
paratope,~1
bivalency~1
(anti-IdI-3a~1
anti-IdI-1)~1
GAVsp~2
GAC-binding~1
(TsDF),~1
alloantigen-primed~2
MLR-Ts.~1
TsDF~7
MLR-Ts~8
BW5147~5
MLR-TsF~2
L3T4-Ly2+~1
MLR-derived~1
TsDF,~1
14,500~1
BW5147-derived~1
BW-TsDF.~1
BW-TsDF,~1
TsDF-unresponsive~1
TsDF-responsive~1
TsDF.~1
antigen-initiated~1
microglobulin-B~1
2M-B)~1
GA5,~1
2M-B,~1
2M-A~2
2M-B~2
2M-B-positive~1
GA5~2
2M-A-positive,~1
2M-B-negative~1
H-3~1
2M-B.~1
Ichthyols~5
shale~1
20-COOH-LTB4.~1
jejunums:~1
propria--around~1
crypts,~1
villi;~1
mucosae;~1
endomysium.~1
(GFD)~1
OKT-6-positive~1
ETAF/IL-1~1
(BMZ)~1
anti-BMZ~1
hemidesmosomes,~1
Yellow~1
48-h)~1
dye-coupled~1
mesenchymally~1
enmeshed~1
vibrissae~1
KL1,~1
56.5~1
KL1~2
KL1-positive~1
KL1-negative~1
Blastospores~1
niger~2
complement-inhibiting~1
10,000-dalton~1
flavus,~1
Iron-binding~1
Challenge~1
nucleic-acid~1
(ADRVs).~1
ADRVs~2
rotavirus.~1
dysenteriae~7
sonnei,~1
flexneri,~1
10(5.04)~1
CD50/mg~2
10(3.95)-10(6.10).~1
serogroups~2
1/1,000~1
10(1.09)-10(3.11)~1
Shiga~3
nonneutralizable~2
p30-related~1
(rp),~1
C-virus~1
p30~2
rp.~1
80-nm~1
virus-like~1
rp~1
cleave.~1
hMC~1
"receptors"~1
heterophilic~1
(HES),~1
turbidimetrically.~1
HES~7
mass/length~5
10(12)~4
daltons/cm~4
reptilase~1
turbidity.~1
reptilase,~1
HES-enhanced~1
reactant,~1
(PMNL).~1
(Agg-CRP)~1
Agg-CRP~8
anti-CRP~1
Agg-CRP,~1
Agg-CRP.~1
(Agg-IgG).~1
Agg-IgG,~1
serum-opsonized~1
Travel,~1
references,~1
opportunities,~1
Travelers'~1
Phipps~1
1913~2
1950.~1
abstracts,~1
1943,~1
8172~1
1940,~1
Adolf~1
Meyer's~2
Director.~1
manic-depressive,~1
neuroses,~1
psychopath,~1
hyperthymergasia,~1
insanity~1
28-year~1
unimproved.~1
readmitted.~1
readmissions,~1
Oximetry,~1
Lambert-Beer~2
Bunsen~1
Kirchhoff~1
invented~2
1860,~1
Hoppe-Seyler,~1
1932~1
Gottingen,~1
Nicolai~1
Kramer~1
Matthes~1
Leipzig,~1
(green~1
infrared)~1
Millikan~1
"oximeter"~1
aviation.~1
Zijlstra~2
Groningen,~1
eight-wavelength~1
Nakajima~1
standard-risk~3
busulfan-cyclophosphamide~1
(BMT).~2
(HDC).~1
8+,~1
11+,~1
14+~1
post-BMT.~1
71)~1
ABMT,~1
mg/m2/d)~1
(LoDAC).~1
ANLL)~1
ANLL),~1
LoDAC~5
LoDAC.~1
(IV-DSA)~1
(DUS)~1
DUS~2
IV-DSA~1
invention~1
Receptivity~1
forerunner~1
aphthae,~1
premaxilla~2
premaxillary~1
broncho-pulmonary~1
improves.~1
hypercarbic~1
vaccine-related~1
sensationalized~1
litigious~1
fervor~1
reiterated:~1
deadly~2
Britain;~1
RIT~2
4237~2
TCID50/ml,~1
oxandrolone~5
mg/kg/day),~1
cm/yr,~1
(-0.1~1
(+2.3~1
(+3.7~1
(+5.4~1
(oxandrolone),~1
(combination).~1
age/bone~1
HA/delta~1
Bayley-Pinneau~1
cm/yr.~1
cm/yr;~1
hGH-stimulated~1
ng/kg/day~1
+0.35~1
(KUB)~1
KUB.~1
17-hydroxyprogesterone,~2
11-deoxycortisol,~1
allotetrahydrocortisol/tetrahydrocortisone~1
hypermineralocorticoid~1
(D&E)~1
D&Es~1
retroflexion,~1
anteflexion,~1
fibroids.~1
Leiomyomatosis~2
peritonealis~2
disseminata~2
leiomyomata.~1
autografted.~1
(FDI)~1
(FDI~1
FDI~2
3.11~1
(unpaired~1
time-sharing~1
bibliographic~1
full-text~1
books.~1
(CD-ROM),~1
affordable~2
time-sharing.~1
Service,~1
Legislation.~1
vouchers~1
Vouchers~1
payroll~2
tax,~1
tax.~1
Tax~2
beneficiaries~2
prefunding~1
taxed,~1
earning~1
beneficiaries.~1
fiscally~1
(formerly,~1
mevinolin),~1
sequestrants.~1
colestipol~1
most-cited~2
JAMA~2
Information.~1
least-cited~1
158.~1
Baruch~1
Blumberg~1
Doisy,~1
Nobel~1
laureates.~1
JAMA's~1
(A-PRC)~1
(TFR),~1
(SV-PRC)~1
nl/min,~1
TFR,~1
SV-PRC,~1
SV-PRC.~1
arteriole:~1
JG-cells;~1
(BLM);~1
insulinopenic~4
structurally,~1
epithelial-specific~1
NaK-ATPase~1
transpeptidase.~1
Ile-Gln-Arg-Thr-Pro-Lys-Ile-Gln-Val-Tyr-Ser-Arg-His-Pro-Ala-Glu.~1
C3g~1
C3g,~1
immunopathological~1
(C3c)~1
univocal~1
2642~1
3677~1
micron2,~3
3275~1
4443~1
2305~1
3920~1
1522~1
(-30%).~1
angiotensin-induced.~1
DOCA/NaCl~1
DOCA-NaCl~2
1K,~2
2K,~2
(1075~1
pg/mg),~4
pg/mg)~2
UK-37.248~1
(dazoxiben,~1
(837~1
ml/min).(ABSTRACT~1
AG:89%,~1
CG:67%~1
TG:60%,~1
"pharmacological~1
synergy".~1
IIb;~1
IV;~1
14.1).~1
11.0)~1
11.3)~1
antimonocyte~1
5.9,~1
(OKB2~1
1.81),~1
Maleic~1
sodium-depletion~1
sodium-loading,~1
sodium-depleted~6
anti-glomerular-basement-membrane~1
(IPK)~1
permselectivity~2
AntiGBM~1
(2.009~1
0.681~1
filter's~1
IPK~1
pre-immunized~4
(antiGBM-GN).~1
(MIF).~1
MIF~4
(OX19~1
(1.95~1
cells/glomerular~1
c/gcs)~2
(1.02~1
macrophages/glomerulus~1
(m/g),~1
m/g).~1
40.81~1
4.32%~1
45.11~1
4.11%~1
38.24~1
3.53%~1
20.86~1
3.85%~1
non-pre-immunized~1
(CSS).~1
CSS,~1
38.40~1
11.70)~1
1.01)~1
CSS/normal~1
17.5.~1
(nonproteinuric)~1
(proteinuric)~1
kidney/early~1
22.89~1
7.15)~1
rabbit.(ABSTRACT~1
Henle.~2
(CPMD)~1
CPMD~5
Loop~1
micropuncture)~1
1798~1
pEq/min~2
2453~1
ng/ml/hr~2
(HRS)~1
redistributes~1
HRS.~2
1/min/m2,~1
(+3.1~1
(weight:~1
-3.7~1
creatinine:~1
nondialyzed)~1
(ARCD),~1
ARCD,~1
(nondialyzed~1
dialyzed),~1
ARCD~3
disappointed~1
"mature"~1
"reversion"~1
Anticancer~1
(cytostatics,~1
implants),~1
benign-appearing,~1
(pulmonic~1
torr),~2
banding)~1
(2/25~1
(3/23~1
(24)~1
[23],~1
[four],~1
[nine],~1
[three]),~1
600).~1
(six).~1
264),~1
Pump-related~1
Baron~1
Larrey~2
Napolean's~1
troops,~1
armies,~1
Larrey's~3
Napoleon's~1
brilliance~1
rein.~1
Battle~1
Antietam~1
(1862),~1
"flying~1
ambulance,"~1
helicopter,~1
volante.~1
humanism~1
wounded,~1
(moving~1
(nonmoving~1
map-guided~1
(HCG)~1
alpha-feto-protein~1
(AFP).~1
continually.~1
Immunoassays~1
Ag)~1
(CIA-RA)~1
haemophiliacs~1
Antigenaemia~1
CIA-RA~1
blot;~1
1127~1
(MRC)'s~1
6-thioguanine--DAT~1
(COAP)~1
AT.~1
(VTE).~1
VTE~2
iodine-125-fibrinogen~1
veins)~1
VTE.~1
ethamsylate~5
multicentre,~2
30/162~1
50/168~1
(29.8%)~1
20/137~1
37/146~1
(25.3%)~1
arterious~1
'Albustix'-negative~1
insulin-infusion~4
5.9-8.8),~1
conventional-treatment~4
7.2-13.4)~1
collections)~1
two-tailed).~1
10(7]~1
(35-468)~1
(29-1580)~1
[31-608]~1
[26-460]~1
self-contained~1
(SCEMIA)~1
SCEMIA~3
diarrhoea/hypokalaemia/achlorhydria~1
"non-functioning"~1
islet-cell~1
(mumps,~1
chickenpox,~1
measles)~1
IgM-IAA~2
IgG-IAA;~1
subjects--in~1
immunocyte~1
(visceral~1
leishmaniasis)~1
(66.6%~1
70.0%,~1
(IFN-B)~1
exacerbating/remitting~1
IFN-B~4
double-blinding.~1
Fine-catheter~1
cyto-sieve~1
traditional-acupuncture~1
six-minute~1
44.4%,~2
33.3%,~1
49.5%~1
acupuncture;~2
23.8%,~1
15.8%,~1
25.9%~1
32.6%,~1
26.1%,~1
(AOM).~1
sulfisoxazole~2
(OME)~1
Tympanostomy~1
technetium-thallium~1
Stim-O-Stam~2
ergogenic~2
(1.24~1
run;~1
d-1),~2
urine/plasma~1
anti-Enterobacteriaceal~1
prostatitis--men~1
infection--are~1
Enterobacteriaceal~2
biophysics~1
sprung~1
rebirth~2
anatomy!~1
Sunderland~1
root-plexus-nerve~1
channels:~1
voltage-gated,~1
agonist-gated,~1
agonist-~1
messenger-modified~1
channels'~1
quarternary~1
venom,~1
(Tensilon)~1
envenoming~4
(Naja~2
philippinensis).~1
5.47~1
9.29~1
speak,~1
postplacebo~1
cobras~1
naja),~1
snakebite.~1
(71.4~1
vaginitis.~1
attack-free,~1
13-cis-Retinoic~1
leukoplakia.~1
0.0002);~1
Cheilitis,~1
ferrokinetics,~1
ferrokinetics~1
t(14;18),~1
cleaved-cell~2
13q32~1
6q~1
2.4.1.1).~1
Phosphorylases~1
(phosphorylation,~1
phosphorylase,~1
AMP-binding~1
6-phosphate.~1
intersubunit~1
allostery~1
phosphorylases.~1
pre-messenger~1
non-denaturing~1
enter.~1
AMP-independent~1
endoribonuclease,~1
catalysing~1
Site-specific~1
endoribonucleases~1
(180K),~1
140K~1
120K~1
(N-CAM180,~1
N-CAM140~3
N-CAM120)~1
N-CAM180~3
N2A~2
N-CAM140,~1
N-CAM180,~1
membrane-cytoskeleton~1
N-CAM180.~2
hormonally-active~1
PHI,~1
49-residue~1
pancreastatin.~1
(170K),~1
HlyB~3
66K~1
haemolysin~1
107K).~1
hydropathy~1
pore-forming~1
ATP-binding~1
Stereotactic~1
thalamotomy~1
Neglect~1
neglect;~1
P-200~1
reticulothalamocortical~1
befalls~1
concert.~1
(HACE)~1
HACE~3
4/12~1
8/19~1
1/6~1
8/16~2
7/11~1
"vanished~1
twin"~1
vanishing~1
chorion-lined~1
amniochorionic~1
prostacyclin-stimulating~1
(24K)~1
metaplastic,~1
24K~7
Avidin-Biotin~1
anti-24K~1
Immunostained~1
hematoxylin-and-eosin-stained~1
parabasal~1
"prickle~1
layer"~1
causes)~1
H&E~1
antiovarian~2
sounding,~1
[SEE]~1
sounding~1
ruptured;~1
rejection-free~5
(CALP)~1
CALP,~1
keratoplasty,~2
CALP~3
reformations~1
globes~1
sub-arachnoid~1
3-week,~1
6-week,~1
meniscal-graft~1
sounds.~1
sound-power~1
sialadenitis,~1
repercussions,~1
(RS13)~1
fixative.~1
decalcified~1
tetroxide,~1
Spurr's~1
odontoblast~1
cemental~1
better-controlled~1
pseudofeedback~1
suggested:~1
diskitis~1
Legg-Calve-Perthes~1
osteochondroses,~1
"toddler's~1
fracture,"~1
ossificians,~1
High-quality~1
echodensity~2
asymmetric.~1
IPE.~2
IPE,~3
Careful,~1
touching,~1
(turning~1
suctioning)~1
frd~1
frdD~1
FrdD~4
frdA~1
frdB~1
DW109~1
(frdD-109),~1
menaquinol-6,~1
viologen.~1
methosulfate~1
2,3-dimethoxy-5-methyl-6-pentyl-1,4-benzoquinone~1
quinone~1
menaquinone~1
coli-derived~1
(IFN-beta~1
(FS-4~1
strain).~1
(respective~1
cross-neutralize~1
anti-IFN-beta~1
(HLA-B7~1
mRNA)~1
1128-nucleotide~1
212-amino~1
-beta~3
Sellers~1
hydropathic~1
exponential-ramp~1
exponentiated~1
sine-wave~1
weighting,~2
cheRcheB~1
(defective~1
demethylation)~1
iontophoretically,~1
sec;~1
adapt,~1
cheZ~1
large:~1
5900~1
Cross-hybridizing~1
930~1
568-645)~1
v-erbA~2
v-erbA.~1
blastocyst-derived~1
(ES~1
transgenesis.~1
pluripotency.~1
transgenesis~1
PRC1-SUC2~1
433-residue~1
(CPY;~1
3.4.16.1)~1
511-residue~1
invertase~4
3.2.1.26).~1
CPY~3
vacuole.~2
"mislocalize"~1
(vpt)~1
periplasm~1
vpt~1
(IL-1)-induced~1
inhibitor).~1
missing;~1
Lacking~1
unrecognizable~1
hydratase-dehydrogenase~1
Bolton-Hunter-labeled~1
Bmax,~1
dish).~1
tachykinins~1
turnover;~1
[Met5]enkephalin-like~4
extracts),~1
12-fold,~1
130-fold~1
(i.p.~1
Orthodontic~1
undermining,~1
stitches~1
triangular,~1
semicircular,~1
circular,~1
mastered~1
pig's~3
podophyllin,~1
Duofilm,~1
Suggested~1
in-nursery~1
Hemorrhoids~1
softeners,~1
hemorrhoidal~1
Tympanocentesis,~1
supraspinous~1
Quervain's~1
lymphoceles~3
anechoic,~1
(occasionally~1
lymphocele.~1
globules~1
[20%]~1
cured).~1
(1-5-week)~1
(78.6%).~1
lymphocele~1
sonograms~6
caudothalamic~4
gangliothalamic~2
perimesencephalic~1
cistern,~1
arc.~2
ganglial~1
peduncular~2
echogenicity.~1
anteriormost~1
hyperechoic~4
Hypoechoic~2
Hyperechoic~1
(exclusive~1
pulvinar).~1
pulvinar.~1
abut~2
ovoid;~1
Thalamic~1
(galenic)~1
(cavum~1
septi~1
pellucidi).~1
septations,~1
wall-motion~2
64%),~1
Mayer-Rokitansky-Kuster-Hauser~1
septated~1
Mayer-Rokitansky~1
agenesis;~1
rudimentary,~1
uteri;~1
vaginas;~1
vaginography~1
fastened~1
fiducial~1
in-plane~1
Coordinate~1
abutted~1
4-F~1
laceration/thrombosis),~1
(50.4%),~1
(9.5%).~1
technetium/thallium~1
(DSA),~1
(PVS),~1
(10-MHz)~1
venograms.~1
non-compressibility~1
Clots~1
(TAU),~1
(TRU).~1
TRU~2
TAU~2
sidewalls,~1
(ATN),~1
(PI).~2
Receiver-operator~1
panhepatic~1
hepatofugal~1
.78,~1
sonograms.~1
1.5-year~1
ovoid,~1
central-mass~1
broad-band~1
spectral-difference~1
attenuating,~1
Calcification,~1
sonograms:~1
IVC,~1
(ioxaglate~1
Renografin-60~1
(diatrizoate~1
sodium).~1
nephrogram~1
Renografin-60.~2
histaminic-type~1
benzoimidazolic~1
hydatidosis.~1
cholerae,~1
enterohemorrhagic~2
muenchen,~1
plasmids),~1
nonfermenting~1
Ewingella~1
americana,~1
Intrageneric~1
microbiologists~1
25.5%;~1
transferability,~1
Intrasellar~1
adenomata.~1
yaws~4
treponemes~2
yaws,~2
myeloneuropathies~1
endemicity,~1
yaws.~1
treponematoses~1
Pneumococcal~1
patients--four~1
(penicillin~1
vancomycin),~1
Blood-culture~1
fungemias~1
SBT.~1
1:64~1
susceptibilities.~1
prereduced,~1
fallacies~1
nonsocial~1
realm,~1
conspecifics.~1
(hpg)~1
(GnRH)~2
GnRH-associated~1
(GAP).~1
hpg~1
HTLV-III/LAV--mediated~1
promoter)~2
enhancerless~1
megabases~1
contour-clamped~3
nonalternating~1
mishap,~1
misjudgment~1
poisons~1
pollutants,~1
cushingoid~1
hypothalamic-pituitary-related~1
dipropionate.~1
Beclomethasone~1
transported.~1
doxepin.~1
fenfluramine,~1
nonsedating~1
doxepin;~1
Ultrasonography~1
Whipples~1
transportal~3
nerves).~1
neurolysis.~1
sutured,~2
relieve,~1
ligature;~1
Bacteroids~1
fragilis,~1
cefbuperazone~1
Timentin~1
(ticarcillin~1
(trimethoprium~1
sulfamethoxazole)~1
Azlocillin,~1
parietes,~1
Computer-directed~1
stereotaxis~1
[18F]fluorodeoxyglucose.~1
Hyperparathyroidism~1
(89.3%)~1
(1886,~1
Marie).~1
(1889,~1
Horsley).~1
(1907,~1
Schloffer)~1
(1910,~1
Hirsch)~1
transethmoidal~1
(1911,~1
Chiari)~1
(Hirsch,~1
Dott,~1
Nager).~1
transethmosphenoidal~1
(1957~1
Gisselsson,~1
Riskaer,~1
Bateman,~1
MacBeth,~1
James).~1
Neurosurgeons~1
radiofluoroscopy~1
(1957,~1
Guiot),~1
encephalography,~1
(1965,~1
Hardy).~1
Microadenomectomy~1
(Hardy).~1
forthcoming.~1
Nonfunctioning~1
piriprost~6
(U-60,~1
257)~1
(PS25).~1
PS25~1
Piriprost~1
theophyllines~1
"knowledgeable"~2
"mini~1
infusions."~1
6.0)mg/l;~1
(5.7)mg/l)~1
(45.5)mg,~1
(198)mg;~1
233(189)mg,~1
788(214)mg)~1
pumps),~1
Acorn~1
disease--namely,~1
highest-lowest/highest~1
(%))~1
-0.54)~1
antileucoprotease,~1
macroglobulin)~1
Antileucoprotease~1
macroglobulin~1
22.5)~1
(6.6).~1
Antileucoprotease,~1
(24.3)~1
(23.4).~1
(160)~1
elastase/ml~1
(130),~1
antielastases~1
ventilation--IPPV)~1
1974-83.~1
undertreatment~1
Prechallenge~1
(Pao2)~2
(PD20~1
347))~1
(CBU)~1
CBU;~1
Pao2~4
(1.6)~1
(0.21)~1
kPa))~1
(2.4)~1
(0.32)~1
leukaemia)~1
(sRaw)~1
(Kco)~1
sRaw~1
rose;~1
Kco~1
bronchiolitis,~1
litres,~1
PEF),~1
breathless.~1
normoxic.~1
Air,~1
(tcPo2,~1
tcPco2),~1
(0.34)~1
(7.16)~1
1/min-1,~2
(2.40~1
Paco2)~1
(3.91)~1
(Pao2~2
(8.01)~1
Paco2~4
(3.43)~1
(3.09)~1
(2.89)~1
(1.38)~1
(3.19)~1
(1.84)~1
Paco2.~1
(Provera).~1
1969-84~1
Liverpool~1
africanum~1
3/103~1
Aza~1
(CsA)-related~1
dose-corrected~1
AUC:dose~1
mL/min/kg~2
post-renal~1
once-daily-treated~1
confirm)~1
Cs~5
Trough~1
OLT~2
RIA:HPLC~1
M8,~1
M13,~1
M17,~1
M18,~1
Maurer~1
prefers.~1
(diarrhea)~1
CsA:~1
nonhormonally~1
cytoscopic~1
(HLe-1)~1
63/67~1
320).~3
Leu-T4+~1
(T-lymphocytes)~1
13/63~1
anti-leu~1
leu-4+~2
leu-12+~1
(B-lymphocytes)~1
infundibulum,~1
epididymal,~1
nontropical~1
climes.~1
sonographically.~1
Calcifications~1
Bursae~1
Communicating~1
bursalike~1
(32/63),~1
supraacetabular~1
(18/63),~1
(12/63).~1
bursae.~1
Arthrography,~1
dichorionic~4
monochorionic~3
diamniotic~6
amnionicity~1
chorionicity~1
Sonographic~2
Sonograms~1
subchorionic~1
preplacental~1
Subchorionic~1
sonogram~4
isoechoic~1
angiofibromas.~1
realizing~1
hemorraghic~1
angiofibromas~1
procedure-oriented~1
allegation~1
Consent~1
precedent~1
(I131)~1
(sonographic~1
(palpation~1
(patterns~1
hydronephrosis)~1
(nephrogram~1
urogram)~1
urography;~1
palpable)~1
vein(s)~1
fertile.~1
coarctectomy.~1
esophagrams.~1
arteriosum.~1
ligamentum.~1
share,~1
toxicological,~1
Trans~1
person-1~1
day-1.~1
Overfeeding~3
(1-18%)~1
8-40%~1
C-peptide,~1
(AAN),~1
100.4%~1
AAN~3
(T11),~2
Within-film~1
area-to-area~1
films).~1
Film-to-film~1
(RIM)~1
(Austin~1
Biologicals~1
TX)~1
RIM~3
294)~1
non-E.~2
99.6).~1
(CF~1
1:8)~1
1:100).~1
(58.3%)~1
Electronucleonics,~1
Zeus~1
Scientific,~1
(22.2%)~1
Gull~1
(FITC)~1
FITC~3
Haemophilus-like~6
(84.6%)~1
macrophage/high-power~1
organisms/oil~1
field);~1
organisms;~1
(OAL-656)~1
(5427~1
1217.3~1
min/ml)~1
(1538~1
110.1~1
min/ml).~1
allotransplantation,~1
peritransplant~1
nephron:~1
arteriole,~1
allotransplant~1
(Aza)~1
99mTc-DTPA,~1
inulin)~1
0.36,~1
99mDTPA~1
diuretics:~1
edema-forming~1
incriminated.~1
Cis-dichlorodiammine~1
nonmutagenic~1
cisplatinum-induced~1
transglomerular~1
oncology;~1
nephrotoxic;~1
Methotrexate-related~1
semustine~1
(CH3-CCNU)~1
Streptozotocin~1
Mitomycin-associated~1
diuresis;~1
hyperhydration~1
mannitol-induced~1
cisplatin-induced~1
Cisplatin-induced~1
supplemented.~1
Cytogenetic,~1
paracentric~1
inv~1
ins(9)(q22.1q34.3q34.1)~1
9q22.1-q34.3,~1
AK1~1
9q34.1-q34.3,~1
9q34.3-qter.~1
aerosols)~1
swallowed.~1
Ipratropium~3
intermediate-size~1
hyper-responsiveness~1
vasoactive,~1
chemotactic,~1
non-immunologic~1
Mediators~1
asthma;~3
non-continuous~1
Bronchospasm,~1
Sympathomimetic~1
Parasympatholytic~1
hypersecretory~1
(pre-challenge)~1
mixed-airway~1
multi-center,~1
metaproterenol.~3
duration),~1
anti-asthma~1
Single-agent~1
emphysema;~1
metaproterenol,~1
90-day,~1
parallel-group~1
days-one,~1
90-mean~1
mild;~1
Afferent~1
Hering-Breuer,~1
"J"~1
larynx;~1
hyperpneic~1
beta-adrenoreceptors~1
Beta-receptor~1
Alpha-adrenoreceptors~1
(substance~1
Husby~1
Rugstad~1
osteoarthritis;~1
2,035~1
postmarketing~2
length/abdominal~2
mm/14~1
prorenin,~1
prorenin~9
nonlaboring~1
(66.2~1
6-6~1
dideuterated~1
calorimetry,~1
hydroxypropyl~3
(2.04~1
4.84%~1
7.26%)~1
4.37%~1
9.84%)~1
J-loop~1
coating:~1
mesh-work~1
transilluminating~1
myofibromatosis~1
low-reflective,~1
Interleukin-1,~1
styde,~1
anti-interleukin-1~1
(PNS)~1
leukodystrophy.~1
anti-GFAP~1
GFAP.~3
Cytoskeletal~1
Bergmann~1
glia,~1
(32-75%~1
(66-79%~1
skeinlike~1
reduplicated~1
Neurophysins~1
neurophysins~4
neurophysins,~1
neurophysin-positive~6
ACTH-positive.~1
giantism~1
podocalyxin~3
Lowicryl~1
K4M~1
incubations),~1
(soles)~1
complimentary.~1
endothelium;~1
podocalyxin-containing~1
plasmalemmae~1
glucose-tolerant~1
186-190~1
intrainsular~1
psychotherapies:~1
anxiety-provoking,~1
time-limited,~1
broad-focus.~1
psychotherapies~2
cost/benefit~1
tachycardia-ventricular~1
lithium-induced~3
threats,~1
cynomolgi~2
689-day~1
10(0)~1
sporozoite~3
Attempted~1
hypnozoite~1
conceptualization.~1
provisos,~1
discarding~1
post-primary~1
vivax.~1
multiply.~1
serum-exposed~1
Fasciola-specific~1
p3~2
immunoelectrotransfer~1
(EITB)~1
fascioliasis.~2
27-38,~1
18-23,~1
31-33~2
westermani~1
electrophoresing~1
10%-15%~1
prestained~1
electroelution.~1
19-23~1
re-electrophoresed,~1
8-week-old~3
antivenoms~6
Malayan~1
(Calloselasma~1
rhodostoma)~1
Thailand,~1
envenoming,~1
(TRC),~1
(GPO),~1
Twyford~6
antivenoms.~1
GPO~5
coagulability,~1
TRC~5
2/15~1
(6/15)~1
13/15.~1
Pyrogenic~1
(8/15)~1
(1/15)~1
(0/16).~1
identifiably~1
envenomed~1
anti-lethal~1
anti-hemorrhagic~1
anti-necrotic~1
anti-procoagulant~1
anti-defibrinogenating~1
ampoules.~1
morphine-prostigmine~2
evocative~1
sphincteroplasties~1
-44~1
decrease).~1
nontransplant-related~2
semiemergent~1
viscera,~1
(1.74~1
catastrophes~1
nondependent,~1
8-MHz)~1
Atheromatous~1
run-in~1
-14/-12~1
-8/-5~1
0.05/p~1
(+1/+3~1
-10/-7~1
-10/-8~1
placebo-ketanserin,~1
-7/-4~1
-26/-10~1
ketanserin.(ABSTRACT~1
orciprenaline~1
1-antagonist~2
sympathicomimetic~1
beta-antagonists.~1
HCI,~1
intervened~1
non-smoke-exposed~2
1,660~1
smoke-injured~1
edema.(ABSTRACT~1
patients's~1
(71.1~1
0.029).~1
catecholamines),~1
(TRC)~1
commenced,~1
norfloxacin;~1
febrile.~1
784)~1
738)~1
HMO.~1
wider.~1
beneficiaries,~1
HMOs.~1
eyeglasses,~1
ration~1
laryngotrachea~1
cricoid,~1
decannulation,~1
(23/30).~1
(computer-assisted~1
(measurement~1
properties),~1
(CIS).~1
osteoperiosteal~1
ozena.~1
Crusting,~1
fetor,~1
(PHFs),~1
Meynert~1
(nbM)~1
AChE-positive~1
(AChE+)~1
NFTs.~2
nbM,~1
AChE+~2
AChE-~1
nbM~2
existed;~1
Neuropeptides~1
neuroregulators.~1
co-localized.~1
zinc-sensitive~1
zinc-poor~1
myoblasts:~1
5.1H11,~2
D5,~1
serum-poor~1
regulatable~1
(CJD),~1
(OKB2+~1
OKB7+)~1
1+).~1
Proliferating~1
(OKT9~1
labeled)~2
multi-beta-lactam~1
carboxy-quinolone,~1
11-day~1
posttherapy.~1
multi-drug-resistant~1
acylases~1
dansylated,~1
polyamide~1
acylase~3
6-aminopenicillanic~1
7-aminodeacetoxycephalosporanic~1
D-(-)-alpha-aminophenylacetic~1
(D-phenylglycylpenicilloic~1
D-phenylglycyldeacetoxycephalosporoic~1
pharmaceutically~1
nafcillin,~1
non-beta-lactam~1
haemolyticus,~3
Oxacillin~1
haemolyticus~1
Vancomycin,~1
Erythromycin,~1
-susceptible~1
highest-molecular-size~1
[kDa])~2
size:~1
8249~3
A95210,~1
2955~1
Zighelboim~1
Tomasz,~1
Antimicrob.~1
Chemother.~1
17:434-442,~1
1980).~1
anomalous-sized~1
penicillin-labeled~3
(PBP~1
1a-related)~1
fluoroquinolones,~1
clindamycin-gentamicin.~1
(methicillin,~1
cephalexin,~1
amdinocillin),~1
(PBPs).~1
antibiotic-susceptible~1
DQ-2556,~1
DQ-2556~3
DQ-2556.~1
myo-inositol~1
(inositol)~1
1266~1
(120-160~1
ingastric~1
4-10,~1
echogenecity~1
1-deamino-8-d-arginine~1
alarm.~1
journeys~1
successes,~1
dry,~1
anti-diuresis~1
venepuncture~1
emobilization~1
(NWTS)~1
(ICE)~1
(CCS);~1
(FH).~1
ICE~5
CCS~1
event-free,~1
NWTS.~1
NWTS~2
(NWTS-2),~1
(NWTS-3)~1
Intramyocardial~2
(anatomical)~1
7.430~1
0.019,~1
7.233~1
6.860~1
0.066~1
6.852~1
7.043~1
0.077~1
harvest,~1
intrapleurally~1
IMA,~2
Y-grafts~1
1,483~1
Timing~1
10:1;~1
3:1;~1
2.5:1.~1
graphics.~1
Fronto-orbital~1
Rib,~1
scapula,~1
Cosmesis~1
(0.83,~1
1.64)~1
(0.49,~1
1.16)~1
(0.53,~1
1.19)~1
(0.47,~1
randomisation.~1
(0.87,~1
2.74).~1
Epoprostenol~1
(prostacyclin)~1
epoprostenol~5
(23)~1
(22).~1
3.8-15.9~1
reinfarction,~1
Non-invasive~1
pmean~2
ppeak,~1
ppeak~1
xamoterol~5
Xamoterol~2
xamoterol.~3
(methoxyflurane~1
(morphine~1
122,~1
On-Demand~1
Computer.~1
harbouring~1
phaeochromocytoma,~1
tumour(s),~1
pustule~3
etretinate-treated~1
8/0~3
(bootlace)~1
(continuous)~1
against-the-rule,~1
gape~1
Hemoglobin's~1
balanced.~1
beta-dimer~2
gamma-dimers~1
2-tetramer.~1
Electrostatic~1
multisubunit~1
VIIa.~1
TF,~1
immunodepleted~1
BaSO4~1
barium-absorbed~3
VII(a)~1
pmol/L),~2
(850~1
(vol/vol).~1
Hjort~1
VIIa-Ca2+-TF~1
X(a)~1
(plasma)~1
(HepG2)~1
(c-fos)~1
(M4)~1
monocyticlike~1
(HB10a)~1
Ia-like~5
"accessory~1
engraftment,~3
(7.2)-positive~1
sorter.~2
HB10a.~1
Pgp-1~7
C71/26~4
Pgp-1.~1
87,000~3
3H-sodium~1
97,000~1
parasite-elicited~1
82,000~1
platelet-dependent~1
M1/70~1
LFA-1~3
(MoAbs).~1
Slot-blot~1
gamma-carboxylation~1
Saturable,~1
125I-transferrin~1
20,900~1
3,160~1
1,520~1
18,330~1
14,760~1
7,120~1
antitransferrin,~1
antiperoxidase~1
Microdensitometric~1
Interchain~1
V-8~1
(N)-terminal~1
(C)-terminal~1
dimerization~1
interdimer~1
postgrafting)~2
graft-v~1
-host~1
[GVHD])~1
(T-sup)~1
12-0-tetradecanoyl-phorbol-13-acetate~1
T-sup~4
T-sup.~2
0.0075,~1
Exact).~1
postgrafting.~2
T-sup,~1
CD18~1
60.3,~2
CD18,~2
(LT)B4,~1
intradermally;~1
(125I-albumin)~1
(myeloperoxidase)~1
60.3~2
PMN-independent~1
Intravital~1
tenuissimus~1
(ZAS).~1
Rolling~1
(FMLP)-induced~1
post-transplant~2
digitally,~1
(ELU)~1
ELU~1
precautionary~1
observation/investigation.~1
(SHO/registrar),~1
proceed--operation~1
laparoscoped.~1
'observation'~1
(11/94:~1
subhepatic~2
non-drainage~2
A2B5~1
A2B5+~2
galactocerebroside+~1
GFAP+A2B5+~1
astrocytes;~1
A2B5-~1
NCAM+;~1
unfasciculated~1
(NHLs)~1
higher-grade~3
lower-grade~2
cannot.~1
Propylthiouracil~1
35-year~1
Rash,~1
arthralgias~2
Vasculitis,~1
rash),~1
thyroglobulin.~1
nonadenomatous~1
(EMA)~1
Cytokeratins~1
epithelia,~2
coelomic~1
cytokeratin.~1
Coexpression~1
masquerades~1
Haitians.~1
non-Haitian~1
(POG)~1
(TS).~1
laterality.~1
140.240~1
p97-like~1
intradermal,~1
junctional,~1
Intrapatient~1
muramidase,~1
antichymotrypsin,~1
avidin-biotin-complex~1
cherubism,~1
muramidase~1
Alpha-1-antichymotrypsin~1
alpha-1-antitrypsin.~1
mononuclear-phagocyte~1
ganglioneuroma~1
6.5-year-old~1
radiated.~1
Histologic,~1
perineuronal~1
1%-48%),~1
1%-10%)~1
N+~2
14.2%)~1
9.2%),~1
melanosome-associated~1
(HMSA)-1~1
HMSA-2,~1
HMSA-2~6
paraffin-processed~2
HMSA-2.~1
(pAb)~1
pAb,~1
pAb~1
thyroxin,~1
keratins,~1
thyroxin~1
tangentially~1
thyroxin),~1
keratin),~1
C-cells~1
anti-lysozyme~1
S-100-positive~1
lysozyme-positive~1
(WDLL)~1
(SCC).~1
SCC.~3
Actinic~1
WDLL.~1
WDLL~2
snap~1
cryostat.~1
isothiocyanate)~1
anti-lactoferrin~2
Judkins~1
overselectivity~2
invalids~1
approachable~1
xamoterol,~2
NE-heart~1
Predose~1
NE-cardiac~1
NE-systolic~1
(Renografin-76)~1
material).~1
t1/2.~1
skilled,~1
smoothness~1
peptides:~1
dynorphins~1
pre-proenkephalin~2
pre-proopiomelanocortin),~1
baroregulation,~1
ontogenesis~1
low-renin~2
(load)~1
reninlike~1
antirenin~1
resetting,~1
Captopril~3
captopril)~1
renin-angiotension~1
furosemide)~1
resistance;~1
hydrochlorothiazide;~1
pressure-overloaded,~1
pressure-overload,~1
pressure-overloaded~1
leucyl~1
high-ATPase,~1
high-contractile~1
myosin),~1
(hand)~1
Matti-Russe~2
Radiocarpal~1
Suspicion~1
unquestionably~1
mainstays~1
wise~1
eventuality.~1
(Swan-Ganz)~1
(AFLP)~1
AFLP~1
Pregnancy,~1
betamimetic~1
Betamimetic~1
(VSCC)~1
well-devised~1
obstetric,~1
(IVGTT)~1
off-~1
on-treatment~1
methandienone~1
(Dianabol).~1
On-treatment,~1
(FPI)~1
IVGTT~1
Bergman~1
insulin;~2
Sg,~2
disposal;~1
model-derived~2
threshold;~2
Sg~2
on-treatment.~1
FPI~1
Dianabol-induced~1
glucagon.(ABSTRACT~1
6-Oxo-prostaglandin~1
(6-oxo-PGF1~1
6-oxo-PGF1~4
99-11,485~1
plasma).~1
6-Oxo-PGF1~1
55-1207~1
haemostasis.~1
yeasts,~1
(QC)~1
QC~7
language;~1
references;~1
competent;~1
QC.~1
reference/standard~1
CBC,~1
calibrators~1
reagent-based~1
tests.(ABSTRACT~1
bank,~1
much?~1
often?~1
says?~1
re-examining~1
serologists~1
better."~1
procedural/technical~1
Procedural/technical~1
implement.~1
commitments,~1
typographic~1
checks.~1
multi-rule~1
formats.~1
constraint,~1
regulator,~1
biohazards,~1
Assuring~1
lab,~1
laboratorian's~1
laboratorian~1
PEEP.~5
PaO2/FIO2~1
0.20.~1
Qsp/Qt~1
(0/18~1
1/20),~1
(PAC)~1
(IJ)~1
timed.~1
air-permeable~1
anticontamination~1
guidewire,~1
consequential.~1
sterile-insertion~1
catheter-maintenance~1
(DO2)~1
DO2.~1
53-72~1
2-agonists~1
triple-crossover~1
(PVBs)~1
theophylline)~1
PVBs~1
Bichat,~1
Paris.~1
immunofluorescent,~1
Methotrexate-induced~1
echopoor~2
postligation~1
Traumatic,~1
Nontraumatic,~1
crepitation.~1
clostridia.~1
nontraumatic,~1
myonecrosis,~1
permits,~1
Vivonex~5
1703~1
CCK-peptides~2
T204~1
1703;~1
(T204;~1
cm3;~1
oil-induced~1
coordinating~1
expels~1
duct-duodenum~1
phlegmonous~1
Phlegmonous~1
(LH-RH)~1
single-bolus~1
LH-RH~8
determinations)~1
ng/l.~1
2.5-micrograms~1
intrafossa~2
operators'~1
didelphic~2
unicornuate,~1
uterus).~1
42.9%;~1
97.8%).~1
False-negatives~1
4.04~1
nonhysterectomized~1
premeal~1
Prior,~1
(CCK8S)~1
CCK8S~2
incretin~1
kinase's~1
histone.~1
insulin-binding~1
Blazar~1
alpha-aminoisobutyrate~1
-precipitable~1
alpha-aminoisobutyrate.~1
Methylamine~1
degradation;~1
(SRIF)~2
micrograms/hr).~1
SRIF,~2
GTP,~1
glycogenolysis,~1
GTP-responsive~2
GTP.~1
muM~1
diethylaminoethyl~1
(DEAE)-cellulose~1
carbohydrate-fed~1
14)]~1
[1.14~1
38)]~2
[1.31~1
16)]~1
[1.54~1
UTP,~2
5'-diphospho-N-acetyl~1
glucosamine~1
13-51%~1
(4-mo-old)~1
10-micrograms/day~1
25-micrograms/day~1
4-mo-old~1
postbiopsy~3
ultrasound-detected~1
intrahepatic,~1
subcapsular).~1
99mTc-dithiopropylthiomine.~1
Pectin~1
28-yr-old~1
brother.~1
biliary-type~1
Azodisal~1
5-amino-salicylic~1
sulphasalazine,~1
azodisal~3
(PG)F2~1
'PGE2~1
alpha'~1
azodisalicylate~1
bd)~1
re-endoscoped~1
anti-ulcer~1
(70.6%)~1
anthropometric,~1
aims:~1
malnutrition;~1
undernutrition.~1
enterally,~1
L-(1-14C)~1
posthepatitic~1
classification:~1
comparable:~1
echo-doppler~1
p.o.),~1
sublingually).~1
isosorbide,~1
(pre-S1),~1
(P24)~1
P24~1
Galactosamine~1
UTP.~1
Amicon~1
Ultra~1
D-galactosamine-induced~1
Male,~1
[14C]sucrose.~1
perfusate.(ABSTRACT~1
HA22T/VGH~1
3B,~1
IB1~4
9B2~4
9B2.~2
hepatomas.~1
U-71038~9
(Boc-Pro-Phe-N-MeHis-Leu~1
psi[CHOHCH2]Val-Ile-Amp),~1
ganglion-blocked~1
renin-infused~2
Captopril,~2
(ZG)~1
ZG~9
18-hydroxy-11-deoxycorticosterone~1
I/mg~3
protein/hr).~1
sodium-deficient~2
protein/hr).(ABSTRACT~1
baroreceptor-heart~1
forthright~1
dire~1
contoured~1
hairline,~1
Transplanted~1
appliance,~1
counteragents.~1
(MAg)~1
denatured,~1
MAg.~2
MAg,~3
sulfate-denatured~1
MAg~5
(28.8%~1
13.6%)~1
(22.4%~1
11.2%).~1
(ER)-binding~1
A-bearing~1
(Anti-ER)~1
Anti-ER~2
1-85~1
(young,~1
13-51~1
5.0-7.4~1
gonadotropin-independent~1
("testotoxicosis")~1
C17-20~1
pubertal-type~1
buserelin~1
yr]~1
(gonadostat)~1
testotoxicosis,~1
IRI/glucose~2
PCO-AN~1
PCO-AN.~1
(CRABP).~1
Biphasic~1
CRABP;~1
Hep3B.~1
Hep3B~2
Kininogenase~1
(125I-high~1
[HMWK])~1
125I-HMWK~1
65,000-mol~1
fragment),~1
(phe-phe-arg-CH2Cl~1
fluoride)~1
20,000-34,000~1
Lysylbradykinin~1
HMWK,~1
kallikreins.~1
Kinin~1
(histamine)~1
glucagon-suppressing~1
hyperglucagonemic~1
phloridzin~2
8%/h~1
alloxan-diabetic~1
6%/h,~1
10%/h~1
phloridzin-pretreated~1
insulin-deprived~1
partially;~1
Palmitate~1
([1-14C]palmitate)~1
84-h~1
partially-purified~1
nondiabetics,~2
10-12-fold~1
92-kDa~1
Glu4:Tyr1.~1
Glu4:Tyr1~1
0.09%,~1
(-72~1
1,10,phenanthroline~1
(-85~1
metalloproteinase(s).~1
myeloperoxidase-hydrogen~1
peroxide-halide~1
(DAF).~1
(AML);~1
anti-DAF~2
(ECGF)~1
ECGF~6
0.1-100~1
48-96~1
specificities;~1
speckled~2
5,6-dichloro-beta-D-ribofuranosylbenzimidazole-treated~1
drug-segregated~1
Scleroderma~1
210,000~1
14,000.~1
Microinjection~2
pTa~1
secretor~1
(Dakopatts)~1
rhabdomyosarcomas,~2
SMP,~1
Anticomplement~1
Ramsey-Hunt~2
anticomplement~4
1/10.~2
titre,~1
anti-VZV~1
repigmented~1
minigrafting~1
C50~1
C241~1
sialosyllactotetraose,~1
C50,~1
C241.~1
(biopsies~1
pathologic-anatomic~1
unlined~1
intracartilaginous~1
bolstered~1
Infarction.~1
timolol-treated~1
isoenzyme-confirmed~1
Predischarge~1
[77%])~1
[23%]).~1
appreciable,~1
(23.0~1
(1,372~1
IU/liter,~1
1,741~1
IU/h)~1
(ISAM).~1
882~1
18.4%)~1
14.2%).~1
(34.9~1
C-100)~1
midpapillary~1
variate~1
width/half~2
microspheres:~1
Composition,~1
self-blood~1
Self-blood~1
(cholesterol~1
(1.1),~1
end-points.~1
abacteriuric~1
Antishock~1
contraindications,~1
Inhal-aid~1
reservoir-delivery~1
Pseudofolliculitis~1
barbae~1
bearded~1
ingrown~1
grooved~1
keloids.~1
pseudofolliculitis~1
wound-repair~1
(AMIA)~1
AMIA~4
anti-Leu-2a,~1
-3a,~1
+14.~1
-1,~1
AMIA,~1
(L12)~1
anti-mannan~2
anti-CA~6
L12~2
mannan-isolated~1
(named~1
autoanti-idiotypic~1
CP-depleted~1
B17)~1
anti-T8~1
anti-T4.~1
lysylbradykinin~5
pro-inflammatory~1
lysylbradykinin.~1
nonallergic,~1
post-challenge~1
(bradykinin~1
(Arg10)~1
lysylbradykinin)~1
(Arg9)~2
475%~1
MERGETPA~2
(D-L-mercaptomethyl-3-guanidino-ethylthiopropanoic~1
amastatin~1
bestatin~1
optima~1
o-phenanthroline,~1
(phosphoramidon)~1
(Captopril).~1
(GP-BP)~1
BP-~1
Cellfree~1
strain-restricted~1
antigen-independent,~1
GP-BP~2
rat-derived~1
BP-1~2
supernatant-activated~1
GP-BP.~1
anti-I-E~1
ultrasupernatant,~1
mixing.~1
AC-derived~1
cell-AC~1
trypanosomes,~1
p63~1
(AChE),~1
5'-nucleotidase,~1
RT6.2--an~1
VSG,~2
anchors~2
glucosamine;~1
(CRD),~1
diacyl~1
DAF-S~2
(DAF~1
PI-specific~1
[PIPLC])~1
CRD.~1
capturing~1
anti-CRD,~1
DAF-S.~1
anti-CRD~1
VSG.~1
Hela~1
CRD~1
phospholipases.~1
leprae~3
(suppressor)~1
LL,~1
immunoaccessible~3
bi-specific~1
(serovars~1
Ba)~1
subspecies-specific~1
(various~1
serovars)~1
non-immunoaccessible~1
subspecies-~1
(MAF)~3
(G1~1
MAF~1
(macrophage-activating~1
(MAF]~1
phosphatidylinositol-4,5-bisphosphate.~1
CTL-stimulus~1
1,2-diacylglycerol~1
(DAG)~1
(IP),~1
MAF-inducing~1
DAG~1
full-spectrum~1
(DP,~1
DR),~1
DNCB.~1
bromodeoxyuridine~1
(BrdU),~1
BrdU.~2
BrdU~1
anti-BrdU~1
OKT-6~1
OKT-6(+)~1
BrdU(+)~1
(16.3~1
BrdU-labeled~1
cycling--therewith~1
self-reproducing~1
(autoAB)~1
autoAB~16
100X~1
50X~1
autoAB.~1
(SBL)~1
SBL;~1
BL.~1
autoAB,~2
Antikeratin~1
antiepidermis~2
(biopsy-proven)~1
(biopsy-negative~1
HSV).~1
(adenovirus)~1
(western~1
subunit-killed~1
(BS-WC)~1
cell-only~1
(WC)~1
K12~1
BS-WC,~1
WC,~1
1,257~1
vibriocidal~1
Inaba~1
WC~1
BS-WC~1
dose-to-dose~1
concentration/MIC~3
antitryptic~1
benzamidine~5
(immobilized)~1
ng/ml/hr).~1
(PRA);~1
benzamidine,~1
(EIA),~1
FDP-14).~1
FDP,~1
("cap-tag~1
procedure"),~1
neoantigenic~1
cross-linked.~1
interprets~1
electrocardiographer~1
statement,~1
Dyspareunia,~1
reaggregate~1
centripetally~1
nucleocapsids,~1
Virion~1
envelopment~1
(SCH).~1
remyelination.~2
Oligodendrocytes~1
anti-SCH~2
system-type~1
ingestive~1
consummatory~1
Separately~1
(night)~1
(light)~1
(12-15%)~1
immunonephelometry~1
aldosteronism,~1
aldosterone-producing~1
252)~1
higher-prevalence~1
mail-in~1
DLIS-positive~1
(relapse)~1
(reinfection).~1
serotyped~1
reinfection;~1
Tympanocentesis~1
Center-Emergency~1
(PCC-ER)~1
143)~1
207).~1
(AIOS).~1
PCC-ER~1
AIOS,~1
AIOS.~1
Carriage~1
"late-onset"~1
birth:~1
intrauterine-acquired~1
year-to-year~1
noncompliant,~2
bladders;~1
Folic~1
5-formyltetrahydrofolic~1
(FTHF)~1
pteroic~1
N-methyl-D-aspartic~1
(NMDA)~1
D-alpha-aminoadipic~1
DL-alpha-epsilon-diaminopimelic~1
MgCl2,~1
NMDA-induced~1
hypermotility,~1
folate-induced~1
diethylester,~1
quisqualic~2
NMDA,~2
FTHF.~2
gamma-D-glutamylaminomethylsulfonic~1
gamma-D-glutamyltaurine,~1
accumbens.(ABSTRACT~1
Neurochemical~1
(3-30~1
(DA)1~1
23390~1
(bolus~2
DA2-selective~1
DA1~1
portion).~1
accident?~1
criticism~1
compassionate.~1
large-group~1
monophosphate/inorganic~1
(MP/Pi)~1
cold-flushed~2
cannulas;~1
cold-storage~1
Surface-coil~1
storage;~1
0.50)~1
nonviability.~1
K2.7~4
OS-RC-2~1
(RCCs)~1
(HIPA)~1
HIPA~5
14C-serotonin~1
(PPP,~1
aspirin-free~1
(PRP,~1
parts).~1
Iloprost,~1
HIPA,~1
thromboxane-independent~1
unavoidable,~1
iloprost~1
HIPA.~1
NY,~1
of-15.8%~1
wishing~1
self-regulation,~1
sired~1
7.9)~1
Men's~1
48.5%.~1
70.8%.~1
anal/genital~1
Douching~1
papillomavirus.~1
papillomavirus,~1
accruing~1
Questionnaire)~1
tricyclics~1
Equity~1
Fiscal~1
full-risk~1
capitation~1
first-round~1
Marshfield,~1
Wis,~1
(11.6%~1
revenue).~1
261.7~1
Reimbursement~1
recognize,~1
gastroplastic~1
immunodotting~2
peroxidase-conjugated~1
v-H-ras~1
(rp-12,~1
rp-28,~2
rp-35,~2
rp-38)~1
gene-activated~2
p21ras~3
rp-12~2
rp-28~1
K-ras-activated~1
rp-35~1
rp-38~2
N-ras-activated~1
rp-12,~1
autoperfusing~1
(6-keto-prostaglandin~1
B2).~1
Collins'~5
prepared:~1
(potassium:~2
mmol/L);~1
implantation;~1
support;~1
thalassaemic~1
partially.~1
Dohme~1
(anti-HBs).~1
Anti-HBs~1
25/29~1
86/90~1
contraindications.~1
(GvHD)~1
flora,the~1
septicaemias~1
rough-mutant~1
J5,~2
endotoxin,and~1
J5~2
("anti-endotoxin")~1
BMT,~1
anti-J5~1
GvHD.~1
11-deoxycorticosterone,~1
insulin/glucagon,~1
non-fentanyl~3
meningoceles~1
encephaloceles~1
cephaloceles,~1
basioccipital~1
cephalocele,~1
mid-1970s,~1
"non-neurologic"~1
neurology.~1
neuropharmacologist,~1
neuroendocrinologist,~1
juxtasellar~1
unanswered,~1
neuropharmacology~1
time-specific~1
Catamenial~1
prolactin)~1
receptor-specific,~1
reservation~1
parodynes~1
non-mu~1
epsilon-mediated~1
contradistinction~2
pro-~1
Jarvik-7~2
flawlessly~1
calcium-treated~1
skeleton)~1
c-erb-A~1
v-erb-A~1
c-erb-A,~1
v-erb-A,~1
Thermostability~1
'protein~1
engineering'~1
thermostability:~1
mesophilic~1
thermostability;~1
thermostability~2
stearothermophilus,~1
cooperativity.~1
(DBC)~1
neurones:~1
2-amino-4-phosphonobutyrate~1
(APB),~1
DBCs.~1
APB~1
DBCs~1
cytolytic-helper~1
underscoring~1
cost-benefit,~1
10,214~1
1.04%.~1
0.93%~1
polyhydramnios.~1
(91.3%).~1
Tripler~1
(68.5%)~1
impractical,~1
antenatally,~1
Ventriculo-amniotic~1
Acupuncture~5
intervention;~1
Visitation~2
nonacupuncture~1
(90.9%)~1
(36.4%);~1
(18.2%);~1
(responders);~1
(non-responders).~1
etiology;~1
wks.~1
(41%~1
mos.,~1
Lymphocytotoxic~1
pre-iridial~1
etodolac.~1
zomepirac,~1
analgesic.~1
(IP-PAP)~1
(31.3%)~1
cancer.(ABSTRACT~1
consider.~1
pathosis.~1
Subtrochanteric~1
inter-subtrochanteric~1
screw-plate~1
schema,~1
Because,~1
Nonsquamous~1
deceptively~1
reticulosis,~1
esthesioneuroblastomas,~1
angiofibromas,~1
electrons,~1
compensators,~1
simulator-aided~1
emergy~1
Possibilities~1
emerge,~1
Post-partum~2
upside~2
cramp~1
downside~2
Episiotomy~1
post-cesarean~1
2-group~1
(TENS-treated~1
TENS-treated),~1
post-cesarean-associated~1
movement-associated~1
afterbirth~1
contractions),~1
(gas~1
pains)~1
(RAS)~1
fronto-parietal~1
hypophysis~1
(angiotensin~1
thermoalgesic~1
epiphysectomy~1
RAS~2
nonabused~2
parts;~1
scribbled~1
(5/52)~1
(1/52)~1
drew~1
.10,~1
one-tailed~2
test).(ABSTRACT~1
rejection;~1
retransplantation~2
transplantation.(ABSTRACT~1
unblinded,~1
(surfactant~1
TA)~1
arterial/alveolar~1
PO2)~1
gavage,~1
dl-alpha-tocopherol~1
8-azidoadenosine~1
(N3ATP)~1
5'-p-fluorosulfonylbenzoyladenosine~1
(5'FSBA),~1
(Tyr-264)~1
24-residue~1
(T-31)~1
257-280.~1
N3ATP~2
T-31~4
TTP;~1
N3ATP-modified~1
photolabel~1
PDE2,~1
RAS2Val19,~1
RAS2~1
PDE2~1
RAS2Val19~1
(adriamycin;~1
DoxR)~1
Multidrug~1
DoxR~4
AdrR~1
publications)~1
(HNs)~1
HNs~3
P1-450)~1
glucuronyltransferase)~1
2.5.1.18).~1
(benzo[a]pyrene)~1
"alarmone"~1
3'-diphosphate~1
(ppGpp)~1
DNA-dependent~1
ppGpp;~1
ppGpp~4
templates.~1
Oligonucleotide-directed,~1
hexamer~3
BAL-31~1
ppGpp.~1
(NPF-1)~1
IMR-32~1
primase-associated~1
high-salt~1
DNA-unwinding~1
NPF-1~4
poly(dC).~1
ternary~2
(11S).~1
(2.5-fold)~1
primase-catalyzed~1
dGMP~1
poly(dC)~2
alpha-amanitin~1
template,~1
[32P]-GTP,~1
[3H]dGTP~1
sucrose-density-gradient~1
hsd~1
potsdam~1
hsdS~4
(variable)~1
(SQ)~1
trinucleotide~2
governs~1
tetra-~1
penta-nucleotide~1
K-12~2
Diacylglycerol-induced~1
(ATP:1,2-diacylglycerol~1
3-phosphotransferase,~1
2.7.1.107)~1
enzyme-membrane~2
polyacrylamide.~1
(step~1
500-~1
750-fold~1
homogenate)~1
vesicle-bound~1
Transin~2
transin~2
premalignant,~1
2116-amino~1
rod-like~1
periodicities~2
myosins.~1
196-residue~1
14.3-nm~1
1,4~1
protease-treated~1
overproduce~1
metalloprotein~1
six-coordinate~1
histidine-39~2
histidine-63~2
five-coordinate~1
(c-fos~1
factor-stimulated~1
C-deficient~1
6-phosphofructokinase~1
(PFK;~1
2.7.1.11)~1
fibers).~1
actin-severing~1
brevin,~2
gelsolin.~1
PFK,~1
detergent-extracted~1
HSP70,~1
HSP70~7
13S~1
noninductive~1
G2.~1
psu~3
"phasmid"~1
(phage-plasmid)~1
P4~2
antitermination~2
morphogenic~1
operons~1
rho-dependent~1
intron/exon~1
40-kilobase~1
alpha-glucosidase~3
3.2.1.3)~1
1,4-linked~1
alpha-D-glucose~1
glycogen-storage~1
alpha-glucosidase.~3
phage,~1
20-kb~2
q21-q23,~1
3.4-kb~2
infantile-onset~1
alpha-glucosidase-deficient~1
pir~4
R6K~4
(Cos405)~1
replicon~2
few-fold~1
pir405~1
Cos~1
replicon.~1
HTLV-IIIRF~1
(effluent)~1
121,~1
oncostatin~4
A375~1
13-acetate.~1
Oncostatin~2
n-propanol~1
18,000,~1
28,000,~1
8402~2
q11)~1
p15)~1
[t(11;14)(p15;q11)].~1
(TCRA);~1
11p15~2
TCRA~1
-0.575;~1
0.22%~1
140-day-old~1
arginine-responsive,~1
glucose-unresponsive~1
papovavirus,~1
Trans-activation~1
Primer-extension~1
More-than-additive~1
LTR-CAT~1
leukemia-specific~1
8.5-kilobase~2
ABL-related~1
(P210c-abl).~1
2550~1
471,~1
P210c-abl~2
phenylethanolamine~3
N-methyltransferase,~2
A1-A7~1
5-hydroxytryptaminergic~1
B1-B9~1
N-methyltransferase-immunoreactive~1
C1-C3~1
A8-A10,~1
(A8,~1
A9)~1
receptor-immunoreactive~1
A12~1
A14,~1
incerta~1
(A13),~1
(A11)~1
Phototropism~1
Phycomyces~2
photosystems~4
m-2).~1
sporangiophores~1
m-2,~2
early-response~1
(15-min~1
late-response~1
70-min~1
Photosystem~1
334,~1
347,~1
dark-adaptation~1
light-adaptation~1
sporangiophore~1
antiphosphotyrosine~2
95-kDa~1
116-kDa~1
galactosyl-(beta~1
1----3)-N-acetylgalactosyminyl(beta~1
1----4)-[N-~1
acetylneuraminyl(alpha~1
2----3)]-galactosyl(beta~1
1----4)glucosyl(beta~1
1----1)~1
(GM1)~1
3q~1
CHEF/18~2
c-Ha-ras~1
pSV2gptEJ.~2
EJ~2
p21,~2
3q.~2
p21.~1
pSV2gpt~1
CHEF~1
3q,~1
Mov~6
respective,~1
coisogenic,~1
129-derived~2
Mov-3~1
Mov-14~4
rejections~2
(Mov-9)~1
viremic.~1
Mov-14,~1
MBL-2~2
RBL-5.~2
Mov-9~1
skin-graft~1
H-43~1
(activator~1
replication)~1
ADR-containing~1
plasminogen-independent~1
plasminogen-dependent~1
p-aminobenzamidine,~1
N-alpha-tosyllysine~1
aprotinin-conjugated~1
[TyrOHase,~1
3-monooxygenase,~1
(2-hydroxylating),~1
mesostriatal~1
TyrOHase,~1
TyrOHase-like~2
striosomes~1
extrastriosomal~1
striosomal~1
striosomes.~1
1783-1794~1
(Electrophorus~1
electricus)~1
electroplax~4
"right-side-out"~1
saponin.~1
permeabilization,~1
("native")~1
trimer~1
carbamoyltransferase,~1
2.1.3.2)~1
Ser-52~1
Lys-84~1
Gln,~1
His-134~1
Ala.~1
trimers~1
Lys~2
trimer,~1
bisubstrate~1
trimer.~1
double-mutant~1
(Lys-84----Gln~1
His-134----Ala)~1
trimers.~2
(dimers,~1
(protein-tyrosine~1
2.7.1.112)~1
(IGF)-I.~1
HepG2.~1
TA1~1
ester-stimulated~1
noninhibiting~1
Reductive~1
Polylysine-containing~1
Poly(L-lysine),~1
poly(D-lysine),~1
poly(L-ornithine)~1
Poly(L-arginine)~1
polydisperse~1
14-residue~1
lysines.~1
NG-108-15~1
inositolphospholipids,~1
4,5-bisphosphate.~1
imidodiphosphate.~1
formylmethionine~1
GGGCCC~1
elongator~2
Overproduction~1
one-step~1
characterize,~1
formylation,~1
formylmethionyl~1
MS2~1
RNA-directed~1
protein-synthesizing~1
AUG-dependent~1
Dideoxy~1
(ENU)~1
O6-alkylguanine~2
O4-alkylthymidine~2
(39/39)~1
MNU-induced~1
C----A~3
24/33~1
ENU~2
7/33~1
T----G~1
1/33~2
C----C~1
transversion,~1
T----C~1
transversion.~1
O4-alkylthymidine/O6-alkylguanine~1
ENU.~1
MNU-~1
ENU-induced~1
5'-GG(A~1
T)-3'.~1
(RMCP~1
chymotrypsin-like~1
alpha-chymotrypsin~2
RMCP~7
Leu-Xaa~1
residues--e.g.,~1
Phe-Phe.~1
o-phenanthroline.~1
apomyoglobin~2
(17,199~1
granule-bound~2
PutA~1
putA,~1
putP~2
putA~2
flavoprotein,~1
1.5.99.8),~1
D-lactate~1
dehydrogenase-membrane~1
(palmitoyl-CoA:L-carnitine~1
O-palmitoyltransferase,~1
2.3.1.21)~1
Nagarse~4
(subtilisin,~1
3.4.21.14).~1
malonyl-CoA~4
Subfractionation~1
shrinking,~1
near-parallel~1
malonyl-CoA-inhibitable~1
out-side-out~1
cosonication.~1
contiguities~1
protein-serine~3
gamma-subunit,~1
CDC2~1
CDC28~1
987-base-pair~1
tdc~2
[Tdc;~1
L-threonine~1
hydro-lyase~1
(deaminating),~1
4.2.1.16],~1
35,238.~1
Tdc~4
[14C]tryptophan~1
"covalent"~1
heptapeptide,~1
54Thr-55Gly-56Ser-57Phe-58Lys-59Ile-~1
60Arg,~1
Lys-58,~1
dehydratases~1
ILV1)~1
ilvA)~1
D-serine~1
(DsdA,~1
dsdA)~1
homology:~1
63-93%~1
dehydratase;~1
DsdA.~1
DsdA~1
Arginase~2
3.5.3.1)~1
ureotelic~1
argininemia,~2
arginase.~1
Oligo(dT)-primed~1
arginase~2
hARG6~2
hARG109,~1
34,732),~1
(nucleotides~1
5128-5265)~1
72-~1
73-base-pair~1
polyomavirus,~1
lymphotropic.~1
Monomeric~1
ferritin-labeled~1
(Fm-Ins),~1
Fm-Ins~7
location--near~1
250-fold~2
insulin--in~1
(CMP)~1
insert-encoded~1
CMP~3
3.4-kilobase~1
precartilaginous~1
CMP,~1
"Anti-liver/kidney~1
microsome"~1
(anti-LKM)~1
tienilic~3
anti-LKM2~5
P-450-8~3
anti-cytochrome~1
anti-organelle~1
filipin-stained~1
Niemann-Pick~7
(LDL)-derived~1
group-D~1
LDL-depleted~1
LDL-supplemented~1
transsutural~2
myoosseous~1
osteometry.~1
evacuations~1
thirty-ninth~1
epithelialization~1
attributed.~1
imbibition.~1
Microradiography~1
triple-fluorochrome~1
throats.~1
allayed~1
(currently~1
start-up~1
staffing.~1
low-efficiency~1
pipetting~1
time-saving~1
conveniences.~1
Fluid,~1
urinalysis)~1
easy-to-operate~1
US-based~2
demarcating~1
subendometrial~2
adnexa,~1
endometriomas~1
70%),~1
"partial~1
nephrocalcinosis,"~1
mercaptoacetyltriglycine~1
o-iodohippurate~1
(OIH)~1
OIH~5
MAG3.~1
(78.6%)~1
(53.1%)~1
(7.06~1
(10.78~1
whole-kidney~1
OIH.~1
US-guided~1
non-Western~1
"Cape~1
colored"~1
race)~1
ascariasis.~4
left-sided,~1
ascariasis~1
omentum)~1
coarse,~1
teratoma.~1
14-83~1
(4-21~1
nonpulsatile,~1
across,~1
anechoic~3
agreed,~1
had.~1
axillary-axillary~1
HO.~1
protozoans~1
recovery),~1
pneumocystosis~3
Acid-fast~1
AIDS-~1
non-AIDS-associated~1
frustrating,~1
animal-model~1
Nineteenth-century~1
Victorian~1
nonvenereal~2
contagion,~1
preindustrial~1
prerevolutionary~1
preconceptions~1
historian~1
osteomyelitis;~1
cell-lymphotropic~1
suppuration~1
echovirus~4
nonmucosal~1
nonnosocomially~1
.11)~1
cesarian~1
nosocomially~2
Attack~1
22%-52%~1
spirochetoses~1
(1951-1985)~1
entomologist~1
Service's~1
1940s~1
well-supported~1
spirochetes.~3
Kelly's~1
Trichosporon~1
beigelii.~1
beigelii~1
nontyphoid~2
prophylaxis)~1
nontyhpoid~1
Urgently~1
azidothymidine,~1
phosphonoformate,~1
antimoniotungstate~1
(HPA-23),~1
suramin.~1
(IFN-alpha-A)~1
nonchromosomal~1
other:~1
possess.~1
turbidimetric~2
penicillins;~1
Michaelis-type~1
quasi-irreversible~1
acyl-enzyme).~1
attained:~1
ampicillin/ml~2
sulbactam/ml;~1
sulbactam/ml.~1
postpartem~1
cylinders.~1
beta-Lactamases~1
cephalosporinase~1
carbenicillin.~1
nonfragilis~1
nucleatum~1
clostridia,~1
butyricum,~1
clostridiiforme~1
ramosum~1
penicillinases.~1
Transferable~1
megadaltons)~2
(38-42~1
inducer,~1
Morganella.~1
acid/amoxicillin,~1
amdinocillin/ampicillin~1
(UTIs).~1
aminopenicillin~2
beta-lactamase-positive.~1
sulbactam/penicillin.~1
(UTI),~1
pus-forming~1
adenitis,~1
(1:2~1
1:3~1
(1:1.2~1
1:1.8~1
gonorrhea.~1
768~1
ampicillin-sensitive~1
appendiceal,~1
upper-gastrointestinal,~1
injection-site~1
(AFP)~5
singly.~1
seizure-induced~1
cell-activating~1
160-216~1
6-85.~1
P210bcr-abl~1
abl-derived~1
bcr-abl-derived~1
185/180-kilodalton~1
6.5-kilobase~1
c-abl-derived~1
riddles~1
elements;~1
(snRNA)-containing~1
(snRNP's)~1
dinoflagellates~1
snRNP's~1
A(U3-6)G.~1
snRNA's,~1
snRNA's~4
A(U5-6)G,~1
spliceosome.~1
non-Sm~1
dispensable.~1
proproteins~1
KEX2~3
prosequence~1
proalbumin.~1
angiogenin,~1
"angiogenic~1
diseases"~1
(HPS)~1
Arkansas~1
"olive"~1
HPS,~1
HPS~1
binge-purge~2
(bulimarexia)~1
familiarity.~1
masqueraders~1
nephrologists~1
fluid-electrolyte~1
nephrologic~1
intramuscular,~1
poloxamer~2
188,~1
security.~1
colorectal,~1
procedentia.~1
therapeutically,~1
capitalize~1
corticoids~2
sunglasses~1
sunglasses.~1
(AMM).~1
AMM~1
meningococcus~1
cereus~1
"magic~1
bullet";~1
drug";~1
Malnutrition,~1
substrate-limited~1
harm,~1
(moxalactam)~1
Isograft~1
Primarily~1
mouse's~1
Isografts~1
perimyocytic~1
long-surviving~1
beta-lactamase-stable~1
(Augmentin)~1
(uncomplicated~1
nosocomial)~1
sixty-year-old~1
Cystoscopically~1
"urethritis"~1
acupuncture,~1
dPRP~1
pressure-rate-product~1
Wmin~1
Wmin),~1
-11%)~1
+67%~1
-44%).~1
polyendocrinopathy-candidosis-ectodermal~1
(APECED).~1
ketoconazole-treated~1
mycological~1
goitre,~1
T3-resin~1
regained.~1
Denmark".~1
Thrombotest~1
(Konakion),~1
K-rich~2
broccoli,~1
wine.~1
spinach,~1
TT-values~2
Konakion,~1
testament~1
neonatology.~2
arises,~1
remembering~1
sulfisoxazole,~1
E-Ferol~1
Solution.~1
sick,~1
epilepsy;~1
student-patient,~1
collaboration.~1
Physician/teacher~1
patients-students~1
"devastated"~1
"compromised"~1
Collaboration~1
MSAFP~3
bypassed.~1
starvation's~1
Tryptophan,~2
Refined~1
autism,~1
niacinamide~1
maladroit~2
Helping~1
SLD~1
Educators~1
prioritize~1
judgments,~1
theirs.~1
maladroitness~1
route:~1
surgeon;~1
ureters:~1
sonography;~1
both:~1
Liver/spleen~1
spleen:~1
head:~1
pathologic/radiologic~1
mucin-filled~1
overwhelms~1
cyclosporine-steroid~1
sonogram:~1
pyramids,~1
pyramid~1
renal-sinus~1
pelvi-infundibular~1
uretero-pelvic~1
SC39902~4
(6,9~1
alpha-epoxy,5S-fluoro-11~1
15S-dehydroxyprosta-6,13E-dien-1-oic~1
(LCCA)~1
ng/kg/min,~2
atrium)~1
LCCA~1
supple~1
picture--a~1
mobility--that~1
antiaggregants~1
(cardiotomy~1
embolectomy),~1
formatting,~1
sugary,~1
(chocolate-coated~1
candy~1
bar;~1
cola~1
crisps)~1
(raisins~1
peanuts;~1
bananas~1
peanuts).~1
processed-food~1
snacks,~1
plasma-glucose~1
whole-food~2
raisin-peanut~1
banana-peanut~1
insulinaemia~1
fiber-depleted~1
Aborigines~1
islanders.~1
Aboriginal~1
bushfoods,~1
foods),~1
bushfoods~2
estrogen-target~1
SHBG,~1
S-Cal,~1
Clay~2
Adams~2
Ultra-Flo.~1
Ortho~1
ELT-800,~1
Ultra-Flo~2
interinstrument~1
alpha-fetoprotein,~1
1-anti-trypsin,~1
B-estradiol-6-carboxymethyloxine-bovine~1
album~2
(FITC-BSA~1
estradiol)~1
hydroxyprogesterone-hemisuccinate~1
tetramethylrhodamine~1
(TMRITC-BSA~1
(NTDs)~1
NTDs~1
(GFAP).~1
NTDs,~2
anencephaly,~1
AFP-~1
(DD-3B6)~1
D-dimer~8
(Dimertest)~1
Dimertest~4
Dimer-test~2
D-dimer/fragment~1
fibrin(ogen)~1
Diagnostics~1
FDPs.~1
fibrinogen-related~1
anti-fibrinogen~1
DD-3B6~1
D-dimer.~1
incriminates~1
56-yr-old~1
7190~1
alpha-Fetoprotein~2
carinii-negative~1
seven-field~1
nonurologic~1
Concise~1
Minimization~1
Aimless~1
quagmire~1
nonproductive.~1
Prorenin,~1
prorenin.~2
Ethicists~1
Medicolegally,~1
1900s~1
"reasonable~1
man"~1
physicians:~1
160/90~3
normogammaglobulinemia~1
mega-mineral-vitamin~1
indiscretions~1
(indiscretion~1
enteritis).~1
Rabelaisian~1
writer~1
Francois~1
Rabelais,~1
vividly~1
20-mg~1
2/96~1
4/80~1
renin-aldosterone~1
high-renin~1
excess;~1
low-renin,~2
enhance,~1
de-arterialization~2
basis)~1
(17.6~1
insulinotropic~6
5:30~1
milliunits/liter~1
milliunits/liter;~1
normoglycemia,~1
"dawn~1
phenomenon"~1
Devoting~1
step-one~4
titrate,~1
alternatives,~1
non-diuretic~1
"stepped-care"~1
captopril.~1
Prospective,~1
Thermolysin-like~1
metalloendopeptidase~1
(TME)~1
oligopeptidase~1
TME~9
(roentgenographic~1
incriminate~1
1911,~1
papovaviruses,~1
obtain,~1
Marek's~1
polythiazide~1
captopril-treated~1
benzene,~1
A/Bangkok)~1
orderly,~1
"metastatic~1
potential."~1
Ha-Ras~1
Hemodynamic,~1
scintigraphic,~1
thrombogenic.~1
restabilize~2
restabilization~1
nitrates)~1
heparin)~1
promising:~1
beta-adrenergic-induced~1
eutopic~2
35);~1
four);~1
proliferative,~1
secretory,~1
Amnioinfusion~1
amnioinfusion.~1
(clear~1
spaces)~1
sonar~2
trachomatis-related~2
(32.6%)~1
acid-positive~1
68.8%,~1
95.3%~1
94.7%.~1
Medicaid-eligible~1
private-practice~1
(WIC),~1
case-management~1
Tubules~1
Schiller-Duval~1
Ultrastructurally~1
endoderm.~1
alpha-fetoprotein-positive.~1
presumes~1
auscultation.~1
(CC25)~1
CC25~2
basolaterally~1
previable,~1
Tocolysis~1
"progestogen"~1
(893,~1
891,~1
878)~1
Todd-Hewitt~2
891~1
Broth.~1
891.~1
Strain-specific~1
MAbA9-C6,~1
retinocytoma~1
fleurettes.~1
medulloepitheliomas,~1
medulloepitheliomas.~1
corneoscleritis,~1
eyedrops;~1
devised.~2
xylene,~2
58-60~1
PLP-fixed~2
Leu-4,~1
OKT8),~1
Leu-14,~1
IgD)~1
(Leu-7,~1
OKT9,~1
OKM1,~1
OKI1,~1
Ki-1,~1
Ki-67,~1
TdT,~1
P21).~1
(DCC).~1
semiquantified~1
(ER-ICA).~1
ER-ICA~5
Alport-type~2
(vimentin,~1
desmin,~1
cytokeratin)~1
Antifibronectin~1
podocytes,~1
podocytes~1
muscle-like~1
(Lea,~1
Leb)~1
Leb.~1
Lea+b-~2
Lea-b+~2
Lea-b-~2
Biologic,~1
(CHRS)~1
(NALD).~1
(di-~1
trihydroxycoprostanoic~1
C29-dicarboxylic~1
hyperaminoaciduria~1
CHRS~1
NALD~2
trilaminar~1
glycolate~1
(plasmalogen)~1
clofibrate,~1
TH;~1
(ALH)~1
ALH,~1
anti-TH~2
PAS-positive~1
ALH.~1
species-dependent.~1
C3bi--complement~1
CR3.~1
(OKM1)~1
(CD11)~1
70-314%)~1
11-37~1
bronchial,~1
nephropathies~1
immunohistology,~1
anti-SC~1
IgA-SC+~1
IgA-SC~1
immunosecretions~1
cacodylate.~1
cacodylate~1
Epon~1
Clara-cell~1
taurine.~1
inception,~1
transferences:~1
mirroring,~1
idealizing,~1
ego.~1
belatedly~1
social-psychological,~1
programs/campaigns~2
Information/motivation~1
Programs/campaigns~1
academics~1
(14/17~1
3/17~1
[OR]~1
9/0,~1
2.4-infinity).~1
swum,~1
2.2-21.5).~1
lake-associated~1
escorted~2
"healthiness,"~1
Vascularity~1
technetium-tagged~1
dessication.~1
hydrated,~1
collagen-ground~1
pervades~1
auspicious~1
Latarjet.~1
Dragstedt~2
alcohol-abusing~1
Methadone~1
RI.~1
Conditioning-test~1
(test)~1
(conditioning)~1
Neocortical~1
(CET).~1
epicortical~1
CET~2
surface-negative~1
CET.~2
disinhibitory~1
mutagen.~1
20-640~1
0.99),~1
(coefficients~1
0.6-1.8%)~1
beta-nicotinamide~1
dinucleotide,~1
semicarbazide~1
Calorie-matched~1
dextromaltose~1
(myosin~1
(LC1,~1
LC2),~1
tropomyosin)~1
tropomyosin~1
calorie-matched~1
(Ac-CHO)~1
non-ADH~2
Ac-CHO~8
(EMR)~1
alcohol-containing~1
EMR~3
4-methylpyrazole.~1
pyrazole-treated~3
(subtracted~1
EMR)~1
(Vu~1
normovolemic~1
(51Cr);~1
(CI);~1
(iodohippurate~1
[131I~1
PAH]~1
clearance);~1
(CH2O),~1
(Cosm),~1
(FENa+)~1
(FEK+);~1
(ng~1
h-1),~3
(pg/ml;~1
(NE~1
(double-isotope~1
state:~1
(ZEEP);~1
(-21%;~1
(-19%;~1
Vu~1
(-55%;~1
FENa+~1
(-39%;~1
Cosm~1
(-36%;~1
CH2O.~1
applied.(ABSTRACT~1
defluorination~5
.2,~1
Emetic~2
Emesis~1
Organophosphate~1
industrial,~1
organophosphates.~1
Promp~1
subvoval~1
paper-mounted~1
(Gough-Wentworth)~1
Volume-pressure~1
Be-KP)~1
Bradykinin-induced~1
(PD35)~1
orally).~1
nebulizer)~1
PD35~2
1.15)~1
0.31)~1
4.45)~1
vagosympathetic~2
methacholine-induced~1
chloralose-urethane-anesthetized,~1
(RL).~1
(C1,~3
(C1),~1
sectioned.~1
1(-1)~1
3.0;~1
parasympathectomy~1
4.3;~1
11.6;~1
vagosympathectomy~1
bill,~1
pneumonitis;~1
immunopathogenesis,~1
iceberg~1
uncovered.~1
LPS).~1
LPS-contaminated~1
(055-B5)~1
14-wk-old~1
micrograms/kg/h~2
endotoxin.(ABSTRACT~1
antimycoplasmal~2
impressively.~1
cyclosporine-based~1
Guadalajara,~1
enteropathogens,~1
theorem~1
draw.~1
drawn)~1
(estimating~1
"gold-standard"~1
approximated.~1
immunopharmacology~1
gamma-interferons~1
interleukin-2;~1
acceptable:~1
analysts~1
tradeoffs~1
1948-49~1
aminothiazole~1
cephem,~1
31523A,~1
1a.~1
31523A.~1
(cefsulodin)~1
(aztreonam)~1
filamentation~1
BM2570~2
150-kilobase~1
self-transferable~1
pIP1527,~1
erxA~2
enterobacteria,~1
pIP1527~1
BM2570.~1
fluoroquinolone-resistant~1
GN14181~1
KL-16.~1
Ar+Br~1
Ar+Bs~1
(s,~1
fluoroquinolones~1
As+Bs~1
As+Br.~1
protozoa.~1
Chlorpromazine,~1
[3H]hypoxanthine~1
[3H]phenylalanine~1
calmidazolium)~1
chlorpromazine),~1
mitochondrion.~1
protozoa,~1
DNCB~3
etretin,~1
dose-finding~1
mg/kg/d).~1
Etretin~1
crusted~1
(Norwegian)~1
Spiders~1
[T3],~1
[T4]~1
[T8]).~1
(ATG)~1
(Upjohn,~1
MI)~1
ATG-resistant~1
ORTHO~1
(ORTHO~1
NJ).~1
78.1~1
52.1).~1
1012~1
1415~1
(jejunum~1
0.7%),~1
(3.0%).~1
(15.9%).~1
phenobarbitone.~1
islets,~2
Basal,~1
CCl4.~1
mattress~1
fibrosarcomatous.~1
soft-part~1
epithelial.~1
Steps~1
double-vessel~1
ventricle:~2
.0001];~1
.0001]).~1
[EDVI])~1
[ESVI]),~1
LVEDVIs)~1
.03).(ABSTRACT~1
overcompetence.~1
82.4%~1
61.8%~1
Good-quality~1
(.10~1
Amantadine~2
dropouts;~1
euphoria.~1
carotene,~1
chemopreventive~1
expectancy)~1
reservations~1
Stroop~2
Testing).~1
toto)~1
simultaneously:~1
five-week,~1
level/clinical~1
(imipramine,~1
56%;~1
(imipramine~1
desipramine)~1
Weight-corrected~1
Systeme~2
capsule-deficient~1
(CDCN)~1
(FMS)~1
Capsule-deficient~1
cryptococcosis,~1
CDCN~2
mucicarmine~3
yeast-forming~1
supraareolar~1
inoculum-dependent~2
(CMNA)~1
CMNA~2
(PACP)~1
radioaerosol.~1
PACP~2
ARDS)~1
ARDS;~1
3.4%/min~1
1.5%/min,~1
C5a/C5adesArg.~1
PACP.~1
Stuart's~1
thioglycollate~1
thioglycollate-transported~1
12.9%.~1
(sonication)~1
.010)~1
"slime"~1
(Immunocompetent)~1
(macrophage~1
defective)~1
bacitracin/streptomycin~1
"monoassociated"~1
10(11)/g~1
MLNs~2
macrophage-defective~1
monoassociated~1
antibiotic-resistant,~1
(esterase-positive)~1
bacteria)~1
small-arteriole~1
intracorneal~3
freehand~1
lamellar-pocket~1
1.3686~1
1.633.~1
lidofilcon-B~1
(refractive~3
1.3686)~1
1.4900D)~1
1.633)~1
closed-loop,~1
Surgidev~1
Style~1
Leiske~1
IOL.~1
20/80).~1
maculopathy.~1
gonioplasty,~1
iridoplasty,~1
flexible-loop~1
epikeratoplasty~1
lenticules,~1
never-used,~1
factory-prepared~1
lyophilization~1
reepithelialization.~2
(SSZ),~1
SSZ~1
SSZ,~2
noncollagenous,~2
nonproteoglycan~2
550,000-dalton~2
Shrapnell's~1
OKT6-positive~1
desmoplakin~3
Intermediate-filaments~1
(fertilization~1
immunofluorescently~1
intermediate-filament~1
desmoplakin.~1
gliallike~1
neuroepithelium,~1
(cis-platinum,~1
mg/m2/d),~1
single-institution~1
AH23848~7
trinitrate~1
A2-mimetic~1
oedematous.~1
vectorcardiography~1
pyrexial~1
warts,~3
warts;~1
(vaginal,~1
anal)~1
(HPV).~1
HPV2~1
HPV4~1
HPV1~1
HPV3~1
HPV4.~1
HPV16~2
HPV6-related~1
carcinomata~1
HPV5~1
HPV5,~1
(alpha-fetoprotein,~1
Schwangerschaftsprotein~1
ascribed,~1
(FBM)~1
tocometry~1
tocolytics~1
FBM.~1
FBM~3
foreshadows~1
40-70~1
805~1
postgrafting~2
postgrafting,~1
synchronously,~1
crippled.~1
Transferred~1
(TBI)~1
Engraftment~1
depletion).~1
leukemia").~1
transbilayer~2
FCR3~1
(K-)~1
knobby~2
Parasitized~1
2,4,6-trinitrobenzene~1
(TNBS)~2
sphingomyelinase~1
(SMC).~1
(PS).~1
exoplasmic~1
(PLA2~1
SMC)~1
TNBS.~1
falciparum-infected~1
protuberances,~1
anti-B1~2
10(4)/microL~1
posttransplant,~3
82-131)~1
glycophorins~4
glycophorin,~1
[alpha-delta]~1
segment);~1
infrequent;~1
S-s-U-phenotypes;~1
antiglycophorin~1
MoAbs;~1
(En(a-),~1
U-,~1
Mi~1
Sta)~1
He+~1
Wrb(-)~1
(HEC),~1
(PGI2),~1
(PA-I).~1
(pI7)~1
"22K~2
factor,"~1
(pI5)~1
(pI7).~1
HEC.~2
PA-I~1
Anti-alpha-fetoprotein~1
anti-AFP~1
scanned,~1
Renographic~1
non-obstructed.~1
wind-pollinated~1
springtime.~1
pollinating~1
Betulaceae~1
Betula~1
(birches),~1
IUIS~1
Standardization.~1
yardstick~1
awaited.~1
alphafetoprotein~1
(HCG).~1
1039~1
subcarinal~1
non-reactive~1
81.3%,~1
(CDDP),~1
(75/191)~1
(incidence,~1
3.9%).~1
(KRT),~1
(VMT),~1
(ALB),~1
(FBG)~1
Grossly~1
tumor-nontumor~1
KRT~1
VMT,~1
FBG,~1
(39/59)~1
Analyzed~1
unilateral).~1
(complete,~1
minor)~1
(CBC)~1
CBC)~1
(normalization~1
counts)~1
(IFN~1
mg/kg/week)~1
(14%,~1
I-III,~1
(skewed~1
tumors--cancer~1
bladder--are~1
urethelial~1
schedule-dependency~1
interferon's~1
(UJ13A,~1
UJ127.11,~1
UJ181.4),~1
(2D1),~1
(LE61),~1
Vimentin,~1
Desmin~1
(Labsystems,~1
Helsinki,~1
Finland),~1
(155)~1
UJ13A~1
antidesmin.~1
pancreatoblastomas,~1
solid-cystic~2
(papillary-cystic)~1
(alpha-amylase,~1
chymotrypsinogen),~1
Lipase,~1
pancreatoblastomas.~2
SCT,~1
rhabdomyoma~1
defervescence~1
(PLI)~1
0.000002).~1
PLI~3
(arterial-to-venous)~1
ng/100g~1
180%,~1
A2/PGH2~3
(CFVs)~1
SQ29,548~7
SQ28,668~2
CFVs~6
SQ28,688.~1
SQ29,548-treated~2
SQ28,668-treated~1
PGI2,~1
SQ29,548.~1
nonstenosed~1
SQ28,688,~1
backscatter~1
(IB)~1
subepicardial,~1
midmyocardial,~1
subepicardium,~1
midmyocardium~1
(APSGN).~1
acid-depleted~1
APSGN,~1
APSGN~3
speckled.~1
sialic-acid~1
APSGN.~1
(TGR)~1
Leu1~1
(cytotoxic~1
(monocyte)~1
OKDR~1
TGR~3
3.2:1.~1
TGR.(ABSTRACT~1
[24,25-(OH)2D3]~1
24,25-(OH)2D3.~1
Osteoid~1
laboratorial~1
(1960-1984)~1
pollicization~2
stump;~1
thumb;~1
nail;~1
well-reconstructed~1
Zenoderm~6
Scotland)~1
lymphaticovenous~2
Lymphology~1
neurofibromas.~1
75.7%.~1
Execution~1
time-limited.~1
imperil~1
investment,~1
pressured.~1
acknowledged,~1
hypomagnesaemia~1
L-adrenaline~3
++4,~1
+++5)~1
(A-scan)~1
+++~1
15-mu~1
-21.2~1
-28.1~1
-36.4~1
4.9%,~1
(-59.2~1
-55.1~1
(3.23~1
PEEP-induced~1
(HFPPV)~1
low-rate~1
(LRCMV).~1
HFPPV~5
(89.91~1
10.24~1
78.43~1
11.13~1
(PaO2/FIO2~1
197.8~1
51.3~1
impaction,~1
CXR~3
hepatosplenomegaly~1
sonography.~1
transpulmonary,~1
IMV.~1
(EEA)~1
Yale-affiliated~1
(APR);~1
SUT~1
verge~1
surgeon-related~1
biofragmentable~1
Enterogastric~1
regurgitating~1
lysolecithin,~1
doubled-blind~1
(HLA-DR)~1
I2-positive~6
endothelia~1
"immune~1
Mucus,~1
acrolein~1
gastrin/cholecystokinin~1
VIP-,~1
SP-,~1
enkephalin-,~1
NPY-immunoreactive~2
gastrin/CCK,~1
SP-~1
enkephalin-immunoreactive~1
"AIDS~1
complex"~1
100-,~1
acarbose,~1
alpha-glucosidases,~1
acarbose~2
262%~1
acarbose.~1
1207~1
31.3.~1
Colitis~1
pericholangitis~1
preexisted.~1
carcinoma).~1
Pericholangitis~1
Actrapid~3
IU/h,~1
alteration(s)~1
basal-rate~1
(2100-0730~1
intermediate-acting~3
buttock.~1
0730~1
massage,~2
0.15%/min~1
0.03%/min~1
mesocolon,~1
mesocolon.~1
longer-acting~1
Mixtures~1
lente~1
premixing~3
(Velosulin~1
Insulatard)~1
(Mixtard).~1
1-to-2~1
insulin-zinc~1
(Actrapid~1
Monotard~3
MC)~1
Free-insulin~1
ketoacidosis.~2
ketones.~2
ketonuria~3
insulinopenia.~1
ketonuria,~1
hydroflumethiazide~1
(HFT)~1
thiazides~2
thiazides.~1
(3.63~1
experiments.(ABSTRACT~1
Intermediate-acting~1
youths.~1
Medi-Jector~2
46.2~1
microU/ml,~4
free/total~1
.0025).~1
needle-injected~1
jet-spray~1
jet-injected~1
(RHPA)~1
corticotropes~2
secretagogues-CRF,~1
(A-II),~1
1:100-1:200~1
ACTH-(25-39)~1
1:20-1:50~1
anti-ACTH~1
RHPA~3
(0.9-1.3%).~1
corticotropes.~1
retroendocytosis.~2
0.4-25~1
reincubated~1
insulin-free~1
(TCA)-precipitable~1
reincubation~1
TCA-precipitable~1
solubilized.~1
B-like~2
anglerfish~3
(gel~1
hydroxylapatite),~1
granule-~2
microsome-enriched~2
lysosome-enriched~1
metallo-enzyme~1
Co++,~1
5.2-6.2.~1
guanidinoethylmercaptosuccinic~1
guanidinopropylsuccinic~1
aminopropylmercaptosuccinic~1
prosomatostatin-II.~1
GnRH-stimulated~2
carboxymethyl~1
214-fold.~1
12,252~1
638,~1
electrophoreses~1
frictional~1
1.05.~1
nongonadal~1
gonadotroph's~2
[Dp-Glu1,pclPhe2,DTrp3.6]GnRH.~1
gonadotroph-enriched~1
(GRF)~1
mammotroph-~1
somatotroph-enriched~1
Readdition~1
GnRH.~1
GRF~1
(Adx)~1
Adx~8
(Adx~2
(insulin)~1
(glucagon)~1
(somatostatin)~1
(micrograms)~3
2001~1
396)~1
600)~1
tail;~1
4.20~1
0.02-0.005),~1
0.01-0.001),~1
0.05-0.005)~1
0.01-0.001).~1
258%~1
FOCUS~4
(IRMAs)~1
hCG/10(6)~1
109-115,~1
121-145,~1
134-140,~1
139-145~1
immunoperoxidase-staining~1
(LHRH-A)~1
LHRH-A,~1
[D-Trp6]~1
ethylamide.~1
LHRH-A.~2
LHRH-A~1
nucleomyofibrillar~1
leupeptin-sensitive~1
(9-10S)~1
(3-7S),~1
molybdate.~2
molybdate-insensitive~1
4-5S~1
3S~1
21-mesylate~1
DNA/cellulose~1
96,900)~1
steroid-labeled~2
42,600).~1
thiol-reactive~1
BuGR-2~1
chymotrypsin-dependent~1
alpha-chymotrypsin.~1
22,000;~1
22K-hGH)~1
diabetogenicity~1
20,000;~1
20K-hGH)~1
(12-day)~1
DNA-derived~1
22K-~5
20K-hGH~5
22K-hGH,~1
pre-hGH~3
20K-hGH-treated~2
apparent;~1
min-1/(microU/ml)~1
min-1/(microU/ml),~1
22K-hGH-treated~1
lamprey,~2
Lamprey~1
LH-releasing~1
GnRHs~1
Tyr3~1
Glu6~1
insulin-degrading~2
110,000)~1
[125I]-insulin~3
HepG2,~1
cross-linker,~1
glucose-dependent~1
(GIP)~1
HPLC-retention~1
represented:~1
GIP(1-42),~1
(wt/wt);~3
GIP-fragment~1
des-tyr-ala-GIP(3-42),~1
(CCK)-33~1
CCK-39~1
HPLC-pure~1
GIP(1-42)~2
pre-cultured~1
des-tyr-ala-GIP(3-42)~2
GIP-preparations~1
CCK-peptides.~1
HPLC-characterization~1
(irGnRH)~1
Ovine~1
(OVX~1
EB).~1
proestrous~2
irGnRH~7
presurge~1
nonsurge~1
(Saffan)~1
CRF-opioid~1
EB-treated~1
(hTg)~1
P3X66~1
Ag8/0~1
hTg.~2
T4-containing~1
hormonogenic~2
CNBr-cleaved~1
inconsistently.~1
Electrolytic~1
PVN-lesioned~1
(PVL)~1
91.2~1
(86.8~1
(95.6~1
PVL~5
[PRL~1
peak:~3
PVL,~4
47.0~1
4.9].~1
5-hydroxy-L-tryptophan~1
(5-HTP;~1
[GH~1
(nanograms~1
peak;~1
3.5].~1
linogliride~7
(McN-3935),~1
linogliride.~1
[5-3H]glucose~1
3H2O,~1
islet.~1
Mannoheptulose~1
Linogliride~1
N-acetylglucosamine,~1
Hemipituitary~1
permeations~1
enzyme-modulating~1
monosaccharides.~1
Postprandially,~1
min].~1
3.3;~1
g/150~1
output-to-splanchnic~1
12,000-Mr~2
beef-pork,~1
beef-pork~1
(phases~1
IRI,~1
(microU/ml),~1
insulin-monomer~1
Overreactivity~1
hyperinsulinism~1
polyanionic~1
(IM-9)~1
(1-50~1
washed.~1
EDTA.~1
poly-L-glutamic~1
poly-L-lysine,~2
succinylated~1
histone,~1
Nauruans~1
[215~1
(IGT)]~1
positive-parameter~1
glucose-insulin~1
term's~1
D-Glucose~1
NADPH/NADP+~1
RINm5F~3
L-Leucine~1
4-methyl-2-oxopentanoate~1
2-aminobicyclo[2,2,1]heptane-2-carboxylic~1
(BCH),~1
L-[U-14C]glutamine~1
BCH~1
(SDR)~1
(NDR)~1
(STZ).~1
(STZ-DR)~1
CM-activated~1
low-Michaelis~1
(39%,~1
SDR;~3
STZ-DR).~3
NDRs.~4
SDRs~2
STZ-DRs~1
(155%,~1
PDE-CM-INH~1
STZ-DRs,~1
dictating~1
NDR~1
(IRI),~1
(IRG)~1
(150-500~1
IRG~1
weight-stabilized~1
[7~1
99.9~1
1.3-kg~1
3-insulin-step,~1
micrograms/h).~1
[from~1
(FFM),~1
.01]~1
nonoxidative~1
36:227-36,~1
BBUF~3
(insulitis).~1
RT1u~1
(UPCC.5)~1
(MUS1.2,~1
MUS1.13,~1
MUP3.21)~1
UPCC.5~1
(ICAg)~1
T-hybridoma~1
mu-haplotype~1
ICAg~1
RT1.D~1
Directional~1
downstream--probably~1
monocomponent~1
G-25.~1
[125I]monoiodoinsulin~1
10(4)/M~1
phosphate-albumin~1
12.7.~1
B22-arginyl~1
(bHGO)~1
bHGO~4
(bGL)~1
hyperinsulinemia,~3
bGL~1
FSG~2
HGO~5
3-[3H]glucose)~1
micrograms/h)~1
(SRIF~1
high-fiber,~1
high-sucrose,~1
obesification.~1
low-K~1
Islets~1
(GH).~1
FCS~3
(100-1000~1
FCS.~1
C/IGF-I~1
0.1-1.0%~1
SM-C/IGF-I.(ABSTRACT~1
counterregulation~1
pre-school-age~1
Counterregulation~1
Predisposition~1
insulin-antibody~5
indistinguishably,~1
-.56,~1
(K1);~1
microU/min,~1
(OGTTs)~1
OGTTs~1
OGTTs.~1
"obese"~1
insulin-receptor-binding~1
ethanol-based~2
microfuge~1
Microfuge~1
ethanol-precipitable~1
precipitability,~1
C57BL/KsJ~1
(+/db)~1
+/db~2
glucopenia~2
pancreases~3
peri-insular~1
[3H]norepinephrine-labeled~1
alpha-cells~3
65-70%~1
3-[3H]glucose,~1
(GNG)~1
(U-[14C]alanine~1
[14C]glucose)~1
(hepatic~1
FEA)~1
GNG~2
FEA~1
patients--based~1
Sleep-related~1
carbapenems.~2
culmination~1
filtrates.~1
filtrates,~2
Bilthoven~1
(W2)~1
(E671)~1
nodes.(ABSTRACT~1
'classical'~1
(anti-HBe)~1
(62.7%)~1
(57.4%)~1
(3-17)~1
seroconversion.(ABSTRACT~1
cirrhosis-specific~2
non-primary~2
(anti-p62,~1
anti-p48)~1
(anti-M2,~1
anti-M4,~1
anti-M8).~1
anti-p62~2
anti-p48.~2
anti-M2,~2
anti-M4~2
anti-M8.~2
noradrenaline--a~1
activity--by~1
(-17.4%),~1
(-12.2%),~1
(-19.7%)~1
(-26.6%)~1
duplicated.~1
(NH3,~1
Lobular~1
(91.5%)~1
superinfections~1
preparations;~1
nonliver-specific~1
dot-blotting,~1
hepatoceullar~1
asian~1
fenestrae)~1
IgA2;~1
hormones--somatostatin,~1
efficiacy~1
exercise-whether~1
manometer-than~1
reninangiotensin~1
Sonographers~1
study--including~1
interfaces--and~1
imaged--with~1
convention~2
conventions,~1
Interstudy~1
Casual~1
echocardiography;~1
methacholine-stimulated~2
[change~1
26.4%]~1
34.9%)~1
6.03~1
6.92~1
(10/strain),~1
ACI,~1
(20/strain)~1
(Buf)~1
MCh~1
(ED150RL)~1
(ED200RL)~1
ED150RL~3
ED200RL~2
1.6-5.3).~1
nose-breathing~1
margin).~1
thirty-six,~1
cystic;~1
corticocancellous~1
(nineteen~1
(twelve~1
refracture,~1
fixators.~1
matrix)~1
mitochondria),~1
incident-light~1
eliminate,~1
Urokinase,~1
125I-protein~1
Ca++-dependent,~1
fluorophosphate,~1
IGF-I-related~1
(IVGG)~1
IVGG~3
HLA-DR-bearing~1
HLA-Dr+~1
insulin-mediated~2
(+50,~1
+100,~1
+500~1
microU/ml).~1
-0.94;~1
-0.75;~1
non-oxidative~1
(NHGB)~1
NHGB~2
microU/ml;~1
arterial-portal~1
6.7,~1
+2~1
+4~1
hepatic-peripheral~1
Monocyte-enriched~1
(0-10(-6)~1
euglycemic,~1
activation-induced~1
fell;~1
0.91),~1
co-encoded~1
(GLPs).~1
GLPs~1
GLP-I(1-37),~1
GLP-I(7-37).~1
GLP-Is~1
GLP-I(7-37)~3
GLP-I(1-37)~1
breaks).~1
Cathepsin~2
(littoral~1
(hepatocytes~1
(alveolar~1
epithelium),~1
(neurones),~1
(histiocytes~1
(parietal~1
pepsin,~1
gastricsin,~1
anti-CEA,~1
HMFG-2~2
E29.~1
ascites),~1
(reactions~1
disregarded).~1
(SS-A)~2
(HLA)-DR3,~1
(SS-B)~1
erythematosus-related~1
petrolatum-based~1
Vulgaris,~1
lamellar,~1
sex-linked,~1
Netherton's,~1
epidermolytic~1
lotion.~1
ichthyotic~1
Adenokeratin~1
(cytokeratin~2
squamokeratin~1
Bullous~2
immunofluorescence;~1
convolutions),~1
foreskin,~1
revival~1
spasm),~1
demand)~1
thrombosis).~1
"physiologic"~3
tone;~1
Nonuniformity~1
(load,~1
activation-inactivation,~1
nonuniformity)~1
activation-inactivation~1
utilized)~1
incoordinate~1
(diltiazem,~1
(diltiazem~1
(0.02/h~1
0.02/h~1
indoramin~3
Basenji~2
greyhound~1
purebred~1
Basenjis,~1
greyhounds.~3
hyperresponsive~1
Basenjis~2
nonisotonic~1
periciliary~1
hypo-osmolar~2
(PD20)~1
[IS])~1
electrotransfer~1
allergosorbent~1
Anaphylactic~1
Withering's~2
1785.~1
foxglove,"~1
parent-strain~3
nylon-adherent~6
Thy-1+Lyt-1+2-~2
(B6-pretreated~1
B6D2F1);~1
B6-pretreated~5
nonresistant~2
(D2-pretreated~1
B6D2F1)~1
MECA-20,~1
MECA-217,~1
post-capillary~1
uterus;~1
MECA-325,~1
(HEV)~1
MECA-325~4
HEV~1
surface;~1
MECA-20~1
extra-lymphoid~2
MECA-217~1
HEV)~1
inflammation-specific~1
B151-TRF1~2
B151-TRF2,~1
MRL/MP-lpr/lpr(MRL/lpr)~1
(BDF1)~1
(GVHR),~1
B151-TRF2-like,~1
B151-TRF1-like,~1
(CFS)~1
B151-TRF1-~1
B151-TRF2-like~2
CFS~1
B151-TRF1-like~1
SLE-like~1
B151-CFS~1
B151-TRF2~3
bromelain-treated~1
(BrMRBC).~1
anti-BrMRBC~1
gp195~4
Camp~1
merozoite-associated~1
(3H7,~1
3B10,~1
7F1,~1
4G12)~1
(gp45),~1
gp45.~1
(7H10)~1
gp45~2
(p45).~1
(3D3,~1
7B11,~1
7B2)~1
83-kDa~1
(p83),~1
[3H]isoleucine~1
p45~1
p83~2
(p73~1
p67).~1
7B11~2
7B2~1
p83,~1
p73,~1
p67,~1
p73.~1
trypomastigote~2
ST1~4
Ly-1.2+,~1
2.2-~1
cruzi-selected~1
strain-specific,~1
shared,~1
co-incubation~1
cruzi-specific~2
cruzi-infected~1
2-C~2
(SPA).~1
436,~1
433,~1
"inducible"~1
B10.S~2
Thymectomy~1
SJL,~1
extravillous~1
cytotrophoblast~1
W6/32-reactive~3
immunohistology.~1
syncytiotrophoblast~1
faithful,~1
NH2-terminus~1
trp-lac~1
(TAC)~1
JM105.~1
Yields~1
beta/liter/10(11)~1
co-chromatographed~1
(TAF).~1
HLA-B27K~1
HLA-B27W~1
HC-10,~1
B-locus~1
anti-HLA-A,-B~1
W6/32,~3
-B7~1
transfected,~1
C91/PL,~1
(LPI~1
(thrombin,~1
elastase),~1
(papain),~1
(pepsin).~1
LPI~3
C91/PL~1
cyclohexamide,~2
boiling~1
substrate-containing~1
MOLT-13,~1
KE-37,~1
Proteinase~1
proteinase-mediated~1
(3D11)~1
circumsporozoite~1
berghei~1
exoerythrocytic~1
(EEF).~1
sporozoites~8
microgram/0.5~1
3D11~5
EEF~1
3D11.~1
3D11-mediated~1
stephensi~1
B2mb~3
B2ma/b~1
B2m~2
(CTL)-mediated~1
CTL-target~7
HLA-A2-~1
HLA-B7-specific~1
HLA-B7,~1
HLA-B7.~1
calcium-sensitive~1
Indo-1~1
(LFA-2/T11),~1
LFA-3~1
killer-~1
Cold-target~1
Ly-2,~1
Ly-5,~1
(TCR),~1
anti-TCR.~1
BCG)~1
BCG-resistant~2
BCG-susceptible~2
C.D2Ityr~2
I-A,~1
I-A.~1
Bcgr~4
Bcgs~3
rIFN-gamma.~1
thymocytotoxic~1
(NTA)~1
NTA's~1
NTA.~1
NTA~2
NTA,~1
SAG-3,~1
NTA-secreting~1
SAG-3~6
cortisol-resistant~1
murine-specific~1
Thy-1.1~1
NTA-positive~1
46,000)~1
promastigote-specific~1
2H7-E10(M-2)~1
alkylation,~1
(46kDa/M-2)~1
Enzymic~1
27,000),~2
heteroserum.~1
3-(trifluoromethyl)-3-([m-125]iodophenyl)-diazirine~1
([125I]TID)~1
46kDa/M-2~1
[125I]TID-labeled~1
(Ldc)~1
Ldc,~1
(Lma),~1
Ldc~14
(FBS),~1
FBS,~1
Lma~3
labeling;~1
nonforeskin~1
(bullous~1
laminin)~1
coordinated,~1
2,255~1
(335),~1
mg/800~1
(TMP-SMZ;~1
218)~1
252,~1
TMP-SMZ,~1
97.5%-98.6%,~1
87.9%-88.8%.~1
TMP-SMZ.~2
Clinic-initiated~1
foscarnet~1
Culture-positive~1
Foscarnet~1
Foscarnet-treated~1
Earlier,~1
patient-initiated~1
(shorter)~1
intramuscularly)~1
much-higher~1
(iv),~1
(im),~1
(sc),~1
Zambian~1
more-frequent~1
lysogeny~2
nephritogenicity,~1
hyaluronidase.~1
streptococci-infected~3
Streptococcus-infected~1
asteroides-specific~1
1:256.~1
EBV-seropositive),~1
postmeasles~1
20%-30%,~1
(table~1
"groups"~1
"groups":~1
caliciviruses,~1
astroviruses,~1
caliciviruses~2
Astroviruses~1
cultivating~1
astroviruses~1
Systematic,~1
sorely~1
diarrheagenic~2
coli:~1
less-developed~1
countries),~1
enteroinvasive~1
dysentery),~1
enteropathogenic~1
diarrhea),~1
O:H~1
plasmid-encoded~1
enterotoxins~1
less-well-defined~1
enteroadherent~1
Hep-2~1
alotted,~1
mounted.~1
make(s)~1
IDSA~1
penems,~1
(BALs)~1
BALs,~2
(HCMV)~1
HCMV~5
equivalents.~1
77.8%.~1
HCMV-associated~1
opsonophagocytosis~2
(III-GBS)~1
III-GBS~3
2,950~1
IgG/dl~1
III-GBS-specific~1
antibody/ml.~1
IgG2-rich~1
III-GBS.~1
opsonophagocytic~4
pepsin-digested~1
opsonin~5
III-GBS,~1
opsonophagocytosis.~1
K12,~1
sensitive).~1
11-kDa~3
2.1-kilobase~1
(serum-sensitive)~1
methyloxidase~2
(18-OH-B),~1
18-hydroxy-11-deoxycorticosterone,~1
Dialysance~2
18-OH-B,~1
18-OH-B~3
18-OH-B/aldosterone~2
(PGE1~1
iloprost,~6
iloprost.~2
prostanoid,~1
pmol/10(9)~4
1857~1
127%~1
153%~1
6).(ABSTRACT~2
decongestant--antihistamine~1
glass-ceramic~1
Ceravital~3
(EDAX,~1
WDAX)~1
implants'~1
etching,~1
tympanoplasty,~1
encouraging:~1
well-tolerated;~1
binges.~1
high-achieving~2
unassertive~1
history-gathering~1
stressors)~1
pneumonia),~2
psychostimulant~3
dextroamphetamine~1
(DEA)~1
psychostimulants~3
MPH~1
DEA~1
agoraphobia.~2
pills,"~1
Leksell~5
Embolisation~2
intra-axial~1
(ML),~1
time-dose~2
KS,~1
ML,~3
8,900~1
6.9%).~1
migrations,~1
10.8%).~1
hyperalimentation.~2
vesicant~1
non-time-consuming.~1
.0008,~1
.0124~1
.0155~1
scale)~4
.0056).~1
randomized;~1
BCD~1
cytoxan,~2
ABVD~4
(Adriamycin,~2
dacarbazine).~1
92.4%~1
(80.8%~1
62.8%;~1
(87.7%~1
77.2%;~1
.06),~1
(77.4%~1
67.9%;~1
MOPP,~1
agent-containing~1
(IRS).~1
(UICC)~1
(ECOG),~1
(SWOG),~1
(SECSG).~1
(Adriamycin;~2
2,000/microL)~1
0-1~1
chemotherapy/radiotherapy~1
(laminar~1
carboplatin~26
remissions)~2
extensive-disease~1
myelo-suppression:~1
WBC,~1
2,999~1
cells/microL;~2
1,499~1
75,000~5
cells/microL.~1
360,~1
parotid.~1
RT;~1
PR);~1
15+~2
carboplatin,~2
recurrent-disease~1
6,500~1
carboplatin.~1
"successful,"~1
S-lactic~1
(s-LDH),~1
s-alkaline~1
epipodophyllotoxin~2
(VM-26),~2
(PE/CADO).~1
immunomagnetic~1
(Kemshead~1
those,~2
(VGPR).~1
CR/VGPR~1
post-diagnosis)~1
arm),~1
arm).~1
(PRs),~1
Schering-Plough,~1
SC-treated~1
IV-treated~2
nephrectomy;~1
transfrontal,~1
transcallosal,~1
sterotaxic~1
differential-pressure~2
medium-pressure~1
(inducing~1
hyper-elevated~1
null-cell~1
(beta-LH),~1
(beta-FSH),~1
(beta-TSH),~1
37.9%~1
beta-FSH~1
beta-LH~1
beta-TSH~1
citations.~2
Wendell~2
Griffith~3
literary~1
clarity.~1
Griffith's~1
Nutrition"~1
Reviews~1
fortunate~4
pioneered.~1
delighted~1
selfless~1
kindness,~1
joy~1
mentor~1
charm~1
rejuvenation,~1
sure,~1
out-of-doors~1
garden,~1
hike~1
Griff~1
Oak~1
cemetery~1
Kirkwood,~1
MO,~1
suburb~1
fortune~1
him.~1
bioactivity).~1
"requirement").~1
[1-14C]leucine~1
Hereford~2
28-d~1
14-d~1
homeorhetic~1
near-maintenance~1
1-d-fasted~1
3-d-fasted~3
872~1
concentration-dependent.~2
1304~2
mumol/min,~1
overfeeding,~2
160%,~1
Carcass~3
hypophagic~1
Overfed~1
microliter/dl~1
microgram/dl~1
reappraise~2
"review~1
systems"~1
pertinence,~1
"rapidly~1
fatal"~1
Judged~1
Non-Escherichia~1
Dacron-urethane~1
(CV),~1
CV.~4
(arterial/alveolar~1
Bronchoscopies~1
tracheobronchitis,~1
D-Leu5]enkephalin~1
(DADLE),~2
mu-activating~1
morphiceptin~3
[N-methyl-Phe3,~1
(PL017).~1
[D-Penicillamine2,~1
D-Penicillamine5]enkephalin~1
(flatter)~1
DADLE.~4
61-fold~1
beta-funaltrexamine,~2
beta-Funaltrexamine~1
mu-delta~2
DADLE,~2
mu-ligand~1
tolerance.(ABSTRACT~1
obstructor.~1
cyclooxygenase,~5
overstated.~1
DA-2-~2
DA-1-like~2
(DA-1)~1
(DA-2)~2
R-sulpiride,~1
DA-2~2
S-sulpiride.~1
SCH-23390,~1
DA-induced~1
cyclase-linked~2
ganglia.(ABSTRACT~1
(RET)~1
RET~7
RET-,~1
inhibitor-treated~1
(NMDA)-induced~1
(KA)-induced~1
KA-induced~1
2-Aminophosphonovalerate~1
PCP-like~1
cyclazocine,~2
PCP-like,~1
PCP/sigma~1
Vanadate~3
orthovanadate~1
cardiodepression~2
weeks:~2
vanadate-treated.~1
Noninjected~1
ketamine-xylazine-anesthetized~1
vanadate-treated~1
[D-Ala2-N-methyl-Phe4-Gly5-ol]enkephalin~1
[D-Ala2-D-Leu5]enkephalin~1
[D-Pen2-D-Pen5]enkephalin~2
[D-Pen2-L-Pen5]enkephalin.~1
[D-Pen2-L-Pen5]enkephalin,~1
shakes.~1
beta-funaltrexamine.~1
(N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH)~1
vermis.~1
butoconazole~1
Butoconazole~1
six-~2
imidazoles~2
Triplet~1
abruption.~1
immature.~1
Transplant~4
dl.~1
dl.,~1
problematical.~1
(synergistic~1
genitalia)~1
Small-Carrion~1
Cynomolgus~3
formalin-killed~2
anti-E.~2
Counteracting~1
Everett~1
Chalmers~2
Fredericton,~1
Brunswick.~1
isolated--a~1
glycolipid,~2
anti-PAA,~2
(anti-PAA)~1
anti-PAA~4
(phytohemagglutinin-~1
MLC-activated~1
T-cells)~1
fifteenfold-increased~1
sixteenfold~1
trophoblasts,~1
anti-PAA.~1
Anti-PAA~3
ganglioside.~1
membrane's~2
proliferation-associated,~1
PAA.~1
(sIgs),~1
(cIgs),~1
(sIg-,~1
cIg-),~2
pre-B-cells~1
(intracytoplasmic~1
mu-chains),~1
(sIg+,~2
cIg+).~1
cIg~1
(perinuclear,~1
paranuclear,~1
vesicular).~1
(CD10)~1
(Parophrys~1
vetulus),~1
bottom-dwelling~1
flatfish,~1
(putative~1
hepatocarcinogens-hepatotoxins~1
hepatocarcinogens,~2
aquatic~4
(BHCG).~1
bonemarrow~4
K-values~6
cytocavitary~1
hyperamylasaemia,~1
hypoinsulinaemia,~1
Dusseldorf.~1
1.71.~1
(40.1%),~1
(27.7%).~1
3.3%.~1
(75.4%).~1
Cholelithiasis~2
CB3717~1
VP16~1
standby~1
amygdalohippocampectomy~1
computer-interactive~1
nondisabling~1
amygdalohippocampectomy.~2
oocyte's~1
follicle-rich,~1
stroma-rich,~1
noncyclic,~1
"aged"~1
Nutrients~2
fitness"~1
fatiguing,~1
systems--physical,~1
spiritual--should~1
harmony.~1
twilight~1
heralds~1
adventure,~1
unrelenting~1
"If~2
it!,"~2
enthuse~1
maxims~1
goal:~1
many.(ABSTRACT~1
midlife~1
"menopausal~1
disservice~1
dedicated.~1
Maturitas~1
Munjack~1
Oziel.~1
gynecologist,~1
psychologist,~1
Advancements~1
Sedative-hypnotic~1
Sleeping~2
pyrimethamine/sulfadoxine,~1
coast~3
chlorproguanil~2
person-weeks~1
(69.2~2
person-weeks,~1
chloroproguanil~1
dihydrofolate-reductase~2
Chlorproguanil~1
doppler-report-available~1
spontaneous)~1
(level~1
Patient-recorded~1
hypoglycaemia.~5
ginkgolide~1
52063~5
Weal~1
PAF,~7
62.4%~1
weal~1
oestradiol/testosterone,~1
mumol/l).~1
135-1135~1
RRT~1
endoscopically-controlled,~1
oesophagitis)~1
undetermined)~1
not-at-risk~1
Asia/Oceania.~1
antimonial~1
antimonate.~1
(52.4%)~1
low-cost,~1
donor-specific~7
Donor-specific~1
Fc-receptor-blocking~1
one-haplotype-mismatched~1
871~1
demonstrably~1
fetalis.~4
youth-onset~1
propositi.~1
propositi,~3
Islet-cell~1
insulin-dependent-diabetes-associated~1
cosegregate~1
(Sustacal),~1
Peripheral-blood~1
empty-site~1
photoactivation~1
(8-methoxypsoralen)~1
methoxsalen,~1
lymphocyte-enriched~1
Query~1
(PDQ)~1
cancer-research~1
directory~2
mainframe,~1
glucose-lowering~2
proinsulin-treated~1
hyperglycemia;~1
hypoglycemia;~2
3'-hydroxy~1
dideoxynucleoside~1
(AZT),~1
reverse,~2
leukopenia;~1
non-tolerance~1
environment:~2
Stewart~2
Wiley~1
vascularize~1
theoretically,~1
verified.~1
(PFs)~1
conjunctively~2
PF-PC~1
(LTD).~1
Accumulated~1
LTD~4
(Glu).~1
quisqualate(QA)-selective~1
4.5S~4
Iac~1
operon,~5
translationally-defective~1
'passenger'~1
(N-methyl-D-aspartate),~1
kainate.~4
kainate/quisqualate~1
pharmacologically-distinguishable~1
(NMDA),~2
(gamma-amino~1
butyric~1
analogy,~3
45-50~1
sub-states~1
Transmitters~1
'fast'~1
'inhibitory~1
transmitters'~2
GABA)~1
'excitatory~1
L-glutamate)~1
property:~2
strychnine-sensitive~1
(QA),~1
(ionotropic~1
(Glu)~1
QA~2
Glu)~1
rat-brain~1
(Gi~2
Go),~1
QA/Glu~2
islet-activating~1
(IAP,~1
toxin),~1
Joro~1
(JSTX),~1
ionotropic~1
virus-bacterial~1
haemagglutinin.~1
deleting~3
(Tyr969)~1
Tyr969~1
Phe969~3
transformed,~2
c-fms(Phe969)~1
c-fms(Tyr969).~1
v-fms/c-fms~1
v-fms.~1
subplate~3
ingrowing~1
matures,~1
subplate.~1
MAP2~5
(microtubule~1
telencephalon~1
learnt~3
98-113~1
HLA-A2-specific~4
q11~1
5.8-kilobase~1
(bcr+)~1
(bcr-).~1
Ph+,~1
bcr-~1
p190~1
bcr+,~1
p210+~1
bcr-,~1
p190+~1
characterize.~1
arabinose-H+~1
xylose-H+~1
lactose-H+~1
(LacY)~1
melibiose-Na+~1
(MelB)~1
Middle-T~1
(p60c-src)~1
p60c-src~7
p60c-src.~1
p90gag-yes~1
Y73~1
(anti-yes~1
c-yes~1
(62K).~1
middle-T-p62c-yes~1
'footprinting'~1
Wang~1
sequencing'~1
Church~1
Gilbert.~1
GAL~7
(UASG)~1
foot-printing~2
transcription-dependent~1
ultraviolet-induced~2
'TATA'~1
cephamycins~1
sulfazecins~1
(monobactams)~1
target-directed~1
cephabacins~1
formadicins.~1
lactivicin,~1
lactivicin~1
dicyclic~1
Bromodeoxyuridine~1
BrdU,~1
LIs~5
slow-growing,~2
laser-assisted~5
(LAMA)~1
(CMSA)~1
LAMA~6
CMSA~5
(wavelength~1
(202~1
multinational~1
magnetic.~1
(CMCT)~1
CMCT~2
contracted.~1
neurophysiology~2
volleys~1
intraaxial~1
brachytherapy,~2
dosimetry,~2
tomography-guided~1
isotope-bearing~1
Brown-Roberts-Wells~3
Dedicated~1
summation.~1
descends~2
stimulus?~1
corticofugal~2
discharge?~1
both?~1
reveals,~2
"killed~1
end"~1
matter;~1
arborizations~1
D:I~1
trivially~1
discharge.(ABSTRACT~1
nitrazine~1
ferning.~1
trunkal~2
22.6%;~1
estolate~1
urealyticum),~1
hominis),~1
(3331~1
(3187~1
.042).~1
.047).~1
mycoplasma-colonized~1
nervous,~2
skinning~2
(Mezlin,~1
Miles~1
Pharmaceuticals),~1
that.~2
bifida.~3
77,015~1
subTenon~2
("subconjunctival")~1
("retrobulbar")~1
non-automated~2
dacryocrystorhinostomy~1
knot.~1
apposed.~1
Evangelista~1
Helmholtz~1
Purkinje's~2
contemporaries.~1
re-examination.~1
"A"~1
well-~1
B-lymphocytic~2
outlines.~1
nonexistent;~1
lymphoplasmacytoid~3
(polykaryocytes).~1
resemblances~1
thyroid),~1
mucosa-associated~1
(MALT)~1
Tyrrell~2
1900.~1
editor~4
pseudomedical~1
magazines.~1
Restorer,~1
piece.~3
(eg.~1
glaucoma),~1
spectacles.~2
fraudulent~1
deceptive~1
enterprises~1
1918.~1
Bend~2
strength/penetration~1
tunneling,~2
grasping,~1
Hecht~1
Fascia~1
Lata~1
Forceps,~1
hemostat.~1
Digit~2
Symbol~2
safranine,~1
sorbose,~1
Yeasts~1
tropicalis,~1
pintolopesii,~1
glabrata,~1
177.~1
niches~1
yeasts.~1
leukoplakias~2
leukoplakias,~1
leukoplakia)--biotypes~1
175,~2
575--rarely~1
occur.(ABSTRACT~1
ridges.~2
CGRP.~1
hypoosmolality~1
illness-induced~1
microbes,~2
intensivist~1
Hypovolemia~1
gravely~1
Judging~3
Drowning~2
opportunity.~1
Ice-water~1
(DFA)~1
vaginas~1
8/47~1
4/43~1
0/49~1
Chlamydia,~2
Chlamydia-positive~1
trachomatis-negative~1
post-World~1
credentials~1
spawned~1
nurse-educators~1
sort.~1
quintessential~1
Intently~1
"doing"~1
investigator--whether~1
journal's~2
socializing~1
intricacies~1
funded,~1
theory-grounded~1
agenda.(ABSTRACT~1
chenodiol~1
(Chenix)~1
Nosebleed~1
picking~1
treat;~1
cocaine-epinephrine~1
toxocariasis.~1
geophagia.~1
hand-to-mouth~1
Toxocariasis~1
demonstrates.~1
Syphilis,~2
latent,~1
(late),~1
darkfield~1
chancre~1
VDRL~5
FTA-ABS.~1
"cardiogenic~1
hypertension."~1
culprit.~1
fertility-control~1
safest,~1
reviving~2
compression-ventilation,~1
postresuscitative~1
gamma-carboxyglutamate~1
"propeptide"~1
(2'-5')oligoadenylate~1
(2-5A)~1
triosephosphate~1
thermostability.~1
heat-induced~2
(Asn-14----Thr-14~1
Asn-78----Ile-78)~1
deamidation,~1
Asn-78~1
dilution-induced~1
synapsis~5
duplexes,~1
strand-transfer~3
Mu.~1
requires,~1
19-kDa~4
phosphoamino~3
H2ts-1~2
[3H]diisopropyl~1
adenovirus-encoded~1
endopeptidase,~1
autocatalysis.~1
EMBL3.~1
(0.7-kilobase~1
I-Pst~2
0.6-kilobase~1
I-HindIII~1
("-1")~1
30-mer~1
(cap)~1
182,~1
169,~1
boxes"~2
"GC~1
G-rich~1
RHO1~5
RHO2~2
Aplysia,~1
(RHO1-His68)~1
HRAS~2
Diploid~1
RHO1-His68~1
sporulate,~1
RHO1.~1
RAS2-Val19.~1
pluripotent,~1
NC-1~1
amphibians~1
HNK-1/NC-1-reactive~1
HNK-1/NC-1~1
HNK-1/NC-1-positive~1
[D-Trp6]LH-RH~4
(analog~1
Gly-6~1
D-tryptophan)~1
N-Ac-[D-Phe(pCI)1,2,D-Trp3,D-Arg6,D-Ala10]LH-RH~1
x-radiation~1
[D-Trp6]LH-RH,~3
liberating~1
propagated.~1
Serially~1
agent-infected~2
immortal,~1
Inspired~1
post-ganglionic~1
prosper~1
meglumine.~1
ioxaglate,~1
McNemar~1
half-lung~1
immunosuppression-associated~1
antilymphocytic~1
Omnipaque~2
(iohexol),~1
meglumine),~1
Isopaque~1
Coronar~1
(metrizoate)~1
T-cell-depleted~3
postallograft~1
thickening;~1
soft-tissue,~1
basal-ganglion~1
Sonographically,~1
arthrosonography~1
non-transmural~1
(non-Q~1
dermatophytosis;~1
versicolor.~2
versicolor;~2
mycoses.~3
corporis.~2
(once~1
Tolerability,~1
Dyschromia~1
candidosis.~4
(regimen~3
chromomycosis,~1
2,094~1
achloric~1
alga,~1
actinomycetes,~1
(1,303),~1
(27),~1
(170),~1
(87),~1
Sporothrix~3
schenckii~4
Dematiaceae,~1
Ittraconazole~1
microsporosis,~1
trichophytosis,~1
meningo-cerebral~1
brasiliensis,~2
fumigatus.~1
lipid-like~1
assemble.~1
(necrosis)~1
(P.~3
brasiliensis)~1
albicans).~1
neoformans);~1
brasiliensis),~1
fumigatus).~1
synthetically.~1
(1956)~1
Griseofulvin~1
distributed,~4
flucytosine-resistant~1
flucytosine.~3
azole~5
triazoles~1
alleviated.~1
therapy--itraconazole~1
day--was~1
mycosis.~1
(15.4%),~1
paracoccidioidomycosis,~2
Madurella~1
grisea,~1
madurae,~1
Pseudochaetosphaeronema~1
larense,~1
carrionii,~1
Fonsecaea~1
pedrosoi~2
carrionii~1
grisea.~1
thermotherapy~1
0.09-0.36~1
0.09-0.78~1
(Histoplasma~1
duboisii)~1
Phialophora~1
parasitica~1
semiinvasive~1
nonmammals,~1
investments.~1
(gene~1
deletion),~1
reassorting~1
flips~1
predecessor~1
preadapt~1
elude~1
RNA-catalyzed~2
multicomponent~4
(snRNPs),~1
U5,~2
U4~1
Leader~1
"signal~1
sequences"~1
Oligonucleotide-directed~1
(neuritic~1
orangutan,~2
bear,~1
28-amino~2
falciparum,~4
chloroquine-resistant~4
chloroquine-sensitive~2
furnish~1
schizophrenias~2
cycloid~2
"Good~1
prognosis"~1
quarter-century.~1
dismally~1
underfunded.~1
hoped,~2
dedication~1
Shriner's~1
BSAB;~1
rudimentary.~2
sepsis--either~1
lower-airway~1
toilet,~1
immunity;~1
undoubedly~1
TBSA)~3
(deep~1
full-thickness)~1
disagreement,~2
"hard~1
"cosmetic~1
appearance,"~1
reharvested,~1
hypermetabolism,~1
(face,~1
arteriogram,~2
"predictive~1
values"~1
bedrest,~1
ATP-MgCl2.~1
cranioplasty,~2
cranioplasty.~1
radioimmunochemotherapy~1
nimustine~1
Picibanil~1
(OK-432)~1
Cox-Mantel~1
pyogenes~7
Su-strain~1
skin-reaction~1
hexachlorocyclohexane,~1
Photographic~1
commenting~1
letter.~2
thorough,~2
("Spectacles:~1
Past,~1
Future,"~1
March-April~1
Modesty~1
me~1
Suffice~1
say,~2
Letocha's~1
solidly~1
erudition~1
kcal/m2/day.~1
kcal/m2/day~2
breakdown)~1
REE)~1
Caucasian)~1
Extracranial/Intracranial~1
(non-operated)~1
(MCAS,~1
(MCAO,~1
EC/IC~4
included).~1
MCAO~2
MCAS~1
Warning~2
MCAS,~2
lenticulocapsular~1
medically-treated~1
(TIA~1
mortality/morbidity~1
(1.7%~2
side).~1
(11.2%).~1
DSA/duplex~1
38,485~1
(dazmagrel)~1
jugular-vein~1
prostacyclin)~2
non-controlled~4
field).~1
IMPS~3
"break-even"~1
"shown~1
benefit"~1
Plum,~1
Walton~1
1,989~1
angiograms)~1
Pourcelot~3
thin-calibered~1
neutralized.~1
anti-HBc.~1
embody~1
government's~3
Third-party~1
"facility"~1
fees,~1
UCR~1
(usual~1
ahead,~1
Politano-Leadbetter~1
ureteroneocystostomy.~2
Sterility~1
quadriplegics.~2
hypothalamic-pituitary-testicular~4
nondrainage~1
Technetium-99m-DTPA~1
(time-activity~1
histogram).~1
Nonobstructive,~1
hydronephrosis.~2
Xanthogranulomatous~2
(25-65~1
(240,~1
(Pressurometer~1
Del~1
Mar~1
Avionics).~1
(causal~1
3-dose~3
19/105~1
17/87~1
14/88~1
2-and~1
2-dose~1
0.00-2.59~1
(circadian~1
bendroflumethiazide~2
2.5-5~2
160-320~1
non-treatment~1
Venesection~1
venesection.~1
DVTs~1
99mTc-glucoheptonate.~1
poles.~1
99mTc-glucoheptonate~2
subendocardial-subepicardial~1
dipyridamole-like~1
Counteraction~1
[AMI])~1
AMI)~1
conventionally)~1
(+60~1
53;~1
(+100~1
78;~2
(+48~1
131;~2
micrograms/kg/min;~2
(DBP;~1
(CSBF)~1
(MVO2)~1
stenotomy~1
(MB-19),~1
immunophenotypes:~1
(allotypes)~1
Ag(c)~1
Ag(g),~1
4*,~1
4v)~1
Apo~11
(arg158----cys)~2
(cys112----arg)~1
isoform,~1
dysbetalipoproteinemia~1
Finns~1
Germans~1
AI,~4
(HDL3)~1
(HDL2)~2
[IDL],~1
[LDL]~1
cascade)~1
Crucial~1
cholesterol-synthesis~1
responsible:~1
Carbohydrates~2
low-cholesterol~1
AIV~2
rates.(ABSTRACT~2
metabolisms~1
glycemia.~4
VLDL-triglyceride~1
prosegment~1
proapolipoprotein~2
(IDL).~1
Cholesterol-enriched~1
dyslipidemias~1
hyperlipoproteinemia)~1
(LDL-IIIA)~1
NHLBI~2
IDL-LDL~1
(HBDH)~1
HBDH,~2
(820~1
HBDH)~3
HBDH).~1
limitation.(ABSTRACT~1
-11.5~1
-12.2~2
hydrochlorothiazide).~1
mono-therapy~1
step-2~1
space;~1
plasmalemma.~1
"superficial~1
barrier"~1
recapitulate~1
circulation-borne~1
concept--that~1
system--has~1
expression(s)~1
attributes,~2
Atherogenic~2
moderation~2
overdeveloped~1
competitiveness~1
steeper.~1
Antiplatelet~2
Persisting~1
blockers);~1
cinnarizine~3
flunarizine.~1
Electrophysiologically,~2
adrenergic-blocking~1
exhibit.~1
gallopamil,~1
bepridil;~1
properties).~1
suppressants~1
automaticity.~1
"final~1
pathway,"~1
dextran).~1
(isradipine)~7
108-068,~1
non-dihydropyridine~2
KB-944,~1
MCI-176,~1
inotropy.~1
KB-944~1
Bepridil~7
MCI-176~1
chronotropy~1
dromotropy.~1
20,000-dalton~1
ensues.~3
caldesmon,~1
actin-containing)~1
calcium-activated,~1
vascular-selective~2
aorto-coronary~1
kidney.(ABSTRACT~2
Nicotine,~1
anipamil,~1
Sprague~2
Dawley~2
weight/day),~1
late--4~1
fashion)~1
8-week,~2
double-crossover,~1
verapamil-SR,~2
regular-formulation~1
twice-a-day~1
qualifying~4
CAPS.~1
1,780%~1
"arrhythmia~1
aggravation"~1
0.052),~1
trials/patient).~1
0.04-0.32~1
1.97%.~1
53-66%).~1
immunoreagents~1
0.805).~1
cystadenocarcinomas~2
cholangiocarcinomatous~1
fucomucins)~1
anti-M1,~1
(1-13~2
M1)~1
0.29;~3
M1),~1
dermatopathic~6
immunolabeling~2
Cytomegelisa~4
Bioproducts,~1
Walkersville,~1
MD)~2
A50-treated~1
(CMV)-specific~1
Cytomegelisa.~4
column/IFA.~1
CMV-IgM~1
column/IFA~1
RF-positive/CMV~1
IgG-positive~1
toxin-dependent~1
nucleoside.~1
1,018~1
Bactec~5
(Johnston~2
Towson,~2
dip~1
(Hylab).~1
recovered:~1
Hylab~3
6B.~1
Tac+,~2
Leu-14+,~1
Leu-M5+,~1
B2-,~2
BA-1-,~1
BA-2-,~1
shigellosis.~1
1.2:1.0.~1
(13.1%)~1
febrile;~1
9.01~1
mmol/L]),~3
[157~1
imperfect,~3
[292~1
nmol/L]~3
[298~1
(26.6~1
[734~1
[687~1
(79.2~1
[2.74~1
538.6~1
[18.67~1
4.79~2
[1.02~1
[1.19~1
thalassemia.~1
cilastatin~5
(60%):~1
Kingella~2
kingae~2
amalonaticus~1
1:512~2
1:16~6
cilastatin.~1
cilastatin's~1
flowmetry.~6
U/min)~2
(-36%),~1
(-50.6%),~1
(-54.3%)~1
hyperacidity.~1
Antiperistaltic~1
Recirculating~1
lipoprotein-lipid~1
probucol.~1
Colestipol~1
20.2%~2
31.9%~1
LDL-to-HDL~2
Probucol~1
probucol,~1
Antihyperlipidemic~1
azathioprine-treated~6
cyclosporine).~1
living-related~8
pretransplant,~2
(THP),~1
THP.~2
THP~17
THP-coated~1
"HDL~1
hypothesis,"~1
westernized~3
obese;~1
magnesium;~2
Senescent~1
observations--that~1
hypertension--constitute~1
Bone-forming~1
ongoing,~2
hormone-mediated~2
postmenopausally,~1
menopause)~1
indirect)~3
irreversibly.~1
connectivity.~1
muscular-skeletal~1
sodium-sensitive,~1
15-day~3
HDL/LDL~1
ADA,~2
evanescent,~1
supper.~1
6,330~1
A1C~6
oncology,~1
gleaned.~1
medicare~2
defensible~1
1300-2000/year)~1
Totally~1
horizon.~1
$2.5~1
$5~2
Vincent's~1
Eye-Bank~1
Restoration,~1
(GN)~3
(LKs)~1
LKs~1
(GL)~2
LK,~2
25/GL;~1
32/GL.~1
MRCOX1~1
[LC]~1
Ig:~1
leukocytes/GL;RK,~1
leukocytes/GL~1
LC+~1
(Giemsa~1
staining:~1
neutrophils);~1
(LyP),~1
Ki-1-positive~1
Reed-Sternberg-like~1
LyP~2
10-20%~4
vesicant,~1
(SM).~1
trypsin-inhibitory~2
alpha-macroglobulin~1
beta-globulin~1
1-globulin~2
2-globulin~1
gravimetrically,~1
1-macroglobulin~1
1M]~1
1M-alpha~1
immuno-peroxidase~1
proteinase-complexed~1
unbounded~1
(NBD-phallacidin),~1
thin-thickness~1
autografts.~5
NBD-phallacidin.~1
actin-staining~1
actin-rich~1
methanol-Carnoy's-fixed,~1
HHF35,~1
pericytes,~2
HHF35~5
42-kd~2
isoelectrophoretic~1
(hyperglycemia~1
life-times~1
(Armstrong,~1
E350,~1
Pasteur,~1
Traub~1
WE)~1
Armstrong~2
(Clone~1
(nucleic~1
Langerhans;~1
LCMV-specific~1
Langerhans,~1
subdiabetogenic~2
(JG)~1
oncocytomas,~1
JG~4
renin-containing~1
renin-positive~1
cytoplasms.~1
eighteenth-century~1
poet~1
Cowper,~1
Cowper's~2
poet's~1
reruptures~1
LAV~1
Argentina.~1
Antequera~1
bunyaviruses~1
Bunyamwera~2
vesiculovirus.~1
Melao~2
Maguari~2
Playas~1
Calchaqui~2
Santiago~1
Estero~1
P126,~1
parasitophorous~1
exoantigens~2
FCR-3)~3
exoantigens,~1
Dot-enzyme~1
(Dot-EIA)~1
Dot-EIA~1
Amodiaquine~1
Filipino~1
amodiaquine~4
(RIII~1
resistance);~1
(RI~1
resistance).~2
zymodeme~4
(Z1,~1
X-10;~1
Z2,~1
ESM;~3
Z3,~1
CAN-3)~1
Colombian~1
"zymodemes"~1
stocks:~1
Z1-like~2
Z3-like~1
zymodemes~2
Z2~1
Z1~1
Z3~1
mefloquine,~1
parasites'~2
Qalyub~1
Governorate~1
Egypt~3
nonemergent~1
misinterpreted.~3
ether;~1
polysorbate;~1
endoscopists,~1
chenodeoxycholate.~1
Ursodeoxycholate,~1
Intragallbladder~1
Chinese)~1
ethanol/kg.~1
Europeans,~1
Within-race~1
thiamine,~2
(167-260%~1
meq/kg),~2
(28Mg,~1
meq/kg~1
acetycholine~1
locomotor-stimulating~1
(MR/N),~1
Sprague-Dawley,~1
MR/N~3
(MRrb)~1
Monoester~1
1213~1
milliunits/10(12)~4
997~3
macrocytosis~2
femtoliters)~1
(1276~1
1101~1
normocytic~2
Triacylglycerols~2
weight/day)~1
lysophospholipids,~2
phosphatidylethanolamines~1
phosphatidylcholines~1
starved.~1
4.1-7.8~1
mmol/liter);~2
mmol/liter).~3
2.0-13.3~1
ketotic~5
seven).~1
microU/ml),~7
(8-11~1
g/kg/day),~1
equicaloric~1
dowel~1
4-methyl~1
ADH-1~1
ADH-2~1
ADH-3~2
ADH-4~2
"pi-ADH").~1
ADH-5~1
"chi-ADH")~1
1956-1969.~1
rigidity/perfectionism,~1
strain/tenseness,~1
asthenic~1
alcoholism/personality~1
disturbances/suicide~1
antisocial/criminal~1
antisociality/criminality.~1
(suicides~1
strain/tenseness~1
rigidity/perfectionism~1
Korsakoff's~2
digit/letter~1
(objects,~1
numbers)~2
constraint-seeking~1
inquiring~2
"Is~2
tool?").~1
hypothesis-scanning~1
pseudo-constraint~1
saw?").~1
Korsakoff~1
visuoperceptual~1
convicted~2
constructed;~1
drinking/driving~4
increases;~2
Undiagnosed~1
incidents.~1
occasion;~1
drank,~1
alcohol-positive~1
Drinkers'~1
drinkers'~2
expectancies.~1
nonproblem~3
endorsements~1
tension).~1
Long-Sleep~1
Short-Sleep~1
(3,4-dihydroxyphenylacetaldehyde)~1
(5-hydroxy-3-acetaldehyde)~1
disulfite~1
5-hydroxy-3-acetaldehyde~2
multibarrel~1
micropipettes~1
tryptamine~1
5-hydroxy-3-acetaldehyde.~1
3,4-Dihydroxyphenylacetaldehyde~1
monoamine-derived~1
benzodiazepine-ethanol~1
(0-36~1
tmax.~1
shy,~1
(32%~2
216,~2
224,~1
g/week,~1
292,~1
144,~2
units/liter.~1
biopsy-semiquantified~1
3-4+~1
centrilobularly~1
calories):~1
0/16,~1
10/17,~1
4/6,~1
3/7~1
5-mon~1
ito~1
necrosis-fibrosis~1
ethanol-inducible~1
P-450ALC~2
"alcohol~1
oxygenase"~1
"microsomal~1
ethanol-oxidizing~4
ketones,~3
nitrosamines,~3
alkanes,~1
alkenes,~1
ethers,~1
transformations,~2
acetone,~2
acetol,~1
p-nitrophenol,~1
aniline,~1
dealkylation~1
dechlorination~1
tetrachloride,~2
pool/hr/g~1
(1-R)-[1-14C,1-2H]ethanol.~1
portae)~1
13.3%.~1
Lieber~1
procarcinogens~2
bewildering~1
buprenorphine.~2
(SPID)~2
cooperate.~2
rid~2
Post-captopril~2
pre-captopril~3
beta-blocker,~1
paroxsysmal~1
"thromboischemic~1
mechanism,"~1
'staccato'~1
myoglobinemia~1
disappear,~1
Bronchopulmonary~2
pseudosequestration~1
heaviness~1
lymphagogue,~2
2210,~1
2210~3
non-refractory~1
subclasses.~1
(Nubain)~1
(Vistaril)~1
migraineurs.~1
ventricles).~1
pressure-controlled~1
gases:~1
Ri,~2
Ra,~2
10-fold;~1
Ri~1
aerosol.(ABSTRACT~1
oculopneumoplethysmography~1
(OPG-Gee)~1
(around~2
99%),~1
OPG-Gee,~3
95.6~2
84.3~1
92.6~1
(70.5%~1
76.5%),~1
(89.5%~1
94.5%),~1
(84.3%~1
peri-orbital~1
(RHCP)~1
RHCP~3
phenyalanine~1
(Doppler-resting~1
(Doppler,~1
[IPG],~1
phleborrheography~1
[PRG])~1
Upper-extremity~1
brachial:distal~1
triphasic;~2
Lower-extremity~1
ankle:~1
.016~1
g/cm2~2
K2HPO4/cm3~1
K2HPO4/cm3.~1
Osteopenia~1
perturbs~1
snorting~1
Narcolepsy,~1
naps~1
cataplexy.~1
philanthropic~1
subspecialization~1
primacy.~1
overdistention~3
Merrimack~1
tongues.~1
supravital~1
heal,~2
refined,~2
Mobius'~2
disorder;~2
Lindeman~1
(HZ)~1
conjectural.~1
fluency,~1
naming,~1
centromedian-parafascicular~1
mamillothalamic~3
RS-533~5
carbapenem~2
tobramycin-resistant~1
W7.~1
bacteriostasis~1
(mecillinam)~1
thermosensitive~1
(PBP)~1
3-specific~1
(amdinocillin)~1
cefsulodin,~1
lysis-inducing~1
PBPs),~1
CFU/g.~1
(146.5~1
ensured,~1
(HTLV-III)/lymphadenopathy-associated~2
HTLV-III/lymphadenopathy-associated~1
HTLV-III-induced~1
HTLV-III-producing~2
Molt-4/HTLV-III~1
azido-TTP~1
Molt-4/HTLV-III.~1
colistin-resistant~2
colistin-susceptible~1
matings.~1
recalcitrant,~1
31/2-year~1
xerosis,~1
1874~1
freckling)~1
(lid,~1
cornea)~1
morphea:~1
(HPVs)~1
HPV-1~1
HPV-2~1
HPV-3~1
HPV-4~1
HPV-5~1
HPV-3-~1
HPV-5-related~1
iododerma~2
postal,~1
(1.0),~1
(56.6%~1
(34.9%~1
21.0%).~1
schooling,~2
(34.2%~1
10.5%).~1
(0.65).~1
Re-admission~1
(0.81~1
(1.65)~1
(0.65].~1
leucomalacia~5
paenchymal~1
(echoes~1
cystic).~1
precystic~1
Haemorrhage,~1
leucomalacia,~1
leucomalacia.~1
microcalcification~1
(Griffiths~1
quotient)~1
periventricular-intraventricular~2
frontal-parietal~1
frontal-parietal-occipital~1
hyperechogenic~1
(dominant)~1
palpable,~1
29-32~1
Eczema~1
(provocation~1
hyper-responsiveness.~1
monobactam~3
(A/C)~1
(G/C)~1
G/C~1
1-blocking~2
1-blockade.~2
(reference~3
1.5-3.0~1
storm~1
OP-41483~1
Japan),~1
1-4.~1
1,025~1
1,654~1
(50/1,025).~1
(214/1,025).~1
(210/875)~1
(162/575)~1
(48/300)~1
7.4%,~1
32.7%.~1
Pulsus~1
paradoxus~3
(RPP).~1
Cardiorespiratory~2
end-inspiration,~2
RPP.~1
shrinks~1
zipper~2
Unzipping~1
(37.3%)~1
"corrected"~2
[2.12~1
(4.5%).~1
Ketanserin,~1
(S2),~1
(13/18)~1
hydroxyindole~1
(fibrotic~1
UTI,~1
intercourse;~1
33.3%.~1
"Therapeutic~1
benefits"~1
Accounts~1
Worsening~2
uncooperative~1
postverapamil~1
3-methoxy-4-hydroxyphenethyleneglycol.~1
norverapamil,~1
CSF/plasma~1
Knowledge-based~1
knowledge-intensive~1
knowledge-based~4
(DWDLL)~1
lymphocyte-types~1
DWDLL~6
(unstimulated~1
nontransformed)~1
NHLs,~1
paracortical,~1
lymphoid-reactive~1
(nontransformed)~1
small-lymphocyte~1
cerebro-ocular~1
(Warburg~1
pg/10~4
microL).~2
(60.7%)~1
HBV-DNA.~1
HBV-DNA,~1
(93.1%~1
[11/12])~1
(15.8%)~1
Erythromelalgia,~1
erythalgia~1
erythermalgia,~1
physiatrists.~1
SICU,~1
whichever~3
(sputum,~1
wound)~1
(fungemia~1
focus).~1
SICU~8
(MLN).~1
(endotoxin-resistant)~1
endotoxemia-induced~1
endotoxemic~2
PMNs,~3
myeloperoxidase-dependent~1
10(2),~3
[0,~1
(alpha-aminoisobutyric~1
supranuclear,~1
infranuclear~1
bias),~1
clinicotopographic~1
trimesters,~1
Ferrier~2
Ferrier's~1
contemporaries,~1
C(IV)22,~2
sublining~2
lymphocyte-rich~3
thickened;~2
multilamellated,~2
densa;~3
uninfiltrated~1
recent.~1
GABA;~2
micro-environment~2
750,000~1
(TENS),~1
(300-600~1
Aldred~1
Warthin~1
lymphomatosum~1
idiosyncrasy~1
Hematoxylin-eosin,~1
Giemsa,~1
anti-C3,~1
reagin-mediated~1
Anti-C3~1
skin-lined~1
recruitment;~1
randomised.~1
Pagetoid~1
(PAV),~1
cytotoxic/suppressor)~1
3a-positive~1
helper/inducer)~1
PAV~1
HLA-DR-negative.~1
Prorenin~4
(enzymatically~1
inactive)~1
pre-ovulatory~1
menopausal/human~1
gonadotrophin.~2
collection;~1
non-stimulated~2
reninsubstrate~1
transpupillary~1
(schwannoma),~1
52,000.~1
52,000-receptor~3
97,000)~1
(DFP),~1
DFP,~1
phenylmethylsulfonylfluoride,~1
48,000)~1
5.0-kilobase~2
Thrombin-dependent~1
cells/mL).~1
gamma-gamma~1
alpha-polymers.~1
125I-labeling~1
activators;~1
IIB)~1
30,000/microL,~1
"endotheliopathy."~1
NIH-3T3~4
B44.1,~1
LeuM3~2
gp55~2
(gp55)~1
55-kilodalton~1
26if,~1
chromosomes/metaphase~1
8-kilobase~2
CML-specific~2
eight-~4
CML,~3
(CFU-GEMM),~1
cancer-forming~1
conceptus.~1
roentgens,~1
protraction~1
(non-stochastic)~1
misguided~2
expecting~2
predictively.~1
groups"~1
inheritable~1
pyloric/prepyloric~1
1,5~1
unscarred~1
54).~1
Diplococcus~1
investigational.~1
Sales~1
(BMRT)~1
BMRT,~1
rosette-like~4
BMRT~1
adeno-~1
doses),~1
42+,~1
(DHL).~1
subtyped.~1
FCC~4
DHL.~1
noncleaved)~1
0.03);~3
DHL~1
two-mutation~1
11p13~3
FUVAC~1
(5-fluorouracil,~1
[doxorubicin]~1
cyclophosphamide).~1
hemibody~1
(HBI)~1
TBI~21
HBI~2
HBI,~1
TBI,~3
(Bristol~1
Myers~1
IN)~1
p62c-myc,~1
p62c-myc~1
(LGL),~2
ultra~1
CD2,~5
CD11,~2
12-0-tetradecanoyl~1
(IL2).~1
anti-CD6~1
CD7~3
(moAbs),~1
anti-CD19~2
(B4)~1
moAb.~1
IL2;~1
(LFT)~2
LFT~6
noncarcinoid~3
(GGTP),~1
(SGPT).~1
E2-positive~2
(44.2%)~1
(20.6%)~1
(34.9%)~1
endocrinic~1
polypoid,~1
leiomyosarcoma,~1
sarcoma:~1
osseous,~1
(TNKH1)~1
n-butyric~1
nevomelanocytic~1
TNKH1~3
maligna,~1
subungual),~1
TNKH1-positive~1
TNKH1-negative~1
TNKH1;~1
(log),~1
"anaplastic"~1
Stage-specific~1
(SSEA-1)~2
SSEA-1;~1
SSEA-1~7
SSEA-1,~2
RCCs~1
immunolocation~1
bizarre,~1
monocytic-histiocytic~1
anticommon~1
polymorphous,~1
osteoblastoma-like~1
tumors),~3
fibroma-like~2
(FLC)~2
FLC~11
(endolymphatic~1
myosis),~1
(collision~1
(carcinosarcoma).~1
(ASAT)~1
therapeutical~1
("muscle~1
type")~1
MMA.~1
MMA~1
MMC,~1
MMA,~1
MMB,~1
MMC.(ABSTRACT~1
vasoactivity~2
Vasodilation~3
constrict~5
disease--elevated~1
platelets--all~1
octaploid~1
polyploid~3
L6-7~1
(indomethacin,~2
(LVH).~1
RaVL~1
SV3~1
(Cornell~1
voltage)~1
Sokolow-Lyon~1
(SV1~1
RV5~1
RV6~1
SLV).~1
practice.(ABSTRACT~1
(Philadelphia,~1
Haven)~1
Occluder~1
Systems.~2
Postrelease~1
embolizations~2
double-disk~1
(C-D)~1
(hemodilution~1
(hypertrophy)~1
0.4(SE)~1
C-D~3
(2.02~2
H.(ABSTRACT~1
re-employment~1
lobulation.~1
incompletely.~1
nonpathogenicity~1
PROM,~2
Nagey~1
Saller~1
symposium.~1
Betamethasone~2
advised),~1
again)~1
inevitable.(ABSTRACT~1
Meis~1
(IPL).~1
(1,529~1
births),~2
IPL~2
(1,327~1
Paramount~1
Papiernik's~1
leave,~2
feel,~1
emulated.~1
PROM.~1
postponing~2
nonviral~3
unethical~1
mysterious~3
anti-TA1~1
pregnancies).~3
TLX~1
TA2~4
anti-TLX~1
"foreign"~1
oncoextraembryonic)~1
(TLX)~5
"self"-antigen,~1
Antigen-reactive~1
TA1-blocking~1
allotypic~4
host-versus-graft~1
anti-TA2~2
oncoextra-embryonic~1
extra-embryonic~1
Multistaged~1
epiperineurium-fascial~1
(EPFS)~1
stumps.~3
microfragments~1
polymethylmethacrylate.~1
Microfragments~1
(MES)~1
Were~1
slender,~1
osteopenic~1
spongiosa,~1
MES~1
echocardiography).~1
indenolol,~1
not-cardioselective~1
200/115~1
Indenolol~2
(strain-gauge~1
(standing,~2
hand-grip)~1
indenolol~1
mashed~3
insulinaemic~1
Haemaccel~5
1000-~2
(SMS),~2
'protected'~1
PAO2~2
HPV,~2
K+/low~1
(PRA).~3
systoloic~1
assignation~1
anti-elastase~1
1PI,~2
anti-leucoprotease~2
deficient:~1
NE/mol~1
0.88-78.80;~1
bronchitic:~1
1.14,~1
0.21-4.66),~1
(2P~3
1PI.~1
(coconut~1
Coconut~2
frequency),~1
para-aminosalicylic~1
kanamycin)~1
kanamycin.~1
multitrauma~1
risk-scoring~1
characteristics),~1
lung-scan~1
contusion)~1
false-negatives.~1
high-volume,~1
low-pressure,~1
Cuff~2
Paw,~2
"just~1
seal"~1
(CaCl2),~1
(Epi),~1
Epi~7
D5W.~1
54-yr-old~1
VF,~2
CGS13080~1
(PPH),~3
professionals:~1
pediatricians,~1
qid)~1
Said~1
constipation-predominant,~1
diarrhea-predominant)~2
diarrhea-predominant~1
Diarrhea-prone~1
constipation-prone~1
4-48~1
(IHA)~2
IHA.~1
Mefenamic~2
feprazone,~1
IHA,~2
feprazone~1
(G-6-PD)~1
NSAID-treated~1
Interprofessional~1
Pharmacists~3
breastfeeding,~2
home-use~1
Antiarrhythmic-induced~1
cibenzoline-induced~1
reactive-type~1
Insulinoma~2
(AHCZ)~1
AHCZ~1
AHCZ.~1
uninsured~3
flourished~1
marketing,~2
productive,~2
groups--contingent~1
(ATC)~1
group--with~1
learning-based~1
nonexperimental~1
30-week~2
(PCOs).~1
100-micrograms~3
gonadotrope.~2
sperm-associated~3
ejaculated~1
88.4%~2
extraacrosomal~2
38-fold~1
(40%,~1
(680~1
10(-4))~1
(835~1
10(-4],~1
(554~1
10(-4),~1
deoxyribose~2
ejaculates.~1
acephalic~1
spermatid~1
anastomosed,~2
microsutured~1
occlusion;~1
2-adrenergic-receptor~1
(beta-TG),~1
2-adrenoceptor-blocking~1
GIT),~1
(somatostatin,~1
SIGIT).~1
OGTT.~2
GIT~1
(5-min~1
normals),~1
SIGIT~1
enlighten~1
(CCK-8S)~1
[3H]inositol-prelabeled~1
CCK-8S~7
CCK-8S.~1
trisphosphate-induced~1
(HIT~3
free-Ca2+~3
HIT~12
(IBMX)~2
glucose-generated~1
weight-maintaining~2
800-1000~1
kcal/day.~1
factored~1
state.(ABSTRACT~1
beta-Cell~1
arginine-stimulated~4
acid-ethanol-extracted~1
7000-8000.~1
beta-cell.~2
T-15~1
dihydroxyacetone,~1
alpha-ketoisovaleric~1
(3-O-methylglucose).~1
Iodoacetate~1
stimulus-secretion~5
large-molecular-weight~2
proinsulin-immunoreactive~1
guanidine-1~1
A-Sepharose-affinity~1
alpha-methyl-mannoside-displaceable~1
N-acetylglucosamine-specific~1
lectin-Sepharose.~1
lectin-reactive~2
proinsulin.~7
Immunochemically~1
(reaction~1
A-Sepharose)~1
guanidine-acetic~1
bond-cleavage~1
67,000-Mr~1
C-peptides~1
(CPRs)~1
[28~3
(IGT);~1
yr],~1
[56~1
(IDDM);~1
.05-.01).~1
[3H]-2-deoxyglucose~1
N-acetyl-Tyr~4
80-110%.~1
(PG~1
aldehyde-osmium~1
resin-embedded~1
II-positive.~1
Brunner's~3
II-negative.~1
II-negative~1
II-containing~1
II-unreactive~1
arbaprostil~2
taurocholate-induced~3
Taurocholate~1
cytoprotective.~1
99m-diethyltriaminopentaacetic~1
orocolonic~1
gamma-scintigraphy~1
cnd~1
guar.~1
(T50)~1
T50~1
Hold-up~1
nondrinkers.~1
alpha-isovaleryl-L-histidyl-L-prolyl-L-phenylalanyl-L-histidyl-ACHPA+~1
++-L-~1
phenylalanyl~1
amide)~1
(3S,4S)-4-amino-5-cyclohexyl-3-hydroxy~1
pentanoic~1
(ACHPA)~1
(enalaprilat)~1
(MK-422)~1
ACHPA-containing~3
(0.003-0.1~1
-48~1
renin-dependent~5
efficacy:~1
polyploidism~1
1-Blockade~1
undesirable.~3
118551,~1
t.i.d.,~4
(Japanese)~1
(enalapril).~1
Discontinuous~1
IU/kg/min)~1
reamings~5
non-operatively,~2
discouraging.~1
haemophilic~1
"cruciate"~1
valgus-varus~1
acetabuli,~1
Wrightington,~1
considerably;~1
protrusio.~1
sclerosed.~1
euglycemia.~1
(Ra),~1
[1.92~1
(1.26~1
OHB,~1
(leprechaunism~1
Insulin-stimulated~4
leprechaunism~1
heptanoate~1
(DHT-hp),~1
seven-carbon~1
DHT-hp,~1
43-55%~1
DHT-hp~6
(ALDO)~1
ALDO,~1
ALDO~5
(ALDO/PRA)~1
ALDO/PRA~2
[34~1
h],~1
(46%;~1
[3.2~1
547~1
pretreatment;~1
U/mL;~5
gate-keeping~1
(60-120~2
lipo-~1
Apolipoproteins~1
immunofluorometric~1
0.17-4.8~1
IU/L;~1
0.03-2.3).~1
progestagen~1
(bacitracin,~1
mg/mL;~1
avidin/biotin~2
syncytiotrophoblasts.~1
midterm~1
syncytiotrophoblasts,~1
trophoblasts.~3
mg/dL]~1
(breakfast)~1
(lunch).~1
hypoinsulinemia.~1
[123I]insulin~8
precipitability.~1
70.9~2
antiinsulin~6
-0.87~1
-0.92;~1
[123I]insulin,~1
70-fold~1
anti-ADA~1
(Leu-CAM)~1
Leu-CAM~3
C3-sensitized~1
3.3%).~1
3.2%)~1
heterosexuals;~1
homosexuals),~1
(LF).~1
LF,~1
CFU-GEMM,~2
osmoprotective~3
reineckate~1
betaine;~1
volume-regulating~1
algae~2
euryhaline~1
Elysia~1
chloritica.~1
betaines~1
fortuitously.~1
10-mg/dl~1
Arterialized~1
G:~1
kg/m2).~1
dl/[min~1
m2]~1
BMI:~1
-0.97;~1
SIP(clamp)~3
(0.046~1
0.037~1
dl/min~1
0.35);~1
0.70)~1
FSIGT,~1
SIP(clamp).~1
laminin-rich~1
(HbMS:~1
44ser----cys)~1
delta-,~1
gamma-,~1
HbMS~3
+-thalassemia~3
HbMS-beta~2
fl,~1
2-6%,~1
anisocytosis~1
HbMS,~1
+-thalassemia,~1
Ro/Sjogren's~1
(SSA).~1
Ro/SSA.~1
serum-bound~1
17-fold.~1
precipitin-positive~1
Anti-La/Sjogren's~1
(SSB)~1
(Sm).~1
11/14~1
4-91~1
(ICCA)~1
antiepithelial~1
anticytokeratin,~1
phosphatase-antialkaline~2
(APAAP)~2
anticytokeratin~2
mesothelium,~2
subregions,~1
non-coordinate~1
decalcification~3
(IFAT)~1
(RMAT)~1
(thyrotoxicosis).~1
Prekeratin~1
cytokeratins)~1
prekeratin~2
Immunohistology~1
Stafford~1
Oxfordshire~1
subgrouped,~1
Immunohistological~2
Legionellosis~1
MB2~4
MT1,~2
weaker,~2
MT1~2
UCHL1,~1
(MT1~1
RAP-5~3
line:~1
regenerative,~1
non-colitic~1
biotin-streptavidin-polyalkaline~1
purplish-blue~1
F7,~1
(Chlamydiazyme)~1
(STD~1
chlamydiae~2
M2(1),~1
dots,~1
XR~1
palmaris,~1
allograft,~9
abscess).~1
tissue-culture~1
nonscarring,~1
pemphigoid,~4
epiboly~1
host/graft~2
adnexae,~1
speaks~1
papulosis,~1
nonconspicuous~1
dermographometer-induced~1
polychemotherapy,~2
mycologically.~1
pedis,~2
"moccasin"~1
pedis.~2
moccasin~1
moccasin-type~1
seborrhea,~1
honor~2
Pace,~1
peroxide--a~1
acne:~1
cornification,~1
chondrodermatitis~1
nodularis~1
helicis,~1
enigma~1
suppurative,~1
later-fibrosing~1
nodularis.~1
Dyskeratotic~1
pearls~1
(SCCs)~2
(65-67~2
Kd).~2
SCCs~4
morphea-like~1
Etching~1
roughening~1
ionomers~1
Bond~1
etching~2
technique".~1
gagging~1
resin-bonded~1
dentures.~1
denture.~2
enamel,~1
dentifrice~2
preestablished,~1
planing.~2
subgingivally~1
root-planing~1
toothpaste~1
planing~1
Keyes~1
Doppler-detected~2
nomogram.~1
-0.85)~1
-0.83)~1
anticardiac~1
(indium-111~1
antimyosin)~1
Count~1
Faint~1
authoring~2
lessons.~1
learner,~1
Eppinger~1
Rothberger~1
Fascicular~1
pollen-free~1
clobetasol~1
17-propionate~1
glucocorticosteroid-induced~1
prerandomized,~1
(TCS)~1
TCS~7
mites-sensitive~1
IgE-enhancing~2
IgE-Sepharose~1
(NF),~1
NFs~3
AFs.~1
antibrain~1
SDAT.~1
Immunoabsorption~1
vascular-reactive~1
antivascular~1
mU/m2~5
infusions)~2
(HGO)~3
(R-38.3G)~1
28(3B1],~1
costimulator~1
Ab,~1
Ab-conjugated~1
Sepharose-coupled~2
(anti-H-binding~1
anti-C3)~1
anti-H-binding~3
C3c,~1
C3c~2
alpha'-chain~1
H-binding~1
(C1)~1
(C1-INH)~1
C1r-independent~4
mitoplasts~1
(HHMP)~1
semi-rough~2
"Strong"~1
HHMP,~1
C1qs2~1
C1s-binding~2
HHM,~1
activator-bound~1
(buccal)~1
stratify,~1
tonofibrillar-desmosomal~1
100,000/20~1
first-passage~2
subcultures,~1
dermal/epidermal~3
arm)~2
microprojections~1
epidermal/dermal~1
downgrowths~1
(preferential~1
unravel,~1
elastosis.~1
gp160.~1
p55~5
(p65~1
p31)~1
p48,~1
p25~1
Proteolytic~2
HA2~1
(HAF)~1
HAF-grown~1
endopeptidase.~1
scalded~1
[TSST-1]~1
protease),~1
TSST-1.~1
less-profound~1
non-menstrual~1
antiendotoxin~2
parenterally.~2
(Sepharose~1
4B;~1
Pharmacia,~1
Sweden),~1
PB-Sepharose~3
endotoxin/kg~1
intraarterially.~1
(EPEC)~1
enteroadhesiveness~1
EPEC,~1
cytotoxin,~1
lysogenic~3
phages.~1
EPEC~7
1,674~1
868~2
doses/mg~1
Phages~1
cytotoxin-producing~1
toxin-converting~2
adherent.~1
Nichols~1
(SF1Ep)~1
Mannose,~1
SF1Ep~1
acid-inhibitable~1
fractionated,~2
220-kilodalton~1
gels).~1
(micro-IF)~1
(19.2%)~1
micro-IF~1
x/divided~2
(41.6~1
57-kDa~1
100-kDa,~1
32-kDa,~1
postabortal~1
membrane-enriched~2
B72.3,~3
variability)~1
125I-B6.2~1
B6.2-reactive~1
B6.2~1
anti-breast~1
MAbs.~3
48/61~1
35/35,~1
-hydroxysteroid~1
41/41.~1
aromatase,~1
aminoglutethimide,~2
Regimens~1
4-hydroxyandrostenedione,~1
18962,~1
aminoglutethimide.~4
seller~1
release-inhibitory~1
neurohypophysis,~1
vasopressin-neurophysin~1
oxytocin-neurophysin,~1
prohormone.~1
oxytocin).~1
somatomedins.~3
(150,000~1
Mr)~1
Proposed~2
silicates~1
(SepPak),~1
Anti-endothelial~1
(AECA)~1
Immunofluorescence,~1
AECA.~2
PSS.~2
Heavy-chain~1
AECA~6
AECA.(ABSTRACT~1
Sar1-Ileu8AII~3
micrograms/kg/4~1
subcutaneously),~1
Sar1-Ileu8-AII~1
renin-AII~1
Correctness~1
Tetrahydrobiopterin~2
Burmese~1
Electron-dense~1
knobs,~1
re-evaluates~1
(alternating)~1
tremograms~1
homocarnosine~1
(providing~1
CNS),~1
peculiarities.~1
hexafluoride,~1
circuit;~1
0.996.~1
t19~1
1.23,~1
(measured)~1
0.969~2
(true)~1
(Multiple~1
0.979.)~1
indisputable~1
neuroma-incontinuity~1
axonotmetic~1
neurotmetic~1
clipping,~1
"wake-up~1
persuade~2
Diethylstilbestrol~1
CEF~2
epidoxorubicin,~2
DES-CEF~5
DES,~1
(24.1%~1
16.1%),~1
27.3%;~1
(35.7%~1
11.1%;~1
(239~1
.041)~1
CEF.~1
myelotoxic,~1
43.3%~1
polychemotherapy.~1
79-C-111,~1
lumpectomy/radiation~1
(Adriamycin~1
[Mead~1
IN]~1
[5-FU]).~1
"adjustment,"~1
fatigue/depression~1
[E:T]~1
[t~1
1.87,~1
.05]).~1
fatigue/depression,~1
CNS-mediated~1
Amsacrine~2
(HiDAc),~1
HiDAc.~2
HiDAc~1
remissions;~1
Intuitively,~1
WBC/microL,~1
Lymphoblast~1
abnormality--t(5;14),~1
(q?,q32)--which~1
G-banding.~1
t(5,14),~1
(q?,q32).~1
historical-control~1
Nonhematological~1
h/mL),~2
(405~5
mL/min/m2).~1
(HLA)-matched~1
centers)~1
hematosarcoma~1
3-pan-T~1
(CD2~2
"D66";~1
"A50";~1
"I21")~1
0.56/kg~1
(fractionated~1
[TBI],~1
significant);~1
(high-risk~1
(provided~2
immunodepletion~3
polychronotopic~2
(Ta~2
T1),~2
(Tis),~1
nonmaintenance~2
six-weekly~1
patient-month~3
(46.8%).~1
.095).~1
MTX/5-FU~1
Carboplatin,~1
4-consecutive~1
mg/m2/wk~1
mg/m2/wk.~2
Disease-specific~1
(PR);~2
pineoblastoma,~1
germinoma,~1
(CR);~1
Carboplatin~1
49,000)~1
chemotherapy-sensitive~1
[99mTc]DTPA~22
one-pool~1
Closest~1
(s.e.e.~4
([99mTc]DTPA)~1
(AMAD)~1
radioaerosols~1
DTPA.~3
[99mTc]diethylenethiaminepentaacetic~1
[131I]orthoiodohippurate~1
Radiopharmaceutical~1
hyperaluminemia~2
hopefully,~2
them?~1
Metallothionein~1
copper-binding~1
copper-loaded~1
copper-MT,~1
sedimentation.~2
(76-82%),~1
(9-12%),~1
(5-7%),~1
(3-4%).~1
quadrangular~1
arena,~1
(12,~3
cadaver)~1
transplants)~4
-2.~1
+1.4~1
-2.1;~1
+2.2~1
cm/yr).~5
cm/yr)~2
stopped:~1
tyrosinemia~3
succinylacetoacetate~1
(SAA),~1
succinylacetone~1
(SA),~2
tyrosyl~4
5-aminolevulinate~2
(ALA).~1
(ALA-D)~1
ALA,~1
ALA-D~1
tyrosinemia.~2
Puberty~2
g/m2),~1
euglycemic-hyperinsulinemic~1
-0.49,~2
-0.57,~1
C/insulinlike~1
-0.45,~1
(eyelids,~1
armpits).~1
Fluorescent~1
(FANA)~2
grainy~1
"limited~1
sclerosis,"~1
involved:~1
"intermediate~1
Minipigs~1
nonburned~1
(MR);~1
(SR);~1
(RR).~2
(CI%).~1
CI%~1
(E)--skin~1
(G)--less~1
(F)--greater~1
(P)--skin~1
(Woodroof)~1
purulence,~1
take,~2
allograft-~1
Biobrane-covered~1
allograft.~6
autografting.~1
allografting~5
1,057~1
Galveston~1
2.7%.~1
(TBSA).~1
unwounded~1
Braided~1
Nonabsorbable~1
vesicourethropexy~1
Cured~1
Transrectal~6
ureteropyeloplasties~1
diverticulum,~3
micrograms/kg/hr~1
gas/liquid~1
hypoxic,~1
(EDs)~1
EDs,~1
arterial-ecchymotic~1
"bruisability,"~1
fingers),~1
friability.~1
buttressed~1
(patency~3
revision).~1
revision)~1
entrapment)~1
anti-desmin~1
(early),~1
(late).~1
VIII.~10
re-endothelialization.~1
Renin-angiotensin~1
MK422,~1
education-motivation-skill~1
tracing/notification~1
monogamous~1
relationships)~1
condom.~1
unsterile~1
concerted,~1
vigorous,~2
Investigational~2
1--discontinue~1
alcohol;~1
2--discontinue~1
3--continue~1
lb);~1
seeming~2
unification.~1
swell.~1
(EMT)~1
(AEDs)~2
(AUTO~1
AED.~1
AUTO~2
admitted,~2
discharged)~2
non-VF~3
shock:~1
AED,~3
standard).~1
pathophysiologies~1
bedside,~2
Wisconsin's~2
PPS.~2
solid-organ~1
collate~1
(MoAb~3
Tac)~1
(1.5-fold,~1
(2.5-fold,~1
(MoAbs~1
E11)~1
nonmetastasizing~2
(P-value~1
T-cell-to-monocyte~1
MAC16~1
NMRI~2
(intestinal~1
uranium-mediated~1
Uranyl~1
(UA,~1
UA-induced~1
sulfate-proteoglycan~2
chondroitinase-ABC~2
Decapsulated~1
(EAC)~1
EACs~1
cells--CR1~1
surgical-induced~1
KCl/kg/hr)~1
Preinfusion~1
Pre-infusion~1
'early'~1
anti-C4~1
anti-C4A~1
anti-C4B,~1
Pheochromocytoma,~1
Intracaval~1
venacavography.~1
(CTX)~4
CTX~6
cis-diamminodichloroplatinum~1
400,000/mm3,~1
91/min.~1
dartos~1
jaw.~2
subdivided,~1
(N-butyl-cyanoacrylate~1
3-0~1
(pounds)~4
7.93~1
6.78~1
provocations.~1
non-narcotic,~1
Neuroablative~1
deafferentiation~1
plexopathy)~1
Deafferentiation~1
afflictions,~1
Non-narcotic,~1
proffers~1
Constipation~1
Opioids~2
regarding:~1
opioids;~3
opioid-tolerant~1
nonopioid~1
(dl-alpha-tocopherol~1
210),~2
(8.8%~1
34.3%;~1
(10.8%~1
40.7%;~1
(10.7%~1
32.6%;~1
herpes-virus~1
marrow-graft~1
II-IV~1
decade;~3
seronegativity~2
(EBV;~1
10.1;~1
(HSV;~1
EBV-seronegativity~1
10172~4
anti-factor-Xa~2
subcutaneously;~1
I125-fibrinogen~1
(28.0%)~1
proximal-vein~1
(cyclosporin~1
acute-on-chronic~1
group-B~2
27-31~1
Group-B~1
(10(6)~1
38%;~2
rhabdomyosarcoma)~1
5-wk~1
lunging~1
trotting~1
pen.~1
(29.1%,~1
(-24.5%,~1
re-absorption~1
(FRU),~1
sweetened~3
(CON).~1
(CON~3
92.7~1
FRU~4
90.6~1
12.4,~1
92.8~1
11.3,~2
pre-drink~1
CON.~1
93.4~1
118.8~1
trials.(ABSTRACT~1
high-lighted~1
imitates.~1
basal-cell~3
skeletal--specifically,~1
rib--abnormalities.~1
lesser-known~1
milia,~1
chalazia,~1
comedones,~1
rhabdomyoma,~1
antiprostaglandins).~1
disorder--as~1
abnormality--lies~1
Prime~1
Fab'-horseradish~1
maleimide~1
Ishikawa~1
I-band~2
A-bands~1
Myonuclei~1
intermyofibrillar~3
capnograph~2
acetylcholine-receptor~2
creatinine),~1
(respiratory~1
difficulty),~1
(stopping~1
failures).~2
sevenfold,~1
magazines,~2
newspapers.~1
steadily,~2
"tar"~1
pack.~1
'small~1
particles',~1
snRNPs.~1
snRNPs~1
'spliceosome',~1
multi-component~1
coevolution~1
abundances~1
Fibrillar~1
(A4)~1
4,500.~1
(Down's~1
Order~2
c-Ha-ras-1~1
Egeland~1
gene-HRAS1~1
gal,~1
ara~1
deo~2
catabolizing~1
deoP2~1
low-pH~2
insulin-secreting~5
condensing~5
ATPases~1
(recA~1
Ustilago~1
(rec~1
(uvsX~1
helix-destabilizing~1
uvsX-protein-catalysed~1
synapsis,~1
(single-strand~1
recA-protein-mediated~1
melt~1
dda~2
template-bound~1
uvsX~2
bacteriophage-infected~1
(Syva~1
Microtrak)~1
249,~1
Microtrak~2
9.2),~1
22.4%).~1
labor).~1
93,~2
Interpreting~1
problematic;~1
underestimating~3
Intrapair~1
unamplified~1
fetoscope~1
fetoscope,~1
quickening,~1
17-22~1
heard,~2
Parity~1
quickening~1
Sonar~1
non-SGA~1
ultrasound-derived~1
15-28~1
Constructed~1
Shepard-Warsof~1
multimode~2
untractable~1
luxated~2
lens-induced~1
Keratinization~1
Dacron-reinforced~1
disk-replacement~2
pemphigoides~1
immunopathologically.~1
pemphigoides.~1
Perilesional~1
Heretofore~1
bone--but~1
root--in~1
prehistoric~3
macroscopic,~1
Methodological~2
drives,~1
P-ergic,~1
endorphinergic~1
nociceptor.~1
(BK,~1
10(-9)-9~1
34-43~1
4.2.~1
'heat~1
sensitization'~1
(616~1
calor~1
'pain~1
receptors,'~1
Streptozyme~3
antistreptolysin~2
antideoxyribonuclease~2
Lot-to-lot~1
1,500/microL)~1
metamyelocyte,~1
treated)~1
treated).~1
(1/97~1
3/99~1
treated),~2
tocopherol-treated~1
(8/121~1
16/111~1
(14/42,~1
(4/43,~1
Digilab~1
pneumotonometer),~1
suctioning,~4
[mean]~1
Suctioning~2
Hg);~3
suctioning),~1
paralysis.(ABSTRACT~1
arrange~2
requires.~1
Ineffective~1
interventions;~1
insulting~1
under-taken~1
Failing~1
azidothymidine.~1
5'-3'~1
3'-3'~1
episomally~1
42-nm~1
discoideum,~1
cAMP-pulsed~2
regulation:~1
endogenous,~1
polymerizes~1
Revertant~1
5.3-7.1~1
7.5-kDa~1
D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2~1
(RC-160)~1
[6-D-tryptophan]luteinizing~1
D-Trp6]LH-RH)~1
Microcapsules~1
RC-160,~2
micrograms/day,~1
[D-Trp6]LH-RH.~1
RC-160.~1
Glucocerebrosidase~1
anti-glucocerebrosidase~1
glucocerebrosidase.~1
(PK-P)~1
bakers'~1
shows,~3
35,000).~1
autophosphorylated.~1
equivalents),~1
Gi~13
Go~11
phosphoenolpyruvate:glycose~2
(PTS)~2
PTS~1
II-BGlc,~2
D-glucopyranosides;~1
[Erni,~1
Trachsel,~1
Postma,~1
Rosenbusch,~1
13726-13730].~1
ptsG~2
mutants:~2
alpha-D-glucoside,~1
non-PTS~1
alpha-glucoside.~1
II-BGlc~2
transcription/translation~1
HT-1080,~1
-Gly-Xaa-Yaa-~4
2(IV)~1
HT-1080~3
62,000,~2
lutropin-releasing~6
hF-GRP.~1
(H-Thr-Asp-Thr-Ser-His-His-Asp-Gln-Asp-His-Pro-Thr-Phe-Asn-OH)~1
follitropin~3
1.2-1.6~1
1.5-kilobase-pair~1
lysostaphin~2
simulans~3
preproenzyme~2
prolysostaphin~1
proenzyme~4
39-base-pair~1
simulans,~1
[L-serine~1
(adding~1
indoleglycerol-phosphate),~1
4.2.1.20],~1
renaturation,~1
refolding~5
refold~3
anti-native-beta~2
colicin~3
colicinogenic~1
bilayers)~1
(Ala----Asp-492,~1
Phe----Pro-493)~1
current-relaxation~1
ill-defined.~1
140,000-dalton~1
RPB2,~1
RPB2~1
138,750~1
polymerases.~2
papillomavirus-1~1
collagen-beta-galactosidase-encoding~1
pJG200~1
I-cleavage~1
AATTGGCGGNNCG,~1
symmetry--ATCGGTG/CACCGAT.~1
subtilisin~8
BPN',~1
kcal/mol~2
cal~1
8.6)].~1
13C)~2
1H-15N~2
isotope-directed~3
15N-bonded~1
sidechains~1
15N-labeled~2
proton-deuterium~1
phenyl[15N]alanine-labeled~1
Phe-66~1
Phe-67.~1
Colony-stimulating~1
J774.2~1
homopolymer,~1
Casein~1
[Manley,~1
Levine,~1
1-2].~1
Homeobox-containing~1
C17S1~1
1003)~1
PCC7.S~1
PSA-1~1
Nonchemical~1
IgH~10
gamma/mu~1
5'::5'~1
PHO5~8
promoter:~1
"TATA"~2
phosphate-controlled~1
(UASpS).~1
UASpS~1
PHO11~1
UASp~1
(RRYRR)~1
pyrimidine)~1
55-110~1
"initiation~1
window"~1
machineries~1
Temperature-sensitive~1
trpE/v-abl~1
phosphotyrosine.~2
v-abl-encoded~1
v-abl-mediated~1
HLA-heterozygous,~1
721,~1
Ka,~1
HLA-B5~1
HLA-C.~1
HLA-A1;~1
HLA-A1,B8;~1
HLA-A2,C;~1
falciparum-derived~1
Pf155~4
C-terminally~2
Val-Glu-His-Asp-Ala-Glu-Glu-Asn,~1
(Glu-Glu-Asn-Val-Glu-His-Asp-Ala).~1
reinvasion~1
Pf155,~1
anti-merozoite~1
(HIVSF2)~1
[formerly~1
syndrome-associated~1
(ARV-2)].~1
env,~1
orf-A~1
orf-B~2
HIVSF2~1
(SNRC)~1
SNRC~1
overworking~1
pharyngoplasty~2
pharyngoplasty.~1
nasendoscopic~1
(variable~1
closure),~1
hyponasal~1
"bucket~1
handle"~1
sensibility.~1
neurofilament-positive~1
Strickland~1
"excellent";~1
"good";~1
"fair";~1
"poor".~1
inks~3
erasure~1
all-purpose~1
concealed,~1
extramucosal~1
In-111~5
pericholangitis-primary~1
HLA-identical,~1
lymphocele,~1
renograms,~1
echograms,~1
cystograms,~1
nephrostograms,~1
semiselective~1
Orthotopic~5
independent).~1
nonkidney~1
pancreaticocystostomy.~1
Directed~2
Immunosuppression,~1
regionalization,~1
craniocerebral,~1
stop-type~1
(reflux)~2
shunt-type~2
physiologic)~2
deferential~1
High-resolution,~1
noncompressible~2
49),~1
(2-mm),~1
appendectomies,~1
(PCOD).~2
PCOD~14
(roundness~1
Bilaterally~1
globular-shaped~1
(0.5-0.8~1
(1.5-2.9~1
(low-resistance)~1
pericallosal,~1
callosomarginal,~1
non-pulse-gated,~1
nondirected~1
extra-CNS~5
fetuses).~1
atrophy),~1
epididymitis).~1
epididymis.~2
outer-membrane~2
lipooligosaccharide,~3
fimbriated,~1
structures;~2
parasitemia,~4
(PAHO)~1
Brasilia,~1
Bolivia,~1
PAHO,~1
hepatology,~1
nephrology.~1
Development.~1
vaccinate,~1
herd~1
world:~1
emphasized:~1
Cross-protection~1
0111.~1
cross-protective~1
respiratory-assist~1
"hotel~1
services"~1
air-ventilating~1
Granulocytopenic~1
Conan~1
Doyle~1
creation,~1
Sherlock~2
Holmes,~1
Doyle's~1
fiction~1
nineteenth~3
Adventure~1
Dying~1
Detective,"~1
Holmes~1
Asiatic~1
1885,~1
(EPEC),~1
(ETEC),~1
(EIEC),~1
(EHEC).~1
ETEC~5
enterotoxins.~1
70-megadalton~1
owe~1
Shiga-like~4
recreational,~1
nonenteric~1
conjunctivae,~1
pestis~1
pestis.~2
70-kilobase~1
bacteriologists~1
invasiveness.~1
non-American~1
siderophore~1
Virulence~1
pYV~1
thiolester~4
nucleophiles,~1
understand,~1
encystation~3
encystation.~1
anticyst~1
antisporozoite~1
RAS1~1
RAS2.~1
CDC25,~1
well-ordered,~1
"genetics"~1
(BPTI)~1
BPTI~3
alanines~1
threonines~1
refolded~1
BPTI.~1
ribavirin.~5
Tn916~3
pAM120,~1
Tn916,~1
Acholeplasma~1
laidlawii~1
pulmonis.~1
excision-insertion~1
12-kilodalton~1
124-amino~1
Catalytic~1
poly(rA)~1
oligo(dT)~1
(strand)~1
(GnRH).~1
SH,~1
polyadenylated,~1
single-beam~1
traps.~1
milliwatts~1
milliwatts.~1
(tRNAs),~1
synthetases.~2
alaS~1
alanine-specific~1
synthetase-tRNA~1
post-trauma,~1
stones--1,~1
collection--were~1
Polybutester~2
nylon.~1
polybutester~2
Baystate~1
not).~1
Site,~1
carcinoma--the~1
infiltrating,~1
Inguinal~1
noninfiltrating,~1
supervoltage~1
residuum~2
enterotomy~1
One-stage~1
axillofemoral-femoral~1
femoral-anterior~1
caval,~1
homografting~1
(rw~2
0.92);~1
CjI~3
0.87),~2
output-septic~1
(CI~4
CjI,~1
PcjO2.~1
rhinorrhoea.~2
Rhinitic~1
rhinorrhoea~2
rhinitic~1
non-rhinitic~1
budesonide~6
pressurised~1
inhaler;~1
(budesonide~1
tetracosactrin~1
anti-N,~1
-Jka,~1
-E-like,~1
-Kell-like,~1
-M,~1
-Leb,~1
-Hl,~1
-H~1
-A1.~1
irradation.~1
zero-haplotype-matched~1
matches;~1
Imuran~1
DST,~1
merits,~1
DST-~1
Cs-treated~1
one-haplotype-matched~1
(Tc/s~1
MHC/antigen~1
readily;~1
cross-match.~1
procurement,~1
buying~1
selling~1
deplored~1
AG-CDC~9
C-CDC~4
DST-sensitized~2
sensitized),~1
functioned.~1
rejections.~2
rejections;~1
donor/recipient~3
1-haplotype~2
2-haplotype~1
disparate.~1
Presensitization,~1
Amos~1
nonpresensitized~1
(567~1
nu~3
(4120~1
h/mL~1
3370~1
nonfunction~3
ATN,~2
-positive~1
antigenemic~1
HBsAg-negative.~1
Nephrogenic~1
urethropexy~1
tied,~1
urethroscope~2
midurethra~1
Anejaculation~1
electro-ejaculation,~1
Ejaculatory~1
"success"~1
colic.~1
Unraveling~1
many.~1
(RDW).~1
preleukemia,~1
Q-T~5
(rate-dependent),~1
(adrenergic-dependent),~1
Q-U~1
(regarding~1
gradient),~1
desynchronized~2
(NRH)~1
NRH~5
myelo-~1
Scintigraphy,~1
NRH.~1
2-cm),~1
nonopacified~1
([peak~1
shift--lowest~1
shift]/[peak~1
shift]),~1
eccentric.~1
thickened.~1
(4/13)~1
(6/17)~1
(2,386~1
1,568~1
2,083~1
1,462~1
presentations--effusion,~1
constriction--occur~1
grave.~2
14,355~1
(pooled~1
SK.~3
[EF]~1
0.003).(ABSTRACT~1
parallel-design~1
(-11.4~1
-12.1~1
Hydrochlorothiazide~3
(-19.5~1
bendrofluazide.~2
double-dummy,~1
172/103~1
147/87~1
179/104~1
165/95~1
bendrofluazide;~1
bendrofluazide~1
dyssynergy.~1
summated~2
rectangular.~1
0.74)~2
mechanoreceptors,~1
cardiography.~1
(idiopathic~2
(215~3
(diameters~1
low-glycemic~2
Additions~1
palatability~3
60-288%.~1
insulinogenic~5
starch-rich~1
isoglucido-lipido-protidic~1
carbohydrate;~1
(475~2
lentils,~5
spaghetti,~1
0.12-92~1
insulinemic~2
0.903;~1
discriminating,~1
iso-glucido-lipido-protidic~1
Insulinemic~1
diabetics:~1
noninsulin~2
corticotrophin-releasing~1
Immunopositivity~1
hypothalami,~3
gangliocytomas,~2
Adrenocorticotrophic~1
CRH-containing~1
stomach/duodenum/appendix,~1
lung/gut.~1
peptide-hormone-producing~1
Isolator~3
Roche~1
Septi-Chek~3
5,262~1
Isolator,~2
Septi-Chek.~1
technic,~3
(ATTs)~1
(thyroglobulin--TG;~1
calcitonin--CT),~1
(desmin;~1
alpha-1-antichymotrypsin--ACT;~1
vimentin)~1
ATTs~2
"sarcomatous").~1
thyroids.~1
Clorox~1
Origin,~1
thyroperoxidase,~1
Spitz~6
unreactive.~1
(hyperplasia,~1
endocrinopathy)~1
anti-nDNA~3
luciliae.~1
kinetoplasts~1
kinetoplasts.~1
phenotyping.~2
(1,338~1
determinations/669~1
"pretransport"~1
(6.7%).~2
Interinstitutional~1
T-antigens~1
(Leu-1-7,9)~1
B-antigens~1
lambda;~1
L14;~1
[CALLA];~1
Ia).~1
B-antigens:~1
CALLA/J5~1
disagreements)~1
disagreements,~2
Leu-5~2
[three~1
disagreements]).~1
avidity,~1
immunotype~3
93%),~1
(MICs90):~1
microgram/mL;~6
1.6/30~1
(Marion~1
Swabs~1
Non-Group~1
urease,~1
(CLOtest)~1
CLOtest~2
CLOtest:~1
rebiopsied~1
subcitrate.~1
lentils~2
entroglucagon,~1
Processing~2
"sludge~1
balls."~1
suprasaturated~1
C9-MA)~1
(IEM)~1
membrano-proliferative~1
(TBMs)~1
IEM~1
Poly~5
C9-MA~3
TBMs,~2
deposited.~1
(DDs)~1
DDs~1
mesangium.(ABSTRACT~1
trisodium~1
Dialysis-associated~1
889~1
.0003)~1
white).~1
patients--pain,~1
diphosphonates~1
(bisphosphonates),~1
variably;~1
insulin-initiation~1
(Lente~1
"rapid"~5
Lente~1
"rapid/intravenous"~1
insulin).~2
sharply;~1
pseudoachalasisa~1
pseudoachalasia~6
Pseudoachalasia~1
pseudoachalasia.~1
esophagogastroscopy~1
imperfectly~1
six-drug~1
(Adriamycin),~2
dacarbazine~2
(ABV/ADV).~1
ABV/ADV.~1
Well-known~1
anuloaortic~1
abnormalities--both~1
abnormalities--are~1
Contradictory~1
frailty~1
double-blinding,~1
(meta-analyses)~1
virologic,~2
Complex.~2
gastroschisis.~2
gastroschisis;~1
gastroschisis,~1
induction-to-delivery~1
Streeter's~1
1920.~1
0.981;~1
6315~1
overwhelming,~1
leukocyte,~1
(error~1
"training~1
set"~1
11.0%.~1
"customized"~1
19-month~2
(41.7%)~1
stain-negative~1
66.7%.~1
1:270~3
opt~2
alpha-fetoprotein/Down~1
"three-contrasts~1
myomas~1
atresias~1
Peptostreptococci~1
Peptococci.~1
Clostridia~1
disiens.~1
gynecology.~1
extended-spectrum~2
metronidazole-gentamicin~4
aerobes).~1
black-pigmented~1
disiens,~1
anaerobius,~1
asaccharolyticus,~1
34;~3
metronidazole-gentamicin.~1
antichlamydial~1
postabortion~1
endomyometritis~4
misdirecting~1
drift)~2
invasive)~1
Gender~2
amniocentesis,~7
92.7%.~1
runners)~1
hormone).~1
"stress-induced"~1
"psychogenic"~1
gm/hr,~1
210.0~1
micrograms/hr~1
hydrochloride-treated~1
6.60~1
Type-specific~1
alobar~1
hypotelorism,~1
(7851~1
tests)~2
syncytiotrophoblast,~1
explant.~1
Gonadotropin-releasing~2
12.3-fold)~1
8.9-fold)~1
subtenon~3
A-scan~3
B-scan~3
echography~3
Echography~2
density;~1
unfrozen~2
BKS-1000~1
(Barraquer-Krumeich-Swinger)~1
graft/host~2
lathing~1
spectacles~2
9.37~1
14.50~1
diopters),~2
diopters).~1
11.00~1
8.50~3
PLAP.~1
PLAP~5
13-16-week~1
nonmucinous~1
membranous;~1
immunoanatomic~1
tissue-associated~1
S-100),~1
(cytokeratins,~1
BALB/cBy~5
(D3TX)~1
(D7TX)~1
(STX),~1
B6AF1,~2
SWRAF1,~2
D7TX~1
STX~1
Epididymovasitis~1
70-90%~1
D3TX;~1
SWRAF1~1
B6AF1~1
epididymovasitis~1
D7TX,~2
STX.~2
complex-like~1
Gastritis~2
Nishizuka~1
nonepidermotropic~1
immunoblasts,~1
Immunophenotypically,~1
monotypic~7
B-cell-associated~1
To15.~1
panepithelial~2
(45-kd)~1
mononucleated~3
(Leu-M3-,~1
CD4-),~1
(Leu-M3+,~1
CD4+/-).~1
(p21)~6
(G1A)~1
(G1B)~1
G1B~1
G1A~1
end;~1
Zymosan-activated~1
windows,~1
0.3-ml~1
(desmoplakins)~1
desmoplakins.~1
Cytokeratin-positive~1
Cytokeratin~1
desmoplakin-positive~1
nephroblastomas.~1
"rudimentary~1
junctions,"~2
"primitive~1
"desmosome-like~1
junctions")~1
(gasoline,~1
anti-basement~4
antibody-associated~1
unleaded~1
gasoline~5
(ABM)~1
ABM~3
instillations~4
anti-GBM/ABM~1
pneumotoxic~1
heroin-associated~1
(HAN)~1
HAN,~2
hypocellularity,~1
tubuloreticular~2
(NBs)~1
NBs~2
granulofibrillary~1
AAN.~1
periglomerular~1
(granulomatous~1
erythematosus).~1
tuft~1
(immunoglobulins~1
complement)~1
anti-tubular~1
anti-TBM~2
heteroantibodies~4
nephritogenicity~1
adjacently~1
transference,~2
primacy~1
"corrective"~1
pre/post-treatment~1
[An~1
(expanded).]~1
(Asn-Ala-Asn-Pro)~1
(NANP)40,~1
(Kikwawila~1
village)~1
hyperendemic.~1
parasitological,~2
anti-(NANP)40~4
anti-sporozoite~1
smears;~1
asexual~4
genetic)~1
(NANP)40-ELISA~1
parasite's~1
chloroquine-susceptible~4
pKs~1
environment).~1
non-weak~2
Geneve/SGE-1~2
monkey-adapted~1
Bolivian~3
Saimiri,~1
schizonts.~1
6,725~1
2,953.~1
trophozoite~4
schizont~4
0.884,~1
stupor,~1
3,642~1
2,864~1
falciparum-endemic~1
vivax-infected~1
Saimiri~1
sciureus~2
Gambia,~1
Sudan,~1
EIgG~1
10%-15%,~1
blocking,~1
4-chloro-1-naphtol.~1
Pools~1
1:64,000.~1
dotting~1
parasitemia.~1
ABS)~1
wells.~3
Cross-evaluation~1
89.6%~1
concording~1
8.35%~1
ELISA+/IFA-~1
2.05%~1
ELISA-/IFA+.~1
ABS~2
species-specificity~1
plasmodial~1
antigenically.~1
GS-E,~2
gerbils,~1
WB-infected~2
GS-E-infected~3
GS-E~2
trabeculas~1
interesting.~1
osteoproductive~1
malpositioning~1
Jugular,~1
Ultrasonographically-assisted~1
Edoardo~1
Bassini,~1
professor~2
pioneered~1
1887~1
1894~1
Bassini's~1
illustrious~1
biographies,~1
Pernicious~2
Shouldice~5
amid~1
(drug,~2
tobacco)~1
elimination;~1
cimetidine),~2
Cambridge/King's~1
Witness~1
CS5~1
CB5.~1
(LG)~1
LG.~1
T-7~1
(48.96~1
6.64~1
LG,~2
44.74~1
meperidine;~1
(94.37~1
7.42~1
76.19~1
5.64~1
meperidine)~1
LG~2
(66.83~1
6.72~1
(46.66~1
6.26~1
(66.44~1
(42.67~1
wit~1
meperidine.(ABSTRACT~1
echocardiology~1
Tl~1
Nonimaging~1
encoded,~1
pentoxifylline--a~1
platelets--followed~1
pmol/10(8)~1
platelets.(ABSTRACT~1
B.C.E.~2
ritualistic,~1
punitive,~1
Fitting~1
Anesthetics~1
opium,~1
soporifics~1
peyote~1
knives,~2
axes,~1
saws.~1
ligature,~1
cautery,~1
bandaging~2
Suture~2
acacia~1
thorns,~1
sinew,~1
Prostheses~2
wood,~1
rags.~1
Dopplers~3
thermography,~1
claudication)~1
(placebo).~2
(maldistribution).~1
flow-promoting~3
OILD~3
constantly.~1
isocyanates,~1
OILD.~1
succeed,~1
triage-oriented~2
3,581~1
(LT)C4,~1
15.0%,~1
cells/min~4
Alpha-(methylamino)~1
isobutyric~1
insulin-modulated~1
(CTH),~1
(Qsp/Qt),~1
(PEEP),~2
(Tvent),~1
FlO2~4
(TO2)~1
CTH~2
-0.55,~1
TO2~1
trypsinlike~1
99mTcDTPA~6
endotoxins.~2
SC-positive~1
Tonofilaments~1
tonofilaments,~1
insomnia/somnolence,~1
84.~1
nephroblastoma.~2
(5.3-8.5)~1
5.69~1
(4.6-7.2)~1
(3.3-6.3)~1
3.17~1
(2.0-4.3)~1
fish-oil~5
eicosapaentanic~1
docosahexenoic~1
MAX-EPA~1
(R.P.~1
Scherer,~1
Clearwater,~1
Florida),~1
placebos.~2
311.0~1
-6.0~1
-1.0).~1
r=0.53;~1
non-referral~1
glycoside~3
-11%~1
Digitalization~1
Scotia.~1
TWAR~5
(2133~1
bled,~1
bled)~1
surface-binding~1
transcriptase).~1
Insomnia,~1
psychosocially~2
insomnia;~1
sleepwalking~1
terrors~1
substrate),~1
Psychopathologic~1
enuresis,~3
sleepwalking,~1
terrors,~1
Psychotherapy~1
osteomas.~1
osteoma.~1
pentadecylcatechol~1
(PDC)~2
heptadecylcatechol~1
(HDC)~2
oak.~1
PDC-HDC~2
hyposensitivity~1
urushiol,~1
oak~1
epithelia-type~1
Russell.~1
paediatric/psychiatric~1
insisted~1
overdiagnosis.~1
(Flexical)~1
Flexical~1
sulphasalazine.~1
Lloyd-Still~1
non-contingent~2
enuresis.~2
dipstrip~1
nonfeeding~1
(IRG).~1
nonfeeder.~1
(SASI~1
(aerobic~1
anaerobic),~1
(80.9%)~1
(12.8%)~1
(67.4%),~1
six-center~1
polytrauma,~1
(Travasol)~1
equimolar,~1
(Travasol~1
Branchamin~1
concentrate)~1
1.0-2.0~1
caloric)~1
0.05-0.4~1
nitrogen;~1
1952-1982.~1
40,350~1
(LRD)~3
haploidentical)~1
(IFA).~2
3-51~1
seropositive),~1
LRD~11
pairing.~1
Mucocele~1
Duncan-Harley~1
subempyema-forming~1
75-mg~2
Aerosolization,~1
undiagnosed.~2
1936,~1
Alfred~1
prophesized~1
1941,~1
Blalock's~1
salmonellosis.~2
yeast-phase~1
"RES~1
blockade,"~1
201/technetium~1
1-selectivity,~1
(34.8%)~1
coronary-care~1
magnesium-treated~1
antiobsessional~1
troubling~2
nonmelancholic~1
(benzedrine),~1
pemoline)~1
psychostimulants,~1
cytomembranous~1
(TRI)~1
(CCC).~1
CLinical~1
TRI~1
(interferons~1
TRI,~2
discordances~1
variety;~1
vasculitides.~3
angiitis,~2
collagen-vascular~1
2750~2
Pathologists.~1
ungraded~1
Cytologically,~1
benign;~1
(available~1
columnar,~1
focally,~3
(myoepithelial)~1
fibromatous~3
mesoblastic~3
nephroma~3
extraperitoneal,~1
pancreaticocystostomy~2
refinements,~1
mutism~2
leukoencephalopathy,~2
18-fluorodeoxyglucose/positron~1
"cerebral~1
congestion"~1
1761,~1
(Dechambre,~1
1838),~1
etat~1
crible~1
(Durand-Fardel,~1
1842),~1
maniac~1
outbursts,~1
Hammond~1
(1871,~1
1878),~1
common...than~1
oblivion~1
(Riva-Rocci,~1
1896;~1
Korotkov,~1
1905)~1
Titanium~1
infiltration),~1
lymphocyte),~1
grade:Leu-2a~1
67-96%~1
trisalicylate,~1
(CMT),~1
(CMT-N),~1
(cmt-n)~1
CMT-N~5
cmt-n~3
dose-adjustment~1
CMT,~2
(7.5%~1
CMT-N)~1
CMT-N,~1
cmt-n,~1
T3+,~4
autoantibody-independent,~1
Indiana/Swiss~1
antiprealbumin~1
methrotrexate~1
nauseated~1
viscerotoxic~2
non-predicted~1
anaesthesia--Seturner~1
1806.~1
craft~1
Ignorance~1
Idiosyncrasy~1
1.9-5~1
(glucose-free)~1
post-spinal~2
(hyperbaric)~1
C1-T4),~1
(plain)~1
C1-T4).~1
de-epidermized~1
(DLE)~1
(DLE-like~1
LP-like).~1
DLE~4
DLE-like~1
DLE.~1
gradings,~1
pityrosporon~1
symphysis-fundal~1
light-for-gestational~1
2771~1
32nd~2
37th~1
Light-for-gestational~1
withheld).~1
Birthweights~1
(viewed~1
unborn~1
birthweight-for-gestational~1
3888~1
'true'~2
223.~1
Acyclovir~7
disciform~1
antivirals~1
antivirals,~1
(KCS)~1
(BJ6~1
hypromellose)~1
stickiness~1
BJ6~1
hypromellose~1
Hypo-osmolarity~1
KCS.~1
ivermectin,~1
microfilaricide,~1
(OCP)~1
Ghana.~1
eight-day~1
DEC,~2
blood-aqueous~2
macrocyclic~1
microfilaricide~1
postgraft.~2
chremophor~1
EL/ethanol)~1
steroid-containing~1
chremophor/ethanol~1
(VP16-213)~1
regimen-related~1
(GpIIb)~1
GpIIIa~7
GpIIb~8
GpIIIa,~3
GpIIb,~1
92,000-Mr~2
GpIIIa.~1
copperhead~1
(beta-fibrin)~1
self-aggregation~1
beta-fibrin)~1
(FPB)~1
beta-fibrin~9
dysfibrinogenemic~1
FPA.~1
(350~4
(thrombin~2
"coarse"~1
"fine"~1
(fiber~1
beta-fibrin,~2
twisting~1
1,100-rad~1
FDC-P1,~1
3)-responsive~1
(CSAs)~1
megakaryocyte,~1
CSAs.~1
Stromal-derived~1
anti-GM-CSF~1
CSAs~1
Va.~3
150-K~1
Bioassay~2
procofactor~2
cofactor,~1
prothrombinase~1
(CSF-1,~1
M-CSF)~1
GM-CSF-treated~1
HLA-compatible~1
(TXA2).~1
hesitancy~1
gonadotrophin,~2
marker(s)~1
peri-acinar~1
glycodeoxycholate~2
(GDOC)~1
enterokinase~3
trypsinogens.~1
GDOC~1
enterokinase.~1
bile-borne~1
investigated--Group~1
(n=10)~1
(UBS)~1
UBS~1
UBS.~1
(STAG)~1
STAG~1
procedure-excision~1
STAG.~1
'old'~1
garments,~1
non-aesthetic~1
'conservative~1
period',~1
'fibroblast',~1
'good~1
tissue',~1
1:1.5~1
electricity,~1
gratifying.~1
coagulated~2
herpeticum~1
(56)~1
(digestion)~1
rubbing~2
inciteful~1
allergens;~1
Constitutional~2
B-symptoms)~1
macrophage-histiocytes.~1
B-symptoms).~1
Anti-IL-1~1
(R-S)~1
(18);~1
B-symptoms.~3
(27/33)~1
R-S~1
(14/18)~1
IL-1-bearing~1
Ki-67-positive~1
(MMTs)~1
MMTs~1
(IPX).~1
IPX~1
(k)~3
Carcinomatous~1
(V+)~1
proliferative-phase~1
discontinuities.~1
rhabdomyoblasts~1
Myofilaments~1
ganglioneurosarcoma~1
ectomesenchyme.~1
0.6-12~1
0.5-3.3~1
HCG-immunoreactive~1
(52%).~1
(0-11~1
12-23~1
post-succinylcholine~1
obtund~2
[beats/min/ng/kg]:~1
+2.26,~2
+1.59;~1
(slopes:~2
+0.94;~1
+2.24,~1
+2.27;~1
dose-adjusted,~1
57).~1
Aprindine~1
Holter-detected~1
aprindine-treated~2
(28/142;~1
VT/day~1
tolerating~1
VT/day,~4
(111In)-labeled~1
111In-lymphocytes.~1
(indium~1
(IE~1
hearts)~1
(postverapamil~1
3.(ABSTRACT~1
(Ccr)~1
glomerulosclerosis,~1
(Ualb/Ucreat~1
2.71)~1
0.72).~2
methylpredonisolone~1
predonisolone.~1
predonisolone,~1
mizoribine~1
Antivimentin~1
colchemid~1
James~2
"osteitis~1
deformans"~1
debilitating,~1
Anglo-Saxon~1
hyperphosphatasemia"~1
interpositioned~1
shade~1
Acetabular~1
hematogeneous~1
(oligopeptides~1
hydroxylysine,~1
hydroxylysine~3
glycosides)~1
(peptides~1
fibrosis).~2
acid-protein~1
pharmacologically,~1
phosphatase)~1
alpha-calcitonin~1
katacalcin,~2
(CGRP).~2
katacalcin~2
neuromodulator.~1
well).~1
Geminal~1
phosphorus-carbon-phosphorus~1
dissolution.~3
microcylindric~1
pagetic~11
(SV5),~1
(PF3).~1
calcitonins,~1
kinetic,~1
calcitonins~1
high-output~3
Caffey's~2
1960,~1
Repositioning~2
Retropharyngeal~2
grunting.~1
Sucking~1
incoordination~1
breastfeed.~2
idea.~1
Mitchell~1
"balance"~1
economies~1
breastfed~2
infants?~1
composition?~1
infections?~1
activity?~1
bottlefed~3
consequences?~1
vital.~1
"physiological~1
neutrality"~1
cooling/surgery/rewarming~1
anovulation,~1
Breastfeeding~1
feeding-related~3
as-yet~1
breastfeeds;~1
suckles,~1
breastfeeding-related~1
"feeding-related"~1
diminished.(ABSTRACT~1
(-)-isoprenaline-evoked~1
2-adrenoceptors,~1
2,3-dinor-derivatives,~1
ionization-GC/MS-validated~1
hours-1.~1
-5.9%~1
(N3TdR)~1
HLPC.~1
N3TdR~3
L/kg/hr.~2
E1-stimulated~1
alpha-chymotrypsin,~2
GTP-dependent~2
adrenaline-mediated~1
metaplasia)~1
Srigley,~1
Toth,~1
issue)~1
correct--namely,~1
lining--the~1
veered~1
monophyletic~1
(argentaffin~1
cells).(ABSTRACT~1
coverings.~1
variants/glioblastoma,~1
subependymoma,~1
(angioblastic~1
mengioma),~1
hemangioblastoma.~1
premelanosomes,~1
Nerve-sheath~1
lamina-like~1
aggressiveness.~1
sinuous~1
glycocalix,~1
"epithelial"~3
"poorly~2
differentiated"~2
desmoplastic/sarcomatoid~1
(MSC)~2
extremes,~1
unspecialized~1
mesothelial-derived~1
enterochromaffin-cell~1
microscopy--that~1
ones--may~2
Histology,~1
heterogenous,~1
taxonomy.~1
pathobiology,~1
he/she~2
"pro-drug"~1
bitolterol,~1
CPIF~1
nebulization.~1
(extravascular~1
ETV,~1
dye),~1
(radiomicrosphere~1
ETV~3
ETV;~1
ETV).~1
PAWP),~1
suffocated.~1
cine-fluoroscopic~1
CPAP.~5
lax,~1
43-83)~1
13-53)~1
43-94),~1
23-83).~1
transcelomic~1
antidesmosomal~1
adenocarcinomatous~1
betamethasone~7
echotomography~1
adenolymphoscintigraphy.~1
Echotomography~1
echotomographies~1
lymphoscintigraphies~1
201-Tl~1
colloid).~1
Rome~1
(GREPCO),~1
cholecystography.~1
(24.3%)~2
gallbladder).~1
Hematochezia~1
Accidental~1
Controversies~1
complexation,~1
intoxicants~1
cathartic~1
fellowships.~1
1.1%/h~1
monospecific,~2
(GR),~1
(paraformaldehyde,~1
bensochinone~1
PBS),~1
Rueber~1
(H-4-II-E)~1
(NHIK~1
3025)~1
core-nucleosome~1
tubulin),~1
anti-GR~1
(peroxidase~2
antiperoxidase)~1
H-4-II-E~1
35-K~1
35K~3
intrarenally~1
Escape~2
sodium-retaining~3
renin-angiotensin.~1
(vehicle-injected~1
5.7;~1
microIU/ml;~1
75.5~1
10(6);~3
receptors/glomerulus;~3
14.8%,~2
up-regulation,~1
105.5~1
(7-60~1
(SAM-DC)~1
piribedil~4
SAM-DC~11
metopirone.~1
(irCRF),~2
(irAVP),~1
(irOT)~1
(PHADX).~1
1560~1
2.2-fold,~1
irAVP~5
(1312~1
AVP-immunostained~1
post-PHADX,~1
irAVP,~1
AVP-immunopositive~1
costained~1
colocalization~1
irOT~3
irOT-positive~1
PHADX~1
immunocytochemistry)~1
adrenalectomy;~1
hypophysiotropic~4
angiotensinogen.~3
des-angiotensin~5
I-angiotensinogen.~3
I-angiotensinogen,~1
I-angiotensinogen~1
(I-ACTH)~1
(I-CRF)~1
I-CRF~8
82.7~1
concentration-activity~1
midpregnant~1
additive;~2
(IGF)/somatomedin~1
250,000,~1
separate.~1
IGF-degrading~1
(KG~4
tolerance)~1
nmol;~1
(250%~1
seco-steroid,~1
stimulatory,~2
alpha-Modified~1
Medium,~1
(Exp~4
(iLH)~1
(10(-11)-10(-8)~2
iLH~4
(3H-Gln)~2
(35S-Met)~2
3H-Gln~7
[3H]galactose,~1
[3H]mannose,~1
[3H]fucose,~1
(10(-11)-10(-9)~2
(3H-Gln~1
35S-Met).~1
35S-Met~8
3H-Gln-labeled~1
(278%)~1
(290%),~1
Gln~3
(280%)~1
GnRH).~1
(164%)~1
(186%)~1
(iLH),~1
(disintegrations~1
min/microgram~1
iLH)~1
(immunoreactive)~1
sham-castrated~1
(RCM-hGH),~1
RCM-hGH~3
3-O-[14C]methylglucose~1
RCM-hGH-induced~1
[125I]iodoinsulin~2
RCM-hGH-treated~2
(CLO)~1
(YOH,~1
(METHOX,~1
micrograms/rat,~2
anti-SS~1
(SS-ab,~1
anti-GHRH~3
(GHRH-ab,~1
SS-ab,~2
CLO~2
GHRH-ab~6
SS-ab~3
YOH~4
GH-lowering~2
METHOX~3
rat:~1
operative;~1
2-adrenoceptors.~1
GHRH~56
SS.~2
self-priming~5
LHRH-stimulated~14
(CSH)~1
somatostatin-14-like~1
(S-14~1
CSH~10
S-14-like~1
D-cells~2
ng/dish.~1
CSH-induced~1
Zamboni's~1
somatostatin-positive~1
CSH-treated~2
D-cells.~1
D-cell~2
CSH-exposed~1
particles/micron2)~1
particles/micron2).~1
immunocytochemically.~1
synergistic;~1
Lactogenic~1
PRL's~1
nontraining~2
km/cycle~1
km).~1
(C-NT)~1
intensity-graded~1
0.034)~1
(Do)~1
(Dov,~1
(TGP)~1
(TGP~1
Dov~2
Do).~1
Do,~1
TGP~2
2.77~3
cm/day,~1
10.32~1
14.61~1
sperm-agglutinating~1
immunobeads~2
buffer;~1
antibody-free~1
magnetite-complexed~1
(ASAP)~1
ASAP~2
(IHH)~2
(incomplete)~1
oligospermic,~2
10(6)/ml~2
nonmotile~1
IHH~11
perpetual~1
LH-RH,~2
well-diagnosed~1
IHH.~1
(medical)~1
rAFS~1
ovulation-induced~1
osmication~2
VIP-immunoreactive.~2
Perikarya~1
polypeptide-immunoreactive~1
plexuses.~1
Applied~2
6-wk,~1
diuresed~1
chemoradiation~1
passaging~1
multiplication,~1
microscopic-~1
microscopic-immunogold~1
progastrin,~1
Golgi;~1
(GRP)~2
pancreata.~1
GRP~6
27-amino~1
peptide-like~1
intrapancreatic~2
(postbinding~1
"molecular"~1
ispaghula~4
collection).~1
ispaghula.~1
ispaghula,~1
symptoms.(ABSTRACT~1
IgA1-proteases.~1
IgA1-protease~1
biscuits~2
fibre)~1
biscuit~2
Ulcers~2
(fat-storing~1
desmin-positive~4
auto-fluorescence.~1
A-positive~1
subculturing.~2
lipocytes~1
paravariceal~7
sclerotherapy)~1
propranolol),~1
well-covered~1
nonvariceal~4
small-for-size~1
(graft)~1
Mg2+-induced~2
80-mEq~1
systolic;~1
diastolic;~1
(p-aminohippurate~1
1108~1
[1-deamino,8-D-arginine]vasopression.~1
60-minutes~1
greatest.~1
Polycentric~1
384-month~1
AN69s.~1
9.85~1
months/pt~1
(384.15~1
hypercatabolism,~1
26.6%;~1
(ABS):~1
polycentric~3
7.23~1
post-dilutional~1
mmol/h),~1
post-BF~3
alkalosis)~1
Kotler's~1
won~1
prescriptive~1
40-mmHg~1
(LBPP),~1
(PEEP;~1
(CPBV)~1
CPBV~2
0.88;~2
(Qva/QT)~1
1008~1
1,008~1
794~1
LBPP.~1
Qva/QT.~1
baroreflex.~1
Isovolumetric~1
tracheae~1
(TMP).~1
TMP.~3
TMP~7
(Lmax)~1
Lmax.~1
TSM.~1
wheels~1
free-eating~1
(SFE)~1
(2-DOG)~1
runners'~1
2-DOG~2
oxidation)~1
SFE~2
("central~1
chemoreceptors")~1
indisputedly~1
(VMS).~1
VMS~4
chemosensitivity.~1
BME-33:~1
361-365,~1
isocapnia~3
"assisting"~1
(inspiratory~2
rising)~1
(P100)~1
(A2)],~1
P100).~1
35:~1
361-366,~1
Acta~1
Scand.~1
120:~1
557-565,~1
respiratory-mechanical~3
(23-27~1
(avg~1
one-for-one~1
(Qdi~1
QCMN,~1
QCMN~2
(L/PCMN)~1
(L/Pdi)~1
L/PCMN~1
L/Pdi.~1
goats.~1
intra-venous~1
purposes)~1
supra-renal~2
intra-aneurysmal~1
Intra-aneurysmal~1
Aneurysmal~1
(Praxilene)~1
Praxilene.~1
cytotrophoblasts~6
(Rd)~4
(IMGU),~1
noninsulin-mediated~1
(NIMGU),~1
insulin-insensitive~3
Rd~8
IMGU~5
NIMGU.~3
NIMGU~4
NIMGU,~1
micrograms/hr)~1
Rd,~1
mg/min;~3
(Rd~1
NIMGU)~1
IMGU.~1
IMGU,~1
NIMGU;~1
(SRIH;~2
micrograms/h~2
Cal/min,~1
(1.19~2
Cal/min;~2
8-step~1
[2.4~1
g/m2;~2
0.004]~1
0.32)~1
infusions;~1
(slope,~1
0-90~1
A14-[125I]insulin~1
radioactivity),~1
[2.65~1
1.21%~1
radioactivity;~2
A14-[125I]~1
A14-[125I]insulin,~1
[125I]iodide,~1
[125I]tyrosine,~1
[hPTH-(1-34)~1
[125I]hPTH-(1-34)~1
PTH-dependent~1
adenylate-cyclase~2
intraislet~1
powerlifters,~1
powerlifters~2
Powerlifters~1
postglucose~1
Postglucose~1
(prorenin)~2
A1c.~1
[10~1
endotrachial~1
stress-mediated~1
(catecholaminergic)~2
agromegalic~1
antagonist-mediated~1
metoclopramide-induced~1
metoclopramide-CRH~1
hyperaminoacidemia,~1
L-[4,5-3H]leucine~1
[1-14C]alpha-ketoisocaproate~1
Hyperinsulinemia~2
leucine-carbon)~1
nonoxidized~1
leucine-carbon~1
(leucine----protein).~1
mumol/liter),~1
leucine----protein~2
hyperaminoacidemia~1
anabolism~3
leucine----protein.~1
1-15),~1
N-formyl-met-leu-phe~1
characterized:~1
chymotrypsin-like,~1
trypsin-like,~1
FMLP-~1
function-inhibiting,~1
anti-PMN~1
glucocorticoid-dependent~2
100-120~2
acidosis-independent~1
(Jv)~1
ultrafiltrate-like~1
serum-like~1
Jv~3
Jv.~1
(Hansen's~1
Karimui.~1
multi-generational~1
non-immunologically~1
emanated~1
kin~1
(nonallergic),~1
rhinitic,~1
rhinitics~1
(PD20FEV1)~2
(Fim+)~2
nonfimbriated~1
(Fim-),~1
(Tox+)~1
(Tox-).~1
Fim+~2
Fim-~2
Tox+~2
is/are~1
its/their~1
Wise~2
jar~2
cabinets~1
jars~2
p62c/myc~2
Koilocytes~1
non-infected~4
koilocytes,~1
graded,~1
"wart~1
score,"~1
balding~4
0.01%,~1
nonvellus~16
self-evaluation~1
180.6~1
179.9~1
191.1~1
comb,~1
(Loniten)~1
target-area~1
291.2~1
553)~1
hairs).~1
hairs)~2
minoxidil;~1
12-month,~1
placebo-to-3%~2
switchover~1
indeterminate)~1
162.8~1
155.4~1
107.1~1
58.2~1
48.8,~1
0.013),~1
scalps~2
Hairs~1
vellus,~1
terminal;~1
nonvellus,~2
158.2~1
270.2~1
156.6~1
287.0~1
162.6~1
246.9~1
415.6,~1
448.5,~1
471.1~1
placebo-3%~1
181,~1
0.0018~1
0.0167~1
Within-group~1
self-limiting.~2
Upjohn-sponsored~1
extemporaneous~2
areata,~2
totalis,~1
universalis.~1
Excellent,~1
regrowth,~1
serviceability~1
mouthrinse~2
Overdentures~1
overdentures.~1
(microgram/kg~2
loading/maintenance~1
37.5/0.375~1
50/0.50~1
75/0.75~1
50/0.25~1
(+4~1
+13%)~1
(-2~2
-13%)~1
9%.(ABSTRACT~1
Rejectors.~1
Rejector~2
pyroninophilic~1
(eosinophils~1
testing).~2
Predictor~2
Others.~1
karyorrhexis~1
intermyocyte~2
41.4.~1
reparative,~1
anti-restenosis~1
Voacanga~1
africana~1
vinburnine,~1
Vinburnine~1
(Cervoxan)~1
anti-VA~1
Unexposed~1
ipratropium,~1
blowings~1
ordinary-dose~1
tenuis,~1
herbarum~1
Cladosporium.~1
Logit~1
molds.~1
mold-allergic~1
(BR).~1
budesonide)~1
UNDW-induced~1
multivitamins~2
folate)~1
nonpathological~1
dopamine-~1
postsynaptically.~1
Presynaptically,~1
Postsynaptically,~1
(man)~1
(rodents).~1
(3H)imipramine~1
(S-1~1
S-2)~1
lifespan.~1
(rarely~1
precocity~1
fetal-type~1
neuroblastoma-like~1
ominous.~1
Achieving~1
imagination~2
physics~1
Obstructing~2
$85,000)~1
priced~1
makers.~1
potassium-adenosine~1
mastocytoma~9
(HLA)-A2~1
(P815-A2+)~1
P815-A2+~1
Bruton's~1
antigen-1,~1
colchicine),~1
30-5-7S~2
30-5-7S,~3
D-end~1
B10.A----B10.BR~1
anti-Dd~2
anti-Ld,~1
anti-Ld~2
immunodominance~1
allocations~2
haploidentical~2
(SCID),~1
Unfractionated~1
non-chimeric~1
non-donor~1
puromycin.~2
binding-enhancing~1
CDw18~2
CDw18-dependent~1
tryptase,~1
tryptase~18
Carnoy's~1
fluid-fixed~1
anti-tryptase~2
faint,~1
tosyl-L-gly-pro-lys-p-nitroanilide~2
tryptase)~1
basophil-enriched~1
tryptase-like~1
basophil,~2
pg,~1
Murine,~1
2-m),~1
2-m.~3
2-ms~1
2-m,~3
2-m~14
(Bushkin,~1
J-S.~1
Pinter,~1
Michaelson,~1
Boyse.~1
83:432).~1
anti-HLA-A2,~1
A28~1
Q6/64~3
CR10-215~6
CR11-115~5
close)~2
bleedings.~2
CR11-351~2
Q5/13,~1
441.~1
anti-MAA~1
antigen-combining~1
cold-target~1
"ADCC-efficient"~1
"ADCC-inefficient"~1
(FcR)~4
(20.8.4),~1
2m~17
(anti-Hu~1
2m)~4
Hu~2
murine-Hu~1
kd;~1
carinii-infected~1
(IU)~1
organs),~1
IU/g~1
(MNP)~1
MNP~5
LCM-immune~2
descendants,~1
Pretreatments~1
(TT).~1
nonidentical.~1
(tryptase+,~2
chymase+)~1
chymase-)~1
U/10(6)~5
(suc-L-ala-ala-pro-phe-p-nitroanilide~1
tryptase/10(6)~1
microgram/10(6)~5
chymase.~1
Tryptase~1
microfluorometry~2
FMLP+~1
Elucidation~2
(Hh)~1
Hh-1b~3
H-2.~1
(ACCb)~1
BALB.B~1
(H-2d~1
H-2b)~1
ACCb,~1
anti-H-2~2
H-2d),~1
(H-2k~1
H-2b),~1
(BMC).~1
donor-derived~2
5-iodo(125I)-2'-deoxyuridine~1
(IUdR)~1
"hybrid~1
resistance".~1
Hh-1b)~2
competition"~1
ACCb~3
H-2d-,~1
Ld-Dd-,~1
Dd-,~1
H-2b-~1
Hh-1b,~1
trans-acting,~1
down-regulatory~2
Hh-1~1
nickel-induced~1
LTT)~1
(MIF)~1
LTT~3
(MMIT)~1
MMIT,~1
MMIT~1
(10(-8]]~1
(ETAF).~1
PAMM~1
212.~1
24-base~1
2.7-~1
1.6-kb~4
first-strand~2
COLO-16~1
bp-IL-1~1
2.7-kb~1
(UVA,~1
mid-wave~1
280-320~1
Allografted,~1
donor-strain~1
galactomannan~4
mannan,~1
mannans~1
inoculating~4
Diuresis,~1
germ-tube~1
concert)~1
ungerminated~1
50%);~1
advanced-spectrum~1
derepression~4
ceftazidime-treated~3
(AAM)~1
AAM~2
berberine~1
(ETEC)~1
restricted-activity~2
mentation~2
attitudes)~1
CFA-sensitized~1
Phosphorylated~1
transection/ligation,~1
perikarya,~3
(HDAra-C)~1
(AML).~3
Rationale~2
.010),~1
HDAra-C~1
(T101)~1
Radioimmunodetection~1
131I-T101~3
100.5~1
150.1~2
144.7~1
mCi,~2
145.0~1
Radioimmunodiagnostic~1
urinary,~1
wholebody~1
(HAMA)~1
CTX.~1
(arm~3
(MTX;~1
CTX,~1
limited-volume~1
(VMV-VAC)~1
64;~1
response-evaluable~1
4,800~1
VMV-VAC~1
CRs).~1
Eligibility~1
(75%;~1
enzyme-immunoassay~1
D547.~1
ER-/PR+~2
ER-/PR-~1
PR+.~1
electrocorticography~2
neurobiology~1
radiosurgery~1
reapplied,~1
stereotaxis.~2
regulatory,~1
uncontrolled.~1
supermarket~1
protein-adequate~1
self-selected,~1
compromised.(ABSTRACT~1
Hyperinsulinemia,~1
best-designed~1
kept.~2
internist's~1
promptness~1
consultant's~1
reply,~2
no-shows~1
minimized,~1
bolstered.~1
espansion~1
PRP-D,~1
Prevaccination~3
(0.027~1
lot,~2
(2.166~1
(0.154~1
(twofold~4
53.8%.~1
retransplantation;~1
55).~3
Piers-Harris~1
(P-H),~1
(STAIC),~1
Nowicki-Strickland~1
(NSLC)~1
Achenbach~1
(CBCL).~1
P-H~1
CBCL,~1
STAIC,~1
NSLC~1
3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic~2
2-amino-7-phosphonoheptanoate,~1
preferring,~1
NMDA-type,~1
NMDA-type~5
muM).~1
KCI~1
muM.~1
NMDA-evoked~2
5.66~1
5.22~2
2-amino-7-phosphonoheptanoate.~1
L-[3H]glutamate~2
L-[3H]glutamate,~1
muM)~1
alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic~1
(quisqualate-type~1
[3H]kainate~1
(kainate-type~1
Audiogenic~1
CF-1~1
CF-1,~1
2-amino-7-phosphonoheptanoic~1
[3H]CPP~2
Triton-treated~1
2-amino-5-phosphonopentanoic~1
homocysteic~1
alpha-aminoadipic~2
N-methyl-aspartate.~1
[3H]CPP.~1
D-2-amino-5-phosphonopentanoic~1
L-homocysteic~1
DL-2-amino-7-phosphonoheptanoic~1
L-serine-O-sulfate~1
ibotenate~1
DL-2-amino-6-phosphonohexanoic~1
N-methyl-L-aspartate.~1
quisqualate-~1
kainate-type~1
DL-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate~1
microM.(ABSTRACT~1
fixed-dose~1
Norethindrone-containing~1
multiphasics~1
dysmenorrheic~2
dysmenorrhea,~1
Performed~1
hyperprolactinemia-amenorrhea~1
(LHRH)~4
(BRCR)~1
Ten-minute~1
(IR-LHRH),~1
IR-LHRH~2
BRCR~2
cephalothoracopagus,~1
twinning,~1
monoamniotic~1
syncephalus~1
cephalothoracopagus~1
causative.~1
neoantigen,~1
2-M)~2
2-M~4
65.7%~1
non-SLE~1
glomerulonephritides~1
2-M.~2
immunoreactant~1
(DEJ)~1
DEJ~6
52.8%~1
(19/36)~1
0.030).~1
representations.~1
Erasmus~1
(Rotterdam~1
1466--Basle~1
1536),~1
China--practitioners~1
western-type~4
medicine--and~1
institutions--23~1
inspectors.~1
Mercer~1
(MUSM)~1
Macon,~1
Georgia.~2
Network~3
(GaIN),~1
GaIN~3
Colleges:~1
"Academic~1
Center."~1
network's~1
MUSM~2
pre-transplant~2
Liddle's~1
hypoaldosteronism,~1
aldosterone-independent~1
immunocytologically~2
3/12~4
(82.8~1
Ecchymosis~1
P-fimbriated~4
(0.036~1
patient-month),~1
culture).~2
unroofed~1
(mab),~1
Mano~4
4/4~4
P3/12,~1
Analysing~1
mabs~4
CEA-like~1
(TCC).~1
(p55)~3
3X~1
2X~2
TCC.~2
bacteria-cell~1
mirabilis~10
11.4.~1
contentions~1
endarterectomies.~1
(accuracy,~1
concomitant,~1
(PG910)~1
PG910/polypropylene~1
prostheses).~1
endothelial-like~2
prosthesis-tissue~2
alpha/TxB2~1
PG910/polypropylene-elicited~1
congregation~1
pneumoplethysmography.~1
(10.8%).~1
39%;~1
79%;~1
nonlocalizing~3
(EC/IC~1
bypass),~1
1377~1
reduce--or~1
increase--the~1
toileting,~2
undressing.~1
(sacred~1
Romans~1
hieron~1
osteon.~1
"sacred"~1
"holy"~1
hieron,~1
sacrificial~1
rites,~1
(themselves~1
sacred),~1
resurrection~2
Judgment.~1
holiness~1
borrowed~1
Egyptians,~1
sacred~1
Osiris,~1
god~1
agriculture.~1
Avarol~1
avarone~2
antimutagenic~1
HTLV-IIIB-infected~1
avarol~1
immunoelectronmicroscopy~2
(S-body).~1
euchromatin.~1
synthetize~1
(RAA)~3
adrenoreceptors~1
hr-1)~2
RAA~3
kaliuretic~1
sub-nephrotoxic~1
non-proteinuric~2
325,~1
38.55~1
8.66~1
42.17~1
7.92~1
parallely~1
collagen.(ABSTRACT~1
anti-glomerular-basement~1
IPK's~1
non-immune~3
(RVR)~2
ml/min/g.~1
Anti-GBM~1
RVR~2
Perfusate~3
(684~1
AI/ml/hr~3
ngAI/ml/hr,~1
Sar1Ala8All~1
(RVR~2
Sara1Ala8All~2
aggrevated~1
(GFR~1
2microglobulin~1
2m),~1
(FE~1
196%)~1
(30,600~1
6,910~1
1,268~1
111).~2
(cyst/serum~4
2m,~2
nonazotemic~2
histotopography~1
AHL)~1
Separations~1
incontiguity~1
complementary:~1
core".~1
VB,~1
interbundle~1
IS,~1
histotopographic~1
AHL~1
IM;~1
IS;~1
OM.~1
nature's~1
ideals.~1
tapers~1
enormously.~2
obivates~1
filtration-reabsorption~1
recta~3
osmotic-concentration~1
recta,~2
Solute,~1
Countercurrent~1
(V1-receptor~1
mediated)~3
(V2-receptor~1
influences.(ABSTRACT~1
hemipancreatectomy~1
hemipancreatectomized~4
216.5~1
Hemipancreatectomized~1
19.98~1
17.03~1
395.6~1
63.0~2
226.2~2
Hemipancreatectomized,~1
pancreaticoduodenal~4
186.0~1
1,087.0~1
656.0~1
hypoinsulinaemia~2
hyperglucagonaemia~2
(epoprostenol)~1
buffer-diluent~1
bypass).~1
prostacyclin-treated~1
650-calorie~1
2.9-g~1
Glenohumeral~1
swimmer~2
coach.~1
multi-centre~1
protein-X,~1
alkaline-phosphatase-linked~1
low-alcohol~3
beer.~1
[30]~1
ethanol/week~1
[8]~1
ml/week~1
beer)~1
normal-alcohol~1
('Surfactant~1
TA')~1
751-1750~1
Haemodynamically~1
(3/17)~1
(9/13).~1
Hypoglycaemia,~1
quinine-treated~1
hyperinsulinaemia,~1
gluconeogenesis.~2
21-base-long~1
21-base~2
phosphorus-32~1
(PFR1-AP)~1
PFR1-AP~2
parasites/microliter.~1
tissues).~2
non-sideroblastic~1
oxygen/70%~2
HLA-matched,~1
(8/13~2
4/27;~1
(6/13~1
1/27,~1
fifteen-fold~1
Bone-marrow~2
leukaemia-free~1
36-54%)~1
(15-29%)~1
(14-38%)~1
(45-67%)~1
colonisation.~1
colonisation;~1
colonising~1
blood-spots~1
Femoral-artery~1
reattendances.~1
MMU-18006~1
surveillance):~1
1-5-month-old~1
liver-cell~1
membrane-expressed~1
50-75~1
6-18~1
centres'~1
(12,500~1
(265)~1
(251)~1
(4/303,~1
1.32%~1
13/365,~1
3.56%).~1
drug-efficacy~2
3.99,~1
intention-to-treat~2
3.84,~1
3.88,~1
2.05,~1
vanishing-bileduct~1
(VBD)~1
VBD~5
bileduct~2
high-titre~1
non-encephalopathic~1
fundoscopic~1
(43/chemotherapy;~1
40/control),~1
(27/chemotherapy;~1
33/control).~1
(III/IV)~1
sinuses).~1
Cytoxan,~1
46%).~1
P-values~1
Immunotechnology~1
animal-ototoxicity~1
cytoskeleton)~1
anti-gentamicin~1
CT-scanning,~1
microslicing,~1
embedding,~1
Perspectives~1
immunotechnology~1
(pseudosarcoma)~1
cytokeratin-positive~1
vimentin-positive~2
antivimentin~1
neuromuscle~1
NMD~1
watch,~1
goniometer,~1
hand-grasp~1
forr~1
instructions;~1
variation?~1
TQNE~1
z-score~1
megascores:~1
Megascores~1
life-extending~1
0.75-1~2
1.5-2~2
dystrophies.~2
polyneuropathies,~1
IgG-antibodies~1
galactocerebroside~1
yellow-fever~1
1942.~1
330,000~1
33.9).~1
15.8),~1
74.8~1
939~2
1133~1
motifs,~2
engineering.~3
microsporidia~3
arthropods,~2
molluscs,~1
annelids,~1
cnidaria~1
ciliates,~1
myxosporidia~1
gregarines.~1
5.8S~1
microsporidium~1
Vairimorpha~1
necatrix~1
eukaryote~1
(top2)~1
conditional-lethal~1
Topoisomerase~1
(top1),~1
top1~2
top2~2
ts~2
swivel~1
(N-methyl-D-aspartate)~2
Kindling~2
(gamma-aminobutyric~2
acid-mediated)~1
(i.p.s.ps).~1
i.p.s.ps~2
ionophoretically~1
NMDA.~1
D-2-amino-5-phosphonovalerate~1
(D-APV).~1
kindling-like~1
(NMDA).~1
(kindling)~1
(e.p.s.ps)~1
NMDA-receptor-mediated~1
dopamine-depleted~1
nonscarred~1
(3.59~1
dropper~1
dermis-fat~6
figure-eight-shaped~1
preplacement~1
Mule~1
"baseball"~1
hypermetropia,~1
esodeviation~1
amblyopia,~2
AC/A~1
binocularity~1
bifixation~1
post-keratoplasty~2
visions~1
Immunotyping~2
allografting,~1
manufactured,~1
biomechanics;~1
osteogenic,~2
osteoinductive,~2
custom-suited~1
mineralized,~1
freezer~1
creeping~1
intercalary~1
donorgraft~1
head)~1
asset~4
geneticist.~1
geneticist~2
nongenetic~1
genetic/etiologic~1
solicited.~1
burden;~1
assimilate~1
receptive.~1
generically,~1
palsy/paralysis~1
functional)~1
otorhinologic~1
legacy~1
"organic~1
theories"~1
integrators~1
recognizable,~1
nystagmoid~1
epiphenomena.~1
Non-narcotic~1
intoxicating~2
amotivational~1
America's~2
encouraged,~2
Societal~1
fad~1
gasoline).~1
Experimentation~1
hallucinogens~2
Perspective~1
lookalike~1
addictiveness~1
Personality,~1
self-perception.~1
teenager,~1
Communicate~1
Provide~1
moralizing~1
lecturing.~1
Clarify~1
personalize~1
Pediatricians,~1
underachievement,~1
motivation.~2
rebelliousness,~1
indifference~2
deviance,~1
58.6)~1
10(-0.5)~1
assay-immunoglobulin~3
rotavirus-seropositive~1
Wellcogen,~2
"antigen"~1
"antigen."~1
focality,~1
Wellcogen~3
drowned~1
hope.~1
Provisions~1
indigent.~1
newest~2
d(GATC)~9
Heteroduplexes~1
four-site~1
strandedness~1
mutH,~3
mutL,~3
mutS~3
mutH~1
strand-specific~3
mutS,~1
uvrD~1
mutHLS~1
32-kDa~4
herbicide-binding~1
33.5-kDa~1
chloroplast.~1
unstacked~1
translocates,~1
thylakoids,~1
granal~2
Posttranslational~1
palmitoylation~1
membrane-protected~1
lamellae,~2
(Kact,~1
serum-starved~2
(MAP-2)~1
MAP-2~5
insulin-stimulatable~2
phosphocellulose,~1
p-Nitrophenyl~1
DL-phosphotyrosine,~1
DL-phosphoserine~1
modulator.~1
uridine.~2
pausing~2
paused~1
photophysics~1
chlorophylls~1
Time-correlated~1
P700~1
chlorophyll~1
a-protein~1
psec)~1
antenna.~1
P700.~1
[Pearlstein,~1
R.M.~1
Photochem.~1
Photobiol.~1
835-844].~1
psec,~1
P700,~1
psec.~1
photoconversion.~1
T-lymphocyte-specific~1
pT49,~1
pT49~2
N-Methyl-D-aspartate~1
(N-Me-D-Asp)~1
N-Me-D-Asp~2
systemically),~2
subconvulsant~1
gamma-aminobutyrate-mediated~1
entopeduncular~1
gamma-aminobutyrate-dependent~1
RIN~2
m5F,~1
pS).~1
(5-7~4
forks.~1
trp,~1
34.5-35.7~1
manA.~1
forks~8
traveling~1
58-kilobase~1
387-445~1
duplicating~1
origin-to-terminus~1
marker-frequency~1
counterclockwise-moving~1
(33.5~1
Okazaki~1
T1-T2~1
"unnatural"~1
oriC-T1~2
-T2~2
terminators.~1
nucleoid~2
half-nucleoid~1
transposase~4
(brFGF)~1
(heFGF)~1
brFGF~5
heFGF~4
18,400.~1
3.5-4.5,~1
pepstatin.~1
anti-FGF~1
heFGF.~1
residue(s)~1
(p15),~1
(pp15)~1
phenylarsine~3
dithiols,~1
pp15~3
receptor-initiated~1
insulin-activated~6
dithiol~2
2,3-dimercaptopropanol~1
monothiol~1
pp15.~1
tyrosine),~1
nick-translation~1
gap-filling~1
"metabolic~1
buffering"~1
phosphocellulose~3
"cytosynalin,"~1
"cytoskeleton"~1
"synapsis."~1
cytosynalin~5
anti-cytosynalin~1
calspectin~3
(nonerythroid~1
fodrin).~1
Cytosynalin~1
low-shear~1
viscometry,~1
Pinocytosis~1
lucifer~2
thioglycolate-elicited~1
J774.2.~1
pinocytosis~2
microperoxidase~2
micrometers;~1
radiate~1
centrosphere~1
acetate-treated~2
erythrocytes;~2
knobless~1
(knobs)~1
(senescent~1
(CR3)~3
C3bi.~1
(RGD).~1
21-residue~1
1383-1403).~1
myristoylated~2
RGD-containing~5
RGD~4
triplet,~1
RGD,~1
thermogenically~1
2',3'-dideoxyadenosine~2
Purine~3
2',3'-dideoxynucleoside-5'-triphosphate~1
"immunological~1
privilege"~1
rat--the~1
terminalis,~2
posterodorsal~1
amygdala--are~1
gonadal-steroid-concentrating~1
cholecystokinin-immunoreactive~1
gonadectomy.~1
gonadectomy,~1
(onc)~1
onc~6
proto-onc~10
virus-negative~1
isogenic;~1
Instead:~1
Proto-onc~1
overinterpretation~1
truncations~1
illegitimate~2
Boveri~1
1914.~1
(Afp)~1
Nuclease-hypersensitive~1
end-labeling~1
albumin-producing~1
Afp-producing~1
Afp~3
"dedifferentiated"~1
lipid-linked~2
UDP-N-acetylglucosamine-dolichyl-phosphate~1
N-acetylglucosaminephosphotransferase~1
(UDP-N-acetyl-D-glucosamine:dolichyl-phosphate-N-acetyl-~1
D-glucosaminephosphotransferase,~1
2.7.8.15),~1
ALG7~5
messages,~1
sugar-donor~1
20-bp~1
-157~1
-139,~1
"walking"~1
SP6,~1
amplifiable~1
Sfi~1
33-~1
44-kilobase-pair~1
Sau3A,~1
end-specific~1
"walking."~1
Cosmid~1
8-(4-chlorophenylthio)-cAMP,~1
tighter~3
Analogs~1
(43.0%)~1
(37.2%).~1
proteinase.~3
pp60c-src~13
c-src-encoded~1
pressure-activated~1
dependence;~1
conductance;~1
cations;~1
osmoregulation~1
osmotaxis.~1
v-sis-related~2
(SSV)-transformed~1
anti-platelet-derived-growth~1
Antigenically~1
non-SSV-transformed~1
SSV-transformed~4
nitrocellulose-based~1
v-sis~5
CABP1.~1
CABP1~5
anti-CABP1~1
culmination.~1
GAL4~3
GAL4.~1
GAL4,~1
Wright-Giemsa-stained~1
(0.3-300~1
neuroendocrine-psychiatric~1
unchallenged.~1
Regrettably,~1
Acalculous~1
33-month~1
cholangiopancreatography;~1
(strictures,~1
walls).~1
Cholangitis~1
(PFCs)~2
perfluorotripropylamine,~1
nonenhancing~3
Fluosol.~1
hematobilia,~1
high-attenuation~4
Midline~1
sagittally,~1
axially.~1
(55.5%),~1
(42.4%),~1
(2.2%).~1
(61.5%),~1
(30.8%),~1
(7.7%).~1
polysplenia,~1
preduodenal~1
portoenterostomy~1
imperceptible~1
2d~1
29-44~1
Meningiomas,~1
310%),~1
180%),~1
neurofibromas,~6
Biplanar,~1
22-~1
14-gauge~1
19-gauge~1
61%).~2
thin-needle~1
(9.8%)~2
ICON~2
prose~1
critique.~1
(PHS)~1
short-stay,~1
130.2~1
PHS~2
extra-long~1
Voltage-sensitive~1
(PAC-2)~1
PN200-110~1
PAC-2~2
169,000~1
nephroblastoma,~1
p13~1
microcell~2
Rif,~1
virion-derived~1
(p66~1
p51).~1
peptide-carrier~1
radiation-attenuated~3
sporozoites,~2
(PN/A,~1
PN/A~2
(PID,~1
trend:~1
PIDs~1
.017).~1
books,~1
chapters,~2
identified).~1
truth-telling~1
items),~4
items)~1
laetrile~1
items).~1
"benefit,"~1
"harm,"~1
861~2
edemic~1
iodine-rich~1
turnover-protein~1
C-calcium~1
Autonomously~1
(AFTNs)~1
"hot"~1
TH-TSH~1
"patchy"~1
(classic~1
Plummer's~1
hyperthyroid.~1
("T3~1
thyrotoxicosis").~1
Hyperfunctioning~1
glucagonomas,~2
vipomas,~1
"silent,"~1
neurocrine,~1
glucagonomas~2
catabolic,~1
vipomas~1
diarrheogenic.~1
endocrinopathies;~1
prognostic.~1
vipomas.~1
non-MEN~1
hematemeses,~1
handed~1
knot,~1
throws~1
elegantly~1
4,900~1
leiomyomatous~2
intramural,~1
endogastric~1
exogastric~2
Richard~1
Wiseman,~1
Royalist~1
(1651),~1
Wiseman's~1
plugs;~1
fragments;~2
tapped~1
(75%);~1
failed-back~1
autodrainage~1
ventriculostoma~1
autodrainage.~1
(Warren~1
phlebosclerotic~1
Hepatofugal~1
0.0048).~1
Mathew~1
0.25.~1
advantages/rewards~1
unmanageable~1
"brittle~1
diabetes"~1
myth~1
Center/Lexington~1
Gonadoblastoma~1
(MGD)~1
gonadectomy;~1
71).~2
nephroblastoma~1
MGD~1
gauged~1
Edema,~1
12-54~1
hydrochlorthiazide~1
(non-responders)~1
(responders)~3
"leaving-one-out-technique",~1
thiazide.~1
Nielsen-Lassen~1
IDIOP~1
(buffering~1
mmol/10~1
pads)~1
Wires,~1
bit~1
hardening~2
angiographers,~1
depressurization~2
"pressure~1
half-time"~1
decoding,~1
(AAo)~1
(DAo)~1
AAo.~1
AAo~3
nonimaging~1
sectored~1
DAo~2
azimuthal~1
(Vel),~1
(Acc),~1
Vel~1
Vel,~1
SV.~1
atheromatosis,~1
atheromatosis.~2
urease.~1
hypochlorhydria.~1
13C-urea~3
pyloridis-associated~1
Proctosigmoidoscopy~1
studding~1
Late-replicating~1
repressed.~1
Housekeeping~1
(constitutively~1
early-replicating~1
R-bands.~1
Tissue-specific~1
late-replicating~3
G-bands~2
G-bands,~1
Lyonize~2
(facultatively~1
heterochromatinize)~1
replicons.~1
frogs,~2
control--i.e.,~1
Lyonization~1
replicons--seems~1
pre-glomerular~1
surfaces;~2
11.4/10.5~1
198.4~1
13.5/10.3~1
nifedipine-treated~1
([Ca2+])~1
contraction-relaxation~1
[Ca2+],~2
Designing~2
(running)~1
0.028)~1
40.1)~1
receptor-antagonists~1
indiscriminately.~1
Menetrier's~1
angioplasties.~1
iron-chelating~1
Tf-receptor~1
Apotransferrin-receptor~1
apotransferrin~1
reno-hepatic~2
developments:~1
(ANRL)~1
reno-portal~1
(RPS)~1
unclipping~1
blood-drained~2
ANRL~1
RPS~3
(one-kidney,~1
one-clip)~1
unclipping;~1
ANRL.~1
unclipping.~5
RPS,~1
(1/13~1
S.E.),~1
3.19.~1
arterionephrosclerosis.~1
C5b-9.~1
"viable~1
motheaten"~1
(mev)~1
immunodeficient,~1
"Mott~1
cells,"~1
"Russell~1
bodies."~1
Mott~6
A-immunogold~1
150-190~1
(nu)~1
mev~1
Schizoaffective~2
(RDC)~1
Family,~1
RDC's~1
Intestinalization,~1
Intestinalization~1
intestinalization~2
(Penrose~1
drains)~1
closed-suction~5
(12,000~1
14,100~1
cells/mm3,~1
(EFAs)~1
EFAs~2
exaggerates~1
dihomo-gamma-linolenic~5
(3M:2F)~1
FAS;~1
525,0000~1
6,600,~1
grandmothers,~1
HbsAg~1
HBV-positive~2
"sake"~1
HBV-negative~1
seromakers.~1
seven-session~1
beverage.~1
breathalyzer~3
elation~1
vigor~1
choosers~3
choosers.~1
Sensation~1
(ALDH)~1
ALDH~4
ALDH1~3
9.5.~1
ALDH2~6
agarose-AMP~1
anti-ALDH1~1
anti-ALDH2~2
ALDH1.~1
"inactive"~1
"deficient"~1
homogenate-supernatants~1
[3H]puromycin~3
peptidyl-[3H]puromycin.~1
peptidyl-[3H]puromycin~2
[3H]Puromycin~1
EFA/prostaglandin~1
guanfacine~6
Guanfacine~2
guanfacine,~1
pmol/mg.~1
acting;~1
pneumoplethysmograph~1
pneumoplethysmogram~1
(CAP),~1
programming,~1
IA-DSA.~1
IA-DSA~1
pantethine~3
twenty-eight-day~1
sphingomyelin/phosphatidylcholine.~1
n3-polyunsaturated~1
insulators~1
topic,~1
"asthma,"~1
"wheeze,"~1
"episodes~1
sputum,"~1
"pneumonia."~1
aerosol-induced~1
H2SO4~3
unbuffered~5
7.0).~2
H2SO4,~1
interpolation;~1
NaOH)~4
NaOH).(ABSTRACT~1
SO2-exposed~1
mucoepithelial~1
Nonrandomized,~1
(registered~1
Registered~1
2.07;~1
1.56;~2
2.37;~1
benefited,~1
tamoxifen-responsive~1
institution--the~1
("limited~1
stage").~1
Chemotherapy:~1
Cyclophosphamide,~1
0.035)~2
(CBre3-EIA),~1
coli-expressed~1
2707~1
T-lymphotrophic~1
CBre3-EIA.~1
CBre3-EIA~1
(99.9%)~1
(99.1%)~1
1599~1
99%).~1
sulfadoxine,~2
necrolysis.~1
justifying~2
2495~1
5698~1
nephrectomies.~1
flagged~1
understanding;~1
specialization.~2
Removable-suture~1
undo~1
removable-suture~1
tightly;~1
microphthalmos.~1
cerebro-oculo-facio-skeletal~1
cloudy~1
reinnervating~1
dispute~1
transfer;~1
subglottis~2
myoperiosteal~2
subglottis,~1
niche.~1
unimplanted~1
blue-lining~1
endosteum.~1
supracricoid~3
hemilaryngopharyngectomy~1
hemilarynx~1
5,348~1
"Klebsiella~1
aerogenes,"~1
84%).~1
Monoglycerides~1
antiviral,~2
(parasitemias~1
(inocula~1
[3H]chloroquine~1
[14C]acetate~1
[14C]aminoisobutyric~2
econazole,~1
ergosterol~8
naftifine,~1
azasterol~1
A25822B,~1
ergosterol.~2
imidazoles,~1
ergosterol,~3
Cerulenin,~1
econazole~1
fluconazole,~1
fluconazole~1
Fluconazole~1
Laotians.~1
clonorchiasis~2
clonorchiasis.~2
Roxithromycin~2
Dark-field-positive~1
Chancres~1
dark-field~4
roxithromycin-treated~2
postinfection.(ABSTRACT~1
(ceftazidime~2
vancomycin)~2
Tigemonam,~2
Tigemonam~3
tigemonam~9
polymyxin-resistant~3
(octapeptin).~1
(KTZ)~1
[3H]KTZ.~1
[3H]KTZ~2
0.1875~1
(optimal~2
KTZ~2
A509U;~1
[AZT])~1
typhimurium,~3
anguillarum.~1
AZT-resistant~1
ML-30~2
[3H]AZT~1
di-,~1
AZT-5'-triphosphate~1
toluene-permeabilized~1
AZT-treated~1
AZT-triphosphate~1
Klenow~1
(T-1,3)~1
(Rdnov)~1
[35S]penicillin~2
pLB100,~1
pLB100~1
plasmid-coded~2
minicells~5
55,000-molecular-weight~1
28,000-molecular-weight~1
MHN1)~1
MHN2)~1
MHN1~2
ampC~7
MHN2~3
3,000-fold~1
K-12.~2
repression-induction~1
ampC.~1
cephalosporinase,~1
53.6%~1
R100~3
R388~1
R388,~1
R6-5,~1
(CZX)~1
(OLT).~1
CZX~2
(clearance~3
weight])~1
ofloxacins~1
luteus~2
(-)-,~1
(+)-ofloxacin;~1
7.24,~1
Blastoconidia~1
250-mg~1
weight/min),~1
constricting,~1
vasodilated,~1
wakings,~1
(fourth)~1
(hepatorenal~1
ureteroneocystostomies~1
ureteroureterostomies~1
ureteroneocystostomy~2
positive-end~1
"skinny~1
needle"~1
.0147).~1
dread~1
rereplacement).~1
fungous~1
3H-imipramine~2
hypercortisolemia~1
placebo]~1
[office-based~1
exposure])~1
amalgamating~1
(week~5
midcourse~2
postbaseline~1
panic.~3
panic-free~1
anti-apo~1
2-plus~2
plus.~2
3-plus~1
histiocytomas~2
1-plus~1
Myxoid~1
anti-beta-EP~1
Leydig's~2
fibrothecomata.~1
beta-EP.~1
strumal~2
non-neuroendocrine~1
calcitonin-positive~1
designation.~1
immunoprofiles~1
(KER)~1
(EMA).~2
KER~2
EMA.~1
EMA~6
seminomas,~1
KER,~1
dichroism,~3
prolactin-producing~1
Extragonadal,~1
nongestational~1
(IOUS)~1
IOUS,~1
shadowing.~2
(coagulative~1
resected;~1
IOUS~1
cryoablations.~1
"sensor"~1
"receptor"~1
(PTH).~1
recognition/transduction~1
calcium-regulated~2
(CPCR-AA),~1
CPCR-AA~5
mL/m2/min;~5
mL/m2/min.~2
sloughed.~1
patient-kept~1
0.054,~1
(K43~1
F77)~1
IgM-RF.~1
IgM-RF)~1
RF-PFC~2
RF-PFC/10(6)~1
RF-PFC,~1
flaps)~1
"undifferentiated."~1
quandary,~1
(prostacyclin).~1
(IPPV)~4
(20.0~1
(sleep~3
E'CO2~1
(CBDC),~1
(CCP),~1
(BP).~3
CCP.~2
CBDC~2
blister.~2
Punch~1
flare-up~6
polysulphone~2
lapel~2
oculotoxicity~1
12-30~1
12-week,~3
pustules,~1
Ki-M8,~1
Ki-M8~5
intracytoplasmatically~1
monocyte/macrophage-related~2
19.9%~1
Ia-antigen,~1
avidin-Biogel~1
(polyacrylamide)~1
69.0%~1
88.0%~1
Ia-positive.~1
pSC101~1
minicells,~1
minicell-containing~1
b558~2
7D5,~1
7D5~3
b558.~1
Bsp-1~4
erythroblastic~1
45-kilodalton~2
KU812,~1
PSIFT;~1
microlymphocytotoxicity;~1
MAIA),~1
MAIA~3
(predictability,~1
recovery).~2
PSIFT~1
(exact~1
associations)~1
contact-activated~1
(reactive~1
center)~1
arginine-directed~2
Arg15-aprotinin,~1
microplates.~2
KL~1
(loose~1
(mol/L)-1s-1~1
(mol/L)-1s1,~1
Arg15-aprotinin~3
XIa,~2
Arg15-aprotinin.~1
("7~1
3")~1
cotrimoxazole~1
"7~1
3"~1
remitters~1
video-microscopy).~1
Attached~1
leukocyte-Candida-endothelial~1
Candida-endothelial~1
microcolony~1
neutrophils:1~1
5637.~2
(HTB9-CM)~1
Blasts~2
HTB9-CM.~2
granulopoietic~1
Thrombin-stimulated~1
fura2~1
PGI2-stimulated~2
thrombin-mediated~1
(G6PD)-deficient~2
malaria-endemic~2
G6PD,~1
G6PD.~4
Km)~1
(NADP)~1
hybridizable~1
G6PD-deficient~3
Bartholomew's~1
orthodox-sized~1
mid-mediastinum,~1
umbilicus~1
beam-flattening~1
weightings~1
individualised~1
radiosensitivities~1
D0~1
Dq~1
hyperfractionation"~1
antileukaemic~1
isoeffective~1
hyperfractionated~1
1.3-1.5~1
Diuretic-enhanced~1
(WKMTT)~1
(T75).~1
WKMTT~2
WKMTT,~1
T75~4
negatives.~1
Pre-natal~1
uropathies.~1
renoureteric~1
(VCU)~1
intraprostatic~1
VCU.~2
observation;~1
D-Trp-6-LHRH~5
"flare"~1
in-dwelling~1
'jiggling'~1
(readjustment~1
jiggling~2
0.01):~1
Jiggling~1
inaccuracy,~1
jiggling,~1
(MyD)~1
hyperinsulinaemia.~3
hyperinsulinaemia~3
fascicle,~1
perineurium~3
Beta-blocker~1
stings,~1
allergists,~1
non-oat~1
3-NO,~1
N3,~1
above),~1
(Study~6
(SNC~1
FCC)~1
(NBL),~1
NBL~3
NBL,~1
Ig)~1
(CIg),~1
NBL.~3
SNC~1
(THP)~3
discovered;~2
rhabdomyomatous~1
Via~1
nephron-sparing~1
hyperimmunized~2
ACHN~2
1611,~1
Collection,~1
Rockville,~1
Maryland),~1
Hybridoma~2
synovial-related~1
(mesenchymal~2
carcinosarcoma.~1
heterogeneities~2
heterogeneities,~1
heterogeneities.~1
Heterogeneities~1
(decline~1
(Doppler~2
(phenoxybenzamine),~1
(propranolol),~1
(captopril).~3
[Na+]i~1
refute~2
(5-HT)-like~1
(5-HT-LI)~1
5-HT-LI~6
nerves.(ABSTRACT~1
acetylsalicylate~2
lower-body~4
-10,~1
dying.~2
dying;~1
prazosin;~1
hydralazine-nitrate~1
hydralazine-isosorbide~1
history.(ABSTRACT~2
circumstantial.~1
intropic~1
appealing.~1
Beta-Blocker~3
(IMSA)~1
IMSA~4
(HCM),~1
(DCM-like~1
HCM),~1
myocytic~1
IMSAs~4
HCM,~2
DCM-like~3
wall)~1
-.59),~1
-.66~1
-.63~1
wall),~1
-.68).~1
Chagas'~6
(VCDs)~1
VCDs.~1
[SD]),~1
ml/sec)~1
Baroreflex~1
vasoselective~1
felodipine.~4
(FSVR)~1
FSVR,~2
baroreflex-mediated~2
FSVR~7
vasomotion,~1
fissuring,~2
Sustained-release~1
(D-SR)~1
(V-SR)~1
D-SR~3
V-SR~3
Biopharmaceutics~1
peak-to-trough~1
cardioprotection~1
beta-blockers;~1
clarification.~5
17/101~1
25/88~1
22/104~1
23/91~1
diltiazem.(ABSTRACT~1
cardioreflex-mediated~1
sublingual/oral~1
predictable;~1
Precipitous~1
dromotropism~1
inotropism.~1
glycosides,~3
stimulus-effect~1
couplers~1
"calcium~1
blockade"~1
channel-mediated~1
(nifedipine,~1
nisoldipine)~1
channel-dependent~1
favorably.~1
parodoxical~1
(afterload~1
deterioration.(ABSTRACT~1
(APGN)~1
APGN~1
starry~3
garland~5
[Sorger~1
1983].~1
rebiopsies~1
APGN,~1
decisive.~1
(27.5%)~1
Korea~2
light-,~1
electron-~1
Meadow~1
[1972]~1
(16.2%)~1
Immunotactoid~1
cryoglobulinemia~8
immunotactoid~1
70),~2
calcium;~1
1,25-(OH)2-vitamin~1
"Trivial"~1
rugs,~1
polyfactorial~1
"avascular"~1
bone-blood~2
Resected,~1
autoclaved,~2
(DABM)~1
(99mTc-MDP),~1
(45Ca),~1
Scintigraphically,~1
DABM-supplemented~5
equalized.~1
Osteocartilaginous~1
either/or~1
nonviability~1
(ligament)~1
limping~1
(avulsion)~1
(tendon).~1
Sunitang,~1
Sunitang~5
Fluradoline~1
Fluradoline,~2
fluradoline,~3
fluradoline~1
earlier--particularly~1
scan--should~1
nonprolapsing~1
"silent"~2
(APRV)~1
(ALI),~1
APRV~6
APRV.~3
Expiration~1
near-ambient,~1
ALI,~1
fibronectin-rich~1
Trach~3
suctions~1
perindopril~4
Perindopril~1
EVLW,~4
(CPPV)~1
aortograms~1
CPPV~1
0.50.~1
0.21).~3
Postextubation~1
postextubation~1
PD20,~1
(preload)~1
(afterload),~1
(synchronous~1
HFJV)~2
(IPPB)~1
ml/kg;~1
IPPB~1
whole-gut~1
cleansings~1
good-to-excellent~1
colostomies~3
35-56;~1
normoazotemic~1
mmol/day.~1
(Pentasa)~1
prednisolone).~1
prednisolone-treated~1
DeNol,~1
meciadanol,~1
(DCCT)~1
adolescents),~2
ophthalmologic,~2
experimental-~1
standard-group~1
DCCT~2
full-scale,~1
copper-reduction~3
penicillins),~1
salicylates.~1
nitrofurantoin,~3
phenazopyridine,~1
pregestational,~1
gestational)~1
depiction,~2
25th,~1
50th,~1
day."~1
AGPs~2
Metformin,~2
biguanide~1
biguanides~1
metformin,~2
5699~1
(60-74~1
FBG~2
(FH),~1
non-insulin-treated~1
Sustacal-~1
C-peptide-positive~3
Sustacal~3
-.29,~2
-.40,~1
.33,~2
Sustacal,~1
$~2
postbreakfast~1
(C-peptide~1
glycosuria)~1
-.78,~1
-.62,~1
clamps,~1
15.37~2
4.94~1
10.92~1
metformin.~2
biofeedback-associated~1
311,000~1
medical-care~2
$1514~1
$548~1
$355).~1
premiums~2
$1000~1
hypermagnesemia.~1
penicillins,~5
Amsacrine,~1
(0.75%)~2
post-baseline~1
xylazine~1
micrograms/15-min~1
infusion),~3
diazoxide-treated~1
tolbutamide,~2
hypoinsulinemias~1
hyperinsulinemias.~1
(NPY)-like~1
NPY-containing~2
NPY-labeled~2
immunoreactivity;~1
GnRH-like~33
GnRH)~4
perturb~2
reesterification~1
Nordihydroguaiaretic~2
lipoxygenase,~1
melittin~2
Lipoxygenase~3
p-hydroxymercuribenzoate,~2
p-hydroxymercuribenzoate.~1
A2-initiated~1
lipoxygenase-mediated~1
cyclooxygenase-mediated~1
diazoxide,~1
(10-25%)~1
CBG,~1
estrophilic~1
impoverishment~1
estrogen-AFP~1
corticosterone-CBG~1
pregnancy-specific~2
KCl-evoked~1
0.568~1
MBH,~1
(159.9~1
196.3~1
24.6,~1
254.7~1
36.8,~2
272.6~1
femtomolars~1
glucagon-related~2
epithelial-like~2
11,000-12,000~1
5,000-6,000.~1
(IRGa)~1
1,457~1
pg/dish,~1
IRGa,~1
IRGa~1
(DBP),~1
56,000-58,000~1
2-glycoprotein,~1
Cytotrophoblasts~1
on/in~1
radioiodinated,~1
57,000~8
immunoisolated~2
Immunoisolation~1
immunoisolation~1
cytotrophoblasts.~1
(GH3~1
deinduced~1
(Dex;~1
Dex,~1
glucocorticoid-stimulated~1
(Northern)~1
BALBc/3T3~2
anti[Thr59]IGF-I~1
micrograms/pulse~4
trials);~1
tethered.~1
post-GnRH~4
10.9),~1
12.7),~1
13.0),~1
4.8)~1
cycles:~2
3.7),~1
5.4),~1
GnRH-LH~2
Monodispersed~1
19-26),~1
mid-(days~1
47-62),~1
80-99)~1
preparturient~1
sows~1
107-112~1
nonrelaxin-releasing~1
[125I]IGF-II~4
1/200th~1
radioactivity)~1
M-1)~4
270K~1
Nanomolar~1
(FR).~1
(D+I)~1
(asterisks~1
0.05):~1
0.414;~1
FR,~2
0.583~1
0.369;~1
0.310~1
0.220;~1
D+I,~1
0.630~1
0.394.~1
0.298~1
0.208~1
0.109~1
D+I~1
glucagon-induced~1
(AcAc)~1
(50-week-old)~1
36-h~1
(8-week-old).~1
AcAc,~1
AcAc~1
beta-myristate,~1
55-65%~1
(Fk),~1
(RLX)~1
(E2).~3
RLX~12
RLX,~1
progestin-dependent~1
MPA-pretreated~1
Antiprogestin,~1
RU486,~1
Fk~3
Fk.~1
RLX.~1
LC7-2~1
ductular,~1
regular.~1
Autocorrelation~1
(cross-correlation~1
codistribution~1
insulin's~5
N6-phenylisopropyl-adenosine,~1
(SF2)~1
lactogens~2
PRL-induced~1
Nb2-11C.~1
SF2~7
derived-growth~1
(12.4-150~1
(Nb2-SP~1
Nb2-HSP)~1
lactogen.~1
Nb2-SP~2
Nb2-HSP~1
SF2,~1
lactogen-induced~1
[125I]hGH.~1
(PLMT)~1
PLMT,~1
PLMT~3
PLMT.~1
lactogen-I~1
(mPL-I)~1
(29-32K),~1
mPL-I~14
(36.5-42K).~1
sulfate-gel~5
(36.5-42K)~7
36.5K,~1
37.5K,~1
39K,~1
40.5K,~1
42K.~1
Deglycosylation~2
29K~2
(29-32K)~2
30.5K,~1
32K.~1
peptide:N-glycosidase~2
30.5K~2
32K~2
28K.~1
mPL-II.~1
mGH.~1
Dilutions~1
lactogenic,~1
LH-like~1
shady~1
Antisperm~1
reproduction;~1
unestablished.~1
(ASA-H)~1
ASA-H~5
(VARN),~1
(VARF),~1
(VARI).~1
VARIs~1
VARNs~2
VARFs~1
VARIs,~1
VARFs,~1
phenantroline,~1
13-cycle~1
five-center~1
Bangalore,~2
Manila,~2
Miguel,~1
Dublin)~1
Auckland,~1
Dublin,~1
Miguel).~1
54.7%~1
difficulty,"~3
"occasional~1
"always~1
(LUFs)~1
LUF~3
azapropazone~1
indomethacin).~2
unruptured.~1
ultrasounds~3
0.914,~1
0.639,~1
perimenarcheal~1
glucagon-activated~2
[14C]glycogen.~1
[14C]glycogen~2
[14C]lactate~2
micrograms/h),~1
infused).~1
intermittently.~1
Hyperinsulinism~1
coli-induced~1
hyperinsulinism,~3
LD70~1
endotoxin;~1
antagonist);~1
naloxone;~1
Met-enkephalin~1
Leu-enkephalin~2
nonimmunoreactive~3
(D-Ala5,~1
D-Trp8)-somatostatin,~1
IU/day)~2
(1350~1
2P~4
(498~1
mm3,~2
631~2
LeuA3~1
(44-yr-old~1
insulin-to-creatinine~1
Reverse-phase~1
8:3~1
1:7~1
Euglycemic-hyperinsulinemic~1
12-wk-old~1
3-[3H]glucose~1
2-deoxy-1-[3H]glucose~1
wk-old~1
mg-1).~1
4-wk-old~1
periovarian~1
(12-wk-old)~1
glibenclamide~4
(FGU)~1
(OGTC)~1
metformin;~1
h.(ABSTRACT~1
passenger-cell~1
IL-1-containing~1
Preculture~1
IL-1-mediated~2
beta-cell-protecting~1
K+)~1
D-glucose.~1
(STZ)-injected~1
(NSIR)~1
NSIR~4
NSIR,~1
125l-labeled~1
NSIR.~2
8.49~1
11.56~1
1.08/microliter~1
vol;~1
combined).(ABSTRACT~1
(Biostator~2
GCIIS)~1
Very-low-density~2
(VLDL-TG)~1
[3H]glycerol~2
VLDL-TG;~1
VLDL-TG~2
synthesis),~1
Biostator~2
h-1).(ABSTRACT~1
Pen~1
infuser).~1
insulin.(ABSTRACT~1
heterogenous.~1
(produced~3
technology)~1
L/mol~2
65-66~3
32-33~4
proinsulins~1
64-65~3
proinsulins.~1
proinsulin;~1
proinsulins.(ABSTRACT~1
25-g~3
20-120~1
(GIR20-120)~1
GIR20-120~2
A14-[125I]monoiodotyrosyl~1
sulfitolysis~1
A-chain.~1
Dansylcadaverine~1
cell-extracted~1
dansylcadaverine.~2
(basal,~2
D5:~1
D1:~1
D5~3
(D5~5
D5.~1
Isotopically~1
NEFA,~1
metabolite.(ABSTRACT~1
Twentieth~1
philosophical,~1
richest~1
Digestive~2
Ultrasonography,~2
non-antidopaminergic~1
(99mTc-sulphur~1
liver).~1
belching,~1
regurgitations,~1
satiety,~1
heartburn)~2
R-binder~5
R-binder.~1
(18/48)~1
(6/42)~1
(10/42,~1
(4/48,~1
sclerotherapy.(ABSTRACT~1
(congestive~1
gastropathy)~2
recommenced.~2
anti-liver-kidney~5
liver-kidney~2
Immunogold~1
peroxisomes,~1
rejection-related~1
retransplantation.~3
venoocclusive~2
antirejection~4
(rejection~1
cholangitis),~1
ductopenia,~1
"burnt-out"~1
ductopenia~1
rejection.(ABSTRACT~1
"hospitalization"~1
alpha-fetoprotein-secreting~1
("Alexander")~1
(K-PLC1,~1
K-PLC2~3
K-PLC3)~1
K-PLC3~2
Hep/G2~1
idiospecific~1
76,000~5
K-PLC1,~1
K-PLC1~4
withdrawal;~2
host-immune~1
systems--plasma~1
vasopressin--were~1
nonhypotensive~1
subjects,(ABSTRACT~1
captopril-induced~3
131I-hippurate~2
renin-mediated~1
postrenal~1
(urinary-to-plasma~1
(mannitol)~1
(furosemide,~1
bumetanide).~1
studiously~1
(preexisting~1
matter?)~1
Skillful~1
insurmountable.~1
hemorrhaging~1
traumatized,~1
sympathectomy-induced~1
Bogetz~1
ourselves,~1
inappropriately,~1
resuscitologists~1
(SVCP)~1
SVCP.~1
(PAP~1
LAP)/2~1
sheep-to-sheep~1
SVCP~3
fluid-to-blood-free~1
(EVF).~1
EVF~1
(EVF~1
Neurohumoral,~1
elevation)~2
(fivefold~1
insignificantly.~1
Pigs~1
(EDD),~1
D%),~1
(WTh),~1
(WTh%),~1
(LVP),~1
hemodynamics]~1
training).~1
EDD~2
D%,~1
WTh%,~1
monosaccharides~2
(2,3-diacylglucosamine~1
1-phosphate)~1
MAGP~2
(2-monoacylglucosamine~1
1-phosphate),~1
tetraacyl~1
IV-A~1
(Federation~1
43:~1
1567,~1
(lipopolysaccharide).~1
MAGP.~1
MAGP,~1
Disaccharide~1
IV-A,~1
(15-min)~1
cyclooxygenase-dependent~2
ester-linked~2
hydroxymyristoyl~1
molecule.(ABSTRACT~1
SD's~1
(0.11-0.90).~1
40-75%),~1
113mIn-transferrin~2
slope/min~1
nonintubated~1
MCh,~3
Rlo.~1
interepithelial~1
pentaacetate~3
(LLD).~1
LLD,~1
LLD~1
0.8%/min,~1
RLD,~1
0.2%/min,~1
Condensing~1
(preferably)~1
osteitis.~1
Anti-inflammatory~1
(DLA)-matched~1
(cryopreserved)~1
(intra-articular)~1
DLA-mismatched~2
DLA-matched~1
anti-DLA~1
mg/dose)~1
GHRH,~2
GHRH.~7
IR-3)~1
IGF-~1
WI-38~6
IR-3~5
IGF-I-~1
IGF-II-stimulated~1
factor-~1
HEL,~2
(GM498~1
HES)~1
(MG63),~1
IGF,~1
(quartile~4
iv;~3
IR-cortisol~2
micrograms/dL).(ABSTRACT~1
0.5-4~1
[N-acetyl-D-pCl-Phe1,2-D-Trp3-D-Lys6-D-Ala10]GnRH,~1
49-59%,~1
41-46%,~1
25-40%.~1
10-28~1
decapeptide.~3
(RICT)~1
(bioimmuno)~1
pulsatility,~3
intrapulse~2
bio:immuno~3
lags~1
0-40~1
(spontaneous)~1
[radioreceptor~1
(RRA)].~1
hypothalami.~1
GnRh~1
RRA.~2
(protease~1
E/NE~1
phosphoacceptor~1
"spotted"~1
Ki67,~2
pseudo~1
HB4~1
HB6~1
ammoniagenesis.~1
potassium-deficient~1
ammonia-mediated~1
312.3~1
3988~3
63-441,~1
catheter-implanted~1
63-441~2
bancroftian~6
microfilaremia,~3
elephantiasis~1
nonparasite~1
nonresponders),~1
(hyporesponders,~1
elephantiasis,~3
Novobiocin,~1
novobiocin~2
(cDDP)~1
Novobiocin~3
cDDP~4
crosslinking,~2
clobetasol-17-propionate~1
superpotent~1
investigator-masked,~1
reemphasized~1
aposition~1
Preplanning~1
camouflaging~1
postvulvectomy~1
anterointernal~1
safeness,~1
(P-31)~1
(allografts).~1
(PCr/Pi),~1
(PCr/ATP~1
(ATP~1
beta/Pi)~1
tesla)~1
isograft~1
PCr/ATP~1
177,000~1
ischemia-producing~7
pre-streptokinase~1
(82.9~1
93.8~1
restudy,~1
post-streptokinase.~1
formulation,~5
powder.~1
L-649,923,~1
3.8-fold.~1
LTD4-inhalation~1
desires.~1
Dehydrated~1
pulverization.~1
Cutaneous,~1
nasal,~1
"key~1
words"~1
lib~4
controlled.(ABSTRACT~1
vinpocetine,~1
apovincamine,~1
vinpocetine~2
(tid)~1
Impression~2
(CGI)~1
(SCAG)~1
(MMSQ).~1
prepost~1
control/comparison~1
over-the~1
Medicare-age~4
group-and~1
capitated~1
per-patient,~1
per-year~1
(8.15~1
6.46),~1
(3.41~1
2.33)~1
($749~1
$623).~1
gatekeepers~1
podiatrists,~1
mortality-related~2
attribute,~1
attribute.~1
ranges"~1
Caregiver~1
incapacity~2
bibliography.~2
publications;~1
viewpoint.~1
unreferred~1
society:~1
ailments~1
sociologic~1
covered.~1
Minneapolis-St.~1
Paul~2
partners:~1
2.71,~1
2.09,~1
.47~1
colipase;~1
mimicry.~1
Metamucil~1
Darvocet~1
N-100s~1
cognitive-behavioral~2
1F5,~1
(Bp~1
anti-immunoglobulins,~1
nonmitogenic~2
1F5-pretreated~1
1F5-primed~1
pretransfused~2
cyclosporin-A,~1
(SAF).~1
SAF,~1
cyclosporin-A.~1
C57BL/KsJ-db/db~2
(scid),~1
(xid),~1
(nu),~1
Y-linked~1
(Yaa),~1
diabetogenesis~2
p73).~1
fibronectin-~1
plasma-coated~2
surfaces).~1
anti-Mo-1~2
anti-Mo-1.~1
(CBA/J,~1
SWR,~1
C57B/6)~1
activity-1~1
(CSA-1)-like~1
phenyl-Sepharose~1
lentil-lectin~1
CSA-like~1
1-dependent,~1
2-producing~3
14,000,~1
14,500,~1
17,000,~1
15,000,~1
electrophoresis.(ABSTRACT~1
(T638)~1
complement-susceptible~1
(b2m)~1
T638~13
b2m~1
anti-HeLa~1
b2m.~1
anti-b2m~1
Antibody-sensitized~1
3H-C4~1
3H-C3~2
C142~1
3H-C3.~1
C142-mediated~1
6.4.~2
6.4:~1
C3(H2O),~1
C3b,Bb~1
Wuchereria~3
bancrofti~5
(CA101)-based~1
positives"~1
nonfilarial~3
(CA86,~1
CA101)~1
untypeable.~1
microfilaria,~1
CA101~1
acetone-killed~1
TML~1
(AKD-TML)~1
AKD-TML~1
CBA/Ca~2
TML-specific~3
anti-LPS-specific~1
(Lpsn,Lpsn);~1
(Lpsd,Lpsd)~2
(Lpsn,Lpsn).~1
late-occurring~1
Jo-1~4
(histidyl-tRNA~1
affinity-purified,~1
(35.8%~1
immunodiffusion-positive~1
immunodiffusion-negative~1
30.5%.~1
ELISA)~1
histidyl-tRNA~2
H130~3
(IgM-kappa)~1
H241~3
(IgG2a-kappa),~1
DNAase,~1
H130,~1
anti-H130.~1
anti-DNA-producing~1
non-DNA~1
RIN,~1
(CELISA).~1
ganglio~1
lacto~1
glycosphingolipids,~1
globo~1
CELISA~2
(1/30~1
1/120)~1
CELISA.~1
anti-RIN~1
anti-islet~2
C.B-17~2
(deficient~1
scid)~1
(replete~1
scid).~1
Epidermis~2
mounts,~1
(DAF-1)~1
DAF-1,~1
(DAF-2)~1
convertase,~1
C4b2a,~1
reincorporate~1
DAF-1~2
DAF-2.~1
DAF-2~1
bancrofti.~2
Dirofilaria~1
immitis,~2
bancrofti,~1
(BPF)~1
(GPE)~1
BPF~5
GPE~4
IF,~1
ME.~2
immunofluorescent-staining~1
(B6XA/J)F1~1
Skn,~1
Skna-specific~1
(SBF)~1
SBF~5
(s/m~1
Radiative~1
ms-1),~1
0.001)].~2
-0.57~1
equivalent"~1
antifibronectin,~1
Ichthyosis~1
mononucleosis-like~1
(IFAs),~1
(ELISAs),~1
(WB).~1
p68~1
Ib/c~1
(Ib/c-GBS)~1
(NICU).~1
[ICs])~1
bacteremic.~1
(ACs).~1
Ib/c-GBS~3
nosocomially,~1
ACs~1
GBS,~1
Ib/c-GBS.~1
phage.~3
infant-to-infant~1
NICU.~1
adenoviruses,~1
(Ad~2
Graham~1
SmaI~1
97.1%~2
41.~1
97.2%~1
Fansidar~3
(pyrimethamine-sulfadoxine)~1
4-aminoquinolines~1
Non-immune~1
(MG/32)~1
regained,~1
ceftazidime;~1
MG/32,~1
G-gentamicin~1
O157:H7~7
Ty21a~4
sonnei.~2
bivalent,~1
organisms/dose)~1
Hematest-positive~2
lot-to-lot~1
euhepatic~1
cauterising~1
Practitioner~1
deception~1
"stress"~1
microtremors~2
lying.~1
speech--or~1
deception--have~1
acoustic/temporal~1
analyzers,~1
stress/nonstress~1
lie/nonlie~1
"examiners"~1
auditors.~1
conjuction~1
xylene-enhanced~1
"dry"~1
wartime,~1
Extraordinary~1
stressors.~1
(t.i.d.),~2
(t.i.d.)~1
(DT7995)~1
(AMSA)~1
(OAP)~1
(PPR)~1
(PPR~3
.40)~2
AMSA-OAP~5
OH]~1
OAP~1
(Ad-OAP).~1
.60)~1
Ad-OAP.~1
Ad-OAP~3
DT7995~1
Ad-OAP,~1
61%)~3
(ANL)~1
10.00~1
15.75~2
(carmustine)~1
cells/kg),~1
500/microL)~1
20,000/microL)~1
1,500/microL.~1
five).~1
500/microL.~1
asphyxiation;~1
klebsiella~1
bacteremia;~3
.037).~1
centenary~1
Geoffrey~1
(1886-1961)~1
thrombo-occlusive~3
Antibiotics,~1
(3.64%)~1
(0.96%)~1
6.77%~1
Doppler-measured~1
0.054).~1
(DID's),~1
DID's~1
(VIP)-,~1
(SP)-,~1
(NPY)-containing~1
(M1)~1
SP-immunoreactive~1
63rd~1
glutide~4
(lactide:glycolide,~1
80:20)~1
pipe-splint.~1
freed-up~1
barrel.~1
"one-knot~1
anastomosis"~1
Acrylic~1
resorb;~1
skulls.~1
parenchyma;~1
[131I]HIPDM~3
(SPMID)~1
[99mTc]HSA~1
SPMID~3
s.d.,~1
0.834)~1
de-iodination~1
[131I]HIPDM,~1
slope-intercept~1
0.989).~1
10%-15%.~1
hydration.~3
(VEDRS)~1
Schlegel~1
Gates~1
([99mTc]DTPA-[131I]hippuran)~1
(anuric~1
[131I]hippuran~3
18-115~1
hemithorax)~1
17-107~1
infinitely~1
[99mTc]DTPA.~2
2.7%-11%)~1
para[(biscarboxylmethyl)-aminomethylcarboxyamino]hippuric~1
([99mTc]PAHIDA),~1
orthoiodohippuran~1
(OIH).~2
[99mTc]PAHIDA~2
PAHIDA~1
polyethylene-carbon~1
[14C]pantothenate~4
(CoA).~1
(46-71%)~1
unacylated~1
(CoASH)~1
acetyl-CoA,~1
(BK)~4
(PGI2).~2
pair-fed.~1
Bk~1
(0-400~1
3-wk~3
PGI2.~4
Pair~1
fructose-control~2
glucose-control~3
fructose-~2
Levamisole~1
glucose-fed~2
oronasal~1
quantitate,~1
(PFC/HA).~1
firmness~1
Prosthodontist~1
denture~3
masticate.~1
(HAB),~1
(HAD).~1
HAO~1
HAD~1
augmentations.~1
microradiography,~2
histometry.~1
perimeters~1
osteotonic~1
46.6%~1
53.4%~2
33.9%~1
mm2/mm3~1
61.9%~1
38.1%~2
onlays,~1
SIDS?~1
populationwide~1
pneumogram,~1
asphyxic~1
pneumograms,~1
monitors:~1
cause(s)~1
unknown.(ABSTRACT~1
(gammaglobulin~1
gammaglobulin,~1
6-weeks~1
(GABS)~1
GABS~1
penicillin-tolerant~2
GABS.~1
REV~3
[alpha-pentyl-3-(2-quinolinylmethoxy)-benzene-methanol]~1
peptidoleukotrienes.~1
([3H]-LTD4)~1
LTC4-,~1
LTE4-induced~1
Kb~5
spasmogens.~1
peptiodoleukotriene-antagonist~1
peptidoleukotrienes~2
lisuride~7
171555~1
(0.008-0.063~1
38393~2
(2.0-16.0~1
saline-lever~1
(-)-sulpiride~1
(0.125-0.5~1
bromuride~1
pirenperone~1
lisuride.~1
(0.0625-0.35~1
(APO)~1
sessions),~1
D2DA~1
nisoxetine,~1
oxidase-inhibited~2
Tc-99m-diethylenetriamine~1
penta-acetic~1
(Tc-99m-DTPA)~1
Tc-99m-DTPA~3
0.5-sec~1
(50.5~1
g/min),~1
(beta-FNA)~1
I-methadone,~1
U-50,~6
488H.~1
nonmu,~1
nalorphine~1
beta-FNA.~1
(DPDPE)~2
selective/nonselective~1
(DPDPE,~2
L-Pen5]enkephalin~1
(DPLPE),~1
Gly-ol]enkephalin,~1
Met5]enkephalin~1
[D-Ser2,~1
Leu5,~1
Thr6]enkephalin~1
[D-Thr2~1
Thr6]enkephalin)~1
DPLPE~3
D-Leu5]enkephalin)~1
morphine-tolerant~2
(morphine)~2
174,864.~2
DPLPE.~1
vasoconstrict~1
Cirazoline,~1
bitartrate~1
(B-HT~1
(selection)~1
bidirectionally~1
breeding,~1
(lineages)~1
[3H]dihydromorphine~3
opioid)~1
(+/-)-hexahydrocannabinol.~1
[3H]D-Pen2,~1
D-Pen5-enkephalin~1
[3H]ethylketocyclazocine~2
binding),~1
[3H]N-(1-[2-theinyl]cyclohexyl)piperidine,~1
benzilate.~1
[3H]etorphine~8
(potent~1
protein-lipid~1
membrane.(ABSTRACT~1
(MeCh)~1
(Hist),~1
MeCh~6
MeCh,~2
muscarinic-M1~1
Hist~4
Hist.~1
CaCl2.(ABSTRACT~1
early-third-trimester~1
purse~1
centromeres,~1
ribonucleoprotein.~1
rheumatologic~4
torcular~1
herophili~1
D-penicillamine.~1
181)~1
Peruvians~1
subjective.~1
rheumatologists,~1
Lipo-PGE1~1
E1)~1
lipo-PGE1~5
quadricepsplasties~1
limp.~1
(TP5),~1
CP-46,665~2
immunomodulator-treated~2
CP-46,665,~1
parvum),~1
TP-5,~1
CP-46,665.~1
parvum-treated~1
Firearms~2
half-century~1
1933-1982.~1
Teenagers,~1
implement,~2
hemiscrotum.~1
ovotestis~2
ovotestis.~1
(glycosaminoglycans,~1
mucopolysaccharides)~2
(GP1)~2
GP1~8
glycoprotein--whether~1
anti-rabbit~2
pre-transplantation~1
prostatism.~1
urolithiasis,~1
Analogues~2
aspirin)~2
221,000~1
174,000~1
aspirin);~1
(59.5%~1
iloprost)~3
(56.7%~1
iloprost).~2
ng/ml.(ABSTRACT~1
27-month~1
arteriotomy,~1
(1.3%),~2
(13.7%),~1
(2.9%).~2
(recurrent~1
(4.1%).~1
arterioarterial~2
cardioarterial~1
In-depth~1
hemopericardium~1
favored;~1
embolectomies~1
polymicrobial,~2
foul-smelling~1
advancing,~1
ketoacidosis~14
morbid,~2
Neuropathy,~1
Neuropathy~1
revascularized.~1
diabetic's~1
foot-related~1
22-year-long~1
rendered.~1
non-diabetics~2
9-impregnated~1
(parallel)~1
woman-weeks~2
0.67;~2
1.07)~1
[0.16~1
0.60])~1
[0.96~1
7.98]).~1
(GCT),~1
9000/microL~1
[9~1
10(9)/L])~1
6000/microL~1
10(9)/L]);~1
high-count~1
covaries~1
Yemenite~1
satisfying,~1
stress--including~1
importance;~1
activatability.~1
nongrowing~2
(C57BL/6J).~1
pair-weighed~2
[4~1
IU/100~1
wt)]~1
alpha-granules~1
alpha-granules).~1
fib~5
fibrinogen-~1
fibrin-related~1
LGV~3
N-nitroso-bis(2-oxopropyl)amine~1
60599-38-4].~1
Artifactual~1
antifibrinolysis.~1
Ducts~1
atypicality~1
fib,~1
proteins--type~1
Monomer~1
Stokes-Einstein~1
externa;~1
perferentially~1
externa,~2
(HMWFC)~1
HMWFC~1
(RPGN).~1
oligo-anuria~1
anti-tubular-basement-membrane-mediated~2
anti-tubular-basement-membrane~1
guanidine-HCl,~1
dodecylsulfate.~1
immuno-overlay~2
ACE-inhibition~2
(enalapril~5
ACE-inhibition.~3
Foundation,~1
isolated;~2
DF.3~4
(ABC~1
immunoperoxidase)~1
synchronous.~2
"metachronous"~2
cystopexy~1
polyurethane-covered~1
corrections,~1
5.27~1
updates,~1
full-width~1
xenotransplantation~2
xenotransplant~1
necks~1
irrelevant.~2
DNA-based~4
nonpaternity.~1
revolutionize~2
EMIT-dau~4
unadulterated~1
THC-COOH~1
false-positive.~2
EMIT~1
delimitation~1
hemalum-phloxine-stained~2
hyperchromasia)~1
oligoastrocytomas~1
tumor.)~1
BB-isoenzyme~2
astroprotein,~1
neuropil,~3
frequency-dependent,~1
phospholipoproteinosis.~1
thoracotomy-lung~1
acid-Schiff-positive~1
osmiophilic~1
phospholipoproteinosis~1
pulmonary-function~1
risk--guidelines,~1
sure--but~1
absolutes.~1
internist-cardiologist,~1
anaphalaxis,~1
hemolysis)~1
(allosensitization~1
infections)~1
antibodies),~1
sickest~1
specifics,~1
familiar.~2
"graying"~1
patient-related~1
109,000~1
heat/phenol-inactivated~1
Vero-cytotoxin-producing~1
(VTEC)~1
VTEC~3
O157.~1
non-fermenters~1
O157~2
VT+~1
serogroups.~1
Immunoprophylaxis~2
310-1207~1
Hypersplenism~1
Pre-transplant~1
life-expectancy~1
variables),~2
Leicestershire.~1
co-variates,~1
haemodialysis,~1
Thai-Burmese~1
weekly).~1
man-weeks~2
human-immunodeficiency-virus-seropositive~1
Padua,~1
AIDS/ARC~2
pranobex.~2
pranobex,~1
Laryngectomized~1
neophonation.~1
catgut.~1
miliwatt~1
welding,~1
stapedotomy.~1
Chronologic~1
(VO2max,~1
courtroom~1
Behcet~2
granulomatoses~1
(GANS)~1
HZO.~1
GANS~2
Gasserian~1
GANS.~1
HZO-associated~1
Sucrase-isomaltase~1
sucrose-splitting~1
cerevisiae,~4
baker's~2
yeast)~1
isomaltase~1
listings~2
Pages~3
Hartford,~1
certifications~1
Marquis~1
Directory~1
Specialists.~1
946~1
headings~1
Pages.~1
"specialists"~1
misrepresentation.~1
Normoglycemia~5
angiotensin-converting-enzyme~2
[NYHA]~1
126)~2
127).~1
group--a~3
0.048).~1
myalgias~3
renal-transplant~1
anti-anti-HLA~3
(antiidiotypic)~1
presensitization~1
anti-donor-HLA~1
cross-matching~1
(L3T4)~3
(Lyt2)~1
cells):~1
CD4+8-~1
CD4-8+~1
positives),~1
CD4+8+~2
positives)~1
CD4-8-~5
negatives).~1
'dead-end~1
Phosphofructokinase~1
site?~1
Glu----Ala~1
fructose-6-phosphate,~1
PEP.~1
Monod-Wyman-Changeux~1
sequence-dependent~1
14-base-pair~1
arrayed~1
half-site)~2
1b).~1
repressor-operator~1
half-site,~2
'recognition~1
alpha-helix'~1
1a).~1
Cro,~1
434.~1
sequence-dependent,~1
'recognition'~1
part)~1
'new-specificity'~1
Repressor~3
[Ala~2
28],~1
28]~1
28-base~1
cdc2~2
cdc2.~1
blastoderm~4
(ftz),~1
cellularized~1
cycle-14~1
ftz~5
maternal-haploid~1
1182~1
(mh~1
1182)~1
daughterless-abo-like~1
(dal)~1
co-released~1
hydrolysed~4
ectophosphohydrolases~1
ectophosphohydrolase~1
adenosine-mediated~1
ectophosphohydrolases.~1
SV5~2
computer-assisted,~1
reaccumulated~1
postamputation~1
thermocontrolled~1
muscle-force~1
polyradiculitis~1
Intrapartum~1
700-1750~1
(electronic~1
124).~1
malignancy)~1
postdatism~1
95.6%~2
185).~1
Metaplasias,~1
Superficially~1
reduplications~1
foresee~1
provocations~2
handicap,~2
(0.81-1.00)~1
0.40-1.00.~1
measurements--biparietal~1
circumference--and~1
parameters--gestational~1
hysterographic~1
nonradiation-affected~1
Hysterography~1
one-half.~2
Lamicel~5
laminaria,~1
0.9-1.1).~1
0.2-0.5).~1
Pourcelot's~1
fetometry.~1
Waveform~1
nonstressed~1
cardiotocography.~2
perimeter/abdominal~2
-4~2
length/head~1
+3~1
gastroschisis~3
27-39%~1
hyperandrogenemic~1
acanthotic~1
preeclampsia/eclampsia,~1
controversy--the~1
18-40%~1
16-30%~1
antiprostaglandins~1
Histiocytic~1
orbito-sinus~1
re-biopsy~1
(Ventilator~1
surgeon-~1
Ventilator~4
(45.8~1
23.1%),~1
ventilator-supported~1
immunohistologic,~1
paving~1
Photoreceptor~1
autopsy-proven~1
False-negative~1
biomechanics.~1
Meniscocondylar~1
facile,~1
74.8%~1
85.0%.~1
significance;~1
0.068)~1
genitals,~1
manageability~1
restorations,~1
extirpation,~1
71.8%~1
amoxicillin-clavulanate~3
Beta-lactamase-producing~1
signs/symptoms~1
otalgia/otorrhea~1
OM/otorrhea~1
effects/complaints,~1
gastrointestinal.~1
melaninogenicus,~1
fragilis),~1
spiramycin)~1
erythromycin)-membered~1
macrolides,~2
spiramycin~2
6-month,~1
9-month,~1
Parentally~1
Innovative~1
AICU.~1
Braden~6
Sore~3
AICU~1
Norton~4
overpredict,~1
overpredicted~2
(Sandimmune)~1
self-direction~1
Self-monitoring~2
(Diabinese)~1
lymphadenitis,~1
parotid)~1
(NAase;~1
acylneuraminyl~1
3.2.1.18).~1
NAase~4
NAases~1
rangeli,~2
NAases.~1
glycoconjugates.~2
246,000~1
"cruzin."~1
(dsDNA)-dependent~1
recA~6
(ssDNA)-dependent~1
dsDNA-dependent~2
Elsewhere~1
protein-catalyzed~1
(pp120)~1
pp120~4
H-35~6
phosphotyrosine~5
pp120.~1
(EF-Tu),~1
tufA~1
(guanine~1
EF-Tu.~1
G-domain~2
K'd~1
EF-Tu~4
mol-1~2
domain),~1
GTPase.~1
Ts,~1
kirromycin.~1
EF-Tu,~1
(fdhF)~1
selenopolypeptide~1
(formate:benzyl~1
viologen~1
1.2.--.--)~1
in-frame~6
UGA~7
fdhF~5
lacZ~3
codon;~1
lacZ.~1
(UCA)~1
(UGC~1
UGU)~1
UCA~2
UGC~1
UGU~1
hydrogenlyase.~1
mycoides~2
UCN~1
boxes.~1
wobble~3
unsubstituted~1
ACG.~1
isoacceptor~1
(methyl~1
viologen)~1
apurinic/apyrimidinic~2
plumbagin,~2
menadione,~2
methosulfate.~1
streptonigrin,~1
hydroperoxide,~1
260-nm~1
ascorbate.~2
paraquat-treated~1
oxyR,~1
H2O2-inducible~1
oxidative-stress~1
regulon.~1
DNA-repair~1
lac~6
(lacI)~1
monocistronic~2
lacI~3
repressor-bound~1
repressor's~1
lacZYA~1
(p21ras)~1
firefly~3
luciferase~1
[Photinus-luciferin:oxygen~1
4-oxidoreductase~1
(decarboxylating,~1
ATP-hydrolyzing),~1
1.13.12.7]~1
Luciferase~1
(Photinus~1
pyralis)~1
firefly's~1
lantern~1
GCN4~10
alpha-helix-permissive~1
Mst~5
220-base-pair~1
160-bp~1
39-bp~2
"THE"~1
(transposon-like~1
element)~2
SINE~1
nonrandom;~1
(APRT)~1
APRTs~1
APRT~5
"CCAAT"~1
flanking,~1
untranslated,~1
AG/GC~1
(guanine)~1
6-thioguanine-resistant~1
3-base-pair~2
frame"~1
transversions~3
(7E6A5)~1
7E6A5~3
Nongoblet~1
Mucus-secreting~1
mucus-secreting~2
7E6A5.~1
Decoding~1
proglucagon,~1
alpha-sialyl-beta-2,3-galactosyl-specific~1
adhesin)~1
S-fimbrial~1
adhesin-enriched~1
(fimbrillin~1
(fimbriae~1
Adhesin~1
fimbrillin~1
adhesins~4
anti-adhesin~1
anti-fimbriae~1
anti-adhesin,~1
anti-fimbriae,~1
anti-adhesive~1
immuno-gold~2
decorates~1
34C9~1
"neural~1
keratin."~1
otic,~1
sphenopalatine,~1
ciliary,~1
1.14.16.2)~1
2.3.1.6).~1
anatomical,~1
7152~1
2164~1
polyprotein~2
rhinoviruses~1
[Niiya,~1
Yamasaki,~1
T.H.~1
Tsuchiya,~1
8902-8906].~1
(antup)~1
mapped.~2
antup~1
15-kilobase-pair~1
carA~1
dnaJ.~1
rpsT~1
flavocytochrome~1
3.0-A~1
flavin-binding~2
8/alpha~1
trimethylamine~2
[3H]inositol-labeled~1
rat-1~2
LiCl,~1
(InsP1)~1
EJ-ras-transfected~8
[3H]InsP3~1
[3H]InsP1.~1
v-src-transformed~2
PDGF-stimulated~4
[3H]InsP1~1
ras-induced~1
bradykinin;~3
[3H]bradykinin~1
"footprinting",~1
phosphatidylinositol-glycan,~1
phosphate-glycan~2
phosphatidylinositol-glycan-specific~2
glycosylated-phosphatidylinositol-membrane-anchored~1
butyl-agarose.~1
phosphatidylinositol;~1
microfluorimetry~1
2C1,~1
microfluorimetry,~1
gastrin-binding~2
gastrin-(2-17)-hexadecapeptide.~1
2C1~1
midlogarithmic-phase~1
manganese-containing~1
(MnSOD),~1
MnSOD~1
heat-mediated~1
dioxygen-dependent~1
(HA~1
Madin-Darby~1
(GHA~1
GHA~1
(CHEF)~1
Na+/H+-antiporter~1
(pHo)-dependence~1
thrombophilia~1
deletion(s)~1
rearrangement(s)~1
exon:~1
(CGA,~1
inframe~1
palindrome~8
(GGATCC----GCATCC)~1
402),~1
invariantly~1
C-deficiency~1
POL1,~1
pol1~3
POL1~2
entered,~1
XIV~1
met4.~1
240-nucleotide~1
GAL1-lacZ~1
(GCN)~1
(GCD)~1
leader.~2
derepressing~1
GCD~1
GCN4-lacZ~1
xthA-~3
xthA+~1
(MNNG)~1
"adaptive~1
response."~1
xthA(-)-dependent~2
MNNG-adapted~1
MNNG,~1
SOS-dependent~2
alkA-~1
3-methyladenine~1
anti-parathyroid~1
proximal-tubule~1
calcium-sensing~1
(owl)~1
surface-coat~2
rhoptry~2
Uganda~1
(FUP)~1
Neurofibrillary~3
disease-affected~1
ubiquitin.~1
tau,~2
neurofilament,~4
neurofibrillar~1
nylon-silicone~2
-24.8~1
-15.2~1
Opsite~1
+14.9~1
+18.2~1
+23.0~1
48.9~1
gm/cm2~4
glutaraldehyde;~2
-26.4~1
evert~1
Tisseel~2
microanastomosis~2
microclamps.~1
(SNR),~1
(FOV),~1
Sonography,~1
cholescintigraphy,~1
(ERCP);~1
canceled~6
Sonographically~2
pyelectasis~3
pelvocalyceal~3
occiput.~2
2,121~1
trisomies.~2
3,825.~1
3,825~1
hysterography~1
someday~1
shigellosis,~1
meningosepticum~1
TMP-SMZ-carbenicillin~1
gentamicin-carbenicillin~1
introital~1
bladders).~1
.037,~1
growth-differentiating~1
Tn5,~1
US5~1
(African~1
rapid-onset,~1
N-methyl-D-aspartate,~1
homocysteate,~1
quinolinate.~1
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate~1
N-methyl-to-aspartate~1
shutting~1
17-kilobase~1
Searle's~3
inactive).~1
alpha-methyl-rho-tyrosine~1
nucleocapsid,~1
protease-like~1
self-cleavage~1
6B7,~1
sternocostoclavicular~1
exemplify~1
pustulosis.~1
Sternocostoclavicular~1
Confederate~2
expend~1
dollars.~4
furlough.~1
Kahn's~1
nigricans)~1
Littre's~2
C4-C5,~1
autograft),~1
cement),~1
Methylmethacrylate~2
wire),~1
fusions).~1
C4-C5~2
"normals."~1
fibrosynovial~1
relevance:~1
constructs.~2
symptom(s)~1
Pseudarthrosis~1
insulin-free.~1
microkatal~4
pancreaticoenteric~1
(9,100~1
2,450~1
thymopentin~2
cefotetan~2
cefotetan,~1
"Arc~1
Riolan"~1
"marginal~1
Drummond"~1
meandering~2
dilative~1
siphon,~1
collateralization~1
multijoint~1
(sensor~1
microcomputer,~2
nasion~1
methodology--e.g.,~1
microinstrumentation,~1
keratometer,~1
lenses--that~1
astigmatic~1
glimpse~1
Stewart's~1
wit,~1
candor,~1
gallantry,~1
(AVCs)~1
AVCs~1
subfascially~1
extrafascially,~1
(ligation~1
mucosa-to-mucosa~1
microgram/kg),~1
emptied.~1
pancreaticojejunal~1
Ultrasonograms~1
unverified~1
disrupted;~1
Banding~1
(exogenous~1
normogonadotropic~1
"stimulation"~1
antiestrogens,~1
irresponsible~1
Nonhormonal~1
novo;~1
emerges.~2
p-glycoprotein~1
"good-risk"~1
signet-ring-shaped~1
sporadically.~1
99.2~1
25/34~1
piperacillin-treated~1
Gm/day)~1
23/38~1
cefamandole-treated~1
Gm/day).~1
(22/23)~1
(41/58)~1
(15/58,~1
(8/58,~2
extraurinary~1
unrevealing.~1
dysraphism~2
syringohydromyelia~2
Fibroglial~1
compartmentalize~1
hemicords~2
bony,~2
hemicords.~1
(IOSS).~1
IOSS~1
(arteries,~1
Next~1
(43%,~1
(Tc-GH)~1
Computer-acquired~1
1-3-min~2
2-4-hr~2
.96).~2
60/40%,~1
Tc-GH~3
Tc-DTPA~2
Tc-GH.~1
Tc-DMSA.~1
fluid-density~1
multiseptated~1
sonogram)~1
through-transmission,~1
hyperechoic.~2
anechoic.~1
through-transmission.~1
Subfascial~2
umbilicovesical~1
short-focus~1
bladder-flap~3
superficial-wound~1
(40/52~1
corroboration~1
(3-6~1
echopenic~1
(7/26~1
27%)~3
(9/21~1
(17-69~1
silicone-induced~1
mineralization;~1
1982-1986~1
"lobule"~1
lobule.~2
(marginated~1
sonographically,~1
(1979-1985),~2
Maternal/fetal~1
megaureter)~1
upper-pole~1
hydronephrosis).~2
1947-1977,~1
symptoms--either~1
umbilical-artery~1
(diagnosed~1
dipstick)~1
umbilical-artery-catheter~1
infusate,~1
Rejection,~1
(hematomas,~1
bilomas,~1
seromas)~1
(70%);~1
recipient;~1
2.2-3.3~1
3.5-5.0~1
left)~1
teratomas,~1
hydrometrocolpos,~1
nafazatrom~4
12-hydroxy-eicosatetraenoic~1
(12-HETE)~3
TxB2),~1
0.25).~1
Nafazatrom~1
coarctectomy-induced~1
nitroprusside;~1
beta-2-receptor~1
Retitration~1
(taking~1
(standing~1
20.1/14.9~1
(ramipril)~2
16.5/13.5~1
more:~1
22.5/20.0~1
20.5/18.6~1
77.1%.~1
82.7%.~1
inhibitors--captopril,~1
perindopril,~1
trandolapril~1
ramipril--on~1
ramipril.(ABSTRACT~1
hyperreninemia~1
ramipril).~1
afterdepolarizations.~1
ionization,~1
conjecture.~2
repolarizing~1
reduce,~1
drug-aggravated~1
nonparoxysmal~1
(multiform)~1
Bidirectional~1
ml/min);~1
(-107~1
-218~1
153%,~1
ventilation-induced~1
(mainstem~1
wedge)~1
(M2).~1
M1.~1
diastole;~1
M2.~1
(863~1
biopsies)~1
ISA-possessing~1
beta-stimulant~1
"down~1
regulates"~1
post-beta-blocking~1
liver-metabolized~1
beta-selective~1
micronutrients,~1
9.04~1
(b).~1
breakfasts~2
Fat-containing~1
butter.~1
Emerging~3
(HLA-ABC+,~4
HLA-DR+,~4
RA+,~3
monocyte-,~3
phosphatase+,~1
ATPase+);~1
monocyte+);~1
HLA-DR+/-,~1
RA-,~1
5'nucleotidase+);~1
Leu-2+,~1
RAweak+,~1
esterase+);~1
(Factor~2
HLA-ABCweak+,~1
HLA-DR-,~1
monocyte-).~1
monocyte-related~1
radical-generating~2
disorganization.~1
Input~1
iron/total~1
capacity/ferritin~1
B12/serum~1
folate/red~1
immunoenzymometric~2
(IEMA).~1
IEMA~2
reactive.~4
Abbott-positive~1
H-9~1
Electro-Nucleonics~1
IEMA,~1
cell-FANA~1
incongruity,~1
prednisolone;~1
-2.2~1
-2.5~1
(-2.1,~1
-2.4,~1
-2.7)~1
(-2.5,~1
-2.2,~1
-2.1)~1
(-2.2,~1
-1.9,~1
-1.8).~1
azathioprine-prednisolone~1
cyclosporine-prednisolone~1
audiology~1
hydrocodone~1
Train~1
robbery~1
1800s~1
1920s.~1
1923,~1
southbound~1
Express~1
Tunnel~1
railway~1
+40,000~1
clerk~1
mountains.~1
headed~1
Dan~1
O'Connell,~1
Heinrich,~1
soiled~1
overalls~1
nearby.~2
botanical~2
woodsman,~1
d'Autremont~1
manhunt,~1
Philippines~1
guilty.~2
pleaded~1
unforeseen~2
criminology~1
ulcer).~1
commode~1
(threshold)~1
perceived,~2
arranging~1
proctogram--a~1
defecate--in~1
(puborectalis~1
rectocele~1
(-2.2~1
RAP-5.~1
(87.4%),~1
(59.4%)~1
(62.4%).~1
anaplasia.~1
ranitidine-treated~3
levamisole;~1
Cognizance~1
ERPF,~2
capillaries;~1
sensed~1
small-mol~1
mosm/kg.~1
volume-AVP~1
volume-sensing~1
"vasopressin-resistant"~1
cystine-aminopeptidase~1
(vasopressinase).~1
pitressin,~1
dDAVP.~1
vasopressinase~1
gravidas.~1
remitted,~1
(overfill~1
hypothesis).~1
shunting)~1
(underfill~1
hypothesis)~1
underfill~1
accompaniments~1
(P-AH,~1
preeclampsia).~1
handling;~1
sensed,~1
"effective"~1
salt-restricted,~1
Dieckmann~1
Michel~1
Gant~1
AII-refractory~1
prostinoids~1
nullipara,~1
chameleonlike~1
presumptive.~1
(170/110~1
(IgAGN,~1
(RN,~1
(FGS,~1
IgAGN,~1
RN,~3
FGS.~1
IgAGN~2
FGS~1
(SCr)~1
IgAN,~1
FGS.(ABSTRACT~1
diabetogenic,~1
lactations~1
excretions,~1
virgins.~1
multiparas,~1
Hypogonadism~1
reported).~1
formyl-met-leu-phe~1
WBCs,~1
dilutes~1
opsonins,~1
(subepithelial,~1
intramembranous,~1
subendothelial,~1
Crescent~1
(30/88,~1
(9/144,~1
(15/26,~1
57%).~1
(74.0%)~1
(96.9%)~1
(slow-release~1
reciprocals~1
(ACDK)~1
ACDK~1
(GKD)~1
Xp21,~1
different-size~1
GKD~2
J-Bir~1
L1.4)~1
GKD/AH/dystrophic-myopathy~1
milder,~2
(Ball~1
LeBel~1
al).~1
Guay~1
ciprofloxacin;~3
non-antibiotic~1
Pirenzipine,~1
N-butyl-scopolaminium~1
metclopramide~1
magnesium-~1
ciprofloxacin's~1
cfxA,~1
gyrA~7
mutation;~2
cfxB,~1
marA.~1
cfxB~1
OmpF,~1
liter/hour)~1
improvement)~4
non-compartmental~1
(hours-1)~1
1.15;~1
k12~1
k21~1
1.31;~1
state/bioavailability~1
clearance/bioavailability~1
SD):~1
Vd/F,~1
liters/kg;~1
Cl/F,~1
772.9~1
(301)~1
(0.8)~1
(MIC90~5
49/post~1
azlocillin.~2
anti-pseudomonal~1
2,250~1
responses).~1
azlocillin),~1
pneumonia)~2
aeruginosa;~1
drug-related.~1
ciprofloxacin-susceptible~1
non-comparative,~1
tracheobronchitis.~1
improvements).~1
Recolonization~1
MRSA;~1
eradication,~2
0.0214).~1
arthrocentesis~2
Osteomyelitis~2
isolate),~7
isolate).~2
(vertigo~1
judged.~1
cinoxacin~1
cinoxacin.~1
urorenal~2
6.98~1
post-therapy,~2
71.2~1
shortcomings,~1
erythromycins,~1
(shorter~1
dosing)~1
(pelvic~1
vaginosis,~1
example)~1
(gonorrhea-chlamydia,~1
gonorrhea-syphilis,~1
chancroid-syphilis),~1
postgonococcal~1
cip,~1
(52.1~1
doxycycline).~1
Chancroid~1
ducreyi.~1
buboes~1
Trimethoprim/sulfamethoxazole~1
shigellosis~5
trimethoprim/sulfamethoxazole-resistant~1
salmonellosis~5
faecium~2
Viridans~1
Corynebacterium,~1
First-step~1
"difficult-to-treat"~1
intraabdominal,~1
intrahepatic),~1
multi-resistant;~1
(61.1~1
(MIC).~1
non-eradicated~1
"dose."~1
osteomyelitis/septic~1
2,829~1
3,981~1
160/800~1
prostatis,~1
Renin/aldosterone~1
telangiectases,~1
malformations;~2
fistulas;~1
dermoplasty~1
Ligation,~1
interpreters~1
strictness~1
inflation-fixed~1
(output~1
mW;~1
horns.~1
8-0~4
nylon;~1
"welded"~1
suppuration,~2
granulation;~1
laser-with-suture~1
(0.125,~1
(+18,~1
+18,~1
+21)~1
1531~1
nonpreeclamptic~1
isothiocyanate-conjugated~2
99.7%.~1
Successively~1
current-generation~1
manipulate,~1
magnify,~1
Harbor-University~1
Postsection~1
(predominantly,~1
bacteroides)~1
postsection~1
chloride;~1
FMTUTOR~2
IBM-PC-compatible~1
instructor-student~1
enthusiastic,~1
underway.~2
Curvilinear~1
millimeters),~1
0.948;~1
0.956;~1
0.969;~1
Nomograms~2
A1c~1
preconceptional~1
(volume/weight~1
1:6).~1
overutilization~3
Diagnosis-related~1
$1,300~1
8041~1
1890~1
unrepresentatively~1
Unopposed~1
hyperstimulation,~2
(Estraderm,~1
CIBA~1
Summit,~1
Jersey)~1
propamidine~1
dibromopropamidine~1
Neosporin,~1
unresponsive,~1
keratocytes~1
200-kilodalton~1
Flexner-Wintersteiner~1
S-antigen,~1
neuron-committed~1
"wild~1
oncogenic,~2
AILD-like~1
[AILD-T])~1
suppressor/killer~1
T-subset~2
AILD-T~1
thrombocytopenias~1
(MKs),~1
anti-GpIb,~1
anti-GpIIb/IIIa,~1
anti-PLA1,~1
MKs~3
anti-GpIb.~1
MKs.~1
mat~1
(FN)-positive~1
(GFAP)-negative~1
swirling~2
plasmalemma,~1
(RDR),~1
gliosarcoma.~1
Around~2
FN-~1
netlike~1
area/perimeter~1
RER~1
positive).~5
(SaI)~1
A/Jax~1
(A/J)~1
thymectomized,~1
bone-marrow-restored~1
(ATxXBM)~1
cyclophosphamide)~2
(dosages~1
HHF35-positive~1
methacarn-fixed,~1
(smooth,~1
cardiac)~1
myoepithelium,~1
trabeculaes.~1
"myofibroblasts,"~1
("fibromatoses")~1
distinct-part~1
exempt~5
(PPS).~1
exemption~1
underpay~1
overpay~1
lithium-treated~1
near-trebling~1
2012~1
Medicaid-covered~1
+6.3~1
2012:~1
290).~1
Clients~1
forebode~1
hemarthrosis,~2
"motion"~1
"delayed~1
motion"~1
hinges~1
mensicus~1
insufficiencies.~1
program.(ABSTRACT~1
s.l.~1
funestus.~1
sporozoite-positive~1
736)~1
537)~1
midguts~1
"body"~1
Togolese~1
desethylchloroquine~1
operating.~1
berghei-parasitized~1
Cheek~2
post-challenge.~1
(beginning~1
(6-9~1
photomicrography,~1
150/130~1
9B11~1
newly-infected~1
schizonts,~1
intraparasitic~1
rhoptries~1
micronemes~1
merozoites.~3
rhoptry-microneme~1
gametocytes,~2
trophozoite-infected~1
ring-infected~1
antifilarial~1
filariasis,~3
chyluria,~1
15%-20%~1
filariasis-endemic~1
ES34,~1
nematodes.~1
brasiliensis-sensitized~3
thioglycollate-elicited,~1
antigen-elicited~3
84%),~1
candidacidal~2
luminol-assisted~1
Permethrin-treated~1
nesting~1
wooded~1
enzootic,~1
leucopus),~1
burrows.~1
infested.~1
Voles~1
(Microtus~1
pennsylvanicus),~1
tick-infested,~1
Laboratory-reared~1
noninvasively;~1
liters/min.~1
0.85.~1
Renovascular~1
autotransplantation,~3
Ga.~1
expedient,~1
fluorocarbons.~1
oxygen-transporting~1
(PaO2).~1
Fluorocarbon~1
'blood',~1
anesthetic;~1
profound;~1
evaluation),~1
complete)~2
Narcotic~1
epinephrine;~1
"hit"~1
"miss"~1
(IJV)~1
IJV.~2
IJV~5
NSS.~1
(PAOD).~1
beta-1-adrenergic~2
PAOD.~1
PAOD~2
Celiprolol~1
(BVR)~1
BVR~1
BVR,~1
PAOD;~1
PAOD,~1
BVR.~1
mIU/mL,~2
ectopia.~1
premenstruation~1
postmenstruation~1
0.45).~1
(MCh),~1
[(15S)-hydroxyl-11~1
alpha,9~2
alpha-(epoxymethano)prosta-5Z,~1
13E-dienoic~1
acid]~2
mol/kg,~1
blockade)~1
27.3%,~1
50.0%,~2
173%~1
mol/kg)~1
350%;~1
(dilation)~1
air-ways~1
subcompartments~1
allergen-~1
mast-cell-associated~1
leukotrienes.~3
Congress.~1
Pit~1
vipers,~1
snakes,~1
exotic~3
snakes~5
overtreatment~2
undertreatment.~1
antivenom.~1
snakes.~2
Antivenom~1
dapsone.~1
sphincters,~1
unsettled.~1
need!~1
1715,~1
defied~2
consensual~1
subcutaneous).~1
texts;~1
dissecting,~1
nonsphincteric~1
anatomic/physiologic~1
Cimino-Brescia~1
endpoints,~1
microbes~2
2'-deoxycoformycin~1
(pentostatin).~1
deoxycoformycin.~1
deoxycoformycin,~1
cross-resistance,~1
perineurial~2
Bungner~1
enigma.~4
antiphospholipids~2
Degos'~2
Pericapillary~1
tot~1
Graft-vs-host~1
self-limiting,~2
receptor-steroid~1
(H222~1
(HCDs)~1
Dakin's~1
(chloramine-T)-soaked~1
(86.8%)~1
sub-lamina~1
acquisita.~2
vesiculopustular~1
dermatosis,~2
predominate:~1
(Waldenstrom's~1
urticarialike~1
mononuclear.~1
Ro(SS-A)~3
La(SS-B)~2
double-diffusion~2
serohyperreactivity.~1
serohyporeactivity.~1
lobectomies,~1
segmentectomies,~2
trisegmentectomies,~1
enucleations~1
cystoduodenostomy~1
cystojejunostomy~1
telescopic~1
"anomalous"~1
Telescopic~1
videotaping.~1
(SV-A).~1
pyloric,~1
0.0005-p~1
SV-A.~3
0.033)~2
SV-A~3
Visick~2
Concatenations,~1
linkings~1
469)~1
IMAs~1
130).~2
93).~1
(11/635);~1
(4/437)~1
(1/117).~1
(6/81).~1
anastomosis.(ABSTRACT~1
(A0).~1
(B2).~1
(+dP/dtmax)~1
+dP/dtmax,~1
A0,~1
79.7~1
A0~1
A0).~1
protection.(ABSTRACT~1
verapamil-treated~2
.034)~1
marcescens)~2
(blood-air)~1
blood),~1
(benzylpenicillin),~1
flucloxacillin,~1
cefuroxime.~2
Cefuroxime~2
nonnecrotizing~1
(QTC)~1
catheters),~1
catheters)~2
(CFU/mL)~1
CFU/mL~2
QTC~2
Malignancy-associated~1
Clodronate~1
(Rx-1)~1
(Rx-2)~1
(Rx-3).~1
Rx-2~1
Rx-1~1
Rx-3~1
protein-to-creatinine~1
single-voided~3
Protein-to-creatinine~1
mU/kg/min.~1
(1614~1
1018~1
(7304~1
(0.028~1
Stirling~1
(Canada),~1
1003~1
Documenting~1
specializing~1
Wards~1
Liveries~1
(1540-1660),~1
guardians~1
1637,~1
Benoni~2
Buck,~1
Jamestown,~1
Benoni's~1
custody~1
exigencies~1
Buck~1
America;~1
350th~1
anniversary~1
petition~1
guardianship.~1
(5-mg)~1
(25-mg)~1
decanoate~1
Checklist-90R~1
gamma-vinyl~1
(GVG)~1
4,5,6,7-tetrahydroisoxazolo-(5,4-c)~1
pyridine-3-ol~1
(THIP)~1
GVG,~1
(GABA)-mediated~1
nondyskinetic~1
compliment~1
syndromally~1
postpsychotic~1
six-week,~1
decanoate,~1
slide-based~2
image-processing~2
bromodeoxyuridine-modified~1
tissue-type-specific~1
"rare~1
events,"~1
personal-computer-based~1
30,278~1
accessioned,~1
1414~1
(1.1%),~1
(3.7%).~1
Soft-tissue,~1
(9.5%),~2
Arthur~1
Rubenstein~1
Chopin~1
Andre~1
Segovia~1
concerts~1
guitar.~1
"training"~2
achievements.~1
respirator-dependent~4
postaspiration,~1
Arterioportal~1
(APFs)~1
APFs.~1
APFs~2
(hemobilia).~1
APF~3
(DVT).~2
5-MHz~1
false-negatives~1
false-positives~1
repeatable.~1
(tolazoline~1
hydrochloride);~1
(14/47).~1
mortality),~1
(transverse~1
nonaccommodative~1
sutures;~1
undercorrections.~1
bifocals~1
24-week,~1
(AZA),~1
mg/week,~1
AZA)~1
AZA~1
Placenta-eluted~1
(PEGG)~1
PEGG,~1
S300~1
antisera).~1
PEGG~4
HLA-bearing~1
anti-DQw1~1
PEGG.~1
Sm/RNP~4
14-kd~2
68-kd-reactive~1
Ethidium~1
anti-Sm/RNP,~1
anti-RNP~3
4.0-12.0~1
anti-RNP,~2
anti-RNP.~1
outer-table~3
undertaking.~1
graft-site~1
asteroides.~2
Short-lived~1
Phenoperidine~1
non-irradiated~2
simultaneously-obtained~1
(PLE).~1
(8-MOP),~1
tretinoin~2
tretinoin-treated~1
antichymotrypsin~1
haemoptysis,~1
saber-sheath~1
epithelial-subepithelial~1
(start-to-peak~1
75-100~1
adenosine-3',5'-monophosphate~1
sulprostone,~1
sulprostone.~1
sulprostone~1
elucidates~1
oestrone,~1
PCO.~3
idoxuridine~5
Idoxuridine~1
non-toxic;~1
4528~1
36,645~1
AFP.~2
amniocentesis;~1
amniocentesis--an~1
levobunolol~7
three-month,~1
46-patient~1
bandage~3
traditionally,~1
Resterilisation~1
keratometry.~1
Blind~1
Chittagong~2
ochraceus,~1
solani.~1
OKT-4~2
(T-helper/inducer~1
OKT-8~1
(T-suppressor/cytotoxic~1
transplant-related~2
IgD+,~1
BA1+,~1
BA2-,~1
B4+,~1
14+,~1
q32.~1
lymphoma/chronic~1
mother-son~1
adherence-dependent~1
glass/plastic~1
CD11b~1
155-kd~1
Mo1~16
155,~2
(WDLL),~1
stratum,~1
(TBI).~2
TBI.~1
(BrdU)~2
.00003)~1
post-BrdU~1
(Tc).~1
.8).~1
myeloablative~1
(CFU-Mix,~1
CFU-GM)~2
(CFU-F)~1
(LTMC).~1
LTMCs,~1
pre-CFU-Mix~1
LTMCs~2
pre-CFU-Mix-ablative~1
diaziquone,~1
myeloablation~1
favic~2
(contributed~1
autoxidation~2
divicine~3
isouramil,~1
fava~1
beans)~1
autoxidizing~1
procalpain,~1
calpain.~1
procalpain~4
autoproteolytic~1
(APH)-treated~1
APH~1
procalpain-calpain~1
favism.~1
IP.~3
IF.~2
gut-wall~1
1981-86,~1
endocavitary~1
Heidelberg.~1
radiation;~3
(FUR).~1
inter-renal~1
renal-child~1
(FSH~1
LH),~1
(GORE-TEX~1
Dacron).~1
0.012)~1
(n.s.).~1
echo-tracking~1
cent/mmHg~2
2.43,~1
(24-96)~1
post-transplant.~3
threatened,~1
ostracism~1
resentment~1
sibling.~3
counsellor~1
(MSAFP)~3
infallible~1
imperfections,~1
value-laden~1
(ASHG)~1
paraganglial,~1
(1:1);~1
presentation),~1
(1.7-32~1
leu-enkephalin,~2
cytokeratins,~2
ASPS.~1
paraganglial~1
benign/malignant~1
1:10,~1
basaloid,~1
curiosity,~2
imagination,~1
punctuated~1
emphasis.~1
succinylcholine:~1
succinylcholine;~1
d-tubo-curarine~1
(dTc)~1
prior;~2
dTc~1
prior.~1
40-48~1
dTc-containing~1
dTc-lidocaine~3
dTc,~1
moderate-severe~1
uterus)~1
0-50~1
0-7~1
oxide:~1
immunolabelling~1
gold-labelled~1
digitations~1
register,~1
myofibrillogenesis.~1
(BAEC)~1
BAEC.~1
Angiotensins~1
angiotensins.~1
endothelial-derived~1
interrogation.~1
2-microsecond~1
reflector.~1
interrogated~1
fibrous,~1
fibrofatty,~1
(-30.0~1
(-43.2~1
(-43.9~1
(-40.7~1
173-756~1
dyslipidemia~1
trans-iliac~1
case:~1
advances:~1
IU/1,~1
90-100%~1
ligations,~1
isthmica~1
nodusa,~1
nontubal~1
rarities~1
myogenic,~1
Dystocia~1
occiput-posterior,~1
augmentation--a~1
asynclitism~1
molding~1
pelvises~2
pelvises,~1
pelvimeter.~1
partograph~1
active-phase~1
pelvis--very~1
inadequate--and~1
classification.(ABSTRACT~1
choose,~1
birthing~1
Gortex~1
Tc-MDP-scintimetry,~1
scintimetric~1
Intracapsular~1
primam~1
platings~2
platings.~1
resecting~1
apposing~1
nonunion;~1
interfragmentary~1
prestressing~1
allografts).~1
Antidonor~1
(DLA)~1
Hilton~1
Thomas,~1
Orr,~1
Hippocrates,~1
Hunter,~1
Lucas-Championniere,~1
"rest~1
healed"~1
substitutive~1
se"~1
Biceps,~1
subscapular,~2
suprailiac~3
(TBF)~1
(suprailiac,~1
subscapular)/peripheral~1
(biceps,~1
triceps)~1
(insulin/glucose)~1
0.01-p~1
0.05-p~2
TBF,~1
TBF~1
(central)~1
Traditionally~1
refusals)~1
complaint"~1
withdrawals.~2
(blacking~1
bronchospasm)~1
complaint-free~1
Ibopamine,~2
(phenobarbital,~1
postload~1
Cilazapril~2
cilazapril,~1
(AT-I)~1
AT-I~3
cilazapril~3
pharmacodynamically~2
(UNa+V),~1
(PAC).~1
PAC.~2
alpha-agonist~3
(NICU),~2
1g~3
nicotinate,~2
cinnamic~4
visually,~3
bioformation.~1
NICU~3
78),~1
eight-week,~1
Cross-over~1
(PEFR),~1
nebulizers.~1
tissue-core~1
mediastinal.~1
Trucut~2
Surecut~2
Menghini)~1
PE;~1
3/97;~1
13/97~1
11/102~1
(49/59)~1
(32/38)~1
tracheostomies.~1
(NSBH).~1
links,~1
NSBH~1
NSHB.~1
(LPC).~1
(Af);~1
IgE-Af,~1
IgG-Af~1
IgA-Af;~1
Af;~1
Af~1
molds;~1
allergy-immunology,~1
mycology,~1
unavailable;~1
0100~1
0820~1
Glucose-clamp~1
Insulin-binding~1
autoimmunities.~1
HbA1c,~2
18.3%~1
oatmeal,~3
cornflakes,~1
high-amylose~3
muffins,~1
low-amylose~1
muffins.~2
Bread,~1
muffins~1
noncommunicable~1
DM-PM~1
enzymatic,~2
Trifluridine,~1
keratitis;~1
trifluridine~1
herpes,~2
rimantadine,~1
amantadine.~1
Single-drug~3
three-dose~3
neomycin/erythromycin.~1
clindamycin/gentamicin~2
metronidazole/gentamicin~1
aerobes.~1
bismesylate~3
central-acting~1
equivalency~2
(SMP).~2
SMP~5
Slow-K~3
mEq/tablet~2
K-Tab~3
tid.~1
reassociated~1
non-beta-cells.~1
non-beta-cells~3
Non-beta-cells~1
isletlike~1
(molecules)~1
Ra),~2
(Rd),~1
(HGP),~1
(MCRg).~1
Glycemia~1
intragastrically.~1
MCRg~1
insulitis~6
insulitis.~3
Thy1.2+,~1
Lyt2+~4
overabundance~1
anti-Lyt2~2
multi-low-dose~1
C-peptide-negative~1
Biostator-directed~1
breakfast,~5
(GC),~1
(PGC).~1
PC)~1
GC).~1
PGC,~1
minimal-modeling~1
Anti-aggregate~1
binding-inhibition~2
insulin-using~3
anti-aggregate~1
delta-cell~3
delta-cells~1
(aFC)~1
streptozocin-diabetic~1
[3H]fucose~1
(L5)~1
aFC.~2
glucopenia,~1
Aosta~1
Anti-virus~2
B1-6,~1
cytomegalovirus),~1
(ICAs),~1
5.0/100,000,~1
11.6/100,000.~1
ICAs~4
membrane-depolarizing~1
Phosphoproteins~1
17,500,~1
17,000-Mr~1
24,000-~1
20,000-Mr~1
phosphoproteins.~1
Ca2+-channel-blocking~1
MHC-class~1
insulin-~3
glucagon-immunoreactive~1
noncholestatic~1
(nephrotoxic~1
fetal),~1
antibrain-type~1
histogenetically~1
(pepsinogen~4
progastricsin),~1
nonpepsinogen~1
anti-SMP~1
anticathepsin~2
SMP.~1
lumbricoides;~1
42,500~1
41,000.~1
less-well-known~1
Addressed~1
hypotensives~1
FIII)~1
Subfractions~1
zein~1
P1-P4~1
pentagastrin--that~1
microgram/kg/h~1
Oxo~1
endoscoped~1
preinclusion~1
pmol/kg/h~3
Pl-gastrin~1
pmol/kg/h.~1
stool;~1
(phosphonoformate,~1
Pharmaceuticals).~1
non-cytomegalovirus~1
opportunist~1
redundancy~2
(mu-type)~1
(kappa-type)~1
naloxone),~1
kappa-receptor~1
mu-antagonist~1
kappa-agonist)~1
prove.~1
flowmeter)~1
(5-300~1
ml/min/g;~1
renin-releasing~11
p-chloroamphetamine-treated,~1
1000-5000~1
5000-10,000)~1
l-phenylisopropyl~1
N6-ethylcarboxamido~1
d-phenylisopropyladenosine~1
l-phenylisopropyladenosine~1
E1.~3
(20-mg~1
short-acting.~1
2-litre~1
self-financed~1
charitable~1
organisations~1
hyperlipidaemia,~1
78.5%.~1
TEFRA~2
rod.~4
rodding~1
femora:~1
axillo-axillary~3
3.03%).~1
PTFE-grafts~1
forefinger,~1
walled~3
slings,~1
sling)~1
sling,~1
tracheomalacia.~1
maximum-tolerated~1
aorto-velography~1
(TAV).~1
(Vp),~1
[an~2
(Sd)],~1
(Md;~1
Sd)~1
0.84),~3
Md~1
TAV~1
CAD.(ABSTRACT~2
aortovelography~1
(TAV),~1
integral:~1
output=stroke~1
undemanding~1
(-24~1
(-8~1
8-16~1
microscopies)~1
Immunohistochemically~2
perifusate~1
suramin,~3
suramin-treated~1
Superactive~2
(osteocalcin)~1
superagonist~3
(HLA-DR+~1
(CD4+~2
(CD8+~2
(CD4+2H4-~1
(CD4+2H4+~1
CD4+2H4-~1
CD4+2H4+~3
(0800-1000~1
Sustacal-stimulated~1
13-39~1
(DCCT).~1
pmol/mL~3
[177~1
(CYC)~1
contraceptive-treated~1
(CVR)~1
CVR~5
CYC~1
CYC,~1
potentiation)~1
(AIR)~1
AIRs~1
[52~1
AIR~1
half-conversion~1
781-fold~1
Polypeptide~1
liter-1~1
cerulein-stimulated~1
E27,~1
(LFA-1).~1
E27~5
LFA-1.~2
E27.~1
heterohybridoma~2
(c-myc,~1
L-myc).~1
L-myc),~1
L-myc)~1
Relapsed~1
(Ks:s)~1
Ks~3
(16.2-37.7~1
(20.7-31.2~1
GM-CSF(rGM-CSF)-treated~1
T-lymphocyte-depleted,~1
monocyte-enriched~1
Enterobactericeae~1
rIL-2-treated~1
IgM-depleted~1
LPS-containing~1
(GtARbACE)~1
GtARbACE~3
phosphoramidon~1
thiorphan~1
phosphoramidon.~2
endopeptidase-like~1
VIIa-tissue~1
3H-Factor~1
Strikingly,~1
25-90%.~1
(HUVE),~1
sulfate-fractionated~1
acrylamide~1
OKB-cALLA,~1
Nu-N1,~2
Nu-N2~1
VIL-A1~2
(common-ALL)~1
CD10);~1
immunoperoxidase.~1
OKB-cALLA~1
Nu-N2,~1
common-ALL.~1
In-113m-labelled~1
9.88A~1
534,~1
(cm3)~2
(cm2)~1
6.7)%.~1
g/cm3.~1
73-450~1
cm2--that~1
185-4000~1
splenomegalies~1
scintigraphs,~1
Heat-killed~2
6-10,~1
legionellas~1
Formolised~1
nonfollicular~1
papulopustular~1
Isotretinoin,~1
tuberculin-sensitive~2
(tuberculosis~1
verrucosa~1
cutis)~1
Laennec.~1
prosector's~2
Osler~2
abiding~1
tubercles.~1
gestationis,~1
glucocorticosteroids.~1
IVa~1
single-blinded~1
(UVL)~1
(topical~1
psoralen)~1
nonminoxidil-treated~1
Vellus,~1
UVL~1
inosiplex,~1
immunomodulator.~1
inosiplex~3
totalis.~1
8-methoxypsoralen,~1
crystalline,~1
acanthomas~1
prechilling,~1
operatory.~1
Gentian~1
Violet~1
microfoam~1
refrigerant,~1
curette~1
nonostial~1
eccentric-concentric~1
Unsteady~1
Cc)~1
Cc).~1
(Gorlin:~1
continuity:~1
0.49).~1
tank.~2
pulsed,~1
stellite~1
Hall-Kastor~1
(238~1
moth,~1
butterfly,~1
caddis~5
chironomid~5
insect-related~2
(silkworm~2
ng/m3;~3
ng/m3)~1
8.24~1
18.19~1
ng/m3).~1
2-agents,~1
inhalers)~1
rotacaps~1
(headache~1
heat-producing~1
nonshivering~1
thermogenesis,~2
uncouples~2
tenuous.~1
corpulence,~1
Case-controlled~1
Brown-Sequard's~1
Stubs~1
Wire~1
Gauge,~1
.0010~1
inches.~1
(Great~1
1884).~1
centuries~3
(MDAC)~1
"superactive"~1
(SAC).~2
slurries~1
carboxymethylcellulose,~1
syrup,~1
Multiple-dose~2
intoxications,~1
Antidote~1
Hydroxycobalamin/sodium~2
hydroxycobalamin/sodium~1
neuroendocrine,~3
responsibilities),~1
millivolts.~2
"fast"~9
"slow"~2
"hyperexcitability"~1
"automatic"~1
repolarize.~1
re-entrant~4
superventricular~1
(depolarized)~1
wider).~1
(verapamil).~1
(Lidocaine)~1
(cardioversion).~1
Thus;~1
cardioversion;~1
(superventricular)~1
(ventricular)~1
needle-puncture~2
needle-bending~1
Thirty-gauge~1
30-gauge~2
assemblies~1
10-mL~2
(mAb).~1
CL-1~2
L22~2
bursa-derived~1
bursas~1
CL-1+/L22+~4
CL-1+/L22-~4
rudiment.~1
pre-bursal~2
rudiment~3
macrophage/dendritic~1
Quail-chick~1
"self~1
X"-reactive~1
H-2Kb-restricted~1
H-2Kbm8~1
dual-reactive~5
bm8~9
VSV-primed~1
cross-reactive,~1
VSV-B6~3
encounters;~1
receptor-determinant~1
(PBML)~1
pre-TLI~1
PBML~2
(G-CSF)~3
32D~3
C13.~1
C13~2
lineage)~1
lactoferrin-containing~1
myeloperoxidase-positive~3
myelocytes~1
3-containing~1
Isobolic~1
(ATLC)~1
donor-B~1
HILDA~2
DA)~1
beta2-microglobulin~1
2m/mg~1
co-located~1
flexneri.~1
(TPE)~2
TPE~6
"suppressor~1
elements"~1
(rHuTNF-alpha)~1
rHuTNF-alpha,~1
Intraperitoneally~1
rHuTNF-alpha.~1
rHuTNF-alpha~6
(lymphotoxin)~1
noncross-reacting~1
immunoresponse~1
"disappear"~1
280.~1
(avidin)~1
(gamma-NGF)~1
C1(activated)-inhibitor~1
(C1-Inh)~1
C1-Inh~3
gamma-NGF~4
benzoyl-arginine-p-nitroanilide~1
(L-BAPNA).~1
C1-Inh.~1
hydroxylamine,~1
gamma-NGF.~1
(tryptase-positive,~2
chymase-negative)~1
chymase-positive)~1
Carnoy's-fixed~1
17,850~1
4,998~1
7,516~1
1,227~1
630,~1
3,4~2
LOU/C~1
serogroups,~1
Sf6-mediated~1
O-polysaccharide~2
tetrasaccharide~2
accommodating~2
octasaccharide.~1
O-factors.~1
salmonella-resistant~2
salmonella-susceptible~2
salmonellae~4
phagetype~2
505,~1
510,~1
M206~1
054~1
02K1+,~1
EGD~1
L347,~1
1.0-fold~1
species-associated~1
(C4D)~1
Reinoculation~1
gamma-irradiation.~1
Lyt-1+2-,~2
Jones-Mote~2
tuberculin-type~2
IFN-gamma.~32
f-met-leu-phe~4
C5a-dependent~1
non-urokinase~1
pre-treated~1
C4b~6
amphibia,~1
serum:~1
C4b:~1
alpha-68,~1
alpha-46,~1
alpha-43,~1
alpha-30~1
(chondrichthyes~1
agnatha)~1
C4bp,~1
AdoMet~6
S-Carbamyl-L-cysteine~1
(SCC),~1
tissue-invasive~1
periodate-sensitive~1
(Tcn-3~1
Tcn-6)~1
periodate-resistant~1
anti-carbohydrate~1
Tcn-3~1
Iodinated~1
(Tcn-2~1
-8)~1
epicuticle~1
cultivation.~1
Tcn-2,~1
Tcn-1,~1
-6,~2
DF3~14
F36/22~3
115-D8~2
(HMFGM)~1
Ca1~3
BT-20)~1
HMFGM.~3
DF3,~1
F36/22,~1
115-D8,~1
tissue-bound~1
CCA-IgG.~2
(7E12H12,~1
isotype)~2
immunotransblot.~1
CCA-IgG~2
7E12H12~2
3,3'-diaminobenzidine.~1
non-gastrointestinal~1
(MIF),~1
1C5/B,~1
Hypaque-isolated~1
1C5/B.~2
cytoplasma.~1
MIF.~1
1C5/B~1
hypocellularity~1
T.B.),~1
Atrophy~1
marrow's~1
(high-low~2
depressed)~1
Kugelberg-Welander~3
myofibres~2
innervated.~1
prolonged;~1
underly~1
reassume~1
P(V)~4
breaths;~1
lung-thorax~1
accommodating,~1
controller,~1
Takuo~1
Aoyagi,~1
bioengineer,~1
Susumu~1
Nakajima,~1
Jack~2
Lloyd~1
connect,~1
(Adr~1
OH])-(3,3-dimethyl-1-triazeno)-~1
imidazole-4-carboxamide~1
Adr,~1
DTIC,~1
cyclophosphamide-DTIC-Adr~1
Adr-DTIC-Actinomycin~1
.59).~1
(CHOP-Bleo),~1
histologies.~2
(NSGCTT)~1
(RPLND)~1
biomarkers~2
(alpha-fetoprotein~1
[AFP]~1
[BHCG]~1
biomarkers,~1
[36%,~1
.014].~1
NSGCTT~1
(MBTO)~1
MBTO~1
(PTHC),~1
PTHC~2
(PTHC~1
prosthesis),~1
("Prophylactic"~1
PTHC.~1
"reverse~2
redistribution"~1
subtraction,~1
intergenerational~2
war-time~1
Nystose~1
fructooligosaccharide~1
beta(1----2)~1
fructosyl~1
beta-Fructosidase~1
nystose~5
Glycosyltransferase~1
#620~1
glucan-type~1
NCTC~2
10449~2
Carbohydrases~1
nystose.~1
(HW)~1
(LW)~1
LW~2
HLs~2
HLs,~1
LWs,~1
LWs.~1
Warfcalc,~1
overanticoagulated,~1
out-performed~1
overanticoagulated~1
computer-dosed~1
Scientists~1
"cognitive~1
bias."~1
dura;~1
settling.~1
DDAVP;~1
(TMP-SMX)~3
TMP-SMX~10
Enterotoxigenic~1
"last~1
stool"~1
TMP-SMX.~1
(HLOC)~1
Piaget's~1
HLOC~3
self-catheterization.~1
(PUPPP)~1
PUPPP~1
gestationis.~1
addictions~1
addiction's~1
naivete,~1
"facts."~1
paradigms,~1
reductionism~1
Zinberg~1
foresaw~1
"Spectrum~1
Problem."~1
researchers,~1
theoreticians,~1
narcotics;~1
sedative/hypnotics,~1
hallucinogens,~1
impressions,~1
superimposed-upon~1
(34.3~2
gravel~1
250).~1
0.42).~1
noncontrolled~2
marginal.~1
Adrenoceptors~1
(Marlex)~1
dessusception.~1
umbilicus,~1
aesthetically,~1
catheterize~1
chair-bound,~1
vasovesiculography~1
E7,~1
647V.~2
E7~4
midgestational~1
kdaltons.~1
onco-fetal~1
(PFSA)~1
Limbs~1
(f50%)~1
f50%~1
Doppler/segmental~1
PFSA.~1
PFSA~1
pressure/Doppler~1
nonprescription,~1
phleborheography,~1
Photoplethysmography~1
PPG~3
hose.~1
0.025):~1
stockings,~4
Innominate~1
radial-cephalic~1
vein-superior~1
awarded~1
practicality.~1
transplants--15~1
recipient--while~1
syndromes:~1
mg/kg/three~1
16.04~1
nitrogen-balance~1
Cholesterol-Lowering~1
(CLAS)~1
colestipol-niacin~1
Erythroderma~1
DXplain~4
AMA/NET--a~1
Association--and~1
Network.~1
physician-users~1
criticisms,~1
3-methylhistidine-to-creatinine~2
anthropometry,~2
(high-leucine)~1
calories/kg~1
nitrogen/kg~1
(power)~1
(T-Ag)~1
Tn-antigen~1
(Tn-Ag)~1
T-Ag~5
galactose-beta-1-3-N-acetylgalactosamine~1
(GalNAc),~1
(PNA).~1
(cT-Ag)~1
Tn-Ag~4
alpha-GalNAc-serine/threonine,~1
(VVA).~1
VVA~2
PNA,~2
avidin-biotin-immunoperoxidase~1
Tn-Ag(+),~1
T-Ag(+),~1
cT-Ag(-),~1
T-Ag(-)~2
cT-Ag(+)~1
cT-Ag.~1
VVA.~1
cT-Ag(+),~1
Tn-Ag;~1
cT-Ag~1
(LEN),~1
(SBA),~1
asparagus~1
double-marker~2
(DC~1
LEN,~1
WGA.~2
LEN~2
(Rama~2
Rama~12
25-I2,~1
25-I1,~1
25-I4,~1
LP34~3
(myoepithelial~1
markers),~1
25-I2~1
flatter,~1
25-I1~3
25-I4~3
LP34.~1
25-floaters~1
25-FL),~1
(ADPKD),~1
(SADPKD),~1
(NADPKD)~1
ADPKD~7
NADPKD~5
SADPKD~4
NADPKD,~1
SADPKD,~1
ADPKD.~1
oligohydramnios.(ABSTRACT~1
dextrose-induced~1
hyperfiltering~6
normofiltering~3
(11.9%;~1
9.2%,~2
Overnight~1
(2-K,~1
1C)~1
125I-AII~2
2-K,~1
RVH.~2
(CEI)~2
(BMAX):~1
140.8~1
nephrectomized.~1
(BMAX~1
cadaveric)~1
CCPD~1
(PDPD).~1
PDPD~2
Flavobacterium,~1
placement)~2
hyperperfusion.~1
pg/min).~1
paraganglionic~1
Secondary,~1
Carney~1
(Carney~1
JA:~1
43:374-382,~1
unnecessarily.~1
incentives,~1
misusing~1
(overutilization)~1
(underutilization).~1
cost-awareness~1
risk-sharing~1
pecuniary~1
noncompliance,~4
[0.5]~1
(3.4[0.4]~1
[RIPA],~1
blot).~1
RIPA~4
assays--all~1
(FSV-1)~1
sporozoite-infected~1
Postimmunization~1
FSV-1~1
non-immunised~1
gametocytes.~1
Parasitaemia~1
parasitaemia~2
84/185~1
20/91~1
24/78~1
rotavirus/oral~1
34/83~1
placebo/oral~1
23/92~1
rotavirus/killed~1
4-53%).~1
electropherotypes.~1
coarse.~1
nares,~2
cheeks,~1
non-compliance~1
17.13.Cl.10~2
106/107~1
unsplit,~1
Polytef.~1
"resistant~1
relapse"),~1
"sensitive~1
relapse").~1
resistant-relapse~1
sensitive-relapse~1
(nodal~1
extra-nodal~1
involvement--16~1
early-phase~5
(rather~4
(TAME)-esterase~1
lavages.~1
TAME-esterase~2
glucocorticosteroids,~1
multipolar~6
aspirate,~4
U;~1
($~1
3,420~1
7,550~1
1,480,~1
(neodymium:yttrium-aluminum-garnet)~1
peptic-ulcer~1
142)~2
Laser-treated~1
Nd:YAG-laser~1
Tryptase,~1
basophils),~1
melon~1
wasp~2
sting,~1
mast-cell-related~1
thyrotropin-suppressive~1
pertechnetate-99m~1
hypofunctional,~1
levothyroxine-treated~1
complement-coated,~1
uncoated,~1
H-142~3
L-363,564~2
non-hydrolysable~1
renins~2
spartic~1
endothiapepsin,~1
endothiapepsin~1
H-256~1
aspartates.~1
alterations:~1
enzyme-catalysed~1
Asp~2
3,100~1
1,6-bisphosphate~1
45.~2
Quisqualate-preferring~1
kainate-preferring~1
(NMDA)-preferring~1
'critical'~1
kittens,~1
NMDA-receptor~1
syrinxes~2
eminent).~1
papers,~2
(3228),~1
(2588),~1
(1732),~1
(1061),~1
(968),~1
Matson~2
(932),~1
Ingraham~1
(651),~1
Scoville~2
(604),~1
Davidoff~1
(540),~1
Elsberg~1
(414).~1
Brain,~1
Jasper,~1
Milner's~1
"Loss~1
lesions."~1
neurosciences;~1
Jean-Martin~1
Charcot,~1
Salpetriere~1
1887-1889.~1
first-hand~1
renowned~1
topics.~1
epileptic.~1
hysteria,~1
surroundings,~1
rambled~1
outskirts,~1
mystery,~1
wanderings~1
spells.~1
1968-1982,~1
Paris).~1
noncontagious~1
(PGB)~1
co-medication~1
carbamazepine;~1
PGB~3
was--1.31~1
diagnostics.~1
retinoblastomas,~3
antibodies:~2
S100,~1
NSE-positive,~1
colcemid~1
subpigment~1
Dutcher~1
Tamale,~1
Ghana,~1
anti-retinal~2
(nerve~1
(S-Ag)~1
onchocerciasis.~2
Acinic~3
granules),~3
(intercalated~1
flattened-to-cuboidal~1
duct-acinar~1
Vitapex,~1
iodoform~1
Vitapex~1
cementoblasts~1
(ScHBr)~1
Cardiac,~1
antisialogogue,~1
antisialogogue~2
ScHBr,~1
(acid~1
buccinator~1
oromaxillary~1
ganglion-like~1
maxillary,~1
mandibular,~1
interdependently,~1
(extraosseous~1
tooth-bearing~1
ameloblastomas;~1
extragingival~1
Calcofluor~1
water-soluble,~1
(cellulose)~1
planar,~1
trans-form~1
fluoresces~1
(345~1
Recuts~1
Grocott's~1
(GMS)~1
notorious~1
Consistently~3
dysmenorrhea.~2
(TOTPAR)~1
'complete~1
relief'~1
'placebo~1
effect'~1
(mesangiocapillary~1
glomerulonephritis),~1
glomerulocosclerosis,~1
unquestioned;~1
advancements,~1
nonexcitable,~1
replenish~2
Urolithiasis~1
States),~1
enigmas~1
immediately)~1
reassurance,~1
afflicting~1
ESRD.~1
bacteriology.~1
Case-fatality~1
ceftazidime-~2
amikacin/carbenicillin-treated~2
amikacin/carbenicillin~2
28.5%)~1
6.4%).~1
infants.(ABSTRACT~1
17.6,~1
18.1,~1
.72).~1
-.08,~1
upsilon~1
Instrument~1
Instrument.~1
(Fisher~1
.0067).~1
nabilone~7
weight-based~1
.003,~1
nabilone,~1
prochlorperazine,~1
.015,~1
(dizziness,~1
alteration)~1
micrograms/kg/d,~1
Nabilone~1
allows;~1
Emporiatrics,~1
mos~2
p40mos,~1
p40mos~4
Mg2+-ATP~1
triphosphates.~1
p40mos-bound~1
p40mos-DNA~1
5'-[beta,~2
gamma-methylene]-triphosphate;~1
N-terminal-deletion~1
p19mos,~1
C-terminal-deletion~1
p25mos,~1
p25mos~1
gamma-methylene]triphosphate,~1
triphosphate-mediated~1
histone-DNA~1
Oligosaccharide~1
host-~1
protein-dependent~1
Invertase~1
psi-2~1
3T3-derived~1
115-130~1
tri-~1
tetraantennary.~1
unprocessed.~1
glycans.~1
mannosidase~1
1-deoxymannojirimycin,~1
glycans~2
glucosidase~1
1-deoxynojirimycin~1
KCN.~1
UvrA~1
UvrB~1
UvrAB~5
strand-displacement~1
activity--unwinding~1
D-loop~1
DnaB,~2
TUF~5
RPG~2
HOMOL1~2
UASrpg~1
pore-limit~1
protein-blotting/nuclease-protection~1
150-kDa~1
blotted~1
bipolarization~1
DNA-replication~1
mini-P1~2
oriC~1
[Fuller,~1
R.S.,~1
Kaguni,~1
J.M.~1
Kornberg,~1
7370-7374].~1
Mini-P1~1
gyrase,~2
Ubiquitin~3
nonlysosomal~1
ubiquitination~1
prepro-alpha-factor~1
(pp~1
(INV)~1
(PRS)~2
pp~8
INV~1
PRS~4
BSC-1~1
(bombesin,~1
(platelet-derived~1
inositolphospholipid~1
cross-regulation~1
GI/TGF-beta~1
Loss-of-function~1
areA~4
nidulans~3
nit-2~6
nidulans.~2
multicopy~5
nitrogen-metabolite~1
1.6.6.3)~1
forward-mutation~1
tetracycline-resistance~1
[cis-diamminedichloroplatinum(II)],~1
intrastrand~3
diadducts~1
ApG~5
GpG~4
bacteria).~1
single-base-pair~1
(ApG~1
GpG).~1
T----T~1
transversions).~1
protein--insulinoma~1
(IAPP)--from~1
IAPP~7
3850~1
Da.~1
1-27~1
IAPP-(7-17)~1
neuropeptide-like~1
CRF-immunostained~2
olive.~1
CRF-immunostaining~1
CRF-immunopositive~1
CRF-immunopositivity~1
(climbing~1
varicosities)~1
dendrodendritic~1
271A6)~1
telencephalon-specific~2
271A6~3
271A6,~1
nontelencephalic~1
Dot-immunobinding~1
271A6.~1
telencephalic~1
271A6-positive~1
telencephalon.~1
X-100-solubilized~1
hormone-enhanced~1
agglutinin-agarose.~1
Kemptide~1
Leu-Arg-Arg-Ala-Ser-Leu-Gly)~1
S6,~1
phosvitin,~1
calmodulin-dependent,~1
cAMP-~2
cGMP-dependent,~1
anti-phosphotyrosine~2
phosphothreonine.~1
tyrosine-phosphorylated,~1
primase~3
T73,6~1
T73,4,6,~1
T73,4,6~1
phage-infected~1
2',3'-dideoxy-3'-azidothymidine,~1
strand.~1
L-strand~2
(H)-~1
(CAR1)~1
catabolite~3
CAR1~4
5'-TAGCCGCCGAGGG-3',~1
(URS1)~1
CYC1.~1
URS~4
CYC1~1
Searches~1
URS1-like~1
3C~2
(capsomer~1
precursor)~1
precursor),~1
Truncation~1
P1.~1
capsomer~1
poliovirus-infected~1
trans)~1
3C.~2
Precursors~2
1D~1
3C--observations~1
P1-P2~3
polioviral~1
open-circular~2
reversing-pulse~1
unphosphorylated~1
counterions~1
Unphosphorylated~1
(OTCase;~1
2-micron~1
(galactose),~1
anti-OTCase~1
antiserum:~1
OTCase~10
kDa);~1
matrix-containing~1
arg3~2
mutant)~1
OTCase,~1
(arginine-23~1
processed;~1
ornithine.~6
(SSC1~1
SSD1),~1
upshift,~1
SSD1~1
SSC1~1
(gyrA~1
gyrB)~1
gyrB~2
relaxation-stimulated~1
pcbA1~1
Weigle~2
recA-lacZ~1
prophage.~1
MLR3,~1
MLR3-binding~1
28-34~1
MLR3~4
OKT3-Sepharose~1
wer~1
MLR3-positive~1
(trypomastigote)~1
trypomastigotes~1
DL-alpha-difluoromethylarginine~1
(F2Me~1
Arg),~1
monofluoromethylagmatine,~1
(E)-alpha-monofluoromethyl-3-4-dehydroarginine--all~1
F2MeArg-treated~1
F2MeArg~4
agmatine~4
putrescine,~3
agmatine.~2
cruzi:~1
K2~1
inoculate~1
spheroplasting,~1
Filter-sterilized~1
segregants~1
2:2~1
4:0~1
mycoviruses.~1
trpE~1
pATH2.~1
166-315~1
166-200~1
alpha-bungarotoxin.~1
expression--i.e.,~1
overlays~1
tecta~1
three-eyed~2
aminophosphonovaleric~1
(APV),~1
receptor/channels~1
eye-specific~3
(RGC)~1
tectal~1
APV~2
desegregation~2
RGC~1
arbor~1
APV-induced~1
APV.~1
sharper~1
receptor/channel~1
tadpole.~1
BMT.~10
refitted~1
myodesis.~1
weight-loading~1
interface-pressure~1
muscle-skin~1
foot-fillet~1
tendon-bearing~1
sensibility,~1
Free-tissue~1
subcuticular~1
brakes~1
antilock~1
pullout~1
deeply.~1
Endosonography~1
uriniferous~1
hypodysplastic~1
(BAE)~1
BAE~1
pleat~1
thinly~1
encased~1
siliconized~1
shield,~1
(608~1
spoke-wheel~1
lobulation~2
ultrasonographic,~1
duplication)~1
Testis-fat~1
postprocessing~1
eigenimage~1
eigenimages~1
angioplastic~1
"Striated"~1
alternating,~1
"three-layer"~1
Interferons~5
range--e.g.,~1
(MOTT)~1
avium-Mycobacterium~1
widened.~2
haemophilum~1
saprophytic~1
MOTT~1
immunodeficiencies,~1
agammaglobulinemia.~1
echoviruses~1
paresthesias.~1
dermatomyositis-like~1
Transposons,~1
transposase(s),~1
nephrotoxicity;~1
(Sporotrichum)~1
pyogenes.~2
crepitus.~1
myonecrosi~1
yeast-like~1
pharmacokinetics),~1
gut).~1
mannan)~1
stabile~1
nanogram-per-milliliter~1
Candidiasis~1
(polyenes~1
imidazoles)~1
polyenes~1
Aspergillosis,~1
transsected.~1
breathing-abolition~1
rate-shortly~1
autotransplantation.~3
autotransplants.~1
factors--granulocyte~1
interleukin-3--have~1
Homeotic~1
flies,~5
enzymology,~1
synaptic,~1
millisecond-to-millisecond~1
macrorestriction~1
endeavors~2
(13.7%)~1
renins.~2
survivals,~1
Osler's~6
excellent-to-good~1
osteoid,~2
intertransverse~1
nonfusion~1
nonfusions~1
Ewald~1
neoplastic-associated~1
"ischemic~1
Latamoxef~1
latamoxef~3
persistant~1
"two~1
loser"~1
1930's~1
principle--less~1
(11.9%),~1
nonpalpable.~1
(41.3%),~1
(47.8%),~1
(58.7%),~1
pain/tenderness~1
groups--a~1
restrictions),~1
(cholesterol-free~1
(caffeine-free~1
close-fitting~1
clothing.~1
seedy~1
ropy~1
masses).~1
pain/tenderness,~1
pain/tenderness.~1
nonuse~1
4741~1
rho:~2
hypermyoglobinemia~1
myoglobinuria,~1
embolectomy.~1
clip-on~1
(TSL)~1
milliamperes~1
(mA)~1
TSL~10
(color,~1
peristalsis)~1
peristalsis,~1
galactosyl-neoglycoalbumin~1
(Tc-NGA)~1
liver-imaging~1
hepatocyte-specific~1
Tc-NGA~8
ligation;~1
retrodifferentiation~1
137th~1
trypsinogen/chymotrypsinogen,~1
emphasising~3
daily-500~1
daily-400~1
26)l~1
(24)l~1
pigs),~1
pigs).~1
(ischemia~1
neuron-disabling~1
Coordinating~1
allocation,~1
(1981-1985)~1
Pittsburgh,~1
(preoperative,~1
postoperative)~1
18,668~1
23,627~1
20,590~1
4241~1
(636)~1
hospitals:~1
Presbyterian~1
(564~3
beds).~1
Diamond-Blackfan~2
(TMP-SMX)-induced~1
sulfamethoxazole-dependent~1
N-4-acetyl-sulfamethoxazole,~1
sulfamethoxazole.~2
Pk.~1
45-66).~1
(VPBs)~1
(double-blind)~1
dBA~1
guanfacine.~2
141/92~1
134/88~1
(IDD's)~1
(CSII).~2
sorbitol,~1
IDD's~1
Ingested~1
(22.00-08.00~1
short-time~1
(tubular)~1
50-65~1
0.387~1
0.330.~1
Toxicosis~1
metrorrhagia~1
(118),~1
(41),~1
7-French~1
Sacks~1
post-ESWL~6
ESWL;~1
Hydronephrosis~1
pre-ESWL~1
terminated,~2
91%;~2
collateral.~1
meteorism.~2
panangiography~1
nonfatal,~1
lakes~1
SHU-454~2
(VGRAM)~1
levels/pixel.~1
echo-contrast~1
VGRAM~2
0.73),~1
contrast-echo~1
0.68).(ABSTRACT~1
vasoconductor~1
indicatons~1
hyperfibrinogenemia~1
Life-style~1
903~1
(nadolol,~1
hydrochlorothiazide);~1
terazosin~3
toleration~1
180)~1
(systolic/diastolic)~3
23.8/17.3~1
23.7/17.1~1
(standing).~1
"mild"~1
hypertension's~1
step-1~2
medications;~2
blockers;~2
(enalapril),~1
(doxazosin),~1
(acebutolol),~1
(amlodipine),~1
biochemical)~1
Phase-1~1
phase-2~1
Proatherogenic~1
-5.9%,~1
+32.4%~1
+7.2%,~1
-5.6%~1
+8.7%,~1
-6.2%~1
(-1.6%)~1
(+0.6%),~1
lipoprotein/total~1
10.5/9.8~1
10.9/10.7~1
8.8/7.7~1
9.7/9.3~1
doxazosin.~2
(568~3
s/cm5)~1
120-minute~2
10-week,~1
100.6,~1
101.0~1
-13/-11~1
-12/-12~1
+1/-1~1
Doxazosin,~1
Terazosin,~1
terazosin-treated~2
84.6~1
[HDL]~1
HCTZ-~1
HCTZ-treated~5
3.31~1
barium-gelatin~1
(injected,~1
casted~1
2-vessel~1
nadolol).~1
indecainide,~2
trail~2
trial)~3
trail.~1
predictive;~1
(101.6~1
mumol/liter.~1
(-0.05,~1
(-0.03,~1
8-center~1
ectopy/hour~1
pirmenol/day~1
36-kd~2
macrophages).~3
interdigitating,~1
Langerhans',~1
questionably~1
L1.~1
(54,~1
(well,~1
differentiated),~1
57-kd~1
54-kd~3
66-kd~1
(FDC)~1
(monocytoid~1
B-cells),~1
FDC~2
TdT-positive~2
myeloblastic,~1
TdT.~2
primitivity~1
Alpha-lactalbumin~1
antilight~1
amyloidosis)~1
hypothetized~1
fungemia~4
BACTEC~7
(seven-day)~1
subculturing~1
Kyushu~1
Fukuoka,~1
metolazone-furosemide~1
thiazide-furosemide~1
kaliuresis.~1
(CsA)/prednisone~1
(Pred)~1
(Aza)/Pred,~1
Aza/Pred~1
Pred~1
CsA/Aza/Pred~2
CsA/Aza/Pred-treated~2
CsA/Aza/Pred.~1
nondialysis~1
drug-drug~2
non-benzodiazepine~2
buspirone--a~1
abuse--are~1
glossitis,~1
normochromic~1
secondaries~1
Alongside~1
D-cell,~1
Verner~1
Morrison~1
VIPoma~1
Lundh~1
SMS,~2
pancreozymin~1
Amantadine,~1
chronic-care~2
vaccine's~1
out-break,~1
Fibrocystic~1
mastodynia~1
cytomegalovirus-induced~1
enterocele~1
schism~1
university-commercial~2
(1/1690).~1
outreach,~1
steroid's~1
receptor-associated~4
potentiator~1
"two-step~1
mechanism"~1
seven-case~2
397,~1
(insulinoma~1
IAPP),~1
antileukocyte~1
MT2~1
MB3~1
immunophenotyped~3
metastases).~1
nonmyasthenics;~1
(phenotypically~1
similar)~1
plasmocid-induced~1
anticathepsin-peroxidase~1
intramyofibral~3
cathepsins.~1
plasmocid~1
macrophageal~1
122:193-198).~1
myocellular~1
bs~1
immunodepression.~1
fibrinoid,~1
coagulative,~1
latent)~1
(CPTs)~1
epithelial-type~1
lu-5~3
(lu-5~1
(87.5%).~1
GFAP,~2
CPTs~1
KL-1~1
CK-7~2
(Ker-7-specific),~1
CK-2~3
(Ker-18-specific)~1
KA-4~2
(Ker-19-specific~1
CK-2-positive~1
CK-7-negative.~1
Cholangiocellular~1
CK-2,~1
CK-7,~1
KA-4.~3
CK-7.~1
10-20-nm~1
Vibratome~1
preadsorptions~1
immunoreaction:~1
neurofilaments;~1
tau;~1
HLA-DQ,~2
compact-type~1
ACTH1-24.~1
adrenalitis,~1
gaps;~1
necrotic;~1
insudation~1
(FAI).~1
beta-antagonists~1
antipanic~1
antiphobic~1
aspartame,~1
beta-blockers--propranolol,~1
betaxolol~5
6,321~1
unavoidable;~1
discriminants~1
cubital~1
eicosatetraynoic~3
bioenergetics.~1
alcoholic-induced~1
Chronobiological~1
infradian~1
Ultradian~1
[DOPAC],~1
[DHPG]~1
[HMPG])~1
subhypnotic~2
DOPAC~3
(BDI),~1
drink),~1
drink).~1
Alcohol-dependent~1
treatment-oriented~1
Representativeness~1
Gangliosides~1
(SPM)~1
SPM~1
mM/min~2
9-13~1
noncompetitive/uncompetitive~1
drinkers;~1
"drunk"~1
Cahalan~1
cutpoints~1
caveat~1
Depressed,~1
(ASP).~1
picture;~1
pathologic-intake~1
ASP,~1
Benzodiazepines~2
under-reporting~1
strokelike~2
image-intensification~1
perivascularly,~1
intraarterially,~1
action.(ABSTRACT~1
microgram/kg,~4
(Ondine's~1
curse)~1
EAA,~1
EAA.~1
"risk"~1
aPTT;~1
XII;~1
(29.9%),~1
(82.5%)~1
pre-anhepatic~1
post-anhepatic~1
complications.(ABSTRACT~1
bupivacaine;~1
three-subgroup~1
(COAD)~1
(improvement~1
performance)~1
acenocoumarol;~1
pentoxifylline--800-1200~1
xanthinolnicotinate,~1
naftidrofuryl,~1
pyridylmethanol,~1
stenocardia,~1
COAD~1
n=7)~1
n=8)~1
173.3~1
3.4/93.3~1
143.3~1
3.4/78.3~1
166.7~1
8.6/98.3~1
146.7~1
12.0/85.0~1
165.6~1
10.5/104.9~1
128.8~1
4.7/84.1~1
154.0~1
10.1/107.8~1
126.3~1
6.0/88.8~1
flowmetry,~1
98.6%.~1
(tL~1
tR).~1
Intraplaque~1
Loratadine,~1
non-sedating~1
Loratadine~1
clemastine,~1
clemastine.~2
Metaproterenol~1
Southam.~1
wears~1
preanesthesia~1
"scoop~1
run"~1
proof.~1
well-controlled,~1
unethical.~1
shouldn't~1
harm?~1
criticism.~1
criticality~1
criticality,~1
care?~1
(TIMP),~1
connective-tissue-derived~1
metalloproteinases,~3
macrophagelike~3
TIMP.~2
(SDS).~1
Buffers~1
SDS-treated~1
TIMP,~1
SDS-containing~1
PMN-derived~1
3H-lysine~1
(3H-HL),~1
(3H-DES).~1
lysed,~1
3H-HL~2
3H-DES,~1
3H-DES~1
cytoplasts,~2
(NE).(ABSTRACT~1
(histamine,~1
prostanoids,~3
neuropeptides)~1
15-HETE).~1
limited-stage,~2
Single-arm~1
thallium-201-technetium-99m~1
ipecac,~1
aand~1
immunodeficiency-associated~1
spike.~1
double-walled~1
(pial)~1
methionine-27~1
CGRP)~1
adrenergic,~2
histaminergic~1
degenerating/regenerating~1
N-CAM-positive~1
(p25),~1
acid-phosphatase-negative,~1
process-bearing~2
alkaline-phosphatase-positive~1
myo-inositol-related~2
K+)-ATPase~1
axoglial~2
dysjunction~3
BB-rats~2
(6-week)~1
Na+-permeability~1
(24-week)~1
dysjunction.~1
2200,~1
0200,~1
hypoglycaemia,~3
HMF/mol~3
Hb)~1
Reflocheck~1
similar.(ABSTRACT~1
fetoprotein~9
Unmodified~1
term)~1
cots.~1
(VBGP)~1
(RYGBP)~1
"sweets~6
eaters"~8
"non-sweets~4
eaters."~1
RYGBP~4
VBGP.~1
VBGPs~5
RYGBPs.~1
RYGBPs,~1
RYGBPs;~1
RYGBPs~2
pg/dl)~2
(461~1
VBGP~2
eaters,"~1
RYGBP.~1
0.8539~1
unusable~1
cyclosporine;~1
episode/patient-month~2
episode/patient-month.~1
(rejection,~1
(cumulative,~1
Ake~1
Senning,~1
redirecting~2
mean])~1
lobectomies.~1
Greece~1
(chlorothiazide~2
mid-range,~1
-13.6~1
-11.6~1
-10.8~1
2/102~2
2/84~1
3/85~1
(two-way~1
(sickle~1
crisis)~2
(ultrasound,~1
scintigraphy)~2
Asymptomatic,~1
acetonemia~1
insulin-withdrawal~2
(-0.15~1
-0.62~1
basal),~1
Duplication~1
described--each~1
(fibrinolytic)~1
likelihood.~2
pH.(ABSTRACT~1
Testament~2
Paul,~1
Testament,~3
condemns~1
documents.~2
Wine~1
God's~1
Testament.~3
abstention~1
implicitly~1
extolled~1
drunkards,~1
salvation,~1
unwilling)~1
noninsured~1
"self-paying",~1
Medicaid,~2
self-paying,~1
Medicare,~1
prescriptions:~1
funds,~2
miscellaneous,~1
filled,~1
medications.(ABSTRACT~1
overdosed~1
(phencyclidine,~1
digoxin)~1
reabsorbed.~1
(theophylline,~1
administer,~2
1330~1
Extrasystoles~1
Breathlessness~2
(Tigason),~1
(99mTcMDP)~1
alarm,~1
99mTcMDP~1
anti-bromodeoxyuridine~1
[3H]-thymidine.~2
(BCC),~1
keloid.~1
[3H]-thymidine,~1
743~1
mg/kg/dose,~1
PMN13F6,~1
PMN7C3,~1
PMN8C7~5
myeloblast,~1
promyelocyte,~1
metamyelocyte~1
PMN13F6~4
PMN7C3~4
antibodies).~3
(PMN13F6,~1
.6533,~1
.005;~2
PMN7C8,~1
.6304,~1
PMN8C7,~1
.5215,~1
-.6206,~1
.005).(ABSTRACT~1
(IVS-1)~1
Anglo~2
Saxon~1
IVS-1~1
heterohybrid~1
5E5,~1
activation-specific~1
5E5~4
95,000,~1
(CIE),~1
beta-positive~1
(S-100~2
beta+~6
3.4%)~1
cellulose-acetate~1
(22.0~3
59Fe-lactoferrin.~1
protamine)~1
Cytosine~1
(BMTs)~1
marrow-ablative~1
4-hydroperoxycyclophosphamide~2
micrograms/mL)-purged~1
-0.80),~1
-0.79),~1
-0.60),~1
-0.66).~1
immunogenotyping~1
lymphocyte-committed~1
(MEG-01)~1
MEG-01~2
105.6~1
K2(1~1
84,000~2
78,000)~1
[35S]-methionine~1
biotin-PAC1,~1
biotin-S12,~1
Platelet-bound~1
(PE).~1
FITC-AP1,~1
PAC1~3
S12~7
PE-streptavidin.~1
biotin-PAC1~1
125I-PAC1~1
.99;~1
PAC1-~1
S12-specific~1
paraformaldehyde.~1
ETS-1~1
granulocyte-colony~1
17q11.2-q21,~1
15;17~1
t(15;17)~2
APL.~1
(AML-CFU)~1
(hMulti-CSF).~1
hMulti-CSF~4
(hG-CSF),~1
(hGM-CSF),~1
hGM-CSF~5
hG-CSF~2
hCSFs,~1
hCSFs~2
Multi-CSF,~1
hGM-CSF,~1
(meta)myelocytes~1
IgM/IgD~1
IgM+/IgD+/lambda+~1
IgM+/IgD-/lambda+~1
antiidiotype~1
"frozen"~1
switching,~1
Resealed~1
hemolysate,~1
dialyzable.~1
invasion-linked~1
batchwise~1
character;~1
ion-exchanger,~1
pan-myeloid~1
MoAb,~1
My7,~3
My9,~1
20.3.~1
HLA-DR-negative~1
My4~2
(GPIIIa),~1
APAAP~4
MoAb;~1
Immunophenotyping~1
t(14;18)(q32;q21)~3
bcl-2,~1
q21~4
18q21~9
(DLCLs),~1
(SNCs).~1
DLCLs~2
oxycone-papaverine~1
pentosanpolysulphate~1
carbenoxolone~1
localisations~1
HCG.~1
(29.6~1
'death',~1
'local~1
recurrence',~1
'all~1
recurrence'~1
'Dukes'~2
classification',~1
'sialomucin~2
present'~1
'histological~2
differentiation'.~2
present',~1
classification'~1
small-parts~2
shadowing,~2
EST~3
2474~1
(BCVP)~1
(ND),~1
lymphocytic,~1
struma~1
ovarii,~1
(LBL).~1
(TLBL,~1
T-cell-restricted~1
T-cell-associated~2
anti-Leu-11~1
"pre-B"~1
BA-1~1
BA-2~1
pre-B-lymphocytes.~1
IgMD~1
resulted:~1
TLBL~1
NK-associated~3
subtypes;~1
LBL.~1
argentaffinity,~1
argyrophilia~1
(Grimelius~1
stain),~1
histopathogenesis.~1
Lieberkuhn.~1
(enterochromaffin)~1
argentaffin~1
Supporting~2
metanephrines~1
(TMn)~1
5-hydroxyindolacetic~1
17-ketosteroids~1
(17KS)~1
androsterone,~1
17-hydroxycorticoids~1
(17OHCS)~1
NE-type.~1
dicarboxylation~1
(APUD)-granules~1
1980;~2
1,000,000~1
Imipenem/cilastatin~2
septicemias~1
69%).~1
VP16-213.~1
(ABMT).~1
chemo(radio)therapy~1
(lymphomas~1
survivor,~1
(28+,~1
CR;~2
(14+~1
59+~1
therapy-related,~1
cure)~1
hepatocellular-cholangiocarcinomas.~1
hepatocellular-cholangiocarcinoma~3
cholangiocarcinomas.~1
cholangiocarcinoma-like~1
hepatocellular-cholangiocarcinoma.~1
hepatocellular-cholangiocarcinoma,~1
alpha-enolase~1
gamma-enolase~5
(SCCL,~1
non-SCCL~3
35-fold,~1
ninefold,~1
gamma/alpha~3
14/18,~1
3/10,~1
SCCL,~1
Lymphography~1
abnormal-appearing~1
sized.~1
overstaging.~1
(TMs)~1
Alpha-fetoprotein,~1
insights,~1
TMs~1
soon.~1
promised~1
morbidities.~1
oncology.~1
Choices~2
chances.~1
retrospective)~1
bladder-preserving~1
(PVB)~1
(PVP16B)~1
PVP16B~4
double-dose~1
carboplatinum,~1
antifols.~1
dichloromethotrexate~1
(M-VAC)~1
Indirectly,~1
disappointingly~1
(IRS-1~1
IRS-2).~1
IRS-III~1
platinum-containing~1
etoposide-containing~1
investigative,~1
Investigative~1
chemohormonal~1
embolization/infarction,~1
social)~1
ureteropyeloscopic~1
nephroureterectomy)~1
interferon),~1
interleukin-2.~5
Leukocyte-derived~1
Enthusiasm~1
host/tumor~1
Candidate~1
indoles.~1
chemoprevention~4
refining,~1
hurdles~1
"reagent."~1
"probe"~1
"dissect"~1
hyperimmunizing~1
B-lymphocytes.~1
(myelomas)~1
(IVU)~1
IVU~1
hygromas~1
microsphere-in-oil~1
(S/O)~1
S/O~3
mammographic,~1
(VPS)~1
(SCCL).~1
VPS~1
HMFG1~1
F36/22;~1
AUA1~1
HMFG1,~1
HMFG2,~1
(T-PLL)~1
thymocytic~9
prolymphocytes~1
T-PLL~1
T-non-T~1
mitogen-dependent~1
14q+;~1
(API)~1
API.~3
Glioblastoma~1
API,~1
expansile,~1
spheric,~1
extranodular~2
(contiguous~1
contiguity,~1
(7.7%),~1
remarkable.~2
fibroleiomyomatous,~1
myxomatous,~1
(pTl,~1
NO,~1
MO).~1
L-platelet~1
(L-PAF),~1
(ang~1
L-PAF~6
(RVR):~1
10(-9)M,~1
10(-8)M,~1
10(-6)M.~1
(iPGE)~1
(iTXB)~1
(INDO)~1
non-INDO~1
change:~1
-26~2
L-PAF-induced~2
ang~3
L-PAF,~1
magnitude.(ABSTRACT~1
renin).~1
1,240~1
prorenin-activating~4
6.5-7.0,~1
aprotinin-affinity~1
chromatographies.~2
Prorenin-activating~1
angiotensin-generating~1
capsular-glomerulosa.~1
fasciculata-medullary~2
capsular-glomerulosa~1
(ZK~1
36374)~1
Iloprost~4
(0.1-100~1
units/g~3
units/g,~1
0.01.(ABSTRACT~1
miniswine.~1
125I-iodocyanopindolol~1
(ICYP)~1
(QNB)~1
1,074~1
KPM/min~1
fmol/mg).(ABSTRACT~1
32-nucleotide-long,~1
(200-250~2
isomyosin.~2
isovolumically~1
(euthyroid~1
(hyperthyroid~1
(+130~1
(+340~1
(-225~1
"nonworking"~1
isomyosins,~1
(Blackman~1
low-noise,~1
high-gain~3
(filter~1
cytoimmunologic~1
Single-beat~1
FFT~1
transplantation)~1
amplitude.(ABSTRACT~1
smoking-induced~2
single-gated~1
"emotional"~1
limbic-hypothalamic~1
reaction"~1
pattern--with~1
salt-volume~1
regulation--is~1
genetic-environmental~1
biobehavioral~5
One-to-one~1
bus~1
Amelia~1
coronary-prone~1
anger.~2
hostility/anger~1
societies.~2
population-wide~2
worksites,~1
churches~1
disadvantages;~1
promotive~2
(VPBs),~1
diminishes,~1
VPB~1
Augmenting~1
life-sustaining,~1
Behaviorally~1
relayed~1
subcortically~1
"mesenchymal~1
susceptibility"~1
"traditional"~1
smoking).~1
fascicularis),~2
(social~1
aggressiveness),~1
necrosis)~1
echoed~1
psychophysiologic~1
predisposition,~2
angerlike~1
Cryogenic~1
profibrillatory~1
annulling~2
muscarinically~1
modernization,~1
sodium/low~1
Indicated~1
arbitrary.~2
sleep-wakefulness~1
superimposed.~2
(dP/dt).~1
Hyperreactivity~1
Post-transplant~1
2-m)~3
0.43,~2
mg/l;~2
cuprophane~2
postdialysis).~1
renal-artery~2
(LCP)~1
LCP.~2
Grid~1
835~1
Bionix~1
(MTS~1
indentor.~1
intracondylar~1
pegs~1
padding~1
Technically,~1
tissues'~1
wear-induced~1
microparticles~2
"silicone~1
synovitis"~1
shear,~2
synovectomy,~1
nonrheumatoid~1
well-informed~2
arrangements.~1
unpreparedness~1
society's~1
non-directive~1
15/101~1
11/88~1
156/100~1
132/81~1
1/17~1
15/18~2
pinacidil.~2
ketogenesis,~2
caecal~1
(200%),~1
(200%)~1
aldosteronomas~1
Sizable~1
(32.0~1
anti-renin~1
(36,000,~1
37,000,~1
48,000),~1
(4.40,~1
5.00).~1
aldosteronoma.~1
gastro-jejunal~1
tethered,~1
unit/kg~2
5.26~1
mmol/l;~2
insulin:~3
pmol/l;~2
108-148~1
115-125~1
Insulin-induced~1
(45,~1
biocide~2
leave-on~2
lotions~1
post-use~2
ingredient,~1
CG.~1
Post-use~1
3032~1
ml/24~2
Electrolyte~1
5580~1
(TID)~1
(PV).~1
TID~1
PV,~1
dextran-40.~1
(BV)~1
BV~1
colloids.(ABSTRACT~1
dazmegrel,~1
GBS-induced~1
GBS;~1
sec/cm5.~1
pulsed-wave~1
(SVRV)~1
(SVLV)~1
SVRV~1
SVLV~1
reflectory~1
Rs.~1
Minimizing~1
(WOB)~1
WOB,~1
CPAP-IMV~1
weighted,~2
(FGF).~1
WOB~2
CPAP/IMV~1
demand-value~1
work/breath~2
900B.~1
Work/breath~1
900C~1
work/time~2
demand-valve~1
FGF.(ABSTRACT~1
polygeline~1
(gelatin)~1
immunochromatographic~1
sample's~2
(NIPPV)~1
Vel-Foam~1
(MIPPV)~1
NIPPV~2
MIPPV~2
(DLexh)~1
exhalation,~1
(RNA).~1
(Qc~1
CORNA~5
.80).~1
(CH4~2
CH4~1
DLexh~2
CH4/L,~1
Dsb:~1
TLC:~1
.68)~1
(VHD)~1
VHD,~1
provocational~1
clock,~2
dyspnea--psychophysical~1
placebo-theophylline~1
sustained-action~1
gastropulmonary~1
mucokinesis.~1
mucostasis.~1
sanctioned~2
(LAR)~4
midrectum~2
(59.4~1
APE,~1
7/1;~1
27/10;~1
25/18;~1
2/3.~1
76.7~2
N.S.)~1
Divided~2
9/149~1
8/145~1
dehiscences,~1
punctures,~1
unverified)~1
gentle,~1
Bacon~1
4-aminosalicylic~1
(4-ASA)~1
Proctoscopic~1
assessing:~1
tenesmus,~1
(absent)~1
(severe).~1
4-ASA~5
1-g~2
two-weeks.~1
rolls~1
participate,~1
.0073).~1
.1995).~1
.1983).~1
Triglycerides,~1
foot-lesion~1
.95.~1
5431~2
1145~1
1.75-2.25~1
Erratic~1
postlunch~1
Ultralente~1
Prestudy~1
preprandial/postprandial~1
33/261~1
12/156~1
11/151~1
0.3%).~1
skin-test~4
animal-species~1
insulin/skin~1
reactions.(ABSTRACT~1
bovine/porcine~5
(lyophilized~1
U100~3
Organon)~1
83-90%~1
deamidized~1
plasticizer,~1
dioctyl~1
phthalate,~1
perfusates,~1
bacteriostatics~1
10-15%.~1
pneumonitis/fibrosis,~1
ng/rat;~1
(icv)~5
ng/rat.~1
benzotript~1
icv~21
RO22-1319~1
(1:3;~1
microliter/rat,~1
icv).~1
0.4-min~1
gonadally~1
(E(2)17~1
20H-estrone~1
(OHE1),~1
(P4)~1
neurosecretion~1
E(2)17~2
OHE1,~2
OHE1~1
catecholestrogen~1
P4.~1
Minipump-induced~2
Synthesis-secretion~1
insulinogenesis~3
synthesis-secretion,~1
synthesis-secretion~1
40-60%.~1
alpha-methyltestosterone~1
receptor-acceptor~4
sites/mg~2
Acceptor~2
RNase,~1
KCl-resistant~3
KCl-extractable~1
Protease~4
-extractable~2
acceptor-binding~2
Mercurial~1
Pyridoxal~1
88-93%~1
[125I]galanin~3
10(-11)-10(-8)~1
M);~2
galanin-binding~1
Galanin-binding~1
bis-(succinimidyl~1
succinate).~1
[125I]galanin-receptor~1
69-amino~1
decapeptide,~1
3-aa~1
56-aa~1
(RM~2
8/5,~2
14-26;~1
39A,~1
40-53)~1
1076,~1
4-8;~1
pGlu~1
Gly)~1
non-LHRH~1
Immunopositive~1
39A.~1
39A~1
immunopositive~1
8/5~2
422),~1
MBH-preoptic~1
(POA).~1
MtTW15~2
castrated.~1
Hyperprolactinemic~1
normoprolactinemic~2
postcastration~2
MBH-POA.~1
Castrated~1
(50%;~1
(NAL)~1
(SPV)~1
-79~1
+740~1
6,306~1
1,839~1
+62~1
+180,000~1
1435~1
[GnRH-Ant;~1
(N-acetyl-D-p-chloro-Phe1,2,D-Trp3,D-Arg6,D-Ala10)GnRH]~1
104-129~1
107-125~1
S16~1
standard)~1
GnRH-Ant~6
(175-300~1
1.75-5~1
GnRH-Ant;~1
GhRH-Ant~1
fetuses;~3
0.065,~1
(44-2C)~1
compendium~1
brain-gut~1
GRF.~7
22-24~1
gluconeogenesis;~1
[3H]etorphine,~1
(EKC),~1
[3H]naloxone,~1
(NIL),~1
Binding-inhibition~1
etorphine-HCl~2
[3H]EKC~3
EKC,~1
NIL~7
45-55%~1
NIL,~1
naloxone-HCl~2
dynorphin-(1-9)~1
alpha-neoendorphin~1
(Leu5)enkephalin~2
(Tyr-D-Ala-Gly-NMe-Phe-Gly-ol);~1
(Leu5)enkephalin.~1
(Leu5)enkephalin;~1
naloxone-HCl,~1
sigma-opiate~1
(+)SKF~1
(N-allylnorcyclazocine),~1
(-)cyclazocine,~1
(micromolar)~1
[3H]PCP~1
opiate-binding~1
6-mM~1
evanescent~1
Tyr-Gly-Gly-Phe-Met-Arg-Phe~1
(YGGFMRF),~1
Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu~1
(YGGFMRGL),~1
[Tyr-Gly-Gly-Phe-Met~1
(YGGFM)].~1
YGGFMRF,~1
YGGFMRGL-like~1
YGGFM-ir~2
gonadotrophs,~2
YGGFMRF-ir~3
YGGFMRGL-~1
YGGFMRF~4
YGGFMRGL-immunoreactivity~1
YGGFMRGL.~1
YGGFMRGL,~1
YGGFM~1
(Tyr-Gly-Gly-Phe-Leu).~1
A-derived~1
SRIF-containing~1
SRIF-positive~1
HRP,~1
luteolysis.~2
progesterone-mediated~1
stalk.~1
N-5-azido-nitrobenzoyloxysuccinimide~1
[125I-Tyr11]somatostatin-14~1
[125I-Tyr11]somatostatin-14,~1
Zwittergent~1
3-12,~1
N,N',N"-triacetylchitotriose,~1
beta-1-4~1
(SMs)~1
1,25-(OH)2D3,SM-C,~1
2-deoxy-D-[1-14C]glucose~1
14C]DG)~1
alpha-[1-14C]~1
insulin/rat,~1
contraction/sec.~1
min/mg~1
insulin-induced,~1
(sham)~1
hindlimb,~1
Denervated~1
264%~1
207%~1
778%,~1
SRIF.~4
[125I-Tyr11]SRIF~3
[equilibrium~1
[I-Tyr11]SRIF~1
[Tyr11]SRIF~1
glyceraldehyde~2
leucine-stimulated~1
glucose-dose~1
(water),~1
glucose/kg~1
exp~1
(56.1~1
Eadie-Scatchard~1
+10~3
mU/min)~2
Glucose-induced~2
mU)~2
(881~1
(GAL)~1
GAL-immunoreactive~2
NKA-containing~2
GAL-containing~2
NKA,~1
CGRP;~1
(extirpation~1
ganglion)~1
NKA-~1
GAL-,~2
NKA/SP-,~2
CGRP-containing~2
prostatein,~2
prostatein~3
testosterone-dependent~2
(pbGH)~1
(rbGH)~1
(2-h)~1
(48-h)~2
acetate-carbon~1
pbGH~2
rbGH~2
E2-fatty~1
E2-17-fatty~1
E2-17-stearate,~1
E2-17~1
beta-acetate,~1
nonlipoprotein~1
[125I]iodo-IGF-I~4
SD)/10(6)~1
IGF-I;~1
Multiplication-stimulating~2
1:300~1
0.03%/10(6)~1
[125I]iodo-IGF-I.~2
Thecal~1
cell-secreted~2
AKR-2B~1
thecal/interstitial~1
cell-granulosa~1
capacitating~1
saline-incubated~1
acrosomes~1
capacitations'~1
mounted,~1
peroxidases~2
(mEGF),~1
preadsorbed~1
(goat~1
3.3'-diaminobenzidine~1
chromogen.~1
immunoglobulin-directed~1
(TAM)~1
(Nolvadex,~1
ici~1
Pharma,~1
Missisauga,~1
Canada)~2
oligozoospermia.~3
17.092~1
(10(6)/ml).~1
(IV-GnRH)~2
(HCA)~2
outside,~1
IV-GnRH~2
(0.30)~1
HCA~3
PCOS~3
(0.07;~1
conceptions;~1
PCOS,~1
oligomenorrhea,~2
superagonist.~3
(D-Nal[2]6-GnRH)~1
bleedings,~1
hyperandrogenic~9
(kg/m2).~1
(DHEAS)~4
-0.84,~1
0.033),~1
prevails~2
(22.5~1
beta-cells,~1
-.37,~1
-.24,~2
.10),~3
-.31,~1
-.25,~1
.24,~1
.29,~1
Photomicrographs~1
Margination~1
microU/ml)-euglycemic~1
(cold~1
GINF~10
(D-[3-3H]glucose)~1
(hot~1
120-180~1
one-compartment,~2
Steele,~1
between-(78%)~1
estimable~1
60-100%~1
B-binding~1
Eight-day~1
cell-1~2
glucose-transport~2
1.5-~2
glucose-potentiated~2
Glucose-potentiated~2
dl,~6
dl;~1
dl).~2
(+260~1
(+438~1
(0-500,000~1
glassware,~1
glassware.~1
1-94~1
(RINm5F).~1
50%-inhibiting~1
syntheses,~1
negative-insulin-feedback~1
Prehepatic~1
15-h~3
(rIL-1),~1
rIL-1.~2
Mannose-~1
leucine-induced~1
granulated,~1
vol/vol)~1
(1400~1
pM).(ABSTRACT~1
Insulin-deficient~1
hyperglycemia-hypoinsulinemia~1
Mixte~1
Delphi~3
(1983-84).~1
investigator.~1
"racing~1
extinction"~1
captive~5
phytoestrogens~2
daidzein~1
genistein.~1
consumes~1
estrogenicity~1
zoos~1
tap).~1
(200-400~1
(40-240~1
Paracentesis~1
(72.8%)~1
readmission,~1
PiM1/PiMduarte,~1
PiM1~1
genotyping~1
thiabendazole.~1
Cholestasis~3
"idiosyncratic"~1
Kashmir~1
Valley,~1
nonshadowing~2
(85.7%).~1
(GCLOs)~1
hypochlorhydria~1
GCLO~2
GCLOs~3
colonize,~1
polymer-coated~1
(Micro-K~1
Extencaps)~1
Micro-K~2
magnification)~1
3.5-mm~1
34JA~1
Microencapsulated~1
(ethyl~1
Extencaps~1
mycetes~2
89.9%~1
multi-drug~1
Managing~1
(GOR)~1
(GOR~3
(antroduodenal~1
coordination)~1
Transpyloric~2
GOR~3
54%),~1
0.79;~1
red-methylene~1
Endoscopically,~1
Cal9-9~3
Cal9-9.~2
homosexual)~1
(Wellferon)~1
MU/m2~1
MU/m2/day.~1
(pressure-natriuresis)~1
abscissa~1
[mEq/day]/mm~2
Nephrectomized~1
extra-renal~1
"convertase"~5
Adrenalectomized~1
Cross-circulation~1
bloods~1
cross-circulation)~1
cross-circulation~1
Prostacyclin,~2
5-hydroperoxyeicosatetraenoic~1
12-hydroperoxyeicosatetraenoic~1
15-hydroperoxyeicosatetraenoic~1
15-hydroxyeicosatetraenoic~4
secretagogue;~1
12-lipoxygenase~2
15-lipoxygenase~1
xenon-washout~1
II)-stimulated~1
(3.7-10.7~1
A-induced~4
hyperreninemic~2
(pDD-1D2)~1
(pRang~1
obesity-induced~1
lb/day~1
overinterpret~1
ascribe~1
trials:~1
(1980),~1
(1982).~1
first-step~3
Benefit~2
(Hypertension~1
Elderly)~1
target-organ~1
di)~1
di~2
splenectomized,~1
close-chested~1
(QLemf),~1
(ICG).~1
(IPPV1),~1
(PEEP1),~1
IPPV1~2
(PEEP2),~1
(IPPV2).~1
Phasic~1
QLemf~2
PEEP1~2
PEEP2.~2
pre-PEEP~1
(10(9)~2
preseptic~1
large-pore~1
SHAM's.~1
39-44~1
39.5-40.0~1
normal-to-high~1
(NHSI)~1
(LSI).~1
LSI.~1
PRA-Tc~1
5.98~1
NHSI~2
LSI~2
thermoreceptors,~1
8-19~1
40-42~1
39.8-40.0~1
isotone~1
bag-in-bottle~1
nonlavaged~1
surfactant-depleted~3
literature-reported~1
Bates-Hazucha~1
loads)~1
(quadratic~1
(EFS;~1
(INDO,~1
M)-pretreated~1
INDO-treated~1
INDO-pretreated~1
EFS-evoked~2
aeroallergens;~1
CPAP-induced~1
electromyograms,~1
(Pes~1
(EMGdi~1
EMGdi/TI),~1
(EMGge),~1
Pes/EMGdi~1
Pdi/EMGdi~1
EMGge~1
actuated~1
Bird~1
servo-motor~1
air-valve~1
mid-ureter~1
interlobar~2
nephrostomy),~1
schistosomiasis).~1
underutilized.(ABSTRACT~1
supratrochlear~2
Zambians~1
(DUS),~1
arterialization.~1
100.8~1
cc/ml,~1
25-200.~1
runoff,~1
Ankle/Brachial~1
DUS,~1
in-situ.~1
Debridement~1
D,L-3-hydroxybutyric~7
priming-continuous~1
[125I]hippurate~1
[51Cr]EDTA,~1
D,L-3-Hydroxybutyrate~1
D,L-3-Hydroxybutyric~1
(hCp14).~1
hCp14~1
prorelaxin.~1
decidua-like~2
hCp14,~1
hCp14.~1
renin)~1
869~1
(IRG),~1
(10-180~1
IRG,~4
SRIH,~5
ng/L)~1
8.16~2
8.17~1
L-[ring-2,6-3H]phenylalanine~1
L-[1-14C]leucine,~1
Postabsorptively,~1
nmol/min~8
(-14~1
(TPE~2
10(3)/microliter;~2
(DEC),~2
eosinophil-dominated~1
non-collagenous~1
(NC1)~1
28-kilodalton~1
NC1~1
monomers,~1
24-kD~1
(HLA)-B8~1
-DRw3,~1
(85%-95%~1
(10%-15%~1
(GMI;~1
Fibrel)~1
scars),~1
recounted~2
terrors.~1
rhyme,~1
"A~2
Rosie,"~1
photo-protection:~1
sun-reactive~1
I-VI;~2
sunscreens;~1
UVB-~1
UVA-absorbing~1
USA;~1
photoaging,~1
parlors~1
fixed-tissue~1
osteomyelitic~3
86-year-old~1
67-year~1
Below-the-knee~1
1,871~1
edentulism,~1
dentures,~1
105,182~1
Supplement~2
(NHIS),~2
pterygomandibular~1
1957,~1
archaeological~3
Antiquities~1
Museums~1
BCE.~1
incisor.~1
Time-intensity~1
SHU~1
off-line,~1
level/pixel~1
time-intensity~2
fit).~1
(washout)~1
theory:~1
e(-bd)]~1
0.73.~1
0.87.(ABSTRACT~1
0.86).~1
videodensitometry-based~1
geometry-based~2
0.88)~1
subset),~2
Anisoylated~1
(APSAC)~1
APSAC~4
APSAC,~1
(APSAC~1
APSAC.~1
three.(ABSTRACT~1
3,290~1
(BHAT).~1
1,640~1
categoric~1
2.69.~1
35.5%~1
present),~1
criteria),~1
criterion)~1
(none).~1
beats/h~1
(3.86)~1
definitions,~1
(+3%)~1
standard-sized~1
cart.~1
possibilities;~1
Cardiomyopathies~1
antiallergic~3
desmethyl~2
Azelastine,~1
Alloreactivity~1
lavage)~1
lectin-dependent~9
Tolerant~1
MLC-induced~1
16/6,~1
lupus-derived~1
16/6-positive~1
scleroderma-polymyositis~1
16/6-bearing~2
anti-RNP/Sm~1
anti-SS-A/SS-B~1
anti-SS-A~1
RNP/Sm~1
SS-A/SS-B.~1
nucleotide-reactive~1
5'-nucleotide-BSA~1
(AMP-,~1
GMP-,~1
CMP-,~1
UMP-,~1
TMP-BSA)~1
nucleotide-BSA~2
anti-GMP~4
anti-AMP~1
anti-TMP~1
anti-UMP~1
anti-CMP~1
GMP-agarose~2
GMP-BSA~1
competition-inhibition~1
guanine-enriched~1
oligo-~2
guanine-dependent,~1
d(G)4~1
d(G)8.~1
proteose-peptone-elicited~1
CSF-enhanced~1
CSF-induced~1
mannose-inhibitable~1
mannose-receptors~1
CSF-treated~1
(G-CSF),~2
(M-CSF),~1
1-stimulated~3
M-CSF~6
multi-CSF,~1
30,000.~2
HRF,~1
anti-IgE;~1
HRF.~2
acid-stripped~1
anti-IgE-Sepharose~1
penicillin-specific~1
immunoprotective~1
0111:B4~3
5B10,~1
O-antigen-deficient~1
5B10~5
IgG2a.~3
core-specific~1
O-antigen-specific~1
(anti-class~2
4E~1
BBM.1~1
(anti-beta~1
2-microglobulin)~1
monocyte/macrophage-type~1
Mo1+~2
dose-dependent;~1
LPS-free~1
8.5.~1
TSK-2000~1
-3000~1
timepoints~1
p150,95-specific~1
(MAb),~2
p150,95,~2
(LFA-1)~2
N-glycanase.~1
146,000~1
132,000~2
165,000~2
137,000~1
149,000~1
(CSN)~1
(MabER)~1
MabER.~1
IgE-BF.~1
MabER~1
(IgA-CIC);~1
IgA-CIC,~1
IgA-CIC~6
(RF)-IgG~1
non-DH~1
15/16~1
0.678,~1
fixation-positive~2
IgA-CIC.~1
uncomplexed~1
0.331-26.0~1
IgA/ml~1
(nl~1
IgA/ml),~1
IgA/ml,~1
nl~2
IgA/ml).~1
8/32~1
(1.1-1.6~1
IgM/ml,~1
IgM/ml).~1
(helper:suppressor~2
2:1)~1
HLA-D-related~1
7:1).~1
(CEs)~1
determinant(s).~1
transglutaminase.~3
epibolin,~1
spreading:~1
Basal-type~1
stratify.~1
FITC-insulin.~1
straightlined,~1
FITC-insulin~4
hematoxylin.~1
FITC-insulin,~1
mercaptoethanol~1
nidogen,~1
remodel~1
depositing~1
(rough~1
vesicles),~1
DJM-1~1
foliaceus)~1
(treated~1
aminopropeptide~5
carboxylpropeptide~4
fibrillogenesis.~2
Chick~1
posthatching~1
(10-day~1
(21-day~1
embryos).~1
pN-collagen/pC-collagen~1
postembryonic~1
skins.~1
pN-collagen~1
(aminopropeptide~1
pC-collagen~1
(carboxylpropeptide~1
Nocardiae~1
nocardiae~2
abscesses;~1
proliferated.~1
cross-protection~2
(LPS;~2
1:60,000)~1
ketodeoxyoctonate~1
[KDO]~1
1:3,200).~1
28%-41%~1
A-KDO~1
LT2~1
galK.~1
K12.~1
minicell~1
0.4-kilobase~1
galT~1
Ty2.~1
nonreverting~1
galactose-induced~1
Enterohemorrhagic~1
(EHEC)~1
(HUS),~2
(Verotoxins~1
[VT]~1
toxins),~1
EHEC~1
EHEC.~2
O26:H11,~2
VT-positive~2
HUS,~2
O26:H11~1
O26~1
H11,~1
(O127:H-)~1
99.8%).~1
Serotype~1
louse-borne~2
leptospirosis,~1
(46.8%~1
reactivated,~2
blood-culturing~1
Fungemia~1
amoeba.~1
histolytica.~1
Tritrichomonas~1
lamblia,~1
castellonii,~1
invadens.~1
lipoteichoic~1
(LTA)~1
fibronectin)~1
thermolysin-generated~1
LTA.~1
LTA~2
LTA,~1
aminofilaremic~1
capacitation,~1
superovulation,~1
sexing,~1
bisection,~1
chain;~3
prostaglandins;~1
oxidase;~1
N-[2-mercaptopropionyl]glycine)~1
catalase)~1
(ibuprofen,~1
nafazatrom,~2
755C,~3
"explosive"~1
SRI63072,~1
preimmunized~1
SRI63072~7
"implantation,"~1
KCl/kg~1
alpha-blocker,~1
alpha-adrenergics~1
potassium-regulatory~1
alpha-Adrenergics~1
spirit.~2
antibiotic-based~1
new;~1
century-old~1
Lemnious~1
Levinus~1
Catlin~1
1800's,~1
Cline,~1
Wells,~1
Griffin~1
suffering.~3
MA-HCl,~1
glutaraldehyde-containing~1
mg/kg--the~1
medicine),~1
reaction:~1
cardiocytes.~5
subpassaged.~1
(BNB)~1
intraaxonally.~1
subperineurial~1
intrafascicular~1
perineurium.~1
BNB.~1
(Ph')~3
-5)~1
-1)~1
86%);~1
Ph'~1
accelerated-phase~1
(Novantrone,~1
Lederle~1
(VMP)~1
(VAP).~1
VMP~3
VAP.~1
VAP~1
VMP.~1
question:~1
circumstances?~1
(H2(15)O)~1
stimulated-state~2
resting-state~1
Intense,~2
medial-to-lateral~1
homonculus~1
bicommissural~1
coordinates)~1
(VIP)-containing~1
Intracortical~1
mean:~1
gm/min)~1
gyri.~1
rolandic~6
CT-stereotaxic~2
puncturing~1
assays:~2
(estrophilin),~1
iodine-125-labeled~1
alpha-methyl-3H-promegestone~1
(3H-R~2
5020)~1
1881),~1
gestagen~2
[99mTC]~1
kidney-to-aorta~1
(K/A),~1
K/A.~1
rubidium.~1
82Rb,~1
99mTc]DTPA)~1
orthoiodohippurate~2
131I]hippuran)~1
(renin-dependent)~1
(volume-dependent)~1
II-dependent~1
gastroduodeno-cecal~1
(99mTc).~1
theophylline).~1
duodenocecal~1
pharmaceutics~1
Cysteine,~1
SAA.~1
dimercaptopropanol),~1
arsenicals~1
roxarsone~1
arsanilic~1
menaquinones~5
Germ-free~1
longum~1
ramosum,~1
vulgatus~2
MK-10~1
MK-9~1
MK-11,~1
MK-8~1
MK-7.~1
coprophagy-preventing~1
portal-drained~3
(PDV)~1
PDV~3
18-25%~1
PDV.~1
Glucose,~2
(VFA),~1
PDV;~1
VFA,~1
Hindquarter~2
Ketosis~1
insulin-independent~1
sheep.(ABSTRACT~1
neck-lamina~1
instruments);~1
TestPack~4
Strep~4
technologists)~1
rayon-tipped~1
68.8%~1
74.8%,~2
94.3%~1
95.6%,~1
81.5%~1
87.9%,~2
89.2%~1
89.9%.~1
4.1).~1
$10,000,~1
$18,000.~1
facteur~1
thymique~1
serique~1
(FTS).~1
FTS.~1
manageable.~1
Beckwith,~1
"gray~1
"crossover"~1
CMN.~3
(HUS)~1
(PGI2~1
determinations).~1
(ng/mg~1
ng/mg/min)~1
HUS~8
[methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)-~2
pyridine-5-carboxylate]~2
28392~4
[ethyl-4-(2-difluoromethoxyphenyl)-1,4,5,7-tetrahydro-2-methyl-~1
5-oxofuro-(3,4-b)-pyridine-3-carboxylate]~1
8644-induced~1
28392.~1
28392,~1
slices.(ABSTRACT~2
IDDM;~1
([3H]CyA)~1
[3H]CyA~1
Pancreata~2
post-treatment;~1
(HL~1
725)~1
13080)~1
256,000~1
32,000/microliter~1
725,~1
725.~1
13080.(ABSTRACT~1
25,637~4
alpha-glucohydrolases.~1
maltase,~2
isomaltase,~1
streptozotocin-treated~1
glucohydrolases~1
cardiomegalies~1
LH-RH.~6
(TSK)~1
(GAG).~1
(newborn,~1
month-old,~1
months-old)~1
58.39~1
53.95~1
rebridement,~1
reduction/internal~2
37.65~1
34.46~1
63.9%.~1
exits.~1
vesicovesicostomy~1
(H,~2
Lea,~1
ALeb)~2
secretor,~1
stage-dependent,~1
Secretors~1
isoantigens~1
non-secretors~2
secretors,~2
(Leb,~1
Lea),~1
X63Ag~1
8.653~1
MoAb-producing~1
10's~2
(IIP).~1
TCCB~1
(36/43),~1
IIP~1
(IIF)~1
nephrotomography~1
alpha-glucosidase,~4
gamma-glutamyl-transferase~2
glucosaminidase~3
microprotein~1
beta-2-microglobulin.~1
gamma-glutamyl-transferase,~1
beta-2-microglobulin,~1
Enzymuria~1
beta-2-microglobulin~3
donated.~1
HLA-1~2
Pre-treatment~1
"swiss-cheese"-appearing~1
Siemen-Elema~1
900-D~1
Ventilator.~1
(cysts~1
kidney).~1
blastematous~1
leiomyocytes,~1
nephroma,~1
tridodecylmethylammonium~1
(TDMAC)~1
TDMAC~3
TDMAC-heparin~3
(Bardex)~1
Uropathogenic~2
enteritidis.~1
Pruitt-Inahara~1
antiadenoviral~1
Serotypes~1
Adenoviral~1
maltitol~5
maltitol.~1
significantly)~1
210th~1
Maltitol~1
N-Nitroso-N-propylurea~1
[(NPU)~1
816-57-9]~1
NPU-target~1
NPU-treated~1
NPU~2
thymuses.~1
NPU-induced~1
(Ha)~1
21,000-dalton~1
p21/micrograms~2
p21-positive~1
point-mutated~1
Hangzhou.~1
S-region~1
X-region~1
C-region~1
X-region,~1
1441~1
1526,~1
52,000-dalton~2
(52kDa-P)~1
52kDa-P,~1
52kDa-P~3
double-stained~1
studies--with~2
patients--aimed~1
"BALB/cV,"~1
harbors~2
milk-transmitted~1
virus-host~1
neoplastic)~2
BALB/cV~5
(BALB/cV)MMTV~3
68K~1
env-related~3
BALB/cV-positive~1
transformation-related,~1
MMTV-encoded~1
MMTV-induced~1
expands,~1
12.86~1
perineum,~1
0.34%~1
needling,~1
65.66~1
18.56~1
(PLG)~1
(IVGTT).~1
ursinus)~1
duodenectomy~1
PLG~1
tomography-based~1
isovolaemic~1
methylprednisolone-treated~3
La;~1
ANA-associated~1
anti-La,~1
stibogluconate~2
Sb/kg~2
chewing-gum~1
specialised~3
734),~1
1022).~1
2238).~1
(haemorrhage~1
leaks).~1
hepatitis-like~3
hepatitis-B-virus~1
Prednisolone,~1
non-renal~2
Potter's~1
dextrose-glycerine-phenol~1
("proliferant")~1
proliferant.~1
supersedes~1
control-arm~1
this)~1
(anti~1
CD4-CD5-CD8,~1
CD2-CD5-CD7,~1
(median)~1
46th~1
(paste~1
(leukocyte~1
investigate:~1
tumor);~1
Marathon~1
fit"~1
Kcal)~1
(MCTs)~2
(LCTs).~1
nutriments~1
[U-13C]glucose,~1
[1-13C]octanoate,~1
[1-13C]palmitate~1
nutriment~2
MCTs,~2
LCTs.~2
LCTs,~2
pre-angiogram~1
medium-large~1
figured~1
specter~1
Hypertriglyceridemia,~1
Hypercholesterolemia,~1
diuretics)~1
[13.3~1
nmol]~2
supraphysiologic~2
proteins).~2
AZT,~3
AZT.~1
amonG~1
Skin-test~1
1987;~1
317:185-91),~1
millimeter)~1
higher--27~1
percent--whereas~1
similar--44~1
white-cell~2
1:32;~1
cryptococcal-antigen~1
34,354~1
1451~1
insulin-clamp~3
[3H]glucose~1
calorimetry)~1
6/112~1
(3.80~1
glycolysis)~1
delta-chain~2
conquer~1
beta-KDO~2
(3-deoxy-beta-D-manno-2-octulopyranosonic~1
(CMP-KDO~2
L-L-dipeptide~1
8-amino-2,8-dideoxy~1
permeases~1
CMP-KDO~2
Pap-pili,~1
hair-like~1
PapA.~1
digalactoside-containing~1
PapE,~2
PapF~3
PapG,~2
PapA,~2
non-piliated~1
digalactoside.~1
PapG~4
trans-complementation~2
digalactoside-specific~1
adhesin.~2
Pap-pili~1
heteropolymers~1
pilin,~1
pilins,~1
PapE~1
PapF,~2
adhesin,~1
PapG.~1
GHz.~1
strychnine-binding~1
neurotransmitter-gated~2
(NANP)3~1
(TT),~1
adjuvanted~1
Seroconversions~1
NANP~1
7-10).~1
vacinee~1
'cysteine-zinc~1
finger'~1
GAL4-encoded~1
motif.~3
gal4~1
cysteine-zinc~1
ZnCl2~1
U6~6
ATTTGCAT,~1
-217,~1
octanucleotide~8
-217~1
-315~1
preceeded~1
II-transcribed~1
non-mendelian~1
segregations~2
6:2~3
tetrads~5
5:3~3
filling-in~1
double-strand~3
pms1~2
(nonrotated)~1
(rotated)~1
CT-visible~1
contrast-enhancing,~1
prelude~2
(intrapartum~1
(29.6%)~1
(NST),~2
87.7%,~1
ultrasound-plus-electronic~1
65.3%,~1
chorioamniotic~1
(membranes~1
organism).~1
(20-60%)~1
peroxidase-H2O2-halide~1
9507~1
(2500~1
median;~1
2217~1
swings,~1
forgetfulness,~1
nonculture-dependent~1
(MicroTrak~1
[Syva~1
Co.])~1
(Chlamydiazyme~1
[Abbott~1
Laboratories])~1
96.3~2
92.9%,~1
84.4%~2
95.2%~1
trouble,~1
dyspareunia,~1
pictorially~1
26-28~1
78.2%;~1
81.8%;~1
90.5%;~1
activities),~1
chemotherapies.~1
fructosamine~3
ultrasonography)~2
macrosomia.~2
ventricle/hemisphere~1
Scalloping~1
"lemon~1
sign,"~1
"banana~1
sign."~1
13-70~1
(95%);~1
hiccups.~1
cardiotocography~1
22-75~1
Deviation~1
Axis~1
modest-dose~1
nondysgerminomatous~1
iris-fixated,~1
sulcus-fixated~1
lens),~1
ski-shaped~1
thick)~1
thread~3
plana,~1
extraocularly~2
exited~1
backlog~1
auxiliaries~1
Pseudophakic~1
Lenses~2
20/60~1
(6/27~2
(FMAb)~1
(IgG-IFT),~1
(IgA-IPAs~1
IgG-IPAs)~1
nonoptimized~1
FMAb~2
IgG-IFT~1
IgA-IPA~2
IgG-IPA~1
Optional~1
higher-than-normal~1
extraocular,~1
mucosal-associated~1
choanae,~1
(be~1
comparability,~1
individuality.~1
Unit-trait~1
categorically~3
rickettsia.~1
pharmacopeia~1
Medicolegal~1
disease?~1
nonbloody~1
moisture,~1
aides~1
RNs,~1
Examination,~1
(CCSE)--were~1
criterion-related,~1
sltA~1
sltB~1
(SLT)~1
H19B.~1
SLT~5
slt~1
(ERBB2)~1
(bp),~1
GGA~1
c-erbB-1~1
(alpha)~1
(epsilon)~1
subunits).~1
80-fold.~1
alpha-epsilon~2
Proofreading~1
(L-ornithine~1
carboxy-lyase,~2
4.1.1.17)~1
(speC),~1
(L-arginine~1
4.1.1.19)~1
(speA),~1
ureohydrolase~2
(agmatinase~1
amidinohydrolase,~1
3.5.3.11)~1
(speB)~1
spermidine.~1
1/2500th~1
spe+~2
activity--1/2000th~1
polyamine-dependent~1
speAB,~1
speC~1
polyamines.~1
(hGM-CSF)~1
deglycosylation.~2
deglycosylation,~1
8-fold.~1
produced-protein--lacking~1
carbohydrate--had~1
hGM-CSFs.~1
Gibbs~4
9.0.~1
(chlorocatechol~1
dioxygenase),~1
muconate~1
cycloisomerase~1
dienelactone~1
chlorocatechols,~1
4.2-kilobase-pair~1
pAC27,~2
maxicells,~1
4.2-kbp~2
tac~2
broad-host-range~1
pMMB22,~1
beta-D-thiogalactopyranoside,~1
386-bp~1
NAH~1
Asn-Pro-Asn-Ala~1
12(38)~2
4.95~1
bonding,~1
src-related~2
Protooncogene~1
c-src~7
c-fgr~3
c-yes)~1
tumor-cell~2
(homologue~1
v-Ha-ras)~1
Growth-rate~1
HRASEJ.~1
Colony-size~1
plates)~1
divided-colony~2
human-tumor-cloning~1
postmeiotic~1
spermatid,~1
meiosis,~1
cell-recognition~1
PE40-TGF-alpha,~1
PE40-TGF-alpha~1
(HBsAg),~2
"e"~1
DNA-transfected~1
antibody-staining~1
tanycytes,~1
rRNA,~1
Shine-Dalgarno~5
operons,~1
high-copy-number~2
cI857,~1
GGAGG~2
CCTCC~2
GTGTG.~1
inefficient.~1
anti-Shine-Dalgarno~1
(rrnB)~1
CACAC,~1
rrnB~1
spectinomycin-resistant~2
C----U~1
1192~1
16S-rRNA~1
phosphoenolpyruvate-dependent~1
IIBgi,~1
IIMtl,~2
IIGlc/enzyme~1
IIIGlc,~1
beta-glucosides,~1
IIBgl~3
IIIGlc~1
His-547~1
HPr~1
His-306~1
IIBgl.~1
IIGlc~1
His-15~1
HPr,~1
His-195,~1
matrix-driven~4
compositionally~1
translocational~1
Boc-Val-Pro-Arg-MCA~1
(Boc~1
butoxycarbonyl;~1
7-amino-4-methylcoumarin)~1
soybean-derived~1
Bowman-Birk~1
chymostatin,~1
L-1-tosylamido-2-phenylethyl~1
ketone,~2
anticarcinogenic~3
Diisopropyl~1
Boc-Val-Pro-Arg-MCA-hydrolyzing~1
pSV2neo,~1
beta-tubulin~2
209-residue~1
24,239.~1
cell-division-control~1
CDC28.~1
bla~6
ompA~1
ribosome-free~1
ribosome-bound~1
channel's~2
VDAC,~1
e-fold~1
0.36-mV~1
VDAC~1
AKT8,~1
AKT8~3
nonviral,~1
cell-related~2
v-akt,~1
v-akt~1
AKT1~2
AKT2,~1
Phencyclidine~1
Mg2+-sensitive~2
Mg2+-insensitive~2
(GP2).~1
(GC1)~1
(GC2).~1
noncompetitively~2
GC1~6
delimits~1
transmitter;~1
Hypothalamic~2
Undifferentiated~1
[oligodendroglia~1
astrocytes]~1
UR2~3
p68gag-ros~1
near-wild-type~1
[poly(Glu,Tyr)]~1
response(s)~1
405-amino~1
45,149)~1
42,646.~1
in-frame,~1
72-base-pair~1
TAA~4
(AATAAA)~1
(serine~1
amyloliquefaciens~3
subtilisins~1
kcat/Km,~1
217)~1
(contact~1
(residue~1
(Ser-156/Ala-169/Leu-217)~1
(Glu-156/Gly-169/Tyr-217)~1
TRM1~3
N2,N2-dimethylguanosine~1
ATGs~1
+49.~1
ATG.~1
AUGs~1
N2,N2-dimethylguanosine-specific~2
methyltransferase,~1
AUGs,~1
83,000~1
(hsp83).~1
hsp83~3
C62.5.~1
C62.5~2
htpG)~1
dnaZ~1
adk~1
htpG~1
hsp83.~1
xylS~6
xylDLEGF~2
m-toluate-degrading~1
m-toluate.~1
m-xylene~3
m-methylbenzyl~3
xylR,~1
xylE~1
xylR~3
xylCAB~1
m-xylene-degrading~1
xyl~1
Pro-OmpA~1
NADH.~1
pro-OmpA~7
[35S]Pro-OmpA~1
OmpA,~1
radiochemically~1
pure.~1
(S100)~1
"trigger~1
assembly-competent~1
pro-OmpA,~1
acid-denatured~1
immunoadsorption.~1
anti-OmpA~1
[35S]pro-OmpA.~1
[35S]pro-OmpA~1
Sedimentation~1
translocation-competent~1
HIR3.5)~1
147,000~1
Cloudman~2
[Nle4,D-Phe7]alpha-melanocyte-stimulating~1
alpha-melanocyte~1
arbors~2
arborization.~1
H-7~4
[1-(5-isoquinolinesulfonyl)-alpha-methyl-piperazine].~1
cAMP:~1
alpha-MSH,~1
(This~1
H-7.)~1
MSH-induced~1
HBT~3
5637-derived~1
5637~2
assembly-favored~1
cone)~1
axoplasm~1
regrew.~1
regrown~1
i.e.,--ends~1
neurites:~1
regrown,~1
(m6)~1
B21,~1
25,740.~1
chromosome-mediated~2
HRAS1-selected~1
sublocalizing~1
11p13.~3
WAGR~2
(Wilms~1
tumor/aniridia/genitourinary~1
abnormalities/mental~1
retardation)~1
overlapping.~1
aniridia,~1
amphiphilic.~1
two-center~1
(U.C.L.A.~1
Georgetown)~1
genioplasty~2
osseus~1
transplant)~2
Ph.D.'s~1
coauthor,~1
analysis'~1
appropriateness,~1
authorship~1
Feinstein's~1
ask,~1
do?"~1
welcomes~1
Informed~1
Entrusted~1
changeable;~1
alienate~1
cancer-screening~1
truth,~1
"shared~1
meaning"~1
weariness,~1
252-253).~1
Nondrug~1
breakthroughs--no~1
unclouded~1
Anticipatory~1
aching/agony~1
launching~1
correctable,~1
misery~1
discomforts~1
(strabismus)~1
dacryocystography~1
dacryocystogram~1
Intraorbital~1
neuro-ophthalmologist~1
locale,~1
chiasm;~1
fossa;~1
lymphangioma,~2
Mesothelial~1
"Ducts"~1
frequencies:~1
(retroplacental)~1
Echomorphologic~1
echomorphologic~2
appearance;~1
(fibroids)~1
Fibroid~2
echotexture~2
hypoechoic,~3
anechoic/cystic~1
fibroid.~1
Fibroids~2
chylomicrons.~2
cholesterol:protein~1
C-III0:apo~1
C-III2~1
triglyceride:protein~1
symptoms--including~1
parasitosis--have~1
(wounds~1
extricate~1
fingernails),~1
demanding;~1
Psychotherapy,~1
pimozide,~2
ones:~1
humans:~2
lentiviruses;~1
irrefutable~1
effect--are~1
food-producing~1
banning~2
Rotaviral~1
5%-10%~1
uroepithelium~1
(UTI).~2
Uropathogens~1
lactobacilli,~1
cooperatively,~1
independent-action,~1
"single-organism,"~1
independent-action~1
polysaccharide-protein~2
polysaccharide-human~1
mating)~1
insecurity,~1
human-to-human~2
transmission--all~1
427),~1
spiropiperidyl~1
rifampin-resistant~1
tropism,~1
Hybridoma-derived~1
cholera-related~1
(P-LT)~1
(H-LT).~1
immunosorption~1
GM1-binding~2
enterotoxins,~1
H-LTs,~1
P-LT,~1
Leprosy~2
Observations,~1
vegetation,~1
armadillos~1
(Dasypus~1
novemcinctus)~1
50%-70%~1
glycolipid-I~1
soil.~1
persuasively~1
leprosy;~1
proof,~1
leprotic~1
conjectural;~1
difficult-to-transmit~1
incubate~2
(extracellular~2
(depletion~1
microorganisms)~1
managed,~2
listerian~1
asepsis.~2
antibiotic-acrylic~1
1895~1
Theobald~1
Rockefeller~1
Smith's~4
honor.~1
Fabyan,~1
affair,~1
eight-inch~1
ten-inch~1
souvenir~1
sketches~1
researches.~1
sketch~1
accomplishments,~1
premier~1
microbiologist~1
erythromycins.~1
deployment~1
Worldwide~1
underanalyzed~1
Chairperson~1
sanitation.~1
"epidemiology~1
knowledge"~1
misused,~1
tutorials,~1
prescribing.~1
Benefit-cost~3
profound.~1
real-dollar~1
"cost"~1
foreseen,~1
cross-fertilization~1
Parasites~1
cross-fertilization.~1
Cas-Br-E~1
hydra~4
patterning~2
hippocampi~2
cornu~1
ammonis~1
erbB-2~5
nrdB~3
T-even~3
32P-guanosine~1
inhibin-like~5
(inhibin-LI)~1
inhibin-LI~2
8-bromo-cyclic~4
(8-bromo-cAMP),~1
cAMP-dependent.~1
(GnRH-LI)~1
GnRH-LI~1
immunoneutralization.~1
(NOD)~4
outcross~1
(NON).~1
Idd-1s,~1
Idd-2s,~1
Thy-1/Alp-1~1
Idd-3s,~1
backcross.~1
Idd-1s~1
Idd-2s~1
insulitis;~1
NOD~14
His64Ala)~1
(kcat/Km)~1
N-succinyl-L-Phe-L-Ala-L-Ala-L-Phe-p-nitroanilide~1
(sFAAF-pNA).~1
His64Ala~2
(sFAHF-pNA)~1
(sFAAF-pNA~1
sFAQF-pNA)~1
substrate-dependent~1
"substrate-assisted~1
catalysis"~1
Adipsin~3
adipsin~8
Adipsin,~1
(db/db~1
ob/ob),~1
adipsin.~1
(cafeteria~1
model).~2
obesities~1
(Arg-Lys-Val-Asp-Val-Arg)~1
18-nucleotide~1
E26~1
erythroid-myeloid~1
v-myb~1
v-ets.~1
COLO~1
99-amino~1
amino-terminus.~1
polyadenylation,~1
poisoning;~2
catenella~1
tamarensis,~1
Gambierdiscus~1
toxicus,~1
ciguatera~3
alimentary.~1
ciguatoxin~1
saxitoxin~1
Clonorchis~2
sinensis~1
Immunodiagnostic~1
fluke,~1
Praziquantel~3
emigrants~1
ophthalmia.~1
business'~1
conveniently,~1
hesitant~1
6972~1
Surgicenter~1
procedures--inguinal~1
orchiopexy,~1
herniorrhaphy--are~1
(THPS)~1
localization:~1
milliunits~2
Criterion~2
THPS.~1
Bayes~2
Theorem~1
Caspian~1
Iran~1
transcerebellar~2
upright;~1
smoothly,~1
drusen,~1
deteriorative~1
(lipofuscin)~1
"newer"~1
"all~1
same."~1
safety:~1
timolol?~2
toxicity?~1
comfortable?~1
effects?~1
"natural~1
habitat,"~1
71.6~2
Hematocrit,~1
37.1%.~1
Three-month~1
B-scan,~1
colestipol,~1
sonographies~1
coinvestigators.~1
58-72~1
16.4%.~1
(Pentastarch),~1
Pentastarch,~1
continuous-flow,~1
250,500,~1
Pentastarch~6
500-,~2
250-ml~1
1.72,~1
250-,~2
500-ml~1
nephroureterectomy.~1
postnephrectomy~1
AIc)~1
2/18~1
5/13~1
3/9~1
AIc~1
CIT.~2
Ketoacidosis~1
alpha1-adrenoceptor~1
(HCTZ),~1
DOX,~2
HCTZ,~3
89.1~1
DOX.~3
triglycerides)~1
27/57;~1
29/53,~1
DOX-~1
benefit-to-risk~1
cardio-thoracic~1
Diffuse,~1
(ARA),~1
prospectively;~1
VACTERL~1
(vertebral~1
fetal-bowel~1
ARA.~1
Multicystic~1
nonfused~1
crossed,~1
Ureteropelvic~1
hydronephrotic,~1
dilatation;~1
(Aloka~1
880,~1
mHz)~1
1.75%)~1
Tygon~1
interrogation~1
transducer).~1
kHz.~4
imaged.(ABSTRACT~1
ventriculogram.~1
(increases~3
(decreases~3
0.02])~1
0.005])~1
powerfully.~1
High-normal~1
escalate~1
salt;~1
Hypertension-associated~1
rarer,~1
extant.~1
norepinephrine/epinephrine~1
(smoking,~1
hypercholesterolemia),~1
failure),~1
anxiety)~1
visits)~1
enjoyment~2
Fear,~1
environment;~1
unnecessary)~1
inhuman~1
thromboatherosclerotic~1
readmissions.~1
(CABS),~1
CABS~1
CABS,~1
(arrhythmic)~1
supervene~1
(PVD),~1
bradyarrhythmia,~1
"nuisance"~1
Nicardipine,~1
nicardipine-induced~1
vasodilation;~1
antiatherogenetic~1
diuretics.(ABSTRACT~1
dihydropyridine-binding~1
nicardipine's~1
inotropicity.~1
chloroform-induced~1
placebo-controlled)~1
placebo-controlled;~1
actions:~2
29/102~1
24/92~1
15/105~1
20/95~1
277.~1
l/ml/90~1
2.2-kg~1
1.4-kg~1
(1,525~1
1,148~1
ng/ml/hour).~2
"snowman"~1
cm3/m2~1
0.15-tesla~1
nonrejecting~2
9-minute~1
densitometry,~2
estimates;~1
Unselected,~1
papavarine-induced~1
PTCA).~1
nonstenotic,~1
nondilated,~1
=22)~1
(ISDN),~1
off-period~1
glucose-based~4
dialysates.~1
low-glycemic-index~1
low-GI~3
Low-GI~1
refrigeration,~1
milk--down~1
Fe/L).~1
Beikost~1
beikost~1
starches~1
fortify~1
1922.~1
Filer~2
fibroplasia,~1
forerunners~1
(bronchopulmonary~1
Conferences~1
telecasts,~1
monographs~1
newsletters,~1
1800s,~1
adulteration~3
appallingly~1
1920,~2
components--aspartate,~1
T-cytotoxic/suppressor~1
(SCCs).~1
technic)~1
anti-TdT~2
TdT-positive.~1
verotoxin-producing~1
appearances,~5
infectious-type~1
verotoxin~1
splenectomies.~1
(ANA).~1
(ANA-),~1
(ANA+).~1
ANA+~6
1:320~1
1:640~1
ANA-~2
"transplant~1
internists"~1
126).~1
3:2).~1
autopsies)~1
Budd-Chiari's~1
liver-directed~2
6175~1
(adjuvant~2
6179~2
oxoloacetate~1
Aim~1
echo-guided~3
92.8%.~1
petechiae,~1
gastroduodenitis~1
pleuritis~3
hemorrhagic.~1
definitively.~1
(ARCD).~1
underrecognized~1
dialysis),~1
(LpA),~1
LpA.~2
pressure."~1
captopril's~1
BP-lowering~1
approved.~1
Converting-enzyme~1
first)~1
decline;~1
disposal.(ABSTRACT~1
(CEIs).~1
CEIs~2
inhibitors'~1
(SRC)~1
Modern,~1
SRC.~1
Betaxolol,~1
advantage;~1
99m-DTPA~1
imuran~1
binge,~1
(CyA),~1
constant;~2
ng/ml/hour)~2
0.29).~1
(-13.8~1
(-6.2~1
than)~1
renin/aldosterone~1
Extracutaneous~1
units/hour.~1
antibacterial,~2
penicillinase-producing~7
non-penicillinase-producing~3
g)/probenecid~1
probenecid.~2
multiclinic,~1
nonbacteremic,~1
Klebsiella/Enterobacter~1
reinfection)~1
agents).~1
multiresistant,~1
(UTIs)~2
marcescens;~1
UTIs.~2
(clean-catch~1
"complicated."~1
aeruginosa),~1
quadriplegia/paraplegia~1
108)~1
Enterobacter)~1
norfloxacin's~2
stead,~1
$7~1
$970.~1
trimethoprim/sulfamethoxazole;~1
trimethoprim/sulfamethoxazole-treated~1
enteropathogen~3
(cfu)/ml~2
pyelitis.~1
Emphysematous~1
pyelitis~1
Intraparenchymal~1
coexists.~1
no-therapy~1
organism(s).~1
(1.67~2
(cyclosporine~3
(diffusing~1
greater-than-expected~1
PSS-related~1
peptide-mapping~1
PRL-immunoreactive~2
8K~1
hPRL.~1
G-hPRL~1
hGH--possibly~1
Seeburg's~1
GH-immunoreactive~1
undertaken;~1
hydramnios.~1
Thirty-minute~1
18,886~1
vitamins)~1
nonvitamin~1
injection-placental~1
material:~1
direct-vision~1
intervillous~2
fetalis,~2
Terminations~1
visualize.~1
meshwork.~1
(sheets~1
cords)~1
(subendothelial~1
(substantia~1
propria).~1
resilient~1
donor-host~1
Ultimate~1
motions,~1
oculocardiac~2
preadjustment~1
promoter-like~1
0.015%~1
0.027%~1
Thymocytes~3
mg/mice),~1
cortisone-resistant~1
anti-keratin~1
Thy-1-positive~1
system--acyl-CoA~1
hydratase,~1
3-ketoacyl-CoA~1
thiolase--in~1
formaldehyde-low~1
K4M.~1
Epon,~1
metaperiodate~2
ethoxide~1
immunolabeling.~1
weakest,~1
immunoreaction.~1
postfixed~1
factors--infections,~1
obstruction--accounted~1
immunologic-mediated~1
Prolamine~1
duct-obstructed~2
rejection--endovasculitis~1
isletitis~2
(BCG)-induced~1
inflammation-induced~1
feltwork~1
(2D-GE)~1
alpha-SM~2
alpha-sarcomeric~1
(alpha-SR)~1
actins.~2
nondistinctive~1
well-differentiated)~1
alpha-SM-actin;~1
vimentin;~1
alpha-SR~3
2D-GE,~1
actins,~1
furnishes~1
amphetamine-like~1
Libido~1
orgasms~2
orgasmic~1
"power"~1
"support"~1
dichotomy.~2
movies~2
continuing-common-source~1
diaper-changing~1
non-foodborne~1
(Indochina~1
boliviensis)~1
mesangioproliferative~1
glomerulonephropathy,~1
slavery~1
Charleston,~1
sewerage-water~1
1890s~1
thereabouts.~1
fatigans).~1
Charleston~1
Asn-Ala-Asn-Pro~1
(NANP)3,~1
Kenyans~2
holoendemic~1
(NANP)3.~1
cell-ELISA~2
(OD492~1
41/50~1
34/50~1
28/30~1
anti-Pf155~1
PFR1,~1
PFR1R,~1
PFR1~2
One-microliter~1
prewet~1
autoradiogram~1
parasites/mm3.~2
PFR~1
Autoradiogram~1
parasites/mm3~1
p-amino~1
(PABA)~1
pyrimethamine-sensitive~1
pyrimethamine-resistant~1
14C-pyrimethamine~1
14C-sulfadoxine,~1
drug-sensitive~1
insect-~2
cultured-derived~1
72,000.~1
XIV/7~1
FUP~1
Tessier.~1
disfigurement~1
vein-artery~1
tapering,~1
unheard~1
gallium,~1
indium,~1
Eventual~1
(intraabdominal,~1
extraabdominal,~1
extremities),~1
sCT-treated~3
"nervousness"~1
(POM)~1
(ATR)~1
(DTC)~1
(SDC)~1
ATR;~1
DTC;~1
0-3.~2
POM,~1
ATR,~1
DTC.~1
ATR~3
POM~2
DTC~3
defasciculant~1
ATR.~1
POM.~2
(hypotension,~1
erythema)~1
releasers~1
(control;~3
1:200,000,~1
Carbonated~1
air-O2~1
N2O-O2~1
preoxygenated~1
well-received~1
(Ppw)~1
(Qva/Qt),~1
(Qt).~1
Ppw~5
(QO2).~1
Qva/Qt~4
Qva/Qt,~1
delivery.(ABSTRACT~1
nonsteroid-dependent~2
bitolterol.~1
(bovine,~1
human)~3
(L/P~3
(700~5
BMS-induced~1
6-yr-old~1
extubated.~1
(VE/SaO2:0.1~1
(VE/PaCO2:2.6~1
l/min/mmHg).~1
CPAP,~1
deteriorated,~1
(VE/CO2:2.1~1
l/min/mmHg).(ABSTRACT~1
formyl-norleucyl-leucyl-phenylalanine~1
(FNLP),~1
(C5f).~1
FNLP,~1
FNLP~1
FNLP.~1
accumulation),~1
02,~1
metabolities~1
facile~1
attainable.~1
(Clara~2
interconnection~1
nonphysiological~1
E-prostaglandins~1
(PGE).~1
angiotension~1
02-mediated~1
TDI,~2
TDI.~2
Exposing~2
Capsaicin-sensitive~1
(D-Arg1,~2
D-Pro2,~3
D-Trp7.9,~2
Leu11)~2
PD50)~1
1.51%~1
PD50~2
1.27%~1
exposure.)~1
(Apnea~1
15/h)~1
apneas;~1
1.8/h;~1
0.5/h;~1
5.9/h;~1
8.7/h;~1
2.0%;~1
shifts/h:~1
1.3:~1
waterproof~1
99mTcO4;~1
True-positive~1
intrathyroid,~1
sheath).~1
crossmatches.~1
retransplantation,~1
immunoassay).~1
(penicillins,~1
monobactams)~1
monobactam),~1
bicyclic~2
Meta-analysis~1
(homogeneity)~1
meta-analysis.~1
(nutritional~1
host),~1
p24).~1
(AJC-1980).~1
Refsum's~1
trioleate~1
(GTO)~1
hexacosanoic~1
73%)~1
post-diet~1
adrenomyeloneuropathy~1
(AMN)~2
AMN~4
(GTS),~1
GTS~1
tics.~1
Quantifiable~1
tics,~1
(0.0075~1
mg/kg/day);~1
adults';~1
ratings;~1
9-alpha-fluorohydrocortisone~1
(MSA)~1
(IOH).~1
MSA,~1
IOH~2
MSA~8
prions.~1
prion~12
(HaPrPSc),~1
(HuPrPCJD)~1
CJD.~3
HaPrPSc~1
(MoPrPCJD)~1
HuPrPCJD,~1
HuPrPCJD~1
MoPrPCJD.~1
MoPrPCJD~1
E-0702,~1
E-0702~4
E-0702-060~1
E-0702-061,~1
OmpF~1
OmpC~1
tonB~1
iron-starved~1
tonB-dependent~1
B0-1165~7
1-carboxy-1-cyclopropoxyamino,4-fluoromethyl~1
monobactam.~1
carumonam.~1
streptococcal,~1
staphylococcal,~1
plasmid-~1
1a-,~1
1c-,~1
1d-mediated~1
monobactams~1
N-dodecylimidazole~1
(C12-Im)~1
C12-Im~7
extract-2%~1
Bacto-Peptone-2%~1
sigmoidal,~1
5.0.~2
C12-Im.~1
mid-logarithmic~1
Vacuolar~1
vacuoles;~1
stationary-phase~1
cefotiam,~2
cefmenoxime,~2
cefotiam~2
cefotiam.~1
(log10~1
vegetation)~1
MBCs.~1
(3.08~1
vegetation).~1
cefmenoxime.~1
concentration/MBC~1
bacteria.(ABSTRACT~1
transconjugants~4
10(9)/liter.~1
10(9)/liter)~1
neutropenic.~1
Nalidixic~1
chlortetracycline~2
(erythro-AZT-TP)~1
1-(3'-azido-2',3'-dideoxy-beta-D-xylofuranosyl)thymine~1
(threo-AZT-TP)~1
myelobastosis~1
(rA)n~1
(dT)12-18~1
polyriboadenylate~1
oligodeoxythymidylate~1
length)-directed~1
erythro-AZT-TP~2
dTTP,~1
threo-AZT-TP~1
150-times-higher~1
isomers.~1
13-5478~1
14-9578,~1
gyrase-catalyzed~1
oxolinic~1
Turbidimetric~1
ketoconazole-resistant~1
penicillin-tetracycline~1
trimethoprimsulfamethoxazole~1
(DTH),~1
(GP),~1
BEX,~1
BEX~1
cutaneously.~1
GP-specific~2
albicans-specific~1
one-fourth,~1
1.7.~1
0.890;~1
6.3-kilobase~1
R46~1
OXA-2~6
OXA-3~2
PSE-4~1
12-mer~1
OXA-2-active-site~1
OXA-3.~1
K-O-~1
Dubos~1
clofazimine.~1
minocycline,~1
gramicidin,~1
gramicidin~1
broilers.~1
slaughter.~1
biotype.~1
tellurite.~2
(dfrI)~1
(bla~1
TEM-1)~1
65-kilobase~1
pIP1531.~1
Dey-Engley~2
disinfectants~1
disinfectant-treated~1
1-ml~1
mentagrophytes,~1
floccosum,~1
niger,~1
Ceftazidime~2
tellurite~1
(Ter)~1
RP4~1
RP4Ter~1
56.4-kilobase~1
replicon,~1
hives.~1
hypnotizability.~1
hypnotizable~2
nonhypnotizable.~1
hives~2
(testing~1
taking)~1
Hypnotizable~1
(ORS)~1
Dhaka~1
ORS~2
wheat-ORS~2
rice-ORS~2
glucose-ORS.~2
days-47~1
(Janssen~1
Ltd),~1
syrup.~1
Oesophagitis~1
oesophagogastroduodenoscopy.~1
Manometry,~1
post-prandial~1
Cisapride,~1
teas~3
coumarin.~1
CBD;~1
0-3~1
(2-5~2
(6-16~1
ultrasonographers~1
(CM),~1
(CZ),~1
PTs,~1
PTs~2
CZ~4
(51.1~1
(44.6~2
60-hour~1
Exam,~1
cholescintigraphic~1
aminotransferase)~2
nonexcretion~1
Xerostomia,~1
nonabsorption~1
Sialometry~1
pathobiology~2
adult-acquired~1
overpowering~1
Cornea~1
postkeratoplasty~1
keratometer.~1
11.68~1
7.95~1
Gold-plated~1
gold-plated~4
otorrhea,~1
biologist.~1
biomaterial-cell~1
polymers,~2
non-transformed~2
biomaterial-tissue~1
protein-competitive~1
protein/glycoprotein/lipid~1
Baier~1
"interface~2
conversion,"~1
conversion."~1
hydrophilicity/hydrophobicity,~1
biomatrices~1
(Diazemuls).~1
vasoconstrictors;~1
over-transfusion;~1
dihematoporphyrin~1
merocyanine-540~1
(MC-540).~1
MC-540~4
cytocidal~1
(HL-60),~2
(Reh),~1
histocytic~1
(SK-DHL-2)~2
lux.~1
29.3%,~1
46.8%,~1
preswitch,~1
switched,~1
postswitch~2
Recipients'~1
preswitch~2
recipients'~2
Ep,~1
haemoglobin,~3
(CyA).~1
others-two~1
Frail~1
mid-cervical~1
1981-83.~1
non-fatal).~1
non-focal~1
non-severe~1
worrying~2
post-hyperaemic~1
Isotope~1
'take'~3
(SSG)~1
edges.~4
sulphadiazine~10
maceration~3
ASIF~1
[17~1
patients]~1
patients])~2
levobunolol-pilocarpine~2
timolol-pilocarpine~2
reactions:~1
blepharoconjunctivitis,~1
3078~1
Regina~1
Early-onset~1
8140~1
7473~1
(91.8%).~1
(23.3%)~1
1568~2
pamphlets~1
1232~1
(68.0%)~1
7158~1
interested.~1
held,~1
(86.5%)~1
antiamylase~1
(atrophic~1
gastritis),~1
suspected/proven~1
carcinoids,~2
"atypical";~1
polypoid.~1
argyrophilic,~2
G-cell~1
serotonin-positive~1
endocrine-cell~1
tumorlets;~1
tumorlets~1
intestinal-like~1
pseudoglandular~2
(HCC).~2
pseudoglands~1
(28/39).~1
pseudopapillary~1
(6/39).~1
microglandular~1
noticing~1
Peptichemio~1
relapsed:~1
Craniopharyngioma,~1
craniopharyngioma,~1
82.5-year-old~1
panhypopituitarism,~1
genesis,~2
(MPAC)~1
descriptors,~1
MPAC~3
measures:~1
patient-saving~1
levamisole,~2
(radiotherapy,~1
Significance~1
oxyphilic~1
Grimelius~1
anti-VIP~1
nonmycosis~1
fungoides-type~1
Sezary-like~3
Ficoll-separated~1
(non-Sezary-like)~1
inflammatory-related~1
waterfall~1
chapters.~1
subendothelium,~1
(pigs~1
Deeper~1
splitting.~1
restenosis?~1
(thermodilution~1
digital-subtraction~2
devised.(ABSTRACT~1
0.18%),~1
(13.64~1
2.37%~1
VPDs/hour)~1
aggravation.~1
Cisplatinum~1
2-drug~1
oro-~1
favourable,~1
hypopharyngeal,~1
unfavourable.~1
(Polycel)~1
Polycel~2
electromicroscopic~1
post-implantation.~2
Plastipore,~1
centroblastic/centrocytic,~1
vasodilative~1
ARF)~1
Non-replacement~1
infoldings~1
backleak,~1
anuria,~1
1980's.~1
salvagable~1
post-maturity.~1
mania),~1
Second-source~1
preemployment~2
malady.~1
around:~1
mechanics;~1
livelihood;~1
overusing~1
semiflexed~1
epicondyle~1
redislocate~1
methylmethacrylate,~1
sawed~1
(OTC)-labeling~1
microradiographic,~1
OTC-labeling~1
nicorandil,~2
preobservation~1
"presystemic"~2
presystemic~3
aspirin;~1
neonates)~1
Moricizine,~1
depolarizations,~1
99.3%,~1
89.0%.~1
JTc~2
moricizine.~1
Moricizine~1
moricizine~1
scriptors~1
Dezocine~1
mEq/hr).~1
noon,~1
AM).~1
para-aminohippurate,~1
calcium-antagonizing~1
0-18.8~1
nmol/ml)~2
0-6.3~1
(3.6-52.6~1
0.726,~1
0.551,~1
0.556,~1
Anti-elastase~1
sol-phase~5
1PI-deficient~3
2M)~2
80-480,~1
80-300,~1
43.2-97.4,~1
sol-phase;~1
0-80.8,~1
sol-phase).~1
elastin-fluorescein~1
succinyltrialanyl-p-nitroanilide~1
sulphonylurea~5
thermic~4
(5.29~2
kJ/min;~1
(5.34~1
kJ/min).~1
(23.14~1
(21.40~1
kJ).~2
(75.8~1
kJ;~1
+39~1
sulphonylurea.~1
5'-pyrophosphate,~1
'low-dose'~1
platelet/vessel~1
drug-binding~1
Individualizing~1
pharmacokinetic-based~1
forecasting,~1
Useful~2
antiepileptic,~1
antiarrhythmic,~1
theses~1
university-affilitated~1
discovering,~1
documenting,~1
"semiquantitative"~1
(FPIA).~1
(TDM),~1
antiarrythmics,~1
antineoplastics,~1
TDM~4
tradition,~1
imitation,~1
TDM,~1
(most)~1
half-lives.(ABSTRACT~1
(TDMCS)~1
TDMCS~1
TDMCS.~1
manual.~1
(LDF)~1
LDF~2
macrocirculatory~1
conjecture~1
(BMT),~3
alimentation,~2
difference--acute~1
16/30~1
0/30~1
cases--suggests~1
post-BMT~2
crumpling~1
(A);~1
(B);~1
(24.9~1
(47.4~1
gastroscopically~1
1296-mg~1
(automaticity),~1
reentry),~1
(antibradycardia,~1
antitachycardia),~1
defibrillator,~2
fulguration,~2
antitachycardiac~1
"tachycardia-bradycardia~1
tachyarrhythmias).~1
pectoris;~1
bronchoprovocation.~1
ciprofloxacin-related~1
cardiovascular-related~1
Pralidoxime~1
Poisindex,~1
resource,~1
nonpoisoned~1
Antacids~1
unconfirmed;~1
antacid-anticoagulant~1
antacid-nitrofurantoin~1
overemphasized;~1
sulfate-,~1
isoniazid-,~1
tetracycline-antacid~1
importance).~1
Salicylate-induced~1
(AIH)~2
(IC-AIH)~1
(IU-AIH)~1
IC-AIH~3
IU-AIH.~2
IU-AIH~1
Epitopes~1
(A4,~1
A8-A10)~1
(B30)~1
(hydroxyl~1
B30).~1
radical-related~1
(12-wk)~1
(GSSG-RD),~1
GSSG-RD~1
(9-12~1
emaciation.~1
tissue-oxidant~1
membrane-producing~2
Myotubes~1
twitching.~1
radioinsulin~1
(Ni)~3
[3H]PGE2~2
dissociable~1
islet).~1
148%~2
184%,~1
quarter-disk~1
1-mm3~1
freeze-thaw~1
anti-lymphocyte~2
non-neoplastic,~1
mucosas.~1
immunocytochemical,~3
isosorbide-5-mononitrate,~1
velocitometer.~1
hepatopetal~2
celiac-mesenteric~1
acidifying~3
lactitol,~1
galactoside-sorbitol~1
disaccharide,~1
nonacidifying~2
tap-water~3
rerandomization~1
polarities,~1
N-acetylglucosamine-~1
mannose-terminated~1
agalactoorosomucoid,~1
ahexosaminoorosomucoid~1
N-acetylglucosamine-terminated~1
mannan.~1
allocated,~2
doses:~1
(received~1
anti-HTLV-III-negative~3
0.02):~1
2A.~2
anti-HTLV-III-positive~3
Homosexual~1
preabsorption~2
therefore:~1
two?~1
CPH)~1
role?~1
countries?~1
carcinogenesis.(ABSTRACT~1
nephrons,~1
uniadrenalectomized~1
regulators,~1
[131I]o-iodohippurate~1
Clipped~1
captopril-enhanced~1
microbore~1
deaminase.~2
postclipping)~1
inhibitor-induced~1
RSCT),~1
precaptopril~1
postcaptopril~1
(-62.42~1
[SD]%;~1
-100%)~1
(+0.57~1
9.83%;~1
+28~1
-13%).~1
RSCT-positive~1
RSCT~1
Interhospital~1
6.3,~4
13.1,~1
14.6,~1
Perfusions~1
(149.6~1
[QBr(s-p)]~1
QBr(s-p)~3
overflowed~1
alpha-naphthylthiourea~5
247%~1
(weight)~1
tracheae.~1
(1,1-dimethyl-4-phenylpiperazinium~1
iodide)~1
alpha-receptors,~1
Gruca~1
inequality.~1
analysed,~2
(Hydron-AgSD)~1
glycol-400,~1
2-OH~1
ethylmethacrylate,~1
(AgSD~1
1%-3%)~1
(silver~1
dressing;~1
Hydron~1
125I-lipoproteins~1
(Hep~2
G2).~1
Chylomicrons,~1
remnants,~2
(NTG-VLDL),~1
HDL-E~2
E-rich~1
Chylomicron~1
HDL-E,~1
NTG-VLDL,~1
HDL-E.~1
E-free~1
lipoprotein-containing~1
0.63;~2
-0.38;~1
-0.46,~1
-0.47,~1
Waist~3
circumference/thigh~1
-0.39;~1
[3-3H]glucose.~2
(impaired~2
insulin-antagonistic~1
posthypoglycemic~1
(2.5-3.5~1
2-kidney-1-clip~1
(2K-1C)~2
2K-1C~6
1-Sar-8-Ile-AII~2
PNS,~1
anti-Lp(a)~1
400,000-700,000~1
(faster~1
B-100),~3
S2,~1
double-band~1
(Lp[a]F,~1
Lp[a]B,~1
Lp[a]S1,~1
Lp[a]S2,~1
Lp[a]S3,~1
Lp[a]S4,~1
Lp[a]0)~1
Phenotypes~1
Lp(a)-trait.~1
123I-insulin~1
(cytophilic~2
insulin-antiinsulin~2
decomplementation,~1
Antiinsulin~1
isotypes),~1
aggregates)~1
aggregates).~2
cytophilic~1
B4.~2
diapedised,~1
upregulate~3
p150,95.~1
monocyte's~1
diapedese.~1
Weight-maintaining~1
fat-rich,~1
"prudent,"~1
carbohydrate-rich,~1
energy-restricted~2
mU/ml).~1
High-fat~1
1,000/mm3~1
2D3,~1
pericrypt~4
2D3~2
filamin.~1
IgAp~1
IgMr~1
(SIgA~1
SIgM)~1
SIgM,~2
(CEA);~1
grade;~1
(B2M),~1
B2M~4
B2M,~1
Plesiomonas~3
shigelloides~1
Plesiomonas.~1
Nigeria~1
(BBG~1
broth)~1
dermatopathology,~1
TEGUMENT,~1
Compaq,~1
dermatologist,~3
printed,~1
optionally,~1
91.8%,~1
ulcers:~2
ulcerous~1
Elase~2
(thyroxine,~1
incontinuity,~1
semipermeable,~1
basting~1
meshing~1
Graft-bed~1
(atrophie~1
blanche)~1
pre-ulcerative,~1
punches.~1
Crown~1
labialis,~1
labialis~1
"loading~1
sealant,~1
light-polymerized~1
autopolymerized~1
enterosoluble~1
(PRW)~1
1359~1
PRW,~1
PRW~3
caffeine-containing~1
instruct~1
kosher~3
normoglycemia.~2
postadmission~1
postcard~1
"ceiling~1
(7.38~1
(5.52~1
89.9%,~1
sucralfate-treated~1
acquired;~1
1-year,~1
cytoprotection.~1
(M-beta~1
M-beta~4
2-m;~2
alloantibody,~1
I-associated~1
Conjugates~1
targets;~1
(LFA)-1,~1
mixes~2
CD2/LFA-3.~1
supra-additive~1
CD2)~1
CD2/LFA-3~1
allosensitized~1
LFA-3.~3
two-pathway~1
interactions:~1
Purified,~1
recombinant-derived~1
titers)~1
anti-CVF~1
GV1.8~4
GV1.10,~1
CVF,~1
GV1.10~3
(peptide-N4-(N-acetyl-beta-glucosaminyl)~1
amidase),~1
N-glycanase,~1
pep~5
Heart-cross-reactive~1
SM5(164-197)C,~1
SM5(164-197)C~3
heart-cross-reactive~1
anti-SM5(164-197)C~2
M5.~1
heart-cross-reactive,~1
(CAP57)~1
CAP57~4
CAP57.~3
(P1G8)~2
P2A5,~1
P1G8~4
P2A5~1
P2A5.~2
CAP57,~1
structure(s)~1
tropica~2
([3H]glucose,~1
-glucosamine,~1
[35S]methionine)-labeled,~1
[125I]lactoperoxidase-labeled,~1
[3H]sugar-labeled~1
glycoconjugate,~2
44,000,~1
92,000,~1
water/100~1
cefotaxime-induced~1
Ivermectin,~1
Liberians~1
ivermectin/kg~2
200-micrograms/kg~2
100-micrograms/kg~2
150-micrograms/kg~1
six-amino-acid~1
chemotaxin.~1
peptidase.~5
streptolysins~1
peptidase-producing~1
flushes.~1
(56.5%)~1
(54.2%).~2
"vaginal~3
peptidase."~1
peptidase"~2
Paul's~2
ecstatic~2
visions.~1
Gabapentin,~1
1-(aminomethyl)~1
cyclohexane~1
myotrophic~1
125I-IGF-I~1
bd),~1
pictures,~1
sequels~1
Budipine,~1
4,4-diphenylpiperidine~1
benserazide)~1
budipine~3
improvement),~1
Oestrogen~2
(oestrophilin)~1
125I-oestradiol~1
classical,~3
3H-methylpromegestone~1
3H-methyltrienolone,~1
gerbil.~1
astroprotein~1
astrocyte-specific~1
caudoputamen~3
(SEM's)~1
microcolonies,~1
catheters'~1
fissures,~1
rugosities,~1
Permeability~1
SEM's~1
hide~1
microcolonies.~1
postextracorporeal~1
(PTTI)~1
post-ESWL.~2
PTTI~2
post-ESWL,~1
[99mTc]hexakis~1
Oropharyngeal-stimulated~1
cephalic-metabolic~1
sucrose/kg,~1
Sucrose-induced~1
0.41,~1
[9.5~1
mg/(min~1
mL/(min~1
kg)].~1
hyperlipemic~1
hyperglycemic.~1
(obese~1
lean)~1
starch-fed~1
hyperlipemia~1
literacy~2
black;~1
(HbA1%)~1
skills;~1
videotapes;~1
0.1-kg~1
HbA1%.~1
diet-and-exercise~1
(GABHS)~5
strategies:~3
"well"~1
GABHS~8
(CCJ)~1
(SCJ)~1
CCJ~2
capsule.(ABSTRACT~1
nonindigent,~1
[D-Arg1,~1
D-Trp7,9,~1
Leu11]-substance~1
([D-Arg]-SP),~1
[D-Arg]-SP~3
i.t.)~1
[D-Arg]-SP,~2
[D-Arg]-SP-induced~2
[D-Arg]-SP.~1
[pGlu5,~1
MePhe8,~1
MeGly9]-substance~1
(5-11)~1
urotensin~5
(0.06-6~1
alpha-methylnorepinephrine.~1
Urotensin~1
IC30~3
nmol/kg,~1
pg/ml-10~1
reperfusion-associated~2
PGI2.(ABSTRACT~1
23390,~1
midbrain-hindbrain,~1
mirroring~1
dopaminomimetic~1
38393-A,~1
171555.~1
alpha-methyltyrosine~1
HBr~1
23390.~1
171555,~1
agonist.(ABSTRACT~1
Cyclopentenone~1
(9-deoxy-delta~1
9,12-PGD2)~1
[3H]PGA2~1
(fractions~1
nucleoplasm~1
PGA2-derived~1
PGA2,~1
12-PGJ2-derived~1
12-PGJ2.~1
DNases~1
matrix.(ABSTRACT~1
3'-deamino-3'-(4"-morpholinyl)adriamycin~1
(MRA)~1
3'-deamino-3'-(3"-cyano-4"-morpholinyl)-adriamycin~1
(MRA-CN),~1
(myeloblastosis)~1
MRA~3
MRA-CN~4
diastereoisomers~2
DNA-template~1
MRA-CN,~1
MRA-CN.~1
DNA-drug~1
MRA)~1
N-trifluoroacetyl-ADR-14-O-hemiadipate~1
DNA-nonbinding~1
anthracycline).~1
drug-discrimination~4
Quadazocine~2
488,~3
dose-ratio~1
6.1,~3
6.4,~2
8.2.~1
urinary-output,~1
postinjection,~2
Deprivation-induced~1
U-50,488-dependent~1
morphine-dependent~1
2033-dependent~1
morphine-dependence~1
trachealis.~2
cartilage-containing~1
antispasmogenic~1
present).~2
(875~1
acetylcholine-~2
B-,~1
salivation.~5
[D-Pro2,D-Trp7,9]-substance~1
neurokinins~1
[D-Pro2,D-Trp6,8,Nle10]-Neurokinin~1
salivation)~1
[D-Pro2,D-Trp6,8,Nle10]-neurokinin~2
[D-Pro2,D-Trp7,9]-Substance~1
neurokinin-induced~1
neurokinin-~1
Dextrorphan~1
(DX),~1
morphinan~1
(lactate~1
quinolinate~1
neuron-protective~3
levorotatory~1
DX,~2
dextromethorphan,~1
DX.~2
"sigma~1
opiate"/phencyclidine~1
receptor-blockade~1
("halothane~1
hepatitis")~1
antigen(s),~1
57,000)~1
(PMS).~1
d,alpha-tocopherol~2
d,alpha-tocopherol.~1
(PMTS).~1
PMTS~4
(PMS),~2
premise.~1
well-conducted~1
bloatedness~1
antimania~1
nonreconstructable~1
remnants.~1
(39)~1
(46),~1
Missile~1
75.3%~1
67.7%~1
(24.2%~2
(17.2~1
multiple.~1
behavioral-pharmacological~2
antabuse~1
(GSVs)~1
GSVs~3
revascularization;~1
GSV,~1
intracranially.~1
casualties.~1
postaccident~1
Vienna~1
hospitals;~2
Moscow.~1
Diagnosis,~1
profitable~1
office,~1
70.6;~1
96)~2
Home,~1
3.5-4.0,~2
3.5-4.0~1
anti-heparan-sulfate-proteoglycan~1
18,000).~1
tannic-acid~2
(ARG).~1
ARG~1
[35S]-sulfate~1
ARG,~2
GuCl~1
charge-density~2
PGs,~2
alterations;~1
intra-graft~1
intertubular~1
synthetized.~1
86.4~1
(11.90~1
(320.4~1
104.5~1
infoldings,~1
secretory-like~1
excretion-amidase~1
(3.70~2
+/-0.37~1
units/day,~1
(18.8~1
ml/day,~1
lukewarm~1
immovable~1
Cytomorphologic~1
leuko-erythroblastic~1
embryonal,~1
intraincisionally~1
5,250~1
48-68~1
aminoacids~2
amyloid-containing~1
calcitonin-gene~1
28-37~1
DAP.~1
CGRP/DAP~1
DAP,~1
unbreakable~1
cross-reaction),~1
immunity-repertoire~1
pestilence.~1
Thirdly,~2
3553~1
nomads~1
Turkana,~1
north-west~1
(2644)~1
R-factor.~1
(mode~1
cephamycins.~1
post-DHE~1
(CAP).~1
CAP,~1
(26,~1
Haematological~1
diabetics;~1
4/15~1
"aware"~1
unawareness;~1
beef/porcine~3
&c),~1
unconsciousness.~1
1-48~1
neuroglycopenia.~1
vestibulocochlear~3
large-fibered~1
small-fibered~1
subdivision,~1
"overlapping~1
porus~3
acusticus.~1
pear-like~1
subdivision.~2
neurectomy,~1
Owens.~1
(IIP)~1
IIP.~1
Otologic~1
thesis,~1
IIP;~1
(MM,~1
BB)~1
(CA-III),~1
luteinizing-hormone-releasing~2
bladder-outlet~1
75.8~1
86;~1
(uptake/delivery)~1
-27~1
+40~1
Cop~8
23,000)~1
L-lysine,~1
L-tyrosine.~1
self-injected~2
0.045).~1
(Kurtzke~2
(Cop~1
(placebo~1
Irritation~1
Chemoradiotherapy~1
peritransplantation~1
Post-transplantation~1
autologous-marrow~2
allogeneic-marrow~2
pretransplantation~1
group--not~1
biologists~3
patient-level~2
copayment.~1
Hampshire)~1
Jersey),~1
10,734~1
month);~1
"ineffective~1
drugs"~2
copayment~2
three-prescription~1
precap~1
Medicaid's~1
($0.4~1
$0.8~1
annually),~1
haematopoietic/stromal~1
'stem~1
cell'.~1
sex-mismatched~1
(non-obese~1
MHC:~2
allo-reactive~1
I-E-expressing~1
(B6(E~1
d))~1
G1/S~1
G0,~1
(TfR)~2
IL-2R~34
IL-2/IL-2R~1
TfR~4
pentadecadeoxyribonucleotide~1
3H-uridine~1
pH-activity~2
dielectric,~1
(rates~1
catalysis)~1
mechanistically.~1
pertubation~1
(Asn~1
155----Ala~1
155).~1
Wells~1
Estell,~1
communication),~2
19-nucleotide~1
24-nucleotide~1
19-mer~1
155,000~1
(155K)~1
83K,~1
55K~3
35K,~1
trivirgatus~2
permeates~1
+60~1
'A'~4
Q2~1
P'3,~1
ORF-1(4)~1
sor5,~1
23K)~1
Transcomplementation~2
co-cultivated~1
centrum-basal~1
diencephalic-mesencephalic~1
cerebroscopy~1
ventriculoscopy~1
placements),~1
1%:~1
intraprocedural~1
(necrosis,~1
discussed.(ABSTRACT~1
Wycis~1
stereoencephalotome~1
epitome~1
nonstereotactic~1
"stereotactic~1
neurosurgery."~1
reawakened~1
Riechert's~1
tumor-infiltrating~3
medulloblastomas~1
exceptional,~1
supersensitivity,~1
arcade,~1
(C')~2
Goldmann-Witmer~1
37.7%~1
13.27%~1
Trichiasis~1
excrescence~1
trichiasis~1
dopplersonographic~1
66.5.~1
supertrochlear~1
superorbital~2
taxed~1
resorbed.~1
Hydroxylapatite~1
fabricating~1
tori.~1
bacteremias.~1
mores~1
life)~7
(HSV,~1
(GGCT)~1
(granular~1
myoblastoma)~1
GGCT~2
spindled,~1
nongranular~1
Pathology,~1
Purpan,~1
Universite~1
Sabatier,~1
Toulouse,~1
nodular-sclerosis~2
IAa,~1
IIAa,~1
IIIA.~1
Dako-EMA~1
(Dako-EMA+,~1
Leu-M1-)~1
(Dako-EMA-,~1
Leu-M1+)~1
Dysesthetic~1
tingling~2
(DPS)~1
Trazodone~1
DPS.~1
lead-in~2
hydrochloride/day~1
before--individuals~1
1-10,~2
(PAG),~2
(SRBCs).~1
remember:~1
Never~3
equivocate~1
final.~1
gubernaculum~1
Orchiopexy~2
retractile,~1
Nonclassic~1
(21-OHD)~1
peripubertally~1
postpubertally.~1
percentile),~2
noncontroversial~2
NVSS.~1
non-GH~1
protests.~1
Goiters~2
"physiologic~1
hyperplasia."~1
Hashitoxicosis~1
dermopathy,~1
Nonthyroid~1
cretinism,~1
(glycemic)~1
nurse-educator,~1
overemphasize~1
"adiposity~1
nature--an~1
obesity--and~1
nurture--the~1
child-family~1
23.75~1
agar-sulfamethoxazole-trimethoprim~1
(Strep-A)~1
Strep-A.~1
Strep-A~2
Todd-Hewitt-sulfamethoxazole-trimethoprim~1
GABHS,~1
season)~1
schedules:~2
sisomicin~2
(C/S)~1
sisomicin,~1
C/S.~2
Hyperpyrexia~1
aminoglycoside,~1
erythromycin-sulfisoxazole~1
(E/S)~1
(5%);~1
E/S~4
pharyngopalatotonsillar~1
sputum-negative~1
pharyngeal,~1
membranoulcerative~1
lesions);~1
"adult"~1
absenteeism.~2
168)~1
153)~1
interaction;~1
temperament,~1
isoetharine~1
methyl-prednisolone-treated~1
Placebo-treated~2
A/H3N2~1
shed,~1
.4,~1
Rimantadine~1
assets~1
undervalued.~1
healthful~1
facilitator~3
commonalities~1
backroads~1
"cookbook"~1
Nontechnologic~1
nurturing.~1
beings--people~1
intangibles,~1
"art"~1
That,~1
inexact~1
affirmation~1
bullets"~1
TT.~1
trying,~1
pace,~1
giver~1
nonopioid)~1
permease~3
(Gly-24----Glu;~1
Gly-24----Arg;~1
Pro-28---Ser;~1
Gly-24,~2
Pro-28----Glu-Ser~1
Pro-28----Arg-Ser)~1
(Phe-Gly-Leu-Phe-Phe-Phe-Phe-Tyr-Phe-Phe-Ile-Met-Gly-~1
Ala-Tyr-Phe-Pro-Phe-Phe-Pro-Ile)~1
galactosides,~1
Arg-24~1
Arg-24,~1
Ser-28.~1
galactoside~1
unoccupied.~1
ATP-dependence~1
La,~1
lon~1
lon-cells~1
immunoblotting).~1
[3H]methyl-casein~1
370,000.~1
260,000~1
fluorophosphate-sensitive~1
Katayama-Fujimura~1
[Katayama-Fujimura,~1
Gottesman,~1
Maurizi,~1
262,~1
4477-4485]~1
ATP-hydrolyzing~1
M13mp19~2
3'-homologous~1
5'-homologous~1
(3'-to-5'~1
direction).~1
8402,~1
camptothecin,~1
Camptotheca~1
300.~2
3.4.23.15)~1
1434-nucleotide~1
preprorenin,~1
402-amino~1
(renin-1)~1
(renin-2),~1
three-amino~1
insertion)~1
Glycoprotein~1
bond(s).~1
plaque-purified.~1
2420~1
extracytoplasmic~3
P2-purinergic~1
ATP-stimulated~2
trisphosphate,~2
gB,~1
VARNA~1
adenovirus-infected~1
gB-1~1
polykaryons.~1
N-(5'-Phosphoribosyl)anthranilate~1
isomerase-indole-3-glycerol-phosphate~1
49,500~1
beta-barrel~1
outward-curving~1
alpha-helices.~1
"channeling"~1
Rhodobacter~3
sphaeroides~3
R-26~1
Rhodopseudomonas~1
viridis~1
[Michel,~1
Epp,~1
Deisenhofer,~1
2445-2451].~1
neurotumor~1
"stem-cell-like"~1
RT4-AC,~1
neuronal-like~1
glial-like.~1
GFAP-immunoreactive~1
(glial-type~1
neuronal-type~1
precociously~1
O2'-dibutyryladenosine~1
77.5~2
PBS2,~1
PBS1~2
pbs1~3
pbs2,~1
PBS2~3
coclustering~1
digalactoside~1
alpha-D-galactopyranosyl-(1----4)-beta-D-galactopyranose~1
[alpha-D-Galp-(1----4)-beta-D-Galp~1
(1----4)Gal]-binding~1
pili,~4
(PapA)~1
papF~1
papG~2
(1----4)Gal-specific~1
pilin~1
PapA~1
digalactoside-binding~1
pilins.~1
gB-specific~1
astrocytes),~1
"unconventional~1
agent,"~1
3'-noncoding~1
(pScr-1).~1
immunocytochemically,~2
(CAI)~1
CAI~2
CAI.~1
anticarcinoembryonic-antigen~1
ZCE-025~3
(In-111~1
ZCE-025)~1
(203.5~1
2.5-80.0~1
ZCE-025.~1
ZCE-025,~1
hyperplasias.~2
hyperechoic,~1
kHz,~1
Three-kilohertz~1
labyrinthitis.~1
endothelialized~4
nonmetal~1
nonturbulent,~1
woven,~1
multifilament~1
alloy;~1
elastic,~1
6-F~1
9-F~1
0.014-inch~1
(0.036-cm)~1
restenoses,~1
PE"~1
aerosol-perfusion~2
hindbrain,~1
fluid-aided~2
(Workup~1
figures.)~1
Fluid-aided~1
triaging~1
Suprahyoid~1
Adenoid~1
enterprise.~1
presidential~1
President~1
Gerald~1
grace~1
"how"~1
things"~1
(NIH)~1
lineal~1
descendant~1
1887.~1
centennial~1
Senate~1
appropriations~1
subcommittees,~1
objectives:~1
pessimism~1
HIS4~5
GCN4,~1
5'-TGACTC-3'~1
BAS1~1
BAS2,~1
BAS2~3
PHO2,~1
nonaquatic~1
fats)~1
Asp,~1
Asp102~1
Asn~2
Ser195-specific~1
Ser195,~1
His57-specific~1
tosyl-L-lysine~1
chloromethylketone,~1
His57~2
kcat~1
catalysis,~1
(MPTP),~1
parkinsonian-like~1
hydroxylase-immunoreactive~3
host-cell~1
E1A's~1
transcriptional-activation~1
(trans-activation)~1
promoters;~1
E1A.~1
sulfation.~1
Runyon~1
Mycobacterium.~1
silently,~1
(IM).~1
oligoclonality~2
t(8;14),~2
5,000/cu~1
Prospectively,~1
cholecystolithiasis.~2
(OCG)~1
overinterpretation,~1
skews~1
.96~1
hyposplenic~1
meningococci,~2
Howell-Jolly~1
Hyposplenic~1
Moebius~1
[HTLV-III/LAV],~1
widespread;~1
(cytomegalovirus,~1
itself),~1
cryptococcus~1
vasculitis)~1
nutrient-stimulated~2
enteroinsular~1
(MG-10),~1
(MG-25),~1
(MG-62)~1
(dextrose)~1
[0-120]~1
MG-10,~1
BA;~1
MG-25,~1
MG-62,~1
MG-25~1
MG-62~1
(USRef~1
(237~1
hours:~2
C3a:~1
176.2~1
ns;~2
C4a:~1
151.4~2
C5a:~1
undetectable).~1
114%~3
formyl-methionyl-leucine-phenylalanine~1
glucan--a~1
1,3~1
polyglucose--and~1
ICR/HSD~1
dextrose;~2
(sub-MIC)~1
glucan-gentamicin~2
territories,~1
phosphometabolites~1
1,6-diphosphate~1
phosphometabolite~1
phosphometabolite.~1
creatine-phosphocreatine~1
[ATP]/[ADP]~1
ship;~1
(TBSA);~1
salt-poor~1
(PAT),~1
postinfusion,~1
clears.~1
Hyperlipidemias~1
(POSCH)~1
multicentered,~1
PIB,~1
PIB;~1
(41.7~1
PIB.~2
Clinics-Coronary~1
diffusates~1
Penicillium~2
ochrochloron.~2
diffusate~1
14,000)~1
mycetoma,~1
2.2%)~1
5.3%].~1
(+0.45%/month~1
6.9%)~1
+27%/month~1
6.5%);~1
(20-60~1
bronchioli,~1
Turret~1
(mass~1
micron);~1
Upmist~1
(MMD~3
microns);~1
Inspiron~1
Mini-neb~1
maximise~1
sol~4
sputum)~1
sols~2
firstly,~1
(inhibited~3
antiprotease)~1
ciliostasis~2
extraction).~1
beating--one~1
defences,~1
Cryoanalgesia~1
cryoanalgesia~1
continents,~1
today--the~1
honored~1
gifted~1
broad-reacting~1
incompatibilities~1
HLA-B.~1
MMs~1
ductocystostomy~1
pancreaticoduodenocystostomy~1
Pancreaticocutaneous~1
pancreaticocystostomy,~1
optics,~1
vasovasostomy,~1
prosthetics,~1
consideration:~1
neurophysiologic,~1
nonrelated~1
procreation.~1
X-~2
Y-bearing~2
justifiable.~3
nephronophthisis~1
oculorenal~1
base-plate,~1
cystourethrogram.~1
ledge~2
1907,~1
since.~1
nonsacral~1
(L7)~1
neuropathophysiology~1
microwaves.~1
(8/11)~1
(9/10),~1
(17/18)~1
Cholangiograms~2
(thrombosis~1
Strictures~1
nonanastomotic.~1
portography)~1
abscesses:~1
pancreatico-duodeno-cystostomy~1
cystograms~2
(duplex~1
sonography)~1
interlobar,~1
(diastolic/systolic~1
diastolic/systolic~1
ratios;~1
created:~1
1.64),~1
1.19).~1
Lipid-lowering~1
Platelet-active~1
aspirin).~2
double-crossover~1
"silent")~1
resting.(ABSTRACT~1
ISIS-1~1
Survival)~1
16,027~1
data-derived~1
enmeshing~1
cytoadhesive~1
expression.(ABSTRACT~1
patency;~1
inflations,~2
inelastic~1
Denudation~1
multifactoral~1
(12.2%~1
MB-creatine~1
[Wilcoxon~1
sum])~1
(11.3%~1
0.0103~1
[2-tail,~1
rank];~1
1,249~1
Seven-year~1
recainam~4
2-part~2
(VPCs).~1
575/hour,~1
1,494)~1
300-mg/day~1
ineffective;~1
900-mg/day~1
1,500-mg/day~1
runs)~1
Recainam~1
("pseudo-tolerance")~1
dilator),~1
upright),~1
2,127~1
392).~1
clarified;~1
shunts)~1
Carter~1
al)~1
+26%~1
(+7~1
+26%.~1
hepatic-splanchnic~2
(+12%~1
enoximone's~1
Bonferroni's~1
(vein~1
extrasystoles;~1
mg/kg.(ABSTRACT~1
(-29%~1
-42%,~1
(-33%~2
-44%)~1
(-30%~1
-46%),~1
-14%).~1
Nitroprusside,~1
(31%,~1
-22%,~1
(dobutamine~1
+18%,~1
-5%,~1
dynes/cm2.~1
1,311~1
1,027~1
17,043)~1
(2.07~1
(1,712~1
1,384~1
17,043),~1
enoximone;~1
(1,880~1
1,254~1
1.5%).(ABSTRACT~1
chemist.~1
(NP),~1
(GDM)~1
(BCAAs:~1
valine),~1
BCAAs~1
GDM~1
Rises~1
mackerel-oil~1
wt/wt)~1
mackerel-oil-fed~1
mackerel-oil-induced~1
monoenes~1
bushfood~2
(Ipomoea~1
costata),~1
(Solanum~1
tuberosum),~1
19%)~1
Caucasians,~4
contradictory.~1
sIgA-~1
avidin-biotin-peroxidase-antiperoxidase~1
(ABPAP)~1
ABPAP~4
technics,~3
ABPAP,~1
suppliers,~1
shipments)~1
commercially,~1
cost-effectively~1
shipments~1
allow,~1
rubber.~1
plastinated~2
touch,~1
odorless,~1
6,686~1
nonantireflux~3
nipples~1
(SNNs)~1
SNNs~1
SNN~2
(SNN).~1
SNN/renal~1
Mehes.~1
SNN.~1
nonheritable~1
11p13,~1
11p~4
3,183~1
dihydralazine~1
(129/82~1
12/6~1
135/86~1
10/5~1
4.16~1
(51),~1
Azotemia~1
Cytopenias~1
ileus).~1
B-induced~1
Flucytosine~1
clearance:~1
Hypercalcemic~1
bioactivation~1
overactivity.~1
adrenal-suppressing~1
breast-feed.~1
varicella-susceptible~1
undeterminant~1
anti-varicella~1
head-to-body~1
villi)~1
nonmolar~1
thoraco-amniotic~1
(GBS-Test)~1
Fetomaternal~1
noncatastrophic~2
(pro-)~1
(MicroTrak)~1
coccoid~1
immunofluorescent-stained~1
MicroTrak~1
8.345~1
8.345.~1
streptokinase-~1
gonadotropin--treated~1
streptokinase-treated~1
trans-4-(aminomethyl)-cyclohexane-carboxylic~2
streptokinase-perfused~1
teratology~1
precepts,~1
compose~1
catheter-protected~1
Compounding~1
Newer,~1
sulfa~2
52/60~1
(86.6%)~1
53/56~1
(94.6%)~1
microphthalmic~1
Bronchioloalveolar~1
(BAC),~1
BAC,~1
BAC)~2
patchily~1
epithelial-stromal~2
(HTB).~1
sulfate-proteoglycan.~1
2-3-cell-thick~1
lamina;~1
completely;~1
secretions;~1
consultations;~1
attended.~1
no-intervention~1
attend,~2
8th,~2
femur-reconstructed~1
graft-tibia~1
buttons,~1
Lambert.~1
screw,~2
Strengths~1
critiqued~1
leave)~1
hampers~1
digital-symbol~1
siting.~1
ventilation-(HFO-A,~1
HFO-A~7
12-203~1
FI02~4
HFO-A:~1
nonpulmonary.~1
(MAwP)~1
MAwP~2
HFO-A,~1
(HFJV).~1
HFJV.~1
(Csmax)~1
Csmax~1
hemorheologically~2
hemostasiologically~2
(Ramires~1
Thrombi~1
(3.28~1
1.99/p~1
0.076).~1
clonidine;~1
-14%,~1
-47%;~1
Insonation~1
72.5%,~1
93.5%.~1
mites/g~1
(D.~1
pt.)~1
pt.~1
(nonallergic)~1
Pointes~1
Unresponsive~1
psychoneurosis.~1
asbestos:~1
"young"~1
spinability~3
methacholine-~1
eosinophils)~3
nonasthmatics.~2
washing,~3
nonasthmatics~2
beset~1
surfactant;~3
ambiguities~1
recycled.~1
Heroic~1
desperate,~1
invented.~1
intrigues~1
They,~1
hope,~1
mycobacteriosis~1
mycobacteremia,~1
unprecedented.~1
III/LAV~1
(Ara-AMP~1
Referral-based~1
liver-disease~1
Ara-AMP,~2
Ara-AMP.~1
(Karnofsky~1
Ara-AMP/placebo~1
Ara-AMP/human~1
units/mL~1
Antigenemia~1
steatotic~1
reduced-size~1
decerebration~2
51.5%)~1
wane~2
varicella;~1
drag"~1
"adjustment~1
phase"~1
(KM)~1
electroimmunodiffusion~1
cefbuperazone.~1
Cefamandole,~1
abattoir~2
poultry~4
antibiograms~1
(8.1%)~1
antibiotic;~1
SHV-1~2
Pancrease,~1
Creon,~1
Forte,~1
Pancreatin~6
Creon~4
Pancrease~5
forte~1
Forte.~1
Creon.~2
selenide~2
electronics.~1
garlicky~2
decentralizing~1
governments.~1
385-bed~1
stitch,~1
"myxoid~1
imitators"~1
Humana~1
imitators,~1
(recurrence~1
5.3%).~1
imitators.~1
extracardiac,~1
(CD),~1
(beta-GU),~1
(AKP),~1
beta-GU~2
AKP~3
(AKP)~1
hind-limb~1
1966-1970.~1
ambulators~2
wheelchairs).~1
cyclosporine-prednisone~1
flush-cooled~1
+21,400;~1
+23,900.~1
azathioprine;~1
antiprotozoal~3
amnesia:~1
amnesia;~1
ALO~11
2145,~1
trabeculoplasty.~2
2145~8
IOPs~2
eyes:~1
gonioplasty~1
iridoplasty~1
long-established~1
(CR3),~1
(CR1).~1
Leu-2a+/Leu-15-~1
cytotoxic)~1
Leu-3a+/Leu-8-~1
Leu-2a+/Leu-15+~1
suppressor)~1
Leu-3a+/Leu-8+~1
inducer)~1
(ISC),~1
two-fold)~1
ISC~4
(72B9)~1
(P3x63Ag8.653).~1
72B9~2
34,000,~1
scleroderma-related~1
14C-valine~4
alpha-2-macroglobulin~1
pre-albumin~2
non-alcohol-related~2
alpha-2-macroglobulin.~2
non-alcoholics)~1
serially:~1
ethanol:~1
Cogfun~1
Maze~1
prompts~3
splinting,~1
zygoma~1
42.2%~1
no-antibiotic~1
(CSF)-derived~1
1:5,~2
(11/12)~1
(HTLV-IIIb)~1
ENV-9~1
immunoreactive.~2
GAG-1~2
GAG-55~2
ENV-9,~1
GAG-55,~1
ENV~1
(ELISA);~1
gp120/160,~1
WB.~1
RIPA,~1
denaturated~1
investigate.~1
mononitrate.~2
132.4~1
(17.1)~1
140.4~1
(13.1)~1
(1.5-15~2
(25W~1
ergometry)~1
haematocrit.~1
anaesthetic-induced~1
near-misses~1
reticence~1
confession~1
mistakes,~1
mishaps.~1
undoubted~1
encompassed.(ABSTRACT~1
tempestuous~1
eventuality~1
tort~2
bankrupting~1
relativity~1
(both)~1
268)~1
AFP)~1
feto-maternal~1
amniocentesis-induced~1
culdocentesis~2
ovulation;~1
Newbury,~1
Berkshire,~1
card.~1
1.08-1.95)~1
1.73;~1
1.16-2.59).~1
Asked~1
1.34-1.81).~1
iso-risk~2
1:400~2
intrapartum)~1
(RI).~1
-0.65).~1
Ninewells~1
linear-array~2
receptor-hormone~1
cycle:~1
Non-ionic~1
KU-812-F~10
KU-812,~1
(SF-C)~1
SF-C,~3
basophil-like~1
SF-C~2
(con~1
bipotential~2
autostimulating~1
Ki-B3~5
centroblastic/centrocytic~1
(m.l.~1
follicular)~1
Ki-B3.~1
kiloDalton~1
(5637-CM).~1
(CT-2)~1
(busulfan,~1
[ara-C],~1
1,365-cGy~1
anti-graft-v-host~1
waned,~1
IgG4)~1
IgG4,~1
Subclass~1
Hib,~1
N-hydroxysuccinimidobiotin;~1
biotinylation~1
14C-cyanate;~1
reinfusion,~1
14C-cyanate~1
reisolate~1
V/Va.~1
(kD).~1
Coagulant~1
97-kD~2
77-kD~2
Va(e)~1
Va(t).~1
52-~3
30-kilodalton~1
28-kD~1
[3H]DFP~1
30-kD~2
[3H]dexamethasone-21-mesylate-labeled~1
methoxysuccinyl-alanyl-alanyl-prolyl-valyl-chloromethylketone,~1
agent-VAD~1
(vincristine-adriamycin-dexamethasone),~1
9+~1
-6,-5)~1
24+~1
(lymphoid~1
lymphoproliferation.~2
(strictly~1
torsion),~1
static-image~2
defining,~1
(torsion)~1
anteversion,~1
26.4%~1
assertions~1
cholecystosonography.~1
detected)~1
Echogenic~1
over-treatment~1
Normocalcaemia~1
0.9449)~1
Visualisation~1
Cavography~1
-29%~1
+52%,~1
(U-ECP),~1
mastocytosis).~1
U-ECP~3
u/l~2
arb.~1
Esch.~6
(5FU)~1
5FU/levamisole~1
urethrally~1
suprapubically~2
(Granuflex,~1
Surgicare)~1
non-adherent~1
Johnson).~1
bandage.~1
kirrhos~1
(tawny),~1
footnote~1
treatise~1
l'auscultation~1
(1819),~1
"Laennec's~1
cirrhosis"~1
commemorate~1
fortunes~1
19th-century~1
preoccupations~1
eponym.~1
spate~1
nonadherence~1
patient-health~1
fibroadenoma)~1
ER-ICA)~1
immuno-staining~1
(IS-CYTO)~1
(IS-HISTO)~1
semi-quantitation~1
(ER-DCC)~1
ER-DCC~1
IS-CYTO~1
IS-HISTO~1
(CABO)~1
CABO,~1
ABO.~2
CABO~4
Myelosuppression-associated~1
effects--neuropathy,~1
fever/chills,~1
impairment--occurred~1
III/IV~1
reendoscopy~1
(interstitial~1
beam)~1
receptor-poor.~1
receptor-poor~2
"compassionate~1
grounds,"~1
28+,~1
(Lipiodol,~1
Fluide),~1
(Gelfoam,~1
Upjohn,~1
(69%);~1
(65%);~1
"tumor-kidney~1
"inflammatory~1
pseudocapsule,"~1
unevaluable),~1
NWTS-3~1
NWTS-1~1
"microsubstaging"~1
ganglioneuroblastoma,~1
violations,~1
(receiving~1
antibody-derived~1
immunoassays)~1
(circulating~1
immunity).~1
beta-1-glycoprotein~1
0.20).~3
linear-analogue~1
velban,~1
Actinomycin-D,~1
cytoxan~1
(VAB-6),~1
(EP),~1
VAB-6.~1
(VUC),~1
(BWC),~1
(BWFCM)~1
VUCs~1
2.63)~1
BWC~4
BWFCM,~1
BWFCM~2
VUC~3
BWFCM.~1
(endodermal~1
extrapericardial~1
organoid~1
Grimelius'~1
typical.~1
(S100),~1
PCN,~1
receptors:~4
PCN;~1
translumbar~1
anesthetizing~1
bubbled~1
CO2-75%~1
Lumen~1
pouch.(ABSTRACT~1
cardiogenesis~1
4-chambered~1
ovo.~1
"cobblestone"~1
10(-11)-10(-7)~1
receptor-coupled~2
0.8-5.5~1
cAMP/min/mg~1
kinase.(ABSTRACT~1
lowering.~2
N-Acetylcysteine~1
(S-ECG)~1
(IC-ECG)~1
S-ECG.~1
Cross-correlation~1
S-ECG~4
(SA-HFQ).~1
IC-ECG~1
SA-HFQ~2
(3.79~1
SA-HFQ,~1
S-ECG,~1
1274~1
iatrogenically~1
OKT3-induced~2
H3-thymidine~1
(Cmax~1
1,466~1
-0.007x,~1
-0.91,~1
Cy,~1
(4.38~1
(7.40~1
5.63~1
7.46~1
0.05-0.001).~1
firearm-related~3
1,756~1
unintentionally,~1
16,573~1
13,841~1
Handguns~1
staggering.~1
$2100,~1
gun-related~1
950,000~1
"premature"~1
$4~1
ingrained~2
adjudication~1
driver,~1
Highway~1
Traffic~1
(NHTSA)~1
(FMVSS).~1
FMVSS.~2
windshields,~1
wheels,~1
dashboards,~1
seats,~1
crashworthiness~1
Motorcyclists,~1
bicyclists,~1
pedestrians~1
vitro):~1
vivo):~2
Osteostim~1
(BGS~1
Milwaukee,~1
Wisconsin)~1
0.121);~1
0.669).~1
prevention;~1
seating,~1
redesign,~1
Frymoyer~1
"glossary"~1
"20th-century~1
LBP"~1
reinforcable~1
hygiene.~1
oophorectomy)~1
nulliparity.~1
mechanical.~1
over-diagnosis,~1
screeners~1
scoliometer~1
deformity;~1
complication-ridden~1
(CDHs)~1
CDH.~2
Ortolani~1
Barlow~1
overemphasis~2
fetoscopy,~1
(1%-3%)~1
cetirizine,~5
four-way~2
(cetirizine,~1
hydroxyzine)~1
Hydroxyzine~1
(HFO),~1
(XeW)~1
constant/min~1
(KXeb)~1
XeW~6
(KXeW)~1
(KXecv).~1
Pig~1
KXew~1
0.25/min~1
0.12/min~1
KXeb~1
KXeW~1
PPV.~2
biofilm,~1
warneri,~1
Diphtheroid),~1
(Propionibacterium),~1
cloacae).~1
FEV1).~1
1.65,~1
4.58,~1
(intraclass~1
0.957,~1
"shunt~1
(SI),~1
(Qva/Qt)~1
CO2(ETCO2)~1
(MHCII)~1
transanally~2
(significantly~1
overtube~2
(I-131)~1
(In-111).~1
Immunoscintigraphy~1
false-negatives).~1
(AISTOM),~1
transstomal~1
(Miles)~1
1.3;~2
89.6~1
possible:~2
ostomates.~1
dissipates~1
misconceptions:~1
"regional~1
enteritis."~1
considering.~1
relic~1
(STa)~1
monoiodinated~1
125I]STa)~1
[125I]STa~1
temperature-,~1
pH-dependent;~1
saturable;~1
Nonlabeled~1
l/mol.~1
Trypsin~2
allowing,~1
antibiotherapy~1
cholangitic~1
mmol/hr,~1
sham-feeding~1
vegetable).~1
GIs~2
GI,~1
GI.~2
high-,~1
ng/12~1
h-1).~3
(89.5%)~1
miscibility~1
human/Monotard~2
(Humulin~2
regular/Humulin~2
NPH)~1
1:4,~2
regular/lente~2
regular/NPH~1
instantly~1
NPH).~1
(UCP)/creatinine~1
51);~1
0.06-0.60~1
48);~1
.988,~1
.904,~1
.902,~1
.716,~1
.731,~1
.557,~1
.641,~1
rubric~1
"shock"~1
distributive~1
(septic,~1
anaphylactoid/anaphylactic),~1
cardiogenic,~1
hypovolemic,~1
2u-Globulin~1
2u-globulin~10
2u-globulin.~1
(300%)~1
2.6-~1
glucose-primed~1
(TDP)~1
TDP~2
apart;~1
TDI;~1
glucose-arginine~2
interphasic~1
86Rb+~3
TPA;~1
nonelectrogenic~1
(REFs),~1
[35S]Cysteine-labeled~1
REFs.~1
REFs,~1
[3H]phenylalanine,~1
[3H]arginine,~1
NH2-terminus.~1
coordinately,~2
(LHRIF),~1
pentobarbital-blocked~1
LHRIF~2
vanadate-induced~6
vanadate-free~2
(EnCa~1
116,000~3
85,000.~1
EnCa~3
Robertsonian~1
HL-1~1
Friendly~1
myeloma-653~1
hPRa~8
1-7.~1
Subisotyping~1
G2b,~1
G1.~1
Ultracentrifugation~1
[3H]progestin-labeled~1
101;~1
triplet.~2
Immunolocalization~1
ranked:~1
(3+)~1
(2-3+)~1
(0-1+).~1
ribonucleases~2
U2.~1
ER-nuclei~2
bone-derived~1
BDGF,~2
neogenesis~5
(10-500~1
neogenesis,~1
insulin-mimetic~1
Concanavalin-A~2
neogenesis.~1
ovarian-independent~1
juvenile,~2
(20-22,~1
26-27,~1
(30-120~1
180-300~1
afternoon).~1
juvenile-peripubertal~1
BC3H-1~3
hydroxyurea-sensitive~1
phorbols~1
1-oleoyl-2-acetyl-sn-glycerol.~1
(Anti-R~1
Anti-R~2
anti-R~5
immunodeplete~1
(anti-R~1
marker).~1
91,000~2
b),~1
Phosphoaminoacid~1
Histone~2
H2b.~1
H2b~1
superimposable,~1
epileptogenesis,~2
classify,~1
"kindling~1
antagonism"~1
antiepileptogenic~1
asynchronous,~2
milestones.~1
counterpart;~1
pharmacogenetics,~1
comedication,~1
drug-eliminating~1
antiepileptics~1
drug-specific,~1
Intercurrent~1
extraoperative~2
(ECoG)~1
ECoG~2
(GnRH)-treated~1
surge).~1
GnRH-treated~2
LH-bio~1
LH/FSH~3
luteinized-unruptured~3
follicles)~1
gossypol-related~1
(IBT).~1
IBTs~1
IBT~1
("GAM-IBT").~1
GAM-IBT-positive~1
Immunobeads.~1
GAM~1
bead's~1
GAM-IBT~1
IBTs.~1
rhetoric~1
belies~1
refer,~1
bandied~1
disclaimed~1
depreciate~1
appeal.~1
Discussions~1
Andrija~1
Stampar,~1
6-12-mo~1
11-127~1
concorded~1
RDEC-1~9
(serotype~1
015:NM)~1
effacing~1
(fimbriae)~1
RDEC-1.~1
Nonpiliated~1
mannose-resistant~1
AF/R1~1
mannose-sensitive~1
piliated~1
RDEC-1,~1
nonpiliated,~1
coaggregate~1
enteroadherence.~1
(CV-3988,~1
BN-52021,~1
Ro-193704).~1
endotoxin-~1
(68.4%)~1
Zymograms~1
isozymograms,~1
Enteroglucagon-containing~1
enteroglucagon-immunoreactive~1
enteroglucagonlike~2
4-16~2
bleeds/patient~1
bleeds/patient-month)~1
disappeared)~1
"manometric"~1
capsaicin-treated,~1
capsaicin-treated~1
slighter~1
(enteric)~1
overemphasised~1
Intravariceal~2
post-oral~1
load;~1
normalized)~1
mg/kg/12~1
captopril-aspirin~2
ng/8~2
entrepreneurial~1
acrylic.~1
moulage~1
"de~1
novo"~1
benignancy~1
(T11)~5
1902,~1
Navratil~1
alveolus,~2
fauces,~1
misquoted.~1
Navratil.~1
(EMP)~2
EMP~4
Trains~1
40-100~1
indium-Woods~1
alloy.~1
Microinjections~1
D,L-homocysteic~1
somato-autonomic~1
(UVNa)~1
Aldo.~2
UVNa.~1
UVNa~1
cardiovascular-pulmonary~1
beta-adrenergically~1
(84.7~1
ml/cmH2O),~1
25-min~1
(volume-displacement~1
Krogh~1
spirometer)~1
1,623~1
Boyle's~1
(-7%).~1
extensors:~1
59-78%;~1
flexors:~1
26-40%).~1
quadrupedal~1
Alexander~1
Kellas~2
(1868-1921)~1
physiologist~1
Everest~3
altitudes,~1
Middlesex~1
expeditions~1
1919~1
expedition~1
anybody~1
Everest."~1
summit.~1
"Mount~1
ascended~1
first-rate~1
[supplementary~1
oxygen]~1
great."~1
physiologists~2
(cAMP).~2
Formalin.~1
beta-agonist-induced~1
microU/mL.~2
glucose)-induced~1
(PCO).~1
AN,~4
non-SHBG~1
0.33;~1
PCO;~1
bio/immuno~4
mannoheptulose~2
STZ.~1
STZ,~2
3.7-fold~1
IBMX-induced~1
IBMX.~1
diisopropylfluorophosphate,~1
1-M~1
agglutinin-conjugated~1
Eluate~1
260-fold~1
b-type~3
22,000.~1
50,000,~1
beta-elimination,~1
Mr-91,000~2
Mr-22,000~3
120,000-135,000~1
PtK2,~2
HEp-2,~1
phalloidin,~2
80,000-~1
75,300-mol~1
53,500-mol~2
myocardial,~1
vinculin~16
anticytoskeletal~2
(DCs),~1
(FCs),~1
FC).~1
[3H]captopril~1
(1K-1C)~1
(6.20~1
1K-1C~2
(3.20~1
(HLA-DS)~1
mycobacterial,~1
pneumocystic~1
subepithelially~1
intraepithelially.~1
infections:~1
(anti-ER)~1
recognises~1
(anti-D5)~1
anti-D5~2
favouring~1
polyomaviruses~1
hybridot~2
deficiency-a~1
Telangiectasias~1
microsclerotherapy.~1
sclerosants,~1
(Sotradecol),~1
hydroxypolyethoxydodecane~1
(polidocanol;~1
Aethoxysklerol),~1
Sclerodex~1
worshippers,~1
sun-induced~1
attune~1
Burow's~1
desires,~1
gratification,~1
tension-reducing~1
manifesting.~1
dentistry's~1
eight-unit~2
Costly~1
remake~1
diet-bacterial~1
periodontology,~1
perimolysis~1
veneer~1
Duplicating~1
(cicatricial)~1
fluocinonide,~1
spray)~1
0.00005~1
0.0017).~1
21/25~1
bees~1
antibody-stained~1
definable,~1
seventeenth~1
guar,~1
glycosuria.~1
JADA,~1
JNE,~1
HERJ.~1
"right"~1
"correct"~1
24-hr)~1
(RAAS)~1
RAAS~2
mesor~1
(rhythm-adjusted~1
(variability~1
mesor)~1
nonphysiologic~1
(24-hr~1
(oscillating~1
(meal,~1
pentagastrin)~1
5-40~1
exocrine,~1
Half-life~1
bradyasystolic~1
microcircuitry~1
on-going~1
hemodynamically-compromising~1
(DIC),~1
(FDP).~1
Athymic~1
(PVG.rnu/rnu)~1
(TDL)~1
TDL-injected~3
TDL~2
non-lpr~1
(A-Thy)~1
chimeras:~1
A-Thy----(MRL/lpr~2
A-Thy)F1~1
A-Thy)F1.~1
engrafted.~1
magnitude),~1
B6/lpr~1
B6/+~1
(MRL/lpr~2
B6/+)F1~1
B6/lpr)F1~1
alloreactivity~3
homozygous)~1
lpr-GVHD,~1
lacto-N-fucopentaose~2
(CD15)~1
LFA-1/HMac-1/gp~2
150,95~2
avidities~1
(CD18)~2
LamB~3
preS2~1
virus:~1
132-145,~1
153-171.~1
(LamB-preS2~1
LamB-preS2~3
LamB.~1
LamB,~1
anti-BN~2
(LEW~3
BN)F1~3
Splenocyte~1
three-component~1
MG-63~1
(TNF)-alpha~2
(IFN)-beta~1
hybridoma/plasmacytoma~1
(HPGF)~1
factor-2~1
1-related~1
(mIL-1)~1
3B~2
mIL-1~4
anti-interleukin~2
33-kDa~1
IgE-coated~1
anti-CR3~2
(OKM1~1
Mo1).~1
anti-beta-chain~1
normodense~3
IgG-mediated~3
platelet-mediated~1
Hodgkin-associated~1
L428~1
Surface-labeling~1
105-~3
tunicamycin-sensitive~1
6-kDa~1
O-Linked~1
transcompartment~1
P-32,~1
Hodgkin-derived~1
(strains~2
JY-1)~1
JY-1~1
(CYA)~1
CYA-treated~1
JY-1.~1
CYA~1
myristate,~1
(OCT),~1
dimethylformamide,~1
(EG),~1
formamide),~1
1.6-(EG)~1
122-fold~1
(OCT)~1
pretreated.~1
(OA,~1
OCT,~1
(Cascas-42).~1
(Moll's~1
catalogue~1
#10),~1
Cascas-42~3
keratin-agarose~1
(IAP-Cascas-42~1
IAP-Cascas-42~3
trypsin-dissociated~1
(Iodo-Gen~1
coadherence~1
(adherence~1
coadherence.~1
phosphatase-conjugated~1
10(4)-1~1
.923-~1
.965).~1
coadherence,~1
type-1,~1
type-1C~4
fluorochrome-conjugated~1
Type-1-fimbriate~1
fimbriae;~1
slide,~1
(HDAg).~1
HDAg~4
woodchucks.~1
HDV-specific~1
MAbs;~1
liver-~1
episiotomies,~1
transmitter-associated~1
(GPR)~1
HDC~1
(BCNU),~1
complication-related~1
post-ABMT~1
PDC~3
chemotherapy-responsive~1
regimens);~1
119875)~1
241240)~1
myelosuppressive.~1
cross-resistant.~1
cisplatin/d~1
45,000/microL;~1
321,000/microL;~1
Modestly~1
Responses,~1
"platinum~1
responsive"~1
(Ann~1
(Rappaport~1
[DH],~1
[DPDL],~1
[DM],~1
[DU])~1
(COPA)~1
(COPA~1
Bleo);~1
(CAP-BOP).~1
45%),~1
COPA~5
Bleo~1
CAP-BOP~1
(Hodgkin's~1
lymphoma),~2
(syngeneic,~1
autologous)~1
free)~1
.11).~1
graft-v-leukemia~1
nonmeasurable~1
methyl-CCNU~1
(MeFA).~1
.14;~1
(SCLC),~1
OH;~1
doxorubicin)~1
VP-16/cisplatin).~1
3,750~1
.20).~1
59.5~1
.56).~1
VP-16/cisplatin~1
(NCOG)~1
receive:~2
cGy/fraction,~1
fractions/wk.~1
.056);~1
.25),~1
[99mTc]diethylenetriaminepentaacetic~1
sodium-iodine-131-o-iodohippurate~1
(HIP)~1
RVH,~1
HIP~5
RAS.~1
RVH-related~1
RVH)~1
slope/intercept;~1
-51.1~1
8.21x~1
0.019x2,~1
dose/45-min~1
activity/I.~1
clearances).~1
sample-based~1
"plateau"~2
MIRD~4
McAfee~1
[99mTc]DTPA(Sn)~1
"plateau".~1
humeri~2
[123I]~2
(NMR),~1
[123I]HPDM~1
substitution;~1
ligands;~1
(CaBP,~1
8800).~1
paracellular.~1
ferry,~1
(wet)~1
(7-8~1
postfeeding,~1
[0.3~1
20:5~1
n-3/(kg~1
weight.d)]~1
Edentulous~1
paris.~1
spironolactone)~1
diuretics;~1
0.091~2
mL/cm~3
H2O/cm~3
67.19~1
36.71~1
41.44~1
22.50~1
0.261~1
0.240~1
0.357~1
0.299~1
(TGV)/sec~1
0.312~1
0.247~1
31.76~1
24.90~1
0.638~1
0.595~1
TGV/sec~2
0.180~2
0.141~1
0.118~1
35.98~1
25.85~1
0.479~1
0.137~1
(HAIR-AN)~1
HAIR-AN~3
hyperandrogenemia.~1
postmenarcheal~1
linear-array,~1
B-scanning,~1
capsulitis.~1
Osteoarthritic~2
metallodependent~1
hydrodynamic~1
APMA.~1
hyaluronate-binding~1
chondroitin-sulfate-rich~1
metalloproteases~7
proteoglycanase.~1
pI,~3
optimum,~1
Ala-Leu~1
Tyr-Leu~1
Gly(Ala)-Leu(Ile)~1
metallo-~1
metalloproteases,~1
gelatinase.~1
25,000.~1
(MMP-3)~1
MMP-2~1
gelatinase),~1
MMP-1,~2
MMP-3~1
Kda.~2
mercurials~1
Kda~1
guanidine-HCl.~1
upsets~1
Arthritic~1
intratrabecular~1
non-collagen~1
metalloproteinase,~2
Looking~1
DISH.~1
osteopenic,~1
deforming,~1
erosive.~1
77.8~1
glycosaminoglycans)~1
pentosanpolysulfate~8
(Elmiron)~3
mm.2),~1
pre-trial~1
post-trial~1
cystoscopically~1
favorably,~1
nocturia.~1
induration.~2
pre-prostatectomy~2
4-quadrant~1
Nucleoli~1
(TCCa)~1
TCCa~2
Suprarenal~1
(AAAs)~1
cases--results~1
Colleges'~1
5393~1
171,205~1
8806~1
$635~1
$482,~1
payer.~1
$20,320.~1
18,720~1
$380~1
unproved~3
prick,~1
provocation-neutralization~1
controversial;~1
well-standardized~1
(baseline),~1
IL-2/lymphokine-activated~1
erythroderma).~1
DR+/Leu-4+~1
misuse.~1
(HIV-Ag)~1
myalgias-arthralgias~1
HIV-Ag.~1
HIV-Ag~2
(XFb)~1
XFb~11
XFb,~1
(HSPN),~1
Dual-label~1
VIII-related)~1
Subendothelial~1
co-deposition~1
HSPN.~1
HSPN,~1
endothelial/subendothelial~1
HSPN~1
monocytes/macrophages.~1
Dialysates~1
bicarbonate-containing~1
blood-concentrations~1
(27.90~1
14.02~1
(RA,~1
188%)~1
(RE,~1
360%)~1
(QA)~1
100.99~1
17.09~1
44.37~1
13.37~1
(0.096~1
clinically-significant~1
055:B5,25~1
78.5~1
U/micrograms~2
units/micrograms)~1
(LPS,~4
group).(ABSTRACT~1
(MCN)~1
(Tyr)~1
Tryptophan~2
conformation)~1
quenched,~1
MCN~2
charge-dependent~1
Concomitants~1
appraise~1
peripherally-derived~1
II-related~1
AV3V.~1
water-conducting~1
nonosmotic~2
Henle;~1
hyponatremia;~1
non-measurable~1
(ANP),~8
ANP.~14
ANP~175
(TPN);~1
venotomies~2
Raaf~1
nitrosourea-based~1
allotransplantation.~2
reverts~2
(bypass~1
bypassed),~1
pericarditis)~1
32.6%~1
triphosphate/diphosphate~4
(vortex-mixing)~1
(ZK36374),~1
(65.0%~1
14-serotonin~1
(81.8%~2
(209,000/microliter)~1
(238,000/microliter)~1
115,000/microliter~1
thromboglobulin~1
pacer~1
(T1),~1
Supervised~1
(ampicillin,~1
Haemophilus.~1
carboxypenicillins,~1
(clavulanic~1
sulbactam)~1
amino-penicillin~1
nonsensitizing,~1
beta-lactamase-resistant,~1
bactericidal,~1
Cephalosporin~1
cefoxitin)~1
cefsulodin)~1
carbapenem)~1
monobactam)~1
today;~1
myths.~1
epidemiological,~1
salt-sensitive,~1
Definitions~3
pressure-risk~1
bleeds,~1
macrovasculature~1
small-resistance~1
peripheral-vasculature~1
convincing.~1
1836,~1
Nephrosclerosis,~1
detractors,~1
everyone,~1
enzyme-inhibiting~1
acceptance;~1
easy;~1
controllable,~1
publications.~4
potassium-maintenance~1
hypokalemia;~1
exercise--whether~1
manometer--than~1
LVH;~1
peripherally-acting~1
Contractility~1
Protecting~1
cardiology.~2
maladjusted,~1
social-work~3
maladjustment.~1
groups-group~1
fetuses),~1
non-classifiable~1
(5).~3
2A)~1
2B)~1
pathological.~1
perinatally.~1
(trimethoprimsulphamethoxazole)~1
megadalton~1
shigellae~1
10.41,~1
Hyperinsulinaemia~1
deleteriously~1
anti-HB~1
HDV,~1
re-transplanted~1
(reinfection~1
2.6.1.44]~1
diced~1
"Diced"~1
26-fold~1
meshed~1
bileducts~3
scolicidal~1
lymphocyte-function-associated~1
non-relapsing~1
immunosurveillance.~1
(CKMB).~1
CKMB~2
(compatible~2
damage).~1
0.053).~1
neurodevelopment~1
(PVH),~1
"prolonged~1
flare"~1
(echodensity~1
cavitating),~1
(PVL).~1
PVL.~2
Echolucent~1
immunisations~3
Organisation.~1
1218~1
(30.8%).~1
Had~2
venotomies,~2
arteriotomies,~2
welded~1
stains;~1
[3H]hydroxyproline~1
Electrosurgical~1
(ESU),~1
(CO2),~1
(SU)~1
(0-4+)~1
(2+),~3
ESU~4
(3+),~1
(1+),~1
(4+),~1
post-BMT,~1
extra-intestinal~1
choleraesuis;~1
reviews.~1
choleraesuis,~1
choleraesuis~1
destructive,~2
Nonvalvular~1
(mural)~1
extra-cardiac~1
(pulsus~1
rub)~1
"adequate~1
course"~1
Tuberous~1
dermatomyositits~2
extraglandular~1
anti-Ro(SS-A)~1
normocomplementemia,~1
neuroaxis~1
Hulusi~1
Behcet,~1
pathergy~1
trauma),~1
nodosum-like~1
(Tzanck~1
simplex)~3
Enormous~1
astronomic~1
motoneuronal~2
EST,~1
(rectal~1
[101~1
[96~1
F]),~1
Treatment--either~1
placebo--was~1
deciliter)~2
[59~1
percent]~2
[29~1
(80.5~1
Plasmodium-infected~1
odd-numbered~1
even-numbered~1
abrupt-withdrawal~2
tapered-dosage~2
latency),~1
soundness~1
line),~2
(streptokinase~2
streptokinase:~1
Child-Pugh~1
81)~1
revenues,~3
spending.~2
base-year~1
profits,~2
windfalls~1
schenckii.~1
retrotransposon,~1
Ty,~1
Ty-VLPs~3
Ty-VLP~1
p1~4
HIV:Ty-VLPs.~1
HSEs~1
HSE-binding~2
protein-HSE~1
Nonequivalent~1
capsomeres~2
lattice.~1
self-assemble~1
capsid-like~1
self-assembly~1
capsomere~1
capsomeres,~1
non-equivalent~1
capsomeres.~1
RAD6~3
ubiquitin-conjugating~1
A4-amyloid~3
5-7).~1
virulence,~1
3-deoxy-D-manno-octulosonate~2
cytidylytransferase~1
synthetase),~1
alpha-C-(1,5-anhydro-7-amino-2,7-dideoxy-D-manno-heptopyranosyl)-carboxy~1
prodrug.~1
schizonts~1
liver-stage-specific~2
(LSA;~1
LSA),~1
amino-acids,~1
'dominant~1
negative'~1
literature--some~1
milliseconds~2
slow-folding~4
non-native~1
reisomerization~1
peptidyl-prolyl~1
cis-trans~1
(PPIase)~1
imidic~1
oligopeptides.~1
refolding.~1
alpha-beta~1
cis-~1
DP).~1
alpha-DQ~1
mixed-isotype~1
isotype-mismatched~1
interisotypic~1
crosspairing~1
HLA-disease~1
(32K)~1
holoenzyme.~2
Asp-Thr-Gly,~1
pattern-recognition,~1
pol-protease~1
leukomalacia;~1
(rolandic)~1
cavitations~1
anti-measles~1
(pit-hGH)~1
scrapie,~2
postreperfusion,~1
postreperfusion.~1
26th~1
(20-80~1
Inaccuracies~1
menstrually~2
35-79~1
postovulation.~1
ovulation-timed~1
Oligohydramnios,~1
5034~1
(nonstress~1
4148~1
(likelihood~2
48.1)~1
51.0).~1
200.0~1
(78.8%)~1
Obstetrical~1
Gynecological~1
Ultrasound,~1
Gynecologists.~1
discordancy.~1
transabdominal/transvesical~1
6.5-MHz~1
crystal)~1
(primary)~2
median).~1
illustrates,~1
prolapse;~1
16-cm~1
(LHRH).~1
medroxyprogesterone;~1
1972-1985~1
(1972-1975),~1
(1976-1978),~1
94.9%,~1
respectively--significantly~1
Laparoscopy,~1
(54.7~1
.0057),~1
6.7%;~1
melphalan-treated~1
lower)~1
A/B)~1
Hagedorn~1
breakfast).~1
16.2%,~1
Nonobese~1
A/Bs),~1
Antenatal~2
0.809,~1
0.798,~1
0.749,~1
Cordocentesis~1
16-40~2
try;~1
Menopausal~1
(nortestosterone~1
derivatives)~1
nortestosterone~1
(norgestrel~1
nonadrogenic~1
17-alpha~1
hydroxyprogesterone~1
minuscule~1
progestogens,~2
hyperestrogenism.~1
Hormones,~1
Added~1
progestogen,~1
estrogen-increased~1
offer.~1
nonorally~1
actions.(ABSTRACT~1
nor-testosterone~1
("postmenopausal")~1
("senile")~1
surmised,~1
Mattress~1
grafts:~1
macrocystic~1
microphthalmia;~1
anophthalmia~1
evisceration.~2
epithelial-lined~1
non-keratinizing,~1
unattractive~1
"ecto-laser"~1
five-and-one-half~1
Healon,~1
.060)~1
.088)~1
aware.~1
Levobunolol~1
levobunolol.~1
Retinoblastoma~1
Wardrop~1
1809,~1
Verhoeff~1
infrequency.~1
product--Virgo~1
system--for~1
VI.~4
VI;~1
sialagogues,~1
saliva-flow~1
polyribosyl~1
booster.~1
(PRQ)~1
Nurturance~1
rewritten~1
PRQ~1
five-subscale~1
Brainstorming~1
(CGEAN)~1
three-round~1
CGEAN~1
equity.~1
Consuming~1
quacks~1
sodium-potassium-adenosine~1
Ranvier.~1
Aldose~5
KIN1~4
KIN2,~2
KIN2~2
identities)~1
mosaics,~1
serine/threonine-specific~1
RAD3~7
anti-RAD3~1
RNA-dependent~1
polymerase).~1
3Cpro,~1
3Dpol.~1
3Cpro~1
3Dpol~2
poly(A).oligo(U)~1
recombinant,~1
Glu-181~4
[Val181]CAP~3
[Leu181]CAP,~1
DNA-sequence-recognition~1
[Leu181]CAP~2
non-consensus-DNA~1
2-fold-related~2
-0.7~1
CAP-DNA~1
Segel~1
Knox,~1
Devreotes,~1
Goldbeter,~1
Segel,~1
2345-2349].~1
"covalent~1
modification."~1
RCs~1
c2~1
Rb.~1
(HPI)~1
(C-peptide-A-chain~1
pig)~1
HPI~1
des-31,32-HPI~1
des-64,65-HPI,~1
C-peptide-A-chain~2
Lys-Arg~1
(pro)secretory~1
Golgi,~1
mainly,~1
gamma-rays,~1
rad52.~1
rad52~1
postreplicative~1
A.T----G.C~1
G.C----A.T)~1
site-to-site~1
single-base-deletion~1
hotspot~1
Streisinger-slippage~1
neutral.~1
gnd~1
6-phosphogluconate~1
10(-7).~1
serum/plasma~1
beta-D-galactoside~5
1408~1
hybrophobic,~1
926~3
SRC~1
as-yet-unknown~1
glycophospholipid,~1
phosphooligosaccharide,~1
"insulin-like"~1
phosphooligosaccharide~7
histidine-10~1
[AspB10]insulin,~1
[AspB10]Insulin~1
superactive~3
flagellar,~2
trans-activate~1
trans-activation,~1
-402~1
-240~1
serum-responsive~1
membrane-protein~1
sphaeroides.~1
McLachlan.~1
Residues~2
electrostatically.~1
carbohydrate-binding~1
(CBP35)~1
CBP35~2
CBP35.~1
recombinogenic~1
propagates~1
on-and-off~1
fimA,~1
promoter-containing~1
314-base-pair~2
fimB~1
fimE,~1
integrase,~1
himA~4
hip/himD,~1
TNYAANNNRTTGAT~1
purine,~1
integration-excision.~1
fim~1
TTTAACTTATTGAT~1
insertionally~1
hip/himD~1
fimA-lacZ~1
switch-generated~1
transductant~1
himA+~1
autogenously~1
L4.~1
L4-mediated~1
postculture~1
oligomerization.~1
halted;~1
reestablishment,~1
nonnociceptive~1
32P-labeling~1
phosphothreonine;~1
(isoproterenol,~1
A-23187~1
"self-care"~1
comprehend~3
overemphasized~1
well-executed~1
Retrusion~1
columella.~1
conchal~1
building-block~1
pharyngostome~1
covering.~1
gullet.~1
pharyngostome,~1
muscle(s),~1
thoracoacromial~1
pharyngostomes.~1
ptotic,~1
tissue-expansion~1
Pennisi~1
Ryan~1
Breasts~1
trapdoor~2
flaplike~1
tactical~1
undamaged,~1
safer;~1
Kunlin's~1
(RHP)~1
Sephardic~1
Jews,~1
Arabs,~1
Turks~1
Armenians.~1
newly-diagnosed~2
(45.6~1
insulin--two~1
safety.(ABSTRACT~1
(methotrexate,~1
CCNU)~1
actively-treated~1
non-palpable~1
Low-cost,~1
Three-phase~1
single-phase~1
unsharpenss,~1
mAs~1
unsharpness~1
Phototimer~1
holder,~1
phototimer~1
source-to-image-receptor~2
work-load~3
thick.(ABSTRACT~1
higher-speed~1
trade-offs.~2
grids,~1
Chester~1
Carlson~1
Battelle~1
1970-1971.~1
cyst/solid~1
problems?~1
40-74.~1
superbly.~1
debating~1
(19.3%)~1
(4.7%),~1
117),~1
(22.0%),~1
(5.1%),~1
4.5-MHz~1
3.9-MHz~1
7.5-MHz~1
(76.3%).~1
(CLSE)~1
air-bronchogram~1
three-center~1
(iothalamate~1
meglumine)~1
(iopamidol).~1
postvenographic~2
unusual-appearing~1
(4.6%),~1
(3.8%),~1
6[in~1
recurs.~1
cervicosupraclavicular,~1
cervicosupraclavicular~1
node-bearing~1
2,178~1
sent,~1
1,611~1
mesentericocaval~1
mucin-hypersecreting~2
pancreatograms,~1
papilla).~1
diagnosis).~1
(periportal~1
collar)~1
(iodized~1
demonstrate.~1
(SCA),~1
(IHA),~1
(CTAP),~1
(Lipiodol).~1
SCA,~1
CTAP,~1
Endovaginal~2
demises)~1
endovaginal~4
radiologic-urologic~1
homothallic~1
SWI~1
silencer~1
mother),~1
ionophores)~1
A4,~1
E4.~1
Lipoxins~1
15-lipoxygenases~1
Lipoxin~1
lipoxygenases~1
(trp)~1
1,10-phenanthroline-copper~1
cuprous~1
coreactant~1
attacking~1
1,10-phenanthroline~1
iminothiolane~1
5-iodoacetamido-1,10-phenanthroline.~1
aroH~1
trpEDCBA~1
corepressor~1
Scission~1
nucleolytic~1
(TNF-alpha),~1
anka~1
berghei-infected~1
beta-hydroxy-delta~1
5-derivatives~1
P-450scc,~1
Scarce~1
"neurosteroids,"~1
proreceptor~7
crossing-over,~2
heterologies~1
9-kilobase~1
heterologies.~1
heterozygosities~1
tetrads.~1
(snRNAs)~1
(snRNPs)~1
snRNAs~1
(snR7,~1
snR14,~2
snR19,~1
snR20)~1
snR7,~1
snR20,~1
snR19~2
nucleotides).~1
(GTATGT),~1
(GTPuAGT).~1
sends~1
Intramolecular~1
INO~4
irides~1
Neurite~1
irides.~1
isoleucyl-transfer~1
superfused,~1
clindamycin/tobramycin~2
L-asparaginase-induced~2
polyps).~1
microcoagulation,~1
--~1
(scoliotic~1
non-scoliotic)~1
week's~4
Toleration~1
toleration;~1
THC,~4
failed;~1
(UTZ)~1
283.9~1
5.45~1
294.1~1
UTZ,~1
successfully).~1
UTZ~1
thallium-210~1
angulations~1
hesitate~1
(estrophilin)~1
(125I-estradiol)~1
estrophilin~1
125I-estradiol~1
(stereotactic~1
Surgery.~1
data-base~1
Breslow's~1
Mantel's~1
(claudicants,~1
200;~1
263)~1
0.58.~1
122]~1
nonpresence~1
341],~1
[Breslow~1
0.68];~1
[nonsmokers,~1
0.69;])~1
0.72),~1
(Breslow,~1
tests).~2
claudicants~1
tests).(ABSTRACT~1
(SGF)~1
intrasplenically~1
pancreases.~1
normoglycemic,~1
SGF.~1
SGF~2
normoglycemic.~1
CS).~1
pancrease~2
PMN-activating~1
026:B6~1
CR1-dependent~1
Chelation~1
ethylenediaminetetra~1
LPS--an~1
[SEM],~1
(917~1
(SPT),~1
machine-readable~1
(IAHG),~1
SPT~4
IAHG~2
5.94~2
SPT-positive~1
IAHG-negative,~1
SPT-negative~1
IAHG-positive.~1
97.14~1
glycosyltransferases~1
ABO/Lewis/secretor~1
(LSD,~1
(HCG,~1
I.M.~1
(2/7).~2
sexologic~1
LSD.~1
water-path~2
(Octoson)~1
soothing~1
Kelfiprim~3
(KP)~2
sulfametopyrazine~1
5:4).~1
posology~2
(MDBT)~1
KP~2
27.0%,~1
4.5%.~1
thrombendarterectomy~1
20/23~1
overdiagnosed~1
counter-regulation~1
U/h~3
(U40)~1
(U100)~1
U40~4
U100.~1
(6.84~1
6.65~1
1.13%,~1
blockages~1
remobilization~1
remobilization.~1
fibre/placebo~1
jugular,~3
portability,~1
hepatofugal.~1
hepatopetal.~1
patency:~1
Portosystemic~1
blood-ammonia~1
portohepatic~1
typhlitis~2
(1-2.5~1
gravidity,~2
Congruity~1
graft-native~1
Resurfacing~1
dyscrasia,~1
aspirations.~1
anterolateral.~1
posteromedial;~1
septations.~1
femur;~1
proton-MR~1
suprasternally.~1
m/sec/sec~5
Air-filled~1
digitization.~1
Failed~1
electrocardiac~1
Ordinarily,~1
53.9).~1
66).~1
(+1.02~1
(+1.80~1
double-product~2
(-4,775,~1
(-33%).(ABSTRACT~1
80/min~1
2-week,~1
nadolol/placebo~1
3).(ABSTRACT~1
ventricle.(ABSTRACT~1
placebo),~1
atenolol).~1
Carvedilol,~2
Q-QS~1
recovery-positive~1
exercise-positive~1
angiocardiographic~1
special-intervention~1
usual-care~1
(SI/UC)~1
1.42,~1
estimates).~1
I--11~1
II--35~1
OKT3+~3
4.50.~1
Indecainide,~1
1,022~1
nausea;~1
complaints.(ABSTRACT~1
ethmozine,~2
ethmozine~8
(VPC)~2
Ethmozine~1
ethmozine.~1
30-min,~1
0.26);~1
25.1,~1
33.6,~1
postprandial.~1
Protein-containing~2
insulin-enhancing~1
"floral"~1
"florid"~1
(PTGC)~1
PTGC~2
perinodal~1
(WIT)~1
rhabdomyomatous,~1
blastematous)~1
WIT~5
heterotransplants~2
glycosubstances,~1
heterotransplants.~1
AE1:AE3~4
(Hybritech~1
Jolla,~1
CAM-5.2~4
(Becton-Dickinson,~1
MAK-6~6
Biosciences,~1
Alameda,~1
CAM-5.2,~1
hepatomas~1
AE1:AE3.~1
Amyloidosis~2
7-18~1
(AB2M)~1
AB2M~3
anti-amyloid~1
curvi-linear~1
(BCDE)~1
differentials'~1
disorder(s)~1
seminomas.~1
group-reactive~1
hexon~1
1-dram~1
low-speed~1
Nephropathic~1
cystine-depleting~1
Postnatally,~1
Scoring~2
DSS,~2
illustrate,~1
(JNIH-7)~1
(JNIH-6)~1
Monocomponent~1
0.5-mL~1
postvaccination~3
manifestation--cardiac,~1
dermatologic.~1
[6.8~1
mEq/L])~1
[139~1
mEq/L];~2
[113~1
[18~1
mEq/L]),~1
(supine/upright:~2
140/580~1
[5/21~1
ng/dL];~2
0.0/0.03~1
[0.0/0.1~1
ng/mL/h]).~2
110/920~1
[4/33~1
0.89/2.17~1
[3.2/7.8~1
ion;~1
incosequential~1
acid-glucose~2
"liver~1
tests"~1
Hyaline~1
Cotugno~1
Bright.~1
vasoconstrictors.~2
immunopathogenetic~1
glomeruli;~1
intraorgan~1
transplantectomies)~1
glomerulopathies~1
nephropathy),~1
glomerulopathy,~1
anisoylated~1
pro-urokinase.~1
Interuniversity~2
Bleeding,~1
eight-point~1
[Saarstedt]~1
255.9~1
228.7~1
280.1~1
260.5~1
post-Sustacal~2
insulin/glipizide,~1
241.1~1
217.0~1
267.2~1
279.0~1
insulin/glipizide~1
simplifying~1
(obesity,~1
inactivity)~2
34.0)~1
500-calorie~1
nutrition-exercise~1
(randomized)~1
(hypertension,~1
(Biostator)~1
MHC-matched~1
(WAS).~1
Successes~1
SCID.~3
treat,~2
MO-1,~1
CR-3~1
deficiencies),~1
WAS,~1
Kostmann's~1
Syndrome),~1
BMT.(ABSTRACT~1
(propositus)~1
MLD.~1
Halsted.~1
Diagnosticians~1
(104/150)~1
(85/104)~1
(61/77)~1
(55/61).~1
self-palpation~1
Guard~1
Biochemical,~1
termination,~2
33-week~2
semiweekly~1
growth-altering~1
aseptically~2
plotted.~2
mumol).~1
Meconium~1
zinc-to-phosphorus~1
(two-year~1
4.97~1
multi-nucleated~1
58.75%;~1
35-80%),~1
Ki67~1
(15-20%~1
Ki67+~1
Mo-2,~2
61D3,~1
63D3.~1
(Leu-3a,b)~1
(63D3)~1
ellipsoids~2
(tingible~1
cels~1
anti-FcR,~1
Leu-M3,~2
25F9,~1
anti-CR3.~1
RP,~1
MZ,~2
(MFH),~2
(FU3~1
FU4)~1
FU3~4
FU4~2
FU3.~1
FU4,~1
Immunoelectron-microscopic~1
stillborn)~1
siderotic~1
siderosis,~1
Reticuloendothelial~1
ante-,~1
internatally~1
hyperferremia~1
(A3,~1
B7)~1
midfetal~1
(Copenhagen)~1
(3H-DHT).~1
thaw-mounted~1
androgen-sensitive~1
"epithelioid"~2
Epithelioid~1
6N.~1
autoradiographic,~1
cytometric,~1
3N~1
6N~1
inappropriate;~1
(LNE)~1
hormone-independent~2
recapitulation~1
rebound,~2
endopolyploidy,~1
bereavement,~1
delinquency,~1
out-of-home~1
intuitive,~1
conceptualization,~1
alienation,~1
seroma,~2
extraanatomical~1
seroma.~2
pseudomembrane~2
well-incorporated~2
popliteal-to-distal~1
valvulotomes~1
nonautogenous~1
condemnation~1
Karmody~1
Albany,~2
recounted.~1
method's~1
DaCosta~1
opposite,~1
friendship.~1
friendship~1
IU/dl~1
coexists,~1
(U-251~1
C6)~1
(ADH)-independent~1
(IMR-32,~1
NB41A3,~1
Neuro-2a)~1
ethanol-metabolizing~2
ADH-independent.~1
ADH-independent~1
(intraperitoneal)~1
alpha-methylparatyrosine,~2
AMPT~2
(inhibitor~1
hydroxylase)~1
UChA~2
consumer)~2
UChB~2
(basic).~1
alcohol-treated~2
ethanol-derived~1
(EDC)~1
EDC)~1
lab~1
EDC,~2
LC).~1
gestation-day~1
sexed.~1
pregnant.(ABSTRACT~1
"local"~2
globally.~1
Figaro~1
32-304~1
determinations;~1
w/v~1
ethanol-containing~1
(6.25-25.0~1
(2.5-10.0~1
ethanol-exposed~1
(ETH)~1
DSPC~1
ETH~2
(82.7~1
aureus)~1
opsonin.~1
acid/ml~2
glutamic-oxaloacetic~1
(SGOT),~1
glutamic-pyruvate~1
(SGPT),~1
1156~2
nonalcoholics),~1
nine-item~4
two-item~1
(SAAST).~1
supraoptimal~2
(18%,~1
calories).~1
60-day-old~1
mg/dl/hr~2
60-day-old-rats.~1
(1-15~1
organ's~1
(P-III-P),~1
(Fab-P-III-P),~1
Fab-P-III-P~3
Fab-P-III-P,~1
P-III-P,~2
hardcore~1
recidivists~1
sobriety~1
Detox~2
0.0076)~1
interdict~1
recidivism.~1
Alcoholics,~1
biological/behavioral~1
(453)~1
0.044),~1
0.146).~1
dropped.~1
abstinent,~1
pints~1
perceptions,~1
menadione~3
additions,~1
ferric-chloride,~1
-ADP~1
-EDTA,~1
.OH.~1
Paraquat~1
.OH,~1
unchelated~1
ferric-ADP~1
Neuron~1
countings~1
Attenuated~1
(RMBF)~1
CAL;~1
RMBF~2
(95-107%)~1
(57-60%)~1
(36-47%)~1
posttreatments~1
spin-label.~1
"strength"~1
"strong~1
"moderate,"~1
"weak,"~1
nonparent~1
"negative,"~1
unigenerational~1
Sons~1
passouts~2
24-49~1
intercorrelate,~1
(zygosity),~1
double-entry~1
twin's~1
zygosity,~1
cohabitation~1
0.40.~1
Co-twins~1
co-twin~1
resemblance.~1
[16,16-dimethylprostaglandin~1
(DMPGE2)]~1
glycoprotein;~1
DMPGE2~7
(0.1-1.5~3
DMPGE2,~3
16-27%,~1
(28-30%)~1
acylation,~1
saturations,~1
(mean-minimum)~1
desaturations,~1
desaturations~2
minimums~1
inferentially,~1
nonataxic~3
A1a~2
hand-eye~1
coordination.~2
Acetaldehyde-modified~1
(25-34,~1
35-44,~1
45-54,~1
55-65~1
(nondrinkers,~1
alcoholics)~1
subtests;~1
Vocabulary,~1
Design.~1
ethanol-associated~1
pyridoxine-sufficient~2
ethanol-enriched~1
(CARTA),~1
[family~2
(FHP)]~1
(FHN)].~1
topping~1
FHP~3
Raven's~1
BAC.~1
nonethanol~1
bourbon~3
phytoestrogen,~1
biochanin~1
beta-sitosterol,~1
phytoestrogen~1
supply/uptake~1
(DO2th)~1
DO2th~2
anesthesia.(ABSTRACT~1
(LASC)~1
(LASM)~1
sufentanil.~1
tended,~1
pervading~1
formats,~1
outlived~1
pathohemorheological~3
hemostasiological~4
significance:~1
hyperreagibility~1
pathohemostasiological~1
penicilloylpolylysine,~1
penicilloate,~1
penilloate~1
interday~2
(Emit)~1
(CVs)~1
6.96%,~1
5.50%,~1
5.23%,~1
CVs~1
Emit~2
5.8%,~1
batches.~1
0.945.~1
zindotrine,~1
pyridazine~1
non-medicated~1
zindotrine~4
PD20FEV1~2
PD20FEV1.~1
Jellyfish~1
nematocysts~1
First-aid~1
nematocyst~1
species-specific.~2
afflictions.~1
toxins/cogeners~1
ethers.~1
venomous~1
Oceans.~1
subfamilies,~1
Laticaudinae~1
Hydrophiinae,~1
poisonous.~1
phylogeny~2
cross-neutralization~1
venoms,~1
myotoxic,~1
Bromelain~1
pineapple~1
debride~1
Third-degree~1
eschars~1
bromelain~2
graftable~1
De-emphasis~1
anhydrosis~1
work-output/thermal~1
thermoregulatory/physical~1
acclimatization,~2
venom;~2
snakebite,~1
paraspecific~1
antivenoms,~1
immunodiagnosis~2
plant-induced~1
photo~1
granulomatous.~1
vary;~1
(2,439~1
altitude-aggravated~2
10,200~1
(3,110~1
14,200~1
(4,329~1
visitors.~1
(HAPE)~2
recreationists~1
Descent~1
AMS,~3
HAPE~4
ascent.~1
High-altitude~1
HAPE,~1
McKinley~1
(allergic)~1
histamines~1
C3a.~1
supine)~1
nonapneic~4
intrapharyngeal~1
(0.090~1
snorer~1
OSA;~1
("floppy"~1
pharynx)~1
Exosurf.~2
Exosurf~3
dipalmitoylphosphatidylcholine,~1
hexadecanol,~1
tyloxapol,~1
Exosurf-treated~3
SAM-~1
SAM-treated~1
lungs.(ABSTRACT~1
(ETV)~1
(Ppaw)~1
(RM)~1
Ppaw~1
EVLW:~1
Immaturity,~1
barotrauma,~1
prematures.~1
(PPV/PEEP).~1
PPV/PEEP~1
(a/A)PO2~2
IO2~2
(oxygenation~1
(a/A)PO2/Paw)~1
dampened.~1
"prn"~3
survivors.(ABSTRACT~1
(ARF),~1
aerated,~2
nonaerated~3
"amount"~1
unexplored.~1
(fetal,~1
life);~1
impressive,~1
"nitroprusside"~1
"restriction"~2
PPH.~4
notoriety.~1
Textbook~1
edited~1
Sabiston,~1
devotes~1
paragraph~1
Augusta~1
staff;~1
dialysis).~1
University-affiliated~1
U/h,~1
-13.1%~1
12.2%).~1
-11.2%~1
11.6%).~1
"Standard"~1
area);~1
Alternating~1
63.2%;~1
Reagin~1
antibody-absorbed~1
postprandially).~1
high-affinity-binding~1
oxy-radical~1
ischemia-reperfusion-induced~1
breakthroughs.~1
internist,~1
confidentiality,~2
One-hundred-eleven~1
21-day,~1
1%-gentamicin~1
acetate-gentamicin~1
consequences)~1
(GB),~1
(TH).~1
(BD).~1
TH.~2
GB,~2
BD)~1
TH)~2
anti-HTLV-I-IgG~1
measurable.~1
datum~3
nonselectivity.~1
microbiological,~1
zinc)~1
(Augmentin;~1
Beecham~1
streptococcal-staphylococcal~1
pyrazofurin~4
3-deazaguanine~5
cytopathogenicity~1
11-fold,~1
Pyrazofurin,~1
3-deazaguanine,~1
2,5-Diamidinoindole~1
carbodine~1
3-adenin-9-yl-2-hydroxypropanoic~1
3-deazauridine,~1
3'-C-methyluridine,~1
5'-deoxy-5-fluorouridine,~1
5-cyanoimidazole-4-carboxamide,~1
ribofuranosyl~1
Tubercidin,~1
5-chlorotubercidin,~1
neplanocin~1
thiosemicarbazone~1
3-methylquercetine~1
GG,~1
spp.),~1
lactobacilli.~1
acetone-water~1
(10:1).~1
bacteriocin;~1
microcin,~1
Effervescent~1
users),~1
aftertaste~1
user).~1
temocillin,~1
tigemonam-PBP~1
aztreonam-PBP~1
3-N-acetyltransferase~2
squaric~2
dibutylester~1
acetone.~1
(28.5%)~1
IgA-class~3
pemphigus.~1
Endomysial~1
laxa~1
(25-36~1
11.83,~1
0.212,~1
50-400~1
dummy,~1
pipette,~1
pyelonephritic~2
traced,~1
Posttherapy~2
NaCl/dextran~2
hypertonic/hyperoncotic~2
Sutureline~1
suturing,~2
sutureline~5
ischemic.~1
Stapling~1
moderately.~1
outperform~1
ileocolostomy~1
unduly,~1
Tetrahydrocortisol~1
angiostatic~1
antiangiogenic.~1
angiogenesis-dependent~1
(Cutler-Ederer)~1
mismatches.~1
angioplasty).~1
dissects~1
PDS~7
(Dyazide).~1
2.0/92~1
2.8/78~1
2.7/78~1
electroversion.~1
99/min~1
72/min~1
143/min)~1
75/min~1
102/min)~1
relapsing.~1
captopril-cysteine~2
cystinuria.~1
Canada-wide~1
228)~1
probabilities,~1
uniqueness,~1
data-bases,~1
choosing.~1
alfa~2
temper;~1
tearfulness;~1
clouding~1
paranoia,~1
alfa,~2
aminodiphosphonate,~2
aminohydroxybutylidene~6
diphosphonate,~11
dichloromethylene~5
diphosphonate.~3
Aminohydroxybutylidene~1
purchased.~1
gentamicin-resistance~1
outbreaks/clusters~1
anahepatic~1
wars,~1
uncut~1
772~2
(73.3%)~1
(69.9%,~1
68.2%,~1
83.3%,~1
91.8%),~1
whole-heart~1
(EMITst)~1
(TLC).~2
EMITst~4
9-carboxy-tetrahydrocannabinol.~1
cannabinoid-positive~1
alpha-antitrypsin~1
1-AT),~1
1-antichymotrypsin.~1
cytotrophoblast.~1
Diagnostically,~1
father)~2
microhematuria.~1
sister.~1
sister).~1
cloverleaf~1
Filariasis~1
cloacal-derived~3
(hCG)-like~1
alpha-hCG~3
alpha-Chain-immunoreactive~1
cyclin,~2
paraffin-section~1
PCNA-positive~2
neuroglia.~1
Epithelium-lined~1
ependyma.~1
chordoid~1
EMA,~1
bruit,~1
(1.6%).~1
megabecquerel~1
(4.05~1
duplicate.~1
irradiation-injured~1
radiotherapy/chemotherapy,~1
(fistula,~1
perforation)~2
8.1%):~1
Suture-associated~1
single-layer~1
alternate-month~1
"maintenance"~1
maintenance"~1
anti-Purkinje~6
1:32,000~1
1:64,000,~1
multilocularis,~1
helminthic~1
(p-aminoclonidine~2
38.7%,~1
drop's~1
2145;~1
2145.~1
(141~1
(49.1%).~1
(873~1
2.59~1
Nonacuity~1
real-world~1
neuritides,~1
atrophies,~1
neuropathies),~1
(spike~1
gaze;~1
reflectivity)~1
reflectivity).~1
neuropathy).~1
Fuchs'~1
Recessive~1
dystrophica~1
(REBD),~1
soft-bandage~1
REBD.~1
REBD~1
2M)-proteinase~1
M-proteinase~1
AffiGel~1
2M-proteinase~2
2M-trypsin~1
2M-kallikrein~1
(coagulation~1
XII).~1
cryoproteins~1
cryocrit~1
9.2-kilobase~1
0.00085,~1
7.2).~1
9.2-kb~2
297,~1
IIc~1
52-88)~1
citizens.~1
self-reported,~1
thoughtfully~2
locatable).~1
(cited~1
contention).~1
50-500~1
micrograms/L,~1
(0-40~1
53,000~2
diurnally.~1
BP-28-IGF~1
anti-BP-28~1
Immunoprecipitable~1
IGF.~1
penicillin/erythromycin~1
Cross-product~1
non-prophylactically~1
right-chest~1
nasoduodenal~1
noncalcifying~1
ADP-collagen~1
(BH)~2
optimized.~1
TX-100~1
Three-step~1
Schiff-base~2
collage,~1
TX-100)~1
ADP-bound~1
annuli~1
(micrograms/mg~1
MemL~1
NatL~1
Closed-circuit~1
alfentanil~35
1379~1
alfentanil,~2
1:13,~1
(PBEir)~1
(CPB);~1
PBEir~2
1:13~1
hypotropia~2
pseudoptosis~1
Warburg~1
oculocerebral~1
HARD~1
agyria,~2
pseudoencephalocele,~1
Peters'~1
PAI,~5
bovine-activated~2
autography.~1
Bovine-activated~1
human-activated~1
profibrinolytic~2
(GpIb),~1
glycocalicin,~1
GpIb~4
vWF-binding~2
ristocetin-induced,~1
epsilon-Aminocaproic~1
(EACA)~2
glycocalicin-related~1
lysine-binding~2
GpIb.~1
EACA~4
plasmin-mediated~2
Nomifensine~2
(Merital,~1
Alival;~1
Hoechst,~1
Frankfurt,~1
FRG),~1
innocent-bystander~1
nomifensine-induced~1
drug-independent~2
E-positive~2
E-negative;~1
e-positive~1
e-negative~1
Rhnull~3
metabolites);~1
hemolytically~1
E-negative~1
metabolite-dependent~1
(PAIs)~3
mobilities,~1
PAIs~3
plasma/serum~1
beta-PAIs~1
comigrated,~1
50,000.~2
guanidine.~1
denaturants.~1
beta-PAI.~1
(HuIFN~1
HuIFN~11
gamma-suppression~1
anti-natural~1
T8+,~1
T4-~1
phenotypes)~1
OKT8-~1
T8-~1
bilharzial~4
37.2%,~1
(SRCA)~1
118630~2
(Zoladex)~2
(luteinising~1
(41.6%)~1
gonadotrophins~2
118630,~1
"mid-cycle"~1
"end-cycle".~1
(superscan).~1
vascularisation~1
vasal~2
feminisation.~1
Ziehl-Neelsen~2
normoglycaemia~2
Hypoglycaemic~1
non-viable,~1
9292~1
26.8%.~1
4491~1
people's~3
smoker,~1
1.35,~1
1.54).~1
1.30),~1
(12.3%).~1
(22.6%).~1
am,~1
home;~2
1959-78~1
1921-5.~1
hypogammaglobulinaemia,~1
cryptosporidiosis,~1
Ayurvedic~1
Alma~1
Ata~1
"health~1
2000,"~1
sanitation,~2
adulterated.~1
verdicts~1
inquest.~1
event--sealing~1
trolleys--entailed~1
pounds.~1
myelotomy.~1
spinothalamic~1
myelotomy~1
mechanoreception~1
tickle,~1
cordotomies~1
herpesviruses,~1
more-rigorous~1
four-and-a-half~1
(obliterative~1
bronchiectasis)~1
corticosteroids;~1
already,~1
build.~1
advocacy.~1
reevaluation,~1
proteoglycan-~1
collagen-degrading~2
(GH-RH)-40~1
GH-RH~3
[Nle27]GH-RH(1-29)-NH2,~1
GH-RH-40,~1
GH-RH-40~1
Nle27~2
analog.(ABSTRACT~1
CaNa2~3
(14C-)EDTA~1
Pb.~2
CaNa2EDTA~3
0.8373;~1
0.0097).~1
0.8967;~1
0.7774;~1
0.138)~1
0.8435;~1
0.0087)~1
chelatability,~1
reequilibration,~1
PbEDTA~2
Isradipine~2
200-110),~1
isradipine~6
Isradipine,~1
isradipine.~2
cromoglycate~23
dinitrochlorobenzene-sensitized~1
toxic-irritant~1
alpha-atrial~4
(ANP)~30
volume-expansion~1
alpha-ANP~21
veno-venous~1
grouped,~1
Alpha-ANP~1
tris-buffer~2
(Vent-Aid~1
lung),~1
Legionella,~2
gonadotropin-gonadal~1
prolactotropes,~1
gonadotropes.~1
TRH-stimulated~9
(GH3)~1
(0-2~1
1,2-diacylglycerol,~1
1,2-diacylglycerol.~2
cells/min,~1
subtracted.~1
acid-pretreated~1
omega),~1
(-32~1
hertz).~1
Vm.~1
4/18~1
(DZ),~1
quartered~1
6-min~2
15-1788~28
benzodiazepine-binding~2
perifusion),~1
11,195~1
(flurazepam,~1
chlordiazepoxide,~2
medazepam),~1
10-nM~1
nullified~2
factor-(1-44)-NH2~1
ineffective.(ABSTRACT~1
(ARL~1
Na,K~3
ouabain-inhibitable~1
Na,K-ATPase~11
diacylglycerols~2
guanylylimidodiphosphate~1
(GMP-PNP),~1
GMP-PNP~2
GMP-PNP,~1
GnRH-,~1
GTP-,~1
GMP-PNP-stimulated~1
phosphate-bound~1
phosphate-phosphocreatinine~1
VIP-induced~3
mammotrophs.~1
immunochemistry,~1
endothelial-follicular~1
high-scatter~1
ADP-ribosylation~8
40-kilodalton~1
hypophysectomized,~2
activator)~1
unmeasureable,~1
FSH-stimulated~25
(hLH),~1
(hFSH),~1
(hTSH),~1
anomeric~1
NeuAc~3
2-3Gal~2
fucose.~1
hTSH~16
R-O-4GalNAc~1
chitobiosyl~2
2-3(6)Gal~1
GalNac-1-,~1
R'-O-6GlcNAc-1-,~1
R"-0-2Man-1-plus~1
hFSH~10
3,6-di-O-substituted~1
1-4(+/-~2
Fuc~2
1-3)GlcNAc-1,~1
1-3)GlcNAc-1-,~1
R"'-O-GalNAc-1-,~1
GalNAc-1.~1
2,4-di-O-substituted~1
triantennary~1
R;~3
R',~1
R",~1
R"'~1
[5~1
E2/ml)~1
E2/ml)]~1
M-exposed~1
(7.5-mm~1
DHT)~1
[1,2-didecanoylglycerol~1
(DiC10)]~1
DiC10.~1
DiC10~2
(PDBu),~1
DiC10,~1
[5-~1
15-HETE)]~1
[unknown~1
lipoxygenase]~1
cyclooxygenase)~1
(P-450scc).~1
alpha-amanitin.~1
(Kmapp~1
globular.~1
Inoculum~1
mitochondrion~1
VIIcd~1
(BU)2cAMP.~1
I-VIIab,~1
I-VIIab~1
VIIcd-XI~1
(Bu)2cAMP.~1
([3H]IPs)~2
PIs~1
[3H]myo-inositol.~1
[3H]IPs~2
microaggregation.~1
[3H]IP~6
1,2-dioctanoylglycerol.~1
gonadotrope,~1
agonist;~1
phospholipid.~2
(CaM)-stimulated~1
CaM~13
Ca2+-CaM~2
Ca2+-directed~1
(ANFs)~1
Bachem~1
ANF-(5-28)~1
ANF-(5-25),~1
ANFs~1
[125I-D-Lys6]GnRH~1
ethylamide~2
dispersed,~1
glucose).~1
(iIGF-I)~1
iIGF-I~8
responsivity.~1
experiments);~1
(methylisobutylxanthine),~1
(3.76~1
gonadotropin-dependent~5
(desensitization)~1
GnRH-receptor~1
(D-Lys6-GnRH)~1
(conditions~1
release),~1
GnRH-mediated~2
LSH/SsLak~1
cyclicity~4
(estrus)~1
SP-treated~2
Intraatrial~1
1200-1500~2
ultrashort-loop~2
bodies).~1
(Epi)~1
(1-1000~2
(Dex),~1
Epi.~1
Epi,~1
Dex.~1
somatotroph-poor~1
3-4.~1
(GRF,~1
coaggregates.~2
lactotroph-enriched~1
thyrotrophs,~1
folliculostellate~1
coaggregation~1
Facilitatory~1
ANF.~9
ng/min).~1
ng/min),~1
(SRIF-14,~1
micrograms/rat)~1
ml/rat,~1
ng/55~1
SRIF-14.~1
Transferrin-specific~1
transferrin-enriched~1
(retinol),~1
Bu2~2
neuromodulators.~1
(pimozide),~1
(atropine)~1
GRF,~3
somatostatinergic~1
Spermidine~1
FSH-induced~3
alpha-difluoromethylornithine,~2
ODC,~1
Bu2cAMP.~2
[3H]ornithine~1
PAs~3
(MSA;~1
MSA-induced~1
(99-126)~1
subfornical~3
125I-rat~1
(99-126),~1
125I-standards.~1
Mediobasal~1
MBHs~2
intrapituitary~2
LHRH-synthesizing~1
hypothalmo-hypophyseal-gonadal~1
E-deficient.~1
LH-testosterone~3
clonic-tonic~1
electroconvulsions~1
valproic~16
pentylenetetrazol-induced~1
GABA-synthesizing~1
epileptogenesis.~1
Phenytoin,~1
(LUF)~1
(64.3%)~1
singletons,~1
(BCPT)~1
(88.9%)~1
(41.7%).~1
Testosterone,~2
dehydroepiandrosterone-sulfate,~2
ovulatory.~2
AB1ER-CR-2XY,~1
hMG~27
ampules)~1
8400~1
ampules),~1
ovulatory;~1
(32.4%),~1
(67.6%).~1
hMG-commercial~1
(hMG-hCG)~1
hMG-hCG~1
55.63~1
24.13~1
64.45~1
26.23~1
53.90~1
23.35~1
60.51~1
25.68~1
0.3441)~1
(32/56)~1
[N-Ac-D-p-Cl-Phe1,2,D-Trp3,D-Arg6,D-Ala10]-GnRH:~1
truncation~3
luteotropic,~1
(hMG),~1
menotropins~1
(HSD)~1
beta-hydroxysteroids~1
(P5)~1
3245~1
5/delta~1
beta-hydroxysteroids,~1
4-3-ketometabolites~1
DHEA-S/delta~1
P5/P~1
(17-OHP5)/17-OHP~1
101.3~2
180.0~1
HSD.~1
reasons;~1
(sulpiride~1
citrate-resistant~1
preference-elevated~1
Luteinizing-releasing~1
(LRH)~1
60-,~1
90-,~1
(TUs)~1
ovulate~2
Oligomenorrheic~1
LRH,~1
LRH~4
incidently~1
PCOD.~2
potencies,~1
(F-test),~1
Page's~1
(DHEA-S),~1
(T/SHBG),~1
F-test.~1
Running-associated~1
Mondays,~1
Wednesdays,~1
nonvegetarian~3
weight/week.~1
(CC),~1
hMG,~1
CC,~2
hMG/CC.~1
(69%,~1
(94%,~1
(77%,~1
(73%,~1
hMG/CC~3
0.0137),~1
0.0011),~1
per-patient~1
(FSH).~3
CC/FSH~2
plasma-estradiol~1
(5-14~1
(5-22~1
angiosarcomatous~1
Waldenstrom~1
macroglobulinemia,~2
2g/100~1
15.4%;~1
Enzyme-based~1
implementations~1
envisaged.~2
bioreactors~1
(iTxB2)~1
sham-irradiated~1
(iPG2)~1
2-[1-14C]deoxy-D-glucose~2
20-Torr~1
100g-1~2
60-Torr~1
177%,~1
(1:100,000)~1
(222.0~1
96.0%~1
H1-receptors~1
Bilateral,~1
denervates,~1
84-,~1
70-,~1
49-Torr~1
cervically~1
Normoxic~2
(fresp)~2
fresp.~1
pigeons,~1
vagotomy;~1
normoxia,~4
breaths/min,~3
28-56%~1
Bates~1
1840-1848,~1
(PIIA)~1
"single"~1
PIIA~7
drives.~1
PIIA.~3
"irritant"~1
lobeline~1
do;~1
inputs;~1
pressure-cardiac~2
beta-adrenergic,~1
PAP-PCWP)~1
PAP-PCWP~2
nonflow-dependent~1
vasopressin.(ABSTRACT~2
weddelli.~1
[78~1
27-min~1
(dives~2
seal's~2
(0.89%~1
(2/3~1
dives.~1
18O2~1
normobaric~5
(hypobaric~1
hyperbaric)~1
hyperoxic)~1
Lung-ODC~1
lung-ODC~2
Morphometrically,~1
alpha-difluoromethylornithine-treated~1
alpha-difluoromethylornithine~3
Gz~5
rides.~1
(PACO2),~1
(fH).~1
fH,~1
ride,~1
rides~1
978-988~1
989-995,~1
[fractional~1
Torr].~3
(logSDQ)~1
consumption),~1
(logSDQ~1
O2.(ABSTRACT~2
(Kf,C)~1
recirculatingly~1
Kf,C~1
Kf,C.~1
equivalent/10(7)~1
(55.4~1
(63.2~2
histamine)~1
1,500-rad~1
vasoreactivity~3
(PGH2-A)~1
PGH2-A,~1
intra-acinar~1
barium-filled~1
PGH2-A.~1
eucapnia.~1
previously:~1
(VT/VD)1.2~1
VTf~1
60:~2
1025-1030,~1
(HFV).~1
(VL).~1
[arterial~2
HFV,~2
(PaO2),~1
VT-f~1
([LA-]a),~1
[35%~1
max)],~1
+0.029~1
Tr~3
[LA-]a~2
-0.031~1
alkalosis.(ABSTRACT~1
46-61~1
technique's~1
(P4),~1
486(17~1
beta-[4-dimethylaminophenyl-1]17~1
alpha-[prop-1-ynyl]estra-4,9-dien-3-one),~1
(ethanol;~1
(delayed)~1
intermenstrual~1
folliculogenesis,~2
P4-like~1
(agonistic)~1
FSH/LH~2
(levonorgestrel)~1
micrograms/day).~1
Levonorgestrel-treated~1
(hMG;~1
FSH)~1
(huFSH).~1
[1268~1
953~1
huFSH~4
hMG-stimulated~2
[7.83~1
0.03]~1
huFSH-stimulated~2
hMG-~1
9.5%;~1
[125I]hCG-binding~1
granulosaluteal~1
(7.5-15~1
somatomedin-stimulating~1
(Eli~1
Lilly)~1
pseudohypoparathyroidism~1
(PsHP)~1
0.25-15~1
(PsHP~2
Ia),~1
PsHP~9
micrograms/12~5
15-21.~1
buserelin.~3
buserelin,~4
(GnRHa)~1
[6-D-(2-naphthyl)alanine]GnRH~1
(nafarelin,~1
Syntex)~1
8.8-~1
3.4-fold,~1
[283~1
pg/ml]~2
ng/dl),~1
GHRH-(1-44)-NH2~1
(TBPA),~1
15-20%~1
TBPA~3
(Appalachian),~1
Appalachian~3
TBPAs~2
M)-stimulated~1
ACTH-stimulated,~1
APA.~2
M)-,~1
mM)-stimulated~1
ANP-induced~5
(OKT3+,~1
OKT4+,~2
OKT8+)~1
undecanoate~1
(hANP),~1
(24-28~1
(64-91~1
hANP~37
hANP.~4
(GHRH),~2
GHRH-like~1
(GHRH-LI)~1
(IGHD)~1
GHRH-LI~10
[7.4~1
3.5-6~1
IGHD,~2
source(s);~1
ingestion;~2
10-yr-old~1
T-lineage~10
kappa-chain~5
micro-calorimetric~1
anhydrase.~1
segment),~1
reabsorption:~1
Aldosterone,~1
tCO2~12
nl/min).~1
tCO2),~1
"symmetrical"~1
Accordingly:~1
entry;~2
Full-length~1
(PAI-1)~1
(HUVEC)~2
PAI-1~17
PAI-1.~2
HUVECs~1
(DOPA).~1
0.031)~2
Carbidopa~2
lactamica.~1
HinfI~1
(Kb)~1
Kb.~2
lactamica~1
Hybridisation~1
neisseria~1
gonorrhoea.~1
(rt-PA)~7
rt-PA/placebo~1
rt-PA~44
interim,~1
acylated~2
streptokinase-human~1
(t-PA)~12
(scu-PA~1
pro-urokinase).~2
fibrinogenolysis~8
t-PA~66
pro-urokinase~2
pelt~1
mouse-pelt~1
mouse-allergic~1
(MA1).~1
MA1~5
19,000~2
3.9.~1
abolition,~1
MA1.~1
MA1,~1
disguise~1
(atopic~1
prerandomized~1
astemizole,~1
wheals,~1
placebo-treatment~1
astemizole-treated~4
culture-filtrate~1
endotoxins,~1
mycotoxins,~1
anti-A.~1
aspergilloma,~1
immunodiagnosis.~2
Aspergillus-induced~1
(PEM)~1
PEM~4
(intense~1
foods)~2
(CPN)~1
CPN~3
Egypt.~1
Metrifonate,~1
32.2,~2
(CE).~1
anti-CE~3
SPDP.~1
anti-CE)~1
heteroantibody-mediated~1
(hFPB)/I-Ak~1
hFPB~6
Arg14~1
APC-associated~1
I-Ak+~1
BH,~4
J11d~4
L3T4a,~2
L3T4b,~1
L3T4a-~1
LFA-1-~1
Lyt-1-like~1
BH-dependent~2
anti-L3T4a~2
anti-LFA-1~5
BH-containing~1
L3T4b~1
micrograms/mouse)~1
L3T4.~2
"panning"~3
OKT3-stimulated~2
TNP-Ficoll.~1
TNP-BSA.~1
LBMC-reconstituted~1
(R-IL~1
SN)~1
(CDF).~1
add-back~1
(L3T4-,~1
corticoresistant~1
(CRT)~1
Thymocyte~3
Microcultures~1
CRT~3
2-dose-dependent~1
CRT,~2
CRT.~1
co-promotor~1
beta-glucuronidase)~1
arylsulfatase),~1
ionophore-mediated~3
(oxidative~2
metabolism)~2
(degranulation).~2
antagonistically~1
hyposecretion.~1
PHA/PMA,~1
T8-depleted~1
3-day-cultured~1
(reIFN-gamma)~1
(anti-Ig)-stimulated~1
reIFN-gamma~2
(BSF-1)-stimulated~1
size-separated~1
reIFN-gamma,~1
IFN-gamma-mediated~3
BSF-1-stimulated~2
sIa.~1
"suppressor"~2
non-cognate~1
lectin-free~1
(CAS).~1
Thy-1.2-positive~1
CAS,~3
(1,25D3)~1
1,25D3-stimulated~1
(A29)~1
immune-modulating~1
A29~6
Ts2~1
TsF2~1
B16G,~1
TsF1~3
A10,~1
previously).~1
70,000.~1
A29-TsF-coated~1
Basophil~1
(anti-IgE)-mediated~1
non-IgE-mediated~1
(f-met~1
A23187)~4
SDM)~1
DZ.~5
(VMZ)~1
(VDZ)~1
3.84~1
0.74.~1
(10(-1)~1
f-met~4
VMZ~1
VDZ~1
0.57.~1
(CMS)~2
(VMS),~1
CMS~5
trifluoromethanesulphonic~1
CMS,~1
200,000,~1
38,000,~1
17,000.~1
leporipoxvirus.~1
MV-associated~1
(TISF)~1
interleukins~1
TISF~2
7D4.~1
ionomycin-mediated~1
Reexposure~1
reinduce~1
lymphocyte-target~2
IA-bearing~2
IE-bearing~1
H-2k,d~1
IA/IEk~1
IA/IEd~1
Lyt-1~4
anti-RCS~1
recognition/binding,~1
(Ea)~1
Ea2,~1
nondisulfide-bonded~1
86,000~1
(28,000)~1
Ea1~2
Ea2~2
Ea3~2
pre-exist~1
mitogenesis,~3
(CSA)-sensitive~1
T3/T~4
(anti-CD3)~1
(OKT3~1
64.1).~1
Anti-CD3~7
AC-depleted~2
96-hr~1
anti-CD3-mediated~1
(gluten-sensitive~1
[GSE])~1
lipid-derived~2
GSE~4
peptic/tryptic~1
beta-scintillation~1
(15-HETE).~1
Mucosa~1
GSE,~1
microwells~1
1/100,000,~1
1/100~1
BUD-27,~1
phospholipid/Ca2+-dependent~1
BUD-27~1
CT6.~2
digestions~2
(HUT-102)~1
PHA-activated~1
Nonactivated~1
SAC.~2
(TcR)~2
clone's~1
anti-clonotypic~2
irrelevant,~1
lymphokine-induced~2
(IC30~1
Cromolyn~9
cercariae,~4
antibody/complement~1
(VMS)~1
VMS.~2
P-associated~1
lymphokine-producing~1
immunized,~1
B10.P~1
larvicidal~1
(T,G)-A--L~2
C3H.SW.~1
Southern,~1
anti-(T,G)-A--L~2
186-2~1
(T,G)-A--L.~1
2-secreting~4
allodeterminants.~1
potential:~1
helper,~2
II-allospecific~1
"nominal"~1
Lyt-2+.~2
discordant:~1
allodeterminants~2
self-Ia.~1
avoid.~1
JRAI~5
suppressor-effector~1
Leu-8-~4
2'Deoxycoformycin~1
(dCF),~1
(AdR)~1
AdR~3
AdR.~2
affected:~1
Lectin~1
Anti-double-stranded~1
anti-idiotype,~1
8.12,~1
Lyt-2-.~2
12-O-tetradecanoylphorbol-2-acetate~1
ionophore).~2
L3T4-Lyt-2-~2
L3T4-/Lyt-2-~1
(anti-IL~1
ART-18~3
(W3/13+)~1
(ED-1+,~1
ED-2+).~1
2R+)~1
2R+.~2
2R+~6
2R.~8
3/13,~1
ED-2.~1
A1-3~1
(post-Tx),~1
2R-~1
A1-3,~1
ART-18-treated~1
A1-3+~1
(anti-Tac).~1
monocyte-activating~1
anti-Tac~19
IFN-gamma-treated~19
IL-2;~1
antigen-dependent,~1
2-enriched~1
tuberculin-purified~1
(PPD)~1
PPD-induced~1
JURKAT,~1
PPD-~1
U937-conditioned~1
12F1,~1
(beta).~1
A-1A5,~1
preclear~1
12F1~3
VLA-1,~3
late"~1
(inactivated~1
SK-N-SH~1
VLA-1-negative~1
VLA-2-negative~1
C8215~1
alloimmune~1
(PRL)-stimulated~1
cyclopeptides~2
didemnin~1
(DB)~1
125I-PRL~1
PRL-dependent~1
near-optimal~1
"cells~1
PRL-stimulated~4
DB~1
cyclopeptide~1
NDGA~7
estrogenized~1
quercetin~1
Erdman~1
eliminated;~1
recrudescing~1
Malarial~1
Gametes~1
gametocytes~4
transmission-blocking~1
gamete-reactive~1
1/4000.~1
gamete-specific~2
HLA-DR-~1
HLA-DQ-restricted.~1
bromelinized~1
isologous~1
linked-base~1
VH~75
94.~1
kappa-9~1
JH,~2
JH1~2
base-long~1
SP2~1
(PC)-specific~1
pSV2gpt,~1
J558L~3
(PC-BSA).~1
pSV2neo~2
transformant.~1
PC-BSA.~1
RFC~2
IgD-coated~1
SRBC,~1
IgD-RFC,~1
IgD-specific~1
IgD-RFC~1
IgD.~2
OgD-RFC~1
IgD+~1
sorter-separated~1
CLP.~1
300)~1
self-HLA~1
split-well~1
L-leucyl-L-leucine~1
(Leu-Leu-OMe)~1
Leu-Leu-OMe~7
alloantigen-induced~1
histo-compatibility~1
DFA/2)F1~1
pre-CTL.~1
TAP,~2
receptor/T3~3
F(ab)~2
TAP-stimulated~1
TAP-mediated~1
nonactivating~1
CD22~5
130/140-Kd~1
HD6,~1
HD6~2
constimulatory~2
proliferate;~1
Anti-CD22~1
anti-Ig-treated~1
low-m.w.~1
50-Kd~1
Bp50,~1
BCGF-like~1
anti-CD22~4
Bp~1
130/140~1
Leu-8~1
Leu-3+8+~3
Leu-3+8-~2
Rhus~1
3-7.~1
HLA-DQ+~1
anti-T6~1
(OKT6)~1
(OKIal)~1
sections;~1
Terfenadine,~1
brain-heart~1
broth.~3
phagosomal~4
phagosomes~1
cytospectrophotometer.~1
GUH-2~1
19247,~1
(CO2).~2
(HCO3-)~1
HCO3-.~2
(CBA~1
C57/BL)~1
superovulatory~2
(32/70)~1
(15/66).~1
(454/32)~1
(77/15).~1
57.8,~1
51.5,~1
53.5%~1
post-hCG~1
hydroperoxides~6
N-formyl-L-methionyl-L-leucyl-L-phenylalanine)~1
activator(s)~1
Fe+3~1
14-labeled~2
methylprednisolone-treated,~1
abscissa,~1
saturability.~1
Glycocholate~1
Na+-stimulated~1
pre-ECA~1
ECA,~1
Unreduced~1
anode.~2
foils~1
(EsD)~1
(0.045~1
multiple-gas~1
0.999,~1
bad,~1
lavish~1
hypercarbia.~3
Puritan-Bennett/Datex~1
N-9000~1
Puritan-Bennett~1
(ABM-1).~1
(SMF)~1
(FAM)~1
SMF).~1
electrocorticograms~2
7.01~1
means).~1
desmoplasia,~1
neurohistological~1
immunohisto-~1
Divergent~1
pericytoplasmic~1
"desmoplastic~1
ganglioglioma"~1
[201Tl]chloride~1
Regioselective~1
fluorination~2
phosgene~1
3,4-dihydroxy-phenyl-L-alanine~1
(5-(benzyl-3',4'-carbonate)-oxazolidine-2,5-dione)~1
acetylhypofluorite~1
[18F]F2~2
Fluorination~1
[18F]acetylhypofluorite~1
6-[18F]fluoro-L-dopa~1
purity;~1
70:16:14~1
2-fluoro~1
Radiochemical~1
acetylhypofluorite,~1
4)%~1
done)~1
mCi/mmol~1
fmol/ml,~2
mmol/kg/d~2
(intralipid)~1
mumol/kg/day)~1
acetoacetate,~1
D-resistant~5
(1,25(OH)2D,~1
calcitriol)~1
TmP/GFR,~1
phosphase~1
normocalcemia.~2
(25(OH)D)~1
TmP/GFR~1
calcitriol.~1
lesion-derived~1
1,25-(OH)2~1
collagenases~4
(HSVEC)~1
microwell~2
attachment-capable~1
HSVs~1
EC/cm2.~1
(BMLA)~1
enzyme-free~1
harvests).~1
fibronectin-specific~1
BMLA~2
secretively~1
health-threatening~1
Surreptitious~1
probability-based~1
Tompkins'~2
("disease")~1
"Projected~1
decisions"~1
(diseased~1
patient-treated~1
patient-not-treated).~1
physicians'.~1
(leaving~1
untreated);~1
undertreatment).~1
flow-meter)~1
methysergide.~2
5HT-2~1
methylester~1
(AME)~1
3H-D-mannitol~3
22Na-preloaded~1
AME/mg~3
AME,~1
efflux.(ABSTRACT~1
(cTALH)~1
(mS~1
cm-2);~1
(CO2~3
Ge;~2
(JKnet)~1
(JClnet);~1
Ba++,~3
Ge.~2
Ba++-insensitive~1
mS~2
dissipative~1
36Cl-.~1
Na+/Cl-~1
blockaded~1
Ba++-sensitive,~1
transcellular,~1
JKnet/JClnet~1
Ve,~1
(mV),~1
Je~1
(pEq~1
omission.~1
cTALH~1
Transcellular~1
Ge,~1
Praziquantel.~1
125I-fibrin~1
(GFA)~1
GFA~4
fibrin/mg/30~1
AA-stimulated~1
GFA.~1
eicosatrienoic~1
(ETA),~1
(ETYA),~1
dihomo-gamma-linoleic~1
(DHL),~1
t-PA,~4
u-PA,~2
u-PA~4
t-PA.~4
GFA,~1
digitalis-like~4
0.07);~1
EI1,~1
EI2,~1
EI3,~1
EI1~1
EI3.~1
Lobectomy,~1
(Ileu-ANP)~1
haemodynamic,~1
Ileu-ANP~3
pre-infusion~1
Ileu-ANP.~2
Christmas~1
1/min~1
Holinger~1
flammable~2
packings~1
fatigable,~1
fatigue-resistant,~1
SR)~1
supposition,~1
(FF,~1
muscles)~2
marihuana~3
delta-9-tetra-hydro-cannabinol)~1
(fb),~1
fb-1.~1
(rest);~1
smoking);~1
Marihuana~3
(94.3~1
119.0~1
18.0,~1
marihuana,~1
1.031,~1
0.0)~1
condition.(ABSTRACT~1
xanthomatized~1
hue~1
(periorbital~1
particular),~1
Touton~1
non-X~1
C1-esterase~2
fibrosis-associated~1
glucoses~1
CF-associated~2
encumbrance~1
burdened~1
shelter-related~1
resistance--an~1
smears--features~1
tuberculosis)~2
contagious.~1
non-A,non-B~2
t(8;~2
P3HR-1,~1
380.~1
V-D-J~2
t(11;~1
t(14;~1
self-transplantation~1
incalculably~1
cI-specific~1
polymorphic)~1
Haemophilia~1
haemophilia~3
grandfather.~2
hotspots.~1
haemoglobin.~1
haemin~5
haeme~1
oxygenase.~1
haemozoin,~1
Indonesia-Indochina~1
Sahuland,~1
'waisted~1
axe'~1
Pleistocene,~1
hafting~1
depolarizing.~1
phototransduction~2
pZ183~2
(pZ183-1)~1
L-chain-related~1
(CSFPP)~1
CSFPP~3
Vb).~1
Vb~5
electromagnetically~1
Vb.~1
Barrier~1
glioblastoma;~1
(12.8~1
barrier-enhanced~1
KPS~1
hemiplegia),~1
nodule(s)~1
postconceptual~1
beta-methasone~2
beta-methasone.~1
hyperthyroxinemia.~2
propythiouracil~1
uptakes,~1
(hypothyroidism,~1
transcend~1
Give~1
isoniazid.~1
gram-for-gram~1
sampling).~1
stomach.(ABSTRACT~1
pressors,~1
cro~2
Cro.~2
Cro~1
partial-length~2
anti-thrombomodulin~1
heteroantibody~1
authenticated~1
thrombomodulin.~1
coated-pit~1
g32P.~1
g32P~2
g32am453~2
TAG~1
TGG~1
(era)~1
(rnc)~1
Era,~1
Era~1
ras-related~1
mu-chain~7
s-mu~1
900-nucleotide~1
regulation;~1
cleavage/polyadenylylation~1
calcium-saturated~4
9-19,~1
calmodulin-(9-19);~1
141-148,~1
calmodulin-(141-148);~1
68-79~1
80-92,~1
calmodulin-(68-79)~2
-(80-92).~1
Crossreactivities~1
solution-phase~1
apocalmodulin~1
solid-support,~1
calmodulin-(80-92)~1
-(141-148).~1
apocalmodulin.~1
Ca2+-saturated~1
71-88.~1
(glutamic~1
ethanol-extracted~1
ATP-generated~2
32Pi-ATP~1
40:26.5:7.5:26,~1
lipid-to-protein~1
200:1.~1
150-fold~1
proteoliposome.~1
Phosphatidylserine,~1
ATP-hydrolytic~1
4-beta-galactosyltransferase~3
2.4.1.38)~1
(PTS).~1
mannose-specific~1
PTS,~1
IIMan,~1
II-AMan~1
II-BMan.~2
ptsM,~2
pel,~1
pel~1
II-BMan~2
ptsM)~1
II-AMan.~1
ptsM~2
pCS13,~1
termentation~1
pel+~2
pCS13~1
manY~2
manZ,~1
(Pel)~1
fermentation,~1
2-deoxyglucose,~1
Pel~2
IIMan~1
IIMan.~1
hydroxylated,~1
presequences.~1
presequence,~1
CT/hR-1~2
"converter"~1
converter~4
converter.~1
Ternary~1
(ICa)~2
ribosylates~1
S]),~1
somatostatin),~1
(GS)~1
Carbonic~1
(CA-II)~1
CA-II~6
restriction-modification~1
6-methyladenine~1
mcrA~1
mcrB~1
restriction).~1
Mcr~3
5-methylcytosine-containing~1
remarkable,~1
melanogaster~20
yakuba~1
(scnDNA)~1
mtDNA.~1
scnDNA~1
1.5-2%~1
interferon-beta,~1
IB-peptide~1
Ef1a~1
C58/J,~1
AKR/J,~1
RF/J,~1
expressor~3
Lyt-2/Lyt-3~1
Ser-specific~1
(Igk-VSera)~1
nonexpressor~2
(Igk-VSerb)~1
(C.C58)~1
C.C58~3
Igk-VSera~2
allele)~2
Igk-VSerb~2
IB-negative~1
Ef1a-negative.~1
BAM5/R~1
BALB/c.~1
"minigene"~1
-2500~1
-159~2
gamma-IFN.~6
-128~1
-107~1
CD1~9
2-microglobulin-binding~1
71-88%~1
phenidone,~1
3-amino-1-[m-(trifluoromethyl)phenyl]-2-pyrazoline~1
755C),~1
hydroquinone,~1
pyrogallol~1
EDRF-induced~1
trinitrate,~1
magnitude)~1
(20-40~1
anti-RS~1
restimulate~1
cytotoxic-T-cell~1
47-kDa~1
(yohimbine),~1
[2-(p-amylcinnamoyl)amino-4-chlorobenzoic~1
(ONO-RS-082)],~1
[ethylisopropylamiloride~1
(EIPA)],~1
A2A9),~1
Ca2+/Mg+~1
(EDTA),~1
ONO-RS-082,~1
A2A9~1
EIPA.~1
subaggregatory~1
H2/thromboxane~1
[(15S)-hydroxy-11~1
alpha-(epoxymethano)prosta-5,13-dienoic~1
(U46619)~1
phospholipase-inhibitory~1
lipomodulin~1
(lipocortin)~1
surface/pericellular~1
matrix-localized~1
mucosal-like~2
pPG-1~2
(pPG-B)~1
(pPG-M).~1
pPG-B~2
pPG-M~2
granule-localized~1
[IL-2~1
(T-cell~1
factor)]~1
serumless,~1
(oligodendrocyte-defined~1
ODM).~1
antibody)-positive~1
Tac-positive~2
anti-benzodiazepine~1
N-desmethyldiazepam~1
(nordiazepam).~1
Benzodiazepine-like~1
benzodiazepine-like~2
origin--and~1
themselves--are~1
[125I-labeled~1
(125I-gp120)]~1
OKT4.~1
125I-gp120~2
"peptide~1
T,"~1
decarboxylase-containing~1
chloride-mediated~1
beta-carboline~3
6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate,~1
imidazobenzodiazepine~1
15-1788,~6
beta-carboline.~1
benzodiazepine-beta-carboline~1
acquaint~1
macroglossia,~2
macroglossia~6
macroglossia.~2
Agencies,~1
nutrition),~1
Reports;~1
January-February~1
Reports.~1
"Alameda~1
7,"~1
exercising,~1
snack,~1
Education,~2
Promotion~7
survey),~1
F.)~1
(NHIS)~1
"exercise~1
capacity"~1
sedentary.~1
Heavier~2
'liver~1
(FAS).~1
Promotion/Disease~1
nation.~2
9,086~1
3,261~1
non-WIC~1
5,825~1
benefit-to-cost~1
($.07,~1
$.90)~1
outlays.~1
Consortium~1
Professions,~1
Nations~1
Fund~2
(UNFPA),~1
Bangladesh's~1
(NIPSOM)~1
microcomputing~1
project's~2
NIPSOM~3
members--three~1
installed--were~1
consortium's~1
self-reliance~1
1906~1
enacted.~1
Food-~1
beverage-transmitted~1
(AHEC)~1
AHEC~6
underserved~2
redrafted~1
authorizing~1
AHECs~3
areas--in~1
care--as~1
programs.(ABSTRACT~1
(visits~1
rooms)~1
population--a~1
24-county~1
Florida--were~1
1,163~1
Buffalo,~1
quit,~1
self-discipline,~1
(enhanced~1
enhancement:~1
sign),~1
retroperitoneum;~1
midabdomen~1
pneumocolon~2
nonconjugative,~1
beta-lactamase-specifying~1
(TnA)~1
parainfluenzae.~1
[83%])~1
[75%]).~1
units/day)~1
reproduce.~1
hpg/hpg~1
neural-specific~1
myelinogenesis~1
oligodendrocyte-substratum~1
ester)~3
nonattached~1
AMP)~2
myelinogenic~1
G0/G1~1
elaborating~1
multisegment~2
(ESML)~1
(OPLL)~3
drill,~2
(18.1%),~1
(27.1%),~1
fair;~1
Discase~1
Intradiscal~1
chymopapain-injected~1
malnutrition?~1
Strictly,~1
starts,~1
fuel,~1
Safe,~1
aversions,~1
religious,~1
manner.(ABSTRACT~1
well-nourished;~1
(curative~1
palliative)~1
TPN~90
anabolism.~1
PEM.~3
PPN~1
CEN~1
Realistic~1
lymphoreticuler~1
(DRG).~1
$1,468,094.00~1
$24,883.00~1
$1,098,431.00~1
somatostatin-rich~2
("somatostatinomas")~1
confirmed;~1
(0.0032-50~1
(V30(p)).~1
(PC10FEV1),~1
(PC35SGaw),~1
(PC30~1
V30(p)).~1
non-mucoid~1
trusted~1
(27/34),~1
non-caseating~1
(olive~1
oil).~1
feed.~1
Vehicles~1
Renacidin~1
irrigate~1
renacidin~1
contemplated,~1
alpha-difluoromethyl~1
(DFMO)~3
methylglyoxal~1
DFMO~24
hormone-resistant~1
Exopolysaccharide~1
biofilm-forming~1
2-nicotinamidethyl~1
Nicorandil~4
pressure-rate~1
(20,420~1
17,480~1
6.(ABSTRACT~1
hypocaloric,~2
Nonprotein~1
881~2
51.5%~1
(120.0~1
(+2.4~1
protein-depleted~1
multiple-isotope~1
(EGPT)~1
(EGPT~1
1.25)~1
EGPT~2
(DAO),~1
B-6-dependent~1
plasma-DAO~2
pyridoxal-5'-phosphate.~1
contrasts,~1
nizatidine,~1
nizatidine~4
Nizatidine~2
lead-mobilization~1
kindreds,~1
ubiquitous.~1
epistatic~2
stramonium~1
abroad;~1
Ipratropium,~1
Pharmacotherapy~1
decades:~1
cromolyn,~1
moderate-to-high-dose~1
3'5'-cyclic~1
(-)isoproterenol-dependent~1
triphosphate)~1
(beta-adrenergic~1
triphosphate-binding~4
component:~1
concluded:~3
Periovulatory~1
blockage.~1
1792~1
alpha-hydroxyprogesterone-progesterone~1
alpha-hydroxylase)~1
androstenedione-17~1
(17,20-desmolase)~1
citrate-human~1
Thyrotropin-releasing~7
desynchronization,~1
lowest-dose~1
highest-dose~1
testolactone,~2
testolactone~1
glycerophospholipids,~1
[14C]prostaglandin~3
glycerophospholipids~1
triacylglycerols~2
cataractous~3
MTs~1
Fibrin/ogen~1
fibrin/ogen~1
(N=8)~1
(N=7)~1
(DFMO,~1
eflornithine)~1
spotty,~1
mesoappendix.~1
(Seberi)~1
Seberi~1
Seberi.~1
eggs/10~1
75Se-selenomethionine-labeled~1
mansoni-infected~4
cell/macrophages~1
Eosinophilotactic~2
japonicum-infected~1
G-200,~1
G-200~1
455,000)~1
13,000)~1
(SmSEA)~1
immunotransfer~1
oxamniquine~1
SmSEA~2
SmSEA,~1
SDS-acrylamide~1
haematobium,~1
phlebotomus~1
Arboledas~5
Caimito~1
Pacui~1
viruses;~1
marsupialis)~1
marsupialis~1
gomezi)~1
gomezi.~1
(transovarial)~2
marsupial-sand~1
phleboviruses~1
Erbotherm~1
mHz~1
(7.66~1
nitroglycerine~4
alfentanil.~5
(4/20),~1
(8/20),~1
(4/14).~1
mmHg-1),~1
(0.90~1
mmHg-1).~1
(ISF)-induced~1
ISF-induced~6
normotension;~2
Hypocapnia~1
normotension,~1
beta-1,~1
D-Ala2-D-Leu5-enkephalin~1
(DADL,~1
[VE]~1
[ET]~1
DADL,~1
(MPAP),~1
(SVR),~1
DADL~4
MABP,~1
MPBP,~1
116.7~1
morphine.(ABSTRACT~1
rheoplethysmographic~1
(RPG)~1
(NTG),~3
1/200~1
gr~1
NTG~32
NTG.~5
food(s)~1
diagrams)~1
card).~1
SCG,~3
pneumotachometer.~1
ventilation/work~1
ABD,~2
(leading~1
(WBC),~1
6-keto-PgF1~4
PgF2~4
microgram/kg).~1
FPL-57231~2
353%~1
195%~2
TxB2;~1
phase.(ABSTRACT~1
agglomerans~1
Tannin~1
(lsc)~1
lsc~2
CBE,~1
Plasma-exchange~1
3818~1
dispenses~1
vials.~1
$.065~1
hemostatically~1
(H.H.D.)~1
microdirect~1
pharyngoscopy.~1
(vincristin~1
[VBM])~1
VBM~3
spectacular,~1
146032,~1
A21978C,~1
146032~4
ticarcillin-CA~1
ticarcillin.~1
284,635;~1
027),~1
Susceptibilities~2
mcg/day~2
Titres~1
(140-235).~1
(1100-20,500),~1
(160-4400).~1
(Intralipid~3
KabiVitrum~1
N/kcal).~1
tumor-host~3
6-3H-glucose~1
6-d2-glucose,~1
U-14C-glucose~1
U-13C-glucose~1
(15N2)-urea~1
U-14C-urea,~1
1,2-13C~1
oxidized)~1
(TPN),~7
mumol/kg/min)~2
mumol/kg/min).~2
Delay,~1
factors--time~1
(need~2
nitroglycerin),~1
support)--independently~1
Differentiating~1
(DMSO),~1
methylsulfonylmethane~1
(MSM),~1
(NMF),~1
42-day-old~1
MSM,~2
MSM)~1
7,12-dimethylbenzanthracene~1
(biplanar~1
(latency~2
MSM.~1
Polar~1
dimethylbenzanthracene-induced~1
22.42~1
1.65%.~1
mol-1),~1
2.13).~1
deadspace.~1
paralysed,~1
anti-c~2
K-Sol~4
McCarey-/Kaufman~1
(M-K)~1
thin.~1
M-K~2
signal-like~1
PF4,~1
cell-reactive~2
MM4,~1
MM4~5
positive),~5
MM4-reactive~2
Zenker~1
macroglobulinemia~5
(PWM)-stimulated~2
PCA-1.~1
Bilineage~1
(null-AL)~1
t(4;17).~1
t(4;17)~1
(q25;q23)~1
tetradecanoyl-phorbol-acetate~1
Double-fluorescence~1
null-AL~1
dual-lineage~1
one-chain~2
Erythropoietic~1
(ETU)~1
ETU~5
blood/d.~3
blood/d,~1
hypoproliferative~1
ETU,~1
ferrokinetic~1
1-adamantanamine~1
(amantadine)~1
anti-pan-T~1
(T101-immunotoxin;~1
T101-IT).~1
T101-IT~1
immunotoxin-mediated~1
marrow-purging~1
(4-HC)~1
(anti-CD5)-Ricin~1
G3.7~1
(anti-CD7)-R~1
4-HC~3
10(8)/mL),~1
ion-dependent,~2
predominates.~1
Mg).~1
TSP-platelet~1
two-receptor~1
auto-antibodies,~1
(FcR).~1
MHC-nonrestricted~1
cells);~1
CD3+~17
FcR+)~1
leukemias;~1
(JK)~1
(KDel)~1
exception;~1
KDel~1
histochemically.~2
BamH1~1
interlineage~1
infidelity,~1
(T0,1,2,N0,1,M0).~1
Counselling~2
1.1:1.0~1
(207/185),~1
4.8:1.0~1
(324/68)~1
15-64~1
(4.2/100,000)~1
non-preventable~1
(over-reliance~1
corticosteroids),~1
Studying~1
(ApoC2)~1
ApoC2~3
non-haemolytic~1
3999~1
Kandang~1
Kerbau~1
Singapore,~1
2.00/1000~1
(7.50/1000),~1
nonhaemolytic~1
reduced;~1
Connaught~2
(1.88%~1
1.98%~1
0.1],~1
0.1]).~1
In-vivo~1
circulation)~1
(alpha-hANP)~4
alpha-hANP,~1
(FAV),~1
(FAF;~1
FAV)~1
pressure/FAF)~1
alpha-hANP~21
0.093~1
microgram/min/100~1
FAV~1
(pANP)~1
80;~1
Intraindividually,~1
FAF~2
pANP,~1
alpha-hANP.~4
(Ser~2
103-ARG~1
cardiocytes~5
101-Tyr~2
126.~1
postrema,~1
solitarius,~1
hypophosphataemic~2
hyperphosphataemic~1
ethylidene-1-hydroxy-1,1-bisphosphonate.~1
(95:5,~1
v/v).~1
Pi/l)~1
Pi/l),~1
(1.97~1
(1.52~1
Na+,K+-dependent~1
(Na+,K+-ATPase)~1
unsaturated.~1
gas-volume~1
five-compartment~1
[RQ])~1
RQ.~2
(BERS)~2
electromorphology~1
BERS~4
BERS.~1
Spike/min~1
spike/min~1
(DESC)~1
sleep-inducing~1
23-79~1
atonic/tonic~1
tonic,~1
atonic,~1
Stories~1
verbose.~1
stories~1
circumstantiality~1
hallucinatory~1
TRH-t~1
(53.7%)~1
zonisamide~3
(1,2-benzisoxazole-3-methanesulfonamide;~1
CI-912).~1
zonisamide.~1
visual-perceptual~1
-0.73;~1
progabide,~2
(1,085~1
DR).~1
(X2~1
13.08,~1
citrate/human~2
blastomeres~1
intercycle~2
3]~3
phases).~1
[186.3~1
159.0~1
(ng/ml)~1
day],~1
(160.5~1
139.1~1
Buserelin~9
27-mm~2
follicle(s)~2
insulinopenia~1
3-methylhistidine,~1
Streptozocin-induced~1
hypoinsulinemia,~1
3-Methylhistidine~1
streptozocin),~1
ketoacidosis,~4
fed).~1
muscle.(ABSTRACT~1
24-h-fasted~1
Glycogenolysis~1
4-200~1
thawing,~2
Batches~1
C/min.~3
DMSO:~1
cryoprotectants,~1
(MNCV)~1
(STZ)-induced~3
(reliable~1
(IBAT),~1
pancreas),~1
(ONO~1
2235,~1
ARI.~1
IBAT,~2
MNCV,~2
12-24-h~1
fasts;~1
7.37-7.85;~1
(PCO2),~1
21-32~1
([TCO2]),~1
16.4-41.4~1
([TBS]),~1
16-93~1
[Na],~2
153-192~1
5.72-7.29;~1
36-101~1
[TCO2],~1
1.21-15.5~1
[TBS],~1
150-305~1
199-266~1
[Na]~1
[TBS].~1
[TBS]~3
6.4-6.6,~1
(HCO3-~1
neutralization),~1
lithogenicity,~1
CaCO3-~1
26-30~1
cross-sectionally~1
pasteurised~1
Lactase~2
Sucrase:~1
Ultracentrifuged~1
Nucleation~1
biles.~1
Ionised~1
topics:~1
appetite;~1
Enteral~6
sadly~1
dietitian.~1
Dietitians,~1
dietetics.~2
improve;~2
mortality?~1
colitis)~2
enterally~3
metals.~2
87.1%~1
methanolysis-high-performance~1
Uridine~1
glucuronyl~1
kernicteric~1
(48-1~1
48-1~2
host-defense.~1
158)~1
380,~1
Cross-immunoelectrophoresis~1
nonelectrolytes~1
[3H]H2O,~1
[14C]urea,~1
[14C]erythritol,~1
[3H]dextran~1
[3H]dextran,~1
(cm~1
[3H]inulin.~1
ductule/duct~2
bile-to-plasma~1
erythritol,~1
taurodehydrocholate.~1
taurolithocholate~1
[3H]inulin,~3
erythritol~1
[14C]mannitol~9
ductule/duct;~1
[14C]erythritol~1
convection,~1
diffusion;~1
transjunctional~1
581~1
(229~1
dl),~1
dl)~1
hypertensive)~1
prepuberty,~1
(1100-1200~1
5'-termini~1
10-20%)~1
run-in,~1
95.1~1
8.9;~1
drug-treated,~3
phosphate/hr/mg;~1
influx.(ABSTRACT~1
saralasin-sensitive;~1
saralasin-resistant.~1
saralasin-sensitive~4
saralasin-resistant~3
(2K1C)~1
126),~1
ng/hr~1
sham-infused.~1
2K1C~2
Saralasin-sensitive,~1
noninfused~1
quality-enhancing~1
bidding~1
windfall~1
(LP).~1
(ELP;~1
mid-LP~1
(MLP:~1
(LLP;~1
(PMP;~1
13-14~1
(ISAb)~1
(ISAs)~1
ELP,~1
ISAs~3
ISAb,~1
LLP~1
PMP,~1
ELP~1
PMP~1
ISAb~1
(IHH).~1
IHH,~1
GnRH-induced~3
anosmic~1
apulsatile~1
bioinactive~1
33-micrograms~1
(P(ET)CO2;~1
P(ET)CO2~2
hCRH.~1
83.5~1
hyperventilatory~2
side-effect.~2
(650%)~1
(440%)~1
(IR-GHRH)~1
(250%)~1
IR-GHRH~2
GHRH-secreting~2
4.5-7.8~1
alactogenesis.~1
beta-Subunit~1
thyrotroph~4
beta/CG~1
Oligonucleotide-primed~1
electrophoresis;~1
M-1);~1
ranges;~1
11-65~1
28-39~1
23187~3
LTB4-synthesizing~1
unattenuated~1
(7-71%).~1
Pyocyanin~3
1-hydroxyphenazine~2
ciliostasis.~1
NKH1+~3
(anti-T11(2)~1
anti-T11(3))~1
(rIL-2).~4
anti-T11(2/3)~2
pseudogamma~1
5.9-kilobase~1
Bst~1
EII~1
(60.0%)~2
(28.8%)~1
reabsorbs~1
Cl--free,~1
Isc.~2
cAMP;~3
amiloride-inhibitable~1
micro-organisms,~1
flow-reducing~1
flecainide.~6
flecainide,~7
Flecainide~7
flecainide~36
(albumin,~1
prealbumin).~1
(2059~1
TE-thymocyte~3
anti-CD-2~2
(LFA-2,~1
anti-LFA-3~4
CD-2~5
anti-LFA-2~1
cell-thymocyte~1
(aGM1).~1
aGM1+~10
aGM1-~1
thymoblasts~1
maturing.~1
MOPC-104E~1
anti-dextran~3
Igh~5
Igh.~1
tetraparental~1
anti-H-2b~1
BALB.B,~1
antidextran~1
H-2-restricted,~1
adaptively~1
BALB.B.~1
(IFN-gamma)-treated~1
(FB)~2
phi),~1
FB,~2
streptodornase~1
(SKSD),~1
SKSD-bearing~2
HLA-D-mismatched~1
EC-promoted~1
(9.3).~2
allo-class~1
HTB-9.3,~1
I-Ab-specific~1
HTB-9.3~2
allo-responses,~1
T3-T6-~6
3H-triamcinolone~1
affinities,~1
removing,~1
Host-vs-graft~1
clonable~5
(TBI),~1
anti-Ly-3T4.~1
125IUdR.~1
IUdR~2
donor-type~2
posttransplantation,~2
tolerizing~1
FD.C/1~3
32Dcl-23,~1
32Dcl-23~2
3-and~1
(rIFN-gamma)~6
phi).~2
rIFN-gamma,~5
rIFN-gamma~24
U/mouse.~1
Toxoplasma.~2
anti-toxoplasma~3
metalloproteinase.~1
7,6,~1
metalloproteinase(s)~1
(TsDF)~1
(MLR-Ts)~1
TsDF-binding~2
alloantigen-stimulated~1
nonrestimulated~1
L3T4-Ly-2+~1
L3T4+-Ly-2--enriched~1
Glutaraldehyde~1
MLR-Ts,~1
reexposure,~1
TsDF-induced~1
alloantigen-reactive~1
TsDF-receptor~1
L-serine,~1
65.9%~1
15.2,~1
L-serine~1
6-trans-LTB4~1
subclass-specific~1
diastereoisomeric~1
sulfoxides~1
la+~1
A23187-challenged~1
(12-Hete),~1
PGD2-generating~1
PGD2/12-HETE~1
4.37~1
radioimmunologic~1
immunoregulatory,~1
CCRF-CEM.~1
co-precipitation~1
digitonin-solubilized~1
A673~6
(anti-CD3a:~1
UCHT1,~1
anti-CD3b:~1
T10B9,~2
anti-CD3c:~1
OKT3)~1
(cCD3)~1
(mCD3)~1
cCD3a~1
cCD3c~1
BrdU-incorporating,~1
CD1-,~1
mCD3-.~1
cCD3+,~2
anti-CD3b~1
co-caps~1
co-modulates~1
cCD3.~1
oedipus~2
mCD3.~1
CD7+~1
cCD3~1
cCD3,~1
(u-PA)~4
multilayer~1
spinosum~1
stratify;~1
DNA-synthesizing~1
308,~1
calcium-resistant~1
24-1,900~1
1-83~1
digestions,~1
Indistinguishable~1
serotyping,~1
biotyping,~1
antibiograms)~1
beta-Galactosidase~1
(GZ)~1
SL3261,~1
aroA~1
pXY411,~1
GZ~2
strain--SL3261(pXY411)--expressed~1
SL3261~1
GZ,~1
apolipoprotein-AI~1
(apo-AI)~1
apo-AII~1
(LVEF).~1
(positive)~1
HDL3-cholesterol~1
(negative),~1
LDL-cholesterol/HDL-cholesterol~1
(positive),~1
HDL2-cholesterol.~1
HDL3-cholesterol,~2
HDL-cholesterol,~1
apo-AI,~3
apo-AII.~1
factors,"~1
(PMI)~1
HDL(3)-cholesterol~1
HDL(3)-cholesterol,~2
apo-AII,~2
HDL-cholesterol):~1
HDL2-cholesterol,~1
PMI,~1
LVEF.(ABSTRACT~1
(t-PA~1
(PA-I~1
ml/25~1
dactinomycin)~1
PA-I.~1
coupled.(ABSTRACT~1
Valproate~1
non-tumourous~1
[20.2~2
(i.c.)]~1
[14.2~1
0.05)]~1
[13.9~1
0.05)].~1
(TTC:AM~1
13.9:14.2)~1
n.s.).~1
0.82x~1
13.33,~1
1.208x~1
3.01,~1
ionophoric~2
indium-binding~1
8-hydroxyquinoline,~1
acetylacetone,~1
nitrilotriacetic~2
[111In]ionophore~1
imbedded~1
liposome.~1
(IG)~1
apoA-I~3
A-IV,~2
apoE-enriched~1
HDL1~1
IV-~1
IG-fed~1
IG~1
canthaxanthin~5
canthaxanthin.~1
immunoenhancement~1
carotenoid~1
biphenyls~3
ODS-od/od~2
ODS-~1
(+/+~1
rat),~1
scurvy~2
PCB,~4
N-demethylase,~1
(DMBA)-induced~1
DMBA~21
116,~1
194,~1
162.~1
post-DMBA~1
DMBA-induced~11
0.2-~2
0.8-mA~2
phosphoryl-serine~1
(P-Ser)~1
0.2-mA~1
P-Ser~1
(ceftizoxime)~1
lowest-cost~1
(respired~1
monitor)~1
Capnography~1
respired~1
prong~1
PetCO2~7
apnea)~1
(LHRH;~1
micrograms/i.v.)~1
prealcohol~1
presucrose~1
mU/kg/min).~1
0.784,~1
(25-48%),~1
co-infusion~1
Ca-channels~1
(+)-[3H]PN~1
(Ptasienski~1
Biophys.~2
Commun.~1
129:~1
910-917,~1
Ca-channel,~1
Mg++,~1
[3H]Bay~3
[3H]PN~1
[3H]nitrendipine,~1
CGS-8216)~1
CGS-8216~1
15-1788-precipitated~2
claw,~1
hypertonus~1
piloerection.~1
benzodiazepine-overdosed~1
vasoconstriction)~2
attained).~2
8.7%,~2
Nitroglycerin,~2
adrenoreceptor-mediated~1
Pb-poisoned~1
(PMA)-stimulated~1
dismutase),~1
(catalase)~1
(dimethylthiourea),~1
nitrovasodilators~5
(WKYs)~1
WKYs.~1
Rubbed~1
(endothelium~1
denuded)~1
WKYs,~1
nitrovasodilators,~1
equipotently~1
BAY-K-8644~3
(+)-PN-205-033~1
kcal/kg/day)~1
(PBD)~3
PBD~4
BCAA-supplemented~1
(IV:~1
169%;~1
306%;~1
VI:~1
770%~1
leuprolide~7
Depot~1
(DRGs)~3
mispayment~1
disability).~1
DRGs,~5
DRGs.~4
DRG-based~2
these--warfarin~1
stockings--compared~1
halved,~2
fourths.~1
saving:~1
costs)~1
+19.40~1
+181.60~1
mg/mo,~1
(-12.0~1
[-0.30~1
causal)~1
Nutrition.~1
workshop,~1
essentiality~1
Keshan~1
guideline.~1
supplemented,~1
Wound-healing~1
(hydroxyproline)~1
(PT3),~1
(PT5).~1
protein-sparing~2
(307~1
(injury),~1
x-rayed~1
methyl-metacrylate,~1
"rubbery"~1
nonfistulous~1
(HPN)~1
(nothing-by-mouth)~1
nutritional,~1
HPN~3
(TPN)~21
(I:~3
BCAA)~1
14C-leucine,~1
gN/kg/48~1
TPN.~9
polyribosome~1
kcal/hr~1
mOsm/Kg~1
stooling.~1
hydrogen.~1
Al/liter),~1
(51-500~1
Al/liter)~1
Al/liter).~1
multitrace~1
Al/liter.~1
micrograms/l.(ABSTRACT~1
ml/hr).~1
intralipids~1
rats--one~1
(carbohydrate~2
group)--to~1
normocaloric~1
hypovolemic-traumatic~1
(PHL)~1
(DPPC--the~1
lecithins~1
DPPC)~1
PHL~1
ml/day~2
TPN,~2
(HDL).~2
Triglyceride,~1
enzymatically,~1
micromethod.~1
[13C]triolein~1
ratio-mass~1
fat/kg~4
(triglycerides:~1
hr/day.~1
discontinuous),~1
g/kg/24~1
(ENS)~2
nonteam~6
(NT).~2
Demographics,~1
(BEE),~1
ENS,~1
(pulmonary,~1
metabolic),~1
team-managed~3
695,~1
(CVCs)~2
CVC~13
5,422~1
4.65%~1
(20/166)~1
0.65%~1
(2/307)~1
CVCs,~1
9,200~1
14.5.~1
3.5%).~1
CVC-related~1
preteam~1
24.0%,~1
$3,700~1
$8,900~1
ingredients.~2
Nonlinear~1
acid-restricted~1
TNA~14
Droplet~1
Wretlind~1
emulsions,~3
emulsifying~1
worrisome.(ABSTRACT~1
6-yr,~1
liter/day)~1
FreAmine~4
elevated:~1
0.03-0.85).~1
(7.0).~1
(alpha-linolenic~1
lab.~1
0.05-0.4).~1
(unsupplemented~1
(net~3
alpha-linolenic~1
mg/12~3
off).~1
(87.1~1
.7~1
.3%)~1
(4623~1
2591~1
329).~1
-180~1
351/2~1
Inverted~1
around,~1
(4.8%).~2
semi-restraining~1
(Hu-IFN-gamma)~1
(ZR-75.1,~1
734-B,~1
BT-20),~1
(CCL-185),~1
(HEP-2).~1
Hu-IFN-gamma,~1
(ZR-75.1~1
734-B)~1
ZR-75.1~1
734-B~1
Hu-IFN-gamma~2
RA-resistant~1
BT-20~4
CCL-185~1
HEP-2~1
[(MM)~1
50-07-7;~1
ng/embryo]~2
aflatoxin~8
[(AFB1)~1
1162-65-8;~1
pyknosis,~1
AFB1~8
trout.~1
difluoromethylornithine~5
(DFMO),~2
DFMO,~1
2.50%~1
(AOM;~1
25843-45-2)~1
AOM,~1
(r-IFN-gamma~1
r-IFN-gamma~4
(nanograms)~1
background)~1
[(DMBA)~5
57-97-6]~3
16561-29-8]~1
N-nitroso-N-methylurea~1
[(NMU)~1
684-93-5;~1
microliter]~1
NMU~3
N-nitroso-N-ethylurea~1
[(NEU)~1
759-73-9;~1
each],~1
(250-~1
400-nm~1
J/m2.~1
DMBA-TPA,~1
NMU-TPA,~1
NEU-TPA,~1
NMU,~1
(PRCA)~1
(FeLV-C),~1
PRCA.~1
PRCA,~1
PRCA~5
Safari~1
PRCAs~1
(Glc-6-PD)~1
FeLV-C~1
Glc-6-PD~1
57-97-6],~1
DMBA),~1
(Mesocricetus~1
auratus)~1
times/week~1
DL-alpha-tocopherol~1
times/wk)~1
NA+,K+-ATPase~3
(rIL2)~3
rIL2-induced~4
58%)~1
"resting"~1
growth-hormone~1
(GH)-deficient~1
growth-hormone-releasing~1
(1-29)~2
NH2.~1
2.7-11.2~1
desensitisation~1
(0.3)%.~1
groups--15~1
40--before~1
perphenazine-stimulated~1
first-pregnancy~1
non-reciprocal~1
unidirectional;~1
(DR2)~1
T-cell-recognized~1
(Dw)~1
(Dw12~1
MN2).~1
DR2-Dw2~1
'blebbing'~1
low-light~1
blebbing,~1
'chemical~1
hypoxia'~1
bleb.~1
Sacramento,~2
DRGs~8
antineural~1
52,000-~2
70,000-dalton~2
70,000-~1
limb-muscles,~1
ragged-red~1
immunotitration~2
adult-onset,~1
encephalomyopathies.~1
glycogen;~1
(COX)~1
COX~1
hexamethylmelamine~3
ambulatory),~1
dominated,~1
1937.~1
regiments~1
Volkmann~1
haversian~2
canals,~1
GDP-bound~1
transducin,~3
5'-[gamma-thio]triphosphate-bound~1
Holotransducin~1
holotransducin~1
transducin~9
Ca2+/calmodulin-stimulated~1
cGMP-stimulated~1
dunce+~6
[Chen,~1
C.-N.,~1
Denome,~1
9313-9317;~1
Sass,~1
Field,~1
Nikawa,~1
Toda,~1
Wigler,~1
9303-9307]~1
270-residue~1
5'-~1
homologies,~1
seven-amino~1
c-Ki-ras,~1
Eip28/29~4
ecdysone-inducible~1
(EIP)~1
28III~2
EIP~4
29III.~1
Kc~1
ecdysone,~1
short-form~1
tetrapeptide.~1
29III,~1
spoVG~4
sporulation.~2
spo0~1
sigma-like~3
spo0A~2
spo0B~1
spo0H~1
anhydrases~1
metalloenzymes~1
CAIII~4
CAII~1
(IgH)~1
protoplast~1
S1-nuclease~1
ATGCAAAT.~1
octamer,~3
(Ser-247)~1
Ser-247~1
Thr-250,~1
T-lymphoid~1
transduction,~4
ester-mediated~1
molecule(s)~1
antigen-pulsed,~1
I-Ad-restricted,~1
3DO-54.8.~1
I-A-associated~1
3DO-54.8~1
pulsing.~1
keyhole-limpet-hemocyanin-specific~2
TH-cell~1
anti-IL-2-receptor~1
T-cell-B-cell~1
MLA~4
ape~3
75,000)~2
54,000-57,000)~1
Hut~2
I-induced~1
Anti-Tac~1
(complementary~1
gonadotropes)~1
photoaffinity-labeling~1
Ca2+-stimulated~1
chase,~3
cell-lineage~1
retrovirus-like~1
roo~1
transposon-mediated~1
Ly-1.~1
threonine-~1
beta-pleated~1
Leu-1.~1
cysteines.~1
plasmablasts~1
secreted/membrane-bound~2
FOS~3
U-937,~1
mono-oxygenase~1
(PAMase)~1
PAMase~5
Glu-His-Pro-Gly,~1
(unpublished~1
COOH-terminally~1
peptide(s)~2
pipettes~1
light-sensitive~4
Hyperpolarization~1
photoreceptor.~1
Dormant~1
thymine-containing~1
(rTNF-alpha)~2
rTNF-alpha,~3
rTNF-alpha~5
rTNF-alpha-mediated~1
MYC,~1
rTNF-alpha-treated~1
microtubule.~1
cross-bridge)~1
kinesin~7
self-consistency~1
ermC~9
subtilis.~2
promoter-proximal~1
ribosome-stalling~1
hisW~5
ilv~1
naladixic~1
acid-resistant~1
Multicopy~1
hisU1820~2
recF,~1
gyrB.~1
superhelicity~1
Pithing,~1
Harvey-ras~1
influence(s)~1
G-protein-regulated~1
(EJ-ras)~1
units/ml;~1
EJ-ras-transformed~1
inositolphospholipids~1
(MEA)~1
calcium-dependent.~1
Ca-cAMP~2
neuron,~3
MEA~5
Cu/histidine~3
(CuCl2~1
(Cu/PGE2),~1
(Cu/forskolin),~1
(Cu/cAMP).~1
pg/15~3
MEA,~2
Cu/PGE2,~1
Cu/forskolin,~1
Cu/cAMP~1
1.46,~1
Cu/histidine.~1
Cu/histidine-treated~1
preadult~2
spacer-length~2
(rDNA),~1
spacers,~1
bowing.~1
intervention--excision~1
epiphysiodesis~1
plate--might~1
glycosomes;~1
purines,~1
pyrimidines,~1
trypanonsome~1
intravenous-narcotic~1
flavus~1
literature),~1
Distinctive,~1
Listerial~1
pleuropulmonary;~1
intraabdominal.~1
Choong-Ku~1
Seoul~1
(PPNG)~1
(non-PPNG).~1
PPNG~2
agar-plate~1
rickettsii~2
recombinant-made~1
rickettsii.~4
EM24(pGAM21),~1
155-kilodalton~1
heat-sensitive~2
pUC8.~1
Gk;~1
"Catch"~1
angstrom~3
2-crystallin~3
-759~1
+45~1
atriopeptins,~3
atriopeptins~6
atriopeptin~21
Vinculin,~1
tsNY68,~1
transformation-sensitive~1
inactivators,~1
clorgyline~2
L-deprenyl,~1
[11C]clorgyline~1
L-[11C]deprenyl~1
(D-)~1
(L-)~1
deprenyl~3
B-rich~1
L-deprenyl.~1
L-deprenyl~4
L-[11C]deprenyl.~1
inactivators~1
sleep-deprived.~1
restoration;~1
fathered.~1
adenectomy,~1
(GCA).~1
Haptoglobin~1
normalised~1
(WM)~1
monozygosity~1
(erythrocyte~1
polymorphism).~1
WM~1
MPSs~3
Mucopolysaccharidoses~1
Hunter's~2
gene-therapy~1
MPSs.~1
(congenital~1
cardiomyopathy)~1
JET.~1
JET~1
remits,~1
PJRT~2
encainide~11
AET,~1
Flecainide,~1
use-dependency~1
Alpha-linolenic~1
20:3n-9~1
18:3n-3,~2
20:5n-3,~2
22:5n-3,~2
22:6n-3,~1
20:3n-9,~1
18:2n-6,~2
20:3n-6,~1
0.2-0.3%~1
0.1-0.2%,~1
BID,~1
(0730-2230~1
4-30%~1
10-44%~1
44-46%~1
40-64%,~1
82-96%~1
91-99%~1
Pepsin~2
[t(14;14)q12q32]~1
(AT).~1
J4~3
relation:~1
10(-7].~1
dioxide-change~1
200/mm3~1
800/mm3~1
reintroduced.~1
A)-driven~1
interleukin-I~1
(IL-I)~1
IL-I~1
Mo-T-cells~1
A-driven~1
Mo-IFN-alpha~1
Rho~1
Kell-sensitized~1
RH-sensitized~1
D-negative~2
D-positive~3
(85.2%)~1
(15.3%)~1
undertreated~1
$1755~1
gossypol-induced~1
(TM4)~1
TM4~3
gossypol/ml~1
fluorochrome,~1
gossypol-treated~1
Cristae~1
organelles'~1
matrixes~1
vacuole-like~1
bronchitis)~1
60,000-100,000~1
mucin-stimulating~1
Stimulatory~2
100,000-300,000~1
product(s)~1
incentive-based~1
contest;~1
in-between~1
cost-effectiveness;~1
fibulocollateral~1
sprain.~1
demographically.~1
nutrition;~1
Ranson's~2
(Na+,K+)-ATPase,~1
agitation-anxiety~1
(Na+,K+)-ATPase~2
"carbohydrate-deficient~1
transferrin"~1
isotransferrins~1
microcolumns~1
5.65,~1
nonalcohol-related~1
(inspired)~1
(NACS)~1
parturients.~1
chloroprocaine.~1
NACS~1
stable:~1
anhepatic~5
preanhepatic~1
(APc)~1
APc~1
criterion),~1
Frequency-dependent~1
(Vdss)~1
Vdss~1
(Vc),~1
(k31).~1
70-kg~1
0.356~1
7.77~2
allergists~1
eosinopenic~1
Alternate-day~1
Non-IgE~1
children?~1
older?~1
allergy?~1
others?~1
CO2-exposed~2
Distended~1
nonparenchyma~1
air-spaces~1
thinner,~1
cuboidal.~1
higher)~2
(Read's~1
variance),~1
(Seldane)~1
histamine-FEV1~1
Gamma,~1
cases/year)~1
choledochotomy,~1
Noncertified~1
hemicolectomy.~1
Stamm,~2
mucosal-lined,~1
Witzel.~2
jejunostomies~1
Roux-en-Y,~1
15/26~1
Witzel~1
jejunostomy.~1
16/19~1
Stamm~1
Karachi,~1
(acute-phase)~1
Burma~2
Nepal,~1
marmoset.~2
epidemic-type~1
Pakistan~1
presumed.~1
non-beta-lactamase-mediated~1
donor)~1
tetM,~1
transposon-borne~1
25.2-megadalton~1
24.5-megadalton~1
1,200-mg~3
(PCC118)~1
(PAO503).~2
lipopolysaccharide-side~1
bloc.~1
procurement.~1
omentum.~1
immunobiology~1
asbestos-exposure~1
96.1%~1
logs/g,~1
burn-wound~2
polysaccharide-~1
(biofilm-)mediated~1
(Pseudomonas~1
epidermidis)~1
self-protective~1
(soft)~1
(PPi)~1
(32Pi)~1
PPi.~1
(cartilage~1
fragments),~2
sneezes,~1
N-alpha-tosyl-L-arginine~1
(TAME-esterase)~1
cell-dominated~1
transient;~1
thalidomide~2
(HVEC)~1
HVEC~2
IXa,~1
CaCl2,~1
S-2222~1
Xa/min~1
12-minute~1
(VIIIt)~1
VIIIt~1
IXa-VIII~3
X-activating~1
Anti-VIII~1
anti-VIII~1
HVEC-bound~1
(PAI1)~1
(t-PA),~3
(PAI~1
prourokinase~1
PAIs,~1
monocytelike~1
(rIFN-gamma).~1
immunophagocytosis.~2
(CALU-3,ATCC,HTB-55)~1
IU/mL.~1
fibrin-specificity,~1
pre-incubation~3
scu-PA-32k~3
8,700~1
CALU-3~1
clot-selective~2
155,95)~1
Mo1.~2
(MPO,~1
(B12BP,~1
(gelatinase-containing~1
organelles)~1
(five-~1
eightfold)~1
B12BP.~1
up-modulation~1
gelatinase-containing~1
(INF-gamma)~1
INF-gamma~4
Detectable~1
cytofluorimetric~1
INF-gamma.~2
INF-gamma,~1
maximises~1
benefit-total-cost~1
profit,~1
layman~1
urinary-colonic~1
20.3).~1
hyperchloraemic~1
cmH2O;~2
unphysiological~1
(Ta,~1
(Epodyl,~1
non-tumour-bearing~1
(AGP:Palb)~1
(AGP:HS)~1
Zoladex,~2
8/65~1
nil~1
AGP:Palb~1
orchiopexy.~1
oligozoospermic,~1
Anti-sperm~1
antitestis~1
Testes~2
ng/l)~3
(1.2)~3
ng/l~2
haemarthrosis~1
12-88~1
12-96~1
1849~1
cryptorchidism.~1
1.58%.~1
0.96%.~1
micturating~1
83.~1
polytef~4
averts~1
748~1
troubled,~1
antigenaemia.~1
rheumatica.~2
(8.8%;~1
(17.7%;~1
2868~1
Scotland's~1
30-64~1
ovolactovegetarian~1
Indium-111-hydroxyquinoline~1
P256,~2
P256~4
aggregometry,~1
diethylenetriaminepenta-acetic~1
mCi)/mg.~1
vivo--that~1
P256--in~1
coughed.~1
(10/25)~1
0.46-0.48;~1
66%).~1
practised.~1
Baroreceptors~1
(88%);~1
dialysis)~2
40.5.~1
overstaffed,~1
understaffed.~1
plead~1
preregistration~2
gained.~1
stressful.~1
145,000~1
non-endoscopists~1
cigars,~2
pipes,~2
habit;~1
(years);~1
chewed,~1
snuffed;~1
Habits,~1
customs,~1
promotor(s)~1
Habits~1
$7.50~1
$42,507~1
4.5-month~1
non-cross~2
poor-prognosis~1
1-12+~1
(MMC-CH)~1
MMC-CH~3
MMC-solution.~1
(2.0-2.4~1
MMC)~1
intracavitarily.~1
dischargeable~1
(IVH).~1
Zubrod's~1
ECHO~3
(E:~1
VP-16-213;~1
C:~3
hydroxydaunorubicin;~1
O:~1
oncovin~1
[vincristine])~1
PRIME~1
(PR:~1
procarbazine;~1
ifosfamide;~1
ME:~1
methotrexate).~1
ECHO.~1
11.50~1
"cancer~1
family"~1
hrs)~1
(documented~1
(2/15)~1
(7/13;~1
(12/15~1
9/13~1
SD/chord~4
-2.1~1
only).(ABSTRACT~1
postpatellectomy~1
ossifications~1
(carboCT)~1
Sudeck's~2
CarboCT~2
cAMP/Cr~1
99mTC-MDP~1
carboCT~2
histomorphometrically~1
transiliac~1
(EHDP)~2
EHDP~2
Porous~1
olecranons~1
bone-porous~1
EHDP-treated~2
Mineralization~1
EHDP.~1
lyophylized~1
intradiscal,~1
intradural,~1
pulposis.~1
reinjections~1
realtime~1
echogenicity,~1
(IR-ANP)~2
1.3-3.7~1
litres~3
mmol/l:~1
IR-ANP~9
IR-ANP,~1
(IrANP),~1
mmol/day),~1
IrANP~6
five-fold,~1
(EPC).~1
Two-ml~1
(106%~1
.001]~1
fibrin),~1
(Paw).~1
(1715~1
1548~1
(182~1
m/m2.~1
electrolytes)~2
carbohydrate-based~2
fat-based~1
(FB;~1
Thermic~1
microgram/kg/hr)~2
(0.05,~1
microgram/kg/hr~1
(shown~1
appraised~2
45Ca2+.~1
calcium/mg~1
maitotoxin,~1
calcium-magnesium~1
orthovanadate,~1
(TGFs)~1
(TGFB)~1
inhibin.~2
TGFB~9
FSH;~2
(1.0-10.0~1
TGFB.~1
TGFB/inhibin~1
D-[5-3H]glucose.~1
(8-Br-cGMP)~1
monobutyryl~2
8-Br-cGMP~3
N-acetylglucosamine.~1
(8-Br-cAMP)~1
8-Br-cGMP,~2
8-Br-cAMP,~3
N-Methyl-N'-nitro-N-nitrosoguanidine,~1
8-Br-5'-GMP~1
8-bromoinosine~1
8-bromoguanosine~1
Glucose-stimulated~1
2-ketoisocaproic~1
8-Br-cGMP.~1
pg/hypothalamus)~1
30-65~1
pg/hypothalamus~2
18-20.~1
0-20~1
50-90.~1
900-1300~1
90-day-old~1
(75-85%)~1
folliculo-stellate~1
Coaggregating~1
redissociated~1
Gln8-GnRH,~1
W-7~3
[N-(6-aminohexyl)5-chloro-1-napthalenesulfonamide]~1
[hpGHRH-(1-44)]~1
Leu27,Gly45-GHRH~1
[GHRH-(1-45)]~1
A1-13-like~1
(Dyn~2
A1-13-IR)~1
hpGHRH-(1-44)~4
Dyn~12
A1-13-IR~9
hpGHRH-(1-44)-induced~1
A1-13-IR.~2
D-pGlu1,~1
D-Phe2,D-Trp3,6-LHRH~1
A1-13-IR,~1
hpGHRH-(1-44),~1
hpGHRH-(1-44).~1
D-Ala6,~1
des-Gly10-LHRH~1
(LHRH-A).~1
[125I]iodo-LHRH-A~1
GHRH-(1-45).~1
GHRH-induced~3
(hyperPRL)~1
hypoprolactinemia~1
(hypoPRL)~1
(CB-154;~1
oil/rat~1
(TP;~1
oil/rat)~1
hypoPRL~2
hyperPRL~2
pituitary-grafted~1
(15K~1
ANP),~1
3K~5
atrial-derived~1
pro-ANP;~1
ANP-(1-126).~2
ANP-(1-126)~2
ANP-related~1
ANP-(99-126);~1
ANP-(99-126)~1
ANP-(92-126)~1
substrate;~1
ANP-(99-126).~1
ANP-like~1
D-Phe-Phe-Arg-Chloromethylketone~1
(D-Phe-Phe-Arg-CMK)~1
D-Phe-Pro-Arg-CMK~1
intracellularly)~1
ANP-processing~1
CMK~1
(GRF)-stimulated~1
GRF-stimulated~4
(5-HT;~1
L-aromatic~2
L-5-hydroxy-tryptophan(L-5-HTP;~1
L-dihydroxyphenylalanine;~1
D,L-o-tyrosine~1
D,L-m-tyrosine~1
benserazide~1
alpha-monofluoromethyldopa~1
GRF-induced~1
Hypothalmic~1
GH-~2
0.1-microM~1
Soay~1
rams~4
photoperiods.~1
(February-May;~1
(July-October).~1
16L:8D)~1
(8L:16D).~1
beta-lipotropin.~1
photoperiod-induced~2
photoperiod.~1
ram.~1
photoperiods,~1
(E2-cells)~1
(PMS-cells)~1
microtubule-tubulin~1
PMS-cells~1
alpha-hydroxypregn-4-en-3-one~1
PMS-cells.~2
E2-cells~1
E2-~1
PMS-cells,~1
LH-induced~2
12,13-didecanoate,~2
Hormone-stimulated~1
hormonogenesis~1
extrahematopoietic~1
250-g~1
(EB;~1
(1-44)~1
(GRF;~1
-0.53;~1
microgram;~1
0.82;~2
secretary~1
110-115,~1
125-130,~2
135-140~1
110-115~4
135-140.~1
(preinjection)~1
125-130~1
135-140,~1
110-140~1
cortisone,~1
diethylstilbestrol-implanted~4
25-40%~1
cAMP-inducing~2
choleragen.~1
12-O-tetradecanoyl-phorbol~2
8-bromo-cAMP.~1
TSH-,~2
(NE)-,~1
(I-)~1
melittin.~1
5,8,11,14-eicosatetraynoic~2
P450-linked~1
epoxygenase~2
piperonyl~2
butoxide~1
2-diethylaminoethyl-2,2-diphenyl~1
valerate,~1
NE-,~1
butoxide.~1
His-ProNH2~1
(TRH~1
PAPase).~1
PAPase~10
PAPase.~2
(-D)~1
(+D)~1
Stern~1
EDTA-containing~1
Harrison~1
Webster.~1
Basolateral~1
(BLMV)~1
Ca2+-transport~1
BLMV~3
-D~3
+D~3
Ca2+/min~1
resealing~1
villus-crypt~2
(GRF),~2
(outer~1
adenohypophyses~1
(conducted~1
GRF)~1
DA).~1
(classical~1
mammotropes)~1
(mammosomatotropes)~1
mammotropes~1
mammosomatotropes~1
dictate,~1
histidyl-proline~1
[C(HP)]~1
C(HP)~5
Veratridine,~1
scrota~1
(FSH:~2
-0.502,~1
-0.533,~1
-0.669,~1
-0.420,~1
glyburide~18
glucosuria,~1
U/day),~2
oxidative,~1
0.4%)~1
(basal:~1
.65,~1
.08;~1
stimulated:~1
glucose-utilizing~1
thioglucose~3
(GTG).~1
[1-14C]2-deoxyglucose~2
GTG-obese~4
(demonstrated~1
ED50),~1
whole-animal~1
(hpGHRH~1
1-44)~1
fundoscopy~1
hpGHRH~4
1-44,~1
glyburide.~1
-.76,~1
polyols~3
DL-glyceraldehyde~1
D-fructose~1
galactitol~1
128436.~1
(B1F6~2
culture-maintained~1
nonimmunosuppressed~2
beagles.(ABSTRACT~1
neoislets,~1
neoislets~3
(Lewis~1
ACI).~1
rotation-mediated~1
alloimmunisation~1
fibrocytic~1
(HBeAg/1~1
HBeAg/2)~1
HBeAg/1~2
HBeAg/2~2
HBeAg/2,~2
HBeAg/2;~1
HBeAg/2.~1
phage-derived~1
$160~1
$48~1
$64~1
($390-$1013~1
$800-$1829),~1
(3.4-4.7~1
1.5-2.1~1
3.0-4.4~1
1.9-2.9~1
254-309~1
397-3478).(ABSTRACT~1
added),~1
PM's,~1
PM's~3
interspike~2
PM's.~2
(LRH)-stimulated~1
60-180~1
LRH-stimulated~1
beta-LPH,~1
(YN),~1
[chronic~1
predicted].~1
(caudad)~1
EN~11
YN.~1
RA's~1
overstretching,~1
alkalosis;~1
control-~1
3-micrograms~1
dopamine;~1
56:~1
338-342,~1
(nondependent)~1
37-42~1
%QCO~1
0.25);~1
(VT/TI)~1
(5.9-6.0%)~1
Constant-flow~1
(CFV)~3
53:~1
483-489,~1
1982).~1
High-velocity~1
CFV~7
carina).~1
normocapnia;~1
(AO).~1
CFV;~1
[Na+],~1
CO2-12%~1
O2-83%~1
PO2;~1
(strong~2
citrate3-).~1
hyperalbuminemia~1
Scheuermann~2
kyphosis;~2
trypan-blue~1
3H-cytidine.~1
viscometry~1
twenty-millimolar~1
pepstatin,~1
aminophenyl~2
diphosphate-glucuronosyltransferase~1
(UDPGT;~1
2.4.1.17)~1
UDPGT~6
(RHA)~4
(elution~5
7.5)~1
4'-hydroxydimethylaminoazobenzene.~1
53,000),~1
UDPGT-specific~1
8.7)~1
4-nitrophenol.~1
8.4),~1
8.0),~1
Isoform~1
galactose-enriched~3
milieu);~1
reductase-linked~1
permeability)~2
(crosslinking)~1
mucopolysaccharidosis~3
Hurler/Scheie~1
alpha-L-iduronidase~1
0.8-7.4,~1
26-45,~1
6.3-14.9%~1
iduronidase~1
nontransplanted,~1
(NADH-ubiquinone~1
oxidoreductase)~1
characterizations.~1
ferricyanide~1
NADH-ferricyanide~3
iron-protein~2
13-kD~1
6,7-dimethoxy-4-ethyl-3-carbomethoxy-beta-carboline~1
(DMCM)~2
(LD94)~1
DMCM~9
(1.5-5~1
(CD50)~1
ethyl-8-fluoro-5,6-dihydro-5-methyl-6-oxo-~1
4H-imidazo[1,5a][1,4]benzodiazodiazepine-3-carboxylate~1
15-1788),~2
Trimetrexate,~2
trimetrexate~11
600-fold~1
(amount~1
trimetrexate,~1
leucovorin,~1
gondii-infected~1
(35-fold)~1
(20-fold).~1
IMCD,~1
(PCT),~2
cross-hybridizes~2
(nonproducing)~1
collagenolysis~1
Delipidated~1
(Apo)~1
Na-K-ATPase~18
spironolactone;~1
compounds--including~1
hemoglobins--catalyze~1
hemoglobin-mediated~1
Na/K~1
septicaemic.~2
cell--derived~1
procoagulant,~1
antigen/procoagulant~1
(3,600~1
rads;~1
MeV),~1
(doxorubicin,~1
Gehan~1
"complete~1
remission,"~1
parapsoriasis~1
earlobes~1
pierced-type~2
earrings.~1
lymphocytoma~1
Immunohistologically,~1
lymphoplasia~1
Recklinghausen~5
tissue-plasminogen~1
(unstable~1
flecainide-treated~1
Nitrate~2
nitrate-sensitive~1
nitroglycerin.(ABSTRACT~1
inhaler,~1
(cr)~1
Spinhaler,~2
cr~3
pl.~1
MHC-unrestricted~3
separable,~1
MHC-antigen~1
(anti-T3~1
anti-Ti)~1
anti-T3.~2
REX~4
anti-Ti.~2
T3.N1,~1
anti-T3-resistant~1
T3.N1~3
T3/Ti~5
(rIFN-gamma),~1
granulocyte/macrophage-colony~1
(rGM-CSF),~1
(rTNF),~1
(Ab-CMC)~1
rGM-CSF,~1
rTNF,~2
Ab-CMC~1
non-adaptive~1
(IFN)-gamma.~1
(PWM)-driven~1
(BCDF)-like~1
PWM-driven~3
PWM-MNC~1
BCDF.~1
125I-recombinant~1
(125I-rHuIFN-gamma)~1
125I-rHuIFN-gamma~2
rHuIFN-gamma~1
rHuIFN-alpha~1
rHuIFN-beta.~1
HuIFN-alpha~1
125I-rHuIFN-alpha~1
Anti-isotypic~1
leukemias:~1
JA3,~2
JM),~1
JM).~1
NP-40~1
TcR/CD3~2
HPB-ALL~2
1C9~1
J5.~1
C9:C5b-8~6
(BLA),~1
(J5-Amp).~1
(C9:C5b-8~1
28,900)~1
J5-Amp~1
310,~1
560,~1
890~2
C5b-9/organism.~1
Curves~1
superimposable.~1
86Rb,~1
505,000)~1
11:1,~1
BLA.~1
disperses~1
pg/cell.~1
Anti-IgE~1
poly-L-lysine.~1
eledoisin~1
physalaemin~1
indomethacin-sensitive~3
indomethacin-reversible~1
Kala-azar~1
Leu-2+-depleted~1
Bihar,~1
Kala-azar,~1
Bihar~1
Kala-azar-resistant~1
kappa-GAT-specific~1
Ab1'~3
network:~1
Ag----Ab1----Ab2----Ab3~1
(Ab1').~1
K1A5~2
K5.1~2
(anti-idiotypic)~1
kappa-1~1
TEPC~1
467,~1
kappa-1A~1
kappa-1C~1
anti-GAT,~1
anti-DNP,~1
anti-flagellin,~1
anti-phosphorylcholine,~1
anti-digoxin,~1
anti-phenyloxazolone,~1
anti-DNA.~1
(17.109)~1
kappa-variable~1
WI-L2-729-HF2,~1
17.109~5
CRI-positive~3
Humkv305,~1
CRI.~1
Humkv305~2
Monocyte-mediated~1
(HC~1
32.2)~1
FcR.~2
32.2.~1
phi-CF)~1
phi-CF~3
Tumor-infiltrating~1
95,652-fold~1
Leu-4+~1
Leu-3+.~1
melanoma-bearing~1
Pgp-1-~5
Pgp-1+~6
(CTLp).~1
H-Y-specific~1
CTLp.~1
CTL-TC~1
I-dependent~1
papain-sensitive~2
LDCC~1
ODCC.~1
carbohydrate-less~1
carbohydrate-less,~1
PVP-coupled~1
(PVP-HRBC)~1
TH1~7
TH2~6
PVP-HRBC~1
(xid~1
mice).~1
I-J-surface~1
anti-PVP~1
anti-mu-treated~1
cell-deprived~3
CD5+~6
CD5-~6
(E:T)~2
unsorted~3
(LAK~1
precursors),~1
E:T~4
CD8-~2
(HNK-1)~1
Leu-7-CD5+~1
Leu-7-~1
(CD5-~1
CD16+)~1
(CD5+~1
Leu-7+).~1
Ig-,~2
(MTG)~1
A7~2
trinitrophenyl-keyhole~1
trinitrophenyl-MTG~1
anti-MTG~1
trinitrophenyl-MTG.~1
MTG,~1
Thy.~1
Thy+~1
L-tyrosine-p-azobenzenearsonate~1
apcs,~1
"degenerate"~1
(syngeneic),~1
Ed~2
LK35.2~1
[3H]arachidonic~5
feed-back~2
productions.~1
isobutyl-3-methyl-1-xanthine,~1
PGE1-induced~4
BW755C,~1
nordihydroguiaretic~1
KJ16-133,~1
F23.1.~1
KJ16-133~1
F23.1,~2
coupled-Sepharose~1
interferon-gamma;~1
Leishmania-sensitized~1
Leishmania-infected~1
antileishmanial~5
anti-IFN-gamma~10
(TcR)-CD3~1
(CD1-/CD3-),~1
(CD1+/CD3-or+),~1
(CD1-/CD3+).~1
prothymocyte~1
(TdT+/HLA-DR+/CD7+/CD2+/CD5-/CD1-/CD3-),~1
(TdT+/HLA-DR-/CD7+/CD2+/CD5+/CD1-/CD3-).~1
CD3-delta~2
CD3-epsilon~2
CD3-~7
prothymocytic~3
TcR-beta~7
TcR-gamma~6
rearranged.~1
TcR-alpha~2
prothymocytes.~1
beta-CD3~1
autoimmune-like~1
297-bp~1
IFN-gamma-inducible~1
anti-5-dimethylaminonaphthalene-1-sulfonyl~1
(anti-Dns)~1
rear-ranged~1
noncoded~1
VH-D~1
D-JH~1
anti-Dns~1
CDR3~1
(LAK).~1
Leu-11-~6
FACS-sorted~1
experiments),~1
(CD3)-,~1
T40~1
(CD7)~2
Cytolysis~4
(C3)~1
parvum-activated~2
Cell-bound~1
phi-mediated~2
target-bound~1
465.12S~1
(HMW-MAA).~1
-DQ,~4
96-kDa~2
CL203.~1
influenza-specific~4
picamolar~1
(Tp103)~1
Tp103~5
Tp103-positive~1
anti-Tp103.~1
"interaction"~1
multimolecular~1
(B6~2
bm12)F1~1
(GVH).~1
anti-B6-TNP)~1
(anti-allo~1
(LA-IL~1
2R).~1
L-14,~1
(HA-IL~1
LA-IL~6
L-14~1
HA-IL~2
2R:~1
(L-14,~1
C30.1)~1
sn-1,2-diacylglycerol~1
N-formyl-Met-Leu-Phe~2
pmol/10(7)~1
N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys~1
t-Boc-Phe-Leu-Phe-Leu-Phe,~1
N-formyl-Met-Leu-Phe-induced~1
(450%~1
plasma/Percoll~1
(5S,12R)-dihydroxy-(6Z,~1
8E,~1
10E,~1
14Z)-eicosatetraenoic~1
(LTB4]~1
(5S)-hydroxy-(6E,~1
8Z,~1
11Z,~1
14Z)~1
HETE),~1
5-HETE,~2
(A23187)-stimulated~2
chromatography-negative~1
C14:0~1
C19:0~1
C16:0,~2
C18:1,~2
C18:0.~2
A23187-stimulated~7
C17:0,~1
1-O-alkyl-2-acyl-glycero-3-phosphocholine~1
hexadecyl~1
(C16:0)~1
1-O-alkyl-2-acyl-glycero-3-phosphocholine.~1
anti-egg~1
E.1,~1
miracidia.~1
E.1~5
Schistosoma.~1
(cercariae)~1
filtration)~1
(isoelectric~1
focusing);~1
Kd;~1
supernatant-containing~1
VK~4
VHT15~1
VK21~1
D-E~2
VHT15-VK21~1
establish,~1
VH-VL~2
"allelic"~1
phenyloxazolone~2
(BALB/c,~1
C57BL-Igha,~2
DBA2,~1
(RF~1
selection.)~1
VKOx1~2
(H3)~1
non-mutated~1
(VKOx2).~1
CDR1~3
(94.5%~1
CDR3.~1
(VKOx1~1
VKOx2~1
J5).~1
VK-JK~1
joining.~1
incited~1
CD3+4-8-clones~1
NK-susceptible~2
-nonsusceptible~1
CD3-NK~1
CD3+4+~4
CD3+4-8-clones.~1
CD3+4-8-~5
anti-CD16~5
CD3+4-8-16+~1
CD3+/Ti~1
WT31~3
sulfonic~1
(TNBS).~1
2-bearing~1
TNBS-self,~1
(AGM1)-bearing~1
(Fxn)~1
Fxn~5
LAK,~1
AGM1+,~1
AGM1+.~1
TNBS-self~1
AGM1+~1
tissue-protective~1
NBR~1
hydroxyeicosatetraenoic~1
A23187;~2
melittin;~1
12-O-tetradecanoylphorbol-13-acetate;~1
1-oleoyl-2-acetyl~1
deesterification~1
polyphosphoinositol~1
(ELDIF),~1
ELDIF~1
(ETAF),~1
(thymulin,~1
thymopoietin,~1
(IL)-1,~2
ELDIF,~1
L-Serine~1
dish~2
L-[3H]serine~1
(Ptd)~1
Ptd~9
choline.~1
ethanolamine;~1
serine-supplemented~1
ethanolamine.~1
Glycosaminoglycan~1
[35S]sulfate,~3
trypsin-accessible~1
deaminative~1
N-sulfated~1
marrow-derived,~1
ATPase+~1
7/40~1
AIDS),~1
p17.~1
p17+~1
LC-associated~1
1:8-1:512~1
1:128).~1
Antifungal~1
1:8,~1
1:16.~2
nephropathia~1
epidemica~1
Puumala~4
vole~2
most-abundant~1
rodent,~1
(W-135)~1
(B:2b)~1
B:2b~1
C:2a~1
W:2a~1
("early")~1
("late")~1
(hMG)/hCG~1
201-400,~1
11-12)~1
15.6,~1
34.5,~1
68.0%,~1
L-forms~2
L-form~2
recirculation,~1
reappear,~1
reversible)~1
post-ischaemic~1
[NSCLC];~1
counselled~2
("standard"~1
(TCI)~1
triazinate.~1
(42.9%).~1
(47.1%;~1
(36.4%;~1
bialkylator~1
(ABMR).~1
Fibonacci~1
platelets/microL~1
nausea/vomiting,~1
(MTD)~1
RG-C6~1
(EB,~1
68,000),~1
(HRP,~1
40,000),~1
(5-FU,~1
fluor-impregnated~1
scintillator~1
70-88%.~1
count-rates.~1
count-rate~1
radiometry~1
[111In]chelates~2
[111In]tropolone~2
[111In]mercaptopyridine-N-oxide.~1
[111In]oxine~4
Powell~1
15O-CO2~4
mCi/liter.~1
15O-O2.~1
14-38~1
Bigler~1
Estimate~1
2-3%~1
mmol/L(P~1
232)~1
NADH-coenzyme~1
NADH-coQ~1
hypotonia;~1
(1-14C)pyruvate,~1
(U-14C)malate,~1
(1-14C)2-ketoglutarate~1
Rotenone-sensitive~1
NADH-CoQ~2
first-part~1
(FPU)~1
FPU~3
FPU.~1
(ADO)~1
vasconstrictor~1
ADO,~2
ADO~3
ADO.~2
nitroglycerine,~1
hydralize~1
(2-chloroadenosine)~1
1248~1
alpha-glycosidase~1
alpha-disaccharidases~1
(C57BLKsJ~1
db/db)~1
food).~1
thirds)~1
(1-beta-D-ribofuranosyl-1,2-4-triazole-3-carboxamide)~1
nonimmunoglobulin~3
E-related~1
narcotic-induced~1
89).~1
KT-362~1
(KT;~1
10(-9)-10(-5)~1
(10-70~1
KT~5
K+-depolarized~1
pre-equilibrated~1
caffeine-induced~2
Ca+-free~1
contraction.(ABSTRACT~1
(6-OHDA)-lesioned~1
SKF-38393,~1
D1-dopamine~1
6-OHDA~1
LY-171555,~1
D2-agonist,~1
SKF-38393~5
LY-171555~3
adult-6-OHDA-lesioned~3
LY-171555.~1
Stereotypic~1
6-OHDA-lesioned~3
(D2-receptor~1
ligand)~2
[3H]SCH~2
(D1-receptor~1
D1-~1
adult-6-OHDA-treated~1
Amphetamine,~1
Amphetamine~3
Interneuronal~1
Ca++-releasable~1
(Na+,K+)-adenosine~2
K+-insensitive~1
phosphorylenzyme~1
[isosorbide~1
5-ISMN]~1
EC-induced~1
aggregation;~1
EC-platelet~1
5.10(-5)~1
2.10(4)~1
6-keto-PGF2~1
Aspirin-treated,~1
PG-accumulation~1
(ISDN-stimulated)~1
95191~20
[3-(2-morpholino-ethyl-amino)-4-cyano-6-phenyl-pyridazine],~1
(MAO).~1
(MAOI).~2
MAOIs~1
moclobemide,~3
clorgyline,~2
pargyline~1
l-deprenyl,~2
indalpine~1
DAergic~2
haloperidol-induced~1
catalepsy~1
95191,~1
MAOIs,~2
beta-phenethylamine-induced~1
3-hydroxy-4-methyl-alpha-phenylethylamine-induced~1
[3-(2-morpholino-ethyl-amino)-4-cyano-6-phenylpyridazine]~1
harmaline,~2
moclobemide~1
cimoxatone.~1
cimoxatone,~1
moclobemide.~1
cimoxatone~1
clorgyline.~1
l-alanine~2
(l-ALA),~1
hypotaurine~5
beta-ALA~2
cardioaccelerans~1
frequency-response~1
(0.1-12.8~1
l-ALA~3
L-ALA~2
[3H]NE,~1
l-ALA.~1
l-ALA,~1
alpha-(methylamino)-isobutyric~1
Hz.(ABSTRACT~1
(0.3-3~1
T6-T7~1
Guanabenz~1
azepine~1
imidazolidine~1
hypotenion~1
postsynaptically~1
(1.25-5~1
flushers~1
superposable.~1
phosphate/mole~1
(0-0.025~1
CaCl2)~1
atropine)~1
entry.(ABSTRACT~1
2-p-chlorophenylpyrazolo[4,3-c]quinolin-3(5H)-one~1
9896)~1
zopiclone~2
(punished)~2
response-produced~2
timeout~1
(0.03-0.3~3
zopiclone.~2
zopiclone,~2
rate-increasing~2
1-Methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine~1
(2-MTTP)~1
1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine~2
(monoamine~1
2-MTTP~7
(MAO~2
1-methyl-4-(3-thienyl)-1,2,3,6-tetrahydropyridine,~1
MPTP;~2
2-MTTP.~1
deprenyl,~1
MAO-B,~3
EXP~5
561,~1
oxidizes~1
MPTP.(ABSTRACT~1
(6-HDA)~1
6-HDA~3
(0.25-8.0~1
6-HDA.~2
6-HDA-treated~2
venoconstriction~1
93423~3
(6-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic~1
91296~6
(5-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylic~1
suriclone~3
(0.003-0.03~1
93423,~1
91296,~2
15-1788.~4
"inverse~1
agonists"~1
(agonist)~1
schedule-controlled~1
(CNZ)~1
(LRZ)~1
CNZ~4
LRZ~2
LRZ.~2
LRZ,~1
pmol/g.~1
rotarod~1
celiac,~1
(P1).~1
(S1).~1
[3H]BK~1
guanyl-5'-yl-imidodiphosphate~2
BK-stimulated~1
5'-(3-O-thio)triphosphate-stimulated~1
(pp)~1
(pv)~1
digitonin-collagenase~1
pv~6
(pp/pv~1
(1.3),~1
(0.73)~1
(0.81).~1
7-ethoxycoumarin~2
O-deethylase,~1
7-ethoxyresorufin~2
O-deethylase~3
benzo(a)pyrene~2
UDP-glucuronosyltransferase~2
pv-region~1
panacinarily,~1
exaggerating~1
Gi)~1
Forskolin-stimulated~1
[32P]ADP-ribosylated~1
identical.(ABSTRACT~1
Hexoprenaline,~1
2-sympathomimetic~1
7.20.~1
7.5-~1
hexoprenaline~1
gold-standard~1
pharmacoangiography~1
Unscheduled~1
(TGr~1
I-III).~1
arginine-free~1
N-methyl-N-nitroso-N'-nitroguanidine~1
procarcinogen~1
4-nitroquinoline-1-oxide~1
(4-NQO;~1
56-57-5).~1
50-32-8),~1
4-NQO,~1
TGr.~1
(AFB1)~3
235,~2
micrograms/kg/day~2
(GGT+)~2
foci-development~2
235-,~1
270-,~1
300-,~1
350-micrograms/kg/day~1
AFB1/kg/day~1
GGT+~6
(GGT+~1
foci)~1
levamisole.~1
antialgic~1
16.3%.~1
bicarbonate-based~1
tromethamine-based~1
protein-type~1
(Bretschneider)~1
flunisolide,~1
insubstantial.~1
no-fault~1
foreseeable~1
light-chain-isotype~1
(LCIS)~1
LCIS~3
LCIS.~1
(LTs)~1
polypectomies~1
tissue-homogenates~1
14C-arachidonic~1
(Tx)B2,~1
(HETE),~1
15-HETE.~1
15-HETE,~1
R3230AC~1
18-21~1
handpiece,~1
25W~1
wave).~1
14/15~1
(93.4%)~1
5/15~1
3/15~1
otolaryngologist/head~1
555-3,333~1
lasing.~1
IVa,~1
IVb~1
1,667~1
dark-colored~1
2,222~1
Channels~1
Industries~1
evaporization,~1
(followup~1
scalpel,~1
ductule~1
plasma-volume~1
(sodium-potassium-ATPase)~1
0.38)~1
(0.18~1
sodium-potassium-ATPase~3
(38.1~1
(18.4~1
"sorbitol-myo-inositol~1
hypothesis"~1
which--the~1
inhibitors--has~1
lighten~1
(IAP)~4
K+-currents~1
nonhydrolysable~1
GTP)~1
ACh-induced~1
K+-current~1
slug~1
(HA)-induced~1
(DA)-induced~1
K+-currents.~1
K+-channels;~1
activations~1
'T-lymphocytotrophic~1
hormone'~1
'modules'~1
stage-specific,~1
(DSE)~1
(sn)RNA~1
Subunits~1
muscarinic-gated~1
(RGD)~1
cell-extracellular~1
RGD-sequence~3
discoidin~1
RGD-recognition~1
gastrulation~1
dorsal-group~1
cell-attachment~1
odorant~1
odorant-stimulated~2
GMP-gated~1
adenylyl~5
Gi,~4
(G-protein).~1
Go,~2
gamma-subunits;~1
G-protein.~2
ganglia;~1
D-Ala2,~1
D-Leu5-enkephalin~1
(DADLE)~1
Go.~1
diplococcus~1
IgA1.~1
MS11~2
106K)~1
169K~1
'helper'~1
(excretion).~1
proform~2
autoproteolysis.~1
matures~2
alpha-protein.~1
20K)~1
interleukin-4~1
125I-labelled-BSF-1~1
80,000.~1
26K)~1
non-N-glycosylated~1
19K~1
Ti-associated~1
immune-precipitated~1
calcium/phospholipid-dependent~2
(PK-C)~2
Gs~8
Gp.~2
aqueduct.~2
Aqueductal~1
collagenase-producing~1
(bursting~1
load),~1
amniochorion~1
noncollagenase-producing~1
[3H]telopeptide-free~1
(18-35~1
U/dL;~2
30C).~1
(37-42~1
U/dL.~1
(24-36~1
fetoscopically~1
isoimmunized~4
venous.~1
(IgG),~1
mucopolysaccharidoses~1
fibrillo-granular~1
subcellular,~1
3-21)~1
(MPS)~1
MPS,~1
degenerations,~1
rod-mediated~1
(ETDRS)~1
reproducibility;~1
ETDRS~2
(WESDR).~1
stereoscopic~1
Airlie~1
grader~3
regraded~1
49.3%~1
15.0%~1
78.5%;~1
90.0%~1
graders,~1
xanthelasma-like~1
2,693~1
Park,~1
Lys-1030,~1
antibody-stimulated~1
light-modulated~1
5'-GMP,~1
5'-AMP.~1
half-saturating~1
Sodium,~1
cesium,~1
cGMP;~1
current-carrying~1
channel-like~1
pero1~3
pers~6
melanogaster,~2
clocks~1
subsegment~1
4.5-kilobase~1
serine-to-asparagine~1
anti-VIII:C~10
(anti-hemophilic~1
VIII:C~9
prerecovery~6
postrecovery~5
Anti-VIII:C~1
(IVIg).~1
IVIg,~2
IVIg.~1
Insolubilized~1
Effective,~1
Officials~1
officials)~1
underreported)~1
(HMSAs).~1
HMSAs~2
HMSA~1
gingivitis,~1
health-endangering~2
noise)~1
impairment).~1
managers,~1
firefighters,~1
fishing~1
worksite.~1
Survey's~1
lot"~2
"almost~1
no"~1
estimates--ranging~1
high--of~1
1991,~1
(CDC).~1
$1.1~1
$8.5~1
1991.~6
Nonpersonal~1
services)~1
$319~1
$542~1
$2.3~1
$3.9~1
$7.0~1
$55.6~1
educated.~1
knowledgeable.~1
population's~1
miscarriage,~3
66-80~1
definitions.(ABSTRACT~1
three-component,~1
program--sex~1
involvement--is~1
sponsor~1
fairs~1
instructors,~1
(OTC)~1
polymedicating~1
drugstores~1
barcode-based~1
discounts~1
375)~2
barcoded~1
(BID)~1
"dummy"~1
BID~2
purchases.~1
campaign,~1
week-long~1
eighth,~1
Willows,~1
television,~1
posters,~1
magnet,~1
meningoceles,~1
neurofibrosarcoma,~1
Isochromosomal,~1
respiratory-deficient~2
mit-,~1
hypersuppressive~1
petite,~1
petite~1
Subtractive~1
nuclear-encoded~3
respiratory-competent~1
RNA's,~1
intergenomic~1
on;~1
Lysosphingolipids~2
sn-1,2-diacylglycerol,~1
lysosphingolipids~3
sn-1,2-diacylglycerol.~1
Krabbe's~1
sphingolipidoses,~1
lysosphingolipid~1
sphingolipids~1
unify~2
4-VPA.~3
hemoprotein,~1
5-hydroxyvalproic~1
Desaturation~1
(olefin~1
olefins~1
synoviocyte~2
neuropeptide.~2
Synoviocytes~1
hypersomnolence,~1
orthopnea,~1
rehabilitating~2
(EtCO2)~1
tourniquet,~1
EtCO2~3
NBIE,~1
burn-care~1
Participating~1
94,594~1
13,671~1
80,923~1
INQUIRE,~1
institution-specific~1
HCFA~1
NBIE~2
Injudicious~1
effects--either~1
Multiagent~1
autografting,~1
(EGI)~1
(AGI)~1
AGI~6
EGI~3
mumol/kg/min~4
mumol/kg/min,~3
0.7%,~1
32.8%~1
host-regulatory~1
Constrictor~1
Kreb's~1
(GM1~1
AGF2)~1
(cortex~1
hippocampus)~1
K-ATPase~7
ganglioside-treated~1
"protecting"~1
(TBHP).~1
TBHP~2
SQ-29548.~1
thromboxane-mediated~3
TBHP,~2
gamma-globulin,~1
anticoagulant-associated~1
preponderance,~1
fugax)~1
noncerebral~1
erythematosus)~1
coexisting.~1
22,346~1
cutoff-to-sample~1
2877~1
(IVIG),~1
IVIG.~2
DATs~1
anti-A,~2
-K.~2
Skeleton-free~1
immunospecifically~1
anti-D.~4
Anti-D~2
mole-1)~1
Cx-positive~1
Somalis.~1
Cx~2
es,~1
(ce)~1
edict~1
remuneration~1
Zoladex~13
118,630)~1
sustained-release,~1
once-monthly~1
dose-modification~1
diverticula.~4
subtrigonal~1
marsupializing~1
99mTc-pyrophosphate~1
(PYP)~1
99mTc-PYP~3
maitotoxin~1
nifedipine);~1
trifluoperazine.~2
cholinergic-induced~1
Cytosolic-free~1
Fura-2/AM~1
2/AM.~1
'0'~1
Ca++/EGTA.~1
rings.(ABSTRACT~1
K+),~1
(WKYs).~1
WKYs;~1
WKYs).~1
receptor-activated~1
[isradipine])~1
200-110.~2
162/103~1
144/88~1
(isradipine),~3
placebo-washout~1
controlled;~1
81%),~1
15/13~1
18/20~1
(collagen,~1
Antiatherogenic~1
vivo:~1
P-Q~1
might.~1
after-load-reducing~1
Antiarteriosclerotic~1
Cardiodepressant~1
conductance)~1
gauge).~1
cardiodepression.~1
verapamil-induced~2
200-110-induced~1
propranolol-pretreated~2
PQ~1
feasability~1
gm-m/m2,~1
(22.1~1
index.(ABSTRACT~1
liters/m2~1
1,726~1
1,099~1
alpha-adrenergically~1
(-4~1
[before~2
nifedipine]~1
[after~2
nifedipine],~1
verapamil],~2
(TPN).~6
B:apo~1
Lactase-deficient~1
yogurt~10
(beta-gal)~1
beta-gal~3
acidify~2
Yogurt~1
yogurt.~2
tube-fed~1
Isocal,~1
Compleat~2
L-carnitine-containing~1
Isocal~4
formulae~2
carnitine/1600~1
0-6~1
8750~1
marasmus.~2
Height,~1
marasmic~3
(AC/age)~1
definitely;~1
(SROP)~1
hospital),~1
SROP.~3
SROP~4
43%)~1
GABHS.~2
pediatrics--the~1
enterolith~1
concretion.~1
enterolith.~1
69-yr-old~1
3H-biotin~3
biotin-containing~1
35S-streptavidin,~1
PC-specific~1
Myxedema~1
(autoimmune~1
hypergonadotropic~2
testosterone/estradiol-binding~1
(Patient~2
Looser~1
D-depleted,~1
defects--oral~1
Light-chain~1
oncogenous~1
(5/7~1
2/29)~1
(4/7~1
4/29).~1
sicca.~2
(VOD)~2
Preparative~1
dimethylbusulfan~1
(DMB),~1
(L-PAM),~1
monocrotaline.~4
VOD~10
DMB~2
(1/10),~1
(9.2-27~1
L-PAM~4
(2/36)~1
(0/2).~1
buthionine~1
sulfoximide~1
(BSO)~1
L-PAM.~3
monocrotaline,~1
VOD,~1
(7/13).~1
BSO~2
monocrotaline~12
VOD.~3
(ANTs)~1
(MAPs).~1
MAPs,~1
(52-68~1
MAP2.~2
anti-ANT~1
MAP2,~2
ANT~10
ANT,~1
ANT.~4
ANT-enriched~2
anti-tau~4
Anti-tau~1
immunostain~3
ANTs~2
perikarial~1
ANTs.~1
sports-related~1
interpret,~1
Crimean-Congo~2
(CCHF)~2
CCHF~6
2,460/8,667~1
140/180~1
347/763~1
32/34~1
Zimbabwe.~1
Hyalomma~2
Tanzania.~1
11/31~1
Eurasia.~1
Eurasia~1
Hyalomma.~1
3,772~1
1,978~1
Zimbabwe~1
(RPHI)~1
(IF).~1
Artiodactyla~1
Perissodactyla~1
camelopardalis~1
(3/3~1
rhinoceros,~1
Ceratotherium~1
simium~1
Diceros~1
bicornis~1
(7/13),~1
eland,~1
Taurotragus~1
oryx~1
(59/127),~1
Syncerus~1
caffer~1
(56/287),~1
kudu,~1
Tragelaphus~1
strepsiceros~1
(17/78),~1
zebra,~1
Equus~1
burchelli~1
(16/93).~1
40/293~1
hares,~1
22/1,305~1
carnivores,~1
insectivores,~1
hyrax.~1
118/1,978~1
hares~1
herbivores)~1
Hyalomma,~1
Toscana~3
Phlebotomus~1
perniciosus~3
23-month~1
insects'~1
eclosion.~2
matings,~1
Rockland~1
CA-I~1
emg~1
Endoneural~1
DL-alpha-difluoromethylornithine~2
(eflornithine;~1
DFMO)~1
a-monofluoromethyldehydroornithine~1
MFMO~5
CH3)~1
TREU~1
LUMP~1
trypanocide~1
g/kg/day,~3
DFMO.~5
(12-15~1
(PBMN)~1
PBMN.~2
CaCl2-extracted~1
tegument~1
schistosomular~3
PBMN~1
Broken~1
1,543~1
1,697~1
g/day,~6
(Na~1
K-ATPase,~1
Mg-ATPase,~1
Ca-ATPase)~1
(250-2000~1
Ca-ATPase~3
tris~1
dienes~1
[18:2(9,~1
11)],~1
18:2(9,~2
11)/18:2(9,~1
16:0~1
abstainers.(ABSTRACT~1
0.6-1.0~1
0.989)~1
(3.29-8.95~1
(VERCO2)~1
isohypercapnic~2
CO2-mediated~1
consciouness~1
VERCO2~2
+2.0~1
VERCO2.~1
equipotency~1
(VDa,~1
VAa)~1
(VDET,~1
VAET)~1
PaCO2-PETCO2,~1
VDa/VT-VDET/VT,~1
VAa-VAET~1
0.61).~1
tissue-pO2~2
pO2-histograms,~1
"representative~1
poll"~1
(endarterectomy,~1
(3,7-dimethyl-1-(5-oxohexyl)-xanthine)~1
pO2-histograms~1
(pO2-histogram)~1
Periaccess~1
(CSEA).~1
CSEAs.~2
(52.9%)~1
CSEAs~3
(98.8%~1
(29.9%~1
$20~1
$96.73~1
CSEA~1
$5,240.~1
(vWF:Ag)~1
pattern--an~1
cofactor/vWF:Ag~1
Infiltrates~1
(ovalbumin~1
immunization)~1
haplotypes)~1
H-2a,~2
ovalbumin-induced~1
susceptibilities:~1
H-2-related~4
lesions.(ABSTRACT~1
Multilumen~1
cafe~3
au~3
lait~3
nonplexiform~1
150.0~1
Limbic~2
phenobarbital;~1
sharpness,~2
parameter).~1
Pyrazinamide~1
Md.).~1
(Susceptibility~1
assays.)~1
further;~1
(Penr)~1
N.C.,~1
Penr.~1
2.6-megadalton~1
Penr~2
penA,~1
mtr,~1
penB.~1
FA19~1
F62~1
(Bla+~1
Bla+~4
enterococcus,~1
HH22.~1
piperacillin;~1
vancomycin;~1
High-level~2
(Gmr)~1
HH22;~1
Gmr~3
Bla+,~1
Bla+-encoding~1
HH22~1
10.2-kilobase~1
PA;~1
840-base-pair~1
penicillinases~1
disseminate.~1
aminoglycoside-modifying~2
(AMEs)~1
Batteries~1
AMEs~2
AMEs.~1
membrane-permeabilizing~1
1-N-phenylnaphthylamine~1
permeabilize~1
dansyl-polymyxin.~1
dansyl-polymyxin~2
self-promoted~1
cation-binding~1
polymxyin.~1
(7H12~1
(7H11~1
agar)~3
MIC/MBC~1
aeurginosa~1
corynebacteria.~1
carboxyquinolones,~1
(difloxacin)~1
Nevus~1
colobomas~2
dermatologic,~1
50-90%.~1
astatic~1
Colic~1
Co-trimoxazole~1
TPN:~1
mass);~1
thyroxin-binding~1
balance);~1
kcal/kg-1/day-1~1
g/kg-1/day-1.~1
nutrition-related~1
(ICU).~2
(equilibrium~1
Thyroxine-binding~2
(DGI).~1
DGI.~2
meningococci~8
gonococcemia~2
meningitidis.~2
Immune-mediated~1
flecanide~4
haptenized~1
(Rockville,~1
Md)~1
163),~1
(minus~1
exclusionary~1
(LAs)~1
LAs;~1
chain-producing~1
glassy~1
(LCD)~1
LCD~3
(NANB)~3
NANB~7
LCD.~1
(gamma-IFN),~1
Ia-inducing~1
gamma-IFN,~2
(50-95%~1
(5-60%).~1
BA-2)~1
83c2)~1
R-17).~1
(Na+-K+)-ATPase.~1
(Na+-K+)-ATPase~2
(Apo~1
A-II),~1
GT)~1
(19/19)~1
(98/122).~1
orally:~1
thiomalate~6
cell-free,~1
(O2-),~1
(OH.).~1
(9.63~1
MJ)~1
emulsion),~1
'big~1
bag',~1
weight-gain~1
50th~2
(rTNF-beta)~1
Nonresponsiveness~1
overcome,~1
rTNF-beta.~1
(rIFN-alpha)~1
rTNF-alpha-induced~1
rTNF-alpha.~1
Cai++])~1
[Cai++]~13
alpha-methylmannoside~1
(alpha-MM)~1
Cai++~1
Ca++-~1
-depleted~1
-depleted,~1
Quin2-loaded~1
cytoplasts.(ABSTRACT~1
(scu-PA),~1
(pro-UK),~1
pro-UK~5
22,000)~1
contortrix,~1
rhodostoma~1
(ancrod),~1
125I-pro-UK~1
(scu-PA).~1
FabIgG,~2
thioether-linking~1
Fab'gamma,~1
FabIgG~2
Fab'gamma~1
noncrosslinked~1
(Ala~1
150-Asn~1
gamma-cleavage~2
(FI),~1
(FII),~1
13,000,~1
Proteolyzed~1
theta)~1
gamma-thrombin).~1
elastase-modified~1
4KB128)~1
(135,000~1
extrafollicular~1
histiocytes).~1
(anti-CD20~1
CD21)~1
(anti-CD19).~1
(To15)~1
(NaF)~1
20-kd~1
40-kd~2
NaF,~2
(PGI2)-induced~1
(stimulatory~1
inhibitory)~1
Ti)~1
hybridoma-secreting~1
(HOTMEC)~1
HOTMEC~3
(tPA)~7
HUVEC.~3
tPA~38
HUVEC~3
once-passaged~1
4388~1
40-69.~1
asked,~1
snored~1
habitually,~1
never.~1
1294),~1
2614),~1
non-snorers~3
non-snorers.~1
(NS);~1
Snoring~3
physiotherapist~1
(549)~1
(67)~1
(16.5%),~1
non-attendance~1
6.11~1
21,500~1
scrape~1
dyskaryotic~3
14-86~1
spatula,~1
spatula.~1
0.010).~1
0.097).~1
Tranexamic~1
dithranol~2
(Wolff~1
Helarium)~1
dithranol.~1
spondyloarthropathy.~1
(54/114;~1
(41/84;~1
49%)~1
(89/334;~1
non-secretion~1
(33-47%).~1
non-secretor~1
hostparasite~1
(anti-HBe).~1
35-59~1
dysmenorrhoea~1
(neuroticism~1
history),~1
Analysis.~1
registers.~2
(33).~1
questionnaires),~1
26358~1
1185~1
koilocytosis,~1
(31.2%~1
33.06%,~1
29.89%,~1
31.76%~1
(21.6%).~1
(21.2%).~1
oestriol,~1
gestrinone,~1
gestrinone~5
0.057).~1
happen,~2
(1.3)~2
IU/day.~1
0.000001;~1
35.6;~1
4.18;~1
1970-1~1
1981-2~2
fever--the~1
1981-2.~1
hypovolaemia~1
geriatricians~2
geriatricians.~1
hyperlipidaemic~1
normolipidaemic~1
kr~1
(1930~1
pounds).~1
dependent)~1
5-24)~1
45-58).~1
polyuria;~1
Hyperglycaemia~1
Hull~1
patients/million~1
(367~1
(94%))~1
(143~1
(93%)),~1
(32%))~1
(14%)).~1
(68%)),~1
(64%)),~1
(71%)).~1
(75))~1
(82%)).~1
(2,6,di-isopropylphenol)~1
alphaxalone-alphadolone~1
sedating~1
poisonous~1
fallacy.~1
neighbours~1
tranquillisers~1
recommendations)~1
(48)~1
(37.3%).~1
(90.7%),~1
allowances,~1
Medicines~1
unclassifiable.~1
57.9,~1
travellers'~1
810~1
refusals,~1
immunisation,~1
expenses,~1
postclinical~1
specialties:~1
gynaecology,~2
paediatrics,~1
multidimensional:~1
dimension--for~1
effectiveness--it~1
another--for~1
dimensions--soft~1
hard;~1
specific--such~1
modestly,~1
meetings,~1
tumor-board~1
trifluorothymidine~1
(F3TDR)~1
cell-cycle-phase-specific~1
antimetabolites,~1
F3TDR~3
(FUDR).~1
antiproliferative,~1
totipotent~1
periodic-acid~1
Schiff,~1
t(11:17);(q23;p13).~1
blasts'~1
HLA/DR+~1
B4+~1
My7+~1
My9+~1
B1-~1
T11-.~1
My9~2
pycoerythrin~1
B4+;~1
My7+;~1
My9+;~1
coexpressing~1
lymphomyeloblasts~1
(lymphoid/myeloid)~1
(LNAA)~1
(STD-TPN),~1
(BCAA-TPN).~1
STD-TPN~1
BCAA-TPN~1
carrier;~1
oro-,~1
Ir-192~2
I-125~1
EMP.~1
SPB.~1
Intracavitary~1
whole-pelvis~2
(Cf)~1
neutron-emitting~1
Cf~1
(pseudomalignant)~1
granulation-tissue~3
(sometimes~2
atypical)~2
tumefactive~1
Flowcytometric~1
misinterpret~1
anthropometry.~1
-1.62~1
dilution-derived~1
-9.3~1
Calorie~1
methylergometrine~1
mid-left~1
[4-28]~1
isooncotic~1
PGH~9
3'-phosphate~3
burst-like~1
5.06~2
lipoxygenase.~2
cosubstrate.~1
ANP-mediated~3
Ca2+-containing~2
prelabelled~1
Ca2+-depleted~1
(Zenker's)~2
stented.~1
Cricopharyngeal~1
water-born~1
(HUS):~1
(2.7-8.4%)~1
(10.1-18.8%)~1
peroxidative~1
ulnohumeral~2
rt-PA.~5
rt-PA-mediated~1
0.0078~1
rt-PA/kg~1
weight)-1~1
plasmin-catalyzed~1
0.466~1
plasmin/dl)-1~1
replete.~1
ANP,~4
PRC;~1
Frusemide~1
non-nucleated~1
[3H]-ouabain~3
thyroxine).~1
(ir-hGRF)~1
ir-hGRF~3
ir-hGRF.~1
unconnected~1
Creatinine,~1
recreate~2
(1-28)~1
day.(ABSTRACT~1
(FHF)~1
K+-ATPase~6
(43-53~1
HFO,~1
fetal).~1
(FPF)~1
air-entry~1
TPP.~1
foam,~1
acidemia)~1
12-bed~1
medical/cardiac~1
availabilities,~1
input;~1
overstaffing,~1
understaffing,~1
(FTEs)~1
FTEs~1
Payment~1
System's~1
Rush-Presbyterian-St.~1
Luke's~1
$2.2~1
$23,129.~1
non-Medicare~4
aeromedically~1
(ICD-9)~1
($13,427~2
$12,700~2
($10,474~1
$10,114~1
cost-based~1
($10,594~1
$9,861~1
($8,024~1
$4,824).~1
$9,524~1
$8,422~1
$7,968~1
$4,800~1
($11,690~1
$11,344).~1
(3-19~1
Diamine~2
(DAO)~2
Crosby~1
DAO~13
(celiac~1
sprue:~1
62;~1
lymphoma:~1
(481~2
104).~1
xylosuria.~1
Mupirocin~3
mupirocin~11
institutional,~1
pharmacies,~1
patients/clients.~1
computerization~2
(VPA),~1
mg/kg/day)-plus-PB~1
megamitochondrial~1
steatoses,~1
VPA-treated~2
VPA-plus-PB~2
valproate.~2
blood/brain~1
menotropin-induced~1
conceptional~1
pattern--A1)~1
(hMG/hCG)-induced~1
Bioassayable~2
(LH-b)~1
LER-907~1
(LH-i)~1
LH-b~2
1420.5~1
LH-i~1
LH-b/LH-i~1
peaked,~1
hMG/hCG-induced~1
(Hoechst~1
[UK]~2
Hounslow,~1
(Metrodin,~1
Serono~1
Welwyn~1
Garden~1
IU/l)~2
3-hour,~1
75-gm,~1
acanthosis,~1
polypronuclear~2
pronuclei)~1
cleave,~1
dibromochloropropane~1
(DBCP)-induced~1
oligozoospermic~4
nonrecovered~1
DBCP~1
L-carnitine,~4
alpha,1-4-glucosidase,~1
glycerylphosphorylcholine~2
error:~1
276.9~1
nmol/ejaculate;~4
U/ejaculate;~4
glycerylphosphorylcholine,~1
mumol/ejaculate)~1
(1757.4~1
mumol/ejaculate,~1
(750.4~1
mumol/ejaculate;~2
(1193.7~1
azoospermia,~2
pro-fertility~1
(FSH)-induced~1
2.2-fold.~1
nonpregnancy,~1
non-LH~2
(15.2%).~1
surge/pregnancy~1
(1219~1
nonpregnancy/non-LH~1
(932~1
glycogen-depleting~1
(NOGD),~1
(MCR),~1
(EGP)~1
"two-level"~1
(100-min~1
D-3-[3H]glucose~1
40-mU~1
400-mU~1
NOGD~1
EGP~1
(4.03~1
mg/dl).(ABSTRACT~1
LP)~1
Glyburide,~1
elevated-glucagon~2
glyburide-infused~1
(interpeak~1
tolrestat,~1
tolrestat~1
L3T4-specific~1
GK1.5.~1
GK1.5~4
GK1.5-treated~2
Thy1+~1
Ly1+~1
(Leu3+)~1
(mitomycin-C~1
5-FUDR)~1
misoprostol~40
Saguinus~1
oedipus,~1
3-5-yr~1
70%-90%~1
5%-10%.~1
46-yr-old~1
(Jmax)~1
phlorhizin-insensitive~1
(passive)~1
(microgram/atrium)~1
(1K1C)~1
1K1C~3
(acetylcholine~1
(nitroprusside~1
8-bromo~2
[cGMP])~1
ED50)~1
Columns~1
(10-300~2
nonprostanoid~1
nitrovasodilators.~1
labile,~1
monoculture~1
5'-triphosphate,~1
vasomotion.~2
cataractogenic~1
cataractogenesis~1
steroid-induced.(ABSTRACT~1
steel-reinforced~1
plafond;~1
"Elephant~1
Man"~1
Frederick~1
Treves.~1
ossicle.~2
GnRH-binding~5
ZR-75-1,~1
MDA-MB-231,~1
Sk~1
MDA-MB-157,~1
1.6-3.0~1
[125I]GnRH~1
(Brc).~1
Brc.~2
[60-330~1
(100-300~1
SMS.~1
Brc~1
(bio-FSH)~1
bio-FSH,~1
pregnanediol-3-glucuronide~1
(PdG)~1
lowland~3
gorillas.~1
days],~1
gorillas;~1
PdG.~2
bio-FSH~10
postmenopause.~1
gorillas,~1
gorillas~1
(A;~1
(D;~1
E2/100)~1
T/100);~1
(ethinyl~1
levonorgestrel)~1
[1.56~1
mmol/m2~4
(1.10~1
(1.30~1
gonadotropin-secreting~3
beta-LH,~2
LH-~1
alpha-subunit-producing~1
(D-Trp6-Pro9-NEt-LHRH)~1
alpha-chain-specific~2
lectin-treated~1
monocyte/macrophages.~1
gamma-interferon;~1
lymphokine(s),~1
lymphokine-thyroid~1
12-tetradecanoylphorbol-13-acetate~1
(Plase~1
(SRIH),~1
Plase~7
(0.125-1.0~1
U/mL).~3
C-evoked~1
IAP.~1
1,4,5-triphosphate,~1
somatotrophs;~1
bromocriptine;~1
ml/120~1
2660~1
1501~1
2176~2
1191~1
154;~1
monlayer~1
GHRH-promoted~1
M.(ABSTRACT~1
20-32~1
9-14~1
meq/24~2
(escape).~1
(escape,~1
53-113~1
ethinylestradiol/day;~1
eugonadal~4
1.5/7~1
1.4/7~1
1.3/7~1
reassignment)~1
Anandron,~1
(LHRH)-stimulated~1
pulses/7~1
(m-SCCM),~1
GnRH;~1
mSCCM~1
FSH-inhibiting~1
m-SCCM~2
alpha-methyl-D-glucoside.~1
Superose-12~1
20-60K,~1
40K.~1
dihydroxyphenylalanine~1
(DOPA),~1
(tilt,~1
diazepam)~1
alpha-methyl-para-tyrosine,~1
DOPA.~1
alpha-Methyl-para-tyrosine~1
Naples,~1
three);~1
peaks)~2
GnRH-TRH.~1
neuroendocrine-gonadal~1
mammals;~1
intraplasmic~1
d-1).~2
isoform.~1
(converted~1
(ANF),~4
(NI)~1
(UNaV)~1
eq/min;~1
(-66~1
(-57~1
12-fold.~1
500%.~3
UNaV~1
-0.10;~1
NI,~1
Serum-denatured~1
(dnTBG)~1
(nTBG)~1
nTBG~5
decaliter~1
747~2
dnTBG~3
TBG-Quebec~2
TBG-Montreal~2
bands:~1
pI.~1
TBGs~1
fmol/cell~1
Histidyl-proline~1
(His-Pro~1
DKP)~1
antibody-enzyme~1
His-Pro~4
DKP~4
glucagon/glicentin,~1
81.~2
sn-1,2-dioctanoylglycerol~1
(diC8)~2
(PGH)~2
coagulopathic,~2
hepatotoxic,~2
aggregations.~1
Xanthomatosis~1
xanthogranulomatosis~2
Platelike~1
85-year-old~1
xerography,~1
laboratory-induced~1
(G11021)~1
(G11035)~1
G11035~4
G11021~3
G11021,~1
G11035.(ABSTRACT~1
(Verapamil~1
CC5,~1
200.6~1
terfenadine,~4
(RQ)~1
nutrition--55~1
(GAAPN)~1
(GFAAPN).~1
nasoenterally~1
(CFPEN).~1
GAAPN~2
GFAAPN~2
CFPEN~2
latae,~2
(glucose-6-phosphate)~1
(UDP-glucose)~1
(AC)-depleted~1
anti-CD3,~1
4F2,~3
Tp44,~3
Anti-CD4~1
(66.1)~1
anti-CD3-stimulated~1
(454)~1
(147~1
446)~1
(LR),~2
LR.~1
anti-CD3-induced~2
4/BSF-1~2
(1,25(OH)2D3),~1
(D10.G4.1~1
[D10~1
cells]),~1
co-addition~1
24,25(OH)2D3~1
lectin-activated~1
these:~2
fluorescent;~1
anti-Ig-stimulated~2
Ig-IgG~1
(mIg-Fc~1
cross-linkage,~1
mIg-Fc~1
gamma-mediated~1
mIg-~1
R-mediated~1
(LGCL).~1
LGCL,~2
(CD3+/Leu-7+/Leu-8-/CR3+)~1
Wright-Giemsa~1
LGCL~2
Fc-IgG~1
CD3+/Leu-7+/CR~1
(Ti~2
re-expression.~1
pre-activation~1
IgE-producing~1
HSB-2~2
reactive:~1
Targets~1
105,000~2
absorption/elution~1
(DNA/histone)~1
pre-clearing~1
MRL/MpJ-lpr/lpr~1
(MRL-lpr)~1
(MAC~1
endotoxin-free~1
3T12~1
peptone-induced~1
"activation",~1
(rTNF)-alpha~1
5000/cell~1
receptors/cell)~1
(MNSF),~1
MNSF,~1
HAT-sensitive~1
(MO6)~1
MNSF.~3
MO6~3
MO6,~1
70,000,~1
pyridine-acetic~2
(hNSF),~1
hNSF~3
hNSF,~1
CL-3~6
B15-TRF~4
2R),~2
B15-TRF,~1
(eight-fold~1
up-regulation.~1
B151K12.~1
(BCL1)~1
mu-specific~1
fourfold)~1
BCG-activated~6
[3H]20:4,~1
lyso(bis)phosphatidic~1
(L(bis)PA)~1
(13.1%~1
1.7),~2
(22.8%~1
(26.7%~1
(PS/PI)~1
0.8%).~1
[3H]20:4~8
L(bis)PA~4
L(bis)PA,~3
Rhizopus~1
delmar~1
[3H]20:4-labeled~1
PS/PI,~1
Hete~1
[32P]i~1
[32P]L(bis)PA~1
deacylation-reacylation~1
deacylate~1
NADPH-oxidase~9
(PK-C),~2
nitrogen-cavitated~1
-generating~1
pre-stimulated~1
activation:~1
PK-C~10
H-7,~2
(Biochem.~1
Comm.~1
134:587,~1
(LT)B4.~1
PKC-specific~1
PKC;~1
B-dependent~1
5-hydroxyicosatetraenoate~2
PAF;~1
IgE-~1
[14C]-arachidonic~1
yoelli~1
17X~1
(PY17X-NL)~1
PY17X-NL~2
Lyt-null~1
blood-stage~1
naive,~1
Ig-negative~2
cell-enriched)~1
monocytosis.~2
Lyt-2T~1
Switch~1
sites--six~1
M35,~1
gamma-unit~1
AGCT~1
GGGG~1
religation~1
gamma-isotypes.~1
(IFN-gamma)-induced~3
(TCR)-alpha~1
kappa-immunoglobulin~1
chain-variable~1
(GK1.5)~1
(3JP)~1
I-Ab+~2
I-A-~1
I-Ad+~1
paraganglioma,~1
host)~1
(DEJ).~1
uroporphyrin~6
(URO),~1
(25-500~1
396-407~1
(3-16~1
10(2)J/m2)~1
44.52~1
58.01~1
(50-5000~1
[3H]Serotonin~1
calcium-independent,~1
URO,~1
9.98~1
Split-dopa~1
(dopa-oxidase)~1
dopa-positive~5
cafe-au-lait~2
albinism~1
tyrosinase-positive~2
sal,~2
feathers~2
tube-derived~1
premelanosomes.~2
Tyrosinase~3
premelanosomes~3
possessed,~1
(capping~1
e+~1
(Pomerantz),~1
albino,~3
ca,~2
dopa-negative~1
wispy~1
tyrosinase.~1
(fibrosing~1
membrane-degrading~1
(superficial~1
nodular-ulcerative~2
types).~1
(DMVEC)~1
DMVEC~4
(IFN-gamma),~10
(UVEC).~1
UVEC.~1
ester-enhanced~1
UVEC~2
CDw18.~1
(tuberculous,~1
miscellaneous).~1
U/liter).~1
sandwiching~1
sonicate~1
burros~1
antigen/ml~1
Lethality~1
[kDa];~1
6.5),~1
6.7-7.5)~1
(kcat,~3
1/min)~1
enzyme-inducible~2
uninducible)~1
Carbenicillin~1
0.1/min)~1
beta-lactamase-inducible~2
12-297/min)~1
dimethylbenz[a]anthracene~1
(DMBA).~2
Huggins~1
tamoxifen's~2
antiestrogens.~1
("crocodile~1
model")~1
(TRH).~2
(hGH)-secreting~1
hGH-secreting~1
samples),~1
(Na-K-ATPase)~1
laminae,~1
14C-lysine~2
isodesmosine,~1
Protein-depleted~1
lucky~1
longer--well~1
induces.~1
hyperaggregability,~1
960)~1
20,000),~1
polar-charged~1
rod-shaped~2
F-state.~1
tangle,~1
(5-fluorouracil~1
[5-FU]-cisplatin)~1
sandwiched~1
cGy/d~1
110.~1
5-FU-cisplatin~1
22+~1
(infield)~1
prohibitive,~1
gm/kg.~1
gm/kg)~1
[111In]T101~3
(CTCL)~1
(erythroderma~1
[131I]T101~3
CTCL;~1
mCi).~1
whole-body,~1
T101.~1
photoscans~3
photoscans.~1
nonmalignant.~1
[131I]metaiodobenzylguanidine~1
[131]MIBG~1
[131I]MIBG,~1
metaphyses.~1
Uncommonly,~1
N-isopropyl~1
p-iodoamphetamine~1
postloading~2
(phenelzine)~1
(deprenyl)~1
(MFO)~1
MFO~1
Efficient,~1
budgeting,~1
GRASP-based~1
(NaB)~1
glycine-and~1
serine-free~1
NaB.~2
benzoyl-CoA,~1
benzoyl-CoA~8
NaB/kg~1
NaB~2
growth-impairing~1
g/kg/wk,~1
streptococcus-,~1
coli-,~1
Two-colour~1
15+)~1
5.9%).~1
(Lansbury's~1
single-color~1
Rioprostil,~1
rioprostil~2
(40-60~1
(radiological~1
Discretion~2
(ACEE).~1
(%BSA)~1
1-10%;~1
11-30%;~1
31-60%~1
ACEE~1
(MLN),~1
(IL2R),~1
(5-80%~1
burns)~1
IL2R-bearing~1
anti-IL2R~1
Mitogen-induced~1
IL2R~5
40-90%~1
PBMC,~1
IL2R-expressing~2
IL2-induced~1
IL2R-endowed~1
postburn).~1
rIL2.~1
up-regulates~1
(high-affinity)~1
Hypermetabolism~1
helper-to-suppressor~1
Morphometric,~1
Malnourished~2
orchidometer~1
andrological~1
99mtechnetium-methylene~2
(relapse~1
progression)~1
(remission)~1
calcium-chelating~2
double-layer~1
111In-labeled,~1
cell-lined~1
indium-labeling~1
97.0%~1
midgrafts~1
compliance:~1
(compliant)~1
(stiff)~1
ECGF,~1
derivation,~1
re-endothelialization~2
blood-contacting~2
micrograms/cm2).~1
micrograms/cm2)~2
fibronectin's~1
125I-ECGF~3
beta;~2
ng/cm2)~1
ECGF.~1
adherences~1
nonradioiodinated~1
1000%~1
1200%~1
LE-II~1
Fibronectin-heparin-ECGF~1
9423~1
diagnoses),~1
higher-paying~1
reclassification,~1
$93~1
rates),~1
[30%~1
(ig)~1
ig~3
"unrestrained,"~1
(TEE),~1
(AEE),~1
(TEE~1
AEE).~1
AEE~3
AEE,~1
glucose-lipid~2
infusates~3
adequate-nitrogen~2
infusates.~2
inadequate-nitrogen~1
calorie,~1
dextrose/amino~1
(Veinamine~1
(180-260~1
(GpI~1
(GpII~1
(GpIII~1
Corpak~1
Recovered~1
diphtheroids,~1
Micrococcus.~1
alimented~1
L-carnitine/kg/day.~1
MCT-alimented~1
adipic~1
(C6),~2
suberic~1
(C8),~2
sebacic~1
(C10).~2
monocarboxylic~1
caproic~1
caprylic~1
capric~1
MCT-group.~1
beta-OH-butyric~2
acid-carnitine~1
Hereby~1
omega-oxidation.~1
(DRGs).~2
($4352-$5124),~1
($16,691~1
4389)~1
($14,118~1
4962)~1
($7692~1
687),~1
1/2-month~1
team;~1
Team-managed~1
nonteam-managed~1
398,~1
390);~1
(TPN)-associated~1
(microliter/min/g~1
Vamin~2
Travasol~5
Travasol.~1
Vamin-perfused~1
Steatosis~1
TPN-induced~1
(TFN)~1
(PCM).~1
TFN,~1
(RID)~1
(20-50~1
PCM.~1
(60-90~1
50-760~1
(TURB)~1
RID~3
0.942~1
81-403~1
(TFNRID~1
(0.931)~1
TFNTURB).~1
TFNTURB~1
4.0%.~1
(TPN)-induced~1
Y-connector.~1
saved,~1
$395.00~1
2)-activated~1
leukopheresis~1
111In-oxine,~2
hypovascular.~1
tumor-feeding~1
(Dex)~1
[vitamin~1
Dex]~1
Dex-treated~2
(C3H/HeJ)~3
dodecylsulfate-polyacrylamide~1
octadecyl~1
[14C]proline~2
[14C]hydroxyproline~2
7,12-dimethylbenz(a)anthracene~1
57-97-6]-induced~1
slices/mouse)~1
gland-free~4
gland/mouse)~1
13-14%~1
(transplanted~1
pad).~1
mammotropic~2
(prolactin~1
steroids)~2
mammae~3
(subcutaneous~1
fat-pad~1
inoculates);~1
mammae;~1
meager~1
(FS/RTA2)~1
FS/RTA2,~1
(beta-gluc)~1
(beta-galac),~1
lysozyme;~1
hyperenzymurias~2
FS/RTA2~3
hyperenzymurias.~1
reversible-complex~1
FS/RTA2.~2
phosphate-dependent~1
(AS-1,~1
AS-1-preserved~1
hypogammaglobulinaemic~1
re-evaluate~1
cast-induced~1
Lambda~1
(C1qSP)~1
166.8~1
micrograms/AHG-equivalents/ml~1
(83.1~1
26.7,~1
Vb)~1
Vc).~2
C1qSP~3
(172.8~1
C1q-binding~4
C1qSP-binding~3
6.6S~3
Large-molecular-weight~1
tocainide.~6
(CMAPs)~1
K-loading.~1
CMAP-decline~1
(400-1200~1
Post-transfusion~1
(collected~1
pasteurized~1
gamma-protein,~1
(CTL)and~1
defence.~1
heterodimer-bearing~1
beta-gal-gamma)~1
35K)~2
45K.~1
in-phase~1
wks)~1
F6C7,~1
F6C7~1
surface-express~1
NKFi.~1
Immunoprecipitations~2
anti-NKFi~1
85K).~1
44K~2
41K.~1
NKFi~1
41K~1
Anti-NKFi~1
(PtdIns),~1
phosphoinositide,~1
(CDP-diglyceride:myoinositol~1
3-phosphatidyltransferase,~1
2.7.8.11),~1
PtdIns,~1
stimulus-responsive~1
GTP)-activated~1
re-synthesis~1
Ca2+/diacylglycerol-dependent~1
aspersa,~1
sulphated~1
(CCK8),~1
CCK8~1
Troponin,~1
TnC~2
Ca2+;~2
TnI~2
TnT~5
'head'~2
'tail'.~1
tropomyosin:~1
gamma-protein~1
CD4-8-(L3T4-,~1
Lyt2-)~1
beta-bearing~3
1.2C~1
2)encodes~1
TCR/CD3~2
CD3+4-8-(T3+,L3T4-,Lyt2-)cells~1
day-15~1
thymi,~1
gamma-specific~1
beta-specific~1
Day-16~1
CD3+,4-,8-~1
CD3-bearing~1
80,000-90,000~1
80-90K)~1
20-28K~1
(Leu4,~1
Ti,~2
48-54K~1
40-44K,~1
40K~2
62K~1
PEER~3
gamma-peptide~1
CD3-associated~5
PEER.~1
PEER,~1
48-base-pair~1
triplicated~3
hominoid~7
artiodactyls.~1
rate-slowdown~1
158-208)~1
(triskelions~1
93-157),~1
(T3)-Ti~1
erythrocyte(E)-receptor,~1
(RBC).~1
'alternative~1
pathway'~1
anti-CD2~7
T11(2)~3
T11(3).~2
42K)~1
T11TS,~1
T11(3)~3
anti-T11(2+3)~1
(1/500)~1
polytherapy.~1
(1/37,000).~1
(LEPs)~1
LEPs~1
electrographically~1
Raters~1
LEP~2
nontemporal~1
(Gonozyme)~1
gonorrhoeae;~1
Gonozyme~7
Gonozyme,~1
97.1%,~1
1965-1985.~1
decades;~1
1965-1975,~2
1976-1985.~1
"medical~2
oophorectomy,"~1
oophorectomy."~1
(hCG)-timed~1
Tocainide~4
0-10-point~1
pain-producing~1
incumbent~1
bites).~1
penicillin-susceptible.~1
Neurofibromatosis,~1
neurofibromatosis's~1
neurofibromatosis-I~1
pseudarthrosis),~1
(VAC).~1
(5,500~1
VAC~6
begun;~1
mutilating,~1
(paracentesis)~1
cycloplegics~1
"bandage"~1
quin-2,~2
tetrakis(acetoxymethyl)~1
quin-2-loaded~1
cAMP-stimulated~1
AM),~1
physiological/metabolic~1
adipocyte.~1
Evolutionary~1
kR,~2
kR;~1
0.258~1
mC/kg)~1
transposon.~2
radio-resistance~1
(immature~1
oocytes)~1
mutation-rate~1
rearranges~2
hominoids~2
epsilon-chain~2
orangutan~2
clock),~1
(silent)~1
protein-encoding~1
alpha1-antitrypsin~1
calibrated:~1
kappa-Ars,~1
Ars-A~7
p-azophenylarsonate)~1
kappa-Ars~2
V-J~3
arginine-96~1
intracodonic~1
anti-HLA-class~1
Mitogenesis~1
steroid-inducible~1
fibrosarcomas.~1
poly(ADP~1
ribose)~2
octadeoxyribonucleotide~1
duplex,~1
1,2-benzopyrone,~1
Poly(ADP~1
[NAD+:poly(adenosine~1
D-ribose)~1
ADP-D-ribosyltransferase,~1
2.4.2.30]~1
non-Watson-Crick~1
quinoxaline~1
antibiotic-oligonucleotide~1
Hoogsteen~3
quinoxaline-binding~1
(differential~1
echinomycin~1
echinomycin-binding~2
pyrocarbonate.~1
pyrocarbonate~3
12-base-pair~1
echinomycin.~1
base-paired.~1
icosanoate~1
(arachidate),~1
Langmuir-Blodgett~1
5.84~1
ninaC~6
nina~1
(neither~2
afterpotential)~1
27E-28B~1
rhabdomeral~1
nuchae~2
(kappa-elastin)~1
elastase-type~3
(membrane-bound~1
protease)~1
(metalloprotease).~1
arterioclerosis.~1
hydroperoxides.~2
cumyl~3
acetophenone~1
alpha-methylbenzyl,~1
benzyl,~1
R'~1
peroxide:~1
XRR'C-OOH~1
H+----XRCO~1
R'H~1
13-hydroperoxy-9,11-octadecadienoic~1
alkanes~1
one-electron~1
homolysis~1
oxygen-oxygen~1
alkoxy~1
beta-scission~1
hydrocarbon.~1
deuteromethane~1
3.6-3.7~2
anti-poly~1
(ADP-ribose)~1
1.3-kb~2
Okayama-Berg~1
[pcD-p(ADPR)P;~1
kb]~1
pSV2-CAT~1
pcD-p(ADPR)P~2
"activity~1
gel"~1
metalloproteins,~1
Phe-87~1
iso-1-cytochrome~1
zinc-substituted~1
pi-cation~1
[NAD+~1
ADP-ribosyltransferase,~1
2.4.2.30].~1
poly(ADP-ribosyl)ation~1
poly(ADP-ribose).~1
poly-(ADP-ribose)~2
nonantigen-bearing~1
antigen-receptor-mediated~1
non-antigen-bearing~1
antigen-nonspecific~2
engagements~1
CD6,~1
CD7,~1
CDw18,~1
crosslinking-induced~1
second-step~1
Crosslinking~2
CD3/T-cell~1
50-fold.~1
50-70%,~1
cereus,~1
"aseptic~1
hypoglycorrhachia,~1
genetics,"~1
monoadducts,~1
bisadduct~5
Na2S2O4~1
dithionite)~1
d(CGTACGTACG)2~1
snugly~1
excitable,~1
I-Ad,~1
I-Ed,~1
I-Ak,~1
I-Ek~1
nonrestriction~1
Hox-3.1,~1
rostro-caudal~1
myc,~1
ras,~2
myc-transfected~1
ras-~1
src-transfected~1
immunoblots,~1
src,~1
Intranuclear~1
ceilings~1
ceilings.~1
cephalosporin)~2
cefamandole)~1
Klebsiella.~1
Otherwise~1
Searching~1
fornicotomy~1
fornix.~1
P100/delta~3
L/min/torr,~1
H2O/torr,~1
-0.86~1
-0.66~1
PCO2).~1
L/min/torr~1
hypoventilated~1
hyperventilated.~1
mercapto-ethanesulphonate~1
(mesna)~1
mesna.~3
67.5%~1
mesna~12
elastase/antileucoprotease~1
antileucoprotease.~2
proteinase-antiproteinase~1
antiglobin~2
(LIAGT)~1
agglutinability~1
LIAGT~2
nonspecificity.~1
alloantiserums~1
(Polybrene,~1
LIP)~1
(LIPAT)~1
low-ionic-strength~1
(LISS)~1
titrated,~1
LIP~3
anti-K,~2
anti-E,~2
anti-Fya,~1
anti-Jka.~2
LIPAT~2
anti-K~2
LISS~2
enzyme-reactive~1
titers;~1
False-positives~1
high-purity,~1
low-fibrinogen,~1
controlled-pore~1
concentrate-specific~1
medium-scale~1
well-equipped~1
high-quality,~1
Prospective-concurrent~1
fossilized~1
saber-toothed~2
(Smilodon~1
californicus),~1
Inspection,~1
"designer~1
revitalized~1
technetium-99m-pyrophosphate~1
(Tc-99m-PYP)~1
sarcoidosis),~1
Tc-99m-PYP~1
76%:~1
conversion),~1
conversion)~1
conversion).~1
(42%):~1
hours/day)~2
submaintenance~2
supramaintenance~2
intraprandial~1
(10.1%,~1
(lactase)~1
acidophilus~2
lactase-rich~1
breath-hydrogen~1
(SAM),~1
Weight-for-length~1
Zn-supplemented~2
-0.66,~2
(0.36),~1
(0.15),~1
(0.27),~1
(0.11),~1
(0.01),~1
(0.10)~1
[0.08]~1
[0.02]).~1
K3EDTA,~1
23.1%~1
electrooptical~1
(Technicon~1
sizing.~1
(MPNST)~1
MPNST~1
Conjoint~1
S-100/Leu-7,~1
S-100/MBP,~1
MBP/Leu-7~1
immunoperoxidase-stained~1
FACS.~1
ITP.~1
Minitek~1
xylose,~1
pipetted~1
non-CO2~1
(red)~1
xylose;~1
("pseudo-Gaucher"~1
pseudo-Gaucher~2
beta-glucosidase.~1
Spices~1
volunteers;~2
(655~1
contents)~1
detrimental,~1
Etidronate~3
(1,107~1
(mid-molecule~1
two-to-one~1
etidronate,~3
Transiliac-crest~1
atrophie~2
blanche~2
triaditis.~1
(eflornithine),~1
trypanosomiasis~2
Belgium~1
difluoromethylornithine,~2
Difluoromethylornithine~1
IgM/IgG~1
"thrombi"~1
cryoglobulinemic~1
meningococcemia~3
diplococcus,~1
meningococcemia,~2
W135,~2
myopericarditis,~1
Florida's~1
depart.~1
4192~1
viridans,~1
lipoxgenase~1
Synaptophysin~4
(SY~1
identical--or~1
similar--protein~1
ganglioneuromas,~1
"neural"~2
synaptophysin~7
parathyroids,~1
SY~3
(D283~1
MED)~1
(IFs)~1
(keratin,~1
polypeptides)~1
D283~1
(20%,~1
neurofibrosarcoma~1
(NFS),~1
(LMS),~1
(FS),~1
(MSS),~1
NFS,~1
LMS,~1
MSS~1
Leu-7+;~1
neurilemmomas~1
LMSs~1
NFSs~1
S-100,~3
interepisode~1
prelithium~1
serotypic~6
FCR-3~2
"competitive~1
assay"~1
(CHAA),~1
precipitated.~1
CHAA,~1
immunoprecipitated.~1
(gp195)~1
(SEA)-stimulated~1
SJe;~5
140-GP~1
egg-focused~1
SEA,~1
(IA)-purified~1
140-GP,~2
egg-sensitized/egg-challenged~1
140-GP-specific~2
A1-1~1
14B3-8),~1
SEA-stimulated~2
japonica.~2
(7A6-5),~1
anti-SEA~1
non-SEA-binding~1
SEA-induced~1
antibody-driven~1
japonica,~1
Mabs.~1
hypocarbia~3
K+]e)~1
[K+]e~6
Spreading~1
hypocarbic~2
normocarbic~3
l-1,~2
normocarbia,~1
(delta[K+]e)~1
[K+]e).~1
delta[K+]e~1
test.(ABSTRACT~1
disopyramide's~1
(augmenting)~1
loading)~1
Controlled-release~3
sustained-~1
controlled-)release~1
clinical-pharmacologic~1
2,800~1
antihistamine.~1
sneezing.~1
H1-blockade.~1
6-k-PGF1~1
Dexamethasone-treatment~1
(ANTU).~2
thiourea,~2
thiocarbamide~2
(IIIB),~1
RLND~1
(IIIA)~1
15.7),~1
(stroke,~1
gangrene).~1
miscarriage~1
condemn~2
centralizes~1
(thereby~1
collapse),~1
scorned~1
18-labeled~1
hyperprolinemia.~1
2-deoxy-2[18F]fluoro-D-glucose~1
hypometabolism,~3
Holder~2
pasteurisation,~1
pasteurisation~1
Noonan~1
g/kg/day).~1
synthesis:~1
catabolism;~1
unabated,~1
TPN;~1
g/kg/day.~1
1942,~1
objections~2
(PSC).~1
incoagulable.~1
protocoagulant~1
(soluble~1
thromboelastogram~1
Epsilon-aminocaproic~1
PSC.~3
Disposal~1
150+~1
EACA.~1
PVS.~1
DIC;~1
NTG)~1
Methemoglobinemia~1
chocolate-brown~1
echocardiographically.~1
staphylococcemic~1
evaluation:~1
50/mm3~1
adipocytic~1
agar-gel-diffusion~1
Anti-S~1
Agar-gel-diffusion~1
staphylococcemias~1
lead-contaminated~1
saturnism;~1
acid-provocative~1
abstinent),~2
abstinent).~1
placebo-compliant~1
annulare,~1
xanthogranulomas,~1
reticulohistiocytomas,~1
xanthelasmas,~1
Chondrocytes,~1
osmolarities~1
minimally,~1
normalization."~1
temporal-limbic~1
hepatitis).~1
surgery-related~1
20/60.~1
Lens-induced~1
(lipoxygenase~1
inhibitors).~1
respiration),~1
respiration)~1
after-effects,~1
(leader~1
cath)~1
(Venflon)~1
Corning~1
(KCN)~1
KCN;~1
SNP.~3
SNP-~2
KCN-treated~2
SNP-treated~1
(PaCO2-PE'CO2)~1
b.p.m.)~2
(extradural)~1
patients--notwithstanding~1
side-effects,~2
Amiel-Tison~1
hypotonia.~1
non-co-axial~1
ADE~3
PE'~2
6.48~1
6.41~1
hypercapnic,~1
5.07~1
command),~1
alfentanil-etomidate~1
(MICs).~1
'Polytar'.~1
'Polytar'~1
fungistatic,~1
'Selsun'~1
'Cetavlon~1
P.C.'~1
'Genisol'~1
fungicidal.~1
'Cetavlon'~1
'Selsun'.~1
Hyperprolactinaemia~1
galactorrhoea.~1
mid-follicular~5
normoprolactinaemic~1
hypopyon~1
Lisch~1
(metabolite)-dependent~1
(ndab)~1
ndab~2
RBC;~1
ndab,~1
173,000~1
bystanders,"~1
sensitization;~1
drug-cell~1
(autoantibodies),~1
(SmIg)~1
(CyIg).~1
SmIg~3
CyIg~5
SmIg-negative~2
SmIg-positive~1
CyIg.~1
3A1~1
(CD2),~1
(CD3)~3
orchestration~1
multi-lineage~1
3A1,~1
LC+,~1
cALLa-,~1
CD19+,~1
CD20+,~1
CD21-,~1
(surface/cytoplasm)-,~1
PC-1+.~1
cell-restricted/associated~1
immunophenotypical~1
(MCCL)~1
granulomonocytic~1
(GM-CSA).~1
ADP-ribosyl~1
(ADPRT).~1
ligase,~1
Breaks~1
(phorbolester~1
(granulocyte~1
G-CSA;~1
3-methoxybenzamide~2
ADPRT~5
switching.~1
VIII)~1
(one-hour)~1
VIII-treated~2
killing:~1
51%).~1
1,270,000~1
function-modulating~1
(eluate).~1
anti-Tac,~3
re-addition~1
T-depleted~2
IL2-depleted~1
IL2-responsive~1
(McAb~1
aIL2r)~1
(42.2%~1
Noninduced~1
aIL2r~3
McAbs~1
(CFU-GEMM,~1
BFUe,~1
BFUe~1
Tannic~1
Granules~1
(OCS)~1
OCS,~1
Granule-to-granule~1
acid-osmium~1
hyperlymphocytosis~1
(NK)-related~1
(HNK1-~1
Leu11-defined~1
(RA)-induced~1
Cytofluorometric~2
(L-243)~1
myeloblast~1
bipotent~1
(myeloid-erythroid)~1
(KG-1,~1
KG-1a,~1
HEL)~1
(ML-3,~1
U937)~2
KG-1~2
KG-1a~1
N-ras-13~1
IgM-secreting~1
(Ph1)-positive~1
TOM-1,~1
TOM-1~7
immunoglobulin-H~1
abl-related~1
2.25-2.75~1
mmol/l),~2
hypocalcaemic,~1
Aminohydroxypropylidene~1
(91%);~1
(91.5%);~1
compressor~2
Zealanders~1
nebulisers.~1
nebulisers,~1
Clwyd~1
956~1
practitioners;~1
collars~1
dorsilumbar~1
excisions)~1
inguinoperineal~1
submammary~2
inguinoperineal,~1
Srivastava~1
immuno-deficiency~1
Srivastava's~1
162/107~1
149/94~1
mmol(mEq)/day.~1
137/88~1
150/97~1
(shrunken)~1
seroepidemiology~1
Kiribati~1
Islands).~1
(188/615)~1
(58/615).~1
(0-70)~1
mother-child~1
Gilbertese~1
intolerable.~1
propantheline.~2
nocturia,~1
organisers~2
replied.~2
organising,~1
(49)~1
remuneration,~1
("district~1
tutors")~1
remuneration.~1
Diamorphine~1
antiemetics,~1
anticholinergics,~1
driver.~1
formidable.~1
Plasticized~2
cheap.~1
51Cr-EDTA.~1
6/7~2
23/29~1
(kappa)~2
paraproteinaemia~1
non-erosive~1
paraproteinaemia,~1
bilharziasis.~1
78.1%.~1
tumour-free~1
bilharziasis~1
regrafted~1
(88.9~1
1972-85,~1
Berkshire~2
Basingstoke~2
Authorities.~1
electoral~4
establishments.~2
registrations~5
0-4,~1
Wessex~1
372.5~1
1972-85~1
Dounreay~3
definite.~1
"hassle"~1
Managerial~1
receive.~1
Ironically,~1
"community~1
care,"~1
sheltered~2
visitor~1
imaginative~1
NdYag~1
patient-scored~1
Glandular~1
diastase~1
(DPAS).~1
(EMA),~2
(FVIIIAg)~1
1-(2-tetrahydrofuryl)-5-fluorouracil,~1
tegafur~4
(FT-207),~1
(FT-G).~1
tegafur,~1
FT-207~2
(UFT).~1
UFT~3
FT-G,~1
(Bain)~1
Bain~6
CO2-profile~1
rebreathed,~1
(TIMI),~1
(rt-PA).~2
(+0.7~1
+1.0~1
(+0.4~1
+0.3~1
hyperkinesis~1
.23],~1
(rt-PA,~2
(I/LV),~1
(rt-PA~4
(I/LV,~1
VI).(ABSTRACT~1
(GTN)~1
nitrate-antianginal~1
GTN~3
GTN-induced~1
SIN-1~1
Tyne~2
actuarially).~1
actuarially)~1
tympanum~1
50Gy~1
(hANP)~3
(non-HD)~1
150/90~2
(cardiothoracic~1
endosteum~1
fronts~2
mm/year~1
front.~1
ethane-1-hydroxy-1,1-diphosphonate~1
(EHDP),~2
3-amino-1-hydroxypropilidene-1,1-diphosphonate~1
(APD).~1
magnifies~1
interferences.~1
rarefying~1
antiosteoclastic~1
99mTc-EHDP~1
(HyPro)~1
nonadjusted~1
aminobisphosphonate~1
(P-C-Ps).~1
P-C-Ps~2
(QDop),~1
(QCO2)~1
(QDD)~1
(QDOP~1
QDD~4
QCO2~5
(QDop~1
0.17;~1
mg/kJ.~1
lipogenesis;~1
one-half,~1
T3/thyroxine~1
(3,3',5'-tri-iodothyronine,~1
rT3),~1
T3/rT3~1
rT3-treated~1
therapist-administered~1
up-draft~1
(UDN),~1
(MDI),~1
q4h~1
UDN.~1
UDN~2
non-ICU~1
$253,487~1
Methacetin~1
O-dealkylation~2
methacetin~1
[13C]methacetin~3
13CO2~3
Accomplishing~1
spreadsheet.~1
GC2)~1
GC2~2
TR-ST~2
cell-Sertoli~2
phophatidylinositols.~1
(5-min)~1
thousand-fold~1
(2500)~1
(OCC)~1
OCC.~3
(A23187~1
ionomycin)~1
OCC,~1
FSH-sensitive~1
ionophore-dependent~1
OCC~1
FSH-dependent~3
GH-regulatory~1
Six-hour~1
(s)~1
ng/10~1
icv,~1
icv-treated~1
icv-injected~1
(1-29)NH2~1
iv-treated~1
326.6~1
(407.2~1
145.4~1
(10(-8)M)~1
synthase)~1
phospholipase-mediated~1
stores)~1
10.5),~1
stimulated)~1
3.0.~1
FSH-stimulated,~1
[125I]hFSH~4
LHRH-~2
proestrous,~1
estrous,~1
30-90~1
mediates,~1
stage-related~1
degenerating.~1
32-,~1
44-day-old~1
75-day-old~1
posthypophysectomy~1
60-micrograms~1
(6-fold)~1
FSH/ml.~1
autocrine-paracrine~1
Hypothalamic-pituitary-end-organ~1
(GHRH)-stimulated~1
GHRH-elicited~2
GH-inhibiting~1
40-41K~1
ribosylated.~1
[125I]Tyr0-SRIF~1
pertussis-insensitive~1
nucleotide-regulatory~1
t0.~1
2-micrograms~1
(t240)~2
(t150)~2
t30.~1
male-related~3
Subnormal~1
3,059~1
4,711~1
1,554~1
neighborhood.~1
25-amino~1
chromatography-pure~1
(0.125-1~1
secretion).~1
microgram/kg.~1
perfused)~2
P(AA)~1
1-14C-P(AA)~1
leucotriene~2
20-hydroxy-LTB4~1
(20-OH-LTB4)~1
(20-COOH-LTB4),~1
unmetabolised~1
acid--for~1
12-hydroxyheptadecatrienoic~1
(HHT),~1
lipoxygenation~2
(ATPase).~1
Na+,K+-ATPase,~4
glycosides.~1
mEq/kg/day,~1
1520~1
(BF).~1
(dialyzer~1
Biospal~1
3000S,~1
301;~1
Qd~1
545;~1
36.76~1
(756~1
CH3COO~1
(677~1
(acetate~2
mEq/dialysis)~1
CO2-T,~1
CO2-D~1
172.8~1
mM/h~3
CO2-T~1
149.2~1
BD.~2
PoO2~1
dialyzer,~1
(ventilated~1
filtered)~1
BD,~1
(BiBF)~1
RDT:~1
BiBF.~1
Na-bicarbonate~1
waste-molecules~1
(BF);~1
ABB~2
0',~1
30',~1
60',~1
120'~1
180'~1
AD-acidosis~1
alkalotic,~1
(QZ)~1
readable~1
cardiograms~1
QZ~10
NB,~2
(EXP)~1
(INSP).~1
[Q(RB)].~1
INSP~3
Q(RB)~2
7-26~1
1/min.~1
QZ(NB)~1
0-200~1
Postmortem,~1
(Qwl/dQl)~2
slides,~1
706)~1
467)~1
Qwl/dQl~2
6.81~1
9.34~1
hydrostatic,~1
(leukotrienes)~1
FPL's)~1
vasoconstriction:~1
7.0%.~1
755C~2
gradational~1
braked~1
VCO2)]~1
l/l~2
VCO2;~3
zenith~1
(HVR)~1
HVR.~4
low-altitude~1
(1,600~2
PACO2)~1
mmHg]~1
pHa)~1
U]~1
often-reported~1
Cyclooxygenase~6
15-micron-diam~1
(ME),~1
Manohar,~1
1571-1577,~1
g-1),~1
ME,~1
adenosine.(ABSTRACT~1
pulse-modulated~1
MWR,~1
GHz)~1
(Sprague-Dawley,~1
13-day~1
MWR~4
mW/g~3
(DSP)~1
DSP.~1
leutinizing~1
CO2;~1
dissimilarities~1
intercostal,~2
(PIIA).~1
extravagal~1
Spike~2
ketamine-anesthetized~1
Pontamine~1
ambigual~1
retroambigual~1
rostrally.~1
inspiratory,~1
(BD),~1
(S/B),~1
(TPF),~1
(PF/TPF),~1
CO2-induced~3
TPF~1
S/B,~1
PF/TPF.~3
S/B~2
VLM,~1
(Rmax),~1
(Rmin),~1
(Est)~1
29.3-87.3~1
Cats~1
Rmax,~1
Rmin,~1
Est~1
Rmax~1
(99mTcDTPA)~1
3H]PGE2)~1
(wet-to-dry)~1
ANTU~4
ANTU-induced~1
ANTU,~2
carina;~1
over-ventilation~1
PaO2's.~1
Positioning~1
cyclooxygenase-derived~1
wedged-bronchoscope~1
attenuated;~1
515%~1
poikilocapnic~3
(4,800~1
(4,100-4,600~1
(3,600-4,300~1
Peak,~1
4,300-m~1
(130-145~1
4-6%~1
CO2-18%~1
(14.7~2
3.2%).~1
O2-50%~1
force-output~1
monocrotaline-induced~1
slow-reacting~1
anaphylaxis-like~1
detection)~1
pneumotachographs.~1
pneumotachograph~1
[125I]Tyr-ovine~2
marmoset,~2
CRH-related~1
peptides;~1
nM],~1
fmol/mg),~1
corticotroph.~1
(PCOD)~1
insulin-resistant.~1
[incremental~1
PCOD,~2
(incremental~1
623.8~1
78.3;~1
0.6%)~1
0.7%;~1
[Ac-delta~1
3Pro1,4F-D-Phe2,D-Trp3,6]LHRH~1
(4F-antagonist),~1
4F-antagonist~3
15-81~1
stimulability~1
-0.42~1
-0.38~1
age-correlated~1
Ca2+-ATPase;~1
pituitary-gonadal~2
Detirelix~3
N-Ac-D-Nal(2)1,~1
D-pCl-Phe2,D-Trp3,~1
D-hArg(Et2)6,~1
D-Ala10]LHRH)~1
10-,~3
12-28~1
(thyrocytes)~1
mU/mL~1
(Uvol),~1
(IDD)~1
[125I]iodohippurate~1
[51Cr]chromium~1
Uvol,~4
RPF,~5
pre-SRIH~2
Uvol.~1
GnRH-analog~1
(GnRH-A),~1
(bioLH)~1
bioLH,~1
bioLH.~3
bioLH~2
hormones).~1
BioLH~1
listeria~4
CAF1~1
(rMuIFN-gamma)~1
rMuIFN-gamma-treated~1
rMuIFN-gamma~1
1,4,5-triphosphate~1
5'-O-(2-thiophosphate)~1
(GDP~1
[32P]ADP~1
42-kD~1
IP3-induced~1
toxin-resistant~1
TxA2-stimulated~1
Histopathologists~1
(streptokinase,~1
activator),~1
(anemic)~1
features--syncope~1
bifascicular~1
block--that~1
quality-adjusted~3
$24,200.~1
$14,300.~1
$6,900.~1
$16,900.~1
bradyarrhythmic~1
Wasting~1
fluid/electrolyte~1
nutritional/metabolic~1
J11d.~1
Cortical-type~1
J11d+.~1
J11d+~6
J11d-~3
(NKH-1)~6
"NK-sensitive"~1
KG1a,~1
non-cytotoxic~2
mu,kappa~1
B4B2,~1
B4B2~8
C57BL/6-like~1
(B6-like)~1
C3H/He-like~1
(C3H-like).~1
B6-like~2
C3H-like~2
BXH~1
B4B2+~4
(C57BL/6xC3H)F1.~1
B4B2+:Lyt-2+~1
anti-IJk~1
anti-IJd~1
Ts1,~1
Ts2,~1
(moAb),~1
Leu-5b,~1
moAb~2
act.~1
Leu-5b~3
(LDCC).~1
2-responsive~1
HT29,~1
(HT29~1
7.9.~2
endopeptidases,~1
(T3/Ti)~2
mannoside~1
(acetylsalicylic~1
(OH.)~1
dimethylthiourea.~1
HOCL~1
HMPS~1
HOCL.~1
SH-dependent~1
hemolysin.~1
Vinblastine~1
CB.20~10
IgH-1~1
anti-L3/T4~2
anti-Lyt-2,~2
anti-L3/T4,~1
L3/T4+~1
Armstrong.~1
anti-Lyt-2-treated~2
Armstrong-triggered~1
interferon-alpha,beta~1
Anti-L3/T4~1
antivesicular~1
protozoan,~1
immunosecretory~1
(weeks~1
halted,~1
(secretory)~1
DJH~5
mu-chains~1
phthalate-specific~1
2E9,~1
anti-phthalate~3
2E9~8
(A/HeHa,~1
C3Hf/HeHa)~1
Anti-phthalate~1
BC.8,~1
IgCH~4
CB.20,~1
C57BL/6)~2
allotype/idiotype~1
nonconcordance~2
SM/J~1
BXD~1
VH-Xmp~1
(pDH7)~1
lambda-chains~2
Basilea~1
(FR1)~1
FR2-CDR2~1
mini-gene~1
14-nucleotide~1
CDR2~1
D-gene~1
lambda-chain~1
pDH7~1
lambda-sequences~1
homology),~1
MRL-lpr/lpr,~2
VH,~2
J558~5
7183~3
Q52~3
S107~3
(IFN)-gamma~3
-beta.~2
[3H]-uridine~1
[3H]Uridine-labeled~1
IFN-activated~1
promoter-associated~1
PHA/PMA-mediated~1
activation-mediated~1
(IFN),~1
parvum-induced~1
anti-IFN-gamma.~1
(M4Be,~1
M3Da,~1
NTerDa)~1
(Doc8,~1
M1Do)~1
Doc8~1
M1Do~1
G75,~1
12,000.~1
Sephadex-separated~1
(TDCF)~1
(M3Da)~1
(M4Be)~2
(M3Da).~1
anti-P15E~1
(TDCF~1
P15E-related~1
(Mlsa,d)~1
non-MHC~7
delta-treated~3
H-2-compatible~2
H-2a,k,j,p~1
H-2f,g~1
H-2b,s~1
responder)F1~1
(non-IgD-treated)~1
genes.(ABSTRACT~1
(MHC)-associated~1
cell/antigen~1
MHC-associated~1
KJ16-133.18~1
KJ16-133.18+,~1
F23.1+,~1
IA-,~1
IE-.~1
(E9.D4)~1
(anti-ABA~1
Iak),~1
(4.35F2)~1
(anti-Iak).~1
phase-coupled~1
plastic-adsorbed)~1
plastic-adsorbed~1
GK1.5,~1
Sepharose-4B~1
superoptimal~1
non-TCR~1
enhanced).~1
Anti-L3T4~1
cell/ligand~1
disruption.(ABSTRACT~1
anti-T6,~2
(Rec-IL~1
(Mo),~1
anti-T8-FITC~1
anti-T4-biotin~1
Mo),~1
T3-T6-thymocytes~1
(T6+)~1
detaches~1
(Tcr)~1
Tcr~4
(lytic)~1
anti-constant~1
anti-variable~1
CD-8~2
Tcr/CD3~1
B1355S,~1
dextran-reactive~4
14-mo-old~2
2-mo-old~3
B1355S~1
dextran-specific~1
phagocyte-activating~1
gondii;~1
pulsing,~1
rIFN-gamma/square~1
antitoxoplasma~2
5.9-fold~1
H2O2-releasing~1
(sperm,~1
trophoblasts)~1
(BeWo)~1
(Jar)~1
inducible.~2
IFN-gamma-enhanced~1
BeWo,~1
Jar~1
(IFN)-alpha~2
IFN-gamma-stimulated~1
1-inducing~1
B-A3,~1
(SAC)-activated~1
(FCS)~1
B-A3~5
2-free~1
BCGF-induced~1
Leu-12,~1
(Leu-4~1
Leu-9),~1
(Tac)~4
Anti-CD23~1
histamine/cell.~1
doxantrazole,~1
quercetin,~1
52694,~1
Pronase-resistant~2
monosulfated~1
disulfated~1
IgE+~1
pokeweek~1
Immunopurified~1
(Vig)~1
(Mod)~1
(Gr)~1
VigGrM~2
ModGrM~5
GrM~6
accessory/regulatory~1
Extensively~1
SEA-~1
KLH-induced~1
supernatant-pretreated~1
L-929~1
phi-derived~3
plaque-reducing~1
(PRF)~1
Vig~4
PRF,~1
PRF~1
IFN-alpha/beta.~1
lymphocyte-activating~1
LAF,~1
regulatory/accessory~1
Fractionated~1
g/ml.~1
(SLP).~1
SLP~3
(S-200)~1
(nonreducing~1
76,000.~1
(S-200~1
SDS-PAGE)~1
Listeria-immune~1
cell-mediated.~1
2.1;~1
lymphopoietic~1
ME-180~2
rTNA~1
SK-MEL-109~2
2)-containing~1
replenishing~1
(OKT3)~2
(beta-IL~1
(IFN-gamma)-lipopolysaccharide~1
(LPS)-mediated~1
p120~2
co-polymer~1
(MVE-II)~1
p120,~1
MVE-II-elicited~1
dinitrofluorobenzene~2
(DNFB)~1
IL-1-pretreated~3
suppressor-cell~1
effector-cell~1
DNFB.~2
CH-effector~3
abrogating~1
blade,~1
reepithelialized~1
morphology;~1
antifolate,~1
antifolates~1
sulfadiazine,~1
93%-100%~1
(EBV)-specific~1
.47,~1
auto-reactive~1
p99~1
27853~1
beta-lactamase-dependent~1
(PA-IGIV;~1
PA-IGIV,~1
PA-IGIV~3
Electroencephalography,~1
(DSM-III),~1
clinico-radiological~1
g-1.~2
blood-space,~1
nerve-water~1
motor-nerve~1
impermeability~2
[PVB])~1
(hemiorchiectomy,~1
hemiorchiectomy~2
azoo-~2
oligozoospermia;~1
interestingly~1
abortion;~1
Hypoxanthine:guanine~1
methotrexate-thymidine~3
(3.375~1
g/m2/24~2
flavum).~1
myelopathy:~1
Inconsistencies~1
favorable;~1
albumin-immunoreactivity~1
inconspicuous~2
oligo-dT-cellulose~1
polyacrylamide-gel~1
(lying).~1
20/min,~2
mmol/kg/d,~3
phosphaturia,~1
(1.34~1
Cohorts~1
content:~1
(aorta,~1
senescence.(ABSTRACT~1
(RCME)~1
8-(diethylamino)-octyl-3,4,5-trimethoxybenzoate.~1
mM)-valinomycin~1
RCME~3
KCl-valinomycin~1
KCl-valinomycin-stimulated~3
A23187-~1
(AA)-~2
[14C]stearic~1
acid-prelabeled~1
10(-8)-5~1
dinoprost~2
SKF-525A,~1
SKF-525A~1
diminution,~1
AA-induced~2
Precontraction~1
monooxygenases~2
relaxing,~2
(103-126),~2
Atriopeptin~3
(103-126)~1
(4-400~1
(0.4-4.0~1
nmol/kg/hr~1
(103-125)~1
(103-123)~1
atriopeptins.~1
(FIGD)~1
FIGD~1
dehydrotestosterone~1
(IVN)~2
IVN~7
non-protein~1
IVN.~2
VIII:C,~1
VIII:Ag,~1
VIII:Ag~1
VIII:Ag/F~1
DVT(+)~1
DVT(-)~1
6-hydroxy-dopamine~1
(6.57~1
mumols/gm./2~1
cervix:~1
impressive.~1
pickled~1
nonfilter~1
sprays.~1
Four-day~1
prediet~1
kilocalories/day)~1
2,074~1
1,277~1
lung-collapse~1
(TB).~1
(2,141~1
sanatoria~1
1954;~1
[standardized~1
24],~1
(SMR~1
1,896~1
1.0-1.3],~1
drinkers)~1
1.0-1.7)~1
1.2-2.4)~1
Bay-region~1
dihydrodiol-epoxide~2
DMBA-DNA~1
eluted,~1
bay-region~1
androgen-treated~3
P5O~4
DPG~2
Androgen-treated~1
androgen-stimulated~1
uropathic~1
anti-THP~2
"cross~1
reactive"~1
sepharose~1
THP,~1
garnet,~1
best).~1
3.4.~1
Neodymium-yttrium~1
1,289~1
ion)~2
ion).~2
5J/cm2~1
(technical~1
laser),~1
Haemonetics~1
Receptaseal~2
"blood-related~1
costs"~1
equipment)~1
($555.00~1
$615.00,~1
($373.00~1
$426.00,~1
glutaraldehyde-preserved~3
Precardiac~1
adhesions).~1
patch-related~1
(pericardial~2
patched)~1
open):~1
Precardial~1
reoperations:~1
Ia)~1
Ib),~1
microgram,~2
Focal,~1
small-to-moderate~1
neuroregulator~1
neuropeptides,~1
depression-distress~1
literatures.~1
(per)~1
Flies~2
pero~2
arrhythmic,~1
perl~3
19-hour~1
29-hour~1
periodicities,~1
Wild-type~1
(amber).~1
(per-)~1
slow-running~1
clocks.~1
hypoactive~1
LFA-2~1
50-58~1
antigen-3~1
(LFA-3)~1
hypermutation~5
(D-J)~1
pre-rearranged~1
kappa-transgenes.~1
kappa-transgenes~1
mutated.~1
transgenes;~1
target;~1
hypermutations~1
heptamer-nonamer~4
copies,~1
tyrosyl-transfer~1
(mutant~1
TP51)~1
non-additive~1
TP51~5
(histidine~1
tyrosyl-tRNA~1
non-polar~1
disfavoured~1
hominid~2
short-period~1
'robust'~2
australopithecine~1
hominids,~1
enamelled~1
australopithecines,~1
apes,~1
hominids~1
erupted~1
hominids.~1
(T3)-T-cell~1
(CD3/Ti)~1
Tp44)~1
Ly-6)~1
Thy-1-dependent~1
CD3/Ti~3
CD3/Ti-~1
CD3/Ti-,~1
Thy-1.2+~1
reconstributed~1
CD8-positive~2
CD8-negative~2
FL-conjugated~3
supertransfecting~1
(HIV-1),~1
(HTLV-4),~1
Senegalese.~1
AIDS-like~1
LAV-2~1
(STLV-3)~1
STLV-3~1
SIV)agm,~1
STLV-3mac,~1
STLV-3smm).~1
HIVs,~1
STLV-3s~1
STLV-3agm,~2
HTLV-4,~1
split-drop~1
alpha-rANP~1
Synapsin~1
dephospho-form~1
synapsin~5
bundling~1
(40-watt~1
0.5-second~2
impacts),~1
106.0~1
9.3).~1
(vasogenic)~1
vocalization,~1
nonmasticatory~1
monoexponential.~1
2.75%~1
CSF/blood-brain~1
2.88,~1
2.42,~1
DN-1417~1
"autorefractory~1
state").~1
DN-1417,~1
admissions)~1
hyperalimentation;~1
emulsion;~1
tubes;~1
independently)~1
candidemia.~1
ketaconazole~1
atypically.~1
Thyroiditis~1
(Inderal),~1
hormone-suppressive~1
KLP)~1
KLP~2
KII~2
nonamer-heptamer~1
KLP,~1
KLP.~1
KLP-DNA~1
2700-fold,~1
5.70~1
10(-10)M.~1
60,500~1
holoreceptor~1
bridge(s).~1
[adrenocorticotropic~1
(ACTH)],~1
somatomammotropin,~3
side-chain-cleavage~1
[P450scc~1
[corrected];~1
reduced-adrenal-ferredoxin:oxygen~1
1.14.15.6]~1
rec+~2
recBC~2
sbcB~2
stable--deletions~1
overgrow~1
palindrome-containing~1
lysogen~1
prophage~1
replication-blocked~1
unreplicated~1
cross-hybridization~2
CD4.~2
beta-strands~1
JA3~3
Ti+,~1
T44+,~1
T40+)~1
gamma-radiation~1
T44,~1
immunoselection,~1
T44+~1
Leu1+~1
T40+~2
4F2+~2
I+~2
Immunoselection~1
anti-T44~3
T44-~1
Leu1-~1
T-cell-specific~2
(T3-~1
Ti-)~1
anti-Ti,~2
either;~1
(T3-,~1
Ti-,~1
T44-,~1
T11+),~1
(lacking~1
anti-M.~1
[aldehyde~1
alditol:NAD(P)+~1
1-oxidoreductase,~1
1.1.1.21]~1
medulla),~1
Ethylenediaminetetraacetato~1
iron(III)~2
[(EDTA)Fe(III)]~1
peroxycarboxylic~2
(YOOH;~1
heterolytic~1
O-O~1
[(EDTA)Fe(III)~1
YOOH----[(EDTA)(FeO)]+~1
YOH].~1
(kYOOH)~1
YOOH~1
(EDTA)Fe(III)~1
sporulation-essential~1
(P31)~1
P31~5
P31.~1
(spoIIE)~1
P31,~1
Microsequencing~1
29-like~1
(P31*)~1
Protease-treated~1
P31*,~2
29-recognized~1
GXXXXGK,~1
DXXG,~1
NKXD~2
130-170~1
NKXW~1
GTP;~3
conservations~1
foot-and-mouth~2
(polio,~1
rhino,~1
encephalomyocarditis,~1
cowpea~1
mosaic)~1
Ecological~1
semelparous~1
47-83%~1
(NK)-like~3
YT~9
IL-2-receptor~1
SENCAR~1
(7,12-dimethylbenz[a]anthracene~1
13-acetate).~1
intrapapillomatous~1
(neurotransmitters~1
ANF-binding~2
association-dissociation~1
supposes~1
marinus~1
tight-seal~1
positive-going~1
muscarine.~1
discernibly~1
(M-current),~1
[Sims,~1
Singer,~1
Walsh,~1
V.,~1
Jr.~1
367,~1
503-529],~1
IL-2-binding~1
IL-2-EGF~1
GPA1,~1
contiguous,~1
54,075.~1
GPA1~1
(tentatively~1
(Go~1
alpha);~1
(472~1
antibiotic-resistance~1
hyphenated~1
(palA)~1
palA~2
pT181~1
3'-extension~1
Khan,~1
rolling-circle~1
TATAAAA~1
polyadenylylation.~1
2-microns~1
(FLP)~1
FLP~4
Int~2
recombinases~1
tyrosine-343~2
FLP.~1
lymphomyeloid~1
p60v-src~4
nontransforming~1
p60c-src,~1
nonmyristoylated~1
detergent-soluble~1
(rDNA)~1
rDNA-deficient~3
X-Y~2
YL.~1
Ybb-,~1
Ybb-chromosome~1
YL~2
(der)~1
predecessors.~1
der(18)~3
H-chain~1
der(14)~3
"N"~1
DH-JH~1
joining,~1
pre-B-cell.~1
150-base-pair~1
18q21,~1
junctures,~1
staggered~2
endonuclease-mediated~1
N-segment~1
(VH~1
VL)~1
W3129,~1
anti-alpha(1----6)-dextran~1
VH441,~1
anti-galactans~1
anti-levans.~1
W3129~2
galactan-~1
levan-specific~1
PC118.~1
(VH).~1
VH81X~1
VHOx2~2
(OVB-3)~1
(10/10)~1
OVB-3~1
(NIMS)~4
postneonatal,~1
(Note:~1
births.)~2
tabulations~2
single-delivery~5
live-birth~1
NIMS~2
tabulations.~1
(IMR)~3
[CI])~1
10.1),~1
Northeast~1
10.6),~1
11.0),~1
12.3).~1
IMR~10
nation:~1
1.09,~1
1.11).~1
grams),~1
grams,~1
State-specific~2
1960.~1
(Infant~1
11.0;~1
IMRs~1
days)--73~1
percent--occurred~2
1,500-1,999~1
year)--51~1
IMR.~1
500-2,499~4
"conditions~1
period,"~1
Prematurity-low~1
trauma-hypoxia-asphyxia~1
500-1,499~2
available)~2
rubric.~1
cohorts;~1
14,714~1
8,674~1
nationally,~1
(NMR)--that~1
births--for~1
NMRs~1
(PNMR)--PNMR~1
survivors--for~1
PNMR~2
PNMRs~2
562,330~1
grams).~1
10-29~1
2,527,813~1
28,499~1
Record~1
2,604~1
postneonates,~1
cohort's~2
intrastate~1
State),~1
100.0.~1
States'~3
areas--50~1
(subsequently~1
States)--from~1
plurality.~1
certificates:~1
NIMS,~1
Statistics.)~1
procedures--these~1
data--affect~1
NIMS.~1
Ambiguities~1
data.(ABSTRACT~1
problems--the~1
Linked~2
specific-mortality~1
nine-State~3
natality~2
93.2~1
underway,~1
1983-86.~1
Services'~1
Evaluation,~1
incursion~1
sociocultural,~1
7,739~1
3,393~1
4,346~1
1-84~1
11-15-year~1
21-50~1
ommatidia~1
sevenless~6
R7~1
(Leu-1+),~1
Ly-1+~3
Leu-1-~6
self-antigens,~1
(Leu-1+)~1
ion-guanosine~1
triphosphate-tubulin~1
ion-induced~1
(BANF)~2
BANF~4
D22S9~1
22q11.~1
coherently~1
deoxyadenylate~1
ori~3
non-bent~1
(subunit~1
alpha-guanine~1
Gk~2
Gs,~1
function--the~1
channel--through~1
satellitism.~1
satellitism~1
IgM-kappa~4
anti-I~1
vasovasostomy.~1
Fusion-coagulation~1
sperm-tight~1
(IrANP)~1
Wolf-Parkinson-White~1
aute~1
(55.9~1
non-polyuria~1
(RNV).~1
RNV~2
Loculated~1
background-subtracted~1
Visually~1
"extent"~1
(96%);~1
feeding-associated~1
1249~2
g/kg/d.~1
HTLV-III/LAV/HIV~1
Preexposure~2
restrictively~1
vasoconstricted~4
immunotyped~1
kappa-bearing~1
lambda-bearing~1
immunoglobulin-negative~1
(histiocytic)~1
hypercapneic~2
spirometric,~1
took,~1
hospital-controlled~1
[35S]polysaccharides~1
[35S]proteoglycans~1
[35S]glycosaminoglycans,~1
(Q-wave)~1
(GLUT).~1
GLUT-induced~1
3H-GLUT~1
nm/mg)~1
(Ca2+,~2
micrograms/mg)~1
digestion)~1
residues/1000~2
[AA]).~1
(Lys~1
Hyl~1
wt);~1
micrograms/mg).~1
(TAC~1
TAC~4
TAC-bearing~5
(WDL),~1
TAC-positive~2
TAC-positive.~2
PDL~1
TAC-negative.~1
(B-cell,~1
T-lymphoblastic~1
lineage-specific,~1
(RAP-5).~1
prostaglandin-forming~1
89Sr.~1
(LTC4),~1
89Sr-treated~1
88Sr~1
PGE2-~2
LTB4-releasing~1
3H-arachidonic~2
89Sr-induced~1
elicitation.~1
PGE2-synthesizing~1
endocrinelike~1
micronests.~1
combinedly~1
subject).~1
nondelusional~2
(TRH),~2
abstract.~2
monies~1
transanastomotic~1
nephrectomies,~1
Triacylglycerol~1
BAC-time~1
(AUCs),~1
AUCs,~2
placebo-placebo;~1
midazolam-placebo;~1
15-1788-placebo;~1
midazolam-RO~1
15-1788-placebo,~1
15-1788-midazolam~2
sessions--although~1
midazolam-placebo~1
15-1788-placebo~1
atrially~1
190-200,~1
post-countershock~1
epicardial-to-endocardial~1
(0.97~1
-0.03)~1
pre-shock~1
(Ang~1
(BW755C)~1
BW755C~1
BW755C.~1
1.28,~1
decrease.(ABSTRACT~1
vasopermeability.~2
(fibrinogenolysis)~1
(decreasing~1
(cv)~1
cv,~1
(pHa~1
pHcv)~1
.31~1
(PcvCO2~1
(PIVA)~1
ointments.~1
venodilation~1
PIVA~1
substrate-velocity~1
[S50]-1,~1
elastase-elastin~1
[S50]-1~1
elastins.~1
S50(-1)~1
separately.(ABSTRACT~1
sloping~2
plateau-knee~1
enterococci--six~1
Zervos~1
perivasculitis.~1
mustard-N-oxide~1
(NMO)~1
burst-evoked~1
pseudothresholds~1
NMO-treated~1
(U-70138F)~1
paldimycin~1
tircarcillin~1
[3H]tobramycin~1
Plotz~1
135:1067-1068,~1
1962).~1
africanum,~1
chelonei)~1
calvulanic~1
amikacin-susceptible~1
antibiotic-free~1
nonpigmented,~1
small-colony~1
noncompartment~1
460.7~1
X-static)~1
X-static~2
blend,~1
(trough),~1
sterilizing~1
Continuous-infusion~1
dose],~2
[intramuscular]).~1
trifluorinated~1
23-6240~2
cantharidin-induced~1
11.95~1
58.6%~1
O-acetylated~1
non-O-acetylated~1
O-acetylation~1
peptidoglycan.~1
monobactam,~1
pro-drug,~1
28100,~1
(Z)-propenyl~1
p-hydroxyphenylglycyl~1
28100~7
catarrhalis;~1
ceftazidime-resistant~1
(PA-48,~1
PA-60),~1
(PA-96)~1
bioinactivation~1
PA-60.~2
beta-lactam,~1
nonhydrolytic~1
PA-48~1
mutationally~1
enzymes)~1
erythromycin-susceptible~1
965)~1
concealed.~1
(VOL),~1
non-weight-losing~1
(WL)~1
d-glycerol~1
1-13C~1
WL~8
lipolysis;~1
lipid.(ABSTRACT~1
shiver~1
Metubine~1
(metocurine)~1
hemangioendotheliomas~1
hemangioendothelioma:~1
cancerization~1
(lymphagitic~1
lymphangiomatosis.~2
budgetary~1
blood-product~2
$111,286~1
savers,~1
oxygenators,~1
surgeries.~1
saver~1
(Sorenson)~1
[0.25])~1
Cerebro-ocular~1
dysplasia-muscular~1
(COD-MD)~1
agyria-micropolygyria,~1
glial-mesodermal~1
heterotopias,~1
microphthalmia,~1
COD-MD~3
Walker-Warburg~2
Warburg)~1
Fukuyama~1
3H-PGE2~1
3H-C20:4~1
(109%).~1
doubling,~1
rate-controlling~1
venturi~1
noncaloric~1
electronystagmograms~1
nystagmic~1
overinjection~1
overinjected~2
Realizing~1
polyvinylchloride,~1
(Mentor~1
Inc,~1
Hingham,~1
Mass)~1
hemilarynx.~1
ignite~2
glow~1
(nonlaser)~1
Laryngologists~1
Fabry's~7
galactosidase~1
angiokeratoma~1
co-operative,~1
Anexate~2
15-1788)~1
(anexate)~1
anexate~1
obey~1
commands,~1
b.p.m.~1
(CPPV),~1
Paw)~1
b.p.m.).~1
(tpa)~1
tpa~7
(a2PI)~1
(dilute~1
(DWBCLT)~1
(DWBCLT~2
DWBCLT~1
a2PI~2
L-lysine~3
anti-tPA-Ig-sepharose.~1
anti-tPA-Ig-sepharose~1
100-kd~2
fibrin-agar~2
zymography.~5
tPA:inhibitor~2
tPA/mL.~1
anti-tPA~2
tPA-depleted~2
tPA-induced~1
zymography,~1
rezymography~1
inhibitor-tPA~1
tPA-inhibitor~1
(PAI-2)~1
endothedial~1
PAIs.~1
(IL-2R)-positive~1
IL-2R-negative~5
IL-2R-specific~3
I3-2R~1
determinant-triggering~1
cytofluorography.~1
(NAB-T)~1
rIL-2,~3
IL-2R-positive~6
anti-IL2-receptor~1
rIL-2-mediated~1
(IF-gamma)~1
CD3-triggered~3
rIF-gamma~1
rIL2-mediated~1
IF-gamma~2
(S12)~1
GMP-140,~1
1,120~1
7,529~1
(M-CSF,~1
M-CSF.~1
M-CSF-like~1
quinMF,~1
[2-(2-amino-4-methyl-5-fluorophenoxy)methyl-8-aminoquinoline-N,N,N',N'-~1
tetraacetic~2
FBAPTA~1
(1,2~1
bis-(2-amino-5-fluorophenoxy)~1
FBAPTA;~1
FBAPTA.~1
(FVIII)~1
FVIII~3
92-kd~3
44-kd~1
80-kd~3
72-kd~1
(alloantibody)~1
(autoantibody)~1
IgG-1~3
IgG-4~3
IgG-3.~1
anti-Rh(D)~7
(IgG1(lambda),~1
H2D5D2)~1
(Rh)~1
(iodo-gen~1
procedure),~1
D--/D--,~1
R2R2~2
R1R1~1
mol/L-1.~1
Rh(D)~7
Rh(D)-positive~2
Rh(D)-negative~1
(Blo.,~1
R2r~2
R0R2)~1
10(5)/cell)~1
mol/L-1)~1
D--/D--~2
29-kd~2
sialoglycoproteins,~1
Blo.~1
(Sporn~1
46:185,~1
A23187-released~1
releasate,~1
adsorbed,~1
overlaid~1
multivalency~1
Xbal~2
BclI~2
BglI/intron~1
(homozygous)~1
BglI~1
BclI/intron~1
Xbal/intron~1
carriership.~1
Taql/St14~1
(THP-1~1
c-myb,~3
c-fos/c-myb~1
(Tis,~1
Tl)~1
Consultant~1
(203/243)~1
taught;~1
apprenticeship~1
done--namely,~1
renal.~1
avail,~1
1981-3~1
Censuses~1
censuses~2
replenished.~1
squads~1
squad~1
splenectomised~1
embolisation,~2
embolisation.~1
Monash~1
anembryonic~1
IU/l,~1
(25th~1
fertilisation.~2
68.1%,~1
16.7%,~1
35-49.~1
39,207~1
35-39.~1
45-49~1
Lambeth~1
"trade~1
off."~1
1,1,1-trichloroethane.~1
sniffed~1
trichloroethane~2
trichloroethane.~1
towns.~2
7729~1
non-fatal)~1
non-Asian~2
Leeds,~1
Luton,~1
Manchester.~1
organisations.~1
Penrith.~1
1980-4,~1
1267~1
Penrith,~1
1153~1
Carlisle.~1
4.7/1000.~1
housing,~1
overcrowding,~1
(microalbuminuria).~1
55-117)~1
(38-57)~1
isoenergetic,~1
(15.0-170.1)~1
(4.1-97.8)~1
25-37.5~1
origin),~1
8-70)~1
7-57)~1
9-72)~1
8-58)~1
thyroxine)~1
childlessness~4
childless.~1
compartmentalizing~1
(anorexia~1
bulimia),~1
Most,~1
consulted.~1
intolerance--for~1
eczema--had~1
tackle~1
urgently.~1
1600-1800~1
street,~1
1964-73~2
1974-85~1
1974-85,~1
periods--about~1
Wales--but~1
organise~1
Midlands.~1
stereoelectrocencephalographic~1
(SEEG)~1
hallucination~2
opercula~1
staring~1
purposeless~1
suprasylvian~1
tumour-derived~1
10,330~1
(cost-benefit~1
$280,000~1
$70,700.~1
0.859~1
"tumour~1
gamma),~1
(SCMC)~1
neopterin,~2
(B2-M),~1
(OKT11,~1
E-AET~1
LeuM2+,~1
LeuM3+~1
(MC-HD),~1
(PMBC)~1
non-T-mononuclear~1
SCMC,~1
B2-M,~1
double-barrel~1
ion-sensitive~1
-50.1~1
(-85.0~1
-97.2~1
-81.2~1
(-93.8~1
change(s)~1
10-60~1
14,15-epoxyeicosatrienoic~1
(14,15-EET)~1
11,12-EET/ml~1
8,9-EET/ml~1
adenosine/ml~1
5,6-EET/ml~1
EETs~2
EETs,~1
nonprostanoids,~1
arachidonate/ml~1
Landis~1
3.79-fold~1
conductivity;~1
subocclusive~1
angiography.(ABSTRACT~1
(FDP),~1
(XDP)~1
XDP~2
XDP/FDP~2
fibrinogenolysis,~1
ineffectively,~1
0.63M~2
0.079M~2
excipient.~1
carbon--changes~1
experimentally-induced~2
(SCG),~2
anti-allergic~1
RES,~1
lactalbumin,~1
[SCG(+)],~1
[SCG(-)]~1
SCG(-)~2
SCG(+)~1
(FBF)~2
radioisotope.~1
FBF~8
cooling).~1
humorally~1
encainide.~1
(alpha-ANP)~2
volume-expanded.~1
(PiaO2)~1
PiaO2~4
18-ga~1
O2-CO2~1
18.6);~1
PiaO2,~1
3.88~1
27.7);~1
15.2).~1
peptide-based,~2
venous-arterial~2
low-flow,~1
low-flow.~1
dp/dtmax).~1
Endotoxic~1
LD80~1
equivolume~1
(alive/total~1
0/5).~1
bronchostenosis.~1
fibrostenosis~1
non-cavitary~1
(HLT)~1
HLT.~1
(female:~1
3.6:1)~1
13-48~1
(PFO)~1
PFO,~1
chlormadinone~1
(CMA),~1
"correctors,"~1
CMA,~2
"noncorrectors"~1
CMA~1
acetyl-5-aminosalicylic~1
(PMNs).~2
[1-14C]arachidonic~1
1-9~1
steroid-like~1
Optimized~1
nonconstant~1
ketonuria.~1
(DKA)~2
(0.65%~1
DKA~3
$1,000,000~1
less-expensive~1
Pumps~1
1137~1
$24~1
$63~1
0.22),~1
$80~1
$3073~1
$3228~1
gram,~1
incurred.~1
hypothalamo-pituitary-thyroid~1
Neonatally~1
androgenization~2
micrograms/rat~1
6-week-castrated~2
TRH-TSH~1
(IRP)~1
IRP~7
substructure~1
(PGE1),~2
expandable;~1
factor-44~1
(GRF).~1
rPRL.~1
perifusion-immunoprecipitation~1
(1.2%~1
Bu2cAMP;~1
nonfluctuating~1
midafternoon~2
E2-exposed~1
Retinal,~1
dioctanoyl~1
[RII51;~1
51,000)~1
49,000)]~1
RII51~10
(10-IU)~1
molecules/granulosa~1
(HEF).~1
estradiol-/FSH-induced~1
RII51.~1
luteinization.~3
(45-70~1
molecules/cell)~2
RII51,~1
(IGF-I)/somatomedin-C~1
somatotropes~1
24.5%).~1
somatostatin-induced~1
somatotropes.~2
(prevents~1
somatotropes,~1
(P450scc)~1
(30-fold)~1
hCG-induced~1
4-22~1
Administering~1
estradiol-primed~1
Collagenases~1
osteoblast.~1
106-01~2
25-fold.~1
immunoneutralized~1
anti-LHRH~1
(LHRH-AS)~1
LHRH-AS~3
[Des~1
Gly10]-LHRH~1
(DG-LHRH)~1
3-ng~1
DG-LHRH~7
nonantiserum-treated~2
0.1-20~1
mTNF~1
hTNF.~1
TNF-enhanced~1
noncyclooxygenase~2
factors-alpha~1
hTNF~1
(transient)~1
lasting)~1
cytophysiological~1
(-)R202-791,~1
54-74%~1
CRF-mediated~5
CRF-bound~6
CdCl2,~1
CdCl2.~1
G-75,~1
20K.~1
75K.~1
Substrate-derived~1
(Sz)-initiated~1
poly-ADP-ribose~1
(p-ADPR)~1
NAD.~1
p-ADPR~2
Sz-induced~1
Sz~4
non-glucose-containing~1
glucose-specific~1
Sz-treated~3
nicotinamide.~1
thymidine-protected~1
Sz)~1
RPMI,~1
Sz's~1
p-ADP-ribosylation~1
[125I]fibrin~1
[(E2)~1
M],~2
[(P)~1
[(T)~1
M]~2
[(DHT)~1
35-210%~1
22-60%.~1
20-39%~1
STZ-diabetes~1
kidney/body~3
protein/kidney~2
saline-citrate-injected~1
(PAs)~1
(tPA),~3
(UK-PA).~1
UK-PA~4
FSH-treated~2
fibrin-independent~1
tPA,~3
UK-PAs.~1
V1-receptor~1
LHRH/LH~1
[N-Ac-D-pCl-Phe1,D-pCl-Phe2,D-Trp3,D-hArg(Et2)6,~1
D-Ala10~1
ram~1
alpha-hydroxy-4-pregnen-20-one~1
(3-HP),~1
3-HP,~2
3-HP~8
26-44%~1
0.001-0.05),~1
(3-HPA),~1
3-HPA~1
(0.001-0.625~1
(14-day)~1
3-HPA.~1
(15-day-old)~1
beta-hydroxy-5~1
alpha-androstan-3-one~1
beta-HP,~1
(0.025-0.625~1
beta-HP~1
administered),~1
(NMA),~1
gonadotropes~4
microgram/min~1
(1.5,~1
excitant~2
AcD2Nal1,4ClPhe2,DTrp3,DArg6,DAla10]~1
GnRH-HOAc)~1
(D,L-2-amino-5-phosphono-valeric~1
NMA-induced~1
BW).~1
hypoprolactinemic~2
(serotonin,~1
TRH)~1
amine.~1
P-Tyramine~2
hemipituitaries~1
[3H]spiperone,~2
diethyldithiocarbanic~1
octopamine~1
[125I-Tyr10]monoiodoglucagon~1
([125I]MIG)~1
[125I]MIG~2
observable.~1
Kact~1
p-hydroxysuccinimidyl~1
azidobenzoate~1
Ns,~1
FSH-mediated~2
[125I]iodo-FSH~7
FSH-binding~1
[125I]VIP~3
glycolbis-(succinimidylsuccinate).~1
guanosine-5'-O-(3-thiotriphosphate)~1
S),~1
guanylylimidodiphosphate,~1
(Ns).~1
58K~4
factor-(1-40)OH,~1
S-dependent~1
VIP-binding~1
n-octyl-beta-D-glucopyranoside.~1
(OT)-binding~1
3-[(3-cholamidopropyl)dimethylammonio]2-hydroxy-1-propanesulfonate~1
(CHAPSO)~1
OT-binding~1
[3H]OT-binding~1
CHAPSO-solubilized~1
[also~1
(LT)]~1
Atria~1
(LPX)~1
nutrient-induced~2
(0-1.7~1
LPX~11
(Ba2+;~1
BW755c~3
[3-amino-1-(trifluomethyl-phenyl)2-pyrazoline]~1
hydroxytoluene)~1
133Ba~1
stores;~1
vitiated~1
Ba2+-induced~1
(5,8,11,14-eicosatetraynoic~1
15-hydroxy-5,8,11,13-eicosatetraenoic~1
NADPH-activated~1
Ca2+),~1
isobutylmethylxanthine-induced~1
[8-(N,N-diethylamino)octyl~1
3,4,5-trimethoxybenzoate~1
stores].~1
redistribution)~1
12-O-tetradecanoyl-phorbol-13-acetate;~1
pool(s).~1
(TRH)-induced~1
(NL,~1
inphase~1
(AN/IN,~1
(LPD,~1
NL~2
AN/IN~1
LPD.~1
(TRH)-stimulated~1
periovulatory,~2
mg/hour)~1
accelerated,~1
hypogonad~1
therapy's~1
"Determine;~2
OvuTest"~2
(Ventco~1
Trading~1
Quebec,~1
(UTG),~1
UTG.~2
flushings,~1
UTG~1
UTG,~1
periovulation~1
(OHS).~1
OHS~4
OHS.~3
68.7%~1
(54.7%)~1
untreatable~1
treatment-independent~3
treatment-associated~1
retrieval).~1
non-IVF-ET~2
IVF-ET,~1
(decade~1
(testes~2
tubules).~1
Forty-five-day-old~1
(FRP).~1
FRP-treated~2
FRP~1
Levonorgestrel,~1
antigonadotropin,~1
Levonorgestrel~1
LDL/VLDL~2
low-response~1
ampule/day~1
normal-response~1
canceling~1
"surge"~6
pinpointed.~1
"nonsurge"~3
canceled,~1
(4/41~1
4/34~1
transfer)~1
(7/61~1
7/56~1
transfer).~1
(788~1
(2.33~1
1.99,~1
(24.4%~1
ovary).~1
pps,~1
81.25%~1
glucose-,~1
potassium-,~1
forskolin-,~1
90-110~1
55-60~1
110-120~1
(ICAs)~1
indirect-immunofluorescence~1
(lab~2
circulated.~1
128.~1
determinations.(ABSTRACT~1
1576,~1
near-saturating~1
Na+-K+-ATPase.~1
1576~2
glucosylation~1
Na+-K+-ATPase,~1
bombesin-induced~1
2%-3%~1
NKH-1+.~1
Panned~1
Leu-11-.~1
100:1,~1
(NKH-1-)~1
NKH-1-,~1
Leu-11-,~1
T8+.~1
(anti-T3)-induced~1
Withholding~1
life-sustaining~2
treads~1
slippery~1
judgments.~1
Courts,~1
self-determination,~1
6-Keto-PGF1~1
(518~1
(ATPase;~1
(NEH)~1
(ouabain~1
(PEH)~1
NEH~3
(10.27~1
Na/LRBC;~1
phosphate/mg~3
sites/RBC;~1
PEH~1
pumps.(ABSTRACT~1
1-25,~1
chloralose/urethan~1
(60:600~1
(mRNA~1
nonatrial~1
dehydrogenase-stimulating~1
586.0~1
norepinephrine-precontracted~1
ng/hr,~1
(DOCA-salt~1
densa,~1
nonfiltering,~1
(Anf)~1
Anf~4
susceptibility-1~1
(Fv-1)~1
Fv-1~1
body-denervated~1
nerve-denervated~1
(HND)~1
CBD,~1
HND~3
He-21%~1
mph-5%~2
mph-8%~1
(Tv)~1
27-62%.~1
Tv~2
18-41%~1
4-15%,~1
9-16%~1
27-32%.~1
(5-hydroxytryptamine;~1
(COI).~1
(LVR)~1
gravimetrically.~1
COI,~1
4.8-123.0~1
0.5-8.2~1
LLL)~1
COI~2
LVR~2
Ra/Rv~1
Ra/Rv.~1
7.6-207.0~1
24.6%.~1
forcings~1
dead-space~1
band-limited~1
(VARF)~1
VARF.~1
Periodicity~1
ACE,~1
(benzoyl-phenylalanyl-alanyl-proline,~1
BPAP)~1
7.1,~1
BPAP~4
causalty.~1
perfusate).~1
margination,~1
videomicroscopic~1
Lehnert~1
53:483-489,~1
inequality,~2
IPPV).~1
retention-excretion~1
(R-E*)~1
medium-solubility~1
Q)~1
IPPV.~1
R-E*~1
CFV.~1
oxidation-reduction~1
fluorocarbon-circulated~1
(605~1
(551~1
CO-mediated~1
b-cytochrome~1
CN-resistant~2
1-mM~1
445-nm~1
aa3-CO~1
km/h.~2
g-1;~1
(brachialis:~1
0.78),~1
(slow-twitch~1
oxidative-glycolytic)~1
heterogeneously~1
160-1,880~1
(-10~1
Theory~1
downstroke~1
(dpH/dt~1
dpH/dt~2
2,4-dinitrophenol.~1
tris(hydroxymethyl)methylamine~1
7.8-51~1
isocapnia.~1
Near-term~1
Gasping~1
(B/I~1
elderly)~2
[386~1
(234~1
(1180~1
(992~1
transition)~2
methyltrienelone~1
(41.3~1
(14.2%)~1
GnRH-deficient~1
(nLH~1
nFSH).~1
nLH~2
nFSH~2
(acromegaly,~1
58;~1
56;~1
TRH;~1
[125I]TSH~1
alpha-subunit-containing~1
GH-containing~1
infertile,~1
B2-microglobulin,~1
(McAg)~1
leucoagglutinin~1
McAg~10
B2-microglobulin~1
thyrocytes,~2
Anti-IFN~1
antiinterleukin-2~1
Anti-HLA-DR~1
INF~1
LAG,~1
DR-negative~1
directly;~1
LAG-induced~1
superagonist,~1
testosterone-secreting~1
leuprolide,~1
.2ml~1
(APir)~1
(NTFir)~1
APir~1
NTFir~1
NTF~1
(vasopressin~1
indomethacin--presumably~1
Formyl-methionylleucylphenylalanine~1
fMLP-activated~1
[Ca2+].~1
A23187-activated~1
[Ca2+]free~2
Neovascularization~1
(GST),~1
GST,~1
Axo-glial~1
preceeding~1
(Na,K)-ATPase~2
bio-breeding~1
dysjunction,~1
n-butyrate,~1
[3H]acetate~2
[3H]GAG~4
[3H]hyaluronate~1
70-90%.~1
Propionate~1
observe,~1
document,~1
signs"~1
Astemizole,~1
angioedema;~1
Alpha-myosin~1
chains).~1
mm/m2,~1
Chrysotherapy~1
corticosteroid-sparing~1
(EAR)~1
EAR~1
comparisons)~1
diproprionate~1
EAR.~1
nonbronchodilator~1
(SCG~1
pteronyssinus.~1
LAR,~1
LAR.~2
nutritionist.~1
nutritionist~1
holds,~1
Geriatricians~1
immunocyte-related,~1
transferrin),~1
non-antigenic~2
thromboxanes.~1
(B2),~1
[3H]AA-prelabeled~1
radioimmuno~1
niflumic~2
ligand-receptor-mediated~1
2-R)~1
2-R~5
cytosol-to-membrane~1
Structure-function~1
2-R.~1
TPA-mediated~1
T3-T~1
"nonfunctional"~1
medullary-type~1
(Lyt-2+~2
CTLp,~1
(LFA)~1
JS-93~2
JS-102~2
(moab)~1
moab~3
(p170,95).~1
IgG-FcR+~2
CD3-4-8-~1
(IgG-FcR)~1
IgG-FcR+,~1
P815,~4
Leu-11c~1
(B73.1)~1
CLB~1
Fc-gran~1
(VD2)~1
MAb).~1
(K562,~1
IgG-FcR,~1
IgG2a),~1
IgG-FcR~3
IgG-FcR.~1
"specificity"~1
cross-inhibit~1
CR11-115.~1
cross-blocking~2
CR11-462.~1
(i.p)~1
125I-IgG1;~1
(EAU).~1
cross-antigenicity~1
IRBP.~2
Leu-3/T4~1
Astrocyte~1
(anti-H-2Ld).~1
immunotherapies~1
(GC-J4,~1
MC-P2,~1
MC-P4)~1
MC-P2~4
MC-P4~5
anti-Leu-7~5
GC-J4.~1
GC-J4~1
GC-J4,~1
MC-P2.~1
CH12.LX,~1
(SRBC),~1
CH12.LX~5
3C7,~2
7D4,~2
3C7~1
[3H]thymidine;~1
7D4~1
5E2,~1
I-like~1
thymocyte-specific~1
cyto-fluorescent~1
5E2~4
R-Ta~1
CT1~1
CT2~1
CT-,~1
Interesting~1
CT+,~1
T200-~1
marrow-derived.~1
20-COOH-LTB4,~1
20-OH-LTB4,~1
5-(S),12-(R)-6-trans-LTB4,~1
5-(S),12-(S)-6-trans-LTB4,~1
[3H]phorbol~1
([3H]PDBu)~1
didecanoate~1
(PDD),~1
[3H]PDBu~1
PMC~5
HUT-78~1
(HSV)-1~1
pinna.~1
HSV-1-gD~2
virus-neutralizing~1
(P28)~1
P28~2
schistosomes:~1
pyocyanine~7
pyocyanine,~1
Pyocyanine~1
Ca2+-Mg2+~1
CT6~4
proto-oncogenes.~1
Factor-independent~1
C-specific,~1
antigen)-restricted~1
182-amino~1
89-amino~1
44-amino~1
membrane-proximal~1
16-amino~1
68%)~1
inositol-trisphosphate~2
(C-kinase)~1
C-kinase~3
12-O-tetradecanoyl-phorbol-13-acetate,~1
signal-dependent~1
cDNA-missing~1
7G7/B6.~2
secret~1
well--all~1
mu-expressers,~1
3-expressers,~2
1-expressers,~1
2b-expresser,~1
incomplete--on~1
KG1,~1
(KG1m)~1
iC3b-mediated~1
OKM10,~1
KG1m~3
Mo1-related~1
EiC3b~2
KG1m-derived~1
KG1~2
AKR-streaker~1
(nustr/nustr)~2
reticuloepithelial~1
(TRE)~1
(stroma)~1
N-tropic~1
infection-susceptible~1
(Fv-1n/n)~2
N-tropic-MuLV-infection-resistant~1
(Fv-1b/n)~1
Fv-1n/n~1
leukemia-incidence~2
Fv-1b/n~1
nustr/nustr~4
N-tropic-MuLV~1
mustr/nustr~1
nustr/+~2
Fv-1n/n-thymus-grafted~1
Qa-1~1
anti-BALB/c~1
anti-Qa-1b~3
anti-Qa-1~3
anti-NZB~1
anti-I-Ad~1
Ia-unrestricted~1
Qa/Tla-encoded~1
Ts-dependent~1
M7/20~5
immunoaugmenting~1
gp67)~1
CD5+/CD3+~1
CD5-induced~3
CD5-stimulated~1
CD3-modulated~1
CD5-modulated~1
Cd5+/CD3-~1
HD37.~1
HD37~2
mAb:~1
anti-Ig-mediated~1
(GaM~1
GaM~3
chain-encoding~1
(blocked~1
CD3/Ti+~1
allo-CTL~1
reactivities.~1
(E6-1)~1
WGA,~1
WGA-induced~1
T3-mutant~1
E6-1~1
(T3.1)~1
WGA-stimulated~1
T3.1~1
sm)~1
sm.~1
sm~2
Homing~1
s.c.-injected~1
radiosensitive.~2
(beta),~1
units/ml,~1
(CD1a-c)~1
CD1c~1
M241~4
NA1/34~1
4A76~1
CD1b~1
(CD1c)~1
NZW~1
G10-passed~1
13,700.~1
scatchard~1
sites/cell)~1
(55,000~1
(45,000~1
2,7-dichlorofluorescein.~1
(VLA)-1,~1
T10,~1
"postactivated"~1
VLA-1.~1
VLA-1:VLA-2~2
VLA-2.~1
ANITA,~1
anti-VHa1~1
(latent)~1
a1~4
a1-like~1
anti-a1~2
deblocked~1
a1,~1
VHa1~1
F(ab)'2~1
form;~1
germ-line-encoded~1
Lipoarabinomannan~1
(LAM)-B~1
LAM-B~1
head-to-head~2
VH108B,~1
intermediate;~2
downstream.~1
V-D.~1
heptamer~2
coding-to-coding~1
flank-to-flank~1
(VL~1
VH)~1
morganii.~2
M603~1
VH/VL~1
DFL16.1~1
JH1,~1
VK8~1
JK5.~1
driven.~1
(r-IFN-gamma)~4
actinomycin-~1
alpha-amanitin-sensitive~1
5.3-5.8.~1
0.8-3.5~1
1.5-30~1
nonphosphorus~2
reincorporated~1
(polyprenoic~1
E-5166)~1
E-5166,~1
E-5166~5
(EGF)-stimulated~1
Sencar~2
7-14.~1
L+)~1
combinations),~1
L+-infected~3
-infected~1
cfu/g)~1
L+~1
C8-depleted~2
Serogroups~1
29E,~2
(PHS-C8Dep;~1
60.5%~1
SBA,~1
C8-deficient~1
PHS-C8Dep,~1
W135~1
meningococci.~2
late-complement~1
H.8-antigen,~1
H.8~1
(porin)~1
PA01~2
F-immunized~1
immunotypes~1
thermistors,~1
earache;~1
otitis,~1
rampant.~1
appear;~1
Arabs.~1
patients-severe~1
diabetes-free.~1
MEO,~1
(AEO)~1
beginnings.~1
AEO~1
occasional.~1
granulations,~2
microabscess~1
operated),~1
Tc99~1
MEO.~1
R:Ag~2
1,171~1
g/dL.~1
(r-GIFN)~1
r-GIFN~4
IU/mg~1
dose-limiting,~1
non-dose-limiting~1
IU/m2/d.~1
oxazaphosphorine~3
cyclophosphamide-~1
uroprotective~2
oxazaphosphorine-induced~1
Twelve,~1
ifosfamide/mesna.~1
mesna,~1
cyclophosphamide/mesna~1
ifosfamide/mesna~1
Mesna~1
ifosfamide-~1
fibrin-plate~1
perineoplastic~3
100-micrograms/ml~1
TPA's~1
[111In]oxine.~2
2-mercaptopyridine-N-oxide~1
(Merc)~1
oxine,~3
[111In]Merc,~1
Merc~3
[111In]Merc-labeled~1
[111In]oxine-labeled~1
[111In]Merc~1
normoactive.~1
neoplasias,~1
1-(p-isothiocyanatobenzyl)-DTPA~1
(SCN-Bz-DTPA),~1
isobutylcarboxycarbonic~1
(MA-DTPA),~1
(CA-DTPA),~1
1-(p-isothiocyanatobenzyl)-ethylenediaminetetraacetic~1
(SCN-Bz-EDTA).~1
(LS-174T).~1
ID/g)~1
chelate-antibody~1
MA-DTPA,~1
CA-DTPA,~1
SCN-Bz-EDTA~1
chelate-B72.3~1
(1.3:1~1
2.5:1)~1
B72.3-SCN-Bz-DTPA~1
5:1)~1
chelate-MAb~1
B72.3-SCN-Bz-DTPA.~1
MAb-chelate~1
TSK-3000~1
111In-SCN-Bz-DTPA~1
chelate-complexes~1
radiopharmaceuticals,~1
(TcO4),~1
([99mTc]GH),~1
51Cr-ethylenedinitrotetraacetate~1
([51Cr]EDTA),~1
diethylenetriaminepentaacetate~2
([99mTc]~1
DTPA),~1
([111In]DTPA),~1
desferoxaminemesylate~1
([67Ga]DFOM),~1
([99mTc]DX)~1
([111In]TF).~1
GSD),~1
nonairspace~1
In-TF~1
0.10%/min)~1
TcO4~2
(6.32~1
0.62%/min),~1
(1.50~1
0.37%/min),~1
[51Cr]EDTA~1
(2.38~1
1.02%/min),~1
(3.51~1
0.40%/min),~1
[111In]DTPA~1
0.42%/min),~1
DFOM~1
0.49%/min)~1
[99mTc]DX~1
(1.81~1
0.75%/min)~1
unsatisfactory;~1
347-5,099~1
officer~2
effectiveness/efficiency~1
Intrinsically~1
kernels~1
59Fe-labeled~2
field-grown~2
FeCl3~1
grain.~1
cysteinesulfinate~4
cysteinesulfinate,~1
1-carbon~2
cysteinesulfinate.~2
hypotaurine.~1
syn-dihydrodiol-epoxide~1
syn-dihydrodiol-epoxide:deoxyadenosine~1
portoenterostomy.~1
nonnitrogen~1
dicloxacillin,~1
beta-lactamase-resistant~1
dicloxacillin)~1
T-agglutination~1
204).~1
dicloxacillin.~1
tolerant.~1
Dicloxacillin~1
dicloxacillin~2
(MeHg)-induced~1
Ca++-containing~1
Ca++-deficient~1
sodium-containing~1
solutions.(ABSTRACT~1
[3H]BAY~4
tiapamil,~1
stereoselectivity,~1
5-Hydroxytryptamine~1
WRK1~4
inositol-bisphosphate~1
inositol-trisphosphate.~1
messenger(s),~1
5-acylimino-~1
imino-substituted~1
methazolamide~4
(Compound~2
(5-acetyl)~1
5-CF3~1
5-propionyl~1
CHCl3-buffer~1
methazolamide.~1
methazolamide,~1
(n-pentyryl),~1
benzothiazole-2-sulfonamides,~1
(CBC)-induced~1
[3H]cyclic~3
N1E-115)~1
CBC-induced~2
[1-(5-isoquinolinesulfonyl)-2-methylpiperazine],~1
receptor-coupling~1
Ca++-calmodulin~1
anti-CaM~4
(native~1
CaM.~1
CaM-C~1
CaM-catalytic~1
Ca++-CaM~1
sacs.~2
(1-84)~3
44-68,~3
53-84~3
65-84~3
AMP-stimulated~3
m/ml)~1
(AuTM)~1
ferrochelatase~1
AuTM~2
AuTM,~1
chrysotherapeutic~1
AuTM.~1
musculotropic~2
receptor-mediated,~1
[Thi5,8-D-Phe7]-bradykinin,~1
Met-Lys-bradykinin~1
Lys-bradykinin~1
[Tyr8]-bradykinin.~1
Arg9~1
Arg9-[Leu8]-bradykinin~1
G25671~5
U46619;~1
endoperoxides/Tx~1
endoperoxide/Tx~1
endarteritis.~1
BID)~1
postminocycline~1
EBV)~1
(GSTM),~1
GSTM/AF~1
GSTM~2
Anatomic,~1
nonstatistician~1
upgrading~2
(S-SupS)~1
(TI-mice)~1
S-SupS~3
TI-mice~2
(ISS,~1
1-12)~1
ISS.~1
adrenocorticotrophin~1
plateaued,~1
(polychlorinated~2
biphenyls)~1
PCDF~2
dibenzofurans),~1
coproporphyrin~5
firefighters~1
fire,~2
Uroporphyrin~2
66-106~1
-0.3844,~1
(mitomycin~1
Extrarenal~1
multifocality,~1
125iodine~3
modalities:~1
0.00005).~1
intranasally)~1
re-stimulated~1
(localized~1
testicle).~1
pneumonopathy.~1
glyburide,~2
[12.8~1
(10.2%~1
03%)~1
(ASV)~1
bioassay;~1
gp85~1
pr76,~1
pr60,~1
ASV-infected~1
pp60v-src~3
ASV.~1
ASV-transformed~1
Replicating~1
Fe2+~1
(ALL,~1
pre-B-phenotype~1
t(8;14)~1
juxtaposing~2
790~1
lymphoma-leukemias,~1
(Manca)~1
(linking~1
B-ALLs~1
B-ALL.~1
IL-2-receptor-positive~1
anti-TAC~1
Indole-3-carbinol~1
(I3C),~1
polynuclear~1
postinitiation~2
I3C,~1
I3C~4
protocols--before~1
Preinitiation~1
AFB1-initiated~1
post-initiation~1
kininase~4
hippuryl-glycylglycine~1
Lysyl-bradykinin~1
(LBK)~1
(kininase~1
tubule:~1
Kininase~2
LBK-hydrolyzing~1
kininases~1
Brattleboro-strain~1
dehydration:~2
178.2~1
8.2;~1
[72~1
82.4~1
8.2].~1
(DI:~2
100.6~1
1-deamino-8-arginine~2
(DDAVP),~1
(AVP:~1
171.3~1
DDAVP:~1
24.6).~1
randomly-arranged~1
Red.~1
Non-amyloidotic~1
coagulolytic~1
thrombo-embolic~2
Activating~1
VIIIc,~1
VIIIr:Ag)~1
31.5%~1
Thrombo-embolic~1
ATm~1
U.Fr)~1
g/liter)~1
3,449~1
Syracuse.~1
13.72~1
56.38%.~1
7.49~1
5.44~1
mastectomies,~1
U/kg),~1
(LHRH,~1
deferoxamine-chelatable~1
prolactin;~1
iron-depletion~1
urea-derived~1
cost-savings~1
broad-brush~1
(North~1
Thames)~1
Funds~1
savings,~1
RHAs~1
pan-ophthalmitis,~1
Immunocompromised~1
predisposed,~1
salivary-gland~3
intrasalivary~1
xanthomatosis,~2
Cholestanol~1
3.5-fold;~1
courtship~5
threonine-glycine~2
(PtdIns(4,5)P2)~1
pertussis.~1
PtdIns(4,5)P2~1
factor),~1
(fibroblast~1
insulin/IGF-I~1
factor-I),~1
toxin's~1
EGF-~1
FGF-induced~1
PtdIns(4,5)P2-phospholipase~1
factor-signalling~1
IL-2R,~3
formation:~1
'affinity~1
conversion'~1
(219~1
'ruler~1
protein',~1
there,~1
(unfertilized~1
echinoderms~1
pronucleus~1
echinoderms,~1
interphase,~1
centrosome~4
cleavages.~1
starfish~1
ago),~1
Olduvai~1
Gorge,~1
specimen's~1
craniodental~1
habilis,~1
postcranial~1
Australopithecus~1
(G-proteins)~1
G-proteins,~2
Gs-mediated~1
(EDRF),~1
hyperlipidaemia~1
looping-out~2
(spc)~1
alpha-J~1
fd~1
(others~1
f1)~1
6,408~1
shingled~1
thwarted~1
solidity~1
liquefy~1
(3750~1
units/70-cc~1
clot)~1
cervicography,~1
cervicography.~1
nondetection~1
family-based,~1
Martin-Lewis~1
1490~1
Keesler~1
prevalence).~1
97.2%,~1
55.1%,~1
Immunoassay.~1
(125I-hFSH)~1
(125I-hLH)~1
125I-hLH~2
mucin-coated~1
Optizyme~2
Extenzyme~2
Softmate~1
Cleaning~1
acetylcysteine~1
radiology--including~1
scanning--the~1
(Insight~1
Phoenix~1
(functions~1
video).~1
cybernetically~1
Epithelial-myoepithelial~1
tiny,~1
thrombin/calcium~1
solution--to~1
coagulum-type~1
surgery--is~1
osteomas~1
pericranium.~1
morbidity--as~1
graft--we~1
liposuction~1
fractures--with~1
polycycloidal~1
tomography--were~1
Sewall-Boyden-McKnaught~1
cranialization~1
(TST)~1
(SAI),~1
(UPP),~2
UPP,~1
indicate.~1
at--or~1
to--the~1
posttracheotomy,~1
papillomatosis)~1
incendiary~1
laser-resistant~3
(FiO2)~1
ignited,~1
combustion.~1
barking~1
hoarseness,~1
laryngotracheobronchitis,~1
spasmotic~1
croup,~2
tracheitis.~1
Tradition,~1
abductors~1
respiration--as~1
otolaryngologists--head~1
(indirect-direct~1
laryngoscopy)~1
staging--as~1
modalities--was~1
glottic,~3
transglottic~3
91.4%~1
osteoneogenesis~1
speech-tracking~1
declining,~1
hemangioma).~1
reinvestigation~1
capillitium~1
Subclassification~1
mode--thus~1
objectionable~1
signed-ranks~1
yet--not~1
uncommonly--their~1
hyoid.~1
suprahyoid,~1
transhyoid,~1
infrahyoid,~1
colliding~1
nasopharyngolaryngoscope~2
mirror.~1
Acrocephalosyndactyly~1
(Apert~1
craniosynostotic~1
syndactyly~1
and--occasionally--conductive~1
media--or~1
media--were~2
procedures--for~1
neuromas--was~1
(resolution,~1
deterioration)~1
hearing--namely,~1
retrolabyrinthine~1
(RVN),~1
(MFVN),~1
(ELS)--have~1
cochleovestibular~2
CVN--rather~1
labyrinthectomy--should~1
aerodynamics~1
otosurgical~1
modern-day~1
labyrinth.~2
Calvarial~1
otologically~1
nystagmus)~1
phase-lag~1
Extubation~1
(1979-1981)~1
(1982-1984).~1
extubate~1
vertigo--or~1
vertigo--may~1
vestibulosuppressive~1
nonlabyrinthine~1
gullet~2
tumor--or~1
metastasis--from~1
Aural~1
diploe~1
1:512)~1
preparations--one~1
Kluyveromyces~1
lactis~4
(Lactaid),~1
(Takamine)--to~1
Guatemalan~1
prehydrolyzed~2
3,250~1
Lactaid~2
6,635~1
codex~1
Takamine~2
lactose-maldigesting~1
[Itoh,~1
Kozasa,~1
T.,~5
Nagata,~1
Nakamura,~1
Katada,~1
Ui,~1
Iwai,~1
Ohtsuka,~1
Kawasaki,~1
Suzuki,~1
Kaziro,~1
3776-3780].~1
(Gs~1
mercurial-resistance~4
pDU1358~2
45-kilobase~1
mercurial~3
Hg2+~1
organomercurials;~1
phenylmercury~1
organomercurials.~1
2153~1
promoter-distal~1
Hg2+-resistance~1
merA~4
merD,~1
URF1,~1
URF2~1
R100.~1
merD~1
merB~2
organomercurial~2
C--Hg~1
phenylmercury.~1
frequent;~1
Primitive~1
endosymbiotic~1
protomitochondria.~1
argininosuccinase~1
(L-argininosuccinate~1
arginine-lyase,~1
4.3.2.1)~1
bromo[U-14C]mesaconic~1
Reactivity,~1
Argininosuccinate~1
trypsin),~1
argininosuccinases~1
[O'Brien,~1
McInnes,~1
Kalumuck,~1
Adcock,~1
7211-7215;~1
Beacham,~1
Schweitzer,~1
Warrick,~1
Carbon,~1
271-279].~1
Gly-Leu-Glu-Xaa-Ala-Gly-Leu-Leu-Thr-Lys;~1
lysine-51~1
(PBE)~1
2300-fold~1
PBE~3
A/gold~1
79,000),~1
(pI,~1
9.8),~1
optima,~1
enzymes:~1
-Gly-Ser-Leu-Ile-COOH.~1
GRPs~2
GRP-inducing~3
GRPs.~1
GRP-induced~2
vitro/in~1
76-kDa~1
GRP,~1
cercopithecoids~1
gibbon-siamang,~1
gorilla,~1
human-chimpanzee.~1
cladistic~3
human-chimpanzee-gorilla~1
trichotomy~1
Est-6~4
esterase-6~1
(Est-6)~1
69A1.~1
Inserts~1
Est-6-null~2
2.3-kb~1
EcoRI-BamHI~1
8-kb~1
B104~1
fine-mapping~1
alpha,25-Dihydroxyvitamin~1
(PBLs).~1
1,25-(OH)2D3-mediated~1
T-lymphocyte-enriched~1
S-LB1)~1
Ab-VDR).~1
Ab-VDR~1
H-2-deficient~1
lung-colonizing~1
3-40~1
lymphokine-based~1
anti-neurofilament~1
(anti-NF)~1
(ANT).~1
Phosphatase~1
ANT-reactive,~1
anti-NF~3
phosphoproteins,~1
L6,~1
recombining~1
12,13-diacetate,~1
adenosine's~1
C's~1
nitr-5.~1
Nitr-5~1
nitr-2~1
nitr-7,~1
whole-cell,~1
Flash-induced~1
chelators,~2
photolyze~1
nitr-5~1
Hololena~2
curta.~1
9000.~1
nonelectrical~1
glycosidases~1
alpha-Mannosidase~1
(AMS1),~1
exoglucanase~1
(BGL1),~1
endochitinase~1
(CTS1)~1
glycosidase~2
prototrophs~1
YEp24~1
glycosidase-overproduction~1
pombe/S.~1
Sch.~1
BGL1~1
CTS1~1
AMS1~3
alpha-mannosidase~5
LEU2~1
overproduction.~1
ams1::LEU2~1
Secreted~1
angiogenesis,~1
growth-controlled~1
stromelysin~2
Stromelysin~3
anti-collagenase-immunoadsorbed~1
13-acetate-treated~1
follitropin,~3
lutropin,~2
cadmium-resistant~1
43-amino~1
(Mtn~1
[Lastowski-Perry,~1
Otto,~1
Maroni,~1
260,~2
1527-1530).~1
(Mto)~1
(SRV-I)~1
(IAP-H18).~1
SRV-I-type~1
Myristoyl~1
CoA:protein~1
N-myristoyltransferase~1
(NMT)~1
NMT~3
acylation;~1
NMT.~1
Ala5~1
Gly-Asn-Ala-Ala-Ala-Ala-Arg-Arg~1
myristoyl-accepting~1
Penta-~1
hexa-peptides~1
NMT-ligand~1
dnaZX~2
DnaZ~2
DnaX.~1
DnaX~3
p-aminobenzyl~1
1-thio-beta-D-galactopyranoside-agarose.~1
dATPase)~1
peptidase-deficient~1
30-fold)~1
Met-Gly-Gly~1
cotransducible~1
leu.~1
overproducer~3
(N-terminal~1
methionine)~1
(methionine-specific~1
aminopeptidase).~1
microtubule-stabilizing~1
(MCSs)~1
MCSs~4
translocator~1
spindle-remnants~1
nonmicrotubule~1
spindle.~2
372-base-pair~1
T)-rich~1
BL6,~1
receptosomes,~1
"unusual"~1
"nonclassical"~1
17.109.~1
Sie,~1
paraproteins,~1
17.109-reactive~2
chain-expressing~1
17.109-positive~1
WI-L2-729-HF2~1
discerning~1
17.109-idiotype-positive~1
complementary-determining~1
17.109-associated~1
allelically~3
beta-alpha~2
Polymorphisms~1
antiphosphocholine~1
(P-Cho)~1
P-Cho,~1
P-Cho~1
A-C~1
r(I)n.r(C12-U)n,~1
[Carter,~1
Strayer,~1
Hubbell,~1
Brodsky,~1
Modif.~1
495-502].~1
HIV-permissive~1
dsRNA~8
T-lymphoblastoid~1
CEM.~1
one-time~3
[250~1
(IU)/ml],~1
IU/ml),~3
Mismatched~1
Oryctolagus~1
cuniculus,~1
localities~1
localities.~1
paraorbital~2
invaginate~1
[3H]arachidonate~2
[3H]diacylglycerol~2
[3H]Glycerol-labeled~1
phospholipid-derived~1
GAP-43~6
466-amino~1
rhodopsins);~1
DNA-packaging~1
virion.~1
(prohead),~1
prohead~1
packaging.~1
PC1~1
topology,~1
Ser70~1
Antibody-producing~1
transgene.~1
interleukin-4,~1
Vectors~1
Vector~1
tranduced~1
nasoenteric~1
unco-operative~1
intrasellar,~1
GRF-producing~1
spindle-formed~1
heterochromatin-rich~1
cytoplasm-containing~1
laminalike~1
meningothelial~1
typical--hypoplasia~1
nervehead~1
islet-enriched,~1
(PDS),~1
catgut,~1
(Dexon)~1
Catgut~1
foreskin.~1
Polyglycolic~1
pharmacoarteriograms~1
arteriogenic~1
unossified,~1
bone-scan~1
unossified~1
self-remitting~1
flecainide-related~1
(activity)-induced~1
large-dose~1
nonadherers~1
closed.(ABSTRACT~1
(DRG~5
"cardiovascular~1
complications"~1
charges;~2
inequities.~1
IU/ml,~1
long-(LCT)~1
LCT,~1
LCT-25%~2
MCT,~1
LCT-50%~2
(IgG-lambda)~1
Mixture~1
vWF:~1
RCo,~1
RCo~2
anodic~4
vWF:Ag.~1
flukes~1
Schistosome~1
Far~1
East,~1
Carribean.~1
Schistosome;~1
hematobium~1
13.1%).~1
"flare-up,"~1
(ESRF)~1
Psychogenic~1
water-drinking~2
polydipsia,~1
(Apo-A1)~1
CIII~1
(Apo-CIII)~1
hyperlipidemias.~2
Apo-A1~2
Apo-CIII~1
SstI,~1
2.2-kb~1
XmnI~1
(X2)~1
SstI~1
(FCH)~1
FCH.~1
Apo-A1/Apo-CIII~1
dysbetalipoproteinemia.~1
(ciprofloxacin,~1
difloxacin,~1
CI-934,~1
megalone)~1
xenopi,~1
method-dependent,~1
cfu/ml),~1
antimicrobials;~1
anaerobiasis.~1
checkerboards~1
checkerboard,~1
macrodilution~4
(microdilution).~1
intraperitoneally).~1
(ICB~2
7453,~1
7933),~1
non-phagocytosed~1
these--low-dose~1
stockings--was~1
cost-saving.~1
$34~1
$88~1
stockings.~1
$50,000~1
$500,000~1
(Chagas'~1
Salvadoran~1
D.C.,~1
Xenodiagnosis~1
reduviid~1
bugs~1
xenodiagnosis~1
Renin-like~1
II/III~5
(56.8~1
SEM],~1
(4.47~1
54/270~1
(4.3%);~1
13/67~2
8/99~2
IgM-negative~2
CPL~1
Imai).~1
collagen/collagenase~2
(3/560)~1
Platelet-poor~1
4-20-week-old~1
Ly~2
small-to-medium~1
"reactive"~1
(VSMCs).~1
Blastic~1
karyolysis~1
JT3,~3
JTB18,~1
CNK6,~2
CNK7,~2
CNK10,~1
hexagonally~1
6.9-nm~1
spacing.~1
JTB18~1
CNK10~1
Laz509,~1
JT3~3
anti-T11(2)~1
T11(3),~1
receptor/antigen~1
polarized,~1
anti-LFA-1,~2
Anti-LFA-1~2
(cytolytic/suppressor)~1
(autoreactive~1
ACTLs),~1
(virus-specific~1
VSCTLs).~1
ACTLs~1
VSCTL~1
[IL-2]~1
anti-Iad~1
anti-IAk,~1
[MHC]~1
ACTL~1
(RS)-like~1
lymphocytic/histiocytic~1
(L/H)~1
lymphocyte-predominant~1
RS-~1
L/H-like~1
LN-2,~1
HeFi-1.~1
RS-like~3
B-immunoblasts,~1
lacunar-,~1
L/H-,~1
DRG-related~1
Triatoma~2
dimidiata~1
Tegucigalpa,~1
Honduras.~1
protracta~1
protracta.~1
Tehuantepec~1
reduviids~1
insect-derived~1
metacyclic~3
prolixus~1
measured)~1
organisms/ml.~1
100-day~1
metacyclics.~1
metacyclics~2
insect-borne~1
vector-transmissible~1
metacyclics,~1
schistosomiasis-endemic~1
Heptavax-B~1
mansoni;~1
tsutsugamushi~3
typhus~3
infectivity,~2
plaquing~3
diluent;~1
Plaquing~1
Easily~1
x40~1
Arumowot,~1
Chagres,~1
Gabek~3
phlebovirus~3
Arumowot~2
Chagres~2
cross-protection.~1
Calot's~1
statistics:~1
unsubstantiated~1
plan.(ABSTRACT~1
Harefield~1
(April~1
8.51~1
5.12~1
(VTiso)~1
VTiso~3
KfA.~1
-0.54~2
cc-~1
Hz-A,~1
18-French~3
(6-French~1
12-French~1
[520~1
French)]~1
(4.52~1
French,~2
hemostat~1
unpremedicated,~1
750,~1
1500,~1
(SNP)-induced~1
SNP,~2
precapillaries~1
SNP-induced~2
arteriolar-venular~2
NTG,~4
(SNP),~1
extra-splanchnic~1
(ESP)~1
ESP~2
NTG-induced~1
NTG-~1
thirteen-week~1
eleven-week~1
Alveolar-macrophage-derived~1
Zymosan~1
postphospholipase~1
cuirass~1
NPV,~1
(MIP~1
12-s~1
(DSV).~1
DSV~2
112%~1
hyperreactivity;~1
epithelial-derived~1
epithelium-intact~1
epithelium-denuded~1
acetate's~1
3800-mg~1
beta-sympathomimetic~1
Flecainide-associated~1
Glyburide~1
thiamphenicol~1
(97.5%)~1
(76.0%)~1
thiamphenicol.~1
Thiamphenicol~1
gonococci.~2
(compound~6
3-deazaguanosine~1
6-aminoallopurinol~1
9-beta-xylofuranosyl~1
ribosylated~1
6-aminopyrazolo(3,4-d)pyrimidin-4-one~1
5-aminoformycin~1
Trypanosomatidae.~1
Trypanosomatidae~2
Ribosylation~1
epimastigotes~2
epimastigotes.~1
19-5247~1
(T2525),~1
scleromyxedema~1
multisite,~1
mmol/L]).~1
etidronate-treated~1
(DAT),~1
monoamine-enhancing~1
L-Deprenyl~1
MAO-B.~1
10-mg/d~1
anxiety/depression,~1
excitement.~1
40-mg/d~1
MAO-A,~1
IgMK~1
edges,~1
welding.~1
LAVA~2
polydioxanone-elicited~1
prosthesis/tissue~1
grossly;~1
photographed;~1
aortic-related~1
Transprosthetic~1
(SLE);~1
(rIL-1~1
GAG,~1
Heptavax~1
postexcisional~1
(subarachnoid)~1
VIIIRAg~1
"hypercoagulable"~1
Co-ordinated~1
(TFF)~1
analyser.~1
TFF.~1
co-operation.~1
TFF~1
postsuxamethonium~1
plasmacholinesterase~1
pre-balloon~1
water-drawing~1
nitroglycerine-induced~1
Nitroglycerine~1
hairbulbs~4
5-72~1
hairbulb~1
8-342~1
formed/three~1
hairbulbs/30~1
colours.~1
hairbulbs.~1
Thiourea~1
diphenylthiourea~1
diazo-sensitized~1
dimethylthiourea,~1
cycles),~1
pregnanediol~2
clomiphene/hMG~1
clomiphene/FSH~1
(CIR)~1
CPH~1
180,000.~1
(PAI-1),~1
Urokinase-type~1
u-PA;~1
plasmin-alpha~1
Plasmin-alpha~1
phytohemagglutinin-containing~1
co-cultivation,~1
quinacrine-stained~1
MC-containing~3
MC-free~1
14.9%)~1
co-cultures.~1
MC;~1
(40.4%~1
71.2%)~1
co-cultures,~2
CLL)~1
IL2/mL).~1
(CLL-4)~1
IL2-binding~1
anti-IL2~1
incubations)~1
surface:~3
IL2-like~1
erythroblasts.~2
Coculture~1
(erythropoietin~1
gamma/A~2
Picograms~1
VIII:C)~1
r-gamma~6
(r-gamma~1
IFN-stimulated~3
deaggregation~1
(PTAs).~1
machineries.~1
IFN-~1
sulphoxidation~3
30/37~1
sulphoxidizers~1
9/28~1
ureteropathy.~1
gynaecomastia~4
oestradiol/testosterone~1
beta-HCG,~1
Euglobulin~1
(ELT),~1
Pre-operatively,~1
s.d.;~3
milliunits/ml,~1
0.094)~1
(160.6~1
152.5~1
hydroxypyroline~1
GORE-TEX~1
hydroxyproline/cm~1
microgram/cm;~3
microgram/cm~1
0.005.~1
25-40~1
(11/16;69%).~1
(presenting~1
25-40)~1
(8/9;~1
(3/8;38%).~1
enprostil~3
dehydroprostaglandin~1
(25/67),~1
(37/66),~1
(41/66),~1
(6/71),~1
(13/69),~1
(20/69).~1
non-recurrence~1
Enprostil~1
"cytoprotection"~1
25,496~1
36,657~1
406)~1
12,526).~1
18,048)~1
17,095)~1
24,550)~1
591)~1
8946).~1
4055~1
2941~1
989~1
counselling,~1
officers'~2
post.~1
Appreciable~1
radiodiagnostic~1
parasuicide--namely,~1
Angie's~1
EastEnders--information~1
parasuicide~1
tailed~1
London--that~1
period--and~1
figures--that~1
parasuicide.~1
(erythroblast)~1
cordocentesis.~1
hyperlacticaemia,~1
"birth~1
asphyxia"~1
15-44~1
non-users.~1
1979-83~1
Inequalities~1
occupationless~1
non-accidental~1
1974-9~1
1980-5~1
compared;~1
"facilitator"~1
check,~1
quadrupled,~1
gestrinone.~1
(5/20)~1
(4/17).~1
(4/16)~1
(6/26)~1
angio-oedema.~1
elaborate).~1
units--whether~1
damp~4
tenants~1
dampness~1
officers.~1
houses,~1
Stockport~1
defibrillator-pacemakers,~1
ambulance,~1
(sural)~1
(tibial)~1
femoris.~1
reflex).~1
Anden~1
(1964)~1
Lundberg~1
(1979).~1
unguentum~2
emulsificans~1
aquosum,~1
hydrophylicum~1
ionogenicum,~1
(Flamazine).~1
(LSI~1
factory)~1
Tygerberg~1
Cape~1
Town.~1
mid-August.~1
ketamine-oxygen~2
7.12-7.15.~1
(DLF),~1
DLF~6
hogbrain~1
Na,K-ATPase.~1
intercorrelated~1
DLF,~2
R:Ag)~1
edetate~1
apatites~1
octacalcium~1
pseudoarthrosis~2
pseudoarthrosis.~1
210,~1
430,~1
2990~1
0.01-0.3~1
nmol/kg.~1
escape.~1
'escape'~1
over-coming~1
types--alpha,~1
gamma--appear~1
IFNa~2
advantages;~1
(daily,~1
unimpressive,~1
systoles.~1
Vasodilating~1
(HDHE)~1
HDHE~6
(MDH)~1
nonorthopedic~1
MDH~2
radiofibrinogen~1
test-proven~1
Ergot-related~1
MDH,~1
carbamazepine-associated~1
Anticonvulsant~1
Valproic~1
beta-galactosidase,~1
growth-suppressing~1
amygdaloid-kindled~1
(pulse-number~1
PNT)~1
seizure-generating~1
PNT.~1
(DZP)~1
PNT~1
(ESM),~1
drug-assessments.~1
gamma-butyrolactone-gamma-carbonyl-L-histidyl-L-prolinamide~1
(DN-1417),~1
(IR-TRH)~1
AM-kindled~2
kindling-induced~2
IR-TRH~1
AM/pyriform~1
convulsion,~1
(unstimulated,~1
sham-operated)~1
(IEA).~1
IEA.~2
absences,~1
IEA~2
Carbamazepine,~1
AED-induced~1
felbamate~1
(PTZ)~1
hexobarbital~5
anti-subcutaneous~1
protected)~1
protected),~1
O-demethylase~2
CNS-depressant~1
(SS-D~1
MS-D,~1
SS-D,~1
uvea,~2
retina),~1
SS-D~3
MS-D~1
(sorbinil~1
tolrestat)~1
65-75%),~1
65-70%),~1
70-100%);~1
55%),~1
uvea.~1
castration.(ABSTRACT~1
binding-site~1
24-48%~1
K+-dependent~2
3-O-methylfluorescein~1
5'-diphosphate-glucuronosyltransferase~1
(UDPGTase)~1
UDPGTase~4
4-methylumbelliferone,~1
4-nitrophenol~2
phenolphthalein~1
5'-diphosphate-glucuronic~1
UDPGTase.~2
tubuli~1
basale~1
291)~1
Acid-induced~1
peptone.~1
mmol/30~2
atriopeptin-28~3
atriopeptin-28,~1
atriopeptin-28)~1
immobilisation,~1
lipoprotein/mL.~1
3.0-~1
N-(6-aminohexyl)5-chloro-1-naphthalenesulfonamide~1
(W-7)~1
ionophore)~1
128.5~1
terbutaline-stimulated~1
beta2-stimulation~1
10.0-15.4~1
202.2~1
(Bayley-Pinneau),~2
202.1~1
(TW~2
198.6~1
(Roche-Wainer-Thissen).~2
-2.6~1
Roche-Wainer-Thissen,~1
TW~1
18-30~2
(12-36~1
50-69%~1
[15.2~1
IU/L].~1
clomiphene-resistant~1
S49.143R~1
Susceptible~1
(3OMG),~1
(ALA),~1
SO4~3
3OMG~2
jejunum;~2
[3H]phlorizin~1
glucose-inhibitable~1
[3H]phlorizin-binding~1
midvillus-to-crypt~1
(6KPGF1~1
([14C]AA)~1
1-benzylimidazole~1
(1-BI).~1
[14C]AA~1
6KPGF1~4
1-BI.~1
PGH2~5
Ouabain-binding~1
pump-mediated~1
Rb/K~3
Ouabain-resistant~1
Deoxygenation~2
rt-PA,~3
(calcitriol),~1
(Pompe's~1
Immuno-electron~1
(1,25[OH]2D3),~1
(S-LB1)~1
(HTLV-1).~1
(Ab-VDR)~1
(t-PA).~1
(reversible)~1
alpha-2-antiplasmin.~1
post-ASA~1
peculiarly~1
BT.~2
ASA-induced~1
blocking.~1
Catecholamine-induced~1
(micrometer~1
squared),~1
alpha-2-adrenoceptor~3
3H-Labeled~1
(3.3%),~1
(82.3%),~1
(10.2%).~1
1-0-hexadecyl-2-arachidonoyl-GPC,~1
20-23%~1
hexadecyl-PAF.~1
surface-marker~1
promonocytic~1
U937/HIV~5
r-interferon-gamma.~1
(CD11a)~2
(CD11b)~1
p150/95~2
(CD11c),~1
phorbolester-induced~1
sulphonamide~4
10-24~1
opsonisation~3
ungroupable~1
meningococcus.~1
agammaglobulinaemic~1
Mupirocin.~2
sterilisation,~1
practising~1
(2-5%)~1
pathologenesis~1
appendicectomies~1
10,500,~1
(MLSO).~1
prolymphocytoid~1
"late-B~1
(CPA).~1
biohazard.~1
Virulent~1
non-toxigenic~2
(D-1).~1
agglutinating~5
sporogenes,~1
A/F,~1
assaccharolyticus.~1
antitoxins~1
0.39%~1
0.47%~1
Watson-Alagille~1
facies.~1
streptokinase/placebo~1
placebo/intracoronary~1
30/h)~1
1,340~1
(1,060~1
567,~1
couplets/h~1
tachycardias/24~1
152.2.~1
tocainide).~1
additive.(ABSTRACT~1
Pump~1
outright~1
(Netherlands~1
Institute).~1
1,179~1
(0.89),~1
1.57.~1
H-2-identical,~1
loci-nonidentical~1
(B10.BR----CBA)~1
"motheaten"~1
(me)~1
xid-induced~1
anti-bromelain-treated-erythrocyte~1
thymocytotoxic)~1
sIgM-positive~1
non-Ly-1+~2
"NK~1
GM1-,~1
Lyt-1-.~2
Lyt-5+,~1
EL/4~1
Hemopoietin-1~1
2-augmented~1
GM1+~1
Ionomycin)~1
lectin-facilitated~1
P-815~1
antigen-mediated,~1
lectin-facilitated,~1
Ionomycin-induced~1
postactivation~1
deletion/inactivation~1
(B10.A~1
B10)F1~1
B10-specific~1
anti-B10~1
B10.A(2R)~1
(KkDb)~1
(KbDd),~1
H-2,~1
anti-Kb~1
anti-Db~1
anti-tolerogen~2
unmodified,~1
10(6).~1
alloaggressiveness~2
nonreconstituted~1
immunoresponsiveness~1
surface-blocking~1
(TH1)~1
M1s~2
M1s-disparate~1
beta:Ek~2
antigen-nonresponsive~1
peripherial~1
Non-responsiveness~1
300/mm3,~1
300/mm3.~1
Dual-color~1
2H4-,~1
HB-11-~1
T-4+~1
A-activated,~1
mitogen-~1
W3/25,~1
p16~2
p27.5~1
mu-chain.~1
eIf-4D.~1
(LCF),~1
LCF-induced~2
LCF,~1
(Ab).~1
BCGF)~1
(TCSN-A)~1
TCSN-A,~1
3300%~1
TCSN-A~3
TCSN-A.~1
IgM-~1
K1D5.~1
TCSN~1
H-2Kb-specific~1
CD1.~1
CD1-~1
r-fos,~1
JE,~2
r-fos~1
maleyl-bovine~1
fucoidan).~1
inophore~1
TGase~9
trans-retinol~1
trans-retinoic~1
dansylcadaverine,~1
TGase,~2
retinoid-induced~1
(IoA),~1
(OpsZ),~1
IoA~1
OpsZ~1
IoA,~1
OpsZ,~1
not:~1
"primed"~1
(BMMC)~1
PT-18~2
(IgE)-dependent~1
ADP-ribosylates~1
N-formyl-L-methionyl-L-leucyl-L-phenylalanine-induced~1
phosphatidylinositides~2
PT-treatment~1
PI-turnover,~1
(IgE-dependent)~1
two--C-reactive~1
(SAA)--increase~1
SAA,~4
2S~4
4S)~1
SPE.~1
Grenada~1
mus~2
spretus.~1
1-C~1
4S.~1
B6.C-H-2bm12~2
antigen-association~1
(LDA)~1
(TIL)~1
TIL~3
(LDCC)~1
LDA~1
(PTL-P)~1
PTL-P).~1
single-hit~1
(CTL-P)~1
(LDCC-reactive)~1
glioma),~1
PBL-T.~1
tumor.(ABSTRACT~1
(HITc)~1
HITc~4
1.B6)~1
"rested"~1
2R;~1
Adoptively~1
1.B6~2
CY,~1
315F6~1
7.0:1~1
2.1:1,~1
0.7:1~1
heteroaggregates,~1
CE-2,~1
(LATI),~1
LATI~3
eosinophils),~1
CE-2~2
LATI.~1
tumor-draining~1
LATI,~1
(TALL-101)~1
II-transformed~1
J-LB1.~1
Tdt,~1
T11);~1
TALL-101~5
(rH)~1
(3A1),~1
chromosomic~1
T-beta~1
J-LB1-CM~1
rHGM-CSF,~1
hapten-coupled,~1
1.077)~1
(HD-EC)~1
HD-EC~7
Thy-1-bearing~2
hapten-coupled~1
B10.A(3R)~2
(I-Jb)~1
(I-Jk)~1
I-A/I-E~1
populations;~1
afferent-acting~1
high-density,~1
I-A+,~1
Maleylated~1
(maleyl-BSA)~1
co-treatment~2
cyclohexamide~2
AMP-induced~1
[CAS]).~1
Thy-,~1
Ig-~1
U/well)~1
U/well~1
Anti-IFN-gamma~2
immunologists~1
Mls-disparate~1
(GaMD)~1
cross-reactive)~1
Mlsd,~1
GaMD-treated~4
null,~1
Mlsa,~1
Mlsb,~1
Mlsd-bearing~1
Crossing~1
Mlsc-responsive~1
(AKR/J)~2
Mlsa/c~3
(AKR~3
(AKR/J),~1
(C3H/HeJ),~1
C3H)~1
nonstimulatory,~1
Mlsd-defined~1
(64.1)~1
PCNA.~1
2TL-p)~1
MHC-reactive~2
(f~2
1/200)~1
1/100).~1
Clonally~1
2TL~1
split-culture~1
2TL-p~1
superposition~1
L3T4+);~1
Iad-restricted~1
Iad~1
R-irradiated~1
3300~1
R-irradiated,~1
conjugate-coated~1
infiltration;~1
-gamma,~1
downregulate~1
Cur~1
Cur.~1
antigen-1-mediated~1
effector/target~1
nonnephritogenic~1
co-functionally~1
(HT-29).~1
SC.~1
second-messenger,~1
(anti-Ig)~1
activational~1
IFN-beta,~4
LTA4,~1
LTA4-synthetase.~1
(H-7),~1
(12-o-tetradecanoylphorbol~1
13-acetate)-induced~1
4-p-bromophenacyl~1
(4-pBPB).~1
4-pBPB~1
arachidonate-induced~1
H-7.~2
Arachidonate~1
post-nuclear~1
LY53857,~1
mCPP,~1
PAPP,~1
pyrilamine~1
casein-elicited~2
detaching~1
(PT)-sensitive~1
(fMet-Leu-Phe).~1
Formyl~1
PT-resistant~1
PT-sensitive~1
N-CAM.~1
endosialidase~1
cell-adhesion~1
3H-uracil~1
IFN-gamma-containing~1
H37Rv.~1
Middelburg~1
(B48-14)~1
LOU/M~1
IR973F~1
B48-14~2
excretion-secretion~1
(EEF)~2
sporozoites),~1
EEF.~2
EEF,~2
"selected"~1
"nonselected"~1
alpha(1----6)dextrans~1
alpha(1----6)dextran~2
stearylisomaltosyl~1
immunochemically.~1
usages~1
anti-alpha(1----6)dextrans~1
VLJL-VH(D)JH~1
groove-type~1
alpha(1----6)dextran.~1
CD4+/CD-~1
CD4+/CD8-~1
Intracameral~1
P91~2
cell-to-tumor~1
UV5C25~3
DTH-mediated~1
athymic,~1
(P91),~1
irrevocable~1
(RCS)~1
L3T4+.~2
v-src-induced~2
Lyt-2,3+~1
down-regulates~1
(Thc)~1
Thc~2
Thc-B~2
Mab)~1
(HTL)~2
(anti-TCR~1
mAb).~1
anti-TCR~10
HTL~8
2-driven~3
12-O-Tetradecanoyl~1
anti-CD~1
conventional,~1
receptors/cell.~1
dose-responses~2
FcR(II)-dependent~1
C8-substituted~1
ribonucleosides~1
8-mercaptoguanosine~1
(8MGuo)~1
(IL-4),~3
(IL-5)~2
8MGuo,~1
24/G1~3
(Con)~1
8MGuo;~1
synergize.~1
[125I]IFN-gamma~3
pronase.~1
strippable.~1
molecules/cell/hr~1
f-Met~4
N217~2
42-kilodalton~1
N4~3
14-kDa~1
N23~4
polyclonal)~1
(PZQ)~1
(mu-suppressed)~1
PZQ~2
mu-suppressed~3
non-drug-treated~1
tubercles~1
PZQ,~1
anti-schistosomal~1
isotypes)~1
3775~1
10(-3)/base~1
pair/cell~1
Ia-specific~2
(cluster~1
Leu-16+~1
B2+~1
Leu-14+~1
Leu-8,~1
rIFN-gamma-induced~2
5.7-~1
6.5-fold~1
alpha-specific)~1
1-3E~1
247-residue~1
protease;~1
CCPI~1
3-10C,~1
homology);~1
lymphoma-derived~3
immuneresponse~1
(L1210/GZL)~1
(11C1)~1
52.~1
11C1~1
2B2.~1
L1210/GZL~1
site-related~1
macrometastases,~1
heteroantiserum~1
ASGM-1~1
ASGM-1+.~1
ASGM-1+~3
macrometastases~2
sixfold.~1
-DP),~1
anti-Leu-8~5
(CD4,~1
(LGL).~1
2)/ml~1
EqT12~1
EqT12+~3
2-inducible~1
tallow~1
trinitrophenylated-Pam~1
lymphnode~1
trinitrophenylated-proteins~1
Into~2
antigen-rich~1
0.5-756~1
mupirocin.~4
650-750~1
(RDEB),~1
RDEB,~1
(DDEB),~1
(DEBS).~1
(EB).~1
hypercontractile.~1
RDEB.~1
(tumor)~1
CTCL.~1
ultraviolet-A~1
xenon-mercury~1
monochromator,~1
(dopa)-~1
tyrosine-incubated~1
tyrosine-positive~1
(OCCCs)~1
OCCCs~2
fertilized.~1
OCCCs.~1
three-cell~1
originated.~1
FF.~1
(IVF-ET).~2
CC/hMG~1
"sub-50"~1
(OCs),~1
(LYN-EE)~1
(LNG-EE),~1
(LYN-EE~1
LNG-EE),~1
Histidine-rich~1
Tissue-type~1
167%;~1
C1-inactivator,~1
LNG-EE~1
51%),~1
LYN-EE~1
LNG-EE.~1
Platelet-bacterial~1
anti-t-PA~2
post-venous~1
(ECLT),~1
3'5'-guanosine~1
(199.6~1
(hANP~1
3'5'-adenosine~1
encephalocoele~1
VR,~1
VR.~1
stylohyoid~1
70-second~1
0.768~1
8-minute~1
hormone--releasing~1
entrants.~1
bis(aminoethanethiol)~1
([99mTc]BAT)~1
sidechain~1
[99mTc]DEA~2
[99mTc]TMPDA.~1
anti,~1
[99mTc]TMPDA~1
[99mTc]DEA-anti~1
DEA-syn~1
0.64%~1
dose/organ,~1
[99mTc]DEA-syn~1
sulfonate,~1
mercaptopyridine-1-oxide)~1
(111In).~1
pyrocarbonate,~1
Merc.~2
(indium)~1
gluten,~1
(TGs)~1
TGs.~1
synthetized~1
B48~1
7-wk~1
(13-50~1
(8-40~1
gluten-fed~1
C-depleted~1
wks~1
(mg/100~1
wt):~1
(suboptimal),~1
(adequate),~1
(ample)~1
saturating).~1
30-50%~1
tissue-saturating~1
(26.1%~1
(9.2%~1
839~1
non-emergency~1
(44.8%~1
42.4%).~1
Phycotene~1
(extract~1
Spirulina~1
Dunaliella~1
algae)~1
dimethylbenz(a)anthracene)-induced~1
MEM;~1
canthaxanthin,~1
MEM,~1
MEM.~2
sham-injected~2
phycotene~2
dimercaprol,~1
Dimercaptosuccinic~1
(DMSA)~1
DMSA~2
CS-514~2
compactin~1
40-mg~2
hypercholesterolemics.~1
28.8%,~1
Oligosaccharides~2
enymatically~1
alpha-amylase,~1
hydrolysis-spectrophotometric~1
(IVN).~1
(IONIP,~1
requirement)~1
IONIP~1
(postoperative)~1
12.95~1
21.04~1
Upward~1
Soyacal)~1
g/kcal/day)~1
Fat-based~1
tumor-~1
instituted:~1
antisepsis~1
MVI-Concentrate~2
(ivn),~1
MVI-Pediatric~2
mannitol),~1
vial/day.~1
blood-urea-nitrogen,~1
ivn.~3
MVI-Pediatric,~1
vial/day,~1
IU/dl)~1
2810~1
hydroxyvitamin~1
OHD)~1
OHD~3
D/dl~1
selenious~1
Se/day~3
glutathione-peroxidase~4
selenium/day~1
160-micrograms~1
drip~1
Ensure,~1
Ensure~7
Plus,~1
Osmolite.~1
methyldopa,~1
comfortable,~1
disoriented,~1
dislodgement,~1
catheter-intravenous~1
cystsic~1
marasmus~2
affects.~1
L-histidinol~5
[cytarabine~1
sulfate]~1
[5-fluorouracil~1
methotrexate]~1
L-histidinol-ara-C~1
L-histidinol-FUra~1
C1q)~1
schistosoma~2
(AWA).~1
AWA~1
anti-circulating~1
antigen/FITC~1
antischistosomal~1
CAA~2
(CAA).~1
five-week-old,~1
(MTAL),~1
(CTAL),~1
(CCD)~1
(MCD)~1
(CCr)~1
MTAL,~1
CTAL~1
MCD,~1
CCr~2
DCT~2
CCD.~1
101-126),~1
(O2,~1
(glutamate,~1
shown:~1
ANF)~1
c'GMP-generating~1
radiation-potentiating~1
rads/day)~1
(2-week~1
2,500/mm3)~1
.49).~1
enterectomy~1
Treitz,~1
33B3.1,~1
cadaveric,~1
33B3.1~4
(ATG).~1
(prednisone/azathioprine)~1
Post-mating~2
pre-mating~1
post-mating~1
inviability~1
inviability,~1
Coyne~1
sub-group.~1
rescues~1
inviable~1
(mitogens~1
lymphokines)~1
'minimal~1
signals',~1
(Is)~1
non-responder~2
(HLA-Dw12-DR2-DQwl)~1
(Sj)~1
HLA-DQwl~1
55K)~1
p70~9
crosslink~1
cyanobacterium~1
Anabaena~1
heterocyst,~1
nitrogen-fixation~1
(nif)~1
heterocyst~3
nifD~2
nifS~3
particulars~1
3/60~1
[10/200])~1
[6/60])~1
Simplifying~1
12-dimethylbenz(alpha)anthracene~1
DMBA-treated~1
prostaglandin-synthesis~1
Oculopharyngeal~1
genealogy~1
Proportions~1
peritumor~1
0.067,~1
0.013).~1
significantly--according~1
infiltration--and~1
Surrounding~1
Hoarseness~1
transglottic,~1
unspecified.~1
untested.~1
50%--with~1
response--but~1
Adenocarcinoma-like~1
Multi-institutional~1
Gell~1
One-millimeter~1
cisplatin-treated~1
Palva's~1
"swinging~2
door"~1
Glasscock,~1
Fisch,~1
Smyth,~1
Pennington.~1
doors."~1
tragal~1
effusion--of~1
duration--randomly~1
periodically;~1
cleared,~1
dye--combined~1
measurement--could~1
performance).~1
S.S.~1
auditory-only~2
spondee~1
patients--more~1
processor--is~1
wound-breaking~1
irradiation-failure~2
ossicle-cup~1
semibiologic~1
capitulum,~1
tympanoossiculoplasty.~1
Extrusion~1
revise,~1
longlasting.~1
rhinometry.~1
youngsters,~1
face-height~1
black-and-white~1
image-printing~1
laser--(in~1
1972)~1
Jako~1
papilloma--heralded~1
recounts~1
laser-ignited~1
tree--for~1
lesions--is~1
Wiet/Meikle~1
neurotologic~1
Photodocumentation~1
extravagant~1
surgery"~1
refuted.~1
photodocumentation~1
transparencies~1
deepithelization~1
cords;~1
microcup~1
Charred~1
carbonaceous~1
reepithelization.~1
laser-injured~1
acousticus.~2
rate--in~1
preservation--was~1
(PTA~3
discrimination),~2
nonserviceable~1
discrimination).~1
eighth-nerve-evoked~1
1507~1
Oakland,~1
Ramsay~3
1202~1
(herpes~2
paralyzed),~1
encephaloceles.~1
patients--each~1
antibody--while~1
calibrating~1
Phonatory~1
quasiperiodic,~1
cycle-to-cycle~1
harmonics.~1
AC-to-DC~1
(ETS)~1
Theraband~1
headset~1
(100%)--which~1
tumors--vestibular~1
complications--and~1
intervention--are~1
procedure--knowing~1
deteriorate--or~1
tympanotomy,~1
up--for~1
time-locked)~1
computer-averaging~1
here--from~1
age--will~1
body);~1
niches.(ABSTRACT~1
"desirable"~1
"desirable,"~1
portwine~1
cordectomy.~1
monitoring--in~1
far--have~1
(IAC);~1
IAC,~2
nerve--which~1
(saccular~1
nerve)--rapidly~1
rotates~2
(C-V)~1
C-V~1
transect~1
mid-IAC,~1
transected.~1
labyrinthectomy~2
Neurotologic~1
(18.9%).~1
Nonepidermoid~1
palatectomy~1
(Bell's)~1
secobarbital~1
(Seconal).~1
cancellation,~1
Saccadic~1
hypermetria~1
(HRCT),~1
precochlear~1
(HNSC)~1
(HPD),~1
argon-dye~1
mW/cm2,~1
post-HPD)~1
post-HPD).~1
HNSC.~1
autogenous,~1
unacceptability~1
heterografts.~1
"non-self,"~1
triggered--usually~1
(A9),~1
UM-SCC-1,~1
expression)~1
(Pattern~1
vascular/stromal~1
0.0011).~2
0.085)~1
0.081)~1
(Patterns~2
0.038)~1
0.062).~1
0.011)~1
(LFU)~1
LFU~1
evaluation)~1
paragangliomas.~1
Bickerstaff~1
neuro-otologic~1
headaches--sometimes~1
antimigraine~1
LMWFs);~1
25000~1
epithelia-overlaying~1
disease--not~1
Streptomycin~1
Shea~1
MRI--as~1
CT--a~1
ethmoid,~1
neck--when~1
scanning--will~1
otolaryngologist--head~1
lesions--which~1
patients--may~1
furuncles.~1
wand~1
guide),~1
Pure-tone~1
word-identification~2
glycerin.~1
(69)~1
variation:~1
8.02)~1
G1G0)~1
0.024),~1
tetraploidy,~1
0.228).~1
carcinomas.(ABSTRACT~1
variables--stromal~1
eosinophilia--was~1
non-neoplastic)~1
(1.7%),~1
sectioning;~1
Paraxial~1
surface-tension-lowering~1
media--both~1
Chickens~1
9-micron-diameter~1
Cochleas~1
camera-lucida.~1
blood-gas~1
extracochlear~2
indifferent~1
(EABRs)~1
function-relating~1
amperes)~1
dB/octave,~1
dB/octave.~1
Extracochlear~1
EABRs~1
Teratomas~1
adjuvant-induced~1
butyricum.~1
itch.~1
Adjuvant-induced~1
grooming,~1
scratching,~1
(astemizole).~1
behaviours.~1
Financing~1
47,776~1
(386~1
388)~1
inliers~1
"trim~1
point")~1
"extreme~1
immaturity"~1
386)~1
"prematurity~1
$27,061~1
outliers.~1
Outliers~1
trim~1
coagulopathy--the~1
Kasabach-Merritt~1
diatheses~1
coagulopathy;~1
cytolytic,~2
transducin-dependent~1
transducin-mediated~2
heterotrimer.~1
transducin-poor~2
(GTP[gamma-S]).~1
GTP[gamma-S]~2
transducin-rich,~1
transducin-poor,~1
ROS.~1
gamma-induced~2
2-interferon~1
BSF-2,~1
1-interferon).~1
1,2-dioctanoylglycerol~1
diC8,~2
H8,~1
H7,~1
diC8-treated~1
[Ca2+]-elevating~1
7-kilobase~1
23-25;~1
5.5-kb~1
grandmother,~1
(+/-)-7~1
alpha-dihydroxy-9~1
alpha-epoxy-7,8,9,~1
10-tetrahydrobenzo[a]pyrene~1
(BPDE)~1
293,~1
supF,~1
10(-4).~2
BPDE-treated~4
(21/30)~1
(30/107)~1
(60/86)~1
(insertions~1
(11/86).~1
61/71~1
transversions,~1
45/61~1
BPDE-induced~1
BPDE~1
labile--i.e.,~1
340-residue~1
37,329~1
comodulates~1
Anti-T3~1
IgMTNP~3
IgDTNP~3
microfluorimetric~1
gamma-radiation.~3
FITC.~1
contact-sensitizing~1
migration-retarded~1
lymphoid-restricted~1
octamer.~2
octameric~1
(TCR)-alpha/-beta~1
(WT31-~1
CD3+).~1
TCR-delta.~1
WM-14,~1
WM-14~2
TCR-gamma-CD3~1
CD3-delta,~1
(Me3NO)~1
Me3NO~3
reductases,~1
curtails~1
reductases.~2
narL~3
narC~1
(frd~1
tor)~1
fnr~1
narC,~1
frd,~1
tor.~1
LexA~1
self-cleavage,~1
LexA,~1
repressors,~1
Serine-119~2
lysine-156~2
nucleophilic~2
serine-119~1
yeast's~1
auxotroph~1
Sterol-depleted~1
unbudded,~1
nonlimiting~1
anti-pp60v-src~1
Ergosterol-stimulated~1
(PrP~1
27-30)~1
PrP~9
27-30~5
detergents.~1
detergent-lipid-protein~2
prion-associated~1
nucleases~1
"scrapie~1
virus."~1
prions~1
IF3~2
infC~9
autocontrol~1
infC-lacZ~1
AUU~2
IF3-dependent~1
alpha(+)~3
seven-base-pair~2
Int,~1
recombinase,~1
Watson-Crick~1
helices--i.e.,~1
anneal--a~1
Int-promoted~1
heteroduplex.~1
noncomplementary~1
nonreciprocal~3
resealed.~1
homology-dependent~2
ends;~1
inhibitors;~1
intraoocyte~1
regulate,~1
gamma:~2
ORF8,~1
ORF8.~3
oligo(dT).~1
second-strand~1
linker,~1
gamma-interferon-related~1
(IL-2);~1
non-Tac~2
(p75).~2
p75~9
b9~1
kappa-J~3
Polyadenylylated~1
stage-~1
lung-stage~1
liver-stage~1
654.2~2
L929).~1
marmosets~6
(Callithrix~1
jacchus)~1
renin-angiotensinogen~1
sodium-poor~1
1:10,000).~1
Pa).~1
formations,~1
Medicare.~1
1,247~1
Sizeable~1
cups.~1
postprogram~1
steroids:~1
50,145~1
TOPS,~1
40-49~1
risks).~1
Finland's~1
Karelia~2
unhealthful~1
studio~1
"Keys~1
84-85"~1
countrywide~2
meaningful,~1
smoking--this~1
2,056~1
cutpoints;~1
Statistics'~1
weight-for-height).~1
Grant~1
allocations.~1
creatively~1
Health's~1
grant's~1
irritations,~1
irritations.~1
dwellings~1
(UFFI),~1
Massachusetts.~1
(ppm)~1
insulation.~1
parties,~1
descriptions.~1
toward,~1
(exemplified~1
home")~1
"acceptability~1
employment"~1
"effects~1
wife,~1
818~1
explored:~1
t-tests~1
continuation.~2
school-linked~1
1974-78~2
2,112~1
counties,~1
graduate;~1
populous~2
non-HMSA~1
data--that~1
certificates--are~1
1968-82.~1
1968-78,~1
(61.4~1
(38.9~2
68-month~1
50-55~1
(28.6%),~1
(owing~1
cochlear,~1
otosclerosis),~1
monofilament,~1
(polydioxanone,~1
PDS)~1
6/0~1
PDS.~1
6-26~1
reestimated.~1
(FIGE)~1
metD~1
(PDGF)-related~1
sis/PDGF~1
corkscrew-like~1
Corkscrew-like~1
"octamer"~1
gut-specific~1
imipenem/cilastatin~1
nasojejunal~1
choledochocholedochostomy~1
choledochojejunostomy~1
974~1
11-15%~1
onwards,~1
photochemically~1
250-micron~1
Fasted,~1
1.2-1.5~1
72-184~1
264-607~1
dextrose-pretreated~1
end-arteriolar~1
prehyperventilation~1
lactate:pyruvate~1
hyperventilation.(ABSTRACT~1
neurosurgeons)~1
estimate).~1
Scatchard's~1
30,300/cell)~1
R0r~1
17,200~1
(mother,~1
MNS,~1
non-fathers~1
(NFs)~1
(96.8%)~1
NFs,~1
(96.7%)~2
BFs.~1
I/ml-h;~1
(AMI~1
OMI).~1
(mRA)~1
(PCW)~1
OMI,~1
mRA,~1
atrial)~1
(i~1
alpha-hANP)~1
29.61,~1
(PCWP;~1
(PAP;~1
(RAP;~1
13.61,~1
ANPs,~1
1--occlusion~1
119);~1
2--occlusion~1
98);~1
3--subtotal~1
VT;~1
lidocaine-responsive~1
paroxysmal,~2
incessant)~1
chronic)~1
abnormality).~1
arrhythmia)~1
0-18~1
L:M~2
0.11-1.42).~1
(60-80%~1
0.52)~1
2.85,~1
Gambia.~1
mixed-substrate~2
chair-adapted~1
depletion-repletion~1
30-d~2
free-feeding.~1
composition).~1
alpha-positive~1
(52.7%)~1
one-needle~1
agent(s),~1
hypophyseoportal~1
immunization).~1
benefit-cost~2
pre-season~1
high--as~1
example.~1
immunization--such~1
antirabies~2
1:50~2
"unprotective~1
levels"~1
1:5),~1
1:50.~1
Booster~1
$120~1
(U.S.)~1
1:5.~1
typhus.~1
normoestrogenic~2
53.7%~1
72.1%~1
breeches~1
(379),~1
(69),~1
(175).~1
(ANTU),~1
flooding.~1
Qwl/dQl,~1
sublobular~1
anti-Factor~1
(9/11)~1
(8/9)~1
(1/5)~1
non-VOD~1
lactate-induced~1
interoceptive~1
anxiogenics.~1
(SNFs)~1
pre-prospective~1
(post-prospective~1
payment).~1
1982-83,~1
SNFs,~1
bed-bound,~1
case-mix~3
SNF,~1
(DRGs),~2
(SII),~1
SII~4
SII,~1
014)~1
210).~1
rectify.~1
Supplements~1
Diazemuls~1
tocainide,~1
tocainide/lidocaine~1
seized.~1
(neutrophil-replete~1
anti-Pseudomonas~1
neutrophil-replete~1
zymosan)~1
O2-)~1
N-acetyl-B-D-glucosaminidase)~1
O2--producing~1
PAM.~1
N-acetyl-B-D-glucosaminidase~1
Harbor-UCLA~1
1,271~1
case-finding~2
on-the-spot~2
tuberculosis),~1
radiogram~1
transportable~1
high-incidence~1
O2-derived~2
normoxia/trypsin,~1
hyperoxia/trypsin,~1
hyperoxia-mediated~1
degranulate.~1
switchboards~1
(free)~1
(0.032).~1
sector's~1
Ota~1
energy-related~1
[U-14C]glutamine,~1
(120-minute)~1
(CMRGlc)~1
spike-and-wave~6
CMRGlc.~2
gangliosidosis.~1
GM1-ganglioside~1
(beta-D-galactopyranosylmethyl-p-nitrophenyltriazene~1
[beta-GalMNT])~1
(NG108-15),~1
Coincidental~1
GM1-ganglioside,~1
beta-GalMNT~1
galactosylceramidase.~1
(PNP)~1
(HGPRT)~1
PNP~4
aetiologies:~1
HGPRT,~1
deoxyguanosine,~1
hypouricaemia)~1
cardiomyopathies.~1
isonitrogenous,~1
[735~1
kJ]/kg/d),~1
(151%~1
preburn)~1
(156%~1
(131%~1
(136%~1
Ear-thickness~1
(GJ)~1
GJ~3
(DGE)~1
retrocolic~1
DGE~3
DGE.~1
"loading"~2
Monocyte-macrophage~1
(monokines)~1
(catabolin)~1
(JDM),~1
capillary:~1
JDM.~2
JDM~1
oxidase-like~1
(GA),~1
(NL)~1
"Stiff'~1
IgE),~1
572-575~2
RGDS-containing~2
572-575.~1
Thr~1
Arg-Gly-Asp-Phe~1
(RGDF)~1
95-98,~1
RGDF~1
(F-V)~1
F-V~2
105,000.~1
F-Va~4
F1F2),~1
MAbs,~1
B38~2
F1F2)~1
C1).~1
F-V.~1
F-Xa~3
F-V/Va~2
F1F2~1
F-Xa.~1
V/Va,~1
1.65-fold~1
3.65-fold,~1
(10E5)~1
Deaggregation~1
utilize.~1
XI-deficient~1
(CRM+)~1
XI:Ag)~1
XI:C)~1
XI:C~3
XI:Ag~2
proposita,~1
Chromatography~1
(DEAE)-Sephadex~1
high-mol-wt~1
(HMWK).~1
Auer~1
lymphoid-associated~2
lymphoid-related~1
(T11~1
paraprotein.~1
lupuslike~1
cardiolipin-cholesterol-dicetyl~1
Cardiolipin~1
cardiolipin,~1
phosphatidylserine-coated~1
cardiolipin-coated~1
coagulation-active~1
L428,~1
3280~1
699)~1
2338~1
(1110)~1
pmol/dl~2
(1346~1
(690)~1
(294)~1
(0.3)~1
pmol/dl;~1
selenoenzyme~1
hazel~1
3.5),~1
study--that~1
practice--are~1
(3898)~1
(158)~1
consulting,~1
1750,~1
surgeries,~1
cephalin~1
wellbeing,~1
hyperbilirubinaemia.~1
non-intervention~1
consultations:~1
manner,"~2
"non-positive~1
borough~1
Brent~1
(126)~1
(sickling~1
severe:~1
whom,~1
macaroni~1
subsiding,~1
Assessors~1
(29/35)~1
(14/35)~1
(19/35)~1
speeding~1
HemoCue~1
mixer.~1
non-fatalities~1
1,000,000).~1
134.21~1
cyclist~1
"mid-block"~1
daylight.~1
traffic,~2
helmets~1
Infirmary,~1
Glasgow,~1
centre's~1
dyskaryosis~2
cytologist's~1
cigar~1
40-54~1
cigars~4
9.2).~1
Council's~1
(1946~1
(3.0%)~1
migration;~1
retrogradely,~1
premalignancy.~2
imaginary,~1
Immunisation~1
sprinkler~6
titres)~1
(random~1
order).~1
hyperglycaemia.~1
opiates:~1
grew,~1
readdicted)~1
Capanna~1
"Regina~1
Margherita"~1
4559~1
Alps~1
Valais.~1
82.0%,~1
rheumatologists'~1
spectrum--patients~1
cancer--neoadjuvant~1
urethra),~1
resection/fulguration~1
Tcis)~1
N1-2.~1
Downstaging~1
unclarified.~1
MMC-related~1
(PCL),~1
myelomatosis.~1
oblique/55~1
oblique/30~1
postero-anterior/lateral~1
(PA/Lat)~1
oblique/60~1
cineradiograms~2
(pNS).~1
0.9x,~1
Vinculin~2
Z-line~1
costameric~1
14C-CO2~2
amiodarone-plus-triiodothyronine(T3)-treated~1
amiodarone-plus-T3~1
hypothyroid-like~1
"sandwich"~1
de-endothelialized~3
"sandwiched"~3
EDRF,~1
(+)-[3H]PN200-110~1
(KD,~1
(+)-PN200-110~2
(Bmax~1
(+/-)-[3H]BAY~1
(+/-)-BAY~3
5FBAPTA-loaded~1
acetoxymethyl~2
5FBAPTA,~1
5FBAPTA~4
(708~1
time-average~1
airspaces~2
(T-1824),~1
T-1824~1
128.9~1
3H-mannitol~1
22Na+.~1
Auriculin~1
45-minute~1
prime,~1
microgram/kg/min;~2
30-second~1
ANF,~5
animal.(ABSTRACT~1
BK;~1
BK,~1
RHC~1
80267,~1
monoglyceride~1
BK.(ABSTRACT~1
(SK,~1
Plasmocytoma~1
light-chains,~1
Light-chains~1
59.4%~1
bioptic~1
tubular-interstitial~1
anti-parasitic~2
(proteinuria~1
age-and-sex-matched~1
(3,058~1
3,410~1
colds,~1
polydypsia,~1
docasahexaenoic,~1
dihomogammalinolenic,~1
(docosahexaenoic:~1
0.045;~1
dihomogammolinolenic:~1
arachidonic:~1
127.1~1
147.0~1
(7.01~1
L/hr)~2
(MPAP)/cardiac~1
(F1O2)~1
F1O2~5
57231~3
MPAP/CI~2
(1-5~1
non-responders,~1
haemodynamics.(ABSTRACT~1
(H1-antagonist)~1
urticariants~1
Non-specific~1
Hypervolemic,~1
Discontinuance~1
(HFCWC)~1
xiphisternum.~1
HFCWC~6
HFCWC,~1
Last~1
(SD)h,~1
1632~1
prehemofiltration~1
posthemofiltration.~1
PPh~1
(VO2/heart~1
4140~1
T3-T4~1
(N1).~1
community-based,~1
CT-RT,~1
MTX-5-FU-Leucovorin~1
[14C]lactulose~4
subject),~1
[13C]glycine,~1
99Tc-sulphur~1
14CO2-lactulose~1
99Tc~1
breath;~1
lactulose;~1
between-subject~1
proinsulin-induced~1
glucocounterregulatory~1
25-38~1
proinsulin-~1
hypoglycemia.(ABSTRACT~1
pro-TRH,~1
Gln-His-Pro-Gly~1
pro-TRH~4
pro-TRH-derived~2
(carboxypeptidase~1
EH;~1
3.4.17.10),~1
[3H]guanidinoethylmercaptosuccinic~2
Co+2-stimulated~1
A)-Sepharose~1
glycopeptides.~1
(5-day-old)~1
(56-day-old)~1
glycopeptides,~1
[3H]glucosamine-labeled~1
56-~1
multiantennary~1
56-day-old~2
A-Sepharose,~1
ontogenesis.~1
midlactation~1
nonsuckled.~1
Suckling~2
midlactating~1
6-hydroxydopamine-treated~1
paraventricular,~1
supraoptic,~1
nonsuckled~1
tuberohypophyseal~1
B-derived~2
ACTH/beta-endorphin,~1
LH/FSH,~1
A-(1-13)-like~1
A1-13-IR).~1
alpha-dihydrotestosterone.~1
2.5-fold);~1
gonadotrophs.~1
(OP).~1
nervotomy~1
LHRH-binding~1
(IR-)~1
IR-ANF~4
IR-ANF,~2
IR-ANF.~1
Secretory-like~1
hamsters;~2
cardiocytes,~1
(immunogold~1
Bupropion,~1
hypophysial~1
Parachlorophenylalanine~1
pizotifen~1
Methysergide,~1
(VIP)-induced~1
(iv,~1
114.7~1
Hypophysiotropic~1
non-TRH~1
Transglutaminase~1
(TGase)~1
[1,4-14C]putrescine~1
TGases~1
monodansylcadaverine.~2
NEM~6
FSH-receptor~2
[125I]hFSH-receptor~2
NEM.~1
5'-monodeiodinating~1
(FRGS)~1
(DTT;~1
20-150~1
[125I]rT3)~1
FRGS~6
(1-60~1
FRGS-induced~2
5'-monodeiodination.~1
FRGS.~1
tert-butanol,~1
2-thiobarbituric~1
NTI~1
oil-injected~1
(NTI)]~1
NTI.(ABSTRACT~1
(PCB;~1
Aroclor~2
1254)~1
polybrominated~1
(PBB;~1
Fire~1
BP-6),~1
L-[125I]T4~1
lengthened)~1
pmm~1
PCB-PBB-induced~2
PCB-PBB~1
PBB.~1
[N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Trp3,D-hArg(Et2)6,D-Ala10~1
]LHRH~1
stumptailed~1
antagonist/kg~2
marked;~1
1.8-4.9~1
hCG.(ABSTRACT~1
(NB~1
steroid-specific,~1
charcoal/hydroxylapatite~1
(PGS)~1
tissue-,~1
PGS~8
72,000]~1
(0.25-10.0~1
(HEF),~1
72,000)~2
(negligible)~1
15-fold)~1
IU),~2
membrane?)~1
TRH-degrading~2
3.4.19.3)~1
3.4.21.26)~1
AtT20.~1
trans-parinaric~1
lysophosphatides~1
current-clamp~1
GH3/B6~1
30-mV~1
peptide-~1
ester-evoked~1
phosphoinositide/PKC~1
TRH's~1
(CSH),~1
cystamine~1
(CS-S),~1
N-acetyl-cysteine,~3
CSh,~1
CS-S~4
metaclopramide,~1
CS-S.~1
metaclopramide.~1
sulfydryl~2
basicity~2
iliaco-femoral~1
levonorgestrel.~1
norgestrel.~1
progestin-induced~1
(hMG/hCG)~1
"step-up"~3
"step-down"~2
days)-resistant~1
D-Trp-6-LH-RH,~1
subcutaneous-per~1
D-Trp-6-LH-RH~1
(94%).~1
Hyperstimulation,~1
normoovulatory~1
vaginal/cervical~1
(6/10~1
0/9,~1
Fischer's~1
yet-to-be~1
microenvironment,~1
hMG/hCG~1
superstimulation~1
obligated~1
BC~2
(proteins)~1
BC.~1
HCO3-/CO2.~1
ultrasonographically.~1
PCOS.~1
(LH-RH),~1
goserelin~1
(Zoladex~1
Macclesfield,~1
(OHSS)~1
menotropin~1
nonconceptual~1
Midluteal~1
(AI)/ml/hr,~1
OHSS,~2
AI/ml/hr,~1
AI/ml/hr.~1
Angiogenesis~1
OHSS.~1
atraumatic,~1
high-fundal~1
"screenee."~1
decision-maker.~1
holiday,~1
5'-deiodinase.~1
(Niacin)~1
(Lopid)~1
resins,~1
(Lorelco),~1
beta-urogastrone/human~2
(URO-EGF)~1
URO-EGF~2
hypoproliferative.~1
urogastrone-epidermal~1
0.088,~1
des-Arg9-bradykinin~3
phenylephrine-precontracted~2
[Leu8]des-Arg9-bradykinin,~1
Des-Arg10-kallidin~1
[Leu8]des-Arg9-bradykinin.~1
160th~1
des-Arg10-kallidin,~1
cyclooxygenase-lipoxygenase~1
755c.~1
des-Arg-kinins~1
(5-nitroxy~1
stearate)~1
(2T'~1
parallel)~1
56.14~1
gauss~1
[G],~1
52.22~1
56.94~1
55.44~1
biomembranes~1
(PCF)~1
PCF,~2
[81~1
PCF.~1
holding.(ABSTRACT~1
k/PaCO2(1-VD/VT)~1
VE-VCO2~2
(SS1,~1
SS2,~1
SS3)~1
SS1~1
140%~1
(VO2max).~1
SS2~2
SS3,~1
SS3~1
(SS1)~1
(SS1),~1
(SS2),~1
(SS3)~1
uncoupling.~1
(ERV)~1
(EELV).~1
EELV,~1
EELV~4
volume-inspiratory~2
diam,~1
alpha-Difluoromethylornithine~1
Taw.~2
humidified,~1
min-1]~1
(PROP,~1
(ATEN,~1
(PLAC)~1
l/breath~4
PLAC~2
PROP~3
ATEN.~2
1.99~2
1-receptors~1
(ATEN),~1
chemosensing~1
60-67~1
(Nembutal),~1
O2-sensitive~1
CO2-92%~1
breakpoint.~1
hold.~1
("noise")~1
nonsteady-state~1
squares,~2
c;~1
1581,~1
endoperoxide,~1
[prostaglandin~1
H2],~1
PGH2.~2
mimic.~1
endoperoxide/thromboxane~1
constant-volume,~1
closed-system~1
respirometer~2
Necessary~1
Ignoring~1
cross-union~5
cross-unions~8
ulna);~2
non-articular~2
ulna).~1
broached~1
Type-1,~1
Type-2,~1
Type-3~3
Type-2~3
Cross-union~1
ulna)~2
forearm).~1
(intra-articular~1
cross-unions.~1
Laterally~1
Discontinuity~1
(DXM)~1
(OVR).~1
OVR,~1
DXM~3
OVR~1
DXM-treated~1
OVR.~1
OVR-induced~1
pre-CRH~1
4-7/dose).~1
hCRH,~1
2-5).~1
3-5),~1
Statural~1
Nycthemeral~1
(chronological~1
10.1-14.6~1
11.0-14.0~1
0.6-1.75~1
[difference,~1
Pinneau's~1
NS)].~1
mU/L,~1
FT4,~1
microgram/mL]~1
(21.9~1
D-Trp6-LHRH,~1
D-Trp6-LHRH~2
Na+/K+~4
(MAJ)~1
pumps/cell~1
MAJ~4
(Nai+~1
mmol/1~1
slow-pressor~3
rapid-pressor~2
9);~2
6-hydroxydopamine,~2
depancreatized,~1
normoglycemic-transplanted~1
glibenclamide.~2
6-hydroxylated~1
6-hydroxyl~1
Glucuronidation~1
hyodeoxy-~1
hyocholic~1
ester/peracetate~1
6-O-beta-D-glucuronides~1
6-O-glucuronidation~1
aequorin,~1
histamine).~1
caffeine-sensitive,~1
indo-1)~1
"primes"~1
chloride-depletion~1
(CDA).~1
CON,~1
Ringer-HCO3~1
non-sodium~1
(DX)~1
(tCO2)~1
VE/CON~1
(-16%)~1
CC/CON;~1
CC/CDA~1
VE/CDA.~1
A-free~1
amination.~1
PS-toxin~2
29.8%~1
70.2%~1
Passively~1
(3-14~1
cristae),~1
NADH-linked~1
20-50%~1
rotenone-sensitive~2
NADH-duroquinone~1
0-10%~2
(NHS)~1
NHS;~1
NHS.~1
Serum-sensitive~1
serum-sensitive,~1
(DGI)~1
ED50:~1
Vasomotility~1
(propranolol~1
(nitroglycerin~1
(113%,~1
(122%,~1
(123%,~1
114%,~1
flow-induced~2
venoconstriction,~2
nitroglycerin;~1
Mahaim~6
incidental.~1
fasciculoventricular~1
(Mahaim)~1
fascicle.~1
Hs-A~2
electrogram).~1
(DSCG)~1
membrane-receptor~1
allergen-inhalation~1
DSCG,~1
(schistosomula~1
mansoni).~1
DSCG~3
formyl-methionyl-leucyl-phenylalanine-induced~1
2.80).~1
3.68)~1
theophyllines,~1
(BDP),~1
SCG.~1
logarithm-natural~1
(Ln)~1
Ln~2
PEF)~1
0.1).(ABSTRACT~1
(bid),~1
chlorpheniramine.~1
(HTPN)~1
HTPN~1
2p)~1
2p-deficient,~1
post-thymic~2
IgG-specific~1
24-2C.3.~1
24-2C.3~3
OVA-pulsed,~1
MHC-bearing~2
antigen:MHC~2
anti-L3T4.~1
strengthening.~1
alpha:beta~1
T/host~1
(ECN)~1
ECN~2
lymphocyte/epidermis~1
ECN.~1
recipient)~1
ECN,~1
(D-Pen)~1
D-Pen~7
PLN,~1
3H-thymidine,~1
PLN.~1
D-Pen-induced~1
D-Pen,~2
L-Pen,~1
other(s)~1
D-Pen-primed~1
(DPH).~1
co-purifying~1
Stringent~1
(NKH-1+)~1
(TNKTAR,~1
(1/103~1
1/185),~1
(1/458).~1
cytofluorography~1
receptor-negative,~1
receptor-positive)~1
biochemistries~1
(PGD2~1
post-cross-linking~1
"influx"~1
diisopropylfluorophosphate.~1
LTB4-pulsed~3
anti-serum~1
(lymphokines~1
(IFN-gamma]~1
(lipopolysaccharide~1
(hk~1
BCG]~1
BCG-infected~3
nitrite/nitrate~7
Thioglycolate-elicited~1
nitrite/nitrate,~1
CeH/HeJ~1
(C3H/He~1
hk~3
(FcgRI)~1
(FcgR1o).~1
FcgR1o~2
FcgRI.~2
FcgRI~2
3G8~3
anti-target~3
heteroantibody,~1
heteroantibodies.~1
(HBcAg)-specific~2
lymphomononuclear~2
HBcAg-specific~4
CD8-DR+~1
(DR)-restricted~1
pre-S(2)Ag).~1
HBcAg-specific,~1
antibody-treated,~1
cell-dependent.~1
IgE-response~1
SJA,~1
A/ST,~1
A/J.~1
class-switch~1
epsilon)~1
TGB5~11
(Id).~1
A--L~1
Id-.~1
(36-60~1
J558),~1
Vk1~3
Vk1A~3
Vk1C~2
subgroups).~1
Vk~2
paucigenic.~1
idiotypy,~1
GT-binding,~1
Id-~1
switching;~1
MPC~1
(bm12)~1
oligonucleotide-mediated~1
Abm12~6
co-transfected~1
Sublines~1
bm12~1
heteroconjugates~1
OKT3.~2
conjugate-dependent~2
conjugate-independent~2
CD4-/CD8-~1
Cytotoxicity,~1
TCR-induced~1
TCR-driven~1
TCR.~1
HTL,~1
T4+2H4-~5
AMLR.~1
imidoester,~1
pimelimidate.~1
Sepharose-immobilized~1
(T3:T4)),~1
three-fold.~1
(T3:T4)~2
Leu-19.~1
CD1,~2
"immature"~1
Tp44-~1
PWM-pulsed~2
sup)~1
PWM-stimulated~1
IFN-gamma-dependent~1
HIS24~1
(s~1
mu+)~1
chain-containing~2
mu+s~1
mu-)~1
HIS24+TdT-mu-~3
lymphocytopoiesis~1
pre-B,~1
TdT+,~2
(tC(a))~1
HIS24+~1
HIS24+TdT-Ig-~3
Ig-HIS24+~1
10(4)/hr/femur~1
TdT+mu-~1
TdT-Ig-).~1
tC(a)~1
non-cycling.~1
10(8)/day;~2
TdT+mu-,~1
10(8)/day.~1
pool;~1
H-2I-Ed~1
alloantigen-presentation~1
CD4-positive,~1
allospecific,~1
DP-lymphocyte~1
DP-positive~1
DQ-positive~1
DR-allospecific~1
TNP-specific,~4
DP-restricted~1
DP-allospecific~1
DQ-allospecific~1
DQ-directed~1
allo-~1
antigen-restricting~1
synergy.~1
MRL/Mp-+/+~1
anti-I-Ak~1
anti-I-Ad.~1
(4-wk-old)~1
-gamma)~1
nonmitogenic,~1
DA4.~1
(IFN-alpha~1
-beta)~1
Helper/inducer~1
Th1)~1
(Th2)~2
WEHI-279~1
Th2~2
Th1~3
maximally.~1
SN.~1
maturation-inducing~1
chain-associated~2
(Alt).~1
(A75,~1
AM1,~2
AM2,~1
AM3)~2
anti-id~3
Alt~3
A75,~1
AM2~3
AM3~2
id;~1
A75~2
(Alt~2
recombinants,~1
AM1~2
(A75~1
anti-CK~1
region),~1
id,~1
A75-~1
AM3-defined~1
lambda-type~2
(FR1).~1
II/V,~1
sub-subgroups~1
B27f,~1
replacements:~1
Asp74,~1
Asp77,~1
Leu81~1
Tyr74,~1
Asn77,~1
Ala81,~1
B27f.~1
HLA-B27.2~1
B27.2~1
B27.3,~1
Cys-192~2
CL-4B~1
glycosaminoglycan-sized~1
ABC-generated~1
disaccharides,~1
cytolysins~1
calmodulin)~1
(r-gamma-IFN).~1
r-gamma-IFN~1
density-defined~1
Density-defined~1
(DD-AM)~1
DD-AM~3
macrophage-stimulating~1
Pristane-elicited~1
tetradecanoylphorbol~1
pristane-elicited~3
TPA-treated,~1
pristane-treated~1
ornithine;~1
L-Ornithine~1
ornithine-inhibited~2
killer-sensitive~1
original,~1
L-ornithine.~1
precytolytic~1
arginine-~1
putrescine-inhibited~1
undepleted,~1
anti-Lyt-1+~1
anti-L3T4+~1
inbred,~1
arthritidis~1
(MAS).~1
H-2j,~1
H-2p,~1
H-2v~1
MAS,~2
H-2b,~1
H-2f,~1
RIIIS~8
(H-2r)~3
MAS~9
nonresponsive,~1
non-major~1
(H2r)~1
(H2k)~1
MAS.~2
(RIIIS~3
B10.RIII)F1~3
gene(s).~1
non-MHC,~1
MAS-nonresponsive~1
C3H.SW~1
RIIIS,~2
B10.RIII,~2
immunoselected~1
Ia-human~1
RJ~2
2.2.5,~1
transacting~1
aIr-1~2
Ia-RJ~1
2.2.5~2
Ia-P388~1
non-species-specific~1
(dex),~1
(IFN-gamma~1
repressor(s).~1
junction-mediated,~1
junction-competent~2
LT/TNF.~2
12-o-tetradecanoylphorbol-13-acetate,~1
LT/TNF-sensitive~1
CL-1D~2
CL-1D.~1
LA25-normal~2
(LA25),~1
pp60v-src,~1
cytolysis/cytostasis~1
(TGase).~1
suprabasal,~1
Cross-linked~1
permeabilized,~1
dopa,~2
5-cysteinyldopa,~2
24565~2
(6-nitroquipazine),~1
melanization~1
dopa.~1
(kD~1
r-IFN-gamma,~1
(r-IFN-beta).~1
lymphocyte-keratinocyte~1
nontumorigenic/tumorigenic~1
(JB-1/JB-8;~1
D1/D11a)~1
nonpromotable,~1
promotable,~1
(JB-6~1
RT101).~1
histoplates.~1
IFN-alpha/beta,~1
nonpromotable~5
promotable~5
Nontumorigenic~1
counterparts;~1
BL6),~1
Jessner's~1
(JLI)~1
T11-positive~1
Ia-positive,~1
receptor-carrying~1
[3H]thymidine-incorporating~1
JLI~2
(serogroups~1
W-135,~1
Z)~1
(unchelated~1
properdin-deficient~4
(Mg++EGTA-chelated~1
properdin.~1
presensitizing~1
properdin-dependent~1
rotavirus-hyperimmunized~1
(neutralization~2
1:6,000~1
1:48);~1
1:20).~1
concentrate-treated~2
(SAF)~1
negative-stain~1
scrapie.~1
SAF~4
SAF-specific,~1
protease-resistant~1
(PrPs)~1
PrPs,~1
SAF.~1
PrPs~3
107,803~1
(ISG)~1
ISG~3
fungistatic~1
azole-loading~1
overridden,~1
Natriuresis,~1
hyperperfused~1
"reserve."~1
Bleomycin,~1
(BPAE)~1
bleomycin-mediated~2
BPAE~4
Bleomycin-mediated~1
(monitored~1
neurooncology,~1
immunopositivity.~1
astroblastomas~1
C-positive.~1
gangliogliomas.~1
neurocytomas~1
C-negative.~1
C-positive~1
neurooncology.~1
(EN).~1
EN).~1
postinjury,~1
carnitine-free~2
epsilon-N-trimethyl-L-lysine~6
gamma-butyrobetaine.~3
gamma-butyrobetaine~5
(PCB)-containing~1
acid/kg~1
(ODS-+/+)~1
13.8%).~1
(ECV)~1
ECV/kg~2
ECV/kg.~1
(303~1
revaccinated~1
reimmunization~2
polysaccharide-outer~1
Post-booster~1
delta-antibody~1
DNA-negative~1
Spinhaler~2
(0.01-30~1
flow-independently~1
(ENK)~1
ENK~3
ENK,~1
I-sulpiride~1
ENK.~2
peptidoleukotriene~1
Ca++-ionophore~2
(LT)D4~1
LTD4).~1
g/2.5~1
ng/min/g~1
Ca++-ionophore-stimulated~1
Sequestered~1
(NDGA)~3
neutrophil-free~1
(AMPH;~1
anorectics~2
AMPH-appropriate~1
mazindol~1
phenmetrazine~1
phentermine~1
chlorphentermine~1
phendimetrazine~1
diethylpropion~1
clortermine~1
mefenorex.~1
(0.3-30.0~1
fenfluramine~1
(1.0-17.0~1
(1.0-100.0~1
Methylphenidate~1
(0.3-17.0~1
nisoxetine~1
bupropion~1
(1.0-30.0~1
propylhexedrine~1
(10.0-100.0~1
fenetylline~1
ganglionic,~1
(0.25-2.0~1
(4.0-32.0~1
(1.0-8.0~1
phenylephrine-mediated~1
933-mediated~1
(0.6,~1
alpha-2-mediated~1
933.(ABSTRACT~1
expansor~1
secundariorum~1
[3H]prazosin)~1
(6-hydroxydopamine-induced)~1
(surgical)~1
ESM.~2
methoxamine-stimulated~2
chemical)~1
(1.4-fold)~1
(4.5-fold)~1
postanaphylactic~6
histaminase~1
pyrilamine.~1
(GSTM)~2
40-150~1
aurosomes~1
Myochrysine~1
(aCL),~1
aCL~4
APTT;~1
2/37~1
aCL.~2
.55~1
aCL;~1
vesicostomy~5
tailoring.~1
resectoscope.~1
(repletion~1
(190/324)~1
pre-TPN~3
(45/62)~1
(CNM)~1
3-liter~2
(CNM:~1
mixtures)~1
7-38].~1
8-28).~1
CNM~3
mumol/24~1
mumol/day),~1
(1.00~1
mumol/day,~1
(MVI~1
concentrate;~1
USV~1
given;~1
MVI;~1
MVI.~1
B3,~1
MVI~1
4-40%~1
multipurpose~1
(SLC),~1
0.427).~1
(RAC)~1
RAC~3
(CVC),~1
Seldinger~1
performed.:~1
exchange:~1
resterilized~1
Guidewire~1
(91.6%).~1
catheter-changing~1
ProcalAmine~3
FreAmineIII~1
isonitrogenously.~1
U/hr.~1
postsurgically,~1
(TPN)-related~1
glucose/fat~2
non-nitrogen~1
liter/kg;~1
insulin/glucagon~1
triglycerides/kg~1
supply).~1
(LCTs),~1
MCTs~1
MCT/LCT~4
C12~1
hepatotoxin.~1
microanalysis,~1
(27.8~1
(309~1
aluminum-loaded~2
hydroxy-vitamin~1
gastrojejunostomy.~1
HN~5
Criticare~1
Osmolite~1
Protein-calorie~1
noncirculating~1
4-yr-old~1
Armour~1
(Intralipid)~1
Reinstitution~1
lipid-free~1
(CIIP),~1
tunnels,~1
A-MuLV~2
(Thy~1
(D)-joining~1
(V)-D-J~1
growth-modulating~1
beta-forms~1
CALU-1~1
SW-48.~1
HBL-100,~1
MDA-MB-415.~1
Late-occurring~1
90SrCl2~1
Radiation-induced~1
hemangiosarcomas,~1
fibrosarcomas,~1
hemangiosarcomas~1
Na/K-ATPase~4
morphological-functional~1
acquistion~1
immunolabel~2
infolding~1
"acetate~1
intolerant"~1
optimally;~1
passive.~1
Electromagnetic~1
occluded)~1
dyslipoproteinaemia~1
non-tuberculous~1
non-infectious~1
tuberculostearic~2
scalae.~1
pre-implant~2
"exploratory~1
cochleostomy"~1
cholesteatoma?~1
coupler,~1
waveguide,~1
coupler~1
waveguide~1
hemoconcentration,~1
(sex~1
globulin-binding~2
non-sex~3
("Nautilus")~1
exercise-associated~1
servicemen~1
Antibiotic-sensitivity~1
milliliter).~1
Korea.~1
widescale~1
Pharmacologically~2
mAChR,~1
(ACh)-induced~1
(mAChR~1
(bearing~2
18K)~1
lectin-stimulated~1
(Ly-2)~1
'self~1
X',~1
L3T4+;~1
CD4+-specific~1
8-14)~1
ectromelia~1
(mousepox)~1
(CD4-,~1
CD8-).~1
dynein,~1
Kinesin,~1
hydrolysable~1
microtubule-activated~3
kinesin,~1
5'-adenylyl~1
imidodiphosphate(AMPPNP)-induced~1
Mg-ATP~1
Mg-free~1
Na3VO4,~1
AMPPNP~1
microtubule-translocating~1
kinesin-driven~1
antigen:class~1
antigen:Ia~1
CD3:alpha:beta.~1
anti-T-cell-receptor~2
co-modulate~1
dEC)~1
IL-2-like~1
dEC~3
gamma/delta~2
taxa,~1
Plio-Pleistocene~1
(AL~1
333-105~1
Taung)~1
(Paranthropus~1
Homo,~1
crania~1
intraspecifically,~1
taxon.~1
taxon~1
pongids,~1
troglodytes,~1
'paranthropine'~1
taxa.~1
cell-stimulator~1
CD4-expressing~1
CD4-dependent.~1
postrolandic~3
prerolandic~4
PCPs~1
generators;~1
carbaryl~1
(1-naphthyl~1
N-methylcarbamate),~1
organophosphates~1
insecticides.~1
(1.2-1.3).~1
.009);~1
antinucleotides~1
anticoagulant-positive~1
anticoagulant-negative~1
.021).~1
132-141~1
aqueous,~1
fluorophotometrically~1
pulverization~1
scleromyxedema,~1
Scleromyxedema~1
keratopathies~1
Barcelona,~1
Spain,~1
serogrouping~1
doxapram~4
mg/kg/h.~5
mg/kg/h,~4
"Occult"~1
.0035).~1
(afebrile,~1
D-receptor-defect~1
alpha-(OH)D3)~1
micrograms/kg/d~1
alpha-(OH)D3,~1
micrograms/kg/d.~1
D-receptor-mediated~1
alpha-(OH)D3.~1
defense;~1
timed-release~1
beta-adrenergics.~1
Once-daily~1
setbacks,~1
corticosteroid,~1
beta-adrenergics,~1
Syrinx~3
AN13~1
rap~1
(recombination~1
plasmid),~1
phage-plasmid~2
cointegrates,~1
p210BCR-ABL~4
phosphotyrosine,~1
tyrosine-phosphorylated~1
185,~1
195,~1
p210BCR-ABL.~1
phosphotyrosine-containing~1
p60src~1
galactose-inducible~1
autophosphorylated~1
tyrosine-416~2
tyrosine-527,~1
tyrosine-527.~1
2.5-5.0~1
histotypes~2
amx,~1
bib,~1
mam,~1
Dl~1
E(spl)~2
histotypes.~1
nonautonomous.~1
nonautonomous~1
1604~6
xanthus.~2
fruiting~2
1604,~1
2788,~1
boxA~1
nutR~4
Rho-dependent~1
tR1~1
Terminators~1
nutR,~1
antiterminate.~1
boxA,~1
(Nus),~1
NusA~1
boxA;~1
antitermination;~1
N-dependent~1
antitermination.~1
(gnt)~1
gnt~5
(gluconokinase,~1
2.7.1.12)~1
permease,~1
(gnt~1
(gntR)~1
(pPL603B).~1
Repression~1
cat-86~1
(pgnt21),~1
gntR~4
pgnt21~1
gntK10~1
gntR1~2
continents~1
mini-X~2
1:4000~1
nomadic~1
"hotspots"~1
t(10;14)(q24;q11)~1
10q+~2
deoxynucleotidyltransferase~3
10q23-q25~1
[the~1
gene)],~1
TCRA).~1
14q-~1
t(10;14)~1
TCRA,~1
10q24,~1
TCL3,~1
deregulation,~1
TCL3~1
10q23-q24.~1
(ALLs),~1
Rearranged~1
(18/66)~1
(24/58)~1
(1/9)~1
(cALLA)~1
(23/46)~1
cALLA+~7
cALLA-~3
(18/56)~1
(0/12)~1
immunoglobulin-positive)~1
(0/3).~1
beta-Chain~1
(2/11)~1
(cIg)-positive~1
(21/35)~1
cIg-negative~1
disease-producing~1
A2b,~1
A2b~4
cross-linkers~1
(2-3%)~1
bone-marrow-derived~3
anti-gamma-chain~1
chain+)~1
gp120-CD4~1
gp120.~1
gp120-adsorbed~1
(small).~1
IL-4,~1
R-positive~2
anti-target-OKT3~1
Conjugate-mediated~1
anti-CD28~2
(anti-CD28)~1
anti-CD3.~1
[Tyr30]inhibin~1
alpha-chain-(1-30).~1
injections)~1
negative-feedback~1
parasite;~1
enter,~1
Mu,~1
transposes~1
mini-Mu~1
Charon~1
21A.~1
6672-base-pair~1
90-bp~1
163-bp~1
2224~1
acid-sequence~1
ceruloplasmin.~1
semiconserved~2
Asp-Leu-Ser-Gln-Thr-Thr/Asn-Leu-Ser-Pro~1
MANN~1
(DR7,DRw53,DQw2,~1
DPw2).~1
beta-related~2
HLA-DR7~1
DP-specific~1
hypermutation.~1
regions(s),~1
HLA-DQ2~1
45-base-pair~1
HinfI/Sau96I~1
(-142~1
-98~1
38-bp~1
Sau96I/Sau96I~1
(-97~1
(-113~1
(-80~1
-71~1
bp),~1
Flanking~1
heptamer-spacer-nonamer~1
38B9,~1
gpt,~1
nonamer;~1
nonamer~1
heptamer)~1
corynebacteria,~1
diphtheriae~2
ulcerans,~1
Protoplasts~1
Transfections~1
corynephage~1
782,~1
pNG2,~1
9500-kDa~1
erythromycin-resistant~2
glutamicum~1
pNG2~4
0.2-150~1
corynebacterial~1
hepatocarcinogen~1
90-base-pair~1
primer-directed~1
protein-transfer~1
liver-derived~1
lambda)-producing~1
chain-uncommitted~1
replication-origin-defective~1
LFA-3-associated~1
drug-based~1
bidentate~1
diammineplatinum~2
platinum-based~1
cis-diamminedichloroplatinum~3
diamminecyclobutane-dicarboxylatoplatinum~3
Adduct~1
"peak")~1
amol~1
Jonckheere's~1
two-sided~2
0.030.~1
buffy-coat~1
amol/micrograms~1
0.032.~1
pI258~3
6.4-kilobase-pair~1
Mercury~1
6404-base-pair~1
(mercuric~1
(organomercurial~1
lyase)~1
cyclase).~1
[Nukada,~1
Tanabe,~1
Takahashi,~1
Noda,~1
Haga,~2
Ichiyama,~1
Kangawa,~1
Hiranaga,~1
Matsuo,~1
Numa,~1
FEBS~1
Lett.~1
197,~1
305-310]~1
(71-75%~1
Choleragen~1
catalyzing,~1
Gilman~1
[Kahn,~1
Gilman,~1
7906-7911]~1
ARF-Gs~1
alpha-independent~1
choleragen-catalyzed~1
compound;~1
auto-ADP-ribosylation~1
imido-beta~1
gamma-diphosphate~1
5'-O-[gamma-thio]triphosphate;~1
5'-O-[beta-thio]diphosphate~1
choleragen~1
ADP-ribosyltransferases~1
LoVo~3
cLV7,~1
(cLV7)~1
cLV7~2
CEA-expressing~1
endonuclease-digested~1
CEA-related~1
mouse-hamster~1
spretus)~1
(Na+,K+-activated~1
phosphohydrolase,~1
3.6.1.3).~1
chromosomes:~1
(Atpa-1)~1
Egf~1
(Atpa-2)~1
P-450PB~1
family/coumarin~1
(Atpa-3)~1
(Atpb)~1
Atpa-3~1
(tat-I),~1
tat-I~5
(phytohemagglutinin,~1
HTLV-I-mediated~1
expansions~1
more-potent~1
Tac-negative~1
anti-Tac.~2
PC61.~1
high-affinity-receptor~1
(IL-2)-producing~1
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-treated~1
hemizygosity~1
autosomes.~1
Fine-structure~1
virus-mediated~1
OKT4A~1
fast-atom-bombardment~1
497.~1
N-cholylglycine~1
465)~1
N-cholyltaurine~1
515),~1
2-fluoro-beta-alanine~4
which:~1
GC-MS.~1
N-cholyl-2-fluoro-beta-alanine~1
cochromatograph~1
(Tyr-D-Ala-Gly-MePhe-Gly-ol~1
Tyr-D-Pen-Gly-Phe-D-Pen~1
5-HT1,~1
GABAB,~1
LH-antibody-coated~1
gonadotropes,~1
(plaques).~1
0.02-0.38)~1
secrete;~1
LH-secretory~1
cachetic,~1
coarsening~1
Scars~1
Coarse,~1
Microcalcifications~1
breasts;~1
nondisulfide-linked~2
processes--both~1
"gating"~1
t(14;18)(q32;q21).~1
Metrazole.~1
Metrazole,~1
Metrazole~1
refractory.~1
bcr/abl~8
P160,~1
myristylation-dependent~1
balanoposthitis~1
AutoAnalyzer~1
hemagglutination-enhancing~1
(octanoate~1
[caprylate]~1
[Cibacron~1
Blue]).~1
low-fatty-acid~1
albumins.~1
octanoate~2
Cibacron~3
albumins,~1
high-fatty-acid,~1
nonpolymerized~1
Blue.~1
anti-U~1
U+~4
rank-correlation~1
0.0005.~1
10-unit~1
pools),~1
regular-volume~1
compile~1
lymphadenectomy-staged~1
Louis),~1
Study).~1
Uro-Oncology~1
Nationwide,~1
radiotherapy-treated~1
normocholesterolemic,~1
Sandoglobulin~1
alpha-interferon,~1
anecdotical~1
(iANP)~1
iANP~3
neurographic~2
(PN).~1
brake~1
(SAPA)~1
sural,~1
(3.58~1
neurography~1
(brake~1
artefactually~1
tourist~1
failed).~1
amiodarone;~1
infarction.(ABSTRACT~1
Encainide~1
encainide,~1
arteriography)~1
nitroglycerin-treated~3
ergonovine-~1
50%-restricted~1
(C/50)~1
(50/C).~1
(C/C~1
50/50).~1
nurtured~1
maltase.~1
50/C~1
C/50~1
C/C~1
L-carnitine;~1
(62.1~1
d-1;~1
(621.1~1
d-1.~1
ketogenicity.~1
ketogenic~2
pyocyanin-fluorescein~1
(PFA),~1
PFA~1
pyocyanin~1
(postthymic)~1
fictitious~1
"nonfather"~1
disputes.~1
multiallele~1
multiloci~1
impossible)~1
one-parent~2
(Caucasians,~1
Hispanics)~3
(HLA,~1
Rh).~1
Beside~1
(93.25%~1
94.62%~1
95.82%~1
(89.59%~1
91.65%~1
92.54%~1
beta-D-galactosidase~1
(Lactrase)~1
Lactrase~5
(milk~1
Lactrase;~1
Lactrase.~1
(349~1
cromoglycate.~1
non-renin-dependent~1
sodium-rich~1
Hypoparathyroidism~1
upheld~1
myeloma;~1
immunocompromise.~1
warm-reactive~1
quinolones)~1
Bauer-Kirby~1
zone-size~1
Plasmid-mediated~1
resolved;~1
amyloid-associated~1
pseudohypertrophy.~1
dual-perfused~1
Antipyrine,~1
ibuprofen-inhibited~1
indomethacin-inhibited~1
carbacyclin,~1
carbacyclin.~1
immunoarchitectural~1
histology:~1
light-chain-restricted~1
L60+~1
41H+,~1
Ki-67+~1
LFA-1-B~1
T-lineage,~1
MB-1+~1
MAC-induced~1
non-nephritogenic,~1
non-C-fixing~1
(planted~1
C-fixing~1
vol/vol~1
albumin),~1
4.27~1
mg/min/g~1
pg/min/g,~1
mg/min/g,~2
protein/min/g~1
MAC-dependent~1
Tx.~1
37,370)~1
21,889).~1
neuroleptics.~1
choreoathetosis,~1
fluvoxamine,~1
self-ratings;~1
Fluvoxamine~1
panicked~2
Egyptian~1
fever-Naples~2
SFN~1
85055,~1
Domestically~1
(TCC~1
yard~1
Xenodiagnoses~1
post-exposure.~1
(20/51)~1
(32/51)~1
1/7~1
trypsin-treated~1
epimastigote~1
(95.6%);~1
nonchagasic~1
amebicidal~1
(1,862~1
amebae~2
Monocyte-derived~1
trophozoites,~1
amebae,~1
reanalyzes~1
Cheever~1
eggs/g~1
fecundity,~1
circumoval~1
backcrosses~1
Nmri~1
fibrosis)~1
Congenic~1
C3H/HeSn~1
B6.H-2k~1
B10.M~1
(H-2f),~1
B10.SM~1
(H-2v),~1
(trickle)~1
Krad-irradiated~1
egg-related~1
anti-schistosome~1
anamnestically~1
trickle~1
legitimately~1
intensity-intervention~1
flowsheets,~1
TISS~6
diverticulization.~1
adjuncts.~1
nonsystemic~1
(Vf)~1
Vf:~1
(0.15%)~1
Vf~7
normocapnia,~2
Vf,~1
CSF.(ABSTRACT~1
(pO2).~1
mixed-venous~1
.21,~1
.15,~1
.10.~1
(CO~1
CaO2)~1
(29.2~1
(QPr);~1
(QSF6);~1
(QCO2).~1
QPr~2
QSF6~2
QPR,~1
QSF6,~2
QPr,~1
(r:0.89,~1
(Haldane~1
(immunotherapy).~1
hyposensitized~1
fluorescent-activated~1
(FACS),~1
(anti-Tac),~1
dust-activated~1
marmosets.~1
N-benzoyl-L-isoleucyl~1
L-glutamyl-glycyl-L-argenine-p-nitroanilide~1
bleomycin-challenged~1
55,500~1
VIIa-like~1
oxygenases~1
oxygenases,~1
Ductus~1
(511~1
monoxide-induced~1
PCO/PO2~1
Metyrapone~1
phenylimidazole,~1
closure/~1
(TISS)~1
(SICU).~1
1286~1
Nonsurvivors~1
4.88~1
totals.~1
kat/L,~1
regularly;~1
elevations;~1
quasi-randomized~1
trials'~1
(pneumothorax,~1
septicemia)~1
0.067.~1
flaws,~1
semiaxial~1
Second-messenger~1
rapidly--the~1
(426~1
Automatisms~1
continuum.~1
Lafora's~3
siblings),~1
Postgonococcal~1
imipenem-cilastatin~6
(MK-0787-MK-791)~1
Cefazolin~2
norfloxacin-resistant~1
PAO4009~1
nfxA~3
nfxB,~1
hex-9001~1
leu-9005~1
pro-9031~1
ilv-9023,~1
nalA~1
transductional~1
F116L.~1
nfxB~4
hypersusceptibility~1
threefold-lower~1
54,000-dalton~1
imipenem-susceptible~2
imipenem-resistant~4
macrolides-lincosamides-streptogramin~2
RYC18F6,~1
clindamycin-susceptible~1
(SBR)~1
SBR~4
SBR.~1
SBRs~2
dose):~1
44.5;~1
56.6;~1
80.6.~1
Cross-resistance~1
46-~1
Macrolides-lincosamides-streptogramin~1
MLS-resistant~1
erm~1
ermA~6
(pNE131)~1
transposon,~1
Tn554,~1
Tn554~1
patterns).~1
Riccardi's~1
(dBCS)~1
Bentley~1
BCR-3500~1
dBCS~4
bubbling~1
Luer-Lok~1
(7.83~1
ml/dl),~1
1971-1980~1
(p-y)~1
p-y)~1
p-y).~2
non-B.~1
housestaff,~1
Temple~1
autonomists~1
preference;~1
strategists~1
paternalists~1
disodium.~1
political,~1
Cost-benefit~1
analysis/cost-effectiveness~1
tPA-treated~1
aborters.~1
anti-Ro.~1
22-2.5)~1
25-3.7),~1
aborters~1
set;~1
"weighting"~1
collagenases,~1
cell-afferent~2
astemizole's~1
Basc~1
brooding~1
nondividing~1
glutamine:~1
chromatography),~1
416,~1
tyrosine-phosphorylating~1
(PTPase)~1
released/mg~1
protein/min,~1
PTPase.~1
PTPase~1
(sIL-2R)~1
(B-CLL).~1
sIL-2R~4
(94.4%),~1
(1,781~1
less-invasive~1
sIL-2R,~1
cell-produced~1
defatted~2
DNase-I.~1
hexosamine~2
27.3%~1
hyalurolyticus~1
glycosaminoglycan)~1
Bio-Gel~1
A-0.5m~1
0.47).~1
4/8/9-A-2,~1
5/6/3-B-3,~1
5/6/1-B-5,~1
4-sulfated,~1
6-sulfated,~1
5/6/3-B-3.~1
Bc/I~1
extragenic~2
multiallelic~1
Bg/II~1
DX13~2
VIII-Bc/I~1
St14-Taq~1
noninformative.~1
grandfather~1
cellular-phase~3
radiofibrin~1
tPA/mL~1
IU/mL)~1
tPA/mL)~1
invoking~1
tPA.~1
desamino~1
D-arginine~1
DDAVP,~1
Technetium-99M~1
(TcPYP)~1
TcPYP~1
biofunctional~1
bioimmunoassay.~1
23-66)~1
32-91)~1
143/96~1
129/84~1
0.44-1.46)~1
ml/min/month~2
0.01-0.40)~1
ml/min/1.74~1
postpones~1
albumin/24~1
h.)~1
overrepresentation~1
semirural~1
Authority.~1
"back~1
up"~1
minister's~1
Methenamine~2
interchanged~1
hippurate.~1
(392~1
(225)~1
10,931~1
contraceptives)~1
11.06.~1
"crisis"~1
voiced~1
underwriting~1
reinsurance~1
"defensive"~1
sulphadiazine,~1
allografted~1
(Figs.~1
21-23).~1
(oat~1
ml/d~1
(S-6810)~1
(86.8%~1
(67.1%),~1
(53.9%),~1
(42.1%).~1
(autoimmune)~1
Immunocytologic~1
Leu-10,~1
Leu-14.~1
B-cell-derived~1
potentiality~2
(57.3~1
feces)~1
coprostanol~3
0.928)~1
0.915).~1
Coprostanol~1
biohydrogenation~1
anerobic~2
beta-sitosterol~1
TxA2,~1
eicosanoid-related~1
Broad-based~1
inhibitors)~1
TxSI~1
TxRA)~1
3.97~1
3.93~1
Wy-47,663,~1
(aortic-ligated)~1
Wy-47,663~2
II-infused~1
(-37~1
(Wy-44,655).(ABSTRACT~1
nanomol/min/100~1
suffusates~1
(40-230~1
microcirculation.(ABSTRACT~1
(alpha-h-ANF)~1
0.0025,~1
Intrajugular~1
right-atrial-appendectomized~1
decrements.(ABSTRACT~1
Single-doses~1
aminoglucoside~1
viridans-group~1
(beta-lactam~1
aminoglucoside),~1
Frequency-~1
5.61~1
abbreviation~1
Poststimulation~1
tocainide-~1
tocainide-induced~1
Vmax-membrane~1
("stunned"~1
(DMTU),~1
DMTU~3
perfusion),~1
microspheres).~1
isoimmunization~4
(hydrops~1
fetalis)~1
autoimmune-associated~2
isoimmunization,~1
(PPF)~1
PPF~1
implications;~1
multiattribute~1
predicted?"~1
vasorelaxant,~1
potassium-dependent~1
(Na+,K+-ATPase),~1
deplete,~1
repleted,~1
mmol/day).~1
Des-amino~1
homoeostatic~1
(APS),~1
(SAPS),~1
(MPM).~1
MPM~9
.9,~1
PtcCO2,~1
.87.~1
.82~1
PPD-tuberculin,~1
TU,~3
PPD-Battey,~1
PPD-Battey~1
PPD-T~1
PPD-T,~1
Waning~1
nonmycobacterial~1
PPD-tuberculin.~1
therapy-induced~1
D/DR,~1
Dwl~1
BfF~1
C4A3,2~1
(BO),~1
MHC-haplotype~1
HLA-B40~1
(synthesis~1
monolayer-cultured~1
advance,~1
DL-difluoromethyl~1
enterokinase,~1
peptidase,~1
DFMO-treated~4
unpredictably.~1
sympathomimetics,~1
bibliography~2
academician~1
all-inclusive~1
difluoromethylornithine.~1
isotonicity~1
admixtures~8
(TNA)~2
admixtures,~2
innoculated~1
triplicate.~1
(acidic),~1
TNA,~1
Transderm-Nitro~1
Nitro-Dur~1
Nitrodisc~1
Anovulatory~1
(9:25~1
2:14).~1
single-ovary~1
MHC-compatible~1
privileged~1
nonimmunologically~1
Na+-K+-dependent~1
weight-bear~1
semiquantitated~1
antiprostacyclin~1
Antiprostaglandin~1
synthase-positive~3
0+~1
Fat-storing~1
(perisinusoidal~1
Nycodenz~1
fat-storing~3
glycosaminoglycans;~1
(3-fold~1
Dermatan~1
(eighth~1
medium-sulfated~1
beta-elimination~1
puromycin-induced~1
(size)~1
Endocytosis~2
isothiocyanate-tagged~1
Coumarin-tagged~1
Beads~1
nonendocytosing,~1
nonsinusoidal~1
("lymphocytes").~1
("lymphocyte":~1
endothelial:Kupffer~2
0.57:1.0:2.0).~1
("lymphocyte":endothelial:Kupffer~2
0.13:1.0:2.4).~1
0.45:1.0:14.6).~1
4,813~1
asymptomatic;~1
Frog~1
N-acetyl-leukotriene~1
N-Acetyl-leukotriene~1
(perinephritic)~1
puncture)~1
(Schiotz~1
tonometer)~1
(thoracic~1
coarctation).~1
(72.0~1
Hacetate~6
HNO3,~1
Hacetate.~1
HCl-~1
Hacetate-acidified~1
preimplanted~1
(CB+)~1
chemodenervated~1
(CB-).~1
CB+~2
CB-~1
2.5%,~1
29,548,~1
29,548.~1
44069~1
Evaporation~1
Osmolarity~1
+14%~1
22Na,~1
36Cl,~1
short-circuited~1
(Pmann),~1
Mannitol~2
Pmann~1
(Prv)~1
reentrance~1
Prv,~1
Pa.~1
Prv~2
fresp~2
HCl-NaOH~2
breathing.(ABSTRACT~1
units/kg)~1
Macromolecule~1
sham-infected~1
Macromolecules~1
[3H]threonine,~1
macromolecule-bound~1
189%)~1
[3H]-threonine~1
110%).~1
open-~1
pneumonia-induced~1
neuromechanical~1
feedbacks~1
(intolerance~1
plausibility~1
expirations.~1
single-alveolus~2
non-oriental~1
non-orientals,~1
Staffing~1
"borrowing"~1
sex-steroid~1
twenty-~1
eightfold,~1
postcastration,~1
(acridine~1
Na+/HCO3~3
Cl-deficient~1
0.648~1
H+/HCO3~1
anti-Leu-1~1
tetra~1
decanoyl~1
K-depleted~2
depletion),~1
nonloaded~1
(HF,~1
ellagic~2
HF-deficient~1
p-nitroaniline~1
H-D-prolyl-L-phenylalanyl-L-arginine-p-nitroanilide~1
clot-promoting~1
thyroxine-binding~4
(FDH),~1
high-TBG~1
productions;~1
FDH~2
TBG;~1
42%);~1
Hansen's~2
sponsorship~1
Carville,~1
LA.~1
800-642-2477.~1
cost-effectiveness,~2
gender-,~1
residence-matched~1
checkers,~1
sentence.~1
(anti-mu)~1
(ISC).~1
SA-stimulated~3
anti-mu-stimulated~2
anti-mu-activated~1
anti-mu-~1
r-IFN-gamma.~1
(TcR)-triggered~1
anti-TcR,~1
CTL-inflicted~1
TC-stimulated~1
mAb;~1
TcR-triggered~1
three-color~2
CD5B~1
CD21,~1
CD19,~1
sIgD,~1
CD5-negative~1
T4+T8+~4
(T3H)~2
T3HT4+T8+~2
(T3L/T3-)~1
T3H~2
T3L/T3-~2
T3HT4+T8-~1
T3HT8+T4-~1
(PHA-blasts)~1
PHA-blasts~7
(hIgMRF)~1
Clonotypes~1
clonotypes,~1
(MRL-lpr/lpr,~1
anti-IgG2a;~1
MRL-+/+,~1
anti-IgG2a~1
2b;~1
C57BL/6-lpr/lpr,~1
anti-IgG1,~1
CH1~1
IgG2b-2a~1
hIgMRF~1
CH2~1
(7183,~1
S107,~1
Q52,~1
J558,~1
J606,~1
36-60,~1
X24)~1
IgMRF~1
pathogenicity;~1
diverse.~1
(2-6).~1
(7-9),~1
surprised~1
lymphocyte-independent~1
hemopoiesis,~1
bioregulatory~1
costimulatory~1
costimulating~1
anti-IgM-preactivated~2
IL-4-induced~2
RL/CD23),~1
(PFA)-fixed~1
(macrophages).~1
PFA-fixed~3
(SIRS)~1
SIRS.~1
(H-2)~1
interferons,~1
discernable,~1
(H-2k,s,d),~1
(H-2b,f),~1
(H-2p)~1
HBcAg/HBeAg~1
residue)~1
H-2s,b~1
p120-140,~1
H-2f,q~1
p100-120,~1
p85-100~1
activator-specific~1
(PAI)~1
monocytes-macrophages,~1
(PAI-2).~1
thioglycollate-induced~1
PAI;~1
Phagocytes~2
microbicidal.~1
biovars~1
venereum~1
(LGV)~1
biovar~5
phagolysosomal~1
Phagolysosomal~1
LGV.~2
phagocytes'~1
biovars,~1
GK1.5)~1
anti-leishmania~1
anti-L3T4-treated~2
major-infected~1
amastigote)-induced~1
8.10)~1
DPw2~2
rearrangements).~1
8.9.~2
DPw2-specific~1
VDJH,~1
endpoints.~1
nonsubclass-~1
nonclass-specific~1
haplotypes;~1
interferon-gamma-induced~1
LPS-activated~1
phenotypic,~1
(HTL),~1
antigen-unresponsive~1
maleylated~1
(maleylated-BSA),~1
maleylated-BSA,~2
pretreat~1
maleylated-BSA~4
macrophage-target~1
Maleylated-BSA~2
BCG-primed~2
Bi-specific~1
(BSMAB)~1
BSMAB~2
hybrid-hybridoma~1
CD3,4~1
(IgG2a,~2
IgG2b)~1
CD3,8~1
IgG2a)~1
3125~1
LPS/dextran~1
sulfate-activated~1
beta-(1-3)-N-acetylgalactosaminyl~1
residues;~1
(Ly-5)~1
receptor-triggered~1
"progression"~2
(G0-G1~1
doubted~1
mucopolysaccharidosis.~1
epilepsia~4
partialis~5
continua,~1
Sparse~1
cuffs,~1
clinico-pathologic~1
Rasmussen.~1
1215)~1
(BF10;~1
RT97).~1
1215~3
(NF-H).~1
RT97~1
recognizes,~1
RT97.~1
NF-H~3
NF-H.~1
illuminate~1
FLC,~3
FLC.~1
pleocytosis)~1
wanted.~1
instant.~1
bellows,~1
capnograms~2
36-segment~1
stethoscopes~2
capnography,~1
senses.~1
disconnected,~1
capnogram.~1
capnogram~1
deviates~1
artifacts).~1
electron-transport~1
4:1),~1
Retrovertebral~1
2.75).~1
9.42~1
corpectomy~1
deficit:~1
OPLL.~1
corpectomy,~1
"clot-specific"~1
preembolic~1
cerebroembolic~1
preembolus~1
Time-density~1
planometry.~1
DSA,~1
2,559~1
TBG.~1
(RRR-alpha-tocopheryl~1
PCB.~6
droplets)~1
fat-supplemented~1
(AFB1)-induced~1
transpeptidase-positive~1
(dose)~1
AFB1-induced~2
(response)~1
occupied,~1
10-12%~1
(6-8%)~1
8-arginine~1
(A10).~1
(NEM)~1
transduces~1
Guanyl-5'-yl~1
(HC).~1
(ICG),~1
(261~1
(249~1
(HOHC)~1
HC.~1
(CIL)~1
HOHC,~1
CIL~1
CIL.(ABSTRACT~1
200-110)~1
darodipine~2
(PY~1
108-068)~1
8216~5
DMCM.~1
L-threo-3,4-dihydroxyphenylserine~1
(L-threo-DOPS)~1
([3H]NE),~1
([3H]DA),~1
[3H]-5-hydroxytryptamine~2
[3H]choline,~2
effluxes~2
superfusates.~1
L-threo-DOPS~5
L-threo-DOPS.~1
channel-blockers~2
calcium-ionophore~1
nimodipin~2
LU-40883~2
D-888~2
channel-blockers.~1
different-type~1
(LDH).~1
(6K-PGF1~1
Nordihydroguarietic~1
nordihydroguarietic~1
6K-PGF1~3
polyreactivity~1
etiopathological~1
Technologies~1
multigenic,~1
(la~1
polytraumatized~1
(PBMC's)~1
INDO),~1
(C-AC).~1
220%~1
(C-AC)~1
INDO.~1
PBMC's~1
OKT3+,~1
IL-2R+~1
30.3%~1
90.1%~1
1574.9x~1
"all-or-none"~1
burns;~1
transfusions)~1
Chernobyl,~1
everywhere.~1
severity-related~1
(Mg)~1
hypomagnesemic~1
gentamycin).~1
diuresis-induced~1
Neopham,~1
Aminosyn,~1
Neopham~1
Aminosyn~5
Neopham.~1
Aminosyn-treated~1
"fine~1
bore"~1
(1978-1985).~1
809~1
491~1
3.5-g~1
85-cm~1
open-ended,~1
(Prima,~1
UK),~1
91-cm~1
3.0-g~1
(Entriflex,~1
Biosearch,~1
Disappointed~1
unweighted.~1
polyurethane,~1
water-activated~1
(Soyacal)~1
1:1:1.~1
5.2%;~1
HBC~1
6.9%;~1
HepatAmine~1
8.0%;~1
NephrAmine~1
0.608~1
0.286~1
0.309~1
Soyacal~1
nutrients:~1
V/V)~1
Vamine~1
(W/V),~1
Vamine-glucose~1
(W/V).~1
disaccharidases;~1
amino-peptidase~1
(TNAs)~1
acid/dextrose~1
[conventional~1
formulations]~1
10(1)-10(2)~1
(CFU/ml)~1
TNAs,~1
TNA.~1
TNAs~1
League~1
PGE-Met,~1
PGE-Met~1
UNaV,~1
FENa,~1
COsm~1
CH2O~1
2580~1
580)~1
2510~1
(440)~1
2920~1
(450)~1
(750)~1
(DKA),~1
osmotic,~1
DKA,~1
(ketoacids~1
biostimulation.~1
CO2-laser-induced~1
transversal~1
pulsed)~1
tissular~1
W;~1
focalization~1
20,000-35,000~1
W/cm2;~1
alpha-motorneuron~1
axodendritic~1
(5,7-DHT)~1
AMN.~1
(MLC-3)~1
MLC-3~5
(elective)~1
98).~1
elective-angioplasty~1
(whereas~1
immediate-angioplasty~1
striped~1
fushi-tarazu~1
(ftz)~1
even-skipped~1
(eve)~1
engrailed~3
eve~2
stripes,~1
best-understood~1
helix-turn-helix~1
ADR1,~1
ADH2,~1
adr1~3
ADR1~1
Phase-dependent~1
left-handed)~1
Linearly~1
Right-handed~1
chirality~1
invisible.~1
'linear~1
imaging'~1
bipartite,~1
polarization-dependent~1
(Band~1
ankyrin~3
(fodrin)~1
K+)ATPase,~1
(TCRs).~1
'accessory'~1
3DT-52.5.8,~1
H-2Dd-bearing~1
3DT-52.5.8~1
CD4:HLA-DR~1
c-fos-protein-like~2
gracile~1
NA-containing~1
converge,~1
prostglandins~1
corticotrophin~1
(irACTH)~1
irACTH~3
irACTH-releasing~1
(lCoBF)~1
thermister/Peltier~1
lCoBF~6
preexcision~1
(COR)~1
g/minute/torr~2
postexcision~1
g/minute.~1
Draining~1
excision.(ABSTRACT~1
melanoma-specific~1
97,000-molecular-weight~1
(p97),~1
48.7,~1
mCi/mg)~1
mCi/mg).~1
(BBB)-modified~1
0.395~1
(rads)~1
(barrier-modified~1
hemisphere),~2
5.46;~1
(non-barrier~1
1.68;~1
98;~1
9.1;~1
39.9;~1
1.33.~1
Prion~2
(PrP)~1
anti-PrP~1
(PrPC)~1
(PrPSc)~1
PrPC~3
brains;~1
astrogliosis.~1
PrPSc,~1
K-digested~1
PrPSc.~1
PrPSc~1
Rochester)~1
first-born,~1
Antifilamin,~1
antivinculin,~1
antitropomyosin~1
Antifilamin~1
antivinculin~1
antifilamin~1
Antitropomyosin~1
electroimmunodiffusion.~1
kappa:free~1
chain:albumin~1
IgG:albumin~1
IgG-kappa~2
(ASA).~1
peritreatment~3
(4-day~1
regimen)~2
drug-taking~1
(high-dose,~1
stearate).~1
(0.0%),~1
(2.9%),~1
erythromycins~1
skull-base~1
spasmolysis.~1
spasm--including~1
techniques--are~1
re-routing~1
challenge--functionally,~1
expediently~1
cheek.~1
(LCR)~1
(SLN)~1
peroxidase-wheat~1
dorsomedialis~1
Apneic~1
SLN.~2
Relevance~1
LCR~1
bud-like~3
impregnation,~1
terminations,~1
Schneiderian~1
(OSP)~1
OSP~1
1,25-dihydroxycalciferol,~1
treatment--including~1
surgery--for~1
outlook?~1
achieved?~1
retrospect?~1
1981-82.~1
phone.~1
(24.1~1
speaking.(ABSTRACT~1
DKA.~2
(Bactigen,~1
Wampole~1
Cranbury,~1
NJ;~1
Directigen,~1
Hynson,~1
Westcott~1
Dunning,~1
MD;~1
Dartford,~1
England)~1
(Haemophilus~1
meningitidis)~1
Directigen~1
counter-balanced,~1
94.1~1
"hyperactive"~1
Additional,~1
46XY~1
cousins.~1
hermaphroditism,~1
anorchia,~1
(Lancet~1
1986;2:299).~1
reimmunized~2
(3.95~1
covariant).~1
polymerase-primase~2
182-kDa~1
(73,~1
cosediments~1
182-~1
73-kDa~1
COS-M6~4
[35S]-cysteine~1
30,000-32,000~1
mock-transfected~1
anti-ricin~1
anti-B-chain~1
asialofetuin~1
7-mo~1
exon-containing~1
tropoelastin,~1
Ca2+-ATPase.~1
Kruppel~5
baculovirus~1
polyhedrin~1
DNA-cellulose,~1
isopenicillin~1
Cephalosporium~1
acremonium~3
(Cys-106~1
Cys-255~3
numbering).~1
Cys-106~2
IPNS~2
(hIR)~1
ros~1
hIR~2
hIR.~1
UIR,~1
p19.~1
UIR~3
UIR-transformed~1
membrane-associated,~1
gag-hIR~1
P75gag-hir.~1
P75gag-hir~1
(AEV)~1
AEV~1
mutated,~1
growth-regulating~1
pp60c-src.~1
AEV-infected~1
p75gag-erbA~1
gp66-68erbB.~1
AEV-transformed~3
6-30~1
hypophosphorylation~1
serine-~1
3H2O)~1
beta-3H]testosterone)~1
pmol/hr~2
2-4)~1
Fetal-neonatal~1
folliculogenesis.~1
target-site~1
adenosine-rich~2
Fw,~1
wi+A~1
Fw~1
transcriptases~1
alternative-processing~1
(v-Ha-ras)~1
Antithymocyte~1
(ATG),~1
immunoadherence~1
HPCA-1~1
hemoglobin-containing~1
(granulocytic~1
macrophagic)~1
(Mustela~1
putorius~1
furo)~1
5,5'-difluoro~1
1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic~1
(BAPTA).~1
5,5'-F2-BAPTA.~1
Ca]o).~1
5,5'-F2-BAPTA,~1
[Ca]o.~2
0.6-4~1
"loose"~1
quartile,~1
Tight-~1
loose-muscle~2
extended)~1
(flexed)~1
(angle~3
tight-muscle~1
276)~1
coverage;~1
bureau~1
Affairs,~1
Interior.~1
Interior~1
Natives.~1
IHS's~1
prevelant~1
McLaughlin~1
Lakota~1
(Sioux)~1
Rock~1
Reservation,~1
priority-setting~1
grassroots~1
clinic's~1
listed,~1
endowing~1
Opportunity.~1
masters~1
PhD;~1
DrPH~1
disciplines:~1
non-Indian~3
entirety.~1
combatting~1
debates,~1
shortsighted.~1
curriculums~1
nurturance~1
cities:~1
paraphernalia.~1
needle-sharing~2
(September~1
education),~1
(Minnesota~1
[MMPI]~1
scores),~1
[mixed]~1
use).~1
needle-sharers~3
"shooting~1
gallery,"~1
nonsharers.~1
Needle-sharing~1
needle-sharing.~1
ready-to-eat~1
(RTE)~1
(NCI).~1
Kellogg~4
Kellogg's~1
All-Bran.~1
supermarkets~1
RTE~2
All-Bran,~1
48-week~1
non-Kellogg~1
granola-type~1
products.(ABSTRACT~1
501-1,000~1
press,~1
Fluoridation~3
index's~1
fluoridation.~1
Parenthood~2
Louisiana,~1
marketing:~1
price,~1
higher-than-expected~1
"T's~1
blues"~1
pentazocine-Talwin~1
("T")--and~1
blues)~1
crushed,~1
heroin.~1
Talwin~4
Nx,~1
(DAWN)~1
Audit~1
Nx.~1
DAWN~1
reformulation.~1
Nx~1
examiners),~1
Smoking,~1
Tobacco,~1
timeframe,~1
sampled,~2
(women,~1
Louisville,~1
KY,~1
risk--workers~1
pallet~1
(TP);~1
(TN)--was~1
(PP~1
TN).~1
workers:~1
dispensary.~1
1981-82~3
1,732~1
18-99~1
old-293~1
outlook,~1
widening.~1
(trunk,~1
extremity).~1
spicules,~1
linkers~1
60D-E.~1
(60A-B),~1
60-kilobase~1
70,200~1
gambiae.~1
germlines~1
pUChsneo~1
G-418.~1
pSV2.~1
Asn102~2
oxyanion~1
nucleophilicity~2
tautomer~1
proton.~1
second-exon~3
(IPN)~1
(MLNS,~1
IPN/MLNS~2
electropotential~2
estimation,~1
(gonadotropins~1
estrogens)~1
fornices~1
(4,000~3
69%/63%~1
chymopapain/high-dose~2
73%/71%~1
chymopapain/low-dose~1
75%/72%~1
postinjectional~1
pseudoradicular~1
B4),~1
Sponge~1
(1196~1
/255~1
NDGA.~1
(AWHL)~1
AWHL~2
dextrose/insulin~1
postexplant~1
(NPS).~1
NPS~2
eight-,~1
X40~1
anastomosis;~1
(10-0~1
sutures).~1
aneurysmal;~1
(CIDKM~1
Poly-5)~1
ml/20~1
kg/min.~1
CIDKM.~1
CIDKM~2
(cimetidine,~3
ketanserin),~1
CID~3
diphenhydramine),~2
(ibuprofen~2
(cimetidine~1
diphenhydramine).~1
(SI).~1
Poly-5,~1
CID,~1
SI.~1
antimetabolite,~1
acivicin,~1
Tumor-carcass~1
ethinyloestradiol~4
l/h/kg)~1
(0.16)~1
l/h/kg;~1
(76.9%~1
oligospermic.~1
Reasonable~1
citrate)~1
(HCG~1
asthenospermia).~1
sperm's~1
sperm)~1
twenty-two-year-old~1
infarcting~2
application)~1
12-hour-daily~2
nonarrhythmic~1
(45%)--those~1
(21%)--those~1
(34%)--those~1
inotropic/vasodilatory~1
ray,~1
chemistry).~1
(IVF),~1
weight-increasing~1
oral)~1
oral;~1
IVF)~1
Pentane,~1
4-minute~1
alumina~1
pentane.~1
Pentane~1
Porasil-D~1
6.34~1
(15.39~1
1.84~1
Esthesioneuroblastoma~1
(EN),~1
lymphoepithelioma,~1
filaments:~1
desmin;~1
(HLE),~1
EN,~1
lymphoepitheliomas,~1
(6/7+,~1
4/7+),~1
(3/3+,~1
1/3+);~1
(3/3+).~1
Chromogranin~2
EN.~2
(5/8+,~1
6/8+),~1
(1/7+,~1
2/7+)~1
(1/3+,~1
3/3+)~1
XII-mediated~1
(C1S-INH)~1
+0.55,~1
C1S-INH~2
C1S-INH-mediated~1
erratic.~1
(Hb-SO2)~1
Hb-SO2~1
misoprostol.~4
Hb-SO2.~1
Misoprostol,~2
(cytoprotective)~1
non-antisecretory~1
cimetidine-controlled~1
(Europe,~1
Argentine~1
Misoprostol~11
misoprostol-treated~1
(achieving~1
1,300-mg~2
subantisecretory~1
naproxen-induced~2
1.22.~1
corpus/fundus~1
misoprostol,~1
chromium-51,~1
2.51~1
0.0023;~1
humanitarian~2
High-affinity,~1
E-type~3
ulcer-healing~1
aminohexane~3
Aminohexane~1
0.266;~1
estrogen-depleted~1
Neurofibromatosis~2
Polyhydramnios,~1
indomethacin/kg~1
weight/day.~1
reformed.~1
acromegalic,~1
superinfections)~1
prophylaxis:~1
82%;~1
wax-embedded~1
(UCHL1,~1
4KB5),~1
B-cell-related~1
(KiB3,~1
MB2,~1
LN1),~1
macrophage-related~1
(Mac411).~1
anti-kappa,~1
anti-lambda,~1
non-phenotype-associated~1
(TAL-1B5,~1
LN3,~1
LN2,~1
MB3),~1
(C3D-1),~1
CD30~1
(BER-H2).~1
Monotypic~1
deciduosarcomas~3
(one-third~1
derivative),~1
Economics~1
"market~1
foregone~1
remediation.~1
205,000~1
(diagnostic~1
Disease-related~1
Mid-range~1
$18,517~1
$17,643~1
$48,544~1
$493,277,~1
$27.9-31.2~1
Sprinting~1
noncorrected~1
flow/metabolism~2
14-15~2
non-temperature-corrected~2
20-100~1
temperature-corrected~1
independently).~1
15-95~1
1-2)~1
isoflurane-nitrous~1
sighs/hr.~1
nonsighing~2
sighers~2
nonsighers.~1
PACO2.~1
Essilor~1
pupillometer.~1
(P0.1),~1
(PETCO2),~1
(P0.1/CO2,~1
VT/CO2,~1
VE/CO2,~2
RR/CO2)~1
(P0.1:7.2,~1
VT:7.2,~1
VE:7.2,~3
RR:7.2)~1
P0.1:7.2,~1
VT:7.2.~1
VE:7.2~1
P0.1:7.2.~1
VE:CO2,~1
P0.1:7.2~1
significant.(ABSTRACT~1
pain:~1
Somnolence~1
spinhaler~1
(bacteria)~1
Microbicidal~1
gamma-treated~1
Blastomycoses~1
acetate-buffered~2
VT/TI.~1
setup.~1
Radicals~1
pathways:~1
lipoxygenases,~1
monooxygenases.~1
occur-localized~1
nephron;~1
(mTALH)~1
Obliterative~1
(-5.25~1
-0.27~1
SD];~1
(-3.61~1
blood-lipid-lowering~1
(SLKC)~1
SLKC.~1
Lactoplate~1
one-year-old~1
staphylomas~1
hyposmia.~1
holoprosencephaly.~1
vernamycin~2
(15.5%),~1
(35.1%),~1
cefadroxil~2
Cefadroxil~1
cefadroxil-treated~2
three-times-daily~1
killing-curve~1
Meningococcal~1
(PCBs),~1
dibenzo-p-dioxins,~1
dibenzofurans~1
Binghamton,~1
NY~1
Firefighters~1
post-fire~1
exposure-related~1
endobrachial~1
(0.03%)~1
ceca.~1
C-25~1
post-CPB~5
11.5%,~1
(ERCP),~1
70.7%~1
arthritogenic~2
anti-MT~2
"zero~1
swallowings~2
(AZT,~1
Retrovir,~1
zidovudine)~1
140,000/mm3.~1
70,000/mm3.~1
2,000,000~1
alpha-A,~1
Monocyte/macrophages~1
immunocytofluorographic~1
-0.60).~1
PUVA-generated~1
Urilos~2
nappy~1
gonadotrophins).~1
changes/24~1
oestrogen-treated~1
UPP~1
oestrogens.~1
Buserelin,~2
intranasally,~1
(Metrodin)~1
i.u.~1
(IL2R)~1
(B-ALL).~1
B-ALL~2
noncleaved-cell~1
spans.~1
(PAIgG),~1
260;~1
Full-body~1
spleen-to-liver~1
(B-PLL).~1
Mitogen-free~1
B-PLL~6
media-induced~1
(NAM),~1
(3AB),~1
(1MN)~1
Nicotinic~1
ribosylation,~1
factor-mediated~1
3AB~1
1MN~3
IL-3-responsive~1
kinase-C~1
(PMA)-induced~1
postirradiation.~1
Catalase,~1
anti-Rh(D),~1
auto-antiidiotype~1
auto-antiidiotypes~1
idiotype-antiidiotype~2
(BAEs)~1
autography~1
(PAI-1).~1
tPA/PAI-1~1
mannose),~1
sulfate),~1
2.5).~1
ECM-associated~1
BAEs~1
hyperadherence~1
(NGs),~1
secretago-gue-mediated~1
(cord~1
(AGs).~1
AGs.~2
ionophor~1
NGs~3
receptor-1~1
(CR-1)~1
blocking-incubation~1
anti-Mac-1~1
(MAbs),~1
fMLP-stimulated~1
peroxidase-negative~2
granule-membrane~1
"addition"~1
NGs.(ABSTRACT~1
G2)~1
antiprothrombin~1
intracellular).~1
(twofold)~1
Endoglycosidase-H~1
mannosyl"~1
carboxylation.~1
arachidonoyl~1
[3H]arachidonate,~1
nonmembranous~1
icosanoid~1
radiodiagnosis~1
man-sievert~1
re-dilated~1
(Ta-T1)~1
instillations.~1
(RI/m)~1
(Zenker's~1
diverticulum).~1
diverticulectomy~2
pharyngolaryngectomy~1
(ICBF)~1
(5.32~1
s.e.m.).~1
torr-1~1
'sludge'~2
4.5-5.9~1
gallbladders,~1
'sludge',~1
12-15,~1
25-28,~1
AI-CIII-AIV~1
4470~1
re-examined,~1
units/1),~1
non-bacteriuric~1
500-2000~1
1251~4
disabilities:~1
101.6~1
17.2)~1
50-147),~1
101.8~1
(13.2)~1
56-127):~1
(32),~1
(49),~1
(68)~1
(70),~1
"malpractice~1
crisis"~1
privatising~1
deterrence~1
(prolonged~1
suffocation~1
(smothering)~1
(18.2%).~1
1363~1
1618~1
(90.8%)~1
Macrovascular~1
(ischaemic~1
proteinuria--mean~1
macroangiopathy~1
macroangiopathy,~1
(pathogenetic?)~1
Gosport~2
Security's~1
11,400),~1
83,000).~1
Boeing~1
airliner~1
escaped.~1
unconvincing.~1
justifications~1
absolute,~1
obligation.~1
honoured.~1
1973-86.~1
Koplik's~1
Pneumonitis~2
(29.4%)~1
Schwartz~1
unvaccinated.~1
42-125)~1
40-103),~1
37-107),~1
39-80)~1
captured.~1
(165%)~1
non-surge~1
(145%).~1
sensitising~1
Luteinising~1
deters~1
about,~1
Blennerhassett~1
1976--discretionary~1
testing--is~1
non-invasively,~1
"free~1
living"~1
MJ/day~1
MJ/day;~1
MJ/100~1
unphysiologically~1
IgA-antigliadin~4
Berger's~1
Geographical~1
1911-4~1
Bortner~4
prone)~1
5936~1
40-59~1
Non-manual~1
(angina~1
Leicestershire~1
collagenase)~1
(HSV)-2~1
dibromomannitol~1
(DBM),~1
DBM~4
busulfan.~1
insures~1
(T11+,~1
Leu-3a+,~1
B1-,~1
ALL-).~1
[PMN]~1
500/microliter)~1
rettgeri.~1
acute.~1
bladder-sparing~1
sidewall,~1
rivaled~1
(astrocytomas,~1
astrocytomas)~1
(neurofibromatosis,~1
tuberose~1
sclerosis),~1
Multicentric~1
Celloidin-embedded~1
textures~1
Homer-Wright~1
neuroectodermic~2
(neuroblastoma,~1
neuroepithelioma).~1
ES,~2
traces.~1
(leu-7)~1
chromatine~1
synaptic-like~1
buttons;~1
neurotubuli,~1
basement-like~1
condensations~1
elongations~1
"neuroectodermal~1
bone."~1
glycan-dependent~1
affinoimmunoelectrophoresis~1
nonmalignancy~1
(micro-)heterogeneity~1
monoamine.~1
S1-~1
methiothepin.~1
platelet-induced~2
damaged-endothelium~1
ETYA,~1
AA861,~1
Chlorpheniramine~1
amine-induced~1
hydroxymethylglutarate~1
mevalonate,~1
compactin,~1
mevastatin~1
(compactin),~1
(mevinolin),~1
simvastatin~1
(synvinolin),~1
eptastatin~1
(CS-514,~1
SQ-31,000),~1
SRI-62320.~1
hydroxyacid~1
Lovastatin~2
(mevinolin,~1
Mevacor),~1
-33%;~1
-40%;~1
-35%;~1
-25%;~1
+10%;~1
-20%.~1
Chagas~1
5771~1
Roscio~2
29.9%~1
nationwide.~1
614)~1
distribution.(ABSTRACT~1
same-dose~1
(14C-acetate)~1
14C-acetate,~1
14CO2.~1
11C-acetate,~1
11C-acetate~2
confounds~1
.0025)~1
(subunits~1
SLE-associated),~1
membranoproliferative)~1
(SLE~1
mass/mm~1
ash/length~3
Lyon~1
axetil~3
Phenoxymethyl~1
(51/60)~1
axetil,~1
(29/33)~1
Meningococci~1
ophthalmia,~1
flumazenil,~2
sedatives.~1
flumazenil~1
glasgow~1
flumazenil-treated~1
(+4.9;~1
(+5.3;~1
(+5.6;~1
Flumazenil~1
1,2-~1
1,3-glyceryl~2
dinitrates~1
mg/200~1
1,2-glyceryl~1
(dinitrate~1
Dinitrate~1
7.36,~1
3.86,~1
sublingual,~1
1,2-dinitrate~1
1,3-dinitrate~1
administration).~1
triphasic,~1
(micrograms/ml)~1
L/m2,~1
Vareas,~1
CLR.~1
(470~1
5,790~1
1,941~1
Posttransplant~1
0.16),~1
(Qt)~1
(PaCO2-PetCO2)~1
PaCO2-PetCO2~3
(ZEEP),~1
(PEEPPi)~1
PEEP5~1
PEEPPi,~1
ZEEP,~1
(ZEEP:~2
13.59~1
PEEPPi:~1
PEEPPi~1
10.54~1
14.15~1
14.20~1
16.53~1
wasteful.~1
Diverticulum~1
histamine-sensitive~1
(conversion~1
estradiol).~1
(methylisobutylxanthinine),~1
19-hydroxyandrostenedione~2
2-step~1
[Dulbecco's~1
(1:1)]~1
methylisobutylxanthinine~1
NIAMDD~1
FSH-2~1
0.01-5.0~1
hTSH,~2
hPRL,~1
0.049.~1
elutions~1
isoelectrically~1
(NIAMDD-hFSH-2),~1
deciphered,~1
(hTSH)~1
Affinities~1
10(8)-10(11)~1
(bTSH),~1
(hLH,~1
hFSH,~5
hCG),~1
cross-reactions:~1
bTSH,~3
hFSH;~4
bTSH;~1
beta-subunit;~1
holo-hormone~1
holo-hormone.~1
holo-hTSH~2
conserved;~1
associated;~1
teleosts,~1
Anguilla~1
anguilla~1
GTH~4
YA.F.)~1
(R.C.,~1
M.J.)~1
eel.~2
Eel~1
[35S]Met~1
Cys.~1
(18.5K),~1
alpha-precursor,~1
eels~2
8.0-~1
8.5-fold~1
M)-induced~2
[3H]-1,25-(OH)2D3~1
(ANFIV102-126)~1
10(-8)M)~1
(10-15%).~1
Mono[125I]-iodo-ANF~1
10(-10)M~1
160,000-190,000~1
sites/cell.~1
[125I]-iodo-ANF~1
angiotensins,~1
[125I]-iodo-ANF.~1
neurohormone~1
ml/h),~1
hCRF~1
ml/h;~1
experiments/group).~1
83.0~1
99.6~1
(ANP).~1
ANP/microgram~1
ng/micrograms~2
ANP(1-126).~1
ANP-specific~1
300-microliter~1
anti-rCRH-41~2
(ic)~1
prazosin-~1
stress-like~1
halved.~1
ic~1
Ether~1
reached.(ABSTRACT~1
calcium-depleted~1
non-cAMP-mediated~1
induced-basal~1
ratio):~1
Bicucullin~1
95103~2
bicucullin~1
Picrotoxin~1
availability)~1
(EGTA,~1
(D-600,~1
(veratridine,~1
(Buserelin~1
D-TRP6-PRO9-N-ET,~1
(Leu8-GnRH,~1
Des-gly10-N~1
picolylamide~1
(BPEC)~1
BPEC-SE~1
continua.~1
Epilepsia~1
continua~3
multiplex,~1
(VPA,~1
hypocarnitinemia~1
L-Carnitine~1
VPA-medicated~1
(amygdala~1
kindling)~1
(SW)~1
(GTCs)~1
SWS.~1
penicillin;~1
GTCs~1
(REM).~1
kindling;~1
GTCs,~1
SW~1
"absence"~1
nonneurological~1
childhood),~1
electroencephalographic/polygraphic/video~1
epilepsies,~1
1264~1
389)~1
191)~1
leiomyomata~2
D-Trp6-LH-RH.~1
(hMG)-stimulated~1
GIFT,~1
(hFSH)~1
irreparable~1
estrone-3-glucuronide~1
(E1-3-G),~1
E1-3-G,~1
E1-3-G~2
(CIA),~1
4-positive~1
antigens--class~1
[DR]~1
2a-positive)~1
postvasectomy~1
0.992;~1
LH:~1
0.833).~1
E2-thyroglobulin~1
E2-immunized~1
enprostil.~1
E2-hyperimmune~1
compiling~1
x-ray;~1
nonhealers;~1
27.2.~1
28.0,~1
(OH)~1
Jejunostomy~1
Vivonex.~1
'elemental'~1
HN,~1
'complete'~1
Enrich~2
bulkless~1
Bulkless~1
(namely~2
T9~3
increased--in~1
(7.63~1
(140.3~1
6.91~1
164.7~1
0.0015)~1
Na+,K+-ATPase.~1
alpha-rat~1
water-electrolyte~1
-cholinergic~2
(140-60~1
rightward.~1
multiplicatively~1
tachypneic~2
(E/CO2).~1
E/CO2~2
(2.97~1
salt-perfused~1
cAMP-linked~1
unhabituated~1
Pdi-stimulus~1
deslanoside-treated~1
deslanoside~3
Pdi-frequency~1
fatigability.~1
0.0008~2
0.0002~1
0.0027~1
diffusivities~1
mannitol:inulin~1
(3.7).~1
0.0024~1
0.0087~1
10(8)/l)~1
coinstillation~1
0.4-1.4~1
(HFP)~1
(VBF)~1
VBF~6
HFP.~1
l.kg-1.min-1.~1
l.kg-1.min-1),~1
l.kg-1.min-1,~1
1.785~1
0.657~1
l-1.kg.min~1
VBF.~1
intraairway~1
fibrinogen-sodium~2
(NPE),~1
fibrinogen-injected~1
congested,~1
liverlike~1
froth~1
tinged~1
Fibrinogen-sodium~1
EVLW-to-blood-free~1
saline-control~1
blood-fre~1
CaO2,~1
[ER~1
(CaO2~1
CVO2)/CaO2,~1
CVO2~1
content]~1
(QO2c)~1
(30-50~1
QO2c~2
(ERc~2
ER)~1
QO2,~1
(14,110~1
ft).~1
saturation)~1
(altitude)~1
values);~2
(fR)~1
CV)~1
VT-high~1
fR~5
(high-frequency~1
HFV).~1
(VT/VD)~1
VT/VD~4
Interclavicular~1
mammals.(ABSTRACT~1
alpha-chloralose-urethan~1
0.564~1
l.min-1~1
kPa-1~1
runs),~1
(apneic~1
(celiprolol,~1
mph/0%~1
(ATge),~1
Slope~2
RPE,~1
GHRH-(1-44)NH2~1
etc.):~1
45.8~1
supresellar~1
(Pergonal)~1
6-oxo-PGF2~1
(OCCC).~1
mL:~1
88;~1
175;~1
325;~1
130;~1
425;~1
860;~1
Graafian~1
consolidates~1
12-28%~1
(70-90%~1
(48-70%~1
(30-56%~1
(80-234~1
ng/20~1
(764-1342~1
0.03-0.5~1
mU/mL,~1
0.4-100~1
mU/mL.~1
3-26~1
10.5)~1
yttrium-90~2
Gold-198~1
yet),~1
microgram/kg)-induced~1
(FSS),~1
(GHD)~1
[FSS,~2
GHD,~4
CGD,~4
(FSS,~2
stimuli);~1
stimuli)].~1
23-35~1
[1302~1
(pg/mL)day~2
4780~1
9360~1
(pmol/L)day,~1
units],~1
[13.5~1
[152~1
(ng/mL)day~2
(nmol/L)day,~1
units].~1
(BCT;~1
Basally,~1
BCT~3
pulses/4~2
(126.1~1
circhoral,~1
[3H]apoprotein~1
(apoA-I)/HDL~1
apoA-I/HDL~5
[0.63~1
1/day;~1
0.001]~1
-0.63;~1
GHRH-(1-44)-stimulated~1
18-25~1
19-26,~1
matched-men~1
(mevinolin)~1
40-180~1
112.~2
million/mL~1
14-16.~1
million/mL,~1
Kallmann's~2
anosmia.~2
rhinencephalon,~1
hyposmia~1
(PDH)~1
PDH~4
6.71~1
0.52.~1
Nonoxidative~1
Na+:H+~2
Cl-:HCO3-~1
(blLPM)~1
(cLPM)~1
ursodeoxycholate~1
(UDCA),~1
outwardly~1
blLPM~2
pH-driven~2
(10-200~1
1,6-diphenyl-1,3,5-hexatriene,~1
12-(9-anthroyloxy)~1
2-(9-anthroyloxy)~1
(2-AS),~1
cLPM~1
HCO3(-)-driven~1
bicarbonate-rich~1
(AP-III)~1
AP-III.~1
AP-III~6
(182.6~1
(244.4~1
AP-III-treated~2
(3.03~1
(3.98~1
(JGC),~1
(Pinet,~1
Corvol,~2
Dench,~1
Bourguignon,~1
Feunteun,~1
Menard,~1
82:8503-8507).~1
musclelike~1
3',5'~1
JGC~3
forskolin-mediated~1
H2-histamine~1
Cai2+,~1
Mounting~1
(beta-END),~1
(suppression~1
beta-END),~1
(monocyte-depleted~1
(ROI)~1
(scavengers~1
hANP)~1
FBF,~1
-0.883,~1
hANP,~1
fashion:~1
GMP).~1
0.724,~1
0.637,~1
meq/min,~1
0.2-mg/dl~1
0.807,~1
FBF-plasma~1
hANP-dependent~1
(ADPRP)~1
ADPRP~5
anti-enzyme~1
116-kD~1
anti-ADPRP~1
cellobiose~2
cellobiose:mannitol~3
jejunums~4
perimeter:lamina~3
duodenal,~1
immunogold-silver~1
(IGSS)~1
(MGUS).~1
MGUS~1
(eccrine~1
apocrine)~1
deep-prick~1
Inoculated~1
ongoing.~1
(rt-PA):~1
("old"~1
rt-PA)~1
("new"~1
rt-PA).~1
113);~1
47);~1
83);~1
fibrinogenolysis.~2
rt-PA;~1
(409~1
(253~1
(2,265~1
nitrate-free~1
MSC.~1
Designs~1
time-efficient.~1
reevaluating~1
.2)~1
(ANOVA),~1
"meal"~1
(31.1~1
(64.9~1
acid-bearing~1
33,000-48,000~1
1-negative~1
rescuing~1
proliferation-related~2
(PDB),~1
PDB-ionomycin-induced~1
h-2b~1
semiallogeneic~1
anti-L3T4(GK-1.5)~1
(H-35-17.2)~1
Ighb~1
(Ti)-alpha~1
Ti-alpha-~1
Ti-beta-chains~1
(H36~1
H38,~1
Ti-alpha~5
H38~1
H36,~3
(CD)-1+~1
CD1-CD3+~2
medullary)~1
H38.~2
CD3-CD1-~1
immunogold-~1
CD1+/Ti-alpha~1
CD1+/Ti-beta~1
CD3-Ti~2
Ti-alpha-chains~1
(PNA)+,~1
(NK)-associated~1
CD1-negative,~1
CD3-negative.~1
CD3-positive~1
CD3-negative,~1
(HNK-1,~1
B73.1)~1
(N901).~1
CD3-T~1
(IP3),~1
PK-C.~1
phosphoinositide-derived~1
mitogen-induced,~1
Activation/proliferation~1
(BXSB~1
W)F1~1
immunostimulants~1
activation/proliferation,~1
sublineage~2
sublineage.~2
(Leu8)~1
CD45R~1
(p220/Leu18/2H4).~1
CD4+p80+,~2
CD4+p80-,~1
CD4+CD45R+,~1
CD4+CD45R-~3
CD4+CD45R-,~1
CD4+p80-~1
CD4+CD45R+~1
Candida-driven~1
suppressor-induction~1
CD4+p80+~1
CD4+CD45R-p80+~3
CD4+CD45R-p80-~1
(Leu3+,~1
Leu8+,~1
2H4-)~1
(TsF1)~1
antigen-derivatized~1
Ts-2~4
factor-presenting~1
I-J,~1
TsF1,~1
Igh-V~1
4-producing~1
(ionomycin)~1
(12-O-tetradecanoylphorbol~1
13-acetate;~1
TPA)~1
costimuli.~1
(iono/rIL~1
(TPA/rIL~1
4-independence~1
TPA/rIL~1
4-dependent~1
4-independent~1
multipotential.~1
anion-exchange,~1
urine-derived~1
itself).~1
antigenicity)~1
BCGF).~1
vivo-preactivated~1
(CLB-CD~1
27/1~2
CLB-CD~2
27/2)~1
9F4),~1
(VIT~1
18A,~1
S152)~1
CD27.~1
CD27~2
(Tp55).~1
Tp55,~1
Tp55~1
(PBM).~1
PCA-inducing~1
Sepharose-conjugated~1
MoAb.~1
(LF)--a~1
conditions--stimulates~1
(MPM)~1
(AMA),~1
iron-free~1
(ApoLF),~1
ApoLF~6
MPM,~1
MPM-bound~1
Diethylaminetriamine-pentaacetic~1
LF-treated~1
MPM--previously~1
O2-.,~1
1O2--was~1
OH.,~1
(PPD].~1
(BCG)-PPD-activated~1
listericidal~1
BCG-PPD-activated~3
listeria-infected~1
Checking~2
O2-consumption~1
(L.~1
gondii),~1
gamma-activated~1
rIFN-gamma-activated~2
C6B2~2
(5'~1
VHII~1
J3~1
J3,~1
Ser-Tyr~2
CDR2.~1
phosphocholine-conjugated~1
nitrophenyl~1
(NPPC),~1
NPPC~1
PCG1-1.~1
VDJ~1
PCG1-1~7
M141~3
DSP2.6~1
JH-3.~2
M141,~1
PC-protein-binding~1
1-bearing~1
VH-specific~1
antigen-inducing~1
nonexpressed~5
(D/J~1
rearrangements)~2
(V/D/J~1
hybridomas--all~1
C57BL/6J)F1~1
H10-4.22,~1
(fluorescence-activated~1
sorter).~1
V/D/J~2
D/J~1
VkIII~16
12-kilobase~1
895-base~1
5-kb~1
germ-like~1
Fab'-anti-L3T4~2
hemocyanin-specific~3
Keyhole~1
trinitrophenyl-specific~3
(Fab'-anti-L3T4-A),~1
Fab'-anti-L3T4-A~1
10(-9)M~1
disialoganglioside~1
IgGs,~1
anti-GD3~2
GD3+~2
anti-cluster~1
9-1~7
CD3-/CD16+~1
CD3+/CD16-~1
Anti-CD16~1
9-1,~1
comodulation~1
9-1.~2
anti-CD18~1
antiglobulin,~1
phenyltrimethylammonium~2
LOP~2
(CRI+-TMA)~1
Ig-1e~2
C57.Ige~1
Ig-1e),~2
(H-2d,~2
(H-2s,~1
Ig-1e)~2
(H-2a,~1
non-Ig-1e~1
1.4-derived~1
Ig-1b)~1
Ig-1c)~1
CRI-TMA~1
idiotype-enhancing~1
CRI+-TMA~1
allotype-linked~1
thyroid-derived~2
M.5~6
constitutively,~1
M.5-T~1
Cytofluorographic~1
FK506,~3
FK506~6
allo-mixed~1
Allo-cytolytic~1
specific-proliferative~1
BC.21~3
KO.6.~1
Ti/T3~1
4-hydroxy-3-nitrophenylacetyl~1
late-acting~1
(anti-Ig/Sepharose)~1
Anti-Ig/Sepharose~1
kDa/pI~1
(p40/pI-5).~1
anti-Ig/Sepharose-induced~1
p40/pI-5.~1
p40/pI-5~4
WEHI-231,~1
My10~5
(HPCA-1)~1
granulocyte-erythroid-macrophage-megakaryocyte~1
Epics~1
Red-labeled~1
anti-My10~1
anti-HLA-DR.~1
(DR-My10-)~1
DR-My10-~1
(My10~1
DR+)~1
(My10+DR+)~1
My10,~1
My10-positive~1
DR++~2
factor-alpha,~1
fractions.(ABSTRACT~1
"immunosuppressive"~1
GVH),~1
"immunostimulatory"~1
(DBA~1
GVH).~1
GVH,~4
anti-F1~2
TNP-self~1
anti-allogeneic~1
azocasein-treated~3
(Ig)G2a~1
cytofluorographic~1
2-Macroglobulin~1
peptone-injected~1
Calmette-Guerin-infected~1
2M-trypsin,~1
2M-methylamine,~1
(p58)~1
[125I]IL-2~1
p58~3
p58.~1
(p58)-~1
(p75)-subunit.~1
(anti-TAC).~1
TNF-alpha-~1
beta-treated~1
(1-80~1
66-104),~1
plate-bound~1
1-80~2
procure~1
Id62~2
H62~1
L62~1
anti-Id62~1
anti-H62~1
anti-L62~1
Id-positive~1
L-chains~1
Id62-positive~1
structure/function~1
burst-dependent~1
anti-influenza~2
anti-PR8~1
anti-X-31~1
X-31-specific~1
PY206~1
PR8,~1
X-31,~1
anti-idiotopes~1
PY206.~1
antiinfluenza~1
anti-idiotope.~1
idiotope-positive~1
culture-enhanced~2
L3T4+T~1
complex-compatible~1
HEPG2.~1
HEPG2~2
(Sj).~1
Sj~1
1/256,000~1
hepatica,~1
Paragoniumus~1
westermani,~1
spiralis.~1
97-kDa~1
postlung~1
anti-Sj~1
HBcAg-induced~1
toxoid).~1
HBcAg-stimulated~1
competent.~1
3':5'~1
(IL-2)-stimulated~1
cAMP-derivative,~1
3':5'-monophosphate~1
c-myb.~1
CL203~1
CL207~1
MAA.~1
96,000.~1
51,000.~1
parvum.~1
HS)~1
PBS,~1
Tris-acetate-buffered~1
(TAS),~1
TAS~2
CaCl+2~1
(TAS-Ca+2),~1
(BPF),~1
TAS-Ca+2.~1
BPF)~3
substrate/buffers.~1
Ca+2,~1
0.001%;~1
0.0001%~1
Ca+2-supplemented~1
filtrations~1
xylometazoline~1
attack-free~1
PRL-regulating~1
(CHAP-5)~1
CHAP-5.~2
single-day~1
uroprotector,~1
(2-mercaptoethane~1
sulphonate),~1
[PR]~1
[CR]).~1
neuroepithelioma,~1
97%;~1
1,132~1
1,648~1
(GnRHA)~1
unevaluable~1
34.7).~1
(Anguilla~1
anguilla)~1
desaturate~1
elvers~4
[1-14C]linoleic~1
eels.~2
trienes~1
tetraenes~1
Compositional~1
docosaenoic~1
22:1n-11,~1
1.15%~1
0.53%~1
L-lysine.HCl~1
gain-feed~1
2.30%).~1
3.45%~2
lysine)~1
lysine.~1
608.4~1
142.2~1
2505~1
1005~1
mL/1.73~1
fmol/L)~1
l/mL/hr),~1
(132.1~1
858.7~1
(99.4~1
1a2a3a~2
"rheumatoid"~1
(EDX)~1
(9/10)~1
(5/5).~1
(7/19)~1
(12/19)~1
(6,700~1
anti-Rh(D)/RBC~1
(1,100~1
molecules/RBC).~1
VDRL,~1
(aCL).~1
Osteophytes~1
Etiopathogenic~1
menisectomy~1
endochondral.~1
mechanical/electrical~1
chemical/hormonal~1
procollagenase~1
gelatinolytic~1
upon:~1
style);~1
write-ups.~1
experts'~1
collected;~1
(citrate,~1
crystal-membrane~2
whewellite,~1
weddellite,~1
brushite,~1
struvite,~1
microcrystals~1
membranolysis~1
weddellite~1
quartz,~1
Whewellite,~1
anorchism~2
anorchism.~2
steroid-independent~1
anorchid~2
(10/664,~1
(6/710,~1
0.8%),~1
units/mL);~1
Contaminants~1
(3.6%);~1
(0.9%).~1
anti-benzo[a]pyrene~1
epoxide-I-DNA~1
4-aminobiphenyl~1
(4-ABP-Hb)~1
femtomole-per-microgram~1
4-ABP-Hb~4
(sample~2
subcultivating~1
cells/dish,~1
cells/-dish.~1
4,4'-bis(dimethylamino)benzophenone,~1
benzo[a]pyrene,~1
7,12-dimethylbenz[a]anthracene,~1
7-(bromomethyl)-12-methylbenz[a]anthracene,~1
dibenz[a,h]anthracene,~1
Tris(2,3-dibromopropyl)~1
benzidine,~1
propyleneimine,~1
N-hydroxy-2-fluorenylacetamide,~1
classes)~1
Noncarcinogens~1
phenanthrene,~1
anthracene,~1
2-aminobiphenyl,~1
replated.~1
added:~1
1254-induced~1
S-9.~1
NADPH-dependent,~1
dimethylnitrosamine,~1
2-naphthylamine,~1
2-aminoanthracene,~1
B1.~1
lasiocarpine~1
303-34-4),~1
1162-65-8),~1
dipentylnitrosamine~1
13256-06-9),~1
non-zero~1
one-at-a-time~1
Polyamines~1
H2T~3
Cell-doubling~1
77th~1
[(PCZ)~1
671-16-9]~1
84th~2
91st~1
fibroadenomas,~3
additivity~1
PCZ~1
DMBA,~1
PCZ,~1
BALB/cMed~1
DIM-1,~2
DIM-2,~2
DIM-3,~1
DIM-4~4
COMMA-D.~1
DIM-3~2
(ductules)~1
[40%~1
(TE50)~1
mo]~1
TE50~1
(TG~4
Heart-lung~1
expectedly~1
tributary.~1
retrain~1
(polydioxine)~1
Ethicon~1
GmbH,~1
aneurysmectomies~1
"linear~1
petrification,"~1
felt,~1
thromboelastographic~2
forewarn~1
0.02]).~1
concealing~1
(FOD)~1
refunded~1
HB~1
microCi/microgram)~1
IL2-receptor-positive~1
anti-asthmatic~1
1970-71~2
asthmatic,~1
19.4%.~1
under-prescribed~1
(DOR).~1
DOR~3
(4.9)~1
AOR~1
octreotide;~1
continous~1
octreotide.~1
(HPD2)~1
dimethylbenzanthracene~1
HPD2~11
cytosol)~1
7.8;~1
gigantic~1
insinuate~1
(BSER)~1
(VER),~1
(NCV),~1
symptom-indicated~1
angiokeratomas~1
(angiokeratoma~1
diffusum~1
universale)~1
Fucosidosis~1
fucosidase.~1
Sialidosis~1
case-mix-adjusted~1
mucoid-exopolysaccharide~2
0.0072~1
mucoid-exopolysaccharide-specific~1
(48-hour)~1
(12-hour~1
sulfhydryl-group~2
subjects--17~1
it--who~1
N-acetylcysteine,~1
develops)~1
M54~4
functionally-rearranged~1
(Ly-1)~1
stringency.~1
intronless,~1
G-protein-coupled~1
Atriopeptin,~2
neuromediator~1
atriopeptin-like~1
IL-2(IL-2R).~1
(double-negative)~1
receptor/CD3~1
IL-2R-bearing~1
TCR),~1
pre-thymic~1
(18K),~1
omega,~1
tetramers.~1
mu-genes,~1
mu-protein~2
domain).~1
omega-chain~1
Laue~1
crystal,~1
X-radiation~1
wiggler~1
Daresbury~1
Source~1
(SRS),~1
millisecond-submillisecond~1
BANF,~1
'tumour~1
suppressor'~1
CD4-CD8-~3
CD4-CD8-,~1
(CD4+CD8-~1
CD4-CD8+)~1
(F23.1)~1
Pseudopodia~1
pseudopodia~9
(AMF)~1
AMF~1
below)~1
Anti-AMF~1
AMF-stimulated~1
'senseorgans'~1
(IL-2R).~1
'cortical~1
type'~2
'medullary~1
CD8;~1
recolonize~1
homing-independent~1
side-branch~1
(bp].~1
non-homologous~1
strand-exchanges~1
Holliday~1
Anti-myelin-associated~1
macroprolactinemia;~1
hypersecretors~1
prolactinomas;~1
macroprolactinemia,~1
prolactinomas.~1
placenta;~1
recurrent-abortion~1
(AL),~2
dermatochalasis~1
antibiotic/corticosteroid~2
$1.937~1
$64.8~1
million).~1
(59:1),~1
(501~1
$1,994~1
prevented)~1
(985~1
$63,484~1
prevented).~2
($148,445~1
($46,041~1
(2.39~1
110.3~1
kcal/kg/d)~1
g/kg/d;~1
30-day-old,~1
(prealbumin)~1
extubate.~1
extubated;~1
(13/13~1
7/14,~1
preextubation~1
acidosis.(ABSTRACT~1
close-to-normal~1
galactose/arginine-grown~1
freeze/thaw--sonication~1
uncoupler-insensitive~1
protonmotive~1
force-driven~1
arginine:ornithine~2
340-amino~1
37,335.~1
non-translated~1
courtship?~1
sex?~1
(olfactory,~1
visual)~1
mates.~1
courtships~1
p-azophenylarsonate~1
(Ars),~1
anti-arsonate~1
C.AL-20,~1
anti-phenyloxazolone~1
anti-levan~1
10-Ars-A~2
variable).~1
(Vh)~1
transgenes~1
nondeleted~1
gamma-interferon-treated~1
enterically~1
(ET-NANBH)~1
tamarins~2
(Saguinus~1
mystax~1
mystax)~1
First-passage~1
ET-NANBH~4
Pakistan,~1
27-~2
ato~1
34-nm-diameter~1
viruslike~1
(VLPs)~1
subpassaged~1
VLPs~2
second-,~1
third-passage~1
second-passage~1
tamarins.~1
ET-NANBH.~1
34-nm~1
geniculorecipient~2
stereopsis,~1
desirable--in~1
"shifter~1
circuits,"~1
diverging~1
shifter~1
plastids~1
cotyledons~1
(etioplasts)~1
pUC~1
pCS75~2
pUC9-CM,~1
ribulose~2
carboxylase/oxygenase~2
Anacystis~1
etioplasts~5
EDTA-washed~1
[32P]-pCS75.~1
etioplasts.~3
(23-200%)~1
(163-235%)~1
EDTA-treated~4
Uncouplers~1
psi),~1
etioplast.~1
hydrolyzable~1
adenyl-5'-yl~1
pCS75.~1
pCS75,~1
pUC9-CM.~1
pUC9-CM~1
plasmid-dependent~1
cotyledon~1
greening~1
Guanosine-5'-[gamma-thio]triphosphate~1
guanosine-5'-[beta-thio]diphosphate~1
bradykinin-stimulated~8
glycerophosphocholine~2
bradykinin-induced~1
opal~3
5'-leader~1
ADP-ribosyltransferase~1
(ADPRT;~1
2.4.2.30)~1
3-aminobenzamide.~1
nebulosa.~1
nebulosa~5
Glued~8
1319~1
heptad-repeat~1
cIII~12
cII~1
cIII-lacZ~1
(r1),~1
r1~2
translation;~1
III-cleaved~1
poly-~1
Lyt2-,L3T4-~1
Non-obese~1
ABMT.~1
glucose-tolerance~1
insulin-containing~1
nonlesioned~2
Bierman~1
"ultimately,~1
scent~1
economist~1
concedes~1
cost-benefit/cost-effectiveness~1
crux.~1
economist's~1
'nation's~1
health'~1
meaningless.~1
undeniable,~1
meaningful."~1
by.~1
Template-guided~1
Iridium-192~1
trimmable~1
21-cm-long~1
ribbons.~1
Ir-192,~1
265%~1
non-neurologic~1
implications:~1
"add-on"~1
PIA.~2
BARI~1
deleterious,~1
sterility,~1
P-DNA~1
insertion-bearing~1
P-element~1
transpositions~1
cocaine-like~1
[3H]mazindol~1
(2,700~1
Syed-Neblett~1
microamperes~2
pH/ion~1
microampere,~1
305.7~1
microampere.~1
radioisotopes~1
trochlear~2
purposely~1
(femoral)~1
AA861~2
trinitrate.~1
metabolite(s).~1
(CSF-SAH)~1
CSF-SAH~2
shorter-lived~1
radionuclides.~1
1329~1
Transfusion-Transmitted~1
(TTV)~1
EIA-recombinant~1
positive/RIA~1
hyperphosphataemia.~1
rewarm~1
frequency-modulated~1
min/24~2
solutions:~1
aggregates/1,000~1
(HPN).~1
(FAP)~1
triene:tetraene~1
oligosaccharide-bound)~1
(65.1~1
(1.83~1
10.1%.~1
"iron~1
index,"~1
(missed~1
aspirations,~1
(Rh+)~1
Rh-~2
Rh+~1
IgG-alkaline~1
0.06-2.3~1
0.6-1.25~1
phlebitic~2
Midarm~1
paratyphl~1
paratyphoid~2
Chloramphenicol-resistant~1
typhi,~1
EVS~5
(95-99)~1
bleed.~1
(98,~1
EVS.~2
EVS,~1
(45)~1
bleeders,~1
"large"~2
"ominous-looking"~1
Paquet's~1
(88,~1
99).~2
Exactly~1
(95,~1
23-yr-old~1
glucuronosyltransferase~1
kernicterus~1
kernicterus.~1
dyscrasias~1
electronmicroscopy,~1
"fractured"~1
dyscrasia.~1
Derivation~1
exponentially)~1
cTBG8)~1
cTBG8~1
Xq11~1
Xq23.~1
Xq21-22~1
(8.0-kb)~1
(5.1-kb)~1
reocclusion;~1
"lytic~1
state"~1
Fibrin-specific~1
"lytic"~1
progressing.~1
clot-dissolving~1
benefit;~1
Streptokinase,~1
(anisoylated~1
plasminogen-streptokinase~1
Ovaries~1
27-day-old~1
theca,~1
stillbirth"~1
161)~1
leukomas~1
colobomas.~1
hypertelorism.~1
diplococci.~1
(rH~1
TNF),~1
(rM~1
gamma-IFN),~1
rH~2
rM~2
Shwartzman's~1
cecum),~1
cyclooxygenase/lipoxygenase~1
(Peak~1
(20-200~1
300%,~1
(TPR)~1
TPR~1
(PEI).~1
polyanion~1
35S-sulfate.~1
1000-nm~1
(2900~1
dpm/mg~1
3005~1
(2025~1
148).~1
g/mg~1
PAN.~2
858~1
(PCBs)~1
dichlorodiphenyl~1
dichloroethene~1
(DDE)~1
DDE~2
(Septicemia~1
bacteria-specific~1
physician-hospital~1
"creep"~1
identification;~1
proctosigmoidoscopes~1
frees~1
Mobilization~1
21-37%~1
(N2O~1
unstimulated,~1
capnographic~1
pneumotachographic~1
(MAC).~1
APACHE~4
13.1)~1
25.8)~1
non-survivors.~1
Flumazepil~1
alfentanil-induced~1
Chlordiazepoxide~1
motionless,~1
flaccid,~1
Analog~2
Cetirizine~1
40-day~1
defending~1
Alveolar-arterial~1
summit."~1
(capillary)~1
(P-3)~1
P-3~7
metiamide~1
H2),~1
muscarinic,~1
serotonergic,~1
ETYA~1
FPL55712~1
primitive.~1
MCTP.~1
MCTP;~1
cysteinyl-containing~2
Saliva,~1
LTs.~1
cuffed,~1
(Dow~1
Corning,~1
Midland,~1
Fixation-off-sensitive~1
myoclonia~1
absences.~1
(LY),~1
LY-ceftriaxone,~1
LY-imipenem,~1
LY-gentamicin~2
(Enterococcus)~1
vancomycin-gentamicin,~1
ampicillin-gentamicin,~1
vancomycin-gentamicin~1
(PCC23)~2
PAO503,~1
PCC23~4
porin.~1
neurofibroma-associated~1
less-uniform,~1
Spandra~2
OpSite~1
Petrolatum~2
Gauze~1
(USP),~1
(Spandra~1
OpSite),~1
Gauze,~1
OpSite.~1
gas-permeable~1
ointment-impregnated~1
ANP)~1
prediuretic~2
'free~1
drink',~1
anticholesterol~1
85-95%~1
90-95%~1
NC-116~1
DC-273~1
PDT-182~1
alloxan;~1
IT-92~1
Armanni-Ebstein~1
Blister~1
zymosan-stimulated,~1
FMLP-stimulated,~1
C3AI~1
FMLP-mediated~1
zymosan-mediated~1
bathed.~1
leukocytoses,~1
(tension),~2
reductase-inhibitor~1
"best"~1
mEq/L]).~1
(Radiometer)~1
2800~1
Pathologists,~1
crossmatching.~1
Ungraded~1
critiques.~1
discontinued:~1
secretory),~1
elastolysis.~1
neuro-oncology.~1
immunopositivity~1
Synaptophysin,~1
(10/10),~1
(8/8),~1
(6/6).~1
(7/9),~1
68-kilodalton~1
NF-positive~1
160-kd~1
cephalosporin.~1
endorphins'~1
naloxone's~1
(QS/QT),~1
(VD/VT),~1
QS/QT,~1
VD/VT,~1
QS/QT~1
history-controlled~1
lupoid~1
cell-to-substrate~2
Citrated~1
intracamerally.~1
63D3)~1
(gamma-IFN).~1
gamma-IFN).~1
SFM,~2
gamma-IFN-treated~1
units/ml),~1
gamma-IFN-mediated~1
anti-gamma-IFN~1
